correlation C 1 1
between C 2 1
maternal C 3 1
and C 4 1
fetal C 5 1
plasma C 6 1
levels C 7 1
of C 8 1
glucose C 9 1
and C 10 1
free C 11 1
fatty C 12 1
acids C 13 1
. C 14 1
correlation C 16 1
coefficients C 17 1
have C 18 1
been C 19 1
determined C 20 1
between C 21 1
the C 22 1
levels C 23 1
of C 24 1
glucose C 25 1
and C 26 1
ffa C 27 1
in C 28 1
maternal C 29 1
and C 30 1
fetal C 31 1
plasma C 32 1
collected C 33 1
at C 34 1
delivery C 35 1
. C 36 1
significant C 38 1
correlations C 39 1
were C 40 1
obtained C 41 1
between C 42 1
the C 43 1
maternal C 44 1
and C 45 1
fetal C 46 1
glucose C 47 1
levels C 48 1
and C 49 1
the C 50 1
maternal C 51 1
and C 52 1
fetal C 53 1
ffa C 54 1
levels C 55 1
. C 56 1
from C 58 1
the C 59 1
size C 60 1
of C 61 1
the C 62 1
correlation C 63 1
coefficients C 64 1
and C 65 1
the C 66 1
slopes C 67 1
of C 68 1
regression C 69 1
lines C 70 1
it C 71 1
appears C 72 1
that C 73 1
the C 74 1
fetal C 75 1
plasma C 76 1
glucose C 77 1
level C 78 1
at C 79 1
delivery C 80 1
is C 81 1
very C 82 1
strongly C 83 1
dependent C 84 1
upon C 85 1
the C 86 1
maternal C 87 1
level C 88 1
whereas C 89 1
the C 90 1
fetal C 91 1
ffa C 92 1
level C 93 1
at C 94 1
delivery C 95 1
is C 96 1
only C 97 1
slightly C 98 1
dependent C 99 1
upon C 100 1
the C 101 1
maternal C 102 1
level C 103 1
. C 104 1
changes C 1 2
of C 2 2
the C 3 2
nucleic C 4 2
acid C 5 2
and C 6 2
phospholipid C 7 2
levels C 8 2
of C 9 2
the C 10 2
livers C 11 2
in C 12 2
the C 13 2
course C 14 2
of C 15 2
fetal C 16 2
and C 17 2
postnatal C 18 2
development C 19 2
. C 20 2
we C 22 2
have C 23 2
followed C 24 2
the C 25 2
evolution C 26 2
of C 27 2
dna C 28 2
, C 29 2
rna C 30 2
and C 31 2
pl C 32 2
in C 33 2
the C 34 2
livers C 35 2
of C 36 2
rat C 37 2
foeti C 38 2
removed C 39 2
between C 40 2
the C 41 2
fifteenth C 42 2
and C 43 2
the C 44 2
twenty C 45 2
- C 46 2
first C 47 2
day C 48 2
of C 49 2
gestation C 50 2
and C 51 2
of C 52 2
young C 53 2
rats C 54 2
newly C 55 2
- C 56 2
born C 57 2
or C 58 2
at C 59 2
weaning C 60 2
. C 61 2
we C 63 2
can C 64 2
observe C 65 2
the C 66 2
following C 67 2
facts C 68 2
. C 69 2
. C 71 2
1 C 73 2
. C 74 2
dna C 76 2
concentration C 77 2
is C 78 2
1100 C 79 2
ug C 80 2
p C 81 2
on C 82 2
the C 83 2
15 C 84 2
th C 85 2
day C 86 2
, C 87 2
it C 88 2
decreases C 89 2
from C 90 2
the C 91 2
19 C 92 2
th C 93 2
day C 94 2
until C 95 2
it C 96 2
reaches C 97 2
a C 98 2
value C 99 2
of C 100 2
280 C 101 2
ug C 102 2
5 C 103 2
days C 104 2
after C 105 2
weaning C 106 2
. C 107 2
2 C 109 2
. C 110 2
rna C 112 2
concentration C 113 2
is C 114 2
1400 C 115 2
ug C 116 2
p C 117 2
on C 118 2
the C 119 2
15 C 120 2
th C 121 2
day C 122 2
and C 123 2
decreases C 124 2
to C 125 2
820 C 126 2
during C 127 2
the C 128 2
same C 129 2
period C 130 2
. C 131 2
3 C 133 2
. C 134 2
pl C 136 2
concentration C 137 2
is C 138 2
low C 139 2
on C 140 2
the C 141 2
15 C 142 2
th C 143 2
day C 144 2
and C 145 2
during C 146 2
foetal C 147 2
life C 148 2
( C 149 2
700 C 150 2
ug C 151 2
) C 152 2
and C 153 2
increases C 154 2
abruptly C 155 2
at C 156 2
birth C 157 2
. C 158 2
4 C 160 2
. C 161 2
the C 163 2
ratios C 164 2
rna C 165 2
cyto C 166 2
/ C 167 2
dna C 168 2
and C 169 2
pl C 170 2
cyto C 171 2
/ C 172 2
dna C 173 2
increase C 174 2
regularly C 175 2
from C 176 2
the C 177 2
18 C 178 2
th C 179 2
day C 180 2
of C 181 2
foetal C 182 2
life C 183 2
. C 184 2
5 C 186 2
. C 187 2
nuclear C 189 2
rna C 190 2
and C 191 2
pl C 192 2
contents C 193 2
are C 194 2
very C 195 2
high C 196 2
throughout C 197 2
the C 198 2
development C 199 2
. C 200 2
6 C 202 2
. C 203 2
these C 205 2
results C 206 2
enable C 207 2
us C 208 2
to C 209 2
characterize C 210 2
three C 211 2
stages C 212 2
in C 213 2
the C 214 2
development C 215 2
of C 216 2
the C 217 2
rat C 218 2
liver C 219 2
. C 220 2
. C 222 2
- C 224 2
from C 225 2
the C 226 2
15 C 227 2
th C 228 2
day C 229 2
to C 230 2
the C 231 2
18 C 232 2
th C 233 2
day C 234 2
of C 235 2
foetal C 236 2
life C 237 2
. C 238 2
. C 240 2
stage C 242 2
of C 243 2
growth C 244 2
through C 245 2
hyperplasia C 246 2
without C 247 2
hypertrophy C 248 2
, C 249 2
- C 250 2
from C 251 2
the C 252 2
19 C 253 2
th C 254 2
day C 255 2
of C 256 2
foetal C 257 2
life C 258 2
to C 259 2
the C 260 2
3 C 261 2
rd C 262 2
day C 263 2
of C 264 2
post C 265 2
- C 266 2
natal C 267 2
life C 268 2
, C 269 2
. C 270 2
stage C 272 2
of C 273 2
cellular C 274 2
reorganisation C 275 2
, C 276 2
- C 277 2
after C 278 2
the C 279 2
3 C 280 2
rd C 281 2
day C 282 2
of C 283 2
post C 284 2
- C 285 2
natal C 286 2
life C 287 2
. C 288 2
. C 290 2
stage C 292 2
of C 293 2
growth C 294 2
through C 295 2
hyperplasia C 296 2
and C 297 2
hypertrophy C 298 2
. C 299 2
surfactant C 1 3
in C 2 3
fetal C 3 3
lamb C 4 3
tracheal C 5 3
fluid C 6 3
. C 7 3
lambs C 9 3
delivered C 10 3
by C 11 3
cesarean C 12 3
section C 13 3
with C 14 3
intact C 15 3
fetal C 16 3
circulation C 17 3
have C 18 3
a C 19 3
fluid C 20 3
filling C 21 3
the C 22 3
trachea C 23 3
. C 24 3
analysis C 26 3
revealed C 27 3
that C 28 3
this C 29 3
fluid C 30 3
contained C 31 3
material C 32 3
high C 33 3
in C 34 3
surface C 35 3
activity C 36 3
in C 37 3
lambs C 38 3
delivered C 39 3
near C 40 3
term C 41 3
, C 42 3
but C 43 3
less C 44 3
surface C 45 3
activity C 46 3
in C 47 3
premature C 48 3
lambs C 49 3
. C 50 3
administration C 52 3
of C 53 3
10 C 54 3
per C 55 3
cent C 56 3
oxygen C 57 3
to C 58 3
the C 59 3
ewe C 60 3
for C 61 3
1 C 62 3
hour C 63 3
prior C 64 3
to C 65 3
delivery C 66 3
did C 67 3
not C 68 3
alter C 69 3
the C 70 3
surfactant C 71 3
properties C 72 3
of C 73 3
the C 74 3
fetal C 75 3
tracheal C 76 3
fluid C 77 3
. C 78 3
two C 80 3
analyses C 81 3
of C 82 3
the C 83 3
fetal C 84 3
tracheal C 85 3
fluid C 86 3
revealed C 87 3
it C 88 3
to C 89 3
contain C 90 3
146 C 91 3
and C 92 3
198 C 93 3
mg C 94 3
. C 95 3
of C 97 3
lipid C 98 3
per C 99 3
100 C 100 3
ml C 101 3
. C 102 3
, C 104 3
30 C 105 3
to C 106 3
40 C 107 3
per C 108 3
cent C 109 3
of C 110 3
which C 111 3
was C 112 3
phospholipid C 113 3
, C 114 3
part C 115 3
of C 116 3
the C 117 3
active C 118 3
component C 119 3
of C 120 3
surfactant C 121 3
. C 122 3
the C 124 3
investigations C 125 3
reported C 126 3
here C 127 3
offer C 128 3
a C 129 3
model C 130 3
for C 131 3
further C 132 3
research C 133 3
into C 134 3
possible C 135 3
intrauterine C 136 3
factors C 137 3
in C 138 3
the C 139 3
pathogenesis C 140 3
of C 141 3
hyaline C 142 3
membrane C 143 3
disease C 144 3
. C 145 3
placental C 1 4
and C 2 4
cord C 3 4
blood C 4 4
lipids C 5 4
. C 6 4
. C 8 4
comparison C 10 4
in C 11 4
a C 12 4
set C 13 4
of C 14 4
double C 15 4
ovum C 16 4
twins C 17 4
, C 18 4
a C 19 4
stillborn C 20 4
and C 21 4
a C 22 4
live C 23 4
- C 24 4
born C 25 4
. C 26 4
1 C 28 4
. C 29 4
determinations C 31 4
of C 32 4
phospholipid C 33 4
, C 34 4
total C 35 4
and C 36 4
free C 37 4
cholesterol C 38 4
, C 39 4
triglyceride C 40 4
and C 41 4
nefa C 42 4
have C 43 4
been C 44 4
made C 45 4
on C 46 4
placental C 47 4
tissue C 48 4
and C 49 4
cord C 50 4
blood C 51 4
in C 52 4
a C 53 4
set C 54 4
of C 55 4
double C 56 4
ovum C 57 4
twins C 58 4
, C 59 4
one C 60 4
stillborn C 61 4
and C 62 4
one C 63 4
live C 64 4
- C 65 4
born C 66 4
. C 67 4
2 C 69 4
. C 70 4
similarities C 72 4
occurred C 73 4
in C 74 4
all C 75 4
fractions C 76 4
studied C 77 4
except C 78 4
the C 79 4
cord C 80 4
blood C 81 4
triglyceride C 82 4
and C 83 4
nefa C 84 4
levels C 85 4
. C 86 4
3 C 88 4
. C 89 4
the C 91 4
serum C 92 4
of C 93 4
the C 94 4
stillborn C 95 4
infant C 96 4
contained C 97 4
one C 98 4
- C 99 4
third C 100 4
as C 101 4
much C 102 4
triglyceride C 103 4
and C 104 4
21 C 105 4
/ C 106 4
2 C 107 4
times C 108 4
as C 109 4
much C 110 4
nefa C 111 4
as C 112 4
did C 113 4
the C 114 4
live C 115 4
- C 116 4
born C 117 4
infant C 118 4
. C 119 4
4 C 121 4
. C 122 4
the C 124 4
phospholipid C 125 4
content C 126 4
and C 127 4
the C 128 4
total C 129 4
lipid C 130 4
content C 131 4
of C 132 4
the C 133 4
stillbirth C 134 4
placenta C 135 4
were C 136 4
the C 137 4
highest C 138 4
studied C 139 4
in C 140 4
this C 141 4
laboratory C 142 4
which C 143 4
includes C 144 4
determinations C 145 4
on C 146 4
26 C 147 4
live C 148 4
births C 149 4
. C 150 4
5 C 152 4
. C 153 4
the C 155 4
suggestion C 156 4
is C 157 4
made C 158 4
that C 159 4
increased C 160 4
lipoprotein C 161 4
lipase C 162 4
activity C 163 4
in C 164 4
the C 165 4
cord C 166 4
blood C 167 4
may C 168 4
accompany C 169 4
intrauterine C 170 4
fetal C 171 4
death C 172 4
. C 173 4
free C 1 5
fatty C 2 5
acid C 3 5
concentration C 4 5
in C 5 5
maternal C 6 5
plasma C 7 5
and C 8 5
fetal C 9 5
body C 10 5
fat C 11 5
content C 12 5
. C 13 5
subcutaneous C 15 5
injection C 16 5
of C 17 5
200 C 18 5
u C 19 5
. C 20 5
. C 21 5
. C 22 5
. C 23 5
. C 24 5
units C 26 5
of C 27 5
heparin C 28 5
into C 29 5
female C 30 5
sprague C 31 5
- C 32 5
dawley C 33 5
rats C 34 5
produced C 35 5
large C 36 5
and C 37 5
sustained C 38 5
elevations C 39 5
of C 40 5
plasma C 41 5
free C 42 5
fatty C 43 5
acids C 44 5
but C 45 5
no C 46 5
significant C 47 5
change C 48 5
in C 49 5
blood C 50 5
glucose C 51 5
. C 52 5
a C 54 5
group C 55 5
of C 56 5
pregnant C 57 5
rats C 58 5
received C 59 5
such C 60 5
injections C 61 5
of C 62 5
heparin C 63 5
3 C 64 5
times C 65 5
daily C 66 5
throughout C 67 5
pregnancy C 68 5
. C 69 5
the C 71 5
fetuses C 72 5
from C 73 5
mothers C 74 5
of C 75 5
this C 76 5
group C 77 5
, C 78 5
at C 79 5
191 C 80 5
/ C 81 5
2 C 82 5
and C 83 5
211 C 84 5
/ C 85 5
2 C 86 5
days C 87 5
of C 88 5
gestation C 89 5
, C 90 5
had C 91 5
significantly C 92 5
more C 93 5
body C 94 5
fat C 95 5
than C 96 5
the C 97 5
fetuses C 98 5
from C 99 5
uninjected C 100 5
mothers C 101 5
. C 102 5
the C 104 5
hypothesis C 105 5
is C 106 5
presented C 107 5
that C 108 5
the C 109 5
maternal C 110 5
free C 111 5
fatty C 112 5
acid C 113 5
concentration C 114 5
in C 115 5
part C 116 5
determines C 117 5
fetal C 118 5
fat C 119 5
accumulation C 120 5
. C 121 5
it C 123 5
is C 124 5
proposed C 125 5
that C 126 5
the C 127 5
body C 128 5
composition C 129 5
changes C 130 5
noted C 131 5
in C 132 5
babies C 133 5
of C 134 5
mothers C 135 5
with C 136 5
diabetes C 137 5
might C 138 5
thus C 139 5
be C 140 5
ascribed C 141 5
to C 142 5
abnormally C 143 5
high C 144 5
maternal C 145 5
plasma C 146 5
free C 147 5
fatty C 148 5
acid C 149 5
concentrations C 150 5
. C 151 5
the C 1 6
concentration C 2 6
of C 3 6
non C 4 6
- C 5 6
esterified C 6 6
fatty C 7 6
acids C 8 6
in C 9 6
maternal C 10 6
and C 11 6
fetal C 12 6
plasma C 13 6
in C 14 6
intact C 15 6
, C 16 6
alloxan C 17 6
- C 18 6
diabetic C 19 6
and C 20 6
x C 21 6
- C 22 6
ray C 23 6
- C 24 6
irradiated C 25 6
rats C 26 6
. C 27 6
determinations C 29 6
of C 30 6
the C 31 6
non C 32 6
- C 33 6
esterified C 34 6
fatty C 35 6
acids C 36 6
in C 37 6
the C 38 6
plasma C 39 6
of C 40 6
pregnant C 41 6
rats C 42 6
showed C 43 6
that C 44 6
there C 45 6
do C 46 6
not C 47 6
exist C 48 6
any C 49 6
increases C 50 6
in C 51 6
the C 52 6
concentrations C 53 6
depending C 54 6
on C 55 6
pregnancy C 56 6
during C 57 6
the C 58 6
period C 59 6
from C 60 6
the C 61 6
20 C 62 6
th C 63 6
- C 64 6
22 C 65 6
nd C 66 6
day C 67 6
of C 68 6
pregnancy C 69 6
. C 70 6
in C 72 6
the C 73 6
fetal C 74 6
plasma C 75 6
the C 76 6
concentrations C 77 6
of C 78 6
non C 79 6
- C 80 6
esterified C 81 6
fatty C 82 6
acids C 83 6
only C 84 6
amounted C 85 6
to C 86 6
40 C 87 6
- C 88 6
50 C 89 6
per C 90 6
cent C 91 6
of C 92 6
the C 93 6
maternal C 94 6
values C 95 6
. C 96 6
with C 98 6
alloxan C 99 6
diabetes C 100 6
produced C 101 6
2 C 102 6
days C 103 6
prior C 104 6
to C 105 6
the C 106 6
test C 107 6
the C 108 6
concentration C 109 6
in C 110 6
the C 111 6
maternal C 112 6
plasma C 113 6
increased C 114 6
three C 115 6
- C 116 6
to C 117 6
fivefold C 118 6
, C 119 6
while C 120 6
at C 121 6
the C 122 6
same C 123 6
time C 124 6
a C 125 6
significant C 126 6
rise C 127 6
was C 128 6
absent C 129 6
in C 130 6
fetal C 131 6
plasma C 132 6
with C 133 6
slightly C 134 6
increased C 135 6
average C 136 6
values C 137 6
. C 138 6
whole C 140 6
- C 141 6
body C 142 6
x C 143 6
- C 144 6
ray C 145 6
exposures C 146 6
( C 147 6
dose C 148 6
. C 149 6
. C 151 6
400 C 153 6
r C 154 6
, C 155 6
dose C 156 6
output C 157 6
. C 158 6
. C 160 6
40 C 162 6
r C 163 6
/ C 164 6
min C 165 6
) C 166 6
of C 167 6
non C 168 6
- C 169 6
pregnant C 170 6
female C 171 6
and C 172 6
of C 173 6
pregnant C 174 6
rats C 175 6
beginning C 176 6
on C 177 6
the C 178 6
17 C 179 6
th C 180 6
day C 181 6
of C 182 6
pregnancy C 183 6
did C 184 6
not C 185 6
result C 186 6
in C 187 6
any C 188 6
changes C 189 6
of C 190 6
the C 191 6
concentration C 192 6
of C 193 6
non C 194 6
- C 195 6
esterified C 196 6
fatty C 197 6
acids C 198 6
immediately C 199 6
after C 200 6
irradiation C 201 6
. C 202 6
lipid C 1 7
metabolism C 2 7
in C 3 7
toxemia C 4 7
and C 5 7
normal C 6 7
pregnancy C 7 7
. C 8 7
the C 10 7
amount C 11 7
and C 12 7
fatty C 13 7
acid C 14 7
composition C 15 7
of C 16 7
total C 17 7
lipid C 18 7
extract C 19 7
from C 20 7
serum C 21 7
were C 22 7
examined C 23 7
in C 24 7
normal C 25 7
pregnant C 26 7
women C 27 7
in C 28 7
the C 29 7
first C 30 7
, C 31 7
second C 32 7
, C 33 7
and C 34 7
third C 35 7
trimesters C 36 7
, C 37 7
and C 38 7
early C 39 7
postpartum C 40 7
period C 41 7
, C 42 7
and C 43 7
in C 44 7
patients C 45 7
with C 46 7
mild C 47 7
and C 48 7
severe C 49 7
preeclampsia C 50 7
and C 51 7
with C 52 7
essential C 53 7
hypertension C 54 7
. C 55 7
placentas C 57 7
at C 58 7
term C 59 7
were C 60 7
also C 61 7
examined C 62 7
for C 63 7
total C 64 7
lipid C 65 7
and C 66 7
its C 67 7
fatty C 68 7
acid C 69 7
composition C 70 7
. C 71 7
in C 73 7
the C 74 7
normal C 75 7
women C 76 7
, C 77 7
total C 78 7
serum C 79 7
lipid C 80 7
increased C 81 7
during C 82 7
pregnancy C 83 7
. C 84 7
the C 86 7
rise C 87 7
was C 88 7
less C 89 7
pronounced C 90 7
in C 91 7
those C 92 7
with C 93 7
preeclampsia C 94 7
or C 95 7
hypertension C 96 7
. C 97 7
serum C 99 7
palmitate C 100 7
was C 101 7
mildly C 102 7
but C 103 7
significantly C 104 7
elevated C 105 7
in C 106 7
preeclampsia C 107 7
. C 108 7
total C 110 7
lipid C 111 7
and C 112 7
arachidonic C 113 7
acid C 114 7
were C 115 7
elevated C 116 7
in C 117 7
the C 118 7
placentas C 119 7
of C 120 7
preeclamptic C 121 7
women C 122 7
. C 123 7
the C 125 7
findings C 126 7
are C 127 7
compared C 128 7
with C 129 7
those C 130 7
obtained C 131 7
from C 132 7
animals C 133 7
developing C 134 7
eclampsia C 135 7
on C 136 7
an C 137 7
experimental C 138 7
basis C 139 7
. C 140 7
essential C 1 8
fatty C 2 8
acids C 3 8
and C 4 8
acids C 5 8
with C 6 8
trans C 7 8
- C 8 8
configuration C 9 8
in C 10 8
the C 11 8
subcutaneous C 12 8
and C 13 8
visceral C 14 8
fat C 15 8
of C 16 8
the C 17 8
newborn C 18 8
. C 19 8
we C 21 8
made C 22 8
an C 23 8
investigation C 24 8
of C 25 8
the C 26 8
subcutaneous C 27 8
and C 28 8
visceral C 29 8
fat C 30 8
in C 31 8
the C 32 8
newborn C 33 8
. C 34 8
we C 36 8
estimated C 37 8
the C 38 8
contents C 39 8
of C 40 8
linolic C 41 8
and C 42 8
linolenic C 43 8
acid C 44 8
and C 45 8
of C 46 8
acids C 47 8
with C 48 8
trans C 49 8
- C 50 8
configuration C 51 8
spectrophotometrically C 52 8
. C 53 8
we C 55 8
were C 56 8
able C 57 8
to C 58 8
show C 59 8
the C 60 8
penetration C 61 8
of C 62 8
these C 63 8
acids C 64 8
through C 65 8
the C 66 8
placental C 67 8
barrier C 68 8
. C 69 8
the C 71 8
essential C 72 8
fatty C 73 8
acid C 74 8
contents C 75 8
of C 76 8
fat C 77 8
in C 78 8
the C 79 8
newborn C 80 8
is C 81 8
low C 82 8
. C 83 8
in C 85 8
immature C 86 8
ones C 87 8
about C 88 8
7 C 89 8
- C 90 8
14 C 91 8
g C 92 8
, C 93 8
there C 94 8
is C 95 8
a C 96 8
rising C 97 8
trend C 98 8
. C 99 8
acetoacetate C 1 9
formation C 2 9
by C 3 9
livers C 4 9
from C 5 9
human C 6 9
fetuses C 7 9
aged C 8 9
8 C 9 9
- C 10 9
17 C 11 9
weeks C 12 9
. C 13 9
slices C 15 9
and C 16 9
homogenates C 17 9
from C 18 9
livers C 19 9
of C 20 9
human C 21 9
fetuses C 22 9
aged C 23 9
8 C 24 9
- C 25 9
17 C 26 9
weeks C 27 9
have C 28 9
a C 29 9
low C 30 9
rate C 31 9
of C 32 9
acetoacetate C 33 9
formation C 34 9
which C 35 9
can C 36 9
be C 37 9
raised C 38 9
by C 39 9
addition C 40 9
of C 41 9
acetate C 42 9
or C 43 9
octanoate C 44 9
to C 45 9
the C 46 9
incubation C 47 9
medium C 48 9
. C 49 9
it C 51 9
was C 52 9
not C 53 9
possible C 54 9
to C 55 9
demonstrate C 56 9
acetoacetate C 57 9
formation C 58 9
by C 59 9
isolated C 60 9
liver C 61 9
mitochondria C 62 9
from C 63 9
17 C 64 9
- C 65 9
week C 66 9
- C 67 9
old C 68 9
fetuses C 69 9
, C 70 9
probably C 71 9
because C 72 9
mitochondria C 73 9
are C 74 9
injured C 75 9
during C 76 9
isolation C 77 9
. C 78 9
changes C 1 10
in C 2 10
blood C 3 10
glucose C 4 10
and C 5 10
non C 6 10
- C 7 10
esterified C 8 10
fatty C 9 10
acids C 10 10
in C 11 10
the C 12 10
foetal C 13 10
and C 14 10
newborn C 15 10
lamb C 16 10
after C 17 10
injection C 18 10
of C 19 10
adrenaline C 20 10
. C 21 10
changes C 23 10
in C 24 10
blood C 25 10
glucose C 26 10
and C 27 10
non C 28 10
- C 29 10
esterified C 30 10
fatty C 31 10
acids C 32 10
after C 33 10
intravenous C 34 10
adrenaline C 35 10
were C 36 10
measured C 37 10
in C 38 10
foetal C 39 10
, C 40 10
newborn C 41 10
and C 42 10
adult C 43 10
sheep C 44 10
in C 45 10
the C 46 10
foetus C 47 10
and C 48 10
immediately C 49 10
after C 50 10
birth C 51 10
there C 52 10
was C 53 10
very C 54 10
little C 55 10
increase C 56 10
in C 57 10
either C 58 10
blood C 59 10
glucose C 60 10
or C 61 10
non C 62 10
- C 63 10
esterified C 64 10
fatty C 65 10
acids C 66 10
after C 67 10
adrenaline C 68 10
. C 69 10
the C 71 10
response C 72 10
of C 73 10
blood C 74 10
glucose C 75 10
to C 76 10
adrenaline C 77 10
had C 78 10
reached C 79 10
adult C 80 10
levels C 81 10
at C 82 10
twenty C 83 10
- C 84 10
four C 85 10
hours C 86 10
of C 87 10
age C 88 10
. C 89 10
the C 91 10
response C 92 10
of C 93 10
non C 94 10
- C 95 10
esterifi C 96 10
- C 97 10
ed C 98 10
fatty C 99 10
acids C 100 10
to C 101 10
adrenaline C 102 10
increased C 103 10
gradually C 104 10
over C 105 10
the C 106 10
first C 107 10
week C 108 10
. C 109 10
electron C 1 11
- C 2 11
microscopic C 3 11
observatations C 4 11
on C 5 11
transference C 6 11
of C 7 11
fat C 8 11
through C 9 11
the C 10 11
human C 11 11
placenta C 12 11
. C 13 11
from C 15 11
the C 16 11
results C 17 11
of C 18 11
our C 19 11
previous C 20 11
and C 21 11
present C 22 11
studied C 23 11
on C 24 11
the C 25 11
transportation C 26 11
of C 27 11
fat C 28 11
through C 29 11
the C 30 11
human C 31 11
placenta C 32 11
by C 33 11
means C 34 11
of C 35 11
electron C 36 11
microscopy C 37 11
, C 38 11
we C 39 11
obtained C 40 11
the C 41 11
following C 42 11
conclusions C 43 11
. C 44 11
1 C 46 11
) C 47 11
neutral C 48 11
fat C 49 11
can C 50 11
permeate C 51 11
through C 52 11
the C 53 11
human C 54 11
placenta C 55 11
without C 56 11
dissociation C 57 11
. C 58 11
2 C 60 11
) C 61 11
almost C 62 11
all C 63 11
processes C 64 11
of C 65 11
fat C 66 11
permeation C 67 11
seem C 68 11
to C 69 11
be C 70 11
due C 71 11
to C 72 11
the C 73 11
biological C 74 11
activity C 75 11
. C 76 11
pinocytosis C 78 11
is C 79 11
most C 80 11
representative C 81 11
, C 82 11
but C 83 11
the C 84 11
authors C 85 11
newly C 86 11
found C 87 11
several C 88 11
facts C 89 11
such C 90 11
as C 91 11
dissolution C 92 11
- C 93 11
like C 94 11
change C 95 11
in C 96 11
the C 97 11
basement C 98 11
membrane C 99 11
and C 100 11
transport C 101 11
via C 102 11
the C 103 11
stroma C 104 11
cell C 105 11
. C 106 11
the C 108 11
authors C 109 11
believe C 110 11
that C 111 11
these C 112 11
results C 113 11
will C 114 11
bring C 115 11
a C 116 11
clue C 117 11
to C 118 11
explain C 119 11
the C 120 11
mechanism C 121 11
of C 122 11
biological C 123 11
transportation C 124 11
of C 125 11
materials C 126 11
through C 127 11
the C 128 11
placenta C 129 11
. C 130 11
the C 1 12
content C 2 12
of C 3 12
phosphatides C 4 12
, C 5 12
triglycerides C 6 12
and C 7 12
cholesterol C 8 12
in C 9 12
placentas C 10 12
, C 11 12
maternal C 12 12
, C 13 12
fetal C 14 12
and C 15 12
new C 16 12
- C 17 12
born C 18 12
liver C 19 12
of C 20 12
the C 21 12
white C 22 12
rat C 23 12
. C 24 12
thin C 26 12
- C 27 12
layer C 28 12
- C 29 12
chromatographic C 30 12
examinations C 31 12
in C 32 12
the C 33 12
maternal C 34 12
rat C 35 12
liver C 36 12
showed C 37 12
different C 38 12
rise C 39 12
of C 40 12
the C 41 12
triglycerides C 42 12
and C 43 12
a C 44 12
significant C 45 12
increase C 46 12
of C 47 12
the C 48 12
esterified C 49 12
cholesterol C 50 12
, C 51 12
however C 52 12
, C 53 12
no C 54 12
striking C 55 12
changes C 56 12
in C 57 12
the C 58 12
content C 59 12
of C 60 12
free C 61 12
cholesterol C 62 12
and C 63 12
lipid C 64 12
phosphorus C 65 12
with C 66 12
the C 67 12
fractions C 68 12
examined C 69 12
( C 70 12
lecithin C 71 12
, C 72 12
colamine C 73 12
cephalin C 74 12
, C 75 12
sphingomyelin C 76 12
and C 77 12
lysolecithin C 78 12
) C 79 12
. C 80 12
as C 82 12
compared C 83 12
to C 84 12
the C 85 12
liver C 86 12
of C 87 12
adult C 88 12
rats C 89 12
, C 90 12
the C 91 12
fetal C 92 12
liver C 93 12
contains C 94 12
a C 95 12
little C 96 12
less C 97 12
than C 98 12
50 C 99 12
per C 100 12
cent C 101 12
lipid C 102 12
phosphorus C 103 12
. C 104 12
the C 106 12
difference C 107 12
is C 108 12
conditioned C 109 12
by C 110 12
the C 111 12
concentrations C 112 12
of C 113 12
lecithin C 114 12
, C 115 12
and C 116 12
colamine C 117 12
cephalin C 118 12
. C 119 12
on C 121 12
the C 122 12
19 C 123 12
th C 124 12
day C 125 12
the C 126 12
content C 127 12
of C 128 12
triglycerides C 129 12
is C 130 12
lower C 131 12
than C 132 12
in C 133 12
the C 134 12
mother C 135 12
rat C 136 12
. C 137 12
referred C 139 12
to C 140 12
the C 141 12
dry C 142 12
weight C 143 12
, C 144 12
there C 145 12
results C 146 12
a C 147 12
decrease C 148 12
of C 149 12
all C 150 12
phosphatide C 151 12
fractions C 152 12
, C 153 12
as C 154 12
well C 155 12
as C 156 12
of C 157 12
the C 158 12
free C 159 12
cholesterol C 160 12
and C 161 12
a C 162 12
slight C 163 12
rise C 164 12
of C 165 12
the C 166 12
triglycerides C 167 12
from C 168 12
the C 169 12
19 C 170 12
th C 171 12
to C 172 12
the C 173 12
22 C 174 12
nd C 175 12
day C 176 12
. C 177 12
the C 179 12
rise C 180 12
of C 181 12
the C 182 12
phosphatide C 183 12
concentrations C 184 12
to C 185 12
the C 186 12
values C 187 12
of C 188 12
adult C 189 12
rats C 190 12
occurs C 191 12
immediately C 192 12
after C 193 12
birth C 194 12
under C 195 12
the C 196 12
influence C 197 12
of C 198 12
milk C 199 12
food C 200 12
, C 201 12
which C 202 12
, C 203 12
moreover C 204 12
, C 205 12
leads C 206 12
to C 207 12
a C 208 12
considerable C 209 12
increase C 210 12
of C 211 12
the C 212 12
triglyceride C 213 12
values C 214 12
. C 215 12
phospholipid C 217 12
- C 218 12
and C 219 12
triglyceride C 220 12
concentrations C 221 12
of C 222 12
the C 223 12
placenta C 224 12
correspond C 225 12
to C 226 12
those C 227 12
of C 228 12
the C 229 12
fetal C 230 12
liver C 231 12
. C 232 12
solely C 234 12
the C 235 12
content C 236 12
of C 237 12
free C 238 12
cholesterol C 239 12
is C 240 12
higher C 241 12
at C 242 12
the C 243 12
end C 244 12
of C 245 12
pregnancy C 246 12
. C 247 12
the C 249 12
content C 250 12
of C 251 12
triglyceride C 252 12
drops C 253 12
towards C 254 12
the C 255 12
22 C 256 12
nd C 257 12
day C 258 12
. C 259 12
analysis C 1 13
of C 2 13
mammalian C 3 13
lens C 4 13
proteins C 5 13
by C 6 13
electrophoresis C 7 13
. C 8 13
lens C 10 13
proteins C 11 13
of C 12 13
different C 13 13
mammalian C 14 13
species C 15 13
were C 16 13
analyzed C 17 13
by C 18 13
two C 19 13
- C 20 13
dimensional C 21 13
starch C 22 13
gel C 23 13
electrophoresis C 24 13
. C 25 13
the C 27 13
number C 28 13
of C 29 13
fractions C 30 13
detected C 31 13
by C 32 13
this C 33 13
means C 34 13
varied C 35 13
from C 36 13
11 C 37 13
- C 38 13
20 C 39 13
. C 40 13
a C 42 13
- C 43 13
crystallin C 44 13
was C 45 13
resolved C 46 13
into C 47 13
two C 48 13
to C 49 13
three C 50 13
components C 51 13
, C 52 13
b C 53 13
- C 54 13
crystallin C 55 13
into C 56 13
5 C 57 13
- C 58 13
11 C 59 13
, C 60 13
and C 61 13
y C 62 13
- C 63 13
crystallin C 64 13
into C 65 13
three C 66 13
to C 67 13
five C 68 13
components C 69 13
. C 70 13
this C 72 13
technique C 73 13
provides C 74 13
a C 75 13
sensitive C 76 13
method C 77 13
for C 78 13
the C 79 13
fractionation C 80 13
of C 81 13
lens C 82 13
proteins C 83 13
and C 84 13
for C 85 13
analyzing C 86 13
species C 87 13
differences C 88 13
. C 89 13
an C 1 14
autoradiographic C 2 14
study C 3 14
on C 4 14
cell C 5 14
migration C 6 14
in C 7 14
the C 8 14
eye C 9 14
lens C 10 14
epithelium C 11 14
from C 12 14
normal C 13 14
and C 14 14
alloxan C 15 14
diabetic C 16 14
rats C 17 14
. C 18 14
lenses C 20 14
from C 21 14
normal C 22 14
and C 23 14
alloxan C 24 14
diabetic C 25 14
rats C 26 14
with C 27 14
and C 28 14
without C 29 14
cataract C 30 14
were C 31 14
investigated C 32 14
by C 33 14
autoradiography C 34 14
4 C 35 14
hours C 36 14
, C 37 14
4 C 38 14
days C 39 14
and C 40 14
8 C 41 14
days C 42 14
after C 43 14
an C 44 14
intraperitoneal C 45 14
injection C 46 14
of C 47 14
h C 48 14
3 C 49 14
- C 50 14
thymidine C 51 14
( C 52 14
0 C 53 14
. C 54 14
. C 55 14
uc C 56 14
/ C 57 14
g C 58 14
body C 59 14
weight C 60 14
) C 61 14
. C 62 14
the C 64 14
rats C 65 14
were C 66 14
made C 67 14
diabetic C 68 14
8 C 69 14
days C 70 14
prior C 71 14
to C 72 14
the C 73 14
injection C 74 14
of C 75 14
thymidine C 76 14
at C 77 14
an C 78 14
age C 79 14
of C 80 14
4 C 81 14
weeks C 82 14
. C 83 14
the C 85 14
position C 86 14
of C 87 14
labelled C 88 14
nuclei C 89 14
of C 90 14
the C 91 14
lens C 92 14
epithelium C 93 14
was C 94 14
noted C 95 14
and C 96 14
their C 97 14
grain C 98 14
numbers C 99 14
counted C 100 14
. C 101 14
the C 103 14
diabetic C 104 14
rats C 105 14
had C 106 14
a C 107 14
lower C 108 14
frequency C 109 14
of C 110 14
labelled C 111 14
nuclei C 112 14
than C 113 14
the C 114 14
controls C 115 14
but C 116 14
after C 117 14
4 C 118 14
hours C 119 14
their C 120 14
grain C 121 14
counts C 122 14
were C 123 14
equal C 124 14
. C 125 14
frequency C 127 14
diagrams C 128 14
of C 129 14
labelled C 130 14
nuclei C 131 14
are C 132 14
given C 133 14
for C 134 14
each C 135 14
of C 136 14
the C 137 14
three C 138 14
experimental C 139 14
periods C 140 14
. C 141 14
a C 143 14
predominant C 144 14
peak C 145 14
appears C 146 14
after C 147 14
4 C 148 14
hours C 149 14
at C 150 14
a C 151 14
distance C 152 14
of C 153 14
30 C 154 14
- C 155 14
60 C 156 14
cells C 157 14
in C 158 14
front C 159 14
of C 160 14
the C 161 14
beginning C 162 14
of C 163 14
the C 164 14
nuclear C 165 14
arc C 166 14
. C 167 14
a C 169 14
successive C 170 14
shift C 171 14
towards C 172 14
this C 173 14
area C 174 14
was C 175 14
observed C 176 14
for C 177 14
the C 178 14
longer C 179 14
experimental C 180 14
periods C 181 14
. C 182 14
the C 184 14
shift C 185 14
of C 186 14
the C 187 14
peaks C 188 14
was C 189 14
more C 190 14
restricted C 191 14
in C 192 14
the C 193 14
diabetic C 194 14
animals C 195 14
. C 196 14
this C 198 14
result C 199 14
may C 200 14
best C 201 14
be C 202 14
interpreted C 203 14
as C 204 14
an C 205 14
effect C 206 14
of C 207 14
an C 208 14
increased C 209 14
time C 210 14
of C 211 14
cell C 212 14
generation C 213 14
. C 214 14
as C 216 14
an C 217 14
appendix C 218 14
a C 219 14
histotechnique C 220 14
for C 221 14
the C 222 14
eye C 223 14
lens C 224 14
is C 225 14
given C 226 14
in C 227 14
collaboration C 228 14
with C 229 14
mrs C 230 14
. C 231 14
gertraude C 233 14
moewis C 234 14
. C 235 14
lens C 1 15
development C 2 15
. C 3 15
. C 5 15
the C 7 15
differentiation C 8 15
of C 9 15
embryonic C 10 15
chick C 11 15
lens C 12 15
epithelial C 13 15
cells C 14 15
in C 15 15
vitro C 16 15
and C 17 15
in C 18 15
vivo C 19 15
. C 20 15
the C 22 15
behavior C 23 15
of C 24 15
lens C 25 15
epithelial C 26 15
cells C 27 15
from C 28 15
six C 29 15
- C 30 15
day C 31 15
chick C 32 15
embryos C 33 15
was C 34 15
studied C 35 15
in C 36 15
three C 37 15
different C 38 15
experimental C 39 15
situations C 40 15
. C 41 15
. C 43 15
( C 45 15
a C 46 15
) C 47 15
explantation C 48 15
into C 49 15
several C 50 15
different C 51 15
fluid C 52 15
culture C 53 15
media C 54 15
, C 55 15
( C 56 15
b C 57 15
) C 58 15
explantation C 59 15
followed C 60 15
by C 61 15
reimplantation C 62 15
into C 63 15
lensectomized C 64 15
embryonic C 65 15
eyes C 66 15
, C 67 15
and C 68 15
( C 69 15
c C 70 15
) C 71 15
explantation C 72 15
followed C 73 15
by C 74 15
reimplantation C 75 15
into C 76 15
the C 77 15
embryonic C 78 15
coelomic C 79 15
cavity C 80 15
. C 81 15
specimens C 83 15
were C 84 15
examined C 85 15
histologically C 86 15
, C 87 15
and C 88 15
the C 89 15
total C 90 15
volume C 91 15
of C 92 15
the C 93 15
lens C 94 15
material C 95 15
of C 96 15
each C 97 15
specimen C 98 15
was C 99 15
determined C 100 15
from C 101 15
the C 102 15
planimetry C 103 15
of C 104 15
serial C 105 15
sections C 106 15
. C 107 15
the C 109 15
results C 110 15
were C 111 15
interpreted C 112 15
as C 113 15
follows C 114 15
. C 115 15
. C 117 15
1 C 119 15
. C 120 15
with C 122 15
a C 123 15
small C 124 15
amount C 125 15
of C 126 15
protein C 127 15
supplement C 128 15
in C 129 15
the C 130 15
culture C 131 15
medium C 132 15
, C 133 15
embryonic C 134 15
lens C 135 15
epithelial C 136 15
cells C 137 15
are C 138 15
capable C 139 15
of C 140 15
a C 141 15
limited C 142 15
amount C 143 15
of C 144 15
independent C 145 15
cytodifferentiation C 146 15
. C 147 15
without C 149 15
protein C 150 15
supplement C 151 15
they C 152 15
fail C 153 15
to C 154 15
undergo C 155 15
any C 156 15
fiber C 157 15
formation C 158 15
. C 159 15
2 C 161 15
. C 162 15
when C 164 15
returned C 165 15
to C 166 15
the C 167 15
eye C 168 15
environment C 169 15
, C 170 15
cultured C 171 15
epithelial C 172 15
explants C 173 15
will C 174 15
respond C 175 15
with C 176 15
a C 177 15
resumption C 178 15
of C 179 15
growth C 180 15
, C 181 15
with C 182 15
further C 183 15
cellular C 184 15
differentiation C 185 15
, C 186 15
and C 187 15
with C 188 15
at C 189 15
least C 190 15
some C 191 15
of C 192 15
the C 193 15
morphogenetic C 194 15
changes C 195 15
necessary C 196 15
to C 197 15
form C 198 15
a C 199 15
lens C 200 15
. C 201 15
the C 203 15
embryonic C 204 15
coelom C 205 15
will C 206 15
not C 207 15
support C 208 15
these C 209 15
responses C 210 15
. C 211 15
3 C 213 15
. C 214 15
the C 216 15
initiation C 217 15
of C 218 15
the C 219 15
formation C 220 15
of C 221 15
lens C 222 15
fibers C 223 15
is C 224 15
not C 225 15
sufficient C 226 15
for C 227 15
their C 228 15
complete C 229 15
autonomous C 230 15
maturation C 231 15
. C 232 15
4 C 234 15
. C 235 15
the C 237 15
internal C 238 15
architecture C 239 15
of C 240 15
the C 241 15
developing C 242 15
lens C 243 15
is C 244 15
not C 245 15
the C 246 15
only C 247 15
determinant C 248 15
of C 249 15
its C 250 15
overall C 251 15
shape C 252 15
. C 253 15
treatment C 1 16
of C 2 16
active C 3 16
chronic C 4 16
hepatitis C 5 16
and C 6 16
lupoid C 7 16
hepatitis C 8 16
with C 9 16
6 C 10 16
- C 11 16
mercaptopurine C 12 16
and C 13 16
azothioprine C 14 16
. C 15 16
6 C 17 16
- C 18 16
mercaptopurine C 19 16
or C 20 16
azothioprine C 21 16
( C 22 16
' C 23 16
imuran C 24 16
' C 25 16
) C 26 16
was C 27 16
used C 28 16
successfully C 29 16
in C 30 16
3 C 31 16
patients C 32 16
with C 33 16
active C 34 16
chronic C 35 16
hepatitis C 36 16
and C 37 16
2 C 38 16
with C 39 16
lupoid C 40 16
hepatitis C 41 16
, C 42 16
for C 43 16
periods C 44 16
up C 45 16
to C 46 16
1 C 47 16
year C 48 16
. C 49 16
these C 51 16
drugs C 52 16
allowed C 53 16
modification C 54 16
and C 55 16
even C 56 16
abolition C 57 16
of C 58 16
discomforting C 59 16
corticosteroid C 60 16
regimes C 61 16
. C 62 16
their C 64 16
action C 65 16
in C 66 16
chronic C 67 16
hepatitis C 68 16
may C 69 16
be C 70 16
analogous C 71 16
to C 72 16
their C 73 16
anti C 74 16
- C 75 16
immune C 76 16
action C 77 16
in C 78 16
suppressing C 79 16
homograft C 80 16
rejection C 81 16
. C 82 16
treatment C 1 17
of C 2 17
collagen C 3 17
diseases C 4 17
with C 5 17
cytostatics C 6 17
. C 7 17
22 C 9 17
patients C 10 17
with C 11 17
collagen C 12 17
diseases C 13 17
and C 14 17
3 C 15 17
patients C 16 17
with C 17 17
other C 18 17
immunological C 19 17
diseases C 20 17
were C 21 17
treated C 22 17
with C 23 17
the C 24 17
cytostatic C 25 17
antimetabolites C 26 17
( C 27 17
' C 28 17
purinethol C 29 17
' C 30 17
) C 31 17
6 C 32 17
- C 33 17
mercaptopurine C 34 17
and C 35 17
( C 36 17
' C 37 17
imuran C 38 17
' C 39 17
) C 40 17
azathioprine C 41 17
for C 42 17
an C 43 17
average C 44 17
period C 45 17
of C 46 17
four C 47 17
months C 48 17
( C 49 17
range C 50 17
one C 51 17
to C 52 17
eleven C 53 17
months C 54 17
) C 55 17
. C 56 17
improvement C 58 17
was C 59 17
obtained C 60 17
in C 61 17
17 C 62 17
patients C 63 17
, C 64 17
. C 65 17
and C 67 17
, C 68 17
in C 69 17
20 C 70 17
out C 71 17
of C 72 17
22 C 73 17
patients C 74 17
who C 75 17
had C 76 17
been C 77 17
on C 78 17
long C 79 17
- C 80 17
term C 81 17
glucocorticoid C 82 17
medication C 83 17
, C 84 17
the C 85 17
steroid C 86 17
therapy C 87 17
could C 88 17
be C 89 17
permanently C 90 17
discontinued C 91 17
. C 92 17
serious C 94 17
complications C 95 17
occurred C 96 17
, C 97 17
in C 98 17
the C 99 17
form C 100 17
of C 101 17
two C 102 17
deaths C 103 17
from C 104 17
pancytopenia C 105 17
and C 106 17
sepsis C 107 17
. C 108 17
the C 110 17
treatment C 111 17
requires C 112 17
careful C 113 17
supervision C 114 17
of C 115 17
the C 116 17
patients C 117 17
, C 118 17
and C 119 17
should C 120 17
only C 121 17
be C 122 17
instituted C 123 17
, C 124 17
on C 125 17
strict C 126 17
indications C 127 17
, C 128 17
when C 129 17
the C 130 17
alternative C 131 17
is C 132 17
long C 133 17
- C 134 17
term C 135 17
glucocorticoid C 136 17
medication C 137 17
. C 138 17
bilateral C 1 18
popliteal C 2 18
cysts C 3 18
in C 4 18
a C 5 18
patient C 6 18
with C 7 18
rheumatoid C 8 18
arthritis C 9 18
. C 10 18
a C 12 18
case C 13 18
of C 14 18
bilateral C 15 18
popliteal C 16 18
cysts C 17 18
and C 18 18
multiple C 19 18
joint C 20 18
subluxations C 21 18
in C 22 18
a C 23 18
patient C 24 18
with C 25 18
rheumatoid C 26 18
arthritis C 27 18
on C 28 18
corticosteroid C 29 18
medication C 30 18
for C 31 18
many C 32 18
years C 33 18
is C 34 18
reported C 35 18
. C 36 18
the C 38 18
effect C 39 18
of C 40 18
long C 41 18
- C 42 18
term C 43 18
corticosteroid C 44 18
therapy C 45 18
on C 46 18
all C 47 18
periarticular C 48 18
connective C 49 18
tissue C 50 18
structure C 51 18
and C 52 18
the C 53 18
relationship C 54 18
of C 55 18
articular C 56 18
disease C 57 18
and C 58 18
popliteal C 59 18
knee C 60 18
cysts C 61 18
to C 62 18
this C 63 18
therapy C 64 18
have C 65 18
been C 66 18
discussed C 67 18
. C 68 18
systemic C 1 19
lupus C 2 19
erythematosus C 3 19
and C 4 19
renal C 5 19
transplantation C 6 19
. C 7 19
. C 9 19
report C 11 19
of C 12 19
two C 13 19
cases C 14 19
. C 15 19
two C 17 19
cases C 18 19
of C 19 19
systemic C 20 19
lupus C 21 19
erythematosus C 22 19
along C 23 19
with C 24 19
terminal C 25 19
uremia C 26 19
secondary C 27 19
to C 28 19
lupus C 29 19
nephritis C 30 19
are C 31 19
presented C 32 19
. C 33 19
both C 35 19
patients C 36 19
were C 37 19
treated C 38 19
with C 39 19
renal C 40 19
hemodialysis C 41 19
and C 42 19
transplantation C 43 19
. C 44 19
certain C 46 19
mechanical C 47 19
, C 48 19
infectious C 49 19
, C 50 19
and C 51 19
immunologic C 52 19
problems C 53 19
were C 54 19
responsible C 55 19
for C 56 19
their C 57 19
death C 58 19
. C 59 19
there C 61 19
was C 62 19
no C 63 19
evidence C 64 19
of C 65 19
resurgence C 66 19
of C 67 19
lupus C 68 19
erythematosus C 69 19
in C 70 19
either C 71 19
patient C 72 19
, C 73 19
and C 74 19
the C 75 19
transplanted C 76 19
kidneys C 77 19
did C 78 19
not C 79 19
show C 80 19
evidence C 81 19
of C 82 19
lupus C 83 19
nephritis C 84 19
. C 85 19
renal C 87 19
transplantation C 88 19
should C 89 19
be C 90 19
considered C 91 19
as C 92 19
a C 93 19
last C 94 19
resort C 95 19
in C 96 19
treatment C 97 19
of C 98 19
patients C 99 19
with C 100 19
terminal C 101 19
lupus C 102 19
nephritis C 103 19
. C 104 19
arteritis C 1 20
and C 2 20
localised C 3 20
periosteal C 4 20
new C 5 20
bone C 6 20
formation C 7 20
. C 8 20
1 C 10 20
. C 11 20
three C 13 20
patients C 14 20
with C 15 20
localised C 16 20
periosteal C 17 20
new C 18 20
bone C 19 20
formation C 20 20
associated C 21 20
with C 22 20
periosteal C 23 20
arteritis C 24 20
and C 25 20
other C 26 20
evidence C 27 20
of C 28 20
systemic C 29 20
lupus C 30 20
erythematosus C 31 20
are C 32 20
described C 33 20
. C 34 20
2 C 36 20
. C 37 20
systemic C 39 20
steroid C 40 20
therapy C 41 20
was C 42 20
valuable C 43 20
in C 44 20
the C 45 20
management C 46 20
of C 47 20
this C 48 20
condition C 49 20
. C 50 20
fine C 1 21
structure C 2 21
of C 3 21
subtilis C 4 21
phage C 5 21
sp C 6 21
- C 7 21
50 C 8 21
. C 9 21
some C 11 21
structural C 12 21
details C 13 21
and C 14 21
anomalous C 15 21
forms C 16 21
of C 17 21
subtilis C 18 21
phage C 19 21
sp C 20 21
- C 21 21
50 C 22 21
are C 23 21
described C 24 21
. C 25 21
genetic C 1 22
transcription C 2 22
during C 3 22
morphogenesis C 4 22
. C 5 22
messenger C 7 22
rna C 8 22
' C 9 22
s C 10 22
from C 11 22
bacillus C 12 22
subtilis C 13 22
undergoing C 14 22
sporulation C 15 22
, C 16 22
germination C 17 22
, C 18 22
or C 19 22
step C 20 22
- C 21 22
down C 22 22
transition C 23 22
have C 24 22
been C 25 22
characterized C 26 22
and C 27 22
compared C 28 22
. C 29 22
hybrid C 31 22
competition C 32 22
experiments C 33 22
indicate C 34 22
that C 35 22
these C 36 22
messengers C 37 22
are C 38 22
derived C 39 22
from C 40 22
distinct C 41 22
genetic C 42 22
loci C 43 22
. C 44 22
the C 46 22
results C 47 22
are C 48 22
consistent C 49 22
with C 50 22
the C 51 22
hypothesis C 52 22
that C 53 22
differential C 54 22
transcription C 55 22
of C 56 22
the C 57 22
genome C 58 22
occurs C 59 22
during C 60 22
morphogenesis C 61 22
. C 62 22
the C 64 22
data C 65 22
also C 66 22
complement C 67 22
previously C 68 22
observed C 69 22
changes C 70 22
in C 71 22
morphology C 72 22
and C 73 22
enzymatic C 74 22
activity C 75 22
in C 76 22
sporulating C 77 22
bacteria C 78 22
. C 79 22
renal C 1 23
amyloidosis C 2 23
a C 3 23
clinicopathological C 4 23
study C 5 23
. C 6 23
the C 8 23
clinical C 9 23
and C 10 23
histopathological C 11 23
data C 12 23
from C 13 23
40 C 14 23
cases C 15 23
of C 16 23
renal C 17 23
amyloidosis C 18 23
diagnosed C 19 23
by C 20 23
percutaneous C 21 23
renal C 22 23
biopsy C 23 23
are C 24 23
presented C 25 23
. C 26 23
twenty C 28 23
- C 29 23
two C 30 23
cases C 31 23
were C 32 23
labelled C 33 23
as C 34 23
' C 35 23
secondary C 36 23
' C 37 23
amyloidosis C 38 23
, C 39 23
as C 40 23
definite C 41 23
aetiological C 42 23
factors C 43 23
responsible C 44 23
for C 45 23
renal C 46 23
amyloidosis C 47 23
could C 48 23
be C 49 23
discovered C 50 23
. C 51 23
the C 53 23
predisposing C 54 23
disease C 55 23
states C 56 23
leading C 57 23
to C 58 23
amyloid C 59 23
deposits C 60 23
in C 61 23
the C 62 23
kidney C 63 23
in C 64 23
the C 65 23
order C 66 23
of C 67 23
frequency C 68 23
were C 69 23
fibrocaseous C 70 23
pulmonary C 71 23
tuberculosis C 72 23
, C 73 23
bronchiectasis C 74 23
, C 75 23
lung C 76 23
abscess C 77 23
, C 78 23
and C 79 23
ileocaecal C 80 23
tuberculosis C 81 23
five C 82 23
cases C 83 23
were C 84 23
labelled C 85 23
as C 86 23
suspected C 87 23
' C 88 23
primary C 89 23
' C 90 23
amyloidosis C 91 23
as C 92 23
a C 93 23
definite C 94 23
evidence C 95 23
of C 96 23
the C 97 23
predisposing C 98 23
disease C 99 23
could C 100 23
not C 101 23
be C 102 23
obtained C 103 23
although C 104 23
the C 105 23
skiagram C 106 23
of C 107 23
chest C 108 23
revealed C 109 23
minimal C 110 23
healed C 111 23
foci C 112 23
. C 113 23
no C 115 23
cause C 116 23
could C 117 23
be C 118 23
determined C 119 23
in C 120 23
thirteen C 121 23
cases C 122 23
, C 123 23
which C 124 23
were C 125 23
, C 126 23
therefore C 127 23
, C 128 23
labelled C 129 23
as C 130 23
' C 131 23
primary C 132 23
' C 133 23
amyloidosis C 134 23
. C 135 23
albuminuria C 137 23
was C 138 23
a C 139 23
constant C 140 23
feature C 141 23
in C 142 23
all C 143 23
the C 144 23
cases C 145 23
and C 146 23
32 C 147 23
cases C 148 23
presented C 149 23
as C 150 23
nephrotic C 151 23
syndrome C 152 23
. C 153 23
the C 155 23
rest C 156 23
of C 157 23
the C 158 23
cases C 159 23
presented C 160 23
with C 161 23
hypertension C 162 23
or C 163 23
renal C 164 23
failure C 165 23
in C 166 23
addition C 167 23
to C 168 23
albuminuria C 169 23
. C 170 23
the C 172 23
ancillary C 173 23
procedure C 174 23
, C 175 23
viz C 176 23
. C 177 23
, C 179 23
congo C 180 23
- C 181 23
red C 182 23
test C 183 23
, C 184 23
gingival C 185 23
and C 186 23
liver C 187 23
biopsies C 188 23
proved C 189 23
to C 190 23
be C 191 23
of C 192 23
limited C 193 23
value C 194 23
in C 195 23
the C 196 23
diagnosis C 197 23
of C 198 23
renal C 199 23
amyloidosis C 200 23
. C 201 23
the C 203 23
importance C 204 23
of C 205 23
percutaneous C 206 23
renal C 207 23
biopsy C 208 23
as C 209 23
a C 210 23
diagnostic C 211 23
tool C 212 23
has C 213 23
been C 214 23
emphasised C 215 23
. C 216 23
idiopathic C 1 24
autoimmune C 2 24
hemolytic C 3 24
anemia C 4 24
and C 5 24
idiopathic C 6 24
thrombocytopenic C 7 24
purpura C 8 24
associated C 9 24
with C 10 24
diffuse C 11 24
hypergammaglobulinemia C 12 24
, C 13 24
amyloidosis C 14 24
, C 15 24
hypoalbuminemia C 16 24
and C 17 24
plasmacytosis C 18 24
. C 19 24
a C 21 24
case C 22 24
is C 23 24
reported C 24 24
of C 25 24
a C 26 24
sixty C 27 24
- C 28 24
nine C 29 24
year C 30 24
old C 31 24
woman C 32 24
with C 33 24
severe C 34 24
, C 35 24
idiopathic C 36 24
, C 37 24
autoimmune C 38 24
hemolytic C 39 24
anemia C 40 24
which C 41 24
was C 42 24
initially C 43 24
controlled C 44 24
by C 45 24
splenectomy C 46 24
. C 47 24
a C 49 24
relapse C 50 24
associated C 51 24
with C 52 24
the C 53 24
development C 54 24
of C 55 24
severe C 56 24
, C 57 24
autoimmune C 58 24
, C 59 24
thrombocytopenic C 60 24
purpura C 61 24
failed C 62 24
to C 63 24
respond C 64 24
to C 65 24
large C 66 24
doses C 67 24
of C 68 24
prednisone C 69 24
, C 70 24
but C 71 24
was C 72 24
controlled C 73 24
to C 74 24
a C 75 24
variable C 76 24
degree C 77 24
with C 78 24
imuran C 79 24
. C 80 24
associated C 82 24
features C 83 24
included C 84 24
diffuse C 85 24
hypergammaglobulinemia C 86 24
, C 87 24
excessive C 88 24
gamma C 89 24
- C 90 24
u C 91 24
proteins C 92 24
in C 93 24
the C 94 24
urine C 95 24
, C 96 24
idiopathic C 97 24
hypoalbuminemia C 98 24
with C 99 24
a C 100 24
greatly C 101 24
reduced C 102 24
total C 103 24
exchangeable C 104 24
albumin C 105 24
pool C 106 24
, C 107 24
amyloidosis C 108 24
in C 109 24
the C 110 24
spleen C 111 24
and C 112 24
other C 113 24
organs C 114 24
, C 115 24
and C 116 24
diffuse C 117 24
plasmacytosis C 118 24
of C 119 24
the C 120 24
bone C 121 24
marrow C 122 24
, C 123 24
lymph C 124 24
nodes C 125 24
, C 126 24
and C 127 24
thoracic C 128 24
and C 129 24
peritoneal C 130 24
fat C 131 24
. C 132 24
these C 134 24
features C 135 24
and C 136 24
their C 137 24
interrelationships C 138 24
are C 139 24
discussed C 140 24
. C 141 24
there C 143 24
was C 144 24
no C 145 24
deficiency C 146 24
in C 147 24
the C 148 24
synthesis C 149 24
of C 150 24
specific C 151 24
neutralizing C 152 24
antibodies C 153 24
against C 154 24
viruses C 155 24
, C 156 24
indicating C 157 24
that C 158 24
a C 159 24
qualitative C 160 24
immune C 161 24
deficiency C 162 24
did C 163 24
not C 164 24
exist C 165 24
. C 166 24
the C 168 24
frequency C 169 24
of C 170 24
occurrence C 171 24
of C 172 24
thrombocytopenic C 173 24
purpura C 174 24
in C 175 24
such C 176 24
a C 177 24
case C 178 24
is C 179 24
discussed C 180 24
, C 181 24
as C 182 24
is C 183 24
the C 184 24
prognosis C 185 24
. C 186 24
the C 188 24
mechanism C 189 24
of C 190 24
action C 191 24
of C 192 24
antimetabolites C 193 24
in C 194 24
inducing C 195 24
a C 196 24
remission C 197 24
in C 198 24
autoimmune C 199 24
hemolytic C 200 24
anemia C 201 24
, C 202 24
as C 203 24
well C 204 24
as C 205 24
the C 206 24
etiology C 207 24
of C 208 24
the C 209 24
disease C 210 24
, C 211 24
is C 212 24
reviewed C 213 24
. C 214 24
corticosteroid C 1 25
therapy C 2 25
of C 3 25
amyloid C 4 25
nephrotic C 5 25
syndrome C 6 25
. C 7 25
the C 9 25
results C 10 25
of C 11 25
treatment C 12 25
with C 13 25
prolonged C 14 25
adrenal C 15 25
corticosteroids C 16 25
in C 17 25
26 C 18 25
adults C 19 25
with C 20 25
amyloid C 21 25
nephrotic C 22 25
syndrome C 23 25
are C 24 25
presented C 25 25
. C 26 25
eight C 28 25
subjects C 29 25
were C 30 25
observed C 31 25
in C 32 25
this C 33 25
series C 34 25
, C 35 25
and C 36 25
18 C 37 25
additional C 38 25
cases C 39 25
were C 40 25
summarized C 41 25
from C 42 25
the C 43 25
literature C 44 25
. C 45 25
twenty C 47 25
- C 48 25
two C 49 25
of C 50 25
the C 51 25
patients C 52 25
were C 53 25
male C 54 25
and C 55 25
four C 56 25
were C 57 25
female C 58 25
. C 59 25
the C 61 25
diagnosis C 62 25
was C 63 25
established C 64 25
by C 65 25
renal C 66 25
biopsy C 67 25
in C 68 25
19 C 69 25
instances C 70 25
and C 71 25
by C 72 25
autopsy C 73 25
in C 74 25
the C 75 25
others C 76 25
, C 77 25
with C 78 25
18 C 79 25
patients C 80 25
considered C 81 25
to C 82 25
have C 83 25
primary C 84 25
amyloidosis C 85 25
and C 86 25
8 C 87 25
, C 88 25
secondary C 89 25
amyloidosis C 90 25
. C 91 25
the C 93 25
majority C 94 25
of C 95 25
the C 96 25
subjects C 97 25
died C 98 25
in C 99 25
renal C 100 25
failure C 101 25
with C 102 25
an C 103 25
average C 104 25
survival C 105 25
after C 106 25
onset C 107 25
of C 108 25
the C 109 25
disease C 110 25
of C 111 25
17 C 112 25
. C 113 25
. C 114 25
months C 115 25
. C 116 25
the C 118 25
renal C 119 25
disease C 120 25
was C 121 25
indistinguishable C 122 25
from C 123 25
that C 124 25
seen C 125 25
in C 126 25
other C 127 25
forms C 128 25
of C 129 25
the C 130 25
nephrotic C 131 25
syndrome C 132 25
, C 133 25
with C 134 25
the C 135 25
possible C 136 25
exceptions C 137 25
of C 138 25
( C 139 25
a C 140 25
) C 141 25
a C 142 25
high C 143 25
incidence C 144 25
of C 145 25
purpuric C 146 25
skin C 147 25
lesions C 148 25
, C 149 25
( C 150 25
b C 151 25
) C 152 25
a C 153 25
low C 154 25
or C 155 25
negligible C 156 25
incidence C 157 25
of C 158 25
hypertension C 159 25
( C 160 25
at C 161 25
times C 162 25
actual C 163 25
hypotension C 164 25
was C 165 25
prominent C 166 25
) C 167 25
, C 168 25
and C 169 25
( C 170 25
c C 171 25
) C 172 25
a C 173 25
rapid C 174 25
and C 175 25
inexorable C 176 25
progression C 177 25
of C 178 25
azotemia C 179 25
despite C 180 25
persistence C 181 25
of C 182 25
the C 183 25
clinical C 184 25
and C 185 25
biochemical C 186 25
characteristics C 187 25
of C 188 25
the C 189 25
nephrotic C 190 25
syndrome C 191 25
. C 192 25
amyloidosis C 194 25
was C 195 25
found C 196 25
by C 197 25
percutaneous C 198 25
renal C 199 25
biopsy C 200 25
in C 201 25
12 C 202 25
per C 203 25
cent C 204 25
of C 205 25
83 C 206 25
adults C 207 25
with C 208 25
the C 209 25
nephotic C 210 25
syndrome C 211 25
. C 212 25
corticosteroids C 214 25
did C 215 25
not C 216 25
appear C 217 25
to C 218 25
affect C 219 25
the C 220 25
progress C 221 25
of C 222 25
the C 223 25
disease C 224 25
and C 225 25
were C 226 25
neither C 227 25
beneficial C 228 25
nor C 229 25
detrimental C 230 25
. C 231 25
in C 233 25
view C 234 25
of C 235 25
the C 236 25
high C 237 25
incidence C 238 25
of C 239 25
deleterious C 240 25
side C 241 25
effects C 242 25
of C 243 25
prolonged C 244 25
corticosteroid C 245 25
therapy C 246 25
and C 247 25
the C 248 25
availability C 249 25
of C 250 25
potent C 251 25
diuretic C 252 25
agents C 253 25
which C 254 25
may C 255 25
be C 256 25
helpful C 257 25
in C 258 25
relieving C 259 25
edema C 260 25
in C 261 25
this C 262 25
disorder C 263 25
, C 264 25
it C 265 25
is C 266 25
felt C 267 25
that C 268 25
corticosteroids C 269 25
are C 270 25
contraindicated C 271 25
in C 272 25
the C 273 25
treatment C 274 25
of C 275 25
amyloid C 276 25
nephrotic C 277 25
syndrome C 278 25
. C 279 25
renal C 1 26
amyloidosis C 2 26
. C 3 26
. C 5 26
a C 7 26
biopsy C 8 26
study C 9 26
. C 10 26
the C 12 26
relationship C 13 26
of C 14 26
the C 15 26
amount C 16 26
of C 17 26
amyloid C 18 26
deposition C 19 26
in C 20 26
the C 21 26
kidney C 22 26
to C 23 26
the C 24 26
clinical C 25 26
picture C 26 26
is C 27 26
reviewed C 28 26
in C 29 26
14 C 30 26
cases C 31 26
of C 32 26
renal C 33 26
amyloidosis C 34 26
diagnosed C 35 26
by C 36 26
renal C 37 26
biopsy C 38 26
. C 39 26
the C 41 26
large C 42 26
percentage C 43 26
of C 44 26
patients C 45 26
who C 46 26
had C 47 26
the C 48 26
nephrotic C 49 26
syndrome C 50 26
( C 51 26
11 C 52 26
patients C 53 26
) C 54 26
probably C 55 26
reflects C 56 26
the C 57 26
criteria C 58 26
for C 59 26
renal C 60 26
biopsy C 61 26
at C 62 26
this C 63 26
institution C 64 26
. C 65 26
the C 67 26
etiology C 68 26
of C 69 26
the C 70 26
amyloid C 71 26
deposition C 72 26
did C 73 26
not C 74 26
seem C 75 26
to C 76 26
be C 77 26
clearly C 78 26
correlated C 79 26
with C 80 26
either C 81 26
the C 82 26
amount C 83 26
of C 84 26
amyloid C 85 26
deposition C 86 26
in C 87 26
the C 88 26
kidney C 89 26
or C 90 26
the C 91 26
severity C 92 26
of C 93 26
the C 94 26
clinical C 95 26
renal C 96 26
disease C 97 26
. C 98 26
all C 100 26
patients C 101 26
had C 102 26
deposits C 103 26
in C 104 26
the C 105 26
glomerulus C 106 26
, C 107 26
and C 108 26
the C 109 26
heavier C 110 26
the C 111 26
deposition C 112 26
the C 113 26
severer C 114 26
the C 115 26
renal C 116 26
disease C 117 26
. C 118 26
of C 120 26
7 C 121 26
patients C 122 26
who C 123 26
had C 124 26
biopsy C 125 26
of C 126 26
the C 127 26
bone C 128 26
marrow C 129 26
, C 130 26
all C 131 26
had C 132 26
abnormal C 133 26
types C 134 26
or C 135 26
numbers C 136 26
of C 137 26
plasma C 138 26
cells C 139 26
. C 140 26
the C 142 26
age C 143 26
range C 144 26
in C 145 26
primary C 146 26
amyloidosis C 147 26
appeared C 148 26
to C 149 26
be C 150 26
about C 151 26
the C 152 26
same C 153 26
as C 154 26
that C 155 26
in C 156 26
amyloidosis C 157 26
secondary C 158 26
to C 159 26
myeloma C 160 26
. C 161 26
amyloidosis C 163 26
should C 164 26
be C 165 26
suspected C 166 26
in C 167 26
patients C 168 26
with C 169 26
proteinuria C 170 26
, C 171 26
the C 172 26
nephrotic C 173 26
syndrome C 174 26
, C 175 26
or C 176 26
renal C 177 26
failure C 178 26
. C 179 26
amyloid C 1 27
goitre C 2 27
a C 3 27
case C 4 27
report C 5 27
. C 6 27
a C 8 27
case C 9 27
of C 10 27
amyloid C 11 27
goitre C 12 27
in C 13 27
an C 14 27
indian C 15 27
female C 16 27
, C 17 27
aged C 18 27
27 C 19 27
years C 20 27
, C 21 27
occurring C 22 27
as C 23 27
a C 24 27
sequelae C 25 27
to C 26 27
pulmonary C 27 27
tuberculosis C 28 27
, C 29 27
is C 30 27
reported C 31 27
. C 32 27
amyloid C 1 28
. C 2 28
. C 4 28
starch C 6 28
gel C 7 28
electrophoretic C 8 28
analysis C 9 28
of C 10 28
some C 11 28
proteins C 12 28
extracted C 13 28
from C 14 28
amyloid C 15 28
. C 16 28
proteins C 18 28
extracted C 19 28
by C 20 28
strong C 21 28
urea C 22 28
from C 23 28
washed C 24 28
tissue C 25 28
of C 26 28
patients C 27 28
with C 28 28
amyloidosis C 29 28
secondary C 30 28
to C 31 28
several C 32 28
diseases C 33 28
or C 34 28
associated C 35 28
with C 36 28
familial C 37 28
mediterranean C 38 28
fever C 39 28
have C 40 28
common C 41 28
major C 42 28
electrophoretic C 43 28
components C 44 28
. C 45 28
in C 47 28
hearts C 48 28
of C 49 28
primary C 50 28
amyloidosis C 51 28
one C 52 28
component C 53 28
in C 54 28
common C 55 28
with C 56 28
the C 57 28
secondary C 58 28
amyloid C 59 28
may C 60 28
be C 61 28
present C 62 28
. C 63 28
however C 65 28
, C 66 28
primary C 67 28
amyloid C 68 28
is C 69 28
much C 70 28
more C 71 28
difficult C 72 28
to C 73 28
dissolve C 74 28
and C 75 28
does C 76 28
not C 77 28
regularly C 78 28
give C 79 28
the C 80 28
components C 81 28
observed C 82 28
when C 83 28
the C 84 28
secondary C 85 28
amyloid C 86 28
is C 87 28
extracted C 88 28
. C 89 28
the C 91 28
big C 92 28
question C 93 28
remains C 94 28
as C 95 28
to C 96 28
what C 97 28
constituent C 98 28
or C 99 28
constituents C 100 28
comprise C 101 28
the C 102 28
fibrils C 103 28
now C 104 28
known C 105 28
to C 106 28
be C 107 28
a C 108 28
part C 109 28
of C 110 28
amyloid C 111 28
. C 112 28
selectivity C 1 29
of C 2 29
protein C 3 29
excretion C 4 29
in C 5 29
patients C 6 29
with C 7 29
the C 8 29
nephrotic C 9 29
syndrome C 10 29
. C 11 29
with C 13 29
a C 14 29
gel C 15 29
diffusion C 16 29
precipitin C 17 29
technique C 18 29
and C 19 29
commercially C 20 29
prepared C 21 29
antisera C 22 29
, C 23 29
urine C 24 29
/ C 25 29
plasma C 26 29
ratios C 27 29
of C 28 29
specific C 29 29
proteins C 30 29
were C 31 29
determined C 32 29
. C 33 29
individual C 35 29
protein C 36 29
clearances C 37 29
, C 38 29
expressed C 39 29
as C 40 29
a C 41 29
percentage C 42 29
of C 43 29
transferrin C 44 29
clearance C 45 29
, C 46 29
were C 47 29
plotted C 48 29
as C 49 29
ordinates C 50 29
against C 51 29
respective C 52 29
molecular C 53 29
weights C 54 29
on C 55 29
a C 56 29
log C 57 29
- C 58 29
log C 59 29
graph C 60 29
. C 61 29
a C 63 29
straight C 64 29
line C 65 29
was C 66 29
evident C 67 29
graphically C 68 29
, C 69 29
its C 70 29
constants C 71 29
were C 72 29
estimated C 73 29
by C 74 29
the C 75 29
method C 76 29
of C 77 29
least C 78 29
squares C 79 29
, C 80 29
and C 81 29
the C 82 29
slope C 83 29
, C 84 29
expressed C 85 29
as C 86 29
, C 87 29
was C 88 29
determined C 89 29
. C 90 29
the C 92 29
slope C 93 29
of C 94 29
the C 95 29
line C 96 29
may C 97 29
be C 98 29
said C 99 29
to C 100 29
express C 101 29
the C 102 29
degree C 103 29
of C 104 29
glomerular C 105 29
selectivity C 106 29
to C 107 29
protein C 108 29
excretion C 109 29
. C 110 29
sixty C 112 29
- C 113 29
five C 114 29
determinations C 115 29
were C 116 29
performed C 117 29
in C 118 29
48 C 119 29
patients C 120 29
. C 121 29
45 C 123 29
satisfying C 124 29
the C 125 29
usual C 126 29
criteria C 127 29
of C 128 29
the C 129 29
nephrotic C 130 29
syndrome C 131 29
. C 132 29
1 C 134 29
) C 135 29
those C 136 29
patients C 137 29
with C 138 29
primary C 139 29
renal C 140 29
disease C 141 29
and C 142 29
the C 143 29
nephrotic C 144 29
syndrome C 145 29
who C 146 29
displayed C 147 29
high C 148 29
selectivity C 149 29
types C 150 29
of C 151 29
proteinuria C 152 29
( C 153 29
greater C 154 29
than C 155 29
the C 156 29
average C 157 29
for C 158 29
the C 159 29
group C 160 29
+ C 161 29
1 C 162 29
sd C 163 29
) C 164 29
usually C 165 29
respond C 166 29
initially C 167 29
to C 168 29
steroid C 169 29
therapy C 170 29
, C 171 29
regardless C 172 29
of C 173 29
the C 174 29
acute C 175 29
or C 176 29
subacute C 177 29
glomerular C 178 29
changes C 179 29
observed C 180 29
on C 181 29
renal C 182 29
biopsy C 183 29
. C 184 29
2 C 186 29
) C 187 29
those C 188 29
patients C 189 29
with C 190 29
chronic C 191 29
renal C 192 29
disease C 193 29
and C 194 29
the C 195 29
nephrotic C 196 29
syndrome C 197 29
display C 198 29
an C 199 29
average C 200 29
and C 201 29
frequently C 202 29
a C 203 29
low C 204 29
selectivity C 205 29
type C 206 29
of C 207 29
proteinuria C 208 29
. C 209 29
3 C 211 29
) C 212 29
there C 213 29
appears C 214 29
to C 215 29
be C 216 29
no C 217 29
characteristic C 218 29
type C 219 29
of C 220 29
selectivity C 221 29
for C 222 29
a C 223 29
given C 224 29
pathologic C 225 29
group C 226 29
of C 227 29
patients C 228 29
with C 229 29
the C 230 29
nephrotic C 231 29
syndrome C 232 29
. C 233 29
4 C 235 29
) C 236 29
the C 237 29
degree C 238 29
of C 239 29
selective C 240 29
protein C 241 29
excretion C 242 29
is C 243 29
not C 244 29
related C 245 29
to C 246 29
the C 247 29
total C 248 29
daily C 249 29
amount C 250 29
of C 251 29
protein C 252 29
being C 253 29
excreted C 254 29
at C 255 29
any C 256 29
one C 257 29
time C 258 29
and C 259 29
remains C 260 29
fairly C 261 29
constant C 262 29
despite C 263 29
fluctuation C 264 29
in C 265 29
the C 266 29
amount C 267 29
of C 268 29
protein C 269 29
being C 270 29
excreted C 271 29
. C 272 29
5 C 274 29
) C 275 29
there C 276 29
is C 277 29
a C 278 29
slight C 279 29
correlation C 280 29
of C 281 29
borderline C 282 29
significance C 283 29
between C 284 29
the C 285 29
degree C 286 29
of C 287 29
selective C 288 29
protein C 289 29
excretion C 290 29
and C 291 29
the C 292 29
duration C 293 29
of C 294 29
the C 295 29
disease C 296 29
, C 297 29
and C 298 29
the C 299 29
initial C 300 29
para C 301 29
- C 302 29
aminohippuric C 303 29
acid C 304 29
clearance C 305 29
. C 306 29
6 C 308 29
) C 309 29
a C 310 29
statistically C 311 29
significant C 312 29
correlation C 313 29
exists C 314 29
between C 315 29
the C 316 29
initial C 317 29
blood C 318 29
urea C 319 29
nitrogen C 320 29
or C 321 29
inulin C 322 29
clearance C 323 29
and C 324 29
the C 325 29
selectivity C 326 29
type C 327 29
of C 328 29
protein C 329 29
excretion C 330 29
. C 331 29
those C 333 29
patients C 334 29
who C 335 29
were C 336 29
not C 337 29
azotemic C 338 29
and C 339 29
had C 340 29
initially C 341 29
near C 342 29
- C 343 29
normal C 344 29
inulin C 345 29
clearances C 346 29
had C 347 29
an C 348 29
average C 349 29
selectivity C 350 29
type C 351 29
or C 352 29
better C 353 29
. C 354 29
7 C 356 29
) C 357 29
it C 358 29
is C 359 29
suggested C 360 29
that C 361 29
if C 362 29
the C 363 29
adult C 364 29
patient C 365 29
is C 366 29
initially C 367 29
azotemic C 368 29
and C 369 29
has C 370 29
a C 371 29
grossly C 372 29
abnormal C 373 29
inulin C 374 29
clearance C 375 29
, C 376 29
response C 377 29
to C 378 29
therapy C 379 29
is C 380 29
unlikely C 381 29
, C 382 29
whereas C 383 29
if C 384 29
the C 385 29
blood C 386 29
urea C 387 29
nitrogen C 388 29
is C 389 29
normal C 390 29
and C 391 29
the C 392 29
inulin C 393 29
clearance C 394 29
is C 395 29
near C 396 29
normal C 397 29
, C 398 29
response C 399 29
to C 400 29
therapy C 401 29
cannot C 402 29
be C 403 29
predicted C 404 29
with C 405 29
any C 406 29
degree C 407 29
of C 408 29
accuracy C 409 29
. C 410 29
further C 412 29
studies C 413 29
of C 414 29
adult C 415 29
patients C 416 29
with C 417 29
the C 418 29
nephrotic C 419 29
syndrome C 420 29
are C 421 29
required C 422 29
to C 423 29
substantiate C 424 29
this C 425 29
premise C 426 29
. C 427 29
some C 1 30
aspects C 2 30
of C 3 30
haemostasis C 4 30
after C 5 30
open C 6 30
- C 7 30
heart C 8 30
surgery C 9 30
. C 10 30
synopsis C 12 30
in C 13 30
two C 14 30
groups C 15 30
of C 16 30
patients C 17 30
undergoing C 18 30
extracorporeal C 19 30
circulation C 20 30
with C 21 30
hypothermia C 22 30
, C 23 30
changes C 24 30
were C 25 30
found C 26 30
in C 27 30
the C 28 30
coagulation C 29 30
mechanism C 30 30
which C 31 30
were C 32 30
probably C 33 30
due C 34 30
to C 35 30
the C 36 30
dosage C 37 30
of C 38 30
polybrene C 39 30
administered C 40 30
. C 41 30
the C 43 30
role C 44 30
of C 45 30
heparin C 46 30
and C 47 30
polybrene C 48 30
and C 49 30
the C 50 30
concept C 51 30
of C 52 30
activation C 53 30
of C 54 30
the C 55 30
coagulation C 56 30
mechanism C 57 30
in C 58 30
the C 59 30
production C 60 30
of C 61 30
bleeding C 62 30
after C 63 30
perfusion C 64 30
are C 65 30
discussed C 66 30
. C 67 30
a C 1 31
case C 2 31
of C 3 31
interventricular C 4 31
septal C 5 31
defect C 6 31
with C 7 31
dextrocardia C 8 31
and C 9 31
situs C 10 31
inversus C 11 31
treated C 12 31
by C 13 31
surgery C 14 31
. C 15 31
a C 17 31
case C 18 31
of C 19 31
interventricular C 20 31
septal C 21 31
defect C 22 31
associated C 23 31
with C 24 31
situs C 25 31
inversus C 26 31
and C 27 31
dextrocardia C 28 31
in C 29 31
twenty C 30 31
year C 31 31
old C 32 31
male C 33 31
patient C 34 31
was C 35 31
presented C 36 31
along C 37 31
with C 38 31
discussion C 39 31
on C 40 31
three C 41 31
types C 42 31
of C 43 31
dextrocardial C 44 31
complexes C 45 31
and C 46 31
with C 47 31
emphasis C 48 31
on C 49 31
the C 50 31
rarity C 51 31
of C 52 31
occurrence C 53 31
of C 54 31
the C 55 31
intracardiac C 56 31
anomalies C 57 31
in C 58 31
true C 59 31
/ C 60 31
mirror C 61 31
- C 62 31
image C 63 31
/ C 64 31
dextrocardia C 65 31
with C 66 31
total C 67 31
situs C 68 31
inversus C 69 31
. C 70 31
a C 72 31
comment C 73 31
was C 74 31
also C 75 31
made C 76 31
on C 77 31
kartagener C 78 31
' C 79 31
s C 80 31
syndrome C 81 31
which C 82 31
was C 83 31
excluded C 84 31
by C 85 31
appropriate C 86 31
radiographic C 87 31
procedures C 88 31
in C 89 31
this C 90 31
case C 91 31
. C 92 31
the C 94 31
closure C 95 31
of C 96 31
the C 97 31
interventricular C 98 31
septal C 99 31
defect C 100 31
with C 101 31
extracorporeal C 102 31
circulation C 103 31
was C 104 31
successfully C 105 31
performed C 106 31
under C 107 31
moderate C 108 31
hypothermia C 109 31
. C 110 31
excretion C 1 32
patterns C 2 32
of C 3 32
urinary C 4 32
metabolites C 5 32
of C 6 32
estradiol C 7 32
- C 8 32
4 C 9 32
- C 10 32
c C 11 32
14 C 12 32
in C 13 32
postmenopausal C 14 32
women C 15 32
with C 16 32
benign C 17 32
and C 18 32
malignant C 19 32
disease C 20 32
of C 21 32
the C 22 32
breast C 23 32
. C 24 32
a C 26 32
study C 27 32
of C 28 32
the C 29 32
excretion C 30 32
patterns C 31 32
of C 32 32
the C 33 32
urinary C 34 32
metabolites C 35 32
of C 36 32
estradiol C 37 32
- C 38 32
4 C 39 32
- C 40 32
c C 41 32
1 C 42 32
j C 43 32
administered C 44 32
to C 45 32
a C 46 32
group C 47 32
of C 48 32
43 C 49 32
postmenopausal C 50 32
women C 51 32
, C 52 32
38 C 53 32
with C 54 32
advanced C 55 32
mammary C 56 32
carcinoma C 57 32
prior C 58 32
to C 59 32
endocrine C 60 32
therapy C 61 32
and C 62 32
5 C 63 32
with C 64 32
benign C 65 32
mammary C 66 32
dysplasia C 67 32
, C 68 32
is C 69 32
reported C 70 32
. C 71 32
a C 73 32
chromatographic C 74 32
method C 75 32
was C 76 32
employed C 77 32
for C 78 32
the C 79 32
determination C 80 32
of C 81 32
estradiol C 82 32
, C 83 32
estrone C 84 32
, C 85 32
and C 86 32
estriol C 87 32
and C 88 32
other C 89 32
estrogen C 90 32
metabolites C 91 32
. C 92 32
the C 94 32
urinary C 95 32
excretion C 96 32
pattern C 97 32
is C 98 32
defined C 99 32
by C 100 32
( C 101 32
a C 102 32
) C 103 32
the C 104 32
extent C 105 32
of C 106 32
excretion C 107 32
of C 108 32
isotope C 109 32
in C 110 32
each C 111 32
of C 112 32
3 C 113 32
successive C 114 32
24 C 115 32
- C 116 32
hr C 117 32
. C 118 32
collection C 120 32
periods C 121 32
, C 122 32
( C 123 32
b C 124 32
) C 125 32
the C 126 32
percentage C 127 32
of C 128 32
the C 129 32
urinary C 130 32
radiometabolites C 131 32
enzymatically C 132 32
hydrolyzed C 133 32
, C 134 32
( C 135 32
c C 136 32
) C 137 32
the C 138 32
relative C 139 32
concentration C 140 32
of C 141 32
the C 142 32
several C 143 32
metabolites C 144 32
in C 145 32
the C 146 32
hydrolyzed C 147 32
fraction C 148 32
. C 149 32
wide C 151 32
subject C 152 32
- C 153 32
to C 154 32
- C 155 32
subject C 156 32
variations C 157 32
were C 158 32
found C 159 32
. C 160 32
the C 162 32
metabolites C 163 32
other C 164 32
than C 165 32
estradiol C 166 32
, C 167 32
estrone C 168 32
, C 169 32
and C 170 32
estriol C 171 32
comprised C 172 32
a C 173 32
large C 174 32
portion C 175 32
of C 176 32
the C 177 32
total C 178 32
estrogens C 179 32
excreted C 180 32
. C 181 32
a C 183 32
significantly C 184 32
lower C 185 32
amount C 186 32
of C 187 32
estradiol C 188 32
was C 189 32
noted C 190 32
in C 191 32
the C 192 32
group C 193 32
of C 194 32
women C 195 32
with C 196 32
mammary C 197 32
carcinoma C 198 32
as C 199 32
compared C 200 32
to C 201 32
the C 202 32
amount C 203 32
found C 204 32
in C 205 32
the C 206 32
group C 207 32
of C 208 32
women C 209 32
with C 210 32
benign C 211 32
mammary C 212 32
dysplasia C 213 32
, C 214 32
suggesting C 215 32
that C 216 32
the C 217 32
former C 218 32
group C 219 32
metabolizes C 220 32
more C 221 32
rapidly C 222 32
the C 223 32
administered C 224 32
estradiol C 225 32
. C 226 32
although C 228 32
the C 229 32
excretion C 230 32
patterns C 231 32
of C 232 32
patients C 233 32
who C 234 32
failed C 235 32
to C 236 32
respond C 237 32
to C 238 32
estrogen C 239 32
treatment C 240 32
( C 241 32
nonresponders C 242 32
) C 243 32
differed C 244 32
the C 245 32
greatest C 246 32
from C 247 32
the C 248 32
patterns C 249 32
associated C 250 32
with C 251 32
benign C 252 32
disease C 253 32
, C 254 32
distinctive C 255 32
patterns C 256 32
of C 257 32
the C 258 32
urinary C 259 32
excretion C 260 32
of C 261 32
isotopic C 262 32
estrogens C 263 32
which C 264 32
allowed C 265 32
a C 266 32
statistically C 267 32
significant C 268 32
or C 269 32
clinically C 270 32
useful C 271 32
separation C 272 32
between C 273 32
responders C 274 32
and C 275 32
nonresponders C 276 32
to C 277 32
subsequent C 278 32
estrogen C 279 32
therapy C 280 32
were C 281 32
not C 282 32
discovered C 283 32
. C 284 32
the C 1 33
localizing C 2 33
significance C 3 33
of C 4 33
limited C 5 33
simultaneous C 6 33
visual C 7 33
form C 8 33
perception C 9 33
. C 10 33
a C 12 33
patient C 13 33
presenting C 14 33
with C 15 33
an C 16 33
isolated C 17 33
/ C 18 33
spelling C 19 33
dyslexia C 20 33
/ C 21 33
and C 22 33
impairment C 23 33
in C 24 33
picture C 25 33
interpretation C 26 33
( C 27 33
simultanagnosia C 28 33
) C 29 33
was C 30 33
shown C 31 33
by C 32 33
tachistoscopic C 33 33
studies C 34 33
to C 35 33
have C 36 33
a C 37 33
pathological C 38 33
limitation C 39 33
of C 40 33
simultaneous C 41 33
form C 42 33
perception C 43 33
. C 44 33
at C 46 33
autopsy C 47 33
a C 48 33
localized C 49 33
lesion C 50 33
was C 51 33
found C 52 33
within C 53 33
the C 54 33
inferior C 55 33
part C 56 33
of C 57 33
the C 58 33
left C 59 33
occipital C 60 33
lobe C 61 33
. C 62 33
these C 64 33
findings C 65 33
are C 66 33
discussed C 67 33
in C 68 33
relation C 69 33
to C 70 33
the C 71 33
problem C 72 33
of C 73 33
the C 74 33
disorder C 75 33
of C 76 33
function C 77 33
underlying C 78 33
/ C 79 33
agnosic C 80 33
alexia C 81 33
/ C 82 33
. C 83 33
visual C 1 34
anosognosia C 2 34
in C 3 34
cortical C 4 34
blindness C 5 34
anton C 6 34
' C 7 34
s C 8 34
symptom C 9 34
. C 10 34
denial C 12 34
of C 13 34
blindness C 14 34
in C 15 34
a C 16 34
case C 17 34
of C 18 34
bilateral C 19 34
hemianopia C 20 34
is C 21 34
presented C 22 34
to C 23 34
acquaint C 24 34
ophthalmologists C 25 34
with C 26 34
this C 27 34
symptom C 28 34
which C 29 34
is C 30 34
well C 31 34
- C 32 34
known C 33 34
to C 34 34
neurologists C 35 34
but C 36 34
is C 37 34
rarely C 38 34
seen C 39 34
by C 40 34
opthalmologists C 41 34
. C 42 34
the C 1 35
development C 2 35
of C 3 35
social C 4 35
attachments C 5 35
in C 6 35
infancy C 7 35
. C 8 35
this C 10 35
report C 11 35
is C 12 35
devoted C 13 35
to C 14 35
the C 15 35
formation C 16 35
and C 17 35
development C 18 35
of C 19 35
social C 20 35
attachments C 21 35
in C 22 35
infancy C 23 35
. C 24 35
it C 26 35
is C 27 35
suggested C 28 35
that C 29 35
the C 30 35
core C 31 35
of C 32 35
the C 33 35
attachment C 34 35
function C 35 35
is C 36 35
represented C 37 35
by C 38 35
the C 39 35
tendency C 40 35
of C 41 35
the C 42 35
young C 43 35
to C 44 35
seek C 45 35
the C 46 35
proximity C 47 35
of C 48 35
certain C 49 35
other C 50 35
members C 51 35
of C 52 35
the C 53 35
species C 54 35
and C 55 35
that C 56 35
the C 57 35
most C 58 35
suitable C 59 35
operational C 60 35
definition C 61 35
may C 62 35
be C 63 35
found C 64 35
in C 65 35
the C 66 35
behavior C 67 35
of C 68 35
the C 69 35
individual C 70 35
when C 71 35
deprived C 72 35
of C 73 35
such C 74 35
proximity C 75 35
. C 76 35
the C 78 35
study C 79 35
takes C 80 35
the C 81 35
form C 82 35
of C 83 35
a C 84 35
longitudinal C 85 35
follow C 86 35
- C 87 35
up C 88 35
, C 89 35
in C 90 35
which C 91 35
60 C 92 35
infants C 93 35
were C 94 35
investigated C 95 35
at C 96 35
four C 97 35
- C 98 35
weekly C 99 35
intervals C 100 35
from C 101 35
the C 102 35
early C 103 35
weeks C 104 35
on C 105 35
up C 106 35
to C 107 35
the C 108 35
end C 109 35
of C 110 35
the C 111 35
first C 112 35
year C 113 35
and C 114 35
again C 115 35
at C 116 35
18 C 117 35
months C 118 35
of C 119 35
age C 120 35
. C 121 35
with C 123 35
the C 124 35
use C 125 35
of C 126 35
an C 127 35
attachment C 128 35
scale C 129 35
, C 130 35
based C 131 35
on C 132 35
seven C 133 35
everyday C 134 35
separation C 135 35
situations C 136 35
, C 137 35
the C 138 35
following C 139 35
three C 140 35
main C 141 35
parameters C 142 35
were C 143 35
explored C 144 35
. C 145 35
. C 147 35
the C 149 35
age C 150 35
at C 151 35
onset C 152 35
of C 153 35
specific C 154 35
attachments C 155 35
, C 156 35
the C 157 35
intensity C 158 35
of C 159 35
such C 160 35
attachments C 161 35
, C 162 35
and C 163 35
the C 164 35
number C 165 35
of C 166 35
objects C 167 35
to C 168 35
whom C 169 35
attachments C 170 35
are C 171 35
formed C 172 35
. C 173 35
a C 175 35
measure C 176 35
of C 177 35
fear C 178 35
- C 179 35
of C 180 35
- C 181 35
strangers C 182 35
was C 183 35
also C 184 35
included C 185 35
. C 186 35
results C 188 35
indicate C 189 35
that C 190 35
the C 191 35
age C 192 35
at C 193 35
onset C 194 35
of C 195 35
specific C 196 35
attachments C 197 35
is C 198 35
generally C 199 35
to C 200 35
be C 201 35
found C 202 35
in C 203 35
the C 204 35
third C 205 35
quarter C 206 35
of C 207 35
the C 208 35
first C 209 35
year C 210 35
, C 211 35
but C 212 35
that C 213 35
this C 214 35
is C 215 35
preceded C 216 35
by C 217 35
a C 218 35
phase C 219 35
of C 220 35
indiscriminate C 221 35
attachment C 222 35
behavior C 223 35
, C 224 35
. C 225 35
that C 227 35
the C 228 35
intensity C 229 35
of C 230 35
specific C 231 35
attachment C 232 35
increases C 233 35
most C 234 35
in C 235 35
the C 236 35
first C 237 35
month C 238 35
following C 239 35
onset C 240 35
and C 241 35
that C 242 35
thereafter C 243 35
fluctuations C 244 35
occur C 245 35
in C 246 35
individual C 247 35
cases C 248 35
which C 249 35
make C 250 35
long C 251 35
- C 252 35
term C 253 35
prediction C 254 35
difficult C 255 35
, C 256 35
. C 257 35
and C 259 35
that C 260 35
multiplicity C 261 35
of C 262 35
objects C 263 35
can C 264 35
be C 265 35
found C 266 35
in C 267 35
some C 268 35
instances C 269 35
at C 270 35
the C 271 35
very C 272 35
beginning C 273 35
of C 274 35
the C 275 35
specific C 276 35
attachment C 277 35
phase C 278 35
, C 279 35
becoming C 280 35
the C 281 35
rule C 282 35
in C 283 35
most C 284 35
of C 285 35
the C 286 35
remaining C 287 35
cases C 288 35
very C 289 35
soon C 290 35
thereafter C 291 35
. C 292 35
correlations C 294 35
between C 295 35
the C 296 35
attachment C 297 35
variables C 298 35
, C 299 35
as C 300 35
well C 301 35
as C 302 35
with C 303 35
the C 304 35
fear C 305 35
- C 306 35
of C 307 35
- C 308 35
strangers C 309 35
measure C 310 35
, C 311 35
are C 312 35
presented C 313 35
, C 314 35
and C 315 35
an C 316 35
examination C 317 35
is C 318 35
also C 319 35
made C 320 35
of C 321 35
the C 322 35
conditions C 323 35
eliciting C 324 35
protest C 325 35
at C 326 35
proximity C 327 35
loss C 328 35
, C 329 35
of C 330 35
the C 331 35
manner C 332 35
in C 333 35
which C 334 35
protest C 335 35
is C 336 35
expressed C 337 35
, C 338 35
and C 339 35
of C 340 35
the C 341 35
conditions C 342 35
necessary C 343 35
to C 344 35
terminate C 345 35
protest C 346 35
. C 347 35
individual C 349 35
differences C 350 35
with C 351 35
regard C 352 35
to C 353 35
the C 354 35
three C 355 35
main C 356 35
parameters C 357 35
were C 358 35
explored C 359 35
in C 360 35
a C 361 35
subgroup C 362 35
of C 363 35
36 C 364 35
infants C 365 35
. C 366 35
a C 368 35
number C 369 35
of C 370 35
variables C 371 35
were C 372 35
examined C 373 35
in C 374 35
relation C 375 35
to C 376 35
these C 377 35
individual C 378 35
differences C 379 35
, C 380 35
and C 381 35
suggestions C 382 35
made C 383 35
regarding C 384 35
the C 385 35
conditions C 386 35
which C 387 35
affect C 388 35
the C 389 35
manifestation C 390 35
of C 391 35
the C 392 35
attachment C 393 35
function C 394 35
. C 395 35
the C 397 35
data C 398 35
are C 399 35
discussed C 400 35
in C 401 35
relation C 402 35
to C 403 35
four C 404 35
themes C 405 35
which C 406 35
emerged C 407 35
from C 408 35
the C 409 35
findings C 410 35
. C 411 35
. C 413 35
the C 415 35
nature C 416 35
of C 417 35
the C 418 35
attachment C 419 35
function C 420 35
, C 421 35
its C 422 35
developmental C 423 35
origins C 424 35
, C 425 35
its C 426 35
developmental C 427 35
trends C 428 35
, C 429 35
and C 430 35
the C 431 35
influence C 432 35
of C 433 35
the C 434 35
social C 435 35
setting C 436 35
. C 437 35
separation C 1 36
anxiety C 2 36
as C 3 36
a C 4 36
cause C 5 36
of C 6 36
early C 7 36
emotional C 8 36
problems C 9 36
in C 10 36
children C 11 36
. C 12 36
in C 14 36
summary C 15 36
, C 16 36
three C 17 36
cases C 18 36
of C 19 36
disturbed C 20 36
behavior C 21 36
in C 22 36
children C 23 36
have C 24 36
been C 25 36
discussed C 26 36
, C 27 36
with C 28 36
particular C 29 36
emphasis C 30 36
on C 31 36
disturbances C 32 36
in C 33 36
feeding C 34 36
, C 35 36
sleeping C 36 36
, C 37 36
and C 38 36
motility C 39 36
. C 40 36
some C 42 36
of C 43 36
the C 44 36
hypotheses C 45 36
have C 46 36
been C 47 36
presented C 48 36
of C 49 36
why C 50 36
such C 51 36
behavior C 52 36
should C 53 36
develop C 54 36
, C 55 36
. C 56 36
the C 58 36
significance C 59 36
of C 60 36
attachment C 61 36
behavior C 62 36
and C 63 36
separation C 64 36
anxiety C 65 36
in C 66 36
infants C 67 36
has C 68 36
been C 69 36
particularly C 70 36
stressed C 71 36
. C 72 36
difficulties C 74 36
in C 75 36
mothering C 76 36
care C 77 36
are C 78 36
threatening C 79 36
to C 80 36
the C 81 36
child C 82 36
' C 83 36
s C 84 36
sense C 85 36
of C 86 36
security C 87 36
and C 88 36
lead C 89 36
to C 90 36
greater C 91 36
experience C 92 36
of C 93 36
separation C 94 36
anxiety C 95 36
, C 96 36
which C 97 36
may C 98 36
then C 99 36
be C 100 36
reflected C 101 36
in C 102 36
various C 103 36
disturbances C 104 36
or C 105 36
alterations C 106 36
in C 107 36
his C 108 36
behavior C 109 36
. C 110 36
this C 112 36
experience C 113 36
of C 114 36
separation C 115 36
anxiety C 116 36
is C 117 36
the C 118 36
result C 119 36
of C 120 36
early C 121 36
life C 122 36
experience C 123 36
, C 124 36
may C 125 36
reach C 126 36
pathologic C 127 36
proportions C 128 36
, C 129 36
and C 130 36
may C 131 36
account C 132 36
for C 133 36
many C 134 36
later C 135 36
problems C 136 36
in C 137 36
children C 138 36
and C 139 36
adults C 140 36
. C 141 36
the C 1 37
production C 2 37
of C 3 37
malignant C 4 37
tumours C 5 37
by C 6 37
nickel C 7 37
in C 8 37
the C 9 37
rat C 10 37
. C 11 37
powdered C 13 37
metallic C 14 37
nickel C 15 37
when C 16 37
injected C 17 37
intramuscularly C 18 37
into C 19 37
rats C 20 37
produced C 21 37
tumours C 22 37
of C 23 37
striated C 24 37
muscle C 25 37
origin C 26 37
, C 27 37
most C 28 37
of C 29 37
which C 30 37
were C 31 37
very C 32 37
well C 33 37
differentiated C 34 37
. C 35 37
studies C 1 38
of C 2 38
nickel C 3 38
carcinogenesis C 4 38
fractionations C 5 38
of C 6 38
nickel C 7 38
in C 8 38
ultracentrifugal C 9 38
supernatants C 10 38
of C 11 38
lung C 12 38
and C 13 38
liver C 14 38
by C 15 38
means C 16 38
of C 17 38
dextran C 18 38
gel C 19 38
chromatography C 20 38
. C 21 38
chromatographic C 23 38
fractionations C 24 38
have C 25 38
been C 26 38
performed C 27 38
on C 28 38
the C 29 38
ultracentrifugal C 30 38
supernatants C 31 38
of C 32 38
homogenates C 33 38
of C 34 38
rat C 35 38
lung C 36 38
and C 37 38
liver C 38 38
by C 39 38
the C 40 38
use C 41 38
of C 42 38
columns C 43 38
of C 44 38
dextran C 45 38
gel C 46 38
( C 47 38
sephadex C 48 38
g C 49 38
- C 50 38
100 C 51 38
) C 52 38
. C 53 38
a C 55 38
major C 56 38
proportion C 57 38
of C 58 38
nickel C 59 38
in C 60 38
these C 61 38
tissue C 62 38
supernatants C 63 38
has C 64 38
been C 65 38
demonstrated C 66 38
to C 67 38
be C 68 38
firmly C 69 38
bound C 70 38
to C 71 38
macromolecular C 72 38
constituents C 73 38
. C 74 38
following C 76 38
acute C 77 38
and C 78 38
chronic C 79 38
inhalation C 80 38
of C 81 38
carcinogenic C 82 38
levels C 83 38
of C 84 38
nickel C 85 38
carbonyl C 86 38
, C 87 38
the C 88 38
predominant C 89 38
increases C 90 38
in C 91 38
the C 92 38
concentrations C 93 38
of C 94 38
nickel C 95 38
have C 96 38
been C 97 38
observed C 98 38
in C 99 38
the C 100 38
macromolecular C 101 38
fractions C 102 38
. C 103 38
these C 105 38
findings C 106 38
are C 107 38
consistent C 108 38
with C 109 38
the C 110 38
previous C 111 38
demonstration C 112 38
of C 113 38
nickel C 114 38
in C 115 38
purified C 116 38
preparations C 117 38
of C 118 38
ribonucleic C 119 38
acids C 120 38
( C 121 38
rna C 122 38
) C 123 38
from C 124 38
several C 125 38
rat C 126 38
tissues C 127 38
, C 128 38
and C 129 38
with C 130 38
the C 131 38
observation C 132 38
of C 133 38
increased C 134 38
concentrations C 135 38
of C 136 38
nickel C 137 38
in C 138 38
high C 139 38
- C 140 38
molecular C 141 38
weight C 142 38
rna C 143 38
from C 144 38
lung C 145 38
and C 146 38
liver C 147 38
following C 148 38
the C 149 38
inhalation C 150 38
of C 151 38
nickel C 152 38
carbonyl C 153 38
. C 154 38
a C 1 39
study C 2 39
of C 3 39
the C 4 39
inhibitory C 5 39
effect C 6 39
of C 7 39
ethylenediaminetetra C 8 39
- C 9 39
acetic C 10 39
acid C 11 39
on C 12 39
the C 13 39
thrombin C 14 39
- C 15 39
fibrinogen C 16 39
reaction C 17 39
. C 18 39
1 C 20 39
. C 21 39
ethylenediaminetetra C 23 39
- C 24 39
acetic C 25 39
acid C 26 39
reversibly C 27 39
inhibits C 28 39
the C 29 39
thrombin C 30 39
- C 31 39
fibrinogen C 32 39
reaction C 33 39
by C 34 39
means C 35 39
of C 36 39
a C 37 39
time C 38 39
- C 39 39
dependent C 40 39
diminution C 41 39
in C 42 39
fibrinogen C 43 39
reactivity C 44 39
. C 45 39
2 C 47 39
. C 48 39
this C 50 39
alteration C 51 39
of C 52 39
fibrinogen C 53 39
is C 54 39
due C 55 39
to C 56 39
some C 57 39
property C 58 39
of C 59 39
the C 60 39
edta C 61 39
molecule C 62 39
in C 63 39
an C 64 39
unchelated C 65 39
form C 66 39
, C 67 39
and C 68 39
is C 69 39
not C 70 39
due C 71 39
to C 72 39
the C 73 39
removal C 74 39
of C 75 39
trace C 76 39
metal C 77 39
ions C 78 39
. C 79 39
3 C 81 39
. C 82 39
possible C 84 39
explanations C 85 39
for C 86 39
this C 87 39
phenomenon C 88 39
are C 89 39
discussed C 90 39
. C 91 39
intradermal C 1 40
test C 2 40
using C 3 40
cobalt C 4 40
chloride C 5 40
. C 6 40
selected C 8 40
groups C 9 40
of C 10 40
patients C 11 40
with C 12 40
cobalt C 13 40
allergy C 14 40
and C 15 40
nickel C 16 40
allergy C 17 40
as C 18 40
well C 19 40
as C 20 40
normal C 21 40
controls C 22 40
were C 23 40
tested C 24 40
intradermally C 25 40
with C 26 40
cobalt C 27 40
chloride C 28 40
in C 29 40
the C 30 40
dilutions C 31 40
10 C 32 40
to C 33 40
10 C 34 40
. C 35 40
reactions C 37 40
of C 38 40
the C 39 40
wheal C 40 40
and C 41 40
flare C 42 40
type C 43 40
appear C 44 40
during C 45 40
the C 46 40
first C 47 40
hours C 48 40
and C 49 40
make C 50 40
the C 51 40
24 C 52 40
- C 53 40
hour C 54 40
reading C 55 40
misleading C 56 40
. C 57 40
the C 59 40
papular C 60 40
response C 61 40
to C 62 40
cobalt C 63 40
chloride C 64 40
10 C 65 40
, C 66 40
when C 67 40
read C 68 40
48 C 69 40
to C 70 40
96 C 71 40
hours C 72 40
after C 73 40
the C 74 40
injection C 75 40
, C 76 40
appears C 77 40
to C 78 40
be C 79 40
a C 80 40
reliable C 81 40
test C 82 40
for C 83 40
cobalt C 84 40
allergy C 85 40
. C 86 40
patients C 88 40
with C 89 40
combined C 90 40
nickel C 91 40
- C 92 40
cobalt C 93 40
allergy C 94 40
were C 95 40
excluded C 96 40
from C 97 40
the C 98 40
study C 99 40
, C 100 40
and C 101 40
the C 102 40
question C 103 40
of C 104 40
group C 105 40
reactions C 106 40
is C 107 40
not C 108 40
discussed C 109 40
. C 110 40
nickel C 112 40
allergics C 113 40
give C 114 40
a C 115 40
somewhat C 116 40
stronger C 117 40
reaction C 118 40
than C 119 40
controls C 120 40
to C 121 40
the C 122 40
slightly C 123 40
impure C 124 40
cobalt C 125 40
chloride C 126 40
. C 127 40
it C 129 40
would C 130 40
be C 131 40
preferable C 132 40
if C 133 40
the C 134 40
degree C 135 40
of C 136 40
purity C 137 40
of C 138 40
the C 139 40
cobalt C 140 40
chloride C 141 40
were C 142 40
ten C 143 40
times C 144 40
greater C 145 40
. C 146 40
measurements C 1 41
of C 2 41
nickel C 3 41
in C 4 41
biological C 5 41
materials C 6 41
by C 7 41
atomic C 8 41
absorption C 9 41
spectrometry C 10 41
. C 11 41
an C 13 41
atomic C 14 41
absorption C 15 41
procedure C 16 41
has C 17 41
been C 18 41
developed C 19 41
which C 20 41
facilitates C 21 41
quantitative C 22 41
measurements C 23 41
of C 24 41
nickel C 25 41
in C 26 41
biological C 27 41
materials C 28 41
, C 29 41
including C 30 41
urine C 31 41
, C 32 41
ribonucleic C 33 41
acids C 34 41
( C 35 41
rna C 36 41
) C 37 41
, C 38 41
and C 39 41
serum C 40 41
proteins C 41 41
. C 42 41
the C 44 41
sensitivity C 45 41
of C 46 41
detection C 47 41
of C 48 41
nickel C 49 41
by C 50 41
the C 51 41
atomic C 52 41
absorption C 53 41
spectrometer C 54 41
( C 55 41
0 C 56 41
. C 57 41
. C 58 41
. C 58 41
p C 59 41
. C 60 41
. C 61 41
. C 62 41
. C 63 41
. C 64 41
) C 66 41
was C 67 41
insufficient C 68 41
to C 69 41
permit C 70 41
direct C 71 41
measurements C 72 41
of C 73 41
nickel C 74 41
in C 75 41
normal C 76 41
urine C 77 41
. C 78 41
therefore C 80 41
, C 81 41
it C 82 41
was C 83 41
necessary C 84 41
to C 85 41
employ C 86 41
a C 87 41
dimethylglyoxime C 88 41
extraction C 89 41
procedure C 90 41
to C 91 41
concentrate C 92 41
the C 93 41
nickel C 94 41
, C 95 41
prior C 96 41
to C 97 41
atomic C 98 41
absorption C 99 41
spectrometry C 100 41
. C 101 41
the C 103 41
coefficients C 104 41
of C 105 41
variation C 106 41
of C 107 41
measurements C 108 41
of C 109 41
nickel C 110 41
in C 111 41
urine C 112 41
and C 113 41
human C 114 41
b C 115 41
- C 116 41
globulins C 117 41
were C 118 41
6 C 119 41
. C 120 41
. C 121 41
and C 122 41
5 C 123 41
. C 124 41
. C 125 41
per C 126 41
cent C 127 41
, C 128 41
respectively C 129 41
. C 130 41
the C 132 41
recovery C 133 41
of C 134 41
nickel C 135 41
added C 136 41
to C 137 41
urine C 138 41
averaged C 139 41
96 C 140 41
per C 141 41
cent C 142 41
, C 143 41
with C 144 41
a C 145 41
range C 146 41
from C 147 41
94 C 148 41
to C 149 41
97 C 150 41
, C 151 41
and C 152 41
the C 153 41
recovery C 154 41
of C 155 41
nickel C 156 41
added C 157 41
to C 158 41
human C 159 41
b C 160 41
- C 161 41
globulin C 162 41
averaged C 163 41
101 C 164 41
per C 165 41
cent C 166 41
, C 167 41
with C 168 41
a C 169 41
range C 170 41
from C 171 41
96 C 172 41
to C 173 41
104 C 174 41
. C 175 41
the C 177 41
mean C 178 41
concentration C 179 41
of C 180 41
nickel C 181 41
in C 182 41
24 C 183 41
- C 184 41
hr C 185 41
. C 186 41
collections C 188 41
of C 189 41
urine C 190 41
from C 191 41
17 C 192 41
normal C 193 41
subjects C 194 41
was C 195 41
1 C 196 41
. C 197 41
. C 198 41
ug C 199 41
. C 200 41
per C 202 41
100 C 203 41
ml C 204 41
. C 205 41
( C 207 41
s C 208 41
. C 209 41
. C 210 41
. C 211 41
= C 213 41
0 C 214 41
. C 215 41
. C 216 41
) C 217 41
, C 218 41
with C 219 41
a C 220 41
range C 221 41
from C 222 41
0 C 223 41
. C 224 41
. C 225 41
to C 226 41
3 C 227 41
. C 228 41
. C 229 41
. C 230 41
the C 232 41
mean C 233 41
urinary C 234 41
excretion C 235 41
of C 236 41
nickel C 237 41
was C 238 41
19 C 239 41
. C 240 41
. C 241 41
ug C 242 41
. C 243 41
per C 245 41
24 C 246 41
hr C 247 41
. C 248 41
( C 250 41
s C 251 41
. C 252 41
. C 253 41
. C 254 41
= C 256 41
10 C 257 41
. C 258 41
. C 259 41
) C 260 41
, C 261 41
with C 262 41
a C 263 41
range C 264 41
from C 265 41
7 C 266 41
. C 267 41
. C 268 41
to C 269 41
37 C 270 41
. C 271 41
. C 272 41
. C 273 41
the C 275 41
mean C 276 41
concentration C 277 41
of C 278 41
nickel C 279 41
in C 280 41
5 C 281 41
preparations C 282 41
of C 283 41
ribonucleic C 284 41
acids C 285 41
from C 286 41
ultracentrifugal C 287 41
supernatants C 288 41
of C 289 41
homogenates C 290 41
of C 291 41
rat C 292 41
lung C 293 41
was C 294 41
48 C 295 41
ug C 296 41
. C 297 41
of C 299 41
ni C 300 41
per C 301 41
gm C 302 41
. C 303 41
of C 305 41
rna C 306 41
, C 307 41
with C 308 41
a C 309 41
range C 310 41
from C 311 41
34 C 312 41
to C 313 41
64 C 314 41
. C 315 41
the C 317 41
mean C 318 41
concentration C 319 41
of C 320 41
nickel C 321 41
in C 322 41
5 C 323 41
preparations C 324 41
of C 325 41
rna C 326 41
from C 327 41
ultracentrifugal C 328 41
supernatants C 329 41
of C 330 41
homogenates C 331 41
of C 332 41
rat C 333 41
liver C 334 41
was C 335 41
29 C 336 41
ug C 337 41
. C 338 41
of C 340 41
ni C 341 41
per C 342 41
gm C 343 41
. C 344 41
of C 346 41
rna C 347 41
, C 348 41
with C 349 41
a C 350 41
range C 351 41
from C 352 41
21 C 353 41
to C 354 41
39 C 355 41
. C 356 41
measurements C 358 41
of C 359 41
nickel C 360 41
were C 361 41
performed C 362 41
upon C 363 41
fractions C 364 41
of C 365 41
human C 366 41
serum C 367 41
proteins C 368 41
, C 369 41
prepared C 370 41
by C 371 41
continuous C 372 41
- C 373 41
flow C 374 41
electrophoresis C 375 41
, C 376 41
and C 377 41
by C 378 41
cold C 379 41
- C 380 41
ethanol C 381 41
precipitation C 382 41
. C 383 41
the C 385 41
highest C 386 41
concentrations C 387 41
of C 388 41
nickel C 389 41
were C 390 41
found C 391 41
in C 392 41
preparations C 393 41
of C 394 41
serum C 395 41
b C 396 41
- C 397 41
globulins C 398 41
. C 399 41
properties C 1 42
of C 2 42
activity C 3 42
of C 4 42
5 C 5 42
' C 6 42
- C 7 42
nucleotidase C 8 42
in C 9 42
human C 10 42
serum C 11 42
, C 12 42
and C 13 42
applications C 14 42
in C 15 42
diagnosis C 16 42
. C 17 42
the C 19 42
influence C 20 42
of C 21 42
mg C 22 42
, C 23 42
ni C 24 42
, C 25 42
and C 26 42
l C 27 42
- C 28 42
histidine C 29 42
on C 30 42
purified C 31 42
preparations C 32 42
of C 33 42
bone C 34 42
and C 35 42
intestinal C 36 42
alkaline C 37 42
phosphatases C 38 42
and C 39 42
5 C 40 42
' C 41 42
- C 42 42
nucleotidase C 43 42
, C 44 42
and C 45 42
on C 46 42
various C 47 42
mixtures C 48 42
of C 49 42
these C 50 42
enzymes C 51 42
has C 52 42
been C 53 42
studied C 54 42
. C 55 42
the C 57 42
extent C 58 42
to C 59 42
which C 60 42
these C 61 42
findings C 62 42
can C 63 42
be C 64 42
utilized C 65 42
in C 66 42
the C 67 42
quantitative C 68 42
assay C 69 42
of C 70 42
5 C 71 42
' C 72 42
- C 73 42
nucleotidase C 74 42
in C 75 42
serum C 76 42
has C 77 42
been C 78 42
evaluated C 79 42
. C 80 42
results C 82 42
are C 83 42
presented C 84 42
on C 85 42
the C 86 42
possible C 87 42
utilization C 88 42
of C 89 42
l C 90 42
- C 91 42
histodine C 92 42
in C 93 42
the C 94 42
simultaneous C 95 42
evaluation C 96 42
of C 97 42
serum C 98 42
alkaline C 99 42
phosphatase C 100 42
and C 101 42
5 C 102 42
' C 103 42
- C 104 42
nucleotidase C 105 42
activity C 106 42
. C 107 42
some C 1 43
2 C 2 43
- C 3 43
iminoselenazolidin C 4 43
- C 5 43
4 C 6 43
- C 7 43
ones C 8 43
and C 9 43
related C 10 43
compounds C 11 43
. C 12 43
a C 14 43
series C 15 43
of C 16 43
2 C 17 43
- C 18 43
iminoselenazolidin C 19 43
- C 20 43
4 C 21 43
- C 22 43
ones C 23 43
, C 24 43
selenazolidine C 25 43
- C 26 43
2 C 27 43
, C 28 43
4 C 29 43
- C 30 43
diones C 31 43
and C 32 43
some C 33 43
2 C 34 43
- C 35 43
alkylidenehydrazones C 36 43
have C 37 43
been C 38 43
synthesised C 39 43
. C 40 43
wide C 42 43
- C 43 43
range C 44 43
screening C 45 43
for C 46 43
biological C 47 43
activity C 48 43
failed C 49 43
to C 50 43
reveal C 51 43
any C 52 43
compounds C 53 43
of C 54 43
promise C 55 43
. C 56 43
the C 1 44
influence C 2 44
of C 3 44
methemoglobinemia C 4 44
on C 5 44
the C 6 44
lethality C 7 44
of C 8 44
some C 9 44
toxic C 10 44
anions C 11 44
, C 12 44
1 C 13 44
. C 14 44
azide C 16 44
. C 17 44
the C 19 44
time C 20 44
course C 21 44
and C 22 44
extent C 23 44
of C 24 44
the C 25 44
methemoglobinemia C 26 44
induced C 27 44
by C 28 44
intraperitoneal C 29 44
sodium C 30 44
nitrite C 31 44
and C 32 44
p C 33 44
- C 34 44
aminopropiophenone C 35 44
( C 36 44
papp C 37 44
) C 38 44
have C 39 44
been C 40 44
characterized C 41 44
in C 42 44
female C 43 44
mice C 44 44
. C 45 44
the C 47 44
peak C 48 44
methemoglobin C 49 44
formation C 50 44
( C 51 44
34 C 52 44
) C 53 44
is C 54 44
achieved C 55 44
in C 56 44
about C 57 44
40 C 58 44
minutes C 59 44
. C 60 44
comparable C 62 44
levels C 63 44
from C 64 44
papp C 65 44
( C 66 44
15 C 67 44
mg C 68 44
/ C 69 44
kg C 70 44
) C 71 44
are C 72 44
achieved C 73 44
more C 74 44
quickly C 75 44
( C 76 44
between C 77 44
5 C 78 44
and C 79 44
10 C 80 44
minutes C 81 44
) C 82 44
but C 83 44
decline C 84 44
more C 85 44
rapidly C 86 44
to C 87 44
normal C 88 44
. C 89 44
both C 91 44
nitrite C 92 44
- C 93 44
and C 94 44
papp C 95 44
- C 96 44
induced C 97 44
methemoglobinemia C 98 44
afford C 99 44
a C 100 44
significant C 101 44
degree C 102 44
of C 103 44
protection C 104 44
against C 105 44
poisoning C 106 44
by C 107 44
sodium C 108 44
azide C 109 44
when C 110 44
administered C 111 44
in C 112 44
an C 113 44
appropriate C 114 44
time C 115 44
sequence C 116 44
. C 117 44
it C 119 44
was C 120 44
not C 121 44
possible C 122 44
under C 123 44
the C 124 44
same C 125 44
circumstances C 126 44
to C 127 44
protect C 128 44
mice C 129 44
against C 130 44
death C 131 44
from C 132 44
fluoride C 133 44
, C 134 44
cyanate C 135 44
, C 136 44
thiocyanate C 137 44
, C 138 44
selenate C 139 44
, C 140 44
or C 141 44
borate C 142 44
, C 143 44
although C 144 44
some C 145 44
prolongation C 146 44
of C 147 44
survival C 148 44
time C 149 44
was C 150 44
seen C 151 44
after C 152 44
fluoride C 153 44
. C 154 44
the C 156 44
formation C 157 44
of C 158 44
the C 159 44
azide C 160 44
- C 161 44
methemoglobin C 162 44
complex C 163 44
has C 164 44
been C 165 44
demonstrated C 166 44
within C 167 44
intact C 168 44
mouse C 169 44
red C 170 44
blood C 171 44
cells C 172 44
, C 173 44
and C 174 44
small C 175 44
amounts C 176 44
of C 177 44
the C 178 44
complex C 179 44
were C 180 44
identified C 181 44
in C 182 44
vivo C 183 44
in C 184 44
an C 185 44
antidotal C 186 44
situation C 187 44
. C 188 44
we C 190 44
think C 191 44
it C 192 44
important C 193 44
that C 194 44
the C 195 44
protective C 196 44
action C 197 44
of C 198 44
methemoglobinemia C 199 44
has C 200 44
been C 201 44
demonstrated C 202 44
to C 203 44
date C 204 44
only C 205 44
against C 206 44
established C 207 44
inhibitors C 208 44
of C 209 44
cytochrome C 210 44
oxidase C 211 44
. C 212 44
selenium C 1 45
as C 2 45
a C 3 45
trace C 4 45
element C 5 45
. C 6 45
an C 8 45
account C 9 45
is C 10 45
given C 11 45
of C 12 45
the C 13 45
discovery C 14 45
of C 15 45
selenium C 16 45
by C 17 45
berzelius C 18 45
and C 19 45
gahn C 20 45
the C 21 45
toxic C 22 45
behaviour C 23 45
of C 24 45
large C 25 45
selenium C 26 45
quantities C 27 45
in C 28 45
soils C 29 45
upon C 30 45
vegetation C 31 45
, C 32 45
animals C 33 45
, C 34 45
and C 35 45
man C 36 45
is C 37 45
surveyed C 38 45
. C 39 45
a C 41 45
review C 42 45
is C 43 45
also C 44 45
given C 45 45
of C 46 45
the C 47 45
role C 48 45
of C 49 45
trace C 50 45
amounts C 51 45
of C 52 45
selenium C 53 45
in C 54 45
the C 55 45
prevention C 56 45
of C 57 45
myopathies C 58 45
in C 59 45
animals C 60 45
. C 61 45
finally C 63 45
, C 64 45
some C 65 45
recent C 66 45
theories C 67 45
on C 68 45
the C 69 45
importance C 70 45
of C 71 45
retinal C 72 45
selenium C 73 45
to C 74 45
vision C 75 45
are C 76 45
mentioned C 77 45
. C 78 45
toxicity C 1 46
of C 2 46
inorganic C 3 46
selenium C 4 46
salts C 5 46
to C 6 46
chick C 7 46
embryos C 8 46
. C 9 46
the C 11 46
effects C 12 46
of C 13 46
selenite C 14 46
and C 15 46
selenate C 16 46
treatment C 17 46
by C 18 46
air C 19 46
cell C 20 46
injection C 21 46
on C 22 46
mortality C 23 46
and C 24 46
growth C 25 46
of C 26 46
14 C 27 46
- C 28 46
day C 29 46
chick C 30 46
embryos C 31 46
during C 32 46
a C 33 46
64 C 34 46
- C 35 46
68 C 36 46
hour C 37 46
period C 38 46
were C 39 46
studied C 40 46
. C 41 46
the C 43 46
ld C 44 46
for C 45 46
selenite C 46 46
- C 47 46
se C 48 46
was C 49 46
about C 50 46
0 C 51 46
. C 52 46
. C 53 46
ppm C 54 46
, C 55 46
based C 56 46
on C 57 46
weight C 58 46
of C 59 46
the C 60 46
egg C 61 46
contents C 62 46
, C 63 46
and C 64 46
that C 65 46
for C 66 46
selenate C 67 46
- C 68 46
se C 69 46
about C 70 46
1 C 71 46
. C 72 46
. C 73 46
- C 74 46
2 C 75 46
. C 76 46
. C 77 46
ppm C 78 46
. C 79 46
growth C 81 46
depression C 82 46
was C 83 46
evident C 84 46
from C 85 46
these C 86 46
treatments C 87 46
, C 88 46
but C 89 46
other C 90 46
gross C 91 46
effects C 92 46
were C 93 46
not C 94 46
prominent C 95 46
. C 96 46
the C 98 46
treatment C 99 46
of C 100 46
embryos C 101 46
with C 102 46
selenite C 103 46
and C 104 46
sulfate C 105 46
together C 106 46
caused C 107 46
a C 108 46
greater C 109 46
mortality C 110 46
than C 111 46
treatment C 112 46
with C 113 46
selenite C 114 46
alone C 115 46
. C 116 46
lesions C 1 47
of C 2 47
the C 3 47
islets C 4 47
of C 5 47
langerhans C 6 47
during C 7 47
injections C 8 47
of C 9 47
sodium C 10 47
selenite C 11 47
administered C 12 47
intravenously C 13 47
. C 14 47
sodium C 16 47
selenite C 17 47
was C 18 47
administered C 19 47
intravenously C 20 47
in C 21 47
rabbits C 22 47
and C 23 47
in C 24 47
dogs C 25 47
repeated C 26 47
injections C 27 47
can C 28 47
lead C 29 47
to C 30 47
the C 31 47
development C 32 47
of C 33 47
a C 34 47
diabetic C 35 47
syndrome C 36 47
in C 37 47
the C 38 47
rabbit C 39 47
. C 40 47
the C 42 47
histological C 43 47
examination C 44 47
of C 45 47
the C 46 47
pancreas C 47 47
in C 48 47
the C 49 47
poisoned C 50 47
animals C 51 47
( C 52 47
dogs C 53 47
and C 54 47
rabbits C 55 47
) C 56 47
has C 57 47
shown C 58 47
the C 59 47
existence C 60 47
of C 61 47
lesions C 62 47
of C 63 47
the C 64 47
islets C 65 47
of C 66 47
langerhans C 67 47
, C 68 47
mostly C 69 47
of C 70 47
the C 71 47
b C 72 47
cells C 73 47
which C 74 47
lose C 75 47
their C 76 47
granules C 77 47
partly C 78 47
or C 79 47
completely C 80 47
. C 81 47
these C 83 47
changes C 84 47
seem C 85 47
analogous C 86 47
to C 87 47
the C 88 47
ones C 89 47
produced C 90 47
by C 91 47
alloxan C 92 47
, C 93 47
. C 94 47
these C 96 47
two C 97 47
poisons C 98 47
act C 99 47
at C 100 47
first C 101 47
by C 102 47
inactivating C 103 47
the C 104 47
sh C 105 47
groups C 106 47
, C 107 47
which C 108 47
leads C 109 47
to C 110 47
a C 111 47
deficiency C 112 47
to C 113 47
which C 114 47
the C 115 47
b C 116 47
cells C 117 47
are C 118 47
very C 119 47
sensitive C 120 47
. C 121 47
toxicity C 1 48
of C 2 48
sulfur C 3 48
- C 4 48
35 C 5 48
, C 6 48
selenium C 7 48
, C 8 48
and C 9 48
tellurium C 10 48
to C 11 48
avian C 12 48
embryos C 13 48
. C 14 48
continuous C 16 48
internal C 17 48
irradiation C 18 48
of C 19 48
chick C 20 48
embryos C 21 48
with C 22 48
sulfur C 23 48
- C 24 48
35 C 25 48
administered C 26 48
on C 27 48
the C 28 48
4 C 29 48
th C 30 48
or C 31 48
8 C 32 48
th C 33 48
day C 34 48
of C 35 48
incubation C 36 48
produced C 37 48
abnormalities C 38 48
similar C 39 48
to C 40 48
those C 41 48
observed C 42 48
in C 43 48
selenium C 44 48
toxicosis C 45 48
of C 46 48
avian C 47 48
embryos C 48 48
. C 49 48
the C 51 48
highest C 52 48
level C 53 48
of C 54 48
sulfur C 55 48
- C 56 48
35 C 57 48
( C 58 48
1600 C 59 48
uc C 60 48
) C 61 48
injected C 62 48
into C 63 48
eggs C 64 48
containing C 65 48
4 C 66 48
- C 67 48
day C 68 48
embryos C 69 48
produced C 70 48
morphological C 71 48
abnormalities C 72 48
more C 73 48
severe C 74 48
than C 75 48
those C 76 48
produced C 77 48
by C 78 48
the C 79 48
same C 80 48
level C 81 48
of C 82 48
radiosulfur C 83 48
administered C 84 48
to C 85 48
8 C 86 48
- C 87 48
day C 88 48
embryos C 89 48
, C 90 48
or C 91 48
by C 92 48
any C 93 48
level C 94 48
of C 95 48
stable C 96 48
selenium C 97 48
tolerated C 98 48
. C 99 48
selenium C 101 48
at C 102 48
levels C 103 48
greater C 104 48
than C 105 48
30 C 106 48
ug C 107 48
killed C 108 48
all C 109 48
the C 110 48
embryos C 111 48
within C 112 48
24 C 113 48
hours C 114 48
after C 115 48
injection C 116 48
. C 117 48
nearly C 119 48
20 C 120 48
times C 121 48
more C 122 48
tellurium C 123 48
than C 124 48
selenium C 125 48
was C 126 48
required C 127 48
to C 128 48
kill C 129 48
all C 130 48
the C 131 48
embryos C 132 48
within C 133 48
24 C 134 48
hours C 135 48
. C 136 48
. C 138 48
no C 140 48
abnormalities C 141 48
were C 142 48
observed C 143 48
in C 144 48
the C 145 48
tellurium C 146 48
- C 147 48
injected C 148 48
embryos C 149 48
. C 150 48
the C 1 49
effect C 2 49
of C 3 49
selenium C 4 49
on C 5 49
the C 6 49
upper C 7 49
respiratory C 8 49
passages C 9 49
. C 10 49
results C 12 49
are C 13 49
reported C 14 49
of C 15 49
examination C 16 49
of C 17 49
workers C 18 49
exposed C 19 49
to C 20 49
selenium C 21 49
, C 22 49
with C 23 49
special C 24 49
reference C 25 49
to C 26 49
chronic C 27 49
changes C 28 49
in C 29 49
the C 30 49
respiratory C 31 49
passages C 32 49
. C 33 49
the C 35 49
findings C 36 49
are C 37 49
the C 38 49
same C 39 49
as C 40 49
reported C 41 49
in C 42 49
the C 43 49
literature C 44 49
. C 45 49
we C 47 49
emphasize C 48 49
the C 49 49
occurrence C 50 49
of C 51 49
teleangiectasias C 52 49
on C 53 49
the C 54 49
uvula C 55 49
and C 56 49
on C 57 49
the C 58 49
posterior C 59 49
palatinal C 60 49
arcs C 61 49
and C 62 49
on C 63 49
the C 64 49
epiglotis C 65 49
. C 66 49
we C 68 49
describe C 69 49
the C 70 49
occurrence C 71 49
of C 72 49
the C 73 49
first C 74 49
poisoning C 75 49
with C 76 49
selenium C 77 49
xyde C 78 49
in C 79 49
this C 80 49
country C 81 49
. C 82 49
the C 84 49
poisoning C 85 49
healed C 86 49
within C 87 49
a C 88 49
few C 89 49
days C 90 49
under C 91 49
symptomatic C 92 49
treatment C 93 49
. C 94 49
the C 96 49
patient C 97 49
had C 98 49
however C 99 49
to C 100 49
be C 101 49
transferred C 102 49
into C 103 49
another C 104 49
shop C 105 49
owing C 106 49
to C 107 49
frequent C 108 49
symptoms C 109 49
due C 110 49
to C 111 49
toxic C 112 49
effect C 113 49
of C 114 49
selenium C 115 49
. C 116 49
we C 118 49
report C 119 49
also C 120 49
on C 121 49
secondary C 122 49
findings C 123 49
in C 124 49
examination C 125 49
of C 126 49
chronic C 127 49
changes C 128 49
and C 129 49
we C 130 49
emphasize C 131 49
particularly C 132 49
the C 133 49
finding C 134 49
of C 135 49
profesional C 136 49
selenium C 137 49
external C 138 49
otitis C 139 49
. C 140 49
the C 1 50
influence C 2 50
of C 3 50
small C 4 50
selenite C 5 50
doses C 6 50
upon C 7 50
the C 8 50
toxic C 9 50
fatty C 10 50
degeneration C 11 50
of C 12 50
the C 13 50
liver C 14 50
. C 15 50
sodium C 17 50
selenite C 18 50
( C 19 50
10 C 20 50
ug C 21 50
/ C 22 50
kg C 23 50
) C 24 50
manifests C 25 50
a C 26 50
lipotropic C 27 50
effect C 28 50
after C 29 50
toxication C 30 50
of C 31 50
the C 32 50
rat C 33 50
by C 34 50
tetrachlorocarbon C 35 50
. C 36 50
this C 38 50
effect C 39 50
is C 40 50
absent C 41 50
when C 42 50
the C 43 50
selenite C 44 50
dose C 45 50
is C 46 50
increased C 47 50
to C 48 50
50 C 49 50
ug C 50 50
/ C 51 50
kg C 52 50
. C 53 50
the C 55 50
level C 56 50
of C 57 50
the C 58 50
total C 59 50
lipides C 60 50
of C 61 50
the C 62 50
liver C 63 50
after C 64 50
ethionine C 65 50
toxication C 66 50
is C 67 50
not C 68 50
significantly C 69 50
influenced C 70 50
by C 71 50
10 C 72 50
ug C 73 50
selenite C 74 50
/ C 75 50
kg C 76 50
. C 77 50
it C 79 50
is C 80 50
increased C 81 50
by C 82 50
50 C 83 50
ug C 84 50
selenite C 85 50
/ C 86 50
kg C 87 50
. C 88 50
selenium C 1 51
- C 2 51
caused C 3 51
tumours C 4 51
. C 5 51
in C 7 51
10 C 8 51
out C 9 51
of C 10 51
23 C 11 51
heterozygous C 12 51
rats C 13 51
administered C 14 51
10 C 15 51
mg C 16 51
na C 17 51
seo C 18 51
per C 19 51
1 C 20 51
kg C 21 51
food C 22 51
( C 23 51
containing C 24 51
12 C 25 51
protein C 26 51
) C 27 51
and C 28 51
surviving C 29 51
for C 30 51
18 C 31 51
months C 32 51
, C 33 51
cancer C 34 51
of C 35 51
the C 36 51
liver C 37 51
( C 38 51
with C 39 51
metastases C 40 51
in C 41 51
the C 42 51
lungs C 43 51
) C 44 51
along C 45 51
with C 46 51
sarcoma C 47 51
and C 48 51
adenoma C 49 51
was C 50 51
recorded C 51 51
. C 52 51
in C 54 51
another C 55 51
series C 56 51
of C 57 51
the C 58 51
yet C 59 51
incompleted C 60 51
experiment C 61 51
the C 62 51
animals C 63 51
were C 64 51
fed C 65 51
higher C 66 51
quantities C 67 51
of C 68 51
protein C 69 51
and C 70 51
selenium C 71 51
. C 72 51
toward C 74 51
14 C 75 51
- C 76 51
19 C 77 51
months C 78 51
in C 79 51
three C 80 51
of C 81 51
them C 82 51
sarcoma C 83 51
was C 84 51
noted C 85 51
. C 86 51
. C 88 51
in C 90 51
two C 91 51
sarcoma C 92 51
of C 93 51
the C 94 51
lymphatic C 95 51
nodes C 96 51
, C 97 51
and C 98 51
in C 99 51
one C 100 51
- C 101 51
of C 102 51
the C 103 51
mediastinum C 104 51
. C 105 51
it C 107 51
is C 108 51
suggested C 109 51
that C 110 51
the C 111 51
changes C 112 51
caused C 113 51
by C 114 51
selenium C 115 51
compounds C 116 51
are C 117 51
to C 118 51
some C 119 51
extent C 120 51
due C 121 51
to C 122 51
their C 123 51
antagonistic C 124 51
relationship C 125 51
with C 126 51
methionine C 127 51
. C 128 51
blood C 1 52
and C 2 52
bone C 3 52
marrow C 4 52
damage C 5 52
caused C 6 52
by C 7 52
drugs C 8 52
. C 9 52
drug C 11 52
side C 12 52
effects C 13 52
on C 14 52
blood C 15 52
and C 16 52
bone C 17 52
marrow C 18 52
are C 19 52
briefly C 20 52
reviewed C 21 52
. C 22 52
they C 24 52
embrace C 25 52
a C 26 52
wide C 27 52
variety C 28 52
of C 29 52
symptoms C 30 52
and C 31 52
pathogenetic C 32 52
mechanisms C 33 52
, C 34 52
and C 35 52
in C 36 52
recent C 37 52
years C 38 52
study C 39 52
of C 40 52
these C 41 52
effects C 42 52
has C 43 52
made C 44 52
important C 45 52
contributions C 46 52
to C 47 52
our C 48 52
knowledge C 49 52
of C 50 52
the C 51 52
immunology C 52 52
, C 53 52
biochemistry C 54 52
and C 55 52
metabolism C 56 52
of C 57 52
the C 58 52
blood C 59 52
cells C 60 52
. C 61 52
hypothermia C 1 53
. C 2 53
. C 4 53
physiologic C 6 53
effects C 7 53
and C 8 53
clinical C 9 53
application C 10 53
. C 11 53
a C 13 53
survey C 14 53
of C 15 53
the C 16 53
background C 17 53
, C 18 53
physiologic C 19 53
effects C 20 53
, C 21 53
indications C 22 53
, C 23 53
technique C 24 53
and C 25 53
complications C 26 53
of C 27 53
hypothermia C 28 53
is C 29 53
presented C 30 53
. C 31 53
the C 33 53
application C 34 53
of C 35 53
this C 36 53
technique C 37 53
is C 38 53
straightforward C 39 53
and C 40 53
safe C 41 53
when C 42 53
used C 43 53
at C 44 53
the C 45 53
proper C 46 53
levels C 47 53
with C 48 53
the C 49 53
proper C 50 53
indications C 51 53
. C 52 53
ehrlich C 1 54
ascites C 2 54
tumor C 3 54
cells C 4 54
agglutination C 5 54
. C 6 54
. C 8 54
the C 10 54
interference C 11 54
exerted C 12 54
by C 13 54
epsilonaminocaproic C 14 54
acid C 15 54
( C 16 54
eac C 17 54
) C 18 54
and C 19 54
its C 20 54
acetyl C 21 54
derivative C 22 54
( C 23 54
eaca C 24 54
) C 25 54
. C 26 54
the C 28 54
activity C 29 54
of C 30 54
epsilon C 31 54
- C 32 54
aminocaproic C 33 54
acid C 34 54
( C 35 54
eac C 36 54
) C 37 54
and C 38 54
of C 39 54
its C 40 54
acetyl C 41 54
derivative C 42 54
( C 43 54
eaca C 44 54
) C 45 54
was C 46 54
studied C 47 54
on C 48 54
antigen C 49 54
- C 50 54
antibody C 51 54
reactions C 52 54
, C 53 54
membrane C 54 54
antigens C 55 54
and C 56 54
immune C 57 54
globulins C 58 54
. C 59 54
in C 61 54
vitro C 62 54
eac C 63 54
and C 64 54
eaca C 65 54
do C 66 54
not C 67 54
affect C 68 54
immune C 69 54
globulins C 70 54
, C 71 54
but C 72 54
they C 73 54
do C 74 54
alter C 75 54
the C 76 54
membrane C 77 54
antigens C 78 54
of C 79 54
ehrlich C 80 54
ascites C 81 54
tumor C 82 54
cells C 83 54
and C 84 54
inhibit C 85 54
the C 86 54
agglutination C 87 54
reaction C 88 54
induced C 89 54
by C 90 54
a C 91 54
specific C 92 54
antiserum C 93 54
. C 94 54
inhibition C 96 54
is C 97 54
only C 98 54
partially C 99 54
due C 100 54
to C 101 54
the C 102 54
antigenic C 103 54
alteration C 104 54
observed C 105 54
, C 106 54
and C 107 54
it C 108 54
represents C 109 54
more C 110 54
prominently C 111 54
a C 112 54
direct C 113 54
interference C 114 54
at C 115 54
the C 116 54
level C 117 54
of C 118 54
the C 119 54
antigen C 120 54
- C 121 54
antibody C 122 54
reaction C 123 54
. C 124 54
the C 126 54
membrane C 127 54
antigen C 128 54
alternations C 129 54
induced C 130 54
by C 131 54
the C 132 54
drugs C 133 54
and C 134 54
by C 135 54
nitrogen C 136 54
mustard C 137 54
were C 138 54
compared C 139 54
, C 140 54
taking C 141 54
into C 142 54
account C 143 54
their C 144 54
toxicity C 145 54
. C 146 54
. C 148 54
eac C 150 54
and C 151 54
eaca C 152 54
were C 153 54
found C 154 54
to C 155 54
be C 156 54
much C 157 54
more C 158 54
active C 159 54
and C 160 54
more C 161 54
specific C 162 54
than C 163 54
nitrogen C 164 54
mustard C 165 54
. C 166 54
study C 1 55
on C 2 55
the C 3 55
behavior C 4 55
of C 5 55
tumor C 6 55
tissue C 7 55
in C 8 55
diffusion C 9 55
chambers C 10 55
against C 11 55
penetrating C 12 55
host C 13 55
cells C 14 55
in C 15 55
tumor C 16 55
- C 17 55
resistant C 18 55
rats C 19 55
. C 20 55
tumour C 22 55
cells C 23 55
in C 24 55
diffusion C 25 55
chambers C 26 55
, C 27 55
which C 28 55
were C 29 55
implanted C 30 55
in C 31 55
tumour C 32 55
- C 33 55
resistant C 34 55
rats C 35 55
, C 36 55
were C 37 55
only C 38 55
destroyed C 39 55
by C 40 55
penetrating C 41 55
immunized C 42 55
host C 43 55
cells C 44 55
when C 45 55
membrane C 46 55
filters C 47 55
of C 48 55
large C 49 55
pore C 50 55
size C 51 55
were C 52 55
used C 53 55
, C 54 55
whereas C 55 55
with C 56 55
filters C 57 55
of C 58 55
small C 59 55
pore C 60 55
size C 61 55
the C 62 55
tumour C 63 55
cells C 64 55
survived C 65 55
and C 66 55
remained C 67 55
virulent C 68 55
. C 69 55
current C 1 56
status C 2 56
of C 3 56
hypothermia C 4 56
. C 5 56
moderate C 7 56
hypothermia C 8 56
has C 9 56
been C 10 56
recommended C 11 56
for C 12 56
many C 13 56
and C 14 56
varied C 15 56
conditions C 16 56
. C 17 56
today C 19 56
its C 20 56
value C 21 56
is C 22 56
being C 23 56
questioned C 24 56
in C 25 56
the C 26 56
light C 27 56
of C 28 56
controlled C 29 56
groups C 30 56
of C 31 56
patients C 32 56
. C 33 56
at C 35 56
the C 36 56
moment C 37 56
its C 38 56
use C 39 56
is C 40 56
justified C 41 56
in C 42 56
certain C 43 56
cardiac C 44 56
and C 45 56
other C 46 56
operations C 47 56
where C 48 56
circulation C 49 56
may C 50 56
be C 51 56
interrupted C 52 56
for C 53 56
short C 54 56
periods C 55 56
. C 56 56
. C 58 56
in C 60 56
general C 61 56
surgical C 62 56
procedures C 63 56
where C 64 56
massive C 65 56
, C 66 56
sudden C 67 56
blood C 68 56
loss C 69 56
may C 70 56
be C 71 56
anticipated C 72 56
. C 73 56
. C 75 56
in C 77 56
neurosurgical C 78 56
operations C 79 56
where C 80 56
a C 81 56
/ C 82 56
relaxed C 83 56
/ C 84 56
brain C 85 56
is C 86 56
required C 87 56
. C 88 56
. C 90 56
following C 92 56
acute C 93 56
hypoxia C 94 56
such C 95 56
as C 96 56
seen C 97 56
in C 98 56
cardiac C 99 56
arrest C 100 56
. C 101 56
. C 103 56
and C 105 56
perhaps C 106 56
in C 107 56
the C 108 56
therapy C 109 56
of C 110 56
acute C 111 56
septicemic C 112 56
shock C 113 56
. C 114 56
profound C 116 56
hypothermia C 117 56
in C 118 56
association C 119 56
with C 120 56
extracorporeal C 121 56
circulation C 122 56
rests C 123 56
on C 124 56
shakier C 125 56
premises C 126 56
, C 127 56
but C 128 56
can C 129 56
be C 130 56
of C 131 56
value C 132 56
in C 133 56
major C 134 56
cardiac C 135 56
operations C 136 56
where C 137 56
asystole C 138 56
is C 139 56
required C 140 56
and C 141 56
in C 142 56
certain C 143 56
neurosurgical C 144 56
procedures C 145 56
where C 146 56
complete C 147 56
interruption C 148 56
of C 149 56
circulation C 150 56
is C 151 56
indicated C 152 56
. C 153 56
there C 155 56
is C 156 56
a C 157 56
great C 158 56
hazard C 159 56
in C 160 56
the C 161 56
development C 162 56
of C 163 56
inadvertent C 164 56
or C 165 56
unrecognized C 166 56
hypothermia C 167 56
in C 168 56
the C 169 56
anesthetized C 170 56
patient C 171 56
. C 172 56
monitoring C 174 56
of C 175 56
body C 176 56
temperature C 177 56
is C 178 56
an C 179 56
important C 180 56
feature C 181 56
of C 182 56
the C 183 56
care C 184 56
of C 185 56
the C 186 56
patient C 187 56
in C 188 56
the C 189 56
operating C 190 56
theater C 191 56
and C 192 56
in C 193 56
the C 194 56
recovery C 195 56
room C 196 56
. C 197 56
hyperglycemic C 1 57
coronary C 2 57
perfusion C 3 57
. C 4 57
. C 6 57
effect C 8 57
of C 9 57
hypothermia C 10 57
on C 11 57
myocardial C 12 57
function C 13 57
during C 14 57
cardiopulmonary C 15 57
bypass C 16 57
. C 17 57
in C 19 57
a C 20 57
series C 21 57
of C 22 57
84 C 23 57
animal C 24 57
experiments C 25 57
hyperglycemic C 26 57
perfusion C 27 57
of C 28 57
the C 29 57
heart C 30 57
gave C 31 57
significant C 32 57
protection C 33 57
to C 34 57
the C 35 57
anoxic C 36 57
heart C 37 57
. C 38 57
this C 40 57
protection C 41 57
was C 42 57
evaluated C 43 57
by C 44 57
ventricular C 45 57
function C 46 57
and C 47 57
contractile C 48 57
force C 49 57
studies C 50 57
and C 51 57
was C 52 57
observed C 53 57
after C 54 57
aortic C 55 57
occlusion C 56 57
at C 57 57
37 C 58 57
, C 59 57
28 C 60 57
and C 61 57
10 C 62 57
degrees C 63 57
c C 64 57
. C 65 57
metabolic C 67 57
data C 68 57
revealed C 69 57
a C 70 57
considerable C 71 57
myocardial C 72 57
glucose C 73 57
uptake C 74 57
, C 75 57
higher C 76 57
coronary C 77 57
ph C 78 57
, C 79 57
higher C 80 57
po C 81 57
and C 82 57
lower C 83 57
pco C 84 57
in C 85 57
the C 86 57
glucose C 87 57
- C 88 57
perfused C 89 57
groups C 90 57
as C 91 57
compared C 92 57
to C 93 57
controls C 94 57
. C 95 57
a C 97 57
hypothesis C 98 57
for C 99 57
the C 100 57
protective C 101 57
effect C 102 57
may C 103 57
be C 104 57
an C 105 57
alteration C 106 57
in C 107 57
metabolic C 108 57
pathway C 109 57
and C 110 57
support C 111 57
of C 112 57
the C 113 57
myocardial C 114 57
enzyme C 115 57
systems C 116 57
associated C 117 57
with C 118 57
high C 119 57
glucose C 120 57
concentration C 121 57
and C 122 57
utilization C 123 57
. C 124 57
specific C 1 58
carcinoembryonic C 2 58
antigens C 3 58
of C 4 58
the C 5 58
human C 6 58
digestive C 7 58
system C 8 58
. C 9 58
a C 11 58
wide C 12 58
variety C 13 58
of C 14 58
human C 15 58
adult C 16 58
and C 17 58
fetal C 18 58
tissues C 19 58
were C 20 58
studied C 21 58
by C 22 58
immunodiffusion C 23 58
techniques C 24 58
in C 25 58
agar C 26 58
gel C 27 58
to C 28 58
determine C 29 58
whether C 30 58
they C 31 58
contained C 32 58
the C 33 58
tumor C 34 58
- C 35 58
specific C 36 58
antigen C 37 58
( C 38 58
s C 39 58
) C 40 58
previously C 41 58
found C 42 58
in C 43 58
colonic C 44 58
cancers C 45 58
. C 46 58
in C 48 58
the C 49 58
adult C 50 58
tissues C 51 58
it C 52 58
was C 53 58
demonstrated C 54 58
that C 55 58
identical C 56 58
antigens C 57 58
were C 58 58
present C 59 58
in C 60 58
all C 61 58
tested C 62 58
specimens C 63 58
of C 64 58
malignant C 65 58
tumors C 66 58
of C 67 58
the C 68 58
entodermally C 69 58
derived C 70 58
epithelium C 71 58
of C 72 58
the C 73 58
gastro C 74 58
- C 75 58
intestinal C 76 58
tract C 77 58
and C 78 58
pancreas C 79 58
, C 80 58
but C 81 58
were C 82 58
absent C 83 58
from C 84 58
all C 85 58
other C 86 58
tested C 87 58
adult C 88 58
tissues C 89 58
. C 90 58
the C 92 58
common C 93 58
antigenic C 94 58
constituents C 95 58
, C 96 58
therefore C 97 58
, C 98 58
represent C 99 58
system C 100 58
- C 101 58
specific C 102 58
cancer C 103 58
antigens C 104 58
of C 105 58
the C 106 58
human C 107 58
digestive C 108 58
system C 109 58
. C 110 58
system C 112 58
- C 113 58
specific C 114 58
cancer C 115 58
antigens C 116 58
have C 117 58
not C 118 58
previously C 119 58
been C 120 58
demonstrated C 121 58
in C 122 58
humans C 123 58
. C 124 58
experiments C 126 58
with C 127 58
fetal C 128 58
tissues C 129 58
demonstrated C 130 58
that C 131 58
identical C 132 58
antigens C 133 58
were C 134 58
also C 135 58
present C 136 58
in C 137 58
fetal C 138 58
gut C 139 58
, C 140 58
liver C 141 58
, C 142 58
and C 143 58
pancreas C 144 58
between C 145 58
2 C 146 58
and C 147 58
6 C 148 58
months C 149 58
of C 150 58
gestation C 151 58
. C 152 58
these C 154 58
components C 155 58
were C 156 58
named C 157 58
/ C 158 58
carcinoembryonic C 159 58
/ C 160 58
antigens C 161 58
of C 162 58
the C 163 58
human C 164 58
digestive C 165 58
system C 166 58
. C 167 58
on C 169 58
the C 170 58
basis C 171 58
of C 172 58
the C 173 58
present C 174 58
findings C 175 58
and C 176 58
the C 177 58
recent C 178 58
work C 179 58
regarding C 180 58
control C 181 58
of C 182 58
the C 183 58
expression C 184 58
of C 185 58
genetic C 186 58
potentialities C 187 58
in C 188 58
various C 189 58
genetic C 190 58
potentialities C 191 58
in C 192 58
various C 193 58
types C 194 58
of C 195 58
cells C 196 58
, C 197 58
it C 198 58
was C 199 58
concluded C 200 58
that C 201 58
the C 202 58
carcinoembryonic C 203 58
antigens C 204 58
represent C 205 58
cellular C 206 58
constituents C 207 58
which C 208 58
are C 209 58
repressed C 210 58
during C 211 58
the C 212 58
course C 213 58
of C 214 58
differentiation C 215 58
of C 216 58
the C 217 58
normal C 218 58
digestive C 219 58
system C 220 58
epithelium C 221 58
and C 222 58
reappear C 223 58
in C 224 58
the C 225 58
corresponding C 226 58
malignant C 227 58
cells C 228 58
by C 229 58
a C 230 58
process C 231 58
of C 232 58
derepressive C 233 58
- C 234 58
dedifferentiation C 235 58
. C 236 58
the C 1 59
course C 2 59
of C 3 59
influenza C 4 59
virus C 5 59
infection C 6 59
in C 7 59
mice C 8 59
. C 9 59
. C 11 59
organ C 13 59
tissues C 14 59
of C 15 59
infected C 16 59
mice C 17 59
tested C 18 59
by C 19 59
electron C 20 59
microscope C 21 59
. C 22 59
using C 24 59
the C 25 59
electron C 26 59
microscope C 27 59
the C 28 59
presence C 29 59
of C 30 59
inclusions C 31 59
could C 32 59
be C 33 59
shown C 34 59
in C 35 59
the C 36 59
lungs C 37 59
and C 38 59
liver C 39 59
of C 40 59
mice C 41 59
infected C 42 59
with C 43 59
the C 44 59
pr C 45 59
8 C 46 59
strain C 47 59
. C 48 59
the C 50 59
inclusions C 51 59
contained C 52 59
particles C 53 59
of C 54 59
size C 55 59
and C 56 59
shape C 57 59
closely C 58 59
resembling C 59 59
the C 60 59
most C 61 59
frequently C 62 59
seen C 63 59
forms C 64 59
of C 65 59
influenza C 66 59
virus C 67 59
. C 68 59
the C 70 59
presence C 71 59
of C 72 59
inclusions C 73 59
in C 74 59
liver C 75 59
tissue C 76 59
might C 77 59
perhaps C 78 59
speak C 79 59
for C 80 59
the C 81 59
possibility C 82 59
of C 83 59
virus C 84 59
multiplication C 85 59
in C 86 59
this C 87 59
organ C 88 59
. C 89 59
comparative C 1 60
bone C 2 60
marrow C 3 60
study C 4 60
using C 5 60
two C 6 60
aspiration C 7 60
needles C 8 60
and C 9 60
two C 10 60
biopsy C 11 60
sites C 12 60
. C 13 60
bone C 15 60
marrow C 16 60
aspiration C 17 60
is C 18 60
now C 19 60
widely C 20 60
used C 21 60
in C 22 60
the C 23 60
diagnosis C 24 60
of C 25 60
hematologic C 26 60
diseases C 27 60
and C 28 60
many C 29 60
conditions C 30 60
not C 31 60
primarily C 32 60
affecting C 33 60
the C 34 60
blood C 35 60
system C 36 60
. C 37 60
a C 39 60
number C 40 60
of C 41 60
techniques C 42 60
have C 43 60
been C 44 60
devised C 45 60
by C 46 60
which C 47 60
a C 48 60
suitable C 49 60
specimen C 50 60
of C 51 60
marrow C 52 60
can C 53 60
be C 54 60
obtained C 55 60
with C 56 60
relatively C 57 60
little C 58 60
discomfort C 59 60
to C 60 60
the C 61 60
patient C 62 60
. C 63 60
the C 65 60
two C 66 60
needle C 67 60
sets C 68 60
described C 69 60
in C 70 60
this C 71 60
paper C 72 60
have C 73 60
been C 74 60
found C 75 60
to C 76 60
be C 77 60
equally C 78 60
reliable C 79 60
in C 80 60
obtaining C 81 60
bone C 82 60
marrow C 83 60
for C 84 60
microscopic C 85 60
study C 86 60
and C 87 60
diagnosis C 88 60
. C 89 60
comparative C 91 60
studies C 92 60
of C 93 60
bone C 94 60
marrow C 95 60
aspirated C 96 60
simultaneously C 97 60
from C 98 60
the C 99 60
iliac C 100 60
crest C 101 60
and C 102 60
the C 103 60
sternum C 104 60
in C 105 60
26 C 106 60
patients C 107 60
show C 108 60
no C 109 60
significant C 110 60
difference C 111 60
. C 112 60
however C 114 60
, C 115 60
there C 116 60
were C 117 60
four C 118 60
instances C 119 60
of C 120 60
dry C 121 60
tap C 122 60
at C 123 60
the C 124 60
iliac C 125 60
site C 126 60
. C 127 60
this C 129 60
fact C 130 60
, C 131 60
in C 132 60
addition C 133 60
to C 134 60
the C 135 60
observation C 136 60
that C 137 60
less C 138 60
discomfort C 139 60
was C 140 60
experienced C 141 60
by C 142 60
the C 143 60
patient C 144 60
when C 145 60
the C 146 60
sternum C 147 60
was C 148 60
used C 149 60
, C 150 60
might C 151 60
indicate C 152 60
that C 153 60
the C 154 60
sternal C 155 60
area C 156 60
is C 157 60
a C 158 60
more C 159 60
reliable C 160 60
and C 161 60
efficient C 162 60
site C 163 60
for C 164 60
obtaining C 165 60
bone C 166 60
marrow C 167 60
. C 168 60
it C 170 60
was C 171 60
also C 172 60
observed C 173 60
during C 174 60
this C 175 60
study C 176 60
that C 177 60
patients C 178 60
experienced C 179 60
less C 180 60
discomfort C 181 60
when C 182 60
the C 183 60
university C 184 60
of C 185 60
illinois C 186 60
needle C 187 60
was C 188 60
used C 189 60
. C 190 60
the C 192 60
major C 193 60
objection C 194 60
to C 195 60
the C 196 60
use C 197 60
of C 198 60
this C 199 60
needle C 200 60
is C 201 60
the C 202 60
inability C 203 60
to C 204 60
obtain C 205 60
a C 206 60
bone C 207 60
core C 208 60
for C 209 60
biopsy C 210 60
. C 211 60
cell C 1 61
populations C 2 61
in C 3 61
the C 4 61
bone C 5 61
marrow C 6 61
of C 7 61
the C 8 61
normal C 9 61
guinea C 10 61
- C 11 61
pig C 12 61
. C 13 61
quantitative C 15 61
data C 16 61
have C 17 61
been C 18 61
obtained C 19 61
for C 20 61
cell C 21 61
- C 22 61
populations C 23 61
in C 24 61
the C 25 61
bone C 26 61
marrow C 27 61
of C 28 61
the C 29 61
normal C 30 61
400 C 31 61
g C 32 61
guinea C 33 61
- C 34 61
pig C 35 61
based C 36 61
on C 37 61
a C 38 61
study C 39 61
of C 40 61
25 C 41 61
animals C 42 61
. C 43 61
there C 45 61
was C 46 61
good C 47 61
agreement C 48 61
between C 49 61
two C 50 61
independent C 51 61
groups C 52 61
of C 53 61
observations C 54 61
and C 55 61
an C 56 61
average C 57 61
of C 58 61
1880000 C 59 61
nucleated C 60 61
cells C 61 61
per C 62 61
c C 63 61
. C 64 61
mm C 66 61
. C 67 61
was C 69 61
found C 70 61
. C 71 61
of C 73 61
this C 74 61
total C 75 61
, C 76 61
27 C 77 61
were C 78 61
lymphocytes C 79 61
, C 80 61
31 C 81 61
granulocyte C 82 61
precursors C 83 61
and C 84 61
26 C 85 61
nucleated C 86 61
erythrocyte C 87 61
precursors C 88 61
. C 89 61
whole C 91 61
body C 92 61
populations C 93 61
have C 94 61
been C 95 61
computed C 96 61
and C 97 61
the C 98 61
implications C 99 61
of C 100 61
the C 101 61
findings C 102 61
discussed C 103 61
. C 104 61
pneumocystis C 1 62
carinii C 2 62
pneumonia C 3 62
. C 4 62
. C 6 62
case C 8 62
studies C 9 62
with C 10 62
electron C 11 62
microscopy C 12 62
. C 13 62
this C 15 62
paper C 16 62
deals C 17 62
with C 18 62
the C 19 62
clinicopathologic C 20 62
findings C 21 62
in C 22 62
2 C 23 62
patients C 24 62
with C 25 62
pneumocystis C 26 62
carinii C 27 62
pneumonia C 28 62
. C 29 62
the C 31 62
first C 32 62
example C 33 62
was C 34 62
in C 35 62
a C 36 62
51 C 37 62
/ C 38 62
2 C 39 62
- C 40 62
month C 41 62
- C 42 62
old C 43 62
white C 44 62
female C 45 62
infant C 46 62
without C 47 62
an C 48 62
underlying C 49 62
disease C 50 62
. C 51 62
the C 53 62
second C 54 62
occurred C 55 62
, C 56 62
in C 57 62
association C 58 62
with C 59 62
cytomegalic C 60 62
inclusion C 61 62
disease C 62 62
of C 63 62
the C 64 62
lungs C 65 62
, C 66 62
in C 67 62
a C 68 62
46 C 69 62
- C 70 62
year C 71 62
- C 72 62
old C 73 62
white C 74 62
woman C 75 62
who C 76 62
had C 77 62
received C 78 62
steroid C 79 62
therapy C 80 62
, C 81 62
cytotoxic C 82 62
agents C 83 62
, C 84 62
and C 85 62
irradiation C 86 62
to C 87 62
the C 88 62
thorax C 89 62
for C 90 62
hodgkin C 91 62
' C 92 62
s C 93 62
disease C 94 62
. C 95 62
an C 97 62
electron C 98 62
microscope C 99 62
was C 100 62
used C 101 62
for C 102 62
the C 103 62
study C 104 62
of C 105 62
the C 106 62
morphology C 107 62
of C 108 62
the C 109 62
organisms C 110 62
in C 111 62
tissue C 112 62
removed C 113 62
at C 114 62
autopsy C 115 62
. C 116 62
the C 1 63
effect C 2 63
of C 3 63
dehydroepiandrosterone C 4 63
on C 5 63
the C 6 63
dehydroxycorticosteroids C 7 63
in C 8 63
the C 9 63
plasms C 10 63
in C 11 63
various C 12 63
stages C 13 63
of C 14 63
breast C 15 63
cancer C 16 63
and C 17 63
mastopathy C 18 63
. C 19 63
the C 21 63
depressing C 22 63
effect C 23 63
of C 24 63
dehydroepiandrosterone C 25 63
on C 26 63
plasma C 27 63
corticosteroids C 28 63
is C 29 63
, C 30 63
on C 31 63
an C 32 63
average C 33 63
, C 34 63
shortened C 35 63
in C 36 63
advanced C 37 63
breast C 38 63
cancer C 39 63
( C 40 63
stage C 41 63
iv C 42 63
) C 43 63
. C 44 63
the C 46 63
lowest C 47 63
corticosteroid C 48 63
values C 49 63
have C 50 63
been C 51 63
found C 52 63
with C 53 63
the C 54 63
three C 55 63
groups C 56 63
of C 57 63
patients C 58 63
6 C 59 63
hours C 60 63
after C 61 63
infusion C 62 63
of C 63 63
dehydroepiandrosterone C 64 63
phosphate C 65 63
. C 66 63
the C 68 63
effect C 69 63
of C 70 63
dehydroepiandrosterone C 71 63
being C 72 63
, C 73 63
still C 74 63
provable C 75 63
after C 76 63
12 C 77 63
hours C 78 63
with C 79 63
the C 80 63
group C 81 63
suffering C 82 63
from C 83 63
mastopathy C 84 63
, C 85 63
the C 86 63
breast C 87 63
cancer C 88 63
group C 89 63
of C 90 63
stage C 91 63
iv C 92 63
had C 93 63
at C 94 63
this C 95 63
time C 96 63
already C 97 63
reached C 98 63
the C 99 63
level C 100 63
of C 101 63
the C 102 63
initial C 103 63
values C 104 63
. C 105 63
the C 107 63
breast C 108 63
cancer C 109 63
group C 110 63
of C 111 63
stage C 112 63
iv C 113 63
had C 114 63
at C 115 63
this C 116 63
time C 117 63
already C 118 63
reached C 119 63
the C 120 63
level C 121 63
of C 122 63
the C 123 63
initial C 124 63
values C 125 63
. C 126 63
the C 128 63
breast C 129 63
cancer C 130 63
group C 131 63
of C 132 63
stage C 133 63
i C 134 63
/ C 135 63
ii C 136 63
behaved C 137 63
intermediately C 138 63
. C 139 63
the C 141 63
less C 142 63
lasting C 143 63
effect C 144 63
of C 145 63
dehydroepiandrosterone C 146 63
is C 147 63
attributed C 148 63
to C 149 63
its C 150 63
accelerated C 151 63
transformation C 152 63
in C 153 63
advanced C 154 63
breast C 155 63
cancer C 156 63
. C 157 63
the C 1 64
meaning C 2 64
of C 3 64
ph C 4 64
at C 5 64
low C 6 64
temperatures C 7 64
during C 8 64
extra C 9 64
- C 10 64
corporeal C 11 64
circulation C 12 64
a C 13 64
review C 14 64
of C 15 64
the C 16 64
temperature C 17 64
gradients C 18 64
occurring C 19 64
during C 20 64
profound C 21 64
hypothermia C 22 64
is C 23 64
made C 24 64
in C 25 64
regard C 26 64
to C 27 64
acid C 28 64
base C 29 64
changes C 30 64
in C 31 64
general C 32 64
, C 33 64
and C 34 64
to C 35 64
ph C 36 64
readings C 37 64
in C 38 64
particular C 39 64
. C 40 64
it C 42 64
is C 43 64
concluded C 44 64
that C 45 64
terms C 46 64
such C 47 64
as C 48 64
' C 49 64
body C 50 64
' C 51 64
, C 52 64
' C 53 64
mean C 54 64
' C 55 64
, C 56 64
' C 57 64
average C 58 64
' C 59 64
and C 60 64
' C 61 64
core C 62 64
' C 63 64
temperature C 64 64
should C 65 64
be C 66 64
discarded C 67 64
and C 68 64
that C 69 64
when C 70 64
a C 71 64
temperature C 72 64
is C 73 64
quoted C 74 64
it C 75 64
should C 76 64
be C 77 64
referred C 78 64
to C 79 64
the C 80 64
site C 81 64
at C 82 64
which C 83 64
it C 84 64
was C 85 64
measured C 86 64
. C 87 64
the C 89 64
main C 90 64
circumstances C 91 64
in C 92 64
which C 93 64
blood C 94 64
ph C 95 64
is C 96 64
measured C 97 64
at C 98 64
a C 99 64
temperature C 100 64
different C 101 64
from C 102 64
that C 103 64
at C 104 64
which C 105 64
the C 106 64
blood C 107 64
is C 108 64
equilibrated C 109 64
with C 110 64
respiratory C 111 64
gases C 112 64
are C 113 64
reviewed C 114 64
by C 115 64
describing C 116 64
the C 117 64
changes C 118 64
which C 119 64
occur C 120 64
during C 121 64
tonometry C 122 64
experiments C 123 64
. C 124 64
in C 126 64
this C 127 64
way C 128 64
fundamental C 129 64
changes C 130 64
can C 131 64
be C 132 64
understood C 133 64
before C 134 64
considering C 135 64
the C 136 64
more C 137 64
complicated C 138 64
sequences C 139 64
of C 140 64
events C 141 64
taking C 142 64
place C 143 64
in C 144 64
the C 145 64
living C 146 64
body C 147 64
. C 148 64
the C 150 64
alterations C 151 64
that C 152 64
occur C 153 64
in C 154 64
the C 155 64
concentrations C 156 64
of C 157 64
protein C 158 64
and C 159 64
bicarbonate C 160 64
ion C 161 64
when C 162 64
whole C 163 64
blood C 164 64
is C 165 64
cooled C 166 64
are C 167 64
reviewed C 168 64
, C 169 64
together C 170 64
with C 171 64
their C 172 64
influence C 173 64
on C 174 64
' C 175 64
correction C 176 64
factors C 177 64
' C 178 64
. C 179 64
the C 181 64
reasons C 182 64
why C 183 64
these C 184 64
factors C 185 64
should C 186 64
not C 187 64
be C 188 64
applied C 189 64
to C 190 64
blood C 191 64
when C 192 64
the C 193 64
living C 194 64
body C 195 64
is C 196 64
undergoing C 197 64
hypothermia C 198 64
involving C 199 64
the C 200 64
use C 201 64
of C 202 64
an C 203 64
extra C 204 64
- C 205 64
corporeal C 206 64
circulation C 207 64
are C 208 64
discussed C 209 64
. C 210 64
examples C 212 64
of C 213 64
the C 214 64
numerical C 215 64
values C 216 64
for C 217 64
blood C 218 64
ph C 219 64
during C 220 64
the C 221 64
two C 222 64
main C 223 64
methods C 224 64
for C 225 64
producing C 226 64
profound C 227 64
hypothermia C 228 64
, C 229 64
one C 230 64
using C 231 64
autogenous C 232 64
lung C 233 64
perfusion C 234 64
and C 235 64
the C 236 64
other C 237 64
a C 238 64
pump C 239 64
- C 240 64
oxygenator C 241 64
are C 242 64
given C 243 64
, C 244 64
with C 245 64
reference C 246 64
to C 247 64
the C 248 64
influence C 249 64
of C 250 64
pco C 251 64
2 C 252 64
upon C 253 64
these C 254 64
values C 255 64
. C 256 64
the C 258 64
existing C 259 64
methods C 260 64
of C 261 64
acid C 262 64
- C 263 64
base C 264 64
measurement C 265 64
appear C 266 64
to C 267 64
be C 268 64
sufficiently C 269 64
accurate C 270 64
to C 271 64
reflect C 272 64
the C 273 64
metabolic C 274 64
component C 275 64
during C 276 64
profound C 277 64
hypothermia C 278 64
. C 279 64
induced C 1 65
tumour C 2 65
resistance C 3 65
in C 4 65
rats C 5 65
. C 6 65
the C 8 65
human C 9 65
sarcoma C 10 65
hs C 11 65
has C 12 65
been C 13 65
grown C 14 65
in C 15 65
weanling C 16 65
rats C 17 65
treated C 18 65
with C 19 65
cortisone C 20 65
. C 21 65
this C 23 65
growth C 24 65
was C 25 65
modified C 26 65
by C 27 65
prior C 28 65
injection C 29 65
of C 30 65
various C 31 65
tissue C 32 65
antigens C 33 65
. C 34 65
active C 36 65
/ C 37 65
immunity C 38 65
/ C 39 65
was C 40 65
produced C 41 65
by C 42 65
using C 43 65
human C 44 65
placenta C 45 65
or C 46 65
embryonic C 47 65
tissue C 48 65
as C 49 65
antigen C 50 65
, C 51 65
and C 52 65
similar C 53 65
results C 54 65
were C 55 65
obtained C 56 65
using C 57 65
suspensions C 58 65
of C 59 65
rapidly C 60 65
growing C 61 65
human C 62 65
tumours C 63 65
. C 64 65
the C 66 65
response C 67 65
to C 68 65
other C 69 65
human C 70 65
tissues C 71 65
varied C 72 65
. C 73 65
. C 75 65
foetal C 77 65
muscle C 78 65
and C 79 65
spleen C 80 65
were C 81 65
active C 82 65
, C 83 65
whereas C 84 65
adult C 85 65
plasma C 86 65
was C 87 65
inactive C 88 65
except C 89 65
from C 90 65
some C 91 65
patients C 92 65
with C 93 65
extensive C 94 65
malignant C 95 65
disease C 96 65
. C 97 65
passive C 99 65
protection C 100 65
was C 101 65
produced C 102 65
by C 103 65
using C 104 65
certain C 105 65
human C 106 65
sera C 107 65
at C 108 65
the C 109 65
time C 110 65
of C 111 65
challenging C 112 65
with C 113 65
hs C 114 65
. C 115 65
sera C 117 65
from C 118 65
five C 119 65
women C 120 65
who C 121 65
aborted C 122 65
showed C 123 65
this C 124 65
characteristic C 125 65
. C 126 65
where C 128 65
the C 129 65
pregnancy C 130 65
continued C 131 65
to C 132 65
term C 133 65
, C 134 65
antisubstances C 135 65
were C 136 65
not C 137 65
found C 138 65
, C 139 65
. C 140 65
and C 142 65
they C 143 65
were C 144 65
present C 145 65
in C 146 65
the C 147 65
puerperium C 148 65
in C 149 65
only C 150 65
two C 151 65
out C 152 65
of C 153 65
fifty C 154 65
cases C 155 65
. C 156 65
further C 158 65
groups C 159 65
of C 160 65
rats C 161 65
were C 162 65
given C 163 65
rat C 164 65
embryonic C 165 65
tissues C 166 65
as C 167 65
antigen C 168 65
, C 169 65
and C 170 65
the C 171 65
tumour C 172 65
challenge C 173 65
was C 174 65
then C 175 65
made C 176 65
with C 177 65
walker C 178 65
tumour C 179 65
, C 180 65
. C 181 65
the C 183 65
results C 184 65
were C 185 65
variable C 186 65
. C 187 65
with C 189 65
a C 190 65
benzpyrene C 191 65
- C 192 65
induced C 193 65
tumour C 194 65
in C 195 65
a C 196 65
pure C 197 65
line C 198 65
of C 199 65
/ C 200 65
wag C 201 65
/ C 202 65
rat C 203 65
the C 204 65
effect C 205 65
was C 206 65
not C 207 65
obtained C 208 65
except C 209 65
in C 210 65
isolated C 211 65
cases C 212 65
. C 213 65
in C 215 65
experiments C 216 65
in C 217 65
mice C 218 65
, C 219 65
using C 220 65
as C 221 65
challenge C 222 65
an C 223 65
irondextran C 224 65
induced C 225 65
mouse C 226 65
sarcoma C 227 65
, C 228 65
prior C 229 65
injection C 230 65
with C 231 65
embryonic C 232 65
mouse C 233 65
liver C 234 65
or C 235 65
placenta C 236 65
increased C 237 65
the C 238 65
resistance C 239 65
to C 240 65
the C 241 65
growth C 242 65
of C 243 65
the C 244 65
tumour C 245 65
, C 246 65
but C 247 65
the C 248 65
tumour C 249 65
has C 250 65
not C 251 65
as C 252 65
yet C 253 65
been C 254 65
produced C 255 65
in C 256 65
a C 257 65
pure C 258 65
- C 259 65
line C 260 65
mouse C 261 65
. C 262 65
on C 264 65
the C 265 65
other C 266 65
hand C 267 65
mouse C 268 65
experiments C 269 65
, C 270 65
using C 271 65
as C 272 65
challenge C 273 65
the C 274 65
crocker C 275 65
tumour C 276 65
, C 277 65
proved C 278 65
negative C 279 65
. C 280 65
it C 282 65
is C 283 65
suggested C 284 65
that C 285 65
immune C 286 65
reactions C 287 65
may C 288 65
play C 289 65
a C 290 65
part C 291 65
in C 292 65
causing C 293 65
some C 294 65
abortions C 295 65
. C 296 65
urinary C 1 66
steroid C 2 66
estimations C 3 66
in C 4 66
the C 5 66
prediction C 6 66
of C 7 66
response C 8 66
to C 9 66
adrenalectomy C 10 66
or C 11 66
hypophysectomy C 12 66
. C 13 66
a C 15 66
clinical C 16 66
trial C 17 66
has C 18 66
been C 19 66
carried C 20 66
out C 21 66
to C 22 66
test C 23 66
the C 24 66
use C 25 66
of C 26 66
the C 27 66
discriminant C 28 66
in C 29 66
assessing C 30 66
the C 31 66
suitability C 32 66
of C 33 66
patients C 34 66
with C 35 66
advanced C 36 66
breast C 37 66
cancer C 38 66
for C 39 66
hypophysectomy C 40 66
or C 41 66
adrenalectomy C 42 66
. C 43 66
patients C 45 66
with C 46 66
positive C 47 66
discriminants C 48 66
submitted C 49 66
to C 50 66
hypophysectomy C 51 66
have C 52 66
a C 53 66
much C 54 66
better C 55 66
prognosis C 56 66
than C 57 66
patients C 58 66
with C 59 66
negative C 60 66
discriminants C 61 66
submitted C 62 66
to C 63 66
adrenalectomy C 64 66
. C 65 66
patients C 67 66
selected C 68 66
for C 69 66
adrenalectomy C 70 66
because C 71 66
of C 72 66
negative C 73 66
discriminants C 74 66
have C 75 66
a C 76 66
significantly C 77 66
worse C 78 66
response C 79 66
to C 80 66
the C 81 66
operation C 82 66
than C 83 66
patients C 84 66
selected C 85 66
by C 86 66
random C 87 66
sample C 88 66
. C 89 66
patients C 91 66
selected C 92 66
for C 93 66
hypophysectomy C 94 66
because C 95 66
of C 96 66
positive C 97 66
discriminants C 98 66
tend C 99 66
to C 100 66
have C 101 66
a C 102 66
better C 103 66
response C 104 66
to C 105 66
the C 106 66
operation C 107 66
than C 108 66
do C 109 66
patients C 110 66
selected C 111 66
by C 112 66
random C 113 66
sample C 114 66
, C 115 66
but C 116 66
the C 117 66
difference C 118 66
is C 119 66
not C 120 66
significant C 121 66
. C 122 66
adrenalectomy C 124 66
is C 125 66
not C 126 66
recommended C 127 66
for C 128 66
patients C 129 66
with C 130 66
negative C 131 66
discriminants C 132 66
. C 133 66
primary C 1 67
epidermoid C 2 67
cancer C 3 67
of C 4 67
the C 5 67
lung C 6 67
. C 7 67
. C 9 67
ultrastructural C 11 67
study C 12 67
. C 13 67
the C 15 67
early C 16 67
epidermoidic C 17 67
epithelioma C 18 67
of C 19 67
the C 20 67
human C 21 67
lung C 22 67
are C 23 67
initiated C 24 67
by C 25 67
the C 26 67
proliferation C 27 67
of C 28 67
body C 29 67
cells C 30 67
whose C 31 67
structure C 32 67
is C 33 67
analogical C 34 67
to C 35 67
that C 36 67
of C 37 67
the C 38 67
medium C 39 67
cells C 40 67
and C 41 67
/ C 42 67
or C 43 67
the C 44 67
modificated C 45 67
basal C 46 67
cells C 47 67
of C 48 67
the C 49 67
normal C 50 67
bronchial C 51 67
wall C 52 67
. C 53 67
the C 55 67
presence C 56 67
of C 57 67
desmosomes C 58 67
and C 59 67
tonofibrils C 60 67
in C 61 67
the C 62 67
cells C 63 67
of C 64 67
the C 65 67
stratum C 66 67
germinativum C 67 67
of C 68 67
the C 69 67
bronchial C 70 67
epithelium C 71 67
and C 72 67
in C 73 67
the C 74 67
cells C 75 67
derived C 76 67
from C 77 67
it C 78 67
, C 79 67
allows C 80 67
us C 81 67
a C 82 67
better C 83 67
understanding C 84 67
of C 85 67
the C 86 67
malpighian C 87 67
metaplasis C 88 67
of C 89 67
this C 90 67
wall C 91 67
and C 92 67
gives C 93 67
account C 94 67
of C 95 67
the C 96 67
epidermoidic C 97 67
evolution C 98 67
of C 99 67
the C 100 67
bronchial C 101 67
epithelioma C 102 67
. C 103 67
certain C 105 67
nuclear C 106 67
and C 107 67
cytoplasmic C 108 67
modifications C 109 67
suggest C 110 67
the C 111 67
possibility C 112 67
of C 113 67
a C 114 67
causal C 115 67
virus C 116 67
. C 117 67
biosynthesis C 1 68
of C 2 68
glycoproteins C 3 68
i C 4 68
. C 5 68
incorporation C 7 68
of C 8 68
glucosamine C 9 68
- C 10 68
c C 11 68
into C 12 68
liver C 13 68
and C 14 68
plasma C 15 68
proteins C 16 68
of C 17 68
the C 18 68
rat C 19 68
. C 20 68
it C 22 68
has C 23 68
been C 24 68
shown C 25 68
that C 26 68
glucosamine C 27 68
- C 28 68
1 C 29 68
- C 30 68
c C 31 68
administered C 32 68
intravenously C 33 68
to C 34 68
fed C 35 68
rats C 36 68
is C 37 68
rapidly C 38 68
removed C 39 68
from C 40 68
the C 41 68
blood C 42 68
stream C 43 68
and C 44 68
appears C 45 68
first C 46 68
as C 47 68
trichloroacetic C 48 68
acid C 49 68
- C 50 68
soluble C 51 68
derivatives C 52 68
in C 53 68
the C 54 68
tissues C 55 68
. C 56 68
this C 58 68
is C 59 68
followed C 60 68
by C 61 68
a C 62 68
conversion C 63 68
to C 64 68
macromolecules C 65 68
. C 66 68
at C 68 68
least C 69 68
80 C 70 68
of C 71 68
the C 72 68
administered C 73 68
compound C 74 68
can C 75 68
be C 76 68
recovered C 77 68
in C 78 68
tissues C 79 68
. C 80 68
the C 82 68
liver C 83 68
is C 84 68
by C 85 68
far C 86 68
the C 87 68
most C 88 68
active C 89 68
organ C 90 68
in C 91 68
accumulating C 92 68
glucosamine C 93 68
. C 94 68
this C 96 68
is C 97 68
rapidly C 98 68
converted C 99 68
to C 100 68
protein C 101 68
- C 102 68
bound C 103 68
components C 104 68
of C 105 68
the C 106 68
liver C 107 68
particulate C 108 68
fraction C 109 68
( C 110 68
microsomes C 111 68
and C 112 68
mitochondria C 113 68
) C 114 68
and C 115 68
is C 116 68
then C 117 68
released C 118 68
to C 119 68
the C 120 68
plasma C 121 68
without C 122 68
appreciable C 123 68
accumulation C 124 68
in C 125 68
the C 126 68
soluble C 127 68
proteins C 128 68
of C 129 68
the C 130 68
liver C 131 68
. C 132 68
it C 134 68
is C 135 68
concluded C 136 68
that C 137 68
the C 138 68
glucosamine C 139 68
is C 140 68
transferred C 141 68
to C 142 68
the C 143 68
peptide C 144 68
chains C 145 68
of C 146 68
glycoproteins C 147 68
at C 148 68
some C 149 68
stage C 150 68
before C 151 68
these C 152 68
proteins C 153 68
are C 154 68
released C 155 68
from C 156 68
the C 157 68
liver C 158 68
particulate C 159 68
fraction C 160 68
. C 161 68
acute C 1 69
experimental C 2 69
pneumococcal C 3 69
( C 4 69
type C 5 69
i C 6 69
) C 7 69
pneumonia C 8 69
in C 9 69
the C 10 69
mouse C 11 69
. C 12 69
. C 14 69
the C 16 69
migration C 17 69
of C 18 69
leucocytes C 19 69
from C 20 69
the C 21 69
pulmonary C 22 69
capillaries C 23 69
into C 24 69
the C 25 69
alveolar C 26 69
spaces C 27 69
as C 28 69
revealed C 29 69
by C 30 69
the C 31 69
electron C 32 69
microscope C 33 69
. C 34 69
in C 36 69
this C 37 69
preliminary C 38 69
study C 39 69
of C 40 69
experimental C 41 69
pneumococcal C 42 69
pulmonary C 43 69
pneumonia C 44 69
in C 45 69
the C 46 69
mouse C 47 69
the C 48 69
leucocytes C 49 69
were C 50 69
observed C 51 69
to C 52 69
pass C 53 69
from C 54 69
the C 55 69
capillaries C 56 69
into C 57 69
the C 58 69
interstitial C 59 69
tissue C 60 69
and C 61 69
eventually C 62 69
into C 63 69
the C 64 69
alveolar C 65 69
spaces C 66 69
through C 67 69
the C 68 69
intercellular C 69 69
junctions C 70 69
of C 71 69
the C 72 69
endothelial C 73 69
and C 74 69
epithelial C 75 69
cell C 76 69
membranes C 77 69
. C 78 69
a C 1 70
light C 2 70
and C 3 70
electron C 4 70
microscope C 5 70
study C 6 70
of C 7 70
developing C 8 70
respiratory C 9 70
tissue C 10 70
in C 11 70
the C 12 70
rat C 13 70
. C 14 70
1 C 16 70
. C 17 70
light C 19 70
microscopic C 20 70
observations C 21 70
on C 22 70
the C 23 70
development C 24 70
of C 25 70
the C 26 70
rat C 27 70
lung C 28 70
have C 29 70
shown C 30 70
the C 31 70
presence C 32 70
of C 33 70
glandular C 34 70
, C 35 70
canalicular C 36 70
and C 37 70
alveolar C 38 70
stages C 39 70
. C 40 70
2 C 42 70
. C 43 70
these C 45 70
same C 46 70
three C 47 70
stages C 48 70
can C 49 70
be C 50 70
identified C 51 70
by C 52 70
electron C 53 70
microscopy C 54 70
and C 55 70
all C 56 70
may C 57 70
be C 58 70
present C 59 70
in C 60 70
different C 61 70
parts C 62 70
of C 63 70
the C 64 70
lung C 65 70
at C 66 70
one C 67 70
time C 68 70
, C 69 70
e C 70 70
. C 71 70
. C 72 70
. C 73 70
at C 75 70
40 C 76 70
and C 77 70
45 C 78 70
mm C 79 70
. C 80 70
c C 82 70
. C 83 70
. C 84 70
. C 85 70
length C 87 70
. C 88 70
3 C 90 70
. C 91 70
in C 93 70
the C 94 70
glandular C 95 70
stage C 96 70
, C 97 70
the C 98 70
lung C 99 70
tissue C 100 70
itself C 101 70
has C 102 70
an C 103 70
immature C 104 70
appearance C 105 70
by C 106 70
light C 107 70
microscopy C 108 70
and C 109 70
by C 110 70
electron C 111 70
microscopy C 112 70
individual C 113 70
cells C 114 70
also C 115 70
are C 116 70
immature C 117 70
in C 118 70
respect C 119 70
of C 120 70
organelles C 121 70
. C 122 70
glycogen C 124 70
is C 125 70
present C 126 70
in C 127 70
immature C 128 70
cells C 129 70
. C 130 70
4 C 132 70
. C 133 70
during C 135 70
the C 136 70
canalicular C 137 70
stage C 138 70
, C 139 70
lung C 140 70
tissue C 141 70
becomes C 142 70
more C 143 70
vascular C 144 70
. C 145 70
5 C 147 70
. C 148 70
throughout C 150 70
all C 151 70
stages C 152 70
of C 153 70
development C 154 70
, C 155 70
the C 156 70
' C 157 70
duct C 158 70
' C 159 70
or C 160 70
' C 161 70
air C 162 70
' C 163 70
spaces C 164 70
are C 165 70
always C 166 70
lined C 167 70
by C 168 70
a C 169 70
continuous C 170 70
and C 171 70
complete C 172 70
epithelium C 173 70
, C 174 70
and C 175 70
blood C 176 70
vessels C 177 70
by C 178 70
a C 179 70
complete C 180 70
endothelium C 181 70
. C 182 70
6 C 184 70
. C 185 70
lamellated C 187 70
inclusion C 188 70
bodies C 189 70
are C 190 70
present C 191 70
in C 192 70
epithelial C 193 70
( C 194 70
endodermal C 195 70
) C 196 70
cells C 197 70
at C 198 70
an C 199 70
early C 200 70
stage C 201 70
of C 202 70
development C 203 70
. C 204 70
7 C 206 70
. C 207 70
micropinocytotic C 209 70
vesicles C 210 70
are C 211 70
present C 212 70
in C 213 70
large C 214 70
numbers C 215 70
in C 216 70
both C 217 70
epithelial C 218 70
and C 219 70
endothelial C 220 70
cytoplasm C 221 70
and C 222 70
it C 223 70
is C 224 70
suggested C 225 70
that C 226 70
in C 227 70
the C 228 70
foetus C 229 70
they C 230 70
may C 231 70
indicate C 232 70
absorption C 233 70
of C 234 70
amniotic C 235 70
fluid C 236 70
from C 237 70
alveolar C 238 70
spaces C 239 70
. C 240 70
8 C 242 70
. C 243 70
the C 245 70
mechanism C 246 70
of C 247 70
alveolar C 248 70
distension C 249 70
is C 250 70
discussed C 251 70
and C 252 70
its C 253 70
nature C 254 70
remains C 255 70
uncertain C 256 70
. C 257 70
9 C 259 70
. C 260 70
respiratory C 262 70
tissue C 263 70
of C 264 70
the C 265 70
rat C 266 70
is C 267 70
not C 268 70
fully C 269 70
differentiated C 270 70
at C 271 70
birth C 272 70
and C 273 70
the C 274 70
importance C 275 70
of C 276 70
this C 277 70
fact C 278 70
in C 279 70
human C 280 70
infants C 281 70
is C 282 70
discussed C 283 70
. C 284 70
10 C 286 70
. C 287 70
the C 289 70
adult C 290 70
blood C 291 70
- C 292 70
air C 293 70
barrier C 294 70
, C 295 70
consisting C 296 70
of C 297 70
epithelium C 298 70
, C 299 70
zona C 300 70
diffusa C 301 70
and C 302 70
endothelium C 303 70
, C 304 70
varies C 305 70
in C 306 70
thickness C 307 70
. C 308 70
this C 310 70
project C 311 70
was C 312 70
performed C 313 70
whilst C 314 70
both C 315 70
of C 316 70
us C 317 70
were C 318 70
in C 319 70
receipt C 320 70
of C 321 70
grants C 322 70
from C 323 70
the C 324 70
medical C 325 70
research C 326 70
council C 327 70
of C 328 70
canada C 329 70
, C 330 70
for C 331 70
which C 332 70
gratitude C 333 70
is C 334 70
expressed C 335 70
. C 336 70
our C 338 70
gratitude C 339 70
is C 340 70
also C 341 70
expressed C 342 70
to C 343 70
miss C 344 70
sylvia C 345 70
smith C 346 70
for C 347 70
typing C 348 70
the C 349 70
manuscript C 350 70
. C 351 70
the C 1 71
pathogenesis C 2 71
of C 3 71
viral C 4 71
influenzal C 5 71
pneumonia C 6 71
in C 7 71
mice C 8 71
. C 9 71
the C 11 71
pathogenesis C 12 71
of C 13 71
influenzal C 14 71
pneumonia C 15 71
in C 16 71
mice C 17 71
was C 18 71
studied C 19 71
by C 20 71
electron C 21 71
microscopy C 22 71
. C 23 71
mice C 25 71
were C 26 71
inoculated C 27 71
with C 28 71
1 C 29 71
. C 30 71
. C 31 71
ld C 32 71
of C 33 71
pr C 34 71
8 C 35 71
influenza C 36 71
virus C 37 71
and C 38 71
killed C 39 71
at C 40 71
varying C 41 71
intervals C 42 71
after C 43 71
inoculation C 44 71
. C 45 71
observations C 47 71
by C 48 71
light C 49 71
microscopy C 50 71
were C 51 71
correlated C 52 71
with C 53 71
those C 54 71
by C 55 71
electron C 56 71
microscopy C 57 71
in C 58 71
order C 59 71
to C 60 71
evaluate C 61 71
the C 62 71
lesions C 63 71
produced C 64 71
. C 65 71
at C 67 71
the C 68 71
periphery C 69 71
, C 70 71
the C 71 71
earliest C 72 71
lesions C 73 71
were C 74 71
focal C 75 71
areas C 76 71
of C 77 71
edema C 78 71
of C 79 71
alveolar C 80 71
lining C 81 71
cells C 82 71
, C 83 71
the C 84 71
capillary C 85 71
endothelium C 86 71
and C 87 71
the C 88 71
interposed C 89 71
basement C 90 71
membrane C 91 71
. C 92 71
this C 94 71
caused C 95 71
an C 96 71
appreciable C 97 71
thickening C 98 71
of C 99 71
the C 100 71
blood C 101 71
- C 102 71
air C 103 71
pathway C 104 71
. C 105 71
hypertrophy C 107 71
, C 108 71
degeneration C 109 71
and C 110 71
desquamation C 111 71
of C 112 71
the C 113 71
alveolar C 114 71
lining C 115 71
and C 116 71
proliferation C 117 71
of C 118 71
alveolar C 119 71
macrophages C 120 71
resulted C 121 71
in C 122 71
complete C 123 71
consolidation C 124 71
, C 125 71
which C 126 71
was C 127 71
progressive C 128 71
up C 129 71
to C 130 71
1 C 131 71
week C 132 71
after C 133 71
infection C 134 71
. C 135 71
the C 137 71
central C 138 71
areas C 139 71
of C 140 71
the C 141 71
lung C 142 71
were C 143 71
affected C 144 71
somewhat C 145 71
differently C 146 71
. C 147 71
at C 149 71
3 C 150 71
days C 151 71
after C 152 71
infection C 153 71
, C 154 71
the C 155 71
nonciliated C 156 71
bronchiolar C 157 71
cells C 158 71
showed C 159 71
considerable C 160 71
hyperplasia C 161 71
of C 162 71
endoplasmic C 163 71
reticulum C 164 71
and C 165 71
apical C 166 71
cytoplasmic C 167 71
edema C 168 71
. C 169 71
viral C 171 71
particles C 172 71
matured C 173 71
at C 174 71
the C 175 71
lumen C 176 71
surface C 177 71
of C 178 71
these C 179 71
cells C 180 71
and C 181 71
were C 182 71
then C 183 71
released C 184 71
into C 185 71
the C 186 71
bronchiolar C 187 71
lumen C 188 71
. C 189 71
the C 191 71
bronchiolar C 192 71
cells C 193 71
, C 194 71
both C 195 71
ciliated C 196 71
and C 197 71
nonciliated C 198 71
, C 199 71
underwent C 200 71
degeneration C 201 71
and C 202 71
sloughed C 203 71
into C 204 71
the C 205 71
bronchiolar C 206 71
lumen C 207 71
. C 208 71
the C 210 71
regenerating C 211 71
epithelium C 212 71
was C 213 71
stratified C 214 71
, C 215 71
and C 216 71
the C 217 71
surface C 218 71
cells C 219 71
were C 220 71
elongated C 221 71
and C 222 71
flattened C 223 71
. C 224 71
the C 226 71
peribronchiolar C 227 71
interstitial C 228 71
tissue C 229 71
gradually C 230 71
became C 231 71
totally C 232 71
infiltrated C 233 71
by C 234 71
cells C 235 71
, C 236 71
mostly C 237 71
of C 238 71
the C 239 71
mononuclear C 240 71
type C 241 71
. C 242 71
studies C 1 72
on C 2 72
aging C 3 72
with C 4 72
horse C 5 72
crystalline C 6 72
lens C 7 72
gel C 8 72
as C 9 72
a C 10 72
contribution C 11 72
to C 12 72
biomorphosis C 13 72
of C 14 72
the C 15 72
mammalian C 16 72
crystalline C 17 72
lens C 18 72
. C 19 72
the C 21 72
effects C 22 72
of C 23 72
biomorphosis C 24 72
- C 25 72
dash C 26 72
the C 27 72
continuous C 28 72
material C 29 72
change C 30 72
in C 31 72
the C 32 72
chemical C 33 72
composition C 34 72
of C 35 72
the C 36 72
organs C 37 72
and C 38 72
tissues C 39 72
- C 40 72
dash C 41 72
are C 42 72
studied C 43 72
on C 44 72
the C 45 72
horse C 46 72
crystalline C 47 72
lens C 48 72
in C 49 72
respect C 50 72
of C 51 72
its C 52 72
amino C 53 72
acid C 54 72
content C 55 72
subject C 56 72
to C 57 72
substantial C 58 72
variations C 59 72
in C 60 72
the C 61 72
course C 62 72
of C 63 72
life C 64 72
. C 65 72
it C 67 72
is C 68 72
shown C 69 72
by C 70 72
electrophoretic C 71 72
and C 72 72
paperchromatographic C 73 72
methods C 74 72
that C 75 72
the C 76 72
qualitative C 77 72
composition C 78 72
of C 79 72
horse C 80 72
crystalline C 81 72
lenses C 82 72
remains C 83 72
quite C 84 72
the C 85 72
same C 86 72
, C 87 72
but C 88 72
that C 89 72
within C 90 72
the C 91 72
individual C 92 72
age C 93 72
stages C 94 72
there C 95 72
occur C 96 72
quantitative C 97 72
variations C 98 72
between C 99 72
the C 100 72
individual C 101 72
amino C 102 72
acids C 103 72
. C 104 72
the C 1 73
role C 2 73
of C 3 73
alveolar C 4 73
inclusion C 5 73
bodies C 6 73
in C 7 73
the C 8 73
developing C 9 73
lung C 10 73
. C 11 73
the C 13 73
developing C 14 73
alveolar C 15 73
epithelium C 16 73
of C 17 73
man C 18 73
and C 19 73
rat C 20 73
contains C 21 73
characteristic C 22 73
inclusion C 23 73
bodies C 24 73
which C 25 73
are C 26 73
heterogeneous C 27 73
structures C 28 73
but C 29 73
basically C 30 73
consist C 31 73
of C 32 73
a C 33 73
system C 34 73
of C 35 73
membranous C 36 73
profiles C 37 73
and C 38 73
a C 39 73
limiting C 40 73
membrane C 41 73
of C 42 73
the C 43 73
unit C 44 73
type C 45 73
. C 46 73
inclusion C 48 73
bodies C 49 73
appear C 50 73
to C 51 73
result C 52 73
from C 53 73
focal C 54 73
cytoplasmic C 55 73
degradation C 56 73
which C 57 73
occurs C 58 73
in C 59 73
the C 60 73
rapidly C 61 73
changing C 62 73
cuboidal C 63 73
alveolar C 64 73
epithelium C 65 73
. C 66 73
some C 68 73
inclusion C 69 73
bodies C 70 73
in C 71 73
the C 72 73
developing C 73 73
rat C 74 73
lung C 75 73
are C 76 73
similar C 77 73
to C 78 73
the C 79 73
so C 80 73
- C 81 73
called C 82 73
/ C 83 73
lamellar C 84 73
transformed C 85 73
mitochondria C 86 73
. C 87 73
/ C 89 73
however C 90 73
, C 91 73
evidence C 92 73
is C 93 73
presented C 94 73
suggesting C 95 73
that C 96 73
alteration C 97 73
of C 98 73
all C 99 73
cytoplasmic C 100 73
membranes C 101 73
may C 102 73
be C 103 73
involved C 104 73
in C 105 73
the C 106 73
process C 107 73
of C 108 73
inclusion C 109 73
body C 110 73
formation C 111 73
. C 112 73
certain C 114 73
images C 115 73
associated C 116 73
with C 117 73
the C 118 73
golgi C 119 73
complex C 120 73
are C 121 73
interpreted C 122 73
as C 123 73
early C 124 73
forms C 125 73
of C 126 73
inclusion C 127 73
bodies C 128 73
. C 129 73
there C 131 73
is C 132 73
also C 133 73
evidence C 134 73
that C 135 73
inclusion C 136 73
bodies C 137 73
enlarge C 138 73
by C 139 73
accretion C 140 73
of C 141 73
membranes C 142 73
which C 143 73
finally C 144 73
are C 145 73
extruded C 146 73
into C 147 73
the C 148 73
alveolar C 149 73
space C 150 73
. C 151 73
inclusion C 153 73
bodies C 154 73
are C 155 73
formed C 156 73
and C 157 73
/ C 158 73
secreted C 159 73
/ C 160 73
in C 161 73
greater C 162 73
number C 163 73
late C 164 73
in C 165 73
fetal C 166 73
life C 167 73
and C 168 73
in C 169 73
early C 170 73
infancy C 171 73
, C 172 73
i C 173 73
. C 174 73
. C 175 73
. C 176 73
, C 178 73
at C 179 73
the C 180 73
time C 181 73
when C 182 73
the C 183 73
cuboidal C 184 73
alveolar C 185 73
epithelium C 186 73
is C 187 73
differentiating C 188 73
to C 189 73
the C 190 73
mature C 191 73
flattened C 192 73
type C 193 73
. C 194 73
the C 196 73
latter C 197 73
contains C 198 73
no C 199 73
inclusion C 200 73
bodies C 201 73
. C 202 73
on C 204 73
the C 205 73
basis C 206 73
of C 207 73
the C 208 73
morphologic C 209 73
characteristics C 210 73
of C 211 73
the C 212 73
inclusion C 213 73
bodies C 214 73
and C 215 73
the C 216 73
distribution C 217 73
of C 218 73
the C 219 73
acid C 220 73
phosphatase C 221 73
reaction C 222 73
, C 223 73
it C 224 73
is C 225 73
concluded C 226 73
that C 227 73
inclusion C 228 73
bodies C 229 73
are C 230 73
lysosomal C 231 73
structures C 232 73
active C 233 73
during C 234 73
remodeling C 235 73
of C 236 73
the C 237 73
developing C 238 73
alveolar C 239 73
epithelium C 240 73
. C 241 73
the C 243 73
possible C 244 73
interrelationship C 245 73
of C 246 73
inclusion C 247 73
bodies C 248 73
and C 249 73
pulmonary C 250 73
surfactant C 251 73
is C 252 73
discussed C 253 73
. C 254 73
retinal C 1 74
detachment C 2 74
, C 3 74
cataract C 4 74
, C 5 74
keratoconus C 6 74
as C 7 74
ocular C 8 74
symptom C 9 74
complex C 10 74
in C 11 74
endogenous C 12 74
eczema C 13 74
. C 14 74
with C 16 74
reference C 17 74
to C 18 74
personal C 19 74
observations C 20 74
the C 21 74
authors C 22 74
describe C 23 74
the C 24 74
ovular C 25 74
changes C 26 74
encountered C 27 74
in C 28 74
endogenous C 29 74
eczema C 30 74
. C 31 74
besides C 33 74
the C 34 74
cataract C 35 74
which C 36 74
has C 37 74
been C 38 74
known C 39 74
to C 40 74
occur C 41 74
already C 42 74
for C 43 74
a C 44 74
long C 45 74
time C 46 74
, C 47 74
retinal C 48 74
detachment C 49 74
, C 50 74
keratoconus C 51 74
and C 52 74
keratoconjunctivitis C 53 74
do C 54 74
still C 55 74
belong C 56 74
to C 57 74
the C 58 74
symptom C 59 74
complex C 60 74
. C 61 74
postural C 1 75
changes C 2 75
in C 3 75
blood C 4 75
distribution C 5 75
and C 6 75
its C 7 75
relation C 8 75
to C 9 75
the C 10 75
change C 11 75
in C 12 75
cardiac C 13 75
output C 14 75
. C 15 75
( C 17 75
1 C 18 75
) C 19 75
cardiac C 20 75
output C 21 75
and C 22 75
the C 23 75
blood C 24 75
content C 25 75
indices C 26 75
of C 27 75
the C 28 75
several C 29 75
parts C 30 75
of C 31 75
the C 32 75
body C 33 75
were C 34 75
measured C 35 75
in C 36 75
18 C 37 75
subjects C 38 75
including C 39 75
patients C 40 75
with C 41 75
various C 42 75
diseases C 43 75
using C 44 75
external C 45 75
radioisotope C 46 75
counting C 47 75
techniques C 48 75
. C 49 75
changes C 51 75
in C 52 75
these C 53 75
2 C 54 75
parameters C 55 75
induced C 56 75
by C 57 75
standing C 58 75
were C 59 75
compared C 60 75
with C 61 75
each C 62 75
other C 63 75
. C 64 75
( C 66 75
2 C 67 75
) C 68 75
average C 69 75
changes C 70 75
in C 71 75
blood C 72 75
distribution C 73 75
produced C 74 75
by C 75 75
standing C 76 75
were C 77 75
as C 78 75
follows C 79 75
. C 80 75
decrease C 82 75
in C 83 75
blood C 84 75
content C 85 75
in C 86 75
the C 87 75
/ C 88 75
lung C 89 75
/ C 90 75
( C 91 75
- C 92 75
25 C 93 75
) C 94 75
and C 95 75
in C 96 75
the C 97 75
/ C 98 75
heart C 99 75
/ C 100 75
( C 101 75
- C 102 75
26 C 103 75
) C 104 75
and C 105 75
increase C 106 75
in C 107 75
the C 108 75
/ C 109 75
thigh C 110 75
/ C 111 75
( C 112 75
+ C 113 75
56 C 114 75
) C 115 75
were C 116 75
statistically C 117 75
significant C 118 75
. C 119 75
no C 121 75
significant C 122 75
change C 123 75
was C 124 75
revealed C 125 75
in C 126 75
the C 127 75
/ C 128 75
head C 129 75
/ C 130 75
, C 131 75
/ C 132 75
palm C 133 75
/ C 134 75
, C 135 75
/ C 136 75
liver C 137 75
/ C 138 75
and C 139 75
/ C 140 75
abdomen C 141 75
/ C 142 75
. C 143 75
( C 145 75
3 C 146 75
) C 147 75
cardiac C 148 75
output C 149 75
and C 150 75
stroke C 151 75
volume C 152 75
decreased C 153 75
by C 154 75
standing C 155 75
in C 156 75
most C 157 75
of C 158 75
the C 159 75
cases C 160 75
. C 161 75
recent C 163 75
data C 164 75
were C 165 75
added C 166 75
to C 167 75
those C 168 75
reported C 169 75
previously C 170 75
and C 171 75
were C 172 75
treated C 173 75
statistically C 174 75
. C 175 75
average C 177 75
decrease C 178 75
in C 179 75
cardiac C 180 75
output C 181 75
was C 182 75
- C 183 75
13 C 184 75
in C 185 75
6 C 186 75
control C 187 75
cases C 188 75
, C 189 75
- C 190 75
35 C 191 75
in C 192 75
16 C 193 75
cases C 194 75
with C 195 75
neurocirculatory C 196 75
asthenia C 197 75
and C 198 75
- C 199 75
35 C 200 75
in C 201 75
10 C 202 75
cases C 203 75
with C 204 75
hyperthyroidism C 205 75
. C 206 75
the C 208 75
difference C 209 75
was C 210 75
significant C 211 75
between C 212 75
control C 213 75
and C 214 75
neurocirculatory C 215 75
asthenia C 216 75
. C 217 75
standing C 219 75
induced C 220 75
a C 221 75
substantial C 222 75
increase C 223 75
in C 224 75
cardiac C 225 75
output C 226 75
in C 227 75
a C 228 75
case C 229 75
of C 230 75
idiopathic C 231 75
nodal C 232 75
rhythm C 233 75
, C 234 75
although C 235 75
there C 236 75
remains C 237 75
a C 238 75
doubt C 239 75
whether C 240 75
it C 241 75
is C 242 75
the C 243 75
ordinary C 244 75
response C 245 75
in C 246 75
this C 247 75
disease C 248 75
. C 249 75
( C 251 75
4 C 252 75
) C 253 75
significant C 254 75
linear C 255 75
correlation C 256 75
was C 257 75
revealed C 258 75
between C 259 75
per C 260 75
cent C 261 75
change C 262 75
of C 263 75
blood C 264 75
content C 265 75
in C 266 75
the C 267 75
/ C 268 75
thigh C 269 75
/ C 270 75
or C 271 75
in C 272 75
the C 273 75
/ C 274 75
lung C 275 75
/ C 276 75
and C 277 75
that C 278 75
of C 279 75
cardiac C 280 75
output C 281 75
or C 282 75
stroke C 283 75
volume C 284 75
induced C 285 75
by C 286 75
standing C 287 75
. C 288 75
minimal C 290 75
blood C 291 75
shift C 292 75
was C 293 75
observed C 294 75
when C 295 75
the C 296 75
latter C 297 75
was C 298 75
extreme C 299 75
, C 300 75
and C 301 75
vice C 302 75
versa C 303 75
. C 304 75
this C 306 75
implies C 307 75
as C 308 75
follows C 309 75
. C 310 75
. C 312 75
reactivity C 314 75
of C 315 75
the C 316 75
heart C 317 75
might C 318 75
be C 319 75
influenced C 320 75
by C 321 75
posture C 322 75
, C 323 75
and C 324 75
transmural C 325 75
pressure C 326 75
of C 327 75
veins C 328 75
and C 329 75
or C 330 75
capillaries C 331 75
is C 332 75
probably C 333 75
adjusted C 334 75
, C 335 75
as C 336 75
in C 337 75
arterioles C 338 75
, C 339 75
to C 340 75
compensate C 341 75
for C 342 75
changes C 343 75
in C 344 75
cardiac C 345 75
output C 346 75
comparative C 1 76
studies C 2 76
of C 3 76
the C 4 76
glycogen C 5 76
content C 6 76
of C 7 76
heart C 8 76
, C 9 76
liver C 10 76
and C 11 76
brain C 12 76
before C 13 76
and C 14 76
after C 15 76
iodine C 16 76
treatment C 17 76
and C 18 76
under C 19 76
conditions C 20 76
of C 21 76
asphyxia C 22 76
. C 23 76
blood C 25 76
sugar C 26 76
level C 27 76
and C 28 76
glycogen C 29 76
concentration C 30 76
in C 31 76
the C 32 76
heart C 33 76
, C 34 76
brain C 35 76
and C 36 76
liver C 37 76
of C 38 76
rabbits C 39 76
after C 40 76
treatment C 41 76
with C 42 76
inorganic C 43 76
iodine C 44 76
, C 45 76
depot C 46 76
insulin C 47 76
, C 48 76
iodine C 49 76
and C 50 76
insulin C 51 76
combined C 52 76
, C 53 76
hostacortine C 54 76
and C 55 76
hostacortine C 56 76
and C 57 76
iodine C 58 76
combined C 59 76
are C 60 76
being C 61 76
examined C 62 76
. C 63 76
a C 65 76
control C 66 76
group C 67 76
remains C 68 76
untreated C 69 76
. C 70 76
in C 72 76
a C 73 76
second C 74 76
test C 75 76
series C 76 76
the C 77 76
glycogen C 78 76
determination C 79 76
under C 80 76
asphyxia C 81 76
( C 82 76
the C 83 76
trachea C 84 76
is C 85 76
being C 86 76
pinched C 87 76
off C 88 76
for C 89 76
three C 90 76
minutes C 91 76
) C 92 76
is C 93 76
repeated C 94 76
. C 95 76
contrary C 97 76
to C 98 76
the C 99 76
brain C 100 76
the C 101 76
glycogen C 102 76
content C 103 76
of C 104 76
the C 105 76
heart C 106 76
muscle C 107 76
is C 108 76
not C 109 76
dependent C 110 76
upon C 111 76
the C 112 76
blood C 113 76
sugar C 114 76
level C 115 76
. C 116 76
after C 118 76
iodine C 119 76
treatment C 120 76
a C 121 76
lowering C 122 76
of C 123 76
the C 124 76
blood C 125 76
sugar C 126 76
becomes C 127 76
noticeable C 128 76
, C 129 76
but C 130 76
also C 131 76
an C 132 76
increase C 133 76
in C 134 76
heart C 135 76
glycogen C 136 76
. C 137 76
the C 139 76
liver C 140 76
glycogen C 141 76
shows C 142 76
greater C 143 76
variations C 144 76
. C 145 76
the C 147 76
levels C 148 76
achieved C 149 76
in C 150 76
these C 151 76
test C 152 76
series C 153 76
therefore C 154 76
show C 155 76
no C 156 76
significant C 157 76
differences C 158 76
during C 159 76
asphyxia C 160 76
there C 161 76
is C 162 76
a C 163 76
significant C 164 76
lowering C 165 76
of C 166 76
glycogen C 167 76
in C 168 76
all C 169 76
three C 170 76
organs C 171 76
. C 172 76
preliminary C 174 76
treatment C 175 76
with C 176 76
iodine C 177 76
succeeds C 178 76
in C 179 76
stopping C 180 76
the C 181 76
lowering C 182 76
of C 183 76
glycogen C 184 76
in C 185 76
the C 186 76
heart C 187 76
muscle C 188 76
and C 189 76
the C 190 76
brain C 191 76
. C 192 76
the C 194 76
possible C 195 76
causes C 196 76
for C 197 76
this C 198 76
phenomenon C 199 76
are C 200 76
being C 201 76
discussed C 202 76
. C 203 76
altered C 1 77
immunologic C 2 77
activity C 3 77
in C 4 77
sarcoidosis C 5 77
. C 6 77
studies C 8 77
in C 9 77
16 C 10 77
patients C 11 77
with C 12 77
sarcoidosis C 13 77
revealed C 14 77
evidence C 15 77
of C 16 77
immunologic C 17 77
alterations C 18 77
other C 19 77
than C 20 77
impaired C 21 77
delayed C 22 77
hypersensitivity C 23 77
. C 24 77
transient C 26 77
impairment C 27 77
of C 28 77
the C 29 77
response C 30 77
of C 31 77
lymphocytes C 32 77
cultured C 33 77
from C 34 77
patients C 35 77
with C 36 77
sarcoidosis C 37 77
to C 38 77
phytohemagglutinin C 39 77
stimulation C 40 77
was C 41 77
found C 42 77
to C 43 77
parallel C 44 77
the C 45 77
clinical C 46 77
severity C 47 77
of C 48 77
the C 49 77
disease C 50 77
. C 51 77
the C 53 77
hemolytic C 54 77
activity C 55 77
of C 56 77
serum C 57 77
complement C 58 77
was C 59 77
increased C 60 77
. C 61 77
a C 63 77
disproportionate C 64 77
increase C 65 77
in C 66 77
serum C 67 77
iga C 68 77
was C 69 77
found C 70 77
characteristic C 71 77
of C 72 77
the C 73 77
hyperglobulinemia C 74 77
of C 75 77
sarcoidosis C 76 77
. C 77 77
these C 79 77
observations C 80 77
indicate C 81 77
that C 82 77
an C 83 77
altered C 84 77
immune C 85 77
response C 86 77
may C 87 77
be C 88 77
important C 89 77
in C 90 77
the C 91 77
pathogenesis C 92 77
of C 93 77
sarcoidosis C 94 77
. C 95 77
a C 97 77
simple C 98 77
hypothesis C 99 77
as C 100 77
to C 101 77
the C 102 77
specific C 103 77
kind C 104 77
of C 105 77
interaction C 106 77
of C 107 77
infectious C 108 77
agent C 109 77
and C 110 77
immunity C 111 77
which C 112 77
might C 113 77
result C 114 77
in C 115 77
the C 116 77
immunologic C 117 77
alterations C 118 77
observed C 119 77
is C 120 77
formulated C 121 77
and C 122 77
presented C 123 77
. C 124 77
electron C 1 78
microscopy C 2 78
of C 3 78
cytoplasmic C 4 78
inclusions C 5 78
within C 6 78
/ C 7 78
macrophages C 8 78
/ C 9 78
of C 10 78
human C 11 78
tissue C 12 78
. C 13 78
the C 15 78
fine C 16 78
structure C 17 78
of C 18 78
inclusions C 19 78
found C 20 78
within C 21 78
the C 22 78
cytoplasm C 23 78
of C 24 78
macrophages C 25 78
of C 26 78
human C 27 78
lung C 28 78
, C 29 78
spleen C 30 78
, C 31 78
skin C 32 78
, C 33 78
lymph C 34 78
node C 35 78
, C 36 78
and C 37 78
rectum C 38 78
has C 39 78
been C 40 78
described C 41 78
. C 42 78
the C 44 78
inclusions C 45 78
appear C 46 78
as C 47 78
concentric C 48 78
or C 49 78
whorled C 50 78
lamellae C 51 78
arranged C 52 78
around C 53 78
a C 54 78
core C 55 78
. C 56 78
each C 58 78
lamella C 59 78
is C 60 78
constructed C 61 78
of C 62 78
discrete C 63 78
, C 64 78
parallel C 65 78
filaments C 66 78
. C 67 78
the C 69 78
inclusions C 70 78
do C 71 78
not C 72 78
resemble C 73 78
currently C 74 78
described C 75 78
viruses C 76 78
or C 77 78
virus C 78 78
- C 79 78
like C 80 78
particles C 81 78
, C 82 78
nor C 83 78
do C 84 78
they C 85 78
resemble C 86 78
asbestos C 87 78
bodies C 88 78
or C 89 78
other C 90 78
known C 91 78
atmospheric C 92 78
pollutants C 93 78
or C 94 78
ingestants C 95 78
. C 96 78
there C 98 78
is C 99 78
some C 100 78
resemblance C 101 78
to C 102 78
lipid C 103 78
phase C 104 78
systems C 105 78
as C 106 78
well C 107 78
as C 108 78
mast C 109 78
cell C 110 78
granules C 111 78
, C 112 78
. C 113 78
possibly C 115 78
the C 116 78
inclusions C 117 78
represent C 118 78
partial C 119 78
intracellular C 120 78
digestion C 121 78
of C 122 78
phagocytized C 123 78
tissue C 124 78
membranes C 125 78
or C 126 78
ingested C 127 78
mast C 128 78
cell C 129 78
granules C 130 78
, C 131 78
respectively C 132 78
. C 133 78
differences C 135 78
and C 136 78
similarities C 137 78
exist C 138 78
between C 139 78
the C 140 78
inclusion C 141 78
bodies C 142 78
of C 143 78
macrophages C 144 78
and C 145 78
the C 146 78
granules C 147 78
of C 148 78
mast C 149 78
cells C 150 78
. C 151 78
such C 153 78
variations C 154 78
could C 155 78
be C 156 78
due C 157 78
to C 158 78
alterations C 159 78
in C 160 78
mast C 161 78
cell C 162 78
granule C 163 78
morphology C 164 78
before C 165 78
or C 166 78
after C 167 78
macrophage C 168 78
ingestion C 169 78
. C 170 78
cytologic C 172 78
distinctions C 173 78
between C 174 78
macrophages C 175 78
laden C 176 78
with C 177 78
mast C 178 78
cell C 179 78
granules C 180 78
and C 181 78
mast C 182 78
cells C 183 78
proper C 184 78
, C 185 78
remains C 186 78
obscure C 187 78
and C 188 78
requires C 189 78
additional C 190 78
experimental C 191 78
evidence C 192 78
for C 193 78
clear C 194 78
electron C 195 78
microscopic C 196 78
differentiation C 197 78
of C 198 78
these C 199 78
two C 200 78
cell C 201 78
types C 202 78
. C 203 78
the C 205 78
exact C 206 78
nature C 207 78
of C 208 78
these C 209 78
highly C 210 78
structured C 211 78
bodies C 212 78
remains C 213 78
speculative C 214 78
histological C 1 79
research C 2 79
on C 3 79
the C 4 79
lens C 5 79
in C 6 79
condition C 7 79
of C 8 79
hypoxia C 9 79
, C 10 79
changes C 11 79
in C 12 79
the C 13 79
mitotic C 14 79
activity C 15 79
of C 16 79
the C 17 79
epithelium C 18 79
. C 19 79
the C 21 79
effect C 22 79
of C 23 79
hypoxia C 24 79
on C 25 79
the C 26 79
mitotic C 27 79
activity C 28 79
of C 29 79
the C 30 79
cells C 31 79
of C 32 79
the C 33 79
lens C 34 79
epithelium C 35 79
was C 36 79
studied C 37 79
in C 38 79
24 C 39 79
rats C 40 79
of C 41 79
the C 42 79
same C 43 79
strain C 44 79
and C 45 79
weight C 46 79
. C 47 79
the C 49 79
hypoxia C 50 79
was C 51 79
obtained C 52 79
in C 53 79
the C 54 79
decompression C 55 79
chamber C 56 79
. C 57 79
the C 59 79
results C 60 79
show C 61 79
that C 62 79
the C 63 79
mitotic C 64 79
activity C 65 79
of C 66 79
the C 67 79
lens C 68 79
epithelium C 69 79
is C 70 79
depressed C 71 79
at C 72 79
any C 73 79
of C 74 79
the C 75 79
examined C 76 79
altitudes C 77 79
( C 78 79
6 C 79 79
. C 80 79
. C 81 79
. C 81 79
. C 81 79
, C 82 79
8 C 83 79
. C 84 79
. C 85 79
. C 85 79
. C 85 79
, C 86 79
9 C 87 79
. C 88 79
. C 89 79
. C 89 79
. C 89 79
m C 90 79
) C 91 79
, C 92 79
. C 93 79
in C 95 79
particular C 96 79
, C 97 79
a C 98 79
marked C 99 79
reduction C 100 79
in C 101 79
the C 102 79
number C 103 79
of C 104 79
the C 105 79
prophases C 106 79
and C 107 79
an C 108 79
accumulation C 109 79
in C 110 79
metaphase C 111 79
was C 112 79
observed C 113 79
. C 114 79
the C 116 79
results C 117 79
were C 118 79
examined C 119 79
from C 120 79
the C 121 79
statistical C 122 79
standpoint C 123 79
and C 124 79
discussed C 125 79
. C 126 79
rate C 1 80
of C 2 80
change C 3 80
of C 4 80
carbon C 5 80
dioxide C 6 80
tension C 7 80
in C 8 80
arterial C 9 80
blood C 10 80
, C 11 80
jugular C 12 80
venous C 13 80
blood C 14 80
and C 15 80
cisternal C 16 80
cerebrospinal C 17 80
fluid C 18 80
on C 19 80
carbon C 20 80
dioxide C 21 80
administration C 22 80
. C 23 80
1 C 25 80
. C 26 80
the C 28 80
rate C 29 80
of C 30 80
change C 31 80
of C 32 80
p C 33 80
in C 34 80
arterial C 35 80
blood C 36 80
and C 37 80
cisternal C 38 80
c C 39 80
. C 40 80
. C 41 80
. C 42 80
. C 43 80
. C 44 80
, C 46 80
was C 47 80
measured C 48 80
following C 49 80
5 C 50 80
percent C 51 80
co C 52 80
administration C 53 80
in C 54 80
eight C 55 80
anaesthetized C 56 80
patients C 57 80
undergoing C 58 80
routine C 59 80
air C 60 80
encephalography C 61 80
. C 62 80
ventilation C 64 80
was C 65 80
maintained C 66 80
constant C 67 80
throughout C 68 80
the C 69 80
procedure C 70 80
by C 71 80
a C 72 80
respirator C 73 80
. C 74 80
in C 76 80
three C 77 80
of C 78 80
the C 79 80
experiments C 80 80
the C 81 80
rate C 82 80
of C 83 80
change C 84 80
of C 85 80
p C 86 80
in C 87 80
the C 88 80
jugular C 89 80
venous C 90 80
blood C 91 80
was C 92 80
also C 93 80
measured C 94 80
. C 95 80
2 C 97 80
. C 98 80
the C 100 80
rise C 101 80
in C 102 80
p C 103 80
varied C 104 80
between C 105 80
25 C 106 80
. C 107 80
. C 108 80
and C 109 80
14 C 110 80
. C 111 80
. C 112 80
mm C 113 80
hg C 114 80
. C 115 80
the C 117 80
final C 118 80
samples C 119 80
of C 120 80
blood C 121 80
and C 122 80
c C 123 80
. C 124 80
. C 125 80
. C 126 80
. C 127 80
. C 128 80
were C 130 80
taken C 131 80
20 C 132 80
- C 133 80
25 C 134 80
min C 135 80
after C 136 80
the C 137 80
start C 138 80
of C 139 80
co C 140 80
administration C 141 80
in C 142 80
five C 143 80
experiments C 144 80
. C 145 80
at C 147 80
this C 148 80
time C 149 80
the C 150 80
mean C 151 80
rise C 152 80
in C 153 80
p C 154 80
was C 155 80
65 C 156 80
. C 157 80
. C 158 80
( C 159 80
maximum C 160 80
range C 161 80
68 C 162 80
. C 163 80
. C 164 80
- C 165 80
61 C 166 80
. C 167 80
. C 168 80
percent C 169 80
) C 170 80
of C 171 80
the C 172 80
rise C 173 80
in C 174 80
p C 175 80
. C 176 80
in C 178 80
the C 179 80
remaining C 180 80
three C 181 80
experiments C 182 80
the C 183 80
final C 184 80
samples C 185 80
were C 186 80
taken C 187 80
at C 188 80
15 C 189 80
min C 190 80
when C 191 80
the C 192 80
rises C 193 80
in C 194 80
p C 195 80
were C 196 80
53 C 197 80
. C 198 80
. C 199 80
, C 200 80
39 C 201 80
. C 202 80
. C 203 80
and C 204 80
38 C 205 80
. C 206 80
. C 207 80
percent C 208 80
of C 209 80
the C 210 80
arterial C 211 80
change C 212 80
. C 213 80
3 C 215 80
. C 216 80
the C 218 80
increases C 219 80
in C 220 80
p C 221 80
were C 222 80
57 C 223 80
. C 224 80
. C 225 80
, C 226 80
76 C 227 80
. C 228 80
. C 229 80
and C 230 80
76 C 231 80
. C 232 80
. C 233 80
percent C 234 80
of C 235 80
those C 236 80
in C 237 80
the C 238 80
arterial C 239 80
blood C 240 80
. C 241 80
the C 243 80
changes C 244 80
in C 245 80
p C 246 80
in C 247 80
the C 248 80
c C 249 80
. C 250 80
. C 251 80
. C 252 80
. C 253 80
. C 254 80
were C 256 80
smaller C 257 80
than C 258 80
in C 259 80
the C 260 80
jugular C 261 80
venous C 262 80
blood C 263 80
in C 264 80
all C 265 80
three C 266 80
experiments C 267 80
. C 268 80
in C 270 80
two C 271 80
of C 272 80
the C 273 80
experiments C 274 80
the C 275 80
final C 276 80
samples C 277 80
were C 278 80
taken C 279 80
15 C 280 80
min C 281 80
after C 282 80
the C 283 80
start C 284 80
of C 285 80
co C 286 80
administration C 287 80
when C 288 80
the C 289 80
increases C 290 80
of C 291 80
p C 292 80
in C 293 80
the C 294 80
c C 295 80
. C 296 80
. C 297 80
. C 298 80
. C 299 80
. C 300 80
were C 302 80
68 C 303 80
. C 304 80
. C 305 80
percent C 306 80
and C 307 80
50 C 308 80
percent C 309 80
of C 310 80
those C 311 80
in C 312 80
jugular C 313 80
venous C 314 80
blood C 315 80
. C 316 80
in C 318 80
one C 319 80
experiment C 320 80
where C 321 80
the C 322 80
final C 323 80
samples C 324 80
were C 325 80
taken C 326 80
at C 327 80
20 C 328 80
min C 329 80
the C 330 80
increase C 331 80
in C 332 80
p C 333 80
was C 334 80
89 C 335 80
percent C 336 80
of C 337 80
the C 338 80
rise C 339 80
in C 340 80
p C 341 80
. C 342 80
4 C 344 80
. C 345 80
there C 347 80
was C 348 80
a C 349 80
delay C 350 80
, C 351 80
following C 352 80
the C 353 80
start C 354 80
of C 355 80
co C 356 80
administration C 357 80
, C 358 80
in C 359 80
the C 360 80
rise C 361 80
of C 362 80
p C 363 80
in C 364 80
jugular C 365 80
venous C 366 80
blood C 367 80
and C 368 80
in C 369 80
the C 370 80
c C 371 80
. C 372 80
. C 373 80
. C 374 80
. C 375 80
. C 376 80
this C 378 80
delay C 379 80
was C 380 80
about C 381 80
1 C 382 80
min C 383 80
in C 384 80
the C 385 80
jugular C 386 80
venous C 387 80
blood C 388 80
but C 389 80
in C 390 80
the C 391 80
c C 392 80
. C 393 80
. C 394 80
. C 395 80
. C 396 80
. C 397 80
it C 399 80
varied C 400 80
from C 401 80
1 C 402 80
. C 403 80
. C 404 80
to C 405 80
4 C 406 80
. C 407 80
. C 408 80
min C 409 80
( C 410 80
mean C 411 80
2 C 412 80
. C 413 80
. C 414 80
) C 415 80
. C 416 80
5 C 418 80
. C 419 80
the C 421 80
rise C 422 80
of C 423 80
p C 424 80
in C 425 80
blood C 426 80
and C 427 80
c C 428 80
. C 429 80
. C 430 80
. C 431 80
. C 432 80
. C 433 80
was C 435 80
exponential C 436 80
. C 437 80
the C 439 80
rise C 440 80
in C 441 80
p C 442 80
in C 443 80
all C 444 80
experiments C 445 80
consisted C 446 80
of C 447 80
a C 448 80
fast C 449 80
component C 450 80
with C 451 80
time C 452 80
constants C 453 80
which C 454 80
varied C 455 80
between C 456 80
0 C 457 80
. C 458 80
. C 459 80
and C 460 80
0 C 461 80
. C 462 80
. C 463 80
min C 464 80
( C 465 80
mean C 466 80
0 C 467 80
. C 468 80
. C 469 80
) C 470 80
and C 471 80
a C 472 80
slow C 473 80
component C 474 80
with C 475 80
time C 476 80
constants C 477 80
varying C 478 80
between C 479 80
6 C 480 80
. C 481 80
. C 482 80
and C 483 80
14 C 484 80
. C 485 80
. C 486 80
( C 487 80
mean C 488 80
11 C 489 80
. C 490 80
. C 491 80
) C 492 80
. C 493 80
the C 495 80
rise C 496 80
in C 497 80
p C 498 80
and C 499 80
p C 500 80
consisted C 501 80
of C 502 80
only C 503 80
one C 504 80
component C 505 80
. C 506 80
the C 508 80
time C 509 80
constants C 510 80
for C 511 80
the C 512 80
changes C 513 80
in C 514 80
jugular C 515 80
venous C 516 80
blood C 517 80
were C 518 80
2 C 519 80
. C 520 80
. C 521 80
, C 522 80
3 C 523 80
. C 524 80
. C 525 80
and C 526 80
4 C 527 80
. C 528 80
. C 529 80
min C 530 80
, C 531 80
whilst C 532 80
in C 533 80
the C 534 80
c C 535 80
. C 536 80
. C 537 80
. C 538 80
. C 539 80
. C 540 80
they C 542 80
varied C 543 80
between C 544 80
6 C 545 80
. C 546 80
. C 547 80
and C 548 80
14 C 549 80
. C 550 80
. C 551 80
( C 552 80
mean C 553 80
11 C 554 80
. C 555 80
. C 556 80
) C 557 80
. C 558 80
6 C 560 80
. C 561 80
it C 563 80
is C 564 80
probable C 565 80
that C 566 80
about C 567 80
40 C 568 80
percent C 569 80
of C 570 80
the C 571 80
increase C 572 80
in C 573 80
ventilation C 574 80
following C 575 80
co C 576 80
administration C 577 80
is C 578 80
due C 579 80
to C 580 80
stimulation C 581 80
of C 582 80
an C 583 80
area C 584 80
in C 585 80
the C 586 80
antero C 587 80
- C 588 80
lateral C 589 80
surface C 590 80
of C 591 80
the C 592 80
medulla C 593 80
sensitive C 594 80
to C 595 80
changes C 596 80
in C 597 80
ph C 598 80
or C 599 80
p C 600 80
( C 601 80
mitchell C 602 80
et C 603 80
al C 604 80
. C 605 80
1963 C 607 80
) C 608 80
. C 609 80
this C 611 80
area C 612 80
is C 613 80
superficial C 614 80
and C 615 80
ventilation C 616 80
is C 617 80
affected C 618 80
by C 619 80
changes C 620 80
in C 621 80
the C 622 80
p C 623 80
of C 624 80
the C 625 80
overlying C 626 80
c C 627 80
. C 628 80
. C 629 80
. C 630 80
. C 631 80
. C 632 80
it C 634 80
can C 635 80
be C 636 80
predicted C 637 80
from C 638 80
our C 639 80
experiments C 640 80
that C 641 80
the C 642 80
rise C 643 80
in C 644 80
p C 645 80
on C 646 80
co C 647 80
administration C 648 80
will C 649 80
take C 650 80
some C 651 80
30 C 652 80
min C 653 80
to C 654 80
be C 655 80
complete C 656 80
. C 657 80
this C 659 80
may C 660 80
explain C 661 80
the C 662 80
slow C 663 80
rise C 664 80
in C 665 80
ventilation C 666 80
on C 667 80
co C 668 80
breathing C 669 80
when C 670 80
compared C 671 80
with C 672 80
the C 673 80
rate C 674 80
of C 675 80
rise C 676 80
of C 677 80
arterial C 678 80
and C 679 80
jugular C 680 80
venous C 681 80
p C 682 80
. C 683 80
studies C 1 81
on C 2 81
the C 3 81
compound C 4 81
lipids C 5 81
from C 6 81
x C 7 81
- C 8 81
ray C 9 81
irradiated C 10 81
animal C 11 81
, C 12 81
ii C 13 81
. C 14 81
biological C 16 81
and C 17 81
biochemical C 18 81
properties C 19 81
of C 20 81
the C 21 81
compound C 22 81
lipids C 23 81
in C 24 81
the C 25 81
x C 26 81
- C 27 81
ray C 28 81
irradiated C 29 81
rabbit C 30 81
organs C 31 81
. C 32 81
for C 34 81
the C 35 81
purpose C 36 81
to C 37 81
clarify C 38 81
the C 39 81
causes C 40 81
of C 41 81
x C 42 81
- C 43 81
ray C 44 81
disturbances C 45 81
a C 46 81
series C 47 81
of C 48 81
experiments C 49 81
have C 50 81
been C 51 81
conducted C 52 81
on C 53 81
biological C 54 81
and C 55 81
biochemical C 56 81
properties C 57 81
of C 58 81
compound C 59 81
lipids C 60 81
extracted C 61 81
from C 62 81
normal C 63 81
and C 64 81
x C 65 81
- C 66 81
ray C 67 81
irradiated C 68 81
rabbit C 69 81
organs C 70 81
with C 71 81
a C 72 81
special C 73 81
reference C 74 81
to C 75 81
the C 76 81
p C 77 81
- C 78 81
labeled C 79 81
compound C 80 81
lipids C 81 81
uptake C 82 81
, C 83 81
inhibitory C 84 81
action C 85 81
to C 86 81
l C 87 81
cell C 88 81
proliferation C 89 81
and C 90 81
uncoupling C 91 81
of C 92 81
oxidative C 93 81
phosphorylation C 94 81
, C 95 81
and C 96 81
the C 97 81
following C 98 81
results C 99 81
have C 100 81
been C 101 81
obtained C 102 81
the C 103 81
compound C 104 81
lipids C 105 81
( C 106 81
lysophosphatide C 107 81
rich C 108 81
fraction C 109 81
) C 110 81
isolated C 111 81
from C 112 81
the C 113 81
x C 114 81
- C 115 81
ray C 116 81
irradiated C 117 81
rabbit C 118 81
organ C 119 81
have C 120 81
been C 121 81
found C 122 81
to C 123 81
possess C 124 81
a C 125 81
strong C 126 81
hemolytic C 127 81
action C 128 81
and C 129 81
also C 130 81
an C 131 81
action C 132 81
to C 133 81
inhibit C 134 81
the C 135 81
cell C 136 81
proliferation C 137 81
as C 138 81
well C 139 81
as C 140 81
to C 141 81
accelerate C 142 81
the C 143 81
respiration C 144 81
of C 145 81
the C 146 81
mitochondria C 147 81
in C 148 81
the C 149 81
rabbit C 150 81
liver C 151 81
and C 152 81
spleen C 153 81
. C 154 81
it C 156 81
has C 157 81
also C 158 81
been C 159 81
proven C 160 81
that C 161 81
they C 162 81
act C 163 81
as C 164 81
to C 165 81
induce C 166 81
a C 167 81
marked C 168 81
swelling C 169 81
of C 170 81
mitochondria C 171 81
, C 172 81
to C 173 81
impede C 174 81
the C 175 81
formation C 176 81
of C 177 81
high C 178 81
energy C 179 81
phosphate C 180 81
as C 181 81
well C 182 81
as C 183 81
to C 184 81
act C 185 81
as C 186 81
an C 187 81
uncoupler C 188 81
of C 189 81
oxidative C 190 81
phosphorylation C 191 81
in C 192 81
vivo C 193 81
. C 194 81
in C 196 81
the C 197 81
test C 198 81
to C 199 81
see C 200 81
the C 201 81
uptake C 202 81
of C 203 81
p C 204 81
- C 205 81
labeled C 206 81
compound C 207 81
lipids C 208 81
by C 209 81
various C 210 81
organs C 211 81
, C 212 81
a C 213 81
marked C 214 81
uptake C 215 81
has C 216 81
been C 217 81
observed C 218 81
in C 219 81
spleen C 220 81
, C 221 81
bone C 222 81
marrow C 223 81
, C 224 81
and C 225 81
liver C 226 81
of C 227 81
both C 228 81
irradiated C 229 81
and C 230 81
non C 231 81
- C 232 81
irradiated C 233 81
groups C 234 81
. C 235 81
further C 237 81
, C 238 81
the C 239 81
uptake C 240 81
of C 241 81
p C 242 81
- C 243 81
labeled C 244 81
compound C 245 81
lipids C 246 81
in C 247 81
the C 248 81
rabbits C 249 81
given C 250 81
intravenous C 251 81
injections C 252 81
of C 253 81
compound C 254 81
lipid C 255 81
fraction C 256 81
for C 257 81
30 C 258 81
consecutive C 259 81
days C 260 81
previously C 261 81
has C 262 81
been C 263 81
found C 264 81
to C 265 81
be C 266 81
greatest C 267 81
in C 268 81
pancreas C 269 81
followed C 270 81
by C 271 81
bone C 272 81
marrow C 273 81
, C 274 81
spleen C 275 81
, C 276 81
liver C 277 81
in C 278 81
the C 279 81
order C 280 81
mentioned C 281 81
in C 282 81
male C 283 81
group C 284 81
, C 285 81
whereas C 286 81
it C 287 81
is C 288 81
greatest C 289 81
in C 290 81
spleen C 291 81
, C 292 81
followed C 293 81
by C 294 81
liver C 295 81
and C 296 81
bone C 297 81
marrow C 298 81
in C 299 81
the C 300 81
female C 301 81
group C 302 81
. C 303 81
with C 305 81
these C 306 81
results C 307 81
the C 308 81
discussion C 309 81
was C 310 81
conducted C 311 81
concerning C 312 81
the C 313 81
relation C 314 81
between C 315 81
the C 316 81
lipid C 317 81
metabolism C 318 81
and C 319 81
x C 320 81
- C 321 81
ray C 322 81
disturbances C 323 81
. C 324 81
cesium C 1 82
- C 2 82
131 C 3 82
uptake C 4 82
and C 5 82
distribution C 6 82
in C 7 82
the C 8 82
human C 9 82
heart C 10 82
. C 11 82
. C 13 82
an C 15 82
analysis C 16 82
of C 17 82
cardiac C 18 82
scans C 19 82
in C 20 82
104 C 21 82
patients C 22 82
. C 23 82
when C 25 82
properly C 26 82
used C 27 82
, C 28 82
cesium C 29 82
- C 30 82
131 C 31 82
is C 32 82
a C 33 82
satisfactory C 34 82
agent C 35 82
for C 36 82
the C 37 82
study C 38 82
of C 39 82
cardiac C 40 82
morphology C 41 82
by C 42 82
photoscanning C 43 82
, C 44 82
which C 45 82
we C 46 82
believe C 47 82
is C 48 82
a C 49 82
useful C 50 82
adjunctive C 51 82
diagnostic C 52 82
procedure C 53 82
in C 54 82
patients C 55 82
for C 56 82
whom C 57 82
the C 58 82
results C 59 82
of C 60 82
other C 61 82
methods C 62 82
of C 63 82
evaluation C 64 82
are C 65 82
at C 66 82
variance C 67 82
with C 68 82
the C 69 82
clinical C 70 82
symptoms C 71 82
of C 72 82
cardiac C 73 82
disease C 74 82
. C 75 82
the C 77 82
studies C 78 82
reported C 79 82
here C 80 82
suggest C 81 82
that C 82 82
perhaps C 83 82
infarction C 84 82
of C 85 82
a C 86 82
subclinical C 87 82
type C 88 82
, C 89 82
size C 90 82
, C 91 82
or C 92 82
location C 93 82
may C 94 82
occur C 95 82
earlier C 96 82
than C 97 82
has C 98 82
been C 99 82
previously C 100 82
thought C 101 82
and C 102 82
that C 103 82
the C 104 82
damage C 105 82
it C 106 82
leaves C 107 82
may C 108 82
not C 109 82
be C 110 82
detectable C 111 82
by C 112 82
any C 113 82
means C 114 82
other C 115 82
than C 116 82
autopsy C 117 82
or C 118 82
a C 119 82
technique C 120 82
such C 121 82
as C 122 82
scanning C 123 82
. C 124 82
we C 126 82
have C 127 82
not C 128 82
yet C 129 82
been C 130 82
able C 131 82
to C 132 82
measure C 133 82
the C 134 82
actual C 135 82
concentration C 136 82
of C 137 82
cesium C 138 82
- C 139 82
131 C 140 82
in C 141 82
the C 142 82
heart C 143 82
at C 144 82
autopsy C 145 82
so C 146 82
that C 147 82
the C 148 82
cold C 149 82
and C 150 82
cool C 151 82
areas C 152 82
could C 153 82
be C 154 82
examined C 155 82
by C 156 82
histologic C 157 82
sections C 158 82
. C 159 82
oxygen C 1 83
consumption C 2 83
of C 3 83
paralysed C 4 83
men C 5 83
exposed C 6 83
to C 7 83
cold C 8 83
. C 9 83
1 C 11 83
. C 12 83
oxygen C 14 83
consumption C 15 83
and C 16 83
carbon C 17 83
dioxide C 18 83
output C 19 83
were C 20 83
measured C 21 83
when C 22 83
human C 23 83
subjects C 24 83
were C 25 83
cooled C 26 83
for C 27 83
80 C 28 83
- C 29 83
210 C 30 83
min C 31 83
. C 32 83
two C 34 83
subjects C 35 83
were C 36 83
normal C 37 83
, C 38 83
one C 39 83
had C 40 83
been C 41 83
almost C 42 83
completely C 43 83
paralysed C 44 83
below C 45 83
the C 46 83
neck C 47 83
by C 48 83
poliomyelitis C 49 83
, C 50 83
and C 51 83
two C 52 83
were C 53 83
unconscious C 54 83
as C 55 83
a C 56 83
result C 57 83
of C 58 83
intracranial C 59 83
damage C 60 83
and C 61 83
were C 62 83
observed C 63 83
with C 64 83
and C 65 83
without C 66 83
paralysing C 67 83
doses C 68 83
of C 69 83
muscle C 70 83
relaxants C 71 83
( C 72 83
d C 73 83
- C 74 83
tubocurarine C 75 83
and C 76 83
gallamine C 77 83
) C 78 83
. C 79 83
2 C 81 83
. C 82 83
when C 84 83
normal C 85 83
subjects C 86 83
and C 87 83
unconscious C 88 83
subjects C 89 83
receiving C 90 83
no C 91 83
drugs C 92 83
were C 93 83
cooled C 94 83
, C 95 83
oxygen C 96 83
consumption C 97 83
and C 98 83
carbon C 99 83
dioxide C 100 83
output C 101 83
rose C 102 83
. C 103 83
3 C 105 83
. C 106 83
when C 108 83
subjects C 109 83
paralysed C 110 83
by C 111 83
disease C 112 83
or C 113 83
drugs C 114 83
were C 115 83
cooled C 116 83
, C 117 83
oxygen C 118 83
consumption C 119 83
and C 120 83
carbon C 121 83
dioxide C 122 83
output C 123 83
were C 124 83
not C 125 83
increased C 126 83
. C 127 83
4 C 129 83
. C 130 83
these C 132 83
observations C 133 83
are C 134 83
consistent C 135 83
with C 136 83
the C 137 83
view C 138 83
that C 139 83
in C 140 83
man C 141 83
the C 142 83
increase C 143 83
in C 144 83
metabolism C 145 83
on C 146 83
cooling C 147 83
for C 148 83
periods C 149 83
up C 150 83
to C 151 83
31 C 152 83
/ C 153 83
2 C 154 83
hr C 155 83
occurs C 156 83
solely C 157 83
in C 158 83
skeletal C 159 83
muscle C 160 83
. C 161 83
heparin C 1 84
levels C 2 84
during C 3 84
and C 4 84
after C 5 84
hypothermic C 6 84
perfusion C 7 84
. C 8 84
1 C 10 84
. C 11 84
perfusion C 13 84
- C 14 84
temperature C 15 84
influences C 16 84
the C 17 84
rate C 18 84
of C 19 84
heparin C 20 84
- C 21 84
loss C 22 84
during C 23 84
extracorporeal C 24 84
circulation C 25 84
, C 26 84
and C 27 84
therefore C 28 84
, C 29 84
the C 30 84
requirement C 31 84
of C 32 84
re C 33 84
- C 34 84
heparinization C 35 84
. C 36 84
2 C 38 84
. C 39 84
heparin C 41 84
half C 42 84
- C 43 84
lives C 44 84
of C 45 84
approximately C 46 84
13 C 47 84
/ C 48 84
4 C 49 84
hours C 50 84
and C 51 84
21 C 52 84
/ C 53 84
2 C 54 84
hours C 55 84
were C 56 84
calculated C 57 84
during C 58 84
perfusions C 59 84
conducted C 60 84
at C 61 84
average C 62 84
temperatures C 63 84
of C 64 84
31 C 65 84
. C 66 84
. C 67 84
and C 68 84
22 C 69 84
. C 70 84
. C 71 84
c C 72 84
. C 73 84
respectively C 75 84
. C 76 84
3 C 78 84
. C 79 84
the C 81 84
rate C 82 84
of C 83 84
heparin C 84 84
- C 85 84
loss C 86 84
during C 87 84
extracorporeal C 88 84
circulation C 89 84
is C 90 84
inconstant C 91 84
in C 92 84
an C 93 84
individual C 94 84
, C 95 84
and C 96 84
variable C 97 84
between C 98 84
individuals C 99 84
, C 100 84
so C 101 84
that C 102 84
exact C 103 84
neutralization C 104 84
requires C 105 84
an C 106 84
accurate C 107 84
estimation C 108 84
of C 109 84
the C 110 84
heparin C 111 84
concentration C 112 84
present C 113 84
at C 114 84
the C 115 84
end C 116 84
of C 117 84
perfusion C 118 84
. C 119 84
4 C 121 84
. C 122 84
the C 124 84
protamine C 125 84
titration C 126 84
test C 127 84
provides C 128 84
a C 129 84
crude C 130 84
but C 131 84
simple C 132 84
and C 133 84
satisfactory C 134 84
means C 135 84
of C 136 84
monitoring C 137 84
free C 138 84
- C 139 84
heparin C 140 84
levels C 141 84
. C 142 84
5 C 144 84
. C 145 84
complete C 147 84
neutralization C 148 84
of C 149 84
heparin C 150 84
is C 151 84
an C 152 84
important C 153 84
factor C 154 84
in C 155 84
minimizing C 156 84
postoperative C 157 84
blood C 158 84
losses C 159 84
. C 160 84
6 C 162 84
. C 163 84
protamine C 165 84
is C 166 84
a C 167 84
less C 168 84
efficient C 169 84
neutralizing C 170 84
agent C 171 84
than C 172 84
polybrene C 173 84
at C 174 84
the C 175 84
same C 176 84
dosage C 177 84
level C 178 84
. C 179 84
it C 181 84
may C 182 84
be C 183 84
most C 184 84
effective C 185 84
in C 186 84
divided C 187 84
dosage C 188 84
. C 189 84
7 C 191 84
. C 192 84
/ C 194 84
rebound C 195 84
/ C 196 84
was C 197 84
detected C 198 84
in C 199 84
5 C 200 84
of C 201 84
45 C 202 84
cases C 203 84
studied C 204 84
, C 205 84
although C 206 84
in C 207 84
only C 208 84
one C 209 84
instance C 210 84
was C 211 84
it C 212 84
of C 213 84
a C 214 84
degree C 215 84
likely C 216 84
to C 217 84
be C 218 84
significant C 219 84
. C 220 84
8 C 222 84
. C 223 84
significant C 225 84
prolongation C 226 84
of C 227 84
the C 228 84
clotting C 229 84
- C 230 84
time C 231 84
resulting C 232 84
from C 233 84
excess C 234 84
neutralizing C 235 84
agent C 236 84
, C 237 84
was C 238 84
not C 239 84
evident C 240 84
in C 241 84
this C 242 84
study C 243 84
. C 244 84
platelet C 1 85
sequestration C 2 85
in C 3 85
man C 4 85
. C 5 85
i C 7 85
. C 8 85
methods C 10 85
. C 11 85
current C 13 85
methods C 14 85
of C 15 85
labeling C 16 85
platelets C 17 85
with C 18 85
chromium C 19 85
using C 20 85
ethylenediamine C 21 85
tetraacetate C 22 85
( C 23 85
edta C 24 85
) C 25 85
as C 26 85
an C 27 85
anticoagulant C 28 85
were C 29 85
found C 30 85
to C 31 85
cause C 32 85
rapid C 33 85
hepatic C 34 85
sequestration C 35 85
of C 36 85
nearly C 37 85
all C 38 85
the C 39 85
transfused C 40 85
platelets C 41 85
about C 42 85
50 C 43 85
returned C 44 85
to C 45 85
the C 46 85
circulation C 47 85
but C 48 85
then C 49 85
were C 50 85
partially C 51 85
destroyed C 52 85
in C 53 85
the C 54 85
spleen C 55 85
. C 56 85
less C 58 85
than C 59 85
one C 60 85
- C 61 85
third C 62 85
survived C 63 85
. C 64 85
evidence C 66 85
is C 67 85
presented C 68 85
which C 69 85
indicates C 70 85
that C 71 85
edta C 72 85
is C 73 85
injurious C 74 85
to C 75 85
platelets C 76 85
. C 77 85
when C 79 85
an C 80 85
acid C 81 85
- C 82 85
citrate C 83 85
medium C 84 85
that C 85 85
buffered C 86 85
plasma C 87 85
at C 88 85
ph C 89 85
6 C 90 85
. C 91 85
. C 92 85
was C 93 85
used C 94 85
as C 95 85
an C 96 85
anticoagulant C 97 85
, C 98 85
36 C 99 85
to C 100 85
85 C 101 85
of C 102 85
the C 103 85
labeled C 104 85
platelets C 105 85
survived C 106 85
( C 107 85
average C 108 85
, C 109 85
62 C 110 85
) C 111 85
, C 112 85
and C 113 85
marked C 114 85
temporary C 115 85
sequestration C 116 85
did C 117 85
not C 118 85
occur C 119 85
. C 120 85
studies C 122 85
in C 123 85
thrombocytopenic C 124 85
persons C 125 85
showed C 126 85
that C 127 85
circulating C 128 85
platelet C 129 85
cr C 130 85
activity C 131 85
measures C 132 85
the C 133 85
true C 134 85
survival C 135 85
of C 136 85
such C 137 85
transfused C 138 85
platelets C 139 85
. C 140 85
the C 142 85
survival C 143 85
and C 144 85
sequestration C 145 85
of C 146 85
platelets C 147 85
were C 148 85
studied C 149 85
in C 150 85
normal C 151 85
subjects C 152 85
. C 153 85
the C 155 85
survival C 156 85
data C 157 85
support C 158 85
the C 159 85
concept C 160 85
that C 161 85
platelets C 162 85
die C 163 85
chiefly C 164 85
by C 165 85
a C 166 85
process C 167 85
of C 168 85
senescence C 169 85
. C 170 85
external C 172 85
scintillation C 173 85
scanning C 174 85
of C 175 85
the C 176 85
various C 177 85
organs C 178 85
suggests C 179 85
that C 180 85
normally C 181 85
the C 182 85
majority C 183 85
of C 184 85
platelets C 185 85
is C 186 85
destroyed C 187 85
in C 188 85
the C 189 85
liver C 190 85
. C 191 85
acute C 1 86
leukemia C 2 86
associated C 3 86
with C 4 86
phenylbutazone C 5 86
treatment C 6 86
. C 7 86
. C 9 86
a C 11 86
review C 12 86
of C 13 86
the C 14 86
literature C 15 86
and C 16 86
report C 17 86
of C 18 86
a C 19 86
further C 20 86
case C 21 86
. C 22 86
the C 24 86
possible C 25 86
toxic C 26 86
reactions C 27 86
to C 28 86
phenylbutazone C 29 86
have C 30 86
been C 31 86
listed C 32 86
, C 33 86
and C 34 86
a C 35 86
review C 36 86
of C 37 86
the C 38 86
literature C 39 86
of C 40 86
haematological C 41 86
complications C 42 86
has C 43 86
shown C 44 86
that C 45 86
16 C 46 86
deaths C 47 86
attributable C 48 86
to C 49 86
agranulocytosis C 50 86
, C 51 86
aplastic C 52 86
anaemia C 53 86
and C 54 86
thrombocytopenia C 55 86
have C 56 86
been C 57 86
recorded C 58 86
. C 59 86
the C 61 86
association C 62 86
between C 63 86
leukaemia C 64 86
and C 65 86
phenylbutazone C 66 86
first C 67 86
suggested C 68 86
by C 69 86
bean C 70 86
( C 71 86
1960 C 72 86
) C 73 86
has C 74 86
been C 75 86
amplified C 76 86
by C 77 86
further C 78 86
reports C 79 86
, C 80 86
which C 81 86
have C 82 86
been C 83 86
reviewed C 84 86
. C 85 86
a C 87 86
further C 88 86
case C 89 86
history C 90 86
has C 91 86
been C 92 86
presented C 93 86
. C 94 86
of C 96 86
the C 97 86
15 C 98 86
patients C 99 86
with C 100 86
acute C 101 86
leukaemia C 102 86
in C 103 86
which C 104 86
the C 105 86
association C 106 86
has C 107 86
been C 108 86
recorded C 109 86
, C 110 86
there C 111 86
were C 112 86
other C 113 86
possible C 114 86
leukaemogenic C 115 86
factors C 116 86
in C 117 86
three C 118 86
, C 119 86
and C 120 86
in C 121 86
a C 122 86
further C 123 86
three C 124 86
the C 125 86
drug C 126 86
had C 127 86
been C 128 86
given C 129 86
for C 130 86
only C 131 86
a C 132 86
short C 133 86
time C 134 86
before C 135 86
the C 136 86
leukaemia C 137 86
was C 138 86
diagnosed C 139 86
. C 140 86
however C 142 86
, C 143 86
in C 144 86
the C 145 86
remaining C 146 86
nine C 147 86
, C 148 86
the C 149 86
histories C 150 86
are C 151 86
such C 152 86
that C 153 86
the C 154 86
phenylbutazone C 155 86
ingestion C 156 86
may C 157 86
have C 158 86
been C 159 86
associated C 160 86
with C 161 86
the C 162 86
development C 163 86
of C 164 86
the C 165 86
leukaemia C 166 86
. C 167 86
further C 169 86
studies C 170 86
, C 171 86
which C 172 86
should C 173 86
include C 174 86
matched C 175 86
controls C 176 86
, C 177 86
are C 178 86
indicated C 179 86
, C 180 86
and C 181 86
will C 182 86
be C 183 86
required C 184 86
before C 185 86
a C 186 86
definite C 187 86
opinion C 188 86
can C 189 86
be C 190 86
given C 191 86
as C 192 86
to C 193 86
any C 194 86
causal C 195 86
relationship C 196 86
between C 197 86
the C 198 86
drug C 199 86
and C 200 86
the C 201 86
disease C 202 86
. C 203 86
absorbed C 1 87
radiation C 2 87
dose C 3 87
and C 4 87
excretion C 5 87
of C 6 87
cesium C 7 87
- C 8 87
131 C 9 87
in C 10 87
humans C 11 87
. C 12 87
data C 14 87
relating C 15 87
to C 16 87
the C 17 87
effective C 18 87
half C 19 87
- C 20 87
life C 21 87
, C 22 87
absorbed C 23 87
dose C 24 87
of C 25 87
radiation C 26 87
, C 27 87
and C 28 87
excretion C 29 87
rates C 30 87
of C 31 87
cesium C 32 87
- C 33 87
131 C 34 87
have C 35 87
been C 36 87
presented C 37 87
. C 38 87
cesium C 40 87
- C 41 87
131 C 42 87
is C 43 87
an C 44 87
excellent C 45 87
material C 46 87
for C 47 87
cardiac C 48 87
scanning C 49 87
, C 50 87
since C 51 87
a C 52 87
very C 53 87
low C 54 87
amount C 55 87
of C 56 87
radiation C 57 87
is C 58 87
absorbed C 59 87
- C 60 87
dash C 61 87
a C 62 87
dose C 63 87
of C 64 87
the C 65 87
order C 66 87
of C 67 87
one C 68 87
twentieth C 69 87
that C 70 87
received C 71 87
in C 72 87
diagnostic C 73 87
x C 74 87
- C 75 87
ray C 76 87
studies C 77 87
of C 78 87
the C 79 87
gastrointestinal C 80 87
tract C 81 87
. C 82 87
absorption C 84 87
of C 85 87
radiation C 86 87
can C 87 87
be C 88 87
reduced C 89 87
further C 90 87
by C 91 87
the C 92 87
administration C 93 87
of C 94 87
a C 95 87
thiazide C 96 87
type C 97 87
of C 98 87
diuretic C 99 87
and C 100 87
, C 101 87
probably C 102 87
, C 103 87
by C 104 87
catharsis C 105 87
after C 106 87
the C 107 87
scan C 108 87
. C 109 87
radiocardiography C 1 88
. C 2 88
. C 4 88
principles C 6 88
and C 7 88
methods C 8 88
. C 9 88
the C 11 88
aa C 12 88
show C 13 88
the C 14 88
importance C 15 88
of C 16 88
radiocardiography C 17 88
, C 18 88
as C 19 88
a C 20 88
method C 21 88
to C 22 88
evaluate C 23 88
the C 24 88
cardiac C 25 88
output C 26 88
, C 27 88
the C 28 88
ventricular C 29 88
volumes C 30 88
and C 31 88
the C 32 88
pulmonary C 33 88
blood C 34 88
volume C 35 88
. C 36 88
in C 38 88
this C 39 88
first C 40 88
paper C 41 88
, C 42 88
they C 43 88
are C 44 88
particulary C 45 88
concerned C 46 88
with C 47 88
some C 48 88
technical C 49 88
aspects C 50 88
, C 51 88
which C 52 88
are C 53 88
very C 54 88
important C 55 88
to C 56 88
collect C 57 88
data C 58 88
. C 59 88
the C 61 88
position C 62 88
of C 63 88
the C 64 88
collimator C 65 88
on C 66 88
the C 67 88
precordium C 68 88
, C 69 88
the C 70 88
injection C 71 88
of C 72 88
isotopes C 73 88
through C 74 88
a C 75 88
catheter C 76 88
, C 77 88
just C 78 88
behind C 79 88
the C 80 88
ventricle C 81 88
near C 82 88
the C 83 88
tricuspid C 84 88
valve C 85 88
, C 86 88
the C 87 88
selection C 88 88
of C 89 88
ratemeter C 90 88
constants C 91 88
the C 92 88
velocity C 93 88
of C 94 88
paper C 95 88
on C 96 88
the C 97 88
recorder C 98 88
and C 99 88
the C 100 88
way C 101 88
to C 102 88
read C 103 88
the C 104 88
area C 105 88
of C 106 88
the C 107 88
curve C 108 88
, C 109 88
were C 110 88
specially C 111 88
discussed C 112 88
. C 113 88
finally C 115 88
, C 116 88
they C 117 88
present C 118 88
the C 119 88
formula C 120 88
used C 121 88
to C 122 88
calculate C 123 88
cardiac C 124 88
output C 125 88
, C 126 88
ventricular C 127 88
volumes C 128 88
and C 129 88
pulmonary C 130 88
blood C 131 88
volumes C 132 88
. C 133 88
reaction C 1 89
of C 2 89
the C 3 89
adrenal C 4 89
cortex C 5 89
during C 6 89
controlled C 7 89
experimental C 8 89
hypothermia C 9 89
. C 10 89
the C 12 89
stress C 13 89
reaction C 14 89
caused C 15 89
by C 16 89
hypothermia C 17 89
was C 18 89
studied C 19 89
in C 20 89
rabbits C 21 89
subjected C 22 89
to C 23 89
controlled C 24 89
hypothermia C 25 89
by C 26 89
immersion C 27 89
in C 28 89
an C 29 89
icebath C 30 89
. C 31 89
some C 33 89
of C 34 89
the C 35 89
animals C 36 89
were C 37 89
re C 38 89
- C 39 89
warmed C 40 89
. C 41 89
to C 43 89
anesthetize C 44 89
the C 45 89
animals C 46 89
, C 47 89
pentobarbitone C 48 89
sodium C 49 89
( C 50 89
nembutal C 51 89
) C 52 89
was C 53 89
given C 54 89
intraperitoneally C 55 89
, C 56 89
and C 57 89
, C 58 89
in C 59 89
some C 60 89
cases C 61 89
, C 62 89
followed C 63 89
by C 64 89
ether C 65 89
anesthesia C 66 89
. C 67 89
further C 69 89
, C 70 89
the C 71 89
stress C 72 89
reaction C 73 89
produced C 74 89
by C 75 89
pentobarbitone C 76 89
alone C 77 89
was C 78 89
studied C 79 89
in C 80 89
five C 81 89
animals C 82 89
, C 83 89
and C 84 89
that C 85 89
of C 86 89
ether C 87 89
anesthesia C 88 89
alone C 89 89
in C 90 89
three C 91 89
. C 92 89
no C 94 89
anesthesia C 95 89
was C 96 89
given C 97 89
to C 98 89
the C 99 89
three C 100 89
rabbits C 101 89
placed C 102 89
in C 103 89
the C 104 89
refrigerator C 105 89
. C 106 89
the C 108 89
variation C 109 89
in C 110 89
distribution C 111 89
and C 112 89
amount C 113 89
of C 114 89
adrenocortical C 115 89
lipids C 116 89
served C 117 89
as C 118 89
an C 119 89
indicator C 120 89
for C 121 89
evaluation C 122 89
of C 123 89
the C 124 89
stress C 125 89
reaction C 126 89
. C 127 89
in C 129 89
all C 130 89
the C 131 89
hypothermia C 132 89
tests C 133 89
there C 134 89
occurred C 135 89
changes C 136 89
in C 137 89
the C 138 89
distribution C 139 89
and C 140 89
amount C 141 89
of C 142 89
cortical C 143 89
lipids C 144 89
, C 145 89
denoting C 146 89
a C 147 89
stress C 148 89
reaction C 149 89
brought C 150 89
about C 151 89
by C 152 89
hypothermia C 153 89
. C 154 89
in C 156 89
rabbits C 157 89
, C 158 89
the C 159 89
barbiturate C 160 89
did C 161 89
not C 162 89
seem C 163 89
to C 164 89
inhibit C 165 89
the C 166 89
stress C 167 89
reaction C 168 89
. C 169 89
this C 171 89
may C 172 89
be C 173 89
attributed C 174 89
partly C 175 89
to C 176 89
the C 177 89
test C 178 89
animal C 179 89
, C 180 89
as C 181 89
such C 182 89
and C 183 89
partly C 184 89
to C 185 89
the C 186 89
fact C 187 89
that C 188 89
shivering C 189 89
of C 190 89
some C 191 89
extent C 192 89
always C 193 89
occurred C 194 89
during C 195 89
the C 196 89
hypothermia C 197 89
experiments C 198 89
. C 199 89
use C 1 90
of C 2 90
a C 3 90
cross C 4 90
- C 5 90
circulation C 6 90
technique C 7 90
in C 8 90
studying C 9 90
respiratory C 10 90
responses C 11 90
to C 12 90
co C 13 90
. C 14 90
the C 16 90
effect C 17 90
of C 18 90
hypercapnia C 19 90
and C 20 90
hypocapnia C 21 90
on C 22 90
ventilation C 23 90
was C 24 90
investigated C 25 90
in C 26 90
cross C 27 90
- C 28 90
circulated C 29 90
dogs C 30 90
in C 31 90
which C 32 90
the C 33 90
recipient C 34 90
dog C 35 90
' C 36 90
s C 37 90
head C 38 90
and C 39 90
neck C 40 90
regions C 41 90
were C 42 90
perfused C 43 90
by C 44 90
blood C 45 90
from C 46 90
a C 47 90
donor C 48 90
dog C 49 90
. C 50 90
hypercapnia C 52 90
of C 53 90
the C 54 90
donor C 55 90
dog C 56 90
was C 57 90
produced C 58 90
by C 59 90
administering C 60 90
co C 61 90
- C 62 90
o C 63 90
- C 64 90
n C 65 90
gas C 66 90
mixtures C 67 90
in C 68 90
the C 69 90
inspired C 70 90
air C 71 90
. C 72 90
hypocapnia C 74 90
was C 75 90
produced C 76 90
by C 77 90
hyperventilating C 78 90
the C 79 90
donor C 80 90
dog C 81 90
with C 82 90
the C 83 90
aid C 84 90
of C 85 90
a C 86 90
respiratory C 87 90
pump C 88 90
. C 89 90
when C 91 90
the C 92 90
donor C 93 90
dog C 94 90
was C 95 90
hyperventilated C 96 90
, C 97 90
the C 98 90
ventilation C 99 90
of C 100 90
the C 101 90
recipient C 102 90
was C 103 90
maintained C 104 90
at C 105 90
or C 106 90
just C 107 90
below C 108 90
its C 109 90
resting C 110 90
level C 111 90
and C 112 90
it C 113 90
was C 114 90
independent C 115 90
of C 116 90
the C 117 90
arterial C 118 90
pco C 119 90
of C 120 90
the C 121 90
donor C 122 90
. C 123 90
the C 125 90
donor C 126 90
dog C 127 90
was C 128 90
apneic C 129 90
when C 130 90
the C 131 90
artificial C 132 90
hyperventilation C 133 90
was C 134 90
suspended C 135 90
and C 136 90
this C 137 90
response C 138 90
was C 139 90
not C 140 90
abolished C 141 90
by C 142 90
vagotomy C 143 90
. C 144 90
bilateral C 146 90
vagotomy C 147 90
caused C 148 90
an C 149 90
increase C 150 90
in C 151 90
ventilation C 152 90
in C 153 90
the C 154 90
recipient C 155 90
when C 156 90
its C 157 90
head C 158 90
was C 159 90
perfused C 160 90
by C 161 90
hypocapnic C 162 90
blood C 163 90
. C 164 90
bilateral C 166 90
removal C 167 90
of C 168 90
the C 169 90
carotid C 170 90
receptors C 171 90
did C 172 90
not C 173 90
influence C 174 90
the C 175 90
response C 176 90
to C 177 90
co C 178 90
qualitatively C 179 90
although C 180 90
there C 181 90
was C 182 90
some C 183 90
reduction C 184 90
in C 185 90
the C 186 90
ventilation C 187 90
of C 188 90
the C 189 90
recipient C 190 90
to C 191 90
cephalic C 192 90
hypercapnia C 193 90
. C 194 90
the C 196 90
ventilation C 197 90
of C 198 90
the C 199 90
recipient C 200 90
dog C 201 90
was C 202 90
best C 203 90
correlated C 204 90
to C 205 90
the C 206 90
ph C 207 90
and C 208 90
pco C 209 90
of C 210 90
its C 211 90
cerebrospinal C 212 90
fluid C 213 90
in C 214 90
both C 215 90
hypercapnic C 216 90
and C 217 90
hypocapnic C 218 90
states C 219 90
. C 220 90
action C 1 91
of C 2 91
phytohaemagglutinin C 3 91
in C 4 91
vitro C 5 91
on C 6 91
the C 7 91
lymphocytes C 8 91
of C 9 91
chronic C 10 91
lymphoid C 11 91
leukaemia C 12 91
. C 13 91
the C 15 91
in C 16 91
vitro C 17 91
action C 18 91
of C 19 91
phytohaemagglutinin C 20 91
has C 21 91
been C 22 91
the C 23 91
subjects C 24 91
of C 25 91
a C 26 91
comparative C 27 91
investigation C 28 91
of C 29 91
the C 30 91
lymphocytes C 31 91
of C 32 91
13 C 33 91
normal C 34 91
subjects C 35 91
and C 36 91
of C 37 91
15 C 38 91
cases C 39 91
of C 40 91
chronic C 41 91
lymphatic C 42 91
leukaemia C 43 91
. C 44 91
in C 46 91
both C 47 91
groups C 48 91
there C 49 91
is C 50 91
cellular C 51 91
change C 52 91
shown C 53 91
by C 54 91
the C 55 91
appearance C 56 91
of C 57 91
large C 58 91
basophil C 59 91
nucleolated C 60 91
cells C 61 91
showing C 62 91
mitotic C 63 91
activity C 64 91
. C 65 91
in C 67 91
all C 68 91
the C 69 91
cases C 70 91
of C 71 91
lymphatic C 72 91
leukaemia C 73 91
the C 74 91
percentage C 75 91
of C 76 91
cells C 77 91
undergoing C 78 91
such C 79 91
change C 80 91
is C 81 91
lower C 82 91
than C 83 91
in C 84 91
normal C 85 91
subjects C 86 91
, C 87 91
and C 88 91
the C 89 91
transformation C 90 91
occurs C 91 91
more C 92 91
slowly C 93 91
. C 94 91
the C 96 91
two C 97 91
phenomena C 98 91
are C 99 91
more C 100 91
striking C 101 91
the C 102 91
higher C 103 91
the C 104 91
initial C 105 91
leucocytosis C 106 91
. C 107 91
these C 109 91
results C 110 91
suggest C 111 91
, C 112 91
in C 113 91
chronic C 114 91
lymphatic C 115 91
leukaemia C 116 91
, C 117 91
the C 118 91
cells C 119 91
affected C 120 91
by C 121 91
the C 122 91
transformation C 123 91
are C 124 91
residual C 125 91
normal C 126 91
lymphoid C 127 91
elements C 128 91
. C 129 91
leukaemic C 131 91
lymphoid C 132 91
cells C 133 91
appear C 134 91
to C 135 91
be C 136 91
incapable C 137 91
of C 138 91
this C 139 91
transformation C 140 91
. C 141 91
demonstration C 1 92
of C 2 92
ventricular C 3 92
aneurysms C 4 92
by C 5 92
radioisotope C 6 92
scanning C 7 92
. C 8 92
radioisotope C 10 92
scanning C 11 92
of C 12 92
the C 13 92
cardiac C 14 92
blood C 15 92
pool C 16 92
after C 17 92
the C 18 92
intravenous C 19 92
injection C 20 92
of C 21 92
i C 22 92
- C 23 92
labeled C 24 92
iodipamide C 25 92
was C 26 92
carried C 27 92
out C 28 92
in C 29 92
14 C 30 92
patients C 31 92
with C 32 92
ventricular C 33 92
aneurysm C 34 92
. C 35 92
in C 37 92
4 C 38 92
, C 39 92
the C 40 92
aneurysm C 41 92
could C 42 92
be C 43 92
demonstrated C 44 92
on C 45 92
neither C 46 92
the C 47 92
anteroposterior C 48 92
chest C 49 92
roentgenogram C 50 92
nor C 51 92
the C 52 92
scan C 53 92
. C 54 92
in C 56 92
5 C 57 92
, C 58 92
the C 59 92
aneurysm C 60 92
was C 61 92
apparent C 62 92
on C 63 92
the C 64 92
radiograph C 65 92
, C 66 92
but C 67 92
the C 68 92
blood C 69 92
pool C 70 92
did C 71 92
not C 72 92
enter C 73 92
the C 74 92
area C 75 92
, C 76 92
suggesting C 77 92
a C 78 92
thrombus C 79 92
within C 80 92
the C 81 92
aneurysm C 82 92
. C 83 92
in C 85 92
5 C 86 92
, C 87 92
the C 88 92
aneurysm C 89 92
was C 90 92
detectable C 91 92
on C 92 92
the C 93 92
film C 94 92
and C 95 92
was C 96 92
also C 97 92
seen C 98 92
to C 99 92
be C 100 92
filled C 101 92
with C 102 92
radioactivity C 103 92
on C 104 92
the C 105 92
scan C 106 92
. C 107 92
presumably C 109 92
these C 110 92
findings C 111 92
showed C 112 92
that C 113 92
a C 114 92
thrombus C 115 92
had C 116 92
not C 117 92
yet C 118 92
formed C 119 92
. C 120 92
blood C 122 92
pool C 123 92
radioisotope C 124 92
scanning C 125 92
appears C 126 92
to C 127 92
be C 128 92
another C 129 92
tool C 130 92
in C 131 92
the C 132 92
diagnosis C 133 92
of C 134 92
ventricular C 135 92
aneurysm C 136 92
, C 137 92
useful C 138 92
also C 139 92
in C 140 92
demonstrating C 141 92
in C 142 92
some C 143 92
patients C 144 92
the C 145 92
presence C 146 92
or C 147 92
absence C 148 92
of C 149 92
an C 150 92
intraluminal C 151 92
clot C 152 92
within C 153 92
the C 154 92
aneurysm C 155 92
. C 156 92
propagation C 1 93
of C 2 93
lactic C 3 93
dehydrogenase C 4 93
- C 5 93
elevating C 6 93
virus C 7 93
in C 8 93
cell C 9 93
culture C 10 93
. C 11 93
primary C 13 93
cultures C 14 93
of C 15 93
adult C 16 93
mouse C 17 93
lung C 18 93
, C 19 93
spleen C 20 93
, C 21 93
and C 22 93
liver C 23 93
and C 24 93
of C 25 93
mouse C 26 93
embryo C 27 93
support C 28 93
the C 29 93
multiplication C 30 93
of C 31 93
the C 32 93
lactic C 33 93
dehydrogenase C 34 93
- C 35 93
elevating C 36 93
virus C 37 93
. C 38 93
such C 40 93
cultures C 41 93
produced C 42 93
virus C 43 93
continuously C 44 93
until C 45 93
they C 46 93
had C 47 93
been C 48 93
subcultured C 49 93
2 C 50 93
- C 51 93
3 C 52 93
times C 53 93
. C 54 93
this C 56 93
corresponded C 57 93
to C 58 93
20 C 59 93
weeks C 60 93
in C 61 93
the C 62 93
case C 63 93
of C 64 93
lung C 65 93
and C 66 93
spleen C 67 93
and C 68 93
to C 69 93
2 C 70 93
- C 71 93
3 C 72 93
weeks C 73 93
with C 74 93
cultures C 75 93
of C 76 93
embryo C 77 93
. C 78 93
viral C 80 93
multiplication C 81 93
was C 82 93
not C 83 93
accompanied C 84 93
by C 85 93
cytologic C 86 93
alterations C 87 93
in C 88 93
the C 89 93
cells C 90 93
or C 91 93
by C 92 93
changes C 93 93
in C 94 93
their C 95 93
rate C 96 93
of C 97 93
synthesis C 98 93
of C 99 93
nucleic C 100 93
acids C 101 93
or C 102 93
protein C 103 93
. C 104 93
infection C 106 93
did C 107 93
not C 108 93
cause C 109 93
detectable C 110 93
changes C 111 93
in C 112 93
either C 113 93
the C 114 93
production C 115 93
of C 116 93
ldh C 117 93
or C 118 93
in C 119 93
its C 120 93
release C 121 93
from C 122 93
cells C 123 93
. C 124 93
transformation C 1 94
of C 2 94
bovine C 3 94
cells C 4 94
in C 5 94
vitro C 6 94
after C 7 94
inoculation C 8 94
of C 9 94
simian C 10 94
virus C 11 94
40 C 12 94
or C 13 94
its C 14 94
nucleic C 15 94
acid C 16 94
. C 17 94
cells C 19 94
of C 20 94
bovine C 21 94
embryonic C 22 94
lung C 23 94
tissue C 24 94
in C 25 94
culture C 26 94
were C 27 94
inoculated C 28 94
with C 29 94
simian C 30 94
virus C 31 94
40 C 32 94
( C 33 94
sv C 34 94
40 C 35 94
) C 36 94
or C 37 94
a C 38 94
phenol C 39 94
extract C 40 94
of C 41 94
a C 42 94
high C 43 94
titer C 44 94
suspension C 45 94
of C 46 94
sv C 47 94
40 C 48 94
. C 49 94
both C 51 94
the C 52 94
virus C 53 94
and C 54 94
the C 55 94
nucleic C 56 94
acid C 57 94
preparation C 58 94
induced C 59 94
proliferative C 60 94
morphological C 61 94
changes C 62 94
characteristic C 63 94
for C 64 94
sv C 65 94
40 C 66 94
transformation C 67 94
. C 68 94
non C 70 94
- C 71 94
infected C 72 94
control C 73 94
cultures C 74 94
and C 75 94
cultures C 76 94
which C 77 94
were C 78 94
inoculated C 79 94
with C 80 94
a C 81 94
preparation C 82 94
of C 83 94
nucleic C 84 94
acid C 85 94
exposed C 86 94
to C 87 94
dnase C 88 94
and C 89 94
maintained C 90 94
under C 91 94
the C 92 94
same C 93 94
conditions C 94 94
as C 95 94
infected C 96 94
cultures C 97 94
showed C 98 94
a C 99 94
regular C 100 94
fibroblastic C 101 94
growth C 102 94
. C 103 94
cell C 105 94
lines C 106 94
of C 107 94
rapidly C 108 94
growing C 109 94
transformed C 110 94
cells C 111 94
have C 112 94
been C 113 94
obtained C 114 94
. C 115 94
most C 117 94
attempts C 118 94
to C 119 94
isolate C 120 94
virus C 121 94
from C 122 94
the C 123 94
transformed C 124 94
cells C 125 94
were C 126 94
negative C 127 94
, C 128 94
but C 129 94
minute C 130 94
amounts C 131 94
of C 132 94
virus C 133 94
were C 134 94
recovered C 135 94
from C 136 94
occasional C 137 94
passages C 138 94
. C 139 94
rapid C 1 95
transformation C 2 95
of C 3 95
human C 4 95
fibroblast C 5 95
cultures C 6 95
by C 7 95
simian C 8 95
virus C 9 95
40 C 10 95
. C 11 95
the C 13 95
risk C 14 95
of C 15 95
systemic C 16 95
embolism C 17 95
is C 18 95
assessed C 19 95
in C 20 95
a C 21 95
group C 22 95
of C 23 95
754 C 24 95
patients C 25 95
with C 26 95
chronic C 27 95
rheumatic C 28 95
heart C 29 95
disease C 30 95
followed C 31 95
over C 32 95
a C 33 95
period C 34 95
of C 35 95
5 C 36 95
, C 37 95
833 C 38 95
patient C 39 95
- C 40 95
years C 41 95
. C 42 95
the C 44 95
incidence C 45 95
of C 46 95
embolism C 47 95
was C 48 95
1 C 49 95
. C 50 95
. C 51 95
per C 52 95
patient C 53 95
- C 54 95
year C 55 95
for C 56 95
the C 57 95
whole C 58 95
group C 59 95
it C 60 95
was C 61 95
seven C 62 95
times C 63 95
higher C 64 95
in C 65 95
atrial C 66 95
fibrillation C 67 95
than C 68 95
in C 69 95
sinus C 70 95
rhythm C 71 95
when C 72 95
the C 73 95
duration C 74 95
of C 75 95
atrial C 76 95
fibrillation C 77 95
was C 78 95
known C 79 95
, C 80 95
it C 81 95
was C 82 95
found C 83 95
that C 84 95
one C 85 95
- C 86 95
third C 87 95
of C 88 95
the C 89 95
emboli C 90 95
occurred C 91 95
within C 92 95
one C 93 95
month C 94 95
and C 95 95
two C 96 95
- C 97 95
thirds C 98 95
within C 99 95
12 C 100 95
months C 101 95
after C 102 95
the C 103 95
onset C 104 95
of C 105 95
atrial C 106 95
fibrillation C 107 95
. C 108 95
the C 110 95
incidence C 111 95
of C 112 95
embolic C 113 95
recurrences C 114 95
was C 115 95
8 C 116 95
per C 117 95
patient C 118 95
- C 119 95
year C 120 95
, C 121 95
irrespective C 122 95
of C 123 95
the C 124 95
nature C 125 95
of C 126 95
the C 127 95
cardiac C 128 95
rhythm C 129 95
, C 130 95
but C 131 95
66 C 132 95
of C 133 95
the C 134 95
recurrences C 135 95
took C 136 95
place C 137 95
within C 138 95
12 C 139 95
months C 140 95
of C 141 95
the C 142 95
initial C 143 95
embolic C 144 95
episode C 145 95
. C 146 95
mitral C 148 95
valvotomy C 149 95
did C 150 95
not C 151 95
eliminate C 152 95
the C 153 95
danger C 154 95
of C 155 95
embolism C 156 95
. C 157 95
it C 159 95
is C 160 95
questionable C 161 95
whether C 162 95
it C 163 95
reduced C 164 95
its C 165 95
incidence C 166 95
. C 167 95
anticoagulant C 169 95
treatment C 170 95
reduced C 171 95
the C 172 95
incidence C 173 95
of C 174 95
embolic C 175 95
recurrences C 176 95
. C 177 95
the C 1 96
tissue C 2 96
reaction C 3 96
to C 4 96
hyperbaric C 5 96
oxygen C 6 96
. C 7 96
hyperbaric C 9 96
oxygen C 10 96
damages C 11 96
tissues C 12 96
exposed C 13 96
in C 14 96
vitro C 15 96
, C 16 96
but C 17 96
their C 18 96
sensitivity C 19 96
varies C 20 96
. C 21 96
if C 23 96
exposure C 24 96
is C 25 96
limited C 26 96
some C 27 96
tissues C 28 96
may C 29 96
recover C 30 96
. C 31 96
the C 33 96
effect C 34 96
appears C 35 96
to C 36 96
depend C 37 96
on C 38 96
oxygen C 39 96
tension C 40 96
rather C 41 96
than C 42 96
raised C 43 96
pressure C 44 96
per C 45 96
se C 46 96
. C 47 96
the C 49 96
tissue C 50 96
reaction C 51 96
may C 52 96
be C 53 96
involved C 54 96
in C 55 96
the C 56 96
clinical C 57 96
application C 58 96
of C 59 96
hyperbaric C 60 96
oxygen C 61 96
. C 62 96
attitudinal C 1 97
factors C 2 97
in C 3 97
congenital C 4 97
heart C 5 97
disease C 6 97
. C 7 97
this C 9 97
study C 10 97
considers C 11 97
the C 12 97
behavioral C 13 97
implications C 14 97
of C 15 97
congenital C 16 97
heart C 17 97
disease C 18 97
for C 19 97
the C 20 97
pediatric C 21 97
patient C 22 97
, C 23 97
his C 24 97
siblings C 25 97
, C 26 97
and C 27 97
his C 28 97
parents C 29 97
. C 30 97
the C 32 97
effects C 33 97
of C 34 97
a C 35 97
disease C 36 97
on C 37 97
the C 38 97
child C 39 97
, C 40 97
on C 41 97
his C 42 97
siblings C 43 97
, C 44 97
and C 45 97
on C 46 97
his C 47 97
parents C 48 97
and C 49 97
the C 50 97
interplay C 51 97
among C 52 97
these C 53 97
individuals C 54 97
are C 55 97
explored C 56 97
. C 57 97
the C 59 97
impact C 60 97
of C 61 97
the C 62 97
physician C 63 97
' C 64 97
s C 65 97
diagnosis C 66 97
is C 67 97
illustrated C 68 97
by C 69 97
the C 70 97
induced C 71 97
significant C 72 97
changes C 73 97
in C 74 97
family C 75 97
attitudes C 76 97
, C 77 97
which C 78 97
are C 79 97
not C 80 97
necessarily C 81 97
related C 82 97
to C 83 97
disease C 84 97
severity C 85 97
or C 86 97
child C 87 97
incapacity C 88 97
. C 89 97
poorer C 91 97
adjustment C 92 97
and C 93 97
anxiety C 94 97
in C 95 97
the C 96 97
cardiac C 97 97
child C 98 97
related C 99 97
more C 100 97
highly C 101 97
to C 102 97
maternal C 103 97
anxiety C 104 97
and C 105 97
pampering C 106 97
than C 107 97
to C 108 97
his C 109 97
degree C 110 97
of C 111 97
incapacity C 112 97
. C 113 97
maternal C 115 97
protectiveness C 116 97
and C 117 97
pampering C 118 97
were C 119 97
significantly C 120 97
greater C 121 97
in C 122 97
the C 123 97
cardiac C 124 97
than C 125 97
in C 126 97
the C 127 97
normal C 128 97
group C 129 97
and C 130 97
were C 131 97
highest C 132 97
in C 133 97
the C 134 97
cyanotic C 135 97
group C 136 97
the C 137 97
best C 138 97
predictor C 139 97
of C 140 97
maternal C 141 97
protectiveness C 142 97
was C 143 97
maternal C 144 97
anxiety C 145 97
, C 146 97
and C 147 97
it C 148 97
was C 149 97
found C 150 97
that C 151 97
the C 152 97
addition C 153 97
of C 154 97
other C 155 97
variables C 156 97
such C 157 97
as C 158 97
incapacity C 159 97
and C 160 97
child C 161 97
dependence C 162 97
failed C 163 97
to C 164 97
improve C 165 97
prediction C 166 97
substantially C 167 97
. C 168 97
maternal C 170 97
anxiety C 171 97
seemed C 172 97
related C 173 97
to C 174 97
the C 175 97
presence C 176 97
rather C 177 97
than C 178 97
to C 179 97
the C 180 97
severity C 181 97
of C 182 97
the C 183 97
heart C 184 97
condition C 185 97
. C 186 97
maternal C 1 98
anxiety C 2 98
during C 3 98
pregnancy C 4 98
and C 5 98
adequacy C 6 98
of C 7 98
mother C 8 98
and C 9 98
child C 10 98
adjustment C 11 98
eight C 12 98
months C 13 98
following C 14 98
childbirth C 15 98
. C 16 98
fifty C 18 98
pregnant C 19 98
women C 20 98
were C 21 98
administered C 22 98
a C 23 98
battery C 24 98
of C 25 98
psychological C 26 98
tests C 27 98
. C 28 98
on C 30 98
the C 31 98
basis C 32 98
of C 33 98
scores C 34 98
obtained C 35 98
from C 36 98
the C 37 98
manifest C 38 98
anxiety C 39 98
scale C 40 98
, C 41 98
these C 42 98
pregnant C 43 98
women C 44 98
were C 45 98
dichotomized C 46 98
into C 47 98
a C 48 98
/ C 49 98
high C 50 98
anxiety C 51 98
/ C 52 98
group C 53 98
and C 54 98
a C 55 98
/ C 56 98
low C 57 98
anxiety C 58 98
/ C 59 98
group C 60 98
. C 61 98
eight C 63 98
months C 64 98
following C 65 98
childbirth C 66 98
, C 67 98
the C 68 98
mothers C 69 98
and C 70 98
children C 71 98
were C 72 98
seen C 73 98
for C 74 98
a C 75 98
psychological C 76 98
assessment C 77 98
. C 78 98
it C 80 98
was C 81 98
found C 82 98
that C 83 98
the C 84 98
women C 85 98
in C 86 98
the C 87 98
/ C 88 98
high C 89 98
anxious C 90 98
/ C 91 98
group C 92 98
evidenced C 93 98
significantly C 94 98
more C 95 98
negative C 96 98
childrearing C 97 98
attitudes C 98 98
. C 99 98
that C 101 98
is C 102 98
, C 103 98
the C 104 98
/ C 105 98
high C 106 98
anxious C 107 98
/ C 108 98
mothers C 109 98
obtained C 110 98
significantly C 111 98
higher C 112 98
scores C 113 98
on C 114 98
the C 115 98
hostility C 116 98
and C 117 98
control C 118 98
factors C 119 98
measured C 120 98
by C 121 98
the C 122 98
pari C 123 98
. C 124 98
on C 126 98
the C 127 98
basis C 128 98
of C 129 98
the C 130 98
examiner C 131 98
' C 132 98
s C 133 98
ratings C 134 98
of C 135 98
the C 136 98
mother C 137 98
' C 138 98
s C 139 98
personality C 140 98
traits C 141 98
, C 142 98
it C 143 98
was C 144 98
found C 145 98
that C 146 98
the C 147 98
women C 148 98
who C 149 98
were C 150 98
highly C 151 98
anxious C 152 98
during C 153 98
pregnancy C 154 98
received C 155 98
much C 156 98
less C 157 98
favorable C 158 98
personality C 159 98
ratings C 160 98
at C 161 98
the C 162 98
time C 163 98
of C 164 98
the C 165 98
8 C 166 98
- C 167 98
month C 168 98
assessment C 169 98
. C 170 98
moreover C 172 98
, C 173 98
there C 174 98
was C 175 98
a C 176 98
significant C 177 98
difference C 178 98
in C 179 98
the C 180 98
proportions C 181 98
of C 182 98
mothers C 183 98
in C 184 98
the C 185 98
two C 186 98
groups C 187 98
who C 188 98
received C 189 98
a C 190 98
favorable C 191 98
rating C 192 98
from C 193 98
the C 194 98
examiner C 195 98
on C 196 98
the C 197 98
basis C 198 98
of C 199 98
his C 200 98
observation C 201 98
of C 202 98
the C 203 98
mother C 204 98
- C 205 98
child C 206 98
interaction C 207 98
during C 208 98
the C 209 98
session C 210 98
. C 211 98
in C 213 98
studying C 214 98
the C 215 98
children C 216 98
of C 217 98
these C 218 98
mothers C 219 98
, C 220 98
it C 221 98
was C 222 98
found C 223 98
that C 224 98
the C 225 98
children C 226 98
of C 227 98
the C 228 98
/ C 229 98
low C 230 98
anxious C 231 98
/ C 232 98
mothers C 233 98
received C 234 98
a C 235 98
significantly C 236 98
higher C 237 98
developmental C 238 98
quotient C 239 98
on C 240 98
the C 241 98
infant C 242 98
mental C 243 98
scale C 244 98
. C 245 98
in C 247 98
keeping C 248 98
with C 249 98
this C 250 98
finding C 251 98
, C 252 98
they C 253 98
also C 254 98
obtained C 255 98
a C 256 98
higher C 257 98
developmental C 258 98
quotient C 259 98
on C 260 98
the C 261 98
motor C 262 98
scale C 263 98
, C 264 98
although C 265 98
on C 266 98
this C 267 98
aspect C 268 98
of C 269 98
the C 270 98
intellectual C 271 98
assessment C 272 98
the C 273 98
difference C 274 98
was C 275 98
not C 276 98
statistically C 277 98
significant C 278 98
. C 279 98
also C 281 98
, C 282 98
the C 283 98
children C 284 98
from C 285 98
the C 286 98
/ C 287 98
low C 288 98
anxious C 289 98
/ C 290 98
mothers C 291 98
tended C 292 98
to C 293 98
receive C 294 98
a C 295 98
score C 296 98
indicative C 297 98
of C 298 98
a C 299 98
more C 300 98
favorable C 301 98
general C 302 98
emotional C 303 98
tone C 304 98
than C 305 98
did C 306 98
the C 307 98
offspring C 308 98
of C 309 98
the C 310 98
/ C 311 98
high C 312 98
anxious C 313 98
/ C 314 98
mothers C 315 98
. C 316 98
this C 318 98
difference C 319 98
between C 320 98
the C 321 98
two C 322 98
groups C 323 98
of C 324 98
children C 325 98
was C 326 98
not C 327 98
statistically C 328 98
significant C 329 98
. C 330 98
in C 332 98
general C 333 98
, C 334 98
the C 335 98
findings C 336 98
were C 337 98
consistent C 338 98
with C 339 98
the C 340 98
predictions C 341 98
that C 342 98
the C 343 98
children C 344 98
who C 345 98
were C 346 98
being C 347 98
reared C 348 98
by C 349 98
women C 350 98
who C 351 98
had C 352 98
been C 353 98
highly C 354 98
anxious C 355 98
during C 356 98
pregnancy C 357 98
would C 358 98
fare C 359 98
less C 360 98
well C 361 98
on C 362 98
tests C 363 98
of C 364 98
intellectual C 365 98
development C 366 98
and C 367 98
indices C 368 98
of C 369 98
emotional C 370 98
adjustment C 371 98
. C 372 98
the C 374 98
findings C 375 98
also C 376 98
were C 377 98
in C 378 98
keeping C 379 98
with C 380 98
the C 381 98
prediction C 382 98
that C 383 98
the C 384 98
highly C 385 98
anxious C 386 98
women C 387 98
during C 388 98
pregnancy C 389 98
would C 390 98
evidence C 391 98
less C 392 98
desirable C 393 98
parental C 394 98
attitudes C 395 98
during C 396 98
their C 397 98
child C 398 98
' C 399 98
s C 400 98
early C 401 98
development C 402 98
and C 403 98
that C 404 98
they C 405 98
would C 406 98
present C 407 98
a C 408 98
less C 409 98
favorable C 410 98
personality C 411 98
picture C 412 98
at C 413 98
a C 414 98
time C 415 98
approximately C 416 98
8 C 417 98
months C 418 98
following C 419 98
pregnancy C 420 98
. C 421 98
maternal C 1 99
separation C 2 99
in C 3 99
the C 4 99
rhesus C 5 99
monkey C 6 99
. C 7 99
the C 9 99
present C 10 99
study C 11 99
involved C 12 99
separation C 13 99
of C 14 99
eight C 15 99
monkey C 16 99
mother C 17 99
- C 18 99
infant C 19 99
pairs C 20 99
for C 21 99
a C 22 99
period C 23 99
of C 24 99
two C 25 99
weeks C 26 99
and C 27 99
measurement C 28 99
of C 29 99
the C 30 99
behavior C 31 99
of C 32 99
the C 33 99
infants C 34 99
before C 35 99
, C 36 99
during C 37 99
and C 38 99
after C 39 99
reunion C 40 99
with C 41 99
their C 42 99
mothers C 43 99
, C 44 99
and C 45 99
of C 46 99
the C 47 99
mothers C 48 99
before C 49 99
and C 50 99
after C 51 99
reunion C 52 99
. C 53 99
all C 55 99
infants C 56 99
showed C 57 99
emotional C 58 99
disturbance C 59 99
in C 60 99
response C 61 99
to C 62 99
separation C 63 99
and C 64 99
drastic C 65 99
decreases C 66 99
in C 67 99
play C 68 99
and C 69 99
other C 70 99
complex C 71 99
social C 72 99
behaviors C 73 99
while C 74 99
separated C 75 99
. C 76 99
it C 78 99
is C 79 99
clear C 80 99
that C 81 99
infant C 82 99
- C 83 99
mother C 84 99
separation C 85 99
produces C 86 99
emotional C 87 99
disturbance C 88 99
in C 89 99
both C 90 99
human C 91 99
and C 92 99
macaque C 93 99
infants C 94 99
and C 95 99
that C 96 99
the C 97 99
patterns C 98 99
of C 99 99
responses C 100 99
following C 101 99
separation C 102 99
are C 103 99
similar C 104 99
in C 105 99
both C 106 99
species C 107 99
. C 108 99
the C 110 99
results C 111 99
obtained C 112 99
in C 113 99
studies C 114 99
of C 115 99
monkey C 116 99
infant C 117 99
- C 118 99
mother C 119 99
separation C 120 99
indicate C 121 99
that C 122 99
sheer C 123 99
physical C 124 99
separation C 125 99
is C 126 99
the C 127 99
crucial C 128 99
aspect C 129 99
of C 130 99
maternal C 131 99
separation C 132 99
for C 133 99
monkeys C 134 99
. C 135 99
undoubtedly C 137 99
other C 138 99
factors C 139 99
associated C 140 99
with C 141 99
separation C 142 99
from C 143 99
the C 144 99
mother C 145 99
are C 146 99
vitally C 147 99
important C 148 99
for C 149 99
human C 150 99
children C 151 99
, C 152 99
and C 153 99
may C 154 99
account C 155 99
in C 156 99
part C 157 99
for C 158 99
the C 159 99
absence C 160 99
or C 161 99
rarity C 162 99
of C 163 99
the C 164 99
detachment C 165 99
stage C 166 99
( C 167 99
as C 168 99
seen C 169 99
in C 170 99
human C 171 99
response C 172 99
pattern C 173 99
) C 174 99
in C 175 99
separated C 176 99
monkey C 177 99
infants C 178 99
. C 179 99
the C 181 99
overall C 182 99
results C 183 99
show C 184 99
considerable C 185 99
similarity C 186 99
in C 187 99
the C 188 99
responses C 189 99
of C 190 99
human C 191 99
children C 192 99
and C 193 99
infant C 194 99
monkeys C 195 99
to C 196 99
separation C 197 99
from C 198 99
the C 199 99
mother C 200 99
. C 201 99
the C 1 100
ophthalmologist C 2 100
' C 3 100
s C 4 100
role C 5 100
in C 6 100
the C 7 100
management C 8 100
of C 9 100
dyslexia C 10 100
. C 11 100
dyslexia C 13 100
is C 14 100
a C 15 100
clinical C 16 100
entity C 17 100
characterized C 18 100
by C 19 100
subnormal C 20 100
reading C 21 100
ability C 22 100
in C 23 100
a C 24 100
person C 25 100
of C 26 100
average C 27 100
or C 28 100
above C 29 100
average C 30 100
intelligence C 31 100
. C 32 100
it C 34 100
is C 35 100
a C 36 100
disease C 37 100
which C 38 100
has C 39 100
different C 40 100
causes C 41 100
in C 42 100
different C 43 100
children C 44 100
. C 45 100
the C 47 100
causes C 48 100
include C 49 100
brain C 50 100
damage C 51 100
in C 52 100
the C 53 100
/ C 54 100
language C 55 100
area C 56 100
, C 57 100
/ C 58 100
hereditary C 59 100
predisposition C 60 100
and C 61 100
such C 62 100
ophthalmic C 63 100
factors C 64 100
as C 65 100
hyperopia C 66 100
, C 67 100
muscle C 68 100
imbalance C 69 100
, C 70 100
aniseikonia C 71 100
or C 72 100
visual C 73 100
immaturity C 74 100
. C 75 100
emotional C 77 100
disturbances C 78 100
, C 79 100
educational C 80 100
immaturity C 81 100
and C 82 100
cerebral C 83 100
dominance C 84 100
may C 85 100
also C 86 100
play C 87 100
some C 88 100
role C 89 100
in C 90 100
the C 91 100
etiology C 92 100
of C 93 100
this C 94 100
condition C 95 100
. C 96 100
the C 98 100
universal C 99 100
symptom C 100 100
is C 101 100
poor C 102 100
reading C 103 100
ability C 104 100
. C 105 100
however C 107 100
, C 108 100
these C 109 100
cases C 110 100
frequently C 111 100
have C 112 100
other C 113 100
associated C 114 100
symptoms C 115 100
such C 116 100
as C 117 100
poor C 118 100
writing C 119 100
, C 120 100
difficulty C 121 100
in C 122 100
reading C 123 100
and C 124 100
writing C 125 100
numbers C 126 100
, C 127 100
inability C 128 100
to C 129 100
read C 130 100
or C 131 100
write C 132 100
musical C 133 100
notes C 134 100
and C 135 100
disorientation C 136 100
for C 137 100
left C 138 100
and C 139 100
right C 140 100
. C 141 100
many C 143 100
of C 144 100
these C 145 100
patients C 146 100
develop C 147 100
personality C 148 100
maladjustments C 149 100
. C 150 100
visual C 152 100
fields C 153 100
often C 154 100
reveal C 155 100
a C 156 100
hemianopia C 157 100
. C 158 100
in C 160 100
any C 161 100
group C 162 100
of C 163 100
poor C 164 100
readers C 165 100
, C 166 100
a C 167 100
large C 168 100
percentage C 169 100
will C 170 100
have C 171 100
ocular C 172 100
, C 173 100
neurologic C 174 100
, C 175 100
psychiatric C 176 100
or C 177 100
psychologic C 178 100
abnormalities C 179 100
and C 180 100
/ C 181 100
or C 182 100
a C 183 100
strong C 184 100
hereditary C 185 100
tendency C 186 100
. C 187 100
the C 189 100
degree C 190 100
to C 191 100
which C 192 100
reading C 193 100
can C 194 100
be C 195 100
learned C 196 100
depends C 197 100
upon C 198 100
the C 199 100
ability C 200 100
of C 201 100
the C 202 100
individual C 203 100
to C 204 100
adjust C 205 100
to C 206 100
the C 207 100
psycho C 208 100
- C 209 100
physiologic C 210 100
needs C 211 100
that C 212 100
are C 213 100
present C 214 100
at C 215 100
the C 216 100
time C 217 100
he C 218 100
reaches C 219 100
/ C 220 100
reading C 221 100
age C 222 100
/ C 223 100
in C 224 100
school C 225 100
. C 226 100
if C 228 100
compensating C 229 100
abilities C 230 100
are C 231 100
present C 232 100
, C 233 100
and C 234 100
if C 235 100
the C 236 100
child C 237 100
' C 238 100
s C 239 100
reaction C 240 100
is C 241 100
a C 242 100
favorable C 243 100
one C 244 100
, C 245 100
he C 246 100
may C 247 100
read C 248 100
well C 249 100
in C 250 100
spite C 251 100
of C 252 100
unfavorable C 253 100
factors C 254 100
, C 255 100
. C 256 100
if C 258 100
not C 259 100
, C 260 100
he C 261 100
may C 262 100
become C 263 100
a C 264 100
/ C 265 100
poor C 266 100
reader C 267 100
/ C 268 100
. C 269 100
these C 271 100
children C 272 100
should C 273 100
be C 274 100
recognized C 275 100
in C 276 100
their C 277 100
first C 278 100
year C 279 100
of C 280 100
school C 281 100
. C 282 100
a C 284 100
complete C 285 100
medical C 286 100
work C 287 100
- C 288 100
up C 289 100
should C 290 100
be C 291 100
managed C 292 100
by C 293 100
an C 294 100
ophthalmologist C 295 100
. C 296 100
a C 298 100
complete C 299 100
ophthalmic C 300 100
examination C 301 100
should C 302 100
first C 303 100
be C 304 100
performed C 305 100
and C 306 100
all C 307 100
possible C 308 100
visual C 309 100
anomalies C 310 100
should C 311 100
be C 312 100
corrected C 313 100
. C 314 100
the C 316 100
ophthalmologist C 317 100
may C 318 100
want C 319 100
a C 320 100
psychometric C 321 100
evaluation C 322 100
, C 323 100
a C 324 100
neurologic C 325 100
opinion C 326 100
to C 327 100
determine C 328 100
the C 329 100
role C 330 100
of C 331 100
organic C 332 100
brain C 333 100
damage C 334 100
, C 335 100
psychiatric C 336 100
consultation C 337 100
for C 338 100
evaluation C 339 100
of C 340 100
emotional C 341 100
disturbances C 342 100
, C 343 100
pediatric C 344 100
consultation C 345 100
for C 346 100
evaluation C 347 100
of C 348 100
the C 349 100
status C 350 100
of C 351 100
the C 352 100
general C 353 100
health C 354 100
and C 355 100
/ C 356 100
or C 357 100
consultation C 358 100
by C 359 100
an C 360 100
otolaryngologist C 361 100
to C 362 100
determine C 363 100
the C 364 100
patient C 365 100
' C 366 100
s C 367 100
hearing C 368 100
ability C 369 100
. C 370 100
with C 372 100
all C 373 100
the C 374 100
necessary C 375 100
information C 376 100
at C 377 100
hand C 378 100
, C 379 100
the C 380 100
ophthalmologist C 381 100
will C 382 100
be C 383 100
able C 384 100
to C 385 100
recommend C 386 100
corrective C 387 100
medical C 388 100
therapy C 389 100
and C 390 100
to C 391 100
advise C 392 100
the C 393 100
parents C 394 100
and C 395 100
teachers C 396 100
about C 397 100
available C 398 100
remedial C 399 100
reading C 400 100
aids C 401 100
. C 402 100
the C 404 100
prognosis C 405 100
is C 406 100
good C 407 100
for C 408 100
most C 409 100
patients C 410 100
since C 411 100
they C 412 100
are C 413 100
of C 414 100
average C 415 100
or C 416 100
above C 417 100
average C 418 100
intelligence C 419 100
, C 420 100
. C 421 100
nearly C 423 100
all C 424 100
cases C 425 100
can C 426 100
be C 427 100
helped C 428 100
. C 429 100
unusual C 1 101
course C 2 101
of C 3 101
internal C 4 101
carotid C 5 101
artery C 6 101
accompanied C 7 101
by C 8 101
bitemporal C 9 101
hemianopia C 10 101
. C 11 101
a C 13 101
case C 14 101
is C 15 101
reported C 16 101
with C 17 101
bitemporal C 18 101
relative C 19 101
hemianopia C 20 101
, C 21 101
craniotomy C 22 101
showing C 23 101
internal C 24 101
carotid C 25 101
arteries C 26 101
to C 27 101
have C 28 101
an C 29 101
unusual C 30 101
course C 31 101
, C 32 101
corresponding C 33 101
to C 34 101
the C 35 101
carotid C 36 101
siphon C 37 101
, C 38 101
with C 39 101
resultant C 40 101
change C 41 101
in C 42 101
shape C 43 101
of C 44 101
the C 45 101
optic C 46 101
nerves C 47 101
. C 48 101
abnormalities C 50 101
of C 51 101
the C 52 101
carotid C 53 101
siphons C 54 101
could C 55 101
not C 56 101
be C 57 101
detected C 58 101
on C 59 101
reviewing C 60 101
the C 61 101
carotid C 62 101
angiograms C 63 101
. C 64 101
evaluation C 66 101
of C 67 101
the C 68 101
optic C 69 101
nerve C 70 101
' C 71 101
s C 72 101
relationship C 73 101
, C 74 101
as C 75 101
can C 76 101
be C 77 101
measured C 78 101
on C 79 101
the C 80 101
pneumograms C 81 101
, C 82 101
indicated C 83 101
that C 84 101
the C 85 101
optic C 86 101
nerves C 87 101
in C 88 101
this C 89 101
case C 90 101
were C 91 101
exposed C 92 101
to C 93 101
compression C 94 101
from C 95 101
the C 96 101
abnormal C 97 101
arteries C 98 101
. C 99 101
frontal C 1 102
lobes C 2 102
and C 3 102
vision C 4 102
. C 5 102
the C 7 102
influence C 8 102
of C 9 102
the C 10 102
frontal C 11 102
lobe C 12 102
on C 13 102
vision C 14 102
is C 15 102
discussed C 16 102
based C 17 102
on C 18 102
the C 19 102
presentation C 20 102
of C 21 102
a C 22 102
rather C 23 102
unusual C 24 102
case C 25 102
. C 26 102
after C 28 102
the C 29 102
operation C 30 102
of C 31 102
a C 32 102
right C 33 102
frontal C 34 102
brain C 35 102
abscess C 36 102
, C 37 102
which C 38 102
never C 39 102
had C 40 102
led C 41 102
to C 42 102
papilledema C 43 102
, C 44 102
there C 45 102
was C 46 102
a C 47 102
pronounced C 48 102
diminution C 49 102
of C 50 102
the C 51 102
visual C 52 102
capacities C 53 102
of C 54 102
the C 55 102
patient C 56 102
, C 57 102
. C 58 102
gradually C 60 102
these C 61 102
disturbances C 62 102
regressed C 63 102
to C 64 102
the C 65 102
point C 66 102
of C 67 102
return C 68 102
of C 69 102
full C 70 102
visual C 71 102
acuity C 72 102
, C 73 102
. C 74 102
but C 76 102
there C 77 102
remained C 78 102
a C 79 102
hemianopic C 80 102
field C 81 102
defect C 82 102
. C 83 102
this C 85 102
and C 86 102
psychological C 87 102
defects C 88 102
in C 89 102
the C 90 102
sense C 91 102
of C 92 102
a C 93 102
partial C 94 102
visual C 95 102
agnosia C 96 102
( C 97 102
which C 98 102
latter C 99 102
are C 100 102
also C 101 102
regressing C 102 102
very C 103 102
well C 104 102
) C 105 102
prompted C 106 102
a C 107 102
discussion C 108 102
of C 109 102
those C 110 102
neuroanatomical C 111 102
and C 112 102
neurophysiological C 113 102
observations C 114 102
pertinent C 115 102
to C 116 102
the C 117 102
findings C 118 102
in C 119 102
this C 120 102
patient C 121 102
. C 122 102
the C 124 102
many C 125 102
data C 126 102
on C 127 102
the C 128 102
fronto C 129 102
- C 130 102
occipital C 131 102
connections C 132 102
in C 133 102
subhuman C 134 102
primates C 135 102
point C 136 102
to C 137 102
the C 138 102
role C 139 102
of C 140 102
the C 141 102
frontal C 142 102
lobe C 143 102
( C 144 102
area C 145 102
8 C 146 102
) C 147 102
in C 148 102
the C 149 102
development C 150 102
of C 151 102
visual C 152 102
disturbances C 153 102
in C 154 102
the C 155 102
sense C 156 102
of C 157 102
a C 158 102
temporary C 159 102
hemianopia C 160 102
with C 161 102
partial C 162 102
visual C 163 102
agnosia C 164 102
and C 165 102
some C 166 102
intellectual C 167 102
deficits C 168 102
. C 169 102
contrary C 171 102
to C 172 102
a C 173 102
single C 174 102
observation C 175 102
in C 176 102
an C 177 102
anthropoid C 178 102
ape C 179 102
, C 180 102
our C 181 102
case C 182 102
would C 183 102
seem C 184 102
to C 185 102
indicate C 186 102
that C 187 102
the C 188 102
aforementioned C 189 102
combination C 190 102
of C 191 102
symptoms C 192 102
may C 193 102
originate C 194 102
in C 195 102
the C 196 102
frontal C 197 102
lobe C 198 102
, C 199 102
. C 200 102
and C 202 102
we C 203 102
hope C 204 102
it C 205 102
will C 206 102
prompt C 207 102
other C 208 102
long C 209 102
- C 210 102
term C 211 102
follow C 212 102
- C 213 102
up C 214 102
studies C 215 102
of C 216 102
similar C 217 102
patients C 218 102
. C 219 102
the C 221 102
continued C 222 102
observation C 223 102
of C 224 102
this C 225 102
patient C 226 102
and C 227 102
perhaps C 228 102
of C 229 102
others C 230 102
will C 231 102
give C 232 102
a C 233 102
possibility C 234 102
to C 235 102
gain C 236 102
insight C 237 102
into C 238 102
the C 239 102
role C 240 102
of C 241 102
the C 242 102
frontal C 243 102
lobe C 244 102
in C 245 102
vision C 246 102
, C 247 102
as C 248 102
has C 249 102
been C 250 102
assumed C 251 102
for C 252 102
animals C 253 102
. C 254 102
physiologic C 1 103
bitemporal C 2 103
hemianopsia C 3 103
in C 4 103
pregnancy C 5 103
. C 6 103
a C 8 103
severe C 9 103
case C 10 103
of C 11 103
bitemporal C 12 103
hemianopsia C 13 103
occurring C 14 103
late C 15 103
in C 16 103
pregnancy C 17 103
is C 18 103
presented C 19 103
. C 20 103
the C 22 103
patient C 23 103
illustrated C 24 103
a C 25 103
typical C 26 103
rapidly C 27 103
progressive C 28 103
course C 29 103
and C 30 103
rapid C 31 103
recovery C 32 103
with C 33 103
complete C 34 103
return C 35 103
of C 36 103
visual C 37 103
fields C 38 103
and C 39 103
visual C 40 103
acuity C 41 103
after C 42 103
delivery C 43 103
was C 44 103
accomplished C 45 103
. C 46 103
the C 48 103
presumed C 49 103
pathologic C 50 103
physiology C 51 103
of C 52 103
this C 53 103
entity C 54 103
is C 55 103
briefly C 56 103
reviewed C 57 103
. C 58 103
evoked C 1 104
response C 2 104
in C 3 104
visual C 4 104
disorders C 5 104
. C 6 104
1 C 8 104
. C 9 104
erg C 11 104
and C 12 104
ver C 13 104
have C 14 104
been C 15 104
recorded C 16 104
from C 17 104
eyelid C 18 104
and C 19 104
lateral C 20 104
occipital C 21 104
electrodes C 22 104
in C 23 104
response C 24 104
to C 25 104
diffuse C 26 104
stroboscopic C 27 104
stimulation C 28 104
. C 29 104
in C 31 104
45 C 32 104
normal C 33 104
subjects C 34 104
ver C 35 104
was C 36 104
found C 37 104
to C 38 104
be C 39 104
composed C 40 104
of C 41 104
an C 42 104
early C 43 104
triphasic C 44 104
potential C 45 104
arising C 46 104
from C 47 104
the C 48 104
occipital C 49 104
region C 50 104
. C 51 104
wave C 53 104
i C 54 104
was C 55 104
present C 56 104
in C 57 104
67 C 58 104
percent C 59 104
of C 60 104
subjects C 61 104
, C 62 104
wave C 63 104
ii C 64 104
in C 65 104
97 C 66 104
percent C 67 104
, C 68 104
and C 69 104
wave C 70 104
iii C 71 104
in C 72 104
100 C 73 104
percent C 74 104
later C 75 104
waves C 76 104
were C 77 104
inconstant C 78 104
and C 79 104
contained C 80 104
components C 81 104
from C 82 104
the C 83 104
vertex C 84 104
reference C 85 104
. C 86 104
no C 88 104
overall C 89 104
asymmetry C 90 104
in C 91 104
ver C 92 104
from C 93 104
right C 94 104
to C 95 104
left C 96 104
was C 97 104
found C 98 104
in C 99 104
normal C 100 104
subjects C 101 104
, C 102 104
although C 103 104
average C 104 104
asymmetry C 105 104
with C 106 104
smaller C 107 104
side C 108 104
compared C 109 104
to C 110 104
larger C 111 104
was C 112 104
19 C 113 104
percent C 114 104
12 C 115 104
. C 116 104
. C 117 104
. C 118 104
on C 120 104
monocular C 121 104
stimulation C 122 104
the C 123 104
contralateral C 124 104
ver C 125 104
was C 126 104
regularly C 127 104
larger C 128 104
than C 129 104
the C 130 104
ipsilateral C 131 104
reflecting C 132 104
predominant C 133 104
retinal C 134 104
representation C 135 104
of C 136 104
the C 137 104
temporal C 138 104
field C 139 104
. C 140 104
2 C 142 104
. C 143 104
a C 145 104
statistically C 146 104
determined C 147 104
criterion C 148 104
of C 149 104
50 C 150 104
percent C 151 104
depression C 152 104
in C 153 104
wave C 154 104
ii C 155 104
successfully C 156 104
identifies C 157 104
most C 158 104
patients C 159 104
with C 160 104
hemianopic C 161 104
defects C 162 104
involving C 163 104
the C 164 104
central C 165 104
10 C 166 104
percent C 167 104
of C 168 104
visual C 169 104
field C 170 104
on C 171 104
tangent C 172 104
screen C 173 104
campimetry C 174 104
. C 175 104
latency C 177 104
asymmetry C 178 104
of C 179 104
six C 180 104
msec C 181 104
. C 182 104
or C 184 104
more C 185 104
and C 186 104
grossly C 187 104
asymmetrical C 188 104
aberrant C 189 104
wave C 190 104
forms C 191 104
are C 192 104
seen C 193 104
in C 194 104
some C 195 104
patients C 196 104
with C 197 104
diffuse C 198 104
cerebral C 199 104
disease C 200 104
and C 201 104
hemianopic C 202 104
defects C 203 104
. C 204 104
3 C 206 104
. C 207 104
severe C 209 104
or C 210 104
diffuse C 211 104
retinal C 212 104
disease C 213 104
is C 214 104
associated C 215 104
with C 216 104
alteration C 217 104
or C 218 104
loss C 219 104
of C 220 104
erg C 221 104
and C 222 104
ver C 223 104
on C 224 104
stimulation C 225 104
of C 226 104
the C 227 104
involved C 228 104
eye C 229 104
. C 230 104
4 C 232 104
. C 233 104
optic C 235 104
nerve C 236 104
disease C 237 104
is C 238 104
indicated C 239 104
by C 240 104
bilateral C 241 104
loss C 242 104
or C 243 104
suppression C 244 104
of C 245 104
ver C 246 104
on C 247 104
stimulation C 248 104
of C 249 104
the C 250 104
involved C 251 104
eye C 252 104
. C 253 104
erg C 255 104
is C 256 104
normal C 257 104
. C 258 104
5 C 260 104
. C 261 104
bilateral C 263 104
prechiasmal C 264 104
involvement C 265 104
is C 266 104
associated C 267 104
with C 268 104
complete C 269 104
suppression C 270 104
of C 271 104
ver C 272 104
. C 273 104
if C 275 104
only C 276 104
waves C 277 104
i C 278 104
and C 279 104
ii C 280 104
are C 281 104
lost C 282 104
, C 283 104
disease C 284 104
is C 285 104
probably C 286 104
, C 287 104
but C 288 104
not C 289 104
conclusively C 290 104
, C 291 104
demonstrated C 292 104
. C 293 104
6 C 295 104
. C 296 104
involvement C 298 104
of C 299 104
nasal C 300 104
retinal C 301 104
fibres C 302 104
is C 303 104
indicated C 304 104
by C 305 104
reversal C 306 104
of C 307 104
the C 308 104
normal C 309 104
contralateral C 310 104
preponderance C 311 104
of C 312 104
ver C 313 104
on C 314 104
monocular C 315 104
stimulation C 316 104
. C 317 104
these C 319 104
changes C 320 104
are C 321 104
observed C 322 104
in C 323 104
chiasmal C 324 104
disease C 325 104
. C 326 104
7 C 328 104
. C 329 104
retrogeniculate C 331 104
blindness C 332 104
is C 333 104
associated C 334 104
with C 335 104
loss C 336 104
of C 337 104
early C 338 104
ver C 339 104
and C 340 104
preservation C 341 104
of C 342 104
late C 343 104
response C 344 104
. C 345 104
nonspecific C 347 104
projections C 348 104
are C 349 104
felt C 350 104
to C 351 104
contribute C 352 104
to C 353 104
the C 354 104
late C 355 104
cortical C 356 104
response C 357 104
to C 358 104
photic C 359 104
stimulation C 360 104
. C 361 104
optokinetic C 1 105
nystagmus C 2 105
and C 3 105
occipital C 4 105
lesions C 5 105
. C 6 105
six C 8 105
cases C 9 105
are C 10 105
presented C 11 105
to C 12 105
invalidate C 13 105
the C 14 105
rule C 15 105
that C 16 105
horizontally C 17 105
symmetric C 18 105
optokinetic C 19 105
responses C 20 105
indicate C 21 105
a C 22 105
vascular C 23 105
etiology C 24 105
in C 25 105
patients C 26 105
with C 27 105
occipital C 28 105
lobe C 29 105
type C 30 105
hemianopias C 31 105
. C 32 105
the C 34 105
converse C 35 105
of C 36 105
this C 37 105
rule C 38 105
is C 39 105
, C 40 105
in C 41 105
our C 42 105
experience C 43 105
, C 44 105
still C 45 105
a C 46 105
valuable C 47 105
observation C 48 105
. C 49 105
that C 51 105
is C 52 105
, C 53 105
asymmetry C 54 105
of C 55 105
horizontal C 56 105
optokinetic C 57 105
responses C 58 105
accompanying C 59 105
an C 60 105
occipital C 61 105
type C 62 105
field C 63 105
defect C 64 105
is C 65 105
a C 66 105
strong C 67 105
indication C 68 105
of C 69 105
a C 70 105
mass C 71 105
lesion C 72 105
. C 73 105
optokinetic C 75 105
nystagmus C 76 105
may C 77 105
be C 78 105
helpful C 79 105
, C 80 105
therefore C 81 105
, C 82 105
as C 83 105
corroborative C 84 105
evidence C 85 105
in C 86 105
diagnosing C 87 105
occipital C 88 105
lobe C 89 105
tumor C 90 105
but C 91 105
not C 92 105
in C 93 105
ruling C 94 105
it C 95 105
out C 96 105
. C 97 105
anaphylactoid C 1 106
shock C 2 106
induced C 3 106
by C 4 106
oral C 5 106
penicillin C 6 106
and C 7 106
resulting C 8 106
in C 9 106
gerstmann C 10 106
' C 11 106
s C 12 106
syndrome C 13 106
. C 14 106
an C 16 106
anaphylactoid C 17 106
reaction C 18 106
to C 19 106
oral C 20 106
penicillin C 21 106
in C 22 106
a C 23 106
46 C 24 106
- C 25 106
year C 26 106
- C 27 106
old C 28 106
woman C 29 106
is C 30 106
described C 31 106
. C 32 106
. C 34 106
after C 36 106
hours C 37 106
of C 38 106
unconsciousness C 39 106
and C 40 106
weeks C 41 106
of C 42 106
confusion C 43 106
she C 44 106
was C 45 106
left C 46 106
with C 47 106
a C 48 106
residual C 49 106
gerstmann C 50 106
' C 51 106
s C 52 106
syndrome C 53 106
. C 54 106
these C 56 106
reactions C 57 106
are C 58 106
less C 59 106
rare C 60 106
than C 61 106
is C 62 106
generally C 63 106
supposed C 64 106
. C 65 106
symptomatology C 67 106
, C 68 106
treatment C 69 106
, C 70 106
diagnosis C 71 106
, C 72 106
and C 73 106
mechanism C 74 106
are C 75 106
discussed C 76 106
, C 77 106
and C 78 106
some C 79 106
of C 80 106
the C 81 106
relevant C 82 106
literature C 83 106
is C 84 106
briefly C 85 106
reviewed C 86 106
. C 87 106
disturbances C 1 107
of C 2 107
the C 3 107
verbal C 4 107
body C 5 107
image C 6 107
. C 7 107
. C 9 107
a C 11 107
particular C 12 107
syndrome C 13 107
of C 14 107
sensory C 15 107
aphasia C 16 107
. C 17 107
1 C 19 107
. C 20 107
the C 22 107
pto C 23 107
syndrome C 24 107
of C 25 107
the C 26 107
dominant C 27 107
hemisphere C 28 107
varies C 29 107
according C 30 107
to C 31 107
the C 32 107
extent C 33 107
and C 34 107
depth C 35 107
of C 36 107
the C 37 107
lesion C 38 107
in C 39 107
the C 40 107
angular C 41 107
and C 42 107
supramarginal C 43 107
areas C 44 107
. C 45 107
the C 47 107
mildest C 48 107
clinical C 49 107
syndrome C 50 107
consists C 51 107
of C 52 107
a C 53 107
vague C 54 107
contralateral C 55 107
sensory C 56 107
impairment C 57 107
associated C 58 107
with C 59 107
dyscalculia C 60 107
, C 61 107
dysgraphia C 62 107
, C 63 107
dyslexia C 64 107
and C 65 107
difficulty C 66 107
in C 67 107
naming C 68 107
. C 69 107
a C 71 107
more C 72 107
extensive C 73 107
lesion C 74 107
is C 75 107
needed C 76 107
to C 77 107
cause C 78 107
the C 79 107
wide C 80 107
variety C 81 107
of C 82 107
classical C 83 107
signs C 84 107
described C 85 107
in C 86 107
parietal C 87 107
lobe C 88 107
disease C 89 107
, C 90 107
among C 91 107
them C 92 107
being C 93 107
gerstmann C 94 107
' C 95 107
s C 96 107
syndrome C 97 107
, C 98 107
which C 99 107
is C 100 107
usually C 101 107
found C 102 107
in C 103 107
association C 104 107
with C 105 107
other C 106 107
manifestations C 107 107
of C 108 107
parietal C 109 107
loss C 110 107
( C 111 107
case C 112 107
1 C 113 107
) C 114 107
. C 115 107
an C 117 107
even C 118 107
more C 119 107
extensive C 120 107
corticosubcortical C 121 107
lesion C 122 107
in C 123 107
the C 124 107
area C 125 107
leads C 126 107
to C 127 107
complete C 128 107
disintegration C 129 107
of C 130 107
naming C 131 107
and C 132 107
understanding C 133 107
of C 134 107
speech C 135 107
( C 136 107
cases C 137 107
3 C 138 107
, C 139 107
4 C 140 107
and C 141 107
5 C 142 107
) C 143 107
. C 144 107
2 C 146 107
. C 147 107
attention C 149 107
is C 150 107
drawn C 151 107
to C 152 107
the C 153 107
difficulties C 154 107
arising C 155 107
from C 156 107
lack C 157 107
of C 158 107
differentiation C 159 107
between C 160 107
the C 161 107
concrete C 162 107
gnostic C 163 107
body C 164 107
image C 165 107
and C 166 107
the C 167 107
abstract C 168 107
verbal C 169 107
body C 170 107
image C 171 107
in C 172 107
investigation C 173 107
of C 174 107
these C 175 107
patients C 176 107
. C 177 107
the C 179 107
aphasic C 180 107
syndrome C 181 107
should C 182 107
be C 183 107
differentiated C 184 107
from C 185 107
disturbances C 186 107
of C 187 107
gnosis C 188 107
by C 189 107
application C 190 107
of C 191 107
separate C 192 107
, C 193 107
non C 194 107
- C 195 107
verbal C 196 107
methods C 197 107
of C 198 107
testing C 199 107
to C 200 107
elicit C 201 107
the C 202 107
impairment C 203 107
of C 204 107
the C 205 107
gnostic C 206 107
body C 207 107
image C 208 107
. C 209 107
the C 211 107
latter C 212 107
may C 213 107
be C 214 107
well C 215 107
compensated C 216 107
for C 217 107
and C 218 107
it C 219 107
is C 220 107
apparently C 221 107
unimpaired C 222 107
in C 223 107
the C 224 107
presence C 225 107
of C 226 107
an C 227 107
aphasic C 228 107
syndrome C 229 107
limited C 230 107
to C 231 107
the C 232 107
verbal C 233 107
body C 234 107
image C 235 107
. C 236 107
3 C 238 107
. C 239 107
disturbances C 241 107
of C 242 107
speech C 243 107
in C 244 107
pto C 245 107
lesions C 246 107
if C 247 107
investigated C 248 107
along C 249 107
quantitative C 250 107
scales C 251 107
of C 252 107
impairment C 253 107
of C 254 107
repetition C 255 107
, C 256 107
understanding C 257 107
and C 258 107
naming C 259 107
, C 260 107
show C 261 107
a C 262 107
regular C 263 107
interrelation C 264 107
. C 265 107
nomination C 267 107
is C 268 107
the C 269 107
most C 270 107
affected C 271 107
, C 272 107
understanding C 273 107
is C 274 107
less C 275 107
affected C 276 107
. C 277 107
repetition C 279 107
is C 280 107
the C 281 107
best C 282 107
preserved C 283 107
function C 284 107
( C 285 107
cases C 286 107
1 C 287 107
- C 288 107
4 C 289 107
) C 290 107
. C 291 107
the C 293 107
same C 294 107
interrelation C 295 107
of C 296 107
these C 297 107
functions C 298 107
is C 299 107
found C 300 107
with C 301 107
regard C 302 107
to C 303 107
the C 304 107
verbal C 305 107
body C 306 107
image C 307 107
. C 308 107
however C 310 107
, C 311 107
understanding C 312 107
and C 313 107
naming C 314 107
of C 315 107
parts C 316 107
of C 317 107
the C 318 107
body C 319 107
show C 320 107
far C 321 107
greater C 322 107
disintegration C 323 107
than C 324 107
understanding C 325 107
and C 326 107
naming C 327 107
of C 328 107
any C 329 107
other C 330 107
categories C 331 107
of C 332 107
words C 333 107
( C 334 107
all C 335 107
cases C 336 107
presented C 337 107
here C 338 107
) C 339 107
. C 340 107
if C 342 107
the C 343 107
aphasic C 344 107
syndrome C 345 107
is C 346 107
subsiding C 347 107
, C 348 107
finger C 349 107
aphasia C 350 107
with C 351 107
some C 352 107
other C 353 107
minor C 354 107
disturbances C 355 107
of C 356 107
verbal C 357 107
body C 358 107
image C 359 107
associated C 360 107
with C 361 107
acalculia C 362 107
may C 363 107
persist C 364 107
( C 365 107
case C 366 107
1 C 367 107
) C 368 107
. C 369 107
thus C 371 107
gerstmann C 372 107
' C 373 107
s C 374 107
/ C 375 107
finger C 376 107
agnosia C 377 107
/ C 378 107
may C 379 107
represent C 380 107
a C 381 107
partial C 382 107
impairment C 383 107
of C 384 107
the C 385 107
verbal C 386 107
body C 387 107
image C 388 107
and C 389 107
be C 390 107
limited C 391 107
to C 392 107
finger C 393 107
aphasia C 394 107
. C 395 107
4 C 397 107
. C 398 107
it C 400 107
is C 401 107
assumed C 402 107
that C 403 107
the C 404 107
verbal C 405 107
body C 406 107
image C 407 107
differs C 408 107
from C 409 107
other C 410 107
categories C 411 107
of C 412 107
verbal C 413 107
symbols C 414 107
owing C 415 107
to C 416 107
the C 417 107
mainly C 418 107
proprioceptive C 419 107
, C 420 107
vestibular C 421 107
and C 422 107
tactile C 423 107
experience C 424 107
forming C 425 107
its C 426 107
specific C 427 107
physiologic C 428 107
background C 429 107
. C 430 107
telereceptive C 432 107
experience C 433 107
is C 434 107
of C 435 107
minor C 436 107
importance C 437 107
in C 438 107
the C 439 107
initial C 440 107
development C 441 107
of C 442 107
the C 443 107
understanding C 444 107
of C 445 107
words C 446 107
defining C 447 107
the C 448 107
body C 449 107
image C 450 107
. C 451 107
in C 453 107
the C 454 107
patients C 455 107
described C 456 107
here C 457 107
, C 458 107
the C 459 107
selectively C 460 107
worse C 461 107
aphasic C 462 107
impairment C 463 107
of C 464 107
the C 465 107
verbal C 466 107
body C 467 107
image C 468 107
, C 469 107
as C 470 107
compared C 471 107
with C 472 107
other C 473 107
categories C 474 107
of C 475 107
words C 476 107
, C 477 107
seem C 478 107
to C 479 107
confirm C 480 107
this C 481 107
assumption C 482 107
. C 483 107
chromosomal C 1 108
patterns C 2 108
in C 3 108
cancer C 4 108
patients C 5 108
during C 6 108
treatment C 7 108
. C 8 108
radiation C 10 108
damages C 11 108
the C 12 108
chromosomes C 13 108
of C 14 108
human C 15 108
cells C 16 108
, C 17 108
and C 18 108
through C 19 108
short C 20 108
- C 21 108
term C 22 108
cultures C 23 108
of C 24 108
white C 25 108
blood C 26 108
cells C 27 108
some C 28 108
of C 29 108
this C 30 108
damage C 31 108
can C 32 108
be C 33 108
assessed C 34 108
. C 35 108
patients C 37 108
with C 38 108
cancer C 39 108
were C 40 108
selected C 41 108
for C 42 108
this C 43 108
study C 44 108
because C 45 108
of C 46 108
the C 47 108
large C 48 108
portions C 49 108
of C 50 108
the C 51 108
blood C 52 108
- C 53 108
forming C 54 108
tissues C 55 108
irradiated C 56 108
in C 57 108
the C 58 108
course C 59 108
of C 60 108
treatment C 61 108
. C 62 108
chromosomal C 64 108
damage C 65 108
may C 66 108
be C 67 108
quantitative C 68 108
with C 69 108
variations C 70 108
from C 71 108
the C 72 108
normal C 73 108
number C 74 108
of C 75 108
46 C 76 108
, C 77 108
or C 78 108
qualitative C 79 108
, C 80 108
thereby C 81 108
showing C 82 108
structural C 83 108
aberrations C 84 108
. C 85 108
counting C 87 108
the C 88 108
chromosomes C 89 108
in C 90 108
cells C 91 108
from C 92 108
cultures C 93 108
grown C 94 108
prior C 95 108
to C 96 108
therapy C 97 108
and C 98 108
at C 99 108
intervals C 100 108
during C 101 108
treatment C 102 108
enables C 103 108
us C 104 108
to C 105 108
determine C 106 108
the C 107 108
variation C 108 108
. C 109 108
stained C 111 108
preparations C 112 108
examined C 113 108
microscopically C 114 108
allow C 115 108
us C 116 108
to C 117 108
recognize C 118 108
these C 119 108
abnormalities C 120 108
which C 121 108
are C 122 108
apparent C 123 108
before C 124 108
, C 125 108
during C 126 108
, C 127 108
and C 128 108
after C 129 108
radiotherapy C 130 108
. C 131 108
the C 133 108
damage C 134 108
appears C 135 108
to C 136 108
be C 137 108
largely C 138 108
random C 139 108
in C 140 108
the C 141 108
chromosomes C 142 108
affected C 143 108
in C 144 108
the C 145 108
different C 146 108
cancers C 147 108
, C 148 108
and C 149 108
the C 150 108
specific C 151 108
aberrations C 152 108
differ C 153 108
from C 154 108
cell C 155 108
to C 156 108
cell C 157 108
. C 158 108
however C 160 108
, C 161 108
there C 162 108
does C 163 108
seem C 164 108
to C 165 108
be C 166 108
some C 167 108
correlation C 168 108
between C 169 108
the C 170 108
appearance C 171 108
of C 172 108
persistent C 173 108
aberrant C 174 108
chromosomes C 175 108
and C 176 108
their C 177 108
frequency C 178 108
. C 179 108
while C 181 108
the C 182 108
peak C 183 108
incidence C 184 108
or C 185 108
/ C 186 108
plateau C 187 108
/ C 188 108
may C 189 108
remain C 190 108
unchanged C 191 108
, C 192 108
the C 193 108
frequency C 194 108
may C 195 108
change C 196 108
. C 197 108
a C 1 109
few C 2 109
interesting C 3 109
neurologic C 4 109
manifestations C 5 109
of C 6 109
migraine C 7 109
. C 8 109
migraine C 10 109
is C 11 109
a C 12 109
complex C 13 109
vascular C 14 109
phenomenon C 15 109
presumably C 16 109
of C 17 109
genetic C 18 109
origin C 19 109
which C 20 109
, C 21 109
through C 22 109
changes C 23 109
induced C 24 109
by C 25 109
either C 26 109
vasoconstriction C 27 109
or C 28 109
vasodilitation C 29 109
, C 30 109
can C 31 109
produce C 32 109
interference C 33 109
with C 34 109
the C 35 109
neurologic C 36 109
system C 37 109
and C 38 109
result C 39 109
in C 40 109
many C 41 109
bizarre C 42 109
and C 43 109
alarming C 44 109
clinical C 45 109
pictures C 46 109
. C 47 109
a C 49 109
few C 50 109
examples C 51 109
of C 52 109
the C 53 109
more C 54 109
interesting C 55 109
neurologic C 56 109
manifestations C 57 109
have C 58 109
been C 59 109
shown C 60 109
. C 61 109
visual C 1 110
neglect C 2 110
. C 3 110
clinical C 5 110
trainees C 6 110
in C 7 110
nursing C 8 110
and C 9 110
in C 10 110
psychology C 11 110
from C 12 110
boston C 13 110
college C 14 110
and C 15 110
simmons C 16 110
college C 17 110
, C 18 110
boston C 19 110
, C 20 110
mass C 21 110
. C 22 110
, C 24 110
collected C 25 110
data C 26 110
and C 27 110
observed C 28 110
patients C 29 110
under C 30 110
the C 31 110
direction C 32 110
of C 33 110
the C 34 110
authors C 35 110
in C 36 110
a C 37 110
pilot C 38 110
program C 39 110
designed C 40 110
to C 41 110
measure C 42 110
visual C 43 110
spatial C 44 110
neglect C 45 110
and C 46 110
to C 47 110
develop C 48 110
rehabilitative C 49 110
material C 50 110
. C 51 110
these C 53 110
measurements C 54 110
and C 55 110
exercises C 56 110
might C 57 110
also C 58 110
be C 59 110
used C 60 110
by C 61 110
nurses C 62 110
in C 63 110
their C 64 110
care C 65 110
of C 66 110
those C 67 110
patients C 68 110
who C 69 110
have C 70 110
had C 71 110
cerebral C 72 110
vascular C 73 110
accidents C 74 110
. C 75 110
the C 77 110
diversity C 78 110
of C 79 110
daily C 80 110
activities C 81 110
in C 82 110
which C 83 110
the C 84 110
patient C 85 110
becomes C 86 110
involved C 87 110
during C 88 110
his C 89 110
hospitalization C 90 110
should C 91 110
provide C 92 110
some C 93 110
indication C 94 110
of C 95 110
the C 96 110
extent C 97 110
to C 98 110
which C 99 110
the C 100 110
compensatory C 101 110
visual C 102 110
neglect C 103 110
therapeutics C 104 110
have C 105 110
been C 106 110
effective C 107 110
. C 108 110
more C 110 110
formal C 111 110
estimates C 112 110
can C 113 110
be C 114 110
obtained C 115 110
by C 116 110
re C 117 110
- C 118 110
administering C 119 110
the C 120 110
battery C 121 110
of C 122 110
visual C 123 110
neglect C 124 110
tests C 125 110
at C 126 110
periodic C 127 110
intervals C 128 110
. C 129 110
nursing C 131 110
personnel C 132 110
adopting C 133 110
a C 134 110
program C 135 110
of C 136 110
therapeutics C 137 110
such C 138 110
as C 139 110
this C 140 110
must C 141 110
bear C 142 110
in C 143 110
mind C 144 110
that C 145 110
patients C 146 110
suffering C 147 110
cerebral C 148 110
insult C 149 110
are C 150 110
usually C 151 110
less C 152 110
adaptive C 153 110
than C 154 110
their C 155 110
nonbrain C 156 110
- C 157 110
injured C 158 110
peers C 159 110
. C 160 110
they C 162 110
develop C 163 110
new C 164 110
habit C 165 110
patterns C 166 110
slowly C 167 110
and C 168 110
regression C 169 110
often C 170 110
will C 171 110
follow C 172 110
apparent C 173 110
fixation C 174 110
at C 175 110
a C 176 110
more C 177 110
adaptive C 178 110
level C 179 110
of C 180 110
response C 181 110
habituation C 182 110
( C 183 110
11 C 184 110
) C 185 110
. C 186 110
however C 188 110
, C 189 110
experimental C 190 110
inquiry C 191 110
has C 192 110
shown C 193 110
that C 194 110
the C 195 110
dimension C 196 110
of C 197 110
behavioral C 198 110
difference C 199 110
between C 200 110
the C 201 110
brain C 202 110
- C 203 110
injured C 204 110
adults C 205 110
and C 206 110
normal C 207 110
adults C 208 110
is C 209 110
one C 210 110
of C 211 110
degree C 212 110
rather C 213 110
than C 214 110
kind C 215 110
- C 216 110
dash C 217 110
a C 218 110
difference C 219 110
that C 220 110
skilled C 221 110
nursing C 222 110
can C 223 110
often C 224 110
reduce C 225 110
( C 226 110
12 C 227 110
) C 228 110
. C 229 110
respiratory C 1 111
changes C 2 111
after C 3 111
open C 4 111
- C 5 111
heart C 6 111
surgery C 7 111
. C 8 111
patients C 10 111
who C 11 111
undergo C 12 111
cardiac C 13 111
surgery C 14 111
with C 15 111
extracorporeal C 16 111
circulation C 17 111
develop C 18 111
significant C 19 111
alveolar C 20 111
- C 21 111
arterial C 22 111
oxygen C 23 111
tension C 24 111
differences C 25 111
and C 26 111
venous C 27 111
admixture C 28 111
in C 29 111
the C 30 111
early C 31 111
post C 32 111
- C 33 111
operative C 34 111
period C 35 111
. C 36 111
up C 38 111
to C 39 111
50 C 40 111
of C 41 111
this C 42 111
abnormality C 43 111
is C 44 111
due C 45 111
to C 46 111
anatomical C 47 111
right C 48 111
to C 49 111
left C 50 111
shunting C 51 111
through C 52 111
the C 53 111
lungs C 54 111
. C 55 111
. C 57 111
the C 59 111
remainder C 60 111
is C 61 111
most C 62 111
likely C 63 111
to C 64 111
be C 65 111
due C 66 111
to C 67 111
ventilation C 68 111
- C 69 111
perfusion C 70 111
inequality C 71 111
. C 72 111
the C 74 111
changes C 75 111
appear C 76 111
to C 77 111
be C 78 111
completely C 79 111
reversible C 80 111
. C 81 111
the C 83 111
cardiopulmonary C 84 111
bypass C 85 111
procedure C 86 111
may C 87 111
be C 88 111
responsible C 89 111
for C 90 111
initiating C 91 111
the C 92 111
underlying C 93 111
pathology C 94 111
, C 95 111
since C 96 111
changes C 97 111
of C 98 111
this C 99 111
magnitude C 100 111
were C 101 111
not C 102 111
found C 103 111
in C 104 111
cardiothoracic C 105 111
surgery C 106 111
patients C 107 111
in C 108 111
whom C 109 111
this C 110 111
technique C 111 111
was C 112 111
not C 113 111
required C 114 111
cardiac C 1 112
malformations C 2 112
associated C 3 112
with C 4 112
ventricular C 5 112
septal C 6 112
defect C 7 112
. C 8 112
in C 10 112
this C 11 112
study C 12 112
, C 13 112
46 C 14 112
necropsy C 15 112
- C 16 112
proved C 17 112
cases C 18 112
of C 19 112
ventricular C 20 112
septal C 21 112
defect C 22 112
associated C 23 112
with C 24 112
another C 25 112
anomaly C 26 112
but C 27 112
not C 28 112
part C 29 112
of C 30 112
a C 31 112
recognized C 32 112
complex C 33 112
were C 34 112
selected C 35 112
. C 36 112
the C 38 112
associated C 39 112
anomalies C 40 112
were C 41 112
classified C 42 112
as C 43 112
( C 44 112
1 C 45 112
) C 46 112
obstructive C 47 112
or C 48 112
positional C 49 112
anomalies C 50 112
of C 51 112
the C 52 112
great C 53 112
vessels C 54 112
, C 55 112
( C 56 112
2 C 57 112
) C 58 112
anomalies C 59 112
responsible C 60 112
for C 61 112
additional C 62 112
shunts C 63 112
, C 64 112
( C 65 112
3 C 66 112
) C 67 112
anomalies C 68 112
causing C 69 112
intraventricular C 70 112
obstruction C 71 112
and C 72 112
( C 73 112
4 C 74 112
) C 75 112
aortic C 76 112
valvular C 77 112
insufficiency C 78 112
. C 79 112
clinical C 81 112
findings C 82 112
were C 83 112
often C 84 112
those C 85 112
of C 86 112
the C 87 112
ventricular C 88 112
septal C 89 112
defect C 90 112
, C 91 112
and C 92 112
the C 93 112
findings C 94 112
related C 95 112
to C 96 112
the C 97 112
associated C 98 112
lesion C 99 112
were C 100 112
frequently C 101 112
obscure C 102 112
. C 103 112
even C 105 112
with C 106 112
special C 107 112
studies C 108 112
, C 109 112
including C 110 112
cardiac C 111 112
catheterization C 112 112
and C 113 112
angiocardiography C 114 112
, C 115 112
there C 116 112
was C 117 112
often C 118 112
failure C 119 112
to C 120 112
arrive C 121 112
at C 122 112
a C 123 112
complete C 124 112
diagnosis C 125 112
. C 126 112
the C 128 112
findings C 129 112
which C 130 112
led C 131 112
to C 132 112
an C 133 112
erroneous C 134 112
or C 135 112
incomplete C 136 112
diagnosis C 137 112
have C 138 112
been C 139 112
presented C 140 112
. C 141 112
when C 143 112
a C 144 112
complete C 145 112
diagnosis C 146 112
was C 147 112
made C 148 112
preoperatively C 149 112
, C 150 112
the C 151 112
procedures C 152 112
leading C 153 112
to C 154 112
it C 155 112
have C 156 112
been C 157 112
outlined C 158 112
. C 159 112
while C 161 112
the C 162 112
diagnostic C 163 112
approach C 164 112
varies C 165 112
with C 166 112
the C 167 112
malformations C 168 112
which C 169 112
may C 170 112
coexist C 171 112
with C 172 112
ventricular C 173 112
septal C 174 112
defect C 175 112
, C 176 112
it C 177 112
was C 178 112
observed C 179 112
that C 180 112
aortography C 181 112
and C 182 112
selective C 183 112
left C 184 112
ventricular C 185 112
angiocardiography C 186 112
were C 187 112
most C 188 112
commonly C 189 112
helpful C 190 112
in C 191 112
identifying C 192 112
occult C 193 112
malformations C 194 112
associated C 195 112
with C 196 112
ventricular C 197 112
septal C 198 112
defect C 199 112
. C 200 112
it C 202 112
is C 203 112
therefore C 204 112
recommended C 205 112
that C 206 112
complete C 207 112
studies C 208 112
, C 209 112
including C 210 112
left C 211 112
- C 212 112
sided C 213 112
cardiac C 214 112
catheterization C 215 112
with C 216 112
left C 217 112
ventricular C 218 112
angiocardiography C 219 112
and C 220 112
aortography C 221 112
, C 222 112
should C 223 112
be C 224 112
considered C 225 112
in C 226 112
all C 227 112
cases C 228 112
in C 229 112
which C 230 112
the C 231 112
clinical C 232 112
, C 233 112
electrocardiographic C 234 112
, C 235 112
and C 236 112
right C 237 112
- C 238 112
sided C 239 112
cardiac C 240 112
catheterization C 241 112
studies C 242 112
are C 243 112
not C 244 112
entirely C 245 112
typical C 246 112
for C 247 112
isolated C 248 112
ventricular C 249 112
septal C 250 112
defect C 251 112
. C 252 112
anatomic C 1 113
types C 2 113
of C 3 113
single C 4 113
or C 5 113
common C 6 113
ventricle C 7 113
in C 8 113
man C 9 113
morphologic C 10 113
and C 11 113
geometric C 12 113
aspects C 13 113
of C 14 113
60 C 15 113
necropsied C 16 113
cases C 17 113
. C 18 113
in C 20 113
60 C 21 113
necropsied C 22 113
cases C 23 113
of C 24 113
single C 25 113
or C 26 113
common C 27 113
ventricle C 28 113
in C 29 113
man C 30 113
, C 31 113
four C 32 113
major C 33 113
unrelated C 34 113
ventricular C 35 113
malformations C 36 113
were C 37 113
found C 38 113
. C 39 113
. C 41 113
( C 43 113
1 C 44 113
) C 45 113
absence C 46 113
of C 47 113
the C 48 113
right C 49 113
ventricular C 50 113
sinus C 51 113
, C 52 113
in C 53 113
47 C 54 113
cases C 55 113
( C 56 113
78 C 57 113
percent C 58 113
) C 59 113
, C 60 113
designated C 61 113
type C 62 113
a C 63 113
, C 64 113
. C 65 113
( C 67 113
2 C 68 113
) C 69 113
absence C 70 113
of C 71 113
the C 72 113
left C 73 113
ventricular C 74 113
sinus C 75 113
, C 76 113
in C 77 113
3 C 78 113
cases C 79 113
( C 80 113
5 C 81 113
percent C 82 113
) C 83 113
, C 84 113
type C 85 113
b C 86 113
, C 87 113
. C 88 113
( C 90 113
3 C 91 113
) C 92 113
absence C 93 113
or C 94 113
rudimentary C 95 113
development C 96 113
of C 97 113
the C 98 113
ventricular C 99 113
septum C 100 113
, C 101 113
in C 102 113
4 C 103 113
cases C 104 113
( C 105 113
7 C 106 113
percent C 107 113
) C 108 113
, C 109 113
type C 110 113
c C 111 113
, C 112 113
. C 113 113
and C 115 113
( C 116 113
4 C 117 113
) C 118 113
absence C 119 113
of C 120 113
both C 121 113
ventricular C 122 113
sinuses C 123 113
and C 124 113
of C 125 113
the C 126 113
ventricular C 127 113
septum C 128 113
, C 129 113
in C 130 113
6 C 131 113
cases C 132 113
( C 133 113
10 C 134 113
percent C 135 113
) C 136 113
, C 137 113
type C 138 113
d C 139 113
. C 140 113
three C 142 113
types C 143 113
of C 144 113
relationship C 145 113
between C 146 113
the C 147 113
great C 148 113
arteries C 149 113
were C 150 113
present C 151 113
. C 152 113
. C 154 113
a C 156 113
normal C 157 113
( C 158 113
solitus C 159 113
) C 160 113
interrelationship C 161 113
, C 162 113
in C 163 113
9 C 164 113
cases C 165 113
( C 166 113
15 C 167 113
percent C 168 113
) C 169 113
, C 170 113
designated C 171 113
type C 172 113
1 C 173 113
, C 174 113
. C 175 113
d C 177 113
- C 178 113
transposition C 179 113
, C 180 113
the C 181 113
transposed C 182 113
aortic C 183 113
valve C 184 113
lying C 185 113
to C 186 113
the C 187 113
right C 188 113
( C 189 113
dextro C 190 113
, C 191 113
or C 192 113
d C 193 113
) C 194 113
, C 195 113
relative C 196 113
to C 197 113
the C 198 113
transposed C 199 113
pulmonary C 200 113
valve C 201 113
, C 202 113
in C 203 113
25 C 204 113
cases C 205 113
( C 206 113
42 C 207 113
percent C 208 113
) C 209 113
, C 210 113
type C 211 113
ii C 212 113
, C 213 113
. C 214 113
and C 216 113
l C 217 113
- C 218 113
transposition C 219 113
, C 220 113
the C 221 113
transposed C 222 113
aortic C 223 113
valve C 224 113
lying C 225 113
to C 226 113
the C 227 113
left C 228 113
( C 229 113
levo C 230 113
or C 231 113
l C 232 113
) C 233 113
, C 234 113
relative C 235 113
to C 236 113
the C 237 113
transposed C 238 113
pulmonary C 239 113
valve C 240 113
, C 241 113
in C 242 113
26 C 243 113
cases C 244 113
( C 245 113
43 C 246 113
percent C 247 113
) C 248 113
, C 249 113
type C 250 113
iii C 251 113
. C 252 113
in C 254 113
none C 255 113
was C 256 113
the C 257 113
inversus C 258 113
interrelationship C 259 113
, C 260 113
type C 261 113
iv C 262 113
, C 263 113
displayed C 264 113
. C 265 113
three C 267 113
types C 268 113
of C 269 113
visceral C 270 113
and C 271 113
atrial C 272 113
situs C 273 113
were C 274 113
found C 275 113
. C 276 113
. C 278 113
solitus C 280 113
, C 281 113
or C 282 113
normal C 283 113
, C 284 113
in C 285 113
50 C 286 113
cases C 287 113
( C 288 113
83 C 289 113
percent C 290 113
) C 291 113
, C 292 113
. C 293 113
inversus C 295 113
, C 296 113
an C 297 113
exact C 298 113
apparent C 299 113
mirror C 300 113
image C 301 113
of C 302 113
normal C 303 113
, C 304 113
in C 305 113
2 C 306 113
cases C 307 113
( C 308 113
3 C 309 113
percent C 310 113
) C 311 113
, C 312 113
. C 313 113
and C 315 113
heterotaxy C 316 113
, C 317 113
the C 318 113
uncertain C 319 113
visceral C 320 113
and C 321 113
atrial C 322 113
situs C 323 113
associated C 324 113
with C 325 113
asplenia C 326 113
, C 327 113
in C 328 113
8 C 329 113
cases C 330 113
( C 331 113
13 C 332 113
percent C 333 113
) C 334 113
. C 335 113
the C 337 113
60 C 338 113
cases C 339 113
were C 340 113
classified C 341 113
segmentally C 342 113
, C 343 113
according C 344 113
to C 345 113
the C 346 113
anatomy C 347 113
of C 348 113
the C 349 113
three C 350 113
cardiac C 351 113
segments C 352 113
. C 353 113
. C 355 113
the C 357 113
great C 358 113
arteries C 359 113
, C 360 113
the C 361 113
ventricular C 362 113
sinuses C 363 113
, C 364 113
and C 365 113
the C 366 113
atria C 367 113
. C 368 113
the C 370 113
classic C 371 113
single C 372 113
ventricle C 373 113
with C 374 113
a C 375 113
rudimentary C 376 113
outlet C 377 113
chamber C 378 113
was C 379 113
found C 380 113
morphologically C 381 113
to C 382 113
be C 383 113
a C 384 113
large C 385 113
left C 386 113
ventricle C 387 113
with C 388 113
a C 389 113
right C 390 113
ventricular C 391 113
infundibulum C 392 113
, C 393 113
the C 394 113
sinus C 395 113
of C 396 113
the C 397 113
right C 398 113
ventricle C 399 113
being C 400 113
absent C 401 113
( C 402 113
type C 403 113
a C 404 113
) C 405 113
. C 406 113
the C 408 113
myocardium C 409 113
of C 410 113
the C 411 113
right C 412 113
ventricular C 413 113
infundibulum C 414 113
, C 415 113
of C 416 113
the C 417 113
right C 418 113
ventricular C 419 113
sinus C 420 113
, C 421 113
and C 422 113
of C 423 113
the C 424 113
left C 425 113
ventricular C 426 113
sinus C 427 113
was C 428 113
identified C 429 113
by C 430 113
the C 431 113
distinctive C 432 113
gross C 433 113
morphologic C 434 113
characteristics C 435 113
of C 436 113
each C 437 113
. C 438 113
the C 440 113
planes C 441 113
of C 442 113
the C 443 113
atrial C 444 113
and C 445 113
ventricular C 446 113
septa C 447 113
, C 448 113
and C 449 113
the C 450 113
relationships C 451 113
between C 452 113
the C 453 113
great C 454 113
arteries C 455 113
at C 456 113
the C 457 113
semilunar C 458 113
valves C 459 113
, C 460 113
were C 461 113
measured C 462 113
as C 463 113
projections C 464 113
upon C 465 113
the C 466 113
horizontal C 467 113
plane C 468 113
, C 469 113
relative C 470 113
to C 471 113
the C 472 113
anteroposterior C 473 113
line C 474 113
. C 475 113
an C 477 113
approach C 478 113
to C 479 113
cardiac C 480 113
anatomy C 481 113
is C 482 113
presented C 483 113
which C 484 113
is C 485 113
segmental C 486 113
, C 487 113
morphologic C 488 113
and C 489 113
geometric C 490 113
. C 491 113
this C 493 113
approach C 494 113
has C 495 113
angiocardiographic C 496 113
, C 497 113
electrocardiographic C 498 113
and C 499 113
embryologic C 500 113
applications C 501 113
. C 502 113
congenital C 1 114
heart C 2 114
disease C 3 114
in C 4 114
the C 5 114
adult C 6 114
. C 7 114
events C 9 114
in C 10 114
the C 11 114
natural C 12 114
course C 13 114
of C 14 114
310 C 15 114
adult C 16 114
patients C 17 114
with C 18 114
proved C 19 114
significant C 20 114
congenital C 21 114
cardiac C 22 114
anomalies C 23 114
have C 24 114
been C 25 114
reviewed C 26 114
to C 27 114
determine C 28 114
incidence C 29 114
, C 30 114
longevity C 31 114
, C 32 114
complications C 33 114
and C 34 114
cause C 35 114
of C 36 114
death C 37 114
. C 38 114
atrial C 40 114
septal C 41 114
defect C 42 114
and C 43 114
patent C 44 114
ductus C 45 114
arteriosus C 46 114
were C 47 114
the C 48 114
most C 49 114
frequently C 50 114
encountered C 51 114
lesions C 52 114
and C 53 114
comprised C 54 114
over C 55 114
one C 56 114
third C 57 114
of C 58 114
the C 59 114
entire C 60 114
series C 61 114
. C 62 114
ventricular C 64 114
septal C 65 114
defect C 66 114
and C 67 114
pulmonic C 68 114
stenosis C 69 114
made C 70 114
up C 71 114
almost C 72 114
a C 73 114
quarter C 74 114
of C 75 114
the C 76 114
group C 77 114
. C 78 114
twenty C 80 114
- C 81 114
two C 82 114
instances C 83 114
of C 84 114
the C 85 114
eisenmenger C 86 114
syndrome C 87 114
secondary C 88 114
to C 89 114
a C 90 114
variety C 91 114
of C 92 114
shunting C 93 114
lesions C 94 114
are C 95 114
included C 96 114
. C 97 114
bacterial C 99 114
endocarditis C 100 114
, C 101 114
sudden C 102 114
death C 103 114
and C 104 114
cardiac C 105 114
decompensation C 106 114
were C 107 114
the C 108 114
greatest C 109 114
threats C 110 114
to C 111 114
these C 112 114
patients C 113 114
. C 114 114
symptoms C 116 114
were C 117 114
minimal C 118 114
until C 119 114
the C 120 114
appearance C 121 114
of C 122 114
heart C 123 114
failure C 124 114
, C 125 114
which C 126 114
was C 127 114
the C 128 114
most C 129 114
common C 130 114
cause C 131 114
of C 132 114
death C 133 114
, C 134 114
especially C 135 114
with C 136 114
older C 137 114
patients C 138 114
. C 139 114
sudden C 141 114
death C 142 114
occurred C 143 114
most C 144 114
often C 145 114
in C 146 114
patients C 147 114
with C 148 114
ventricular C 149 114
septal C 150 114
defect C 151 114
. C 152 114
although C 154 114
the C 155 114
clinical C 156 114
features C 157 114
are C 158 114
usually C 159 114
characteristic C 160 114
of C 161 114
a C 162 114
congenital C 163 114
malformation C 164 114
, C 165 114
young C 166 114
adults C 167 114
with C 168 114
acyanotic C 169 114
congenital C 170 114
heart C 171 114
disease C 172 114
are C 173 114
often C 174 114
misdiagnosed C 175 114
as C 176 114
rheumatic C 177 114
, C 178 114
. C 179 114
and C 181 114
in C 182 114
older C 183 114
patients C 184 114
, C 185 114
presenting C 186 114
manifestations C 187 114
are C 188 114
frequently C 189 114
attributed C 190 114
to C 191 114
arteriosclerotic C 192 114
heart C 193 114
disease C 194 114
. C 195 114
at C 197 114
times C 198 114
an C 199 114
associated C 200 114
acquired C 201 114
cardiovascular C 202 114
disorder C 203 114
may C 204 114
alter C 205 114
the C 206 114
basic C 207 114
syndrome C 208 114
. C 209 114
three C 211 114
quarters C 212 114
of C 213 114
the C 214 114
patients C 215 114
survive C 216 114
and C 217 114
continue C 218 114
under C 219 114
observation C 220 114
the C 221 114
ability C 222 114
of C 223 114
many C 224 114
to C 225 114
live C 226 114
active C 227 114
, C 228 114
productive C 229 114
lives C 230 114
and C 231 114
to C 232 114
withstand C 233 114
stress C 234 114
, C 235 114
surgery C 236 114
, C 237 114
both C 238 114
cardiac C 239 114
and C 240 114
non C 241 114
- C 242 114
cardiac C 243 114
, C 244 114
and C 245 114
pregnancy C 246 114
was C 247 114
impressive C 248 114
. C 249 114
further C 251 114
observation C 252 114
of C 253 114
the C 254 114
patient C 255 114
with C 256 114
congenital C 257 114
heart C 258 114
disease C 259 114
but C 260 114
without C 261 114
surgical C 262 114
intervention C 263 114
is C 264 114
essential C 265 114
for C 266 114
accurate C 267 114
evaluation C 268 114
of C 269 114
the C 270 114
long C 271 114
term C 272 114
efficacy C 273 114
of C 274 114
cardiac C 275 114
surgery C 276 114
. C 277 114
a C 1 115
study C 2 115
of C 3 115
ventricular C 4 115
septal C 5 115
defect C 6 115
associated C 7 115
with C 8 115
aortic C 9 115
insufficiency C 10 115
. C 11 115
clinical C 13 115
, C 14 115
electrocardiographic C 15 115
, C 16 115
radiographic C 17 115
, C 18 115
and C 19 115
hemodynamic C 20 115
findings C 21 115
in C 22 115
12 C 23 115
children C 24 115
with C 25 115
the C 26 115
combination C 27 115
of C 28 115
a C 29 115
ventricular C 30 115
septal C 31 115
defect C 32 115
and C 33 115
aortic C 34 115
insufficiency C 35 115
are C 36 115
presented C 37 115
. C 38 115
the C 40 115
left C 41 115
- C 42 115
to C 43 115
- C 44 115
right C 45 115
shunt C 46 115
was C 47 115
determined C 48 115
to C 49 115
be C 50 115
small C 51 115
or C 52 115
moderate C 53 115
in C 54 115
all C 55 115
, C 56 115
and C 57 115
significant C 58 115
aortic C 59 115
insufficiency C 60 115
was C 61 115
documented C 62 115
by C 63 115
aortography C 64 115
in C 65 115
11 C 66 115
patients C 67 115
. C 68 115
clinical C 70 115
indication C 71 115
of C 72 115
aortic C 73 115
insufficiency C 74 115
as C 75 115
manifested C 76 115
by C 77 115
an C 78 115
aortic C 79 115
diastolic C 80 115
murmur C 81 115
first C 82 115
appeared C 83 115
at C 84 115
an C 85 115
average C 86 115
age C 87 115
of C 88 115
6 C 89 115
years C 90 115
in C 91 115
7 C 92 115
patients C 93 115
, C 94 115
with C 95 115
concomitant C 96 115
widening C 97 115
of C 98 115
the C 99 115
pulse C 100 115
pressure C 101 115
in C 102 115
4 C 103 115
. C 104 115
progressive C 106 115
left C 107 115
ventricular C 108 115
hypertrophy C 109 115
was C 110 115
noted C 111 115
electrocardiographically C 112 115
, C 113 115
with C 114 115
progressive C 115 115
cardiac C 116 115
hypertrophy C 117 115
and C 118 115
aortic C 119 115
dilatation C 120 115
on C 121 115
x C 122 115
- C 123 115
ray C 124 115
examination C 125 115
in C 126 115
2 C 127 115
patients C 128 115
. C 129 115
progression C 131 115
of C 132 115
the C 133 115
hemodynamic C 134 115
disability C 135 115
does C 136 115
not C 137 115
appear C 138 115
to C 139 115
be C 140 115
common C 141 115
in C 142 115
childhood C 143 115
, C 144 115
however C 145 115
. C 146 115
ventricular C 1 116
septal C 2 116
defect C 3 116
and C 4 116
aortic C 5 116
regurgitation C 6 116
clinical C 7 116
, C 8 116
hemodynamic C 9 116
and C 10 116
surgical C 11 116
considerations C 12 116
. C 13 116
the C 15 116
clinical C 16 116
, C 17 116
hemodynamic C 18 116
, C 19 116
angiographic C 20 116
and C 21 116
anatomic C 22 116
findings C 23 116
in C 24 116
fifteen C 25 116
patients C 26 116
with C 27 116
ventricular C 28 116
septal C 29 116
defect C 30 116
complicated C 31 116
by C 32 116
aortic C 33 116
regurgitation C 34 116
are C 35 116
presented C 36 116
. C 37 116
in C 39 116
this C 40 116
combination C 41 116
of C 42 116
malformations C 43 116
the C 44 116
aortic C 45 116
regurgitation C 46 116
is C 47 116
acquired C 48 116
and C 49 116
results C 50 116
from C 51 116
prolapse C 52 116
of C 53 116
an C 54 116
aortic C 55 116
valve C 56 116
leaflet C 57 116
into C 58 116
the C 59 116
septal C 60 116
defect C 61 116
. C 62 116
the C 64 116
strategic C 65 116
location C 66 116
of C 67 116
the C 68 116
septal C 69 116
defect C 70 116
in C 71 116
relation C 72 116
to C 73 116
the C 74 116
aortic C 75 116
leaflets C 76 116
appears C 77 116
to C 78 116
be C 79 116
more C 80 116
important C 81 116
to C 82 116
the C 83 116
development C 84 116
of C 85 116
this C 86 116
complication C 87 116
than C 88 116
the C 89 116
size C 90 116
of C 91 116
the C 92 116
defect C 93 116
or C 94 116
the C 95 116
magnitude C 96 116
of C 97 116
the C 98 116
shunt C 99 116
through C 100 116
it C 101 116
. C 102 116
the C 104 116
onset C 105 116
of C 106 116
aortic C 107 116
regurgitation C 108 116
occurs C 109 116
during C 110 116
early C 111 116
childhood C 112 116
and C 113 116
, C 114 116
once C 115 116
present C 116 116
, C 117 116
tends C 118 116
to C 119 116
become C 120 116
more C 121 116
severe C 122 116
. C 123 116
careful C 125 116
observation C 126 116
of C 127 116
patients C 128 116
with C 129 116
these C 130 116
defects C 131 116
is C 132 116
indicated C 133 116
following C 134 116
the C 135 116
appearance C 136 116
of C 137 116
aortic C 138 116
regurgitation C 139 116
since C 140 116
rapid C 141 116
progression C 142 116
to C 143 116
severe C 144 116
left C 145 116
ventricular C 146 116
failure C 147 116
is C 148 116
not C 149 116
uncommon C 150 116
. C 151 116
ventricular C 153 116
septal C 154 116
defect C 155 116
and C 156 116
aortic C 157 116
regurgitation C 158 116
must C 159 116
be C 160 116
distinguished C 161 116
from C 162 116
other C 163 116
cardiovascular C 164 116
abnormalities C 165 116
producing C 166 116
a C 167 116
wide C 168 116
pulse C 169 116
pressure C 170 116
with C 171 116
a C 172 116
continuous C 173 116
or C 174 116
to C 175 116
- C 176 116
and C 177 116
- C 178 116
fro C 179 116
murmur C 180 116
. C 181 116
cardiac C 183 116
catheterization C 184 116
and C 185 116
thoracic C 186 116
aortography C 187 116
are C 188 116
the C 189 116
diagnostic C 190 116
procedures C 191 116
most C 192 116
helpful C 193 116
in C 194 116
this C 195 116
differentiation C 196 116
. C 197 116
the C 199 116
operative C 200 116
treatment C 201 116
of C 202 116
ventricular C 203 116
septal C 204 116
defect C 205 116
and C 206 116
aortic C 207 116
regurgitation C 208 116
is C 209 116
reviewed C 210 116
and C 211 116
, C 212 116
on C 213 116
the C 214 116
basis C 215 116
of C 216 116
the C 217 116
present C 218 116
and C 219 116
previously C 220 116
reported C 221 116
results C 222 116
, C 223 116
suggested C 224 116
plans C 225 116
for C 226 116
surgical C 227 116
management C 228 116
are C 229 116
presented C 230 116
. C 231 116
current C 1 117
techniques C 2 117
in C 3 117
the C 4 117
surgical C 5 117
approach C 6 117
to C 7 117
aortic C 8 117
and C 9 117
mitral C 10 117
valvular C 11 117
disease C 12 117
. C 13 117
1 C 15 117
. C 16 117
the C 18 117
aortic C 19 117
and C 20 117
mitral C 21 117
valves C 22 117
can C 23 117
be C 24 117
operated C 25 117
upon C 26 117
successfully C 27 117
and C 28 117
totally C 29 117
replaced C 30 117
with C 31 117
a C 32 117
prosthetic C 33 117
device C 34 117
of C 35 117
the C 36 117
ball C 37 117
- C 38 117
valve C 39 117
type C 40 117
with C 41 117
good C 42 117
long C 43 117
- C 44 117
term C 45 117
results C 46 117
. C 47 117
seventy C 49 117
- C 50 117
four C 51 117
cases C 52 117
are C 53 117
reported C 54 117
. C 55 117
2 C 57 117
. C 58 117
in C 60 117
aortic C 61 117
valvular C 62 117
disease C 63 117
the C 64 117
outcome C 65 117
in C 66 117
the C 67 117
immediate C 68 117
postoperative C 69 117
period C 70 117
is C 71 117
influenced C 72 117
primarily C 73 117
by C 74 117
the C 75 117
presence C 76 117
of C 77 117
calcific C 78 117
aortic C 79 117
stenosis C 80 117
as C 81 117
well C 82 117
as C 83 117
the C 84 117
presence C 85 117
or C 86 117
absence C 87 117
of C 88 117
disease C 89 117
in C 90 117
the C 91 117
coronary C 92 117
arteries C 93 117
. C 94 117
3 C 96 117
. C 97 117
we C 99 117
have C 100 117
significantly C 101 117
decreased C 102 117
the C 103 117
appearance C 104 117
of C 105 117
a C 106 117
low C 107 117
- C 108 117
output C 109 117
syndrome C 110 117
postoperatively C 111 117
in C 112 117
patients C 113 117
who C 114 117
are C 115 117
suffering C 116 117
from C 117 117
severe C 118 117
mitral C 119 117
disease C 120 117
by C 121 117
leaving C 122 117
the C 123 117
papillary C 124 117
muscle C 125 117
- C 126 117
chordae C 127 117
tendineae C 128 117
- C 129 117
mural C 130 117
leaflet C 131 117
relationship C 132 117
intact C 133 117
. C 134 117
we C 136 117
feel C 137 117
this C 138 117
adds C 139 117
strength C 140 117
to C 141 117
each C 142 117
contraction C 143 117
. C 144 117
4 C 146 117
. C 147 117
there C 149 117
have C 150 117
been C 151 117
no C 152 117
late C 153 117
deaths C 154 117
in C 155 117
the C 156 117
follow C 157 117
- C 158 117
up C 159 117
period C 160 117
to C 161 117
date C 162 117
( C 163 117
thirty C 164 117
months C 165 117
) C 166 117
in C 167 117
any C 168 117
patient C 169 117
with C 170 117
replacement C 171 117
of C 172 117
aortic C 173 117
or C 174 117
mitral C 175 117
valves C 176 117
with C 177 117
the C 178 117
ball C 179 117
- C 180 117
valve C 181 117
prosthesis C 182 117
. C 183 117
effects C 1 118
of C 2 118
aortic C 3 118
regurgitation C 4 118
on C 5 118
left C 6 118
ventricular C 7 118
performance C 8 118
direct C 9 118
determinations C 10 118
of C 11 118
aortic C 12 118
blood C 13 118
flow C 14 118
before C 15 118
and C 16 118
after C 17 118
valve C 18 118
replacement C 19 118
. C 20 118
the C 22 118
volume C 23 118
of C 24 118
regurgitant C 25 118
blood C 26 118
flow C 27 118
and C 28 118
its C 29 118
effects C 30 118
on C 31 118
the C 32 118
performance C 33 118
of C 34 118
the C 35 118
left C 36 118
ventricle C 37 118
were C 38 118
assessed C 39 118
at C 40 118
operation C 41 118
in C 42 118
14 C 43 118
patients C 44 118
with C 45 118
varying C 46 118
degrees C 47 118
of C 48 118
aortic C 49 118
regurgitation C 50 118
. C 51 118
instantaneous C 53 118
forward C 54 118
and C 55 118
regurgitant C 56 118
flows C 57 118
in C 58 118
the C 59 118
ascending C 60 118
aorta C 61 118
were C 62 118
measured C 63 118
with C 64 118
a C 65 118
sine C 66 118
- C 67 118
wave C 68 118
electromagnetic C 69 118
flowmeter C 70 118
simultaneously C 71 118
with C 72 118
left C 73 118
ventricular C 74 118
and C 75 118
aortic C 76 118
pressures C 77 118
. C 78 118
in C 80 118
eight C 81 118
patients C 82 118
who C 83 118
had C 84 118
aortic C 85 118
regurgitation C 86 118
without C 87 118
associated C 88 118
stenosis C 89 118
, C 90 118
63 C 91 118
to C 92 118
75 C 93 118
percent C 94 118
of C 95 118
the C 96 118
total C 97 118
forward C 98 118
stroke C 99 118
volume C 100 118
regurgitated C 101 118
during C 102 118
the C 103 118
succeeding C 104 118
diastole C 105 118
. C 106 118
the C 108 118
calculated C 109 118
regurgitant C 110 118
orifice C 111 118
areas C 112 118
ranged C 113 118
from C 114 118
0 C 115 118
. C 116 118
. C 117 118
. C 117 118
to C 118 118
0 C 119 118
. C 120 118
. C 121 118
. C 121 118
cm C 122 118
/ C 123 118
m C 124 118
. C 125 118
after C 127 118
replacement C 128 118
of C 129 118
the C 130 118
aortic C 131 118
valve C 132 118
with C 133 118
a C 134 118
starr C 135 118
- C 136 118
edwards C 137 118
prosthesis C 138 118
, C 139 118
the C 140 118
absence C 141 118
of C 142 118
regurgitant C 143 118
flow C 144 118
was C 145 118
proved C 146 118
in C 147 118
every C 148 118
patient C 149 118
, C 150 118
and C 151 118
the C 152 118
records C 153 118
of C 154 118
aortic C 155 118
blood C 156 118
flow C 157 118
closely C 158 118
resembled C 159 118
those C 160 118
seen C 161 118
in C 162 118
patients C 163 118
with C 164 118
normal C 165 118
aortic C 166 118
valves C 167 118
. C 168 118
net C 170 118
forward C 171 118
blood C 172 118
flow C 173 118
increased C 174 118
by C 175 118
an C 176 118
average C 177 118
of C 178 118
60 C 179 118
percent C 180 118
, C 181 118
total C 182 118
left C 183 118
ventricular C 184 118
stroke C 185 118
volume C 186 118
fell C 187 118
42 C 188 118
percent C 189 118
, C 190 118
and C 191 118
the C 192 118
mean C 193 118
aortic C 194 118
pressure C 195 118
rose C 196 118
29 C 197 118
percent C 198 118
. C 199 118
the C 201 118
pressure C 202 118
work C 203 118
of C 204 118
the C 205 118
left C 206 118
ventricle C 207 118
was C 208 118
elevated C 209 118
preoperatively C 210 118
in C 211 118
five C 212 118
of C 213 118
the C 214 118
eight C 215 118
patients C 216 118
( C 217 118
average C 218 118
89 C 219 118
g C 220 118
- C 221 118
m C 222 118
stroke C 223 118
/ C 224 118
m C 225 118
) C 226 118
and C 227 118
fell C 228 118
significantly C 229 118
to C 230 118
an C 231 118
average C 232 118
of C 233 118
34 C 234 118
g C 235 118
- C 236 118
m C 237 118
stroke C 238 118
m C 239 118
after C 240 118
valve C 241 118
replacement C 242 118
. C 243 118
kinetic C 245 118
ventricular C 246 118
work C 247 118
was C 248 118
high C 249 118
in C 250 118
seven C 251 118
of C 252 118
the C 253 118
eight C 254 118
patients C 255 118
and C 256 118
comprised C 257 118
10 C 258 118
percent C 259 118
of C 260 118
total C 261 118
work C 262 118
before C 263 118
replacement C 264 118
but C 265 118
only C 266 118
4 C 267 118
. C 268 118
. C 269 118
percent C 270 118
afterward C 271 118
. C 272 118
similar C 274 118
observations C 275 118
were C 276 118
made C 277 118
in C 278 118
five C 279 118
patients C 280 118
with C 281 118
aortic C 282 118
stenosis C 283 118
and C 284 118
associated C 285 118
aortic C 286 118
regurgitation C 287 118
, C 288 118
ranging C 289 118
in C 290 118
severity C 291 118
from C 292 118
24 C 293 118
to C 294 118
72 C 295 118
percent C 296 118
of C 297 118
total C 298 118
forward C 299 118
stroke C 300 118
volume C 301 118
. C 302 118
in C 304 118
four C 305 118
patients C 306 118
in C 307 118
whom C 308 118
the C 309 118
valve C 310 118
was C 311 118
replaced C 312 118
, C 313 118
no C 314 118
residual C 315 118
regurgitation C 316 118
was C 317 118
present C 318 118
afterward C 319 118
, C 320 118
and C 321 118
net C 322 118
forward C 323 118
flow C 324 118
rose C 325 118
an C 326 118
average C 327 118
of C 328 118
49 C 329 118
percent C 330 118
. C 331 118
kinetic C 333 118
left C 334 118
ventricular C 335 118
work C 336 118
was C 337 118
extremely C 338 118
high C 339 118
in C 340 118
every C 341 118
patient C 342 118
and C 343 118
averaged C 344 118
26 C 345 118
percent C 346 118
of C 347 118
total C 348 118
work C 349 118
preoperatively C 350 118
and C 351 118
13 C 352 118
percent C 353 118
after C 354 118
valve C 355 118
replacement C 356 118
. C 357 118
in C 359 118
this C 360 118
group C 361 118
, C 362 118
pressure C 363 118
work C 364 118
was C 365 118
variable C 366 118
both C 367 118
before C 368 118
and C 369 118
after C 370 118
operation C 371 118
. C 372 118
the C 374 118
studies C 375 118
described C 376 118
provide C 377 118
definitive C 378 118
information C 379 118
concerning C 380 118
the C 381 118
effects C 382 118
of C 383 118
aortic C 384 118
valve C 385 118
disease C 386 118
on C 387 118
left C 388 118
ventricular C 389 118
performance C 390 118
in C 391 118
man C 392 118
and C 393 118
document C 394 118
the C 395 118
favorable C 396 118
changes C 397 118
in C 398 118
flow C 399 118
, C 400 118
pressure C 401 118
, C 402 118
and C 403 118
left C 404 118
ventricular C 405 118
work C 406 118
which C 407 118
immediately C 408 118
follow C 409 118
aortic C 410 118
valve C 411 118
replacement C 412 118
. C 413 118
the C 1 119
absorption C 2 119
and C 3 119
hepatic C 4 119
uptake C 5 119
of C 6 119
orally C 7 119
ingested C 8 119
radioactive C 9 119
vitamin C 10 119
b C 11 119
in C 12 119
hepato C 13 119
- C 14 119
splenic C 15 119
bilharziasis C 16 119
. C 17 119
the C 19 119
absorbed C 20 119
plasma C 21 119
radioactivity C 22 119
and C 23 119
hepatic C 24 119
uptake C 25 119
of C 26 119
orally C 27 119
ingested C 28 119
vitamin C 29 119
b C 30 119
tagged C 31 119
with C 32 119
co C 33 119
were C 34 119
measured C 35 119
in C 36 119
52 C 37 119
subjects C 38 119
, C 39 119
26 C 40 119
normals C 41 119
and C 42 119
26 C 43 119
suffering C 44 119
from C 45 119
bilharziasis C 46 119
. C 47 119
the C 49 119
results C 50 119
of C 51 119
the C 52 119
present C 53 119
work C 54 119
indicate C 55 119
that C 56 119
the C 57 119
absorption C 58 119
and C 59 119
hepatic C 60 119
uptake C 61 119
of C 62 119
this C 63 119
vitamin C 64 119
are C 65 119
within C 66 119
normal C 67 119
limits C 68 119
in C 69 119
hepatosplenic C 70 119
bilharziasis C 71 119
irrespective C 72 119
of C 73 119
the C 74 119
stage C 75 119
of C 76 119
the C 77 119
disease C 78 119
, C 79 119
the C 80 119
size C 81 119
of C 82 119
the C 83 119
organs C 84 119
affected C 85 119
and C 86 119
the C 87 119
presence C 88 119
or C 89 119
absence C 90 119
of C 91 119
associated C 92 119
peripheral C 93 119
neuritis C 94 119
. C 95 119
early C 1 120
effects C 2 120
of C 3 120
digitalis C 4 120
on C 5 120
central C 6 120
hemodynamics C 7 120
in C 8 120
normal C 9 120
subjects C 10 120
. C 11 120
the C 13 120
intravenous C 14 120
administration C 15 120
of C 16 120
lanatoside C 17 120
c C 18 120
in C 19 120
7 C 20 120
normal C 21 120
subjects C 22 120
had C 23 120
the C 24 120
following C 25 120
effects C 26 120
. C 27 120
. C 29 120
1 C 31 120
. C 32 120
an C 34 120
early C 35 120
significant C 36 120
reduction C 37 120
of C 38 120
heart C 39 120
rate C 40 120
. C 41 120
2 C 43 120
. C 44 120
a C 46 120
significant C 47 120
transient C 48 120
reduction C 49 120
of C 50 120
cardiac C 51 120
output C 52 120
. C 53 120
3 C 55 120
. C 56 120
a C 58 120
significant C 59 120
increase C 60 120
of C 61 120
the C 62 120
stroke C 63 120
volume C 64 120
initially C 65 120
accompanied C 66 120
by C 67 120
a C 68 120
significant C 69 120
rise C 70 120
of C 71 120
the C 72 120
end C 73 120
- C 74 120
diastolic C 75 120
volume C 76 120
with C 77 120
unchanged C 78 120
systolic C 79 120
rate C 80 120
of C 81 120
emptying C 82 120
. C 83 120
the C 85 120
increase C 86 120
of C 87 120
end C 88 120
- C 89 120
diastolic C 90 120
volume C 91 120
seems C 92 120
to C 93 120
be C 94 120
related C 95 120
to C 96 120
the C 97 120
lengthening C 98 120
of C 99 120
the C 100 120
diastolic C 101 120
filling C 102 120
period C 103 120
. C 104 120
later C 106 120
on C 107 120
, C 108 120
the C 109 120
systolic C 110 120
emptying C 111 120
rate C 112 120
increases C 113 120
, C 114 120
and C 115 120
the C 116 120
ventricular C 117 120
volumes C 118 120
decrease C 119 120
, C 120 120
suggesting C 121 120
an C 122 120
inotropic C 123 120
effect C 124 120
of C 125 120
the C 126 120
drug C 127 120
. C 128 120
4 C 130 120
. C 131 120
a C 133 120
significant C 134 120
increase C 135 120
of C 136 120
pulmonary C 137 120
blood C 138 120
volume C 139 120
, C 140 120
parallel C 141 120
to C 142 120
the C 143 120
increase C 144 120
of C 145 120
the C 146 120
stroke C 147 120
volume C 148 120
, C 149 120
suggestive C 150 120
of C 151 120
a C 152 120
passive C 153 120
relation C 154 120
between C 155 120
the C 156 120
two C 157 120
variables C 158 120
. C 159 120
measurement C 1 121
of C 2 121
pericardial C 3 121
fluid C 4 121
correlated C 5 121
with C 6 121
the C 7 121
i C 8 121
- C 9 121
cholografin C 10 121
and C 11 121
ihsa C 12 121
heart C 13 121
scan C 14 121
. C 15 121
in C 17 121
23 C 18 121
patients C 19 121
undergoing C 20 121
open C 21 121
- C 22 121
heart C 23 121
surgery C 24 121
in C 25 121
whom C 26 121
the C 27 121
pericardial C 28 121
contents C 29 121
were C 30 121
accurately C 31 121
measured C 32 121
, C 33 121
and C 34 121
in C 35 121
11 C 36 121
additional C 37 121
patients C 38 121
examined C 39 121
at C 40 121
autopsy C 41 121
or C 42 121
by C 43 121
pericardiocentesis C 44 121
, C 45 121
isotopic C 46 121
photoscans C 47 121
of C 48 121
the C 49 121
heart C 50 121
were C 51 121
made C 52 121
and C 53 121
the C 54 121
results C 55 121
were C 56 121
correlated C 57 121
. C 58 121
the C 60 121
most C 61 121
accurate C 62 121
means C 63 121
of C 64 121
diagnosis C 65 121
of C 66 121
pericardial C 67 121
effusion C 68 121
was C 69 121
found C 70 121
to C 71 121
be C 72 121
the C 73 121
ratio C 74 121
of C 75 121
the C 76 121
maximum C 77 121
transverse C 78 121
cardiac C 79 121
diameters C 80 121
on C 81 121
scan C 82 121
and C 83 121
roentgenogram C 84 121
. C 85 121
in C 87 121
patients C 88 121
with C 89 121
less C 90 121
than C 91 121
100 C 92 121
cc C 93 121
of C 94 121
pericardial C 95 121
fluid C 96 121
this C 97 121
ratio C 98 121
was C 99 121
greater C 100 121
than C 101 121
0 C 102 121
. C 103 121
. C 104 121
. C 104 121
, C 105 121
and C 106 121
it C 107 121
was C 108 121
less C 109 121
than C 110 121
this C 111 121
in C 112 121
cases C 113 121
of C 114 121
effusion C 115 121
of C 116 121
200 C 117 121
cc C 118 121
or C 119 121
more C 120 121
. C 121 121
measurement C 123 121
of C 124 121
the C 125 121
difference C 126 121
of C 127 121
these C 128 121
diameters C 129 121
, C 130 121
and C 131 121
visible C 132 121
separation C 133 121
of C 134 121
the C 135 121
cardiac C 136 121
blood C 137 121
pool C 138 121
from C 139 121
the C 140 121
pulmonary C 141 121
vasculature C 142 121
and C 143 121
liver C 144 121
aided C 145 121
in C 146 121
the C 147 121
diagnosis C 148 121
. C 149 121
pericardial C 151 121
effusions C 152 121
of C 153 121
200 C 154 121
- C 155 121
300 C 156 121
cc C 157 121
or C 158 121
greater C 159 121
can C 160 121
be C 161 121
detected C 162 121
by C 163 121
isotopic C 164 121
photoscanning C 165 121
. C 166 121
although C 168 121
cardiac C 169 121
dilatation C 170 121
and C 171 121
/ C 172 121
or C 173 121
hypertrophy C 174 121
decrease C 175 121
the C 176 121
sensitivity C 177 121
of C 178 121
the C 179 121
technique C 180 121
somewhat C 181 121
, C 182 121
a C 183 121
definite C 184 121
diagnosis C 185 121
of C 186 121
pericardial C 187 121
effusion C 188 121
can C 189 121
be C 190 121
made C 191 121
even C 192 121
when C 193 121
cardiomegaly C 194 121
exists C 195 121
. C 196 121
aneurysm C 1 122
of C 2 122
the C 3 122
membranous C 4 122
septum C 5 122
. C 6 122
1 C 8 122
. C 9 122
aneurysms C 11 122
of C 12 122
the C 13 122
membranous C 14 122
septum C 15 122
are C 16 122
relatively C 17 122
rare C 18 122
lesions C 19 122
presumably C 20 122
developing C 21 122
on C 22 122
a C 23 122
congenital C 24 122
basis C 25 122
. C 26 122
these C 28 122
aneurysms C 29 122
originate C 30 122
in C 31 122
the C 32 122
left C 33 122
ventricle C 34 122
immediately C 35 122
beneath C 36 122
the C 37 122
aortic C 38 122
valve C 39 122
and C 40 122
bulge C 41 122
into C 42 122
the C 43 122
right C 44 122
ventricle C 45 122
, C 46 122
the C 47 122
septal C 48 122
leaflet C 49 122
of C 50 122
the C 51 122
tricuspid C 52 122
valve C 53 122
or C 54 122
into C 55 122
the C 56 122
right C 57 122
atrium C 58 122
. C 59 122
2 C 61 122
. C 62 122
many C 64 122
of C 65 122
these C 66 122
aneurysms C 67 122
do C 68 122
not C 69 122
produce C 70 122
symptoms C 71 122
. C 72 122
others C 74 122
may C 75 122
cause C 76 122
right C 77 122
ventricular C 78 122
outflow C 79 122
tract C 80 122
obstruction C 81 122
or C 82 122
may C 83 122
rupture C 84 122
and C 85 122
result C 86 122
in C 87 122
a C 88 122
septal C 89 122
defect C 90 122
. C 91 122
the C 93 122
resulting C 94 122
shunt C 95 122
will C 96 122
be C 97 122
from C 98 122
the C 99 122
left C 100 122
ventricle C 101 122
into C 102 122
the C 103 122
right C 104 122
atrium C 105 122
or C 106 122
ventricle C 107 122
. C 108 122
3 C 110 122
. C 111 122
an C 113 122
aneurysm C 114 122
of C 115 122
the C 116 122
membranous C 117 122
septum C 118 122
may C 119 122
be C 120 122
an C 121 122
isolated C 122 122
abnormality C 123 122
or C 124 122
be C 125 122
associated C 126 122
with C 127 122
other C 128 122
congenital C 129 122
cardiac C 130 122
defects C 131 122
, C 132 122
particularly C 133 122
aortic C 134 122
valvular C 135 122
insufficiency C 136 122
. C 137 122
membranous C 139 122
septal C 140 122
aneurysms C 141 122
may C 142 122
be C 143 122
the C 144 122
site C 145 122
of C 146 122
bacterial C 147 122
endocarditis C 148 122
or C 149 122
thrombus C 150 122
formation C 151 122
. C 152 122
4 C 154 122
. C 155 122
aneurysms C 157 122
resembling C 158 122
those C 159 122
arising C 160 122
from C 161 122
the C 162 122
membranous C 163 122
septum C 164 122
may C 165 122
occur C 166 122
as C 167 122
part C 168 122
of C 169 122
the C 170 122
complex C 171 122
of C 172 122
deformities C 173 122
produced C 174 122
by C 175 122
an C 176 122
endocardial C 177 122
cushion C 178 122
defect C 179 122
. C 180 122
however C 182 122
, C 183 122
the C 184 122
angiographic C 185 122
features C 186 122
diagnostic C 187 122
of C 188 122
a C 189 122
cushion C 190 122
defect C 191 122
can C 192 122
still C 193 122
be C 194 122
recognized C 195 122
. C 196 122
5 C 198 122
. C 199 122
the C 201 122
presence C 202 122
of C 203 122
a C 204 122
septal C 205 122
aneurysm C 206 122
can C 207 122
be C 208 122
established C 209 122
only C 210 122
by C 211 122
angiocardiography C 212 122
. C 213 122
the C 215 122
diagnostic C 216 122
features C 217 122
as C 218 122
seen C 219 122
on C 220 122
the C 221 122
left C 222 122
ventricular C 223 122
angiocardiogram C 224 122
are C 225 122
presented C 226 122
. C 227 122
distribution C 1 123
of C 2 123
transfused C 3 123
tritiated C 4 123
cytidine C 5 123
- C 6 123
labeled C 7 123
leukocytes C 8 123
and C 9 123
red C 10 123
cells C 11 123
in C 12 123
the C 13 123
bone C 14 123
marrow C 15 123
of C 16 123
normal C 17 123
and C 18 123
irradiated C 19 123
rat C 20 123
. C 21 123
in C 23 123
normal C 24 123
rats C 25 123
and C 26 123
after C 27 123
total C 28 123
body C 29 123
irradiation C 30 123
with C 31 123
550 C 32 123
r C 33 123
of C 34 123
x C 35 123
- C 36 123
rays C 37 123
, C 38 123
the C 39 123
fate C 40 123
in C 41 123
the C 42 123
bone C 43 123
marrow C 44 123
of C 45 123
labeled C 46 123
nucleated C 47 123
and C 48 123
red C 49 123
cells C 50 123
of C 51 123
transfused C 52 123
peripheral C 53 123
blood C 54 123
was C 55 123
observed C 56 123
autoradiographically C 57 123
. C 58 123
labeled C 60 123
nucleated C 61 123
cells C 62 123
, C 63 123
most C 64 123
of C 65 123
which C 66 123
were C 67 123
lymphocyte C 68 123
- C 69 123
like C 70 123
cells C 71 123
, C 72 123
readily C 73 123
migrated C 74 123
into C 75 123
the C 76 123
marrow C 77 123
parenchyma C 78 123
in C 79 123
normal C 80 123
animals C 81 123
( C 82 123
2 C 83 123
cells C 84 123
/ C 85 123
1 C 86 123
, C 87 123
000 C 88 123
parenchymal C 89 123
cells C 90 123
/ C 91 123
hr C 92 123
. C 93 123
) C 95 123
. C 96 123
following C 98 123
irradiation C 99 123
to C 100 123
at C 101 123
least C 102 123
27 C 103 123
- C 104 123
51 C 105 123
hr C 106 123
. C 107 123
, C 109 123
this C 110 123
migration C 111 123
appeared C 112 123
to C 113 123
be C 114 123
relatively C 115 123
increased C 116 123
. C 117 123
beyond C 119 123
this C 120 123
time C 121 123
, C 122 123
parenchymal C 123 123
areas C 124 123
were C 125 123
more C 126 123
difficult C 127 123
to C 128 123
be C 129 123
defined C 130 123
as C 131 123
such C 132 123
. C 133 123
labeled C 135 123
red C 136 123
cells C 137 123
were C 138 123
rarely C 139 123
observed C 140 123
to C 141 123
enter C 142 123
parenchyma C 143 123
despite C 144 123
the C 145 123
presence C 146 123
of C 147 123
nonlabeled C 148 123
erythrocytes C 149 123
within C 150 123
the C 151 123
parenchymal C 152 123
structure C 153 123
after C 154 123
irradiation C 155 123
. C 156 123
the C 158 123
vascular C 159 123
bed C 160 123
following C 161 123
irradiation C 162 123
increased C 163 123
greatly C 164 123
as C 165 123
the C 166 123
parenchyma C 167 123
diminished C 168 123
to C 169 123
a C 170 123
minimum C 171 123
of C 172 123
less C 173 123
than C 174 123
10 C 175 123
percent C 176 123
control C 177 123
at C 178 123
75 C 179 123
hr C 180 123
. C 181 123
despite C 183 123
these C 184 123
changes C 185 123
in C 186 123
the C 187 123
architecture C 188 123
of C 189 123
the C 190 123
marrow C 191 123
, C 192 123
the C 193 123
average C 194 123
density C 195 123
of C 196 123
labeled C 197 123
cells C 198 123
per C 199 123
area C 200 123
of C 201 123
marrow C 202 123
corresponded C 203 123
to C 204 123
values C 205 123
expected C 206 123
on C 207 123
the C 208 123
assumption C 209 123
of C 210 123
a C 211 123
free C 212 123
- C 213 123
flowing C 214 123
circulation C 215 123
. C 216 123
the C 218 123
technique C 219 123
used C 220 123
at C 221 123
present C 222 123
did C 223 123
not C 224 123
allow C 225 123
us C 226 123
to C 227 123
distinguish C 228 123
, C 229 123
at C 230 123
all C 231 123
times C 232 123
, C 233 123
between C 234 123
a C 235 123
free C 236 123
- C 237 123
flowing C 238 123
circulation C 239 123
through C 240 123
intact C 241 123
sinusoids C 242 123
or C 243 123
through C 244 123
areas C 245 123
in C 246 123
which C 247 123
the C 248 123
sinusoidal C 249 123
wall C 250 123
, C 251 123
as C 252 123
such C 253 123
, C 254 123
was C 255 123
destroyed C 256 123
. C 257 123
factors C 1 124
limiting C 2 124
survival C 3 124
after C 4 124
circulatory C 5 124
occlusion C 6 124
under C 7 124
hypothermia C 8 124
and C 9 124
hyperbaric C 10 124
oxygenation C 11 124
. C 12 124
thirty C 14 124
minutes C 15 124
of C 16 124
circulatory C 17 124
occlusion C 18 124
with C 19 124
mild C 20 124
hypothermia C 21 124
and C 22 124
hyperbaric C 23 124
oxygen C 24 124
ventilation C 25 124
resulted C 26 124
in C 27 124
a C 28 124
mortality C 29 124
of C 30 124
83 C 31 124
. C 32 124
. C 33 124
percent C 34 124
in C 35 124
animals C 36 124
. C 37 124
when C 39 124
coronary C 40 124
perfusion C 41 124
from C 42 124
a C 43 124
reservoir C 44 124
was C 45 124
added C 46 124
, C 47 124
the C 48 124
mortality C 49 124
rate C 50 124
was C 51 124
22 C 52 124
percent C 53 124
. C 54 124
ventricular C 56 124
fibrillation C 57 124
was C 58 124
much C 59 124
more C 60 124
easily C 61 124
reversed C 62 124
after C 63 124
coronary C 64 124
perfusion C 65 124
. C 66 124
there C 68 124
was C 69 124
no C 70 124
evidence C 71 124
of C 72 124
brain C 73 124
damage C 74 124
in C 75 124
survivors C 76 124
which C 77 124
leads C 78 124
to C 79 124
the C 80 124
conclusion C 81 124
that C 82 124
the C 83 124
brain C 84 124
tolerates C 85 124
circulatory C 86 124
arrest C 87 124
better C 88 124
than C 89 124
the C 90 124
heart C 91 124
under C 92 124
these C 93 124
conditions C 94 124
. C 95 124
the C 1 125
effect C 2 125
of C 3 125
hypothermia C 4 125
on C 5 125
circulatory C 6 125
reflexes C 7 125
in C 8 125
the C 9 125
human C 10 125
. C 11 125
total C 13 125
circulatory C 14 125
occlusion C 15 125
and C 16 125
release C 17 125
result C 18 125
in C 19 125
hemodynamic C 20 125
phenomena C 21 125
which C 22 125
provide C 23 125
an C 24 125
index C 25 125
of C 26 125
integrity C 27 125
of C 28 125
some C 29 125
cardiovascular C 30 125
reflexes C 31 125
. C 32 125
these C 34 125
include C 35 125
carotid C 36 125
sinus C 37 125
and C 38 125
aortic C 39 125
baroceptors C 40 125
, C 41 125
arteriolar C 42 125
vasomotor C 43 125
tone C 44 125
, C 45 125
and C 46 125
venomotor C 47 125
reactivity C 48 125
. C 49 125
baroceptor C 51 125
depression C 52 125
appears C 53 125
at C 54 125
a C 55 125
more C 56 125
moderate C 57 125
level C 58 125
of C 59 125
cooling C 60 125
than C 61 125
does C 62 125
the C 63 125
sympathetic C 64 125
, C 65 125
vasomotor C 66 125
, C 67 125
depression C 68 125
. C 69 125
below C 71 125
28 C 72 125
degrees C 73 125
c C 74 125
. C 75 125
both C 77 125
are C 78 125
significantly C 79 125
depressed C 80 125
, C 81 125
although C 82 125
probably C 83 125
not C 84 125
totally C 85 125
abolished C 86 125
. C 87 125
the C 89 125
level C 90 125
of C 91 125
28 C 92 125
degrees C 93 125
c C 94 125
. C 95 125
is C 97 125
a C 98 125
critical C 99 125
physiological C 100 125
level C 101 125
and C 102 125
may C 103 125
represent C 104 125
an C 105 125
important C 106 125
limit C 107 125
in C 108 125
the C 109 125
clinical C 110 125
use C 111 125
of C 112 125
hypothermia C 113 125
. C 114 125
studies C 1 126
in C 2 126
perfusion C 3 126
hypothermia C 4 126
with C 5 126
special C 6 126
reference C 7 126
to C 8 126
/ C 9 126
deep C 10 126
hypothermia C 11 126
/ C 12 126
and C 13 126
circulatory C 14 126
arrest C 15 126
. C 16 126
1 C 18 126
. C 19 126
perfusion C 21 126
hypothermia C 22 126
produces C 23 126
large C 24 126
temperature C 25 126
gradients C 26 126
within C 27 126
the C 28 126
body C 29 126
since C 30 126
organs C 31 126
are C 32 126
cooled C 33 126
roughly C 34 126
in C 35 126
proportion C 36 126
to C 37 126
their C 38 126
basal C 39 126
blood C 40 126
flows C 41 126
. C 42 126
the C 44 126
difference C 45 126
between C 46 126
the C 47 126
coldest C 48 126
and C 49 126
the C 50 126
warmest C 51 126
portion C 52 126
of C 53 126
the C 54 126
body C 55 126
after C 56 126
30 C 57 126
minutes C 58 126
of C 59 126
perfusion C 60 126
exceeds C 61 126
25 C 62 126
c C 63 126
. C 64 126
2 C 66 126
. C 67 126
the C 69 126
average C 70 126
body C 71 126
temperature C 72 126
, C 73 126
which C 74 126
provides C 75 126
a C 76 126
proper C 77 126
measure C 78 126
of C 79 126
total C 80 126
body C 81 126
cooling C 82 126
, C 83 126
may C 84 126
be C 85 126
calculated C 86 126
from C 87 126
the C 88 126
arteriovenous C 89 126
temperature C 90 126
difference C 91 126
and C 92 126
the C 93 126
extracorporeal C 94 126
flow C 95 126
rate C 96 126
. C 97 126
3 C 99 126
. C 100 126
true C 102 126
/ C 103 126
deep C 104 126
/ C 105 126
hypothermia C 106 126
is C 107 126
not C 108 126
obtainable C 109 126
by C 110 126
reasonable C 111 126
periods C 112 126
of C 113 126
perfusion C 114 126
alone C 115 126
. C 116 126
4 C 118 126
. C 119 126
an C 121 126
important C 122 126
rise C 123 126
of C 124 126
core C 125 126
temperatures C 126 126
occurs C 127 126
during C 128 126
circulatory C 129 126
arrest C 130 126
in C 131 126
hypothermia C 132 126
because C 133 126
of C 134 126
relatively C 135 126
high C 136 126
average C 137 126
body C 138 126
temperature C 139 126
. C 140 126
5 C 142 126
. C 143 126
high C 145 126
average C 146 126
body C 147 126
temperatures C 148 126
lead C 149 126
to C 150 126
continuing C 151 126
production C 152 126
of C 153 126
lactic C 154 126
acid C 155 126
in C 156 126
muscle C 157 126
tissue C 158 126
, C 159 126
whereas C 160 126
low C 161 126
core C 162 126
temperatures C 163 126
impair C 164 126
lactic C 165 126
acid C 166 126
metabolism C 167 126
. C 168 126
thus C 170 126
metabolic C 171 126
acidosis C 172 126
is C 173 126
progressive C 174 126
in C 175 126
prolonged C 176 126
perfusion C 177 126
hypothermia C 178 126
, C 179 126
and C 180 126
is C 181 126
accentuated C 182 126
by C 183 126
total C 184 126
circulatory C 185 126
arrest C 186 126
. C 187 126
progressive C 189 126
acidosis C 190 126
may C 191 126
be C 192 126
minimized C 193 126
by C 194 126
uniform C 195 126
profound C 196 126
cooling C 197 126
by C 198 126
combining C 199 126
external C 200 126
with C 201 126
perfusion C 202 126
hypothermia C 203 126
. C 204 126
6 C 206 126
diluents C 207 126
appear C 208 126
to C 209 126
have C 210 126
little C 211 126
effect C 212 126
on C 213 126
total C 214 126
body C 215 126
heat C 216 126
exchange C 217 126
during C 218 126
perfusion C 219 126
cooling C 220 126
. C 221 126
7 C 223 126
. C 224 126
perfusion C 226 126
warming C 227 126
has C 228 126
a C 229 126
differentially C 230 126
greater C 231 126
effect C 232 126
on C 233 126
core C 234 126
organs C 235 126
. C 236 126
though C 238 126
these C 239 126
are C 240 126
readily C 241 126
brought C 242 126
to C 243 126
a C 244 126
normal C 245 126
range C 246 126
, C 247 126
much C 248 126
of C 249 126
the C 250 126
animal C 251 126
may C 252 126
remain C 253 126
cold C 254 126
. C 255 126
application C 1 127
of C 2 127
the C 3 127
emission C 4 127
spectrograph C 5 127
to C 6 127
the C 7 127
analytical C 8 127
needs C 9 127
of C 10 127
the C 11 127
industrial C 12 127
hygiene C 13 127
laboratory C 14 127
. C 15 127
examples C 17 127
of C 18 127
unique C 19 127
applications C 20 127
of C 21 127
the C 22 127
principles C 23 127
of C 24 127
emission C 25 127
spectroscopy C 26 127
to C 27 127
industrial C 28 127
hygiene C 29 127
problems C 30 127
are C 31 127
provided C 32 127
. C 33 127
a C 35 127
discussion C 36 127
of C 37 127
qualitative C 38 127
, C 39 127
semiquantitative C 40 127
and C 41 127
quantitative C 42 127
methods C 43 127
of C 44 127
spectrographic C 45 127
analysis C 46 127
is C 47 127
presented C 48 127
. C 49 127
these C 51 127
methods C 52 127
include C 53 127
representative C 54 127
applications C 55 127
which C 56 127
are C 57 127
made C 58 127
for C 59 127
the C 60 127
analysis C 61 127
of C 62 127
the C 63 127
metallic C 64 127
constituents C 65 127
of C 66 127
body C 67 127
tissues C 68 127
and C 69 127
fluids C 70 127
from C 71 127
human C 72 127
and C 73 127
animal C 74 127
subjects C 75 127
, C 76 127
industrial C 77 127
process C 78 127
materials C 79 127
, C 80 127
ores C 81 127
, C 82 127
and C 83 127
environmental C 84 127
dusts C 85 127
and C 86 127
fumes C 87 127
. C 88 127
brief C 90 127
descriptions C 91 127
of C 92 127
sample C 93 127
preparation C 94 127
techniques C 95 127
required C 96 127
for C 97 127
successful C 98 127
analyses C 99 127
are C 100 127
also C 101 127
presented C 102 127
. C 103 127
nickel C 1 128
carbonyl C 2 128
. C 3 128
. C 5 128
its C 7 128
detection C 8 128
and C 9 128
potential C 10 128
for C 11 128
formation C 12 128
. C 13 128
recent C 15 128
recommendations C 16 128
for C 17 128
control C 18 128
of C 19 128
nickel C 20 128
carbonyl C 21 128
exposures C 22 128
have C 23 128
been C 24 128
considered C 25 128
in C 26 128
the C 27 128
design C 28 128
of C 29 128
a C 30 128
simple C 31 128
, C 32 128
sensitive C 33 128
field C 34 128
method C 35 128
for C 36 128
sampling C 37 128
nickel C 38 128
carbonyl C 39 128
in C 40 128
air C 41 128
and C 42 128
process C 43 128
gases C 44 128
. C 45 128
the C 47 128
method C 48 128
involves C 49 128
collection C 50 128
in C 51 128
dilute C 52 128
aqueous C 53 128
hcl C 54 128
, C 55 128
ph C 56 128
adjustment C 57 128
, C 58 128
nickel C 59 128
complex C 60 128
development C 61 128
with C 62 128
alpha C 63 128
- C 64 128
furildioxime C 65 128
, C 66 128
and C 67 128
extraction C 68 128
with C 69 128
chloroform C 70 128
. C 71 128
color C 73 128
intensity C 74 128
is C 75 128
compared C 76 128
visually C 77 128
( C 78 128
or C 79 128
for C 80 128
greater C 81 128
accuracy C 82 128
, C 83 128
spectrophotometrically C 84 128
) C 85 128
with C 86 128
liquid C 87 128
standards C 88 128
. C 89 128
sensitivities C 91 128
on C 92 128
the C 93 128
order C 94 128
of C 95 128
0 C 96 128
. C 97 128
. C 98 128
. C 98 128
. C 98 128
ppm C 99 128
are C 100 128
obtainable C 101 128
. C 102 128
a C 104 128
detailed C 105 128
development C 106 128
of C 107 128
the C 108 128
thermodynamics C 109 128
associated C 110 128
with C 111 128
the C 112 128
formation C 113 128
of C 114 128
nickel C 115 128
carbonyl C 116 128
is C 117 128
also C 118 128
presented C 119 128
to C 120 128
show C 121 128
the C 122 128
maximum C 123 128
concentrations C 124 128
of C 125 128
nickel C 126 128
carbonyl C 127 128
that C 128 128
may C 129 128
be C 130 128
formed C 131 128
over C 132 128
a C 133 128
wide C 134 128
range C 135 128
of C 136 128
co C 137 128
concentrations C 138 128
, C 139 128
temperatures C 140 128
and C 141 128
pressures C 142 128
. C 143 128
polarographic C 1 129
determination C 2 129
of C 3 129
heavy C 4 129
metals C 5 129
in C 6 129
air C 7 129
samples C 8 129
. C 9 129
the C 11 129
polarograph C 12 129
possesses C 13 129
the C 14 129
required C 15 129
sensitivity C 16 129
and C 17 129
specificity C 18 129
to C 19 129
make C 20 129
it C 21 129
the C 22 129
method C 23 129
of C 24 129
choice C 25 129
for C 26 129
analysis C 27 129
for C 28 129
a C 29 129
variety C 30 129
of C 31 129
heavy C 32 129
metals C 33 129
in C 34 129
air C 35 129
. C 36 129
two C 38 129
commercial C 39 129
polarographs C 40 129
are C 41 129
compared C 42 129
and C 43 129
both C 44 129
found C 45 129
adequate C 46 129
on C 47 129
the C 48 129
basis C 49 129
of C 50 129
analysis C 51 129
for C 52 129
lead C 53 129
. C 54 129
determinations C 56 129
may C 57 129
be C 58 129
made C 59 129
for C 60 129
antimony C 61 129
, C 62 129
copper C 63 129
, C 64 129
lead C 65 129
, C 66 129
cadmium C 67 129
, C 68 129
chromium C 69 129
, C 70 129
nickel C 71 129
, C 72 129
cobalt C 73 129
, C 74 129
manganese C 75 129
, C 76 129
and C 77 129
others C 78 129
. C 79 129
the C 1 130
inorganic C 2 130
constituents C 3 130
of C 4 130
human C 5 130
teeth C 6 130
and C 7 130
bone C 8 130
examined C 9 130
by C 10 130
x C 11 130
- C 12 130
ray C 13 130
emission C 14 130
spectrography C 15 130
. C 16 130
x C 18 130
- C 19 130
ray C 20 130
emission C 21 130
spectrography C 22 130
has C 23 130
been C 24 130
applied C 25 130
to C 26 130
study C 27 130
of C 28 130
the C 29 130
elemental C 30 130
composition C 31 130
of C 32 130
human C 33 130
teeth C 34 130
, C 35 130
enamel C 36 130
, C 37 130
dentine C 38 130
and C 39 130
bone C 40 130
. C 41 130
the C 43 130
material C 44 130
consisted C 45 130
of C 46 130
eight C 47 130
crushed C 48 130
teeth C 49 130
, C 50 130
enamel C 51 130
and C 52 130
dentine C 53 130
powder C 54 130
separated C 55 130
from C 56 130
eighteen C 57 130
teeth C 58 130
, C 59 130
and C 60 130
four C 61 130
pieces C 62 130
of C 63 130
buccal C 64 130
cortical C 65 130
mandibular C 66 130
bone C 67 130
. C 68 130
the C 70 130
teeth C 71 130
did C 72 130
not C 73 130
have C 74 130
fillings C 75 130
. C 76 130
the C 78 130
whole C 79 130
material C 80 130
contained C 81 130
nineteen C 82 130
elements C 83 130
, C 84 130
of C 85 130
which C 86 130
the C 87 130
main C 88 130
ones C 89 130
were C 90 130
calcium C 91 130
and C 92 130
phosphorus C 93 130
. C 94 130
in C 96 130
all C 97 130
the C 98 130
samples C 99 130
of C 100 130
tooth C 101 130
material C 102 130
, C 103 130
there C 104 130
were C 105 130
found C 106 130
ca C 107 130
, C 108 130
p C 109 130
, C 110 130
cl C 111 130
, C 112 130
fe C 113 130
, C 114 130
zn C 115 130
, C 116 130
sr C 117 130
and C 118 130
k C 119 130
, C 120 130
and C 121 130
the C 122 130
bone C 123 130
also C 124 130
contained C 125 130
ni C 126 130
. C 127 130
the C 129 130
time C 130 130
needed C 131 130
for C 132 130
a C 133 130
semi C 134 130
- C 135 130
quantitative C 136 130
analysis C 137 130
compares C 138 130
very C 139 130
favourably C 140 130
with C 141 130
that C 142 130
needed C 143 130
for C 144 130
other C 145 130
methods C 146 130
. C 147 130
a C 1 131
kinetic C 2 131
study C 3 131
of C 4 131
nickel C 5 131
( C 6 131
ii C 7 131
) C 8 131
, C 9 131
complexes C 10 131
of C 11 131
sulfur C 12 131
- C 13 131
containing C 14 131
amino C 15 131
acid C 16 131
the C 17 131
rate C 18 131
expression C 19 131
for C 20 131
the C 21 131
ethylenediaminetetraacetic C 22 131
acid C 23 131
( C 24 131
edta C 25 131
) C 26 131
ligand C 27 131
exchange C 28 131
reaction C 29 131
with C 30 131
nickel C 31 131
( C 32 131
cysteine C 33 131
) C 34 131
is C 35 131
. C 36 131
. C 38 131
rate C 40 131
= C 41 131
k C 42 131
( C 43 131
complex C 44 131
) C 45 131
+ C 46 131
kedta C 47 131
( C 48 131
complex C 49 131
) C 50 131
( C 51 131
edta C 52 131
) C 53 131
. C 54 131
this C 56 131
two C 57 131
- C 58 131
term C 59 131
rate C 60 131
expression C 61 131
is C 62 131
characteristic C 63 131
of C 64 131
square C 65 131
planar C 66 131
complexes C 67 131
and C 68 131
agrees C 69 131
with C 70 131
the C 71 131
square C 72 131
planar C 73 131
configuration C 74 131
of C 75 131
ni C 76 131
( C 77 131
cysteine C 78 131
) C 79 131
reported C 80 131
on C 81 131
the C 82 131
basis C 83 131
of C 84 131
spectral C 85 131
studies C 86 131
the C 87 131
edta C 88 131
- C 89 131
independent C 90 131
term C 91 131
of C 92 131
the C 93 131
rate C 94 131
expression C 95 131
is C 96 131
an C 97 131
acid C 98 131
- C 99 131
catalyzed C 100 131
term C 101 131
and C 102 131
can C 103 131
be C 104 131
written C 105 131
k C 106 131
( C 107 131
h C 108 131
) C 109 131
( C 110 131
complex C 111 131
) C 112 131
. C 113 131
the C 115 131
value C 116 131
of C 117 131
kn C 118 131
is C 119 131
2 C 120 131
. C 121 131
. C 122 131
x C 123 131
10 C 124 131
m C 125 131
sec C 126 131
while C 127 131
the C 128 131
value C 129 131
of C 130 131
kedta C 131 131
is C 132 131
only C 133 131
on C 134 131
the C 135 131
order C 136 131
of C 137 131
10 C 138 131
- C 139 131
10 C 140 131
m C 141 131
sec C 142 131
. C 143 131
the C 145 131
edta C 146 131
reaction C 147 131
with C 148 131
ni C 149 131
( C 150 131
cysteine C 151 131
) C 152 131
methyl C 153 131
ester C 154 131
) C 155 131
is C 156 131
very C 157 131
similar C 158 131
to C 159 131
the C 160 131
reaction C 161 131
with C 162 131
ni C 163 131
( C 164 131
cysteine C 165 131
) C 166 131
. C 167 131
when C 169 131
the C 170 131
sulfur C 171 131
- C 172 131
containing C 173 131
amino C 174 131
acid C 175 131
ligand C 176 131
contains C 177 131
a C 178 131
thiol C 179 131
ether C 180 131
, C 181 131
the C 182 131
kinetic C 183 131
differences C 184 131
are C 185 131
striking C 186 131
. C 187 131
ligand C 189 131
exchange C 190 131
reactions C 191 131
of C 192 131
edta C 193 131
, C 194 131
triethylenetetramine C 195 131
, C 196 131
and C 197 131
diethylenetriamine C 198 131
with C 199 131
nickel C 200 131
- C 201 131
methionine C 202 131
complexes C 203 131
are C 204 131
several C 205 131
orders C 206 131
of C 207 131
magnitude C 208 131
faster C 209 131
and C 210 131
give C 211 131
products C 212 131
that C 213 131
are C 214 131
mixed C 215 131
- C 216 131
ligand C 217 131
complexes C 218 131
. C 219 131
the C 221 131
results C 222 131
of C 223 131
this C 224 131
kinetic C 225 131
study C 226 131
of C 227 131
amino C 228 131
acid C 229 131
complexes C 230 131
containing C 231 131
sulfhydryl C 232 131
and C 233 131
thiol C 234 131
ether C 235 131
sulfur C 236 131
groups C 237 131
support C 238 131
other C 239 131
studies C 240 131
at C 241 131
equilibrium C 242 131
which C 243 131
suggest C 244 131
sulfur C 245 131
coordination C 246 131
and C 247 131
square C 248 131
planar C 249 131
complexes C 250 131
for C 251 131
the C 252 131
sulfhydryl C 253 131
groups C 254 131
and C 255 131
octahedral C 256 131
complexes C 257 131
with C 258 131
no C 259 131
sulfur C 260 131
coordination C 261 131
for C 262 131
thiol C 263 131
ethers C 264 131
. C 265 131
the C 1 132
action C 2 132
of C 3 132
metal C 4 132
ions C 5 132
on C 6 132
tobacco C 7 132
mosaic C 8 132
virus C 9 132
ribonucleic C 10 132
acid C 11 132
. C 12 132
added C 14 132
transition C 15 132
metal C 16 132
ions C 17 132
stabilize C 18 132
the C 19 132
secondary C 20 132
structure C 21 132
of C 22 132
tobacco C 23 132
mosaic C 24 132
virus C 25 132
ribonucleic C 26 132
acid C 27 132
( C 28 132
tmv C 29 132
- C 30 132
rna C 31 132
) C 32 132
as C 33 132
evidenced C 34 132
by C 35 132
a C 36 132
reduction C 37 132
in C 38 132
the C 39 132
absorbancy C 40 132
change C 41 132
of C 42 132
heated C 43 132
nucleic C 44 132
acid C 45 132
solutions C 46 132
. C 47 132
in C 49 132
spite C 50 132
of C 51 132
this C 52 132
stabilization C 53 132
of C 54 132
secondary C 55 132
structure C 56 132
, C 57 132
heating C 58 132
in C 59 132
the C 60 132
presence C 61 132
of C 62 132
metal C 63 132
ions C 64 132
results C 65 132
in C 66 132
the C 67 132
loss C 68 132
of C 69 132
biological C 70 132
activity C 71 132
due C 72 132
to C 73 132
the C 74 132
hydrolysis C 75 132
of C 76 132
phosphodiester C 77 132
bonds C 78 132
. C 79 132
thus C 81 132
, C 82 132
all C 83 132
heavy C 84 132
metal C 85 132
ions C 86 132
of C 87 132
the C 88 132
iib C 89 132
and C 90 132
first C 91 132
- C 92 132
transition C 93 132
elements C 94 132
studied C 95 132
caused C 96 132
a C 97 132
rapid C 98 132
loss C 99 132
of C 100 132
biological C 101 132
activity C 102 132
of C 103 132
tmv C 104 132
- C 105 132
rna C 106 132
at C 107 132
ph C 108 132
6 C 109 132
. C 110 132
. C 111 132
and C 112 132
65 C 113 132
. C 114 132
calcium C 116 132
and C 117 132
magnesium C 118 132
ions C 119 132
, C 120 132
while C 121 132
not C 122 132
affecting C 123 132
secondary C 124 132
structure C 125 132
at C 126 132
65 C 127 132
and C 128 132
ph C 129 132
8 C 130 132
. C 131 132
. C 132 132
, C 133 132
caused C 134 132
a C 135 132
rapid C 136 132
loss C 137 132
of C 138 132
biological C 139 132
activity C 140 132
. C 141 132
at C 143 132
ph C 144 132
5 C 145 132
. C 146 132
. C 147 132
and C 148 132
room C 149 132
temperature C 150 132
lead C 151 132
ions C 152 132
catalyzed C 153 132
the C 154 132
hydrolysis C 155 132
of C 156 132
rna C 157 132
to C 158 132
i C 159 132
' C 160 132
( C 161 132
3 C 162 132
' C 163 132
) C 164 132
- C 165 132
mononucleotides C 166 132
, C 167 132
. C 168 132
on C 170 132
long C 171 132
standing C 172 132
, C 173 132
nucleosides C 174 132
were C 175 132
formed C 176 132
. C 177 132
chromium C 1 133
, C 2 133
lead C 3 133
, C 4 133
cadmium C 5 133
, C 6 133
nickel C 7 133
and C 8 133
titanium C 9 133
in C 10 133
mice C 11 133
. C 12 133
. C 14 133
effect C 16 133
on C 17 133
mortality C 18 133
, C 19 133
tumors C 20 133
and C 21 133
tissue C 22 133
levels C 23 133
. C 24 133
about C 26 133
700 C 27 133
mice C 28 133
were C 29 133
given C 30 133
throughout C 31 133
their C 32 133
lives C 33 133
5 C 34 133
ppm C 35 133
cadmium C 36 133
, C 37 133
lead C 38 133
, C 39 133
chromium C 40 133
, C 41 133
nickel C 42 133
or C 43 133
titanium C 44 133
in C 45 133
drinking C 46 133
water C 47 133
while C 48 133
fed C 49 133
a C 50 133
diet C 51 133
deficient C 52 133
in C 53 133
cadmium C 54 133
and C 55 133
low C 56 133
in C 57 133
other C 58 133
metals C 59 133
. C 60 133
tissue C 62 133
concentrations C 63 133
comparable C 64 133
to C 65 133
those C 66 133
of C 67 133
man C 68 133
were C 69 133
observed C 70 133
. C 71 133
sex C 73 133
differences C 74 133
appeared C 75 133
. C 76 133
mortality C 78 133
of C 79 133
females C 80 133
was C 81 133
unaffected C 82 133
. C 83 133
mortality C 85 133
of C 86 133
males C 87 133
on C 88 133
cadmium C 89 133
, C 90 133
lead C 91 133
and C 92 133
nickel C 93 133
was C 94 133
increased C 95 133
compared C 96 133
with C 97 133
that C 98 133
of C 99 133
the C 100 133
chromium C 101 133
group C 102 133
, C 103 133
and C 104 133
of C 105 133
those C 106 133
on C 107 133
cadmium C 108 133
and C 109 133
lead C 110 133
compared C 111 133
with C 112 133
the C 113 133
controls C 114 133
. C 115 133
longevity C 117 133
of C 118 133
the C 119 133
oldest C 120 133
10 C 121 133
of C 122 133
both C 123 133
sexes C 124 133
was C 125 133
less C 126 133
in C 127 133
lead C 128 133
and C 129 133
titanium C 130 133
groups C 131 133
, C 132 133
and C 133 133
of C 134 133
males C 135 133
in C 136 133
cadmium C 137 133
group C 138 133
, C 139 133
compared C 140 133
with C 141 133
controls C 142 133
. C 143 133
no C 145 133
metal C 146 133
was C 147 133
carcinogenic C 148 133
, C 149 133
. C 150 133
incidence C 152 133
of C 153 133
tumors C 154 133
in C 155 133
males C 156 133
on C 157 133
cadmium C 158 133
and C 159 133
lead C 160 133
, C 161 133
and C 162 133
in C 163 133
females C 164 133
given C 165 133
nickel C 166 133
was C 167 133
decreased C 168 133
. C 169 133
body C 171 133
weights C 172 133
at C 173 133
death C 174 133
were C 175 133
greater C 176 133
in C 177 133
titanium C 178 133
, C 179 133
chromium C 180 133
and C 181 133
lead C 182 133
groups C 183 133
. C 184 133
large C 186 133
increments C 187 133
of C 188 133
titanium C 189 133
, C 190 133
moderate C 191 133
increments C 192 133
of C 193 133
cadmium C 194 133
and C 195 133
nickel C 196 133
, C 197 133
and C 198 133
lesser C 199 133
increments C 200 133
of C 201 133
chromium C 202 133
and C 203 133
lead C 204 133
were C 205 133
observed C 206 133
in C 207 133
5 C 208 133
organs C 209 133
, C 210 133
compared C 211 133
with C 212 133
controls C 213 133
. C 214 133
higher C 216 133
concentrations C 217 133
of C 218 133
cadmium C 219 133
and C 220 133
titanium C 221 133
occurred C 222 133
in C 223 133
younger C 224 133
mice C 225 133
and C 226 133
the C 227 133
other C 228 133
metals C 229 133
did C 230 133
not C 231 133
increase C 232 133
markedly C 233 133
in C 234 133
tissues C 235 133
with C 236 133
age C 237 133
. C 238 133
all C 240 133
metals C 241 133
except C 242 133
chromium C 243 133
exhibited C 244 133
one C 245 133
or C 246 133
more C 247 133
signs C 248 133
of C 249 133
innate C 250 133
toxicity C 251 133
. C 252 133
synergistic C 1 134
effects C 2 134
between C 3 134
antioxidants C 4 134
and C 5 134
selenium C 6 134
or C 7 134
vitamin C 8 134
e C 9 134
. C 10 134
several C 12 134
antioxidants C 13 134
when C 14 134
fed C 15 134
to C 16 134
chicks C 17 134
at C 18 134
relatively C 19 134
high C 20 134
levels C 21 134
in C 22 134
an C 23 134
experimental C 24 134
diet C 25 134
were C 26 134
ineffective C 27 134
in C 28 134
preventing C 29 134
the C 30 134
exudates C 31 134
and C 32 134
mortality C 33 134
from C 34 134
a C 35 134
combined C 36 134
deficiency C 37 134
of C 38 134
selenium C 39 134
and C 40 134
vitamin C 41 134
e C 42 134
. C 43 134
some C 45 134
of C 46 134
the C 47 134
compounds C 48 134
were C 49 134
toxic C 50 134
, C 51 134
as C 52 134
evidenced C 53 134
by C 54 134
sudden C 55 134
death C 56 134
or C 57 134
subcutaneous C 58 134
hemorrhages C 59 134
. C 60 134
when C 62 134
amounts C 63 134
of C 64 134
either C 65 134
selenite C 66 134
or C 67 134
a C 68 134
- C 69 134
tocopheryl C 70 134
acetate C 71 134
, C 72 134
which C 73 134
individually C 74 134
had C 75 134
little C 76 134
or C 77 134
no C 78 134
effect C 79 134
on C 80 134
symptoms C 81 134
, C 82 134
were C 83 134
given C 84 134
with C 85 134
the C 86 134
antioxidants C 87 134
signs C 88 134
of C 89 134
deficiency C 90 134
and C 91 134
mortality C 92 134
were C 93 134
prevented C 94 134
, C 95 134
and C 96 134
toxicity C 97 134
also C 98 134
was C 99 134
eliminated C 100 134
. C 101 134
the C 1 135
expression C 2 135
of C 3 135
urine C 4 135
analysis C 5 135
results C 6 135
- C 7 135
dash C 8 135
observations C 9 135
on C 10 135
the C 11 135
use C 12 135
of C 13 135
a C 14 135
specific C 15 135
gravity C 16 135
correction C 17 135
. C 18 135
urine C 20 135
analyses C 21 135
are C 22 135
very C 23 135
useful C 24 135
for C 25 135
measuring C 26 135
the C 27 135
extent C 28 135
of C 29 135
exposure C 30 135
to C 31 135
certain C 32 135
toxic C 33 135
substances C 34 135
. C 35 135
the C 37 135
types C 38 135
of C 39 135
specimen C 40 135
obtainable C 41 135
from C 42 135
persons C 43 135
employed C 44 135
in C 45 135
industry C 46 135
, C 47 135
and C 48 135
the C 49 135
effect C 50 135
of C 51 135
concentration C 52 135
variations C 53 135
are C 54 135
discussed C 55 135
. C 56 135
in C 58 135
expressing C 59 135
the C 60 135
results C 61 135
of C 62 135
analysis C 63 135
it C 64 135
is C 65 135
shown C 66 135
that C 67 135
a C 68 135
concentration C 69 135
correction C 70 135
is C 71 135
essential C 72 135
. C 73 135
the C 75 135
correction C 76 135
based C 77 135
on C 78 135
specific C 79 135
gravity C 80 135
is C 81 135
the C 82 135
easiest C 83 135
to C 84 135
apply C 85 135
. C 86 135
the C 88 135
mean C 89 135
specific C 90 135
gravity C 91 135
for C 92 135
persons C 93 135
resident C 94 135
in C 95 135
the C 96 135
u C 97 135
. C 98 135
. C 99 135
. C 100 135
has C 102 135
been C 103 135
found C 104 135
to C 105 135
be C 106 135
around C 107 135
1 C 108 135
. C 109 135
. C 110 135
. C 110 135
. C 110 135
, C 111 135
a C 112 135
figure C 113 135
considerably C 114 135
lower C 115 135
than C 116 135
the C 117 135
mean C 118 135
of C 119 135
1 C 120 135
. C 121 135
. C 122 135
. C 122 135
. C 122 135
used C 123 135
by C 124 135
many C 125 135
workers C 126 135
( C 127 135
particularly C 128 135
in C 129 135
the C 130 135
u C 131 135
. C 132 135
. C 133 135
. C 134 135
. C 135 135
. C 136 135
) C 138 135
. C 139 135
the C 141 135
implications C 142 135
of C 143 135
this C 144 135
on C 145 135
the C 146 135
results C 147 135
of C 148 135
urine C 149 135
analysis C 150 135
are C 151 135
indicated C 152 135
. C 153 135
activation C 1 136
and C 2 136
inactivation C 3 136
of C 4 136
p C 5 136
- C 6 136
hydroxyphenylpyruvate C 7 136
hydroxylase C 8 136
. C 9 136
1 C 11 136
. C 12 136
p C 14 136
- C 15 136
hydroxyphenylpyruvate C 16 136
hydroxylase C 17 136
( C 18 136
ec C 19 136
1 C 20 136
. C 21 136
. C 22 136
. C 22 136
. C 23 136
. C 24 136
. C 25 136
. C 26 136
. C 26 136
) C 27 136
is C 28 136
reversibly C 29 136
inactivated C 30 136
by C 31 136
dialysis C 32 136
, C 33 136
storage C 34 136
, C 35 136
purification C 36 136
involving C 37 136
ammonium C 38 136
sulfate C 39 136
fractionation C 40 136
, C 41 136
and C 42 136
treatment C 43 136
with C 44 136
oxidizing C 45 136
agents C 46 136
. C 47 136
the C 49 136
inactive C 50 136
enzyme C 51 136
is C 52 136
reactivated C 53 136
by C 54 136
various C 55 136
reducing C 56 136
agents C 57 136
. C 58 136
2 C 60 136
. C 61 136
metal C 63 136
- C 64 136
chelating C 65 136
agents C 66 136
inhibited C 67 136
enzyme C 68 136
activity C 69 136
. C 70 136
1 C 72 136
, C 73 136
10 C 74 136
- C 75 136
phenanthroline C 76 136
and C 77 136
4 C 78 136
, C 79 136
7 C 80 136
- C 81 136
diphenyl C 82 136
- C 83 136
1 C 84 136
, C 85 136
10 C 86 136
- C 87 136
phenanthroline C 88 136
( C 89 136
fe C 90 136
sensitive C 91 136
) C 92 136
strongly C 93 136
inhibited C 94 136
, C 95 136
but C 96 136
2 C 97 136
, C 98 136
9 C 99 136
- C 100 136
dimethyl C 101 136
- C 102 136
1 C 103 136
, C 104 136
10 C 105 136
- C 106 136
phenanthroline C 107 136
( C 108 136
cu C 109 136
specific C 110 136
) C 111 136
did C 112 136
not C 113 136
. C 114 136
1 C 116 136
, C 117 136
10 C 118 136
- C 119 136
phenanthroline C 120 136
- C 121 136
treated C 122 136
p C 123 136
- C 124 136
hydroxyphenylpyruvate C 125 136
hydroxyl C 126 136
- C 127 136
ase C 128 136
was C 129 136
reactivated C 130 136
specifically C 131 136
by C 132 136
fe C 133 136
in C 134 136
the C 135 136
presence C 136 136
of C 137 136
a C 138 136
reducing C 139 136
agent C 140 136
, C 141 136
indicating C 142 136
a C 143 136
role C 144 136
for C 145 136
fe C 146 136
in C 147 136
enzyme C 148 136
activity C 149 136
. C 150 136
3 C 152 136
. C 153 136
nonoxidative C 155 136
sulfhydryl C 156 136
reagents C 157 136
did C 158 136
not C 159 136
materially C 160 136
inhibit C 161 136
the C 162 136
enzyme C 163 136
activity C 164 136
under C 165 136
various C 166 136
conditions C 167 136
. C 168 136
responses C 1 137
of C 2 137
b C 3 137
. C 4 137
subtilis C 6 137
( C 7 137
atcc C 8 137
558 C 9 137
) C 10 137
to C 11 137
streptomycin C 12 137
. C 13 137
to C 15 137
observe C 16 137
in C 17 137
detail C 18 137
the C 19 137
influence C 20 137
of C 21 137
streptomycin C 22 137
on C 23 137
the C 24 137
growth C 25 137
of C 26 137
sm C 27 137
dependent C 28 137
type C 29 137
, C 30 137
the C 31 137
author C 32 137
chose C 33 137
b C 34 137
. C 35 137
subtilis C 37 137
( C 38 137
atcc C 39 137
558 C 40 137
) C 41 137
and C 42 137
made C 43 137
experiments C 44 137
on C 45 137
its C 46 137
responses C 47 137
to C 48 137
streptomycin C 49 137
, C 50 137
with C 51 137
special C 52 137
reference C 53 137
to C 54 137
the C 55 137
relation C 56 137
of C 57 137
the C 58 137
sm C 59 137
concentration C 60 137
with C 61 137
spore C 62 137
formation C 63 137
of C 64 137
its C 65 137
sm C 66 137
dependent C 67 137
type C 68 137
together C 69 137
with C 70 137
germination C 71 137
and C 72 137
outgrowth C 73 137
of C 74 137
the C 75 137
spores C 76 137
formed C 77 137
. C 78 137
the C 80 137
results C 81 137
are C 82 137
as C 83 137
follows C 84 137
. C 85 137
1 C 87 137
. C 88 137
among C 90 137
18 C 91 137
x C 92 137
10 C 93 137
cells C 94 137
of C 95 137
wild C 96 137
type C 97 137
of C 98 137
b C 99 137
. C 100 137
subtilis C 102 137
( C 103 137
atcc C 104 137
558 C 105 137
) C 106 137
about C 107 137
3 C 108 137
, C 109 137
200 C 110 137
cells C 111 137
of C 112 137
sm C 113 137
resistant C 114 137
and C 115 137
one C 116 137
cell C 117 137
of C 118 137
sm C 119 137
dependent C 120 137
are C 121 137
found C 122 137
as C 123 137
its C 124 137
mutant C 125 137
. C 126 137
2 C 128 137
. C 129 137
b C 131 137
. C 132 137
substilis C 134 137
( C 135 137
atcc C 136 137
558 C 137 137
) C 138 137
shows C 139 137
normal C 140 137
growth C 141 137
at C 142 137
sm C 143 137
concentration C 144 137
below C 145 137
10 C 146 137
r C 147 137
/ C 148 137
ml C 149 137
, C 150 137
but C 151 137
the C 152 137
growth C 153 137
declines C 154 137
rapidly C 155 137
between C 156 137
sm C 157 137
10 C 158 137
r C 159 137
/ C 160 137
ml C 161 137
- C 162 137
20 C 163 137
r C 164 137
/ C 165 137
m C 166 137
l C 167 137
, C 168 137
and C 169 137
the C 170 137
growth C 171 137
stops C 172 137
entirely C 173 137
at C 174 137
sm C 175 137
concentration C 176 137
20 C 177 137
r C 178 137
/ C 179 137
ml C 180 137
. C 181 137
3 C 183 137
. C 184 137
sm C 186 137
resistant C 187 137
type C 188 137
grows C 189 137
well C 190 137
between C 191 137
sm C 192 137
0 C 193 137
. C 194 137
. C 195 137
r C 196 137
/ C 197 137
ml C 198 137
- C 199 137
sm C 200 137
2 C 201 137
, C 202 137
000 C 203 137
r C 204 137
/ C 205 137
ml C 206 137
, C 207 137
the C 208 137
growth C 209 137
declines C 210 137
rapidly C 211 137
at C 212 137
about C 213 137
sm C 214 137
10 C 215 137
, C 216 137
000 C 217 137
r C 218 137
/ C 219 137
ml C 220 137
. C 221 137
4 C 223 137
. C 224 137
sm C 226 137
dependent C 227 137
type C 228 137
shows C 229 137
normal C 230 137
growth C 231 137
between C 232 137
sm C 233 137
10 C 234 137
, C 235 137
000 C 236 137
r C 237 137
/ C 238 137
ml C 239 137
- C 240 137
20 C 241 137
r C 242 137
/ C 243 137
m C 244 137
l C 245 137
, C 246 137
the C 247 137
growth C 248 137
get C 249 137
worth C 250 137
below C 251 137
sm C 252 137
10 C 253 137
r C 254 137
/ C 255 137
ml C 256 137
, C 257 137
and C 258 137
the C 259 137
cell C 260 137
shape C 261 137
elongates C 262 137
several C 263 137
times C 264 137
, C 265 137
at C 266 137
sm C 267 137
below C 268 137
1 C 269 137
r C 270 137
/ C 271 137
ml C 272 137
each C 273 137
cell C 274 137
becomes C 275 137
filamentous C 276 137
form C 277 137
and C 278 137
has C 279 137
several C 280 137
ten C 281 137
times C 282 137
length C 283 137
of C 284 137
normal C 285 137
cell C 286 137
, C 287 137
as C 288 137
if C 289 137
the C 290 137
cells C 291 137
have C 292 137
stopped C 293 137
to C 294 137
divide C 295 137
at C 296 137
low C 297 137
sm C 298 137
concentration C 299 137
. C 300 137
6 C 302 137
. C 303 137
the C 305 137
germination C 306 137
and C 307 137
outgrowth C 308 137
of C 309 137
spores C 310 137
of C 311 137
the C 312 137
sm C 313 137
dependent C 314 137
type C 315 137
slow C 316 137
down C 317 137
with C 318 137
decline C 319 137
of C 320 137
sm C 321 137
concentration C 322 137
, C 323 137
but C 324 137
the C 325 137
germinated C 326 137
spores C 327 137
grow C 328 137
in C 329 137
normal C 330 137
forms C 331 137
until C 332 137
sm C 333 137
concentration C 334 137
reaches C 335 137
7 C 336 137
. C 337 137
. C 338 137
r C 339 137
/ C 340 137
ml C 341 137
, C 342 137
then C 343 137
the C 344 137
germination C 345 137
becomes C 346 137
much C 347 137
slower C 348 137
, C 349 137
and C 350 137
the C 351 137
cells C 352 137
grow C 353 137
in C 354 137
filamentous C 355 137
forms C 356 137
or C 357 137
irregular C 358 137
forms C 359 137
. C 360 137
at C 362 137
extremely C 363 137
low C 364 137
sm C 365 137
concentration C 366 137
both C 367 137
germination C 368 137
and C 369 137
outgrowth C 370 137
nearly C 371 137
stop C 372 137
. C 373 137
phospholipids C 1 138
of C 2 138
the C 3 138
bovine C 4 138
, C 5 138
rabbit C 6 138
, C 7 138
and C 8 138
human C 9 138
lens C 10 138
. C 11 138
the C 13 138
phospholipids C 14 138
of C 15 138
bovine C 16 138
, C 17 138
rabbit C 18 138
, C 19 138
and C 20 138
human C 21 138
lenses C 22 138
contain C 23 138
cephalin C 24 138
lecithin C 25 138
, C 26 138
and C 27 138
sphingomyelin C 28 138
but C 29 138
their C 30 138
distribution C 31 138
differs C 32 138
with C 33 138
each C 34 138
species C 35 138
. C 36 138
there C 38 138
is C 39 138
suggestive C 40 138
evidence C 41 138
that C 42 138
there C 43 138
may C 44 138
also C 45 138
be C 46 138
plasmalogen C 47 138
in C 48 138
the C 49 138
lens C 50 138
, C 51 138
but C 52 138
, C 53 138
if C 54 138
so C 55 138
, C 56 138
it C 57 138
represents C 58 138
a C 59 138
minor C 60 138
phospholipid C 61 138
component C 62 138
. C 63 138
the C 65 138
fatty C 66 138
acid C 67 138
composition C 68 138
of C 69 138
each C 70 138
phospholipid C 71 138
differs C 72 138
in C 73 138
each C 74 138
species C 75 138
, C 76 138
with C 77 138
most C 78 138
of C 79 138
the C 80 138
differences C 81 138
centering C 82 138
around C 83 138
16 C 84 138
. C 85 138
. C 87 138
. C 88 138
, C 89 138
18 C 90 138
. C 91 138
. C 93 138
. C 94 138
, C 95 138
and C 96 138
24 C 97 138
. C 98 138
. C 100 138
. C 101 138
. C 102 138
surgical C 1 139
aspects C 2 139
of C 3 139
heart C 4 139
disease C 5 139
in C 6 139
pregnancy C 7 139
. C 8 139
the C 10 139
ideal C 11 139
management C 12 139
of C 13 139
the C 14 139
pregnant C 15 139
woman C 16 139
with C 17 139
heart C 18 139
disease C 19 139
is C 20 139
medical C 21 139
, C 22 139
if C 23 139
feasible C 24 139
. C 25 139
the C 27 139
operative C 28 139
experience C 29 139
with C 30 139
mitral C 31 139
valvulotomy C 32 139
in C 33 139
pregnancy C 34 139
has C 35 139
expanded C 36 139
. C 37 139
this C 39 139
procedure C 40 139
is C 41 139
now C 42 139
indicated C 43 139
when C 44 139
progressive C 45 139
cardiac C 46 139
disability C 47 139
develops C 48 139
during C 49 139
the C 50 139
first C 51 139
or C 52 139
second C 53 139
trimester C 54 139
and C 55 139
when C 56 139
the C 57 139
proven C 58 139
dominant C 59 139
lesion C 60 139
is C 61 139
mitral C 62 139
stenosis C 63 139
. C 64 139
when C 66 139
other C 67 139
lesions C 68 139
are C 69 139
present C 70 139
, C 71 139
especially C 72 139
those C 73 139
requiring C 74 139
pump C 75 139
oxygenator C 76 139
perfusion C 77 139
, C 78 139
the C 79 139
risk C 80 139
must C 81 139
be C 82 139
carefully C 83 139
measured C 84 139
. C 85 139
damage C 87 139
to C 88 139
the C 89 139
fetus C 90 139
may C 91 139
result C 92 139
from C 93 139
reduced C 94 139
placental C 95 139
blood C 96 139
flow C 97 139
. C 98 139
traumatic C 1 140
lesions C 2 140
of C 3 140
the C 4 140
optic C 5 140
chiasma C 6 140
. C 7 140
. C 9 140
a C 11 140
report C 12 140
of C 13 140
four C 14 140
cases C 15 140
. C 16 140
case C 18 140
histories C 19 140
of C 20 140
four C 21 140
patients C 22 140
who C 23 140
suffered C 24 140
severe C 25 140
head C 26 140
trauma C 27 140
resulting C 28 140
in C 29 140
complete C 30 140
bitemporal C 31 140
hemianopia C 32 140
are C 33 140
presented C 34 140
. C 35 140
the C 37 140
optic C 38 140
chiasm C 39 140
was C 40 140
visualized C 41 140
in C 42 140
only C 43 140
one C 44 140
patient C 45 140
. C 46 140
it C 48 140
was C 49 140
markedly C 50 140
swollen C 51 140
and C 52 140
disintegrated C 53 140
. C 54 140
this C 56 140
appearance C 57 140
was C 58 140
consistent C 59 140
with C 60 140
multiple C 61 140
minute C 62 140
tears C 63 140
of C 64 140
the C 65 140
crossed C 66 140
fibres C 67 140
in C 68 140
the C 69 140
median C 70 140
sagittal C 71 140
plane C 72 140
. C 73 140
other C 75 140
theories C 76 140
to C 77 140
explain C 78 140
the C 79 140
bitemporal C 80 140
field C 81 140
defect C 82 140
are C 83 140
discussed C 84 140
. C 85 140
lung C 1 141
cancer C 2 141
. C 3 141
. C 5 141
an C 7 141
evolutionary C 8 141
approach C 9 141
. C 10 141
lung C 12 141
cancer C 13 141
is C 14 141
presented C 15 141
as C 16 141
an C 17 141
example C 18 141
of C 19 141
somatic C 20 141
mutation C 21 141
. C 22 141
in C 24 141
contrast C 25 141
to C 26 141
previous C 27 141
theories C 28 141
the C 29 141
following C 30 141
are C 31 141
defined C 32 141
. C 33 141
. C 35 141
( C 37 141
a C 38 141
) C 39 141
the C 40 141
major C 41 141
growth C 42 141
controlling C 43 141
mechanism C 44 141
, C 45 141
. C 46 141
( C 48 141
b C 49 141
) C 50 141
the C 51 141
mutation C 52 141
found C 53 141
in C 54 141
cancer C 55 141
, C 56 141
. C 57 141
and C 59 141
( C 60 141
c C 61 141
) C 62 141
the C 63 141
environmental C 64 141
changes C 65 141
in C 66 141
the C 67 141
lungs C 68 141
of C 69 141
patients C 70 141
who C 71 141
smoke C 72 141
cigarettes C 73 141
which C 74 141
can C 75 141
select C 76 141
this C 77 141
mutant C 78 141
. C 79 141
the C 1 142
effects C 2 142
of C 3 142
electrophoretically C 4 142
separated C 5 142
lens C 6 142
proteins C 7 142
on C 8 142
lens C 9 142
regeneration C 10 142
in C 11 142
diemyctylus C 12 142
viridescens C 13 142
. C 14 142
in C 16 142
the C 17 142
present C 18 142
study C 19 142
, C 20 142
lenses C 21 142
were C 22 142
removed C 23 142
from C 24 142
the C 25 142
eyes C 26 142
of C 27 142
adult C 28 142
anesthetized C 29 142
newts C 30 142
, C 31 142
macerated C 32 142
in C 33 142
0 C 34 142
. C 35 142
. C 36 142
. C 36 142
m C 37 142
borate C 38 142
buffer C 39 142
at C 40 142
ph C 41 142
8 C 42 142
. C 43 142
. C 44 142
, C 45 142
and C 46 142
separated C 47 142
by C 48 142
starch C 49 142
gel C 50 142
electrophoresis C 51 142
. C 52 142
upon C 54 142
staining C 55 142
with C 56 142
amido C 57 142
black C 58 142
10 C 59 142
- C 60 142
b C 61 142
, C 62 142
seven C 63 142
distinct C 64 142
staining C 65 142
areas C 66 142
appeared C 67 142
in C 68 142
the C 69 142
blocks C 70 142
. C 71 142
three C 73 142
bands C 74 142
moved C 75 142
toward C 76 142
the C 77 142
anode C 78 142
, C 79 142
and C 80 142
three C 81 142
toward C 82 142
the C 83 142
cathode C 84 142
. C 85 142
in C 87 142
addition C 88 142
, C 89 142
a C 90 142
seventh C 91 142
moiety C 92 142
represented C 93 142
by C 94 142
a C 95 142
smear C 96 142
of C 97 142
material C 98 142
moved C 99 142
toward C 100 142
the C 101 142
anode C 102 142
one C 103 142
millimeter C 104 142
times C 105 142
five C 106 142
tenths C 107 142
millimeter C 108 142
plugs C 109 142
were C 110 142
removed C 111 142
from C 112 142
each C 113 142
of C 114 142
these C 115 142
areas C 116 142
and C 117 142
were C 118 142
placed C 119 142
into C 120 142
freshly C 121 142
lentectomized C 122 142
eyes C 123 142
. C 124 142
plugs C 126 142
from C 127 142
most C 128 142
strongly C 129 142
positive C 130 142
and C 131 142
most C 132 142
weakly C 133 142
negative C 134 142
proteins C 135 142
inhibited C 136 142
lens C 137 142
regeneration C 138 142
. C 139 142
in C 141 142
addition C 142 142
, C 143 142
plugs C 144 142
from C 145 142
the C 146 142
area C 147 142
containing C 148 142
the C 149 142
weakly C 150 142
negative C 151 142
protein C 152 142
induced C 153 142
either C 154 142
lenses C 155 142
with C 156 142
aberrant C 157 142
polarity C 158 142
or C 159 142
double C 160 142
centered C 161 142
lenses C 162 142
with C 163 142
centers C 164 142
of C 165 142
opposed C 166 142
polarity C 167 142
. C 168 142
all C 170 142
other C 171 142
protein C 172 142
bands C 173 142
had C 174 142
no C 175 142
significant C 176 142
effect C 177 142
on C 178 142
regeneration C 179 142
. C 180 142
in C 182 142
addition C 183 142
to C 184 142
the C 185 142
above C 186 142
experiments C 187 142
, C 188 142
homogenates C 189 142
and C 190 142
proteinasedigested C 191 142
homogenates C 192 142
of C 193 142
lenses C 194 142
were C 195 142
injected C 196 142
into C 197 142
eyes C 198 142
following C 199 142
lentectomy C 200 142
. C 201 142
three C 203 142
5 C 204 142
- C 205 142
ul C 206 142
samples C 207 142
were C 208 142
injected C 209 142
in C 210 142
each C 211 142
case C 212 142
over C 213 142
a C 214 142
six C 215 142
day C 216 142
period C 217 142
. C 218 142
injection C 220 142
of C 221 142
the C 222 142
plain C 223 142
homogenate C 224 142
stimulated C 225 142
lens C 226 142
regeneration C 227 142
markedly C 228 142
, C 229 142
while C 230 142
the C 231 142
proteinase C 232 142
destroyed C 233 142
the C 234 142
stimulatory C 235 142
activity C 236 142
. C 237 142
theoretical C 239 142
considerations C 240 142
of C 241 142
the C 242 142
above C 243 142
data C 244 142
are C 245 142
discussed C 246 142
. C 247 142
enzymic C 1 143
synthesis C 2 143
of C 3 143
deoxyribonucleic C 4 143
acid C 5 143
xviii C 6 143
. C 7 143
the C 9 143
repair C 10 143
of C 11 143
partially C 12 143
single C 13 143
- C 14 143
stranded C 15 143
dna C 16 143
templates C 17 143
by C 18 143
dna C 19 143
polymerase C 20 143
. C 21 143
a C 23 143
partially C 24 143
single C 25 143
- C 26 143
stranded C 27 143
dna C 28 143
, C 29 143
prepared C 30 143
by C 31 143
limited C 32 143
digestion C 33 143
of C 34 143
each C 35 143
strand C 36 143
with C 37 143
exonuclease C 38 143
iii C 39 143
, C 40 143
can C 41 143
be C 42 143
restored C 43 143
to C 44 143
its C 45 143
native C 46 143
, C 47 143
fully C 48 143
double C 49 143
- C 50 143
stranded C 51 143
structure C 52 143
by C 53 143
escherichia C 54 143
coli C 55 143
dna C 56 143
polymerase C 57 143
. C 58 143
the C 60 143
rate C 61 143
of C 62 143
synthesis C 63 143
observed C 64 143
in C 65 143
the C 66 143
repair C 67 143
of C 68 143
such C 69 143
a C 70 143
partially C 71 143
degraded C 72 143
primer C 73 143
in C 74 143
the C 75 143
polymerase C 76 143
system C 77 143
is C 78 143
faster C 79 143
than C 80 143
that C 81 143
seen C 82 143
with C 83 143
a C 84 143
native C 85 143
dna C 86 143
. C 87 143
the C 89 143
newly C 90 143
synthesized C 91 143
dna C 92 143
is C 93 143
covalently C 94 143
attached C 95 143
to C 96 143
the C 97 143
primer C 98 143
. C 99 143
the C 101 143
fully C 102 143
repaired C 103 143
dna C 104 143
resembles C 105 143
the C 106 143
original C 107 143
native C 108 143
dna C 109 143
as C 110 143
judged C 111 143
by C 112 143
its C 113 143
appearance C 114 143
in C 115 143
electron C 116 143
micrographs C 117 143
, C 118 143
cscl C 119 143
density C 120 143
- C 121 143
gradient C 122 143
analysis C 123 143
, C 124 143
denaturability C 125 143
and C 126 143
genetic C 127 143
activity C 128 143
. C 129 143
dna C 131 143
synthesis C 132 143
which C 133 143
follows C 134 143
the C 135 143
repair C 136 143
phase C 137 143
produces C 138 143
a C 139 143
structure C 140 143
that C 141 143
is C 142 143
not C 143 143
covalently C 144 143
linked C 145 143
to C 146 143
the C 147 143
primer C 148 143
and C 149 143
resembles C 150 143
, C 151 143
in C 152 143
its C 153 143
nondenaturability C 154 143
, C 155 143
branched C 156 143
appearance C 157 143
, C 158 143
and C 159 143
lack C 160 143
of C 161 143
genetic C 162 143
activity C 163 143
, C 164 143
the C 165 143
product C 166 143
obtained C 167 143
with C 168 143
a C 169 143
native C 170 143
dna C 171 143
primer C 172 143
( C 173 143
schildkraut C 174 143
, C 175 143
richardson C 176 143
+ C 177 143
kornberg C 178 143
, C 179 143
1964 C 180 143
) C 181 143
. C 182 143
on C 1 144
the C 2 144
mechanism C 3 144
of C 4 144
genetic C 5 144
recombination C 6 144
in C 7 144
transforming C 8 144
bacillus C 9 144
subtilis C 10 144
. C 11 144
the C 13 144
molecular C 14 144
fate C 15 144
of C 16 144
transforming C 17 144
dna C 18 144
in C 19 144
competent C 20 144
bacillus C 21 144
subtilis C 22 144
has C 23 144
been C 24 144
studied C 25 144
. C 26 144
the C 28 144
physical C 29 144
differentiation C 30 144
of C 31 144
transforming C 32 144
dna C 33 144
and C 34 144
the C 35 144
genetic C 36 144
material C 37 144
of C 38 144
recipient C 39 144
bacteria C 40 144
was C 41 144
effected C 42 144
by C 43 144
employing C 44 144
the C 45 144
isotopes C 46 144
n C 47 144
and C 48 144
p C 49 144
. C 50 144
competent C 52 144
bacteria C 53 144
labeled C 54 144
with C 55 144
n C 56 144
and C 57 144
p C 58 144
were C 59 144
allowed C 60 144
to C 61 144
incorporate C 62 144
n C 63 144
p C 64 144
- C 65 144
labeled C 66 144
transforming C 67 144
dna C 68 144
intracellularly C 69 144
. C 70 144
dna C 72 144
was C 73 144
isolated C 74 144
from C 75 144
these C 76 144
recipient C 77 144
cells C 78 144
and C 79 144
centrifuged C 80 144
in C 81 144
cesium C 82 144
chloride C 83 144
. C 84 144
analysis C 86 144
of C 87 144
drop C 88 144
fractions C 89 144
collected C 90 144
at C 91 144
equilibrium C 92 144
showed C 93 144
the C 94 144
presence C 95 144
of C 96 144
radioactivity C 97 144
in C 98 144
a C 99 144
region C 100 144
of C 101 144
density C 102 144
corresponding C 103 144
to C 104 144
recipient C 105 144
dna C 106 144
. C 107 144
material C 109 144
contribution C 110 144
from C 111 144
donor C 112 144
dna C 113 144
to C 114 144
the C 115 144
resident C 116 144
dna C 117 144
did C 118 144
not C 119 144
occur C 120 144
when C 121 144
genetically C 122 144
inert C 123 144
bacillus C 124 144
cereus C 125 144
dna C 126 144
was C 127 144
substituted C 128 144
for C 129 144
homologous C 130 144
dna C 131 144
. C 132 144
it C 134 144
was C 135 144
concluded C 136 144
that C 137 144
radioactivity C 138 144
appearing C 139 144
in C 140 144
the C 141 144
unlabeled C 142 144
resident C 143 144
dna C 144 144
was C 145 144
not C 146 144
the C 147 144
result C 148 144
of C 149 144
degradation C 150 144
of C 151 144
input C 152 144
( C 153 144
p C 154 144
) C 155 144
dna C 156 144
and C 157 144
subsequent C 158 144
incorporation C 159 144
by C 160 144
normal C 161 144
metabolic C 162 144
processes C 163 144
. C 164 144
since C 166 144
single C 167 144
- C 168 144
stranded C 169 144
dna C 170 144
of C 171 144
donor C 172 144
origin C 173 144
was C 174 144
not C 175 144
detected C 176 144
, C 177 144
nor C 178 144
was C 179 144
there C 180 144
evidence C 181 144
for C 182 144
the C 183 144
non C 184 144
- C 185 144
specific C 186 144
aggregation C 187 144
of C 188 144
donor C 189 144
and C 190 144
recipient C 191 144
dna C 192 144
, C 193 144
it C 194 144
was C 195 144
concluded C 196 144
that C 197 144
the C 198 144
observed C 199 144
physical C 200 144
association C 201 144
of C 202 144
transforming C 203 144
and C 204 144
recipient C 205 144
dna C 206 144
occurs C 207 144
as C 208 144
a C 209 144
result C 210 144
of C 211 144
genetic C 212 144
recombination C 213 144
in C 214 144
transformed C 215 144
b C 216 144
. C 217 144
subtilis C 219 144
. C 220 144
physical C 1 145
and C 2 145
biological C 3 145
studies C 4 145
on C 5 145
transforming C 6 145
dna C 7 145
. C 8 145
bacillus C 10 145
subtilis C 11 145
transforming C 12 145
dna C 13 145
prepared C 14 145
by C 15 145
the C 16 145
method C 17 145
described C 18 145
, C 19 145
has C 20 145
an C 21 145
average C 22 145
molecular C 23 145
weight C 24 145
of C 25 145
11 C 26 145
. C 27 145
. C 28 145
million C 29 145
. C 30 145
the C 32 145
dna C 33 145
is C 34 145
heterogeneous C 35 145
, C 36 145
as C 37 145
judged C 38 145
by C 39 145
chemical C 40 145
composition C 41 145
, C 42 145
thermo C 43 145
- C 44 145
spectral C 45 145
and C 46 145
pyenographic C 47 145
properties C 48 145
. C 49 145
these C 51 145
properties C 52 145
have C 53 145
been C 54 145
used C 55 145
to C 56 145
fractionate C 57 145
some C 58 145
of C 59 145
the C 60 145
biologically C 61 145
active C 62 145
molecules C 63 145
which C 64 145
show C 65 145
higher C 66 145
specific C 67 145
activities C 68 145
in C 69 145
transforming C 70 145
respective C 71 145
auxotrophs C 72 145
. C 73 145
comparison C 1 146
of C 2 146
mutation C 3 146
and C 4 146
inactivation C 5 146
rates C 6 146
induced C 7 146
in C 8 146
bacteriophage C 9 146
and C 10 146
transforming C 11 146
dna C 12 146
by C 13 146
various C 14 146
mutagens C 15 146
. C 16 146
inactivation C 18 146
and C 19 146
mutation C 20 146
rates C 21 146
were C 22 146
measured C 23 146
for C 24 146
t C 25 146
4 C 26 146
phages C 27 146
and C 28 146
bacillus C 29 146
subtilis C 30 146
transforming C 31 146
dna C 32 146
treated C 33 146
by C 34 146
low C 35 146
ph C 36 146
, C 37 146
nitrous C 38 146
acid C 39 146
, C 40 146
or C 41 146
hydroxylamine C 42 146
at C 43 146
different C 44 146
temperatures C 45 146
. C 46 146
the C 48 146
frequency C 49 146
of C 50 146
mutants C 51 146
increased C 52 146
linearly C 53 146
with C 54 146
time C 55 146
for C 56 146
all C 57 146
three C 58 146
agents C 59 146
, C 60 146
whereas C 61 146
the C 62 146
logarithm C 63 146
of C 64 146
survival C 65 146
gave C 66 146
a C 67 146
linear C 68 146
plot C 69 146
only C 70 146
for C 71 146
nitrous C 72 146
acid C 73 146
and C 74 146
low C 75 146
ph C 76 146
. C 77 146
an C 79 146
arrhenius C 80 146
plot C 81 146
showed C 82 146
the C 83 146
same C 84 146
slopes C 85 146
for C 86 146
both C 87 146
inactivation C 88 146
and C 89 146
mutation C 90 146
rates C 91 146
after C 92 146
treatment C 93 146
with C 94 146
low C 95 146
ph C 96 146
or C 97 146
nitrous C 98 146
acid C 99 146
, C 100 146
. C 101 146
for C 103 146
the C 104 146
latter C 105 146
agent C 106 146
the C 107 146
slope C 108 146
remained C 109 146
unaltered C 110 146
even C 111 146
when C 112 146
the C 113 146
dna C 114 146
was C 115 146
treated C 116 146
in C 117 146
the C 118 146
denaturated C 119 146
state C 120 146
. C 121 146
in C 123 146
contrast C 124 146
, C 125 146
mutation C 126 146
rates C 127 146
obtained C 128 146
after C 129 146
the C 130 146
exposure C 131 146
to C 132 146
hydroxylamine C 133 146
differed C 134 146
greatly C 135 146
for C 136 146
native C 137 146
or C 138 146
denatured C 139 146
dna C 140 146
, C 141 146
phage C 142 146
t C 143 146
4 C 144 146
being C 145 146
intermediate C 146 146
. C 147 146
treatment C 149 146
by C 150 146
low C 151 146
ph C 152 146
or C 153 146
nitrous C 154 146
acid C 155 146
interrupted C 156 146
the C 157 146
genetic C 158 146
linkage C 159 146
between C 160 146
tryptophan C 161 146
and C 162 146
histidine C 163 146
, C 164 146
the C 165 146
interrupting C 166 146
hits C 167 146
being C 168 146
about C 169 146
1 C 170 146
/ C 171 146
3 C 172 146
as C 173 146
frequent C 174 146
as C 175 146
lethal C 176 146
hits C 177 146
, C 178 146
independent C 179 146
of C 180 146
the C 181 146
temperature C 182 146
. C 183 146
autolysis C 1 147
of C 2 147
bacillus C 3 147
subtilis C 4 147
by C 5 147
glucose C 6 147
depletion C 7 147
. C 8 147
in C 10 147
cultures C 11 147
in C 12 147
minimal C 13 147
medium C 14 147
, C 15 147
rapid C 16 147
lysis C 17 147
of C 18 147
cells C 19 147
of C 20 147
bacillus C 21 147
subtilis C 22 147
was C 23 147
observed C 24 147
as C 25 147
soon C 26 147
as C 27 147
the C 28 147
carbon C 29 147
source C 30 147
, C 31 147
e C 32 147
. C 33 147
. C 34 147
. C 35 147
glucose C 37 147
, C 38 147
had C 39 147
been C 40 147
completely C 41 147
consumed C 42 147
. C 43 147
the C 45 147
cells C 46 147
died C 47 147
and C 48 147
ultraviolet C 49 147
- C 50 147
absorbing C 51 147
material C 52 147
was C 53 147
excreted C 54 147
in C 55 147
the C 56 147
medium C 57 147
. C 58 147
the C 60 147
results C 61 147
suggest C 62 147
that C 63 147
the C 64 147
cells C 65 147
lyse C 66 147
because C 67 147
of C 68 147
the C 69 147
presence C 70 147
of C 71 147
autolytic C 72 147
enzymes C 73 147
. C 74 147
in C 76 147
the C 77 147
presence C 78 147
of C 79 147
glucose C 80 147
the C 81 147
damage C 82 147
to C 83 147
the C 84 147
cell C 85 147
wall C 86 147
caused C 87 147
by C 88 147
these C 89 147
enzymes C 90 147
is C 91 147
repaired C 92 147
immediately C 93 147
. C 94 147
plasma C 1 148
17 C 2 148
- C 3 148
hydroxycorticosteroids C 4 148
and C 5 148
17 C 6 148
- C 7 148
oxosteroids C 8 148
in C 9 148
patients C 10 148
with C 11 148
breast C 12 148
cancer C 13 148
and C 14 148
in C 15 148
normal C 16 148
women C 17 148
. C 18 148
( C 20 148
1 C 21 148
) C 22 148
17 C 23 148
- C 24 148
hydroxycorticosteroids C 25 148
( C 26 148
17 C 27 148
- C 28 148
ohcs C 29 148
) C 30 148
and C 31 148
17 C 32 148
- C 33 148
oxosteroids C 34 148
were C 35 148
measured C 36 148
in C 37 148
the C 38 148
plasma C 39 148
of C 40 148
normal C 41 148
women C 42 148
, C 43 148
patients C 44 148
with C 45 148
early C 46 148
breast C 47 148
cancer C 48 148
and C 49 148
in C 50 148
patients C 51 148
with C 52 148
advanced C 53 148
metastatic C 54 148
disease C 55 148
. C 56 148
( C 58 148
2 C 59 148
) C 60 148
the C 61 148
mean C 62 148
plasma C 63 148
17 C 64 148
- C 65 148
ohcs C 66 148
level C 67 148
was C 68 148
found C 69 148
to C 70 148
be C 71 148
normal C 72 148
in C 73 148
the C 74 148
early C 75 148
stages C 76 148
of C 77 148
the C 78 148
disease C 79 148
but C 80 148
was C 81 148
raised C 82 148
in C 83 148
the C 84 148
advanced C 85 148
disease C 86 148
. C 87 148
in C 89 148
both C 90 148
groups C 91 148
of C 92 148
patients C 93 148
the C 94 148
variance C 95 148
was C 96 148
significantly C 97 148
greater C 98 148
than C 99 148
in C 100 148
normal C 101 148
women C 102 148
. C 103 148
( C 105 148
3 C 106 148
) C 107 148
the C 108 148
mean C 109 148
plasma C 110 148
17 C 111 148
- C 112 148
oxosteroid C 113 148
level C 114 148
in C 115 148
both C 116 148
early C 117 148
and C 118 148
advanced C 119 148
breast C 120 148
cancer C 121 148
was C 122 148
not C 123 148
significantly C 124 148
different C 125 148
from C 126 148
the C 127 148
normal C 128 148
level C 129 148
but C 130 148
the C 131 148
variance C 132 148
was C 133 148
increased C 134 148
. C 135 148
( C 137 148
4 C 138 148
) C 139 148
there C 140 148
is C 141 148
a C 142 148
significant C 143 148
correlation C 144 148
between C 145 148
the C 146 148
plasma C 147 148
17 C 148 148
- C 149 148
ohcs C 150 148
and C 151 148
17 C 152 148
- C 153 148
oxosteroids C 154 148
in C 155 148
normal C 156 148
women C 157 148
which C 158 148
was C 159 148
not C 160 148
found C 161 148
in C 162 148
the C 163 148
cancer C 164 148
patients C 165 148
. C 166 148
( C 168 148
5 C 169 148
) C 170 148
in C 171 148
patients C 172 148
with C 173 148
advanced C 174 148
breast C 175 148
cancer C 176 148
, C 177 148
the C 178 148
levels C 179 148
of C 180 148
plasma C 181 148
17 C 182 148
- C 183 148
oxosteroids C 184 148
were C 185 148
significantly C 186 148
correlated C 187 148
with C 188 148
the C 189 148
amounts C 190 148
of C 191 148
11 C 192 148
- C 193 148
deoxy C 194 148
- C 195 148
17 C 196 148
- C 197 148
oxosteroids C 198 148
found C 199 148
in C 200 148
the C 201 148
urine C 202 148
. C 203 148
there C 205 148
was C 206 148
no C 207 148
correlation C 208 148
between C 209 148
plasma C 210 148
and C 211 148
urinary C 212 148
17 C 213 148
- C 214 148
ohcs C 215 148
. C 216 148
( C 218 148
6 C 219 148
) C 220 148
the C 221 148
physiological C 222 148
significance C 223 148
of C 224 148
these C 225 148
findings C 226 148
is C 227 148
discussed C 228 148
. C 229 148
hormone C 1 149
therapy C 2 149
in C 3 149
metastatic C 4 149
breast C 5 149
cancer C 6 149
. C 7 149
. C 9 149
clinical C 11 149
response C 12 149
and C 13 149
urinary C 14 149
gonadotrophins C 15 149
. C 16 149
the C 18 149
total C 19 149
urinary C 20 149
gonadotrophin C 21 149
output C 22 149
of C 23 149
a C 24 149
group C 25 149
of C 26 149
post C 27 149
menopausal C 28 149
women C 29 149
with C 30 149
metastatic C 31 149
breast C 32 149
carcinoma C 33 149
undergoing C 34 149
hormone C 35 149
therapy C 36 149
, C 37 149
which C 38 149
in C 39 149
every C 40 149
case C 41 149
initially C 42 149
consisted C 43 149
of C 44 149
treatment C 45 149
with C 46 149
diethylstilboestrol C 47 149
, C 48 149
des C 49 149
( C 50 149
ca C 51 149
. C 52 149
20 C 54 149
mg C 55 149
/ C 56 149
d C 57 149
) C 58 149
, C 59 149
has C 60 149
been C 61 149
studied C 62 149
for C 63 149
periods C 64 149
varying C 65 149
from C 66 149
seven C 67 149
months C 68 149
to C 69 149
31 C 70 149
/ C 71 149
2 C 72 149
years C 73 149
. C 74 149
no C 76 149
correlation C 77 149
between C 78 149
gonadotrophin C 79 149
output C 80 149
and C 81 149
clinical C 82 149
response C 83 149
was C 84 149
found C 85 149
, C 86 149
except C 87 149
that C 88 149
in C 89 149
all C 90 149
cases C 91 149
showing C 92 149
objective C 93 149
regression C 94 149
urinary C 95 149
gonadotrophin C 96 149
remained C 97 149
low C 98 149
throughout C 99 149
the C 100 149
remission C 101 149
period C 102 149
. C 103 149
a C 105 149
low C 106 149
level C 107 149
of C 108 149
gonadotrophin C 109 149
output C 110 149
was C 111 149
not C 112 149
, C 113 149
however C 114 149
, C 115 149
necessarily C 116 149
indicative C 117 149
of C 118 149
a C 119 149
good C 120 149
clinical C 121 149
remission C 122 149
. C 123 149
following C 125 149
withdrawal C 126 149
of C 127 149
des C 128 149
, C 129 149
and C 130 149
independent C 131 149
of C 132 149
the C 133 149
period C 134 149
of C 135 149
therapy C 136 149
, C 137 149
recovery C 138 149
to C 139 149
pre C 140 149
- C 141 149
treatment C 142 149
levels C 143 149
was C 144 149
the C 145 149
rule C 146 149
rather C 147 149
than C 148 149
the C 149 149
exception C 150 149
. C 151 149
a C 153 149
small C 154 149
group C 155 149
of C 156 149
patients C 157 149
maintained C 158 149
on C 159 149
a C 160 149
lower C 161 149
dose C 162 149
of C 163 149
des C 164 149
( C 165 149
3 C 166 149
- C 167 149
5 C 168 149
mg C 169 149
/ C 170 149
d C 171 149
) C 172 149
showed C 173 149
the C 174 149
same C 175 149
degree C 176 149
of C 177 149
suppression C 178 149
of C 179 149
urinary C 180 149
output C 181 149
as C 182 149
those C 183 149
receiving C 184 149
20 C 185 149
mg C 186 149
/ C 187 149
d C 188 149
, C 189 149
and C 190 149
several C 191 149
of C 192 149
these C 193 149
exhibited C 194 149
objective C 195 149
remissions C 196 149
. C 197 149
the C 199 149
study C 200 149
has C 201 149
emphasised C 202 149
the C 203 149
importance C 204 149
of C 205 149
site C 206 149
specificity C 207 149
in C 208 149
the C 209 149
response C 210 149
to C 211 149
hormone C 212 149
therapy C 213 149
, C 214 149
and C 215 149
underlines C 216 149
the C 217 149
difficulties C 218 149
of C 219 149
relating C 220 149
the C 221 149
clinical C 222 149
response C 223 149
of C 224 149
the C 225 149
patient C 226 149
as C 227 149
a C 228 149
whole C 229 149
to C 230 149
changes C 231 149
in C 232 149
hormonal C 233 149
environment C 234 149
. C 235 149
plasma C 1 150
androgens C 2 150
in C 3 150
women C 4 150
i C 5 150
. C 6 150
normal C 8 150
and C 9 150
non C 10 150
- C 11 150
hirsute C 12 150
females C 13 150
, C 14 150
oophorectomized C 15 150
and C 16 150
adrenalectomized C 17 150
patients C 18 150
. C 19 150
1 C 21 150
. C 22 150
in C 24 150
a C 25 150
group C 26 150
of C 27 150
20 C 28 150
normal C 29 150
non C 30 150
- C 31 150
hirsute C 32 150
females C 33 150
age C 34 150
17 C 35 150
to C 36 150
38 C 37 150
, C 38 150
18 C 39 150
non C 40 150
- C 41 150
hirsute C 42 150
patients C 43 150
with C 44 150
varied C 45 150
genito C 46 150
- C 47 150
urinary C 48 150
disorders C 49 150
, C 50 150
8 C 51 150
oophorectomized C 52 150
and C 53 150
or C 54 150
adrenalectomized C 55 150
patients C 56 150
plasma C 57 150
testosterone C 58 150
was C 59 150
measured C 60 150
by C 61 150
the C 62 150
method C 63 150
of C 64 150
finkelstein C 65 150
et C 66 150
al C 67 150
. C 68 150
( C 70 150
1961 C 71 150
) C 72 150
. C 73 150
conjugated C 75 150
androsterone C 76 150
and C 77 150
conjugated C 78 150
dhea C 79 150
were C 80 150
determined C 81 150
by C 82 150
a C 83 150
modified C 84 150
method C 85 150
of C 86 150
migeon C 87 150
+ C 88 150
plager C 89 150
( C 90 150
1955 C 91 150
) C 92 150
. C 93 150
2 C 95 150
. C 96 150
mean C 98 150
baseline C 99 150
values C 100 150
in C 101 150
normal C 102 150
females C 103 150
were C 104 150
. C 105 150
. C 106 150
. C 106 150
. C 107 150
. C 108 150
. C 108 150
ug C 109 150
/ C 110 150
100 C 111 150
ml C 112 150
testosterone C 113 150
, C 114 150
11 C 115 150
. C 116 150
. C 117 150
5 C 118 150
. C 119 150
. C 120 150
ug C 121 150
/ C 122 150
100 C 123 150
ml C 124 150
conjugated C 125 150
androsterone C 126 150
, C 127 150
and C 128 150
29 C 129 150
. C 130 150
. C 131 150
15 C 132 150
. C 133 150
. C 134 150
ug C 135 150
/ C 136 150
100 C 137 150
ml C 138 150
conjugated C 139 150
dhea C 140 150
. C 141 150
no C 143 150
significant C 144 150
response C 145 150
to C 146 150
hcg C 147 150
could C 148 150
be C 149 150
seen C 150 150
dexamethasone C 151 150
affected C 152 150
the C 153 150
conjugated C 154 150
dhea C 155 150
significantly C 156 150
, C 157 150
but C 158 150
did C 159 150
not C 160 150
seem C 161 150
to C 162 150
affect C 163 150
conjugated C 164 150
androsterone C 165 150
or C 166 150
testosterone C 167 150
. C 168 150
3 C 170 150
. C 171 150
the C 173 150
non C 174 150
- C 175 150
hirsute C 176 150
patients C 177 150
showed C 178 150
essentially C 179 150
the C 180 150
same C 181 150
pattern C 182 150
. C 183 150
an C 185 150
effect C 186 150
of C 187 150
dexamethasone C 188 150
on C 189 150
the C 190 150
levels C 191 150
of C 192 150
conjugated C 193 150
androsterone C 194 150
was C 195 150
demonstrated C 196 150
. C 197 150
4 C 199 150
. C 200 150
oophorectomized C 202 150
women C 203 150
had C 204 150
baseline C 205 150
values C 206 150
for C 207 150
the C 208 150
conjugates C 209 150
in C 210 150
the C 211 150
range C 212 150
of C 213 150
normals C 214 150
. C 215 150
testosterone C 217 150
, C 218 150
however C 219 150
, C 220 150
was C 221 150
low C 222 150
with C 223 150
an C 224 150
average C 225 150
of C 226 150
. C 227 150
. C 228 150
. C 228 150
. C 228 150
ug C 229 150
/ C 230 150
100 C 231 150
ml C 232 150
. C 233 150
in C 235 150
the C 236 150
adrenalectomized C 237 150
patients C 238 150
no C 239 150
androgens C 240 150
were C 241 150
detectable C 242 150
. C 243 150
oophorectomy C 1 151
and C 2 151
cortisone C 3 151
treatment C 4 151
as C 5 151
a C 6 151
method C 7 151
of C 8 151
eliminating C 9 151
oestrogen C 10 151
production C 11 151
in C 12 151
patients C 13 151
with C 14 151
breast C 15 151
cancer C 16 151
. C 17 151
the C 19 151
urinary C 20 151
excretion C 21 151
of C 22 151
oestrone C 23 151
, C 24 151
oestradiol C 25 151
- C 26 151
17 C 27 151
b C 28 151
, C 29 151
oestriol C 30 151
, C 31 151
and C 32 151
17 C 33 151
- C 34 151
hydroxycorticosteroids C 35 151
has C 36 151
been C 37 151
estimated C 38 151
in C 39 151
55 C 40 151
premenopausal C 41 151
and C 42 151
91 C 43 151
postmenopausal C 44 151
women C 45 151
with C 46 151
breast C 47 151
cancer C 48 151
at C 49 151
various C 50 151
stages C 51 151
of C 52 151
the C 53 151
disease C 54 151
before C 55 151
therapy C 56 151
. C 57 151
the C 59 151
depletion C 60 151
of C 61 151
oestrogen C 62 151
excretion C 63 151
caused C 64 151
by C 65 151
oophorectomy C 66 151
combined C 67 151
with C 68 151
cortisone C 69 151
treatment C 70 151
was C 71 151
studied C 72 151
in C 73 151
the C 74 151
patients C 75 151
with C 76 151
metastasising C 77 151
breast C 78 151
tumours C 79 151
( C 80 151
32 C 81 151
premenopausal C 82 151
and C 83 151
56 C 84 151
postmenopausal C 85 151
subjects C 86 151
) C 87 151
. C 88 151
patients C 90 151
with C 91 151
disseminating C 92 151
breast C 93 151
cancer C 94 151
excreted C 95 151
significantly C 96 151
larger C 97 151
quantities C 98 151
of C 99 151
oestriol C 100 151
than C 101 151
healthy C 102 151
women C 103 151
of C 104 151
the C 105 151
same C 106 151
age C 107 151
, C 108 151
whether C 109 151
pre C 110 151
- C 111 151
or C 112 151
postmenopausal C 113 151
. C 114 151
the C 116 151
excretion C 117 151
of C 118 151
oestrone C 119 151
and C 120 151
oestradiol C 121 151
- C 122 151
17 C 123 151
b C 124 151
was C 125 151
similar C 126 151
in C 127 151
cancer C 128 151
patients C 129 151
and C 130 151
healthy C 131 151
women C 132 151
of C 133 151
corresponding C 134 151
age C 135 151
. C 136 151
oophorectomy C 138 151
reduced C 139 151
the C 140 151
oestrogen C 141 151
excretion C 142 151
not C 143 151
only C 144 151
in C 145 151
premenopausal C 146 151
subjects C 147 151
but C 148 151
also C 149 151
in C 150 151
quite C 151 151
a C 152 151
number C 153 151
of C 154 151
postmenopausal C 155 151
patients C 156 151
, C 157 151
particularly C 158 151
in C 159 151
those C 160 151
who C 161 151
were C 162 151
still C 163 151
excreting C 164 151
significant C 165 151
amounts C 166 151
of C 167 151
oestrogens C 168 151
. C 169 151
this C 171 151
decrease C 172 151
in C 173 151
the C 174 151
oestrogen C 175 151
output C 176 151
was C 177 151
transient C 178 151
and C 179 151
was C 180 151
followed C 181 151
by C 182 151
a C 183 151
compensatory C 184 151
increase C 185 151
, C 186 151
possibly C 187 151
of C 188 151
adrenal C 189 151
origin C 190 151
. C 191 151
cortisone C 193 151
administered C 194 151
within C 195 151
a C 196 151
month C 197 151
after C 198 151
the C 199 151
oophorectomy C 200 151
at C 201 151
a C 202 151
dosage C 203 151
of C 204 151
50 C 205 151
mg C 206 151
per C 207 151
day C 208 151
rapidly C 209 151
depressed C 210 151
the C 211 151
secondary C 212 151
rise C 213 151
in C 214 151
the C 215 151
oestrogen C 216 151
output C 217 151
to C 218 151
a C 219 151
level C 220 151
of C 221 151
about C 222 151
4 C 223 151
to C 224 151
5 C 225 151
ug C 226 151
/ C 227 151
24 C 228 151
h C 229 151
irrespective C 230 151
of C 231 151
the C 232 151
age C 233 151
of C 234 151
the C 235 151
patient C 236 151
. C 237 151
this C 239 151
excretion C 240 151
level C 241 151
was C 242 151
unchanged C 243 151
as C 244 151
long C 245 151
as C 246 151
cortisone C 247 151
was C 248 151
given C 249 151
in C 250 151
an C 251 151
adequate C 252 151
dose C 253 151
, C 254 151
but C 255 151
increased C 256 151
rapidly C 257 151
when C 258 151
the C 259 151
cortisone C 260 151
treatment C 261 151
was C 262 151
discontinued C 263 151
. C 264 151
oophorectomy C 266 151
combined C 267 151
with C 268 151
adequate C 269 151
cortisone C 270 151
treatment C 271 151
seems C 272 151
to C 273 151
offer C 274 151
an C 275 151
alternative C 276 151
to C 277 151
the C 278 151
extensive C 279 151
surgical C 280 151
porcedures C 281 151
undertaken C 282 151
to C 283 151
eliminate C 284 151
oestrogen C 285 151
production C 286 151
in C 287 151
breast C 288 151
cancer C 289 151
patients C 290 151
. C 291 151
some C 1 152
reactions C 2 152
of C 3 152
cytotoxic C 4 152
antibodies C 5 152
against C 6 152
previously C 7 152
unknown C 8 152
mouse C 9 152
isoantigens C 10 152
. C 11 152
the C 13 152
antiserum C 14 152
produced C 15 152
in C 16 152
c C 17 152
3 C 18 152
h C 19 152
/ C 20 152
he C 21 152
against C 22 152
c C 23 152
3 C 24 152
h C 25 152
/ C 26 152
st C 27 152
lymphosarcoma C 28 152
6 C 29 152
c C 30 152
3 C 31 152
hed C 32 152
contains C 33 152
a C 34 152
mixture C 35 152
of C 36 152
at C 37 152
least C 38 152
two C 39 152
antibodies C 40 152
of C 41 152
different C 42 152
properties C 43 152
and C 44 152
specificities C 45 152
. C 46 152
anti C 48 152
h C 49 152
- C 50 152
5 C 51 152
a C 52 152
is C 53 152
a C 54 152
hemagglutinating C 55 152
antibody C 56 152
removed C 57 152
by C 58 152
absorption C 59 152
with C 60 152
red C 61 152
cells C 62 152
and C 63 152
many C 64 152
tissues C 65 152
. C 66 152
anti C 68 152
v C 69 152
is C 70 152
a C 71 152
cytotoxin C 72 152
reacting C 73 152
with C 74 152
c C 75 152
3 C 76 152
h C 77 152
/ C 78 152
st C 79 152
tissue C 80 152
and C 81 152
6 C 82 152
c C 83 152
3 C 84 152
hed C 85 152
but C 86 152
not C 87 152
with C 88 152
red C 89 152
cells C 90 152
. C 91 152
the C 93 152
reciprocal C 94 152
antiserum C 95 152
c C 96 152
3 C 97 152
h C 98 152
/ C 99 152
st C 100 152
anti C 101 152
c C 102 152
3 C 103 152
h C 104 152
/ C 105 152
he C 106 152
sarcoma C 107 152
mc C 108 152
1 C 109 152
m C 110 152
is C 111 152
more C 112 152
complex C 113 152
. C 114 152
it C 116 152
contains C 117 152
the C 118 152
hemagglutinin C 119 152
anti C 120 152
h C 121 152
- C 122 152
6 C 123 152
a C 124 152
and C 125 152
a C 126 152
variety C 127 152
of C 128 152
cytotoxins C 129 152
. C 130 152
one C 132 152
appears C 133 152
to C 134 152
be C 135 152
specific C 136 152
for C 137 152
c C 138 152
3 C 139 152
h C 140 152
/ C 141 152
he C 142 152
tissues C 143 152
and C 144 152
the C 145 152
tumor C 146 152
mc C 147 152
1 C 148 152
m C 149 152
. C 150 152
another C 152 152
reacts C 153 152
with C 154 152
antigens C 155 152
on C 156 152
the C 157 152
c C 158 152
3 C 159 152
h C 160 152
/ C 161 152
go C 162 152
carcinoma C 163 152
bp C 164 152
8 C 165 152
. C 166 152
two C 168 152
additional C 169 152
cytotoxins C 170 152
may C 171 152
also C 172 152
be C 173 152
present C 174 152
. C 175 152
immunization C 177 152
between C 178 152
sublines C 179 152
of C 180 152
the C 181 152
same C 182 152
inbred C 183 152
strain C 184 152
can C 185 152
result C 186 152
in C 187 152
the C 188 152
production C 189 152
of C 190 152
a C 191 152
variety C 192 152
of C 193 152
antibodies C 194 152
directed C 195 152
against C 196 152
unrelated C 197 152
antigens C 198 152
present C 199 152
on C 200 152
even C 201 152
long C 202 152
transplanted C 203 152
cells C 204 152
. C 205 152
the C 207 152
significance C 208 152
of C 209 152
on C 1 153
the C 2 153
value C 3 153
of C 4 153
thymectomy C 5 153
in C 6 153
adult C 7 153
mice C 8 153
as C 9 153
a C 10 153
means C 11 153
of C 12 153
potentiating C 13 153
the C 14 153
immunosuppressive C 15 153
action C 16 153
of C 17 153
melphalan C 18 153
( C 19 153
l C 20 153
- C 21 153
phenylalanine C 22 153
mustard C 23 153
) C 24 153
. C 25 153
thymectomy C 27 153
has C 28 153
been C 29 153
found C 30 153
to C 31 153
be C 32 153
ineffective C 33 153
as C 34 153
a C 35 153
means C 36 153
of C 37 153
potentiating C 38 153
the C 39 153
immunosuppressive C 40 153
action C 41 153
of C 42 153
melphalan C 43 153
in C 44 153
adult C 45 153
cba C 46 153
- C 47 153
p C 48 153
mice C 49 153
challenged C 50 153
with C 51 153
a C 52 153
- C 53 153
strain C 54 153
mammary C 55 153
carcinoma C 56 153
transplants C 57 153
. C 58 153
this C 60 153
was C 61 153
true C 62 153
when C 63 153
the C 64 153
thymectomy C 65 153
was C 66 153
performed C 67 153
2 C 68 153
days C 69 153
, C 70 153
4 C 71 153
weeks C 72 153
or C 73 153
7 C 74 153
weeks C 75 153
prior C 76 153
to C 77 153
injection C 78 153
of C 79 153
a C 80 153
single C 81 153
dose C 82 153
( C 83 153
15 C 84 153
mg C 85 153
/ C 86 153
kg C 87 153
body C 88 153
weight C 89 153
) C 90 153
of C 91 153
melphalan C 92 153
, C 93 153
administered C 94 153
24 C 95 153
hours C 96 153
prior C 97 153
to C 98 153
tumour C 99 153
transplantation C 100 153
, C 101 153
and C 102 153
also C 103 153
when C 104 153
thymectomy C 105 153
was C 106 153
combined C 107 153
with C 108 153
multiple C 109 153
doses C 110 153
of C 111 153
melphalan C 112 153
given C 113 153
before C 114 153
and C 115 153
after C 116 153
tumour C 117 153
transplantation C 118 153
. C 119 153
these C 121 153
findings C 122 153
are C 123 153
discussed C 124 153
. C 125 153
studies C 1 154
on C 2 154
the C 3 154
kinetics C 4 154
of C 5 154
transplantation C 6 154
immunity C 7 154
. C 8 154
using C 10 154
the C 11 154
parameter C 12 154
of C 13 154
the C 14 154
number C 15 154
of C 16 154
tumor C 17 154
cells C 18 154
necessary C 19 154
to C 20 154
produce C 21 154
s C 22 154
. C 23 154
. C 24 154
. C 25 154
tumors C 27 154
in C 28 154
allogeneic C 29 154
animals C 30 154
at C 31 154
varying C 32 154
intervals C 33 154
after C 34 154
antigenic C 35 154
stimulation C 36 154
, C 37 154
immunity C 38 154
was C 39 154
found C 40 154
to C 41 154
be C 42 154
in C 43 154
force C 44 154
as C 45 154
early C 46 154
as C 47 154
2 C 48 154
days C 49 154
after C 50 154
primary C 51 154
antigenic C 52 154
stimulation C 53 154
. C 54 154
it C 56 154
reached C 57 154
a C 58 154
peak C 59 154
at C 60 154
8 C 61 154
- C 62 154
10 C 63 154
days C 64 154
and C 65 154
had C 66 154
largely C 67 154
subsided C 68 154
by C 69 154
the C 70 154
end C 71 154
of C 72 154
a C 73 154
month C 74 154
. C 75 154
this C 77 154
method C 78 154
was C 79 154
also C 80 154
applied C 81 154
to C 82 154
the C 83 154
quantitative C 84 154
study C 85 154
of C 86 154
the C 87 154
onset C 88 154
, C 89 154
degree C 90 154
, C 91 154
and C 92 154
duration C 93 154
of C 94 154
immunity C 95 154
elicited C 96 154
by C 97 154
skin C 98 154
grafts C 99 154
. C 100 154
the C 102 154
results C 103 154
obtained C 104 154
with C 105 154
inocula C 106 154
of C 107 154
large C 108 154
numbers C 109 154
of C 110 154
tumor C 111 154
cells C 112 154
( C 113 154
10 C 114 154
percent C 115 154
) C 116 154
were C 117 154
comparable C 118 154
to C 119 154
those C 120 154
obtained C 121 154
with C 122 154
massive C 123 154
skin C 124 154
grafts C 125 154
. C 126 154
the C 128 154
differences C 129 154
in C 130 154
the C 131 154
degree C 132 154
of C 133 154
antigenic C 134 154
stimulation C 135 154
resulting C 136 154
from C 137 154
different C 138 154
routes C 139 154
of C 140 154
inoculation C 141 154
were C 142 154
studied C 143 154
. C 144 154
it C 146 154
was C 147 154
found C 148 154
that C 149 154
the C 150 154
intradermal C 151 154
( C 152 154
i C 153 154
. C 154 154
. C 155 154
. C 156 154
) C 158 154
route C 159 154
of C 160 154
inoculation C 161 154
resulted C 162 154
in C 163 154
a C 164 154
more C 165 154
intense C 166 154
antigenic C 167 154
stimulation C 168 154
than C 169 154
the C 170 154
s C 171 154
. C 172 154
. C 173 154
. C 174 154
route C 176 154
. C 177 154
when C 179 154
both C 180 154
routes C 181 154
of C 182 154
inoculation C 183 154
were C 184 154
used C 185 154
simultaneously C 186 154
the C 187 154
pattern C 188 154
of C 189 154
growth C 190 154
of C 191 154
the C 192 154
s C 193 154
. C 194 154
. C 195 154
. C 196 154
tumor C 198 154
was C 199 154
influenced C 200 154
by C 201 154
the C 202 154
i C 203 154
. C 204 154
. C 205 154
. C 206 154
inoculation C 208 154
. C 209 154
. C 211 154
an C 213 154
i C 214 154
. C 215 154
. C 216 154
. C 217 154
inoculum C 219 154
given C 220 154
24 C 221 154
or C 222 154
48 C 223 154
hr C 224 154
earlier C 225 154
caused C 226 154
marked C 227 154
suppression C 228 154
of C 229 154
growth C 230 154
of C 231 154
the C 232 154
s C 233 154
. C 234 154
. C 235 154
. C 236 154
tumor C 238 154
, C 239 154
while C 240 154
when C 241 154
an C 242 154
i C 243 154
. C 244 154
. C 245 154
. C 246 154
inoculation C 248 154
was C 249 154
preceded C 250 154
by C 251 154
an C 252 154
s C 253 154
. C 254 154
. C 255 154
. C 256 154
inoculation C 258 154
, C 259 154
although C 260 154
there C 261 154
was C 262 154
an C 263 154
appreciable C 264 154
effect C 265 154
on C 266 154
the C 267 154
growth C 268 154
size C 269 154
, C 270 154
the C 271 154
growth C 272 154
curves C 273 154
of C 274 154
the C 275 154
2 C 276 154
tumors C 277 154
were C 278 154
always C 279 154
parallel C 280 154
. C 281 154
there C 283 154
was C 284 154
no C 285 154
correlation C 286 154
between C 287 154
cytotoxic C 288 154
activity C 289 154
and C 290 154
the C 291 154
degree C 292 154
of C 293 154
immunity C 294 154
in C 295 154
force C 296 154
at C 297 154
a C 298 154
given C 299 154
time C 300 154
. C 301 154
evidence C 1 155
for C 2 155
an C 3 155
immunological C 4 155
reaction C 5 155
of C 6 155
the C 7 155
host C 8 155
directed C 9 155
against C 10 155
its C 11 155
own C 12 155
actively C 13 155
growing C 14 155
primary C 15 155
tumor C 16 155
. C 17 155
cells C 19 155
isolated C 20 155
from C 21 155
primary C 22 155
benzo C 23 155
( C 24 155
a C 25 155
) C 26 155
pyrene C 27 155
- C 28 155
induced C 29 155
fibrosarcomas C 30 155
in C 31 155
rats C 32 155
of C 33 155
a C 34 155
pure C 35 155
line C 36 155
were C 37 155
tested C 38 155
for C 39 155
their C 40 155
ability C 41 155
to C 42 155
grow C 43 155
as C 44 155
autografts C 45 155
when C 46 155
injected C 47 155
back C 48 155
into C 49 155
the C 50 155
autochthonous C 51 155
host C 52 155
. C 53 155
the C 55 155
autograft C 56 155
did C 57 155
not C 58 155
take C 59 155
if C 60 155
the C 61 155
primary C 62 155
tumor C 63 155
had C 64 155
been C 65 155
removed C 66 155
but C 67 155
grew C 68 155
occasionally C 69 155
in C 70 155
animals C 71 155
in C 72 155
which C 73 155
the C 74 155
major C 75 155
part C 76 155
of C 77 155
the C 78 155
tumor C 79 155
was C 80 155
left C 81 155
. C 82 155
in C 84 155
every C 85 155
instance C 86 155
the C 87 155
sarcoma C 88 155
cells C 89 155
grew C 90 155
when C 91 155
injected C 92 155
into C 93 155
syngeneic C 94 155
recipients C 95 155
in C 96 155
these C 97 155
recipients C 98 155
the C 99 155
growth C 100 155
of C 101 155
the C 102 155
sarcoma C 103 155
cells C 104 155
was C 105 155
prevented C 106 155
or C 107 155
retarded C 108 155
when C 109 155
they C 110 155
were C 111 155
mixed C 112 155
in C 113 155
vitro C 114 155
, C 115 155
prior C 116 155
to C 117 155
injection C 118 155
, C 119 155
with C 120 155
spleen C 121 155
cells C 122 155
from C 123 155
animals C 124 155
that C 125 155
had C 126 155
been C 127 155
immunized C 128 155
against C 129 155
the C 130 155
tumor C 131 155
. C 132 155
autochthonous C 134 155
spleen C 135 155
cells C 136 155
taken C 137 155
from C 138 155
the C 139 155
animal C 140 155
with C 141 155
the C 142 155
tumor C 143 155
behaved C 144 155
in C 145 155
this C 146 155
test C 147 155
like C 148 155
those C 149 155
from C 150 155
immunized C 151 155
animals C 152 155
as C 153 155
long C 154 155
as C 155 155
the C 156 155
spleen C 157 155
was C 158 155
taken C 159 155
3 C 160 155
weeks C 161 155
after C 162 155
removal C 163 155
of C 164 155
the C 165 155
tumor C 166 155
. C 167 155
when C 169 155
the C 170 155
spleen C 171 155
and C 172 155
tumor C 173 155
were C 174 155
removed C 175 155
at C 176 155
the C 177 155
same C 178 155
time C 179 155
, C 180 155
however C 181 155
, C 182 155
autochthonous C 183 155
spleen C 184 155
cells C 185 155
did C 186 155
not C 187 155
behave C 188 155
like C 189 155
spleen C 190 155
cells C 191 155
from C 192 155
immunized C 193 155
animals C 194 155
and C 195 155
did C 196 155
not C 197 155
interfere C 198 155
with C 199 155
the C 200 155
growth C 201 155
of C 202 155
the C 203 155
tumor C 204 155
. C 205 155
the C 207 155
results C 208 155
of C 209 155
both C 210 155
the C 211 155
autograft C 212 155
and C 213 155
spleen C 214 155
cell C 215 155
experiments C 216 155
suggest C 217 155
that C 218 155
rats C 219 155
react C 220 155
actively C 221 155
against C 222 155
their C 223 155
own C 224 155
growing C 225 155
primary C 226 155
tumors C 227 155
, C 228 155
but C 229 155
that C 230 155
the C 231 155
tumor C 232 155
exhausts C 233 155
the C 234 155
supply C 235 155
of C 236 155
lymphocytes C 237 155
responsible C 238 155
for C 239 155
this C 240 155
reaction C 241 155
. C 242 155
after C 244 155
the C 245 155
tumor C 246 155
is C 247 155
removed C 248 155
, C 249 155
the C 250 155
concentration C 251 155
of C 252 155
antitumor C 253 155
lymphocytes C 254 155
in C 255 155
the C 256 155
spleen C 257 155
builds C 258 155
up C 259 155
and C 260 155
the C 261 155
animals C 262 155
can C 263 155
reject C 264 155
an C 265 155
autograft C 266 155
. C 267 155
- C 269 155
j C 270 155
nat C 271 155
cancer C 272 155
inst C 273 155
36 C 274 155
. C 275 155
. C 277 155
29 C 279 155
- C 280 155
35 C 281 155
, C 282 155
1966 C 283 155
. C 284 155
a C 1 156
comparison C 2 156
of C 3 156
the C 4 156
cytologic C 5 156
effects C 6 156
of C 7 156
leurosine C 8 156
methiodide C 9 156
and C 10 156
vinblastine C 11 156
in C 12 156
tissue C 13 156
culture C 14 156
. C 15 156
comparison C 17 156
of C 18 156
the C 19 156
degree C 20 156
and C 21 156
duration C 22 156
of C 23 156
arrest C 24 156
of C 25 156
metaphases C 26 156
in C 27 156
tissue C 28 156
culture C 29 156
cells C 30 156
by C 31 156
leurosine C 32 156
methiodide C 33 156
and C 34 156
vinblastine C 35 156
was C 36 156
made C 37 156
, C 38 156
. C 39 156
colchicine C 41 156
and C 42 156
demecolcine C 43 156
were C 44 156
included C 45 156
for C 46 156
reference C 47 156
purposes C 48 156
. C 49 156
all C 51 156
four C 52 156
drugs C 53 156
produced C 54 156
a C 55 156
similar C 56 156
cytologic C 57 156
effect C 58 156
, C 59 156
but C 60 156
vinblastine C 61 156
was C 62 156
most C 63 156
active C 64 156
and C 65 156
remained C 66 156
active C 67 156
for C 68 156
the C 69 156
longest C 70 156
period C 71 156
of C 72 156
time C 73 156
. C 74 156
comparison C 1 157
of C 2 157
central C 3 157
aortic C 4 157
and C 5 157
peripheral C 6 157
artery C 7 157
pressure C 8 157
curves C 9 157
. C 10 157
brachial C 12 157
artery C 13 157
and C 14 157
central C 15 157
aortic C 16 157
pressures C 17 157
were C 18 157
compared C 19 157
in C 20 157
50 C 21 157
consecutive C 22 157
patients C 23 157
subjected C 24 157
to C 25 157
retrograde C 26 157
left C 27 157
heart C 28 157
catheterization C 29 157
in C 30 157
order C 31 157
to C 32 157
re C 33 157
- C 34 157
emphasize C 35 157
the C 36 157
fact C 37 157
that C 38 157
the C 39 157
two C 40 157
pressures C 41 157
are C 42 157
not C 43 157
necessarily C 44 157
identical C 45 157
. C 46 157
in C 48 157
43 C 49 157
cases C 50 157
the C 51 157
systemic C 52 157
systolic C 53 157
pressure C 54 157
peaks C 55 157
exceeded C 56 157
those C 57 157
in C 58 157
the C 59 157
central C 60 157
aorta C 61 157
while C 62 157
in C 63 157
seven C 64 157
these C 65 157
pressures C 66 157
were C 67 157
equal C 68 157
. C 69 157
the C 71 157
average C 72 157
pressure C 73 157
difference C 74 157
was C 75 157
22 C 76 157
. C 77 157
. C 78 157
mm C 79 157
. C 80 157
hg C 82 157
. C 83 157
the C 85 157
greatest C 86 157
differences C 87 157
occurred C 88 157
in C 89 157
cases C 90 157
of C 91 157
aortic C 92 157
regurgitation C 93 157
and C 94 157
could C 95 157
be C 96 157
extreme C 97 157
, C 98 157
the C 99 157
brachial C 100 157
artery C 101 157
systolic C 102 157
pressure C 103 157
exceeding C 104 157
that C 105 157
in C 106 157
the C 107 157
aorta C 108 157
by C 109 157
more C 110 157
than C 111 157
100 C 112 157
mm C 113 157
. C 114 157
hg C 116 157
in C 117 157
some C 118 157
instances C 119 157
. C 120 157
the C 122 157
least C 123 157
differences C 124 157
occurred C 125 157
in C 126 157
cases C 127 157
of C 128 157
aortic C 129 157
stenosis C 130 157
but C 131 157
significant C 132 157
differences C 133 157
occasionally C 134 157
existed C 135 157
, C 136 157
leading C 137 157
to C 138 157
erroneous C 139 157
estimation C 140 157
of C 141 157
valve C 142 157
orifice C 143 157
size C 144 157
if C 145 157
the C 146 157
systemic C 147 157
rather C 148 157
than C 149 157
the C 150 157
aortic C 151 157
systolic C 152 157
pressure C 153 157
was C 154 157
used C 155 157
. C 156 157
changes C 1 158
in C 2 158
sphingosine C 3 158
and C 4 158
fatty C 5 158
acid C 6 158
components C 7 158
of C 8 158
the C 9 158
gangliosides C 10 158
in C 11 158
developing C 12 158
rat C 13 158
and C 14 158
human C 15 158
brain C 16 158
. C 17 158
rat C 19 158
brain C 20 158
increases C 21 158
in C 22 158
weight C 23 158
after C 24 158
birth C 25 158
in C 26 158
three C 27 158
stages C 28 158
. C 29 158
. C 31 158
( C 33 158
i C 34 158
) C 35 158
rapidly C 36 158
for C 37 158
the C 38 158
first C 39 158
2 C 40 158
weeks C 41 158
, C 42 158
( C 43 158
ii C 44 158
) C 45 158
at C 46 158
a C 47 158
lower C 48 158
rate C 49 158
from C 50 158
2 C 51 158
to C 52 158
5 C 53 158
weeks C 54 158
, C 55 158
and C 56 158
( C 57 158
iii C 58 158
) C 59 158
at C 60 158
a C 61 158
still C 62 158
lower C 63 158
rate C 64 158
from C 65 158
5 C 66 158
weeks C 67 158
to C 68 158
5 C 69 158
months C 70 158
. C 71 158
during C 73 158
the C 74 158
succeeding C 75 158
period C 76 158
, C 77 158
designated C 78 158
iv C 79 158
, C 80 158
it C 81 158
maintains C 82 158
constant C 83 158
weight C 84 158
up C 85 158
to C 86 158
1 C 87 158
year C 88 158
of C 89 158
age C 90 158
. C 91 158
brain C 93 158
ganglioside C 94 158
content C 95 158
increased C 96 158
linearly C 97 158
during C 98 158
i C 99 158
and C 100 158
ii C 101 158
, C 102 158
more C 103 158
slowly C 104 158
during C 105 158
iii C 106 158
, C 107 158
and C 108 158
diminished C 109 158
during C 110 158
iv C 111 158
. C 112 158
the C 114 158
appearance C 115 158
of C 116 158
measurable C 117 158
amounts C 118 158
of C 119 158
brain C 120 158
sphingomyelin C 121 158
and C 122 158
cerebroside C 123 158
succeeded C 124 158
that C 125 158
of C 126 158
ganglioside C 127 158
. C 128 158
ceramide C 130 158
with C 131 158
c C 132 158
- C 133 158
sphingosine C 134 158
and C 135 158
c C 136 158
fatty C 137 158
acid C 138 158
was C 139 158
found C 140 158
in C 141 158
a C 142 158
large C 143 158
proportion C 144 158
of C 145 158
all C 146 158
three C 147 158
sphingolipids C 148 158
upon C 149 158
their C 150 158
first C 151 158
appearance C 152 158
in C 153 158
measurable C 154 158
quantity C 155 158
. C 156 158
c C 158 158
fatty C 159 158
acid C 160 158
in C 161 158
cerebroside C 162 158
rapidly C 163 158
declined C 164 158
to C 165 158
a C 166 158
negligible C 167 158
level C 168 158
, C 169 158
while C 170 158
in C 171 158
gangliosides C 172 158
and C 173 158
sphingomyelin C 174 158
it C 175 158
declined C 176 158
slowly C 177 158
but C 178 158
remained C 179 158
the C 180 158
major C 181 158
fatty C 182 158
acid C 183 158
component C 184 158
. C 185 158
cerebrosides C 187 158
and C 188 158
sphingomyelin C 189 158
contained C 190 158
c C 191 158
- C 192 158
sphingosine C 193 158
almost C 194 158
exclusively C 195 158
at C 196 158
all C 197 158
stages C 198 158
of C 199 158
rat C 200 158
brain C 201 158
growth C 202 158
. C 203 158
gangliosides C 205 158
contained C 206 158
c C 207 158
- C 208 158
sphingosine C 209 158
almost C 210 158
exclusively C 211 158
at C 212 158
birth C 213 158
, C 214 158
but C 215 158
subsequently C 216 158
accumulated C 217 158
c C 218 158
- C 219 158
sphingosine C 220 158
until C 221 158
they C 222 158
had C 223 158
nearly C 224 158
equal C 225 158
quantities C 226 158
of C 227 158
each C 228 158
base C 229 158
type C 230 158
. C 231 158
changes C 233 158
in C 234 158
human C 235 158
brain C 236 158
gangliosides C 237 158
resemble C 238 158
those C 239 158
in C 240 158
rat C 241 158
. C 242 158
in C 244 158
tay C 245 158
- C 246 158
sachs C 247 158
disease C 248 158
, C 249 158
gangliosides C 250 158
have C 251 158
c C 252 158
- C 253 158
sphingosine C 254 158
predominantly C 255 158
, C 256 158
and C 257 158
a C 258 158
high C 259 158
content C 260 158
of C 261 158
c C 262 158
fatty C 263 158
acid C 264 158
. C 265 158
studies C 1 159
of C 2 159
the C 3 159
generalized C 4 159
shwartzman C 5 159
reaction C 6 159
induced C 7 159
by C 8 159
diet C 9 159
vi C 10 159
. C 11 159
effects C 13 159
of C 14 159
pregnancy C 15 159
on C 16 159
lipid C 17 159
composition C 18 159
of C 19 159
serum C 20 159
and C 21 159
tissues C 22 159
. C 23 159
pregnancy C 25 159
induced C 26 159
profound C 27 159
alterations C 28 159
in C 29 159
the C 30 159
lipid C 31 159
composition C 32 159
of C 33 159
serum C 34 159
and C 35 159
tissues C 36 159
. C 37 159
( C 39 159
1 C 40 159
) C 41 159
there C 42 159
is C 43 159
an C 44 159
elevation C 45 159
of C 46 159
total C 47 159
serum C 48 159
lipid C 49 159
, C 50 159
phospholipid C 51 159
, C 52 159
triglyceride C 53 159
, C 54 159
free C 55 159
fatty C 56 159
acid C 57 159
and C 58 159
cholesterol C 59 159
, C 60 159
. C 61 159
( C 63 159
2 C 64 159
) C 65 159
while C 66 159
the C 67 159
total C 68 159
lipid C 69 159
of C 70 159
the C 71 159
liver C 72 159
and C 73 159
kidney C 74 159
are C 75 159
increased C 76 159
, C 77 159
that C 78 159
of C 79 159
the C 80 159
depot C 81 159
fat C 82 159
is C 83 159
decreased C 84 159
, C 85 159
. C 86 159
( C 88 159
3 C 89 159
) C 90 159
palmitate C 91 159
and C 92 159
oleate C 93 159
are C 94 159
increased C 95 159
in C 96 159
serum C 97 159
and C 98 159
liver C 99 159
, C 100 159
. C 101 159
( C 103 159
4 C 104 159
) C 105 159
arachidonate C 106 159
and C 107 159
stearate C 108 159
are C 109 159
decreased C 110 159
in C 111 159
serum C 112 159
and C 113 159
liver C 114 159
, C 115 159
. C 116 159
and C 118 159
( C 119 159
5 C 120 159
) C 121 159
placentas C 122 159
contain C 123 159
more C 124 159
stearate C 125 159
than C 126 159
the C 127 159
other C 128 159
organs C 129 159
of C 130 159
the C 131 159
pregnant C 132 159
rat C 133 159
and C 134 159
also C 135 159
have C 136 159
a C 137 159
higher C 138 159
water C 139 159
content C 140 159
. C 141 159
the C 143 159
decrease C 144 159
in C 145 159
depot C 146 159
total C 147 159
fat C 148 159
, C 149 159
. C 150 159
elevation C 152 159
of C 153 159
serum C 154 159
, C 155 159
liver C 156 159
and C 157 159
kidney C 158 159
total C 159 159
fat C 160 159
, C 161 159
. C 162 159
and C 164 159
elevation C 165 159
of C 166 159
serum C 167 159
free C 168 159
fatty C 169 159
acids C 170 159
suggest C 171 159
that C 172 159
pregnancy C 173 159
induced C 174 159
mobilization C 175 159
of C 176 159
depot C 177 159
fat C 178 159
. C 179 159
the C 181 159
increase C 182 159
in C 183 159
proportion C 184 159
of C 185 159
liver C 186 159
and C 187 159
serum C 188 159
palmitate C 189 159
suggests C 190 159
that C 191 159
pregnancy C 192 159
induces C 193 159
increased C 194 159
lipogenesis C 195 159
from C 196 159
the C 197 159
acetate C 198 159
pool C 199 159
. C 200 159
the C 202 159
appearance C 203 159
of C 204 159
an C 205 159
increased C 206 159
amount C 207 159
of C 208 159
long C 209 159
- C 210 159
chain C 211 159
fatty C 212 159
acids C 213 159
in C 214 159
the C 215 159
liver C 216 159
may C 217 159
be C 218 159
due C 219 159
to C 220 159
the C 221 159
increased C 222 159
intake C 223 159
of C 224 159
dietary C 225 159
fat C 226 159
. C 227 159
the C 229 159
decrease C 230 159
in C 231 159
arachidonate C 232 159
and C 233 159
stearate C 234 159
in C 235 159
serum C 236 159
and C 237 159
liver C 238 159
suggests C 239 159
a C 240 159
relative C 241 159
decrease C 242 159
in C 243 159
mitochondrial C 244 159
fatty C 245 159
acid C 246 159
synthesis C 247 159
electron C 1 160
microscopy C 2 160
of C 3 160
the C 4 160
bovine C 5 160
lung C 6 160
. C 7 160
. C 9 160
the C 11 160
normal C 12 160
blood C 13 160
- C 14 160
air C 15 160
barrier C 16 160
. C 17 160
lungs C 19 160
of C 20 160
20 C 21 160
healthy C 22 160
, C 23 160
mature C 24 160
cattle C 25 160
were C 26 160
fixed C 27 160
in C 28 160
oso C 29 160
, C 30 160
embedded C 31 160
in C 32 160
a C 33 160
polyester C 34 160
resin C 35 160
, C 36 160
and C 37 160
studied C 38 160
via C 39 160
electron C 40 160
microscopy C 41 160
. C 42 160
the C 44 160
blood C 45 160
- C 46 160
air C 47 160
barrier C 48 160
was C 49 160
widely C 50 160
variable C 51 160
in C 52 160
thickness C 53 160
and C 54 160
consistency C 55 160
. C 56 160
there C 58 160
was C 59 160
a C 60 160
continuous C 61 160
epithelial C 62 160
alveolar C 63 160
lining C 64 160
. C 65 160
the C 67 160
cytoplasm C 68 160
of C 69 160
some C 70 160
of C 71 160
the C 72 160
epithelial C 73 160
cells C 74 160
contained C 75 160
membrane C 76 160
- C 77 160
bound C 78 160
aggregates C 79 160
of C 80 160
granules C 81 160
which C 82 160
may C 83 160
be C 84 160
secretory C 85 160
structures C 86 160
. C 87 160
the C 89 160
epithelium C 90 160
rested C 91 160
on C 92 160
a C 93 160
basement C 94 160
membrane C 95 160
, C 96 160
which C 97 160
in C 98 160
turn C 99 160
was C 100 160
continuous C 101 160
with C 102 160
or C 103 160
rested C 104 160
on C 105 160
an C 106 160
adjacent C 107 160
capillary C 108 160
endothelial C 109 160
basement C 110 160
membrane C 111 160
, C 112 160
or C 113 160
continued C 114 160
into C 115 160
merging C 116 160
connective C 117 160
tissue C 118 160
. C 119 160
the C 121 160
capillary C 122 160
endothelium C 123 160
was C 124 160
not C 125 160
fenestrated C 126 160
, C 127 160
. C 128 160
it C 130 160
was C 131 160
a C 132 160
continuous C 133 160
cellular C 134 160
membrane C 135 160
. C 136 160
both C 138 160
the C 139 160
epithelium C 140 160
and C 141 160
endothelium C 142 160
contained C 143 160
numerous C 144 160
caveolae C 145 160
and C 146 160
pinocytotic C 147 160
vesicles C 148 160
. C 149 160
cells C 151 160
of C 152 160
the C 153 160
alveolar C 154 160
wall C 155 160
included C 156 160
fibroblasts C 157 160
, C 158 160
lymphocytes C 159 160
, C 160 160
macrophages C 161 160
, C 162 160
and C 163 160
an C 164 160
occasional C 165 160
mast C 166 160
cell C 167 160
. C 168 160
very C 170 160
little C 171 160
elastin C 172 160
was C 173 160
observed C 174 160
. C 175 160
a C 1 161
sensitive C 2 161
and C 3 161
specific C 4 161
fluorescence C 5 161
assay C 6 161
for C 7 161
tissue C 8 161
serotonin C 9 161
. C 10 161
a C 12 161
sensitive C 13 161
and C 14 161
specific C 15 161
method C 16 161
for C 17 161
the C 18 161
estimation C 19 161
of C 20 161
serotonin C 21 161
in C 22 161
biological C 23 161
materials C 24 161
is C 25 161
described C 26 161
. C 27 161
in C 29 161
this C 30 161
method C 31 161
, C 32 161
serotonin C 33 161
is C 34 161
reacted C 35 161
with C 36 161
ninhydrin C 37 161
to C 38 161
form C 39 161
a C 40 161
product C 41 161
whose C 42 161
fluorescence C 43 161
is C 44 161
eight C 45 161
times C 46 161
more C 47 161
intense C 48 161
than C 49 161
the C 50 161
native C 51 161
fluorescence C 52 161
of C 53 161
serotonin C 54 161
in C 55 161
strong C 56 161
acid C 57 161
solution C 58 161
. C 59 161
with C 61 161
this C 62 161
method C 63 161
it C 64 161
is C 65 161
possible C 66 161
to C 67 161
measure C 68 161
serotonin C 69 161
in C 70 161
organs C 71 161
in C 72 161
which C 73 161
endogenous C 74 161
serotonin C 75 161
had C 76 161
not C 77 161
been C 78 161
previously C 79 161
detected C 80 161
and C 81 161
to C 82 161
study C 83 161
the C 84 161
subcellular C 85 161
distribution C 86 161
of C 87 161
this C 88 161
amine C 89 161
in C 90 161
the C 91 161
rat C 92 161
pineal C 93 161
and C 94 161
adrenal C 95 161
glands C 96 161
. C 97 161
effects C 1 162
of C 2 162
ruminal C 3 162
insufflation C 4 162
on C 5 162
cerebral C 6 162
circulation C 7 162
and C 8 162
metabolism C 9 162
in C 10 162
the C 11 162
goat C 12 162
. C 13 162
the C 15 162
effects C 16 162
of C 17 162
nitrogen C 18 162
insufflation C 19 162
of C 20 162
the C 21 162
cannulated C 22 162
rumen C 23 162
were C 24 162
studied C 25 162
in C 26 162
10 C 27 162
goats C 28 162
. C 29 162
parameters C 31 162
which C 32 162
were C 33 162
measured C 34 162
included C 35 162
cerebral C 36 162
blood C 37 162
flow C 38 162
, C 39 162
mean C 40 162
carotid C 41 162
arterial C 42 162
pressure C 43 162
, C 44 162
pressure C 45 162
in C 46 162
the C 47 162
confluence C 48 162
of C 49 162
sinuses C 50 162
, C 51 162
cerebrospinal C 52 162
fluid C 53 162
pressure C 54 162
, C 55 162
blood C 56 162
oxygen C 57 162
and C 58 162
carbon C 59 162
dioxide C 60 162
contents C 61 162
, C 62 162
packed C 63 162
cell C 64 162
volume C 65 162
( C 66 162
pcv C 67 162
) C 68 162
, C 69 162
and C 70 162
hemoglobin C 71 162
concentration C 72 162
values C 73 162
for C 74 162
cerebrovascular C 75 162
resistance C 76 162
and C 77 162
cerebral C 78 162
o C 79 162
utilization C 80 162
were C 81 162
calculated C 82 162
. C 83 162
increased C 85 162
ruminal C 86 162
pressure C 87 162
had C 88 162
little C 89 162
effect C 90 162
on C 91 162
cerebral C 92 162
blood C 93 162
flow C 94 162
and C 95 162
cerebrovascular C 96 162
resistance C 97 162
. C 98 162
cerebral C 100 162
o C 101 162
utilization C 102 162
was C 103 162
decreased C 104 162
when C 105 162
the C 106 162
intraruminal C 107 162
pressure C 108 162
was C 109 162
increased C 110 162
. C 111 162
this C 113 162
decrease C 114 162
was C 115 162
caused C 116 162
by C 117 162
a C 118 162
reduction C 119 162
in C 120 162
arterial C 121 162
o C 122 162
content C 123 162
and C 124 162
a C 125 162
consequent C 126 162
decrease C 127 162
in C 128 162
cerebral C 129 162
arteriovenous C 130 162
o C 131 162
difference C 132 162
. C 133 162
mean C 135 162
arterial C 136 162
, C 137 162
venous C 138 162
sinus C 139 162
, C 140 162
and C 141 162
cerebrospinal C 142 162
fluid C 143 162
pressures C 144 162
were C 145 162
increased C 146 162
as C 147 162
the C 148 162
intraruminal C 149 162
pressure C 150 162
was C 151 162
increased C 152 162
. C 153 162
increases C 155 162
in C 156 162
pcv C 157 162
and C 158 162
hemoglobin C 159 162
concentration C 160 162
were C 161 162
not C 162 162
related C 163 162
to C 164 162
the C 165 162
elevated C 166 162
intraruminal C 167 162
pressure C 168 162
. C 169 162
central C 171 162
nervous C 172 162
system C 173 162
signs C 174 162
in C 175 162
goats C 176 162
with C 177 162
acute C 178 162
ruminal C 179 162
tympany C 180 162
may C 181 162
be C 182 162
caused C 183 162
by C 184 162
cerebral C 185 162
hypoxia C 186 162
. C 187 162
the C 189 162
nature C 190 162
of C 191 162
the C 192 162
hypertensive C 193 162
changes C 194 162
associated C 195 162
with C 196 162
increased C 197 162
ruminal C 198 162
pressure C 199 162
were C 200 162
demonstrated C 201 162
, C 202 162
but C 203 162
due C 204 162
to C 205 162
the C 206 162
influence C 207 162
of C 208 162
multiple C 209 162
factors C 210 162
on C 211 162
fluid C 212 162
compartments C 213 162
, C 214 162
no C 215 162
conclusions C 216 162
could C 217 162
be C 218 162
made C 219 162
about C 220 162
the C 221 162
mechanism C 222 162
of C 223 162
these C 224 162
pressure C 225 162
responses C 226 162
. C 227 162
mechanical C 229 162
factors C 230 162
, C 231 162
however C 232 162
, C 233 162
may C 234 162
be C 235 162
involved C 236 162
. C 237 162
a C 1 163
comparison C 2 163
between C 3 163
inhaled C 4 163
dust C 5 163
and C 6 163
the C 7 163
dust C 8 163
recovered C 9 163
from C 10 163
human C 11 163
lungs C 12 163
. C 13 163
experiments C 15 163
on C 16 163
the C 17 163
loss C 18 163
of C 19 163
dust C 20 163
particles C 21 163
during C 22 163
breathing C 23 163
indicate C 24 163
total C 25 163
deposition C 26 163
in C 27 163
the C 28 163
respiratory C 29 163
tract C 30 163
, C 31 163
. C 32 163
subjection C 34 163
of C 35 163
the C 36 163
results C 37 163
to C 38 163
qualitative C 39 163
arguments C 40 163
may C 41 163
give C 42 163
information C 43 163
about C 44 163
alveolar C 45 163
deposition C 46 163
. C 47 163
measurements C 49 163
of C 50 163
insoluble C 51 163
dust C 52 163
recovered C 53 163
post C 54 163
mortem C 55 163
from C 56 163
human C 57 163
lungs C 58 163
give C 59 163
the C 60 163
absolute C 61 163
retention C 62 163
of C 63 163
dust C 64 163
which C 65 163
was C 66 163
deposited C 67 163
in C 68 163
the C 69 163
alveoli C 70 163
and C 71 163
subsequently C 72 163
shifted C 73 163
, C 74 163
probably C 75 163
to C 76 163
a C 77 163
large C 78 163
extent C 79 163
, C 80 163
to C 81 163
the C 82 163
lymphatic C 83 163
vessels C 84 163
of C 85 163
the C 86 163
lungs C 87 163
. C 88 163
experimental C 90 163
results C 91 163
for C 92 163
total C 93 163
deposition C 94 163
and C 95 163
absolute C 96 163
retention C 97 163
are C 98 163
discussed C 99 163
in C 100 163
connection C 101 163
with C 102 163
the C 103 163
health C 104 163
risk C 105 163
due C 106 163
to C 107 163
inhaling C 108 163
insoluble C 109 163
particles C 110 163
, C 111 163
such C 112 163
as C 113 163
plutonium C 114 163
dioxide C 115 163
. C 116 163
dual C 1 164
cation C 2 164
activation C 3 164
of C 4 164
bovine C 5 164
lens C 6 164
autolysis C 7 164
. C 8 164
the C 10 164
autolytic C 11 164
activity C 12 164
of C 13 164
bovine C 14 164
lens C 15 164
extracts C 16 164
at C 17 164
55 C 18 164
c C 19 164
. C 20 164
and C 22 164
ph C 23 164
7 C 24 164
. C 25 164
. C 26 164
has C 27 164
been C 28 164
shown C 29 164
to C 30 164
be C 31 164
markedly C 32 164
influenced C 33 164
by C 34 164
the C 35 164
simultaneous C 36 164
presence C 37 164
of C 38 164
mono C 39 164
- C 40 164
and C 41 164
divalent C 42 164
cations C 43 164
. C 44 164
of C 46 164
the C 47 164
cations C 48 164
tested C 49 164
, C 50 164
na C 51 164
at C 52 164
2 C 53 164
. C 54 164
. C 55 164
to C 56 164
5 C 57 164
mm C 58 164
. C 59 164
and C 61 164
mg C 62 164
at C 63 164
5 C 64 164
to C 65 164
10 C 66 164
mm C 67 164
. C 68 164
produce C 70 164
the C 71 164
best C 72 164
activation C 73 164
. C 74 164
the C 76 164
stimulation C 77 164
is C 78 164
synergistic C 79 164
. C 80 164
on C 82 164
the C 83 164
basis C 84 164
of C 85 164
results C 86 164
obtained C 87 164
here C 88 164
and C 89 164
in C 90 164
other C 91 164
laboratories C 92 164
, C 93 164
the C 94 164
suggestion C 95 164
is C 96 164
made C 97 164
that C 98 164
this C 99 164
combination C 100 164
of C 101 164
cations C 102 164
may C 103 164
be C 104 164
required C 105 164
for C 106 164
activation C 107 164
of C 108 164
the C 109 164
neutral C 110 164
proteinase C 111 164
of C 112 164
the C 113 164
lens C 114 164
. C 115 164
in C 117 164
the C 118 164
presence C 119 164
of C 120 164
mg C 121 164
and C 122 164
average C 123 164
physiologic C 124 164
lenticular C 125 164
levels C 126 164
of C 127 164
both C 128 164
na C 129 164
and C 130 164
k C 131 164
, C 132 164
autolysis C 133 164
is C 134 164
suppressed C 135 164
to C 136 164
the C 137 164
basal C 138 164
level C 139 164
obtainable C 140 164
in C 141 164
the C 142 164
presence C 143 164
of C 144 164
mg C 145 164
alone C 146 164
. C 147 164
nucleic C 1 165
acid C 2 165
metabolism C 3 165
in C 4 165
the C 5 165
lens C 6 165
iii C 7 165
. C 8 165
effect C 10 165
of C 11 165
x C 12 165
- C 13 165
radiation C 14 165
. C 15 165
a C 17 165
previous C 18 165
communication C 19 165
reported C 20 165
an C 21 165
increased C 22 165
in C 23 165
vivo C 24 165
incorporation C 25 165
of C 26 165
p C 27 165
- C 28 165
32 C 29 165
into C 30 165
the C 31 165
albuminoid C 32 165
rna C 33 165
fraction C 34 165
of C 35 165
the C 36 165
rat C 37 165
lens C 38 165
6 C 39 165
hours C 40 165
after C 41 165
the C 42 165
animal C 43 165
had C 44 165
been C 45 165
exposed C 46 165
to C 47 165
x C 48 165
- C 49 165
radiation C 50 165
( C 51 165
1 C 52 165
, C 53 165
500 C 54 165
r C 55 165
) C 56 165
. C 57 165
in C 59 165
the C 60 165
present C 61 165
study C 62 165
, C 63 165
the C 64 165
in C 65 165
vitro C 66 165
uptake C 67 165
of C 68 165
p C 69 165
- C 70 165
32 C 71 165
and C 72 165
c C 73 165
- C 74 165
14 C 75 165
- C 76 165
adenine C 77 165
by C 78 165
albuminoid C 79 165
, C 80 165
ribosomal C 81 165
, C 82 165
and C 83 165
soluble C 84 165
rna C 85 165
fractions C 86 165
of C 87 165
normal C 88 165
and C 89 165
x C 90 165
- C 91 165
irradiated C 92 165
rat C 93 165
lenses C 94 165
was C 95 165
measured C 96 165
. C 97 165
the C 99 165
rna C 100 165
fractions C 101 165
were C 102 165
extracted C 103 165
by C 104 165
sodium C 105 165
dodecyl C 106 165
sulfate C 107 165
in C 108 165
0 C 109 165
. C 110 165
. C 111 165
per C 112 165
cent C 113 165
nacl C 114 165
. C 115 165
the C 117 165
specific C 118 165
rna C 119 165
fractions C 120 165
were C 121 165
also C 122 165
hydrolyzed C 123 165
, C 124 165
chromatographed C 125 165
( C 126 165
on C 127 165
paper C 128 165
) C 129 165
, C 130 165
and C 131 165
the C 132 165
activity C 133 165
of C 134 165
the C 135 165
individual C 136 165
nucleotides C 137 165
( C 138 165
as C 139 165
well C 140 165
as C 141 165
the C 142 165
specific C 143 165
rna C 144 165
fractions C 145 165
) C 146 165
was C 147 165
determined C 148 165
. C 149 165
an C 151 165
experiment C 152 165
was C 153 165
also C 154 165
performed C 155 165
in C 156 165
which C 157 165
the C 158 165
capsules C 159 165
were C 160 165
removed C 161 165
( C 162 165
after C 163 165
the C 164 165
3 C 165 165
hour C 166 165
incubation C 167 165
period C 168 165
) C 169 165
and C 170 165
the C 171 165
activities C 172 165
determined C 173 165
in C 174 165
the C 175 165
nucleic C 176 165
acids C 177 165
extracted C 178 165
from C 179 165
the C 180 165
capsules C 181 165
and C 182 165
in C 183 165
the C 184 165
three C 185 165
rna C 186 165
fractions C 187 165
of C 188 165
the C 189 165
remaining C 190 165
lens C 191 165
matter C 192 165
. C 193 165
the C 195 165
results C 196 165
of C 197 165
these C 198 165
experiments C 199 165
indicate C 200 165
that C 201 165
the C 202 165
incorporation C 203 165
of C 204 165
p C 205 165
- C 206 165
32 C 207 165
and C 208 165
c C 209 165
- C 210 165
14 C 211 165
- C 212 165
adenine C 213 165
into C 214 165
albuminoid C 215 165
rna C 216 165
was C 217 165
markedly C 218 165
stimulated C 219 165
1 C 220 165
hour C 221 165
after C 222 165
1 C 223 165
, C 224 165
500 C 225 165
r C 226 165
whole C 227 165
body C 228 165
radiation C 229 165
. C 230 165
there C 232 165
was C 233 165
no C 234 165
significant C 235 165
effect C 236 165
on C 237 165
ribosomal C 238 165
or C 239 165
soluble C 240 165
fractions C 241 165
. C 242 165
the C 244 165
effect C 245 165
of C 246 165
formaldehyde C 247 165
and C 248 165
heating C 249 165
on C 250 165
x C 251 165
- C 252 165
irradiated C 253 165
albuminoid C 254 165
rna C 255 165
was C 256 165
much C 257 165
less C 258 165
than C 259 165
on C 260 165
the C 261 165
albuminoid C 262 165
rna C 263 165
derived C 264 165
from C 265 165
control C 266 165
animals C 267 165
. C 268 165
changes C 1 166
in C 2 166
dna C 3 166
, C 4 166
rna C 5 166
, C 6 166
and C 7 166
protein C 8 166
synthesis C 9 166
in C 10 166
the C 11 166
developing C 12 166
lens C 13 166
. C 14 166
lens C 16 166
cell C 17 166
dna C 18 166
, C 19 166
rna C 20 166
, C 21 166
and C 22 166
protein C 23 166
synthesis C 24 166
in C 25 166
the C 26 166
developing C 27 166
mouse C 28 166
eye C 29 166
were C 30 166
studied C 31 166
with C 32 166
the C 33 166
use C 34 166
of C 35 166
tritium C 36 166
- C 37 166
labeled C 38 166
thymidine C 39 166
, C 40 166
uridine C 41 166
, C 42 166
and C 43 166
l C 44 166
- C 45 166
leucine C 46 166
and C 47 166
autoradiographic C 48 166
techniques C 49 166
. C 50 166
in C 52 166
the C 53 166
mouse C 54 166
embryonic C 55 166
lens C 56 166
, C 57 166
epithelial C 58 166
cells C 59 166
undergoing C 60 166
dna C 61 166
synthesis C 62 166
were C 63 166
found C 64 166
over C 65 166
the C 66 166
entire C 67 166
anterior C 68 166
lens C 69 166
surface C 70 166
. C 71 166
from C 73 166
birth C 74 166
and C 75 166
until C 76 166
the C 77 166
eyes C 78 166
opened C 79 166
the C 80 166
percentage C 81 166
of C 82 166
epithelial C 83 166
cells C 84 166
undergoing C 85 166
dna C 86 166
synthesis C 87 166
rapidly C 88 166
decreased C 89 166
. C 90 166
later C 92 166
the C 93 166
percentage C 94 166
of C 95 166
epithelial C 96 166
cells C 97 166
undergoing C 98 166
dna C 99 166
synthesis C 100 166
was C 101 166
nearly C 102 166
constant C 103 166
as C 104 166
the C 105 166
germinative C 106 166
zone C 107 166
became C 108 166
localized C 109 166
in C 110 166
the C 111 166
lens C 112 166
equator C 113 166
region C 114 166
. C 115 166
rna C 117 166
synthesis C 118 166
occurred C 119 166
in C 120 166
all C 121 166
nucleated C 122 166
cells C 123 166
of C 124 166
the C 125 166
developing C 126 166
lens C 127 166
from C 128 166
the C 129 166
embryonic C 130 166
stage C 131 166
until C 132 166
the C 133 166
eyelids C 134 166
opened C 135 166
. C 136 166
with C 138 166
lens C 139 166
maturity C 140 166
the C 141 166
h C 142 166
uridine C 143 166
was C 144 166
incorporated C 145 166
into C 146 166
the C 147 166
rna C 148 166
of C 149 166
only C 150 166
the C 151 166
more C 152 166
superficial C 153 166
cells C 154 166
. C 155 166
a C 157 166
similar C 158 166
pattern C 159 166
of C 160 166
tritium C 161 166
incorporation C 162 166
was C 163 166
seen C 164 166
with C 165 166
h C 166 166
l C 167 166
- C 168 166
leucine C 169 166
. C 170 166
amino C 1 167
acid C 2 167
transport C 3 167
in C 4 167
the C 5 167
lens C 6 167
in C 7 167
relation C 8 167
to C 9 167
sugar C 10 167
cataracts C 11 167
. C 12 167
the C 14 167
steady C 15 167
state C 16 167
distribution C 17 167
of C 18 167
free C 19 167
amino C 20 167
acids C 21 167
between C 22 167
the C 23 167
lens C 24 167
and C 25 167
aqueous C 26 167
humor C 27 167
is C 28 167
significantly C 29 167
reduced C 30 167
in C 31 167
diabetic C 32 167
rabbits C 33 167
and C 34 167
also C 35 167
in C 36 167
rats C 37 167
fed C 38 167
rations C 39 167
containing C 40 167
high C 41 167
concentrations C 42 167
of C 43 167
xylose C 44 167
or C 45 167
galactose C 46 167
. C 47 167
the C 49 167
reduction C 50 167
in C 51 167
the C 52 167
level C 53 167
of C 54 167
amino C 55 167
acids C 56 167
in C 57 167
the C 58 167
lens C 59 167
is C 60 167
apparently C 61 167
a C 62 167
direct C 63 167
effect C 64 167
of C 65 167
the C 66 167
high C 67 167
concentration C 68 167
of C 69 167
sugars C 70 167
, C 71 167
but C 72 167
it C 73 167
is C 74 167
doubtful C 75 167
whether C 76 167
it C 77 167
is C 78 167
related C 79 167
to C 80 167
cataract C 81 167
formation C 82 167
. C 83 167
visco C 1 168
- C 2 168
elastic C 3 168
properties C 4 168
of C 5 168
the C 6 168
lens C 7 168
. C 8 168
the C 10 168
dynamic C 11 168
visco C 12 168
- C 13 168
elastic C 14 168
properties C 15 168
of C 16 168
human C 17 168
, C 18 168
monkey C 19 168
and C 20 168
rabbit C 21 168
lenses C 22 168
have C 23 168
been C 24 168
measured C 25 168
with C 26 168
a C 27 168
dynamic C 28 168
rheometer C 29 168
. C 30 168
the C 32 168
value C 33 168
for C 34 168
the C 35 168
apparent C 36 168
elastic C 37 168
modulus C 38 168
( C 39 168
young C 40 168
modulus C 41 168
) C 42 168
of C 43 168
the C 44 168
lens C 45 168
was C 46 168
found C 47 168
to C 48 168
be C 49 168
10 C 50 168
- C 51 168
10 C 52 168
dyne C 53 168
/ C 54 168
cm C 55 168
in C 56 168
humans C 57 168
and C 58 168
10 C 59 168
- C 60 168
10 C 61 168
dyne C 62 168
/ C 63 168
cm C 64 168
in C 65 168
monkeys C 66 168
and C 67 168
rabbits C 68 168
. C 69 168
the C 71 168
value C 72 168
for C 73 168
the C 74 168
loss C 75 168
tangent C 76 168
was C 77 168
0 C 78 168
. C 79 168
. C 80 168
- C 81 168
0 C 82 168
. C 83 168
. C 84 168
in C 85 168
the C 86 168
human C 87 168
lens C 88 168
and C 89 168
0 C 90 168
. C 91 168
. C 92 168
- C 93 168
0 C 94 168
. C 95 168
. C 96 168
in C 97 168
rabbit C 98 168
and C 99 168
monkey C 100 168
lenses C 101 168
. C 102 168
elastic C 104 168
moduli C 105 168
and C 106 168
loss C 107 168
tangents C 108 168
of C 109 168
the C 110 168
lenses C 111 168
showed C 112 168
poor C 113 168
dependence C 114 168
on C 115 168
temperature C 116 168
at C 117 168
15 C 118 168
- C 119 168
55 C 120 168
c C 121 168
and C 122 168
on C 123 168
frequency C 124 168
of C 125 168
oscillation C 126 168
at C 127 168
0 C 128 168
. C 129 168
. C 130 168
. C 130 168
- C 131 168
25 C 132 168
c C 133 168
/ C 134 168
s C 135 168
. C 136 168
the C 138 168
lenses C 139 168
showed C 140 168
linear C 141 168
visco C 142 168
- C 143 168
elasticity C 144 168
when C 145 168
the C 146 168
amplitude C 147 168
of C 148 168
oscillation C 149 168
was C 150 168
below C 151 168
0 C 152 168
. C 153 168
. C 154 168
. C 154 168
mm C 155 168
, C 156 168
and C 157 168
they C 158 168
showed C 159 168
nonlinear C 160 168
visco C 161 168
- C 162 168
elasticity C 163 168
when C 164 168
the C 165 168
amplitude C 166 168
exceeded C 167 168
0 C 168 168
. C 169 168
. C 170 168
. C 170 168
mm C 171 168
. C 172 168
carbonic C 1 169
anhydrase C 2 169
distribution C 3 169
in C 4 169
rabbit C 5 169
lens C 6 169
. C 7 169
the C 9 169
distribution C 10 169
of C 11 169
carbonic C 12 169
anhydrase C 13 169
activity C 14 169
in C 15 169
the C 16 169
mature C 17 169
rabbit C 18 169
lens C 19 169
was C 20 169
determined C 21 169
. C 22 169
the C 24 169
activities C 25 169
in C 26 169
nucleus C 27 169
, C 28 169
cortex C 29 169
, C 30 169
epithelium C 31 169
with C 32 169
anterior C 33 169
capsule C 34 169
, C 35 169
anterior C 36 169
capsule C 37 169
, C 38 169
and C 39 169
posterior C 40 169
capsule C 41 169
were C 42 169
, C 43 169
respectively C 44 169
, C 45 169
2484 C 46 169
( C 47 169
256 C 48 169
) C 49 169
, C 50 169
1571 C 51 169
( C 52 169
87 C 53 169
) C 54 169
, C 55 169
545 C 56 169
( C 57 169
93 C 58 169
) C 59 169
, C 60 169
159 C 61 169
( C 62 169
39 C 63 169
) C 64 169
and C 65 169
65 C 66 169
( C 67 169
49 C 68 169
) C 69 169
moles C 70 169
co C 71 169
/ C 72 169
kg C 73 169
wet C 74 169
tissue C 75 169
wt C 76 169
per C 77 169
hr C 78 169
at C 79 169
0 C 80 169
c C 81 169
. C 82 169
it C 84 169
was C 85 169
concluded C 86 169
, C 87 169
on C 88 169
the C 89 169
basis C 90 169
of C 91 169
the C 92 169
available C 93 169
evidence C 94 169
, C 95 169
that C 96 169
carbonic C 97 169
anhydrase C 98 169
cannot C 99 169
play C 100 169
a C 101 169
primary C 102 169
role C 103 169
in C 104 169
the C 105 169
cation C 106 169
transport C 107 169
system C 108 169
of C 109 169
the C 110 169
lens C 111 169
. C 112 169
changes C 1 170
in C 2 170
weight C 3 170
and C 4 170
adenosine C 5 170
triphosphate C 6 170
content C 7 170
in C 8 170
the C 9 170
lens C 10 170
of C 11 170
the C 12 170
xylose C 13 170
- C 14 170
fed C 15 170
rat C 16 170
. C 17 170
xylitol C 19 170
and C 20 170
sorbitol C 21 170
accumulated C 22 170
in C 23 170
the C 24 170
lens C 25 170
of C 26 170
the C 27 170
xylose C 28 170
- C 29 170
fed C 30 170
rat C 31 170
two C 32 170
days C 33 170
before C 34 170
loss C 35 170
of C 36 170
adenosine C 37 170
triphosphate C 38 170
, C 39 170
and C 40 170
cataractous C 41 170
changes C 42 170
, C 43 170
were C 44 170
apparent C 45 170
. C 46 170
the C 48 170
maximum C 49 170
degree C 50 170
of C 51 170
cataract C 52 170
occurred C 53 170
when C 54 170
the C 55 170
level C 56 170
of C 57 170
the C 58 170
polyols C 59 170
was C 60 170
at C 61 170
its C 62 170
highest C 63 170
. C 64 170
regression C 66 170
of C 67 170
cataract C 68 170
was C 69 170
accompanied C 70 170
by C 71 170
decrease C 72 170
in C 73 170
polyol C 74 170
concentration C 75 170
and C 76 170
restoration C 77 170
of C 78 170
the C 79 170
level C 80 170
of C 81 170
atp C 82 170
. C 83 170
the C 85 170
lens C 86 170
of C 87 170
the C 88 170
xylose C 89 170
- C 90 170
fed C 91 170
rat C 92 170
did C 93 170
not C 94 170
usually C 95 170
increase C 96 170
in C 97 170
weight C 98 170
. C 99 170
identification C 1 171
of C 2 171
species C 3 171
- C 4 171
specific C 5 171
and C 6 171
organ C 7 171
- C 8 171
specific C 9 171
antigens C 10 171
in C 11 171
lens C 12 171
proteins C 13 171
. C 14 171
the C 16 171
species C 17 171
- C 18 171
specific C 19 171
and C 20 171
organ C 21 171
- C 22 171
specific C 23 171
antigens C 24 171
of C 25 171
lens C 26 171
were C 27 171
investigated C 28 171
by C 29 171
gel C 30 171
diffusion C 31 171
and C 32 171
immunoelectrophoresis C 33 171
techniques C 34 171
. C 35 171
it C 37 171
was C 38 171
found C 39 171
that C 40 171
rabbit C 41 171
antiserum C 42 171
to C 43 171
bovine C 44 171
lens C 45 171
showed C 46 171
cross C 47 171
reaction C 48 171
with C 49 171
other C 50 171
bovine C 51 171
tissues C 52 171
. C 53 171
these C 55 171
cross C 56 171
- C 57 171
reacting C 58 171
antigens C 59 171
were C 60 171
the C 61 171
b C 62 171
- C 63 171
- C 64 171
and C 65 171
y C 66 171
- C 67 171
crystallins C 68 171
. C 69 171
there C 71 171
were C 72 171
two C 73 171
major C 74 171
and C 75 171
a C 76 171
minor C 77 171
organ C 78 171
- C 79 171
specific C 80 171
antigen C 81 171
in C 82 171
lens C 83 171
. C 84 171
both C 86 171
the C 87 171
major C 88 171
antigens C 89 171
had C 90 171
a C 91 171
mobility C 92 171
and C 93 171
were C 94 171
identified C 95 171
as C 96 171
the C 97 171
a C 98 171
- C 99 171
crystallin C 100 171
of C 101 171
lens C 102 171
. C 103 171
an C 1 172
electron C 2 172
microscopic C 3 172
study C 4 172
of C 5 172
wolffian C 6 172
lens C 7 172
regeneration C 8 172
in C 9 172
the C 10 172
adult C 11 172
newt C 12 172
. C 13 172
changes C 15 172
in C 16 172
the C 17 172
morphology C 18 172
of C 19 172
cells C 20 172
during C 21 172
the C 22 172
regenerative C 23 172
tissue C 24 172
transformation C 25 172
of C 26 172
the C 27 172
pigmented C 28 172
epithelium C 29 172
of C 30 172
the C 31 172
iris C 32 172
into C 33 172
lens C 34 172
in C 35 172
the C 36 172
adult C 37 172
newt C 38 172
triturus C 39 172
viridescens C 40 172
were C 41 172
studied C 42 172
in C 43 172
ultrathin C 44 172
sections C 45 172
using C 46 172
the C 47 172
electron C 48 172
microscope C 49 172
. C 50 172
in C 52 172
addition C 53 172
, C 54 172
quantitative C 55 172
analyses C 56 172
with C 57 172
electron C 58 172
micrographs C 59 172
were C 60 172
performed C 61 172
. C 62 172
the C 64 172
cells C 65 172
of C 66 172
the C 67 172
normal C 68 172
iris C 69 172
are C 70 172
characterized C 71 172
by C 72 172
an C 73 172
abundance C 74 172
of C 75 172
melanin C 76 172
granules C 77 172
, C 78 172
an C 79 172
extensive C 80 172
smooth C 81 172
- C 82 172
- C 83 172
surfaced C 84 172
endoplasmic C 85 172
reticulum C 86 172
, C 87 172
and C 88 172
irregular C 89 172
indentations C 90 172
of C 91 172
the C 92 172
nuclear C 93 172
membrane C 94 172
. C 95 172
after C 97 172
lens C 98 172
removal C 99 172
, C 100 172
the C 101 172
first C 102 172
visible C 103 172
changes C 104 172
are C 105 172
detected C 106 172
in C 107 172
nuclei C 108 172
of C 109 172
the C 110 172
mediodorsal C 111 172
iris C 112 172
cells C 113 172
and C 114 172
involve C 115 172
an C 116 172
increase C 117 172
in C 118 172
the C 119 172
number C 120 172
of C 121 172
primary C 122 172
nucleoli C 123 172
. C 124 172
later C 126 172
, C 127 172
the C 128 172
nuclei C 129 172
enlarge C 130 172
and C 131 172
become C 132 172
spherical C 133 172
, C 134 172
and C 135 172
prominent C 136 172
nucleoli C 137 172
appear C 138 172
. C 139 172
these C 141 172
nucleoli C 142 172
can C 143 172
be C 144 172
distinguished C 145 172
from C 146 172
the C 147 172
normal C 148 172
nucleoli C 149 172
by C 150 172
the C 151 172
presence C 152 172
of C 153 172
the C 154 172
granular C 155 172
cortex C 156 172
surrounding C 157 172
the C 158 172
fibrous C 159 172
core C 160 172
. C 161 172
the C 163 172
pigment C 164 172
granules C 165 172
seem C 166 172
to C 167 172
be C 168 172
completely C 169 172
extruded C 170 172
into C 171 172
the C 172 172
intercellular C 173 172
spaces C 174 172
and C 175 172
subsequently C 176 172
taken C 177 172
up C 178 172
by C 179 172
leucocytes C 180 172
. C 181 172
the C 183 172
endoplasmic C 184 172
reticulum C 185 172
disintegrates C 186 172
gradually C 187 172
and C 188 172
finally C 189 172
almost C 190 172
disappears C 191 172
. C 192 172
there C 194 172
is C 195 172
a C 196 172
significant C 197 172
increase C 198 172
of C 199 172
ribosomes C 200 172
in C 201 172
the C 202 172
cytoplasm C 203 172
. C 204 172
later C 206 172
, C 207 172
the C 208 172
cytoplasmic C 209 172
matrix C 210 172
also C 211 172
acquires C 212 172
fibrous C 213 172
elements C 214 172
( C 215 172
about C 216 172
50 C 217 172
a C 218 172
wide C 219 172
) C 220 172
of C 221 172
low C 222 172
density C 223 172
, C 224 172
probably C 225 172
corresponding C 226 172
in C 227 172
nature C 228 172
to C 229 172
the C 230 172
main C 231 172
components C 232 172
of C 233 172
a C 234 172
normal C 235 172
lens C 236 172
cell C 237 172
. C 238 172
these C 240 172
and C 241 172
other C 242 172
changes C 243 172
in C 244 172
the C 245 172
transforming C 246 172
cells C 247 172
are C 248 172
discussed C 249 172
. C 250 172
growth C 1 173
of C 2 173
several C 3 173
human C 4 173
cell C 5 173
lines C 6 173
in C 7 173
newborn C 8 173
rats C 9 173
. C 10 173
when C 12 173
injected C 13 173
intravenously C 14 173
into C 15 173
newborn C 16 173
rats C 17 173
, C 18 173
eight C 19 173
human C 20 173
tissue C 21 173
- C 22 173
cultured C 23 173
cancer C 24 173
cell C 25 173
lines C 26 173
- C 27 173
dash C 28 173
h C 29 173
. C 30 173
. C 31 173
. C 31 173
. C 32 173
2 C 34 173
, C 35 173
detroit C 36 173
6 C 37 173
, C 38 173
j C 39 173
- C 40 173
111 C 41 173
, C 42 173
rp C 43 173
41 C 44 173
, C 45 173
rp C 46 173
212 C 47 173
, C 48 173
adeno C 49 173
cx C 50 173
1 C 51 173
, C 52 173
ovary C 53 173
2 C 54 173
, C 55 173
and C 56 173
mac C 57 173
21 C 58 173
- C 59 173
dash C 60 173
grew C 61 173
progressively C 62 173
in C 63 173
lung C 64 173
and C 65 173
other C 66 173
organs C 67 173
of C 68 173
more C 69 173
than C 70 173
50 C 71 173
per C 72 173
cent C 73 173
of C 74 173
the C 75 173
animals C 76 173
and C 77 173
commonly C 78 173
caused C 79 173
death C 80 173
after C 81 173
5 C 82 173
- C 83 173
8 C 84 173
weeks C 85 173
. C 86 173
two C 88 173
other C 89 173
human C 90 173
cell C 91 173
lines C 92 173
- C 93 173
dash C 94 173
the C 95 173
carcinoma C 96 173
h C 97 173
. C 98 173
. C 99 173
. C 99 173
. C 100 173
1 C 102 173
and C 103 173
the C 104 173
presumably C 105 173
normal C 106 173
amnion C 107 173
b C 108 173
- C 109 173
dash C 110 173
grew C 111 173
less C 112 173
frequently C 113 173
and C 114 173
rarely C 115 173
caused C 116 173
death C 117 173
or C 118 173
illness C 119 173
. C 120 173
the C 1 174
human C 2 174
tumor C 3 174
- C 4 174
egg C 5 174
host C 6 174
system C 7 174
iii C 8 174
. C 9 174
tumor C 11 174
- C 12 174
inhibitory C 13 174
properties C 14 174
of C 15 174
tenuazonic C 16 174
acid C 17 174
. C 18 174
the C 20 174
fermented C 21 174
broth C 22 174
of C 23 174
a C 24 174
culture C 25 174
of C 26 174
alternaria C 27 174
tenuis C 28 174
auct C 29 174
. C 30 174
inhibited C 32 174
the C 33 174
growth C 34 174
of C 35 174
the C 36 174
human C 37 174
adenocarcinoma C 38 174
( C 39 174
h C 40 174
. C 41 174
. C 42 174
. C 42 174
. C 43 174
1 C 45 174
) C 46 174
in C 47 174
the C 48 174
embryonated C 49 174
egg C 50 174
with C 51 174
the C 52 174
aid C 53 174
of C 54 174
studies C 55 174
in C 56 174
the C 57 174
egg C 58 174
- C 59 174
tumor C 60 174
system C 61 174
the C 62 174
active C 63 174
agent C 64 174
was C 65 174
isolated C 66 174
and C 67 174
identified C 68 174
as C 69 174
tenuazonic C 70 174
acid C 71 174
. C 72 174
tenuazonic C 74 174
acid C 75 174
was C 76 174
produced C 77 174
by C 78 174
a C 79 174
number C 80 174
of C 81 174
alternaria C 82 174
isolates C 83 174
and C 84 174
by C 85 174
an C 86 174
aspergillustamarii C 87 174
and C 88 174
a C 89 174
phoma C 90 174
sp C 91 174
. C 92 174
compared C 94 174
with C 95 174
tenuazonic C 96 174
acid C 97 174
, C 98 174
on C 99 174
a C 100 174
molar C 101 174
basis C 102 174
, C 103 174
about C 104 174
20 C 105 174
times C 106 174
as C 107 174
much C 108 174
hadacidin C 109 174
or C 110 174
6 C 111 174
- C 112 174
mercaptopurine C 113 174
, C 114 174
2 C 115 174
times C 116 174
as C 117 174
much C 118 174
azaserine C 119 174
, C 120 174
but C 121 174
only C 122 174
1 C 123 174
/ C 124 174
20 C 125 174
as C 126 174
much C 127 174
triethylenemelamine C 128 174
( C 129 174
tem C 130 174
) C 131 174
were C 132 174
required C 133 174
to C 134 174
achieve C 135 174
the C 136 174
same C 137 174
inhibition C 138 174
of C 139 174
h C 140 174
. C 141 174
. C 142 174
. C 142 174
. C 143 174
1 C 145 174
tumor C 146 174
growth C 147 174
in C 148 174
the C 149 174
egg C 150 174
. C 151 174
tenuazonic C 153 174
acid C 154 174
was C 155 174
more C 156 174
effective C 157 174
against C 158 174
h C 159 174
. C 160 174
. C 161 174
. C 161 174
. C 162 174
1 C 164 174
than C 165 174
against C 166 174
another C 167 174
transplantable C 168 174
human C 169 174
tumor C 170 174
, C 171 174
a C 172 174
- C 173 174
42 C 174 174
. C 175 174
tenuazonic C 177 174
acid C 178 174
, C 179 174
compared C 180 174
with C 181 174
puromycin C 182 174
, C 183 174
more C 184 174
specifically C 185 174
inhibited C 186 174
tumor C 187 174
growth C 188 174
in C 189 174
the C 190 174
egg C 191 174
- C 192 174
tumor C 193 174
system C 194 174
. C 195 174
the C 1 175
occurrence C 2 175
of C 3 175
biologic C 4 175
crystals C 5 175
in C 6 175
tumor C 7 175
and C 8 175
nontumor C 9 175
cultures C 10 175
of C 11 175
c C 12 175
3 C 13 175
h C 14 175
/ C 15 175
hej C 16 175
mice C 17 175
. C 18 175
crystalline C 20 175
structures C 21 175
of C 22 175
various C 23 175
types C 24 175
have C 25 175
been C 26 175
found C 27 175
in C 28 175
primary C 29 175
tissue C 30 175
cultures C 31 175
of C 32 175
neoplastic C 33 175
and C 34 175
non C 35 175
- C 36 175
neoplastic C 37 175
tissues C 38 175
from C 39 175
c C 40 175
3 C 41 175
h C 42 175
/ C 43 175
hej C 44 175
mice C 45 175
. C 46 175
all C 48 175
of C 49 175
the C 50 175
cultures C 51 175
of C 52 175
mammary C 53 175
carcinoma C 54 175
tissue C 55 175
contained C 56 175
the C 57 175
crystals C 58 175
. C 59 175
the C 61 175
crystals C 62 175
were C 63 175
found C 64 175
in C 65 175
varying C 66 175
incidence C 67 175
in C 68 175
the C 69 175
cultures C 70 175
of C 71 175
several C 72 175
other C 73 175
tissues C 74 175
with C 75 175
the C 76 175
exception C 77 175
of C 78 175
those C 79 175
from C 80 175
the C 81 175
kidney C 82 175
. C 83 175
a C 85 175
' C 86 175
dialysis C 87 175
compartment C 88 175
' C 89 175
was C 90 175
not C 91 175
essential C 92 175
for C 93 175
the C 94 175
formation C 95 175
of C 96 175
the C 97 175
crystals C 98 175
. C 99 175
the C 101 175
development C 102 175
of C 103 175
the C 104 175
crystals C 105 175
was C 106 175
accelerated C 107 175
by C 108 175
a C 109 175
modification C 110 175
of C 111 175
the C 112 175
culture C 113 175
medium C 114 175
. C 115 175
a C 1 176
comparison C 2 176
of C 3 176
the C 4 176
fine C 5 176
structure C 6 176
of C 7 176
cultured C 8 176
mac C 9 176
- C 10 176
21 C 11 176
and C 12 176
hela C 13 176
cell C 14 176
. C 15 176
the C 17 176
fine C 18 176
structure C 19 176
of C 20 176
a C 21 176
cultured C 22 176
mucoid C 23 176
adenocarcinoma C 24 176
cell C 25 176
of C 26 176
human C 27 176
lung C 28 176
( C 29 176
mac C 30 176
- C 31 176
21 C 32 176
) C 33 176
is C 34 176
described C 35 176
and C 36 176
compared C 37 176
with C 38 176
the C 39 176
fine C 40 176
structure C 41 176
of C 42 176
the C 43 176
hela C 44 176
cell C 45 176
. C 46 176
the C 48 176
differences C 49 176
in C 50 176
fine C 51 176
structure C 52 176
between C 53 176
the C 54 176
two C 55 176
strains C 56 176
are C 57 176
primarily C 58 176
quantitative C 59 176
. C 60 176
the C 62 176
mac C 63 176
- C 64 176
21 C 65 176
cell C 66 176
differed C 67 176
, C 68 176
however C 69 176
, C 70 176
in C 71 176
the C 72 176
following C 73 176
respects C 74 176
. C 75 176
. C 77 176
a C 79 176
spindle C 80 176
- C 81 176
shaped C 82 176
cell C 83 176
with C 84 176
larger C 85 176
nucleus C 86 176
and C 87 176
increased C 88 176
nuclear C 89 176
membrane C 90 176
invaginations C 91 176
, C 92 176
and C 93 176
considerably C 94 176
larger C 95 176
amounts C 96 176
of C 97 176
perinuclear C 98 176
golgi C 99 176
apparatus C 100 176
. C 101 176
the C 103 176
cytoplasm C 104 176
contained C 105 176
areas C 106 176
of C 107 176
low C 108 176
density C 109 176
, C 110 176
undefined C 111 176
by C 112 176
a C 113 176
limiting C 114 176
membrane C 115 176
, C 116 176
which C 117 176
are C 118 176
thought C 119 176
to C 120 176
be C 121 176
accumulations C 122 176
of C 123 176
mucin C 124 176
. C 125 176
the C 127 176
two C 128 176
cell C 129 176
strains C 130 176
contained C 131 176
numerous C 132 176
multivesicular C 133 176
bodies C 134 176
, C 135 176
some C 136 176
with C 137 176
lamellae C 138 176
in C 139 176
various C 140 176
stages C 141 176
of C 142 176
development C 143 176
, C 144 176
suggesting C 145 176
that C 146 176
these C 147 176
organelles C 148 176
may C 149 176
be C 150 176
involved C 151 176
in C 152 176
the C 153 176
formation C 154 176
of C 155 176
the C 156 176
lipide C 157 176
- C 158 176
rich C 159 176
, C 160 176
myelinated C 161 176
structures C 162 176
observed C 163 176
in C 164 176
both C 165 176
hela C 166 176
and C 167 176
mac C 168 176
- C 169 176
21 C 170 176
cells C 171 176
. C 172 176
the C 174 176
number C 175 176
of C 176 176
myelinated C 177 176
bodies C 178 176
was C 179 176
found C 180 176
to C 181 176
be C 182 176
inversely C 183 176
proportional C 184 176
to C 185 176
the C 186 176
ph C 187 176
of C 188 176
the C 189 176
medium C 190 176
. C 191 176
effect C 1 177
of C 2 177
parathyroid C 3 177
and C 4 177
other C 5 177
human C 6 177
tumors C 7 177
and C 8 177
tissues C 9 177
on C 10 177
bone C 11 177
resorption C 12 177
in C 13 177
tissue C 14 177
culture C 15 177
. C 16 177
mouse C 18 177
calvaria C 19 177
were C 20 177
grown C 21 177
in C 22 177
tissue C 23 177
culture C 24 177
in C 25 177
combination C 26 177
with C 27 177
single C 28 177
or C 29 177
multiple C 30 177
fragments C 31 177
of C 32 177
a C 33 177
variety C 34 177
of C 35 177
human C 36 177
tumors C 37 177
and C 38 177
glandular C 39 177
tissues C 40 177
to C 41 177
determine C 42 177
their C 43 177
capacity C 44 177
to C 45 177
enhance C 46 177
bone C 47 177
resorption C 48 177
. C 49 177
single C 51 177
fragments C 52 177
of C 53 177
parathyroid C 54 177
adenoma C 55 177
tissue C 56 177
consistently C 57 177
enhanced C 58 177
resorption C 59 177
in C 60 177
both C 61 177
the C 62 177
frontal C 63 177
and C 64 177
the C 65 177
parietal C 66 177
bones C 67 177
. C 68 177
except C 70 177
for C 71 177
one C 72 177
squamous C 73 177
- C 74 177
- C 75 177
cell C 76 177
carcinoma C 77 177
of C 78 177
the C 79 177
lung C 80 177
which C 81 177
had C 82 177
some C 83 177
activity C 84 177
all C 85 177
other C 86 177
tissues C 87 177
tested C 88 177
as C 89 177
single C 90 177
fragments C 91 177
had C 92 177
no C 93 177
enhancing C 94 177
effect C 95 177
. C 96 177
on C 98 177
the C 99 177
other C 100 177
hand C 101 177
, C 102 177
all C 103 177
human C 104 177
tissues C 105 177
enhanced C 106 177
resorption C 107 177
when C 108 177
multiple C 109 177
fragments C 110 177
were C 111 177
placed C 112 177
in C 113 177
a C 114 177
halo C 115 177
around C 116 177
the C 117 177
calvarium C 118 177
, C 119 177
suggesting C 120 177
the C 121 177
presence C 122 177
of C 123 177
lesser C 124 177
amounts C 125 177
of C 126 177
resorption C 127 177
- C 128 177
enhancing C 129 177
factors C 130 177
in C 131 177
other C 132 177
human C 133 177
tissues C 134 177
. C 135 177
limited C 1 178
growth C 2 178
period C 3 178
of C 4 178
human C 5 178
lung C 6 178
cell C 7 178
lines C 8 178
transformed C 9 178
by C 10 178
simian C 11 178
virus C 12 178
40 C 13 178
. C 14 178
summary C 16 178
- C 17 178
- C 18 178
infection C 19 178
of C 20 178
human C 21 178
cell C 22 178
strains C 23 178
with C 24 178
simian C 25 178
virus C 26 178
40 C 27 178
induced C 28 178
virus C 29 178
replication C 30 178
and C 31 178
cell C 32 178
transformation C 33 178
with C 34 178
the C 35 178
changes C 36 178
in C 37 178
morphology C 38 178
and C 39 178
cytology C 40 178
described C 41 178
by C 42 178
previous C 43 178
investigators C 44 178
. C 45 178
although C 47 178
transformation C 48 178
greatly C 49 178
enhanced C 50 178
growth C 51 178
potentials C 52 178
of C 53 178
the C 54 178
strains C 55 178
, C 56 178
only C 57 178
2 C 58 178
of C 59 178
23 C 60 178
transformed C 61 178
cultures C 62 178
appear C 63 178
to C 64 178
have C 65 178
attained C 66 178
autonomous C 67 178
growth C 68 178
. C 69 178
- C 71 178
- C 72 178
j C 73 178
nat C 74 178
cancer C 75 178
inst C 76 178
33 C 77 178
. C 78 178
. C 80 178
227 C 82 178
- C 83 178
236 C 84 178
, C 85 178
1964 C 86 178
. C 87 178
bacteriophages C 1 179
that C 2 179
lyse C 3 179
mycobacteria C 4 179
and C 5 179
corynebacteria C 6 179
, C 7 179
and C 8 179
show C 9 179
cytopathogenic C 10 179
effect C 11 179
on C 12 179
tissue C 13 179
cultures C 14 179
of C 15 179
renal C 16 179
cells C 17 179
of C 18 179
cercopithecus C 19 179
aethiops C 20 179
. C 21 179
. C 23 179
a C 25 179
preliminary C 26 179
communication C 27 179
. C 28 179
bacteriophages C 30 179
isolated C 31 179
from C 32 179
sputum C 33 179
and C 34 179
resection C 35 179
specimens C 36 179
of C 37 179
pa C 38 179
- C 39 179
tients C 40 179
suffering C 41 179
from C 42 179
carcinoma C 43 179
of C 44 179
the C 45 179
lung C 46 179
were C 47 179
found C 48 179
to C 49 179
lyse C 50 179
coryne C 51 179
- C 52 179
bacteria C 53 179
and C 54 179
mycobacteria C 55 179
, C 56 179
and C 57 179
to C 58 179
produce C 59 179
a C 60 179
cytopathogenic C 61 179
effect C 62 179
on C 63 179
certain C 64 179
cells C 65 179
in C 66 179
tissue C 67 179
cultures C 68 179
. C 69 179
from C 71 179
the C 72 179
same C 73 179
and C 74 179
other C 75 179
patients C 76 179
with C 77 179
neoplastic C 78 179
disease C 79 179
, C 80 179
bacteria C 81 179
were C 82 179
isolated C 83 179
and C 84 179
described C 85 179
as C 86 179
coryne C 87 179
- C 88 179
my C 89 179
- C 90 179
cobacteria C 91 179
because C 92 179
of C 93 179
bacteriological C 94 179
features C 95 179
they C 96 179
shared C 97 179
with C 98 179
both C 99 179
species C 100 179
. C 101 179
these C 103 179
bacteria C 104 179
, C 105 179
which C 106 179
either C 107 179
were C 108 179
sensitive C 109 179
to C 110 179
mycobacterio C 111 179
- C 112 179
phages C 113 179
and C 114 179
corynebacteriophages C 115 179
or C 116 179
were C 117 179
phage C 118 179
- C 119 179
immune C 120 179
lysogenic C 121 179
bacteria C 122 179
, C 123 179
could C 124 179
be C 125 179
induced C 126 179
to C 127 179
produce C 128 179
lytic C 129 179
particles C 130 179
with C 131 179
phagolytic C 132 179
activity C 133 179
on C 134 179
corynebacteria C 135 179
and C 136 179
mycobacteria C 137 179
and C 138 179
a C 139 179
cytopathogenic C 140 179
effect C 141 179
on C 142 179
hela C 143 179
cells C 144 179
and C 145 179
on C 146 179
the C 147 179
renal C 148 179
cells C 149 179
of C 150 179
cercopithecus C 151 179
. C 152 179
gel C 1 180
filtration C 2 180
of C 3 180
the C 4 180
soluble C 5 180
proteins C 6 180
from C 7 180
normal C 8 180
and C 9 180
cataractous C 10 180
human C 11 180
lenses C 12 180
. C 13 180
the C 15 180
soluble C 16 180
proteins C 17 180
of C 18 180
normal C 19 180
and C 20 180
cataractous C 21 180
lenses C 22 180
were C 23 180
separated C 24 180
according C 25 180
to C 26 180
their C 27 180
molecular C 28 180
size C 29 180
on C 30 180
the C 31 180
polysaccharide C 32 180
gel C 33 180
sephadex C 34 180
g C 35 180
- C 36 180
100 C 37 180
. C 38 180
in C 40 180
cataractous C 41 180
as C 42 180
well C 43 180
as C 44 180
in C 45 180
normal C 46 180
lenses C 47 180
4 C 48 180
different C 49 180
compo C 50 180
- C 51 180
nents C 52 180
were C 53 180
obtained C 54 180
. C 55 180
during C 57 180
the C 58 180
evolution C 59 180
of C 60 180
cataract C 61 180
there C 62 180
is C 63 180
a C 64 180
pre C 65 180
- C 66 180
ferential C 67 180
decrease C 68 180
of C 69 180
the C 70 180
low C 71 180
molecular C 72 180
weight C 73 180
proteins C 74 180
of C 75 180
the C 76 180
lens C 77 180
. C 78 180
these C 80 180
disappeared C 81 180
completely C 82 180
in C 83 180
mature C 84 180
and C 85 180
hypermature C 86 180
cataract C 87 180
. C 88 180
on C 90 180
the C 91 180
other C 92 180
hand C 93 180
, C 94 180
the C 95 180
proteins C 96 180
of C 97 180
high C 98 180
molecular C 99 180
weight C 100 180
( C 101 180
e C 102 180
. C 103 180
. C 104 180
. C 105 180
, C 107 180
- C 108 180
crystallin C 109 180
) C 110 180
are C 111 180
very C 112 180
resistant C 113 180
to C 114 180
the C 115 180
pathological C 116 180
process C 117 180
. C 118 180
the C 120 180
electrophoretic C 121 180
pattern C 122 180
of C 123 180
the C 124 180
low C 125 180
molecular C 126 180
weight C 127 180
proteins C 128 180
in C 129 180
the C 130 180
normal C 131 180
lens C 132 180
revea C 133 180
- C 134 180
led C 135 180
several C 136 180
fractions C 137 180
distributed C 138 180
over C 139 180
a C 140 180
large C 141 180
mobility C 142 180
area C 143 180
. C 144 180
after C 146 180
immunoelectrophoresis C 147 180
, C 148 180
3 C 149 180
different C 150 180
precipitin C 151 180
lines C 152 180
were C 153 180
obtained C 154 180
. C 155 180
the C 1 181
insoluble C 2 181
proteins C 3 181
of C 4 181
bovine C 5 181
crystalline C 6 181
lens C 7 181
. C 8 181
the C 10 181
insoluble C 11 181
lens C 12 181
proteins C 13 181
, C 14 181
the C 15 181
albuminoids C 16 181
, C 17 181
of C 18 181
the C 19 181
adult C 20 181
bovine C 21 181
lens C 22 181
cortex C 23 181
can C 24 181
be C 25 181
rendered C 26 181
soluble C 27 181
by C 28 181
raising C 29 181
the C 30 181
ph C 31 181
of C 32 181
their C 33 181
washed C 34 181
suspension C 35 181
in C 36 181
0 C 37 181
. C 38 181
. C 39 181
nacl C 40 181
to C 41 181
10 C 42 181
. C 43 181
. C 44 181
and C 45 181
then C 46 181
reducing C 47 181
it C 48 181
again C 49 181
to C 50 181
ph C 51 181
7 C 52 181
. C 53 181
. C 54 181
. C 55 181
the C 57 181
sedimentation C 58 181
constant C 59 181
of C 60 181
the C 61 181
dissolved C 62 181
protein C 63 181
is C 64 181
10 C 65 181
. C 66 181
. C 67 181
s C 68 181
, C 69 181
. C 70 181
its C 72 181
molecular C 73 181
weight C 74 181
is C 75 181
estimated C 76 181
to C 77 181
be C 78 181
360 C 79 181
, C 80 181
000 C 81 181
12 C 82 181
, C 83 181
000 C 84 181
. C 85 181
the C 87 181
amino C 88 181
acid C 89 181
composition C 90 181
is C 91 181
approximately C 92 181
the C 93 181
same C 94 181
as C 95 181
that C 96 181
of C 97 181
the C 98 181
soluble C 99 181
- C 100 181
crysta C 101 181
- C 102 181
llin C 103 181
fraction C 104 181
, C 105 181
a C 106 181
kinship C 107 181
which C 108 181
is C 109 181
also C 110 181
apparent C 111 181
from C 112 181
their C 113 181
immunochemi C 114 181
- C 115 181
cal C 116 181
properties C 117 181
. C 118 181
it C 120 181
is C 121 181
suggested C 122 181
that C 123 181
the C 124 181
initial C 125 181
insoluble C 126 181
protein C 127 181
is C 128 181
a C 129 181
molecular C 130 181
aggregate C 131 181
of C 132 181
- C 133 181
crystallin C 134 181
, C 135 181
which C 136 181
is C 137 181
dissociated C 138 181
in C 139 181
alkaline C 140 181
solutions C 141 181
to C 142 181
molecules C 143 181
exhibiting C 144 181
a C 145 181
sedimentation C 146 181
constant C 147 181
of C 148 181
10 C 149 181
. C 150 181
. C 151 181
s C 152 181
. C 153 181
glucose C 1 182
6 C 2 182
- C 3 182
phosphate C 4 182
dehydrogenase C 5 182
and C 6 182
6 C 7 182
- C 8 182
phosphogluconate C 9 182
dehydrogenase C 10 182
in C 11 182
lens C 12 182
and C 13 182
blood C 14 182
of C 15 182
different C 16 182
species C 17 182
. C 18 182
the C 20 182
activities C 21 182
of C 22 182
glucose C 23 182
6 C 24 182
- C 25 182
phosphate C 26 182
and C 27 182
6 C 28 182
- C 29 182
phosphogluconate C 30 182
dehydro C 31 182
- C 32 182
genase C 33 182
were C 34 182
measured C 35 182
in C 36 182
the C 37 182
lens C 38 182
and C 39 182
erythrocytes C 40 182
of C 41 182
man C 42 182
and C 43 182
several C 44 182
other C 45 182
species C 46 182
. C 47 182
there C 49 182
is C 50 182
a C 51 182
wide C 52 182
variation C 53 182
between C 54 182
individuals C 55 182
of C 56 182
the C 57 182
same C 58 182
species C 59 182
, C 60 182
but C 61 182
there C 62 182
seemed C 63 182
no C 64 182
correlation C 65 182
between C 66 182
the C 67 182
activity C 68 182
of C 69 182
either C 70 182
enzyme C 71 182
in C 72 182
the C 73 182
lens C 74 182
and C 75 182
their C 76 182
activity C 77 182
in C 78 182
the C 79 182
erythrocytes C 80 182
of C 81 182
the C 82 182
same C 83 182
species C 84 182
. C 85 182
there C 87 182
is C 88 182
a C 89 182
wide C 90 182
range C 91 182
of C 92 182
activity C 93 182
of C 94 182
both C 95 182
glucose C 96 182
6 C 97 182
- C 98 182
phos C 99 182
- C 100 182
phate C 101 182
dehydrogenase C 102 182
and C 103 182
6 C 104 182
- C 105 182
phosphogluconate C 106 182
dehydrogenase C 107 182
in C 108 182
the C 109 182
lens C 110 182
and C 111 182
in C 112 182
the C 113 182
blood C 114 182
of C 115 182
different C 116 182
species C 117 182
. C 118 182
several C 120 182
species C 121 182
had C 122 182
glucose C 123 182
6 C 124 182
- C 125 182
phos C 126 182
- C 127 182
phate C 128 182
dehydrogenase C 129 182
activity C 130 182
in C 131 182
erythrocytes C 132 182
below C 133 182
the C 134 182
level C 135 182
considered C 136 182
/ C 137 182
deficient C 138 182
/ C 139 182
in C 140 182
man C 141 182
. C 142 182
the C 144 182
sorbitol C 145 182
content C 146 182
of C 147 182
the C 148 182
lens C 149 182
was C 150 182
not C 151 182
correla C 152 182
- C 153 182
ted C 154 182
with C 155 182
glucose C 156 182
6 C 157 182
- C 158 182
phosphate C 159 182
dehydrogenase C 160 182
activity C 161 182
. C 162 182
nucleic C 1 183
acid C 2 183
metabolism C 3 183
in C 4 183
the C 5 183
lens C 6 183
iii C 7 183
. C 8 183
effect C 10 183
of C 11 183
x C 12 183
- C 13 183
radiation C 14 183
. C 15 183
a C 17 183
previous C 18 183
communication C 19 183
reported C 20 183
an C 21 183
increased C 22 183
in C 23 183
vivo C 24 183
incorporation C 25 183
of C 26 183
p C 27 183
- C 28 183
32 C 29 183
into C 30 183
the C 31 183
albuminoid C 32 183
rna C 33 183
fraction C 34 183
of C 35 183
the C 36 183
rat C 37 183
lens C 38 183
6 C 39 183
hours C 40 183
after C 41 183
the C 42 183
animal C 43 183
had C 44 183
been C 45 183
exposed C 46 183
to C 47 183
x C 48 183
- C 49 183
radiation C 50 183
( C 51 183
1 C 52 183
, C 53 183
500 C 54 183
r C 55 183
) C 56 183
. C 57 183
in C 59 183
the C 60 183
present C 61 183
stody C 62 183
, C 63 183
the C 64 183
in C 65 183
vitro C 66 183
uptake C 67 183
of C 68 183
p C 69 183
- C 70 183
32 C 71 183
and C 72 183
c C 73 183
- C 74 183
14 C 75 183
- C 76 183
adenine C 77 183
by C 78 183
albuminoid C 79 183
, C 80 183
ribosomal C 81 183
, C 82 183
and C 83 183
soluble C 84 183
rna C 85 183
fractions C 86 183
of C 87 183
normal C 88 183
and C 89 183
x C 90 183
- C 91 183
irradiated C 92 183
rat C 93 183
lenses C 94 183
was C 95 183
measured C 96 183
. C 97 183
the C 99 183
rna C 100 183
fractions C 101 183
were C 102 183
extracted C 103 183
by C 104 183
sodium C 105 183
dodecyl C 106 183
sulfate C 107 183
in C 108 183
0 C 109 183
. C 110 183
. C 111 183
per C 112 183
cent C 113 183
nacl C 114 183
. C 115 183
the C 117 183
specific C 118 183
rna C 119 183
fractions C 120 183
were C 121 183
also C 122 183
hydrolyzed C 123 183
, C 124 183
chromatographed C 125 183
( C 126 183
on C 127 183
paper C 128 183
) C 129 183
, C 130 183
and C 131 183
the C 132 183
ac C 133 183
- C 134 183
tivity C 135 183
of C 136 183
the C 137 183
individual C 138 183
nucleotides C 139 183
( C 140 183
as C 141 183
well C 142 183
as C 143 183
the C 144 183
specific C 145 183
rna C 146 183
frac C 147 183
- C 148 183
tions C 149 183
) C 150 183
was C 151 183
determined C 152 183
. C 153 183
an C 155 183
experiment C 156 183
was C 157 183
also C 158 183
performed C 159 183
in C 160 183
which C 161 183
the C 162 183
capsules C 163 183
were C 164 183
removed C 165 183
( C 166 183
after C 167 183
the C 168 183
3 C 169 183
hour C 170 183
incubation C 171 183
period C 172 183
) C 173 183
and C 174 183
the C 175 183
activities C 176 183
determined C 177 183
in C 178 183
the C 179 183
nucleic C 180 183
acids C 181 183
extracted C 182 183
from C 183 183
the C 184 183
capsules C 185 183
and C 186 183
in C 187 183
the C 188 183
three C 189 183
rna C 190 183
fractions C 191 183
of C 192 183
the C 193 183
remaining C 194 183
lens C 195 183
matter C 196 183
. C 197 183
the C 199 183
results C 200 183
of C 201 183
these C 202 183
experiments C 203 183
indicate C 204 183
that C 205 183
the C 206 183
incorporation C 207 183
of C 208 183
p C 209 183
- C 210 183
32 C 211 183
and C 212 183
c C 213 183
- C 214 183
14 C 215 183
- C 216 183
adenine C 217 183
into C 218 183
albuminoid C 219 183
rna C 220 183
was C 221 183
markedly C 222 183
stimulated C 223 183
1 C 224 183
hour C 225 183
after C 226 183
1 C 227 183
, C 228 183
500 C 229 183
r C 230 183
whole C 231 183
body C 232 183
radiation C 233 183
. C 234 183
there C 236 183
was C 237 183
no C 238 183
significant C 239 183
effect C 240 183
on C 241 183
ribosomal C 242 183
or C 243 183
soluble C 244 183
fractions C 245 183
. C 246 183
the C 248 183
effect C 249 183
of C 250 183
formaldehyde C 251 183
and C 252 183
heating C 253 183
on C 254 183
x C 255 183
- C 256 183
irradiated C 257 183
albuminoid C 258 183
rna C 259 183
was C 260 183
much C 261 183
less C 262 183
than C 263 183
on C 264 183
the C 265 183
albuminoid C 266 183
rna C 267 183
derived C 268 183
from C 269 183
control C 270 183
animals C 271 183
. C 272 183
an C 1 184
investigation C 2 184
of C 3 184
mitotic C 4 184
control C 5 184
in C 6 184
the C 7 184
rabbit C 8 184
lens C 9 184
epithelium C 10 184
. C 11 184
a C 13 184
water C 14 184
soluble C 15 184
substance C 16 184
which C 17 184
inhibits C 18 184
mitosis C 19 184
in C 20 184
the C 21 184
rabbit C 22 184
lens C 23 184
epithelium C 24 184
has C 25 184
been C 26 184
found C 27 184
to C 28 184
be C 29 184
present C 30 184
in C 31 184
young C 32 184
and C 33 184
old C 34 184
rabbit C 35 184
lenses C 36 184
. C 37 184
it C 39 184
has C 40 184
a C 41 184
high C 42 184
molecular C 43 184
weight C 44 184
and C 45 184
is C 46 184
relatively C 47 184
stable C 48 184
at C 49 184
room C 50 184
tempera C 51 184
- C 52 184
ture C 53 184
. C 54 184
the C 56 184
inhibitory C 57 184
factor C 58 184
is C 59 184
associated C 60 184
with C 61 184
the C 62 184
y C 63 184
- C 64 184
crystallin C 65 184
frac C 66 184
- C 67 184
tion C 68 184
and C 69 184
exists C 70 184
throughout C 71 184
the C 72 184
young C 73 184
lens C 74 184
, C 75 184
although C 76 184
the C 77 184
activity C 78 184
in C 79 184
the C 80 184
nuclear C 81 184
region C 82 184
( C 83 184
on C 84 184
a C 85 184
wet C 86 184
weight C 87 184
basis C 88 184
) C 89 184
is C 90 184
less C 91 184
than C 92 184
half C 93 184
that C 94 184
of C 95 184
the C 96 184
cortex C 97 184
and C 98 184
epithelium C 99 184
. C 100 184
the C 1 185
identification C 2 185
of C 3 185
lysosomal C 4 185
enzymes C 5 185
in C 6 185
bovine C 7 185
lens C 8 185
epithelium C 9 185
. C 10 185
biochemical C 12 185
studies C 13 185
are C 14 185
described C 15 185
for C 16 185
the C 17 185
isolation C 18 185
of C 19 185
lysosomes C 20 185
( C 21 185
identified C 22 185
as C 23 185
such C 24 185
by C 25 185
the C 26 185
activities C 27 185
of C 28 185
their C 29 185
enzymes C 30 185
) C 31 185
in C 32 185
the C 33 185
cells C 34 185
of C 35 185
the C 36 185
bovine C 37 185
lens C 38 185
epithelium C 39 185
. C 40 185
the C 42 185
various C 43 185
fractions C 44 185
assayed C 45 185
for C 46 185
lysosomal C 47 185
enzymes C 48 185
showed C 49 185
contamination C 50 185
of C 51 185
mitochondrial C 52 185
and C 53 185
soluble C 54 185
cytoplasmic C 55 185
material C 56 185
in C 57 185
the C 58 185
two C 59 185
isolation C 60 185
procedures C 61 185
employed C 62 185
. C 63 185
protein C 1 186
synthesis C 2 186
and C 3 186
polyribosomes C 4 186
in C 5 186
the C 6 186
calf C 7 186
lens C 8 186
. C 9 186
a C 11 186
cell C 12 186
- C 13 186
free C 14 186
system C 15 186
capable C 16 186
of C 17 186
incorporating C 18 186
amino C 19 186
acid C 20 186
into C 21 186
protein C 22 186
has C 23 186
been C 24 186
isolated C 25 186
from C 26 186
calf C 27 186
lens C 28 186
. C 29 186
polyribosomes C 31 186
have C 32 186
been C 33 186
shown C 34 186
to C 35 186
be C 36 186
present C 37 186
in C 38 186
the C 39 186
ribosomal C 40 186
fraction C 41 186
and C 42 186
to C 43 186
be C 44 186
responsible C 45 186
for C 46 186
most C 47 186
of C 48 186
the C 49 186
protein C 50 186
- C 51 186
synthesizing C 52 186
capacity C 53 186
of C 54 186
this C 55 186
fraction C 56 186
. C 57 186
the C 59 186
polyribosomes C 60 186
have C 61 186
been C 62 186
examined C 63 186
by C 64 186
electron C 65 186
microscopy C 66 186
and C 67 186
appear C 68 186
to C 69 186
be C 70 186
composed C 71 186
of C 72 186
long C 73 186
strands C 74 186
of C 75 186
ribonucleic C 76 186
acid C 77 186
, C 78 186
ranging C 79 186
from C 80 186
7 C 81 186
, C 82 186
000 C 83 186
a C 84 186
to C 85 186
20 C 86 186
, C 87 186
000 C 88 186
a C 89 186
, C 90 186
and C 91 186
con C 92 186
- C 93 186
taining C 94 186
a C 95 186
large C 96 186
number C 97 186
of C 98 186
ribosomes C 99 186
with C 100 186
an C 101 186
average C 102 186
diameter C 103 186
of C 104 186
about C 105 186
140 C 106 186
a C 107 186
. C 108 186
measurement C 1 187
of C 2 187
oxygen C 3 187
tensions C 4 187
in C 5 187
cerebral C 6 187
tissues C 7 187
of C 8 187
rats C 9 187
exposed C 10 187
to C 11 187
high C 12 187
pressures C 13 187
of C 14 187
oxygen C 15 187
. C 16 187
brain C 18 187
and C 19 187
cerebrospinal C 20 187
oxygen C 21 187
tensions C 22 187
have C 23 187
been C 24 187
measured C 25 187
in C 26 187
rats C 27 187
breathing C 28 187
air C 29 187
or C 30 187
in C 31 187
various C 32 187
high C 33 187
pressures C 34 187
of C 35 187
oxygen C 36 187
( C 37 187
ohp C 38 187
) C 39 187
. C 40 187
addition C 42 187
of C 43 187
5 C 44 187
percent C 45 187
co C 46 187
2 C 47 187
to C 48 187
the C 49 187
inspired C 50 187
oxygen C 51 187
raised C 52 187
cerebral C 53 187
oxygen C 54 187
tensions C 55 187
when C 56 187
rats C 57 187
were C 58 187
exposed C 59 187
to C 60 187
2 C 61 187
atm C 62 187
abs C 63 187
or C 64 187
above C 65 187
. C 66 187
inhibition C 68 187
of C 69 187
75 C 70 187
hemoglobin C 71 187
saturation C 72 187
by C 73 187
para C 74 187
- C 75 187
aminopropriophenone C 76 187
lowered C 77 187
cerebral C 78 187
po C 79 187
in C 80 187
rats C 81 187
breathing C 82 187
air C 83 187
, C 84 187
but C 85 187
not C 86 187
in C 87 187
rats C 88 187
exposed C 89 187
to C 90 187
ohp C 91 187
. C 92 187
the C 94 187
rate C 95 187
of C 96 187
rise C 97 187
of C 98 187
cerebral C 99 187
po C 100 187
to C 101 187
a C 102 187
steady C 103 187
level C 104 187
after C 105 187
rapid C 106 187
compression C 107 187
was C 108 187
found C 109 187
to C 110 187
be C 111 187
faster C 112 187
than C 113 187
the C 114 187
rate C 115 187
of C 116 187
fall C 117 187
to C 118 187
a C 119 187
steady C 120 187
level C 121 187
following C 122 187
decompression C 123 187
. C 124 187
addition C 126 187
of C 127 187
co C 128 187
to C 129 187
the C 130 187
inspired C 131 187
gas C 132 187
mixture C 133 187
increased C 134 187
the C 135 187
rate C 136 187
of C 137 187
rise C 138 187
of C 139 187
cerebral C 140 187
po C 141 187
. C 142 187
the C 144 187
anesthetics C 145 187
urethane C 146 187
and C 147 187
pentobarbital C 148 187
sodium C 149 187
did C 150 187
not C 151 187
affect C 152 187
cerebral C 153 187
po C 154 187
in C 155 187
rats C 156 187
breathing C 157 187
air C 158 187
or C 159 187
oxygen C 160 187
at C 161 187
4 C 162 187
atm C 163 187
. C 164 187
the C 166 187
results C 167 187
are C 168 187
discussed C 169 187
in C 170 187
relation C 171 187
to C 172 187
factors C 173 187
contributing C 174 187
to C 175 187
oxygen C 176 187
poisoning C 177 187
at C 178 187
high C 179 187
pressures C 180 187
. C 181 187
release C 1 188
of C 2 188
free C 3 188
fatty C 4 188
acids C 5 188
from C 6 188
adipose C 7 188
tissue C 8 188
obtained C 9 188
from C 10 188
newborn C 11 188
infants C 12 188
. C 13 188
summary C 15 188
the C 16 188
role C 17 188
played C 18 188
by C 19 188
mobilization C 20 188
of C 21 188
free C 22 188
fatty C 23 188
acids C 24 188
( C 25 188
ffa C 26 188
) C 27 188
from C 28 188
adipose C 29 188
tissue C 30 188
in C 31 188
producing C 32 188
the C 33 188
typically C 34 188
high C 35 188
serum C 36 188
ffa C 37 188
levels C 38 188
of C 39 188
human C 40 188
infants C 41 188
has C 42 188
been C 43 188
studied C 44 188
. C 45 188
ffa C 47 188
concentrations C 48 188
in C 49 188
the C 50 188
serum C 51 188
and C 52 188
subcuta C 53 188
- C 54 188
neous C 55 188
adipose C 56 188
tissue C 57 188
from C 58 188
the C 59 188
gluteal C 60 188
region C 61 188
were C 62 188
determined C 63 188
during C 64 188
postnatal C 65 188
development C 66 188
. C 67 188
a C 69 188
maximum C 70 188
level C 71 188
was C 72 188
reached C 73 188
within C 74 188
24 C 75 188
hr C 76 188
after C 77 188
birth C 78 188
, C 79 188
after C 80 188
which C 81 188
there C 82 188
was C 83 188
a C 84 188
gradual C 85 188
fall C 86 188
. C 87 188
in C 89 188
serum C 90 188
the C 91 188
ffa C 92 188
level C 93 188
at C 94 188
the C 95 188
end C 96 188
of C 97 188
12 C 98 188
months C 99 188
was C 100 188
still C 101 188
higher C 102 188
than C 103 188
that C 104 188
in C 105 188
adults C 106 188
, C 107 188
while C 108 188
the C 109 188
ffa C 110 188
level C 111 188
in C 112 188
adipose C 113 188
tissue C 114 188
was C 115 188
lower C 116 188
at C 117 188
3 C 118 188
months C 119 188
than C 120 188
in C 121 188
adults C 122 188
. C 123 188
incubation C 125 188
of C 126 188
small C 127 188
pieces C 128 188
of C 129 188
adipose C 130 188
tissue C 131 188
in C 132 188
krebs C 133 188
- C 134 188
ringer C 135 188
phosphate C 136 188
buffer C 137 188
containing C 138 188
4 C 139 188
albumin C 140 188
led C 141 188
to C 142 188
release C 143 188
of C 144 188
ffa C 145 188
into C 146 188
the C 147 188
medium C 148 188
. C 149 188
this C 151 188
release C 152 188
could C 153 188
be C 154 188
suppressed C 155 188
by C 156 188
the C 157 188
addition C 158 188
of C 159 188
glucose C 160 188
( C 161 188
200 C 162 188
mg C 163 188
/ C 164 188
100 C 165 188
ml C 166 188
) C 167 188
for C 168 188
tissue C 169 188
from C 170 188
all C 171 188
age C 172 188
groups C 173 188
except C 174 188
the C 175 188
youngest C 176 188
( C 177 188
0 C 178 188
- C 179 188
15 C 180 188
hr C 181 188
after C 182 188
birth C 183 188
) C 184 188
detection C 1 189
of C 2 189
pericardial C 3 189
effusion C 4 189
by C 5 189
radioisotope C 6 189
heart C 7 189
scanning C 8 189
. C 9 189
a C 11 189
marked C 12 189
difference C 13 189
between C 14 189
the C 15 189
cardiac C 16 189
silhouette C 17 189
on C 18 189
the C 19 189
six C 20 189
- C 21 189
foot C 22 189
chest C 23 189
roentgenogram C 24 189
and C 25 189
the C 26 189
cardiac C 27 189
blood C 28 189
pool C 29 189
, C 30 189
determined C 31 189
by C 32 189
radioiso C 33 189
- C 34 189
tope C 35 189
scanning C 36 189
, C 37 189
has C 38 189
been C 39 189
shown C 40 189
to C 41 189
be C 42 189
consistent C 43 189
with C 44 189
pericardial C 45 189
effusion C 46 189
and C 47 189
/ C 48 189
or C 49 189
thickening C 50 189
. C 51 189
it C 53 189
has C 54 189
also C 55 189
been C 56 189
observed C 57 189
that C 58 189
the C 59 189
cardiac C 60 189
blood C 61 189
pool C 62 189
is C 63 189
separated C 64 189
from C 65 189
the C 66 189
liver C 67 189
margin C 68 189
by C 69 189
the C 70 189
interposition C 71 189
of C 72 189
peri C 73 189
- C 74 189
cardial C 75 189
fluid C 76 189
and C 77 189
/ C 78 189
or C 79 189
thickening C 80 189
. C 81 189
this C 83 189
separation C 84 189
was C 85 189
not C 86 189
demonstrated C 87 189
in C 88 189
the C 89 189
presence C 90 189
of C 91 189
a C 92 189
normal C 93 189
pericardium C 94 189
. C 95 189
to C 97 189
appreciate C 98 189
these C 99 189
features C 100 189
, C 101 189
400 C 102 189
c C 103 189
. C 104 189
of C 106 189
radioiodinated C 107 189
human C 108 189
serum C 109 189
albumin C 110 189
and C 111 189
50 C 112 189
c C 113 189
. C 114 189
of C 116 189
colloidal C 117 189
radiogold C 118 189
were C 119 189
used C 120 189
for C 121 189
scanning C 122 189
. C 123 189
the C 125 189
former C 126 189
outlined C 127 189
the C 128 189
blood C 129 189
pool C 130 189
and C 131 189
the C 132 189
latter C 133 189
demonstrated C 134 189
the C 135 189
position C 136 189
of C 137 189
the C 138 189
liver C 139 189
. C 140 189
on C 1 190
the C 2 190
mechanism C 3 190
of C 4 190
erythropoietin C 5 190
- C 6 190
induced C 7 190
differentiation C 8 190
iv C 9 190
. C 10 190
some C 12 190
characteristics C 13 190
of C 14 190
erythropoietin C 15 190
action C 16 190
on C 17 190
hemoglobin C 18 190
synthesis C 19 190
in C 20 190
marrow C 21 190
cell C 22 190
culture C 23 190
. C 24 190
some C 26 190
of C 27 190
the C 28 190
characteristics C 29 190
of C 30 190
the C 31 190
erythropoietin C 32 190
stimulation C 33 190
of C 34 190
hemo C 35 190
- C 36 190
globin C 37 190
synthesis C 38 190
by C 39 190
rat C 40 190
marrow C 41 190
cells C 42 190
in C 43 190
culture C 44 190
have C 45 190
been C 46 190
studied C 47 190
. C 48 190
the C 50 190
relationship C 51 190
between C 52 190
cell C 53 190
number C 54 190
and C 55 190
rate C 56 190
of C 57 190
hemoglobin C 58 190
synthesis C 59 190
at C 60 190
va C 61 190
- C 62 190
rious C 63 190
levels C 64 190
of C 65 190
erythropoietin C 66 190
is C 67 190
sigmoid C 68 190
rather C 69 190
than C 70 190
linear C 71 190
suggesting C 72 190
a C 73 190
cooperative C 74 190
action C 75 190
among C 76 190
the C 77 190
sensitive C 78 190
cells C 79 190
. C 80 190
the C 82 190
magnitude C 83 190
of C 84 190
the C 85 190
erythropoietin C 86 190
effect C 87 190
on C 88 190
the C 89 190
cells C 90 190
increases C 91 190
with C 92 190
time C 93 190
of C 94 190
contact C 95 190
with C 96 190
the C 97 190
hormone C 98 190
, C 99 190
. C 100 190
at C 102 190
the C 103 190
time C 104 190
of C 105 190
one C 106 190
- C 107 190
half C 108 190
maximal C 109 190
effect C 110 190
there C 111 190
is C 112 190
no C 113 190
discer C 114 190
- C 115 190
nible C 116 190
loss C 117 190
of C 118 190
erythropoietin C 119 190
from C 120 190
the C 121 190
culture C 122 190
medium C 123 190
. C 124 190
a C 126 190
previously C 127 190
des C 128 190
- C 129 190
cribed C 130 190
lag C 131 190
time C 132 190
in C 133 190
the C 134 190
response C 135 190
to C 136 190
erythropoietin C 137 190
appears C 138 190
to C 139 190
be C 140 190
largely C 141 190
due C 142 190
to C 143 190
the C 144 190
conditions C 145 190
of C 146 190
culture C 147 190
and C 148 190
disappears C 149 190
when C 150 190
the C 151 190
cells C 152 190
are C 153 190
pre C 154 190
- C 155 190
- C 156 190
incubated C 157 190
for C 158 190
9 C 159 190
h C 160 190
. C 161 190
replacement C 163 190
of C 164 190
a C 165 190
large C 166 190
fraction C 167 190
of C 168 190
the C 169 190
medium C 170 190
at C 171 190
24 C 172 190
- C 173 190
h C 174 190
intervals C 175 190
enabled C 176 190
the C 177 190
cells C 178 190
to C 179 190
continue C 180 190
hemoglobin C 181 190
synthesis C 182 190
for C 183 190
an C 184 190
additional C 185 190
24 C 186 190
h C 187 190
. C 188 190
the C 1 191
occurrence C 2 191
of C 3 191
megakaryocytes C 4 191
in C 5 191
the C 6 191
peripheral C 7 191
blood C 8 191
of C 9 191
dogs C 10 191
. C 11 191
a C 13 191
study C 14 191
of C 15 191
megakaryocytes C 16 191
in C 17 191
buffy C 18 191
coat C 19 191
smears C 20 191
from C 21 191
26 C 22 191
dogs C 23 191
revealed C 24 191
that C 25 191
no C 26 191
unusual C 27 191
characteristics C 28 191
were C 29 191
consistently C 30 191
associated C 31 191
with C 32 191
appea C 33 191
- C 34 191
rance C 35 191
of C 36 191
megakaryocytes C 37 191
in C 38 191
the C 39 191
peripheral C 40 191
blood C 41 191
. C 42 191
moderate C 1 192
hypothermia C 2 192
in C 3 192
man C 4 192
. C 5 192
. C 7 192
haemodynamic C 9 192
and C 10 192
metabolic C 11 192
effects C 12 192
. C 13 192
studies C 15 192
were C 16 192
performed C 17 192
on C 18 192
four C 19 192
patients C 20 192
undergoing C 21 192
intracranial C 22 192
opera C 23 192
- C 24 192
tion C 25 192
during C 26 192
the C 27 192
induction C 28 192
and C 29 192
reversal C 30 192
of C 31 192
surface C 32 192
hypothermia C 33 192
to C 34 192
30 C 35 192
c C 36 192
. C 37 192
oxygen C 39 192
uptake C 40 192
decreased C 41 192
an C 42 192
average C 43 192
of C 44 192
26 C 45 192
per C 46 192
cent C 47 192
from C 48 192
34 C 49 192
to C 50 192
30 C 51 192
c C 52 192
to C 53 192
a C 54 192
mean C 55 192
value C 56 192
of C 57 192
48 C 58 192
per C 59 192
cent C 60 192
of C 61 192
predicted C 62 192
basal C 63 192
uptake C 64 192
. C 65 192
at C 67 192
the C 68 192
same C 69 192
time C 70 192
, C 71 192
cardiac C 72 192
output C 73 192
decreased C 74 192
only C 75 192
11 C 76 192
. C 77 192
. C 78 192
per C 79 192
cent C 80 192
, C 81 192
resulting C 82 192
in C 83 192
a C 84 192
consistent C 85 192
rise C 86 192
in C 87 192
calculated C 88 192
mixed C 89 192
venous C 90 192
oxygen C 91 192
saturation C 92 192
from C 93 192
a C 94 192
mean C 95 192
of C 96 192
76 C 97 192
to C 98 192
81 C 99 192
per C 100 192
cent C 101 192
at C 102 192
30 C 103 192
c C 104 192
. C 105 192
as C 107 192
a C 108 192
result C 109 192
of C 110 192
this C 111 192
and C 112 192
the C 113 192
effect C 114 192
of C 115 192
cooling C 116 192
on C 117 192
oxygen C 118 192
dissociation C 119 192
, C 120 192
the C 121 192
estimated C 122 192
tension C 123 192
of C 124 192
oxygen C 125 192
in C 126 192
mixed C 127 192
venous C 128 192
blood C 129 192
remained C 130 192
virtually C 131 192
unchanged C 132 192
. C 133 192
when C 135 192
shivering C 136 192
was C 137 192
allowed C 138 192
to C 139 192
occur C 140 192
in C 141 192
two C 142 192
patients C 143 192
, C 144 192
oxygen C 145 192
uptake C 146 192
increased C 147 192
approximately C 148 192
50 C 149 192
per C 150 192
cent C 151 192
without C 152 192
any C 153 192
concomitant C 154 192
increase C 155 192
in C 156 192
cardiac C 157 192
output C 158 192
. C 159 192
observed C 161 192
right C 162 192
atrial C 163 192
and C 164 192
svc C 165 192
oxygen C 166 192
saturations C 167 192
correlated C 168 192
well C 169 192
with C 170 192
calculated C 171 192
mixed C 172 192
venous C 173 192
oxygen C 174 192
saturations C 175 192
with C 176 192
regard C 177 192
to C 178 192
direction C 179 192
and C 180 192
magnitude C 181 192
of C 182 192
change C 183 192
with C 184 192
change C 185 192
in C 186 192
temperature C 187 192
. C 188 192
the C 1 193
spectrum C 2 193
of C 3 193
lupus C 4 193
nephritis C 5 193
. C 6 193
fifty C 8 193
cases C 9 193
of C 10 193
sle C 11 193
have C 12 193
been C 13 193
collected C 14 193
over C 15 193
a C 16 193
ten C 17 193
year C 18 193
period C 19 193
and C 20 193
the C 21 193
incidence C 22 193
and C 23 193
clinical C 24 193
picture C 25 193
of C 26 193
ln C 27 193
reviewed C 28 193
in C 29 193
the C 30 193
light C 31 193
of C 32 193
other C 33 193
published C 34 193
data C 35 193
. C 36 193
lupus C 38 193
nephritis C 39 193
, C 40 193
like C 41 193
sle C 42 193
, C 43 193
has C 44 193
a C 45 193
variable C 46 193
pattern C 47 193
of C 48 193
its C 49 193
own C 50 193
with C 51 193
a C 52 193
wide C 53 193
spectrum C 54 193
of C 55 193
renal C 56 193
involvement C 57 193
- C 58 193
dash C 59 193
evaluation C 60 193
of C 61 193
therapy C 62 193
and C 63 193
prognosis C 64 193
will C 65 193
have C 66 193
to C 67 193
be C 68 193
conducted C 69 193
against C 70 193
this C 71 193
background C 72 193
. C 73 193
lupus C 75 193
nephritis C 76 193
may C 77 193
present C 78 193
as C 79 193
a C 80 193
renal C 81 193
syndrome C 82 193
only C 83 193
, C 84 193
without C 85 193
any C 86 193
of C 87 193
the C 88 193
other C 89 193
manifestations C 90 193
of C 91 193
sle C 92 193
. C 93 193
renal C 95 193
involvement C 96 193
in C 97 193
sle C 98 193
is C 99 193
common C 100 193
, C 101 193
but C 102 193
this C 103 193
does C 104 193
not C 105 193
necessarily C 106 193
indicate C 107 193
a C 108 193
poor C 109 193
short C 110 193
- C 111 193
term C 112 193
prognosis C 113 193
. C 114 193
in C 116 193
the C 117 193
peter C 118 193
bent C 119 193
brigham C 120 193
hospital C 121 193
series C 122 193
a C 123 193
sustained C 124 193
raised C 125 193
blood C 126 193
pressure C 127 193
and C 128 193
the C 129 193
onset C 130 193
of C 131 193
renal C 132 193
insufficiency C 133 193
influenced C 134 193
the C 135 193
prognosis C 136 193
adversely C 137 193
. C 138 193
comparison C 1 194
of C 2 194
ultraviolet C 3 194
sensitivity C 4 194
of C 5 194
bacillus C 6 194
subtilis C 7 194
bacteriophage C 8 194
spo C 9 194
2 C 10 194
and C 11 194
its C 12 194
infectious C 13 194
dna C 14 194
. C 15 194
deoxyribonucleic C 17 194
acid C 18 194
extracted C 19 194
from C 20 194
a C 21 194
clear C 22 194
plaque C 23 194
mutant C 24 194
of C 25 194
the C 26 194
temperate C 27 194
phage C 28 194
, C 29 194
spo C 30 194
2 C 31 194
, C 32 194
was C 33 194
infectious C 34 194
when C 35 194
incubated C 36 194
with C 37 194
competent C 38 194
cultures C 39 194
of C 40 194
bacillus C 41 194
subtilis C 42 194
168 C 43 194
m C 44 194
. C 45 194
the C 47 194
relationship C 48 194
between C 49 194
numbers C 50 194
of C 51 194
infectious C 52 194
centers C 53 194
and C 54 194
dna C 55 194
concentration C 56 194
was C 57 194
linear C 58 194
. C 59 194
the C 61 194
sensitivity C 62 194
of C 63 194
the C 64 194
infectious C 65 194
dna C 66 194
to C 67 194
ultraviolet C 68 194
light C 69 194
was C 70 194
much C 71 194
greater C 72 194
than C 73 194
that C 74 194
of C 75 194
the C 76 194
free C 77 194
phage C 78 194
when C 79 194
b C 80 194
. C 81 194
subtilis C 83 194
168 C 84 194
m C 85 194
was C 86 194
used C 87 194
as C 88 194
host C 89 194
. C 90 194
acriflavin C 92 194
, C 93 194
which C 94 194
inhibits C 95 194
host C 96 194
cell C 97 194
reactivation C 98 194
, C 99 194
increased C 100 194
the C 101 194
rate C 102 194
of C 103 194
ultraviolet C 104 194
inactivation C 105 194
of C 106 194
the C 107 194
free C 108 194
phage C 109 194
so C 110 194
that C 111 194
it C 112 194
approached C 113 194
the C 114 194
inactivation C 115 194
rate C 116 194
of C 117 194
the C 118 194
phage C 119 194
dna C 120 194
. C 121 194
acriflavin C 123 194
had C 124 194
little C 125 194
effect C 126 194
on C 127 194
the C 128 194
survival C 129 194
curves C 130 194
of C 131 194
the C 132 194
infectious C 133 194
dna C 134 194
. C 135 194
non C 137 194
- C 138 194
host C 139 194
reactivating C 140 194
mutants C 141 194
( C 142 194
hcr C 143 194
) C 144 194
of C 145 194
b C 146 194
. C 147 194
subtilis C 149 194
168 C 150 194
m C 151 194
were C 152 194
isolated C 153 194
. C 154 194
the C 156 194
survival C 157 194
curves C 158 194
of C 159 194
spo C 160 194
2 C 161 194
phage C 162 194
were C 163 194
much C 164 194
steeper C 165 194
when C 166 194
the C 167 194
hcr C 168 194
mutant C 169 194
was C 170 194
used C 171 194
as C 172 194
a C 173 194
host C 174 194
than C 175 194
those C 176 194
obtained C 177 194
when C 178 194
the C 179 194
hcr C 180 194
parental C 181 194
strain C 182 194
was C 183 194
used C 184 194
as C 185 194
a C 186 194
host C 187 194
. C 188 194
ultraviolet C 190 194
sensitivity C 191 194
of C 192 194
the C 193 194
phage C 194 194
dna C 195 194
was C 196 194
still C 197 194
greater C 198 194
than C 199 194
that C 200 194
of C 201 194
the C 202 194
free C 203 194
phage C 204 194
even C 205 194
when C 206 194
b C 207 194
. C 208 194
subtilis C 210 194
hcr C 211 194
was C 212 194
used C 213 194
as C 214 194
host C 215 194
, C 216 194
but C 217 194
the C 218 194
difference C 219 194
in C 220 194
sensitivity C 221 194
was C 222 194
much C 223 194
less C 224 194
than C 225 194
the C 226 194
difference C 227 194
obtained C 228 194
with C 229 194
b C 230 194
. C 231 194
subtilis C 233 194
hcr C 234 194
as C 235 194
a C 236 194
host C 237 194
. C 238 194
possible C 240 194
explanations C 241 194
for C 242 194
the C 243 194
greater C 244 194
ultraviolet C 245 194
sensitivity C 246 194
of C 247 194
the C 248 194
infectious C 249 194
dna C 250 194
are C 251 194
discussed C 252 194
. C 253 194
the C 1 195
isolation C 2 195
and C 3 195
morphology C 4 195
of C 5 195
some C 6 195
new C 7 195
bacteriophages C 8 195
specific C 9 195
for C 10 195
bacillus C 11 195
and C 12 195
acetobacter C 13 195
species C 14 195
. C 15 195
the C 17 195
best C 18 195
natural C 19 195
habitat C 20 195
for C 21 195
bacteriophages C 22 195
is C 23 195
probably C 24 195
a C 25 195
semi C 26 195
- C 27 195
solid C 28 195
medium C 29 195
containing C 30 195
actively C 31 195
dividing C 32 195
host C 33 195
bacteria C 34 195
. C 35 195
such C 37 195
conditions C 38 195
are C 39 195
provided C 40 195
for C 41 195
bacillus C 42 195
and C 43 195
acetobacter C 44 195
species C 45 195
in C 46 195
rotting C 47 195
grass C 48 195
and C 49 195
apples C 50 195
, C 51 195
respectively C 52 195
. C 53 195
the C 55 195
bacillus C 56 195
phages C 57 195
found C 58 195
included C 59 195
one C 60 195
with C 61 195
a C 62 195
large C 63 195
head C 64 195
and C 65 195
a C 66 195
contractile C 67 195
tail C 68 195
, C 69 195
and C 70 195
also C 71 195
a C 72 195
so C 73 195
- C 74 195
called C 75 195
killer C 76 195
particle C 77 195
, C 78 195
which C 79 195
had C 80 195
a C 81 195
350 C 82 195
a C 83 195
head C 84 195
and C 85 195
a C 86 195
long C 87 195
contractile C 88 195
tail C 89 195
. C 90 195
this C 92 195
particle C 93 195
had C 94 195
the C 95 195
property C 96 195
of C 97 195
killing C 98 195
but C 99 195
not C 100 195
multiplying C 101 195
within C 102 195
a C 103 195
sensitive C 104 195
cell C 105 195
. C 106 195
a C 108 195
new C 109 195
morphological C 110 195
type C 111 195
of C 112 195
virulent C 113 195
bacillus C 114 195
phage C 115 195
was C 116 195
also C 117 195
isolated C 118 195
, C 119 195
. C 120 195
its C 122 195
head C 123 195
was C 124 195
oblong C 125 195
and C 126 195
the C 127 195
tail C 128 195
consisted C 129 195
of C 130 195
a C 131 195
short C 132 195
needle C 133 195
and C 134 195
a C 135 195
plate C 136 195
the C 137 195
one C 138 195
acetobacter C 139 195
phage C 140 195
found C 141 195
resembled C 142 195
coliphage C 143 195
t C 144 195
3 C 145 195
but C 146 195
was C 147 195
of C 148 195
particular C 149 195
interest C 150 195
because C 151 195
of C 152 195
the C 153 195
prominence C 154 195
of C 155 195
the C 156 195
head C 157 195
capsomeres C 158 195
and C 159 195
the C 160 195
three C 161 195
- C 162 195
pronged C 163 195
tail C 164 195
. C 165 195
characterization C 1 196
of C 2 196
bacillus C 3 196
subtilis C 4 196
bacteriophages C 5 196
. C 6 196
brodetsky C 8 196
, C 9 196
anna C 10 196
m C 11 196
. C 12 196
( C 14 196
university C 15 196
of C 16 196
california C 17 196
, C 18 196
los C 19 196
angeles C 20 196
) C 21 196
, C 22 196
and C 23 196
w C 24 196
. C 25 196
r C 27 196
. C 28 196
romig C 30 196
. C 31 196
characterization C 33 196
of C 34 196
bacillus C 35 196
subtilis C 36 196
bacteriophages C 37 196
. C 38 196
j C 40 196
. C 41 196
bacteriol C 43 196
. C 44 196
90 C 46 196
. C 47 196
. C 49 196
. C 50 196
. C 50 196
. C 50 196
. C 50 196
- C 51 196
1663 C 52 196
. C 53 196
1965 C 55 196
. C 56 196
- C 58 196
- C 59 196
a C 60 196
group C 61 196
of C 62 196
six C 63 196
phages C 64 196
, C 65 196
sp C 66 196
5 C 67 196
, C 68 196
sp C 69 196
6 C 70 196
, C 71 196
sp C 72 196
7 C 73 196
, C 74 196
sp C 75 196
8 C 76 196
, C 77 196
sp C 78 196
9 C 79 196
, C 80 196
and C 81 196
sp C 82 196
13 C 83 196
, C 84 196
which C 85 196
use C 86 196
the C 87 196
marburg C 88 196
strain C 89 196
of C 90 196
bacillus C 91 196
subtilis C 92 196
as C 93 196
host C 94 196
was C 95 196
characterized C 96 196
. C 97 196
these C 99 196
phages C 100 196
, C 101 196
referred C 102 196
to C 103 196
as C 104 196
group C 105 196
1 C 106 196
, C 107 196
were C 108 196
examined C 109 196
for C 110 196
the C 111 196
following C 112 196
properties C 113 196
. C 114 196
. C 116 196
host C 118 196
range C 119 196
, C 120 196
plaque C 121 196
morphology C 122 196
, C 123 196
stability C 124 196
, C 125 196
adsorption C 126 196
kinetics C 127 196
, C 128 196
one C 129 196
- C 130 196
step C 131 196
growth C 132 196
characteristics C 133 196
, C 134 196
calcium C 135 196
requirements C 136 196
, C 137 196
serum C 138 196
neutralization C 139 196
, C 140 196
thermal C 141 196
inactivation C 142 196
, C 143 196
and C 144 196
inactivation C 145 196
by C 146 196
ultraviolet C 147 196
irradiation C 148 196
. C 149 196
five C 151 196
unrelated C 152 196
b C 153 196
. C 154 196
subtilis C 156 196
phages C 157 196
, C 158 196
sp C 159 196
3 C 160 196
, C 161 196
sp C 162 196
10 C 163 196
, C 164 196
pbs C 165 196
1 C 166 196
, C 167 196
sp C 168 196
alpha C 169 196
, C 170 196
and C 171 196
sp C 172 196
beta C 173 196
, C 174 196
were C 175 196
included C 176 196
in C 177 196
the C 178 196
studies C 179 196
. C 180 196
when C 182 196
first C 183 196
isolated C 184 196
, C 185 196
none C 186 196
of C 187 196
the C 188 196
group C 189 196
1 C 190 196
phages C 191 196
was C 192 196
able C 193 196
to C 194 196
replicate C 195 196
efficiently C 196 196
on C 197 196
b C 198 196
. C 199 196
subtilis C 201 196
sb C 202 196
19 C 203 196
, C 204 196
a C 205 196
mutant C 206 196
of C 207 196
the C 208 196
/ C 209 196
transforming C 210 196
/ C 211 196
b C 212 196
. C 213 196
subtilis C 215 196
168 C 216 196
. C 217 196
host C 219 196
range C 220 196
mutants C 221 196
capable C 222 196
of C 223 196
growth C 224 196
in C 225 196
sb C 226 196
19 C 227 196
were C 228 196
isolated C 229 196
for C 230 196
all C 231 196
of C 232 196
the C 233 196
group C 234 196
1 C 235 196
phages C 236 196
except C 237 196
sp C 238 196
13 C 239 196
, C 240 196
and C 241 196
are C 242 196
designated C 243 196
the C 244 196
/ C 245 196
star C 246 196
/ C 247 196
phages C 248 196
( C 249 196
sp C 250 196
5 C 251 196
through C 252 196
sp C 253 196
9 C 254 196
) C 255 196
. C 256 196
for C 258 196
characterization C 259 196
, C 260 196
sb C 261 196
19 C 262 196
was C 263 196
used C 264 196
as C 265 196
host C 266 196
for C 267 196
the C 268 196
star C 269 196
phages C 270 196
, C 271 196
and C 272 196
another C 273 196
b C 274 196
. C 275 196
subtilis C 277 196
mutant C 278 196
, C 279 196
168 C 280 196
b C 281 196
, C 282 196
was C 283 196
host C 284 196
for C 285 196
sp C 286 196
13 C 287 196
. C 288 196
transduction C 1 197
in C 2 197
bacillus C 3 197
subtilis C 4 197
. C 5 197
( C 7 197
i C 8 197
) C 9 197
comparative C 10 197
examinations C 11 197
have C 12 197
shown C 13 197
that C 14 197
the C 15 197
temperate C 16 197
subtilis C 17 197
phages C 18 197
can C 19 197
be C 20 197
divided C 21 197
into C 22 197
two C 23 197
groups C 24 197
. C 25 197
b C 27 197
. C 28 197
subtilis C 30 197
strain C 31 197
nrs C 32 197
231 C 33 197
was C 34 197
an C 35 197
adequate C 36 197
common C 37 197
host C 38 197
sensitive C 39 197
to C 40 197
all C 41 197
the C 42 197
examined C 43 197
temperate C 44 197
phages C 45 197
. C 46 197
owing C 48 197
to C 49 197
certain C 50 197
technical C 51 197
advantages C 52 197
this C 53 197
strain C 54 197
was C 55 197
found C 56 197
suitable C 57 197
for C 58 197
the C 59 197
titration C 60 197
subtilis C 61 197
phages C 62 197
. C 63 197
( C 65 197
ii C 66 197
) C 67 197
some C 68 197
cultural C 69 197
differences C 70 197
have C 71 197
been C 72 197
revealed C 73 197
among C 74 197
substrains C 75 197
of C 76 197
b C 77 197
. C 78 197
subtilis C 80 197
168 C 81 197
ind C 82 197
auxotrophs C 83 197
maintained C 84 197
in C 85 197
various C 86 197
laboratories C 87 197
. C 88 197
cells C 90 197
in C 91 197
one C 92 197
of C 93 197
these C 94 197
cultures C 95 197
were C 96 197
partly C 97 197
capable C 98 197
and C 99 197
partly C 100 197
incapable C 101 197
of C 102 197
using C 103 197
ammonia C 104 197
. C 105 197
ammonia C 107 197
assimilation C 108 197
was C 109 197
transducible C 110 197
to C 111 197
ammonia C 112 197
negative C 113 197
bacteria C 114 197
. C 115 197
( C 117 197
iii C 118 197
) C 119 197
after C 120 197
mitomycin C 121 197
c C 122 197
or C 123 197
ultraviolet C 124 197
ray C 125 197
induction C 126 197
the C 127 197
examined C 128 197
b C 129 197
. C 130 197
subtilis C 132 197
strains C 133 197
liberated C 134 197
/ C 135 197
bacteriocin C 136 197
/ C 137 197
- C 138 197
like C 139 197
principles C 140 197
. C 141 197
this C 143 197
finding C 144 197
is C 145 197
probably C 146 197
analogous C 147 197
to C 148 197
that C 149 197
of C 150 197
seaman C 151 197
et C 152 197
al C 153 197
. C 154 197
concerning C 156 197
pbsx C 157 197
defective C 158 197
phages C 159 197
. C 160 197
on C 162 197
the C 163 197
basis C 164 197
of C 165 197
bacteriocin C 166 197
production C 167 197
the C 168 197
examined C 169 197
strains C 170 197
were C 171 197
divided C 172 197
into C 173 197
two C 174 197
groups C 175 197
. C 176 197
( C 178 197
iv C 179 197
) C 180 197
several C 181 197
temperate C 182 197
phages C 183 197
isolated C 184 197
in C 185 197
our C 186 197
laboratory C 187 197
were C 188 197
presumably C 189 197
identical C 190 197
with C 191 197
phage C 192 197
pbs C 193 197
1 C 194 197
. C 195 197
phage C 197 197
sp C 198 197
10 C 199 197
differed C 200 197
from C 201 197
these C 202 197
agents C 203 197
both C 204 197
in C 205 197
antigenic C 206 197
structure C 207 197
and C 208 197
in C 209 197
host C 210 197
range C 211 197
. C 212 197
( C 214 197
v C 215 197
) C 216 197
transduction C 217 197
by C 218 197
some C 219 197
lysates C 220 197
of C 221 197
pbs C 222 197
1 C 223 197
- C 224 197
type C 225 197
phages C 226 197
was C 227 197
observed C 228 197
at C 229 197
frequencies C 230 197
of C 231 197
the C 232 197
order C 233 197
of C 234 197
10 C 235 197
. C 236 197
considerably C 238 197
more C 239 197
and C 240 197
less C 241 197
effective C 242 197
phage C 243 197
materials C 244 197
were C 245 197
yielded C 246 197
by C 247 197
some C 248 197
lysogenic C 249 197
transductants C 250 197
. C 251 197
thus C 253 197
transducing C 254 197
phages C 255 197
active C 256 197
in C 257 197
the C 258 197
order C 259 197
of C 260 197
10 C 261 197
were C 262 197
prepared C 263 197
. C 264 197
( C 266 197
vi C 267 197
) C 268 197
transduction C 269 197
frequency C 270 197
, C 271 197
in C 272 197
addition C 273 197
to C 274 197
the C 275 197
properties C 276 197
of C 277 197
the C 278 197
phage C 279 197
, C 280 197
was C 281 197
influenced C 282 197
by C 283 197
the C 284 197
physiological C 285 197
condition C 286 197
of C 287 197
bacteria C 288 197
. C 289 197
( C 291 197
vii C 292 197
) C 293 197
transduction C 294 197
of C 295 197
indole C 296 197
and C 297 197
histidine C 298 197
loci C 299 197
was C 300 197
studied C 301 197
by C 302 197
use C 303 197
of C 304 197
his C 305 197
derivatives C 306 197
of C 307 197
strain C 308 197
168 C 309 197
ind C 310 197
. C 311 197
the C 1 198
carrier C 2 198
state C 3 198
of C 4 198
bacillus C 5 198
subtilis C 6 198
infected C 7 198
with C 8 198
the C 9 198
transducing C 10 198
bacteriophage C 11 198
sp C 12 198
10 C 13 198
. C 14 198
bacteriophage C 16 198
sp C 17 198
10 C 18 198
may C 19 198
infect C 20 198
bacillus C 21 198
subtilis C 22 198
to C 23 198
form C 24 198
a C 25 198
carrier C 26 198
system C 27 198
. C 28 198
the C 30 198
infected C 31 198
bacteria C 32 198
give C 33 198
rise C 34 198
to C 35 198
infected C 36 198
organisms C 37 198
after C 38 198
six C 39 198
or C 40 198
more C 41 198
successive C 42 198
single C 43 198
- C 44 198
colony C 45 198
isolations C 46 198
. C 47 198
about C 49 198
60 C 50 198
of C 51 198
the C 52 198
spores C 53 198
derived C 54 198
from C 55 198
such C 56 198
an C 57 198
infected C 58 198
culture C 59 198
yield C 60 198
clones C 61 198
that C 62 198
produce C 63 198
phage C 64 198
, C 65 198
and C 66 198
such C 67 198
spores C 68 198
retain C 69 198
their C 70 198
ability C 71 198
to C 72 198
produce C 73 198
phage C 74 198
even C 75 198
after C 76 198
treatment C 77 198
with C 78 198
antiserum C 79 198
and C 80 198
heating C 81 198
at C 82 198
80 C 83 198
. C 84 198
four C 86 198
hours C 87 198
' C 88 198
incubation C 89 198
of C 90 198
carrier C 91 198
spores C 92 198
in C 93 198
nutrient C 94 198
broth C 95 198
yields C 96 198
cultures C 97 198
having C 98 198
more C 99 198
than C 100 198
10 C 101 198
infective C 102 198
centers C 103 198
per C 104 198
bacterium C 105 198
. C 106 198
cultivation C 108 198
of C 109 198
infected C 110 198
organisms C 111 198
in C 112 198
medium C 113 198
containing C 114 198
sp C 115 198
10 C 116 198
antiserum C 117 198
leads C 118 198
to C 119 198
loss C 120 198
of C 121 198
phage C 122 198
and C 123 198
loss C 124 198
of C 125 198
immunity C 126 198
to C 127 198
phage C 128 198
infection C 129 198
. C 130 198
dna C 132 198
with C 133 198
a C 134 198
density C 135 198
characteristic C 136 198
of C 137 198
viral C 138 198
dna C 139 198
can C 140 198
be C 141 198
detected C 142 198
in C 143 198
infected C 144 198
bacteria C 145 198
. C 146 198
extracts C 148 198
of C 149 198
infected C 150 198
bacteria C 151 198
contain C 152 198
a C 153 198
phage C 154 198
- C 155 198
induced C 156 198
deoxyribonuclease C 157 198
activity C 158 198
which C 159 198
attacks C 160 198
both C 161 198
phage C 162 198
and C 163 198
bacterial C 164 198
dna C 165 198
in C 166 198
vitro C 167 198
. C 168 198
the C 170 198
phage C 171 198
- C 172 198
bacterial C 173 198
complex C 174 198
is C 175 198
therefore C 176 198
best C 177 198
described C 178 198
as C 179 198
a C 180 198
carrier C 181 198
state C 182 198
. C 183 198
the C 185 198
dna C 186 198
of C 187 198
the C 188 198
phage C 189 198
and C 190 198
of C 191 198
b C 192 198
. C 193 198
subtilis C 195 198
are C 196 198
chemically C 197 198
different C 198 198
. C 199 198
enzymatically C 201 198
prepared C 202 198
complementary C 203 198
virus C 204 198
rna C 205 198
has C 206 198
no C 207 198
homology C 208 198
with C 209 198
bacterial C 210 198
dna C 211 198
. C 212 198
the C 214 198
lack C 215 198
of C 216 198
homology C 217 198
of C 218 198
this C 219 198
transducing C 220 198
phage C 221 198
dna C 222 198
with C 223 198
the C 224 198
dna C 225 198
of C 226 198
its C 227 198
host C 228 198
and C 229 198
the C 230 198
failure C 231 198
to C 232 198
form C 233 198
a C 234 198
truly C 235 198
lysogenic C 236 198
relationship C 237 198
reinforce C 238 198
previous C 239 198
conclusions C 240 198
that C 241 198
transducing C 242 198
bacterial C 243 198
dna C 244 198
is C 245 198
incorporated C 246 198
into C 247 198
the C 248 198
sp C 249 198
10 C 250 198
virus C 251 198
particle C 252 198
without C 253 198
any C 254 198
recombination C 255 198
between C 256 198
viral C 257 198
and C 258 198
bacterial C 259 198
dna C 260 198
. C 261 198
infectivity C 1 199
of C 2 199
dna C 3 199
isolated C 4 199
from C 5 199
bacillus C 6 199
subtilis C 7 199
bacteriophage C 8 199
, C 9 199
sp C 10 199
82 C 11 199
. C 12 199
sp C 14 199
82 C 15 199
, C 16 199
a C 17 199
newly C 18 199
isolated C 19 199
bacteriophage C 20 199
of C 21 199
bacillus C 22 199
subtilis C 23 199
, C 24 199
is C 25 199
described C 26 199
. C 27 199
sp C 29 199
82 C 30 199
is C 31 199
closely C 32 199
related C 33 199
to C 34 199
sp C 35 199
8 C 36 199
, C 37 199
but C 38 199
differs C 39 199
from C 40 199
sp C 41 199
8 C 42 199
in C 43 199
the C 44 199
density C 45 199
of C 46 199
its C 47 199
denatured C 48 199
dna C 49 199
and C 50 199
in C 51 199
its C 52 199
plating C 53 199
effciency C 54 199
on C 55 199
b C 56 199
. C 57 199
subtilis C 59 199
strain C 60 199
sb C 61 199
- C 62 199
1 C 63 199
. C 64 199
dna C 66 199
isolated C 67 199
from C 68 199
this C 69 199
phage C 70 199
can C 71 199
be C 72 199
recovered C 73 199
in C 74 199
molecular C 75 199
weight C 76 199
equivalent C 77 199
to C 78 199
the C 79 199
amount C 80 199
contained C 81 199
in C 82 199
a C 83 199
single C 84 199
phage C 85 199
( C 86 199
approximately C 87 199
130 C 88 199
x C 89 199
10 C 90 199
daltons C 91 199
) C 92 199
. C 93 199
dna C 95 199
of C 96 199
this C 97 199
molecular C 98 199
weight C 99 199
, C 100 199
but C 101 199
not C 102 199
half C 103 199
pieces C 104 199
, C 105 199
is C 106 199
infective C 107 199
in C 108 199
competent C 109 199
b C 110 199
. C 111 199
subtilis C 113 199
. C 114 199
the C 116 199
response C 117 199
of C 118 199
plaque C 119 199
- C 120 199
forming C 121 199
ability C 122 199
to C 123 199
dna C 124 199
concentration C 125 199
suggests C 126 199
that C 127 199
four C 128 199
whole C 129 199
molecules C 130 199
are C 131 199
required C 132 199
to C 133 199
initiate C 134 199
an C 135 199
infective C 136 199
center C 137 199
. C 138 199
recombination C 140 199
studies C 141 199
with C 142 199
mixed C 143 199
dna C 144 199
' C 145 199
s C 146 199
of C 147 199
two C 148 199
non C 149 199
- C 150 199
allelic C 151 199
temperature C 152 199
- C 153 199
sensitive C 154 199
mutants C 155 199
confirm C 156 199
the C 157 199
existence C 158 199
of C 159 199
an C 160 199
obligatory C 161 199
co C 162 199
- C 163 199
operative C 164 199
infective C 165 199
process C 166 199
. C 167 199
a C 169 199
second C 170 199
infective C 171 199
procedure C 172 199
that C 173 199
utilizes C 174 199
extracted C 175 199
phage C 176 199
dna C 177 199
is C 178 199
described C 179 199
. C 180 199
in C 182 199
this C 183 199
system C 184 199
, C 185 199
low C 186 199
concentrations C 187 199
of C 188 199
wild C 189 199
- C 190 199
type C 191 199
dna C 192 199
are C 193 199
exposed C 194 199
to C 195 199
the C 196 199
cells C 197 199
. C 198 199
at C 200 199
these C 201 199
concentrations C 202 199
the C 203 199
multiple C 204 199
- C 205 199
event C 206 199
nature C 207 199
of C 208 199
phage C 209 199
dna C 210 199
infection C 211 199
precludes C 212 199
the C 213 199
formation C 214 199
of C 215 199
unaided C 216 199
plaques C 217 199
. C 218 199
however C 220 199
, C 221 199
by C 222 199
subsequently C 223 199
superinfecting C 224 199
the C 225 199
dna C 226 199
- C 227 199
infected C 228 199
cells C 229 199
with C 230 199
a C 231 199
temperature C 232 199
- C 233 199
sensitive C 234 199
mutant C 235 199
and C 236 199
plating C 237 199
under C 238 199
selective C 239 199
conditions C 240 199
, C 241 199
genetic C 242 199
rescue C 243 199
of C 244 199
the C 245 199
infecting C 246 199
dna C 247 199
is C 248 199
accomplished C 249 199
and C 250 199
detected C 251 199
. C 252 199
infective C 254 199
centers C 255 199
elicited C 256 199
by C 257 199
this C 258 199
/ C 259 199
marker C 260 199
rescue C 261 199
/ C 262 199
phenomenon C 263 199
are C 264 199
directly C 265 199
proportional C 266 199
to C 267 199
dna C 268 199
concentration C 269 199
. C 270 199
the C 272 199
time C 273 199
of C 274 199
attainment C 275 199
of C 276 199
dnase C 277 199
resistance C 278 199
by C 279 199
phage C 280 199
dna C 281 199
infective C 282 199
centers C 283 199
that C 284 199
have C 285 199
irreversibly C 286 199
adsorbed C 287 199
dna C 288 199
can C 289 199
be C 290 199
measured C 291 199
. C 292 199
phage C 294 199
dna C 295 199
infective C 296 199
centers C 297 199
require C 298 199
at C 299 199
least C 300 199
13 C 301 199
minutes C 302 199
to C 303 199
become C 304 199
totally C 305 199
dnase C 306 199
resistant C 307 199
. C 308 199
the C 310 199
reasons C 311 199
for C 312 199
the C 313 199
failure C 314 199
of C 315 199
single C 316 199
phage C 317 199
dna C 318 199
molecules C 319 199
to C 320 199
carry C 321 199
out C 322 199
an C 323 199
infection C 324 199
are C 325 199
discussed C 326 199
in C 327 199
terms C 328 199
of C 329 199
a C 330 199
specific C 331 199
breakage C 332 199
- C 333 199
reunion C 334 199
psychology C 1 200
of C 2 200
children C 3 200
' C 4 200
s C 5 200
dental C 6 200
treatment C 7 200
. C 8 200
the C 10 200
communication C 11 200
deals C 12 200
with C 13 200
influences C 14 200
involved C 15 200
in C 16 200
the C 17 200
development C 18 200
of C 19 200
the C 20 200
child C 21 200
' C 22 200
s C 23 200
attitude C 24 200
to C 25 200
dental C 26 200
treatment C 27 200
. C 28 200
they C 30 200
are C 31 200
extrinsic C 32 200
( C 33 200
educational C 34 200
etc C 35 200
. C 36 200
) C 38 200
and C 39 200
intrinsic C 40 200
( C 41 200
constitutional C 42 200
and C 43 200
hereditary C 44 200
) C 45 200
. C 46 200
their C 48 200
understanding C 49 200
helps C 50 200
to C 51 200
determine C 52 200
the C 53 200
correct C 54 200
psychological C 55 200
policy C 56 200
for C 57 200
the C 58 200
management C 59 200
of C 60 200
the C 61 200
child C 62 200
in C 63 200
the C 64 200
surgery C 65 200
. C 66 200
the C 68 200
aim C 69 200
of C 70 200
psychology C 71 200
applied C 72 200
in C 73 200
dentistry C 74 200
is C 75 200
to C 76 200
discover C 77 200
a C 78 200
mode C 79 200
of C 80 200
treatment C 81 200
procedure C 82 200
which C 83 200
would C 84 200
ensure C 85 200
that C 86 200
the C 87 200
child C 88 200
will C 89 200
not C 90 200
be C 91 200
subject C 92 200
to C 93 200
any C 94 200
psychic C 95 200
traumatization C 96 200
( C 97 200
psychophylaxis C 98 200
) C 99 200
. C 100 200
its C 102 200
second C 103 200
aim C 104 200
is C 105 200
the C 106 200
management C 107 200
of C 108 200
the C 109 200
so C 110 200
called C 111 200
difficult C 112 200
child C 113 200
and C 114 200
his C 115 200
treatment C 116 200
. C 117 200
to C 119 200
understand C 120 200
better C 121 200
the C 122 200
child C 123 200
' C 124 200
s C 125 200
frame C 126 200
of C 127 200
mind C 128 200
during C 129 200
dental C 130 200
treatment C 131 200
the C 132 200
situation C 133 200
in C 134 200
the C 135 200
surgery C 136 200
is C 137 200
dealt C 138 200
with C 139 200
step C 140 200
by C 141 200
step C 142 200
as C 143 200
the C 144 200
child C 145 200
experiences C 146 200
it C 147 200
through C 148 200
his C 149 200
senses C 150 200
and C 151 200
his C 152 200
psyche C 153 200
. C 154 200
beside C 156 200
the C 157 200
basic C 158 200
senses C 159 200
- C 160 200
dash C 161 200
hearing C 162 200
and C 163 200
seeing C 164 200
- C 165 200
dash C 166 200
others C 167 200
are C 168 200
also C 169 200
affected C 170 200
. C 171 200
. C 173 200
touch C 175 200
( C 176 200
pressure C 177 200
sensation C 178 200
) C 179 200
, C 180 200
smell C 181 200
and C 182 200
taste C 183 200
. C 184 200
children C 186 200
during C 187 200
dental C 188 200
treatment C 189 200
are C 190 200
nearly C 191 200
always C 192 200
in C 193 200
a C 194 200
state C 195 200
of C 196 200
raised C 197 200
emotional C 198 200
tension C 199 200
and C 200 200
are C 201 200
susceptible C 202 200
to C 203 200
anxiety C 204 200
reactions C 205 200
. C 206 200
according C 208 200
to C 209 200
the C 210 200
degree C 211 200
of C 212 200
fear C 213 200
which C 214 200
they C 215 200
manifest C 216 200
children C 217 200
may C 218 200
be C 219 200
classed C 220 200
into C 221 200
categories C 222 200
of C 223 200
cooperating C 224 200
and C 225 200
difficult C 226 200
patients C 227 200
. C 228 200
the C 230 200
psychological C 231 200
procedure C 232 200
for C 233 200
the C 234 200
treatment C 235 200
of C 236 200
children C 237 200
of C 238 200
both C 239 200
groups C 240 200
is C 241 200
based C 242 200
on C 243 200
the C 244 200
principles C 245 200
summarized C 246 200
in C 247 200
the C 248 200
section C 249 200
' C 250 200
psychophylaxis C 251 200
in C 252 200
dentistry C 253 200
' C 254 200
. C 255 200
in C 257 200
difficult C 258 200
children C 259 200
it C 260 200
is C 261 200
often C 262 200
necessary C 263 200
to C 264 200
employ C 265 200
yet C 266 200
other C 267 200
psychological C 268 200
measures C 269 200
- C 270 200
psychotherapy C 271 200
, C 272 200
suggestion C 273 200
etc C 274 200
. C 275 200
in C 277 200
extremely C 278 200
exacting C 279 200
cases C 280 200
premedication C 281 200
helps C 282 200
sometimes C 283 200
to C 284 200
find C 285 200
contact C 286 200
with C 287 200
the C 288 200
child C 289 200
. C 290 200
the C 292 200
experimental C 293 200
part C 294 200
of C 295 200
the C 296 200
work C 297 200
demonstrates C 298 200
the C 299 200
following C 300 200
findings C 301 200
1 C 302 200
. C 303 200
dental C 305 200
treatment C 306 200
consists C 307 200
of C 308 200
a C 309 200
series C 310 200
of C 311 200
interdependent C 312 200
traumatizing C 313 200
impulses C 314 200
. C 315 200
many C 317 200
of C 318 200
them C 319 200
appear C 320 200
only C 321 200
after C 322 200
a C 323 200
close C 324 200
analysis C 325 200
of C 326 200
the C 327 200
situation C 328 200
. C 329 200
2 C 331 200
. C 332 200
the C 334 200
adverse C 335 200
response C 336 200
similar C 337 200
to C 338 200
that C 339 200
elicited C 340 200
by C 341 200
pain C 342 200
may C 343 200
be C 344 200
due C 345 200
also C 346 200
to C 347 200
sensory C 348 200
impressions C 349 200
with C 350 200
a C 351 200
negative C 352 200
emotional C 353 200
background C 354 200
. C 355 200
3 C 357 200
. C 358 200
psychic C 360 200
traumatization C 361 200
of C 362 200
the C 363 200
child C 364 200
during C 365 200
dental C 366 200
treatment C 367 200
can C 368 200
be C 369 200
prevented C 370 200
by C 371 200
relatively C 372 200
simple C 373 200
psychological C 374 200
measures C 375 200
. C 376 200
relation C 1 201
of C 2 201
emotional C 3 201
changes C 4 201
during C 5 201
pregnancy C 6 201
to C 7 201
obstetric C 8 201
complications C 9 201
in C 10 201
unmarried C 11 201
primigravidas C 12 201
. C 13 201
this C 15 201
study C 16 201
was C 17 201
designed C 18 201
to C 19 201
assess C 20 201
the C 21 201
psychological C 22 201
changes C 23 201
experienced C 24 201
by C 25 201
white C 26 201
unmarried C 27 201
primigravidas C 28 201
during C 29 201
pregnancy C 30 201
, C 31 201
the C 32 201
relationship C 33 201
between C 34 201
manifest C 35 201
anxiety C 36 201
and C 37 201
clinical C 38 201
factors C 39 201
such C 40 201
as C 41 201
labor C 42 201
time C 43 201
and C 44 201
mean C 45 201
birth C 46 201
weight C 47 201
, C 48 201
and C 49 201
the C 50 201
personality C 51 201
differences C 52 201
between C 53 201
/ C 54 201
normal C 55 201
/ C 56 201
and C 57 201
/ C 58 201
abnormal C 59 201
/ C 60 201
obstetric C 61 201
cases C 62 201
. C 63 201
the C 65 201
kent C 66 201
egy C 67 201
intelligence C 68 201
scale C 69 201
, C 70 201
the C 71 201
taylor C 72 201
manifest C 73 201
anxiety C 74 201
scale C 75 201
, C 76 201
and C 77 201
the C 78 201
mmpi C 79 201
were C 80 201
administered C 81 201
to C 82 201
160 C 83 201
obstetric C 84 201
patients C 85 201
at C 86 201
the C 87 201
beginning C 88 201
of C 89 201
the C 90 201
third C 91 201
trimester C 92 201
of C 93 201
pregnancy C 94 201
, C 95 201
with C 96 201
the C 97 201
mmpi C 98 201
and C 99 201
taylor C 100 201
being C 101 201
readministered C 102 201
post C 103 201
partum C 104 201
. C 105 201
reliable C 107 201
group C 108 201
personality C 109 201
changes C 110 201
observed C 111 201
from C 112 201
pre C 113 201
- C 114 201
to C 115 201
postdelivery C 116 201
supported C 117 201
the C 118 201
contention C 119 201
that C 120 201
pregnancy C 121 201
is C 122 201
a C 123 201
time C 124 201
of C 125 201
emotional C 126 201
upset C 127 201
. C 128 201
following C 130 201
delivery C 131 201
, C 132 201
each C 133 201
patient C 134 201
was C 135 201
classified C 136 201
as C 137 201
normal C 138 201
or C 139 201
abnormal C 140 201
dependent C 141 201
on C 142 201
the C 143 201
clinical C 144 201
course C 145 201
of C 146 201
parturition C 147 201
, C 148 201
delivery C 149 201
, C 150 201
and C 151 201
condition C 152 201
of C 153 201
the C 154 201
offspring C 155 201
. C 156 201
there C 158 201
were C 159 201
no C 160 201
significant C 161 201
differences C 162 201
between C 163 201
these C 164 201
groups C 165 201
with C 166 201
respect C 167 201
to C 168 201
age C 169 201
or C 170 201
intelligence C 171 201
. C 172 201
reliable C 174 201
differences C 175 201
were C 176 201
found C 177 201
, C 178 201
however C 179 201
, C 180 201
for C 181 201
manifest C 182 201
anxiety C 183 201
and C 184 201
total C 185 201
labor C 186 201
times C 187 201
. C 188 201
in C 190 201
addition C 191 201
, C 192 201
a C 193 201
positive C 194 201
relationship C 195 201
was C 196 201
found C 197 201
between C 198 201
manifest C 199 201
anxiety C 200 201
and C 201 201
birth C 202 201
weights C 203 201
. C 204 201
personality C 206 201
differences C 207 201
found C 208 201
at C 209 201
predelivery C 210 201
between C 211 201
the C 212 201
subgroups C 213 201
were C 214 201
largely C 215 201
attributable C 216 201
to C 217 201
the C 218 201
abnormal C 219 201
group C 220 201
' C 221 201
s C 222 201
greater C 223 201
neuroticism C 224 201
, C 225 201
anxiety C 226 201
, C 227 201
and C 228 201
use C 229 201
of C 230 201
the C 231 201
ruminative C 232 201
ego C 233 201
defenses C 234 201
. C 235 201
post C 237 201
partum C 238 201
, C 239 201
the C 240 201
personality C 241 201
characteristics C 242 201
of C 243 201
the C 244 201
subgroups C 245 201
were C 246 201
quite C 247 201
similar C 248 201
. C 249 201
both C 251 201
groups C 252 201
showed C 253 201
greater C 254 201
personality C 255 201
stability C 256 201
following C 257 201
delivery C 258 201
, C 259 201
with C 260 201
the C 261 201
most C 262 201
striking C 263 201
changes C 264 201
from C 265 201
predelivery C 266 201
demonstrable C 267 201
in C 268 201
the C 269 201
abnormal C 270 201
group C 271 201
. C 272 201
the C 274 201
magnitude C 275 201
of C 276 201
these C 277 201
changes C 278 201
were C 279 201
interpreted C 280 201
as C 281 201
emotional C 282 201
lability C 283 201
and C 284 201
related C 285 201
to C 286 201
obstetric C 287 201
complications C 288 201
by C 289 201
activation C 290 201
of C 291 201
various C 292 201
physiological C 293 201
regulator C 294 201
systems C 295 201
. C 296 201
stranger C 1 202
and C 2 202
separation C 3 202
anxiety C 4 202
in C 5 202
infancy C 6 202
. C 7 202
anxiety C 9 202
responses C 10 202
to C 11 202
strangers C 12 202
and C 13 202
to C 14 202
separations C 15 202
from C 16 202
mother C 17 202
were C 18 202
studied C 19 202
longitudinally C 20 202
in C 21 202
19 C 22 202
infants C 23 202
between C 24 202
the C 25 202
ages C 26 202
of C 27 202
three C 28 202
and C 29 202
23 C 30 202
months C 31 202
by C 32 202
direct C 33 202
observations C 34 202
and C 35 202
by C 36 202
interviews C 37 202
with C 38 202
the C 39 202
mother C 40 202
. C 41 202
benjamin C 43 202
' C 44 202
s C 45 202
hypotheses C 46 202
concerning C 47 202
the C 48 202
differentiation C 49 202
and C 50 202
immediate C 51 202
dynamics C 52 202
of C 53 202
infantile C 54 202
stranger C 55 202
and C 56 202
separation C 57 202
anxiety C 58 202
were C 59 202
supported C 60 202
by C 61 202
the C 62 202
findings C 63 202
. C 64 202
differences C 66 202
in C 67 202
onset C 68 202
, C 69 202
period C 70 202
of C 71 202
highest C 72 202
intensity C 73 202
, C 74 202
termination C 75 202
, C 76 202
and C 77 202
ratios C 78 202
in C 79 202
individuals C 80 202
were C 81 202
found C 82 202
between C 83 202
the C 84 202
two C 85 202
anxieties C 86 202
. C 87 202
tests C 89 202
of C 90 202
the C 91 202
relationship C 92 202
between C 93 202
the C 94 202
two C 95 202
anxieties C 96 202
were C 97 202
supportive C 98 202
of C 99 202
deductive C 100 202
predictions C 101 202
made C 102 202
by C 103 202
benjamin C 104 202
. C 105 202
sex C 107 202
differences C 108 202
in C 109 202
intensity C 110 202
of C 111 202
the C 112 202
two C 113 202
anxieties C 114 202
were C 115 202
found C 116 202
. C 117 202
mental C 1 203
retardation C 2 203
related C 3 203
to C 4 203
hypercalcaemia C 5 203
. C 6 203
for C 8 203
more C 9 203
than C 10 203
20 C 11 203
years C 12 203
a C 13 203
number C 14 203
of C 15 203
retarded C 16 203
children C 17 203
and C 18 203
adolescents C 19 203
have C 20 203
been C 21 203
observed C 22 203
who C 23 203
show C 24 203
points C 25 203
of C 26 203
striking C 27 203
similarity C 28 203
. C 29 203
we C 31 203
recognise C 32 203
in C 33 203
them C 34 203
a C 35 203
well C 36 203
- C 37 203
defined C 38 203
type C 39 203
that C 40 203
is C 41 203
clearly C 42 203
distinguishable C 43 203
from C 44 203
other C 45 203
forms C 46 203
of C 47 203
mental C 48 203
deficiency C 49 203
. C 50 203
they C 52 203
are C 53 203
therefore C 54 203
described C 55 203
in C 56 203
detail C 57 203
. C 58 203
some C 60 203
of C 61 203
the C 62 203
children C 63 203
have C 64 203
had C 65 203
infantile C 66 203
hypercalcaemia C 67 203
but C 68 203
it C 69 203
is C 70 203
assumed C 71 203
that C 72 203
other C 73 203
aetiological C 74 203
factors C 75 203
are C 76 203
also C 77 203
involved C 78 203
. C 79 203
there C 81 203
is C 82 203
a C 83 203
characteristic C 84 203
facies C 85 203
and C 86 203
usually C 87 203
congenital C 88 203
heart C 89 203
disease C 90 203
ordination C 91 203
is C 92 203
poor C 93 203
. C 94 203
there C 96 203
is C 97 203
a C 98 203
constant C 99 203
failure C 100 203
to C 101 203
thrive C 102 203
in C 103 203
infancy C 104 203
, C 105 203
with C 106 203
episodes C 107 203
of C 108 203
vomiting C 109 203
, C 110 203
often C 111 203
with C 112 203
constipation C 113 203
. C 114 203
mentally C 116 203
the C 117 203
children C 118 203
also C 119 203
show C 120 203
great C 121 203
similarities C 122 203
. C 123 203
their C 125 203
iq C 126 203
is C 127 203
about C 128 203
40 C 129 203
- C 130 203
50 C 131 203
but C 132 203
they C 133 203
show C 134 203
outstanding C 135 203
loquacity C 136 203
and C 137 203
a C 138 203
great C 139 203
ability C 140 203
to C 141 203
establish C 142 203
interper C 143 203
- C 144 203
sonal C 145 203
contacts C 146 203
. C 147 203
this C 149 203
stands C 150 203
against C 151 203
a C 152 203
background C 153 203
of C 154 203
insecurity C 155 203
and C 156 203
anxiety C 157 203
. C 158 203
psychological C 1 204
effects C 2 204
of C 3 204
circumcision C 4 204
. C 5 204
in C 7 204
order C 8 204
to C 9 204
evaluate C 10 204
the C 11 204
psychological C 12 204
effects C 13 204
of C 14 204
circumcision C 15 204
, C 16 204
a C 17 204
small C 18 204
study C 19 204
was C 20 204
arranged C 21 204
in C 22 204
which C 23 204
twelve C 24 204
children C 25 204
, C 26 204
from C 27 204
average C 28 204
and C 29 204
low C 30 204
socio C 31 204
- C 32 204
economic C 33 204
level C 34 204
, C 35 204
were C 36 204
given C 37 204
goodenough C 38 204
dam C 39 204
test C 40 204
, C 41 204
cat C 42 204
, C 43 204
rorschach C 44 204
and C 45 204
two C 46 204
sets C 47 204
of C 48 204
stories C 49 204
, C 50 204
prior C 51 204
to C 52 204
the C 53 204
operation C 54 204
and C 55 204
following C 56 204
it C 57 204
. C 58 204
the C 60 204
results C 61 204
of C 62 204
the C 63 204
tests C 64 204
showed C 65 204
that C 66 204
circumcision C 67 204
, C 68 204
performed C 69 204
around C 70 204
the C 71 204
phallic C 72 204
stage C 73 204
is C 74 204
perceived C 75 204
by C 76 204
the C 77 204
child C 78 204
as C 79 204
an C 80 204
act C 81 204
of C 82 204
aggression C 83 204
and C 84 204
castration C 85 204
. C 86 204
it C 88 204
has C 89 204
detrimental C 90 204
effects C 91 204
on C 92 204
the C 93 204
child C 94 204
' C 95 204
s C 96 204
functioning C 97 204
and C 98 204
adaptation C 99 204
, C 100 204
particularly C 101 204
on C 102 204
his C 103 204
ego C 104 204
strength C 105 204
. C 106 204
by C 108 204
weakening C 109 204
the C 110 204
controlling C 111 204
and C 112 204
defensive C 113 204
mechanisms C 114 204
of C 115 204
the C 116 204
ego C 117 204
, C 118 204
and C 119 204
initiating C 120 204
regression C 121 204
, C 122 204
it C 123 204
loosens C 124 204
the C 125 204
previously C 126 204
hidden C 127 204
fears C 128 204
, C 129 204
anxieties C 130 204
, C 131 204
and C 132 204
instinctual C 133 204
impulses C 134 204
, C 135 204
and C 136 204
renders C 137 204
a C 138 204
feeling C 139 204
of C 140 204
reality C 141 204
to C 142 204
them C 143 204
. C 144 204
what C 146 204
is C 147 204
expressed C 148 204
following C 149 204
the C 150 204
operation C 151 204
is C 152 204
primitive C 153 204
, C 154 204
archaic C 155 204
, C 156 204
and C 157 204
unsocialized C 158 204
in C 159 204
character C 160 204
. C 161 204
as C 163 204
a C 164 204
defensive C 165 204
control C 166 204
and C 167 204
protection C 168 204
against C 169 204
the C 170 204
surge C 171 204
of C 172 204
the C 173 204
instinctual C 174 204
forces C 175 204
coming C 176 204
from C 177 204
within C 178 204
and C 179 204
the C 180 204
threats C 181 204
coming C 182 204
from C 183 204
outside C 184 204
, C 185 204
the C 186 204
ego C 187 204
of C 188 204
the C 189 204
child C 190 204
seeks C 191 204
safety C 192 204
in C 193 204
total C 194 204
withdrawal C 195 204
, C 196 204
thus C 197 204
isolates C 198 204
and C 199 204
insulates C 200 204
itself C 201 204
from C 202 204
disturbing C 203 204
stimuli C 204 204
. C 205 204
the C 207 204
results C 208 204
of C 209 204
the C 210 204
study C 211 204
raised C 212 204
some C 213 204
questions C 214 204
concerning C 215 204
certain C 216 204
psychoanalytic C 217 204
formulations C 218 204
, C 219 204
for C 220 204
which C 221 204
further C 222 204
research C 223 204
was C 224 204
suggested C 225 204
. C 226 204
possibilities C 228 204
for C 229 204
future C 230 204
research C 231 204
were C 232 204
also C 233 204
discussed C 234 204
. C 235 204
changes C 1 205
in C 2 205
children C 3 205
' C 4 205
s C 5 205
behavior C 6 205
after C 7 205
hospitalization C 8 205
some C 9 205
dimensions C 10 205
of C 11 205
response C 12 205
and C 13 205
their C 14 205
correlates C 15 205
. C 16 205
changes C 18 205
in C 19 205
387 C 20 205
children C 21 205
' C 22 205
s C 23 205
behavior C 24 205
following C 25 205
hospitalization C 26 205
were C 27 205
evaluated C 28 205
by C 29 205
means C 30 205
of C 31 205
a C 32 205
questionnaire C 33 205
sent C 34 205
to C 35 205
parents C 36 205
a C 37 205
week C 38 205
after C 39 205
discharge C 40 205
. C 41 205
factor C 43 205
analyses C 44 205
revealed C 45 205
that C 46 205
children C 47 205
' C 48 205
s C 49 205
responses C 50 205
to C 51 205
hospitalization C 52 205
and C 53 205
illness C 54 205
were C 55 205
of C 56 205
six C 57 205
types C 58 205
. C 59 205
. C 61 205
( C 63 205
i C 64 205
) C 65 205
general C 66 205
anxiety C 67 205
and C 68 205
regression C 69 205
, C 70 205
( C 71 205
ii C 72 205
) C 73 205
separation C 74 205
anxiety C 75 205
, C 76 205
( C 77 205
iii C 78 205
) C 79 205
anxiety C 80 205
about C 81 205
sleep C 82 205
, C 83 205
( C 84 205
iv C 85 205
) C 86 205
eating C 87 205
disturbance C 88 205
, C 89 205
( C 90 205
v C 91 205
) C 92 205
aggression C 93 205
toward C 94 205
authority C 95 205
, C 96 205
and C 97 205
( C 98 205
vi C 99 205
) C 100 205
apathy C 101 205
- C 102 205
withdrawal C 103 205
. C 104 205
scores C 106 205
for C 107 205
these C 108 205
six C 109 205
factors C 110 205
( C 111 205
types C 112 205
of C 113 205
responses C 114 205
) C 115 205
as C 116 205
well C 117 205
as C 118 205
a C 119 205
total C 120 205
score C 121 205
, C 122 205
were C 123 205
analyzed C 124 205
by C 125 205
univariate C 126 205
and C 127 205
, C 128 205
in C 129 205
most C 130 205
cases C 131 205
, C 132 205
multivariate C 133 205
analyses C 134 205
of C 135 205
variance C 136 205
. C 137 205
four C 139 205
variables C 140 205
- C 141 205
dash C 142 205
sex C 143 205
, C 144 205
prior C 145 205
hospitalization C 146 205
, C 147 205
degree C 148 205
of C 149 205
pain C 150 205
experienced C 151 205
during C 152 205
hospitalization C 153 205
, C 154 205
and C 155 205
birth C 156 205
order C 157 205
- C 158 205
dash C 159 205
were C 160 205
essentially C 161 205
unrelated C 162 205
to C 163 205
any C 164 205
type C 165 205
of C 166 205
response C 167 205
by C 168 205
any C 169 205
analysis C 170 205
. C 171 205
age C 173 205
, C 174 205
duration C 175 205
of C 176 205
hospitalization C 177 205
, C 178 205
and C 179 205
occupational C 180 205
status C 181 205
were C 182 205
each C 183 205
significantly C 184 205
related C 185 205
to C 186 205
one C 187 205
or C 188 205
more C 189 205
types C 190 205
of C 191 205
responses C 192 205
. C 193 205
comparison C 195 205
of C 196 205
the C 197 205
mean C 198 205
factor C 199 205
and C 200 205
total C 201 205
scores C 202 205
for C 203 205
the C 204 205
full C 205 205
sample C 206 205
with C 207 205
the C 208 205
levels C 209 205
indicative C 210 205
of C 211 205
no C 212 205
overall C 213 205
change C 214 205
indicated C 215 205
that C 216 205
the C 217 205
combination C 218 205
of C 219 205
illness C 220 205
and C 221 205
hospitalization C 222 205
is C 223 205
a C 224 205
psychologically C 225 205
upsetting C 226 205
experience C 227 205
for C 228 205
children C 229 205
in C 230 205
general C 231 205
, C 232 205
resulting C 233 205
in C 234 205
increased C 235 205
separation C 236 205
anxiety C 237 205
, C 238 205
increased C 239 205
sleep C 240 205
anxiety C 241 205
, C 242 205
and C 243 205
increased C 244 205
aggression C 245 205
toward C 246 205
authority C 247 205
. C 248 205
isozymes C 1 206
of C 2 206
lactic C 3 206
dehydrogenase C 4 206
. C 5 206
. C 7 206
sequential C 9 206
alterations C 10 206
during C 11 206
development C 12 206
. C 13 206
applications C 15 206
of C 16 206
isozymes C 17 206
in C 18 206
various C 19 206
biological C 20 206
contexts C 21 206
have C 22 206
been C 23 206
reviewed C 24 206
. C 25 206
diagnosis C 27 206
of C 28 206
several C 29 206
disease C 30 206
states C 31 206
has C 32 206
been C 33 206
facilitated C 34 206
by C 35 206
examination C 36 206
of C 37 206
the C 38 206
serum C 39 206
isozyme C 40 206
pattern C 41 206
which C 42 206
has C 43 206
been C 44 206
shown C 45 206
to C 46 206
correlate C 47 206
in C 48 206
some C 49 206
conditions C 50 206
with C 51 206
the C 52 206
isozyme C 53 206
pattern C 54 206
of C 55 206
pathologically C 56 206
involved C 57 206
tissues C 58 206
. C 59 206
physico C 61 206
- C 62 206
chemical C 63 206
studies C 64 206
of C 65 206
human C 66 206
ldh C 67 206
isozymes C 68 206
have C 69 206
revealed C 70 206
differences C 71 206
among C 72 206
isozymes C 73 206
in C 74 206
affinity C 75 206
for C 76 206
a C 77 206
given C 78 206
substrate C 79 206
. C 80 206
comparative C 82 206
studies C 83 206
of C 84 206
ldh C 85 206
isozymes C 86 206
within C 87 206
the C 88 206
erythrocyte C 89 206
from C 90 206
various C 91 206
vertebrate C 92 206
species C 93 206
demonstrated C 94 206
a C 95 206
marked C 96 206
species C 97 206
variation C 98 206
in C 99 206
the C 100 206
number C 101 206
of C 102 206
ldh C 103 206
isozymes C 104 206
, C 105 206
in C 106 206
the C 107 206
distribution C 108 206
of C 109 206
total C 110 206
ldh C 111 206
activity C 112 206
among C 113 206
them C 114 206
, C 115 206
and C 116 206
in C 117 206
their C 118 206
electrophoretic C 119 206
mobilities C 120 206
. C 121 206
during C 123 206
development C 124 206
of C 125 206
chick C 126 206
, C 127 206
rabbit C 128 206
, C 129 206
and C 130 206
human C 131 206
tissues C 132 206
characteristic C 133 206
sequential C 134 206
alterations C 135 206
in C 136 206
the C 137 206
ldh C 138 206
isozyme C 139 206
pattern C 140 206
occurred C 141 206
and C 142 206
consisted C 143 206
for C 144 206
liver C 145 206
and C 146 206
muscle C 147 206
in C 148 206
loss C 149 206
of C 150 206
the C 151 206
most C 152 206
rapidly C 153 206
migrating C 154 206
anodal C 155 206
bands C 156 206
and C 157 206
increased C 158 206
activity C 159 206
in C 160 206
the C 161 206
cathodal C 162 206
bands C 163 206
and C 164 206
slower C 165 206
migrating C 166 206
anodal C 167 206
bands C 168 206
. C 169 206
in C 171 206
heart C 172 206
the C 173 206
reverse C 174 206
changes C 175 206
were C 176 206
observed C 177 206
. C 178 206
if C 180 206
high C 181 206
enough C 182 206
ldh C 183 206
activities C 184 206
of C 185 206
early C 186 206
fetal C 187 206
tissue C 188 206
extracts C 189 206
were C 190 206
applied C 191 206
to C 192 206
the C 193 206
gel C 194 206
the C 195 206
full C 196 206
complement C 197 206
of C 198 206
ldh C 199 206
isozymes C 200 206
was C 201 206
observed C 202 206
, C 203 206
. C 204 206
however C 206 206
, C 207 206
in C 208 206
lower C 209 206
concentrations C 210 206
the C 211 206
cathodal C 212 206
bands C 213 206
, C 214 206
which C 215 206
in C 216 206
the C 217 206
starch C 218 206
gel C 219 206
disappear C 220 206
more C 221 206
rapidly C 222 206
on C 223 206
dilution C 224 206
than C 225 206
do C 226 206
the C 227 206
anodal C 228 206
bands C 229 206
, C 230 206
were C 231 206
not C 232 206
observed C 233 206
. C 234 206
a C 236 206
species C 237 206
- C 238 206
specific C 239 206
isozyme C 240 206
pattern C 241 206
is C 242 206
obtained C 243 206
in C 244 206
long C 245 206
term C 246 206
culture C 247 206
of C 248 206
rabbit C 249 206
, C 250 206
chick C 251 206
, C 252 206
and C 253 206
human C 254 206
cells C 255 206
. C 256 206
independently C 258 206
of C 259 206
the C 260 206
tissue C 261 206
of C 262 206
origin C 263 206
, C 264 206
there C 265 206
occurs C 266 206
in C 267 206
cells C 268 206
in C 269 206
culture C 270 206
a C 271 206
sequential C 272 206
series C 273 206
of C 274 206
isozyme C 275 206
alterations C 276 206
characterized C 277 206
by C 278 206
decreased C 279 206
intensity C 280 206
of C 281 206
rapidly C 282 206
migrating C 283 206
anodal C 284 206
bands C 285 206
. C 286 206
the C 288 206
shift C 289 206
toward C 290 206
prominence C 291 206
of C 292 206
cathodal C 293 206
isozymes C 294 206
during C 295 206
both C 296 206
fetal C 297 206
development C 298 206
and C 299 206
tissue C 300 206
culture C 301 206
can C 302 206
be C 303 206
explained C 304 206
by C 305 206
postulating C 306 206
the C 307 206
increased C 308 206
activity C 309 206
of C 310 206
the C 311 206
gene C 312 206
producing C 313 206
one C 314 206
of C 315 206
the C 316 206
subunits C 317 206
of C 318 206
ldh C 319 206
with C 320 206
a C 321 206
concomitant C 322 206
decrease C 323 206
in C 324 206
the C 325 206
activity C 326 206
of C 327 206
the C 328 206
gene C 329 206
producing C 330 206
the C 331 206
second C 332 206
subunit C 333 206
. C 334 206
practical C 336 206
applications C 337 206
of C 338 206
the C 339 206
study C 340 206
of C 341 206
isozymes C 342 206
in C 343 206
tissue C 344 206
culture C 345 206
were C 346 206
discussed C 347 206
. C 348 206
establishment C 1 207
of C 2 207
a C 3 207
cell C 4 207
line C 5 207
in C 6 207
vitro C 7 207
from C 8 207
a C 9 207
case C 10 207
of C 11 207
human C 12 207
lung C 13 207
cancer C 14 207
. C 15 207
1 C 17 207
) C 18 207
one C 19 207
cell C 20 207
line C 21 207
has C 22 207
been C 23 207
established C 24 207
from C 25 207
the C 26 207
pneumonectomized C 27 207
specimen C 28 207
of C 29 207
a C 30 207
case C 31 207
with C 32 207
lung C 33 207
cancer C 34 207
, C 35 207
which C 36 207
was C 37 207
diagnosed C 38 207
as C 39 207
undifferentiated C 40 207
cell C 41 207
carcinoma C 42 207
and C 43 207
partially C 44 207
adenocarcinoma C 45 207
by C 46 207
its C 47 207
histological C 48 207
findings C 49 207
and C 50 207
was C 51 207
characterized C 52 207
with C 53 207
intracytoplasmic C 54 207
fat C 55 207
droplets C 56 207
in C 57 207
them C 58 207
. C 59 207
2 C 61 207
) C 62 207
the C 63 207
morphological C 64 207
changes C 65 207
of C 66 207
the C 67 207
cells C 68 207
were C 69 207
repeated C 70 207
but C 71 207
they C 72 207
have C 73 207
been C 74 207
stabilized C 75 207
to C 76 207
their C 77 207
epithelial C 78 207
shapes C 79 207
after C 80 207
the C 81 207
35 C 82 207
th C 83 207
transfer C 84 207
. C 85 207
the C 87 207
cell C 88 207
atypy C 89 207
of C 90 207
the C 91 207
culture C 92 207
was C 93 207
remarkable C 94 207
. C 95 207
phagocytosis C 97 207
of C 98 207
the C 99 207
cell C 100 207
line C 101 207
has C 102 207
not C 103 207
been C 104 207
observed C 105 207
. C 106 207
it C 108 207
was C 109 207
characterized C 110 207
that C 111 207
the C 112 207
intracytoplasmic C 113 207
droplets C 114 207
found C 115 207
in C 116 207
the C 117 207
original C 118 207
cancer C 119 207
cells C 120 207
have C 121 207
been C 122 207
maintained C 123 207
in C 124 207
the C 125 207
cultured C 126 207
cells C 127 207
, C 128 207
even C 129 207
in C 130 207
their C 131 207
mitotic C 132 207
stage C 133 207
, C 134 207
throughout C 135 207
the C 136 207
cultural C 137 207
course C 138 207
. C 139 207
3 C 141 207
) C 142 207
concerning C 143 207
the C 144 207
chromosomal C 145 207
constitution C 146 207
diploid C 147 207
cells C 148 207
were C 149 207
only C 150 207
15 C 151 207
per C 152 207
cent C 153 207
. C 154 207
the C 156 207
range C 157 207
of C 158 207
chromosome C 159 207
number C 160 207
did C 161 207
not C 162 207
show C 163 207
sharp C 164 207
peak C 165 207
, C 166 207
forming C 167 207
two C 168 207
groups C 169 207
of C 170 207
near C 171 207
diploid C 172 207
and C 173 207
near C 174 207
tetraploid C 175 207
ranges C 176 207
. C 177 207
4 C 179 207
) C 180 207
transplanting C 181 207
the C 182 207
cell C 183 207
to C 184 207
cheekpouches C 185 207
of C 186 207
golden C 187 207
hamsters C 188 207
, C 189 207
the C 190 207
implanted C 191 207
cells C 192 207
grew C 193 207
from C 194 207
the C 195 207
inoculum C 196 207
of C 197 207
10 C 198 207
cells C 199 207
in C 200 207
conditioned C 201 207
animal C 202 207
but C 203 207
did C 204 207
not C 205 207
show C 206 207
the C 207 207
invasiveness C 208 207
to C 209 207
neighbour C 210 207
tissue C 211 207
and C 212 207
metastasis C 213 207
to C 214 207
other C 215 207
organs C 216 207
. C 217 207
factors C 1 208
influencing C 2 208
development C 3 208
of C 4 208
tumors C 5 208
in C 6 208
frogs C 7 208
. C 8 208
( C 10 208
1 C 11 208
) C 12 208
study C 13 208
of C 14 208
75 C 15 208
spontaneous C 16 208
tumors C 17 208
of C 18 208
vermont C 19 208
frogs C 20 208
showed C 21 208
three C 22 208
pathological C 23 208
grades C 24 208
of C 25 208
malignancy C 26 208
present C 27 208
. C 28 208
. C 30 208
aggressive C 32 208
renal C 33 208
adenocarcinoma C 34 208
in C 35 208
some C 36 208
30 C 37 208
per C 38 208
cent C 39 208
, C 40 208
medium C 41 208
adenocarcinoma C 42 208
in C 43 208
50 C 44 208
per C 45 208
cent C 46 208
, C 47 208
and C 48 208
lower C 49 208
grade C 50 208
mixed C 51 208
with C 52 208
tumors C 53 208
of C 54 208
undetermined C 55 208
origin C 56 208
in C 57 208
the C 58 208
remaining C 59 208
20 C 60 208
per C 61 208
cent C 62 208
. C 63 208
( C 65 208
2 C 66 208
) C 67 208
correlation C 68 208
with C 69 208
parasite C 70 208
infections C 71 208
( C 72 208
trematodes C 73 208
) C 74 208
was C 75 208
demonstrable C 76 208
in C 77 208
only C 78 208
few C 79 208
cases C 80 208
in C 81 208
the C 82 208
kidney C 83 208
. C 84 208
hyperplasias C 86 208
and C 87 208
neoplasias C 88 208
grading C 89 208
into C 90 208
lung C 91 208
primary C 92 208
carcinoma C 93 208
have C 94 208
been C 95 208
found C 96 208
in C 97 208
the C 98 208
lung C 99 208
in C 100 208
r C 101 208
. C 102 208
pipiens C 104 208
. C 105 208
temperatures C 107 208
below C 108 208
15 C 109 208
c C 110 208
. C 111 208
protected C 113 208
animals C 114 208
from C 115 208
lung C 116 208
as C 117 208
well C 118 208
as C 119 208
kidney C 120 208
disease C 121 208
. C 122 208
higher C 124 208
temperatures C 125 208
disturbed C 126 208
the C 127 208
host C 128 208
- C 129 208
parasite C 130 208
relationships C 131 208
and C 132 208
led C 133 208
to C 134 208
higher C 135 208
incidence C 136 208
of C 137 208
malignancy C 138 208
. C 139 208
in C 141 208
the C 142 208
bullfrog C 143 208
, C 144 208
precancer C 145 208
was C 146 208
clearly C 147 208
associated C 148 208
with C 149 208
the C 150 208
worm C 151 208
attachment C 152 208
discs C 153 208
. C 154 208
( C 156 208
3 C 157 208
) C 158 208
other C 159 208
histological C 160 208
types C 161 208
of C 162 208
tumors C 163 208
in C 164 208
vermont C 165 208
frogs C 166 208
included C 167 208
lymphosarcomas C 168 208
, C 169 208
liposarcoma C 170 208
, C 171 208
mesothelioma C 172 208
, C 173 208
epithelioma C 174 208
, C 175 208
and C 176 208
adrenal C 177 208
and C 178 208
cartilage C 179 208
tumors C 180 208
of C 181 208
uncertain C 182 208
malignancy C 183 208
. C 184 208
( C 186 208
4 C 187 208
) C 188 208
improved C 189 208
methods C 190 208
of C 191 208
obtaining C 192 208
tumor C 193 208
filtrates C 194 208
allowed C 195 208
greater C 196 208
probability C 197 208
of C 198 208
inducing C 199 208
malignancy C 200 208
with C 201 208
direct C 202 208
renal C 203 208
injection C 204 208
. C 205 208
in C 207 208
106 C 208 208
frogs C 209 208
37 C 210 208
per C 211 208
cent C 212 208
developed C 213 208
histologically C 214 208
provable C 215 208
cancers C 216 208
in C 217 208
the C 218 208
ranges C 219 208
of C 220 208
three C 221 208
to C 222 208
seven C 223 208
months C 224 208
. C 225 208
twenty C 227 208
- C 228 208
six C 229 208
per C 230 208
cent C 231 208
showed C 232 208
some C 233 208
pre C 234 208
- C 235 208
cancer C 236 208
response C 237 208
and C 238 208
43 C 239 208
per C 240 208
cent C 241 208
were C 242 208
negative C 243 208
. C 244 208
within C 246 208
the C 247 208
series C 248 208
receiving C 249 208
filtrate C 250 208
from C 251 208
high C 252 208
malignancy C 253 208
donors C 254 208
one C 255 208
group C 256 208
yielded C 257 208
100 C 258 208
per C 259 208
cent C 260 208
positive C 261 208
, C 262 208
the C 263 208
others C 264 208
50 C 265 208
and C 266 208
38 C 267 208
per C 268 208
cent C 269 208
, C 270 208
respectively C 271 208
. C 272 208
( C 274 208
5 C 275 208
) C 276 208
among C 277 208
animals C 278 208
injected C 279 208
with C 280 208
/ C 281 208
low C 282 208
/ C 283 208
malignancy C 284 208
filtrate C 285 208
, C 286 208
fewer C 287 208
tumors C 288 208
resulted C 289 208
. C 290 208
some C 292 208
of C 293 208
these C 294 208
were C 295 208
clearly C 296 208
vesicular C 297 208
carcinomas C 298 208
and C 299 208
could C 300 208
be C 301 208
classed C 302 208
as C 303 208
lung C 304 208
tumors C 305 208
. C 306 208
( C 308 208
6 C 309 208
) C 310 208
improved C 311 208
tissue C 312 208
culture C 313 208
methods C 314 208
allowed C 315 208
explants C 316 208
to C 317 208
live C 318 208
in C 319 208
liquid C 320 208
media C 321 208
under C 322 208
perforated C 323 208
cellophane C 324 208
up C 325 208
to C 326 208
one C 327 208
year C 328 208
. C 329 208
slower C 331 208
growth C 332 208
, C 333 208
aided C 334 208
by C 335 208
lower C 336 208
temperatures C 337 208
( C 338 208
16 C 339 208
c C 340 208
. C 341 208
) C 343 208
improved C 344 208
the C 345 208
microecology C 346 208
of C 347 208
cell C 348 208
types C 349 208
and C 350 208
allowed C 351 208
detailed C 352 208
daily C 353 208
observations C 354 208
of C 355 208
each C 356 208
cell C 357 208
' C 358 208
s C 359 208
intranuclear C 360 208
and C 361 208
intranucleolar C 362 208
physiology C 363 208
for C 364 208
extended C 365 208
time C 366 208
- C 367 208
lapse C 368 208
cine C 369 208
- C 370 208
photography C 371 208
. C 372 208
( C 374 208
7 C 375 208
) C 376 208
mechanisms C 377 208
for C 378 208
malignant C 379 208
transformation C 380 208
are C 381 208
related C 382 208
to C 383 208
increased C 384 208
activity C 385 208
and C 386 208
production C 387 208
of C 388 208
nucleolar C 389 208
dna C 390 208
and C 391 208
rna C 392 208
. C 393 208
the C 395 208
infective C 396 208
dna C 397 208
hypothesis C 398 208
is C 399 208
not C 400 208
classical C 401 208
virus C 402 208
theory C 403 208
, C 404 208
but C 405 208
it C 406 208
does C 407 208
offer C 408 208
detailed C 409 208
support C 410 208
. C 411 208
mitotic C 1 209
lymphocytes C 2 209
in C 3 209
primary C 4 209
tissue C 5 209
cultures C 6 209
of C 7 209
normal C 8 209
and C 9 209
neoplastic C 10 209
human C 11 209
lung C 12 209
. C 13 209
normal C 15 209
and C 16 209
tumor C 17 209
tissue C 18 209
explants C 19 209
from C 20 209
33 C 21 209
resected C 22 209
human C 23 209
lungs C 24 209
were C 25 209
studied C 26 209
in C 27 209
vitro C 28 209
. C 29 209
lymphocyte C 31 209
mitoses C 32 209
were C 33 209
observed C 34 209
in C 35 209
tissue C 36 209
cultures C 37 209
derived C 38 209
from C 39 209
12 C 40 209
of C 41 209
the C 42 209
lungs C 43 209
. C 44 209
the C 46 209
ability C 47 209
of C 48 209
lymphocytes C 49 209
to C 50 209
undergo C 51 209
mitotic C 52 209
division C 53 209
in C 54 209
human C 55 209
lung C 56 209
tissue C 57 209
culture C 58 209
has C 59 209
not C 60 209
been C 61 209
reported C 62 209
previously C 63 209
. C 64 209
in C 66 209
the C 67 209
autologous C 68 209
systems C 69 209
used C 70 209
lymphocyte C 71 209
mitoses C 72 209
were C 73 209
much C 74 209
more C 75 209
common C 76 209
in C 77 209
cellular C 78 209
outgrowths C 79 209
derived C 80 209
from C 81 209
non C 82 209
- C 83 209
neoplastic C 84 209
tissue C 85 209
than C 86 209
they C 87 209
were C 88 209
in C 89 209
the C 90 209
outgrowths C 91 209
derived C 92 209
from C 93 209
cancer C 94 209
- C 95 209
bearing C 96 209
explants C 97 209
. C 98 209
no C 100 209
differences C 101 209
were C 102 209
observed C 103 209
in C 104 209
the C 105 209
total C 106 209
number C 107 209
of C 108 209
nondividing C 109 209
lymphocytes C 110 209
present C 111 209
in C 112 209
the C 113 209
non C 114 209
- C 115 209
neoplastic C 116 209
and C 117 209
neoplastic C 118 209
preparations C 119 209
. C 120 209
the C 122 209
in C 123 209
ritro C 124 209
systems C 125 209
employed C 126 209
are C 127 209
promising C 128 209
tools C 129 209
for C 130 209
further C 131 209
contributions C 132 209
to C 133 209
an C 134 209
already C 135 209
well C 136 209
established C 137 209
clinicopathologic C 138 209
relationship C 139 209
between C 140 209
lymphocytes C 141 209
and C 142 209
cancer C 143 209
cells C 144 209
. C 145 209
phase C 147 209
contrast C 148 209
and C 149 209
time C 150 209
- C 151 209
lapse C 152 209
cinephotomicrographic C 153 209
records C 154 209
were C 155 209
obtained C 156 209
of C 157 209
the C 158 209
mitotic C 159 209
process C 160 209
and C 161 209
special C 162 209
attention C 163 209
was C 164 209
paid C 165 209
to C 166 209
the C 167 209
structural C 168 209
details C 169 209
. C 170 209
certain C 172 209
findings C 173 209
were C 174 209
of C 175 209
particular C 176 209
interest C 177 209
, C 178 209
namely C 179 209
the C 180 209
formation C 181 209
of C 182 209
a C 183 209
dense C 184 209
chromatin C 185 209
ring C 186 209
during C 187 209
telophase C 188 209
, C 189 209
the C 190 209
variable C 191 209
occurrence C 192 209
of C 193 209
cytoplasmic C 194 209
bubbling C 195 209
, C 196 209
and C 197 209
the C 198 209
death C 199 209
of C 200 209
lymphocytes C 201 209
during C 202 209
early C 203 209
metaphase C 204 209
( C 205 209
/ C 206 209
exploding C 207 209
/ C 208 209
metaphase C 209 209
) C 210 209
. C 211 209
an C 213 209
elaboration C 214 209
and C 215 209
discussion C 216 209
of C 217 209
these C 218 209
findings C 219 209
have C 220 209
been C 221 209
presented C 222 209
. C 223 209
studies C 1 210
on C 2 210
transformation C 3 210
of C 4 210
syrian C 5 210
hamster C 6 210
cells C 7 210
by C 8 210
simian C 9 210
virus C 10 210
40 C 11 210
( C 12 210
sv C 13 210
40 C 14 210
) C 15 210
. C 16 210
. C 18 210
acquisition C 20 210
of C 21 210
oncogenicity C 22 210
by C 23 210
virus C 24 210
- C 25 210
exposed C 26 210
cells C 27 210
apparently C 28 210
unassociated C 29 210
with C 30 210
the C 31 210
viral C 32 210
genome C 33 210
. C 34 210
lines C 36 210
of C 37 210
syrian C 38 210
hamster C 39 210
lung C 40 210
and C 41 210
liver C 42 210
cells C 43 210
originally C 44 210
exposed C 45 210
as C 46 210
primary C 47 210
cultures C 48 210
to C 49 210
large C 50 210
doses C 51 210
of C 52 210
sv C 53 210
40 C 54 210
exhibited C 55 210
increased C 56 210
growth C 57 210
rate C 58 210
, C 59 210
high C 60 210
plating C 61 210
efficiency C 62 210
, C 63 210
morphological C 64 210
transformation C 65 210
, C 66 210
and C 67 210
, C 68 210
in C 69 210
some C 70 210
instances C 71 210
, C 72 210
oncogenic C 73 210
potential C 74 210
after C 75 210
unusually C 76 210
long C 77 210
intervals C 78 210
. C 79 210
in C 81 210
at C 82 210
least C 83 210
two C 84 210
lines C 85 210
acquisition C 86 210
of C 87 210
oncogenic C 88 210
potential C 89 210
occurred C 90 210
independently C 91 210
of C 92 210
morphological C 93 210
transformation C 94 210
. C 95 210
in C 97 210
none C 98 210
of C 99 210
a C 100 210
total C 101 210
of C 102 210
11 C 103 210
cell C 104 210
lines C 105 210
studied C 106 210
in C 107 210
detail C 108 210
was C 109 210
conclusive C 110 210
evidence C 111 210
for C 112 210
the C 113 210
presence C 114 210
of C 115 210
the C 116 210
sv C 117 210
40 C 118 210
genome C 119 210
obtained C 120 210
. C 121 210
eye C 1 211
and C 2 211
kidney C 3 211
tissue C 4 211
reactions C 5 211
to C 6 211
heterologous C 7 211
anti C 8 211
- C 9 211
uveal C 10 211
antibodies C 11 211
. C 12 211
the C 14 211
uvea C 15 211
, C 16 211
lens C 17 211
capsule C 18 211
and C 19 211
kidney C 20 211
glomerulus C 21 211
in C 22 211
the C 23 211
albino C 24 211
wistar C 25 211
rat C 26 211
have C 27 211
a C 28 211
common C 29 211
antigenic C 30 211
component C 31 211
( C 32 211
s C 33 211
) C 34 211
. C 35 211
the C 37 211
uvea C 38 211
and C 39 211
lens C 40 211
capsule C 41 211
in C 42 211
the C 43 211
pigmented C 44 211
bovine C 45 211
eye C 46 211
also C 47 211
have C 48 211
a C 49 211
common C 50 211
antigenic C 51 211
component C 52 211
( C 53 211
s C 54 211
) C 55 211
. C 56 211
these C 58 211
results C 59 211
were C 60 211
demonstrated C 61 211
by C 62 211
the C 63 211
immunofluorescence C 64 211
technique C 65 211
. C 66 211
the C 68 211
common C 69 211
antigenic C 70 211
sites C 71 211
in C 72 211
the C 73 211
uvea C 74 211
were C 75 211
assumed C 76 211
to C 77 211
be C 78 211
the C 79 211
basement C 80 211
membrane C 81 211
surrounding C 82 211
the C 83 211
vascular C 84 211
trees C 85 211
in C 86 211
the C 87 211
tissues C 88 211
. C 89 211
the C 91 211
possibility C 92 211
of C 93 211
the C 94 211
basement C 95 211
membrane C 96 211
participation C 97 211
as C 98 211
an C 99 211
antigenic C 100 211
source C 101 211
for C 102 211
inducing C 103 211
sympathetic C 104 211
ophthalmia C 105 211
is C 106 211
discussed C 107 211
. C 108 211
experiments C 1 212
dealing C 2 212
with C 3 212
the C 4 212
role C 5 212
played C 6 212
by C 7 212
the C 8 212
aqueous C 9 212
humor C 10 212
and C 11 212
retina C 12 212
in C 13 212
lens C 14 212
regeneration C 15 212
of C 16 212
adult C 17 212
newts C 18 212
. C 19 212
1 C 21 212
. C 22 212
these C 24 212
three C 25 212
groups C 26 212
of C 27 212
experiments C 28 212
involve C 29 212
approximately C 30 212
140 C 31 212
eyes C 32 212
of C 33 212
adult C 34 212
newts C 35 212
, C 36 212
triturus C 37 212
v C 38 212
. C 39 212
viridescens C 41 212
. C 42 212
they C 44 212
were C 45 212
devised C 46 212
to C 47 212
examine C 48 212
what C 49 212
, C 50 212
if C 51 212
any C 52 212
, C 53 212
role C 54 212
the C 55 212
aqueous C 56 212
humor C 57 212
plays C 58 212
during C 59 212
lens C 60 212
regeneration C 61 212
from C 62 212
the C 63 212
dorsal C 64 212
iris C 65 212
. C 66 212
2 C 68 212
. C 69 212
many C 71 212
daily C 72 212
injections C 73 212
of C 74 212
aqueous C 75 212
humor C 76 212
from C 77 212
normal C 78 212
eyes C 79 212
were C 80 212
made C 81 212
in C 82 212
lentectomized C 83 212
eyes C 84 212
for C 85 212
as C 86 212
long C 87 212
as C 88 212
96 C 89 212
days C 90 212
in C 91 212
some C 92 212
cases C 93 212
. C 94 212
as C 96 212
controls C 97 212
some C 98 212
lensless C 99 212
eyes C 100 212
were C 101 212
daily C 102 212
injected C 103 212
with C 104 212
holtfreter C 105 212
' C 106 212
s C 107 212
solution C 108 212
. C 109 212
in C 111 212
others C 112 212
aqueous C 113 212
humor C 114 212
was C 115 212
merely C 116 212
withdrawn C 117 212
. C 118 212
3 C 120 212
) C 121 212
procedures C 122 212
for C 123 212
the C 124 212
injection C 125 212
experiments C 126 212
are C 127 212
difficult C 128 212
to C 129 212
control C 130 212
. C 131 212
however C 133 212
, C 134 212
the C 135 212
most C 136 212
successful C 137 212
cases C 138 212
showed C 139 212
varying C 140 212
degrees C 141 212
of C 142 212
inhibition C 143 212
and C 144 212
retardation C 145 212
of C 146 212
lens C 147 212
regeneration C 148 212
. C 149 212
4 C 151 212
. C 152 212
pairs C 154 212
of C 155 212
eyes C 156 212
were C 157 212
united C 158 212
at C 159 212
large C 160 212
adjacent C 161 212
wound C 162 212
openings C 163 212
to C 164 212
provide C 165 212
a C 166 212
common C 167 212
reservoir C 168 212
of C 169 212
aqueous C 170 212
humor C 171 212
bathing C 172 212
both C 173 212
lenses C 174 212
and C 175 212
dorsal C 176 212
irises C 177 212
. C 178 212
in C 180 212
some C 181 212
cases C 182 212
the C 183 212
eyes C 184 212
were C 185 212
placed C 186 212
on C 187 212
the C 188 212
side C 189 212
of C 190 212
the C 191 212
body C 192 212
. C 193 212
in C 195 212
others C 196 212
more C 197 212
successful C 198 212
unions C 199 212
were C 200 212
made C 201 212
by C 202 212
fusing C 203 212
a C 204 212
transplanted C 205 212
eye C 206 212
to C 207 212
the C 208 212
right C 209 212
eye C 210 212
of C 211 212
a C 212 212
host C 213 212
. C 214 212
5 C 216 212
. C 217 212
approximately C 219 212
three C 220 212
months C 221 212
after C 222 212
operation C 223 212
one C 224 212
of C 225 212
two C 226 212
large C 227 212
lens C 228 212
regenerates C 229 212
in C 230 212
a C 231 212
pair C 232 212
of C 233 212
perfectly C 234 212
fused C 235 212
eyes C 236 212
was C 237 212
removed C 238 212
. C 239 212
six C 241 212
weeks C 242 212
later C 243 212
a C 244 212
new C 245 212
large C 246 212
lens C 247 212
regenerate C 248 212
reappeared C 249 212
in C 250 212
most C 251 212
of C 252 212
the C 253 212
lentectomized C 254 212
units C 255 212
in C 256 212
the C 257 212
presence C 258 212
of C 259 212
the C 260 212
intact C 261 212
lens C 262 212
of C 263 212
the C 264 212
other C 265 212
unit C 266 212
6 C 267 212
. C 268 212
there C 270 212
is C 271 212
a C 272 212
strong C 273 212
possibility C 274 212
that C 275 212
the C 276 212
more C 277 212
than C 278 212
normal C 279 212
amount C 280 212
of C 281 212
neural C 282 212
retina C 283 212
present C 284 212
provided C 285 212
a C 286 212
more C 287 212
powerful C 288 212
retinal C 289 212
factor C 290 212
for C 291 212
lens C 292 212
regeneration C 293 212
than C 294 212
the C 295 212
inhibiting C 296 212
influence C 297 212
of C 298 212
the C 299 212
intact C 300 212
lens C 301 212
in C 302 212
the C 303 212
environment C 304 212
. C 305 212
correlation C 1 213
between C 2 213
the C 3 213
mast C 4 213
cells C 5 213
and C 6 213
histamine C 7 213
content C 8 213
of C 9 213
the C 10 213
eye C 11 213
in C 12 213
cattle C 13 213
. C 14 213
the C 16 213
authors C 17 213
have C 18 213
examined C 19 213
the C 20 213
mast C 21 213
cell C 22 213
content C 23 213
of C 24 213
the C 25 213
eyes C 26 213
of C 27 213
cattle C 28 213
and C 29 213
have C 30 213
established C 31 213
that C 32 213
most C 33 213
of C 34 213
the C 35 213
mast C 36 213
cells C 37 213
are C 38 213
contained C 39 213
in C 40 213
the C 41 213
conjunctiva C 42 213
, C 43 213
the C 44 213
optic C 45 213
nerve C 46 213
and C 47 213
the C 48 213
ocular C 49 213
muscles C 50 213
, C 51 213
. C 52 213
fewer C 54 213
occur C 55 213
in C 56 213
the C 57 213
sclera C 58 213
and C 59 213
iris C 60 213
, C 61 213
and C 62 213
least C 63 213
in C 64 213
the C 65 213
ciliary C 66 213
body C 67 213
and C 68 213
choroid C 69 213
. C 70 213
cornea C 72 213
, C 73 213
lens C 74 213
and C 75 213
retina C 76 213
do C 77 213
not C 78 213
contain C 79 213
mast C 80 213
cells C 81 213
. C 82 213
the C 84 213
histamine C 85 213
content C 86 213
of C 87 213
the C 88 213
ocular C 89 213
tissues C 90 213
and C 91 213
their C 92 213
mast C 93 213
cell C 94 213
contents C 95 213
generally C 96 213
run C 97 213
parallel C 98 213
. C 99 213
however C 101 213
, C 102 213
the C 103 213
cornea C 104 213
is C 105 213
exceptional C 106 213
in C 107 213
that C 108 213
its C 109 213
histamine C 110 213
does C 111 213
not C 112 213
occur C 113 213
in C 114 213
a C 115 213
bound C 116 213
state C 117 213
but C 118 213
in C 119 213
some C 120 213
form C 121 213
which C 122 213
is C 123 213
readily C 124 213
available C 125 213
to C 126 213
a C 127 213
mild C 128 213
process C 129 213
of C 130 213
extraction C 131 213
( C 132 213
tyrode C 133 213
solution C 134 213
at C 135 213
4 C 136 213
c C 137 213
) C 138 213
. C 139 213
studies C 1 214
in C 2 214
sickle C 3 214
cell C 4 214
anemia C 5 214
xxi C 6 214
. C 7 214
clinico C 9 214
- C 10 214
pathological C 11 214
aspects C 12 214
of C 13 214
neurological C 14 214
manifestations C 15 214
. C 16 214
neurologic C 18 214
manifestations C 19 214
are C 20 214
frequent C 21 214
in C 22 214
patients C 23 214
who C 24 214
have C 25 214
sickle C 26 214
cell C 27 214
disease C 28 214
. C 29 214
these C 31 214
manifestations C 32 214
may C 33 214
be C 34 214
the C 35 214
earliest C 36 214
presenting C 37 214
signs C 38 214
and C 39 214
symptoms C 40 214
and C 41 214
they C 42 214
are C 43 214
so C 44 214
variable C 45 214
that C 46 214
the C 47 214
patient C 48 214
may C 49 214
be C 50 214
erroneously C 51 214
diagnosed C 52 214
as C 53 214
having C 54 214
conditions C 55 214
such C 56 214
as C 57 214
meningitis C 58 214
, C 59 214
poliomyelitis C 60 214
, C 61 214
subdural C 62 214
hematoma C 63 214
, C 64 214
neoplasm C 65 214
, C 66 214
subarachnoid C 67 214
hemorrhage C 68 214
, C 69 214
lead C 70 214
encephalitis C 71 214
, C 72 214
subacute C 73 214
bacterial C 74 214
endocarditis C 75 214
, C 76 214
and C 77 214
congenital C 78 214
malformations C 79 214
of C 80 214
the C 81 214
brain C 82 214
. C 83 214
furthermore C 85 214
, C 86 214
development C 87 214
of C 88 214
these C 89 214
manifestations C 90 214
cannot C 91 214
be C 92 214
predicted C 93 214
on C 94 214
the C 95 214
basis C 96 214
of C 97 214
the C 98 214
type C 99 214
of C 100 214
crisis C 101 214
involved C 102 214
. C 103 214
prognosis C 105 214
following C 106 214
neurological C 107 214
involvement C 108 214
is C 109 214
unpredictable C 110 214
, C 111 214
but C 112 214
recurrent C 113 214
episodes C 114 214
, C 115 214
together C 116 214
with C 117 214
abnormal C 118 214
electroencephalographic C 119 214
readings C 120 214
suggest C 121 214
a C 122 214
poor C 123 214
outcome C 124 214
. C 125 214
such C 127 214
patients C 128 214
die C 129 214
or C 130 214
are C 131 214
the C 132 214
victims C 133 214
of C 134 214
rather C 135 214
severe C 136 214
neurological C 137 214
deficits C 138 214
. C 139 214
neurological C 141 214
examination C 142 214
of C 143 214
these C 144 214
patients C 145 214
suggests C 146 214
diffuse C 147 214
involvement C 148 214
of C 149 214
the C 150 214
cerebral C 151 214
hemispheres C 152 214
. C 153 214
examination C 155 214
of C 156 214
the C 157 214
pathological C 158 214
material C 159 214
, C 160 214
however C 161 214
, C 162 214
often C 163 214
fails C 164 214
to C 165 214
reveal C 166 214
thromboses C 167 214
. C 168 214
the C 170 214
striking C 171 214
findings C 172 214
are C 173 214
infarcts C 174 214
in C 175 214
the C 176 214
white C 177 214
matter C 178 214
and C 179 214
perivascular C 180 214
hemorrhages C 181 214
. C 182 214
the C 184 214
thesis C 185 214
that C 186 214
the C 187 214
abnormal C 188 214
neurological C 189 214
findings C 190 214
in C 191 214
these C 192 214
patients C 193 214
are C 194 214
actually C 195 214
due C 196 214
to C 197 214
sickle C 198 214
cell C 199 214
disease C 200 214
is C 201 214
supported C 202 214
by C 203 214
the C 204 214
fact C 205 214
that C 206 214
all C 207 214
such C 208 214
symptoms C 209 214
appear C 210 214
in C 211 214
association C 212 214
with C 213 214
clinical C 214 214
circumstances C 215 214
known C 216 214
to C 217 214
induce C 218 214
sickling C 219 214
. C 220 214
these C 222 214
include C 223 214
surgery C 224 214
and C 225 214
anesthesia C 226 214
, C 227 214
fever C 228 214
and C 229 214
infection C 230 214
. C 231 214
attenuation C 1 215
curves C 2 215
of C 3 215
the C 4 215
human C 5 215
eye C 6 215
under C 7 215
normal C 8 215
and C 9 215
pathological C 10 215
conditions C 11 215
. C 12 215
a C 14 215
method C 15 215
is C 16 215
described C 17 215
which C 18 215
allows C 19 215
the C 20 215
determination C 21 215
of C 22 215
/ C 23 215
attenuation C 24 215
curves C 25 215
/ C 26 215
of C 27 215
the C 28 215
human C 29 215
eye C 30 215
. C 31 215
those C 33 215
curves C 34 215
are C 35 215
obtained C 36 215
by C 37 215
plotting C 38 215
the C 39 215
critical C 40 215
depth C 41 215
of C 42 215
modulation C 43 215
( C 44 215
cmd C 45 215
) C 46 215
as C 47 215
a C 48 215
function C 49 215
of C 50 215
the C 51 215
critical C 52 215
fusion C 53 215
frequency C 54 215
( C 55 215
cff C 56 215
) C 57 215
. C 58 215
routine C 60 215
experiments C 61 215
were C 62 215
carried C 63 215
out C 64 215
for C 65 215
a C 66 215
2 C 67 215
test C 68 215
field C 69 215
showing C 70 215
a C 71 215
sinusoidal C 72 215
periodical C 73 215
variation C 74 215
of C 75 215
its C 76 215
luminance C 77 215
, C 78 215
surrounded C 79 215
by C 80 215
an C 81 215
extensive C 82 215
area C 83 215
with C 84 215
a C 85 215
luminance C 86 215
equal C 87 215
to C 88 215
the C 89 215
average C 90 215
luminance C 91 215
of C 92 215
the C 93 215
test C 94 215
field C 95 215
. C 96 215
attenuation C 98 215
curves C 99 215
were C 100 215
obtained C 101 215
for C 102 215
normal C 103 215
observers C 104 215
under C 105 215
different C 106 215
experimental C 107 215
conditions C 108 215
and C 109 215
for C 110 215
a C 111 215
number C 112 215
of C 113 215
patients C 114 215
. C 115 215
it C 117 215
is C 118 215
shown C 119 215
that C 120 215
this C 121 215
method C 122 215
affords C 123 215
us C 124 215
information C 125 215
which C 126 215
cannot C 127 215
be C 128 215
obtained C 129 215
by C 130 215
means C 131 215
of C 132 215
the C 133 215
classical C 134 215
methods C 135 215
for C 136 215
measuring C 137 215
the C 138 215
cff C 139 215
. C 140 215
central C 1 216
nervous C 2 216
system C 3 216
manifestations C 4 216
of C 5 216
periarteritis C 6 216
nodosa C 7 216
. C 8 216
in C 10 216
the C 11 216
114 C 12 216
cases C 13 216
of C 14 216
pathologically C 15 216
proved C 16 216
periarteritis C 17 216
nodosa C 18 216
reviewed C 19 216
, C 20 216
53 C 21 216
patients C 22 216
( C 23 216
46 C 24 216
percent C 25 216
) C 26 216
had C 27 216
symptoms C 28 216
and C 29 216
signs C 30 216
of C 31 216
central C 32 216
nervous C 33 216
system C 34 216
or C 35 216
cranial C 36 216
nerve C 37 216
involvement C 38 216
. C 39 216
thirty C 41 216
- C 42 216
nine C 43 216
patients C 44 216
had C 45 216
both C 46 216
cerebral C 47 216
manifestations C 48 216
and C 49 216
neuropathy C 50 216
, C 51 216
38 C 52 216
had C 53 216
neuropathy C 54 216
alone C 55 216
, C 56 216
and C 57 216
14 C 58 216
had C 59 216
only C 60 216
cerebral C 61 216
symptoms C 62 216
and C 63 216
signs C 64 216
. C 65 216
the C 67 216
most C 68 216
common C 69 216
cerebral C 70 216
manifestation C 71 216
was C 72 216
that C 73 216
of C 74 216
mental C 75 216
derangement C 76 216
, C 77 216
usually C 78 216
an C 79 216
organic C 80 216
psychosis C 81 216
or C 82 216
confusional C 83 216
state C 84 216
. C 85 216
headache C 87 216
, C 88 216
convulsions C 89 216
, C 90 216
blurred C 91 216
vision C 92 216
, C 93 216
vertigo C 94 216
, C 95 216
and C 96 216
sudden C 97 216
unilateral C 98 216
visual C 99 216
loss C 100 216
were C 101 216
the C 102 216
most C 103 216
common C 104 216
symptoms C 105 216
referable C 106 216
to C 107 216
the C 108 216
central C 109 216
nervous C 110 216
system C 111 216
. C 112 216
the C 114 216
most C 115 216
common C 116 216
abnormalities C 117 216
on C 118 216
examination C 119 216
were C 120 216
retinopathy C 121 216
, C 122 216
hemiparesis C 123 216
, C 124 216
and C 125 216
signs C 126 216
of C 127 216
a C 128 216
brainstem C 129 216
lesion C 130 216
. C 131 216
there C 133 216
was C 134 216
no C 135 216
difference C 136 216
in C 137 216
duration C 138 216
of C 139 216
life C 140 216
, C 141 216
after C 142 216
onset C 143 216
of C 144 216
disease C 145 216
, C 146 216
in C 147 216
those C 148 216
with C 149 216
and C 150 216
those C 151 216
without C 152 216
central C 153 216
nervous C 154 216
system C 155 216
involvement C 156 216
. C 157 216
see C 1 217
- C 2 217
saw C 3 217
nystagmus C 4 217
an C 5 217
unusual C 6 217
sign C 7 217
of C 8 217
lesions C 9 217
near C 10 217
the C 11 217
third C 12 217
ventricle C 13 217
. C 14 217
a C 16 217
case C 17 217
of C 18 217
see C 19 217
- C 20 217
saw C 21 217
nystagmus C 22 217
in C 23 217
a C 24 217
child C 25 217
with C 26 217
craniopharyngioma C 27 217
and C 28 217
bitemporal C 29 217
hemianopsia C 30 217
is C 31 217
described C 32 217
, C 33 217
and C 34 217
reference C 35 217
is C 36 217
made C 37 217
to C 38 217
previous C 39 217
case C 40 217
reports C 41 217
. C 42 217
the C 44 217
basis C 45 217
for C 46 217
this C 47 217
curious C 48 217
sign C 49 217
is C 50 217
not C 51 217
clear C 52 217
, C 53 217
but C 54 217
the C 55 217
site C 56 217
of C 57 217
the C 58 217
lesion C 59 217
must C 60 217
be C 61 217
considered C 62 217
to C 63 217
be C 64 217
in C 65 217
the C 66 217
region C 67 217
of C 68 217
the C 69 217
third C 70 217
ventricle C 71 217
, C 72 217
since C 73 217
bitemporal C 74 217
hemianopsia C 75 217
is C 76 217
a C 77 217
necessary C 78 217
part C 79 217
of C 80 217
the C 81 217
syndrome C 82 217
. C 83 217
the C 85 217
sign C 86 217
is C 87 217
not C 88 217
common C 89 217
but C 90 217
when C 91 217
present C 92 217
points C 93 217
to C 94 217
a C 95 217
lesion C 96 217
near C 97 217
the C 98 217
third C 99 217
ventricle C 100 217
. C 101 217
implications C 1 218
of C 2 218
gerstmann C 3 218
' C 4 218
s C 5 218
syndrome C 6 218
. C 7 218
of C 9 218
465 C 10 218
consecutive C 11 218
patients C 12 218
subjected C 13 218
to C 14 218
a C 15 218
standardized C 16 218
battery C 17 218
of C 18 218
neuropsychological C 19 218
tests C 20 218
, C 21 218
111 C 22 218
had C 23 218
one C 24 218
or C 25 218
more C 26 218
components C 27 218
of C 28 218
gerstmann C 29 218
' C 30 218
s C 31 218
syndrome C 32 218
. C 33 218
each C 35 218
of C 36 218
these C 37 218
111 C 38 218
patients C 39 218
had C 40 218
some C 41 218
evidence C 42 218
of C 43 218
organic C 44 218
brain C 45 218
dysfunction C 46 218
in C 47 218
addition C 48 218
to C 49 218
gerstmann C 50 218
components C 51 218
. C 52 218
as C 54 218
the C 55 218
number C 56 218
of C 57 218
gerstmann C 58 218
components C 59 218
increased C 60 218
, C 61 218
the C 62 218
responsible C 63 218
brain C 64 218
lesions C 65 218
tended C 66 218
to C 67 218
be C 68 218
larger C 69 218
, C 70 218
more C 71 218
highly C 72 218
destructive C 73 218
of C 74 218
tissue C 75 218
, C 76 218
and C 77 218
to C 78 218
cause C 79 218
greater C 80 218
neurological C 81 218
impairment C 82 218
. C 83 218
every C 85 218
patient C 86 218
with C 87 218
four C 88 218
gerstmann C 89 218
components C 90 218
had C 91 218
associated C 92 218
evidence C 93 218
of C 94 218
severe C 95 218
impairment C 96 218
of C 97 218
brain C 98 218
functions C 99 218
and C 100 218
the C 101 218
lesion C 102 218
or C 103 218
underlying C 104 218
disease C 105 218
was C 106 218
likely C 107 218
to C 108 218
compromise C 109 218
survival C 110 218
of C 111 218
the C 112 218
patient C 113 218
. C 114 218
the C 116 218
syndrome C 117 218
is C 118 218
not C 119 218
to C 120 218
be C 121 218
regarded C 122 218
as C 123 218
an C 124 218
autonomous C 125 218
entity C 126 218
, C 127 218
but C 128 218
merges C 129 218
with C 130 218
numerous C 131 218
other C 132 218
neurological C 133 218
deficits C 134 218
, C 135 218
notably C 136 218
dysphasia C 137 218
in C 138 218
agreement C 139 218
with C 140 218
benton C 141 218
, C 142 218
we C 143 218
find C 144 218
no C 145 218
justification C 146 218
for C 147 218
singling C 148 218
out C 149 218
the C 150 218
four C 151 218
gerstmann C 152 218
components C 153 218
as C 154 218
a C 155 218
separate C 156 218
syndrome C 157 218
, C 158 218
unless C 159 218
one C 160 218
is C 161 218
also C 162 218
prepared C 163 218
to C 164 218
recognize C 165 218
that C 166 218
any C 167 218
other C 168 218
arbitrary C 169 218
groups C 170 218
of C 171 218
concurrent C 172 218
deficits C 173 218
are C 174 218
also C 175 218
separate C 176 218
syndromes C 177 218
. C 178 218
in C 180 218
at C 181 218
least C 182 218
three C 183 218
of C 184 218
23 C 185 218
patients C 186 218
with C 187 218
all C 188 218
four C 189 218
gerstmann C 190 218
components C 191 218
, C 192 218
the C 193 218
angular C 194 218
gyrus C 195 218
, C 196 218
as C 197 218
shown C 198 218
by C 199 218
necropsy C 200 218
examination C 201 218
, C 202 218
was C 203 218
not C 204 218
involved C 205 218
by C 206 218
the C 207 218
lesion C 208 218
. C 209 218
however C 211 218
, C 212 218
the C 213 218
probability C 214 218
that C 215 218
the C 216 218
left C 217 218
hemisphere C 218 218
contained C 219 218
a C 220 218
lesion C 221 218
increased C 222 218
with C 223 218
the C 224 218
number C 225 218
of C 226 218
gerstmann C 227 218
components C 228 218
, C 229 218
and C 230 218
the C 231 218
probability C 232 218
of C 233 218
involvement C 234 218
of C 235 218
the C 236 218
left C 237 218
posterior C 238 218
parasylvian C 239 218
area C 240 218
also C 241 218
increased C 242 218
with C 243 218
the C 244 218
increase C 245 218
in C 246 218
the C 247 218
number C 248 218
of C 249 218
gerstmann C 250 218
components C 251 218
. C 252 218
with C 254 218
two C 255 218
, C 256 218
three C 257 218
, C 258 218
or C 259 218
four C 260 218
gerstmann C 261 218
components C 262 218
, C 263 218
the C 264 218
lesions C 265 218
were C 266 218
never C 267 218
restricted C 268 218
to C 269 218
the C 270 218
angular C 271 218
gyrus C 272 218
but C 273 218
tended C 274 218
to C 275 218
spread C 276 218
widely C 277 218
over C 278 218
the C 279 218
parietal C 280 218
, C 281 218
temporal C 282 218
, C 283 218
and C 284 218
occipital C 285 218
lobes C 286 218
. C 287 218
as C 289 218
to C 290 218
localizing C 291 218
significance C 292 218
, C 293 218
gerstmann C 294 218
' C 295 218
s C 296 218
syndrome C 297 218
has C 298 218
approximately C 299 218
the C 300 218
same C 301 218
degree C 302 218
of C 303 218
cogency C 304 218
as C 305 218
dysphasia C 306 218
. C 307 218
alterations C 1 219
of C 2 219
visual C 3 219
evoked C 4 219
response C 5 219
in C 6 219
the C 7 219
presence C 8 219
of C 9 219
homonymous C 10 219
visual C 11 219
defects C 12 219
. C 13 219
the C 15 219
visual C 16 219
evoked C 17 219
response C 18 219
( C 19 219
ver C 20 219
) C 21 219
was C 22 219
studied C 23 219
by C 24 219
means C 25 219
of C 26 219
computer C 27 219
averaging C 28 219
in C 29 219
32 C 30 219
normal C 31 219
subjects C 32 219
, C 33 219
nineteen C 34 219
patients C 35 219
without C 36 219
visual C 37 219
disorder C 38 219
but C 39 219
with C 40 219
unilateral C 41 219
cerebral C 42 219
lesions C 43 219
, C 44 219
and C 45 219
30 C 46 219
patients C 47 219
with C 48 219
homonymous C 49 219
visual C 50 219
field C 51 219
defects C 52 219
. C 53 219
an C 55 219
early C 56 219
negative C 57 219
- C 58 219
positive C 59 219
- C 60 219
negative C 61 219
complex C 62 219
was C 63 219
recorded C 64 219
between C 65 219
laterally C 66 219
placed C 67 219
occipital C 68 219
electrodes C 69 219
and C 70 219
a C 71 219
vertex C 72 219
reference C 73 219
. C 74 219
latencies C 76 219
were C 77 219
prolonged C 78 219
in C 79 219
the C 80 219
hemianopic C 81 219
patients C 82 219
. C 83 219
some C 85 219
amplitude C 86 219
asymmetries C 87 219
were C 88 219
noted C 89 219
in C 90 219
the C 91 219
brain C 92 219
- C 93 219
damaged C 94 219
controls C 95 219
but C 96 219
were C 97 219
more C 98 219
pronounced C 99 219
in C 100 219
patients C 101 219
with C 102 219
visual C 103 219
defects C 104 219
. C 105 219
the C 107 219
recordings C 108 219
in C 109 219
the C 110 219
hemianopic C 111 219
patients C 112 219
were C 113 219
differentiated C 114 219
from C 115 219
those C 116 219
in C 117 219
both C 118 219
control C 119 219
groups C 120 219
by C 121 219
the C 122 219
presence C 123 219
of C 124 219
aberrant C 125 219
wave C 126 219
forms C 127 219
( C 128 219
2 C 129 219
cases C 130 219
) C 131 219
, C 132 219
. C 133 219
prolonged C 135 219
latencies C 136 219
( C 137 219
3 C 138 219
cases C 139 219
) C 140 219
, C 141 219
. C 142 219
and C 144 219
amplitude C 145 219
depression C 146 219
of C 147 219
greater C 148 219
then C 149 219
50 C 150 219
per C 151 219
cent C 152 219
of C 153 219
the C 154 219
positive C 155 219
wave C 156 219
on C 157 219
the C 158 219
abnormal C 159 219
side C 160 219
( C 161 219
16 C 162 219
cases C 163 219
) C 164 219
. C 165 219
pathologic C 167 219
verification C 168 219
was C 169 219
obtained C 170 219
in C 171 219
three C 172 219
patients C 173 219
and C 174 219
demonstrated C 175 219
a C 176 219
correspondence C 177 219
between C 178 219
alterations C 179 219
in C 180 219
the C 181 219
ver C 182 219
and C 183 219
the C 184 219
presence C 185 219
of C 186 219
lesions C 187 219
of C 188 219
the C 189 219
geniculocalcarine C 190 219
system C 191 219
. C 192 219
cerebro C 1 220
- C 2 220
vascular C 3 220
lesions C 4 220
and C 5 220
livedo C 6 220
reticularis C 7 220
. C 8 220
extensive C 10 220
livedo C 11 220
reticularis C 12 220
has C 13 220
been C 14 220
observed C 15 220
in C 16 220
one C 17 220
man C 18 220
and C 19 220
five C 20 220
women C 21 220
who C 22 220
have C 23 220
suffered C 24 220
from C 25 220
a C 26 220
series C 27 220
of C 28 220
cerebrovascular C 29 220
lesions C 30 220
. C 31 220
the C 33 220
neurological C 34 220
disabilities C 35 220
have C 36 220
included C 37 220
aphasia C 38 220
, C 39 220
homonymous C 40 220
hemianopia C 41 220
and C 42 220
hemiplegia C 43 220
but C 44 220
have C 45 220
been C 46 220
remarkable C 47 220
for C 48 220
the C 49 220
degree C 50 220
of C 51 220
recovery C 52 220
which C 53 220
has C 54 220
occurred C 55 220
. C 56 220
it C 58 220
is C 59 220
presumed C 60 220
that C 61 220
the C 62 220
livedo C 63 220
which C 64 220
has C 65 220
been C 66 220
found C 67 220
in C 68 220
only C 69 220
one C 70 220
patient C 71 220
without C 72 220
neurological C 73 220
lesions C 74 220
is C 75 220
related C 76 220
to C 77 220
the C 78 220
cerebrovascular C 79 220
incidents C 80 220
. C 81 220
investigations C 83 220
have C 84 220
failed C 85 220
to C 86 220
show C 87 220
any C 88 220
evidence C 89 220
of C 90 220
polyarteritis C 91 220
nodosa C 92 220
, C 93 220
disseminated C 94 220
lupus C 95 220
erythematosus C 96 220
and C 97 220
thrombocythaemia C 98 220
and C 99 220
an C 100 220
arteritis C 101 220
of C 102 220
unrecognized C 103 220
type C 104 220
is C 105 220
suggested C 106 220
as C 107 220
the C 108 220
etiology C 109 220
. C 110 220
seesaw C 1 221
nystagmus C 2 221
case C 3 221
report C 4 221
elucidating C 5 221
the C 6 221
mechanism C 7 221
. C 8 221
the C 10 221
eighth C 11 221
recorded C 12 221
case C 13 221
of C 14 221
see C 15 221
- C 16 221
saw C 17 221
nystagmus C 18 221
is C 19 221
reported C 20 221
. C 21 221
features C 23 221
in C 24 221
this C 25 221
case C 26 221
are C 27 221
analyzed C 28 221
and C 29 221
evidence C 30 221
to C 31 221
suggest C 32 221
that C 33 221
this C 34 221
form C 35 221
of C 36 221
nystagmus C 37 221
is C 38 221
ocular C 39 221
rather C 40 221
than C 41 221
central C 42 221
in C 43 221
origin C 44 221
is C 45 221
offered C 46 221
. C 47 221
see C 49 221
- C 50 221
saw C 51 221
, C 52 221
nystagmus C 53 221
, C 54 221
unlike C 55 221
true C 56 221
vertical C 57 221
nystagmus C 58 221
, C 59 221
is C 60 221
not C 61 221
of C 62 221
itself C 63 221
indicative C 64 221
of C 65 221
a C 66 221
brain C 67 221
stem C 68 221
lesion C 69 221
. C 70 221
supratentorial C 1 222
paratransversal C 2 222
meningiomas C 3 222
. C 4 222
the C 6 222
author C 7 222
describes C 8 222
6 C 9 222
cases C 10 222
of C 11 222
supratentorial C 12 222
paratransversal C 13 222
meningioma C 14 222
. C 15 222
clinically C 17 222
, C 18 222
the C 19 222
development C 20 222
of C 21 222
these C 22 222
tumours C 23 222
is C 24 222
slow C 25 222
and C 26 222
the C 27 222
chief C 28 222
neurological C 29 222
signs C 30 222
are C 31 222
. C 32 222
. C 34 222
homonymous C 36 222
hemianopia C 37 222
, C 38 222
contralateral C 39 222
hemiparesis C 40 222
and C 41 222
speech C 42 222
disorders C 43 222
when C 44 222
the C 45 222
tumour C 46 222
is C 47 222
on C 48 222
the C 49 222
dominant C 50 222
side C 51 222
radiologically C 52 222
, C 53 222
carotid C 54 222
angiography C 55 222
permits C 56 222
identification C 57 222
of C 58 222
these C 59 222
tumours C 60 222
easily C 61 222
. C 62 222
surgically C 64 222
, C 65 222
the C 66 222
tumours C 67 222
were C 68 222
removed C 69 222
completely C 70 222
and C 71 222
, C 72 222
although C 73 222
in C 74 222
2 C 75 222
cases C 76 222
the C 77 222
transverse C 78 222
sinus C 79 222
had C 80 222
to C 81 222
be C 82 222
resected C 83 222
, C 84 222
this C 85 222
caused C 86 222
no C 87 222
damage C 88 222
. C 89 222
one C 91 222
patient C 92 222
, C 93 222
who C 94 222
was C 95 222
operated C 96 222
on C 97 222
twice C 98 222
and C 99 222
whose C 100 222
histological C 101 222
specimen C 102 222
on C 103 222
the C 104 222
second C 105 222
occasion C 106 222
showed C 107 222
that C 108 222
the C 109 222
meningioma C 110 222
was C 111 222
malignant C 112 222
, C 113 222
died C 114 222
seven C 115 222
months C 116 222
after C 117 222
the C 118 222
second C 119 222
operation C 120 222
. C 121 222
the C 123 222
other C 124 222
patients C 125 222
are C 126 222
well C 127 222
and C 128 222
free C 129 222
of C 130 222
neurological C 131 222
deficits C 132 222
from C 133 222
1 C 134 222
to C 135 222
12 C 136 222
years C 137 222
after C 138 222
operation C 139 222
. C 140 222
life C 1 223
span C 2 223
and C 3 223
lymphoma C 4 223
- C 5 223
incidence C 6 223
of C 7 223
mice C 8 223
injected C 9 223
at C 10 223
birth C 11 223
with C 12 223
spleen C 13 223
cells C 14 223
across C 15 223
a C 16 223
weak C 17 223
histocompatibility C 18 223
locus C 19 223
. C 20 223
newborn C 22 223
cogenic C 23 223
c C 24 223
h C 25 223
mice C 26 223
receiving C 27 223
injections C 28 223
across C 29 223
a C 30 223
weak C 31 223
( C 32 223
h C 33 223
- C 34 223
i C 35 223
h C 36 223
- C 37 223
i C 38 223
) C 39 223
histocompatibility C 40 223
barrier C 41 223
exhibited C 42 223
life C 43 223
- C 44 223
shortening C 45 223
and C 46 223
a C 47 223
high C 48 223
incidence C 49 223
of C 50 223
lymphomatous C 51 223
disease C 52 223
during C 53 223
mid C 54 223
- C 55 223
adult C 56 223
life C 57 223
. C 58 223
in C 60 223
control C 61 223
experiments C 62 223
( C 63 223
h C 64 223
- C 65 223
i C 66 223
h C 67 223
- C 68 223
i C 69 223
) C 70 223
lymphomatous C 71 223
disease C 72 223
developed C 73 223
much C 74 223
later C 75 223
life C 76 223
. C 77 223
both C 79 223
mouse C 80 223
strains C 81 223
when C 82 223
not C 83 223
given C 84 223
injections C 85 223
as C 86 223
new C 87 223
- C 88 223
borns C 89 223
manifest C 90 223
only C 91 223
a C 92 223
negligible C 93 223
incidence C 94 223
of C 95 223
lymphoma C 96 223
or C 97 223
leukemia C 98 223
. C 99 223
these C 101 223
findings C 102 223
are C 103 223
variably C 104 223
interpretable C 105 223
in C 106 223
terms C 107 223
of C 108 223
oncogenic C 109 223
virology C 110 223
, C 111 223
and C 112 223
of C 113 223
the C 114 223
immunologic C 115 223
theories C 116 223
of C 117 223
aging C 118 223
and C 119 223
cancer C 120 223
by C 121 223
analogy C 122 223
with C 123 223
transplantation C 124 223
disease C 125 223
mechanisms C 126 223
. C 127 223
the C 1 224
heterogeneity C 2 224
of C 3 224
rheumatoid C 4 224
factors C 5 224
and C 6 224
the C 7 224
genetic C 8 224
control C 9 224
of C 10 224
polypeptide C 11 224
chains C 12 224
of C 13 224
globulin C 14 224
. C 15 224
( C 17 224
1 C 18 224
) C 19 224
evidence C 20 224
is C 21 224
presented C 22 224
that C 23 224
most C 24 224
rf C 25 224
proteins C 26 224
are C 27 224
heterogeneous C 28 224
in C 29 224
their C 30 224
antigenic C 31 224
composition C 32 224
although C 33 224
occasional C 34 224
ones C 35 224
are C 36 224
homogeneous C 37 224
and C 38 224
thus C 39 224
resemble C 40 224
the C 41 224
paraproteins C 42 224
. C 43 224
( C 45 224
2 C 46 224
) C 47 224
studies C 48 224
pointing C 49 224
out C 50 224
some C 51 224
of C 52 224
the C 53 224
difficulties C 54 224
encountered C 55 224
with C 56 224
currently C 57 224
available C 58 224
preparations C 59 224
of C 60 224
polypeptide C 61 224
chains C 62 224
in C 63 224
the C 64 224
genetic C 65 224
mapping C 66 224
of C 67 224
globulin C 68 224
are C 69 224
described C 70 224
. C 71 224
progynon C 1 225
, C 2 225
a C 3 225
depot C 4 225
preparation C 5 225
with C 6 225
oestrogenic C 7 225
action C 8 225
, C 9 225
in C 10 225
the C 11 225
treatment C 12 225
of C 13 225
prostatic C 14 225
carcinoma C 15 225
. C 16 225
a C 18 225
derivative C 19 225
of C 20 225
a C 21 225
natural C 22 225
oestrogen C 23 225
- C 24 225
dash C 25 225
oestradiol C 26 225
undecylate C 27 225
, C 28 225
progynon C 29 225
- C 30 225
depot C 31 225
- C 32 225
dash C 33 225
was C 34 225
given C 35 225
in C 36 225
depot C 37 225
form C 38 225
by C 39 225
injection C 40 225
to C 41 225
a C 42 225
group C 43 225
of C 44 225
patients C 45 225
with C 46 225
prostatic C 47 225
carcinoma C 48 225
. C 49 225
the C 51 225
study C 52 225
showed C 53 225
progynon C 54 225
- C 55 225
depot C 56 225
to C 57 225
reduce C 58 225
the C 59 225
excretion C 60 225
of C 61 225
androgen C 62 225
metabolites C 63 225
in C 64 225
the C 65 225
urine C 66 225
. C 67 225
the C 69 225
results C 70 225
suggest C 71 225
that C 72 225
the C 73 225
preparation C 74 225
reduced C 75 225
the C 76 225
testicular C 77 225
production C 78 225
of C 79 225
androgens C 80 225
but C 81 225
probably C 82 225
not C 83 225
that C 84 225
of C 85 225
the C 86 225
adrenal C 87 225
glands C 88 225
. C 89 225
the C 91 225
depot C 92 225
effect C 93 225
and C 94 225
clinical C 95 225
action C 96 225
of C 97 225
the C 98 225
preparation C 99 225
are C 100 225
described C 101 225
briefly C 102 225
. C 103 225
/ C 1 226
urinary C 2 226
17 C 3 226
- C 4 226
ketosteroid C 5 226
excretion C 6 226
study C 7 226
in C 8 226
radiation C 9 226
induced C 10 226
menopause C 11 226
in C 12 226
carcinoma C 13 226
breast C 14 226
. C 15 226
/ C 17 226
. C 18 226
( C 20 226
1 C 21 226
) C 22 226
urinary C 23 226
17 C 24 226
- C 25 226
ketosteroid C 26 226
estimation C 27 226
results C 28 226
are C 29 226
given C 30 226
in C 31 226
11 C 32 226
patients C 33 226
subjected C 34 226
to C 35 226
radiotherapeutic C 36 226
sterilisation C 37 226
. C 38 226
( C 40 226
2 C 41 226
) C 42 226
a C 43 226
high C 44 226
dosage C 45 226
level C 46 226
was C 47 226
used C 48 226
in C 49 226
all C 50 226
these C 51 226
cases C 52 226
. C 53 226
( C 55 226
3 C 56 226
) C 57 226
results C 58 226
indicate C 59 226
some C 60 226
suppression C 61 226
of C 62 226
ovarian C 63 226
function C 64 226
within C 65 226
2 C 66 226
weeks C 67 226
of C 68 226
sterilisation C 69 226
. C 70 226
prostatic C 1 227
cancer C 2 227
of C 3 227
a C 4 227
young C 5 227
person C 6 227
with C 7 227
primary C 8 227
hypogonadism C 9 227
. C 10 227
the C 12 227
prostatic C 13 227
carcinoma C 14 227
of C 15 227
a C 16 227
34 C 17 227
years C 18 227
old C 19 227
man C 20 227
with C 21 227
primary C 22 227
hypogonadism C 23 227
was C 24 227
presented C 25 227
. C 26 227
endocrine C 28 227
environment C 29 227
of C 30 227
relative C 31 227
estrogenic C 32 227
excess C 33 227
is C 34 227
suspected C 35 227
to C 36 227
have C 37 227
played C 38 227
the C 39 227
leading C 40 227
part C 41 227
in C 42 227
pathogenesis C 43 227
of C 44 227
this C 45 227
case C 46 227
. C 47 227
urinary C 1 228
excretion C 2 228
of C 3 228
neutral C 4 228
17 C 5 228
- C 6 228
ketosteroids C 7 228
and C 8 228
pregnanediol C 9 228
by C 10 228
patients C 11 228
with C 12 228
prostatic C 13 228
cancer C 14 228
and C 15 228
benign C 16 228
prostatic C 17 228
hypertrophy C 18 228
. C 19 228
urinary C 21 228
neutral C 22 228
17 C 23 228
- C 24 228
ketosteroid C 25 228
fractions C 26 228
and C 27 228
pregnanediol C 28 228
excreted C 29 228
by C 30 228
21 C 31 228
patients C 32 228
with C 33 228
prostatic C 34 228
cancer C 35 228
, C 36 228
17 C 37 228
patients C 38 228
with C 39 228
benign C 40 228
hypertrophy C 41 228
, C 42 228
and C 43 228
59 C 44 228
clinically C 45 228
well C 46 228
subjects C 47 228
were C 48 228
assayed C 49 228
to C 50 228
determine C 51 228
whether C 52 228
differences C 53 228
exist C 54 228
. C 55 228
patients C 57 228
with C 58 228
prostatic C 59 228
cancer C 60 228
and C 61 228
those C 62 228
with C 63 228
benign C 64 228
hypertrophy C 65 228
excreted C 66 228
significantly C 67 228
less C 68 228
androsterone C 69 228
than C 70 228
the C 71 228
clinically C 72 228
well C 73 228
subjects C 74 228
. C 75 228
a C 77 228
disproportionately C 78 228
lower C 79 228
level C 80 228
of C 81 228
androsterone C 82 228
than C 83 228
etiocholanolone C 84 228
resulted C 85 228
in C 86 228
a C 87 228
significantly C 88 228
lower C 89 228
androsterone C 90 228
/ C 91 228
etiocholanolone C 92 228
ratio C 93 228
in C 94 228
both C 95 228
groups C 96 228
. C 97 228
the C 99 228
specificity C 100 228
of C 101 228
the C 102 228
findings C 103 228
is C 104 228
discussed C 105 228
. C 106 228
the C 108 228
lower C 109 228
levels C 110 228
of C 111 228
androsterone C 112 228
excreted C 113 228
by C 114 228
patients C 115 228
with C 116 228
benign C 117 228
hypertrophy C 118 228
were C 119 228
associated C 120 228
with C 121 228
an C 122 228
extended C 123 228
period C 124 228
of C 125 228
hospitalization C 126 228
. C 127 228
patients C 129 228
hospitalized C 130 228
less C 131 228
than C 132 228
5 C 133 228
days C 134 228
excreted C 135 228
androsterone C 136 228
at C 137 228
levels C 138 228
not C 139 228
significantly C 140 228
different C 141 228
from C 142 228
the C 143 228
clinically C 144 228
well C 145 228
subjects C 146 228
. C 147 228
lower C 149 228
levels C 150 228
of C 151 228
androsterone C 152 228
excreted C 153 228
by C 154 228
patients C 155 228
with C 156 228
prostatic C 157 228
cancer C 158 228
were C 159 228
not C 160 228
explained C 161 228
by C 162 228
the C 163 228
presence C 164 228
of C 165 228
metastasis C 166 228
, C 167 228
the C 168 228
duration C 169 228
of C 170 228
hospitalization C 171 228
, C 172 228
loss C 173 228
of C 174 228
appetite C 175 228
, C 176 228
or C 177 228
other C 178 228
definable C 179 228
differences C 180 228
, C 181 228
when C 182 228
each C 183 228
was C 184 228
considered C 185 228
singly C 186 228
. C 187 228
the C 189 228
possible C 190 228
interrelationships C 191 228
of C 192 228
clinical C 193 228
differences C 194 228
prevent C 195 228
assigning C 196 228
lower C 197 228
excretion C 198 228
levels C 199 228
to C 200 228
the C 201 228
cancer C 202 228
state C 203 228
alone C 204 228
. C 205 228
i C 1 229
. C 2 229
urinary C 4 229
excretion C 5 229
of C 6 229
neutral C 7 229
17 C 8 229
- C 9 229
ketosteroids C 10 229
and C 11 229
pregnanediol C 12 229
by C 13 229
patients C 14 229
with C 15 229
breast C 16 229
cancer C 17 229
and C 18 229
benign C 19 229
breast C 20 229
disease C 21 229
. C 22 229
urinary C 24 229
levels C 25 229
of C 26 229
neutral C 27 229
17 C 28 229
- C 29 229
ketosteroid C 30 229
fractions C 31 229
and C 32 229
pregnanediol C 33 229
excreted C 34 229
by C 35 229
114 C 36 229
women C 37 229
, C 38 229
56 C 39 229
premenopausal C 40 229
and C 41 229
58 C 42 229
postmenopausal C 43 229
, C 44 229
were C 45 229
determined C 46 229
. C 47 229
subjects C 49 229
studied C 50 229
were C 51 229
included C 52 229
in C 53 229
4 C 54 229
premenopausal C 55 229
groups C 56 229
( C 57 229
breast C 58 229
cancer C 59 229
6 C 60 229
, C 61 229
benign C 62 229
breast C 63 229
disease C 64 229
18 C 65 229
, C 66 229
sick C 67 229
control C 68 229
8 C 69 229
, C 70 229
well C 71 229
control C 72 229
24 C 73 229
) C 74 229
and C 75 229
3 C 76 229
postmenopausal C 77 229
groups C 78 229
( C 79 229
breast C 80 229
cancer C 81 229
21 C 82 229
, C 83 229
sick C 84 229
control C 85 229
17 C 86 229
, C 87 229
well C 88 229
control C 89 229
20 C 90 229
) C 91 229
. C 92 229
levels C 94 229
of C 95 229
androsterone C 96 229
and C 97 229
etiocholanolone C 98 229
excreted C 99 229
by C 100 229
premenopausal C 101 229
patients C 102 229
with C 103 229
breast C 104 229
cancer C 105 229
were C 106 229
significantly C 107 229
less C 108 229
than C 109 229
levels C 110 229
excreted C 111 229
by C 112 229
other C 113 229
premenopausal C 114 229
groups C 115 229
, C 116 229
and C 117 229
they C 118 229
did C 119 229
not C 120 229
differ C 121 229
significantly C 122 229
from C 123 229
levels C 124 229
excreted C 125 229
by C 126 229
postmenopausal C 127 229
patients C 128 229
with C 129 229
breast C 130 229
cancer C 131 229
. C 132 229
disproportionately C 134 229
lower C 135 229
levels C 136 229
of C 137 229
the C 138 229
11 C 139 229
- C 140 229
desoxy C 141 229
- C 142 229
17 C 143 229
- C 144 229
ketosteroids C 145 229
than C 146 229
11 C 147 229
- C 148 229
oxy C 149 229
- C 150 229
17 C 151 229
- C 152 229
ketosteroids C 153 229
excreted C 154 229
by C 155 229
premenopausal C 156 229
patients C 157 229
with C 158 229
cancer C 159 229
resulted C 160 229
in C 161 229
significantly C 162 229
lower C 163 229
ratios C 164 229
than C 165 229
those C 166 229
found C 167 229
in C 168 229
other C 169 229
premenopausal C 170 229
groups C 171 229
. C 172 229
ratios C 174 229
associated C 175 229
with C 176 229
premenopausal C 177 229
patients C 178 229
with C 179 229
cancer C 180 229
did C 181 229
not C 182 229
differ C 183 229
significantly C 184 229
from C 185 229
those C 186 229
of C 187 229
postmenopausal C 188 229
patients C 189 229
with C 190 229
cancer C 191 229
. C 192 229
lower C 194 229
levels C 195 229
of C 196 229
androsterone C 197 229
and C 198 229
etiocholanolone C 199 229
were C 200 229
not C 201 229
explained C 202 229
by C 203 229
debilitation C 204 229
. C 205 229
the C 1 230
morphologic C 2 230
demonstration C 3 230
of C 4 230
an C 5 230
alveolar C 6 230
lining C 7 230
layer C 8 230
and C 9 230
its C 10 230
relationship C 11 230
to C 12 230
pulmonary C 13 230
surfactant C 14 230
. C 15 230
the C 17 230
presence C 18 230
of C 19 230
an C 20 230
alveolar C 21 230
lining C 22 230
layer C 23 230
was C 24 230
histologically C 25 230
demonstrated C 26 230
in C 27 230
animal C 28 230
lungs C 29 230
by C 30 230
ultraviolet C 31 230
microscopy C 32 230
. C 33 230
this C 35 230
layer C 36 230
appeared C 37 230
as C 38 230
a C 39 230
thin C 40 230
fluorescent C 41 230
line C 42 230
at C 43 230
the C 44 230
air C 45 230
- C 46 230
tissue C 47 230
interface C 48 230
. C 49 230
the C 51 230
fluorescent C 52 230
lining C 53 230
layer C 54 230
could C 55 230
be C 56 230
abolished C 57 230
from C 58 230
lung C 59 230
sections C 60 230
by C 61 230
extraction C 62 230
with C 63 230
chloroform C 64 230
. C 65 230
. C 67 230
. C 68 230
. C 68 230
. C 68 230
. C 68 230
. C 68 230
. C 68 230
. C 68 230
. C 68 230
and C 69 230
was C 70 230
diminished C 71 230
by C 72 230
digestion C 73 230
with C 74 230
cl C 75 230
. C 76 230
. C 77 230
. C 77 230
. C 77 230
. C 77 230
. C 77 230
. C 77 230
. C 77 230
a C 78 230
- C 79 230
toxin C 80 230
lecithinase C 81 230
, C 82 230
suggesting C 83 230
that C 84 230
the C 85 230
structure C 86 230
was C 87 230
a C 88 230
lecithin C 89 230
- C 90 230
containing C 91 230
lipid C 92 230
. C 93 230
an C 95 230
alveolar C 96 230
lining C 97 230
structure C 98 230
was C 99 230
also C 100 230
identified C 101 230
by C 102 230
the C 103 230
use C 104 230
of C 105 230
phosphatide C 106 230
and C 107 230
polysaccharide C 108 230
stains C 109 230
, C 110 230
suggesting C 111 230
that C 112 230
the C 113 230
lipid C 114 230
was C 115 230
a C 116 230
phosphatide C 117 230
, C 118 230
but C 119 230
that C 120 230
a C 121 230
mucopolysaccharide C 122 230
component C 123 230
might C 124 230
also C 125 230
be C 126 230
present C 127 230
. C 128 230
bilateral C 130 230
cervical C 131 230
vagotomy C 132 230
resulted C 133 230
in C 134 230
diminution C 135 230
or C 136 230
loss C 137 230
of C 138 230
the C 139 230
fluorescent C 140 230
alveolar C 141 230
lines C 142 230
and C 143 230
abnormal C 144 230
surface C 145 230
tension C 146 230
properties C 147 230
of C 148 230
lung C 149 230
extracts C 150 230
. C 151 230
this C 153 230
suggested C 154 230
that C 155 230
the C 156 230
presence C 157 230
of C 158 230
the C 159 230
fluorescent C 160 230
material C 161 230
was C 162 230
associated C 163 230
with C 164 230
the C 165 230
surface C 166 230
activity C 167 230
of C 168 230
the C 169 230
lung C 170 230
. C 171 230
alveolar C 173 230
lining C 174 230
structure C 175 230
could C 176 230
not C 177 230
be C 178 230
demonstrated C 179 230
by C 180 230
electron C 181 230
microscopy C 182 230
, C 183 230
even C 184 230
with C 185 230
special C 186 230
staining C 187 230
techniques C 188 230
. C 189 230
experimental C 1 231
emphysema C 2 231
basis C 3 231
, C 4 231
review C 5 231
, C 6 231
and C 7 231
critique C 8 231
. C 9 231
normal C 11 231
lung C 12 231
structure C 13 231
has C 14 231
been C 15 231
described C 16 231
as C 17 231
a C 18 231
rich C 19 231
capillary C 20 231
bed C 21 231
in C 22 231
a C 23 231
finely C 24 231
partitioned C 25 231
airspace C 26 231
with C 27 231
unique C 28 231
surface C 29 231
- C 30 231
active C 31 231
effects C 32 231
. C 33 231
morphologic C 35 231
criteria C 36 231
of C 37 231
the C 38 231
lesions C 39 231
of C 40 231
human C 41 231
pulmonary C 42 231
emphysema C 43 231
include C 44 231
evidence C 45 231
of C 46 231
destruction C 47 231
, C 48 231
residual C 49 231
vascular C 50 231
remnants C 51 231
, C 52 231
the C 53 231
absence C 54 231
of C 55 231
significant C 56 231
amounts C 57 231
of C 58 231
fibrosis C 59 231
, C 60 231
and C 61 231
altered C 62 231
conducting C 63 231
airways C 64 231
without C 65 231
anatomic C 66 231
obstruction C 67 231
. C 68 231
experimental C 70 231
studies C 71 231
relating C 72 231
to C 73 231
the C 74 231
pathogenesis C 75 231
of C 76 231
emphysema C 77 231
have C 78 231
been C 79 231
reviewed C 80 231
and C 81 231
critically C 82 231
evaluated C 83 231
. C 84 231
stress C 86 231
has C 87 231
been C 88 231
placed C 89 231
on C 90 231
the C 91 231
necessity C 92 231
to C 93 231
control C 94 231
the C 95 231
biologic C 96 231
factors C 97 231
influencing C 98 231
the C 99 231
action C 100 231
of C 101 231
any C 102 231
specific C 103 231
etiologic C 104 231
agent C 105 231
. C 106 231
alveolar C 1 232
lining C 2 232
cells C 3 232
and C 4 232
pulmonary C 5 232
reticuloendothelial C 6 232
system C 7 232
of C 8 232
the C 9 232
rabbit C 10 232
. C 11 232
complete C 13 232
freund C 14 232
' C 15 232
s C 16 232
adjuvant C 17 232
was C 18 232
injected C 19 232
intravenously C 20 232
into C 21 232
rabbits C 22 232
and C 23 232
the C 24 232
cellular C 25 232
response C 26 232
in C 27 232
the C 28 232
lungs C 29 232
was C 30 232
investigated C 31 232
. C 32 232
the C 34 232
population C 35 232
of C 36 232
cells C 37 232
within C 38 232
the C 39 232
alveolar C 40 232
spaces C 41 232
was C 42 232
contributed C 43 232
to C 44 232
by C 45 232
monocytes C 46 232
of C 47 232
the C 48 232
circulation C 49 232
, C 50 232
mesenchymal C 51 232
cells C 52 232
of C 53 232
the C 54 232
alveolar C 55 232
walls C 56 232
and C 57 232
epithelial C 58 232
lining C 59 232
cells C 60 232
of C 61 232
the C 62 232
alveoli C 63 232
. C 64 232
the C 66 232
abnormal C 67 232
epithelial C 68 232
lining C 69 232
during C 70 232
the C 71 232
proliferative C 72 232
phase C 73 232
was C 74 232
the C 75 232
result C 76 232
of C 77 232
an C 78 232
increase C 79 232
in C 80 232
size C 81 232
and C 82 232
number C 83 232
of C 84 232
the C 85 232
cells C 86 232
that C 87 232
line C 88 232
the C 89 232
normal C 90 232
alveoli C 91 232
. C 92 232
as C 94 232
healing C 95 232
progressed C 96 232
, C 97 232
a C 98 232
structurally C 99 232
normal C 100 232
alveolar C 101 232
lining C 102 232
was C 103 232
found C 104 232
. C 105 232
time C 1 233
course C 2 233
of C 3 233
changes C 4 233
in C 5 233
surface C 6 233
tension C 7 233
and C 8 233
morphology C 9 233
of C 10 233
alveolar C 11 233
epithelial C 12 233
cells C 13 233
in C 14 233
co C 15 233
2 C 16 233
- C 17 233
induced C 18 233
hyaline C 19 233
membrane C 20 233
disease C 21 233
. C 22 233
atelectasis C 24 233
and C 25 233
hyaline C 26 233
membranes C 27 233
produced C 28 233
by C 29 233
exposure C 30 233
of C 31 233
guinea C 32 233
pigs C 33 233
to C 34 233
15 C 35 233
percent C 36 233
co C 37 233
2 C 38 233
were C 39 233
found C 40 233
to C 41 233
be C 42 233
associated C 43 233
with C 44 233
disappearance C 45 233
of C 46 233
lamellar C 47 233
bodies C 48 233
in C 49 233
the C 50 233
large C 51 233
alveolar C 52 233
lining C 53 233
cells C 54 233
( C 55 233
granular C 56 233
pneumocytes C 57 233
) C 58 233
and C 59 233
an C 60 233
associated C 61 233
decrease C 62 233
in C 63 233
surfactant C 64 233
as C 65 233
indicated C 66 233
in C 67 233
the C 68 233
rise C 69 233
of C 70 233
minimal C 71 233
surface C 72 233
tension C 73 233
of C 74 233
the C 75 233
lungs C 76 233
. C 77 233
this C 79 233
process C 80 233
is C 81 233
limited C 82 233
to C 83 233
the C 84 233
uncompensated C 85 233
phase C 86 233
of C 87 233
respiratory C 88 233
acidosis C 89 233
and C 90 233
is C 91 233
reversed C 92 233
during C 93 233
the C 94 233
compensatory C 95 233
phase C 96 233
. C 97 233
the C 99 233
parallel C 100 233
time C 101 233
course C 102 233
in C 103 233
changes C 104 233
of C 105 233
surface C 106 233
tension C 107 233
and C 108 233
alterations C 109 233
of C 110 233
lamellar C 111 233
bodies C 112 233
in C 113 233
the C 114 233
granular C 115 233
pneumocytes C 116 233
provides C 117 233
additional C 118 233
evidence C 119 233
for C 120 233
the C 121 233
identification C 122 233
of C 123 233
the C 124 233
latter C 125 233
as C 126 233
the C 127 233
cells C 128 233
responsible C 129 233
for C 130 233
the C 131 233
secretion C 132 233
of C 133 233
surfactant C 134 233
. C 135 233
cortisone C 1 234
and C 2 234
atypical C 3 234
pulmonary C 4 234
/ C 5 234
epithelial C 6 234
/ C 7 234
hyperplasia C 8 234
further C 9 234
studies C 10 234
including C 11 234
electron C 12 234
microscopy C 13 234
, C 14 234
tissue C 15 234
culture C 16 234
, C 17 234
animal C 18 234
transplantation C 19 234
and C 20 234
long C 21 234
term C 22 234
observations C 23 234
. C 24 234
previous C 26 234
work C 27 234
in C 28 234
rabbits C 29 234
showed C 30 234
that C 31 234
there C 32 234
was C 33 234
a C 34 234
proliferation C 35 234
of C 36 234
cells C 37 234
within C 38 234
pulmonary C 39 234
alveoli C 40 234
following C 41 234
intratracheal C 42 234
injection C 43 234
of C 44 234
nitric C 45 234
acid C 46 234
and C 47 234
that C 48 234
the C 49 234
proliferation C 50 234
was C 51 234
greatly C 52 234
enhanced C 53 234
by C 54 234
the C 55 234
administration C 56 234
of C 57 234
cortisone C 58 234
to C 59 234
the C 60 234
animals C 61 234
. C 62 234
electron C 64 234
microscopic C 65 234
observations C 66 234
indicated C 67 234
that C 68 234
these C 69 234
were C 70 234
morphologically C 71 234
large C 72 234
alveolar C 73 234
lining C 74 234
cells C 75 234
. C 76 234
tissue C 78 234
culture C 79 234
studies C 80 234
of C 81 234
damaged C 82 234
and C 83 234
normal C 84 234
lung C 85 234
with C 86 234
and C 87 234
without C 88 234
cortisone C 89 234
showed C 90 234
no C 91 234
evidence C 92 234
for C 93 234
a C 94 234
direct C 95 234
effect C 96 234
of C 97 234
the C 98 234
drug C 99 234
on C 100 234
the C 101 234
proliferation C 102 234
of C 103 234
these C 104 234
cells C 105 234
. C 106 234
this C 108 234
observation C 109 234
, C 110 234
together C 111 234
with C 112 234
the C 113 234
knowledge C 114 234
that C 115 234
fibrosis C 116 234
was C 117 234
delayed C 118 234
in C 119 234
the C 120 234
cortisone C 121 234
treated C 122 234
animals C 123 234
, C 124 234
support C 125 234
the C 126 234
thesis C 127 234
that C 128 234
the C 129 234
cortisone C 130 234
effect C 131 234
is C 132 234
an C 133 234
indirect C 134 234
one C 135 234
. C 136 234
transplantation C 138 234
of C 139 234
damaged C 140 234
lung C 141 234
tissue C 142 234
to C 143 234
hamster C 144 234
cheek C 145 234
pouch C 146 234
failed C 147 234
to C 148 234
reveal C 149 234
evidence C 150 234
of C 151 234
growth C 152 234
. C 153 234
within C 155 234
the C 156 234
period C 157 234
of C 158 234
observation C 159 234
( C 160 234
99 C 161 234
to C 162 234
420 C 163 234
days C 164 234
) C 165 234
there C 166 234
was C 167 234
evidence C 168 234
that C 169 234
the C 170 234
proliferation C 171 234
subsided C 172 234
considerably C 173 234
and C 174 234
no C 175 234
neoplasms C 176 234
developed C 177 234
some C 1 235
observations C 2 235
on C 3 235
myelin C 4 235
- C 5 235
glial C 6 235
relationships C 7 235
and C 8 235
on C 9 235
the C 10 235
etiology C 11 235
of C 12 235
the C 13 235
cerebrospinal C 14 235
fluid C 15 235
exchange C 16 235
lesion C 17 235
. C 18 235
the C 20 235
present C 21 235
paper C 22 235
presents C 23 235
cytological C 24 235
observations C 25 235
from C 26 235
developing C 27 235
kitten C 28 235
spinal C 29 235
cord C 30 235
and C 31 235
from C 32 235
spinal C 33 235
cord C 34 235
white C 35 235
matter C 36 235
reacting C 37 235
to C 38 235
injury C 39 235
it C 40 235
also C 41 235
presents C 42 235
some C 43 235
recent C 44 235
experiments C 45 235
on C 46 235
the C 47 235
mechanism C 48 235
of C 49 235
etiology C 50 235
of C 51 235
the C 52 235
csf C 53 235
exchange C 54 235
lesion C 55 235
. C 56 235
drawing C 58 235
on C 59 235
these C 60 235
various C 61 235
sources C 62 235
, C 63 235
the C 64 235
authors C 65 235
propose C 66 235
specific C 67 235
functions C 68 235
for C 69 235
some C 70 235
of C 71 235
the C 72 235
cell C 73 235
types C 74 235
present C 75 235
in C 76 235
spinal C 77 235
cord C 78 235
white C 79 235
matter C 80 235
. C 81 235
lactate C 1 236
and C 2 236
pyruvate C 3 236
in C 4 236
the C 5 236
brain C 6 236
of C 7 236
rats C 8 236
during C 9 236
hyperventilation C 10 236
. C 11 236
experiments C 13 236
on C 14 236
anesthetized C 15 236
and C 16 236
curarized C 17 236
rats C 18 236
under C 19 236
artificial C 20 236
ventilation C 21 236
show C 22 236
that C 23 236
during C 24 236
hyperventilation C 25 236
lactate C 26 236
and C 27 236
pyruvate C 28 236
are C 29 236
markedly C 30 236
increased C 31 236
both C 32 236
in C 33 236
blood C 34 236
and C 35 236
in C 36 236
brain C 37 236
. C 38 236
the C 40 236
lactate C 41 236
/ C 42 236
pyruvate C 43 236
ratio C 44 236
which C 45 236
remains C 46 236
in C 47 236
blood C 48 236
the C 49 236
same C 50 236
as C 51 236
in C 52 236
control C 53 236
conditions C 54 236
, C 55 236
is C 56 236
systematically C 57 236
decreased C 58 236
in C 59 236
brain C 60 236
. C 61 236
during C 63 236
hypoxia C 64 236
( C 65 236
ventilation C 66 236
with C 67 236
7 C 68 236
oxygen C 69 236
in C 70 236
nitrogen C 71 236
) C 72 236
lactate C 73 236
rises C 74 236
markedly C 75 236
in C 76 236
blood C 77 236
and C 78 236
in C 79 236
brain C 80 236
. C 81 236
the C 83 236
lactate C 84 236
/ C 85 236
pyruvate C 86 236
ratio C 87 236
which C 88 236
is C 89 236
strongly C 90 236
increased C 91 236
in C 92 236
blood C 93 236
shows C 94 236
a C 95 236
small C 96 236
rise C 97 236
in C 98 236
brain C 99 236
. C 100 236
these C 102 236
observations C 103 236
could C 104 236
indicate C 105 236
that C 106 236
a C 107 236
different C 108 236
mechanism C 109 236
is C 110 236
responsible C 111 236
for C 112 236
the C 113 236
rise C 114 236
of C 115 236
lactate C 116 236
in C 117 236
brain C 118 236
during C 119 236
hypoxia C 120 236
and C 121 236
hyperventilation C 122 236
. C 123 236
the C 125 236
important C 126 236
augmentation C 127 236
of C 128 236
lactate C 129 236
in C 130 236
brain C 131 236
during C 132 236
hyperventilation C 133 236
can C 134 236
give C 135 236
an C 136 236
explanation C 137 236
for C 138 236
the C 139 236
delayed C 140 236
rise C 141 236
which C 142 236
is C 143 236
seen C 144 236
in C 145 236
the C 146 236
lactate C 147 236
level C 148 236
in C 149 236
cerebrospinal C 150 236
fluid C 151 236
in C 152 236
these C 153 236
conditions C 154 236
. C 155 236
cisternal C 1 237
fluid C 2 237
oxygen C 3 237
tension C 4 237
in C 5 237
man C 6 237
. C 7 237
using C 9 237
a C 10 237
beckman C 11 237
micro C 12 237
- C 13 237
oxygen C 14 237
- C 15 237
electrode C 16 237
we C 17 237
have C 18 237
studied C 19 237
the C 20 237
oxygen C 21 237
tension C 22 237
simultaneously C 23 237
in C 24 237
the C 25 237
cisterna C 26 237
magna C 27 237
, C 28 237
the C 29 237
internal C 30 237
jugular C 31 237
vein C 32 237
and C 33 237
in C 34 237
arterial C 35 237
blood C 36 237
under C 37 237
various C 38 237
conditions C 39 237
. C 40 237
the C 42 237
results C 43 237
suggest C 44 237
that C 45 237
the C 46 237
cisternal C 47 237
oxygen C 48 237
tension C 49 237
to C 50 237
some C 51 237
degree C 52 237
reflects C 53 237
the C 54 237
average C 55 237
oxygen C 56 237
tension C 57 237
of C 58 237
the C 59 237
surrounding C 60 237
brain C 61 237
tissue C 62 237
and C 63 237
besides C 64 237
reflecting C 65 237
the C 66 237
available C 67 237
free C 68 237
oxygen C 69 237
to C 70 237
the C 71 237
brain C 72 237
it C 73 237
registrates C 74 237
changes C 75 237
of C 76 237
short C 77 237
duration C 78 237
in C 79 237
the C 80 237
cerebral C 81 237
blood C 82 237
flow C 83 237
. C 84 237
ventricular C 1 238
septal C 2 238
defect C 3 238
with C 4 238
prolapsed C 5 238
aortic C 6 238
valve C 7 238
and C 8 238
outflow C 9 238
tract C 10 238
obstruction C 11 238
. C 12 238
a C 14 238
case C 15 238
of C 16 238
ventricular C 17 238
septal C 18 238
defect C 19 238
combined C 20 238
with C 21 238
aortic C 22 238
valvular C 23 238
lesion C 24 238
and C 25 238
infundibular C 26 238
pulmonic C 27 238
stenosis C 28 238
is C 29 238
described C 30 238
. C 31 238
the C 33 238
right C 34 238
coronary C 35 238
cusp C 36 238
of C 37 238
the C 38 238
aortic C 39 238
valve C 40 238
, C 41 238
protruding C 42 238
through C 43 238
the C 44 238
ventricular C 45 238
septal C 46 238
defect C 47 238
, C 48 238
was C 49 238
demonstrated C 50 238
by C 51 238
right C 52 238
ventricular C 53 238
angiocardiography C 54 238
as C 55 238
a C 56 238
polyp C 57 238
- C 58 238
like C 59 238
mass C 60 238
in C 61 238
the C 62 238
right C 63 238
ventricular C 64 238
outflow C 65 238
tract C 66 238
. C 67 238
cardiac C 69 238
catheterization C 70 238
and C 71 238
angiocardiography C 72 238
showed C 73 238
progressive C 74 238
right C 75 238
ventricular C 76 238
outflow C 77 238
obstruction C 78 238
. C 79 238
functional C 1 239
adaptations C 2 239
of C 3 239
the C 4 239
right C 5 239
ventricular C 6 239
outflow C 7 239
tract C 8 239
in C 9 239
congenital C 10 239
heart C 11 239
disease C 12 239
. C 13 239
functional C 15 239
adaptations C 16 239
in C 17 239
the C 18 239
right C 19 239
ventricular C 20 239
outflow C 21 239
tract C 22 239
have C 23 239
been C 24 239
discussed C 25 239
in C 26 239
relation C 27 239
to C 28 239
the C 29 239
development C 30 239
of C 31 239
acquired C 32 239
/ C 33 239
pulmonary C 34 239
stenosis C 35 239
/ C 36 239
. C 37 239
it C 39 239
is C 40 239
concluded C 41 239
that C 42 239
physical C 43 239
forces C 44 239
as C 45 239
well C 46 239
as C 47 239
structural C 48 239
abnormalities C 49 239
may C 50 239
greatly C 51 239
influence C 52 239
both C 53 239
the C 54 239
clinical C 55 239
picture C 56 239
and C 57 239
the C 58 239
life C 59 239
history C 60 239
of C 61 239
many C 62 239
patients C 63 239
with C 64 239
congenital C 65 239
heart C 66 239
lesions C 67 239
. C 68 239
the C 70 239
importance C 71 239
of C 72 239
further C 73 239
serial C 74 239
haemodynamic C 75 239
studies C 76 239
to C 77 239
provide C 78 239
a C 79 239
fuller C 80 239
understanding C 81 239
of C 82 239
the C 83 239
natural C 84 239
course C 85 239
of C 86 239
many C 87 239
lesions C 88 239
is C 89 239
stressed C 90 239
, C 91 239
so C 92 239
that C 93 239
better C 94 239
advice C 95 239
about C 96 239
prognosis C 97 239
and C 98 239
the C 99 239
optimal C 100 239
time C 101 239
for C 102 239
surgical C 103 239
treatment C 104 239
may C 105 239
be C 106 239
given C 107 239
. C 108 239
mitral C 1 240
atresia C 2 240
associated C 3 240
with C 4 240
pulmonary C 5 240
venous C 6 240
anomalies C 7 240
. C 8 240
pulmonary C 10 240
venous C 11 240
anomalies C 12 240
were C 13 240
observed C 14 240
in C 15 240
5 C 16 240
among C 17 240
29 C 18 240
specimens C 19 240
with C 20 240
mitral C 21 240
atresia C 22 240
. C 23 240
in C 25 240
4 C 26 240
of C 27 240
these C 28 240
5 C 29 240
the C 30 240
anomalous C 31 240
pulmonary C 32 240
veins C 33 240
took C 34 240
the C 35 240
form C 36 240
of C 37 240
anomalous C 38 240
pulmonary C 39 240
venous C 40 240
connexion C 41 240
. C 42 240
in C 44 240
the C 45 240
remaining C 46 240
case C 47 240
the C 48 240
pulmonary C 49 240
venous C 50 240
anomaly C 51 240
was C 52 240
represented C 53 240
by C 54 240
cor C 55 240
triatriatum C 56 240
. C 57 240
in C 59 240
3 C 60 240
( C 61 240
group C 62 240
i C 63 240
) C 64 240
, C 65 240
mitral C 66 240
atresia C 67 240
and C 68 240
premature C 69 240
closure C 70 240
of C 71 240
the C 72 240
foramen C 73 240
ovale C 74 240
coexisted C 75 240
. C 76 240
the C 78 240
anomalous C 79 240
pulmonary C 80 240
venous C 81 240
connexions C 82 240
in C 83 240
this C 84 240
group C 85 240
provided C 86 240
collateral C 87 240
routes C 88 240
for C 89 240
the C 90 240
flow C 91 240
of C 92 240
pulmonary C 93 240
venous C 94 240
blood C 95 240
, C 96 240
and C 97 240
can C 98 240
be C 99 240
understood C 100 240
as C 101 240
developing C 102 240
en C 103 240
response C 104 240
to C 105 240
obstruction C 106 240
at C 107 240
the C 108 240
foramen C 109 240
ovale C 110 240
when C 111 240
the C 112 240
mitral C 113 240
valve C 114 240
is C 115 240
atretic C 116 240
. C 117 240
in C 119 240
the C 120 240
remaining C 121 240
2 C 122 240
( C 123 240
group C 124 240
ii C 125 240
) C 126 240
no C 127 240
such C 128 240
causative C 129 240
factor C 130 240
could C 131 240
be C 132 240
invoked C 133 240
. C 134 240
in C 136 240
one C 137 240
of C 138 240
the C 139 240
latter C 140 240
group C 141 240
total C 142 240
anomalous C 143 240
pulmonary C 144 240
venous C 145 240
connexion C 146 240
coexisted C 147 240
with C 148 240
a C 149 240
common C 150 240
atrium C 151 240
. C 152 240
in C 154 240
the C 155 240
other C 156 240
, C 157 240
cor C 158 240
triatriatum C 159 240
coexisted C 160 240
with C 161 240
a C 162 240
patent C 163 240
foramen C 164 240
ovale C 165 240
. C 166 240
pulmonary C 168 240
venous C 169 240
obstruction C 170 240
occurred C 171 240
in C 172 240
each C 173 240
of C 174 240
the C 175 240
5 C 176 240
cases C 177 240
. C 178 240
basal C 1 241
metabolic C 2 241
rate C 3 241
after C 4 241
cardiovascular C 5 241
surgery C 6 241
. C 7 241
the C 9 241
basal C 10 241
metabolic C 11 241
rate C 12 241
and C 13 241
respiratory C 14 241
equivalent C 15 241
of C 16 241
patients C 17 241
were C 18 241
determined C 19 241
during C 20 241
8 C 21 241
days C 22 241
of C 23 241
convalescence C 24 241
from C 25 241
cardiovascular C 26 241
surgical C 27 241
operations C 28 241
performed C 29 241
with C 30 241
or C 31 241
without C 32 241
cardiopulmonary C 33 241
bypass C 34 241
. C 35 241
the C 37 241
results C 38 241
were C 39 241
compared C 40 241
in C 41 241
patients C 42 241
who C 43 241
had C 44 241
undergone C 45 241
operation C 46 241
for C 47 241
different C 48 241
diseases C 49 241
. C 50 241
metabolic C 52 241
rate C 53 241
in C 54 241
the C 55 241
majority C 56 241
of C 57 241
cases C 58 241
was C 59 241
increased C 60 241
but C 61 241
was C 62 241
commensurate C 63 241
with C 64 241
body C 65 241
temperature C 66 241
. C 67 241
some C 69 241
patients C 70 241
, C 71 241
particularly C 72 241
those C 73 241
requiring C 74 241
open C 75 241
operation C 76 241
on C 77 241
the C 78 241
aortic C 79 241
valve C 80 241
, C 81 241
had C 82 241
raised C 83 241
metabolic C 84 241
rates C 85 241
which C 86 241
could C 87 241
not C 88 241
be C 89 241
explained C 90 241
solely C 91 241
by C 92 241
pyrexia C 93 241
. C 94 241
all C 96 241
types C 97 241
of C 98 241
patients C 99 241
in C 100 241
this C 101 241
series C 102 241
had C 103 241
elevated C 104 241
respiratory C 105 241
equivalents C 106 241
which C 107 241
persisted C 108 241
throughout C 109 241
convalescence C 110 241
. C 111 241
these C 113 241
equivalents C 114 241
were C 115 241
greater C 116 241
in C 117 241
patients C 118 241
treated C 119 241
with C 120 241
cardiopulmonary C 121 241
bypass C 122 241
than C 123 241
in C 124 241
patients C 125 241
treated C 126 241
without C 127 241
bypass C 128 241
. C 129 241
surgical C 1 242
treatment C 2 242
of C 3 242
ventricular C 4 242
septal C 5 242
defect C 6 242
. C 7 242
the C 9 242
surgical C 10 242
technique C 11 242
of C 12 242
closure C 13 242
of C 14 242
ventricular C 15 242
septal C 16 242
defects C 17 242
in C 18 242
80 C 19 242
cases C 20 242
( C 21 242
37 C 22 242
cases C 23 242
of C 24 242
isolated C 25 242
defects C 26 242
and C 27 242
43 C 28 242
cases C 29 242
of C 30 242
tetralogy C 31 242
of C 32 242
fallot C 33 242
) C 34 242
is C 35 242
discussed C 36 242
in C 37 242
the C 38 242
light C 39 242
of C 40 242
the C 41 242
follow C 42 242
- C 43 242
up C 44 242
results C 45 242
. C 46 242
the C 48 242
use C 49 242
of C 50 242
a C 51 242
patch C 52 242
for C 53 242
closure C 54 242
has C 55 242
reduced C 56 242
the C 57 242
incidence C 58 242
of C 59 242
recurrence C 60 242
to C 61 242
4 C 62 242
percent C 63 242
, C 64 242
com C 65 242
- C 66 242
pared C 67 242
with C 68 242
18 C 69 242
percent C 70 242
when C 71 242
direct C 72 242
suture C 73 242
was C 74 242
performed C 75 242
. C 76 242
the C 78 242
incidence C 79 242
of C 80 242
heart C 81 242
block C 82 242
also C 83 242
decreased C 84 242
from C 85 242
15 C 86 242
percent C 87 242
, C 88 242
when C 89 242
direct C 90 242
suture C 91 242
was C 92 242
used C 93 242
, C 94 242
to C 95 242
4 C 96 242
percent C 97 242
with C 98 242
a C 99 242
patch C 100 242
. C 101 242
the C 103 242
transatrial C 104 242
approach C 105 242
is C 106 242
preferred C 107 242
for C 108 242
isolated C 109 242
ventricular C 110 242
septal C 111 242
defects C 112 242
, C 113 242
. C 114 242
the C 116 242
ventricular C 117 242
approach C 118 242
is C 119 242
preferred C 120 242
for C 121 242
cases C 122 242
with C 123 242
tetralogy C 124 242
of C 125 242
fallot C 126 242
. C 127 242
in C 129 242
cases C 130 242
combined C 131 242
with C 132 242
aortic C 133 242
insufficiency C 134 242
only C 135 242
small C 136 242
defects C 137 242
are C 138 242
closed C 139 242
through C 140 242
the C 141 242
aorta C 142 242
. C 143 242
larger C 145 242
defects C 146 242
are C 147 242
closed C 148 242
in C 149 242
the C 150 242
usual C 151 242
way C 152 242
at C 153 242
a C 154 242
first C 155 242
stage C 156 242
operation C 157 242
, C 158 242
and C 159 242
a C 160 242
total C 161 242
valve C 162 242
prosthesis C 163 242
is C 164 242
introduced C 165 242
at C 166 242
a C 167 242
second C 168 242
operation C 169 242
. C 170 242
there C 172 242
was C 173 242
an C 174 242
operative C 175 242
mortality C 176 242
of C 177 242
6 C 178 242
percent C 179 242
in C 180 242
isolated C 181 242
ventricular C 182 242
septal C 183 242
defects C 184 242
, C 185 242
compared C 186 242
with C 187 242
27 C 188 242
percent C 189 242
in C 190 242
cyanotic C 191 242
patients C 192 242
with C 193 242
tetralogy C 194 242
of C 195 242
fallot C 196 242
. C 197 242
some C 1 243
hemodynamic C 2 243
observations C 3 243
in C 4 243
congenital C 5 243
heart C 6 243
disease C 7 243
with C 8 243
special C 9 243
reference C 10 243
to C 11 243
pressure C 12 243
curves C 13 243
in C 14 243
ductus C 15 243
arteriosus C 16 243
. C 17 243
hemodynamic C 19 243
observations C 20 243
in C 21 243
100 C 22 243
congenital C 23 243
heart C 24 243
disease C 25 243
cases C 26 243
are C 27 243
made C 28 243
based C 29 243
on C 30 243
data C 31 243
in C 32 243
the C 33 243
department C 34 243
of C 35 243
pediatrics C 36 243
, C 37 243
kyoto C 38 243
university C 39 243
between C 40 243
may C 41 243
1961 C 42 243
and C 43 243
december C 44 243
1963 C 45 243
. C 46 243
we C 48 243
have C 49 243
classified C 50 243
these C 51 243
100 C 52 243
cases C 53 243
according C 54 243
to C 55 243
the C 56 243
malformation C 57 243
from C 58 243
the C 59 243
hemodynamic C 60 243
view C 61 243
point C 62 243
. C 63 243
our C 65 243
cases C 66 243
were C 67 243
classified C 68 243
into C 69 243
the C 70 243
following C 71 243
groups C 72 243
. C 73 243
( C 75 243
1 C 76 243
) C 77 243
ventricular C 78 243
septal C 79 243
defect C 80 243
35 C 81 243
cases C 82 243
small C 83 243
ventricular C 84 243
septal C 85 243
defect C 86 243
20 C 87 243
moderate C 88 243
ventricular C 89 243
septal C 90 243
defect C 91 243
9 C 92 243
marked C 93 243
ventricular C 94 243
septal C 95 243
defect C 96 243
4 C 97 243
ventricular C 98 243
septal C 99 243
defect C 100 243
with C 101 243
pulmonary C 102 243
stenosis C 103 243
2 C 104 243
( C 105 243
2 C 106 243
) C 107 243
patent C 108 243
ductus C 109 243
arteriosus C 110 243
21 C 111 243
( C 112 243
3 C 113 243
) C 114 243
atrial C 115 243
septal C 116 243
defect C 117 243
19 C 118 243
atrial C 119 243
septal C 120 243
defect C 121 243
14 C 122 243
atrial C 123 243
septal C 124 243
defect C 125 243
with C 126 243
pulmonary C 127 243
stenosis C 128 243
5 C 129 243
( C 130 243
4 C 131 243
) C 132 243
pulmonary C 133 243
stenosis C 134 243
5 C 135 243
( C 136 243
5 C 137 243
) C 138 243
tetralogy C 139 243
of C 140 243
fallot C 141 243
14 C 142 243
( C 143 243
6 C 144 243
) C 145 243
aortic C 146 243
stenosis C 147 243
3 C 148 243
( C 149 243
7 C 150 243
) C 151 243
aortic C 152 243
insufficiency C 153 243
3 C 154 243
aortic C 155 243
insufficiency C 156 243
with C 157 243
ventricular C 158 243
septal C 159 243
defect C 160 243
2 C 161 243
aortic C 162 243
insufficiency C 163 243
with C 164 243
pulmonary C 165 243
stenosis C 166 243
1 C 167 243
in C 168 243
sonre C 169 243
small C 170 243
ventricular C 171 243
septal C 172 243
defect C 173 243
, C 174 243
we C 175 243
tried C 176 243
the C 177 243
vasoactive C 178 243
drugs C 179 243
. C 180 243
phenylephrine C 182 243
was C 183 243
injected C 184 243
slowly C 185 243
into C 186 243
the C 187 243
right C 188 243
ventricle C 189 243
via C 190 243
the C 191 243
catheter C 192 243
, C 193 243
a C 194 243
rapid C 195 243
rise C 196 243
in C 197 243
femoral C 198 243
arterial C 199 243
pressure C 200 243
associated C 201 243
with C 202 243
bradycardia C 203 243
and C 204 243
intensiffication C 205 243
of C 206 243
the C 207 243
systolic C 208 243
murmur C 209 243
was C 210 243
observed C 211 243
. C 212 243
after C 214 243
the C 215 243
administration C 216 243
of C 217 243
amyl C 218 243
nitrite C 219 243
, C 220 243
a C 221 243
rapid C 222 243
fall C 223 243
in C 224 243
femoral C 225 243
arterial C 226 243
pressure C 227 243
associated C 228 243
with C 229 243
tachycardia C 230 243
and C 231 243
softening C 232 243
of C 233 243
the C 234 243
sys C 235 243
- C 236 243
tolic C 237 243
murmur C 238 243
was C 239 243
observed C 240 243
. C 241 243
in C 243 243
patent C 244 243
ductus C 245 243
arteriosus C 246 243
, C 247 243
when C 248 243
the C 249 243
cardiac C 250 243
catheter C 251 243
is C 252 243
withdrawn C 253 243
slowly C 254 243
from C 255 243
the C 256 243
aorta C 257 243
into C 258 243
the C 259 243
pulmonary C 260 243
artery C 261 243
, C 262 243
the C 263 243
outstanding C 264 243
pressure C 265 243
curve C 266 243
is C 267 243
recorded C 268 243
in C 269 243
ductus C 270 243
arteriosus C 271 243
. C 272 243
the C 274 243
systolic C 275 243
pressure C 276 243
curve C 277 243
in C 278 243
the C 279 243
ductus C 280 243
arteriosus C 281 243
is C 282 243
the C 283 243
same C 284 243
as C 285 243
the C 286 243
systolic C 287 243
pressure C 288 243
in C 289 243
the C 290 243
aorta C 291 243
and C 292 243
the C 293 243
diastolic C 294 243
pressure C 295 243
curve C 296 243
in C 297 243
the C 298 243
ductus C 299 243
arteriosus C 300 243
has C 301 243
a C 302 243
diastolic C 303 243
dip C 304 243
followed C 305 243
by C 306 243
a C 307 243
late C 308 243
diastolic C 309 243
pressure C 310 243
peak C 311 243
. C 312 243
in C 314 243
patent C 315 243
ductus C 316 243
arteriosus C 317 243
, C 318 243
when C 319 243
the C 320 243
cardiac C 321 243
catheter C 322 243
is C 323 243
withdrawn C 324 243
from C 325 243
the C 326 243
left C 327 243
pulmonary C 328 243
artery C 329 243
to C 330 243
the C 331 243
right C 332 243
ventricle C 333 243
, C 334 243
the C 335 243
pressure C 336 243
curve C 337 243
reveals C 338 243
a C 339 243
considerable C 340 243
characteristic C 341 243
rise C 342 243
in C 343 243
pulmonary C 344 243
arterial C 345 243
pressure C 346 243
which C 347 243
is C 348 243
regarded C 349 243
as C 350 243
an C 351 243
effect C 352 243
of C 353 243
the C 354 243
transmission C 355 243
of C 356 243
systemic C 357 243
pressure C 358 243
through C 359 243
the C 360 243
ductus C 361 243
arteriosus C 362 243
. C 363 243
a C 1 244
study C 2 244
on C 3 244
the C 4 244
direction C 5 244
of C 6 244
inscription C 7 244
of C 8 244
the C 9 244
vectorcardiographic C 10 244
t C 11 244
- C 12 244
loop C 13 244
in C 14 244
left C 15 244
and C 16 244
right C 17 244
ventricular C 18 244
hypertrophy C 19 244
. C 20 244
( C 22 244
1 C 23 244
) C 24 244
frank C 25 244
lead C 26 244
vectorcardiogram C 27 244
was C 28 244
recorded C 29 244
in C 30 244
30 C 31 244
normal C 32 244
persons C 33 244
and C 34 244
in C 35 244
323 C 36 244
cases C 37 244
with C 38 244
hypertension C 39 244
and C 40 244
acquired C 41 244
and C 42 244
congenital C 43 244
heart C 44 244
disease C 45 244
the C 46 244
t C 47 244
- C 48 244
loop C 49 244
was C 50 244
classified C 51 244
into C 52 244
8 C 53 244
types C 54 244
according C 55 244
to C 56 244
the C 57 244
directions C 58 244
of C 59 244
inscription C 60 244
in C 61 244
3 C 62 244
planar C 63 244
projections C 64 244
. C 65 244
frequently C 67 244
observed C 68 244
types C 69 244
were C 70 244
examined C 71 244
with C 72 244
the C 73 244
direction C 74 244
of C 75 244
the C 76 244
maximal C 77 244
t C 78 244
vector C 79 244
. C 80 244
( C 82 244
2 C 83 244
) C 84 244
in C 85 244
majority C 86 244
of C 87 244
normal C 88 244
cases C 89 244
, C 90 244
the C 91 244
t C 92 244
- C 93 244
loop C 94 244
was C 95 244
inscribed C 96 244
counterclockwise C 97 244
in C 98 244
horizontal C 99 244
and C 100 244
clockwise C 101 244
in C 102 244
sagittal C 103 244
planes C 104 244
. C 105 244
( C 107 244
3 C 108 244
) C 109 244
in C 110 244
left C 111 244
ventricular C 112 244
hypertrophy C 113 244
, C 114 244
abnormal C 115 244
inscription C 116 244
of C 117 244
the C 118 244
t C 119 244
- C 120 244
loop C 121 244
was C 122 244
observed C 123 244
with C 124 244
abnormal C 125 244
rightward C 126 244
and C 127 244
superior C 128 244
deviation C 129 244
of C 130 244
its C 131 244
maximal C 132 244
vector C 133 244
and C 134 244
the C 135 244
t C 136 244
- C 137 244
loop C 138 244
oriented C 139 244
more C 140 244
than C 141 244
120 C 142 244
in C 143 244
horizontal C 144 244
plane C 145 244
was C 146 244
usually C 147 244
accompanied C 148 244
by C 149 244
abnormal C 150 244
inscription C 151 244
. C 152 244
percentage C 154 244
of C 155 244
abnormal C 156 244
inscription C 157 244
was C 158 244
higher C 159 244
in C 160 244
cases C 161 244
with C 162 244
cardiac C 163 244
complaints C 164 244
. C 165 244
( C 167 244
4 C 168 244
) C 169 244
in C 170 244
right C 171 244
ventricular C 172 244
hypertrophy C 173 244
, C 174 244
directional C 175 244
change C 176 244
of C 177 244
the C 178 244
t C 179 244
- C 180 244
loop C 181 244
was C 182 244
relatively C 183 244
small C 184 244
but C 185 244
changes C 186 244
in C 187 244
inscription C 188 244
of C 189 244
it C 190 244
were C 191 244
common C 192 244
. C 193 244
the C 195 244
t C 196 244
- C 197 244
loop C 198 244
was C 199 244
always C 200 244
inscribed C 201 244
abnormally C 202 244
in C 203 244
cases C 204 244
with C 205 244
abnormal C 206 244
inscription C 207 244
of C 208 244
the C 209 244
qrs C 210 244
- C 211 244
loop C 212 244
. C 213 244
( C 215 244
5 C 216 244
) C 217 244
the C 218 244
concept C 219 244
of C 220 244
the C 221 244
polar C 222 244
vector C 223 244
was C 224 244
found C 225 244
to C 226 244
be C 227 244
valuable C 228 244
in C 229 244
studying C 230 244
the C 231 244
inscription C 232 244
and C 233 244
the C 234 244
direction C 235 244
of C 236 244
the C 237 244
t C 238 244
- C 239 244
loop C 240 244
. C 241 244
significance C 243 244
of C 244 244
changes C 245 244
in C 246 244
inscription C 247 244
of C 248 244
the C 249 244
t C 250 244
- C 251 244
loop C 252 244
was C 253 244
discussed C 254 244
. C 255 244
pulmonary C 1 245
vascular C 2 245
plexiform C 3 245
lesion C 4 245
pathogenetic C 5 245
studies C 6 245
. C 7 245
an C 9 245
attempt C 10 245
was C 11 245
made C 12 245
to C 13 245
test C 14 245
the C 15 245
theory C 16 245
that C 17 245
in C 18 245
pulmonary C 19 245
arterial C 20 245
hypertension C 21 245
, C 22 245
the C 23 245
plexiform C 24 245
lesion C 25 245
is C 26 245
a C 27 245
jet C 28 245
lesion C 29 245
beyond C 30 245
points C 31 245
of C 32 245
arterial C 33 245
stenosis C 34 245
resulting C 35 245
from C 36 245
nonspecific C 37 245
intimal C 38 245
thickening C 39 245
. C 40 245
in C 42 245
39 C 43 245
subjects C 44 245
with C 45 245
such C 46 245
congenital C 47 245
communications C 48 245
as C 49 245
are C 50 245
associated C 51 245
with C 52 245
pulmonary C 53 245
arterial C 54 245
hypertension C 55 245
, C 56 245
the C 57 245
lungs C 58 245
were C 59 245
studied C 60 245
histologically C 61 245
. C 62 245
in C 64 245
each C 65 245
, C 66 245
there C 67 245
was C 68 245
an C 69 245
additional C 70 245
element C 71 245
of C 72 245
pulmonary C 73 245
venous C 74 245
obstruction C 75 245
. C 76 245
it C 78 245
is C 79 245
likely C 80 245
that C 81 245
in C 82 245
the C 83 245
absence C 84 245
of C 85 245
pulmonary C 86 245
venous C 87 245
obstruction C 88 245
, C 89 245
adult C 90 245
patients C 91 245
with C 92 245
only C 93 245
the C 94 245
congenital C 95 245
communication C 96 245
would C 97 245
have C 98 245
developed C 99 245
plexiform C 100 245
lesions C 101 245
. C 102 245
in C 104 245
the C 105 245
three C 106 245
adult C 107 245
patients C 108 245
in C 109 245
the C 110 245
study C 111 245
, C 112 245
no C 113 245
plexiform C 114 245
lesions C 115 245
were C 116 245
identified C 117 245
. C 118 245
among C 120 245
the C 121 245
36 C 122 245
infants C 123 245
or C 124 245
children C 125 245
, C 126 245
one C 127 245
subject C 128 245
showed C 129 245
plexiform C 130 245
lesions C 131 245
, C 132 245
a C 133 245
53 C 134 245
- C 135 245
day C 136 245
- C 137 245
old C 138 245
girl C 139 245
with C 140 245
mitral C 141 245
atresia C 142 245
, C 143 245
ventricular C 144 245
septal C 145 245
defect C 146 245
, C 147 245
and C 148 245
patent C 149 245
ductus C 150 245
arteriosus C 151 245
. C 152 245
while C 154 245
the C 155 245
findings C 156 245
in C 157 245
the C 158 245
three C 159 245
adult C 160 245
subjects C 161 245
support C 162 245
the C 163 245
theory C 164 245
regarding C 165 245
the C 166 245
genesis C 167 245
of C 168 245
plexiform C 169 245
lesions C 170 245
, C 171 245
the C 172 245
findings C 173 245
in C 174 245
the C 175 245
one C 176 245
infant C 177 245
with C 178 245
plexiform C 179 245
lesions C 180 245
appear C 181 245
to C 182 245
contradict C 183 245
it C 184 245
. C 185 245
renal C 1 246
hemosiderosis C 2 246
( C 3 246
blue C 4 246
kidney C 5 246
) C 6 246
in C 7 246
patients C 8 246
with C 9 246
valvular C 10 246
heart C 11 246
disease C 12 246
. C 13 246
anatomic C 15 246
evidence C 16 246
of C 17 246
intravascular C 18 246
hemolysis C 19 246
, C 20 246
i C 21 246
. C 22 246
. C 23 246
. C 24 246
, C 26 246
renal C 27 246
hemosiderosis C 28 246
, C 29 246
was C 30 246
found C 31 246
at C 32 246
necropsy C 33 246
in C 34 246
4 C 35 246
of C 36 246
132 C 37 246
patients C 38 246
who C 39 246
died C 40 246
of C 41 246
severe C 42 246
valvular C 43 246
heart C 44 246
disease C 45 246
. C 46 246
the C 48 246
aortic C 49 246
valve C 50 246
in C 51 246
each C 52 246
of C 53 246
these C 54 246
4 C 55 246
patients C 56 246
was C 57 246
heavily C 58 246
calcified C 59 246
, C 60 246
immobile C 61 246
, C 62 246
and C 63 246
portions C 64 246
of C 65 246
the C 66 246
calcific C 67 246
deposits C 68 246
were C 69 246
in C 70 246
direct C 71 246
contact C 72 246
with C 73 246
the C 74 246
blood C 75 246
. C 76 246
hemolysis C 78 246
in C 79 246
each C 80 246
patient C 81 246
was C 82 246
attributable C 83 246
to C 84 246
direct C 85 246
trauma C 86 246
to C 87 246
erythrocytes C 88 246
traversing C 89 246
the C 90 246
stenotic C 91 246
valve C 92 246
, C 93 246
and C 94 246
the C 95 246
frequency C 96 246
of C 97 246
trauma C 98 246
was C 99 246
increased C 100 246
by C 101 246
an C 102 246
associated C 103 246
regurgitant C 104 246
flow C 105 246
. C 106 246
renal C 108 246
hemosiderosis C 109 246
was C 110 246
not C 111 246
observed C 112 246
in C 113 246
any C 114 246
patient C 115 246
with C 116 246
isolated C 117 246
mitral C 118 246
valve C 119 246
disease C 120 246
, C 121 246
or C 122 246
in C 123 246
those C 124 246
with C 125 246
combined C 126 246
mitral C 127 246
and C 128 246
tricuspid C 129 246
valve C 130 246
malformations C 131 246
. C 132 246
tumor C 1 247
scanning C 2 247
with C 3 247
radioactive C 4 247
cesium C 5 247
. C 6 247
fourteen C 8 247
patients C 9 247
with C 10 247
cancer C 11 247
were C 12 247
scanned C 13 247
10 C 14 247
minutes C 15 247
to C 16 247
48 C 17 247
hours C 18 247
after C 19 247
injection C 20 247
of C 21 247
radioactive C 22 247
cs C 23 247
. C 24 247
and C 26 247
satisfactory C 27 247
scans C 28 247
of C 29 247
the C 30 247
tumors C 31 247
were C 32 247
obtained C 33 247
in C 34 247
seven C 35 247
. C 36 247
positive C 38 247
scans C 39 247
were C 40 247
obtained C 41 247
in C 42 247
large C 43 247
, C 44 247
superficial C 45 247
tumors C 46 247
, C 47 247
in C 48 247
a C 49 247
pulmonary C 50 247
lymphoma C 51 247
, C 52 247
and C 53 247
in C 54 247
a C 55 247
carcinoma C 56 247
of C 57 247
the C 58 247
upper C 59 247
third C 60 247
of C 61 247
the C 62 247
esophagus C 63 247
. C 64 247
the C 66 247
negative C 67 247
scans C 68 247
were C 69 247
all C 70 247
in C 71 247
abdominal C 72 247
tumors C 73 247
. C 74 247
correlations C 76 247
were C 77 247
made C 78 247
with C 79 247
data C 80 247
obtained C 81 247
from C 82 247
external C 83 247
counting C 84 247
and C 85 247
by C 86 247
well C 87 247
scintillation C 88 247
counting C 89 247
of C 90 247
biopsy C 91 247
specimens C 92 247
. C 93 247
two C 95 247
modes C 96 247
of C 97 247
uptake C 98 247
are C 99 247
suggested C 100 247
. C 101 247
. C 103 247
( C 105 247
a C 106 247
) C 107 247
early C 108 247
uptake C 109 247
due C 110 247
to C 111 247
vascularity C 112 247
and C 113 247
probably C 114 247
not C 115 247
proportional C 116 247
to C 117 247
stable C 118 247
cesium C 119 247
content C 120 247
. C 121 247
. C 123 247
and C 125 247
( C 126 247
b C 127 247
) C 128 247
a C 129 247
later C 130 247
uptake C 131 247
based C 132 247
upon C 133 247
greater C 134 247
alkali C 135 247
metal C 136 247
content C 137 247
of C 138 247
tumors C 139 247
than C 140 247
of C 141 247
normal C 142 247
tissue C 143 247
. C 144 247
lung C 1 248
scanning C 2 248
with C 3 248
colloidal C 4 248
risa C 5 248
. C 6 248
the C 8 248
use C 9 248
of C 10 248
colloidal C 11 248
risa C 12 248
injected C 13 248
intravenously C 14 248
in C 15 248
a C 16 248
particle C 17 248
size C 18 248
of C 19 248
10 C 20 248
. C 21 248
. C 22 248
. C 22 248
microns C 23 248
followed C 24 248
by C 25 248
lung C 26 248
photoscanning C 27 248
offers C 28 248
a C 29 248
practical C 30 248
, C 31 248
atraumatic C 32 248
method C 33 248
of C 34 248
visualizing C 35 248
pulmonary C 36 248
artery C 37 248
occlusions C 38 248
in C 39 248
the C 40 248
dog C 41 248
the C 42 248
fact C 43 248
that C 44 248
the C 45 248
particles C 46 248
have C 47 248
a C 48 248
relatively C 49 248
short C 50 248
biological C 51 248
half C 52 248
- C 53 248
life C 54 248
appears C 55 248
to C 56 248
decrease C 57 248
the C 58 248
radiation C 59 248
dose C 60 248
delivered C 61 248
and C 62 248
the C 63 248
duration C 64 248
of C 65 248
occlusion C 66 248
of C 67 248
pulmonary C 68 248
capillaries C 69 248
as C 70 248
compared C 71 248
to C 72 248
ceramic C 73 248
microspheres C 74 248
. C 75 248
work C 77 248
is C 78 248
in C 79 248
progress C 80 248
to C 81 248
apply C 82 248
this C 83 248
technique C 84 248
to C 85 248
the C 86 248
study C 87 248
of C 88 248
pulmonary C 89 248
artery C 90 248
occlusion C 91 248
in C 92 248
the C 93 248
human C 94 248
. C 95 248
multivariate C 1 249
comparison C 2 249
of C 3 249
results C 4 249
of C 5 249
treatment C 6 249
in C 7 249
chronic C 8 249
lymphocytic C 9 249
and C 10 249
chronic C 11 249
granulocytic C 12 249
leukemia C 13 249
. C 14 249
the C 16 249
results C 17 249
of C 18 249
several C 19 249
clinical C 20 249
trials C 21 249
have C 22 249
been C 23 249
analyzed C 24 249
by C 25 249
multivariate C 26 249
procedures C 27 249
which C 28 249
rely C 29 249
completely C 30 249
on C 31 249
laboratory C 32 249
findings C 33 249
and C 34 249
do C 35 249
not C 36 249
involve C 37 249
scoring C 38 249
specific C 39 249
changes C 40 249
or C 41 249
subjective C 42 249
evaluations C 43 249
. C 44 249
statistically C 46 249
significant C 47 249
differences C 48 249
among C 49 249
drugs C 50 249
after C 51 249
three C 52 249
months C 53 249
of C 54 249
therapy C 55 249
were C 56 249
demonstrated C 57 249
. C 58 249
a C 60 249
relationship C 61 249
between C 62 249
the C 63 249
multivariate C 64 249
method C 65 249
and C 66 249
the C 67 249
subjective C 68 249
evaluation C 69 249
was C 70 249
demonstrated C 71 249
which C 72 249
indicates C 73 249
that C 74 249
if C 75 249
the C 76 249
subjective C 77 249
evaluation C 78 249
is C 79 249
an C 80 249
estimate C 81 249
of C 82 249
the C 83 249
physiologic C 84 249
state C 85 249
or C 86 249
prognosis C 87 249
of C 88 249
the C 89 249
patient C 90 249
, C 91 249
then C 92 249
so C 93 249
are C 94 249
the C 95 249
completely C 96 249
objective C 97 249
techniques C 98 249
used C 99 249
here C 100 249
. C 101 249
oxacillin C 1 250
- C 2 250
- C 3 250
apparent C 4 250
hematologic C 5 250
and C 6 250
hepatic C 7 250
toxicity C 8 250
. C 9 250
bone C 11 250
marrow C 12 250
depression C 13 250
and C 14 250
hepatocellular C 15 250
dysfunction C 16 250
developed C 17 250
in C 18 250
an C 19 250
allergic C 20 250
woman C 21 250
receiving C 22 250
3 C 23 250
. C 24 250
. C 25 250
gm C 26 250
. C 27 250
of C 29 250
sodium C 30 250
oxacillin C 31 250
by C 32 250
mouth C 33 250
daily C 34 250
for C 35 250
nearly C 36 250
three C 37 250
months C 38 250
. C 39 250
discontinuing C 41 250
the C 42 250
drug C 43 250
and C 44 250
administering C 45 250
corticosteroids C 46 250
and C 47 250
antibiotics C 48 250
resulted C 49 250
in C 50 250
apparent C 51 250
recovery C 52 250
. C 53 250
the C 55 250
toxic C 56 250
potentialities C 57 250
of C 58 250
oxacillin C 59 250
should C 60 250
be C 61 250
appreciated C 62 250
. C 63 250
drugs C 1 251
and C 2 251
neonatal C 3 251
jaundice C 4 251
. C 5 251
this C 7 251
paper C 8 251
is C 9 251
not C 10 251
intended C 11 251
as C 12 251
an C 13 251
exhaustive C 14 251
review C 15 251
of C 16 251
bilirubin C 17 251
metabolism C 18 251
nor C 19 251
of C 20 251
the C 21 251
many C 22 251
factors C 23 251
which C 24 251
may C 25 251
result C 26 251
in C 27 251
exaggerated C 28 251
physiologic C 29 251
jaundice C 30 251
. C 31 251
. C 33 251
for C 35 251
such C 36 251
a C 37 251
review C 38 251
the C 39 251
interested C 40 251
reader C 41 251
is C 42 251
referred C 43 251
to C 44 251
the C 45 251
excellent C 46 251
articles C 47 251
by C 48 251
zuelzer C 49 251
and C 50 251
brown C 51 251
. C 52 251
brief C 54 251
mention C 55 251
has C 56 251
been C 57 251
made C 58 251
of C 59 251
the C 60 251
mechanism C 61 251
by C 62 251
which C 63 251
certain C 64 251
drugs C 65 251
may C 66 251
contribute C 67 251
to C 68 251
the C 69 251
development C 70 251
of C 71 251
hyperbilirubinemia C 72 251
. C 73 251
a C 75 251
few C 76 251
drugs C 77 251
, C 78 251
the C 79 251
water C 80 251
- C 81 251
soluble C 82 251
vitamin C 83 251
k C 84 251
derivatives C 85 251
, C 86 251
sulfasoxazole C 87 251
( C 88 251
gantrisin C 89 251
) C 90 251
, C 91 251
the C 92 251
salicylates C 93 251
, C 94 251
and C 95 251
novobiocin C 96 251
have C 97 251
been C 98 251
unequivocally C 99 251
shown C 100 251
to C 101 251
affect C 102 251
adversely C 103 251
the C 104 251
newborn C 105 251
infant C 106 251
' C 107 251
s C 108 251
ability C 109 251
to C 110 251
handle C 111 251
bilirubin C 112 251
. C 113 251
in C 115 251
time C 116 251
other C 117 251
compounds C 118 251
will C 119 251
definitely C 120 251
be C 121 251
incriminated C 122 251
. C 123 251
it C 125 251
is C 126 251
important C 127 251
to C 128 251
remember C 129 251
that C 130 251
the C 131 251
administration C 132 251
of C 133 251
a C 134 251
drug C 135 251
to C 136 251
a C 137 251
mother C 138 251
just C 139 251
prior C 140 251
to C 141 251
delivery C 142 251
may C 143 251
result C 144 251
in C 145 251
appreciable C 146 251
concentrations C 147 251
of C 148 251
the C 149 251
compound C 150 251
in C 151 251
the C 152 251
infant C 153 251
' C 154 251
s C 155 251
serum C 156 251
, C 157 251
and C 158 251
that C 159 251
drugs C 160 251
administered C 161 251
to C 162 251
the C 163 251
nursing C 164 251
mother C 165 251
may C 166 251
be C 167 251
excreted C 168 251
in C 169 251
breast C 170 251
milk C 171 251
and C 172 251
thereby C 173 251
absorbed C 174 251
by C 175 251
the C 176 251
infant C 177 251
. C 178 251
careful C 180 251
consideration C 181 251
of C 182 251
the C 183 251
drugs C 184 251
given C 185 251
not C 186 251
only C 187 251
to C 188 251
the C 189 251
newborn C 190 251
but C 191 251
also C 192 251
to C 193 251
the C 194 251
mother C 195 251
is C 196 251
therefore C 197 251
essential C 198 251
if C 199 251
we C 200 251
are C 201 251
to C 202 251
avoid C 203 251
what C 204 251
may C 205 251
be C 206 251
termed C 207 251
iatrogenic C 208 251
hyperbilirubinemia C 209 251
. C 210 251
amputation C 1 252
in C 2 252
patients C 3 252
over C 4 252
80 C 5 252
years C 6 252
of C 7 252
age C 8 252
. C 9 252
although C 11 252
patients C 12 252
over C 13 252
80 C 14 252
years C 15 252
of C 16 252
age C 17 252
can C 18 252
be C 19 252
expected C 20 252
to C 21 252
have C 22 252
poor C 23 252
physical C 24 252
reserve C 25 252
and C 26 252
many C 27 252
co C 28 252
- C 29 252
existing C 30 252
diseases C 31 252
, C 32 252
our C 33 252
observations C 34 252
show C 35 252
that C 36 252
nevertheless C 37 252
they C 38 252
can C 39 252
be C 40 252
subjected C 41 252
to C 42 252
surgical C 43 252
procedures C 44 252
without C 45 252
undue C 46 252
mortality C 47 252
. C 48 252
the C 50 252
mortality C 51 252
rate C 52 252
can C 53 252
be C 54 252
maintained C 55 252
at C 56 252
a C 57 252
minimum C 58 252
if C 59 252
the C 60 252
surgeon C 61 252
considers C 62 252
the C 63 252
factors C 64 252
that C 65 252
contribute C 66 252
to C 67 252
its C 68 252
increase C 69 252
in C 70 252
the C 71 252
elderly C 72 252
. C 73 252
this C 75 252
necessitates C 76 252
. C 77 252
. C 79 252
1 C 81 252
) C 82 252
careful C 83 252
evaluation C 84 252
of C 85 252
the C 86 252
patient C 87 252
and C 88 252
treatment C 89 252
of C 90 252
any C 91 252
pre C 92 252
- C 93 252
existing C 94 252
or C 95 252
co C 96 252
- C 97 252
existing C 98 252
disease C 99 252
, C 100 252
2 C 101 252
) C 102 252
proper C 103 252
control C 104 252
of C 105 252
electrolytes C 106 252
, C 107 252
3 C 108 252
) C 109 252
avoidance C 110 252
of C 111 252
infection C 112 252
, C 113 252
4 C 114 252
) C 115 252
prompt C 116 252
correction C 117 252
of C 118 252
any C 119 252
postoperative C 120 252
hypotension C 121 252
, C 122 252
5 C 123 252
) C 124 252
postoperative C 125 252
pulmonary C 126 252
ventilation C 127 252
and C 128 252
tracheal C 129 252
cleansing C 130 252
, C 131 252
and C 132 252
6 C 133 252
) C 134 252
avoidance C 135 252
of C 136 252
prolonged C 137 252
surgical C 138 252
procedures C 139 252
. C 140 252
a C 142 252
group C 143 252
of C 144 252
26 C 145 252
patients C 146 252
past C 147 252
the C 148 252
age C 149 252
of C 150 252
80 C 151 252
years C 152 252
underwent C 153 252
amputation C 154 252
of C 155 252
a C 156 252
lower C 157 252
extremity C 158 252
, C 159 252
without C 160 252
undue C 161 252
mortality C 162 252
( C 163 252
9 C 164 252
deaths C 165 252
) C 166 252
. C 167 252
lumbar C 169 252
sympathectomy C 170 252
is C 171 252
not C 172 252
considered C 173 252
advisable C 174 252
in C 175 252
these C 176 252
aged C 177 252
pa C 178 252
- C 179 252
tients C 180 252
. C 181 252
the C 183 252
standard C 184 252
mid C 185 252
- C 186 252
thigh C 187 252
operation C 188 252
can C 189 252
be C 190 252
questioned C 191 252
in C 192 252
the C 193 252
younger C 194 252
patient C 195 252
, C 196 252
but C 197 252
it C 198 252
is C 199 252
the C 200 252
procedure C 201 252
of C 202 252
choice C 203 252
for C 204 252
removal C 205 252
of C 206 252
a C 207 252
gangrenous C 208 252
extremity C 209 252
in C 210 252
patients C 211 252
over C 212 252
80 C 213 252
years C 214 252
of C 215 252
age C 216 252
. C 217 252
radical C 1 253
operation C 2 253
for C 3 253
ventricular C 4 253
septal C 5 253
defect C 6 253
in C 7 253
infancy C 8 253
. C 9 253
ventricular C 11 253
septal C 12 253
defect C 13 253
is C 14 253
the C 15 253
most C 16 253
common C 17 253
congenital C 18 253
anomaly C 19 253
of C 20 253
the C 21 253
heart C 22 253
in C 23 253
infancy C 24 253
, C 25 253
and C 26 253
has C 27 253
a C 28 253
poor C 29 253
prognosis C 30 253
. C 31 253
we C 33 253
have C 34 253
operated C 35 253
upon C 36 253
18 C 37 253
infants C 38 253
all C 39 253
under C 40 253
one C 41 253
year C 42 253
of C 43 253
age C 44 253
for C 45 253
ventricular C 46 253
septal C 47 253
defect C 48 253
. C 49 253
there C 51 253
has C 52 253
been C 53 253
successful C 54 253
repair C 55 253
in C 56 253
16 C 57 253
cases C 58 253
. C 59 253
at C 61 253
present C 62 253
, C 63 253
hypothermia C 64 253
with C 65 253
a C 66 253
surface C 67 253
cooling C 68 253
method C 69 253
has C 70 253
proved C 71 253
to C 72 253
be C 73 253
superior C 74 253
to C 75 253
the C 76 253
artificial C 77 253
heart C 78 253
- C 79 253
lung C 80 253
machine C 81 253
because C 82 253
of C 83 253
the C 84 253
simplicity C 85 253
and C 86 253
the C 87 253
good C 88 253
operative C 89 253
results C 90 253
with C 91 253
its C 92 253
use C 93 253
. C 94 253
in C 96 253
addition C 97 253
, C 98 253
early C 99 253
operation C 100 253
during C 101 253
the C 102 253
infantile C 103 253
period C 104 253
will C 105 253
cause C 106 253
less C 107 253
psychological C 108 253
impact C 109 253
on C 110 253
infants C 111 253
. C 112 253
these C 114 253
advantages C 115 253
are C 116 253
sufficient C 117 253
for C 118 253
us C 119 253
to C 120 253
advocate C 121 253
radical C 122 253
operation C 123 253
of C 124 253
ventricular C 125 253
septal C 126 253
defect C 127 253
in C 128 253
infancy C 129 253
, C 130 253
even C 131 253
including C 132 253
the C 133 253
severely C 134 253
ill C 135 253
children C 136 253
. C 137 253
specific C 1 254
suppression C 2 254
of C 3 254
tumor C 4 254
growth C 5 254
by C 6 254
isolated C 7 254
peritoneal C 8 254
macrophages C 9 254
from C 10 254
immunized C 11 254
mice C 12 254
. C 13 254
methods C 15 254
were C 16 254
presented C 17 254
by C 18 254
which C 19 254
macrophages C 20 254
may C 21 254
be C 22 254
isolated C 23 254
from C 24 254
the C 25 254
peritoneal C 26 254
cell C 27 254
population C 28 254
of C 29 254
mice C 30 254
. C 31 254
these C 33 254
cells C 34 254
, C 35 254
and C 36 254
for C 37 254
comparison C 38 254
peritoneal C 39 254
lymphocytes C 40 254
and C 41 254
lymph C 42 254
node C 43 254
cells C 44 254
, C 45 254
were C 46 254
tested C 47 254
for C 48 254
immunologic C 49 254
activity C 50 254
by C 51 254
injecting C 52 254
a C 53 254
mixture C 54 254
of C 55 254
the C 56 254
test C 57 254
cells C 58 254
and C 59 254
tumor C 60 254
cells C 61 254
subcutaneously C 62 254
into C 63 254
irradiated C 64 254
mice C 65 254
. C 66 254
each C 68 254
cell C 69 254
type C 70 254
, C 71 254
when C 72 254
obtained C 73 254
from C 74 254
immunized C 75 254
mice C 76 254
, C 77 254
was C 78 254
capable C 79 254
of C 80 254
suppressing C 81 254
the C 82 254
growth C 83 254
of C 84 254
the C 85 254
specific C 86 254
tumor C 87 254
cells C 88 254
. C 89 254
the C 91 254
results C 92 254
are C 93 254
discussed C 94 254
with C 95 254
respect C 96 254
to C 97 254
a C 98 254
possible C 99 254
specific C 100 254
immunologic C 101 254
function C 102 254
for C 103 254
macrophages C 104 254
in C 105 254
graft C 106 254
rejection C 107 254
. C 108 254
effect C 1 255
of C 2 255
heterologous C 3 255
antiserum C 4 255
and C 5 255
complement C 6 255
on C 7 255
glycolysis C 8 255
of C 9 255
tumor C 10 255
cells C 11 255
. C 12 255
the C 14 255
effect C 15 255
of C 16 255
heterologous C 17 255
antiserum C 18 255
and C 19 255
complement C 20 255
on C 21 255
glucose C 22 255
metabolism C 23 255
of C 24 255
rat C 25 255
ascites C 26 255
tumor C 27 255
cells C 28 255
was C 29 255
examined C 30 255
to C 31 255
clarify C 32 255
the C 33 255
mechanism C 34 255
of C 35 255
the C 36 255
cytotoxic C 37 255
effect C 38 255
of C 39 255
antibody C 40 255
. C 41 255
1 C 43 255
. C 44 255
lactate C 46 255
- C 47 255
production C 48 255
of C 49 255
the C 50 255
target C 51 255
cells C 52 255
was C 53 255
inhibited C 54 255
by C 55 255
the C 56 255
cooperation C 57 255
of C 58 255
antiserum C 59 255
and C 60 255
complement C 61 255
, C 62 255
while C 63 255
no C 64 255
inhibition C 65 255
was C 66 255
observed C 67 255
when C 68 255
the C 69 255
cells C 70 255
were C 71 255
subjected C 72 255
to C 73 255
either C 74 255
antiserum C 75 255
or C 76 255
complement C 77 255
alone C 78 255
. C 79 255
the C 81 255
inhibition C 82 255
of C 83 255
lactate C 84 255
- C 85 255
production C 86 255
was C 87 255
observed C 88 255
under C 89 255
both C 90 255
acrobic C 91 255
and C 92 255
anacrobic C 93 255
conditions C 94 255
. C 95 255
no C 97 255
effect C 98 255
of C 99 255
the C 100 255
antiserum C 101 255
and C 102 255
complement C 103 255
was C 104 255
observed C 105 255
on C 106 255
the C 107 255
oxygen C 108 255
consumption C 109 255
of C 110 255
the C 111 255
cells C 112 255
. C 113 255
2 C 115 255
. C 116 255
the C 118 255
amount C 119 255
of C 120 255
antiserum C 121 255
necessary C 122 255
for C 123 255
the C 124 255
inhibition C 125 255
of C 126 255
lactate C 127 255
- C 128 255
production C 129 255
of C 130 255
the C 131 255
cells C 132 255
was C 133 255
determined C 134 255
in C 135 255
the C 136 255
presence C 137 255
of C 138 255
a C 139 255
definite C 140 255
amount C 141 255
of C 142 255
complement C 143 255
, C 144 255
and C 145 255
it C 146 255
was C 147 255
found C 148 255
that C 149 255
the C 150 255
degree C 151 255
of C 152 255
inhibition C 153 255
was C 154 255
not C 155 255
in C 156 255
parallel C 157 255
with C 158 255
the C 159 255
concentration C 160 255
of C 161 255
antiserum C 162 255
beyond C 163 255
a C 164 255
certain C 165 255
threshold C 166 255
. C 167 255
on C 169 255
the C 170 255
other C 171 255
hand C 172 255
, C 173 255
a C 174 255
parallelism C 175 255
was C 176 255
observed C 177 255
between C 178 255
the C 179 255
amount C 180 255
of C 181 255
complement C 182 255
and C 183 255
the C 184 255
rate C 185 255
of C 186 255
inhibition C 187 255
of C 188 255
lactate C 189 255
- C 190 255
production C 191 255
when C 192 255
different C 193 255
amounts C 194 255
of C 195 255
complement C 196 255
were C 197 255
added C 198 255
to C 199 255
a C 200 255
definite C 201 255
amount C 202 255
of C 203 255
antiserum C 204 255
. C 205 255
3 C 207 255
. C 208 255
similar C 210 255
inhibitory C 211 255
effects C 212 255
of C 213 255
the C 214 255
antiserum C 215 255
and C 216 255
complement C 217 255
on C 218 255
lactate C 219 255
- C 220 255
production C 221 255
of C 222 255
the C 223 255
cells C 224 255
from C 225 255
glucose C 226 255
, C 227 255
fructose C 228 255
- C 229 255
1 C 230 255
, C 231 255
6 C 232 255
- C 233 255
diphosphate C 234 255
, C 235 255
and C 236 255
pyruvate C 237 255
suggested C 238 255
that C 239 255
the C 240 255
inhibition C 241 255
occurred C 242 255
toward C 243 255
the C 244 255
final C 245 255
step C 246 255
of C 247 255
glycolytic C 248 255
process C 249 255
of C 250 255
the C 251 255
cells C 252 255
. C 253 255
soluble C 1 256
tissue C 2 256
antigens C 3 256
in C 4 256
human C 5 256
brain C 6 256
tumor C 7 256
and C 8 256
cerebrospinal C 9 256
fluid C 10 256
. C 11 256
an C 13 256
a C 14 256
- C 15 256
2 C 16 256
globulin C 17 256
antigen C 18 256
present C 19 256
in C 20 256
human C 21 256
glioblastomas C 22 256
and C 23 256
immunologically C 24 256
identical C 25 256
with C 26 256
antigens C 27 256
present C 28 256
in C 29 256
human C 30 256
brain C 31 256
, C 32 256
liver C 33 256
, C 34 256
spleen C 35 256
, C 36 256
and C 37 256
metastatic C 38 256
carcinoma C 39 256
cyst C 40 256
fluid C 41 256
has C 42 256
been C 43 256
described C 44 256
. C 45 256
this C 47 256
protein C 48 256
antigen C 49 256
is C 50 256
not C 51 256
present C 52 256
in C 53 256
plasma C 54 256
, C 55 256
wbc C 56 256
, C 57 256
or C 58 256
normal C 59 256
csf C 60 256
. C 61 256
it C 63 256
has C 64 256
been C 65 256
demonstrated C 66 256
in C 67 256
the C 68 256
csf C 69 256
of C 70 256
three C 71 256
of C 72 256
27 C 73 256
patients C 74 256
with C 75 256
tumors C 76 256
of C 77 256
the C 78 256
central C 79 256
nervous C 80 256
system C 81 256
. C 82 256
when C 84 256
present C 85 256
, C 86 256
it C 87 256
may C 88 256
represent C 89 256
a C 90 256
specific C 91 256
tissue C 92 256
protein C 93 256
fraction C 94 256
contributed C 95 256
by C 96 256
either C 97 256
the C 98 256
tumor C 99 256
itself C 100 256
or C 101 256
the C 102 256
adjacent C 103 256
cns C 104 256
tissue C 105 256
. C 106 256
the C 108 256
major C 109 256
protein C 110 256
components C 111 256
of C 112 256
normal C 113 256
and C 114 256
abnormal C 115 256
csf C 116 256
are C 117 256
derived C 118 256
from C 119 256
, C 120 256
or C 121 256
, C 122 256
at C 123 256
least C 124 256
, C 125 256
antigenically C 126 256
identical C 127 256
to C 128 256
, C 129 256
the C 130 256
plasma C 131 256
proteins C 132 256
. C 133 256
the C 1 257
apparent C 2 257
immunofluorescence C 3 257
of C 4 257
tissue C 5 257
mast C 6 257
cells C 7 257
. C 8 257
both C 10 257
rat C 11 257
mast C 12 257
cells C 13 257
and C 14 257
rat C 15 257
cosinophils C 16 257
exhibited C 17 257
fluorescence C 18 257
in C 19 257
blue C 20 257
violet C 21 257
light C 22 257
after C 23 257
treatment C 24 257
with C 25 257
fitc C 26 257
- C 27 257
conjugated C 28 257
rabbit C 29 257
anti C 30 257
- C 31 257
rat C 32 257
g C 33 257
- C 34 257
globulin C 35 257
and C 36 257
in C 37 257
each C 38 257
cell C 39 257
this C 40 257
fluorescence C 41 257
was C 42 257
immunologically C 43 257
nonspecific C 44 257
. C 45 257
whereas C 47 257
cosinophils C 48 257
fluoresced C 49 257
after C 50 257
treatment C 51 257
with C 52 257
fluorescein C 53 257
alone C 54 257
, C 55 257
mast C 56 257
cells C 57 257
fluoresced C 58 257
only C 59 257
after C 60 257
treatment C 61 257
with C 62 257
a C 63 257
protein C 64 257
conjugate C 65 257
containing C 66 257
g C 67 257
- C 68 257
globulin C 69 257
. C 70 257
the C 72 257
phenomenon C 73 257
was C 74 257
observed C 75 257
in C 76 257
cells C 77 257
from C 78 257
different C 79 257
organs C 80 257
and C 81 257
the C 82 257
fluorescence C 83 257
was C 84 257
seen C 85 257
to C 86 257
be C 87 257
associated C 88 257
with C 89 257
the C 90 257
cytoplasmic C 91 257
granules C 92 257
normally C 93 257
present C 94 257
in C 95 257
these C 96 257
cells C 97 257
. C 98 257
the C 1 258
determinants C 2 258
of C 3 258
cerebrospinal C 4 258
fluid C 5 258
po C 6 258
2 C 7 258
the C 8 258
effects C 9 258
of C 10 258
oxygen C 11 258
and C 12 258
carbon C 13 258
dioxide C 14 258
breathing C 15 258
in C 16 258
patients C 17 258
with C 18 258
chronic C 19 258
lung C 20 258
disease C 21 258
. C 22 258
the C 24 258
lumbar C 25 258
cerebrospinal C 26 258
fluid C 27 258
po C 28 258
2 C 29 258
of C 30 258
some C 31 258
hypoxemic C 32 258
hypercapnic C 33 258
patients C 34 258
with C 35 258
chronic C 36 258
lung C 37 258
disease C 38 258
is C 39 258
the C 40 258
same C 41 258
as C 42 258
that C 43 258
of C 44 258
patients C 45 258
without C 46 258
chronic C 47 258
lung C 48 258
disease C 49 258
. C 50 258
breathing C 52 258
95 C 53 258
oxygen C 54 258
with C 55 258
5 C 56 258
carbon C 57 258
dioxide C 58 258
increased C 59 258
lumbar C 60 258
cerebrospinal C 61 258
fluid C 62 258
po C 63 258
2 C 64 258
more C 65 258
than C 66 258
breathing C 67 258
95 C 68 258
oxygen C 69 258
with C 70 258
5 C 71 258
nitrogen C 72 258
. C 73 258
the C 75 258
change C 76 258
in C 77 258
cerebrospinal C 78 258
fluid C 79 258
po C 80 258
2 C 81 258
is C 82 258
closely C 83 258
related C 84 258
to C 85 258
the C 86 258
change C 87 258
in C 88 258
arterial C 89 258
pco C 90 258
2 C 91 258
, C 92 258
and C 93 258
this C 94 258
relationship C 95 258
is C 96 258
similar C 97 258
to C 98 258
the C 99 258
relationship C 100 258
between C 101 258
arterial C 102 258
pco C 103 258
2 C 104 258
and C 105 258
cerebral C 106 258
blood C 107 258
flow C 108 258
in C 109 258
patients C 110 258
with C 111 258
and C 112 258
without C 113 258
hypercapnia C 114 258
. C 115 258
interpretation C 117 258
of C 118 258
these C 119 258
observations C 120 258
must C 121 258
be C 122 258
qualified C 123 258
by C 124 258
the C 125 258
following C 126 258
. C 127 258
. C 129 258
cisternal C 131 258
cerebrospinal C 132 258
fluid C 133 258
po C 134 258
2 C 135 258
differs C 136 258
from C 137 258
lumbar C 138 258
cerebrospinal C 139 258
fluid C 140 258
po C 141 258
2 C 142 258
in C 143 258
its C 144 258
response C 145 258
to C 146 258
breathing C 147 258
oxygen C 148 258
with C 149 258
carbon C 150 258
dioxide C 151 258
, C 152 258
. C 153 258
regulation C 155 258
of C 156 258
blood C 157 258
flow C 158 258
to C 159 258
the C 160 258
spinal C 161 258
cord C 162 258
and C 163 258
nerve C 164 258
roots C 165 258
is C 166 258
not C 167 258
known C 168 258
to C 169 258
be C 170 258
comparable C 171 258
to C 172 258
that C 173 258
of C 174 258
the C 175 258
brain C 176 258
, C 177 258
. C 178 258
and C 180 258
factors C 181 258
other C 182 258
than C 183 258
blood C 184 258
flow C 185 258
may C 186 258
have C 187 258
contributed C 188 258
to C 189 258
the C 190 258
changes C 191 258
of C 192 258
cerebrospinal C 193 258
fluid C 194 258
po C 195 258
2 C 196 258
. C 197 258
the C 1 259
behavior C 2 259
of C 3 259
lymphocytes C 4 259
in C 5 259
primary C 6 259
explants C 7 259
of C 8 259
human C 9 259
lung C 10 259
cancer C 11 259
in C 12 259
vitro C 13 259
. C 14 259
the C 16 259
activity C 17 259
of C 18 259
lymphocytes C 19 259
within C 20 259
outgrowths C 21 259
from C 22 259
explanted C 23 259
tissue C 24 259
fragments C 25 259
of C 26 259
20 C 27 259
human C 28 259
lung C 29 259
cancers C 30 259
has C 31 259
been C 32 259
studied C 33 259
. C 34 259
the C 36 259
study C 37 259
included C 38 259
cancer C 39 259
- C 40 259
bearing C 41 259
tissue C 42 259
explants C 43 259
from C 44 259
all C 45 259
cases C 46 259
and C 47 259
noncancerbearing C 48 259
lung C 49 259
tissue C 50 259
from C 51 259
4 C 52 259
of C 53 259
the C 54 259
20 C 55 259
cases C 56 259
. C 57 259
five C 59 259
major C 60 259
categories C 61 259
of C 62 259
lymphocytic C 63 259
behavior C 64 259
were C 65 259
derived C 66 259
from C 67 259
the C 68 259
study C 69 259
, C 70 259
namely C 71 259
. C 72 259
. C 74 259
( C 76 259
1 C 77 259
) C 78 259
emigration C 79 259
and C 80 259
migration C 81 259
of C 82 259
lymphocytes C 83 259
from C 84 259
the C 85 259
explant C 86 259
, C 87 259
. C 88 259
( C 90 259
2 C 91 259
) C 92 259
clustering C 93 259
of C 94 259
lymphocytes C 95 259
around C 96 259
/ C 97 259
target C 98 259
/ C 99 259
cells C 100 259
, C 101 259
. C 102 259
( C 104 259
3 C 105 259
) C 106 259
ameboid C 107 259
transformation C 108 259
of C 109 259
lymphocytes C 110 259
, C 111 259
. C 112 259
( C 114 259
4 C 115 259
) C 116 259
lymphocytic C 117 259
congregation C 118 259
, C 119 259
. C 120 259
and C 122 259
( C 123 259
5 C 124 259
) C 125 259
emperipolesis C 126 259
. C 127 259
criteria C 129 259
for C 130 259
these C 131 259
different C 132 259
lymphocytic C 133 259
activities C 134 259
have C 135 259
been C 136 259
amplified C 137 259
or C 138 259
introduced C 139 259
. C 140 259
findings C 142 259
of C 143 259
particular C 144 259
interest C 145 259
were C 146 259
. C 147 259
. C 149 259
( C 151 259
1 C 152 259
) C 153 259
the C 154 259
frequency C 155 259
of C 156 259
both C 157 259
via C 158 259
ble C 159 259
and C 160 259
nonviable C 161 259
lymphocytes C 162 259
within C 163 259
the C 164 259
vacuoles C 165 259
of C 166 259
other C 167 259
cells C 168 259
. C 169 259
this C 171 259
observation C 172 259
is C 173 259
considered C 174 259
to C 175 259
be C 176 259
an C 177 259
absolute C 178 259
criterion C 179 259
for C 180 259
the C 181 259
recogni C 182 259
- C 183 259
tion C 184 259
of C 185 259
emperipolesis C 186 259
. C 187 259
a C 189 259
subsequent C 190 259
/ C 191 259
inclusionbody C 192 259
/ C 193 259
appearance C 194 259
of C 195 259
the C 196 259
dead C 197 259
lymphocytes C 198 259
has C 199 259
been C 200 259
observed C 201 259
. C 202 259
( C 204 259
2 C 205 259
) C 206 259
the C 207 259
intimate C 208 259
relationship C 209 259
of C 210 259
ameboid C 211 259
forms C 212 259
of C 213 259
lymphocytes C 214 259
to C 215 259
selected C 216 259
cells C 217 259
, C 218 259
resulting C 219 259
in C 220 259
a C 221 259
juxtanuclear C 222 259
and C 223 259
frequently C 224 259
unipolar C 225 259
crowding C 226 259
of C 227 259
one C 228 259
cell C 229 259
by C 230 259
numerous C 231 259
lymphocytes C 232 259
while C 233 259
nearby C 234 259
cells C 235 259
were C 236 259
totally C 237 259
devoid C 238 259
of C 239 259
ameboid C 240 259
lymphocytes C 241 259
. C 242 259
reasons C 244 259
are C 245 259
given C 246 259
to C 247 259
support C 248 259
the C 249 259
impression C 250 259
that C 251 259
this C 252 259
phenomenon C 253 259
is C 254 259
re C 255 259
lated C 256 259
to C 257 259
sensitization C 258 259
. C 259 259
there C 261 259
is C 262 259
also C 263 259
the C 264 259
possibility C 265 259
that C 266 259
the C 267 259
phenomenon C 268 259
may C 269 259
indicate C 270 259
that C 271 259
the C 272 259
lymphocyte C 273 259
is C 274 259
/ C 275 259
conditioned C 276 259
/ C 277 259
. C 278 259
( C 280 259
3 C 281 259
) C 282 259
the C 283 259
apparent C 284 259
entry C 285 259
of C 286 259
the C 287 259
lymphocyte C 288 259
into C 289 259
the C 290 259
cell C 291 259
has C 292 259
been C 293 259
recorded C 294 259
by C 295 259
timelapse C 296 259
cinematography C 297 259
. C 298 259
a C 300 259
lymphocyte C 301 259
relationship C 302 259
to C 303 259
cancer C 304 259
cells C 305 259
was C 306 259
infrequently C 307 259
found C 308 259
although C 309 259
explants C 310 259
of C 311 259
15 C 312 259
of C 313 259
the C 314 259
20 C 315 259
cases C 316 259
produced C 317 259
identifiable C 318 259
cancer C 319 259
cells C 320 259
and C 321 259
lymphocytes C 322 259
emigrated C 323 259
from C 324 259
the C 325 259
explants C 326 259
of C 327 259
all C 328 259
20 C 329 259
cases C 330 259
. C 331 259
it C 333 259
is C 334 259
not C 335 259
apparent C 336 259
from C 337 259
this C 338 259
limited C 339 259
study C 340 259
whether C 341 259
this C 342 259
is C 343 259
a C 344 259
significant C 345 259
finding C 346 259
. C 347 259
ventricular C 1 260
septal C 2 260
defect C 3 260
with C 4 260
aortic C 5 260
insufficiency C 6 260
a C 7 260
clinical C 8 260
and C 9 260
hemodynamic C 10 260
study C 11 260
of C 12 260
18 C 13 260
proved C 14 260
cases C 15 260
. C 16 260
eighteen C 18 260
patients C 19 260
with C 20 260
the C 21 260
combination C 22 260
of C 23 260
ventricular C 24 260
septal C 25 260
defect C 26 260
and C 27 260
aortic C 28 260
insufficiency C 29 260
were C 30 260
studied C 31 260
. C 32 260
nine C 34 260
also C 35 260
had C 36 260
infundibular C 37 260
pulmonary C 38 260
stenosis C 39 260
. C 40 260
seventeen C 42 260
were C 43 260
treated C 44 260
by C 45 260
open C 46 260
- C 47 260
heart C 48 260
operations C 49 260
. C 50 260
the C 52 260
physical C 53 260
findings C 54 260
were C 55 260
those C 56 260
of C 57 260
a C 58 260
typical C 59 260
ventricular C 60 260
defect C 61 260
murmur C 62 260
and C 63 260
thrill C 64 260
together C 65 260
with C 66 260
an C 67 260
aortic C 68 260
insufficiency C 69 260
blow C 70 260
and C 71 260
a C 72 260
wide C 73 260
pulse C 74 260
pressure C 75 260
. C 76 260
a C 78 260
systolic C 79 260
murmur C 80 260
at C 81 260
the C 82 260
upper C 83 260
left C 84 260
sternal C 85 260
border C 86 260
with C 87 260
thrill C 88 260
is C 89 260
strongly C 90 260
suggestive C 91 260
of C 92 260
the C 93 260
additional C 94 260
lesion C 95 260
of C 96 260
infundibular C 97 260
pulmonary C 98 260
stenosis C 99 260
, C 100 260
but C 101 260
the C 102 260
presence C 103 260
or C 104 260
absence C 105 260
of C 106 260
infundibular C 107 260
pulmonary C 108 260
stenosis C 109 260
was C 110 260
indicated C 111 260
most C 112 260
accurately C 113 260
at C 114 260
cardiac C 115 260
catheterization C 116 260
and C 117 260
on C 118 260
inspection C 119 260
at C 120 260
operation C 121 260
. C 122 260
it C 124 260
was C 125 260
not C 126 260
of C 127 260
sufficient C 128 260
severity C 129 260
for C 130 260
signs C 131 260
of C 132 260
additional C 133 260
right C 134 260
ventricular C 135 260
hypertrophy C 136 260
to C 137 260
appear C 138 260
on C 139 260
the C 140 260
electrocardiogram C 141 260
. C 142 260
retrograde C 144 260
aortography C 145 260
serves C 146 260
to C 147 260
demonstrate C 148 260
the C 149 260
severity C 150 260
of C 151 260
the C 152 260
aortic C 153 260
regurgitation C 154 260
. C 155 260
the C 157 260
problem C 158 260
of C 159 260
the C 160 260
surgical C 161 260
correction C 162 260
of C 163 260
these C 164 260
lesions C 165 260
will C 166 260
be C 167 260
the C 168 260
subject C 169 260
of C 170 260
a C 171 260
separate C 172 260
communication C 173 260
. C 174 260
radioisotope C 1 261
photoscanning C 2 261
as C 3 261
a C 4 261
diagnostic C 5 261
aid C 6 261
in C 7 261
cardiovascular C 8 261
disease C 9 261
a C 10 261
safe C 11 261
, C 12 261
simple C 13 261
method C 14 261
for C 15 261
diagnosing C 16 261
pericardial C 17 261
effusion C 18 261
and C 19 261
aneurysm C 20 261
. C 21 261
radioisotope C 23 261
scanning C 24 261
is C 25 261
a C 26 261
safe C 27 261
, C 28 261
simple C 29 261
, C 30 261
and C 31 261
useful C 32 261
method C 33 261
for C 34 261
the C 35 261
diagnosis C 36 261
of C 37 261
pericardial C 38 261
effusion C 39 261
and C 40 261
aortic C 41 261
aneurysm C 42 261
. C 43 261
the C 45 261
whole C 46 261
- C 47 261
body C 48 261
radiation C 49 261
dose C 50 261
, C 51 261
approximately C 52 261
25 C 53 261
millirads C 54 261
from C 55 261
300 C 56 261
of C 57 261
i C 58 261
131 C 59 261
- C 60 261
sodium C 61 261
iodipamide C 62 261
, C 63 261
is C 64 261
no C 65 261
greater C 66 261
than C 67 261
the C 68 261
dose C 69 261
received C 70 261
from C 71 261
a C 72 261
standard C 73 261
posteroanterior C 74 261
chest C 75 261
roentgenogram C 76 261
or C 77 261
a C 78 261
blood C 79 261
volume C 80 261
determination C 81 261
. C 82 261
there C 84 261
are C 85 261
no C 86 261
side C 87 261
effects C 88 261
or C 89 261
complications C 90 261
from C 91 261
the C 92 261
procedure C 93 261
, C 94 261
and C 95 261
it C 96 261
is C 97 261
well C 98 261
tolerated C 99 261
by C 100 261
the C 101 261
patient C 102 261
. C 103 261
the C 105 261
scan C 106 261
can C 107 261
be C 108 261
repeated C 109 261
at C 110 261
intervals C 111 261
to C 112 261
assess C 113 261
progress C 114 261
of C 115 261
the C 116 261
disease C 117 261
or C 118 261
response C 119 261
to C 120 261
treatment C 121 261
. C 122 261
cardiovascular C 124 261
scanning C 125 261
with C 126 261
radioactive C 127 261
isotopes C 128 261
can C 129 261
be C 130 261
recommended C 131 261
as C 132 261
a C 133 261
useful C 134 261
and C 135 261
safe C 136 261
diagnostic C 137 261
tool C 138 261
. C 139 261
studies C 1 262
of C 2 262
hematology C 3 262
and C 4 262
bone C 5 262
marrow C 6 262
morphology C 7 262
in C 8 262
vitamin C 9 262
e C 10 262
- C 11 262
deficient C 12 262
pigs C 13 262
. C 14 262
forty C 16 262
- C 17 262
four C 18 262
pigs C 19 262
were C 20 262
used C 21 262
in C 22 262
two C 23 262
experiments C 24 262
whose C 25 262
purpose C 26 262
was C 27 262
to C 28 262
produce C 29 262
a C 30 262
deficiency C 31 262
of C 32 262
vitamin C 33 262
e C 34 262
. C 35 262
the C 37 262
anemia C 38 262
and C 39 262
changes C 40 262
in C 41 262
bone C 42 262
marrow C 43 262
morphology C 44 262
occurring C 45 262
in C 46 262
the C 47 262
vitamin C 48 262
e C 49 262
- C 50 262
deficient C 51 262
state C 52 262
are C 53 262
described C 54 262
. C 55 262
the C 57 262
hematologic C 58 262
disorders C 59 262
include C 60 262
low C 61 262
hemoglobin C 62 262
and C 63 262
hematocrit C 64 262
values C 65 262
, C 66 262
leucocytosis C 67 262
and C 68 262
granulocytosis C 69 262
. C 70 262
nuclear C 72 262
abnormalities C 73 262
were C 74 262
observed C 75 262
in C 76 262
the C 77 262
erythroid C 78 262
precursors C 79 262
in C 80 262
the C 81 262
bone C 82 262
marrow C 83 262
, C 84 262
many C 85 262
of C 86 262
the C 87 262
cells C 88 262
being C 89 262
multinucleated C 90 262
. C 91 262
giant C 93 262
multinucleated C 94 262
cells C 95 262
of C 96 262
megakaryocyte C 97 262
type C 98 262
were C 99 262
frequently C 100 262
found C 101 262
. C 102 262
significance C 1 263
of C 2 263
blood C 3 263
groups C 4 263
in C 5 263
homotransplantation C 6 263
of C 7 263
marrow C 8 263
in C 9 263
the C 10 263
dog C 11 263
ten C 12 263
dogs C 13 263
were C 14 263
given C 15 263
1 C 16 263
, C 17 263
500 C 18 263
r C 19 263
whole C 20 263
- C 21 263
body C 22 263
irradiation C 23 263
and C 24 263
an C 25 263
infusion C 26 263
of C 27 263
allogeneic C 28 263
marrow C 29 263
from C 30 263
a C 31 263
donor C 32 263
matched C 33 263
with C 34 263
respect C 35 263
to C 36 263
six C 37 263
erythrocyte C 38 263
antigens C 39 263
. C 40 263
methotrexate C 42 263
was C 43 263
given C 44 263
to C 45 263
reduce C 46 263
secondary C 47 263
syndromes C 48 263
. C 49 263
four C 51 263
dogs C 52 263
survived C 53 263
. C 54 263
in C 56 263
a C 57 263
similar C 58 263
experiment C 59 263
with C 60 263
10 C 61 263
dogs C 62 263
, C 63 263
in C 64 263
which C 65 263
no C 66 263
effort C 67 263
was C 68 263
made C 69 263
to C 70 263
match C 71 263
donors C 72 263
and C 73 263
recipients C 74 263
, C 75 263
three C 76 263
dogs C 77 263
survived C 78 263
. C 79 263
it C 81 263
was C 82 263
concluded C 83 263
that C 84 263
matching C 85 263
of C 86 263
donor C 87 263
and C 88 263
recipient C 89 263
for C 90 263
these C 91 263
six C 92 263
red C 93 263
cell C 94 263
antigens C 95 263
did C 96 263
not C 97 263
increase C 98 263
significantly C 99 263
the C 100 263
longterm C 101 263
survival C 102 263
rate C 103 263
of C 104 263
lethally C 105 263
irradiated C 106 263
dogs C 107 263
with C 108 263
allogeneic C 109 263
marrow C 110 263
grafts C 111 263
. C 112 263
radioautographic C 1 264
studies C 2 264
of C 3 264
bone C 4 264
marrow C 5 264
lymphocytes C 6 264
in C 7 264
vivo C 8 264
and C 9 264
in C 10 264
diffusion C 11 264
chamber C 12 264
cultures C 13 264
. C 14 264
radioautography C 16 264
with C 17 264
tritiated C 18 264
thymidine C 19 264
has C 20 264
been C 21 264
utilized C 22 264
to C 23 264
examine C 24 264
the C 25 264
turnover C 26 264
rate C 27 264
and C 28 264
origin C 29 264
of C 30 264
small C 31 264
lymphocytes C 32 264
in C 33 264
the C 34 264
bone C 35 264
marrow C 36 264
of C 37 264
the C 38 264
guinea C 39 264
- C 40 264
pig C 41 264
. C 42 264
very C 44 264
few C 45 264
marrow C 46 264
lymphocytes C 47 264
were C 48 264
initially C 49 264
labeled C 50 264
by C 51 264
a C 52 264
single C 53 264
injection C 54 264
of C 55 264
tritiated C 56 264
thymidine C 57 264
, C 58 264
but C 59 264
thereafter C 60 264
the C 61 264
number C 62 264
of C 63 264
labeled C 64 264
lym C 65 264
phocytes C 66 264
rapidly C 67 264
increased C 68 264
to C 69 264
high C 70 264
maximum C 71 264
levels C 72 264
at C 73 264
3 C 74 264
days C 75 264
. C 76 264
analysis C 78 264
of C 79 264
the C 80 264
labeling C 81 264
curves C 82 264
and C 83 264
grain C 84 264
counts C 85 264
indicates C 86 264
that C 87 264
the C 88 264
population C 89 264
of C 90 264
marrow C 91 264
lymphocytes C 92 264
is C 93 264
maintained C 94 264
in C 95 264
a C 96 264
dynamic C 97 264
steady C 98 264
state C 99 264
with C 100 264
an C 101 264
average C 102 264
turnover C 103 264
time C 104 264
of C 105 264
3 C 106 264
days C 107 264
or C 108 264
less C 109 264
. C 110 264
suspensions C 112 264
of C 113 264
bone C 114 264
marrow C 115 264
cells C 116 264
were C 117 264
isolated C 118 264
from C 119 264
the C 120 264
circulation C 121 264
within C 122 264
intraperitoneal C 123 264
diffusion C 124 264
chambers C 125 264
after C 126 264
short C 127 264
- C 128 264
term C 129 264
labeling C 130 264
with C 131 264
tritiated C 132 264
thymidine C 133 264
in C 134 264
vivo C 135 264
. C 136 264
although C 138 264
very C 139 264
few C 140 264
small C 141 264
lymphocytes C 142 264
were C 143 264
labeled C 144 264
when C 145 264
introduced C 146 264
into C 147 264
the C 148 264
diffusion C 149 264
chambers C 150 264
, C 151 264
a C 152 264
considerable C 153 264
percentage C 154 264
became C 155 264
labeled C 156 264
during C 157 264
the C 158 264
subsequent C 159 264
culture C 160 264
period C 161 264
. C 162 264
tritiated C 164 264
thymidine C 165 264
was C 166 264
also C 167 264
administered C 168 264
intravenously C 169 264
whilst C 170 264
excluded C 171 264
from C 172 264
one C 173 264
hind C 174 264
limb C 175 264
by C 176 264
the C 177 264
application C 178 264
of C 179 264
an C 180 264
occlusive C 181 264
compression C 182 264
bandage C 183 264
for C 184 264
20 C 185 264
minutes C 186 264
. C 187 264
very C 189 264
few C 190 264
labeled C 191 264
small C 192 264
lymphocytes C 193 264
were C 194 264
found C 195 264
after C 196 264
72 C 197 264
hours C 198 264
in C 199 264
the C 200 264
tibial C 201 264
marrow C 202 264
of C 203 264
the C 204 264
initially C 205 264
occluded C 206 264
limb C 207 264
, C 208 264
whereas C 209 264
the C 210 264
normal C 211 264
high C 212 264
percentage C 213 264
was C 214 264
labeled C 215 264
in C 216 264
the C 217 264
control C 218 264
tibial C 219 264
marrow C 220 264
. C 221 264
these C 223 264
experiments C 224 264
do C 225 264
not C 226 264
demonstrate C 227 264
any C 228 264
large C 229 264
- C 230 264
scale C 231 264
influx C 232 264
of C 233 264
small C 234 264
lymphocytes C 235 264
from C 236 264
the C 237 264
blood C 238 264
stream C 239 264
into C 240 264
the C 241 264
marrow C 242 264
parenchyma C 243 264
. C 244 264
they C 246 264
suggest C 247 264
that C 248 264
newly C 249 264
formed C 250 264
small C 251 264
lymphocytes C 252 264
appear C 253 264
in C 254 264
the C 255 264
marrow C 256 264
as C 257 264
a C 258 264
result C 259 264
of C 260 264
the C 261 264
division C 262 264
of C 263 264
locally C 264 264
situated C 265 264
precursor C 266 264
cells C 267 264
, C 268 264
but C 269 264
the C 270 264
mechanism C 271 264
of C 272 264
intramedullary C 273 264
lymphocytopoiesis C 274 264
is C 275 264
uncertain C 276 264
. C 277 264
/ C 279 264
transitional C 280 264
/ C 281 264
cells C 282 264
, C 283 264
intermediate C 284 264
in C 285 264
morphology C 286 264
between C 287 264
blast C 288 264
cells C 289 264
and C 290 264
small C 291 264
lymphocytes C 292 264
, C 293 264
synthesize C 294 264
dna C 295 264
and C 296 264
are C 297 264
actively C 298 264
proliferative C 299 264
, C 300 264
but C 301 264
they C 302 264
do C 303 264
not C 304 264
appear C 305 264
to C 306 264
account C 307 264
fully C 308 264
for C 309 264
the C 310 264
rate C 311 264
of C 312 264
lymphocyte C 313 264
production C 314 264
. C 315 264
certain C 317 264
large C 318 264
, C 319 264
undifferentiated C 320 264
labeled C 321 264
cells C 322 264
appeared C 323 264
in C 324 264
the C 325 264
bone C 326 264
marrow C 327 264
as C 328 264
a C 329 264
result C 330 264
of C 331 264
hematogenous C 332 264
migration C 333 264
. C 334 264
some C 336 264
implications C 337 264
of C 338 264
these C 339 264
findings C 340 264
are C 341 264
discussed C 342 264
. C 343 264
autoradiographic C 1 265
study C 2 265
on C 3 265
the C 4 265
origin C 5 265
and C 6 265
fate C 7 265
of C 8 265
small C 9 265
lymphoid C 10 265
cells C 11 265
in C 12 265
the C 13 265
dog C 14 265
bone C 15 265
marrow C 16 265
. C 17 265
. C 19 265
effect C 21 265
of C 22 265
femoral C 23 265
artery C 24 265
clamping C 25 265
during C 26 265
in C 27 265
vivo C 28 265
availability C 29 265
of C 30 265
h C 31 265
3 C 32 265
- C 33 265
thymidine C 34 265
. C 35 265
the C 37 265
origin C 38 265
and C 39 265
fate C 40 265
of C 41 265
small C 42 265
lymphoid C 43 265
cells C 44 265
in C 45 265
the C 46 265
dog C 47 265
bone C 48 265
marrow C 49 265
were C 50 265
studied C 51 265
autoradiographically C 52 265
by C 53 265
observing C 54 265
the C 55 265
effect C 56 265
of C 57 265
clamping C 58 265
of C 59 265
the C 60 265
femoral C 61 265
artery C 62 265
during C 63 265
in C 64 265
vivo C 65 265
availability C 66 265
of C 67 265
h C 68 265
3 C 69 265
- C 70 265
thymidine C 71 265
. C 72 265
heavily C 74 265
labeled C 75 265
small C 76 265
lymphoid C 77 265
cells C 78 265
appeared C 79 265
in C 80 265
the C 81 265
bone C 82 265
marrow C 83 265
of C 84 265
the C 85 265
clamped C 86 265
leg C 87 265
3 C 88 265
hours C 89 265
after C 90 265
injection C 91 265
of C 92 265
the C 93 265
tracer C 94 265
and C 95 265
increased C 96 265
in C 97 265
number C 98 265
up C 99 265
to C 100 265
6 C 101 265
days C 102 265
. C 103 265
the C 105 265
labeling C 106 265
indices C 107 265
of C 108 265
these C 109 265
cells C 110 265
, C 111 265
however C 112 265
, C 113 265
were C 114 265
significantly C 115 265
lower C 116 265
than C 117 265
those C 118 265
of C 119 265
control C 120 265
marrow C 121 265
. C 122 265
a C 124 265
possible C 125 265
interpretation C 126 265
is C 127 265
that C 128 265
dog C 129 265
bone C 130 265
marrow C 131 265
contains C 132 265
two C 133 265
populations C 134 265
of C 135 265
small C 136 265
lympho C 137 265
id C 138 265
cells C 139 265
, C 140 265
one C 141 265
migrating C 142 265
into C 143 265
the C 144 265
marrow C 145 265
via C 146 265
the C 147 265
blood C 148 265
stream C 149 265
, C 150 265
the C 151 265
other C 152 265
originating C 153 265
from C 154 265
local C 155 265
precursor C 156 265
cells C 157 265
within C 158 265
the C 159 265
marrow C 160 265
. C 161 265
there C 163 265
was C 164 265
no C 165 265
evidence C 166 265
for C 167 265
a C 168 265
transformation C 169 265
of C 170 265
migrated C 171 265
small C 172 265
lymphoid C 173 265
cells C 174 265
into C 175 265
erythroblasts C 176 265
during C 177 265
the C 178 265
first C 179 265
48 C 180 265
hours C 181 265
after C 182 265
injection C 183 265
of C 184 265
h C 185 265
3 C 186 265
- C 187 265
thymidine C 188 265
. C 189 265
the C 1 266
lymphocyte C 2 266
in C 3 266
guinea C 4 266
- C 5 266
pig C 6 266
bone C 7 266
marrow C 8 266
. C 9 266
the C 11 266
structure C 12 266
and C 13 266
distribution C 14 266
of C 15 266
lymphocytes C 16 266
in C 17 266
the C 18 266
bone C 19 266
marrow C 20 266
of C 21 266
normal C 22 266
400 C 23 266
g C 24 266
guinea C 25 266
- C 26 266
pigs C 27 266
have C 28 266
been C 29 266
studied C 30 266
by C 31 266
means C 32 266
of C 33 266
light C 34 266
microscopy C 35 266
, C 36 266
electron C 37 266
microscopy C 38 266
, C 39 266
and C 40 266
radioautography C 41 266
. C 42 266
the C 44 266
study C 45 266
of C 46 266
structural C 47 266
organization C 48 266
by C 49 266
all C 50 266
three C 51 266
techniques C 52 266
confirms C 53 266
the C 54 266
morphological C 55 266
identity C 56 266
of C 57 266
the C 58 266
marrow C 59 266
small C 60 266
lymphocytes C 61 266
with C 62 266
small C 63 266
lymphocytes C 64 266
in C 65 266
other C 66 266
situations C 67 266
and C 68 266
affords C 69 266
added C 70 266
proof C 71 266
of C 72 266
the C 73 266
presence C 74 266
of C 75 266
a C 76 266
series C 77 266
of C 78 266
cells C 79 266
transitional C 80 266
in C 81 266
appearance C 82 266
between C 83 266
small C 84 266
lymphocytes C 85 266
and C 86 266
blast C 87 266
cells C 88 266
. C 89 266
unlike C 91 266
the C 92 266
small C 93 266
lymphocytes C 94 266
, C 95 266
transitional C 96 266
cells C 97 266
show C 98 266
evidence C 99 266
of C 100 266
dna C 101 266
synthesis C 102 266
. C 103 266
marrow C 105 266
small C 106 266
lymphocytes C 107 266
and C 108 266
transitional C 109 266
cells C 110 266
are C 111 266
diffusely C 112 266
scattered C 113 266
throughout C 114 266
the C 115 266
parenchyma C 116 266
, C 117 266
often C 118 266
situated C 119 266
in C 120 266
close C 121 266
proximity C 122 266
to C 123 266
the C 124 266
sinusoidal C 125 266
endothelium C 126 266
. C 127 266
they C 129 266
are C 130 266
also C 131 266
found C 132 266
characteristically C 133 266
concentrated C 134 266
within C 135 266
some C 136 266
of C 137 266
the C 138 266
sinusoids C 139 266
, C 140 266
. C 141 266
this C 143 266
is C 144 266
termed C 145 266
/ C 146 266
lymphocyte C 147 266
loading C 148 266
/ C 149 266
. C 150 266
the C 152 266
findings C 153 266
are C 154 266
discussed C 155 266
with C 156 266
particular C 157 266
reference C 158 266
to C 159 266
the C 160 266
possible C 161 266
origin C 162 266
, C 163 266
interrelationship C 164 266
and C 165 266
fate C 166 266
of C 167 266
these C 168 266
cells C 169 266
. C 170 266
surgical C 1 267
treatment C 2 267
of C 3 267
atrial C 4 267
septal C 5 267
defect C 6 267
under C 7 267
hypothermia C 8 267
. C 9 267
the C 11 267
technique C 12 267
of C 13 267
inflow C 14 267
occlusion C 15 267
under C 16 267
30 C 17 267
c C 18 267
. C 19 267
hypothermia C 21 267
was C 22 267
adopted C 23 267
for C 24 267
direct C 25 267
visual C 26 267
correction C 27 267
in C 28 267
133 C 29 267
consecutive C 30 267
cases C 31 267
of C 32 267
atrial C 33 267
septal C 34 267
defect C 35 267
of C 36 267
the C 37 267
secundum C 38 267
variety C 39 267
and C 40 267
the C 41 267
associated C 42 267
anomalies C 43 267
. C 44 267
the C 46 267
use C 47 267
of C 48 267
extracorporeal C 49 267
circulation C 50 267
combined C 51 267
with C 52 267
hypothermia C 53 267
was C 54 267
reserved C 55 267
for C 56 267
the C 57 267
repair C 58 267
of C 59 267
two C 60 267
cases C 61 267
of C 62 267
ostium C 63 267
primum C 64 267
defects C 65 267
. C 66 267
the C 68 267
over C 69 267
- C 70 267
all C 71 267
operative C 72 267
mortality C 73 267
was C 74 267
4 C 75 267
. C 76 267
post C 78 267
- C 79 267
operative C 80 267
evaluation C 81 267
showed C 82 267
that C 83 267
the C 84 267
results C 85 267
have C 86 267
been C 87 267
good C 88 267
in C 89 267
almost C 90 267
all C 91 267
patients C 92 267
, C 93 267
including C 94 267
those C 95 267
with C 96 267
pulmonary C 97 267
hypertension C 98 267
. C 99 267
since C 101 267
an C 102 267
ostium C 103 267
primum C 104 267
defect C 105 267
requires C 106 267
cardio C 107 267
- C 108 267
pulmonary C 109 267
bypass C 110 267
for C 111 267
its C 112 267
closure C 113 267
, C 114 267
the C 115 267
pre C 116 267
- C 117 267
operative C 118 267
recognition C 119 267
of C 120 267
the C 121 267
defect C 122 267
is C 123 267
highly C 124 267
desirable C 125 267
in C 126 267
the C 127 267
selection C 128 267
of C 129 267
patients C 130 267
for C 131 267
operation C 132 267
and C 133 267
in C 134 267
planning C 135 267
the C 136 267
procedure C 137 267
itself C 138 267
. C 139 267
the C 141 267
information C 142 267
derived C 143 267
from C 144 267
the C 145 267
clinical C 146 267
examination C 147 267
and C 148 267
appropriate C 149 267
diagnostic C 150 267
studies C 151 267
has C 152 267
been C 153 267
found C 154 267
to C 155 267
be C 156 267
consistently C 157 267
accurate C 158 267
in C 159 267
the C 160 267
pre C 161 267
- C 162 267
operative C 163 267
differentiation C 164 267
of C 165 267
the C 166 267
primum C 167 267
from C 168 267
the C 169 267
secundum C 170 267
defect C 171 267
. C 172 267
therefore C 174 267
, C 175 267
the C 176 267
unexpected C 177 267
discovery C 178 267
of C 179 267
a C 180 267
primum C 181 267
defect C 182 267
at C 183 267
operation C 184 267
was C 185 267
not C 186 267
a C 187 267
problem C 188 267
. C 189 267
in C 191 267
our C 192 267
experience C 193 267
, C 194 267
open C 195 267
- C 196 267
heart C 197 267
surgery C 198 267
under C 199 267
30 C 200 267
c C 201 267
. C 202 267
hypothermia C 204 267
for C 205 267
the C 206 267
repair C 207 267
of C 208 267
an C 209 267
atrial C 210 267
septal C 211 267
defect C 212 267
of C 213 267
the C 214 267
secundum C 215 267
type C 216 267
and C 217 267
the C 218 267
associated C 219 267
anomalies C 220 267
is C 221 267
a C 222 267
safe C 223 267
and C 224 267
practical C 225 267
technique C 226 267
and C 227 267
effectively C 228 267
corrects C 229 267
the C 230 267
anomaly C 231 267
with C 232 267
minimal C 233 267
risk C 234 267
. C 235 267
internal C 1 268
cooling C 2 268
for C 3 268
general C 4 268
hypothermia C 5 268
. C 6 268
a C 8 268
further C 9 268
presentation C 10 268
is C 11 268
offered C 12 268
on C 13 268
the C 14 268
advantageous C 15 268
use C 16 268
of C 17 268
intragastric C 18 268
temperature C 19 268
control C 20 268
as C 21 268
an C 22 268
adjunct C 23 268
in C 24 268
general C 25 268
hypothermia C 26 268
. C 27 268
a C 29 268
device C 30 268
is C 31 268
described C 32 268
which C 33 268
accomplishes C 34 268
this C 35 268
end C 36 268
with C 37 268
no C 38 268
encountered C 39 268
deleterious C 40 268
side C 41 268
effects C 42 268
, C 43 268
minimal C 44 268
technical C 45 268
involvement C 46 268
, C 47 268
and C 48 268
minor C 49 268
expense C 50 268
. C 51 268
observations C 53 268
are C 54 268
recorded C 55 268
on C 56 268
rates C 57 268
of C 58 268
temperature C 59 268
change C 60 268
according C 61 268
to C 62 268
sex C 63 268
, C 64 268
weight C 65 268
, C 66 268
and C 67 268
type C 68 268
of C 69 268
surgery C 70 268
performed C 71 268
. C 72 268
late C 1 269
effects C 2 269
of C 3 269
regional C 4 269
renal C 5 269
hypothermia C 6 269
. C 7 269
in C 9 269
summary C 10 269
, C 11 269
one C 12 269
can C 13 269
safely C 14 269
conclude C 15 269
that C 16 269
no C 17 269
deleterious C 18 269
effects C 19 269
were C 20 269
created C 21 269
in C 22 269
dogs C 23 269
observed C 24 269
over C 25 269
a C 26 269
period C 27 269
of C 28 269
3 C 29 269
years C 30 269
following C 31 269
renal C 32 269
ischemia C 33 269
of C 34 269
6 C 35 269
hours C 36 269
' C 37 269
duration C 38 269
protected C 39 269
by C 40 269
hypothermia C 41 269
. C 42 269
the C 44 269
blood C 45 269
pressure C 46 269
failed C 47 269
to C 48 269
climb C 49 269
, C 50 269
there C 51 269
was C 52 269
no C 53 269
evidence C 54 269
of C 55 269
azotemia C 56 269
, C 57 269
and C 58 269
careful C 59 269
microscopic C 60 269
studies C 61 269
failed C 62 269
to C 63 269
reveal C 64 269
histological C 65 269
evidence C 66 269
of C 67 269
renal C 68 269
, C 69 269
vascular C 70 269
or C 71 269
cardiac C 72 269
damage C 73 269
. C 74 269
renal C 76 269
function C 77 269
, C 78 269
as C 79 269
demonstrated C 80 269
by C 81 269
creatinine C 82 269
and C 83 269
pah C 84 269
, C 85 269
was C 86 269
preserved C 87 269
and C 88 269
there C 89 269
was C 90 269
no C 91 269
delay C 92 269
in C 93 269
wound C 94 269
healing C 95 269
. C 96 269
mesenteric C 1 270
vascular C 2 270
response C 3 270
to C 4 270
hypothermia C 5 270
. C 6 270
1 C 8 270
. C 9 270
total C 11 270
and C 12 270
segmental C 13 270
resistances C 14 270
were C 15 270
studied C 16 270
in C 17 270
the C 18 270
mesenteries C 19 270
of C 20 270
37 C 21 270
dogs C 22 270
, C 23 270
and C 24 270
the C 25 270
effects C 26 270
of C 27 270
hypothermia C 28 270
, C 29 270
changes C 30 270
in C 31 270
blood C 32 270
viscosity C 33 270
and C 34 270
epinephrine C 35 270
on C 36 270
these C 37 270
resistances C 38 270
were C 39 270
compared C 40 270
. C 41 270
2 C 43 270
. C 44 270
cooling C 46 270
to C 47 270
15 C 48 270
c C 49 270
. C 50 270
caused C 52 270
an C 53 270
increased C 54 270
mesenteric C 55 270
resistance C 56 270
in C 57 270
94 C 58 270
per C 59 270
cent C 60 270
of C 61 270
animals C 62 270
with C 63 270
approximately C 64 270
90 C 65 270
per C 66 270
cent C 67 270
of C 68 270
the C 69 270
resistance C 70 270
rise C 71 270
contributed C 72 270
by C 73 270
the C 74 270
arterial C 75 270
segment C 76 270
. C 77 270
small C 79 270
vessel C 80 270
resistance C 81 270
increased C 82 270
in C 83 270
52 C 84 270
per C 85 270
cent C 86 270
. C 87 270
there C 89 270
was C 90 270
no C 91 270
evidence C 92 270
of C 93 270
venous C 94 270
constriction C 95 270
3 C 96 270
. C 97 270
blood C 99 270
viscosity C 100 270
appeared C 101 270
to C 102 270
play C 103 270
a C 104 270
minor C 105 270
role C 106 270
. C 107 270
4 C 109 270
. C 110 270
it C 112 270
is C 113 270
suggested C 114 270
that C 115 270
hemorrhagic C 116 270
necrosis C 117 270
of C 118 270
the C 119 270
bowel C 120 270
wall C 121 270
is C 122 270
due C 123 270
to C 124 270
intense C 125 270
vasoconstriction C 126 270
in C 127 270
the C 128 270
precapillary C 129 270
vessels C 130 270
with C 131 270
subsequent C 132 270
distal C 133 270
anoxia C 134 270
and C 135 270
cellular C 136 270
damage C 137 270
. C 138 270
the C 1 271
response C 2 271
of C 3 271
dogs C 4 271
to C 5 271
perfusion C 6 271
and C 7 271
arrest C 8 271
of C 9 271
circulation C 10 271
at C 11 271
near C 12 271
zero C 13 271
cerebral C 14 271
temperatures C 15 271
. C 16 271
1 C 18 271
. C 19 271
twenty C 21 271
- C 22 271
six C 23 271
dogs C 24 271
were C 25 271
cooled C 26 271
by C 27 271
a C 28 271
whole C 29 271
body C 30 271
, C 31 271
closed C 32 271
chest C 33 271
perfusion C 34 271
technique C 35 271
to C 36 271
end C 37 271
perfusion C 38 271
brain C 39 271
temperatures C 40 271
of C 41 271
14 C 42 271
. C 43 271
. C 44 271
to C 45 271
0 C 46 271
. C 47 271
. C 48 271
c C 49 271
. C 50 271
inclusive C 52 271
. C 53 271
2 C 55 271
. C 56 271
there C 58 271
were C 59 271
no C 60 271
deaths C 61 271
in C 62 271
the C 63 271
group C 64 271
of C 65 271
six C 66 271
dogs C 67 271
in C 68 271
which C 69 271
the C 70 271
end C 71 271
perfusion C 72 271
brain C 73 271
temperature C 74 271
was C 75 271
10 C 76 271
. C 77 271
. C 78 271
c C 79 271
. C 80 271
or C 82 271
higher C 83 271
. C 84 271
3 C 86 271
. C 87 271
in C 89 271
the C 90 271
17 C 91 271
dogs C 92 271
cooled C 93 271
to C 94 271
brain C 95 271
temperatures C 96 271
of C 97 271
5 C 98 271
. C 99 271
. C 100 271
c C 101 271
. C 102 271
or C 104 271
less C 105 271
there C 106 271
were C 107 271
nine C 108 271
deaths C 109 271
, C 110 271
of C 111 271
which C 112 271
five C 113 271
occurred C 114 271
quickly C 115 271
from C 116 271
cardiovascular C 117 271
failure C 118 271
, C 119 271
while C 120 271
four C 121 271
resulted C 122 271
from C 123 271
gross C 124 271
neurologic C 125 271
disturbances C 126 271
. C 127 271
4 C 129 271
. C 130 271
there C 132 271
was C 133 271
no C 134 271
evidence C 135 271
of C 136 271
aortic C 137 271
incompetence C 138 271
during C 139 271
whole C 140 271
body C 141 271
, C 142 271
closed C 143 271
chest C 144 271
hypothermic C 145 271
perfusion C 146 271
. C 147 271
5 C 149 271
. C 150 271
the C 152 271
lower C 153 271
the C 154 271
temperature C 155 271
of C 156 271
the C 157 271
brain C 158 271
at C 159 271
the C 160 271
end C 161 271
of C 162 271
the C 163 271
cooling C 164 271
perfusion C 165 271
, C 166 271
the C 167 271
greater C 168 271
was C 169 271
the C 170 271
passive C 171 271
transfer C 172 271
of C 173 271
heat C 174 271
from C 175 271
the C 176 271
environment C 177 271
. C 178 271
effects C 1 272
of C 2 272
graded C 3 272
hemorrhage C 4 272
on C 5 272
cardiopulmonary C 6 272
functions C 7 272
of C 8 272
hypothermic C 9 272
dogs C 10 272
. C 11 272
experiments C 13 272
were C 14 272
conducted C 15 272
on C 16 272
anesthetized C 17 272
dogs C 18 272
subjected C 19 272
to C 20 272
moderate C 21 272
hypothermia C 22 272
( C 23 272
28 C 24 272
c C 25 272
. C 26 272
) C 28 272
and C 29 272
then C 30 272
bled C 31 272
in C 32 272
percentages C 33 272
of C 34 272
the C 35 272
estimated C 36 272
blood C 37 272
volume C 38 272
. C 39 272
respiratory C 41 272
work C 42 272
was C 43 272
not C 44 272
influenced C 45 272
by C 46 272
the C 47 272
degree C 48 272
of C 49 272
hemorrhage C 50 272
pulmonary C 51 272
ventilation C 52 272
, C 53 272
respiratory C 54 272
rate C 55 272
and C 56 272
tidal C 57 272
volume C 58 272
were C 59 272
not C 60 272
influenced C 61 272
significantly C 62 272
as C 63 272
a C 64 272
result C 65 272
of C 66 272
blood C 67 272
withdrawal C 68 272
. C 69 272
physiologic C 71 272
dead C 72 272
space C 73 272
as C 74 272
a C 75 272
percentage C 76 272
of C 77 272
tidal C 78 272
volume C 79 272
increased C 80 272
with C 81 272
hemorrhage C 82 272
. C 83 272
oxygen C 85 272
consumption C 86 272
decreased C 87 272
as C 88 272
the C 89 272
hemorrhage C 90 272
was C 91 272
made C 92 272
more C 93 272
severe C 94 272
, C 95 272
whereas C 96 272
carbon C 97 272
dioxide C 98 272
production C 99 272
was C 100 272
unchanged C 101 272
, C 102 272
indicating C 103 272
a C 104 272
shift C 105 272
in C 106 272
the C 107 272
respiratory C 108 272
exchange C 109 272
ratio C 110 272
. C 111 272
cardiac C 113 272
output C 114 272
decreased C 115 272
78 C 116 272
per C 117 272
cent C 118 272
from C 119 272
control C 120 272
level C 121 272
when C 122 272
35 C 123 272
per C 124 272
cent C 125 272
of C 126 272
the C 127 272
estimated C 128 272
blood C 129 272
volume C 130 272
was C 131 272
withdrawn C 132 272
. C 133 272
systemic C 135 272
arterial C 136 272
pressures C 137 272
decreased C 138 272
markedly C 139 272
but C 140 272
heart C 141 272
rate C 142 272
was C 143 272
not C 144 272
changed C 145 272
as C 146 272
a C 147 272
result C 148 272
of C 149 272
blood C 150 272
withdrawal C 151 272
. C 152 272
comparison C 154 272
of C 155 272
responses C 156 272
to C 157 272
hemorrhage C 158 272
in C 159 272
hypothermia C 160 272
and C 161 272
normothermia C 162 272
is C 163 272
discussed C 164 272
. C 165 272
hypothermia C 1 273
in C 2 273
management C 3 273
of C 4 273
acute C 5 273
renal C 6 273
failure C 7 273
. C 8 273
1 C 10 273
. C 11 273
prolonged C 13 273
hypothermia C 14 273
begun C 15 273
in C 16 273
the C 17 273
period C 18 273
immediately C 19 273
following C 20 273
the C 21 273
infusion C 22 273
of C 23 273
epinephrine C 24 273
into C 25 273
the C 26 273
renal C 27 273
artery C 28 273
appears C 29 273
to C 30 273
give C 31 273
partial C 32 273
protection C 33 273
against C 34 273
renal C 35 273
damage C 36 273
. C 37 273
2 C 39 273
. C 40 273
shorter C 42 273
periods C 43 273
of C 44 273
hypothermia C 45 273
do C 46 273
not C 47 273
appear C 48 273
to C 49 273
be C 50 273
beneficial C 51 273
. C 52 273
3 C 54 273
. C 55 273
prolonged C 57 273
hypothermia C 58 273
at C 59 273
28 C 60 273
to C 61 273
30 C 62 273
c C 63 273
. C 64 273
has C 66 273
a C 67 273
mortality C 68 273
rate C 69 273
of C 70 273
50 C 71 273
percent C 72 273
to C 73 273
60 C 74 273
percent C 75 273
. C 76 273
2803 C 1 274
. C 2 274
effect C 4 274
of C 5 274
dosage C 6 274
on C 7 274
endotoxin C 8 274
- C 9 274
induced C 10 274
changes C 11 274
in C 12 274
the C 13 274
reticuloendothelial C 14 274
system C 15 274
of C 16 274
rabbits C 17 274
tissues C 18 274
were C 19 274
removed C 20 274
from C 21 274
rabbits C 22 274
4 C 23 274
and C 24 274
24 C 25 274
hr C 26 274
. C 27 274
following C 29 274
an C 30 274
i C 31 274
. C 32 274
. C 33 274
. C 34 274
injection C 36 274
of C 37 274
5 C 38 274
, C 39 274
25 C 40 274
, C 41 274
or C 42 274
200 C 43 274
ug C 44 274
of C 45 274
endotoxin C 46 274
. C 47 274
explants C 49 274
of C 50 274
tissues C 51 274
from C 52 274
normal C 53 274
and C 54 274
injected C 55 274
animals C 56 274
were C 57 274
grown C 58 274
in C 59 274
a C 60 274
coagulated C 61 274
plasma C 62 274
medium C 63 274
and C 64 274
in C 65 274
medium C 66 274
containing C 67 274
1 C 68 274
ug C 69 274
/ C 70 274
ml C 71 274
of C 72 274
endotoxin C 73 274
. C 74 274
the C 76 274
migration C 77 274
and C 78 274
growth C 79 274
of C 80 274
cells C 81 274
were C 82 274
observed C 83 274
during C 84 274
the C 85 274
following C 86 274
week C 87 274
of C 88 274
incubation C 89 274
. C 90 274
the C 92 274
inhibition C 93 274
or C 94 274
stimulation C 95 274
of C 96 274
cells C 97 274
of C 98 274
the C 99 274
reticuloendothelial C 100 274
system C 101 274
( C 102 274
res C 103 274
) C 104 274
at C 105 274
different C 106 274
host C 107 274
sites C 108 274
after C 109 274
endotoxin C 110 274
administration C 111 274
depended C 112 274
on C 113 274
the C 114 274
dosage C 115 274
and C 116 274
on C 117 274
the C 118 274
known C 119 274
capacity C 120 274
of C 121 274
different C 122 274
organs C 123 274
to C 124 274
take C 125 274
up C 126 274
circulating C 127 274
endotoxin C 128 274
. C 129 274
macro C 131 274
- C 132 274
phage C 133 274
migration C 134 274
was C 135 274
suppressed C 136 274
in C 137 274
cultures C 138 274
of C 139 274
spleen C 140 274
removed C 141 274
4 C 142 274
hr C 143 274
. C 144 274
after C 146 274
a C 147 274
dose C 148 274
of C 149 274
hibited C 150 274
by C 151 274
200 C 152 274
ug C 153 274
, C 154 274
but C 155 274
macrophages C 156 274
in C 157 274
lymph C 158 274
node C 159 274
, C 160 274
testis C 161 274
, C 162 274
and C 163 274
thymus C 164 274
showed C 165 274
an C 166 274
in C 167 274
- C 168 274
crease C 169 274
in C 170 274
numbers C 171 274
, C 172 274
in C 173 274
extent C 174 274
of C 175 274
migration C 176 274
and C 177 274
in C 178 274
phagocytic C 179 274
activity C 180 274
. C 181 274
widespread C 183 274
res C 184 274
stimulation C 185 274
was C 186 274
seen C 187 274
in C 188 274
tissues C 189 274
removed C 190 274
24 C 191 274
hr C 192 274
after C 193 274
the C 194 274
largest C 195 274
dose C 196 274
. C 197 274
in C 199 274
ad C 200 274
- C 201 274
dition C 202 274
to C 203 274
the C 204 274
restoration C 205 274
of C 206 274
re C 207 274
cell C 208 274
activity C 209 274
in C 210 274
spleen C 211 274
and C 212 274
lung C 213 274
there C 214 274
was C 215 274
a C 216 274
marked C 217 274
increase C 218 274
in C 219 274
the C 220 274
migration C 221 274
of C 222 274
large C 223 274
phagocytic C 224 274
cells C 225 274
from C 226 274
bone C 227 274
marrow C 228 274
, C 229 274
as C 230 274
well C 231 274
as C 232 274
other C 233 274
organs C 234 274
. C 235 274
macrophages C 237 274
from C 238 274
endotoxin C 239 274
- C 240 274
injected C 241 274
animals C 242 274
were C 243 274
as C 244 274
sensitive C 245 274
as C 246 274
normal C 247 274
macrophages C 248 274
to C 249 274
added C 250 274
endotoxin C 251 274
in C 252 274
vitro C 253 274
. C 254 274
3075 C 1 275
. C 2 275
vaccinia C 4 275
pneumonia C 5 275
in C 6 275
mice C 7 275
. C 8 275
a C 10 275
light C 11 275
and C 12 275
electron C 13 275
microscopic C 14 275
and C 15 275
viral C 16 275
assay C 17 275
study C 18 275
swiss C 19 275
white C 20 275
mice C 21 275
between C 22 275
2 C 23 275
and C 24 275
4 C 25 275
days C 26 275
of C 27 275
age C 28 275
developed C 29 275
generalized C 30 275
vaccinia C 31 275
viral C 32 275
infection C 33 275
2 C 34 275
to C 35 275
7 C 36 275
days C 37 275
after C 38 275
intranasal C 39 275
inoculation C 40 275
. C 41 275
gross C 43 275
and C 44 275
histologic C 45 275
evidence C 46 275
of C 47 275
pneumonia C 48 275
was C 49 275
seen C 50 275
in C 51 275
more C 52 275
than C 53 275
80 C 54 275
% C 55 275
of C 56 275
approximately C 57 275
300 C 58 275
mice C 59 275
. C 60 275
virus C 62 275
was C 63 275
re C 64 275
- C 65 275
covered C 66 275
in C 67 275
relatively C 68 275
high C 69 275
titers C 70 275
from C 71 275
the C 72 275
lungs C 73 275
( C 74 275
10 C 75 275
pfu C 76 275
per C 77 275
g C 78 275
) C 79 275
during C 80 275
the C 81 275
per C 82 275
- C 83 275
iod C 84 275
when C 85 275
pneumonia C 86 275
developed C 87 275
; C 88 275
viremia C 89 275
was C 90 275
also C 91 275
present C 92 275
, C 93 275
but C 94 275
virus C 95 275
titers C 96 275
in C 97 275
the C 98 275
blood C 99 275
stream C 100 275
remained C 101 275
much C 102 275
below C 103 275
those C 104 275
in C 105 275
the C 106 275
lungs C 107 275
. C 108 275
histologically C 110 275
, C 111 275
vaccinia C 112 275
pneumonia C 113 275
was C 114 275
characterized C 115 275
by C 116 275
large C 117 275
swollen C 118 275
mononuclear C 119 275
cells C 120 275
giving C 121 275
rise C 122 275
to C 123 275
marked C 124 275
widening C 125 275
of C 126 275
alveolar C 127 275
septa C 128 275
. C 129 275
only C 131 275
scattered C 132 275
neutrophils C 133 275
were C 134 275
noted C 135 275
, C 136 275
usually C 137 275
in C 138 275
association C 139 275
with C 140 275
cell C 141 275
necrosis C 142 275
. C 143 275
exudation C 145 275
of C 146 275
edema C 147 275
fluid C 148 275
and C 149 275
red C 150 275
cells C 151 275
into C 152 275
al C 153 275
- C 154 275
veoli C 155 275
was C 156 275
considered C 157 275
the C 158 275
result C 159 275
of C 160 275
viral C 161 275
replication C 162 275
and C 163 275
cytopathic C 164 275
effect C 165 275
on C 166 275
cells C 167 275
comprising C 168 275
alveolar C 169 275
septa C 170 275
. C 171 275
various C 173 275
forms C 174 275
of C 175 275
vaccinia C 176 275
virus C 177 275
were C 178 275
observed C 179 275
by C 180 275
elec C 181 275
- C 182 275
tron C 183 275
microscopy C 184 275
within C 185 275
both C 186 275
' C 187 275
type C 188 275
i C 189 275
' C 190 275
and C 191 275
' C 192 275
type C 193 275
ii C 194 275
' C 195 275
alveolar C 196 275
lining C 197 275
cells C 198 275
, C 199 275
capillary C 200 275
endothelial C 201 275
cells C 202 275
, C 203 275
and C 204 275
interstitial C 205 275
cells C 206 275
within C 207 275
alveolar C 208 275
walls C 209 275
. C 210 275
these C 212 275
infected C 213 275
inter C 214 275
- C 215 275
stitial C 216 275
cells C 217 275
were C 218 275
probably C 219 275
derived C 220 275
from C 221 275
fixed C 222 275
macrophages C 223 275
and C 224 275
were C 225 275
noted C 226 275
also C 227 275
around C 228 275
bronchioles C 229 275
. C 230 275
virus C 232 275
particles C 233 275
were C 234 275
similarly C 235 275
observed C 236 275
in C 237 275
bronchiolar C 238 275
epi C 239 275
- C 240 275
thelium C 241 275
and C 242 275
surrounding C 243 275
smooth C 244 275
muscle C 245 275
cells C 246 275
. C 247 275
the C 249 275
earliest C 250 275
pathologic C 251 275
ultrastruc C 252 275
- C 253 275
tural C 254 275
change C 255 275
noted C 256 275
in C 257 275
virus C 258 275
infected C 259 275
cells C 260 275
was C 261 275
intracellular C 262 275
edema C 263 275
, C 264 275
evidenced C 265 275
by C 266 275
low C 267 275
electron C 268 275
density C 269 275
of C 270 275
the C 271 275
background C 272 275
cytoplasmic C 273 275
material C 274 275
and C 275 275
dilatation C 276 275
of C 277 275
the C 278 275
endoplasmic C 279 275
reticulum C 280 275
. C 281 275
more C 283 275
extensive C 284 275
changes C 285 275
resulted C 286 275
in C 287 275
cell C 288 275
necrosis C 289 275
with C 290 275
release C 291 275
of C 292 275
virus C 293 275
particles C 294 275
into C 295 275
the C 296 275
extracellular C 297 275
space C 298 275
. C 299 275
1161 C 1 276
. C 2 276
electron C 4 276
microscopy C 5 276
of C 6 276
the C 7 276
bovine C 8 276
lungs C 9 276
lattice C 10 276
and C 11 276
lamellar C 12 276
structures C 13 276
in C 14 276
the C 15 276
alveolar C 16 276
lumen C 17 276
in C 18 276
an C 19 276
electron C 20 276
microscopic C 21 276
study C 22 276
of C 23 276
samples C 24 276
from C 25 276
the C 26 276
lungs C 27 276
of C 28 276
20 C 29 276
normal C 30 276
cattle C 31 276
, C 32 276
and C 33 276
from C 34 276
4 C 35 276
with C 36 276
high C 37 276
mountain C 38 276
disease C 39 276
, C 40 276
lattice C 41 276
and C 42 276
lamellar C 43 276
structures C 44 276
were C 45 276
obser C 46 276
- C 47 276
ved C 48 276
free C 49 276
in C 50 276
the C 51 276
alveolar C 52 276
lumens C 53 276
in C 54 276
25 C 55 276
% C 56 276
of C 57 276
the C 58 276
normal C 59 276
cattle C 60 276
and C 61 276
in C 62 276
100 C 63 276
% C 64 276
of C 65 276
those C 66 276
with C 67 276
high C 68 276
mountain C 69 276
disease C 70 276
. C 71 276
in C 73 276
one C 74 276
specimen C 75 276
, C 76 276
a C 77 276
lattice C 78 276
and C 79 276
lamellar C 80 276
structure C 81 276
was C 82 276
ob C 83 276
- C 84 276
served C 85 276
in C 86 276
a C 87 276
vacuole C 88 276
within C 89 276
an C 90 276
alveolar C 91 276
epithelial C 92 276
cell C 93 276
. C 94 276
all C 96 276
others C 97 276
were C 98 276
extracellular C 99 276
. C 100 276
the C 102 276
shape C 103 276
and C 104 276
dimensions C 105 276
of C 106 276
these C 107 276
lattice C 108 276
and C 109 276
lamellar C 110 276
structures C 111 276
were C 112 276
similar C 113 276
to C 114 276
those C 115 276
described C 116 276
by C 117 276
other C 118 276
workers C 119 276
in C 120 276
experiments C 121 276
involving C 122 276
intratracheal C 123 276
injections C 124 276
of C 125 276
silicon C 126 276
and C 127 276
oleic C 128 276
and C 129 276
linoleic C 130 276
acid C 131 276
. C 132 276
this C 134 276
is C 135 276
the C 136 276
first C 137 276
report C 138 276
of C 139 276
the C 140 276
structures C 141 276
free C 142 276
in C 143 276
the C 144 276
alveolar C 145 276
lumens C 146 276
of C 147 276
apparently C 148 276
normal C 149 276
cattle C 150 276
. C 151 276
1162 C 1 277
. C 2 277
electron C 4 277
microscopy C 5 277
of C 6 277
the C 7 277
bovine C 8 277
lungs C 9 277
the C 10 277
blood C 11 277
- C 12 277
air C 13 277
barrier C 14 277
in C 15 277
acute C 16 277
pulmonary C 17 277
emphysema C 18 277
electron C 19 277
microscopic C 20 277
studies C 21 277
of C 22 277
experimentally C 23 277
induced C 24 277
acute C 25 277
pulmonary C 26 277
emphy C 27 277
- C 28 277
sema C 29 277
in C 30 277
2 C 31 277
cows C 32 277
yielded C 33 277
the C 34 277
following C 35 277
findings C 36 277
alveolar C 37 277
epithelial C 38 277
edema C 39 277
and C 40 277
cyto C 41 277
- C 42 277
lysis C 43 277
, C 44 277
endothelial C 45 277
' C 46 277
thinning C 47 277
' C 48 277
and C 49 277
cytolysis C 50 277
, C 51 277
excessive C 52 277
elastic C 53 277
and C 54 277
collagenous C 55 277
alveo C 56 277
- C 57 277
lar C 58 277
wall C 59 277
fibrosis C 60 277
, C 61 277
hyperplasia C 62 277
of C 63 277
alveolar C 64 277
wall C 65 277
smooth C 66 277
muscle C 67 277
, C 68 277
numerous C 69 277
intra C 70 277
- C 71 277
alveolar C 72 277
lattice C 73 277
and C 74 277
lamellar C 75 277
bodies C 76 277
, C 77 277
hyaline C 78 277
membrane C 79 277
formation C 80 277
, C 81 277
hypertrophied C 82 277
endothelial C 83 277
perikaryons C 84 277
, C 85 277
numerous C 86 277
alveolar C 87 277
macrophages C 88 277
, C 89 277
and C 90 277
alveolar C 91 277
epithelial C 92 277
secretion C 93 277
of C 94 277
an C 95 277
electron C 96 277
- C 97 277
dense C 98 277
amorphous C 99 277
mass C 100 277
. C 101 277
it C 103 277
was C 104 277
postulated C 105 277
that C 106 277
the C 107 277
lattice C 108 277
and C 109 277
lamellar C 110 277
bodies C 111 277
were C 112 277
a C 113 277
result C 114 277
of C 115 277
degenerating C 116 277
alveolar C 117 277
epithelial C 118 277
cells C 119 277
. C 120 277
1560 C 1 278
. C 2 278
the C 4 278
ultrastructure C 5 278
of C 6 278
the C 7 278
lungs C 8 278
of C 9 278
lambs C 10 278
. C 11 278
the C 13 278
relation C 14 278
of C 15 278
osmiophilic C 16 278
inclusions C 17 278
and C 18 278
alveolar C 19 278
lining C 20 278
layer C 21 278
to C 22 278
fetal C 23 278
maturation C 24 278
and C 25 278
experimentally C 26 278
produced C 27 278
respiratory C 28 278
distress C 29 278
the C 30 278
lungs C 31 278
in C 32 278
69 C 33 278
fetal C 34 278
and C 35 278
newborn C 36 278
lambs C 37 278
were C 38 278
studied C 39 278
. C 40 278
osmiophilic C 42 278
inclusion C 43 278
bodies C 44 278
first C 45 278
appeared C 46 278
at C 47 278
about C 48 278
121 C 49 278
days C 50 278
gestation C 51 278
and C 52 278
their C 53 278
total C 54 278
number C 55 278
increased C 56 278
with C 57 278
maturation C 58 278
. C 59 278
normal C 61 278
surface C 62 278
activity C 63 278
of C 64 278
lung C 65 278
extracts C 66 278
was C 67 278
detectable C 68 278
a C 69 278
few C 70 278
days C 71 278
following C 72 278
the C 73 278
appearance C 74 278
of C 75 278
inclusion C 76 278
bodies C 77 278
. C 78 278
the C 80 278
excretory C 81 278
nature C 82 278
of C 83 278
the C 84 278
type C 85 278
ii C 86 278
alveolar C 87 278
epithelial C 88 278
cell C 89 278
, C 90 278
the C 91 278
phospholipid C 92 278
nature C 93 278
of C 94 278
the C 95 278
inclusion C 96 278
body C 97 278
content C 98 278
, C 99 278
the C 100 278
decrease C 101 278
in C 102 278
the C 103 278
number C 104 278
of C 105 278
inclusion C 106 278
bodies C 107 278
and C 108 278
their C 109 278
loss C 110 278
of C 111 278
density C 112 278
associated C 113 278
with C 114 278
respiratory C 115 278
distress C 116 278
and C 117 278
with C 118 278
the C 119 278
loss C 120 278
of C 121 278
normal C 122 278
surface C 123 278
activity C 124 278
of C 125 278
lung C 126 278
ex C 127 278
- C 128 278
tracts C 129 278
provide C 130 278
strong C 131 278
evidence C 132 278
that C 133 278
inclusion C 134 278
bodies C 135 278
are C 136 278
the C 137 278
source C 138 278
of C 139 278
pulmonary C 140 278
surfactant C 141 278
. C 142 278
a C 144 278
dense C 145 278
osmiophilic C 146 278
alveolar C 147 278
lining C 148 278
layer C 149 278
in C 150 278
mammals C 151 278
is C 152 278
described C 153 278
. C 154 278
since C 156 278
the C 157 278
presence C 158 278
of C 159 278
such C 160 278
a C 161 278
layer C 162 278
is C 163 278
well C 164 278
correlated C 165 278
with C 166 278
surface C 167 278
tension C 168 278
values C 169 278
and C 170 278
the C 171 278
number C 172 278
of C 173 278
inclusions C 174 278
, C 175 278
it C 176 278
is C 177 278
suggested C 178 278
that C 179 278
this C 180 278
layer C 181 278
consists C 182 278
of C 183 278
surface C 184 278
active C 185 278
substances C 186 278
. C 187 278
the C 189 278
difficulty C 190 278
in C 191 278
detecting C 192 278
such C 193 278
an C 194 278
osmiophilic C 195 278
layer C 196 278
in C 197 278
other C 198 278
mammals C 199 278
is C 200 278
thought C 201 278
to C 202 278
be C 203 278
, C 204 278
at C 205 278
least C 206 278
in C 207 278
part C 208 278
, C 209 278
due C 210 278
to C 211 278
species C 212 278
differences C 213 278
in C 214 278
the C 215 278
compo C 216 278
- C 217 278
sition C 218 278
of C 219 278
materials C 220 278
constituting C 221 278
the C 222 278
pulmonary C 223 278
surfactant C 224 278
. C 225 278
cytologic C 227 278
immaturity C 228 278
exists C 229 278
until C 230 278
lamb C 231 278
fetuses C 232 278
reach C 233 278
135 C 234 278
days C 235 278
gestation C 236 278
. C 237 278
this C 239 278
is C 240 278
considered C 241 278
to C 242 278
be C 243 278
the C 244 278
basis C 245 278
for C 246 278
the C 247 278
susceptibility C 248 278
of C 249 278
immature C 250 278
lambs C 251 278
to C 252 278
respiratory C 253 278
distress C 254 278
. C 255 278
fibrin C 257 278
with C 258 278
230 C 259 278
a C 260 278
periodicity C 261 278
is C 262 278
a C 263 278
component C 264 278
, C 265 278
although C 266 278
a C 267 278
small C 268 278
one C 269 278
, C 270 278
of C 271 278
hyaline C 272 278
membranes C 273 278
in C 274 278
lambs C 275 278
. C 276 278
in C 278 278
view C 279 278
of C 280 278
the C 281 278
fact C 282 278
that C 283 278
mature C 284 278
fibrin C 285 278
appearing C 286 278
as C 287 278
bundles C 288 278
of C 289 278
fibrils C 290 278
is C 291 278
rare C 292 278
- C 293 278
ly C 294 278
found C 295 278
, C 296 278
it C 297 278
is C 298 278
suggested C 299 278
that C 300 278
the C 301 278
bulk C 302 278
of C 303 278
the C 304 278
hyaline C 305 278
membrane C 306 278
is C 307 278
not C 308 278
a C 309 278
mature C 310 278
fi C 311 278
- C 312 278
brin C 313 278
, C 314 278
but C 315 278
probably C 316 278
consists C 317 278
of C 318 278
polymers C 319 278
of C 320 278
fibrinogen C 321 278
and C 322 278
serum C 323 278
protein C 324 278
. C 325 278
1685 C 1 279
. C 2 279
differentiation C 4 279
of C 5 279
exfoliative C 6 279
broncho C 7 279
- C 8 279
alveolar C 9 279
disease C 10 279
from C 11 279
desquamative C 12 279
interstitial C 13 279
pneumonia C 14 279
three C 15 279
cases C 16 279
are C 17 279
presented C 18 279
of C 19 279
the C 20 279
pulmonary C 21 279
disease C 22 279
described C 23 279
by C 24 279
liebow C 25 279
and C 26 279
asso C 27 279
- C 28 279
ciates C 29 279
and C 30 279
named C 31 279
by C 32 279
them C 33 279
desquamative C 34 279
interstitial C 35 279
pneumonia C 36 279
. C 37 279
the C 39 279
cases C 40 279
support C 41 279
the C 42 279
existence C 43 279
of C 44 279
the C 45 279
entity C 46 279
and C 47 279
the C 48 279
contention C 49 279
that C 50 279
it C 51 279
had C 52 279
not C 53 279
been C 54 279
previously C 55 279
described C 56 279
. C 57 279
a C 59 279
differential C 60 279
diagnosis C 61 279
between C 62 279
exfoliative C 63 279
bronchoalveolar C 64 279
disease C 65 279
and C 66 279
desquamative C 67 279
interstitial C 68 279
pneumonia C 69 279
is C 70 279
submitted C 71 279
. C 72 279
clinical C 74 279
, C 75 279
roentgenologic C 76 279
and C 77 279
histopathologic C 78 279
mani C 79 279
- C 80 279
festations C 81 279
are C 82 279
tabulated C 83 279
for C 84 279
each C 85 279
condition C 86 279
and C 87 279
the C 88 279
differences C 89 279
between C 90 279
them C 91 279
are C 92 279
em C 93 279
- C 94 279
phasized C 95 279
. C 96 279
additional C 98 279
symptoms C 99 279
, C 100 279
changes C 101 279
and C 102 279
phenomena C 103 279
not C 104 279
previously C 105 279
recorded C 106 279
are C 107 279
introduced C 108 279
. C 109 279
the C 111 279
most C 112 279
distinctive C 113 279
differences C 114 279
between C 115 279
the C 116 279
2 C 117 279
diseases C 118 279
were C 119 279
found C 120 279
in C 121 279
the C 122 279
histopathologic C 123 279
manifestations C 124 279
. C 125 279
3831 C 1 280
. C 2 280
lysosomes C 4 280
in C 5 280
the C 6 280
rat C 7 280
sciatic C 8 280
nerve C 9 280
following C 10 280
crush C 11 280
peripheral C 12 280
nerves C 13 280
undergoing C 14 280
degeneration C 15 280
are C 16 280
favorable C 17 280
material C 18 280
for C 19 280
studying C 20 280
the C 21 280
types C 22 280
, C 23 280
origins C 24 280
, C 25 280
and C 26 280
functions C 27 280
of C 28 280
lysosomes C 29 280
. C 30 280
the C 32 280
following C 33 280
lysosomes C 34 280
are C 35 280
described C 36 280
( C 37 280
a C 38 280
) C 39 280
autophagic C 40 280
vacuoles C 41 280
in C 42 280
altered C 43 280
schwann C 44 280
cells C 45 280
. C 46 280
within C 48 280
these C 49 280
vacuoles C 50 280
the C 51 280
myelin C 52 280
and C 53 280
much C 54 280
of C 55 280
the C 56 280
axoplasm C 57 280
which C 58 280
it C 59 280
encloses C 60 280
in C 61 280
the C 62 280
normal C 63 280
nerve C 64 280
are C 65 280
degraded C 66 280
( C 67 280
wal C 68 280
- C 69 280
lerian C 70 280
degeneration C 71 280
) C 72 280
. C 73 280
the C 75 280
delimiting C 76 280
membranes C 77 280
of C 78 280
the C 79 280
vacuoles C 80 280
apparently C 81 280
form C 82 280
from C 83 280
myelin C 84 280
lamellae C 85 280
. C 86 280
considered C 88 280
as C 89 280
possible C 90 280
sources C 91 280
of C 92 280
their C 93 280
acid C 94 280
phosphatase C 95 280
are C 96 280
golgi C 97 280
vesicles C 98 280
( C 99 280
primary C 100 280
lysosomes C 101 280
) C 102 280
, C 103 280
lysosomes C 104 280
of C 105 280
the C 106 280
dense C 107 280
body C 108 280
type C 109 280
, C 110 280
and C 111 280
the C 112 280
endo C 113 280
- C 114 280
plasmic C 115 280
reticulum C 116 280
which C 117 280
lies C 118 280
close C 119 280
to C 120 280
the C 121 280
vacuoles C 122 280
. C 123 280
( C 125 280
b C 126 280
) C 127 280
mebranous C 128 280
bodies C 129 280
that C 130 280
accu C 131 280
- C 132 280
mulate C 133 280
focally C 134 280
in C 135 280
myelinated C 136 280
fibers C 137 280
in C 138 280
a C 139 280
zone C 140 280
extending C 141 280
2 C 142 280
to C 143 280
3 C 144 280
mm C 145 280
distal C 146 280
to C 147 280
the C 148 280
crush C 149 280
. C 150 280
these C 152 280
appear C 153 280
to C 154 280
arise C 155 280
from C 156 280
the C 157 280
endoplasmic C 158 280
reticulum C 159 280
in C 160 280
which C 161 280
demonstrable C 162 280
acid C 163 280
phosphatase C 164 280
activity C 165 280
increases C 166 280
markedly C 167 280
within C 168 280
2 C 169 280
hours C 170 280
after C 171 280
the C 172 280
nerve C 173 280
is C 174 280
crushed C 175 280
. C 176 280
( C 178 280
c C 179 280
) C 180 280
autophagic C 181 280
vacuoles C 182 280
in C 183 280
the C 184 280
axoplasm C 185 280
of C 186 280
fibers C 187 280
proximal C 188 280
to C 189 280
the C 190 280
crush C 191 280
. C 192 280
the C 194 280
break C 195 280
- C 196 280
down C 197 280
of C 198 280
organelles C 199 280
within C 200 280
these C 201 280
vacuoles C 202 280
may C 203 280
have C 204 280
significance C 205 280
for C 206 280
the C 207 280
reorganization C 208 280
of C 209 280
the C 210 280
axoplasm C 211 280
preparatory C 212 280
to C 213 280
regeneration C 214 280
. C 215 280
( C 217 280
d C 218 280
) C 219 280
phagocytic C 220 280
vacuoles C 221 280
of C 222 280
altered C 223 280
schwann C 224 280
cells C 225 280
. C 226 280
as C 228 280
myelin C 229 280
degeneration C 230 280
begins C 231 280
, C 232 280
some C 233 280
axoplasm C 234 280
is C 235 280
exposed C 236 280
. C 237 280
this C 239 280
is C 240 280
apparently C 241 280
engulfed C 242 280
by C 243 280
the C 244 280
filopodia C 245 280
of C 246 280
the C 247 280
schwann C 248 280
cells C 249 280
, C 250 280
and C 251 280
degraded C 252 280
within C 253 280
the C 254 280
phagocytic C 255 280
vacuoles C 256 280
thus C 257 280
formed C 258 280
. C 259 280
( C 261 280
e C 262 280
) C 263 280
multivesicular C 264 280
bodies C 265 280
in C 266 280
the C 267 280
axoplasm C 268 280
of C 269 280
myelina C 270 280
- C 271 280
ted C 272 280
fibers C 273 280
. C 274 280
these C 276 280
are C 277 280
generally C 278 280
seen C 279 280
near C 280 280
the C 281 280
nodes C 282 280
of C 283 280
ranvier C 284 280
. C 285 280
2431 C 1 281
. C 2 281
histochemistry C 4 281
of C 5 281
surface C 6 281
epithelial C 7 281
and C 8 281
pleural C 9 281
mucins C 10 281
in C 11 281
mammalian C 12 281
lung C 13 281
. C 14 281
the C 16 281
demonstration C 17 281
of C 18 281
sialomucin C 19 281
in C 20 281
alveolar C 21 281
cuboidal C 22 281
epithelium C 23 281
sialo C 24 281
- C 25 281
and C 26 281
sulfomucins C 27 281
have C 28 281
been C 29 281
demonstrated C 30 281
histochemically C 31 281
in C 32 281
the C 33 281
surface C 34 281
layer C 35 281
of C 36 281
the C 37 281
lung C 38 281
and C 39 281
pleura C 40 281
from C 41 281
rabbit C 42 281
, C 43 281
syrian C 44 281
hamster C 45 281
, C 46 281
guinea C 47 281
pig C 48 281
, C 49 281
mouse C 50 281
, C 51 281
and C 52 281
man C 53 281
. C 54 281
sialomucin C 56 281
predominates C 57 281
in C 58 281
the C 59 281
distal C 60 281
bronchial C 61 281
tree C 62 281
and C 63 281
covers C 64 281
the C 65 281
alveolar C 66 281
epithelial C 67 281
surface C 68 281
. C 69 281
the C 71 281
possible C 72 281
significance C 73 281
of C 74 281
these C 75 281
observations C 76 281
is C 77 281
discussed C 78 281
. C 79 281
617 C 1 282
. C 2 282
maturation C 4 282
of C 5 282
postnatal C 6 282
human C 7 282
lung C 8 282
and C 9 282
the C 10 282
idiopathic C 11 282
respiratory C 12 282
distress C 13 282
syndrome C 14 282
maturation C 15 282
and C 16 282
pathologic C 17 282
alterations C 18 282
of C 19 282
the C 20 282
lung C 21 282
in C 22 282
19 C 23 282
newborn C 24 282
infants C 25 282
who C 26 282
died C 27 282
of C 28 282
idiopathic C 29 282
respiratory C 30 282
distress C 31 282
syndrome C 32 282
were C 33 282
studied C 34 282
by C 35 282
light C 36 282
- C 37 282
and C 38 282
electron C 39 282
microscopy C 40 282
. C 41 282
normal C 43 282
lungs C 44 282
from C 45 282
6 C 46 282
fetuses C 47 282
and C 48 282
11 C 49 282
new C 50 282
- C 51 282
borns C 52 282
served C 53 282
as C 54 282
controls C 55 282
. C 56 282
in C 58 282
all C 59 282
infants C 60 282
with C 61 282
idiopathic C 62 282
respiratory C 63 282
distress C 64 282
syndrome C 65 282
, C 66 282
respiratory C 67 282
bronchio C 68 282
- C 69 282
les C 70 282
and C 71 282
alveolar C 72 282
ducts C 73 282
usually C 74 282
presented C 75 282
the C 76 282
histologic C 77 282
pattern C 78 282
of C 79 282
mature C 80 282
lungs C 81 282
, C 82 282
i C 83 282
. C 84 282
. C 85 282
. C 86 282
they C 88 282
were C 89 282
predominantly C 90 282
lined C 91 282
by C 92 282
type C 93 282
i C 94 282
cells C 95 282
, C 96 282
which C 97 282
also C 98 282
formed C 99 282
the C 100 282
epithelial C 101 282
component C 102 282
of C 103 282
most C 104 282
blood C 105 282
- C 106 282
air C 107 282
barriers C 108 282
. C 109 282
well C 111 282
expanded C 112 282
alveoli C 113 282
exhibited C 114 282
a C 115 282
similar C 116 282
pattern C 117 282
, C 118 282
whereas C 119 282
collapsed C 120 282
alveoli C 121 282
were C 122 282
lined C 123 282
by C 124 282
numerous C 125 282
type C 126 282
ii C 127 282
cells C 128 282
which C 129 282
par C 130 282
- C 131 282
ticipated C 132 282
in C 133 282
the C 134 282
formation C 135 282
of C 136 282
poorly C 137 282
developed C 138 282
blood C 139 282
- C 140 282
air C 141 282
barriers C 142 282
. C 143 282
the C 145 282
capacity C 146 282
of C 147 282
type C 148 282
ii C 149 282
cells C 150 282
to C 151 282
produce C 152 282
in C 153 282
- C 154 282
clusion C 155 282
bodies C 156 282
seemed C 157 282
to C 158 282
increase C 159 282
with C 160 282
survival C 161 282
beyond C 162 282
the C 163 282
14 C 164 282
th C 165 282
hr C 166 282
of C 167 282
age C 168 282
. C 169 282
secretion C 171 282
of C 172 282
inclusion C 173 282
bodies C 174 282
and C 175 282
presumably C 176 282
surfactant C 177 282
into C 178 282
alveolar C 179 282
spaces C 180 282
did C 181 282
occur C 182 282
but C 183 282
only C 184 282
in C 185 282
the C 186 282
lungs C 187 282
of C 188 282
infants C 189 282
older C 190 282
than C 191 282
2 C 192 282
days C 193 282
. C 194 282
how C 196 282
- C 197 282
ever C 198 282
, C 199 282
this C 200 282
process C 201 282
was C 202 282
not C 203 282
accompanied C 204 282
by C 205 282
reduction C 206 282
in C 207 282
the C 208 282
number C 209 282
of C 210 282
type C 211 282
ii C 212 282
cells C 213 282
per C 214 282
alveolus C 215 282
as C 216 282
in C 217 282
the C 218 282
nor C 219 282
- C 220 282
mal C 221 282
lung C 222 282
. C 223 282
the C 225 282
distribution C 226 282
of C 227 282
pathologic C 228 282
changes C 229 282
in C 230 282
idio C 231 282
- C 232 282
pathic C 233 282
respiratory C 234 282
distress C 235 282
syndrome C 236 282
appeared C 237 282
to C 238 282
be C 239 282
determined C 240 282
by C 241 282
the C 242 282
degree C 243 282
of C 244 282
maturity C 245 282
of C 246 282
the C 247 282
air C 248 282
sacs C 249 282
. C 250 282
structurally C 252 282
mature C 253 282
air C 254 282
sacs C 255 282
were C 256 282
associated C 257 282
with C 258 282
da C 259 282
- C 260 282
mage C 261 282
of C 262 282
epithelial C 263 282
lining C 264 282
and C 265 282
hyaline C 266 282
membrane C 267 282
forma C 268 282
- C 269 282
tion C 270 282
. C 271 282
in C 273 282
contrast C 274 282
, C 275 282
collapsed C 276 282
alveoli C 277 282
revealed C 278 282
an C 279 282
intact C 280 282
epithelial C 281 282
lining C 282 282
and C 283 282
marked C 284 282
septal C 285 282
edema C 286 282
but C 287 282
were C 288 282
free C 289 282
of C 290 282
hyaline C 291 282
membranes C 292 282
. C 293 282
the C 295 282
findings C 296 282
of C 297 282
this C 298 282
study C 299 282
sug C 300 282
- C 301 282
gested C 302 282
that C 303 282
transudation C 304 282
of C 305 282
plasma C 306 282
through C 307 282
well C 308 282
develop C 309 282
- C 310 282
ed C 311 282
blood C 312 282
- C 313 282
air C 314 282
barriers C 315 282
was C 316 282
responsible C 317 282
for C 318 282
epithelial C 319 282
damage C 320 282
and C 321 282
hyaline C 322 282
- C 323 282
membrane C 324 282
formation C 325 282
in C 326 282
air C 327 282
sacs C 328 282
. C 329 282
they C 331 282
also C 332 282
suggested C 333 282
that C 334 282
alveolar C 335 282
collapse C 336 282
and C 337 282
presuma C 338 282
- C 339 282
bly C 340 282
lack C 341 282
of C 342 282
surfactant C 343 282
were C 344 282
related C 345 282
to C 346 282
abnormal C 347 282
matura C 348 282
- C 349 282
tion C 350 282
of C 351 282
the C 352 282
epithelial C 353 282
lining C 354 282
and C 355 282
to C 356 282
septal C 357 282
edema C 358 282
. C 359 282
903 C 1 283
. C 2 283
lattice C 4 283
structures C 5 283
and C 6 283
osmiophilic C 7 283
bodies C 8 283
in C 9 283
the C 10 283
developing C 11 283
respiratory C 12 283
tissue C 13 283
of C 14 283
rats C 15 283
osmiophilic C 16 283
inclusions C 17 283
have C 18 283
been C 19 283
observed C 20 283
in C 21 283
the C 22 283
lungs C 23 283
of C 24 283
rats C 25 283
particularly C 26 283
in C 27 283
the C 28 283
20 C 29 283
- C 30 283
day C 31 283
rat C 32 283
embryo C 33 283
and C 34 283
newborn C 35 283
up C 36 283
to C 37 283
3 C 38 283
days C 39 283
post C 40 283
partum C 41 283
. C 42 283
these C 44 283
inclusions C 45 283
are C 46 283
present C 47 283
in C 48 283
the C 49 283
large C 50 283
alveolar C 51 283
cells C 52 283
as C 53 283
dense C 54 283
lamin C 55 283
- C 56 283
ated C 57 283
structures C 58 283
of C 59 283
variable C 60 283
size C 61 283
and C 62 283
configuration C 63 283
. C 64 283
they C 66 283
generally C 67 283
consist C 68 283
of C 69 283
concentrically C 70 283
arranged C 71 283
membranes C 72 283
and C 73 283
have C 74 283
the C 75 283
appearance C 76 283
of C 77 283
myelin C 78 283
figures C 79 283
, C 80 283
usually C 81 283
with C 82 283
a C 83 283
dense C 84 283
center C 85 283
. C 86 283
these C 88 283
osmiophilic C 89 283
inclusions C 90 283
are C 91 283
fre C 92 283
- C 93 283
quently C 94 283
seen C 95 283
in C 96 283
direct C 97 283
contact C 98 283
with C 99 283
the C 100 283
cell C 101 283
membranes C 102 283
and C 103 283
the C 104 283
alveolar C 105 283
space C 106 283
. C 107 283
the C 109 283
alveolar C 110 283
space C 111 283
contains C 112 283
numerous C 113 283
osmiophilic C 114 283
myelin C 115 283
figures C 116 283
which C 117 283
are C 118 283
thought C 119 283
to C 120 283
originate C 121 283
from C 122 283
the C 123 283
intracellular C 124 283
osmiophilic C 125 283
inclu C 126 283
- C 127 283
sions C 128 283
. C 129 283
they C 131 283
may C 132 283
extrude C 133 283
through C 134 283
a C 135 283
channel C 136 283
formed C 137 283
in C 138 283
- C 139 283
side C 140 283
the C 141 283
cell C 142 283
or C 143 283
by C 144 283
rupture C 145 283
of C 146 283
the C 147 283
cell C 148 283
membrane C 149 283
. C 150 283
secre C 152 283
- C 153 283
tion C 154 283
materials C 155 283
may C 156 283
occasionally C 157 283
be C 158 283
seen C 159 283
in C 160 283
the C 161 283
cyto C 162 283
- C 163 283
plasm C 164 283
of C 165 283
the C 166 283
large C 167 283
alveolar C 168 283
epithelial C 169 283
cells C 170 283
. C 171 283
these C 173 283
cells C 174 283
appear C 175 283
to C 176 283
be C 177 283
in C 178 283
the C 179 283
process C 180 283
of C 181 283
degeneration C 182 283
. C 183 283
their C 185 283
cell C 186 283
surfaces C 187 283
are C 188 283
disrupted C 189 283
and C 190 283
the C 191 283
cytoplasm C 192 283
is C 193 283
continuous C 194 283
with C 195 283
materials C 196 283
in C 197 283
the C 198 283
air C 199 283
space C 200 283
. C 201 283
the C 203 283
lattice C 204 283
structure C 205 283
in C 206 283
the C 207 283
alveolar C 208 283
space C 209 283
may C 210 283
originate C 211 283
from C 212 283
the C 213 283
cytoplas C 214 283
- C 215 283
mic C 216 283
secretion C 217 283
material C 218 283
. C 219 283
the C 221 283
cytoplasmic C 222 283
secretion C 223 283
ma C 224 283
- C 225 283
terial C 226 283
in C 227 283
the C 228 283
cell C 229 283
and C 230 283
the C 231 283
lattice C 232 283
structures C 233 283
in C 234 283
the C 235 283
air C 236 283
space C 237 283
disappear C 238 283
after C 239 283
the C 240 283
rats C 241 283
are C 242 283
3 C 243 283
days C 244 283
old C 245 283
. C 246 283
( C 248 283
i C 249 283
, C 250 283
t C 251 283
* C 252 283
) C 253 283
454 C 1 284
. C 2 284
xanthogranuloma C 4 284
( C 5 284
xanthoma C 6 284
) C 7 284
of C 8 284
choroid C 9 284
plexus C 10 284
. C 11 284
the C 13 284
origin C 14 284
of C 15 284
foamy C 16 284
( C 17 284
xanthoma C 18 284
) C 19 284
cells C 20 284
a C 21 284
case C 22 284
of C 23 284
a C 24 284
3 C 25 284
- C 26 284
month C 27 284
- C 28 284
old C 29 284
infant C 30 284
with C 31 284
intense C 32 284
pro C 33 284
- C 34 284
liferation C 35 284
of C 36 284
choroidal C 37 284
epithelium C 38 284
with C 39 284
foamy C 40 284
cells C 41 284
, C 42 284
a C 43 284
second C 44 284
similar C 45 284
case C 46 284
in C 47 284
a C 48 284
9 C 49 284
- C 50 284
month C 51 284
- C 52 284
old C 53 284
infant C 54 284
with C 55 284
gener C 56 284
- C 57 284
alized C 58 284
glycogen C 59 284
storage C 60 284
disease C 61 284
and C 62 284
a C 63 284
case C 64 284
of C 65 284
a C 66 284
51 C 67 284
- C 68 284
year C 69 284
- C 70 284
old C 71 284
male C 72 284
with C 73 284
bilateral C 74 284
xanthogranuloma C 75 284
of C 76 284
choroid C 77 284
plexus C 78 284
and C 79 284
proliferation C 80 284
of C 81 284
the C 82 284
choroidal C 83 284
epithelial C 84 284
cells C 85 284
are C 86 284
discussed C 87 284
. C 88 284
the C 90 284
pathogenesis C 91 284
of C 92 284
the C 93 284
foamy C 94 284
xanthoma C 95 284
cells C 96 284
in C 97 284
the C 98 284
stroma C 99 284
of C 100 284
the C 101 284
choroid C 102 284
plexus C 103 284
, C 104 284
particularly C 105 284
, C 106 284
is C 107 284
discussed C 108 284
. C 109 284
the C 111 284
authors C 112 284
believe C 113 284
that C 114 284
the C 115 284
origin C 116 284
of C 117 284
foamy C 118 284
cells C 119 284
and C 120 284
the C 121 284
mode C 122 284
of C 123 284
formation C 124 284
of C 125 284
such C 126 284
a C 127 284
xanthogranuloma C 128 284
can C 129 284
be C 130 284
explained C 131 284
by C 132 284
the C 133 284
proliferative C 134 284
capability C 135 284
and C 136 284
the C 137 284
phagocytic C 138 284
activity C 139 284
of C 140 284
the C 141 284
choroid C 142 284
epithelium C 143 284
. C 144 284
choroidal C 146 284
epithelial C 147 284
cells C 148 284
can C 149 284
be C 150 284
regarded C 151 284
as C 152 284
fixed C 153 284
macrophages C 154 284
which C 155 284
becomes C 156 284
wandering C 157 284
phagocytes C 158 284
after C 159 284
detachment C 160 284
. C 161 284
disintegration C 163 284
of C 164 284
these C 165 284
foamy C 166 284
cells C 167 284
then C 168 284
releases C 169 284
the C 170 284
lipid C 171 284
content C 172 284
into C 173 284
the C 174 284
interstitium C 175 284
and C 176 284
provokes C 177 284
a C 178 284
re C 179 284
- C 180 284
sponse C 181 284
of C 182 284
macrophages C 183 284
and C 184 284
multinucleated C 185 284
giant C 186 284
cells C 187 284
of C 188 284
the C 189 284
foreign C 190 284
- C 191 284
body C 192 284
type C 193 284
. C 194 284
hemorrhage C 196 284
is C 197 284
also C 198 284
considered C 199 284
as C 200 284
a C 201 284
factor C 202 284
involved C 203 284
in C 204 284
the C 205 284
formation C 206 284
of C 207 284
xanthogranuloma C 208 284
. C 209 284
4 C 1 285
. C 2 285
mixed C 4 285
hematopoietic C 5 285
and C 6 285
pulmonary C 7 285
origin C 8 285
of C 9 285
' C 10 285
alveolar C 11 285
macrophages C 12 285
' C 13 285
as C 14 285
demonstrated C 15 285
by C 16 285
chromosome C 17 285
markers C 18 285
the C 19 285
origin C 20 285
of C 21 285
alveolar C 22 285
macrophages C 23 285
was C 24 285
investiga C 25 285
- C 26 285
ted C 27 285
in C 28 285
mouse C 29 285
chimeras C 30 285
in C 31 285
which C 32 285
the C 33 285
hematopoietic C 34 285
cells C 35 285
could C 36 285
be C 37 285
identified C 38 285
by C 39 285
marker C 40 285
chromosomes C 41 285
. C 42 285
by C 44 285
chro C 45 285
- C 46 285
mosome C 47 285
analysis C 48 285
it C 49 285
was C 50 285
found C 51 285
that C 52 285
in C 53 285
both C 54 285
normal C 55 285
lungs C 56 285
and C 57 285
in C 58 285
lungs C 59 285
exposed C 60 285
to C 61 285
an C 62 285
irritant C 63 285
, C 64 285
approximately C 65 285
two C 66 285
- C 67 285
thirds C 68 285
of C 69 285
the C 70 285
dividing C 71 285
cells C 72 285
which C 73 285
could C 74 285
be C 75 285
recovered C 76 285
by C 77 285
lung C 78 285
washing C 79 285
arose C 80 285
from C 81 285
the C 82 285
hematopoietic C 83 285
system C 84 285
and C 85 285
one C 86 285
- C 87 285
third C 88 285
were C 89 285
of C 90 285
pulmonary C 91 285
origin C 92 285
. C 93 285
632 C 1 286
. C 2 286
pulmonary C 4 286
alveolar C 5 286
proteinosis C 6 286
. C 7 286
a C 9 286
study C 10 286
using C 11 286
enzyme C 12 286
histochemistry C 13 286
, C 14 286
electron C 15 286
microscopy C 16 286
, C 17 286
and C 18 286
surface C 19 286
tension C 20 286
measurement C 21 286
lung C 22 286
biopsies C 23 286
from C 24 286
4 C 25 286
patients C 26 286
with C 27 286
pulmonary C 28 286
al C 29 286
- C 30 286
veolar C 31 286
proteinosis C 32 286
were C 33 286
studied C 34 286
using C 35 286
histochemical C 36 286
me C 37 286
- C 38 286
thods C 39 286
, C 40 286
electron C 41 286
microscopy C 42 286
, C 43 286
and C 44 286
surface C 45 286
tension C 46 286
mea C 47 286
- C 48 286
surement C 49 286
. C 50 286
the C 52 286
lipid C 53 286
- C 54 286
rich C 55 286
intraalveolar C 56 286
fluid C 57 286
contained C 58 286
material C 59 286
with C 60 286
the C 61 286
staining C 62 286
reactions C 63 286
and C 64 286
ultrastructure C 65 286
of C 66 286
phospholipid C 67 286
. C 68 286
although C 70 286
many C 71 286
alveoli C 72 286
were C 73 286
lined C 74 286
by C 75 286
enzymatically C 76 286
active C 77 286
, C 78 286
secreting C 79 286
granular C 80 286
pneumonocy C 81 286
- C 82 286
tes C 83 286
, C 84 286
extracts C 85 286
of C 86 286
proteinotic C 87 286
tissue C 88 286
were C 89 286
not C 90 286
surface C 91 286
active C 92 286
, C 93 286
and C 94 286
, C 95 286
in C 96 286
fact C 97 286
, C 98 286
inhibited C 99 286
normal C 100 286
surfactant C 101 286
. C 102 286
some C 104 286
of C 105 286
the C 106 286
cells C 107 286
free C 108 286
in C 109 286
the C 110 286
intraalveolar C 111 286
material C 112 286
were C 113 286
de C 114 286
- C 115 286
generating C 116 286
sloughed C 117 286
granular C 118 286
pneumonocytes C 119 286
. C 120 286
at C 122 286
the C 123 286
margins C 124 286
of C 125 286
the C 126 286
lesions C 127 286
were C 128 286
lipid C 129 286
- C 130 286
filled C 131 286
macrophages C 132 286
which C 133 286
appear C 134 286
to C 135 286
play C 136 286
a C 137 286
role C 138 286
in C 139 286
the C 140 286
removal C 141 286
of C 142 286
the C 143 286
mate C 144 286
- C 145 286
rial C 146 286
. C 147 286
these C 149 286
observations C 150 286
indicate C 151 286
that C 152 286
alveolar C 153 286
protein C 154 286
- C 155 286
osis C 156 286
is C 157 286
not C 158 286
a C 159 286
primary C 160 286
overproduction C 161 286
of C 162 286
surfactant C 163 286
and C 164 286
are C 165 286
consistent C 166 286
with C 167 286
the C 168 286
concept C 169 286
that C 170 286
the C 171 286
alveolar C 172 286
clear C 173 286
- C 174 286
ing C 175 286
process C 176 286
is C 177 286
defective C 178 286
in C 179 286
this C 180 286
disease C 181 286
. C 182 286
1688 C 1 287
. C 2 287
surface C 4 287
phenomena C 5 287
in C 6 287
lungs C 7 287
in C 8 287
health C 9 287
and C 10 287
disease C 11 287
in C 12 287
summary C 13 287
, C 14 287
the C 15 287
authors C 16 287
have C 17 287
attempted C 18 287
to C 19 287
bring C 20 287
together C 21 287
the C 22 287
multiple C 23 287
observations C 24 287
which C 25 287
seem C 26 287
germane C 27 287
to C 28 287
the C 29 287
understanding C 30 287
of C 31 287
surface C 32 287
phenomena C 33 287
in C 34 287
lungs C 35 287
in C 36 287
health C 37 287
and C 38 287
disease C 39 287
. C 40 287
to C 42 287
this C 43 287
end C 44 287
, C 45 287
the C 46 287
contributions C 47 287
of C 48 287
anatomists C 49 287
and C 50 287
pathologists C 51 287
on C 52 287
the C 53 287
fine C 54 287
structure C 55 287
of C 56 287
alveolar C 57 287
cells C 58 287
and C 59 287
their C 60 287
lining C 61 287
are C 62 287
fundamental C 63 287
. C 64 287
the C 66 287
concepts C 67 287
of C 68 287
alveolar C 69 287
stability C 70 287
required C 71 287
the C 72 287
special C 73 287
insights C 74 287
of C 75 287
physiologists C 76 287
who C 77 287
were C 78 287
concerned C 79 287
with C 80 287
the C 81 287
causes C 82 287
of C 83 287
bubble C 84 287
stability C 85 287
as C 86 287
they C 87 287
related C 88 287
to C 89 287
the C 90 287
particular C 91 287
problems C 92 287
posed C 93 287
by C 94 287
a C 95 287
lung C 96 287
of C 97 287
several C 98 287
millions C 99 287
of C 100 287
bubbles C 101 287
arranged C 102 287
in C 103 287
parallel C 104 287
. C 105 287
soon C 107 287
the C 108 287
contributions C 109 287
of C 110 287
the C 111 287
chemists C 112 287
became C 113 287
significant C 114 287
as C 115 287
methods C 116 287
of C 117 287
identification C 118 287
and C 119 287
assay C 120 287
of C 121 287
the C 122 287
al C 123 287
- C 124 287
veolar C 125 287
lining C 126 287
material C 127 287
were C 128 287
of C 129 287
interest C 130 287
. C 131 287
clinicians C 133 287
asked C 134 287
what C 135 287
relevance C 136 287
these C 137 287
studies C 138 287
had C 139 287
to C 140 287
atelectasis C 141 287
as C 142 287
it C 143 287
occurs C 144 287
in C 145 287
disease C 146 287
, C 147 287
and C 148 287
soon C 149 287
the C 150 287
question C 151 287
of C 152 287
when C 153 287
the C 154 287
surfac C 155 287
- C 156 287
tant C 157 287
appeared C 158 287
in C 159 287
development C 160 287
occurred C 161 287
to C 162 287
those C 163 287
concerned C 164 287
with C 165 287
premature C 166 287
infants C 167 287
. C 168 287
students C 170 287
of C 171 287
metabolism C 172 287
began C 173 287
to C 174 287
focus C 175 287
on C 176 287
the C 177 287
lung C 178 287
as C 179 287
a C 180 287
site C 181 287
of C 182 287
phospholipid C 183 287
synthesis C 184 287
, C 185 287
and C 186 287
their C 187 287
tools C 188 287
seem C 189 287
most C 190 287
promising C 191 287
at C 192 287
this C 193 287
time C 194 287
in C 195 287
unearthing C 196 287
possible C 197 287
errors C 198 287
in C 199 287
metabolism C 200 287
which C 201 287
may C 202 287
express C 203 287
themselves C 204 287
in C 205 287
disease C 206 287
. C 207 287
surgeons C 209 287
who C 210 287
undertake C 211 287
per C 212 287
- C 213 287
fusion C 214 287
of C 215 287
the C 216 287
isolated C 217 287
lung C 218 287
ask C 219 287
the C 220 287
requirements C 221 287
of C 222 287
that C 223 287
organ C 224 287
with C 225 287
respect C 226 287
to C 227 287
the C 228 287
nutrients C 229 287
and C 230 287
environment C 231 287
of C 232 287
the C 233 287
alveolar C 234 287
cells C 235 287
, C 236 287
and C 237 287
anesthesiologists C 238 287
inquire C 239 287
into C 240 287
the C 241 287
possibilities C 242 287
of C 243 287
mechanical C 244 287
injury C 245 287
to C 246 287
the C 247 287
alveoli C 248 287
during C 249 287
artificial C 250 287
respiration C 251 287
. C 252 287
the C 254 287
problems C 255 287
posed C 256 287
to C 257 287
the C 258 287
reviewers C 259 287
of C 260 287
a C 261 287
subject C 262 287
which C 263 287
touches C 264 287
so C 265 287
many C 266 287
disciplines C 267 287
are C 268 287
obvious C 269 287
. C 270 287
doubtless C 272 287
some C 273 287
pertinent C 274 287
studies C 275 287
have C 276 287
been C 277 287
omitted C 278 287
although C 279 287
uninten C 280 287
- C 281 287
tionally C 282 287
; C 283 287
others C 284 287
may C 285 287
have C 286 287
been C 287 287
misinterpreted C 288 287
through C 289 287
lack C 290 287
of C 291 287
qualifications C 292 287
as C 293 287
spe C 294 287
- C 295 287
cialists C 296 287
in C 297 287
all C 298 287
specialties C 299 287
. C 300 287
the C 302 287
authors C 303 287
hope C 304 287
they C 305 287
have C 306 287
provided C 307 287
evidence C 308 287
that C 309 287
the C 310 287
forces C 311 287
of C 312 287
surface C 313 287
tension C 314 287
cannot C 315 287
be C 316 287
ignored C 317 287
in C 318 287
an C 319 287
organ C 320 287
with C 321 287
an C 322 287
air C 323 287
- C 324 287
liquid C 325 287
interface C 326 287
of C 327 287
some C 328 287
70 C 329 287
m C 330 287
2 C 331 287
. C 332 287
they C 334 287
further C 335 287
hope C 336 287
they C 337 287
have C 338 287
described C 339 287
some C 340 287
of C 341 287
the C 342 287
properties C 343 287
of C 344 287
the C 345 287
film C 346 287
at C 347 287
the C 348 287
alveolar C 349 287
- C 350 287
air C 351 287
interface C 352 287
which C 353 287
operate C 354 287
to C 355 287
produce C 356 287
stability C 357 287
of C 358 287
the C 359 287
alveoli C 360 287
. C 361 287
they C 363 287
hold C 364 287
the C 365 287
belief C 366 287
that C 367 287
study C 368 287
of C 369 287
the C 370 287
metabolism C 371 287
of C 372 287
the C 373 287
alveolar C 374 287
lining C 375 287
layer C 376 287
will C 377 287
further C 378 287
their C 379 287
understanding C 380 287
of C 381 287
a C 382 287
number C 383 287
of C 384 287
disease C 385 287
processes C 386 287
in C 387 287
which C 388 287
it C 389 287
may C 390 287
be C 391 287
altered C 392 287
. C 393 287
and C 395 287
lastly C 396 287
, C 397 287
they C 398 287
hope C 399 287
for C 400 287
much C 401 287
closer C 402 287
communication C 403 287
between C 404 287
workers C 405 287
in C 406 287
many C 407 287
disciplines C 408 287
who C 409 287
can C 410 287
elucidate C 411 287
this C 412 287
remarkable C 413 287
subject C 414 287
best C 415 287
through C 416 287
cooperative C 417 287
studies C 418 287
. C 419 287
1689 C 1 288
. C 2 288
alterations C 4 288
in C 5 288
pulmonary C 6 288
surface C 7 288
active C 8 288
lipids C 9 288
during C 10 288
ex C 11 288
- C 12 288
posure C 13 288
to C 14 288
increased C 15 288
oxygen C 16 288
tension C 17 288
the C 18 288
syndrome C 19 288
of C 20 288
progressive C 21 288
respiratory C 22 288
distress C 23 288
, C 24 288
pulmonary C 25 288
edema C 26 288
, C 27 288
and C 28 288
increased C 29 288
pulmonary C 30 288
surface C 31 288
tension C 32 288
was C 33 288
induced C 34 288
in C 35 288
8 C 36 288
dogs C 37 288
by C 38 288
exposure C 39 288
to C 40 288
oxygen C 41 288
tensions C 42 288
greater C 43 288
than C 44 288
550 C 45 288
mm C 46 288
hg C 47 288
for C 48 288
44 C 49 288
. C 50 288
. C 51 288
and C 52 288
52 C 53 288
hours C 54 288
. C 55 288
pulmonary C 57 288
surfactant C 58 288
was C 59 288
extracted C 60 288
by C 61 288
endobronchial C 62 288
washing C 63 288
for C 64 288
measurement C 65 288
of C 66 288
lipid C 67 288
composition C 68 288
and C 69 288
surface C 70 288
activity C 71 288
. C 72 288
five C 74 288
dogs C 75 288
developed C 76 288
respiratory C 77 288
distress C 78 288
without C 79 288
pulmonary C 80 288
edema C 81 288
. C 82 288
in C 84 288
these C 85 288
dogs C 86 288
endobronchial C 87 288
wash C 88 288
surface C 89 288
tension C 90 288
was C 91 288
normal C 92 288
or C 93 288
slightly C 94 288
increased C 95 288
, C 96 288
and C 97 288
total C 98 288
lipid C 99 288
distribution C 100 288
was C 101 288
essentially C 102 288
normal C 103 288
. C 104 288
esterified C 106 288
fatty C 107 288
acids C 108 288
in C 109 288
the C 110 288
lecithin C 111 288
frac C 112 288
- C 113 288
tion C 114 288
were C 115 288
consistently C 116 288
altered C 117 288
with C 118 288
a C 119 288
reduction C 120 288
in C 121 288
palmitate C 122 288
and C 123 288
total C 124 288
saturated C 125 288
fatty C 126 288
acids C 127 288
. C 128 288
three C 130 288
dogs C 131 288
developed C 132 288
pulmonary C 133 288
edema C 134 288
with C 135 288
increased C 136 288
surface C 137 288
tension C 138 288
, C 139 288
in C 140 288
- C 141 288
creased C 142 288
total C 143 288
lipid C 144 288
and C 145 288
protein C 146 288
, C 147 288
and C 148 288
relatively C 149 288
decreased C 150 288
total C 151 288
phospholipid C 152 288
in C 153 288
the C 154 288
endobronchial C 155 288
washings C 156 288
. C 157 288
esterified C 159 288
fatty C 160 288
acids C 161 288
in C 162 288
the C 163 288
lecithin C 164 288
fraction C 165 288
were C 166 288
marked C 167 288
- C 168 288
ly C 169 288
altered C 170 288
with C 171 288
palmitate C 172 288
levels C 173 288
about C 174 288
1 C 175 288
/ C 176 288
3 C 177 288
normal C 178 288
. C 179 288
esterified C 181 288
arachidonate C 182 288
was C 183 288
pre C 184 288
- C 185 288
sent C 186 288
that C 187 288
was C 188 288
attributed C 189 288
to C 190 288
intra C 191 288
- C 192 288
alveolar C 193 288
plasma C 194 288
. C 195 288
electron C 197 288
micrographs C 198 288
of C 199 288
the C 200 288
lung C 201 288
after C 202 288
oxygen C 203 288
exposure C 204 288
showed C 205 288
thickening C 206 288
of C 207 288
alveolar C 208 288
basement C 209 288
membrane C 210 288
and C 211 288
altera C 212 288
- C 213 288
tions C 214 288
in C 215 288
the C 216 288
structure C 217 288
of C 218 288
the C 219 288
lamellar C 220 288
bodies C 221 288
of C 222 288
the C 223 288
type C 224 288
ii C 225 288
alveolar C 226 288
epithelial C 227 288
cells C 228 288
. C 229 288
3805 C 1 289
. C 2 289
cisternal C 4 289
fluid C 5 289
oxygen C 6 289
tension C 7 289
in C 8 289
man C 9 289
measurement C 10 289
of C 11 289
cerebral C 12 289
oxygen C 13 289
tension C 14 289
in C 15 289
man C 16 289
has C 17 289
been C 18 289
hampered C 19 289
by C 20 289
technical C 21 289
dif C 22 289
- C 23 289
ficulties C 24 289
. C 25 289
the C 27 289
authors C 28 289
present C 29 289
a C 30 289
method C 31 289
in C 32 289
which C 33 289
a C 34 289
beckman C 35 289
microelectrode C 36 289
was C 37 289
introduced C 38 289
into C 39 289
the C 40 289
cisterna C 41 289
magna C 42 289
and C 43 289
oxygen C 44 289
tension C 45 289
measured C 46 289
, C 47 289
the C 48 289
hypothesis C 49 289
being C 50 289
that C 51 289
measurement C 52 289
of C 53 289
oxygen C 54 289
tension C 55 289
in C 56 289
a C 57 289
fluid C 58 289
which C 59 289
equilibrates C 60 289
with C 61 289
the C 62 289
average C 63 289
cerebral C 64 289
oxygen C 65 289
tension C 66 289
should C 67 289
give C 68 289
reliable C 69 289
measure C 70 289
of C 71 289
cerebral C 72 289
oxygen C 73 289
tension C 74 289
. C 75 289
in C 77 289
their C 78 289
subjects C 79 289
, C 80 289
inhalation C 81 289
of C 82 289
pure C 83 289
oxygen C 84 289
produced C 85 289
an C 86 289
increase C 87 289
in C 88 289
the C 89 289
oxygen C 90 289
tension C 91 289
in C 92 289
the C 93 289
cisternal C 94 289
fluid C 95 289
as C 96 289
well C 97 289
as C 98 289
in C 99 289
the C 100 289
arterial C 101 289
blood C 102 289
without C 103 289
any C 104 289
alteration C 105 289
of C 106 289
the C 107 289
oxygen C 108 289
tension C 109 289
in C 110 289
the C 111 289
bulb C 112 289
of C 113 289
the C 114 289
internal C 115 289
jugular C 116 289
vein C 117 289
, C 118 289
whereas C 119 289
inhalation C 120 289
of C 121 289
95 C 122 289
% C 123 289
oxygen C 124 289
and C 125 289
5 C 126 289
% C 127 289
carbon C 128 289
dioxide C 129 289
increased C 130 289
the C 131 289
oxygen C 132 289
tension C 133 289
in C 134 289
the C 135 289
cisternal C 136 289
fluid C 137 289
as C 138 289
well C 139 289
as C 140 289
in C 141 289
the C 142 289
arterial C 143 289
and C 144 289
venous C 145 289
blood C 146 289
. C 147 289
5 C 149 289
% C 150 289
carbon C 151 289
dioxide C 152 289
in C 153 289
air C 154 289
produced C 155 289
an C 156 289
increase C 157 289
in C 158 289
the C 159 289
cisternal C 160 289
oxygen C 161 289
tension C 162 289
; C 163 289
a C 164 289
fall C 165 289
in C 166 289
arterial C 167 289
blood C 168 289
pressure C 169 289
associated C 170 289
with C 171 289
the C 172 289
introduction C 173 289
of C 174 289
the C 175 289
suboccipital C 176 289
needle C 177 289
was C 178 289
accom C 179 289
- C 180 289
panied C 181 289
by C 182 289
a C 183 289
decrease C 184 289
in C 185 289
cisternal C 186 289
oxygen C 187 289
tension C 188 289
which C 189 289
then C 190 289
rose C 191 289
simultaneously C 192 289
with C 193 289
the C 194 289
increase C 195 289
in C 196 289
arterial C 197 289
blood C 198 289
pressure C 199 289
that C 200 289
followed C 201 289
infusion C 202 289
of C 203 289
dextran C 204 289
. C 205 289
intravenous C 207 289
injection C 208 289
of C 209 289
xanthinol C 210 289
niacinate C 211 289
induced C 212 289
in C 213 289
all C 214 289
patients C 215 289
a C 216 289
more C 217 289
or C 218 289
less C 219 289
pronounced C 220 289
fall C 221 289
in C 222 289
arterial C 223 289
blood C 224 289
pressure C 225 289
and C 226 289
at C 227 289
the C 228 289
same C 229 289
time C 230 289
the C 231 289
cisternal C 232 289
oxygen C 233 289
tension C 234 289
fell C 235 289
; C 236 289
administration C 237 289
of C 238 289
aramine C 239 289
was C 240 289
associated C 241 289
with C 242 289
a C 243 289
rise C 244 289
in C 245 289
arterial C 246 289
blood C 247 289
pressure C 248 289
plus C 249 289
a C 250 289
rise C 251 289
in C 252 289
cisternal C 253 289
oxygen C 254 289
tension C 255 289
. C 256 289
4181 C 1 290
. C 2 290
cerebrospinal C 4 290
fluid C 5 290
in C 6 290
man C 7 290
native C 8 290
to C 9 290
high C 10 290
altitude C 11 290
csf C 12 290
ph C 13 290
was C 14 290
shown C 15 290
in C 16 290
a C 17 290
prior C 18 290
report C 19 290
to C 20 290
remain C 21 290
essentially C 22 290
constant C 23 290
during C 24 290
8 C 25 290
days C 26 290
of C 27 290
acclimatization C 28 290
to C 29 290
3 C 30 290
, C 31 290
800 C 32 290
m C 33 290
. C 34 290
in C 36 290
order C 37 290
to C 38 290
further C 39 290
evaluate C 40 290
the C 41 290
possible C 42 290
role C 43 290
of C 44 290
csf C 45 290
acid C 46 290
- C 47 290
base C 48 290
equilibria C 49 290
in C 50 290
the C 51 290
regulation C 52 290
of C 53 290
respiration C 54 290
, C 55 290
20 C 56 290
peruvian C 57 290
andean C 58 290
na C 59 290
- C 60 290
tives C 61 290
were C 62 290
studied C 63 290
at C 64 290
altitudes C 65 290
of C 66 290
3 C 67 290
, C 68 290
720 C 69 290
- C 70 290
4 C 71 290
, C 72 290
820 C 73 290
m C 74 290
. C 75 290
in C 77 290
10 C 78 290
subjects C 79 290
at C 80 290
3 C 81 290
, C 82 290
720 C 83 290
m C 84 290
, C 85 290
means C 86 290
were C 87 290
csf C 88 290
ph C 89 290
7 C 90 290
. C 91 290
. C 92 290
. C 92 290
. C 92 290
, C 93 290
pco C 94 290
, C 95 290
43 C 96 290
, C 97 290
hco C 98 290
3 C 99 290
- C 100 290
21 C 101 290
. C 102 290
. C 103 290
, C 104 290
na C 105 290
+ C 106 290
136 C 107 290
, C 108 290
k C 109 290
+ C 110 290
2 C 111 290
. C 112 290
. C 113 290
, C 114 290
cl C 115 290
- C 116 290
124 C 117 290
, C 118 290
lactate C 119 290
30 C 120 290
mg C 121 290
/ C 122 290
100 C 123 290
ml C 124 290
. C 125 290
arterial C 127 290
blood C 128 290
ph C 129 290
7 C 130 290
. C 131 290
. C 132 290
. C 132 290
, C 133 290
pco C 134 290
, C 135 290
32 C 136 290
. C 137 290
. C 138 290
, C 139 290
hco C 140 290
3 C 141 290
- C 142 290
21 C 143 290
. C 144 290
. C 145 290
, C 146 290
na C 147 290
+ C 148 290
136 C 149 290
, C 150 290
k C 151 290
+ C 152 290
4 C 153 290
. C 154 290
. C 155 290
, C 156 290
cl C 157 290
- C 158 290
107 C 159 290
, C 160 290
hematocrit C 161 290
49 C 162 290
, C 163 290
sao C 164 290
, C 165 290
89 C 166 290
. C 167 290
. C 168 290
. C 169 290
in C 171 290
6 C 172 290
subjects C 173 290
at C 174 290
4 C 175 290
, C 176 290
545 C 177 290
m C 178 290
and C 179 290
4 C 180 290
at C 181 290
4 C 182 290
, C 183 290
820 C 184 290
m C 185 290
csf C 186 290
values C 187 290
were C 188 290
not C 189 290
significantly C 190 290
different C 191 290
; C 192 290
mean C 193 290
arterial C 194 290
pco C 195 290
, C 196 290
was C 197 290
32 C 198 290
. C 199 290
. C 200 290
and C 201 290
32 C 202 290
. C 203 290
. C 204 290
, C 205 290
respectively C 206 290
. C 207 290
the C 209 290
only C 210 290
significant C 211 290
variations C 212 290
with C 213 290
altitude C 214 290
were C 215 290
the C 216 290
expected C 217 290
lowering C 218 290
of C 219 290
pao C 220 290
, C 221 290
to C 222 290
47 C 223 290
and C 224 290
43 C 225 290
. C 226 290
. C 227 290
mm C 228 290
hg C 229 290
, C 230 290
and C 231 290
of C 232 290
sao C 233 290
, C 234 290
to C 235 290
84 C 236 290
. C 237 290
. C 238 290
and C 239 290
80 C 240 290
. C 241 290
. C 242 290
, C 243 290
and C 244 290
increase C 245 290
of C 246 290
hematocrit C 247 290
to C 248 290
67 C 249 290
% C 250 290
and C 251 290
75 C 252 290
% C 253 290
, C 254 290
respectively C 255 290
. C 256 290
the C 258 290
natives C 259 290
differed C 260 290
from C 261 290
recently C 262 290
acclimatized C 263 290
sea C 264 290
- C 265 290
level C 266 290
residents C 267 290
in C 268 290
showing C 269 290
less C 270 290
ventilation C 271 290
( C 272 290
higher C 273 290
pco C 274 290
, C 275 290
) C 276 290
in C 277 290
response C 278 290
to C 279 290
the C 280 290
ex C 281 290
- C 282 290
isting C 283 290
hypoxia C 284 290
, C 285 290
and C 286 290
less C 287 290
alkaline C 288 290
arterial C 289 290
blood C 290 290
. C 291 290
the C 293 290
difference C 294 290
appears C 295 290
to C 296 290
relate C 297 290
to C 298 290
peripheral C 299 290
chemoreceptor C 300 290
response C 301 290
to C 302 290
hypoxia C 303 290
rather C 304 290
than C 305 290
central C 306 290
medullary C 307 290
chemoreceptor C 308 290
. C 309 290
1116 C 1 291
. C 2 291
na C 4 291
, C 5 291
k C 6 291
, C 7 291
ca C 8 291
, C 9 291
mg C 10 291
, C 11 291
and C 12 291
cl C 13 291
concentrations C 14 291
in C 15 291
choroid C 16 291
plexus C 17 291
fluid C 18 291
and C 19 291
cisternal C 20 291
fluid C 21 291
compared C 22 291
with C 23 291
plasma C 24 291
ultrafiltrate C 25 291
in C 26 291
7 C 27 291
cats C 28 291
the C 29 291
concentrations C 30 291
of C 31 291
na C 32 291
, C 33 291
k C 34 291
, C 35 291
ca C 36 291
, C 37 291
mg C 38 291
, C 39 291
and C 40 291
cl C 41 291
were C 42 291
measured C 43 291
in C 44 291
plasma C 45 291
ultrafiltrate C 46 291
, C 47 291
newly C 48 291
formed C 49 291
choroid C 50 291
plexus C 51 291
fluid C 52 291
, C 53 291
and C 54 291
cisterna C 55 291
magna C 56 291
fluid C 57 291
. C 58 291
the C 60 291
choroid C 61 291
plexus C 62 291
fluid C 63 291
did C 64 291
not C 65 291
differ C 66 291
from C 67 291
plasma C 68 291
ultrafiltrate C 69 291
in C 70 291
cl C 71 291
and C 72 291
k C 73 291
concentra C 74 291
- C 75 291
tion C 76 291
but C 77 291
contained C 78 291
higher C 79 291
na C 80 291
, C 81 291
markedly C 82 291
higher C 83 291
mg C 84 291
, C 85 291
and C 86 291
lower C 87 291
ca C 88 291
concentrations C 89 291
than C 90 291
the C 91 291
ultrafiltrate C 92 291
. C 93 291
cisterna C 95 291
magna C 96 291
fluid C 97 291
differed C 98 291
from C 99 291
the C 100 291
ultrafiltrate C 101 291
with C 102 291
respect C 103 291
to C 104 291
all C 105 291
5 C 106 291
electrolytes C 107 291
, C 108 291
containing C 109 291
higher C 110 291
concentrations C 111 291
of C 112 291
cl C 113 291
, C 114 291
na C 115 291
, C 116 291
and C 117 291
mg C 118 291
and C 119 291
lower C 120 291
concentrations C 121 291
of C 122 291
k C 123 291
and C 124 291
ca C 125 291
. C 126 291
it C 128 291
differed C 129 291
from C 130 291
choroid C 131 291
plexus C 132 291
fluid C 133 291
in C 134 291
con C 135 291
- C 136 291
taining C 137 291
a C 138 291
higher C 139 291
concentration C 140 291
of C 141 291
cl C 142 291
but C 143 291
lower C 144 291
concentrations C 145 291
of C 146 291
k C 147 291
, C 148 291
ca C 149 291
, C 150 291
and C 151 291
mg C 152 291
. C 153 291
hco C 155 291
3 C 156 291
- C 157 291
concentration C 158 291
, C 159 291
calculated C 160 291
on C 161 291
the C 162 291
basis C 163 291
of C 164 291
the C 165 291
charge C 166 291
balance C 167 291
, C 168 291
was C 169 291
7 C 170 291
mm C 171 291
/ C 172 291
kg C 173 291
h C 174 291
2 C 175 291
o C 176 291
higher C 177 291
in C 178 291
choroid C 179 291
plexus C 180 291
fluid C 181 291
than C 182 291
in C 183 291
cisterna C 184 291
magna C 185 291
fluid C 186 291
, C 187 291
suggesting C 188 291
an C 189 291
ele C 190 291
- C 191 291
vated C 192 291
ph C 193 291
at C 194 291
the C 195 291
former C 196 291
site C 197 291
. C 198 291
without C 200 291
measurement C 201 291
of C 202 291
the C 203 291
potential C 204 291
difference C 205 291
be C 206 291
- C 207 291
tween C 208 291
the C 209 291
csf C 210 291
and C 211 291
plasma C 212 291
, C 213 291
definitive C 214 291
conclusions C 215 291
could C 216 291
not C 217 291
be C 218 291
drawn C 219 291
as C 220 291
to C 221 291
which C 222 291
cations C 223 291
were C 224 291
actively C 225 291
transported C 226 291
. C 227 291
the C 229 291
fact C 230 291
that C 231 291
the C 232 291
distribution C 233 291
ratio C 234 291
between C 235 291
cerebro C 236 291
- C 237 291
spinal C 238 291
fluid C 239 291
and C 240 291
ultrafiltrate C 241 291
of C 242 291
one C 243 291
divalent C 244 291
cation C 245 291
was C 246 291
in C 247 291
the C 248 291
opposite C 249 291
direction C 250 291
from C 251 291
that C 252 291
of C 253 291
the C 254 291
other C 255 291
, C 256 291
and C 257 291
that C 258 291
this C 259 291
was C 260 291
also C 261 291
true C 262 291
of C 263 291
the C 264 291
monovalent C 265 291
cations C 266 291
, C 267 291
was C 268 291
taken C 269 291
as C 270 291
evidence C 271 291
that C 272 291
the C 273 291
mechanisms C 274 291
involved C 275 291
in C 276 291
cation C 277 291
transfer C 278 291
are C 279 291
quite C 280 291
selec C 281 291
- C 282 291
tive C 283 291
. C 284 291
though C 286 291
not C 287 291
proven C 288 291
, C 289 291
active C 290 291
transport C 291 291
was C 292 291
considered C 293 291
the C 294 291
most C 295 291
likely C 296 291
explana C 297 291
- C 298 291
tion C 299 291
of C 300 291
these C 301 291
findings C 302 291
. C 303 291
the C 305 291
data C 306 291
suggest C 307 291
that C 308 291
these C 309 291
specific C 310 291
transfer C 311 291
mechanisms C 312 291
subserve C 313 291
a C 314 291
homeostatic C 315 291
function C 316 291
with C 317 291
regard C 318 291
to C 319 291
mg C 320 291
and C 321 291
k C 322 291
in C 323 291
the C 324 291
cerebrospinal C 325 291
fluid C 326 291
. C 327 291
3230 C 1 292
. C 2 292
cerebral C 4 292
hemodynamics C 5 292
, C 6 292
blood C 7 292
gases C 8 292
, C 9 292
and C 10 292
electrolytes C 11 292
during C 12 292
breath C 13 292
- C 14 292
holding C 15 292
and C 16 292
the C 17 292
valsalva C 18 292
maneuver C 19 292
continuous C 20 292
recordings C 21 292
of C 22 292
arterial C 23 292
and C 24 292
internal C 25 292
jugular C 26 292
blood C 27 292
oxygen C 28 292
tension C 29 292
, C 30 292
oxy C 31 292
- C 32 292
gen C 33 292
saturation C 34 292
, C 35 292
carbon C 36 292
dioxide C 37 292
tension C 38 292
, C 39 292
ph C 40 292
, C 41 292
sodium C 42 292
and C 43 292
potassium C 44 292
, C 45 292
together C 46 292
with C 47 292
peco C 48 292
2 C 49 292
, C 50 292
blood C 51 292
pressure C 52 292
, C 53 292
and C 54 292
electroencephalogram C 55 292
were C 56 292
obtained C 57 292
to C 58 292
compare C 59 292
the C 60 292
effects C 61 292
of C 62 292
inspiratory C 63 292
and C 64 292
expiratory C 65 292
breath C 66 292
- C 67 292
holding C 68 292
and C 69 292
the C 70 292
valsalva C 71 292
maneuver C 72 292
on C 73 292
the C 74 292
cerebral C 75 292
circulation C 76 292
and C 77 292
cerebral C 78 292
oxygen C 79 292
availability C 80 292
in C 81 292
man C 82 292
. C 83 292
during C 85 292
the C 86 292
inter C 87 292
- C 88 292
val C 89 292
of C 90 292
tolerated C 91 292
breath C 92 292
- C 93 292
holding C 94 292
for C 95 292
69 C 96 292
seconds C 97 292
or C 98 292
less C 99 292
, C 100 292
jugular C 101 292
venous C 102 292
oxygen C 103 292
tension C 104 292
was C 105 292
increased C 106 292
owing C 107 292
to C 108 292
increased C 109 292
cerebral C 110 292
blood C 111 292
flow C 112 292
resulting C 113 292
from C 114 292
an C 115 292
increase C 116 292
of C 117 292
arterial C 118 292
carbon C 119 292
dioxide C 120 292
tension C 121 292
. C 122 292
there C 124 292
was C 125 292
a C 126 292
statistically C 127 292
significant C 128 292
correlation C 129 292
between C 130 292
changes C 131 292
in C 132 292
jpo C 133 292
2 C 134 292
and C 135 292
paco C 136 292
2 C 137 292
, C 138 292
which C 139 292
proved C 140 292
to C 141 292
be C 142 292
more C 143 292
or C 144 292
less C 145 292
linear C 146 292
for C 147 292
both C 148 292
increases C 149 292
and C 150 292
decreases C 151 292
of C 152 292
paco C 153 292
2 C 154 292
4 C 155 292
mm C 156 292
. C 157 292
above C 159 292
and C 160 292
below C 161 292
control C 162 292
levels C 163 292
. C 164 292
no C 166 292
threshold C 167 292
was C 168 292
found C 169 292
for C 170 292
changes C 171 292
in C 172 292
paco C 173 292
2 C 174 292
altering C 175 292
effective C 176 292
cerebral C 177 292
perfusion C 178 292
and C 179 292
cerebral C 180 292
venous C 181 292
po C 182 292
2 C 183 292
, C 184 292
extremely C 185 292
small C 186 292
changes C 187 292
in C 188 292
paco C 189 292
2 C 190 292
( C 191 292
less C 192 292
than C 193 292
1 C 194 292
mm C 195 292
. C 196 292
hg C 198 292
) C 199 292
altered C 200 292
cerebral C 201 292
oxygen C 202 292
availability C 203 292
within C 204 292
10 C 205 292
to C 206 292
20 C 207 292
seconds C 208 292
. C 209 292
during C 211 292
the C 212 292
valsalva C 213 292
maneuver C 214 292
a C 215 292
consistent C 216 292
reduction C 217 292
of C 218 292
jugular C 219 292
oxygen C 220 292
tension C 221 292
was C 222 292
found C 223 292
associated C 224 292
with C 225 292
the C 226 292
sudden C 227 292
fall C 228 292
in C 229 292
arterial C 230 292
blood C 231 292
pressure C 232 292
and C 233 292
reduction C 234 292
of C 235 292
arterial C 236 292
carbon C 237 292
dioxide C 238 292
tension C 239 292
. C 240 292
the C 242 292
rapid C 243 292
changes C 244 292
in C 245 292
cerebral C 246 292
hemodynamics C 247 292
and C 248 292
cerebral C 249 292
oxy C 250 292
- C 251 292
gen C 252 292
availability C 253 292
during C 254 292
the C 255 292
procedure C 256 292
are C 257 292
briefly C 258 292
discussed C 259 292
. C 260 292
2344 C 1 293
. C 2 293
respiratory C 4 293
and C 5 293
cardiovascular C 6 293
changes C 7 293
during C 8 293
rapid C 9 293
spon C 10 293
- C 11 293
taneous C 12 293
variations C 13 293
of C 14 293
ventricular C 15 293
fluid C 16 293
pressure C 17 293
in C 18 293
pa C 19 293
- C 20 293
tients C 21 293
with C 22 293
intracranial C 23 293
hypertension C 24 293
in C 25 293
patients C 26 293
with C 27 293
intracranial C 28 293
hypertension C 29 293
the C 30 293
ventricular C 31 293
fluid C 32 293
pressure C 33 293
( C 34 293
vfp C 35 293
) C 36 293
curve C 37 293
is C 38 293
characterized C 39 293
by C 40 293
3 C 41 293
main C 42 293
forms C 43 293
of C 44 293
spontaneous C 45 293
variations C 46 293
. C 47 293
two C 49 293
of C 50 293
these C 51 293
forms C 52 293
are C 53 293
of C 54 293
a C 55 293
rhythmical C 56 293
nature C 57 293
, C 58 293
and C 59 293
are C 60 293
here C 61 293
called C 62 293
1 C 63 293
- C 64 293
per C 65 293
- C 66 293
minute C 67 293
waves C 68 293
and C 69 293
6 C 70 293
- C 71 293
per C 72 293
- C 73 293
minute C 74 293
waves C 75 293
, C 76 293
respectively C 77 293
, C 78 293
in C 79 293
accordance C 80 293
with C 81 293
the C 82 293
dominating C 83 293
frequency C 84 293
. C 85 293
the C 87 293
third C 88 293
form C 89 293
- C 90 293
irregularly C 91 293
appearing C 92 293
waves C 93 293
of C 94 293
large C 95 293
amplitude C 96 293
and C 97 293
duration C 98 293
- C 99 293
is C 100 293
called C 101 293
plateau C 102 293
waves C 103 293
in C 104 293
accordance C 105 293
with C 106 293
the C 107 293
usual C 108 293
shape C 109 293
of C 110 293
the C 111 293
fluctuations C 112 293
. C 113 293
respiratory C 115 293
and C 116 293
cardio C 117 293
- C 118 293
vascular C 119 293
changes C 120 293
accompanying C 121 293
these C 122 293
variations C 123 293
of C 124 293
the C 125 293
vfp C 126 293
were C 127 293
studied C 128 293
by C 129 293
simultaneous C 130 293
recording C 131 293
, C 132 293
in C 133 293
various C 134 293
combinations C 135 293
, C 136 293
of C 137 293
the C 138 293
vfp C 139 293
, C 140 293
the C 141 293
pulmonary C 142 293
ventilation C 143 293
, C 144 293
the C 145 293
pco C 146 293
2 C 147 293
of C 148 293
the C 149 293
expiratory C 150 293
air C 151 293
, C 152 293
the C 153 293
arterial C 154 293
and C 155 293
the C 156 293
venous C 157 293
blood C 158 293
pressure C 159 293
, C 160 293
and C 161 293
the C 162 293
pulse C 163 293
frequency C 164 293
. C 165 293
it C 167 293
was C 168 293
found C 169 293
that C 170 293
the C 171 293
rhythmic C 172 293
vfp C 173 293
vari C 174 293
- C 175 293
ations C 176 293
of C 177 293
the C 178 293
1 C 179 293
- C 180 293
per C 181 293
- C 182 293
minute C 183 293
type C 184 293
occurred C 185 293
synchronously C 186 293
with C 187 293
the C 188 293
respiratory C 189 293
peri C 190 293
- C 191 293
ods C 192 293
in C 193 293
cheyne C 194 293
- C 195 293
stokes C 196 293
breathing C 197 293
. C 198 293
synchronously C 200 293
appearing C 201 293
variations C 202 293
in C 203 293
systemic C 204 293
blood C 205 293
pressure C 206 293
, C 207 293
in C 208 293
pulse C 209 293
frequency C 210 293
, C 211 293
as C 212 293
well C 213 293
as C 214 293
in C 215 293
consciousness C 216 293
and C 217 293
in C 218 293
muscular C 219 293
tone C 220 293
of C 221 293
the C 222 293
limbs C 223 293
were C 224 293
also C 225 293
noted C 226 293
. C 227 293
the C 229 293
respiratory C 230 293
midposition C 231 293
shifted C 232 293
towards C 233 293
the C 234 293
inspiratory C 235 293
side C 236 293
during C 237 293
the C 238 293
periods C 239 293
of C 240 293
hyperpnoea C 241 293
. C 242 293
the C 244 293
6 C 245 293
- C 246 293
per C 247 293
- C 248 293
minute C 249 293
waves C 250 293
were C 251 293
entirely C 252 293
synchronous C 253 293
with C 254 293
variations C 255 293
in C 256 293
the C 257 293
systemic C 258 293
arterial C 259 293
blood C 260 293
pressure C 261 293
of C 262 293
the C 263 293
traube C 264 293
- C 265 293
hering C 266 293
- C 267 293
mayer C 268 293
type C 269 293
. C 270 293
long C 272 293
sequences C 273 293
of C 274 293
these C 275 293
waves C 276 293
were C 277 293
observed C 278 293
only C 279 293
when C 280 293
the C 281 293
vfp C 282 293
level C 283 293
was C 284 293
considerably C 285 293
elevated C 286 293
. C 287 293
the C 289 293
plateau C 290 293
waves C 291 293
were C 292 293
not C 293 293
accom C 294 293
- C 295 293
panied C 296 293
by C 297 293
corresponding C 298 293
elevations C 299 293
of C 300 293
the C 301 293
arterial C 302 293
or C 303 293
venous C 304 293
systemic C 305 293
blood C 306 293
pres C 307 293
- C 308 293
sure C 309 293
. C 310 293
simultaneously C 312 293
with C 313 293
the C 314 293
crests C 315 293
of C 316 293
the C 317 293
plateau C 318 293
waves C 319 293
sudden C 320 293
changes C 321 293
often C 322 293
occurred C 323 293
in C 324 293
the C 325 293
pulse C 326 293
frequency C 327 293
( C 328 293
from C 329 293
bradycardia C 330 293
to C 331 293
tachycardia C 332 293
) C 333 293
, C 334 293
and C 335 293
in C 336 293
the C 337 293
res C 338 293
- C 339 293
piratory C 340 293
pattern C 341 293
, C 342 293
sometimes C 343 293
also C 344 293
in C 345 293
the C 346 293
degree C 347 293
of C 348 293
consciousness C 349 293
and C 350 293
in C 351 293
the C 352 293
muscu C 353 293
- C 354 293
lar C 355 293
tone C 356 293
. C 357 293
there C 359 293
were C 360 293
also C 361 293
long C 362 293
sequences C 363 293
of C 364 293
6 C 365 293
- C 366 293
per C 367 293
- C 368 293
minute C 369 293
waves C 370 293
. C 371 293
the C 373 293
deep C 374 293
, C 375 293
irre C 376 293
- C 377 293
gular C 378 293
breathing C 379 293
seen C 380 293
in C 381 293
this C 382 293
stage C 383 293
induced C 384 293
a C 385 293
considerable C 386 293
hypocapnia C 387 293
preceeding C 388 293
the C 389 293
final C 390 293
critical C 391 293
fall C 392 293
in C 393 293
the C 394 293
vfp C 395 293
ending C 396 293
the C 397 293
plateau C 398 293
wave C 399 293
. C 400 293
in C 402 293
most C 403 293
instances C 404 293
, C 405 293
how C 406 293
- C 407 293
ever C 408 293
, C 409 293
this C 410 293
fall C 411 293
did C 412 293
not C 413 293
begin C 414 293
until C 415 293
several C 416 293
minutes C 417 293
after C 418 293
the C 419 293
appearance C 420 293
of C 421 293
the C 422 293
hypo C 423 293
- C 424 293
capnia C 425 293
. C 426 293
82 C 1 294
. C 2 294
central C 4 294
nervous C 5 294
system C 6 294
lesions C 7 294
in C 8 294
rats C 9 294
exposed C 10 294
to C 11 294
oxygen C 12 294
at C 13 294
high C 14 294
pressure C 15 294
adult C 16 294
female C 17 294
rats C 18 294
paralyzed C 19 294
by C 20 294
repeated C 21 294
exposures C 22 294
to C 23 294
oxygen C 24 294
at C 25 294
high C 26 294
pressure C 27 294
were C 28 294
found C 29 294
to C 30 294
have C 31 294
cns C 32 294
le C 33 294
- C 34 294
sions C 35 294
of C 36 294
2 C 37 294
types C 38 294
( C 39 294
1 C 40 294
) C 41 294
focal C 42 294
necrosis C 43 294
of C 44 294
individual C 45 294
neurons C 46 294
within C 47 294
certain C 48 294
nuclear C 49 294
groups C 50 294
, C 51 294
and C 52 294
( C 53 294
2 C 54 294
) C 55 294
complete C 56 294
or C 57 294
partial C 58 294
necrosis C 59 294
of C 60 294
nuclear C 61 294
groups C 62 294
with C 63 294
frequent C 64 294
damage C 65 294
to C 66 294
mye C 67 294
- C 68 294
lin C 69 294
, C 70 294
axons C 71 294
, C 72 294
and C 73 294
glia C 74 294
in C 75 294
the C 76 294
area C 77 294
involved C 78 294
. C 79 294
both C 81 294
types C 82 294
were C 83 294
usually C 84 294
bilateral C 85 294
and C 86 294
symmetrical C 87 294
. C 88 294
lesions C 90 294
of C 91 294
the C 92 294
first C 93 294
type C 94 294
were C 95 294
found C 96 294
consistently C 97 294
in C 98 294
the C 99 294
superior C 100 294
olivary C 101 294
complex C 102 294
, C 103 294
ventral C 104 294
cochlear C 105 294
nuclei C 106 294
, C 107 294
and C 108 294
nuclei C 109 294
of C 110 294
the C 111 294
spinal C 112 294
tract C 113 294
of C 114 294
cranial C 115 294
nerve C 116 294
v C 117 294
. C 118 294
lesions C 120 294
of C 121 294
the C 122 294
second C 123 294
type C 124 294
were C 125 294
found C 126 294
consistently C 127 294
in C 128 294
the C 129 294
substantia C 130 294
nigra C 131 294
and C 132 294
globus C 133 294
pal C 134 294
- C 135 294
lidus C 136 294
, C 137 294
were C 138 294
frequent C 139 294
in C 140 294
the C 141 294
rhinencephalon C 142 294
, C 143 294
and C 144 294
never C 145 294
occurred C 146 294
in C 147 294
the C 148 294
neocortex C 149 294
. C 150 294
747 C 1 295
. C 2 295
electrode C 4 295
size C 5 295
and C 6 295
tissue C 7 295
po C 8 295
2 C 9 295
measurement C 10 295
in C 11 295
rats C 12 295
exposed C 13 295
to C 14 295
air C 15 295
or C 16 295
high C 17 295
pressure C 18 295
oxygen C 19 295
a C 20 295
comparison C 21 295
has C 22 295
been C 23 295
made C 24 295
of C 25 295
values C 26 295
of C 27 295
po C 28 295
2 C 29 295
recorded C 30 295
in C 31 295
several C 32 295
rat C 33 295
tissues C 34 295
with C 35 295
60 C 36 295
- C 37 295
u C 38 295
or C 39 295
330 C 40 295
- C 41 295
u C 42 295
flexible C 43 295
gold C 44 295
electrodes C 45 295
. C 46 295
although C 48 295
qualitatively C 49 295
both C 50 295
sizes C 51 295
of C 52 295
elec C 53 295
- C 54 295
trodes C 55 295
give C 56 295
similar C 57 295
results C 58 295
, C 59 295
the C 60 295
quantitative C 61 295
values C 62 295
of C 63 295
po C 64 295
2 C 65 295
differ C 66 295
. C 67 295
such C 69 295
large C 70 295
differ C 71 295
- C 72 295
ences C 73 295
as C 74 295
are C 75 295
found C 76 295
in C 77 295
some C 78 295
cases C 79 295
between C 80 295
electrodes C 81 295
varying C 82 295
only C 83 295
in C 84 295
physical C 85 295
di C 86 295
- C 87 295
mensions C 88 295
are C 89 295
thought C 90 295
to C 91 295
reflect C 92 295
the C 93 295
amount C 94 295
of C 95 295
trauma C 96 295
caused C 97 295
in C 98 295
the C 99 295
tissue C 100 295
under C 101 295
in C 102 295
- C 103 295
vestigation C 104 295
due C 105 295
to C 106 295
electrode C 107 295
insertion C 108 295
. C 109 295
errors C 111 295
in C 112 295
po C 113 295
2 C 114 295
estimations C 115 295
due C 116 295
to C 117 295
tissue C 118 295
da C 119 295
- C 120 295
mage C 121 295
are C 122 295
considered C 123 295
to C 124 295
outweigh C 125 295
any C 126 295
other C 127 295
errors C 128 295
such C 129 295
as C 130 295
those C 131 295
due C 132 295
to C 133 295
electrode C 134 295
calibration C 135 295
. C 136 295
soft C 138 295
, C 139 295
highly C 140 295
vascular C 141 295
tissues C 142 295
, C 143 295
such C 144 295
as C 145 295
liver C 146 295
, C 147 295
kidney C 148 295
and C 149 295
spleen C 150 295
, C 151 295
which C 152 295
show C 153 295
macroscopic C 154 295
bruising C 155 295
over C 156 295
quite C 157 295
a C 158 295
large C 159 295
area C 160 295
when C 161 295
electrodes C 162 295
are C 163 295
inserted C 164 295
, C 165 295
show C 166 295
the C 167 295
greatest C 168 295
difference C 169 295
in C 170 295
estimations C 171 295
of C 172 295
the C 173 295
po C 174 295
2 C 175 295
value C 176 295
. C 177 295
recordings C 179 295
of C 180 295
tissue C 181 295
po C 182 295
2 C 183 295
were C 184 295
made C 185 295
while C 186 295
animals C 187 295
breathed C 188 295
air C 189 295
and C 190 295
when C 191 295
compressed C 192 295
to C 193 295
4 C 194 295
or C 195 295
5 C 196 295
atm C 197 295
. C 198 295
in C 200 295
pure C 201 295
oxygen C 202 295
, C 203 295
and C 204 295
the C 205 295
pattern C 206 295
of C 207 295
response C 208 295
of C 209 295
tissue C 210 295
po C 211 295
2 C 212 295
to C 213 295
such C 214 295
exposure C 215 295
of C 216 295
the C 217 295
ani C 218 295
- C 219 295
mal C 220 295
to C 221 295
high C 222 295
pressures C 223 295
of C 224 295
oxygen C 225 295
is C 226 295
described C 227 295
. C 228 295
3384 C 1 296
. C 2 296
adrenergic C 4 296
effects C 5 296
in C 6 296
splenic C 7 296
po C 8 296
2 C 9 296
of C 10 296
rats C 11 296
in C 12 296
air C 13 296
or C 14 296
oxygen C 15 296
at C 16 296
5 C 17 296
atmospheres C 18 296
oxygen C 19 296
tensions C 20 296
have C 21 296
been C 22 296
measured C 23 296
in C 24 296
the C 25 296
spleens C 26 296
of C 27 296
rats C 28 296
breathing C 29 296
air C 30 296
and C 31 296
during C 32 296
exposure C 33 296
of C 34 296
the C 35 296
animals C 36 296
to C 37 296
5 C 38 296
atm C 39 296
abs C 40 296
of C 41 296
oxygen C 42 296
( C 43 296
hpo C 44 296
) C 45 296
. C 46 296
the C 48 296
response C 49 296
of C 50 296
splenic C 51 296
po C 52 296
2 C 53 296
to C 54 296
compression C 55 296
was C 56 296
complex C 57 296
, C 58 296
usually C 59 296
reaching C 60 296
a C 61 296
peak C 62 296
value C 63 296
immediately C 64 296
after C 65 296
com C 66 296
- C 67 296
pression C 68 296
, C 69 296
then C 70 296
falling C 71 296
to C 72 296
a C 73 296
lower C 74 296
value C 75 296
. C 76 296
this C 78 296
form C 79 296
of C 80 296
response C 81 296
has C 82 296
been C 83 296
termed C 84 296
a C 85 296
hump C 86 296
response C 87 296
. C 88 296
after C 90 296
adrenalectomy C 91 296
or C 92 296
bretylium C 93 296
tosylate C 94 296
injection C 95 296
the C 96 296
hump C 97 296
res C 98 296
- C 99 296
ponse C 100 296
of C 101 296
po C 102 296
2 C 103 296
after C 104 296
compression C 105 296
was C 106 296
almost C 107 296
abolished C 108 296
, C 109 296
and C 110 296
the C 111 296
values C 112 296
of C 113 296
splenic C 114 296
po C 115 296
2 C 116 296
at C 117 296
5 C 118 296
atm C 119 296
were C 120 296
considerably C 121 296
higher C 122 296
than C 123 296
in C 124 296
control C 125 296
animals C 126 296
. C 127 296
a C 129 296
combination C 130 296
of C 131 296
adrena C 132 296
- C 133 296
lectomy C 134 296
and C 135 296
bretylium C 136 296
tosylate C 137 296
also C 138 296
markedly C 139 296
reduced C 140 296
the C 141 296
number C 142 296
of C 143 296
hump C 144 296
responses C 145 296
, C 146 296
but C 147 296
unexpectedly C 148 296
significantly C 149 296
lowered C 150 296
splenic C 151 296
oxygen C 152 296
tensions C 153 296
, C 154 296
both C 155 296
when C 156 296
the C 157 296
ani C 158 296
- C 159 296
mals C 160 296
were C 161 296
under C 162 296
ambient C 163 296
conditions C 164 296
or C 165 296
at C 166 296
5 C 167 296
atm C 168 296
of C 169 296
oxygen C 170 296
. C 171 296
cardiac C 173 296
rate C 174 296
and C 175 296
blood C 176 296
pressure C 177 296
were C 178 296
studied C 179 296
in C 180 296
an C 181 296
attempt C 182 296
to C 183 296
find C 184 296
the C 185 296
explanation C 186 296
of C 187 296
this C 188 296
latter C 189 296
effect C 190 296
, C 191 296
and C 192 296
while C 193 296
blood C 194 296
pressure C 195 296
was C 196 296
the C 197 296
same C 198 296
in C 199 296
adrenalectomized C 200 296
rats C 201 296
and C 202 296
control C 203 296
rats C 204 296
after C 205 296
bretylium C 206 296
injection C 207 296
, C 208 296
adrenalectomy C 209 296
potentiated C 210 296
the C 211 296
bradycardia C 212 296
produced C 213 296
by C 214 296
brety C 215 296
- C 216 296
lium C 217 296
tosylate C 218 296
. C 219 296
10642 C 1 297
. C 2 297
the C 4 297
effects C 5 297
of C 6 297
antioxidants C 7 297
on C 8 297
high C 9 297
pressure C 10 297
oxygen C 11 297
toxicity C 12 297
several C 13 297
commonly C 14 297
used C 15 297
antioxidants C 16 297
have C 17 297
been C 18 297
tested C 19 297
for C 20 297
their C 21 297
effect C 22 297
against C 23 297
poison C 24 297
- C 25 297
ing C 26 297
due C 27 297
to C 28 297
high C 29 297
pressures C 30 297
of C 31 297
oxygen C 32 297
( C 33 297
ohp C 34 297
) C 35 297
. C 36 297
the C 38 297
tests C 39 297
used C 40 297
were C 41 297
preconclusive C 42 297
pe C 43 297
- C 44 297
riod C 45 297
and C 46 297
survival C 47 297
time C 48 297
of C 49 297
mice C 50 297
at C 51 297
5 C 52 297
atm C 53 297
absolute C 54 297
oxygen C 55 297
, C 56 297
lung C 57 297
damage C 58 297
in C 59 297
rats C 60 297
ex C 61 297
- C 62 297
posed C 63 297
to C 64 297
5 C 65 297
atm C 66 297
oxygen C 67 297
for C 68 297
1 C 69 297
hr C 70 297
. C 71 297
, C 73 297
and C 74 297
post C 75 297
ohp C 76 297
paralysis C 77 297
in C 78 297
rats C 79 297
following C 80 297
deep C 81 297
pentobarbital C 82 297
- C 83 297
na C 84 297
anesthesia C 85 297
and C 86 297
ohp C 87 297
at C 88 297
4 C 89 297
atm C 90 297
for C 91 297
30 C 92 297
min C 93 297
. C 94 297
2 C 96 297
, C 97 297
5 C 98 297
- C 99 297
bis C 100 297
( C 101 297
1 C 102 297
, C 103 297
1 C 104 297
- C 105 297
dimethyl C 106 297
- C 107 297
propyl C 108 297
) C 109 297
hydroquinone C 110 297
gave C 111 297
excellent C 112 297
protection C 113 297
against C 114 297
ohp C 115 297
toxicity C 116 297
in C 117 297
all C 118 297
tests C 119 297
, C 120 297
and C 121 297
several C 122 297
other C 123 297
antioxidants C 124 297
also C 125 297
protected C 126 297
against C 127 297
ohp C 128 297
toxicity C 129 297
but C 130 297
their C 131 297
potency C 132 297
and C 133 297
effectiveness C 134 297
varied C 135 297
for C 136 297
the C 137 297
different C 138 297
criteria C 139 297
of C 140 297
oxygen C 141 297
poisoning C 142 297
tested C 143 297
in C 144 297
the C 145 297
experiments C 146 297
. C 147 297
3716 C 1 298
. C 2 298
glycolytic C 4 298
control C 5 298
mechanisms C 6 298
. C 7 298
i C 9 298
. C 10 298
inhibition C 12 298
of C 13 298
glycolysis C 14 298
by C 15 298
acetate C 16 298
and C 17 298
pyruvate C 18 298
in C 19 298
the C 20 298
isolated C 21 298
, C 22 298
perfused C 23 298
rat C 24 298
heart C 25 298
acetate C 26 298
or C 27 298
pyruvate C 28 298
had C 29 298
similar C 30 298
effects C 31 298
on C 32 298
the C 33 298
over C 34 298
- C 35 298
all C 36 298
metabolism C 37 298
of C 38 298
glucose C 39 298
. C 40 298
gly C 42 298
- C 43 298
colytic C 44 298
flux C 45 298
was C 46 298
decreased C 47 298
in C 48 298
both C 49 298
the C 50 298
presence C 51 298
and C 52 298
absence C 53 298
of C 54 298
insulin C 55 298
, C 56 298
glucose C 57 298
oxidation C 58 298
was C 59 298
greatly C 60 298
decreased C 61 298
, C 62 298
and C 63 298
the C 64 298
conversion C 65 298
of C 66 298
glucose C 67 298
to C 68 298
glycogen C 69 298
and C 70 298
lac C 71 298
- C 72 298
tate C 73 298
was C 74 298
promoted C 75 298
. C 76 298
glucose C 78 298
phosphorylation C 79 298
was C 80 298
decreased C 81 298
in C 82 298
the C 83 298
presence C 84 298
but C 85 298
not C 86 298
in C 87 298
the C 88 298
absence C 89 298
of C 90 298
insulin C 91 298
. C 92 298
hexokinase C 94 298
, C 95 298
phosphofructokinase C 96 298
, C 97 298
glyceraldehyde C 98 298
phos C 99 298
- C 100 298
phate C 101 298
dehydrogenase C 102 298
, C 103 298
and C 104 298
pyruvic C 105 298
kinase C 106 298
are C 107 298
far C 108 298
displaced C 109 298
from C 110 298
equilibrium C 111 298
, C 112 298
while C 113 298
the C 114 298
other C 115 298
enzymic C 116 298
steps C 117 298
of C 118 298
glycolysis C 119 298
are C 120 298
maintained C 121 298
either C 122 298
at C 123 298
equilibrium C 124 298
or C 125 298
fairly C 126 298
close C 127 298
to C 128 298
equilibrium C 129 298
. C 130 298
in C 132 298
different C 133 298
metabolic C 134 298
situations C 135 298
, C 136 298
glycolytic C 137 298
flux C 138 298
may C 139 298
be C 140 298
affec C 141 298
- C 142 298
ted C 143 298
by C 144 298
those C 145 298
steps C 146 298
which C 147 298
are C 148 298
far C 149 298
displaced C 150 298
from C 151 298
equilibrium C 152 298
. C 153 298
increased C 155 298
levels C 156 298
of C 157 298
the C 158 298
hexose C 159 298
monophosphates C 160 298
, C 161 298
and C 162 298
decreased C 163 298
levels C 164 298
of C 165 298
the C 166 298
other C 167 298
glycolytic C 168 298
inter C 169 298
- C 170 298
mediates C 171 298
between C 172 298
fructose C 173 298
1 C 174 298
, C 175 298
6 C 176 298
- C 177 298
diphosphate C 178 298
and C 179 298
pyruvate C 180 298
after C 181 298
the C 182 298
addition C 183 298
of C 184 298
10 C 185 298
mm C 186 298
acetate C 187 298
indicate C 188 298
that C 189 298
glycolytic C 190 298
flux C 191 298
was C 192 298
decreased C 193 298
by C 194 298
inhibition C 195 298
of C 196 298
phosphofructo C 197 298
- C 198 298
kinase C 199 298
. C 200 298
after C 202 298
the C 203 298
addition C 204 298
of C 205 298
10 C 206 298
mm C 207 298
pyruvate C 208 298
, C 209 298
fructose C 210 298
1 C 211 298
, C 212 298
6 C 213 298
- C 214 298
diphosphate C 215 298
, C 216 298
and C 217 298
triose C 218 298
- C 219 298
phosphate C 220 298
accumulated C 221 298
as C 222 298
a C 223 298
result C 224 298
of C 225 298
an C 226 298
inhibition C 227 298
of C 228 298
either C 229 298
glyceraldehyde C 230 298
phosphate C 231 298
dehydrogenase C 232 298
or C 233 298
phosphoglyceric C 234 298
kinase C 235 298
. C 236 298
acetate C 238 298
had C 239 298
little C 240 298
effect C 241 298
on C 242 298
the C 243 298
total C 244 298
con C 245 298
- C 246 298
tent C 247 298
of C 248 298
oxidized C 249 298
or C 250 298
reduced C 251 298
di C 252 298
- C 253 298
or C 254 298
triphosphopyridine C 255 298
nucleotides C 256 298
, C 257 298
but C 258 298
slightly C 259 298
de C 260 298
- C 261 298
creased C 262 298
the C 263 298
ratio C 264 298
of C 265 298
nad C 266 298
to C 267 298
nadh C 268 298
2 C 269 298
in C 270 298
the C 271 298
cytoplasm C 272 298
, C 273 298
as C 274 298
estimated C 275 298
from C 276 298
the C 277 298
ratios C 278 298
of C 279 298
lactate C 280 298
to C 281 298
pyruvate C 282 298
and C 283 298
a C 284 298
- C 285 298
glycerophosphate C 286 298
to C 287 298
dihydroxyacetone C 288 298
phosphate C 289 298
. C 290 298
pyru C 292 298
- C 293 298
vate C 294 298
increased C 295 298
the C 296 298
total C 297 298
content C 298 298
of C 299 298
nadh C 300 298
2 C 301 298
and C 302 298
nadph C 303 298
2 C 304 298
as C 305 298
shown C 306 298
both C 307 298
by C 308 298
an C 309 298
increase C 310 298
of C 311 298
fluorescence C 312 298
in C 313 298
the C 314 298
intact C 315 298
heart C 316 298
, C 317 298
and C 318 298
by C 319 298
tissue C 320 298
analyses C 321 298
, C 322 298
but C 323 298
the C 324 298
ratio C 325 298
of C 326 298
nad C 327 298
to C 328 298
nadii C 329 298
2 C 330 298
in C 331 298
the C 332 298
cytoplasm C 333 298
was C 334 298
greatly C 335 298
increased C 336 298
. C 337 298
these C 339 298
results C 340 298
demonstrate C 341 298
com C 342 298
- C 343 298
partmentation C 344 298
of C 345 298
pyridine C 346 298
nucleotides C 347 298
between C 348 298
cytoplasm C 349 298
and C 350 298
mitochondria C 351 298
in C 352 298
the C 353 298
intact C 354 298
cell C 355 298
. C 356 298
after C 358 298
the C 359 298
addition C 360 298
of C 361 298
acetate C 362 298
, C 363 298
citrate C 364 298
was C 365 298
the C 366 298
only C 367 298
intermediate C 368 298
of C 369 298
the C 370 298
citric C 371 298
acid C 372 298
cycle C 373 298
which C 374 298
increased C 375 298
greatly C 376 298
in C 377 298
amount C 378 298
, C 379 298
while C 380 298
oxaloacetate C 381 298
levels C 382 298
de C 383 298
- C 384 298
creased C 385 298
. C 386 298
after C 388 298
the C 389 298
addition C 390 298
of C 391 298
pyruvate C 392 298
, C 393 298
the C 394 298
levels C 395 298
of C 396 298
citrate C 397 298
, C 398 298
a C 399 298
- C 400 298
ketoglutarate C 401 298
, C 402 298
ma C 403 298
- C 404 298
late C 405 298
, C 406 298
and C 407 298
oxaloacetate C 408 298
were C 409 298
all C 410 298
greatly C 411 298
elevated C 412 298
. C 413 298
the C 415 298
glutamic C 416 298
- C 417 298
oxaloacetate C 418 298
trans C 419 298
- C 420 298
aminase C 421 298
reaction C 422 298
as C 423 298
measured C 424 298
from C 425 298
the C 426 298
total C 427 298
contents C 428 298
of C 429 298
the C 430 298
reactants C 431 298
in C 432 298
the C 433 298
tissue C 434 298
remained C 435 298
close C 436 298
to C 437 298
equilibrium C 438 298
. C 439 298
changes C 441 298
in C 442 298
the C 443 298
concentrations C 444 298
of C 445 298
the C 446 298
adenine C 447 298
nu C 448 298
- C 449 298
cleotides C 450 298
were C 451 298
insufficient C 452 298
to C 453 298
account C 454 298
for C 455 298
the C 456 298
inhibition C 457 298
of C 458 298
phosphofructokinase C 459 298
, C 460 298
but C 461 298
the C 462 298
results C 463 298
are C 464 298
consistent C 465 298
with C 466 298
control C 467 298
at C 468 298
this C 469 298
step C 470 298
being C 471 298
mediated C 472 298
by C 473 298
citrate C 474 298
. C 475 298
244 C 1 299
. C 2 299
oxygen C 4 299
tension C 5 299
in C 6 299
human C 7 299
malignant C 8 299
disease C 9 299
under C 10 299
hyperbaric C 11 299
conditions C 12 299
oxygen C 13 299
tensions C 14 299
were C 15 299
recorded C 16 299
continuously C 17 299
in C 18 299
tumours C 19 299
and C 20 299
normal C 21 299
tissues C 22 299
of C 23 299
34 C 24 299
pa C 25 299
- C 26 299
tients C 27 299
pressurized C 28 299
in C 29 299
pure C 30 299
oxygen C 31 299
to C 32 299
4 C 33 299
atmospheres C 34 299
absolute C 35 299
. C 36 299
mean C 38 299
rises C 39 299
to C 40 299
620 C 41 299
mm C 42 299
. C 43 299
hg C 45 299
and C 46 299
320 C 47 299
mm C 48 299
. C 49 299
hg C 51 299
for C 52 299
tumours C 53 299
and C 54 299
normal C 55 299
tissues C 56 299
respectively C 57 299
were C 58 299
recorded C 59 299
. C 60 299
with C 62 299
patients C 63 299
breathing C 64 299
air C 65 299
at C 66 299
atmospheric C 67 299
pressure C 68 299
22 C 69 299
/ C 70 299
90 C 71 299
( C 72 299
24 C 73 299
% C 74 299
) C 75 299
of C 76 299
tumour C 77 299
elec C 78 299
- C 79 299
trodes C 80 299
registered C 81 299
po C 82 299
2 C 83 299
values C 84 299
of C 85 299
less C 86 299
than C 87 299
4 C 88 299
mm C 89 299
. C 90 299
hg C 92 299
compared C 93 299
to C 94 299
only C 95 299
2 C 96 299
/ C 97 299
39 C 98 299
( C 99 299
5 C 100 299
% C 101 299
) C 102 299
of C 103 299
normal C 104 299
tissue C 105 299
electrodes C 106 299
. C 107 299
the C 109 299
results C 110 299
obtained C 111 299
suggest C 112 299
that C 113 299
oxygen C 114 299
polarography C 115 299
as C 116 299
a C 117 299
meth C 118 299
- C 119 299
od C 120 299
for C 121 299
determining C 122 299
po C 123 299
2 C 124 299
in C 125 299
' C 126 299
solid C 127 299
' C 128 299
tissues C 129 299
in C 130 299
vivo C 131 299
is C 132 299
complicated C 133 299
by C 134 299
many C 135 299
artefacts C 136 299
- C 137 299
particularly C 138 299
tissue C 139 299
damage C 140 299
due C 141 299
to C 142 299
electrode C 143 299
trauma C 144 299
- C 145 299
which C 146 299
reduce C 147 299
its C 148 299
value C 149 299
to C 150 299
clin C 151 299
- C 152 299
ical C 153 299
research C 154 299
concerned C 155 299
with C 156 299
accurate C 157 299
information C 158 299
of C 159 299
absolute C 160 299
po C 161 299
2 C 162 299
values C 163 299
in C 164 299
intact C 165 299
tissues C 166 299
. C 167 299
7839 C 1 300
. C 2 300
. C 3 300
. C 3 300
. C 3 300
. C 3 300
. C 3 300
. C 3 300
. C 3 300
. C 3 300
ph C 4 300
and C 5 300
the C 6 300
blood C 7 300
- C 8 300
brain C 9 300
barrier C 10 300
a C 11 300
method C 12 300
was C 13 300
described C 14 300
for C 15 300
measuring C 16 300
the C 17 300
ph C 18 300
, C 19 300
dc C 20 300
and C 21 300
ac C 22 300
potentials C 23 300
concurrently C 24 300
on C 25 300
the C 26 300
cerebral C 27 300
cortex C 28 300
of C 29 300
the C 30 300
adult C 31 300
cat C 32 300
, C 33 300
under C 34 300
conditions C 35 300
of C 36 300
controlled C 37 300
ventilation C 38 300
. C 39 300
kittens C 41 300
and C 42 300
rabbits C 43 300
were C 44 300
also C 45 300
studied C 46 300
. C 47 300
the C 49 300
cortical C 50 300
ph C 51 300
response C 52 300
to C 53 300
i C 54 300
. C 55 300
. C 56 300
. C 57 300
nahco C 59 300
3 C 60 300
was C 61 300
acidic C 62 300
and C 63 300
was C 64 300
accompanied C 65 300
by C 66 300
a C 67 300
dc C 68 300
negativity C 69 300
, C 70 300
while C 71 300
the C 72 300
blood C 73 300
became C 74 300
alkaline C 75 300
. C 76 300
such C 78 300
an C 79 300
acidic C 80 300
response C 81 300
was C 82 300
present C 83 300
in C 84 300
the C 85 300
rabbit C 86 300
and C 87 300
kitten C 88 300
. C 89 300
it C 91 300
was C 92 300
not C 93 300
present C 94 300
in C 95 300
a C 96 300
number C 97 300
of C 98 300
other C 99 300
tissues C 100 300
in C 101 300
the C 102 300
cat C 103 300
, C 104 300
including C 105 300
the C 106 300
dura C 107 300
. C 108 300
the C 110 300
cortical C 111 300
acidic C 112 300
response C 113 300
was C 114 300
not C 115 300
affected C 116 300
, C 117 300
qualitatively C 118 300
, C 119 300
by C 120 300
i C 121 300
. C 122 300
. C 123 300
. C 124 300
acetazolamide C 126 300
, C 127 300
prolonged C 128 300
hypoxia C 129 300
or C 130 300
10 C 131 300
% C 132 300
( C 133 300
v C 134 300
/ C 135 300
v C 136 300
) C 137 300
co C 138 300
2 C 139 300
. C 140 300
it C 142 300
was C 143 300
reduced C 144 300
reversibly C 145 300
by C 146 300
20 C 147 300
% C 148 300
( C 149 300
v C 150 300
/ C 151 300
v C 152 300
) C 153 300
co C 154 300
2 C 155 300
. C 156 300
it C 158 300
was C 159 300
not C 160 300
affected C 161 300
by C 162 300
removal C 163 300
of C 164 300
the C 165 300
arachnoid C 166 300
membrane C 167 300
. C 168 300
the C 170 300
cortical C 171 300
ph C 172 300
response C 173 300
to C 174 300
an C 175 300
i C 176 300
. C 177 300
. C 178 300
. C 179 300
nh C 181 300
4 C 182 300
+ C 183 300
salt C 184 300
solution C 185 300
was C 186 300
complex C 187 300
. C 188 300
nh C 190 300
4 C 191 300
c C 192 300
1 C 193 300
did C 194 300
not C 195 300
produce C 196 300
an C 197 300
alkaline C 198 300
response C 199 300
. C 200 300
the C 202 300
cortical C 203 300
ph C 204 300
response C 205 300
to C 206 300
an C 207 300
alkaline C 208 300
or C 209 300
an C 210 300
acidic C 211 300
sodium C 212 300
phosphate C 213 300
solution C 214 300
was C 215 300
augmented C 216 300
but C 217 300
not C 218 300
changed C 219 300
in C 220 300
its C 221 300
direction C 222 300
following C 223 300
treatment C 224 300
of C 225 300
the C 226 300
cortex C 227 300
with C 228 300
n C 229 300
- C 230 300
butanol C 231 300
. C 232 300
the C 234 300
results C 235 300
were C 236 300
interpreted C 237 300
in C 238 300
terms C 239 300
of C 240 300
a C 241 300
restriction C 242 300
of C 243 300
hco C 244 300
3 C 245 300
- C 246 300
by C 247 300
the C 248 300
blood C 249 300
- C 250 300
brain C 251 300
barrier C 252 300
, C 253 300
through C 254 300
which C 255 300
co C 256 300
2 C 257 300
can C 258 300
pass C 259 300
. C 260 300
this C 262 300
restriction C 263 300
is C 264 300
probably C 265 300
non C 266 300
- C 267 300
specific C 268 300
for C 269 300
inorganic C 270 300
ions C 271 300
, C 272 300
and C 273 300
perhaps C 274 300
for C 275 300
other C 276 300
substances C 277 300
. C 278 300
it C 280 300
does C 281 300
not C 282 300
appear C 283 300
to C 284 300
be C 285 300
related C 286 300
to C 287 300
a C 288 300
low C 289 300
cerebral C 290 300
extracellular C 291 300
space C 292 300
, C 293 300
and C 294 300
is C 295 300
independent C 296 300
of C 297 300
substantial C 298 300
oxidative C 299 300
metabolism C 300 300
. C 301 300
7083 C 1 301
. C 2 301
brain C 4 301
damage C 5 301
and C 6 301
paralysis C 7 301
in C 8 301
animals C 9 301
exposed C 10 301
to C 11 301
high C 12 301
pressure C 13 301
oxygen C 14 301
- C 15 301
pharmacological C 16 301
and C 17 301
biochemical C 18 301
observations C 19 301
single C 20 301
exposures C 21 301
of C 22 301
high C 23 301
pressure C 24 301
oxygen C 25 301
( C 26 301
ohp C 27 301
) C 28 301
at C 29 301
30 C 30 301
- C 31 301
66 C 32 301
gauge C 33 301
pressure C 34 301
caused C 35 301
cns C 36 301
damage C 37 301
and C 38 301
paralysis C 39 301
in C 40 301
rats C 41 301
and C 42 301
mice C 43 301
but C 44 301
guinea C 45 301
- C 46 301
pigs C 47 301
, C 48 301
rabbits C 49 301
, C 50 301
and C 51 301
man C 52 301
did C 53 301
not C 54 301
show C 55 301
such C 56 301
sequelae C 57 301
. C 58 301
the C 60 301
cns C 61 301
damage C 62 301
in C 63 301
rats C 64 301
was C 65 301
greatly C 66 301
increased C 67 301
by C 68 301
cns C 69 301
- C 70 301
de C 71 301
- C 72 301
pressant C 73 301
drugs C 74 301
( C 75 301
pentobarbital C 76 301
, C 77 301
paraldehyde C 78 301
, C 79 301
n C 80 301
2 C 81 301
o C 82 301
and C 83 301
phencyclidine C 84 301
) C 85 301
given C 86 301
before C 87 301
ex C 88 301
- C 89 301
posure C 90 301
to C 91 301
ohp C 92 301
. C 93 301
the C 95 301
cns C 96 301
lesions C 97 301
were C 98 301
also C 99 301
potentiated C 100 301
by C 101 301
raised C 102 301
respired C 103 301
pco C 104 301
2 C 105 301
, C 106 301
by C 107 301
acetazolamide C 108 301
and C 109 301
by C 110 301
nh C 111 301
4 C 112 301
c C 113 301
1 C 114 301
, C 115 301
whilst C 116 301
protection C 117 301
was C 118 301
afforded C 119 301
by C 120 301
methaemoglobinae C 121 301
- C 122 301
mia C 123 301
by C 124 301
tham C 125 301
, C 126 301
by C 127 301
2 C 128 301
4 C 129 301
- C 130 301
dinitrophenol C 131 301
and C 132 301
by C 133 301
serotonin C 134 301
against C 135 301
the C 136 301
barbiturate C 137 301
and C 138 301
co C 139 301
2 C 140 301
potentiation C 141 301
of C 142 301
ohp C 143 301
brain C 144 301
damage C 145 301
. C 146 301
ohp C 148 301
- C 149 301
induced C 150 301
brain C 151 301
damage C 152 301
was C 153 301
not C 154 301
modified C 155 301
by C 156 301
hypothermia C 157 301
( C 158 301
cp C 159 301
2 C 160 301
) C 161 301
, C 162 301
electroconvulsive C 163 301
shock C 164 301
treatment C 165 301
during C 166 301
ohp C 167 301
, C 168 301
cerebral C 169 301
x C 170 301
- C 171 301
irradiation C 172 301
, C 173 301
adrenalectomy C 174 301
or C 175 301
cortisone C 176 301
, C 177 301
slow C 178 301
decompression C 179 301
rates C 180 301
, C 181 301
spinal C 182 301
block C 183 301
with C 184 301
local C 185 301
anaesthetic C 186 301
, C 187 301
' C 188 301
conditioning C 189 301
' C 190 301
of C 191 301
rats C 192 301
to C 193 301
ohp C 194 301
, C 195 301
hyper C 196 301
- C 197 301
and C 198 301
hypoglycaemia C 199 301
, C 200 301
or C 201 301
alterations C 202 301
in C 203 301
tissue C 204 301
histamine C 205 301
levels C 206 301
. C 207 301
the C 209 301
results C 210 301
are C 211 301
discussed C 212 301
in C 213 301
relation C 214 301
to C 215 301
pos C 216 301
- C 217 301
sible C 218 301
biochemical C 219 301
mechanisms C 220 301
and C 221 301
theories C 222 301
of C 223 301
oxygen C 224 301
poisoning C 225 301
. C 226 301
8914 C 1 302
. C 2 302
the C 4 302
effect C 5 302
of C 6 302
hypoxia C 7 302
on C 8 302
oxygen C 9 302
consumption C 10 302
of C 11 302
cerebral C 12 302
cortex C 13 302
, C 14 302
liver C 15 302
slices C 16 302
and C 17 302
of C 18 302
diaphragm C 19 302
in C 20 302
vitro C 21 302
during C 22 302
post C 23 302
- C 24 302
natal C 25 302
development C 26 302
of C 27 302
the C 28 302
rat C 29 302
oxygen C 30 302
consumption C 31 302
of C 32 302
slices C 33 302
from C 34 302
the C 35 302
liver C 36 302
and C 37 302
cerebral C 38 302
cortex C 39 302
and C 40 302
of C 41 302
the C 42 302
cut C 43 302
dia C 44 302
- C 45 302
phragm C 46 302
was C 47 302
determined C 48 302
in C 49 302
rats C 50 302
aged C 51 302
5 C 52 302
, C 53 302
10 C 54 302
, C 55 302
14 C 56 302
, C 57 302
20 C 58 302
and C 59 302
25 C 60 302
days C 61 302
and C 62 302
in C 63 302
adult C 64 302
animals C 65 302
. C 66 302
under C 68 302
hypoxic C 69 302
conditions C 70 302
( C 71 302
gas C 72 302
phase C 73 302
10 C 74 302
% C 75 302
oxygen C 76 302
, C 77 302
90 C 78 302
% C 79 302
nitrogen C 80 302
) C 81 302
oxygen C 82 302
consumption C 83 302
of C 84 302
liver C 85 302
slices C 86 302
and C 87 302
diaghragm C 88 302
is C 89 302
decreased C 90 302
by C 91 302
about C 92 302
25 C 93 302
% C 94 302
in C 95 302
all C 96 302
age C 97 302
groups C 98 302
. C 99 302
hypoxia C 101 302
, C 102 302
however C 103 302
, C 104 302
did C 105 302
not C 106 302
affect C 107 302
oxygen C 108 302
consumption C 109 302
of C 110 302
slices C 111 302
of C 112 302
the C 113 302
cortex C 114 302
from C 115 302
5 C 116 302
- C 117 302
day C 118 302
- C 119 302
old C 120 302
rats C 121 302
and C 122 302
its C 123 302
inhibitory C 124 302
effect C 125 302
only C 126 302
appeared C 127 302
later C 128 302
as C 129 302
the C 130 302
normal C 131 302
oxygen C 132 302
consumption C 133 302
started C 134 302
to C 135 302
rise C 136 302
. C 137 302
the C 139 302
inhibitory C 140 302
effect C 141 302
of C 142 302
hypoxia C 143 302
was C 144 302
greatest C 145 302
in C 146 302
adult C 147 302
animals C 148 302
. C 149 302
5407 C 1 303
. C 2 303
hypoxic C 4 303
- C 5 303
hypercapnic C 6 303
interaction C 7 303
in C 8 303
subjects C 9 303
with C 10 303
bilateral C 11 303
cerebral C 12 303
dysfunction C 13 303
to C 14 303
analyze C 15 303
cerebral C 16 303
influences C 17 303
modifying C 18 303
autonomic C 19 303
respiratory C 20 303
responses C 21 303
, C 22 303
the C 23 303
authors C 24 303
compared C 25 303
normals C 26 303
and C 27 303
patients C 28 303
with C 29 303
bilateral C 30 303
pyramidal C 31 303
tract C 32 303
disease C 33 303
for C 34 303
their C 35 303
ventilatory C 36 303
response C 37 303
to C 38 303
hypoxia C 39 303
and C 40 303
hypoxia C 41 303
- C 42 303
hypercapnia C 43 303
. C 44 303
during C 46 303
eucapnia C 47 303
, C 48 303
the C 49 303
2 C 50 303
groups C 51 303
showed C 52 303
similar C 53 303
hypoxic C 54 303
responses C 55 303
. C 56 303
during C 58 303
hypercapnia C 59 303
, C 60 303
the C 61 303
ventilatory C 62 303
response C 63 303
to C 64 303
hypoxia C 65 303
was C 66 303
greater C 67 303
in C 68 303
the C 69 303
brain C 70 303
- C 71 303
damaged C 72 303
subjects C 73 303
. C 74 303
this C 76 303
apparent C 77 303
aug C 78 303
- C 79 303
mentation C 80 303
, C 81 303
however C 82 303
, C 83 303
was C 84 303
due C 85 303
entirely C 86 303
to C 87 303
anoxia C 88 303
interacting C 89 303
with C 90 303
an C 91 303
abnormally C 92 303
fa C 93 303
- C 94 303
cilitated C 95 303
carbon C 96 303
dioxide C 97 303
sensitivity C 98 303
compared C 99 303
with C 100 303
normals C 101 303
, C 102 303
brain C 103 303
- C 104 303
damaged C 105 303
patients C 106 303
at C 107 303
pao C 108 303
, C 109 303
90 C 110 303
- C 111 303
100 C 112 303
mm C 113 303
hg C 114 303
showed C 115 303
an C 116 303
85 C 117 303
% C 118 303
greater C 119 303
co C 120 303
2 C 121 303
response C 122 303
, C 123 303
and C 124 303
at C 125 303
pao C 126 303
, C 127 303
50 C 128 303
mm C 129 303
hg C 130 303
showed C 131 303
a C 132 303
79 C 133 303
% C 134 303
greater C 135 303
co C 136 303
2 C 137 303
response C 138 303
. C 139 303
since C 141 303
cerebral C 142 303
dysfunction C 143 303
facilitated C 144 303
the C 145 303
ven C 146 303
- C 147 303
tilatory C 148 303
response C 149 303
to C 150 303
hypoxia C 151 303
- C 152 303
hypercapnia C 153 303
combined C 154 303
but C 155 303
not C 156 303
the C 157 303
response C 158 303
to C 159 303
hypoxia C 160 303
alone C 161 303
, C 162 303
the C 163 303
results C 164 303
imply C 165 303
that C 166 303
the C 167 303
2 C 168 303
respiratory C 169 303
stimuli C 170 303
interact C 171 303
centrally C 172 303
rather C 173 303
than C 174 303
peripherally C 175 303
. C 176 303
3917 C 1 304
. C 2 304
plasma C 4 304
free C 5 304
fatty C 6 304
acid C 7 304
and C 8 304
blood C 9 304
sugar C 10 304
levels C 11 304
in C 12 304
newborn C 13 304
infants C 14 304
and C 15 304
their C 16 304
mothers C 17 304
simultaneous C 18 304
plasma C 19 304
free C 20 304
fatty C 21 304
acid C 22 304
( C 23 304
ffa C 24 304
) C 25 304
and C 26 304
blood C 27 304
sugar C 28 304
levels C 29 304
were C 30 304
determined C 31 304
for C 32 304
fasting C 33 304
newborn C 34 304
infants C 35 304
during C 36 304
the C 37 304
first C 38 304
24 C 39 304
hours C 40 304
of C 41 304
life C 42 304
, C 43 304
for C 44 304
their C 45 304
cord C 46 304
bloods C 47 304
, C 48 304
and C 49 304
for C 50 304
their C 51 304
mothers C 52 304
at C 53 304
delivery C 54 304
. C 55 304
the C 57 304
following C 58 304
observations C 59 304
were C 60 304
made C 61 304
. C 62 304
in C 64 304
con C 65 304
- C 66 304
trol C 67 304
infants C 68 304
the C 69 304
mean C 70 304
ffa C 71 304
level C 72 304
rose C 73 304
about C 74 304
three C 75 304
times C 76 304
the C 77 304
cord C 78 304
level C 79 304
after C 80 304
birth C 81 304
and C 82 304
was C 83 304
accompanied C 84 304
by C 85 304
a C 86 304
25 C 87 304
% C 88 304
drop C 89 304
in C 90 304
the C 91 304
mean C 92 304
blood C 93 304
sugar C 94 304
level C 95 304
. C 96 304
thereafter C 98 304
, C 99 304
the C 100 304
mean C 101 304
blood C 102 304
sugar C 103 304
level C 104 304
remained C 105 304
relatively C 106 304
constant C 107 304
, C 108 304
but C 109 304
the C 110 304
mean C 111 304
ffa C 112 304
level C 113 304
varied C 114 304
from C 115 304
2 C 116 304
. C 117 304
. C 118 304
to C 119 304
3 C 120 304
times C 121 304
the C 122 304
cord C 123 304
level C 124 304
. C 125 304
there C 127 304
was C 128 304
no C 129 304
significant C 130 304
correlation C 131 304
between C 132 304
the C 133 304
length C 134 304
of C 135 304
maternal C 136 304
fasting C 137 304
prior C 138 304
to C 139 304
delivery C 140 304
and C 141 304
the C 142 304
infant C 143 304
ffa C 144 304
level C 145 304
; C 146 304
there C 147 304
was C 148 304
, C 149 304
however C 150 304
, C 151 304
a C 152 304
significant C 153 304
negative C 154 304
correlation C 155 304
between C 156 304
the C 157 304
length C 158 304
of C 159 304
maternal C 160 304
fasting C 161 304
prior C 162 304
to C 163 304
delivery C 164 304
and C 165 304
the C 166 304
infant C 167 304
blood C 168 304
sugar C 169 304
level C 170 304
at C 171 304
24 C 172 304
hours C 173 304
of C 174 304
age C 175 304
. C 176 304
high C 178 304
ffa C 179 304
levels C 180 304
occurred C 181 304
in C 182 304
the C 183 304
infants C 184 304
of C 185 304
obese C 186 304
mothers C 187 304
and C 188 304
low C 189 304
levels C 190 304
were C 191 304
observed C 192 304
in C 193 304
infants C 194 304
with C 195 304
delayed C 196 304
respirations C 197 304
, C 198 304
in C 199 304
infants C 200 304
of C 201 304
preeclamptic C 202 304
mothers C 203 304
, C 204 304
and C 205 304
in C 206 304
infants C 207 304
of C 208 304
diabetic C 209 304
mothers C 210 304
. C 211 304
2933 C 1 305
. C 2 305
the C 4 305
essential C 5 305
fatty C 6 305
acid C 7 305
requirement C 8 305
of C 9 305
infants C 10 305
and C 11 305
the C 12 305
assessment C 13 305
of C 14 305
their C 15 305
dietary C 16 305
intake C 17 305
of C 18 305
linoleate C 19 305
by C 20 305
serum C 21 305
fatty C 22 305
acid C 23 305
analysis C 24 305
the C 25 305
content C 26 305
of C 27 305
polyunsaturated C 28 305
fatty C 29 305
acids C 30 305
in C 31 305
serum C 32 305
total C 33 305
fatty C 34 305
acids C 35 305
was C 36 305
related C 37 305
to C 38 305
the C 39 305
dietary C 40 305
intake C 41 305
of C 42 305
linoleate C 43 305
in C 44 305
243 C 45 305
infants C 46 305
two C 47 305
to C 48 305
four C 49 305
months C 50 305
of C 51 305
age C 52 305
and C 53 305
in C 54 305
197 C 55 305
infants C 56 305
eleven C 57 305
to C 58 305
twelve C 59 305
months C 60 305
of C 61 305
age C 62 305
. C 63 305
the C 65 305
curves C 66 305
relating C 67 305
triene C 68 305
tetraene C 69 305
ratio C 70 305
to C 71 305
dietary C 72 305
linoleate C 73 305
indicated C 74 305
approximately C 75 305
1 C 76 305
per C 77 305
cent C 78 305
of C 79 305
total C 80 305
calories C 81 305
as C 82 305
minimal C 83 305
linoleate C 84 305
requirement C 85 305
. C 86 305
the C 88 305
exponential C 89 305
equations C 90 305
relating C 91 305
dienoic C 92 305
, C 93 305
trienoic C 94 305
and C 95 305
tetraenoic C 96 305
acids C 97 305
to C 98 305
dietary C 99 305
linoleate C 100 305
were C 101 305
derived C 102 305
by C 103 305
computer C 104 305
methods C 105 305
. C 106 305
these C 108 305
yielded C 109 305
constants C 110 305
from C 111 305
which C 112 305
the C 113 305
minimal C 114 305
nutrient C 115 305
requirement C 116 305
could C 117 305
be C 118 305
calculated C 119 305
. C 120 305
the C 122 305
best C 123 305
estimates C 124 305
were C 125 305
obtained C 126 305
from C 127 305
the C 128 305
triene C 129 305
and C 130 305
tetraene C 131 305
data C 132 305
for C 133 305
two C 134 305
to C 135 305
four C 136 305
months C 137 305
' C 138 305
old C 139 305
infants C 140 305
and C 141 305
were C 142 305
found C 143 305
to C 144 305
be C 145 305
approximately C 146 305
1 C 147 305
. C 148 305
. C 149 305
per C 150 305
cent C 151 305
of C 152 305
the C 153 305
caloric C 154 305
intake C 155 305
. C 156 305
the C 158 305
nutritive C 159 305
status C 160 305
with C 161 305
respect C 162 305
to C 163 305
linoleate C 164 305
may C 165 305
be C 166 305
estimated C 167 305
by C 168 305
means C 169 305
of C 170 305
logarithmic C 171 305
regression C 172 305
equations C 173 305
. C 174 305
the C 176 305
equation C 177 305
for C 178 305
two C 179 305
to C 180 305
four C 181 305
months C 182 305
' C 183 305
old C 184 305
infants C 185 305
is C 186 305
log C 187 305
10 C 188 305
dietary C 189 305
linoleate C 190 305
= C 191 305
- C 192 305
1 C 193 305
. C 194 305
. C 195 305
. C 195 305
. C 195 305
+ C 196 305
0 C 197 305
. C 198 305
. C 199 305
. C 199 305
. C 199 305
. C 199 305
( C 200 305
di C 201 305
- C 202 305
tri C 203 305
+ C 204 305
tetra C 205 305
) C 206 305
. C 207 305
the C 209 305
data C 210 305
for C 211 305
eleven C 212 305
to C 213 305
twelve C 214 305
months C 215 305
' C 216 305
old C 217 305
infants C 218 305
were C 219 305
found C 220 305
to C 221 305
have C 222 305
greater C 223 305
scatter C 224 305
and C 225 305
give C 226 305
lower C 227 305
triene C 228 305
tetraene C 229 305
ratios C 230 305
at C 231 305
comparable C 232 305
linoleate C 233 305
intakes C 234 305
. C 235 305
the C 237 305
scatter C 238 305
and C 239 305
displacement C 240 305
are C 241 305
considered C 242 305
to C 243 305
be C 244 305
due C 245 305
to C 246 305
supplements C 247 305
of C 248 305
solid C 249 305
food C 250 305
to C 251 305
the C 252 305
basic C 253 305
diet C 254 305
not C 255 305
considered C 256 305
in C 257 305
the C 258 305
calculated C 259 305
dietary C 260 305
linoleate C 261 305
. C 262 305
74 C 1 306
. C 2 306
analytic C 4 306
study C 5 306
of C 6 306
the C 7 306
a C 8 306
- C 9 306
and C 10 306
b C 11 306
- C 12 306
lipoprotein C 13 306
micellar C 14 306
groups C 15 306
and C 16 306
of C 17 306
nonesterified C 18 306
fatty C 19 306
acids C 20 306
of C 21 306
the C 22 306
plasma C 23 306
in C 24 306
normal C 25 306
pregnancy C 26 306
an C 27 306
analytical C 28 306
study C 29 306
has C 30 306
been C 31 306
made C 32 306
on C 33 306
39 C 34 306
patients C 35 306
, C 36 306
using C 37 306
a C 38 306
chemical C 39 306
method C 40 306
which C 41 306
allows C 42 306
the C 43 306
simultaneous C 44 306
detailed C 45 306
evaluation C 46 306
of C 47 306
the C 48 306
lipidic C 49 306
and C 50 306
a C 51 306
- C 52 306
and C 53 306
b C 54 306
- C 55 306
liproproteinic C 56 306
fractions C 57 306
of C 58 306
the C 59 306
plasma C 60 306
. C 61 306
in C 63 306
addition C 64 306
the C 65 306
non C 66 306
- C 67 306
esterified C 68 306
fatty C 69 306
acids C 70 306
have C 71 306
been C 72 306
titrated C 73 306
, C 74 306
the C 75 306
b C 76 306
- C 77 306
proteins C 78 306
and C 79 306
the C 80 306
uric C 81 306
acid C 82 306
assayed C 83 306
, C 84 306
and C 85 306
numerous C 86 306
indices C 87 306
and C 88 306
deducible C 89 306
ratios C 90 306
made C 91 306
from C 92 306
the C 93 306
data C 94 306
obtained C 95 306
. C 96 306
the C 98 306
existence C 99 306
of C 100 306
quantitative C 101 306
dyslipidemia C 102 306
has C 103 306
been C 104 306
proven C 105 306
, C 106 306
starting C 107 306
gradually C 108 306
, C 109 306
especially C 110 306
in C 111 306
the C 112 306
4 C 113 306
th C 114 306
- C 115 306
5 C 116 306
th C 117 306
month C 118 306
of C 119 306
pregnancy C 120 306
, C 121 306
and C 122 306
most C 123 306
- C 124 306
ly C 125 306
regarding C 126 306
the C 127 306
b C 128 306
- C 129 306
lipoproteins C 130 306
, C 131 306
prevalently C 132 306
the C 133 306
slow C 134 306
subfractions C 135 306
, C 136 306
greater C 137 306
increase C 138 306
of C 139 306
glycerides C 140 306
than C 141 306
phosphatides C 142 306
and C 143 306
cholesterol C 144 306
, C 145 306
but C 146 306
with C 147 306
a C 148 306
non C 149 306
- C 150 306
proportional C 151 306
in C 152 306
- C 153 306
crease C 154 306
of C 155 306
b C 156 306
- C 157 306
proteins C 158 306
( C 159 306
lower C 160 306
proteinic C 161 306
content C 162 306
) C 163 306
. C 164 306
it C 166 306
has C 167 306
, C 168 306
moreover C 169 306
, C 170 306
been C 171 306
noted C 172 306
that C 173 306
there C 174 306
is C 175 306
a C 176 306
prevalent C 177 306
rise C 178 306
of C 179 306
free C 180 306
cholesterol C 181 306
in C 182 306
the C 183 306
fraction C 184 306
of C 185 306
b C 186 306
- C 187 306
lipoproteins C 188 306
with C 189 306
a C 190 306
reduction C 191 306
of C 192 306
the C 193 306
total C 194 306
esterification C 195 306
coefficient C 196 306
. C 197 306
the C 199 306
morphological C 200 306
picture C 201 306
of C 202 306
the C 203 306
lipidic C 204 306
rate C 205 306
in C 206 306
pregnancy C 207 306
shows C 208 306
characteristics C 209 306
which C 210 306
, C 211 306
according C 212 306
to C 213 306
the C 214 306
authors C 215 306
, C 216 306
are C 217 306
like C 218 306
those C 219 306
to C 220 306
be C 221 306
seen C 222 306
in C 223 306
the C 224 306
lipidic C 225 306
rate C 226 306
of C 227 306
male C 228 306
presenility C 229 306
. C 230 306
75 C 1 307
. C 2 307
behavior C 4 307
of C 5 307
polyunsaturated C 6 307
fatty C 7 307
acids C 8 307
in C 9 307
physiological C 10 307
pregnancy C 11 307
by C 12 307
the C 13 307
enzymatic C 14 307
lipoxidase C 15 307
method C 16 307
of C 17 307
macgee C 18 307
et C 19 307
al C 20 307
. C 21 307
, C 23 307
the C 24 307
author C 25 307
measured C 26 307
polyun C 27 307
- C 28 307
satured C 29 307
fatty C 30 307
acids C 31 307
( C 32 307
p C 33 307
. C 34 307
. C 35 307
. C 36 307
. C 37 307
. C 38 307
) C 40 307
in C 41 307
healthy C 42 307
pregnant C 43 307
women C 44 307
at C 45 307
full C 46 307
term C 47 307
of C 48 307
pregnancy C 49 307
. C 50 307
before C 52 307
labour C 53 307
there C 54 307
are C 55 307
in C 56 307
the C 57 307
blood C 58 307
75 C 59 307
- C 60 307
95 C 61 307
mg C 62 307
. C 63 307
% C 65 307
of C 66 307
p C 67 307
. C 68 307
. C 69 307
. C 70 307
. C 71 307
. C 72 307
, C 74 307
i C 75 307
. C 76 307
. C 77 307
. C 78 307
10 C 80 307
- C 81 307
15 C 82 307
% C 83 307
more C 84 307
than C 85 307
in C 86 307
non C 87 307
- C 88 307
pregnant C 89 307
women C 90 307
; C 91 307
during C 92 307
labour C 93 307
p C 94 307
. C 95 307
. C 96 307
. C 97 307
. C 98 307
. C 99 307
increase C 101 307
very C 102 307
much C 103 307
, C 104 307
100 C 105 307
- C 106 307
137 C 107 307
mg C 108 307
. C 109 307
% C 111 307
, C 112 307
about C 113 307
50 C 114 307
% C 115 307
more C 116 307
than C 117 307
before C 118 307
labour C 119 307
. C 120 307
5196 C 1 308
. C 2 308
effects C 4 308
of C 5 308
nutritional C 6 308
deficiency C 7 308
of C 8 308
unsaturated C 9 308
fats C 10 308
on C 11 308
the C 12 308
distribution C 13 308
of C 14 308
fatty C 15 308
acids C 16 308
in C 17 308
rat C 18 308
liver C 19 308
mitochondrial C 20 308
phospholipids C 21 308
the C 22 308
fatty C 23 308
acid C 24 308
composition C 25 308
of C 26 308
liver C 27 308
mitochondrial C 28 308
phospholipids C 29 308
from C 30 308
rats C 31 308
rendered C 32 308
deficient C 33 308
in C 34 308
essential C 35 308
unsaturated C 36 308
fatty C 37 308
acids C 38 308
has C 39 308
been C 40 308
determined C 41 308
, C 42 308
and C 43 308
compared C 44 308
with C 45 308
that C 46 308
of C 47 308
rats C 48 308
fed C 49 308
a C 50 308
diet C 51 308
containing C 52 308
corn C 53 308
oil C 54 308
. C 55 308
in C 57 308
addition C 58 308
to C 59 308
marked C 60 308
reductions C 61 308
in C 62 308
the C 63 308
amounts C 64 308
of C 65 308
linoleic C 66 308
and C 67 308
arachidonic C 68 308
acids C 69 308
esterified C 70 308
at C 71 308
the C 72 308
b C 73 308
- C 74 308
position C 75 308
of C 76 308
ethanol C 77 308
- C 78 308
amine C 79 308
- C 80 308
, C 81 308
inositol C 82 308
- C 83 308
, C 84 308
and C 85 308
choline C 86 308
glycerophosphatides C 87 308
, C 88 308
the C 89 308
deficiency C 90 308
resulted C 91 308
in C 92 308
ex C 93 308
- C 94 308
tensive C 95 308
changes C 96 308
in C 97 308
the C 98 308
distribution C 99 308
of C 100 308
saturated C 101 308
acids C 102 308
at C 103 308
both C 104 308
the C 105 308
a C 106 308
- C 107 308
and C 108 308
b C 109 308
- C 110 308
positions C 111 308
. C 112 308
palmitoleic C 114 308
and C 115 308
oleic C 116 308
acids C 117 308
were C 118 308
increased C 119 308
in C 120 308
amount C 121 308
in C 122 308
fat C 123 308
deficiency C 124 308
, C 125 308
and C 126 308
large C 127 308
amounts C 128 308
of C 129 308
docosatrienoic C 130 308
acids C 131 308
appeared C 132 308
in C 133 308
these C 134 308
3 C 135 308
phospholipids C 136 308
. C 137 308
the C 139 308
fatty C 140 308
acids C 141 308
of C 142 308
the C 143 308
sphingomyelins C 144 308
were C 145 308
not C 146 308
altered C 147 308
as C 148 308
a C 149 308
result C 150 308
of C 151 308
essential C 152 308
fatty C 153 308
acid C 154 308
deficiency C 155 308
. C 156 308
the C 158 308
data C 159 308
demonstrate C 160 308
that C 161 308
each C 162 308
phospholipid C 163 308
is C 164 308
unique C 165 308
in C 166 308
the C 167 308
way C 168 308
in C 169 308
which C 170 308
its C 171 308
fatty C 172 308
acid C 173 308
moieties C 174 308
change C 175 308
in C 176 308
response C 177 308
to C 178 308
feeding C 179 308
a C 180 308
fat C 181 308
deficient C 182 308
diet C 183 308
. C 184 308
3204 C 1 309
. C 2 309
interventricular C 4 309
septal C 5 309
defects C 6 309
with C 7 309
aortic C 8 309
insufficiency C 9 309
sanchez C 10 309
f C 11 309
. C 12 309
- C 14 309
villaran C 15 309
e C 16 309
. C 17 309
the C 19 309
coincidence C 20 309
of C 21 309
these C 22 309
2 C 23 309
malformations C 24 309
permits C 25 309
their C 26 309
diagnosis C 27 309
provided C 28 309
that C 29 309
a C 30 309
careful C 31 309
evaluation C 32 309
is C 33 309
made C 34 309
of C 35 309
the C 36 309
hemodynamic C 37 309
and C 38 309
oximetric C 39 309
data C 40 309
, C 41 309
on C 42 309
the C 43 309
basis C 44 309
of C 45 309
specific C 46 309
auscultatory C 47 309
features C 48 309
. C 49 309
even C 51 309
then C 52 309
, C 53 309
a C 54 309
differentiation C 55 309
from C 56 309
other C 57 309
cardiopathies C 58 309
patent C 59 309
ductus C 60 309
arteriosus C 61 309
with C 62 309
/ C 63 309
without C 64 309
pulmonary C 65 309
hypertension C 66 309
, C 67 309
aortopulmonary C 68 309
sep C 69 309
- C 70 309
tal C 71 309
defect C 72 309
, C 73 309
interventricular C 74 309
communication C 75 309
, C 76 309
truncus C 77 309
arteriosus C 78 309
, C 79 309
aneurysm C 80 309
of C 81 309
the C 82 309
sinus C 83 309
aortae C 84 309
ruptured C 85 309
into C 86 309
right C 87 309
cavities C 88 309
- C 89 309
is C 90 309
not C 91 309
simple C 92 309
. C 93 309
for C 95 309
this C 96 309
an C 97 309
analysis C 98 309
of C 99 309
the C 100 309
course C 101 309
of C 102 309
the C 103 309
syndrome C 104 309
together C 105 309
with C 106 309
the C 107 309
information C 108 309
supplied C 109 309
by C 110 309
phonocardiography C 111 309
, C 112 309
catheterization C 113 309
, C 114 309
angiocardiography C 115 309
, C 116 309
radiology C 117 309
and C 118 309
ecg C 119 309
( C 120 309
in C 121 309
this C 122 309
order C 123 309
of C 124 309
importance C 125 309
) C 126 309
are C 127 309
indispensable C 128 309
. C 129 309
an C 131 309
analysis C 132 309
is C 133 309
made C 134 309
of C 135 309
5 C 136 309
cases C 137 309
in C 138 309
which C 139 309
, C 140 309
in C 141 309
the C 142 309
absence C 143 309
of C 144 309
ana C 145 309
- C 146 309
tomical C 147 309
confirmation C 148 309
, C 149 309
concrete C 150 309
data C 151 309
were C 152 309
obtained C 153 309
on C 154 309
which C 155 309
to C 156 309
base C 157 309
the C 158 309
diagnosis C 159 309
. C 160 309
2579 C 1 310
. C 2 310
measurement C 4 310
of C 5 310
aortic C 6 310
regurgitation C 7 310
by C 8 310
upstream C 9 310
sampling C 10 310
with C 11 310
continuous C 12 310
infusion C 13 310
of C 14 310
indicator C 15 310
a C 16 310
direct C 17 310
and C 18 310
theoretically C 19 310
valid C 20 310
method C 21 310
for C 22 310
the C 23 310
measurement C 24 310
of C 25 310
aortic C 26 310
regurgitation C 27 310
involves C 28 310
the C 29 310
recording C 30 310
of C 31 310
indicator C 32 310
concentrations C 33 310
from C 34 310
the C 35 310
left C 36 310
ventricle C 37 310
and C 38 310
a C 39 310
down C 40 310
- C 41 310
stream C 42 310
site C 43 310
during C 44 310
aortic C 45 310
root C 46 310
injection C 47 310
. C 48 310
however C 50 310
, C 51 310
this C 52 310
method C 53 310
has C 54 310
yielded C 55 310
erratic C 56 310
results C 57 310
when C 58 310
applied C 59 310
to C 60 310
man C 61 310
in C 62 310
the C 63 310
authors C 64 310
' C 65 310
laboratory C 66 310
when C 67 310
using C 68 310
the C 69 310
sudden C 70 310
in C 71 310
- C 72 310
jection C 73 310
technique C 74 310
. C 75 310
therefore C 77 310
, C 78 310
the C 79 310
upstream C 80 310
sampling C 81 310
method C 82 310
, C 83 310
using C 84 310
continuous C 85 310
in C 86 310
- C 87 310
fusion C 88 310
of C 89 310
indicator C 90 310
, C 91 310
was C 92 310
evaluated C 93 310
in C 94 310
18 C 95 310
patients C 96 310
with C 97 310
aortic C 98 310
regurgitation C 99 310
during C 100 310
retrograde C 101 310
aortic C 102 310
and C 103 310
transseptal C 104 310
left C 105 310
ventricular C 106 310
catheterization C 107 310
. C 108 310
the C 110 310
continuous C 111 310
infusion C 112 310
technique C 113 310
was C 114 310
compared C 115 310
with C 116 310
the C 117 310
technique C 118 310
of C 119 310
sudden C 120 310
injection C 121 310
in C 122 310
10 C 123 310
patients C 124 310
and C 125 310
with C 126 310
aortic C 127 310
valvulography C 128 310
in C 129 310
14 C 130 310
patients C 131 310
. C 132 310
measurements C 134 310
of C 135 310
forward C 136 310
flow C 137 310
obtained C 138 310
with C 139 310
continuous C 140 310
infusions C 141 310
into C 142 310
the C 143 310
aortic C 144 310
root C 145 310
were C 146 310
not C 147 310
significantly C 148 310
different C 149 310
from C 150 310
measurements C 151 310
obtained C 152 310
with C 153 310
sudden C 154 310
injections C 155 310
into C 156 310
the C 157 310
pulmonary C 158 310
artery C 159 310
. C 160 310
recordings C 162 310
of C 163 310
indicator C 164 310
concentrations C 165 310
from C 166 310
the C 167 310
left C 168 310
ventricle C 169 310
, C 170 310
during C 171 310
continuous C 172 310
infusions C 173 310
into C 174 310
the C 175 310
aortic C 176 310
root C 177 310
, C 178 310
demonstrated C 179 310
readily C 180 310
evident C 181 310
equilibrium C 182 310
plateaus C 183 310
. C 184 310
the C 186 310
resultant C 187 310
measurements C 188 310
of C 189 310
regurgitant C 190 310
flow C 191 310
were C 192 310
highly C 193 310
reproducible C 194 310
and C 195 310
not C 196 310
impaired C 197 310
by C 198 310
nonsimultaneity C 199 310
of C 200 310
upstream C 201 310
and C 202 310
downstream C 203 310
sampling C 204 310
. C 205 310
the C 207 310
percentage C 208 310
error C 209 310
of C 210 310
estimate C 211 310
at C 212 310
95 C 213 310
% C 214 310
confidence C 215 310
limits C 216 310
was C 217 310
22 C 218 310
% C 219 310
of C 220 310
the C 221 310
measurement C 222 310
for C 223 310
regurgitant C 224 310
flow C 225 310
, C 226 310
13 C 227 310
% C 228 310
for C 229 310
total C 230 310
flow C 231 310
, C 232 310
and C 233 310
9 C 234 310
% C 235 310
for C 236 310
the C 237 310
regurgitant C 238 310
fraction C 239 310
of C 240 310
total C 241 310
flow C 242 310
. C 243 310
the C 245 310
correspond C 246 310
- C 247 310
ing C 248 310
errors C 249 310
of C 250 310
estimate C 251 310
for C 252 310
the C 253 310
sudden C 254 310
injection C 255 310
technique C 256 310
were C 257 310
4 C 258 310
times C 259 310
larger C 260 310
. C 261 310
re C 263 310
- C 264 310
gurgitant C 265 310
flow C 266 310
by C 267 310
the C 268 310
continuous C 269 310
infusion C 270 310
method C 271 310
ranged C 272 310
from C 273 310
0 C 274 310
. C 275 310
. C 276 310
- C 277 310
30 C 278 310
. C 279 310
. C 280 310
l C 281 310
/ C 282 310
min C 283 310
, C 284 310
total C 285 310
flow C 286 310
from C 287 310
3 C 288 310
. C 289 310
. C 290 310
- C 291 310
36 C 292 310
. C 293 310
. C 294 310
l C 295 310
/ C 296 310
min C 297 310
, C 298 310
and C 299 310
the C 300 310
regurgitant C 301 310
fraction C 302 310
of C 303 310
total C 304 310
flow C 305 310
from C 306 310
12 C 307 310
- C 308 310
86 C 309 310
% C 310 310
. C 311 310
ranking C 313 310
of C 314 310
patients C 315 310
by C 316 310
the C 317 310
magnitudes C 318 310
of C 319 310
regurgitant C 320 310
and C 321 310
total C 322 310
flow C 323 310
did C 324 310
not C 325 310
correspond C 326 310
to C 327 310
ranking C 328 310
by C 329 310
angiographic C 330 310
criteria C 331 310
of C 332 310
severity C 333 310
. C 334 310
however C 336 310
, C 337 310
an C 338 310
excellent C 339 310
correlation C 340 310
prevailed C 341 310
between C 342 310
angiographic C 343 310
grade C 344 310
and C 345 310
the C 346 310
regurgitant C 347 310
fraction C 348 310
of C 349 310
total C 350 310
flow C 351 310
, C 352 310
demonstrating C 353 310
that C 354 310
this C 355 310
variable C 356 310
is C 357 310
the C 358 310
most C 359 310
meaningful C 360 310
expression C 361 310
of C 362 310
severity C 363 310
. C 364 310
the C 366 310
correlation C 367 310
( C 368 310
0 C 369 310
. C 370 310
. C 371 310
. C 371 310
. C 371 310
) C 372 310
between C 373 310
the C 374 310
angiographic C 375 310
grade C 376 310
and C 377 310
the C 378 310
regurgitant C 379 310
fraction C 380 310
measured C 381 310
by C 382 310
the C 383 310
continuous C 384 310
infusion C 385 310
technique C 386 310
was C 387 310
clearly C 388 310
superior C 389 310
to C 390 310
that C 391 310
obtained C 392 310
with C 393 310
the C 394 310
sudden C 395 310
injection C 396 310
technique C 397 310
( C 398 310
0 C 399 310
. C 400 310
. C 401 310
. C 401 310
. C 401 310
) C 402 310
. C 403 310
mild C 405 310
regurgitation C 406 310
was C 407 310
equivalent C 408 310
to C 409 310
a C 410 310
regurgitant C 411 310
fraction C 412 310
of C 413 310
< C 414 310
25 C 415 310
% C 416 310
, C 417 310
moderate C 418 310
regurgitation C 419 310
to C 420 310
a C 421 310
fraction C 422 310
of C 423 310
25 C 424 310
- C 425 310
50 C 426 310
% C 427 310
, C 428 310
moderately C 429 310
severe C 430 310
regurgitation C 431 310
to C 432 310
a C 433 310
fraction C 434 310
of C 435 310
50 C 436 310
- C 437 310
75 C 438 310
% C 439 310
and C 440 310
severe C 441 310
regurgitation C 442 310
to C 443 310
a C 444 310
fraction C 445 310
of C 446 310
> C 447 310
75 C 448 310
% C 449 310
. C 450 310
it C 452 310
is C 453 310
concluded C 454 310
that C 455 310
the C 456 310
upstream C 457 310
sampling C 458 310
method C 459 310
during C 460 310
con C 461 310
- C 462 310
tinuous C 463 310
infusion C 464 310
of C 465 310
indicator C 466 310
, C 467 310
because C 468 310
of C 469 310
its C 470 310
sensitivity C 471 310
, C 472 310
reliability C 473 310
, C 474 310
applicability C 475 310
to C 476 310
multiple C 477 310
measurements C 478 310
, C 479 310
and C 480 310
validity C 481 310
in C 482 310
the C 483 310
presence C 484 310
of C 485 310
mitral C 486 310
regurgitation C 487 310
is C 488 310
the C 489 310
most C 490 310
useful C 491 310
method C 492 310
for C 493 310
quantifying C 494 310
aortic C 495 310
regurgitation C 496 310
in C 497 310
man C 498 310
. C 499 310
2950 C 1 311
. C 2 311
aortico C 4 311
- C 5 311
left C 6 311
ventricular C 7 311
tunnel C 8 311
. C 9 311
a C 11 311
cause C 12 311
of C 13 311
massive C 14 311
aortic C 15 311
regurgitation C 16 311
and C 17 311
of C 18 311
intracardiac C 19 311
aneurysm C 20 311
the C 21 311
clinical C 22 311
, C 23 311
roentgenographic C 24 311
, C 25 311
hemodynamic C 26 311
and C 27 311
pathologic C 28 311
findings C 29 311
in C 30 311
a C 31 311
14 C 32 311
- C 33 311
year C 34 311
- C 35 311
old C 36 311
boy C 37 311
with C 38 311
aortico C 39 311
- C 40 311
left C 41 311
ventricular C 42 311
tunnel C 43 311
are C 44 311
presented C 45 311
. C 46 311
the C 48 311
accessory C 49 311
channel C 50 311
between C 51 311
the C 52 311
aorta C 53 311
and C 54 311
left C 55 311
ventricle C 56 311
resulted C 57 311
in C 58 311
massive C 59 311
aortic C 60 311
regurgitation C 61 311
, C 62 311
and C 63 311
the C 64 311
portion C 65 311
of C 66 311
the C 67 311
tunnel C 68 311
which C 69 311
traversed C 70 311
the C 71 311
ventricular C 72 311
septum C 73 311
was C 74 311
aneurysmal C 75 311
, C 76 311
displaced C 77 311
the C 78 311
posterior C 79 311
wall C 80 311
of C 81 311
the C 82 311
right C 83 311
ventricle C 84 311
and C 85 311
caused C 86 311
severe C 87 311
obstruction C 88 311
to C 89 311
right C 90 311
ventricular C 91 311
outflow C 92 311
. C 93 311
the C 95 311
presence C 96 311
of C 97 311
associated C 98 311
cardiovascular C 99 311
anomalies C 100 311
, C 101 311
in C 102 311
this C 103 311
and C 104 311
previously C 105 311
reported C 106 311
cases C 107 311
, C 108 311
suggests C 109 311
that C 110 311
the C 111 311
malformation C 112 311
is C 113 311
congenital C 114 311
rather C 115 311
than C 116 311
acquired C 117 311
. C 118 311
the C 120 311
clinical C 121 311
and C 122 311
hemodynamic C 123 311
manifestations C 124 311
of C 125 311
aortico C 126 311
- C 127 311
left C 128 311
ventricular C 129 311
tunnel C 130 311
are C 131 311
indistinguishable C 132 311
from C 133 311
those C 134 311
observed C 135 311
with C 136 311
the C 137 311
more C 138 311
common C 139 311
forms C 140 311
of C 141 311
aortic C 142 311
regurgitation C 143 311
, C 144 311
and C 145 311
the C 146 311
correct C 147 311
diagnosis C 148 311
can C 149 311
be C 150 311
established C 151 311
only C 152 311
by C 153 311
thoracic C 154 311
aortography C 155 311
. C 156 311
the C 158 311
malformation C 159 311
is C 160 311
usually C 161 311
recognized C 162 311
in C 163 311
childhood C 164 311
; C 165 311
since C 166 311
aortic C 167 311
regurgitant C 168 311
flow C 169 311
can C 170 311
be C 171 311
abolished C 172 311
by C 173 311
simple C 174 311
closure C 175 311
of C 176 311
the C 177 311
aortic C 178 311
ostium C 179 311
, C 180 311
and C 181 311
without C 182 311
aortic C 183 311
valve C 184 311
replacement C 185 311
, C 186 311
the C 187 311
indications C 188 311
for C 189 311
operative C 190 311
treatment C 191 311
differ C 192 311
from C 193 311
those C 194 311
which C 195 311
apply C 196 311
in C 197 311
aortic C 198 311
regurgitation C 199 311
due C 200 311
to C 201 311
a C 202 311
valvular C 203 311
anomaly C 204 311
. C 205 311
502 C 1 312
. C 2 312
the C 4 312
haemodynamic C 5 312
implications C 6 312
of C 7 312
the C 8 312
bisferiens C 9 312
pulse C 10 312
a C 11 312
bisferiens C 12 312
carotid C 13 312
arterial C 14 312
displacement C 15 312
pulse C 16 312
was C 17 312
recorded C 18 312
in C 19 312
10 C 20 312
patients C 21 312
with C 22 312
severe C 23 312
aortic C 24 312
valvular C 25 312
disease C 26 312
. C 27 312
the C 29 312
braunwald C 30 312
test C 31 312
indicated C 32 312
that C 33 312
moderately C 34 312
severe C 35 312
, C 36 312
severe C 37 312
, C 38 312
or C 39 312
gross C 40 312
aortic C 41 312
regurgitation C 42 312
was C 43 312
present C 44 312
in C 45 312
each C 46 312
. C 47 312
the C 49 312
absence C 50 312
of C 51 312
a C 52 312
peak C 53 312
systolic C 54 312
aortic C 55 312
pressure C 56 312
gradient C 57 312
in C 58 312
certain C 59 312
cases C 60 312
, C 61 312
particularly C 62 312
in C 63 312
those C 64 312
with C 65 312
the C 66 312
most C 67 312
severe C 68 312
regurgitation C 69 312
, C 70 312
suggested C 71 312
their C 72 312
freedom C 73 312
from C 74 312
an C 75 312
element C 76 312
of C 77 312
stenosis C 78 312
. C 79 312
the C 81 312
anacrotic C 82 312
wave C 83 312
and C 84 312
the C 85 312
peak C 86 312
of C 87 312
the C 88 312
aortic C 89 312
pressure C 90 312
pulse C 91 312
were C 92 312
found C 93 312
to C 94 312
coincide C 95 312
with C 96 312
the C 97 312
percussion C 98 312
and C 99 312
the C 100 312
tidal C 101 312
waves C 102 312
of C 103 312
the C 104 312
simultaneously C 105 312
recorded C 106 312
carotid C 107 312
ar C 108 312
- C 109 312
terial C 110 312
displacement C 111 312
curves C 112 312
. C 113 312
it C 115 312
is C 116 312
suggested C 117 312
that C 118 312
amplitude C 119 312
of C 120 312
the C 121 312
peak C 122 312
of C 123 312
the C 124 312
anacro C 125 312
- C 126 312
tic C 127 312
wave C 128 312
is C 129 312
proportional C 130 312
to C 131 312
the C 132 312
rate C 133 312
of C 134 312
change C 135 312
of C 136 312
momentum C 137 312
of C 138 312
the C 139 312
ejected C 140 312
blood C 141 312
, C 142 312
and C 143 312
that C 144 312
the C 145 312
amplitude C 146 312
of C 147 312
the C 148 312
corresponding C 149 312
percussion C 150 312
wave C 151 312
of C 152 312
displacement C 153 312
is C 154 312
modified C 155 312
by C 156 312
the C 157 312
distensibility C 158 312
of C 159 312
the C 160 312
artery C 161 312
. C 162 312
the C 164 312
depth C 165 312
and C 166 312
shape C 167 312
of C 168 312
the C 169 312
trough C 170 312
between C 171 312
the C 172 312
two C 173 312
peaks C 174 312
is C 175 312
thought C 176 312
to C 177 312
depend C 178 312
upon C 179 312
the C 180 312
magnitude C 181 312
and C 182 312
slope C 183 312
of C 184 312
the C 185 312
two C 186 312
waves C 187 312
rather C 188 312
than C 189 312
upon C 190 312
a C 191 312
venturi C 192 312
effect C 193 312
. C 194 312
it C 196 312
is C 197 312
suggested C 198 312
that C 199 312
the C 200 312
condition C 201 312
of C 202 312
the C 203 312
arterial C 204 312
wall C 205 312
, C 206 312
the C 207 312
dia C 208 312
- C 209 312
stolic C 210 312
blood C 211 312
pressure C 212 312
, C 213 312
and C 214 312
the C 215 312
stroke C 216 312
volume C 217 312
can C 218 312
influence C 219 312
the C 220 312
pulse C 221 312
sufficiently C 222 312
to C 223 312
preclude C 224 312
its C 225 312
use C 226 312
as C 227 312
a C 228 312
simple C 229 312
guide C 230 312
to C 231 312
the C 232 312
nature C 233 312
of C 234 312
the C 235 312
aortic C 236 312
valve C 237 312
lesion C 238 312
. C 239 312
2753 C 1 313
. C 2 313
left C 4 313
ventricular C 5 313
function C 6 313
following C 7 313
replacement C 8 313
of C 9 313
the C 10 313
aortic C 11 313
valve C 12 313
. C 13 313
hemodynamic C 15 313
responses C 16 313
to C 17 313
muscular C 18 313
exercise C 19 313
evaluations C 20 313
of C 21 313
left C 22 313
ventricular C 23 313
myocardial C 24 313
function C 25 313
were C 26 313
carried C 27 313
out C 28 313
in C 29 313
14 C 30 313
patients C 31 313
4 C 32 313
- C 33 313
16 C 34 313
mth C 35 313
after C 36 313
stenotic C 37 313
or C 38 313
regurgitant C 39 313
malformations C 40 313
of C 41 313
the C 42 313
aortic C 43 313
valve C 44 313
had C 45 313
been C 46 313
corrected C 47 313
by C 48 313
valve C 49 313
replacement C 50 313
. C 51 313
the C 53 313
circulatory C 54 313
responses C 55 313
to C 56 313
exercise C 57 313
, C 58 313
judged C 59 313
by C 60 313
the C 61 313
increases C 62 313
in C 63 313
cardiac C 64 313
output C 65 313
in C 66 313
relation C 67 313
to C 68 313
the C 69 313
increases C 70 313
in C 71 313
oxygen C 72 313
consumption C 73 313
, C 74 313
were C 75 313
normal C 76 313
or C 77 313
only C 78 313
mildly C 79 313
reduced C 80 313
in C 81 313
12 C 82 313
patients C 83 313
. C 84 313
in C 86 313
5 C 87 313
patients C 88 313
the C 89 313
relationships C 90 313
between C 91 313
the C 92 313
change C 93 313
in C 94 313
the C 95 313
left C 96 313
ventricular C 97 313
end C 98 313
- C 99 313
diastolic C 100 313
pressure C 101 313
and C 102 313
the C 103 313
alteration C 104 313
in C 105 313
the C 106 313
stroke C 107 313
volume C 108 313
were C 109 313
also C 110 313
normal C 111 313
, C 112 313
a C 113 313
fall C 114 313
or C 115 313
an C 116 313
increase C 117 313
in C 118 313
left C 119 313
ventricular C 120 313
end C 121 313
- C 122 313
diastolic C 123 313
pressure C 124 313
of C 125 313
less C 126 313
than C 127 313
3 C 128 313
mm C 129 313
hg C 130 313
being C 131 313
accompanied C 132 313
by C 133 313
an C 134 313
increase C 135 313
in C 136 313
stroke C 137 313
volume C 138 313
. C 139 313
in C 141 313
8 C 142 313
patients C 143 313
, C 144 313
however C 145 313
, C 146 313
abnormal C 147 313
increases C 148 313
in C 149 313
the C 150 313
left C 151 313
ventricular C 152 313
end C 153 313
- C 154 313
diastolic C 155 313
pressure C 156 313
occurred C 157 313
during C 158 313
exercise C 159 313
, C 160 313
and C 161 313
in C 162 313
4 C 163 313
the C 164 313
left C 165 313
ventricular C 166 313
end C 167 313
- C 168 313
diastolic C 169 313
pressure C 170 313
was C 171 313
increased C 172 313
to C 173 313
levels C 174 313
above C 175 313
12 C 176 313
mm C 177 313
hg C 178 313
. C 179 313
variable C 181 313
alterations C 182 313
in C 183 313
the C 184 313
stroke C 185 313
volume C 186 313
accompanied C 187 313
these C 188 313
increases C 189 313
in C 190 313
end C 191 313
- C 192 313
diastolic C 193 313
pressure C 194 313
. C 195 313
it C 197 313
is C 198 313
suggested C 199 313
that C 200 313
in C 201 313
the C 202 313
3 C 203 313
patients C 204 313
who C 205 313
exhibited C 206 313
simultaneous C 207 313
increases C 208 313
in C 209 313
left C 210 313
ven C 211 313
- C 212 313
tricular C 213 313
end C 214 313
- C 215 313
diastolic C 216 313
pressure C 217 313
and C 218 313
stroke C 219 313
volume C 220 313
, C 221 313
the C 222 313
changes C 223 313
were C 224 313
either C 225 313
a C 226 313
mani C 227 313
- C 228 313
festation C 229 313
of C 230 313
the C 231 313
frank C 232 313
- C 233 313
starling C 234 313
mechanism C 235 313
, C 236 313
or C 237 313
primarily C 238 313
the C 239 313
result C 240 313
of C 241 313
a C 242 313
positive C 243 313
inotropic C 244 313
influence C 245 313
. C 246 313
in C 248 313
the C 249 313
5 C 250 313
patients C 251 313
who C 252 313
exhibited C 253 313
increases C 254 313
in C 255 313
left C 256 313
ventricular C 257 313
end C 258 313
- C 259 313
diastolic C 260 313
pressure C 261 313
, C 262 313
but C 263 313
no C 264 313
change C 265 313
or C 266 313
a C 267 313
fall C 268 313
in C 269 313
stroke C 270 313
volume C 271 313
, C 272 313
it C 273 313
is C 274 313
proposed C 275 313
that C 276 313
a C 277 313
distinct C 278 313
depression C 279 313
of C 280 313
left C 281 313
ventricular C 282 313
performance C 283 313
was C 284 313
present C 285 313
. C 286 313
thus C 288 313
, C 289 313
while C 290 313
the C 291 313
cardiac C 292 313
output C 293 313
response C 294 313
was C 295 313
adequate C 296 313
to C 297 313
meet C 298 313
the C 299 313
stress C 300 313
of C 301 313
exercise C 302 313
in C 303 313
the C 304 313
majority C 305 313
of C 306 313
the C 307 313
patients C 308 313
studied C 309 313
following C 310 313
aortic C 311 313
valve C 312 313
replacement C 313 313
, C 314 313
determination C 315 313
of C 316 313
the C 317 313
relationship C 318 313
between C 319 313
the C 320 313
left C 321 313
ventricular C 322 313
end C 323 313
- C 324 313
diastolic C 325 313
pressure C 326 313
and C 327 313
the C 328 313
stroke C 329 313
volume C 330 313
permitted C 331 313
the C 332 313
detection C 333 313
of C 334 313
abnormalities C 335 313
in C 336 313
the C 337 313
function C 338 313
of C 339 313
the C 340 313
left C 341 313
ventricle C 342 313
. C 343 313
2497 C 1 314
. C 2 314
pulmonary C 4 314
atresia C 5 314
with C 6 314
intact C 7 314
ventricular C 8 314
septum C 9 314
when C 10 314
the C 11 314
pulmonary C 12 314
valve C 13 314
is C 14 314
atretic C 15 314
and C 16 314
the C 17 314
ventricular C 18 314
septum C 19 314
intact C 20 314
, C 21 314
the C 22 314
right C 23 314
ventricle C 24 314
usually C 25 314
consists C 26 314
of C 27 314
a C 28 314
small C 29 314
chamber C 30 314
with C 31 314
a C 32 314
very C 33 314
thick C 34 314
wall C 35 314
capable C 36 314
of C 37 314
de C 38 314
- C 39 314
veloping C 40 314
high C 41 314
pressure C 42 314
. C 43 314
this C 45 314
pathologic C 46 314
picture C 47 314
is C 48 314
associated C 49 314
with C 50 314
clinical C 51 314
findings C 52 314
similar C 53 314
to C 54 314
those C 55 314
in C 56 314
tricuspid C 57 314
atresia C 58 314
- C 59 314
cyanosis C 60 314
, C 61 314
decreased C 62 314
pulmonary C 63 314
flow C 64 314
, C 65 314
left C 66 314
ven C 67 314
- C 68 314
tricular C 69 314
preponderance C 70 314
on C 71 314
the C 72 314
electrocardiogram C 73 314
, C 74 314
and C 75 314
early C 76 314
death C 77 314
. C 78 314
the C 80 314
diagnosis C 81 314
may C 82 314
be C 83 314
confirmed C 84 314
by C 85 314
heart C 86 314
catheterization C 87 314
and C 88 314
selective C 89 314
angiocardiography C 90 314
with C 91 314
in C 92 314
- C 93 314
jection C 94 314
into C 95 314
the C 96 314
right C 97 314
ventricle C 98 314
, C 99 314
but C 100 314
the C 101 314
risk C 102 314
is C 103 314
great C 104 314
. C 105 314
surgery C 107 314
has C 108 314
never C 109 314
been C 110 314
suc C 111 314
- C 112 314
cessful C 113 314
in C 114 314
the C 115 314
past C 116 314
; C 117 314
but C 118 314
because C 119 314
of C 120 314
the C 121 314
equally C 122 314
hopeless C 123 314
prognosis C 124 314
on C 125 314
medical C 126 314
treat C 127 314
- C 128 314
ment C 129 314
, C 130 314
attempts C 131 314
should C 132 314
continue C 133 314
to C 134 314
be C 135 314
made C 136 314
. C 137 314
anastomosis C 139 314
of C 140 314
the C 141 314
superior C 142 314
vena C 143 314
cava C 144 314
to C 145 314
the C 146 314
right C 147 314
pulmonary C 148 314
artery C 149 314
appears C 150 314
to C 151 314
offer C 152 314
hope C 153 314
of C 154 314
success C 155 314
in C 156 314
the C 157 314
future C 158 314
. C 159 314
1635 C 1 315
. C 2 315
intra C 4 315
- C 5 315
atrial C 6 315
pressure C 7 315
measurement C 8 315
and C 9 315
electrocardiography C 10 315
in C 11 315
the C 12 315
detailed C 13 315
diagnosis C 14 315
of C 15 315
atrial C 16 315
septal C 17 315
defect C 18 315
after C 19 315
discussing C 20 315
the C 21 315
possibilities C 22 315
and C 23 315
limitations C 24 315
of C 25 315
different C 26 315
methods C 27 315
for C 28 315
identifying C 29 315
the C 30 315
anatomical C 31 315
type C 32 315
of C 33 315
atrial C 34 315
septal C 35 315
defect C 36 315
, C 37 315
the C 38 315
authors C 39 315
suggest C 40 315
a C 41 315
more C 42 315
useful C 43 315
new C 44 315
method C 45 315
. C 46 315
this C 48 315
consists C 49 315
in C 50 315
simultaneous C 51 315
recording C 52 315
of C 53 315
both C 54 315
the C 55 315
pressure C 56 315
curve C 57 315
and C 58 315
endocavitary C 59 315
electrocardiogram C 60 315
during C 61 315
withdrawal C 62 315
of C 63 315
the C 64 315
catheter C 65 315
from C 66 315
the C 67 315
left C 68 315
into C 69 315
the C 70 315
right C 71 315
atrium C 72 315
. C 73 315
in C 75 315
the C 76 315
ostium C 77 315
primum C 78 315
type C 79 315
, C 80 315
the C 81 315
septal C 82 315
foramen C 83 315
has C 84 315
no C 85 315
infe C 86 315
- C 87 315
rior C 88 315
margin C 89 315
, C 90 315
and C 91 315
the C 92 315
point C 93 315
of C 94 315
the C 95 315
catheter C 96 315
during C 97 315
retraction C 98 315
( C 99 315
unlike C 100 315
in C 101 315
the C 102 315
ostium C 103 315
secundum C 104 315
type C 105 315
) C 106 315
rests C 107 315
on C 108 315
the C 109 315
intermediate C 110 315
section C 111 315
of C 112 315
the C 113 315
atrioventricular C 114 315
septum C 115 315
. C 116 315
the C 118 315
endocavitary C 119 315
electrocardiogram C 120 315
in C 121 315
the C 122 315
zone C 123 315
of C 124 315
passage C 125 315
between C 126 315
the C 127 315
two C 128 315
atria C 129 315
shows C 130 315
the C 131 315
typical C 132 315
pattern C 133 315
of C 134 315
the C 135 315
intermediate C 136 315
section C 137 315
of C 138 315
the C 139 315
atrioventricular C 140 315
septum C 141 315
; C 142 315
the C 143 315
pressure C 144 315
curve C 145 315
may C 146 315
show C 147 315
a C 148 315
pattern C 149 315
of C 150 315
the C 151 315
atrial C 152 315
of C 153 315
intravalvular C 154 315
type C 155 315
. C 156 315
1636 C 1 316
. C 2 316
ventricular C 4 316
septal C 5 316
aneurysms C 6 316
. C 7 316
a C 9 316
report C 10 316
of C 11 316
two C 12 316
cases C 13 316
two C 14 316
cases C 15 316
of C 16 316
ventriuclar C 17 316
cuptal C 18 316
aneurysm C 19 316
are C 20 316
reported C 21 316
, C 22 316
one C 23 316
in C 24 316
the C 25 316
membranous C 26 316
and C 27 316
one C 28 316
in C 29 316
the C 30 316
muscular C 31 316
portion C 32 316
. C 33 316
the C 35 316
diagnosis C 36 316
was C 37 316
made C 38 316
by C 39 316
selective C 40 316
left C 41 316
ventricular C 42 316
angiogra C 43 316
- C 44 316
phy C 45 316
. C 46 316
it C 48 316
is C 49 316
suggested C 50 316
that C 51 316
these C 52 316
cases C 53 316
represent C 54 316
spontaneous C 55 316
closure C 56 316
of C 57 316
a C 58 316
ventricular C 59 316
septal C 60 316
defect C 61 316
with C 62 316
weakness C 63 316
and C 64 316
aneurysmal C 65 316
formation C 66 316
due C 67 316
to C 68 316
the C 69 316
high C 70 316
left C 71 316
ventricular C 72 316
pressure C 73 316
. C 74 316
both C 76 316
are C 77 316
asymptomatic C 78 316
and C 79 316
hemodynamically C 80 316
within C 81 316
normal C 82 316
limits C 83 316
. C 84 316
surgical C 86 316
repair C 87 316
of C 88 316
the C 89 316
aneurysms C 90 316
is C 91 316
not C 92 316
considered C 93 316
necessary C 94 316
. C 95 316
1642 C 1 317
. C 2 317
electrode C 4 317
catheters C 5 317
and C 6 317
the C 7 317
diagnosis C 8 317
of C 9 317
ebstein C 10 317
' C 11 317
s C 12 317
anomaly C 13 317
of C 14 317
the C 15 317
tricuspid C 16 317
valve C 17 317
the C 18 317
successful C 19 317
surgical C 20 317
treatment C 21 317
of C 22 317
ebstein C 23 317
' C 24 317
s C 25 317
anomaly C 26 317
calls C 27 317
for C 28 317
accurate C 29 317
pre C 30 317
- C 31 317
ope C 32 317
- C 33 317
rative C 34 317
assessment C 35 317
of C 36 317
the C 37 317
nature C 38 317
and C 39 317
severity C 40 317
of C 41 317
the C 42 317
tricuspid C 43 317
valvular C 44 317
lesion C 45 317
. C 46 317
the C 48 317
increased C 49 317
risk C 50 317
of C 51 317
cardiac C 52 317
catheterization C 53 317
in C 54 317
this C 55 317
condition C 56 317
has C 57 317
been C 58 317
matched C 59 317
by C 60 317
in C 61 317
- C 62 317
creased C 63 317
experience C 64 317
of C 65 317
intracardiac C 66 317
techniques C 67 317
, C 68 317
and C 69 317
provided C 70 317
the C 71 317
examination C 72 317
is C 73 317
in C 74 317
skilled C 75 317
hands C 76 317
, C 77 317
patients C 78 317
with C 79 317
ebstein C 80 317
' C 81 317
s C 82 317
anomaly C 83 317
should C 84 317
be C 85 317
investigated C 86 317
in C 87 317
the C 88 317
same C 89 317
way C 90 317
as C 91 317
those C 92 317
with C 93 317
any C 94 317
other C 95 317
serious C 96 317
congenital C 97 317
heart C 98 317
lesion C 99 317
for C 100 317
whom C 101 317
surgery C 102 317
is C 103 317
con C 104 317
- C 105 317
templated C 106 317
. C 107 317
the C 109 317
diagnostic C 110 317
value C 111 317
of C 112 317
electrode C 113 317
catheters C 114 317
is C 115 317
discussed C 116 317
, C 117 317
and C 118 317
the C 119 317
intra C 120 317
- C 121 317
cardiac C 122 317
electrocardiographic C 123 317
features C 124 317
of C 125 317
ebstein C 126 317
' C 127 317
s C 128 317
anomaly C 129 317
are C 130 317
illustrated C 131 317
. C 132 317
false C 134 317
positive C 135 317
and C 136 317
false C 137 317
negative C 138 317
records C 139 317
are C 140 317
demonstrated C 141 317
and C 142 317
the C 143 317
mechanism C 144 317
of C 145 317
their C 146 317
production C 147 317
is C 148 317
explained C 149 317
. C 150 317
it C 152 317
is C 153 317
concluded C 154 317
that C 155 317
, C 156 317
though C 157 317
helpful C 158 317
, C 159 317
intracardiac C 160 317
electro C 161 317
- C 162 317
cardiographic C 163 317
evidence C 164 317
should C 165 317
be C 166 317
regarded C 167 317
as C 168 317
confirmatory C 169 317
rather C 170 317
than C 171 317
diagnostic C 172 317
. C 173 317
records C 175 317
made C 176 317
with C 177 317
electrode C 178 317
catheters C 179 317
during C 180 317
cardiac C 181 317
catheterization C 182 317
should C 183 317
be C 184 317
con C 185 317
- C 186 317
sidered C 187 317
only C 188 317
along C 189 317
with C 190 317
the C 191 317
other C 192 317
clinical C 193 317
, C 194 317
electrocardiographic C 195 317
, C 196 317
and C 197 317
radiological C 198 317
features C 199 317
of C 200 317
the C 201 317
case C 202 317
, C 203 317
and C 204 317
should C 205 317
not C 206 317
be C 207 317
relied C 208 317
upon C 209 317
as C 210 317
the C 211 317
definitive C 212 317
method C 213 317
in C 214 317
the C 215 317
diagnosis C 216 317
of C 217 317
ebstein C 218 317
' C 219 317
s C 220 317
anomaly C 221 317
. C 222 317
3326 C 1 318
. C 2 318
unusual C 4 318
aneurysm C 5 318
of C 6 318
the C 7 318
membranous C 8 318
interventricular C 9 318
septum C 10 318
the C 11 318
case C 12 318
of C 13 318
a C 14 318
patient C 15 318
with C 16 318
a C 17 318
huge C 18 318
aneurysm C 19 318
of C 20 318
the C 21 318
membranous C 22 318
interventricular C 23 318
septum C 24 318
is C 25 318
presented C 26 318
. C 27 318
this C 29 318
is C 30 318
believed C 31 318
to C 32 318
be C 33 318
the C 34 318
first C 35 318
such C 36 318
patient C 37 318
to C 38 318
have C 39 318
undergone C 40 318
successful C 41 318
resection C 42 318
. C 43 318
934 C 1 319
. C 2 319
laevocardia C 4 319
with C 5 319
situs C 6 319
inversus C 7 319
. C 8 319
a C 10 319
case C 11 319
report C 12 319
and C 13 319
a C 14 319
review C 15 319
of C 16 319
literature C 17 319
a C 18 319
case C 19 319
of C 20 319
levocardia C 21 319
, C 22 319
with C 23 319
inversion C 24 319
of C 25 319
the C 26 319
cham C 27 319
- C 28 319
bers C 29 319
of C 30 319
the C 31 319
heart C 32 319
and C 33 319
transposition C 34 319
of C 35 319
the C 36 319
great C 37 319
vessels C 38 319
and C 39 319
situs C 40 319
inversus C 41 319
, C 42 319
has C 43 319
been C 44 319
described C 45 319
. C 46 319
gross C 48 319
cyanosis C 49 319
and C 50 319
clubbing C 51 319
were C 52 319
present C 53 319
and C 54 319
were C 55 319
due C 56 319
to C 57 319
a C 58 319
veno C 59 319
- C 60 319
arteri C 61 319
- C 62 319
al C 63 319
shunt C 64 319
through C 65 319
a C 66 319
right C 67 319
- C 68 319
sided C 69 319
superior C 70 319
vena C 71 319
cava C 72 319
open C 73 319
- C 74 319
ing C 75 319
into C 76 319
the C 77 319
arterial C 78 319
atrium C 79 319
and C 80 319
passage C 81 319
of C 82 319
venous C 83 319
blood C 84 319
into C 85 319
the C 86 319
aorta C 87 319
through C 88 319
a C 89 319
ventricular C 90 319
septal C 91 319
defect C 92 319
. C 93 319
the C 95 319
case C 96 319
was C 97 319
complicated C 98 319
with C 99 319
right C 100 319
- C 101 319
sided C 102 319
hemiplegia C 103 319
and C 104 319
with C 105 319
the C 106 319
development C 107 319
of C 108 319
a C 109 319
liver C 110 319
abscess C 111 319
. C 112 319
a C 114 319
review C 115 319
of C 116 319
the C 117 319
literature C 118 319
with C 119 319
prognosis C 120 319
and C 121 319
possible C 122 319
etiology C 123 319
of C 124 319
the C 125 319
condition C 126 319
has C 127 319
also C 128 319
been C 129 319
made C 130 319
. C 131 319
1831 C 1 320
. C 2 320
postoperative C 4 320
aneurysm C 5 320
of C 6 320
the C 7 320
right C 8 320
ventricle C 9 320
twelve C 10 320
patients C 11 320
with C 12 320
postoperative C 13 320
aneurysm C 14 320
of C 15 320
the C 16 320
right C 17 320
ventricular C 18 320
outflow C 19 320
tract C 20 320
after C 21 320
corrective C 22 320
surgery C 23 320
for C 24 320
pulmonic C 25 320
valvar C 26 320
stenosis C 27 320
, C 28 320
ventricular C 29 320
septal C 30 320
defect C 31 320
and C 32 320
tetralogy C 33 320
of C 34 320
fallot C 35 320
are C 36 320
reported C 37 320
. C 38 320
the C 40 320
literature C 41 320
is C 42 320
reviewed C 43 320
and C 44 320
the C 45 320
pathogenesis C 46 320
is C 47 320
discussed C 48 320
. C 49 320
different C 51 320
diagnostic C 52 320
tests C 53 320
are C 54 320
evaluated C 55 320
stressing C 56 320
the C 57 320
role C 58 320
of C 59 320
roentgen C 60 320
examinations C 61 320
and C 62 320
the C 63 320
importance C 64 320
of C 65 320
careful C 66 320
follow C 67 320
- C 68 320
up C 69 320
by C 70 320
intercalative C 71 320
chest C 72 320
roent C 73 320
- C 74 320
genography C 75 320
. C 76 320
1991 C 1 321
. C 2 321
ventricular C 4 321
septal C 5 321
defect C 6 321
with C 7 321
aortic C 8 321
regurgitation C 9 321
. C 10 321
medical C 12 321
and C 13 321
pathologic C 14 321
aspects C 15 321
thirty C 16 321
- C 17 321
four C 18 321
patients C 19 321
with C 20 321
ventricular C 21 321
septal C 22 321
defect C 23 321
and C 24 321
aortic C 25 321
regurgitation C 26 321
, C 27 321
repre C 28 321
- C 29 321
senting C 30 321
less C 31 321
than C 32 321
5 C 33 321
% C 34 321
of C 35 321
the C 36 321
patients C 37 321
with C 38 321
ventricular C 39 321
septal C 40 321
defect C 41 321
, C 42 321
are C 43 321
discussed C 44 321
. C 45 321
a C 47 321
loud C 48 321
, C 49 321
systolic C 50 321
murmur C 51 321
, C 52 321
characteristic C 53 321
of C 54 321
ventricular C 55 321
septal C 56 321
defect C 57 321
, C 58 321
is C 59 321
noted C 60 321
dur C 61 321
- C 62 321
ing C 63 321
infancy C 64 321
, C 65 321
whereas C 66 321
evidences C 67 321
of C 68 321
aortic C 69 321
regurgitation C 70 321
( C 71 321
protodiastolic C 72 321
murmur C 73 321
and C 74 321
wide C 75 321
pulse C 76 321
pressure C 77 321
) C 78 321
does C 79 321
not C 80 321
usually C 81 321
appear C 82 321
until C 83 321
some C 84 321
time C 85 321
between C 86 321
2 C 87 321
and C 88 321
10 C 89 321
years C 90 321
of C 91 321
age C 92 321
. C 93 321
clinical C 95 321
and C 96 321
catheterization C 97 321
data C 98 321
indicate C 99 321
that C 100 321
the C 101 321
principal C 102 321
hemody C 103 321
- C 104 321
namic C 105 321
load C 106 321
is C 107 321
aortic C 108 321
regurgitation C 109 321
, C 110 321
whereas C 111 321
the C 112 321
ventricular C 113 321
septal C 114 321
defect C 115 321
does C 116 321
not C 117 321
usually C 118 321
result C 119 321
in C 120 321
a C 121 321
large C 122 321
pulmonary C 123 321
blood C 124 321
flow C 125 321
or C 126 321
high C 127 321
pulmonary C 128 321
arterial C 129 321
pressure C 130 321
. C 131 321
in C 133 321
about C 134 321
50 C 135 321
% C 136 321
of C 137 321
the C 138 321
patients C 139 321
, C 140 321
a C 141 321
significant C 142 321
pressure C 143 321
gradient C 144 321
across C 145 321
the C 146 321
right C 147 321
ven C 148 321
- C 149 321
tricular C 150 321
outflow C 151 321
tract C 152 321
exists C 153 321
. C 154 321
detailed C 156 321
pathologic C 157 321
studies C 158 321
indicate C 159 321
that C 160 321
the C 161 321
ventricular C 162 321
septal C 163 321
defects C 164 321
are C 165 321
high C 166 321
and C 167 321
anterior C 168 321
and C 169 321
encroach C 170 321
to C 171 321
a C 172 321
greater C 173 321
or C 174 321
lesser C 175 321
degree C 176 321
on C 177 321
the C 178 321
membranous C 179 321
bulbar C 180 321
septum C 181 321
. C 182 321
the C 184 321
right C 185 321
coronary C 186 321
cusp C 187 321
is C 188 321
the C 189 321
one C 190 321
most C 191 321
severely C 192 321
involved C 193 321
, C 194 321
and C 195 321
, C 196 321
by C 197 321
its C 198 321
prolapse C 199 321
, C 200 321
causes C 201 321
aortic C 202 321
regurgitation C 203 321
; C 204 321
the C 205 321
noncoronary C 206 321
cusp C 207 321
is C 208 321
always C 209 321
less C 210 321
severely C 211 321
affected C 212 321
. C 213 321
the C 215 321
anatomic C 216 321
basis C 217 321
of C 218 321
the C 219 321
pressure C 220 321
gradient C 221 321
ob C 222 321
- C 223 321
served C 224 321
across C 225 321
the C 226 321
right C 227 321
ventricular C 228 321
outflow C 229 321
tract C 230 321
is C 231 321
not C 232 321
always C 233 321
clear C 234 321
. C 235 321
2431 C 1 322
. C 2 322
the C 4 322
natural C 5 322
history C 6 322
of C 7 322
arrhythmias C 8 322
following C 9 322
septal C 10 322
defect C 11 322
reapir C 12 322
the C 13 322
repair C 14 322
of C 15 322
191 C 16 322
atrial C 17 322
and C 18 322
ventricular C 19 322
septal C 20 322
defects C 21 322
between C 22 322
1955 C 23 322
and C 24 322
1961 C 25 322
was C 26 322
reviewed C 27 322
to C 28 322
determine C 29 322
the C 30 322
incidence C 31 322
and C 32 322
prognosis C 33 322
of C 34 322
arrhythmias C 35 322
related C 36 322
to C 37 322
operation C 38 322
. C 39 322
cases C 41 322
included C 42 322
90 C 43 322
ventricular C 44 322
septal C 45 322
defects C 46 322
, C 47 322
61 C 48 322
atrial C 49 322
defects C 50 322
of C 51 322
the C 52 322
ostium C 53 322
secundum C 54 322
type C 55 322
, C 56 322
and C 57 322
40 C 58 322
of C 59 322
the C 60 322
ostium C 61 322
primum C 62 322
variety C 63 322
. C 64 322
nodal C 66 322
rhythms C 67 322
, C 68 322
second C 69 322
degree C 70 322
blocks C 71 322
, C 72 322
complete C 73 322
heart C 74 322
block C 75 322
, C 76 322
and C 77 322
flutter C 78 322
or C 79 322
fibrillation C 80 322
that C 81 322
persisted C 82 322
after C 83 322
completion C 84 322
of C 85 322
operation C 86 322
were C 87 322
analyzed C 88 322
, C 89 322
while C 90 322
intermittent C 91 322
ectopic C 92 322
beats C 93 322
, C 94 322
sinus C 95 322
tachycardia C 96 322
, C 97 322
and C 98 322
bundle C 99 322
branch C 100 322
blocks C 101 322
were C 102 322
excluded C 103 322
. C 104 322
fifteen C 106 322
per C 107 322
cent C 108 322
of C 109 322
the C 110 322
patients C 111 322
with C 112 322
ventricular C 113 322
defects C 114 322
, C 115 322
17 C 116 322
% C 117 322
with C 118 322
ostium C 119 322
primum C 120 322
defects C 121 322
, C 122 322
and C 123 322
35 C 124 322
% C 125 322
with C 126 322
ostium C 127 322
secundum C 128 322
defects C 129 322
developed C 130 322
abnormal C 131 322
rhythms C 132 322
associated C 133 322
with C 134 322
repair C 135 322
. C 136 322
of C 138 322
18 C 139 322
patients C 140 322
whose C 141 322
arrhythmias C 142 322
began C 143 322
during C 144 322
operation C 145 322
, C 146 322
there C 147 322
were C 148 322
8 C 149 322
deaths C 150 322
; C 151 322
no C 152 322
fatalities C 153 322
occurred C 154 322
in C 155 322
the C 156 322
24 C 157 322
patients C 158 322
who C 159 322
developed C 160 322
arrhythmias C 161 322
in C 162 322
the C 163 322
postoperative C 164 322
period C 165 322
. C 166 322
seven C 168 322
deaths C 169 322
were C 170 322
associated C 171 322
with C 172 322
complete C 173 322
heart C 174 322
block C 175 322
and C 176 322
one C 177 322
with C 178 322
second C 179 322
degree C 180 322
block C 181 322
. C 182 322
although C 184 322
only C 185 322
one C 186 322
half C 187 322
of C 188 322
the C 189 322
patients C 190 322
who C 191 322
developed C 192 322
arrhythmias C 193 322
had C 194 322
pulmonary C 195 322
artery C 196 322
pressure C 197 322
greater C 198 322
than C 199 322
30 C 200 322
mm C 201 322
. C 202 322
hg C 204 322
systolic C 205 322
, C 206 322
all C 207 322
fatalities C 208 322
occurred C 209 322
in C 210 322
this C 211 322
group C 212 322
. C 213 322
four C 215 322
of C 216 322
the C 217 322
deaths C 218 322
followed C 219 322
surgery C 220 322
with C 221 322
the C 222 322
use C 223 322
of C 224 322
the C 225 322
pump C 226 322
oxygenator C 227 322
in C 228 322
children C 229 322
under C 230 322
30 C 231 322
months C 232 322
of C 233 322
age C 234 322
. C 235 322
thirty C 237 322
- C 238 322
eight C 239 322
per C 240 322
cent C 241 322
of C 242 322
the C 243 322
abnormal C 244 322
rhythms C 245 322
that C 246 322
began C 247 322
in C 248 322
the C 249 322
postoperative C 250 322
period C 251 322
were C 252 322
nodal C 253 322
. C 254 322
flutter C 256 322
and C 257 322
fibrillation C 258 322
were C 259 322
common C 260 322
following C 261 322
repair C 262 322
of C 263 322
atrial C 264 322
secundum C 265 322
defects C 266 322
in C 267 322
patients C 268 322
over C 269 322
15 C 270 322
yr C 271 322
. C 272 322
of C 274 322
age C 275 322
but C 276 322
did C 277 322
not C 278 322
occur C 279 322
in C 280 322
younger C 281 322
patients C 282 322
. C 283 322
deaths C 285 322
from C 286 322
heart C 287 322
block C 288 322
occurred C 289 322
in C 290 322
the C 291 322
first C 292 322
30 C 293 322
days C 294 322
following C 295 322
operation C 296 322
except C 297 322
one C 298 322
, C 299 322
5 C 300 322
months C 301 322
later C 302 322
. C 303 322
survivors C 305 322
of C 306 322
complete C 307 322
heart C 308 322
block C 309 322
reverted C 310 322
to C 311 322
a C 312 322
less C 313 322
serious C 314 322
arrhythmia C 315 322
or C 316 322
normal C 317 322
rhythm C 318 322
within C 319 322
3 C 320 322
months C 321 322
. C 322 322
1021 C 1 323
. C 2 323
left C 4 323
ventricular C 5 323
angiocardiography C 6 323
in C 7 323
the C 8 323
study C 9 323
of C 10 323
ventricular C 11 323
septal C 12 323
defects C 13 323
sixty C 14 323
- C 15 323
five C 16 323
cases C 17 323
of C 18 323
ventricular C 19 323
septal C 20 323
defect C 21 323
were C 22 323
studied C 23 323
by C 24 323
left C 25 323
angiocardiography C 26 323
. C 27 323
the C 29 323
left C 30 323
ventricle C 31 323
was C 32 323
entered C 33 323
by C 34 323
retrograde C 35 323
arterial C 36 323
catheterization C 37 323
with C 38 323
a C 39 323
catheter C 40 323
having C 41 323
a C 42 323
j C 43 323
- C 44 323
shaped C 45 323
tip C 46 323
. C 47 323
this C 49 323
procedure C 50 323
appears C 51 323
to C 52 323
be C 53 323
little C 54 323
, C 55 323
or C 56 323
no C 57 323
more C 58 323
, C 59 323
hazardous C 60 323
than C 61 323
right C 62 323
- C 63 323
sided C 64 323
angiocardiography C 65 323
. C 66 323
ventricular C 68 323
septal C 69 323
defects C 70 323
may C 71 323
be C 72 323
divided C 73 323
into C 74 323
5 C 75 323
types C 76 323
, C 77 323
depending C 78 323
on C 79 323
their C 80 323
location C 81 323
in C 82 323
the C 83 323
ventricular C 84 323
septum C 85 323
. C 86 323
the C 88 323
anatomic C 89 323
and C 90 323
radiological C 91 323
features C 92 323
of C 93 323
the C 94 323
septum C 95 323
and C 96 323
septal C 97 323
defects C 98 323
are C 99 323
described C 100 323
. C 101 323
selective C 103 323
in C 104 323
- C 105 323
jection C 106 323
of C 107 323
contrast C 108 323
material C 109 323
into C 110 323
the C 111 323
left C 112 323
ventricle C 113 323
opacifies C 114 323
the C 115 323
blood C 116 323
passing C 117 323
through C 118 323
the C 119 323
defect C 120 323
in C 121 323
the C 122 323
septum C 123 323
and C 124 323
permits C 125 323
preoperative C 126 323
localization C 127 323
of C 128 323
the C 129 323
defect C 130 323
in C 131 323
rela C 132 323
- C 133 323
tion C 134 323
to C 135 323
identifiable C 136 323
anatomic C 137 323
landmarks C 138 323
. C 139 323
multiple C 141 323
defects C 142 323
of C 143 323
the C 144 323
septum C 145 323
are C 146 323
well C 147 323
de C 148 323
- C 149 323
monstrated C 150 323
. C 151 323
such C 153 323
information C 154 323
may C 155 323
be C 156 323
of C 157 323
considerable C 158 323
value C 159 323
to C 160 323
the C 161 323
surgeon C 162 323
under C 163 323
- C 164 323
taking C 165 323
repair C 166 323
of C 167 323
the C 168 323
septum C 169 323
. C 170 323
left C 172 323
ventriculography C 173 323
, C 174 323
often C 175 323
combined C 176 323
with C 177 323
supraval C 178 323
- C 179 323
vular C 180 323
aortography C 181 323
, C 182 323
has C 183 323
been C 184 323
used C 185 323
, C 186 323
when C 187 323
indicated C 188 323
, C 189 323
to C 190 323
differentiate C 191 323
between C 192 323
mitral C 193 323
insufficiency C 194 323
and C 195 323
ventricular C 196 323
septal C 197 323
defect C 198 323
and C 199 323
in C 200 323
the C 201 323
detection C 202 323
of C 203 323
other C 204 323
cardiac C 205 323
ano C 206 323
- C 207 323
malies C 208 323
whose C 209 323
manifestations C 210 323
are C 211 323
marked C 212 323
by C 213 323
those C 214 323
of C 215 323
the C 216 323
septal C 217 323
lesion C 218 323
. C 219 323
this C 221 323
tech C 222 323
- C 223 323
nique C 224 323
is C 225 323
well C 226 323
suited C 227 323
to C 228 323
the C 229 323
postoperative C 230 323
study C 231 323
of C 232 323
patients C 233 323
following C 234 323
repair C 235 323
of C 236 323
the C 237 323
septal C 238 323
defect C 239 323
and C 240 323
for C 241 323
follow C 242 323
- C 243 323
up C 244 323
studies C 245 323
in C 246 323
patients C 247 323
not C 248 323
operated C 249 323
upon C 250 323
to C 251 323
clarify C 252 323
the C 253 323
natural C 254 323
history C 255 323
of C 256 323
defects C 257 323
in C 258 323
different C 259 323
portions C 260 323
of C 261 323
the C 262 323
ventricular C 263 323
septum C 264 323
. C 265 323
4105 C 1 324
. C 2 324
free C 4 324
fatty C 5 324
acid C 6 324
metabolism C 7 324
in C 8 324
chinese C 9 324
hamsters C 10 324
in C 11 324
normal C 12 324
chinese C 13 324
hamsters C 14 324
( C 15 324
cricetulus C 16 324
griseus C 17 324
) C 18 324
the C 19 324
mean C 20 324
concentration C 21 324
of C 22 324
free C 23 324
fatty C 24 324
acids C 25 324
( C 26 324
ffa C 27 324
) C 28 324
in C 29 324
serum C 30 324
varied C 31 324
from C 32 324
group C 33 324
to C 34 324
group C 35 324
, C 36 324
but C 37 324
was C 38 324
( C 39 324
1 C 40 324
) C 41 324
consistently C 42 324
4 C 43 324
to C 44 324
9 C 45 324
times C 46 324
greater C 47 324
than C 48 324
in C 49 324
rats C 50 324
, C 51 324
dogs C 52 324
, C 53 324
or C 54 324
man C 55 324
; C 56 324
( C 57 324
2 C 58 324
) C 59 324
slightly C 60 324
higher C 61 324
than C 62 324
in C 63 324
syrian C 64 324
hamsters C 65 324
; C 66 324
( C 67 324
3 C 68 324
) C 69 324
two C 70 324
- C 71 324
to C 72 324
four C 73 324
- C 74 324
fold C 75 324
higher C 76 324
than C 77 324
in C 78 324
fasting C 79 324
or C 80 324
alloxan C 81 324
- C 82 324
diabetic C 83 324
rats C 84 324
. C 85 324
the C 87 324
epididymal C 88 324
adipose C 89 324
tissue C 90 324
of C 91 324
the C 92 324
chinese C 93 324
hamster C 94 324
( C 95 324
1 C 96 324
) C 97 324
had C 98 324
initial C 99 324
concentrations C 100 324
of C 101 324
ffa C 102 324
comparable C 103 324
to C 104 324
those C 105 324
in C 106 324
the C 107 324
rat C 108 324
and C 109 324
syrian C 110 324
hamster C 111 324
; C 112 324
( C 113 324
2 C 114 324
) C 115 324
released C 116 324
, C 117 324
in C 118 324
the C 119 324
same C 120 324
time C 121 324
interval C 122 324
, C 123 324
8 C 124 324
- C 125 324
to C 126 324
10 C 127 324
- C 128 324
fold C 129 324
more C 130 324
ffa C 131 324
in C 132 324
vitro C 133 324
than C 134 324
this C 135 324
tissue C 136 324
of C 137 324
the C 138 324
rat C 139 324
; C 140 324
( C 141 324
3 C 142 324
) C 143 324
had C 144 324
higher C 145 324
concentrations C 146 324
of C 147 324
ffa C 148 324
after C 149 324
incubation C 150 324
than C 151 324
the C 152 324
incubated C 153 324
tissue C 154 324
of C 155 324
the C 156 324
rat C 157 324
. C 158 324
the C 160 324
retroperitoneal C 161 324
( C 162 324
perirenal C 163 324
) C 164 324
adipose C 165 324
tissue C 166 324
of C 167 324
the C 168 324
chinese C 169 324
hamster C 170 324
was C 171 324
less C 172 324
ac C 173 324
- C 174 324
tive C 175 324
in C 176 324
release C 177 324
of C 178 324
fatty C 179 324
acids C 180 324
in C 181 324
vitro C 182 324
than C 183 324
the C 184 324
epididymal C 185 324
, C 186 324
but C 187 324
was C 188 324
, C 189 324
however C 190 324
, C 191 324
more C 192 324
active C 193 324
than C 194 324
the C 195 324
epididymal C 196 324
adipose C 197 324
tissue C 198 324
of C 199 324
the C 200 324
rat C 201 324
. C 202 324
these C 204 324
characteristics C 205 324
of C 206 324
ffa C 207 324
metabolism C 208 324
in C 209 324
the C 210 324
chinese C 211 324
hamster C 212 324
were C 213 324
apparently C 214 324
attributable C 215 324
to C 216 324
species C 217 324
, C 218 324
not C 219 324
to C 220 324
age C 221 324
, C 222 324
diet C 223 324
, C 224 324
or C 225 324
sex C 226 324
. C 227 324
in C 229 324
the C 230 324
chinese C 231 324
hamster C 232 324
, C 233 324
the C 234 324
weight C 235 324
of C 236 324
the C 237 324
epididymal C 238 324
adipose C 239 324
tis C 240 324
- C 241 324
sue C 242 324
per C 243 324
gram C 244 324
of C 245 324
body C 246 324
was C 247 324
relatively C 248 324
high C 249 324
. C 250 324
it C 252 324
appears C 253 324
that C 254 324
in C 255 324
this C 256 324
species C 257 324
the C 258 324
rate C 259 324
of C 260 324
release C 261 324
of C 262 324
fatty C 263 324
acids C 264 324
from C 265 324
adipose C 266 324
tissue C 267 324
is C 268 324
great C 269 324
, C 270 324
leading C 271 324
to C 272 324
high C 273 324
ffa C 274 324
concentra C 275 324
- C 276 324
tions C 277 324
in C 278 324
serum C 279 324
. C 280 324
in C 282 324
chinese C 283 324
hamster C 284 324
and C 285 324
rat C 286 324
adipose C 287 324
tissues C 288 324
in C 289 324
vitro C 290 324
, C 291 324
glucose C 292 324
and C 293 324
in C 294 324
- C 295 324
sulin C 296 324
( C 297 324
separately C 298 324
) C 299 324
reduced C 300 324
the C 301 324
rate C 302 324
of C 303 324
release C 304 324
of C 305 324
ffa C 306 324
and C 307 324
the C 308 324
amount C 309 324
of C 310 324
ffa C 311 324
in C 312 324
the C 313 324
tissues C 314 324
, C 315 324
but C 316 324
glucose C 317 324
and C 318 324
insulin C 319 324
together C 320 324
produced C 321 324
the C 322 324
greatest C 323 324
reduction C 324 324
. C 325 324
the C 327 324
net C 328 324
reduction C 329 324
in C 330 324
ffa C 331 324
release C 332 324
by C 333 324
glucose C 334 324
and C 335 324
insulin C 336 324
in C 337 324
vitro C 338 324
was C 339 324
greater C 340 324
in C 341 324
tissue C 342 324
from C 343 324
the C 344 324
chinese C 345 324
hamster C 346 324
. C 347 324
insulin C 349 324
markedly C 350 324
increased C 351 324
glucose C 352 324
uptake C 353 324
by C 354 324
the C 355 324
adipose C 356 324
tis C 357 324
- C 358 324
sues C 359 324
of C 360 324
both C 361 324
species C 362 324
. C 363 324
the C 365 324
possible C 366 324
relation C 367 324
of C 368 324
the C 369 324
results C 370 324
to C 371 324
spontaneous C 372 324
diabetes C 373 324
in C 374 324
the C 375 324
chinese C 376 324
hamster C 377 324
is C 378 324
discussed C 379 324
. C 380 324
95 C 1 325
. C 2 325
changes C 4 325
in C 5 325
serum C 6 325
non C 7 325
- C 8 325
esterified C 9 325
fatty C 10 325
acid C 11 325
levels C 12 325
in C 13 325
spon C 14 325
- C 15 325
taneous C 16 325
and C 17 325
in C 18 325
oxytocin C 19 325
induced C 20 325
labour C 21 325
the C 22 325
nonesterified C 23 325
fatty C 24 325
acid C 25 325
( C 26 325
nefa C 27 325
) C 28 325
concentration C 29 325
of C 30 325
serum C 31 325
rises C 32 325
progressively C 33 325
during C 34 325
the C 35 325
course C 36 325
of C 37 325
normal C 38 325
labor C 39 325
. C 40 325
the C 42 325
rise C 43 325
appears C 44 325
to C 45 325
be C 46 325
related C 47 325
to C 48 325
the C 49 325
duration C 50 325
of C 51 325
labor C 52 325
. C 53 325
the C 55 325
use C 56 325
of C 57 325
oxytocin C 58 325
to C 59 325
induce C 60 325
and C 61 325
stimulate C 62 325
labor C 63 325
does C 64 325
not C 65 325
alter C 66 325
the C 67 325
normal C 68 325
pattern C 69 325
of C 70 325
rise C 71 325
in C 72 325
nefa C 73 325
provided C 74 325
it C 75 325
is C 76 325
given C 77 325
in C 78 325
physiologic C 79 325
dosage C 80 325
. C 81 325
the C 83 325
levels C 84 325
of C 85 325
nefa C 86 325
in C 87 325
the C 88 325
umbilical C 89 325
vein C 90 325
and C 91 325
the C 92 325
umbilical C 93 325
artery C 94 325
at C 95 325
delivery C 96 325
are C 97 325
comparable C 98 325
and C 99 325
always C 100 325
significantly C 101 325
lower C 102 325
than C 103 325
the C 104 325
maternal C 105 325
level C 106 325
. C 107 325
the C 109 325
maternal C 110 325
/ C 111 325
fetal C 112 325
ratio C 113 325
varies C 114 325
between C 115 325
1 C 116 325
. C 117 325
. C 118 325
1 C 119 325
and C 120 325
3 C 121 325
. C 122 325
. C 123 325
1 C 124 325
in C 125 325
this C 126 325
series C 127 325
. C 128 325
following C 130 325
delivery C 131 325
the C 132 325
nefa C 133 325
levels C 134 325
begin C 135 325
to C 136 325
fall C 137 325
almost C 138 325
immediately C 139 325
. C 140 325
the C 142 325
rate C 143 325
of C 144 325
fall C 145 325
is C 146 325
10 C 147 325
- C 148 325
30 C 149 325
% C 150 325
of C 151 325
the C 152 325
delivery C 153 325
value C 154 325
in C 155 325
the C 156 325
1 C 157 325
st C 158 325
hour C 159 325
, C 160 325
30 C 161 325
- C 162 325
50 C 163 325
% C 164 325
within C 165 325
18 C 166 325
hr C 167 325
. C 168 325
and C 170 325
50 C 171 325
- C 172 325
70 C 173 325
% C 174 325
within C 175 325
36 C 176 325
hr C 177 325
. C 178 325
1545 C 1 326
. C 2 326
the C 4 326
effect C 5 326
of C 6 326
combined C 7 326
glucose C 8 326
and C 9 326
insulin C 10 326
infusions C 11 326
on C 12 326
the C 13 326
lipoid C 14 326
and C 15 326
carbohydrate C 16 326
metabolism C 17 326
of C 18 326
the C 19 326
parturient C 20 326
woman C 21 326
and C 22 326
of C 23 326
the C 24 326
fetus C 25 326
the C 26 326
infusion C 27 326
of C 28 326
glucose C 29 326
with C 30 326
insulin C 31 326
during C 32 326
delivery C 33 326
was C 34 326
used C 35 326
by C 36 326
the C 37 326
authors C 38 326
pri C 39 326
- C 40 326
marily C 41 326
in C 42 326
order C 43 326
to C 44 326
determine C 45 326
, C 46 326
whether C 47 326
the C 48 326
utilization C 49 326
of C 50 326
glucose C 51 326
can C 52 326
be C 53 326
enhanced C 54 326
under C 55 326
these C 56 326
conditions C 57 326
. C 58 326
they C 60 326
wanted C 61 326
to C 62 326
investigate C 63 326
, C 64 326
whether C 65 326
the C 66 326
increase C 67 326
of C 68 326
unesteri C 69 326
- C 70 326
fied C 71 326
fatty C 72 326
acids C 73 326
in C 74 326
the C 75 326
cord C 76 326
blood C 77 326
which C 78 326
takes C 79 326
place C 80 326
after C 81 326
a C 82 326
sole C 83 326
glucose C 84 326
infusion C 85 326
in C 86 326
the C 87 326
mother C 88 326
, C 89 326
could C 90 326
be C 91 326
caused C 92 326
by C 93 326
the C 94 326
low C 95 326
capability C 96 326
of C 97 326
glucose C 98 326
utilization C 99 326
in C 100 326
the C 101 326
fetus C 102 326
. C 103 326
the C 105 326
infusion C 106 326
during C 107 326
delivery C 108 326
which C 109 326
consisted C 110 326
of C 111 326
the C 112 326
application C 113 326
of C 114 326
500 C 115 326
ml C 116 326
of C 117 326
10 C 118 326
% C 119 326
glucose C 120 326
and C 121 326
16 C 122 326
u C 123 326
of C 124 326
insulin C 125 326
over C 126 326
a C 127 326
period C 128 326
of C 129 326
30 C 130 326
min C 131 326
. C 132 326
brought C 134 326
about C 135 326
a C 136 326
greater C 137 326
decrease C 138 326
of C 139 326
unesterified C 140 326
fatty C 141 326
acids C 142 326
in C 143 326
the C 144 326
parturient C 145 326
woman C 146 326
as C 147 326
compared C 148 326
with C 149 326
the C 150 326
infusion C 151 326
of C 152 326
glucose C 153 326
exclusively C 154 326
. C 155 326
the C 157 326
reason C 158 326
for C 159 326
this C 160 326
result C 161 326
is C 162 326
thought C 163 326
to C 164 326
be C 165 326
due C 166 326
to C 167 326
a C 168 326
better C 169 326
utili C 170 326
- C 171 326
zation C 172 326
of C 173 326
glucose C 174 326
which C 175 326
is C 176 326
favorably C 177 326
influenced C 178 326
by C 179 326
insulin C 180 326
. C 181 326
during C 183 326
the C 184 326
infusion C 185 326
of C 186 326
glucose C 187 326
with C 188 326
insulin C 189 326
, C 190 326
an C 191 326
increase C 192 326
in C 193 326
the C 194 326
values C 195 326
of C 196 326
lactic C 197 326
and C 198 326
pyruvic C 199 326
acid C 200 326
took C 201 326
place C 202 326
in C 203 326
the C 204 326
parturient C 205 326
women C 206 326
; C 207 326
this C 208 326
was C 209 326
probably C 210 326
due C 211 326
to C 212 326
an C 213 326
accelerated C 214 326
glycolysis C 215 326
and C 216 326
an C 217 326
increased C 218 326
production C 219 326
of C 220 326
lactic C 221 326
acid C 222 326
, C 223 326
but C 224 326
not C 225 326
caused C 226 326
by C 227 326
a C 228 326
higher C 229 326
share C 230 326
of C 231 326
the C 232 326
anaerobic C 233 326
metabolism C 234 326
. C 235 326
in C 237 326
the C 238 326
cord C 239 326
blood C 240 326
, C 241 326
there C 242 326
were C 243 326
likewise C 244 326
increased C 245 326
values C 246 326
of C 247 326
lactic C 248 326
and C 249 326
py C 250 326
- C 251 326
ruvic C 252 326
acid C 253 326
as C 254 326
a C 255 326
reflection C 256 326
of C 257 326
the C 258 326
higher C 259 326
values C 260 326
of C 261 326
these C 262 326
substances C 263 326
in C 264 326
the C 265 326
mother C 266 326
. C 267 326
the C 269 326
formation C 270 326
of C 271 326
these C 272 326
products C 273 326
of C 274 326
metabolic C 275 326
breakdown C 276 326
by C 277 326
the C 278 326
fetus C 279 326
, C 280 326
however C 281 326
, C 282 326
was C 283 326
not C 284 326
significantly C 285 326
increased C 286 326
. C 287 326
after C 289 326
infusion C 290 326
of C 291 326
glucose C 292 326
with C 293 326
insulin C 294 326
, C 295 326
the C 296 326
other C 297 326
investigated C 298 326
parameter C 299 326
values C 300 326
, C 301 326
including C 302 326
those C 303 326
of C 304 326
the C 305 326
levels C 306 326
of C 307 326
unesterified C 308 326
fatty C 309 326
acids C 310 326
are C 311 326
found C 312 326
in C 313 326
the C 314 326
cord C 315 326
blood C 316 326
in C 317 326
similar C 318 326
amounts C 319 326
as C 320 326
after C 321 326
infusion C 322 326
of C 323 326
glucose C 324 326
alone C 325 326
. C 326 326
these C 328 326
re C 329 326
- C 330 326
sults C 331 326
cannot C 332 326
reliably C 333 326
prove C 334 326
the C 335 326
passage C 336 326
of C 337 326
insulin C 338 326
through C 339 326
the C 340 326
placenta C 341 326
especially C 342 326
after C 343 326
a C 344 326
continued C 345 326
study C 346 326
of C 347 326
the C 348 326
metabolic C 349 326
values C 350 326
in C 351 326
newborns C 352 326
. C 353 326
as C 355 326
a C 356 326
proof C 357 326
of C 358 326
the C 359 326
passage C 360 326
of C 361 326
insulin C 362 326
through C 363 326
the C 364 326
placenta C 365 326
could C 366 326
not C 367 326
be C 368 326
established C 369 326
, C 370 326
it C 371 326
is C 372 326
possible C 373 326
that C 374 326
after C 375 326
an C 376 326
intake C 377 326
of C 378 326
insulin C 379 326
the C 380 326
increase C 381 326
of C 382 326
unesterified C 383 326
fatty C 384 326
acids C 385 326
in C 386 326
the C 387 326
cord C 388 326
blood C 389 326
could C 390 326
be C 391 326
caused C 392 326
by C 393 326
a C 394 326
relative C 395 326
insufficiency C 396 326
of C 397 326
the C 398 326
insular C 399 326
apparatus C 400 326
of C 401 326
the C 402 326
fetus C 403 326
. C 404 326
the C 406 326
most C 407 326
probable C 408 326
reason C 409 326
for C 410 326
the C 411 326
increase C 412 326
of C 413 326
unesterified C 414 326
fatty C 415 326
acids C 416 326
is C 417 326
the C 418 326
different C 419 326
depo C 420 326
- C 421 326
sition C 422 326
and C 423 326
metabolization C 424 326
of C 425 326
unesterified C 426 326
fatty C 427 326
acids C 428 326
in C 429 326
the C 430 326
course C 431 326
of C 432 326
intrauterine C 433 326
life C 434 326
. C 435 326
1547 C 1 327
. C 2 327
glucose C 4 327
and C 5 327
nonesterified C 6 327
fatty C 7 327
acid C 8 327
levels C 9 327
in C 10 327
maternal C 11 327
and C 12 327
cord C 13 327
plasma C 14 327
the C 15 327
authors C 16 327
established C 17 327
in C 18 327
44 C 19 327
healthy C 20 327
women C 21 327
at C 22 327
the C 23 327
moment C 24 327
of C 25 327
delivery C 26 327
the C 27 327
contents C 28 327
of C 29 327
glucose C 30 327
and C 31 327
free C 32 327
fatty C 33 327
acids C 34 327
in C 35 327
the C 36 327
blood C 37 327
of C 38 327
the C 39 327
mother C 40 327
and C 41 327
of C 42 327
the C 43 327
umbilical C 44 327
cord C 45 327
. C 46 327
the C 48 327
concentration C 49 327
of C 50 327
both C 51 327
substances C 52 327
was C 53 327
significantly C 54 327
higher C 55 327
in C 56 327
the C 57 327
mother C 58 327
than C 59 327
in C 60 327
the C 61 327
infant C 62 327
. C 63 327
the C 65 327
relation C 66 327
for C 67 327
free C 68 327
fatty C 69 327
acids C 70 327
was C 71 327
1 C 72 327
. C 73 327
. C 74 327
1 C 75 327
, C 76 327
that C 77 327
for C 78 327
glucose C 79 327
1 C 80 327
. C 81 327
. C 82 327
1 C 83 327
. C 84 327
the C 86 327
relation C 87 327
glucose C 88 327
fatty C 89 327
acids C 90 327
in C 91 327
the C 92 327
mother C 93 327
was C 94 327
significantly C 95 327
different C 96 327
from C 97 327
that C 98 327
in C 99 327
the C 100 327
infant C 101 327
. C 102 327
3294 C 1 328
. C 2 328
epinephrine C 4 328
infusions C 5 328
in C 6 328
normal C 7 328
and C 8 328
toxemic C 9 328
pregnancies C 10 328
. C 11 328
ii C 13 328
. C 14 328
plasma C 16 328
glucose C 17 328
, C 18 328
nonesterified C 19 328
fatty C 20 328
acid C 21 328
, C 22 328
and C 23 328
epineph C 24 328
- C 25 328
rine C 26 328
- C 27 328
norepinephrine C 28 328
alterations C 29 328
seven C 30 328
controls C 31 328
and C 32 328
9 C 33 328
preeclamptic C 34 328
patients C 35 328
were C 36 328
infused C 37 328
with C 38 328
different C 39 328
amounts C 40 328
of C 41 328
epinephrine C 42 328
. C 43 328
plasma C 45 328
nefa C 46 328
, C 47 328
glucose C 48 328
and C 49 328
catecholamines C 50 328
were C 51 328
determined C 52 328
before C 53 328
, C 54 328
during C 55 328
and C 56 328
after C 57 328
epinephrine C 58 328
infusion C 59 328
. C 60 328
the C 62 328
toxemic C 63 328
patient C 64 328
responds C 65 328
to C 66 328
the C 67 328
metabolic C 68 328
effects C 69 328
of C 70 328
infused C 71 328
epinephrine C 72 328
in C 73 328
a C 74 328
manner C 75 328
similar C 76 328
to C 77 328
that C 78 328
of C 79 328
the C 80 328
normal C 81 328
pregnant C 82 328
patient C 83 328
. C 84 328
the C 86 328
increased C 87 328
levels C 88 328
of C 89 328
nefa C 90 328
in C 91 328
pregnant C 92 328
patients C 93 328
are C 94 328
explained C 95 328
by C 96 328
a C 97 328
com C 98 328
- C 99 328
plicated C 100 328
biochemical C 101 328
mechanism C 102 328
involving C 103 328
an C 104 328
increased C 105 328
availability C 106 328
of C 107 328
cortisone C 108 328
- C 109 328
like C 110 328
steroids C 111 328
, C 112 328
slightly C 113 328
increased C 114 328
amounts C 115 328
of C 116 328
thyroid C 117 328
, C 118 328
hormones C 119 328
, C 120 328
etc C 121 328
. C 122 328
, C 124 328
resulting C 125 328
in C 126 328
an C 127 328
alteration C 128 328
of C 129 328
carbohydrate C 130 328
utilization C 131 328
. C 132 328
the C 134 328
study C 135 328
leads C 136 328
to C 137 328
the C 138 328
conclusion C 139 328
that C 140 328
epi C 141 328
- C 142 328
nephrine C 143 328
is C 144 328
not C 145 328
an C 146 328
etiologic C 147 328
agent C 148 328
in C 149 328
toxemia C 150 328
of C 151 328
pregnancy C 152 328
. C 153 328
766 C 1 329
. C 2 329
a C 4 329
lipid C 5 329
- C 6 329
mobilizing C 7 329
substance C 8 329
in C 9 329
the C 10 329
serum C 11 329
of C 12 329
pregnant C 13 329
wo C 14 329
- C 15 329
men C 16 329
, C 17 329
of C 18 329
probable C 19 329
placental C 20 329
origin C 21 329
a C 22 329
substance C 23 329
capable C 24 329
of C 25 329
inducing C 26 329
free C 27 329
fatty C 28 329
acid C 29 329
( C 30 329
ffa C 31 329
) C 32 329
release C 33 329
was C 34 329
found C 35 329
in C 36 329
the C 37 329
sera C 38 329
of C 39 329
12 C 40 329
from C 41 329
13 C 42 329
pregnant C 43 329
women C 44 329
. C 45 329
the C 47 329
rat C 48 329
epididymal C 49 329
fat C 50 329
pad C 51 329
was C 52 329
used C 53 329
for C 54 329
bioassay C 55 329
. C 56 329
this C 58 329
substance C 59 329
circulates C 60 329
in C 61 329
late C 62 329
pregnancy C 63 329
and C 64 329
disappears C 65 329
within C 66 329
5 C 67 329
days C 68 329
post C 69 329
partum C 70 329
. C 71 329
it C 73 329
is C 74 329
present C 75 329
in C 76 329
crude C 77 329
placental C 78 329
extracts C 79 329
and C 80 329
is C 81 329
removed C 82 329
by C 83 329
their C 84 329
deproteination C 85 329
. C 86 329
it C 88 329
is C 89 329
nondialyzable C 90 329
. C 91 329
application C 93 329
of C 94 329
pituitary C 95 329
extraction C 96 329
procedure C 97 329
to C 98 329
placentae C 99 329
yielded C 100 329
active C 101 329
fractions C 102 329
where C 103 329
pituitary C 104 329
growth C 105 329
hormone C 106 329
is C 107 329
usually C 108 329
found C 109 329
. C 110 329
in C 112 329
accordance C 113 329
with C 114 329
these C 115 329
facts C 116 329
a C 117 329
hypothesis C 118 329
concerning C 119 329
a C 120 329
part C 121 329
of C 122 329
metabolic C 123 329
changes C 124 329
occurring C 125 329
during C 126 329
preg C 127 329
- C 128 329
nancy C 129 329
was C 130 329
pronounced C 131 329
as C 132 329
follows C 133 329
. C 134 329
the C 136 329
described C 137 329
substance C 138 329
diminishes C 139 329
maternal C 140 329
glu C 141 329
- C 142 329
cose C 143 329
consumption C 144 329
through C 145 329
the C 146 329
elevation C 147 329
of C 148 329
plasma C 149 329
free C 150 329
fatty C 151 329
acids C 152 329
, C 153 329
or C 154 329
by C 155 329
direct C 156 329
in C 157 329
- C 158 329
hibition C 159 329
of C 160 329
glucose C 161 329
uptake C 162 329
, C 163 329
or C 164 329
both C 165 329
. C 166 329
this C 168 329
permits C 169 329
a C 170 329
preferential C 171 329
shunting C 172 329
of C 173 329
glucose C 174 329
to C 175 329
the C 176 329
fetus C 177 329
. C 178 329
at C 180 329
the C 181 329
same C 182 329
time C 183 329
, C 184 329
increased C 185 329
plasma C 186 329
free C 187 329
fatty C 188 329
acid C 189 329
levels C 190 329
would C 191 329
serve C 192 329
as C 193 329
the C 194 329
alternative C 195 329
maternal C 196 329
energy C 197 329
substrate C 198 329
. C 199 329
elevated C 201 329
maternal C 202 329
insulin C 203 329
levels C 204 329
during C 205 329
late C 206 329
pregnancy C 207 329
stabilize C 208 329
the C 209 329
degree C 210 329
of C 211 329
maternal C 212 329
lipid C 213 329
mobilization C 214 329
. C 215 329
the C 217 329
contrainsulin C 218 329
properties C 219 329
of C 220 329
a C 221 329
substance C 222 329
capable C 223 329
of C 224 329
mobilizing C 225 329
free C 226 329
fatty C 227 329
acids C 228 329
and C 229 329
inhibiting C 230 329
mater C 231 329
- C 232 329
nal C 233 329
glucose C 234 329
utilization C 235 329
would C 236 329
pose C 237 329
a C 238 329
diabetogenic C 239 329
challenge C 240 329
, C 241 329
and C 242 329
in C 243 329
the C 244 329
face C 245 329
of C 246 329
com C 247 329
- C 248 329
promised C 249 329
maternal C 250 329
insulin C 251 329
reserves C 252 329
, C 253 329
provoke C 254 329
overt C 255 329
or C 256 329
worsen C 257 329
existing C 258 329
diabetes C 259 329
mellitus C 260 329
. C 261 329
3682 C 1 330
. C 2 330
metabolism C 4 330
of C 5 330
free C 6 330
fatty C 7 330
acids C 8 330
during C 9 330
perinatal C 10 330
life C 11 330
of C 12 330
lambs C 13 330
there C 14 330
is C 15 330
a C 16 330
rapid C 17 330
rise C 18 330
of C 19 330
free C 20 330
fatty C 21 330
acids C 22 330
in C 23 330
blood C 24 330
plasma C 25 330
after C 26 330
birth C 27 330
in C 28 330
newborn C 29 330
lambs C 30 330
. C 31 330
this C 33 330
study C 34 330
confirms C 35 330
this C 36 330
rise C 37 330
, C 38 330
caused C 39 330
by C 40 330
an C 41 330
augmented C 42 330
mobilization C 43 330
of C 44 330
these C 45 330
acids C 46 330
from C 47 330
the C 48 330
tissues C 49 330
. C 50 330
norepinephrine C 52 330
easily C 53 330
mobilizes C 54 330
free C 55 330
fatty C 56 330
acids C 57 330
in C 58 330
adult C 59 330
ewes C 60 330
. C 61 330
in C 63 330
newborn C 64 330
lambs C 65 330
this C 66 330
special C 67 330
effect C 68 330
is C 69 330
lacking C 70 330
, C 71 330
though C 72 330
cardiovascular C 73 330
re C 74 330
- C 75 330
sponses C 76 330
are C 77 330
clearly C 78 330
demonstrable C 79 330
. C 80 330
blocking C 82 330
the C 83 330
sympathetic C 84 330
nervous C 85 330
system C 86 330
in C 87 330
newborn C 88 330
lambs C 89 330
inhibits C 90 330
the C 91 330
rapid C 92 330
rise C 93 330
of C 94 330
free C 95 330
fatty C 96 330
acids C 97 330
after C 98 330
birth C 99 330
. C 100 330
this C 102 330
is C 103 330
com C 104 330
- C 105 330
patible C 106 330
with C 107 330
the C 108 330
concept C 109 330
, C 110 330
that C 111 330
increased C 112 330
activity C 113 330
of C 114 330
these C 115 330
sympathetic C 116 330
nerves C 117 330
after C 118 330
birth C 119 330
is C 120 330
an C 121 330
important C 122 330
factor C 123 330
for C 124 330
free C 125 330
fatty C 126 330
acids C 127 330
mobilization C 128 330
. C 129 330
during C 131 330
intrauterine C 132 330
life C 133 330
there C 134 330
is C 135 330
an C 136 330
ample C 137 330
study C 138 330
of C 139 330
carbohydrates C 140 330
and C 141 330
the C 142 330
organism C 143 330
uses C 144 330
them C 145 330
as C 146 330
an C 147 330
energy C 148 330
source C 149 330
. C 150 330
hypoglycaemia C 152 330
resulting C 153 330
from C 154 330
sudden C 155 330
carbohydrate C 156 330
deprivation C 157 330
at C 158 330
birth C 159 330
, C 160 330
demonstrates C 161 330
with C 162 330
rising C 163 330
free C 164 330
fatty C 165 330
acids C 166 330
the C 167 330
change C 168 330
- C 169 330
over C 170 330
to C 171 330
( C 172 330
tissue C 173 330
) C 174 330
fat C 175 330
as C 176 330
main C 177 330
source C 178 330
of C 179 330
energy C 180 330
. C 181 330
1163 C 1 331
. C 2 331
the C 4 331
effect C 5 331
of C 6 331
glucose C 7 331
infusions C 8 331
on C 9 331
the C 10 331
lipoid C 11 331
and C 12 331
the C 13 331
carbohydrate C 14 331
metabolism C 15 331
of C 16 331
the C 17 331
parturient C 18 331
woman C 19 331
and C 20 331
the C 21 331
fetus C 22 331
in C 23 331
20 C 24 331
parturient C 25 331
women C 26 331
who C 27 331
were C 28 331
given C 29 331
glucose C 30 331
infusions C 31 331
during C 32 331
the C 33 331
expulsive C 34 331
stage C 35 331
of C 36 331
labor C 37 331
, C 38 331
the C 39 331
authors C 40 331
were C 41 331
able C 42 331
to C 43 331
observe C 44 331
an C 45 331
unusual C 46 331
hyperglycemia C 47 331
and C 48 331
a C 49 331
decrease C 50 331
in C 51 331
unesterified C 52 331
fatty C 53 331
acids C 54 331
( C 55 331
uefa C 56 331
) C 57 331
. C 58 331
the C 60 331
uefa C 61 331
- C 62 331
level C 63 331
usually C 64 331
increases C 65 331
regularly C 66 331
during C 67 331
delivery C 68 331
. C 69 331
likewise C 71 331
, C 72 331
the C 73 331
values C 74 331
of C 75 331
esterified C 76 331
fatty C 77 331
acids C 78 331
( C 79 331
efa C 80 331
) C 81 331
showed C 82 331
an C 83 331
in C 84 331
- C 85 331
crease C 86 331
above C 87 331
the C 88 331
normally C 89 331
present C 90 331
levels C 91 331
in C 92 331
women C 93 331
who C 94 331
had C 95 331
received C 96 331
a C 97 331
glucose C 98 331
in C 99 331
- C 100 331
fusion C 101 331
during C 102 331
the C 103 331
expulsive C 104 331
stage C 105 331
of C 106 331
labor C 107 331
. C 108 331
the C 110 331
results C 111 331
show C 112 331
that C 113 331
during C 114 331
delivery C 115 331
both C 116 331
hyperglycemia C 117 331
and C 118 331
the C 119 331
increase C 120 331
in C 121 331
lipoids C 122 331
are C 123 331
predominantly C 124 331
due C 125 331
to C 126 331
the C 127 331
energy C 128 331
demands C 129 331
of C 130 331
the C 131 331
organism C 132 331
. C 133 331
however C 135 331
, C 136 331
there C 137 331
is C 138 331
also C 139 331
evidence C 140 331
that C 141 331
other C 142 331
, C 143 331
hitherto C 144 331
un C 145 331
- C 146 331
known C 147 331
factors C 148 331
may C 149 331
play C 150 331
a C 151 331
role C 152 331
. C 153 331
in C 155 331
the C 156 331
fetus C 157 331
, C 158 331
the C 159 331
infusion C 160 331
of C 161 331
glucose C 162 331
leads C 163 331
to C 164 331
an C 165 331
in C 166 331
- C 167 331
creased C 168 331
glucose C 169 331
retention C 170 331
. C 171 331
the C 173 331
infusion C 174 331
, C 175 331
however C 176 331
, C 177 331
does C 178 331
not C 179 331
bring C 180 331
about C 181 331
a C 182 331
decrease C 183 331
, C 184 331
but C 185 331
, C 186 331
contrary C 187 331
to C 188 331
the C 189 331
expectations C 190 331
, C 191 331
an C 192 331
increase C 193 331
in C 194 331
the C 195 331
uefa C 196 331
- C 197 331
values C 198 331
. C 199 331
in C 201 331
general C 202 331
, C 203 331
such C 204 331
a C 205 331
reaction C 206 331
is C 207 331
not C 208 331
found C 209 331
in C 210 331
any C 211 331
of C 212 331
the C 213 331
subsequent C 214 331
periods C 215 331
of C 216 331
life C 217 331
. C 218 331
further C 220 331
inves C 221 331
- C 222 331
tigations C 223 331
were C 224 331
conducted C 225 331
in C 226 331
order C 227 331
to C 228 331
find C 229 331
an C 230 331
explanation C 231 331
for C 232 331
the C 233 331
paradox C 234 331
uefa C 235 331
- C 236 331
reaction C 237 331
. C 238 331
as C 240 331
shown C 241 331
by C 242 331
an C 243 331
analysis C 244 331
of C 245 331
the C 246 331
lactic C 247 331
acid C 248 331
and C 249 331
the C 250 331
pyruvic C 251 331
acid C 252 331
values C 253 331
, C 254 331
the C 255 331
increase C 256 331
in C 257 331
the C 258 331
uefa C 259 331
can C 260 331
most C 261 331
probably C 262 331
not C 263 331
be C 264 331
attributed C 265 331
to C 266 331
an C 267 331
impairment C 268 331
in C 269 331
the C 270 331
fetal C 271 331
metabolic C 272 331
conditions C 273 331
. C 274 331
the C 276 331
administration C 277 331
of C 278 331
physiological C 279 331
saline C 280 331
infusions C 281 331
to C 282 331
10 C 283 331
parturient C 284 331
women C 285 331
under C 286 331
equal C 287 331
conditions C 288 331
revealed C 289 331
that C 290 331
the C 291 331
cause C 292 331
for C 293 331
the C 294 331
uefa C 295 331
- C 296 331
increase C 297 331
can C 298 331
apparently C 299 331
neither C 300 331
be C 301 331
found C 302 331
in C 303 331
hemodynamic C 304 331
changes C 305 331
due C 306 331
to C 307 331
the C 308 331
infusion C 309 331
nor C 310 331
in C 311 331
changes C 312 331
of C 313 331
the C 314 331
electrolyte C 315 331
balance C 316 331
, C 317 331
but C 318 331
rather C 319 331
in C 320 331
an C 321 331
adaptation C 322 331
insufficiency C 323 331
of C 324 331
the C 325 331
fetal C 326 331
islet C 327 331
cells C 328 331
, C 329 331
respectively C 330 331
in C 331 331
a C 332 331
different C 333 331
fat C 334 331
mobilization C 335 331
or C 336 331
fat C 337 331
deposition C 338 331
. C 339 331
1320 C 1 332
. C 2 332
the C 4 332
plasma C 5 332
free C 6 332
fatty C 7 332
acid C 8 332
composition C 9 332
and C 10 332
blood C 11 332
glucose C 12 332
of C 13 332
normal C 14 332
and C 15 332
diabetic C 16 332
pregnant C 17 332
women C 18 332
and C 19 332
of C 20 332
their C 21 332
new C 22 332
- C 23 332
borns C 24 332
the C 25 332
blood C 26 332
glucose C 27 332
and C 28 332
plasma C 29 332
ffa C 30 332
content C 31 332
and C 32 332
composition C 33 332
of C 34 332
the C 35 332
newborns C 36 332
of C 37 332
normal C 38 332
women C 39 332
, C 40 332
gestational C 41 332
diabetics C 42 332
, C 43 332
and C 44 332
insulin C 45 332
- C 46 332
dependent C 47 332
diabetics C 48 332
were C 49 332
analyzed C 50 332
. C 51 332
normal C 53 332
maternal C 54 332
ffa C 55 332
levels C 56 332
were C 57 332
twice C 58 332
the C 59 332
fetal C 60 332
values C 61 332
; C 62 332
by C 63 332
2 C 64 332
hr C 65 332
of C 66 332
age C 67 332
ffa C 68 332
in C 69 332
- C 70 332
creased C 71 332
4 C 72 332
- C 73 332
fold C 74 332
over C 75 332
initial C 76 332
values C 77 332
in C 78 332
normal C 79 332
infants C 80 332
, C 81 332
while C 82 332
infants C 83 332
of C 84 332
gestational C 85 332
diabetics C 86 332
had C 87 332
a C 88 332
3 C 89 332
- C 90 332
fold C 91 332
rise C 92 332
, C 93 332
and C 94 332
those C 95 332
of C 96 332
insulin C 97 332
dependent C 98 332
diabetics C 99 332
only C 100 332
2 C 101 332
- C 102 332
fold C 103 332
. C 104 332
blood C 106 332
sugar C 107 332
at C 108 332
the C 109 332
same C 110 332
time C 111 332
decreased C 112 332
and C 113 332
there C 114 332
was C 115 332
an C 116 332
inverse C 117 332
relationship C 118 332
be C 119 332
- C 120 332
tween C 121 332
blood C 122 332
glucose C 123 332
in C 124 332
the C 125 332
normal C 126 332
infants C 127 332
and C 128 332
ffa C 129 332
. C 130 332
this C 132 332
relationship C 133 332
is C 134 332
altered C 135 332
in C 136 332
the C 137 332
infant C 138 332
of C 139 332
the C 140 332
diabetic C 141 332
mother C 142 332
. C 143 332
gas C 145 332
chromatography C 146 332
of C 147 332
plasma C 148 332
indicated C 149 332
a C 150 332
higher C 151 332
ratio C 152 332
of C 153 332
unsaturated C 154 332
to C 155 332
saturated C 156 332
ffa C 157 332
in C 158 332
mothers C 159 332
compared C 160 332
to C 161 332
infants C 162 332
. C 163 332
no C 165 332
pattern C 166 332
differences C 167 332
were C 168 332
noted C 169 332
between C 170 332
the C 171 332
normal C 172 332
and C 173 332
diabetic C 174 332
mothers C 175 332
, C 176 332
except C 177 332
that C 178 332
the C 179 332
latter C 180 332
had C 181 332
higher C 182 332
oleic C 183 332
acid C 184 332
. C 185 332
in C 187 332
the C 188 332
initial C 189 332
2 C 190 332
hr C 191 332
of C 192 332
life C 193 332
, C 194 332
the C 195 332
patterns C 196 332
changed C 197 332
, C 198 332
although C 199 332
no C 200 332
differences C 201 332
were C 202 332
noted C 203 332
between C 204 332
infants C 205 332
of C 206 332
diabetic C 207 332
mothers C 208 332
and C 209 332
normals C 210 332
. C 211 332
the C 213 332
observations C 214 332
suggest C 215 332
( C 216 332
1 C 217 332
) C 218 332
the C 219 332
metabolic C 220 332
interrelationships C 221 332
of C 222 332
glucose C 223 332
and C 224 332
ffa C 225 332
in C 226 332
the C 227 332
normal C 228 332
infant C 229 332
are C 230 332
different C 231 332
from C 232 332
those C 233 332
in C 234 332
the C 235 332
infant C 236 332
of C 237 332
the C 238 332
diabetic C 239 332
mother C 240 332
, C 241 332
the C 242 332
latter C 243 332
infant C 244 332
having C 245 332
a C 246 332
state C 247 332
of C 248 332
physiologic C 249 332
hyperinsulinism C 250 332
; C 251 332
( C 252 332
2 C 253 332
) C 254 332
plasma C 255 332
ffa C 256 332
in C 257 332
the C 258 332
fetus C 259 332
is C 260 332
derived C 261 332
from C 262 332
both C 263 332
fetal C 264 332
fat C 265 332
synthesis C 266 332
as C 267 332
well C 268 332
as C 269 332
placental C 270 332
transfers C 271 332
; C 272 332
( C 273 332
3 C 274 332
) C 275 332
the C 276 332
infant C 277 332
of C 278 332
the C 279 332
diabetic C 280 332
mother C 281 332
does C 282 332
not C 283 332
differ C 284 332
from C 285 332
the C 286 332
normal C 287 332
as C 288 332
regards C 289 332
ffa C 290 332
com C 291 332
- C 292 332
position C 293 332
. C 294 332
3107 C 1 333
. C 2 333
lipids C 4 333
of C 5 333
human C 6 333
placenta C 7 333
the C 8 333
chloroform C 9 333
- C 10 333
methanol C 11 333
- C 12 333
soluble C 13 333
components C 14 333
of C 15 333
4 C 16 333
human C 17 333
placentae C 18 333
were C 19 333
isolated C 20 333
by C 21 333
rubber C 22 333
membrane C 23 333
dialysis C 24 333
and C 25 333
gas C 26 333
chromatography C 27 333
, C 28 333
and C 29 333
analysed C 30 333
. C 31 333
two C 33 333
thirds C 34 333
of C 35 333
the C 36 333
total C 37 333
lipids C 38 333
consisted C 39 333
of C 40 333
phosphatides C 41 333
with C 42 333
lecithin C 43 333
as C 44 333
the C 45 333
main C 46 333
component C 47 333
( C 48 333
22 C 49 333
. C 50 333
. C 51 333
% C 52 333
) C 53 333
, C 54 333
colamine C 55 333
cephalin C 56 333
( C 57 333
13 C 58 333
% C 59 333
) C 60 333
and C 61 333
sphingomyelin C 62 333
( C 63 333
7 C 64 333
. C 65 333
. C 66 333
% C 67 333
) C 68 333
. C 69 333
free C 71 333
cholesterol C 72 333
form C 73 333
- C 74 333
ed C 75 333
14 C 76 333
% C 77 333
of C 78 333
the C 79 333
total C 80 333
lipids C 81 333
, C 82 333
while C 83 333
cholesterol C 84 333
esters C 85 333
accounted C 86 333
for C 87 333
6 C 88 333
% C 89 333
and C 90 333
trigly C 91 333
- C 92 333
cerides C 93 333
for C 94 333
13 C 95 333
% C 96 333
. C 97 333
investigation C 99 333
of C 100 333
the C 101 333
phosphatide C 102 333
fatty C 103 333
acids C 104 333
by C 105 333
gas C 106 333
chromatography C 107 333
showed C 108 333
a C 109 333
content C 110 333
of C 111 333
60 C 112 333
% C 113 333
saturated C 114 333
, C 115 333
27 C 116 333
% C 117 333
simple C 118 333
unsaturated C 119 333
and C 120 333
12 C 121 333
% C 122 333
polyunsaturated C 123 333
acids C 124 333
. C 125 333
the C 127 333
fatty C 128 333
acids C 129 333
of C 130 333
the C 131 333
triglycerides C 132 333
consisted C 133 333
of C 134 333
about C 135 333
50 C 136 333
% C 137 333
saturated C 138 333
and C 139 333
25 C 140 333
% C 141 333
each C 142 333
of C 143 333
simple C 144 333
and C 145 333
polyunsaturated C 146 333
acids C 147 333
. C 148 333
the C 150 333
polyenoic C 151 333
acids C 152 333
( C 153 333
30 C 154 333
% C 155 333
) C 156 333
of C 157 333
the C 158 333
cholesterol C 159 333
fatty C 160 333
acids C 161 333
had C 162 333
a C 163 333
high C 164 333
content C 165 333
of C 166 333
linoleic C 167 333
acid C 168 333
, C 169 333
about C 170 333
one C 171 333
quarter C 172 333
that C 173 333
of C 174 333
the C 175 333
total C 176 333
acids C 177 333
. C 178 333
377 C 1 334
. C 2 334
experimental C 4 334
study C 5 334
of C 6 334
sensitization C 7 334
to C 8 334
nickel C 9 334
sensitization C 10 334
was C 11 334
effected C 12 334
by C 13 334
epicutaneous C 14 334
application C 15 334
of C 16 334
nickel C 17 334
sulfate C 18 334
in C 19 334
15 C 20 334
guinea C 21 334
- C 22 334
pigs C 23 334
. C 24 334
it C 26 334
was C 27 334
confirmed C 28 334
by C 29 334
the C 30 334
appearance C 31 334
of C 32 334
eczematiform C 33 334
lesions C 34 334
in C 35 334
skin C 36 334
tests C 37 334
with C 38 334
nickel C 39 334
sulfate C 40 334
. C 41 334
for C 43 334
maintenance C 44 334
of C 45 334
the C 46 334
animals C 47 334
in C 48 334
good C 49 334
general C 50 334
condition C 51 334
it C 52 334
was C 53 334
necessary C 54 334
to C 55 334
add C 56 334
vit C 57 334
. C 58 334
c C 60 334
and C 61 334
antiinfective C 62 334
agents C 63 334
to C 64 334
the C 65 334
diet C 66 334
. C 67 334
for C 69 334
this C 70 334
reason C 71 334
the C 72 334
allergenicity C 73 334
of C 74 334
the C 75 334
ni C 76 334
salt C 77 334
had C 78 334
to C 79 334
be C 80 334
augmented C 81 334
by C 82 334
the C 83 334
use C 84 334
of C 85 334
adjuvants C 86 334
( C 87 334
freund C 88 334
' C 89 334
s C 90 334
complete C 91 334
adjuvant C 92 334
or C 93 334
alum C 94 334
) C 95 334
. C 96 334
such C 98 334
adjuvants C 99 334
act C 100 334
by C 101 334
stimulating C 102 334
the C 103 334
res C 104 334
. C 105 334
the C 107 334
method C 108 334
for C 109 334
sensitization C 110 334
of C 111 334
guinea C 112 334
- C 113 334
pigs C 114 334
to C 115 334
metal C 116 334
salts C 117 334
having C 118 334
been C 119 334
worked C 120 334
out C 121 334
, C 122 334
it C 123 334
is C 124 334
now C 125 334
proposed C 126 334
to C 127 334
study C 128 334
the C 129 334
mechanism C 130 334
of C 131 334
such C 132 334
sensitization C 133 334
, C 134 334
the C 135 334
biological C 136 334
disturbances C 137 334
involved C 138 334
and C 139 334
the C 140 334
possible C 141 334
existence C 142 334
of C 143 334
cross C 144 334
- C 145 334
sensitizations C 146 334
. C 147 334
2285 C 1 335
. C 2 335
some C 4 335
remarks C 5 335
on C 6 335
the C 7 335
nickel C 8 335
dermatitis C 9 335
by C 10 335
non C 11 335
- C 12 335
occupational C 13 335
contact C 14 335
this C 15 335
dermatitis C 16 335
represents C 17 335
2 C 18 335
% C 19 335
of C 20 335
the C 21 335
skin C 22 335
diseases C 23 335
observed C 24 335
at C 25 335
the C 26 335
allergologic C 27 335
outpatients C 28 335
department C 29 335
of C 30 335
the C 31 335
dermatological C 32 335
clinic C 33 335
of C 34 335
milan C 35 335
. C 36 335
the C 38 335
disorder C 39 335
is C 40 335
more C 41 335
frequent C 42 335
in C 43 335
women C 44 335
and C 45 335
prefers C 46 335
the C 47 335
thighs C 48 335
( C 49 335
girdles C 50 335
, C 51 335
keys C 52 335
) C 53 335
and C 54 335
the C 55 335
wrist C 56 335
( C 57 335
watch C 58 335
) C 59 335
; C 60 335
its C 61 335
incubation C 62 335
period C 63 335
is C 64 335
generally C 65 335
long C 66 335
and C 67 335
a C 68 335
peculiar C 69 335
papulo C 70 335
- C 71 335
vesicular C 72 335
follicular C 73 335
and C 74 335
lichenoid C 75 335
eruption C 76 335
often C 77 335
follows C 78 335
. C 79 335
3200 C 1 336
. C 2 336
studies C 4 336
on C 5 336
the C 6 336
binding C 7 336
of C 8 336
protein C 9 336
by C 10 336
nickel C 11 336
. C 12 336
with C 14 336
special C 15 336
reference C 16 336
to C 17 336
its C 18 336
role C 19 336
in C 20 336
nickel C 21 336
sensitivity C 22 336
the C 23 336
reaction C 24 336
between C 25 336
nickel C 26 336
and C 27 336
proteins C 28 336
was C 29 336
studied C 30 336
using C 31 336
the C 32 336
technique C 33 336
of C 34 336
equilibrium C 35 336
dialysis C 36 336
. C 37 336
in C 39 336
most C 40 336
of C 41 336
the C 42 336
experiments C 43 336
crystalline C 44 336
bovine C 45 336
serum C 46 336
albumen C 47 336
was C 48 336
used C 49 336
. C 50 336
the C 52 336
nickel C 53 336
- C 54 336
protein C 55 336
complex C 56 336
was C 57 336
of C 58 336
low C 59 336
stability C 60 336
, C 61 336
the C 62 336
quantity C 63 336
of C 64 336
nickel C 65 336
bound C 66 336
by C 67 336
the C 68 336
protein C 69 336
being C 70 336
dependent C 71 336
on C 72 336
the C 73 336
concentration C 74 336
of C 75 336
free C 76 336
nickel C 77 336
ions C 78 336
, C 79 336
the C 80 336
ph C 81 336
, C 82 336
and C 83 336
the C 84 336
particular C 85 336
protein C 86 336
used C 87 336
. C 88 336
the C 90 336
sites C 91 336
of C 92 336
binding C 93 336
of C 94 336
the C 95 336
nickel C 96 336
ions C 97 336
were C 98 336
primarily C 99 336
carboxyl C 100 336
and C 101 336
amino C 102 336
groups C 103 336
. C 104 336
the C 106 336
author C 107 336
concluded C 108 336
that C 109 336
it C 110 336
was C 111 336
unlikely C 112 336
that C 113 336
nickel C 114 336
behaved C 115 336
as C 116 336
a C 117 336
hapten C 118 336
capable C 119 336
of C 120 336
initiating C 121 336
an C 122 336
allergic C 123 336
response C 124 336
. C 125 336
2596 C 1 337
. C 2 337
experimental C 4 337
nickel C 5 337
contact C 6 337
sensitization C 7 337
in C 8 337
man C 9 337
in C 10 337
16 C 11 337
of C 12 337
172 C 13 337
male C 14 337
prisoners C 15 337
contact C 16 337
- C 17 337
type C 18 337
delayed C 19 337
hypersensitivity C 20 337
was C 21 337
induced C 22 337
experimentally C 23 337
by C 24 337
repeated C 25 337
application C 26 337
of C 27 337
25 C 28 337
% C 29 337
nicl C 30 337
2 C 31 337
in C 32 337
a C 33 337
0 C 34 337
. C 35 337
. C 36 337
% C 37 337
sodium C 38 337
lauryl C 39 337
sulphate C 40 337
solution C 41 337
on C 42 337
the C 43 337
skin C 44 337
. C 45 337
test C 47 337
reactions C 48 337
with C 49 337
5 C 50 337
% C 51 337
nicl C 52 337
2 C 53 337
with C 54 337
occlusion C 55 337
were C 56 337
found C 57 337
to C 58 337
be C 59 337
irritating C 60 337
. C 61 337
no C 63 337
experimentally C 64 337
sensitized C 65 337
subject C 66 337
demonstrated C 67 337
clinical C 68 337
sensitivity C 69 337
to C 70 337
the C 71 337
metal C 72 337
in C 73 337
his C 74 337
environment C 75 337
. C 76 337
1013 C 1 338
. C 2 338
hand C 4 338
eczema C 5 338
the C 6 338
clinical C 7 338
aspects C 8 338
of C 9 338
106 C 10 338
cases C 11 338
of C 12 338
hand C 13 338
eczema C 14 338
are C 15 338
reviewed C 16 338
. C 17 338
the C 19 338
clinical C 20 338
types C 21 338
are C 22 338
defined C 23 338
nummular C 24 338
eczema C 25 338
, C 26 338
nickel C 27 338
allergy C 28 338
, C 29 338
atopic C 30 338
dermatitis C 31 338
, C 32 338
hyperkeratotic C 33 338
dermatitis C 34 338
of C 35 338
the C 36 338
palms C 37 338
, C 38 338
hand C 39 338
eczema C 40 338
post C 41 338
partum C 42 338
, C 43 338
mycotic C 44 338
eczema C 45 338
, C 46 338
contact C 47 338
dermatitis C 48 338
, C 49 338
occupational C 50 338
eczema C 51 338
and C 52 338
idiopathic C 53 338
eczema C 54 338
. C 55 338
the C 57 338
results C 58 338
of C 59 338
the C 60 338
patch C 61 338
tests C 62 338
, C 63 338
the C 64 338
influence C 65 338
of C 66 338
psychological C 67 338
and C 68 338
psychiatric C 69 338
factors C 70 338
, C 71 338
the C 72 338
effect C 73 338
of C 74 338
water C 75 338
and C 76 338
cleansers C 77 338
, C 78 338
the C 79 338
diagnosis C 80 338
, C 81 338
treatment C 82 338
and C 83 338
prognosis C 84 338
are C 85 338
discussed C 86 338
. C 87 338
in C 89 338
39 C 90 338
% C 91 338
no C 92 338
significant C 93 338
causative C 94 338
factor C 95 338
could C 96 338
be C 97 338
found C 98 338
. C 99 338
in C 101 338
many C 102 338
cases C 103 338
where C 104 338
causative C 105 338
factors C 106 338
could C 107 338
be C 108 338
identified C 109 338
these C 110 338
were C 111 338
probably C 112 338
no C 113 338
more C 114 338
than C 115 338
contributory C 116 338
, C 117 338
superimposed C 118 338
upon C 119 338
an C 120 338
underlying C 121 338
idiopathic C 122 338
eczema C 123 338
. C 124 338
670 C 1 339
. C 2 339
steroid C 4 339
aerosol C 5 339
spray C 6 339
in C 7 339
contact C 8 339
dermatitis C 9 339
. C 10 339
prophylactic C 12 339
use C 13 339
with C 14 339
particular C 15 339
reference C 16 339
to C 17 339
nickel C 18 339
hypersensitivity C 19 339
proper C 20 339
use C 21 339
of C 22 339
topical C 23 339
aerosol C 24 339
dexamethasone C 25 339
( C 26 339
decadron C 27 339
) C 28 339
spray C 29 339
affords C 30 339
complete C 31 339
protection C 32 339
to C 33 339
patients C 34 339
with C 35 339
nickel C 36 339
sensitivity C 37 339
. C 38 339
this C 40 339
clinical C 41 339
result C 42 339
is C 43 339
confirmed C 44 339
by C 45 339
the C 46 339
results C 47 339
of C 48 339
patch C 49 339
testing C 50 339
nickel C 51 339
- C 52 339
sensitive C 53 339
patients C 54 339
with C 55 339
a C 56 339
5 C 57 339
% C 58 339
nickel C 59 339
sulfate C 60 339
solution C 61 339
and C 62 339
nickel C 63 339
coins C 64 339
. C 65 339
a C 67 339
combination C 68 339
of C 69 339
dexamethasone C 70 339
and C 71 339
an C 72 339
isopropylmyristate C 73 339
film C 74 339
is C 75 339
necessary C 76 339
for C 77 339
successful C 78 339
prophylaxis C 79 339
; C 80 339
the C 81 339
individual C 82 339
components C 83 339
alone C 84 339
do C 85 339
not C 86 339
protect C 87 339
these C 88 339
patients C 89 339
. C 90 339
clinical C 92 339
and C 93 339
patch C 94 339
test C 95 339
results C 96 339
indicate C 97 339
that C 98 339
a C 99 339
moderate C 100 339
degree C 101 339
of C 102 339
protection C 103 339
is C 104 339
afforded C 105 339
to C 106 339
patients C 107 339
with C 108 339
paraphenylenediamine C 109 339
sensitivity C 110 339
. C 111 339
patch C 113 339
test C 114 339
results C 115 339
indicate C 116 339
that C 117 339
the C 118 339
spray C 119 339
does C 120 339
not C 121 339
protect C 122 339
against C 123 339
poison C 124 339
ivy C 125 339
and C 126 339
ragweed C 127 339
oleoresin C 128 339
, C 129 339
potassium C 130 339
dichromate C 131 339
, C 132 339
certain C 133 339
rubber C 134 339
accelerators C 135 339
, C 136 339
and C 137 339
monobenzyl C 138 339
ether C 139 339
of C 140 339
hydroquinone C 141 339
. C 142 339
it C 144 339
affords C 145 339
a C 146 339
moderate C 147 339
protection C 148 339
against C 149 339
formaldehyde C 150 339
. C 151 339
no C 153 339
tests C 154 339
were C 155 339
done C 156 339
with C 157 339
patients C 158 339
with C 159 339
formaldehyde C 160 339
hypersensitivity C 161 339
. C 162 339
a C 164 339
fair C 165 339
degree C 166 339
of C 167 339
protection C 168 339
was C 169 339
obtained C 170 339
by C 171 339
the C 172 339
use C 173 339
of C 174 339
the C 175 339
spray C 176 339
in C 177 339
housewives C 178 339
eczema C 179 339
presumably C 180 339
due C 181 339
to C 182 339
irritants C 183 339
present C 184 339
in C 185 339
soap C 186 339
and C 187 339
detergents C 188 339
. C 189 339
2078 C 1 340
. C 2 340
the C 4 340
pathogenesis C 5 340
of C 6 340
contact C 7 340
eczema C 8 340
due C 9 340
to C 10 340
detergents C 11 340
for C 12 340
domestic C 13 340
use C 14 340
the C 15 340
thesis C 16 340
is C 17 340
maintained C 18 340
that C 19 340
eczema C 20 340
due C 21 340
to C 22 340
household C 23 340
detergents C 24 340
is C 25 340
pathogenically C 26 340
linked C 27 340
with C 28 340
allergic C 29 340
contact C 30 340
sensitization C 31 340
to C 32 340
metallic C 33 340
salts C 34 340
, C 35 340
especially C 36 340
chromium C 37 340
and C 38 340
nickel C 39 340
. C 40 340
in C 42 340
a C 43 340
series C 44 340
of C 45 340
20 C 46 340
cases C 47 340
of C 48 340
contact C 49 340
eczema C 50 340
attributable C 51 340
to C 52 340
detergents C 53 340
, C 54 340
the C 55 340
existence C 56 340
of C 57 340
sensitization C 58 340
to C 59 340
these C 60 340
metals C 61 340
was C 62 340
demonstrated C 63 340
by C 64 340
the C 65 340
patch C 66 340
test C 67 340
. C 68 340
likewise C 70 340
, C 71 340
in C 72 340
the C 73 340
analysis C 74 340
of C 75 340
9 C 76 340
samples C 77 340
of C 78 340
different C 79 340
detergents C 80 340
used C 81 340
for C 82 340
washing C 83 340
, C 84 340
in C 85 340
all C 86 340
of C 87 340
them C 88 340
chromium C 89 340
and C 90 340
nickel C 91 340
were C 92 340
found C 93 340
to C 94 340
be C 95 340
present C 96 340
in C 97 340
a C 98 340
proportion C 99 340
which C 100 340
, C 101 340
for C 102 340
either C 103 340
of C 104 340
these C 105 340
metals C 106 340
, C 107 340
varied C 108 340
between C 109 340
1 C 110 340
and C 111 340
5 C 112 340
p C 113 340
. C 114 340
. C 115 340
. C 116 340
. C 117 340
. C 118 340
4010 C 1 341
. C 2 341
studies C 4 341
of C 5 341
nickel C 6 341
carcinogenesis C 7 341
. C 8 341
the C 10 341
subcellular C 11 341
partition C 12 341
of C 13 341
nickel C 14 341
in C 15 341
lung C 16 341
and C 17 341
liver C 18 341
following C 19 341
inhalation C 20 341
of C 21 341
nickel C 22 341
carbonyl C 23 341
wistar C 24 341
rats C 25 341
were C 26 341
exposed C 27 341
by C 28 341
inhalation C 29 341
to C 30 341
nickel C 31 341
carbonyl C 32 341
either C 33 341
once C 34 341
only C 35 341
at C 36 341
a C 37 341
concentration C 38 341
of C 39 341
80 C 40 341
ppm C 41 341
for C 42 341
60 C 43 341
minutes C 44 341
( C 45 341
0 C 46 341
. C 47 341
. C 48 341
. C 48 341
mg C 49 341
ni C 50 341
( C 51 341
co C 52 341
) C 53 341
4 C 54 341
/ C 55 341
l C 56 341
. C 57 341
. C 58 341
. C 58 341
. C 58 341
) C 59 341
, C 60 341
or C 61 341
repeatedly C 62 341
at C 63 341
4 C 64 341
ppm C 65 341
( C 66 341
0 C 67 341
. C 68 341
. C 69 341
. C 69 341
mg C 70 341
ni C 71 341
( C 72 341
co C 73 341
) C 74 341
4 C 75 341
/ C 76 341
l C 77 341
. C 78 341
air C 80 341
) C 81 341
for C 82 341
30 C 83 341
minutes C 84 341
3 C 85 341
times C 86 341
weekly C 87 341
for C 88 341
1 C 89 341
year C 90 341
. C 91 341
they C 93 341
were C 94 341
killed C 95 341
24 C 96 341
hours C 97 341
after C 98 341
( C 99 341
the C 100 341
final C 101 341
period C 102 341
of C 103 341
) C 104 341
exposure C 105 341
. C 106 341
nuclear C 108 341
, C 109 341
mitochondrial C 110 341
, C 111 341
microsomal C 112 341
and C 113 341
supernatant C 114 341
fractions C 115 341
were C 116 341
isolated C 117 341
from C 118 341
lung C 119 341
and C 120 341
liver C 121 341
homogenates C 122 341
and C 123 341
measurements C 124 341
of C 125 341
the C 126 341
nickel C 127 341
, C 128 341
nitrogen C 129 341
and C 130 341
rna C 131 341
- C 132 341
content C 133 341
of C 134 341
each C 135 341
subcellular C 136 341
fraction C 137 341
were C 138 341
made C 139 341
. C 140 341
the C 142 341
greatest C 143 341
ratios C 144 341
of C 145 341
nickel C 146 341
to C 147 341
nitrogen C 148 341
were C 149 341
in C 150 341
the C 151 341
nuclear C 152 341
fractions C 153 341
of C 154 341
both C 155 341
liver C 156 341
and C 157 341
lung C 158 341
, C 159 341
but C 160 341
increased C 161 341
amounts C 162 341
of C 163 341
nickel C 164 341
were C 165 341
also C 166 341
found C 167 341
in C 168 341
the C 169 341
microsomal C 170 341
and C 171 341
supernatant C 172 341
fractions C 173 341
of C 174 341
both C 175 341
liver C 176 341
and C 177 341
lung C 178 341
and C 179 341
in C 180 341
the C 181 341
mitochondrial C 182 341
fraction C 183 341
of C 184 341
lung C 185 341
. C 186 341
188 C 1 342
. C 2 342
studies C 4 342
of C 5 342
nickel C 6 342
carcinogenesis C 7 342
; C 8 342
metastasizing C 9 342
pulmonary C 10 342
tumors C 11 342
in C 12 342
rats C 13 342
induced C 14 342
by C 15 342
the C 16 342
inhalation C 17 342
of C 18 342
nickel C 19 342
carbonyl C 20 342
in C 21 342
a C 22 342
combined C 23 342
series C 24 342
of C 25 342
studies C 26 342
, C 27 342
6 C 28 342
out C 29 342
of C 30 342
409 C 31 342
rats C 32 342
( C 33 342
n C 34 342
. C 35 342
. C 36 342
. C 37 342
only C 39 342
195 C 40 342
survived C 41 342
for C 42 342
more C 43 342
than C 44 342
3 C 45 342
wk C 46 342
. C 47 342
) C 49 342
exposed C 50 342
to C 51 342
nickel C 52 342
carbonyl C 53 342
developed C 54 342
pulmonary C 55 342
carcinoma C 56 342
with C 57 342
metastases C 58 342
. C 59 342
the C 61 342
lesions C 62 342
included C 63 342
the C 64 342
common C 65 342
types C 66 342
of C 67 342
pulmonary C 68 342
cancer C 69 342
, C 70 342
squamous C 71 342
cell C 72 342
carcinoma C 73 342
, C 74 342
adenocarcinoma C 75 342
and C 76 342
anaplastic C 77 342
carcinoma C 78 342
. C 79 342
all C 81 342
of C 82 342
the C 83 342
pulmonary C 84 342
lesions C 85 342
were C 86 342
found C 87 342
between C 88 342
24 C 89 342
and C 90 342
27 C 91 342
mth C 92 342
. C 93 342
after C 95 342
the C 96 342
initial C 97 342
exposure C 98 342
to C 99 342
nickel C 100 342
carbonyl C 101 342
. C 102 342
the C 104 342
amount C 105 342
of C 106 342
nickel C 107 342
found C 108 342
capable C 109 342
of C 110 342
inducing C 111 342
lung C 112 342
cancer C 113 342
in C 114 342
the C 115 342
rat C 116 342
was C 117 342
comparable C 118 342
to C 119 342
the C 120 342
amount C 121 342
of C 122 342
nickel C 123 342
inhaled C 124 342
by C 125 342
persons C 126 342
smoking C 127 342
less C 128 342
than C 129 342
15 C 130 342
cigarettes C 131 342
per C 132 342
day C 133 342
for C 134 342
a C 135 342
period C 136 342
of C 137 342
a C 138 342
year C 139 342
. C 140 342
the C 142 342
mean C 143 342
weight C 144 342
of C 145 342
rats C 146 342
chronically C 147 342
exposed C 148 342
to C 149 342
nickel C 150 342
carbonyl C 151 342
was C 152 342
found C 153 342
to C 154 342
be C 155 342
consistently C 156 342
less C 157 342
than C 158 342
that C 159 342
of C 160 342
the C 161 342
control C 162 342
rats C 163 342
throughout C 164 342
the C 165 342
entire C 166 342
3 C 167 342
- C 168 342
year C 169 342
period C 170 342
of C 171 342
study C 172 342
. C 173 342
189 C 1 343
. C 2 343
influence C 4 343
of C 5 343
age C 6 343
, C 7 343
sex C 8 343
and C 9 343
glandular C 10 343
extirpation C 11 343
on C 12 343
muscle C 13 343
carcinogenesis C 14 343
in C 15 343
rats C 16 343
the C 17 343
carcinogenic C 18 343
effect C 19 343
of C 20 343
a C 21 343
single C 22 343
intramuscular C 23 343
injection C 24 343
of C 25 343
nickel C 26 343
sulphide C 27 343
in C 28 343
an C 29 343
aqueous C 30 343
suspension C 31 343
to C 32 343
which C 33 343
penicillin C 34 343
g C 35 343
had C 36 343
been C 37 343
added C 38 343
was C 39 343
compared C 40 343
in C 41 343
male C 42 343
and C 43 343
female C 44 343
castrated C 45 343
, C 46 343
hypophysectomized C 47 343
or C 48 343
intact C 49 343
, C 50 343
rats C 51 343
of C 52 343
different C 53 343
ages C 54 343
. C 55 343
the C 57 343
response C 58 343
seemed C 59 343
most C 60 343
marked C 61 343
in C 62 343
intact C 63 343
females C 64 343
injected C 65 343
when C 66 343
2 C 67 343
mth C 68 343
. C 69 343
old C 71 343
. C 72 343
castrated C 74 343
or C 75 343
hypophysectomized C 76 343
2 C 77 343
- C 78 343
month C 79 343
old C 80 343
females C 81 343
were C 82 343
less C 83 343
responsive C 84 343
. C 85 343
one C 87 343
- C 88 343
month C 89 343
old C 90 343
intact C 91 343
males C 92 343
were C 93 343
more C 94 343
responsive C 95 343
than C 96 343
2 C 97 343
- C 98 343
month C 99 343
or C 100 343
3 C 101 343
- C 102 343
month C 103 343
old C 104 343
intact C 105 343
males C 106 343
, C 107 343
1 C 108 343
- C 109 343
month C 110 343
old C 111 343
castrated C 112 343
males C 113 343
, C 114 343
or C 115 343
1 C 116 343
- C 117 343
month C 118 343
old C 119 343
intact C 120 343
females C 121 343
. C 122 343
more C 124 343
data C 125 343
would C 126 343
be C 127 343
required C 128 343
before C 129 343
firm C 130 343
conclusions C 131 343
could C 132 343
be C 133 343
drawn C 134 343
from C 135 343
these C 136 343
results C 137 343
. C 138 343
3176 C 1 344
. C 2 344
studies C 4 344
of C 5 344
trace C 6 344
metal C 7 344
metabolism C 8 344
electron C 9 344
paramagnetic C 10 344
resonance C 11 344
of C 12 344
manganese C 13 344
in C 14 344
ribonucleic C 15 344
acids C 16 344
the C 17 344
electron C 18 344
paramagnetic C 19 344
resonance C 20 344
spectrum C 21 344
pattern C 22 344
of C 23 344
manganese C 24 344
was C 25 344
readily C 26 344
detected C 27 344
in C 28 344
all C 29 344
of C 30 344
the C 31 344
samples C 32 344
of C 33 344
rna C 34 344
. C 35 344
the C 37 344
resonance C 38 344
patterns C 39 344
indicate C 40 344
that C 41 344
manganese C 42 344
is C 43 344
present C 44 344
in C 45 344
rna C 46 344
in C 47 344
a C 48 344
divalent C 49 344
state C 50 344
and C 51 344
suggest C 52 344
that C 53 344
manganese C 54 344
is C 55 344
located C 56 344
at C 57 344
the C 58 344
center C 59 344
of C 60 344
a C 61 344
distorted C 62 344
octahedron C 63 344
of C 64 344
oxygen C 65 344
atoms C 66 344
. C 67 344
from C 69 344
the C 70 344
intensity C 71 344
of C 72 344
nominally C 73 344
forbidden C 74 344
resonances C 75 344
, C 76 344
the C 77 344
crystal C 78 344
field C 79 344
splitting C 80 344
parameter C 81 344
d C 82 344
was C 83 344
estimated C 84 344
to C 85 344
be C 86 344
0 C 87 344
. C 88 344
. C 89 344
. C 89 344
cm C 90 344
- C 91 344
1 C 92 344
. C 93 344
4790 C 1 345
. C 2 345
metal C 4 345
chelates C 5 345
as C 6 345
potential C 7 345
reactivators C 8 345
of C 9 345
organic C 10 345
phosphate C 11 345
poisoned C 12 345
acetylcholinesterase C 13 345
as C 14 345
part C 15 345
of C 16 345
a C 17 345
study C 18 345
to C 19 345
investigate C 20 345
metal C 21 345
chelates C 22 345
as C 23 345
possible C 24 345
reactivators C 25 345
of C 26 345
phosphate C 27 345
poisoned C 28 345
acetylcholinesterase C 29 345
, C 30 345
it C 31 345
is C 32 345
shown C 33 345
that C 34 345
chelates C 35 345
act C 36 345
as C 37 345
inhibitors C 38 345
of C 39 345
the C 40 345
enzyme C 41 345
. C 42 345
in C 44 345
addition C 45 345
, C 46 345
copper C 47 345
and C 48 345
nickel C 49 345
chelates C 50 345
of C 51 345
2 C 52 345
- C 53 345
pyridinealdoxime C 54 345
catalyze C 55 345
the C 56 345
decomposition C 57 345
of C 58 345
dfp C 59 345
and C 60 345
sarin C 61 345
. C 62 345
compared C 64 345
to C 65 345
2 C 66 345
- C 67 345
pam C 68 345
, C 69 345
however C 70 345
, C 71 345
these C 72 345
chelates C 73 345
are C 74 345
very C 75 345
poor C 76 345
reactivators C 77 345
, C 78 345
probably C 79 345
because C 80 345
of C 81 345
an C 82 345
improper C 83 345
alignment C 84 345
of C 85 345
the C 86 345
oxine C 87 345
oxygen C 88 345
in C 89 345
the C 90 345
chelate C 91 345
- C 92 345
enzyme C 93 345
complex C 94 345
. C 95 345
3446 C 1 346
. C 2 346
effect C 4 346
of C 5 346
nicl C 6 346
2 C 7 346
on C 8 346
an C 9 346
isolated C 10 346
ranvier C 11 346
node C 12 346
an C 13 346
attempt C 14 346
was C 15 346
made C 16 346
to C 17 346
explain C 18 346
the C 19 346
extreme C 20 346
prolongation C 21 346
of C 22 346
the C 23 346
nodal C 24 346
potential C 25 346
by C 26 346
0 C 27 346
. C 28 346
. C 29 346
- C 30 346
1 C 31 346
. C 32 346
. C 33 346
mm C 34 346
nicl C 35 346
2 C 36 346
in C 37 346
terms C 38 346
of C 39 346
the C 40 346
ionic C 41 346
theory C 42 346
. C 43 346
the C 45 346
effects C 46 346
of C 47 346
nicl C 48 346
2 C 49 346
at C 50 346
room C 51 346
temperature C 52 346
are C 53 346
similar C 54 346
to C 55 346
those C 56 346
of C 57 346
temperature C 58 346
reduction C 59 346
decreased C 60 346
maximum C 61 346
rate C 62 346
of C 63 346
rise C 64 346
of C 65 346
the C 66 346
action C 67 346
potential C 68 346
, C 69 346
lengthened C 70 346
action C 71 346
potential C 72 346
duration C 73 346
, C 74 346
elevated C 75 346
threshold C 76 346
, C 77 346
increased C 78 346
tendency C 79 346
for C 80 346
repetitive C 81 346
activity C 82 346
; C 83 346
in C 84 346
addition C 85 346
, C 86 346
the C 87 346
amplitude C 88 346
of C 89 346
the C 90 346
action C 91 346
potential C 92 346
is C 93 346
slightly C 94 346
increased C 95 346
. C 96 346
the C 98 346
long C 99 346
- C 100 346
lasting C 101 346
plateaus C 102 346
of C 103 346
the C 104 346
responses C 105 346
obtained C 106 346
under C 107 346
the C 108 346
combined C 109 346
influence C 110 346
of C 111 346
nicl C 112 346
2 C 113 346
and C 114 346
temperature C 115 346
reduction C 116 346
are C 117 346
shortened C 118 346
by C 119 346
cathodal C 120 346
polarization C 121 346
, C 122 346
strong C 123 346
anodal C 124 346
polarization C 125 346
and C 126 346
decrease C 127 346
of C 128 346
( C 129 346
na C 130 346
) C 131 346
0 C 132 346
. C 133 346
the C 135 346
plateau C 136 346
can C 137 346
be C 138 346
prematurely C 139 346
terminated C 140 346
by C 141 346
short C 142 346
anodal C 143 346
pulses C 144 346
of C 145 346
critical C 146 346
amplitude C 147 346
; C 148 346
short C 149 346
cathodal C 150 346
pulses C 151 346
reduce C 152 346
the C 153 346
duration C 154 346
of C 155 346
the C 156 346
plateau C 157 346
gradually C 158 346
with C 159 346
increasing C 160 346
pulse C 161 346
strength C 162 346
. C 163 346
increased C 165 346
( C 166 346
k C 167 346
) C 168 346
0 C 169 346
prolongs C 170 346
plateau C 171 346
duration C 172 346
; C 173 346
the C 174 346
steep C 175 346
repolarization C 176 346
phase C 177 346
which C 178 346
normally C 179 346
terminates C 180 346
the C 181 346
plateau C 182 346
is C 183 346
replaced C 184 346
by C 185 346
a C 186 346
long C 187 346
lasting C 188 346
after C 189 346
- C 190 346
depolarization C 191 346
with C 192 346
stepwise C 193 346
potential C 194 346
decline C 195 346
. C 196 346
the C 198 346
amplitude C 199 346
of C 200 346
k C 201 346
- C 202 346
depolarization C 203 346
is C 204 346
not C 205 346
influenced C 206 346
by C 207 346
nicl C 208 346
2 C 209 346
or C 210 346
temperature C 211 346
reduction C 212 346
. C 213 346
1 C 215 346
. C 216 346
. C 217 346
mm C 218 346
nicl C 219 346
2 C 220 346
changes C 221 346
the C 222 346
relation C 223 346
between C 224 346
maximum C 225 346
rate C 226 346
of C 227 346
rise C 228 346
and C 229 346
steady C 230 346
- C 231 346
state C 232 346
polarization C 233 346
; C 234 346
the C 235 346
potential C 236 346
change C 237 346
required C 238 346
for C 239 346
50 C 240 346
% C 241 346
sodium C 242 346
inactivation C 243 346
is C 244 346
+ C 245 346
8 C 246 346
mv C 247 346
in C 248 346
normal C 249 346
ringer C 250 346
' C 251 346
s C 252 346
solution C 253 346
and C 254 346
+ C 255 346
16 C 256 346
mv C 257 346
in C 258 346
the C 259 346
presence C 260 346
of C 261 346
1 C 262 346
. C 263 346
. C 264 346
mm C 265 346
nicl C 266 346
2 C 267 346
( C 268 346
22 C 269 346
c C 270 346
. C 271 346
) C 273 346
. C 274 346
1 C 276 346
. C 277 346
. C 278 346
mm C 279 346
nicl C 280 346
2 C 281 346
increases C 282 346
the C 283 346
time C 284 346
constant C 285 346
of C 286 346
delayed C 287 346
rectification C 288 346
as C 289 346
measured C 290 346
in C 291 346
na C 292 346
- C 293 346
poor C 294 346
solutions C 295 346
at C 296 346
4 C 297 346
c C 298 346
. C 299 346
by C 301 346
a C 302 346
factor C 303 346
of C 304 346
about C 305 346
2 C 306 346
. C 307 346
the C 309 346
decrease C 310 346
of C 311 346
action C 312 346
potential C 313 346
under C 314 346
cathodal C 315 346
polarization C 316 346
is C 317 346
slightly C 318 346
delayed C 319 346
by C 320 346
nicl C 321 346
2 C 322 346
. C 323 346
it C 325 346
is C 326 346
concluded C 327 346
that C 328 346
prolongation C 329 346
of C 330 346
the C 331 346
nodal C 332 346
action C 333 346
potential C 334 346
by C 335 346
nicl C 336 346
2 C 337 346
is C 338 346
due C 339 346
to C 340 346
delayed C 341 346
and C 342 346
reduced C 343 346
inactivation C 344 346
of C 345 346
na C 346 346
permeability C 347 346
and C 348 346
delayed C 349 346
increase C 350 346
of C 351 346
k C 352 346
permeability C 353 346
; C 354 346
part C 355 346
of C 356 346
the C 357 346
nicl C 358 346
2 C 359 346
- C 360 346
effect C 361 346
could C 362 346
be C 363 346
explained C 364 346
by C 365 346
assuming C 366 346
competition C 367 346
between C 368 346
ni C 369 346
+ C 370 346
+ C 371 346
and C 372 346
ca C 373 346
+ C 374 346
+ C 375 346
for C 376 346
specific C 377 346
sites C 378 346
at C 379 346
the C 380 346
membrane C 381 346
. C 382 346
2302 C 1 347
. C 2 347
the C 4 347
carcinogenic C 5 347
activities C 6 347
of C 7 347
n C 8 347
- C 9 347
hydroxy C 10 347
- C 11 347
2 C 12 347
- C 13 347
acetylaminofluorene C 14 347
and C 15 347
its C 16 347
metal C 17 347
chelates C 18 347
as C 19 347
a C 20 347
function C 21 347
of C 22 347
retention C 23 347
at C 24 347
the C 25 347
injection C 26 347
site C 27 347
the C 28 347
carcinogenic C 29 347
activities C 30 347
of C 31 347
s C 32 347
. C 33 347
. C 34 347
. C 35 347
administered C 37 347
n C 38 347
- C 39 347
hydroxy C 40 347
- C 41 347
2 C 42 347
- C 43 347
acetylaminofluorene C 44 347
( C 45 347
n C 46 347
- C 47 347
hydroxy C 48 347
- C 49 347
aaf C 50 347
) C 51 347
and C 52 347
a C 53 347
variety C 54 347
of C 55 347
its C 56 347
metal C 57 347
chelates C 58 347
indicate C 59 347
that C 60 347
greater C 61 347
activity C 62 347
locally C 63 347
is C 64 347
associated C 65 347
with C 66 347
a C 67 347
longer C 68 347
retention C 69 347
of C 70 347
the C 71 347
chelates C 72 347
at C 73 347
the C 74 347
site C 75 347
of C 76 347
injection C 77 347
with C 78 347
a C 79 347
slow C 80 347
release C 81 347
of C 82 347
n C 83 347
- C 84 347
hydroxy C 85 347
- C 86 347
aaf C 87 347
to C 88 347
the C 89 347
surrounding C 90 347
tissue C 91 347
. C 92 347
no C 94 347
tumors C 95 347
were C 96 347
obtained C 97 347
at C 98 347
the C 99 347
sites C 100 347
of C 101 347
4 C 102 347
injections C 103 347
of C 104 347
n C 105 347
- C 106 347
hydroxy C 107 347
- C 108 347
aaf C 109 347
( C 110 347
3 C 111 347
. C 112 347
. C 113 347
mg C 114 347
. C 115 347
/ C 117 347
injection C 118 347
) C 119 347
, C 120 347
but C 121 347
4 C 122 347
and C 123 347
16 C 124 347
of C 125 347
20 C 126 347
rats C 127 347
developed C 128 347
sarcomas C 129 347
at C 130 347
the C 131 347
sites C 132 347
of C 133 347
8 C 134 347
and C 135 347
16 C 136 347
injections C 137 347
, C 138 347
respectively C 139 347
. C 140 347
the C 142 347
nickelous C 143 347
, C 144 347
cobaltous C 145 347
, C 146 347
ferric C 147 347
, C 148 347
or C 149 347
cupric C 150 347
chelates C 151 347
induced C 152 347
moderate C 153 347
to C 154 347
high C 155 347
incidences C 156 347
of C 157 347
sarcomas C 158 347
with C 159 347
1 C 160 347
or C 161 347
4 C 162 347
injections C 163 347
; C 164 347
in C 165 347
these C 166 347
cases C 167 347
one C 168 347
- C 169 347
half C 170 347
of C 171 347
the C 172 347
administered C 173 347
n C 174 347
- C 175 347
hydroxy C 176 347
- C 177 347
aaf C 178 347
was C 179 347
retained C 180 347
at C 181 347
the C 182 347
injection C 183 347
site C 184 347
for C 185 347
4 C 186 347
- C 187 347
50 C 188 347
days C 189 347
. C 190 347
the C 192 347
manganous C 193 347
and C 194 347
zinc C 195 347
chelates C 196 347
and C 197 347
the C 198 347
potassium C 199 347
salt C 200 347
were C 201 347
less C 202 347
active C 203 347
at C 204 347
the C 205 347
injection C 206 347
site C 207 347
; C 208 347
the C 209 347
half C 210 347
- C 211 347
retention C 212 347
times C 213 347
for C 214 347
these C 215 347
ranged C 216 347
from C 217 347
2 C 218 347
. C 219 347
. C 220 347
hr C 221 347
. C 222 347
to C 224 347
2 C 225 347
. C 226 347
. C 227 347
days C 228 347
. C 229 347
the C 231 347
comparable C 232 347
half C 233 347
- C 234 347
retention C 235 347
time C 236 347
for C 237 347
n C 238 347
- C 239 347
hydroxy C 240 347
- C 241 347
aaf C 242 347
was C 243 347
about C 244 347
2 C 245 347
hr C 246 347
. C 247 347
injection C 249 347
of C 250 347
the C 251 347
metal C 252 347
derivatives C 253 347
s C 254 347
. C 255 347
c C 257 347
. C 258 347
with C 260 347
short C 261 347
half C 262 347
- C 263 347
retention C 264 347
times C 265 347
resulted C 266 347
in C 267 347
higher C 268 347
incidences C 269 347
of C 270 347
mammary C 271 347
tumors C 272 347
than C 273 347
injection C 274 347
of C 275 347
the C 276 347
derivatives C 277 347
with C 278 347
half C 279 347
- C 280 347
retention C 281 347
times C 282 347
of C 283 347
4 C 284 347
or C 285 347
more C 286 347
days C 287 347
. C 288 347
when C 290 347
administered C 291 347
in C 292 347
the C 293 347
food C 294 347
the C 295 347
cupric C 296 347
chelate C 297 347
of C 298 347
n C 299 347
- C 300 347
hydroxy C 301 347
- C 302 347
aaf C 303 347
induced C 304 347
the C 305 347
same C 306 347
spectrum C 307 347
of C 308 347
tumors C 309 347
as C 310 347
n C 311 347
- C 312 347
hydroxy C 313 347
- C 314 347
aaf C 315 347
, C 316 347
but C 317 347
the C 318 347
incidences C 319 347
were C 320 347
lower C 321 347
. C 322 347
while C 324 347
the C 325 347
prolonged C 326 347
retention C 327 347
of C 328 347
the C 329 347
material C 330 347
at C 331 347
the C 332 347
injection C 333 347
site C 334 347
may C 335 347
account C 336 347
for C 337 347
the C 338 347
greater C 339 347
carcinogenic C 340 347
activities C 341 347
of C 342 347
the C 343 347
metal C 344 347
chelates C 345 347
, C 346 347
serious C 347 347
consideration C 348 347
must C 349 347
also C 350 347
be C 351 347
given C 352 347
to C 353 347
the C 354 347
possible C 355 347
importance C 356 347
of C 357 347
chelation C 358 347
of C 359 347
carcinogens C 360 347
or C 361 347
their C 362 347
metabolites C 363 347
to C 364 347
cellular C 365 347
constituents C 366 347
. C 367 347
12083 C 1 348
. C 2 348
generation C 4 348
of C 5 348
action C 6 348
potentials C 7 348
in C 8 348
single C 9 348
ranvier C 10 348
' C 11 348
s C 12 348
nodes C 13 348
of C 14 348
isolated C 15 348
frog C 16 348
nerve C 17 348
fibres C 18 348
under C 19 348
the C 20 348
influence C 21 348
of C 22 348
nickel C 23 348
and C 24 348
cadmium C 25 348
ions C 26 348
( C 27 348
russian C 28 348
) C 29 348
by C 30 348
experimenting C 31 348
on C 32 348
single C 33 348
ranvier C 34 348
' C 35 348
s C 36 348
nodes C 37 348
of C 38 348
frog C 39 348
isolated C 40 348
nerve C 41 348
fibres C 42 348
it C 43 348
was C 44 348
shown C 45 348
that C 46 348
, C 47 348
along C 48 348
with C 49 348
a C 50 348
marked C 51 348
prolongation C 52 348
of C 53 348
the C 54 348
repolarization C 55 348
phase C 56 348
of C 57 348
the C 58 348
action C 59 348
potential C 60 348
( C 61 348
ap C 62 348
) C 63 348
, C 64 348
ni C 65 348
and C 66 348
cd C 67 348
ions C 68 348
also C 69 348
caused C 70 348
a C 71 348
rise C 72 348
of C 73 348
the C 74 348
critical C 75 348
membrane C 76 348
depolarization C 77 348
level C 78 348
and C 79 348
an C 80 348
increased C 81 348
ap C 82 348
amplitude C 83 348
with C 84 348
somewhat C 85 348
reduced C 86 348
steepness C 87 348
of C 88 348
its C 89 348
ascending C 90 348
phase C 91 348
. C 92 348
ni C 94 348
and C 95 348
cd C 96 348
ions C 97 348
restored C 98 348
the C 99 348
ap C 100 348
generation C 101 348
in C 102 348
the C 103 348
nodes C 104 348
of C 105 348
ranvier C 106 348
altered C 107 348
by C 108 348
a C 109 348
0 C 110 348
. C 111 348
. C 112 348
. C 112 348
% C 113 348
procaine C 114 348
solution C 115 348
, C 116 348
by C 117 348
an C 118 348
excess C 119 348
of C 120 348
potassium C 121 348
ions C 122 348
00 C 123 348
mm C 124 348
/ C 125 348
1 C 126 348
. C 127 348
of C 129 348
kcl C 130 348
) C 131 348
or C 132 348
by C 133 348
slight C 134 348
mechanical C 135 348
injury C 136 348
during C 137 348
dissection C 138 348
. C 139 348
it C 141 348
was C 142 348
only C 143 348
with C 144 348
a C 145 348
reduced C 146 348
na C 147 348
concentration C 148 348
in C 149 348
the C 150 348
medium C 151 348
that C 152 348
the C 153 348
restoration C 154 348
of C 155 348
ap C 156 348
could C 157 348
be C 158 348
achieved C 159 348
. C 160 348
ni C 162 348
and C 163 348
cd C 164 348
ions C 165 348
considerably C 166 348
slowed C 167 348
down C 168 348
and C 169 348
weakened C 170 348
the C 171 348
cathodal C 172 348
rise C 173 348
of C 174 348
the C 175 348
critical C 176 348
level C 177 348
and C 178 348
the C 179 348
ap C 180 348
reduction C 181 348
. C 182 348
cysteine C 184 348
( C 185 348
10 C 186 348
- C 187 348
2 C 188 348
to C 189 348
10 C 190 348
- C 191 348
3 C 192 348
m C 193 348
) C 194 348
eliminated C 195 348
all C 196 348
the C 197 348
effects C 198 348
of C 199 348
the C 200 348
mentioned C 201 348
ions C 202 348
. C 203 348
a C 205 348
suggestion C 206 348
is C 207 348
made C 208 348
that C 209 348
by C 210 348
binding C 211 348
the C 212 348
sh C 213 348
- C 214 348
groups C 215 348
of C 216 348
the C 217 348
nerve C 218 348
fibre C 219 348
proteins C 220 348
, C 221 348
nickel C 222 348
and C 223 348
cadmium C 224 348
reduce C 225 348
the C 226 348
rate C 227 348
of C 228 348
inactivation C 229 348
and C 230 348
the C 231 348
increase C 232 348
of C 233 348
potassium C 234 348
permeability C 235 348
in C 236 348
depolarization C 237 348
and C 238 348
also C 239 348
weaken C 240 348
the C 241 348
initial C 242 348
inactivation C 243 348
and C 244 348
the C 245 348
increase C 246 348
of C 247 348
potassium C 248 348
permeability C 249 348
in C 250 348
depolarization C 251 348
, C 252 348
as C 253 348
well C 254 348
as C 255 348
weaken C 256 348
the C 257 348
initial C 258 348
inactivation C 259 348
of C 260 348
the C 261 348
membrane C 262 348
( C 263 348
i C 264 348
- C 265 348
h C 266 348
) C 267 348
, C 268 348
whenever C 269 348
this C 270 348
happened C 271 348
to C 272 348
be C 273 348
raised C 274 348
by C 275 348
previous C 276 348
influences C 277 348
. C 278 348
1287 C 1 349
. C 2 349
agnostic C 4 349
alexia C 5 349
and C 6 349
constructive C 7 349
apraxia C 8 349
with C 9 349
regressive C 10 349
evolution C 11 349
in C 12 349
a C 13 349
child C 14 349
of C 15 349
12 C 16 349
yr C 17 349
. C 18 349
of C 20 349
age C 21 349
after C 22 349
an C 23 349
acute C 24 349
encephalopathy C 25 349
, C 26 349
the C 27 349
etiology C 28 349
of C 29 349
which C 30 349
could C 31 349
not C 32 349
be C 33 349
determined C 34 349
, C 35 349
a C 36 349
boy C 37 349
of C 38 349
11 C 39 349
yr C 40 349
. C 41 349
and C 43 349
10 C 44 349
mth C 45 349
. C 46 349
of C 48 349
age C 49 349
developed C 50 349
a C 51 349
syndrome C 52 349
of C 53 349
agnostic C 54 349
alexia C 55 349
and C 56 349
constructive C 57 349
apraxia C 58 349
which C 59 349
was C 60 349
remarkably C 61 349
pure C 62 349
. C 63 349
the C 65 349
intellectual C 66 349
functions C 67 349
were C 68 349
normal C 69 349
as C 70 349
determined C 71 349
by C 72 349
iq C 73 349
tests C 74 349
, C 75 349
speech C 76 349
was C 77 349
not C 78 349
disturbed C 79 349
either C 80 349
. C 81 349
the C 83 349
child C 84 349
could C 85 349
not C 86 349
read C 87 349
or C 88 349
copy C 89 349
a C 90 349
text C 91 349
, C 92 349
but C 93 349
was C 94 349
fully C 95 349
able C 96 349
to C 97 349
write C 98 349
( C 99 349
both C 100 349
freely C 101 349
and C 102 349
dictated C 103 349
) C 104 349
. C 105 349
the C 107 349
patient C 108 349
could C 109 349
not C 110 349
read C 111 349
what C 112 349
he C 113 349
had C 114 349
written C 115 349
. C 116 349
this C 118 349
shows C 119 349
the C 120 349
characteristic C 121 349
features C 122 349
of C 123 349
agnostic C 124 349
apraxia C 125 349
. C 126 349
motor C 128 349
activity C 129 349
and C 130 349
performance C 131 349
were C 132 349
normal C 133 349
, C 134 349
but C 135 349
the C 136 349
child C 137 349
had C 138 349
extreme C 139 349
difficulty C 140 349
in C 141 349
constructing C 142 349
geometric C 143 349
forms C 144 349
, C 145 349
even C 146 349
elementary C 147 349
, C 148 349
either C 149 349
spontaneously C 150 349
or C 151 349
by C 152 349
copying C 153 349
. C 154 349
this C 156 349
remarkable C 157 349
syndrome C 158 349
disappeared C 159 349
, C 160 349
and C 161 349
during C 162 349
its C 163 349
involution C 164 349
it C 165 349
was C 166 349
followed C 167 349
up C 168 349
. C 169 349
1288 C 1 350
. C 2 350
the C 4 350
symptomatology C 5 350
of C 6 350
the C 7 350
parietal C 8 350
cerebral C 9 350
syndrome C 10 350
of C 11 350
the C 12 350
dominant C 13 350
hemisphere C 14 350
. C 15 350
parietal C 17 350
dyslexia C 18 350
and C 19 350
conduction C 20 350
aphasia C 21 350
this C 22 350
is C 23 350
a C 24 350
very C 25 350
comprehensive C 26 350
study C 27 350
on C 28 350
a C 29 350
patient C 30 350
. C 31 350
in C 33 350
the C 34 350
beginning C 35 350
there C 36 350
was C 37 350
a C 38 350
pronounced C 39 350
gerstmann C 40 350
' C 41 350
s C 42 350
syndrome C 43 350
, C 44 350
with C 45 350
autotopagnosia C 46 350
for C 47 350
parts C 48 350
of C 49 350
the C 50 350
face C 51 350
, C 52 350
dyspraxia C 53 350
and C 54 350
constructive C 55 350
apraxia C 56 350
and C 57 350
dyslexia C 58 350
. C 59 350
the C 61 350
autotopagnosia C 62 350
and C 63 350
mild C 64 350
left C 65 350
- C 66 350
right C 67 350
disturbances C 68 350
showed C 69 350
marked C 70 350
regression C 71 350
. C 72 350
actual C 74 350
hemianopsia C 75 350
was C 76 350
not C 77 350
observed C 78 350
, C 79 350
but C 80 350
tachistoscopy C 81 350
revealed C 82 350
that C 83 350
perception C 84 350
of C 85 350
the C 86 350
right C 87 350
field C 88 350
of C 89 350
vision C 90 350
was C 91 350
poor C 92 350
. C 93 350
audiometric C 95 350
examination C 96 350
showed C 97 350
a C 98 350
conduction C 99 350
deafness C 100 350
and C 101 350
disturbed C 102 350
binaural C 103 350
word C 104 350
synthesis C 105 350
. C 106 350
the C 108 350
disturbances C 109 350
were C 110 350
examined C 111 350
meticulously C 112 350
and C 113 350
tested C 114 350
for C 115 350
symptom C 116 350
relationships C 117 350
, C 118 350
which C 119 350
became C 120 350
evident C 121 350
in C 122 350
the C 123 350
various C 124 350
factors C 125 350
concerned C 126 350
with C 127 350
creative C 128 350
ability C 129 350
. C 130 350
4544 C 1 351
. C 2 351
observations C 4 351
on C 5 351
colour C 6 351
agnosia C 7 351
a C 8 351
56 C 9 351
- C 10 351
year C 11 351
- C 12 351
old C 13 351
right C 14 351
- C 15 351
handed C 16 351
man C 17 351
, C 18 351
following C 19 351
the C 20 351
formation C 21 351
of C 22 351
a C 23 351
left C 24 351
posterior C 25 351
subdural C 26 351
hematoma C 27 351
developed C 28 351
' C 29 351
spelling C 30 351
dyslexia C 31 351
' C 32 351
and C 33 351
impaired C 34 351
picture C 35 351
interpretation C 36 351
, C 37 351
which C 38 351
resolved C 39 351
, C 40 351
and C 41 351
color C 42 351
agnosia C 43 351
, C 44 351
which C 45 351
persisted C 46 351
. C 47 351
the C 49 351
latter C 50 351
impaired C 51 351
the C 52 351
use C 53 351
both C 54 351
of C 55 351
color C 56 351
information C 57 351
and C 58 351
of C 59 351
the C 60 351
names C 61 351
of C 62 351
the C 63 351
colors C 64 351
. C 65 351
this C 67 351
may C 68 351
be C 69 351
explained C 70 351
as C 71 351
a C 72 351
disorder C 73 351
impairing C 74 351
the C 75 351
recollection C 76 351
and C 77 351
formation C 78 351
of C 79 351
associations C 80 351
between C 81 351
color C 82 351
names C 83 351
and C 84 351
other C 85 351
types C 86 351
of C 87 351
information C 88 351
, C 89 351
with C 90 351
resulting C 91 351
interference C 92 351
in C 93 351
any C 94 351
task C 95 351
in C 96 351
which C 97 351
colors C 98 351
or C 99 351
their C 100 351
names C 101 351
have C 102 351
to C 103 351
be C 104 351
placed C 105 351
in C 106 351
a C 107 351
specific C 108 351
context C 109 351
. C 110 351
the C 112 351
alternative C 113 351
views C 114 351
of C 115 351
willbrand C 116 351
( C 117 351
1887 C 118 351
) C 119 351
that C 120 351
here C 121 351
a C 122 351
limited C 123 351
dysphasia C 124 351
, C 125 351
and C 126 351
of C 127 351
sittig C 128 351
( C 129 351
1921 C 130 351
) C 131 351
that C 132 351
a C 133 351
recognition C 134 351
defect C 135 351
is C 136 351
simultaneously C 137 351
present C 138 351
, C 139 351
cannot C 140 351
be C 141 351
excluded C 142 351
. C 143 351
in C 145 351
the C 146 351
present C 147 351
and C 148 351
in C 149 351
previously C 150 351
reported C 151 351
cases C 152 351
the C 153 351
causative C 154 351
lesion C 155 351
seems C 156 351
to C 157 351
have C 158 351
been C 159 351
posteriorly C 160 351
located C 161 351
in C 162 351
the C 163 351
dominant C 164 351
hemisphere C 165 351
, C 166 351
in C 167 351
the C 168 351
borderland C 169 351
between C 170 351
the C 171 351
area C 172 351
receiving C 173 351
visual C 174 351
input C 175 351
and C 176 351
the C 177 351
language C 178 351
or C 179 351
verbal C 180 351
recording C 181 351
area C 182 351
. C 183 351
652 C 1 352
. C 2 352
bitemporal C 4 352
hemianopia C 5 352
two C 6 352
stages C 7 352
can C 8 352
be C 9 352
distinguished C 10 352
in C 11 352
the C 12 352
development C 13 352
of C 14 352
bitemporal C 15 352
hemianopia C 16 352
in C 17 352
hypophyseal C 18 352
tumors C 19 352
. C 20 352
the C 22 352
first C 23 352
stage C 24 352
is C 25 352
the C 26 352
consequence C 27 352
of C 28 352
direct C 29 352
pressure C 30 352
of C 31 352
the C 32 352
tumor C 33 352
on C 34 352
the C 35 352
lower C 36 352
side C 37 352
of C 38 352
the C 39 352
chiasma C 40 352
. C 41 352
hence C 43 352
its C 44 352
start C 45 352
with C 46 352
upper C 47 352
quadrantic C 48 352
field C 49 352
defects C 50 352
. C 51 352
in C 53 352
this C 54 352
stage C 55 352
the C 56 352
visual C 57 352
disorder C 58 352
is C 59 352
amenable C 60 352
to C 61 352
prompt C 62 352
and C 63 352
complete C 64 352
restoration C 65 352
. C 66 352
with C 68 352
progressing C 69 352
growth C 70 352
of C 71 352
the C 72 352
tumor C 73 352
the C 74 352
second C 75 352
stage C 76 352
follows C 77 352
as C 78 352
consequence C 79 352
of C 80 352
constriction C 81 352
by C 82 352
the C 83 352
circle C 84 352
of C 85 352
vessels C 86 352
. C 87 352
in C 89 352
this C 90 352
stage C 91 352
nerve C 92 352
fibers C 93 352
are C 94 352
being C 95 352
destroyed C 96 352
. C 97 352
therefore C 99 352
, C 100 352
after C 101 352
pressure C 102 352
relieving C 103 352
operation C 104 352
no C 105 352
restoration C 106 352
occurs C 107 352
, C 108 352
or C 109 352
to C 110 352
a C 111 352
limited C 112 352
extent C 113 352
only C 114 352
. C 115 352
387 C 1 353
. C 2 353
ophthalmic C 4 353
manifestations C 5 353
of C 6 353
bilateral C 7 353
non C 8 353
- C 9 353
occipital C 10 353
cerebral C 11 353
lesions C 12 353
twelve C 13 353
patients C 14 353
are C 15 353
described C 16 353
with C 17 353
neuro C 18 353
- C 19 353
ophthalmic C 20 353
symptoms C 21 353
resulting C 22 353
from C 23 353
bilateral C 24 353
cerebral C 25 353
lesions C 26 353
in C 27 353
areas C 28 353
other C 29 353
than C 30 353
the C 31 353
occipital C 32 353
lobes C 33 353
. C 34 353
the C 36 353
symptoms C 37 353
and C 38 353
signs C 39 353
are C 40 353
categorized C 41 353
as C 42 353
follows C 43 353
group C 44 353
i C 45 353
those C 46 353
showing C 47 353
predominant C 48 353
disturbances C 49 353
in C 50 353
visual C 51 353
object C 52 353
recognition C 53 353
( C 54 353
visual C 55 353
agnosia C 56 353
) C 57 353
and C 58 353
disturbances C 59 353
of C 60 353
visual C 61 353
spatial C 62 353
localization C 63 353
. C 64 353
group C 66 353
iia C 67 353
those C 68 353
having C 69 353
defects C 70 353
in C 71 353
voluntary C 72 353
control C 73 353
of C 74 353
eye C 75 353
movements C 76 353
( C 77 353
ocular C 78 353
motor C 79 353
apraxia C 80 353
) C 81 353
. C 82 353
group C 84 353
iib C 85 353
those C 86 353
with C 87 353
persistent C 88 353
palsies C 89 353
of C 90 353
conjugate C 91 353
gaze C 92 353
. C 93 353
although C 95 353
these C 96 353
symptoms C 97 353
may C 98 353
be C 99 353
present C 100 353
to C 101 353
some C 102 353
extent C 103 353
with C 104 353
unilateral C 105 353
lesions C 106 353
, C 107 353
they C 108 353
are C 109 353
much C 110 353
more C 111 353
profound C 112 353
and C 113 353
less C 114 353
able C 115 353
to C 116 353
be C 117 353
compensated C 118 353
with C 119 353
bilateral C 120 353
lesions C 121 353
. C 122 353
the C 124 353
evidence C 125 353
in C 126 353
the C 127 353
present C 128 353
cases C 129 353
suggests C 130 353
a C 131 353
biparieto C 132 353
- C 133 353
temporal C 134 353
localization C 135 353
for C 136 353
the C 137 353
lesions C 138 353
causing C 139 353
visual C 140 353
agnosia C 141 353
, C 142 353
disturbances C 143 353
of C 144 353
spatial C 145 353
localization C 146 353
, C 147 353
and C 148 353
ocular C 149 353
motor C 150 353
apraxia C 151 353
, C 152 353
and C 153 353
a C 154 353
more C 155 353
frontal C 156 353
localization C 157 353
for C 158 353
the C 159 353
lesions C 160 353
causing C 161 353
prolonged C 162 353
paralysis C 163 353
of C 164 353
conjugate C 165 353
gaze C 166 353
. C 167 353
1774 C 1 354
. C 2 354
the C 4 354
speed C 5 354
of C 6 354
reading C 7 354
. C 8 354
basis C 10 354
for C 11 354
a C 12 354
clinical C 13 354
function C 14 354
test C 15 354
as C 16 354
an C 17 354
easily C 18 354
comprehensible C 19 354
measure C 20 354
for C 21 354
the C 22 354
capability C 23 354
of C 24 354
reading C 25 354
, C 26 354
the C 27 354
author C 28 354
recommends C 29 354
the C 30 354
determination C 31 354
of C 32 354
the C 33 354
reading C 34 354
speed C 35 354
for C 36 354
supplementation C 37 354
of C 38 354
the C 39 354
ocular C 40 354
function C 41 354
tests C 42 354
. C 43 354
the C 45 354
method C 46 354
in C 47 354
question C 48 354
constitutes C 49 354
a C 50 354
senso C 51 354
- C 52 354
motor C 53 354
efficiency C 54 354
test C 55 354
which C 56 354
is C 57 354
of C 58 354
value C 59 354
in C 60 354
the C 61 354
appraisal C 62 354
of C 63 354
haemianopias C 64 354
, C 65 354
paracentral C 66 354
and C 67 354
central C 68 354
defects C 69 354
of C 70 354
the C 71 354
visual C 72 354
field C 73 354
, C 74 354
in C 75 354
squint C 76 354
amblyopias C 77 354
and C 78 354
in C 79 354
spontaneous C 80 354
nystagmus C 81 354
. C 82 354
1303 C 1 355
. C 2 355
the C 4 355
problem C 5 355
of C 6 355
visual C 7 355
agnosia C 8 355
this C 9 355
is C 10 355
a C 11 355
critical C 12 355
assessment C 13 355
of C 14 355
the C 15 355
ancient C 16 355
and C 17 355
modern C 18 355
theories C 19 355
on C 20 355
visual C 21 355
agnosia C 22 355
. C 23 355
an C 25 355
original C 26 355
description C 27 355
of C 28 355
the C 29 355
subjective C 30 355
world C 31 355
of C 32 355
these C 33 355
patients C 34 355
is C 35 355
also C 36 355
given C 37 355
. C 38 355
visual C 40 355
agnosia C 41 355
is C 42 355
a C 43 355
rare C 44 355
disorder C 45 355
, C 46 355
but C 47 355
it C 48 355
has C 49 355
led C 50 355
to C 51 355
comprehensive C 52 355
discussions C 53 355
, C 54 355
for C 55 355
instance C 56 355
, C 57 355
by C 58 355
the C 59 355
fact C 60 355
that C 61 355
the C 62 355
problem C 63 355
of C 64 355
normal C 65 355
visual C 66 355
perception C 67 355
is C 68 355
always C 69 355
involved C 70 355
. C 71 355
bay C 73 355
' C 74 355
s C 75 355
view C 76 355
, C 77 355
which C 78 355
denies C 79 355
the C 80 355
existence C 81 355
of C 82 355
agnosia C 83 355
as C 84 355
a C 85 355
separate C 86 355
phenomenon C 87 355
in C 88 355
perception C 89 355
disorders C 90 355
, C 91 355
is C 92 355
especially C 93 355
dealt C 94 355
with C 95 355
. C 96 355
it C 98 355
is C 99 355
affirmed C 100 355
that C 101 355
no C 102 355
case C 103 355
has C 104 355
been C 105 355
described C 106 355
in C 107 355
the C 108 355
literature C 109 355
in C 110 355
which C 111 355
visual C 112 355
agnosia C 113 355
is C 114 355
decidedly C 115 355
a C 116 355
pure C 117 355
and C 118 355
isolated C 119 355
phenomenon C 120 355
. C 121 355
mostly C 123 355
there C 124 355
are C 125 355
also C 126 355
disturbances C 127 355
in C 128 355
the C 129 355
intellectual C 130 355
interpretation C 131 355
of C 132 355
visual C 133 355
data C 134 355
. C 135 355
often C 137 355
there C 138 355
is C 139 355
metamorphopsia C 140 355
or C 141 355
asthenopia C 142 355
. C 143 355
there C 145 355
is C 146 355
no C 147 355
localized C 148 355
prestriate C 149 355
gnostic C 150 355
center C 151 355
for C 152 355
visual C 153 355
impressions C 154 355
. C 155 355
the C 157 355
older C 158 355
concept C 159 355
of C 160 355
higher C 161 355
and C 162 355
lower C 163 355
levels C 164 355
of C 165 355
perception C 166 355
and C 167 355
perception C 168 355
disorders C 169 355
is C 170 355
also C 171 355
criticized C 172 355
. C 173 355
visual C 175 355
perception C 176 355
is C 177 355
not C 178 355
a C 179 355
passive C 180 355
, C 181 355
but C 182 355
a C 183 355
very C 184 355
active C 185 355
process C 186 355
, C 187 355
in C 188 355
which C 189 355
neurophysiological C 190 355
and C 191 355
psychological C 192 355
aspects C 193 355
are C 194 355
involved C 195 355
. C 196 355
each C 198 355
of C 199 355
these C 200 355
can C 201 355
be C 202 355
disturbed C 203 355
, C 204 355
leading C 205 355
to C 206 355
various C 207 355
degrees C 208 355
of C 209 355
visual C 210 355
perception C 211 355
disturbance C 212 355
. C 213 355
2496 C 1 356
. C 2 356
dysbarism C 4 356
among C 5 356
hyperbaric C 6 356
personnel C 7 356
a C 8 356
survey C 9 356
of C 10 356
the C 11 356
effects C 12 356
of C 13 356
hyperbaric C 14 356
exposure C 15 356
on C 16 356
62 C 17 356
medical C 18 356
personnel C 19 356
exposed C 20 356
to C 21 356
1 C 22 356
, C 23 356
516 C 24 356
compressions C 25 356
and C 26 356
decompressions C 27 356
revealed C 28 356
no C 29 356
case C 30 356
of C 31 356
permanent C 32 356
ill C 33 356
effect C 34 356
. C 35 356
pain C 37 356
in C 38 356
the C 39 356
ears C 40 356
or C 41 356
sinuses C 42 356
was C 43 356
the C 44 356
most C 45 356
common C 46 356
symptom C 47 356
but C 48 356
could C 49 356
often C 50 356
be C 51 356
ameliorated C 52 356
or C 53 356
avoided C 54 356
by C 55 356
the C 56 356
valsalva C 57 356
technique C 58 356
of C 59 356
forced C 60 356
insufflation C 61 356
with C 62 356
the C 63 356
nostrils C 64 356
occluded C 65 356
. C 66 356
the C 68 356
most C 69 356
serious C 70 356
symptoms C 71 356
encountered C 72 356
were C 73 356
3 C 74 356
episodes C 75 356
of C 76 356
transient C 77 356
homonymous C 78 356
hemianopsia C 79 356
. C 80 356
the C 82 356
classic C 83 356
symptoms C 84 356
of C 85 356
decompression C 86 356
sickness C 87 356
extremity C 88 356
pains C 89 356
( C 90 356
the C 91 356
' C 92 356
bends C 93 356
' C 94 356
) C 95 356
, C 96 356
pulmonary C 97 356
or C 98 356
substernal C 99 356
distress C 100 356
( C 101 356
the C 102 356
' C 103 356
chokes C 104 356
' C 105 356
) C 106 356
, C 107 356
and C 108 356
skin C 109 356
dysesthesias C 110 356
occurred C 111 356
only C 112 356
rarely C 113 356
, C 114 356
and C 115 356
were C 116 356
so C 117 356
mild C 118 356
or C 119 356
so C 120 356
fleeting C 121 356
as C 122 356
to C 123 356
require C 124 356
no C 125 356
treatment C 126 356
. C 127 356
a C 129 356
further C 130 356
reduction C 131 356
in C 132 356
symptoms C 133 356
without C 134 356
increase C 135 356
in C 136 356
decompression C 137 356
time C 138 356
may C 139 356
be C 140 356
obtained C 141 356
by C 142 356
the C 143 356
inhalation C 144 356
of C 145 356
100 C 146 356
% C 147 356
oxygen C 148 356
during C 149 356
decompression C 150 356
stops C 151 356
at C 152 356
pressures C 153 356
below C 154 356
26 C 155 356
. C 156 356
. C 157 356
pounds C 158 356
per C 159 356
square C 160 356
inch C 161 356
gauge C 162 356
( C 163 356
psig C 164 356
) C 165 356
. C 166 356
2996 C 1 357
. C 2 357
visual C 4 357
static C 5 357
agnosia C 6 357
with C 7 357
special C 8 357
reference C 9 357
to C 10 357
literal C 11 357
agnosic C 12 357
alexia C 13 357
this C 14 357
is C 15 357
a C 16 357
report C 17 357
of C 18 357
2 C 19 357
, C 20 357
right C 21 357
- C 22 357
handed C 23 357
adults C 24 357
who C 25 357
had C 26 357
' C 27 357
visual C 28 357
agnosia C 29 357
( C 30 357
with C 31 357
predominance C 32 357
of C 33 357
literal C 34 357
alexia C 35 357
) C 36 357
' C 37 357
. C 38 357
recognition C 40 357
of C 41 357
letters C 42 357
was C 43 357
poor C 44 357
or C 45 357
nonexistent C 46 357
when C 47 357
the C 48 357
patient C 49 357
simply C 50 357
viewed C 51 357
the C 52 357
material C 53 357
( C 54 357
static C 55 357
method C 56 357
) C 57 357
but C 58 357
if C 59 357
the C 60 357
letter C 61 357
was C 62 357
slowly C 63 357
developed C 64 357
for C 65 357
them C 66 357
, C 67 357
they C 68 357
were C 69 357
able C 70 357
to C 71 357
identify C 72 357
it C 73 357
( C 74 357
dynamic C 75 357
method C 76 357
) C 77 357
. C 78 357
one C 80 357
patient C 81 357
had C 82 357
vascular C 83 357
pathology C 84 357
which C 85 357
was C 86 357
considered C 87 357
to C 88 357
involve C 89 357
both C 90 357
occipital C 91 357
lobes C 92 357
and C 93 357
the C 94 357
2 C 95 357
nd C 96 357
patient C 97 357
had C 98 357
the C 99 357
surgical C 100 357
removal C 101 357
of C 102 357
the C 103 357
left C 104 357
occipital C 105 357
lobe C 106 357
for C 107 357
an C 108 357
angioma C 109 357
. C 110 357
1388 C 1 358
. C 2 358
optic C 4 358
agnosia C 5 358
semeiological C 6 358
and C 7 358
pathogenetic C 8 358
aspects C 9 358
the C 10 358
authors C 11 358
discuss C 12 358
the C 13 358
classical C 14 358
concept C 15 358
of C 16 358
agnosia C 17 358
and C 18 358
make C 19 358
a C 20 358
survey C 21 358
of C 22 358
pathogenetical C 23 358
factors C 24 358
which C 25 358
determine C 26 358
its C 27 358
phenomenology C 28 358
. C 29 358
the C 31 358
original C 32 358
and C 33 358
traditional C 34 358
concept C 35 358
of C 36 358
such C 37 358
a C 38 358
term C 39 358
implied C 40 358
the C 41 358
loss C 42 358
of C 43 358
the C 44 358
capacity C 45 358
to C 46 358
recognize C 47 358
objects C 48 358
, C 49 358
when C 50 358
the C 51 358
functions C 52 358
of C 53 358
sense C 54 358
organs C 55 358
are C 56 358
undamaged C 57 358
. C 58 358
the C 60 358
psychological C 61 358
studies C 62 358
on C 63 358
perception C 64 358
and C 65 358
the C 66 358
modern C 67 358
physiology C 68 358
of C 69 358
vision C 70 358
allow C 71 358
to C 72 358
avoid C 73 358
the C 74 358
dichotomy C 75 358
between C 76 358
sensation C 77 358
and C 78 358
perception C 79 358
and C 80 358
to C 81 358
affirm C 82 358
their C 83 358
identity C 84 358
. C 85 358
cortex C 87 358
and C 88 358
recptors C 89 358
are C 90 358
closely C 91 358
bound C 92 358
and C 93 358
function C 94 358
in C 95 358
unison C 96 358
. C 97 358
every C 99 358
cortical C 100 358
alteration C 101 358
is C 102 358
thus C 103 358
reflected C 104 358
in C 105 358
sensorial C 106 358
functions C 107 358
; C 108 358
it C 109 358
is C 110 358
therefore C 111 358
that C 112 358
on C 113 358
practical C 114 358
semeiological C 115 358
grounds C 116 358
it C 117 358
is C 118 358
possible C 119 358
to C 120 358
obtain C 121 358
a C 122 358
congruous C 123 358
information C 124 358
of C 125 358
the C 126 358
corresponding C 127 358
cortical C 128 358
functionality C 129 358
through C 130 358
an C 131 358
exploration C 132 358
of C 133 358
sense C 134 358
organs C 135 358
carried C 136 358
out C 137 358
by C 138 358
suitable C 139 358
means C 140 358
. C 141 358
since C 143 358
we C 144 358
are C 145 358
confronted C 146 358
with C 147 358
functional C 148 358
changes C 149 358
, C 150 358
exploration C 151 358
methods C 152 358
must C 153 358
be C 154 358
fit C 155 358
to C 156 358
evaluate C 157 358
dynamic C 158 358
aspects C 159 358
of C 160 358
perception C 161 358
in C 162 358
connection C 163 358
with C 164 358
the C 165 358
temporalization C 166 358
and C 167 358
spatialization C 168 358
of C 169 358
stimuli C 170 358
. C 171 358
such C 173 358
methods C 174 358
are C 175 358
now C 176 358
quite C 177 358
numerous C 178 358
and C 179 358
often C 180 358
complex C 181 358
a C 182 358
particular C 183 358
stress C 184 358
is C 185 358
laid C 186 358
on C 187 358
local C 188 358
adaptation C 189 358
, C 190 358
flicker C 191 358
fusion C 192 358
, C 193 358
and C 194 358
tachistoscopy C 195 358
on C 196 358
account C 197 358
of C 198 358
their C 199 358
significance C 200 358
and C 201 358
suitability C 202 358
. C 203 358
by C 205 358
such C 206 358
methods C 207 358
it C 208 358
is C 209 358
possible C 210 358
to C 211 358
show C 212 358
those C 213 358
functional C 214 358
deficits C 215 358
or C 216 358
pathological C 217 358
disturbances C 218 358
of C 219 358
sensorial C 220 358
functions C 221 358
which C 222 358
are C 223 358
also C 224 358
behind C 225 358
the C 226 358
pathology C 227 358
of C 228 358
visual C 229 358
recognition C 230 358
. C 231 358
fluctuation C 233 358
, C 234 358
extinction C 235 358
, C 236 358
alteration C 237 358
in C 238 358
the C 239 358
perception C 240 358
of C 241 358
movement C 242 358
, C 243 358
both C 244 358
real C 245 358
and C 246 358
apparent C 247 358
, C 248 358
changes C 249 358
in C 250 358
adaptation C 251 358
to C 252 358
light C 253 358
and C 254 358
darkness C 255 358
are C 256 358
all C 257 358
phenomena C 258 358
which C 259 358
can C 260 358
be C 261 358
detected C 262 358
instrumentally C 263 358
and C 264 358
which C 265 358
, C 266 358
at C 267 358
the C 268 358
same C 269 358
time C 270 358
, C 271 358
may C 272 358
be C 273 358
of C 274 358
determinant C 275 358
importance C 276 358
for C 277 358
the C 278 358
onset C 279 358
of C 280 358
' C 281 358
agnosic C 282 358
' C 283 358
behaviour C 284 358
. C 285 358
the C 287 358
complexity C 288 358
of C 289 358
the C 290 358
latter C 291 358
, C 292 358
on C 293 358
the C 294 358
other C 295 358
hand C 296 358
, C 297 358
cannot C 298 358
always C 299 358
be C 300 358
explained C 301 358
by C 302 358
sensorial C 303 358
disturbances C 304 358
only C 305 358
other C 306 358
mechanisms C 307 358
, C 308 358
with C 309 358
a C 310 358
function C 311 358
complementary C 312 358
but C 313 358
not C 314 358
less C 315 358
indispensable C 316 358
to C 317 358
the C 318 358
dynamics C 319 358
of C 320 358
perceptive C 321 358
processes C 322 358
, C 323 358
may C 324 358
intervene C 325 358
and C 326 358
interfere C 327 358
in C 328 358
it C 329 358
. C 330 358
on C 332 358
the C 333 358
basis C 334 358
of C 335 358
the C 336 358
latest C 337 358
neurophysiological C 338 358
data C 339 358
the C 340 358
attention C 341 358
is C 342 358
called C 343 358
to C 344 358
ocular C 345 358
motility C 346 358
and C 347 358
proprioceptivity C 348 358
, C 349 358
centrifugal C 350 358
innervation C 351 358
of C 352 358
sensorial C 353 358
receptors C 354 358
, C 355 358
and C 356 358
vestibular C 357 358
afferences C 358 358
. C 359 358
a C 361 358
particular C 362 358
clinico C 363 358
- C 364 358
pathogenetical C 365 358
significance C 366 358
is C 367 358
attached C 368 358
by C 369 358
the C 370 358
authors C 371 358
to C 372 358
the C 373 358
association C 374 358
of C 375 358
lateral C 376 358
visual C 377 358
disturbances C 378 358
with C 379 358
altered C 380 358
proprioceptive C 381 358
and C 382 358
kinesthetic C 383 358
information C 384 358
from C 385 358
the C 386 358
corresponding C 387 358
half C 388 358
- C 389 358
body C 390 358
such C 391 358
association C 392 358
in C 393 358
fact C 394 358
is C 395 358
nearly C 396 358
always C 397 358
present C 398 358
among C 399 358
the C 400 358
factors C 401 358
responsible C 402 358
for C 403 358
the C 404 358
most C 405 358
strictly C 406 358
' C 407 358
spatial C 408 358
' C 409 358
errors C 410 358
of C 411 358
' C 412 358
agnosic C 413 358
' C 414 358
pathology C 415 358
. C 416 358
in C 418 358
the C 419 358
light C 420 358
of C 421 358
these C 422 358
pathogenetical C 423 358
considerations C 424 358
as C 425 358
well C 426 358
as C 427 358
of C 428 358
suitable C 429 358
semeiological C 430 358
findings C 431 358
, C 432 358
the C 433 358
authors C 434 358
deem C 435 358
it C 436 358
convenient C 437 358
to C 438 358
divide C 439 358
their C 440 358
cases C 441 358
into C 442 358
3 C 443 358
categories C 444 358
with C 445 358
distinct C 446 358
clinical C 447 358
features C 448 358
( C 449 358
a C 450 358
) C 451 358
cases C 452 358
in C 453 358
which C 454 358
altered C 455 358
visual C 456 358
behaviour C 457 358
may C 458 358
be C 459 358
related C 460 358
to C 461 358
changes C 462 358
of C 463 358
the C 464 358
visual C 465 358
function C 466 358
and C 467 358
of C 468 358
its C 469 358
complementary C 470 358
mechanisms C 471 358
; C 472 358
( C 473 358
b C 474 358
) C 475 358
cases C 476 358
in C 477 358
which C 478 358
hemianopia C 479 358
is C 480 358
associated C 481 358
with C 482 358
a C 483 358
homolateral C 484 358
deficit C 485 358
of C 486 358
somatic C 487 358
proprioceptivity C 488 358
; C 489 358
( C 490 358
c C 491 358
) C 492 358
cases C 493 358
in C 494 358
which C 495 358
the C 496 358
changes C 497 358
in C 498 358
behaviour C 499 358
are C 500 358
chiefly C 501 358
, C 502 358
but C 503 358
not C 504 358
only C 505 358
, C 506 358
due C 507 358
to C 508 358
a C 509 358
dissolution C 510 358
of C 511 358
the C 512 358
symbolic C 513 358
sphere C 514 358
. C 515 358
2568 C 1 359
. C 2 359
clinical C 4 359
observations C 5 359
on C 6 359
hemianopia C 7 359
( C 8 359
japanese C 9 359
) C 10 359
the C 11 359
clinical C 12 359
findings C 13 359
in C 14 359
19 C 15 359
cases C 16 359
of C 17 359
hemianopia C 18 359
were C 19 359
analyzed C 20 359
. C 21 359
hemianopia C 23 359
was C 24 359
caused C 25 359
most C 26 359
frequently C 27 359
by C 28 359
vascular C 29 359
lesions C 30 359
of C 31 359
the C 32 359
central C 33 359
nervous C 34 359
mianopsia C 35 359
, C 36 359
and C 37 359
by C 38 359
tumors C 39 359
. C 40 359
wilbrand C 42 359
' C 43 359
s C 44 359
prism C 45 359
sign C 46 359
, C 47 359
which C 48 359
is C 49 359
generally C 50 359
taken C 51 359
as C 52 359
evidence C 53 359
of C 54 359
an C 55 359
optic C 56 359
tract C 57 359
lesion C 58 359
, C 59 359
was C 60 359
positive C 61 359
in C 62 359
one C 63 359
case C 64 359
with C 65 359
a C 66 359
parietal C 67 359
lesion C 68 359
. C 69 359
no C 71 359
case C 72 359
showed C 73 359
a C 74 359
cogwheel C 75 359
movement C 76 359
of C 77 359
the C 78 359
eyeball C 79 359
. C 80 359
optokinetic C 82 359
nystagmus C 83 359
was C 84 359
positive C 85 359
in C 86 359
3 C 87 359
cases C 88 359
, C 89 359
one C 90 359
of C 91 359
which C 92 359
proved C 93 359
to C 94 359
have C 95 359
a C 96 359
parieto C 97 359
- C 98 359
occipital C 99 359
aneurysm C 100 359
. C 101 359
the C 103 359
etiological C 104 359
factor C 105 359
could C 106 359
not C 107 359
be C 108 359
identified C 109 359
in C 110 359
the C 111 359
remaining C 112 359
2 C 113 359
cases C 114 359
. C 115 359
macular C 117 359
sparing C 118 359
was C 119 359
found C 120 359
to C 121 359
be C 122 359
symptomatic C 123 359
of C 124 359
an C 125 359
occipital C 126 359
lobe C 127 359
lesion C 128 359
. C 129 359
incongruity C 131 359
of C 132 359
the C 133 359
2 C 134 359
fields C 135 359
was C 136 359
observed C 137 359
in C 138 359
2 C 139 359
cases C 140 359
with C 141 359
an C 142 359
occipital C 143 359
lobe C 144 359
lesion C 145 359
. C 146 359
as C 148 359
for C 149 359
the C 150 359
prognosis C 151 359
, C 152 359
hemianoptic C 153 359
field C 154 359
defects C 155 359
remained C 156 359
stationary C 157 359
in C 158 359
cases C 159 359
of C 160 359
vascular C 161 359
lesions C 162 359
. C 163 359
on C 165 359
the C 166 359
other C 167 359
hand C 168 359
perfect C 169 359
recovery C 170 359
of C 171 359
the C 172 359
visual C 173 359
field C 174 359
defect C 175 359
occurred C 176 359
in C 177 359
cases C 178 359
with C 179 359
an C 180 359
occipital C 181 359
lobe C 182 359
tumor C 183 359
and C 184 359
in C 185 359
hypophyseal C 186 359
hypertrophy C 187 359
caused C 188 359
by C 189 359
pregnancy C 190 359
. C 191 359
the C 193 359
visual C 194 359
acuity C 195 359
of C 196 359
hemianoptic C 197 359
patients C 198 359
was C 199 359
fairly C 200 359
good C 201 359
and C 202 359
no C 203 359
deterioration C 204 359
occurred C 205 359
during C 206 359
the C 207 359
observation C 208 359
period C 209 359
of C 210 359
about C 211 359
4 C 212 359
years C 213 359
. C 214 359
only C 216 359
one C 217 359
patient C 218 359
out C 219 359
of C 220 359
the C 221 359
present C 222 359
series C 223 359
died C 224 359
. C 225 359
these C 227 359
results C 228 359
suggest C 229 359
that C 230 359
a C 231 359
favorable C 232 359
vital C 233 359
prognosis C 234 359
can C 235 359
be C 236 359
accorded C 237 359
to C 238 359
hemianoptic C 239 359
subjects C 240 359
. C 241 359
1384 C 1 360
. C 2 360
importance C 4 360
of C 5 360
campimetry C 6 360
and C 7 360
carotid C 8 360
and C 9 360
vertebral C 10 360
angiography C 11 360
in C 12 360
thrombosis C 13 360
of C 14 360
the C 15 360
posterior C 16 360
cerebral C 17 360
artery C 18 360
the C 19 360
authors C 20 360
report C 21 360
a C 22 360
case C 23 360
of C 24 360
thrombosis C 25 360
of C 26 360
the C 27 360
posterior C 28 360
cerebral C 29 360
artery C 30 360
which C 31 360
presented C 32 360
only C 33 360
lateral C 34 360
homonymous C 35 360
hemianopia C 36 360
and C 37 360
stress C 38 360
the C 39 360
importance C 40 360
of C 41 360
campimetry C 42 360
and C 43 360
of C 44 360
carotid C 45 360
angiography C 46 360
beside C 47 360
vertebral C 48 360
angiography C 49 360
. C 50 360
375 C 1 361
. C 2 361
hemianopsia C 4 361
and C 5 361
glaucoma C 6 361
after C 7 361
a C 8 361
discussion C 9 361
of C 10 361
the C 11 361
bibliographic C 12 361
references C 13 361
to C 14 361
the C 15 361
few C 16 361
observations C 17 361
on C 18 361
the C 19 361
simultaneous C 20 361
occurrence C 21 361
of C 22 361
hemianopsias C 23 361
and C 24 361
glaucoma C 25 361
the C 26 361
author C 27 361
states C 28 361
on C 29 361
the C 30 361
basis C 31 361
of C 32 361
his C 33 361
experiences C 34 361
the C 35 361
following C 36 361
points C 37 361
homonymous C 38 361
hemianopsias C 39 361
occasionally C 40 361
take C 41 361
place C 42 361
in C 43 361
glaucoma C 44 361
, C 45 361
although C 46 361
no C 47 361
direct C 48 361
relation C 49 361
can C 50 361
be C 51 361
established C 52 361
between C 53 361
the C 54 361
former C 55 361
and C 56 361
the C 57 361
glaucoma C 58 361
. C 59 361
it C 61 361
has C 62 361
to C 63 361
be C 64 361
pointed C 65 361
out C 66 361
, C 67 361
however C 68 361
, C 69 361
that C 70 361
in C 71 361
other C 72 361
older C 73 361
patients C 74 361
, C 75 361
for C 76 361
example C 77 361
in C 78 361
those C 79 361
with C 80 361
retinal C 81 361
detachment C 82 361
, C 83 361
neuritis C 84 361
, C 85 361
etc C 86 361
. C 87 361
who C 89 361
are C 90 361
likewise C 91 361
subjected C 92 361
to C 93 361
repeated C 94 361
and C 95 361
exact C 96 361
perimetry C 97 361
, C 98 361
such C 99 361
hemianopsias C 100 361
do C 101 361
not C 102 361
occur C 103 361
, C 104 361
or C 105 361
are C 106 361
to C 107 361
be C 108 361
found C 109 361
at C 110 361
a C 111 361
lesser C 112 361
rate C 113 361
than C 114 361
in C 115 361
glaucoma C 116 361
. C 117 361
a C 119 361
homonymous C 120 361
hemianopsia C 121 361
has C 122 361
to C 123 361
be C 124 361
taken C 125 361
into C 126 361
consideration C 127 361
also C 128 361
in C 129 361
the C 130 361
event C 131 361
of C 132 361
a C 133 361
sudden C 134 361
impairment C 135 361
of C 136 361
the C 137 361
visual C 138 361
field C 139 361
in C 140 361
a C 141 361
glaucomatous C 142 361
patient C 143 361
or C 144 361
when C 145 361
the C 146 361
hemianopic C 147 361
defect C 148 361
supervenes C 149 361
in C 150 361
addition C 151 361
to C 152 361
the C 153 361
visual C 154 361
field C 155 361
defect C 156 361
due C 157 361
to C 158 361
glaucoma C 159 361
. C 160 361
in C 162 361
cases C 163 361
of C 164 361
binasal C 165 361
hemianopsia C 166 361
, C 167 361
the C 168 361
simultaneous C 169 361
presence C 170 361
of C 171 361
glaucoma C 172 361
is C 173 361
not C 174 361
a C 175 361
rare C 176 361
incident C 177 361
. C 178 361
whether C 180 361
the C 181 361
binasal C 182 361
hemianopsia C 183 361
is C 184 361
the C 185 361
result C 186 361
of C 187 361
the C 188 361
gradual C 189 361
development C 190 361
of C 191 361
a C 192 361
glaucomatous C 193 361
visual C 194 361
field C 195 361
with C 196 361
nasal C 197 361
defects C 198 361
or C 199 361
whether C 200 361
it C 201 361
constitutes C 202 361
an C 203 361
independent C 204 361
symptom C 205 361
to C 206 361
a C 207 361
certain C 208 361
extent C 209 361
, C 210 361
cannot C 211 361
always C 212 361
be C 213 361
clarified C 214 361
in C 215 361
the C 216 361
individual C 217 361
case C 218 361
. C 219 361
obviously C 221 361
the C 222 361
condition C 223 361
of C 224 361
the C 225 361
basal C 226 361
cerebral C 227 361
vessels C 228 361
plays C 229 361
a C 230 361
certain C 231 361
role C 232 361
in C 233 361
the C 234 361
development C 235 361
of C 236 361
glaucoma C 237 361
, C 238 361
even C 239 361
if C 240 361
this C 241 361
role C 242 361
cannot C 243 361
be C 244 361
clearly C 245 361
defined C 246 361
as C 247 361
yet C 248 361
. C 249 361
in C 251 361
cases C 252 361
of C 253 361
binasal C 254 361
hemianopsia C 255 361
, C 256 361
a C 257 361
glaucoma C 258 361
has C 259 361
to C 260 361
be C 261 361
ruled C 262 361
out C 263 361
before C 264 361
radical C 265 361
diagnostic C 266 361
and C 267 361
therapeutic C 268 361
measures C 269 361
are C 270 361
carried C 271 361
out C 272 361
. C 273 361
1131 C 1 362
. C 2 362
disorders C 4 362
of C 5 362
oculomotor C 6 362
functions C 7 362
in C 8 362
lesions C 9 362
of C 10 362
the C 11 362
optic C 12 362
pathway C 13 362
at C 14 362
the C 15 362
parieto C 16 362
- C 17 362
occipital C 18 362
level C 19 362
and C 20 362
their C 21 362
significance C 22 362
in C 23 362
topical C 24 362
diagnosis C 25 362
paresis C 26 362
of C 27 362
ocular C 28 362
movements C 29 362
to C 30 362
the C 31 362
hemianopic C 32 362
side C 33 362
is C 34 362
described C 35 362
in C 36 362
9 C 37 362
patients C 38 362
with C 39 362
acute C 40 362
vascular C 41 362
lesions C 42 362
in C 43 362
the C 44 362
parieto C 45 362
- C 46 362
occipital C 47 362
region C 48 362
. C 49 362
in C 51 362
7 C 52 362
cases C 53 362
the C 54 362
paresis C 55 362
was C 56 362
of C 57 362
the C 58 362
dissociated C 59 362
type C 60 362
with C 61 362
inability C 62 362
to C 63 362
follow C 64 362
the C 65 362
moving C 66 362
finger C 67 362
, C 68 362
while C 69 362
ocular C 70 362
movement C 71 362
in C 72 362
a C 73 362
verbally C 74 362
stated C 75 362
direction C 76 362
was C 77 362
quite C 78 362
normal C 79 362
. C 80 362
in C 82 362
the C 83 362
remaining C 84 362
2 C 85 362
patients C 86 362
in C 87 362
whom C 88 362
the C 89 362
oedema C 90 362
extended C 91 362
into C 92 362
the C 93 362
frontal C 94 362
region C 95 362
there C 96 362
was C 97 362
complete C 98 362
paresis C 99 362
of C 100 362
all C 101 362
conjugate C 102 362
movements C 103 362
. C 104 362
conjugate C 106 362
paresis C 107 362
receded C 108 362
hand C 109 362
- C 110 362
in C 111 362
- C 112 362
hand C 113 362
with C 114 362
the C 115 362
parietal C 116 362
symptomatology C 117 362
even C 118 362
if C 119 362
the C 120 362
hemianopia C 121 362
persisted C 122 362
. C 123 362
the C 125 362
oculomotor C 126 362
disorders C 127 362
referred C 128 362
to C 129 362
have C 130 362
never C 131 362
been C 132 362
observed C 133 362
in C 134 362
lesions C 135 362
which C 136 362
did C 137 362
not C 138 362
extend C 139 362
beyond C 140 362
the C 141 362
occipital C 142 362
region C 143 362
. C 144 362
conjugate C 146 362
paresis C 147 362
has C 148 362
in C 149 362
all C 150 362
cases C 151 362
drawn C 152 362
attention C 153 362
to C 154 362
the C 155 362
presence C 156 362
of C 157 362
hemianopia C 158 362
unobserved C 159 362
by C 160 362
the C 161 362
patients C 162 362
and C 163 362
this C 164 362
has C 165 362
led C 166 362
to C 167 362
a C 168 362
more C 169 362
accurate C 170 362
topical C 171 362
diagnosis C 172 362
. C 173 362
2333 C 1 363
. C 2 363
binocularity C 4 363
in C 5 363
anomalous C 6 363
retinal C 7 363
correspondence C 8 363
patients C 9 363
with C 10 363
anomalous C 11 363
retinal C 12 363
correspondence C 13 363
demonstrate C 14 363
complete C 15 363
bitemporal C 16 363
or C 17 363
binasal C 18 363
hemianopia C 19 363
when C 20 363
tested C 21 363
for C 22 363
binocular C 23 363
vision C 24 363
; C 25 363
exotropes C 26 363
have C 27 363
a C 28 363
binasal C 29 363
suppression C 30 363
and C 31 363
esotropes C 32 363
a C 33 363
bitemporal C 34 363
suppression C 35 363
. C 36 363
this C 38 363
is C 39 363
contrary C 40 363
to C 41 363
the C 42 363
prevailing C 43 363
concept C 44 363
of C 45 363
the C 46 363
function C 47 363
of C 48 363
the C 49 363
peripheral C 50 363
retina C 51 363
in C 52 363
anomalous C 53 363
retinal C 54 363
correspondence C 55 363
. C 56 363
6 C 58 363
references C 59 363
. C 60 363
2120 C 1 364
. C 2 364
thioguanine C 4 364
in C 5 364
the C 6 364
treatment C 7 364
of C 8 364
certain C 9 364
autoimmune C 10 364
, C 11 364
immunologic C 12 364
and C 13 364
related C 14 364
diseases C 15 364
the C 16 364
therapeutic C 17 364
effectiveness C 18 364
of C 19 364
6 C 20 364
- C 21 364
thioguanine C 22 364
has C 23 364
been C 24 364
evaluated C 25 364
over C 26 364
the C 27 364
past C 28 364
3 C 29 364
years C 30 364
in C 31 364
19 C 32 364
patients C 33 364
with C 34 364
diverse C 35 364
syndromes C 36 364
. C 37 364
only C 39 364
patients C 40 364
with C 41 364
severe C 42 364
debilitating C 43 364
disease C 44 364
unresponsive C 45 364
to C 46 364
conventional C 47 364
therapy C 48 364
were C 49 364
treated C 50 364
. C 51 364
remissions C 53 364
occurred C 54 364
in C 55 364
2 C 56 364
of C 57 364
5 C 58 364
patients C 59 364
with C 60 364
systemic C 61 364
lupus C 62 364
erythematosus C 63 364
, C 64 364
in C 65 364
1 C 66 364
patient C 67 364
each C 68 364
with C 69 364
dermatomyositis C 70 364
and C 71 364
necrotizing C 72 364
angiitis C 73 364
, C 74 364
2 C 75 364
patients C 76 364
with C 77 364
psoriasis C 78 364
and C 79 364
2 C 80 364
of C 81 364
4 C 82 364
patients C 83 364
with C 84 364
atopic C 85 364
disease C 86 364
. C 87 364
improvement C 89 364
occurred C 90 364
in C 91 364
other C 92 364
patients C 93 364
with C 94 364
these C 95 364
diseases C 96 364
and C 97 364
in C 98 364
2 C 99 364
of C 100 364
4 C 101 364
patients C 102 364
with C 103 364
neurodermatitis C 104 364
. C 105 364
two C 107 364
patients C 108 364
with C 109 364
scleroderma C 110 364
experienced C 111 364
only C 112 364
equivocal C 113 364
benefit C 114 364
. C 115 364
significant C 117 364
toxicity C 118 364
attributable C 119 364
to C 120 364
the C 121 364
drug C 122 364
was C 123 364
observed C 124 364
in C 125 364
5 C 126 364
patients C 127 364
. C 128 364
assessment C 130 364
of C 131 364
the C 132 364
eventual C 133 364
value C 134 364
of C 135 364
these C 136 364
agents C 137 364
in C 138 364
therapy C 139 364
requires C 140 364
further C 141 364
study C 142 364
. C 143 364
hypotheses C 145 364
regarding C 146 364
the C 147 364
mechanism C 148 364
of C 149 364
action C 150 364
of C 151 364
these C 152 364
agents C 153 364
and C 154 364
the C 155 364
significance C 156 364
of C 157 364
clinical C 158 364
response C 159 364
are C 160 364
discussed C 161 364
. C 162 364
2469 C 1 365
. C 2 365
the C 4 365
nature C 5 365
of C 6 365
collagen C 7 365
disease C 8 365
, C 9 365
particularly C 10 365
of C 11 365
systemic C 12 365
lupus C 13 365
erythematosus C 14 365
( C 15 365
sle C 16 365
) C 17 365
, C 18 365
with C 19 365
special C 20 365
reference C 21 365
to C 22 365
renal C 23 365
lesions C 24 365
( C 25 365
japanese C 26 365
) C 27 365
from C 28 365
the C 29 365
results C 30 365
of C 31 365
examination C 32 365
of C 33 365
161 C 34 365
autopsy C 35 365
cases C 36 365
of C 37 365
collagen C 38 365
diseases C 39 365
, C 40 365
rheumatic C 41 365
fever C 42 365
and C 43 365
polyarteritis C 44 365
nodosa C 45 365
( C 46 365
pn C 47 365
) C 48 365
are C 49 365
considered C 50 365
as C 51 365
diseases C 52 365
of C 53 365
hyperergic C 54 365
nature C 55 365
, C 56 365
showing C 57 365
pronounced C 58 365
specific C 59 365
manifestation C 60 365
in C 61 365
particular C 62 365
organs C 63 365
. C 64 365
as C 66 365
the C 67 365
reactivity C 68 365
becomes C 69 365
lower C 70 365
, C 71 365
this C 72 365
specific C 73 365
localization C 74 365
becomes C 75 365
less C 76 365
significant C 77 365
and C 78 365
many C 79 365
organs C 80 365
become C 81 365
affected C 82 365
in C 83 365
sle C 84 365
. C 85 365
it C 87 365
may C 88 365
accordingly C 89 365
be C 90 365
supposed C 91 365
that C 92 365
sle C 93 365
is C 94 365
not C 95 365
a C 96 365
disease C 97 365
of C 98 365
hypersensitivity C 99 365
but C 100 365
one C 101 365
occurring C 102 365
in C 103 365
a C 104 365
state C 105 365
of C 106 365
exhaustion C 107 365
of C 108 365
reactability C 109 365
after C 110 365
prolonged C 111 365
sensitization C 112 365
. C 113 365
moreover C 115 365
, C 116 365
a C 117 365
sle C 118 365
- C 119 365
like C 120 365
syndrome C 121 365
arises C 122 365
not C 123 365
only C 124 365
in C 125 365
the C 126 365
end C 127 365
stage C 128 365
of C 129 365
parasepsis C 130 365
, C 131 365
nephritis C 132 365
, C 133 365
nephrosis C 134 365
and C 135 365
some C 136 365
cases C 137 365
of C 138 365
prolonged C 139 365
sensitization C 140 365
by C 141 365
myco C 142 365
. C 143 365
. C 144 365
. C 144 365
but C 145 365
also C 146 365
in C 147 365
pn C 148 365
, C 149 365
pss C 150 365
, C 151 365
dm C 152 365
and C 153 365
rheumatism C 154 365
. C 155 365
it C 157 365
may C 158 365
therefore C 159 365
be C 160 365
conceivable C 161 365
that C 162 365
sle C 163 365
is C 164 365
a C 165 365
syndrome C 166 365
rather C 167 365
than C 168 365
a C 169 365
separate C 170 365
entity C 171 365
. C 172 365
it C 174 365
is C 175 365
most C 176 365
important C 177 365
to C 178 365
consider C 179 365
whether C 180 365
sle C 181 365
- C 182 365
like C 183 365
symptomatology C 184 365
may C 185 365
be C 186 365
regarded C 187 365
as C 188 365
a C 189 365
process C 190 365
equal C 191 365
to C 192 365
an C 193 365
auto C 194 365
- C 195 365
immunization C 196 365
and C 197 365
whether C 198 365
the C 199 365
key C 200 365
to C 201 365
morphological C 202 365
elucidation C 203 365
of C 204 365
the C 205 365
auto C 206 365
- C 207 365
immune C 208 365
phenomenon C 209 365
may C 210 365
lie C 211 365
hidden C 212 365
in C 213 365
this C 214 365
problem C 215 365
. C 216 365
420 C 1 366
. C 2 366
therapy C 4 366
of C 5 366
lupus C 6 366
nephropathies C 7 366
by C 8 366
6 C 9 366
- C 10 366
mercaptopurine C 11 366
corticosteroid C 12 366
therapy C 13 366
improved C 14 366
the C 15 366
general C 16 366
prognosis C 17 366
of C 18 366
sle C 19 366
, C 20 366
but C 21 366
has C 22 366
no C 23 366
detectable C 24 366
effect C 25 366
on C 26 366
the C 27 366
nephropathy C 28 366
and C 29 366
this C 30 366
is C 31 366
actually C 32 366
the C 33 366
main C 34 366
cause C 35 366
of C 36 366
death C 37 366
. C 38 366
a C 40 366
new C 41 366
therapeutic C 42 366
method C 43 366
is C 44 366
presented C 45 366
using C 46 366
6 C 47 366
- C 48 366
mp C 49 366
purinethol C 50 366
( C 51 366
leupurin C 52 366
) C 53 366
which C 54 366
produced C 55 366
2 C 56 366
remissions C 57 366
in C 58 366
6 C 59 366
consecutive C 60 366
cases C 61 366
total C 62 366
and C 63 366
in C 64 366
4 C 65 366
cases C 66 366
with C 67 366
severe C 68 366
nephropathy C 69 366
definite C 70 366
remission C 71 366
. C 72 366
it C 74 366
should C 75 366
be C 76 366
emphasized C 77 366
that C 78 366
5 C 79 366
of C 80 366
the C 81 366
cases C 82 366
reported C 83 366
had C 84 366
definite C 85 366
npn C 86 366
elevation C 87 366
, C 88 366
accordingly C 89 366
they C 90 366
are C 91 366
considered C 92 366
hopeless C 93 366
. C 94 366
2475 C 1 367
. C 2 367
lupus C 4 367
erythematosus C 5 367
with C 6 367
fatal C 7 367
hemorrhage C 8 367
into C 9 367
the C 10 367
liver C 11 367
and C 12 367
lesions C 13 367
resembling C 14 367
those C 15 367
of C 16 367
periarteritis C 17 367
nodosa C 18 367
and C 19 367
malignant C 20 367
hypertension C 21 367
. C 22 367
immunocytochemical C 24 367
observations C 25 367
a C 26 367
firmly C 27 367
established C 28 367
case C 29 367
of C 30 367
lupus C 31 367
erythematosus C 32 367
with C 33 367
histologic C 34 367
characteristics C 35 367
of C 36 367
periarteritis C 37 367
nodosa C 38 367
and C 39 367
fatal C 40 367
hemorrhage C 41 367
is C 42 367
presented C 43 367
. C 44 367
immunocytochemical C 46 367
studies C 47 367
were C 48 367
done C 49 367
to C 50 367
explore C 51 367
the C 52 367
possibility C 53 367
of C 54 367
the C 55 367
vascular C 56 367
lesions C 57 367
being C 58 367
immunological C 59 367
in C 60 367
type C 61 367
. C 62 367
by C 64 367
immuno C 65 367
- C 66 367
fluorescent C 67 367
techniques C 68 367
y C 69 367
- C 70 367
globulin C 71 367
, C 72 367
human C 73 367
serum C 74 367
complement C 75 367
, C 76 367
albumin C 77 367
and C 78 367
fibrinogen C 79 367
were C 80 367
demonstrated C 81 367
in C 82 367
the C 83 367
vascular C 84 367
lesions C 85 367
. C 86 367
y C 88 367
- C 89 367
globulin C 90 367
in C 91 367
the C 92 367
renal C 93 367
glomeruli C 94 367
was C 95 367
associated C 96 367
only C 97 367
with C 98 367
complement C 99 367
. C 100 367
the C 102 367
conclusion C 103 367
is C 104 367
that C 105 367
lupus C 106 367
erythematosus C 107 367
is C 108 367
primarily C 109 367
an C 110 367
immunological C 111 367
disease C 112 367
with C 113 367
complex C 114 367
auto C 115 367
- C 116 367
immune C 117 367
mechanisms C 118 367
operative C 119 367
. C 120 367
198 C 1 368
. C 2 368
early C 4 368
experiences C 5 368
with C 6 368
azathioprine C 7 368
in C 8 368
ulcerative C 9 368
colitis C 10 368
. C 11 368
a C 13 368
note C 14 368
of C 15 368
caution C 16 368
azathioprine C 17 368
was C 18 368
administered C 19 368
to C 20 368
10 C 21 368
patients C 22 368
with C 23 368
ulcerative C 24 368
colitis C 25 368
classified C 26 368
as C 27 368
' C 28 368
very C 29 368
severe C 30 368
' C 31 368
in C 32 368
2 C 33 368
, C 34 368
' C 35 368
moderately C 36 368
severe C 37 368
' C 38 368
in C 39 368
7 C 40 368
and C 41 368
' C 42 368
relatively C 43 368
mild C 44 368
' C 45 368
in C 46 368
1 C 47 368
patient C 48 368
, C 49 368
in C 50 368
conjunction C 51 368
with C 52 368
' C 53 368
standard C 54 368
' C 55 368
therapy C 56 368
and C 57 368
adrenal C 58 368
corticosteroids C 59 368
in C 60 368
8 C 61 368
of C 62 368
the C 63 368
10 C 64 368
patients C 65 368
. C 66 368
the C 68 368
possible C 69 368
beneficial C 70 368
therapeutic C 71 368
effects C 72 368
of C 73 368
azathioprine C 74 368
in C 75 368
this C 76 368
small C 77 368
series C 78 368
cannot C 79 368
be C 80 368
evaluated C 81 368
definitively C 82 368
because C 83 368
of C 84 368
the C 85 368
concurrent C 86 368
medication C 87 368
and C 88 368
the C 89 368
preliminary C 90 368
uncontrolled C 91 368
observations C 92 368
. C 93 368
however C 95 368
, C 96 368
clinical C 97 368
improvement C 98 368
was C 99 368
apparent C 100 368
in C 101 368
8 C 102 368
of C 103 368
the C 104 368
10 C 105 368
patients C 106 368
; C 107 368
and C 108 368
in C 109 368
2 C 110 368
patients C 111 368
, C 112 368
the C 113 368
favorable C 114 368
course C 115 368
occurred C 116 368
in C 117 368
the C 118 368
absence C 119 368
of C 120 368
steroid C 121 368
therapy C 122 368
. C 123 368
in C 125 368
2 C 126 368
additional C 127 368
patients C 128 368
, C 129 368
the C 130 368
favorable C 131 368
course C 132 368
was C 133 368
maintained C 134 368
during C 135 368
the C 136 368
administration C 137 368
of C 138 368
azathioprine C 139 368
following C 140 368
the C 141 368
discontinuance C 142 368
of C 143 368
prolonged C 144 368
steroid C 145 368
therapy C 146 368
. C 147 368
in C 149 368
1 C 150 368
patient C 151 368
, C 152 368
the C 153 368
administration C 154 368
of C 155 368
azathioprine C 156 368
was C 157 368
associated C 158 368
with C 159 368
amelioration C 160 368
of C 161 368
an C 162 368
arthritis C 163 368
and C 164 368
pyoderma C 165 368
gangrenosum C 166 368
which C 167 368
did C 168 368
not C 169 368
respond C 170 368
to C 171 368
the C 172 368
use C 173 368
of C 174 368
steroids C 175 368
and C 176 368
other C 177 368
medication C 178 368
. C 179 368
immuno C 181 368
- C 182 368
suppressive C 183 368
observations C 184 368
were C 185 368
limited C 186 368
. C 187 368
the C 189 368
established C 190 368
delayed C 191 368
hypersensitivity C 192 368
response C 193 368
, C 194 368
as C 195 368
reflected C 196 368
in C 197 368
various C 198 368
skin C 199 368
tests C 200 368
, C 201 368
was C 202 368
unchanged C 203 368
during C 204 368
the C 205 368
administration C 206 368
of C 207 368
azathioprine C 208 368
. C 209 368
azathioprine C 211 368
had C 212 368
no C 213 368
discernible C 214 368
toxic C 215 368
effects C 216 368
upon C 217 368
the C 218 368
kidneys C 219 368
or C 220 368
the C 221 368
liver C 222 368
in C 223 368
2 C 224 368
patients C 225 368
, C 226 368
1 C 227 368
with C 228 368
postnecrotic C 229 368
cirrhosis C 230 368
and C 231 368
the C 232 368
other C 233 368
with C 234 368
serum C 235 368
hepatitis C 236 368
. C 237 368
gastro C 239 368
- C 240 368
intestinal C 241 368
symptoms C 242 368
( C 243 368
anorexia C 244 368
, C 245 368
epigastric C 246 368
discomfort C 247 368
, C 248 368
and C 249 368
nausea C 250 368
) C 251 368
occurred C 252 368
in C 253 368
8 C 254 368
patients C 255 368
. C 256 368
mild C 258 368
to C 259 368
moderate C 260 368
leukopenia C 261 368
developed C 262 368
in C 263 368
8 C 264 368
patients C 265 368
and C 266 368
, C 267 368
in C 268 368
2 C 269 368
individuals C 270 368
, C 271 368
was C 272 368
accompanied C 273 368
by C 274 368
thrombocytopenia C 275 368
. C 276 368
temporary C 278 368
alopecia C 279 368
occurred C 280 368
in C 281 368
1 C 282 368
woman C 283 368
. C 284 368
the C 286 368
hematopoietic C 287 368
effects C 288 368
developed C 289 368
within C 290 368
2 C 291 368
or C 292 368
3 C 293 368
wk C 294 368
of C 295 368
therapy C 296 368
with C 297 368
azathioprine C 298 368
at C 299 368
a C 300 368
dosage C 301 368
level C 302 368
of C 303 368
4 C 304 368
- C 305 368
6 C 306 368
mg C 307 368
/ C 308 368
kg C 309 368
/ C 310 368
day C 311 368
. C 312 368
azathioprine C 314 368
does C 315 368
not C 316 368
exert C 317 368
the C 318 368
rapid C 319 368
beneficial C 320 368
effect C 321 368
in C 322 368
ulcerative C 323 368
colitis C 324 368
noted C 325 368
with C 326 368
corticotropin C 327 368
and C 328 368
adrenal C 329 368
corticosteroids C 330 368
. C 331 368
therefore C 333 368
, C 334 368
its C 335 368
use C 336 368
in C 337 368
severe C 338 368
ulcerative C 339 368
colitis C 340 368
requiring C 341 368
intensive C 342 368
therapy C 343 368
probably C 344 368
is C 345 368
undesirable C 346 368
. C 347 368
azathioprine C 349 368
, C 350 368
on C 351 368
the C 352 368
basis C 353 368
of C 354 368
these C 355 368
initial C 356 368
observations C 357 368
, C 358 368
may C 359 368
be C 360 368
considered C 361 368
for C 362 368
moderately C 363 368
severe C 364 368
ulcerative C 365 368
colitis C 366 368
, C 367 368
under C 368 368
circumstances C 369 368
permitting C 370 368
controlled C 371 368
and C 372 368
prolonged C 373 368
therapeutic C 374 368
trial C 375 368
as C 376 368
adjunct C 377 368
medication C 378 368
, C 379 368
but C 380 368
with C 381 368
careful C 382 368
supervision C 383 368
for C 384 368
prevention C 385 368
of C 386 368
toxicity C 387 368
, C 388 368
especially C 389 368
leukopenia C 390 368
. C 391 368
1281 C 1 369
. C 2 369
effect C 4 369
of C 5 369
fluoropyrimidines C 6 369
on C 7 369
delayed C 8 369
cutaneous C 9 369
hypersensitivity C 10 369
the C 11 369
ability C 12 369
to C 13 369
express C 14 369
delayed C 15 369
cutaneous C 16 369
hypersensitivity C 17 369
was C 18 369
assessed C 19 369
in C 20 369
51 C 21 369
patients C 22 369
with C 23 369
carcinoma C 24 369
. C 25 369
evidence C 27 369
is C 28 369
presented C 29 369
that C 30 369
5 C 31 369
- C 32 369
fluorouracil C 33 369
and C 34 369
5 C 35 369
- C 36 369
fluoro C 37 369
- C 38 369
2 C 39 369
' C 40 369
- C 41 369
deoxyuridine C 42 369
paradoxically C 43 369
potentiate C 44 369
this C 45 369
parameter C 46 369
of C 47 369
immune C 48 369
responsiveness C 49 369
. C 50 369
248 C 1 370
. C 2 370
data C 4 370
on C 5 370
etiology C 6 370
, C 7 370
pathogenesis C 8 370
, C 9 370
treatment C 10 370
results C 11 370
and C 12 370
survival C 13 370
period C 14 370
in C 15 370
560 C 16 370
patients C 17 370
with C 18 370
cirrhosis C 19 370
of C 20 370
the C 21 370
liver C 22 370
statistics C 23 370
were C 24 370
compiled C 25 370
from C 26 370
a C 27 370
total C 28 370
of C 29 370
560 C 30 370
cases C 31 370
chosen C 32 370
at C 33 370
random C 34 370
, C 35 370
of C 36 370
cirrhosis C 37 370
of C 38 370
the C 39 370
liver C 40 370
. C 41 370
the C 43 370
figures C 44 370
refer C 45 370
to C 46 370
the C 47 370
age C 48 370
and C 49 370
sex C 50 370
of C 51 370
the C 52 370
patients C 53 370
, C 54 370
as C 55 370
well C 56 370
as C 57 370
to C 58 370
the C 59 370
etiology C 60 370
and C 61 370
the C 62 370
hepatic C 63 370
morphology C 64 370
. C 65 370
as C 67 370
the C 68 370
date C 69 370
of C 70 370
death C 71 370
of C 72 370
304 C 73 370
of C 74 370
the C 75 370
subjects C 76 370
was C 77 370
known C 78 370
, C 79 370
it C 80 370
was C 81 370
possible C 82 370
to C 83 370
calculate C 84 370
the C 85 370
survival C 86 370
time C 87 370
after C 88 370
the C 89 370
diagnosis C 90 370
was C 91 370
made C 92 370
. C 93 370
only C 95 370
36 C 96 370
% C 97 370
survived C 98 370
the C 99 370
time C 100 370
of C 101 370
diagnosis C 102 370
by C 103 370
1 C 104 370
year C 105 370
, C 106 370
16 C 107 370
% C 108 370
by C 109 370
3 C 110 370
years C 111 370
, C 112 370
and C 113 370
8 C 114 370
% C 115 370
by C 116 370
5 C 117 370
years C 118 370
. C 119 370
these C 121 370
figures C 122 370
show C 123 370
that C 124 370
modern C 125 370
therapy C 126 370
of C 127 370
liver C 128 370
cirrhosis C 129 370
has C 130 370
up C 131 370
to C 132 370
now C 133 370
not C 134 370
succeeded C 135 370
to C 136 370
prolong C 137 370
the C 138 370
life C 139 370
of C 140 370
the C 141 370
majority C 142 370
of C 143 370
the C 144 370
victims C 145 370
. C 146 370
in C 148 370
many C 149 370
cases C 150 370
, C 151 370
however C 152 370
, C 153 370
it C 154 370
is C 155 370
possible C 156 370
to C 157 370
a C 158 370
large C 159 370
extent C 160 370
to C 161 370
relieve C 162 370
the C 163 370
patients C 164 370
' C 165 370
suffering C 166 370
by C 167 370
improving C 168 370
the C 169 370
appetite C 170 370
and C 171 370
the C 172 370
general C 173 370
condition C 174 370
and C 175 370
by C 176 370
eliminating C 177 370
ascites C 178 370
and C 179 370
periods C 180 370
of C 181 370
hemorrhage C 182 370
and C 183 370
stupor C 184 370
. C 185 370
particular C 187 370
attention C 188 370
should C 189 370
be C 190 370
paid C 191 370
to C 192 370
the C 193 370
prophylaxis C 194 370
of C 195 370
the C 196 370
disease C 197 370
and C 198 370
, C 199 370
by C 200 370
studying C 201 370
the C 202 370
survival C 203 370
time C 204 370
assessments C 205 370
and C 206 370
therapeutic C 207 370
reports C 208 370
, C 209 370
to C 210 370
the C 211 370
method C 212 370
of C 213 370
selection C 214 370
of C 215 370
the C 216 370
subjects C 217 370
. C 218 370
897 C 1 371
. C 2 371
chronic C 4 371
renal C 5 371
diseases C 6 371
and C 7 371
pregnancy C 8 371
a C 9 371
review C 10 371
a C 11 371
review C 12 371
is C 13 371
given C 14 371
of C 15 371
the C 16 371
reciprocal C 17 371
relationships C 18 371
between C 19 371
chronic C 20 371
renal C 21 371
disease C 22 371
and C 23 371
pregnancy C 24 371
. C 25 371
after C 27 371
a C 28 371
short C 29 371
review C 30 371
of C 31 371
the C 32 371
most C 33 371
important C 34 371
changes C 35 371
in C 36 371
renal C 37 371
function C 38 371
due C 39 371
to C 40 371
normal C 41 371
pregnancy C 42 371
, C 43 371
the C 44 371
diagnosis C 45 371
of C 46 371
chronic C 47 371
renal C 48 371
disease C 49 371
is C 50 371
discussed C 51 371
. C 52 371
subsequently C 54 371
, C 55 371
the C 56 371
following C 57 371
complications C 58 371
of C 59 371
pregnancy C 60 371
are C 61 371
discussed C 62 371
individually C 63 371
chronic C 64 371
pyelonephritis C 65 371
, C 66 371
chronic C 67 371
glomerulonephritis C 68 371
, C 69 371
lupus C 70 371
erythematosus C 71 371
, C 72 371
the C 73 371
nephrotic C 74 371
syndrome C 75 371
, C 76 371
diabetic C 77 371
nephropathy C 78 371
and C 79 371
polycystic C 80 371
disease C 81 371
of C 82 371
the C 83 371
kidney C 84 371
. C 85 371
the C 87 371
paper C 88 371
is C 89 371
concluded C 90 371
by C 91 371
a C 92 371
discussion C 93 371
on C 94 371
the C 95 371
influence C 96 371
of C 97 371
pregnancy C 98 371
on C 99 371
the C 100 371
different C 101 371
renal C 102 371
affections C 103 371
. C 104 371
4193 C 1 372
. C 2 372
the C 4 372
occurrence C 5 372
to C 6 372
cytomegalovirus C 7 372
infections C 8 372
in C 9 372
childhood C 10 372
leukemia C 11 372
. C 12 372
report C 14 372
of C 15 372
three C 16 372
cases C 17 372
cytomegalic C 18 372
inclusion C 19 372
disease C 20 372
( C 21 372
cmid C 22 372
) C 23 372
presented C 24 372
the C 25 372
following C 26 372
clinical C 27 372
findings C 28 372
in C 29 372
three C 30 372
children C 31 372
with C 32 372
acute C 33 372
leukemia C 34 372
persistent C 35 372
high C 36 372
temperature C 37 372
, C 38 372
cough C 39 372
, C 40 372
vomiting C 41 372
, C 42 372
diarrhea C 43 372
, C 44 372
hepatosplenomegaly C 45 372
, C 46 372
rales C 47 372
, C 48 372
and C 49 372
terminal C 50 372
icterus C 51 372
. C 52 372
pancytopenia C 54 372
was C 55 372
present C 56 372
in C 57 372
all C 58 372
, C 59 372
including C 60 372
two C 61 372
children C 62 372
in C 63 372
leukemic C 64 372
remission C 65 372
. C 66 372
roentgenographic C 68 372
evidence C 69 372
of C 70 372
pneumonia C 71 372
did C 72 372
not C 73 372
appear C 74 372
until C 75 372
the C 76 372
third C 77 372
week C 78 372
after C 79 372
the C 80 372
onset C 81 372
of C 82 372
symptoms C 83 372
. C 84 372
abnormalities C 86 372
in C 87 372
liver C 88 372
function C 89 372
tests C 90 372
were C 91 372
late C 92 372
findings C 93 372
. C 94 372
intranuclear C 96 372
inclusions C 97 372
were C 98 372
seen C 99 372
in C 100 372
urine C 101 372
sediments C 102 372
of C 103 372
two C 104 372
patients C 105 372
. C 106 372
in C 108 372
neither C 109 372
of C 110 372
these C 111 372
patients C 112 372
were C 113 372
intranuclear C 114 372
inclusions C 115 372
demonstrable C 116 372
in C 117 372
the C 118 372
sputa C 119 372
. C 120 372
virus C 122 372
culture C 123 372
from C 124 372
urine C 125 372
was C 126 372
done C 127 372
in C 128 372
one C 129 372
of C 130 372
these C 131 372
patients C 132 372
and C 133 372
cytopathogenic C 134 372
changes C 135 372
characteristic C 136 372
of C 137 372
cytomegalovirus C 138 372
( C 139 372
cmv C 140 372
) C 141 372
were C 142 372
demonstrated C 143 372
. C 144 372
cmid C 146 372
was C 147 372
the C 148 372
cause C 149 372
of C 150 372
death C 151 372
in C 152 372
these C 153 372
three C 154 372
children C 155 372
, C 156 372
all C 157 372
of C 158 372
whom C 159 372
had C 160 372
received C 161 372
chemotherapy C 162 372
with C 163 372
agents C 164 372
known C 165 372
to C 166 372
have C 167 372
immunosuppressive C 168 372
properties C 169 372
. C 170 372
. C 1 373
on C 3 373
chorea C 4 373
, C 5 373
lupus C 6 373
erythematosus C 7 373
, C 8 373
and C 9 373
cerebral C 10 373
arteritis C 11 373
a C 12 373
woman C 13 373
aged C 14 373
33 C 15 373
developed C 16 373
chorea C 17 373
10 C 18 373
yr C 19 373
after C 20 373
the C 21 373
onset C 22 373
of C 23 373
systemic C 24 373
lupus C 25 373
erythematosus C 26 373
( C 27 373
sle C 28 373
) C 29 373
. C 30 373
she C 32 373
had C 33 373
experienced C 34 373
an C 35 373
asymptomatic C 36 373
interval C 37 373
of C 38 373
8 C 39 373
yr C 40 373
. C 41 373
the C 43 373
abnormal C 44 373
movements C 45 373
persisted C 46 373
for C 47 373
5 C 48 373
mth C 49 373
, C 50 373
but C 51 373
then C 52 373
subsided C 53 373
after C 54 373
short C 55 373
- C 56 373
term C 57 373
administration C 58 373
of C 59 373
6 C 60 373
- C 61 373
mercaptopurine C 62 373
. C 63 373
there C 65 373
are C 66 373
11 C 67 373
previous C 68 373
descriptions C 69 373
of C 70 373
chorea C 71 373
patients C 72 373
with C 73 373
sle C 74 373
. C 75 373
in C 77 373
3 C 78 373
out C 79 373
of C 80 373
4 C 81 373
autopsied C 82 373
cases C 83 373
, C 84 373
extensive C 85 373
cerebral C 86 373
lesions C 87 373
due C 88 373
to C 89 373
diffuse C 90 373
arteritis C 91 373
were C 92 373
found C 93 373
. C 94 373
the C 96 373
cns C 97 373
changes C 98 373
were C 99 373
quite C 100 373
similar C 101 373
to C 102 373
those C 103 373
found C 104 373
in C 105 373
chorea C 106 373
minor C 107 373
. C 108 373
1878 C 1 374
. C 2 374
pharmacologic C 4 374
actions C 5 374
on C 6 374
cellular C 7 374
immunity C 8 374
the C 9 374
following C 10 374
chapters C 11 374
of C 12 374
interest C 13 374
in C 14 374
the C 15 374
field C 16 374
of C 17 374
drugs C 18 374
and C 19 374
immunity C 20 374
processes C 21 374
are C 22 374
included C 23 374
manifestations C 24 374
of C 25 374
cellular C 26 374
immunity C 27 374
. C 28 374
states C 30 374
of C 31 374
reduced C 32 374
immunologic C 33 374
reactivity C 34 374
. C 35 374
present C 37 374
status C 38 374
of C 39 374
pharmacologic C 40 374
immunosuppression C 41 374
. C 42 374
tests C 44 374
for C 45 374
susceptibility C 46 374
of C 47 374
tuberculin C 48 374
reactions C 49 374
to C 50 374
pharmacologic C 51 374
action C 52 374
. C 53 374
tests C 55 374
for C 56 374
susceptibility C 57 374
of C 58 374
transplantation C 59 374
immunity C 60 374
to C 61 374
pharmacologic C 62 374
action C 63 374
. C 64 374
comparative C 66 374
susceptibilities C 67 374
of C 68 374
tuberculin C 69 374
and C 70 374
skin C 71 374
homotransplantation C 72 374
reactions C 73 374
to C 74 374
pharmacologic C 75 374
action C 76 374
. C 77 374
2625 C 1 375
. C 2 375
chromosome C 4 375
aberrations C 5 375
in C 6 375
human C 7 375
cells C 8 375
following C 9 375
treatment C 10 375
with C 11 375
imuran C 12 375
five C 13 375
women C 14 375
with C 15 375
various C 16 375
collagen C 17 375
diseases C 18 375
were C 19 375
studied C 20 375
. C 21 375
bone C 23 375
marrow C 24 375
aspirates C 25 375
were C 26 375
obtained C 27 375
from C 28 375
each C 29 375
patient C 30 375
before C 31 375
and C 32 375
12 C 33 375
to C 34 375
24 C 35 375
days C 36 375
after C 37 375
start C 38 375
of C 39 375
imuran C 40 375
( C 41 375
azothioprine C 42 375
) C 43 375
therapy C 44 375
. C 45 375
fifty C 47 375
metaphases C 48 375
from C 49 375
each C 50 375
sample C 51 375
were C 52 375
counted C 53 375
. C 54 375
in C 56 375
patients C 57 375
nos C 58 375
. C 59 375
1 C 61 375
and C 62 375
2 C 63 375
the C 64 375
increase C 65 375
in C 66 375
cells C 67 375
with C 68 375
structural C 69 375
abnormalities C 70 375
during C 71 375
therapy C 72 375
is C 73 375
significant C 74 375
. C 75 375
the C 77 375
aberrations C 78 375
found C 79 375
were C 80 375
mostly C 81 375
breaks C 82 375
of C 83 375
the C 84 375
chromatid C 85 375
and C 86 375
chromosomal C 87 375
type C 88 375
. C 89 375
a C 91 375
few C 92 375
abnormal C 93 375
chromosomes C 94 375
were C 95 375
seen C 96 375
, C 97 375
among C 98 375
which C 99 375
a C 100 375
ring C 101 375
chromosome C 102 375
. C 103 375
in C 105 375
patient C 106 375
no C 107 375
. C 108 375
1 C 110 375
chromatid C 111 375
exchanges C 112 375
were C 113 375
seen C 114 375
in C 115 375
three C 116 375
cells C 117 375
. C 118 375
3645 C 1 376
. C 2 376
autoimmune C 4 376
hepatitis C 5 376
in C 6 376
30 C 7 376
% C 8 376
of C 9 376
301 C 10 376
patients C 11 376
with C 12 376
cirrhosis C 13 376
, C 14 376
the C 15 376
cause C 16 376
was C 17 376
uncertain C 18 376
. C 19 376
of C 21 376
these C 22 376
90 C 23 376
cases C 24 376
the C 25 376
clinical C 26 376
picture C 27 376
of C 28 376
active C 29 376
chronic C 30 376
hepatitis C 31 376
could C 32 376
be C 33 376
recognized C 34 376
in C 35 376
69 C 36 376
, C 37 376
and C 38 376
26 C 39 376
of C 40 376
these C 41 376
were C 42 376
characterized C 43 376
as C 44 376
lupoid C 45 376
hepatitis C 46 376
. C 47 376
the C 49 376
relationship C 50 376
between C 51 376
active C 52 376
chronic C 53 376
hepatitis C 54 376
, C 55 376
lupoid C 56 376
hepatitis C 57 376
and C 58 376
sle C 59 376
was C 60 376
studied C 61 376
in C 62 376
3 C 63 376
groups C 64 376
of C 65 376
25 C 66 376
cases C 67 376
each C 68 376
. C 69 376
a C 71 376
comparison C 72 376
was C 73 376
then C 74 376
made C 75 376
between C 76 376
the C 77 376
possible C 78 376
etiological C 79 376
factors C 80 376
, C 81 376
the C 82 376
systemic C 83 376
manifestations C 84 376
, C 85 376
the C 86 376
survival C 87 376
rate C 88 376
, C 89 376
the C 90 376
histological C 91 376
appearances C 92 376
, C 93 376
the C 94 376
biochemical C 95 376
tests C 96 376
, C 97 376
the C 98 376
autoimmune C 99 376
reactions C 100 376
and C 101 376
the C 102 376
results C 103 376
of C 104 376
the C 105 376
immunosuppressive C 106 376
drugs C 107 376
. C 108 376
from C 110 376
this C 111 376
study C 112 376
a C 113 376
concept C 114 376
emerged C 115 376
according C 116 376
to C 117 376
which C 118 376
a C 119 376
proportion C 120 376
of C 121 376
cases C 122 376
of C 123 376
cirrhosis C 124 376
occurring C 125 376
in C 126 376
adequately C 127 376
nourished C 128 376
individuals C 129 376
can C 130 376
be C 131 376
attributed C 132 376
to C 133 376
the C 134 376
end C 135 376
result C 136 376
of C 137 376
an C 138 376
autoimmune C 139 376
reaction C 140 376
. C 141 376
766 C 1 377
. C 2 377
a C 4 377
comparison C 5 377
of C 6 377
the C 7 377
effects C 8 377
of C 9 377
selected C 10 377
cytotoxic C 11 377
agents C 12 377
on C 13 377
the C 14 377
primary C 15 377
agglutinin C 16 377
response C 17 377
in C 18 377
rats C 19 377
injected C 20 377
with C 21 377
sheep C 22 377
erythrocytes C 23 377
a C 24 377
comparative C 25 377
study C 26 377
was C 27 377
made C 28 377
of C 29 377
the C 30 377
effects C 31 377
of C 32 377
several C 33 377
cytotoxic C 34 377
agents C 35 377
, C 36 377
given C 37 377
at C 38 377
maximally C 39 377
tolerable C 40 377
doses C 41 377
, C 42 377
on C 43 377
the C 44 377
primary C 45 377
agglutinin C 46 377
response C 47 377
in C 48 377
rats C 49 377
immunized C 50 377
with C 51 377
sheep C 52 377
erythrocytes C 53 377
given C 54 377
intraperitoneally C 55 377
. C 56 377
antigen C 58 377
was C 59 377
given C 60 377
before C 61 377
, C 62 377
at C 63 377
the C 64 377
beginning C 65 377
, C 66 377
or C 67 377
in C 68 377
the C 69 377
middle C 70 377
of C 71 377
a C 72 377
5 C 73 377
- C 74 377
day C 75 377
course C 76 377
of C 77 377
drug C 78 377
treatment C 79 377
. C 80 377
chlormethine C 82 377
( C 83 377
mechlorethamine C 84 377
) C 85 377
, C 86 377
5 C 87 377
- C 88 377
fluorouracil C 89 377
, C 90 377
and C 91 377
5 C 92 377
- C 93 377
fluoro C 94 377
- C 95 377
2 C 96 377
' C 97 377
- C 98 377
deoxyuridine C 99 377
did C 100 377
not C 101 377
suppress C 102 377
the C 103 377
primary C 104 377
response C 105 377
significantly C 106 377
. C 107 377
methotrexate C 109 377
, C 110 377
6 C 111 377
- C 112 377
mercaptopurine C 113 377
, C 114 377
6 C 115 377
- C 116 377
mercaptopurine C 117 377
roboside C 118 377
and C 119 377
2 C 120 377
- C 121 377
amino C 122 377
- C 123 377
6 C 124 377
- C 125 377
( C 126 377
( C 127 377
1 C 128 377
- C 129 377
methyl C 130 377
- C 131 377
4 C 132 377
- C 133 377
nitro C 134 377
- C 135 377
5 C 136 377
- C 137 377
imidazolyl C 138 377
) C 139 377
thio C 140 377
) C 141 377
purine C 142 377
prolonged C 143 377
induction C 144 377
time C 145 377
and C 146 377
suppressed C 147 377
peak C 148 377
titer C 149 377
maximally C 150 377
when C 151 377
immunization C 152 377
was C 153 377
performed C 154 377
one C 155 377
to C 156 377
three C 157 377
days C 158 377
prior C 159 377
to C 160 377
drug C 161 377
treatment C 162 377
. C 163 377
vinblastine C 165 377
did C 166 377
not C 167 377
affect C 168 377
peak C 169 377
titer C 170 377
, C 171 377
but C 172 377
did C 173 377
prolong C 174 377
induction C 175 377
time C 176 377
when C 177 377
antigen C 178 377
was C 179 377
given C 180 377
2 C 181 377
days C 182 377
prior C 183 377
to C 184 377
drug C 185 377
treatment C 186 377
. C 187 377
cyclophosphamide C 189 377
markedly C 190 377
prolonged C 191 377
induction C 192 377
time C 193 377
and C 194 377
suppressed C 195 377
peak C 196 377
titer C 197 377
irrespective C 198 377
of C 199 377
the C 200 377
time C 201 377
of C 202 377
antigen C 203 377
administration C 204 377
. C 205 377
the C 207 377
antimetabolites C 208 377
appeared C 209 377
to C 210 377
suppress C 211 377
maximally C 212 377
the C 213 377
intermediate C 214 377
stage C 215 377
of C 216 377
the C 217 377
primary C 218 377
response C 219 377
. C 220 377
cyclophosphamide C 222 377
appeared C 223 377
to C 224 377
suppress C 225 377
all C 226 377
stages C 227 377
. C 228 377
1959 C 1 378
. C 2 378
analysis C 4 378
of C 5 378
mechanism C 6 378
of C 7 378
immunosuppressive C 8 378
drugs C 9 378
in C 10 378
renal C 11 378
homotransplantation C 12 378
dammin C 13 378
g C 14 378
. C 15 378
j C 17 378
. C 18 378
a C 20 378
long C 21 378
- C 22 378
term C 23 378
study C 24 378
of C 25 378
the C 26 378
mechanism C 27 378
of C 28 378
action C 29 378
of C 30 378
immunosuppressive C 31 378
drugs C 32 378
has C 33 378
been C 34 378
completed C 35 378
in C 36 378
bilaterally C 37 378
nephrectomized C 38 378
dogs C 39 378
with C 40 378
kidney C 41 378
homotransplants C 42 378
. C 43 378
over C 45 378
1 C 46 378
, C 47 378
000 C 48 378
test C 49 378
animals C 50 378
with C 51 378
24 C 52 378
different C 53 378
drug C 54 378
protocols C 55 378
have C 56 378
been C 57 378
analyzed C 58 378
. C 59 378
increasing C 61 378
numbers C 62 378
of C 63 378
long C 64 378
surviving C 65 378
animals C 66 378
have C 67 378
posed C 68 378
many C 69 378
questions C 70 378
regarding C 71 378
the C 72 378
status C 73 378
treated C 74 378
host C 75 378
. C 76 378
the C 78 378
current C 79 378
drug C 80 378
protocol C 81 378
of C 82 378
azathioprine C 83 378
and C 84 378
diazoacetylserine C 85 378
( C 86 378
' C 87 378
azaserine C 88 378
' C 89 378
) C 90 378
has C 91 378
produced C 92 378
90 C 93 378
% C 94 378
50 C 95 378
- C 96 378
day C 97 378
survivors C 98 378
and C 99 378
50 C 100 378
% C 101 378
100 C 102 378
- C 103 378
day C 104 378
survivors C 105 378
. C 106 378
the C 108 378
following C 109 378
observations C 110 378
have C 111 378
been C 112 378
documented C 113 378
all C 114 378
animals C 115 378
on C 116 378
prolonged C 117 378
drug C 118 378
therapy C 119 378
are C 120 378
immunologically C 121 378
competent C 122 378
; C 123 378
drug C 124 378
therapy C 125 378
can C 126 378
be C 127 378
stopped C 128 378
successfully C 129 378
in C 130 378
some C 131 378
but C 132 378
not C 133 378
all C 134 378
animals C 135 378
; C 136 378
long C 137 378
surviving C 138 378
kidneys C 139 378
apparently C 140 378
are C 141 378
protected C 142 378
in C 143 378
some C 144 378
way C 145 378
in C 146 378
the C 147 378
new C 148 378
environment C 149 378
because C 150 378
a C 151 378
second C 152 378
donor C 153 378
kidney C 154 378
can C 155 378
be C 156 378
rejected C 157 378
while C 158 378
the C 159 378
first C 160 378
survives C 161 378
; C 162 378
retransplantation C 163 378
of C 164 378
a C 165 378
long C 166 378
surviving C 167 378
kidney C 168 378
back C 169 378
to C 170 378
its C 171 378
original C 172 378
host C 173 378
did C 174 378
not C 175 378
lead C 176 378
to C 177 378
a C 178 378
decrease C 179 378
in C 180 378
renal C 181 378
function C 182 378
; C 183 378
long C 184 378
surviving C 185 378
kidneys C 186 378
successfully C 187 378
retransplanted C 188 378
back C 189 378
to C 190 378
their C 191 378
original C 192 378
donors C 193 378
are C 194 378
rejected C 195 378
when C 196 378
transplanted C 197 378
to C 198 378
third C 199 378
party C 200 378
, C 201 378
non C 202 378
- C 203 378
drug C 204 378
treated C 205 378
recipients C 206 378
; C 207 378
immune C 208 378
paralysis C 209 378
does C 210 378
not C 211 378
account C 212 378
for C 213 378
the C 214 378
prolonged C 215 378
survival C 216 378
because C 217 378
the C 218 378
second C 219 378
donor C 220 378
kidney C 221 378
which C 222 378
constitutes C 223 378
a C 224 378
double C 225 378
dose C 226 378
of C 227 378
antigen C 228 378
is C 229 378
rejected C 230 378
while C 231 378
the C 232 378
first C 233 378
continues C 234 378
to C 235 378
survive C 236 378
; C 237 378
absorption C 238 378
or C 239 378
metabolism C 240 378
of C 241 378
the C 242 378
drug C 243 378
does C 244 378
not C 245 378
account C 246 378
for C 247 378
the C 248 378
variation C 249 378
in C 250 378
results C 251 378
because C 252 378
two C 253 378
kidneys C 254 378
, C 255 378
each C 256 378
from C 257 378
separate C 258 378
donors C 259 378
, C 260 378
can C 261 378
be C 262 378
rejected C 263 378
differentially C 264 378
in C 265 378
the C 266 378
same C 267 378
drug C 268 378
treated C 269 378
host C 270 378
; C 271 378
and C 272 378
all C 273 378
hosts C 274 378
are C 275 378
sensitized C 276 378
against C 277 378
the C 278 378
recipient C 279 378
and C 280 378
this C 281 378
sensitization C 282 378
continues C 283 378
even C 284 378
in C 285 378
those C 286 378
animals C 287 378
successfully C 288 378
weaned C 289 378
from C 290 378
drugs C 291 378
. C 292 378
additional C 294 378
analyses C 295 378
of C 296 378
the C 297 378
relationship C 298 378
of C 299 378
skin C 300 378
homografts C 301 378
and C 302 378
kidney C 303 378
homografts C 304 378
reveal C 305 378
the C 306 378
following C 307 378
skin C 308 378
homografts C 309 378
are C 310 378
universally C 311 378
rejected C 312 378
within C 313 378
20 C 314 378
days C 315 378
by C 316 378
hosts C 317 378
treated C 318 378
with C 319 378
the C 320 378
drug C 321 378
regimen C 322 378
which C 323 378
protects C 324 378
kidney C 325 378
homografts C 326 378
sometimes C 327 378
permanently C 328 378
. C 329 378
when C 331 378
skin C 332 378
and C 333 378
kidney C 334 378
homografts C 335 378
from C 336 378
the C 337 378
same C 338 378
donor C 339 378
are C 340 378
placed C 341 378
simultaneously C 342 378
skin C 343 378
survival C 344 378
is C 345 378
prolonged C 346 378
while C 347 378
kidney C 348 378
survival C 349 378
is C 350 378
shortened C 351 378
. C 352 378
this C 354 378
paradoxical C 355 378
effect C 356 378
probably C 357 378
is C 358 378
explained C 359 378
by C 360 378
the C 361 378
production C 362 378
of C 363 378
antibodies C 364 378
by C 365 378
skin C 366 378
which C 367 378
are C 368 378
absorbed C 369 378
by C 370 378
the C 371 378
rejecting C 372 378
kidney C 373 378
. C 374 378
additional C 376 378
observations C 377 378
indicate C 378 378
that C 379 378
drug C 380 378
- C 381 378
treated C 382 378
animals C 383 378
, C 384 378
male C 385 378
and C 386 378
female C 387 378
, C 388 378
are C 389 378
fertile C 390 378
and C 391 378
that C 392 378
multiple C 393 378
rejection C 394 378
processes C 395 378
can C 396 378
produce C 397 378
generalized C 398 378
immunological C 399 378
picture C 400 378
in C 401 378
the C 402 378
host C 403 378
similar C 404 378
to C 405 378
an C 406 378
autoimmune C 407 378
disease C 408 378
process C 409 378
. C 410 378
3083 C 1 379
. C 2 379
myocardial C 4 379
toxicity C 5 379
of C 6 379
contrast C 7 379
agents C 8 379
used C 9 379
in C 10 379
angiography C 11 379
the C 12 379
myocardial C 13 379
toxicity C 14 379
of C 15 379
many C 16 379
current C 17 379
and C 18 379
some C 19 379
experimental C 20 379
contrast C 21 379
agents C 22 379
has C 23 379
been C 24 379
studied C 25 379
in C 26 379
dogs C 27 379
, C 28 379
by C 29 379
use C 30 379
of C 31 379
a C 32 379
previously C 33 379
unreported C 34 379
method C 35 379
of C 36 379
occlusion C 37 379
retrograde C 38 379
coronary C 39 379
venography C 40 379
as C 41 379
well C 42 379
as C 43 379
the C 44 379
familiar C 45 379
technique C 46 379
of C 47 379
selective C 48 379
coronary C 49 379
arterial C 50 379
catheterization C 51 379
. C 52 379
the C 54 379
following C 55 379
conclusions C 56 379
appear C 57 379
justified C 58 379
in C 59 379
the C 60 379
light C 61 379
of C 62 379
the C 63 379
experiments C 64 379
not C 65 379
only C 66 379
the C 67 379
iodine C 68 379
- C 69 379
containing C 70 379
radicals C 71 379
with C 72 379
which C 73 379
the C 74 379
contrast C 75 379
agents C 76 379
are C 77 379
so C 78 379
often C 79 379
identified C 80 379
( C 81 379
acetrizoates C 82 379
, C 83 379
diatrizoates C 84 379
, C 85 379
iothalamates C 86 379
, C 87 379
etc C 88 379
. C 89 379
) C 91 379
, C 92 379
but C 93 379
also C 94 379
the C 95 379
final C 96 379
salification C 97 379
products C 98 379
appear C 99 379
to C 100 379
be C 101 379
responsible C 102 379
for C 103 379
the C 104 379
widely C 105 379
divergent C 106 379
degrees C 107 379
of C 108 379
myocardial C 109 379
toxicity C 110 379
of C 111 379
contrast C 112 379
agents C 113 379
, C 114 379
to C 115 379
the C 116 379
point C 117 379
that C 118 379
differ C 119 379
- C 120 379
ent C 121 379
salts C 122 379
of C 123 379
the C 124 379
same C 125 379
compound C 126 379
behave C 127 379
as C 128 379
entirely C 129 379
different C 130 379
agents C 131 379
both C 132 379
chemically C 133 379
and C 134 379
biologically C 135 379
. C 136 379
the C 138 379
results C 139 379
seem C 140 379
to C 141 379
indicate C 142 379
the C 143 379
dominance C 144 379
of C 145 379
sodium C 146 379
ion C 147 379
and C 148 379
/ C 149 379
or C 150 379
the C 151 379
protective C 152 379
effect C 153 379
of C 154 379
methylglucamine C 155 379
salts C 156 379
with C 157 379
respect C 158 379
to C 159 379
the C 160 379
myocardial C 161 379
toxi C 162 379
- C 163 379
city C 164 379
of C 165 379
current C 166 379
radiopaque C 167 379
media C 168 379
. C 169 379
reported C 171 379
, C 172 379
yet C 173 379
unexplained C 174 379
, C 175 379
electrocardiographic C 176 379
changes C 177 379
occurring C 178 379
within C 179 379
one C 180 379
to C 181 379
two C 182 379
seconds C 183 379
from C 184 379
the C 185 379
beginning C 186 379
of C 187 379
massive C 188 379
caval C 189 379
high C 190 379
- C 191 379
pressure C 192 379
injections C 193 379
appear C 194 379
to C 195 379
find C 196 379
a C 197 379
causal C 198 379
relationship C 199 379
in C 200 379
the C 201 379
myocardial C 202 379
ir C 203 379
- C 204 379
ritability C 205 379
induced C 206 379
by C 207 379
the C 208 379
distention C 209 379
of C 210 379
the C 211 379
coronary C 212 379
veins C 213 379
and C 214 379
the C 215 379
myocardial C 216 379
infiltra C 217 379
- C 218 379
tion C 219 379
which C 220 379
is C 221 379
intentionally C 222 379
enhanced C 223 379
with C 224 379
our C 225 379
retrograde C 226 379
injection C 227 379
techniques C 228 379
. C 229 379
a C 231 379
pe C 232 379
- C 233 379
culiar C 234 379
trait C 235 379
, C 236 379
shared C 237 379
in C 238 379
varying C 239 379
degrees C 240 379
by C 241 379
all C 242 379
radiopaque C 243 379
agents C 244 379
tested C 245 379
, C 246 379
is C 247 379
their C 248 379
ability C 249 379
to C 250 379
increase C 251 379
coronary C 252 379
blood C 253 379
flow C 254 379
. C 255 379
the C 257 379
clinical C 258 379
significance C 259 379
of C 260 379
this C 261 379
phenome C 262 379
- C 263 379
non C 264 379
, C 265 379
however C 266 379
, C 267 379
remains C 268 379
to C 269 379
be C 270 379
established C 271 379
. C 272 379
these C 274 379
studies C 275 379
re C 276 379
- C 277 379
emphasize C 278 379
the C 279 379
limita C 280 379
- C 281 379
tions C 282 379
of C 283 379
the C 284 379
standard C 285 379
toxicity C 286 379
studies C 287 379
conducted C 288 379
in C 289 379
animals C 290 379
. C 291 379
it C 293 379
should C 294 379
be C 295 379
clear C 296 379
from C 297 379
the C 298 379
results C 299 379
reported C 300 379
that C 301 379
agents C 302 379
to C 303 379
be C 304 379
administered C 305 379
into C 306 379
the C 307 379
coronary C 308 379
circulation C 309 379
demand C 310 379
investigation C 311 379
in C 312 379
regard C 313 379
to C 314 379
their C 315 379
potential C 316 379
toxicity C 317 379
by C 318 379
the C 319 379
methods C 320 379
described C 321 379
herein C 322 379
or C 323 379
variations C 324 379
thereof C 325 379
. C 326 379
in C 328 379
fact C 329 379
, C 330 379
similar C 331 379
tests C 332 379
should C 333 379
be C 334 379
carried C 335 379
out C 336 379
for C 337 379
all C 338 379
or C 339 379
- C 340 379
gans C 341 379
to C 342 379
be C 343 379
subjected C 344 379
to C 345 379
radiographic C 346 379
examination C 347 379
via C 348 379
the C 349 379
vascular C 350 379
bed C 351 379
. C 352 379
the C 354 379
authors C 355 379
hope C 356 379
that C 357 379
this C 358 379
presentation C 359 379
will C 360 379
stimulate C 361 379
renewed C 362 379
investigation C 363 379
, C 364 379
particularly C 365 379
in C 366 379
view C 367 379
of C 368 379
the C 369 379
growing C 370 379
clinical C 371 379
applications C 372 379
of C 373 379
selective C 374 379
cardiovascular C 375 379
opacification C 376 379
tech C 377 379
- C 378 379
niques C 379 379
. C 380 379
2476 C 1 380
. C 2 380
studies C 4 380
on C 5 380
cardiac C 6 380
dimensions C 7 380
in C 8 380
intact C 9 380
, C 10 380
unanesthetized C 11 380
man C 12 380
. C 13 380
i C 15 380
. C 16 380
description C 18 380
of C 19 380
techniques C 20 380
and C 21 380
their C 22 380
validation C 23 380
. C 24 380
ii C 26 380
. C 27 380
effects C 29 380
of C 30 380
respiration C 31 380
. C 32 380
iii C 34 380
. C 35 380
effects C 37 380
of C 38 380
muscular C 39 380
exercise C 40 380
a C 41 380
method C 42 380
is C 43 380
described C 44 380
which C 45 380
permits C 46 380
measurement C 47 380
of C 48 380
relative C 49 380
changes C 50 380
in C 51 380
the C 52 380
exter C 53 380
- C 54 380
nal C 55 380
dimensions C 56 380
of C 57 380
individual C 58 380
cardiac C 59 380
chambers C 60 380
throughout C 61 380
the C 62 380
cardiac C 63 380
cycle C 64 380
in C 65 380
intact C 66 380
, C 67 380
unanaesthetized C 68 380
man C 69 380
. C 70 380
it C 72 380
consists C 73 380
of C 74 380
suturing C 75 380
multiple C 76 380
radiopaque C 77 380
silver C 78 380
- C 79 380
tantalum C 80 380
clips C 81 380
to C 82 380
the C 83 380
surface C 84 380
of C 85 380
the C 86 380
heart C 87 380
at C 88 380
the C 89 380
time C 90 380
of C 91 380
cardiac C 92 380
operations C 93 380
. C 94 380
in C 96 380
the C 97 380
postopera C 98 380
- C 99 380
tive C 100 380
period C 101 380
, C 102 380
cineradiograms C 103 380
are C 104 380
obtained C 105 380
and C 106 380
the C 107 380
distances C 108 380
between C 109 380
clips C 110 380
are C 111 380
mea C 112 380
- C 113 380
sured C 114 380
on C 115 380
each C 116 380
individual C 117 380
frame C 118 380
. C 119 380
this C 121 380
technique C 122 380
has C 123 380
been C 124 380
found C 125 380
to C 126 380
be C 127 380
safe C 128 380
and C 129 380
has C 130 380
been C 131 380
employed C 132 380
in C 133 380
68 C 134 380
patients C 135 380
without C 136 380
any C 137 380
complications C 138 380
. C 139 380
as C 141 380
a C 142 380
result C 143 380
of C 144 380
studies C 145 380
in C 146 380
8 C 147 380
patients C 148 380
utilizing C 149 380
biplane C 150 380
serial C 151 380
exposures C 152 380
, C 153 380
the C 154 380
effects C 155 380
of C 156 380
rotation C 157 380
of C 158 380
the C 159 380
heart C 160 380
in C 161 380
the C 162 380
sagittal C 163 380
plane C 164 380
during C 165 380
the C 166 380
cardiac C 167 380
and C 168 380
respiratory C 169 380
cycles C 170 380
were C 171 380
determined C 172 380
precisely C 173 380
. C 174 380
if C 176 380
clips C 177 380
were C 178 380
properly C 179 380
placed C 180 380
on C 181 380
the C 182 380
heart C 183 380
, C 184 380
the C 185 380
possible C 186 380
errors C 187 380
resulting C 188 380
from C 189 380
such C 190 380
rotation C 191 380
were C 192 380
found C 193 380
to C 194 380
be C 195 380
quite C 196 380
small C 197 380
. C 198 380
during C 200 380
inspiration C 201 380
right C 202 380
ventricular C 203 380
dimen C 204 380
- C 205 380
sions C 206 380
increased C 207 380
, C 208 380
while C 209 380
the C 210 380
opposite C 211 380
occurred C 212 380
during C 213 380
expiration C 214 380
and C 215 380
during C 216 380
the C 217 380
val C 218 380
- C 219 380
salva C 220 380
manoeuvre C 221 380
. C 222 380
left C 224 380
ventricular C 225 380
dimensions C 226 380
exhibited C 227 380
little C 228 380
change C 229 380
during C 230 380
normal C 231 380
respiration C 232 380
. C 233 380
during C 235 380
deep C 236 380
, C 237 380
slow C 238 380
inspiration C 239 380
, C 240 380
the C 241 380
changes C 242 380
in C 243 380
dimensions C 244 380
of C 245 380
the C 246 380
left C 247 380
ventricle C 248 380
lagged C 249 380
behind C 250 380
those C 251 380
of C 252 380
the C 253 380
right C 254 380
ventricle C 255 380
by C 256 380
1 C 257 380
to C 258 380
5 C 259 380
( C 260 380
generally C 261 380
2 C 262 380
or C 263 380
3 C 264 380
) C 265 380
car C 266 380
- C 267 380
diac C 268 380
cycles C 269 380
; C 270 380
the C 271 380
magnitude C 272 380
of C 273 380
the C 274 380
changes C 275 380
in C 276 380
the C 277 380
dimensions C 278 380
of C 279 380
the C 280 380
left C 281 380
ventricle C 282 380
was C 283 380
smaller C 284 380
than C 285 380
that C 286 380
which C 287 380
occurred C 288 380
in C 289 380
the C 290 380
right C 291 380
ventricle C 292 380
. C 293 380
the C 295 380
effects C 296 380
on C 297 380
ventricular C 298 380
dimensions C 299 380
of C 300 380
light C 301 380
muscular C 302 380
exercise C 303 380
performed C 304 380
in C 305 380
the C 306 380
supine C 307 380
position C 308 380
were C 309 380
studied C 310 380
in C 311 380
9 C 312 380
patients C 313 380
. C 314 380
the C 316 380
end C 317 380
- C 318 380
diastolic C 319 380
dimensions C 320 380
decreased C 321 380
by C 322 380
an C 323 380
average C 324 380
of C 325 380
6 C 326 380
. C 327 380
. C 328 380
% C 329 380
of C 330 380
con C 331 380
- C 332 380
trol C 333 380
in C 334 380
the C 335 380
right C 336 380
ventricle C 337 380
, C 338 380
and C 339 380
by C 340 380
an C 341 380
average C 342 380
of C 343 380
5 C 344 380
. C 345 380
. C 346 380
% C 347 380
in C 348 380
the C 349 380
left C 350 380
ventricle C 351 380
. C 352 380
end C 354 380
- C 355 380
sys C 356 380
- C 357 380
tolic C 358 380
dimensions C 359 380
decreased C 360 380
by C 361 380
an C 362 380
average C 363 380
of C 364 380
5 C 365 380
. C 366 380
. C 367 380
% C 368 380
of C 369 380
control C 370 380
in C 371 380
the C 372 380
right C 373 380
ventricle C 374 380
and C 375 380
by C 376 380
an C 377 380
average C 378 380
of C 379 380
6 C 380 380
. C 381 380
. C 382 380
% C 383 380
in C 384 380
the C 385 380
left C 386 380
ventricle C 387 380
. C 388 380
these C 390 380
decreases C 391 380
are C 392 380
considered C 393 380
to C 394 380
approximate C 395 380
one C 396 380
- C 397 380
half C 398 380
of C 399 380
the C 400 380
resting C 401 380
stroke C 402 380
volume C 403 380
. C 404 380
in C 406 380
the C 407 380
4 C 408 380
patients C 409 380
in C 410 380
whom C 411 380
the C 412 380
rate C 413 380
of C 414 380
right C 415 380
ventricular C 416 380
pressure C 417 380
rise C 418 380
was C 419 380
determined C 420 380
continuously C 421 380
, C 422 380
exercise C 423 380
re C 424 380
- C 425 380
sulted C 426 380
in C 427 380
an C 428 380
elevation C 429 380
of C 430 380
dp C 431 380
/ C 432 380
dt C 433 380
while C 434 380
ventricular C 435 380
end C 436 380
- C 437 380
diastolic C 438 380
dimensions C 439 380
decreased C 440 380
. C 441 380
these C 443 380
data C 444 380
are C 445 380
interpreted C 446 380
to C 447 380
indicate C 448 380
that C 449 380
an C 450 380
increase C 451 380
in C 452 380
myocardial C 453 380
contractility C 454 380
occurs C 455 380
during C 456 380
muscular C 457 380
exercise C 458 380
in C 459 380
man C 460 380
. C 461 380
3765 C 1 381
. C 2 381
radioactive C 4 381
isotope C 5 381
determination C 6 381
of C 7 381
myocardial C 8 381
blood C 9 381
flow C 10 381
by C 11 381
surface C 12 381
counting C 13 381
and C 14 381
ratio C 15 381
formula C 16 381
wilkinson C 17 381
d C 18 381
. C 19 381
the C 21 381
results C 22 381
presented C 23 381
here C 24 381
have C 25 381
a C 26 381
large C 27 381
scale C 28 381
error C 29 381
and C 30 381
a C 31 381
large C 32 381
scatter C 33 381
, C 34 381
so C 35 381
that C 36 381
the C 37 381
authors C 38 381
recommend C 39 381
that C 40 381
further C 41 381
clinical C 42 381
use C 43 381
of C 44 381
this C 45 381
method C 46 381
should C 47 381
not C 48 381
be C 49 381
at C 50 381
- C 51 381
tempted C 52 381
. C 53 381
if C 55 381
the C 56 381
coronary C 57 381
portion C 58 381
of C 59 381
the C 60 381
flow C 61 381
rate C 62 381
curve C 63 381
exists C 64 381
, C 65 381
then C 66 381
a C 67 381
change C 68 381
in C 69 381
the C 70 381
present C 71 381
instrumentation C 72 381
is C 73 381
needed C 74 381
to C 75 381
allow C 76 381
use C 77 381
of C 78 381
the C 79 381
technique C 80 381
of C 81 381
sevelius C 82 381
and C 83 381
johnson C 84 381
in C 85 381
defining C 86 381
a C 87 381
coronary C 88 381
portion C 89 381
of C 90 381
the C 91 381
flow C 92 381
rate C 93 381
. C 94 381
an C 96 381
attempt C 97 381
is C 98 381
made C 99 381
to C 100 381
evaluate C 101 381
the C 102 381
possible C 103 381
source C 104 381
of C 105 381
errors C 106 381
. C 107 381
1379 C 1 382
. C 2 382
risa C 4 382
- C 5 382
ventriculography C 6 382
and C 7 382
risa C 8 382
- C 9 382
cisternography C 10 382
some C 11 382
general C 12 382
experience C 13 382
of C 14 382
the C 15 382
authors C 16 382
with C 17 382
risa C 18 382
- C 19 382
ventriculography C 20 382
and C 21 382
risa C 22 382
- C 23 382
cis C 24 382
- C 25 382
ternography C 26 382
is C 27 382
related C 28 382
. C 29 382
they C 31 382
conclude C 32 382
that C 33 382
the C 34 382
former C 35 382
technique C 36 382
may C 37 382
be C 38 382
particularly C 39 382
useful C 40 382
in C 41 382
detecting C 42 382
intraventricular C 43 382
tumors C 44 382
and C 45 382
internal C 46 382
hydrocephalus C 47 382
as C 48 382
well C 49 382
as C 50 382
assessing C 51 382
the C 52 382
efficiency C 53 382
of C 54 382
surgical C 55 382
shunts C 56 382
; C 57 382
the C 58 382
latter C 59 382
technique C 60 382
may C 61 382
be C 62 382
useful C 63 382
in C 64 382
the C 65 382
study C 66 382
of C 67 382
normal C 68 382
csf C 69 382
circulation C 70 382
as C 71 382
well C 72 382
as C 73 382
in C 74 382
cases C 75 382
of C 76 382
csf C 77 382
leaks C 78 382
, C 79 382
arachnoiditis C 80 382
and C 81 382
external C 82 382
hydrocephalus C 83 382
. C 84 382
3485 C 1 383
. C 2 383
measurement C 4 383
of C 5 383
the C 6 383
cardiac C 7 383
output C 8 383
and C 9 383
ventricular C 10 383
volumes C 11 383
by C 12 383
radiocardiography C 13 383
cardiac C 14 383
output C 15 383
was C 16 383
measured C 17 383
by C 18 383
external C 19 383
counting C 20 383
after C 21 383
injection C 22 383
of C 23 383
radioisotopes C 24 383
( C 25 383
rihsa C 26 383
and C 27 383
erythrocytes C 28 383
- C 29 383
cr C 30 383
51 C 31 383
) C 32 383
. C 33 383
the C 35 383
results C 36 383
in C 37 383
113 C 38 383
subjects C 39 383
, C 40 383
including C 41 383
16 C 42 383
normals C 43 383
, C 44 383
are C 45 383
presented C 46 383
and C 47 383
compared C 48 383
with C 49 383
the C 50 383
results C 51 383
by C 52 383
other C 53 383
methods C 54 383
. C 55 383
cardiac C 57 383
output C 58 383
at C 59 383
rest C 60 383
and C 61 383
after C 62 383
exercise C 63 383
was C 64 383
compared C 65 383
in C 66 383
65 C 67 383
subjects C 68 383
. C 69 383
the C 71 383
principle C 72 383
of C 73 383
ventricular C 74 383
volume C 75 383
measurement C 76 383
by C 77 383
radioisotope C 78 383
- C 79 383
cardiography C 80 383
is C 81 383
discussed C 82 383
. C 83 383
the C 85 383
results C 86 383
of C 87 383
measurement C 88 383
of C 89 383
the C 90 383
ventricular C 91 383
volume C 92 383
in C 93 383
17 C 94 383
normal C 95 383
subjects C 96 383
and C 97 383
90 C 98 383
patients C 99 383
, C 100 383
and C 101 383
of C 102 383
measurement C 103 383
of C 104 383
the C 105 383
ventricular C 106 383
volume C 107 383
in C 108 383
57 C 109 383
patients C 110 383
, C 111 383
are C 112 383
presented C 113 383
. C 114 383
3762 C 1 384
. C 2 384
aberrant C 4 384
left C 5 384
coronary C 6 384
artery C 7 384
five C 8 384
cases C 9 384
of C 10 384
aberrant C 11 384
coronary C 12 384
artery C 13 384
are C 14 384
presented C 15 384
, C 16 384
with C 17 384
emphasis C 18 384
on C 19 384
the C 20 384
angio C 21 384
- C 22 384
graphic C 23 384
features C 24 384
and C 25 384
differentiation C 26 384
from C 27 384
endocardial C 28 384
fibroelastosis C 29 384
. C 30 384
clinical C 32 384
and C 33 384
electrocardiographic C 34 384
features C 35 384
may C 36 384
suggest C 37 384
the C 38 384
proper C 39 384
diagnosis C 40 384
, C 41 384
but C 42 384
only C 43 384
angio C 44 384
- C 45 384
graphy C 46 384
can C 47 384
conclusively C 48 384
demonstrate C 49 384
the C 50 384
continuity C 51 384
between C 52 384
the C 53 384
pulmonary C 54 384
artery C 55 384
and C 56 384
the C 57 384
left C 58 384
coronary C 59 384
artery C 60 384
. C 61 384
in C 63 384
these C 64 384
cases C 65 384
, C 66 384
blood C 67 384
flow C 68 384
was C 69 384
from C 70 384
the C 71 384
pulmonary C 72 384
artery C 73 384
to C 74 384
the C 75 384
coronary C 76 384
artery C 77 384
( C 78 384
forward C 79 384
) C 80 384
in C 81 384
2 C 82 384
cases C 83 384
, C 84 384
and C 85 384
from C 86 384
the C 87 384
coronary C 88 384
artery C 89 384
to C 90 384
the C 91 384
pulmonary C 92 384
artery C 93 384
( C 94 384
retrograde C 95 384
) C 96 384
in C 97 384
the C 98 384
other C 99 384
3 C 100 384
. C 101 384
when C 103 384
the C 104 384
diagnosis C 105 384
of C 106 384
aberrant C 107 384
coronary C 108 384
artery C 109 384
is C 110 384
suspected C 111 384
, C 112 384
selective C 113 384
left C 114 384
- C 115 384
sided C 116 384
angiocardiography C 117 384
should C 118 384
be C 119 384
the C 120 384
angiographic C 121 384
procedure C 122 384
of C 123 384
choice C 124 384
. C 125 384
the C 127 384
differentiation C 128 384
from C 129 384
endocardial C 130 384
fibroelas C 131 384
- C 132 384
tosis C 133 384
and C 134 384
other C 135 384
myocardiopathies C 136 384
is C 137 384
usually C 138 384
not C 139 384
a C 140 384
problem C 141 384
with C 142 384
such C 143 384
a C 144 384
study C 145 384
, C 146 384
but C 147 384
may C 148 384
be C 149 384
more C 150 384
difficult C 151 384
with C 152 384
intravenous C 153 384
angiocardiography C 154 384
. C 155 384
with C 157 384
this C 158 384
latter C 159 384
type C 160 384
of C 161 384
study C 162 384
, C 163 384
the C 164 384
coronary C 165 384
arteries C 166 384
are C 167 384
not C 168 384
generally C 169 384
visible C 170 384
, C 171 384
but C 172 384
a C 173 384
persistently C 174 384
thin C 175 384
la C 176 384
- C 177 384
teral C 178 384
aspect C 179 384
of C 180 384
the C 181 384
left C 182 384
ventricular C 183 384
wall C 184 384
should C 185 384
suggest C 186 384
the C 187 384
proper C 188 384
diagnosis C 189 384
. C 190 384
sub C 192 384
- C 193 384
sequent C 194 384
confirmation C 195 384
by C 196 384
a C 197 384
left C 198 384
- C 199 384
sided C 200 384
injection C 201 384
is C 202 384
advisable C 203 384
. C 204 384
4159 C 1 385
. C 2 385
detection C 4 385
of C 5 385
heart C 6 385
shunts C 7 385
by C 8 385
means C 9 385
of C 10 385
i C 11 385
125 C 12 385
external C 13 385
scintillation C 14 385
detection C 15 385
of C 16 385
a C 17 385
pure C 18 385
dilution C 19 385
curve C 20 385
originating C 21 385
in C 22 385
the C 23 385
right C 24 385
ven C 25 385
- C 26 385
tricle C 27 385
has C 28 385
been C 29 385
pursued C 30 385
by C 31 385
investigators C 32 385
for C 33 385
many C 34 385
yr C 35 385
. C 36 385
the C 38 385
use C 39 385
of C 40 385
the C 41 385
soft C 42 385
photons C 43 385
of C 44 385
125 C 45 385
i C 46 385
offers C 47 385
an C 48 385
improved C 49 385
method C 50 385
of C 51 385
determination C 52 385
by C 53 385
allowing C 54 385
excellent C 55 385
collimation C 56 385
through C 57 385
2 C 58 385
mechanisms C 59 385
( C 60 385
1 C 61 385
) C 62 385
a C 63 385
small C 64 385
half C 65 385
value C 66 385
layer C 67 385
of C 68 385
2 C 69 385
cm C 70 385
in C 71 385
tissue C 72 385
, C 73 385
and C 74 385
( C 75 385
2 C 76 385
) C 77 385
uni C 78 385
- C 79 385
directionality C 80 385
, C 81 385
in C 82 385
part C 83 385
due C 84 385
to C 85 385
all C 86 385
- C 87 385
or C 88 385
- C 89 385
none C 90 385
photoelectric C 91 385
absorption C 92 385
of C 93 385
these C 94 385
photons C 95 385
as C 96 385
compared C 97 385
with C 98 385
the C 99 385
pluridirectionality C 100 385
due C 101 385
to C 102 385
compton C 103 385
scatter C 104 385
in C 105 385
the C 106 385
case C 107 385
of C 108 385
131 C 109 385
i C 110 385
. C 111 385
in C 113 385
30 C 114 385
normal C 115 385
individuals C 116 385
, C 117 385
externally C 118 385
detected C 119 385
dilution C 120 385
curves C 121 385
from C 122 385
the C 123 385
right C 124 385
heart C 125 385
ventricle C 126 385
and C 127 385
arterial C 128 385
dilution C 129 385
curves C 130 385
obtained C 131 385
by C 132 385
arterial C 133 385
puncture C 134 385
are C 135 385
compared C 136 385
. C 137 385
five C 139 385
hundred C 140 385
microcuries C 141 385
of C 142 385
125 C 143 385
i C 144 385
are C 145 385
injected C 146 385
into C 147 385
an C 148 385
antecubital C 149 385
vein C 150 385
. C 151 385
the C 153 385
amount C 154 385
of C 155 385
radiation C 156 385
absorbed C 157 385
from C 158 385
a C 159 385
500 C 160 385
uc C 161 385
dose C 162 385
in C 163 385
an C 164 385
adult C 165 385
of C 166 385
70 C 167 385
kilos C 168 385
is C 169 385
1000 C 170 385
to C 171 385
2000 C 172 385
mrads C 173 385
when C 174 385
injected C 175 385
in C 176 385
the C 177 385
form C 178 385
of C 179 385
125 C 180 385
i C 181 385
iodide C 182 385
. C 183 385
the C 185 385
use C 186 385
of C 187 385
125 C 188 385
i C 189 385
orthoiodohippu C 190 385
- C 191 385
rate C 192 385
is C 193 385
advised C 194 385
due C 195 385
to C 196 385
its C 197 385
short C 198 385
biological C 199 385
half C 200 385
- C 201 385
period C 202 385
and C 203 385
the C 204 385
integrated C 205 385
whole C 206 385
- C 207 385
body C 208 385
radiation C 209 385
exposure C 210 385
is C 211 385
decreased C 212 385
100 C 213 385
- C 214 385
fold C 215 385
in C 216 385
comparison C 217 385
with C 218 385
the C 219 385
125 C 220 385
i C 221 385
iodide C 222 385
. C 223 385
the C 225 385
shape C 226 385
of C 227 385
the C 228 385
right C 229 385
heart C 230 385
curve C 231 385
is C 232 385
very C 233 385
similar C 234 385
to C 235 385
the C 236 385
arterial C 237 385
dilution C 238 385
curve C 239 385
with C 240 385
a C 241 385
13 C 242 385
5 C 243 385
% C 244 385
excess C 245 385
of C 246 385
counts C 247 385
originating C 248 385
outside C 249 385
the C 250 385
right C 251 385
ventricle C 252 385
area C 253 385
. C 254 385
the C 256 385
descending C 257 385
segment C 258 385
of C 259 385
the C 260 385
right C 261 385
ventricle C 262 385
curve C 263 385
has C 264 385
a C 265 385
minimum C 266 385
count C 267 385
rate C 268 385
of C 269 385
only C 270 385
12 C 271 385
2 C 272 385
% C 273 385
of C 274 385
the C 275 385
peak C 276 385
of C 277 385
the C 278 385
curve C 279 385
as C 280 385
compared C 281 385
with C 282 385
the C 283 385
arterial C 284 385
curve C 285 385
of C 286 385
10 C 287 385
2 C 288 385
. C 289 385
. C 290 385
% C 291 385
. C 292 385
a C 294 385
mean C 295 385
t C 296 385
1 C 297 385
/ C 298 385
2 C 299 385
of C 300 385
the C 301 385
descending C 302 385
down C 303 385
slope C 304 385
of C 305 385
the C 306 385
right C 307 385
ventricle C 308 385
is C 309 385
1 C 310 385
. C 311 385
. C 312 385
. C 312 385
0 C 313 385
. C 314 385
. C 315 385
. C 315 385
sec C 316 385
. C 317 385
for C 319 385
the C 320 385
right C 321 385
heart C 322 385
curve C 323 385
and C 324 385
2 C 325 385
. C 326 385
. C 327 385
0 C 328 385
. C 329 385
. C 330 385
. C 330 385
sec C 331 385
. C 332 385
for C 334 385
the C 335 385
arterial C 336 385
curve C 337 385
. C 338 385
the C 340 385
clinical C 341 385
usefulness C 342 385
of C 343 385
this C 344 385
procedure C 345 385
in C 346 385
20 C 347 385
patients C 348 385
with C 349 385
atrial C 350 385
septal C 351 385
defects C 352 385
and C 353 385
9 C 354 385
patients C 355 385
with C 356 385
ventricular C 357 385
sep C 358 385
- C 359 385
tal C 360 385
defects C 361 385
is C 362 385
analyzed C 363 385
. C 364 385
it C 366 385
seems C 367 385
possible C 368 385
to C 369 385
perform C 370 385
selective C 371 385
right C 372 385
- C 373 385
heart C 374 385
radiocardio C 375 385
- C 376 385
graphy C 377 385
by C 378 385
means C 379 385
of C 380 385
external C 381 385
precordial C 382 385
detection C 383 385
of C 384 385
125 C 385 385
i C 386 385
. C 387 385
the C 389 385
method C 390 385
is C 391 385
simple C 392 385
and C 393 385
reproducible C 394 385
. C 395 385
4160 C 1 386
. C 2 386
clinical C 4 386
applications C 5 386
of C 6 386
quantitative C 7 386
radiocardiography C 8 386
. C 9 386
i C 11 386
. C 12 386
results C 14 386
in C 15 386
normal C 16 386
subjects C 17 386
and C 18 386
changes C 19 386
with C 20 386
age C 21 386
a C 22 386
technique C 23 386
is C 24 386
described C 25 386
for C 26 386
routine C 27 386
determinations C 28 386
at C 29 386
the C 30 386
bedside C 31 386
of C 32 386
blood C 33 386
volume C 34 386
, C 35 386
cardiac C 36 386
output C 37 386
and C 38 386
pulmonary C 39 386
blood C 40 386
volume C 41 386
by C 42 386
means C 43 386
of C 44 386
the C 45 386
method C 46 386
of C 47 386
quantitative C 48 386
radiocardiography C 49 386
. C 50 386
the C 52 386
instrumentation C 53 386
is C 54 386
simple C 55 386
, C 56 386
the C 57 386
technique C 58 386
is C 59 386
easy C 60 386
to C 61 386
perform C 62 386
and C 63 386
causes C 64 386
little C 65 386
trouble C 66 386
to C 67 386
the C 68 386
patients C 69 386
, C 70 386
only C 71 386
one C 72 386
injection C 73 386
of C 74 386
about C 75 386
50 C 76 386
uc C 77 386
of C 78 386
rihsa C 79 386
being C 80 386
needed C 81 386
. C 82 386
thirty C 84 386
- C 85 386
nine C 86 386
patients C 87 386
aged C 88 386
17 C 89 386
- C 90 386
83 C 91 386
yr C 92 386
. C 93 386
, C 95 386
free C 96 386
of C 97 386
cardiovascular C 98 386
or C 99 386
re C 100 386
- C 101 386
spiratory C 102 386
disorders C 103 386
, C 104 386
were C 105 386
studied C 106 386
. C 107 386
the C 109 386
results C 110 386
obtained C 111 386
are C 112 386
in C 113 386
close C 114 386
agreement C 115 386
with C 116 386
previous C 117 386
reports C 118 386
. C 119 386
only C 121 386
the C 122 386
cardiac C 123 386
index C 124 386
showed C 125 386
a C 126 386
significant C 127 386
decrease C 128 386
with C 129 386
age C 130 386
, C 131 386
while C 132 386
the C 133 386
reduction C 134 386
of C 135 386
blood C 136 386
volume C 137 386
and C 138 386
of C 139 386
pulmonary C 140 386
blood C 141 386
volume C 142 386
was C 143 386
slight C 144 386
. C 145 386
a C 147 386
close C 148 386
statistical C 149 386
correlation C 150 386
was C 151 386
found C 152 386
between C 153 386
pbv C 154 386
and C 155 386
sv C 156 386
, C 157 386
and C 158 386
was C 159 386
interpreted C 160 386
as C 161 386
a C 162 386
dependence C 163 386
of C 164 386
pbv C 165 386
on C 166 386
sv C 167 386
. C 168 386
2725 C 1 387
. C 2 387
demonstration C 4 387
of C 5 387
myocardial C 6 387
infarction C 7 387
by C 8 387
photoscans C 9 387
of C 10 387
the C 11 387
heart C 12 387
in C 13 387
man C 14 387
intravenously C 15 387
injected C 16 387
radioiodinated C 17 387
oleic C 18 387
acid C 19 387
was C 20 387
incorporated C 21 387
into C 22 387
heart C 23 387
muscle C 24 387
in C 25 387
sufficient C 26 387
concentration C 27 387
to C 28 387
permit C 29 387
recording C 30 387
photoscans C 31 387
of C 32 387
the C 33 387
heart C 34 387
in C 35 387
man C 36 387
. C 37 387
in C 39 387
3 C 40 387
fatal C 41 387
cases C 42 387
of C 43 387
massive C 44 387
septal C 45 387
myocardial C 46 387
infarction C 47 387
, C 48 387
injection C 49 387
of C 50 387
the C 51 387
radioiodin C 52 387
- C 53 387
ated C 54 387
fatty C 55 387
acid C 56 387
( C 57 387
rifa C 58 387
) C 59 387
was C 60 387
made C 61 387
during C 62 387
life C 63 387
; C 64 387
at C 65 387
necropsy C 66 387
photoscans C 67 387
of C 68 387
the C 69 387
excised C 70 387
heart C 71 387
showed C 72 387
a C 73 387
discrete C 74 387
area C 75 387
of C 76 387
absent C 77 387
radioactivity C 78 387
corresponding C 79 387
to C 80 387
the C 81 387
infarcted C 82 387
interventricular C 83 387
septum C 84 387
. C 85 387
photoscans C 87 387
of C 88 387
the C 89 387
heart C 90 387
were C 91 387
made C 92 387
during C 93 387
life C 94 387
in C 95 387
42 C 96 387
pa C 97 387
- C 98 387
tients C 99 387
, C 100 387
9 C 101 387
of C 102 387
whom C 103 387
had C 104 387
suffered C 105 387
recent C 106 387
myocardial C 107 387
infarction C 108 387
. C 109 387
there C 111 387
were C 112 387
definite C 113 387
areas C 114 387
of C 115 387
deceased C 116 387
radioactivity C 117 387
corresponding C 118 387
to C 119 387
the C 120 387
location C 121 387
of C 122 387
the C 123 387
infarction C 124 387
, C 125 387
judged C 126 387
by C 127 387
the C 128 387
electrocardiogram C 129 387
, C 130 387
in C 131 387
4 C 132 387
, C 133 387
and C 134 387
probable C 135 387
areas C 136 387
of C 137 387
decreased C 138 387
radioactivity C 139 387
in C 140 387
2 C 141 387
, C 142 387
of C 143 387
the C 144 387
9 C 145 387
cases C 146 387
of C 147 387
myocardial C 148 387
infarction C 149 387
. C 150 387
the C 152 387
technic C 153 387
as C 154 387
presently C 155 387
employed C 156 387
just C 157 387
approaches C 158 387
the C 159 387
limits C 160 387
of C 161 387
definition C 162 387
of C 163 387
infarction C 164 387
in C 165 387
acute C 166 387
cases C 167 387
. C 168 387
modification C 170 387
of C 171 387
the C 172 387
biochemical C 173 387
principles C 174 387
or C 175 387
further C 176 387
development C 177 387
of C 178 387
the C 179 387
y C 180 387
- C 181 387
camera C 182 387
may C 183 387
bring C 184 387
the C 185 387
method C 186 387
to C 187 387
a C 188 387
level C 189 387
of C 190 387
diagnostic C 191 387
usefulness C 192 387
. C 193 387
2716 C 1 388
. C 2 388
y C 4 388
- C 5 388
angiocardiography C 6 388
recordings C 7 388
were C 8 388
made C 9 388
, C 10 388
simultaneously C 11 388
with C 12 388
the C 13 388
y C 14 388
- C 15 388
cardiogram C 16 388
, C 17 388
of C 18 388
a C 19 388
pulmonary C 20 388
an C 21 388
- C 22 388
giogram C 23 388
by C 24 388
means C 25 388
of C 26 388
a C 27 388
collimator C 28 388
placed C 29 388
in C 30 388
the C 31 388
left C 32 388
scapular C 33 388
region C 34 388
and C 35 388
of C 36 388
carotid C 37 388
angiogram C 38 388
by C 39 388
a C 40 388
collimator C 41 388
centered C 42 388
on C 43 388
the C 44 388
axis C 45 388
of C 46 388
the C 47 388
external C 48 388
auditory C 49 388
canal C 50 388
. C 51 388
the C 53 388
3 C 54 388
curves C 55 388
yielded C 56 388
very C 57 388
interesting C 58 388
information C 59 388
on C 60 388
the C 61 388
chronology C 62 388
of C 63 388
the C 64 388
various C 65 388
car C 66 388
- C 67 388
diac C 68 388
cycles C 69 388
. C 70 388
the C 72 388
pattern C 73 388
of C 74 388
the C 75 388
pulmonary C 76 388
and C 77 388
carotid C 78 388
y C 79 388
- C 80 388
angiograms C 81 388
was C 82 388
valuable C 83 388
in C 84 388
several C 85 388
pathologic C 86 388
conditions C 87 388
. C 88 388
it C 90 388
is C 91 388
more C 92 388
logical C 93 388
to C 94 388
measure C 95 388
the C 96 388
cardiac C 97 388
output C 98 388
on C 99 388
the C 100 388
carotid C 101 388
curve C 102 388
than C 103 388
on C 104 388
the C 105 388
y C 106 388
- C 107 388
cardiogram C 108 388
, C 109 388
especially C 110 388
if C 111 388
there C 112 388
are C 113 388
shunts C 114 388
. C 115 388
the C 117 388
pulmonary C 118 388
curve C 119 388
allows C 120 388
rectification C 121 388
of C 122 388
the C 123 388
time C 124 388
constant C 125 388
of C 126 388
emptying C 127 388
of C 128 388
the C 129 388
left C 130 388
cavities C 131 388
of C 132 388
the C 133 388
heart C 134 388
. C 135 388
as C 137 388
regards C 138 388
chronologic C 139 388
information C 140 388
on C 141 388
cardiac C 142 388
cycles C 143 388
, C 144 388
atten C 145 388
- C 146 388
tion C 147 388
is C 148 388
drawn C 149 388
to C 150 388
the C 151 388
fact C 152 388
that C 153 388
in C 154 388
the C 155 388
pulmonary C 156 388
circulation C 157 388
long C 158 388
and C 159 388
short C 160 388
circuits C 161 388
can C 162 388
be C 163 388
demonstrated C 164 388
. C 165 388
the C 167 388
characteristic C 168 388
times C 169 388
can C 170 388
be C 171 388
measured C 172 388
. C 173 388
between C 175 388
the C 176 388
time C 177 388
that C 178 388
the C 179 388
radioactive C 180 388
material C 181 388
appears C 182 388
in C 183 388
the C 184 388
left C 185 388
cavities C 186 388
and C 187 388
the C 188 388
time C 189 388
that C 190 388
it C 191 388
leaves C 192 388
the C 193 388
carotid C 194 388
, C 195 388
there C 196 388
is C 197 388
an C 198 388
interval C 199 388
of C 200 388
3 C 201 388
- C 202 388
4 C 203 388
systoles C 204 388
, C 205 388
which C 206 388
represents C 207 388
the C 208 388
time C 209 388
neces C 210 388
- C 211 388
sary C 212 388
for C 213 388
left C 214 388
circular C 215 388
filling C 216 388
. C 217 388
the C 219 388
validity C 220 388
of C 221 388
calculation C 222 388
of C 223 388
the C 224 388
cardiac C 225 388
output C 226 388
with C 227 388
the C 228 388
stewart C 229 388
- C 230 388
hamilton C 231 388
formula C 232 388
is C 233 388
discussed C 234 388
. C 235 388
this C 237 388
is C 238 388
valid C 239 388
if C 240 388
the C 241 388
collimator C 242 388
covers C 243 388
a C 244 388
small C 245 388
volume C 246 388
of C 247 388
the C 248 388
principal C 249 388
channel C 250 388
. C 251 388
it C 253 388
remains C 254 388
to C 255 388
be C 256 388
shown C 257 388
if C 258 388
such C 259 388
a C 260 388
calculation C 261 388
is C 262 388
valid C 263 388
for C 264 388
larger C 265 388
cavities C 266 388
, C 267 388
or C 268 388
for C 269 388
2 C 270 388
cavities C 271 388
, C 272 388
through C 273 388
which C 274 388
the C 275 388
radioactive C 276 388
material C 277 388
passes C 278 388
successively C 279 388
, C 280 388
and C 281 388
which C 282 388
have C 283 388
different C 284 388
c C 285 388
( C 286 388
t C 287 388
) C 288 388
functions C 289 388
as C 290 388
well C 291 388
as C 292 388
for C 293 388
all C 294 388
tissue C 295 388
' C 296 388
seen C 297 388
' C 298 388
by C 299 388
the C 300 388
collimator C 301 388
, C 302 388
some C 303 388
of C 304 388
which C 305 388
are C 306 388
not C 307 388
yet C 308 388
irrigated C 309 388
with C 310 388
the C 311 388
radioactive C 312 388
blood C 313 388
, C 314 388
while C 315 388
in C 316 388
other C 317 388
areas C 318 388
recirculation C 319 388
has C 320 388
already C 321 388
started C 322 388
. C 323 388
these C 325 388
aspects C 326 388
, C 327 388
and C 328 388
their C 329 388
application C 330 388
to C 331 388
the C 332 388
pulmonary C 333 388
angiogram C 334 388
, C 335 388
are C 336 388
discussed C 337 388
in C 338 388
detail C 339 388
. C 340 388
with C 342 388
the C 343 388
authors C 344 388
' C 345 388
technique C 346 388
, C 347 388
y C 348 388
- C 349 388
angiogram C 350 388
is C 351 388
especially C 352 388
valuable C 353 388
, C 354 388
as C 355 388
correc C 356 388
- C 357 388
tion C 358 388
for C 359 388
the C 360 388
time C 361 388
constant C 362 388
of C 363 388
the C 364 388
decrease C 365 388
of C 366 388
the C 367 388
left C 368 388
peak C 369 388
is C 370 388
based C 371 388
on C 372 388
the C 373 388
lengthening C 374 388
of C 375 388
this C 376 388
curve C 377 388
. C 378 388
this C 380 388
again C 381 388
serves C 382 388
as C 383 388
a C 384 388
basis C 385 388
for C 386 388
determining C 387 388
the C 388 388
left C 389 388
ventricular C 390 388
volume C 391 388
. C 392 388
2717 C 1 389
. C 2 389
the C 4 389
value C 5 389
of C 6 389
quantitative C 7 389
radiocardiography C 8 389
in C 9 389
the C 10 389
study C 11 389
of C 12 389
hemodynamics C 13 389
six C 14 389
normal C 15 389
subjects C 16 389
and C 17 389
7 C 18 389
patients C 19 389
with C 20 389
mitral C 21 389
stenosis C 22 389
were C 23 389
studied C 24 389
. C 25 389
quantitative C 27 389
radiocardiographic C 28 389
investigations C 29 389
( C 30 389
rihsa C 31 389
) C 32 389
were C 33 389
performed C 34 389
according C 35 389
to C 36 389
donato C 37 389
' C 38 389
s C 39 389
method C 40 389
. C 41 389
the C 43 389
stroke C 44 389
volume C 45 389
as C 46 389
well C 47 389
as C 48 389
the C 49 389
cardiac C 50 389
output C 51 389
were C 52 389
found C 53 389
to C 54 389
be C 55 389
decreased C 56 389
in C 57 389
mitral C 58 389
stenosis C 59 389
, C 60 389
the C 61 389
right C 62 389
ventricular C 63 389
evacuation C 64 389
ratio C 65 389
diminished C 66 389
, C 67 389
and C 68 389
the C 69 389
pul C 70 389
- C 71 389
monary C 72 389
circulation C 73 389
time C 74 389
prolonged C 75 389
. C 76 389
the C 78 389
results C 79 389
pertaining C 80 389
to C 81 389
diastolic C 82 389
right C 83 389
ventricu C 84 389
- C 85 389
lar C 86 389
capacity C 87 389
, C 88 389
right C 89 389
ventricular C 90 389
resting C 91 389
blood C 92 389
volume C 93 389
and C 94 389
pulmonary C 95 389
blood C 96 389
volume C 97 389
proved C 98 389
inconclusive C 99 389
. C 100 389
3056 C 1 390
. C 2 390
the C 4 390
localization C 5 390
of C 6 390
aortic C 7 390
shunts C 8 390
developed C 9 390
by C 10 390
a C 11 390
precordial C 12 390
registration C 13 390
of C 14 390
i C 15 390
131 C 16 390
injected C 17 390
into C 18 390
the C 19 390
aorta C 20 390
at C 21 390
different C 22 390
levels C 23 390
a C 24 390
technique C 25 390
for C 26 390
localizing C 27 390
shunts C 28 390
of C 29 390
aortic C 30 390
origin C 31 390
is C 32 390
described C 33 390
, C 34 390
based C 35 390
on C 36 390
the C 37 390
analysis C 38 390
of C 39 390
precordial C 40 390
records C 41 390
of C 42 390
i C 43 390
131 C 44 390
injected C 45 390
at C 46 390
different C 47 390
aortic C 48 390
levels C 49 390
. C 50 390
seven C 52 390
patients C 53 390
with C 54 390
patent C 55 390
ductus C 56 390
arteriosus C 57 390
( C 58 390
pda C 59 390
) C 60 390
, C 61 390
1 C 62 390
with C 63 390
a C 64 390
coronary C 65 390
av C 66 390
fistula C 67 390
, C 68 390
2 C 69 390
with C 70 390
ventricular C 71 390
septal C 72 390
defect C 73 390
( C 74 390
vsd C 75 390
) C 76 390
, C 77 390
1 C 78 390
with C 79 390
atrial C 80 390
septal C 81 390
defect C 82 390
( C 83 390
asd C 84 390
) C 85 390
, C 86 390
3 C 87 390
with C 88 390
mitral C 89 390
regurgitation C 90 390
, C 91 390
2 C 92 390
with C 93 390
aortic C 94 390
regurgitation C 95 390
and C 96 390
2 C 97 390
with C 98 390
systemic C 99 390
hypertension C 100 390
were C 101 390
studied C 102 390
. C 103 390
retro C 105 390
- C 106 390
grade C 107 390
arterial C 108 390
catheterization C 109 390
by C 110 390
seldinger C 111 390
' C 112 390
s C 113 390
technique C 114 390
was C 115 390
performed C 116 390
in C 117 390
all C 118 390
the C 119 390
patients C 120 390
, C 121 390
as C 122 390
well C 123 390
as C 124 390
right C 125 390
- C 126 390
sided C 127 390
catheterization C 128 390
in C 129 390
those C 130 390
with C 131 390
congenital C 132 390
cardiopathies C 133 390
, C 134 390
and C 135 390
transseptal C 136 390
catheterization C 137 390
in C 138 390
those C 139 390
with C 140 390
valvulopathies C 141 390
. C 142 390
a C 144 390
dose C 145 390
of C 146 390
5 C 147 390
- C 148 390
15 C 149 390
uc C 150 390
of C 151 390
na C 152 390
i C 153 390
131 C 154 390
was C 155 390
injected C 156 390
at C 157 390
the C 158 390
levels C 159 390
of C 160 390
the C 161 390
aortic C 162 390
root C 163 390
, C 164 390
the C 165 390
ascending C 166 390
aorta C 167 390
, C 168 390
the C 169 390
aortic C 170 390
arch C 171 390
, C 172 390
the C 173 390
origin C 174 390
of C 175 390
the C 176 390
left C 177 390
subclavian C 178 390
artery C 179 390
( C 180 390
ductus C 181 390
level C 182 390
) C 183 390
and C 184 390
the C 185 390
descending C 186 390
aorta C 187 390
( C 188 390
post C 189 390
- C 190 390
ductus C 191 390
level C 192 390
) C 193 390
. C 194 390
precordial C 196 390
curves C 197 390
were C 198 390
obtained C 199 390
by C 200 390
means C 201 390
of C 202 390
a C 203 390
2 C 204 390
- C 205 390
inch C 206 390
thallium C 207 390
- C 208 390
acti C 209 390
- C 210 390
vated C 211 390
nai C 212 390
crystal C 213 390
focused C 214 390
over C 215 390
the C 216 390
3 C 217 390
rd C 218 390
left C 219 390
intercostal C 220 390
space C 221 390
at C 222 390
the C 223 390
sternal C 224 390
margin C 225 390
. C 226 390
the C 228 390
shunt C 229 390
outlet C 230 390
can C 231 390
be C 232 390
detected C 233 390
by C 234 390
obtaining C 235 390
simultaneous C 236 390
venous C 237 390
dilution C 238 390
curves C 239 390
from C 240 390
the C 241 390
right C 242 390
chambers C 243 390
and C 244 390
the C 245 390
pulmonary C 246 390
artery C 247 390
. C 248 390
the C 250 390
latter C 251 390
technique C 252 390
was C 253 390
used C 254 390
in C 255 390
2 C 256 390
patients C 257 390
with C 258 390
pda C 259 390
, C 260 390
1 C 261 390
with C 262 390
coronary C 263 390
av C 264 390
fistula C 265 390
and C 266 390
1 C 267 390
with C 268 390
vsd C 269 390
. C 270 390
these C 272 390
curves C 273 390
were C 274 390
obtained C 275 390
by C 276 390
continuous C 277 390
withdrawal C 278 390
of C 279 390
blood C 280 390
which C 281 390
had C 282 390
flowed C 283 390
through C 284 390
a C 285 390
well C 286 390
scintillation C 287 390
counter C 288 390
. C 289 390
the C 291 390
crystal C 292 390
pulses C 293 390
were C 294 390
carried C 295 390
to C 296 390
ratemeters C 297 390
which C 298 390
worked C 299 390
with C 300 390
the C 301 390
following C 302 390
time C 303 390
constants C 304 390
0 C 305 390
. C 306 390
. C 307 390
. C 307 390
- C 308 390
0 C 309 390
. C 310 390
. C 311 390
. C 311 390
sec C 312 390
for C 313 390
the C 314 390
precordial C 315 390
curves C 316 390
and C 317 390
0 C 318 390
. C 319 390
. C 320 390
sec C 321 390
for C 322 390
the C 323 390
venous C 324 390
curves C 325 390
. C 326 390
a C 328 390
direct C 329 390
recorder C 330 390
with C 331 390
a C 332 390
5 C 333 390
- C 334 390
mm C 335 390
/ C 336 390
sec C 337 390
paper C 338 390
speed C 339 390
was C 340 390
used C 341 390
. C 342 390
normal C 344 390
precordial C 345 390
curves C 346 390
after C 347 390
injecting C 348 390
above C 349 390
the C 350 390
aortic C 351 390
valve C 352 390
were C 353 390
obtained C 354 390
in C 355 390
patients C 356 390
with C 357 390
arterial C 358 390
hypertension C 359 390
, C 360 390
mitral C 361 390
regurgitation C 362 390
and C 363 390
asd C 364 390
and C 365 390
vsd C 366 390
. C 367 390
a C 369 390
swift C 370 390
downslope C 371 390
which C 372 390
fell C 373 390
down C 374 390
near C 375 390
the C 376 390
baseline C 377 390
level C 378 390
and C 379 390
the C 380 390
recirculatory C 381 390
area C 382 390
was C 383 390
observed C 384 390
. C 385 390
1671 C 1 391
. C 2 391
the C 4 391
use C 5 391
of C 6 391
99 C 7 391
m C 8 391
tc C 9 391
pertechnetate C 10 391
in C 11 391
cardiac C 12 391
scanning C 13 391
technetium C 14 391
99 C 15 391
m C 16 391
pertechnetate C 17 391
has C 18 391
been C 19 391
utilized C 20 391
in C 21 391
the C 22 391
aas C 23 391
' C 24 391
laboratory C 25 391
for C 26 391
scanning C 27 391
the C 28 391
cardiac C 29 391
blood C 30 391
pool C 31 391
. C 32 391
the C 34 391
delineation C 35 391
of C 36 391
the C 37 391
heart C 38 391
pool C 39 391
and C 40 391
surrounding C 41 391
vasculature C 42 391
is C 43 391
comparable C 44 391
to C 45 391
that C 46 391
obtained C 47 391
with C 48 391
the C 49 391
standard C 50 391
131 C 51 391
i C 52 391
compounds C 53 391
now C 54 391
in C 55 391
use C 56 391
. C 57 391
in C 59 391
the C 60 391
authors C 61 391
' C 62 391
hands C 63 391
99 C 64 391
m C 65 391
tc C 66 391
had C 67 391
the C 68 391
following C 69 391
advantages C 70 391
since C 71 391
they C 72 391
routinely C 73 391
utilized C 74 391
99 C 75 391
m C 76 391
tc C 77 391
for C 78 391
brain C 79 391
and C 80 391
thyroid C 81 391
scans C 82 391
, C 83 391
it C 84 391
is C 85 391
available C 86 391
, C 87 391
eliminating C 88 391
the C 89 391
purchase C 90 391
and C 91 391
shelf C 92 391
decay C 93 391
of C 94 391
other C 95 391
materials C 96 391
. C 97 391
three C 99 391
to C 100 391
5 C 101 391
mc C 102 391
quantities C 103 391
may C 104 391
be C 105 391
administered C 106 391
with C 107 391
relatively C 108 391
low C 109 391
patient C 110 391
radiation C 111 391
dosage C 112 391
. C 113 391
the C 115 391
associated C 116 391
high C 117 391
count C 118 391
rate C 119 391
permits C 120 391
rapid C 121 391
scanning C 122 391
. C 123 391
the C 125 391
identification C 126 391
of C 127 391
pericardial C 128 391
effusions C 129 391
is C 130 391
enhanced C 131 391
by C 132 391
the C 133 391
radio C 134 391
- C 135 391
activity C 136 391
in C 137 391
the C 138 391
stomach C 139 391
which C 140 391
in C 141 391
some C 142 391
cases C 143 391
becomes C 144 391
abnormally C 145 391
separated C 146 391
from C 147 391
the C 148 391
cardiac C 149 391
blood C 150 391
pool C 151 391
. C 152 391
2012 C 1 392
. C 2 392
the C 4 392
use C 5 392
of C 6 392
technetium C 7 392
99 C 8 392
m C 9 392
as C 10 392
a C 11 392
clinical C 12 392
tracer C 13 392
element C 14 392
the C 15 392
physical C 16 392
properties C 17 392
, C 18 392
metabolism C 19 392
and C 20 392
radiation C 21 392
dose C 22 392
of C 23 392
tc C 24 392
99 C 25 392
m C 26 392
are C 27 392
discussed C 28 392
and C 29 392
compared C 30 392
with C 31 392
those C 32 392
of C 33 392
i C 34 392
123 C 35 392
, C 36 392
i C 37 392
125 C 38 392
, C 39 392
i C 40 392
131 C 41 392
and C 42 392
i C 43 392
132 C 44 392
. C 45 392
it C 47 392
is C 48 392
shown C 49 392
that C 50 392
with C 51 392
tc C 52 392
99 C 53 392
m C 54 392
the C 55 392
highest C 56 392
' C 57 392
in C 58 392
vivo C 59 392
' C 60 392
counting C 61 392
rates C 62 392
are C 63 392
obtained C 64 392
for C 65 392
a C 66 392
given C 67 392
internal C 68 392
radiation C 69 392
dose C 70 392
, C 71 392
so C 72 392
that C 73 392
mea C 74 392
- C 75 392
surements C 76 392
of C 77 392
high C 78 392
statistical C 79 392
accuracy C 80 392
may C 81 392
safely C 82 392
be C 83 392
made C 84 392
. C 85 392
the C 87 392
y C 88 392
- C 89 392
ray C 90 392
energy C 91 392
is C 92 392
near C 93 392
optimum C 94 392
for C 95 392
scanning C 96 392
and C 97 392
the C 98 392
observation C 99 392
of C 100 392
transients C 101 392
allowing C 102 392
light C 103 392
- C 104 392
weight C 105 392
collima C 106 392
- C 107 392
tors C 108 392
to C 109 392
be C 110 392
used C 111 392
. C 112 392
while C 114 392
tc C 115 392
99 C 116 392
m C 117 392
tagged C 118 392
albumin C 119 392
is C 120 392
considered C 121 392
superior C 122 392
to C 123 392
risa C 124 392
for C 125 392
ap C 126 392
- C 127 392
plications C 128 392
such C 129 392
as C 130 392
brain C 131 392
scanning C 132 392
, C 133 392
placentography C 134 392
and C 135 392
the C 136 392
measurement C 137 392
of C 138 392
cardiac C 139 392
output C 140 392
, C 141 392
i C 142 392
123 C 143 392
if C 144 392
it C 145 392
becomes C 146 392
available C 147 392
will C 148 392
be C 149 392
preferable C 150 392
for C 151 392
thyroid C 152 392
scanning C 153 392
. C 154 392
2626 C 1 393
. C 2 393
a C 4 393
study C 5 393
of C 6 393
central C 7 393
arteriovenous C 8 393
shunts C 9 393
by C 10 393
precordial C 11 393
recording C 12 393
of C 13 393
radioalbumin C 14 393
dilution C 15 393
curves C 16 393
precordial C 17 393
dilution C 18 393
curves C 19 393
of C 20 393
185 C 21 393
patients C 22 393
were C 23 393
studied C 24 393
, C 25 393
56 C 26 393
of C 27 393
them C 28 393
without C 29 393
cardio C 30 393
- C 31 393
vascular C 32 393
disease C 33 393
, C 34 393
48 C 35 393
with C 36 393
central C 37 393
arteriovenous C 38 393
shunts C 39 393
and C 40 393
45 C 41 393
with C 42 393
various C 43 393
cardiac C 44 393
diseases C 45 393
. C 46 393
collimation C 48 393
was C 49 393
not C 50 393
used C 51 393
, C 52 393
allowing C 53 393
only C 54 393
minimal C 55 393
quantities C 56 393
of C 57 393
radioactive C 58 393
material C 59 393
( C 60 393
0 C 61 393
. C 62 393
. C 63 393
- C 64 393
2 C 65 393
. C 66 393
. C 67 393
uc C 68 393
. C 69 393
of C 71 393
i C 72 393
131 C 73 393
- C 74 393
tagged C 75 393
albumin C 76 393
) C 77 393
to C 78 393
be C 79 393
utilized C 80 393
. C 81 393
the C 83 393
precordial C 84 393
focusing C 85 393
zone C 86 393
was C 87 393
a C 88 393
critical C 89 393
factor C 90 393
in C 91 393
this C 92 393
technique C 93 393
. C 94 393
the C 96 393
application C 97 393
of C 98 393
different C 99 393
discrimina C 100 393
- C 101 393
tion C 102 393
factors C 103 393
, C 104 393
among C 105 393
them C 106 393
the C 107 393
ratio C 108 393
between C 109 393
the C 110 393
minimal C 111 393
concentration C 112 393
and C 113 393
the C 114 393
latter C 115 393
- C 116 393
an C 117 393
index C 118 393
proposed C 119 393
here C 120 393
- C 121 393
made C 122 393
possible C 123 393
the C 124 393
diagnosis C 125 393
in C 126 393
46 C 127 393
of C 128 393
the C 129 393
48 C 130 393
patients C 131 393
with C 132 393
shunts C 133 393
. C 134 393
this C 136 393
method C 137 393
was C 138 393
shown C 139 393
to C 140 393
be C 141 393
as C 142 393
sensitive C 143 393
as C 144 393
classical C 145 393
oximetry C 146 393
done C 147 393
during C 148 393
cardiac C 149 393
catheterization C 150 393
. C 151 393
the C 153 393
curves C 154 393
in C 155 393
pure C 156 393
valvular C 157 393
stenosis C 158 393
do C 159 393
not C 160 393
show C 161 393
similar C 162 393
changes C 163 393
to C 164 393
the C 165 393
shunts C 166 393
. C 167 393
on C 169 393
the C 170 393
other C 171 393
hand C 172 393
, C 173 393
these C 174 393
changes C 175 393
are C 176 393
shown C 177 393
in C 178 393
certain C 179 393
val C 180 393
- C 181 393
vular C 182 393
regurgitations C 183 393
. C 184 393
this C 186 393
fact C 187 393
becomes C 188 393
the C 189 393
most C 190 393
important C 191 393
limiting C 192 393
factor C 193 393
in C 194 393
the C 195 393
diagnosis C 196 393
of C 197 393
central C 198 393
arteriovenous C 199 393
shunts C 200 393
. C 201 393
cardiac C 203 393
failure C 204 393
does C 205 393
not C 206 393
preclude C 207 393
the C 208 393
diagnosis C 209 393
, C 210 393
providing C 211 393
one C 212 393
can C 213 393
exclude C 214 393
valvular C 215 393
regurgitation C 216 393
by C 217 393
other C 218 393
means C 219 393
. C 220 393
the C 222 393
method C 223 393
is C 224 393
thus C 225 393
, C 226 393
in C 227 393
spite C 228 393
of C 229 393
its C 230 393
limitations C 231 393
, C 232 393
of C 233 393
extreme C 234 393
value C 235 393
in C 236 393
diagnosing C 237 393
central C 238 393
arteriovenous C 239 393
shunts C 240 393
, C 241 393
especially C 242 393
when C 243 393
the C 244 393
results C 245 393
are C 246 393
analyzed C 247 393
together C 248 393
with C 249 393
clinical C 250 393
information C 1 394
. C 2 394
2724 C 4 394
. C 5 394
primary C 7 394
epidermoid C 8 394
cancers C 9 394
of C 10 394
the C 11 394
lung C 12 394
. C 13 394
electron C 15 394
micro C 16 394
- C 17 394
scopic C 18 394
study C 19 394
an C 20 394
electron C 21 394
microscopic C 22 394
study C 23 394
was C 24 394
made C 25 394
of C 26 394
8 C 27 394
squamous C 28 394
cell C 29 394
, C 30 394
3 C 31 394
undifferentiated C 32 394
, C 33 394
and C 34 394
3 C 35 394
alveolar C 36 394
carcinomas C 37 394
of C 38 394
the C 39 394
lung C 40 394
on C 41 394
biopsy C 42 394
specimens C 43 394
embedded C 44 394
in C 45 394
methacryl C 46 394
- C 47 394
ate C 48 394
. C 49 394
the C 51 394
squamous C 52 394
cell C 53 394
carcinomas C 54 394
were C 55 394
found C 56 394
to C 57 394
contain C 58 394
cylindrical C 59 394
cells C 60 394
with C 61 394
glycogen C 62 394
granules C 63 394
, C 64 394
scanty C 65 394
mitochondria C 66 394
, C 67 394
a C 68 394
reticular C 69 394
endoplasm C 70 394
which C 71 394
was C 72 394
chiefly C 73 394
vesicular C 74 394
, C 75 394
numerous C 76 394
free C 77 394
ribosomes C 78 394
, C 79 394
and C 80 394
bundles C 81 394
of C 82 394
confluent C 83 394
fibrils C 84 394
in C 85 394
the C 86 394
desmo C 87 394
- C 88 394
somes C 89 394
. C 90 394
the C 92 394
authors C 93 394
also C 94 394
observed C 95 394
in C 96 394
the C 97 394
center C 98 394
of C 99 394
the C 100 394
tumor C 101 394
nodes C 102 394
, C 103 394
cells C 104 394
richer C 105 394
in C 106 394
tonofibrils C 107 394
which C 108 394
enveloped C 109 394
the C 110 394
nucleus C 111 394
, C 112 394
and C 113 394
cells C 114 394
in C 115 394
which C 116 394
all C 117 394
the C 118 394
cytoplasmic C 119 394
organelles C 120 394
had C 121 394
almost C 122 394
disappeared C 123 394
except C 124 394
for C 125 394
tonofibrils C 126 394
or C 127 394
cells C 128 394
packed C 129 394
with C 130 394
keratohyalin C 131 394
and C 132 394
even C 133 394
lipid C 134 394
granules C 135 394
sometimes C 136 394
arranged C 137 394
in C 138 394
lamellar C 139 394
formations C 140 394
of C 141 394
the C 142 394
myelin C 143 394
type C 144 394
. C 145 394
the C 147 394
picture C 148 394
as C 149 394
a C 150 394
whole C 151 394
was C 152 394
that C 153 394
so C 154 394
often C 155 394
seen C 156 394
in C 157 394
the C 158 394
optic C 159 394
microscope C 160 394
tumor C 161 394
foci C 162 394
formed C 163 394
of C 164 394
slightly C 165 394
differentiated C 166 394
cells C 167 394
at C 168 394
the C 169 394
periphery C 170 394
which C 171 394
became C 172 394
more C 173 394
differentiated C 174 394
as C 175 394
one C 176 394
approaches C 177 394
the C 178 394
center C 179 394
. C 180 394
the C 182 394
undifferenti C 183 394
- C 184 394
ated C 185 394
cells C 186 394
resembled C 187 394
more C 188 394
the C 189 394
intermediate C 190 394
bronchial C 191 394
cells C 192 394
than C 193 394
the C 194 394
basal C 195 394
cells C 196 394
. C 197 394
the C 199 394
paper C 200 394
does C 201 394
not C 202 394
describe C 203 394
the C 204 394
undifferentiated C 205 394
and C 206 394
alveolar C 207 394
carcinomas C 208 394
. C 209 394
1375 C 1 395
. C 2 395
loss C 4 395
of C 5 395
neoplastic C 6 395
properties C 7 395
in C 8 395
vitro C 9 395
. C 10 395
ii C 12 395
. C 13 395
observations C 15 395
on C 16 395
kb C 17 395
sublines C 18 395
ten C 19 395
sublines C 20 395
of C 21 395
the C 22 395
kb C 23 395
cell C 24 395
line C 25 395
obtained C 26 395
from C 27 395
a C 28 395
number C 29 395
of C 30 395
different C 31 395
laboratories C 32 395
were C 33 395
reexamined C 34 395
with C 35 395
respect C 36 395
to C 37 395
chromosome C 38 395
number C 39 395
and C 40 395
heterotransplantability C 41 395
to C 42 395
the C 43 395
syrian C 44 395
hamster C 45 395
cheek C 46 395
pouch C 47 395
. C 48 395
twelve C 50 395
clonal C 51 395
cultures C 52 395
derived C 53 395
from C 54 395
2 C 55 395
of C 56 395
these C 57 395
sublines C 58 395
were C 59 395
similarly C 60 395
examined C 61 395
. C 62 395
three C 64 395
sublines C 65 395
differed C 66 395
from C 67 395
one C 68 395
another C 69 395
and C 70 395
from C 71 395
the C 72 395
kb C 73 395
cell C 74 395
line C 75 395
originally C 76 395
studied C 77 395
, C 78 395
which C 79 395
was C 80 395
heterotransplantable C 81 395
with C 82 395
inocula C 83 395
of C 84 395
circa C 85 395
10 C 86 395
cells C 87 395
. C 88 395
only C 90 395
2 C 91 395
of C 92 395
the C 93 395
sublines C 94 395
could C 95 395
be C 96 395
heterotransplanted C 97 395
with C 98 395
inocula C 99 395
of C 100 395
less C 101 395
than C 102 395
10 C 103 395
4 C 104 395
cells C 105 395
; C 106 395
5 C 107 395
were C 108 395
heterotransplantable C 109 395
with C 110 395
inocula C 111 395
of C 112 395
10 C 113 395
4 C 114 395
- C 115 395
10 C 116 395
6 C 117 395
cells C 118 395
; C 119 395
and C 120 395
2 C 121 395
failed C 122 395
to C 123 395
heterotransplant C 124 395
, C 125 395
even C 126 395
with C 127 395
inocula C 128 395
of C 129 395
10 C 130 395
6 C 131 395
cells C 132 395
. C 133 395
similar C 135 395
differences C 136 395
in C 137 395
heterotransplantability C 138 395
were C 139 395
observed C 140 395
among C 141 395
the C 142 395
clonal C 143 395
derivatives C 144 395
of C 145 395
2 C 146 395
of C 147 395
these C 148 395
sublines C 149 395
. C 150 395
although C 152 395
the C 153 395
modal C 154 395
numbers C 155 395
of C 156 395
these C 157 395
sublines C 158 395
and C 159 395
clonal C 160 395
derivatives C 161 395
were C 162 395
basically C 163 395
similar C 164 395
, C 165 395
ranging C 166 395
from C 167 395
73 C 168 395
to C 169 395
80 C 170 395
, C 171 395
a C 172 395
few C 173 395
lines C 174 395
had C 175 395
a C 176 395
chromosome C 177 395
of C 178 395
sufficient C 179 395
- C 180 395
ly C 181 395
distinctive C 182 395
morphology C 183 395
to C 184 395
serve C 185 395
as C 186 395
a C 187 395
marker C 188 395
. C 189 395
there C 191 395
was C 192 395
, C 193 395
however C 194 395
, C 195 395
no C 196 395
apparent C 197 395
correlation C 198 395
between C 199 395
these C 200 395
minor C 201 395
karyotypic C 202 395
differences C 203 395
and C 204 395
heterotransplantability C 205 395
. C 206 395
possible C 208 395
differences C 209 395
between C 210 395
non C 211 395
- C 212 395
heterotransplantable C 213 395
and C 214 395
heterotransplantable C 215 395
sublines C 216 395
with C 217 395
respect C 218 395
to C 219 395
the C 220 395
pattern C 221 395
of C 222 395
variability C 223 395
in C 224 395
cytoplasmic C 225 395
protein C 226 395
and C 227 395
cyto C 228 395
- C 229 395
plasmic C 230 395
ribonucleic C 231 395
( C 232 395
rna C 233 395
) C 234 395
content C 235 395
per C 236 395
cell C 237 395
remain C 238 395
to C 239 395
be C 240 395
studied C 241 395
in C 242 395
detail C 243 395
. C 244 395
for C 246 395
i C 247 395
of C 248 395
this C 249 395
series C 250 395
of C 251 395
articles C 252 395
see C 253 395
exc C 254 395
. C 255 395
medica C 257 395
cancer C 258 395
, C 259 395
1965 C 260 395
, C 261 395
abstr C 262 395
. C 263 395
no C 265 395
. C 266 395
2378 C 268 395
. C 269 395
1377 C 1 396
. C 2 396
establishment C 4 396
of C 5 396
a C 6 396
tissue C 7 396
culture C 8 396
strain C 9 396
jtc C 10 396
- C 11 396
14 C 12 396
from C 13 396
actino C 14 396
- C 15 396
mycin C 16 396
- C 17 396
induced C 18 396
ascites C 19 396
sarcoma C 20 396
, C 21 396
and C 22 396
its C 23 396
biological C 24 396
characters C 25 396
cell C 26 396
line C 27 396
jtc C 28 396
- C 29 396
14 C 30 396
has C 31 396
been C 32 396
maintained C 33 396
for C 34 396
more C 35 396
than C 36 396
2 C 37 396
yr C 38 396
. C 39 396
and C 41 396
subcultured C 42 396
93 C 43 396
times C 44 396
. C 45 396
cells C 47 396
from C 48 396
the C 49 396
10 C 50 396
th C 51 396
subculture C 52 396
on C 53 396
subcutaneous C 54 396
injection C 55 396
into C 56 396
mice C 57 396
produced C 58 396
tumors C 59 396
identical C 60 396
with C 61 396
those C 62 396
produced C 63 396
by C 64 396
the C 65 396
original C 66 396
cells C 67 396
. C 68 396
judged C 70 396
by C 71 396
the C 72 396
time C 73 396
taken C 74 396
to C 75 396
kill C 76 396
mice C 77 396
on C 78 396
intraperitoneal C 79 396
injection C 80 396
the C 81 396
tissue C 82 396
culture C 83 396
cells C 84 396
were C 85 396
not C 86 396
as C 87 396
malignant C 88 396
as C 89 396
the C 90 396
original C 91 396
tumor C 92 396
cells C 93 396
. C 94 396
after C 96 396
passage C 97 396
in C 98 396
animals C 99 396
the C 100 396
cells C 101 396
were C 102 396
easily C 103 396
re C 104 396
- C 105 396
established C 106 396
in C 107 396
culture C 108 396
in C 109 396
vitro C 110 396
. C 111 396
1378 C 1 397
. C 2 397
microcinematographic C 4 397
study C 5 397
of C 6 397
the C 7 397
mechanism C 8 397
of C 9 397
cancerous C 10 397
invasion C 11 397
in C 12 397
cultures C 13 397
of C 14 397
normal C 15 397
tissue C 16 397
combined C 17 397
with C 18 397
malignant C 19 397
cells C 20 397
normal C 21 397
myocardium C 22 397
of C 23 397
newborn C 24 397
c C 25 397
3 C 26 397
h C 27 397
mice C 28 397
was C 29 397
cultivated C 30 397
in C 31 397
vitro C 32 397
in C 33 397
contact C 34 397
with C 35 397
homologous C 36 397
sarcomatous C 37 397
cells C 38 397
( C 39 397
strain C 40 397
n C 41 397
1 C 42 397
and C 43 397
strain C 44 397
nctc C 45 397
) C 46 397
and C 47 397
studied C 48 397
by C 49 397
micro C 50 397
- C 51 397
cinematography C 52 397
for C 53 397
22 C 54 397
days C 55 397
. C 56 397
it C 58 397
was C 59 397
found C 60 397
that C 61 397
the C 62 397
tumor C 63 397
cells C 64 397
tend C 65 397
to C 66 397
move C 67 397
apart C 68 397
, C 69 397
and C 70 397
with C 71 397
more C 72 397
vigorous C 73 397
and C 74 397
rapid C 75 397
movements C 76 397
some C 77 397
of C 78 397
them C 79 397
called C 80 397
' C 81 397
commando C 82 397
' C 83 397
s C 84 397
' C 85 397
make C 86 397
their C 87 397
way C 88 397
into C 89 397
the C 90 397
group C 91 397
of C 92 397
normal C 93 397
cells C 94 397
but C 95 397
are C 96 397
arrested C 97 397
wherever C 98 397
they C 99 397
meet C 100 397
a C 101 397
compact C 102 397
group C 103 397
of C 104 397
these C 105 397
cells C 106 397
. C 107 397
this C 109 397
then C 110 397
demonstrates C 111 397
, C 112 397
on C 113 397
the C 114 397
one C 115 397
hand C 116 397
, C 117 397
direct C 118 397
aggresivity C 119 397
of C 120 397
the C 121 397
tumor C 122 397
cells C 123 397
and C 124 397
, C 125 397
on C 126 397
the C 127 397
other C 128 397
, C 129 397
the C 130 397
' C 131 397
group C 132 397
' C 133 397
defence C 134 397
of C 135 397
the C 136 397
normal C 137 397
cells C 138 397
. C 139 397
2413 C 1 398
. C 2 398
the C 4 398
presence C 5 398
of C 6 398
lymphocytes C 7 398
in C 8 398
long C 9 398
term C 10 398
cultures C 11 398
of C 12 398
newborn C 13 398
mouse C 14 398
thymic C 15 398
epithelium C 16 398
thymic C 17 398
epithelial C 18 398
cells C 19 398
derived C 20 398
from C 21 398
newborn C 22 398
mouse C 23 398
thymic C 24 398
fragments C 25 398
were C 26 398
cultured C 27 398
in C 28 398
vitro C 29 398
for C 30 398
over C 31 398
22 C 32 398
mth C 33 398
. C 34 398
subcultures C 36 398
were C 37 398
started C 38 398
by C 39 398
transferring C 40 398
minute C 41 398
cell C 42 398
sheets C 43 398
obtained C 44 398
by C 45 398
mechanical C 46 398
scraping C 47 398
of C 48 398
the C 49 398
original C 50 398
culture C 51 398
when C 52 398
it C 53 398
was C 54 398
14 C 55 398
mth C 56 398
old C 57 398
or C 58 398
older C 59 398
. C 60 398
lymphocytes C 62 398
, C 63 398
many C 64 398
of C 65 398
them C 66 398
with C 67 398
the C 68 398
morphological C 69 398
appearance C 70 398
of C 71 398
plasma C 72 398
cells C 73 398
, C 74 398
were C 75 398
seen C 76 398
in C 77 398
the C 78 398
subcultures C 79 398
. C 80 398
intact C 82 398
lymphocytes C 83 398
, C 84 398
as C 85 398
well C 86 398
as C 87 398
mitotic C 88 398
figures C 89 398
were C 90 398
seen C 91 398
within C 92 398
cytoplasmatic C 93 398
vacuoles C 94 398
of C 95 398
the C 96 398
epithelial C 97 398
cells C 98 398
. C 99 398
the C 101 398
possible C 102 398
bearing C 103 398
of C 104 398
these C 105 398
observations C 106 398
on C 107 398
the C 108 398
origin C 109 398
of C 110 398
the C 111 398
thymic C 112 398
lymphocytes C 113 398
is C 114 398
briefly C 115 398
discussed C 116 398
. C 117 398
3748 C 1 399
. C 2 399
four C 4 399
separate C 5 399
tumour C 6 399
clones C 7 399
derived C 8 399
from C 9 399
a C 10 399
transplantable C 11 399
pleo C 12 399
- C 13 399
morphic C 14 399
carcinoma C 15 399
of C 16 399
the C 17 399
lung C 18 399
in C 19 399
a C 20 399
heterozygous C 21 399
mouse C 22 399
a C 23 399
metastasising C 24 399
pleomorphic C 25 399
adenocarcinoma C 26 399
in C 27 399
the C 28 399
lung C 29 399
of C 30 399
an C 31 399
untreated C 32 399
hetero C 33 399
- C 34 399
zygous C 35 399
male C 36 399
mouse C 37 399
was C 38 399
successfully C 39 399
transplanted C 40 399
to C 41 399
4 C 42 399
brothers C 43 399
by C 44 399
the C 45 399
' C 46 399
plating C 47 399
' C 48 399
technique C 49 399
of C 50 399
henderson C 51 399
and C 52 399
rous C 53 399
. C 54 399
by C 56 399
' C 57 399
plating C 58 399
' C 59 399
multiple C 60 399
small C 61 399
grafts C 62 399
in C 63 399
air C 64 399
bells C 65 399
in C 66 399
the C 67 399
subcutaneous C 68 399
tissues C 69 399
of C 70 399
the C 71 399
new C 72 399
hosts C 73 399
it C 74 399
was C 75 399
possible C 76 399
to C 77 399
select C 78 399
4 C 79 399
different C 80 399
clones C 81 399
of C 82 399
transplantable C 83 399
tumour C 84 399
for C 85 399
further C 86 399
study C 87 399
. C 88 399
the C 90 399
histological C 91 399
peculiarities C 92 399
of C 93 399
different C 94 399
parts C 95 399
of C 96 399
the C 97 399
original C 98 399
tumour C 99 399
were C 100 399
reproduced C 101 399
in C 102 399
the C 103 399
different C 104 399
clones C 105 399
a C 106 399
i C 107 399
, C 108 399
ii C 109 399
, C 110 399
iii C 111 399
, C 112 399
and C 113 399
b C 114 399
. C 115 399
retrospective C 117 399
study C 118 399
of C 119 399
the C 120 399
primary C 121 399
tumour C 122 399
and C 123 399
of C 124 399
its C 125 399
metastases C 126 399
provided C 127 399
some C 128 399
interesting C 129 399
clues C 130 399
to C 131 399
routes C 132 399
of C 133 399
metastasis C 134 399
and C 135 399
the C 136 399
selective C 137 399
survival C 138 399
of C 139 399
malignant C 140 399
cells C 141 399
. C 142 399
it C 144 399
is C 145 399
concluded C 146 399
that C 147 399
by C 148 399
the C 149 399
cloning C 150 399
of C 151 399
transplantable C 152 399
cells C 153 399
, C 154 399
at C 155 399
the C 156 399
first C 157 399
serial C 158 399
passage C 159 399
, C 160 399
valuable C 161 399
information C 162 399
about C 163 399
the C 164 399
histogenesis C 165 399
and C 166 399
potential C 167 399
malignancy C 168 399
of C 169 399
the C 170 399
primary C 171 399
tumour C 172 399
can C 173 399
be C 174 399
obtained C 175 399
. C 176 399
lastly C 178 399
, C 179 399
the C 180 399
highly C 181 399
malignant C 182 399
character C 183 399
of C 184 399
4 C 185 399
clones C 186 399
of C 187 399
tumour C 188 399
cells C 189 399
apparently C 190 399
derived C 191 399
from C 192 399
the C 193 399
familiar C 194 399
clinically C 195 399
benign C 196 399
adenoma C 197 399
of C 198 399
the C 199 399
mouse C 200 399
lung C 201 399
may C 202 399
be C 203 399
of C 204 399
some C 205 399
interest C 206 399
, C 207 399
from C 208 399
the C 209 399
point C 210 399
of C 211 399
view C 212 399
of C 213 399
prognosis C 214 399
based C 215 399
on C 216 399
histology C 217 399
. C 218 399
2379 C 1 400
. C 2 400
in C 4 400
- C 5 400
vitro C 6 400
culture C 7 400
of C 8 400
pulmonary C 9 400
tumors C 10 400
in C 11 400
hamsters C 12 400
caused C 13 400
by C 14 400
adenovirus C 15 400
12 C 16 400
it C 17 400
is C 18 400
known C 19 400
that C 20 400
the C 21 400
adenoviruses C 22 400
12 C 23 400
and C 24 400
18 C 25 400
provoke C 26 400
malignant C 27 400
tumors C 28 400
in C 29 400
the C 30 400
new C 31 400
- C 32 400
born C 33 400
hamster C 34 400
. C 35 400
the C 37 400
authors C 38 400
made C 39 400
a C 40 400
study C 41 400
of C 42 400
the C 43 400
histogenesis C 44 400
of C 45 400
these C 46 400
tumors C 47 400
and C 48 400
examined C 49 400
the C 50 400
specific C 51 400
changes C 52 400
brought C 53 400
about C 54 400
in C 55 400
the C 56 400
cells C 57 400
by C 58 400
the C 59 400
virus C 60 400
infection C 61 400
malignancy C 62 400
, C 63 400
presence C 64 400
of C 65 400
viral C 66 400
antigen C 67 400
, C 68 400
reactions C 69 400
to C 70 400
superinfection C 71 400
. C 72 400
when C 74 400
new C 75 400
- C 76 400
born C 77 400
hamsters C 78 400
were C 79 400
inoculated C 80 400
in C 81 400
the C 82 400
chest C 83 400
with C 84 400
adenovirus C 85 400
12 C 86 400
, C 87 400
malignant C 88 400
tumors C 89 400
developed C 90 400
in C 91 400
one C 92 400
or C 93 400
two C 94 400
months C 95 400
, C 96 400
in C 97 400
16 C 98 400
animals C 99 400
out C 100 400
of C 101 400
22 C 102 400
. C 103 400
these C 105 400
tumors C 106 400
presented C 107 400
an C 108 400
epithelial C 109 400
aspect C 110 400
and C 111 400
were C 112 400
of C 113 400
bronchiolo C 114 400
- C 115 400
alveolar C 116 400
origin C 117 400
. C 118 400
they C 120 400
were C 121 400
transplant C 122 400
- C 123 400
able C 124 400
in C 125 400
vivo C 126 400
; C 127 400
if C 128 400
they C 129 400
were C 130 400
cultured C 131 400
in C 132 400
vitro C 133 400
, C 134 400
they C 135 400
consisted C 136 400
in C 137 400
the C 138 400
first C 139 400
few C 140 400
cultures C 141 400
of C 142 400
macrophages C 143 400
, C 144 400
fibroblasts C 145 400
and C 146 400
epithelium C 147 400
. C 148 400
in C 150 400
subsequent C 151 400
passages C 152 400
, C 153 400
there C 154 400
was C 155 400
a C 156 400
progressive C 157 400
disappearance C 158 400
of C 159 400
the C 160 400
macrophages C 161 400
and C 162 400
fibroblasts C 163 400
. C 164 400
in C 166 400
some C 167 400
cases C 168 400
, C 169 400
the C 170 400
culture C 171 400
after C 172 400
seven C 173 400
passages C 174 400
was C 175 400
of C 176 400
a C 177 400
purely C 178 400
epithelial C 179 400
nature C 180 400
, C 181 400
and C 182 400
when C 183 400
it C 184 400
was C 185 400
reimplanted C 186 400
into C 187 400
hamsters C 188 400
at C 189 400
this C 190 400
time C 191 400
it C 192 400
gave C 193 400
rise C 194 400
to C 195 400
the C 196 400
rapid C 197 400
development C 198 400
of C 199 400
an C 200 400
epithelial C 201 400
tumor C 202 400
. C 203 400
in C 205 400
the C 206 400
tumor C 207 400
cultures C 208 400
, C 209 400
no C 210 400
adenovirus C 211 400
could C 212 400
be C 213 400
demonstrated C 214 400
. C 215 400
nor C 217 400
could C 218 400
cultures C 219 400
of C 220 400
the C 221 400
pulmonary C 222 400
tumors C 223 400
, C 224 400
or C 225 400
cultures C 226 400
of C 227 400
normal C 228 400
hamster C 229 400
lung C 230 400
be C 231 400
infected C 232 400
with C 233 400
adenovirus C 234 400
. C 235 400
it C 237 400
appears C 238 400
that C 239 400
the C 240 400
lung C 241 400
of C 242 400
the C 243 400
hamster C 244 400
in C 245 400
an C 246 400
organotyp C 247 400
- C 248 400
ical C 249 400
culture C 250 400
constitutes C 251 400
a C 252 400
means C 253 400
of C 254 400
choice C 255 400
for C 256 400
the C 257 400
malignant C 258 400
transformation C 259 400
of C 260 400
adenovirus C 261 400
12 C 262 400
. C 263 400
133 C 1 401
. C 2 401
demonstration C 4 401
, C 5 401
purification C 6 401
, C 7 401
and C 8 401
partial C 9 401
characterization C 10 401
of C 11 401
ab C 12 401
- C 13 401
normal C 14 401
( C 15 401
hsl C 16 401
) C 17 401
antigens C 18 401
in C 19 401
stable C 20 401
human C 21 401
cell C 22 401
lines C 23 401
the C 24 401
existence C 25 401
of C 26 401
abnormal C 27 401
human C 28 401
stable C 29 401
line C 30 401
( C 31 401
hsl C 32 401
) C 33 401
antigens C 34 401
common C 35 401
to C 36 401
a C 37 401
number C 38 401
of C 39 401
stable C 40 401
human C 41 401
cell C 42 401
lines C 43 401
, C 44 401
but C 45 401
absent C 46 401
from C 47 401
normal C 48 401
human C 49 401
tissues C 50 401
and C 51 401
normal C 52 401
human C 53 401
diploid C 54 401
cell C 55 401
strains C 56 401
in C 57 401
tissue C 58 401
culture C 59 401
, C 60 401
was C 61 401
demonstrated C 62 401
by C 63 401
agar C 64 401
gel C 65 401
microimmunodiffusion C 66 401
. C 67 401
hsl C 69 401
was C 70 401
detected C 71 401
in C 72 401
hela C 73 401
- C 74 401
sj C 75 401
, C 76 401
hela C 77 401
- C 78 401
mba C 79 401
, C 80 401
hela C 81 401
- C 82 401
s C 83 401
3 C 84 401
, C 85 401
chang C 86 401
conjunctiva C 87 401
, C 88 401
syverton C 89 401
' C 90 401
s C 91 401
embryo C 92 401
esophagus C 93 401
, C 94 401
chang C 95 401
liver C 96 401
, C 97 401
and C 98 401
j C 99 401
- C 100 401
iii C 101 401
. C 102 401
it C 104 401
was C 105 401
not C 106 401
detected C 107 401
in C 108 401
henle C 109 401
' C 110 401
s C 111 401
human C 112 401
intestine C 113 401
or C 114 401
detroit C 115 401
- C 116 401
6 C 117 401
. C 118 401
it C 120 401
was C 121 401
absent C 122 401
from C 123 401
two C 124 401
normal C 125 401
diploid C 126 401
strains C 127 401
, C 128 401
wi C 129 401
- C 130 401
38 C 131 401
and C 132 401
sj C 133 401
- C 134 401
dhl C 135 401
, C 136 401
and C 137 401
was C 138 401
not C 139 401
found C 140 401
in C 141 401
a C 142 401
variety C 143 401
of C 144 401
concentrated C 145 401
extracts C 146 401
of C 147 401
fresh C 148 401
human C 149 401
organs C 150 401
. C 151 401
hsl C 153 401
was C 154 401
not C 155 401
associated C 156 401
with C 157 401
contamination C 158 401
by C 159 401
pleuropneumonia C 160 401
- C 161 401
like C 162 401
organisms C 163 401
( C 164 401
pplo C 165 401
) C 166 401
of C 167 401
cell C 168 401
lines C 169 401
. C 170 401
the C 172 401
purest C 173 401
hsl C 174 401
preparations C 175 401
obtained C 176 401
from C 177 401
hela C 178 401
- C 179 401
sj C 180 401
by C 181 401
ammonium C 182 401
sulfate C 183 401
fractiona C 184 401
- C 185 401
tion C 186 401
yielded C 187 401
absorption C 188 401
spectra C 189 401
characteristic C 190 401
of C 191 401
protein C 192 401
and C 193 401
were C 194 401
inactivated C 195 401
by C 196 401
trypsin C 197 401
. C 198 401
sephadex C 200 401
chromatography C 201 401
indicated C 202 401
a C 203 401
particle C 204 401
weight C 205 401
of C 206 401
approximately C 207 401
150 C 208 401
, C 209 401
000 C 210 401
; C 211 401
hsl C 212 401
was C 213 401
not C 214 401
sedimented C 215 401
at C 216 401
125 C 217 401
, C 218 401
000 C 219 401
x C 220 401
g C 221 401
. C 222 401
in C 224 401
0 C 225 401
. C 226 401
. C 227 401
. C 227 401
m C 228 401
po C 229 401
4 C 230 401
buffer C 231 401
, C 232 401
activity C 233 401
was C 234 401
virtually C 235 401
completely C 236 401
eliminated C 237 401
after C 238 401
2 C 239 401
minutes C 240 401
at C 241 401
50 C 242 401
c C 243 401
. C 244 401
, C 246 401
8 C 247 401
minutes C 248 401
at C 249 401
45 C 250 401
c C 251 401
. C 252 401
, C 254 401
or C 255 401
80 C 256 401
minutes C 257 401
at C 258 401
40 C 259 401
c C 260 401
. C 261 401
preliminary C 263 401
studies C 264 401
with C 265 401
fluorescent C 266 401
anti C 267 401
- C 268 401
hsl C 269 401
globulin C 270 401
indicated C 271 401
that C 272 401
hsl C 273 401
was C 274 401
not C 275 401
a C 276 401
surface C 277 401
antigen C 278 401
; C 279 401
rabbit C 280 401
antisera C 281 401
to C 282 401
purified C 283 401
hsl C 284 401
fractions C 285 401
were C 286 401
not C 287 401
cytotoxic C 288 401
to C 289 401
hela C 290 401
cells C 291 401
. C 292 401
the C 294 401
best C 295 401
preparations C 296 401
of C 297 401
hsl C 298 401
still C 299 401
contained C 300 401
a C 301 401
trace C 302 401
of C 303 401
common C 304 401
human C 305 401
antigen C 306 401
and C 307 401
appeared C 308 401
to C 309 401
consist C 310 401
of C 311 401
multiple C 312 401
components C 313 401
active C 314 401
in C 315 401
immunoprecipitation C 316 401
. C 317 401
electrophoresis C 319 401
indicated C 320 401
the C 321 401
in C 322 401
- C 323 401
homogeneity C 324 401
of C 325 401
this C 326 401
material C 327 401
. C 328 401
1696 C 1 402
. C 2 402
further C 4 402
comparative C 5 402
studies C 6 402
on C 7 402
two C 8 402
isogenic C 9 402
cell C 10 402
lines C 11 402
of C 12 402
autologous C 13 402
origin C 14 402
, C 15 402
one C 16 402
of C 17 402
which C 18 402
is C 19 402
tumor C 20 402
- C 21 402
producing C 22 402
a C 23 402
single C 24 402
explant C 25 402
of C 26 402
normal C 27 402
lung C 28 402
tissue C 29 402
from C 30 402
an C 31 402
adult C 32 402
female C 33 402
mouse C 34 402
c C 35 402
57 C 36 402
bl C 37 402
provided C 38 402
2 C 39 402
cell C 40 402
lines C 41 402
. C 42 402
one C 44 402
remained C 45 402
normal C 46 402
and C 47 402
is C 48 402
referred C 49 402
to C 50 402
as C 51 402
pg C 52 402
, C 53 402
the C 54 402
other C 55 402
became C 56 402
malignant C 57 402
and C 58 402
is C 59 402
designated C 60 402
as C 61 402
pt C 62 402
. C 63 402
with C 65 402
successive C 66 402
in C 67 402
vitro C 68 402
passages C 69 402
by C 70 402
tryp C 71 402
- C 72 402
sinization C 73 402
the C 74 402
tumour C 75 402
- C 76 402
inducing C 77 402
capacity C 78 402
of C 79 402
the C 80 402
pt C 81 402
line C 82 402
considerably C 83 402
decreased C 84 402
its C 85 402
tumour C 86 402
- C 87 402
producing C 88 402
capacity C 89 402
as C 90 402
well C 91 402
as C 92 402
its C 93 402
acrobic C 94 402
glycolysis C 95 402
coefficient C 96 402
, C 97 402
while C 98 402
the C 99 402
pg C 100 402
line C 101 402
showed C 102 402
no C 103 402
appreciable C 104 402
change C 105 402
. C 106 402
results C 108 402
of C 109 402
chromosome C 110 402
studies C 111 402
are C 112 402
de C 113 402
- C 114 402
scribed C 115 402
, C 116 402
but C 117 402
proved C 118 402
inconclusive C 119 402
. C 120 402
similar C 122 402
experiments C 123 402
were C 124 402
also C 125 402
carried C 126 402
out C 127 402
on C 128 402
cell C 129 402
lines C 130 402
derived C 131 402
from C 132 402
the C 133 402
pt C 134 402
line C 135 402
and C 136 402
their C 137 402
results C 138 402
are C 139 402
discussed C 140 402
. C 141 402
1202 C 1 403
. C 2 403
characteristics C 4 403
of C 5 403
human C 6 403
adenovirus C 7 403
type C 8 403
12 C 9 403
induced C 10 403
hamster C 11 403
tumor C 12 403
cells C 13 403
in C 14 403
tissue C 15 403
culture C 16 403
characteristics C 17 403
of C 18 403
a C 19 403
human C 20 403
adenovirus C 21 403
type C 22 403
12 C 23 403
induced C 24 403
hamster C 25 403
tumor C 26 403
serially C 27 403
pro C 28 403
- C 29 403
pagated C 30 403
in C 31 403
vitro C 32 403
are C 33 403
described C 34 403
. C 35 403
these C 37 403
include C 38 403
small C 39 403
cell C 40 403
size C 41 403
, C 42 403
epithelioid C 43 403
appear C 44 403
- C 45 403
ance C 46 403
, C 47 403
rapid C 48 403
growth C 49 403
rate C 50 403
, C 51 403
resistance C 52 403
to C 53 403
superinfection C 54 403
with C 55 403
a C 56 403
- C 57 403
12 C 58 403
, C 59 403
and C 60 403
transplant C 61 403
- C 62 403
ability C 63 403
to C 64 403
weanling C 65 403
hamsters C 66 403
. C 67 403
these C 69 403
cells C 70 403
grew C 71 403
either C 72 403
as C 73 403
monolayers C 74 403
or C 75 403
as C 76 403
balls C 77 403
of C 78 403
aggregated C 79 403
cells C 80 403
detached C 81 403
from C 82 403
the C 83 403
glass C 84 403
, C 85 403
depending C 86 403
on C 87 403
whether C 88 403
calf C 89 403
serum C 90 403
or C 91 403
horse C 92 403
serum C 93 403
was C 94 403
added C 95 403
to C 96 403
the C 97 403
eagle C 98 403
' C 99 403
s C 100 403
medium C 101 403
. C 102 403
attempts C 104 403
to C 105 403
demonstrate C 106 403
virus C 107 403
activity C 108 403
by C 109 403
subculture C 110 403
of C 111 403
supernatant C 112 403
fluids C 113 403
and C 114 403
lysed C 115 403
cells C 116 403
into C 117 403
hela C 118 403
cells C 119 403
, C 120 403
mixed C 121 403
culture C 122 403
with C 123 403
human C 124 403
and C 125 403
hamster C 126 403
cells C 127 403
, C 128 403
electron C 129 403
microscopy C 130 403
, C 131 403
and C 132 403
inoculation C 133 403
of C 134 403
newborn C 135 403
hamsters C 136 403
with C 137 403
irradiated C 138 403
tumor C 139 403
cells C 140 403
were C 141 403
negative C 142 403
. C 143 403
142 C 1 404
. C 2 404
trials C 4 404
of C 5 404
heterotransplantation C 6 404
of C 7 404
human C 8 404
cancer C 9 404
in C 10 404
rabbits C 11 404
and C 12 404
kleisbauer C 13 404
a C 14 404
. C 15 404
trials C 17 404
of C 18 404
transplantation C 19 404
of C 20 404
human C 21 404
tumours C 22 404
( C 23 404
some C 24 404
20 C 25 404
, C 26 404
almost C 27 404
all C 28 404
carcinomas C 29 404
) C 30 404
in C 31 404
the C 32 404
pleural C 33 404
cavity C 34 404
of C 35 404
large C 36 404
rabbits C 37 404
( C 38 404
6 C 39 404
months C 40 404
old C 41 404
flanders C 42 404
, C 43 404
weighing C 44 404
3 C 45 404
kg C 46 404
. C 47 404
) C 49 404
gave C 50 404
negative C 51 404
results C 52 404
also C 53 404
when C 54 404
cortisone C 55 404
treatment C 56 404
was C 57 404
associated C 58 404
with C 59 404
it C 60 404
, C 61 404
though C 62 404
in C 63 404
the C 64 404
cortisone C 65 404
treated C 66 404
animals C 67 404
the C 68 404
necrosis C 69 404
of C 70 404
the C 71 404
tumours C 72 404
was C 73 404
less C 74 404
massive C 75 404
. C 76 404
examination C 78 404
of C 79 404
the C 80 404
grafted C 81 404
tumour C 82 404
was C 83 404
carried C 84 404
out C 85 404
at C 86 404
different C 87 404
times C 88 404
( C 89 404
from C 90 404
8 C 91 404
to C 92 404
365 C 93 404
days C 94 404
after C 95 404
transplantation C 96 404
) C 97 404
and C 98 404
was C 99 404
also C 100 404
controlled C 101 404
by C 102 404
radiographic C 103 404
examina C 104 404
- C 105 404
tions C 106 404
. C 107 404
detailed C 109 404
description C 110 404
of C 111 404
the C 112 404
giant C 113 404
cell C 114 404
reactions C 115 404
around C 116 404
the C 117 404
tumours C 118 404
and C 119 404
in C 120 404
the C 121 404
adjoining C 122 404
lung C 123 404
. C 124 404
1207 C 1 405
. C 2 405
solitary C 4 405
mast C 5 405
cell C 6 405
granuloma C 7 405
( C 8 405
histiocytoma C 9 405
) C 10 405
of C 11 405
the C 12 405
lung C 13 405
. C 14 405
a C 16 405
histopathologic C 17 405
, C 18 405
tissue C 19 405
culture C 20 405
and C 21 405
time C 22 405
- C 23 405
lapse C 24 405
cinemato C 25 405
- C 26 405
graphic C 27 405
study C 28 405
a C 29 405
pulmonary C 30 405
histiocytoma C 31 405
in C 32 405
a C 33 405
57 C 34 405
- C 35 405
year C 36 405
- C 37 405
old C 38 405
woman C 39 405
was C 40 405
studied C 41 405
intensively C 42 405
histo C 43 405
- C 44 405
pathologically C 45 405
and C 46 405
by C 47 405
other C 48 405
techniques C 49 405
. C 50 405
abundant C 52 405
mast C 53 405
cells C 54 405
were C 55 405
found C 56 405
within C 57 405
the C 58 405
lesion C 59 405
, C 60 405
a C 61 405
previously C 62 405
unreported C 63 405
finding C 64 405
. C 65 405
tissue C 67 405
culture C 68 405
studies C 69 405
suggested C 70 405
that C 71 405
the C 72 405
process C 73 405
is C 74 405
reactive C 75 405
rather C 76 405
than C 77 405
neoplastic C 78 405
. C 79 405
some C 81 405
plasma C 82 405
- C 83 405
cell C 84 405
granulomas C 85 405
of C 86 405
the C 87 405
lung C 88 405
may C 89 405
be C 90 405
mast C 91 405
cell C 92 405
histiocytomas C 93 405
. C 94 405
2773 C 1 406
. C 2 406
the C 4 406
value C 5 406
of C 6 406
fluorescence C 7 406
cytology C 8 406
for C 9 406
the C 10 406
cytodiagnosis C 11 406
of C 12 406
pulmonary C 13 406
cancer C 14 406
the C 15 406
paper C 16 406
discusses C 17 406
the C 18 406
test C 19 406
results C 20 406
of C 21 406
527 C 22 406
tissue C 23 406
samples C 24 406
sent C 25 406
in C 26 406
for C 27 406
the C 28 406
cytodiag C 29 406
- C 30 406
nostics C 31 406
of C 32 406
lung C 33 406
cancer C 34 406
and C 35 406
compares C 36 406
the C 37 406
method C 38 406
of C 39 406
ao C 40 406
- C 41 406
fluorochromation C 42 406
with C 43 406
other C 44 406
methods C 45 406
of C 46 406
preparation C 47 406
. C 48 406
by C 50 406
means C 51 406
of C 52 406
applying C 53 406
ao C 54 406
- C 55 406
fluorochromation C 56 406
, C 57 406
the C 58 406
rate C 59 406
of C 60 406
er C 61 406
- C 62 406
roneously C 63 406
positive C 64 406
findings C 65 406
could C 66 406
be C 67 406
reduced C 68 406
. C 69 406
the C 71 406
rate C 72 406
of C 73 406
erroneously C 74 406
negative C 75 406
find C 76 406
- C 77 406
ings C 78 406
was C 79 406
somewhat C 80 406
higher C 81 406
but C 82 406
the C 83 406
total C 84 406
diagnostic C 85 406
precision C 86 406
of C 87 406
93 C 88 406
% C 89 406
was C 90 406
3 C 91 406
% C 92 406
higher C 93 406
than C 94 406
in C 95 406
all C 96 406
other C 97 406
methods C 98 406
applied C 99 406
. C 100 406
2774 C 1 407
. C 2 407
pitfalls C 4 407
in C 5 407
the C 6 407
clinical C 7 407
and C 8 407
histologic C 9 407
diagnosis C 10 407
of C 11 407
broncho C 12 407
- C 13 407
genic C 14 407
carcinoma C 15 407
a C 16 407
necropsy C 17 407
study C 18 407
of C 19 407
380 C 20 407
cases C 21 407
of C 22 407
extrathoracic C 23 407
carcinoma C 24 407
revealed C 25 407
that C 26 407
pulmonary C 27 407
metastases C 28 407
occurred C 29 407
in C 30 407
almost C 31 407
50 C 32 407
% C 33 407
of C 34 407
the C 35 407
cases C 36 407
and C 37 407
bronchial C 38 407
metastases C 39 407
in C 40 407
over C 41 407
25 C 42 407
% C 43 407
. C 44 407
there C 46 407
were C 47 407
39 C 48 407
cases C 49 407
( C 50 407
10 C 51 407
. C 52 407
. C 53 407
% C 54 407
) C 55 407
in C 56 407
the C 57 407
series C 58 407
with C 59 407
clinical C 60 407
features C 61 407
simulating C 62 407
bronchogenic C 63 407
carcinoma C 64 407
and C 65 407
in C 66 407
24 C 67 407
( C 68 407
62 C 69 407
% C 70 407
) C 71 407
of C 72 407
these C 73 407
cases C 74 407
there C 75 407
was C 76 407
cytologic C 77 407
and C 78 407
/ C 79 407
or C 80 407
histologic C 81 407
confirmation C 82 407
. C 83 407
carcinomas C 85 407
of C 86 407
the C 87 407
pancreas C 88 407
presented C 89 407
the C 90 407
greatest C 91 407
source C 92 407
of C 93 407
diagnostic C 94 407
error C 95 407
accounting C 96 407
for C 97 407
more C 98 407
than C 99 407
one C 100 407
- C 101 407
third C 102 407
of C 103 407
the C 104 407
39 C 105 407
cases C 106 407
; C 107 407
the C 108 407
primary C 109 407
site C 110 407
second C 111 407
in C 112 407
frequency C 113 407
was C 114 407
carcinoma C 115 407
of C 116 407
the C 117 407
kidney C 118 407
. C 119 407
bronchial C 121 407
metastases C 122 407
were C 123 407
chiefly C 124 407
responsible C 125 407
for C 126 407
the C 127 407
clinical C 128 407
, C 129 407
cytologic C 130 407
, C 131 407
and C 132 407
histologic C 133 407
findings C 134 407
compatible C 135 407
with C 136 407
the C 137 407
diagnosis C 138 407
of C 139 407
bronchogenic C 140 407
carcinoma C 141 407
. C 142 407
secondary C 144 407
growths C 145 407
in C 146 407
the C 147 407
lungs C 148 407
may C 149 407
present C 150 407
roentgenologically C 151 407
as C 152 407
solitary C 153 407
tumors C 154 407
indistinguishable C 155 407
from C 156 407
primary C 157 407
lung C 158 407
cancer C 159 407
. C 160 407
metastatic C 162 407
lesions C 163 407
in C 164 407
lymph C 165 407
nodes C 166 407
, C 167 407
bronchi C 168 407
, C 169 407
and C 170 407
lung C 171 407
may C 172 407
exhibit C 173 407
pleomor C 174 407
- C 175 407
phic C 176 407
features C 177 407
simulating C 178 407
squamous C 179 407
cell C 180 407
carcinoma C 181 407
. C 182 407
the C 184 407
diagnosis C 185 407
of C 186 407
bronchioloalveo C 187 407
- C 188 407
lar C 189 407
carcinoma C 190 407
in C 191 407
resected C 192 407
lung C 193 407
tissue C 194 407
is C 195 407
a C 196 407
presumptive C 197 407
conclusion C 198 407
inasmuch C 199 407
as C 200 407
the C 201 407
identical C 202 407
morphological C 203 407
features C 204 407
may C 205 407
be C 206 407
reproduced C 207 407
by C 208 407
metastases C 209 407
from C 210 407
duct C 211 407
or C 212 407
glandular C 213 407
carcinomas C 214 407
. C 215 407
the C 217 407
simulation C 218 407
of C 219 407
bronchogenic C 220 407
carcinoma C 221 407
by C 222 407
metastatic C 223 407
tum C 224 407
- C 225 407
ors C 226 407
occurs C 227 407
with C 228 407
sufficient C 229 407
frequency C 230 407
to C 231 407
challenge C 232 407
the C 233 407
diagnostic C 234 407
accuracy C 235 407
of C 236 407
deaths C 237 407
certified C 238 407
as C 239 407
bronchogenic C 240 407
carcinoma C 241 407
with C 242 407
necropsy C 243 407
exclusion C 244 407
of C 245 407
other C 246 407
primary C 247 407
sites C 248 407
. C 249 407
4396 C 1 408
. C 2 408
effects C 4 408
of C 5 408
arginine C 6 408
deprivation C 7 408
, C 8 408
ultraviolet C 9 408
radiation C 10 408
, C 11 408
and C 12 408
x C 13 408
- C 14 408
radiation C 15 408
on C 16 408
cultured C 17 408
kb C 18 408
cells C 19 408
. C 20 408
a C 22 408
cytochemical C 23 408
and C 24 408
ultrastructural C 25 408
study C 26 408
cultured C 27 408
kb C 28 408
cells C 29 408
( C 30 408
derived C 31 408
from C 32 408
a C 33 408
human C 34 408
oral C 35 408
carcinoma C 36 408
) C 37 408
grown C 38 408
in C 39 408
monolayers C 40 408
were C 41 408
injured C 42 408
by C 43 408
one C 44 408
of C 45 408
three C 46 408
agents C 47 408
starvation C 48 408
by C 49 408
arginine C 50 408
deprivation C 51 408
or C 52 408
treatment C 53 408
with C 54 408
high C 55 408
doses C 56 408
of C 57 408
either C 58 408
ultraviolet C 59 408
radiation C 60 408
or C 61 408
x C 62 408
- C 63 408
radiation C 64 408
. C 65 408
the C 67 408
different C 68 408
agents C 69 408
produced C 70 408
changes C 71 408
in C 72 408
nucleolar C 73 408
structure C 74 408
and C 75 408
varying C 76 408
accumulations C 77 408
of C 78 408
triglyceride C 79 408
and C 80 408
glycogen C 81 408
. C 82 408
all C 84 408
three C 85 408
agents C 86 408
produced C 87 408
an C 88 408
increase C 89 408
in C 90 408
number C 91 408
and C 92 408
size C 93 408
of C 94 408
lyso C 95 408
- C 96 408
somes C 97 408
. C 98 408
these C 100 408
were C 101 408
studied C 102 408
in C 103 408
acid C 104 408
phosphatase C 105 408
preparations C 106 408
, C 107 408
viewed C 108 408
by C 109 408
both C 110 408
light C 111 408
and C 112 408
electron C 113 408
microscopy C 114 408
, C 115 408
and C 116 408
, C 117 408
occasionally C 118 408
, C 119 408
in C 120 408
vital C 121 408
dye C 122 408
, C 123 408
esterase C 124 408
, C 125 408
and C 126 408
aryl C 127 408
sul C 128 408
- C 129 408
fatase C 130 408
preparations C 131 408
. C 132 408
ultrastructurally C 134 408
, C 135 408
alterations C 136 408
in C 137 408
lysosomes C 138 408
suggested C 139 408
that C 140 408
' C 141 408
residual C 142 408
bodies C 143 408
' C 144 408
developed C 145 408
in C 146 408
a C 147 408
variety C 148 408
of C 149 408
ways C 150 408
, C 151 408
i C 152 408
. C 153 408
. C 154 408
. C 155 408
, C 157 408
from C 158 408
the C 159 408
endoplasmic C 160 408
retic C 161 408
- C 162 408
ulum C 163 408
, C 164 408
multivesicular C 165 408
bodies C 166 408
, C 167 408
or C 168 408
autophagic C 169 408
vacuoles C 170 408
. C 171 408
following C 173 408
all C 174 408
three C 175 408
agents C 176 408
, C 177 408
the C 178 408
endoplasmic C 179 408
reticulum C 180 408
assumed C 181 408
the C 182 408
form C 183 408
of C 184 408
' C 185 408
rough C 186 408
' C 187 408
or C 188 408
' C 189 408
smooth C 190 408
' C 191 408
whorls C 192 408
, C 193 408
and C 194 408
, C 195 408
after C 196 408
two C 197 408
of C 198 408
the C 199 408
agents C 200 408
, C 201 408
arginine C 202 408
deprivation C 203 408
or C 204 408
ultraviolet C 205 408
radiation C 206 408
, C 207 408
it C 208 408
acquired C 209 408
cytochemically C 210 408
demonstrable C 211 408
acid C 212 408
phosphatase C 213 408
activity C 214 408
. C 215 408
near C 217 408
connections C 218 408
between C 219 408
the C 220 408
endoplasmic C 221 408
reticulum C 222 408
and C 223 408
lysosomes C 224 408
raise C 225 408
the C 226 408
possibility C 227 408
that C 228 408
in C 229 408
kb C 230 408
cells C 231 408
, C 232 408
at C 233 408
least C 234 408
when C 235 408
injured C 236 408
, C 237 408
the C 238 408
endoplasmic C 239 408
reticulum C 240 408
is C 241 408
involved C 242 408
in C 243 408
the C 244 408
formation C 245 408
of C 246 408
lysosomes C 247 408
and C 248 408
the C 249 408
transport C 250 408
of C 251 408
acid C 252 408
phosphatase C 253 408
to C 254 408
them C 255 408
. C 256 408
1106 C 1 409
. C 2 409
the C 4 409
simultaneous C 5 409
use C 6 409
of C 7 409
extracorporal C 8 409
circulation C 9 409
and C 10 409
hypothermia C 11 409
in C 12 409
the C 13 409
surgery C 14 409
of C 15 409
the C 16 409
heart C 17 409
the C 18 409
operative C 19 409
technique C 20 409
of C 21 409
cardiac C 22 409
surgery C 23 409
under C 24 409
conditions C 25 409
of C 26 409
deep C 27 409
hypothermia C 28 409
with C 29 409
simultaneous C 30 409
use C 31 409
of C 32 409
a C 33 409
pump C 34 409
oxygenator C 35 409
and C 36 409
cardiopulmonary C 37 409
bypass C 38 409
is C 39 409
described C 40 409
. C 41 409
in C 43 409
the C 44 409
majority C 45 409
of C 46 409
cases C 47 409
the C 48 409
patients C 49 409
were C 50 409
cooled C 51 409
with C 52 409
water C 53 409
at C 54 409
2 C 55 409
c C 56 409
. C 57 409
and C 59 409
the C 60 409
perfusion C 61 409
volume C 62 409
was C 63 409
reduced C 64 409
by C 65 409
more C 66 409
than C 67 409
50 C 68 409
% C 69 409
during C 70 409
hypothermia C 71 409
. C 72 409
in C 74 409
others C 75 409
, C 76 409
a C 77 409
gradient C 78 409
of C 79 409
10 C 80 409
c C 81 409
. C 82 409
between C 84 409
blood C 85 409
and C 86 409
water C 87 409
was C 88 409
maintained C 89 409
and C 90 409
the C 91 409
perfusion C 92 409
volume C 93 409
was C 94 409
reduced C 95 409
by C 96 409
less C 97 409
than C 98 409
50 C 99 409
% C 100 409
. C 101 409
the C 103 409
data C 104 409
presented C 105 409
show C 106 409
that C 107 409
neither C 108 409
technique C 109 409
leads C 110 409
to C 111 409
hypoxic C 112 409
changes C 113 409
in C 114 409
the C 115 409
cerebrum C 116 409
and C 117 409
internal C 118 409
organs C 119 409
, C 120 409
provided C 121 409
the C 122 409
mean C 123 409
arterial C 124 409
pressure C 125 409
is C 126 409
kept C 127 409
between C 128 409
70 C 129 409
and C 130 409
90 C 131 409
mm C 132 409
. C 133 409
hg C 135 409
during C 136 409
perfusion C 137 409
. C 138 409
the C 140 409
overall C 141 409
mortality C 142 409
in C 143 409
the C 144 409
authors C 145 409
' C 146 409
168 C 147 409
cases C 148 409
- C 149 409
most C 150 409
of C 151 409
which C 152 409
had C 153 409
congenital C 154 409
heart C 155 409
disease C 156 409
- C 157 409
was C 158 409
14 C 159 409
. C 160 409
. C 161 409
% C 162 409
. C 163 409
in C 165 409
53 C 166 409
cases C 167 409
of C 168 409
tetralogy C 169 409
of C 170 409
fallot C 171 409
- C 172 409
most C 173 409
of C 174 409
them C 175 409
cyanotic C 176 409
- C 177 409
the C 178 409
vsd C 179 409
was C 180 409
closed C 181 409
by C 182 409
taking C 183 409
a C 184 409
flap C 185 409
of C 186 409
tissue C 187 409
from C 188 409
the C 189 409
crista C 190 409
supraventricularis C 191 409
. C 192 409
in C 194 409
this C 195 409
group C 196 409
mortality C 197 409
was C 198 409
24 C 199 409
. C 200 409
. C 201 409
% C 202 409
. C 203 409
464 C 1 410
. C 2 410
cardiac C 4 410
performance C 5 410
in C 6 410
hypothermia C 7 410
. C 8 410
an C 10 410
experimental C 11 410
study C 12 410
of C 13 410
left C 14 410
ventricular C 15 410
power C 16 410
, C 17 410
oxygen C 18 410
consumption C 19 410
, C 20 410
and C 21 410
efficiency C 22 410
in C 23 410
dogs C 24 410
multiple C 25 410
cardiac C 26 410
parameters C 27 410
have C 28 410
been C 29 410
measured C 30 410
in C 31 410
30 C 32 410
dogs C 33 410
cooled C 34 410
to C 35 410
20 C 36 410
c C 37 410
. C 38 410
aortic C 40 410
blood C 41 410
temperature C 42 410
. C 43 410
the C 45 410
parameters C 46 410
have C 47 410
been C 48 410
expressed C 49 410
both C 50 410
as C 51 410
absolute C 52 410
values C 53 410
and C 54 410
as C 55 410
percentages C 56 410
of C 57 410
normothermic C 58 410
values C 59 410
. C 60 410
at C 62 410
normothermia C 63 410
, C 64 410
dogs C 65 410
with C 66 410
closed C 67 410
chest C 68 410
had C 69 410
an C 70 410
ascending C 71 410
aorta C 72 410
flow C 73 410
of C 74 410
154 C 75 410
% C 76 410
and C 77 410
a C 78 410
left C 79 410
ventricular C 80 410
external C 81 410
power C 82 410
of C 83 410
183 C 84 410
% C 85 410
of C 86 410
the C 87 410
corresponding C 88 410
values C 89 410
for C 90 410
dogs C 91 410
with C 92 410
open C 93 410
chest C 94 410
. C 95 410
both C 97 410
ascending C 98 410
aorta C 99 410
flow C 100 410
and C 101 410
left C 102 410
circumflex C 103 410
coronary C 104 410
artery C 105 410
flow C 106 410
were C 107 410
reduced C 108 410
to C 109 410
25 C 110 410
% C 111 410
of C 112 410
normothermic C 113 410
level C 114 410
at C 115 410
20 C 116 410
c C 117 410
. C 118 410
aortic C 120 410
arch C 121 410
mean C 122 410
pressure C 123 410
was C 124 410
reduced C 125 410
to C 126 410
50 C 127 410
% C 128 410
of C 129 410
normothermic C 130 410
level C 131 410
at C 132 410
20 C 133 410
c C 134 410
. C 135 410
total C 137 410
peripheral C 138 410
resistance C 139 410
was C 140 410
increased C 141 410
to C 142 410
205 C 143 410
% C 144 410
of C 145 410
normothermic C 146 410
level C 147 410
at C 148 410
20 C 149 410
c C 150 410
. C 151 410
left C 153 410
ventricular C 154 410
external C 155 410
power C 156 410
was C 157 410
decreased C 158 410
to C 159 410
11 C 160 410
% C 161 410
of C 162 410
normothermic C 163 410
level C 164 410
at C 165 410
20 C 166 410
c C 167 410
. C 168 410
left C 170 410
ventricular C 171 410
oxygen C 172 410
consumption C 173 410
was C 174 410
decreased C 175 410
to C 176 410
31 C 177 410
% C 178 410
of C 179 410
nor C 180 410
- C 181 410
mothermic C 182 410
level C 183 410
at C 184 410
20 C 185 410
c C 186 410
. C 187 410
mechanical C 189 410
efficiency C 190 410
of C 191 410
the C 192 410
left C 193 410
ventricular C 194 410
myocardium C 195 410
was C 196 410
decreased C 197 410
to C 198 410
39 C 199 410
% C 200 410
of C 201 410
normothermic C 202 410
level C 203 410
at C 204 410
20 C 205 410
c C 206 410
. C 207 410
3270 C 1 411
. C 2 411
tolerance C 4 411
of C 5 411
dogs C 6 411
to C 7 411
deep C 8 411
hypothermia C 9 411
. C 10 411
controlled C 12 411
and C 13 411
maintained C 14 411
with C 15 411
a C 16 411
pump C 17 411
oxygenator C 18 411
the C 19 411
advantages C 20 411
of C 21 411
hypothermia C 22 411
of C 23 411
below C 24 411
10 C 25 411
c C 26 411
for C 27 411
2 C 28 411
hr C 29 411
, C 30 411
induced C 31 411
and C 32 411
maintained C 33 411
by C 34 411
extracorporeal C 35 411
circulation C 36 411
of C 37 411
200 C 38 411
min C 39 411
. C 40 411
, C 42 411
were C 43 411
compared C 44 411
to C 45 411
partial C 46 411
bypass C 47 411
of C 48 411
the C 49 411
same C 50 411
duration C 51 411
during C 52 411
normothermia C 53 411
. C 54 411
in C 56 411
the C 57 411
normothermic C 58 411
group C 59 411
9 C 60 411
dogs C 61 411
out C 62 411
of C 63 411
12 C 64 411
lived C 65 411
. C 66 411
in C 68 411
the C 69 411
hypothermic C 70 411
group C 71 411
6 C 72 411
dogs C 73 411
out C 74 411
of C 75 411
15 C 76 411
( C 77 411
40 C 78 411
% C 79 411
) C 80 411
survived C 81 411
when C 82 411
perfused C 83 411
at C 84 411
the C 85 411
high C 86 411
flow C 87 411
of C 88 411
55 C 89 411
cc C 90 411
/ C 91 411
kg C 92 411
/ C 93 411
min C 94 411
. C 95 411
eleven C 97 411
dogs C 98 411
out C 99 411
of C 100 411
15 C 101 411
( C 102 411
70 C 103 411
% C 104 411
) C 105 411
survived C 106 411
when C 107 411
the C 108 411
flow C 109 411
rate C 110 411
was C 111 411
reduced C 112 411
to C 113 411
25 C 114 411
cc C 115 411
/ C 116 411
kg C 117 411
/ C 118 411
min C 119 411
when C 120 411
the C 121 411
temperature C 122 411
was C 123 411
below C 124 411
10 C 125 411
c C 126 411
. C 127 411
the C 129 411
death C 130 411
in C 131 411
the C 132 411
high C 133 411
flow C 134 411
group C 135 411
were C 136 411
due C 137 411
mainly C 138 411
to C 139 411
postperfusion C 140 411
lung C 141 411
changes C 142 411
even C 143 411
when C 144 411
low C 145 411
pulmonary C 146 411
venous C 147 411
pressure C 148 411
was C 149 411
assured C 150 411
by C 151 411
venting C 152 411
in C 153 411
the C 154 411
left C 155 411
atrial C 156 411
chamber C 157 411
. C 158 411
me C 160 411
- C 161 411
tabolic C 162 411
acidosis C 163 411
occurred C 164 411
in C 165 411
all C 166 411
groups C 167 411
; C 168 411
though C 169 411
greater C 170 411
in C 171 411
the C 172 411
high C 173 411
flow C 174 411
, C 175 411
with C 176 411
the C 177 411
low C 178 411
flow C 179 411
intermediate C 180 411
between C 181 411
the C 182 411
former C 183 411
and C 184 411
the C 185 411
normothermic C 186 411
group C 187 411
. C 188 411
this C 190 411
change C 191 411
to C 192 411
a C 193 411
great C 194 411
degree C 195 411
, C 196 411
can C 197 411
be C 198 411
explained C 199 411
by C 200 411
the C 201 411
lung C 202 411
changes C 203 411
. C 204 411
1593 C 1 412
. C 2 412
bleeding C 4 412
tendencies C 5 412
associated C 6 412
with C 7 412
profound C 8 412
- C 9 412
hypothermia C 10 412
technics C 11 412
in C 12 412
neurologic C 13 412
surgery C 14 412
forty C 15 412
- C 16 412
three C 17 412
patients C 18 412
with C 19 412
bleeding C 20 412
intracranial C 21 412
aneurysms C 22 412
were C 23 412
operated C 24 412
on C 25 412
under C 26 412
deep C 27 412
hypothermia C 28 412
and C 29 412
with C 30 412
the C 31 412
aid C 32 412
of C 33 412
extracorporeal C 34 412
circulation C 35 412
. C 36 412
the C 38 412
open C 39 412
- C 40 412
thorax C 41 412
method C 42 412
was C 43 412
used C 44 412
in C 45 412
18 C 46 412
cases C 47 412
and C 48 412
the C 49 412
closed C 50 412
- C 51 412
thorax C 52 412
method C 53 412
in C 54 412
25 C 55 412
. C 56 412
the C 58 412
following C 59 412
points C 60 412
are C 61 412
made C 62 412
( C 63 412
1 C 64 412
) C 65 412
the C 66 412
closed C 67 412
- C 68 412
thorax C 69 412
method C 70 412
is C 71 412
considered C 72 412
superior C 73 412
to C 74 412
the C 75 412
open C 76 412
- C 77 412
thorax C 78 412
method C 79 412
in C 80 412
several C 81 412
respects C 82 412
; C 83 412
( C 84 412
2 C 85 412
) C 86 412
meticulous C 87 412
hemostasis C 88 412
is C 89 412
essential C 90 412
to C 91 412
control C 92 412
the C 93 412
oozing C 94 412
that C 95 412
occurs C 96 412
during C 97 412
extracorporeal C 98 412
circulation C 99 412
under C 100 412
profound C 101 412
hypothermia C 102 412
until C 103 412
the C 104 412
heparin C 105 412
antagonist C 106 412
can C 107 412
become C 108 412
effective C 109 412
and C 110 412
body C 111 412
temperature C 112 412
can C 113 412
return C 114 412
to C 115 412
normal C 116 412
; C 117 412
( C 118 412
3 C 119 412
) C 120 412
significant C 121 412
thrombocytopenia C 122 412
may C 123 412
develop C 124 412
during C 125 412
extracorporeal C 126 412
cir C 127 412
- C 128 412
culation C 129 412
, C 130 412
and C 131 412
inhibition C 132 412
of C 133 412
the C 134 412
thrombin C 135 412
- C 136 412
fibrinogen C 137 412
reaction C 138 412
by C 139 412
factors C 140 412
other C 141 412
than C 142 412
heparin C 143 412
may C 144 412
cause C 145 412
a C 146 412
major C 147 412
coagulation C 148 412
defect C 149 412
and C 150 412
may C 151 412
also C 152 412
, C 153 412
by C 154 412
mimicking C 155 412
the C 156 412
he C 157 412
- C 158 412
parin C 159 412
effect C 160 412
, C 161 412
lead C 162 412
to C 163 412
the C 164 412
excessive C 165 412
use C 166 412
of C 167 412
heparin C 168 412
antagonists C 169 412
; C 170 412
( C 171 412
4 C 172 412
) C 173 412
pathologic C 174 412
changes C 175 412
in C 176 412
microcirculation C 177 412
during C 178 412
extracorporeal C 179 412
circulation C 180 412
may C 181 412
be C 182 412
determinants C 183 412
of C 184 412
a C 185 412
hemorrhagic C 186 412
tendency C 187 412
. C 188 412
4088 C 1 413
. C 2 413
the C 4 413
use C 5 413
of C 6 413
hypothermia C 7 413
and C 8 413
dehydration C 9 413
in C 10 413
the C 11 413
treatment C 12 413
of C 13 413
severe C 14 413
cerebral C 15 413
hypoxia C 16 413
the C 17 413
rational C 18 413
for C 19 413
using C 20 413
hypothermia C 21 413
or C 22 413
cerebral C 23 413
dehydration C 24 413
is C 25 413
to C 26 413
suppress C 27 413
or C 28 413
re C 29 413
- C 30 413
verse C 31 413
progressive C 32 413
or C 33 413
delayed C 34 413
cerebral C 35 413
damage C 36 413
after C 37 413
hypoxia C 38 413
. C 39 413
it C 41 413
is C 42 413
suggested C 43 413
that C 44 413
damage C 45 413
of C 46 413
this C 47 413
nature C 48 413
results C 49 413
from C 50 413
injury C 51 413
to C 52 413
the C 53 413
astroglia C 54 413
and C 55 413
oligodendroglia C 56 413
, C 57 413
especially C 58 413
the C 59 413
former C 60 413
. C 61 413
experimental C 63 413
and C 64 413
clinical C 65 413
evidence C 66 413
favors C 67 413
lowering C 68 413
of C 69 413
the C 70 413
body C 71 413
temperature C 72 413
immediately C 73 413
after C 74 413
any C 75 413
episode C 76 413
of C 77 413
hypoxia C 78 413
accompanied C 79 413
by C 80 413
impor C 81 413
- C 82 413
tant C 83 413
damage C 84 413
to C 85 413
the C 86 413
brain C 87 413
. C 88 413
the C 90 413
rational C 91 413
for C 92 413
using C 93 413
dehydration C 94 413
is C 95 413
insecure C 96 413
and C 97 413
its C 98 413
results C 99 413
are C 100 413
uncertain C 101 413
. C 102 413
this C 104 413
treatment C 105 413
should C 106 413
probably C 107 413
be C 108 413
reserved C 109 413
for C 110 413
cases C 111 413
in C 112 413
which C 113 413
a C 114 413
raised C 115 413
cerebrospinal C 116 413
fluid C 117 413
pressure C 118 413
has C 119 413
been C 120 413
proved C 121 413
, C 122 413
and C 123 413
in C 124 413
which C 125 413
other C 126 413
measures C 127 413
, C 128 413
especially C 129 413
hypothermia C 130 413
, C 131 413
are C 132 413
either C 133 413
not C 134 413
available C 135 413
or C 136 413
have C 137 413
failed C 138 413
. C 139 413
7828 C 1 414
. C 2 414
selective C 4 414
cerebral C 5 414
hypothermia C 6 414
physiology C 7 414
and C 8 414
technic C 9 414
a C 10 414
safe C 11 414
, C 12 414
suitable C 13 414
technique C 14 414
for C 15 414
producing C 16 414
selective C 17 414
brain C 18 414
cooling C 19 414
by C 20 414
a C 21 414
perfusion C 22 414
method C 23 414
is C 24 414
described C 25 414
. C 26 414
of C 28 414
15 C 29 414
dogs C 30 414
, C 31 414
7 C 32 414
survived C 33 414
. C 34 414
the C 36 414
salient C 37 414
features C 38 414
aiding C 39 414
survival C 40 414
are C 41 414
discussed C 42 414
. C 43 414
the C 45 414
use C 46 414
of C 47 414
a C 48 414
direct C 49 414
vasodilator C 50 414
( C 51 414
papaverine C 52 414
) C 53 414
in C 54 414
the C 55 414
perfusate C 56 414
to C 57 414
relieve C 58 414
vasospasm C 59 414
markedly C 60 414
reduced C 61 414
cooling C 62 414
time C 63 414
and C 64 414
represented C 65 414
the C 66 414
most C 67 414
signi C 68 414
- C 69 414
ficant C 70 414
technical C 71 414
advance C 72 414
over C 73 414
previously C 74 414
described C 75 414
methods C 76 414
. C 77 414
an C 79 414
acid C 80 414
base C 81 414
analysis C 82 414
utilizing C 83 414
the C 84 414
siggaard C 85 414
- C 86 414
andersen C 87 414
curve C 88 414
nomogram C 89 414
was C 90 414
performed C 91 414
on C 92 414
4 C 93 414
dogs C 94 414
and C 95 414
no C 96 414
significant C 97 414
acidosis C 98 414
noted C 99 414
during C 100 414
selective C 101 414
brain C 102 414
cooling C 103 414
. C 104 414
a C 106 414
definite C 107 414
arteriovenous C 108 414
lactic C 109 414
acid C 110 414
difference C 111 414
developed C 112 414
at C 113 414
hypothermic C 114 414
temperatures C 115 414
indicating C 116 414
the C 117 414
brain C 118 414
may C 119 414
metabolize C 120 414
this C 121 414
substance C 122 414
in C 123 414
preference C 124 414
to C 125 414
glucose C 126 414
at C 127 414
lowered C 128 414
brain C 129 414
tempera C 130 414
- C 131 414
tures C 132 414
, C 133 414
the C 134 414
reasons C 135 414
for C 136 414
which C 137 414
were C 138 414
discussed C 139 414
. C 140 414
the C 142 414
rate C 143 414
of C 144 414
disappearance C 145 414
of C 146 414
physi C 147 414
- C 148 414
cally C 149 414
dissolved C 150 414
oxygen C 151 414
( C 152 414
po C 153 414
2 C 154 414
) C 155 414
was C 156 414
measured C 157 414
in C 158 414
the C 159 414
brain C 160 414
following C 161 414
ischemia C 162 414
at C 163 414
dif C 164 414
- C 165 414
ferent C 166 414
temperatures C 167 414
. C 168 414
the C 170 414
average C 171 414
rate C 172 414
of C 173 414
disappearance C 174 414
at C 175 414
20 C 176 414
c C 177 414
. C 178 414
was C 180 414
40 C 181 414
% C 182 414
of C 183 414
the C 184 414
rate C 185 414
at C 186 414
37 C 187 414
c C 188 414
. C 189 414
the C 191 414
discrepancy C 192 414
between C 193 414
this C 194 414
finding C 195 414
and C 196 414
the C 197 414
in C 198 414
vitro C 199 414
oxygen C 200 414
utili C 201 414
- C 202 414
zation C 203 414
rate C 204 414
at C 205 414
the C 206 414
same C 207 414
temperature C 208 414
was C 209 414
discussed C 210 414
. C 211 414
948 C 1 415
. C 2 415
. C 3 415
. C 3 415
. C 3 415
. C 3 415
. C 3 415
. C 3 415
. C 3 415
activity C 4 415
in C 5 415
cranio C 6 415
- C 7 415
cerebral C 8 415
hypothermia C 9 415
the C 10 415
onset C 11 415
of C 12 415
hypothermia C 13 415
rarely C 14 415
alters C 15 415
the C 16 415
heart C 17 415
rate C 18 415
. C 19 415
as C 21 415
it C 22 415
deepens C 23 415
to C 24 415
35 C 25 415
- C 26 415
32 C 27 415
, C 28 415
the C 29 415
rate C 30 415
slows C 31 415
, C 32 415
and C 33 415
at C 34 415
the C 35 415
level C 36 415
of C 37 415
30 C 38 415
- C 39 415
29 C 40 415
it C 41 415
usually C 42 415
amounts C 43 415
to C 44 415
only C 45 415
half C 46 415
its C 47 415
original C 48 415
va C 49 415
- C 50 415
lue C 51 415
. C 52 415
at C 54 415
28 C 55 415
or C 56 415
below C 57 415
, C 58 415
the C 59 415
development C 60 415
of C 61 415
bradycardia C 62 415
is C 63 415
observed C 64 415
. C 65 415
after C 67 415
warming C 68 415
to C 69 415
32 C 70 415
the C 71 415
normal C 72 415
heart C 73 415
rate C 74 415
is C 75 415
restored C 76 415
. C 77 415
during C 79 415
operations C 80 415
on C 81 415
the C 82 415
abdominal C 83 415
organs C 84 415
the C 85 415
heart C 86 415
rate C 87 415
is C 88 415
only C 89 415
slightly C 90 415
modified C 91 415
. C 92 415
the C 94 415
appearance C 95 415
of C 96 415
solitary C 97 415
extrasystoles C 98 415
is C 99 415
rare C 100 415
and C 101 415
is C 102 415
usually C 103 415
associated C 104 415
with C 105 415
stimulation C 106 415
of C 107 415
the C 108 415
diaphragm C 109 415
. C 110 415
the C 112 415
most C 113 415
marked C 114 415
changes C 115 415
in C 116 415
the C 117 415
heart C 118 415
rate C 119 415
are C 120 415
observed C 121 415
during C 122 415
operations C 123 415
on C 124 415
the C 125 415
heart C 126 415
, C 127 415
especially C 128 415
if C 129 415
it C 130 415
is C 131 415
excluded C 132 415
from C 133 415
the C 134 415
circulation C 135 415
. C 136 415
an C 138 415
idioventricular C 139 415
rhythm C 140 415
may C 141 415
develop C 142 415
before C 143 415
the C 144 415
heart C 145 415
stops C 146 415
beating C 147 415
. C 148 415
after C 150 415
removal C 151 415
of C 152 415
the C 153 415
ligatures C 154 415
from C 155 415
the C 156 415
venae C 157 415
cavae C 158 415
the C 159 415
nor C 160 415
- C 161 415
mal C 162 415
rhythm C 163 415
is C 164 415
restored C 165 415
. C 166 415
as C 168 415
the C 169 415
temperature C 170 415
falls C 171 415
, C 172 415
the C 173 415
excitability C 174 415
of C 175 415
the C 176 415
myocardium C 177 415
increases C 178 415
. C 179 415
conduction C 181 415
is C 182 415
more C 183 415
resistant C 184 415
. C 185 415
areflexia C 187 415
continues C 188 415
even C 189 415
during C 190 415
direct C 191 415
sti C 192 415
- C 193 415
mulation C 194 415
of C 195 415
reflexogenic C 196 415
zones C 197 415
. C 198 415
in C 200 415
the C 201 415
surgical C 202 415
stage C 203 415
of C 204 415
cranio C 205 415
- C 206 415
cerebral C 207 415
hypothermia C 208 415
it C 209 415
is C 210 415
clear C 211 415
that C 212 415
no C 213 415
significant C 214 415
degree C 215 415
of C 216 415
energy C 217 415
or C 218 415
hemodynamic C 219 415
insufficiency C 220 415
deve C 221 415
- C 222 415
lops C 223 415
, C 224 415
whether C 225 415
in C 226 415
experimental C 227 415
conditions C 228 415
or C 229 415
during C 230 415
operations C 231 415
on C 232 415
patients C 233 415
. C 234 415
at C 236 415
opera C 237 415
- C 238 415
tion C 239 415
a C 240 415
well C 241 415
- C 242 415
marked C 243 415
stabilization C 244 415
of C 245 415
the C 246 415
contractile C 247 415
power C 248 415
of C 249 415
the C 250 415
myocardium C 251 415
may C 252 415
be C 253 415
observed C 254 415
. C 255 415
946 C 1 416
. C 2 416
respiration C 4 416
in C 5 416
hypothermia C 6 416
. C 7 416
i C 9 416
. C 10 416
respiratory C 12 416
pattern C 13 416
and C 14 416
acid C 15 416
- C 16 416
base C 17 416
balance C 18 416
in C 19 416
the C 20 416
blood C 21 416
mongrel C 22 416
dogs C 23 416
, C 24 416
under C 25 416
light C 26 416
pentobarbital C 27 416
anesthesia C 28 416
, C 29 416
were C 30 416
made C 31 416
hypothermic C 32 416
by C 33 416
im C 34 416
- C 35 416
mersing C 36 416
them C 37 416
in C 38 416
ice C 39 416
water C 40 416
and C 41 416
then C 42 416
normothermic C 43 416
in C 44 416
warm C 45 416
water C 46 416
. C 47 416
in C 49 416
the C 50 416
course C 51 416
of C 52 416
cooling C 53 416
, C 54 416
the C 55 416
respiratory C 56 416
rate C 57 416
and C 58 416
pulmonary C 59 416
ventilation C 60 416
, C 61 416
after C 62 416
an C 63 416
initial C 64 416
increase C 65 416
, C 66 416
were C 67 416
reduced C 68 416
as C 69 416
the C 70 416
rectal C 71 416
temperature C 72 416
fell C 73 416
, C 74 416
and C 75 416
spontaneous C 76 416
respiration C 77 416
was C 78 416
ar C 79 416
- C 80 416
rested C 81 416
at C 82 416
rectal C 83 416
temperatures C 84 416
of C 85 416
21 C 86 416
- C 87 416
25 C 88 416
c C 89 416
. C 90 416
alveolar C 92 416
pco C 93 416
2 C 94 416
was C 95 416
increased C 96 416
, C 97 416
after C 98 416
an C 99 416
initial C 100 416
slight C 101 416
lowering C 102 416
, C 103 416
with C 104 416
the C 105 416
progress C 106 416
of C 107 416
hypothermia C 108 416
. C 109 416
arterial C 111 416
ph C 112 416
and C 113 416
standard C 114 416
bicarbonate C 115 416
( C 116 416
jorgensen C 117 416
and C 118 416
astrup C 119 416
) C 120 416
decreased C 121 416
, C 122 416
and C 123 416
the C 124 416
alkalinity C 125 416
of C 126 416
the C 127 416
blood C 128 416
coh C 129 416
/ C 130 416
ch C 131 416
( C 132 416
winterstein C 133 416
) C 134 416
decreased C 135 416
markedly C 136 416
during C 137 416
hypothermia C 138 416
. C 139 416
these C 141 416
findings C 142 416
suggest C 143 416
both C 144 416
respiratory C 145 416
and C 146 416
metabolic C 147 416
acidosis C 148 416
as C 149 416
the C 150 416
mechanisms C 151 416
concerned C 152 416
. C 153 416
in C 155 416
the C 156 416
course C 157 416
of C 158 416
rewarming C 159 416
all C 160 416
these C 161 416
changes C 162 416
disappeared C 163 416
rapidly C 164 416
and C 165 416
completely C 166 416
though C 167 416
the C 168 416
venti C 169 416
- C 170 416
latory C 171 416
stimulation C 172 416
observed C 173 416
as C 174 416
an C 175 416
initial C 176 416
transitory C 177 416
phenomenon C 178 416
during C 179 416
cooling C 180 416
failed C 181 416
to C 182 416
occur C 183 416
. C 184 416
896 C 1 417
. C 2 417
studies C 4 417
on C 5 417
blood C 6 417
viscosity C 7 417
and C 8 417
its C 9 417
significance C 10 417
in C 11 417
anesthesia C 12 417
the C 13 417
principles C 14 417
for C 15 417
measuring C 16 417
blood C 17 417
viscosity C 18 417
have C 19 417
been C 20 417
discussed C 21 417
. C 22 417
although C 24 417
blood C 25 417
does C 26 417
not C 27 417
behave C 28 417
in C 29 417
a C 30 417
newtonian C 31 417
manner C 32 417
, C 33 417
the C 34 417
data C 35 417
obtained C 36 417
in C 37 417
in C 38 417
vitro C 39 417
measurement C 40 417
are C 41 417
useful C 42 417
. C 43 417
a C 45 417
modified C 46 417
simple C 47 417
method C 48 417
for C 49 417
measuring C 50 417
blood C 51 417
viscosity C 52 417
relative C 53 417
to C 54 417
nor C 55 417
- C 56 417
mal C 57 417
saline C 58 417
has C 59 417
been C 60 417
described C 61 417
. C 62 417
there C 64 417
is C 65 417
essentially C 66 417
no C 67 417
difference C 68 417
in C 69 417
viscosity C 70 417
be C 71 417
- C 72 417
tween C 73 417
fresh C 74 417
blood C 75 417
and C 76 417
heparinized C 77 417
blood C 78 417
and C 79 417
between C 80 417
plasma C 81 417
and C 82 417
serum C 83 417
. C 84 417
viscosity C 86 417
varies C 87 417
with C 88 417
the C 89 417
quantity C 90 417
and C 91 417
nature C 92 417
of C 93 417
proteins C 94 417
in C 95 417
plasma C 96 417
and C 97 417
the C 98 417
cellular C 99 417
concentra C 100 417
- C 101 417
tion C 102 417
. C 103 417
halothane C 105 417
and C 106 417
thiopental C 107 417
sodium C 108 417
reduce C 109 417
blood C 110 417
viscosity C 111 417
and C 112 417
seem C 113 417
to C 114 417
be C 115 417
indicat C 116 417
- C 117 417
ed C 118 417
in C 119 417
conditions C 120 417
in C 121 417
which C 122 417
there C 123 417
is C 124 417
hemoconcentration C 125 417
and C 126 417
a C 127 417
tendency C 128 417
for C 129 417
red C 130 417
blood C 131 417
cells C 132 417
to C 133 417
aggregate C 134 417
. C 135 417
cyclopropane C 137 417
, C 138 417
hypothermia C 139 417
, C 140 417
and C 141 417
norepinephrine C 142 417
tend C 143 417
to C 144 417
raise C 145 417
blood C 146 417
viscosity C 147 417
and C 148 417
would C 149 417
seem C 150 417
to C 151 417
be C 152 417
contraindicated C 153 417
when C 154 417
the C 155 417
microcirculation C 156 417
is C 157 417
failing C 158 417
. C 159 417
4612 C 1 418
. C 2 418
flow C 4 418
considerations C 5 418
in C 6 418
regional C 7 418
cerebral C 8 418
hypothermia C 9 418
it C 10 418
is C 11 418
suggested C 12 418
that C 13 418
low C 14 418
flows C 15 418
are C 16 418
dangerous C 17 418
and C 18 418
may C 19 418
cause C 20 418
anoxia C 21 418
either C 22 418
directly C 23 418
or C 24 418
by C 25 418
interfering C 26 418
with C 27 418
cooling C 28 418
. C 29 418
sixty C 31 418
dogs C 32 418
have C 33 418
been C 34 418
subjected C 35 418
to C 36 418
local C 37 418
cerebral C 38 418
hypothermia C 39 418
by C 40 418
the C 41 418
method C 42 418
of C 43 418
femoral C 44 418
to C 45 418
carotid C 46 418
cooling C 47 418
of C 48 418
arterial C 49 418
blood C 50 418
with C 51 418
per C 52 418
- C 53 418
fusion C 54 418
at C 55 418
a C 56 418
predetermined C 57 418
pressure C 58 418
rather C 59 418
than C 60 418
predetermined C 61 418
flow C 62 418
rate C 63 418
. C 64 418
the C 66 418
cir C 67 418
- C 68 418
cuit C 69 418
is C 70 418
described C 71 418
and C 72 418
its C 73 418
advantages C 74 418
for C 75 418
clinical C 76 418
use C 77 418
mentioned C 78 418
together C 79 418
with C 80 418
its C 81 418
in C 82 418
- C 83 418
accuracies C 84 418
as C 85 418
a C 86 418
method C 87 418
of C 88 418
scientific C 89 418
investigation C 90 418
. C 91 418
these C 93 418
are C 94 418
chiefly C 95 418
concerned C 96 418
with C 97 418
maintenance C 98 418
of C 99 418
systemic C 100 418
blood C 101 418
pressure C 102 418
which C 103 418
may C 104 418
require C 105 418
the C 106 418
injection C 107 418
of C 108 418
pressor C 109 418
agents C 110 418
. C 111 418
evidence C 113 418
for C 114 418
reduction C 115 418
in C 116 418
flow C 117 418
at C 118 418
low C 119 418
temperatures C 120 418
is C 121 418
discussed C 122 418
and C 123 418
evidence C 124 418
presented C 125 418
that C 126 418
this C 127 418
is C 128 418
not C 129 418
only C 130 418
due C 131 418
to C 132 418
increase C 133 418
in C 134 418
viscosity C 135 418
but C 136 418
that C 137 418
there C 138 418
is C 139 418
an C 140 418
active C 141 418
spasm C 142 418
, C 143 418
manifested C 144 418
by C 145 418
' C 146 418
rewarming C 147 418
humps C 148 418
' C 149 418
which C 150 418
occur C 151 418
in C 152 418
the C 153 418
cooling C 154 418
graphs C 155 418
. C 156 418
mean C 158 418
carotid C 159 418
flow C 160 418
rates C 161 418
were C 162 418
determined C 163 418
by C 164 418
a C 165 418
revolution C 166 418
counter C 167 418
attached C 168 418
to C 169 418
a C 170 418
pump C 171 418
of C 172 418
fixed C 173 418
stroke C 174 418
volume C 175 418
, C 176 418
the C 177 418
output C 178 418
of C 179 418
which C 180 418
was C 181 418
linked C 182 418
to C 183 418
the C 184 418
per C 185 418
- C 186 418
fusion C 187 418
pressure C 188 418
and C 189 418
thus C 190 418
determined C 191 418
by C 192 418
the C 193 418
resistance C 194 418
. C 195 418
the C 197 418
place C 198 418
of C 199 418
added C 200 418
co C 201 418
2 C 202 418
is C 203 418
discussed C 204 418
particularly C 205 418
in C 206 418
relation C 207 418
to C 208 418
the C 209 418
fall C 210 418
in C 211 418
partial C 212 418
pressure C 213 418
which C 214 418
accompa C 215 418
- C 216 418
nies C 217 418
the C 218 418
cooling C 219 418
of C 220 418
the C 221 418
blood C 222 418
. C 223 418
the C 225 418
addition C 226 418
of C 227 418
5 C 228 418
% C 229 418
co C 230 418
2 C 231 418
did C 232 418
not C 233 418
increase C 234 418
total C 235 418
carotid C 236 418
flows C 237 418
. C 238 418
halothane C 240 418
had C 241 418
been C 242 418
used C 243 418
as C 244 418
an C 245 418
anesthetic C 246 418
because C 247 418
of C 248 418
its C 249 418
sympatholytic C 250 418
ac C 251 418
- C 252 418
tion C 253 418
. C 254 418
it C 256 418
has C 257 418
increased C 258 418
flows C 259 418
by C 260 418
37 C 261 418
% C 262 418
and C 263 418
abolished C 264 418
' C 265 418
rewarming C 266 418
humps C 267 418
' C 268 418
. C 269 418
rheomacro C 271 418
- C 272 418
dex C 273 418
used C 274 418
as C 275 418
a C 276 418
priming C 277 418
fluid C 278 418
instead C 279 418
of C 280 418
blood C 281 418
produced C 282 418
increased C 283 418
flow C 284 418
averaging C 285 418
75 C 286 418
% C 287 418
but C 288 418
did C 289 418
not C 290 418
abolish C 291 418
spasm C 292 418
. C 293 418
it C 295 418
is C 296 418
suggested C 297 418
that C 298 418
cooling C 299 418
faster C 300 418
than C 301 418
1 C 302 418
c C 303 418
. C 304 418
per C 306 418
minute C 307 418
is C 308 418
not C 309 418
intrinsically C 310 418
dangerous C 311 418
if C 312 418
spasm C 313 418
is C 314 418
prevented C 315 418
and C 316 418
high C 317 418
flow C 318 418
maintained C 319 418
by C 320 418
the C 321 418
methods C 322 418
described C 323 418
. C 324 418
4613 C 1 419
. C 2 419
selective C 4 419
brain C 5 419
cooling C 6 419
produced C 7 419
by C 8 419
cerebral C 9 419
ventricular C 10 419
perfusion C 11 419
hypothermic C 12 419
cerebral C 13 419
ventricular C 14 419
perfusion C 15 419
was C 16 419
applied C 17 419
to C 18 419
dogs C 19 419
. C 20 419
shivering C 22 419
appear C 23 419
- C 24 419
ed C 25 419
to C 26 419
be C 27 419
directly C 28 419
related C 29 419
to C 30 419
the C 31 419
cns C 32 419
temperature C 33 419
rather C 34 419
than C 35 419
the C 36 419
peripheral C 37 419
body C 38 419
temperature C 39 419
. C 40 419
selective C 42 419
heating C 43 419
of C 44 419
the C 45 419
brain C 46 419
- C 47 419
stem C 48 419
produced C 49 419
panting C 50 419
. C 51 419
rewarming C 53 419
of C 54 419
the C 55 419
body C 56 419
was C 57 419
retarded C 58 419
by C 59 419
the C 60 419
initiation C 61 419
of C 62 419
heat C 63 419
loss C 64 419
mechanisms C 65 419
controlled C 66 419
cen C 67 419
- C 68 419
trally C 69 419
when C 70 419
hyperthermic C 71 419
perfusion C 72 419
was C 73 419
used C 74 419
. C 75 419
shivering C 77 419
disappeared C 78 419
but C 79 419
panting C 80 419
was C 81 419
unaffected C 82 419
by C 83 419
pentobarbital C 84 419
anesthesia C 85 419
. C 86 419
cooling C 88 419
of C 89 419
one C 90 419
or C 91 419
both C 92 419
frontal C 93 419
areas C 94 419
and C 95 419
the C 96 419
anterior C 97 419
part C 98 419
of C 99 419
the C 100 419
third C 101 419
ventricle C 102 419
did C 103 419
not C 104 419
significantly C 105 419
affect C 106 419
the C 107 419
respiratory C 108 419
or C 109 419
circulatory C 110 419
systems C 111 419
but C 112 419
brain C 113 419
- C 114 419
stem C 115 419
hypothermia C 116 419
produced C 117 419
distinct C 118 419
respiratory C 119 419
and C 120 419
circulatory C 121 419
reactions C 122 419
. C 123 419
it C 125 419
is C 126 419
suggested C 127 419
that C 128 419
cooling C 129 419
of C 130 419
the C 131 419
3 C 132 419
rd C 133 419
and C 134 419
4 C 135 419
th C 136 419
ventricu C 137 419
- C 138 419
lar C 139 419
areas C 140 419
may C 141 419
be C 142 419
utilized C 143 419
for C 144 419
anesthetic C 145 419
purposes C 146 419
. C 147 419
1139 C 1 420
. C 2 420
optimal C 4 420
coronary C 5 420
flow C 6 420
in C 7 420
the C 8 420
bypassed C 9 420
normothermic C 10 420
and C 11 420
hypothermic C 12 420
heart C 13 420
a C 14 420
series C 15 420
of C 16 420
experiments C 17 420
were C 18 420
conducted C 19 420
in C 20 420
dogs C 21 420
in C 22 420
which C 23 420
bypass C 24 420
flow C 25 420
, C 26 420
temperature C 27 420
, C 28 420
and C 29 420
direct C 30 420
coronary C 31 420
perfusion C 32 420
pressure C 33 420
were C 34 420
varied C 35 420
. C 36 420
coronary C 38 420
flow C 39 420
, C 40 420
coronary C 41 420
ven C 42 420
- C 43 420
ous C 44 420
saturation C 45 420
, C 46 420
myocardial C 47 420
oxygen C 48 420
consumption C 49 420
( C 50 420
mvo C 51 420
2 C 52 420
) C 53 420
, C 54 420
and C 55 420
coronary C 56 420
vascular C 57 420
re C 58 420
- C 59 420
sistance C 60 420
were C 61 420
assayed C 62 420
. C 63 420
coronary C 65 420
flow C 66 420
as C 67 420
a C 68 420
percentage C 69 420
of C 70 420
total C 71 420
bypass C 72 420
flow C 73 420
did C 74 420
not C 75 420
vary C 76 420
appreciably C 77 420
at C 78 420
varying C 79 420
levels C 80 420
of C 81 420
bypass C 82 420
flow C 83 420
. C 84 420
induction C 86 420
of C 87 420
hypothermia C 88 420
, C 89 420
when C 90 420
total C 91 420
bypass C 92 420
flow C 93 420
is C 94 420
constant C 95 420
, C 96 420
results C 97 420
in C 98 420
decreasing C 99 420
coronary C 100 420
flow C 101 420
. C 102 420
induction C 104 420
of C 105 420
hy C 106 420
- C 107 420
pothermia C 108 420
when C 109 420
maintaining C 110 420
a C 111 420
constant C 112 420
bypass C 113 420
pressure C 114 420
results C 115 420
in C 116 420
an C 117 420
increasing C 118 420
coronary C 119 420
flow C 120 420
with C 121 420
temperatures C 122 420
down C 123 420
to C 124 420
22 C 125 420
c C 126 420
. C 127 420
further C 129 420
cooling C 130 420
causes C 131 420
a C 132 420
reduction C 133 420
in C 134 420
flow C 135 420
. C 136 420
using C 138 420
isolated C 139 420
coronary C 140 420
perfusion C 141 420
at C 142 420
100 C 143 420
mm C 144 420
. C 145 420
hg C 147 420
, C 148 420
coronary C 149 420
flow C 150 420
fell C 151 420
and C 152 420
resistance C 153 420
rose C 154 420
during C 155 420
the C 156 420
first C 157 420
15 C 158 420
min C 159 420
. C 160 420
of C 162 420
bypass C 163 420
. C 164 420
using C 166 420
isolated C 167 420
coronary C 168 420
perfu C 169 420
- C 170 420
sion C 171 420
at C 172 420
100 C 173 420
mm C 174 420
. C 175 420
hg C 177 420
, C 178 420
induction C 179 420
of C 180 420
moderate C 181 420
hypothermia C 182 420
( C 183 420
25 C 184 420
c C 185 420
. C 186 420
) C 188 420
caused C 189 420
an C 190 420
increase C 191 420
in C 192 420
coronary C 193 420
flow C 194 420
and C 195 420
venous C 196 420
saturation C 197 420
and C 198 420
a C 199 420
decrease C 200 420
in C 201 420
cardiovascular C 202 420
resistance C 203 420
and C 204 420
mvo C 205 420
2 C 206 420
. C 207 420
under C 209 420
the C 210 420
same C 211 420
conditions C 212 420
, C 213 420
induction C 214 420
of C 215 420
hypothermia C 216 420
to C 217 420
18 C 218 420
c C 219 420
. C 220 420
produced C 222 420
similar C 223 420
changes C 224 420
but C 225 420
caused C 226 420
myocardial C 227 420
hemorrhage C 228 420
and C 229 420
ventricular C 230 420
fibrillation C 231 420
. C 232 420
pro C 234 420
- C 235 420
found C 236 420
hypothermia C 237 420
probably C 238 420
leads C 239 420
to C 240 420
excessive C 241 420
fragility C 242 420
of C 243 420
the C 244 420
capillary C 245 420
bed C 246 420
. C 247 420
reduc C 249 420
- C 250 420
tion C 251 420
of C 252 420
perfusion C 253 420
pressure C 254 420
to C 255 420
50 C 256 420
mm C 257 420
. C 258 420
hg C 260 420
at C 261 420
near C 262 420
normothermia C 263 420
reduced C 264 420
coronary C 265 420
flow C 266 420
and C 267 420
slightly C 268 420
reduced C 269 420
venous C 270 420
saturation C 271 420
and C 272 420
mvo C 273 420
2 C 274 420
. C 275 420
the C 277 420
same C 278 420
reduction C 279 420
of C 280 420
perfu C 281 420
- C 282 420
sion C 283 420
pressure C 284 420
at C 285 420
18 C 286 420
c C 287 420
. C 288 420
produced C 290 420
similar C 291 420
but C 292 420
less C 293 420
marked C 294 420
changes C 295 420
. C 296 420
reduction C 298 420
to C 299 420
25 C 300 420
mm C 301 420
. C 302 420
hg C 304 420
at C 305 420
18 C 306 420
c C 307 420
. C 308 420
markedly C 310 420
reduced C 311 420
coronary C 312 420
flow C 313 420
, C 314 420
venous C 315 420
saturation C 316 420
, C 317 420
and C 318 420
mvo C 319 420
2 C 320 420
initially C 321 420
, C 322 420
but C 323 420
with C 324 420
partial C 325 420
recovery C 326 420
later C 327 420
. C 328 420
from C 330 420
this C 331 420
data C 332 420
of C 333 420
acute C 334 420
experiments C 335 420
in C 336 420
dogs C 337 420
, C 338 420
coronary C 339 420
perfusion C 340 420
using C 341 420
moderate C 342 420
hypothermia C 343 420
( C 344 420
about C 345 420
31 C 346 420
c C 347 420
. C 348 420
) C 350 420
and C 351 420
50 C 352 420
mm C 353 420
. C 354 420
hg C 356 420
, C 357 420
slightly C 358 420
pulsatile C 359 420
mean C 360 420
pressure C 361 420
appears C 362 420
optimal C 363 420
. C 364 420
974 C 1 421
. C 2 421
extracorporeal C 4 421
hypothermia C 5 421
without C 6 421
thoracotomy C 7 421
. C 8 421
an C 10 421
ex C 11 421
- C 12 421
perimental C 13 421
study C 14 421
in C 15 421
the C 16 421
use C 17 421
of C 18 421
cold C 19 421
for C 20 421
neurosurgery C 21 421
and C 22 421
cancericidal C 23 421
perfusions C 24 421
this C 25 421
paper C 26 421
includes C 27 421
minor C 28 421
clinical C 29 421
notes C 30 421
on C 31 421
open C 32 421
heart C 33 421
surgery C 34 421
and C 35 421
cancer C 36 421
perfusion C 37 421
but C 38 421
contains C 39 421
no C 40 421
experimental C 41 421
information C 42 421
on C 43 421
neurosurgery C 44 421
or C 45 421
cancer C 46 421
perfusions C 47 421
. C 48 421
a C 50 421
method C 51 421
of C 52 421
closed C 53 421
- C 54 421
chest C 55 421
hypothermic C 56 421
perfusion C 57 421
in C 58 421
30 C 59 421
dogs C 60 421
is C 61 421
reported C 62 421
. C 63 421
the C 65 421
authors C 66 421
utilize C 67 421
drainage C 68 421
of C 69 421
superior C 70 421
and C 71 421
inferior C 72 421
cavae C 73 421
by C 74 421
gravity C 75 421
. C 76 421
the C 78 421
volume C 79 421
of C 80 421
venous C 81 421
drainage C 82 421
sometimes C 83 421
enhanced C 84 421
by C 85 421
transfusions C 86 421
or C 87 421
12 C 88 421
. C 89 421
. C 90 421
% C 91 421
low C 92 421
molecular C 93 421
weight C 94 421
dex C 95 421
- C 96 421
tran C 97 421
determined C 98 421
the C 99 421
flow C 100 421
rate C 101 421
. C 102 421
cooling C 104 421
was C 105 421
maintained C 106 421
for C 107 421
quite C 108 421
variable C 109 421
periods C 110 421
apparently C 111 421
generally C 112 421
to C 113 421
an C 114 421
unspecified C 115 421
esophageal C 116 421
temperature C 117 421
. C 118 421
perfusion C 120 421
time C 121 421
va C 122 421
- C 123 421
ried C 124 421
from C 125 421
30 C 126 421
min C 127 421
. C 128 421
to C 130 421
4 C 131 421
hr C 132 421
. C 133 421
animals C 135 421
with C 136 421
low C 137 421
flows C 138 421
were C 139 421
perfused C 140 421
longer C 141 421
, C 142 421
had C 143 421
a C 144 421
high C 145 421
- C 146 421
er C 147 421
incidence C 148 421
of C 149 421
ventricular C 150 421
fibrillation C 151 421
, C 152 421
and C 153 421
a C 154 421
very C 155 421
low C 156 421
survival C 157 421
rate C 158 421
. C 159 421
eleven C 161 421
ani C 162 421
- C 163 421
mals C 164 421
survived C 165 421
. C 166 421
all C 168 421
had C 169 421
pre C 170 421
- C 171 421
cooling C 172 421
flow C 173 421
rates C 174 421
above C 175 421
40 C 176 421
ml C 177 421
. C 178 421
/ C 180 421
kg C 181 421
. C 182 421
/ C 184 421
min C 185 421
. C 186 421
, C 188 421
good C 189 421
flow C 190 421
rates C 191 421
during C 192 421
the C 193 421
perfusion C 194 421
, C 195 421
and C 196 421
only C 197 421
3 C 198 421
had C 199 421
ventricular C 200 421
fibrillation C 201 421
. C 202 421
flow C 204 421
rates C 205 421
and C 206 421
survival C 207 421
were C 208 421
increased C 209 421
in C 210 421
animals C 211 421
receiving C 212 421
low C 213 421
molecular C 214 421
weight C 215 421
dextran C 216 421
. C 217 421
four C 219 421
- C 220 421
teen C 221 421
of C 222 421
15 C 223 421
animals C 224 421
with C 225 421
ventricular C 226 421
fibrillation C 227 421
were C 228 421
defibrillated C 229 421
electrically C 230 421
, C 231 421
8 C 232 421
re C 233 421
- C 234 421
gained C 235 421
' C 236 421
adequate C 237 421
' C 238 421
cardiac C 239 421
function C 240 421
, C 241 421
but C 242 421
only C 243 421
3 C 244 421
survived C 245 421
. C 246 421
some C 248 421
interesting C 249 421
data C 250 421
on C 251 421
regional C 252 421
cooling C 253 421
of C 254 421
the C 255 421
lower C 256 421
half C 257 421
of C 258 421
the C 259 421
body C 260 421
is C 261 421
presented C 262 421
. C 263 421
the C 265 421
authors C 266 421
conclude C 267 421
without C 268 421
sufficient C 269 421
evidence C 270 421
that C 271 421
the C 272 421
most C 273 421
important C 274 421
factor C 275 421
in C 276 421
the C 277 421
mortality C 278 421
in C 279 421
hypo C 280 421
- C 281 421
thermic C 282 421
perfusion C 283 421
is C 284 421
the C 285 421
ability C 286 421
to C 287 421
maintain C 288 421
' C 289 421
a C 290 421
flow C 291 421
rate C 292 421
approaching C 293 421
the C 294 421
estimated C 295 421
normothermic C 296 421
cardiac C 297 421
output C 298 421
of C 299 421
the C 300 421
animal C 301 421
' C 302 421
2406 C 1 422
. C 2 422
profound C 4 422
hypothermia C 5 422
the C 6 422
aim C 7 422
of C 8 422
hypothermia C 9 422
is C 10 422
protection C 11 422
of C 12 422
vital C 13 422
cerebral C 14 422
structures C 15 422
from C 16 422
hypoxia C 17 422
during C 18 422
aneurysm C 19 422
repair C 20 422
; C 21 422
profound C 22 422
hypothermia C 23 422
is C 24 422
also C 25 422
valuable C 26 422
in C 27 422
operating C 28 422
on C 29 422
certain C 30 422
cardiac C 31 422
defects C 32 422
which C 33 422
cannot C 34 422
be C 35 422
repaired C 36 422
even C 37 422
with C 38 422
whole C 39 422
body C 40 422
perfusion C 41 422
. C 42 422
since C 44 422
the C 45 422
time C 46 422
needed C 47 422
for C 48 422
aneurysm C 49 422
repair C 50 422
often C 51 422
exceeded C 52 422
the C 53 422
safe C 54 422
limit C 55 422
of C 56 422
8 C 57 422
to C 58 422
12 C 59 422
minutes C 60 422
without C 61 422
circulation C 62 422
afforded C 63 422
by C 64 422
surface C 65 422
hypothermia C 66 422
of C 67 422
29 C 68 422
to C 69 422
30 C 70 422
c C 71 422
. C 72 422
, C 74 422
the C 75 422
authors C 76 422
have C 77 422
investigated C 78 422
the C 79 422
drew C 80 422
( C 81 422
open C 82 422
- C 83 422
chest C 84 422
) C 85 422
technic C 86 422
, C 87 422
the C 88 422
closed C 89 422
- C 90 422
chest C 91 422
method C 92 422
, C 93 422
and C 94 422
isolated C 95 422
cerebral C 96 422
perfusion C 97 422
. C 98 422
the C 100 422
drew C 101 422
technic C 102 422
consists C 103 422
of C 104 422
substituting C 105 422
two C 106 422
pumps C 107 422
for C 108 422
the C 109 422
heart C 110 422
while C 111 422
the C 112 422
patient C 113 422
' C 114 422
s C 115 422
lungs C 116 422
act C 117 422
as C 118 422
the C 119 422
oxygenator C 120 422
. C 121 422
because C 123 422
of C 124 422
its C 125 422
disadvantages C 126 422
( C 127 422
the C 128 422
large C 129 422
amounts C 130 422
of C 131 422
blood C 132 422
needed C 133 422
and C 134 422
the C 135 422
morbidity C 136 422
due C 137 422
to C 138 422
intra C 139 422
- C 140 422
cardiac C 141 422
cannulation C 142 422
and C 143 422
median C 144 422
sternotomy C 145 422
) C 146 422
, C 147 422
a C 148 422
closed C 149 422
- C 150 422
chest C 151 422
method C 152 422
was C 153 422
developed C 154 422
, C 155 422
using C 156 422
a C 157 422
mayo C 158 422
- C 159 422
gibbons C 160 422
vertical C 161 422
- C 162 422
sheet C 163 422
pump C 164 422
- C 165 422
oxygenator C 166 422
to C 167 422
provide C 168 422
the C 169 422
perfusion C 170 422
and C 171 422
extracorporeal C 172 422
cooling C 173 422
without C 174 422
requiring C 175 422
thoracotomy C 176 422
. C 177 422
in C 179 422
cerebral C 180 422
perfusion C 181 422
, C 182 422
blood C 183 422
is C 184 422
taken C 185 422
from C 186 422
one C 187 422
artery C 188 422
, C 189 422
pumped C 190 422
through C 191 422
a C 192 422
heat C 193 422
exchanger C 194 422
, C 195 422
and C 196 422
returned C 197 422
to C 198 422
another C 199 422
artery C 200 422
. C 201 422
the C 203 422
authors C 204 422
describe C 205 422
anesthetic C 206 422
technics C 207 422
, C 208 422
offer C 209 422
comparisons C 210 422
of C 211 422
the C 212 422
three C 213 422
methods C 214 422
, C 215 422
give C 216 422
instructions C 217 422
pertaining C 218 422
to C 219 422
the C 220 422
production C 221 422
of C 222 422
hypothermia C 223 422
, C 224 422
and C 225 422
list C 226 422
the C 227 422
problems C 228 422
encountered C 229 422
in C 230 422
the C 231 422
management C 232 422
of C 233 422
these C 234 422
cases C 235 422
. C 236 422
3194 C 1 423
. C 2 423
systemic C 4 423
hypothermia C 5 423
via C 6 423
gastric C 7 423
cooling C 8 423
eight C 9 423
dogs C 10 423
underwent C 11 423
gastric C 12 423
cooling C 13 423
for C 14 423
systemic C 15 423
hypothermia C 16 423
. C 17 423
each C 19 423
dog C 20 423
was C 21 423
cooled C 22 423
with C 23 423
the C 24 423
balloon C 25 423
filled C 26 423
with C 27 423
a C 28 423
' C 29 423
safe C 30 423
' C 31 423
volume C 32 423
based C 33 423
on C 34 423
weight C 35 423
( C 36 423
20 C 37 423
ml C 38 423
/ C 39 423
kg C 40 423
) C 41 423
and C 42 423
subjected C 43 423
to C 44 423
cooling C 45 423
with C 46 423
the C 47 423
balloon C 48 423
filled C 49 423
maximally C 50 423
, C 51 423
but C 52 423
safely C 53 423
to C 54 423
a C 55 423
pressure C 56 423
of C 57 423
10 C 58 423
mm C 59 423
hg C 60 423
. C 61 423
consistently C 63 423
, C 64 423
the C 65 423
latter C 66 423
procedure C 67 423
was C 68 423
far C 69 423
more C 70 423
efficient C 71 423
, C 72 423
averaging C 73 423
2 C 74 423
. C 75 423
. C 76 423
times C 77 423
as C 78 423
rapid C 79 423
for C 80 423
all C 81 423
degrees C 82 423
of C 83 423
hypothermia C 84 423
. C 85 423
a C 87 423
decrease C 88 423
in C 89 423
core C 90 423
temperature C 91 423
by C 92 423
7 C 93 423
c C 94 423
re C 95 423
- C 96 423
quired C 97 423
an C 98 423
average C 99 423
of C 100 423
only C 101 423
28 C 102 423
. C 103 423
. C 104 423
minutes C 105 423
. C 106 423
on C 108 423
comparison C 109 423
with C 110 423
clinical C 111 423
reports C 112 423
of C 113 423
hy C 114 423
- C 115 423
pothermia C 116 423
induced C 117 423
by C 118 423
the C 119 423
usual C 120 423
gastric C 121 423
cooling C 122 423
, C 123 423
an C 124 423
improved C 125 423
efficiency C 126 423
of C 127 423
two C 128 423
- C 129 423
fold C 130 423
to C 131 423
three C 132 423
- C 133 423
fold C 134 423
is C 135 423
still C 136 423
noted C 137 423
. C 138 423
3820 C 1 424
. C 2 424
the C 4 424
dubious C 5 424
haemopoietic C 6 424
stem C 7 424
cell C 8 424
function C 9 424
of C 10 424
the C 11 424
lym C 12 424
- C 13 424
phoid C 14 424
cells C 15 424
of C 16 424
the C 17 424
blood C 18 424
. C 19 424
autoradiographic C 21 424
studies C 22 424
on C 23 424
dogs C 24 424
the C 25 424
migration C 26 424
, C 27 424
fate C 28 424
and C 29 424
turnover C 30 424
of C 31 424
lymphoid C 32 424
cells C 33 424
in C 34 424
blood C 35 424
and C 36 424
bone C 37 424
marrow C 38 424
of C 39 424
irradiated C 40 424
and C 41 424
non C 42 424
- C 43 424
irradiated C 44 424
dogs C 45 424
were C 46 424
studied C 47 424
by C 48 424
serial C 49 424
autoradiography C 50 424
with C 51 424
co C 52 424
- C 53 424
ping C 54 424
of C 55 424
the C 56 424
hind C 57 424
legs C 58 424
during C 59 424
the C 60 424
plasma C 61 424
clearance C 62 424
time C 63 424
of C 64 424
h C 65 424
3 C 66 424
- C 67 424
thymidine C 68 424
injected C 69 424
into C 70 424
an C 71 424
anterior C 72 424
vein C 73 424
. C 74 424
in C 76 424
irradiated C 77 424
dogs C 78 424
, C 79 424
the C 80 424
h C 81 424
3 C 82 424
- C 83 424
thymidine C 84 424
injection C 85 424
procedure C 86 424
was C 87 424
car C 88 424
- C 89 424
ried C 90 424
out C 91 424
during C 92 424
the C 93 424
early C 94 424
recovery C 95 424
phase C 96 424
following C 97 424
250 C 98 424
r C 99 424
whole C 100 424
body C 101 424
x C 102 424
- C 103 424
irradiation C 104 424
. C 105 424
conclusive C 107 424
evidence C 108 424
of C 109 424
transformation C 110 424
of C 111 424
hematogenous C 112 424
bone C 113 424
marrow C 114 424
lymphoid C 115 424
cells C 116 424
into C 117 424
hemopoietic C 118 424
precursors C 119 424
was C 120 424
not C 121 424
found C 122 424
. C 123 424
however C 125 424
, C 126 424
in C 127 424
the C 128 424
light C 129 424
of C 130 424
the C 131 424
individual C 132 424
grain C 133 424
counts C 134 424
transformation C 135 424
of C 136 424
a C 137 424
few C 138 424
lymphoid C 139 424
cells C 140 424
into C 141 424
hemopoietic C 142 424
cells C 143 424
cannot C 144 424
be C 145 424
ruled C 146 424
out C 147 424
. C 148 424
the C 150 424
data C 151 424
obtained C 152 424
from C 153 424
a C 154 424
dog C 155 424
in C 156 424
the C 157 424
very C 158 424
early C 159 424
recovery C 160 424
phase C 161 424
following C 162 424
whole C 163 424
body C 164 424
irradiation C 165 424
strongly C 166 424
indicate C 167 424
such C 168 424
a C 169 424
transformation C 170 424
. C 171 424
3927 C 1 425
. C 2 425
studies C 4 425
on C 5 425
growth C 6 425
and C 7 425
cytomorphosis C 8 425
in C 9 425
the C 10 425
thymo C 11 425
- C 12 425
lympha C 13 425
- C 14 425
tic C 15 425
systems C 16 425
- C 17 425
with C 18 425
special C 19 425
reference C 20 425
to C 21 425
the C 22 425
influence C 23 425
of C 24 425
the C 25 425
thymus C 26 425
and C 27 425
the C 28 425
thyroid C 29 425
in C 30 425
guinea C 31 425
- C 32 425
pigs C 33 425
migratory C 34 425
streams C 35 425
of C 36 425
lymphocytes C 37 425
between C 38 425
different C 39 425
parts C 40 425
of C 41 425
the C 42 425
thymo C 43 425
- C 44 425
lymphatic C 45 425
system C 46 425
were C 47 425
evaluated C 48 425
by C 49 425
comparisons C 50 425
between C 51 425
lymphocyte C 52 425
populations C 53 425
in C 54 425
thoracic C 55 425
- C 56 425
duct C 57 425
lymph C 58 425
and C 59 425
arterial C 60 425
and C 61 425
venous C 62 425
blood C 63 425
, C 64 425
especially C 65 425
thymic C 66 425
venous C 67 425
blood C 68 425
. C 69 425
by C 71 425
re C 72 425
- C 73 425
cording C 74 425
organ C 75 425
weights C 76 425
in C 77 425
sham C 78 425
- C 79 425
operated C 80 425
and C 81 425
thymectomized C 82 425
guinea C 83 425
- C 84 425
pigs C 85 425
, C 86 425
treated C 87 425
with C 88 425
thyroxin C 89 425
or C 90 425
untreated C 91 425
, C 92 425
the C 93 425
importance C 94 425
of C 95 425
the C 96 425
thymus C 97 425
and C 98 425
the C 99 425
thyroid C 100 425
for C 101 425
growth C 102 425
and C 103 425
regeneration C 104 425
in C 105 425
the C 106 425
thymo C 107 425
- C 108 425
lymphatic C 109 425
system C 110 425
was C 111 425
studied C 112 425
. C 113 425
the C 115 425
main C 116 425
results C 117 425
are C 118 425
as C 119 425
follows C 120 425
. C 121 425
there C 123 425
is C 124 425
a C 125 425
considerable C 126 425
venous C 127 425
output C 128 425
of C 129 425
lymphocytes C 130 425
with C 131 425
low C 132 425
mito C 133 425
- C 134 425
chondrial C 135 425
content C 136 425
( C 137 425
small C 138 425
lymphocytes C 139 425
) C 140 425
from C 141 425
the C 142 425
thymus C 143 425
in C 144 425
normal C 145 425
young C 146 425
guinea C 147 425
- C 148 425
pigs C 149 425
. C 150 425
this C 152 425
explains C 153 425
the C 154 425
much C 155 425
higher C 156 425
incidence C 157 425
of C 158 425
small C 159 425
lymphocytes C 160 425
in C 161 425
blood C 162 425
than C 163 425
in C 164 425
tho C 165 425
- C 166 425
racic C 167 425
- C 168 425
duct C 169 425
lymph C 170 425
. C 171 425
neonatal C 173 425
thymectomy C 174 425
causes C 175 425
lymphatic C 176 425
hypotrophy C 177 425
with C 178 425
defi C 179 425
- C 180 425
ciency C 181 425
of C 182 425
lymphocytes C 183 425
and C 184 425
pyroninophilic C 185 425
cells C 186 425
in C 187 425
relation C 188 425
to C 189 425
reticular C 190 425
ones C 191 425
. C 192 425
body C 194 425
growth C 195 425
and C 196 425
survival C 197 425
of C 198 425
the C 199 425
animals C 200 425
are C 201 425
not C 202 425
affected C 203 425
. C 204 425
in C 206 425
the C 207 425
thymus C 208 425
, C 209 425
exogenous C 210 425
thyroxin C 211 425
most C 212 425
probably C 213 425
promotes C 214 425
differentiation C 215 425
of C 216 425
large C 217 425
basophilic C 218 425
cells C 219 425
to C 220 425
small C 221 425
lymphocytes C 222 425
, C 223 425
resulting C 224 425
in C 225 425
an C 226 425
increased C 227 425
output C 228 425
of C 229 425
small C 230 425
lymphocytes C 231 425
. C 232 425
in C 234 425
the C 235 425
lymph C 236 425
nodes C 237 425
, C 238 425
thyroxin C 239 425
promotes C 240 425
differentiation C 241 425
of C 242 425
large C 243 425
pyroninophilic C 244 425
cells C 245 425
( C 246 425
' C 247 425
transitional C 248 425
cells C 249 425
' C 250 425
) C 251 425
into C 252 425
immature C 253 425
and C 254 425
mature C 255 425
plasma C 256 425
cells C 257 425
. C 258 425
the C 260 425
effects C 261 425
of C 262 425
thyroxin C 263 425
on C 264 425
dif C 265 425
- C 266 425
ferentiation C 267 425
are C 268 425
followed C 269 425
by C 270 425
an C 271 425
increased C 272 425
growth C 273 425
of C 274 425
the C 275 425
thymo C 276 425
- C 277 425
lymphatic C 278 425
organs C 279 425
, C 280 425
characterized C 281 425
by C 282 425
an C 283 425
increased C 284 425
incidence C 285 425
of C 286 425
large C 287 425
basophilic C 288 425
cells C 289 425
and C 290 425
increased C 291 425
weight C 292 425
of C 293 425
the C 294 425
lymphatic C 295 425
organs C 296 425
. C 297 425
growth C 299 425
of C 300 425
the C 301 425
thymus C 302 425
and C 303 425
lymph C 304 425
nodes C 305 425
precedes C 306 425
that C 307 425
of C 308 425
the C 309 425
red C 310 425
splenic C 311 425
pulp C 312 425
. C 313 425
this C 315 425
delayed C 316 425
splenic C 317 425
response C 318 425
is C 319 425
not C 320 425
due C 321 425
to C 322 425
a C 323 425
transformation C 324 425
of C 325 425
an C 326 425
increased C 327 425
number C 328 425
of C 329 425
immigrated C 330 425
thymic C 331 425
lymphocytes C 332 425
, C 333 425
as C 334 425
neonatal C 335 425
thymectomy C 336 425
does C 337 425
not C 338 425
prevent C 339 425
the C 340 425
thyroxin C 341 425
- C 342 425
stimulated C 343 425
occurrence C 344 425
of C 345 425
large C 346 425
basophilic C 347 425
cells C 348 425
in C 349 425
the C 350 425
red C 351 425
splenic C 352 425
pulp C 353 425
. C 354 425
the C 356 425
thyroxin C 357 425
- C 358 425
stimulated C 359 425
growth C 360 425
of C 361 425
the C 362 425
lymphatic C 363 425
system C 364 425
is C 365 425
ac C 366 425
- C 367 425
companied C 368 425
by C 369 425
an C 370 425
increased C 371 425
output C 372 425
of C 373 425
larger C 374 425
lymphocytes C 375 425
through C 376 425
the C 377 425
thoracic C 378 425
duct C 379 425
, C 380 425
resulting C 381 425
in C 382 425
an C 383 425
increased C 384 425
number C 385 425
of C 386 425
larger C 387 425
lymphocytes C 388 425
in C 389 425
the C 390 425
blood C 391 425
. C 392 425
in C 394 425
postnatally C 395 425
thymectomized C 396 425
animals C 397 425
, C 398 425
having C 399 425
a C 400 425
normal C 401 425
( C 402 425
or C 403 425
above C 404 425
normal C 405 425
) C 406 425
amount C 407 425
of C 408 425
circulating C 409 425
small C 410 425
lymphocytes C 411 425
, C 412 425
thyroxin C 413 425
produces C 414 425
a C 415 425
drastic C 416 425
decrease C 417 425
in C 418 425
the C 419 425
number C 420 425
of C 421 425
small C 422 425
blood C 423 425
lymphocytes C 424 425
, C 425 425
indicating C 426 425
a C 427 425
decreased C 428 425
delivery C 429 425
and C 430 425
/ C 431 425
or C 432 425
increased C 433 425
disappear C 434 425
- C 435 425
ance C 436 425
of C 437 425
these C 438 425
cells C 439 425
to C 440 425
and C 441 425
from C 442 425
the C 443 425
blood C 444 425
, C 445 425
respectively C 446 425
. C 447 425
this C 449 425
decrease C 450 425
in C 451 425
number C 452 425
of C 453 425
small C 454 425
lymphocytes C 455 425
is C 456 425
not C 457 425
seen C 458 425
in C 459 425
sham C 460 425
- C 461 425
operated C 462 425
animals C 463 425
. C 464 425
as C 466 425
judged C 467 425
by C 468 425
studies C 469 425
of C 470 425
organ C 471 425
weights C 472 425
, C 473 425
the C 474 425
thyroxin C 475 425
- C 476 425
stimulated C 477 425
growth C 478 425
and C 479 425
regeneration C 480 425
of C 481 425
the C 482 425
lymphatic C 483 425
tissue C 484 425
are C 485 425
influenced C 486 425
antagonistically C 487 425
by C 488 425
thymectomy C 489 425
and C 490 425
synergistically C 491 425
by C 492 425
local C 493 425
factors C 494 425
in C 495 425
involuted C 496 425
tissue C 497 425
. C 498 425
815 C 1 426
. C 2 426
the C 4 426
origin C 5 426
of C 6 426
macrophages C 7 426
from C 8 426
bone C 9 426
marrow C 10 426
in C 11 426
the C 12 426
rat C 13 426
skin C 14 426
windows C 15 426
' C 16 426
and C 17 426
subcutaneous C 18 426
coverslips C 19 426
were C 20 426
applied C 21 426
to C 22 426
rats C 23 426
in C 24 426
a C 25 426
study C 26 426
designed C 27 426
to C 28 426
identify C 29 426
the C 30 426
tissues C 31 426
in C 32 426
which C 33 426
the C 34 426
precursors C 35 426
of C 36 426
macrophages C 37 426
proliferate C 38 426
. C 39 426
lympho C 41 426
- C 42 426
cyte C 43 426
- C 44 426
depletion C 45 426
by C 46 426
either C 47 426
chronic C 48 426
drainage C 49 426
from C 50 426
the C 51 426
thoracic C 52 426
duct C 53 426
or C 54 426
400 C 55 426
rads C 56 426
of C 57 426
x C 58 426
- C 59 426
irradiation C 60 426
failed C 61 426
to C 62 426
suppress C 63 426
the C 64 426
emigration C 65 426
of C 66 426
macrophages C 67 426
or C 68 426
to C 69 426
reduce C 70 426
the C 71 426
pro C 72 426
- C 73 426
portion C 74 426
of C 75 426
them C 76 426
which C 77 426
became C 78 426
labelled C 79 426
after C 80 426
an C 81 426
injection C 82 426
of C 83 426
tritiated C 84 426
thymidine C 85 426
. C 86 426
x C 88 426
- C 89 426
irradiation C 90 426
with C 91 426
750 C 92 426
rads C 93 426
suppressed C 94 426
the C 95 426
emigration C 96 426
and C 97 426
the C 98 426
labelling C 99 426
of C 100 426
the C 101 426
exudate C 102 426
macrophages C 103 426
. C 104 426
both C 106 426
were C 107 426
restored C 108 426
to C 109 426
normal C 110 426
when C 111 426
the C 112 426
tibial C 113 426
marrow C 114 426
was C 115 426
shielded C 116 426
during C 117 426
irradiation C 118 426
. C 119 426
radioactively C 121 426
- C 122 426
labelled C 123 426
cell C 124 426
suspensions C 125 426
obtained C 126 426
from C 127 426
thoracic C 128 426
duct C 129 426
lymph C 130 426
, C 131 426
lymph C 132 426
nodes C 133 426
, C 134 426
thymus C 135 426
, C 136 426
spleen C 137 426
and C 138 426
bone C 139 426
marrow C 140 426
were C 141 426
transfused C 142 426
into C 143 426
syngeneic C 144 426
recipients C 145 426
. C 146 426
the C 148 426
emigration C 149 426
of C 150 426
labelled C 151 426
macrophages C 152 426
on C 153 426
to C 154 426
coverslips C 155 426
could C 156 426
be C 157 426
demonstrated C 158 426
only C 159 426
in C 160 426
recipients C 161 426
of C 162 426
labelled C 163 426
bone C 164 426
marrow C 165 426
and C 166 426
spleen C 167 426
cells C 168 426
. C 169 426
labelled C 171 426
monocytes C 172 426
were C 173 426
found C 174 426
in C 175 426
the C 176 426
blood C 177 426
of C 178 426
rats C 179 426
which C 180 426
had C 181 426
received C 182 426
injections C 183 426
of C 184 426
labelled C 185 426
bone C 186 426
marrow C 187 426
. C 188 426
it C 190 426
was C 191 426
concluded C 192 426
that C 193 426
in C 194 426
the C 195 426
rat C 196 426
, C 197 426
bone C 198 426
marrow C 199 426
, C 200 426
and C 201 426
to C 202 426
a C 203 426
lesser C 204 426
extent C 205 426
spleen C 206 426
, C 207 426
are C 208 426
major C 209 426
sources C 210 426
of C 211 426
the C 212 426
macrophages C 213 426
which C 214 426
emigrate C 215 426
into C 216 426
foci C 217 426
of C 218 426
acute C 219 426
, C 220 426
non C 221 426
- C 222 426
bacterial C 223 426
inflammation C 224 426
. C 225 426
1786 C 1 427
. C 2 427
studies C 4 427
of C 5 427
the C 6 427
leucocyte C 7 427
compartment C 8 427
in C 9 427
guinea C 10 427
- C 11 427
pig C 12 427
bone C 13 427
marrow C 14 427
after C 15 427
acute C 16 427
haemorrhage C 17 427
and C 18 427
severe C 19 427
hypoxia C 20 427
evidence C 21 427
for C 22 427
a C 23 427
common C 24 427
stem C 25 427
- C 26 427
cell C 27 427
after C 28 427
a C 29 427
large C 30 427
acute C 31 427
hemorrhage C 32 427
, C 33 427
the C 34 427
absolute C 35 427
le C 36 427
- C 37 427
vels C 38 427
of C 39 427
neutrophils C 40 427
, C 41 427
eosinophils C 42 427
, C 43 427
and C 44 427
basophils C 45 427
in C 46 427
guinea C 47 427
pig C 48 427
bone C 49 427
marrow C 50 427
are C 51 427
considerably C 52 427
reduced C 53 427
. C 54 427
all C 56 427
stages C 57 427
of C 58 427
differentiation C 59 427
are C 60 427
involved C 61 427
, C 62 427
the C 63 427
decline C 64 427
in C 65 427
myelo C 66 427
- C 67 427
blasts C 68 427
and C 69 427
promyelocytes C 70 427
being C 71 427
particularly C 72 427
marked C 73 427
. C 74 427
exposure C 76 427
to C 77 427
severe C 78 427
hypoxia C 79 427
also C 80 427
temporarily C 81 427
depresses C 82 427
the C 83 427
number C 84 427
of C 85 427
marrow C 86 427
granulocytes C 87 427
. C 88 427
bone C 90 427
marrow C 91 427
lymphocytes C 92 427
are C 93 427
only C 94 427
slightly C 95 427
reduced C 96 427
after C 97 427
a C 98 427
single C 99 427
he C 100 427
- C 101 427
morrhage C 102 427
but C 103 427
in C 104 427
the C 105 427
later C 106 427
stages C 107 427
of C 108 427
severe C 109 427
hypoxia C 110 427
their C 111 427
numbers C 112 427
are C 113 427
greatly C 114 427
reduced C 115 427
. C 116 427
assuming C 118 427
the C 119 427
supply C 120 427
of C 121 427
stem C 122 427
cells C 123 427
in C 124 427
the C 125 427
bone C 126 427
marrow C 127 427
is C 128 427
not C 129 427
unlimited C 130 427
, C 131 427
the C 132 427
de C 133 427
- C 134 427
crease C 135 427
in C 136 427
marrow C 137 427
granulocytes C 138 427
and C 139 427
lymphocytes C 140 427
follow C 141 427
- C 142 427
ing C 143 427
marked C 144 427
erythropoietic C 145 427
stimulation C 146 427
appears C 147 427
to C 148 427
favor C 149 427
a C 150 427
monophyletic C 151 427
theory C 152 427
of C 153 427
hemopoiesis C 154 427
; C 155 427
a C 156 427
heavy C 157 427
demand C 158 427
for C 159 427
stem C 160 427
cells C 161 427
to C 162 427
differentiate C 163 427
into C 164 427
the C 165 427
erythron C 166 427
may C 167 427
temporarily C 168 427
restrict C 169 427
the C 170 427
number C 171 427
entering C 172 427
the C 173 427
leukon C 174 427
. C 175 427
the C 177 427
hypoxic C 178 427
animals C 179 427
showed C 180 427
a C 181 427
considerable C 182 427
loss C 183 427
of C 184 427
body C 185 427
weight C 186 427
and C 187 427
the C 188 427
notable C 189 427
reduction C 190 427
of C 191 427
marrow C 192 427
lymphocytes C 193 427
in C 194 427
the C 195 427
later C 196 427
stages C 197 427
of C 198 427
hypoxia C 199 427
may C 200 427
be C 201 427
specifically C 202 427
related C 203 427
to C 204 427
a C 205 427
generalized C 206 427
atrophy C 207 427
of C 208 427
lymphoid C 209 427
tissue C 210 427
. C 211 427
using C 213 427
h C 214 427
3 C 215 427
- C 216 427
thymi C 217 427
- C 218 427
dine C 219 427
there C 220 427
is C 221 427
evidence C 222 427
of C 223 427
active C 224 427
dna C 225 427
synthesis C 226 427
in C 227 427
guinea C 228 427
pig C 229 427
metamyelocytes C 230 427
. C 231 427
although C 233 427
dna C 234 427
- C 235 427
synthesis C 236 427
was C 237 427
found C 238 427
in C 239 427
metamyelocytes C 240 427
of C 241 427
normal C 242 427
marrow C 243 427
, C 244 427
after C 245 427
hemorrhage C 246 427
these C 247 427
cells C 248 427
form C 249 427
a C 250 427
much C 251 427
larger C 252 427
proportion C 253 427
of C 254 427
the C 255 427
total C 256 427
synthesizing C 257 427
cells C 258 427
in C 259 427
the C 260 427
granulocyte C 261 427
compartment C 262 427
and C 263 427
also C 264 427
the C 265 427
ratio C 266 427
of C 267 427
labeled C 268 427
metamyelocytes C 269 427
to C 270 427
myelocytes C 271 427
is C 272 427
considerably C 273 427
increased C 274 427
. C 275 427
microspectrophotometric C 277 427
measurements C 278 427
of C 279 427
the C 280 427
feulgen C 281 427
dna C 282 427
- C 283 427
content C 284 427
of C 285 427
metamyelo C 286 427
- C 287 427
cytes C 288 427
after C 289 427
hemorrhage C 290 427
show C 291 427
that C 292 427
there C 293 427
are C 294 427
2 C 295 427
populations C 296 427
of C 297 427
these C 298 427
cells C 299 427
. C 300 427
one C 302 427
group C 303 427
has C 304 427
values C 305 427
typical C 306 427
of C 307 427
resting C 308 427
or C 309 427
nonsynthesizing C 310 427
cells C 311 427
but C 312 427
a C 313 427
2 C 314 427
nd C 315 427
group C 316 427
shows C 317 427
a C 318 427
complete C 319 427
range C 320 427
of C 321 427
dna C 322 427
- C 323 427
values C 324 427
up C 325 427
to C 326 427
levels C 327 427
characteristic C 328 427
of C 329 427
those C 330 427
found C 331 427
in C 332 427
dividing C 333 427
cells C 334 427
. C 335 427
certain C 337 427
small C 338 427
mononuclear C 339 427
cells C 340 427
with C 341 427
minimal C 342 427
but C 343 427
deeply C 344 427
basophilic C 345 427
cytoplasm C 346 427
are C 347 427
a C 348 427
dis C 349 427
- C 350 427
tinctive C 351 427
group C 352 427
of C 353 427
dna C 354 427
- C 355 427
synthesizing C 356 427
cells C 357 427
in C 358 427
marrow C 359 427
af C 360 427
- C 361 427
ter C 362 427
hemorrhage C 363 427
. C 364 427
morphologically C 366 427
, C 367 427
there C 368 427
appears C 369 427
to C 370 427
be C 371 427
a C 372 427
complete C 373 427
sequence C 374 427
between C 375 427
these C 376 427
cells C 377 427
and C 378 427
procrythro C 379 427
- C 380 427
blasts C 381 427
. C 382 427
3831 C 1 428
. C 2 428
relative C 4 428
ability C 5 428
of C 6 428
parental C 7 428
marrow C 8 428
to C 9 428
repopulate C 10 428
lethal C 11 428
- C 12 428
ly C 13 428
irradiated C 14 428
f C 15 428
1 C 16 428
hybrids C 17 428
lethally C 18 428
irradiate C 19 428
( C 20 428
c C 21 428
57 C 22 428
bl C 23 428
x C 24 428
101 C 25 428
) C 26 428
f C 27 428
1 C 28 428
mice C 29 428
injected C 30 428
with C 31 428
a C 32 428
mixture C 33 428
of C 34 428
10 C 35 428
million C 36 428
c C 37 428
57 C 38 428
bl C 39 428
and C 40 428
10 C 41 428
million C 42 428
101 C 43 428
bone C 44 428
- C 45 428
marrow C 46 428
cells C 47 428
were C 48 428
repopulated C 49 428
only C 50 428
by C 51 428
the C 52 428
101 C 53 428
bone C 54 428
- C 55 428
marrow C 56 428
cells C 57 428
. C 58 428
experiments C 60 428
with C 61 428
other C 62 428
cell C 63 428
mixtures C 64 428
indicated C 65 428
that C 66 428
the C 67 428
101 C 68 428
marrow C 69 428
was C 70 428
relatively C 71 428
nine C 72 428
times C 73 428
as C 74 428
efficient C 75 428
as C 76 428
c C 77 428
57 C 78 428
bl C 79 428
marrow C 80 428
in C 81 428
repopulating C 82 428
lethally C 83 428
irradiated C 84 428
( C 85 428
c C 86 428
57 C 87 428
bl C 88 428
x C 89 428
101 C 90 428
) C 91 428
f C 92 428
1 C 93 428
mice C 94 428
. C 95 428
results C 97 428
from C 98 428
additional C 99 428
strain C 100 428
combina C 101 428
- C 102 428
tions C 103 428
suggested C 104 428
that C 105 428
the C 106 428
behavior C 107 428
of C 108 428
the C 109 428
donor C 110 428
marrows C 111 428
was C 112 428
not C 113 428
determined C 114 428
solely C 115 428
by C 116 428
h C 117 428
- C 118 428
2 C 119 428
factors C 120 428
. C 121 428
c C 123 428
57 C 124 428
bl C 125 428
marrow C 126 428
, C 127 428
which C 128 428
frequently C 129 428
regresses C 130 428
in C 131 428
irradiated C 132 428
f C 133 428
1 C 134 428
mice C 135 428
, C 136 428
has C 137 428
shown C 138 428
to C 139 428
be C 140 428
relatively C 141 428
less C 142 428
capable C 143 428
of C 144 428
repopulating C 145 428
the C 146 428
recipient C 147 428
than C 148 428
regularly C 149 428
retained C 150 428
parental C 151 428
marrow C 152 428
. C 153 428
the C 155 428
differences C 156 428
in C 157 428
the C 158 428
relative C 159 428
abilities C 160 428
of C 161 428
parental C 162 428
mar C 163 428
- C 164 428
rows C 165 428
to C 166 428
repopulate C 167 428
f C 168 428
1 C 169 428
mice C 170 428
cannot C 171 428
as C 172 428
yet C 173 428
be C 174 428
fully C 175 428
explained C 176 428
. C 177 428
they C 179 428
might C 180 428
be C 181 428
corre C 182 428
- C 183 428
lated C 184 428
with C 185 428
physiological C 186 428
differences C 187 428
between C 188 428
the C 189 428
parental C 190 428
marrows C 191 428
or C 192 428
with C 193 428
a C 194 428
micro C 195 428
- C 196 428
environmental C 197 428
advantage C 198 428
of C 199 428
one C 200 428
hematopoietic C 201 428
cell C 202 428
type C 203 428
over C 204 428
another C 205 428
in C 206 428
the C 207 428
irradiated C 208 428
recipient C 209 428
. C 210 428
immunological C 212 428
and C 213 428
physiological C 214 428
factors C 215 428
that C 216 428
might C 217 428
favor C 218 428
this C 219 428
selective C 220 428
growth C 221 428
are C 222 428
discussed C 223 428
. C 224 428
3832 C 1 429
. C 2 429
pluripotent C 4 429
stem C 5 429
cell C 6 429
function C 7 429
of C 8 429
the C 9 429
mouse C 10 429
marrow C 11 429
' C 12 429
lymphocyte C 13 429
' C 14 429
bone C 15 429
marrow C 16 429
from C 17 429
normal C 18 429
and C 19 429
polycythemic C 20 429
mice C 21 429
was C 22 429
filtered C 23 429
through C 24 429
glass C 25 429
wool C 26 429
columns C 27 429
to C 28 429
remove C 29 429
cells C 30 429
other C 31 429
than C 32 429
' C 33 429
lymphocytes C 34 429
' C 35 429
. C 36 429
for C 38 429
a C 39 429
given C 40 429
number C 41 429
of C 42 429
nucleated C 43 429
cells C 44 429
, C 45 429
filtered C 46 429
marrow C 47 429
was C 48 429
more C 49 429
efficient C 50 429
than C 51 429
the C 52 429
original C 53 429
marrow C 54 429
in C 55 429
repopulating C 56 429
the C 57 429
spleen C 58 429
of C 59 429
an C 60 429
isogenic C 61 429
recipient C 62 429
previously C 63 429
exposed C 64 429
to C 65 429
lethal C 66 429
irradiation C 67 429
. C 68 429
the C 70 429
proliferative C 71 429
capacity C 72 429
of C 73 429
both C 74 429
the C 75 429
filtered C 76 429
and C 77 429
unfiltered C 78 429
marrow C 79 429
suspensions C 80 429
ap C 81 429
- C 82 429
peared C 83 429
to C 84 429
be C 85 429
a C 86 429
constant C 87 429
function C 88 429
of C 89 429
the C 90 429
number C 91 429
of C 92 429
small C 93 429
and C 94 429
medium C 95 429
' C 96 429
lymphocytes C 97 429
' C 98 429
present C 99 429
and C 100 429
not C 101 429
of C 102 429
any C 103 429
other C 104 429
cell C 105 429
type C 106 429
. C 107 429
2045 C 1 430
. C 2 430
the C 4 430
effect C 5 430
of C 6 430
unilateral C 7 430
limb C 8 430
shield C 9 430
- C 10 430
ing C 11 430
on C 12 430
the C 13 430
haemopoietic C 14 430
response C 15 430
of C 16 430
the C 17 430
guinea C 18 430
- C 19 430
pig C 20 430
to C 21 430
gamma C 22 430
irradiation C 23 430
guineapigs C 24 430
were C 25 430
exposed C 26 430
to C 27 430
150 C 28 430
r C 29 430
- C 30 430
irradiation C 31 430
whilst C 32 430
approx C 33 430
. C 34 430
1 C 36 430
/ C 37 430
5 C 38 430
of C 39 430
the C 40 430
total C 41 430
bone C 42 430
marrow C 43 430
was C 44 430
protect C 45 430
- C 46 430
ed C 47 430
by C 48 430
shielding C 49 430
2 C 50 430
limbs C 51 430
. C 52 430
quantitative C 54 430
cell C 55 430
counts C 56 430
of C 57 430
both C 58 430
the C 59 430
shielded C 60 430
and C 61 430
irradiated C 62 430
marrow C 63 430
were C 64 430
combined C 65 430
with C 66 430
observations C 67 430
on C 68 430
the C 69 430
thymus C 70 430
, C 71 430
spleen C 72 430
and C 73 430
blood C 74 430
during C 75 430
the C 76 430
recovery C 77 430
period C 78 430
, C 79 430
and C 80 430
compared C 81 430
with C 82 430
the C 83 430
effects C 84 430
of C 85 430
whole C 86 430
- C 87 430
body C 88 430
irradiation C 89 430
. C 90 430
following C 92 430
whole C 93 430
- C 94 430
body C 95 430
irradiation C 96 430
( C 97 430
150 C 98 430
r C 99 430
) C 100 430
the C 101 430
thymus C 102 430
shows C 103 430
a C 104 430
delayed C 105 430
secondary C 106 430
cellular C 107 430
depletion C 108 430
coinciding C 109 430
with C 110 430
a C 111 430
marked C 112 430
splenic C 113 430
hyperplasia C 114 430
. C 115 430
both C 117 430
phenomena C 118 430
were C 119 430
eliminated C 120 430
by C 121 430
limb C 122 430
shielding C 123 430
. C 124 430
the C 126 430
lymphocytes C 127 430
in C 128 430
the C 129 430
irradiated C 130 430
marrow C 131 430
of C 132 430
partially C 133 430
shiel C 134 430
- C 135 430
ded C 136 430
animals C 137 430
continued C 138 430
to C 139 430
show C 140 430
both C 141 430
the C 142 430
overshoot C 143 430
and C 144 430
the C 145 430
secondary C 146 430
fall C 147 430
in C 148 430
numbers C 149 430
which C 150 430
characterize C 151 430
recovery C 152 430
from C 153 430
whole C 154 430
- C 155 430
body C 156 430
irradiation C 157 430
( C 158 430
150 C 159 430
r C 160 430
) C 161 430
. C 162 430
after C 164 430
an C 165 430
initial C 166 430
fall C 167 430
in C 168 430
numbers C 169 430
of C 170 430
erythroid C 171 430
and C 172 430
granulocytic C 173 430
precursors C 174 430
, C 175 430
the C 176 430
shielded C 177 430
marrow C 178 430
showed C 179 430
a C 180 430
temporary C 181 430
increase C 182 430
in C 183 430
granulocytopoiesis C 184 430
coinciding C 185 430
with C 186 430
an C 187 430
abortive C 188 430
phase C 189 430
of C 190 430
granulocytopoiesis C 191 430
in C 192 430
the C 193 430
irradiated C 194 430
marrow C 195 430
. C 196 430
there C 198 430
was C 199 430
no C 200 430
evidence C 201 430
of C 202 430
any C 203 430
effective C 204 430
colonization C 205 430
of C 206 430
irradiated C 207 430
marrow C 208 430
by C 209 430
cells C 210 430
from C 211 430
the C 212 430
shielded C 213 430
marrow C 214 430
. C 215 430
the C 217 430
signi C 218 430
- C 219 430
ficance C 220 430
of C 221 430
these C 222 430
findings C 223 430
is C 224 430
discussed C 225 430
. C 226 430
4311 C 1 431
. C 2 431
studies C 4 431
on C 5 431
intravenous C 6 431
transfusion C 7 431
of C 8 431
thymus C 9 431
cells C 10 431
and C 11 431
lymphnode C 12 431
cells C 13 431
. C 14 431
iii C 16 431
. C 17 431
influence C 19 431
of C 20 431
transfused C 21 431
thymus C 22 431
cells C 23 431
and C 24 431
lymphnode C 25 431
cells C 26 431
on C 27 431
the C 28 431
bone C 29 431
marrow C 30 431
in C 31 431
rabbits C 32 431
transfused C 33 431
with C 34 431
thymus C 35 431
cells C 36 431
and C 37 431
lymphnode C 38 431
cells C 39 431
the C 40 431
peripheral C 41 431
blood C 42 431
and C 43 431
bone C 44 431
marrow C 45 431
were C 46 431
studied C 47 431
. C 48 431
the C 50 431
transfusion C 51 431
of C 52 431
thymus C 53 431
cells C 54 431
caused C 55 431
a C 56 431
peripheral C 57 431
lymphocytosis C 58 431
and C 59 431
a C 60 431
diminution C 61 431
of C 62 431
lymphoid C 63 431
cells C 64 431
in C 65 431
the C 66 431
bone C 67 431
marrow C 68 431
of C 69 431
both C 70 431
young C 71 431
and C 72 431
adult C 73 431
rabbits C 74 431
. C 75 431
the C 77 431
transfusion C 78 431
of C 79 431
lymphnode C 80 431
cells C 81 431
resulted C 82 431
in C 83 431
a C 84 431
peripheral C 85 431
lympho C 86 431
- C 87 431
penia C 88 431
, C 89 431
and C 90 431
an C 91 431
initial C 92 431
increase C 93 431
and C 94 431
a C 95 431
subsequent C 96 431
diminution C 97 431
of C 98 431
lymphoid C 99 431
cells C 100 431
in C 101 431
the C 102 431
bone C 103 431
marrow C 104 431
. C 105 431
it C 107 431
is C 108 431
suggested C 109 431
that C 110 431
lymphoid C 111 431
cells C 112 431
in C 113 431
the C 114 431
bone C 115 431
marrow C 116 431
may C 117 431
be C 118 431
lympho C 119 431
- C 120 431
cytes C 121 431
which C 122 431
are C 123 431
stored C 124 431
or C 125 431
discharged C 126 431
according C 127 431
to C 128 431
a C 129 431
variety C 130 431
of C 131 431
conditions C 132 431
. C 133 431
further C 135 431
- C 136 431
more C 137 431
, C 138 431
thymus C 139 431
cells C 140 431
are C 141 431
thought C 142 431
to C 143 431
mobilize C 144 431
lymphocytes C 145 431
from C 146 431
the C 147 431
bone C 148 431
marrow C 149 431
to C 150 431
the C 151 431
peripheral C 152 431
blood C 153 431
. C 154 431
5041 C 1 432
. C 2 432
studies C 4 432
on C 5 432
hypoxia C 6 432
. C 7 432
iii C 9 432
. C 10 432
the C 12 432
differential C 13 432
response C 14 432
of C 15 432
the C 16 432
bone C 17 432
marrow C 18 432
to C 19 432
primary C 20 432
and C 21 432
secondary C 22 432
hypoxia C 23 432
twenty C 24 432
- C 25 432
five C 26 432
adult C 27 432
male C 28 432
guinea C 29 432
pigs C 30 432
were C 31 432
placed C 32 432
in C 33 432
a C 34 432
decompression C 35 432
chamber C 36 432
, C 37 432
at C 38 432
a C 39 432
simulated C 40 432
altitude C 41 432
of C 42 432
14 C 43 432
, C 44 432
000 C 45 432
feet C 46 432
for C 47 432
5 C 48 432
days C 49 432
, C 50 432
then C 51 432
kept C 52 432
in C 53 432
ordinary C 54 432
air C 55 432
for C 56 432
5 C 57 432
days C 58 432
, C 59 432
and C 60 432
finally C 61 432
returned C 62 432
to C 63 432
the C 64 432
decompression C 65 432
chamber C 66 432
to C 67 432
be C 68 432
subjected C 69 432
to C 70 432
hypoxia C 71 432
a C 72 432
second C 73 432
time C 74 432
, C 75 432
for C 76 432
periods C 77 432
ranging C 78 432
from C 79 432
1 C 80 432
to C 81 432
5 C 82 432
days C 83 432
. C 84 432
during C 86 432
this C 87 432
period C 88 432
of C 89 432
secondary C 90 432
hypoxia C 91 432
quantitative C 92 432
studies C 93 432
were C 94 432
made C 95 432
of C 96 432
the C 97 432
changes C 98 432
in C 99 432
the C 100 432
blood C 101 432
and C 102 432
bone C 103 432
marrow C 104 432
. C 105 432
in C 107 432
secondary C 108 432
as C 109 432
in C 110 432
primary C 111 432
hypoxia C 112 432
there C 113 432
is C 114 432
a C 115 432
significant C 116 432
increase C 117 432
in C 118 432
the C 119 432
nucleated C 120 432
red C 121 432
cells C 122 432
of C 123 432
the C 124 432
marrow C 125 432
. C 126 432
in C 128 432
secondary C 129 432
hypoxia C 130 432
, C 131 432
however C 132 432
, C 133 432
there C 134 432
is C 135 432
a C 136 432
very C 137 432
marked C 138 432
increase C 139 432
in C 140 432
the C 141 432
marrow C 142 432
lymphocytes C 143 432
, C 144 432
whereas C 145 432
in C 146 432
primary C 147 432
hypoxia C 148 432
the C 149 432
lymphocytes C 150 432
fall C 151 432
. C 152 432
the C 154 432
marrow C 155 432
reticulocytes C 156 432
remain C 157 432
at C 158 432
a C 159 432
fairly C 160 432
constant C 161 432
level C 162 432
despite C 163 432
marked C 164 432
fluctuations C 165 432
in C 166 432
erythropoiesis C 167 432
. C 168 432
1044 C 1 433
. C 2 433
an C 4 433
investigation C 5 433
of C 6 433
lymphocyte C 7 433
production C 8 433
in C 9 433
guinea C 10 433
- C 11 433
pig C 12 433
bone C 13 433
marrow C 14 433
evidence C 15 433
from C 16 433
a C 17 433
variety C 18 433
of C 19 433
experiments C 20 433
indicates C 21 433
that C 22 433
lymphocytes C 23 433
are C 24 433
produced C 25 433
in C 26 433
guinea C 27 433
- C 28 433
pig C 29 433
bone C 30 433
marrow C 31 433
. C 32 433
under C 34 433
certain C 35 433
conditions C 36 433
the C 37 433
numbers C 38 433
produced C 39 433
appear C 40 433
to C 41 433
be C 42 433
considerable C 43 433
. C 44 433
during C 46 433
recovery C 47 433
from C 48 433
irradiation C 49 433
there C 50 433
are C 51 433
numerous C 52 433
telophases C 53 433
in C 54 433
marrow C 55 433
smears C 56 433
which C 57 433
appear C 58 433
to C 59 433
be C 60 433
forming C 61 433
small C 62 433
lymphocytes C 63 433
. C 64 433
moreover C 66 433
, C 67 433
many C 68 433
lymphocytes C 69 433
are C 70 433
still C 71 433
found C 72 433
in C 73 433
shielded C 74 433
bone C 75 433
marrow C 76 433
after C 77 433
the C 78 433
rest C 79 433
of C 80 433
the C 81 433
body C 82 433
, C 83 433
in C 84 433
- C 85 433
cluding C 86 433
the C 87 433
conventional C 88 433
lymphoid C 89 433
tissues C 90 433
, C 91 433
has C 92 433
received C 93 433
lethal C 94 433
or C 95 433
supra C 96 433
- C 97 433
lethal C 98 433
irra C 99 433
- C 100 433
diation C 101 433
. C 102 433
almost C 104 433
50 C 105 433
% C 106 433
of C 107 433
these C 108 433
cells C 109 433
are C 110 433
formed C 111 433
after C 112 433
the C 113 433
irradiation C 114 433
. C 115 433
finally C 117 433
, C 118 433
when C 119 433
bone C 120 433
marrow C 121 433
is C 122 433
cultured C 123 433
in C 124 433
the C 125 433
peritoneal C 126 433
cavity C 127 433
of C 128 433
a C 129 433
host C 130 433
whose C 131 433
own C 132 433
lymphocyte C 133 433
production C 134 433
has C 135 433
been C 136 433
suppressed C 137 433
by C 138 433
irradiation C 139 433
, C 140 433
small C 141 433
percentages C 142 433
of C 143 433
newly C 144 433
- C 145 433
formed C 146 433
small C 147 433
lymphocytes C 148 433
are C 149 433
found C 150 433
in C 151 433
this C 152 433
marrow C 153 433
. C 154 433
103 C 1 434
. C 2 434
repopulation C 4 434
of C 5 434
bone C 6 434
marrow C 7 434
in C 8 434
mice C 9 434
number C 10 434
and C 11 434
type C 12 434
of C 13 434
cells C 14 434
required C 15 434
for C 16 434
post C 17 434
- C 18 434
x C 19 434
- C 20 434
irradiation C 21 434
protection C 22 434
fractionation C 23 434
of C 24 434
cells C 25 434
from C 26 434
mouse C 27 434
bone C 28 434
marrow C 29 434
and C 30 434
autologous C 31 434
mouse C 32 434
spleen C 33 434
indi C 34 434
- C 35 434
cates C 36 434
that C 37 434
the C 38 434
cell C 39 434
responsible C 40 434
for C 41 434
bone C 42 434
marrow C 43 434
repopulation C 44 434
and C 45 434
x C 46 434
- C 47 434
irradiation C 48 434
protection C 49 434
resembles C 50 434
the C 51 434
small C 52 434
lymphocyte C 53 434
. C 54 434
experiments C 56 434
with C 57 434
injection C 58 434
of C 59 434
different C 60 434
numbers C 61 434
of C 62 434
bone C 63 434
marrow C 64 434
and C 65 434
spleen C 66 434
cells C 67 434
and C 68 434
observations C 69 434
on C 70 434
survival C 71 434
obtained C 72 434
by C 73 434
fractional C 74 434
irradiation C 75 434
of C 76 434
the C 77 434
entire C 78 434
body C 79 434
and C 80 434
of C 81 434
extirpation C 82 434
of C 83 434
the C 84 434
shielded C 85 434
spleen C 86 434
after C 87 434
irradiation C 88 434
indicate C 89 434
that C 90 434
approximately C 91 434
3 C 92 434
x C 93 434
10 C 94 434
4 C 95 434
cells C 96 434
of C 97 434
this C 98 434
type C 99 434
are C 100 434
required C 101 434
to C 102 434
provide C 103 434
50 C 104 434
% C 105 434
survival C 106 434
, C 107 434
and C 108 434
that C 109 434
approximately C 110 434
this C 111 434
number C 112 434
migrates C 113 434
from C 114 434
the C 115 434
shielded C 116 434
extremity C 117 434
or C 118 434
spleen C 119 434
of C 120 434
a C 121 434
mouse C 122 434
per C 123 434
hour C 124 434
( C 125 434
slightly C 126 434
faster C 127 434
for C 128 434
spleen C 129 434
and C 130 434
slower C 131 434
for C 132 434
bone C 133 434
marrow C 134 434
) C 135 434
. C 136 434
104 C 1 435
. C 2 435
hyperbasophilic C 4 435
cells C 5 435
as C 6 435
an C 7 435
indication C 8 435
of C 9 435
proliferation C 10 435
of C 11 435
bone C 12 435
marrow C 13 435
transplanted C 14 435
to C 15 435
irradiated C 16 435
dogs C 17 435
a C 18 435
study C 19 435
was C 20 435
made C 21 435
of C 22 435
hyperbasophilic C 23 435
cells C 24 435
which C 25 435
appeared C 26 435
following C 27 435
transplantation C 28 435
of C 29 435
bone C 30 435
marrow C 31 435
to C 32 435
20 C 33 435
irradiated C 34 435
mongrel C 35 435
dogs C 36 435
of C 37 435
both C 38 435
sexes C 39 435
. C 40 435
in C 42 435
the C 43 435
main C 44 435
series C 45 435
of C 46 435
experiments C 47 435
the C 48 435
animals C 49 435
were C 50 435
irradiated C 51 435
with C 52 435
a C 53 435
dosage C 54 435
of C 55 435
600 C 56 435
r C 57 435
. C 58 435
, C 60 435
using C 61 435
a C 62 435
four C 63 435
- C 64 435
tube C 65 435
rum C 66 435
- C 67 435
3 C 68 435
x C 69 435
- C 70 435
ray C 71 435
machine C 72 435
voltage C 73 435
200 C 74 435
kv C 75 435
, C 76 435
current C 77 435
10 C 78 435
ma C 79 435
, C 80 435
filters C 81 435
0 C 82 435
. C 83 435
. C 84 435
cu C 85 435
mm C 86 435
+ C 87 435
1 C 88 435
. C 89 435
. C 90 435
mm C 91 435
. C 92 435
. C 93 435
. C 93 435
, C 94 435
target C 95 435
distance C 96 435
60 C 97 435
cm C 98 435
. C 99 435
, C 101 435
rate C 102 435
18 C 103 435
- C 104 435
22 C 105 435
r C 106 435
. C 107 435
/ C 109 435
min C 110 435
. C 111 435
at C 113 435
1 C 114 435
- C 115 435
2 C 116 435
days C 117 435
after C 118 435
irradiation C 119 435
, C 120 435
a C 121 435
suspension C 122 435
of C 123 435
bone C 124 435
marrow C 125 435
cells C 126 435
in C 127 435
a C 128 435
dosage C 129 435
of C 130 435
10 C 131 435
9 C 132 435
- C 133 435
5 C 134 435
x C 135 435
10 C 136 435
9 C 137 435
nuclear C 138 435
cells C 139 435
was C 140 435
administered C 141 435
i C 142 435
. C 143 435
. C 144 435
. C 145 435
the C 147 435
marrow C 148 435
was C 149 435
obtained C 150 435
by C 151 435
aspiration C 152 435
from C 153 435
various C 154 435
skeletal C 155 435
bones C 156 435
or C 157 435
by C 158 435
compression C 159 435
from C 160 435
the C 161 435
sternum C 162 435
, C 163 435
ribs C 164 435
and C 165 435
other C 166 435
bones C 167 435
. C 168 435
a C 170 435
study C 171 435
was C 172 435
made C 173 435
of C 174 435
the C 175 435
morphological C 176 435
composition C 177 435
of C 178 435
the C 179 435
blood C 180 435
and C 181 435
bone C 182 435
marrow C 183 435
before C 184 435
irradiation C 185 435
and C 186 435
at C 187 435
1 C 188 435
- C 189 435
5 C 190 435
, C 191 435
10 C 192 435
, C 193 435
15 C 194 435
, C 195 435
20 C 196 435
, C 197 435
25 C 198 435
and C 199 435
30 C 200 435
days C 201 435
after C 202 435
irradiation C 203 435
and C 204 435
transfusion C 205 435
of C 206 435
bone C 207 435
mar C 208 435
- C 209 435
row C 210 435
, C 211 435
and C 212 435
thereafter C 213 435
at C 214 435
10 C 215 435
- C 216 435
15 C 217 435
days C 218 435
intervals C 219 435
. C 220 435
smears C 222 435
of C 223 435
blood C 224 435
and C 225 435
marrow C 226 435
were C 227 435
stained C 228 435
with C 229 435
azure C 230 435
- C 231 435
ii C 232 435
- C 233 435
eosin C 234 435
. C 235 435
it C 237 435
was C 238 435
found C 239 435
that C 240 435
distinctive C 241 435
cells C 242 435
with C 243 435
basophilic C 244 435
proto C 245 435
- C 246 435
plasm C 247 435
and C 248 435
frequent C 249 435
incidence C 250 435
of C 251 435
an C 252 435
immature C 253 435
nucleus C 254 435
were C 255 435
present C 256 435
in C 257 435
the C 258 435
blood C 259 435
of C 260 435
dogs C 261 435
following C 262 435
irradiation C 263 435
with C 264 435
600 C 265 435
r C 266 435
. C 267 435
and C 269 435
transplantation C 270 435
of C 271 435
bone C 272 435
marrow C 273 435
. C 274 435
hyper C 276 435
- C 277 435
basophilic C 278 435
cells C 279 435
appeared C 280 435
in C 281 435
the C 282 435
blood C 283 435
at C 284 435
2 C 285 435
- C 286 435
4 C 287 435
days C 288 435
after C 289 435
transplantation C 290 435
and C 291 435
attained C 292 435
a C 293 435
maximum C 294 435
14 C 295 435
- C 296 435
21 C 297 435
days C 298 435
later C 299 435
; C 300 435
thereafter C 301 435
their C 302 435
number C 303 435
diminished C 304 435
rapidly C 305 435
. C 306 435
the C 308 435
trend C 309 435
of C 310 435
number C 311 435
of C 312 435
hyperbasophilic C 313 435
cells C 314 435
coincided C 315 435
with C 316 435
that C 317 435
of C 318 435
other C 319 435
donor C 320 435
elements C 321 435
( C 322 435
leukocytes C 323 435
, C 324 435
erythrocytes C 325 435
) C 326 435
. C 327 435
hyperbasophilic C 329 435
cells C 330 435
were C 331 435
not C 332 435
found C 333 435
during C 334 435
acute C 335 435
radia C 336 435
- C 337 435
tion C 338 435
sickness C 339 435
in C 340 435
dogs C 341 435
which C 342 435
were C 343 435
not C 344 435
given C 345 435
injections C 346 435
of C 347 435
bone C 348 435
marrow C 349 435
. C 350 435
they C 352 435
were C 353 435
found C 354 435
3 C 355 435
mth C 356 435
. C 357 435
after C 359 435
transplantation C 360 435
of C 361 435
bone C 362 435
marrow C 363 435
to C 364 435
nonirradiated C 365 435
puppies C 366 435
at C 367 435
2 C 368 435
- C 369 435
3 C 370 435
days C 371 435
of C 372 435
age C 373 435
. C 374 435
when C 376 435
the C 377 435
irradiation C 378 435
dosage C 379 435
was C 380 435
increased C 381 435
to C 382 435
800 C 383 435
- C 384 435
1 C 385 435
, C 386 435
000 C 387 435
r C 388 435
. C 389 435
, C 391 435
the C 392 435
number C 393 435
of C 394 435
hyperbasophilic C 395 435
cells C 396 435
increased C 397 435
and C 398 435
attained C 399 435
a C 400 435
peak C 401 435
sooner C 402 435
than C 403 435
after C 404 435
the C 405 435
600 C 406 435
r C 407 435
. C 408 435
dosage C 410 435
. C 411 435
such C 413 435
cells C 414 435
were C 415 435
formed C 416 435
from C 417 435
the C 418 435
donor C 419 435
cells C 420 435
. C 421 435
172 C 1 436
. C 2 436
autoradiographic C 4 436
studies C 5 436
of C 6 436
lymphoid C 7 436
cells C 8 436
in C 9 436
blood C 10 436
and C 11 436
bone C 12 436
marrow C 13 436
of C 14 436
nor C 15 436
- C 16 436
mal C 17 436
and C 18 436
irradiated C 19 436
dogs C 20 436
the C 21 436
migration C 22 436
, C 23 436
fate C 24 436
, C 25 436
and C 26 436
turnover C 27 436
of C 28 436
lymphoid C 29 436
cells C 30 436
in C 31 436
blood C 32 436
and C 33 436
bone C 34 436
marrow C 35 436
of C 36 436
4 C 37 436
irradiated C 38 436
and C 39 436
4 C 40 436
non C 41 436
- C 42 436
irradiated C 43 436
dogs C 44 436
were C 45 436
studied C 46 436
by C 47 436
serial C 48 436
autoradiography C 49 436
with C 50 436
clamping C 51 436
of C 52 436
the C 53 436
hind C 54 436
legs C 55 436
during C 56 436
the C 57 436
plasma C 58 436
clear C 59 436
- C 60 436
ance C 61 436
time C 62 436
of C 63 436
h C 64 436
3 C 65 436
- C 66 436
thymidine C 67 436
injected C 68 436
into C 69 436
an C 70 436
anterior C 71 436
vein C 72 436
. C 73 436
in C 75 436
irradiated C 76 436
dogs C 77 436
, C 78 436
the C 79 436
h C 80 436
3 C 81 436
- C 82 436
thymidine C 83 436
injection C 84 436
pro C 85 436
- C 86 436
cedure C 87 436
was C 88 436
carried C 89 436
out C 90 436
during C 91 436
the C 92 436
early C 93 436
recovery C 94 436
phase C 95 436
after C 96 436
250 C 97 436
r C 98 436
of C 99 436
whole C 100 436
- C 101 436
body C 102 436
x C 103 436
- C 104 436
irradiation C 105 436
. C 106 436
the C 108 436
results C 109 436
on C 110 436
2 C 111 436
irradiated C 112 436
and C 113 436
2 C 114 436
normal C 115 436
dogs C 116 436
were C 117 436
described C 118 436
in C 119 436
de C 120 436
- C 121 436
tail C 122 436
. C 123 436
migration C 125 436
of C 126 436
lymphoid C 127 436
cells C 128 436
from C 129 436
blood C 130 436
to C 131 436
marrow C 132 436
parenchyma C 133 436
was C 134 436
confirmed C 135 436
in C 136 436
the C 137 436
irradiated C 138 436
dogs C 139 436
. C 140 436
con C 142 436
- C 143 436
clusive C 144 436
evidence C 145 436
of C 146 436
transformation C 147 436
of C 148 436
these C 149 436
cells C 150 436
into C 151 436
hemopoietic C 152 436
precursors C 153 436
was C 154 436
not C 155 436
found C 156 436
. C 157 436
the C 159 436
relative C 160 436
number C 161 436
of C 162 436
large C 163 436
lymphoid C 164 436
cells C 165 436
, C 166 436
the C 167 436
labeling C 168 436
index C 169 436
of C 170 436
the C 171 436
whole C 172 436
population C 173 436
of C 174 436
lymphoid C 175 436
cells C 176 436
, C 177 436
and C 178 436
that C 179 436
of C 180 436
small C 181 436
lymphoid C 182 436
cells C 183 436
were C 184 436
increased C 185 436
in C 186 436
irradiated C 187 436
marrow C 188 436
; C 189 436
few C 190 436
initially C 191 436
labeled C 192 436
small C 193 436
lymphoid C 194 436
cells C 195 436
could C 196 436
also C 197 436
be C 198 436
observed C 199 436
. C 200 436
these C 202 436
data C 203 436
indicate C 204 436
that C 205 436
the C 206 436
pattern C 207 436
of C 208 436
pro C 209 436
- C 210 436
liferation C 211 436
of C 212 436
lymphoid C 213 436
cells C 214 436
is C 215 436
changed C 216 436
in C 217 436
irradiated C 218 436
re C 219 436
- C 220 436
generating C 221 436
bone C 222 436
marrow C 223 436
. C 224 436
175 C 1 437
. C 2 437
lysozyme C 4 437
in C 5 437
bone C 6 437
marrow C 7 437
and C 8 437
periph C 9 437
- C 10 437
eral C 11 437
blood C 12 437
cells C 13 437
by C 14 437
means C 15 437
of C 16 437
an C 17 437
indirect C 18 437
histochemical C 19 437
technique C 20 437
, C 21 437
the C 22 437
intracellular C 23 437
lysozyme C 24 437
of C 25 437
the C 26 437
formed C 27 437
elements C 28 437
of C 29 437
the C 30 437
peripheral C 31 437
blood C 32 437
and C 33 437
bone C 34 437
marrow C 35 437
was C 36 437
estimated C 37 437
. C 38 437
evi C 40 437
- C 41 437
dence C 42 437
is C 43 437
presented C 44 437
that C 45 437
monocytes C 46 437
, C 47 437
as C 48 437
well C 49 437
as C 50 437
mature C 51 437
neutrophils C 52 437
and C 53 437
their C 54 437
precursors C 55 437
extending C 56 437
back C 57 437
to C 58 437
the C 59 437
progranulocyte C 60 437
, C 61 437
contain C 62 437
significant C 63 437
amounts C 64 437
of C 65 437
this C 66 437
en C 67 437
- C 68 437
zyme C 69 437
. C 70 437
a C 72 437
rare C 73 437
mature C 74 437
eosinophil C 75 437
demonstrated C 76 437
a C 77 437
trace C 78 437
of C 79 437
lysozyme C 80 437
activity C 81 437
. C 82 437
there C 84 437
was C 85 437
no C 86 437
evidence C 87 437
of C 88 437
lyso C 89 437
- C 90 437
zyme C 91 437
activity C 92 437
in C 93 437
basophils C 94 437
, C 95 437
erythrocytes C 96 437
, C 97 437
megakaryo C 98 437
- C 99 437
cytes C 100 437
, C 101 437
platelets C 102 437
, C 103 437
plasma C 104 437
cells C 105 437
, C 106 437
tissue C 107 437
mast C 108 437
cells C 109 437
or C 110 437
bone C 111 437
marrow C 112 437
reticuloendothelial C 113 437
cells C 114 437
. C 115 437
1770 C 1 438
. C 2 438
proliferative C 4 438
activity C 5 438
of C 6 438
the C 7 438
lymphatic C 8 438
tissues C 9 438
of C 10 438
rats C 11 438
as C 12 438
studied C 13 438
with C 14 438
tritium C 15 438
- C 16 438
labelled C 17 438
thymidine C 18 438
cytokinetic C 19 438
data C 20 438
are C 21 438
presented C 22 438
, C 23 438
employing C 24 438
quantitation C 25 438
of C 26 438
h C 27 438
3 C 28 438
dna C 29 438
in C 30 438
the C 31 438
lymphatic C 32 438
tissues C 33 438
of C 34 438
normal C 35 438
rats C 36 438
serially C 37 438
sacrificed C 38 438
after C 39 438
h C 40 438
3 C 41 438
tdr C 42 438
administration C 43 438
. C 44 438
a C 46 438
marked C 47 438
difference C 48 438
in C 49 438
the C 50 438
patterns C 51 438
of C 52 438
initial C 53 438
labeling C 54 438
and C 55 438
label C 56 438
loss C 57 438
was C 58 438
observed C 59 438
between C 60 438
the C 61 438
thymus C 62 438
and C 63 438
peripheral C 64 438
lymphatic C 65 438
tissue C 66 438
. C 67 438
the C 69 438
data C 70 438
are C 71 438
compatible C 72 438
with C 73 438
other C 74 438
indica C 75 438
- C 76 438
tions C 77 438
of C 78 438
rapid C 79 438
cell C 80 438
renewal C 81 438
in C 82 438
the C 83 438
thymus C 84 438
. C 85 438
there C 87 438
is C 88 438
suppression C 89 438
of C 90 438
initial C 91 438
uptake C 92 438
of C 93 438
h C 94 438
3 C 95 438
tdr C 96 438
into C 97 438
the C 98 438
dna C 99 438
of C 100 438
each C 101 438
large C 102 438
lymphocytic C 103 438
progenitor C 104 438
cell C 105 438
in C 106 438
the C 107 438
thymus C 108 438
, C 109 438
appa C 110 438
- C 111 438
rently C 112 438
because C 113 438
of C 114 438
a C 115 438
feedback C 116 438
of C 117 438
thymidine C 118 438
containing C 119 438
material C 120 438
from C 121 438
small C 122 438
lympho C 123 438
- C 124 438
cytes C 125 438
in C 126 438
the C 127 438
thymus C 128 438
. C 129 438
depletion C 131 438
of C 132 438
the C 133 438
thymus C 134 438
of C 135 438
small C 136 438
cells C 137 438
, C 138 438
as C 139 438
by C 140 438
operative C 141 438
stress C 142 438
or C 143 438
whole C 144 438
body C 145 438
x C 146 438
- C 147 438
ray C 148 438
, C 149 438
leads C 150 438
to C 151 438
a C 152 438
marked C 153 438
increase C 154 438
in C 155 438
the C 156 438
uptake C 157 438
of C 158 438
h C 159 438
3 C 160 438
tdr C 161 438
into C 162 438
the C 163 438
dna C 164 438
of C 165 438
large C 166 438
thymocytes C 167 438
. C 168 438
this C 170 438
finding C 171 438
, C 172 438
which C 173 438
is C 174 438
in C 175 438
agreement C 176 438
with C 177 438
the C 178 438
previous C 179 438
findings C 180 438
of C 181 438
sugino C 182 438
et C 183 438
al C 184 438
. C 185 438
suggesting C 187 438
transfer C 188 438
of C 189 438
thymine C 190 438
nucleotides C 191 438
from C 192 438
small C 193 438
thy C 194 438
- C 195 438
mus C 196 438
lymphocytes C 197 438
to C 198 438
precursor C 199 438
cells C 200 438
, C 201 438
may C 202 438
or C 203 438
may C 204 438
not C 205 438
be C 206 438
related C 207 438
to C 208 438
the C 209 438
apparent C 210 438
transfer C 211 438
of C 212 438
dna C 213 438
label C 214 438
between C 215 438
thymic C 216 438
cells C 217 438
. C 218 438
the C 220 438
evidence C 221 438
for C 222 438
the C 223 438
latter C 224 438
consists C 225 438
of C 226 438
the C 227 438
curvilinear C 228 438
dilution C 229 438
of C 230 438
the C 231 438
dna C 232 438
label C 233 438
in C 234 438
the C 235 438
thymus C 236 438
proliferating C 237 438
cell C 238 438
population C 239 438
and C 240 438
the C 241 438
relationship C 242 438
between C 243 438
the C 244 438
rate C 245 438
of C 246 438
dna C 247 438
label C 248 438
dilution C 249 438
in C 250 438
large C 251 438
cells C 252 438
and C 253 438
the C 254 438
dna C 255 438
in C 256 438
the C 257 438
small C 258 438
cells C 259 438
in C 260 438
the C 261 438
thymus C 262 438
. C 263 438
after C 265 438
the C 266 438
dna C 267 438
label C 268 438
in C 269 438
progenitor C 270 438
cells C 271 438
in C 272 438
the C 273 438
thymus C 274 438
and C 275 438
lymph C 276 438
nodes C 277 438
has C 278 438
entered C 279 438
the C 280 438
small C 281 438
cell C 282 438
population C 283 438
, C 284 438
the C 285 438
subsequent C 286 438
dilution C 287 438
of C 288 438
grains C 289 438
in C 290 438
these C 291 438
dividing C 292 438
cells C 293 438
follows C 294 438
the C 295 438
same C 296 438
slope C 297 438
as C 298 438
the C 299 438
loss C 300 438
of C 301 438
radio C 302 438
- C 303 438
activity C 304 438
from C 305 438
the C 306 438
entire C 307 438
lymph C 308 438
node C 309 438
. C 310 438
there C 312 438
is C 313 438
a C 314 438
long C 315 438
retention C 316 438
of C 317 438
some C 318 438
h C 319 438
3 C 320 438
dna C 321 438
label C 322 438
in C 323 438
the C 324 438
dividing C 325 438
lymph C 326 438
node C 327 438
cell C 328 438
population C 329 438
. C 330 438
this C 332 438
suggests C 333 438
that C 334 438
the C 335 438
loss C 336 438
of C 337 438
radioacti C 338 438
- C 339 438
vity C 340 438
from C 341 438
the C 342 438
dividing C 343 438
cells C 344 438
and C 345 438
from C 346 438
the C 347 438
small C 348 438
cell C 349 438
population C 350 438
as C 351 438
a C 352 438
whole C 353 438
occurs C 354 438
e C 355 438
- C 356 438
qually C 357 438
. C 358 438
this C 360 438
pattern C 361 438
prevails C 362 438
regardless C 363 438
of C 364 438
whether C 365 438
the C 366 438
percentage C 367 438
of C 368 438
large C 369 438
and C 370 438
small C 371 438
cells C 372 438
is C 373 438
altered C 374 438
experimentally C 375 438
. C 376 438
these C 378 438
findings C 379 438
can C 380 438
be C 381 438
explained C 382 438
by C 383 438
an C 384 438
inter C 385 438
- C 386 438
change C 387 438
of C 388 438
the C 389 438
dna C 390 438
nuclear C 391 438
label C 392 438
between C 393 438
small C 394 438
lymphocytes C 395 438
and C 396 438
large C 397 438
lymphocytes C 398 438
. C 399 438
this C 401 438
could C 402 438
occur C 403 438
by C 404 438
some C 405 438
process C 406 438
such C 407 438
as C 408 438
phagocytosis C 409 438
or C 410 438
pinocytosis C 411 438
, C 412 438
or C 413 438
by C 414 438
trans C 415 438
- C 416 438
formation C 417 438
of C 418 438
the C 419 438
small C 420 438
lymphocyte C 421 438
into C 422 438
a C 423 438
large C 424 438
, C 425 438
dividing C 426 438
cell C 427 438
. C 428 438
the C 430 438
data C 431 438
fit C 432 438
best C 433 438
with C 434 438
the C 435 438
latter C 436 438
possibility C 437 438
. C 438 438
all C 440 438
or C 441 438
any C 442 438
of C 443 438
these C 444 438
mechanisms C 445 438
would C 446 438
lead C 447 438
to C 448 438
an C 449 438
equilibration C 450 438
of C 451 438
the C 452 438
dna C 453 438
label C 454 438
between C 455 438
large C 456 438
and C 457 438
small C 458 438
cells C 459 438
. C 460 438
this C 462 438
finding C 463 438
prevents C 464 438
the C 465 438
assign C 466 438
- C 467 438
ment C 468 438
of C 469 438
a C 470 438
finite C 471 438
life C 472 438
span C 473 438
to C 474 438
lymphocytes C 475 438
on C 476 438
the C 477 438
basis C 478 438
of C 479 438
dna C 480 438
labeling C 481 438
kinetics C 482 438
. C 483 438
ne C 485 438
- C 486 438
vertheless C 487 438
, C 488 438
there C 489 438
appear C 490 438
to C 491 438
be C 492 438
at C 493 438
least C 494 438
two C 495 438
different C 496 438
types C 497 438
of C 498 438
lymphocytes C 499 438
. C 500 438
one C 502 438
, C 503 438
the C 504 438
' C 505 438
thymus C 506 438
- C 507 438
type C 508 438
' C 509 438
lymphocyte C 510 438
, C 511 438
is C 512 438
found C 513 438
in C 514 438
the C 515 438
thymus C 516 438
cortex C 517 438
, C 518 438
bone C 519 438
marrow C 520 438
and C 521 438
ger C 522 438
- C 523 438
minal C 524 438
centers C 525 438
of C 526 438
lymphoid C 527 438
follicles C 528 438
. C 529 438
the C 531 438
other C 532 438
type C 533 438
, C 534 438
found C 535 438
abundantly C 536 438
in C 537 438
the C 538 438
wide C 539 438
- C 540 438
spread C 541 438
peripheral C 542 438
lymphatic C 543 438
tissue C 544 438
, C 545 438
shows C 546 438
a C 547 438
very C 548 438
prolonged C 549 438
retention C 550 438
of C 551 438
dna C 552 438
la C 553 438
- C 554 438
bel C 555 438
and C 556 438
is C 557 438
believed C 558 438
to C 559 438
be C 560 438
recirculating C 561 438
, C 562 438
' C 563 438
immunologically C 564 438
committed C 565 438
' C 566 438
cells C 567 438
described C 568 438
by C 569 438
others C 570 438
. C 571 438
these C 573 438
cells C 574 438
do C 575 438
not C 576 438
appear C 577 438
to C 578 438
enter C 579 438
the C 580 438
thymus C 581 438
cortex C 582 438
. C 583 438
6674 C 1 439
. C 2 439
the C 4 439
free C 5 439
and C 6 439
glucuronic C 7 439
acid C 8 439
- C 9 439
bound C 10 439
17 C 11 439
- C 12 439
hydroxy C 13 439
- C 14 439
corticosteroids C 15 439
in C 16 439
the C 17 439
plasma C 18 439
of C 19 439
patients C 20 439
with C 21 439
cancer C 22 439
of C 23 439
the C 24 439
breast C 25 439
on C 26 439
i C 27 439
. C 28 439
. C 29 439
. C 30 439
infusion C 32 439
of C 33 439
acth C 34 439
seventeen C 35 439
patients C 36 439
with C 37 439
advanced C 38 439
mammary C 39 439
cancer C 40 439
were C 41 439
given C 42 439
an C 43 439
infusion C 44 439
with C 45 439
3 C 46 439
u C 47 439
. C 48 439
of C 50 439
acth C 51 439
in C 52 439
5 C 53 439
hr C 54 439
. C 55 439
and C 57 439
6 C 58 439
others C 59 439
an C 60 439
infusion C 61 439
of C 62 439
25 C 63 439
u C 64 439
. C 65 439
determinations C 67 439
were C 68 439
made C 69 439
of C 70 439
the C 71 439
plasma C 72 439
17 C 73 439
- C 74 439
hydroxy C 75 439
- C 76 439
corticosteroids C 77 439
, C 78 439
free C 79 439
and C 80 439
bound C 81 439
to C 82 439
glucuronic C 83 439
acid C 84 439
both C 85 439
before C 86 439
and C 87 439
after C 88 439
the C 89 439
infusion C 90 439
. C 91 439
in C 93 439
rapidly C 94 439
growing C 95 439
carcinomas C 96 439
, C 97 439
high C 98 439
initial C 99 439
values C 100 439
were C 101 439
found C 102 439
for C 103 439
the C 104 439
free C 105 439
corticosteroids C 106 439
( C 107 439
more C 108 439
than C 109 439
20 C 110 439
ug C 111 439
. C 112 439
/ C 114 439
100 C 115 439
ml C 116 439
. C 117 439
of C 119 439
plasma C 120 439
) C 121 439
. C 122 439
the C 124 439
ratio C 125 439
of C 126 439
free C 127 439
to C 128 439
bound C 129 439
corticosteroids C 130 439
is C 131 439
for C 132 439
stage C 133 439
iv C 134 439
patients C 135 439
1 C 136 439
. C 137 439
. C 138 439
on C 139 439
the C 140 439
average C 141 439
, C 142 439
and C 143 439
approximately C 144 439
1 C 145 439
for C 146 439
the C 147 439
mixed C 148 439
forms C 149 439
stage C 150 439
iv C 151 439
+ C 152 439
m C 153 439
. C 154 439
these C 156 439
ratios C 157 439
are C 158 439
not C 159 439
altered C 160 439
by C 161 439
acth C 162 439
. C 163 439
shifts C 165 439
in C 166 439
the C 167 439
ratio C 168 439
of C 169 439
free C 170 439
to C 171 439
bound C 172 439
corticosteroids C 173 439
with C 174 439
acth C 175 439
treatment C 176 439
can C 177 439
be C 178 439
seen C 179 439
, C 180 439
depending C 181 439
on C 182 439
the C 183 439
initial C 184 439
value C 185 439
of C 186 439
the C 187 439
free C 188 439
corticosteroids C 189 439
. C 190 439
the C 192 439
administration C 193 439
of C 194 439
3 C 195 439
u C 196 439
. C 197 439
is C 199 439
enough C 200 439
and C 201 439
the C 202 439
5 C 203 439
hr C 204 439
. C 205 439
value C 207 439
is C 208 439
some C 209 439
70 C 210 439
% C 211 439
, C 212 439
related C 213 439
to C 214 439
a C 215 439
maximal C 216 439
stimulation C 217 439
with C 218 439
25 C 219 439
u C 220 439
. C 221 439
4179 C 1 440
. C 2 440
reduced C 4 440
estriol C 5 440
excretion C 6 440
in C 7 440
patients C 8 440
with C 9 440
breast C 10 440
cancer C 11 440
prior C 12 440
to C 13 440
endocrine C 14 440
therapy C 15 440
the C 16 440
urinary C 17 440
quotient C 18 440
of C 19 440
estriol C 20 440
/ C 21 440
estrone C 22 440
+ C 23 440
estradiol C 24 440
- C 25 440
17 C 26 440
b C 27 440
( C 28 440
eq C 29 440
) C 30 440
was C 31 440
measured C 32 440
chemically C 33 440
in C 34 440
women C 35 440
with C 36 440
and C 37 440
without C 38 440
breast C 39 440
cancer C 40 440
, C 41 440
as C 42 440
an C 43 440
in C 44 440
- C 45 440
dex C 46 440
of C 47 440
the C 48 440
ratio C 49 440
of C 50 440
noncarcinogenic C 51 440
impeded C 52 440
es C 53 440
- C 54 440
trogens C 55 440
to C 56 440
mammary C 57 440
carcinogenic C 58 440
estrogens C 59 440
. C 60 440
in C 62 440
34 C 63 440
controls C 64 440
, C 65 440
the C 66 440
median C 67 440
eq C 68 440
was C 69 440
1 C 70 440
. C 71 440
. C 72 440
before C 73 440
and C 74 440
1 C 75 440
. C 76 440
. C 77 440
after C 78 440
menopause C 79 440
, C 80 440
with C 81 440
only C 82 440
21 C 83 440
% C 84 440
of C 85 440
the C 86 440
patients C 87 440
sub C 88 440
- C 89 440
normal C 90 440
. C 91 440
in C 93 440
26 C 94 440
breast C 95 440
cancer C 96 440
patients C 97 440
without C 98 440
endo C 99 440
- C 100 440
crine C 101 440
treatment C 102 440
or C 103 440
recent C 104 440
surgery C 105 440
, C 106 440
the C 107 440
median C 108 440
eq C 109 440
was C 110 440
0 C 111 440
. C 112 440
. C 113 440
and C 114 440
0 C 115 440
. C 116 440
. C 117 440
respectively C 118 440
, C 119 440
with C 120 440
62 C 121 440
% C 122 440
of C 123 440
the C 124 440
pa C 125 440
- C 126 440
tients C 127 440
subnormal C 128 440
. C 129 440
after C 131 440
major C 132 440
surgery C 133 440
or C 134 440
hormo C 135 440
- C 136 440
nal C 137 440
therapy C 138 440
, C 139 440
only C 140 440
23 C 141 440
% C 142 440
of C 143 440
53 C 144 440
patients C 145 440
were C 146 440
subnor C 147 440
- C 148 440
mal C 149 440
, C 150 440
no C 151 440
remissions C 152 440
being C 153 440
observed C 154 440
unless C 155 440
the C 156 440
eq C 157 440
rose C 158 440
toward C 159 440
normal C 160 440
. C 161 440
matching C 163 440
of C 164 440
24 C 165 440
controls C 166 440
and C 167 440
patients C 168 440
in C 169 440
pairs C 170 440
by C 171 440
age C 172 440
and C 173 440
ovarian C 174 440
status C 175 440
in C 176 440
the C 177 440
wilcoxon C 178 440
test C 179 440
indicated C 180 440
that C 181 440
the C 182 440
decreased C 183 440
eq C 184 440
ex C 185 440
- C 186 440
creted C 187 440
in C 188 440
untreated C 189 440
cancer C 190 440
was C 191 440
significant C 192 440
at C 193 440
the C 194 440
0 C 195 440
. C 196 440
. C 197 440
% C 198 440
confidence C 199 440
level C 200 440
. C 201 440
the C 203 440
marked C 204 440
increase C 205 440
in C 206 440
eq C 207 440
induced C 208 440
by C 209 440
castration C 210 440
and C 211 440
androgen C 212 440
, C 213 440
estrogen C 214 440
, C 215 440
and C 216 440
corticosteroid C 217 440
therapy C 218 440
suggests C 219 440
that C 220 440
normaliza C 221 440
- C 222 440
tion C 223 440
of C 224 440
a C 225 440
precancerous C 226 440
metabolic C 227 440
imbalance C 228 440
be C 229 440
- C 230 440
tween C 231 440
impeded C 232 440
and C 233 440
active C 234 440
estrogens C 235 440
derived C 236 440
from C 237 440
ovarian C 238 440
and C 239 440
adrenocortical C 240 440
sources C 241 440
contributed C 242 440
to C 243 440
arrested C 244 440
growth C 245 440
of C 246 440
estradiol C 247 440
- C 248 440
dependent C 249 440
metastases C 250 440
. C 251 440
1107 C 1 441
. C 2 441
urinary C 4 441
excretion C 5 441
of C 6 441
estrone C 7 441
, C 8 441
estradiol C 9 441
and C 10 441
estriol C 11 441
by C 12 441
pa C 13 441
- C 14 441
tients C 15 441
with C 16 441
breast C 17 441
cancer C 18 441
and C 19 441
benign C 20 441
breast C 21 441
disease C 22 441
premenopausal C 23 441
patients C 24 441
with C 25 441
breast C 26 441
cancer C 27 441
and C 28 441
benign C 29 441
breast C 30 441
disease C 31 441
appear C 32 441
to C 33 441
ex C 34 441
- C 35 441
crete C 36 441
a C 37 441
significantly C 38 441
lower C 39 441
percentage C 40 441
of C 41 441
the C 42 441
total C 43 441
estrogen C 44 441
as C 45 441
estrone C 46 441
and C 47 441
a C 48 441
signifi C 49 441
- C 50 441
cantly C 51 441
higher C 52 441
percentage C 53 441
as C 54 441
estriol C 55 441
than C 56 441
women C 57 441
in C 58 441
the C 59 441
premenopausal C 60 441
control C 61 441
group C 62 441
. C 63 441
there C 65 441
was C 66 441
no C 67 441
significant C 68 441
difference C 69 441
in C 70 441
the C 71 441
excretion C 72 441
of C 73 441
total C 74 441
estrogen C 75 441
between C 76 441
cancer C 77 441
groups C 78 441
and C 79 441
controls C 80 441
in C 81 441
good C 82 441
health C 83 441
. C 84 441
postmenopausal C 86 441
patients C 87 441
with C 88 441
cancer C 89 441
excreted C 90 441
higher C 91 441
levels C 92 441
of C 93 441
estriol C 94 441
than C 95 441
postmenopausal C 96 441
control C 97 441
groups C 98 441
. C 99 441
the C 101 441
increase C 102 441
in C 103 441
estriol C 104 441
excretion C 105 441
cannot C 106 441
be C 107 441
explained C 108 441
by C 109 441
debilitation C 110 441
. C 111 441
5323 C 1 442
. C 2 442
systemic C 4 442
effects C 5 442
of C 6 442
androgenic C 7 442
and C 8 442
estrogenic C 9 442
hormones C 10 442
in C 11 442
advanced C 12 442
breast C 13 442
cancer C 14 442
the C 15 442
systemic C 16 442
effects C 17 442
of C 18 442
diethylstilbestrol C 19 442
( C 20 442
45 C 21 442
patients C 22 442
) C 23 442
, C 24 442
testosterone C 25 442
propionate C 26 442
( C 27 442
48 C 28 442
patients C 29 442
) C 30 442
, C 31 442
and C 32 442
both C 33 442
hormones C 34 442
( C 35 442
22 C 36 442
patients C 37 442
) C 38 442
were C 39 442
studied C 40 442
during C 41 442
the C 42 442
treatment C 43 442
( C 44 442
six C 45 442
weeks C 46 442
to C 47 442
over C 48 442
three C 49 442
months C 50 442
) C 51 442
of C 52 442
advanced C 53 442
breast C 54 442
cancer C 55 442
in C 56 442
postmenopausal C 57 442
women C 58 442
. C 59 442
serious C 61 442
complications C 62 442
included C 63 442
induced C 64 442
hypercalcemia C 65 442
and C 66 442
fluid C 67 442
re C 68 442
- C 69 442
tention C 70 442
. C 71 442
physiologic C 73 442
effects C 74 442
such C 75 442
as C 76 442
urinary C 77 442
incontinence C 78 442
( C 79 442
diethylstilbestrol C 80 442
) C 81 442
, C 82 442
virilization C 83 442
( C 84 442
testosterone C 85 442
) C 86 442
, C 87 442
or C 88 442
nausea C 89 442
and C 90 442
vomiting C 91 442
did C 92 442
not C 93 442
necessitate C 94 442
disconti C 95 442
- C 96 442
nuance C 97 442
of C 98 442
treatment C 99 442
. C 100 442
androgenic C 102 442
therapy C 103 442
stimulated C 104 442
erythropoiesis C 105 442
. C 106 442
observa C 108 442
- C 109 442
tions C 110 442
on C 111 442
the C 112 442
systemic C 113 442
reactions C 114 442
to C 115 442
these C 116 442
hormonal C 117 442
agents C 118 442
definitely C 119 442
contribute C 120 442
to C 121 442
the C 122 442
evaluation C 123 442
of C 124 442
sex C 125 442
steroid C 126 442
therapy C 127 442
. C 128 442
3478 C 1 443
. C 2 443
the C 4 443
effect C 5 443
of C 6 443
dehydroepiandrosterone C 7 443
on C 8 443
the C 9 443
17 C 10 443
- C 11 443
hydroxycorti C 12 443
- C 13 443
costeroids C 14 443
in C 15 443
the C 16 443
plasma C 17 443
in C 18 443
various C 19 443
stages C 20 443
of C 21 443
cancer C 22 443
and C 23 443
other C 24 443
diseases C 25 443
of C 26 443
the C 27 443
breast C 28 443
the C 29 443
reducing C 30 443
effect C 31 443
of C 32 443
dehydroepiandrosterone C 33 443
on C 34 443
the C 35 443
plasma C 36 443
corticosteroids C 37 443
is C 38 443
on C 39 443
the C 40 443
average C 41 443
shortened C 42 443
in C 43 443
advanced C 44 443
( C 45 443
stage C 46 443
iv C 47 443
) C 48 443
cases C 49 443
of C 50 443
breast C 51 443
cancer C 52 443
. C 53 443
in C 55 443
3 C 56 443
groups C 57 443
of C 58 443
patients C 59 443
, C 60 443
the C 61 443
lowest C 62 443
corticosteroid C 63 443
levels C 64 443
were C 65 443
found C 66 443
up C 67 443
to C 68 443
6 C 69 443
hr C 70 443
. C 71 443
after C 73 443
infusion C 74 443
of C 75 443
dehydroepiandrosterone C 76 443
- C 77 443
phosphate C 78 443
. C 79 443
in C 81 443
patients C 82 443
with C 83 443
mastopathy C 84 443
the C 85 443
effect C 86 443
was C 87 443
still C 88 443
detectable C 89 443
12 C 90 443
hr C 91 443
. C 92 443
later C 94 443
; C 95 443
in C 96 443
patients C 97 443
with C 98 443
breast C 99 443
cancer C 100 443
in C 101 443
stage C 102 443
iv C 103 443
the C 104 443
initial C 105 443
levels C 106 443
were C 107 443
reached C 108 443
at C 109 443
that C 110 443
time C 111 443
. C 112 443
in C 114 443
cases C 115 443
with C 116 443
stages C 117 443
i C 118 443
and C 119 443
ii C 120 443
lesions C 121 443
, C 122 443
the C 123 443
findings C 124 443
were C 125 443
intermediate C 126 443
. C 127 443
the C 129 443
shortening C 130 443
is C 131 443
attributed C 132 443
to C 133 443
a C 134 443
more C 135 443
intensive C 136 443
transformation C 137 443
of C 138 443
dehydroepiandrosterone C 139 443
in C 140 443
advanced C 141 443
cases C 142 443
of C 143 443
breast C 144 443
cancer C 145 443
. C 146 443
5274 C 1 444
. C 2 444
urinary C 4 444
excretion C 5 444
of C 6 444
estrone C 7 444
, C 8 444
estradiol C 9 444
and C 10 444
estriol C 11 444
by C 12 444
patients C 13 444
with C 14 444
prostatic C 15 444
cancer C 16 444
and C 17 444
benign C 18 444
prostatic C 19 444
hypertrophy C 20 444
and C 21 444
hopkins C 22 444
c C 23 444
. C 24 444
. C 25 444
. C 26 444
urinary C 28 444
estrone C 29 444
, C 30 444
estradiol C 31 444
, C 32 444
and C 33 444
estriol C 34 444
fractions C 35 444
excreted C 36 444
by C 37 444
21 C 38 444
patients C 39 444
with C 40 444
prostatic C 41 444
cancer C 42 444
, C 43 444
17 C 44 444
patients C 45 444
with C 46 444
benign C 47 444
hypertrophy C 48 444
, C 49 444
and C 50 444
59 C 51 444
clinically C 52 444
well C 53 444
subjects C 54 444
were C 55 444
assayed C 56 444
to C 57 444
determine C 58 444
whether C 59 444
differences C 60 444
exist C 61 444
. C 62 444
absolute C 64 444
levels C 65 444
of C 66 444
estrone C 67 444
, C 68 444
estradiol C 69 444
, C 70 444
and C 71 444
estriol C 72 444
fractions C 73 444
were C 74 444
not C 75 444
significantly C 76 444
different C 77 444
. C 78 444
the C 80 444
excretion C 81 444
of C 82 444
relatively C 83 444
lower C 84 444
levels C 85 444
of C 86 444
estrone C 87 444
and C 88 444
estradiol C 89 444
, C 90 444
and C 91 444
relatively C 92 444
higher C 93 444
levels C 94 444
of C 95 444
estriol C 96 444
by C 97 444
patients C 98 444
with C 99 444
prostatic C 100 444
cancer C 101 444
compared C 102 444
to C 103 444
clinically C 104 444
well C 105 444
subjects C 106 444
resulted C 107 444
in C 108 444
significantly C 109 444
lower C 110 444
proportions C 111 444
of C 112 444
the C 113 444
total C 114 444
estrogen C 115 444
being C 116 444
excreted C 117 444
as C 118 444
estrone C 119 444
and C 120 444
estradiol C 121 444
. C 122 444
differences C 124 444
in C 125 444
the C 126 444
proportions C 127 444
of C 128 444
estrogen C 129 444
frac C 130 444
- C 131 444
tions C 132 444
between C 133 444
patients C 134 444
with C 135 444
benign C 136 444
hypertrophy C 137 444
and C 138 444
clinically C 139 444
well C 140 444
subjects C 141 444
were C 142 444
not C 143 444
significant C 144 444
. C 145 444
with C 147 444
the C 148 444
exception C 149 444
of C 150 444
a C 151 444
significantly C 152 444
higher C 153 444
percentage C 154 444
of C 155 444
the C 156 444
total C 157 444
estrogen C 158 444
being C 159 444
excreted C 160 444
as C 161 444
estrone C 162 444
by C 163 444
the C 164 444
patients C 165 444
with C 166 444
benign C 167 444
hypertrophy C 168 444
, C 169 444
differences C 170 444
between C 171 444
that C 172 444
group C 173 444
and C 174 444
the C 175 444
cancer C 176 444
group C 177 444
were C 178 444
also C 179 444
not C 180 444
significant C 181 444
. C 182 444
clinical C 184 444
variations C 185 444
between C 186 444
the C 187 444
3 C 188 444
groups C 189 444
, C 190 444
and C 191 444
within C 192 444
the C 193 444
cancer C 194 444
and C 195 444
hypertrophy C 196 444
groups C 197 444
, C 198 444
preclude C 199 444
assignment C 200 444
of C 201 444
significant C 202 444
differences C 203 444
to C 204 444
prostatic C 205 444
dystrophies C 206 444
alone C 207 444
. C 208 444
cancer C 210 444
patients C 211 444
experiencing C 212 444
inanition C 213 444
due C 214 444
to C 215 444
a C 216 444
loss C 217 444
of C 218 444
appetite C 219 444
excreted C 220 444
significantly C 221 444
lower C 222 444
levels C 223 444
of C 224 444
estrone C 225 444
than C 226 444
patients C 227 444
who C 228 444
reported C 229 444
no C 230 444
loss C 231 444
of C 232 444
appetite C 233 444
. C 234 444
significantly C 236 444
lower C 237 444
levels C 238 444
of C 239 444
estrone C 240 444
were C 241 444
excreted C 242 444
by C 243 444
patients C 244 444
with C 245 444
benign C 246 444
hyper C 247 444
- C 248 444
trophy C 249 444
hospitalized C 250 444
6 C 251 444
days C 252 444
or C 253 444
more C 254 444
compared C 255 444
to C 256 444
patients C 257 444
hospitalized C 258 444
5 C 259 444
days C 260 444
or C 261 444
less C 262 444
. C 263 444
a C 265 444
significantly C 266 444
higher C 267 444
urinary C 268 444
estrone C 269 444
- C 270 444
androsterone C 271 444
ratio C 272 444
was C 273 444
present C 274 444
in C 275 444
the C 276 444
cancer C 277 444
group C 278 444
than C 279 444
in C 280 444
the C 281 444
clinically C 282 444
well C 283 444
group C 284 444
. C 285 444
it C 287 444
is C 288 444
not C 289 444
believed C 290 444
, C 291 444
however C 292 444
, C 293 444
that C 294 444
an C 295 444
arbi C 296 444
- C 297 444
trary C 298 444
ratio C 299 444
can C 300 444
be C 301 444
used C 302 444
to C 303 444
suggest C 304 444
an C 305 444
internal C 306 444
estrogen C 307 444
- C 308 444
androgen C 309 444
imbalance C 310 444
. C 311 444
28029 C 1 445
enzymic C 2 445
synthesis C 3 445
of C 4 445
steroid C 5 445
sulfates C 6 445
. C 7 445
ii C 9 445
. C 10 445
presence C 12 445
of C 13 445
steroid C 14 445
sulfo C 15 445
- C 16 445
kinase C 17 445
in C 18 445
human C 19 445
mammary C 20 445
carcinoma C 21 445
extracts C 22 445
extracts C 23 445
of C 24 445
human C 25 445
primary C 26 445
and C 27 445
secondary C 28 445
mammary C 29 445
carcinomas C 30 445
were C 31 445
shown C 32 445
to C 33 445
contain C 34 445
steroid C 35 445
sulfokinase C 36 445
( C 37 445
s C 38 445
) C 39 445
in C 40 445
every C 41 445
case C 42 445
examined C 43 445
. C 44 445
examination C 46 445
of C 47 445
normal C 48 445
breast C 49 445
tissue C 50 445
surrounding C 51 445
the C 52 445
tumors C 53 445
revealed C 54 445
very C 55 445
weak C 56 445
steroid C 57 445
sulfokinase C 58 445
activity C 59 445
in C 60 445
some C 61 445
instances C 62 445
. C 63 445
this C 65 445
was C 66 445
thought C 67 445
to C 68 445
be C 69 445
due C 70 445
to C 71 445
the C 72 445
fibrous C 73 445
nature C 74 445
and C 75 445
poor C 76 445
cellularity C 77 445
of C 78 445
the C 79 445
normal C 80 445
breast C 81 445
tissue C 82 445
. C 83 445
normal C 85 445
ovarian C 86 445
tissue C 87 445
specimens C 88 445
, C 89 445
obtained C 90 445
from C 91 445
cancer C 92 445
patients C 93 445
undergoing C 94 445
oophorectomy C 95 445
, C 96 445
did C 97 445
not C 98 445
generally C 99 445
contain C 100 445
the C 101 445
enzyme C 102 445
, C 103 445
but C 104 445
trace C 105 445
levels C 106 445
were C 107 445
detected C 108 445
in C 109 445
1 C 110 445
of C 111 445
5 C 112 445
specimens C 113 445
examined C 114 445
. C 115 445
steroids C 117 445
, C 118 445
without C 119 445
necessarily C 120 445
showing C 121 445
conversion C 122 445
to C 123 445
steroid C 124 445
sulfate C 125 445
, C 126 445
were C 127 445
observed C 128 445
to C 129 445
increase C 130 445
the C 131 445
incorporation C 132 445
of C 133 445
s C 134 445
35 C 135 445
- C 136 445
sulfate C 137 445
into C 138 445
one C 139 445
of C 140 445
the C 141 445
products C 142 445
formed C 143 445
enzy C 144 445
- C 145 445
mically C 146 445
on C 147 445
incubating C 148 445
breast C 149 445
tissue C 150 445
extracts C 151 445
with C 152 445
s C 153 445
35 C 154 445
- C 155 445
adenosine C 156 445
- C 157 445
3 C 158 445
' C 159 445
- C 160 445
phosphate C 161 445
- C 162 445
5 C 163 445
' C 164 445
- C 165 445
phosphosulfate C 166 445
. C 167 445
3752 C 1 446
. C 2 446
steroid C 4 446
excretion C 5 446
in C 6 446
early C 7 446
breast C 8 446
cancer C 9 446
patients C 10 446
with C 11 446
advanced C 12 446
breast C 13 446
cancer C 14 446
who C 15 446
subsequently C 16 446
fail C 17 446
to C 18 446
respond C 19 446
to C 20 446
adrenalec C 21 446
- C 22 446
tomy C 23 446
or C 24 446
hypophysectomy C 25 446
have C 26 446
been C 27 446
found C 28 446
to C 29 446
excrete C 30 446
abnormal C 31 446
amounts C 32 446
of C 33 446
the C 34 446
urinary C 35 446
metabolites C 36 446
of C 37 446
androgen C 38 446
and C 39 446
cortisol C 40 446
. C 41 446
when C 43 446
similar C 44 446
measurements C 45 446
are C 46 446
carried C 47 446
out C 48 446
on C 49 446
patients C 50 446
with C 51 446
early C 52 446
breast C 53 446
cancer C 54 446
, C 55 446
it C 56 446
is C 57 446
found C 58 446
that C 59 446
approximately C 60 446
half C 61 446
the C 62 446
cases C 63 446
presenting C 64 446
for C 65 446
mastectomy C 66 446
are C 67 446
also C 68 446
excreting C 69 446
abnormal C 70 446
amounts C 71 446
of C 72 446
these C 73 446
steroids C 74 446
. C 75 446
subsequent C 77 446
follow C 78 446
- C 79 446
up C 80 446
shows C 81 446
that C 82 446
these C 83 446
cases C 84 446
tend C 85 446
to C 86 446
have C 87 446
a C 88 446
poor C 89 446
progno C 90 446
- C 91 446
sis C 92 446
, C 93 446
and C 94 446
a C 95 446
trial C 96 446
had C 97 446
therefore C 98 446
been C 99 446
started C 100 446
in C 101 446
which C 102 446
the C 103 446
abnormality C 104 446
is C 105 446
being C 106 446
cor C 107 446
- C 108 446
rected C 109 446
. C 110 446
in C 112 446
addition C 113 446
, C 114 446
it C 115 446
seems C 116 446
possible C 117 446
that C 118 446
the C 119 446
deficiency C 120 446
in C 121 446
adrogen C 122 446
excretion C 123 446
may C 124 446
precede C 125 446
the C 126 446
onset C 127 446
of C 128 446
the C 129 446
disease C 130 446
. C 131 446
this C 133 446
problem C 134 446
is C 135 446
being C 136 446
investigated C 137 446
in C 138 446
a C 139 446
trial C 140 446
involving C 141 446
urinary C 142 446
steroid C 143 446
estimations C 144 446
in C 145 446
5000 C 146 446
normal C 147 446
women C 148 446
. C 149 446
the C 151 446
measurements C 152 446
are C 153 446
being C 154 446
compared C 155 446
with C 156 446
the C 157 446
subsequent C 158 446
development C 159 446
of C 160 446
breast C 161 446
cancer C 162 446
. C 163 446
2365 C 1 447
. C 2 447
the C 4 447
excretion C 5 447
of C 6 447
oestrone C 7 447
, C 8 447
pregnanediol C 9 447
and C 10 447
pregnanetriol C 11 447
in C 12 447
breast C 13 447
cancer C 14 447
patients C 15 447
. C 16 447
i C 18 447
. C 19 447
excretion C 21 447
after C 22 447
spontaneous C 23 447
menopause C 24 447
the C 25 447
urinary C 26 447
excretion C 27 447
of C 28 447
oestrone C 29 447
, C 30 447
pregnanediol C 31 447
and C 32 447
pregnanetriol C 33 447
was C 34 447
determined C 35 447
in C 36 447
a C 37 447
series C 38 447
of C 39 447
postmenopausal C 40 447
breast C 41 447
cancer C 42 447
patients C 43 447
receiving C 44 447
no C 45 447
endocrine C 46 447
treat C 47 447
- C 48 447
ment C 49 447
. C 50 447
the C 52 447
steroid C 53 447
excretion C 54 447
was C 55 447
studied C 56 447
both C 57 447
in C 58 447
relation C 59 447
to C 60 447
the C 61 447
age C 62 447
of C 63 447
the C 64 447
patients C 65 447
as C 66 447
well C 67 447
as C 68 447
in C 69 447
relation C 70 447
to C 71 447
the C 72 447
time C 73 447
elapsed C 74 447
since C 75 447
the C 76 447
last C 77 447
menstrual C 78 447
cycle C 79 447
. C 80 447
the C 82 447
results C 83 447
indicate C 84 447
that C 85 447
after C 86 447
an C 87 447
initial C 88 447
slow C 89 447
decrease C 90 447
from C 91 447
the C 92 447
age C 93 447
of C 94 447
the C 95 447
menopause C 96 447
onward C 97 447
, C 98 447
the C 99 447
excretion C 100 447
of C 101 447
oestrone C 102 447
and C 103 447
preganediol C 104 447
increases C 105 447
again C 106 447
. C 107 447
a C 109 447
new C 110 447
maximum C 111 447
was C 112 447
found C 113 447
in C 114 447
the C 115 447
group C 116 447
10 C 117 447
- C 118 447
15 C 119 447
yr C 120 447
. C 121 447
after C 123 447
the C 124 447
menopause C 125 447
. C 126 447
the C 128 447
excretion C 129 447
of C 130 447
pregnanetriol C 131 447
however C 132 447
, C 133 447
remains C 134 447
relatively C 135 447
constant C 136 447
after C 137 447
a C 138 447
more C 139 447
rapid C 140 447
fall C 141 447
during C 142 447
the C 143 447
first C 144 447
few C 145 447
years C 146 447
after C 147 447
the C 148 447
menopause C 149 447
. C 150 447
2366 C 1 448
. C 2 448
the C 4 448
excretion C 5 448
of C 6 448
oestrone C 7 448
, C 8 448
pregnanediol C 9 448
and C 10 448
pregnanetriol C 11 448
in C 12 448
breast C 13 448
cancer C 14 448
patients C 15 448
. C 16 448
ii C 18 448
. C 19 448
effect C 21 448
of C 22 448
ovariectomy C 23 448
, C 24 448
ovarian C 25 448
irradiation C 26 448
and C 27 448
corticos C 28 448
- C 29 448
teroids C 30 448
. C 31 448
the C 33 448
urinary C 34 448
excretion C 35 448
of C 36 448
oestrone C 37 448
, C 38 448
pregnanediol C 39 448
and C 40 448
pregnanetriol C 41 448
was C 42 448
determined C 43 448
in C 44 448
breast C 45 448
cancer C 46 448
patients C 47 448
at C 48 448
different C 49 448
stages C 50 448
of C 51 448
their C 52 448
endocrine C 53 448
treatment C 54 448
. C 55 448
the C 57 448
results C 58 448
demonstrate C 59 448
that C 60 448
corticosteroids C 61 448
in C 62 448
substitution C 63 448
doses C 64 448
( C 65 448
cortisone C 66 448
50 C 67 448
mg C 68 448
. C 69 448
daily C 71 448
or C 72 448
prednisone C 73 448
10 C 74 448
mg C 75 448
. C 76 448
daily C 78 448
, C 79 448
divided C 80 448
in C 81 448
4 C 82 448
daily C 83 448
doses C 84 448
) C 85 448
are C 86 448
very C 87 448
effective C 88 448
in C 89 448
depressing C 90 448
the C 91 448
excretion C 92 448
of C 93 448
all C 94 448
3 C 95 448
steroids C 96 448
in C 97 448
postmenopausal C 98 448
patients C 99 448
. C 100 448
this C 102 448
is C 103 448
in C 104 448
agreement C 105 448
with C 106 448
the C 107 448
clinical C 108 448
impression C 109 448
that C 110 448
these C 111 448
easily C 112 448
tolerated C 113 448
small C 114 448
doses C 115 448
of C 116 448
corticosteroids C 117 448
have C 118 448
the C 119 448
same C 120 448
therapeutic C 121 448
effect C 122 448
as C 123 448
adrenalectomy C 124 448
in C 125 448
patients C 126 448
with C 127 448
breast C 128 448
cancer C 129 448
. C 130 448
the C 132 448
results C 133 448
indicate C 134 448
that C 135 448
the C 136 448
ovaries C 137 448
may C 138 448
contribute C 139 448
to C 140 448
the C 141 448
production C 142 448
of C 143 448
oestrogens C 144 448
for C 145 448
many C 146 448
years C 147 448
after C 148 448
the C 149 448
menopause C 150 448
, C 151 448
and C 152 448
that C 153 448
this C 154 448
production C 155 448
is C 156 448
depressed C 157 448
by C 158 448
ovarian C 159 448
irradiation C 160 448
. C 161 448
this C 163 448
is C 164 448
in C 165 448
agreement C 166 448
with C 167 448
the C 168 448
clinical C 169 448
observation C 170 448
that C 171 448
ovarian C 172 448
irra C 173 448
- C 174 448
diation C 175 448
has C 176 448
a C 177 448
therapeutic C 178 448
value C 179 448
in C 180 448
postmenopausal C 181 448
women C 182 448
with C 183 448
breast C 184 448
cancer C 185 448
. C 186 448
414 C 1 449
. C 2 449
estimation C 4 449
of C 5 449
the C 6 449
urinary C 7 449
17 C 8 449
- C 9 449
ketosteroids C 10 449
in C 11 449
the C 12 449
diagnosis C 13 449
of C 14 449
car C 15 449
- C 16 449
cinoma C 17 449
of C 18 449
the C 19 449
prostate C 20 449
in C 21 449
33 C 22 449
patients C 23 449
with C 24 449
histologically C 25 449
confirmed C 26 449
carcinoma C 27 449
and C 28 449
in C 29 449
37 C 30 449
patients C 31 449
with C 32 449
confirmed C 33 449
benign C 34 449
hyperplasia C 35 449
of C 36 449
the C 37 449
prostate C 38 449
the C 39 449
amount C 40 449
of C 41 449
neutral C 42 449
17 C 43 449
- C 44 449
ketosteroids C 45 449
was C 46 449
estimated C 47 449
in C 48 449
24 C 49 449
- C 50 449
hr C 51 449
. C 52 449
samples C 54 449
of C 55 449
urine C 56 449
. C 57 449
the C 59 449
results C 60 449
revealed C 61 449
that C 62 449
, C 63 449
contrary C 64 449
to C 65 449
reports C 66 449
in C 67 449
the C 68 449
literature C 69 449
, C 70 449
this C 71 449
diagnostic C 72 449
method C 73 449
is C 74 449
quite C 75 449
unreliable C 76 449
. C 77 449
raised C 79 449
17 C 80 449
- C 81 449
ketosteroid C 82 449
levels C 83 449
were C 84 449
found C 85 449
also C 86 449
in C 87 449
a C 88 449
high C 89 449
percentage C 90 449
of C 91 449
control C 92 449
subjects C 93 449
. C 94 449
moreover C 96 449
, C 97 449
the C 98 449
estimation C 99 449
of C 100 449
17 C 101 449
- C 102 449
ketosteroids C 103 449
is C 104 449
a C 105 449
very C 106 449
laborious C 107 449
biochemical C 108 449
method C 109 449
and C 110 449
involves C 111 449
a C 112 449
relatively C 113 449
great C 114 449
experimental C 115 449
error C 116 449
. C 117 449
2820 C 1 450
. C 2 450
influence C 4 450
of C 5 450
small C 6 450
doses C 7 450
of C 8 450
corticosteroids C 9 450
on C 10 450
the C 11 450
excretion C 12 450
of C 13 450
pregnanetriol C 14 450
and C 15 450
oestrone C 16 450
in C 17 450
a C 18 450
series C 19 450
of C 20 450
patients C 21 450
with C 22 450
breast C 23 450
cancer C 24 450
excretion C 25 450
of C 26 450
oestrone C 27 450
and C 28 450
pregnanetriol C 29 450
was C 30 450
determined C 31 450
. C 32 450
with C 34 450
administration C 35 450
of C 36 450
corticosteroids C 37 450
oestrone C 38 450
excretion C 39 450
in C 40 450
postmenopausal C 41 450
women C 42 450
diminished C 43 450
67 C 44 450
% C 45 450
. C 46 450
a C 48 450
decrease C 49 450
of C 50 450
pregnanetriol C 51 450
ex C 52 450
- C 53 450
cretion C 54 450
values C 55 450
was C 56 450
observed C 57 450
as C 58 450
well C 59 450
. C 60 450
evidently C 62 450
a C 63 450
low C 64 450
oestrone C 65 450
excretion C 66 450
in C 67 450
patients C 68 450
subjected C 69 450
to C 70 450
corticosteroid C 71 450
therapy C 72 450
is C 73 450
due C 74 450
to C 75 450
a C 76 450
depression C 77 450
of C 78 450
the C 79 450
adrenal C 80 450
function C 81 450
. C 82 450
5062 C 1 451
. C 2 451
urinary C 4 451
ii C 5 451
- C 6 451
deoxy C 7 451
- C 8 451
17 C 9 451
- C 10 451
oxosteroids C 11 451
in C 12 451
british C 13 451
and C 14 451
japanese C 15 451
women C 16 451
with C 17 451
reference C 18 451
to C 19 451
the C 20 451
incidence C 21 451
of C 22 451
breast C 23 451
cancer C 24 451
japanese C 25 451
women C 26 451
excrete C 27 451
more C 28 451
andosterene C 29 451
( C 30 451
5 C 31 451
a C 32 451
) C 33 451
relative C 34 451
to C 35 451
aetiocholanone C 36 451
( C 37 451
5 C 38 451
b C 39 451
) C 40 451
than C 41 451
do C 42 451
british C 43 451
women C 44 451
living C 45 451
in C 46 451
tokyo C 47 451
. C 48 451
the C 50 451
mean C 51 451
5 C 52 451
a C 53 451
/ C 54 451
5 C 55 451
b C 56 451
ratio C 57 451
in C 58 451
the C 59 451
former C 60 451
is C 61 451
1 C 62 451
. C 63 451
. C 64 451
and C 65 451
in C 66 451
the C 67 451
latter C 68 451
1 C 69 451
. C 70 451
. C 71 451
, C 72 451
and C 73 451
these C 74 451
means C 75 451
differ C 76 451
significantly C 77 451
. C 78 451
the C 80 451
ratio C 81 451
is C 82 451
markedly C 83 451
affected C 84 451
by C 85 451
thyroid C 86 451
function C 87 451
, C 88 451
and C 89 451
thyroid C 90 451
disease C 91 451
has C 92 451
been C 93 451
reported C 94 451
to C 95 451
affect C 96 451
the C 97 451
incidence C 98 451
of C 99 451
breast C 100 451
cancer C 101 451
which C 102 451
in C 103 451
japan C 104 451
is C 105 451
only C 106 451
one C 107 451
eighth C 108 451
of C 109 451
that C 110 451
in C 111 451
white C 112 451
women C 113 451
in C 114 451
north C 115 451
america C 116 451
or C 117 451
great C 118 451
britain C 119 451
. C 120 451
5318 C 1 452
. C 2 452
the C 4 452
plasma C 5 452
17 C 6 452
- C 7 452
ketosteroids C 8 452
and C 9 452
17 C 10 452
- C 11 452
hydrocorticosteroids C 12 452
in C 13 452
women C 14 452
with C 15 452
breast C 16 452
cancer C 17 452
in C 18 452
100 C 19 452
women C 20 452
in C 21 452
the C 22 452
menopause C 23 452
with C 24 452
breast C 25 452
cancer C 26 452
the C 27 452
mean C 28 452
level C 29 452
of C 30 452
plasma C 31 452
17 C 32 452
- C 33 452
ketosteroids C 34 452
( C 35 452
17 C 36 452
- C 37 452
ks C 38 452
) C 39 452
and C 40 452
17 C 41 452
- C 42 452
hydroxycorticosteroids C 43 452
( C 44 452
17 C 45 452
- C 46 452
ohcs C 47 452
) C 48 452
was C 49 452
significantly C 50 452
higher C 51 452
than C 52 452
in C 53 452
normal C 54 452
women C 55 452
of C 56 452
equivalent C 57 452
age C 58 452
. C 59 452
in C 61 452
67 C 62 452
young C 63 452
women C 64 452
only C 65 452
the C 66 452
level C 67 452
of C 68 452
the C 69 452
plasma C 70 452
17 C 71 452
- C 72 452
ohcs C 73 452
was C 74 452
significantly C 75 452
higher C 76 452
than C 77 452
normal C 78 452
. C 79 452
in C 81 452
menopausal C 82 452
women C 83 452
with C 84 452
breast C 85 452
cancer C 86 452
whether C 87 452
treated C 88 452
or C 89 452
not C 90 452
there C 91 452
is C 92 452
no C 93 452
correlation C 94 452
between C 95 452
the C 96 452
level C 97 452
of C 98 452
the C 99 452
plasma C 100 452
17 C 101 452
- C 102 452
ks C 103 452
and C 104 452
that C 105 452
of C 106 452
17 C 107 452
- C 108 452
ohcs C 109 452
. C 110 452
5319 C 1 453
. C 2 453
urinary C 4 453
porter C 5 453
- C 6 453
silber C 7 453
chromogens C 8 453
following C 9 453
intravenous C 10 453
metho C 11 453
- C 12 453
pyrapone C 13 453
and C 14 453
acth C 15 453
in C 16 453
patients C 17 453
with C 18 453
breast C 19 453
cancer C 20 453
urinary C 21 453
porter C 22 453
- C 23 453
silber C 24 453
chromogens C 25 453
have C 26 453
been C 27 453
measured C 28 453
in C 29 453
2 C 30 453
groups C 31 453
of C 32 453
patients C 33 453
with C 34 453
breast C 35 453
cancer C 36 453
before C 37 453
, C 38 453
during C 39 453
and C 40 453
after C 41 453
intravenous C 42 453
methopyrapone C 43 453
and C 44 453
acth C 45 453
administration C 46 453
. C 47 453
the C 49 453
control C 50 453
group C 51 453
consisted C 52 453
of C 53 453
females C 54 453
free C 55 453
of C 56 453
disease C 57 453
5 C 58 453
years C 59 453
or C 60 453
more C 61 453
following C 62 453
mastectomy C 63 453
while C 64 453
the C 65 453
study C 66 453
group C 67 453
had C 68 453
documented C 69 453
metastatic C 70 453
disease C 71 453
. C 72 453
no C 74 453
significant C 75 453
difference C 76 453
in C 77 453
the C 78 453
urinary C 79 453
porter C 80 453
- C 81 453
silber C 82 453
chromo C 83 453
- C 84 453
gens C 85 453
was C 86 453
found C 87 453
between C 88 453
the C 89 453
2 C 90 453
groups C 91 453
on C 92 453
any C 93 453
day C 94 453
during C 95 453
the C 96 453
course C 97 453
of C 98 453
the C 99 453
study C 100 453
and C 101 453
were C 102 453
within C 103 453
the C 104 453
range C 105 453
of C 106 453
normal C 107 453
as C 108 453
measured C 109 453
in C 110 453
this C 111 453
laboratory C 112 453
. C 113 453
it C 115 453
is C 116 453
concluded C 117 453
that C 118 453
the C 119 453
functional C 120 453
reserve C 121 453
capacity C 122 453
for C 123 453
both C 124 453
pituitary C 125 453
acth C 126 453
secretion C 127 453
and C 128 453
adreno C 129 453
- C 130 453
cortical C 131 453
steroidogenesis C 132 453
in C 133 453
patients C 134 453
with C 135 453
advanced C 136 453
metastatic C 137 453
breast C 138 453
cancer C 139 453
is C 140 453
rela C 141 453
- C 142 453
tively C 143 453
normal C 144 453
. C 145 453
2349 C 1 454
. C 2 454
amyloidosis C 4 454
in C 5 454
the C 6 454
autopsy C 7 454
material C 8 454
of C 9 454
the C 10 454
pathology C 11 454
department C 12 454
of C 13 454
tuberculosis C 14 454
institute C 15 454
, C 16 454
warsaw C 17 454
, C 18 454
in C 19 454
1945 C 20 454
- C 21 454
1962 C 22 454
the C 23 454
autopsy C 24 454
material C 25 454
of C 26 454
the C 27 454
pathology C 28 454
department C 29 454
of C 30 454
the C 31 454
tuberculosis C 32 454
institute C 33 454
, C 34 454
in C 35 454
1945 C 36 454
- C 37 454
1962 C 38 454
, C 39 454
included C 40 454
1218 C 41 454
postmortem C 42 454
examinations C 43 454
of C 44 454
patients C 45 454
who C 46 454
died C 47 454
from C 48 454
tuberculo C 49 454
- C 50 454
sis C 51 454
. C 52 454
in C 54 454
111 C 55 454
cases C 56 454
tuberculosis C 57 454
was C 58 454
complicated C 59 454
by C 60 454
amyloidosis C 61 454
. C 62 454
in C 64 454
1945 C 65 454
- C 66 454
1957 C 67 454
amy C 68 454
- C 69 454
loidosis C 70 454
accounted C 71 454
for C 72 454
8 C 73 454
. C 74 454
. C 75 454
% C 76 454
of C 77 454
the C 78 454
cases C 79 454
; C 80 454
in C 81 454
1958 C 82 454
- C 83 454
1962 C 84 454
this C 85 454
percentage C 86 454
was C 87 454
10 C 88 454
. C 89 454
. C 90 454
. C 91 454
there C 93 454
was C 94 454
no C 95 454
difference C 96 454
in C 97 454
the C 98 454
incidence C 99 454
between C 100 454
men C 101 454
and C 102 454
women C 103 454
, C 104 454
the C 105 454
only C 106 454
difference C 107 454
between C 108 454
the C 109 454
two C 110 454
sexes C 111 454
was C 112 454
that C 113 454
the C 114 454
peak C 115 454
tuberculosis C 116 454
fatality C 117 454
curve C 118 454
in C 119 454
men C 120 454
was C 121 454
in C 122 454
the C 123 454
40 C 124 454
- C 125 454
60 C 126 454
years C 127 454
age C 128 454
group C 129 454
, C 130 454
and C 131 454
that C 132 454
of C 133 454
amyloidosis C 134 454
at C 135 454
the C 136 454
20 C 137 454
- C 138 454
30 C 139 454
age C 140 454
group C 141 454
, C 142 454
while C 143 454
in C 144 454
women C 145 454
the C 146 454
greatest C 147 454
number C 148 454
of C 149 454
death C 150 454
from C 151 454
tuberculosis C 152 454
was C 153 454
in C 154 454
the C 155 454
20 C 156 454
- C 157 454
30 C 158 454
age C 159 454
group C 160 454
, C 161 454
and C 162 454
from C 163 454
amyloidosis C 164 454
in C 165 454
the C 166 454
30 C 167 454
- C 168 454
40 C 169 454
age C 170 454
group C 171 454
. C 172 454
766 C 1 455
. C 2 455
certain C 4 455
features C 5 455
of C 6 455
the C 7 455
haemogram C 8 455
in C 9 455
patients C 10 455
with C 11 455
pulmonary C 12 455
tuberculosis C 13 455
complicated C 14 455
by C 15 455
amyloidosis C 16 455
( C 17 455
russian C 18 455
) C 19 455
regression C 20 455
of C 21 455
amyloidosis C 22 455
in C 23 455
the C 24 455
early C 25 455
stages C 26 455
seems C 27 455
possible C 28 455
and C 29 455
for C 30 455
this C 31 455
reason C 32 455
russian C 33 455
clinicians C 34 455
are C 35 455
exploring C 36 455
the C 37 455
possibilities C 38 455
of C 39 455
finding C 40 455
means C 41 455
of C 42 455
early C 43 455
diagnosis C 44 455
of C 45 455
this C 46 455
complication C 47 455
. C 48 455
the C 50 455
author C 51 455
studied C 52 455
300 C 53 455
complete C 54 455
clinical C 55 455
blood C 56 455
analyses C 57 455
made C 58 455
in C 59 455
60 C 60 455
patients C 61 455
, C 62 455
viz C 63 455
. C 64 455
30 C 66 455
with C 67 455
chronic C 68 455
fibrocavernous C 69 455
and C 70 455
cirrhotic C 71 455
forms C 72 455
of C 73 455
tb C 74 455
com C 75 455
- C 76 455
plicated C 77 455
by C 78 455
amyloidosis C 79 455
and C 80 455
30 C 81 455
with C 82 455
the C 83 455
same C 84 455
forms C 85 455
of C 86 455
tb C 87 455
without C 88 455
amyloidosis C 89 455
. C 90 455
from C 92 455
detailed C 93 455
serial C 94 455
study C 95 455
of C 96 455
the C 97 455
haemogram C 98 455
in C 99 455
patients C 100 455
with C 101 455
pulmonary C 102 455
tb C 103 455
it C 104 455
is C 105 455
possible C 106 455
to C 107 455
diagnose C 108 455
associated C 109 455
amyloidosis C 110 455
of C 111 455
the C 112 455
internal C 113 455
organs C 114 455
in C 115 455
its C 116 455
initial C 117 455
stage C 118 455
. C 119 455
the C 121 455
presence C 122 455
of C 123 455
amyloidosis C 124 455
of C 125 455
the C 126 455
internal C 127 455
organs C 128 455
can C 129 455
be C 130 455
inferred C 131 455
from C 132 455
the C 133 455
following C 134 455
changes C 135 455
in C 136 455
the C 137 455
blood C 138 455
picture C 139 455
( C 140 455
a C 141 455
) C 142 455
the C 143 455
appearance C 144 455
of C 145 455
normochromic C 146 455
and C 147 455
hypochromic C 148 455
anaemia C 149 455
in C 150 455
patients C 151 455
with C 152 455
various C 153 455
forms C 154 455
of C 155 455
tb C 156 455
( C 157 455
with C 158 455
the C 159 455
exception C 160 455
of C 161 455
tb C 162 455
of C 163 455
the C 164 455
kidneys C 165 455
, C 166 455
intestinal C 167 455
tract C 168 455
or C 169 455
larynx C 170 455
, C 171 455
and C 172 455
of C 173 455
caseous C 174 455
lymph C 175 455
nodes C 176 455
) C 177 455
, C 178 455
( C 179 455
b C 180 455
) C 181 455
progressive C 182 455
increase C 183 455
in C 184 455
the C 185 455
leucocyte C 186 455
count C 187 455
with C 188 455
a C 189 455
neutrophil C 190 455
shift C 191 455
to C 192 455
the C 193 455
left C 194 455
not C 195 455
corresponding C 196 455
with C 197 455
a C 198 455
phase C 199 455
of C 200 455
quiescence C 201 455
of C 202 455
the C 203 455
main C 204 455
disease C 205 455
, C 206 455
( C 207 455
c C 208 455
) C 209 455
consistently C 210 455
high C 211 455
esr C 212 455
in C 213 455
the C 214 455
absence C 215 455
of C 216 455
an C 217 455
active C 218 455
process C 219 455
, C 220 455
( C 221 455
d C 222 455
) C 223 455
thrombocytosis C 224 455
in C 225 455
the C 226 455
phase C 227 455
of C 228 455
subsidence C 229 455
of C 230 455
a C 231 455
flare C 232 455
- C 233 455
up C 234 455
, C 235 455
and C 236 455
also C 237 455
changes C 238 455
in C 239 455
the C 240 455
thrombocytic C 241 455
formula C 242 455
tending C 243 455
towards C 244 455
the C 245 455
appearance C 246 455
of C 247 455
de C 248 455
- C 249 455
generative C 250 455
forms C 251 455
and C 252 455
old C 253 455
and C 254 455
mature C 255 455
thrombocytes C 256 455
. C 257 455
1319 C 1 456
. C 2 456
diffuse C 4 456
tracheo C 5 456
- C 6 456
bronchial C 7 456
amyloidosis C 8 456
a C 9 456
rare C 10 456
variant C 11 456
of C 12 456
a C 13 456
protean C 14 456
disease C 15 456
a C 16 456
patient C 17 456
with C 18 456
diffuse C 19 456
tracheo C 20 456
- C 21 456
bronchial C 22 456
amyloidosis C 23 456
is C 24 456
described C 25 456
; C 26 456
brief C 27 456
clinical C 28 456
details C 29 456
supplement C 30 456
those C 31 456
published C 32 456
in C 33 456
a C 34 456
previous C 35 456
report C 36 456
( C 37 456
prowse C 38 456
, C 39 456
1958 C 40 456
) C 41 456
and C 42 456
are C 43 456
followed C 44 456
by C 45 456
an C 46 456
account C 47 456
of C 48 456
the C 49 456
necropsy C 50 456
findings C 51 456
and C 52 456
the C 53 456
histological C 54 456
appearances C 55 456
at C 56 456
the C 57 456
site C 58 456
of C 59 456
amyloid C 60 456
deposition C 61 456
. C 62 456
the C 64 456
literature C 65 456
is C 66 456
reviewed C 67 456
and C 68 456
arguments C 69 456
are C 70 456
advanced C 71 456
in C 72 456
favour C 73 456
of C 74 456
a C 75 456
common C 76 456
aetiology C 77 456
for C 78 456
amyloidosis C 79 456
in C 80 456
all C 81 456
its C 82 456
forms C 83 456
. C 84 456
if C 86 456
this C 87 456
acts C 88 456
through C 89 456
the C 90 456
immunity C 91 456
mechanism C 92 456
, C 93 456
it C 94 456
is C 95 456
suggested C 96 456
that C 97 456
variations C 98 456
in C 99 456
the C 100 456
site C 101 456
, C 102 456
strength C 103 456
, C 104 456
duration C 105 456
, C 106 456
and C 107 456
frequency C 108 456
of C 109 456
the C 110 456
antigen C 111 456
stimulus C 112 456
and C 113 456
the C 114 456
antibody C 115 456
response C 116 456
may C 117 456
determine C 118 456
the C 119 456
nature C 120 456
and C 121 456
distribution C 122 456
of C 123 456
the C 124 456
amyloid C 125 456
deposits C 126 456
. C 127 456
2091 C 1 457
. C 2 457
modern C 4 457
methods C 5 457
of C 6 457
treatment C 7 457
of C 8 457
visceral C 9 457
amyloidosis C 10 457
in C 11 457
patients C 12 457
with C 13 457
pulmonary C 14 457
tuberculosis C 15 457
( C 16 457
russian C 17 457
) C 18 457
the C 19 457
immediate C 20 457
and C 21 457
long C 22 457
- C 23 457
term C 24 457
results C 25 457
of C 26 457
treatment C 27 457
during C 28 457
1945 C 29 457
- C 30 457
1962 C 31 457
of C 32 457
414 C 33 457
patients C 34 457
with C 35 457
pulmonary C 36 457
tuberculosis C 37 457
complicated C 38 457
by C 39 457
amyloidosis C 40 457
were C 41 457
studied C 42 457
. C 43 457
hormonal C 45 457
( C 46 457
corticosteroid C 47 457
) C 48 457
therapy C 49 457
is C 50 457
the C 51 457
pathogenetic C 52 457
treatment C 53 457
for C 54 457
visceral C 55 457
amyloidosis C 56 457
and C 57 457
is C 58 457
indicated C 59 457
in C 60 457
the C 61 457
proteinuric C 62 457
and C 63 457
early C 64 457
edema C 65 457
- C 66 457
hypotonic C 67 457
phase C 68 457
of C 69 457
amyloidosis C 70 457
when C 71 457
the C 72 457
functional C 73 457
capacity C 74 457
of C 75 457
the C 76 457
kidneys C 77 457
and C 78 457
the C 79 457
liver C 80 457
is C 81 457
still C 82 457
adequate C 83 457
. C 84 457
in C 86 457
the C 87 457
azotemic C 88 457
phase C 89 457
of C 90 457
amyloidosis C 91 457
, C 92 457
hormonal C 93 457
( C 94 457
corticosteroid C 95 457
) C 96 457
therapy C 97 457
is C 98 457
not C 99 457
indicated C 100 457
, C 101 457
since C 102 457
it C 103 457
leads C 104 457
to C 105 457
rapid C 106 457
deterioration C 107 457
in C 108 457
the C 109 457
patient C 110 457
' C 111 457
s C 112 457
condition C 113 457
. C 114 457
since C 116 457
hypoxemia C 117 457
is C 118 457
one C 119 457
of C 120 457
the C 121 457
main C 122 457
factors C 123 457
in C 124 457
the C 125 457
pathogenesis C 126 457
of C 127 457
amyloidosis C 128 457
, C 129 457
oxygen C 130 457
therapy C 131 457
is C 132 457
rational C 133 457
patho C 134 457
- C 135 457
genetic C 136 457
therapy C 137 457
for C 138 457
patients C 139 457
with C 140 457
pulmonary C 141 457
tuberculosis C 142 457
complicated C 143 457
by C 144 457
hypoxemia C 145 457
and C 146 457
with C 147 457
symptoms C 148 457
of C 149 457
the C 150 457
proteinuric C 151 457
or C 152 457
edema C 153 457
- C 154 457
hypotonic C 155 457
phase C 156 457
of C 157 457
amyloidosis C 158 457
( C 159 457
without C 160 457
ascites C 161 457
) C 162 457
, C 163 457
in C 164 457
the C 165 457
form C 166 457
of C 167 457
subcutaneous C 168 457
introduction C 169 457
of C 170 457
oxygen C 171 457
or C 172 457
oxy C 173 457
- C 174 457
geno C 175 457
- C 176 457
peritoneum C 177 457
. C 178 457
in C 180 457
patients C 181 457
with C 182 457
pulmonary C 183 457
tuberculosis C 184 457
surgical C 185 457
interven C 186 457
- C 187 457
tion C 188 457
on C 189 457
account C 190 457
of C 191 457
the C 192 457
main C 193 457
process C 194 457
is C 195 457
indicated C 196 457
only C 197 457
in C 198 457
the C 199 457
early C 200 457
stages C 201 457
of C 202 457
amyloi C 203 457
- C 204 457
dosis C 205 457
when C 206 457
pronounced C 207 457
functional C 208 457
disorders C 209 457
of C 210 457
the C 211 457
kidneys C 212 457
and C 213 457
liver C 214 457
are C 215 457
absent C 216 457
. C 217 457
co C 219 457
- C 220 457
joint C 221 457
therapy C 222 457
using C 223 457
protein C 224 457
vitamins C 225 457
( C 226 457
particularly C 227 457
ascorbic C 228 457
acid C 229 457
) C 230 457
, C 231 457
hormonal C 232 457
( C 233 457
corticos C 234 457
- C 235 457
teroid C 236 457
) C 237 457
preparations C 238 457
, C 239 457
oxygen C 240 457
and C 241 457
desensitizing C 242 457
agents C 243 457
and C 244 457
elimination C 245 457
of C 246 457
all C 247 457
foci C 248 457
of C 249 457
infection C 250 457
is C 251 457
indicated C 252 457
in C 253 457
treatment C 254 457
of C 255 457
pulmonary C 256 457
tuberculosis C 257 457
with C 258 457
even C 259 457
the C 260 457
earliest C 261 457
signs C 262 457
of C 263 457
amyloidosis C 264 457
. C 265 457
2317 C 1 458
. C 2 458
the C 4 458
use C 5 458
of C 6 458
needle C 7 458
biopsy C 8 458
of C 9 458
the C 10 458
liver C 11 458
in C 12 458
the C 13 458
diagnosis C 14 458
of C 15 458
visceral C 16 458
amyloidosis C 17 458
in C 18 458
patients C 19 458
with C 20 458
pulmonary C 21 458
tuberculosis C 22 458
( C 23 458
russian C 24 458
) C 25 458
the C 26 458
results C 27 458
of C 28 458
86 C 29 458
puncture C 30 458
biopsies C 31 458
of C 32 458
the C 33 458
liver C 34 458
in C 35 458
84 C 36 458
patients C 37 458
with C 38 458
pulmonary C 39 458
tuber C 40 458
- C 41 458
culosis C 42 458
( C 43 458
55 C 44 458
men C 45 458
and C 46 458
31 C 47 458
women C 48 458
aged C 49 458
from C 50 458
18 C 51 458
to C 52 458
73 C 53 458
yr C 54 458
. C 55 458
) C 57 458
for C 58 458
the C 59 458
purpose C 60 458
of C 61 458
diagnosing C 62 458
amyloidosis C 63 458
are C 64 458
reported C 65 458
. C 66 458
puncture C 68 458
was C 69 458
performed C 70 458
when C 71 458
amyloidosis C 72 458
was C 73 458
suspected C 74 458
on C 75 458
the C 76 458
basis C 77 458
of C 78 458
the C 79 458
case C 80 458
history C 81 458
( C 82 458
destructive C 83 458
process C 84 458
of C 85 458
more C 86 458
than C 87 458
2 C 88 458
- C 89 458
3 C 90 458
years C 91 458
' C 92 458
duration C 93 458
) C 94 458
, C 95 458
clinical C 96 458
signs C 97 458
in C 98 458
the C 99 458
form C 100 458
of C 101 458
enlargement C 102 458
of C 103 458
the C 104 458
liver C 105 458
and C 106 458
spleen C 107 458
, C 108 458
edema C 109 458
, C 110 458
changes C 111 458
in C 112 458
the C 113 458
blood C 114 458
picture C 115 458
and C 116 458
blood C 117 458
protein C 118 458
formula C 119 458
, C 120 458
and C 121 458
changes C 122 458
in C 123 458
the C 124 458
urine C 125 458
( C 126 458
proteinuria C 127 458
, C 128 458
cylindruria C 129 458
, C 130 458
isohyposthenuria C 131 458
) C 132 458
. C 133 458
amyloidosis C 135 458
was C 136 458
diagnosed C 137 458
or C 138 458
its C 139 458
presence C 140 458
surmised C 141 458
before C 142 458
puncture C 143 458
in C 144 458
23 C 145 458
patients C 146 458
; C 147 458
the C 148 458
puncture C 149 458
biopsy C 150 458
confirmed C 151 458
the C 152 458
diagnosis C 153 458
in C 154 458
14 C 155 458
and C 156 458
refuted C 157 458
it C 158 458
in C 159 458
9 C 160 458
of C 161 458
them C 162 458
. C 163 458
in C 165 458
8 C 166 458
patients C 167 458
without C 168 458
clinical C 169 458
symptoms C 170 458
, C 171 458
amyloidosis C 172 458
was C 173 458
diagnosed C 174 458
on C 175 458
the C 176 458
basis C 177 458
of C 178 458
the C 179 458
puncture C 180 458
biopsy C 181 458
alone C 182 458
. C 183 458
in C 185 458
9 C 186 458
cases C 187 458
with C 188 458
fatal C 189 458
out C 190 458
- C 191 458
come C 192 458
, C 193 458
the C 194 458
post C 195 458
- C 196 458
mortem C 197 458
findings C 198 458
coincided C 199 458
with C 200 458
the C 201 458
results C 202 458
of C 203 458
the C 204 458
bioptic C 205 458
puncture C 206 458
. C 207 458
of C 209 458
the C 210 458
62 C 211 458
patients C 212 458
in C 213 458
whom C 214 458
amyloidosis C 215 458
was C 216 458
not C 217 458
detected C 218 458
by C 219 458
biopsy C 220 458
, C 221 458
31 C 222 458
had C 223 458
moderate C 224 458
dystrophic C 225 458
changes C 226 458
and C 227 458
9 C 228 458
had C 229 458
marked C 230 458
dystrophic C 231 458
changes C 232 458
while C 233 458
in C 234 458
22 C 235 458
cases C 236 458
no C 237 458
patho C 238 458
- C 239 458
logical C 240 458
changes C 241 458
were C 242 458
found C 243 458
; C 244 458
6 C 245 458
of C 246 458
these C 247 458
patients C 248 458
later C 249 458
developed C 250 458
amyloidosis C 251 458
. C 252 458
these C 254 458
findings C 255 458
supported C 256 458
the C 257 458
contention C 258 458
that C 259 458
liver C 260 458
amyloidosis C 261 458
is C 262 458
linked C 263 458
with C 264 458
dystrophic C 265 458
changes C 266 458
in C 267 458
the C 268 458
epithelial C 269 458
cells C 270 458
. C 271 458
marked C 273 458
dystrophic C 274 458
changes C 275 458
can C 276 458
precede C 277 458
amyloidosis C 278 458
or C 279 458
may C 280 458
occur C 281 458
simultaneously C 282 458
with C 283 458
it C 284 458
. C 285 458
moderate C 287 458
dystrophic C 288 458
changes C 289 458
are C 290 458
quite C 291 458
common C 292 458
in C 293 458
patients C 294 458
with C 295 458
an C 296 458
exacerbating C 297 458
tuberculous C 298 458
process C 299 458
in C 300 458
the C 301 458
lungs C 302 458
. C 303 458
the C 305 458
wide C 306 458
applica C 307 458
- C 308 458
tion C 309 458
of C 310 458
bioptic C 311 458
puncture C 312 458
of C 313 458
the C 314 458
liver C 315 458
in C 316 458
indicated C 317 458
cases C 318 458
can C 319 458
increase C 320 458
our C 321 458
knowledge C 322 458
of C 323 458
the C 324 458
morphological C 325 458
changes C 326 458
taking C 327 458
place C 328 458
in C 329 458
the C 330 458
liver C 331 458
in C 332 458
tb C 333 458
. C 334 458
2701 C 1 459
. C 2 459
the C 4 459
role C 5 459
of C 6 459
certain C 7 459
additional C 8 459
factors C 9 459
in C 10 459
the C 11 459
development C 12 459
of C 13 459
amyloidosis C 14 459
, C 15 459
and C 16 459
its C 17 459
prophylaxis C 18 459
in C 19 459
patients C 20 459
with C 21 459
pulmonary C 22 459
tuberculosis C 23 459
( C 24 459
russian C 25 459
) C 26 459
in C 27 459
patients C 28 459
with C 29 459
chronic C 30 459
fibrocavernous C 31 459
tuberculosis C 32 459
of C 33 459
the C 34 459
lungs C 35 459
, C 36 459
any C 37 459
toxic C 38 459
- C 39 459
aller C 40 459
- C 41 459
gic C 42 459
side C 43 459
reactions C 44 459
to C 45 459
antibacterial C 46 459
therapy C 47 459
, C 48 459
chronic C 49 459
foci C 50 459
or C 51 459
infection C 52 459
and C 53 459
diseases C 54 459
with C 55 459
an C 56 459
allergic C 57 459
component C 58 459
can C 59 459
contribute C 60 459
to C 61 459
the C 62 459
development C 63 459
of C 64 459
amyloidosis C 65 459
. C 66 459
the C 68 459
early C 69 459
detection C 70 459
and C 71 459
clearing C 72 459
of C 73 459
chronic C 74 459
foci C 75 459
of C 76 459
infection C 77 459
and C 78 459
effective C 79 459
measures C 80 459
against C 81 459
even C 82 459
mildly C 83 459
pronounced C 84 459
toxic C 85 459
- C 86 459
allergic C 87 459
side C 88 459
reactions C 89 459
are C 90 459
of C 91 459
prime C 92 459
impor C 93 459
- C 94 459
tance C 95 459
in C 96 459
the C 97 459
prevention C 98 459
of C 99 459
amyloidosis C 100 459
. C 101 459
the C 103 459
unsystematic C 104 459
and C 105 459
prolonged C 106 459
administra C 107 459
- C 108 459
tion C 109 459
of C 110 459
antibacterial C 111 459
preparations C 112 459
, C 113 459
along C 114 459
with C 115 459
their C 116 459
toxic C 117 459
side C 118 459
effects C 119 459
, C 120 459
tends C 121 459
to C 122 459
in C 123 459
- C 124 459
crease C 125 459
the C 126 459
incidence C 127 459
of C 128 459
amyloidosis C 129 459
in C 130 459
patients C 131 459
with C 132 459
chronic C 133 459
fibrocavernous C 134 459
pulmon C 135 459
- C 136 459
ary C 137 459
tb C 138 459
. C 139 459
individual C 141 459
constitutional C 142 459
factors C 143 459
are C 144 459
of C 145 459
great C 146 459
importance C 147 459
in C 148 459
the C 149 459
development C 150 459
of C 151 459
side C 152 459
effects C 153 459
. C 154 459
side C 156 459
reactions C 157 459
to C 158 459
chemopreparations C 159 459
, C 160 459
in C 161 459
cases C 162 459
of C 163 459
hypofunction C 164 459
of C 165 459
the C 166 459
liver C 167 459
and C 168 459
kidneys C 169 459
and C 170 459
autonomic C 171 459
dysfunction C 172 459
promote C 173 459
the C 174 459
development C 175 459
of C 176 459
dys C 177 459
- C 178 459
trophic C 179 459
processes C 180 459
, C 181 459
as C 182 459
is C 183 459
confirmed C 184 459
by C 185 459
the C 186 459
high C 187 459
frequency C 188 459
of C 189 459
toxic C 190 459
- C 191 459
allergic C 192 459
reac C 193 459
- C 194 459
tions C 195 459
in C 196 459
patients C 197 459
with C 198 459
fibrocavernous C 199 459
pulmonary C 200 459
tb C 201 459
who C 202 459
later C 203 459
develop C 204 459
amyloidosis C 205 459
. C 206 459
the C 208 459
administration C 209 459
of C 210 459
desensitizing C 211 459
drugs C 212 459
to C 213 459
patients C 214 459
showing C 215 459
side C 216 459
reactions C 217 459
there C 218 459
- C 219 459
fore C 220 459
helps C 221 459
to C 222 459
prevent C 223 459
amyloidosis C 224 459
in C 225 459
cases C 226 459
of C 227 459
chronic C 228 459
fibrocavernous C 229 459
tb C 230 459
, C 231 459
and C 232 459
chemo C 233 459
- C 234 459
therapy C 235 459
should C 236 459
be C 237 459
automatically C 238 459
combined C 239 459
with C 240 459
the C 241 459
administration C 242 459
of C 243 459
desensitizing C 244 459
and C 245 459
stimulatory C 246 459
drugs C 247 459
in C 248 459
this C 249 459
class C 250 459
of C 251 459
case C 252 459
. C 253 459
1835 C 1 460
. C 2 460
the C 4 460
decrease C 5 460
of C 6 460
the C 7 460
steroids C 8 460
in C 9 460
the C 10 460
urine C 11 460
in C 12 460
the C 13 460
course C 14 460
of C 15 460
lung C 16 460
tb C 17 460
. C 18 460
( C 20 460
the C 21 460
therapeutic C 22 460
value C 23 460
of C 24 460
their C 25 460
increase C 26 460
after C 27 460
calciferol C 28 460
) C 29 460
quantitative C 30 460
determination C 31 460
of C 32 460
the C 33 460
urinary C 34 460
steroids C 35 460
in C 36 460
38 C 37 460
patients C 38 460
with C 39 460
extensive C 40 460
ul C 41 460
- C 42 460
cero C 43 460
- C 44 460
caseous C 45 460
pulmonary C 46 460
tb C 47 460
confirmed C 48 460
that C 49 460
the C 50 460
17 C 51 460
- C 52 460
ketosteroids C 53 460
are C 54 460
always C 55 460
decreased C 56 460
in C 57 460
these C 58 460
cases C 59 460
. C 60 460
calciferol C 62 460
, C 63 460
in C 64 460
the C 65 460
form C 66 460
of C 67 460
one C 68 460
ampoule C 69 460
of C 70 460
vit C 71 460
. C 72 460
d C 74 460
2 C 75 460
of C 76 460
600 C 77 460
, C 78 460
000 C 79 460
u C 80 460
. C 81 460
every C 83 460
10 C 84 460
days C 85 460
, C 86 460
in C 87 460
combination C 88 460
with C 89 460
active C 90 460
tuberculostatic C 91 460
drugs C 92 460
, C 93 460
in C 94 460
the C 95 460
majority C 96 460
of C 97 460
the C 98 460
cases C 99 460
leads C 100 460
to C 101 460
an C 102 460
increase C 103 460
of C 104 460
the C 105 460
urinary C 106 460
17 C 107 460
- C 108 460
ketosteroids C 109 460
from C 110 460
50 C 111 460
to C 112 460
100 C 113 460
% C 114 460
in C 115 460
2 C 116 460
mth C 117 460
. C 118 460
it C 120 460
appears C 121 460
that C 122 460
the C 123 460
calciferol C 124 460
exerts C 125 460
its C 126 460
action C 127 460
through C 128 460
proteolysis C 129 460
; C 130 460
it C 131 460
stimulates C 132 460
the C 133 460
liquefaction C 134 460
and C 135 460
evacuation C 136 460
of C 137 460
the C 138 460
caseous C 139 460
material C 140 460
. C 141 460
this C 143 460
proteolytic C 144 460
effect C 145 460
is C 146 460
related C 147 460
to C 148 460
that C 149 460
of C 150 460
the C 151 460
mineralocorticoids C 152 460
, C 153 460
which C 154 460
are C 155 460
phlogistic C 156 460
and C 157 460
proteolytic C 158 460
sub C 159 460
- C 160 460
stances C 161 460
. C 162 460
calciferol C 164 460
offers C 165 460
the C 166 460
advantage C 167 460
over C 168 460
these C 169 460
substances C 170 460
that C 171 460
it C 172 460
does C 173 460
not C 174 460
affect C 175 460
the C 176 460
electrolytes C 177 460
and C 178 460
is C 179 460
well C 180 460
tolerated C 181 460
by C 182 460
the C 183 460
organism C 184 460
. C 185 460
for C 187 460
this C 188 460
reason C 189 460
, C 190 460
good C 191 460
results C 192 460
may C 193 460
be C 194 460
expected C 195 460
from C 196 460
its C 197 460
administration C 198 460
in C 199 460
cases C 200 460
of C 201 460
extensive C 202 460
pulmonary C 203 460
tb C 204 460
, C 205 460
in C 206 460
which C 207 460
the C 208 460
myc C 209 460
. C 210 460
tuberculosis C 212 460
has C 213 460
remained C 214 460
sensitive C 215 460
to C 216 460
the C 217 460
administered C 218 460
tuberculostic C 219 460
drugs C 220 460
but C 221 460
nevertheless C 222 460
does C 223 460
not C 224 460
proceed C 225 460
towards C 226 460
recovery C 227 460
because C 228 460
of C 229 460
the C 230 460
marked C 231 460
caseous C 232 460
lesions C 233 460
. C 234 460
in C 236 460
such C 237 460
cases C 238 460
calciferol C 239 460
treatment C 240 460
leads C 241 460
to C 242 460
a C 243 460
rapid C 244 460
and C 245 460
pronounced C 246 460
decrease C 247 460
of C 248 460
the C 249 460
radiological C 250 460
shadows C 251 460
, C 252 460
improves C 253 460
the C 254 460
general C 255 460
condition C 256 460
and C 257 460
also C 258 460
modifies C 259 460
the C 260 460
steroid C 261 460
metabolism C 262 460
rendered C 263 460
abnormal C 264 460
by C 265 460
the C 266 460
disease C 267 460
. C 268 460
1837 C 1 461
. C 2 461
development C 4 461
of C 5 461
amylosis C 6 461
in C 7 461
less C 8 461
than C 9 461
2 C 10 461
months C 11 461
in C 12 461
the C 13 461
course C 14 461
of C 15 461
a C 16 461
primary C 17 461
tb C 18 461
infection C 19 461
the C 20 461
case C 21 461
is C 22 461
reported C 23 461
of C 24 461
a C 25 461
previously C 26 461
healthy C 27 461
young C 28 461
north C 29 461
- C 30 461
african C 31 461
male C 32 461
, C 33 461
in C 34 461
whom C 35 461
a C 36 461
post C 37 461
- C 38 461
primary C 39 461
ulcero C 40 461
- C 41 461
infiltrative C 42 461
tb C 43 461
in C 44 461
less C 45 461
than C 46 461
2 C 47 461
mth C 48 461
. C 49 461
led C 51 461
to C 52 461
the C 53 461
development C 54 461
of C 55 461
visceral C 56 461
amyloidosis C 57 461
, C 58 461
which C 59 461
could C 60 461
be C 61 461
confirmed C 62 461
by C 63 461
biopsies C 64 461
of C 65 461
the C 66 461
kidney C 67 461
and C 68 461
liver C 69 461
. C 70 461
during C 72 461
treatment C 73 461
with C 74 461
antibiotics C 75 461
, C 76 461
the C 77 461
hepatic C 78 461
amyloidosis C 79 461
regressed C 80 461
parallel C 81 461
with C 82 461
the C 83 461
improvement C 84 461
of C 85 461
the C 86 461
tb C 87 461
, C 88 461
and C 89 461
the C 90 461
biological C 91 461
signs C 92 461
of C 93 461
the C 94 461
renal C 95 461
amyloidosis C 96 461
dis C 97 461
- C 98 461
appeared C 99 461
with C 100 461
the C 101 461
exception C 102 461
of C 103 461
a C 104 461
pronounced C 105 461
proteinuria C 106 461
, C 107 461
the C 108 461
persistence C 109 461
of C 110 461
which C 111 461
renders C 112 461
the C 113 461
long C 114 461
- C 115 461
term C 116 461
prognosis C 117 461
highly C 118 461
doubtful C 119 461
. C 120 461
2216 C 1 462
. C 2 462
the C 4 462
relations C 5 462
between C 6 462
lupus C 7 462
erythematosus C 8 462
and C 9 462
diseases C 10 462
of C 11 462
the C 12 462
lympho C 13 462
- C 14 462
reticular C 15 462
system C 16 462
a C 17 462
case C 18 462
report C 19 462
of C 20 462
a C 21 462
patient C 22 462
with C 23 462
led C 24 462
( C 25 462
aged C 26 462
48 C 27 462
years C 28 462
) C 29 462
, C 30 462
who C 31 462
developed C 32 462
secondarily C 33 462
a C 34 462
lymphoblastic C 35 462
sarcoma C 36 462
. C 37 462
when C 39 462
the C 40 462
sarcomatous C 41 462
degeneration C 42 462
of C 43 462
the C 44 462
lympho C 45 462
- C 46 462
reticular C 47 462
system C 48 462
became C 49 462
apparent C 50 462
, C 51 462
the C 52 462
serological C 53 462
and C 54 462
immuno C 55 462
- C 56 462
hematological C 57 462
tests C 58 462
, C 59 462
typical C 60 462
for C 61 462
led C 62 462
, C 63 462
were C 64 462
negative C 65 462
. C 66 462
to C 68 462
interpret C 69 462
the C 70 462
observation C 71 462
, C 72 462
62 C 73 462
further C 74 462
patients C 75 462
with C 76 462
lymphogranuloma C 77 462
, C 78 462
lymphosarcoma C 79 462
, C 80 462
leukemias C 81 462
, C 82 462
other C 83 462
malignant C 84 462
tumors C 85 462
, C 86 462
sar C 87 462
- C 88 462
coidosis C 89 462
, C 90 462
and C 91 462
tuberculosis C 92 462
were C 93 462
investigated C 94 462
serologically C 95 462
and C 96 462
immunohematolo C 97 462
- C 98 462
gically C 99 462
. C 100 462
antinuclear C 102 462
factors C 103 462
were C 104 462
found C 105 462
in C 106 462
serum C 107 462
of C 108 462
4 C 109 462
patients C 110 462
with C 111 462
lymphogranulo C 112 462
- C 113 462
ma C 114 462
, C 115 462
one C 116 462
patient C 117 462
with C 118 462
anaplastic C 119 462
carcinoma C 120 462
, C 121 462
and C 122 462
one C 123 462
patient C 124 462
with C 125 462
metastasizing C 126 462
mixed C 127 462
parotid C 128 462
- C 129 462
tumor C 130 462
. C 131 462
the C 133 462
identity C 134 462
of C 135 462
the C 136 462
antinuclear C 137 462
antibodies C 138 462
with C 139 462
those C 140 462
found C 141 462
in C 142 462
led C 143 462
could C 144 462
not C 145 462
be C 146 462
proved C 147 462
by C 148 462
different C 149 462
methods C 150 462
. C 151 462
the C 153 462
importance C 154 462
of C 155 462
certain C 156 462
diseases C 157 462
of C 158 462
the C 159 462
lympho C 160 462
- C 161 462
reticular C 162 462
system C 163 462
for C 164 462
the C 165 462
production C 166 462
of C 167 462
antinuclear C 168 462
factors C 169 462
was C 170 462
dis C 171 462
- C 172 462
cussed C 173 462
. C 174 462
4417 C 1 463
. C 2 463
value C 4 463
and C 5 463
significance C 6 463
of C 7 463
the C 8 463
prednisolone C 9 463
test C 10 463
in C 11 463
diseases C 12 463
of C 13 463
the C 14 463
kidney C 15 463
twelve C 16 463
normal C 17 463
subjects C 18 463
, C 19 463
18 C 20 463
cases C 21 463
of C 22 463
tubulo C 23 463
- C 24 463
interstitial C 25 463
nephropathy C 26 463
, C 27 463
12 C 28 463
cases C 29 463
of C 30 463
glomerular C 31 463
nephropathy C 32 463
and C 33 463
17 C 34 463
cases C 35 463
of C 36 463
other C 37 463
renal C 38 463
disorders C 39 463
were C 40 463
investigated C 41 463
. C 42 463
all C 44 463
patients C 45 463
were C 46 463
given C 47 463
a C 48 463
prednisolone C 49 463
test C 50 463
, C 51 463
with C 52 463
urine C 53 463
culture C 54 463
before C 55 463
and C 56 463
after C 57 463
the C 58 463
test C 59 463
, C 60 463
and C 61 463
in C 62 463
many C 63 463
instances C 64 463
determination C 65 463
of C 66 463
the C 67 463
urinary C 68 463
osmolarity C 69 463
; C 70 463
the C 71 463
urinary C 72 463
sediment C 73 463
was C 74 463
examined C 75 463
with C 76 463
the C 77 463
sternheimer C 78 463
and C 79 463
malbin C 80 463
staining C 81 463
technique C 82 463
and C 83 463
with C 84 463
the C 85 463
peroxydase C 86 463
stain C 87 463
to C 88 463
investigate C 89 463
the C 90 463
urinary C 91 463
cytology C 92 463
. C 93 463
with C 95 463
the C 96 463
criteria C 97 463
adopted C 98 463
, C 99 463
the C 100 463
test C 101 463
was C 102 463
negative C 103 463
in C 104 463
the C 105 463
normals C 106 463
and C 107 463
was C 108 463
positive C 109 463
in C 110 463
61 C 111 463
. C 112 463
. C 113 463
% C 114 463
of C 115 463
the C 116 463
cases C 117 463
of C 118 463
chronic C 119 463
pyelonephritis C 120 463
and C 121 463
in C 122 463
12 C 123 463
. C 124 463
. C 125 463
% C 126 463
of C 127 463
the C 128 463
remaining C 129 463
cases C 130 463
of C 131 463
unequivocally C 132 463
non C 133 463
- C 134 463
infectious C 135 463
renal C 136 463
disease C 137 463
. C 138 463
the C 140 463
increase C 141 463
of C 142 463
the C 143 463
urinary C 144 463
bacterial C 145 463
count C 146 463
after C 147 463
cortico C 148 463
- C 149 463
steroid C 150 463
administration C 151 463
, C 152 463
and C 153 463
investigation C 154 463
of C 155 463
the C 156 463
various C 157 463
components C 158 463
of C 159 463
the C 160 463
urinary C 161 463
sediment C 162 463
also C 163 463
supplied C 164 463
useful C 165 463
diagnostic C 166 463
information C 167 463
. C 168 463
on C 170 463
the C 171 463
contrary C 172 463
, C 173 463
the C 174 463
stern C 175 463
- C 176 463
heimer C 177 463
- C 178 463
malbin C 179 463
stain C 180 463
for C 181 463
the C 182 463
urinary C 183 463
sediment C 184 463
proved C 185 463
of C 186 463
little C 187 463
use C 188 463
. C 189 463
564 C 1 464
. C 2 464
tumoral C 4 464
amyloidosis C 5 464
of C 6 464
the C 7 464
lung C 8 464
an C 9 464
incidental C 10 464
finding C 11 464
at C 12 464
necropsy C 13 464
on C 14 464
a C 15 464
woman C 16 464
aged C 17 464
95 C 18 464
was C 19 464
a C 20 464
tumor C 21 464
- C 22 464
like C 23 464
mass C 24 464
, C 25 464
8 C 26 464
. C 27 464
. C 28 464
x C 29 464
6 C 30 464
. C 31 464
. C 32 464
x C 33 464
6 C 34 464
cm C 35 464
. C 36 464
, C 38 464
in C 39 464
the C 40 464
lower C 41 464
lobe C 42 464
of C 43 464
the C 44 464
left C 45 464
lung C 46 464
. C 47 464
the C 49 464
detailed C 50 464
structure C 51 464
of C 52 464
this C 53 464
may C 54 464
suggested C 55 464
angioma C 56 464
of C 57 464
hamartoma C 58 464
; C 59 464
the C 60 464
stroma C 61 464
and C 62 464
some C 63 464
vessels C 64 464
contained C 65 464
amyloid C 66 464
. C 67 464
amyloid C 69 464
is C 70 464
not C 71 464
uncommon C 72 464
in C 73 464
the C 74 464
stroma C 75 464
of C 76 464
tumors C 77 464
. C 78 464
a C 80 464
summary C 81 464
of C 82 464
17 C 83 464
tumoral C 84 464
amyloid C 85 464
cases C 86 464
reported C 87 464
by C 88 464
others C 89 464
is C 90 464
included C 91 464
. C 92 464
7364 C 1 465
. C 2 465
experimental C 4 465
amyloidosis C 5 465
in C 6 465
immunity C 7 465
much C 8 465
of C 9 465
interest C 10 465
in C 11 465
the C 12 465
mechanism C 13 465
of C 14 465
experimental C 15 465
amyloidosis C 16 465
as C 17 465
a C 18 465
result C 19 465
of C 20 465
the C 21 465
parenteral C 22 465
introduction C 23 465
of C 24 465
foreign C 25 465
protein C 26 465
has C 27 465
been C 28 465
centered C 29 465
around C 30 465
the C 31 465
nature C 32 465
of C 33 465
the C 34 465
links C 35 465
leading C 36 465
to C 37 465
cytological C 38 465
and C 39 465
biochemical C 40 465
changes C 41 465
in C 42 465
tissues C 43 465
and C 44 465
body C 45 465
fluids C 46 465
. C 47 465
some C 49 465
of C 50 465
the C 51 465
authors C 52 465
suggested C 53 465
that C 54 465
such C 55 465
links C 56 465
may C 57 465
be C 58 465
of C 59 465
immunological C 60 465
nature C 61 465
. C 62 465
there C 64 465
is C 65 465
however C 66 465
, C 67 465
no C 68 465
clear C 69 465
- C 70 465
cut C 71 465
proof C 72 465
either C 73 465
in C 74 465
favor C 75 465
of C 76 465
or C 77 465
against C 78 465
the C 79 465
theory C 80 465
of C 81 465
an C 82 465
immunological C 83 465
origin C 84 465
of C 85 465
amyloid C 86 465
. C 87 465
since C 89 465
injection C 90 465
of C 91 465
proteins C 92 465
during C 93 465
the C 94 465
perinatal C 95 465
period C 96 465
prevents C 97 465
an C 98 465
immune C 99 465
response C 100 465
when C 101 465
the C 102 465
animal C 103 465
is C 104 465
subsequently C 105 465
challenged C 106 465
with C 107 465
the C 108 465
same C 109 465
antigen C 110 465
, C 111 465
the C 112 465
authors C 113 465
studied C 114 465
amyloidosis C 115 465
caused C 116 465
by C 117 465
casein C 118 465
in C 119 465
mice C 120 465
treated C 121 465
after C 122 465
birth C 123 465
with C 124 465
this C 125 465
protein C 126 465
. C 127 465
mice C 129 465
exposed C 130 465
soon C 131 465
after C 132 465
birth C 133 465
to C 134 465
casein C 135 465
ac C 136 465
- C 137 465
quire C 138 465
an C 139 465
immune C 140 465
tolerance C 141 465
to C 142 465
this C 143 465
antigen C 144 465
. C 145 465
this C 147 465
was C 148 465
demonstrated C 149 465
by C 150 465
the C 151 465
absence C 152 465
of C 153 465
circulating C 154 465
antibodies C 155 465
as C 156 465
measured C 157 465
by C 158 465
the C 159 465
disappearance C 160 465
of C 161 465
i C 162 465
- C 163 465
labeled C 164 465
casein C 165 465
from C 166 465
the C 167 465
circulation C 168 465
and C 169 465
by C 170 465
means C 171 465
of C 172 465
passive C 173 465
hemagglutination C 174 465
tests C 175 465
with C 176 465
ascitic C 177 465
fluids C 178 465
. C 179 465
both C 181 465
tolerant C 182 465
and C 183 465
control C 184 465
animals C 185 465
developed C 186 465
amyloidosis C 187 465
to C 188 465
the C 189 465
same C 190 465
extent C 191 465
. C 192 465
the C 194 465
results C 195 465
imply C 196 465
that C 197 465
the C 198 465
pathogenesis C 199 465
of C 200 465
amyloidosis C 201 465
does C 202 465
not C 203 465
rest C 204 465
upon C 205 465
a C 206 465
classic C 207 465
immunological C 208 465
basis C 209 465
; C 210 465
they C 211 465
do C 212 465
not C 213 465
exclude C 214 465
the C 215 465
possibility C 216 465
, C 217 465
that C 218 465
the C 219 465
disease C 220 465
may C 221 465
be C 222 465
due C 223 465
to C 224 465
some C 225 465
auto C 226 465
- C 227 465
immune C 228 465
process C 229 465
. C 230 465
3535 C 1 466
. C 2 466
electron C 4 466
microscopic C 5 466
study C 6 466
of C 7 466
six C 8 466
cases C 9 466
of C 10 466
human C 11 466
renal C 12 466
amyloidosis C 13 466
this C 14 466
study C 15 466
is C 16 466
particularly C 17 466
concerned C 18 466
with C 19 466
( C 20 466
a C 21 466
) C 22 466
the C 23 466
basal C 24 466
membrane C 25 466
in C 26 466
the C 27 466
different C 28 466
stages C 29 466
; C 30 466
and C 31 466
( C 32 466
b C 33 466
) C 34 466
the C 35 466
intercapillary C 36 466
spaces C 37 466
in C 38 466
the C 39 466
early C 40 466
stages C 41 466
. C 42 466
the C 44 466
conclusions C 45 466
may C 46 466
be C 47 466
put C 48 466
as C 49 466
follows C 50 466
( C 51 466
1 C 52 466
) C 53 466
the C 54 466
amyloid C 55 466
substance C 56 466
seems C 57 466
to C 58 466
have C 59 466
a C 60 466
fibrillar C 61 466
structure C 62 466
from C 63 466
the C 64 466
start C 65 466
. C 66 466
( C 68 466
2 C 69 466
) C 70 466
when C 71 466
the C 72 466
walls C 73 466
of C 74 466
the C 75 466
peripheral C 76 466
capillary C 77 466
loops C 78 466
are C 79 466
thickened C 80 466
by C 81 466
voluminous C 82 466
amyloid C 83 466
deposits C 84 466
, C 85 466
the C 86 466
hyaline C 87 466
aspect C 88 466
of C 89 466
the C 90 466
primitive C 91 466
basal C 92 466
membrane C 93 466
persists C 94 466
, C 95 466
but C 96 466
its C 97 466
structure C 98 466
is C 99 466
altered C 100 466
by C 101 466
the C 102 466
presence C 103 466
of C 104 466
multiple C 105 466
amyloid C 106 466
fibrils C 107 466
. C 108 466
( C 110 466
3 C 111 466
) C 112 466
on C 113 466
the C 114 466
other C 115 466
hand C 116 466
, C 117 466
in C 118 466
the C 119 466
initial C 120 466
stages C 121 466
, C 122 466
amyloid C 123 466
fibrils C 124 466
cannot C 125 466
be C 126 466
seen C 127 466
in C 128 466
the C 129 466
' C 130 466
lamina C 131 466
densa C 132 466
' C 133 466
of C 134 466
the C 135 466
basal C 136 466
membrane C 137 466
; C 138 466
they C 139 466
only C 140 466
appear C 141 466
on C 142 466
the C 143 466
epithelial C 144 466
and C 145 466
endo C 146 466
- C 147 466
thelial C 148 466
surfaces C 149 466
of C 150 466
the C 151 466
membrane C 152 466
. C 153 466
this C 155 466
suggests C 156 466
that C 157 466
amyloidosis C 158 466
represents C 159 466
an C 160 466
abnormal C 161 466
precipitate C 162 466
of C 163 466
extrinsic C 164 466
origin C 165 466
, C 166 466
rather C 167 466
than C 168 466
a C 169 466
transformation C 170 466
' C 171 466
in C 172 466
situ C 173 466
' C 174 466
of C 175 466
the C 176 466
basal C 177 466
membrane C 178 466
. C 179 466
( C 181 466
4 C 182 466
) C 183 466
in C 184 466
the C 185 466
very C 186 466
early C 187 466
stages C 188 466
of C 189 466
amyloid C 190 466
infiltration C 191 466
into C 192 466
the C 193 466
glomeruli C 194 466
the C 195 466
fibrillar C 196 466
substance C 197 466
is C 198 466
found C 199 466
first C 200 466
in C 201 466
the C 202 466
intercapillary C 203 466
spaces C 204 466
, C 205 466
only C 206 466
later C 207 466
does C 208 466
it C 209 466
reach C 210 466
the C 211 466
peripheral C 212 466
capillary C 213 466
walls C 214 466
. C 215 466
3544 C 1 467
. C 2 467
morphology C 4 467
and C 5 467
development C 6 467
of C 7 467
infectious C 8 467
- C 9 467
toxic C 10 467
affections C 11 467
of C 12 467
the C 13 467
kidneys C 14 467
in C 15 467
pulmonary C 16 467
tuberculosis C 17 467
( C 18 467
russian C 19 467
) C 20 467
the C 21 467
kidneys C 22 467
of C 23 467
75 C 24 467
patients C 25 467
dead C 26 467
from C 27 467
tb C 28 467
of C 29 467
the C 30 467
lungs C 31 467
and C 32 467
of C 33 467
30 C 34 467
rabbits C 35 467
with C 36 467
pulmonary C 37 467
tb C 38 467
were C 39 467
examined C 40 467
. C 41 467
the C 43 467
first C 44 467
lesions C 45 467
develop C 46 467
in C 47 467
the C 48 467
glomeruli C 49 467
, C 50 467
followed C 51 467
by C 52 467
changes C 53 467
in C 54 467
the C 55 467
stroma C 56 467
and C 57 467
tubules C 58 467
. C 59 467
infectious C 61 467
- C 62 467
toxic C 63 467
affection C 64 467
of C 65 467
the C 66 467
kidneys C 67 467
is C 68 467
a C 69 467
complex C 70 467
and C 71 467
prolonged C 72 467
process C 73 467
involving C 74 467
organic C 75 467
immune C 76 467
reactions C 77 467
, C 78 467
lymphostasis C 79 467
, C 80 467
venous C 81 467
stasis C 82 467
and C 83 467
finally C 84 467
nephrosclerosis C 85 467
. C 86 467
infectious C 88 467
- C 89 467
toxic C 90 467
lesions C 91 467
were C 92 467
found C 93 467
in C 94 467
one C 95 467
third C 96 467
of C 97 467
the C 98 467
patients C 99 467
who C 100 467
died C 101 467
of C 102 467
pulmonary C 103 467
tb C 104 467
. C 105 467
these C 107 467
changes C 108 467
had C 109 467
produced C 110 467
clinical C 111 467
manifestations C 112 467
, C 113 467
on C 114 467
the C 115 467
basis C 116 467
of C 117 467
which C 118 467
the C 119 467
following C 120 467
affections C 121 467
had C 122 467
been C 123 467
diagnosed C 124 467
nephritis C 125 467
, C 126 467
nephrosis C 127 467
, C 128 467
amyloi C 129 467
- C 130 467
dosis C 131 467
. C 132 467
antibacterial C 134 467
therapy C 135 467
of C 136 467
the C 137 467
pulmonary C 138 467
process C 139 467
reduced C 140 467
the C 141 467
renal C 142 467
lesions C 143 467
. C 144 467
how C 146 467
- C 147 467
ever C 148 467
, C 149 467
severe C 150 467
infectious C 151 467
- C 152 467
toxic C 153 467
affection C 154 467
of C 155 467
the C 156 467
kidneys C 157 467
may C 158 467
develop C 159 467
after C 160 467
recovery C 161 467
from C 162 467
pulmonary C 163 467
tb C 164 467
. C 165 467
3553 C 1 468
. C 2 468
diffuse C 4 468
nodular C 5 468
amyloidosis C 6 468
of C 7 468
the C 8 468
lungs C 9 468
in C 10 468
a C 11 468
59 C 12 468
- C 13 468
year C 14 468
- C 15 468
old C 16 468
man C 17 468
, C 18 468
who C 19 468
12 C 20 468
yr C 21 468
. C 22 468
previously C 24 468
had C 25 468
ceased C 26 468
working C 27 468
in C 28 468
an C 29 468
aluminium C 30 468
factory C 31 468
and C 32 468
who C 33 468
had C 34 468
died C 35 468
from C 36 468
respiratory C 37 468
insufficiency C 38 468
, C 39 468
the C 40 468
postmortem C 41 468
examination C 42 468
revealed C 43 468
disseminated C 44 468
nodules C 45 468
in C 46 468
the C 47 468
lungs C 48 468
. C 49 468
the C 51 468
nodules C 52 468
were C 53 468
sharply C 54 468
defined C 55 468
, C 56 468
of C 57 468
a C 58 468
greyish C 59 468
color C 60 468
and C 61 468
of C 62 468
a C 63 468
doughy C 64 468
consistency C 65 468
and C 66 468
could C 67 468
easily C 68 468
be C 69 468
removed C 70 468
from C 71 468
their C 72 468
capsules C 73 468
. C 74 468
the C 76 468
diagnosis C 77 468
of C 78 468
amyloidosis C 79 468
was C 80 468
made C 81 468
on C 82 468
the C 83 468
basis C 84 468
of C 85 468
the C 86 468
histological C 87 468
findings C 88 468
, C 89 468
the C 90 468
staining C 91 468
qualities C 92 468
of C 93 468
the C 94 468
material C 95 468
, C 96 468
its C 97 468
intraseptal C 98 468
and C 99 468
periarteriolar C 100 468
localization C 101 468
, C 102 468
and C 103 468
the C 104 468
existence C 105 468
of C 106 468
plasmocytic C 107 468
infiltrates C 108 468
and C 109 468
foreign C 110 468
- C 111 468
body C 112 468
giant C 113 468
- C 114 468
cell C 115 468
granulomas C 116 468
. C 117 468
amyloid C 119 468
deposits C 120 468
were C 121 468
also C 122 468
found C 123 468
in C 124 468
the C 125 468
spleen C 126 468
, C 127 468
kidney C 128 468
and C 129 468
some C 130 468
coronary C 131 468
branches C 132 468
. C 133 468
in C 135 468
regard C 136 468
to C 137 468
the C 138 468
pathogenesis C 139 468
, C 140 468
it C 141 468
is C 142 468
suggested C 143 468
that C 144 468
the C 145 468
exposure C 146 468
to C 147 468
aluminium C 148 468
products C 149 468
for C 150 468
more C 151 468
than C 152 468
10 C 153 468
yr C 154 468
. C 155 468
might C 157 468
have C 158 468
constituted C 159 468
a C 160 468
predisposing C 161 468
factor C 162 468
. C 163 468
3724 C 1 469
. C 2 469
the C 4 469
bacterial C 5 469
induction C 6 469
of C 7 469
homograft C 8 469
sensitivity C 9 469
. C 10 469
ii C 12 469
. C 13 469
effects C 15 469
of C 16 469
sensitization C 17 469
with C 18 469
staphylococci C 19 469
and C 20 469
other C 21 469
microorganisms C 22 469
heat C 23 469
- C 24 469
killed C 25 469
strains C 26 469
of C 27 469
staph C 28 469
. C 29 469
aureus C 31 469
and C 32 469
staph C 33 469
. C 34 469
albus C 36 469
can C 37 469
induce C 38 469
in C 39 469
guinea C 40 469
pigs C 41 469
a C 42 469
state C 43 469
of C 44 469
altered C 45 469
reactivity C 46 469
to C 47 469
skin C 48 469
homografts C 49 469
which C 50 469
is C 51 469
indistinguishable C 52 469
from C 53 469
that C 54 469
which C 55 469
results C 56 469
from C 57 469
sensitization C 58 469
with C 59 469
homologous C 60 469
tissues C 61 469
or C 62 469
group C 63 469
a C 64 469
streptococci C 65 469
. C 66 469
challenge C 68 469
of C 69 469
suitably C 70 469
prepared C 71 469
recipients C 72 469
with C 73 469
1 C 74 469
st C 75 469
- C 76 469
set C 77 469
skin C 78 469
homografts C 79 469
obtained C 80 469
from C 81 469
unrelated C 82 469
randomly C 83 469
selected C 84 469
donors C 85 469
elicits C 86 469
white C 87 469
graft C 88 469
reactions C 89 469
or C 90 469
accelera C 91 469
- C 92 469
ted C 93 469
rejections C 94 469
of C 95 469
such C 96 469
grafts C 97 469
. C 98 469
other C 100 469
bacteria C 101 469
tested C 102 469
included C 103 469
lancefield C 104 469
streptococcal C 105 469
groups C 106 469
b C 107 469
, C 108 469
c C 109 469
, C 110 469
d C 111 469
, C 112 469
e C 113 469
, C 114 469
g C 115 469
, C 116 469
h C 117 469
, C 118 469
l C 119 469
, C 120 469
and C 121 469
o C 122 469
, C 123 469
pneumococcus C 124 469
types C 125 469
ii C 126 469
, C 127 469
iii C 128 469
, C 129 469
xiv C 130 469
and C 131 469
a C 132 469
rough C 133 469
strain C 134 469
, C 135 469
c C 136 469
. C 137 469
xerosis C 139 469
, C 140 469
b C 141 469
. C 142 469
subtilis C 144 469
, C 145 469
e C 146 469
. C 147 469
coli C 149 469
, C 150 469
a C 151 469
. C 152 469
aerogenes C 154 469
, C 155 469
s C 156 469
. C 157 469
typhimurium C 159 469
, C 160 469
pr C 161 469
. C 162 469
vul C 164 469
- C 165 469
garis C 166 469
, C 167 469
n C 168 469
. C 169 469
catarrhalis C 171 469
, C 172 469
h C 173 469
. C 174 469
influenzae C 176 469
, C 177 469
and C 178 469
2 C 179 469
human C 180 469
virulent C 181 469
strains C 182 469
of C 183 469
myc C 184 469
. C 185 469
tuber C 187 469
- C 188 469
culosis C 189 469
. C 190 469
none C 192 469
of C 193 469
these C 194 469
microorganisms C 195 469
was C 196 469
active C 197 469
in C 198 469
the C 199 469
induction C 200 469
of C 201 469
homograft C 202 469
sensitivity C 203 469
in C 204 469
the C 205 469
guinea C 206 469
pig C 207 469
. C 208 469
pretreatment C 210 469
of C 211 469
recipients C 212 469
with C 213 469
gram C 214 469
- C 215 469
negative C 216 469
bac C 217 469
- C 218 469
terial C 219 469
suspensions C 220 469
was C 221 469
associated C 222 469
with C 223 469
a C 224 469
slight C 225 469
increase C 226 469
in C 227 469
the C 228 469
mean C 229 469
survival C 230 469
time C 231 469
of C 232 469
1 C 233 469
st C 234 469
- C 235 469
set C 236 469
skin C 237 469
homografts C 238 469
. C 239 469
results C 241 469
of C 242 469
this C 243 469
study C 244 469
suggest C 245 469
the C 246 469
presence C 247 469
in C 248 469
staphylo C 249 469
- C 250 469
cocci C 251 469
, C 252 469
as C 253 469
well C 254 469
as C 255 469
in C 256 469
group C 257 469
a C 258 469
streptococci C 259 469
, C 260 469
of C 261 469
antigens C 262 469
related C 263 469
in C 264 469
their C 265 469
biologic C 266 469
ef C 267 469
- C 268 469
fects C 269 469
to C 270 469
tissue C 271 469
transplantation C 272 469
antigens C 273 469
. C 274 469
6590 C 1 470
. C 2 470
structure C 4 470
and C 5 470
function C 6 470
of C 7 470
cross C 8 470
- C 9 470
linked C 10 470
dna C 11 470
. C 12 470
i C 14 470
. C 15 470
reversible C 17 470
denaturation C 18 470
and C 19 470
bacillus C 20 470
subtilis C 21 470
transformation C 22 470
reaction C 23 470
of C 24 470
nitrous C 25 470
acid C 26 470
with C 27 470
dna C 28 470
results C 29 470
in C 30 470
covalent C 31 470
linkage C 32 470
of C 33 470
complementary C 34 470
polynucleotide C 35 470
strands C 36 470
. C 37 470
the C 39 470
resulting C 40 470
material C 41 470
denatures C 42 470
reversibly C 43 470
and C 44 470
retains C 45 470
biological C 46 470
activity C 47 470
in C 48 470
bacterial C 49 470
transformation C 50 470
. C 51 470
4958 C 1 471
. C 2 471
the C 4 471
mechanism C 5 471
of C 6 471
messenger C 7 471
- C 8 471
rna C 9 471
replication C 10 471
in C 11 471
bacteria C 12 471
the C 13 471
transformation C 14 471
of C 15 471
bacillus C 16 471
subtilis C 17 471
sb C 18 471
25 C 19 471
his C 20 471
- C 21 471
tryp C 22 471
- C 23 471
by C 24 471
two C 25 471
linked C 26 471
genetic C 27 471
mar C 28 471
- C 29 471
kers C 30 471
under C 31 471
the C 32 471
action C 33 471
of C 34 471
hybrid C 35 471
molecules C 36 471
of C 37 471
dna C 38 471
was C 39 471
investigated C 40 471
. C 41 471
the C 43 471
molecular C 44 471
hybrids C 45 471
were C 46 471
obtained C 47 471
by C 48 471
thermal C 49 471
denaturation C 50 471
and C 51 471
annealing C 52 471
of C 53 471
a C 54 471
mixture C 55 471
of C 56 471
two C 57 471
dna C 58 471
' C 59 471
s C 60 471
, C 61 471
each C 62 471
one C 63 471
extracted C 64 471
from C 65 471
a C 66 471
single C 67 471
auxotrophic C 68 471
strain C 69 471
( C 70 471
h C 71 471
25 C 72 471
his C 73 471
- C 74 471
and C 75 471
168 C 76 471
tryp C 77 471
- C 78 471
) C 79 471
. C 80 471
the C 82 471
formation C 83 471
of C 84 471
the C 85 471
heterozygous C 86 471
dna C 87 471
double C 88 471
helices C 89 471
was C 90 471
proved C 91 471
by C 92 471
special C 93 471
experi C 94 471
- C 95 471
ments C 96 471
. C 97 471
the C 99 471
transformation C 100 471
procedure C 101 471
excluded C 102 471
dna C 103 471
synthesis C 104 471
by C 105 471
recipient C 106 471
cells C 107 471
prior C 108 471
to C 109 471
the C 110 471
formation C 111 471
of C 112 471
enzymes C 113 471
for C 114 471
histidine C 115 471
and C 116 471
tryptophane C 117 471
synthesis C 118 471
. C 119 471
it C 121 471
was C 122 471
found C 123 471
that C 124 471
heterozygous C 125 471
molecules C 126 471
of C 127 471
dna C 128 471
are C 129 471
able C 130 471
to C 131 471
transform C 132 471
in C 133 471
these C 134 471
conditions C 135 471
the C 136 471
double C 137 471
auxotrophic C 138 471
cells C 139 471
to C 140 471
prototrophic C 141 471
ones C 142 471
. C 143 471
this C 145 471
means C 146 471
that C 147 471
both C 148 471
strands C 149 471
of C 150 471
the C 151 471
dna C 152 471
double C 153 471
helix C 154 471
can C 155 471
serve C 156 471
as C 157 471
templates C 158 471
for C 159 471
the C 160 471
m C 161 471
- C 162 471
rna C 163 471
synthesis C 164 471
. C 165 471
the C 167 471
possi C 168 471
- C 169 471
bility C 170 471
of C 171 471
a C 172 471
secondary C 173 471
replication C 174 471
of C 175 471
m C 176 471
- C 177 471
rna C 178 471
outside C 179 471
the C 180 471
chromosome C 181 471
under C 182 471
the C 183 471
action C 184 471
of C 185 471
rna C 186 471
- C 187 471
polymerases C 188 471
, C 189 471
using C 190 471
rna C 191 471
as C 192 471
a C 193 471
primer C 194 471
, C 195 471
is C 196 471
discussed C 197 471
. C 198 471
2567 C 1 472
. C 2 472
the C 4 472
molecular C 5 472
basis C 6 472
of C 7 472
histidase C 8 472
induction C 9 472
in C 10 472
bacillus C 11 472
subtilis C 12 472
bacillus C 13 472
subtilis C 14 472
growing C 15 472
at C 16 472
37 C 17 472
on C 18 472
glutamate C 19 472
, C 20 472
as C 21 472
only C 22 472
carbon C 23 472
source C 24 472
, C 25 472
is C 26 472
induced C 27 472
to C 28 472
form C 29 472
histidase C 30 472
by C 31 472
l C 32 472
- C 33 472
histidine C 34 472
. C 35 472
this C 37 472
enzyme C 38 472
, C 39 472
converting C 40 472
histidine C 41 472
to C 42 472
urocanic C 43 472
acid C 44 472
, C 45 472
was C 46 472
isolated C 47 472
in C 48 472
a C 49 472
purified C 50 472
form C 51 472
. C 52 472
a C 54 472
highly C 55 472
sensitive C 56 472
and C 57 472
convenient C 58 472
assay C 59 472
for C 60 472
the C 61 472
induced C 62 472
enzyme C 63 472
is C 64 472
described C 65 472
and C 66 472
applied C 67 472
to C 68 472
show C 69 472
that C 70 472
histidase C 71 472
appears C 72 472
in C 73 472
the C 74 472
cell C 75 472
5 C 76 472
min C 77 472
. C 78 472
after C 80 472
addition C 81 472
of C 82 472
the C 83 472
inducer C 84 472
. C 85 472
histidase C 87 472
- C 88 472
synthesizing C 89 472
capacity C 90 472
appears C 91 472
after C 92 472
2 C 93 472
min C 94 472
. C 95 472
and C 97 472
decays C 98 472
exponentially C 99 472
after C 100 472
addition C 101 472
of C 102 472
actinomycin C 103 472
( C 104 472
an C 105 472
inhibitor C 106 472
of C 107 472
dna C 108 472
- C 109 472
dependent C 110 472
rna C 111 472
synthesis C 112 472
) C 113 472
. C 114 472
the C 116 472
half C 117 472
- C 118 472
time C 119 472
value C 120 472
of C 121 472
histidase C 122 472
- C 123 472
synthesizing C 124 472
capacity C 125 472
of C 126 472
2 C 127 472
. C 128 472
. C 129 472
is C 130 472
high C 131 472
, C 132 472
compared C 133 472
with C 134 472
the C 135 472
half C 136 472
- C 137 472
time C 138 472
value C 139 472
of C 140 472
messenger C 141 472
rna C 142 472
. C 143 472
the C 145 472
histidase C 146 472
formation C 147 472
after C 148 472
addition C 149 472
of C 150 472
actinomycin C 151 472
was C 152 472
not C 153 472
only C 154 472
due C 155 472
to C 156 472
protein C 157 472
synthesis C 158 472
directed C 159 472
by C 160 472
accumulated C 161 472
m C 162 472
- C 163 472
rna C 164 472
but C 165 472
also C 166 472
by C 167 472
conversion C 168 472
of C 169 472
an C 170 472
enzymatical C 171 472
- C 172 472
ly C 173 472
inactive C 174 472
protein C 175 472
, C 176 472
present C 177 472
on C 178 472
the C 179 472
moment C 180 472
of C 181 472
actinomycin C 182 472
addition C 183 472
and C 184 472
product C 185 472
of C 186 472
the C 187 472
specific C 188 472
m C 189 472
- C 190 472
rna C 191 472
, C 192 472
to C 193 472
the C 194 472
active C 195 472
enzyme C 196 472
. C 197 472
the C 199 472
existence C 200 472
of C 201 472
this C 202 472
enzyme C 203 472
pre C 204 472
- C 205 472
cursor C 206 472
was C 207 472
shown C 208 472
by C 209 472
means C 210 472
of C 211 472
experiments C 212 472
performed C 213 472
in C 214 472
the C 215 472
presence C 216 472
of C 217 472
chlor C 218 472
- C 219 472
amphenicof C 220 472
. C 221 472
finally C 223 472
, C 224 472
numerical C 225 472
values C 226 472
for C 227 472
the C 228 472
steady C 229 472
state C 230 472
of C 231 472
histidase C 232 472
synthesis C 233 472
, C 234 472
reached C 235 472
9 C 236 472
min C 237 472
. C 238 472
after C 240 472
addition C 241 472
of C 242 472
the C 243 472
inducer C 244 472
, C 245 472
are C 246 472
calculated C 247 472
, C 248 472
on C 249 472
the C 250 472
basis C 251 472
of C 252 472
ki C 253 472
- C 254 472
netics C 255 472
of C 256 472
histidase C 257 472
synthetic C 258 472
capacity C 259 472
, C 260 472
precursor C 261 472
and C 262 472
enzyme C 263 472
formation C 264 472
the C 265 472
cell C 266 472
contains C 267 472
sufficient C 268 472
precursor C 269 472
to C 270 472
form C 271 472
approximately C 272 472
100 C 273 472
molecules C 274 472
of C 275 472
histidase C 276 472
. C 277 472
the C 279 472
cell C 280 472
produces C 281 472
approximately C 282 472
50 C 283 472
molecules C 284 472
histidase C 285 472
per C 286 472
min C 287 472
. C 288 472
the C 290 472
cell C 291 472
ac C 292 472
- C 293 472
quires C 294 472
and C 295 472
loses C 296 472
, C 297 472
every C 298 472
minute C 299 472
, C 300 472
the C 301 472
capacity C 302 472
to C 303 472
make C 304 472
15 C 305 472
molecules C 306 472
of C 307 472
histidase C 308 472
per C 309 472
minute C 310 472
. C 311 472
the C 313 472
maximal C 314 472
enzyme C 315 472
level C 316 472
is C 317 472
15 C 318 472
, C 319 472
000 C 320 472
molecules C 321 472
per C 322 472
cell C 323 472
. C 324 472
2542 C 1 473
. C 2 473
symposium C 4 473
on C 5 473
the C 6 473
fine C 7 473
structure C 8 473
and C 9 473
replication C 10 473
of C 11 473
bacteria C 12 473
and C 13 473
their C 14 473
parts C 15 473
. C 16 473
ii C 18 473
. C 19 473
bacterial C 21 473
cytoplasm C 22 473
comparison C 23 473
of C 24 473
the C 25 473
fine C 26 473
structure C 27 473
of C 28 473
the C 29 473
cytoplasm C 30 473
of C 31 473
the C 32 473
bacterial C 33 473
cell C 34 473
with C 35 473
that C 36 473
of C 37 473
the C 38 473
' C 39 473
cell C 40 473
in C 41 473
general C 42 473
' C 43 473
reveals C 44 473
important C 45 473
differences C 46 473
leading C 47 473
to C 48 473
the C 49 473
conclusion C 50 473
that C 51 473
, C 52 473
in C 53 473
the C 54 473
bacterial C 55 473
cytoplasm C 56 473
, C 57 473
there C 58 473
is C 59 473
little C 60 473
differentiation C 61 473
into C 62 473
separate C 63 473
functional C 64 473
en C 65 473
- C 66 473
tities C 67 473
. C 68 473
there C 70 473
is C 71 473
no C 72 473
nuclear C 73 473
membrane C 74 473
, C 75 473
and C 76 473
fine C 77 473
fibrils C 78 473
appear C 79 473
to C 80 473
extend C 81 473
from C 82 473
the C 83 473
nucleo C 84 473
- C 85 473
plasm C 86 473
into C 87 473
the C 88 473
cytoplasm C 89 473
where C 90 473
they C 91 473
may C 92 473
expand C 93 473
in C 94 473
all C 95 473
directions C 96 473
. C 97 473
the C 99 473
cytoplasm C 100 473
is C 101 473
not C 102 473
necessarily C 103 473
intersected C 104 473
by C 105 473
membranous C 106 473
profiles C 107 473
of C 108 473
special C 109 473
configuration C 110 473
, C 111 473
as C 112 473
is C 113 473
borne C 114 473
out C 115 473
by C 116 473
e C 117 473
. C 118 473
coli C 120 473
b C 121 473
and C 122 473
other C 123 473
gram C 124 473
- C 125 473
negative C 126 473
organisms C 127 473
. C 128 473
when C 130 473
membranous C 131 473
profiles C 132 473
of C 133 473
special C 134 473
configuration C 135 473
are C 136 473
present C 137 473
, C 138 473
as C 139 473
in C 140 473
the C 141 473
gram C 142 473
- C 143 473
positive C 144 473
b C 145 473
. C 146 473
subtilis C 148 473
, C 149 473
these C 150 473
do C 151 473
not C 152 473
appear C 153 473
differentiated C 154 473
into C 155 473
clearly C 156 473
definable C 157 473
endoplasmic C 158 473
reticulum C 159 473
, C 160 473
golgi C 161 473
substance C 162 473
, C 163 473
microbodies C 164 473
, C 165 473
etc C 166 473
. C 167 473
, C 169 473
and C 170 473
mitochondria C 171 473
. C 172 473
as C 174 473
for C 175 473
kinetosomes C 176 473
, C 177 473
the C 178 473
presence C 179 473
of C 180 473
centrioles C 181 473
is C 182 473
perhaps C 183 473
not C 184 473
very C 185 473
likely C 186 473
. C 187 473
the C 189 473
experiments C 190 473
in C 191 473
which C 192 473
tellurite C 193 473
is C 194 473
re C 195 473
- C 196 473
duced C 197 473
in C 198 473
the C 199 473
cells C 200 473
suggest C 201 473
that C 202 473
there C 203 473
are C 204 473
structures C 205 473
at C 206 473
the C 207 473
base C 208 473
of C 209 473
the C 210 473
flagella C 211 473
with C 212 473
reductive C 213 473
capacity C 214 473
. C 215 473
however C 217 473
, C 218 473
upon C 219 473
application C 220 473
of C 221 473
the C 222 473
tetranitro C 223 473
- C 224 473
blue C 225 473
tetrazolium C 226 473
technic C 227 473
to C 228 473
b C 229 473
. C 230 473
subtilis C 232 473
, C 233 473
these C 234 473
are C 235 473
not C 236 473
stained C 237 473
. C 238 473
they C 240 473
are C 241 473
presumably C 242 473
identical C 243 473
with C 244 473
basal C 245 473
granules C 246 473
. C 247 473
the C 249 473
membranous C 250 473
structures C 251 473
in C 252 473
b C 253 473
. C 254 473
subtilis C 256 473
are C 257 473
called C 258 473
chondrioids C 259 473
by C 260 473
the C 261 473
author C 262 473
because C 263 473
probably C 264 473
one C 265 473
of C 266 473
their C 267 473
functions C 268 473
is C 269 473
that C 270 473
they C 271 473
are C 272 473
the C 273 473
sites C 274 473
of C 275 473
the C 276 473
respiratory C 277 473
enzyme C 278 473
chain C 279 473
. C 280 473
in C 282 473
the C 283 473
gram C 284 473
- C 285 473
negative C 286 473
p C 287 473
. C 288 473
vulgaris C 290 473
, C 291 473
the C 292 473
probable C 293 473
site C 294 473
of C 295 473
the C 296 473
respiratory C 297 473
chain C 298 473
has C 299 473
a C 300 473
structure C 301 473
very C 302 473
different C 303 473
from C 304 473
that C 305 473
in C 306 473
the C 307 473
bacillus C 308 473
; C 309 473
it C 310 473
is C 311 473
not C 312 473
clear C 313 473
whether C 314 473
membranes C 315 473
are C 316 473
involved C 317 473
in C 318 473
their C 319 473
structure C 320 473
. C 321 473
morphologically C 323 473
, C 324 473
even C 325 473
in C 326 473
b C 327 473
. C 328 473
subtilis C 330 473
chondrioids C 331 473
differ C 332 473
fundamentally C 333 473
from C 334 473
the C 335 473
mitochondria C 336 473
in C 337 473
that C 338 473
they C 339 473
are C 340 473
not C 341 473
built C 342 473
up C 343 473
from C 344 473
composite C 345 473
membranes C 346 473
, C 347 473
they C 348 473
are C 349 473
extensions C 350 473
of C 351 473
the C 352 473
plasma C 353 473
membrane C 354 473
, C 355 473
and C 356 473
they C 357 473
may C 358 473
not C 359 473
be C 360 473
completely C 361 473
closed C 362 473
systems C 363 473
. C 364 473
regarding C 366 473
this C 367 473
last C 368 473
point C 369 473
, C 370 473
it C 371 473
was C 372 473
observed C 373 473
that C 374 473
chondrioids C 375 473
may C 376 473
possibly C 377 473
stand C 378 473
in C 379 473
open C 380 473
connection C 381 473
with C 382 473
the C 383 473
cell C 384 473
' C 385 473
s C 386 473
environment C 387 473
, C 388 473
since C 389 473
its C 390 473
lumen C 391 473
is C 392 473
not C 393 473
separated C 394 473
from C 395 473
the C 396 473
cell C 397 473
wall C 398 473
by C 399 473
a C 400 473
plasma C 401 473
membrane C 402 473
. C 403 473
although C 405 473
as C 406 473
yet C 407 473
nothing C 408 473
is C 409 473
known C 410 473
about C 411 473
this C 412 473
, C 413 473
it C 414 473
does C 415 473
not C 416 473
seem C 417 473
to C 418 473
be C 419 473
precluded C 420 473
that C 421 473
these C 422 473
membranous C 423 473
organelles C 424 473
may C 425 473
function C 426 473
also C 427 473
as C 428 473
intracellular C 429 473
transport C 430 473
systems C 431 473
. C 432 473
contrary C 434 473
to C 435 473
porter C 436 473
' C 437 473
s C 438 473
ideas C 439 473
about C 440 473
er C 441 473
, C 442 473
the C 443 473
chondrioids C 444 473
are C 445 473
not C 446 473
extensions C 447 473
of C 448 473
a C 449 473
nuclear C 450 473
envelope C 451 473
, C 452 473
but C 453 473
of C 454 473
the C 455 473
plasma C 456 473
membrane C 457 473
. C 458 473
on C 460 473
the C 461 473
other C 462 473
hand C 463 473
, C 464 473
they C 465 473
are C 466 473
in C 467 473
the C 468 473
nuclear C 469 473
area C 470 473
, C 471 473
in C 472 473
direct C 473 473
contact C 474 473
with C 475 473
the C 476 473
nucleoplasm C 477 473
, C 478 473
and C 479 473
therefore C 480 473
, C 481 473
perhaps C 482 473
, C 483 473
they C 484 473
need C 485 473
not C 486 473
carry C 487 473
in C 488 473
their C 489 473
interior C 490 473
some C 491 473
dna C 492 473
, C 493 473
as C 494 473
is C 495 473
now C 496 473
becoming C 497 473
known C 498 473
for C 499 473
ordinary C 500 473
mitochondria C 501 473
. C 502 473
the C 504 473
chromatophore C 505 473
vesicle C 506 473
is C 507 473
of C 508 473
a C 509 473
simple C 510 473
structure C 511 473
and C 512 473
in C 513 473
connection C 514 473
with C 515 473
the C 516 473
plasma C 517 473
membrane C 518 473
. C 519 473
it C 521 473
is C 522 473
covered C 523 473
by C 524 473
a C 525 473
single C 526 473
membrane C 527 473
and C 528 473
thus C 529 473
resembles C 530 473
the C 531 473
granum C 532 473
disc C 533 473
, C 534 473
but C 535 473
it C 536 473
is C 537 473
much C 538 473
smaller C 539 473
. C 540 473
in C 542 473
tissue C 543 473
cells C 544 473
, C 545 473
an C 546 473
im C 547 473
- C 548 473
portant C 549 473
function C 550 473
of C 551 473
the C 552 473
er C 553 473
is C 554 473
the C 555 473
support C 556 473
of C 557 473
protein C 558 473
synthesis C 559 473
by C 560 473
ribosomes C 561 473
bound C 562 473
to C 563 473
their C 564 473
surfaces C 565 473
. C 566 473
evidence C 568 473
is C 569 473
now C 570 473
accumulating C 571 473
that C 572 473
the C 573 473
active C 574 473
complexes C 575 473
for C 576 473
poly C 577 473
- C 578 473
peptide C 579 473
synthesis C 580 473
in C 581 473
bacteria C 582 473
are C 583 473
also C 584 473
membrane C 585 473
- C 586 473
bound C 587 473
and C 588 473
are C 589 473
series C 590 473
of C 591 473
70 C 592 473
s C 593 473
ribo C 594 473
- C 595 473
somes C 596 473
using C 597 473
the C 598 473
same C 599 473
messenger C 600 473
rna C 601 473
molecule C 602 473
. C 603 473
it C 605 473
remains C 606 473
a C 607 473
contradictory C 608 473
situ C 609 473
- C 610 473
ation C 611 473
that C 612 473
the C 613 473
particles C 614 473
obtained C 615 473
here C 616 473
through C 617 473
release C 618 473
of C 619 473
cytoplasm C 620 473
from C 621 473
protoplasts C 622 473
in C 623 473
diluted C 624 473
, C 625 473
rather C 626 473
crude C 627 473
fixing C 628 473
media C 629 473
, C 630 473
and C 631 473
identified C 632 473
as C 633 473
ribosomes C 634 473
, C 635 473
could C 636 473
not C 637 473
be C 638 473
recognized C 639 473
as C 640 473
such C 641 473
in C 642 473
thin C 643 473
sections C 644 473
of C 645 473
the C 646 473
ryter C 647 473
- C 648 473
kellenberger C 649 473
fixed C 650 473
protoplasts C 651 473
. C 652 473
this C 654 473
point C 655 473
is C 656 473
much C 657 473
in C 658 473
need C 659 473
of C 660 473
clarification C 661 473
. C 662 473
but C 664 473
even C 665 473
if C 666 473
the C 667 473
cytoplasm C 668 473
in C 669 473
the C 670 473
thin C 671 473
sections C 672 473
of C 673 473
the C 674 473
protoplasts C 675 473
is C 676 473
in C 677 473
a C 678 473
state C 679 473
of C 680 473
dispersion C 681 473
brought C 682 473
about C 683 473
artificially C 684 473
, C 685 473
it C 686 473
is C 687 473
still C 688 473
apparent C 689 473
from C 690 473
the C 691 473
various C 692 473
micrographs C 693 473
that C 694 473
basically C 695 473
the C 696 473
cytoplasm C 697 473
is C 698 473
a C 699 473
network C 700 473
of C 701 473
presumably C 702 473
linear C 703 473
arrays C 704 473
, C 705 473
with C 706 473
many C 707 473
interconnections C 708 473
due C 709 473
to C 710 473
fibrillar C 711 473
systems C 712 473
. C 713 473
fibrils C 715 473
from C 716 473
the C 717 473
nucleoplasm C 718 473
penetrate C 719 473
deeply C 720 473
into C 721 473
the C 722 473
cytoplasm C 723 473
. C 724 473
the C 726 473
presence C 727 473
of C 728 473
fine C 729 473
fibrils C 730 473
of C 731 473
various C 732 473
thicknesses C 733 473
, C 734 473
electron C 735 473
densities C 736 473
, C 737 473
and C 738 473
orientations C 739 473
makes C 740 473
high C 741 473
- C 742 473
resolution C 743 473
study C 744 473
of C 745 473
the C 746 473
cytoplasmic C 747 473
details C 748 473
an C 749 473
intriguing C 750 473
prospect C 751 473
from C 752 473
which C 753 473
much C 754 473
fundamental C 755 473
information C 756 473
can C 757 473
be C 758 473
gained C 759 473
. C 760 473
the C 762 473
organizational C 763 473
pattern C 764 473
on C 765 473
the C 766 473
ultrastructural C 767 473
level C 768 473
in C 769 473
bacteria C 770 473
reveals C 771 473
fundamental C 772 473
similarities C 773 473
and C 774 473
divergen C 775 473
- C 776 473
cies C 777 473
from C 778 473
that C 779 473
in C 780 473
the C 781 473
' C 782 473
cell C 783 473
in C 784 473
general C 785 473
' C 786 473
. C 787 473
906 C 1 474
. C 2 474
molecular C 4 474
mechanism C 5 474
of C 6 474
genetic C 7 474
recombination C 8 474
in C 9 474
bacterial C 10 474
transformation C 11 474
the C 12 474
mechanism C 13 474
of C 14 474
dna C 15 474
incorporation C 16 474
into C 17 474
the C 18 474
recipient C 19 474
cell C 20 474
chromosome C 21 474
was C 22 474
in C 23 474
- C 24 474
vestigated C 25 474
in C 26 474
a C 27 474
b C 28 474
. C 29 474
subtilis C 31 474
transformation C 32 474
system C 33 474
. C 34 474
the C 36 474
recipient C 37 474
cells C 38 474
were C 39 474
auxo C 40 474
- C 41 474
trophic C 42 474
for C 43 474
2 C 44 474
linked C 45 474
markers C 46 474
. C 47 474
hybrid C 49 474
dna C 50 474
used C 51 474
for C 52 474
transformation C 53 474
was C 54 474
heterozy C 55 474
- C 56 474
gous C 57 474
for C 58 474
one C 59 474
of C 60 474
these C 61 474
markers C 62 474
. C 63 474
no C 65 474
differences C 66 474
in C 67 474
transformation C 68 474
activity C 69 474
were C 70 474
found C 71 474
when C 72 474
the C 73 474
effect C 74 474
of C 75 474
native C 76 474
and C 77 474
hybrid C 78 474
dna C 79 474
was C 80 474
compared C 81 474
. C 82 474
according C 84 474
to C 85 474
the C 86 474
authors C 87 474
this C 88 474
observation C 89 474
is C 90 474
easily C 91 474
explained C 92 474
if C 93 474
we C 94 474
accept C 95 474
that C 96 474
each C 97 474
of C 98 474
both C 99 474
complementary C 100 474
strands C 101 474
of C 102 474
the C 103 474
donor C 104 474
dna C 105 474
can C 106 474
be C 107 474
incorporated C 108 474
into C 109 474
the C 110 474
recipient C 111 474
chromosome C 112 474
with C 113 474
equal C 114 474
probability C 115 474
. C 116 474
the C 118 474
results C 119 474
on C 120 474
the C 121 474
segregation C 122 474
of C 123 474
genetic C 124 474
characters C 125 474
in C 126 474
the C 127 474
pro C 128 474
- C 129 474
geny C 130 474
of C 131 474
transformed C 132 474
cells C 133 474
are C 134 474
also C 135 474
consistent C 136 474
with C 137 474
the C 138 474
model C 139 474
of C 140 474
independent C 141 474
incorpo C 142 474
- C 143 474
ration C 144 474
of C 145 474
both C 146 474
dna C 147 474
strands C 148 474
. C 149 474
some C 151 474
calculations C 152 474
were C 153 474
done C 154 474
on C 155 474
the C 156 474
probability C 157 474
of C 158 474
the C 159 474
integration C 160 474
of C 161 474
a C 162 474
single C 163 474
dna C 164 474
strand C 165 474
carrying C 166 474
a C 167 474
particular C 168 474
genetic C 169 474
marker C 170 474
, C 171 474
and C 172 474
on C 173 474
the C 174 474
probability C 175 474
of C 176 474
recombination C 177 474
leading C 178 474
to C 179 474
double C 180 474
transformants C 181 474
. C 182 474
1520 C 1 475
. C 2 475
multiplication C 4 475
of C 5 475
bacteriophages C 6 475
the C 7 475
reproduction C 8 475
of C 9 475
bacteriophages C 10 475
requires C 11 475
the C 12 475
participation C 13 475
of C 14 475
bacterial C 15 475
metabol C 16 475
- C 17 475
ism C 18 475
. C 19 475
synthesis C 21 475
of C 22 475
the C 23 475
viral C 24 475
protein C 25 475
components C 26 475
is C 27 475
accomplished C 28 475
by C 29 475
the C 30 475
same C 31 475
me C 32 475
- C 33 475
chanism C 34 475
as C 35 475
ordinarily C 36 475
produces C 37 475
bacterial C 38 475
proteins C 39 475
; C 40 475
however C 41 475
, C 42 475
for C 43 475
the C 44 475
synthesis C 45 475
of C 46 475
nucleic C 47 475
acids C 48 475
( C 49 475
dna C 50 475
or C 51 475
rna C 52 475
) C 53 475
enzymes C 54 475
may C 55 475
be C 56 475
required C 57 475
which C 58 475
are C 59 475
not C 60 475
present C 61 475
in C 62 475
non C 63 475
- C 64 475
infected C 65 475
bacteria C 66 475
; C 67 475
their C 68 475
formation C 69 475
is C 70 475
then C 71 475
induced C 72 475
by C 73 475
the C 74 475
virus C 75 475
itself C 76 475
. C 77 475
the C 79 475
fundamental C 80 475
biological C 81 475
processes C 82 475
of C 83 475
replication C 84 475
, C 85 475
transcription C 86 475
and C 87 475
translation C 88 475
are C 89 475
discussed C 90 475
in C 91 475
this C 92 475
context C 93 475
. C 94 475
1361 C 1 476
. C 2 476
the C 4 476
mechanism C 5 476
of C 6 476
histidase C 7 476
induction C 8 476
and C 9 476
formation C 10 476
in C 11 476
bacillus C 12 476
subtilis C 13 476
the C 14 476
role C 15 476
of C 16 476
the C 17 476
inducer C 18 476
, C 19 476
l C 20 476
- C 21 476
histidine C 22 476
, C 23 476
in C 24 476
the C 25 476
synthesis C 26 476
of C 27 476
histidase C 28 476
( C 29 476
l C 30 476
- C 31 476
histidine C 32 476
am C 33 476
- C 34 476
monia C 35 476
lyase C 36 476
) C 37 476
in C 38 476
b C 39 476
. C 40 476
subtilis C 42 476
was C 43 476
investigated C 44 476
. C 45 476
it C 47 476
was C 48 476
found C 49 476
that C 50 476
induced C 51 476
cells C 52 476
poisoned C 53 476
with C 54 476
actinomycin C 55 476
, C 56 476
an C 57 476
inhibitor C 58 476
of C 59 476
rna C 60 476
synthesis C 61 476
, C 62 476
lose C 63 476
their C 64 476
capacity C 65 476
for C 66 476
the C 67 476
forma C 68 476
- C 69 476
tion C 70 476
of C 71 476
a C 72 476
protein C 73 476
precursor C 74 476
of C 75 476
histidase C 76 476
at C 77 476
a C 78 476
rate C 79 476
which C 80 476
is C 81 476
independent C 82 476
of C 83 476
the C 84 476
presence C 85 476
or C 86 476
absence C 87 476
of C 88 476
the C 89 476
inducer C 90 476
. C 91 476
these C 93 476
results C 94 476
show C 95 476
that C 96 476
the C 97 476
inducer C 98 476
does C 99 476
not C 100 476
increase C 101 476
the C 102 476
intracellular C 103 476
level C 104 476
of C 105 476
histidase C 106 476
- C 107 476
specific C 108 476
messenger C 109 476
rna C 110 476
by C 111 476
preventing C 112 476
the C 113 476
des C 114 476
- C 115 476
truction C 116 476
of C 117 476
the C 118 476
major C 119 476
portion C 120 476
of C 121 476
this C 122 476
material C 123 476
, C 124 476
the C 125 476
fraction C 126 476
that C 127 476
is C 128 476
engaged C 129 476
in C 130 476
pro C 131 476
- C 132 476
tein C 133 476
synthesis C 134 476
. C 135 476
the C 137 476
possibility C 138 476
has C 139 476
not C 140 476
been C 141 476
excluded C 142 476
that C 143 476
the C 144 476
inducer C 145 476
exerts C 146 476
its C 147 476
effect C 148 476
by C 149 476
bringing C 150 476
about C 151 476
the C 152 476
stabilization C 153 476
of C 154 476
the C 155 476
messenger C 156 476
rna C 157 476
that C 158 476
is C 159 476
still C 160 476
attached C 161 476
to C 162 476
dna C 163 476
or C 164 476
has C 165 476
not C 166 476
yet C 167 476
become C 168 476
attached C 169 476
to C 170 476
ribosomes C 171 476
. C 172 476
alternatively C 174 476
, C 175 476
the C 176 476
inducer C 177 476
may C 178 476
actually C 179 476
stimulate C 180 476
the C 181 476
synthesis C 182 476
of C 183 476
histidase C 184 476
- C 185 476
specific C 186 476
messenger C 187 476
rna C 188 476
. C 189 476
the C 191 476
conver C 192 476
- C 193 476
sion C 194 476
of C 195 476
the C 196 476
precursor C 197 476
to C 198 476
active C 199 476
enzyme C 200 476
appears C 201 476
to C 202 476
involve C 203 476
polymerization C 204 476
of C 205 476
mono C 206 476
- C 207 476
mers C 208 476
, C 209 476
rather C 210 476
than C 211 476
the C 212 476
release C 213 476
of C 214 476
ribosome C 215 476
- C 216 476
bound C 217 476
inactive C 218 476
enzyme C 219 476
. C 220 476
1362 C 1 477
. C 2 477
the C 4 477
synthesis C 5 477
of C 6 477
phage C 7 477
and C 8 477
host C 9 477
dna C 10 477
in C 11 477
the C 12 477
establishment C 13 477
of C 14 477
lysogeny C 15 477
a C 16 477
method C 17 477
of C 18 477
extraction C 19 477
is C 20 477
described C 21 477
which C 22 477
prevents C 23 477
excessive C 24 477
fragmentation C 25 477
of C 26 477
bac C 27 477
- C 28 477
terial C 29 477
dna C 30 477
. C 31 477
the C 33 477
larger C 34 477
bacterial C 35 477
dna C 36 477
can C 37 477
then C 38 477
be C 39 477
separated C 40 477
from C 41 477
the C 42 477
phage C 43 477
dna C 44 477
on C 45 477
sucrose C 46 477
gradients C 47 477
. C 48 477
the C 50 477
relative C 51 477
amounts C 52 477
of C 53 477
phage C 54 477
and C 55 477
host C 56 477
dna C 57 477
made C 58 477
at C 59 477
various C 60 477
times C 61 477
during C 62 477
infection C 63 477
of C 64 477
s C 65 477
. C 66 477
typhimurium C 68 477
with C 69 477
phage C 70 477
p C 71 477
22 C 72 477
leading C 73 477
to C 74 477
lysogeny C 75 477
have C 76 477
been C 77 477
determined C 78 477
. C 79 477
phage C 81 477
- C 82 477
specific C 83 477
dna C 84 477
synthesis C 85 477
begins C 86 477
at C 87 477
about C 88 477
4 C 89 477
min C 90 477
, C 91 477
continues C 92 477
to C 93 477
increase C 94 477
for C 95 477
2 C 96 477
- C 97 477
4 C 98 477
min C 99 477
, C 100 477
and C 101 477
then C 102 477
decreases C 103 477
until C 104 477
complete C 105 477
repression C 106 477
is C 107 477
attained C 108 477
at C 109 477
16 C 110 477
min C 111 477
. C 112 477
autonomous C 114 477
phage C 115 477
dna C 116 477
synthesis C 117 477
remains C 118 477
repressed C 119 477
from C 120 477
then C 121 477
on C 122 477
. C 123 477
bac C 125 477
- C 126 477
teria C 127 477
- C 128 477
specific C 129 477
synthesis C 130 477
proceeds C 131 477
at C 132 477
a C 133 477
decreasing C 134 477
rate C 135 477
until C 136 477
about C 137 477
16 C 138 477
min C 139 477
, C 140 477
when C 141 477
almost C 142 477
complete C 143 477
inhibition C 144 477
is C 145 477
reached C 146 477
. C 147 477
when C 149 477
dna C 150 477
synthesis C 151 477
recovers C 152 477
in C 153 477
the C 154 477
in C 155 477
- C 156 477
fected C 157 477
cells C 158 477
, C 159 477
only C 160 477
host C 161 477
- C 162 477
specific C 163 477
material C 164 477
is C 165 477
made C 166 477
. C 167 477
a C 169 477
new C 170 477
species C 171 477
of C 172 477
dna C 173 477
, C 174 477
which C 175 477
is C 176 477
made C 177 477
only C 178 477
when C 179 477
phage C 180 477
dna C 181 477
is C 182 477
synthesized C 183 477
, C 184 477
has C 185 477
been C 186 477
detected C 187 477
. C 188 477
the C 190 477
possible C 191 477
implica C 192 477
- C 193 477
tions C 194 477
of C 195 477
these C 196 477
findings C 197 477
in C 198 477
the C 199 477
understanding C 200 477
of C 201 477
the C 202 477
lysogenic C 203 477
interaction C 204 477
is C 205 477
discussed C 206 477
. C 207 477
438 C 1 478
. C 2 478
lag C 4 478
period C 5 478
characterizing C 6 478
the C 7 478
entry C 8 478
of C 9 478
transforming C 10 478
deoxyribonucleic C 11 478
acid C 12 478
into C 13 478
bacillus C 14 478
subtilis C 15 478
the C 16 478
kinetics C 17 478
of C 18 478
appearance C 19 478
of C 20 478
transformants C 21 478
as C 22 478
a C 23 478
function C 24 478
of C 25 478
time C 26 478
of C 27 478
exposure C 28 478
to C 29 478
dna C 30 478
has C 31 478
been C 32 478
studied C 33 478
. C 34 478
a C 36 478
short C 37 478
lag C 38 478
period C 39 478
of C 40 478
approximately C 41 478
1 C 42 478
min C 43 478
at C 44 478
37 C 45 478
c C 46 478
is C 47 478
evi C 48 478
- C 49 478
dent C 50 478
when C 51 478
the C 52 478
transformation C 53 478
is C 54 478
terminated C 55 478
with C 56 478
deoxyribonuclease C 57 478
. C 58 478
the C 60 478
length C 61 478
of C 62 478
this C 63 478
lag C 64 478
is C 65 478
independent C 66 478
of C 67 478
the C 68 478
genetic C 69 478
trait C 70 478
transferred C 71 478
. C 72 478
moreover C 74 478
, C 75 478
the C 76 478
lag C 77 478
is C 78 478
unaf C 79 478
- C 80 478
fected C 81 478
by C 82 478
transforming C 83 478
dna C 84 478
concentration C 85 478
, C 86 478
by C 87 478
the C 88 478
presence C 89 478
of C 90 478
homologous C 91 478
unmarked C 92 478
dna C 93 478
, C 94 478
and C 95 478
by C 96 478
shearing C 97 478
and C 98 478
cross C 99 478
- C 100 478
linking C 101 478
of C 102 478
the C 103 478
transforming C 104 478
dna C 105 478
. C 106 478
the C 108 478
lag C 109 478
shows C 110 478
a C 111 478
strong C 112 478
inverse C 113 478
temperature C 114 478
dependence C 115 478
. C 116 478
the C 118 478
energy C 119 478
of C 120 478
activation C 121 478
is C 122 478
13 C 123 478
. C 124 478
. C 125 478
kcal C 126 478
. C 127 478
the C 129 478
lag C 130 478
is C 131 478
abolished C 132 478
when C 133 478
the C 134 478
transformation C 135 478
is C 136 478
terminated C 137 478
by C 138 478
washing C 139 478
instead C 140 478
of C 141 478
by C 142 478
addition C 143 478
of C 144 478
deoxyribonuclease C 145 478
. C 146 478
these C 148 478
results C 149 478
are C 150 478
taken C 151 478
to C 152 478
indicate C 153 478
an C 154 478
immediate C 155 478
adsorption C 156 478
of C 157 478
dna C 158 478
to C 159 478
cells C 160 478
, C 161 478
followed C 162 478
by C 163 478
a C 164 478
deoxyribonuclease C 165 478
- C 166 478
sensitive C 167 478
period C 168 478
of C 169 478
1 C 170 478
min C 171 478
, C 172 478
during C 173 478
which C 174 478
time C 175 478
the C 176 478
genetic C 177 478
trait C 178 478
is C 179 478
entering C 180 478
the C 181 478
cell C 182 478
. C 183 478
these C 185 478
results C 186 478
make C 187 478
feasible C 188 478
an C 189 478
investigation C 190 478
of C 191 478
the C 192 478
configuration C 193 478
assumed C 194 478
by C 195 478
the C 196 478
dna C 197 478
molecule C 198 478
during C 199 478
entry C 200 478
into C 201 478
the C 202 478
cell C 203 478
. C 204 478
439 C 1 479
. C 2 479
configuration C 4 479
of C 5 479
transforming C 6 479
deoxyribonucleic C 7 479
acid C 8 479
during C 9 479
entry C 10 479
into C 11 479
bacillus C 12 479
subtilis C 13 479
a C 14 479
correlation C 15 479
was C 16 479
obtained C 17 479
between C 18 479
map C 19 479
distance C 20 479
and C 21 479
the C 22 479
length C 23 479
of C 24 479
the C 25 479
lag C 26 479
period C 27 479
preceding C 28 479
the C 29 479
appearance C 30 479
of C 31 479
pairs C 32 479
of C 33 479
genetic C 34 479
traits C 35 479
after C 36 479
the C 37 479
addition C 38 479
of C 39 479
dna C 40 479
to C 41 479
a C 42 479
competent C 43 479
culture C 44 479
of C 45 479
b C 46 479
. C 47 479
subtilis C 49 479
. C 50 479
the C 52 479
results C 53 479
are C 54 479
taken C 55 479
to C 56 479
indicate C 57 479
that C 58 479
dna C 59 479
enters C 60 479
competent C 61 479
cells C 62 479
in C 63 479
lengthwise C 64 479
fashion C 65 479
. C 66 479
the C 68 479
smallest C 69 479
length C 70 479
of C 71 479
transforming C 72 479
dna C 73 479
which C 74 479
can C 75 479
participate C 76 479
in C 77 479
a C 78 479
recombination C 79 479
event C 80 479
, C 81 479
and C 82 479
the C 83 479
number C 84 479
of C 85 479
nucleotide C 86 479
pairs C 87 479
which C 88 479
enter C 89 479
the C 90 479
cell C 91 479
per C 92 479
unit C 93 479
time C 94 479
, C 95 479
have C 96 479
been C 97 479
estimated C 98 479
. C 99 479
the C 101 479
evidence C 102 479
indicates C 103 479
that C 104 479
only C 105 479
part C 106 479
of C 107 479
the C 108 479
lag C 109 479
period C 110 479
is C 111 479
devoted C 112 479
to C 113 479
the C 114 479
transport C 115 479
of C 116 479
dna C 117 479
into C 118 479
the C 119 479
cell C 120 479
. C 121 479
the C 123 479
significance C 124 479
of C 125 479
these C 126 479
results C 127 479
with C 128 479
respect C 129 479
to C 130 479
the C 131 479
mechanism C 132 479
of C 133 479
entry C 134 479
of C 135 479
dna C 136 479
into C 137 479
the C 138 479
cell C 139 479
is C 140 479
discussed C 141 479
. C 142 479
2564 C 1 480
. C 2 480
chemical C 4 480
inactivation C 5 480
and C 6 480
reactivation C 7 480
of C 8 480
transforming C 9 480
dna C 10 480
( C 11 480
russian C 12 480
) C 13 480
the C 14 480
kinetics C 15 480
of C 16 480
the C 17 480
inactivation C 18 480
of C 19 480
linked C 20 480
and C 21 480
unlinked C 22 480
genetic C 23 480
markers C 24 480
by C 25 480
means C 26 480
of C 27 480
hno C 28 480
2 C 29 480
or C 30 480
uv C 31 480
light C 32 480
was C 33 480
studied C 34 480
. C 35 480
closely C 37 480
linked C 38 480
markers C 39 480
are C 40 480
inactivated C 41 480
simul C 42 480
- C 43 480
taneously C 44 480
, C 45 480
unlinked C 46 480
markers C 47 480
are C 48 480
inactivated C 49 480
independently C 50 480
. C 51 480
it C 53 480
seems C 54 480
that C 55 480
the C 56 480
chemical C 57 480
attack C 58 480
on C 59 480
dna C 60 480
impairs C 61 480
a C 62 480
large C 63 480
part C 64 480
of C 65 480
macromolecule C 66 480
, C 67 480
including C 68 480
many C 69 480
cistrons C 70 480
. C 71 480
it C 73 480
was C 74 480
shown C 75 480
by C 76 480
genetic C 77 480
experiments C 78 480
that C 79 480
chemical C 80 480
inactivation C 81 480
prac C 82 480
- C 83 480
tically C 84 480
does C 85 480
not C 86 480
influence C 87 480
the C 88 480
process C 89 480
of C 90 480
dna C 91 480
inclusion C 92 480
into C 93 480
competent C 94 480
cells C 95 480
. C 96 480
by C 98 480
means C 99 480
of C 100 480
viscosity C 101 480
measurements C 102 480
it C 103 480
was C 104 480
shown C 105 480
that C 106 480
the C 107 480
molecular C 108 480
weight C 109 480
and C 110 480
macromolecular C 111 480
properties C 112 480
of C 113 480
dna C 114 480
do C 115 480
not C 116 480
significantly C 117 480
change C 118 480
during C 119 480
chemical C 120 480
inactivation C 121 480
by C 122 480
means C 123 480
of C 124 480
hno C 125 480
2 C 126 480
. C 127 480
two C 129 480
explanations C 130 480
for C 131 480
the C 132 480
inactivation C 133 480
of C 134 480
trans C 135 480
- C 136 480
forming C 137 480
activity C 138 480
of C 139 480
dna C 140 480
are C 141 480
discussed C 142 480
( C 143 480
1 C 144 480
) C 145 480
structural C 146 480
deteriorations C 147 480
, C 148 480
preventing C 149 480
integration C 150 480
of C 151 480
dna C 152 480
molecule C 153 480
into C 154 480
the C 155 480
genome C 156 480
of C 157 480
recipient C 158 480
cell C 159 480
, C 160 480
or C 161 480
( C 162 480
2 C 163 480
) C 164 480
deletion C 165 480
of C 166 480
a C 167 480
chain C 168 480
unit C 169 480
out C 170 480
of C 171 480
dna C 172 480
chain C 173 480
resulting C 174 480
in C 175 480
wrong C 176 480
reading C 177 480
of C 178 480
code C 179 480
triplets C 180 480
. C 181 480
it C 183 480
was C 184 480
previously C 185 480
described C 186 480
in C 187 480
the C 188 480
literature C 189 480
that C 190 480
extensive C 191 480
inactivation C 192 480
leads C 193 480
to C 194 480
a C 195 480
state C 196 480
of C 197 480
dna C 198 480
, C 199 480
apparently C 200 480
more C 201 480
resistant C 202 480
than C 203 480
the C 204 480
initial C 205 480
one C 206 480
. C 207 480
inactivation C 209 480
does C 210 480
not C 211 480
con C 212 480
- C 213 480
firm C 214 480
to C 215 480
exponential C 216 480
kinetics C 217 480
. C 218 480
the C 220 480
authors C 221 480
discuss C 222 480
the C 223 480
coding C 224 480
mistake C 225 480
hypothesis C 226 480
as C 227 480
an C 228 480
explanation C 229 480
for C 230 480
this C 231 480
remarkable C 232 480
fact C 233 480
. C 234 480
extensive C 236 480
hno C 237 480
2 C 238 480
or C 239 480
uv C 240 480
light C 241 480
action C 242 480
re C 243 480
- C 244 480
sults C 245 480
in C 246 480
multiple C 247 480
lesions C 248 480
in C 249 480
the C 250 480
dna C 251 480
molecule C 252 480
and C 253 480
leads C 254 480
to C 255 480
reactivation C 256 480
because C 257 480
the C 258 480
deletions C 259 480
restore C 260 480
correct C 261 480
reading C 262 480
of C 263 480
the C 264 480
code C 265 480
in C 266 480
a C 267 480
large C 268 480
part C 269 480
of C 270 480
dna C 271 480
molecule C 272 480
. C 273 480
on C 275 480
the C 276 480
basis C 277 480
of C 278 480
this C 279 480
explanation C 280 480
reactivation C 281 480
of C 282 480
chemically C 283 480
injured C 284 480
dna C 285 480
by C 286 480
means C 287 480
of C 288 480
fusion C 289 480
and C 290 480
annealing C 291 480
with C 292 480
homologous C 293 480
but C 294 480
genetically C 295 480
inactive C 296 480
dna C 297 480
, C 298 480
or C 299 480
by C 300 480
slight C 301 480
fragmentation C 302 480
of C 303 480
dna C 304 480
by C 305 480
means C 306 480
of C 307 480
ultrasonic C 308 480
vibrations C 309 480
may C 310 480
be C 311 480
expected C 312 480
. C 313 480
attempts C 315 480
to C 316 480
achieve C 317 480
reactivation C 318 480
by C 319 480
both C 320 480
methods C 321 480
gave C 322 480
positive C 323 480
results C 324 480
. C 325 480
2565 C 1 481
. C 2 481
separation C 4 481
of C 5 481
the C 6 481
transforming C 7 481
and C 8 481
viral C 9 481
deoxyribonucleic C 10 481
acids C 11 481
of C 12 481
a C 13 481
transducing C 14 481
bacteriophage C 15 481
of C 16 481
bacillus C 17 481
subtilis C 18 481
the C 19 481
authors C 20 481
used C 21 481
the C 22 481
transducing C 23 481
b C 24 481
. C 25 481
subtilis C 27 481
phage C 28 481
ps C 29 481
10 C 30 481
and C 31 481
present C 32 481
the C 33 481
fol C 34 481
- C 35 481
lowing C 36 481
experimental C 37 481
data C 38 481
dna C 39 481
isolated C 40 481
from C 41 481
ps C 42 481
10 C 43 481
is C 44 481
effective C 45 481
for C 46 481
transformation C 47 481
of C 48 481
competent C 49 481
b C 50 481
. C 51 481
subtilis C 53 481
cells C 54 481
. C 55 481
ps C 57 481
10 C 58 481
dna C 59 481
is C 60 481
distinguishable C 61 481
from C 62 481
b C 63 481
. C 64 481
subtilis C 66 481
dna C 67 481
by C 68 481
its C 69 481
higher C 70 481
density C 71 481
in C 72 481
a C 73 481
cs C 74 481
2 C 75 481
so C 76 481
4 C 77 481
gradient C 78 481
and C 79 481
its C 80 481
lower C 81 481
thermal C 82 481
denaturation C 83 481
temperature C 84 481
. C 85 481
the C 87 481
transforming C 88 481
activity C 89 481
present C 90 481
in C 91 481
dna C 92 481
from C 93 481
ps C 94 481
10 C 95 481
denatures C 96 481
at C 97 481
a C 98 481
temperature C 99 481
characteristic C 100 481
of C 101 481
b C 102 481
. C 103 481
subtilis C 105 481
dna C 106 481
rather C 107 481
than C 108 481
of C 109 481
viral C 110 481
dna C 111 481
. C 112 481
the C 114 481
transforming C 115 481
activity C 116 481
of C 117 481
ps C 118 481
10 C 119 481
dna C 120 481
bands C 121 481
in C 122 481
a C 123 481
cs C 124 481
2 C 125 481
so C 126 481
4 C 127 481
gradient C 128 481
with C 129 481
bacterial C 130 481
dna C 131 481
. C 132 481
this C 134 481
data C 135 481
indicated C 136 481
that C 137 481
bacterial C 138 481
dna C 139 481
is C 140 481
incorporated C 141 481
into C 142 481
phage C 143 481
ps C 144 481
10 C 145 481
without C 146 481
being C 147 481
integrated C 148 481
in C 149 481
the C 150 481
viral C 151 481
dna C 152 481
. C 153 481
this C 155 481
incorporated C 156 481
bacterial C 157 481
dna C 158 481
is C 159 481
involved C 160 481
in C 161 481
transduction C 162 481
. C 163 481
2529 C 1 482
. C 2 482
repair C 4 482
of C 5 482
damage C 6 482
induced C 7 482
by C 8 482
a C 9 482
monofunctional C 10 482
alkylating C 11 482
agent C 12 482
in C 13 482
a C 14 482
transformable C 15 482
, C 16 482
ultraviolet C 17 482
- C 18 482
sensitive C 19 482
strain C 20 482
of C 21 482
bacillus C 22 482
subtilis C 23 482
a C 24 482
uv C 25 482
sensitive C 26 482
, C 27 482
transformable C 28 482
strain C 29 482
of C 30 482
b C 31 482
. C 32 482
subtilis C 34 482
( C 35 482
uvr C 36 482
- C 37 482
) C 38 482
was C 39 482
unable C 40 482
to C 41 482
carry C 42 482
out C 43 482
host C 44 482
cell C 45 482
reactivation C 46 482
of C 47 482
the C 48 482
virulent C 49 482
bacteriophage C 50 482
spo C 51 482
1 C 52 482
. C 53 482
the C 55 482
ratio C 56 482
of C 57 482
the C 58 482
slopes C 59 482
( C 60 482
kuvr C 61 482
- C 62 482
/ C 63 482
kuvr C 64 482
+ C 65 482
) C 66 482
of C 67 482
the C 68 482
uv C 69 482
inactivation C 70 482
curves C 71 482
was C 72 482
6 C 73 482
- C 74 482
8 C 75 482
for C 76 482
cells C 77 482
or C 78 482
for C 79 482
whole C 80 482
phage C 81 482
, C 82 482
and C 83 482
2 C 84 482
for C 85 482
indole C 86 482
+ C 87 482
transforming C 88 482
dna C 89 482
or C 90 482
for C 91 482
spo C 92 482
1 C 93 482
phage C 94 482
dna C 95 482
measured C 96 482
in C 97 482
a C 98 482
transforming C 99 482
system C 100 482
. C 101 482
whole C 103 482
phage C 104 482
inactivated C 105 482
with C 106 482
nitrogen C 107 482
mustard C 108 482
showed C 109 482
greater C 110 482
survival C 111 482
on C 112 482
uvr C 113 482
+ C 114 482
cells C 115 482
than C 116 482
on C 117 482
uvr C 118 482
- C 119 482
; C 120 482
there C 121 482
was C 122 482
no C 123 482
such C 124 482
difference C 125 482
for C 126 482
whole C 127 482
phage C 128 482
inactivated C 129 482
with C 130 482
methyl C 131 482
methanesulfonate C 132 482
. C 133 482
whole C 135 482
uvr C 136 482
+ C 137 482
cells C 138 482
recovered C 139 482
from C 140 482
uv C 141 482
induced C 142 482
damage C 143 482
, C 144 482
as C 145 482
determined C 146 482
by C 147 482
an C 148 482
increase C 149 482
in C 150 482
extractable C 151 482
transforming C 152 482
activity C 153 482
during C 154 482
a C 155 482
period C 156 482
of C 157 482
incubation C 158 482
in C 159 482
which C 160 482
net C 161 482
dna C 162 482
synthesis C 163 482
did C 164 482
not C 165 482
occur C 166 482
. C 167 482
uvr C 169 482
- C 170 482
cells C 171 482
were C 172 482
unable C 173 482
to C 174 482
reco C 175 482
- C 176 482
ver C 177 482
from C 178 482
uv C 179 482
induced C 180 482
damage C 181 482
but C 182 482
they C 183 482
did C 184 482
recover C 185 482
from C 186 482
methyl C 187 482
methanesulfonate C 188 482
induced C 189 482
damage C 190 482
in C 191 482
similar C 192 482
experiments C 193 482
. C 194 482
density C 196 482
labeled C 197 482
( C 198 482
h C 199 482
2 C 200 482
n C 201 482
15 C 202 482
) C 203 482
methyl C 204 482
methanesul C 205 482
- C 206 482
fonate C 207 482
treated C 208 482
uvr C 209 482
+ C 210 482
cells C 211 482
incubated C 212 482
in C 213 482
( C 214 482
h C 215 482
1 C 216 482
n C 217 482
14 C 218 482
) C 219 482
medium C 220 482
containing C 221 482
( C 222 482
h C 223 482
3 C 224 482
) C 225 482
thymidine C 226 482
show C 227 482
- C 228 482
ed C 229 482
a C 230 482
3 C 231 482
- C 232 482
fold C 233 482
increase C 234 482
in C 235 482
extractable C 236 482
transforming C 237 482
activity C 238 482
, C 239 482
with C 240 482
no C 241 482
formation C 242 482
of C 243 482
new C 244 482
dna C 245 482
molecules C 246 482
as C 247 482
determined C 248 482
by C 249 482
pyknometric C 250 482
analysis C 251 482
. C 252 482
the C 254 482
repair C 255 482
of C 256 482
damage C 257 482
in C 258 482
- C 259 482
duced C 260 482
by C 261 482
uv C 262 482
irradiation C 263 482
differs C 264 482
by C 265 482
at C 266 482
least C 267 482
one C 268 482
step C 269 482
from C 270 482
the C 271 482
repair C 272 482
of C 273 482
damage C 274 482
in C 275 482
- C 276 482
duced C 277 482
by C 278 482
methyl C 279 482
methanesulfonate C 280 482
. C 281 482
1451 C 1 483
. C 2 483
the C 4 483
biosynthesis C 5 483
of C 6 483
5 C 7 483
- C 8 483
hydroxymethyldeoxyuridylic C 9 483
acid C 10 483
in C 11 483
bacteriophage C 12 483
- C 13 483
infected C 14 483
bacillus C 15 483
subtilis C 16 483
when C 17 483
phage C 18 483
e C 19 483
, C 20 483
which C 21 483
contains C 22 483
5 C 23 483
- C 24 483
hydroxymethyluracil C 25 483
in C 26 483
its C 27 483
dna C 28 483
in C 29 483
place C 30 483
of C 31 483
thymine C 32 483
, C 33 483
infects C 34 483
b C 35 483
. C 36 483
subtilis C 38 483
, C 39 483
enzyme C 40 483
changes C 41 483
occur C 42 483
in C 43 483
the C 44 483
host C 45 483
organism C 46 483
which C 47 483
can C 48 483
account C 49 483
for C 50 483
the C 51 483
synthesis C 52 483
of C 53 483
the C 54 483
abnormal C 55 483
base C 56 483
. C 57 483
deoxycytidylate C 59 483
deaminase C 60 483
increases C 61 483
at C 62 483
least C 63 483
90 C 64 483
- C 65 483
fold C 66 483
and C 67 483
the C 68 483
product C 69 483
of C 70 483
its C 71 483
action C 72 483
, C 73 483
deoxyuridylic C 74 483
acid C 75 483
, C 76 483
is C 77 483
converted C 78 483
directly C 79 483
into C 80 483
the C 81 483
deoxynucleotide C 82 483
of C 83 483
5 C 84 483
- C 85 483
hydroxymethyluracil C 86 483
by C 87 483
a C 88 483
hydroxymethylase C 89 483
enzyme C 90 483
. C 91 483
the C 93 483
activity C 94 483
of C 95 483
thymidylate C 96 483
synthetase C 97 483
, C 98 483
which C 99 483
also C 100 483
uses C 101 483
deoxyuridylic C 102 483
acid C 103 483
as C 104 483
substrate C 105 483
, C 106 483
decreases C 107 483
rapidly C 108 483
after C 109 483
phage C 110 483
infection C 111 483
. C 112 483
5574 C 1 484
. C 2 484
death C 4 484
anxiety C 5 484
in C 6 484
children C 7 484
with C 8 484
a C 9 484
fatal C 10 484
illness C 11 484
the C 12 484
author C 13 484
reports C 14 484
studies C 15 484
of C 16 484
a C 17 484
series C 18 484
of C 19 484
50 C 20 484
children C 21 484
hospitalized C 22 484
because C 23 484
of C 24 484
fatal C 25 484
illness C 26 484
due C 27 484
to C 28 484
leukemia C 29 484
or C 30 484
some C 31 484
other C 32 484
form C 33 484
of C 34 484
cancer C 35 484
. C 36 484
it C 38 484
was C 39 484
postulated C 40 484
that C 41 484
the C 42 484
younger C 43 484
children C 44 484
would C 45 484
experience C 46 484
separation C 47 484
anxiety C 48 484
while C 49 484
the C 50 484
older C 51 484
children C 52 484
would C 53 484
be C 54 484
more C 55 484
likely C 56 484
to C 57 484
experience C 58 484
death C 59 484
anxiety C 60 484
. C 61 484
in C 63 484
general C 64 484
the C 65 484
hypothesis C 66 484
was C 67 484
supported C 68 484
by C 69 484
the C 70 484
results C 71 484
of C 72 484
the C 73 484
study C 74 484
. C 75 484
there C 77 484
was C 78 484
some C 79 484
evidence C 80 484
to C 81 484
indicate C 82 484
that C 83 484
the C 84 484
younger C 85 484
children C 86 484
perceive C 87 484
death C 88 484
anxiety C 89 484
but C 90 484
deal C 91 484
with C 92 484
it C 93 484
in C 94 484
more C 95 484
symbolic C 96 484
form C 97 484
. C 98 484
in C 100 484
older C 101 484
children C 102 484
, C 103 484
it C 104 484
was C 105 484
felt C 106 484
that C 107 484
boys C 108 484
tended C 109 484
to C 110 484
react C 111 484
to C 112 484
death C 113 484
anxiety C 114 484
by C 115 484
acting C 116 484
out C 117 484
behavior C 118 484
while C 119 484
girls C 120 484
tended C 121 484
to C 122 484
become C 123 484
depressed C 124 484
. C 125 484
1209 C 1 485
. C 2 485
the C 4 485
theory C 5 485
and C 6 485
practice C 7 485
of C 8 485
the C 9 485
family C 10 485
diagnostic C 11 485
. C 12 485
ii C 14 485
. C 15 485
theoretical C 17 485
aspects C 18 485
and C 19 485
resident C 20 485
education C 21 485
family C 22 485
intervention C 23 485
and C 24 485
observation C 25 485
have C 26 485
proved C 27 485
useful C 28 485
in C 29 485
3 C 30 485
areas C 31 485
. C 32 485
the C 34 485
1 C 35 485
st C 36 485
of C 37 485
these C 38 485
is C 39 485
observation C 40 485
of C 41 485
the C 42 485
psychosocial C 43 485
context C 44 485
in C 45 485
the C 46 485
patient C 47 485
. C 48 485
on C 50 485
admission C 51 485
to C 52 485
a C 53 485
mental C 54 485
hospital C 55 485
the C 56 485
phenomenon C 57 485
of C 58 485
extrusion C 59 485
and C 60 485
separ C 61 485
- C 62 485
ation C 63 485
from C 64 485
the C 65 485
family C 66 485
is C 67 485
evident C 68 485
, C 69 485
and C 70 485
the C 71 485
need C 72 485
for C 73 485
study C 74 485
of C 75 485
the C 76 485
interaction C 77 485
between C 78 485
the C 79 485
patient C 80 485
and C 81 485
his C 82 485
family C 83 485
milieu C 84 485
is C 85 485
vital C 86 485
. C 87 485
the C 89 485
2 C 90 485
nd C 91 485
area C 92 485
where C 93 485
the C 94 485
family C 95 485
inter C 96 485
- C 97 485
view C 98 485
has C 99 485
a C 100 485
major C 101 485
role C 102 485
is C 103 485
resident C 104 485
education C 105 485
. C 106 485
the C 108 485
tra C 109 485
- C 110 485
ditional C 111 485
medical C 112 485
education C 113 485
of C 114 485
the C 115 485
ill C 116 485
prepares C 117 485
the C 118 485
stu C 119 485
- C 120 485
dent C 121 485
for C 122 485
consideration C 123 485
of C 124 485
the C 125 485
multifactorial C 126 485
problems C 127 485
of C 128 485
emotional C 129 485
disorder C 130 485
in C 131 485
which C 132 485
balances C 133 485
between C 134 485
mem C 135 485
- C 136 485
bers C 137 485
of C 138 485
a C 139 485
group C 140 485
may C 141 485
be C 142 485
the C 143 485
issue C 144 485
rather C 145 485
than C 146 485
external C 147 485
pathogenes C 148 485
. C 149 485
the C 151 485
family C 152 485
interview C 153 485
offers C 154 485
a C 155 485
unique C 156 485
point C 157 485
of C 158 485
observation C 159 485
of C 160 485
factually C 161 485
evident C 162 485
and C 163 485
emotionally C 164 485
con C 165 485
- C 166 485
vincing C 167 485
group C 168 485
data C 169 485
. C 170 485
in C 172 485
addition C 173 485
to C 174 485
the C 175 485
observation C 176 485
of C 177 485
family C 178 485
phenomena C 179 485
, C 180 485
mutual C 181 485
understanding C 182 485
of C 183 485
others C 184 485
' C 185 485
problems C 186 485
is C 187 485
created C 188 485
. C 189 485
finally C 191 485
, C 192 485
the C 193 485
family C 194 485
interview C 195 485
serves C 196 485
as C 197 485
an C 198 485
instrument C 199 485
for C 200 485
data C 201 485
collection C 202 485
and C 203 485
hypo C 204 485
- C 205 485
thesis C 206 485
seeking C 207 485
in C 208 485
relating C 209 485
individual C 210 485
psychopathology C 211 485
to C 212 485
family C 213 485
adaptations C 214 485
. C 215 485
the C 217 485
patient C 218 485
and C 219 485
his C 220 485
family C 221 485
at C 222 485
the C 223 485
time C 224 485
of C 225 485
admission C 226 485
are C 227 485
dealing C 228 485
with C 229 485
a C 230 485
crisis C 231 485
. C 232 485
some C 234 485
- C 235 485
times C 236 485
this C 237 485
is C 238 485
traumatic C 239 485
, C 240 485
such C 241 485
as C 242 485
the C 243 485
unexpected C 244 485
loss C 245 485
of C 246 485
a C 247 485
young C 248 485
marital C 249 485
partner C 250 485
, C 251 485
an C 252 485
unexpected C 253 485
illness C 254 485
, C 255 485
or C 256 485
a C 257 485
financial C 258 485
reverse C 259 485
. C 260 485
more C 262 485
commonly C 263 485
, C 264 485
however C 265 485
, C 266 485
it C 267 485
is C 268 485
developmental C 269 485
being C 270 485
a C 271 485
natural C 272 485
part C 273 485
of C 274 485
the C 275 485
life C 276 485
cycle C 277 485
. C 278 485
characteristically C 280 485
, C 281 485
the C 282 485
developmental C 283 485
task C 284 485
involved C 285 485
in C 286 485
dealing C 287 485
with C 288 485
the C 289 485
crises C 290 485
has C 291 485
been C 292 485
postponed C 293 485
so C 294 485
that C 295 485
one C 296 485
does C 297 485
not C 298 485
see C 299 485
the C 300 485
family C 301 485
at C 302 485
the C 303 485
age C 304 485
specific C 305 485
and C 306 485
ap C 307 485
- C 308 485
propriate C 309 485
time C 310 485
for C 311 485
this C 312 485
task C 313 485
. C 314 485
the C 316 485
crisis C 317 485
emerges C 318 485
dis C 319 485
- C 320 485
ruptively C 321 485
because C 322 485
of C 323 485
inevitable C 324 485
biological C 325 485
maturation C 326 485
, C 327 485
personal C 328 485
decision C 329 485
, C 330 485
or C 331 485
social C 332 485
expectation C 333 485
. C 334 485
a C 336 485
primary C 337 485
concern C 338 485
of C 339 485
the C 340 485
leader C 341 485
is C 342 485
to C 343 485
determine C 344 485
what C 345 485
life C 346 485
task C 347 485
is C 348 485
being C 349 485
faced C 350 485
. C 351 485
families C 353 485
have C 354 485
a C 355 485
mentally C 356 485
ill C 357 485
member C 358 485
not C 359 485
merely C 360 485
because C 361 485
they C 362 485
are C 363 485
dealing C 364 485
with C 365 485
the C 366 485
vicissitudes C 367 485
of C 368 485
life C 369 485
. C 370 485
they C 372 485
are C 373 485
unable C 374 485
to C 375 485
cope C 376 485
with C 377 485
the C 378 485
crisis C 379 485
, C 380 485
be C 381 485
- C 382 485
cause C 383 485
of C 384 485
the C 385 485
feelings C 386 485
which C 387 485
are C 388 485
aroused C 389 485
. C 390 485
each C 392 485
life C 393 485
cri C 394 485
- C 395 485
sis C 396 485
leads C 397 485
to C 398 485
a C 399 485
particular C 400 485
constellation C 401 485
of C 402 485
effects C 403 485
in C 404 485
any C 405 485
given C 406 485
family C 407 485
. C 408 485
these C 410 485
include C 411 485
primarily C 412 485
, C 413 485
sadness C 414 485
, C 415 485
anger C 416 485
, C 417 485
and C 418 485
guilt C 419 485
, C 420 485
but C 421 485
there C 422 485
may C 423 485
well C 424 485
be C 425 485
specific C 426 485
affective C 427 485
con C 428 485
- C 429 485
stellations C 430 485
appropriate C 431 485
to C 432 485
different C 433 485
developmental C 434 485
tasks C 435 485
. C 436 485
the C 438 485
patient C 439 485
' C 440 485
s C 441 485
inability C 442 485
to C 443 485
cope C 444 485
with C 445 485
a C 446 485
life C 447 485
crisis C 448 485
is C 449 485
due C 450 485
to C 451 485
his C 452 485
particular C 453 485
adaptation C 454 485
of C 455 485
a C 456 485
style C 457 485
of C 458 485
dealing C 459 485
with C 460 485
feelings C 461 485
that C 462 485
is C 463 485
employed C 464 485
by C 465 485
other C 466 485
members C 467 485
of C 468 485
the C 469 485
family C 470 485
. C 471 485
265 C 1 486
. C 2 486
studies C 4 486
in C 5 486
personality C 6 486
. C 7 486
ii C 9 486
. C 10 486
a C 12 486
bio C 13 486
- C 14 486
psychological C 15 486
and C 16 486
experimental C 17 486
approach C 18 486
to C 19 486
problems C 20 486
of C 21 486
human C 22 486
adaptation C 23 486
in C 24 486
modern C 25 486
society C 26 486
experimentally C 27 486
determined C 28 486
fixation C 29 486
- C 30 486
ambivalence C 31 486
measures C 32 486
are C 33 486
related C 34 486
to C 35 486
some C 36 486
anxiety C 37 486
estimates C 38 486
obtain C 39 486
- C 40 486
ed C 41 486
from C 42 486
a C 43 486
projective C 44 486
test C 45 486
in C 46 486
a C 47 486
group C 48 486
of C 49 486
male C 50 486
adolescents C 51 486
. C 52 486
it C 54 486
is C 55 486
shown C 56 486
that C 57 486
( C 58 486
1 C 59 486
) C 60 486
fixation C 61 486
increases C 62 486
with C 63 486
increase C 64 486
in C 65 486
corporal C 66 486
injury C 67 486
anxiety C 68 486
when C 69 486
ambivalence C 70 486
is C 71 486
kept C 72 486
con C 73 486
- C 74 486
stant C 75 486
, C 76 486
( C 77 486
2 C 78 486
) C 79 486
ambivalence C 80 486
increases C 81 486
with C 82 486
increase C 83 486
in C 84 486
separa C 85 486
- C 86 486
tion C 87 486
anxiety C 88 486
when C 89 486
fixation C 90 486
is C 91 486
kept C 92 486
constant C 93 486
, C 94 486
( C 95 486
3 C 96 486
) C 97 486
extremely C 98 486
hetero C 99 486
- C 100 486
fixated C 101 486
subjects C 102 486
show C 103 486
presence C 104 486
of C 105 486
intense C 106 486
guilt C 107 486
and C 108 486
absence C 109 486
of C 110 486
aggression C 111 486
towards C 112 486
the C 113 486
mother C 114 486
; C 115 486
one C 116 486
ef C 117 486
- C 118 486
fect C 119 486
of C 120 486
this C 121 486
system C 122 486
of C 123 486
organizers C 124 486
seems C 125 486
to C 126 486
be C 127 486
suicidal C 128 486
tendencies C 129 486
, C 130 486
( C 131 486
4 C 132 486
) C 133 486
extremely C 134 486
ambivalent C 135 486
subjects C 136 486
have C 137 486
in C 138 486
- C 139 486
tense C 140 486
separation C 141 486
anxiety C 142 486
; C 143 486
one C 144 486
effect C 145 486
seems C 146 486
to C 147 486
be C 148 486
suicidal C 149 486
tendencies C 150 486
combined C 151 486
with C 152 486
high C 153 486
ambition C 154 486
and C 155 486
impaired C 156 486
cognitive C 157 486
capacity C 158 486
. C 159 486
2837 C 1 487
. C 2 487
early C 4 487
indicators C 5 487
of C 6 487
outcome C 7 487
in C 8 487
schizophrenia C 9 487
the C 10 487
case C 11 487
material C 12 487
of C 13 487
50 C 14 487
persons C 15 487
who C 16 487
were C 17 487
seen C 18 487
at C 19 487
a C 20 487
child C 21 487
guidance C 22 487
center C 23 487
in C 24 487
child C 25 487
- C 26 487
hood C 27 487
or C 28 487
adolescence C 29 487
and C 30 487
were C 31 487
later C 32 487
hospitalized C 33 487
with C 34 487
schizophrenia C 35 487
were C 36 487
examined C 37 487
intensively C 38 487
. C 39 487
the C 41 487
study C 42 487
concentrated C 43 487
especially C 44 487
on C 45 487
the C 46 487
differences C 47 487
associated C 48 487
with C 49 487
chronicity C 50 487
vs C 51 487
. C 52 487
hospital C 54 487
release C 55 487
. C 56 487
the C 58 487
following C 59 487
12 C 60 487
factors C 61 487
were C 62 487
significantly C 63 487
related C 64 487
to C 65 487
chronicity C 66 487
( C 67 487
1 C 68 487
) C 69 487
psychotic C 70 487
or C 71 487
schizoid C 72 487
pathology C 73 487
in C 74 487
the C 75 487
mothering C 76 487
person C 77 487
, C 78 487
( C 79 487
2 C 80 487
) C 81 487
no C 82 487
se C 83 487
- C 84 487
paration C 85 487
of C 86 487
any C 87 487
kind C 88 487
from C 89 487
the C 90 487
pathogenic C 91 487
families C 92 487
, C 93 487
( C 94 487
3 C 95 487
) C 96 487
pre C 97 487
- C 98 487
illness C 99 487
history C 100 487
of C 101 487
poor C 102 487
so C 103 487
- C 104 487
cial C 105 487
and C 106 487
sexual C 107 487
adjustment C 108 487
, C 109 487
( C 110 487
4 C 111 487
) C 112 487
failure C 113 487
to C 114 487
continue C 115 487
in C 116 487
treatment C 117 487
( C 118 487
during C 119 487
childhood C 120 487
) C 121 487
for C 122 487
at C 123 487
least C 124 487
3 C 125 487
mth C 126 487
. C 127 487
, C 129 487
( C 130 487
5 C 131 487
) C 132 487
less C 133 487
acting C 134 487
out C 135 487
in C 136 487
the C 137 487
community C 138 487
, C 139 487
( C 140 487
6 C 141 487
) C 142 487
neither C 143 487
disorientation C 144 487
nor C 145 487
confusion C 146 487
on C 147 487
admission C 148 487
, C 149 487
( C 150 487
7 C 151 487
) C 152 487
no C 153 487
symptoms C 154 487
of C 155 487
depressive C 156 487
psychosis C 157 487
, C 158 487
( C 159 487
8 C 160 487
) C 161 487
premor C 162 487
- C 163 487
bid C 164 487
schizoid C 165 487
personality C 166 487
, C 167 487
( C 168 487
9 C 169 487
) C 170 487
no C 171 487
clear C 172 487
precipitating C 173 487
events C 174 487
, C 175 487
( C 176 487
10 C 177 487
) C 178 487
no C 179 487
concern C 180 487
with C 181 487
dying C 182 487
during C 183 487
the C 184 487
acute C 185 487
phase C 186 487
of C 187 487
the C 188 487
illness C 189 487
, C 190 487
( C 191 487
11 C 192 487
) C 193 487
length C 194 487
of C 195 487
onset C 196 487
over C 197 487
6 C 198 487
mth C 199 487
. C 200 487
, C 202 487
and C 203 487
( C 204 487
12 C 205 487
) C 206 487
schi C 207 487
- C 208 487
zophrenic C 209 487
reaction C 210 487
in C 211 487
patients C 212 487
' C 213 487
heredity C 214 487
. C 215 487
items C 217 487
1 C 218 487
, C 219 487
2 C 220 487
, C 221 487
and C 222 487
5 C 223 487
were C 224 487
derived C 225 487
from C 226 487
early C 227 487
life C 228 487
history C 229 487
data C 230 487
and C 231 487
are C 232 487
thought C 233 487
to C 234 487
be C 235 487
new C 236 487
to C 237 487
the C 238 487
literature C 239 487
of C 240 487
prognosis C 241 487
in C 242 487
schizo C 243 487
- C 244 487
phrenia C 245 487
. C 246 487
the C 248 487
remaining C 249 487
8 C 250 487
factors C 251 487
can C 252 487
be C 253 487
scored C 254 487
from C 255 487
hospital C 256 487
data C 257 487
alone C 258 487
, C 259 487
and C 260 487
have C 261 487
been C 262 487
cited C 263 487
in C 264 487
previous C 265 487
prognostic C 266 487
studies C 267 487
. C 268 487
4854 C 1 488
. C 2 488
on C 4 488
the C 5 488
formation C 6 488
of C 7 488
object C 8 488
- C 9 488
relations C 10 488
and C 11 488
identifications C 12 488
of C 13 488
the C 14 488
kibbutz C 15 488
child C 16 488
some C 17 488
of C 18 488
the C 19 488
issues C 20 488
relevant C 21 488
to C 22 488
the C 23 488
early C 24 488
stages C 25 488
of C 26 488
object C 27 488
relation C 28 488
formation C 29 488
and C 30 488
identification C 31 488
of C 32 488
kibbutz C 33 488
children C 34 488
are C 35 488
discussed C 36 488
. C 37 488
for C 39 488
this C 40 488
purpose C 41 488
the C 42 488
child C 43 488
rearing C 44 488
milieu C 45 488
of C 46 488
the C 47 488
kibbutz C 48 488
child C 49 488
is C 50 488
described C 51 488
and C 52 488
some C 53 488
clinical C 54 488
illustrations C 55 488
are C 56 488
given C 57 488
. C 58 488
the C 60 488
relationship C 61 488
to C 62 488
the C 63 488
mother C 64 488
is C 65 488
seen C 66 488
as C 67 488
the C 68 488
main C 69 488
object C 70 488
- C 71 488
relation C 72 488
and C 73 488
those C 74 488
to C 75 488
the C 76 488
educators C 77 488
as C 78 488
transient C 79 488
- C 80 488
interchangeable C 81 488
need C 82 488
- C 83 488
satisfying C 84 488
relationships C 85 488
. C 86 488
on C 88 488
the C 89 488
basis C 90 488
of C 91 488
retrospective C 92 488
analytical C 93 488
material C 94 488
it C 95 488
appears C 96 488
that C 97 488
in C 98 488
the C 99 488
course C 100 488
of C 101 488
development C 102 488
the C 103 488
two C 104 488
relations C 105 488
as C 106 488
well C 107 488
as C 108 488
the C 109 488
two C 110 488
respective C 111 488
, C 112 488
originally C 113 488
distinct C 114 488
, C 115 488
object C 116 488
represen C 117 488
- C 118 488
tations C 119 488
are C 120 488
synthetised C 121 488
into C 122 488
one C 123 488
. C 124 488
the C 126 488
conditions C 127 488
of C 128 488
communal C 129 488
education C 130 488
, C 131 488
character C 132 488
- C 133 488
ised C 134 488
by C 135 488
double C 136 488
object C 137 488
- C 138 488
relation C 139 488
formation C 140 488
from C 141 488
birth C 142 488
on C 143 488
, C 144 488
are C 145 488
seen C 146 488
as C 147 488
factors C 148 488
that C 149 488
in C 150 488
- C 151 488
tensify C 152 488
the C 153 488
' C 154 488
normative C 155 488
crisis C 156 488
of C 157 488
infancy C 158 488
' C 159 488
, C 160 488
especially C 161 488
the C 162 488
transition C 163 488
from C 164 488
the C 165 488
symbio C 166 488
- C 167 488
tic C 168 488
to C 169 488
the C 170 488
separation C 171 488
- C 172 488
individuation C 173 488
stage C 174 488
of C 175 488
object C 176 488
- C 177 488
relation C 178 488
development C 179 488
. C 180 488
4846 C 1 489
. C 2 489
the C 4 489
meaning C 5 489
of C 6 489
crying C 7 489
the C 8 489
multiple C 9 489
meanings C 10 489
of C 11 489
crying C 12 489
are C 13 489
reviewed C 14 489
and C 15 489
, C 16 489
in C 17 489
particular C 18 489
, C 19 489
stress C 20 489
is C 21 489
laid C 22 489
on C 23 489
tears C 24 489
as C 25 489
a C 26 489
response C 27 489
to C 28 489
some C 29 489
type C 30 489
of C 31 489
separation C 32 489
loss C 33 489
. C 34 489
2953 C 1 490
. C 2 490
the C 4 490
death C 5 490
of C 6 490
a C 7 490
parent C 8 490
in C 9 490
the C 10 490
case C 11 490
of C 12 490
depressive C 13 490
illnesses C 14 490
the C 15 490
death C 16 490
of C 17 490
either C 18 490
parent C 19 490
prior C 20 490
to C 21 490
the C 22 490
child C 23 490
reach C 24 490
- C 25 490
ing C 26 490
the C 27 490
age C 28 490
of C 29 490
15 C 30 490
seemed C 31 490
to C 32 490
be C 33 490
correlated C 34 490
as C 35 490
a C 36 490
significant C 37 490
contributory C 38 490
factor C 39 490
. C 40 490
with C 42 490
this C 43 490
exception C 44 490
, C 45 490
statistical C 46 490
studies C 47 490
suggest C 48 490
that C 49 490
it C 50 490
is C 51 490
the C 52 490
death C 53 490
of C 54 490
a C 55 490
mother C 56 490
in C 57 490
the C 58 490
first C 59 490
7 C 60 490
yr C 61 490
. C 62 490
of C 64 490
a C 65 490
child C 66 490
' C 67 490
s C 68 490
life C 69 490
, C 70 490
as C 71 490
opposed C 72 490
to C 73 490
that C 74 490
of C 75 490
a C 76 490
father C 77 490
, C 78 490
that C 79 490
is C 80 490
potentially C 81 490
an C 82 490
etiologi C 83 490
- C 84 490
cal C 85 490
factor C 86 490
for C 87 490
the C 88 490
future C 89 490
development C 90 490
of C 91 490
psychoses C 92 490
, C 93 490
delinquency C 94 490
and C 95 490
psychoneuroses C 96 490
. C 97 490
the C 99 490
case C 100 490
histories C 101 490
of C 102 490
6 C 103 490
boys C 104 490
who C 105 490
had C 106 490
lost C 107 490
their C 108 490
fathers C 109 490
were C 110 490
given C 111 490
. C 112 490
in C 114 490
each C 115 490
instance C 116 490
there C 117 490
was C 118 490
distinct C 119 490
evidence C 120 490
that C 121 490
the C 122 490
psychological C 123 490
symptoms C 124 490
and C 125 490
behavioral C 126 490
disturb C 127 490
- C 128 490
ances C 129 490
were C 130 490
to C 131 490
be C 132 490
attributed C 133 490
in C 134 490
large C 135 490
measure C 136 490
to C 137 490
the C 138 490
effect C 139 490
of C 140 490
the C 141 490
death C 142 490
upon C 143 490
the C 144 490
child C 145 490
, C 146 490
and C 147 490
that C 148 490
in C 149 490
some C 150 490
cases C 151 490
the C 152 490
symptom C 153 490
choice C 154 490
was C 155 490
to C 156 490
be C 157 490
correlated C 158 490
with C 159 490
specific C 160 490
cir C 161 490
- C 162 490
cumstances C 163 490
surrounding C 164 490
the C 165 490
death C 166 490
of C 167 490
the C 168 490
father C 169 490
. C 170 490
in C 172 490
some C 173 490
cases C 174 490
it C 175 490
was C 176 490
the C 177 490
unresolved C 178 490
grief C 179 490
reaction C 180 490
in C 181 490
the C 182 490
mother C 183 490
which C 184 490
helped C 185 490
to C 186 490
perpetuate C 187 490
the C 188 490
disorder C 189 490
in C 190 490
the C 191 490
child C 192 490
. C 193 490
re C 195 490
- C 196 490
solution C 197 490
of C 198 490
this C 199 490
in C 200 490
the C 201 490
mother C 202 490
during C 203 490
therapy C 204 490
led C 205 490
to C 206 490
improvement C 207 490
in C 208 490
the C 209 490
child C 210 490
' C 211 490
s C 212 490
func C 213 490
- C 214 490
tioning C 215 490
. C 216 490
in C 218 490
other C 219 490
instances C 220 490
improvement C 221 490
occurred C 222 490
especially C 223 490
when C 224 490
the C 225 490
child C 226 490
ceased C 227 490
to C 228 490
be C 229 490
preoccupied C 230 490
with C 231 490
a C 232 490
close C 233 490
identification C 234 490
with C 235 490
the C 236 490
dead C 237 490
father C 238 490
. C 239 490
those C 241 490
boys C 242 490
who C 243 490
were C 244 490
involved C 245 490
most C 246 490
closely C 247 490
in C 248 490
their C 249 490
mother C 250 490
' C 251 490
s C 252 490
grief C 253 490
reactions C 254 490
were C 255 490
the C 256 490
ones C 257 490
who C 258 490
were C 259 490
most C 260 490
disturbed C 261 490
. C 262 490
the C 264 490
brief C 265 490
treatment C 266 490
given C 267 490
these C 268 490
boys C 269 490
and C 270 490
their C 271 490
mothers C 272 490
appeared C 273 490
to C 274 490
be C 275 490
responsible C 276 490
for C 277 490
the C 278 490
considerable C 279 490
amelioration C 280 490
of C 281 490
symptoms C 282 490
that C 283 490
resulted C 284 490
. C 285 490
ther C 287 490
- C 288 490
apeutic C 289 490
intervention C 290 490
is C 291 490
worthwhile C 292 490
, C 293 490
especially C 294 490
in C 295 490
those C 296 490
instances C 297 490
where C 298 490
there C 299 490
is C 300 490
an C 301 490
unresolved C 302 490
grief C 303 490
reaction C 304 490
in C 305 490
the C 306 490
mother C 307 490
. C 308 490
1848 C 1 491
. C 2 491
the C 4 491
child C 5 491
' C 6 491
s C 7 491
concept C 8 491
of C 9 491
death C 10 491
in C 11 491
this C 12 491
translation C 13 491
of C 14 491
a C 15 491
paper C 16 491
, C 17 491
which C 18 491
first C 19 491
appeared C 20 491
in C 21 491
1912 C 22 491
, C 23 491
it C 24 491
is C 25 491
shown C 26 491
, C 27 491
according C 28 491
to C 29 491
freud C 30 491
, C 31 491
how C 32 491
far C 33 491
a C 34 491
child C 35 491
' C 36 491
s C 37 491
appreciation C 38 491
of C 39 491
being C 40 491
dead C 41 491
differs C 42 491
from C 43 491
its C 44 491
true C 45 491
signifi C 46 491
- C 47 491
cance C 48 491
. C 49 491
death C 51 491
means C 52 491
a C 53 491
reversible C 54 491
decrease C 55 491
in C 56 491
life C 57 491
functions C 58 491
, C 59 491
that C 60 491
can C 61 491
be C 62 491
interrupted C 63 491
at C 64 491
any C 65 491
time C 66 491
, C 67 491
like C 68 491
sleep C 69 491
. C 70 491
at C 72 491
other C 73 491
times C 74 491
it C 75 491
may C 76 491
mean C 77 491
a C 78 491
temporary C 79 491
separation C 80 491
; C 81 491
but C 82 491
always C 83 491
it C 84 491
is C 85 491
in C 86 491
man C 87 491
' C 88 491
s C 89 491
power C 90 491
to C 91 491
change C 92 491
it C 93 491
. C 94 491
in C 96 491
this C 97 491
concept C 98 491
, C 99 491
the C 100 491
child C 101 491
' C 102 491
s C 103 491
unconscious C 104 491
finds C 105 491
license C 106 491
for C 107 491
his C 108 491
sadism C 109 491
. C 110 491
cruelty C 112 491
to C 113 491
animals C 114 491
and C 115 491
death C 116 491
wishes C 117 491
against C 118 491
persons C 119 491
close C 120 491
to C 121 491
him C 122 491
appear C 123 491
, C 124 491
in C 125 491
overcompensation C 126 491
, C 127 491
as C 128 491
exaggerated C 129 491
pity C 130 491
for C 131 491
dead C 132 491
creatures C 133 491
and C 134 491
the C 135 491
belief C 136 491
in C 137 491
man C 138 491
' C 139 491
s C 140 491
power C 141 491
over C 142 491
life C 143 491
and C 144 491
death C 145 491
. C 146 491
1849 C 1 492
. C 2 492
mother C 4 492
child C 5 492
interaction C 6 492
during C 7 492
separation C 8 492
individuation C 9 492
after C 10 492
a C 11 492
stage C 12 492
of C 13 492
normal C 14 492
autism C 15 492
during C 16 492
the C 17 492
1 C 18 492
st C 19 492
weeks C 20 492
of C 21 492
extrauterine C 22 492
life C 23 492
, C 24 492
the C 25 492
infant C 26 492
passes C 27 492
into C 28 492
a C 29 492
symbiotic C 30 492
phase C 31 492
, C 32 492
gradually C 33 492
emerging C 34 492
from C 35 492
this C 36 492
stage C 37 492
of C 38 492
dual C 39 492
unity C 40 492
at C 41 492
the C 42 492
end C 43 492
of C 44 492
the C 45 492
5 C 46 492
th C 47 492
mth C 48 492
and C 49 492
during C 50 492
the C 51 492
6 C 52 492
th C 53 492
mth C 54 492
. C 55 492
just C 57 492
before C 58 492
this C 59 492
, C 60 492
the C 61 492
next C 62 492
phase C 63 492
separation C 64 492
individuation C 65 492
begins C 66 492
. C 67 492
four C 69 492
characteristic C 70 492
subphases C 71 492
of C 72 492
this C 73 492
separation C 74 492
individuation C 75 492
process C 76 492
are C 77 492
described C 78 492
differentiation C 79 492
, C 80 492
the C 81 492
practicing C 82 492
period C 83 492
, C 84 492
association C 85 492
and C 86 492
a C 87 492
stage C 88 492
, C 89 492
characterized C 90 492
by C 91 492
unfolding C 92 492
of C 93 492
complex C 94 492
cognitive C 95 492
functions C 96 492
. C 97 492
the C 99 492
relation C 100 492
of C 101 492
mother C 102 492
and C 103 492
child C 104 492
throughout C 105 492
these C 106 492
subphases C 107 492
are C 108 492
studied C 109 492
and C 110 492
illustrated C 111 492
by C 112 492
clinical C 113 492
material C 114 492
. C 115 492
a C 117 492
poor C 118 492
relation C 119 492
between C 120 492
mother C 121 492
and C 122 492
child C 123 492
in C 124 492
1 C 125 492
subphase C 126 492
does C 127 492
not C 128 492
necessarily C 129 492
or C 130 492
usually C 131 492
preclude C 132 492
impressive C 133 492
changes C 134 492
for C 135 492
the C 136 492
better C 137 492
in C 138 492
the C 139 492
next C 140 492
subphase C 141 492
. C 142 492
2736 C 1 493
. C 2 493
the C 4 493
emotional C 5 493
needs C 6 493
of C 7 493
children C 8 493
in C 9 493
hospital C 10 493
hospitalization C 11 493
of C 12 493
a C 13 493
child C 14 493
for C 15 493
physical C 16 493
reasons C 17 493
brings C 18 493
with C 19 493
it C 20 493
separation C 21 493
from C 22 493
pa C 23 493
- C 24 493
rents C 25 493
, C 26 493
siblings C 27 493
and C 28 493
familiar C 29 493
surroundings C 30 493
, C 31 493
as C 32 493
well C 33 493
as C 34 493
the C 35 493
probability C 36 493
of C 37 493
subjection C 38 493
to C 39 493
frightening C 40 493
and C 41 493
painful C 42 493
procedures C 43 493
. C 44 493
unless C 46 493
steps C 47 493
are C 48 493
taken C 49 493
to C 50 493
prevent C 51 493
or C 52 493
modify C 53 493
the C 54 493
resultant C 55 493
stress C 56 493
, C 57 493
behavioral C 58 493
disturbances C 59 493
may C 60 493
arise C 61 493
and C 62 493
may C 63 493
result C 64 493
in C 65 493
per C 66 493
- C 67 493
manent C 68 493
damage C 69 493
to C 70 493
the C 71 493
developing C 72 493
personality C 73 493
. C 74 493
2906 C 1 494
. C 2 494
early C 4 494
childhood C 5 494
separations C 6 494
every C 7 494
child C 8 494
in C 9 494
this C 10 494
long C 11 494
- C 12 494
term C 13 494
study C 14 494
of C 15 494
child C 16 494
rearing C 17 494
showed C 18 494
significant C 19 494
reactions C 20 494
to C 21 494
ordinary C 22 494
separations C 23 494
by C 24 494
about C 25 494
1 C 26 494
yr C 27 494
. C 28 494
of C 30 494
age C 31 494
. C 32 494
the C 34 494
similar C 35 494
pattern C 36 494
of C 37 494
response C 38 494
in C 39 494
this C 40 494
group C 41 494
of C 42 494
children C 43 494
suggests C 44 494
a C 45 494
biologically C 46 494
determined C 47 494
cause C 48 494
. C 49 494
the C 51 494
clinging C 52 494
reaction C 53 494
appeared C 54 494
when C 55 494
the C 56 494
child C 57 494
became C 58 494
mobile C 59 494
and C 60 494
able C 61 494
to C 62 494
move C 63 494
away C 64 494
from C 65 494
his C 66 494
mother C 67 494
re C 68 494
- C 69 494
gardless C 70 494
of C 71 494
the C 72 494
frequency C 73 494
or C 74 494
duration C 75 494
of C 76 494
his C 77 494
separations C 78 494
. C 79 494
the C 81 494
majority C 82 494
of C 83 494
the C 84 494
mothers C 85 494
did C 86 494
not C 87 494
understand C 88 494
this C 89 494
natural C 90 494
phenomenon C 91 494
and C 92 494
regarded C 93 494
the C 94 494
clinging C 95 494
and C 96 494
crying C 97 494
of C 98 494
the C 99 494
1 C 100 494
- C 101 494
year C 102 494
- C 103 494
old C 104 494
as C 105 494
evidence C 106 494
of C 107 494
spoiled C 108 494
or C 109 494
regressed C 110 494
behavior C 111 494
. C 112 494
the C 114 494
pediatrician C 115 494
can C 116 494
be C 117 494
helpful C 118 494
to C 119 494
a C 120 494
mother C 121 494
by C 122 494
anticipating C 123 494
and C 124 494
explaining C 125 494
separation C 126 494
responses C 127 494
, C 128 494
by C 129 494
indi C 130 494
- C 131 494
cating C 132 494
their C 133 494
universality C 134 494
, C 135 494
and C 136 494
by C 137 494
giving C 138 494
specific C 139 494
recommendations C 140 494
for C 141 494
gradual C 142 494
changes C 143 494
to C 144 494
modify C 145 494
these C 146 494
reactions C 147 494
. C 148 494
9787 C 1 495
. C 2 495
changes C 4 495
in C 5 495
developmental C 6 495
quotient C 7 495
under C 8 495
two C 9 495
conditions C 10 495
of C 11 495
maternal C 12 495
separation C 13 495
. C 14 495
developmental C 16 495
scales C 17 495
were C 18 495
administered C 19 495
to C 20 495
2 C 21 495
groups C 22 495
of C 23 495
infants C 24 495
during C 25 495
and C 26 495
sub C 27 495
- C 28 495
sequent C 29 495
to C 30 495
a C 31 495
temporary C 32 495
period C 33 495
of C 34 495
institutionalization C 35 495
. C 36 495
although C 38 495
both C 39 495
groups C 40 495
experienced C 41 495
maternal C 42 495
separa C 43 495
- C 44 495
tion C 45 495
, C 46 495
only C 47 495
1 C 48 495
group C 49 495
was C 50 495
subjected C 51 495
to C 52 495
deprivation C 53 495
, C 54 495
in C 55 495
that C 56 495
it C 57 495
received C 58 495
very C 59 495
much C 60 495
less C 61 495
stimulation C 62 495
than C 63 495
the C 64 495
other C 65 495
. C 66 495
results C 68 495
from C 69 495
a C 70 495
longitudinal C 71 495
testing C 72 495
program C 73 495
show C 74 495
that C 75 495
the C 76 495
scores C 77 495
of C 78 495
the C 79 495
deprived C 80 495
group C 81 495
during C 82 495
the C 83 495
period C 84 495
of C 85 495
separation C 86 495
were C 87 495
significantly C 88 495
lower C 89 495
than C 90 495
those C 91 495
of C 92 495
the C 93 495
nondeprived C 94 495
group C 95 495
, C 96 495
no C 97 495
progressive C 98 495
de C 99 495
- C 100 495
terioration C 101 495
of C 102 495
scores C 103 495
took C 104 495
place C 105 495
in C 106 495
the C 107 495
course C 108 495
of C 109 495
institutionalization C 110 495
, C 111 495
immediately C 112 495
following C 113 495
return C 114 495
home C 115 495
, C 116 495
while C 117 495
the C 118 495
scores C 119 495
of C 120 495
the C 121 495
nondeprived C 122 495
group C 123 495
re C 124 495
- C 125 495
mained C 126 495
constant C 127 495
, C 128 495
those C 129 495
of C 130 495
the C 131 495
deprived C 132 495
infants C 133 495
jumped C 134 495
to C 135 495
the C 136 495
level C 137 495
of C 138 495
the C 139 495
other C 140 495
group C 141 495
. C 142 495
3 C 144 495
theories C 145 495
regarding C 146 495
the C 147 495
mechanism C 148 495
underlying C 149 495
the C 150 495
association C 151 495
between C 152 495
deprivation C 153 495
and C 154 495
developmental C 155 495
retardation C 156 495
are C 157 495
exam C 158 495
- C 159 495
ined C 160 495
and C 161 495
it C 162 495
is C 163 495
suggested C 164 495
that C 165 495
an C 166 495
explanation C 167 495
in C 168 495
moti C 169 495
- C 170 495
vational C 171 495
terms C 172 495
best C 173 495
fits C 174 495
the C 175 495
results C 176 495
obtained C 177 495
. C 178 495
1808 C 1 496
. C 2 496
separation C 4 496
anxiety C 5 496
a C 6 496
factor C 7 496
in C 8 496
the C 9 496
object C 10 496
relations C 11 496
of C 12 496
schizophrenic C 13 496
patients C 14 496
. C 15 496
the C 17 496
thesis C 18 496
is C 19 496
advanced C 20 496
that C 21 496
special C 22 496
vulnerability C 23 496
to C 24 496
separation C 25 496
anxiety C 26 496
is C 27 496
a C 28 496
crucial C 29 496
factor C 30 496
in C 31 496
the C 32 496
schizophrenic C 33 496
' C 34 496
s C 35 496
difficulty C 36 496
in C 37 496
establishing C 38 496
and C 39 496
maintaining C 40 496
satisfactory C 41 496
interpersonal C 42 496
relationships C 43 496
. C 44 496
2 C 46 496
major C 47 496
reasons C 48 496
for C 49 496
this C 50 496
are C 51 496
lack C 52 496
of C 53 496
autonomy C 54 496
and C 55 496
lack C 56 496
of C 57 496
object C 58 496
constancy C 59 496
. C 60 496
without C 62 496
a C 63 496
stable C 64 496
autonomous C 65 496
capacity C 66 496
for C 67 496
self C 68 496
- C 69 496
regulation C 70 496
and C 71 496
adaptation C 72 496
, C 73 496
he C 74 496
is C 75 496
inordi C 76 496
- C 77 496
nately C 78 496
dependent C 79 496
upon C 80 496
others C 81 496
for C 82 496
help C 83 496
, C 84 496
protection C 85 496
, C 86 496
and C 87 496
direction C 88 496
. C 89 496
without C 91 496
object C 92 496
constancy C 93 496
, C 94 496
he C 95 496
is C 96 496
unable C 97 496
to C 98 496
maintain C 99 496
a C 100 496
stable C 101 496
representation C 102 496
of C 103 496
the C 104 496
needed C 105 496
person C 106 496
in C 107 496
the C 108 496
latter C 109 496
' C 110 496
s C 111 496
absence C 112 496
. C 113 496
evidence C 115 496
is C 116 496
presented C 117 496
from C 118 496
the C 119 496
intensive C 120 496
psychotherapy C 121 496
of C 122 496
schizophrenic C 123 496
patients C 124 496
. C 125 496
many C 127 496
of C 128 496
the C 129 496
vicissitudes C 130 496
of C 131 496
the C 132 496
doctor C 133 496
- C 134 496
patient C 135 496
relation C 136 496
- C 137 496
ship C 138 496
center C 139 496
about C 140 496
the C 141 496
patient C 142 496
' C 143 496
s C 144 496
separation C 145 496
anxiety C 146 496
and C 147 496
his C 148 496
attempted C 149 496
defenses C 150 496
against C 151 496
it C 152 496
. C 153 496
these C 155 496
include C 156 496
clinging C 157 496
, C 158 496
perceptual C 159 496
and C 160 496
cognitive C 161 496
distortions C 162 496
designed C 163 496
to C 164 496
deny C 165 496
separation C 166 496
, C 167 496
and C 168 496
recourse C 169 496
to C 170 496
substitute C 171 496
objects C 172 496
. C 173 496
promi C 175 496
- C 176 496
nent C 177 496
in C 178 496
many C 179 496
of C 180 496
these C 181 496
efforts C 182 496
is C 183 496
the C 184 496
attempt C 185 496
to C 186 496
reverse C 187 496
passive C 188 496
victimization C 189 496
into C 190 496
active C 191 496
mastery C 192 496
. C 193 496
the C 195 496
practical C 196 496
implications C 197 496
of C 198 496
this C 199 496
thesis C 200 496
for C 201 496
the C 202 496
treatment C 203 496
of C 204 496
schiz C 205 496
- C 206 496
ophrenic C 207 496
patients C 208 496
are C 209 496
discussed C 210 496
. C 211 496
9101 C 1 497
. C 2 497
separation C 4 497
experiences C 5 497
and C 6 497
health C 7 497
records C 8 497
in C 9 497
a C 10 497
group C 11 497
of C 12 497
normal C 13 497
adults C 14 497
. C 15 497
about C 17 497
25 C 18 497
% C 19 497
of C 20 497
455 C 21 497
ostensibly C 22 497
normal C 23 497
ss C 24 497
reported C 25 497
a C 26 497
recent C 27 497
" C 28 497
separation C 29 497
experience C 30 497
" C 31 497
as C 32 497
defined C 33 497
in C 34 497
this C 35 497
study C 36 497
. C 37 497
the C 39 497
frequency C 40 497
of C 41 497
visits C 42 497
to C 43 497
the C 44 497
dis C 45 497
- C 46 497
pensary C 47 497
for C 48 497
symptomatic C 49 497
complaints C 50 497
was C 51 497
not C 52 497
signifi C 53 497
- C 54 497
cantly C 55 497
higher C 56 497
among C 57 497
those C 58 497
who C 59 497
reported C 60 497
separation C 61 497
than C 62 497
among C 63 497
those C 64 497
who C 65 497
did C 66 497
not C 67 497
. C 68 497
the C 70 497
data C 71 497
suggest C 72 497
that C 73 497
an C 74 497
apparent C 75 497
association C 76 497
between C 77 497
relatively C 78 497
high C 79 497
cornell C 80 497
medical C 81 497
index C 82 497
score C 83 497
and C 84 497
history C 85 497
of C 86 497
separation C 87 497
experience C 88 497
may C 89 497
be C 90 497
understandable C 91 497
in C 92 497
terms C 93 497
of C 94 497
a C 95 497
cause C 96 497
- C 97 497
effect C 98 497
relationship C 99 497
between C 100 497
separation C 101 497
experience C 102 497
and C 103 497
illness C 104 497
. C 105 497
11306 C 1 498
. C 2 498
separation C 4 498
and C 5 498
attempted C 6 498
suicide C 7 498
. C 8 498
of C 10 498
3 C 11 498
groups C 12 498
of C 13 498
psychiatric C 14 498
patients C 15 498
- C 16 498
at C 17 498
- C 18 498
tempted C 19 498
suicides C 20 498
, C 21 498
those C 22 498
with C 23 498
suicidal C 24 498
urges C 25 498
, C 26 498
and C 27 498
non C 28 498
- C 29 498
suicides C 30 498
- C 31 498
there C 32 498
were C 33 498
significantly C 34 498
more C 35 498
attempted C 36 498
suicides C 37 498
among C 38 498
patients C 39 498
with C 40 498
a C 41 498
history C 42 498
of C 43 498
childhood C 44 498
and C 45 498
antecedent C 46 498
separation C 47 498
than C 48 498
controls C 49 498
. C 50 498
in C 52 498
childhood C 53 498
the C 54 498
significant C 55 498
difference C 56 498
was C 57 498
found C 58 498
primarily C 59 498
in C 60 498
the C 61 498
period C 62 498
from C 63 498
birth C 64 498
to C 65 498
7 C 66 498
yr C 67 498
. C 68 498
there C 70 498
was C 71 498
no C 72 498
significant C 73 498
interaction C 74 498
between C 75 498
childhood C 76 498
and C 77 498
antecendent C 78 498
separation C 79 498
and C 80 498
suicide C 81 498
attempt C 82 498
or C 83 498
suicide C 84 498
urge C 85 498
. C 86 498
1463 C 1 499
. C 2 499
investigations C 4 499
of C 5 499
lens C 6 499
protein C 7 499
and C 8 499
microelectrophoresis C 9 499
of C 10 499
hydrosoluble C 11 499
protein C 12 499
in C 13 499
senile C 14 499
cataract C 15 499
the C 16 499
investigations C 17 499
on C 18 499
lens C 19 499
protein C 20 499
and C 21 499
on C 22 499
agar C 23 499
- C 24 499
microelectrophoresis C 25 499
of C 26 499
hydro C 27 499
- C 28 499
soluble C 29 499
protein C 30 499
in C 31 499
normal C 32 499
lenses C 33 499
and C 34 499
in C 35 499
those C 36 499
affected C 37 499
with C 38 499
senile C 39 499
cataract C 40 499
re C 41 499
- C 42 499
vealed C 43 499
the C 44 499
following C 45 499
facts C 46 499
( C 47 499
1 C 48 499
) C 49 499
in C 50 499
opaque C 51 499
lenses C 52 499
, C 53 499
a C 54 499
diminution C 55 499
of C 56 499
the C 57 499
total C 58 499
protein C 59 499
and C 60 499
the C 61 499
soluble C 62 499
protein C 63 499
takes C 64 499
place C 65 499
, C 66 499
as C 67 499
well C 68 499
as C 69 499
an C 70 499
increase C 71 499
in C 72 499
the C 73 499
amount C 74 499
of C 75 499
in C 76 499
- C 77 499
soluble C 78 499
protein C 79 499
. C 80 499
the C 82 499
decrease C 83 499
in C 84 499
the C 85 499
quantity C 86 499
of C 87 499
soluble C 88 499
protein C 89 499
is C 90 499
higher C 91 499
than C 92 499
the C 93 499
increase C 94 499
of C 95 499
insoluble C 96 499
protein C 97 499
which C 98 499
does C 99 499
not C 100 499
only C 101 499
point C 102 499
to C 103 499
a C 104 499
transformation C 105 499
of C 106 499
the C 107 499
soluble C 108 499
protein C 109 499
into C 110 499
the C 111 499
insoluble C 112 499
variety C 113 499
, C 114 499
but C 115 499
also C 116 499
to C 117 499
the C 118 499
disappearance C 119 499
of C 120 499
a C 121 499
protein C 122 499
fraction C 123 499
from C 124 499
the C 125 499
lens C 126 499
. C 127 499
changes C 129 499
in C 130 499
the C 131 499
quantity C 132 499
of C 133 499
soluble C 134 499
protein C 135 499
are C 136 499
accompanied C 137 499
by C 138 499
the C 139 499
decrease C 140 499
of C 141 499
protein C 142 499
in C 143 499
slow C 144 499
fractions C 145 499
of C 146 499
the C 147 499
electropherogram C 148 499
and C 149 499
even C 150 499
by C 151 499
the C 152 499
disappearance C 153 499
of C 154 499
these C 155 499
fractions C 156 499
and C 157 499
the C 158 499
increase C 159 499
of C 160 499
the C 161 499
amount C 162 499
of C 163 499
protein C 164 499
in C 165 499
fractions C 166 499
of C 167 499
medium C 168 499
velocity C 169 499
. C 170 499
with C 172 499
the C 173 499
development C 174 499
of C 175 499
cataract C 176 499
and C 177 499
the C 178 499
mature C 179 499
phase C 180 499
of C 181 499
cataract C 182 499
, C 183 499
all C 184 499
these C 185 499
processes C 186 499
become C 187 499
more C 188 499
and C 189 499
more C 190 499
distinct C 191 499
. C 192 499
in C 194 499
this C 195 499
respect C 196 499
, C 197 499
a C 198 499
strong C 199 499
parallelism C 200 499
exists C 201 499
between C 202 499
the C 203 499
protein C 204 499
changes C 205 499
and C 206 499
the C 207 499
clinical C 208 499
picture C 209 499
of C 210 499
senile C 211 499
cataract C 212 499
. C 213 499
( C 215 499
2 C 216 499
) C 217 499
qualitative C 218 499
and C 219 499
quantitative C 220 499
changes C 221 499
which C 222 499
occur C 223 499
in C 224 499
the C 225 499
protein C 226 499
of C 227 499
normal C 228 499
lenses C 229 499
with C 230 499
advancing C 231 499
age C 232 499
show C 233 499
a C 234 499
character C 235 499
similar C 236 499
to C 237 499
those C 238 499
in C 239 499
senile C 240 499
cataract C 241 499
, C 242 499
however C 243 499
, C 244 499
they C 245 499
are C 246 499
less C 247 499
pronounced C 248 499
. C 249 499
in C 251 499
this C 252 499
instance C 253 499
, C 254 499
the C 255 499
de C 256 499
- C 257 499
crease C 258 499
in C 259 499
the C 260 499
quantity C 261 499
of C 262 499
soluble C 263 499
protein C 264 499
is C 265 499
likewise C 266 499
closely C 267 499
associated C 268 499
with C 269 499
the C 270 499
diminution C 271 499
of C 272 499
the C 273 499
protein C 274 499
content C 275 499
in C 276 499
the C 277 499
slow C 278 499
fractions C 279 499
of C 280 499
the C 281 499
electropherogram C 282 499
. C 283 499
( C 285 499
3 C 286 499
) C 287 499
the C 288 499
changes C 289 499
in C 290 499
the C 291 499
soluble C 292 499
protein C 293 499
content C 294 499
of C 295 499
the C 296 499
lens C 297 499
and C 298 499
the C 299 499
alterations C 300 499
of C 301 499
the C 302 499
protein C 303 499
amounts C 304 499
in C 305 499
the C 306 499
slow C 307 499
fractions C 308 499
which C 309 499
always C 310 499
accompany C 311 499
the C 312 499
former C 313 499
, C 314 499
play C 315 499
the C 316 499
principal C 317 499
role C 318 499
in C 319 499
the C 320 499
aging C 321 499
process C 322 499
of C 323 499
the C 324 499
lens C 325 499
and C 326 499
in C 327 499
the C 328 499
development C 329 499
of C 330 499
senile C 331 499
cataract C 332 499
. C 333 499
( C 335 499
4 C 336 499
) C 337 499
the C 338 499
investigations C 339 499
seem C 340 499
to C 341 499
indicate C 342 499
that C 343 499
the C 344 499
aging C 345 499
processes C 346 499
, C 347 499
of C 348 499
lenses C 349 499
as C 350 499
well C 351 499
as C 352 499
the C 353 499
development C 354 499
of C 355 499
senile C 356 499
cataract C 357 499
are C 358 499
of C 359 499
a C 360 499
similar C 361 499
character C 362 499
, C 363 499
but C 364 499
of C 365 499
different C 366 499
intensity C 367 499
. C 368 499
( C 370 499
5 C 371 499
) C 372 499
undoubtedly C 373 499
, C 374 499
the C 375 499
processes C 376 499
of C 377 499
transition C 378 499
from C 379 499
slow C 380 499
fractions C 381 499
of C 382 499
soluble C 383 499
protein C 384 499
into C 385 499
faster C 386 499
ones C 387 499
and C 388 499
the C 389 499
transformation C 390 499
of C 391 499
part C 392 499
of C 393 499
the C 394 499
soluble C 395 499
protein C 396 499
into C 397 499
insoluble C 398 499
protein C 399 499
which C 400 499
is C 401 499
likely C 402 499
to C 403 499
be C 404 499
associated C 405 499
with C 406 499
these C 407 499
processes C 408 499
as C 409 499
well C 410 499
as C 411 499
the C 412 499
partial C 413 499
disappearance C 414 499
of C 415 499
total C 416 499
protein C 417 499
from C 418 499
the C 419 499
lens C 420 499
seem C 421 499
to C 422 499
play C 423 499
a C 424 499
very C 425 499
important C 426 499
part C 427 499
in C 428 499
the C 429 499
mechanisms C 430 499
pertaining C 431 499
to C 432 499
the C 433 499
development C 434 499
of C 435 499
cataract C 436 499
. C 437 499
1949 C 1 500
. C 2 500
studies C 4 500
on C 5 500
the C 6 500
soluble C 7 500
proteins C 8 500
of C 9 500
bovine C 10 500
lens C 11 500
. C 12 500
immuno C 14 500
- C 15 500
chemical C 16 500
analyses C 17 500
of C 18 500
protein C 19 500
fractions C 20 500
the C 21 500
lyophilized C 22 500
soluble C 23 500
lens C 24 500
proteins C 25 500
were C 26 500
dissolved C 27 500
in C 28 500
0 C 29 500
. C 30 500
. C 31 500
. C 31 500
. C 31 500
m C 32 500
phosphate C 33 500
buffer C 34 500
at C 35 500
ph C 36 500
6 C 37 500
. C 38 500
. C 39 500
and C 40 500
the C 41 500
solution C 42 500
was C 43 500
subjected C 44 500
to C 45 500
column C 46 500
chromatography C 47 500
on C 48 500
deae C 49 500
( C 50 500
die C 51 500
- C 52 500
thylamino C 53 500
ethyl C 54 500
) C 55 500
cellulose C 56 500
. C 57 500
elution C 59 500
was C 60 500
accomplished C 61 500
by C 62 500
changing C 63 500
the C 64 500
ph C 65 500
and C 66 500
ionic C 67 500
strength C 68 500
of C 69 500
the C 70 500
eluting C 71 500
buffer C 72 500
. C 73 500
the C 75 500
components C 76 500
were C 77 500
fractionated C 78 500
by C 79 500
stepwise C 80 500
elu C 81 500
- C 82 500
tion C 83 500
. C 84 500
the C 86 500
lens C 87 500
proteins C 88 500
were C 89 500
separated C 90 500
into C 91 500
17 C 92 500
fractions C 93 500
by C 94 500
column C 95 500
chromatogra C 96 500
- C 97 500
phy C 98 500
. C 99 500
these C 101 500
fractions C 102 500
were C 103 500
compared C 104 500
with C 105 500
a C 106 500
, C 107 500
b C 108 500
and C 109 500
y C 110 500
crystallines C 111 500
for C 112 500
electrophore C 113 500
- C 114 500
tic C 115 500
mobility C 116 500
, C 117 500
and C 118 500
the C 119 500
antigenic C 120 500
purity C 121 500
of C 122 500
each C 123 500
fraction C 124 500
was C 125 500
examined C 126 500
immunochemi C 127 500
- C 128 500
cally C 129 500
. C 130 500
the C 132 500
results C 133 500
showed C 134 500
that C 135 500
while C 136 500
the C 137 500
fractions C 138 500
were C 139 500
not C 140 500
completely C 141 500
pure C 142 500
they C 143 500
were C 144 500
purer C 145 500
than C 146 500
the C 147 500
a C 148 500
, C 149 500
b C 150 500
and C 151 500
y C 152 500
crystalline C 153 500
fractions C 154 500
, C 155 500
and C 156 500
that C 157 500
f C 158 500
- C 159 500
1 C 160 500
- C 161 500
a C 162 500
, C 163 500
b C 164 500
, C 165 500
c C 166 500
and C 167 500
d C 168 500
corresponded C 169 500
to C 170 500
y C 171 500
crystalline C 172 500
, C 173 500
while C 174 500
f C 175 500
- C 176 500
2 C 177 500
- C 178 500
a C 179 500
, C 180 500
b C 181 500
, C 182 500
c C 183 500
, C 184 500
d C 185 500
, C 186 500
e C 187 500
and C 188 500
f C 189 500
corresponded C 190 500
to C 191 500
b C 192 500
crystalline C 193 500
and C 194 500
f C 195 500
- C 196 500
3 C 197 500
, C 198 500
4 C 199 500
, C 200 500
5 C 201 500
, C 202 500
6 C 203 500
, C 204 500
7 C 205 500
, C 206 500
8 C 207 500
and C 208 500
9 C 209 500
to C 210 500
a C 211 500
crystalline C 212 500
. C 213 500
3107 C 1 501
. C 2 501
studies C 4 501
on C 5 501
y C 6 501
- C 7 501
crystallin C 8 501
from C 9 501
calf C 10 501
lens C 11 501
. C 12 501
ii C 14 501
. C 15 501
purification C 17 501
and C 18 501
some C 19 501
properties C 20 501
of C 21 501
the C 22 501
main C 23 501
protein C 24 501
components C 25 501
four C 26 501
proteins C 27 501
belonging C 28 501
to C 29 501
the C 30 501
y C 31 501
- C 32 501
crystallin C 33 501
group C 34 501
were C 35 501
purified C 36 501
by C 37 501
chromatography C 38 501
on C 39 501
sulphoethyl C 40 501
- C 41 501
sephadex C 42 501
and C 43 501
phosphate C 44 501
- C 45 501
cellulose C 46 501
columns C 47 501
. C 48 501
the C 50 501
proteins C 51 501
were C 52 501
homo C 53 501
- C 54 501
geneous C 55 501
in C 56 501
gel C 57 501
and C 58 501
immunoelectrophoresis C 59 501
experiments C 60 501
and C 61 501
could C 62 501
be C 63 501
crystallized C 64 501
. C 65 501
their C 67 501
molecular C 68 501
weights C 69 501
, C 70 501
n C 71 501
- C 72 501
terminal C 73 501
amino C 74 501
acid C 75 501
sequences C 76 501
and C 77 501
antigenic C 78 501
structures C 79 501
were C 80 501
all C 81 501
similar C 82 501
, C 83 501
but C 84 501
their C 85 501
amino C 86 501
acid C 87 501
compositions C 88 501
and C 89 501
the C 90 501
sulphydryl C 91 501
groups C 92 501
con C 93 501
- C 94 501
tained C 95 501
showed C 96 501
certain C 97 501
dissimilarities C 98 501
. C 99 501
it C 101 501
is C 102 501
probable C 103 501
that C 104 501
the C 105 501
4 C 106 501
proteins C 107 501
possess C 108 501
small C 109 501
differences C 110 501
in C 111 501
their C 112 501
primary C 113 501
structure C 114 501
, C 115 501
which C 116 501
are C 117 501
not C 118 501
associated C 119 501
with C 120 501
the C 121 501
antigenic C 122 501
sites C 123 501
and C 124 501
which C 125 501
may C 126 501
have C 127 501
arisen C 128 501
from C 129 501
mutations C 130 501
during C 131 501
evolution C 132 501
. C 133 501
3105 C 1 502
. C 2 502
studies C 4 502
on C 5 502
the C 6 502
subunits C 7 502
of C 8 502
a C 9 502
- C 10 502
crystallin C 11 502
and C 12 502
their C 13 502
recombi C 14 502
- C 15 502
nation C 16 502
earlier C 17 502
investigations C 18 502
have C 19 502
shown C 20 502
that C 21 502
, C 22 502
in C 23 502
the C 24 502
presence C 25 502
of C 26 502
high C 27 502
concentrations C 28 502
of C 29 502
urea C 30 502
, C 31 502
a C 32 502
- C 33 502
crystallin C 34 502
from C 35 502
bovine C 36 502
lens C 37 502
is C 38 502
split C 39 502
into C 40 502
a C 41 502
number C 42 502
of C 43 502
subunits C 44 502
with C 45 502
apparent C 46 502
- C 47 502
ly C 48 502
different C 49 502
electrophoretic C 50 502
mobilities C 51 502
but C 52 502
similar C 53 502
molecular C 54 502
weights C 55 502
. C 56 502
the C 58 502
recom C 59 502
- C 60 502
bination C 61 502
of C 62 502
these C 63 502
subunits C 64 502
after C 65 502
removal C 66 502
of C 67 502
the C 68 502
urea C 69 502
has C 70 502
been C 71 502
studied C 72 502
by C 73 502
ultracentri C 74 502
- C 75 502
fugation C 76 502
and C 77 502
immunoprecipitation C 78 502
techniques C 79 502
. C 80 502
it C 82 502
was C 83 502
found C 84 502
that C 85 502
maximal C 86 502
recombina C 87 502
- C 88 502
tion C 89 502
was C 90 502
obtained C 91 502
when C 92 502
the C 93 502
ionic C 94 502
strength C 95 502
during C 96 502
the C 97 502
removal C 98 502
of C 99 502
the C 100 502
urea C 101 502
was C 102 502
high C 103 502
( C 104 502
> C 105 502
0 C 106 502
. C 107 502
. C 108 502
) C 109 502
, C 110 502
whereas C 111 502
at C 112 502
low C 113 502
ionic C 114 502
strengths C 115 502
a C 116 502
molecule C 117 502
with C 118 502
only C 119 502
half C 120 502
the C 121 502
molecular C 122 502
weight C 123 502
of C 124 502
native C 125 502
a C 126 502
- C 127 502
crystallin C 128 502
and C 129 502
a C 130 502
much C 131 502
lower C 132 502
sedimentation C 133 502
coefficient C 134 502
was C 135 502
obtained C 136 502
. C 137 502
a C 139 502
complete C 140 502
recovery C 141 502
of C 142 502
the C 143 502
structure C 144 502
of C 145 502
native C 146 502
a C 147 502
- C 148 502
crystallin C 149 502
was C 150 502
never C 151 502
obtained C 152 502
, C 153 502
even C 154 502
at C 155 502
high C 156 502
ionic C 157 502
strengths C 158 502
, C 159 502
as C 160 502
was C 161 502
evident C 162 502
from C 163 502
electrophoretic C 164 502
and C 165 502
quantitative C 166 502
preci C 167 502
- C 168 502
pitin C 169 502
analyses C 170 502
. C 171 502
the C 173 502
subunits C 174 502
were C 175 502
fractionated C 176 502
by C 177 502
chromatography C 178 502
on C 179 502
deae C 180 502
- C 181 502
cellu C 182 502
- C 183 502
lose C 184 502
in C 185 502
the C 186 502
presence C 187 502
of C 188 502
7 C 189 502
m C 190 502
urea C 191 502
. C 192 502
the C 194 502
purification C 195 502
was C 196 502
followed C 197 502
by C 198 502
polyacrylamide C 199 502
- C 200 502
gel C 201 502
electrophoresis C 202 502
. C 203 502
after C 205 502
removal C 206 502
of C 207 502
the C 208 502
urea C 209 502
at C 210 502
high C 211 502
ionic C 212 502
strength C 213 502
, C 214 502
2 C 215 502
of C 216 502
the C 217 502
fractions C 218 502
obtained C 219 502
showed C 220 502
reactions C 221 502
of C 222 502
only C 223 502
partial C 224 502
identity C 225 502
with C 226 502
native C 227 502
a C 228 502
- C 229 502
crystallin C 230 502
in C 231 502
immunodiffusion C 232 502
tests C 233 502
, C 234 502
but C 235 502
all C 236 502
other C 237 502
fractions C 238 502
showed C 239 502
complete C 240 502
identity C 241 502
. C 242 502
the C 244 502
differences C 245 502
in C 246 502
the C 247 502
electrophoretic C 248 502
mobilities C 249 502
of C 250 502
the C 251 502
fractions C 252 502
in C 253 502
the C 254 502
presence C 255 502
of C 256 502
urea C 257 502
persisted C 258 502
after C 259 502
removal C 260 502
of C 261 502
the C 262 502
urea C 263 502
. C 264 502
all C 266 502
fractions C 267 502
had C 268 502
much C 269 502
higher C 270 502
sedimen C 271 502
- C 272 502
tation C 273 502
coefficients C 274 502
in C 275 502
the C 276 502
absence C 277 502
of C 278 502
urea C 279 502
than C 280 502
in C 281 502
its C 282 502
presence C 283 502
, C 284 502
although C 285 502
the C 286 502
values C 287 502
for C 288 502
urea C 289 502
- C 290 502
treated C 291 502
unfractionated C 292 502
a C 293 502
- C 294 502
crystallin C 295 502
obtained C 296 502
after C 297 502
removal C 298 502
of C 299 502
the C 300 502
urea C 301 502
were C 302 502
not C 303 502
reached C 304 502
even C 305 502
at C 306 502
high C 307 502
ionic C 308 502
strengths C 309 502
. C 310 502
the C 312 502
amino C 313 502
acid C 314 502
composition C 315 502
of C 316 502
the C 317 502
fractions C 318 502
was C 319 502
found C 320 502
to C 321 502
differ C 322 502
. C 323 502
these C 325 502
observations C 326 502
suggest C 327 502
that C 328 502
a C 329 502
- C 330 502
crystallin C 331 502
is C 332 502
com C 333 502
- C 334 502
posed C 335 502
of C 336 502
a C 337 502
number C 338 502
of C 339 502
chemically C 340 502
different C 341 502
, C 342 502
but C 343 502
related C 344 502
, C 345 502
subunits C 346 502
of C 347 502
approximately C 348 502
the C 349 502
same C 350 502
size C 351 502
, C 352 502
which C 353 502
are C 354 502
bound C 355 502
together C 356 502
by C 357 502
nonspecific C 358 502
, C 359 502
noncovalent C 360 502
bonds C 361 502
, C 362 502
pos C 363 502
- C 364 502
sibly C 365 502
hydrophobic C 366 502
bonds C 367 502
. C 368 502
moreover C 370 502
, C 371 502
when C 372 502
isolated C 373 502
, C 374 502
these C 375 502
subunits C 376 502
have C 377 502
the C 378 502
ability C 379 502
to C 380 502
associate C 381 502
and C 382 502
form C 383 502
molecules C 384 502
of C 385 502
high C 386 502
molecular C 387 502
weight C 388 502
. C 389 502
3106 C 1 503
. C 2 503
fractionation C 4 503
of C 5 503
b C 6 503
- C 7 503
crystallin C 8 503
from C 9 503
calf C 10 503
lens C 11 503
by C 12 503
gel C 13 503
fil C 14 503
- C 15 503
tration C 16 503
b C 17 503
- C 18 503
crystallin C 19 503
was C 20 503
isolated C 21 503
from C 22 503
calf C 23 503
lenses C 24 503
by C 25 503
a C 26 503
combination C 27 503
of C 28 503
gel C 29 503
filtration C 30 503
on C 31 503
sephadex C 32 503
g C 33 503
- C 34 503
75 C 35 503
and C 36 503
vertical C 37 503
- C 38 503
column C 39 503
zone C 40 503
electrophoresis C 41 503
. C 42 503
it C 44 503
was C 45 503
subdivided C 46 503
into C 47 503
4 C 48 503
fractions C 49 503
by C 50 503
subsequent C 51 503
gel C 52 503
filtration C 53 503
on C 54 503
dextran C 55 503
gels C 56 503
with C 57 503
low C 58 503
cross C 59 503
- C 60 503
linkage C 61 503
. C 62 503
each C 64 503
fraction C 65 503
showed C 66 503
only C 67 503
1 C 68 503
major C 69 503
peak C 70 503
in C 71 503
the C 72 503
ultracentrifuge C 73 503
, C 74 503
the C 75 503
sedimentation C 76 503
coefficients C 77 503
of C 78 503
which C 79 503
were C 80 503
13 C 81 503
. C 82 503
. C 83 503
, C 84 503
9 C 85 503
. C 86 503
. C 87 503
, C 88 503
4 C 89 503
. C 90 503
. C 91 503
and C 92 503
4 C 93 503
. C 94 503
. C 95 503
s C 96 503
for C 97 503
fractions C 98 503
i C 99 503
- C 100 503
iv C 101 503
, C 102 503
respectively C 103 503
. C 104 503
however C 106 503
, C 107 503
all C 108 503
4 C 109 503
fractions C 110 503
contained C 111 503
some C 112 503
additional C 113 503
minor C 114 503
components C 115 503
, C 116 503
as C 117 503
revealed C 118 503
by C 119 503
sedimentation C 120 503
and C 121 503
immunoelectrophoretic C 122 503
analyses C 123 503
. C 124 503
the C 126 503
fractionation C 127 503
procedure C 128 503
may C 129 503
be C 130 503
of C 131 503
value C 132 503
as C 133 503
a C 134 503
first C 135 503
step C 136 503
in C 137 503
the C 138 503
isolation C 139 503
of C 140 503
individual C 141 503
proteins C 142 503
of C 143 503
the C 144 503
b C 145 503
- C 146 503
crystal C 147 503
- C 148 503
lin C 149 503
group C 150 503
. C 151 503
195 C 1 504
. C 2 504
properties C 4 504
of C 5 504
a C 6 504
cold C 7 504
- C 8 504
precipitable C 9 504
protein C 10 504
fraction C 11 504
in C 12 504
the C 13 504
lens C 14 504
a C 15 504
soluble C 16 504
protein C 17 504
fraction C 18 504
which C 19 504
precipitates C 20 504
in C 21 504
aqueous C 22 504
solutions C 23 504
at C 24 504
temperatures C 25 504
below C 26 504
10 C 27 504
c C 28 504
has C 29 504
been C 30 504
isolated C 31 504
from C 32 504
the C 33 504
rat C 34 504
lens C 35 504
. C 36 504
this C 38 504
fraction C 39 504
appears C 40 504
to C 41 504
be C 42 504
re C 43 504
- C 44 504
sponsible C 45 504
for C 46 504
the C 47 504
reversible C 48 504
' C 49 504
cold C 50 504
cataract C 51 504
' C 52 504
which C 53 504
has C 54 504
been C 55 504
seen C 56 504
to C 57 504
develop C 58 504
when C 59 504
young C 60 504
mammals C 61 504
are C 62 504
exposed C 63 504
to C 64 504
temperatures C 65 504
below C 66 504
10 C 67 504
c C 68 504
. C 69 504
as C 71 504
the C 72 504
rat C 73 504
ages C 74 504
, C 75 504
the C 76 504
concentration C 77 504
of C 78 504
this C 79 504
protein C 80 504
fraction C 81 504
decreases C 82 504
, C 83 504
but C 84 504
the C 85 504
fraction C 86 504
does C 87 504
not C 88 504
com C 89 504
- C 90 504
pletely C 91 504
disappear C 92 504
, C 93 504
even C 94 504
from C 95 504
the C 96 504
lenses C 97 504
of C 98 504
3 C 99 504
- C 100 504
year C 101 504
- C 102 504
old C 103 504
rats C 104 504
. C 105 504
although C 107 504
the C 108 504
molecular C 109 504
species C 110 504
comprising C 111 504
this C 112 504
fraction C 113 504
appear C 114 504
to C 115 504
be C 116 504
homogeneous C 117 504
in C 118 504
the C 119 504
ultracentrifuge C 120 504
, C 121 504
disc C 122 504
electrophoresis C 123 504
and C 124 504
immunodiffusion C 125 504
have C 126 504
shown C 127 504
that C 128 504
they C 129 504
are C 130 504
a C 131 504
heterogeneous C 132 504
mixture C 133 504
of C 134 504
a C 135 504
- C 136 504
, C 137 504
b C 138 504
- C 139 504
and C 140 504
y C 141 504
- C 142 504
crystallin C 143 504
subunits C 144 504
. C 145 504
the C 147 504
ability C 148 504
of C 149 504
the C 150 504
cold C 151 504
- C 152 504
precipitable C 153 504
protein C 154 504
( C 155 504
ccp C 156 504
) C 157 504
fraction C 158 504
to C 159 504
precipitate C 160 504
in C 161 504
the C 162 504
cold C 163 504
depends C 164 504
upon C 165 504
its C 166 504
concentration C 167 504
and C 168 504
the C 169 504
ionic C 170 504
strength C 171 504
and C 172 504
ph C 173 504
of C 174 504
the C 175 504
solvent C 176 504
. C 177 504
in C 179 504
solutions C 180 504
of C 181 504
ph C 182 504
4 C 183 504
. C 184 504
. C 185 504
, C 186 504
some C 187 504
aggregation C 188 504
of C 189 504
the C 190 504
4 C 191 504
s C 192 504
cpp C 193 504
occurs C 194 504
to C 195 504
form C 196 504
a C 197 504
17 C 198 504
s C 199 504
component C 200 504
, C 201 504
which C 202 504
no C 203 504
longer C 204 504
precipitates C 205 504
in C 206 504
the C 207 504
cold C 208 504
. C 209 504
the C 211 504
ability C 212 504
of C 213 504
this C 214 504
protein C 215 504
fraction C 216 504
to C 217 504
precipitate C 218 504
in C 219 504
the C 220 504
cold C 221 504
may C 222 504
depend C 223 504
on C 224 504
hydrophobic C 225 504
bonding C 226 504
and C 227 504
its C 228 504
influence C 229 504
on C 230 504
the C 231 504
conformation C 232 504
of C 233 504
the C 234 504
protein C 235 504
. C 236 504
773 C 1 505
. C 2 505
the C 4 505
effect C 5 505
of C 6 505
radiation C 7 505
on C 8 505
lenticular C 9 505
epithelial C 10 505
enzymes C 11 505
in C 12 505
young C 13 505
rabbits C 14 505
the C 15 505
mitochondrial C 16 505
fraction C 17 505
and C 18 505
the C 19 505
soluble C 20 505
fraction C 21 505
of C 22 505
the C 23 505
epithelial C 24 505
cells C 25 505
of C 26 505
the C 27 505
lens C 28 505
from C 29 505
6 C 30 505
- C 31 505
week C 32 505
- C 33 505
old C 34 505
new C 35 505
zealand C 36 505
white C 37 505
male C 38 505
rabbits C 39 505
, C 40 505
exposed C 41 505
to C 42 505
800 C 43 505
r C 44 505
of C 45 505
whole C 46 505
- C 47 505
head C 48 505
x C 49 505
- C 50 505
irradiation C 51 505
, C 52 505
were C 53 505
evaluated C 54 505
for C 55 505
glucose C 56 505
6 C 57 505
- C 58 505
phosphate C 59 505
dehydrogenase C 60 505
, C 61 505
isocitrate C 62 505
dehydrogenase C 63 505
, C 64 505
malate C 65 505
dehydrogenase C 66 505
, C 67 505
glutathione C 68 505
reductase C 69 505
, C 70 505
glyceraldehydephos C 71 505
- C 72 505
phate C 73 505
dehydrogenase C 74 505
, C 75 505
purine C 76 505
nucleoside C 77 505
phosphorylase C 78 505
, C 79 505
nadph C 80 505
2 C 81 505
diaphorase C 82 505
, C 83 505
and C 84 505
nadh C 85 505
2 C 86 505
cytochrome C 87 505
c C 88 505
reductase C 89 505
activities C 90 505
. C 91 505
increased C 93 505
enzyme C 94 505
activities C 95 505
were C 96 505
noted C 97 505
in C 98 505
the C 99 505
irradiated C 100 505
lenticular C 101 505
tissues C 102 505
for C 103 505
purine C 104 505
nucleoside C 105 505
phosphorylase C 106 505
, C 107 505
nadph C 108 505
2 C 109 505
diaphorase C 110 505
and C 111 505
nadh C 112 505
2 C 113 505
cytochrome C 114 505
c C 115 505
reductase C 116 505
. C 117 505
decreased C 119 505
activities C 120 505
for C 121 505
glucose C 122 505
6 C 123 505
- C 124 505
phosphate C 125 505
dehydrogenase C 126 505
, C 127 505
malate C 128 505
dehydrogenase C 129 505
, C 130 505
glutathione C 131 505
reductase C 132 505
and C 133 505
gly C 134 505
- C 135 505
ceraldehydephosphate C 136 505
dehydrogenase C 137 505
were C 138 505
observed C 139 505
in C 140 505
the C 141 505
lenticular C 142 505
tissues C 143 505
of C 144 505
ir C 145 505
- C 146 505
radiated C 147 505
animals C 148 505
. C 149 505
the C 151 505
activity C 152 505
of C 153 505
isocitrate C 154 505
dehydrogenase C 155 505
was C 156 505
the C 157 505
same C 158 505
in C 159 505
the C 160 505
ir C 161 505
- C 162 505
radiated C 163 505
and C 164 505
in C 165 505
the C 166 505
control C 167 505
animals C 168 505
. C 169 505
465 C 1 506
. C 2 506
conversion C 4 506
of C 5 506
a C 6 506
- C 7 506
crystallin C 8 506
of C 9 506
bovine C 10 506
lens C 11 506
into C 12 506
insoluble C 13 506
protein C 14 506
in C 15 506
vitro C 16 506
a C 17 506
- C 18 506
crystallin C 19 506
can C 20 506
be C 21 506
converted C 22 506
into C 23 506
an C 24 506
insoluble C 25 506
form C 26 506
by C 27 506
treatment C 28 506
with C 29 506
alloxan C 30 506
and C 31 506
to C 32 506
a C 33 506
very C 34 506
small C 35 506
extent C 36 506
with C 37 506
iodoacetate C 38 506
. C 39 506
other C 41 506
reagents C 42 506
such C 43 506
as C 44 506
hcl C 45 506
, C 46 506
naoh C 47 506
, C 48 506
reduced C 49 506
glutathione C 50 506
, C 51 506
hydrogen C 52 506
peroxide C 53 506
, C 54 506
mercaptoethanol C 55 506
, C 56 506
were C 57 506
not C 58 506
able C 59 506
to C 60 506
convert C 61 506
a C 62 506
- C 63 506
crys C 64 506
- C 65 506
tallin C 66 506
into C 67 506
an C 68 506
insoluble C 69 506
form C 70 506
. C 71 506
the C 73 506
alloxan C 74 506
treated C 75 506
insoluble C 76 506
a C 77 506
- C 78 506
crystallin C 79 506
could C 80 506
be C 81 506
made C 82 506
soluble C 83 506
by C 84 506
treatment C 85 506
with C 86 506
7 C 87 506
m C 88 506
urea C 89 506
. C 90 506
the C 92 506
product C 93 506
thus C 94 506
made C 95 506
soluble C 96 506
had C 97 506
the C 98 506
same C 99 506
electrophoretic C 100 506
mobility C 101 506
as C 102 506
a C 103 506
- C 104 506
crystallin C 105 506
, C 106 506
but C 107 506
showed C 108 506
cross C 109 506
reaction C 110 506
with C 111 506
a C 112 506
- C 113 506
crystallin C 114 506
in C 115 506
ouchterlony C 116 506
plate C 117 506
and C 118 506
did C 119 506
not C 120 506
have C 121 506
proteolytic C 122 506
activity C 123 506
. C 124 506
alloxan C 126 506
was C 127 506
effective C 128 506
in C 129 506
producing C 130 506
cataract C 131 506
of C 132 506
rabbit C 133 506
lens C 134 506
when C 135 506
very C 136 506
small C 137 506
amounts C 138 506
were C 139 506
injected C 140 506
into C 141 506
the C 142 506
aqueous C 143 506
. C 144 506
1972 C 1 507
. C 2 507
structural C 4 507
studies C 5 507
of C 6 507
a C 7 507
- C 8 507
crystallin C 9 507
a C 10 507
- C 11 507
crystallin C 12 507
has C 13 507
been C 14 507
isolated C 15 507
from C 16 507
the C 17 507
cortex C 18 507
of C 19 507
ox C 20 507
lens C 21 507
by C 22 507
isoelectric C 23 507
precipitation C 24 507
followed C 25 507
by C 26 507
chromatography C 27 507
on C 28 507
deae C 29 507
- C 30 507
cellulose C 31 507
. C 32 507
the C 34 507
amino C 35 507
acid C 36 507
composition C 37 507
is C 38 507
in C 39 507
agreement C 40 507
with C 41 507
that C 42 507
reported C 43 507
for C 44 507
a C 45 507
- C 46 507
crystallin C 47 507
prepared C 48 507
by C 49 507
a C 50 507
different C 51 507
method C 52 507
. C 53 507
there C 55 507
is C 56 507
one C 57 507
thiol C 58 507
group C 59 507
/ C 60 507
20 C 61 507
, C 62 507
000 C 63 507
g C 64 507
. C 65 507
of C 67 507
protein C 68 507
( C 69 507
20 C 70 507
, C 71 507
000 C 72 507
is C 73 507
the C 74 507
order C 75 507
of C 76 507
magnitude C 77 507
of C 78 507
the C 79 507
sub C 80 507
- C 81 507
unit C 82 507
molecular C 83 507
weight C 84 507
) C 85 507
, C 86 507
and C 87 507
disulphide C 88 507
bonds C 89 507
are C 90 507
absent C 91 507
. C 92 507
the C 94 507
thiol C 95 507
group C 96 507
has C 97 507
been C 98 507
alkylated C 99 507
with C 100 507
radioactive C 101 507
iodoacetate C 102 507
in C 103 507
the C 104 507
presence C 105 507
of C 106 507
urea C 107 507
. C 108 507
partial C 110 507
acid C 111 507
hydroly C 112 507
- C 113 507
sis C 114 507
of C 115 507
the C 116 507
alkylated C 117 507
protein C 118 507
gives C 119 507
, C 120 507
according C 121 507
to C 122 507
the C 123 507
conditions C 124 507
, C 125 507
mainly C 126 507
3 C 127 507
radioactive C 128 507
peptides C 129 507
or C 130 507
nearly C 131 507
exclusively C 132 507
one C 133 507
radioactive C 134 507
dipeptide C 135 507
. C 136 507
the C 138 507
dipeptide C 139 507
is C 140 507
n C 141 507
- C 142 507
seryl C 143 507
- C 144 507
( C 145 507
s C 146 507
- C 147 507
carboxymethyl C 148 507
) C 149 507
cysteine C 150 507
, C 151 507
ser C 152 507
- C 153 507
cmcys C 154 507
. C 155 507
the C 157 507
2 C 158 507
other C 159 507
peptides C 160 507
are C 161 507
probably C 162 507
the C 163 507
tri C 164 507
- C 165 507
peptides C 166 507
related C 167 507
to C 168 507
ser C 169 507
- C 170 507
cmcys C 171 507
. C 172 507
the C 174 507
simplest C 175 507
interpretation C 176 507
of C 177 507
these C 178 507
results C 179 507
is C 180 507
that C 181 507
the C 182 507
sequence C 183 507
around C 184 507
the C 185 507
cysteine C 186 507
residue C 187 507
is C 188 507
a C 189 507
common C 190 507
structural C 191 507
feature C 192 507
of C 193 507
the C 194 507
sub C 195 507
- C 196 507
units C 197 507
of C 198 507
a C 199 507
- C 200 507
crystallin C 201 507
. C 202 507
1751 C 1 508
. C 2 508
on C 4 508
the C 5 508
subunits C 6 508
of C 7 508
a C 8 508
- C 9 508
crystallin C 10 508
a C 11 508
- C 12 508
crystallin C 13 508
was C 14 508
isolated C 15 508
from C 16 508
total C 17 508
water C 18 508
- C 19 508
soluble C 20 508
lens C 21 508
extract C 22 508
by C 23 508
preparative C 24 508
zone C 25 508
electrophoresis C 26 508
on C 27 508
starch C 28 508
or C 29 508
pevikon C 30 508
c C 31 508
870 C 32 508
blocks C 33 508
and C 34 508
purified C 35 508
by C 36 508
density C 37 508
gradient C 38 508
centrifugation C 39 508
and C 40 508
sephadex C 41 508
chromatography C 42 508
. C 43 508
these C 45 508
preparations C 46 508
were C 47 508
treated C 48 508
with C 49 508
urea C 50 508
or C 51 508
sodium C 52 508
dodecyl C 53 508
sulphate C 54 508
and C 55 508
submitted C 56 508
to C 57 508
electrophoresis C 58 508
on C 59 508
polyacrylamide C 60 508
gels C 61 508
containing C 62 508
either C 63 508
urea C 64 508
or C 65 508
sodium C 66 508
dodecyl C 67 508
sulphate C 68 508
. C 69 508
whereas C 71 508
in C 72 508
7 C 73 508
m C 74 508
urea C 75 508
a C 76 508
large C 77 508
number C 78 508
of C 79 508
zones C 80 508
was C 81 508
detected C 82 508
, C 83 508
only C 84 508
three C 85 508
bands C 86 508
were C 87 508
observed C 88 508
in C 89 508
1 C 90 508
% C 91 508
sodium C 92 508
dodecyl C 93 508
sulphate C 94 508
. C 95 508
on C 97 508
the C 98 508
other C 99 508
hand C 100 508
, C 101 508
the C 102 508
sedimentation C 103 508
coefficient C 104 508
had C 105 508
the C 106 508
same C 107 508
value C 108 508
in C 109 508
both C 110 508
media C 111 508
. C 112 508
the C 114 508
authors C 115 508
re C 116 508
- C 117 508
investigated C 118 508
the C 119 508
n C 120 508
- C 121 508
terminal C 122 508
amino C 123 508
acid C 124 508
content C 125 508
in C 126 508
the C 127 508
starch C 128 508
block C 129 508
preparations C 130 508
and C 131 508
compared C 132 508
the C 133 508
result C 134 508
with C 135 508
that C 136 508
obtained C 137 508
from C 138 508
the C 139 508
preparations C 140 508
isolated C 141 508
according C 142 508
to C 143 508
their C 144 508
new C 145 508
procedure C 146 508
. C 147 508
the C 149 508
concentration C 150 508
of C 151 508
dinitrophenyl C 152 508
- C 153 508
glutamic C 154 508
acid C 155 508
was C 156 508
lower C 157 508
in C 158 508
the C 159 508
purified C 160 508
samples C 161 508
. C 162 508
urea C 164 508
- C 165 508
treated C 166 508
samples C 167 508
had C 168 508
the C 169 508
same C 170 508
concentration C 171 508
of C 172 508
n C 173 508
- C 174 508
terminal C 175 508
glutamic C 176 508
acid C 177 508
whereas C 178 508
the C 179 508
concentration C 180 508
of C 181 508
the C 182 508
' C 183 508
trace C 184 508
' C 185 508
end C 186 508
- C 187 508
groups C 188 508
did C 189 508
not C 190 508
change C 191 508
. C 192 508
sedimentation C 194 508
- C 195 508
diffusion C 196 508
equilibrium C 197 508
in C 198 508
the C 199 508
analytical C 200 508
ultracentrifuge C 201 508
revealed C 202 508
a C 203 508
slight C 204 508
heterogeneity C 205 508
in C 206 508
the C 207 508
purified C 208 508
samples C 209 508
. C 210 508
electron C 212 508
micrographs C 213 508
of C 214 508
electrophoretic C 215 508
and C 216 508
of C 217 508
further C 218 508
purified C 219 508
samples C 220 508
were C 221 508
very C 222 508
similar C 223 508
. C 224 508
at C 226 508
neutral C 227 508
or C 228 508
slightly C 229 508
alkaline C 230 508
ph C 231 508
they C 232 508
showed C 233 508
almost C 234 508
uniform C 235 508
spherical C 236 508
aggregates C 237 508
in C 238 508
which C 239 508
a C 240 508
substructure C 241 508
was C 242 508
observed C 243 508
. C 244 508
at C 246 508
acid C 247 508
ph C 248 508
, C 249 508
coiled C 250 508
filaments C 251 508
rather C 252 508
than C 253 508
small C 254 508
globules C 255 508
could C 256 508
be C 257 508
demonstrated C 258 508
. C 259 508
1752 C 1 509
. C 2 509
separation C 4 509
of C 5 509
the C 6 509
soluble C 7 509
proteins C 8 509
of C 9 509
bovine C 10 509
lenses C 11 509
on C 12 509
polyacrylamide C 13 509
gels C 14 509
the C 15 509
soluble C 16 509
proteins C 17 509
of C 18 509
bovine C 19 509
lenses C 20 509
were C 21 509
separated C 22 509
by C 23 509
gel C 24 509
filtration C 25 509
on C 26 509
polyacryl C 27 509
- C 28 509
amide C 29 509
gels C 30 509
. C 31 509
the C 33 509
presence C 34 509
of C 35 509
ethylenediaminetetra C 36 509
- C 37 509
acetate C 38 509
in C 39 509
the C 40 509
buffer C 41 509
was C 42 509
found C 43 509
to C 44 509
be C 45 509
essential C 46 509
for C 47 509
achieving C 48 509
a C 49 509
good C 50 509
separation C 51 509
of C 52 509
the C 53 509
lens C 54 509
homogenate C 55 509
into C 56 509
four C 57 509
fractions C 58 509
- C 59 509
a C 60 509
, C 61 509
b C 62 509
, C 63 509
c C 64 509
and C 65 509
d C 66 509
. C 67 509
ultracentrifugal C 69 509
, C 70 509
electrophoretic C 71 509
and C 72 509
immunochemical C 73 509
analyses C 74 509
were C 75 509
used C 76 509
to C 77 509
compare C 78 509
these C 79 509
fractions C 80 509
with C 81 509
the C 82 509
soluble C 83 509
crystallin C 84 509
fractions C 85 509
of C 86 509
the C 87 509
lens C 88 509
. C 89 509
fraction C 91 509
a C 92 509
was C 93 509
compared C 94 509
with C 95 509
a C 96 509
- C 97 509
crystallin C 98 509
, C 99 509
fractions C 100 509
b C 101 509
and C 102 509
c C 103 509
with C 104 509
b C 105 509
- C 106 509
crystallin C 107 509
and C 108 509
fraction C 109 509
d C 110 509
with C 111 509
y C 112 509
- C 113 509
crystallin C 114 509
. C 115 509
the C 117 509
distribution C 118 509
of C 119 509
these C 120 509
four C 121 509
protein C 122 509
fractions C 123 509
in C 124 509
the C 125 509
nuclear C 126 509
and C 127 509
cortical C 128 509
parts C 129 509
of C 130 509
calf C 131 509
and C 132 509
cow C 133 509
lenses C 134 509
was C 135 509
determined C 136 509
. C 137 509
the C 139 509
oxidation C 140 509
- C 141 509
sensitive C 142 509
protein C 143 509
fraction C 144 509
of C 145 509
the C 146 509
calf C 147 509
lenses C 148 509
was C 149 509
separated C 150 509
from C 151 509
fraction C 152 509
b C 153 509
on C 154 509
an C 155 509
se C 156 509
- C 157 509
sephadex C 158 509
column C 159 509
. C 160 509
1745 C 1 510
. C 2 510
the C 4 510
deaggregation C 5 510
of C 6 510
bovine C 7 510
lens C 8 510
a C 9 510
- C 10 510
crystallin C 11 510
sedimentation C 12 510
equilibrium C 13 510
studies C 14 510
of C 15 510
lens C 16 510
a C 17 510
- C 18 510
crystallin C 19 510
at C 20 510
neutral C 21 510
ph C 22 510
indicate C 23 510
that C 24 510
this C 25 510
material C 26 510
is C 27 510
composed C 28 510
of C 29 510
a C 30 510
number C 31 510
of C 32 510
different C 33 510
sized C 34 510
species C 35 510
. C 36 510
a C 38 510
study C 39 510
of C 40 510
the C 41 510
effect C 42 510
of C 43 510
alkali C 44 510
upon C 45 510
a C 46 510
- C 47 510
crystallin C 48 510
indicates C 49 510
a C 50 510
progressive C 51 510
deaggregation C 52 510
of C 53 510
the C 54 510
ma C 55 510
- C 56 510
terial C 57 510
with C 58 510
increasing C 59 510
ph C 60 510
. C 61 510
sedimentation C 63 510
equilibrium C 64 510
studies C 65 510
were C 66 510
performed C 67 510
at C 68 510
ph C 69 510
12 C 70 510
. C 71 510
. C 72 510
as C 73 510
well C 74 510
as C 75 510
in C 76 510
guanidine C 77 510
hydrochloride C 78 510
, C 79 510
7 C 80 510
m C 81 510
urea C 82 510
, C 83 510
and C 84 510
with C 85 510
succinylated C 86 510
material C 87 510
. C 88 510
under C 90 510
all C 91 510
of C 92 510
these C 93 510
conditions C 94 510
a C 95 510
molecular C 96 510
heterogeneity C 97 510
was C 98 510
observed C 99 510
. C 100 510
the C 102 510
data C 103 510
indicate C 104 510
that C 105 510
independent C 106 510
species C 107 510
coexisted C 108 510
under C 109 510
most C 110 510
dissociating C 111 510
conditions C 112 510
. C 113 510
the C 115 510
weight C 116 510
average C 117 510
molecular C 118 510
weights C 119 510
of C 120 510
the C 121 510
succinylated C 122 510
, C 123 510
and C 124 510
of C 125 510
the C 126 510
alkali C 127 510
- C 128 510
, C 129 510
urea C 130 510
- C 131 510
, C 132 510
and C 133 510
guanidine C 134 510
hydrochloride C 135 510
- C 136 510
treated C 137 510
material C 138 510
were C 139 510
found C 140 510
to C 141 510
have C 142 510
an C 143 510
integral C 144 510
relation C 145 510
- C 146 510
ship C 147 510
of C 148 510
8 C 149 510
4 C 150 510
2 C 151 510
1 C 152 510
, C 153 510
respectively C 154 510
. C 155 510
since C 157 510
a C 158 510
constant C 159 510
ratio C 160 510
of C 161 510
m C 162 510
2 C 163 510
mw C 164 510
was C 165 510
found C 166 510
, C 167 510
it C 168 510
was C 169 510
concluded C 170 510
that C 171 510
the C 172 510
same C 173 510
spread C 174 510
of C 175 510
distribution C 176 510
of C 177 510
molecular C 178 510
species C 179 510
occurred C 180 510
for C 181 510
each C 182 510
of C 183 510
the C 184 510
deaggregating C 185 510
conditions C 186 510
. C 187 510
the C 189 510
results C 190 510
in C 191 510
guanidine C 192 510
hydrochloride C 193 510
could C 194 510
not C 195 510
be C 196 510
evaluated C 197 510
in C 198 510
this C 199 510
manner C 200 510
because C 201 510
of C 202 510
a C 203 510
small C 204 510
concentration C 205 510
dependence C 206 510
. C 207 510
these C 209 510
conclusions C 210 510
imply C 211 510
that C 212 510
not C 213 510
only C 214 510
the C 215 510
weight C 216 510
average C 217 510
molecular C 218 510
weight C 219 510
in C 220 510
7 C 221 510
m C 222 510
urea C 223 510
but C 224 510
the C 225 510
actual C 226 510
molecular C 227 510
weight C 228 510
of C 229 510
each C 230 510
individual C 231 510
species C 232 510
in C 233 510
urea C 234 510
was C 235 510
one C 236 510
- C 237 510
half C 238 510
of C 239 510
the C 240 510
value C 241 510
to C 242 510
be C 243 510
found C 244 510
in C 245 510
alkali C 246 510
and C 247 510
one C 248 510
- C 249 510
quarter C 250 510
that C 251 510
of C 252 510
the C 253 510
succinylated C 254 510
material C 255 510
. C 256 510
1747 C 1 511
. C 2 511
the C 4 511
problem C 5 511
of C 6 511
albuminoid C 7 511
albuminoid C 8 511
is C 9 511
the C 10 511
main C 11 511
constituent C 12 511
of C 13 511
the C 14 511
insoluble C 15 511
fraction C 16 511
of C 17 511
the C 18 511
lens C 19 511
proteins C 20 511
. C 21 511
albuminoid C 23 511
from C 24 511
the C 25 511
cortex C 26 511
of C 27 511
ox C 28 511
lens C 29 511
has C 30 511
been C 31 511
fractionated C 32 511
on C 33 511
deae C 34 511
- C 35 511
cellulose C 36 511
in C 37 511
7 C 38 511
m C 39 511
urea C 40 511
; C 41 511
peptide C 42 511
maps C 43 511
of C 44 511
the C 45 511
fractions C 46 511
are C 47 511
very C 48 511
similar C 49 511
to C 50 511
those C 51 511
from C 52 511
the C 53 511
corre C 54 511
- C 55 511
sponding C 56 511
fractions C 57 511
from C 58 511
a C 59 511
- C 60 511
crystallin C 61 511
. C 62 511
albuminoid C 64 511
can C 65 511
be C 66 511
regarded C 67 511
as C 68 511
an C 69 511
insoluble C 70 511
a C 71 511
- C 72 511
crystallin C 73 511
. C 74 511
an C 76 511
undiluted C 77 511
ground C 78 511
lens C 79 511
is C 80 511
clear C 81 511
but C 82 511
becomes C 83 511
turbid C 84 511
on C 85 511
dilution C 86 511
. C 87 511
if C 89 511
albuminoid C 90 511
is C 91 511
present C 92 511
in C 93 511
the C 94 511
normal C 95 511
lens C 96 511
, C 97 511
it C 98 511
does C 99 511
not C 100 511
cause C 101 511
turbidity C 102 511
even C 103 511
when C 104 511
the C 105 511
cellular C 106 511
structure C 107 511
is C 108 511
disrupted C 109 511
. C 110 511
it C 112 511
is C 113 511
perhaps C 114 511
more C 115 511
likely C 116 511
that C 117 511
the C 118 511
albuminoid C 119 511
is C 120 511
formed C 121 511
on C 122 511
dilution C 123 511
of C 124 511
the C 125 511
lens C 126 511
mush C 127 511
. C 128 511
the C 130 511
high C 131 511
concentration C 132 511
of C 133 511
proteins C 134 511
in C 135 511
the C 136 511
lens C 137 511
, C 138 511
especially C 139 511
in C 140 511
the C 141 511
nucleus C 142 511
, C 143 511
entails C 144 511
a C 145 511
high C 146 511
degree C 147 511
of C 148 511
order C 149 511
, C 150 511
which C 151 511
will C 152 511
be C 153 511
destroyed C 154 511
on C 155 511
dilution C 156 511
this C 157 511
phenomenon C 158 511
may C 159 511
well C 160 511
be C 161 511
connected C 162 511
with C 163 511
the C 164 511
precipitation C 165 511
of C 166 511
the C 167 511
albuminoid C 168 511
. C 169 511
787 C 1 512
. C 2 512
further C 4 512
autoradiographic C 5 512
studies C 6 512
of C 7 512
the C 8 512
lens C 9 512
epithelium C 10 512
. C 11 512
normal C 13 512
and C 14 512
x C 15 512
- C 16 512
irradiated C 17 512
rat C 18 512
eyes C 19 512
cell C 20 512
proliferation C 21 512
and C 22 512
migration C 23 512
in C 24 512
the C 25 512
lens C 26 512
epithelium C 27 512
of C 28 512
normal C 29 512
and C 30 512
x C 31 512
- C 32 512
irradiated C 33 512
rat C 34 512
eyes C 35 512
were C 36 512
studied C 37 512
by C 38 512
means C 39 512
of C 40 512
autoradiography C 41 512
after C 42 512
labelling C 43 512
with C 44 512
tritiated C 45 512
thymidine C 46 512
. C 47 512
cells C 49 512
of C 50 512
the C 51 512
normal C 52 512
lens C 53 512
epithelium C 54 512
require C 55 512
16 C 56 512
hr C 57 512
. C 58 512
to C 60 512
pass C 61 512
from C 62 512
the C 63 512
beginning C 64 512
of C 65 512
the C 66 512
synthesizing C 67 512
period C 68 512
to C 69 512
the C 70 512
completion C 71 512
of C 72 512
mitosis C 73 512
. C 74 512
this C 76 512
interval C 77 512
is C 78 512
partitioned C 79 512
as C 80 512
follows C 81 512
s C 82 512
period C 83 512
, C 84 512
approximately C 85 512
10 C 86 512
hr C 87 512
. C 88 512
; C 90 512
g C 91 512
2 C 92 512
, C 93 512
slightly C 94 512
less C 95 512
than C 96 512
5 C 97 512
hr C 98 512
; C 99 512
and C 100 512
mitosis C 101 512
, C 102 512
72 C 103 512
min C 104 512
. C 105 512
following C 107 512
division C 108 512
, C 109 512
labelled C 110 512
daughter C 111 512
cells C 112 512
migrate C 113 512
from C 114 512
the C 115 512
germinative C 116 512
zone C 117 512
to C 118 512
the C 119 512
postequatorial C 120 512
rows C 121 512
, C 122 512
and C 123 512
by C 124 512
2 C 125 512
weeks C 126 512
after C 127 512
tracer C 128 512
injection C 129 512
many C 130 512
radioactive C 131 512
nuclei C 132 512
are C 133 512
found C 134 512
in C 135 512
the C 136 512
lens C 137 512
bow C 138 512
. C 139 512
epithelial C 141 512
cells C 142 512
irradiated C 143 512
while C 144 512
in C 145 512
the C 146 512
dna C 147 512
synthesis C 148 512
phase C 149 512
undergo C 150 512
degeneration C 151 512
beginning C 152 512
approximately C 153 512
8 C 154 512
hr C 155 512
. C 156 512
after C 158 512
exposure C 159 512
. C 160 512
the C 162 512
onset C 163 512
of C 164 512
cell C 165 512
death C 166 512
corresponds C 167 512
to C 168 512
the C 169 512
time C 170 512
at C 171 512
which C 172 512
these C 173 512
cells C 174 512
would C 175 512
normally C 176 512
be C 177 512
preparing C 178 512
for C 179 512
mitosis C 180 512
indicating C 181 512
that C 182 512
they C 183 512
die C 184 512
in C 185 512
abortive C 186 512
divisions C 187 512
. C 188 512
a C 190 512
small C 191 512
percentage C 192 512
of C 193 512
the C 194 512
originally C 195 512
labelled C 196 512
cells C 197 512
survived C 198 512
until C 199 512
3 C 200 512
days C 201 512
after C 202 512
irradi C 203 512
- C 204 512
ation C 205 512
, C 206 512
but C 207 512
by C 208 512
2 C 209 512
weeks C 210 512
this C 211 512
number C 212 512
fell C 213 512
almost C 214 512
to C 215 512
zero C 216 512
. C 217 512
the C 219 512
loss C 220 512
of C 221 512
radioactive C 222 512
cells C 223 512
occurred C 224 512
most C 225 512
rapidly C 226 512
in C 227 512
the C 228 512
equatorial C 229 512
zone C 230 512
. C 231 512
2627 C 1 513
. C 2 513
chicken C 4 513
lens C 5 513
development C 6 513
epithelial C 7 513
cell C 8 513
production C 9 513
and C 10 513
migration C 11 513
in C 12 513
the C 13 513
earliest C 14 513
stages C 15 513
of C 16 513
chicken C 17 513
lens C 18 513
development C 19 513
, C 20 513
cell C 21 513
division C 22 513
occurred C 23 513
over C 24 513
the C 25 513
entire C 26 513
lens C 27 513
. C 28 513
cell C 30 513
division C 31 513
first C 32 513
stopped C 33 513
in C 34 513
the C 35 513
posterior C 36 513
side C 37 513
of C 38 513
the C 39 513
lens C 40 513
vesicle C 41 513
, C 42 513
as C 43 513
the C 44 513
cells C 45 513
differentiated C 46 513
into C 47 513
primary C 48 513
lens C 49 513
fibers C 50 513
. C 51 513
after C 53 513
the C 54 513
annular C 55 513
pad C 56 513
developed C 57 513
, C 58 513
cell C 59 513
division C 60 513
occurred C 61 513
, C 62 513
for C 63 513
the C 64 513
most C 65 513
part C 66 513
, C 67 513
in C 68 513
the C 69 513
anterior C 70 513
surface C 71 513
epithelial C 72 513
cells C 73 513
. C 74 513
shortly C 76 513
after C 77 513
hatching C 78 513
and C 79 513
thereafter C 80 513
, C 81 513
a C 82 513
germinative C 83 513
zone C 84 513
, C 85 513
consisting C 86 513
of C 87 513
a C 88 513
narrow C 89 513
band C 90 513
of C 91 513
epithelial C 92 513
cells C 93 513
adjacent C 94 513
to C 95 513
the C 96 513
annular C 97 513
pad C 98 513
developed C 99 513
. C 100 513
the C 102 513
cells C 103 513
from C 104 513
the C 105 513
germinative C 106 513
zone C 107 513
migrated C 108 513
slowly C 109 513
and C 110 513
differentiated C 111 513
first C 112 513
into C 113 513
annular C 114 513
pad C 115 513
cells C 116 513
and C 117 513
then C 118 513
into C 119 513
lens C 120 513
cortex C 121 513
fibers C 122 513
over C 123 513
an C 124 513
estimated C 125 513
2 C 126 513
- C 127 513
year C 128 513
period C 129 513
. C 130 513
this C 132 513
slow C 133 513
migration C 134 513
of C 135 513
cells C 136 513
in C 137 513
the C 138 513
lens C 139 513
is C 140 513
discussed C 141 513
in C 142 513
relation C 143 513
to C 144 513
the C 145 513
failure C 146 513
of C 147 513
the C 148 513
adult C 149 513
chicken C 150 513
to C 151 513
de C 152 513
- C 153 513
velop C 154 513
radiation C 155 513
cataracts C 156 513
. C 157 513
1494 C 1 514
. C 2 514
selenium C 4 514
content C 5 514
of C 6 514
fish C 7 514
flour C 8 514
in C 9 514
relation C 10 514
to C 11 514
kwashiorkor C 12 514
and C 13 514
dental C 14 514
caries C 15 514
the C 16 514
fact C 17 514
that C 18 514
fish C 19 514
flour C 20 514
was C 21 514
shown C 22 514
to C 23 514
be C 24 514
a C 25 514
rich C 26 514
source C 27 514
of C 28 514
dietary C 29 514
selenium C 30 514
( C 31 514
169 C 32 514
p C 33 514
. C 34 514
. C 35 514
. C 36 514
. C 37 514
. C 38 514
may C 40 514
have C 41 514
important C 42 514
implications C 43 514
( C 44 514
i C 45 514
. C 46 514
. C 47 514
. C 48 514
deleterious C 50 514
effect C 51 514
on C 52 514
teeth C 53 514
) C 54 514
in C 55 514
the C 56 514
treatment C 57 514
and C 58 514
prevention C 59 514
of C 60 514
protein C 61 514
malnutrition C 62 514
. C 63 514
it C 65 514
indicates C 66 514
that C 67 514
some C 68 514
disease C 69 514
syndromes C 70 514
in C 71 514
man C 72 514
may C 73 514
be C 74 514
a C 75 514
manifestation C 76 514
of C 77 514
selenium C 78 514
deficiency C 79 514
. C 80 514
it C 82 514
is C 83 514
recommended C 84 514
that C 85 514
the C 86 514
role C 87 514
played C 88 514
by C 89 514
selenium C 90 514
in C 91 514
protein C 92 514
malnutrition C 93 514
should C 94 514
be C 95 514
given C 96 514
serious C 97 514
consideration C 98 514
by C 99 514
research C 100 514
workers C 101 514
. C 102 514
2192 C 1 515
. C 2 515
selenium C 4 515
content C 5 515
of C 6 515
fresh C 7 515
eggs C 8 515
during C 9 515
a C 10 515
study C 11 515
of C 12 515
effects C 13 515
of C 14 515
traces C 15 515
of C 16 515
se C 17 515
on C 18 515
dental C 19 515
caries C 20 515
the C 21 515
authors C 22 515
determined C 23 515
this C 24 515
element C 25 515
in C 26 515
eggs C 27 515
. C 28 515
whole C 30 515
egg C 31 515
contains C 32 515
appreciable C 33 515
amounts C 34 515
of C 35 515
se C 36 515
; C 37 515
this C 38 515
is C 39 515
found C 40 515
chiefly C 41 515
in C 42 515
the C 43 515
yolk C 44 515
( C 45 515
mean C 46 515
value C 47 515
0 C 48 515
. C 49 515
. C 50 515
. C 50 515
. C 50 515
0 C 51 515
. C 52 515
. C 53 515
. C 53 515
. C 53 515
p C 54 515
. C 55 515
. C 56 515
. C 57 515
. C 58 515
. C 59 515
) C 61 515
with C 62 515
only C 63 515
0 C 64 515
. C 65 515
. C 66 515
. C 66 515
. C 66 515
0 C 67 515
. C 68 515
. C 69 515
. C 69 515
. C 69 515
p C 70 515
. C 71 515
. C 72 515
. C 73 515
. C 74 515
. C 75 515
in C 77 515
the C 78 515
white C 79 515
. C 80 515
1541 C 1 516
. C 2 516
selenium C 4 516
content C 5 516
of C 6 516
human C 7 516
milk C 8 516
possible C 9 516
effect C 10 516
on C 11 516
dental C 12 516
caries C 13 516
selenium C 14 516
appears C 15 516
to C 16 516
be C 17 516
a C 18 516
factor C 19 516
capable C 20 516
of C 21 516
increasing C 22 516
susceptibility C 23 516
to C 24 516
dental C 25 516
caries C 26 516
in C 27 516
children C 28 516
and C 29 516
rats C 30 516
. C 31 516
in C 33 516
an C 34 516
area C 35 516
considered C 36 516
to C 37 516
be C 38 516
nonseleniferous C 39 516
, C 40 516
milk C 41 516
collected C 42 516
from C 43 516
15 C 44 516
mothers C 45 516
( C 46 516
17 C 47 516
- C 48 516
44 C 49 516
yr C 50 516
. C 51 516
old C 53 516
) C 54 516
of C 55 516
low C 56 516
socio C 57 516
- C 58 516
economic C 59 516
class C 60 516
had C 61 516
a C 62 516
mean C 63 516
selenium C 64 516
content C 65 516
of C 66 516
0 C 67 516
. C 68 516
. C 69 516
. C 69 516
. C 69 516
p C 70 516
. C 71 516
. C 72 516
. C 73 516
. C 74 516
. C 75 516
( C 77 516
standard C 78 516
error C 79 516
0 C 80 516
. C 81 516
. C 82 516
. C 82 516
. C 82 516
) C 83 516
. C 84 516
1577 C 1 517
. C 2 517
mode C 4 517
of C 5 517
action C 6 517
of C 7 517
selenium C 8 517
in C 9 517
relation C 10 517
to C 11 517
biological C 12 517
activity C 13 517
of C 14 517
tocopherols C 15 517
dietary C 16 517
selenium C 17 517
at C 18 517
levels C 19 517
below C 20 517
1 C 21 517
ppm C 22 517
has C 23 517
a C 24 517
partially C 25 517
beneficial C 26 517
effect C 27 517
upon C 28 517
nutritional C 29 517
muscular C 30 517
dystrophy C 31 517
but C 32 517
is C 33 517
ineffective C 34 517
or C 35 517
detrimental C 36 517
at C 37 517
higher C 38 517
levels C 39 517
. C 40 517
the C 42 517
role C 43 517
of C 44 517
selenium C 45 517
in C 46 517
improving C 47 517
the C 48 517
effectiveness C 49 517
of C 50 517
vitamin C 51 517
e C 52 517
is C 53 517
due C 54 517
at C 55 517
least C 56 517
in C 57 517
part C 58 517
to C 59 517
the C 60 517
fact C 61 517
that C 62 517
dietary C 63 517
selenium C 64 517
increases C 65 517
the C 66 517
retention C 67 517
of C 68 517
the C 69 517
a C 70 517
- C 71 517
tocopherols C 72 517
, C 73 517
especially C 74 517
d C 75 517
- C 76 517
a C 77 517
- C 78 517
tocopherol C 79 517
. C 80 517
this C 82 517
has C 83 517
been C 84 517
shown C 85 517
by C 86 517
chemical C 87 517
determination C 88 517
of C 89 517
plasma C 90 517
tocopherols C 91 517
and C 92 517
also C 93 517
by C 94 517
tracing C 95 517
the C 96 517
activities C 97 517
of C 98 517
tritiated C 99 517
tocopherols C 100 517
and C 101 517
selenium C 102 517
75 C 103 517
in C 104 517
serum C 105 517
and C 106 517
in C 107 517
various C 108 517
fractions C 109 517
of C 110 517
serum C 111 517
proteins C 112 517
in C 113 517
chicks C 114 517
receiving C 115 517
these C 116 517
nutrients C 117 517
alone C 118 517
and C 119 517
in C 120 517
combination C 121 517
. C 122 517
se C 124 517
75 C 125 517
and C 126 517
h C 127 517
3 C 128 517
- C 129 517
a C 130 517
- C 131 517
tocopherol C 132 517
activities C 133 517
followed C 134 517
each C 135 517
other C 136 517
very C 137 517
closely C 138 517
in C 139 517
the C 140 517
serum C 141 517
proteins C 142 517
. C 143 517
these C 145 517
studies C 146 517
indicated C 147 517
that C 148 517
vitamin C 149 517
e C 150 517
may C 151 517
be C 152 517
carried C 153 517
by C 154 517
a C 155 517
selenolipoprotein C 156 517
fraction C 157 517
associated C 158 517
with C 159 517
serum C 160 517
y C 161 517
- C 162 517
globulin C 163 517
. C 164 517
thus C 166 517
, C 167 517
one C 168 517
biological C 169 517
role C 170 517
of C 171 517
selenium C 172 517
appears C 173 517
to C 174 517
lie C 175 517
in C 176 517
a C 177 517
selenium C 178 517
- C 179 517
containing C 180 517
compound C 181 517
which C 182 517
acts C 183 517
as C 184 517
a C 185 517
carrier C 186 517
of C 187 517
vitamin C 188 517
e C 189 517
and C 190 517
which C 191 517
may C 192 517
function C 193 517
in C 194 517
absorption C 195 517
, C 196 517
retention C 197 517
, C 198 517
prevention C 199 517
of C 200 517
destruction C 201 517
, C 202 517
and C 203 517
perhaps C 204 517
transfer C 205 517
across C 206 517
cell C 207 517
membranes C 208 517
of C 209 517
d C 210 517
- C 211 517
a C 212 517
- C 213 517
tocopherol C 214 517
, C 215 517
thereby C 216 517
enhancing C 217 517
its C 218 517
biological C 219 517
activity C 220 517
in C 221 517
the C 222 517
blood C 223 517
and C 224 517
perhaps C 225 517
in C 226 517
cells C 227 517
throughout C 228 517
the C 229 517
body C 230 517
. C 231 517
3123 C 1 518
. C 2 518
effect C 4 518
of C 5 518
sodium C 6 518
selenate C 7 518
on C 8 518
acute C 9 518
poisoning C 10 518
with C 11 518
thallium C 12 518
experiments C 13 518
were C 14 518
performed C 15 518
on C 16 518
wistar C 17 518
rats C 18 518
weighing C 19 518
150 C 20 518
- C 21 518
200 C 22 518
g C 23 518
. C 24 518
thallium C 26 518
was C 27 518
ad C 28 518
- C 29 518
ministered C 30 518
s C 31 518
. C 32 518
. C 33 518
. C 34 518
in C 36 518
doses C 37 518
of C 38 518
20 C 39 518
mg C 40 518
/ C 41 518
kg C 42 518
and C 43 518
30 C 44 518
mg C 45 518
/ C 46 518
kg C 47 518
. C 48 518
sodium C 50 518
selenate C 51 518
was C 52 518
given C 53 518
per C 54 518
os C 55 518
in C 56 518
doses C 57 518
of C 58 518
10 C 59 518
mg C 60 518
/ C 61 518
kg C 62 518
2 C 63 518
hr C 64 518
after C 65 518
poisoning C 66 518
and C 67 518
5 C 68 518
mg C 69 518
/ C 70 518
kg C 71 518
daily C 72 518
for C 73 518
the C 74 518
next C 75 518
2 C 76 518
days C 77 518
. C 78 518
results C 80 518
indicate C 81 518
that C 82 518
sodium C 83 518
selenate C 84 518
protects C 85 518
the C 86 518
animals C 87 518
from C 88 518
death C 89 518
. C 90 518
it C 92 518
binds C 93 518
the C 94 518
thallium C 95 518
ions C 96 518
and C 97 518
increases C 98 518
their C 99 518
deposition C 100 518
in C 101 518
organs C 102 518
. C 103 518
comparison C 105 518
of C 106 518
the C 107 518
level C 108 518
of C 109 518
thallium C 110 518
in C 111 518
organs C 112 518
of C 113 518
treated C 114 518
rats C 115 518
shows C 116 518
that C 117 518
selenate C 118 518
increases C 119 518
in C 120 518
liver C 121 518
by C 122 518
290 C 123 518
. C 124 518
. C 125 518
% C 126 518
, C 127 518
in C 128 518
kidneys C 129 518
by C 130 518
326 C 131 518
. C 132 518
. C 133 518
% C 134 518
and C 135 518
in C 136 518
bones C 137 518
by C 138 518
210 C 139 518
. C 140 518
. C 141 518
% C 142 518
. C 143 518
no C 145 518
influence C 146 518
of C 147 518
selenate C 148 518
on C 149 518
excretion C 150 518
of C 151 518
thallium C 152 518
in C 153 518
the C 154 518
urine C 155 518
was C 156 518
found C 157 518
, C 158 518
but C 159 518
fecal C 160 518
excretion C 161 518
of C 162 518
thallium C 163 518
increased C 164 518
by C 165 518
an C 166 518
average C 167 518
of C 168 518
45 C 169 518
% C 170 518
of C 171 518
the C 172 518
treated C 173 518
animals C 174 518
. C 175 518
2281 C 1 519
. C 2 519
inhibition C 4 519
of C 5 519
active C 6 519
transport C 7 519
of C 8 519
sugars C 9 519
through C 10 519
rat C 11 519
intestine C 12 519
in C 13 519
vitro C 14 519
. C 15 519
ii C 17 519
. C 18 519
action C 20 519
of C 21 519
mepacrine C 22 519
, C 23 519
atractyloside C 24 519
and C 25 519
selenite C 26 519
it C 27 519
is C 28 519
shown C 29 519
that C 30 519
mepacrine C 31 519
, C 32 519
atractyloside C 33 519
and C 34 519
selenite C 35 519
, C 36 519
which C 37 519
had C 38 519
been C 39 519
regarded C 40 519
as C 41 519
inhibitors C 42 519
of C 43 519
intestinal C 44 519
absorption C 45 519
of C 46 519
glucose C 47 519
, C 48 519
are C 49 519
inhibitors C 50 519
of C 51 519
active C 52 519
transport C 53 519
of C 54 519
sugars C 55 519
in C 56 519
sacs C 57 519
of C 58 519
everted C 59 519
jejunum C 60 519
of C 61 519
rat C 62 519
( C 63 519
wilson C 64 519
and C 65 519
wiseman C 66 519
' C 67 519
s C 68 519
method C 69 519
) C 70 519
. C 71 519
mepacrine C 73 519
5 C 74 519
x C 75 519
10 C 76 519
- C 77 519
3 C 78 519
m C 79 519
and C 80 519
10 C 81 519
- C 82 519
2 C 83 519
m C 84 519
inhibit C 85 519
, C 86 519
by C 87 519
85 C 88 519
% C 89 519
and C 90 519
100 C 91 519
% C 92 519
respectively C 93 519
, C 94 519
the C 95 519
active C 96 519
transport C 97 519
of C 98 519
galactose C 99 519
. C 100 519
with C 102 519
atractyloside C 103 519
10 C 104 519
- C 105 519
5 C 106 519
m C 107 519
and C 108 519
10 C 109 519
- C 110 519
3 C 111 519
m C 112 519
, C 113 519
the C 114 519
inhibitions C 115 519
were C 116 519
77 C 117 519
% C 118 519
and C 119 519
100 C 120 519
% C 121 519
and C 122 519
, C 123 519
with C 124 519
selenite C 125 519
10 C 126 519
- C 127 519
4 C 128 519
m C 129 519
and C 130 519
10 C 131 519
- C 132 519
3 C 133 519
m C 134 519
, C 135 519
about C 136 519
70 C 137 519
% C 138 519
. C 139 519
in C 141 519
general C 142 519
the C 143 519
inhibitors C 144 519
are C 145 519
effective C 146 519
within C 147 519
orders C 148 519
of C 149 519
magnitude C 150 519
which C 151 519
are C 152 519
similar C 153 519
in C 154 519
vivo C 155 519
and C 156 519
in C 157 519
vitro C 158 519
. C 159 519
atractyloside C 161 519
is C 162 519
rather C 163 519
more C 164 519
effective C 165 519
in C 166 519
vitro C 167 519
than C 168 519
in C 169 519
vivo C 170 519
, C 171 519
and C 172 519
mepacrine C 173 519
rather C 174 519
less C 175 519
. C 176 519
it C 178 519
is C 179 519
easier C 180 519
to C 181 519
achieve C 182 519
total C 183 519
inhibitions C 184 519
of C 185 519
the C 186 519
active C 187 519
transport C 188 519
of C 189 519
sugars C 190 519
in C 191 519
vitro C 192 519
than C 193 519
of C 194 519
intestinal C 195 519
absorption C 196 519
from C 197 519
isotonic C 198 519
solutions C 199 519
in C 200 519
vivo C 201 519
. C 202 519
2284 C 1 520
. C 2 520
analogs C 4 520
parasympathetic C 5 520
neuroeffectors C 6 520
. C 7 520
ii C 9 520
. C 10 520
comparative C 12 520
pharmacological C 13 520
studies C 14 520
of C 15 520
acetylcholine C 16 520
, C 17 520
its C 18 520
thio C 19 520
and C 20 520
seleno C 21 520
analogs C 22 520
, C 23 520
and C 24 520
their C 25 520
hydrolysis C 26 520
products C 27 520
acetylthiocholine C 28 520
and C 29 520
acetylselenocholine C 30 520
exert C 31 520
acetylcholine C 32 520
- C 33 520
like C 34 520
effects C 35 520
on C 36 520
the C 37 520
guinea C 38 520
- C 39 520
pig C 40 520
ileum C 41 520
and C 42 520
frog C 43 520
rectus C 44 520
abdominis C 45 520
preparations C 46 520
. C 47 520
with C 49 520
the C 50 520
latter C 51 520
preparation C 52 520
, C 53 520
responses C 54 520
to C 55 520
acetylthiocholine C 56 520
and C 57 520
acetylselenocholine C 58 520
, C 59 520
in C 60 520
contrast C 61 520
to C 62 520
that C 63 520
to C 64 520
acetylcholine C 65 520
, C 66 520
are C 67 520
not C 68 520
enhanced C 69 520
by C 70 520
the C 71 520
addition C 72 520
of C 73 520
an C 74 520
anticholinesterase C 75 520
. C 76 520
this C 78 520
is C 79 520
attributable C 80 520
to C 81 520
the C 82 520
relatively C 83 520
high C 84 520
activity C 85 520
of C 86 520
the C 87 520
hydrolysis C 88 520
products C 89 520
, C 90 520
cholinethiol C 91 520
and C 92 520
cholineselenol C 93 520
; C 94 520
acetylthiocholine C 95 520
and C 96 520
acetyselenocholine C 97 520
undergo C 98 520
enzymatic C 99 520
hydrolysis C 100 520
at C 101 520
approximately C 102 520
the C 103 520
same C 104 520
rate C 105 520
as C 106 520
does C 107 520
acetylcholine C 108 520
. C 109 520
the C 111 520
hydrolysis C 112 520
products C 113 520
of C 114 520
acetylthiocholine C 115 520
and C 116 520
acetylselenocholine C 117 520
, C 118 520
which C 119 520
have C 120 520
effects C 121 520
on C 122 520
the C 123 520
guinea C 124 520
- C 125 520
pig C 126 520
ileum C 127 520
comparable C 128 520
to C 129 520
those C 130 520
of C 131 520
the C 132 520
parent C 133 520
esters C 134 520
, C 135 520
are C 136 520
readily C 137 520
oxidized C 138 520
in C 139 520
air C 140 520
to C 141 520
the C 142 520
relatively C 143 520
inactive C 144 520
choline C 145 520
disulfide C 146 520
and C 147 520
choline C 148 520
diselenide C 149 520
, C 150 520
respectively C 151 520
. C 152 520
these C 154 520
observations C 155 520
are C 156 520
helpful C 157 520
in C 158 520
explaining C 159 520
many C 160 520
of C 161 520
the C 162 520
apparently C 163 520
contradictory C 164 520
statements C 165 520
in C 166 520
the C 167 520
literature C 168 520
regarding C 169 520
the C 170 520
actions C 171 520
of C 172 520
acetylthiocholine C 173 520
. C 174 520
3604 C 1 521
. C 2 521
cytotoxicity C 4 521
of C 5 521
organophosphorus C 6 521
compounds C 7 521
. C 8 521
comparative C 10 521
activities C 11 521
of C 12 521
trimethyl C 13 521
derivatives C 14 521
of C 15 521
thiophosphoric C 16 521
and C 17 521
selenophosphoric C 18 521
acids C 19 521
on C 20 521
vegetable C 21 521
( C 22 521
pisum C 23 521
root C 24 521
) C 25 521
and C 26 521
human C 27 521
( C 28 521
hela C 29 521
) C 30 521
cells C 31 521
of C 32 521
the C 33 521
4 C 34 521
compounds C 35 521
studied C 36 521
, C 37 521
the C 38 521
seleno C 39 521
compounds C 40 521
were C 41 521
more C 42 521
cytotoxic C 43 521
for C 44 521
hela C 45 521
cells C 46 521
than C 47 521
their C 48 521
thio C 49 521
analogues C 50 521
, C 51 521
whereas C 52 521
the C 53 521
activities C 54 521
on C 55 521
pisum C 56 521
root C 57 521
cells C 58 521
were C 59 521
equal C 60 521
. C 61 521
the C 63 521
parent C 64 521
phosphoric C 65 521
acid C 66 521
derivatives C 67 521
have C 68 521
a C 69 521
wider C 70 521
activity C 71 521
range C 72 521
on C 73 521
hela C 74 521
cells C 75 521
than C 76 521
the C 77 521
seleno C 78 521
and C 79 521
thio C 80 521
derivatives C 81 521
. C 82 521
further C 84 521
studies C 85 521
are C 86 521
in C 87 521
progress C 88 521
. C 89 521
3640 C 1 522
. C 2 522
poisoning C 4 522
with C 5 522
sodium C 6 522
selenite C 7 522
chronic C 8 522
poisoning C 9 522
with C 10 522
na C 11 522
selenite C 12 522
( C 13 522
in C 14 522
the C 15 522
drinking C 16 522
water C 17 522
) C 18 522
causes C 19 522
hepatic C 20 522
cirrhosis C 21 522
, C 22 522
usually C 23 522
of C 24 522
atrophic C 25 522
type C 26 522
, C 27 522
in C 28 522
rats C 29 522
. C 30 522
in C 32 522
rabbits C 33 522
there C 34 522
seems C 35 522
to C 36 522
be C 37 522
a C 38 522
definite C 39 522
diabetogenic C 40 522
action C 41 522
, C 42 522
while C 43 522
attempts C 44 522
to C 45 522
demonstrate C 46 522
such C 47 522
action C 48 522
in C 49 522
dogs C 50 522
have C 51 522
so C 52 522
far C 53 522
given C 54 522
inconclusive C 55 522
results C 56 522
. C 57 522
the C 59 522
difference C 60 522
between C 61 522
these C 62 522
2 C 63 522
species C 64 522
is C 65 522
perhaps C 66 522
due C 67 522
to C 68 522
the C 69 522
technique C 70 522
used C 71 522
( C 72 522
different C 73 522
spacing C 74 522
of C 75 522
injections C 76 522
for C 77 522
practical C 78 522
reasons C 79 522
) C 80 522
. C 81 522
the C 83 522
action C 84 522
of C 85 522
selenite C 86 522
on C 87 522
the C 88 522
pancreas C 89 522
is C 90 522
discussed C 91 522
and C 92 522
it C 93 522
is C 94 522
pointed C 95 522
out C 96 522
that C 97 522
se C 98 522
can C 99 522
replace C 100 522
s C 101 522
in C 102 522
sh C 103 522
groups C 104 522
, C 105 522
thus C 106 522
rendering C 107 522
the C 108 522
latter C 109 522
ineffective C 110 522
. C 111 522
both C 113 522
in C 114 522
effects C 115 522
on C 116 522
the C 117 522
liver C 118 522
and C 119 522
in C 120 522
those C 121 522
on C 122 522
the C 123 522
pancreas C 124 522
se C 125 522
seems C 126 522
to C 127 522
resemble C 128 522
alloxan C 129 522
. C 130 522
2552 C 1 523
. C 2 523
the C 4 523
tissue C 5 523
distribution C 6 523
of C 7 523
se C 8 523
75 C 9 523
- C 10 523
selenouracil C 11 523
and C 12 523
se C 13 523
75 C 14 523
- C 15 523
selenourea C 16 523
when C 17 523
selenium C 18 523
analogues C 19 523
of C 20 523
thiouracil C 21 523
and C 22 523
thiourea C 23 523
labelled C 24 523
with C 25 523
se C 26 523
75 C 27 523
were C 28 523
injected C 29 523
into C 30 523
rabbits C 31 523
, C 32 523
high C 33 523
radioactivity C 34 523
appeared C 35 523
in C 36 523
lung C 37 523
, C 38 523
liver C 39 523
and C 40 523
kidney C 41 523
. C 42 523
the C 44 523
animal C 45 523
' C 46 523
s C 47 523
lungs C 48 523
could C 49 523
be C 50 523
visualised C 51 523
by C 52 523
photoscanning C 53 523
, C 54 523
but C 55 523
quality C 56 523
was C 57 523
poor C 58 523
, C 59 523
and C 60 523
neither C 61 523
compound C 62 523
is C 63 523
recommended C 64 523
for C 65 523
trial C 66 523
for C 67 523
lung C 68 523
or C 69 523
adrenal C 70 523
scanning C 71 523
in C 72 523
man C 73 523
. C 74 523
1142 C 1 524
. C 2 524
sodium C 4 524
selenate C 5 524
toxicosis C 6 524
pathology C 7 524
and C 8 524
pathogenesis C 9 524
of C 10 524
sodium C 11 524
selenate C 12 524
toxicosis C 13 524
in C 14 524
sheep C 15 524
the C 16 524
pathogenesis C 17 524
of C 18 524
selenium C 19 524
toxicosis C 20 524
was C 21 524
studied C 22 524
in C 23 524
30 C 24 524
ewes C 25 524
fed C 26 524
subtoxic C 27 524
to C 28 524
toxic C 29 524
levels C 30 524
of C 31 524
sodium C 32 524
selenate C 33 524
for C 34 524
1 C 35 524
to C 36 524
5 C 37 524
mth C 38 524
. C 39 524
seventeen C 41 524
of C 42 524
the C 43 524
30 C 44 524
died C 45 524
of C 46 524
selenium C 47 524
toxicosis C 48 524
. C 49 524
the C 51 524
most C 52 524
severe C 53 524
and C 54 524
consistent C 55 524
pathologic C 56 524
changes C 57 524
were C 58 524
found C 59 524
in C 60 524
the C 61 524
myocardium C 62 524
and C 63 524
lungs C 64 524
. C 65 524
myocardial C 67 524
alterations C 68 524
were C 69 524
focal C 70 524
to C 71 524
diffuse C 72 524
degeneration C 73 524
, C 74 524
necrosis C 75 524
and C 76 524
early C 77 524
replacement C 78 524
fibrosis C 79 524
. C 80 524
pulmonary C 82 524
changes C 83 524
, C 84 524
consisting C 85 524
of C 86 524
edema C 87 524
and C 88 524
interstitial C 89 524
hemorrhages C 90 524
, C 91 524
were C 92 524
typical C 93 524
of C 94 524
the C 95 524
degenerative C 96 524
processes C 97 524
which C 98 524
characterize C 99 524
passive C 100 524
congestion C 101 524
of C 102 524
the C 103 524
lungs C 104 524
resulting C 105 524
from C 106 524
left C 107 524
ventricular C 108 524
insufficiency C 109 524
. C 110 524
atrophy C 112 524
of C 113 524
lymphoid C 114 524
centers C 115 524
in C 116 524
the C 117 524
spleen C 118 524
and C 119 524
lymph C 120 524
nodes C 121 524
was C 122 524
common C 123 524
. C 124 524
degenerative C 126 524
changes C 127 524
were C 128 524
occasionally C 129 524
found C 130 524
in C 131 524
liver C 132 524
, C 133 524
kidneys C 134 524
, C 135 524
and C 136 524
gastrointestinal C 137 524
tract C 138 524
. C 139 524
1143 C 1 525
. C 2 525
sodium C 4 525
selenate C 5 525
toxicosis C 6 525
the C 7 525
distribution C 8 525
of C 9 525
selenium C 10 525
within C 11 525
the C 12 525
body C 13 525
after C 14 525
prolonged C 15 525
feeding C 16 525
of C 17 525
toxic C 18 525
quantities C 19 525
of C 20 525
sodium C 21 525
selenate C 22 525
to C 23 525
sheep C 24 525
the C 25 525
distribution C 26 525
of C 27 525
selenium C 28 525
in C 29 525
the C 30 525
body C 31 525
tissues C 32 525
of C 33 525
adult C 34 525
sheep C 35 525
fed C 36 525
subtoxic C 37 525
to C 38 525
toxic C 39 525
quantities C 40 525
of C 41 525
sodium C 42 525
selenate C 43 525
daily C 44 525
for C 45 525
1 C 46 525
to C 47 525
5 C 48 525
mth C 49 525
. C 50 525
varied C 52 525
with C 53 525
the C 54 525
tissue C 55 525
type C 56 525
and C 57 525
with C 58 525
the C 59 525
level C 60 525
and C 61 525
duration C 62 525
of C 63 525
selenium C 64 525
consumption C 65 525
. C 66 525
selenium C 68 525
concentration C 69 525
was C 70 525
highest C 71 525
in C 72 525
the C 73 525
liver C 74 525
, C 75 525
followed C 76 525
by C 77 525
( C 78 525
in C 79 525
descending C 80 525
order C 81 525
) C 82 525
the C 83 525
kidneys C 84 525
, C 85 525
lungs C 86 525
, C 87 525
spleen C 88 525
, C 89 525
myocardium C 90 525
, C 91 525
skeletal C 92 525
muscles C 93 525
, C 94 525
and C 95 525
brain C 96 525
. C 97 525
1172 C 1 526
. C 2 526
studies C 4 526
on C 5 526
selenium C 6 526
toxicity C 7 526
and C 8 526
chondroitin C 9 526
sulfate C 10 526
and C 11 526
taurine C 12 526
biosynthesis C 13 526
in C 14 526
the C 15 526
chick C 16 526
embryo C 17 526
fourteen C 18 526
- C 19 526
day C 20 526
- C 21 526
old C 22 526
chick C 23 526
embryos C 24 526
were C 25 526
used C 26 526
in C 27 526
in C 28 526
vivo C 29 526
experiments C 30 526
. C 31 526
a C 33 526
toxic C 34 526
selenite C 35 526
treatment C 36 526
did C 37 526
not C 38 526
cause C 39 526
a C 40 526
reduction C 41 526
in C 42 526
the C 43 526
extent C 44 526
of C 45 526
sulfate C 46 526
- C 47 526
s C 48 526
incorporation C 49 526
into C 50 526
chondroitin C 51 526
sulfate C 52 526
or C 53 526
into C 54 526
taurine C 55 526
or C 56 526
a C 57 526
reduction C 58 526
in C 59 526
the C 60 526
observed C 61 526
tissue C 62 526
levels C 63 526
of C 64 526
these C 65 526
metabolites C 66 526
. C 67 526
rather C 69 526
, C 70 526
the C 71 526
taurine C 72 526
level C 73 526
was C 74 526
significantly C 75 526
greater C 76 526
with C 77 526
the C 78 526
embryos C 79 526
which C 80 526
received C 81 526
selenium C 82 526
. C 83 526
the C 85 526
extent C 86 526
of C 87 526
the C 88 526
incorporation C 89 526
of C 90 526
selenite C 91 526
- C 92 526
se C 93 526
into C 94 526
the C 95 526
metabolites C 96 526
was C 97 526
low C 98 526
or C 99 526
not C 100 526
significant C 101 526
. C 102 526
843 C 1 527
. C 2 527
reactions C 4 527
of C 5 527
seleno C 6 527
- C 7 527
and C 8 527
sulfoamino C 9 527
acids C 10 527
with C 11 527
hydroperoxides C 12 527
reactions C 13 527
of C 14 527
methionine C 15 527
, C 16 527
cystine C 17 527
and C 18 527
their C 19 527
selenium C 20 527
analogues C 21 527
with C 22 527
hydrogen C 23 527
peroxide C 24 527
and C 25 527
organic C 26 527
peroxides C 27 527
have C 28 527
been C 29 527
studied C 30 527
. C 31 527
methionine C 33 527
reacts C 34 527
most C 35 527
rapidly C 36 527
with C 37 527
hydrogen C 38 527
peroxide C 39 527
but C 40 527
selenocystine C 41 527
causes C 42 527
the C 43 527
most C 44 527
decomposition C 45 527
; C 46 527
both C 47 527
react C 48 527
much C 49 527
more C 50 527
slowly C 51 527
with C 52 527
organic C 53 527
peroxides C 54 527
. C 55 527
the C 57 527
results C 58 527
suggest C 59 527
that C 60 527
selenocystine C 61 527
may C 62 527
act C 63 527
as C 64 527
a C 65 527
biological C 66 527
antioxidant C 67 527
. C 68 527
2127 C 1 528
. C 2 528
selenium C 4 528
toxicity C 5 528
in C 6 528
domestic C 7 528
animals C 8 528
the C 9 528
article C 10 528
, C 11 528
with C 12 528
an C 13 528
extensive C 14 528
bibliography C 15 528
, C 16 528
is C 17 528
a C 18 528
compendium C 19 528
of C 20 528
available C 21 528
information C 22 528
on C 23 528
selenium C 24 528
toxicity C 25 528
in C 26 528
domestic C 27 528
animals C 28 528
. C 29 528
literature C 31 528
reveals C 32 528
evidence C 33 528
of C 34 528
organically C 35 528
bound C 36 528
se C 37 528
being C 38 528
more C 39 528
biologically C 40 528
active C 41 528
, C 42 528
when C 43 528
given C 44 528
orally C 45 528
to C 46 528
domestic C 47 528
animals C 48 528
, C 49 528
than C 50 528
inorganic C 51 528
se C 52 528
salts C 53 528
. C 54 528
there C 56 528
is C 57 528
also C 58 528
variation C 59 528
in C 60 528
toxicity C 61 528
of C 62 528
organic C 63 528
se C 64 528
analogs C 65 528
. C 66 528
when C 68 528
exposed C 69 528
to C 70 528
ruminal C 71 528
digestion C 72 528
, C 73 528
there C 74 528
is C 75 528
considerable C 76 528
reduction C 77 528
of C 78 528
se C 79 528
salts C 80 528
to C 81 528
the C 82 528
relatively C 83 528
biologically C 84 528
inactive C 85 528
elemental C 86 528
se C 87 528
; C 88 528
which C 89 528
may C 90 528
result C 91 528
in C 92 528
fecal C 93 528
excretion C 94 528
of C 95 528
se C 96 528
, C 97 528
as C 98 528
such C 99 528
, C 100 528
to C 101 528
as C 102 528
much C 103 528
as C 104 528
40 C 105 528
% C 106 528
of C 107 528
a C 108 528
single C 109 528
oral C 110 528
dose C 111 528
. C 112 528
fluorine C 114 528
, C 115 528
molybdenum C 116 528
, C 117 528
chromium C 118 528
, C 119 528
vanadium C 120 528
, C 121 528
cadmium C 122 528
, C 123 528
zinc C 124 528
, C 125 528
cobalt C 126 528
, C 127 528
nickel C 128 528
and C 129 528
uranium C 130 528
increase C 131 528
se C 132 528
toxicity C 133 528
. C 134 528
arsenic C 136 528
and C 137 528
tungsten C 138 528
give C 139 528
some C 140 528
protection C 141 528
against C 142 528
it C 143 528
. C 144 528
bromobenzene C 146 528
, C 147 528
benzene C 148 528
, C 149 528
and C 150 528
napthalene C 151 528
mobilize C 152 528
tissue C 153 528
se C 154 528
and C 155 528
stimulate C 156 528
its C 157 528
excretion C 158 528
. C 159 528
since C 161 528
se C 162 528
preparations C 163 528
designed C 164 528
for C 165 528
topical C 166 528
application C 167 528
in C 168 528
treatment C 169 528
of C 170 528
skin C 171 528
disease C 172 528
have C 173 528
been C 174 528
available C 175 528
for C 176 528
use C 177 528
in C 178 528
both C 179 528
man C 180 528
and C 181 528
dogs C 182 528
, C 183 528
the C 184 528
literature C 185 528
has C 186 528
reported C 187 528
cases C 188 528
of C 189 528
poisoning C 190 528
from C 191 528
misuse C 192 528
of C 193 528
such C 194 528
preparations C 195 528
. C 196 528
selenium C 198 528
, C 199 528
properly C 200 528
used C 201 528
, C 202 528
can C 203 528
be C 204 528
a C 205 528
valuable C 206 528
therapeutic C 207 528
agent C 208 528
, C 209 528
though C 210 528
certain C 211 528
salts C 212 528
of C 213 528
se C 214 528
must C 215 528
be C 216 528
regarded C 217 528
as C 218 528
potentially C 219 528
toxic C 220 528
. C 221 528
however C 223 528
, C 224 528
there C 225 528
is C 226 528
considerable C 227 528
latitude C 228 528
between C 229 528
therapeutic C 230 528
and C 231 528
/ C 232 528
or C 233 528
nutritional C 234 528
and C 235 528
toxic C 236 528
doses C 237 528
of C 238 528
these C 239 528
salts C 240 528
. C 241 528
1845 C 1 529
. C 2 529
further C 4 529
studies C 5 529
on C 6 529
specific C 7 529
transplantation C 8 529
antigens C 9 529
in C 10 529
rous C 11 529
sarcoma C 12 529
of C 13 529
mice C 14 529
mice C 15 529
allografted C 16 529
with C 17 529
different C 18 529
sarcomas C 19 529
, C 20 529
induced C 21 529
by C 22 529
the C 23 529
schmidt C 24 529
- C 25 529
ruppin C 26 529
variant C 27 529
of C 28 529
rous C 29 529
sarcoma C 30 529
virus C 31 529
( C 32 529
rsv C 33 529
- C 34 529
sr C 35 529
) C 36 529
, C 37 529
showed C 38 529
a C 39 529
resistance C 40 529
against C 41 529
subsequent C 42 529
isografting C 43 529
of C 44 529
9 C 45 529
different C 46 529
rous C 47 529
sarcomas C 48 529
. C 49 529
transplantation C 51 529
resistance C 52 529
could C 53 529
also C 54 529
be C 55 529
induced C 56 529
by C 57 529
rous C 58 529
mouse C 59 529
tumor C 60 529
cells C 61 529
x C 62 529
- C 63 529
irradiated C 64 529
with C 65 529
8000 C 66 529
r C 67 529
or C 68 529
with C 69 529
cell C 70 529
- C 71 529
free C 72 529
tumor C 73 529
extracts C 74 529
, C 75 529
containing C 76 529
no C 77 529
demonstrable C 78 529
virus C 79 529
. C 80 529
no C 82 529
transplantation C 83 529
resistance C 84 529
could C 85 529
be C 86 529
demon C 87 529
- C 88 529
strated C 89 529
after C 90 529
allograft C 91 529
pretreatment C 92 529
with C 93 529
various C 94 529
polyoma C 95 529
tumors C 96 529
or C 97 529
non C 98 529
- C 99 529
viral C 100 529
tu C 101 529
- C 102 529
mors C 103 529
. C 104 529
allograft C 106 529
pretreatment C 107 529
with C 108 529
rous C 109 529
tumors C 110 529
induced C 111 529
no C 112 529
demonstrable C 113 529
resistance C 114 529
against C 115 529
isografting C 116 529
of C 117 529
polyoma C 118 529
tumors C 119 529
. C 120 529
inoculation C 122 529
of C 123 529
rsv C 124 529
- C 125 529
sr C 126 529
or C 127 529
rous C 128 529
chicken C 129 529
sar C 130 529
- C 131 529
coma C 132 529
suspension C 133 529
into C 134 529
adult C 135 529
mice C 136 529
gave C 137 529
no C 138 529
clear C 139 529
cut C 140 529
resistance C 141 529
against C 142 529
isograft C 143 529
- C 144 529
ing C 145 529
of C 146 529
mouse C 147 529
sarcomas C 148 529
. C 149 529
neither C 151 529
after C 152 529
allografting C 153 529
of C 154 529
rous C 155 529
tumors C 156 529
nor C 157 529
after C 158 529
virus C 159 529
or C 160 529
chicken C 161 529
sarcoma C 162 529
inoculation C 163 529
into C 164 529
adult C 165 529
mice C 166 529
could C 167 529
virus C 168 529
- C 169 529
neutralizing C 170 529
activity C 171 529
be C 172 529
demonstrated C 173 529
in C 174 529
the C 175 529
sera C 176 529
. C 177 529
the C 179 529
results C 180 529
demonstrate C 181 529
the C 182 529
presence C 183 529
of C 184 529
common C 185 529
, C 186 529
speci C 187 529
- C 188 529
fic C 189 529
transplantation C 190 529
antigen C 191 529
( C 192 529
s C 193 529
) C 194 529
in C 195 529
different C 196 529
rous C 197 529
sarcomas C 198 529
in C 199 529
mice C 200 529
and C 201 529
speak C 202 529
against C 203 529
an C 204 529
identity C 205 529
between C 206 529
the C 207 529
transplantation C 208 529
antigen C 209 529
( C 210 529
s C 211 529
) C 212 529
and C 213 529
viral C 214 529
antigen C 215 529
( C 216 529
s C 217 529
) C 218 529
. C 219 529
1846 C 1 530
. C 2 530
anaphylactic C 4 530
tests C 5 530
in C 6 530
model C 7 530
tumour C 8 530
antigen C 9 530
investigations C 10 530
the C 11 530
efficacy C 12 530
of C 13 530
anaphylactic C 14 530
tests C 15 530
in C 16 530
detecting C 17 530
' C 18 530
tumor C 19 530
' C 20 530
antigen C 21 530
in C 22 530
serum C 23 530
was C 24 530
investi C 25 530
- C 26 530
gated C 27 530
. C 28 530
a C 30 530
simple C 31 530
model C 32 530
of C 33 530
a C 34 530
tumor C 35 530
- C 36 530
antigen C 37 530
study C 38 530
was C 39 530
carried C 40 530
out C 41 530
using C 42 530
rat C 43 530
tissue C 44 530
and C 45 530
rat C 46 530
serum C 47 530
, C 48 530
with C 49 530
bovine C 50 530
y C 51 530
- C 52 530
globulin C 53 530
( C 54 530
byg C 55 530
) C 56 530
acting C 57 530
as C 58 530
a C 59 530
mock C 60 530
cancer C 61 530
antigen C 62 530
. C 63 530
it C 65 530
was C 66 530
found C 67 530
that C 68 530
if C 69 530
byg C 70 530
( C 71 530
absolute C 72 530
dosage C 73 530
100 C 74 530
ug C 75 530
. C 76 530
) C 78 530
had C 79 530
formed C 80 530
1 C 81 530
/ C 82 530
6 C 83 530
of C 84 530
the C 85 530
antigen C 86 530
mix C 87 530
- C 88 530
ture C 89 530
used C 90 530
for C 91 530
sensitization C 92 530
it C 93 530
was C 94 530
readily C 95 530
detected C 96 530
when C 97 530
present C 98 530
in C 99 530
a C 100 530
concentration C 101 530
of C 102 530
10 C 103 530
- C 104 530
3 C 105 530
in C 106 530
the C 107 530
serum C 108 530
used C 109 530
for C 110 530
challenge C 111 530
, C 112 530
but C 113 530
not C 114 530
invariably C 115 530
detected C 116 530
in C 117 530
a C 118 530
concentra C 119 530
- C 120 530
tion C 121 530
of C 122 530
10 C 123 530
- C 124 530
4 C 125 530
. C 126 530
if C 128 530
byg C 129 530
( C 130 530
absolute C 131 530
dosage C 132 530
50 C 133 530
ug C 134 530
. C 135 530
) C 137 530
had C 138 530
formed C 139 530
approximately C 140 530
1 C 141 530
/ C 142 530
50 C 143 530
of C 144 530
the C 145 530
sensitizing C 146 530
mixture C 147 530
, C 148 530
it C 149 530
was C 150 530
infrequently C 151 530
detected C 152 530
even C 153 530
when C 154 530
present C 155 530
in C 156 530
the C 157 530
challeng C 158 530
- C 159 530
ing C 160 530
serum C 161 530
in C 162 530
a C 163 530
concentration C 164 530
of C 165 530
10 C 166 530
- C 167 530
2 C 168 530
. C 169 530
it C 171 530
is C 172 530
concluded C 173 530
that C 174 530
anaphylactic C 175 530
tests C 176 530
used C 177 530
in C 178 530
this C 179 530
context C 180 530
do C 181 530
not C 182 530
have C 183 530
a C 184 530
very C 185 530
high C 186 530
sensitivity C 187 530
or C 188 530
discriminatory C 189 530
capacity C 190 530
. C 191 530
1066 C 1 531
. C 2 531
the C 4 531
effect C 5 531
of C 6 531
lymphoid C 7 531
cells C 8 531
from C 9 531
the C 10 531
lymph C 11 531
of C 12 531
specifically C 13 531
immunised C 14 531
sheep C 15 531
on C 16 531
the C 17 531
growth C 18 531
of C 19 531
primary C 20 531
sarcomata C 21 531
in C 22 531
rats C 23 531
the C 24 531
growth C 25 531
of C 26 531
primary C 27 531
fibrosarcomata C 28 531
induced C 29 531
in C 30 531
rats C 31 531
with C 32 531
3 C 33 531
: C 34 531
4 C 35 531
- C 36 531
benzpyrene C 37 531
was C 38 531
retarded C 39 531
by C 40 531
the C 41 531
injection C 42 531
of C 43 531
lymphocytes C 44 531
obtained C 45 531
from C 46 531
the C 47 531
efferent C 48 531
duct C 49 531
of C 50 531
a C 51 531
lymph C 52 531
node C 53 531
in C 54 531
a C 55 531
sheep C 56 531
immunized C 57 531
with C 58 531
a C 59 531
piece C 60 531
of C 61 531
the C 62 531
tumor C 63 531
to C 64 531
be C 65 531
treated C 66 531
. C 67 531
the C 69 531
action C 70 531
of C 71 531
the C 72 531
heterologous C 73 531
lym C 74 531
- C 75 531
phocytes C 76 531
was C 77 531
specific C 78 531
to C 79 531
the C 80 531
particular C 81 531
tumor C 82 531
used C 83 531
for C 84 531
immunization C 85 531
suggesting C 86 531
that C 87 531
reaction C 88 531
against C 89 531
tumor C 90 531
- C 91 531
specific C 92 531
antigens C 93 531
is C 94 531
involved C 95 531
. C 96 531
the C 98 531
cells C 99 531
responsible C 100 531
are C 101 531
believed C 102 531
to C 103 531
be C 104 531
medium C 105 531
- C 106 531
sized C 107 531
pyroninophilic C 108 531
lymphocytes C 109 531
which C 110 531
may C 111 531
stimulate C 112 531
the C 113 531
immune C 114 531
system C 115 531
of C 116 531
the C 117 531
host C 118 531
to C 119 531
react C 120 531
against C 121 531
the C 122 531
autochthonous C 123 531
tumor C 124 531
. C 125 531
2570 C 1 532
. C 2 532
treatment C 4 532
of C 5 532
canine C 6 532
neoplasms C 7 532
with C 8 532
autogenous C 9 532
vaccinial C 10 532
preparations C 11 532
inbred C 12 532
mice C 13 532
with C 14 532
transplantable C 15 532
sarcoma C 16 532
and C 17 532
carcinoma C 18 532
were C 19 532
treated C 20 532
with C 21 532
im C 22 532
- C 23 532
plants C 24 532
of C 25 532
their C 26 532
tumours C 27 532
which C 28 532
had C 29 532
been C 30 532
grown C 31 532
in C 32 532
strains C 33 532
of C 34 532
mice C 35 532
normally C 36 532
resistant C 37 532
to C 38 532
the C 39 532
tumours C 40 532
. C 41 532
complete C 43 532
regression C 44 532
of C 45 532
transplantable C 46 532
tumours C 47 532
was C 48 532
noted C 49 532
in C 50 532
22 C 51 532
% C 52 532
of C 53 532
the C 54 532
treated C 55 532
mice C 56 532
and C 57 532
78 C 58 532
% C 59 532
had C 60 532
life C 61 532
spans C 62 532
double C 63 532
that C 64 532
of C 65 532
untreated C 66 532
controls C 67 532
. C 68 532
one C 70 532
dog C 71 532
with C 72 532
spontaneous C 73 532
scirrhous C 74 532
mammary C 75 532
carcinoma C 76 532
and C 77 532
another C 78 532
with C 79 532
lymphosarcoma C 80 532
were C 81 532
treated C 82 532
with C 83 532
implants C 84 532
of C 85 532
their C 86 532
own C 87 532
tumours C 88 532
after C 89 532
growth C 90 532
in C 91 532
cortisone C 92 532
- C 93 532
treated C 94 532
mice C 95 532
. C 96 532
regression C 98 532
of C 99 532
the C 100 532
spontaneous C 101 532
neoplasms C 102 532
followed C 103 532
in C 104 532
both C 105 532
cases C 106 532
. C 107 532
it C 109 532
is C 110 532
suggested C 111 532
that C 112 532
growth C 113 532
of C 114 532
a C 115 532
neoplasm C 116 532
in C 117 532
a C 118 532
foreign C 119 532
host C 120 532
alters C 121 532
the C 122 532
mole C 123 532
- C 124 532
cular C 125 532
structure C 126 532
of C 127 532
the C 128 532
neoplasm C 129 532
, C 130 532
making C 131 532
it C 132 532
antigenic C 133 532
when C 134 532
returned C 135 532
to C 136 532
the C 137 532
original C 138 532
host C 139 532
. C 140 532
antigens C 142 532
produced C 143 532
are C 144 532
also C 145 532
effective C 146 532
against C 147 532
the C 148 532
original C 149 532
lesions C 150 532
. C 151 532
744 C 1 533
. C 2 533
studies C 4 533
on C 5 533
protein C 6 533
and C 7 533
nucleic C 8 533
acid C 9 533
metabolism C 10 533
in C 11 533
virus C 12 533
- C 13 533
in C 14 533
- C 15 533
fected C 16 533
mammalian C 17 533
cells C 18 533
. C 19 533
the C 21 533
formation C 22 533
of C 23 533
a C 24 533
virus C 25 533
- C 26 533
specific C 27 533
antigen C 28 533
in C 29 533
krebs C 30 533
ii C 31 533
ascites C 32 533
- C 33 533
tumour C 34 533
cells C 35 533
infected C 36 533
with C 37 533
ence C 38 533
- C 39 533
phalomyocarditis C 40 533
virus C 41 533
krebs C 42 533
ii C 43 533
mouse C 44 533
ascites C 45 533
- C 46 533
tumor C 47 533
cells C 48 533
infected C 49 533
with C 50 533
encephalomyocarditis C 51 533
virus C 52 533
were C 53 533
found C 54 533
to C 55 533
contain C 56 533
, C 57 533
in C 58 533
addition C 59 533
to C 60 533
mature C 61 533
virus C 62 533
, C 63 533
a C 64 533
virus C 65 533
- C 66 533
specific C 67 533
protein C 68 533
antigen C 69 533
. C 70 533
an C 72 533
assay C 73 533
, C 74 533
based C 75 533
on C 76 533
the C 77 533
ability C 78 533
of C 79 533
this C 80 533
antigen C 81 533
to C 82 533
block C 83 533
the C 84 533
neutralization C 85 533
of C 86 533
purified C 87 533
virus C 88 533
by C 89 533
its C 90 533
specific C 91 533
antiserum C 92 533
, C 93 533
was C 94 533
developed C 95 533
. C 96 533
this C 98 533
antigen C 99 533
was C 100 533
present C 101 533
both C 102 533
in C 103 533
the C 104 533
cul C 105 533
- C 106 533
ture C 107 533
fluid C 108 533
17 C 109 533
hr C 110 533
. C 111 533
after C 113 533
the C 114 533
infection C 115 533
of C 116 533
cells C 117 533
with C 118 533
virus C 119 533
and C 120 533
intracellularly C 121 533
, C 122 533
where C 123 533
its C 124 533
titer C 125 533
increased C 126 533
at C 127 533
a C 128 533
time C 129 533
when C 130 533
viral C 131 533
capsid C 132 533
protein C 133 533
was C 134 533
being C 135 533
synthesized C 136 533
. C 137 533
within C 139 533
the C 140 533
cell C 141 533
, C 142 533
it C 143 533
was C 144 533
mostly C 145 533
localized C 146 533
in C 147 533
the C 148 533
soluble C 149 533
cell C 150 533
sap C 151 533
. C 152 533
in C 154 533
contrast C 155 533
with C 156 533
virus C 157 533
, C 158 533
the C 159 533
anti C 160 533
- C 161 533
gen C 162 533
did C 163 533
not C 164 533
agglutinate C 165 533
sheep C 166 533
erythrocytes C 167 533
, C 168 533
and C 169 533
its C 170 533
immunological C 171 533
properties C 172 533
were C 173 533
destroyed C 174 533
by C 175 533
digestion C 176 533
with C 177 533
trypsin C 178 533
. C 179 533
ribonucleic C 181 533
acid C 182 533
was C 183 533
not C 184 533
detected C 185 533
in C 186 533
concentrat C 187 533
- C 188 533
ed C 189 533
preparations C 190 533
of C 191 533
the C 192 533
antigen C 193 533
, C 194 533
nor C 195 533
was C 196 533
the C 197 533
titer C 198 533
of C 199 533
antigen C 200 533
affected C 201 533
by C 202 533
ribonuclease C 203 533
. C 204 533
the C 206 533
antigen C 207 533
had C 208 533
a C 209 533
sedimentation C 210 533
coefficient C 211 533
( C 212 533
20 C 213 533
) C 214 533
of C 215 533
approx C 216 533
. C 217 533
14 C 219 533
s C 220 533
, C 221 533
and C 222 533
its C 223 533
diffusion C 224 533
co C 225 533
- C 226 533
efficient C 227 533
, C 228 533
determined C 229 533
by C 230 533
the C 231 533
method C 232 533
of C 233 533
allison C 234 533
and C 235 533
humphrey C 236 533
( C 237 533
1960 C 238 533
) C 239 533
, C 240 533
was C 241 533
3 C 242 533
. C 243 533
. C 244 533
x C 245 533
10 C 246 533
- C 247 533
7 C 248 533
sq C 249 533
. C 250 533
cm C 252 533
. C 253 533
sec C 255 533
. C 256 533
- C 258 533
1 C 259 533
. C 260 533
the C 262 533
particle C 263 533
weight C 264 533
of C 265 533
the C 266 533
antigen C 267 533
was C 268 533
hence C 269 533
420 C 270 533
, C 271 533
000 C 272 533
40 C 273 533
, C 274 533
000 C 275 533
. C 276 533
the C 278 533
capsid C 279 533
protein C 280 533
from C 281 533
purified C 282 533
encephalomyocarditis C 283 533
virus C 284 533
could C 285 533
be C 286 533
degraded C 287 533
by C 288 533
treat C 289 533
- C 290 533
ment C 291 533
with C 292 533
ethanolamine C 293 533
into C 294 533
a C 295 533
protein C 296 533
of C 297 533
sedimentation C 298 533
coefficient C 299 533
( C 300 533
20 C 301 533
) C 302 533
of C 303 533
approx C 304 533
. C 305 533
4 C 307 533
s C 308 533
. C 309 533
the C 311 533
14 C 312 533
s C 313 533
antigen C 314 533
, C 315 533
when C 316 533
similarly C 317 533
treated C 318 533
, C 319 533
yielded C 320 533
a C 321 533
protein C 322 533
of C 323 533
similar C 324 533
size C 325 533
. C 326 533
however C 328 533
, C 329 533
no C 330 533
such C 331 533
smaller C 332 533
antigen C 333 533
was C 334 533
detected C 335 533
in C 336 533
virus C 337 533
- C 338 533
infected C 339 533
cells C 340 533
. C 341 533
it C 343 533
is C 344 533
concluded C 345 533
that C 346 533
the C 347 533
non C 348 533
- C 349 533
hemagglutinating C 350 533
antigen C 351 533
represents C 352 533
a C 353 533
polymeric C 354 533
form C 355 533
of C 356 533
the C 357 533
basic C 358 533
viral C 359 533
capsid C 360 533
- C 361 533
protein C 362 533
molecule C 363 533
and C 364 533
that C 365 533
it C 366 533
is C 367 533
synthesized C 368 533
in C 369 533
the C 370 533
cytoplasm C 371 533
of C 372 533
infected C 373 533
cells C 374 533
. C 375 533
it C 377 533
may C 378 533
be C 379 533
either C 380 533
an C 381 533
intermediate C 382 533
or C 383 533
a C 384 533
by C 385 533
- C 386 533
product C 387 533
in C 388 533
the C 389 533
process C 390 533
of C 391 533
viral C 392 533
capsid C 393 533
- C 394 533
protein C 395 533
syn C 396 533
- C 397 533
thesis C 398 533
. C 399 533
1368 C 1 534
. C 2 534
immunologic C 4 534
competence C 5 534
and C 6 534
induction C 7 534
of C 8 534
neoplasms C 9 534
by C 10 534
polyoma C 11 534
virus C 12 534
thymectomy C 13 534
at C 14 534
3 C 15 534
days C 16 534
of C 17 534
age C 18 534
in C 19 534
several C 20 534
inbred C 21 534
strains C 22 534
of C 23 534
mice C 24 534
and C 25 534
in C 26 534
an C 27 534
f C 28 534
1 C 29 534
hybrid C 30 534
resulted C 31 534
in C 32 534
a C 33 534
strikingly C 34 534
increased C 35 534
frequency C 36 534
of C 37 534
neoplasms C 38 534
following C 39 534
infection C 40 534
with C 41 534
polyoma C 42 534
virus C 43 534
. C 44 534
age C 46 534
susceptibility C 47 534
was C 48 534
extended C 49 534
to C 50 534
at C 51 534
least C 52 534
30 C 53 534
days C 54 534
of C 55 534
age C 56 534
in C 57 534
highly C 58 534
resistant C 59 534
c C 60 534
57 C 61 534
bl C 62 534
mice C 63 534
. C 64 534
the C 66 534
usual C 67 534
stigmata C 68 534
associated C 69 534
with C 70 534
thymectomy C 71 534
at C 72 534
birth C 73 534
were C 74 534
not C 75 534
found C 76 534
in C 77 534
the C 78 534
3 C 79 534
- C 80 534
day C 81 534
thymectomized C 82 534
mice C 83 534
. C 84 534
nonetheless C 86 534
the C 87 534
methods C 88 534
used C 89 534
to C 90 534
restore C 91 534
immunologically C 92 534
deficient C 93 534
thymectomized C 94 534
neonates C 95 534
were C 96 534
also C 97 534
effective C 98 534
in C 99 534
restoring C 100 534
the C 101 534
capacity C 102 534
to C 103 534
resist C 104 534
polyoma C 105 534
virus C 106 534
tumor C 107 534
induction C 108 534
: C 109 534
adult C 110 534
syngeneic C 111 534
spleen C 112 534
cells C 113 534
, C 114 534
thymus C 115 534
tissue C 116 534
in C 117 534
millipore C 118 534
diffusion C 119 534
chambers C 120 534
and C 121 534
syngeneic C 122 534
thymus C 123 534
grafts C 124 534
. C 125 534
growth C 127 534
curves C 128 534
of C 129 534
polyoma C 130 534
virus C 131 534
in C 132 534
kidney C 133 534
, C 134 534
salivary C 135 534
glands C 136 534
and C 137 534
liver C 138 534
were C 139 534
quite C 140 534
similar C 141 534
in C 142 534
thymectomized C 143 534
and C 144 534
intact C 145 534
litter C 146 534
mates C 147 534
. C 148 534
hemagglutination C 150 534
- C 151 534
inhibition C 152 534
antibodies C 153 534
deter C 154 534
- C 155 534
mined C 156 534
periodically C 157 534
up C 158 534
to C 159 534
30 C 160 534
days C 161 534
after C 162 534
infection C 163 534
were C 164 534
also C 165 534
similar C 166 534
in C 167 534
both C 168 534
groups C 169 534
. C 170 534
these C 172 534
results C 173 534
are C 174 534
discussed C 175 534
in C 176 534
terms C 177 534
of C 178 534
a C 179 534
concept C 180 534
involving C 181 534
virus C 182 534
- C 183 534
specific C 184 534
' C 185 534
tumor C 186 534
' C 187 534
antigens C 188 534
and C 189 534
the C 190 534
immunologic C 191 534
status C 192 534
of C 193 534
the C 194 534
animal C 195 534
. C 196 534
1848 C 1 535
. C 2 535
antigen C 4 535
analysis C 5 535
of C 6 535
sera C 7 535
from C 8 535
patients C 9 535
with C 10 535
malignant C 11 535
tumors C 12 535
by C 13 535
immunodiffusion C 14 535
methods C 15 535
immunoelectrophoresis C 16 535
and C 17 535
ouchterlony C 18 535
' C 19 535
s C 20 535
method C 21 535
were C 22 535
used C 23 535
for C 24 535
the C 25 535
antigen C 26 535
analy C 27 535
- C 28 535
sis C 29 535
of C 30 535
sera C 31 535
from C 32 535
320 C 33 535
cancer C 34 535
patients C 35 535
; C 36 535
250 C 37 535
normal C 38 535
or C 39 535
non C 40 535
- C 41 535
tumorous C 42 535
cases C 43 535
served C 44 535
as C 45 535
controls C 46 535
. C 47 535
immunoelectrophoresis C 49 535
showed C 50 535
abnormal C 51 535
precipitin C 52 535
lines C 53 535
which C 54 535
could C 55 535
not C 56 535
be C 57 535
demonstrated C 58 535
in C 59 535
normal C 60 535
sera C 61 535
. C 62 535
most C 64 535
of C 65 535
the C 66 535
abnormal C 67 535
antigens C 68 535
were C 69 535
demonstrated C 70 535
in C 71 535
the C 72 535
a C 73 535
2 C 74 535
- C 75 535
and C 76 535
b C 77 535
1 C 78 535
- C 79 535
globulin C 80 535
fractions C 81 535
. C 82 535
the C 84 535
distribution C 85 535
of C 86 535
these C 87 535
antigens C 88 535
differed C 89 535
in C 90 535
individual C 91 535
cases C 92 535
and C 93 535
was C 94 535
not C 95 535
related C 96 535
to C 97 535
the C 98 535
histopathological C 99 535
classification C 100 535
and C 101 535
site C 102 535
of C 103 535
the C 104 535
tumors C 105 535
. C 106 535
however C 108 535
, C 109 535
these C 110 535
antigens C 111 535
increased C 112 535
in C 113 535
parallel C 114 535
with C 115 535
growth C 116 535
of C 117 535
the C 118 535
tumors C 119 535
and C 120 535
disappeared C 121 535
or C 122 535
markedly C 123 535
decreased C 124 535
after C 125 535
surgical C 126 535
removal C 127 535
of C 128 535
the C 129 535
tumor C 130 535
tissue C 131 535
. C 132 535
almost C 134 535
all C 135 535
sera C 136 535
of C 137 535
patients C 138 535
with C 139 535
myeloma C 140 535
, C 141 535
leukemia C 142 535
, C 143 535
and C 144 535
malignant C 145 535
lymph C 146 535
- C 147 535
oma C 148 535
formed C 149 535
one C 150 535
characteristic C 151 535
line C 152 535
in C 153 535
the C 154 535
b C 155 535
2 C 156 535
- C 157 535
globulin C 158 535
region C 159 535
and C 160 535
they C 161 535
could C 162 535
be C 163 535
dif C 164 535
- C 165 535
ferentiated C 166 535
from C 167 535
the C 168 535
patterns C 169 535
in C 170 535
cases C 171 535
of C 172 535
carcinoma C 173 535
. C 174 535
2354 C 1 536
. C 2 536
isoantigenic C 4 536
properties C 5 536
of C 6 536
tumors C 7 536
transgressing C 8 536
histocompatibility C 9 536
barriers C 10 536
of C 11 536
the C 12 536
h C 13 536
- C 14 536
2 C 15 536
system C 16 536
sublines C 17 536
capable C 18 536
of C 19 536
transgressing C 20 536
h C 21 536
- C 22 536
2 C 23 536
histocompatibility C 24 536
barriers C 25 536
have C 26 536
been C 27 536
derived C 28 536
from C 29 536
strictly C 30 536
strain C 31 536
- C 32 536
specific C 33 536
tumors C 34 536
by C 35 536
1 C 36 536
) C 37 536
passage C 38 536
through C 39 536
newborn C 40 536
hosts C 41 536
of C 42 536
a C 43 536
foreign C 44 536
genotype C 45 536
; C 46 536
2 C 47 536
) C 48 536
passage C 49 536
through C 50 536
adult C 51 536
h C 52 536
- C 53 536
2 C 54 536
incompatible C 55 536
recipients C 56 536
pretreated C 57 536
with C 58 536
isoantisera C 59 536
directed C 60 536
against C 61 536
the C 62 536
tumor C 63 536
cells C 64 536
. C 65 536
the C 67 536
nonspecific C 68 536
character C 69 536
induced C 70 536
by C 71 536
these C 72 536
procedures C 73 536
was C 74 536
usually C 75 536
expressed C 76 536
in C 77 536
a C 78 536
number C 79 536
of C 80 536
different C 81 536
h C 82 536
- C 83 536
2 C 84 536
incompa C 85 536
- C 86 536
tible C 87 536
recipients C 88 536
. C 89 536
the C 91 536
changes C 92 536
responsible C 93 536
for C 94 536
the C 95 536
conversion C 96 536
to C 97 536
nonspecific C 98 536
growth C 99 536
appeared C 100 536
to C 101 536
proceed C 102 536
in C 103 536
a C 104 536
stepwise C 105 536
fashion C 106 536
. C 107 536
expression C 109 536
of C 110 536
the C 111 536
nonspecific C 112 536
character C 113 536
required C 114 536
exposure C 115 536
to C 116 536
the C 117 536
foreign C 118 536
host C 119 536
environment C 120 536
for C 121 536
more C 122 536
than C 123 536
30 C 124 536
days C 125 536
. C 126 536
at C 128 536
this C 129 536
stage C 130 536
and C 131 536
during C 132 536
the C 133 536
subsequent C 134 536
3 C 135 536
transfer C 136 536
generations C 137 536
, C 138 536
reversion C 139 536
to C 140 536
strain C 141 536
- C 142 536
specific C 143 536
growth C 144 536
occurred C 145 536
on C 146 536
back C 147 536
- C 148 536
transfer C 149 536
to C 150 536
the C 151 536
strain C 152 536
of C 153 536
origin C 154 536
; C 155 536
after C 156 536
4 C 157 536
passages C 158 536
in C 159 536
the C 160 536
foreign C 161 536
hosts C 162 536
the C 163 536
nonspecific C 164 536
character C 165 536
was C 166 536
permanently C 167 536
established C 168 536
, C 169 536
however C 170 536
, C 171 536
and C 172 536
could C 173 536
not C 174 536
be C 175 536
reverted C 176 536
by C 177 536
prolonged C 178 536
passage C 179 536
in C 180 536
the C 181 536
original C 182 536
host C 183 536
genotype C 184 536
. C 185 536
the C 187 536
growth C 188 536
rate C 189 536
of C 190 536
strain C 191 536
- C 192 536
specific C 193 536
tumors C 194 536
and C 195 536
their C 196 536
nonspecific C 197 536
sublines C 198 536
was C 199 536
compared C 200 536
in C 201 536
the C 202 536
strain C 203 536
of C 204 536
origin C 205 536
. C 206 536
no C 208 536
difference C 209 536
was C 210 536
found C 211 536
with C 212 536
one C 213 536
tumor C 214 536
, C 215 536
while C 216 536
the C 217 536
strain C 218 536
- C 219 536
specific C 220 536
line C 221 536
grew C 222 536
better C 223 536
than C 224 536
the C 225 536
nonspecific C 226 536
sublines C 227 536
with C 228 536
another C 229 536
. C 230 536
this C 232 536
difference C 233 536
was C 234 536
detected C 235 536
in C 236 536
the C 237 536
homozygous C 238 536
strain C 239 536
of C 240 536
origin C 241 536
and C 242 536
in C 243 536
different C 244 536
semi C 245 536
- C 246 536
isologous C 247 536
f C 248 536
1 C 249 536
hybrids C 250 536
. C 251 536
all C 253 536
lines C 254 536
grew C 255 536
better C 256 536
in C 257 536
the C 258 536
homozygous C 259 536
strain C 260 536
than C 261 536
in C 262 536
the C 263 536
f C 264 536
1 C 265 536
hybrids C 266 536
, C 267 536
however C 268 536
. C 269 536
a C 271 536
comparison C 272 536
was C 273 536
made C 274 536
between C 275 536
the C 276 536
concentration C 277 536
of C 278 536
h C 279 536
- C 280 536
2 C 281 536
isoantigenic C 282 536
surface C 283 536
determinants C 284 536
in C 285 536
strain C 286 536
- C 287 536
specific C 288 536
tumors C 289 536
and C 290 536
their C 291 536
nonspecific C 292 536
sublines C 293 536
by C 294 536
a C 295 536
quantitative C 296 536
absorption C 297 536
technique C 298 536
in C 299 536
vitro C 300 536
. C 301 536
all C 303 536
nonspecific C 304 536
sublines C 305 536
had C 306 536
a C 307 536
lower C 308 536
concentration C 309 536
of C 310 536
h C 311 536
- C 312 536
2 C 313 536
isoantigens C 314 536
than C 315 536
the C 316 536
strain C 317 536
- C 318 536
specific C 319 536
tumors C 320 536
. C 321 536
this C 323 536
suggests C 324 536
that C 325 536
nonspecific C 326 536
tumors C 327 536
develop C 328 536
as C 329 536
a C 330 536
result C 331 536
of C 332 536
immunoselection C 333 536
of C 334 536
variants C 335 536
resistant C 336 536
to C 337 536
the C 338 536
homograft C 339 536
reaction C 340 536
and C 341 536
are C 342 536
characterized C 343 536
by C 344 536
a C 345 536
lowered C 346 536
concentration C 347 536
of C 348 536
h C 349 536
- C 350 536
2 C 351 536
antigens C 352 536
. C 353 536
2371 C 1 537
. C 2 537
participation C 4 537
of C 5 537
7 C 6 537
s C 7 537
and C 8 537
19 C 9 537
s C 10 537
antibodies C 11 537
in C 12 537
enhancement C 13 537
and C 14 537
resistance C 15 537
to C 16 537
methylcholanthrene C 17 537
- C 18 537
induced C 19 537
tumours C 20 537
serum C 21 537
factors C 22 537
responsible C 23 537
for C 24 537
enhancement C 25 537
and C 26 537
resistance C 27 537
to C 28 537
methylcholanthrene C 29 537
- C 30 537
induced C 31 537
tumors C 32 537
in C 33 537
a C 34 537
syngeneic C 35 537
system C 36 537
in C 37 537
mice C 38 537
were C 39 537
studied C 40 537
. C 41 537
they C 43 537
were C 44 537
found C 45 537
to C 46 537
be C 47 537
part C 48 537
of C 49 537
the C 50 537
serum C 51 537
immunoglobulin C 52 537
system C 53 537
. C 54 537
the C 56 537
active C 57 537
components C 58 537
of C 59 537
specific C 60 537
anti C 61 537
- C 62 537
tumor C 63 537
serum C 64 537
were C 65 537
always C 66 537
contained C 67 537
in C 68 537
the C 69 537
7 C 70 537
s C 71 537
( C 72 537
y C 73 537
- C 74 537
2 C 75 537
) C 76 537
and C 77 537
19 C 78 537
s C 79 537
( C 80 537
y C 81 537
- C 82 537
1 C 83 537
m C 84 537
) C 85 537
fraction C 86 537
, C 87 537
while C 88 537
no C 89 537
activity C 90 537
was C 91 537
detected C 92 537
in C 93 537
the C 94 537
4 C 95 537
s C 96 537
fraction C 97 537
. C 98 537
in C 100 537
sera C 101 537
which C 102 537
in C 103 537
the C 104 537
given C 105 537
dose C 106 537
enhanced C 107 537
growth C 108 537
of C 109 537
the C 110 537
tumor C 111 537
graft C 112 537
, C 113 537
enhancing C 114 537
activity C 115 537
was C 116 537
present C 117 537
in C 118 537
both C 119 537
the C 120 537
7 C 121 537
s C 122 537
and C 123 537
19 C 124 537
s C 125 537
fraction C 126 537
of C 127 537
the C 128 537
serum C 129 537
and C 130 537
was C 131 537
higher C 132 537
in C 133 537
the C 134 537
former C 135 537
. C 136 537
in C 138 537
sera C 139 537
which C 140 537
in C 141 537
the C 142 537
given C 143 537
dose C 144 537
influenced C 145 537
the C 146 537
interaction C 147 537
of C 148 537
the C 149 537
organism C 150 537
with C 151 537
the C 152 537
tumor C 153 537
by C 154 537
producing C 155 537
resistance C 156 537
to C 157 537
the C 158 537
tumor C 159 537
graft C 160 537
, C 161 537
both C 162 537
fractions C 163 537
were C 164 537
again C 165 537
active C 166 537
, C 167 537
the C 168 537
activity C 169 537
of C 170 537
fraction C 171 537
19 C 172 537
s C 173 537
being C 174 537
higher C 175 537
than C 176 537
that C 177 537
of C 178 537
fraction C 179 537
7 C 180 537
s C 181 537
. C 182 537
2372 C 1 538
. C 2 538
the C 4 538
effect C 5 538
of C 6 538
immunity C 7 538
against C 8 538
sex C 9 538
- C 10 538
antigen C 11 538
on C 12 538
a C 13 538
tumour C 14 538
graft C 15 538
containing C 16 538
sex C 17 538
- C 18 538
antigen C 19 538
the C 20 538
tumor C 21 538
bp C 22 538
1 C 23 538
induced C 24 538
by C 25 538
benzpyrene C 26 538
in C 27 538
c C 28 538
57 C 29 538
bl C 30 538
male C 31 538
mice C 32 538
contains C 33 538
sex C 34 538
- C 35 538
antigen C 36 538
. C 37 538
sex C 39 538
- C 40 538
antigen C 41 538
is C 42 538
not C 43 538
lost C 44 538
during C 45 538
growth C 46 538
of C 47 538
tumor C 48 538
against C 49 538
immunity C 50 538
directed C 51 538
against C 52 538
this C 53 538
antigen C 54 538
. C 55 538
the C 57 538
tumor C 58 538
, C 59 538
however C 60 538
, C 61 538
becomes C 62 538
more C 63 538
resistant C 64 538
to C 65 538
immunity C 66 538
and C 67 538
the C 68 538
content C 69 538
of C 70 538
sex C 71 538
- C 72 538
antigen C 73 538
is C 74 538
decreased C 75 538
. C 76 538
2373 C 1 539
. C 2 539
factors C 4 539
influencing C 5 539
the C 6 539
induction C 7 539
of C 8 539
enhancement C 9 539
and C 10 539
re C 11 539
- C 12 539
sistance C 13 539
to C 14 539
methylcholanthrene C 15 539
- C 16 539
induced C 17 539
tumours C 18 539
in C 19 539
a C 20 539
syn C 21 539
- C 22 539
geneic C 23 539
system C 24 539
active C 25 539
immunological C 26 539
enhancement C 27 539
of C 28 539
the C 29 539
growth C 30 539
of C 31 539
methylcholanthrene C 32 539
- C 33 539
induced C 34 539
tu C 35 539
- C 36 539
mors C 37 539
was C 38 539
demonstrated C 39 539
in C 40 539
a C 41 539
syngeneic C 42 539
system C 43 539
in C 44 539
mice C 45 539
. C 46 539
enhancement C 48 539
was C 49 539
detected C 50 539
3 C 51 539
- C 52 539
5 C 53 539
wk C 54 539
. C 55 539
after C 57 539
preimmunization C 58 539
with C 59 539
irradiated C 60 539
tumor C 61 539
suspension C 62 539
and C 63 539
was C 64 539
succeeded C 65 539
after C 66 539
the C 67 539
6 C 68 539
th C 69 539
wk C 70 539
. C 71 539
by C 73 539
the C 74 539
development C 75 539
of C 76 539
resistance C 77 539
to C 78 539
the C 79 539
tumor C 80 539
. C 81 539
analysis C 83 539
by C 84 539
means C 85 539
of C 86 539
adoptive C 87 539
and C 88 539
passive C 89 539
transfer C 90 539
showed C 91 539
these C 92 539
to C 93 539
be C 94 539
true C 95 539
immunological C 96 539
phenomena C 97 539
. C 98 539
enhancement C 100 539
and C 101 539
resistance C 102 539
were C 103 539
transferred C 104 539
by C 105 539
serum C 106 539
and C 107 539
by C 108 539
the C 109 539
lymph C 110 539
node C 111 539
cells C 112 539
of C 113 539
preimmunized C 114 539
mice C 115 539
. C 116 539
threshold C 118 539
doses C 119 539
of C 120 539
tumor C 121 539
cells C 122 539
were C 123 539
found C 124 539
to C 125 539
be C 126 539
the C 127 539
most C 128 539
satisfactory C 129 539
for C 130 539
the C 131 539
detection C 132 539
of C 133 539
resistance C 134 539
and C 135 539
enhancement C 136 539
in C 137 539
this C 138 539
system C 139 539
. C 140 539
5512 C 1 540
. C 2 540
antigenic C 4 540
properties C 5 540
of C 6 540
human C 7 540
tumours C 8 540
preliminary C 9 540
studies C 10 540
on C 11 540
the C 12 540
antigenic C 13 540
properties C 14 540
of C 15 540
human C 16 540
tumours C 17 540
have C 18 540
been C 19 540
carried C 20 540
out C 21 540
using C 22 540
heterologous C 23 540
antisera C 24 540
, C 25 540
prepared C 26 540
in C 27 540
rabbits C 28 540
, C 29 540
against C 30 540
a C 31 540
number C 32 540
of C 33 540
different C 34 540
cancerous C 35 540
and C 36 540
normal C 37 540
tissues C 38 540
. C 39 540
after C 41 540
repeated C 42 540
absorptions C 43 540
, C 44 540
antisera C 45 540
were C 46 540
obtained C 47 540
which C 48 540
reacted C 49 540
only C 50 540
with C 51 540
tissue C 52 540
antigens C 53 540
. C 54 540
some C 56 540
antisera C 57 540
, C 58 540
after C 59 540
ab C 60 540
- C 61 540
sorption C 62 540
with C 63 540
normal C 64 540
tissues C 65 540
, C 66 540
reacted C 67 540
only C 68 540
with C 69 540
tumours C 70 540
. C 71 540
seventy C 73 540
- C 74 540
two C 75 540
tumour C 76 540
and C 77 540
31 C 78 540
normal C 79 540
tissue C 80 540
extracts C 81 540
were C 82 540
studied C 83 540
by C 84 540
means C 85 540
of C 86 540
the C 87 540
ouchterlony C 88 540
agar C 89 540
gel C 90 540
double C 91 540
diffusion C 92 540
technique C 93 540
. C 94 540
the C 96 540
results C 97 540
showed C 98 540
the C 99 540
presence C 100 540
of C 101 540
an C 102 540
antigen C 103 540
or C 104 540
antigens C 105 540
in C 106 540
some C 107 540
human C 108 540
malignant C 109 540
tumours C 110 540
which C 111 540
were C 112 540
not C 113 540
detectable C 114 540
in C 115 540
normal C 116 540
tissues C 117 540
, C 118 540
in C 119 540
foetal C 120 540
tissues C 121 540
, C 122 540
or C 123 540
in C 124 540
hela C 125 540
cells C 126 540
. C 127 540
in C 129 540
addition C 130 540
, C 131 540
there C 132 540
was C 133 540
some C 134 540
loss C 135 540
of C 136 540
normal C 137 540
tissue C 138 540
antigens C 139 540
from C 140 540
tumours C 141 540
. C 142 540
attempts C 144 540
are C 145 540
being C 146 540
made C 147 540
to C 148 540
isolate C 149 540
and C 150 540
characterize C 151 540
these C 152 540
tumour C 153 540
and C 154 540
normal C 155 540
tissue C 156 540
antigens C 157 540
. C 158 540
5514 C 1 541
. C 2 541
the C 4 541
incorporation C 5 541
of C 6 541
sv C 7 541
40 C 8 541
genetic C 9 541
material C 10 541
into C 11 541
adenovirus C 12 541
7 C 13 541
as C 14 541
measured C 15 541
by C 16 541
intranuclear C 17 541
synthesis C 18 541
of C 19 541
sv C 20 541
40 C 21 541
tumor C 22 541
antigen C 23 541
the C 24 541
l C 25 541
. C 26 541
. C 27 541
. C 28 541
strain C 30 541
of C 31 541
adenovirus C 32 541
7 C 33 541
, C 34 541
free C 35 541
of C 36 541
detectable C 37 541
infectious C 38 541
sv C 39 541
40 C 40 541
virus C 41 541
, C 42 541
induced C 43 541
sv C 44 541
40 C 45 541
tumour C 46 541
antigen C 47 541
, C 48 541
demonstrable C 49 541
by C 50 541
fluorescent C 51 541
antibody C 52 541
staining C 53 541
, C 54 541
in C 55 541
green C 56 541
mon C 57 541
- C 58 541
key C 59 541
kidney C 60 541
, C 61 541
rabbit C 62 541
kidney C 63 541
, C 64 541
hamster C 65 541
embryo C 66 541
and C 67 541
human C 68 541
embryo C 69 541
kidney C 70 541
cell C 71 541
cultures C 72 541
. C 73 541
in C 75 541
green C 76 541
monkey C 77 541
and C 78 541
human C 79 541
cell C 80 541
cultures C 81 541
there C 82 541
was C 83 541
a C 84 541
cytopathic C 85 541
effect C 86 541
and C 87 541
more C 88 541
cells C 89 541
contained C 90 541
the C 91 541
sv C 92 541
40 C 93 541
tumour C 94 541
antigen C 95 541
than C 96 541
in C 97 541
the C 98 541
other C 99 541
types C 100 541
of C 101 541
culture C 102 541
. C 103 541
adenovirus C 105 541
7 C 106 541
viral C 107 541
antiserum C 108 541
neutralized C 109 541
the C 110 541
sv C 111 541
40 C 112 541
tumour C 113 541
antigen C 114 541
inducing C 115 541
ability C 116 541
of C 117 541
the C 118 541
l C 119 541
. C 120 541
. C 121 541
. C 122 541
strain C 124 541
virus C 125 541
but C 126 541
anti C 127 541
- C 128 541
sv C 129 541
40 C 130 541
monkey C 131 541
serum C 132 541
and C 133 541
serum C 134 541
from C 135 541
sv C 136 541
40 C 137 541
tumour C 138 541
bearing C 139 541
hamsters C 140 541
did C 141 541
not C 142 541
. C 143 541
an C 145 541
adenovirus C 146 541
7 C 147 541
preparation C 148 541
propagated C 149 541
exclusively C 150 541
in C 151 541
human C 152 541
tissue C 153 541
did C 154 541
not C 155 541
induce C 156 541
the C 157 541
sv C 158 541
40 C 159 541
tumour C 160 541
antigen C 161 541
. C 162 541
the C 164 541
sv C 165 541
40 C 166 541
tumour C 167 541
antigen C 168 541
was C 169 541
entirely C 170 541
localised C 171 541
within C 172 541
the C 173 541
cell C 174 541
nuclei C 175 541
and C 176 541
appeared C 177 541
to C 178 541
be C 179 541
transmitted C 180 541
to C 181 541
daughter C 182 541
cells C 183 541
during C 184 541
mitosis C 185 541
. C 186 541
264 C 1 542
. C 2 542
fluorescent C 4 542
antibodies C 5 542
to C 6 542
human C 7 542
cancer C 8 542
- C 9 542
specific C 10 542
dna C 11 542
and C 12 542
nuclear C 13 542
proteins C 14 542
specific C 15 542
antigens C 16 542
have C 17 542
been C 18 542
demonstrated C 19 542
in C 20 542
certain C 21 542
cancers C 22 542
. C 23 542
in C 25 542
this C 26 542
study C 27 542
they C 28 542
were C 29 542
obtained C 30 542
from C 31 542
an C 32 542
adenocarcinoma C 33 542
of C 34 542
the C 35 542
colon C 36 542
and C 37 542
an C 38 542
ewing C 39 542
' C 40 542
s C 41 542
sarcoma C 42 542
. C 43 542
homogenates C 45 542
were C 46 542
prepared C 47 542
and C 48 542
male C 49 542
rabbits C 50 542
were C 51 542
immunized C 52 542
. C 53 542
the C 55 542
animals C 56 542
were C 57 542
bled C 58 542
to C 59 542
death C 60 542
10 C 61 542
days C 62 542
after C 63 542
the C 64 542
last C 65 542
injection C 66 542
. C 67 542
testing C 69 542
included C 70 542
fluorescent C 71 542
antibody C 72 542
methods C 73 542
and C 74 542
agar C 75 542
- C 76 542
gel C 77 542
horizontal C 78 542
double C 79 542
- C 80 542
diffusion C 81 542
precipitin C 82 542
test C 83 542
. C 84 542
the C 86 542
pattern C 87 542
of C 88 542
reaction C 89 542
of C 90 542
these C 91 542
antibodies C 92 542
against C 93 542
various C 94 542
cancers C 95 542
seems C 96 542
to C 97 542
be C 98 542
dependent C 99 542
upon C 100 542
the C 101 542
source C 102 542
of C 103 542
the C 104 542
cancerous C 105 542
dna C 106 542
- C 107 542
bound C 108 542
proteins C 109 542
and C 110 542
the C 111 542
salt C 112 542
concentration C 113 542
used C 114 542
in C 115 542
their C 116 542
isolation C 117 542
. C 118 542
human C 120 542
cancer C 121 542
- C 122 542
specific C 123 542
cross C 124 542
nuclear C 125 542
antigens C 126 542
seem C 127 542
to C 128 542
be C 129 542
cross C 130 542
reacting C 131 542
rather C 132 542
than C 133 542
identical C 134 542
in C 135 542
structure C 136 542
. C 137 542
the C 139 542
cancer C 140 542
- C 141 542
specific C 142 542
antibodies C 143 542
could C 144 542
be C 145 542
removed C 146 542
only C 147 542
with C 148 542
absorption C 149 542
of C 150 542
the C 151 542
immune C 152 542
globulins C 153 542
with C 154 542
cancerous C 155 542
tissues C 156 542
. C 157 542
salt C 159 542
- C 160 542
soluble C 161 542
human C 162 542
dna C 163 542
- C 164 542
bound C 165 542
proteins C 166 542
from C 167 542
an C 168 542
adenocarcinoma C 169 542
of C 170 542
the C 171 542
colon C 172 542
and C 173 542
an C 174 542
ewing C 175 542
' C 176 542
s C 177 542
sarcoma C 178 542
induced C 179 542
the C 180 542
formation C 181 542
of C 182 542
cancer C 183 542
specific C 184 542
antibodies C 185 542
which C 186 542
showed C 187 542
positive C 188 542
fta C 189 542
re C 190 542
- C 191 542
actions C 192 542
( C 193 542
to C 194 542
a C 195 542
maximum C 196 542
titer C 197 542
of C 198 542
1 C 199 542
/ C 200 542
128 C 201 542
) C 202 542
against C 203 542
95 C 204 542
% C 205 542
of C 206 542
the C 207 542
cancerous C 208 542
tissues C 209 542
studied C 210 542
. C 211 542
these C 213 542
cancer C 214 542
- C 215 542
specific C 216 542
antibodies C 217 542
gave C 218 542
similar C 219 542
fta C 220 542
reactions C 221 542
with C 222 542
cell C 223 542
nuclei C 224 542
of C 225 542
normal C 226 542
appearing C 227 542
liver C 228 542
parenchyma C 229 542
adjacent C 230 542
to C 231 542
metastatic C 232 542
carcinoma C 233 542
of C 234 542
colon C 235 542
, C 236 542
nor C 237 542
- C 238 542
mal C 239 542
appearing C 240 542
colon C 241 542
near C 242 542
to C 243 542
metastatic C 244 542
carcinoma C 245 542
of C 246 542
the C 247 542
colon C 248 542
, C 249 542
normal C 250 542
appearing C 251 542
colon C 252 542
near C 253 542
to C 254 542
carcinoma C 255 542
of C 256 542
the C 257 542
colon C 258 542
, C 259 542
and C 260 542
a C 261 542
long C 262 542
- C 263 542
standing C 264 542
case C 265 542
of C 266 542
chronic C 267 542
ulcerative C 268 542
colitis C 269 542
. C 270 542
evidence C 272 542
is C 273 542
shown C 274 542
that C 275 542
this C 276 542
finding C 277 542
possibly C 278 542
may C 279 542
represent C 280 542
a C 281 542
serological C 282 542
detection C 283 542
of C 284 542
an C 285 542
early C 286 542
or C 287 542
latent C 288 542
cancerous C 289 542
change C 290 542
in C 291 542
morphologically C 292 542
normal C 293 542
cells C 294 542
. C 295 542
these C 297 542
cancer C 298 542
- C 299 542
specific C 300 542
antigens C 301 542
have C 302 542
been C 303 542
identified C 304 542
as C 305 542
rounded C 306 542
, C 307 542
intranuclear C 308 542
dna C 309 542
- C 310 542
bodies C 311 542
and C 312 542
nuclear C 313 542
proteins C 314 542
which C 315 542
can C 316 542
be C 317 542
specifically C 318 542
destroyed C 319 542
by C 320 542
dnase C 321 542
trypsin C 322 542
. C 323 542
266 C 1 543
. C 2 543
immunology C 4 543
of C 5 543
the C 6 543
cancer C 7 543
cell C 8 543
: C 9 543
tumour C 10 543
- C 11 543
specific C 12 543
antigens C 13 543
after C 14 543
a C 15 543
broad C 16 543
historical C 17 543
survey C 18 543
of C 19 543
immunological C 20 543
studies C 21 543
of C 22 543
cancer C 23 543
, C 24 543
a C 25 543
review C 26 543
is C 27 543
given C 28 543
of C 29 543
the C 30 543
evidence C 31 543
showing C 32 543
that C 33 543
antigens C 34 543
present C 35 543
in C 36 543
normal C 37 543
cells C 38 543
are C 39 543
missing C 40 543
from C 41 543
the C 42 543
malignant C 43 543
cells C 44 543
that C 45 543
arise C 46 543
from C 47 543
the C 48 543
same C 49 543
tissue C 50 543
. C 51 543
this C 53 543
evidence C 54 543
is C 55 543
considered C 56 543
in C 57 543
con C 58 543
- C 59 543
junction C 60 543
with C 61 543
the C 62 543
deletion C 63 543
hypothesis C 64 543
of C 65 543
carcinogenesis C 66 543
, C 67 543
and C 68 543
the C 69 543
author C 70 543
emphasizes C 71 543
, C 72 543
that C 73 543
in C 74 543
his C 75 543
view C 76 543
, C 77 543
the C 78 543
key C 79 543
event C 80 543
in C 81 543
carcinogenesis C 82 543
is C 83 543
enzymatic C 84 543
deletion C 85 543
. C 86 543
antigenic C 88 543
gain C 89 543
and C 90 543
intensification C 91 543
in C 92 543
the C 93 543
course C 94 543
of C 95 543
spontaneous C 96 543
, C 97 543
chemical C 98 543
, C 99 543
and C 100 543
viral C 101 543
carcino C 102 543
- C 103 543
genesis C 104 543
is C 105 543
reviewed C 106 543
, C 107 543
together C 108 543
with C 109 543
experiments C 110 543
demonstrating C 111 543
the C 112 543
existence C 113 543
of C 114 543
tumour C 115 543
- C 116 543
specific C 117 543
antigens C 118 543
. C 119 543
the C 121 543
question C 122 543
is C 123 543
then C 124 543
posed C 125 543
: C 126 543
if C 127 543
tumours C 128 543
have C 129 543
specific C 130 543
anti C 131 543
- C 132 543
gens C 133 543
, C 134 543
why C 135 543
is C 136 543
evidence C 137 543
for C 138 543
their C 139 543
rejection C 140 543
so C 141 543
scanty C 142 543
? C 143 543
the C 144 543
occasional C 145 543
spontaneous C 146 543
re C 147 543
- C 148 543
gression C 149 543
points C 150 543
to C 151 543
host C 152 543
resistance C 153 543
but C 154 543
its C 155 543
rarity C 156 543
suggests C 157 543
that C 158 543
tolerance C 159 543
generally C 160 543
develops C 161 543
. C 162 543
consideration C 164 543
is C 165 543
given C 166 543
to C 167 543
the C 168 543
application C 169 543
of C 170 543
immunological C 171 543
methods C 172 543
to C 173 543
therapy C 174 543
and C 175 543
although C 176 543
current C 177 543
achievement C 178 543
in C 179 543
this C 180 543
field C 181 543
is C 182 543
limited C 183 543
, C 184 543
new C 185 543
immunological C 186 543
stratagems C 187 543
might C 188 543
yet C 189 543
transform C 190 543
the C 191 543
picture C 192 543
. C 193 543
finally C 195 543
a C 196 543
plea C 197 543
is C 198 543
made C 199 543
for C 200 543
the C 201 543
integra C 202 543
- C 203 543
tion C 204 543
of C 205 543
the C 206 543
disciplines C 207 543
of C 208 543
immunology C 209 543
and C 210 543
cellular C 211 543
differentiation C 212 543
. C 213 543
the C 215 543
prospect C 216 543
is C 217 543
raised C 218 543
that C 219 543
through C 220 543
a C 221 543
synthetic C 222 543
and C 223 543
holistic C 224 543
approach C 225 543
we C 226 543
might C 227 543
discover C 228 543
the C 229 543
suscepti C 230 543
- C 231 543
bility C 232 543
of C 233 543
the C 234 543
cancer C 235 543
cell C 236 543
to C 237 543
re C 238 543
- C 239 543
differentiation C 240 543
and C 241 543
re C 242 543
- C 243 543
recognition C 244 543
. C 245 543
effets C 1 544
de C 2 544
la C 3 544
carence C 4 544
potassique C 5 544
chez C 6 544
le C 7 544
rat C 8 544
sur C 9 544
le C 10 544
squelette C 11 544
, C 12 544
le C 13 544
cholesterol C 14 544
plasmatique C 15 544
l C 16 544
' C 17 544
histologie C 18 544
des C 19 544
surrenales C 20 544
r C 21 544
. C 22 544
habib C 24 544
, C 25 544
j C 26 544
. C 27 544
lefebvre C 29 544
et C 30 544
p C 31 544
. C 32 544
royer C 34 544
potassium C 35 544
deficiency C 36 544
in C 37 544
the C 38 544
male C 39 544
rat C 40 544
at C 41 544
the C 42 544
time C 43 544
of C 44 544
weaning C 45 544
, C 46 544
provokes C 47 544
an C 48 544
increase C 49 544
in C 50 544
the C 51 544
weight C 52 544
of C 53 544
the C 54 544
suprarenals C 55 544
, C 56 544
an C 57 544
atrophy C 58 544
of C 59 544
the C 60 544
glomerular C 61 544
zone C 62 544
and C 63 544
a C 64 544
lipoid C 65 544
hypertrophy C 66 544
of C 67 544
the C 68 544
fasciculae C 69 544
. C 70 544
it C 72 544
causes C 73 544
a C 74 544
rise C 75 544
in C 76 544
the C 77 544
level C 78 544
of C 79 544
the C 80 544
blood C 81 544
cholesterol C 82 544
. C 83 544
it C 85 544
reduces C 86 544
the C 87 544
phosphate C 88 544
level C 89 544
in C 90 544
the C 91 544
blood C 92 544
and C 93 544
increases C 94 544
the C 95 544
phosphate C 96 544
in C 97 544
the C 98 544
urine C 99 544
. C 100 544
the C 102 544
blood C 103 544
calcium C 104 544
level C 105 544
is C 106 544
not C 107 544
altered C 108 544
but C 109 544
a C 110 544
hypocalciuria C 111 544
is C 112 544
noted C 113 544
. C 114 544
it C 116 544
leads C 117 544
to C 118 544
a C 119 544
severe C 120 544
osteopathy C 121 544
which C 122 544
has C 123 544
been C 124 544
investigated C 125 544
by C 126 544
radiography C 127 544
, C 128 544
microradiography C 129 544
and C 130 544
histological C 131 544
and C 132 544
bio C 133 544
- C 134 544
chemical C 135 544
study C 136 544
of C 137 544
the C 138 544
skeleton C 139 544
. C 140 544
the C 142 544
following C 143 544
are C 144 544
the C 145 544
charac C 146 544
- C 147 544
teristics C 148 544
: C 149 544
arrest C 150 544
of C 151 544
osseous C 152 544
growth C 153 544
, C 154 544
delay C 155 544
of C 156 544
maturation C 157 544
, C 158 544
arrest C 159 544
of C 160 544
chondrogenesis C 161 544
, C 162 544
formation C 163 544
of C 164 544
dense C 165 544
metaphyseal C 166 544
lines C 167 544
or C 168 544
lines C 169 544
of C 170 544
arrest C 171 544
, C 172 544
osteoporosis C 173 544
. C 174 544
these C 176 544
facts C 177 544
are C 178 544
discussed C 179 544
and C 180 544
compared C 181 544
to C 182 544
the C 183 544
analogous C 184 544
changes C 185 544
found C 186 544
in C 187 544
the C 188 544
syndrome C 189 544
of C 190 544
chronic C 191 544
idiopathic C 192 544
hypo C 193 544
- C 194 544
kalaemia C 195 544
with C 196 544
hyperkaluria C 197 544
in C 198 544
the C 199 544
infant C 200 544
. C 201 544
vergleichende C 1 545
renale C 2 545
phosphatelearance C 3 545
- C 4 545
untersuchungen C 5 545
beim C 6 545
hyperparathyreoidismus C 7 545
und C 8 545
beim C 9 545
sog C 10 545
. C 11 545
phosphatdiabetes C 13 545
the C 14 545
analysis C 15 545
of C 16 545
the C 17 545
function C 18 545
of C 19 545
the C 20 545
kidneys C 21 545
give C 22 545
a C 23 545
contribution C 24 545
to C 25 545
the C 26 545
pathophysiology C 27 545
of C 28 545
two C 29 545
different C 30 545
diseases C 31 545
of C 32 545
general C 33 545
osteopathies C 34 545
whose C 35 545
pathogenesis C 36 545
or C 37 545
etiology C 38 545
are C 39 545
still C 40 545
not C 41 545
clear C 42 545
in C 43 545
some C 44 545
points C 45 545
. C 46 545
the C 48 545
phosphate C 49 545
clearance C 50 545
pre C 51 545
- C 52 545
and C 53 545
postoperative C 54 545
in C 55 545
one C 56 545
patient C 57 545
with C 58 545
hyper C 59 545
- C 60 545
parathyroidism C 61 545
showed C 62 545
that C 63 545
after C 64 545
the C 65 545
removal C 66 545
of C 67 545
the C 68 545
adenoma C 69 545
of C 70 545
the C 71 545
parathyroid C 72 545
the C 73 545
renal C 74 545
reabsorption C 75 545
of C 76 545
phosphate C 77 545
improved C 78 545
only C 79 545
tempo C 80 545
- C 81 545
rary C 82 545
as C 83 545
a C 84 545
secondary C 85 545
form C 86 545
of C 87 545
hyperparathyroidism C 88 545
was C 89 545
already C 90 545
present C 91 545
. C 92 545
in C 94 545
a C 95 545
patient C 96 545
with C 97 545
a C 98 545
" C 99 545
phosphatdiabetes C 100 545
" C 101 545
the C 102 545
clearance C 103 545
examination C 104 545
showed C 105 545
that C 106 545
under C 107 545
a C 108 545
high C 109 545
dosage C 110 545
of C 111 545
vitamin C 112 545
d C 113 545
the C 114 545
reabsorption C 115 545
of C 116 545
phosphate C 117 545
did C 118 545
not C 119 545
increase C 120 545
. C 121 545
based C 123 545
on C 124 545
these C 125 545
results C 126 545
we C 127 545
have C 128 545
not C 129 545
continued C 130 545
therapy C 131 545
with C 132 545
vitamin C 133 545
d C 134 545
which C 135 545
is C 136 545
certainly C 137 545
not C 138 545
indifferent C 139 545
. C 140 545
comparative C 142 545
renal C 143 545
clearance C 144 545
examinations C 145 545
were C 146 545
carried C 147 545
out C 148 545
in C 149 545
10 C 150 545
patients C 151 545
which C 152 545
did C 153 545
not C 154 545
show C 155 545
any C 156 545
disturbances C 157 545
of C 158 545
calcium C 159 545
/ C 160 545
phosphate C 161 545
- C 162 545
metabolism C 163 545
. C 164 545
the C 1 546
unreliability C 2 546
of C 3 546
the C 4 546
titan C 5 546
yellow C 6 546
method C 7 546
for C 8 546
the C 9 546
determination C 10 546
of C 11 546
magnesium C 12 546
in C 13 546
patients C 14 546
receiving C 15 546
intravenous C 16 546
calcium C 17 546
gluconate C 18 546
gluconate C 19 546
was C 20 546
found C 21 546
to C 22 546
interfere C 23 546
with C 24 546
the C 25 546
determination C 26 546
of C 27 546
magnesium C 28 546
by C 29 546
the C 30 546
titan C 31 546
yellow C 32 546
method C 33 546
. C 34 546
with C 36 546
this C 37 546
method C 38 546
, C 39 546
false C 40 546
low C 41 546
results C 42 546
were C 43 546
found C 44 546
in C 45 546
the C 46 546
serum C 47 546
and C 48 546
urine C 49 546
of C 50 546
patients C 51 546
receiving C 52 546
intravenous C 53 546
calcium C 54 546
gluconate C 55 546
. C 56 546
the C 58 546
interference C 59 546
can C 60 546
be C 61 546
prevented C 62 546
by C 63 546
ashing C 64 546
of C 65 546
the C 66 546
specimen C 67 546
. C 68 546
absorption C 1 547
and C 2 547
excretion C 3 547
of C 4 547
toxogonin C 5 547
, C 6 547
an C 7 547
alkyl C 8 547
- C 9 547
phosphate C 10 547
antidote C 11 547
, C 12 547
after C 13 547
intramuscular C 14 547
injection C 15 547
in C 16 547
man C 17 547
tolerance C 18 547
, C 19 547
absorption C 20 547
and C 21 547
urinary C 22 547
excretion C 23 547
stu C 24 547
- C 25 547
dies C 26 547
of C 27 547
toxogonin C 28 547
( C 29 547
bis C 30 547
- C 31 547
( C 32 547
4 C 33 547
- C 34 547
hydroxyiminomethyl C 35 547
- C 36 547
pyridine C 37 547
- C 38 547
1 C 39 547
- C 40 547
methyl C 41 547
) C 42 547
ether C 43 547
dichloride C 44 547
) C 45 547
, C 46 547
a C 47 547
specific C 48 547
anti C 49 547
- C 50 547
dote C 51 547
in C 52 547
poisoning C 53 547
by C 54 547
esterase C 55 547
- C 56 547
blocking C 57 547
organic C 58 547
phosphates C 59 547
, C 60 547
were C 61 547
made C 62 547
on C 63 547
11 C 64 547
men C 65 547
by C 66 547
intramuscular C 67 547
injection C 68 547
of C 69 547
250 C 70 547
mg C 71 547
. C 72 547
( C 74 547
ca C 75 547
. C 76 547
3 C 78 547
mg C 79 547
. C 80 547
/ C 82 547
kg C 83 547
. C 84 547
) C 86 547
of C 87 547
the C 88 547
drug C 89 547
, C 90 547
given C 91 547
by C 92 547
self C 93 547
- C 94 547
injection C 95 547
ampoules C 96 547
. C 97 547
injections C 99 547
made C 100 547
with C 101 547
the C 102 547
automatic C 103 547
ampoule C 104 547
autule C 105 547
caused C 106 547
no C 107 547
local C 108 547
irritation C 109 547
. C 110 547
certain C 112 547
facial C 113 547
symptoms C 114 547
reported C 115 547
can C 116 547
for C 117 547
the C 118 547
time C 119 547
being C 120 547
be C 121 547
regarded C 122 547
as C 123 547
resorptive C 124 547
side C 125 547
- C 126 547
effects C 127 547
of C 128 547
toxogonin C 129 547
. C 130 547
maximum C 132 547
blood C 133 547
levels C 134 547
of C 135 547
6 C 136 547
ug C 137 547
. C 138 547
/ C 140 547
ml C 141 547
. C 142 547
were C 144 547
recorded C 145 547
within C 146 547
20 C 147 547
minutes C 148 547
. C 149 547
even C 151 547
after C 152 547
four C 153 547
hours C 154 547
the C 155 547
level C 156 547
was C 157 547
still C 158 547
1 C 159 547
- C 160 547
2 C 161 547
ug C 162 547
. C 163 547
/ C 165 547
ml C 166 547
. C 167 547
, C 169 547
a C 170 547
concentra C 171 547
- C 172 547
tion C 173 547
amply C 174 547
sufficient C 175 547
to C 176 547
ensure C 177 547
reactivation C 178 547
of C 179 547
blood C 180 547
esterases C 181 547
. C 182 547
of C 184 547
the C 185 547
injected C 186 547
dose C 187 547
, C 188 547
52 C 189 547
% C 190 547
was C 191 547
excreted C 192 547
in C 193 547
the C 194 547
urine C 195 547
after C 196 547
two C 197 547
hours C 198 547
, C 199 547
87 C 200 547
% C 201 547
after C 202 547
eight C 203 547
hours C 204 547
. C 205 547
toxogonin C 207 547
appears C 208 547
to C 209 547
pass C 210 547
through C 211 547
the C 212 547
body C 213 547
un C 214 547
- C 215 547
changed C 216 547
. C 217 547
the C 1 548
study C 2 548
of C 3 548
osteoporosis C 4 548
and C 5 548
osteomalacia C 6 548
radiological C 7 548
evidence C 8 548
strongly C 9 548
suggests C 10 548
that C 11 548
osteoporosis C 12 548
( C 13 548
with C 14 548
the C 15 548
possible C 16 548
exception C 17 548
of C 18 548
acute C 19 548
immobilization C 20 548
osteoporosis C 21 548
) C 22 548
may C 23 548
be C 24 548
an C 25 548
irrever C 26 548
- C 27 548
sible C 28 548
condition C 29 548
. C 30 548
the C 32 548
changes C 33 548
therefore C 34 548
to C 35 548
be C 36 548
expected C 37 548
in C 38 548
calcium C 39 548
balance C 40 548
when C 41 548
an C 42 548
osteoporotic C 43 548
is C 44 548
treated C 45 548
are C 46 548
small C 47 548
compared C 48 548
with C 49 548
those C 50 548
often C 51 548
seen C 52 548
in C 53 548
osteomalacia C 54 548
. C 55 548
methods C 57 548
of C 58 548
obtaining C 59 548
more C 60 548
accurate C 61 548
calcium C 62 548
balances C 63 548
are C 64 548
needed C 65 548
to C 66 548
show C 67 548
these C 68 548
small C 69 548
changes C 70 548
, C 71 548
especially C 72 548
when C 73 548
a C 74 548
high C 75 548
calcium C 76 548
intake C 77 548
is C 78 548
used C 79 548
. C 80 548
the C 82 548
method C 83 548
of C 84 548
continuous C 85 548
marking C 86 548
of C 87 548
stools C 88 548
with C 89 548
chromium C 90 548
sesquioxide C 91 548
seems C 92 548
to C 93 548
provide C 94 548
just C 95 548
such C 96 548
a C 97 548
method C 98 548
. C 99 548
using C 101 548
this C 102 548
method C 103 548
, C 104 548
it C 105 548
has C 106 548
so C 107 548
far C 108 548
proved C 109 548
impossible C 110 548
to C 111 548
obtain C 112 548
prolonged C 113 548
large C 114 548
positive C 115 548
calcium C 116 548
balances C 117 548
in C 118 548
osteoporosis C 119 548
on C 120 548
either C 121 548
high C 122 548
calcium C 123 548
intake C 124 548
, C 125 548
anabolic C 126 548
hormones C 127 548
, C 128 548
or C 129 548
sodium C 130 548
fluoride C 131 548
. C 132 548
two C 134 548
alternative C 135 548
therapies C 136 548
to C 137 548
vitamin C 138 548
d C 139 548
have C 140 548
been C 141 548
explored C 142 548
for C 143 548
use C 144 548
in C 145 548
vitamin C 146 548
d C 147 548
- C 148 548
resistant C 149 548
osteomalacia C 150 548
. C 151 548
atp C 153 548
has C 154 548
been C 155 548
found C 156 548
to C 157 548
be C 158 548
inneffective C 159 548
. C 160 548
intravenous C 162 548
phosphate C 163 548
alone C 164 548
has C 165 548
been C 166 548
ineffective C 167 548
in C 168 548
producing C 169 548
positive C 170 548
calcium C 171 548
balances C 172 548
, C 173 548
but C 174 548
is C 175 548
effective C 176 548
as C 177 548
a C 178 548
complement C 179 548
to C 180 548
vitamin C 181 548
d C 182 548
under C 183 548
certain C 184 548
conditions C 185 548
. C 186 548
the C 1 549
aetiology C 2 549
and C 3 549
treatment C 4 549
of C 5 549
urinary C 6 549
calculus C 7 549
investigations C 8 549
in C 9 549
this C 10 549
laboratory C 11 549
have C 12 549
been C 13 549
based C 14 549
on C 15 549
the C 16 549
hypothesis C 17 549
that C 18 549
calculus C 19 549
formation C 20 549
is C 21 549
primarily C 22 549
a C 23 549
process C 24 549
of C 25 549
crystallization C 26 549
from C 27 549
super C 28 549
- C 29 549
saturated C 30 549
solutions C 31 549
rather C 32 549
than C 33 549
one C 34 549
of C 35 549
adsorption C 36 549
on C 37 549
a C 38 549
specific C 39 549
protein C 40 549
matrix C 41 549
, C 42 549
as C 43 549
has C 44 549
been C 45 549
postulated C 46 549
by C 47 549
boyce C 48 549
and C 49 549
his C 50 549
colleagues C 51 549
( C 52 549
boyce C 53 549
and C 54 549
king C 55 549
, C 56 549
1963 C 57 549
) C 58 549
. C 59 549
that C 61 549
crystallization C 62 549
is C 63 549
the C 64 549
primary C 65 549
factor C 66 549
is C 67 549
strongly C 68 549
suggested C 69 549
by C 70 549
the C 71 549
recent C 72 549
studies C 73 549
of C 74 549
vermeulen C 75 549
, C 76 549
lyon C 77 549
and C 78 549
gill C 79 549
( C 80 549
1964 C 81 549
) C 82 549
. C 83 549
these C 85 549
authors C 86 549
produced C 87 549
artificial C 88 549
concretions C 89 549
which C 90 549
closely C 91 549
resembled C 92 549
urinary C 93 549
calculi C 94 549
by C 95 549
immersing C 96 549
a C 97 549
rotating C 98 549
wire C 99 549
loop C 100 549
in C 101 549
normal C 102 549
urine C 103 549
for C 104 549
several C 105 549
days C 106 549
and C 107 549
slowly C 108 549
adding C 109 549
the C 110 549
appropriate C 111 549
stone C 112 549
- C 113 549
forming C 114 549
elements C 115 549
. C 116 549
if C 118 549
the C 119 549
above C 120 549
hypothesis C 121 549
is C 122 549
correct C 123 549
then C 124 549
the C 125 549
factors C 126 549
of C 127 549
primary C 128 549
interest C 129 549
in C 130 549
urinary C 131 549
stone C 132 549
formation C 133 549
are C 134 549
those C 135 549
responsible C 136 549
for C 137 549
supersaturation C 138 549
, C 139 549
nucleation C 140 549
and C 141 549
crystal C 142 549
poisoning C 143 549
. C 144 549
much C 146 549
remains C 147 549
to C 148 549
be C 149 549
learnt C 150 549
about C 151 549
these C 152 549
various C 153 549
factors C 154 549
, C 155 549
their C 156 549
inter C 157 549
- C 158 549
relationships C 159 549
, C 160 549
and C 161 549
their C 162 549
relative C 163 549
importance C 164 549
. C 165 549
the C 167 549
significance C 168 549
of C 169 549
the C 170 549
urinary C 171 549
colloids C 172 549
( C 173 549
proteins C 174 549
, C 175 549
muco C 176 549
- C 177 549
proteins C 178 549
and C 179 549
polysaccharides C 180 549
) C 181 549
in C 182 549
calculus C 183 549
formation C 184 549
is C 185 549
still C 186 549
not C 187 549
clear C 188 549
but C 189 549
it C 190 549
is C 191 549
probable C 192 549
that C 193 549
they C 194 549
play C 195 549
an C 196 549
important C 197 549
secondary C 198 549
role C 199 549
in C 200 549
binding C 201 549
crystalline C 202 549
precipitates C 203 549
to C 204 549
form C 205 549
a C 206 549
non C 207 549
- C 208 549
friable C 209 549
calculus C 210 549
. C 211 549
since C 213 549
time C 214 549
is C 215 549
an C 216 549
important C 217 549
factor C 218 549
in C 219 549
crystal C 220 549
growth C 221 549
such C 222 549
non C 223 549
- C 224 549
specific C 225 549
binding C 226 549
by C 227 549
proteins C 228 549
would C 229 549
increase C 230 549
the C 231 549
chances C 232 549
of C 233 549
stone C 234 549
growth C 235 549
and C 236 549
retention C 237 549
within C 238 549
the C 239 549
upper C 240 549
urinary C 241 549
tract C 242 549
. C 243 549
control C 1 550
of C 2 550
idiopathic C 3 550
hypercalciuria C 4 550
the C 5 550
paper C 6 550
discusses C 7 550
the C 8 550
causes C 9 550
of C 10 550
hypercalciuria C 11 550
and C 12 550
describes C 13 550
15 C 14 550
cases C 15 550
of C 16 550
different C 17 550
origins C 18 550
all C 19 550
of C 20 550
which C 21 550
presented C 22 550
similarly C 23 550
with C 24 550
renal C 25 550
stones C 26 550
. C 27 550
the C 29 550
diagnosis C 30 550
of C 31 550
idiopathic C 32 550
hypercalciuria C 33 550
was C 34 550
made C 35 550
by C 36 550
exclusion C 37 550
. C 38 550
the C 40 550
effects C 41 550
of C 42 550
dietary C 43 550
restriction C 44 550
of C 45 550
calcium C 46 550
, C 47 550
sodium C 48 550
bicarbonate C 49 550
, C 50 550
cortisone C 51 550
, C 52 550
sodium C 53 550
phosphate C 54 550
, C 55 550
sodium C 56 550
phytate C 57 550
, C 58 550
and C 59 550
cellulose C 60 550
phosphate C 61 550
were C 62 550
demonstrated C 63 550
by C 64 550
calcium C 65 550
and C 66 550
phosphorus C 67 550
balance C 68 550
techniques C 69 550
. C 70 550
all C 72 550
were C 73 550
shown C 74 550
to C 75 550
have C 76 550
some C 77 550
urinary C 78 550
- C 79 550
calcium C 80 550
- C 81 550
lowering C 82 550
effect C 83 550
. C 84 550
finally C 86 550
, C 87 550
a C 88 550
chlorothiazide C 89 550
derivative C 90 550
- C 91 550
- C 92 550
namely C 93 550
, C 94 550
bendrofluazide C 95 550
- C 96 550
- C 97 550
was C 98 550
also C 99 550
demonstrated C 100 550
to C 101 550
have C 102 550
a C 103 550
hypocalciuric C 104 550
effect C 105 550
, C 106 550
and C 107 550
the C 108 550
mode C 109 550
of C 110 550
action C 111 550
is C 112 550
discussed C 113 550
. C 114 550
effects C 1 551
of C 2 551
parathyroid C 3 551
hormone C 4 551
and C 5 551
other C 6 551
proteins C 7 551
in C 8 551
vitro C 9 551
on C 10 551
mitochondrial C 11 551
metabolism C 12 551
it C 13 551
is C 14 551
apparent C 15 551
that C 16 551
in C 17 551
addition C 18 551
to C 19 551
parathyroid C 20 551
hormone C 21 551
, C 22 551
several C 23 551
non C 24 551
- C 25 551
hormonal C 26 551
basic C 27 551
proteins C 28 551
stimulate C 29 551
mitochondrial C 30 551
respiration C 31 551
, C 32 551
ion C 33 551
transport C 34 551
, C 35 551
and C 36 551
atpase C 37 551
, C 38 551
but C 39 551
inhibit C 40 551
the C 41 551
32 C 42 551
pi C 43 551
- C 44 551
atp C 45 551
exchange C 46 551
reaction C 47 551
. C 48 551
thus C 50 551
these C 51 551
effects C 52 551
may C 53 551
not C 54 551
be C 55 551
so C 56 551
uniquely C 57 551
a C 58 551
measure C 59 551
of C 60 551
the C 61 551
biological C 62 551
actions C 63 551
of C 64 551
parathyroid C 65 551
hormone C 66 551
as C 67 551
the C 68 551
previous C 69 551
reports C 70 551
suggested C 71 551
. C 72 551
rasmussen C 74 551
et C 75 551
al C 76 551
. C 77 551
( C 79 551
1964 C 80 551
) C 81 551
have C 82 551
also C 83 551
isolated C 84 551
from C 85 551
parathyroid C 86 551
extracts C 87 551
a C 88 551
protein C 89 551
that C 90 551
is C 91 551
inert C 92 551
in C 93 551
vivo C 94 551
but C 95 551
stimulates C 96 551
mitochondrial C 97 551
transport C 98 551
of C 99 551
phosphate C 100 551
in C 101 551
vitro C 102 551
. C 103 551
they C 105 551
postulated C 106 551
that C 107 551
this C 108 551
protein C 109 551
might C 110 551
be C 111 551
yet C 112 551
another C 113 551
biologically C 114 551
important C 115 551
factor C 116 551
produced C 117 551
by C 118 551
para C 119 551
- C 120 551
thyroid C 121 551
glands C 122 551
. C 123 551
the C 125 551
latter C 126 551
speculation C 127 551
may C 128 551
not C 129 551
be C 130 551
warranted C 131 551
in C 132 551
view C 133 551
of C 134 551
the C 135 551
uncertain C 136 551
specificity C 137 551
of C 138 551
protein C 139 551
effects C 140 551
on C 141 551
mitochondria C 142 551
. C 143 551
all C 145 551
of C 146 551
our C 147 551
tests C 148 551
completed C 149 551
to C 150 551
date C 151 551
show C 152 551
that C 153 551
the C 154 551
non C 155 551
- C 156 551
hormonal C 157 551
parathyroid C 158 551
proteins C 159 551
c C 160 551
1 C 161 551
and C 162 551
c C 163 551
2 C 164 551
are C 165 551
unrelated C 166 551
either C 167 551
biologically C 168 551
, C 169 551
immunologically C 170 551
, C 171 551
or C 172 551
chemically C 173 551
( C 174 551
by C 175 551
amino C 176 551
- C 177 551
acid C 178 551
analysis C 179 551
) C 180 551
to C 181 551
the C 182 551
parathyroid C 183 551
hormone C 184 551
. C 185 551
further C 187 551
rigorous C 188 551
studies C 189 551
are C 190 551
necessary C 191 551
to C 192 551
precisely C 193 551
determine C 194 551
whether C 195 551
any C 196 551
effects C 197 551
of C 198 551
parathyroid C 199 551
hormone C 200 551
on C 201 551
mitochondria C 202 551
validly C 203 551
reflect C 204 551
the C 205 551
mechanism C 206 551
of C 207 551
action C 208 551
of C 209 551
the C 210 551
hormone C 211 551
and C 212 551
whether C 213 551
it C 214 551
is C 215 551
sound C 216 551
to C 217 551
use C 218 551
the C 219 551
in C 220 551
vitro C 221 551
tests C 222 551
as C 223 551
bioassay C 224 551
tools C 225 551
. C 226 551
the C 1 552
treatment C 2 552
of C 3 552
phosphatic C 4 552
encrusted C 5 552
cystitis C 6 552
( C 7 552
alkaline C 8 552
cystitis C 9 552
) C 10 552
with C 11 552
nalidixic C 12 552
acid C 13 552
. C 14 552
phosphatic C 16 552
encrusted C 17 552
cystitis C 18 552
is C 19 552
caused C 20 552
by C 21 552
persistent C 22 552
infection C 23 552
by C 24 552
b C 25 552
. C 26 552
proteus C 28 552
or C 29 552
ps C 30 552
. C 31 552
pyocyaneus C 33 552
associated C 34 552
with C 35 552
an C 36 552
alkaline C 37 552
urine C 38 552
. C 39 552
its C 41 552
incidence C 42 552
may C 43 552
be C 44 552
increasing C 45 552
and C 46 552
may C 47 552
follow C 48 552
megavoltage C 49 552
therapy C 50 552
of C 51 552
a C 52 552
bladder C 53 552
tumour C 54 552
. C 55 552
its C 57 552
incidence C 58 552
in C 59 552
post C 60 552
- C 61 552
radiation C 62 552
cases C 63 552
is C 64 552
2 C 65 552
per C 66 552
cent C 67 552
. C 68 552
mandelamine C 70 552
often C 71 552
fails C 72 552
to C 73 552
relieve C 74 552
this C 75 552
condition C 76 552
. C 77 552
in C 79 552
this C 80 552
series C 81 552
of C 82 552
ten C 83 552
patients C 84 552
who C 85 552
had C 86 552
failed C 87 552
to C 88 552
respond C 89 552
to C 90 552
mandelamine C 91 552
, C 92 552
eight C 93 552
responded C 94 552
to C 95 552
treatment C 96 552
with C 97 552
nalidixic C 98 552
acid C 99 552
. C 100 552
no C 102 552
side C 103 552
effect C 104 552
of C 105 552
treatment C 106 552
was C 107 552
noted C 108 552
in C 109 552
the C 110 552
series C 111 552
. C 112 552
nalidixic C 114 552
acid C 115 552
is C 116 552
of C 117 552
value C 118 552
in C 119 552
the C 120 552
treatment C 121 552
of C 122 552
b C 123 552
. C 124 552
proteus C 126 552
infections C 127 552
of C 128 552
the C 129 552
urinary C 130 552
tract C 131 552
, C 132 552
and C 133 552
is C 134 552
the C 135 552
drug C 136 552
of C 137 552
choice C 138 552
in C 139 552
the C 140 552
treatment C 141 552
of C 142 552
phosphatic C 143 552
encrusted C 144 552
cystitis C 145 552
. C 146 552
role C 1 553
of C 2 553
the C 3 553
liver C 4 553
in C 5 553
the C 6 553
glycoprotein C 7 553
mobilizing C 8 553
property C 9 553
of C 10 553
parathyroid C 11 553
extract C 12 553
studies C 13 553
were C 14 553
carried C 15 553
out C 16 553
to C 17 553
de C 18 553
- C 19 553
termine C 20 553
the C 21 553
action C 22 553
of C 23 553
hepatectomy C 24 553
on C 25 553
the C 26 553
glycoprotein C 27 553
action C 28 553
of C 29 553
pte C 30 553
as C 31 553
well C 32 553
as C 33 553
on C 34 553
pte C 35 553
- C 36 553
induced C 37 553
renal C 38 553
calcification C 39 553
and C 40 553
deposi C 41 553
- C 42 553
tion C 43 553
of C 44 553
glycoprotein C 45 553
. C 46 553
our C 48 553
data C 49 553
showed C 50 553
that C 51 553
in C 52 553
hepatectomized C 53 553
rats C 54 553
, C 55 553
pte C 56 553
no C 57 553
longer C 58 553
caused C 59 553
an C 60 553
elevation C 61 553
in C 62 553
serum C 63 553
glycoproteins C 64 553
. C 65 553
how C 67 553
- C 68 553
ever C 69 553
, C 70 553
hepatectomy C 71 553
did C 72 553
not C 73 553
alter C 74 553
the C 75 553
forma C 76 553
- C 77 553
tion C 78 553
of C 79 553
glycoprotein C 80 553
tubular C 81 553
casts C 82 553
produced C 83 553
by C 84 553
pte C 85 553
administration C 86 553
. C 87 553
the C 89 553
data C 90 553
suggest C 91 553
that C 92 553
the C 93 553
liver C 94 553
is C 95 553
the C 96 553
major C 97 553
source C 98 553
of C 99 553
the C 100 553
ele C 101 553
- C 102 553
vated C 103 553
serum C 104 553
glycoproteins C 105 553
found C 106 553
in C 107 553
rats C 108 553
re C 109 553
- C 110 553
ceiving C 111 553
pte C 112 553
. C 113 553
in C 115 553
addition C 116 553
, C 117 553
it C 118 553
is C 119 553
possible C 120 553
that C 121 553
pte C 122 553
may C 123 553
have C 124 553
a C 125 553
direct C 126 553
stimulating C 127 553
action C 128 553
on C 129 553
biosynthesis C 130 553
of C 131 553
glycoprotein C 132 553
by C 133 553
the C 134 553
kidney C 135 553
. C 136 553
distribution C 1 554
and C 2 554
excretion C 3 554
of C 4 554
radioactivity C 5 554
after C 6 554
parenteral C 7 554
administration C 8 554
of C 9 554
radioactive C 10 554
polydiethylstilbestrol C 11 554
phosphate C 12 554
to C 13 554
rats C 14 554
and C 15 554
a C 16 554
cow C 17 554
. C 18 554
polydiethylstilbestrol C 20 554
phosphate C 21 554
( C 22 554
psp C 23 554
) C 24 554
, C 25 554
a C 26 554
water C 27 554
soluble C 28 554
polyester C 29 554
of C 30 554
phos C 31 554
- C 32 554
phoric C 33 554
acid C 34 554
and C 35 554
diethylstilbestrol C 36 554
, C 37 554
was C 38 554
in C 39 554
- C 40 554
jected C 41 554
in C 42 554
rats C 43 554
and C 44 554
a C 45 554
cow C 46 554
and C 47 554
the C 48 554
distribution C 49 554
and C 50 554
excretion C 51 554
of C 52 554
radioactivity C 53 554
were C 54 554
followed C 55 554
in C 56 554
both C 57 554
species C 58 554
. C 59 554
after C 61 554
a C 62 554
subcutaneous C 63 554
or C 64 554
intramuscular C 65 554
injection C 66 554
the C 67 554
bulk C 68 554
of C 69 554
the C 70 554
radio C 71 554
- C 72 554
activity C 73 554
was C 74 554
accumulated C 75 554
at C 76 554
the C 77 554
site C 78 554
of C 79 554
injec C 80 554
- C 81 554
tion C 82 554
. C 83 554
the C 85 554
disappearance C 86 554
of C 87 554
radioactivity C 88 554
from C 89 554
this C 90 554
depot C 91 554
was C 92 554
very C 93 554
slow C 94 554
. C 95 554
as C 97 554
late C 98 554
as C 99 554
90 C 100 554
days C 101 554
after C 102 554
the C 103 554
injection C 104 554
into C 105 554
rats C 106 554
, C 107 554
20 C 108 554
% C 109 554
of C 110 554
the C 111 554
administered C 112 554
radioactivity C 113 554
was C 114 554
still C 115 554
accumu C 116 554
- C 117 554
lated C 118 554
at C 119 554
the C 120 554
site C 121 554
of C 122 554
injection C 123 554
. C 124 554
the C 126 554
liver C 127 554
was C 128 554
very C 129 554
effective C 130 554
in C 131 554
removing C 132 554
labeled C 133 554
material C 134 554
from C 135 554
circulating C 136 554
blood C 137 554
. C 138 554
twenty C 140 554
- C 141 554
four C 142 554
hours C 143 554
after C 144 554
intravenous C 145 554
injection C 146 554
in C 147 554
rats C 148 554
, C 149 554
about C 150 554
50 C 151 554
% C 152 554
of C 153 554
the C 154 554
radioactivity C 155 554
was C 156 554
recovered C 157 554
from C 158 554
this C 159 554
organ C 160 554
. C 161 554
the C 163 554
distribution C 164 554
of C 165 554
radioactivity C 166 554
in C 167 554
the C 168 554
cow C 169 554
indicated C 170 554
that C 171 554
the C 172 554
polymer C 173 554
was C 174 554
preferably C 175 554
accumulated C 176 554
in C 177 554
organs C 178 554
containing C 179 554
reticuloendothelial C 180 554
cells C 181 554
. C 182 554
study C 1 555
of C 2 555
phosphate C 3 555
excretion C 4 555
by C 5 555
the C 6 555
stop C 7 555
- C 8 555
flow C 9 555
technique C 10 555
m C 11 555
. C 12 555
de C 14 555
myttenaere C 15 555
the C 16 555
stop C 17 555
- C 18 555
flow C 19 555
technique C 20 555
has C 21 555
been C 22 555
applied C 23 555
to C 24 555
the C 25 555
dog C 26 555
in C 27 555
an C 28 555
attempt C 29 555
to C 30 555
rule C 31 555
out C 32 555
tubular C 33 555
secretion C 34 555
of C 35 555
phosphate C 36 555
and C 37 555
to C 38 555
locate C 39 555
the C 40 555
site C 41 555
of C 42 555
action C 43 555
of C 44 555
parathyroid C 45 555
hormone C 46 555
( C 47 555
p C 48 555
. C 49 555
. C 50 555
. C 51 555
. C 52 555
. C 53 555
) C 55 555
on C 56 555
the C 57 555
renal C 58 555
tubule C 59 555
. C 60 555
under C 62 555
the C 63 555
experimental C 64 555
conditions C 65 555
used C 66 555
, C 67 555
no C 68 555
significant C 69 555
inward C 70 555
transtubular C 71 555
movement C 72 555
of C 73 555
p C 74 555
32 C 75 555
could C 76 555
be C 77 555
demonstrated C 78 555
, C 79 555
ruling C 80 555
out C 81 555
tubular C 82 555
secretion C 83 555
of C 84 555
phosphate C 85 555
. C 86 555
stop C 88 555
- C 89 555
flow C 90 555
experiments C 91 555
performed C 92 555
in C 93 555
parathyroidectomized C 94 555
dogs C 95 555
before C 96 555
and C 97 555
after C 98 555
p C 99 555
. C 100 555
. C 101 555
. C 102 555
. C 103 555
. C 104 555
administration C 106 555
demonstrated C 107 555
inhibition C 108 555
of C 109 555
phosphorus C 110 555
reabsorption C 111 555
by C 112 555
the C 113 555
hormone C 114 555
. C 115 555
in C 117 555
addition C 118 555
, C 119 555
the C 120 555
stop C 121 555
- C 122 555
flow C 123 555
pattern C 124 555
indicated C 125 555
that C 126 555
this C 127 555
phenomenon C 128 555
took C 129 555
place C 130 555
mainly C 131 555
in C 132 555
the C 133 555
distal C 134 555
part C 135 555
of C 136 555
the C 137 555
proximal C 138 555
tubules C 139 555
. C 140 555
stupor C 1 556
, C 2 556
hypercalcemia C 3 556
and C 4 556
carcinoma C 5 556
of C 6 556
the C 7 556
renal C 8 556
pelvis C 9 556
since C 10 556
albright C 11 556
suggested C 12 556
that C 13 556
some C 14 556
tumors C 15 556
" C 16 556
might C 17 556
be C 18 556
producing C 19 556
parathyroid C 20 556
hormone C 21 556
, C 22 556
" C 23 556
hy C 24 556
- C 25 556
percalcemia C 26 556
associated C 27 556
with C 28 556
malignant C 29 556
tumors C 30 556
with C 31 556
- C 32 556
out C 33 556
bony C 34 556
metastases C 35 556
has C 36 556
been C 37 556
recorded C 38 556
with C 39 556
increas C 40 556
- C 41 556
ing C 42 556
frequency C 43 556
. C 44 556
transitional C 46 556
- C 47 556
cell C 48 556
carcinoma C 49 556
of C 50 556
the C 51 556
renal C 52 556
pelvis C 53 556
is C 54 556
here C 55 556
added C 56 556
to C 57 556
the C 58 556
list C 59 556
of C 60 556
neoplasms C 61 556
that C 62 556
hypercalcemia C 63 556
may C 64 556
accompany C 65 556
. C 66 556
anodized C 1 557
aluminium C 2 557
grains C 3 557
labelled C 4 557
with C 5 557
radiophosphorus C 6 557
for C 7 557
medical C 8 557
purposes C 9 557
g C 10 557
. C 11 557
b C 13 557
. C 14 557
fasolo C 16 557
, C 17 557
r C 18 557
. C 19 557
malvano C 21 557
, C 22 557
u C 23 557
. C 24 557
rosa C 26 557
and C 27 557
e C 28 557
. C 29 557
zimmer C 31 557
interstitial C 32 557
b C 33 557
- C 34 557
therapy C 35 557
, C 36 557
by C 37 557
implantation C 38 557
in C 39 557
tissues C 40 557
of C 41 557
radioactive C 42 557
sources C 43 557
, C 44 557
is C 45 557
widely C 46 557
applied C 47 557
to C 48 557
the C 49 557
treatment C 50 557
of C 51 557
certain C 52 557
forms C 53 557
of C 54 557
human C 55 557
malignancies C 56 557
. C 57 557
among C 59 557
the C 60 557
radio C 61 557
- C 62 557
elements C 63 557
proposed C 64 557
for C 65 557
this C 66 557
therapeutic C 67 557
technique C 68 557
, C 69 557
yttrium C 70 557
- C 71 557
90 C 72 557
and C 73 557
gold C 74 557
- C 75 557
198 C 76 557
are C 77 557
the C 78 557
most C 79 557
generally C 80 557
used C 81 557
. C 82 557
radiophosphorus C 84 557
( C 85 557
32 C 86 557
p C 87 557
) C 88 557
shows C 89 557
some C 90 557
attractive C 91 557
features C 92 557
because C 93 557
of C 94 557
its C 95 557
suitable C 96 557
half C 97 557
- C 98 557
life C 99 557
( C 100 557
14 C 101 557
. C 102 557
. C 103 557
days C 104 557
) C 105 557
and C 106 557
its C 107 557
rather C 108 557
high C 109 557
- C 110 557
energy C 111 557
b C 112 557
- C 113 557
emission C 114 557
( C 115 557
maximum C 116 557
energy C 117 557
1 C 118 557
. C 119 557
. C 120 557
. C 120 557
mev C 121 557
) C 122 557
; C 123 557
but C 124 557
the C 125 557
use C 126 557
of C 127 557
this C 128 557
radionuclide C 129 557
is C 130 557
limited C 131 557
by C 132 557
the C 133 557
diffi C 134 557
- C 135 557
culties C 136 557
found C 137 557
in C 138 557
the C 139 557
preparation C 140 557
of C 141 557
safe C 142 557
solid C 143 557
sources C 144 557
. C 145 557
the C 147 557
only C 148 557
techniques C 149 557
we C 150 557
have C 151 557
found C 152 557
in C 153 557
the C 154 557
literature C 155 557
are C 156 557
those C 157 557
reported C 158 557
by C 159 557
riechert C 160 557
and C 161 557
mundinger C 162 557
and C 163 557
by C 164 557
rames C 165 557
and C 166 557
moravek C 167 557
, C 168 557
who C 169 557
used C 170 557
respectively C 171 557
small C 172 557
plastic C 173 557
capsules C 174 557
filled C 175 557
with C 176 557
phosphomolybdic C 177 557
acid C 178 557
solution C 179 557
, C 180 557
and C 181 557
ca C 182 557
( C 183 557
po C 184 557
4 C 185 557
) C 186 557
, C 187 557
grains C 188 557
, C 189 557
labelled C 190 557
with C 191 557
phosphorus C 192 557
- C 193 557
32 C 194 557
. C 195 557
these C 197 557
methods C 198 557
require C 199 557
a C 200 557
delicate C 201 557
preparative C 202 557
work C 203 557
, C 204 557
and C 205 557
, C 206 557
moreover C 207 557
, C 208 557
a C 209 557
large C 210 557
b C 211 557
- C 212 557
self C 213 557
- C 214 557
absorption C 215 557
effect C 216 557
can C 217 557
be C 218 557
expected C 219 557
in C 220 557
both C 221 557
cases C 222 557
. C 223 557
a C 225 557
new C 226 557
simple C 227 557
method C 228 557
for C 229 557
the C 230 557
preparation C 231 557
of C 232 557
grains C 233 557
labelled C 234 557
with C 235 557
phosphorus C 236 557
- C 237 557
32 C 238 557
basically C 239 557
consists C 240 557
in C 241 557
ad C 242 557
- C 243 557
sorbing C 244 557
labelled C 245 557
po C 246 557
4 C 247 557
3 C 248 557
- C 249 557
ions C 250 557
on C 251 557
an C 252 557
active C 253 557
aluminium C 254 557
oxide C 255 557
film C 256 557
produced C 257 557
by C 258 557
anodic C 259 557
oxidation C 260 557
of C 261 557
aluminium C 262 557
wire C 263 557
. C 264 557
the C 266 557
adsorption C 267 557
capacity C 268 557
of C 269 557
the C 270 557
oxide C 271 557
film C 272 557
for C 273 557
po C 274 557
3 C 275 557
3 C 276 557
- C 277 557
ions C 278 557
is C 279 557
quite C 280 557
high C 281 557
, C 282 557
but C 283 557
the C 284 557
process C 285 557
is C 286 557
reversible C 287 557
: C 288 557
the C 289 557
phos C 290 557
- C 291 557
phorus C 292 557
- C 293 557
32 C 294 557
activity C 295 557
is C 296 557
partially C 297 557
desorbed C 298 557
, C 299 557
even C 300 557
after C 301 557
' C 302 557
sealing C 303 557
' C 304 557
in C 305 557
boiling C 306 557
water C 307 557
, C 308 557
when C 309 557
the C 310 557
labelled C 311 557
wire C 312 557
is C 313 557
kept C 314 557
in C 315 557
isotonic C 316 557
sodium C 317 557
chloride C 318 557
solution C 319 557
. C 320 557
effect C 1 558
of C 2 558
parathyroidectomy C 3 558
and C 4 558
ferric C 5 558
dextrin C 6 558
upon C 7 558
calciphylactic C 8 558
sensitization C 9 558
by C 10 558
uremia C 11 558
experiments C 12 558
on C 13 558
the C 14 558
rat C 15 558
indicate C 16 558
that C 17 558
calciphy C 18 558
- C 19 558
lactic C 20 558
sensitization C 21 558
can C 22 558
be C 23 558
achieved C 24 558
by C 25 558
bilateral C 26 558
nephrectomy C 27 558
. C 28 558
intravenous C 30 558
administration C 31 558
of C 32 558
a C 33 558
ferric C 34 558
dextrin C 35 558
preparation C 36 558
( C 37 558
fe C 38 558
- C 39 558
din C 40 558
) C 41 558
induces C 42 558
selective C 43 558
calcification C 44 558
in C 45 558
the C 46 558
buccal C 47 558
mucosa C 48 558
, C 49 558
esophagus C 50 558
, C 51 558
trachea C 52 558
and C 53 558
mediastinum C 54 558
of C 55 558
the C 56 558
nephrectomized C 57 558
rat C 58 558
although C 59 558
it C 60 558
produces C 61 558
no C 62 558
such C 63 558
changes C 64 558
in C 65 558
intact C 66 558
control C 67 558
animals C 68 558
. C 69 558
conversely C 71 558
, C 72 558
fe C 73 558
- C 74 558
din C 75 558
prevents C 76 558
the C 77 558
cardiovascular C 78 558
calcification C 79 558
normally C 80 558
elicited C 81 558
by C 82 558
nephrectomy C 83 558
. C 84 558
parathy C 86 558
- C 87 558
roidectomy C 88 558
protects C 89 558
the C 90 558
nephrectomized C 91 558
rat C 92 558
against C 93 558
the C 94 558
fe C 95 558
- C 96 558
din C 97 558
- C 98 558
induced C 99 558
calciphylaxis C 100 558
. C 101 558
hence C 103 558
, C 104 558
it C 105 558
may C 106 558
be C 107 558
concluded C 108 558
that C 109 558
: C 110 558
1 C 111 558
) C 112 558
autologous C 113 558
parathyroid C 114 558
hormone C 115 558
, C 116 558
in C 117 558
amounts C 118 558
secreted C 119 558
by C 120 558
the C 121 558
glands C 122 558
, C 123 558
can C 124 558
act C 125 558
as C 126 558
a C 127 558
calciphylactic C 128 558
sensitizer C 129 558
and C 130 558
2 C 131 558
) C 132 558
fe C 133 558
- C 134 558
din C 135 558
is C 136 558
highly C 137 558
effective C 138 558
in C 139 558
protecting C 140 558
the C 141 558
cardiovascular C 142 558
system C 143 558
against C 144 558
uremic C 145 558
damage C 146 558
. C 147 558
mediastinal C 1 559
parathyroid C 2 559
adenoma C 3 559
a C 4 559
case C 5 559
of C 6 559
hyperparathyroidism C 7 559
with C 8 559
hypercalcemic C 9 559
crisis C 10 559
is C 11 559
presented C 12 559
. C 13 559
the C 15 559
tumor C 16 559
was C 17 559
a C 18 559
well C 19 559
differentiated C 20 559
and C 21 559
encapsulated C 22 559
parathyroid C 23 559
adenoma C 24 559
, C 25 559
un C 26 559
- C 27 559
usually C 28 559
located C 29 559
in C 30 559
the C 31 559
anterior C 32 559
mediastinum C 33 559
, C 34 559
lying C 35 559
both C 36 559
within C 37 559
and C 38 559
without C 39 559
the C 40 559
pericardial C 41 559
sac C 42 559
. C 43 559
the C 45 559
surgical C 46 559
approach C 47 559
was C 48 559
directly C 49 559
through C 50 559
the C 51 559
sternum C 52 559
with C 53 559
a C 54 559
mediastinal C 55 559
exploration C 56 559
. C 57 559
the C 59 559
postoperative C 60 559
course C 61 559
was C 62 559
uneventful C 63 559
and C 64 559
gratifying C 65 559
, C 66 559
with C 67 559
complete C 68 559
correction C 69 559
of C 70 559
both C 71 559
symptoms C 72 559
and C 73 559
abnormal C 74 559
laboratory C 75 559
findings C 76 559
. C 77 559
clinical C 1 560
experience C 2 560
with C 3 560
primary C 4 560
hyperparathyroidism C 5 560
: C 6 560
evaluation C 7 560
of C 8 560
treatment C 9 560
forty C 10 560
- C 11 560
four C 12 560
patients C 13 560
with C 14 560
" C 15 560
operatively C 16 560
proven C 17 560
" C 18 560
hyperparathyroidism C 19 560
were C 20 560
evaluated C 21 560
to C 22 560
decide C 23 560
1 C 24 560
) C 25 560
whether C 26 560
or C 27 560
not C 28 560
the C 29 560
diagnosis C 30 560
could C 31 560
be C 32 560
substantiated C 33 560
by C 34 560
some C 35 560
postoperative C 36 560
observations C 37 560
other C 38 560
than C 39 560
the C 40 560
gross C 41 560
anatomic C 42 560
diagnosis C 43 560
of C 44 560
the C 45 560
operative C 46 560
specimen C 47 560
and C 48 560
2 C 49 560
) C 50 560
what C 51 560
the C 52 560
long C 53 560
term C 54 560
value C 55 560
of C 56 560
operative C 57 560
treatment C 58 560
would C 59 560
be C 60 560
. C 61 560
it C 63 560
was C 64 560
found C 65 560
that C 66 560
an C 67 560
immediate C 68 560
and C 69 560
significant C 70 560
fall C 71 560
in C 72 560
urinary C 73 560
phosphorus C 74 560
excretion C 75 560
best C 76 560
documented C 77 560
the C 78 560
diagnosis C 79 560
of C 80 560
primary C 81 560
hyperparathyroidism C 82 560
. C 83 560
over C 85 560
intervals C 86 560
up C 87 560
to C 88 560
10 C 89 560
years C 90 560
, C 91 560
follow C 92 560
- C 93 560
up C 94 560
of C 95 560
the C 96 560
patients C 97 560
suggested C 98 560
a C 99 560
favourable C 100 560
response C 101 560
of C 102 560
the C 103 560
disease C 104 560
to C 105 560
operative C 106 560
treatment C 107 560
. C 108 560
the C 1 561
dilution C 2 561
test C 3 561
as C 4 561
a C 5 561
measure C 6 561
of C 7 561
renal C 8 561
function C 9 561
in C 10 561
niobium C 11 561
- C 12 561
poisoned C 13 561
rats C 14 561
control C 15 561
, C 16 561
female C 17 561
, C 18 561
albino C 19 561
rats C 20 561
given C 21 561
a C 22 561
water C 23 561
load C 24 561
of C 25 561
50 C 26 561
ml C 27 561
/ C 28 561
kg C 29 561
, C 30 561
excreted C 31 561
50 C 32 561
per C 33 561
cent C 34 561
of C 35 561
this C 36 561
load C 37 561
as C 38 561
urine C 39 561
within C 40 561
94 C 41 561
11 C 42 561
minutes C 43 561
( C 44 561
teu C 45 561
50 C 46 561
) C 47 561
. C 48 561
the C 50 561
administration C 51 561
of C 52 561
a C 53 561
single C 54 561
intraperitoneal C 55 561
dose C 56 561
ranging C 57 561
from C 58 561
10 C 59 561
to C 60 561
30 C 61 561
mg C 62 561
nb C 63 561
/ C 64 561
kg C 65 561
resulted C 66 561
in C 67 561
2 C 68 561
- C 69 561
to C 70 561
4 C 71 561
- C 72 561
fold C 73 561
increases C 74 561
in C 75 561
the C 76 561
teu C 77 561
50 C 78 561
value C 79 561
24 C 80 561
hours C 81 561
after C 82 561
the C 83 561
niobium C 84 561
was C 85 561
injected C 86 561
. C 87 561
when C 89 561
niobium C 90 561
was C 91 561
complexed C 92 561
with C 93 561
ascorbic C 94 561
acid C 95 561
prior C 96 561
to C 97 561
injection C 98 561
the C 99 561
teu C 100 561
50 C 101 561
value C 102 561
was C 103 561
within C 104 561
control C 105 561
limits C 106 561
. C 107 561
however C 109 561
, C 110 561
rats C 111 561
given C 112 561
a C 113 561
single C 114 561
intraperitoneal C 115 561
dose C 116 561
of C 117 561
niobium C 118 561
and C 119 561
then C 120 561
given C 121 561
3 C 122 561
doses C 123 561
of C 124 561
ascorbic C 125 561
acid C 126 561
at C 127 561
intervals C 128 561
of C 129 561
1 C 130 561
, C 131 561
3 C 132 561
, C 133 561
and C 134 561
6 C 135 561
hours C 136 561
showed C 137 561
teu C 138 561
50 C 139 561
values C 140 561
that C 141 561
were C 142 561
not C 143 561
markedly C 144 561
different C 145 561
from C 146 561
those C 147 561
observed C 148 561
in C 149 561
rats C 150 561
given C 151 561
niobium C 152 561
only C 153 561
. C 154 561
increased C 156 561
teu C 157 561
50 C 158 561
values C 159 561
were C 160 561
observed C 161 561
in C 162 561
rats C 163 561
given C 164 561
single C 165 561
intraperitoneal C 166 561
doses C 167 561
of C 168 561
uranyl C 169 561
nitrate C 170 561
( C 171 561
1 C 172 561
. C 173 561
. C 174 561
- C 175 561
2 C 176 561
. C 177 561
. C 178 561
mg C 179 561
u C 180 561
/ C 181 561
kg C 182 561
) C 183 561
, C 184 561
mercuric C 185 561
chloride C 186 561
( C 187 561
2 C 188 561
. C 189 561
. C 190 561
mg C 191 561
hg C 192 561
/ C 193 561
kg C 194 561
) C 195 561
and C 196 561
sodium C 197 561
tripolyphosphate C 198 561
( C 199 561
480 C 200 561
mg C 201 561
/ C 202 561
kg C 203 561
) C 204 561
. C 205 561
influence C 1 562
of C 2 562
parathyroid C 3 562
activity C 4 562
on C 5 562
ion C 6 562
exchange C 7 562
in C 8 562
various C 9 562
tissues C 10 562
1 C 11 562
. C 12 562
balance C 14 562
data C 15 562
from C 16 562
three C 17 562
patients C 18 562
with C 19 562
hypoparathyroidism C 20 562
, C 21 562
who C 22 562
were C 23 562
given C 24 562
parathyroid C 25 562
extract C 26 562
, C 27 562
are C 28 562
presented C 29 562
. C 30 562
the C 32 562
metabolic C 33 562
response C 34 562
was C 35 562
complex C 36 562
. C 37 562
the C 39 562
data C 40 562
demonstrate C 41 562
losses C 42 562
of C 43 562
phosphate C 44 562
, C 45 562
magnesium C 46 562
, C 47 562
sodium C 48 562
and C 49 562
potassium C 50 562
which C 51 562
were C 52 562
not C 53 562
accounted C 54 562
for C 55 562
by C 56 562
destruction C 57 562
of C 58 562
either C 59 562
bone C 60 562
or C 61 562
non C 62 562
- C 63 562
osseous C 64 562
tissues C 65 562
. C 66 562
preferential C 68 562
depletion C 69 562
of C 70 562
these C 71 562
minerals C 72 562
from C 73 562
bone C 74 562
, C 75 562
or C 76 562
loss C 77 562
from C 78 562
non C 79 562
- C 80 562
osseous C 81 562
tissues C 82 562
, C 83 562
must C 84 562
be C 85 562
presumed C 86 562
. C 87 562
2 C 89 562
. C 90 562
the C 92 562
exchange C 93 562
of C 94 562
ca C 95 562
45 C 96 562
, C 97 562
mg C 98 562
28 C 99 562
, C 100 562
and C 101 562
p C 102 562
32 C 103 562
in C 104 562
a C 105 562
spectrum C 106 562
of C 107 562
rat C 108 562
tissues C 109 562
has C 110 562
been C 111 562
studied C 112 562
in C 113 562
sham C 114 562
operated C 115 562
, C 116 562
parathyroidectomized C 117 562
, C 118 562
and C 119 562
parathyroid C 120 562
extract C 121 562
treated C 122 562
rats C 123 562
. C 124 562
the C 126 562
effects C 127 562
of C 128 562
parathyroidectomy C 129 562
on C 130 562
the C 131 562
development C 132 562
of C 133 562
magnesium C 134 562
deficiency C 135 562
were C 136 562
determined C 137 562
. C 138 562
3 C 140 562
. C 141 562
four C 143 562
hours C 144 562
after C 145 562
parathyroidectomy C 146 562
, C 147 562
increased C 148 562
transport C 149 562
of C 150 562
calcium C 151 562
into C 152 562
bone C 153 562
, C 154 562
kidney C 155 562
, C 156 562
intestine C 157 562
, C 158 562
liver C 159 562
, C 160 562
brain C 161 562
, C 162 562
and C 163 562
muscle C 164 562
was C 165 562
found C 166 562
. C 167 562
six C 169 562
days C 170 562
after C 171 562
parathyroidectomy C 172 562
equilibrium C 173 562
had C 174 562
been C 175 562
reestablished C 176 562
and C 177 562
exchange C 178 562
rates C 179 562
were C 180 562
identical C 181 562
to C 182 562
those C 183 562
in C 184 562
sham C 185 562
operated C 186 562
animals C 187 562
. C 188 562
4 C 190 562
. C 191 562
the C 193 562
administration C 194 562
of C 195 562
parathyroid C 196 562
extract C 197 562
was C 198 562
associated C 199 562
with C 200 562
de C 201 562
- C 202 562
creased C 203 562
transport C 204 562
of C 205 562
ca C 206 562
15 C 207 562
, C 208 562
mg C 209 562
28 C 210 562
, C 211 562
and C 212 562
p C 213 562
32 C 214 562
into C 215 562
bone C 216 562
. C 217 562
ca C 219 562
15 C 220 562
exchange C 221 562
in C 222 562
kidney C 223 562
was C 224 562
reduced C 225 562
but C 226 562
in C 227 562
all C 228 562
other C 229 562
tissues C 230 562
exchange C 231 562
of C 232 562
ca C 233 562
15 C 234 562
and C 235 562
mg C 236 562
28 C 237 562
was C 238 562
in C 239 562
- C 240 562
creased C 241 562
. C 242 562
p C 244 562
32 C 245 562
exchange C 246 562
in C 247 562
both C 248 562
intestine C 249 562
and C 250 562
kidney C 251 562
was C 252 562
mardedly C 253 562
increased C 254 562
in C 255 562
animals C 256 562
receiving C 257 562
the C 258 562
extract C 259 562
. C 260 562
5 C 262 562
. C 263 562
parathyroidectomy C 265 562
greatly C 266 562
minimized C 267 562
the C 268 562
manifestations C 269 562
of C 270 562
mag C 271 562
- C 272 562
nesium C 273 562
deficiency C 274 562
in C 275 562
young C 276 562
rats C 277 562
on C 278 562
magnesium C 279 562
deficient C 280 562
diets C 281 562
. C 282 562
6 C 284 562
. C 285 562
the C 287 562
results C 288 562
suggest C 289 562
that C 290 562
parathyroid C 291 562
hormone C 292 562
may C 293 562
affect C 294 562
the C 295 562
trans C 296 562
- C 297 562
port C 298 562
and C 299 562
exchange C 300 562
of C 301 562
calcium C 302 562
, C 303 562
magnesium C 304 562
, C 305 562
and C 306 562
phosphate C 307 562
( C 308 562
and C 309 562
perhaps C 310 562
sodium C 311 562
and C 312 562
potassium C 313 562
) C 314 562
in C 315 562
tissues C 316 562
other C 317 562
than C 318 562
those C 319 562
usually C 320 562
considered C 321 562
to C 322 562
be C 323 562
target C 324 562
organs C 325 562
. C 326 562
effects C 1 563
of C 2 563
alkalosis C 3 563
on C 4 563
plasma C 5 563
concentration C 6 563
and C 7 563
urinary C 8 563
excretion C 9 563
of C 10 563
inorganic C 11 563
phosphate C 12 563
in C 13 563
man C 14 563
acute C 15 563
respiratory C 16 563
and C 17 563
metabolic C 18 563
alkalosis C 19 563
have C 20 563
been C 21 563
shown C 22 563
to C 23 563
depress C 24 563
plasma C 25 563
phosphorus C 26 563
con C 27 563
- C 28 563
centration C 29 563
in C 30 563
normal C 31 563
man C 32 563
. C 33 563
the C 35 563
fall C 36 563
in C 37 563
plasma C 38 563
phosphorus C 39 563
concentration C 40 563
is C 41 563
greater C 42 563
in C 43 563
respiratory C 44 563
than C 45 563
in C 46 563
comparable C 47 563
levels C 48 563
of C 49 563
extracellular C 50 563
meta C 51 563
- C 52 563
bolic C 53 563
alkalosis C 54 563
. C 55 563
this C 57 563
fall C 58 563
is C 59 563
not C 60 563
attributable C 61 563
to C 62 563
in C 63 563
- C 64 563
creased C 65 563
renal C 66 563
excretion C 67 563
or C 68 563
to C 69 563
migration C 70 563
into C 71 563
red C 72 563
blood C 73 563
cells C 74 563
. C 75 563
the C 77 563
evaluation C 78 563
of C 79 563
low C 80 563
serum C 81 563
phos C 82 563
- C 83 563
phorus C 84 563
concentrations C 85 563
should C 86 563
always C 87 563
be C 88 563
carried C 89 563
out C 90 563
with C 91 563
a C 92 563
knowledge C 93 563
of C 94 563
the C 95 563
ph C 96 563
and C 97 563
total C 98 563
co C 99 563
2 C 100 563
content C 101 563
of C 102 563
the C 103 563
plasma C 104 563
. C 105 563
the C 1 564
relationship C 2 564
between C 3 564
vitamin C 4 564
d C 5 564
and C 6 564
parathyroid C 7 564
hormone C 8 564
marit C 9 564
von C 10 564
stedingk C 11 564
the C 12 564
effect C 13 564
of C 14 564
parathyroidectomy C 15 564
and C 16 564
parathy C 17 564
- C 18 564
roid C 19 564
hormone C 20 564
administration C 21 564
upon C 22 564
the C 23 564
concentra C 24 564
- C 25 564
tions C 26 564
of C 27 564
plasma C 28 564
calcium C 29 564
and C 30 564
phosphate C 31 564
have C 32 564
been C 33 564
measured C 34 564
in C 35 564
vitamin C 36 564
d C 37 564
- C 38 564
deficient C 39 564
rats C 40 564
and C 41 564
the C 42 564
re C 43 564
- C 44 564
sults C 45 564
compared C 46 564
to C 47 564
those C 48 564
observed C 49 564
in C 50 564
d C 51 564
- C 52 564
fed C 53 564
ani C 54 564
- C 55 564
mals C 56 564
. C 57 564
also C 59 564
, C 60 564
the C 61 564
influence C 62 564
of C 63 564
dietary C 64 564
calcium C 65 564
and C 66 564
phosphate C 67 564
content C 68 564
upon C 69 564
these C 70 564
responses C 71 564
has C 72 564
been C 73 564
investigated C 74 564
. C 75 564
parathyroidectomy C 77 564
in C 78 564
the C 79 564
d C 80 564
- C 81 564
fed C 82 564
ani C 83 564
- C 84 564
mal C 85 564
results C 86 564
in C 87 564
a C 88 564
rapid C 89 564
fall C 90 564
in C 91 564
plasma C 92 564
calcium C 93 564
and C 94 564
a C 95 564
biphasic C 96 564
plasma C 97 564
phosphate C 98 564
response C 99 564
with C 100 564
an C 101 564
initial C 102 564
fall C 103 564
followed C 104 564
by C 105 564
a C 106 564
striking C 107 564
rise C 108 564
. C 109 564
in C 111 564
contrast C 112 564
, C 113 564
parathyroidectomy C 114 564
in C 115 564
the C 116 564
d C 117 564
- C 118 564
deficient C 119 564
rat C 120 564
is C 121 564
fol C 122 564
- C 123 564
lowed C 124 564
by C 125 564
no C 126 564
significant C 127 564
change C 128 564
in C 129 564
plasma C 130 564
calcium C 131 564
and C 132 564
an C 133 564
immediate C 134 564
rise C 135 564
in C 136 564
plasma C 137 564
phosphate C 138 564
that C 139 564
can C 140 564
be C 141 564
prevented C 142 564
by C 143 564
the C 144 564
administration C 145 564
of C 146 564
para C 147 564
- C 148 564
thyroid C 149 564
hormone C 150 564
. C 151 564
dietary C 153 564
phosphate C 154 564
restriction C 155 564
abolished C 156 564
the C 157 564
effect C 158 564
of C 159 564
parathyroidectomy C 160 564
in C 161 564
both C 162 564
groups C 163 564
of C 164 564
animals C 165 564
. C 166 564
administration C 168 564
of C 169 564
a C 170 564
dose C 171 564
of C 172 564
500 C 173 564
u C 174 564
of C 175 564
hormone C 176 564
to C 177 564
the C 178 564
intact C 179 564
d C 180 564
- C 181 564
deficient C 182 564
rat C 183 564
had C 184 564
little C 185 564
influence C 186 564
upon C 187 564
plasma C 188 564
calcium C 189 564
; C 190 564
a C 191 564
dose C 192 564
of C 193 564
2 C 194 564
, C 195 564
000 C 196 564
u C 197 564
did C 198 564
in C 199 564
- C 200 564
crease C 201 564
plasma C 202 564
calcium C 203 564
. C 204 564
a C 206 564
dose C 207 564
of C 208 564
25 C 209 564
u C 210 564
was C 211 564
suffi C 212 564
- C 213 564
cient C 214 564
to C 215 564
increase C 216 564
the C 217 564
plasma C 218 564
calcium C 219 564
of C 220 564
the C 221 564
d C 222 564
- C 223 564
fed C 224 564
animal C 225 564
. C 226 564
these C 228 564
results C 229 564
are C 230 564
discussed C 231 564
in C 232 564
relation C 233 564
to C 234 564
the C 235 564
effects C 236 564
of C 237 564
vitamin C 238 564
d C 239 564
and C 240 564
parathyroid C 241 564
hor C 242 564
- C 243 564
mone C 244 564
upon C 245 564
mitochondrial C 246 564
metabolism C 247 564
. C 248 564
decrease C 1 565
in C 2 565
serum C 3 565
and C 4 565
urinary C 5 565
phosphorus C 6 565
in C 7 565
man C 8 565
in C 9 565
the C 10 565
course C 11 565
of C 12 565
pyrotherapy C 13 565
during C 14 565
the C 15 565
fever C 16 565
peak C 17 565
occurring C 18 565
a C 19 565
few C 20 565
hours C 21 565
after C 22 565
the C 23 565
in C 24 565
- C 25 565
jection C 26 565
, C 27 565
urinary C 28 565
phosphorus C 29 565
( C 30 565
up C 31 565
) C 32 565
dis C 33 565
- C 34 565
appears C 35 565
entirely C 36 565
. C 37 565
this C 39 565
fact C 40 565
cannot C 41 565
be C 42 565
accounted C 43 565
for C 44 565
by C 45 565
the C 46 565
parallel C 47 565
decrease C 48 565
in C 49 565
gfr C 50 565
, C 51 565
because C 52 565
serum C 53 565
phosphorus C 54 565
level C 55 565
( C 56 565
sp C 57 565
) C 58 565
does C 59 565
not C 60 565
increase C 61 565
( C 62 565
as C 63 565
it C 64 565
would C 65 565
be C 66 565
expected C 67 565
to C 68 565
, C 69 565
should C 70 565
retention C 71 565
occur C 72 565
) C 73 565
but C 74 565
on C 75 565
the C 76 565
contrary C 77 565
, C 78 565
it C 79 565
, C 80 565
too C 81 565
, C 82 565
declines C 83 565
to C 84 565
a C 85 565
marked C 86 565
degree C 87 565
. C 88 565
the C 90 565
possibility C 91 565
that C 92 565
changes C 93 565
in C 94 565
sp C 95 565
and C 96 565
up C 97 565
could C 98 565
have C 99 565
been C 100 565
brought C 101 565
about C 102 565
by C 103 565
an C 104 565
increased C 105 565
utilization C 106 565
of C 107 565
glucose C 108 565
was C 109 565
also C 110 565
considered C 111 565
. C 112 565
an C 114 565
intravenous C 115 565
glucose C 116 565
toler C 117 565
- C 118 565
ance C 119 565
test C 120 565
( C 121 565
method C 122 565
of C 123 565
macho C 124 565
and C 125 565
licko C 126 565
( C 127 565
8 C 128 565
) C 129 565
) C 130 565
was C 131 565
carried C 132 565
out C 133 565
in C 134 565
another C 135 565
group C 136 565
of C 137 565
patients C 138 565
on C 139 565
control C 140 565
days C 141 565
and C 142 565
on C 143 565
days C 144 565
of C 145 565
pyrotherapy C 146 565
five C 147 565
hours C 148 565
after C 149 565
the C 150 565
pyrogen C 151 565
administration C 152 565
. C 153 565
an C 155 565
increase C 156 565
in C 157 565
the C 158 565
rate C 159 565
of C 160 565
" C 161 565
glucose C 162 565
utilization C 163 565
" C 164 565
was C 165 565
observed C 166 565
( C 167 565
table C 168 565
2 C 169 565
) C 170 565
. C 171 565
however C 173 565
a C 174 565
different C 175 565
opinion C 176 565
is C 177 565
found C 178 565
in C 179 565
the C 180 565
literature C 181 565
. C 182 565
in C 184 565
the C 185 565
course C 186 565
of C 187 565
glucose C 188 565
tolerance C 189 565
tests C 190 565
, C 191 565
conn C 192 565
( C 193 565
3 C 194 565
) C 195 565
and C 196 565
comparini C 197 565
( C 198 565
9 C 199 565
) C 200 565
observed C 201 565
a C 202 565
lowered C 203 565
rate C 204 565
of C 205 565
glucose C 206 565
utilization C 207 565
in C 208 565
febrile C 209 565
subjects C 210 565
. C 211 565
malizia C 213 565
( C 214 565
10 C 215 565
) C 216 565
found C 217 565
an C 218 565
accentuated C 219 565
rate C 220 565
of C 221 565
decline C 222 565
of C 223 565
serum C 224 565
phosphorus C 225 565
during C 226 565
glucose C 227 565
tolerance C 228 565
tests C 229 565
in C 230 565
subjects C 231 565
with C 232 565
high C 233 565
temperatures C 234 565
, C 235 565
but C 236 565
the C 237 565
glycemic C 238 565
responses C 239 565
did C 240 565
not C 241 565
differ C 242 565
from C 243 565
those C 244 565
ob C 245 565
- C 246 565
tained C 247 565
when C 248 565
controls C 249 565
without C 250 565
fever C 251 565
were C 252 565
subjected C 253 565
to C 254 565
the C 255 565
same C 256 565
tests C 257 565
. C 258 565
whether C 260 565
it C 261 565
be C 262 565
for C 263 565
utilization C 264 565
purposes C 265 565
or C 266 565
not C 267 565
, C 268 565
the C 269 565
fact C 270 565
remains C 271 565
that C 272 565
a C 273 565
massive C 274 565
transfer C 275 565
of C 276 565
phosphorus C 277 565
from C 278 565
the C 279 565
serum C 280 565
into C 281 565
the C 282 565
tissues C 283 565
takes C 284 565
place C 285 565
in C 286 565
fever C 287 565
. C 288 565
relationship C 1 566
of C 2 566
maximal C 3 566
tubular C 4 566
phosphate C 5 566
reabsorption C 6 566
to C 7 566
filtration C 8 566
rate C 9 566
in C 10 566
the C 11 566
dog C 12 566
a C 13 566
maximal C 14 566
renal C 15 566
tubular C 16 566
rate C 17 566
of C 18 566
reabsorption C 19 566
of C 20 566
phos C 21 566
- C 22 566
phate C 23 566
( C 24 566
tmp C 25 566
) C 26 566
has C 27 566
been C 28 566
demonstrated C 29 566
in C 30 566
the C 31 566
normal C 32 566
dog C 33 566
. C 34 566
in C 36 566
the C 37 566
dog C 38 566
, C 39 566
as C 40 566
in C 41 566
the C 42 566
man C 43 566
, C 44 566
considerable C 45 566
variability C 46 566
in C 47 566
the C 48 566
tmp C 49 566
often C 50 566
occurs C 51 566
. C 52 566
while C 54 566
some C 55 566
of C 56 566
this C 57 566
variability C 58 566
remains C 59 566
unex C 60 566
- C 61 566
plained C 62 566
, C 63 566
a C 64 566
direct C 65 566
relationship C 66 566
between C 67 566
glomerular C 68 566
filtration C 69 566
rate C 70 566
( C 71 566
gfr C 72 566
) C 73 566
and C 74 566
tmp C 75 566
can C 76 566
be C 77 566
demonstrated C 78 566
when C 79 566
the C 80 566
gfr C 81 566
is C 82 566
varied C 83 566
over C 84 566
a C 85 566
wide C 86 566
range C 87 566
. C 88 566
this C 90 566
relationship C 91 566
suggests C 92 566
that C 93 566
glomerular C 94 566
intermittency C 95 566
may C 96 566
exist C 97 566
in C 98 566
the C 99 566
dog C 100 566
. C 101 566
human C 1 567
growth C 2 567
hormone C 3 567
clinical C 4 567
measurement C 5 567
, C 6 567
response C 7 567
to C 8 567
hypoglycemia C 9 567
and C 10 567
suppression C 11 567
by C 12 567
corticosteroids C 13 567
a C 14 567
standard C 15 567
test C 16 567
of C 17 567
growth C 18 567
- C 19 567
hormone C 20 567
secretory C 21 567
ca C 22 567
- C 23 567
pacity C 24 567
, C 25 567
based C 26 567
on C 27 567
radioimmunoassay C 28 567
of C 29 567
plasma C 30 567
growth C 31 567
hormone C 32 567
after C 33 567
insulin C 34 567
hypoglycemia C 35 567
, C 36 567
is C 37 567
described C 38 567
. C 39 567
in C 41 567
normal C 42 567
subjects C 43 567
a C 44 567
standard C 45 567
insulin C 46 567
tolerance C 47 567
test C 48 567
, C 49 567
caus C 50 567
- C 51 567
ing C 52 567
an C 53 567
average C 54 567
blood C 55 567
glucose C 56 567
drop C 57 567
to C 58 567
34 C 59 567
per C 60 567
cent C 61 567
of C 62 567
resting C 63 567
values C 64 567
, C 65 567
produced C 66 567
a C 67 567
mean C 68 567
rise C 69 567
in C 70 567
growth C 71 567
hor C 72 567
- C 73 567
mone C 74 567
to C 75 567
45 C 76 567
. C 77 567
. C 78 567
millimicrogm C 79 567
. C 80 567
per C 82 567
milliliter C 83 567
at C 84 567
one C 85 567
hour C 86 567
, C 87 567
with C 88 567
a C 89 567
total C 90 567
range C 91 567
of C 92 567
25 C 93 567
to C 94 567
70 C 95 567
millimicrogm C 96 567
. C 97 567
per C 99 567
mil C 100 567
- C 101 567
liliter C 102 567
. C 103 567
no C 105 567
response C 106 567
was C 107 567
observed C 108 567
in C 109 567
5 C 110 567
hypopituitary C 111 567
subjects C 112 567
. C 113 567
under C 115 567
comparable C 116 567
hypoglycemic C 117 567
stimulation C 118 567
glu C 119 567
- C 120 567
cocorticoid C 121 567
- C 122 567
treated C 123 567
patients C 124 567
showed C 125 567
a C 126 567
marked C 127 567
in C 128 567
- C 129 567
hibition C 130 567
of C 131 567
the C 132 567
growth C 133 567
- C 134 567
hormone C 135 567
response C 136 567
, C 137 567
which C 138 567
was C 139 567
related C 140 567
to C 141 567
dose C 142 567
. C 143 567
subjects C 145 567
receiving C 146 567
more C 147 567
than C 148 567
60 C 149 567
mg C 150 567
. C 151 567
of C 153 567
cortisol C 154 567
equivalent C 155 567
per C 156 567
day C 157 567
showed C 158 567
a C 159 567
mean C 160 567
plasma C 161 567
rise C 162 567
to C 163 567
6 C 164 567
. C 165 567
. C 166 567
millimicrogm C 167 567
. C 168 567
per C 170 567
milliliter C 171 567
( C 172 567
range C 173 567
, C 174 567
1 C 175 567
. C 176 567
. C 177 567
to C 178 567
13 C 179 567
millimicrogm C 180 567
. C 181 567
) C 183 567
. C 184 567
subjects C 186 567
receiving C 187 567
20 C 188 567
to C 189 567
60 C 190 567
mg C 191 567
. C 192 567
of C 194 567
cortisol C 195 567
equivalent C 196 567
per C 197 567
day C 198 567
showed C 199 567
a C 200 567
mean C 201 567
rise C 202 567
to C 203 567
16 C 204 567
. C 205 567
. C 206 567
millimicrogm C 207 567
. C 208 567
per C 210 567
milliliter C 211 567
( C 212 567
range C 213 567
, C 214 567
13 C 215 567
to C 216 567
20 C 217 567
millimicrogm C 218 567
. C 219 567
) C 221 567
. C 222 567
inhibition C 224 567
of C 225 567
human C 226 567
growth C 227 567
hormone C 228 567
was C 229 567
also C 230 567
affected C 231 567
by C 232 567
duration C 233 567
of C 234 567
glucocorticoid C 235 567
treatment C 236 567
, C 237 567
be C 238 567
- C 239 567
ing C 240 567
greater C 241 567
with C 242 567
long C 243 567
- C 244 567
term C 245 567
than C 246 567
with C 247 567
short C 248 567
- C 249 567
term C 250 567
ad C 251 567
- C 252 567
ministration C 253 567
. C 254 567
obesity C 1 568
and C 2 568
plasma C 3 568
levels C 4 568
of C 5 568
insulin C 6 568
and C 7 568
growth C 8 568
hormone C 9 568
studies C 10 568
of C 11 568
serum C 12 568
levels C 13 568
of C 14 568
glucose C 15 568
, C 16 568
free C 17 568
fatty C 18 568
acids C 19 568
, C 20 568
insulin C 21 568
, C 22 568
and C 23 568
growth C 24 568
hormone C 25 568
during C 26 568
prolonged C 27 568
fasting C 28 568
suggest C 29 568
that C 30 568
insulin C 31 568
and C 32 568
growth C 33 568
hormone C 34 568
are C 35 568
not C 36 568
responsible C 37 568
for C 38 568
certain C 39 568
metabolic C 40 568
abnormalities C 41 568
accompanying C 42 568
obesity C 43 568
. C 44 568
hypophysectomy C 1 569
, C 2 569
replacement C 3 569
therapy C 4 569
, C 5 569
and C 6 569
the C 7 569
tolerance C 8 569
of C 9 569
the C 10 569
euryhaline C 11 569
killifish C 12 569
, C 13 569
fundulus C 14 569
heteroclitus C 15 569
, C 16 569
to C 17 569
hypotonic C 18 569
media C 19 569
hypophysectomized C 20 569
fundulus C 21 569
heteroclitus C 22 569
, C 23 569
as C 24 569
previously C 25 569
reported C 26 569
, C 27 569
survive C 28 569
only C 29 569
a C 30 569
few C 31 569
days C 32 569
after C 33 569
transfer C 34 569
from C 35 569
salt C 36 569
to C 37 569
fresh C 38 569
water C 39 569
. C 40 569
survival C 42 569
time C 43 569
is C 44 569
the C 45 569
same C 46 569
when C 47 569
fish C 48 569
are C 49 569
tested C 50 569
2 C 51 569
weeks C 52 569
or C 53 569
2 C 54 569
months C 55 569
after C 56 569
hypophysectomy C 57 569
. C 58 569
gradual C 60 569
dilution C 61 569
of C 62 569
the C 63 569
external C 64 569
medium C 65 569
produces C 66 569
failure C 67 569
at C 68 569
an C 69 569
average C 70 569
salinity C 71 569
of C 72 569
0 C 73 569
. C 74 569
. C 75 569
. C 75 569
% C 76 569
( C 77 569
0 C 78 569
. C 79 569
. C 80 569
. C 80 569
- C 81 569
0 C 82 569
. C 83 569
. C 84 569
. C 84 569
% C 85 569
) C 86 569
. C 87 569
this C 89 569
salinity C 90 569
is C 91 569
comparable C 92 569
to C 93 569
that C 94 569
causing C 95 569
failure C 96 569
after C 97 569
abrupt C 98 569
transfer C 99 569
. C 100 569
although C 102 569
failure C 103 569
is C 104 569
associated C 105 569
with C 106 569
hypochloremia C 107 569
, C 108 569
daily C 109 569
injections C 110 569
of C 111 569
a C 112 569
balanced C 113 569
salt C 114 569
solution C 115 569
or C 116 569
0 C 117 569
. C 118 569
. C 119 569
% C 120 569
nacl C 121 569
shorten C 122 569
survival C 123 569
. C 124 569
daily C 126 569
injections C 127 569
of C 128 569
teleostean C 129 569
neurohypophysial C 130 569
peptides C 131 569
, C 132 569
arginine C 133 569
vasotocin C 134 569
( C 135 569
2 C 136 569
. C 137 569
. C 138 569
. C 138 569
and C 139 569
0 C 140 569
. C 141 569
. C 142 569
. C 142 569
. C 142 569
. C 142 569
pressor C 143 569
mu C 144 569
per C 145 569
gram C 146 569
) C 147 569
and C 148 569
isotocin C 149 569
( C 150 569
1 C 151 569
. C 152 569
. C 153 569
. C 153 569
and C 154 569
0 C 155 569
. C 156 569
. C 157 569
. C 157 569
. C 157 569
oxytocic C 158 569
mu C 159 569
per C 160 569
gram C 161 569
) C 162 569
do C 163 569
not C 164 569
prolong C 165 569
survival C 166 569
. C 167 569
an C 169 569
extract C 170 569
of C 171 569
caudal C 172 569
neurosecretory C 173 569
tissue C 174 569
( C 175 569
urophysis C 176 569
) C 177 569
from C 178 569
male C 179 569
tilapia C 180 569
mossambica C 181 569
had C 182 569
no C 183 569
beneficial C 184 569
action C 185 569
at C 186 569
doses C 187 569
of C 188 569
50 C 189 569
ug C 190 569
per C 191 569
gram C 192 569
every C 193 569
other C 194 569
day C 195 569
. C 196 569
purified C 198 569
ovine C 199 569
prolactin C 200 569
. C 201 569
105 C 203 569
mu C 204 569
per C 205 569
gram C 206 569
on C 207 569
alternate C 208 569
days C 209 569
, C 210 569
maintained C 211 569
survival C 212 569
of C 213 569
10 C 214 569
of C 215 569
11 C 216 569
fish C 217 569
for C 218 569
the C 219 569
duration C 220 569
of C 221 569
the C 222 569
28 C 223 569
- C 224 569
day C 225 569
test C 226 569
period C 227 569
in C 228 569
fresh C 229 569
water C 230 569
, C 231 569
irrespective C 232 569
of C 233 569
the C 234 569
period C 235 569
of C 236 569
pretreatment C 237 569
in C 238 569
salt C 239 569
water C 240 569
. C 241 569
purified C 243 569
bovine C 244 569
prolactin C 245 569
prolonged C 246 569
survival C 247 569
and C 248 569
2 C 249 569
of C 250 569
6 C 251 569
fish C 252 569
were C 253 569
maintained C 254 569
for C 255 569
28 C 256 569
days C 257 569
. C 258 569
purified C 260 569
bovine C 261 569
growth C 262 569
hormone C 263 569
was C 264 569
ineffective C 265 569
. C 266 569
monkey C 268 569
growth C 269 569
hormone C 270 569
containing C 271 569
2 C 272 569
u C 273 569
per C 274 569
milligram C 275 569
of C 276 569
prolactin C 277 569
activity C 278 569
, C 279 569
administered C 280 569
at C 281 569
a C 282 569
dose C 283 569
of C 284 569
20 C 285 569
ug C 286 569
per C 287 569
gram C 288 569
( C 289 569
equivalent C 290 569
to C 291 569
40 C 292 569
mu C 293 569
per C 294 569
gram C 295 569
prolactin C 296 569
activity C 297 569
) C 298 569
, C 299 569
prolonged C 300 569
survival C 301 569
. C 302 569
human C 304 569
growth C 305 569
hormone C 306 569
containing C 307 569
4 C 308 569
u C 309 569
per C 310 569
milligram C 311 569
of C 312 569
prolactin C 313 569
activity C 314 569
, C 315 569
at C 316 569
a C 317 569
dose C 318 569
of C 319 569
20 C 320 569
ug C 321 569
per C 322 569
gram C 323 569
( C 324 569
equivalent C 325 569
to C 326 569
80 C 327 569
ml C 328 569
per C 329 569
gram C 330 569
prolactin C 331 569
activity C 332 569
) C 333 569
also C 334 569
prolonged C 335 569
survival C 336 569
and C 337 569
4 C 338 569
of C 339 569
6 C 340 569
fish C 341 569
were C 342 569
maintained C 343 569
for C 344 569
28 C 345 569
days C 346 569
. C 347 569
the C 349 569
ability C 350 569
of C 351 569
pituitary C 352 569
preparations C 353 569
to C 354 569
protect C 355 569
hypophysectomized C 356 569
f C 357 569
. C 358 569
heteroclitus C 360 569
from C 361 569
failure C 362 569
in C 363 569
fresh C 364 569
water C 365 569
appears C 366 569
to C 367 569
be C 368 569
related C 369 569
to C 370 569
their C 371 569
prolactin C 372 569
activity C 373 569
and C 374 569
not C 375 569
to C 376 569
their C 377 569
content C 378 569
of C 379 569
neurohypophysial C 380 569
peptides C 381 569
. C 382 569
this C 384 569
suggests C 385 569
that C 386 569
an C 387 569
adenohypophysial C 388 569
hormone C 389 569
resembling C 390 569
mammalian C 391 569
prolactin C 392 569
is C 393 569
essential C 394 569
for C 395 569
survival C 396 569
of C 397 569
this C 398 569
fish C 399 569
in C 400 569
hypotonic C 401 569
external C 402 569
media C 403 569
. C 404 569
carp C 406 569
pituitary C 407 569
preparations C 408 569
do C 409 569
not C 410 569
protect C 411 569
hypophysectomized C 412 569
f C 413 569
. C 414 569
heteroclitus C 416 569
although C 417 569
f C 418 569
. C 419 569
heteroclitus C 421 569
pituitaries C 422 569
are C 423 569
known C 424 569
to C 425 569
be C 426 569
effective C 427 569
. C 428 569
resistance C 1 570
to C 2 570
human C 3 570
growth C 4 570
hormone C 5 570
in C 6 570
pituitary C 7 570
dwarfism C 8 570
: C 9 570
clinical C 10 570
and C 11 570
immunologic C 12 570
studies C 13 570
thirteen C 14 570
pituitary C 15 570
dwarfs C 16 570
have C 17 570
been C 18 570
treated C 19 570
with C 20 570
human C 21 570
growth C 22 570
hormone C 23 570
( C 24 570
hgh C 25 570
) C 26 570
, C 27 570
and C 28 570
growth C 29 570
acceleration C 30 570
with C 31 570
doses C 32 570
of C 33 570
5 C 34 570
- C 35 570
7 C 36 570
mg C 37 570
/ C 38 570
week C 39 570
has C 40 570
been C 41 570
observed C 42 570
in C 43 570
all C 44 570
but C 45 570
one C 46 570
patient C 47 570
. C 48 570
on C 50 570
therapy C 51 570
, C 52 570
this C 53 570
7 C 54 570
1 C 55 570
/ C 56 570
2 C 57 570
- C 58 570
year C 59 570
- C 60 570
old C 61 570
girl C 62 570
grew C 63 570
at C 64 570
a C 65 570
rate C 66 570
of C 67 570
1 C 68 570
. C 69 570
. C 70 570
. C 70 570
cm C 71 570
/ C 72 570
month C 73 570
for C 74 570
7 C 75 570
months C 76 570
. C 77 570
thereafter C 79 570
, C 80 570
despite C 81 570
larger C 82 570
doses C 83 570
of C 84 570
growth C 85 570
hormone C 86 570
( C 87 570
15 C 88 570
mg C 89 570
/ C 90 570
week C 91 570
) C 92 570
, C 93 570
growth C 94 570
rate C 95 570
fell C 96 570
to C 97 570
0 C 98 570
. C 99 570
. C 100 570
. C 100 570
cm C 101 570
/ C 102 570
month C 103 570
. C 104 570
this C 106 570
rate C 107 570
of C 108 570
growth C 109 570
persisted C 110 570
after C 111 570
stopping C 112 570
hgh C 113 570
. C 114 570
on C 116 570
retreatment C 117 570
on C 118 570
2 C 119 570
occasions C 120 570
, C 121 570
acceleration C 122 570
of C 123 570
growth C 124 570
did C 125 570
not C 126 570
occur C 127 570
. C 128 570
antibodies C 130 570
to C 131 570
hgh C 132 570
, C 133 570
absent C 134 570
in C 135 570
her C 136 570
serum C 137 570
before C 138 570
treatment C 139 570
, C 140 570
were C 141 570
repeatedly C 142 570
demonstrated C 143 570
in C 144 570
her C 145 570
serum C 146 570
in C 147 570
high C 148 570
concentra C 149 570
- C 150 570
tion C 151 570
( C 152 570
hgh C 153 570
binding C 154 570
capacity C 155 570
up C 156 570
to C 157 570
100 C 158 570
mg C 159 570
/ C 160 570
1 C 161 570
) C 162 570
during C 163 570
treatment C 164 570
. C 165 570
comparable C 167 570
titers C 168 570
of C 169 570
anti C 170 570
- C 171 570
body C 172 570
have C 173 570
not C 174 570
been C 175 570
found C 176 570
in C 177 570
any C 178 570
of C 179 570
the C 180 570
12 C 181 570
other C 182 570
patients C 183 570
receiving C 184 570
long C 185 570
- C 186 570
term C 187 570
hgh C 188 570
treat C 189 570
- C 190 570
ment C 191 570
. C 192 570
the C 194 570
specificity C 195 570
of C 196 570
the C 197 570
human C 198 570
anti C 199 570
- C 200 570
hgh C 201 570
serum C 202 570
differed C 203 570
from C 204 570
rabbit C 205 570
anti C 206 570
- C 207 570
hgh C 208 570
serum C 209 570
. C 210 570
whereas C 212 570
both C 213 570
monkey C 214 570
growth C 215 570
hormone C 216 570
( C 217 570
mgh C 218 570
) C 219 570
and C 220 570
hgh C 221 570
were C 222 570
effective C 223 570
inhibitors C 224 570
of C 225 570
the C 226 570
binding C 227 570
of C 228 570
hgh C 229 570
- C 230 570
131 C 231 570
i C 232 570
by C 233 570
rabbit C 234 570
antiserum C 235 570
, C 236 570
only C 237 570
hgh C 238 570
was C 239 570
an C 240 570
effective C 241 570
inhibitor C 242 570
with C 243 570
human C 244 570
antiserum C 245 570
. C 246 570
in C 248 570
like C 249 570
manner C 250 570
, C 251 570
a C 252 570
crude C 253 570
placental C 254 570
extract C 255 570
which C 256 570
was C 257 570
an C 258 570
effective C 259 570
in C 260 570
- C 261 570
hibitor C 262 570
for C 263 570
rabbit C 264 570
antiserum C 265 570
was C 266 570
ineffective C 267 570
with C 268 570
human C 269 570
anti C 270 570
- C 271 570
hgh C 272 570
serum C 273 570
. C 274 570
influence C 1 571
of C 2 571
alloxan C 3 571
diabetes C 4 571
on C 5 571
growth C 6 571
hormone C 7 571
content C 8 571
of C 9 571
the C 10 571
rat C 11 571
hypophysis C 12 571
homog C 13 571
- C 14 571
enates C 15 571
of C 16 571
adenophypophysial C 17 571
tissue C 18 571
obtained C 19 571
from C 20 571
alloxan C 21 571
- C 22 571
injected C 23 571
adult C 24 571
male C 25 571
rats C 26 571
varying C 27 571
in C 28 571
duration C 29 571
and C 30 571
severity C 31 571
of C 32 571
diabetes C 33 571
, C 34 571
as C 35 571
well C 36 571
as C 37 571
from C 38 571
diabetic C 39 571
rats C 40 571
maintained C 41 571
on C 42 571
an C 43 571
insulin C 44 571
replacement C 45 571
regimen C 46 571
, C 47 571
were C 48 571
assayed C 49 571
in C 50 571
immature C 51 571
hypophysectomized C 52 571
female C 53 571
rats C 54 571
. C 55 571
the C 57 571
ability C 58 571
of C 59 571
these C 60 571
crude C 61 571
hypophysial C 62 571
extracts C 63 571
to C 64 571
encourage C 65 571
tibial C 66 571
cartilage C 67 571
width C 68 571
ex C 69 571
- C 70 571
pansion C 71 571
gain C 72 571
in C 73 571
body C 74 571
weight C 75 571
, C 76 571
and C 77 571
to C 78 571
depress C 79 571
hematocrit C 80 571
and C 81 571
blood C 82 571
area C 83 571
levels C 84 571
was C 85 571
determined C 86 571
. C 87 571
significant C 89 571
decrements C 90 571
in C 91 571
ability C 92 571
to C 93 571
increase C 94 571
epiphysial C 95 571
cartilage C 96 571
width C 97 571
and C 98 571
ability C 99 571
to C 100 571
depress C 101 571
hematocrits C 102 571
were C 103 571
noted C 104 571
14 C 105 571
to C 106 571
28 C 107 571
days C 108 571
following C 109 571
injection C 110 571
of C 111 571
alloxan C 112 571
. C 113 571
increasing C 115 571
the C 116 571
intensity C 117 571
of C 118 571
the C 119 571
diabetic C 120 571
state C 121 571
was C 122 571
associated C 123 571
with C 124 571
decreased C 125 571
growth C 126 571
- C 127 571
promoting C 128 571
potency C 129 571
of C 130 571
hypo C 131 571
- C 132 571
physial C 133 571
preparations C 134 571
as C 135 571
well C 136 571
as C 137 571
with C 138 571
decreased C 139 571
ability C 140 571
to C 141 571
influence C 142 571
the C 143 571
hematological C 144 571
indices C 145 571
. C 146 571
hypophysial C 148 571
extracts C 149 571
taken C 150 571
from C 151 571
insulin C 152 571
- C 153 571
treated C 154 571
diabetic C 155 571
rats C 156 571
contained C 157 571
more C 158 571
growth C 159 571
hormone C 160 571
than C 161 571
equivalent C 162 571
amounts C 163 571
of C 164 571
tissue C 165 571
obtained C 166 571
from C 167 571
control C 168 571
rats C 169 571
. C 170 571
it C 172 571
is C 173 571
concluded C 174 571
that C 175 571
the C 176 571
adenohypophyses C 177 571
of C 178 571
diabetic C 179 571
rats C 180 571
contain C 181 571
diminished C 182 571
amounts C 183 571
of C 184 571
growth C 185 571
hormone C 186 571
and C 187 571
the C 188 571
insulin C 189 571
repairs C 190 571
or C 191 571
encourages C 192 571
greater C 193 571
than C 194 571
normal C 195 571
ac C 196 571
- C 197 571
cumulation C 198 571
of C 199 571
somatotrophin C 200 571
in C 201 571
these C 202 571
animals C 203 571
. C 204 571
pheochromocytoma C 1 572
without C 2 572
hypertension C 3 572
the C 4 572
patient C 5 572
developed C 6 572
symptoms C 7 572
of C 8 572
pheochromo C 9 572
- C 10 572
cytoma C 11 572
about C 12 572
15 C 13 572
years C 14 572
after C 15 572
the C 16 572
diagnosis C 17 572
of C 18 572
eosinophilic C 19 572
adenoma C 20 572
of C 21 572
the C 22 572
pituitary C 23 572
gland C 24 572
. C 25 572
the C 27 572
predominating C 28 572
symptoms C 29 572
were C 30 572
profuse C 31 572
sweating C 32 572
and C 33 572
tachycardia C 34 572
. C 35 572
hypertension C 37 572
, C 38 572
hyperglycemia C 39 572
, C 40 572
and C 41 572
glycosuria C 42 572
were C 43 572
absent C 44 572
. C 45 572
the C 47 572
relation C 48 572
of C 49 572
the C 50 572
quan C 51 572
- C 52 572
tity C 53 572
and C 54 572
the C 55 572
relative C 56 572
composition C 57 572
of C 58 572
catechol C 59 572
amines C 60 572
to C 61 572
the C 62 572
symptomatology C 63 572
is C 64 572
discussed C 65 572
. C 66 572
some C 68 572
speculation C 69 572
regarding C 70 572
the C 71 572
etiological C 72 572
importance C 73 572
of C 74 572
hypersecretion C 75 572
of C 76 572
growth C 77 572
hormone C 78 572
in C 79 572
pheochromo C 80 572
- C 81 572
cytoma C 82 572
seems C 83 572
to C 84 572
be C 85 572
in C 86 572
order C 87 572
. C 88 572
hypoglycemia C 1 573
, C 2 573
growth C 3 573
retardation C 4 573
, C 5 573
and C 6 573
probable C 7 573
isolated C 8 573
growth C 9 573
hormone C 10 573
deficiency C 11 573
in C 12 573
a C 13 573
1 C 14 573
- C 15 573
year C 16 573
- C 17 573
old C 18 573
child C 19 573
a C 20 573
heretofore C 21 573
unreported C 22 573
association C 23 573
of C 24 573
defects C 25 573
, C 26 573
namely C 27 573
hypoglycemia C 28 573
, C 29 573
growth C 30 573
retardation C 31 573
, C 32 573
and C 33 573
deficiency C 34 573
of C 35 573
serum C 36 573
growth C 37 573
hormonelike C 38 573
activity C 39 573
in C 40 573
a C 41 573
1 C 42 573
- C 43 573
year C 44 573
- C 45 573
old C 46 573
child C 47 573
is C 48 573
described C 49 573
. C 50 573
human C 52 573
growth C 53 573
hormone C 54 573
( C 55 573
hgh C 56 573
) C 57 573
, C 58 573
3 C 59 573
mg C 60 573
. C 61 573
a C 63 573
day C 64 573
for C 65 573
7 C 66 573
days C 67 573
, C 68 573
doubled C 69 573
the C 70 573
fasting C 71 573
blood C 72 573
sugar C 73 573
, C 74 573
prevented C 75 573
the C 76 573
postprandial C 77 573
hypoglycemia C 78 573
, C 79 573
and C 80 573
reversed C 81 573
the C 82 573
sensitivity C 83 573
to C 84 573
tolbutamide C 85 573
and C 86 573
leucine C 87 573
. C 88 573
treatment C 90 573
with C 91 573
1 C 92 573
mg C 93 573
. C 94 573
of C 96 573
hgh C 97 573
3 C 98 573
times C 99 573
a C 100 573
week C 101 573
produced C 102 573
a C 103 573
growth C 104 573
of C 105 573
7 C 106 573
inches C 107 573
in C 108 573
3 C 109 573
months C 110 573
compared C 111 573
to C 112 573
a C 113 573
growth C 114 573
of C 115 573
1 C 116 573
inch C 117 573
in C 118 573
the C 119 573
previous C 120 573
13 C 121 573
months C 122 573
. C 123 573
since C 125 573
the C 126 573
protein C 127 573
- C 128 573
bound C 129 573
- C 130 573
iodine C 131 573
and C 132 573
the C 133 573
response C 134 573
to C 135 573
methopyrapone C 136 573
were C 137 573
normal C 138 573
and C 139 573
the C 140 573
blood C 141 573
level C 142 573
of C 143 573
growth C 144 573
hormone C 145 573
was C 146 573
low C 147 573
, C 148 573
this C 149 573
case C 150 573
is C 151 573
presented C 152 573
as C 153 573
a C 154 573
probable C 155 573
isolated C 156 573
growth C 157 573
hormone C 158 573
deficiency C 159 573
. C 160 573
production C 1 574
, C 2 574
secretion C 3 574
, C 4 574
and C 5 574
availability C 6 574
of C 7 574
insulin C 8 574
a C 9 574
more C 10 574
precise C 11 574
understanding C 12 574
of C 13 574
the C 14 574
metabolic C 15 574
phase C 16 574
of C 17 574
diabetes C 18 574
mellitus C 19 574
requires C 20 574
reliable C 21 574
information C 22 574
concerning C 23 574
the C 24 574
synthesis C 25 574
, C 26 574
manner C 27 574
of C 28 574
release C 29 574
and C 30 574
transport C 31 574
of C 32 574
insulin C 33 574
, C 34 574
as C 35 574
well C 36 574
as C 37 574
of C 38 574
the C 39 574
behavior C 40 574
of C 41 574
agents C 42 574
which C 43 574
interfere C 44 574
with C 45 574
the C 46 574
actions C 47 574
of C 48 574
the C 49 574
hormone C 50 574
by C 51 574
inhibition C 52 574
or C 53 574
destruction C 54 574
. C 55 574
we C 57 574
shall C 58 574
deal C 59 574
with C 60 574
a C 61 574
variety C 62 574
of C 63 574
these C 64 574
problems C 65 574
here C 66 574
and C 67 574
it C 68 574
might C 69 574
be C 70 574
helpful C 71 574
at C 72 574
the C 73 574
outset C 74 574
to C 75 574
outline C 76 574
first C 77 574
our C 78 574
present C 79 574
understanding C 80 574
of C 81 574
the C 82 574
chemical C 83 574
structure C 84 574
of C 85 574
insulin C 86 574
since C 87 574
many C 88 574
useful C 89 574
hints C 90 574
flow C 91 574
out C 92 574
of C 93 574
a C 94 574
consideration C 95 574
of C 96 574
the C 97 574
nature C 98 574
of C 99 574
the C 100 574
molecule C 101 574
. C 102 574
growth C 1 575
and C 2 575
growth C 3 575
retardation C 4 575
various C 5 575
attempts C 6 575
have C 7 575
been C 8 575
made C 9 575
over C 10 575
the C 11 575
years C 12 575
to C 13 575
define C 14 575
growth C 15 575
. C 16 575
from C 18 575
the C 19 575
standpoint C 20 575
of C 21 575
this C 22 575
review C 23 575
, C 24 575
growth C 25 575
is C 26 575
the C 27 575
physiological C 28 575
accretion C 29 575
of C 30 575
new C 31 575
tissue C 32 575
which C 33 575
is C 34 575
reflected C 35 575
in C 36 575
the C 37 575
acquisition C 38 575
of C 39 575
protein C 40 575
and C 41 575
water C 42 575
. C 43 575
this C 45 575
process C 46 575
in C 47 575
almost C 48 575
all C 49 575
instances C 50 575
leads C 51 575
to C 52 575
increase C 53 575
in C 54 575
size C 55 575
( C 56 575
length C 57 575
, C 58 575
weight C 59 575
, C 60 575
and C 61 575
volume C 62 575
) C 63 575
and C 64 575
actively C 65 575
progresses C 66 575
from C 67 575
the C 68 575
fertilization C 69 575
of C 70 575
the C 71 575
ovum C 72 575
to C 73 575
the C 74 575
period C 75 575
of C 76 575
sexual C 77 575
maturity C 78 575
where C 79 575
millions C 80 575
of C 81 575
cells C 82 575
are C 83 575
present C 84 575
in C 85 575
a C 86 575
state C 87 575
of C 88 575
advanced C 89 575
organization C 90 575
. C 91 575
with C 93 575
further C 94 575
time C 95 575
, C 96 575
growth C 97 575
is C 98 575
less C 99 575
and C 100 575
, C 101 575
indeed C 102 575
, C 103 575
may C 104 575
become C 105 575
negative C 106 575
insofar C 107 575
as C 108 575
cells C 109 575
are C 110 575
lost C 111 575
. C 112 575
long C 1 576
- C 2 576
term C 3 576
treatment C 4 576
of C 5 576
hypopituitary C 6 576
and C 7 576
of C 8 576
achondroplastic C 9 576
dwarfism C 10 576
with C 11 576
human C 12 576
growth C 13 576
hormone C 14 576
we C 15 576
have C 16 576
treated C 17 576
an C 18 576
8 C 19 576
year C 20 576
old C 21 576
hypopi C 22 576
- C 23 576
tuitary C 24 576
dwarf C 25 576
intermittently C 26 576
with C 27 576
hgh C 28 576
( C 29 576
wilhelmi C 30 576
) C 31 576
for C 32 576
4 C 33 576
years C 34 576
. C 35 576
with C 37 576
1 C 38 576
mg C 39 576
. C 40 576
3 C 42 576
times C 43 576
a C 44 576
week C 45 576
the C 46 576
monthly C 47 576
growth C 48 576
rate C 49 576
was C 50 576
1 C 51 576
/ C 52 576
4 C 53 576
inch C 54 576
. C 55 576
as C 57 576
treatment C 58 576
continued C 59 576
he C 60 576
became C 61 576
resistant C 62 576
. C 63 576
increasing C 65 576
the C 66 576
dosage C 67 576
to C 68 576
3 C 69 576
mg C 70 576
. C 71 576
3 C 73 576
times C 74 576
a C 75 576
week C 76 576
at C 77 576
the C 78 576
age C 79 576
of C 80 576
12 C 81 576
induced C 82 576
a C 83 576
monthly C 84 576
growth C 85 576
rate C 86 576
of C 87 576
2 C 88 576
/ C 89 576
5 C 90 576
inch C 91 576
. C 92 576
this C 94 576
growth C 95 576
- C 96 576
promoting C 97 576
effect C 98 576
is C 99 576
at C 100 576
least C 101 576
as C 102 576
great C 103 576
as C 104 576
that C 105 576
reported C 106 576
for C 107 576
the C 108 576
li C 109 576
and C 110 576
raben C 111 576
preparations C 112 576
. C 113 576
we C 115 576
have C 116 576
also C 117 576
treated C 118 576
a C 119 576
15 C 120 576
year C 121 576
old C 122 576
severely C 123 576
de C 124 576
- C 125 576
formed C 126 576
' C 127 576
achondroplastic C 128 576
' C 129 576
dwarf C 130 576
for C 131 576
a C 132 576
year C 133 576
. C 134 576
with C 136 576
3 C 137 576
mg C 138 576
. C 139 576
3 C 141 576
times C 142 576
a C 143 576
week C 144 576
he C 145 576
grew C 146 576
1 C 147 576
/ C 148 576
2 C 149 576
inch C 150 576
in C 151 576
the C 152 576
first C 153 576
month C 154 576
. C 155 576
the C 157 576
spurt C 158 576
in C 159 576
growth C 160 576
subsided C 161 576
. C 162 576
with C 164 576
5 C 165 576
mg C 166 576
. C 167 576
3 C 169 576
times C 170 576
a C 171 576
week C 172 576
he C 173 576
grew C 174 576
another C 175 576
1 C 176 576
/ C 177 576
2 C 178 576
inch C 179 576
in C 180 576
a C 181 576
month C 182 576
, C 183 576
but C 184 576
growth C 185 576
was C 186 576
not C 187 576
main C 188 576
- C 189 576
tained C 190 576
. C 191 576
acromegaly C 1 577
the C 2 577
effects C 3 577
of C 4 577
various C 5 577
steroid C 6 577
hormones C 7 577
on C 8 577
the C 9 577
insulin C 10 577
- C 11 577
induced C 12 577
growth C 13 577
hormone C 14 577
response C 15 577
and C 16 577
peter C 17 577
h C 18 577
. C 19 577
forsham C 21 577
the C 22 577
availability C 23 577
of C 24 577
a C 25 577
sensitive C 26 577
assay C 27 577
for C 28 577
human C 29 577
growth C 30 577
hormone C 31 577
has C 32 577
made C 33 577
it C 34 577
possible C 35 577
to C 36 577
directly C 37 577
measure C 38 577
the C 39 577
effects C 40 577
of C 41 577
various C 42 577
agents C 43 577
purported C 44 577
to C 45 577
alter C 46 577
growth C 47 577
patterns C 48 577
. C 49 577
acromegalic C 51 577
patients C 52 577
present C 53 577
a C 54 577
special C 55 577
problem C 56 577
both C 57 577
in C 58 577
early C 59 577
diagnosis C 60 577
and C 61 577
in C 62 577
therapy C 63 577
. C 64 577
being C 66 577
able C 67 577
to C 68 577
measure C 69 577
growth C 70 577
hormone C 71 577
in C 72 577
these C 73 577
patients C 74 577
provides C 75 577
an C 76 577
accurate C 77 577
index C 78 577
of C 79 577
activity C 80 577
and C 81 577
a C 82 577
precise C 83 577
measure C 84 577
of C 85 577
therapeutic C 86 577
effectiveness C 87 577
. C 88 577
in C 90 577
an C 91 577
attempt C 92 577
to C 93 577
determine C 94 577
whether C 95 577
a C 96 577
pituitary C 97 577
block C 98 577
of C 99 577
growth C 100 577
hormone C 101 577
secretion C 102 577
is C 103 577
feasible C 104 577
in C 105 577
this C 106 577
condition C 107 577
, C 108 577
a C 109 577
study C 110 577
was C 111 577
made C 112 577
of C 113 577
the C 114 577
effects C 115 577
of C 116 577
estrogen C 117 577
, C 118 577
androgen C 119 577
and C 120 577
glucocorticoid C 121 577
administration C 122 577
on C 123 577
growth C 124 577
hormone C 125 577
response C 126 577
to C 127 577
a C 128 577
standard C 129 577
insulin C 130 577
tolerance C 131 577
test C 132 577
in C 133 577
a C 134 577
patient C 135 577
with C 136 577
active C 137 577
acro C 138 577
- C 139 577
megaly C 140 577
. C 141 577
in C 143 577
the C 144 577
dosage C 145 577
schedules C 146 577
used C 147 577
in C 148 577
this C 149 577
study C 150 577
, C 151 577
it C 152 577
was C 153 577
not C 154 577
possible C 155 577
to C 156 577
suppress C 157 577
either C 158 577
basal C 159 577
growth C 160 577
hormone C 161 577
secretion C 162 577
or C 163 577
blunt C 164 577
its C 165 577
responsiveness C 166 577
to C 167 577
the C 168 577
normal C 169 577
physiologic C 170 577
stimulus C 171 577
of C 172 577
hypoglycemia C 173 577
. C 174 577
practical C 1 578
human C 2 578
growth C 3 578
hormone C 4 578
preparation C 5 578
and C 6 578
clinical C 7 578
use C 8 578
human C 9 578
growth C 10 578
hormone C 11 578
was C 12 578
prepared C 13 578
from C 14 578
acetone C 15 578
- C 16 578
dried C 17 578
pituitary C 18 578
powder C 19 578
by C 20 578
hot C 21 578
glacial C 22 578
acetic C 23 578
acid C 24 578
extraction C 25 578
and C 26 578
subsequent C 27 578
precipita C 28 578
- C 29 578
tion C 30 578
by C 31 578
sodium C 32 578
chloride C 33 578
and C 34 578
cold C 35 578
acetone C 36 578
. C 37 578
the C 39 578
yield C 40 578
was C 41 578
13 C 42 578
per C 43 578
cent C 44 578
and C 45 578
the C 46 578
preparation C 47 578
was C 48 578
called C 49 578
practical C 50 578
growth C 51 578
hormone C 52 578
in C 53 578
recognition C 54 578
of C 55 578
its C 56 578
complement C 57 578
of C 58 578
corticotropin C 59 578
. C 60 578
treatment C 62 578
of C 63 578
two C 64 578
dwarfs C 65 578
with C 66 578
practical C 67 578
growth C 68 578
hormone C 69 578
in C 70 578
aqueous C 71 578
solution C 72 578
, C 73 578
1 C 74 578
or C 75 578
2 C 76 578
mg C 77 578
intra C 78 578
- C 79 578
muscularly C 80 578
on C 81 578
alternate C 82 578
days C 83 578
, C 84 578
accelerated C 85 578
the C 86 578
growth C 87 578
rate C 88 578
and C 89 578
there C 90 578
were C 91 578
no C 92 578
physical C 93 578
signs C 94 578
or C 95 578
laboratory C 96 578
indications C 97 578
of C 98 578
adrenal C 99 578
stimulation C 100 578
or C 101 578
other C 102 578
adverse C 103 578
effects C 104 578
. C 105 578
the C 107 578
preparation C 108 578
is C 109 578
recom C 110 578
- C 111 578
mended C 112 578
for C 113 578
its C 114 578
safety C 115 578
, C 116 578
simplicity C 117 578
and C 118 578
relatively C 119 578
good C 120 578
yield C 121 578
. C 122 578
hypophysectomy C 1 579
and C 2 579
the C 3 579
lipolytic C 4 579
action C 5 579
of C 6 579
epinephrine C 7 579
in C 8 579
vitro C 9 579
the C 10 579
response C 11 579
of C 12 579
normal C 13 579
adipose C 14 579
tissue C 15 579
to C 16 579
epinephrine C 17 579
( C 18 579
0 C 19 579
. C 20 579
. C 21 579
. C 21 579
ug C 22 579
/ C 23 579
ml C 24 579
incubation C 25 579
medium C 26 579
) C 27 579
is C 28 579
completely C 29 579
abolished C 30 579
by C 31 579
hypo C 32 579
- C 33 579
physectomy C 34 579
of C 35 579
the C 36 579
donor C 37 579
rats C 38 579
. C 39 579
treatment C 41 579
of C 42 579
hypophysectomized C 43 579
rats C 44 579
with C 45 579
crude C 46 579
, C 47 579
whole C 48 579
rat C 49 579
pituitary C 50 579
extract C 51 579
restored C 52 579
the C 53 579
lipolytic C 54 579
ac C 55 579
- C 56 579
tion C 57 579
of C 58 579
epinephrine C 59 579
to C 60 579
normal C 61 579
. C 62 579
posterior C 64 579
pi C 65 579
- C 66 579
tuitary C 67 579
extract C 68 579
and C 69 579
corticotropin C 70 579
replacement C 71 579
was C 72 579
without C 73 579
effect C 74 579
. C 75 579
thyrotropin C 77 579
injections C 78 579
produced C 79 579
a C 80 579
partial C 81 579
, C 82 579
and C 83 579
growth C 84 579
hormone C 85 579
treatment C 86 579
a C 87 579
full C 88 579
restoration C 89 579
of C 90 579
the C 91 579
lipolytic C 92 579
action C 93 579
of C 94 579
epinephrine C 95 579
. C 96 579
treatment C 98 579
of C 99 579
hypo C 100 579
- C 101 579
physectomized C 102 579
rats C 103 579
with C 104 579
cortisol C 105 579
or C 106 579
cortico C 107 579
- C 108 579
sterone C 109 579
reestablished C 110 579
the C 111 579
sensitivity C 112 579
of C 113 579
their C 114 579
adipose C 115 579
tissue C 116 579
to C 117 579
epinephrine C 118 579
, C 119 579
but C 120 579
only C 121 579
when C 122 579
relatively C 123 579
large C 124 579
doses C 125 579
of C 126 579
these C 127 579
hormones C 128 579
were C 129 579
given C 130 579
. C 131 579
physiological C 133 579
doses C 134 579
of C 135 579
triiodothyronine C 136 579
( C 137 579
1 C 138 579
ug C 139 579
/ C 140 579
rat C 141 579
/ C 142 579
day C 143 579
) C 144 579
, C 145 579
however C 146 579
, C 147 579
restored C 148 579
the C 149 579
nor C 150 579
- C 151 579
mal C 152 579
response C 153 579
to C 154 579
epinephrine C 155 579
. C 156 579
it C 158 579
is C 159 579
concluded C 160 579
that C 161 579
several C 162 579
endocrine C 163 579
factors C 164 579
can C 165 579
influence C 166 579
the C 167 579
lipolytic C 168 579
action C 169 579
of C 170 579
epinephrine C 171 579
but C 172 579
that C 173 579
their C 174 579
physiological C 175 579
importance C 176 579
cannot C 177 579
yet C 178 579
be C 179 579
quantitated C 180 579
. C 181 579
c C 1 580
- C 2 580
acetyl C 3 580
bovine C 4 580
growth C 5 580
hormone C 6 580
a C 7 580
procedure C 8 580
is C 9 580
described C 10 580
for C 11 580
labeling C 12 580
bovine C 13 580
growth C 14 580
hormone C 15 580
and C 16 580
human C 17 580
albumin C 18 580
with C 19 580
c C 20 580
- C 21 580
acetylation C 22 580
. C 23 580
the C 25 580
labeled C 26 580
molecule C 27 580
was C 28 580
biologically C 29 580
and C 30 580
antigenically C 31 580
similar C 32 580
to C 33 580
unlabeled C 34 580
bovine C 35 580
growth C 36 580
hormone C 37 580
. C 38 580
following C 40 580
administration C 41 580
of C 42 580
the C 43 580
labeled C 44 580
hormone C 45 580
to C 46 580
animals C 47 580
, C 48 580
the C 49 580
label C 50 580
appeared C 51 580
to C 52 580
remain C 53 580
attached C 54 580
to C 55 580
the C 56 580
growth C 57 580
hormone C 58 580
molecule C 59 580
for C 60 580
at C 61 580
least C 62 580
4 C 63 580
hours C 64 580
. C 65 580
administra C 67 580
- C 68 580
tion C 69 580
of C 70 580
the C 71 580
labeled C 72 580
hormone C 73 580
promoted C 74 580
growth C 75 580
in C 76 580
hypophysec C 77 580
- C 78 580
tomized C 79 580
rats C 80 580
and C 81 580
increased C 82 580
the C 83 580
free C 84 580
fatty C 85 580
acid C 86 580
concentration C 87 580
in C 88 580
rabbit C 89 580
serum C 90 580
to C 91 580
a C 92 580
degree C 93 580
comparable C 94 580
with C 95 580
that C 96 580
seen C 97 580
following C 98 580
administration C 99 580
of C 100 580
unlabeled C 101 580
growth C 102 580
hormone C 103 580
. C 104 580
rabbit C 106 580
anti C 107 580
- C 108 580
bovine C 109 580
growth C 110 580
hormone C 111 580
serum C 112 580
neutralized C 113 580
the C 114 580
rat C 115 580
growth C 116 580
response C 117 580
to C 118 580
the C 119 580
acetylated C 120 580
hormone C 121 580
, C 122 580
and C 123 580
immunized C 124 580
rabbits C 125 580
had C 126 580
altered C 127 580
isotope C 128 580
dilution C 129 580
and C 130 580
no C 131 580
increase C 132 580
in C 133 580
serum C 134 580
free C 135 580
fatty C 136 580
acids C 137 580
after C 138 580
intravenous C 139 580
injection C 140 580
of C 141 580
the C 142 580
labeled C 143 580
hormone C 144 580
. C 145 580
growth C 1 581
hormone C 2 581
growth C 3 581
hormone C 4 581
influences C 5 581
protein C 6 581
, C 7 581
fat C 8 581
, C 9 581
carbohydrate C 10 581
, C 11 581
and C 12 581
mineral C 13 581
metabolism C 14 581
. C 15 581
it C 17 581
promotes C 18 581
nitrogen C 19 581
retention C 20 581
, C 21 581
growth C 22 581
of C 23 581
cartilage C 24 581
, C 25 581
transportation C 26 581
of C 27 581
amino C 28 581
acids C 29 581
through C 30 581
the C 31 581
cell C 32 581
wall C 33 581
, C 34 581
and C 35 581
incorporation C 36 581
of C 37 581
amino C 38 581
acids C 39 581
into C 40 581
protein C 41 581
. C 42 581
this C 44 581
factor C 45 581
mo C 46 581
- C 47 581
bilizes C 48 581
free C 49 581
fatty C 50 581
acids C 51 581
from C 52 581
adipose C 53 581
tissue C 54 581
and C 55 581
increases C 56 581
the C 57 581
serum C 58 581
concentration C 59 581
of C 60 581
these C 61 581
substances C 62 581
; C 63 581
long C 64 581
- C 65 581
term C 66 581
administration C 67 581
of C 68 581
this C 69 581
hormone C 70 581
is C 71 581
followed C 72 581
by C 73 581
depletion C 74 581
of C 75 581
body C 76 581
fat C 77 581
stores C 78 581
and C 79 581
inhibition C 80 581
of C 81 581
fatty C 82 581
acid C 83 581
synthesis C 84 581
. C 85 581
in C 87 581
diabetic C 88 581
subjects C 89 581
growth C 90 581
hor C 91 581
- C 92 581
mone C 93 581
administration C 94 581
is C 95 581
followed C 96 581
by C 97 581
hyper C 98 581
- C 99 581
glycemia C 100 581
, C 101 581
glycosuria C 102 581
, C 103 581
and C 104 581
ketosis C 105 581
; C 106 581
its C 107 581
effect C 108 581
on C 109 581
carbohydrate C 110 581
metabolism C 111 581
in C 112 581
normal C 113 581
sub C 114 581
- C 115 581
jects C 116 581
is C 117 581
more C 118 581
subtle C 119 581
. C 120 581
sodium C 122 581
, C 123 581
potassium C 124 581
, C 125 581
and C 126 581
inorganic C 127 581
phosphate C 128 581
are C 129 581
retained C 130 581
following C 131 581
the C 132 581
administration C 133 581
of C 134 581
growth C 135 581
hormone C 136 581
. C 137 581
hypercalciuria C 139 581
also C 140 581
accompanies C 141 581
such C 142 581
treat C 143 581
- C 144 581
ment C 145 581
, C 146 581
an C 147 581
effect C 148 581
mediated C 149 581
through C 150 581
the C 151 581
para C 152 581
- C 153 581
thyroid C 154 581
glands C 155 581
. C 156 581
human C 158 581
growth C 159 581
hormone C 160 581
may C 161 581
be C 162 581
detected C 163 581
in C 164 581
the C 165 581
serum C 166 581
through C 167 581
the C 168 581
use C 169 581
of C 170 581
the C 171 581
radio C 172 581
- C 173 581
immunoassay C 174 581
. C 175 581
the C 177 581
hypothalamus C 178 581
is C 179 581
inti C 180 581
- C 181 581
mately C 182 581
involved C 183 581
with C 184 581
the C 185 581
control C 186 581
of C 187 581
the C 188 581
secretion C 189 581
and C 190 581
release C 191 581
of C 192 581
growth C 193 581
hormone C 194 581
from C 195 581
the C 196 581
pituitary C 197 581
. C 198 581
there C 200 581
is C 201 581
a C 202 581
correlation C 203 581
between C 204 581
the C 205 581
availability C 206 581
of C 207 581
glucose C 208 581
for C 209 581
me C 210 581
- C 211 581
tabolism C 212 581
and C 213 581
the C 214 581
plasma C 215 581
concentration C 216 581
of C 217 581
growth C 218 581
hormone C 219 581
; C 220 581
when C 221 581
glucose C 222 581
is C 223 581
unavail C 224 581
- C 225 581
able C 226 581
growth C 227 581
hormone C 228 581
is C 229 581
released C 230 581
in C 231 581
order C 232 581
to C 233 581
provide C 234 581
a C 235 581
substitute C 236 581
source C 237 581
of C 238 581
energy C 239 581
, C 240 581
fatty C 241 581
acids C 242 581
. C 243 581
the C 245 581
administration C 246 581
of C 247 581
growth C 248 581
hormone C 249 581
to C 250 581
the C 251 581
patient C 252 581
with C 253 581
hypopituitarism C 254 581
is C 255 581
fol C 256 581
- C 257 581
lowed C 258 581
by C 259 581
growth C 260 581
in C 261 581
many C 262 581
instances C 263 581
, C 264 581
but C 265 581
it C 266 581
has C 267 581
not C 268 581
usually C 269 581
been C 270 581
effective C 271 581
in C 272 581
promoting C 273 581
growth C 274 581
in C 275 581
individuals C 276 581
with C 277 581
other C 278 581
abnormali C 279 581
- C 280 581
ties C 281 581
. C 282 581
acquired C 284 581
resistance C 285 581
to C 286 581
the C 287 581
effect C 288 581
of C 289 581
growth C 290 581
hormone C 291 581
is C 292 581
accompanied C 293 581
by C 294 581
the C 295 581
de C 296 581
- C 297 581
velopment C 298 581
of C 299 581
antibodies C 300 581
directed C 301 581
against C 302 581
this C 303 581
protein C 304 581
. C 305 581
recent C 1 582
advances C 2 582
in C 3 582
physiology C 4 582
of C 5 582
bone C 6 582
: C 7 582
part C 8 582
i C 9 582
our C 10 582
introductory C 11 582
textbook C 12 582
summarizes C 13 582
knowledge C 14 582
of C 15 582
the C 16 582
biochemistry C 17 582
and C 18 582
physiology C 19 582
of C 20 582
bone C 21 582
and C 22 582
calcium C 23 582
metabolism C 24 582
up C 25 582
through C 26 582
1960 C 27 582
. C 28 582
in C 30 582
this C 31 582
lecture C 32 582
, C 33 582
we C 34 582
will C 35 582
outline C 36 582
a C 37 582
few C 38 582
important C 39 582
advances C 40 582
appearing C 41 582
since C 42 582
that C 43 582
time C 44 582
. C 45 582
references C 47 582
to C 48 582
the C 49 582
original C 50 582
literature C 51 582
need C 52 582
not C 53 582
be C 54 582
repeated C 55 582
here C 56 582
. C 57 582
the C 59 582
object C 60 582
is C 61 582
to C 62 582
bring C 63 582
some C 64 582
of C 65 582
the C 66 582
subjects C 67 582
we C 68 582
are C 69 582
investigating C 70 582
up C 71 582
- C 72 582
to C 73 582
- C 74 582
date C 75 582
and C 76 582
to C 77 582
present C 78 582
new C 79 582
problems C 80 582
for C 81 582
laboratory C 82 582
research C 83 582
. C 84 582
the C 86 582
hypothetical C 87 582
new C 88 582
hormone C 89 582
, C 90 582
calcitonin C 91 582
, C 92 582
of C 93 582
copp C 94 582
and C 95 582
cameron C 96 582
will C 97 582
be C 98 582
discussed C 99 582
in C 100 582
detail C 101 582
in C 102 582
dr C 103 582
. C 104 582
mclean C 106 582
' C 107 582
s C 108 582
lecture C 109 582
on C 110 582
the C 111 582
parathyroid C 112 582
glands C 113 582
and C 114 582
bone C 115 582
. C 116 582
hyperplastic C 1 583
lesions C 2 583
of C 3 583
mouse C 4 583
mammary C 5 583
glands C 6 583
after C 7 583
treatment C 8 583
with C 9 583
3 C 10 583
- C 11 583
methyl C 12 583
- C 13 583
cholanthrene C 14 583
hyperplastic C 15 583
lesions C 16 583
were C 17 583
present C 18 583
in C 19 583
the C 20 583
mammary C 21 583
glands C 22 583
of C 23 583
mice C 24 583
treated C 25 583
with C 26 583
3 C 27 583
- C 28 583
methylcholanthrene C 29 583
and C 30 583
exogenous C 31 583
hormones C 32 583
. C 33 583
the C 35 583
lesions C 36 583
were C 37 583
similar C 38 583
to C 39 583
those C 40 583
found C 41 583
in C 42 583
glands C 43 583
that C 44 583
were C 45 583
exposed C 46 583
to C 47 583
mammary C 48 583
tumor C 49 583
virus C 50 583
. C 51 583
it C 53 583
is C 54 583
probable C 55 583
that C 56 583
the C 57 583
production C 58 583
of C 59 583
mammary C 60 583
gland C 61 583
hyper C 62 583
- C 63 583
plastic C 64 583
lesions C 65 583
could C 66 583
serve C 67 583
as C 68 583
a C 69 583
measure C 70 583
of C 71 583
the C 72 583
effectiveness C 73 583
of C 74 583
a C 75 583
chemical C 76 583
compound C 77 583
as C 78 583
a C 79 583
carcinogenic C 80 583
agent C 81 583
for C 82 583
the C 83 583
mammary C 84 583
gland C 85 583
. C 86 583
bone C 1 584
growth C 2 584
and C 3 584
metabolic C 4 584
studies C 5 584
of C 6 584
premature C 7 584
infants C 8 584
treated C 9 584
with C 10 584
human C 11 584
growth C 12 584
hormone C 13 584
the C 14 584
influence C 15 584
of C 16 584
exogenous C 17 584
human C 18 584
growth C 19 584
hormone C 20 584
on C 21 584
growth C 22 584
and C 23 584
metabo C 24 584
- C 25 584
lism C 26 584
of C 27 584
premature C 28 584
infants C 29 584
was C 30 584
observed C 31 584
. C 32 584
it C 34 584
was C 35 584
not C 36 584
possible C 37 584
to C 38 584
register C 39 584
any C 40 584
in C 41 584
- C 42 584
crease C 43 584
of C 44 584
linear C 45 584
bone C 46 584
growth C 47 584
after C 48 584
hormone C 49 584
administration C 50 584
; C 51 584
concomitantly C 52 584
urinary C 53 584
hy C 54 584
- C 55 584
droxyproline C 56 584
excretion C 57 584
did C 58 584
not C 59 584
change C 60 584
significantly C 61 584
. C 62 584
nitrogen C 64 584
balance C 65 584
studies C 66 584
indicated C 67 584
a C 68 584
sharp C 69 584
increase C 70 584
of C 71 584
nitrogen C 72 584
retention C 73 584
, C 74 584
due C 75 584
to C 76 584
a C 77 584
reduced C 78 584
urinary C 79 584
excretion C 80 584
, C 81 584
in C 82 584
all C 83 584
infants C 84 584
. C 85 584
calcium C 87 584
and C 88 584
phosphorus C 89 584
balances C 90 584
rose C 91 584
in C 92 584
three C 93 584
out C 94 584
of C 95 584
four C 96 584
premature C 97 584
infants C 98 584
treated C 99 584
with C 100 584
growth C 101 584
hormone C 102 584
, C 103 584
but C 104 584
the C 105 584
characteris C 106 584
- C 107 584
tic C 108 584
sth C 109 584
calciuric C 110 584
action C 111 584
of C 112 584
sth C 113 584
was C 114 584
not C 115 584
observed C 116 584
. C 117 584
furthermore C 119 584
, C 120 584
sth C 121 584
failed C 122 584
to C 123 584
in C 124 584
- C 125 584
duce C 126 584
any C 127 584
significant C 128 584
increase C 129 584
in C 130 584
nefa C 131 584
serum C 132 584
concentration C 133 584
of C 134 584
premature C 135 584
infants C 136 584
. C 137 584
it C 139 584
may C 140 584
therefore C 141 584
be C 142 584
concluded C 143 584
that C 144 584
the C 145 584
metabolic C 146 584
response C 147 584
of C 148 584
premature C 149 584
infants C 150 584
to C 151 584
sth C 152 584
differs C 153 584
consistently C 154 584
from C 155 584
that C 156 584
normally C 157 584
observed C 158 584
in C 159 584
more C 160 584
mature C 161 584
subjects C 162 584
. C 163 584
growth C 1 585
hormone C 2 585
action C 3 585
on C 4 585
rat C 5 585
liver C 6 585
rna C 7 585
polymerase C 8 585
the C 9 585
effect C 10 585
of C 11 585
growth C 12 585
hormone C 13 585
on C 14 585
the C 15 585
activity C 16 585
of C 17 585
the C 18 585
rna C 19 585
polymerase C 20 585
measured C 21 585
in C 22 585
this C 23 585
system C 24 585
is C 25 585
shown C 26 585
in C 27 585
table C 28 585
2 C 29 585
. C 30 585
it C 32 585
can C 33 585
be C 34 585
seen C 35 585
that C 36 585
hypophysectomy C 37 585
of C 38 585
the C 39 585
rat C 40 585
results C 41 585
in C 42 585
decreased C 43 585
activity C 44 585
of C 45 585
the C 46 585
rna C 47 585
polymerase C 48 585
and C 49 585
that C 50 585
the C 51 585
injection C 52 585
of C 53 585
1 C 54 585
mg C 55 585
of C 56 585
human C 57 585
growth C 58 585
hormone C 59 585
into C 60 585
the C 61 585
rat C 62 585
12 C 63 585
h C 64 585
before C 65 585
death C 66 585
increased C 67 585
the C 68 585
enzyme C 69 585
activity C 70 585
both C 71 585
in C 72 585
hypophysectomized C 73 585
rats C 74 585
and C 75 585
in C 76 585
normal C 77 585
rats C 78 585
. C 79 585
however C 81 585
, C 82 585
the C 83 585
stimulating C 84 585
effect C 85 585
of C 86 585
growth C 87 585
hormone C 88 585
was C 89 585
only C 90 585
seen C 91 585
in C 92 585
the C 93 585
absence C 94 585
of C 95 585
high C 96 585
concentrations C 97 585
of C 98 585
ammon C 99 585
- C 100 585
ium C 101 585
sulphate C 102 585
; C 103 585
raising C 104 585
the C 105 585
ionic C 106 585
strength C 107 585
of C 108 585
the C 109 585
assay C 110 585
medium C 111 585
abolished C 112 585
the C 113 585
growth C 114 585
hormone C 115 585
effect C 116 585
. C 117 585
it C 119 585
should C 120 585
be C 121 585
mentioned C 122 585
that C 123 585
addition C 124 585
of C 125 585
growth C 126 585
hormone C 127 585
in C 128 585
vitro C 129 585
in C 130 585
the C 131 585
presence C 132 585
or C 133 585
absence C 134 585
of C 135 585
ammonium C 136 585
sulphate C 137 585
has C 138 585
had C 139 585
no C 140 585
significant C 141 585
effect C 142 585
on C 143 585
the C 144 585
labelling C 145 585
of C 146 585
the C 147 585
rna C 148 585
by C 149 585
the C 150 585
nuclear C 151 585
preparations C 152 585
. C 153 585
mammary C 1 586
growth C 2 586
in C 3 586
rats C 4 586
treated C 5 586
with C 6 586
somatotropin C 7 586
during C 8 586
pregnancy C 9 586
and C 10 586
/ C 11 586
or C 12 586
lactation C 13 586
groups C 14 586
of C 15 586
rats C 16 586
received C 17 586
daily C 18 586
injections C 19 586
of C 20 586
2 C 21 586
mg C 22 586
somatotropin C 23 586
( C 24 586
sth C 25 586
) C 26 586
from C 27 586
either C 28 586
day C 29 586
3 C 30 586
- C 31 586
19 C 32 586
of C 33 586
pregnancy C 34 586
or C 35 586
day C 36 586
1 C 37 586
- C 38 586
13 C 39 586
of C 40 586
lactation C 41 586
. C 42 586
another C 44 586
group C 45 586
of C 46 586
rats C 47 586
received C 48 586
graded C 49 586
increments C 50 586
( C 51 586
0 C 52 586
. C 53 586
. C 54 586
- C 55 586
3 C 56 586
. C 57 586
. C 58 586
mg C 59 586
) C 60 586
of C 61 586
sth C 62 586
every C 63 586
6 C 64 586
days C 65 586
during C 66 586
both C 67 586
pregnancy C 68 586
and C 69 586
lactation C 70 586
. C 71 586
other C 73 586
groups C 74 586
of C 75 586
rats C 76 586
served C 77 586
as C 78 586
pregnancy C 79 586
and C 80 586
lactation C 81 586
controls C 82 586
. C 83 586
mammary C 85 586
gland C 86 586
deoxyribonucleic C 87 586
acid C 88 586
( C 89 586
dna C 90 586
) C 91 586
content C 92 586
was C 93 586
determined C 94 586
in C 95 586
all C 96 586
rats C 97 586
and C 98 586
milk C 99 586
yield C 100 586
was C 101 586
determined C 102 586
in C 103 586
all C 104 586
rats C 105 586
carried C 106 586
to C 107 586
day C 108 586
14 C 109 586
postpartum C 110 586
. C 111 586
significant C 113 586
increases C 114 586
in C 115 586
mam C 116 586
- C 117 586
mary C 118 586
dna C 119 586
occurred C 120 586
in C 121 586
all C 122 586
rats C 123 586
treated C 124 586
with C 125 586
sth C 126 586
irrespective C 127 586
of C 128 586
dose C 129 586
or C 130 586
schedule C 131 586
of C 132 586
in C 133 586
- C 134 586
jections C 135 586
when C 136 586
compared C 137 586
to C 138 586
gestation C 139 586
controls C 140 586
. C 141 586
a C 143 586
significant C 144 586
elevation C 145 586
in C 146 586
mammary C 147 586
dna C 148 586
above C 149 586
the C 150 586
lactation C 151 586
control C 152 586
level C 153 586
was C 154 586
also C 155 586
evident C 156 586
in C 157 586
rats C 158 586
receiving C 159 586
the C 160 586
hormone C 161 586
and C 162 586
carried C 163 586
to C 164 586
day C 165 586
14 C 166 586
of C 167 586
lactation C 168 586
. C 169 586
milk C 171 586
yield C 172 586
of C 173 586
rats C 174 586
treated C 175 586
with C 176 586
graded C 177 586
increments C 178 586
of C 179 586
sth C 180 586
was C 181 586
significantly C 182 586
greater C 183 586
than C 184 586
that C 185 586
of C 186 586
control C 187 586
lactators C 188 586
but C 189 586
milk C 190 586
yield C 191 586
of C 192 586
rats C 193 586
re C 194 586
- C 195 586
ceiving C 196 586
a C 197 586
constant C 198 586
daily C 199 586
dose C 200 586
of C 201 586
the C 202 586
hormone C 203 586
did C 204 586
not C 205 586
differ C 206 586
from C 207 586
that C 208 586
of C 209 586
controls C 210 586
. C 211 586
growth C 1 587
retardation C 2 587
accompanying C 3 587
diabetes C 4 587
insipidus C 5 587
: C 6 587
an C 7 587
additional C 8 587
mechanism C 9 587
? C 10 587
from C 11 587
the C 12 587
above C 13 587
considerations C 14 587
, C 15 587
we C 16 587
may C 17 587
divide C 18 587
patients C 19 587
with C 20 587
nephrogenic C 21 587
diabetes C 22 587
insipidus C 23 587
into C 24 587
at C 25 587
least C 26 587
two C 27 587
categories C 28 587
: C 29 587
( C 30 587
1 C 31 587
) C 32 587
those C 33 587
who C 34 587
fail C 35 587
to C 36 587
respond C 37 587
to C 38 587
currently C 39 587
available C 40 587
therapeutic C 41 587
products C 42 587
as C 43 587
well C 44 587
as C 45 587
to C 46 587
their C 47 587
own C 48 587
presumably C 49 587
normal C 50 587
secretion C 51 587
of C 52 587
adh C 53 587
; C 54 587
( C 55 587
2 C 56 587
) C 57 587
those C 58 587
with C 59 587
similar C 60 587
similar C 61 587
unresponsiveness C 62 587
to C 63 587
treatment C 64 587
but C 65 587
with C 66 587
presumably C 67 587
reduced C 68 587
secretion C 69 587
of C 70 587
adh C 71 587
. C 72 587
the C 74 587
adh C 75 587
- C 76 587
growth C 77 587
hormone C 78 587
theory C 79 587
may C 80 587
well C 81 587
account C 82 587
in C 83 587
part C 84 587
for C 85 587
growth C 86 587
retardation C 87 587
in C 88 587
the C 89 587
later C 90 587
group C 91 587
. C 92 587
studies C 1 588
on C 2 588
growth C 3 588
hormone C 4 588
secretion C 5 588
in C 6 588
rats C 7 588
with C 8 588
the C 9 588
hypophysis C 10 588
autotransplanted C 11 588
to C 12 588
the C 13 588
kidney C 14 588
capsule C 15 588
the C 16 588
secretory C 17 588
capacity C 18 588
of C 19 588
the C 20 588
pituitary C 21 588
gland C 22 588
, C 23 588
autotransplanted C 24 588
to C 25 588
the C 26 588
kidney C 27 588
capsule C 28 588
, C 29 588
was C 30 588
studied C 31 588
with C 32 588
special C 33 588
regard C 34 588
to C 35 588
the C 36 588
secretion C 37 588
of C 38 588
growth C 39 588
hormone C 40 588
( C 41 588
gh C 42 588
) C 43 588
. C 44 588
body C 46 588
weight C 47 588
, C 48 588
body C 49 588
length C 50 588
, C 51 588
tibial C 52 588
epiphyseal C 53 588
width C 54 588
and C 55 588
the C 56 588
mammary C 57 588
gland C 58 588
development C 59 588
after C 60 588
testosterone C 61 588
stimulation C 62 588
were C 63 588
studied C 64 588
. C 65 588
body C 67 588
growth C 68 588
and C 69 588
tibial C 70 588
epiphyseal C 71 588
width C 72 588
were C 73 588
markedly C 74 588
reduced C 75 588
in C 76 588
the C 77 588
rats C 78 588
with C 79 588
transplanted C 80 588
hypophysis C 81 588
, C 82 588
but C 83 588
not C 84 588
as C 85 588
much C 86 588
as C 87 588
in C 88 588
the C 89 588
hypophys C 90 588
- C 91 588
ectomized C 92 588
controls C 93 588
. C 94 588
after C 96 588
injections C 97 588
of C 98 588
0 C 99 588
. C 100 588
. C 101 588
. C 101 588
mg C 102 588
testosterone C 103 588
propionate C 104 588
daily C 105 588
for C 106 588
10 C 107 588
days C 108 588
, C 109 588
only C 110 588
a C 111 588
few C 112 588
groups C 113 588
of C 114 588
alveoli C 115 588
were C 116 588
seen C 117 588
in C 118 588
the C 119 588
mam C 120 588
- C 121 588
mary C 122 588
glands C 123 588
of C 124 588
the C 125 588
transplanted C 126 588
rats C 127 588
. C 128 588
these C 130 588
observations C 131 588
show C 132 588
that C 133 588
there C 134 588
is C 135 588
a C 136 588
considerable C 137 588
deficiency C 138 588
of C 139 588
gh C 140 588
in C 141 588
rats C 142 588
with C 143 588
the C 144 588
pituitary C 145 588
gland C 146 588
auto C 147 588
- C 148 588
transplanted C 149 588
to C 150 588
the C 151 588
kidney C 152 588
capsule C 153 588
. C 154 588
however C 156 588
, C 157 588
the C 158 588
development C 159 588
of C 160 588
a C 161 588
few C 162 588
alveoli C 163 588
in C 164 588
the C 165 588
mammary C 166 588
glands C 167 588
is C 168 588
in C 169 588
favour C 170 588
of C 171 588
the C 172 588
theory C 173 588
that C 174 588
a C 175 588
small C 176 588
amount C 177 588
of C 178 588
gh C 179 588
is C 180 588
secreted C 181 588
from C 182 588
the C 183 588
transplanted C 184 588
pituitary C 185 588
tissue C 186 588
. C 187 588
injections C 189 588
of C 190 588
a C 191 588
purified C 192 588
vasopressin C 193 588
preparation C 194 588
( C 195 588
pitressin C 196 588
) C 197 588
in C 198 588
the C 199 588
rats C 200 588
with C 201 588
autotransplanted C 202 588
hypophysis C 203 588
did C 204 588
not C 205 588
influence C 206 588
body C 207 588
growth C 208 588
, C 209 588
tibial C 210 588
epiphyseal C 211 588
width C 212 588
or C 213 588
mammary C 214 588
gland C 215 588
development C 216 588
. C 217 588
further C 219 588
, C 220 588
no C 221 588
effect C 222 588
of C 223 588
pitressin C 224 588
was C 225 588
seen C 226 588
on C 227 588
the C 228 588
tibial C 229 588
epiphyseal C 230 588
cartilage C 231 588
of C 232 588
rats C 233 588
with C 234 588
intact C 235 588
pituitary C 236 588
gland C 237 588
as C 238 588
has C 239 588
been C 240 588
reported C 241 588
by C 242 588
del C 243 588
vecchio C 244 588
et C 245 588
al C 246 588
. C 247 588
( C 249 588
1958 C 250 588
) C 251 588
and C 252 588
hiroshige C 253 588
& C 254 588
itoh C 255 588
( C 256 588
1960 C 257 588
) C 258 588
. C 259 588
these C 261 588
experiments C 262 588
therefore C 263 588
do C 264 588
not C 265 588
support C 266 588
the C 267 588
view C 268 588
that C 269 588
vasopressin C 270 588
acts C 271 588
as C 272 588
a C 273 588
gh C 274 588
releasing C 275 588
factor C 276 588
. C 277 588
the C 1 589
effect C 2 589
of C 3 589
human C 4 589
growth C 5 589
hormone C 6 589
in C 7 589
hypopituitary C 8 589
dwarfism C 9 589
human C 10 589
growth C 11 589
hormone C 12 589
( C 13 589
hgh C 14 589
) C 15 589
raben C 16 589
has C 17 589
been C 18 589
used C 19 589
in C 20 589
a C 21 589
dosage C 22 589
of C 23 589
2 C 24 589
mg C 25 589
. C 26 589
/ C 28 589
m C 29 589
. C 30 589
. C 31 589
/ C 32 589
day C 33 589
or C 34 589
5 C 35 589
mg C 36 589
. C 37 589
/ C 39 589
m C 40 589
. C 41 589
. C 42 589
twice C 43 589
weekly C 44 589
. C 45 589
this C 47 589
dosage C 48 589
is C 49 589
probably C 50 589
in C 51 589
or C 52 589
below C 53 589
, C 54 589
but C 55 589
certainly C 56 589
not C 57 589
above C 58 589
, C 59 589
the C 60 589
range C 61 589
of C 62 589
physiological C 63 589
replacement C 64 589
therapy C 65 589
. C 66 589
in C 68 589
a C 69 589
standardized C 70 589
five C 71 589
- C 72 589
day C 73 589
metabolic C 74 589
hgh C 75 589
test C 76 589
hypopituitary C 77 589
dwarfs C 78 589
retain C 79 589
more C 80 589
n C 81 589
than C 82 589
children C 83 589
without C 84 589
gh C 85 589
deficiency C 86 589
. C 87 589
this C 89 589
test C 90 589
is C 91 589
valuable C 92 589
diagnostic C 93 589
help C 94 589
in C 95 589
hypopituitary C 96 589
dwarfism C 97 589
. C 98 589
a C 100 589
prolonged C 101 589
treatment C 102 589
with C 103 589
hgh C 104 589
accelerates C 105 589
growth C 106 589
in C 107 589
hypopituitary C 108 589
dwarfs C 109 589
but C 110 589
not C 111 589
in C 112 589
children C 113 589
without C 114 589
gh C 115 589
deficiency C 116 589
. C 117 589
growth C 119 589
rate C 120 589
, C 121 589
induced C 122 589
by C 123 589
this C 124 589
treatment C 125 589
, C 126 589
is C 127 589
first C 128 589
above C 129 589
average C 130 589
and C 131 589
later C 132 589
average C 133 589
or C 134 589
below C 135 589
average C 136 589
for C 137 589
age C 138 589
. C 139 589
this C 141 589
decreasing C 142 589
response C 143 589
to C 144 589
hgh C 145 589
is C 146 589
typical C 147 589
for C 148 589
the C 149 589
general C 150 589
phenomenon C 151 589
of C 152 589
catch C 153 589
- C 154 589
up C 155 589
growth C 156 589
and C 157 589
is C 158 589
not C 159 589
caused C 160 589
by C 161 589
the C 162 589
develop C 163 589
- C 164 589
ment C 165 589
of C 166 589
antibodies C 167 589
. C 168 589
of C 170 589
9 C 171 589
hypopituitary C 172 589
dwarfs C 173 589
, C 174 589
treated C 175 589
for C 176 589
at C 177 589
least C 178 589
9 C 179 589
months C 180 589
, C 181 589
3 C 182 589
were C 183 589
growth C 184 589
resistant C 185 589
from C 186 589
the C 187 589
beginning C 188 589
in C 189 589
spite C 190 589
of C 191 589
a C 192 589
high C 193 589
n C 194 589
retention C 195 589
in C 196 589
the C 197 589
preceding C 198 589
hgh C 199 589
test C 200 589
. C 201 589
this C 203 589
resistance C 204 589
is C 205 589
caused C 206 589
by C 207 589
the C 208 589
development C 209 589
of C 210 589
high C 211 589
titres C 212 589
of C 213 589
specific C 214 589
hgh C 215 589
antibodies C 216 589
in C 217 589
the C 218 589
very C 219 589
first C 220 589
few C 221 589
months C 222 589
of C 223 589
treatment C 224 589
. C 225 589
these C 227 589
antibodies C 228 589
suppress C 229 589
the C 230 589
effect C 231 589
of C 232 589
hgh C 233 589
both C 234 589
on C 235 589
metabolism C 236 589
and C 237 589
on C 238 589
growth C 239 589
. C 240 589
the C 242 589
unexpected C 243 589
occasional C 244 589
induction C 245 589
in C 246 589
man C 247 589
of C 248 589
antibodies C 249 589
against C 250 589
a C 251 589
homologous C 252 589
protein C 253 589
hormone C 254 589
is C 255 589
of C 256 589
great C 257 589
interest C 258 589
. C 259 589
the C 261 589
possibility C 262 589
that C 263 589
these C 264 589
antibodies C 265 589
might C 266 589
be C 267 589
active C 268 589
not C 269 589
only C 270 589
against C 271 589
the C 272 589
homogenous C 273 589
but C 274 589
also C 275 589
against C 276 589
the C 277 589
endogenous C 278 589
hormone C 279 589
could C 280 589
have C 281 589
a C 282 589
far C 283 589
- C 284 589
reaching C 285 589
biological C 286 589
importance C 287 589
. C 288 589
effects C 1 590
of C 2 590
short C 3 590
term C 4 590
administration C 5 590
of C 6 590
hysiological C 7 590
doses C 8 590
of C 9 590
human C 10 590
growth C 11 590
hormone C 12 590
in C 13 590
three C 14 590
patients C 15 590
with C 16 590
turner C 17 590
' C 18 590
s C 19 590
syndrome C 20 590
h C 21 590
. C 22 590
e C 24 590
. C 25 590
sjoberg C 27 590
the C 28 590
effect C 29 590
of C 30 590
apparently C 31 590
physiological C 32 590
doses C 33 590
of C 34 590
human C 35 590
growth C 36 590
hormone C 37 590
was C 38 590
investigated C 39 590
in C 40 590
three C 41 590
patients C 42 590
with C 43 590
turner C 44 590
' C 45 590
s C 46 590
syndrome C 47 590
in C 48 590
short C 49 590
term C 50 590
metabolic C 51 590
balance C 52 590
studies C 53 590
. C 54 590
the C 56 590
subjects C 57 590
presented C 58 590
an C 59 590
abnormal C 60 590
sex C 61 590
chro C 62 590
- C 63 590
mosome C 64 590
constitution C 65 590
and C 66 590
an C 67 590
increased C 68 590
level C 69 590
of C 70 590
sulphation C 71 590
factor C 72 590
activity C 73 590
in C 74 590
serum C 75 590
. C 76 590
two C 78 590
dose C 79 590
levels C 80 590
of C 81 590
hormone C 82 590
were C 83 590
used C 84 590
, C 85 590
and C 86 590
there C 87 590
appeared C 88 590
an C 89 590
anabolic C 90 590
response C 91 590
to C 92 590
both C 93 590
. C 94 590
no C 96 590
correlation C 97 590
with C 98 590
dose C 99 590
was C 100 590
obtained C 101 590
for C 102 590
any C 103 590
of C 104 590
the C 105 590
parameters C 106 590
used C 107 590
except C 108 590
for C 109 590
urinary C 110 590
magnesium C 111 590
, C 112 590
where C 113 590
the C 114 590
retention C 115 590
was C 116 590
greater C 117 590
with C 118 590
the C 119 590
higher C 120 590
dose C 121 590
. C 122 590
the C 124 590
sulphation C 125 590
factor C 126 590
activity C 127 590
of C 128 590
serum C 129 590
in C 130 590
- C 131 590
creased C 132 590
during C 133 590
hormone C 134 590
administration C 135 590
in C 136 590
the C 137 590
one C 138 590
case C 139 590
studied C 140 590
in C 141 590
this C 142 590
respect C 143 590
. C 144 590
the C 146 590
urinary C 147 590
excretion C 148 590
of C 149 590
hydroxyproline C 150 590
was C 151 590
within C 152 590
the C 153 590
normal C 154 590
range C 155 590
in C 156 590
the C 157 590
two C 158 590
patients C 159 590
studied C 160 590
in C 161 590
this C 162 590
respect C 163 590
, C 164 590
and C 165 590
was C 166 590
not C 167 590
altered C 168 590
by C 169 590
growth C 170 590
hormone C 171 590
. C 172 590
all C 174 590
patients C 175 590
had C 176 590
an C 177 590
increased C 178 590
urinary C 179 590
excretion C 180 590
of C 181 590
creatine C 182 590
which C 183 590
at C 184 590
present C 185 590
cannot C 186 590
be C 187 590
explained C 188 590
. C 189 590
the C 191 590
creatinuria C 192 590
diminished C 193 590
during C 194 590
growth C 195 590
hormone C 196 590
treatment C 197 590
. C 198 590
the C 200 590
mechanism C 201 590
behind C 202 590
the C 203 590
retarded C 204 590
growth C 205 590
is C 206 590
discussed C 207 590
. C 208 590
it C 210 590
is C 211 590
suggested C 212 590
that C 213 590
a C 214 590
major C 215 590
factor C 216 590
might C 217 590
be C 218 590
a C 219 590
defect C 220 590
in C 221 590
the C 222 590
center C 223 590
for C 224 590
linear C 225 590
growth C 226 590
, C 227 590
i C 228 590
. C 229 590
. C 230 590
. C 231 590
the C 233 590
epiphyses C 234 590
that C 235 590
would C 236 590
make C 237 590
these C 238 590
less C 239 590
responsive C 240 590
to C 241 590
all C 242 590
the C 243 590
factors C 244 590
normally C 245 590
stimulating C 246 590
the C 247 590
growth C 248 590
processes C 249 590
in C 250 590
the C 251 590
epiphyseal C 252 590
zones C 253 590
. C 254 590
the C 1 591
effect C 2 591
of C 3 591
growth C 4 591
hormone C 5 591
on C 6 591
kidney C 7 591
transamidinase C 8 591
in C 9 591
the C 10 591
hypophysectomized C 11 591
mouse C 12 591
the C 13 591
role C 14 591
of C 15 591
growth C 16 591
hormone C 17 591
and C 18 591
certain C 19 591
other C 20 591
endocrine C 21 591
factors C 22 591
in C 23 591
re C 24 591
- C 25 591
gulating C 26 591
kidney C 27 591
transamidinase C 28 591
has C 29 591
been C 30 591
investigated C 31 591
in C 32 591
the C 33 591
mouse C 34 591
. C 35 591
the C 37 591
kidney C 38 591
transamidinase C 39 591
values C 40 591
are C 41 591
low C 42 591
following C 43 591
hypophysectomy C 44 591
. C 45 591
growth C 47 591
hormone C 48 591
administration C 49 591
in C 50 591
doses C 51 591
of C 52 591
0 C 53 591
. C 54 591
. C 55 591
to C 56 591
5 C 57 591
. C 58 591
. C 59 591
ug C 60 591
/ C 61 591
day C 62 591
( C 63 591
ovine C 64 591
nih C 65 591
) C 66 591
restore C 67 591
the C 68 591
enzyme C 69 591
activity C 70 591
towards C 71 591
normal C 72 591
. C 73 591
a C 75 591
bioassay C 76 591
for C 77 591
growth C 78 591
hormone C 79 591
is C 80 591
suggested C 81 591
based C 82 591
on C 83 591
the C 84 591
determination C 85 591
of C 86 591
the C 87 591
total C 88 591
kidney C 89 591
transamidinase C 90 591
. C 91 591
intact C 93 591
mice C 94 591
that C 95 591
had C 96 591
been C 97 591
given C 98 591
relatively C 99 591
large C 100 591
doses C 101 591
of C 102 591
triiodothyronin C 103 591
had C 104 591
low C 105 591
enzyme C 106 591
activities C 107 591
. C 108 591
enzyme C 110 591
values C 111 591
in C 112 591
alloxan C 113 591
- C 114 591
treated C 115 591
mice C 116 591
were C 117 591
normal C 118 591
. C 119 591
influence C 1 592
of C 2 592
hormones C 3 592
on C 4 592
tumor C 5 592
growth C 6 592
and C 7 592
plasma C 8 592
prolactin C 9 592
levels C 10 592
in C 11 592
rats C 12 592
bearing C 13 592
a C 14 592
pituitary C 15 592
" C 16 592
mammotropic C 17 592
" C 18 592
tumor C 19 592
the C 20 592
effects C 21 592
of C 22 592
estradiol C 23 592
, C 24 592
cortisol C 25 592
acetate C 26 592
, C 27 592
thyroxine C 28 592
, C 29 592
or C 30 592
thiouracil C 31 592
on C 32 592
tumor C 33 592
growth C 34 592
, C 35 592
organ C 36 592
weights C 37 592
, C 38 592
and C 39 592
plasma C 40 592
prolactin C 41 592
levels C 42 592
were C 43 592
determined C 44 592
in C 45 592
rats C 46 592
bearing C 47 592
a C 48 592
furth C 49 592
pituitary C 50 592
" C 51 592
mammotropic C 52 592
" C 53 592
tumor C 54 592
( C 55 592
mtt C 56 592
. C 57 592
. C 58 592
. C 58 592
) C 59 592
. C 60 592
this C 62 592
tumor C 63 592
is C 64 592
known C 65 592
to C 66 592
secrete C 67 592
large C 68 592
amounts C 69 592
of C 70 592
adrenocorticotropin C 71 592
, C 72 592
somatotropin C 73 592
, C 74 592
and C 75 592
prolactin C 76 592
, C 77 592
but C 78 592
no C 79 592
follicle C 80 592
- C 81 592
stimulating C 82 592
hormone C 83 592
, C 84 592
luteinizing C 85 592
hormone C 86 592
, C 87 592
or C 88 592
thyrotropin C 89 592
. C 90 592
at C 92 592
the C 93 592
dose C 94 592
levels C 95 592
used C 96 592
, C 97 592
estradiol C 98 592
significantly C 99 592
suppressed C 100 592
tumor C 101 592
growth C 102 592
without C 103 592
influencing C 104 592
body C 105 592
growth C 106 592
, C 107 592
and C 108 592
it C 109 592
partially C 110 592
inhibited C 111 592
enlargement C 112 592
of C 113 592
the C 114 592
adrenals C 115 592
and C 116 592
atrophy C 117 592
of C 118 592
the C 119 592
thymus C 120 592
. C 121 592
cortisol C 123 592
acetate C 124 592
significantly C 125 592
reduced C 126 592
both C 127 592
tumor C 128 592
and C 129 592
body C 130 592
growth C 131 592
. C 132 592
thyroxine C 134 592
had C 135 592
no C 136 592
significant C 137 592
effect C 138 592
on C 139 592
tumor C 140 592
growth C 141 592
but C 142 592
enhanced C 143 592
the C 144 592
somatotropic C 145 592
effect C 146 592
as C 147 592
indicated C 148 592
by C 149 592
increases C 150 592
in C 151 592
body C 152 592
growth C 153 592
and C 154 592
organ C 155 592
weights C 156 592
. C 157 592
thiouracil C 159 592
had C 160 592
no C 161 592
significant C 162 592
effect C 163 592
on C 164 592
tumor C 165 592
or C 166 592
body C 167 592
growth C 168 592
, C 169 592
although C 170 592
it C 171 592
significantly C 172 592
increased C 173 592
thyroid C 174 592
weight C 175 592
. C 176 592
estradiol C 178 592
, C 179 592
cortisol C 180 592
acetate C 181 592
, C 182 592
and C 183 592
thyroxine C 184 592
each C 185 592
increased C 186 592
the C 187 592
plasma C 188 592
prolactin C 189 592
levels C 190 592
of C 191 592
the C 192 592
tumor C 193 592
- C 194 592
bearing C 195 592
rats C 196 592
. C 197 592
studies C 1 593
with C 2 593
human C 3 593
growth C 4 593
hormone C 5 593
ten C 6 593
dwarfed C 7 593
patients C 8 593
whose C 9 593
short C 10 593
stature C 11 593
was C 12 593
of C 13 593
varying C 14 593
aetiology C 15 593
were C 16 593
studied C 17 593
by C 18 593
investigation C 19 593
of C 20 593
some C 21 593
of C 22 593
the C 23 593
metabolic C 24 593
effects C 25 593
of C 26 593
human C 27 593
growth C 28 593
hormone C 29 593
, C 30 593
10 C 31 593
mg C 32 593
. C 33 593
being C 35 593
administered C 36 593
daily C 37 593
for C 38 593
a C 39 593
period C 40 593
of C 41 593
5 C 42 593
to C 43 593
9 C 44 593
days C 45 593
. C 46 593
the C 48 593
patients C 49 593
were C 50 593
maintained C 51 593
on C 52 593
a C 53 593
constant C 54 593
diet C 55 593
during C 56 593
a C 57 593
preliminary C 58 593
control C 59 593
period C 60 593
, C 61 593
while C 62 593
receiving C 63 593
hgh C 64 593
, C 65 593
and C 66 593
in C 67 593
7 C 68 593
patients C 69 593
from C 70 593
2 C 71 593
to C 72 593
7 C 73 593
days C 74 593
in C 75 593
the C 76 593
post C 77 593
- C 78 593
hgh C 79 593
period C 80 593
. C 81 593
hgh C 83 593
produced C 84 593
a C 85 593
reduction C 86 593
in C 87 593
serum C 88 593
cholesterol C 89 593
, C 90 593
with C 91 593
a C 92 593
rebound C 93 593
on C 94 593
withdrawal C 95 593
, C 96 593
in C 97 593
7 C 98 593
; C 99 593
a C 100 593
delayed C 101 593
clearance C 102 593
of C 103 593
fat C 104 593
from C 105 593
the C 106 593
blood C 107 593
after C 108 593
a C 109 593
fat C 110 593
load C 111 593
in C 112 593
9 C 113 593
; C 114 593
and C 115 593
the C 116 593
appearance C 117 593
of C 118 593
pre C 119 593
- C 120 593
b C 121 593
lipoprotein C 122 593
in C 123 593
the C 124 593
fasting C 125 593
state C 126 593
, C 127 593
as C 128 593
measured C 129 593
by C 130 593
paper C 131 593
electrophoresis C 132 593
, C 133 593
in C 134 593
all C 135 593
of C 136 593
them C 137 593
. C 138 593
the C 140 593
fall C 141 593
in C 142 593
serum C 143 593
cholesterol C 144 593
and C 145 593
the C 146 593
rebound C 147 593
on C 148 593
withdrawal C 149 593
of C 150 593
hgh C 151 593
has C 152 593
some C 153 593
relevance C 154 593
to C 155 593
the C 156 593
observation C 157 593
that C 158 593
hypercholesterolaemia C 159 593
occurs C 160 593
in C 161 593
some C 162 593
hypopituitary C 163 593
patients C 164 593
even C 165 593
in C 166 593
the C 167 593
absence C 168 593
of C 169 593
hypothyroidism C 170 593
. C 171 593
no C 173 593
change C 174 593
was C 175 593
observed C 176 593
in C 177 593
tests C 178 593
of C 179 593
thyroid C 180 593
and C 181 593
adrenocortical C 182 593
function C 183 593
during C 184 593
the C 185 593
short C 186 593
- C 187 593
term C 188 593
high C 189 593
dosage C 190 593
administration C 191 593
of C 192 593
hgh C 193 593
. C 194 593
hypopituitary C 196 593
patients C 197 593
show C 198 593
a C 199 593
considerable C 200 593
retention C 201 593
of C 202 593
nitrogen C 203 593
on C 204 593
hgh C 205 593
administration C 206 593
, C 207 593
and C 208 593
we C 209 593
have C 210 593
confirmed C 211 593
the C 212 593
work C 213 593
of C 214 593
prader C 215 593
and C 216 593
his C 217 593
colleagues C 218 593
that C 219 593
this C 220 593
provides C 221 593
a C 222 593
valuable C 223 593
diagnostic C 224 593
test C 225 593
for C 226 593
growth C 227 593
hormone C 228 593
deficiency C 229 593
. C 230 593
the C 232 593
measurement C 233 593
of C 234 593
urinary C 235 593
nitrogen C 236 593
excretion C 237 593
after C 238 593
the C 239 593
withdrawal C 240 593
of C 241 593
hgh C 242 593
also C 243 593
promises C 244 593
to C 245 593
be C 246 593
a C 247 593
useful C 248 593
investigation C 249 593
in C 250 593
the C 251 593
differential C 252 593
diagnosis C 253 593
of C 254 593
short C 255 593
stature C 256 593
. C 257 593
nitrogen C 259 593
excretion C 260 593
in C 261 593
the C 262 593
withdrawal C 263 593
phase C 264 593
in C 265 593
hypopituitary C 266 593
children C 267 593
returns C 268 593
slowly C 269 593
to C 270 593
its C 271 593
pre C 272 593
- C 273 593
hgh C 274 593
levels C 275 593
; C 276 593
two C 277 593
non C 278 593
- C 279 593
hypopituitary C 280 593
dwarfed C 281 593
children C 282 593
excreted C 283 593
much C 284 593
more C 285 593
nitrogen C 286 593
in C 287 593
the C 288 593
withdrawal C 289 593
period C 290 593
than C 291 593
they C 292 593
retained C 293 593
in C 294 593
the C 295 593
hgh C 296 593
period C 297 593
. C 298 593
one C 300 593
primordial C 301 593
dwarf C 302 593
showed C 303 593
a C 304 593
negligible C 305 593
change C 306 593
in C 307 593
urinary C 308 593
nitrogen C 309 593
excretion C 310 593
both C 311 593
in C 312 593
the C 313 593
hgh C 314 593
and C 315 593
in C 316 593
the C 317 593
post C 318 593
- C 319 593
hgh C 320 593
periods C 321 593
. C 322 593
hormonal C 1 594
modification C 2 594
of C 3 594
the C 4 594
distribution C 5 594
of C 6 594
1 C 7 594
- C 8 594
amino C 9 594
- C 10 594
cyclopentanecarboxylic C 11 594
acid C 12 594
- C 13 594
1 C 14 594
- C 15 594
c C 16 594
14 C 17 594
in C 18 594
the C 19 594
rat C 20 594
four C 21 594
hormones C 22 594
have C 23 594
been C 24 594
examined C 25 594
for C 26 594
their C 27 594
ability C 28 594
to C 29 594
alter C 30 594
the C 31 594
distribution C 32 594
in C 33 594
the C 34 594
rat C 35 594
of C 36 594
the C 37 594
new C 38 594
model C 39 594
amino C 40 594
acid C 41 594
, C 42 594
1 C 43 594
- C 44 594
aminocyclopentanecarboxylic C 45 594
acid C 46 594
- C 47 594
1 C 48 594
- C 49 594
c C 50 594
14 C 51 594
. C 52 594
although C 54 594
the C 55 594
total C 56 594
tissue C 57 594
concentrations C 58 594
of C 59 594
this C 60 594
amino C 61 594
acid C 62 594
were C 63 594
considerably C 64 594
less C 65 594
than C 66 594
those C 67 594
found C 68 594
previously C 69 594
for C 70 594
a C 71 594
- C 72 594
aminoisobutyric C 73 594
acid C 74 594
, C 75 594
the C 76 594
changes C 77 594
produced C 78 594
by C 79 594
the C 80 594
hormones C 81 594
were C 82 594
much C 83 594
the C 84 594
same C 85 594
for C 86 594
both C 87 594
amino C 88 594
acids C 89 594
. C 90 594
hydrocortisone C 92 594
elevated C 93 594
the C 94 594
liver C 95 594
level C 96 594
of C 97 594
1 C 98 594
- C 99 594
aminocyclopentanecarboxylic C 100 594
acid C 101 594
within C 102 594
2 C 103 594
hr C 104 594
. C 105 594
bovine C 107 594
growth C 108 594
hormone C 109 594
accelerated C 110 594
entry C 111 594
of C 112 594
the C 113 594
amino C 114 594
acid C 115 594
into C 116 594
both C 117 594
skeletal C 118 594
muscle C 119 594
and C 120 594
liver C 121 594
of C 122 594
hypophysectomized C 123 594
rats C 124 594
within C 125 594
1 C 126 594
hr C 127 594
. C 128 594
testosterone C 130 594
propionate C 131 594
elevated C 132 594
its C 133 594
distribution C 134 594
ratio C 135 594
in C 136 594
the C 137 594
kidney C 138 594
but C 139 594
not C 140 594
in C 141 594
skeletal C 142 594
muscle C 143 594
, C 144 594
whereas C 145 594
b C 146 594
- C 147 594
estradiol C 148 594
significantly C 149 594
increased C 150 594
uptake C 151 594
of C 152 594
the C 153 594
model C 154 594
amino C 155 594
acid C 156 594
only C 157 594
by C 158 594
the C 159 594
immature C 160 594
uterus C 161 594
. C 162 594
only C 164 594
growth C 165 594
hormone C 166 594
produced C 167 594
a C 168 594
significant C 169 594
change C 170 594
in C 171 594
the C 172 594
serum C 173 594
level C 174 594
of C 175 594
1 C 176 594
- C 177 594
aminocyclopentanecarboxylic C 178 594
acid C 179 594
under C 180 594
the C 181 594
conditions C 182 594
used C 183 594
. C 184 594
insulin C 1 595
and C 2 595
insulin C 3 595
antagonism C 4 595
as C 5 595
i C 6 595
said C 7 595
earlier C 8 595
, C 9 595
no C 10 595
simple C 11 595
answer C 12 595
has C 13 595
yet C 14 595
emerged C 15 595
from C 16 595
the C 17 595
large C 18 595
amount C 19 595
of C 20 595
research C 21 595
that C 22 595
has C 23 595
been C 24 595
directed C 25 595
toward C 26 595
determining C 27 595
the C 28 595
nature C 29 595
of C 30 595
the C 31 595
substance C 32 595
or C 33 595
substances C 34 595
responsible C 35 595
for C 36 595
the C 37 595
diabetes C 38 595
- C 39 595
inducing C 40 595
and C 41 595
insulin C 42 595
- C 43 595
antagonizing C 44 595
actions C 45 595
of C 46 595
the C 47 595
anterior C 48 595
lobe C 49 595
of C 50 595
the C 51 595
pituitary C 52 595
gland C 53 595
, C 54 595
and C 55 595
to C 56 595
ascertaining C 57 595
their C 58 595
mechanism C 59 595
of C 60 595
action C 61 595
. C 62 595
growth C 64 595
hormone C 65 595
and C 66 595
corticotropin C 67 595
certainly C 68 595
qualify C 69 595
, C 70 595
but C 71 595
so C 72 595
do C 73 595
any C 74 595
other C 75 595
factors C 76 595
that C 77 595
can C 78 595
increase C 79 595
the C 80 595
mobilization C 81 595
of C 82 595
fats C 83 595
as C 84 595
plasma C 85 595
albumin C 86 595
- C 87 595
bound C 88 595
free C 89 595
fatty C 90 595
acids C 91 595
. C 92 595
the C 94 595
idea C 95 595
that C 96 595
the C 97 595
yet C 98 595
incompletely C 99 595
characterized C 100 595
insulin C 101 595
antagonist C 102 595
in C 103 595
the C 104 595
pancreas C 105 595
may C 106 595
be C 107 595
liberated C 108 595
into C 109 595
the C 110 595
blood C 111 595
under C 112 595
the C 113 595
influence C 114 595
of C 115 595
growth C 116 595
hormone C 117 595
and C 118 595
may C 119 595
play C 120 595
a C 121 595
role C 122 595
in C 123 595
the C 124 595
process C 125 595
by C 126 595
which C 127 595
growth C 128 595
hormone C 129 595
diminishes C 130 595
the C 131 595
activity C 132 595
of C 133 595
insulin C 134 595
in C 135 595
promoting C 136 595
the C 137 595
utilization C 138 595
of C 139 595
glucose C 140 595
is C 141 595
attractive C 142 595
to C 143 595
me C 144 595
, C 145 595
but C 146 595
still C 147 595
remains C 148 595
to C 149 595
be C 150 595
confirmed C 151 595
. C 152 595
relationships C 1 596
of C 2 596
growth C 3 596
hormone C 4 596
, C 5 596
steroids C 6 596
and C 7 596
relaxin C 8 596
in C 9 596
the C 10 596
transformation C 11 596
of C 12 596
pubic C 13 596
joint C 14 596
cartilage C 15 596
to C 16 596
ligament C 17 596
in C 18 596
hypophysectomized C 19 596
mice C 20 596
the C 21 596
histological C 22 596
changes C 23 596
occurring C 24 596
in C 25 596
the C 26 596
pubic C 27 596
joint C 28 596
of C 29 596
hormonally C 30 596
treated C 31 596
intact C 32 596
or C 33 596
hypophysectomized C 34 596
mice C 35 596
have C 36 596
been C 37 596
studied C 38 596
. C 39 596
estrogen C 41 596
treatment C 42 596
resulted C 43 596
in C 44 596
bone C 45 596
resorption C 46 596
and C 47 596
transformation C 48 596
of C 49 596
the C 50 596
cartilage C 51 596
caps C 52 596
of C 53 596
the C 54 596
pubic C 55 596
bones C 56 596
to C 57 596
fibrocartilage C 58 596
in C 59 596
intact C 60 596
mice C 61 596
but C 62 596
not C 63 596
in C 64 596
hypophysectomized C 65 596
mice C 66 596
. C 67 596
furthermore C 69 596
, C 70 596
relaxin C 71 596
failed C 72 596
to C 73 596
influence C 74 596
the C 75 596
appearance C 76 596
of C 77 596
the C 78 596
pubic C 79 596
joint C 80 596
of C 81 596
estrogen C 82 596
- C 83 596
primed C 84 596
hypophysectomized C 85 596
mice C 86 596
, C 87 596
whereas C 88 596
it C 89 596
induced C 90 596
the C 91 596
development C 92 596
of C 93 596
long C 94 596
interpubic C 95 596
ligaments C 96 596
in C 97 596
intact C 98 596
mice C 99 596
. C 100 596
when C 102 596
growth C 103 596
hormone C 104 596
( C 105 596
sth C 106 596
) C 107 596
was C 108 596
administered C 109 596
to C 110 596
hypophysectomized C 111 596
mice C 112 596
, C 113 596
the C 114 596
pubic C 115 596
joints C 116 596
responded C 117 596
to C 118 596
estrogen C 119 596
with C 120 596
bone C 121 596
resorption C 122 596
and C 123 596
transformation C 124 596
of C 125 596
the C 126 596
cartilage C 127 596
caps C 128 596
to C 129 596
fibrocartilage C 130 596
. C 131 596
sth C 133 596
treatment C 134 596
also C 135 596
restored C 136 596
the C 137 596
ability C 138 596
of C 139 596
the C 140 596
pubic C 141 596
joint C 142 596
of C 143 596
hypophysectomized C 144 596
mice C 145 596
to C 146 596
proliferate C 147 596
long C 148 596
interpubic C 149 596
ligaments C 150 596
when C 151 596
estrogen C 152 596
and C 153 596
relaxin C 154 596
were C 155 596
administered C 156 596
. C 157 596
progesterone C 159 596
specifically C 160 596
inhibited C 161 596
ligament C 162 596
formation C 163 596
due C 164 596
to C 165 596
relaxin C 166 596
injection C 167 596
without C 168 596
altering C 169 596
the C 170 596
histological C 171 596
changes C 172 596
associated C 173 596
with C 174 596
estrogen C 175 596
treatment C 176 596
, C 177 596
both C 178 596
in C 179 596
intact C 180 596
mice C 181 596
and C 182 596
in C 183 596
sth C 184 596
- C 185 596
maintained C 186 596
, C 187 596
hypophysectomized C 188 596
mice C 189 596
. C 190 596
effect C 1 597
of C 2 597
testosterone C 3 597
propionate C 4 597
and C 5 597
growth C 6 597
hormone C 7 597
on C 8 597
growth C 9 597
and C 10 597
chemical C 11 597
composition C 12 597
of C 13 597
muscle C 14 597
and C 15 597
other C 16 597
tissues C 17 597
in C 18 597
hypophysectomized C 19 597
male C 20 597
rats C 21 597
the C 22 597
effect C 23 597
of C 24 597
testosterone C 25 597
propionate C 26 597
and C 27 597
growth C 28 597
hormone C 29 597
on C 30 597
the C 31 597
growth C 32 597
of C 33 597
muscle C 34 597
, C 35 597
bone C 36 597
, C 37 597
pelt C 38 597
, C 39 597
viscera C 40 597
and C 41 597
seminal C 42 597
vesicles C 43 597
was C 44 597
studied C 45 597
in C 46 597
hypophysectomized C 47 597
male C 48 597
rats C 49 597
. C 50 597
testosterone C 52 597
( C 53 597
0 C 54 597
. C 55 597
. C 56 597
mg C 57 597
/ C 58 597
day C 59 597
) C 60 597
stimulated C 61 597
growth C 62 597
in C 63 597
the C 64 597
levator C 65 597
ani C 66 597
muscle C 67 597
and C 68 597
seminal C 69 597
vesicles C 70 597
but C 71 597
had C 72 597
no C 73 597
effect C 74 597
on C 75 597
the C 76 597
other C 77 597
tissues C 78 597
studied C 79 597
. C 80 597
growth C 82 597
hormone C 83 597
( C 84 597
0 C 85 597
. C 86 597
. C 87 597
mg C 88 597
/ C 89 597
day C 90 597
) C 91 597
accelerated C 92 597
growth C 93 597
in C 94 597
all C 95 597
tissues C 96 597
except C 97 597
the C 98 597
seminal C 99 597
vesicles C 100 597
. C 101 597
testosterone C 103 597
did C 104 597
not C 105 597
enhance C 106 597
the C 107 597
growth C 108 597
- C 109 597
promoting C 110 597
effect C 111 597
of C 112 597
growth C 113 597
hormone C 114 597
in C 115 597
any C 116 597
tissue C 117 597
except C 118 597
the C 119 597
levator C 120 597
ani C 121 597
muscle C 122 597
. C 123 597
growth C 125 597
hormone C 126 597
stimulated C 127 597
deposition C 128 597
of C 129 597
myosin C 130 597
, C 131 597
sarcoplasmic C 132 597
proteins C 133 597
, C 134 597
collagen C 135 597
and C 136 597
alkali C 137 597
- C 138 597
soluble C 139 597
proteins C 140 597
in C 141 597
the C 142 597
thigh C 143 597
muscle C 144 597
of C 145 597
hypophysectomized C 146 597
rats C 147 597
. C 148 597
the C 150 597
composition C 151 597
of C 152 597
the C 153 597
muscle C 154 597
in C 155 597
treated C 156 597
and C 157 597
control C 158 597
hypophysectomized C 159 597
rats C 160 597
was C 161 597
the C 162 597
same C 163 597
as C 164 597
that C 165 597
in C 166 597
normal C 167 597
rats C 168 597
. C 169 597
growth C 171 597
hormone C 172 597
also C 173 597
increased C 174 597
the C 175 597
collagen C 176 597
, C 177 597
keratin C 178 597
- C 179 597
clastin C 180 597
and C 181 597
globular C 182 597
protein C 183 597
content C 184 597
of C 185 597
the C 186 597
pelt C 187 597
. C 188 597
the C 190 597
effect C 191 597
of C 192 597
growth C 193 597
hormone C 194 597
on C 195 597
the C 196 597
proteins C 197 597
of C 198 597
muscle C 199 597
and C 200 597
pelt C 201 597
was C 202 597
not C 203 597
enhanced C 204 597
by C 205 597
testosterone C 206 597
. C 207 597
testosterone C 209 597
given C 210 597
alone C 211 597
had C 212 597
no C 213 597
effect C 214 597
on C 215 597
the C 216 597
chemical C 217 597
composition C 218 597
or C 219 597
content C 220 597
of C 221 597
the C 222 597
muscle C 223 597
and C 224 597
pelt C 225 597
in C 226 597
hypophysectomized C 227 597
rats C 228 597
. C 229 597
growth C 1 598
hormone C 2 598
and C 3 598
diabetes C 4 598
mellitus C 5 598
since C 6 598
the C 7 598
advent C 8 598
of C 9 598
insulin C 10 598
the C 11 598
vascular C 12 598
and C 13 598
neurological C 14 598
lesions C 15 598
have C 16 598
replaced C 17 598
ketoacidosis C 18 598
as C 19 598
the C 20 598
major C 21 598
problem C 22 598
in C 23 598
diabetes C 24 598
. C 25 598
although C 27 598
good C 28 598
control C 29 598
of C 30 598
hyperglycemia C 31 598
and C 32 598
glycosuria C 33 598
with C 34 598
diet C 35 598
and C 36 598
insulin C 37 598
may C 38 598
influence C 39 598
favorably C 40 598
the C 41 598
development C 42 598
of C 43 598
the C 44 598
ocular C 45 598
angiopathy C 46 598
, C 47 598
there C 48 598
remains C 49 598
a C 50 598
high C 51 598
incidence C 52 598
of C 53 598
these C 54 598
lesions C 55 598
with C 56 598
resulting C 57 598
blindness C 58 598
despite C 59 598
such C 60 598
good C 61 598
control C 62 598
. C 63 598
growth C 65 598
hormone C 66 598
may C 67 598
be C 68 598
a C 69 598
major C 70 598
factor C 71 598
in C 72 598
the C 73 598
pathophysiology C 74 598
of C 75 598
diabetes C 76 598
mellitus C 77 598
and C 78 598
its C 79 598
effects C 80 598
may C 81 598
be C 82 598
a C 83 598
reflection C 84 598
of C 85 598
the C 86 598
genetic C 87 598
disturbance C 88 598
. C 89 598
its C 91 598
importance C 92 598
was C 93 598
first C 94 598
realized C 95 598
by C 96 598
the C 97 598
classical C 98 598
experiments C 99 598
of C 100 598
houssay C 101 598
and C 102 598
those C 103 598
of C 104 598
young C 105 598
which C 106 598
revealed C 107 598
its C 108 598
diabetogenic C 109 598
effects C 110 598
in C 111 598
experimental C 112 598
animals C 113 598
. C 114 598
the C 116 598
association C 117 598
of C 118 598
acromegaly C 119 598
with C 120 598
diabetes C 121 598
has C 122 598
been C 123 598
for C 124 598
a C 125 598
long C 126 598
time C 127 598
the C 128 598
major C 129 598
argument C 130 598
in C 131 598
support C 132 598
of C 133 598
the C 134 598
hypothesis C 135 598
of C 136 598
the C 137 598
diabetogenic C 138 598
effect C 139 598
of C 140 598
growth C 141 598
hormone C 142 598
in C 143 598
man C 144 598
. C 145 598
experiments C 1 599
on C 2 599
the C 3 599
contribution C 4 599
of C 5 599
somatotrophin C 6 599
to C 7 599
prenatal C 8 599
growth C 9 599
in C 10 599
the C 11 599
rat C 12 599
hypophyseoprivus C 13 599
in C 14 599
a C 15 599
fetal C 16 599
rat C 17 599
induced C 18 599
by C 19 599
decapitating C 20 599
the C 21 599
fetus C 22 599
in C 23 599
utero C 24 599
retards C 25 599
fetal C 26 599
growth C 27 599
. C 28 599
this C 30 599
effect C 31 599
can C 32 599
be C 33 599
prevented C 34 599
by C 35 599
injected C 36 599
somatotrophin C 37 599
. C 38 599
these C 40 599
observations C 41 599
substantially C 42 599
support C 43 599
the C 44 599
view C 45 599
that C 46 599
in C 47 599
the C 48 599
normal C 49 599
rat C 50 599
shortly C 51 599
before C 52 599
birth C 53 599
the C 54 599
fetal C 55 599
somatotrophin C 56 599
from C 57 599
the C 58 599
developing C 59 599
hypophysis C 60 599
governs C 61 599
in C 62 599
part C 63 599
the C 64 599
prenatal C 65 599
growth C 66 599
which C 67 599
occurs C 68 599
at C 69 599
that C 70 599
time C 71 599
. C 72 599
although C 74 599
complete C 75 599
hypophysectomy C 76 599
of C 77 599
a C 78 599
pregnant C 79 599
rat C 80 599
retards C 81 599
the C 82 599
growth C 83 599
of C 84 599
fetuses C 85 599
, C 86 599
the C 87 599
manner C 88 599
of C 89 599
its C 90 599
action C 91 599
is C 92 599
obscure C 93 599
. C 94 599
in C 96 599
an C 97 599
individual C 98 599
litter C 99 599
, C 100 599
combined C 101 599
hypophysectomy C 102 599
of C 103 599
the C 104 599
mother C 105 599
and C 106 599
hypophyseoprivus C 107 599
in C 108 599
a C 109 599
fetus C 110 599
retards C 111 599
fetal C 112 599
growth C 113 599
but C 114 599
not C 115 599
to C 116 599
any C 117 599
greater C 118 599
extent C 119 599
than C 120 599
hypophysectomy C 121 599
of C 122 599
the C 123 599
mother C 124 599
without C 125 599
hypophyseoprivus C 126 599
in C 127 599
the C 128 599
fetus C 129 599
. C 130 599
in C 132 599
the C 133 599
intact C 134 599
fetus C 135 599
injections C 136 599
of C 137 599
somatotrophin C 138 599
( C 139 599
armour C 140 599
) C 141 599
do C 142 599
not C 143 599
accelerate C 144 599
fetal C 145 599
growth C 146 599
, C 147 599
presumably C 148 599
because C 149 599
ample C 150 599
fetal C 151 599
somatotrophin C 152 599
from C 153 599
the C 154 599
developing C 155 599
hypophysis C 156 599
is C 157 599
present C 158 599
. C 159 599
insulin C 1 600
and C 2 600
protein C 3 600
metabolism C 4 600
the C 5 600
present C 6 600
status C 7 600
of C 8 600
protein C 9 600
synthesis C 10 600
within C 11 600
cells C 12 600
has C 13 600
been C 14 600
outlined C 15 600
. C 16 600
protein C 18 600
is C 19 600
formed C 20 600
in C 21 600
the C 22 600
absence C 23 600
of C 24 600
insulin C 25 600
; C 26 600
the C 27 600
net C 28 600
formation C 29 600
of C 30 600
protein C 31 600
is C 32 600
accelerated C 33 600
by C 34 600
insulin C 35 600
. C 36 600
the C 38 600
effects C 39 600
of C 40 600
insulin C 41 600
on C 42 600
protein C 43 600
metabolism C 44 600
take C 45 600
place C 46 600
independently C 47 600
of C 48 600
the C 49 600
transport C 50 600
of C 51 600
glucose C 52 600
or C 53 600
amino C 54 600
acids C 55 600
into C 56 600
the C 57 600
cell C 58 600
; C 59 600
of C 60 600
glycogen C 61 600
synthesis C 62 600
; C 63 600
and C 64 600
of C 65 600
the C 66 600
stimulation C 67 600
of C 68 600
high C 69 600
energy C 70 600
phosphate C 71 600
formation C 72 600
. C 73 600
in C 75 600
the C 76 600
case C 77 600
of C 78 600
protein C 79 600
metabolism C 80 600
, C 81 600
as C 82 600
in C 83 600
certain C 84 600
studies C 85 600
on C 86 600
the C 87 600
pathways C 88 600
of C 89 600
glucose C 90 600
and C 91 600
fat C 92 600
metabolism C 93 600
, C 94 600
these C 95 600
observations C 96 600
reveal C 97 600
striking C 98 600
intracellular C 99 600
effects C 100 600
of C 101 600
insulin C 102 600
in C 103 600
many C 104 600
tissues C 105 600
. C 106 600
within C 108 600
most C 109 600
tissues C 110 600
the C 111 600
effect C 112 600
of C 113 600
insulin C 114 600
appears C 115 600
to C 116 600
find C 117 600
expression C 118 600
predominantly C 119 600
at C 120 600
the C 121 600
microsomal C 122 600
level C 123 600
. C 124 600
incidentally C 126 600
, C 127 600
other C 128 600
hormones C 129 600
which C 130 600
affect C 131 600
protein C 132 600
metabolism C 133 600
such C 134 600
as C 135 600
growth C 136 600
or C 137 600
sex C 138 600
hormones C 139 600
appear C 140 600
to C 141 600
act C 142 600
at C 143 600
the C 144 600
microsomes C 145 600
. C 146 600
the C 148 600
fact C 149 600
that C 150 600
insulin C 151 600
exerts C 152 600
effects C 153 600
on C 154 600
protein C 155 600
metabolism C 156 600
at C 157 600
other C 158 600
intracellular C 159 600
sites C 160 600
as C 161 600
well C 162 600
as C 163 600
the C 164 600
above C 165 600
independent C 166 600
effects C 167 600
leads C 168 600
one C 169 600
to C 170 600
agree C 171 600
that C 172 600
its C 173 600
action C 174 600
consists C 175 600
of C 176 600
a C 177 600
stimulation C 178 600
of C 179 600
multiple C 180 600
, C 181 600
seemingly C 182 600
unrelated C 183 600
, C 184 600
metabolic C 185 600
events C 186 600
. C 187 600
the C 189 600
fact C 190 600
that C 191 600
an C 192 600
immediate C 193 600
effect C 194 600
of C 195 600
insulin C 196 600
on C 197 600
protein C 198 600
synthesis C 199 600
is C 200 600
independent C 201 600
of C 202 600
the C 203 600
immediate C 204 600
need C 205 600
for C 206 600
extracellular C 207 600
glucose C 208 600
or C 209 600
amino C 210 600
acids C 211 600
does C 212 600
not C 213 600
mean C 214 600
that C 215 600
the C 216 600
sustained C 217 600
functioning C 218 600
of C 219 600
cells C 220 600
is C 221 600
likewise C 222 600
independent C 223 600
. C 224 600
the C 226 600
biochemist C 227 600
is C 228 600
fully C 229 600
aware C 230 600
of C 231 600
metabolic C 232 600
defects C 233 600
in C 234 600
diabetes C 235 600
which C 236 600
are C 237 600
not C 238 600
altered C 239 600
by C 240 600
insulin C 241 600
in C 242 600
vitro C 243 600
, C 244 600
but C 245 600
which C 246 600
demand C 247 600
varying C 248 600
periods C 249 600
of C 250 600
pretreatment C 251 600
of C 252 600
the C 253 600
animal C 254 600
. C 255 600
it C 257 600
is C 258 600
also C 259 600
known C 260 600
that C 261 600
in C 262 600
diabetes C 263 600
some C 264 600
proteins C 265 600
( C 266 600
enzymes C 267 600
) C 268 600
may C 269 600
be C 270 600
deficient C 271 600
while C 272 600
others C 273 600
may C 274 600
be C 275 600
produced C 276 600
in C 277 600
excess C 278 600
in C 279 600
the C 280 600
absence C 281 600
of C 282 600
insulin C 283 600
. C 284 600
it C 286 600
is C 287 600
suggested C 288 600
that C 289 600
the C 290 600
physician C 291 600
desires C 292 600
at C 293 600
least C 294 600
two C 295 600
kinds C 296 600
of C 297 600
relation C 298 600
between C 299 600
these C 300 600
fundamental C 301 600
studies C 302 600
and C 303 600
his C 304 600
patients C 305 600
. C 306 600
one C 308 600
is C 309 600
the C 310 600
possible C 311 600
relation C 312 600
of C 313 600
a C 314 600
deficiency C 315 600
of C 316 600
insulin C 317 600
action C 318 600
to C 319 600
pathological C 320 600
processes C 321 600
in C 322 600
tissues C 323 600
which C 324 600
have C 325 600
not C 326 600
as C 327 600
yet C 328 600
been C 329 600
examined C 330 600
by C 331 600
the C 332 600
methods C 333 600
described C 334 600
. C 335 600
the C 337 600
other C 338 600
is C 339 600
the C 340 600
need C 341 600
for C 342 600
more C 343 600
accurate C 344 600
measurements C 345 600
of C 346 600
the C 347 600
metabolic C 348 600
disorder C 349 600
and C 350 600
its C 351 600
control C 352 600
than C 353 600
such C 354 600
things C 355 600
as C 356 600
urinary C 357 600
and C 358 600
blood C 359 600
glucose C 360 600
. C 361 600
in C 363 600
developing C 364 600
such C 365 600
future C 366 600
improvements C 367 600
, C 368 600
the C 369 600
place C 370 600
of C 371 600
insulin C 372 600
in C 373 600
protein C 374 600
biosynthesis C 375 600
must C 376 600
be C 377 600
kept C 378 600
in C 379 600
mind C 380 600
. C 381 600
the C 1 601
influence C 2 601
of C 3 601
blood C 4 601
glucose C 5 601
on C 6 601
the C 7 601
plasma C 8 601
concentration C 9 601
of C 10 601
growth C 11 601
hormone C 12 601
a C 13 601
. C 14 601
berson C 16 601
, C 17 601
m C 18 601
. C 19 601
. C 20 601
. C 21 601
a C 23 601
sensitive C 24 601
and C 25 601
specific C 26 601
assay C 27 601
method C 28 601
has C 29 601
been C 30 601
used C 31 601
to C 32 601
demonstrate C 33 601
acute C 34 601
changes C 35 601
in C 36 601
plasma C 37 601
hgh C 38 601
in C 39 601
normal C 40 601
and C 41 601
diabetic C 42 601
subjects C 43 601
. C 44 601
hgh C 46 601
secretion C 47 601
is C 48 601
suppressed C 49 601
by C 50 601
glucose C 51 601
administration C 52 601
and C 53 601
markedly C 54 601
stimulated C 55 601
by C 56 601
hypoglycemia C 57 601
, C 58 601
by C 59 601
interference C 60 601
with C 61 601
intracellular C 62 601
glucose C 63 601
utilization C 64 601
. C 65 601
high C 67 601
levels C 68 601
of C 69 601
hgh C 70 601
were C 71 601
also C 72 601
observed C 73 601
during C 74 601
prolonged C 75 601
fasting C 76 601
, C 77 601
after C 78 601
exercise C 79 601
, C 80 601
and C 81 601
four C 82 601
to C 83 601
six C 84 601
hours C 85 601
following C 86 601
oral C 87 601
glucose C 88 601
administration C 89 601
. C 90 601
abnormalities C 92 601
in C 93 601
hgh C 94 601
secretion C 95 601
were C 96 601
found C 97 601
in C 98 601
association C 99 601
with C 100 601
acromegaly C 101 601
and C 102 601
obesity C 103 601
, C 104 601
and C 105 601
following C 106 601
section C 107 601
of C 108 601
the C 109 601
hypophyseal C 110 601
stalk C 111 601
. C 112 601
the C 114 601
half C 115 601
time C 116 601
for C 117 601
disappearance C 118 601
of C 119 601
endogenous C 120 601
plasma C 121 601
hgh C 122 601
is C 123 601
twenty C 124 601
to C 125 601
thirty C 126 601
minutes C 127 601
. C 128 601
failure C 1 602
to C 2 602
thrive C 3 602
: C 4 602
the C 5 602
diencephalic C 6 602
syndrome C 7 602
of C 8 602
infancy C 9 602
and C 10 602
childhood C 11 602
we C 12 602
have C 13 602
presented C 14 602
a C 15 602
case C 16 602
of C 17 602
a C 18 602
patient C 19 602
with C 20 602
an C 21 602
astrocytoma C 22 602
of C 23 602
the C 24 602
optic C 25 602
chiasm C 26 602
who C 27 602
demonstrated C 28 602
the C 29 602
features C 30 602
of C 31 602
the C 32 602
" C 33 602
diencephalic C 34 602
" C 35 602
or C 36 602
" C 37 602
failure C 38 602
- C 39 602
to C 40 602
- C 41 602
thrive C 42 602
" C 43 602
syndrome C 44 602
. C 45 602
overactivity C 47 602
, C 48 602
overalertness C 49 602
and C 50 602
emaciation C 51 602
were C 52 602
significant C 53 602
symptoms C 54 602
in C 55 602
this C 56 602
patient C 57 602
. C 58 602
roentgenograms C 60 602
characteristically C 61 602
demonstrate C 62 602
normal C 63 602
bone C 64 602
growth C 65 602
, C 66 602
good C 67 602
muscular C 68 602
outline C 69 602
, C 70 602
and C 71 602
absent C 72 602
subcutaneous C 73 602
fat C 74 602
. C 75 602
increased C 77 602
growth C 78 602
hormone C 79 602
was C 80 602
found C 81 602
and C 82 602
may C 83 602
be C 84 602
a C 85 602
factor C 86 602
in C 87 602
the C 88 602
disturbed C 89 602
lipid C 90 602
metabolism C 91 602
. C 92 602
increased C 1 603
stature C 2 603
the C 3 603
fact C 4 603
that C 5 603
some C 6 603
patients C 7 603
respond C 8 603
to C 9 603
growth C 10 603
- C 11 603
hormone C 12 603
administration C 13 603
with C 14 603
linear C 15 603
growth C 16 603
does C 17 603
not C 18 603
indicate C 19 603
growth C 20 603
- C 21 603
hormone C 22 603
deficiency C 23 603
or C 24 603
hypopituitarism C 25 603
. C 26 603
yet C 28 603
this C 29 603
appears C 30 603
to C 31 603
be C 32 603
the C 33 603
main C 34 603
factor C 35 603
that C 36 603
led C 37 603
these C 38 603
authors C 39 603
to C 40 603
assume C 41 603
that C 42 603
their C 43 603
patients C 44 603
were C 45 603
suffering C 46 603
from C 47 603
hypopituitarism C 48 603
. C 49 603
the C 51 603
conclusion C 52 603
that C 53 603
children C 54 603
with C 55 603
growth C 56 603
retardation C 57 603
should C 58 603
be C 59 603
subjected C 60 603
to C 61 603
a C 62 603
short C 63 603
trial C 64 603
period C 65 603
of C 66 603
treatment C 67 603
with C 68 603
growth C 69 603
hormone C 70 603
to C 71 603
single C 72 603
out C 73 603
those C 74 603
who C 75 603
are C 76 603
deficient C 77 603
in C 78 603
growth C 79 603
hormone C 80 603
is C 81 603
therefore C 82 603
of C 83 603
questionable C 84 603
validity C 85 603
. C 86 603
rather C 88 603
, C 89 603
because C 90 603
of C 91 603
the C 92 603
limited C 93 603
supply C 94 603
of C 95 603
human C 96 603
growth C 97 603
hormone C 98 603
, C 99 603
it C 100 603
appears C 101 603
that C 102 603
much C 103 603
more C 104 603
stringent C 105 603
criteria C 106 603
for C 107 603
administration C 108 603
of C 109 603
human C 110 603
growth C 111 603
hormone C 112 603
should C 113 603
be C 114 603
advocated C 115 603
. C 116 603
every C 118 603
effort C 119 603
should C 120 603
be C 121 603
made C 122 603
to C 123 603
uncover C 124 603
the C 125 603
patients C 126 603
who C 127 603
might C 128 603
benefit C 129 603
from C 130 603
growth C 131 603
hormone C 132 603
by C 133 603
utilizing C 134 603
reliable C 135 603
tests C 136 603
of C 137 603
pituitary C 138 603
function C 139 603
and C 140 603
perfecting C 141 603
a C 142 603
suitable C 143 603
growth C 144 603
- C 145 603
hormone C 146 603
assay C 147 603
. C 148 603
those C 150 603
who C 151 603
have C 152 603
more C 153 603
than C 154 603
suggestive C 155 603
evidence C 156 603
of C 157 603
hypopituitarism C 158 603
and C 159 603
growth C 160 603
- C 161 603
hormone C 162 603
deficiency C 163 603
should C 164 603
then C 165 603
be C 166 603
treated C 167 603
and C 168 603
carefully C 169 603
evaluated C 170 603
for C 171 603
response C 172 603
after C 173 603
long C 174 603
- C 175 603
term C 176 603
treatment C 177 603
. C 178 603
on C 1 604
language C 2 604
disorders C 3 604
in C 4 604
young C 5 604
children C 6 604
: C 7 604
a C 8 604
reorganization C 9 604
of C 10 604
thinking C 11 604
current C 12 604
questions C 13 604
and C 14 604
confusions C 15 604
about C 16 604
the C 17 604
use C 18 604
of C 19 604
the C 20 604
term C 21 604
aphasia C 22 604
with C 23 604
reference C 24 604
to C 25 604
young C 26 604
children C 27 604
seem C 28 604
often C 29 604
to C 30 604
reflect C 31 604
semantic C 32 604
problems C 33 604
accruing C 34 604
from C 35 604
professional C 36 604
habits C 37 604
of C 38 604
thinking C 39 604
in C 40 604
terms C 41 604
of C 42 604
etiologic C 43 604
and C 44 604
pathologic C 45 604
labels C 46 604
. C 47 604
it C 49 604
is C 50 604
argued C 51 604
that C 52 604
if C 53 604
the C 54 604
term C 55 604
aphasia C 56 604
is C 57 604
generalized C 58 604
simply C 59 604
to C 60 604
refer C 61 604
to C 62 604
inabilities C 63 604
or C 64 604
interferences C 65 604
in C 66 604
the C 67 604
development C 68 604
of C 69 604
language C 70 604
comprehension C 71 604
and C 72 604
use C 73 604
, C 74 604
then C 75 604
it C 76 604
is C 77 604
the C 78 604
task C 79 604
of C 80 604
an C 81 604
evaluating C 82 604
group C 83 604
to C 84 604
describe C 85 604
as C 86 604
well C 87 604
as C 88 604
possible C 89 604
, C 90 604
and C 91 604
in C 92 604
detail C 93 604
, C 94 604
the C 95 604
specific C 96 604
impairments C 97 604
of C 98 604
function C 99 604
in C 100 604
each C 101 604
child C 102 604
. C 103 604
this C 105 604
task C 106 604
commonly C 107 604
requires C 108 604
the C 109 604
use C 110 604
of C 111 604
an C 112 604
extensive C 113 604
period C 114 604
of C 115 604
" C 116 604
diagnostic C 117 604
teaching C 118 604
, C 119 604
" C 120 604
wherein C 121 604
care C 122 604
is C 123 604
taken C 124 604
to C 125 604
explore C 126 604
which C 127 604
sensory C 128 604
and C 129 604
motor C 130 604
modalities C 131 604
are C 132 604
working C 133 604
and C 134 604
which C 135 604
are C 136 604
not C 137 604
, C 138 604
and C 139 604
whether C 140 604
integration C 141 604
of C 142 604
various C 143 604
stimuli C 144 604
is C 145 604
taking C 146 604
place C 147 604
. C 148 604
some C 150 604
current C 151 604
ideas C 152 604
are C 153 604
discussed C 154 604
with C 155 604
reference C 156 604
to C 157 604
descriptions C 158 604
of C 159 604
impairment C 160 604
, C 161 604
causal C 162 604
factors C 163 604
that C 164 604
are C 165 604
fairly C 166 604
unique C 167 604
in C 168 604
childhood C 169 604
, C 170 604
some C 171 604
thoughts C 172 604
about C 173 604
the C 174 604
neurophysiology C 175 604
of C 176 604
the C 177 604
human C 178 604
" C 179 604
language C 180 604
system C 181 604
, C 182 604
" C 183 604
and C 184 604
some C 185 604
psychosocial C 186 604
factors C 187 604
important C 188 604
for C 189 604
language C 190 604
- C 191 604
learning C 192 604
. C 193 604
special C 195 604
attention C 196 604
is C 197 604
given C 198 604
to C 199 604
various C 200 604
relations C 201 604
, C 202 604
in C 203 604
terms C 204 604
of C 205 604
temporal C 206 604
resolving C 207 604
power C 208 604
, C 209 604
between C 210 604
sensation C 211 604
and C 212 604
sensory C 213 604
integration C 214 604
. C 215 604
a C 217 604
scheme C 218 604
, C 219 604
or C 220 604
model C 221 604
, C 222 604
is C 223 604
suggested C 224 604
which C 225 604
may C 226 604
prove C 227 604
fruitful C 228 604
for C 229 604
experimental C 230 604
design C 231 604
in C 232 604
attacking C 233 604
some C 234 604
of C 235 604
these C 236 604
problems C 237 604
at C 238 604
a C 239 604
prelanguage C 240 604
or C 241 604
premeaning C 242 604
level C 243 604
. C 244 604
it C 246 604
is C 247 604
argued C 248 604
that C 249 604
the C 250 604
proportion C 251 604
of C 252 604
" C 253 604
unknowns C 254 604
" C 255 604
can C 256 604
be C 257 604
reduced C 258 604
by C 259 604
careful C 260 604
study C 261 604
based C 262 604
on C 263 604
information C 264 604
about C 265 604
impaired C 266 604
functions C 267 604
within C 268 604
the C 269 604
sensory C 270 604
- C 271 604
integrative C 272 604
- C 273 604
motor C 274 604
complex C 275 604
, C 276 604
without C 277 604
particular C 278 604
regard C 279 604
for C 280 604
" C 281 604
site C 282 604
and C 283 604
extent C 284 604
of C 285 604
lesion C 286 604
. C 287 604
" C 289 604
therapy C 1 605
for C 2 605
hearing C 3 605
- C 4 605
impaired C 5 605
children C 6 605
in C 7 605
comparison C 8 605
with C 9 605
the C 10 605
u C 11 605
. C 12 605
. C 13 605
. C 14 605
. C 15 605
. C 16 605
and C 18 605
europe C 19 605
, C 20 605
canada C 21 605
is C 22 605
still C 23 605
in C 24 605
the C 25 605
early C 26 605
stages C 27 605
of C 28 605
developing C 29 605
rehabilitative C 30 605
services C 31 605
for C 32 605
speech C 33 605
and C 34 605
hearing C 35 605
- C 36 605
impaired C 37 605
children C 38 605
and C 39 605
adults C 40 605
. C 41 605
they C 43 605
are C 44 605
available C 45 605
in C 46 605
some C 47 605
large C 48 605
canadian C 49 605
cities C 50 605
, C 51 605
but C 52 605
in C 53 605
the C 54 605
opinion C 55 605
of C 56 605
the C 57 605
authors C 58 605
, C 59 605
these C 60 605
services C 61 605
and C 62 605
more C 63 605
should C 64 605
be C 65 605
made C 66 605
available C 67 605
to C 68 605
the C 69 605
hearing C 70 605
impaired C 71 605
of C 72 605
every C 73 605
canadian C 74 605
community C 75 605
. C 76 605
specialists C 78 605
in C 79 605
the C 80 605
rehabilitation C 81 605
of C 82 605
communication C 83 605
problems C 84 605
, C 85 605
along C 86 605
with C 87 605
members C 88 605
of C 89 605
other C 90 605
medical C 91 605
, C 92 605
paramedical C 93 605
and C 94 605
social C 95 605
services C 96 605
, C 97 605
recognize C 98 605
the C 99 605
vast C 100 605
variety C 101 605
of C 102 605
communication C 103 605
problems C 104 605
that C 105 605
can C 106 605
occur C 107 605
in C 108 605
persons C 109 605
of C 110 605
all C 111 605
ages C 112 605
, C 113 605
the C 114 605
tremendous C 115 605
handicap C 116 605
that C 117 605
such C 118 605
problems C 119 605
represent C 120 605
to C 121 605
the C 122 605
individual C 123 605
, C 124 605
the C 125 605
loss C 126 605
that C 127 605
such C 128 605
handicapped C 129 605
persons C 130 605
represent C 131 605
to C 132 605
our C 133 605
society C 134 605
and C 135 605
the C 136 605
pressing C 137 605
need C 138 605
for C 139 605
efficient C 140 605
and C 141 605
effective C 142 605
rehabilitation C 143 605
. C 144 605
more C 146 605
practically C 147 605
, C 148 605
it C 149 605
is C 150 605
hoped C 151 605
that C 152 605
this C 153 605
article C 154 605
has C 155 605
made C 156 605
its C 157 605
readers C 158 605
more C 159 605
aware C 160 605
of C 161 605
the C 162 605
vast C 163 605
variety C 164 605
of C 165 605
rehabilitative C 166 605
procedures C 167 605
available C 168 605
today C 169 605
for C 170 605
the C 171 605
hearing C 172 605
impaired C 173 605
. C 174 605
with C 176 605
a C 177 605
better C 178 605
understanding C 179 605
of C 180 605
the C 181 605
problems C 182 605
of C 183 605
defective C 184 605
hearing C 185 605
, C 186 605
it C 187 605
is C 188 605
hoped C 189 605
that C 190 605
all C 191 605
readers C 192 605
, C 193 605
professional C 194 605
and C 195 605
non C 196 605
- C 197 605
professional C 198 605
, C 199 605
will C 200 605
join C 201 605
in C 202 605
mutual C 203 605
support C 204 605
for C 205 605
the C 206 605
establishment C 207 605
of C 208 605
these C 209 605
vitally C 210 605
needed C 211 605
services C 212 605
in C 213 605
their C 214 605
respective C 215 605
communities C 216 605
. C 217 605
baby C 1 606
habits C 2 606
, C 3 606
genesis C 4 606
and C 5 606
ontogenesis C 6 606
for C 7 606
adam C 8 606
may C 9 606
be C 10 606
looked C 11 606
upon C 12 606
as C 13 606
the C 14 606
personification C 15 606
of C 16 606
paleolithic C 17 606
man C 18 606
- C 19 606
100 C 20 606
, C 21 606
000 C 22 606
generations C 23 606
of C 24 606
primitive C 25 606
human C 26 606
animal C 27 606
- C 28 606
whose C 29 606
evolution C 30 606
can C 31 606
be C 32 606
of C 33 606
vast C 34 606
importance C 35 606
to C 36 606
the C 37 606
understanding C 38 606
of C 39 606
the C 40 606
ontogenesis C 41 606
of C 42 606
the C 43 606
behavior C 44 606
of C 45 606
babies C 46 606
. C 47 606
not C 49 606
for C 50 606
nothing C 51 606
did C 52 606
the C 53 606
deuteronomist C 54 606
reiterate C 55 606
" C 56 606
remember C 57 606
the C 58 606
days C 59 606
of C 60 606
old C 61 606
, C 62 606
consider C 63 606
the C 64 606
years C 65 606
of C 66 606
many C 67 606
generations C 68 606
" C 69 606
speech C 1 607
therapy C 2 607
with C 3 607
selected C 4 607
patients C 5 607
with C 6 607
congenital C 7 607
velopharyngeal C 8 607
inadequacy C 9 607
this C 10 607
paper C 11 607
has C 12 607
described C 13 607
the C 14 607
clinical C 15 607
speech C 16 607
problems C 17 607
of C 18 607
three C 19 607
patients C 20 607
without C 21 607
cleft C 22 607
palates C 23 607
but C 24 607
with C 25 607
velopharyngeal C 26 607
inadequacy C 27 607
. C 28 607
pharyngeal C 30 607
flap C 31 607
surgery C 32 607
was C 33 607
performed C 34 607
on C 35 607
each C 36 607
patient C 37 607
after C 38 607
speech C 39 607
therapy C 40 607
was C 41 607
found C 42 607
to C 43 607
be C 44 607
ineffective C 45 607
following C 46 607
systematic C 47 607
trial C 48 607
. C 49 607
therapy C 51 607
continued C 52 607
following C 53 607
the C 54 607
surgery C 55 607
. C 56 607
the C 58 607
youngest C 59 607
child C 60 607
, C 61 607
a C 62 607
first C 63 607
grader C 64 607
, C 65 607
realized C 66 607
normal C 67 607
speech C 68 607
following C 69 607
the C 70 607
surgery C 71 607
and C 72 607
therapy C 73 607
. C 74 607
the C 76 607
two C 77 607
other C 78 607
children C 79 607
continue C 80 607
to C 81 607
have C 82 607
aberrant C 83 607
but C 84 607
improved C 85 607
speech C 86 607
. C 87 607
stimulus C 1 608
overload C 2 608
, C 3 608
action C 4 608
cycles C 5 608
, C 6 608
and C 7 608
the C 8 608
completion C 9 608
gradient C 10 608
systematic C 11 608
inquiries C 12 608
into C 13 608
the C 14 608
origin C 15 608
of C 16 608
certain C 17 608
emotional C 18 608
disturbances C 19 608
of C 20 608
infants C 21 608
show C 22 608
that C 23 608
consistent C 24 608
maternal C 25 608
care C 26 608
is C 27 608
vital C 28 608
for C 29 608
the C 30 608
child C 31 608
' C 32 608
s C 33 608
normal C 34 608
physical C 35 608
, C 36 608
psychic C 37 608
, C 38 608
and C 39 608
social C 40 608
development C 41 608
, C 42 608
indeed C 43 608
, C 44 608
for C 45 608
his C 46 608
survival C 47 608
. C 48 608
the C 50 608
most C 51 608
elementary C 52 608
precondition C 53 608
for C 54 608
consistent C 55 608
maternal C 56 608
care C 57 608
is C 58 608
the C 59 608
physical C 60 608
presence C 61 608
of C 62 608
the C 63 608
mother C 64 608
or C 65 608
her C 66 608
substitute C 67 608
. C 68 608
it C 70 608
has C 71 608
, C 72 608
however C 73 608
, C 74 608
become C 75 608
increasingly C 76 608
apparent C 77 608
that C 78 608
children C 79 608
' C 80 608
s C 81 608
development C 82 608
can C 83 608
also C 84 608
be C 85 608
stunted C 86 608
, C 87 608
and C 88 608
that C 89 608
they C 90 608
suffer C 91 608
damage C 92 608
of C 93 608
varying C 94 608
extent C 95 608
by C 96 608
the C 97 608
attention C 98 608
of C 99 608
, C 100 608
and C 101 608
close C 102 608
contact C 103 608
with C 104 608
, C 105 608
a C 106 608
mother C 107 608
who C 108 608
dispenses C 109 608
what C 110 608
seems C 111 608
to C 112 608
be C 113 608
the C 114 608
" C 115 608
wrong C 116 608
kind C 117 608
of C 118 608
mothering C 119 608
" C 120 608
. C 121 608
a C 123 608
model C 124 608
of C 125 608
the C 126 608
mother C 127 608
- C 128 608
baby C 129 608
interaction C 130 608
is C 131 608
proposed C 132 608
to C 133 608
explicate C 134 608
the C 135 608
dynamics C 136 608
of C 137 608
the C 138 608
" C 139 608
wrong C 140 608
kind C 141 608
of C 142 608
mothering C 143 608
" C 144 608
and C 145 608
its C 146 608
consequences C 147 608
: C 148 608
my C 149 608
proposition C 150 608
is C 151 608
that C 152 608
the C 153 608
mutual C 154 608
exchanges C 155 608
between C 156 608
mother C 157 608
and C 158 608
baby C 159 608
consist C 160 608
in C 161 608
a C 162 608
give C 163 608
and C 164 608
take C 165 608
of C 166 608
action C 167 608
and C 168 608
reaction C 169 608
between C 170 608
the C 171 608
two C 172 608
partners C 173 608
, C 174 608
which C 175 608
requires C 176 608
from C 177 608
each C 178 608
of C 179 608
them C 180 608
both C 181 608
active C 182 608
and C 183 608
passive C 184 608
responses C 185 608
. C 186 608
these C 188 608
responses C 189 608
form C 190 608
series C 191 608
and C 192 608
chains C 193 608
, C 194 608
the C 195 608
single C 196 608
links C 197 608
of C 198 608
which C 199 608
consist C 200 608
in C 201 608
what C 202 608
i C 203 608
call C 204 608
" C 205 608
action C 206 608
cycles C 207 608
, C 208 608
" C 209 608
each C 210 608
completed C 211 608
in C 212 608
itself C 213 608
and C 214 608
at C 215 608
the C 216 608
same C 217 608
time C 218 608
anticipating C 219 608
the C 220 608
next C 221 608
link C 222 608
. C 223 608
i C 225 608
designated C 226 608
these C 227 608
seriated C 228 608
response C 229 608
exchanges C 230 608
as C 231 608
the C 232 608
" C 233 608
precursor C 234 608
of C 235 608
dialogue C 236 608
, C 237 608
" C 238 608
as C 239 608
a C 240 608
primal C 241 608
dialogue C 242 608
. C 243 608
the C 245 608
dialogue C 246 608
acts C 247 608
as C 248 608
a C 249 608
vector C 250 608
of C 251 608
the C 252 608
baby C 253 608
' C 254 608
s C 255 608
development C 256 608
, C 257 608
influencing C 258 608
its C 259 608
direction C 260 608
and C 261 608
stimulating C 262 608
it C 263 608
to C 264 608
adaptive C 265 608
efforts C 266 608
and C 267 608
psychic C 268 608
growth C 269 608
. C 270 608
it C 272 608
follows C 273 608
that C 274 608
inappropriate C 275 608
mothering C 276 608
( C 277 608
quantitatively C 278 608
as C 279 608
well C 280 608
as C 281 608
qualitatively C 282 608
) C 283 608
results C 284 608
in C 285 608
what C 286 608
is C 287 608
referred C 288 608
to C 289 608
at C 290 608
this C 291 608
time C 292 608
as C 293 608
the C 294 608
" C 295 608
derailment C 296 608
" C 297 608
of C 298 608
the C 299 608
primal C 300 608
dialogue C 301 608
. C 302 608
controlled C 304 608
experiments C 305 608
with C 306 608
animals C 307 608
, C 308 608
findings C 309 608
of C 310 608
experimental C 311 608
psychology C 312 608
, C 313 608
and C 314 608
, C 315 608
lastly C 316 608
, C 317 608
clinical C 318 608
findings C 319 608
illustrate C 320 608
the C 321 608
mechanics C 322 608
of C 323 608
the C 324 608
derailed C 325 608
dialogue C 326 608
and C 327 608
its C 328 608
sequelae C 329 608
. C 330 608
in C 332 608
the C 333 608
cases C 334 608
under C 335 608
review C 336 608
a C 337 608
surfeit C 338 608
of C 339 608
stimulation C 340 608
, C 341 608
a C 342 608
psychic C 343 608
overloading C 344 608
, C 345 608
resulted C 346 608
in C 347 608
the C 348 608
derailment C 349 608
of C 350 608
dialogue C 351 608
. C 352 608
overloading C 354 608
prevents C 355 608
its C 356 608
subject C 357 608
from C 358 608
completing C 359 608
actions C 360 608
or C 361 608
responses C 362 608
initiated C 363 608
by C 364 608
him C 365 608
. C 366 608
long C 368 608
- C 369 608
lasting C 370 608
overload C 371 608
results C 372 608
in C 373 608
the C 374 608
cumulation C 375 608
of C 376 608
" C 377 608
incompleted C 378 608
action C 379 608
cycles C 380 608
" C 381 608
. C 382 608
the C 384 608
sequelae C 385 608
of C 386 608
this C 387 608
cumulation C 388 608
are C 389 608
profound C 390 608
changes C 391 608
in C 392 608
the C 393 608
behavior C 394 608
of C 395 608
the C 396 608
individual C 397 608
. C 398 608
these C 400 608
changes C 401 608
are C 402 608
manifested C 403 608
in C 404 608
a C 405 608
departure C 406 608
from C 407 608
the C 408 608
norms C 409 608
of C 410 608
individual C 411 608
and C 412 608
social C 413 608
behavior C 414 608
patterns C 415 608
that C 416 608
are C 417 608
maladaptive C 418 608
for C 419 608
the C 420 608
individual C 421 608
and C 422 608
asyntonic C 423 608
with C 424 608
his C 425 608
society C 426 608
, C 427 608
that C 428 608
is C 429 608
, C 430 608
asocial C 431 608
. C 432 608
the C 434 608
derailment C 435 608
of C 436 608
the C 437 608
dialogue C 438 608
is C 439 608
triggered C 440 608
, C 441 608
perhaps C 442 608
even C 443 608
caused C 444 608
, C 445 608
by C 446 608
the C 447 608
nature C 448 608
of C 449 608
the C 450 608
social C 451 608
setting C 452 608
. C 453 608
one C 455 608
setting C 456 608
, C 457 608
over C 458 608
- C 459 608
population C 460 608
, C 461 608
is C 462 608
extensively C 463 608
discussed C 464 608
in C 465 608
connection C 466 608
with C 467 608
an C 468 608
animal C 469 608
experiment C 470 608
, C 471 608
and C 472 608
the C 473 608
implications C 474 608
for C 475 608
the C 476 608
human C 477 608
community C 478 608
are C 479 608
examined C 480 608
. C 481 608
children C 1 609
at C 2 609
kelbourne C 3 609
kelbourne C 4 609
school C 5 609
, C 6 609
glasgow C 7 609
, C 8 609
which C 9 609
educates C 10 609
both C 11 609
spastic C 12 609
and C 13 609
aphasic C 14 609
children C 15 609
, C 16 609
is C 17 609
the C 18 609
first C 19 609
school C 20 609
of C 21 609
its C 22 609
kind C 23 609
to C 24 609
be C 25 609
administered C 26 609
by C 27 609
a C 28 609
local C 29 609
education C 30 609
authority C 31 609
. C 32 609
its C 34 609
aphasic C 35 609
department C 36 609
, C 37 609
largely C 38 609
experimental C 39 609
in C 40 609
nature C 41 609
, C 42 609
contains C 43 609
children C 44 609
aged C 45 609
three C 46 609
to C 47 609
eight C 48 609
. C 49 609
in C 51 609
the C 52 609
spastics C 53 609
department C 54 609
there C 55 609
are C 56 609
45 C 57 609
children C 58 609
with C 59 609
severe C 60 609
physical C 61 609
handicaps C 62 609
and C 63 609
their C 64 609
ages C 65 609
range C 66 609
from C 67 609
3 C 68 609
to C 69 609
16 C 70 609
. C 71 609
the C 73 609
school C 74 609
, C 75 609
which C 76 609
celebrated C 77 609
its C 78 609
golden C 79 609
jubilee C 80 609
last C 81 609
year C 82 609
, C 83 609
has C 84 609
its C 85 609
origins C 86 609
in C 87 609
the C 88 609
maryhill C 89 609
hall C 90 609
public C 91 609
school C 92 609
for C 93 609
defective C 94 609
and C 95 609
epileptic C 96 609
children C 97 609
which C 98 609
opened C 99 609
in C 100 609
1907 C 101 609
with C 102 609
12 C 103 609
pupils C 104 609
in C 105 609
premises C 106 609
of C 107 609
which C 108 609
, C 109 609
as C 110 609
an C 111 609
h C 112 609
. C 113 609
. C 114 609
. C 115 609
. C 116 609
. C 117 609
reported C 119 609
four C 120 609
years C 121 609
later C 122 609
, C 123 609
' C 124 609
it C 125 609
was C 126 609
impossible C 127 609
to C 128 609
speak C 129 609
favourably C 130 609
' C 131 609
. C 132 609
the C 134 609
report C 135 609
continued C 136 609
, C 137 609
' C 138 609
a C 139 609
public C 140 609
hall C 141 609
, C 142 609
used C 143 609
frequently C 144 609
in C 145 609
the C 146 609
evenings C 147 609
for C 148 609
public C 149 609
entertainments C 150 609
, C 151 609
lacking C 152 609
proper C 153 609
cloakrooms C 154 609
, C 155 609
bare C 156 609
in C 157 609
appearance C 158 609
, C 159 609
and C 160 609
generally C 161 609
comfortless C 162 609
, C 163 609
should C 164 609
not C 165 609
be C 166 609
used C 167 609
for C 168 609
this C 169 609
purpose C 170 609
' C 171 609
. C 172 609
the C 174 609
inspector C 175 609
' C 176 609
s C 177 609
words C 178 609
did C 179 609
not C 180 609
go C 181 609
unheeded C 182 609
and C 183 609
seven C 184 609
years C 185 609
later C 186 609
the C 187 609
children C 188 609
were C 189 609
transferred C 190 609
with C 191 609
others C 192 609
to C 193 609
the C 194 609
new C 195 609
buildings C 196 609
of C 197 609
percy C 198 609
street C 199 609
special C 200 609
school C 201 609
. C 202 609
in C 204 609
the C 205 609
1950 C 206 609
s C 207 609
the C 208 609
name C 209 609
was C 210 609
changed C 211 609
to C 212 609
kelbourne C 213 609
school C 214 609
. C 215 609
between C 217 609
and C 218 609
through C 219 609
two C 220 609
world C 221 609
wars C 222 609
the C 223 609
school C 224 609
provided C 225 609
education C 226 609
for C 227 609
physically C 228 609
and C 229 609
mentally C 230 609
handicapped C 231 609
children C 232 609
but C 233 609
in C 234 609
1955 C 235 609
a C 236 609
new C 237 609
unit C 238 609
was C 239 609
added C 240 609
and C 241 609
spastic C 242 609
children C 243 609
were C 244 609
admitted C 245 609
for C 246 609
the C 247 609
first C 248 609
time C 249 609
. C 250 609
gradually C 252 609
the C 253 609
emphasis C 254 609
shifted C 255 609
from C 256 609
children C 257 609
with C 258 609
other C 259 609
physical C 260 609
and C 261 609
mental C 262 609
handicaps C 263 609
to C 264 609
the C 265 609
cerebrally C 266 609
palsied C 267 609
and C 268 609
finally C 269 609
the C 270 609
entire C 271 609
building C 272 609
became C 273 609
available C 274 609
for C 275 609
spastics C 276 609
. C 277 609
two C 279 609
years C 280 609
ago C 281 609
the C 282 609
aphasic C 283 609
children C 284 609
joined C 285 609
the C 286 609
school C 287 609
. C 288 609
miss C 290 609
e C 291 609
. C 292 609
. C 293 609
. C 294 609
hamilton C 296 609
is C 297 609
the C 298 609
headmistress C 299 609
. C 300 609
deafness C 1 610
methods C 2 610
of C 3 610
detection C 4 610
, C 5 610
diagnosis C 6 610
, C 7 610
and C 8 610
management C 9 610
of C 10 610
deafness C 11 610
in C 12 610
children C 13 610
depend C 14 610
so C 15 610
entirely C 16 610
on C 17 610
a C 18 610
knowledge C 19 610
of C 20 610
the C 21 610
processes C 22 610
involved C 23 610
in C 24 610
communication C 25 610
by C 26 610
speech C 27 610
and C 28 610
in C 29 610
the C 30 610
acquisition C 31 610
of C 32 610
this C 33 610
skill C 34 610
that C 35 610
i C 36 610
propose C 37 610
to C 38 610
consider C 39 610
them C 40 610
first C 41 610
. C 42 610
it C 44 610
will C 45 610
be C 46 610
found C 47 610
that C 48 610
the C 49 610
practical C 50 610
steps C 51 610
to C 52 610
be C 53 610
taken C 54 610
in C 55 610
dealing C 56 610
with C 57 610
patients C 58 610
flow C 59 610
naturally C 60 610
from C 61 610
this C 62 610
knowledge C 63 610
. C 64 610
pharyngoplasty C 1 611
in C 2 611
speech C 3 611
where C 4 611
adequate C 5 611
palate C 6 611
repair C 7 611
is C 8 611
undertaken C 9 611
at C 10 611
1 C 11 611
year C 12 611
there C 13 611
is C 14 611
no C 15 611
indication C 16 611
for C 17 611
pharyngoplasty C 18 611
as C 19 611
well C 20 611
at C 21 611
that C 22 611
age C 23 611
. C 24 611
pharyngoplasty C 26 611
is C 27 611
indicated C 28 611
as C 29 611
a C 30 611
" C 31 611
supportive C 32 611
" C 33 611
operation C 34 611
only C 35 611
when C 36 611
the C 37 611
result C 38 611
of C 39 611
the C 40 611
palate C 41 611
repair C 42 611
can C 43 611
be C 44 611
assessed C 45 611
( C 46 611
5 C 47 611
years C 48 611
plus C 49 611
) C 50 611
, C 51 611
and C 52 611
where C 53 611
the C 54 611
speech C 55 611
result C 56 611
proves C 57 611
disappointing C 58 611
. C 59 611
the C 61 611
figure C 62 611
of C 63 611
171 C 64 611
pharyngoplastics C 65 611
in C 66 611
944 C 67 611
cases C 68 611
applies C 69 611
to C 70 611
the C 71 611
known C 72 611
speech C 73 611
results C 74 611
up C 75 611
to C 76 611
april C 77 611
1963 C 78 611
. C 79 611
it C 81 611
follows C 82 611
that C 83 611
with C 84 611
follow C 85 611
- C 86 611
up C 87 611
of C 88 611
the C 89 611
more C 90 611
recent C 91 611
primary C 92 611
cases C 93 611
pharyngoplasty C 94 611
may C 95 611
well C 96 611
be C 97 611
necessary C 98 611
in C 99 611
some C 100 611
. C 101 611
the C 103 611
hynes C 104 611
pharyngoplasty C 105 611
has C 106 611
proved C 107 611
to C 108 611
be C 109 611
the C 110 611
most C 111 611
satisfactory C 112 611
. C 113 611
verbal C 1 612
effects C 2 612
in C 3 612
the C 4 612
intermediate C 5 612
- C 6 612
size C 7 612
transportation C 8 612
problem C 9 612
preschool C 10 612
children C 11 612
were C 12 612
given C 13 612
an C 14 612
intermediate C 15 612
- C 16 612
size C 17 612
discrimination C 18 612
problem C 19 612
, C 20 612
told C 21 612
before C 22 612
each C 23 612
response C 24 612
that C 25 612
the C 26 612
reward C 27 612
was C 28 612
under C 29 612
the C 30 612
" C 31 612
medium C 32 612
" C 33 612
stimulus C 34 612
: C 35 612
and C 36 612
1 C 37 612
- C 38 612
and C 39 612
3 C 40 612
- C 41 612
step C 42 612
transposition C 43 612
tests C 44 612
. C 45 612
during C 47 612
training C 48 612
, C 49 612
group C 50 612
i C 51 612
was C 52 612
group C 53 612
ii C 54 612
was C 55 612
told C 56 612
that C 57 612
it C 58 612
was C 59 612
" C 60 612
not C 61 612
under C 62 612
the C 63 612
big C 64 612
or C 65 612
little C 66 612
one C 67 612
" C 68 612
; C 69 612
and C 70 612
group C 71 612
iii C 72 612
was C 73 612
not C 74 612
told C 75 612
anything C 76 612
. C 77 612
the C 79 612
verbalizations C 80 612
were C 81 612
not C 82 612
given C 83 612
during C 84 612
the C 85 612
tests C 86 612
. C 87 612
groups C 89 612
i C 90 612
and C 91 612
ii C 92 612
learned C 93 612
the C 94 612
initial C 95 612
discrimination C 96 612
faster C 97 612
than C 98 612
group C 99 612
iii C 100 612
, C 101 612
and C 102 612
transposed C 103 612
more C 104 612
than C 105 612
group C 106 612
iii C 107 612
, C 108 612
but C 109 612
there C 110 612
was C 111 612
a C 112 612
distance C 113 612
effect C 114 612
in C 115 612
all C 116 612
three C 117 612
groups C 118 612
. C 119 612
these C 121 612
results C 122 612
, C 123 612
and C 124 612
other C 125 612
data C 126 612
, C 127 612
suggest C 128 612
that C 129 612
the C 130 612
deficiency C 131 612
in C 132 612
the C 133 612
verbal C 134 612
control C 135 612
over C 136 612
motor C 137 612
behavior C 138 612
in C 139 612
young C 140 612
children C 141 612
arises C 142 612
from C 143 612
deficiencies C 144 612
in C 145 612
both C 146 612
the C 147 612
decoding C 148 612
and C 149 612
encoding C 150 612
processes C 151 612
. C 152 612
the C 1 613
acquisition C 2 613
of C 3 613
formal C 4 613
features C 5 613
of C 6 613
language C 7 613
children C 8 613
from C 9 613
different C 10 613
groups C 11 613
do C 12 613
not C 13 613
learn C 14 613
the C 15 613
same C 16 613
uses C 17 613
and C 18 613
functions C 19 613
for C 20 613
language C 21 613
. C 22 613
but C 24 613
every C 25 613
child C 26 613
must C 27 613
learn C 28 613
the C 29 613
formal C 30 613
features C 31 613
, C 32 613
or C 33 613
the C 34 613
" C 35 613
code C 36 613
" C 37 613
for C 38 613
his C 39 613
language C 40 613
, C 41 613
thus C 42 613
creating C 43 613
a C 44 613
constant C 45 613
in C 46 613
every C 47 613
language C 48 613
acquisition C 49 613
situation C 50 613
. C 51 613
mongolism C 1 614
- C 2 614
some C 3 614
clinical C 4 614
aspects C 5 614
this C 6 614
is C 7 614
a C 8 614
review C 9 614
of C 10 614
86 C 11 614
mongoloids C 12 614
seen C 13 614
over C 14 614
5 C 15 614
years C 16 614
at C 17 614
the C 18 614
nebraska C 19 614
psychiatric C 20 614
institute C 21 614
. C 22 614
one C 24 614
- C 25 614
half C 26 614
of C 27 614
the C 28 614
sample C 29 614
were C 30 614
evaluated C 31 614
before C 32 614
their C 33 614
second C 34 614
birthday C 35 614
. C 36 614
eighteen C 38 614
per C 39 614
cent C 40 614
of C 41 614
the C 42 614
cases C 43 614
for C 44 614
whom C 45 614
birth C 46 614
weight C 47 614
data C 48 614
were C 49 614
available C 50 614
weighed C 51 614
less C 52 614
than C 53 614
5 C 54 614
1 C 55 614
/ C 56 614
2 C 57 614
lbs C 58 614
. C 59 614
, C 61 614
double C 62 614
the C 63 614
national C 64 614
rate C 65 614
for C 66 614
prematurity C 67 614
. C 68 614
there C 70 614
was C 71 614
a C 72 614
bi C 73 614
- C 74 614
modal C 75 614
distribution C 76 614
of C 77 614
mother C 78 614
' C 79 614
s C 80 614
age C 81 614
at C 82 614
the C 83 614
birth C 84 614
of C 85 614
the C 86 614
mongoloid C 87 614
child C 88 614
. C 89 614
pregnancy C 91 614
, C 92 614
labor C 93 614
and C 94 614
delivery C 95 614
complications C 96 614
were C 97 614
reported C 98 614
in C 99 614
almost C 100 614
one C 101 614
- C 102 614
half C 103 614
of C 104 614
the C 105 614
cases C 106 614
. C 107 614
seven C 109 614
per C 110 614
cent C 111 614
were C 112 614
breech C 113 614
deliveries C 114 614
. C 115 614
all C 117 614
cases C 118 614
were C 119 614
mr C 120 614
. C 121 614
the C 123 614
most C 124 614
frequent C 125 614
type C 126 614
was C 127 614
moderate C 128 614
. C 129 614
most C 131 614
frequently C 132 614
mentioned C 133 614
characteristics C 134 614
were C 135 614
: C 136 614
generalized C 137 614
hypotonia C 138 614
( C 139 614
all C 140 614
but C 141 614
2 C 142 614
cases C 143 614
) C 144 614
; C 145 614
psychiatric C 146 614
disorders C 147 614
, C 148 614
11 C 149 614
cases C 150 614
; C 151 614
abnormal C 152 614
eeg C 153 614
, C 154 614
8 C 155 614
cases C 156 614
; C 157 614
hearing C 158 614
loss C 159 614
, C 160 614
5 C 161 614
cases C 162 614
. C 163 614
learning C 1 615
problems C 2 615
in C 3 615
children C 4 615
: C 5 615
ii C 6 615
. C 7 615
emotional C 9 615
aspects C 10 615
at C 11 615
the C 12 615
last C 13 615
meeting C 14 615
we C 15 615
tried C 16 615
to C 17 615
deal C 18 615
with C 19 615
a C 20 615
general C 21 615
over C 22 615
- C 23 615
all C 24 615
approach C 25 615
to C 26 615
the C 27 615
problem C 28 615
of C 29 615
learning C 30 615
, C 31 615
considering C 32 615
it C 33 615
not C 34 615
merely C 35 615
as C 36 615
a C 37 615
problem C 38 615
in C 39 615
reading C 40 615
, C 41 615
but C 42 615
learning C 43 615
in C 44 615
general C 45 615
which C 46 615
begins C 47 615
at C 48 615
birth C 49 615
. C 50 615
we C 52 615
hope C 53 615
to C 54 615
deal C 55 615
with C 56 615
this C 57 615
problem C 58 615
at C 59 615
a C 60 615
relatively C 61 615
high C 62 615
level C 63 615
and C 64 615
we C 65 615
want C 66 615
to C 67 615
have C 68 615
the C 69 615
emotional C 70 615
problems C 71 615
dealt C 72 615
with C 73 615
in C 74 615
this C 75 615
manner C 76 615
rather C 77 615
than C 78 615
in C 79 615
terms C 80 615
of C 81 615
diagnostic C 82 615
criteria C 83 615
. C 84 615
the C 86 615
child C 87 615
with C 88 615
learning C 89 615
problems C 90 615
should C 91 615
not C 92 615
be C 93 615
compartmentalized C 94 615
in C 95 615
terms C 96 615
of C 97 615
" C 98 615
organicity C 99 615
" C 100 615
and C 101 615
" C 102 615
nonorganicity C 103 615
" C 104 615
. C 105 615
the C 107 615
subject C 108 615
of C 109 615
this C 110 615
talk C 111 615
, C 112 615
then C 113 615
, C 114 615
is C 115 615
emotional C 116 615
issues C 117 615
in C 118 615
learning C 119 615
. C 120 615
management C 1 616
of C 2 616
communication C 3 616
problems C 4 616
in C 5 616
infants C 6 616
and C 7 616
children C 8 616
early C 9 616
detection C 10 616
and C 11 616
referral C 12 616
of C 13 616
a C 14 616
child C 15 616
with C 16 616
a C 17 616
hearing C 18 616
or C 19 616
speech C 20 616
- C 21 616
language C 22 616
problem C 23 616
is C 24 616
feasible C 25 616
and C 26 616
in C 27 616
most C 28 616
cases C 29 616
, C 30 616
very C 31 616
critical C 32 616
. C 33 616
further C 35 616
consultation C 36 616
can C 37 616
then C 38 616
be C 39 616
obtained C 40 616
and C 41 616
the C 42 616
child C 43 616
placed C 44 616
on C 45 616
a C 46 616
training C 47 616
program C 48 616
geared C 49 616
to C 50 616
his C 51 616
needs C 52 616
. C 53 616
the C 1 617
formation C 2 617
of C 3 617
a C 4 617
cleft C 5 617
palate C 6 617
unit C 7 617
- C 8 617
a C 9 617
preliminary C 10 617
report C 11 617
with C 12 617
cleft C 13 617
palates C 14 617
, C 15 617
as C 16 617
in C 17 617
other C 18 617
surgical C 19 617
fields C 20 617
, C 21 617
changing C 22 617
techniques C 23 617
and C 24 617
better C 25 617
management C 26 617
of C 27 617
the C 28 617
patient C 29 617
as C 30 617
a C 31 617
whole C 32 617
render C 33 617
inexcusable C 34 617
the C 35 617
operative C 36 617
procedures C 37 617
that C 38 617
merely C 39 617
drag C 40 617
together C 41 617
the C 42 617
edges C 43 617
of C 44 617
the C 45 617
defect C 46 617
and C 47 617
then C 48 617
leave C 49 617
a C 50 617
cosmetically C 51 617
and C 52 617
functionally C 53 617
crippled C 54 617
child C 55 617
, C 56 617
to C 57 617
adapt C 58 617
itself C 59 617
as C 60 617
best C 61 617
it C 62 617
may C 63 617
to C 64 617
the C 65 617
harsh C 66 617
competition C 67 617
of C 68 617
the C 69 617
outside C 70 617
world C 71 617
. C 72 617
ironically C 74 617
the C 75 617
problem C 76 617
of C 77 617
congenital C 78 617
defects C 79 617
increases C 80 617
as C 81 617
our C 82 617
competence C 83 617
to C 84 617
deal C 85 617
with C 86 617
them C 87 617
advances C 88 617
. C 89 617
in C 91 617
the C 92 617
past C 93 617
these C 94 617
cases C 95 617
struggled C 96 617
to C 97 617
take C 98 617
their C 99 617
place C 100 617
on C 101 617
the C 102 617
marriage C 103 617
market C 104 617
but C 105 617
the C 106 617
more C 107 617
skilled C 108 617
our C 109 617
rehabilitative C 110 617
procedures C 111 617
become C 112 617
, C 113 617
the C 114 617
more C 115 617
likely C 116 617
are C 117 617
they C 118 617
to C 119 617
perpetuate C 120 617
their C 121 617
disability C 122 617
, C 123 617
since C 124 617
a C 125 617
significant C 126 617
number C 127 617
show C 128 617
a C 129 617
hereditary C 130 617
tendency C 131 617
. C 132 617
acquisition C 1 618
of C 2 618
language C 3 618
although C 4 618
the C 5 618
work C 6 618
of C 7 618
bullowa C 8 618
, C 9 618
jones C 10 618
, C 11 618
and C 12 618
bever C 13 618
has C 14 618
some C 15 618
of C 16 618
its C 17 618
greatest C 18 618
promise C 19 618
in C 20 618
the C 21 618
light C 22 618
it C 23 618
may C 24 618
shed C 25 618
on C 26 618
the C 27 618
development C 28 618
of C 29 618
functions C 30 618
of C 31 618
language C 32 618
in C 33 618
children C 34 618
, C 35 618
the C 36 618
promise C 37 618
cannot C 38 618
be C 39 618
realized C 40 618
unless C 41 618
the C 42 618
authors C 43 618
give C 44 618
a C 45 618
great C 46 618
deal C 47 618
of C 48 618
explicit C 49 618
attention C 50 618
to C 51 618
the C 52 618
framework C 53 618
of C 54 618
such C 55 618
analysis C 56 618
, C 57 618
for C 58 618
there C 59 618
is C 60 618
not C 61 618
, C 62 618
as C 63 618
may C 64 618
be C 65 618
the C 66 618
case C 67 618
for C 68 618
phonological C 69 618
and C 70 618
grammatical C 71 618
development C 72 618
, C 73 618
anything C 74 618
like C 75 618
a C 76 618
satisfactory C 77 618
body C 78 618
of C 79 618
linguistic C 80 618
theory C 81 618
and C 82 618
method C 83 618
as C 84 618
to C 85 618
the C 86 618
terminal C 87 618
state C 88 618
. C 89 618
while C 91 618
a C 92 618
good C 93 618
deal C 94 618
may C 95 618
be C 96 618
learned C 97 618
without C 98 618
such C 99 618
a C 100 618
theory C 101 618
, C 102 618
and C 103 618
necessarily C 104 618
must C 105 618
be C 106 618
so C 107 618
learned C 108 618
, C 109 618
since C 110 618
the C 111 618
work C 112 618
in C 113 618
progress C 114 618
cannot C 115 618
be C 116 618
suspended C 117 618
until C 118 618
such C 119 618
an C 120 618
unpredictable C 121 618
millenium C 122 618
, C 123 618
it C 124 618
still C 125 618
would C 126 618
be C 127 618
a C 128 618
pity C 129 618
if C 130 618
the C 131 618
chance C 132 618
were C 133 618
lost C 134 618
for C 135 618
the C 136 618
interaction C 137 618
of C 138 618
the C 139 618
acquisition C 140 618
of C 141 618
data C 142 618
and C 143 618
the C 144 618
improvement C 145 618
of C 146 618
theoretical C 147 618
notions C 148 618
. C 149 618
let C 151 618
me C 152 618
complete C 153 618
my C 154 618
discussion C 155 618
by C 156 618
developing C 157 618
my C 158 618
argument C 159 618
in C 160 618
two C 161 618
ways C 162 618
: C 163 618
( C 164 618
a C 165 618
) C 166 618
by C 167 618
briefly C 168 618
stating C 169 618
the C 170 618
nature C 171 618
of C 172 618
the C 173 618
problem C 174 618
with C 175 618
regard C 176 618
to C 177 618
the C 178 618
terminal C 179 618
state C 180 618
of C 181 618
verbal C 182 618
development C 183 618
, C 184 618
( C 185 618
b C 186 618
) C 187 618
and C 188 618
by C 189 618
indicating C 190 618
what C 191 618
present C 192 618
and C 193 618
future C 194 618
contribution C 195 618
such C 196 618
fields C 197 618
as C 198 618
anthropology C 199 618
, C 200 618
sociology C 201 618
, C 202 618
and C 203 618
social C 204 618
psychology C 205 618
may C 206 618
be C 207 618
able C 208 618
to C 209 618
make C 210 618
to C 211 618
the C 212 618
solution C 213 618
of C 214 618
the C 215 618
problem C 216 618
. C 217 618
the C 1 619
speech C 2 619
production C 3 619
and C 4 619
spoken C 5 619
language C 6 619
of C 7 619
the C 8 619
deaf C 9 619
the C 10 619
distinction C 11 619
was C 12 619
made C 13 619
between C 14 619
speech C 15 619
production C 16 619
and C 17 619
spoken C 18 619
language C 19 619
in C 20 619
analysing C 21 619
the C 22 619
oral C 23 619
output C 24 619
of C 25 619
those C 26 619
with C 27 619
hearing C 28 619
impairment C 29 619
. C 30 619
a C 32 619
brief C 33 619
review C 34 619
of C 35 619
studies C 36 619
in C 37 619
both C 38 619
areas C 39 619
was C 40 619
undertaken C 41 619
, C 42 619
including C 43 619
the C 44 619
report C 45 619
of C 46 619
a C 47 619
new C 48 619
electronic C 49 619
visual C 50 619
monitoring C 51 619
device C 52 619
, C 53 619
the C 54 619
glossal C 55 619
transducer C 56 619
. C 57 619
it C 59 619
was C 60 619
postulated C 61 619
that C 62 619
the C 63 619
deaf C 64 619
utilise C 65 619
a C 66 619
unique C 67 619
visual C 68 619
- C 69 619
to C 70 619
- C 71 619
motor C 72 619
conversion C 73 619
within C 74 619
the C 75 619
brain C 76 619
when C 77 619
speaking C 78 619
and C 79 619
monitor C 80 619
conscously C 81 619
by C 82 619
tactile C 83 619
- C 84 619
kinaesthetic C 85 619
control C 86 619
. C 87 619
the C 89 619
more C 90 619
recent C 91 619
studies C 92 619
relate C 93 619
to C 94 619
the C 95 619
syntactical C 96 619
features C 97 619
of C 98 619
the C 99 619
speech C 100 619
of C 101 619
the C 102 619
deaf C 103 619
. C 104 619
these C 106 619
show C 107 619
that C 108 619
deafness C 109 619
creates C 110 619
telegraphic C 111 619
speech C 112 619
with C 113 619
reduced C 114 619
sentence C 115 619
length C 116 619
and C 117 619
omissions C 118 619
of C 119 619
essential C 120 619
words C 121 619
such C 122 619
as C 123 619
functors C 124 619
. C 125 619
the C 127 619
speech C 128 619
of C 129 619
the C 130 619
deaf C 131 619
seems C 132 619
to C 133 619
contain C 134 619
mostly C 135 619
nouns C 136 619
and C 137 619
verbs C 138 619
, C 139 619
with C 140 619
a C 141 619
limited C 142 619
number C 143 619
of C 144 619
words C 145 619
used C 146 619
to C 147 619
expand C 148 619
verb C 149 619
forms C 150 619
. C 151 619
cognitive C 1 620
functioning C 2 620
in C 3 620
early C 4 620
infantile C 5 620
autism C 6 620
: C 7 620
an C 8 620
examination C 9 620
of C 10 620
four C 11 620
cases C 12 620
by C 13 620
means C 14 620
of C 15 620
the C 16 620
wechsler C 17 620
intelligence C 18 620
scale C 19 620
for C 20 620
children C 21 620
the C 22 620
results C 23 620
are C 24 620
communicated C 25 620
which C 26 620
were C 27 620
obtained C 28 620
from C 29 620
an C 30 620
examination C 31 620
, C 32 620
by C 33 620
means C 34 620
of C 35 620
the C 36 620
wechsler C 37 620
intelligence C 38 620
scale C 39 620
for C 40 620
children C 41 620
, C 42 620
of C 43 620
four C 44 620
cases C 45 620
of C 46 620
early C 47 620
infantile C 48 620
autism C 49 620
. C 50 620
these C 52 620
cases C 53 620
had C 54 620
developed C 55 620
in C 56 620
such C 57 620
a C 58 620
way C 59 620
that C 60 620
a C 61 620
reliable C 62 620
investigation C 63 620
by C 64 620
means C 65 620
of C 66 620
a C 67 620
mental C 68 620
test C 69 620
had C 70 620
become C 71 620
possible C 72 620
. C 73 620
according C 75 620
to C 76 620
their C 77 620
full C 78 620
scale C 79 620
iq C 80 620
' C 81 620
s C 82 620
the C 83 620
four C 84 620
cases C 85 620
fell C 86 620
within C 87 620
the C 88 620
category C 89 620
of C 90 620
dull C 91 620
normal C 92 620
intelligence C 93 620
or C 94 620
less C 95 620
. C 96 620
all C 98 620
of C 99 620
them C 100 620
showed C 101 620
a C 102 620
considerable C 103 620
discrepancy C 104 620
between C 105 620
the C 106 620
verbal C 107 620
and C 108 620
the C 109 620
performance C 110 620
iq C 111 620
, C 112 620
the C 113 620
performance C 114 620
iq C 115 620
being C 116 620
of C 117 620
much C 118 620
higher C 119 620
value C 120 620
. C 121 620
the C 123 620
composition C 124 620
of C 125 620
the C 126 620
autistic C 127 620
test C 128 620
profiles C 129 620
was C 130 620
characterized C 131 620
by C 132 620
a C 133 620
large C 134 620
variability C 135 620
in C 136 620
the C 137 620
subtest C 138 620
scores C 139 620
, C 140 620
discriminating C 141 620
the C 142 620
autistic C 143 620
group C 144 620
significantly C 145 620
from C 146 620
non C 147 620
- C 148 620
autistic C 149 620
control C 150 620
groups C 151 620
. C 152 620
the C 154 620
subtest C 155 620
score C 156 620
divergencies C 157 620
, C 158 620
responsible C 159 620
for C 160 620
the C 161 620
large C 162 620
variability C 163 620
, C 164 620
showed C 165 620
a C 166 620
distinct C 167 620
pattern C 168 620
, C 169 620
being C 170 620
specific C 171 620
for C 172 620
the C 173 620
autistic C 174 620
group C 175 620
as C 176 620
a C 177 620
whole C 178 620
. C 179 620
this C 181 620
group C 182 620
could C 183 620
be C 184 620
considered C 185 620
as C 186 620
a C 187 620
distinct C 188 620
group C 189 620
particularly C 190 620
by C 191 620
a C 192 620
marked C 193 620
tendency C 194 620
to C 195 620
achieve C 196 620
poorly C 197 620
and C 198 620
far C 199 620
below C 200 620
the C 201 620
subject C 202 620
' C 203 620
s C 204 620
average C 205 620
level C 206 620
in C 207 620
the C 208 620
subtests C 209 620
comprehension C 210 620
and C 211 620
vocabulary C 212 620
, C 213 620
and C 214 620
to C 215 620
achieve C 216 620
superiorly C 217 620
and C 218 620
far C 219 620
above C 220 620
that C 221 620
level C 222 620
in C 223 620
the C 224 620
subtests C 225 620
block C 226 620
design C 227 620
and C 228 620
object C 229 620
assembly C 230 620
. C 231 620
by C 233 620
specifying C 234 620
the C 235 620
mental C 236 620
functions C 237 620
, C 238 620
conditional C 239 620
for C 240 620
success C 241 620
in C 242 620
these C 243 620
four C 244 620
subtests C 245 620
that C 246 620
occupy C 247 620
extreme C 248 620
positions C 249 620
within C 250 620
the C 251 620
autistic C 252 620
test C 253 620
profiles C 254 620
, C 255 620
it C 256 620
was C 257 620
concluded C 258 620
that C 259 620
the C 260 620
autistic C 261 620
patients C 262 620
apparently C 263 620
were C 264 620
able C 265 620
to C 266 620
achieve C 267 620
well C 268 620
, C 269 620
or C 270 620
even C 271 620
superiorly C 272 620
, C 273 620
only C 274 620
if C 275 620
the C 276 620
task C 277 620
could C 278 620
be C 279 620
performed C 280 620
on C 281 620
a C 282 620
purely C 283 620
perceptual C 284 620
level C 285 620
. C 286 620
but C 288 620
they C 289 620
failed C 290 620
as C 291 620
soon C 292 620
as C 293 620
an C 294 620
appeal C 295 620
was C 296 620
made C 297 620
to C 298 620
thinking C 299 620
proper C 300 620
. C 301 620
this C 303 620
was C 304 620
thought C 305 620
to C 306 620
be C 307 620
due C 308 620
to C 309 620
a C 310 620
disability C 311 620
in C 312 620
dealing C 313 620
with C 314 620
imaginary C 315 620
things C 316 620
and C 317 620
imaginary C 318 620
situations C 319 620
, C 320 620
or C 321 620
, C 322 620
in C 323 620
other C 324 620
words C 325 620
, C 326 620
to C 327 620
an C 328 620
incapability C 329 620
to C 330 620
objectify C 331 620
what C 332 620
is C 333 620
not C 334 620
actually C 335 620
present C 336 620
in C 337 620
the C 338 620
subject C 339 620
' C 340 620
s C 341 620
concrete C 342 620
situation C 343 620
. C 344 620
it C 346 620
is C 347 620
proposed C 348 620
that C 349 620
this C 350 620
impairment C 351 620
could C 352 620
be C 353 620
reduced C 354 620
to C 355 620
a C 356 620
lack C 357 620
of C 358 620
symbolic C 359 620
means C 360 620
, C 361 620
being C 362 620
the C 363 620
correlate C 364 620
of C 365 620
a C 366 620
defective C 367 620
or C 368 620
insufficiently C 369 620
developed C 370 620
language C 371 620
in C 372 620
the C 373 620
patients C 374 620
. C 375 620
it C 377 620
is C 378 620
further C 379 620
proposed C 380 620
that C 381 620
children C 382 620
suffering C 383 620
from C 384 620
early C 385 620
infantile C 386 620
autism C 387 620
might C 388 620
not C 389 620
be C 390 620
able C 391 620
, C 392 620
or C 393 620
at C 394 620
a C 395 620
later C 396 620
stage C 397 620
only C 398 620
, C 399 620
to C 400 620
reach C 401 620
that C 402 620
level C 403 620
of C 404 620
language C 405 620
development C 406 620
in C 407 620
which C 408 620
words C 409 620
can C 410 620
be C 411 620
used C 412 620
as C 413 620
symbols C 414 620
, C 415 620
representing C 416 620
absent C 417 620
things C 418 620
and C 419 620
absent C 420 620
situations C 421 620
. C 422 620
otologic C 1 621
care C 2 621
of C 3 621
cleft C 4 621
palate C 5 621
cases C 6 621
the C 7 621
purpose C 8 621
of C 9 621
this C 10 621
study C 11 621
was C 12 621
to C 13 621
review C 14 621
the C 15 621
ear C 16 621
pathology C 17 621
in C 18 621
480 C 19 621
patients C 20 621
whose C 21 621
cleft C 22 621
palates C 23 621
had C 24 621
previously C 25 621
been C 26 621
repaired C 27 621
. C 28 621
despite C 30 621
concern C 31 621
over C 32 621
speech C 33 621
regression C 34 621
, C 35 621
tonsil C 36 621
and C 37 621
adenoid C 38 621
surgery C 39 621
was C 40 621
carried C 41 621
out C 42 621
on C 43 621
66 C 44 621
of C 45 621
these C 46 621
patients C 47 621
. C 48 621
when C 50 621
carefully C 51 621
done C 52 621
, C 53 621
this C 54 621
was C 55 621
accomplished C 56 621
with C 57 621
considerable C 58 621
overall C 59 621
improvement C 60 621
, C 61 621
particularly C 62 621
for C 63 621
the C 64 621
benefit C 65 621
of C 66 621
the C 67 621
conductive C 68 621
hearing C 69 621
loss C 70 621
. C 71 621
sixteen C 73 621
cases C 74 621
had C 75 621
exact C 76 621
documentation C 77 621
of C 78 621
these C 79 621
results C 80 621
by C 81 621
virtue C 82 621
of C 83 621
speech C 84 621
recording C 85 621
and C 86 621
accurate C 87 621
audiometric C 88 621
records C 89 621
. C 90 621
congenital C 1 622
heart C 2 622
disease C 3 622
, C 4 622
deaf C 5 622
- C 6 622
mutism C 7 622
and C 8 622
associated C 9 622
somatic C 10 622
malformations C 11 622
occurring C 12 622
in C 13 622
several C 14 622
members C 15 622
of C 16 622
one C 17 622
family C 18 622
m C 19 622
. C 20 622
. C 21 622
. C 22 622
and C 24 622
patrick C 25 622
h C 26 622
. C 27 622
lehan C 29 622
, C 30 622
m C 31 622
. C 32 622
. C 33 622
. C 34 622
a C 36 622
unique C 37 622
family C 38 622
is C 39 622
described C 40 622
in C 41 622
which C 42 622
the C 43 622
mother C 44 622
and C 45 622
four C 46 622
of C 47 622
her C 48 622
eight C 49 622
children C 50 622
have C 51 622
pulmonary C 52 622
stenosis C 53 622
. C 54 622
two C 56 622
of C 57 622
the C 58 622
four C 59 622
affected C 60 622
children C 61 622
are C 62 622
deaf C 63 622
- C 64 622
mutes C 65 622
; C 66 622
one C 67 622
of C 68 622
these C 69 622
has C 70 622
, C 71 622
in C 72 622
addition C 73 622
to C 74 622
the C 75 622
pulmonary C 76 622
valvular C 77 622
stenosis C 78 622
, C 79 622
idiopathic C 80 622
hypertrophic C 81 622
subaortic C 82 622
stenosis C 83 622
. C 84 622
all C 86 622
the C 87 622
affected C 88 622
children C 89 622
had C 90 622
several C 91 622
associated C 92 622
somatic C 93 622
malformations C 94 622
. C 95 622
genetic C 97 622
and C 98 622
nongenetic C 99 622
factors C 100 622
and C 101 622
their C 102 622
role C 103 622
in C 104 622
the C 105 622
development C 106 622
of C 107 622
the C 108 622
malformations C 109 622
are C 110 622
discussed C 111 622
. C 112 622
it C 114 622
is C 115 622
suggested C 116 622
that C 117 622
the C 118 622
cardiac C 119 622
defect C 120 622
is C 121 622
transmitted C 122 622
by C 123 622
a C 124 622
single C 125 622
non C 126 622
- C 127 622
sex C 128 622
- C 129 622
linked C 130 622
genetic C 131 622
factor C 132 622
( C 133 622
dominant C 134 622
autosomal C 135 622
inheritance C 136 622
) C 137 622
. C 138 622
in C 140 622
the C 141 622
presence C 142 622
of C 143 622
a C 144 622
normal C 145 622
karyotype C 146 622
it C 147 622
appears C 148 622
that C 149 622
a C 150 622
single C 151 622
dose C 152 622
of C 153 622
either C 154 622
a C 155 622
point C 156 622
mutation C 157 622
, C 158 622
or C 159 622
a C 160 622
small C 161 622
deletion C 162 622
or C 163 622
translocation C 164 622
is C 165 622
the C 166 622
most C 167 622
likely C 168 622
cause C 169 622
. C 170 622
histidinemia C 1 623
a C 2 623
review C 3 623
of C 4 623
published C 5 623
reports C 6 623
of C 7 623
histidinemia C 8 623
indicates C 9 623
that C 10 623
this C 11 623
condition C 12 623
has C 13 623
a C 14 623
variability C 15 623
of C 16 623
clinical C 17 623
and C 18 623
biochemical C 19 623
expression C 20 623
. C 21 623
three C 23 623
children C 24 623
with C 25 623
histidinemia C 26 623
, C 27 623
born C 28 623
of C 29 623
a C 30 623
consanguineous C 31 623
marriage C 32 623
are C 33 623
reported C 34 623
here C 35 623
. C 36 623
they C 38 623
had C 39 623
blond C 40 623
hair C 41 623
, C 42 623
blue C 43 623
eyes C 44 623
, C 45 623
speech C 46 623
defects C 47 623
, C 48 623
mental C 49 623
retardation C 50 623
, C 51 623
and C 52 623
a C 53 623
peculiar C 54 623
eeg C 55 623
abnormality C 56 623
. C 57 623
they C 59 623
also C 60 623
exhibited C 61 623
characteristic C 62 623
biochemical C 63 623
findings C 64 623
of C 65 623
the C 66 623
disease C 67 623
: C 68 623
elevated C 69 623
blood C 70 623
and C 71 623
urine C 72 623
histidine C 73 623
, C 74 623
increased C 75 623
urine C 76 623
imidazolepyruvic C 77 623
acid C 78 623
, C 79 623
and C 80 623
a C 81 623
sustained C 82 623
high C 83 623
rise C 84 623
in C 85 623
plasma C 86 623
histidine C 87 623
following C 88 623
an C 89 623
oral C 90 623
histidine C 91 623
tolerance C 92 623
test C 93 623
. C 94 623
they C 96 623
did C 97 623
not C 98 623
, C 99 623
however C 100 623
, C 101 623
have C 102 623
the C 103 623
reduction C 104 623
of C 105 623
skin C 106 623
histidine C 107 623
a C 108 623
- C 109 623
deaminase C 110 623
activity C 111 623
which C 112 623
has C 113 623
been C 114 623
observed C 115 623
in C 116 623
some C 117 623
children C 118 623
with C 119 623
this C 120 623
condition C 121 623
. C 122 623
tests C 124 623
for C 125 623
determination C 126 623
of C 127 623
heterozygotes C 128 623
in C 129 623
the C 130 623
family C 131 623
were C 132 623
not C 133 623
successful C 134 623
. C 135 623
parental C 137 623
consanguinity C 138 623
and C 139 623
normal C 140 623
skin C 141 623
a C 142 623
- C 143 623
deaminase C 144 623
activity C 145 623
set C 146 623
these C 147 623
children C 148 623
apart C 149 623
from C 150 623
other C 151 623
reported C 152 623
cases C 153 623
. C 154 623
the C 156 623
first C 157 623
lends C 158 623
support C 159 623
to C 160 623
the C 161 623
hypothesis C 162 623
that C 163 623
histidinemia C 164 623
is C 165 623
inherited C 166 623
as C 167 623
an C 168 623
autosomal C 169 623
recessive C 170 623
trait C 171 623
; C 172 623
the C 173 623
second C 174 623
supports C 175 623
the C 176 623
idea C 177 623
that C 178 623
the C 179 623
genic C 180 623
fault C 181 623
which C 182 623
results C 183 623
in C 184 623
reduced C 185 623
histidine C 186 623
a C 187 623
- C 188 623
deaminase C 189 623
activity C 190 623
can C 191 623
be C 192 623
expressed C 193 623
to C 194 623
a C 195 623
different C 196 623
degree C 197 623
in C 198 623
different C 199 623
tissues C 200 623
. C 201 623
these C 203 623
children C 204 623
seem C 205 623
to C 206 623
represent C 207 623
a C 208 623
variant C 209 623
of C 210 623
histidinemia C 211 623
where C 212 623
liver C 213 623
histidase C 214 623
activity C 215 623
is C 216 623
reduced C 217 623
while C 218 623
skin C 219 623
histidase C 220 623
activity C 221 623
is C 222 623
present C 223 623
. C 224 623
interpretation C 1 624
within C 2 624
the C 3 624
metaphor C 4 624
analytic C 5 624
investigation C 6 624
of C 7 624
the C 8 624
use C 9 624
of C 10 624
the C 11 624
metaphor C 12 624
was C 13 624
first C 14 624
given C 15 624
impetus C 16 624
by C 17 624
ella C 18 624
freeman C 19 624
sharpe C 20 624
( C 21 624
1950 C 22 624
) C 23 624
, C 24 624
who C 25 624
explored C 26 624
the C 27 624
symbolic C 28 624
meaning C 29 624
of C 30 624
particular C 31 624
metaphoric C 32 624
phrases C 33 624
with C 34 624
reference C 35 624
to C 36 624
the C 37 624
body C 38 624
and C 39 624
libidinal C 40 624
needs C 41 624
. C 42 624
currently C 44 624
, C 45 624
interest C 46 624
has C 47 624
become C 48 624
focused C 49 624
upon C 50 624
the C 51 624
use C 52 624
of C 53 624
the C 54 624
metaphor C 55 624
as C 56 624
a C 57 624
self C 58 624
- C 59 624
conscious C 60 624
, C 61 624
rational C 62 624
therapeutic C 63 624
technique C 64 624
of C 65 624
communication C 66 624
, C 67 624
of C 68 624
particular C 69 624
value C 70 624
with C 71 624
those C 72 624
patients C 73 624
who C 74 624
have C 75 624
reached C 76 624
" C 77 624
the C 78 624
borderline C 79 624
of C 80 624
sanity C 81 624
" C 82 624
. C 83 624
ekstein C 85 624
( C 86 624
1961 C 87 624
) C 88 624
and C 89 624
ekstein C 90 624
and C 91 624
wallerstein C 92 624
( C 93 624
1957 C 94 624
) C 95 624
have C 96 624
emphasized C 97 624
that C 98 624
the C 99 624
use C 100 624
of C 101 624
the C 102 624
metaphor C 103 624
should C 104 624
be C 105 624
regarded C 106 624
as C 107 624
an C 108 624
essential C 109 624
technique C 110 624
for C 111 624
gradually C 112 624
establishing C 113 624
communication C 114 624
and C 115 624
initial C 116 624
insight C 117 624
with C 118 624
borderline C 119 624
and C 120 624
schizophrenic C 121 624
patients C 122 624
but C 123 624
that C 124 624
it C 125 624
must C 126 624
not C 127 624
be C 128 624
regarded C 129 624
as C 130 624
a C 131 624
treatment C 132 624
technique C 133 624
in C 134 624
itself C 135 624
. C 136 624
it C 138 624
is C 139 624
but C 140 624
a C 141 624
preliminary C 142 624
approximation C 143 624
to C 144 624
the C 145 624
final C 146 624
therapeutic C 147 624
act C 148 624
, C 149 624
which C 150 624
ultimately C 151 624
will C 152 624
consist C 153 624
of C 154 624
a C 155 624
classical C 156 624
interpretation C 157 624
at C 158 624
the C 159 624
level C 160 624
of C 161 624
the C 162 624
secondary C 163 624
process C 164 624
. C 165 624
the C 167 624
use C 168 624
of C 169 624
the C 170 624
metaphor C 171 624
derives C 172 624
its C 173 624
primary C 174 624
value C 175 624
from C 176 624
maintaining C 177 624
contact C 178 624
with C 179 624
patients C 180 624
who C 181 624
are C 182 624
constantly C 183 624
in C 184 624
danger C 185 624
of C 186 624
being C 187 624
inundated C 188 624
by C 189 624
a C 190 624
break C 191 624
- C 192 624
through C 193 624
of C 194 624
primary C 195 624
- C 196 624
process C 197 624
material C 198 624
. C 199 624
evolution C 1 625
of C 2 625
a C 3 625
characteristic C 4 625
speech C 5 625
disorder C 6 625
in C 7 625
juvenile C 8 625
cerebral C 9 625
lipidosis C 10 625
juvenile C 11 625
cerebral C 12 625
lipidosis C 13 625
is C 14 625
being C 15 625
diagnosed C 16 625
with C 17 625
increasing C 18 625
frequency C 19 625
in C 20 625
this C 21 625
country C 22 625
, C 23 625
especially C 24 625
in C 25 625
schools C 26 625
for C 27 625
the C 28 625
visually C 29 625
handicapped C 30 625
. C 31 625
the C 33 625
manifestations C 34 625
of C 35 625
rapidly C 36 625
developing C 37 625
loss C 38 625
of C 39 625
vision C 40 625
, C 41 625
seizures C 42 625
, C 43 625
muscular C 44 625
rigidity C 45 625
, C 46 625
ataxia C 47 625
, C 48 625
retinitis C 49 625
pigmentosa C 50 625
and C 51 625
eeg C 52 625
abnormalities C 53 625
are C 54 625
well C 55 625
known C 56 625
in C 57 625
this C 58 625
disorder C 59 625
. C 60 625
a C 62 625
speech C 63 625
disorder C 64 625
described C 65 625
as C 66 625
a C 67 625
" C 68 625
lolling C 69 625
, C 70 625
stammering C 71 625
speech C 72 625
" C 73 625
was C 74 625
mentioned C 75 625
by C 76 625
sjogren C 77 625
( C 78 625
1931 C 79 625
) C 80 625
in C 81 625
his C 82 625
comprehensive C 83 625
description C 84 625
of C 85 625
juvenile C 86 625
amaurotic C 87 625
idiocy C 88 625
, C 89 625
but C 90 625
this C 91 625
has C 92 625
not C 93 625
been C 94 625
emphasized C 95 625
in C 96 625
recent C 97 625
descriptions C 98 625
. C 99 625
this C 101 625
report C 102 625
, C 103 625
based C 104 625
upon C 105 625
an C 106 625
analysis C 107 625
of C 108 625
5 C 109 625
cases C 110 625
, C 111 625
describes C 112 625
the C 113 625
evolution C 114 625
of C 115 625
a C 116 625
characteristic C 117 625
form C 118 625
of C 119 625
speech C 120 625
pathology C 121 625
that C 122 625
is C 123 625
invariably C 124 625
present C 125 625
in C 126 625
juvenile C 127 625
cerebral C 128 625
lipidosis C 129 625
. C 130 625
the C 132 625
initial C 133 625
speech C 134 625
abnormality C 135 625
seen C 136 625
early C 137 625
in C 138 625
the C 139 625
disorder C 140 625
is C 141 625
a C 142 625
hesitancy C 143 625
of C 144 625
speech C 145 625
and C 146 625
occasional C 147 625
repetition C 148 625
of C 149 625
words C 150 625
. C 151 625
in C 153 625
time C 154 625
, C 155 625
dysarthria C 156 625
becomes C 157 625
evident C 158 625
with C 159 625
slurring C 160 625
, C 161 625
nasality C 162 625
and C 163 625
impairment C 164 625
of C 165 625
phonation C 166 625
similar C 167 625
to C 168 625
that C 169 625
seen C 170 625
in C 171 625
pseudobulbar C 172 625
palsy C 173 625
. C 174 625
in C 176 625
addition C 177 625
to C 178 625
the C 179 625
dysarthria C 180 625
, C 181 625
a C 182 625
highly C 183 625
characteristic C 184 625
perseverative C 185 625
speech C 186 625
appears C 187 625
which C 188 625
often C 189 625
has C 190 625
a C 191 625
close C 192 625
resemblance C 193 625
to C 194 625
true C 195 625
stuttering C 196 625
. C 197 625
this C 199 625
stuttering C 200 625
- C 201 625
like C 202 625
speech C 203 625
has C 204 625
been C 205 625
observed C 206 625
in C 207 625
4 C 208 625
of C 209 625
the C 210 625
5 C 211 625
cases C 212 625
at C 213 625
some C 214 625
time C 215 625
during C 216 625
the C 217 625
course C 218 625
of C 219 625
their C 220 625
illnesses C 221 625
. C 222 625
as C 224 625
the C 225 625
speech C 226 625
patterns C 227 625
deteriorate C 228 625
, C 229 625
the C 230 625
patient C 231 625
becomes C 232 625
less C 233 625
communicative C 234 625
and C 235 625
finally C 236 625
lapses C 237 625
into C 238 625
mutism C 239 625
. C 240 625
the C 242 625
speech C 243 625
disorder C 244 625
is C 245 625
often C 246 625
the C 247 625
most C 248 625
disabling C 249 625
aspect C 250 625
of C 251 625
this C 252 625
syndrome C 253 625
. C 254 625
relation C 1 626
of C 2 626
crying C 3 626
activity C 4 626
in C 5 626
early C 6 626
infancy C 7 626
to C 8 626
speech C 9 626
and C 10 626
intellectual C 11 626
development C 12 626
at C 13 626
age C 14 626
three C 15 626
years C 16 626
rosenfeld C 17 626
cries C 18 626
of C 19 626
38 C 20 626
infants C 21 626
, C 22 626
age C 23 626
4 C 24 626
to C 25 626
10 C 26 626
days C 27 626
, C 28 626
were C 29 626
measured C 30 626
for C 31 626
outburst C 32 626
frequency C 33 626
during C 34 626
the C 35 626
most C 36 626
active C 37 626
20 C 38 626
- C 39 626
sec C 40 626
. C 41 626
period C 43 626
of C 44 626
crying C 45 626
. C 46 626
crying C 48 626
scores C 49 626
showed C 50 626
a C 51 626
significant C 52 626
correlation C 53 626
( C 54 626
. C 55 626
. C 56 626
. C 56 626
) C 57 626
with C 58 626
stanford C 59 626
- C 60 626
binet C 61 626
iq C 62 626
at C 63 626
3 C 64 626
years C 65 626
, C 66 626
a C 67 626
borderline C 68 626
correlation C 69 626
( C 70 626
. C 71 626
. C 72 626
. C 72 626
) C 73 626
with C 74 626
cattell C 75 626
iq C 76 626
at C 77 626
15 C 78 626
to C 79 626
20 C 80 626
months C 81 626
, C 82 626
and C 83 626
a C 84 626
nonsignificant C 85 626
trend C 86 626
with C 87 626
speech C 88 626
ratings C 89 626
at C 90 626
3 C 91 626
years C 92 626
. C 93 626
although C 95 626
no C 96 626
correlations C 97 626
were C 98 626
adequate C 99 626
for C 100 626
individual C 101 626
prediction C 102 626
, C 103 626
infant C 104 626
crying C 105 626
is C 106 626
deemed C 107 626
worthy C 108 626
of C 109 626
further C 110 626
investigation C 111 626
as C 112 626
a C 113 626
possible C 114 626
indicator C 115 626
of C 116 626
intellectual C 117 626
potential C 118 626
. C 119 626
labial C 1 627
supportive C 2 627
appliance C 3 627
the C 4 627
patient C 5 627
with C 6 627
a C 7 627
repaired C 8 627
cleft C 9 627
lip C 10 627
and C 11 627
palate C 12 627
and C 13 627
an C 14 627
associated C 15 627
displacement C 16 627
and C 17 627
deficiency C 18 627
of C 19 627
the C 20 627
premaxilla C 21 627
presents C 22 627
problems C 23 627
which C 24 627
may C 25 627
be C 26 627
of C 27 627
concern C 28 627
to C 29 627
the C 30 627
plastic C 31 627
surgeon C 32 627
, C 33 627
speech C 34 627
pathologist C 35 627
, C 36 627
orthodontist C 37 627
, C 38 627
and C 39 627
prosthodontist C 40 627
. C 41 627
the C 43 627
upper C 44 627
lip C 45 627
may C 46 627
appear C 47 627
flat C 48 627
or C 49 627
retruded C 50 627
in C 51 627
relation C 52 627
to C 53 627
the C 54 627
lower C 55 627
lip C 56 627
. C 57 627
when C 59 627
maxillary C 60 627
anterior C 61 627
teeth C 62 627
are C 63 627
missing C 64 627
, C 65 627
either C 66 627
congenitally C 67 627
, C 68 627
naturally C 69 627
( C 70 627
as C 71 627
in C 72 627
the C 73 627
mixed C 74 627
dentition C 75 627
period C 76 627
) C 77 627
, C 78 627
or C 79 627
because C 80 627
of C 81 627
neglect C 82 627
, C 83 627
the C 84 627
upper C 85 627
lip C 86 627
may C 87 627
appear C 88 627
to C 89 627
be C 90 627
rolled C 91 627
under C 92 627
the C 93 627
premaxilla C 94 627
. C 95 627
the C 97 627
lower C 98 627
lip C 99 627
usually C 100 627
assumes C 101 627
a C 102 627
characteristic C 103 627
' C 104 627
pouty C 105 627
' C 106 627
appearance C 107 627
. C 108 627
this C 110 627
complex C 111 627
of C 112 627
tissue C 113 627
deformities C 114 627
also C 115 627
may C 116 627
be C 117 627
important C 118 627
in C 119 627
the C 120 627
articulation C 121 627
of C 122 627
speech C 123 627
sounds C 124 627
. C 125 627
fricatives C 127 627
and C 128 627
plosives C 129 627
are C 130 627
difficult C 131 627
to C 132 627
produce C 133 627
correctly C 134 627
because C 135 627
of C 136 627
the C 137 627
malposition C 138 627
of C 139 627
the C 140 627
lip C 141 627
. C 142 627
there C 144 627
may C 145 627
be C 146 627
interference C 147 627
with C 148 627
direction C 149 627
of C 150 627
air C 151 627
current C 152 627
, C 153 627
contact C 154 627
of C 155 627
tongue C 156 627
to C 157 627
alveolar C 158 627
ridge C 159 627
, C 160 627
and C 161 627
normal C 162 627
contact C 163 627
of C 164 627
lips C 165 627
. C 166 627
corrective C 168 627
procedures C 169 627
are C 170 627
designed C 171 627
to C 172 627
improve C 173 627
the C 174 627
labial C 175 627
profile C 176 627
and C 177 627
to C 178 627
establish C 179 627
more C 180 627
normal C 181 627
relationships C 182 627
of C 183 627
intraoral C 184 627
structures C 185 627
. C 186 627
these C 188 627
procedures C 189 627
, C 190 627
employed C 191 627
individually C 192 627
or C 193 627
in C 194 627
combination C 195 627
, C 196 627
may C 197 627
include C 198 627
othodontic C 199 627
movement C 200 627
of C 201 627
maxillary C 202 627
segments C 203 627
, C 204 627
dental C 205 627
prosthesis C 206 627
, C 207 627
and C 208 627
cheiloplasty C 209 627
. C 210 627
another C 212 627
more C 213 627
recently C 214 627
developed C 215 627
adjunct C 216 627
involves C 217 627
autogenous C 218 627
osscous C 219 627
implantation C 220 627
in C 221 627
the C 222 627
cleft C 223 627
areas C 224 627
. C 225 627
heterogeneity C 1 628
of C 2 628
the C 3 628
' C 4 628
cleft C 5 628
palate C 6 628
population C 7 628
' C 8 628
and C 9 628
research C 10 628
designs C 11 628
the C 12 628
primary C 13 628
point C 14 628
made C 15 628
in C 16 628
this C 17 628
paper C 18 628
is C 19 628
that C 20 628
we C 21 628
must C 22 628
reject C 23 628
the C 24 628
notion C 25 628
that C 26 628
there C 27 628
is C 28 628
some C 29 628
inherent C 30 628
, C 31 628
universal C 32 628
commonality C 33 628
among C 34 628
individuals C 35 628
who C 36 628
are C 37 628
born C 38 628
with C 39 628
a C 40 628
cleft C 41 628
lip C 42 628
and C 43 628
/ C 44 628
or C 45 628
cleft C 46 628
palate C 47 628
. C 48 628
we C 50 628
must C 51 628
recognize C 52 628
the C 53 628
various C 54 628
pertinent C 55 628
subgroups C 56 628
within C 57 628
this C 58 628
population C 59 628
. C 60 628
this C 62 628
does C 63 628
not C 64 628
mean C 65 628
, C 66 628
however C 67 628
, C 68 628
that C 69 628
one C 70 628
must C 71 628
always C 72 628
recognize C 73 628
the C 74 628
smallest C 75 628
subgroup C 76 628
in C 77 628
doing C 78 628
a C 79 628
given C 80 628
study C 81 628
. C 82 628
on C 84 628
the C 85 628
contrary C 86 628
, C 87 628
we C 88 628
would C 89 628
defend C 90 628
the C 91 628
use C 92 628
of C 93 628
fewest C 94 628
possible C 95 628
subgroups C 96 628
consistent C 97 628
with C 98 628
the C 99 628
specific C 100 628
research C 101 628
purpose C 102 628
. C 103 628
nevertheless C 105 628
, C 106 628
we C 107 628
feel C 108 628
that C 109 628
time C 110 628
spent C 111 628
considering C 112 628
the C 113 628
purposes C 114 628
of C 115 628
a C 116 628
study C 117 628
and C 118 628
the C 119 628
subgroups C 120 628
which C 121 628
need C 122 628
to C 123 628
be C 124 628
identified C 125 628
will C 126 628
tend C 127 628
to C 128 628
minimize C 129 628
the C 130 628
number C 131 628
of C 132 628
contradictory C 133 628
results C 134 628
, C 135 628
and C 136 628
will C 137 628
assist C 138 628
us C 139 628
in C 140 628
the C 141 628
interpretation C 142 628
of C 143 628
the C 144 628
observations C 145 628
that C 146 628
our C 147 628
insight C 148 628
and C 149 628
technology C 150 628
make C 151 628
possible C 152 628
. C 153 628
cineradiographic C 1 629
comparison C 2 629
of C 3 629
normal C 4 629
to C 5 629
noncleft C 6 629
subjects C 7 629
with C 8 629
velopharyngeal C 9 629
inadequacy C 10 629
cineradiographic C 11 629
studies C 12 629
of C 13 629
the C 14 629
normal C 15 629
subjects C 16 629
were C 17 629
compared C 18 629
with C 19 629
studies C 20 629
of C 21 629
noncleft C 22 629
subjects C 23 629
who C 24 629
demonstrated C 25 629
velopharyngeal C 26 629
inadequacy C 27 629
. C 28 629
the C 30 629
following C 31 629
conclusions C 32 629
were C 33 629
made C 34 629
: C 35 629
a C 36 629
) C 37 629
there C 38 629
was C 39 629
a C 40 629
significant C 41 629
difference C 42 629
between C 43 629
soft C 44 629
palate C 45 629
length C 46 629
in C 47 629
normals C 48 629
and C 49 629
the C 50 629
velopharyngeal C 51 629
inadequacy C 52 629
group C 53 629
. C 54 629
b C 56 629
) C 57 629
there C 58 629
was C 59 629
not C 60 629
a C 61 629
significant C 62 629
difference C 63 629
between C 64 629
depth C 65 629
of C 66 629
nasopharynx C 67 629
in C 68 629
normal C 69 629
and C 70 629
the C 71 629
velopharyngeal C 72 629
inadequacy C 73 629
group C 74 629
. C 75 629
c C 77 629
) C 78 629
the C 79 629
difference C 80 629
of C 81 629
the C 82 629
means C 83 629
of C 84 629
the C 85 629
soft C 86 629
palate C 87 629
length C 88 629
and C 89 629
depth C 90 629
of C 91 629
nasopharynx C 92 629
between C 93 629
the C 94 629
normals C 95 629
and C 96 629
velopharyngeal C 97 629
inadequacy C 98 629
group C 99 629
was C 100 629
significant C 101 629
. C 102 629
d C 104 629
) C 105 629
the C 106 629
thickness C 107 629
of C 108 629
the C 109 629
soft C 110 629
palate C 111 629
was C 112 629
greater C 113 629
in C 114 629
the C 115 629
normal C 116 629
than C 117 629
the C 118 629
abnormal C 119 629
group C 120 629
. C 121 629
e C 123 629
) C 124 629
in C 125 629
70 C 126 629
% C 127 629
of C 128 629
the C 129 629
normal C 130 629
and C 131 629
velopharyngeal C 132 629
inadequacy C 133 629
groups C 134 629
the C 135 629
height C 136 629
of C 137 629
soft C 138 629
palate C 139 629
elevation C 140 629
was C 141 629
above C 142 629
the C 143 629
palatal C 144 629
plane C 145 629
. C 146 629
f C 148 629
) C 149 629
in C 150 629
80 C 151 629
% C 152 629
of C 153 629
the C 154 629
normal C 155 629
group C 156 629
the C 157 629
height C 158 629
of C 159 629
velopharyngeal C 160 629
closure C 161 629
took C 162 629
place C 163 629
below C 164 629
the C 165 629
palatal C 166 629
plane C 167 629
. C 168 629
none C 170 629
of C 171 629
the C 172 629
subjects C 173 629
in C 174 629
the C 175 629
velopharyngeal C 176 629
inadequacy C 177 629
group C 178 629
obtained C 179 629
velopharyngeal C 180 629
closure C 181 629
. C 182 629
g C 184 629
) C 185 629
there C 186 629
was C 187 629
no C 188 629
significant C 189 629
correlation C 190 629
between C 191 629
amount C 192 629
of C 193 629
gap C 194 629
and C 195 629
voice C 196 629
quality C 197 629
. C 198 629
h C 200 629
) C 201 629
there C 202 629
was C 203 629
no C 204 629
significant C 205 629
correlation C 206 629
between C 207 629
amount C 208 629
of C 209 629
gap C 210 629
and C 211 629
intelligibility C 212 629
of C 213 629
speech C 214 629
. C 215 629
i C 217 629
) C 218 629
there C 219 629
was C 220 629
a C 221 629
difference C 222 629
between C 223 629
vital C 224 629
capacity C 225 629
readings C 226 629
for C 227 629
the C 228 629
velopharyngeal C 229 629
inadequacy C 230 629
group C 231 629
with C 232 629
nose C 233 629
occluded C 234 629
and C 235 629
unoccluded C 236 629
. C 237 629
j C 239 629
) C 240 629
the C 241 629
correlation C 242 629
coefficient C 243 629
between C 244 629
quality C 245 629
judgment C 246 629
and C 247 629
intelligibility C 248 629
judgment C 249 629
was C 250 629
highly C 251 629
significant C 252 629
. C 253 629
spontaneous C 1 630
verbal C 2 630
rehearsal C 3 630
in C 4 630
a C 5 630
memory C 6 630
task C 7 630
as C 8 630
a C 9 630
function C 10 630
of C 11 630
age C 12 630
a C 13 630
distinction C 14 630
is C 15 630
made C 16 630
between C 17 630
2 C 18 630
alternative C 19 630
hypotheses C 20 630
for C 21 630
explaining C 22 630
an C 23 630
often C 24 630
- C 25 630
reported C 26 630
deficiency C 27 630
in C 28 630
verbally C 29 630
mediated C 30 630
performance C 31 630
during C 32 630
early C 33 630
childhood C 34 630
: C 35 630
( C 36 630
1 C 37 630
) C 38 630
the C 39 630
verbal C 40 630
response C 41 630
is C 42 630
made C 43 630
, C 44 630
but C 45 630
tends C 46 630
not C 47 630
to C 48 630
mediate C 49 630
performance C 50 630
( C 51 630
" C 52 630
mediational C 53 630
- C 54 630
deficiency C 55 630
hypothesis C 56 630
" C 57 630
) C 58 630
; C 59 630
( C 60 630
2 C 61 630
) C 62 630
the C 63 630
verbal C 64 630
response C 65 630
tends C 66 630
not C 67 630
to C 68 630
be C 69 630
made C 70 630
( C 71 630
" C 72 630
production C 73 630
- C 74 630
deficiency C 75 630
hypothesis C 76 630
" C 77 630
) C 78 630
. C 79 630
a C 81 630
study C 82 630
is C 83 630
described C 84 630
which C 85 630
attempts C 86 630
to C 87 630
meet C 88 630
the C 89 630
ideal C 90 630
criteria C 91 630
for C 92 630
a C 93 630
test C 94 630
of C 95 630
the C 96 630
production C 97 630
- C 98 630
deficiency C 99 630
hypothesis C 100 630
. C 101 630
the C 103 630
method C 104 630
used C 105 630
was C 106 630
that C 107 630
of C 108 630
direct C 109 630
observation C 110 630
of C 111 630
s C 112 630
' C 113 630
s C 114 630
spontaneous C 115 630
verbalizations C 116 630
, C 117 630
and C 118 630
the C 119 630
hypothesis C 120 630
was C 121 630
confirmed C 122 630
by C 123 630
the C 124 630
finding C 125 630
that C 126 630
kindergarteners C 127 630
are C 128 630
less C 129 630
likely C 130 630
than C 131 630
older C 132 630
children C 133 630
to C 134 630
rehearse C 135 630
stimulus C 136 630
names C 137 630
in C 138 630
a C 139 630
nonverbal C 140 630
serial C 141 630
recall C 142 630
task C 143 630
. C 144 630
early C 1 631
experience C 2 631
and C 3 631
the C 4 631
socialization C 5 631
of C 6 631
cognitive C 7 631
modes C 8 631
in C 9 631
children C 10 631
this C 11 631
paper C 12 631
deals C 13 631
with C 14 631
the C 15 631
question C 16 631
: C 17 631
what C 18 631
is C 19 631
cultural C 20 631
deprivation C 21 631
and C 22 631
how C 23 631
does C 24 631
it C 25 631
act C 26 631
to C 27 631
shape C 28 631
and C 29 631
depress C 30 631
the C 31 631
resources C 32 631
of C 33 631
the C 34 631
human C 35 631
mind C 36 631
? C 37 631
the C 38 631
arguments C 39 631
presented C 40 631
are C 41 631
: C 42 631
first C 43 631
, C 44 631
that C 45 631
the C 46 631
behavior C 47 631
which C 48 631
leads C 49 631
to C 50 631
social C 51 631
, C 52 631
educational C 53 631
, C 54 631
and C 55 631
economic C 56 631
poverty C 57 631
is C 58 631
socialized C 59 631
in C 60 631
early C 61 631
childhood C 62 631
; C 63 631
second C 64 631
, C 65 631
that C 66 631
the C 67 631
central C 68 631
quality C 69 631
involved C 70 631
in C 71 631
the C 72 631
effects C 73 631
of C 74 631
cultural C 75 631
deprivation C 76 631
is C 77 631
a C 78 631
lack C 79 631
of C 80 631
cognitive C 81 631
meaning C 82 631
in C 83 631
the C 84 631
mother C 85 631
- C 86 631
child C 87 631
communication C 88 631
system C 89 631
; C 90 631
and C 91 631
, C 92 631
third C 93 631
, C 94 631
that C 95 631
the C 96 631
growth C 97 631
of C 98 631
cognitive C 99 631
processes C 100 631
is C 101 631
fostered C 102 631
in C 103 631
family C 104 631
control C 105 631
systems C 106 631
which C 107 631
offer C 108 631
and C 109 631
permit C 110 631
a C 111 631
wide C 112 631
range C 113 631
of C 114 631
alternatives C 115 631
of C 116 631
action C 117 631
and C 118 631
thought C 119 631
and C 120 631
that C 121 631
such C 122 631
growth C 123 631
is C 124 631
constricted C 125 631
by C 126 631
systems C 127 631
of C 128 631
control C 129 631
which C 130 631
offer C 131 631
predetermined C 132 631
solutions C 133 631
and C 134 631
few C 135 631
alternatives C 136 631
for C 137 631
consideration C 138 631
and C 139 631
choice C 140 631
. C 141 631
the C 143 631
research C 144 631
group C 145 631
was C 146 631
composed C 147 631
of C 148 631
160 C 149 631
negro C 150 631
mothers C 151 631
and C 152 631
their C 153 631
4 C 154 631
- C 155 631
year C 156 631
- C 157 631
old C 158 631
children C 159 631
selected C 160 631
from C 161 631
four C 162 631
different C 163 631
social C 164 631
status C 165 631
levels C 166 631
. C 167 631
the C 169 631
data C 170 631
are C 171 631
presented C 172 631
to C 173 631
show C 174 631
social C 175 631
status C 176 631
differences C 177 631
among C 178 631
the C 179 631
four C 180 631
groups C 181 631
with C 182 631
respect C 183 631
to C 184 631
cognitive C 185 631
functioning C 186 631
and C 187 631
linguistic C 188 631
codes C 189 631
and C 190 631
to C 191 631
offer C 192 631
examples C 193 631
of C 194 631
relations C 195 631
between C 196 631
maternal C 197 631
and C 198 631
child C 199 631
behavior C 200 631
that C 201 631
are C 202 631
congruent C 203 631
with C 204 631
the C 205 631
general C 206 631
lines C 207 631
of C 208 631
argument C 209 631
laid C 210 631
out C 211 631
. C 212 631
recovery C 1 632
of C 2 632
mycoplasmas C 3 632
in C 4 632
the C 5 632
study C 6 632
of C 7 632
human C 8 632
leukaemia C 9 632
and C 10 632
other C 11 632
malignancies C 12 632
numerous C 13 632
reports C 14 632
have C 15 632
been C 16 632
published C 17 632
concerning C 18 632
the C 19 632
necessity C 20 632
of C 21 632
testing C 22 632
for C 23 632
the C 24 632
presence C 25 632
of C 26 632
mycoplasmas C 27 632
before C 28 632
the C 29 632
interpretation C 30 632
of C 31 632
experiments C 32 632
performed C 33 632
in C 34 632
cell C 35 632
cultures C 36 632
. C 37 632
such C 39 632
tests C 40 632
are C 41 632
especially C 42 632
important C 43 632
when C 44 632
the C 45 632
presence C 46 632
of C 47 632
viruses C 48 632
is C 49 632
suspected C 50 632
, C 51 632
since C 52 632
recent C 53 632
evidence C 54 632
indicates C 55 632
that C 56 632
some C 57 632
mycoplasmas C 58 632
are C 59 632
capable C 60 632
of C 61 632
eliciting C 62 632
a C 63 632
transmissible C 64 632
cytopathic C 65 632
effect C 66 632
. C 67 632
in C 69 632
addition C 70 632
, C 71 632
some C 72 632
mycoplasmas C 73 632
and C 74 632
viruses C 75 632
share C 76 632
properties C 77 632
, C 78 632
such C 79 632
as C 80 632
size C 81 632
, C 82 632
filterability C 83 632
, C 84 632
morphology C 85 632
in C 86 632
electron C 87 632
microscopy C 88 632
, C 89 632
sensitivity C 90 632
to C 91 632
ether C 92 632
, C 93 632
ability C 94 632
to C 95 632
haemagglutinate C 96 632
and C 97 632
cause C 98 632
haemadsorption C 99 632
, C 100 632
interference C 101 632
with C 102 632
virus C 103 632
replication C 104 632
in C 105 632
vitro C 106 632
, C 107 632
lack C 108 632
of C 109 632
inhibition C 110 632
by C 111 632
certain C 112 632
commonly C 113 632
used C 114 632
antibiotics C 115 632
and C 116 632
inhibition C 117 632
of C 118 632
growth C 119 632
by C 120 632
homologous C 121 632
antiserum C 122 632
. C 123 632
thus C 125 632
, C 126 632
the C 127 632
absence C 128 632
of C 129 632
ordinary C 130 632
bacteria C 131 632
and C 132 632
moulds C 133 632
in C 134 632
preparations C 135 632
eliciting C 136 632
a C 137 632
cytopathic C 138 632
effect C 139 632
in C 140 632
cell C 141 632
cultures C 142 632
is C 143 632
an C 144 632
unreliable C 145 632
criterion C 146 632
for C 147 632
viral C 148 632
identification C 149 632
. C 150 632
great C 152 632
caution C 153 632
should C 154 632
be C 155 632
exercised C 156 632
in C 157 632
classifying C 158 632
new C 159 632
agents C 160 632
as C 161 632
viruses C 162 632
, C 163 632
especially C 164 632
as C 165 632
myxo C 166 632
- C 167 632
viruses C 168 632
, C 169 632
without C 170 632
adequate C 171 632
testing C 172 632
to C 173 632
exclude C 174 632
their C 175 632
identity C 176 632
as C 177 632
mycoplasmas C 178 632
. C 179 632
pneumonia C 1 633
due C 2 633
to C 3 633
mycoplasma C 4 633
pneumoniae C 5 633
its C 6 633
incidence C 7 633
in C 8 633
the C 9 633
membership C 10 633
of C 11 633
a C 12 633
co C 13 633
- C 14 633
operative C 15 633
medical C 16 633
group C 17 633
ruth C 18 633
mcmahan C 19 633
, C 20 633
edmund C 21 633
r C 22 633
. C 23 633
clarke C 25 633
, C 26 633
william C 27 633
a C 28 633
. C 29 633
maccoll C 31 633
, C 32 633
and C 33 633
j C 34 633
. C 35 633
thomas C 37 633
grayston C 38 633
a C 39 633
total C 40 633
of C 41 633
1051 C 42 633
cases C 43 633
of C 44 633
pneumonia C 45 633
occurred C 46 633
in C 47 633
72 C 48 633
, C 49 633
992 C 50 633
persons C 51 633
who C 52 633
were C 53 633
members C 54 633
of C 55 633
a C 56 633
medical C 57 633
co C 58 633
- C 59 633
operative C 60 633
in C 61 633
the C 62 633
period C 63 633
december C 64 633
1 C 65 633
, C 66 633
1963 C 67 633
, C 68 633
to C 69 633
december C 70 633
31 C 71 633
, C 72 633
1964 C 73 633
. C 74 633
the C 76 633
annual C 77 633
rate C 78 633
of C 79 633
pneumonia C 80 633
was C 81 633
12 C 82 633
. C 83 633
. C 84 633
per C 85 633
1000 C 86 633
. C 87 633
isolation C 89 633
of C 90 633
mycoplasma C 91 633
pneumoniae C 92 633
from C 93 633
throat C 94 633
swabs C 95 633
was C 96 633
attempted C 97 633
in C 98 633
over C 99 633
half C 100 633
the C 101 633
cases C 102 633
reported C 103 633
, C 104 633
and C 105 633
paired C 106 633
blood C 107 633
specimens C 108 633
were C 109 633
obtained C 110 633
in C 111 633
one C 112 633
third C 113 633
. C 114 633
on C 116 633
the C 117 633
basis C 118 633
of C 119 633
laboratory C 120 633
examination C 121 633
of C 122 633
these C 123 633
specimens C 124 633
, C 125 633
the C 126 633
incidence C 127 633
of C 128 633
clinically C 129 633
recognized C 130 633
pneumonia C 131 633
due C 132 633
to C 133 633
m C 134 633
. C 135 633
pneumoniae C 137 633
was C 138 633
between C 139 633
1 C 140 633
and C 141 633
1 C 142 633
. C 143 633
. C 144 633
persons C 145 633
per C 146 633
1000 C 147 633
per C 148 633
year C 149 633
. C 150 633
although C 152 633
peak C 153 633
rates C 154 633
of C 155 633
pneumonia C 156 633
occurred C 157 633
under C 158 633
five C 159 633
years C 160 633
of C 161 633
age C 162 633
( C 163 633
45 C 164 633
per C 165 633
1000 C 166 633
) C 167 633
pneumonia C 168 633
due C 169 633
to C 170 633
m C 171 633
. C 172 633
pneumoniae C 174 633
was C 175 633
uncommon C 176 633
in C 177 633
this C 178 633
age C 179 633
group C 180 633
. C 181 633
it C 183 633
was C 184 633
most C 185 633
common C 186 633
in C 187 633
children C 188 633
five C 189 633
to C 190 633
nine C 191 633
years C 192 633
old C 193 633
, C 194 633
and C 195 633
was C 196 633
frequently C 197 633
the C 198 633
cause C 199 633
of C 200 633
pneumonia C 201 633
in C 202 633
adolescents C 203 633
( C 204 633
ten C 205 633
to C 206 633
nineteen C 207 633
years C 208 633
of C 209 633
age C 210 633
) C 211 633
. C 212 633
the C 214 633
rates C 215 633
in C 216 633
children C 217 633
in C 218 633
primary C 219 633
school C 220 633
was C 221 633
twice C 222 633
the C 223 633
average C 224 633
incidence C 225 633
. C 226 633
m C 228 633
. C 229 633
pneumoniae C 231 633
pneumonia C 232 633
also C 233 633
differed C 234 633
from C 235 633
the C 236 633
pneumonias C 237 633
of C 238 633
other C 239 633
etiology C 240 633
in C 241 633
that C 242 633
it C 243 633
occurred C 244 633
throughout C 245 633
the C 246 633
year C 247 633
, C 248 633
with C 249 633
no C 250 633
seasonal C 251 633
excess C 252 633
whereas C 253 633
total C 254 633
pneumonia C 255 633
showed C 256 633
a C 257 633
predominance C 258 633
in C 259 633
winter C 260 633
. C 261 633
the C 263 633
typical C 264 633
clinical C 265 633
syndrome C 266 633
of C 267 633
the C 268 633
pneumonias C 269 633
in C 270 633
which C 271 633
m C 272 633
. C 273 633
pneumoniae C 275 633
was C 276 633
isolated C 277 633
was C 278 633
one C 279 633
of C 280 633
prominent C 281 633
systemic C 282 633
manifestations C 283 633
of C 284 633
headache C 285 633
and C 286 633
fever C 287 633
, C 288 633
but C 289 633
few C 290 633
respiratory C 291 633
symptoms C 292 633
occurred C 293 633
except C 294 633
cough C 295 633
. C 296 633
upper C 298 633
- C 299 633
respiratory C 300 633
- C 301 633
tract C 302 633
complaints C 303 633
and C 304 633
an C 305 633
elevated C 306 633
white C 307 633
- C 308 633
cell C 309 633
count C 310 633
were C 311 633
much C 312 633
more C 313 633
frequent C 314 633
in C 315 633
the C 316 633
other C 317 633
pneumonias C 318 633
. C 319 633
the C 321 633
patients C 322 633
with C 323 633
m C 324 633
. C 325 633
pneumoniae C 327 633
pneumonia C 328 633
were C 329 633
almost C 330 633
never C 331 633
hospitalized C 332 633
but C 333 633
suffered C 334 633
significant C 335 633
absenteeism C 336 633
. C 337 633
they C 339 633
came C 340 633
from C 341 633
larger C 342 633
families C 343 633
, C 344 633
usually C 345 633
with C 346 633
children C 347 633
of C 348 633
school C 349 633
age C 350 633
. C 351 633
reporting C 353 633
physicians C 354 633
were C 355 633
usually C 356 633
correct C 357 633
in C 358 633
diagnosing C 359 633
these C 360 633
pneumonias C 361 633
as C 362 633
" C 363 633
atypical C 364 633
" C 365 633
or C 366 633
" C 367 633
viral C 368 633
. C 369 633
" C 371 633
establishment C 1 634
of C 2 634
a C 3 634
turkey C 4 634
flock C 5 634
free C 6 634
of C 7 634
' C 8 634
n C 9 634
' C 10 634
strain C 11 634
mycoplasma C 12 634
mycoplasma C 13 634
of C 14 634
the C 15 634
' C 16 634
n C 17 634
' C 18 634
strain C 19 634
are C 20 634
frequently C 21 634
isolated C 22 634
from C 23 634
turkey C 24 634
poults C 25 634
affected C 26 634
with C 27 634
airsacculitis C 28 634
but C 29 634
free C 30 634
of C 31 634
mycoplasma C 32 634
gallisepticum C 33 634
. C 34 634
research C 36 634
on C 37 634
the C 38 634
' C 39 634
n C 40 634
' C 41 634
strain C 42 634
has C 43 634
been C 44 634
impeded C 45 634
by C 46 634
the C 47 634
presence C 48 634
of C 49 634
a C 50 634
high C 51 634
proportion C 52 634
of C 53 634
turkey C 54 634
poults C 55 634
with C 56 634
airsacculitis C 57 634
in C 58 634
all C 59 634
breeding C 60 634
flocks C 61 634
examined C 62 634
, C 63 634
by C 64 634
the C 65 634
difficulty C 66 634
of C 67 634
culturing C 68 634
and C 69 634
identifying C 70 634
the C 71 634
mycoplasma C 72 634
strains C 73 634
, C 74 634
and C 75 634
by C 76 634
the C 77 634
lack C 78 634
of C 79 634
a C 80 634
practical C 81 634
serologic C 82 634
test C 83 634
. C 84 634
this C 86 634
communication C 87 634
describes C 88 634
the C 89 634
establishment C 90 634
of C 91 634
a C 92 634
small C 93 634
nucleus C 94 634
of C 95 634
' C 96 634
n C 97 634
' C 98 634
- C 99 634
free C 100 634
turkeys C 101 634
from C 102 634
a C 103 634
commercial C 104 634
breeding C 105 634
flock C 106 634
known C 107 634
to C 108 634
carry C 109 634
' C 110 634
n C 111 634
' C 112 634
mycoplasma C 113 634
. C 114 634
hens C 116 634
and C 117 634
toms C 118 634
for C 119 634
the C 120 634
production C 121 634
of C 122 634
' C 123 634
n C 124 634
' C 125 634
- C 126 634
free C 127 634
poults C 128 634
were C 129 634
selected C 130 634
from C 131 634
the C 132 634
parent C 133 634
flock C 134 634
by C 135 634
serology C 136 634
and C 137 634
culture C 138 634
. C 139 634
septicemia C 1 635
due C 2 635
to C 3 635
mycoplasma C 4 635
hominis C 5 635
type C 6 635
1 C 7 635
viola C 8 635
m C 9 635
. C 10 635
young C 12 635
, C 13 635
ph C 14 635
. C 15 635
. C 16 635
. C 17 635
, C 19 635
and C 20 635
sheldon C 21 635
m C 22 635
. C 23 635
wolff C 25 635
, C 26 635
m C 27 635
. C 28 635
. C 29 635
. C 30 635
a C 32 635
febrile C 33 635
illness C 34 635
that C 35 635
followed C 36 635
therapeutic C 37 635
abortion C 38 635
and C 39 635
was C 40 635
accompanied C 41 635
by C 42 635
the C 43 635
presence C 44 635
of C 45 635
mycoplasma C 46 635
hominis C 47 635
type C 48 635
1 C 49 635
in C 50 635
the C 51 635
blood C 52 635
is C 53 635
described C 54 635
. C 55 635
the C 57 635
patient C 58 635
upon C 59 635
recovery C 60 635
exhibited C 61 635
a C 62 635
specific C 63 635
antibody C 64 635
response C 65 635
to C 66 635
the C 67 635
mycoplasma C 68 635
isolated C 69 635
from C 70 635
the C 71 635
blood C 72 635
, C 73 635
as C 74 635
well C 75 635
as C 76 635
to C 77 635
another C 78 635
strain C 79 635
of C 80 635
the C 81 635
same C 82 635
serotype C 83 635
. C 84 635
these C 86 635
findings C 87 635
are C 88 635
regarded C 89 635
as C 90 635
additional C 91 635
evidence C 92 635
for C 93 635
the C 94 635
pathogenicity C 95 635
of C 96 635
m C 97 635
. C 98 635
hominis C 100 635
type C 101 635
1 C 102 635
organisms C 103 635
, C 104 635
particularly C 105 635
in C 106 635
situations C 107 635
favoring C 108 635
their C 109 635
dissemination C 110 635
from C 111 635
the C 112 635
female C 113 635
genital C 114 635
tract C 115 635
. C 116 635
infectie C 1 636
door C 2 636
mycoplasma C 3 636
hominis C 4 636
bij C 5 636
een C 6 636
pasgeborene C 7 636
mycoplasma C 8 636
hominis C 9 636
infection C 10 636
in C 11 636
a C 12 636
newborn C 13 636
child C 14 636
. C 15 636
- C 17 636
- C 18 636
in C 19 636
a C 20 636
baby C 21 636
born C 22 636
by C 23 636
a C 24 636
difficult C 25 636
forceps C 26 636
delivery C 27 636
, C 28 636
abscesses C 29 636
began C 30 636
to C 31 636
form C 32 636
in C 33 636
the C 34 636
neck C 35 636
a C 36 636
few C 37 636
days C 38 636
after C 39 636
birth C 40 636
. C 41 636
mycoplasma C 43 636
hominis C 44 636
was C 45 636
recovered C 46 636
from C 47 636
the C 48 636
pus C 49 636
. C 50 636
some C 1 637
intraspecies C 2 637
differences C 3 637
in C 4 637
antigens C 5 637
on C 6 637
the C 7 637
surface C 8 637
of C 9 637
certain C 10 637
living C 11 637
human C 12 637
cells C 13 637
surface C 14 637
antigens C 15 637
of C 16 637
several C 17 637
types C 18 637
of C 19 637
living C 20 637
cells C 21 637
of C 22 637
human C 23 637
origin C 24 637
were C 25 637
partially C 26 637
characterized C 27 637
with C 28 637
hyperimmune C 29 637
antisera C 30 637
prepared C 31 637
in C 32 637
the C 33 637
rabbit C 34 637
against C 35 637
living C 36 637
hela C 37 637
cells C 38 637
and C 39 637
living C 40 637
, C 41 637
uncultured C 42 637
, C 43 637
full C 44 637
- C 45 637
term C 46 637
, C 47 637
human C 48 637
amnion C 49 637
cells C 50 637
. C 51 637
hemagglutination C 53 637
, C 54 637
mixed C 55 637
- C 56 637
agglutination C 57 637
, C 58 637
and C 59 637
direct C 60 637
and C 61 637
indirect C 62 637
immunofluorescence C 63 637
( C 64 637
fab C 65 637
) C 66 637
techniques C 67 637
were C 68 637
employed C 69 637
. C 70 637
with C 72 637
these C 73 637
techniques C 74 637
and C 75 637
fractional C 76 637
absorption C 77 637
procedures C 78 637
, C 79 637
common C 80 637
and C 81 637
specific C 82 637
cell C 83 637
antigens C 84 637
were C 85 637
detected C 86 637
on C 87 637
the C 88 637
surface C 89 637
of C 90 637
several C 91 637
human C 92 637
living C 93 637
cells C 94 637
: C 95 637
uncultured C 96 637
and C 97 637
primary C 98 637
amnion C 99 637
, C 100 637
two C 101 637
established C 102 637
human C 103 637
cell C 104 637
lines C 105 637
( C 106 637
rp C 107 637
am C 108 637
1 C 109 637
and C 110 637
u C 111 637
amnion C 112 637
) C 113 637
of C 114 637
presumed C 115 637
normal C 116 637
origin C 117 637
and C 118 637
two C 119 637
( C 120 637
hela C 121 637
and C 122 637
hep C 123 637
- C 124 637
2 C 125 637
) C 126 637
of C 127 637
presumed C 128 637
malignant C 129 637
origin C 130 637
, C 131 637
and C 132 637
human C 133 637
erythrocytes C 134 637
. C 135 637
none C 137 637
of C 138 637
the C 139 637
antigens C 140 637
were C 141 637
found C 142 637
on C 143 637
nctc C 144 637
2555 C 145 637
mouse C 146 637
cells C 147 637
. C 148 637
the C 150 637
human C 151 637
cells C 152 637
possessed C 153 637
species C 154 637
- C 155 637
related C 156 637
antigens C 157 637
demonstrable C 158 637
by C 159 637
hemagglutination C 160 637
. C 161 637
after C 163 637
removal C 164 637
of C 165 637
the C 166 637
hemagglutinins C 167 637
by C 168 637
absorption C 169 637
with C 170 637
human C 171 637
erythrocytes C 172 637
, C 173 637
antibody C 174 637
in C 175 637
high C 176 637
titer C 177 637
for C 178 637
the C 179 637
homologous C 180 637
cells C 181 637
was C 182 637
detected C 183 637
by C 184 637
fab C 185 637
methods C 186 637
. C 187 637
in C 189 637
addition C 190 637
, C 191 637
some C 192 637
changes C 193 637
in C 194 637
antigens C 195 637
on C 196 637
the C 197 637
surface C 198 637
of C 199 637
amnion C 200 637
cells C 201 637
during C 202 637
primary C 203 637
culture C 204 637
were C 205 637
observed C 206 637
. C 207 637
finally C 209 637
, C 210 637
an C 211 637
antigen C 212 637
was C 213 637
found C 214 637
on C 215 637
hela C 216 637
and C 217 637
hep C 218 637
- C 219 637
2 C 220 637
cells C 221 637
, C 222 637
by C 223 637
use C 224 637
of C 225 637
anti C 226 637
- C 227 637
hela C 228 637
serum C 229 637
absorbed C 230 637
with C 231 637
human C 232 637
erythrocytes C 233 637
and C 234 637
rp C 235 637
am C 236 637
1 C 237 637
cells C 238 637
, C 239 637
that C 240 637
was C 241 637
not C 242 637
found C 243 637
on C 244 637
either C 245 637
human C 246 637
erythrocytes C 247 637
, C 248 637
uncultured C 249 637
amnion C 250 637
cells C 251 637
, C 252 637
or C 253 637
on C 254 637
the C 255 637
cells C 256 637
of C 257 637
the C 258 637
two C 259 637
established C 260 637
amnion C 261 637
cell C 262 637
lines C 263 637
. C 264 637
at C 266 637
the C 267 637
dilutions C 268 637
used C 269 637
in C 270 637
the C 271 637
tests C 272 637
, C 273 637
antibodies C 274 637
to C 275 637
the C 276 637
abo C 277 637
blood C 278 637
group C 279 637
isoanti C 280 637
- C 281 637
gens C 282 637
, C 283 637
forssman C 284 637
hapten C 285 637
, C 286 637
or C 287 637
adsorbed C 288 637
serum C 289 637
proteins C 290 637
could C 291 637
not C 292 637
account C 293 637
for C 294 637
the C 295 637
antigens C 296 637
detected C 297 637
. C 298 637
the C 300 637
possibility C 301 637
that C 302 637
mycoplasma C 303 637
sp C 304 637
. C 305 637
antigens C 307 637
were C 308 637
responsible C 309 637
for C 310 637
the C 311 637
reactions C 312 637
was C 313 637
inconsistent C 314 637
with C 315 637
the C 316 637
results C 317 637
. C 318 637
the C 320 637
specificity C 321 637
of C 322 637
the C 323 637
fab C 324 637
methods C 325 637
on C 326 637
living C 327 637
cells C 328 637
was C 329 637
confirmed C 330 637
. C 331 637
coombs C 1 638
- C 2 638
positive C 3 638
hemolytic C 4 638
anemia C 5 638
and C 6 638
generalized C 7 638
amyloidosis C 8 638
in C 9 638
mice C 10 638
following C 11 638
transmission C 12 638
of C 13 638
subcellular C 14 638
leukemic C 15 638
material C 16 638
following C 17 638
transmission C 18 638
with C 19 638
cell C 20 638
- C 21 638
free C 22 638
supernatant C 23 638
fluid C 24 638
or C 25 638
with C 26 638
virus C 27 638
ex C 28 638
- C 29 638
tract C 30 638
of C 31 638
leukemic C 32 638
tissue C 33 638
or C 34 638
plasma C 35 638
from C 36 638
vari C 37 638
- C 38 638
ous C 39 638
types C 40 638
of C 41 638
murine C 42 638
plasma C 43 638
cell C 44 638
leukemias C 45 638
a C 46 638
disease C 47 638
developed C 48 638
, C 49 638
characterized C 50 638
by C 51 638
hyper C 52 638
- C 53 638
gammaglobulinemia C 54 638
, C 55 638
weight C 56 638
loss C 57 638
, C 58 638
anemia C 59 638
, C 60 638
marked C 61 638
splenic C 62 638
, C 63 638
renal C 64 638
and C 65 638
hepatic C 66 638
amyloido C 67 638
- C 68 638
sis C 69 638
and C 70 638
plasma C 71 638
cell C 72 638
infiltrations C 73 638
in C 74 638
the C 75 638
lungs C 76 638
. C 77 638
the C 79 638
disease C 80 638
was C 81 638
also C 82 638
transmissible C 83 638
through C 84 638
the C 85 638
placenta C 86 638
or C 87 638
with C 88 638
the C 89 638
milk C 90 638
of C 91 638
infected C 92 638
mice C 93 638
. C 94 638
in C 96 638
dba C 97 638
/ C 98 638
2 C 99 638
males C 100 638
the C 101 638
incidence C 102 638
of C 103 638
the C 104 638
disease C 105 638
was C 106 638
much C 107 638
higher C 108 638
( C 109 638
100 C 110 638
% C 111 638
) C 112 638
, C 113 638
the C 114 638
sur C 115 638
- C 116 638
vival C 117 638
shorter C 118 638
and C 119 638
the C 120 638
anemia C 121 638
much C 122 638
more C 123 638
severe C 124 638
than C 125 638
was C 126 638
the C 127 638
case C 128 638
in C 129 638
dba C 130 638
/ C 131 638
2 C 132 638
females C 133 638
and C 134 638
in C 135 638
( C 136 638
dba C 137 638
/ C 138 638
2 C 139 638
x C 140 638
cba C 141 638
) C 142 638
f C 143 638
1 C 144 638
mice C 145 638
of C 146 638
both C 147 638
sexes C 148 638
. C 149 638
it C 151 638
is C 152 638
proposed C 153 638
that C 154 638
the C 155 638
development C 156 638
of C 157 638
the C 158 638
lesions C 159 638
is C 160 638
mediated C 161 638
through C 162 638
an C 163 638
auto C 164 638
- C 165 638
immune C 166 638
mechanism C 167 638
created C 168 638
by C 169 638
the C 170 638
antigenic C 171 638
effect C 172 638
of C 173 638
the C 174 638
virus C 175 638
- C 176 638
transformed C 177 638
host C 178 638
cells C 179 638
. C 180 638
the C 1 639
ph C 2 639
6 C 3 639
antigen C 4 639
in C 5 639
strains C 6 639
of C 7 639
pasteurella C 8 639
pseudotuberculosis C 9 639
and C 10 639
its C 11 639
relation C 12 639
to C 13 639
biological C 14 639
activities C 15 639
it C 16 639
may C 17 639
be C 18 639
concluded C 19 639
that C 20 639
only C 21 639
part C 22 639
of C 23 639
the C 24 639
p C 25 639
. C 26 639
pseudotuberculosis C 28 639
strains C 29 639
can C 30 639
synthesize C 31 639
the C 32 639
ph C 33 639
6 C 34 639
antigen C 35 639
, C 36 639
whereas C 37 639
this C 38 639
property C 39 639
seems C 40 639
to C 41 639
be C 42 639
shared C 43 639
by C 44 639
all C 45 639
the C 46 639
strains C 47 639
of C 48 639
p C 49 639
. C 50 639
pestis C 52 639
. C 53 639
as C 55 639
in C 56 639
the C 57 639
case C 58 639
of C 59 639
p C 60 639
. C 61 639
pestis C 63 639
, C 64 639
three C 65 639
kinds C 66 639
of C 67 639
biological C 68 639
activi C 69 639
- C 70 639
ties C 71 639
were C 72 639
related C 73 639
to C 74 639
the C 75 639
presence C 76 639
of C 77 639
the C 78 639
ph C 79 639
6 C 80 639
antigen C 81 639
isolated C 82 639
from C 83 639
a C 84 639
strain C 85 639
of C 86 639
p C 87 639
. C 88 639
pseudotubercu C 90 639
- C 91 639
losis C 92 639
. C 93 639
serological C 1 640
relationships C 2 640
among C 3 640
human C 4 640
mycoplasmas C 5 640
as C 6 640
shown C 7 640
by C 8 640
complement C 9 640
- C 10 640
fixation C 11 640
and C 12 640
gel C 13 640
diffusion C 14 640
and C 15 640
robert C 16 640
m C 17 640
. C 18 640
chanock C 20 640
antigenic C 21 640
relationships C 22 640
among C 23 640
human C 24 640
mycoplasmas C 25 640
were C 26 640
studied C 27 640
by C 28 640
complement C 29 640
- C 30 640
fixation C 31 640
and C 32 640
agar C 33 640
gel C 34 640
diffusion C 35 640
techniques C 36 640
. C 37 640
four C 39 640
recognized C 40 640
human C 41 640
species C 42 640
. C 43 640
mycoplasma C 45 640
hominis C 46 640
type C 47 640
1 C 48 640
, C 49 640
m C 50 640
. C 51 640
hominis C 53 640
type C 54 640
2 C 55 640
, C 56 640
m C 57 640
. C 58 640
salivarium C 60 640
, C 61 640
and C 62 640
m C 63 640
. C 64 640
fermentans C 66 640
were C 67 640
antigenically C 68 640
distinct C 69 640
in C 70 640
these C 71 640
tests C 72 640
. C 73 640
in C 75 640
addition C 76 640
, C 77 640
m C 78 640
. C 79 640
pneumoniae C 81 640
( C 82 640
eaton C 83 640
agent C 84 640
, C 85 640
the C 86 640
etiological C 87 640
agent C 88 640
of C 89 640
cold C 90 640
agglutinin C 91 640
- C 92 640
positive C 93 640
atypical C 94 640
pneumonia C 95 640
) C 96 640
was C 97 640
different C 98 640
from C 99 640
these C 100 640
four C 101 640
species C 102 640
. C 103 640
although C 105 640
these C 106 640
species C 107 640
were C 108 640
distinct C 109 640
, C 110 640
evidence C 111 640
of C 112 640
shared C 113 640
antigenic C 114 640
components C 115 640
was C 116 640
obtained C 117 640
in C 118 640
complement C 119 640
- C 120 640
fixation C 121 640
and C 122 640
agar C 123 640
gel C 124 640
diffusion C 125 640
tests C 126 640
. C 127 640
since C 129 640
rabbits C 130 640
were C 131 640
immunized C 132 640
with C 133 640
mycoplasmas C 134 640
grown C 135 640
in C 136 640
rabbit C 137 640
muscle C 138 640
infu C 139 640
- C 140 640
sion C 141 640
broth C 142 640
supplemented C 143 640
with C 144 640
rabbit C 145 640
serum C 146 640
or C 147 640
, C 148 640
in C 149 640
the C 150 640
case C 151 640
of C 152 640
m C 153 640
. C 154 640
pneumoniae C 156 640
, C 157 640
with C 158 640
infected C 159 640
chick C 160 640
embryo C 161 640
lung C 162 640
suspension C 163 640
, C 164 640
the C 165 640
possibility C 166 640
that C 167 640
the C 168 640
heterologous C 169 640
reactions C 170 640
resulted C 171 640
from C 172 640
antibody C 173 640
to C 174 640
growth C 175 640
medium C 176 640
components C 177 640
could C 178 640
be C 179 640
excluded C 180 640
. C 181 640
four C 183 640
recent C 184 640
mycoplasma C 185 640
isolates C 186 640
from C 187 640
the C 188 640
oro C 189 640
- C 190 640
pharynx C 191 640
were C 192 640
analyzed C 193 640
, C 194 640
and C 195 640
three C 196 640
were C 197 640
shown C 198 640
to C 199 640
be C 200 640
closely C 201 640
related C 202 640
to C 203 640
m C 204 640
. C 205 640
hominis C 207 640
type C 208 640
1 C 209 640
, C 210 640
and C 211 640
the C 212 640
fourth C 213 640
was C 214 640
closely C 215 640
related C 216 640
to C 217 640
m C 218 640
. C 219 640
salivarium C 221 640
. C 222 640
although C 224 640
the C 225 640
recent C 226 640
isolates C 227 640
could C 228 640
not C 229 640
be C 230 640
dis C 231 640
- C 232 640
tinguished C 233 640
from C 234 640
the C 235 640
related C 236 640
" C 237 640
prototype C 238 640
" C 239 640
human C 240 640
species C 241 640
by C 242 640
complement C 243 640
- C 244 640
fixation C 245 640
, C 246 640
differences C 247 640
could C 248 640
be C 249 640
detected C 250 640
by C 251 640
the C 252 640
agar C 253 640
gel C 254 640
diffusion C 255 640
technique C 256 640
. C 257 640
mammalian C 1 641
cell C 2 641
cultures C 3 641
contaminated C 4 641
with C 5 641
pleuropneumonia C 6 641
- C 7 641
like C 8 641
organisms C 9 641
ii C 10 641
. C 11 641
effect C 13 641
of C 14 641
pplo C 15 641
on C 16 641
cell C 17 641
morphology C 18 641
in C 19 641
established C 20 641
monolayer C 21 641
cultures C 22 641
the C 23 641
occurrence C 24 641
of C 25 641
cytopathogenic C 26 641
changes C 27 641
in C 28 641
monolayer C 29 641
cultures C 30 641
of C 31 641
pplo C 32 641
- C 33 641
contaminated C 34 641
mammalian C 35 641
cells C 36 641
has C 37 641
been C 38 641
shown C 39 641
to C 40 641
be C 41 641
related C 42 641
to C 43 641
deficiency C 44 641
of C 45 641
arginine C 46 641
in C 47 641
the C 48 641
medium C 49 641
. C 50 641
the C 52 641
same C 53 641
effects C 54 641
were C 55 641
seen C 56 641
when C 57 641
the C 58 641
cell C 59 641
culture C 60 641
medium C 61 641
was C 62 641
depleted C 63 641
by C 64 641
pplo C 65 641
prior C 66 641
to C 67 641
application C 68 641
to C 69 641
pplo C 70 641
- C 71 641
free C 72 641
cell C 73 641
cultures C 74 641
even C 75 641
though C 76 641
viable C 77 641
pplo C 78 641
were C 79 641
no C 80 641
longer C 81 641
present C 82 641
. C 83 641
the C 85 641
fact C 86 641
that C 87 641
the C 88 641
same C 89 641
picture C 90 641
resulted C 91 641
in C 92 641
the C 93 641
absence C 94 641
of C 95 641
pplo C 96 641
when C 97 641
either C 98 641
arginine C 99 641
or C 100 641
glucose C 101 641
were C 102 641
omitted C 103 641
from C 104 641
the C 105 641
medium C 106 641
would C 107 641
indicate C 108 641
that C 109 641
, C 110 641
while C 111 641
the C 112 641
defi C 113 641
- C 114 641
ciency C 115 641
created C 116 641
under C 117 641
the C 118 641
conditions C 119 641
described C 120 641
was C 121 641
specific C 122 641
, C 123 641
the C 124 641
cellular C 125 641
changes C 126 641
could C 127 641
as C 128 641
well C 129 641
be C 130 641
the C 131 641
result C 132 641
of C 133 641
omission C 134 641
or C 135 641
depletion C 136 641
of C 137 641
other C 138 641
mam C 139 641
- C 140 641
malian C 141 641
cell C 142 641
growth C 143 641
requirements C 144 641
. C 145 641
the C 147 641
importance C 148 641
of C 149 641
surveillance C 150 641
of C 151 641
cell C 152 641
lines C 153 641
for C 154 641
the C 155 641
presence C 156 641
of C 157 641
pplo C 158 641
to C 159 641
avoid C 160 641
misinterpretation C 161 641
of C 162 641
cytopathogenic C 163 641
effects C 164 641
was C 165 641
stressed C 166 641
. C 167 641
suppression C 1 642
of C 2 642
rous C 3 642
sarcoma C 4 642
virus C 5 642
growth C 6 642
in C 7 642
tissue C 8 642
cultures C 9 642
by C 10 642
mycoplasma C 11 642
orale C 12 642
an C 13 642
agent C 14 642
which C 15 642
produced C 16 642
cell C 17 642
destruction C 18 642
in C 19 642
human C 20 642
diploid C 21 642
and C 22 642
chick C 23 642
- C 24 642
embryo C 25 642
fibroblasts C 26 642
was C 27 642
isolated C 28 642
from C 29 642
wi C 30 642
- C 31 642
26 C 32 642
strain C 33 642
of C 34 642
human C 35 642
diploid C 36 642
fibroblasts C 37 642
and C 38 642
shown C 39 642
to C 40 642
be C 41 642
a C 42 642
mycoplasma C 43 642
. C 44 642
the C 46 642
multiplication C 47 642
of C 48 642
rous C 49 642
sarcoma C 50 642
virus C 51 642
( C 52 642
rsv C 53 642
) C 54 642
and C 55 642
rous C 56 642
associated C 57 642
virus C 58 642
( C 59 642
rav C 60 642
) C 61 642
was C 62 642
inhibited C 63 642
in C 64 642
wi C 65 642
- C 66 642
26 C 67 642
, C 68 642
wi C 69 642
- C 70 642
38 C 71 642
, C 72 642
and C 73 642
chick C 74 642
- C 75 642
embryo C 76 642
fibroblasts C 77 642
infected C 78 642
with C 79 642
this C 80 642
mycoplasma C 81 642
. C 82 642
the C 84 642
mycoplasma C 85 642
isolate C 86 642
, C 87 642
designated C 88 642
strain C 89 642
941 C 90 642
, C 91 642
reacted C 92 642
strongly C 93 642
in C 94 642
the C 95 642
complement C 96 642
- C 97 642
fixation C 98 642
test C 99 642
with C 100 642
antiserum C 101 642
to C 102 642
mycoplasma C 103 642
orale C 104 642
ch C 105 642
19299 C 106 642
, C 107 642
an C 108 642
isolate C 109 642
obtained C 110 642
from C 111 642
the C 112 642
human C 113 642
oral C 114 642
cavity C 115 642
. C 116 642
the C 118 642
cytopathic C 119 642
effect C 120 642
of C 121 642
mycoplasma C 122 642
strain C 123 642
941 C 124 642
could C 125 642
be C 126 642
eliminated C 127 642
by C 128 642
growing C 129 642
the C 130 642
mycoplasma C 131 642
on C 132 642
an C 133 642
artificial C 134 642
agar C 135 642
medium C 136 642
before C 137 642
inoculation C 138 642
into C 139 642
chick C 140 642
- C 141 642
embryo C 142 642
fibroblasts C 143 642
. C 144 642
serial C 146 642
passage C 147 642
in C 148 642
chick C 149 642
- C 150 642
embryo C 151 642
fibroblasts C 152 642
restored C 153 642
the C 154 642
cytopathogenicity C 155 642
of C 156 642
the C 157 642
agar C 158 642
- C 159 642
grown C 160 642
mycoplasma C 161 642
. C 162 642
however C 164 642
, C 165 642
growth C 166 642
of C 167 642
rsv C 168 642
and C 169 642
rav C 170 642
was C 171 642
inhibited C 172 642
by C 173 642
both C 174 642
the C 175 642
tissue C 176 642
culture C 177 642
- C 178 642
grown C 179 642
and C 180 642
the C 181 642
agar C 182 642
- C 183 642
grown C 184 642
941 C 185 642
strain C 186 642
, C 187 642
and C 188 642
also C 189 642
by C 190 642
the C 191 642
ch C 192 642
19299 C 193 642
strain C 194 642
which C 195 642
did C 196 642
not C 197 642
produce C 198 642
any C 199 642
cytopathic C 200 642
effect C 201 642
. C 202 642
a C 1 643
method C 2 643
for C 3 643
direct C 4 643
demonstration C 5 643
of C 6 643
pleuropneumonia C 7 643
- C 8 643
like C 9 643
organisms C 10 643
in C 11 643
cultured C 12 643
cells C 13 643
. C 14 643
direct C 16 643
microscopic C 17 643
observation C 18 643
of C 19 643
pleuropneumonia C 20 643
- C 21 643
like C 22 643
organisms C 23 643
( C 24 643
pplo C 25 643
) C 26 643
in C 27 643
cell C 28 643
cultures C 29 643
is C 30 643
easily C 31 643
accomplished C 32 643
follow C 33 643
- C 34 643
ing C 35 643
hypotonic C 36 643
treatment C 37 643
, C 38 643
air C 39 643
- C 40 643
drying C 41 643
and C 42 643
staining C 43 643
with C 44 643
orcein C 45 643
. C 46 643
a C 48 643
rapid C 49 643
technique C 50 643
using C 51 643
fl C 52 643
human C 53 643
amnion C 54 643
cells C 55 643
, C 56 643
inoculated C 57 643
with C 58 643
su C 59 643
- C 60 643
pernatant C 61 643
from C 62 643
suspected C 63 643
cultures C 64 643
, C 65 643
is C 66 643
de C 67 643
- C 68 643
scribed C 69 643
. C 70 643
the C 72 643
demonstration C 73 643
of C 74 643
pplo C 75 643
con C 76 643
- C 77 643
tamination C 78 643
of C 79 643
30 C 80 643
cell C 81 643
lines C 82 643
by C 83 643
this C 84 643
rapid C 85 643
method C 86 643
was C 87 643
in C 88 643
complete C 89 643
agreement C 90 643
with C 91 643
re C 92 643
- C 93 643
sults C 94 643
of C 95 643
pplo C 96 643
- C 97 643
agar C 98 643
techniques C 99 643
. C 100 643
a C 1 644
fatal C 2 644
septicemic C 3 644
disease C 4 644
of C 5 644
infant C 6 644
puppies C 7 644
caused C 8 644
by C 9 644
cytopathogenic C 10 644
organisms C 11 644
with C 12 644
characteristics C 13 644
of C 14 644
mycoplasma C 15 644
. C 16 644
pathogenic C 18 644
organisms C 19 644
were C 20 644
iso C 21 644
- C 22 644
lated C 23 644
from C 24 644
2 C 25 644
outbreaks C 26 644
of C 27 644
a C 28 644
fatal C 29 644
septicemic C 30 644
disease C 31 644
of C 32 644
infant C 33 644
puppies C 34 644
and C 35 644
from C 36 644
dog C 37 644
kidney C 38 644
cells C 39 644
that C 40 644
degenerated C 41 644
spontaneously C 42 644
. C 43 644
the C 45 644
iso C 46 644
- C 47 644
lates C 48 644
were C 49 644
indistinguishable C 50 644
serologically C 51 644
and C 52 644
possessed C 53 644
characteristics C 54 644
of C 55 644
mycoplasma C 56 644
. C 57 644
the C 59 644
pathogenic C 60 644
organisms C 61 644
were C 62 644
cytopathogenic C 63 644
for C 64 644
dog C 65 644
kidney C 66 644
cell C 67 644
cultures C 68 644
, C 69 644
and C 70 644
in C 71 644
inoculated C 72 644
puppies C 73 644
, C 74 644
produced C 75 644
pathological C 76 644
changes C 77 644
that C 78 644
resembled C 79 644
those C 80 644
seen C 81 644
in C 82 644
natural C 83 644
cases C 84 644
. C 85 644
le C 87 644
- C 88 644
sions C 89 644
consisted C 90 644
principally C 91 644
of C 92 644
necrosis C 93 644
and C 94 644
hemorrhage C 95 644
. C 96 644
the C 98 644
isolates C 99 644
were C 100 644
culturally C 101 644
and C 102 644
serologically C 103 644
distinct C 104 644
from C 105 644
recognized C 106 644
canine C 107 644
mycoplasma C 108 644
species C 109 644
. C 110 644
chromosome C 1 645
changes C 2 645
in C 3 645
pplo C 4 645
- C 5 645
infected C 6 645
fl C 7 645
human C 8 645
amnion C 9 645
cells C 10 645
. C 11 645
characteristic C 13 645
chromosome C 14 645
changes C 15 645
were C 16 645
observed C 17 645
in C 18 645
pplo C 19 645
- C 20 645
infected C 21 645
fl C 22 645
human C 23 645
amnion C 24 645
cells C 25 645
. C 26 645
these C 28 645
changes C 29 645
included C 30 645
a C 31 645
gradual C 32 645
reduction C 33 645
in C 34 645
chromosome C 35 645
numbers C 36 645
, C 37 645
increase C 38 645
in C 39 645
chromosome C 40 645
aberrations C 41 645
, C 42 645
and C 43 645
the C 44 645
appearance C 45 645
of C 46 645
3 C 47 645
new C 48 645
varieties C 49 645
. C 50 645
although C 52 645
some C 53 645
of C 54 645
the C 55 645
aberrations C 56 645
appeared C 57 645
early C 58 645
after C 59 645
infec C 60 645
- C 61 645
tion C 62 645
, C 63 645
most C 64 645
changes C 65 645
developed C 66 645
slowly C 67 645
, C 68 645
over C 69 645
a C 70 645
period C 71 645
of C 72 645
several C 73 645
months C 74 645
. C 75 645
studies C 1 646
on C 2 646
mycoplasma C 3 646
pneumoniae C 4 646
infection C 5 646
in C 6 646
sweden C 7 646
sera C 8 646
from C 9 646
107 C 10 646
cases C 11 646
of C 12 646
pneumonia C 13 646
and C 14 646
132 C 15 646
cases C 16 646
of C 17 646
milder C 18 646
respiratory C 19 646
infection C 20 646
were C 21 646
examined C 22 646
by C 23 646
the C 24 646
cf C 25 646
test C 26 646
against C 27 646
m C 28 646
. C 29 646
pneumoniae C 31 646
antigen C 32 646
. C 33 646
thirty C 35 646
- C 36 646
five C 37 646
patients C 38 646
with C 39 646
pneumonia C 40 646
and C 41 646
2 C 42 646
patients C 43 646
with C 44 646
bronchitis C 45 646
had C 46 646
serologic C 47 646
evidence C 48 646
of C 49 646
m C 50 646
. C 51 646
pneumoniae C 53 646
infection C 54 646
. C 55 646
all C 57 646
cases C 58 646
which C 59 646
had C 60 646
a C 61 646
significant C 62 646
antibody C 63 646
rise C 64 646
with C 65 646
the C 66 646
cf C 67 646
test C 68 646
also C 69 646
showed C 70 646
a C 71 646
corresponding C 72 646
rise C 73 646
with C 74 646
the C 75 646
fluorescent C 76 646
antibody C 77 646
test C 78 646
. C 79 646
m C 81 646
. C 82 646
pneumoniae C 84 646
was C 85 646
isolated C 86 646
from C 87 646
10 C 88 646
of C 89 646
18 C 90 646
serologically C 91 646
positive C 92 646
cases C 93 646
. C 94 646
cold C 96 646
agglutinins C 97 646
were C 98 646
demon C 99 646
- C 100 646
strated C 101 646
in C 102 646
17 C 103 646
of C 104 646
37 C 105 646
cases C 106 646
( C 107 646
46 C 108 646
per C 109 646
cent C 110 646
) C 111 646
with C 112 646
m C 113 646
. C 114 646
pneumoniae C 116 646
infection C 117 646
. C 118 646
m C 120 646
. C 121 646
pneumoniae C 123 646
infections C 124 646
occurred C 125 646
during C 126 646
all C 127 646
seasons C 128 646
of C 129 646
the C 130 646
year C 131 646
and C 132 646
were C 133 646
most C 134 646
common C 135 646
in C 136 646
older C 137 646
children C 138 646
and C 139 646
young C 140 646
adults C 141 646
. C 142 646
the C 144 646
clinical C 145 646
features C 146 646
of C 147 646
the C 148 646
cases C 149 646
with C 150 646
m C 151 646
. C 152 646
pneumoniae C 154 646
infection C 155 646
in C 156 646
this C 157 646
study C 158 646
re C 159 646
- C 160 646
semble C 161 646
those C 162 646
described C 163 646
in C 164 646
similar C 165 646
investigations C 166 646
in C 167 646
other C 168 646
countries C 169 646
. C 170 646
spontane C 1 647
genetische C 2 647
veranderungen C 3 647
am C 4 647
zellstamm C 5 647
l C 6 647
( C 7 647
earle C 8 647
) C 9 647
the C 10 647
chromosomal C 11 647
constitution C 12 647
of C 13 647
a C 14 647
clone C 15 647
of C 16 647
the C 17 647
cell C 18 647
strain C 19 647
, C 20 647
, C 21 647
l C 22 647
' C 23 647
' C 24 647
was C 25 647
studied C 26 647
by C 27 647
repeated C 28 647
chromosomal C 29 647
analyses C 30 647
within C 31 647
2 C 32 647
years C 33 647
. C 34 647
there C 36 647
resulted C 37 647
the C 38 647
stability C 39 647
of C 40 647
the C 41 647
cellular C 42 647
clone C 43 647
with C 44 647
regard C 45 647
to C 46 647
the C 47 647
tested C 48 647
feature C 49 647
for C 50 647
the C 51 647
duration C 52 647
of C 53 647
about C 54 647
one C 55 647
year C 56 647
. C 57 647
the C 59 647
maximal C 60 647
number C 61 647
of C 62 647
chromosomes C 63 647
amounted C 64 647
to C 65 647
60 C 66 647
- C 67 647
64 C 68 647
. C 69 647
in C 71 647
later C 72 647
tests C 73 647
a C 74 647
spon C 75 647
- C 76 647
taneous C 77 647
doubling C 78 647
of C 79 647
the C 80 647
chromosomal C 81 647
number C 82 647
( C 83 647
maximum C 84 647
120 C 85 647
chromosomes C 86 647
) C 87 647
was C 88 647
ascertained C 89 647
. C 90 647
the C 92 647
cause C 93 647
of C 94 647
this C 95 647
phenomenon C 96 647
could C 97 647
not C 98 647
yet C 99 647
be C 100 647
cleared C 101 647
up C 102 647
. C 103 647
this C 105 647
new C 106 647
chromosomal C 107 647
pattern C 108 647
remained C 109 647
unchanged C 110 647
in C 111 647
the C 112 647
subsequent C 113 647
examination C 114 647
period C 115 647
of C 116 647
6 C 117 647
months C 118 647
. C 119 647
as C 121 647
was C 122 647
proved C 123 647
by C 124 647
these C 125 647
observations C 126 647
, C 127 647
under C 128 647
the C 129 647
present C 130 647
cultivation C 131 647
- C 132 647
conditions C 133 647
cell C 134 647
populations C 135 647
can C 136 647
be C 137 647
retained C 138 647
stabile C 139 647
in C 140 647
vitro C 141 647
for C 142 647
a C 143 647
certain C 144 647
period C 145 647
. C 146 647
the C 148 647
defined C 149 647
substances C 150 647
, C 151 647
however C 152 647
, C 153 647
still C 154 647
imply C 155 647
unknown C 156 647
factors C 157 647
which C 158 647
may C 159 647
have C 160 647
a C 161 647
mutagenous C 162 647
effect C 163 647
, C 164 647
so C 165 647
that C 166 647
sudden C 167 647
changes C 168 647
of C 169 647
cell C 170 647
populations C 171 647
may C 172 647
result C 173 647
. C 174 647
the C 176 647
respective C 177 647
physiological C 178 647
features C 179 647
are C 180 647
hardly C 181 647
known C 182 647
as C 183 647
yet C 184 647
. C 185 647
chromosome C 1 648
changes C 2 648
in C 3 648
human C 4 648
diploid C 5 648
- C 6 648
cell C 7 648
cultures C 8 648
infected C 9 648
with C 10 648
mycoplasma C 11 648
this C 12 648
communication C 13 648
shows C 14 648
that C 15 648
mycoplasma C 16 648
may C 17 648
also C 18 648
change C 19 648
cell C 20 648
chromosomes C 21 648
, C 22 648
and C 23 648
therefore C 24 648
emphasizes C 25 648
the C 26 648
need C 27 648
for C 28 648
caution C 29 648
in C 30 648
interpreting C 31 648
experimental C 32 648
results C 33 648
without C 34 648
adequately C 35 648
testing C 36 648
for C 37 648
the C 38 648
presence C 39 648
of C 40 648
mycoplasma C 41 648
. C 42 648
chromosome C 44 648
damage C 45 648
similar C 46 648
to C 47 648
that C 48 648
described C 49 648
here C 50 648
has C 51 648
been C 52 648
induced C 53 648
by C 54 648
viruses C 55 648
in C 56 648
cell C 57 648
cultures C 58 648
and C 59 648
in C 60 648
blood C 61 648
cul C 62 648
- C 63 648
tures C 64 648
. C 65 648
chromosomal C 67 648
abnormalities C 68 648
have C 69 648
also C 70 648
been C 71 648
reported C 72 648
in C 73 648
blood C 74 648
cultures C 75 648
and C 76 648
bone C 77 648
marrow C 78 648
from C 79 648
leukaemic C 80 648
patients C 81 648
. C 82 648
evaluation C 1 649
of C 2 649
tylosin C 3 649
in C 4 649
preventing C 5 649
egg C 6 649
transmission C 7 649
of C 8 649
mycoplasma C 9 649
gallisepticum C 10 649
in C 11 649
chickens C 12 649
the C 13 649
inoculation C 14 649
of C 15 649
mycoplasma C 16 649
gallisepticum C 17 649
infective C 18 649
yolk C 19 649
into C 20 649
the C 21 649
left C 22 649
posterior C 23 649
thoracic C 24 649
air C 25 649
sac C 26 649
of C 27 649
laying C 28 649
chickens C 29 649
resulted C 30 649
in C 31 649
an C 32 649
infection C 33 649
which C 34 649
produced C 35 649
a C 36 649
rate C 37 649
of C 38 649
egg C 39 649
infection C 40 649
satisfactory C 41 649
for C 42 649
experimental C 43 649
purposes C 44 649
. C 45 649
culturing C 47 649
of C 48 649
all C 49 649
live C 50 649
embryonating C 51 649
eggs C 52 649
as C 53 649
well C 54 649
as C 55 649
all C 56 649
dead C 57 649
and C 58 649
infertile C 59 649
eggs C 60 649
was C 61 649
necessary C 62 649
to C 63 649
determine C 64 649
the C 65 649
rate C 66 649
of C 67 649
egg C 68 649
infection C 69 649
. C 70 649
tylosin C 72 649
, C 73 649
either C 74 649
injected C 75 649
subcutaneously C 76 649
, C 77 649
administered C 78 649
in C 79 649
the C 80 649
drinking C 81 649
water C 82 649
, C 83 649
or C 84 649
employed C 85 649
in C 86 649
an C 87 649
egg C 88 649
- C 89 649
dipping C 90 649
solution C 91 649
, C 92 649
greatly C 93 649
reduced C 94 649
but C 95 649
did C 96 649
not C 97 649
completely C 98 649
eliminate C 99 649
egg C 100 649
infection C 101 649
. C 102 649
in C 104 649
the C 105 649
3 C 106 649
egg C 107 649
dipping C 108 649
trials C 109 649
, C 110 649
only C 111 649
11 C 112 649
isolates C 113 649
of C 114 649
m C 115 649
. C 116 649
gallisepticum C 118 649
were C 119 649
ob C 120 649
- C 121 649
tained C 122 649
from C 123 649
2329 C 124 649
tylosin C 125 649
- C 126 649
dipped C 127 649
eggs C 128 649
, C 129 649
compared C 130 649
to C 131 649
400 C 132 649
isolates C 133 649
from C 134 649
2984 C 135 649
control C 136 649
eggs C 137 649
. C 138 649
epidemiology C 1 650
of C 2 650
mycoplasma C 3 650
pneumoniae C 4 650
infection C 5 650
in C 6 650
families C 7 650
and C 8 650
ruth C 9 650
mcmahan C 10 650
the C 11 650
transmission C 12 650
and C 13 650
clinical C 14 650
manifestations C 15 650
of C 16 650
in C 17 650
- C 18 650
fection C 19 650
with C 20 650
mycoplasma C 21 650
pneumoniae C 22 650
were C 23 650
studied C 24 650
in C 25 650
114 C 26 650
families C 27 650
in C 28 650
which C 29 650
there C 30 650
was C 31 650
a C 32 650
case C 33 650
of C 34 650
atypical C 35 650
pneumonia C 36 650
. C 37 650
m C 39 650
pneumoniae C 40 650
was C 41 650
isolated C 42 650
from C 43 650
a C 44 650
throat C 45 650
culture C 46 650
of C 47 650
the C 48 650
index C 49 650
pneumonia C 50 650
patient C 51 650
in C 52 650
36 C 53 650
of C 54 650
these C 55 650
families C 56 650
. C 57 650
trans C 59 650
- C 60 650
mission C 61 650
to C 62 650
other C 63 650
family C 64 650
members C 65 650
occurred C 66 650
in C 67 650
23 C 68 650
of C 69 650
the C 70 650
36 C 71 650
families C 72 650
. C 73 650
in C 75 650
these C 76 650
23 C 77 650
families C 78 650
, C 79 650
84 C 80 650
% C 81 650
of C 82 650
the C 83 650
children C 84 650
and C 85 650
41 C 86 650
% C 87 650
of C 88 650
the C 89 650
adults C 90 650
were C 91 650
infected C 92 650
. C 93 650
the C 95 650
index C 96 650
cases C 97 650
are C 98 650
included C 99 650
. C 100 650
of C 102 650
the C 103 650
total C 104 650
59 C 105 650
patients C 106 650
with C 107 650
family C 108 650
- C 109 650
contact C 110 650
infections C 111 650
, C 112 650
42 C 113 650
had C 114 650
lower C 115 650
- C 116 650
respiratory C 117 650
- C 118 650
tract C 119 650
symptoms C 120 650
, C 121 650
6 C 122 650
had C 123 650
pharyngitis C 124 650
alone C 125 650
, C 126 650
9 C 127 650
( C 128 650
all C 129 650
children C 130 650
) C 131 650
were C 132 650
asympto C 133 650
- C 134 650
matic C 135 650
, C 136 650
and C 137 650
2 C 138 650
had C 139 650
probably C 140 650
unrelated C 141 650
symptoms C 142 650
. C 143 650
the C 145 650
time C 146 650
intervals C 147 650
between C 148 650
cases C 149 650
within C 150 650
a C 151 650
family C 152 650
suggested C 153 650
a C 154 650
median C 155 650
incubation C 156 650
period C 157 650
of C 158 650
23 C 159 650
days C 160 650
. C 161 650
treatment C 163 650
with C 164 650
tetracycline C 165 650
seemed C 166 650
neither C 167 650
to C 168 650
cure C 169 650
the C 170 650
symptoms C 171 650
com C 172 650
- C 173 650
pletely C 174 650
nor C 175 650
to C 176 650
abolish C 177 650
the C 178 650
carrier C 179 650
state C 180 650
that C 181 650
often C 182 650
lasted C 183 650
one C 184 650
to C 185 650
three C 186 650
months C 187 650
. C 188 650
case C 1 651
of C 2 651
salpingitis C 3 651
due C 4 651
to C 5 651
pleuro C 6 651
- C 7 651
pneumonalike C 8 651
organisms C 9 651
a C 10 651
case C 11 651
of C 12 651
acute C 13 651
salpingitis C 14 651
following C 15 651
a C 16 651
diagnostic C 17 651
curettage C 18 651
and C 19 651
aspiration C 20 651
of C 21 651
the C 22 651
pouch C 23 651
of C 24 651
douglas C 25 651
is C 26 651
described C 27 651
. C 28 651
this C 30 651
case C 31 651
was C 32 651
resistant C 33 651
to C 34 651
penicillin C 35 651
and C 36 651
streptomycin C 37 651
therapy C 38 651
. C 39 651
a C 41 651
pure C 42 651
culture C 43 651
of C 44 651
pleuropneu C 45 651
- C 46 651
monia C 47 651
like C 48 651
organisms C 49 651
( C 50 651
pplo C 51 651
) C 52 651
grew C 53 651
from C 54 651
pus C 55 651
removed C 56 651
from C 57 651
the C 58 651
secon C 59 651
- C 60 651
dary C 61 651
pyosalpinx C 62 651
by C 63 651
aspiration C 64 651
. C 65 651
these C 67 651
organisms C 68 651
were C 69 651
sensitive C 70 651
to C 71 651
tetra C 72 651
- C 73 651
cycline C 74 651
which C 75 651
cured C 76 651
the C 77 651
adnexal C 78 651
infection C 79 651
. C 80 651
no C 82 651
pplo C 83 651
were C 84 651
found C 85 651
in C 86 651
the C 87 651
vaginal C 88 651
discharge C 89 651
. C 90 651
pplo C 92 651
have C 93 651
frequently C 94 651
been C 95 651
isolated C 96 651
from C 97 651
the C 98 651
vaginae C 99 651
of C 100 651
healthy C 101 651
and C 102 651
infected C 103 651
women C 104 651
. C 105 651
however C 107 651
, C 108 651
only C 109 651
9 C 110 651
cases C 111 651
of C 112 651
pelvic C 113 651
inflammatory C 114 651
disease C 115 651
with C 116 651
a C 117 651
pure C 118 651
culture C 119 651
of C 120 651
pplo C 121 651
have C 122 651
been C 123 651
reported C 124 651
. C 125 651
the C 127 651
possibi C 128 651
- C 129 651
lity C 130 651
that C 131 651
these C 132 651
growths C 133 651
of C 134 651
pplo C 135 651
in C 136 651
the C 137 651
internal C 138 651
genitalia C 139 651
followed C 140 651
the C 141 651
use C 142 651
of C 143 651
antibiotic C 144 651
therapy C 145 651
is C 146 651
discussed C 147 651
. C 148 651
infection C 150 651
with C 151 651
pplo C 152 651
should C 153 651
be C 154 651
considered C 155 651
when C 156 651
pelvic C 157 651
inflam C 158 651
- C 159 651
matory C 160 651
disease C 161 651
proves C 162 651
resistant C 163 651
to C 164 651
the C 165 651
common C 166 651
antibiotics C 167 651
. C 168 651
the C 1 652
serological C 2 652
differentiation C 3 652
of C 4 652
mycoplasma C 5 652
strains C 6 652
( C 7 652
pleuro C 8 652
- C 9 652
pneumonia C 10 652
- C 11 652
like C 12 652
organisms C 13 652
) C 14 652
from C 15 652
various C 16 652
sources C 17 652
a C 18 652
complement C 19 652
fixation C 20 652
test C 21 652
with C 22 652
rabbit C 23 652
antisera C 24 652
was C 25 652
used C 26 652
to C 27 652
differentiate C 28 652
82 C 29 652
cultures C 30 652
of C 31 652
mycoplasma C 32 652
from C 33 652
man C 34 652
, C 35 652
mammalian C 36 652
cell C 37 652
cultures C 38 652
, C 39 652
laboratory C 40 652
rats C 41 652
and C 42 652
mice C 43 652
, C 44 652
cattle C 45 652
, C 46 652
goats C 47 652
, C 48 652
poultry C 49 652
, C 50 652
embryonated C 51 652
eggs C 52 652
and C 53 652
sewage C 54 652
. C 55 652
seventeen C 57 652
serotypes C 58 652
were C 59 652
distinguished C 60 652
, C 61 652
5 C 62 652
from C 63 652
man C 64 652
, C 65 652
1 C 66 652
from C 67 652
mammalian C 68 652
cell C 69 652
cultures C 70 652
, C 71 652
4 C 72 652
from C 73 652
rats C 74 652
and C 75 652
mice C 76 652
, C 77 652
4 C 78 652
from C 79 652
cattle C 80 652
and C 81 652
goats C 82 652
, C 83 652
2 C 84 652
from C 85 652
poultry C 86 652
and C 87 652
one C 88 652
saprophytic C 89 652
. C 90 652
most C 92 652
of C 93 652
these C 94 652
corresponded C 95 652
to C 96 652
recognized C 97 652
species C 98 652
of C 99 652
mycoplasma C 100 652
, C 101 652
but C 102 652
1 C 103 652
of C 104 652
human C 105 652
origin C 106 652
( C 107 652
represented C 108 652
by C 109 652
1 C 110 652
strain C 111 652
, C 112 652
navel C 113 652
) C 114 652
, C 115 652
and C 116 652
1 C 117 652
from C 118 652
tissue C 119 652
cultures C 120 652
( C 121 652
5 C 122 652
strains C 123 652
) C 124 652
, C 125 652
may C 126 652
represent C 127 652
new C 128 652
species C 129 652
. C 130 652
r C 132 652
38 C 133 652
, C 134 652
one C 135 652
of C 136 652
the C 137 652
serotypes C 138 652
from C 139 652
rats C 140 652
, C 141 652
could C 142 652
be C 143 652
distinguished C 144 652
from C 145 652
the C 146 652
species C 147 652
m C 148 652
. C 149 652
arthritidis C 151 652
, C 152 652
but C 153 652
is C 154 652
probably C 155 652
an C 156 652
antigenic C 157 652
variant C 158 652
rather C 159 652
than C 160 652
a C 161 652
distinct C 162 652
species C 163 652
. C 164 652
two C 166 652
species C 167 652
hitherto C 168 652
recognized C 169 652
as C 170 652
distinct C 171 652
m C 172 652
. C 173 652
arthritidis C 175 652
and C 176 652
m C 177 652
. C 178 652
hominis C 180 652
type C 181 652
2 C 182 652
, C 183 652
could C 184 652
not C 185 652
be C 186 652
distinguished C 187 652
and C 188 652
appear C 189 652
to C 190 652
constitute C 191 652
a C 192 652
single C 193 652
species C 194 652
. C 195 652
these C 197 652
findings C 198 652
illustrate C 199 652
the C 200 652
necessity C 201 652
, C 202 652
from C 203 652
the C 204 652
viewpoint C 205 652
of C 206 652
taxonomy C 207 652
, C 208 652
of C 209 652
comparing C 210 652
mycoplasma C 211 652
strains C 212 652
by C 213 652
serological C 214 652
methods C 215 652
. C 216 652
the C 218 652
serotypes C 219 652
of C 220 652
human C 221 652
and C 222 652
animal C 223 652
origin C 224 652
were C 225 652
largely C 226 652
host C 227 652
- C 228 652
specific C 229 652
. C 230 652
exceptions C 232 652
were C 233 652
the C 234 652
inclusion C 235 652
of C 236 652
m C 237 652
. C 238 652
arthritidis C 240 652
from C 241 652
rats C 242 652
and C 243 652
m C 244 652
. C 245 652
hominis C 247 652
type C 248 652
2 C 249 652
from C 250 652
man C 251 652
in C 252 652
a C 253 652
single C 254 652
serotype C 255 652
, C 256 652
the C 257 652
finding C 258 652
of C 259 652
a C 260 652
bovine C 261 652
organism C 262 652
among C 263 652
the C 264 652
strains C 265 652
isolated C 266 652
from C 267 652
goats C 268 652
and C 269 652
of C 270 652
a C 271 652
saprophytic C 272 652
strain C 273 652
in C 274 652
a C 275 652
rat C 276 652
. C 277 652
in C 279 652
relation C 280 652
to C 281 652
the C 282 652
aetiology C 283 652
of C 284 652
disease C 285 652
in C 286 652
man C 287 652
and C 288 652
animals C 289 652
, C 290 652
the C 291 652
isolation C 292 652
of C 293 652
an C 294 652
endogenous C 295 652
mycoplasma C 296 652
from C 297 652
embryonated C 298 652
eggs C 299 652
used C 300 652
to C 301 652
passage C 302 652
infective C 303 652
material C 304 652
illustrates C 305 652
the C 306 652
importance C 307 652
of C 308 652
identifying C 309 652
these C 310 652
organisms C 311 652
serologically C 312 652
. C 313 652
the C 315 652
demonstration C 316 652
of C 317 652
mixed C 318 652
mycoplasma C 319 652
infections C 320 652
in C 321 652
lesions C 322 652
in C 323 652
two C 324 652
rats C 325 652
shows C 326 652
the C 327 652
necessity C 328 652
of C 329 652
adequately C 330 652
purifying C 331 652
all C 332 652
cultures C 333 652
of C 334 652
mycoplasma C 335 652
before C 336 652
examination C 337 652
. C 338 652
spiramycin C 1 653
in C 2 653
the C 3 653
treatment C 4 653
of C 5 653
experimental C 6 653
mycoplasmosis C 7 653
in C 8 653
day C 9 653
- C 10 653
old C 11 653
chicks C 12 653
and C 13 653
turkey C 14 653
poults C 15 653
day C 16 653
- C 17 653
old C 18 653
chicks C 19 653
and C 20 653
turkey C 21 653
poults C 22 653
experimentally C 23 653
infected C 24 653
with C 25 653
m C 26 653
. C 27 653
gallisepticum C 29 653
have C 30 653
been C 31 653
treated C 32 653
at C 33 653
the C 34 653
time C 35 653
of C 36 653
infection C 37 653
, C 38 653
with C 39 653
spiramycin C 40 653
administered C 41 653
by C 42 653
subcutaneous C 43 653
injection C 44 653
or C 45 653
drinking C 46 653
water C 47 653
medication C 48 653
. C 49 653
a C 51 653
dose C 52 653
of C 53 653
100 C 54 653
mg C 55 653
/ C 56 653
kg C 57 653
. C 58 653
bodyweight C 60 653
by C 61 653
subcutaneous C 62 653
injection C 63 653
or C 64 653
an C 65 653
0 C 66 653
. C 67 653
. C 68 653
. C 68 653
per C 69 653
cent C 70 653
. C 71 653
concentration C 73 653
in C 74 653
the C 75 653
drinking C 76 653
water C 77 653
continuously C 78 653
for C 79 653
three C 80 653
days C 81 653
eliminated C 82 653
the C 83 653
infection C 84 653
in C 85 653
most C 86 653
of C 87 653
the C 88 653
birds C 89 653
, C 90 653
which C 91 653
remained C 92 653
free C 93 653
of C 94 653
air C 95 653
- C 96 653
sac C 97 653
lesions C 98 653
and C 99 653
did C 100 653
not C 101 653
react C 102 653
to C 103 653
the C 104 653
slide C 105 653
agg C 106 653
- C 107 653
lutination C 108 653
or C 109 653
haemagglutination C 110 653
inhibition C 111 653
tests C 112 653
. C 113 653
further C 1 654
studies C 2 654
of C 3 654
agents C 4 654
isolated C 5 654
from C 6 654
tissue C 7 654
cultures C 8 654
inoculated C 9 654
with C 10 654
human C 11 654
leukaemic C 12 654
bone C 13 654
- C 14 654
marrow C 15 654
d C 16 654
. C 17 654
a C 19 654
. C 20 654
woods C 22 654
mycoplasmas C 23 654
were C 24 654
isolated C 25 654
from C 26 654
tissue C 27 654
cultures C 28 654
inoculated C 29 654
with C 30 654
bone C 31 654
- C 32 654
marrow C 33 654
from C 34 654
leukaemic C 35 654
patients C 36 654
. C 37 654
all C 39 654
cultures C 40 654
which C 41 654
showed C 42 654
a C 43 654
cytopathic C 44 654
effect C 45 654
contained C 46 654
mycoplasmas C 47 654
. C 48 654
there C 50 654
was C 51 654
no C 52 654
evidence C 53 654
of C 54 654
mycoplasmas C 55 654
in C 56 654
control C 57 654
cultures C 58 654
. C 59 654
the C 61 654
mycoplasmas C 62 654
isolated C 63 654
seemed C 64 654
biologically C 65 654
and C 66 654
serologic C 67 654
- C 68 654
ally C 69 654
to C 70 654
be C 71 654
of C 72 654
one C 73 654
strain C 74 654
which C 75 654
was C 76 654
different C 77 654
from C 78 654
any C 79 654
previously C 80 654
reported C 81 654
as C 82 654
being C 83 654
isolated C 84 654
from C 85 654
human C 86 654
sources C 87 654
although C 88 654
there C 89 654
was C 90 654
some C 91 654
relationship C 92 654
to C 93 654
a C 94 654
rodent C 95 654
mycoplasma C 96 654
, C 97 654
m C 98 654
. C 99 654
pulmonis C 101 654
. C 102 654
mycoplasmas C 104 654
cannot C 105 654
readily C 106 654
be C 107 654
distinguished C 108 654
from C 109 654
viruses C 110 654
electron C 111 654
- C 112 654
microscopically C 113 654
. C 114 654
the C 116 654
relationship C 117 654
of C 118 654
mycoplasmas C 119 654
to C 120 654
leukaemia C 121 654
is C 122 654
not C 123 654
yet C 124 654
clear C 125 654
. C 126 654
microbiological C 1 655
studies C 2 655
of C 3 655
reiter C 4 655
' C 5 655
s C 6 655
disease C 7 655
attempts C 8 655
were C 9 655
made C 10 655
to C 11 655
demonstrate C 12 655
viruses C 13 655
and C 14 655
pplo C 15 655
in C 16 655
body C 17 655
fluids C 18 655
and C 19 655
synovial C 20 655
tissues C 21 655
of C 22 655
patients C 23 655
with C 24 655
various C 25 655
rheumatic C 26 655
diseases C 27 655
. C 28 655
all C 30 655
attempts C 31 655
to C 32 655
demonstrate C 33 655
viruses C 34 655
were C 35 655
negative C 36 655
. C 37 655
pplo C 39 655
were C 40 655
looked C 41 655
for C 42 655
in C 43 655
499 C 44 655
specimens C 45 655
from C 46 655
114 C 47 655
patients C 48 655
with C 49 655
rheumatic C 50 655
and C 51 655
non C 52 655
- C 53 655
rheumatic C 54 655
diseases C 55 655
. C 56 655
whereas C 58 655
these C 59 655
organisms C 60 655
were C 61 655
readily C 62 655
isolated C 63 655
from C 64 655
genito C 65 655
- C 66 655
urinary C 67 655
specimens C 68 655
, C 69 655
they C 70 655
were C 71 655
found C 72 655
in C 73 655
none C 74 655
of C 75 655
31 C 76 655
synovial C 77 655
fluid C 78 655
specimens C 79 655
. C 80 655
they C 82 655
could C 83 655
not C 84 655
be C 85 655
grown C 86 655
from C 87 655
synovial C 88 655
tissue C 89 655
biopsies C 90 655
of C 91 655
patients C 92 655
with C 93 655
rheumatoid C 94 655
arthritis C 95 655
, C 96 655
ankylosing C 97 655
spondylitis C 98 655
, C 99 655
gout C 100 655
, C 101 655
gonococcal C 102 655
arthritis C 103 655
, C 104 655
psoriatic C 105 655
arthritis C 106 655
, C 107 655
traumatic C 108 655
arthritis C 109 655
, C 110 655
or C 111 655
arthritis C 112 655
accompanying C 113 655
ulcerative C 114 655
colitis C 115 655
, C 116 655
but C 117 655
they C 118 655
were C 119 655
present C 120 655
in C 121 655
one C 122 655
and C 123 655
possibly C 124 655
in C 125 655
two C 126 655
of C 127 655
eight C 128 655
synovial C 129 655
tissue C 130 655
specimens C 131 655
from C 132 655
patients C 133 655
with C 134 655
reiter C 135 655
' C 136 655
s C 137 655
disease C 138 655
. C 139 655
complement C 141 655
- C 142 655
fixation C 143 655
tests C 144 655
were C 145 655
negative C 146 655
in C 147 655
nine C 148 655
patients C 149 655
with C 150 655
reiter C 151 655
' C 152 655
s C 153 655
disease C 154 655
, C 155 655
including C 156 655
the C 157 655
two C 158 655
from C 159 655
whose C 160 655
synovial C 161 655
tissues C 162 655
pplo C 163 655
were C 164 655
thought C 165 655
to C 166 655
have C 167 655
been C 168 655
isolated C 169 655
. C 170 655
recovery C 1 656
of C 2 656
a C 3 656
pleuropneumonia C 4 656
- C 5 656
like C 6 656
organism C 7 656
( C 8 656
p C 9 656
. C 10 656
. C 11 656
. C 12 656
. C 13 656
. C 14 656
. C 15 656
. C 16 656
) C 18 656
from C 19 656
the C 20 656
genitalia C 21 656
of C 22 656
the C 23 656
female C 24 656
albino C 25 656
rat C 26 656
the C 27 656
genital C 28 656
organs C 29 656
of C 30 656
seventy C 31 656
- C 32 656
seven C 33 656
nonproductive C 34 656
breeder C 35 656
female C 36 656
rats C 37 656
were C 38 656
examined C 39 656
grossly C 40 656
and C 41 656
histologically C 42 656
and C 43 656
bacteriological C 44 656
cultures C 45 656
of C 46 656
the C 47 656
uterus C 48 656
and C 49 656
ovaries C 50 656
were C 51 656
made C 52 656
. C 53 656
three C 55 656
of C 56 656
the C 57 656
seventy C 58 656
- C 59 656
seven C 60 656
animals C 61 656
showed C 62 656
a C 63 656
purulent C 64 656
salpingitis C 65 656
and C 66 656
oophoritis C 67 656
. C 68 656
a C 70 656
pleuropneumonia C 71 656
- C 72 656
like C 73 656
organism C 74 656
was C 75 656
isolated C 76 656
from C 77 656
the C 78 656
uterus C 79 656
and C 80 656
ovaries C 81 656
of C 82 656
29 C 83 656
% C 84 656
of C 85 656
the C 86 656
animals C 87 656
examined C 88 656
. C 89 656
the C 91 656
cultures C 92 656
obtained C 93 656
from C 94 656
the C 95 656
genitalia C 96 656
were C 97 656
compared C 98 656
with C 99 656
the C 100 656
p C 101 656
. C 102 656
. C 103 656
. C 104 656
. C 105 656
. C 106 656
. C 107 656
. C 108 656
isolated C 110 656
from C 111 656
the C 112 656
middle C 113 656
ears C 114 656
of C 115 656
some C 116 656
of C 117 656
these C 118 656
same C 119 656
animals C 120 656
and C 121 656
the C 122 656
two C 123 656
appeared C 124 656
to C 125 656
be C 126 656
identical C 127 656
. C 128 656
intraperitoneal C 130 656
injection C 131 656
of C 132 656
the C 133 656
p C 134 656
. C 135 656
. C 136 656
. C 137 656
. C 138 656
. C 139 656
. C 140 656
. C 141 656
cultures C 143 656
into C 144 656
young C 145 656
rats C 146 656
and C 147 656
mice C 148 656
produced C 149 656
oophoritis C 150 656
and C 151 656
salpingitis C 152 656
in C 153 656
the C 154 656
mice C 155 656
but C 156 656
not C 157 656
in C 158 656
the C 159 656
rats C 160 656
. C 161 656
chronic C 1 657
respiratory C 2 657
disease C 3 657
in C 4 657
mice C 5 657
and C 6 657
rats C 7 657
chronic C 8 657
respiratory C 9 657
disease C 10 657
( C 11 657
crd C 12 657
) C 13 657
in C 14 657
both C 15 657
mice C 16 657
and C 17 657
rats C 18 657
embraces C 19 657
two C 20 657
separate C 21 657
entities C 22 657
, C 23 657
namely C 24 657
: C 25 657
infectious C 26 657
catarrh C 27 657
caused C 28 657
by C 29 657
mycoplasmas C 30 657
( C 31 657
pleuropneumonia C 32 657
- C 33 657
like C 34 657
organisms C 35 657
) C 36 657
and C 37 657
enzootic C 38 657
bronchiectasis C 39 657
by C 40 657
a C 41 657
virus C 42 657
. C 43 657
the C 45 657
two C 46 657
syndromes C 47 657
are C 48 657
discussed C 49 657
in C 50 657
regard C 51 657
to C 52 657
their C 53 657
etiology C 54 657
, C 55 657
pathologic C 56 657
manifestations C 57 657
, C 58 657
and C 59 657
transmission C 60 657
. C 61 657
particular C 63 657
attention C 64 657
is C 65 657
paid C 66 657
to C 67 657
the C 68 657
relation C 69 657
of C 70 657
mycoplasmas C 71 657
to C 72 657
infectious C 73 657
catarrh C 74 657
. C 75 657
the C 77 657
morphologic C 78 657
and C 79 657
cultural C 80 657
characteristics C 81 657
of C 82 657
the C 83 657
catarrhal C 84 657
types C 85 657
of C 86 657
these C 87 657
organisms C 88 657
are C 89 657
considered C 90 657
from C 91 657
the C 92 657
standpoint C 93 657
of C 94 657
differential C 95 657
diagnosis C 96 657
. C 97 657
the C 99 657
importance C 100 657
of C 101 657
crd C 102 657
in C 103 657
the C 104 657
maintenance C 105 657
of C 106 657
breeding C 107 657
colonies C 108 657
and C 109 657
in C 110 657
the C 111 657
use C 112 657
of C 113 657
animals C 114 657
for C 115 657
experimental C 116 657
purposes C 117 657
is C 118 657
stressed C 119 657
. C 120 657
methods C 122 657
for C 123 657
the C 124 657
establishment C 125 657
of C 126 657
specific C 127 657
pathogen C 128 657
- C 129 657
free C 130 657
colonies C 131 657
, C 132 657
as C 133 657
a C 134 657
means C 135 657
of C 136 657
control C 137 657
, C 138 657
are C 139 657
briefly C 140 657
outlined C 141 657
together C 142 657
with C 143 657
observations C 144 657
on C 145 657
a C 146 657
cesarean C 147 657
- C 148 657
derived C 149 657
line C 150 657
of C 151 657
swiss C 152 657
mice C 153 657
. C 154 657
further C 1 658
observations C 2 658
of C 3 658
the C 4 658
lymphomas C 5 658
of C 6 658
african C 7 658
children C 8 658
during C 9 658
1963 C 10 658
, C 11 658
cytopathogenic C 12 658
, C 13 658
filtrable C 14 658
agents C 15 658
were C 16 658
frequently C 17 658
encountered C 18 658
in C 19 658
cultures C 20 658
of C 21 658
embryonic C 22 658
human C 23 658
kidney C 24 658
cells C 25 658
following C 26 658
their C 27 658
inoculation C 28 658
with C 29 658
supernatant C 30 658
fluids C 31 658
from C 32 658
primary C 33 658
human C 34 658
amnion C 35 658
cultures C 36 658
which C 37 658
had C 38 658
previously C 39 658
been C 40 658
exposed C 41 658
to C 42 658
extracts C 43 658
of C 44 658
tumors C 45 658
and C 46 658
other C 47 658
specimens C 48 658
from C 49 658
east C 50 658
african C 51 658
children C 52 658
with C 53 658
malignant C 54 658
lymphomas C 55 658
of C 56 658
the C 57 658
kind C 58 658
described C 59 658
by C 60 658
burkitt C 61 658
and C 62 658
others C 63 658
. C 64 658
the C 66 658
results C 67 658
seemed C 68 658
noteworthy C 69 658
because C 70 658
they C 71 658
suggested C 72 658
an C 73 658
intimate C 74 658
association C 75 658
between C 76 658
the C 77 658
agents C 78 658
and C 79 658
the C 80 658
disease C 81 658
, C 82 658
and C 83 658
also C 84 658
because C 85 658
of C 86 658
the C 87 658
nature C 88 658
of C 89 658
the C 90 658
isolations C 91 658
which C 92 658
involved C 93 658
two C 94 658
phenomena C 95 658
, C 96 658
an C 97 658
initial C 98 658
induction C 99 658
of C 100 658
a C 101 658
peculiar C 102 658
spindling C 103 658
and C 104 658
twisting C 105 658
of C 106 658
the C 107 658
amnion C 108 658
cells C 109 658
( C 110 658
fig C 111 658
. C 112 658
1 C 114 658
) C 115 658
and C 116 658
subsequently C 117 658
destructive C 118 658
changes C 119 658
in C 120 658
kidney C 121 658
cells C 122 658
inoculated C 123 658
with C 124 658
fluid C 125 658
from C 126 658
such C 127 658
altered C 128 658
amnion C 129 658
cultures C 130 658
. C 131 658
the C 133 658
direct C 134 658
inoculation C 135 658
of C 136 658
embryonic C 137 658
kidney C 138 658
cells C 139 658
with C 140 658
extracts C 141 658
of C 142 658
tumors C 143 658
or C 144 658
bone C 145 658
marrow C 146 658
never C 147 658
caused C 148 658
cytopathogenic C 149 658
effects C 150 658
nor C 151 658
did C 152 658
the C 153 658
isolated C 154 658
, C 155 658
transmissible C 156 658
agents C 157 658
have C 158 658
the C 159 658
capacity C 160 658
to C 161 658
induce C 162 658
the C 163 658
amnion C 164 658
lesions C 165 658
. C 166 658
nevertheless C 168 658
, C 169 658
the C 170 658
two C 171 658
effects C 172 658
were C 173 658
closely C 174 658
associated C 175 658
and C 176 658
clearly C 177 658
related C 178 658
to C 179 658
the C 180 658
specimens C 181 658
. C 182 658
the C 184 658
cytopathogenic C 185 658
agents C 186 658
were C 187 658
later C 188 658
cultivated C 189 658
on C 190 658
protein C 191 658
- C 192 658
rich C 193 658
media C 194 658
and C 195 658
found C 196 658
to C 197 658
have C 198 658
the C 199 658
characteristics C 200 658
of C 201 658
mycoplasma C 202 658
. C 203 658
they C 205 658
failed C 206 658
to C 207 658
induce C 208 658
tumors C 209 658
in C 210 658
a C 211 658
variety C 212 658
of C 213 658
animals C 214 658
, C 215 658
and C 216 658
serologic C 217 658
tests C 218 658
in C 219 658
which C 220 658
they C 221 658
served C 222 658
as C 223 658
antigen C 224 658
gave C 225 658
suggestive C 226 658
but C 227 658
inconclusive C 228 658
evidence C 229 658
of C 230 658
a C 231 658
relationship C 232 658
to C 233 658
the C 234 658
disease C 235 658
. C 236 658
the C 238 658
mycoplasma C 239 658
also C 240 658
failed C 241 658
to C 242 658
induce C 243 658
the C 244 658
amnion C 245 658
lesions C 246 658
caused C 247 658
by C 248 658
the C 249 658
specimens C 250 658
. C 251 658
mycoplasma C 1 659
species C 2 659
of C 3 659
man C 4 659
at C 5 659
present C 6 659
, C 7 659
six C 8 659
distinct C 9 659
species C 10 659
of C 11 659
mycoplasmas C 12 659
are C 13 659
known C 14 659
to C 15 659
infect C 16 659
man C 17 659
. C 18 659
certain C 20 659
biological C 21 659
and C 22 659
ecological C 23 659
properties C 24 659
of C 25 659
these C 26 659
agents C 27 659
have C 28 659
been C 29 659
defined C 30 659
. C 31 659
one C 33 659
species C 34 659
, C 35 659
m C 36 659
. C 37 659
pneumoniae C 39 659
, C 40 659
has C 41 659
been C 42 659
definitely C 43 659
shown C 44 659
to C 45 659
be C 46 659
an C 47 659
important C 48 659
respiratory C 49 659
- C 50 659
tract C 51 659
pathogen C 52 659
, C 53 659
and C 54 659
another C 55 659
species C 56 659
, C 57 659
m C 58 659
. C 59 659
hominis C 61 659
type C 62 659
1 C 63 659
, C 64 659
may C 65 659
play C 66 659
a C 67 659
role C 68 659
in C 69 659
respiratory C 70 659
- C 71 659
tract C 72 659
and C 73 659
genital C 74 659
- C 75 659
tract C 76 659
disease C 77 659
. C 78 659
pleuropneumonia C 1 660
- C 2 660
like C 3 660
organisms C 4 660
despite C 5 660
their C 6 660
small C 7 660
size C 8 660
, C 9 660
the C 10 660
pplo C 11 660
carry C 12 660
the C 13 660
full C 14 660
complement C 15 660
of C 16 660
the C 17 660
chemical C 18 660
com C 19 660
- C 20 660
pounds C 21 660
and C 22 660
enzymes C 23 660
contained C 24 660
in C 25 660
larger C 26 660
bacteria C 27 660
and C 28 660
in C 29 660
cells C 30 660
. C 31 660
they C 33 660
contain C 34 660
both C 35 660
dna C 36 660
and C 37 660
rna C 38 660
, C 39 660
and C 40 660
in C 41 660
their C 42 660
independent C 43 660
metabolism C 44 660
they C 45 660
are C 46 660
essentially C 47 660
like C 48 660
other C 49 660
free C 50 660
living C 51 660
cells C 52 660
in C 53 660
contrast C 54 660
to C 55 660
the C 56 660
viruses C 57 660
which C 58 660
have C 59 660
no C 60 660
independent C 61 660
metabolism C 62 660
outside C 63 660
the C 64 660
living C 65 660
host C 66 660
cell C 67 660
. C 68 660
several C 70 660
strains C 71 660
of C 72 660
pplo C 73 660
have C 74 660
been C 75 660
cultivated C 76 660
from C 77 660
the C 78 660
mucous C 79 660
membranes C 80 660
of C 81 660
apparently C 82 660
normal C 83 660
human C 84 660
subjects C 85 660
, C 86 660
espe C 87 660
- C 88 660
cially C 89 660
from C 90 660
the C 91 660
respiratory C 92 660
and C 93 660
urinary C 94 660
tracts C 95 660
. C 96 660
until C 98 660
recently C 99 660
, C 100 660
however C 101 660
, C 102 660
definite C 103 660
evidence C 104 660
of C 105 660
the C 106 660
association C 107 660
between C 108 660
the C 109 660
pplo C 110 660
and C 111 660
clear C 112 660
- C 113 660
ly C 114 660
defined C 115 660
clinical C 116 660
disease C 117 660
in C 118 660
the C 119 660
human C 120 660
sub C 121 660
- C 122 660
ject C 123 660
was C 124 660
lacking C 125 660
. C 126 660
in C 128 660
1962 C 129 660
it C 130 660
became C 131 660
evident C 132 660
that C 133 660
the C 134 660
so C 135 660
- C 136 660
called C 137 660
eaton C 138 660
" C 139 660
virus C 140 660
, C 141 660
" C 142 660
originally C 143 660
isolated C 144 660
by C 145 660
eaton C 146 660
and C 147 660
his C 148 660
associates C 149 660
in C 150 660
1944 C 151 660
from C 152 660
patients C 153 660
with C 154 660
primary C 155 660
atypical C 156 660
pneu C 157 660
- C 158 660
monia C 159 660
, C 160 660
was C 161 660
in C 162 660
reality C 163 660
a C 164 660
pleuropneumonia C 165 660
- C 166 660
like C 167 660
organism C 168 660
. C 169 660
typical C 171 660
pplo C 172 660
colonies C 173 660
are C 174 660
pro C 175 660
- C 176 660
duced C 177 660
on C 178 660
a C 179 660
cell C 180 660
- C 181 660
free C 182 660
agar C 183 660
medium C 184 660
which C 185 660
is C 186 660
enriched C 187 660
by C 188 660
the C 189 660
addition C 190 660
of C 191 660
blood C 192 660
serum C 193 660
or C 194 660
yeast C 195 660
. C 196 660
a C 198 660
number C 199 660
of C 200 660
strains C 201 660
of C 202 660
pplo C 203 660
has C 204 660
now C 205 660
been C 206 660
identified C 207 660
, C 208 660
and C 209 660
in C 210 660
recognition C 211 660
of C 212 660
their C 213 660
unique C 214 660
characteristics C 215 660
, C 216 660
they C 217 660
have C 218 660
been C 219 660
classi C 220 660
- C 221 660
fied C 222 660
in C 223 660
a C 224 660
separate C 225 660
order C 226 660
, C 227 660
the C 228 660
mycoplasmatales C 229 660
, C 230 660
genus C 231 660
mycoplasma C 232 660
. C 233 660
problems C 1 661
of C 2 661
disease C 3 661
of C 4 661
parathyroid C 5 661
glands C 6 661
if C 7 661
biochemical C 8 661
tests C 9 661
indicate C 10 661
unequivocally C 11 661
that C 12 661
there C 13 661
is C 14 661
a C 15 661
functioning C 16 661
parathyroid C 17 661
tumour C 18 661
, C 19 661
usually C 20 661
an C 21 661
adenoma C 22 661
, C 23 661
its C 24 661
removal C 25 661
will C 26 661
relieve C 27 661
symptoms C 28 661
and C 29 661
prevent C 30 661
any C 31 661
further C 32 661
damage C 33 661
to C 34 661
organs C 35 661
such C 36 661
as C 37 661
the C 38 661
kidneys C 39 661
. C 40 661
in C 42 661
80 C 43 661
per C 44 661
cent C 45 661
, C 46 661
of C 47 661
such C 48 661
cases C 49 661
the C 50 661
operation C 51 661
is C 52 661
not C 53 661
particularly C 54 661
difficult C 55 661
to C 56 661
anyone C 57 661
with C 58 661
experience C 59 661
of C 60 661
thyroid C 61 661
surgery C 62 661
. C 63 661
the C 65 661
tumour C 66 661
is C 67 661
seldom C 68 661
of C 69 661
great C 70 661
size C 71 661
, C 72 661
usually C 73 661
less C 74 661
than C 75 661
half C 76 661
an C 77 661
inch C 78 661
in C 79 661
diameter C 80 661
, C 81 661
but C 82 661
a C 83 661
careful C 84 661
search C 85 661
in C 86 661
the C 87 661
expected C 88 661
position C 89 661
, C 90 661
in C 91 661
close C 92 661
apposition C 93 661
to C 94 661
the C 95 661
posterior C 96 661
surface C 97 661
of C 98 661
the C 99 661
thyroid C 100 661
lobes C 101 661
, C 102 661
will C 103 661
usually C 104 661
reveal C 105 661
it C 106 661
. C 107 661
such C 109 661
adenomata C 110 661
are C 111 661
usually C 112 661
more C 113 661
brown C 114 661
in C 115 661
colour C 116 661
than C 117 661
the C 118 661
normal C 119 661
yellow C 120 661
gland C 121 661
; C 122 661
but C 123 661
in C 124 661
some C 125 661
20 C 126 661
per C 127 661
cent C 128 661
, C 129 661
of C 130 661
cases C 131 661
one C 132 661
or C 133 661
more C 134 661
of C 135 661
the C 136 661
glands C 137 661
may C 138 661
be C 139 661
aberrant C 140 661
, C 141 661
or C 142 661
possibly C 143 661
absent C 144 661
, C 145 661
and C 146 661
super C 147 661
- C 148 661
numerary C 149 661
glands C 150 661
may C 151 661
be C 152 661
present C 153 661
. C 154 661
it C 156 661
is C 157 661
usually C 158 661
one C 159 661
of C 160 661
the C 161 661
lower C 162 661
pair C 163 661
of C 164 661
glands C 165 661
which C 166 661
occupies C 167 661
an C 168 661
ectopic C 169 661
position C 170 661
and C 171 661
, C 172 661
as C 173 661
i C 174 661
explained C 175 661
in C 176 661
the C 177 661
outline C 178 661
of C 179 661
the C 180 661
embryological C 181 661
development C 182 661
, C 183 661
it C 184 661
may C 185 661
accompany C 186 661
the C 187 661
thymus C 188 661
into C 189 661
the C 190 661
mediasti C 191 661
- C 192 661
num C 193 661
, C 194 661
rather C 195 661
a C 196 661
vast C 197 661
area C 198 661
in C 199 661
which C 200 661
to C 201 661
seek C 202 661
a C 203 661
small C 204 661
tumour C 205 661
. C 206 661
such C 208 661
an C 209 661
exploration C 210 661
cannot C 211 661
be C 212 661
lightly C 213 661
undertaken C 214 661
, C 215 661
but C 216 661
if C 217 661
the C 218 661
evidence C 219 661
is C 220 661
indisputable C 221 661
the C 222 661
burden C 223 661
must C 224 661
be C 225 661
shouldered C 226 661
. C 227 661
it C 229 661
is C 230 661
correct C 231 661
policy C 232 661
, C 233 661
i C 234 661
believe C 235 661
, C 236 661
first C 237 661
to C 238 661
carry C 239 661
out C 240 661
a C 241 661
thorough C 242 661
exploration C 243 661
of C 244 661
the C 245 661
neck C 246 661
, C 247 661
and C 248 661
if C 249 661
this C 250 661
proves C 251 661
un C 252 661
- C 253 661
availing C 254 661
, C 255 661
to C 256 661
inspect C 257 661
the C 258 661
mediastinum C 259 661
through C 260 661
a C 261 661
sternum C 262 661
- C 263 661
splitting C 264 661
incision C 265 661
some C 266 661
two C 267 661
weeks C 268 661
later C 269 661
, C 270 661
rather C 271 661
than C 272 661
completing C 273 661
this C 274 661
major C 275 661
undertaking C 276 661
at C 277 661
one C 278 661
session C 279 661
. C 280 661
the C 1 662
age C 2 662
factor C 3 662
in C 4 662
experimental C 5 662
hypertension C 6 662
of C 7 662
the C 8 662
dca C 9 662
type C 10 662
in C 11 662
rats C 12 662
rats C 13 662
aged C 14 662
25 C 15 662
and C 16 662
86 C 17 662
days C 18 662
were C 19 662
sensibilised C 20 662
by C 21 662
unilateral C 22 662
nephrectomy C 23 662
and C 24 662
a C 25 662
week C 26 662
later C 27 662
were C 28 662
given C 29 662
1 C 30 662
. C 31 662
. C 32 662
mg C 33 662
/ C 34 662
100 C 35 662
g C 36 662
dca C 37 662
every C 38 662
third C 39 662
day C 40 662
for C 41 662
6 C 42 662
weeks C 43 662
and C 44 662
a C 45 662
1 C 46 662
% C 47 662
nacl C 48 662
solution C 49 662
to C 50 662
drink C 51 662
. C 52 662
the C 54 662
younger C 55 662
rats C 56 662
reacted C 57 662
with C 58 662
a C 59 662
greater C 60 662
increase C 61 662
in C 62 662
blood C 63 662
pressure C 64 662
, C 65 662
more C 66 662
so C 67 662
male C 68 662
rats C 69 662
. C 70 662
hypertrophy C 72 662
of C 73 662
the C 74 662
heart C 75 662
and C 76 662
kidneys C 77 662
and C 78 662
mortality C 79 662
and C 80 662
supression C 81 662
of C 82 662
growth C 83 662
were C 84 662
also C 85 662
all C 86 662
more C 87 662
evident C 88 662
in C 89 662
the C 90 662
younger C 91 662
age C 92 662
group C 93 662
. C 94 662
only C 96 662
male C 97 662
rats C 98 662
given C 99 662
the C 100 662
steroid C 101 662
hormone C 102 662
starting C 103 662
from C 104 662
day C 105 662
25 C 106 662
showed C 107 662
permanent C 108 662
suppression C 109 662
of C 110 662
growth C 111 662
. C 112 662
response C 1 663
of C 2 663
a C 3 663
serum C 4 663
glycoprotein C 5 663
to C 6 663
tissue C 7 663
injury C 8 663
and C 9 663
necrosis C 10 663
1 C 11 663
. C 12 663
the C 14 663
response C 15 663
to C 16 663
necrosis C 17 663
, C 18 663
hyperplasia C 19 663
and C 20 663
tumour C 21 663
growth C 22 663
a C 23 663
serum C 24 663
glycoprotein C 25 663
of C 26 663
the C 27 663
rat C 28 663
underwent C 29 663
a C 30 663
20 C 31 663
- C 32 663
fold C 33 663
increase C 34 663
during C 35 663
15 C 36 663
days C 37 663
growth C 38 663
of C 39 663
the C 40 663
walker C 41 663
tumour C 42 663
and C 43 663
this C 44 663
increase C 45 663
was C 46 663
not C 47 663
affected C 48 663
when C 49 663
the C 50 663
rats C 51 663
were C 52 663
treated C 53 663
with C 54 663
terramycin C 55 663
. C 56 663
the C 58 663
protein C 59 663
increased C 60 663
at C 61 663
the C 62 663
same C 63 663
or C 64 663
a C 65 663
greater C 66 663
rate C 67 663
when C 68 663
rats C 69 663
were C 70 663
subjected C 71 663
to C 72 663
ischaemic C 73 663
necrosis C 74 663
of C 75 663
one C 76 663
kidney C 77 663
or C 78 663
of C 79 663
two C 80 663
- C 81 663
thirds C 82 663
of C 83 663
the C 84 663
liver C 85 663
. C 86 663
boiled C 88 663
kidney C 89 663
tissue C 90 663
, C 91 663
on C 92 663
the C 93 663
other C 94 663
hand C 95 663
, C 96 663
had C 97 663
little C 98 663
effect C 99 663
upon C 100 663
the C 101 663
protein C 102 663
response C 103 663
, C 104 663
and C 105 663
kidney C 106 663
hyperplasia C 107 663
had C 108 663
none C 109 663
. C 110 663
it C 112 663
is C 113 663
suggested C 114 663
that C 115 663
this C 116 663
protein C 117 663
increase C 118 663
is C 119 663
a C 120 663
response C 121 663
to C 122 663
substances C 123 663
liberated C 124 663
from C 125 663
damaged C 126 663
or C 127 663
necrotic C 128 663
cells C 129 663
. C 130 663
the C 1 664
natural C 2 664
history C 3 664
of C 4 664
autoimmune C 5 664
disease C 6 664
in C 7 664
nzb C 8 664
mice C 9 664
a C 10 664
comparison C 11 664
with C 12 664
the C 13 664
pattern C 14 664
of C 15 664
human C 16 664
autoimmune C 17 664
manifestations C 18 664
all C 19 664
mice C 20 664
of C 21 664
the C 22 664
nzb C 23 664
/ C 24 664
bl C 25 664
strain C 26 664
spon C 27 664
- C 28 664
taneously C 29 664
develop C 30 664
serological C 31 664
and C 32 664
pathological C 33 664
evidence C 34 664
of C 35 664
autoimmune C 36 664
dis C 37 664
- C 38 664
ease C 39 664
during C 40 664
adult C 41 664
life C 42 664
. C 43 664
the C 45 664
nzb C 46 664
/ C 47 664
bl C 48 664
strain C 49 664
was C 50 664
developed C 51 664
by C 52 664
dr C 53 664
. C 54 664
marianne C 56 664
bielschow C 57 664
- C 58 664
sky C 59 664
in C 60 664
dunedin C 61 664
, C 62 664
new C 63 664
zealand C 64 664
, C 65 664
by C 66 664
inbreed C 67 664
- C 68 664
ing C 69 664
from C 70 664
an C 71 664
outbred C 72 664
colony C 73 664
of C 74 664
mixed C 75 664
coat C 76 664
color C 77 664
. C 78 664
several C 80 664
inbred C 81 664
strains C 82 664
- C 83 664
- C 84 664
nzb C 85 664
, C 86 664
nzc C 87 664
, C 88 664
nzo C 89 664
, C 90 664
nzw C 91 664
, C 92 664
nzy C 93 664
, C 94 664
and C 95 664
others C 96 664
, C 97 664
have C 98 664
been C 99 664
evolved C 100 664
in C 101 664
dunedin C 102 664
from C 103 664
the C 104 664
original C 105 664
col C 106 664
- C 107 664
ony C 108 664
. C 109 664
evidence C 111 664
for C 112 664
autoimmune C 113 664
disease C 114 664
in C 115 664
the C 116 664
nzb C 117 664
strain C 118 664
was C 119 664
first C 120 664
reported C 121 664
by C 122 664
bielschowsky C 123 664
, C 124 664
helyer C 125 664
, C 126 664
and C 127 664
howie C 128 664
who C 129 664
found C 130 664
evidence C 131 664
of C 132 664
an C 133 664
autoimmune C 134 664
hemo C 135 664
- C 136 664
lytic C 137 664
anemia C 138 664
. C 139 664
the C 141 664
dunedin C 142 664
group C 143 664
used C 144 664
the C 145 664
presence C 146 664
of C 147 664
agglutinins C 148 664
for C 149 664
ficin C 150 664
- C 151 664
treated C 152 664
red C 153 664
cells C 154 664
as C 155 664
the C 156 664
index C 157 664
of C 158 664
the C 159 664
disease C 160 664
. C 161 664
the C 1 665
remaining C 2 665
kidney C 3 665
in C 4 665
irradiated C 5 665
survivors C 6 665
of C 7 665
wilms C 8 665
' C 9 665
s C 10 665
tumor C 11 665
the C 12 665
intravenous C 13 665
urograms C 14 665
of C 15 665
10 C 16 665
patients C 17 665
who C 18 665
had C 19 665
survived C 20 665
5 C 21 665
years C 22 665
after C 23 665
irradiation C 24 665
for C 25 665
wilms C 26 665
' C 27 665
s C 28 665
tumor C 29 665
were C 30 665
studied C 31 665
for C 32 665
kidney C 33 665
size C 34 665
and C 35 665
configuration C 36 665
. C 37 665
the C 39 665
diseased C 40 665
kidney C 41 665
had C 42 665
been C 43 665
removed C 44 665
by C 45 665
nephrectomy C 46 665
. C 47 665
the C 49 665
remaining C 50 665
kidneys C 51 665
had C 52 665
been C 53 665
sub C 54 665
- C 55 665
jected C 56 665
to C 57 665
varying C 58 665
doses C 59 665
of C 60 665
ionizing C 61 665
radia C 62 665
- C 63 665
tion C 64 665
at C 65 665
the C 66 665
time C 67 665
the C 68 665
area C 69 665
of C 70 665
the C 71 665
diseased C 72 665
kidney C 73 665
was C 74 665
irradiated C 75 665
. C 76 665
in C 78 665
none C 79 665
was C 80 665
there C 81 665
evidence C 82 665
of C 83 665
atrophy C 84 665
. C 85 665
all C 87 665
were C 88 665
within C 89 665
the C 90 665
range C 91 665
of C 92 665
expected C 93 665
normal C 94 665
size C 95 665
and C 96 665
most C 97 665
of C 98 665
them C 99 665
were C 100 665
enlarged C 101 665
. C 102 665
cellular C 1 666
proliferation C 2 666
and C 3 666
deoxyribonucleic C 4 666
acid C 5 666
synthesis C 6 666
in C 7 666
compensating C 8 666
kidneys C 9 666
of C 10 666
mice C 11 666
and C 12 666
the C 13 666
effect C 14 666
of C 15 666
food C 16 666
and C 17 666
water C 18 666
restriction C 19 666
compensatory C 20 666
enlargement C 21 666
of C 22 666
the C 23 666
kid C 24 666
- C 25 666
ney C 26 666
occurred C 27 666
after C 28 666
unilateral C 29 666
nephrectomy C 30 666
in C 31 666
mice C 32 666
. C 33 666
fourteen C 35 666
days C 36 666
after C 37 666
the C 38 666
removal C 39 666
of C 40 666
one C 41 666
kidney C 42 666
the C 43 666
surviving C 44 666
renal C 45 666
tissue C 46 666
6 C 47 666
weighed C 48 666
23 C 49 666
per C 50 666
cent C 51 666
more C 52 666
than C 53 666
single C 54 666
kid C 55 666
- C 56 666
neys C 57 666
from C 58 666
sham C 59 666
- C 60 666
operated C 61 666
animals C 62 666
. C 63 666
the C 65 666
hyperplastic C 66 666
response C 67 666
of C 68 666
the C 69 666
cortex C 70 666
on C 71 666
the C 72 666
second C 73 666
postoperative C 74 666
day C 75 666
was C 76 666
8 C 77 666
times C 78 666
greater C 79 666
than C 80 666
that C 81 666
seen C 82 666
in C 83 666
the C 84 666
same C 85 666
zone C 86 666
of C 87 666
kidneys C 88 666
from C 89 666
sham C 90 666
- C 91 666
operated C 92 666
animals C 93 666
. C 94 666
by C 96 666
10 C 97 666
days C 98 666
after C 99 666
surgery C 100 666
the C 101 666
mitotic C 102 666
index C 103 666
of C 104 666
the C 105 666
cortex C 106 666
returned C 107 666
to C 108 666
control C 109 666
values C 110 666
. C 111 666
the C 113 666
outer C 114 666
medulla C 115 666
also C 116 666
underwent C 117 666
hyperplasia C 118 666
but C 119 666
only C 120 666
on C 121 666
the C 122 666
second C 123 666
day C 124 666
following C 125 666
unilateral C 126 666
nephrectomy C 127 666
was C 128 666
the C 129 666
increase C 130 666
significant C 131 666
. C 132 666
an C 134 666
increase C 135 666
in C 136 666
mitotic C 137 666
activity C 138 666
was C 139 666
found C 140 666
in C 141 666
the C 142 666
inner C 143 666
medulla C 144 666
of C 145 666
surviving C 146 666
kidneys C 147 666
, C 148 666
but C 149 666
it C 150 666
was C 151 666
not C 152 666
statistically C 153 666
signifi C 154 666
- C 155 666
cant C 156 666
. C 157 666
both C 159 666
starvation C 160 666
for C 161 666
48 C 162 666
hours C 163 666
and C 164 666
water C 165 666
restriction C 166 666
for C 167 666
60 C 168 666
hours C 169 666
prevented C 170 666
the C 171 666
hyper C 172 666
- C 173 666
plastic C 174 666
responses C 175 666
in C 176 666
the C 177 666
remaining C 178 666
kidneys C 179 666
2 C 180 666
days C 181 666
after C 182 666
unilateral C 183 666
nephrectomy C 184 666
. C 185 666
when C 187 666
water C 188 666
was C 189 666
given C 190 666
48 C 191 666
hours C 192 666
after C 193 666
unilateral C 194 666
nephrectomy C 195 666
( C 196 666
after C 197 666
60 C 198 666
hours C 199 666
of C 200 666
water C 201 666
restriction C 202 666
) C 203 666
significant C 204 666
increases C 205 666
in C 206 666
mitotic C 207 666
activity C 208 666
were C 209 666
noted C 210 666
in C 211 666
the C 212 666
cortex C 213 666
of C 214 666
remain C 215 666
- C 216 666
ing C 217 666
kidneys C 218 666
on C 219 666
the C 220 666
fourth C 221 666
and C 222 666
fifth C 223 666
post C 224 666
- C 225 666
operative C 226 666
days C 227 666
. C 228 666
however C 230 666
, C 231 666
even C 232 666
after C 233 666
free C 234 666
access C 235 666
to C 236 666
food C 237 666
was C 238 666
allowed C 239 666
( C 240 666
after C 241 666
48 C 242 666
hours C 243 666
without C 244 666
food C 245 666
) C 246 666
no C 247 666
significant C 248 666
increase C 249 666
in C 250 666
mitotic C 251 666
frequency C 252 666
of C 253 666
the C 254 666
remaining C 255 666
kidney C 256 666
was C 257 666
found C 258 666
. C 259 666
deoxyribonucleic C 261 666
acid C 262 666
synthesis C 263 666
in C 264 666
con C 265 666
- C 266 666
trol C 267 666
kidneys C 268 666
of C 269 666
mice C 270 666
was C 271 666
highest C 272 666
in C 273 666
the C 274 666
cor C 275 666
- C 276 666
tex C 277 666
and C 278 666
lowest C 279 666
in C 280 666
the C 281 666
inner C 282 666
medulla C 283 666
as C 284 666
revealed C 285 666
by C 286 666
radioautographic C 287 666
studies C 288 666
fol C 289 666
- C 290 666
lowing C 291 666
the C 292 666
injection C 293 666
of C 294 666
tritiated C 295 666
thymidine C 296 666
. C 297 666
two C 299 666
days C 300 666
following C 301 666
removal C 302 666
of C 303 666
one C 304 666
kidney C 305 666
the C 306 666
labeling C 307 666
index C 308 666
of C 309 666
the C 310 666
cortex C 311 666
of C 312 666
remaining C 313 666
kidneys C 314 666
increased C 315 666
3 C 316 666
- C 317 666
fold C 318 666
. C 319 666
no C 321 666
statistically C 322 666
significant C 323 666
increases C 324 666
of C 325 666
deoxyribonucleic C 326 666
acid C 327 666
synthesis C 328 666
were C 329 666
noted C 330 666
in C 331 666
either C 332 666
the C 333 666
outer C 334 666
or C 335 666
inner C 336 666
medullary C 337 666
regions C 338 666
of C 339 666
the C 340 666
remaining C 341 666
kidneys C 342 666
. C 343 666
compensatory C 1 667
renal C 2 667
enlargement C 3 667
hypertrophy C 4 667
versus C 5 667
hyperplasia C 6 667
after C 7 667
unilateral C 8 667
nephrectomy C 9 667
in C 10 667
the C 11 667
mouse C 12 667
, C 13 667
the C 14 667
compensatory C 15 667
growth C 16 667
of C 17 667
the C 18 667
remaining C 19 667
kidney C 20 667
is C 21 667
characterized C 22 667
by C 23 667
an C 24 667
increase C 25 667
in C 26 667
rna C 27 667
and C 28 667
protein C 29 667
synthesis C 30 667
within C 31 667
the C 32 667
first C 33 667
hour C 34 667
. C 35 667
dna C 37 667
synthesis C 38 667
remains C 39 667
un C 40 667
- C 41 667
changed C 42 667
for C 43 667
about C 44 667
18 C 45 667
hours C 46 667
and C 47 667
then C 48 667
rises C 49 667
to C 50 667
a C 51 667
maximum C 52 667
at C 53 667
48 C 54 667
hours C 55 667
. C 56 667
by C 58 667
the C 59 667
end C 60 667
of C 61 667
the C 62 667
fifth C 63 667
day C 64 667
, C 65 667
when C 66 667
dna C 67 667
synthesis C 68 667
has C 69 667
passed C 70 667
its C 71 667
peak C 72 667
and C 73 667
is C 74 667
in C 75 667
decline C 76 667
, C 77 667
cellular C 78 667
hyperplasia C 79 667
has C 80 667
accounted C 81 667
for C 82 667
only C 83 667
one C 84 667
- C 85 667
fourth C 86 667
of C 87 667
the C 88 667
increase C 89 667
in C 90 667
kidney C 91 667
weight C 92 667
. C 93 667
thus C 95 667
it C 96 667
is C 97 667
shown C 98 667
that C 99 667
cell C 100 667
hypertrophy C 101 667
is C 102 667
both C 103 667
the C 104 667
primary C 105 667
and C 106 667
the C 107 667
predominant C 108 667
response C 109 667
in C 110 667
the C 111 667
early C 112 667
phase C 113 667
of C 114 667
compen C 115 667
- C 116 667
satory C 117 667
renal C 118 667
enlargement C 119 667
. C 120 667
cell C 1 668
proliferation C 2 668
in C 3 668
experimental C 4 668
hydronephrosis C 5 668
and C 6 668
compensatory C 7 668
renal C 8 668
hyperplasia C 9 668
mitosis C 10 668
counts C 11 668
and C 12 668
autoradiographic C 13 668
counts C 14 668
of C 15 668
nuclei C 16 668
labeled C 17 668
with C 18 668
tritiated C 19 668
thymidine C 20 668
were C 21 668
made C 22 668
in C 23 668
the C 24 668
renal C 25 668
cortex C 26 668
of C 27 668
male C 28 668
rats C 29 668
in C 30 668
which C 31 668
the C 32 668
left C 33 668
ureter C 34 668
was C 35 668
ligated C 36 668
. C 37 668
these C 39 668
were C 40 668
compared C 41 668
with C 42 668
corresponding C 43 668
counts C 44 668
in C 45 668
the C 46 668
remaining C 47 668
kidney C 48 668
after C 49 668
left C 50 668
nephrectomy C 51 668
, C 52 668
and C 53 668
in C 54 668
sham C 55 668
- C 56 668
operated C 57 668
controls C 58 668
24 C 59 668
, C 60 668
48 C 61 668
and C 62 668
72 C 63 668
hours C 64 668
after C 65 668
operation C 66 668
. C 67 668
the C 69 668
cortex C 70 668
of C 71 668
the C 72 668
kidney C 73 668
on C 74 668
the C 75 668
obstructed C 76 668
side C 77 668
showed C 78 668
a C 79 668
greater C 80 668
number C 81 668
of C 82 668
tritium C 83 668
- C 84 668
labeled C 85 668
nuclei C 86 668
and C 87 668
mitotic C 88 668
figures C 89 668
than C 90 668
in C 91 668
the C 92 668
kidney C 93 668
undergoing C 94 668
com C 95 668
- C 96 668
pensatory C 97 668
hyperplasia C 98 668
. C 99 668
epithelial C 101 668
and C 102 668
interstitial C 103 668
cells C 104 668
responded C 105 668
simul C 106 668
- C 107 668
taneously C 108 668
on C 109 668
the C 110 668
obstructed C 111 668
side C 112 668
, C 113 668
whereas C 114 668
in C 115 668
the C 116 668
remaining C 117 668
kidney C 118 668
after C 119 668
nephrectomy C 120 668
, C 121 668
the C 122 668
epithelial C 123 668
response C 124 668
preceded C 125 668
a C 126 668
slight C 127 668
interstitial C 128 668
re C 129 668
- C 130 668
sponse C 131 668
by C 132 668
48 C 133 668
hours C 134 668
. C 135 668
the C 137 668
contralateral C 138 668
kidney C 139 668
in C 140 668
rats C 141 668
subjected C 142 668
to C 143 668
ureteral C 144 668
ligation C 145 668
showed C 146 668
no C 147 668
response C 148 668
. C 149 668
we C 151 668
concluded C 152 668
that C 153 668
the C 154 668
early C 155 668
response C 156 668
of C 157 668
increased C 158 668
dna C 159 668
synthesis C 160 668
and C 161 668
cell C 162 668
division C 163 668
in C 164 668
the C 165 668
obstructed C 166 668
kidney C 167 668
was C 168 668
not C 169 668
mediated C 170 668
by C 171 668
humoral C 172 668
factors C 173 668
; C 174 668
it C 175 668
was C 176 668
localized C 177 668
and C 178 668
probably C 179 668
had C 180 668
a C 181 668
different C 182 668
mechanism C 183 668
than C 184 668
the C 185 668
proliferative C 186 668
response C 187 668
occurring C 188 668
in C 189 668
compensatory C 190 668
renal C 191 668
hyperplasia C 192 668
. C 193 668
renal C 1 669
factors C 2 669
in C 3 669
the C 4 669
pathogenesis C 5 669
of C 6 669
hypertension C 7 669
renal C 8 669
arteriography C 9 669
and C 10 669
other C 11 669
modern C 12 669
diagnostic C 13 669
procedures C 14 669
have C 15 669
provided C 16 669
the C 17 669
means C 18 669
of C 19 669
establishing C 20 669
a C 21 669
close C 22 669
relationship C 23 669
between C 24 669
high C 25 669
blood C 26 669
pressure C 27 669
and C 28 669
renovascular C 29 669
disease C 30 669
. C 31 669
many C 33 669
of C 34 669
these C 35 669
cases C 36 669
are C 37 669
amenable C 38 669
to C 39 669
surgical C 40 669
cure C 41 669
. C 42 669
at C 44 669
the C 45 669
present C 46 669
time C 47 669
there C 48 669
is C 49 669
no C 50 669
single C 51 669
test C 52 669
for C 53 669
the C 54 669
definitive C 55 669
diagnosis C 56 669
of C 57 669
renal C 58 669
hypertension C 59 669
. C 60 669
careful C 62 669
and C 63 669
intensive C 64 669
studies C 65 669
are C 66 669
mandatory C 67 669
in C 68 669
the C 69 669
selection C 70 669
of C 71 669
cases C 72 669
suitable C 73 669
for C 74 669
surgery C 75 669
, C 76 669
since C 77 669
hypertension C 78 669
has C 79 669
many C 80 669
etiologic C 81 669
factors C 82 669
and C 83 669
involves C 84 669
many C 85 669
complex C 86 669
and C 87 669
sometimes C 88 669
obscure C 89 669
mechanisms C 90 669
. C 91 669
aortography C 93 669
, C 94 669
intravenous C 95 669
urography C 96 669
and C 97 669
split C 98 669
- C 99 669
function C 100 669
tests C 101 669
are C 102 669
among C 103 669
the C 104 669
most C 105 669
important C 106 669
methods C 107 669
for C 108 669
definitive C 109 669
diagnosis C 110 669
and C 111 669
for C 112 669
the C 113 669
planning C 114 669
of C 115 669
appropriate C 116 669
surgical C 117 669
procedures C 118 669
. C 119 669
at C 121 669
operation C 122 669
, C 123 669
the C 124 669
most C 125 669
commonly C 126 669
observed C 127 669
cause C 128 669
of C 129 669
renal C 130 669
arterial C 131 669
con C 132 669
- C 133 669
striction C 134 669
in C 135 669
the C 136 669
elderly C 137 669
is C 138 669
atherosclerosis C 139 669
, C 140 669
whereas C 141 669
in C 142 669
younger C 143 669
patients C 144 669
it C 145 669
is C 146 669
hyperplasia C 147 669
of C 148 669
the C 149 669
intimal C 150 669
and C 151 669
muscular C 152 669
coats C 153 669
of C 154 669
the C 155 669
renal C 156 669
artery C 157 669
and C 158 669
its C 159 669
branches C 160 669
. C 161 669
renovascular C 163 669
surgery C 164 669
may C 165 669
require C 166 669
a C 167 669
variety C 168 669
of C 169 669
technical C 170 669
procedures C 171 669
. C 172 669
in C 174 669
the C 175 669
successful C 176 669
cases C 177 669
there C 178 669
is C 179 669
a C 180 669
striking C 181 669
and C 182 669
permanent C 183 669
reduction C 184 669
in C 185 669
blood C 186 669
pressure C 187 669
. C 188 669
the C 190 669
accuracy C 191 669
of C 192 669
blood C 193 669
pressure C 194 669
readings C 195 669
is C 196 669
emphasized C 197 669
, C 198 669
since C 199 669
hypertension C 200 669
is C 201 669
usually C 202 669
discovered C 203 669
for C 204 669
the C 205 669
first C 206 669
time C 207 669
during C 208 669
the C 209 669
course C 210 669
of C 211 669
a C 212 669
routine C 213 669
physical C 214 669
examination C 215 669
. C 216 669
cell C 1 670
proliferation C 2 670
in C 3 670
compensatory C 4 670
renal C 5 670
growth C 6 670
rats C 7 670
with C 8 670
one C 9 670
kidney C 10 670
removed C 11 670
showed C 12 670
a C 13 670
progressive C 14 670
increase C 15 670
in C 16 670
weight C 17 670
of C 18 670
the C 19 670
remaining C 20 670
kidney C 21 670
over C 22 670
a C 23 670
six C 24 670
- C 25 670
week C 26 670
period C 27 670
. C 28 670
autoradiographic C 30 670
and C 31 670
radiochemical C 32 670
studies C 33 670
with C 34 670
3 C 35 670
h C 36 670
- C 37 670
thymidine C 38 670
indicated C 39 670
that C 40 670
the C 41 670
increase C 42 670
in C 43 670
new C 44 670
kidney C 45 670
cell C 46 670
formation C 47 670
was C 48 670
maximal C 49 670
forty C 50 670
- C 51 670
eight C 52 670
to C 53 670
seventy C 54 670
- C 55 670
two C 56 670
hours C 57 670
after C 58 670
unilateral C 59 670
nephrectomy C 60 670
. C 61 670
this C 63 670
early C 64 670
response C 65 670
was C 66 670
chiefly C 67 670
due C 68 670
to C 69 670
the C 70 670
production C 71 670
of C 72 670
new C 73 670
cells C 74 670
by C 75 670
the C 76 670
renal C 77 670
cortical C 78 670
tubules C 79 670
. C 80 670
normal C 82 670
rates C 83 670
of C 84 670
tubule C 85 670
cell C 86 670
turnover C 87 670
were C 88 670
achieved C 89 670
two C 90 670
weeks C 91 670
after C 92 670
operation C 93 670
. C 94 670
the C 96 670
glomerular C 97 670
tufts C 98 670
contained C 99 670
fewer C 100 670
new C 101 670
cells C 102 670
and C 103 670
their C 104 670
peak C 105 670
production C 106 670
was C 107 670
delayed C 108 670
to C 109 670
the C 110 670
one C 111 670
- C 112 670
week C 113 670
period C 114 670
with C 115 670
a C 116 670
slow C 117 670
decline C 118 670
thereafter C 119 670
. C 120 670
rats C 122 670
forty C 123 670
- C 124 670
eight C 125 670
hours C 126 670
after C 127 670
unilateral C 128 670
nephrectomy C 129 670
were C 130 670
chosen C 131 670
as C 132 670
a C 133 670
model C 134 670
to C 135 670
study C 136 670
the C 137 670
effect C 138 670
of C 139 670
various C 140 670
substances C 141 670
on C 142 670
the C 143 670
magnitude C 144 670
of C 145 670
new C 146 670
cell C 147 670
formation C 148 670
. C 149 670
the C 151 670
number C 152 670
of C 153 670
dna C 154 670
- C 155 670
synthesising C 156 670
cells C 157 670
in C 158 670
the C 159 670
stimulated C 160 670
kidney C 161 670
was C 162 670
reduced C 163 670
by C 164 670
treatment C 165 670
with C 166 670
hydrocortisone C 167 670
, C 168 670
acth C 169 670
, C 170 670
9 C 171 670
, C 172 670
10 C 173 670
- C 174 670
dimethyl C 175 670
- C 176 670
1 C 177 670
, C 178 670
2 C 179 670
- C 180 670
benzanthracene C 181 670
, C 182 670
and C 183 670
1 C 184 670
, C 185 670
2 C 186 670
- C 187 670
benzanthracene C 188 670
; C 189 670
the C 190 670
numbers C 191 670
were C 192 670
increased C 193 670
by C 194 670
the C 195 670
administration C 196 670
of C 197 670
deoxycorticosterone C 198 670
and C 199 670
aldosterone C 200 670
. C 201 670
effects C 1 671
of C 2 671
adrenalectomy C 3 671
on C 4 671
the C 5 671
parathyroids C 6 671
in C 7 671
nephrectomized C 8 671
rats C 9 671
rat C 10 671
parathyroids C 11 671
were C 12 671
studied C 13 671
both C 14 671
after C 15 671
nephrectomy C 16 671
and C 17 671
after C 18 671
com C 19 671
- C 20 671
bined C 21 671
nephrectomy C 22 671
and C 23 671
adrenalectomy C 24 671
. C 25 671
as C 27 671
early C 28 671
as C 29 671
24 C 30 671
hours C 31 671
after C 32 671
nephrectomy C 33 671
there C 34 671
were C 35 671
morphological C 36 671
indications C 37 671
of C 38 671
increased C 39 671
para C 40 671
- C 41 671
thyroid C 42 671
activity C 43 671
in C 44 671
the C 45 671
form C 46 671
of C 47 671
increased C 48 671
glandular C 49 671
volume C 50 671
and C 51 671
enlarged C 52 671
cell C 53 671
nuclei C 54 671
. C 55 671
the C 57 671
corresponding C 58 671
changes C 59 671
after C 60 671
combined C 61 671
nephrectomy C 62 671
and C 63 671
adrenalectomy C 64 671
were C 65 671
less C 66 671
marked C 67 671
and C 68 671
the C 69 671
total C 70 671
serum C 71 671
calcium C 72 671
was C 73 671
higher C 74 671
than C 75 671
after C 76 671
nephrectomy C 77 671
only C 78 671
. C 79 671
these C 81 671
observations C 82 671
suggest C 83 671
that C 84 671
the C 85 671
adrenals C 86 671
could C 87 671
induce C 88 671
a C 89 671
change C 90 671
in C 91 671
calcium C 92 671
homeostasis C 93 671
opposite C 94 671
to C 95 671
that C 96 671
of C 97 671
the C 98 671
parathyroids C 99 671
. C 100 671
pathogenesis C 1 672
of C 2 672
polycystic C 3 672
kidneys C 4 672
microdissection C 5 672
confirms C 6 672
our C 7 672
previous C 8 672
de C 9 672
- C 10 672
scription C 11 672
of C 12 672
an C 13 672
uncommon C 14 672
variety C 15 672
of C 16 672
poly C 17 672
- C 18 672
cystic C 19 672
kidney C 20 672
found C 21 672
only C 22 672
in C 23 672
the C 24 672
newborn C 25 672
periods C 26 672
. C 27 672
it C 29 672
is C 30 672
characterized C 31 672
by C 32 672
symmetrical C 33 672
enlargement C 34 672
caused C 35 672
by C 36 672
saccular C 37 672
or C 38 672
cylindri C 39 672
- C 40 672
cal C 41 672
increase C 42 672
in C 43 672
size C 44 672
of C 45 672
all C 46 672
collecting C 47 672
tubules C 48 672
. C 49 672
the C 51 672
number C 52 672
and C 53 672
relative C 54 672
length C 55 672
of C 56 672
different C 57 672
generations C 58 672
of C 59 672
collecting C 60 672
tubules C 61 672
are C 62 672
normal C 63 672
. C 64 672
nephrons C 66 672
are C 67 672
present C 68 672
in C 69 672
normal C 70 672
numbers C 71 672
, C 72 672
and C 73 672
their C 74 672
attachment C 75 672
to C 76 672
collecting C 77 672
tubules C 78 672
is C 79 672
normal C 80 672
. C 81 672
the C 83 672
pattern C 84 672
of C 85 672
the C 86 672
nephrons C 87 672
is C 88 672
nor C 89 672
- C 90 672
mal C 91 672
except C 92 672
for C 93 672
minimal C 94 672
localized C 95 672
areas C 96 672
of C 97 672
dilatation C 98 672
. C 99 672
interstitial C 101 672
connective C 102 672
tissue C 103 672
is C 104 672
not C 105 672
increased C 106 672
. C 107 672
intrahepatic C 109 672
bile C 110 672
ducts C 111 672
are C 112 672
in C 113 672
- C 114 672
variably C 115 672
cystic C 116 672
. C 117 672
siblings C 119 672
may C 120 672
be C 121 672
affected C 122 672
. C 123 672
we C 125 672
believe C 126 672
that C 127 672
in C 128 672
such C 129 672
kidneys C 130 672
the C 131 672
be C 132 672
- C 133 672
havior C 134 672
of C 135 672
the C 136 672
ampullae C 137 672
of C 138 672
the C 139 672
branches C 140 672
of C 141 672
the C 142 672
ureteral C 143 672
bud C 144 672
is C 145 672
normal C 146 672
and C 147 672
that C 148 672
secondary C 149 672
hyperplasia C 150 672
of C 151 672
the C 152 672
interstitial C 153 672
portions C 154 672
of C 155 672
the C 156 672
branches C 157 672
is C 158 672
responsible C 159 672
for C 160 672
the C 161 672
greatly C 162 672
in C 163 672
- C 164 672
creased C 165 672
renal C 166 672
size C 167 672
. C 168 672
concurrence C 1 673
of C 2 673
hyperplasia C 3 673
and C 4 673
neoplasia C 5 673
of C 6 673
the C 7 673
parathyroid C 8 673
glands C 9 673
the C 10 673
concurrence C 11 673
of C 12 673
parathyroid C 13 673
hyperplasia C 14 673
and C 15 673
neoplasia C 16 673
in C 17 673
a C 18 673
group C 19 673
of C 20 673
six C 21 673
patients C 22 673
is C 23 673
re C 24 673
- C 25 673
ported C 26 673
. C 27 673
two C 29 673
patients C 30 673
had C 31 673
long C 32 673
- C 33 673
standing C 34 673
renal C 35 673
disease C 36 673
with C 37 673
azotemia C 38 673
and C 39 673
hyperphosphatemia C 40 673
. C 41 673
in C 43 673
both C 44 673
hypercalcemia C 45 673
developed C 46 673
while C 47 673
they C 48 673
were C 49 673
under C 50 673
observation C 51 673
and C 52 673
they C 53 673
were C 54 673
found C 55 673
to C 56 673
have C 57 673
parathyroid C 58 673
adenomas C 59 673
as C 60 673
well C 61 673
as C 62 673
hyper C 63 673
- C 64 673
plasia C 65 673
of C 66 673
the C 67 673
other C 68 673
glands C 69 673
. C 70 673
a C 72 673
third C 73 673
patient C 74 673
followed C 75 673
an C 76 673
apparently C 77 673
similar C 78 673
course C 79 673
. C 80 673
one C 82 673
pa C 83 673
- C 84 673
tient C 85 673
with C 86 673
primary C 87 673
hyperparathyroidism C 88 673
due C 89 673
to C 90 673
a C 91 673
large C 92 673
mediastinal C 93 673
adenoma C 94 673
displayed C 95 673
hyper C 96 673
- C 97 673
plasia C 98 673
of C 99 673
other C 100 673
glands C 101 673
in C 102 673
association C 103 673
with C 104 673
moder C 105 673
- C 106 673
ate C 107 673
renal C 108 673
insufficiency C 109 673
. C 110 673
two C 112 673
patients C 113 673
with C 114 673
pri C 115 673
- C 116 673
mary C 117 673
generalized C 118 673
parathyroid C 119 673
hyperplasia C 120 673
were C 121 673
found C 122 673
to C 123 673
have C 124 673
superimposed C 125 673
neoplastic C 126 673
lesions C 127 673
: C 128 673
multiple C 129 673
adenomatous C 130 673
nodules C 131 673
in C 132 673
one C 133 673
, C 134 673
adenocar C 135 673
- C 136 673
cinoma C 137 673
in C 138 673
the C 139 673
other C 140 673
. C 141 673
these C 143 673
observations C 144 673
add C 145 673
new C 146 673
dimensions C 147 673
to C 148 673
the C 149 673
diagnosis C 150 673
and C 151 673
therapy C 152 673
of C 153 673
parathyroid C 154 673
disorders C 155 673
. C 156 673
they C 158 673
indicate C 159 673
the C 160 673
necessity C 161 673
of C 162 673
examining C 163 673
all C 164 673
four C 165 673
parathyroid C 166 673
areas C 167 673
at C 168 673
time C 169 673
of C 170 673
surgery C 171 673
. C 172 673
they C 174 673
also C 175 673
emphasize C 176 673
that C 177 673
hypercalcemia C 178 673
developing C 179 673
in C 180 673
patients C 181 673
with C 182 673
chronic C 183 673
renal C 184 673
disease C 185 673
is C 186 673
a C 187 673
manifesta C 188 673
- C 189 673
tion C 190 673
of C 191 673
autonomous C 192 673
parathyroid C 193 673
function C 194 673
. C 195 673
experimentelle C 1 674
nierenvergroberung C 2 674
nach C 3 674
unilateraler C 4 674
nephrektomie C 5 674
bei C 6 674
ratten C 7 674
untersuchungen C 8 674
mit C 9 674
3 C 10 674
h C 11 674
- C 12 674
thymidin C 13 674
in C 14 674
this C 15 674
paper C 16 674
it C 17 674
is C 18 674
attempted C 19 674
to C 20 674
clarify C 21 674
certain C 22 674
questions C 23 674
as C 24 674
to C 25 674
the C 26 674
mechanism C 27 674
of C 28 674
compensatory C 29 674
renal C 30 674
hypertrophy C 31 674
by C 32 674
means C 33 674
of C 34 674
histological C 35 674
, C 36 674
cytological C 37 674
, C 38 674
and C 39 674
autoradiographical C 40 674
examinations C 41 674
in C 42 674
nephrectomy C 43 674
experiments C 44 674
on C 45 674
young C 46 674
and C 47 674
grown C 48 674
rats C 49 674
. C 50 674
based C 52 674
on C 53 674
the C 54 674
results C 55 674
of C 56 674
this C 57 674
investigation C 58 674
the C 59 674
process C 60 674
of C 61 674
compensatory C 62 674
renal C 63 674
hypertrophy C 64 674
must C 65 674
be C 66 674
imagined C 67 674
as C 68 674
follows C 69 674
: C 70 674
as C 71 674
early C 72 674
as C 73 674
two C 74 674
hours C 75 674
after C 76 674
unilateral C 77 674
nephrectomy C 78 674
, C 79 674
a C 80 674
distinct C 81 674
increase C 82 674
of C 83 674
the C 84 674
mitosis C 85 674
index C 86 674
without C 87 674
a C 88 674
simultaneous C 89 674
increase C 90 674
in C 91 674
dna C 92 674
- C 93 674
synthesizing C 94 674
cells C 95 674
was C 96 674
observed C 97 674
in C 98 674
the C 99 674
remaining C 100 674
kidney C 101 674
. C 102 674
it C 104 674
is C 105 674
assumed C 106 674
that C 107 674
a C 108 674
cell C 109 674
division C 110 674
of C 111 674
polyploid C 112 674
cells C 113 674
is C 114 674
involved C 115 674
, C 116 674
which C 117 674
were C 118 674
in C 119 674
a C 120 674
prolonged C 121 674
premitotic C 122 674
rest C 123 674
phase C 124 674
. C 125 674
after C 127 674
a C 128 674
latent C 129 674
period C 130 674
of C 131 674
48 C 132 674
hours C 133 674
, C 134 674
the C 135 674
dna C 136 674
- C 137 674
synthesizing C 138 674
cells C 139 674
and C 140 674
dividing C 141 674
cells C 142 674
start C 143 674
to C 144 674
increase C 145 674
. C 146 674
the C 148 674
maximum C 149 674
of C 150 674
the C 151 674
regenerative C 152 674
processes C 153 674
is C 154 674
reached C 155 674
between C 156 674
the C 157 674
3 C 158 674
rd C 159 674
and C 160 674
4 C 161 674
th C 162 674
day C 163 674
after C 164 674
nephrectomy C 165 674
. C 166 674
twenty C 168 674
days C 169 674
after C 170 674
unilateral C 171 674
nephrectomy C 172 674
, C 173 674
the C 174 674
regenerative C 175 674
processes C 176 674
are C 177 674
largely C 178 674
concluded C 179 674
. C 180 674
all C 182 674
tubule C 183 674
sections C 184 674
participate C 185 674
in C 186 674
the C 187 674
compensatory C 188 674
renal C 189 674
hypertrophy C 190 674
. C 191 674
although C 193 674
the C 194 674
regenerative C 195 674
processes C 196 674
are C 197 674
most C 198 674
marked C 199 674
in C 200 674
the C 201 674
central C 202 674
section C 203 674
, C 204 674
one C 205 674
cannot C 206 674
speak C 207 674
of C 208 674
the C 209 674
development C 210 674
of C 211 674
an C 212 674
actual C 213 674
indifference C 214 674
zone C 215 674
in C 216 674
the C 217 674
regenerating C 218 674
kidney C 219 674
. C 220 674
in C 222 674
young C 223 674
test C 224 674
animals C 225 674
, C 226 674
compensatory C 227 674
renal C 228 674
hypertrophy C 229 674
is C 230 674
determined C 231 674
more C 232 674
by C 233 674
mitotic C 234 674
cell C 235 674
division C 236 674
, C 237 674
in C 238 674
older C 239 674
test C 240 674
animals C 241 674
more C 242 674
by C 243 674
polyploidization C 244 674
processes C 245 674
. C 246 674
the C 248 674
results C 249 674
of C 250 674
these C 251 674
investigations C 252 674
provide C 253 674
no C 254 674
certain C 255 674
indications C 256 674
for C 257 674
the C 258 674
assumption C 259 674
that C 260 674
amitotic C 261 674
nuclear C 262 674
divisions C 263 674
play C 264 674
a C 265 674
major C 266 674
part C 267 674
in C 268 674
compensatory C 269 674
renal C 270 674
hypertrophy C 271 674
. C 272 674
proliferation C 274 674
processes C 275 674
which C 276 674
in C 277 674
extent C 278 674
and C 279 674
localization C 280 674
run C 281 674
parallel C 282 674
to C 283 674
the C 284 674
regeneration C 285 674
of C 286 674
the C 287 674
parenchyma C 288 674
, C 289 674
are C 290 674
also C 291 674
observed C 292 674
in C 293 674
the C 294 674
cells C 295 674
of C 296 674
the C 297 674
connective C 298 674
tissue C 299 674
of C 300 674
the C 301 674
renal C 302 674
vessels C 303 674
. C 304 674
abscopal C 1 675
effects C 2 675
of C 3 675
whole C 4 675
- C 5 675
body C 6 675
x C 7 675
- C 8 675
irradiation C 9 675
on C 10 675
compensatory C 11 675
hypertrophy C 12 675
of C 13 675
the C 14 675
rat C 15 675
kidney C 16 675
. C 17 675
the C 19 675
weight C 20 675
and C 21 675
dna C 22 675
content C 23 675
of C 24 675
normal C 25 675
growing C 26 675
( C 27 675
i C 28 675
. C 29 675
. C 30 675
. C 31 675
, C 33 675
intact C 34 675
) C 35 675
, C 36 675
and C 37 675
hypertrophying C 38 675
( C 39 675
i C 40 675
. C 41 675
. C 42 675
. C 43 675
, C 45 675
following C 46 675
uninephrectomy C 47 675
) C 48 675
rat C 49 675
kidneys C 50 675
were C 51 675
obtained C 52 675
from C 53 675
several C 54 675
hundred C 55 675
sprague C 56 675
- C 57 675
dawley C 58 675
white C 59 675
rats C 60 675
. C 61 675
the C 63 675
effect C 64 675
of C 65 675
whole C 66 675
body C 67 675
x C 68 675
irradiation C 69 675
with C 70 675
500 C 71 675
rad C 72 675
and C 73 675
local C 74 675
irradiation C 75 675
to C 76 675
the C 77 675
kidney C 78 675
with C 79 675
1000 C 80 675
rad C 81 675
, C 82 675
was C 83 675
then C 84 675
determined C 85 675
by C 86 675
following C 87 675
the C 88 675
rate C 89 675
and C 90 675
degree C 91 675
of C 92 675
hypertrophy C 93 675
and C 94 675
the C 95 675
dna C 96 675
content C 97 675
of C 98 675
the C 99 675
kidney C 100 675
. C 101 675
when C 103 675
calculated C 104 675
on C 105 675
the C 106 675
basis C 107 675
of C 108 675
body C 109 675
surface C 110 675
area C 111 675
, C 112 675
a C 113 675
constant C 114 675
ratio C 115 675
of C 116 675
kidney C 117 675
weight C 118 675
and C 119 675
of C 120 675
kidney C 121 675
dna C 122 675
was C 123 675
found C 124 675
in C 125 675
the C 126 675
normal C 127 675
, C 128 675
non C 129 675
- C 130 675
hypertrophying C 131 675
kidneys C 132 675
of C 133 675
5 C 134 675
- C 135 675
12 C 136 675
week C 137 675
old C 138 675
rats C 139 675
. C 140 675
after C 142 675
21 C 143 675
days C 144 675
of C 145 675
hypertrophy C 146 675
these C 147 675
values C 148 675
increased C 149 675
approximately C 150 675
50 C 151 675
per C 152 675
cent C 153 675
over C 154 675
normal C 155 675
in C 156 675
rats C 157 675
4 C 158 675
- C 159 675
6 C 160 675
weeks C 161 675
old C 162 675
at C 163 675
the C 164 675
time C 165 675
of C 166 675
nephrectomy C 167 675
. C 168 675
for C 170 675
animals C 171 675
6 C 172 675
- C 173 675
14 C 174 675
weeks C 175 675
old C 176 675
at C 177 675
the C 178 675
time C 179 675
of C 180 675
nephrectomy C 181 675
the C 182 675
corresponding C 183 675
increase C 184 675
was C 185 675
only C 186 675
about C 187 675
20 C 188 675
per C 189 675
cent C 190 675
. C 191 675
following C 193 675
uninephrectomy C 194 675
and C 195 675
x C 196 675
irradiation C 197 675
with C 198 675
1000 C 199 675
rad C 200 675
to C 201 675
the C 202 675
exteriorized C 203 675
remaining C 204 675
kidney C 205 675
, C 206 675
4 C 207 675
week C 208 675
old C 209 675
rats C 210 675
whose C 211 675
bodies C 212 675
were C 213 675
lead C 214 675
- C 215 675
shielded C 216 675
during C 217 675
irradiation C 218 675
showed C 219 675
no C 220 675
body C 221 675
weight C 222 675
growth C 223 675
retardation C 224 675
, C 225 675
no C 226 675
significant C 227 675
difference C 228 675
in C 229 675
the C 230 675
dna C 231 675
content C 232 675
of C 233 675
the C 234 675
kidney C 235 675
, C 236 675
and C 237 675
a C 238 675
small C 239 675
but C 240 675
significant C 241 675
decrease C 242 675
in C 243 675
weight C 244 675
increment C 245 675
of C 246 675
the C 247 675
hypertrophying C 248 675
kidney C 249 675
after C 250 675
21 C 251 675
days C 252 675
. C 253 675
rats C 255 675
exposed C 256 675
to C 257 675
500 C 258 675
rad C 259 675
of C 260 675
x C 261 675
rays C 262 675
with C 263 675
the C 264 675
kidney C 265 675
shielded C 266 675
during C 267 675
irradiation C 268 675
, C 269 675
when C 270 675
compared C 271 675
with C 272 675
nonirradiated C 273 675
controls C 274 675
, C 275 675
showed C 276 675
body C 277 675
weight C 278 675
growth C 279 675
retardation C 280 675
, C 281 675
a C 282 675
reduction C 283 675
in C 284 675
the C 285 675
dna C 286 675
content C 287 675
of C 288 675
the C 289 675
kidney C 290 675
, C 291 675
and C 292 675
a C 293 675
reduction C 294 675
in C 295 675
the C 296 675
amount C 297 675
of C 298 675
kidney C 299 675
hypertrophy C 300 675
21 C 301 675
days C 302 675
following C 303 675
uninephrectomy C 304 675
. C 305 675
a C 307 675
still C 308 675
greater C 309 675
inhibition C 310 675
of C 311 675
both C 312 675
kidney C 313 675
compensatory C 314 675
hypertrophy C 315 675
and C 316 675
the C 317 675
increase C 318 675
in C 319 675
dna C 320 675
content C 321 675
of C 322 675
the C 323 675
kidney C 324 675
occurred C 325 675
after C 326 675
500 C 327 675
rad C 328 675
whole C 329 675
body C 330 675
irradiation C 331 675
. C 332 675
food C 334 675
restriction C 335 675
in C 336 675
nonirradiated C 337 675
4 C 338 675
week C 339 675
old C 340 675
rats C 341 675
resulting C 342 675
in C 343 675
body C 344 675
weight C 345 675
growth C 346 675
retardation C 347 675
, C 348 675
elicited C 349 675
a C 350 675
marked C 351 675
reduction C 352 675
in C 353 675
kidney C 354 675
weight C 355 675
and C 356 675
in C 357 675
dna C 358 675
content C 359 675
of C 360 675
the C 361 675
hypertrophying C 362 675
kidney C 363 675
21 C 364 675
days C 365 675
after C 366 675
uninephrectomy C 367 675
. C 368 675
it C 370 675
is C 371 675
concluded C 372 675
that C 373 675
the C 374 675
reduction C 375 675
in C 376 675
kidney C 377 675
hypertrophy C 378 675
following C 379 675
whole C 380 675
body C 381 675
x C 382 675
irradiation C 383 675
with C 384 675
500 C 385 675
rad C 386 675
is C 387 675
due C 388 675
in C 389 675
some C 390 675
measure C 391 675
to C 392 675
an C 393 675
abscopal C 394 675
or C 395 675
indirect C 396 675
effect C 397 675
, C 398 675
secondary C 399 675
to C 400 675
decreased C 401 675
body C 402 675
weight C 403 675
. C 404 675
radiation C 1 676
effects C 2 676
renal C 3 676
enlargement C 4 676
in C 5 676
the C 6 676
mouse C 7 676
three C 8 676
hours C 9 676
following C 10 676
unilateral C 11 676
nephrectomy C 12 676
weanling C 13 676
female C 14 676
cf C 15 676
- C 16 676
1 C 17 676
mice C 18 676
were C 19 676
subjected C 20 676
to C 21 676
local C 22 676
abdominal C 23 676
or C 24 676
total C 25 676
body C 26 676
exposure C 27 676
to C 28 676
either C 29 676
500 C 30 676
or C 31 676
600 C 32 676
r C 33 676
. C 34 676
other C 36 676
groups C 37 676
were C 38 676
given C 39 676
1350 C 40 676
r C 41 676
to C 42 676
half C 43 676
the C 44 676
abdomen C 45 676
with C 46 676
and C 47 676
without C 48 676
prior C 49 676
nephrectomy C 50 676
. C 51 676
signifi C 53 676
- C 54 676
cant C 55 676
decreases C 56 676
in C 57 676
renal C 58 676
weight C 59 676
gain C 60 676
compared C 61 676
to C 62 676
controls C 63 676
were C 64 676
obtained C 65 676
in C 66 676
the C 67 676
600 C 68 676
r C 69 676
total C 70 676
body C 71 676
group C 72 676
and C 73 676
in C 74 676
the C 75 676
locally C 76 676
irradiated C 77 676
ani C 78 676
- C 79 676
mals C 80 676
given C 81 676
1350 C 82 676
r C 83 676
. C 84 676
when C 86 676
the C 87 676
renal C 88 676
weight C 89 676
changes C 90 676
are C 91 676
compared C 92 676
on C 93 676
the C 94 676
basis C 95 676
of C 96 676
the C 97 676
ratio C 98 676
of C 99 676
renal C 100 676
weight C 101 676
to C 102 676
body C 103 676
weight C 104 676
in C 105 676
per C 106 676
cent C 107 676
, C 108 676
an C 109 676
increase C 110 676
from C 111 676
. C 112 676
. C 113 676
. C 113 676
% C 114 676
to C 115 676
. C 116 676
. C 117 676
. C 117 676
% C 118 676
is C 119 676
seen C 120 676
in C 121 676
animals C 122 676
subjected C 123 676
to C 124 676
nephrectomy C 125 676
alone C 126 676
. C 127 676
the C 129 676
final C 130 676
value C 131 676
in C 132 676
all C 133 676
of C 134 676
the C 135 676
irradiated C 136 676
and C 137 676
nephrectomized C 138 676
groups C 139 676
was C 140 676
similar C 141 676
, C 142 676
ranging C 143 676
from C 144 676
. C 145 676
. C 146 676
. C 146 676
% C 147 676
to C 148 676
1 C 149 676
. C 150 676
. C 151 676
% C 152 676
. C 153 676
the C 155 676
results C 156 676
suggest C 157 676
that C 158 676
irradiation C 159 676
in C 160 676
these C 161 676
dose C 162 676
ranges C 163 676
does C 164 676
not C 165 676
exert C 166 676
a C 167 676
direct C 168 676
inhibitory C 169 676
effect C 170 676
on C 171 676
renal C 172 676
weight C 173 676
increase C 174 676
but C 175 676
it C 176 676
limits C 177 676
body C 178 676
weight C 179 676
gain C 180 676
which C 181 676
influences C 182 676
kidney C 183 676
weight C 184 676
. C 185 676
renal C 1 677
hyperplasia C 2 677
and C 3 677
neoplasia C 4 677
in C 5 677
rats C 6 677
given C 7 677
dimethylnitrosamine C 8 677
multiple C 9 677
foci C 10 677
of C 11 677
hyperplasia C 12 677
and C 13 677
neoplasia C 14 677
were C 15 677
induced C 16 677
in C 17 677
the C 18 677
kidney C 19 677
of C 20 677
rats C 21 677
that C 22 677
had C 23 677
been C 24 677
dosed C 25 677
orally C 26 677
with C 27 677
dimethylnitrosamine C 28 677
. C 29 677
the C 31 677
younger C 32 677
rats C 33 677
and C 34 677
the C 35 677
male C 36 677
sex C 37 677
had C 38 677
a C 39 677
greater C 40 677
incidence C 41 677
of C 42 677
renal C 43 677
tumors C 44 677
. C 45 677
the C 47 677
hyperplastic C 48 677
or C 49 677
neoplastic C 50 677
lesions C 51 677
were C 52 677
classified C 53 677
into C 54 677
two C 55 677
groups C 56 677
on C 57 677
the C 58 677
basis C 59 677
of C 60 677
their C 61 677
histogenesis C 62 677
, C 63 677
namely C 64 677
that C 65 677
of C 66 677
tubular C 67 677
epithelial C 68 677
origin C 69 677
and C 70 677
that C 71 677
of C 72 677
interstitial C 73 677
cell C 74 677
origin C 75 677
. C 76 677
dimethylnitrosamine C 78 677
is C 79 677
recommended C 80 677
as C 81 677
a C 82 677
useful C 83 677
chemical C 84 677
compound C 85 677
for C 86 677
the C 87 677
study C 88 677
of C 89 677
renal C 90 677
carcinogenesis C 91 677
. C 92 677
the C 1 678
role C 2 678
of C 3 678
age C 4 678
and C 5 678
x C 6 678
- C 7 678
irradiation C 8 678
on C 9 678
kidney C 10 678
function C 11 678
in C 12 678
the C 13 678
mouse C 14 678
female C 15 678
mouse C 16 678
kidneys C 17 678
show C 18 678
a C 19 678
decline C 20 678
with C 21 678
respect C 22 678
to C 23 678
age C 24 678
in C 25 678
the C 26 678
ability C 27 678
to C 28 678
concentrate C 29 678
the C 30 678
urine C 31 678
during C 32 678
a C 33 678
24 C 34 678
- C 35 678
hour C 36 678
water C 37 678
fast C 38 678
. C 39 678
x C 41 678
- C 42 678
irradiation C 43 678
early C 44 678
in C 45 678
life C 46 678
has C 47 678
no C 48 678
measurable C 49 678
long C 50 678
- C 51 678
term C 52 678
effect C 53 678
on C 54 678
this C 55 678
process C 56 678
. C 57 678
kidney C 59 678
cortex C 60 678
slices C 61 678
of C 62 678
old C 63 678
female C 64 678
mice C 65 678
can C 66 678
concentrate C 67 678
p C 68 678
- C 69 678
aminohippuric C 70 678
acid C 71 678
against C 72 678
a C 73 678
concentration C 74 678
gradient C 75 678
equally C 76 678
as C 77 678
well C 78 678
as C 79 678
slices C 80 678
from C 81 678
young C 82 678
mice C 83 678
. C 84 678
there C 86 678
is C 87 678
no C 88 678
loss C 89 678
in C 90 678
this C 91 678
ability C 92 678
by C 93 678
cortex C 94 678
slices C 95 678
from C 96 678
young C 97 678
or C 98 678
old C 99 678
female C 100 678
x C 101 678
- C 102 678
irradiated C 103 678
mice C 104 678
. C 105 678
it C 107 678
is C 108 678
uncertain C 109 678
whether C 110 678
compensatory C 111 678
renal C 112 678
hypertrophy C 113 678
after C 114 678
unilateral C 115 678
nephrectomy C 116 678
declines C 117 678
with C 118 678
age C 119 678
in C 120 678
nonirradiated C 121 678
mice C 122 678
. C 123 678
x C 125 678
- C 126 678
irradiation C 127 678
does C 128 678
cause C 129 678
a C 130 678
reduction C 131 678
in C 132 678
the C 133 678
degree C 134 678
of C 135 678
compensatory C 136 678
renal C 137 678
hypertrophy C 138 678
in C 139 678
the C 140 678
aging C 141 678
mouse C 142 678
. C 143 678
this C 145 678
reduction C 146 678
may C 147 678
represent C 148 678
a C 149 678
loss C 150 678
in C 151 678
the C 152 678
ability C 153 678
of C 154 678
kidney C 155 678
cells C 156 678
to C 157 678
undergo C 158 678
cell C 159 678
division C 160 678
. C 161 678
the C 163 678
administration C 164 678
of C 165 678
testosterone C 166 678
propionate C 167 678
to C 168 678
old C 169 678
mice C 170 678
during C 171 678
compen C 172 678
- C 173 678
satory C 174 678
renal C 175 678
hypertrophy C 176 678
results C 177 678
in C 178 678
an C 179 678
increased C 180 678
hypertrophy C 181 678
. C 182 678
the C 184 678
increase C 185 678
is C 186 678
relatively C 187 678
the C 188 678
same C 189 678
for C 190 678
irradiated C 191 678
and C 192 678
nonirradiated C 193 678
mice C 194 678
, C 195 678
indicating C 196 678
the C 197 678
lack C 198 678
of C 199 678
a C 200 678
long C 201 678
- C 202 678
term C 203 678
effect C 204 678
of C 205 678
x C 206 678
- C 207 678
irradiation C 208 678
to C 209 678
reduce C 210 678
the C 211 678
ability C 212 678
of C 213 678
a C 214 678
target C 215 678
organ C 216 678
to C 217 678
respond C 218 678
to C 219 678
a C 220 678
hormone C 221 678
. C 222 678
the C 224 678
over C 225 678
- C 226 678
all C 227 678
conclusion C 228 678
of C 229 678
this C 230 678
study C 231 678
, C 232 678
with C 233 678
respect C 234 678
to C 235 678
" C 236 678
radiation C 237 678
- C 238 678
induced C 239 678
aging C 240 678
, C 241 678
" C 242 678
is C 243 678
that C 244 678
x C 245 678
- C 246 678
irradiation C 247 678
of C 248 678
the C 249 678
female C 250 678
swiss C 251 678
mouse C 252 678
early C 253 678
in C 254 678
life C 255 678
does C 256 678
not C 257 678
have C 258 678
a C 259 678
pronounced C 260 678
effect C 261 678
on C 262 678
kidney C 263 678
function C 264 678
late C 265 678
in C 266 678
life C 267 678
but C 268 678
may C 269 678
have C 270 678
a C 271 678
long C 272 678
- C 273 678
term C 274 678
effect C 275 678
on C 276 678
those C 277 678
processes C 278 678
concerned C 279 678
with C 280 678
cell C 281 678
division C 282 678
. C 283 678
hyperaldosteronism C 1 679
, C 2 679
hyperplasia C 3 679
of C 4 679
the C 5 679
juxtaglomerular C 6 679
complex C 7 679
, C 8 679
normal C 9 679
blood C 10 679
pressure C 11 679
, C 12 679
and C 13 679
dwarfism C 14 679
: C 15 679
report C 16 679
of C 17 679
a C 18 679
case C 19 679
a C 20 679
patient C 21 679
with C 22 679
the C 23 679
syndrome C 24 679
of C 25 679
hyperal C 26 679
- C 27 679
dosteronism C 28 679
, C 29 679
hyperplasia C 30 679
of C 31 679
the C 32 679
juxtaglo C 33 679
- C 34 679
merular C 35 679
complex C 36 679
, C 37 679
dwarfism C 38 679
, C 39 679
and C 40 679
normal C 41 679
blood C 42 679
pressure C 43 679
is C 44 679
reported C 45 679
in C 46 679
detail C 47 679
. C 48 679
in C 50 679
this C 51 679
patient C 52 679
, C 53 679
the C 54 679
aldosterone C 55 679
secretion C 56 679
rate C 57 679
in C 58 679
- C 59 679
creased C 60 679
significantly C 61 679
and C 62 679
the C 63 679
serum C 64 679
potas C 65 679
- C 66 679
sium C 67 679
rose C 68 679
slightly C 69 679
with C 70 679
sodium C 71 679
depriva C 72 679
- C 73 679
tion C 74 679
. C 75 679
with C 77 679
a C 78 679
low C 79 679
- C 80 679
sodium C 81 679
diet C 82 679
urinary C 83 679
sodi C 84 679
- C 85 679
um C 86 679
fell C 87 679
to C 88 679
zero C 89 679
. C 90 679
spironolactone C 92 679
with C 93 679
a C 94 679
low C 95 679
- C 96 679
sodium C 97 679
diet C 98 679
raised C 99 679
serum C 100 679
potassium C 101 679
to C 102 679
nor C 103 679
- C 104 679
mal C 105 679
. C 106 679
infusion C 108 679
of C 109 679
albumin C 110 679
, C 111 679
however C 112 679
, C 113 679
resul C 114 679
- C 115 679
ted C 116 679
in C 117 679
a C 118 679
rapid C 119 679
increase C 120 679
in C 121 679
serum C 122 679
potassium C 123 679
and C 124 679
a C 125 679
fall C 126 679
in C 127 679
aldosterone C 128 679
secretion C 129 679
rate C 130 679
. C 131 679
the C 133 679
unique C 134 679
features C 135 679
in C 136 679
this C 137 679
patient C 138 679
are C 139 679
the C 140 679
re C 141 679
- C 142 679
sponse C 143 679
to C 144 679
albumin C 145 679
and C 146 679
the C 147 679
lowering C 148 679
of C 149 679
uri C 150 679
- C 151 679
nary C 152 679
sodium C 153 679
to C 154 679
zero C 155 679
in C 156 679
response C 157 679
to C 158 679
a C 159 679
low C 160 679
- C 161 679
sodium C 162 679
intake C 163 679
. C 164 679
in C 166 679
all C 167 679
other C 168 679
essentials C 169 679
, C 170 679
the C 171 679
case C 172 679
resembles C 173 679
the C 174 679
two C 175 679
previously C 176 679
reported C 177 679
cases C 178 679
. C 179 679
treatment C 181 679
by C 182 679
subtotal C 183 679
adrenalecto C 184 679
- C 185 679
my C 186 679
was C 187 679
not C 188 679
curative C 189 679
. C 190 679
the C 1 680
juxtaglomerular C 2 680
cells C 3 680
of C 4 680
the C 5 680
kidney C 6 680
and C 7 680
the C 8 680
zona C 9 680
glomerulosa C 10 680
of C 11 680
the C 12 680
adrenal C 13 680
cortex C 14 680
in C 15 680
the C 16 680
sodium C 17 680
losing C 18 680
and C 19 680
the C 20 680
hypertensive C 21 680
forms C 22 680
of C 23 680
virilizing C 24 680
adrenal C 25 680
hyperplasia C 26 680
pathological C 27 680
and C 28 680
biochemical C 29 680
observations C 30 680
are C 31 680
presented C 32 680
in C 33 680
two C 34 680
cases C 35 680
of C 36 680
virilizing C 37 680
ad C 38 680
- C 39 680
renal C 40 680
hyperplasia C 41 680
: C 42 680
one C 43 680
of C 44 680
the C 45 680
sodium C 46 680
- C 47 680
losing C 48 680
type C 49 680
and C 50 680
the C 51 680
other C 52 680
of C 53 680
the C 54 680
hypertensive C 55 680
type C 56 680
. C 57 680
examination C 59 680
of C 60 680
the C 61 680
kidneys C 62 680
revealed C 63 680
hyper C 64 680
- C 65 680
trophy C 66 680
of C 67 680
the C 68 680
juxtaglomerular C 69 680
cells C 70 680
in C 71 680
the C 72 680
case C 73 680
exhibiting C 74 680
excessive C 75 680
sodium C 76 680
loss C 77 680
. C 78 680
the C 80 680
adrenal C 81 680
cortex C 82 680
showed C 83 680
hypertrophy C 84 680
of C 85 680
the C 86 680
zona C 87 680
glomerulosa C 88 680
. C 89 680
it C 91 680
is C 92 680
hypothesized C 93 680
that C 94 680
the C 95 680
chronic C 96 680
state C 97 680
of C 98 680
sodium C 99 680
loss C 100 680
caused C 101 680
changes C 102 680
in C 103 680
the C 104 680
intravascular C 105 680
compartment C 106 680
which C 107 680
led C 108 680
to C 109 680
compensatory C 110 680
activity C 111 680
of C 112 680
the C 113 680
juxtaglomerular C 114 680
cells C 115 680
with C 116 680
resultant C 117 680
stimula C 118 680
- C 119 680
tion C 120 680
of C 121 680
the C 122 680
zona C 123 680
glomerulosa C 124 680
. C 125 680
examination C 127 680
of C 128 680
the C 129 680
hypertensive C 130 680
case C 131 680
( C 132 680
known C 133 680
to C 134 680
involve C 135 680
a C 136 680
different C 137 680
enzyme C 138 680
defi C 139 680
- C 140 680
cit C 141 680
) C 142 680
showed C 143 680
hypertrophy C 144 680
of C 145 680
the C 146 680
zona C 147 680
glom C 148 680
- C 149 680
erulosa C 150 680
without C 151 680
hypertrophy C 152 680
of C 153 680
the C 154 680
juxta C 155 680
- C 156 680
glomerular C 157 680
cells C 158 680
. C 159 680
the C 161 680
intrinsic C 162 680
overproduc C 163 680
- C 164 680
tion C 165 680
of C 166 680
sodium C 167 680
- C 168 680
retaining C 169 680
steroids C 170 680
associated C 171 680
with C 172 680
the C 173 680
genetic C 174 680
defect C 175 680
in C 176 680
this C 177 680
clinical C 178 680
form C 179 680
could C 180 680
account C 181 680
for C 182 680
both C 183 680
the C 184 680
hypertension C 185 680
and C 186 680
the C 187 680
absence C 188 680
of C 189 680
hypertrophy C 190 680
of C 191 680
the C 192 680
juxta C 193 680
- C 194 680
glomerular C 195 680
apparatus C 196 680
. C 197 680
studies C 1 681
on C 2 681
eperythrozoon C 3 681
infection C 4 681
in C 5 681
sheep C 6 681
the C 7 681
intravenous C 8 681
inoculation C 9 681
of C 10 681
blood C 11 681
from C 12 681
sheep C 13 681
in C 14 681
the C 15 681
parasi C 16 681
- C 17 681
taemic C 18 681
stage C 19 681
of C 20 681
eperythrozoon C 21 681
infection C 22 681
produced C 23 681
detectable C 24 681
parasitaemia C 25 681
in C 26 681
recipient C 27 681
sheep C 28 681
within C 29 681
7 C 30 681
days C 31 681
. C 32 681
the C 34 681
parasitaemia C 35 681
lasted C 36 681
from C 37 681
3 C 38 681
to C 39 681
12 C 40 681
weeks C 41 681
and C 42 681
was C 43 681
accompanied C 44 681
by C 45 681
anaemia C 46 681
and C 47 681
occasionally C 48 681
by C 49 681
icterus C 50 681
. C 51 681
no C 53 681
other C 54 681
symptoms C 55 681
developed C 56 681
and C 57 681
in C 58 681
a C 59 681
controlled C 60 681
experiment C 61 681
on C 62 681
hoggs C 63 681
there C 64 681
was C 65 681
no C 66 681
significant C 67 681
difference C 68 681
in C 69 681
weight C 70 681
gain C 71 681
between C 72 681
infected C 73 681
and C 74 681
control C 75 681
animals C 76 681
. C 77 681
a C 79 681
concurrent C 80 681
attack C 81 681
of C 82 681
tick C 83 681
- C 84 681
borne C 85 681
fever C 86 681
led C 87 681
to C 88 681
the C 89 681
disappearance C 90 681
of C 91 681
eperythrozoon C 92 681
from C 93 681
the C 94 681
circulating C 95 681
blood C 96 681
. C 97 681
it C 99 681
is C 100 681
suggested C 101 681
that C 102 681
this C 103 681
phenomenon C 104 681
may C 105 681
be C 106 681
caused C 107 681
by C 108 681
the C 109 681
pyrexia C 110 681
. C 111 681
the C 113 681
incubation C 114 681
period C 115 681
following C 116 681
the C 117 681
inoculation C 118 681
of C 119 681
infected C 120 681
blood C 121 681
in C 122 681
ten C 123 681
3 C 124 681
to C 125 681
4 C 126 681
week C 127 681
old C 128 681
lambs C 129 681
varied C 130 681
from C 131 681
3 C 132 681
to C 133 681
6 C 134 681
weeks C 135 681
. C 136 681
in C 138 681
eight C 139 681
of C 140 681
these C 141 681
animals C 142 681
the C 143 681
symptoms C 144 681
were C 145 681
less C 146 681
severe C 147 681
than C 148 681
in C 149 681
adult C 150 681
sheep C 151 681
, C 152 681
but C 153 681
the C 154 681
two C 155 681
smallest C 156 681
lambs C 157 681
developed C 158 681
a C 159 681
profound C 160 681
anaemia C 161 681
and C 162 681
failed C 163 681
to C 164 681
gain C 165 681
weight C 166 681
. C 167 681
culture C 169 681
of C 170 681
the C 171 681
organism C 172 681
on C 173 681
sheep C 174 681
blood C 175 681
agar C 176 681
or C 177 681
on C 178 681
sheep C 179 681
kidney C 180 681
monolayers C 181 681
was C 182 681
unsuccessful C 183 681
as C 184 681
was C 185 681
the C 186 681
attempted C 187 681
transmission C 188 681
of C 189 681
the C 190 681
infection C 191 681
to C 192 681
mice C 193 681
. C 194 681
the C 196 681
transference C 197 681
of C 198 681
keds C 199 681
and C 200 681
lice C 201 681
from C 202 681
infected C 203 681
to C 204 681
uninfected C 205 681
sheep C 206 681
failed C 207 681
to C 208 681
transmit C 209 681
the C 210 681
infection C 211 681
, C 212 681
but C 213 681
a C 214 681
sheep C 215 681
was C 216 681
infected C 217 681
by C 218 681
the C 219 681
intravenous C 220 681
inoculation C 221 681
of C 222 681
ground C 223 681
- C 224 681
up C 225 681
lice C 226 681
from C 227 681
an C 228 681
infected C 229 681
animal C 230 681
. C 231 681
the C 233 681
only C 234 681
characteristic C 235 681
histopathological C 236 681
changes C 237 681
in C 238 681
infected C 239 681
sheep C 240 681
were C 241 681
lymphoid C 242 681
hyperplasia C 243 681
of C 244 681
the C 245 681
malphigian C 246 681
corpuscles C 247 681
in C 248 681
the C 249 681
spleen C 250 681
and C 251 681
deposition C 252 681
of C 253 681
haemosiderin C 254 681
in C 255 681
the C 256 681
cells C 257 681
of C 258 681
the C 259 681
proximal C 260 681
convoluted C 261 681
tubules C 262 681
in C 263 681
the C 264 681
kidney C 265 681
cortex C 266 681
. C 267 681
age C 1 682
differences C 2 682
in C 3 682
cellular C 4 682
proliferation C 5 682
in C 6 682
rat C 7 682
kidneys C 8 682
the C 9 682
hyperplastic C 10 682
response C 11 682
to C 12 682
unilateral C 13 682
ne C 14 682
- C 15 682
phrectomy C 16 682
after C 17 682
48 C 18 682
hours C 19 682
in C 20 682
the C 21 682
cortex C 22 682
and C 23 682
medulla C 24 682
of C 25 682
the C 26 682
remaining C 27 682
kidneys C 28 682
of C 29 682
weanling C 30 682
and C 31 682
young C 32 682
adult C 33 682
rats C 34 682
was C 35 682
studied C 36 682
by C 37 682
means C 38 682
of C 39 682
autoradiography C 40 682
. C 41 682
tritiated C 43 682
- C 44 682
thymidine C 45 682
, C 46 682
which C 47 682
is C 48 682
destined C 49 682
exclusively C 50 682
for C 51 682
nucleoprotein C 52 682
synthe C 53 682
- C 54 682
sis C 55 682
, C 56 682
was C 57 682
administered C 58 682
to C 59 682
11 C 60 682
control C 61 682
and C 62 682
11 C 63 682
ex C 64 682
- C 65 682
perimental C 66 682
rats C 67 682
4 C 68 682
hours C 69 682
prior C 70 682
to C 71 682
sacrifice C 72 682
. C 73 682
labeled C 75 682
tubular C 76 682
cells C 77 682
were C 78 682
rare C 79 682
in C 80 682
control C 81 682
tissues C 82 682
, C 83 682
especially C 84 682
in C 85 682
medulla C 86 682
, C 87 682
where C 88 682
the C 89 682
per C 90 682
- C 91 682
centages C 92 682
did C 93 682
not C 94 682
differ C 95 682
greatly C 96 682
for C 97 682
the C 98 682
two C 99 682
age C 100 682
groups C 101 682
. C 102 682
in C 104 682
the C 105 682
cortex C 106 682
of C 107 682
controls C 108 682
such C 109 682
cells C 110 682
were C 111 682
three C 112 682
times C 113 682
more C 114 682
frequent C 115 682
for C 116 682
weanling C 117 682
rats C 118 682
than C 119 682
for C 120 682
adults C 121 682
. C 122 682
significant C 124 682
increases C 125 682
in C 126 682
per C 127 682
- C 128 682
centages C 129 682
of C 130 682
labeled C 131 682
cells C 132 682
over C 133 682
control C 134 682
levels C 135 682
were C 136 682
found C 137 682
in C 138 682
both C 139 682
regions C 140 682
of C 141 682
the C 142 682
remaining C 143 682
kidneys C 144 682
for C 145 682
both C 146 682
age C 147 682
groups C 148 682
. C 149 682
the C 151 682
percentage C 152 682
of C 153 682
increase C 154 682
was C 155 682
greater C 156 682
in C 157 682
medulla C 158 682
than C 159 682
in C 160 682
cortex C 161 682
and C 162 682
most C 163 682
pronounced C 164 682
in C 165 682
medulla C 166 682
of C 167 682
the C 168 682
young C 169 682
adult C 170 682
rats C 171 682
. C 172 682
phospholipids C 1 683
of C 2 683
the C 3 683
sexual C 4 683
segment C 5 683
of C 6 683
the C 7 683
kidney C 8 683
of C 9 683
the C 10 683
indian C 11 683
house C 12 683
lizard C 13 683
, C 14 683
hemidactylus C 15 683
flaviviridis C 16 683
ruppell C 17 683
the C 18 683
indian C 19 683
house C 20 683
lizard C 21 683
, C 22 683
hemidactylus C 23 683
flaviviridis C 24 683
breeds C 25 683
seas C 26 683
- C 27 683
onally C 28 683
. C 29 683
in C 31 683
a C 32 683
sexually C 33 683
mature C 34 683
male C 35 683
lizard C 36 683
, C 37 683
from C 38 683
october C 39 683
to C 40 683
may C 41 683
of C 42 683
the C 43 683
following C 44 683
year C 45 683
, C 46 683
the C 47 683
secondary C 48 683
and C 49 683
tertiary C 50 683
collecting C 51 683
tubules C 52 683
of C 53 683
the C 54 683
kidney C 55 683
are C 56 683
hypertrophied C 57 683
forming C 58 683
the C 59 683
sexual C 60 683
seg C 61 683
- C 62 683
ment C 63 683
. C 64 683
the C 66 683
development C 67 683
of C 68 683
the C 69 683
sexual C 70 683
segment C 71 683
is C 72 683
synchronous C 73 683
with C 74 683
the C 75 683
testicular C 76 683
cycle C 77 683
and C 78 683
maximum C 79 683
development C 80 683
occurs C 81 683
during C 82 683
the C 83 683
period C 84 683
when C 85 683
the C 86 683
testes C 87 683
are C 88 683
spermatogenically C 89 683
active C 90 683
. C 91 683
the C 93 683
sex C 94 683
- C 95 683
ual C 96 683
segment C 97 683
is C 98 683
not C 99 683
developed C 100 683
in C 101 683
the C 102 683
females C 103 683
in C 104 683
any C 105 683
season C 106 683
of C 107 683
the C 108 683
year C 109 683
; C 110 683
it C 111 683
is C 112 683
completely C 113 683
regressed C 114 683
in C 115 683
males C 116 683
during C 117 683
sexual C 118 683
quiescence C 119 683
( C 120 683
june C 121 683
and C 122 683
july C 123 683
) C 124 683
. C 125 683
injection C 127 683
of C 128 683
4 C 129 683
. C 130 683
. C 131 683
mg C 132 683
of C 133 683
testosterone C 134 683
propionate C 135 683
over C 136 683
two C 137 683
weeks C 138 683
stimulated C 139 683
the C 140 683
regressed C 141 683
sexual C 142 683
segment C 143 683
to C 144 683
hyper C 145 683
- C 146 683
trophy C 147 683
in C 148 683
males C 149 683
during C 150 683
quiescence C 151 683
and C 152 683
also C 153 683
in C 154 683
females C 155 683
. C 156 683
the C 158 683
apical C 159 683
portions C 160 683
of C 161 683
the C 162 683
cells C 163 683
of C 164 683
the C 165 683
sexual C 166 683
segment C 167 683
are C 168 683
loaded C 169 683
with C 170 683
granular C 171 683
secretions C 172 683
which C 173 683
are C 174 683
stained C 175 683
with C 176 683
baker C 177 683
' C 178 683
s C 179 683
acid C 180 683
hae C 181 683
- C 182 683
matein C 183 683
and C 184 683
phosphomolybdic C 185 683
acid C 186 683
- C 187 683
stannous C 188 683
chloride C 189 683
, C 190 683
indicating C 191 683
the C 192 683
presence C 193 683
of C 194 683
choline C 195 683
- C 196 683
containing C 197 683
phospholipids C 198 683
. C 199 683
the C 201 683
composi C 202 683
- C 203 683
tion C 204 683
of C 205 683
the C 206 683
phospholipids C 207 683
of C 208 683
the C 209 683
sexual C 210 683
segment C 211 683
, C 212 683
which C 213 683
is C 214 683
a C 215 683
unique C 216 683
feature C 217 683
of C 218 683
the C 219 683
lizards C 220 683
and C 221 683
snakes C 222 683
, C 223 683
is C 224 683
unknown C 225 683
. C 226 683
this C 228 683
preliminary C 229 683
communication C 230 683
describes C 231 683
the C 232 683
isolation C 233 683
and C 234 683
quantitative C 235 683
estimation C 236 683
of C 237 683
phospholipids C 238 683
present C 239 683
in C 240 683
the C 241 683
sexual C 242 683
segment C 243 683
of C 244 683
the C 245 683
indian C 246 683
house C 247 683
lizard C 248 683
, C 249 683
hemidactylus C 250 683
flaviviridis C 251 683
ruppell C 252 683
. C 253 683
( C 1 684
on C 2 684
the C 3 684
erythropoietic C 4 684
effect C 5 684
of C 6 684
different C 7 684
tissue C 8 684
suspensions C 9 684
) C 10 684
the C 11 684
stimulating C 12 684
effect C 13 684
on C 14 684
erythropoiesis C 15 684
of C 16 684
regenerated C 17 684
liver C 18 684
and C 19 684
hyper C 20 684
- C 21 684
trophic C 22 684
kidney C 23 684
tissue C 24 684
after C 25 684
partial C 26 684
hepatectomy C 27 684
and C 28 684
unilateral C 29 684
nephrectomy C 30 684
respectively C 31 684
was C 32 684
studied C 33 684
in C 34 684
the C 35 684
rat C 36 684
by C 37 684
means C 38 684
of C 39 684
the C 40 684
erythrocyte C 41 684
count C 42 684
, C 43 684
haemo C 44 684
- C 45 684
globin C 46 684
determination C 47 684
, C 48 684
reticulocyte C 49 684
count C 50 684
and C 51 684
59 C 52 684
fe C 53 684
utilization C 54 684
. C 55 684
the C 57 684
reticulocyte C 58 684
count C 59 684
and C 60 684
59 C 61 684
fe C 62 684
utilization C 63 684
increased C 64 684
significantly C 65 684
after C 66 684
treatment C 67 684
with C 68 684
normal C 69 684
liver C 70 684
and C 71 684
renal C 72 684
tissue C 73 684
and C 74 684
more C 75 684
strongly C 76 684
after C 77 684
regenerated C 78 684
liver C 79 684
and C 80 684
hypertrophic C 81 684
kidney C 82 684
tissue C 83 684
. C 84 684
the C 86 684
same C 87 684
effect C 88 684
was C 89 684
seen C 90 684
after C 91 684
treatment C 92 684
with C 93 684
the C 94 684
sera C 95 684
of C 96 684
rats C 97 684
which C 98 684
had C 99 684
undergone C 100 684
partial C 101 684
hepatectomy C 102 684
or C 103 684
unilateral C 104 684
nephrectomy C 105 684
. C 106 684
hemihypertrophy C 1 685
and C 2 685
medullary C 3 685
sponge C 4 685
kidney C 5 685
congenital C 6 685
hemihypertrophy C 7 685
is C 8 685
an C 9 685
over C 10 685
- C 11 685
growth C 12 685
of C 13 685
one C 14 685
side C 15 685
of C 16 685
the C 17 685
body C 18 685
which C 19 685
is C 20 685
associated C 21 685
with C 22 685
an C 23 685
asymmetry C 24 685
beyond C 25 685
the C 26 685
ex C 27 685
- C 28 685
pected C 29 685
range C 30 685
. C 31 685
it C 33 685
is C 34 685
to C 35 685
be C 36 685
distinguished C 37 685
from C 38 685
hemiatrophy C 39 685
in C 40 685
which C 41 685
atrophy C 42 685
or C 43 685
withering C 44 685
of C 45 685
one C 46 685
half C 47 685
of C 48 685
the C 49 685
body C 50 685
has C 51 685
occurred C 52 685
, C 53 685
usually C 54 685
be C 55 685
- C 56 685
cause C 57 685
of C 58 685
neurological C 59 685
lesions C 60 685
. C 61 685
this C 63 685
condition C 64 685
of C 65 685
hemihypertrophy C 66 685
, C 67 685
though C 68 685
rare C 69 685
, C 70 685
is C 71 685
very C 72 685
frequently C 73 685
associated C 74 685
with C 75 685
other C 76 685
congenital C 77 685
abnormalities C 78 685
. C 79 685
these C 81 685
include C 82 685
several C 83 685
in C 84 685
the C 85 685
urogenital C 86 685
tract C 87 685
, C 88 685
such C 89 685
as C 90 685
hypospadias C 91 685
, C 92 685
cryptorchidism C 93 685
, C 94 685
unilateral C 95 685
renal C 96 685
hypertrophy C 97 685
and C 98 685
an C 99 685
increased C 100 685
incidence C 101 685
of C 102 685
wilms C 103 685
' C 104 685
tumour C 105 685
. C 106 685
chemical C 1 686
aspects C 2 686
of C 3 686
compensatory C 4 686
renal C 5 686
hypertrophy C 6 686
the C 7 686
effect C 8 686
of C 9 686
unilateral C 10 686
nephrectomy C 11 686
on C 12 686
the C 13 686
size C 14 686
and C 15 686
composition C 16 686
of C 17 686
the C 18 686
remaining C 19 686
kidney C 20 686
has C 21 686
been C 22 686
investigated C 23 686
in C 24 686
rats C 25 686
. C 26 686
in C 28 686
normal C 29 686
rats C 30 686
the C 31 686
right C 32 686
kidney C 33 686
is C 34 686
, C 35 686
on C 36 686
the C 37 686
average C 38 686
, C 39 686
significantly C 40 686
heavier C 41 686
than C 42 686
the C 43 686
left C 44 686
and C 45 686
has C 46 686
a C 47 686
higher C 48 686
total C 49 686
content C 50 686
of C 51 686
dna C 52 686
and C 53 686
rna C 54 686
. C 55 686
the C 57 686
2 C 58 686
kidneys C 59 686
have C 60 686
almost C 61 686
identical C 62 686
ratios C 63 686
of C 64 686
rna C 65 686
/ C 66 686
dna C 67 686
and C 68 686
protein C 69 686
/ C 70 686
dna C 71 686
. C 72 686
after C 74 686
unilateral C 75 686
nephrectomy C 76 686
the C 77 686
surviving C 78 686
kidney C 79 686
increases C 80 686
steadily C 81 686
in C 82 686
wet C 83 686
and C 84 686
dry C 85 686
weight C 86 686
for C 87 686
the C 88 686
1 C 89 686
st C 90 686
4 C 91 686
days C 92 686
after C 93 686
the C 94 686
operation C 95 686
. C 96 686
this C 98 686
is C 99 686
accompanied C 100 686
by C 101 686
a C 102 686
much C 103 686
slower C 104 686
increase C 105 686
in C 106 686
total C 107 686
dna C 108 686
content C 109 686
and C 110 686
by C 111 686
a C 112 686
dramatic C 113 686
increase C 114 686
in C 115 686
rna C 116 686
/ C 117 686
dna C 118 686
ratio C 119 686
. C 120 686
the C 122 686
rna C 123 686
/ C 124 686
dna C 125 686
ratio C 126 686
in C 127 686
kidney C 128 686
is C 129 686
also C 130 686
affected C 131 686
by C 132 686
diet C 133 686
, C 134 686
being C 135 686
higher C 136 686
on C 137 686
a C 138 686
high C 139 686
- C 140 686
protein C 141 686
than C 142 686
on C 143 686
a C 144 686
low C 145 686
- C 146 686
protein C 147 686
intake C 148 686
. C 149 686
moreover C 151 686
, C 152 686
the C 153 686
rise C 154 686
in C 155 686
rna C 156 686
/ C 157 686
dna C 158 686
ratio C 159 686
that C 160 686
follows C 161 686
unilateral C 162 686
nephrectomy C 163 686
is C 164 686
greater C 165 686
in C 166 686
animals C 167 686
fed C 168 686
a C 169 686
high C 170 686
- C 171 686
protein C 172 686
diet C 173 686
. C 174 686
the C 176 686
changes C 177 686
in C 178 686
kidney C 179 686
weight C 180 686
and C 181 686
in C 182 686
total C 183 686
contents C 184 686
of C 185 686
dna C 186 686
, C 187 686
rna C 188 686
, C 189 686
protein C 190 686
, C 191 686
and C 192 686
lipid C 193 686
phosphorus C 194 686
resulting C 195 686
from C 196 686
the C 197 686
feeding C 198 686
of C 199 686
a C 200 686
high C 201 686
- C 202 686
protein C 203 686
diet C 204 686
were C 205 686
found C 206 686
to C 207 686
be C 208 686
of C 209 686
approximately C 210 686
the C 211 686
same C 212 686
magnitude C 213 686
as C 214 686
those C 215 686
in C 216 686
the C 217 686
remaining C 218 686
kidney C 219 686
4 C 220 686
days C 221 686
after C 222 686
unilateral C 223 686
nephrectomy C 224 686
. C 225 686
the C 227 686
rna C 228 686
/ C 229 686
dna C 230 686
and C 231 686
protein C 232 686
/ C 233 686
dna C 234 686
ratios C 235 686
are C 236 686
also C 237 686
greater C 238 686
in C 239 686
rats C 240 686
fed C 241 686
a C 242 686
diet C 243 686
containing C 244 686
10 C 245 686
% C 246 686
urea C 247 686
, C 248 686
but C 249 686
the C 250 686
increase C 251 686
is C 252 686
much C 253 686
less C 254 686
than C 255 686
that C 256 686
in C 257 686
the C 258 686
remaining C 259 686
kidney C 260 686
after C 261 686
unilateral C 262 686
nephrectomy C 263 686
. C 264 686
the C 1 687
antidiuretic C 2 687
mechanism C 3 687
of C 4 687
hydrochlorothia C 5 687
- C 6 687
zide C 7 687
in C 8 687
the C 9 687
treatment C 10 687
of C 11 687
diabetes C 12 687
insipidus C 13 687
the C 14 687
changes C 15 687
in C 16 687
water C 17 687
and C 18 687
electro C 19 687
- C 20 687
lyte C 21 687
balance C 22 687
during C 23 687
hydrochlorothiazide C 24 687
therapy C 25 687
in C 26 687
2 C 27 687
patients C 28 687
with C 29 687
vasopressin C 30 687
- C 31 687
deficient C 32 687
diabetes C 33 687
insipidus C 34 687
were C 35 687
studi C 36 687
- C 37 687
ed C 38 687
. C 39 687
in C 41 687
1 C 42 687
case C 43 687
, C 44 687
under C 45 687
fixed C 46 687
daily C 47 687
so C 48 687
- C 49 687
dium C 50 687
intake C 51 687
, C 52 687
the C 53 687
urinary C 54 687
sodium C 55 687
excre C 56 687
- C 57 687
tion C 58 687
markedly C 59 687
increased C 60 687
on C 61 687
the C 62 687
first C 63 687
day C 64 687
of C 65 687
treatment C 66 687
, C 67 687
but C 68 687
the C 69 687
urinary C 70 687
volume C 71 687
began C 72 687
to C 73 687
fall C 74 687
on C 75 687
the C 76 687
second C 77 687
day C 78 687
and C 79 687
per C 80 687
- C 81 687
sisted C 82 687
low C 83 687
for C 84 687
3 C 85 687
days C 86 687
after C 87 687
discontinua C 88 687
- C 89 687
tion C 90 687
of C 91 687
the C 92 687
drug C 93 687
. C 94 687
in C 96 687
the C 97 687
other C 98 687
case C 99 687
the C 100 687
urinary C 101 687
volume C 102 687
markedly C 103 687
decreased C 104 687
when C 105 687
the C 106 687
daily C 107 687
sodium C 108 687
intake C 109 687
was C 110 687
strict C 111 687
- C 112 687
ly C 113 687
limited C 114 687
. C 115 687
it C 117 687
further C 118 687
decreased C 119 687
on C 120 687
hydrochlorothiazide C 121 687
therapy C 122 687
but C 123 687
after C 124 687
sodium C 125 687
intake C 126 687
was C 127 687
restored C 128 687
it C 129 687
returned C 130 687
to C 131 687
the C 132 687
pretreatment C 133 687
level C 134 687
despite C 135 687
con C 136 687
- C 137 687
tinued C 138 687
use C 139 687
of C 140 687
the C 141 687
drug C 142 687
. C 143 687
the C 145 687
antidiuretic C 146 687
action C 147 687
of C 148 687
hydro C 149 687
- C 150 687
chlorothiazide C 151 687
in C 152 687
the C 153 687
treatment C 154 687
of C 155 687
dia C 156 687
- C 157 687
betes C 158 687
insipidus C 159 687
is C 160 687
believed C 161 687
to C 162 687
be C 163 687
related C 164 687
to C 165 687
the C 166 687
sodium C 167 687
depletion C 168 687
state C 169 687
of C 170 687
the C 171 687
body C 172 687
brought C 173 687
about C 174 687
by C 175 687
increased C 176 687
output C 177 687
or C 178 687
decreased C 179 687
intake C 180 687
of C 181 687
sodium C 182 687
. C 183 687
sodium C 185 687
and C 186 687
water C 187 687
reabsorption C 188 687
in C 189 687
the C 190 687
proximal C 191 687
convoluted C 192 687
tubules C 193 687
in C 194 687
the C 195 687
kidney C 196 687
in C 197 687
- C 198 687
creases C 199 687
and C 200 687
the C 201 687
amount C 202 687
of C 203 687
glomerular C 204 687
filtrate C 205 687
reaching C 206 687
the C 207 687
distal C 208 687
convoluted C 209 687
tubules C 210 687
decreases C 211 687
. C 212 687
thus C 214 687
the C 215 687
final C 216 687
urinary C 217 687
volume C 218 687
falls C 219 687
. C 220 687
the C 1 688
action C 2 688
of C 3 688
oral C 4 688
diuretics C 5 688
in C 6 688
diabetes C 7 688
insipidus C 8 688
chronic C 9 688
administration C 10 688
of C 11 688
chlorothiazide C 12 688
and C 13 688
other C 14 688
thiazide C 15 688
analogues C 16 688
in C 17 688
diabetes C 18 688
insipidus C 19 688
results C 20 688
in C 21 688
a C 22 688
striking C 23 688
reduction C 24 688
in C 25 688
urinary C 26 688
volume C 27 688
with C 28 688
increase C 29 688
in C 30 688
urinary C 31 688
osmolality C 32 688
. C 33 688
this C 35 688
curious C 36 688
antidiuretic C 37 688
action C 38 688
was C 39 688
first C 40 688
described C 41 688
by C 42 688
crawford C 43 688
& C 44 688
kennedy C 45 688
( C 46 688
1959 C 47 688
) C 48 688
, C 49 688
and C 50 688
though C 51 688
it C 52 688
has C 53 688
since C 54 688
been C 55 688
widely C 56 688
confirmed C 57 688
in C 58 688
both C 59 688
the C 60 688
pituitary C 61 688
and C 62 688
nephrogenic C 63 688
forms C 64 688
of C 65 688
the C 66 688
disease C 67 688
, C 68 688
its C 69 688
precise C 70 688
mechanism C 71 688
remains C 72 688
obscure C 73 688
. C 74 688
a C 76 688
number C 77 688
of C 78 688
investigators C 79 688
have C 80 688
sought C 81 688
to C 82 688
explain C 83 688
the C 84 688
phenom C 85 688
- C 86 688
enon C 87 688
entirely C 88 688
on C 89 688
the C 90 688
basis C 91 688
of C 92 688
the C 93 688
renal C 94 688
actions C 95 688
of C 96 688
these C 97 688
drugs C 98 688
( C 99 688
earley C 100 688
& C 101 688
orloff C 102 688
1962 C 103 688
, C 104 688
goodman C 105 688
& C 106 688
carter C 107 688
1962 C 108 688
) C 109 688
, C 110 688
whilst C 111 688
others C 112 688
have C 113 688
contended C 114 688
that C 115 688
abatement C 116 688
of C 117 688
polyuria C 118 688
may C 119 688
be C 120 688
secondary C 121 688
to C 122 688
a C 123 688
central C 124 688
effect C 125 688
of C 126 688
the C 127 688
thiazides C 128 688
in C 129 688
decreasing C 130 688
thirst C 131 688
( C 132 688
robson C 133 688
& C 134 688
lambie C 135 688
1962 C 136 688
, C 137 688
skadhauge C 138 688
1963 C 139 688
) C 140 688
. C 141 688
over C 143 688
the C 144 688
past C 145 688
two C 146 688
years C 147 688
, C 148 688
we C 149 688
have C 150 688
conducted C 151 688
detailed C 152 688
in C 153 688
- C 154 688
patient C 155 688
studies C 156 688
of C 157 688
the C 158 688
action C 159 688
of C 160 688
various C 161 688
diuretic C 162 688
drugs C 163 688
of C 164 688
the C 165 688
thiazide C 166 688
and C 167 688
other C 168 688
series C 169 688
in C 170 688
a C 171 688
group C 172 688
of C 173 688
7 C 174 688
patients C 175 688
with C 176 688
pituitary C 177 688
diabetes C 178 688
insipidus C 179 688
. C 180 688
investigations C 1 689
into C 2 689
the C 3 689
thiazide C 4 689
- C 5 689
induced C 6 689
antidiuresis C 7 689
in C 8 689
patients C 9 689
with C 10 689
diabetes C 11 689
insipidus C 12 689
plasma C 13 689
sodium C 14 689
, C 15 689
osmolality C 16 689
and C 17 689
serum C 18 689
chloride C 19 689
, C 20 689
together C 21 689
with C 22 689
creatinine C 23 689
clear C 24 689
- C 25 689
ance C 26 689
, C 27 689
were C 28 689
studied C 29 689
before C 30 689
and C 31 689
during C 32 689
thiazide C 33 689
treatment C 34 689
of C 35 689
7 C 36 689
patients C 37 689
with C 38 689
diabetes C 39 689
insipidus C 40 689
. C 41 689
the C 43 689
diuresis C 44 689
was C 45 689
reduced C 46 689
by C 47 689
28 C 48 689
- C 49 689
39 C 50 689
% C 51 689
. C 52 689
the C 54 689
urine C 55 689
osmolality C 56 689
was C 57 689
increased C 58 689
by C 59 689
7 C 60 689
- C 61 689
128 C 62 689
% C 63 689
. C 64 689
an C 66 689
average C 67 689
decrease C 68 689
in C 69 689
plasma C 70 689
sodium C 71 689
of C 72 689
4 C 73 689
meq C 74 689
/ C 75 689
i C 76 689
, C 77 689
in C 78 689
plasma C 79 689
osmolality C 80 689
of C 81 689
21 C 82 689
mosm C 83 689
/ C 84 689
kg C 85 689
, C 86 689
and C 87 689
in C 88 689
serum C 89 689
chloride C 90 689
of C 91 689
8 C 92 689
meq C 93 689
/ C 94 689
i C 95 689
was C 96 689
observed C 97 689
. C 98 689
only C 100 689
in C 101 689
one C 102 689
pa C 103 689
- C 104 689
tient C 105 689
was C 106 689
the C 107 689
creatinine C 108 689
clearance C 109 689
re C 110 689
- C 111 689
duced C 112 689
significantly C 113 689
. C 114 689
the C 116 689
thirst C 117 689
- C 118 689
feeling C 119 689
was C 120 689
reduced C 121 689
even C 122 689
from C 123 689
the C 124 689
first C 125 689
day C 126 689
of C 127 689
treat C 128 689
- C 129 689
ment C 130 689
. C 131 689
the C 133 689
diuresis C 134 689
was C 135 689
not C 136 689
minimal C 137 689
until C 138 689
the C 139 689
third C 140 689
to C 141 689
fourth C 142 689
day C 143 689
. C 144 689
if C 146 689
the C 147 689
diuresis C 148 689
was C 149 689
corrected C 150 689
for C 151 689
the C 152 689
extra C 153 689
electrolyte C 154 689
ex C 155 689
- C 156 689
cretion C 157 689
initiated C 158 689
by C 159 689
the C 160 689
thiazide C 161 689
, C 162 689
the C 163 689
antidiuresis C 164 689
was C 165 689
found C 166 689
to C 167 689
be C 168 689
operating C 169 689
to C 170 689
the C 171 689
full C 172 689
extent C 173 689
even C 174 689
on C 175 689
the C 176 689
first C 177 689
day C 178 689
of C 179 689
treatment C 180 689
. C 181 689
it C 183 689
is C 184 689
concluded C 185 689
that C 186 689
the C 187 689
antidiuresis C 188 689
is C 189 689
mainly C 190 689
secondary C 191 689
to C 192 689
the C 193 689
natriuresis C 194 689
and C 195 689
to C 196 689
a C 197 689
certain C 198 689
degree C 199 689
due C 200 689
to C 201 689
a C 202 689
decreased C 203 689
thirst C 204 689
- C 205 689
feeling C 206 689
; C 207 689
but C 208 689
there C 209 689
seems C 210 689
also C 211 689
to C 212 689
be C 213 689
a C 214 689
direct C 215 689
renal C 216 689
action C 217 689
, C 218 689
involving C 219 689
at C 220 689
least C 221 689
a C 222 689
reduc C 223 689
- C 224 689
tion C 225 689
of C 226 689
the C 227 689
glomerular C 228 689
filtration C 229 689
rate C 230 689
. C 231 689
a C 233 689
pronounced C 234 689
antidiuresis C 235 689
was C 236 689
found C 237 689
by C 238 689
a C 239 689
water C 240 689
deprivation C 241 689
test C 242 689
after C 243 689
thiazide C 244 689
treatment C 245 689
in C 246 689
one C 247 689
patient C 248 689
. C 249 689
salt C 1 690
and C 2 690
water C 3 690
the C 4 690
antidiuretic C 5 690
effect C 6 690
of C 7 690
thiazides C 8 690
is C 9 690
thus C 10 690
the C 11 690
result C 12 690
of C 13 690
the C 14 690
induced C 15 690
sodium C 16 690
deficit C 17 690
. C 18 690
the C 20 690
fall C 21 690
in C 22 690
serum C 23 690
osmolality C 24 690
may C 25 690
be C 26 690
contributory C 27 690
by C 28 690
reducing C 29 690
thirst C 30 690
. C 31 690
as C 33 690
depletion C 34 690
of C 35 690
body C 36 690
sodium C 37 690
will C 38 690
be C 39 690
self C 40 690
- C 41 690
limiting C 42 690
the C 43 690
major C 44 690
hazard C 45 690
to C 46 690
the C 47 690
use C 48 690
of C 49 690
thiazides C 50 690
is C 51 690
potassium C 52 690
depletion C 53 690
. C 54 690
treatment C 56 690
of C 57 690
patients C 58 690
with C 59 690
vasopressin C 60 690
insufficiency C 61 690
type C 62 690
of C 63 690
diabetes C 64 690
insipidus C 65 690
with C 66 690
thiazides C 67 690
is C 68 690
only C 69 690
indicated C 70 690
for C 71 690
those C 72 690
who C 73 690
are C 74 690
intolerant C 75 690
of C 76 690
hormone C 77 690
replace C 78 690
- C 79 690
ment C 80 690
. C 81 690
in C 83 690
nephrogenic C 84 690
diabetes C 85 690
insipidus C 86 690
thiazides C 87 690
have C 88 690
a C 89 690
more C 90 690
important C 91 690
therapeutic C 92 690
application C 93 690
. C 94 690
nephrogenic C 1 691
diabetes C 2 691
insipidus C 3 691
chlorothiazide C 4 691
has C 5 691
been C 6 691
found C 7 691
of C 8 691
value C 9 691
in C 10 691
establishing C 11 691
and C 12 691
maintaining C 13 691
adequate C 14 691
hydra C 15 691
- C 16 691
tion C 17 691
in C 18 691
some C 19 691
patients C 20 691
; C 21 691
its C 22 691
exact C 23 691
mechanism C 24 691
of C 25 691
action C 26 691
is C 27 691
not C 28 691
known C 29 691
. C 30 691
the C 32 691
antidiuretic C 33 691
effects C 34 691
of C 35 691
chlorothiazide C 36 691
and C 37 691
its C 38 691
analogues C 39 691
have C 40 691
been C 41 691
studied C 42 691
in C 43 691
six C 44 691
patients C 45 691
with C 46 691
ndi C 47 691
, C 48 691
two C 49 691
of C 50 691
whom C 51 691
were C 52 691
infants C 53 691
less C 54 691
than C 55 691
six C 56 691
months C 57 691
of C 58 691
age C 59 691
. C 60 691
dehydrated C 62 691
infants C 63 691
showed C 64 691
a C 65 691
dramatic C 66 691
response C 67 691
to C 68 691
treatment C 69 691
. C 70 691
with C 72 691
those C 73 691
unable C 74 691
to C 75 691
achieve C 76 691
an C 77 691
optimal C 78 691
fluid C 79 691
intake C 80 691
prior C 81 691
to C 82 691
treat C 83 691
- C 84 691
ment C 85 691
, C 86 691
the C 87 691
initial C 88 691
beneficial C 89 691
response C 90 691
was C 91 691
asso C 92 691
- C 93 691
ciated C 94 691
with C 95 691
an C 96 691
increased C 97 691
fluid C 98 691
intake C 99 691
. C 100 691
follow C 102 691
- C 103 691
ing C 104 691
this C 105 691
initial C 106 691
antidiuretic C 107 691
response C 108 691
, C 109 691
a C 110 691
vari C 111 691
- C 112 691
able C 113 691
degree C 114 691
of C 115 691
" C 116 691
escape C 117 691
" C 118 691
or C 119 691
resistance C 120 691
to C 121 691
the C 122 691
action C 123 691
of C 124 691
the C 125 691
drug C 126 691
commonly C 127 691
occurred C 128 691
. C 129 691
de C 131 691
- C 132 691
spite C 133 691
the C 134 691
unpredictability C 135 691
of C 136 691
a C 137 691
prolonged C 138 691
anti C 139 691
- C 140 691
diuretic C 141 691
response C 142 691
, C 143 691
a C 144 691
therapeutic C 145 691
trial C 146 691
of C 147 691
chloro C 148 691
- C 149 691
thiazide C 150 691
in C 151 691
ndi C 152 691
seems C 153 691
warranted C 154 691
if C 155 691
diet C 156 691
alone C 157 691
is C 158 691
not C 159 691
sufficient C 160 691
to C 161 691
maintain C 162 691
hydration C 163 691
. C 164 691
it C 166 691
must C 167 691
be C 168 691
remembered C 169 691
, C 170 691
however C 171 691
, C 172 691
that C 173 691
this C 174 691
drug C 175 691
is C 176 691
po C 177 691
- C 178 691
tentially C 179 691
toxic C 180 691
. C 181 691
fluid C 1 692
and C 2 692
electrolyte C 3 692
metabolism C 4 692
in C 5 692
nephrogenic C 6 692
diabetes C 7 692
insipidus C 8 692
the C 9 692
body C 10 692
fluid C 11 692
volumes C 12 692
have C 13 692
been C 14 692
fol C 15 692
- C 16 692
lowed C 17 692
in C 18 692
two C 19 692
infants C 20 692
with C 21 692
nephrogenic C 22 692
diabetes C 23 692
insipidus C 24 692
. C 25 692
without C 27 692
treatment C 28 692
both C 29 692
patients C 30 692
had C 31 692
a C 32 692
low C 33 692
extracellular C 34 692
fluid C 35 692
volume C 36 692
( C 37 692
ecv C 38 692
) C 39 692
and C 40 692
a C 41 692
normal C 42 692
to C 43 692
low C 44 692
- C 45 692
normal C 46 692
total C 47 692
body C 48 692
water C 49 692
( C 50 692
tbw C 51 692
) C 52 692
. C 53 692
following C 55 692
thiazide C 56 692
therapy C 57 692
( C 58 692
case C 59 692
1 C 60 692
) C 61 692
and C 62 692
during C 63 692
a C 64 692
fluid C 65 692
deprivation C 66 692
test C 67 692
( C 68 692
case C 69 692
2 C 70 692
) C 71 692
a C 72 692
further C 73 692
reduction C 74 692
of C 75 692
ecv C 76 692
and C 77 692
tbw C 78 692
was C 79 692
found C 80 692
. C 81 692
untreated C 83 692
both C 84 692
patients C 85 692
revealed C 86 692
a C 87 692
se C 88 692
- C 89 692
vere C 90 692
hypernatriemia C 91 692
without C 92 692
any C 93 692
increase C 94 692
in C 95 692
the C 96 692
urinary C 97 692
aldosterone C 98 692
excretion C 99 692
. C 100 692
the C 102 692
first C 103 692
patient C 104 692
had C 105 692
a C 106 692
cerebral C 107 692
atro C 108 692
- C 109 692
phy C 110 692
and C 111 692
a C 112 692
rightsided C 113 692
hydronephrosis C 114 692
, C 115 692
a C 116 692
higher C 117 692
diuresis C 118 692
and C 119 692
a C 120 692
lower C 121 692
concentration C 122 692
capacity C 123 692
was C 124 692
found C 125 692
on C 126 692
this C 127 692
side C 128 692
. C 129 692
the C 131 692
patient C 132 692
was C 133 692
treated C 134 692
continuously C 135 692
with C 136 692
thiazide C 137 692
. C 138 692
when C 140 692
an C 141 692
ordinary C 142 692
house C 143 692
diet C 144 692
was C 145 692
given C 146 692
this C 147 692
drug C 148 692
could C 149 692
only C 150 692
maintain C 151 692
normal C 152 692
electrolytemia C 153 692
in C 154 692
combination C 155 692
with C 156 692
spirolactone C 157 692
. C 158 692
a C 160 692
considerable C 161 692
increase C 162 692
in C 163 692
height C 164 692
and C 165 692
psychic C 166 692
development C 167 692
took C 168 692
place C 169 692
during C 170 692
this C 171 692
combined C 172 692
treatment C 173 692
. C 174 692
it C 176 692
is C 177 692
noted C 178 692
, C 179 692
that C 180 692
nephrogenic C 181 692
diabetes C 182 692
insipidus C 183 692
may C 184 692
be C 185 692
present C 186 692
in C 187 692
infants C 188 692
with C 189 692
unexplained C 190 692
fever C 191 692
and C 192 692
vomiting C 193 692
in C 194 692
the C 195 692
absence C 196 692
of C 197 692
polydipsia C 198 692
and C 199 692
polyuria C 200 692
. C 201 692
the C 203 692
urine C 204 692
may C 205 692
even C 206 692
be C 207 692
hypertonic C 208 692
. C 209 692
diuretics C 1 693
in C 2 693
pediatric C 3 693
practice C 4 693
clinical C 5 693
notes C 6 693
and C 7 693
comments C 8 693
with C 9 693
the C 10 693
development C 11 693
of C 12 693
more C 13 693
and C 14 693
more C 15 693
potent C 16 693
oral C 17 693
diuretics C 18 693
in C 19 693
recent C 20 693
years C 21 693
, C 22 693
these C 23 693
drugs C 24 693
which C 25 693
were C 26 693
once C 27 693
looked C 28 693
upon C 29 693
as C 30 693
being C 31 693
of C 32 693
only C 33 693
limited C 34 693
usefulness C 35 693
in C 36 693
pediatrics C 37 693
are C 38 693
now C 39 693
receiving C 40 693
clinical C 41 693
application C 42 693
. C 43 693
they C 45 693
per C 46 693
- C 47 693
mit C 48 693
a C 49 693
new C 50 693
approach C 51 693
to C 52 693
the C 53 693
management C 54 693
of C 55 693
edematous C 56 693
states C 57 693
. C 58 693
that C 60 693
most C 61 693
of C 62 693
them C 63 693
can C 64 693
be C 65 693
given C 66 693
orally C 67 693
is C 68 693
a C 69 693
significant C 70 693
advantage C 71 693
, C 72 693
par C 73 693
- C 74 693
ticularly C 75 693
when C 76 693
coupled C 77 693
with C 78 693
their C 79 693
relative C 80 693
lack C 81 693
of C 82 693
toxicity C 83 693
. C 84 693
although C 86 693
the C 87 693
number C 88 693
of C 89 693
patients C 90 693
in C 91 693
the C 92 693
pediatric C 93 693
age C 94 693
range C 95 693
who C 96 693
require C 97 693
these C 98 693
agents C 99 693
is C 100 693
relatively C 101 693
small C 102 693
, C 103 693
they C 104 693
are C 105 693
valuable C 106 693
adjuncts C 107 693
in C 108 693
the C 109 693
management C 110 693
of C 111 693
chronic C 112 693
renal C 113 693
disease C 114 693
, C 115 693
refractory C 116 693
heart C 117 693
failure C 118 693
, C 119 693
and C 120 693
hyper C 121 693
- C 122 693
tension C 123 693
. C 124 693
this C 126 693
discussion C 127 693
reviews C 128 693
their C 129 693
pharma C 130 693
- C 131 693
cology C 132 693
and C 133 693
clinical C 134 693
indications C 135 693
. C 136 693
the C 1 694
role C 2 694
of C 3 694
aldosterone C 4 694
and C 5 694
vasopressin C 6 694
in C 7 694
the C 8 694
postural C 9 694
changes C 10 694
in C 11 694
renal C 12 694
excretion C 13 694
in C 14 694
normal C 15 694
subjects C 16 694
and C 17 694
patients C 18 694
with C 19 694
idiopathic C 20 694
edema C 21 694
the C 22 694
effects C 23 694
of C 24 694
the C 25 694
upright C 26 694
posture C 27 694
( C 28 694
leisurely C 29 694
walking C 30 694
for C 31 694
2 C 32 694
hours C 33 694
) C 34 694
on C 35 694
half C 36 694
- C 37 694
hourly C 38 694
urine C 39 694
volume C 40 694
, C 41 694
and C 42 694
excretion C 43 694
of C 44 694
sodium C 45 694
and C 46 694
creatinine C 47 694
were C 48 694
studied C 49 694
in C 50 694
13 C 51 694
normal C 52 694
subjects C 53 694
and C 54 694
13 C 55 694
patients C 56 694
with C 57 694
idiopathic C 58 694
edema C 59 694
, C 60 694
while C 61 694
they C 62 694
drank C 63 694
150 C 64 694
or C 65 694
300 C 66 694
ml C 67 694
. C 68 694
of C 70 694
0 C 71 694
. C 72 694
. C 73 694
. C 73 694
per C 74 694
cent C 75 694
sodium C 76 694
chloride C 77 694
solution C 78 694
every C 79 694
half C 80 694
hour C 81 694
. C 82 694
when C 84 694
the C 85 694
2 C 86 694
hours C 87 694
of C 88 694
walking C 89 694
were C 90 694
compared C 91 694
with C 92 694
a C 93 694
preceding C 94 694
recumbent C 95 694
period C 96 694
of C 97 694
4 C 98 694
hours C 99 694
, C 100 694
both C 101 694
groups C 102 694
were C 103 694
found C 104 694
to C 105 694
show C 106 694
a C 107 694
significant C 108 694
antidiuresis C 109 694
upright C 110 694
. C 111 694
the C 113 694
administration C 114 694
of C 115 694
ethanol C 116 694
during C 117 694
the C 118 694
last C 119 694
half C 120 694
hour C 121 694
of C 122 694
recumbency C 123 694
abolished C 124 694
the C 125 694
fall C 126 694
in C 127 694
urine C 128 694
flow C 129 694
and C 130 694
in C 131 694
free C 132 694
water C 133 694
clear C 134 694
- C 135 694
ance C 136 694
during C 137 694
the C 138 694
first C 139 694
hour C 140 694
of C 141 694
walking C 142 694
in C 143 694
the C 144 694
normal C 145 694
subjects C 146 694
and C 147 694
significantly C 148 694
re C 149 694
- C 150 694
duced C 151 694
this C 152 694
fall C 153 694
in C 154 694
the C 155 694
patients C 156 694
with C 157 694
edema C 158 694
. C 159 694
sodium C 161 694
excretion C 162 694
in C 163 694
the C 164 694
normal C 165 694
subjects C 166 694
was C 167 694
slightly C 168 694
but C 169 694
not C 170 694
significantly C 171 694
lower C 172 694
when C 173 694
upright C 174 694
than C 175 694
when C 176 694
recum C 177 694
- C 178 694
bent C 179 694
, C 180 694
but C 181 694
in C 182 694
the C 183 694
edematous C 184 694
patients C 185 694
was C 186 694
significantly C 187 694
lower C 188 694
when C 189 694
upright C 190 694
and C 191 694
fell C 192 694
progressively C 193 694
over C 194 694
the C 195 694
2 C 196 694
hour C 197 694
period C 198 694
. C 199 694
ad C 201 694
- C 202 694
ministration C 203 694
of C 204 694
spironolactone C 205 694
or C 206 694
d C 207 694
- C 208 694
amphetamine C 209 694
increased C 210 694
sodium C 211 694
excretion C 212 694
during C 213 694
recumbency C 214 694
in C 215 694
both C 216 694
groups C 217 694
but C 218 694
increased C 219 694
sodium C 220 694
excretion C 221 694
upright C 222 694
only C 223 694
in C 224 694
the C 225 694
edematous C 226 694
patients C 227 694
to C 228 694
equal C 229 694
that C 230 694
of C 231 694
the C 232 694
normal C 233 694
subjects C 234 694
. C 235 694
creatinine C 237 694
excre C 238 694
- C 239 694
tion C 240 694
was C 241 694
not C 242 694
changed C 243 694
in C 244 694
either C 245 694
group C 246 694
by C 247 694
posture C 248 694
or C 249 694
drug C 250 694
therapy C 251 694
. C 252 694
similar C 254 694
studies C 255 694
were C 256 694
performed C 257 694
on C 258 694
5 C 259 694
patients C 260 694
with C 261 694
un C 262 694
- C 263 694
treated C 264 694
diabetes C 265 694
insipidus C 266 694
and C 267 694
on C 268 694
6 C 269 694
pa C 270 694
- C 271 694
tients C 272 694
with C 273 694
adrenal C 274 694
insufficiency C 275 694
treated C 276 694
with C 277 694
hydrocortisone C 278 694
alone C 279 694
. C 280 694
lack C 282 694
of C 283 694
al C 284 694
- C 285 694
dosterone C 286 694
( C 287 694
in C 288 694
adrenal C 289 694
insufficiency C 290 694
) C 291 694
did C 292 694
not C 293 694
increase C 294 694
the C 295 694
amount C 296 694
of C 297 694
sodium C 298 694
ex C 299 694
- C 300 694
creted C 301 694
above C 302 694
that C 303 694
of C 304 694
normal C 305 694
subjects C 306 694
in C 307 694
recumbency C 308 694
and C 309 694
did C 310 694
not C 311 694
prevent C 312 694
the C 313 694
oc C 314 694
- C 315 694
currence C 316 694
of C 317 694
significant C 318 694
sodium C 319 694
retention C 320 694
in C 321 694
the C 322 694
upright C 323 694
posture C 324 694
. C 325 694
however C 327 694
, C 328 694
lack C 329 694
of C 330 694
adh C 331 694
( C 332 694
in C 333 694
diabetes C 334 694
insipidus C 335 694
) C 336 694
delayed C 337 694
the C 338 694
antidiuresis C 339 694
upright C 340 694
for C 341 694
30 C 342 694
minutes C 343 694
. C 344 694
the C 346 694
results C 347 694
indicate C 348 694
that C 349 694
adh C 350 694
release C 351 694
is C 352 694
probably C 353 694
responsible C 354 694
for C 355 694
the C 356 694
reduction C 357 694
in C 358 694
urine C 359 694
volume C 360 694
during C 361 694
the C 362 694
first C 363 694
30 C 364 694
min C 365 694
- C 366 694
utes C 367 694
after C 368 694
assuming C 369 694
the C 370 694
upright C 371 694
posture C 372 694
, C 373 694
but C 374 694
not C 375 694
thereafter C 376 694
. C 377 694
the C 379 694
excessive C 380 694
magni C 381 694
- C 382 694
tude C 383 694
of C 384 694
the C 385 694
orthostatic C 386 694
antidiuresis C 387 694
in C 388 694
idiopathic C 389 694
edema C 390 694
probably C 391 694
results C 392 694
from C 393 694
a C 394 694
cause C 395 694
other C 396 694
than C 397 694
adh C 398 694
release C 399 694
, C 400 694
since C 401 694
it C 402 694
is C 403 694
not C 404 694
completely C 405 694
overcome C 406 694
by C 407 694
ethanol C 408 694
. C 409 694
reduced C 411 694
na C 412 694
excretion C 413 694
during C 414 694
2 C 415 694
hours C 416 694
in C 417 694
the C 418 694
upright C 419 694
posture C 420 694
can C 421 694
occur C 422 694
in C 423 694
the C 424 694
absence C 425 694
of C 426 694
circulating C 427 694
aldosterone C 428 694
, C 429 694
but C 430 694
the C 431 694
abnormal C 432 694
magnitude C 433 694
of C 434 694
the C 435 694
na C 436 694
re C 437 694
- C 438 694
tention C 439 694
in C 440 694
the C 441 694
patients C 442 694
with C 443 694
idiopathic C 444 694
edema C 445 694
probably C 446 694
results C 447 694
from C 448 694
hyperal C 449 694
- C 450 694
dosteronism C 451 694
. C 452 694
the C 1 695
use C 2 695
and C 3 695
mode C 4 695
of C 5 695
action C 6 695
of C 7 695
ethacrynic C 8 695
acid C 9 695
in C 10 695
nephrogenic C 11 695
diabetes C 12 695
insipidus C 13 695
the C 14 695
use C 15 695
of C 16 695
diuretic C 17 695
agents C 18 695
in C 19 695
the C 20 695
treatment C 21 695
of C 22 695
nephrogenic C 23 695
diabetes C 24 695
insipidus C 25 695
had C 26 695
been C 27 695
re C 28 695
- C 29 695
ported C 30 695
to C 31 695
result C 32 695
in C 33 695
decreased C 34 695
urine C 35 695
volume C 36 695
and C 37 695
decreased C 38 695
clearance C 39 695
of C 40 695
free C 41 695
water C 42 695
. C 43 695
a C 45 695
study C 46 695
of C 47 695
the C 48 695
use C 49 695
of C 50 695
ethacrynic C 51 695
acid C 52 695
, C 53 695
a C 54 695
potent C 55 695
saluretic C 56 695
agent C 57 695
, C 58 695
was C 59 695
instituted C 60 695
in C 61 695
patients C 62 695
with C 63 695
nephrogenic C 64 695
diabetes C 65 695
insipidus C 66 695
in C 67 695
an C 68 695
attempt C 69 695
to C 70 695
achieve C 71 695
a C 72 695
significant C 73 695
antidiuretic C 74 695
response C 75 695
while C 76 695
allowing C 77 695
a C 78 695
liberal C 79 695
sodium C 80 695
diet C 81 695
. C 82 695
intravenous C 84 695
ethacrynic C 85 695
acid C 86 695
resulted C 87 695
in C 88 695
de C 89 695
- C 90 695
creased C 91 695
urine C 92 695
volume C 93 695
, C 94 695
decreased C 95 695
clearance C 96 695
of C 97 695
free C 98 695
water C 99 695
and C 100 695
decreased C 101 695
rpf C 102 695
and C 103 695
gfr C 104 695
. C 105 695
prolonged C 107 695
oral C 108 695
administration C 109 695
of C 110 695
ethacrynic C 111 695
acid C 112 695
promoted C 113 695
a C 114 695
significant C 115 695
antidiuretic C 116 695
re C 117 695
- C 118 695
sponse C 119 695
when C 120 695
the C 121 695
daily C 122 695
sodium C 123 695
intake C 124 695
was C 125 695
limited C 126 695
to C 127 695
60 C 128 695
meq C 129 695
. C 130 695
the C 132 695
effect C 133 695
of C 134 695
ethacrynic C 135 695
acid C 136 695
on C 137 695
renal C 138 695
function C 139 695
, C 140 695
potassium C 141 695
and C 142 695
chlo C 143 695
- C 144 695
ride C 145 695
excretion C 146 695
, C 147 695
and C 148 695
uric C 149 695
acid C 150 695
metabolism C 151 695
are C 152 695
discussed C 153 695
. C 154 695
the C 1 696
treatment C 2 696
of C 3 696
pituitary C 4 696
responsive C 5 696
diabetes C 6 696
insipidus C 7 696
in C 8 696
evaluating C 9 696
therapy C 10 696
in C 11 696
diabetes C 12 696
insipidus C 13 696
, C 14 696
it C 15 696
is C 16 696
important C 17 696
to C 18 696
note C 19 696
we C 20 696
are C 21 696
altering C 22 696
only C 23 696
ten C 24 696
per C 25 696
cent C 26 696
of C 27 696
the C 28 696
reabsorption C 29 696
function C 30 696
of C 31 696
the C 32 696
kidney C 33 696
. C 34 696
the C 36 696
kidney C 37 696
function C 38 696
in C 39 696
a C 40 696
case C 41 696
of C 42 696
diabetes C 43 696
insipidus C 44 696
is C 45 696
as C 46 696
efficient C 47 696
in C 48 696
its C 49 696
activity C 50 696
as C 51 696
are C 52 696
biological C 53 696
tests C 54 696
. C 55 696
the C 57 696
purpose C 58 696
of C 59 696
therapy C 60 696
is C 61 696
patient C 62 696
convenience C 63 696
, C 64 696
economy C 65 696
, C 66 696
and C 67 696
normal C 68 696
function C 69 696
in C 70 696
society C 71 696
. C 72 696
the C 74 696
diabetes C 75 696
insipidus C 76 696
itself C 77 696
does C 78 696
not C 79 696
alter C 80 696
the C 81 696
life C 82 696
span C 83 696
, C 84 696
however C 85 696
, C 86 696
secondary C 87 696
factors C 88 696
may C 89 696
introduce C 90 696
it C 91 696
into C 92 696
a C 93 696
health C 94 696
problem C 95 696
. C 96 696
lysyl C 98 696
- C 99 696
8 C 100 696
- C 101 696
vasopressin C 102 696
nasal C 103 696
spray C 104 696
is C 105 696
effective C 106 696
, C 107 696
offers C 108 696
a C 109 696
maximum C 110 696
of C 111 696
conve C 112 696
- C 113 696
nience C 114 696
, C 115 696
and C 116 696
has C 117 696
produced C 118 696
no C 119 696
untoward C 120 696
reactions C 121 696
. C 122 696
it C 124 696
is C 125 696
, C 126 696
as C 127 696
expected C 128 696
, C 129 696
ineffective C 130 696
in C 131 696
the C 132 696
treatment C 133 696
of C 134 696
extrapituitary C 135 696
( C 136 696
pituitary C 137 696
unresponsive C 138 696
) C 139 696
diabetes C 140 696
insipidus C 141 696
. C 142 696
antidiuretic C 1 697
effect C 2 697
of C 3 697
hydrochlorothiazide C 4 697
in C 5 697
diabetes C 6 697
insipidus C 7 697
and C 8 697
ch C 9 697
' C 10 697
iuan C 11 697
- C 12 697
lu C 13 697
12 C 14 697
cases C 15 697
of C 16 697
diabetes C 17 697
insipidus C 18 697
were C 19 697
studied C 20 697
during C 21 697
hydrochlorothia C 22 697
- C 23 697
zide C 24 697
therapy C 25 697
under C 26 697
a C 27 697
fixed C 28 697
diet C 29 697
. C 30 697
the C 32 697
symptoms C 33 697
, C 34 697
blood C 35 697
pressure C 36 697
, C 37 697
urinary C 38 697
volume C 39 697
, C 40 697
blood C 41 697
and C 42 697
urinary C 43 697
electrolytes C 44 697
, C 45 697
plasma C 46 697
volume C 47 697
, C 48 697
electrocardiogram C 49 697
and C 50 697
hypertonic C 51 697
saline C 52 697
intravenous C 53 697
drip C 54 697
test C 55 697
were C 56 697
compared C 57 697
before C 58 697
and C 59 697
after C 60 697
treat C 61 697
- C 62 697
ment C 63 697
. C 64 697
a C 66 697
daily C 67 697
dose C 68 697
of C 69 697
100 C 70 697
- C 71 697
150 C 72 697
mg C 73 697
brought C 74 697
down C 75 697
the C 76 697
urinary C 77 697
volume C 78 697
to C 79 697
about C 80 697
50 C 81 697
% C 82 697
of C 83 697
the C 84 697
pretreatment C 85 697
value C 86 697
. C 87 697
the C 89 697
initial C 90 697
antidiuretic C 91 697
effect C 92 697
was C 93 697
noted C 94 697
8 C 95 697
hours C 96 697
after C 97 697
medication C 98 697
and C 99 697
the C 100 697
maximal C 101 697
effect C 102 697
after C 103 697
the C 104 697
fourth C 105 697
or C 106 697
fifth C 107 697
day C 108 697
. C 109 697
owing C 111 697
to C 112 697
the C 113 697
kaluretic C 114 697
action C 115 697
of C 116 697
the C 117 697
drug C 118 697
, C 119 697
2 C 120 697
- C 121 697
4 C 122 697
gm C 123 697
of C 124 697
potassium C 125 697
salt C 126 697
was C 127 697
also C 128 697
given C 129 697
each C 130 697
day C 131 697
. C 132 697
satisfactory C 134 697
re C 135 697
- C 136 697
sults C 137 697
were C 138 697
obtained C 139 697
with C 140 697
dietary C 141 697
sodium C 142 697
ion C 143 697
at C 144 697
not C 145 697
more C 146 697
than C 147 697
200 C 148 697
meq C 149 697
daily C 150 697
, C 151 697
but C 152 697
ingestion C 153 697
of C 154 697
excessive C 155 697
table C 156 697
salt C 157 697
fre C 158 697
- C 159 697
quently C 160 697
diminished C 161 697
or C 162 697
even C 163 697
destroyed C 164 697
the C 165 697
therapeutic C 166 697
effect C 167 697
. C 168 697
the C 170 697
physical C 171 697
signs C 172 697
, C 173 697
blood C 174 697
pres C 175 697
- C 176 697
sure C 177 697
and C 178 697
ecg C 179 697
were C 180 697
essentially C 181 697
un C 182 697
- C 183 697
changed C 184 697
and C 185 697
the C 186 697
plasma C 187 697
volumes C 188 697
were C 189 697
altered C 190 697
after C 191 697
treatment C 192 697
. C 193 697
the C 195 697
hyper C 196 697
- C 197 697
tonic C 198 697
saline C 199 697
test C 200 697
was C 201 697
improved C 202 697
in C 203 697
some C 204 697
of C 205 697
the C 206 697
patients C 207 697
. C 208 697
low C 210 697
salt C 211 697
syndrome C 212 697
was C 213 697
fre C 214 697
- C 215 697
quently C 216 697
encountered C 217 697
as C 218 697
the C 219 697
therapy C 220 697
continued C 221 697
over C 222 697
1 C 223 697
month C 224 697
. C 225 697
but C 227 697
this C 228 697
and C 229 697
even C 230 697
secondary C 231 697
failure C 232 697
could C 233 697
be C 234 697
pre C 235 697
- C 236 697
vented C 237 697
by C 238 697
timely C 239 697
use C 240 697
of C 241 697
intermittent C 242 697
or C 243 697
alternative C 244 697
regimen C 245 697
. C 246 697
the C 248 697
therapeutic C 249 697
mechanism C 250 697
, C 251 697
indications C 252 697
and C 253 697
side C 254 697
effects C 255 697
of C 256 697
the C 257 697
drug C 258 697
were C 259 697
briefly C 260 697
discussed C 261 697
. C 262 697
the C 264 697
drug C 265 697
might C 266 697
possibly C 267 697
act C 268 697
through C 269 697
the C 270 697
mechanism C 271 697
of C 272 697
salt C 273 697
depletion C 274 697
, C 275 697
contraction C 276 697
of C 277 697
extracel C 278 697
- C 279 697
lular C 280 697
fluid C 281 697
volume C 282 697
and C 283 697
decrease C 284 697
of C 285 697
renal C 286 697
glomerular C 287 697
filtrate C 288 697
, C 289 697
and C 290 697
in C 291 697
consequence C 292 697
urinary C 293 697
volume C 294 697
decreases C 295 697
and C 296 697
thirst C 297 697
is C 298 697
alleviated C 299 697
. C 300 697
the C 1 698
effect C 2 698
of C 3 698
hydrochlorothiazide C 4 698
on C 5 698
water C 6 698
intake C 7 698
and C 8 698
plasma C 9 698
osmolality C 10 698
in C 11 698
diabetes C 12 698
insipidus C 13 698
in C 14 698
the C 15 698
rat C 16 698
a C 17 698
fall C 18 698
in C 19 698
plasma C 20 698
osmolality C 21 698
accompanied C 22 698
the C 23 698
reduction C 24 698
of C 25 698
urine C 26 698
volume C 27 698
in C 28 698
rats C 29 698
with C 30 698
hypothalamic C 31 698
diabetes C 32 698
insipidus C 33 698
, C 34 698
given C 35 698
hydrochlorothiazide C 36 698
and C 37 698
an C 38 698
otherwise C 39 698
normal C 40 698
diet C 41 698
. C 42 698
the C 44 698
plasma C 45 698
concentration C 46 698
was C 47 698
not C 48 698
reduced C 49 698
with C 50 698
a C 51 698
high C 52 698
sodium C 53 698
intake C 54 698
, C 55 698
although C 56 698
urine C 57 698
volume C 58 698
still C 59 698
fell C 60 698
. C 61 698
normal C 63 698
rats C 64 698
and C 65 698
hypo C 66 698
- C 67 698
thalamic C 68 698
obese C 69 698
rats C 70 698
increased C 71 698
their C 72 698
water C 73 698
turnover C 74 698
after C 75 698
hydrochlorothiazide C 76 698
, C 77 698
yet C 78 698
their C 79 698
plasma C 80 698
concentration C 81 698
fell C 82 698
. C 83 698
moreover C 85 698
the C 86 698
antidiuretic C 87 698
response C 88 698
to C 89 698
vasopressin C 90 698
, C 91 698
which C 92 698
is C 93 698
purely C 94 698
renal C 95 698
, C 96 698
was C 97 698
also C 98 698
accompanied C 99 698
by C 100 698
plasma C 101 698
dilution C 102 698
; C 103 698
although C 104 698
it C 105 698
is C 106 698
self C 107 698
- C 108 698
evident C 109 698
that C 110 698
rats C 111 698
which C 112 698
drink C 113 698
less C 114 698
are C 115 698
less C 116 698
thirsty C 117 698
, C 118 698
the C 119 698
reduction C 120 698
in C 121 698
thirst C 122 698
after C 123 698
hydrochlorothiazide C 124 698
may C 125 698
not C 126 698
be C 127 698
a C 128 698
direct C 129 698
result C 130 698
of C 131 698
the C 132 698
change C 133 698
in C 134 698
plasma C 135 698
osmolality C 136 698
. C 137 698
as C 139 698
previously C 140 698
shown C 141 698
in C 142 698
patients C 143 698
( C 144 698
kennedy C 145 698
and C 146 698
hill C 147 698
, C 148 698
1963 C 149 698
) C 150 698
a C 151 698
high C 152 698
sodium C 153 698
intake C 154 698
increased C 155 698
free C 156 698
water C 157 698
clearance C 158 698
in C 159 698
diabetes C 160 698
insipidus C 161 698
but C 162 698
did C 163 698
not C 164 698
interfere C 165 698
with C 166 698
the C 167 698
reduction C 168 698
of C 169 698
polyuria C 170 698
by C 171 698
hydrochlorothiazide C 172 698
, C 173 698
whereas C 174 698
a C 175 698
high C 176 698
potassium C 177 698
intake C 178 698
reduced C 179 698
free C 180 698
water C 181 698
clearance C 182 698
and C 183 698
prevented C 184 698
any C 185 698
effect C 186 698
of C 187 698
the C 188 698
drug C 189 698
on C 190 698
urine C 191 698
volume C 192 698
. C 193 698
antidiuretic C 1 699
properties C 2 699
of C 3 699
chlorothiazide C 4 699
in C 5 699
diabetes C 6 699
insipidus C 7 699
dogs C 8 699
chlorothiazide C 9 699
was C 10 699
found C 11 699
to C 12 699
decrease C 13 699
urine C 14 699
volume C 15 699
and C 16 699
increase C 17 699
urine C 18 699
con C 19 699
- C 20 699
centration C 21 699
in C 22 699
diabetes C 23 699
insipidus C 24 699
dogs C 25 699
. C 26 699
there C 28 699
was C 29 699
no C 30 699
change C 31 699
in C 32 699
gfr C 33 699
, C 34 699
rpf C 35 699
, C 36 699
tmpah C 37 699
, C 38 699
plasma C 39 699
volume C 40 699
, C 41 699
extracellular C 42 699
fluid C 43 699
or C 44 699
total C 45 699
body C 46 699
water C 47 699
. C 48 699
the C 50 699
one C 51 699
con C 52 699
- C 53 699
sistent C 54 699
altered C 55 699
function C 56 699
was C 57 699
a C 58 699
decrease C 59 699
in C 60 699
" C 61 699
free C 62 699
water C 63 699
" C 64 699
clearance C 65 699
. C 66 699
diazoxide C 68 699
and C 69 699
mercuhydrin C 70 699
were C 71 699
not C 72 699
antidiuretic C 73 699
. C 74 699
it C 76 699
is C 77 699
believed C 78 699
that C 79 699
the C 80 699
antidiuretic C 81 699
action C 82 699
is C 83 699
dependent C 84 699
on C 85 699
the C 86 699
chlorothiazide C 87 699
- C 88 699
induced C 89 699
saluresis C 90 699
. C 91 699
although C 93 699
the C 94 699
mechanism C 95 699
of C 96 699
this C 97 699
antidiuresis C 98 699
has C 99 699
not C 100 699
been C 101 699
clearly C 102 699
de C 103 699
- C 104 699
fined C 105 699
, C 106 699
it C 107 699
seems C 108 699
best C 109 699
explained C 110 699
by C 111 699
postu C 112 699
- C 113 699
lating C 114 699
a C 115 699
decrease C 116 699
in C 117 699
filtrate C 118 699
reaching C 119 699
the C 120 699
distal C 121 699
nephron C 122 699
( C 123 699
giving C 124 699
a C 125 699
decreased C 126 699
final C 127 699
urine C 128 699
volume C 129 699
) C 130 699
coupled C 131 699
with C 132 699
inhibition C 133 699
of C 134 699
solute C 135 699
reabsorption C 136 699
in C 137 699
the C 138 699
distal C 139 699
tubule C 140 699
( C 141 699
preventing C 142 699
the C 143 699
selective C 144 699
reabsorption C 145 699
of C 146 699
solute C 147 699
in C 148 699
the C 149 699
distal C 150 699
tubule C 151 699
that C 152 699
is C 153 699
nor C 154 699
- C 155 699
mally C 156 699
seen C 157 699
, C 158 699
accounting C 159 699
for C 160 699
the C 161 699
increase C 162 699
in C 163 699
urine C 164 699
concentration C 165 699
) C 166 699
. C 167 699
the C 169 699
possible C 170 699
role C 171 699
of C 172 699
the C 173 699
mineralocorticoids C 174 699
in C 175 699
the C 176 699
antidiuretic C 177 699
response C 178 699
to C 179 699
chlorothiazide C 180 699
therapy C 181 699
was C 182 699
investigated C 183 699
in C 184 699
diabetes C 185 699
in C 186 699
- C 187 699
sipidus C 188 699
and C 189 699
adrenalectomized C 190 699
dogs C 191 699
. C 192 699
ad C 194 699
- C 195 699
ministration C 196 699
of C 197 699
sodium C 198 699
- C 199 699
retaining C 200 699
steroids C 201 699
to C 202 699
diabetes C 203 699
insipidus C 204 699
dogs C 205 699
did C 206 699
not C 207 699
re C 208 699
- C 209 699
produce C 210 699
the C 211 699
urinary C 212 699
changes C 213 699
associated C 214 699
with C 215 699
chlorothiazide C 216 699
therapy C 217 699
. C 218 699
in C 220 699
addition C 221 699
, C 222 699
the C 223 699
antidiuretic C 224 699
response C 225 699
to C 226 699
chlorothia C 227 699
- C 228 699
zide C 229 699
was C 230 699
not C 231 699
altered C 232 699
by C 233 699
adrenalectomy C 234 699
or C 235 699
spironolactone C 236 699
administration C 237 699
. C 238 699
there C 240 699
- C 241 699
fore C 242 699
, C 243 699
the C 244 699
presence C 245 699
of C 246 699
the C 247 699
sodium C 248 699
- C 249 699
retain C 250 699
- C 251 699
ing C 252 699
steroids C 253 699
are C 254 699
not C 255 699
essential C 256 699
for C 257 699
the C 258 699
anti C 259 699
- C 260 699
diuretic C 261 699
response C 262 699
of C 263 699
chlorothiazide C 264 699
in C 265 699
diabetes C 266 699
insipidus C 267 699
. C 268 699
stable C 1 700
strontium C 2 700
in C 3 700
human C 4 700
bone C 5 700
: C 6 700
geographical C 7 700
and C 8 700
age C 9 700
differences C 10 700
in C 11 700
the C 12 700
united C 13 700
kingdom C 14 700
and C 15 700
their C 16 700
correlation C 17 700
with C 18 700
levels C 19 700
of C 20 700
strontium C 21 700
- C 22 700
90 C 23 700
a C 24 700
re C 25 700
- C 26 700
assessment C 27 700
has C 28 700
been C 29 700
made C 30 700
of C 31 700
published C 32 700
data C 33 700
of C 34 700
other C 35 700
workers C 36 700
on C 37 700
sr C 38 700
and C 39 700
90 C 40 700
sr C 41 700
in C 42 700
human C 43 700
bone C 44 700
. C 45 700
in C 47 700
different C 48 700
parts C 49 700
of C 50 700
great C 51 700
britain C 52 700
the C 53 700
mean C 54 700
ratio C 55 700
of C 56 700
stable C 57 700
sr C 58 700
to C 59 700
ca C 60 700
in C 61 700
adult C 62 700
human C 63 700
bones C 64 700
ranged C 65 700
from C 66 700
240 C 67 700
to C 68 700
475 C 69 700
ug C 70 700
/ C 71 700
g C 72 700
. C 73 700
extreme C 75 700
values C 76 700
were C 77 700
found C 78 700
even C 79 700
as C 80 700
close C 81 700
as C 82 700
40 C 83 700
miles C 84 700
apart C 85 700
( C 86 700
carlisle C 87 700
v C 88 700
. C 89 700
westmorland C 91 700
) C 92 700
. C 93 700
perinatal C 95 700
levels C 96 700
of C 97 700
stable C 98 700
sr C 99 700
were C 100 700
correlated C 101 700
with C 102 700
adult C 103 700
levels C 104 700
. C 105 700
an C 107 700
estimate C 108 700
of C 109 700
placental C 110 700
discrimination C 111 700
may C 112 700
be C 113 700
derived C 114 700
from C 115 700
the C 116 700
ratio C 117 700
, C 118 700
perinatal C 119 700
level C 120 700
: C 121 700
adult C 122 700
level C 123 700
of C 124 700
about C 125 700
0 C 126 700
. C 127 700
. C 128 700
. C 129 700
the C 131 700
concentration C 132 700
of C 133 700
stable C 134 700
sr C 135 700
in C 136 700
bones C 137 700
of C 138 700
children C 139 700
from C 140 700
2 C 141 700
to C 142 700
5 C 143 700
years C 144 700
old C 145 700
or C 146 700
more C 147 700
was C 148 700
not C 149 700
demonstrably C 150 700
different C 151 700
from C 152 700
that C 153 700
of C 154 700
adults C 155 700
except C 156 700
in C 157 700
one C 158 700
area C 159 700
, C 160 700
carlisle C 161 700
. C 162 700
with C 164 700
the C 165 700
striking C 166 700
exception C 167 700
of C 168 700
london C 169 700
and C 170 700
south C 171 700
- C 172 700
east C 173 700
england C 174 700
the C 175 700
change C 176 700
from C 177 700
perinatal C 178 700
to C 179 700
adult C 180 700
levels C 181 700
occurred C 182 700
in C 183 700
the C 184 700
2 C 185 700
nd C 186 700
year C 187 700
of C 188 700
life C 189 700
: C 190 700
there C 191 700
was C 192 700
no C 193 700
particular C 194 700
change C 195 700
during C 196 700
the C 197 700
first C 198 700
9 C 199 700
months C 200 700
or C 201 700
so C 202 700
. C 203 700
in C 205 700
london C 206 700
and C 207 700
south C 208 700
- C 209 700
east C 210 700
england C 211 700
the C 212 700
pattern C 213 700
of C 214 700
change C 215 700
with C 216 700
age C 217 700
was C 218 700
quite C 219 700
different C 220 700
: C 221 700
there C 222 700
was C 223 700
a C 224 700
progressive C 225 700
rise C 226 700
in C 227 700
sr C 228 700
level C 229 700
from C 230 700
shortly C 231 700
after C 232 700
birth C 233 700
to C 234 700
the C 235 700
end C 236 700
of C 237 700
the C 238 700
1 C 239 700
st C 240 700
year C 241 700
by C 242 700
which C 243 700
time C 244 700
adult C 245 700
levels C 246 700
were C 247 700
reached C 248 700
. C 249 700
it C 251 700
is C 252 700
concluded C 253 700
that C 254 700
geographical C 255 700
differences C 256 700
need C 257 700
to C 258 700
be C 259 700
taken C 260 700
into C 261 700
account C 262 700
when C 263 700
making C 264 700
physiological C 265 700
deductions C 266 700
about C 267 700
turnover C 268 700
of C 269 700
bone C 270 700
salt C 271 700
from C 272 700
changes C 273 700
with C 274 700
age C 275 700
in C 276 700
the C 277 700
level C 278 700
of C 279 700
stable C 280 700
sr C 281 700
. C 282 700
when C 284 700
children C 285 700
in C 286 700
the C 287 700
south C 288 700
- C 289 700
east C 290 700
of C 291 700
england C 292 700
and C 293 700
the C 294 700
rest C 295 700
of C 296 700
the C 297 700
united C 298 700
kingdom C 299 700
were C 300 700
compared C 301 700
, C 302 700
there C 303 700
seemed C 304 700
to C 305 700
be C 306 700
a C 307 700
broad C 308 700
inverse C 309 700
correlation C 310 700
between C 311 700
levels C 312 700
of C 313 700
stable C 314 700
sr C 315 700
and C 316 700
of C 317 700
90 C 318 700
sr C 319 700
. C 320 700
detailed C 322 700
analysis C 323 700
of C 324 700
perinatal C 325 700
results C 326 700
from C 327 700
one C 328 700
area C 329 700
suggested C 330 700
that C 331 700
the C 332 700
level C 333 700
of C 334 700
stable C 335 700
sr C 336 700
in C 337 700
bone C 338 700
was C 339 700
somewhat C 340 700
higher C 341 700
in C 342 700
summer C 343 700
than C 344 700
in C 345 700
winter C 346 700
and C 347 700
somewhat C 348 700
higher C 349 700
in C 350 700
anatomically C 351 700
normal C 352 700
babies C 353 700
than C 354 700
in C 355 700
babies C 356 700
dying C 357 700
with C 358 700
gross C 359 700
congenital C 360 700
defects C 361 700
. C 362 700
90 C 364 700
sr C 365 700
showed C 366 700
the C 367 700
seasonal C 368 700
change C 369 700
only C 370 700
. C 371 700
fibrin C 1 701
and C 2 701
thrombosis C 3 701
in C 4 701
the C 5 701
central C 6 701
nervous C 7 701
system C 8 701
in C 9 701
children C 10 701
with C 11 701
particular C 12 701
reference C 13 701
to C 14 701
congenital C 15 701
hydrocephalus C 16 701
while C 17 701
rare C 18 701
metabolic C 19 701
and C 20 701
degenerative C 21 701
diseases C 22 701
of C 23 701
the C 24 701
central C 25 701
nervous C 26 701
system C 27 701
in C 28 701
children C 29 701
are C 30 701
reported C 31 701
at C 32 701
great C 33 701
length C 34 701
, C 35 701
the C 36 701
much C 37 701
commoner C 38 701
diseases C 39 701
relating C 40 701
to C 41 701
vascular C 42 701
incidents C 43 701
are C 44 701
rarely C 45 701
discussed C 46 701
. C 47 701
only C 49 701
those C 50 701
aspects C 51 701
of C 52 701
disease C 53 701
of C 54 701
the C 55 701
central C 56 701
nervous C 57 701
system C 58 701
related C 59 701
to C 60 701
thrombosis C 61 701
and C 62 701
the C 63 701
deposition C 64 701
of C 65 701
fibrin C 66 701
will C 67 701
be C 68 701
discussed C 69 701
here C 70 701
; C 71 701
diseases C 72 701
related C 73 701
to C 74 701
general C 75 701
vasculitis C 76 701
and C 77 701
aneurysm C 78 701
are C 79 701
omitted C 80 701
. C 81 701
the C 83 701
conditions C 84 701
discussed C 85 701
here C 86 701
fall C 87 701
into C 88 701
two C 89 701
main C 90 701
categories C 91 701
: C 92 701
first C 93 701
, C 94 701
the C 95 701
presence C 96 701
of C 97 701
thrombosis C 98 701
in C 99 701
small C 100 701
blood C 101 701
vessels C 102 701
or C 103 701
in C 104 701
the C 105 701
large C 106 701
superficial C 107 701
veins C 108 701
draining C 109 701
the C 110 701
brain C 111 701
, C 112 701
and C 113 701
second C 114 701
, C 115 701
the C 116 701
deposition C 117 701
of C 118 701
fibrin C 119 701
either C 120 701
in C 121 701
the C 122 701
ventricles C 123 701
or C 124 701
on C 125 701
the C 126 701
membranes C 127 701
overlying C 128 701
the C 129 701
brain C 130 701
in C 131 701
association C 132 701
with C 133 701
thrombotic C 134 701
lesions C 135 701
, C 136 701
haemorrhage C 137 701
, C 138 701
or C 139 701
infiltration C 140 701
. C 141 701
hydrocephalus C 1 702
due C 2 702
to C 3 702
unrecognized C 4 702
cerebellar C 5 702
astrocytoma C 6 702
treated C 7 702
by C 8 702
ventriculoatrial C 9 702
shunt C 10 702
for C 11 702
four C 12 702
years C 13 702
a C 14 702
case C 15 702
of C 16 702
a C 17 702
9 C 18 702
- C 19 702
year C 20 702
- C 21 702
old C 22 702
girl C 23 702
is C 24 702
presented C 25 702
in C 26 702
whom C 27 702
prolonged C 28 702
palliation C 29 702
of C 30 702
signs C 31 702
of C 32 702
increased C 33 702
intracranial C 34 702
pressure C 35 702
, C 36 702
presumed C 37 702
to C 38 702
be C 39 702
due C 40 702
to C 41 702
aqueductal C 42 702
obstruction C 43 702
, C 44 702
was C 45 702
achieved C 46 702
by C 47 702
means C 48 702
of C 49 702
a C 50 702
ventriculoatrial C 51 702
shunt C 52 702
. C 53 702
four C 55 702
years C 56 702
after C 57 702
placement C 58 702
of C 59 702
the C 60 702
shunt C 61 702
, C 62 702
signs C 63 702
of C 64 702
a C 65 702
cerebellar C 66 702
mass C 67 702
became C 68 702
apparent C 69 702
. C 70 702
the C 72 702
neoplasm C 73 702
, C 74 702
a C 75 702
cystic C 76 702
astrocytoma C 77 702
, C 78 702
was C 79 702
subsequently C 80 702
totally C 81 702
resected C 82 702
and C 83 702
the C 84 702
shunt C 85 702
was C 86 702
removed C 87 702
. C 88 702
air C 90 702
studies C 91 702
demonstrating C 92 702
diminution C 93 702
of C 94 702
ventricular C 95 702
size C 96 702
within C 97 702
this C 98 702
four C 99 702
year C 100 702
period C 101 702
are C 102 702
compared C 103 702
. C 104 702
hydrocephalus C 1 703
the C 2 703
problem C 3 703
of C 4 703
hydrocephalus C 5 703
, C 6 703
formerly C 7 703
a C 8 703
hopeless C 9 703
one C 10 703
, C 11 703
has C 12 703
in C 13 703
recent C 14 703
years C 15 703
begun C 16 703
to C 17 703
yield C 18 703
to C 19 703
clinical C 20 703
research C 21 703
. C 22 703
the C 24 703
indications C 25 703
for C 26 703
the C 27 703
new C 28 703
forms C 29 703
of C 30 703
treatment C 31 703
, C 32 703
and C 33 703
their C 34 703
drawbacks C 35 703
, C 36 703
are C 37 703
clearly C 38 703
delineated C 39 703
in C 40 703
this C 41 703
discussion C 42 703
by C 43 703
a C 44 703
leading C 45 703
authority C 46 703
in C 47 703
the C 48 703
field C 49 703
. C 50 703
a C 1 704
case C 2 704
of C 3 704
unilateral C 4 704
hydrocephalus C 5 704
secondary C 6 704
to C 7 704
occlusion C 8 704
of C 9 704
one C 10 704
foramen C 11 704
of C 12 704
monro C 13 704
a C 14 704
unique C 15 704
case C 16 704
of C 17 704
unilateral C 18 704
obstructive C 19 704
hydro C 20 704
- C 21 704
cephalus C 22 704
secondary C 23 704
to C 24 704
occlusion C 25 704
of C 26 704
one C 27 704
foramen C 28 704
of C 29 704
monro C 30 704
by C 31 704
gliomatosis C 32 704
in C 33 704
a C 34 704
3 C 35 704
- C 36 704
day C 37 704
- C 38 704
old C 39 704
infant C 40 704
is C 41 704
reported C 42 704
. C 43 704
calcification C 1 705
within C 2 705
congenital C 3 705
aneurysms C 4 705
of C 5 705
the C 6 705
vein C 7 705
of C 8 705
galen C 9 705
thirty C 10 705
- C 11 705
one C 12 705
cases C 13 705
of C 14 705
aneurysm C 15 705
of C 16 705
the C 17 705
vein C 18 705
of C 19 705
galen C 20 705
had C 21 705
been C 22 705
reported C 23 705
previ C 24 705
- C 25 705
ously C 26 705
. C 27 705
calcification C 29 705
within C 30 705
the C 31 705
wall C 32 705
of C 33 705
the C 34 705
aneurysm C 35 705
was C 36 705
visible C 37 705
on C 38 705
plain C 39 705
skull C 40 705
roent C 41 705
- C 42 705
genograms C 43 705
in C 44 705
6 C 45 705
of C 46 705
this C 47 705
number C 48 705
. C 49 705
the C 51 705
present C 52 705
communication C 53 705
describes C 54 705
an C 55 705
additional C 56 705
case C 57 705
in C 58 705
which C 59 705
calcification C 60 705
of C 61 705
the C 62 705
aneurysm C 63 705
was C 64 705
discovered C 65 705
at C 66 705
the C 67 705
age C 68 705
of C 69 705
9 C 70 705
years C 71 705
, C 72 705
the C 73 705
youngest C 74 705
patient C 75 705
heretofore C 76 705
reported C 77 705
. C 78 705
ventriculo C 1 706
- C 2 706
venous C 3 706
shunts C 4 706
for C 5 706
infantile C 6 706
hydrocephalus C 7 706
a C 8 706
review C 9 706
of C 10 706
48 C 11 706
hydrocephalic C 12 706
patients C 13 706
treated C 14 706
with C 15 706
atrioventricular C 16 706
shunts C 17 706
during C 18 706
a C 19 706
5 C 20 706
- C 21 706
year C 22 706
period C 23 706
has C 24 706
been C 25 706
presented C 26 706
. C 27 706
we C 29 706
have C 30 706
discussed C 31 706
function C 32 706
of C 33 706
the C 34 706
shunt C 35 706
, C 36 706
complica C 37 706
- C 38 706
tions C 39 706
of C 40 706
the C 41 706
procedure C 42 706
, C 43 706
and C 44 706
revisions C 45 706
neces C 46 706
- C 47 706
sitated C 48 706
by C 49 706
nonfunctioning C 50 706
. C 51 706
the C 53 706
overall C 54 706
75 C 55 706
per C 56 706
cent C 57 706
survival C 58 706
rate C 59 706
and C 60 706
14 C 61 706
. C 62 706
. C 63 706
per C 64 706
cent C 65 706
in C 66 706
- C 67 706
fection C 68 706
rate C 69 706
is C 70 706
comparable C 71 706
to C 72 706
that C 73 706
in C 74 706
other C 75 706
series C 76 706
. C 77 706
the C 79 706
major C 80 706
cause C 81 706
of C 82 706
death C 83 706
in C 84 706
our C 85 706
pa C 86 706
- C 87 706
tients C 88 706
has C 89 706
been C 90 706
infection C 91 706
. C 92 706
our C 94 706
experience C 95 706
to C 96 706
date C 97 706
supports C 98 706
the C 99 706
ob C 100 706
- C 101 706
servation C 102 706
that C 103 706
spontaneous C 104 706
arrest C 105 706
of C 106 706
the C 107 706
hy C 108 706
- C 109 706
drocephalic C 110 706
process C 111 706
does C 112 706
not C 113 706
occur C 114 706
once C 115 706
a C 116 706
ventriculo C 117 706
- C 118 706
venous C 119 706
shunt C 120 706
has C 121 706
been C 122 706
estab C 123 706
- C 124 706
lished C 125 706
. C 126 706
meticulous C 128 706
introduction C 129 706
of C 130 706
a C 131 706
ventriculo C 132 706
- C 133 706
venous C 134 706
shunt C 135 706
appears C 136 706
to C 137 706
be C 138 706
the C 139 706
present C 140 706
treat C 141 706
- C 142 706
ment C 143 706
of C 144 706
choice C 145 706
for C 146 706
patients C 147 706
with C 148 706
severe C 149 706
hy C 150 706
- C 151 706
drocephalus C 152 706
. C 153 706
results C 155 706
are C 156 706
only C 157 706
satisfactory C 158 706
when C 159 706
the C 160 706
patients C 161 706
are C 162 706
carefully C 163 706
followed C 164 706
and C 165 706
complications C 166 706
recognized C 167 706
and C 168 706
treated C 169 706
promptly C 170 706
. C 171 706
congenital C 1 707
malformations C 2 707
of C 3 707
c C 4 707
. C 5 707
. C 6 707
. C 7 707
. C 8 707
. C 9 707
it C 11 707
seems C 12 707
that C 13 707
only C 14 707
a C 15 707
small C 16 707
proportion C 17 707
of C 18 707
malformations C 19 707
of C 20 707
the C 21 707
central C 22 707
nervous C 23 707
system C 24 707
can C 25 707
be C 26 707
explained C 27 707
in C 28 707
simple C 29 707
genetical C 30 707
terms C 31 707
and C 32 707
that C 33 707
most C 34 707
are C 35 707
dependent C 36 707
, C 37 707
to C 38 707
some C 39 707
extent C 40 707
at C 41 707
least C 42 707
, C 43 707
on C 44 707
environmental C 45 707
factors C 46 707
. C 47 707
the C 49 707
nature C 50 707
of C 51 707
these C 52 707
has C 53 707
yet C 54 707
to C 55 707
be C 56 707
determined C 57 707
. C 58 707
dr C 60 707
. C 61 707
williamson C 63 707
found C 64 707
that C 65 707
the C 66 707
maternal C 67 707
aunts C 68 707
, C 69 707
uncles C 70 707
, C 71 707
and C 72 707
cousins C 73 707
of C 74 707
her C 75 707
index C 76 707
cases C 77 707
of C 78 707
anencephalus C 79 707
and C 80 707
spina C 81 707
bifida C 82 707
were C 83 707
more C 84 707
frequently C 85 707
affected C 86 707
than C 87 707
the C 88 707
paternal C 89 707
relatives C 90 707
were C 91 707
. C 92 707
she C 94 707
suggested C 95 707
that C 96 707
mothers C 97 707
of C 98 707
affected C 99 707
children C 100 707
had C 101 707
some C 102 707
genetic C 103 707
factor C 104 707
which C 105 707
modifies C 106 707
the C 107 707
intra C 108 707
- C 109 707
uterine C 110 707
environment C 111 707
and C 112 707
thus C 113 707
predisposes C 114 707
the C 115 707
embryo C 116 707
to C 117 707
these C 118 707
malformations C 119 707
. C 120 707
such C 122 707
a C 123 707
hypothesis C 124 707
opens C 125 707
up C 126 707
interesting C 127 707
possibilities C 128 707
, C 129 707
but C 130 707
before C 131 707
accepting C 132 707
it C 133 707
one C 134 707
would C 135 707
have C 136 707
to C 137 707
be C 138 707
satisfied C 139 707
that C 140 707
the C 141 707
higher C 142 707
incidence C 143 707
in C 144 707
maternal C 145 707
relatives C 146 707
is C 147 707
not C 148 707
merely C 149 707
due C 150 707
to C 151 707
the C 152 707
fact C 153 707
that C 154 707
the C 155 707
history C 156 707
is C 157 707
obtained C 158 707
in C 159 707
most C 160 707
cases C 161 707
from C 162 707
the C 163 707
mother C 164 707
. C 165 707
experimental C 1 708
studies C 2 708
on C 3 708
cerebrospinal C 4 708
fluid C 5 708
flow C 6 708
a C 7 708
mixed C 8 708
suspension C 9 708
of C 10 708
kaolin C 11 708
and C 12 708
lyco C 13 708
- C 14 708
podium C 15 708
was C 16 708
injected C 17 708
into C 18 708
the C 19 708
cisterna C 20 708
magna C 21 708
of C 22 708
dogs C 23 708
. C 24 708
blockade C 26 708
of C 27 708
csf C 28 708
space C 29 708
was C 30 708
produced C 31 708
successfully C 32 708
in C 33 708
63 C 34 708
of C 35 708
75 C 36 708
dogs C 37 708
; C 38 708
in C 39 708
48 C 40 708
of C 41 708
the C 42 708
63 C 43 708
, C 44 708
ventricular C 45 708
dilatation C 46 708
of C 47 708
more C 48 708
than C 49 708
interme C 50 708
- C 51 708
diate C 52 708
degree C 53 708
was C 54 708
observed C 55 708
. C 56 708
in C 58 708
these C 59 708
hydrocephalic C 60 708
dogs C 61 708
experimental C 62 708
shunting C 63 708
was C 64 708
performed C 65 708
either C 66 708
between C 67 708
the C 68 708
lateral C 69 708
ventricle C 70 708
and C 71 708
the C 72 708
lumbar C 73 708
cistern C 74 708
or C 75 708
be C 76 708
- C 77 708
tween C 78 708
the C 79 708
unilateral C 80 708
lateral C 81 708
ventricle C 82 708
and C 83 708
the C 84 708
contralateral C 85 708
cerebral C 86 708
subarachnoid C 87 708
space C 88 708
. C 89 708
uni C 91 708
- C 92 708
directional C 93 708
, C 94 708
steady C 95 708
csf C 96 708
flow C 97 708
averaged C 98 708
0 C 99 708
. C 100 708
. C 101 708
. C 101 708
ml C 102 708
. C 103 708
per C 105 708
hour C 106 708
in C 107 708
the C 108 708
cases C 109 708
of C 110 708
the C 111 708
former C 112 708
shunting C 113 708
, C 114 708
and C 115 708
the C 116 708
flow C 117 708
averaged C 118 708
0 C 119 708
. C 120 708
. C 121 708
. C 121 708
ml C 122 708
. C 123 708
per C 125 708
hour C 126 708
in C 127 708
the C 128 708
cases C 129 708
of C 130 708
the C 131 708
latter C 132 708
shunting C 133 708
. C 134 708
csf C 136 708
flow C 137 708
rate C 138 708
from C 139 708
the C 140 708
ventricle C 141 708
toward C 142 708
the C 143 708
cerebral C 144 708
subarachnoid C 145 708
space C 146 708
was C 147 708
larger C 148 708
when C 149 708
intraventricular C 150 708
pressure C 151 708
was C 152 708
higher C 153 708
. C 154 708
this C 156 708
in C 157 708
- C 158 708
crease C 159 708
in C 160 708
flow C 161 708
rate C 162 708
parallel C 163 708
to C 164 708
increasing C 165 708
pres C 166 708
- C 167 708
sure C 168 708
probably C 169 708
results C 170 708
from C 171 708
an C 172 708
increase C 173 708
in C 174 708
csf C 175 708
absorption C 176 708
. C 177 708
there C 179 708
seems C 180 708
to C 181 708
be C 182 708
an C 183 708
upper C 184 708
limit C 185 708
of C 186 708
the C 187 708
flow C 188 708
rate C 189 708
as C 190 708
the C 191 708
pressure C 192 708
is C 193 708
raised C 194 708
. C 195 708
transient C 197 708
reflux C 198 708
of C 199 708
csf C 200 708
flow C 201 708
was C 202 708
induced C 203 708
by C 204 708
jugular C 205 708
or C 206 708
abdominal C 207 708
compression C 208 708
. C 209 708
following C 211 708
intravenous C 212 708
administration C 213 708
of C 214 708
hy C 215 708
- C 216 708
pertonic C 217 708
solutions C 218 708
, C 219 708
csf C 220 708
flow C 221 708
rate C 222 708
decreased C 223 708
parallel C 224 708
to C 225 708
the C 226 708
fall C 227 708
of C 228 708
csf C 229 708
pressure C 230 708
and C 231 708
re C 232 708
- C 233 708
gained C 234 708
the C 235 708
original C 236 708
value C 237 708
as C 238 708
the C 239 708
pressure C 240 708
was C 241 708
recovered C 242 708
. C 243 708
when C 245 708
the C 246 708
pressure C 247 708
fell C 248 708
as C 249 708
low C 250 708
as C 251 708
50 C 252 708
mm C 253 708
. C 254 708
of C 256 708
water C 257 708
the C 258 708
flow C 259 708
almost C 260 708
stopped C 261 708
. C 262 708
the C 1 709
dandy C 2 709
- C 3 709
walker C 4 709
syndrome C 5 709
the C 6 709
dandy C 7 709
- C 8 709
walker C 9 709
syndrome C 10 709
is C 11 709
a C 12 709
specific C 13 709
morbid C 14 709
entity C 15 709
in C 16 709
which C 17 709
the C 18 709
fourth C 19 709
ventricle C 20 709
is C 21 709
grossly C 22 709
dilated C 23 709
and C 24 709
there C 25 709
is C 26 709
a C 27 709
congenital C 28 709
malformation C 29 709
of C 30 709
the C 31 709
cerebellar C 32 709
vermis C 33 709
. C 34 709
it C 36 709
is C 37 709
nearly C 38 709
always C 39 709
associated C 40 709
with C 41 709
atresia C 42 709
of C 43 709
the C 44 709
foramen C 45 709
of C 46 709
magendie C 47 709
, C 48 709
and C 49 709
in C 50 709
many C 51 709
cases C 52 709
with C 53 709
atresia C 54 709
of C 55 709
the C 56 709
foramina C 57 709
of C 58 709
luschka C 59 709
also C 60 709
. C 61 709
the C 63 709
lateral C 64 709
and C 65 709
third C 66 709
ventricles C 67 709
are C 68 709
usually C 69 709
dilated C 70 709
. C 71 709
figure C 73 709
1 C 74 709
illustrates C 75 709
a C 76 709
specimen C 77 709
of C 78 709
the C 79 709
condition C 80 709
. C 81 709
most C 83 709
cases C 84 709
present C 85 709
in C 86 709
infancy C 87 709
, C 88 709
but C 89 709
others C 90 709
are C 91 709
discovered C 92 709
in C 93 709
childhood C 94 709
and C 95 709
in C 96 709
adult C 97 709
life C 98 709
. C 99 709
the C 101 709
oldest C 102 709
patient C 103 709
recorded C 104 709
to C 105 709
have C 106 709
had C 107 709
this C 108 709
anomaly C 109 709
was C 110 709
aged C 111 709
59 C 112 709
years C 113 709
. C 114 709
the C 116 709
first C 117 709
recognized C 118 709
case C 119 709
was C 120 709
published C 121 709
by C 122 709
dandy C 123 709
and C 124 709
blackfen C 125 709
in C 126 709
1914 C 127 709
, C 128 709
but C 129 709
the C 130 709
best C 131 709
early C 132 709
description C 133 709
of C 134 709
the C 135 709
condition C 136 709
is C 137 709
that C 138 709
of C 139 709
taggart C 140 709
and C 141 709
walker C 142 709
( C 143 709
1944 C 144 709
) C 145 709
, C 146 709
who C 147 709
concluded C 148 709
that C 149 709
the C 150 709
cerebellar C 151 709
lesions C 152 709
were C 153 709
consequent C 154 709
upon C 155 709
the C 156 709
atresia C 157 709
of C 158 709
the C 159 709
foramen C 160 709
of C 161 709
magendie C 162 709
. C 163 709
in C 165 709
1954 C 166 709
benda C 167 709
proposed C 168 709
the C 169 709
term C 170 709
" C 171 709
dandy C 172 709
- C 173 709
walker C 174 709
syndrome C 175 709
" C 176 709
. C 177 709
a C 1 710
probable C 2 710
epidemic C 3 710
of C 4 710
congenital C 5 710
hydrocephalus C 6 710
in C 7 710
1940 C 8 710
- C 9 710
1941 C 10 710
a C 11 710
peak C 12 710
in C 13 710
the C 14 710
incidence C 15 710
of C 16 710
congenital C 17 710
hydrocephalus C 18 710
in C 19 710
1940 C 20 710
- C 21 710
41 C 22 710
is C 23 710
described C 24 710
; C 25 710
reasons C 26 710
are C 27 710
given C 28 710
for C 29 710
believing C 30 710
it C 31 710
to C 32 710
be C 33 710
a C 34 710
genuine C 35 710
phenomenon C 36 710
, C 37 710
though C 38 710
it C 39 710
is C 40 710
too C 41 710
late C 42 710
to C 43 710
find C 44 710
the C 45 710
cause C 46 710
. C 47 710
epidemics C 49 710
of C 50 710
malformations C 51 710
are C 52 710
to C 53 710
be C 54 710
detected C 55 710
promptly C 56 710
only C 57 710
if C 58 710
the C 59 710
incidence C 60 710
of C 61 710
malformations C 62 710
in C 63 710
a C 64 710
defined C 65 710
population C 66 710
is C 67 710
studied C 68 710
continuously C 69 710
; C 70 710
and C 71 710
for C 72 710
some C 73 710
epidemics C 74 710
the C 75 710
population C 76 710
studied C 77 710
must C 78 710
be C 79 710
very C 80 710
large C 81 710
indeed C 82 710
. C 83 710
functional C 1 711
craniology C 2 711
: C 3 711
an C 4 711
aid C 5 711
in C 6 711
interpreting C 7 711
roentgenograms C 8 711
of C 9 711
the C 10 711
skull C 11 711
analysis C 12 711
of C 13 711
the C 14 711
form C 15 711
of C 16 711
the C 17 711
skull C 18 711
is C 19 711
facilitated C 20 711
by C 21 711
considering C 22 711
it C 23 711
to C 24 711
be C 25 711
composed C 26 711
of C 27 711
a C 28 711
number C 29 711
of C 30 711
functional C 31 711
components C 32 711
. C 33 711
for C 35 711
the C 36 711
roentgenologist C 37 711
' C 38 711
s C 39 711
purposes C 40 711
, C 41 711
division C 42 711
into C 43 711
the C 44 711
facial C 45 711
or C 46 711
somatic C 47 711
skeleton C 48 711
and C 49 711
the C 50 711
neu C 51 711
- C 52 711
ral C 53 711
skeleton C 54 711
is C 55 711
valuable C 56 711
, C 57 711
as C 58 711
is C 59 711
the C 60 711
recognition C 61 711
of C 62 711
three C 63 711
functionally C 64 711
separate C 65 711
portions C 66 711
within C 67 711
each C 68 711
calvarial C 69 711
bone C 70 711
: C 71 711
the C 72 711
inner C 73 711
table C 74 711
, C 75 711
the C 76 711
diploe C 77 711
and C 78 711
the C 79 711
outer C 80 711
table C 81 711
. C 82 711
the C 84 711
base C 85 711
of C 86 711
the C 87 711
skull C 88 711
is C 89 711
the C 90 711
only C 91 711
por C 92 711
- C 93 711
tion C 94 711
that C 95 711
is C 96 711
preformed C 97 711
in C 98 711
cartilage C 99 711
. C 100 711
this C 102 711
ac C 103 711
- C 104 711
counts C 105 711
for C 106 711
the C 107 711
unusual C 108 711
appearance C 109 711
of C 110 711
the C 111 711
skull C 112 711
in C 113 711
achondroplasia C 114 711
. C 115 711
in C 117 711
addition C 118 711
, C 119 711
the C 120 711
base C 121 711
apparently C 122 711
is C 123 711
more C 124 711
closely C 125 711
related C 126 711
to C 127 711
facial C 128 711
and C 129 711
general C 130 711
somatic C 131 711
growth C 132 711
than C 133 711
to C 134 711
neural C 135 711
growth C 136 711
. C 137 711
calvarial C 139 711
bone C 140 711
forms C 141 711
directly C 142 711
from C 143 711
membrane C 144 711
within C 145 711
the C 146 711
cerebral C 147 711
capsule C 148 711
. C 149 711
consequently C 151 711
, C 152 711
the C 153 711
size C 154 711
and C 155 711
shape C 156 711
of C 157 711
the C 158 711
cal C 159 711
- C 160 711
varia C 161 711
directly C 162 711
reflect C 163 711
the C 164 711
form C 165 711
of C 166 711
the C 167 711
grow C 168 711
- C 169 711
ing C 170 711
neural C 171 711
mass C 172 711
. C 173 711
the C 175 711
inner C 176 711
table C 177 711
of C 178 711
the C 179 711
calvaria C 180 711
at C 181 711
all C 182 711
ages C 183 711
is C 184 711
intimately C 185 711
related C 186 711
to C 187 711
the C 188 711
dura C 189 711
mater C 190 711
and C 191 711
directly C 192 711
reflects C 193 711
the C 194 711
form C 195 711
of C 196 711
the C 197 711
dura C 198 711
mater C 199 711
. C 200 711
consequently C 202 711
, C 203 711
the C 204 711
inner C 205 711
table C 206 711
re C 207 711
- C 208 711
flects C 209 711
the C 210 711
form C 211 711
of C 212 711
the C 213 711
arachnoid C 214 711
mater C 215 711
and C 216 711
, C 217 711
usually C 218 711
, C 219 711
of C 220 711
the C 221 711
brain C 222 711
as C 223 711
well C 224 711
. C 225 711
the C 227 711
outer C 228 711
table C 229 711
of C 230 711
the C 231 711
calvaria C 232 711
serves C 233 711
not C 234 711
only C 235 711
to C 236 711
protect C 237 711
the C 238 711
brain C 239 711
but C 240 711
also C 241 711
to C 242 711
anchor C 243 711
many C 244 711
of C 245 711
the C 246 711
intrinsic C 247 711
and C 248 711
extrinsic C 249 711
muscles C 250 711
of C 251 711
the C 252 711
skull C 253 711
. C 254 711
its C 256 711
form C 257 711
, C 258 711
particularly C 259 711
in C 260 711
thick C 261 711
- C 262 711
skulled C 263 711
mammals C 264 711
such C 265 711
as C 266 711
the C 267 711
pig C 268 711
, C 269 711
is C 270 711
determined C 271 711
more C 272 711
by C 273 711
the C 274 711
demands C 275 711
of C 276 711
these C 277 711
muscles C 278 711
and C 279 711
of C 280 711
the C 281 711
scalp C 282 711
than C 283 711
by C 284 711
the C 285 711
form C 286 711
of C 287 711
the C 288 711
brain C 289 711
. C 290 711
the C 292 711
principal C 293 711
function C 294 711
of C 295 711
the C 296 711
diploe C 297 711
is C 298 711
to C 299 711
form C 300 711
a C 301 711
lightweight C 302 711
yet C 303 711
rigid C 304 711
separation C 305 711
of C 306 711
the C 307 711
two C 308 711
osseous C 309 711
tables C 310 711
. C 311 711
in C 313 711
addition C 314 711
, C 315 711
it C 316 711
serves C 317 711
as C 318 711
a C 319 711
site C 320 711
of C 321 711
hematopoiesis C 322 711
; C 323 711
for C 324 711
this C 325 711
reason C 326 711
it C 327 711
may C 328 711
tend C 329 711
to C 330 711
a C 331 711
specific C 332 711
volume C 333 711
at C 334 711
a C 335 711
given C 336 711
age C 337 711
. C 338 711
the C 340 711
calvarial C 341 711
sutures C 342 711
oppose C 343 711
separa C 344 711
- C 345 711
tion C 346 711
of C 347 711
the C 348 711
bones C 349 711
of C 350 711
the C 351 711
calvaria C 352 711
while C 353 711
al C 354 711
- C 355 711
lowing C 356 711
relative C 357 711
motion C 358 711
between C 359 711
them C 360 711
. C 361 711
when C 363 711
the C 364 711
calvarial C 365 711
bones C 366 711
are C 367 711
passively C 368 711
car C 369 711
- C 370 711
ried C 371 711
apart C 372 711
with C 373 711
the C 374 711
expanding C 375 711
cerebral C 376 711
cap C 377 711
- C 378 711
sule C 379 711
by C 380 711
the C 381 711
growth C 382 711
of C 383 711
the C 384 711
neural C 385 711
mass C 386 711
, C 387 711
their C 388 711
areas C 389 711
are C 390 711
increased C 391 711
by C 392 711
the C 393 711
deposition C 394 711
of C 395 711
bone C 396 711
in C 397 711
the C 398 711
suture C 399 711
margins C 400 711
. C 401 711
the C 403 711
sutures C 404 711
, C 405 711
however C 406 711
, C 407 711
do C 408 711
not C 409 711
function C 410 711
as C 411 711
epiphyses C 412 711
and C 413 711
have C 414 711
no C 415 711
innate C 416 711
growth C 417 711
potential C 418 711
: C 419 711
removal C 420 711
of C 421 711
a C 422 711
suture C 423 711
does C 424 711
not C 425 711
disturb C 426 711
final C 427 711
skull C 428 711
form C 429 711
. C 430 711
because C 432 711
the C 433 711
calvaria C 434 711
represents C 435 711
ossi C 436 711
- C 437 711
fication C 438 711
of C 439 711
the C 440 711
cerebral C 441 711
capsule C 442 711
, C 443 711
it C 444 711
is C 445 711
small C 446 711
when C 447 711
the C 448 711
neural C 449 711
mass C 450 711
is C 451 711
small C 452 711
. C 453 711
the C 455 711
de C 456 711
- C 457 711
formity C 458 711
of C 459 711
the C 460 711
skull C 461 711
and C 462 711
the C 463 711
secondary C 464 711
changes C 465 711
that C 466 711
occur C 467 711
in C 468 711
the C 469 711
air C 470 711
sinuses C 471 711
and C 472 711
the C 473 711
diploe C 474 711
can C 475 711
be C 476 711
explained C 477 711
in C 478 711
terms C 479 711
of C 480 711
the C 481 711
functional C 482 711
cranial C 483 711
components C 484 711
. C 485 711
the C 487 711
op C 488 711
- C 489 711
posite C 490 711
changes C 491 711
occur C 492 711
when C 493 711
the C 494 711
neural C 495 711
mass C 496 711
is C 497 711
abnormally C 498 711
large C 499 711
. C 500 711
the C 502 711
correlation C 503 711
between C 504 711
skull C 505 711
size C 506 711
and C 507 711
intelligence C 508 711
is C 509 711
only C 510 711
fair C 511 711
. C 512 711
the C 514 711
presence C 515 711
of C 516 711
a C 517 711
brain C 518 711
of C 519 711
distinctly C 520 711
abnormal C 521 711
size C 522 711
, C 523 711
however C 524 711
, C 525 711
may C 526 711
be C 527 711
inferred C 528 711
from C 529 711
plain C 530 711
roentgeno C 531 711
- C 532 711
grams C 533 711
of C 534 711
the C 535 711
skull C 536 711
. C 537 711
premature C 539 711
closure C 540 711
of C 541 711
the C 542 711
cranial C 543 711
su C 544 711
- C 545 711
tures C 546 711
may C 547 711
be C 548 711
due C 549 711
to C 550 711
an C 551 711
abnormal C 552 711
form C 553 711
of C 554 711
the C 555 711
cranial C 556 711
base C 557 711
and C 558 711
possibly C 559 711
of C 560 711
the C 561 711
primi C 562 711
- C 563 711
tive C 564 711
chondrocranium C 565 711
that C 566 711
precedes C 567 711
it C 568 711
. C 569 711
the C 571 711
abnormality C 572 711
is C 573 711
mediated C 574 711
through C 575 711
the C 576 711
dural C 577 711
fiber C 578 711
tracts C 579 711
that C 580 711
underlie C 581 711
the C 582 711
major C 583 711
cal C 584 711
- C 585 711
varial C 586 711
sutures C 587 711
. C 588 711
hydrocephalus C 1 712
: C 2 712
changes C 3 712
in C 4 712
formation C 5 712
and C 6 712
absorption C 7 712
of C 8 712
cerebrospinal C 9 712
fluid C 10 712
within C 11 712
the C 12 712
cerebral C 13 712
ventricles C 14 712
formation C 15 712
, C 16 712
flow C 17 712
and C 18 712
absorption C 19 712
of C 20 712
cerebrospinal C 21 712
fluid C 22 712
were C 23 712
measured C 24 712
in C 25 712
normal C 26 712
and C 27 712
progressively C 28 712
hydrocephalic C 29 712
dogs C 30 712
by C 31 712
steady C 32 712
- C 33 712
state C 34 712
studies C 35 712
during C 36 712
ventricular C 37 712
per C 38 712
- C 39 712
fusion C 40 712
. C 41 712
the C 43 712
formation C 44 712
of C 45 712
cerebrospinal C 46 712
fluid C 47 712
was C 48 712
found C 49 712
to C 50 712
be C 51 712
constant C 52 712
, C 53 712
independent C 54 712
of C 55 712
hydrostatic C 56 712
pressure C 57 712
, C 58 712
and C 59 712
unaffected C 60 712
by C 61 712
the C 62 712
development C 63 712
of C 64 712
hydrocephalus C 65 712
. C 66 712
the C 68 712
normal C 69 712
dog C 70 712
produced C 71 712
0 C 72 712
. C 73 712
. C 74 712
. C 74 712
. C 74 712
ml C 75 712
. C 76 712
cerebrospinal C 78 712
fluid C 79 712
/ C 80 712
min C 81 712
. C 82 712
in C 84 712
the C 85 712
lateral C 86 712
ventricles C 87 712
, C 88 712
0 C 89 712
. C 90 712
. C 91 712
. C 91 712
. C 91 712
ml C 92 712
. C 93 712
cere C 95 712
- C 96 712
brospinal C 97 712
fluid C 98 712
/ C 99 712
min C 100 712
. C 101 712
in C 103 712
the C 104 712
4 C 105 712
th C 106 712
ventricle C 107 712
and C 108 712
0 C 109 712
. C 110 712
. C 111 712
. C 111 712
ml C 112 712
. C 113 712
cerebrospinal C 115 712
fluid C 116 712
/ C 117 712
min C 118 712
. C 119 712
in C 121 712
the C 122 712
sub C 123 712
- C 124 712
arachnoid C 125 712
space C 126 712
. C 127 712
the C 129 712
intraventricular C 130 712
forma C 131 712
- C 132 712
tion C 133 712
of C 134 712
fluid C 135 712
was C 136 712
calculated C 137 712
to C 138 712
be C 139 712
0 C 140 712
. C 141 712
. C 142 712
. C 142 712
ml C 143 712
. C 144 712
cerebrospinal C 146 712
fluid C 147 712
/ C 148 712
min C 149 712
. C 150 712
/ C 152 712
gm C 153 712
. C 154 712
of C 156 712
choroid C 157 712
plexus C 158 712
, C 159 712
and C 160 712
0 C 161 712
. C 162 712
. C 163 712
. C 163 712
. C 163 712
. C 163 712
- C 164 712
3 C 165 712
ml C 166 712
. C 167 712
cerebrospinal C 169 712
fluid C 170 712
/ C 171 712
min C 172 712
. C 173 712
/ C 175 712
cm C 176 712
. C 177 712
. C 178 712
of C 179 712
ependymal C 180 712
surface C 181 712
. C 182 712
absorption C 184 712
of C 185 712
cerebrospinal C 186 712
fluid C 187 712
was C 188 712
found C 189 712
to C 190 712
take C 191 712
place C 192 712
within C 193 712
the C 194 712
ventricles C 195 712
as C 196 712
well C 197 712
as C 198 712
in C 199 712
the C 200 712
subarachnoid C 201 712
spaces C 202 712
. C 203 712
the C 205 712
re C 206 712
- C 207 712
sistance C 208 712
to C 209 712
absorption C 210 712
of C 211 712
cerebrospinal C 212 712
fluid C 213 712
in C 214 712
the C 215 712
normal C 216 712
ventricle C 217 712
was C 218 712
much C 219 712
higher C 220 712
than C 221 712
in C 222 712
the C 223 712
hydrocephalic C 224 712
ventricle C 225 712
. C 226 712
the C 228 712
decrease C 229 712
in C 230 712
resistance C 231 712
occurred C 232 712
as C 233 712
the C 234 712
ventricular C 235 712
volume C 236 712
increased C 237 712
and C 238 712
the C 239 712
ependyma C 240 712
became C 241 712
flattened C 242 712
so C 243 712
that C 244 712
in C 245 712
chronic C 246 712
hydrocephalus C 247 712
the C 248 712
resistance C 249 712
was C 250 712
not C 251 712
significantly C 252 712
different C 253 712
than C 254 712
in C 255 712
the C 256 712
normal C 257 712
dog C 258 712
. C 259 712
the C 261 712
theory C 262 712
of C 263 712
re C 264 712
- C 265 712
stricted C 266 712
diffusion C 267 712
was C 268 712
applied C 269 712
to C 270 712
the C 271 712
data C 272 712
to C 273 712
calculate C 274 712
the C 275 712
diffusive C 276 712
permeabilities C 277 712
of C 278 712
crea C 279 712
- C 280 712
tinine C 281 712
and C 282 712
urea C 283 712
, C 284 712
and C 285 712
from C 286 712
this C 287 712
the C 288 712
mean C 289 712
pore C 290 712
radius C 291 712
within C 292 712
the C 293 712
ventricle C 294 712
. C 295 712
using C 297 712
formation C 298 712
of C 299 712
cerebrospinal C 300 712
fluid C 301 712
and C 302 712
data C 303 712
on C 304 712
absorption C 305 712
, C 306 712
the C 307 712
hydrocephalic C 308 712
animals C 309 712
could C 310 712
not C 311 712
be C 312 712
distinguished C 313 712
from C 314 712
the C 315 712
normal C 316 712
with C 317 712
sufficient C 318 712
accuracy C 319 712
to C 320 712
suggest C 321 712
using C 322 712
this C 323 712
as C 324 712
a C 325 712
clinical C 326 712
test C 327 712
. C 328 712
the C 330 712
reason C 331 712
for C 332 712
this C 333 712
is C 334 712
that C 335 712
intraventricular C 336 712
pressure C 337 712
has C 338 712
always C 339 712
been C 340 712
considered C 341 712
as C 342 712
if C 343 712
it C 344 712
were C 345 712
constant C 346 712
when C 347 712
, C 348 712
in C 349 712
fact C 350 712
, C 351 712
it C 352 712
is C 353 712
changing C 354 712
constantly C 355 712
. C 356 712
the C 358 712
problem C 359 712
of C 360 712
ventricular C 361 712
enlargement C 362 712
concerns C 363 712
the C 364 712
ability C 365 712
of C 366 712
the C 367 712
craniospinal C 368 712
contents C 369 712
to C 370 712
adjust C 371 712
to C 372 712
and C 373 712
absorb C 374 712
the C 375 712
small C 376 712
but C 377 712
very C 378 712
rapid C 379 712
changes C 380 712
in C 381 712
intracranial C 382 712
contents C 383 712
that C 384 712
occur C 385 712
with C 386 712
each C 387 712
beat C 388 712
of C 389 712
the C 390 712
pulse C 391 712
. C 392 712
dural C 1 713
sinus C 2 713
pressure C 3 713
in C 4 713
normal C 5 713
and C 6 713
hydrocephalic C 7 713
dogs C 8 713
simultaneous C 9 713
measurement C 10 713
of C 11 713
cerebro C 12 713
- C 13 713
spinal C 14 713
fluid C 15 713
pressure C 16 713
( C 17 713
csfp C 18 713
) C 19 713
and C 20 713
venous C 21 713
pressure C 22 713
in C 23 713
the C 24 713
anterior C 25 713
( C 26 713
ssvp C 27 713
) C 28 713
and C 29 713
poste C 30 713
- C 31 713
rior C 32 713
sagittal C 33 713
sinus C 34 713
( C 35 713
tvp C 36 713
) C 37 713
has C 38 713
demonstrated C 39 713
that C 40 713
in C 41 713
the C 42 713
normal C 43 713
dog C 44 713
the C 45 713
mean C 46 713
pressures C 47 713
are C 48 713
related C 49 713
as C 50 713
follows C 51 713
: C 52 713
csfp C 53 713
> C 54 713
ssvp C 55 713
> C 56 713
tvp C 57 713
. C 58 713
the C 60 713
statistical C 61 713
relationship C 62 713
between C 63 713
the C 64 713
pres C 65 713
- C 66 713
sures C 67 713
has C 68 713
shown C 69 713
a C 70 713
poor C 71 713
correlation C 72 713
of C 73 713
ssvp C 74 713
and C 75 713
tvp C 76 713
with C 77 713
changes C 78 713
in C 79 713
csfp C 80 713
. C 81 713
on C 83 713
the C 84 713
other C 85 713
hand C 86 713
, C 87 713
in C 88 713
the C 89 713
hydrocephalic C 90 713
dog C 91 713
, C 92 713
ssvp C 93 713
rises C 94 713
to C 95 713
meet C 96 713
csfp C 97 713
and C 98 713
is C 99 713
related C 100 713
to C 101 713
fluid C 102 713
pressure C 103 713
in C 104 713
a C 105 713
1 C 106 713
: C 107 713
1 C 108 713
fashion C 109 713
. C 110 713
this C 112 713
could C 113 713
be C 114 713
ex C 115 713
- C 116 713
pected C 117 713
to C 118 713
cause C 119 713
a C 120 713
" C 121 713
non C 122 713
venting C 123 713
" C 124 713
of C 125 713
acute C 126 713
changes C 127 713
of C 128 713
csfp C 129 713
and C 130 713
a C 131 713
decrease C 132 713
in C 133 713
fluid C 134 713
ab C 135 713
- C 136 713
sorption C 137 713
. C 138 713
it C 140 713
is C 141 713
postulated C 142 713
that C 143 713
the C 144 713
mechanism C 145 713
of C 146 713
ssvp C 147 713
elevation C 148 713
is C 149 713
a C 150 713
partial C 151 713
occlusion C 152 713
of C 153 713
the C 154 713
sinus C 155 713
. C 156 713
intraventricular C 1 714
papilloma C 2 714
a C 3 714
case C 4 714
of C 5 714
intraventricular C 6 714
papilloma C 7 714
of C 8 714
the C 9 714
left C 10 714
lateral C 11 714
ventricle C 12 714
is C 13 714
reported C 14 714
. C 15 714
craniotomy C 17 714
was C 18 714
performed C 19 714
and C 20 714
removal C 21 714
of C 22 714
the C 23 714
tumor C 24 714
was C 25 714
ac C 26 714
- C 27 714
complished C 28 714
without C 29 714
incident C 30 714
. C 31 714
the C 33 714
literature C 34 714
is C 35 714
reviewed C 36 714
. C 37 714
an C 39 714
unusual C 40 714
although C 41 714
perhaps C 42 714
relatively C 43 714
unim C 44 714
- C 45 714
portant C 46 714
observation C 47 714
in C 48 714
the C 49 714
reported C 50 714
case C 51 714
was C 52 714
that C 53 714
for C 54 714
four C 55 714
or C 56 714
five C 57 714
days C 58 714
postoperatively C 59 714
the C 60 714
patient C 61 714
, C 62 714
a C 63 714
17 C 64 714
- C 65 714
month C 66 714
- C 67 714
old C 68 714
female C 69 714
, C 70 714
kept C 71 714
her C 72 714
head C 73 714
tilted C 74 714
to C 75 714
the C 76 714
right C 77 714
but C 78 714
at C 79 714
the C 80 714
time C 81 714
she C 82 714
left C 83 714
the C 84 714
hospital C 85 714
she C 86 714
was C 87 714
holding C 88 714
it C 89 714
erect C 90 714
and C 91 714
unsupported C 92 714
and C 93 714
was C 94 714
sustaining C 95 714
weight C 96 714
satisfactorily C 97 714
on C 98 714
both C 99 714
feet C 100 714
. C 101 714
five C 1 715
- C 2 715
year C 3 715
comparative C 4 715
study C 5 715
of C 6 715
hydrocephalus C 7 715
in C 8 715
children C 9 715
with C 10 715
and C 11 715
without C 12 715
operation C 13 715
( C 14 715
113 C 15 715
cases C 16 715
) C 17 715
on C 18 715
the C 19 715
basis C 20 715
of C 21 715
a C 22 715
5 C 23 715
- C 24 715
year C 25 715
study C 26 715
of C 27 715
113 C 28 715
hy C 29 715
- C 30 715
drocephalic C 31 715
children C 32 715
of C 33 715
whom C 34 715
65 C 35 715
were C 36 715
oper C 37 715
- C 38 715
ated C 39 715
on C 40 715
early C 41 715
with C 42 715
ventriculo C 43 715
- C 44 715
atrial C 45 715
shunting C 46 715
and C 47 715
48 C 48 715
were C 49 715
not C 50 715
operated C 51 715
on C 52 715
, C 53 715
all C 54 715
of C 55 715
them C 56 715
hav C 57 715
- C 58 715
ing C 59 715
been C 60 715
studied C 61 715
periodically C 62 715
in C 63 715
a C 64 715
similar C 65 715
manner C 66 715
to C 67 715
determine C 68 715
mortality C 69 715
, C 70 715
morbidity C 71 715
, C 72 715
intelligence C 73 715
, C 74 715
and C 75 715
related C 76 715
factors C 77 715
, C 78 715
the C 79 715
follow C 80 715
- C 81 715
ing C 82 715
conclusions C 83 715
are C 84 715
justified C 85 715
: C 86 715
the C 87 715
program C 88 715
in C 89 715
which C 90 715
shunting C 91 715
opera C 92 715
- C 93 715
tions C 94 715
were C 95 715
done C 96 715
apparently C 97 715
gives C 98 715
significant C 99 715
advantages C 100 715
to C 101 715
the C 102 715
children C 103 715
over C 104 715
the C 105 715
program C 106 715
in C 107 715
which C 108 715
no C 109 715
shunting C 110 715
operations C 111 715
were C 112 715
done C 113 715
( C 114 715
based C 115 715
on C 116 715
life C 117 715
- C 118 715
table C 119 715
data C 120 715
projected C 121 715
from C 122 715
birth C 123 715
to C 124 715
10 C 125 715
years C 126 715
) C 127 715
survival C 128 715
: C 129 715
61 C 130 715
. C 131 715
. C 132 715
per C 133 715
cent C 134 715
as C 135 715
compared C 136 715
to C 137 715
22 C 138 715
. C 139 715
. C 140 715
per C 141 715
cent C 142 715
; C 143 715
number C 144 715
of C 145 715
competent C 146 715
children C 147 715
( C 148 715
i C 149 715
. C 150 715
. C 151 715
. C 152 715
of C 154 715
75 C 155 715
or C 156 715
better C 157 715
) C 158 715
: C 159 715
33 C 160 715
. C 161 715
. C 162 715
per C 163 715
cent C 164 715
vs C 165 715
. C 166 715
5 C 168 715
. C 169 715
. C 170 715
per C 171 715
cent C 172 715
; C 173 715
number C 174 715
of C 175 715
noncompetitive C 176 715
children C 177 715
( C 178 715
i C 179 715
. C 180 715
. C 181 715
. C 182 715
below C 184 715
75 C 185 715
) C 186 715
: C 187 715
27 C 188 715
. C 189 715
. C 190 715
per C 191 715
cent C 192 715
vs C 193 715
. C 194 715
16 C 196 715
. C 197 715
. C 198 715
per C 199 715
cent C 200 715
. C 201 715
the C 203 715
major C 204 715
cause C 205 715
of C 206 715
death C 207 715
and C 208 715
morbid C 209 715
- C 210 715
ity C 211 715
in C 212 715
both C 213 715
groups C 214 715
is C 215 715
infection C 216 715
. C 217 715
in C 219 715
the C 220 715
operative C 221 715
group C 222 715
, C 223 715
morbidity C 224 715
associated C 225 715
with C 226 715
the C 227 715
shunting C 228 715
procedure C 229 715
is C 230 715
related C 231 715
to C 232 715
obstruction C 233 715
of C 234 715
the C 235 715
shunt C 236 715
and C 237 715
septicemia C 238 715
. C 239 715
the C 241 715
early C 242 715
occlusions C 243 715
show C 244 715
a C 245 715
correlation C 246 715
with C 247 715
abnormal C 248 715
, C 249 715
inflammatory C 250 715
type C 251 715
of C 252 715
spinal C 253 715
fluid C 254 715
being C 255 715
shunted C 256 715
into C 257 715
the C 258 715
blood C 259 715
stream C 260 715
. C 261 715
the C 263 715
late C 264 715
obstructions C 265 715
are C 266 715
associated C 267 715
with C 268 715
mechanical C 269 715
breakage C 270 715
of C 271 715
the C 272 715
shunt C 273 715
or C 274 715
factors C 275 715
of C 276 715
growth C 277 715
causing C 278 715
retraction C 279 715
of C 280 715
the C 281 715
cardiac C 282 715
end C 283 715
from C 284 715
the C 285 715
atrium C 286 715
. C 287 715
prompt C 289 715
re C 290 715
- C 291 715
establishment C 292 715
of C 293 715
a C 294 715
functioning C 295 715
shunt C 296 715
has C 297 715
been C 298 715
possible C 299 715
in C 300 715
all C 301 715
instances C 302 715
. C 303 715
periodic C 305 715
follow C 306 715
- C 307 715
up C 308 715
examinations C 309 715
, C 310 715
irrespective C 311 715
of C 312 715
symptoms C 313 715
, C 314 715
have C 315 715
proved C 316 715
invaluable C 317 715
in C 318 715
early C 319 715
recognition C 320 715
of C 321 715
malfunctioning C 322 715
shunts C 323 715
. C 324 715
septicemia C 326 715
usually C 327 715
required C 328 715
removal C 329 715
of C 330 715
the C 331 715
shunt C 332 715
. C 333 715
from C 335 715
the C 336 715
program C 337 715
of C 338 715
periodic C 339 715
evalua C 340 715
- C 341 715
tions C 342 715
, C 343 715
including C 344 715
" C 345 715
bubble C 346 715
" C 347 715
ventriculograms C 348 715
, C 349 715
studies C 350 715
of C 351 715
clearance C 352 715
of C 353 715
risa C 354 715
, C 355 715
and C 356 715
psycho C 357 715
- C 358 715
logical C 359 715
testings C 360 715
, C 361 715
correlations C 362 715
showed C 363 715
: C 364 715
intellectual C 365 715
ability C 366 715
seemed C 367 715
associated C 368 715
with C 369 715
width C 370 715
of C 371 715
cerebral C 372 715
mantle C 373 715
; C 374 715
width C 375 715
of C 376 715
cerebral C 377 715
mantle C 378 715
in C 379 715
hydrocepha C 380 715
- C 381 715
lus C 382 715
decreases C 383 715
with C 384 715
ventricular C 385 715
pressures C 386 715
of C 387 715
120 C 388 715
or C 389 715
over C 390 715
; C 391 715
it C 392 715
increases C 393 715
with C 394 715
pres C 395 715
- C 396 715
sures C 397 715
less C 398 715
than C 399 715
this C 400 715
; C 401 715
prolonged C 402 715
shunting C 403 715
of C 404 715
cerebrospinal C 405 715
fluid C 406 715
can C 407 715
give C 408 715
dramatic C 409 715
increase C 410 715
in C 411 715
width C 412 715
of C 413 715
cerebral C 414 715
mantle C 415 715
, C 416 715
apparently C 417 715
irrespective C 418 715
of C 419 715
basic C 420 715
etiology C 421 715
of C 422 715
the C 423 715
hydrocephalus C 424 715
; C 425 715
intellectual C 426 715
capacity C 427 715
could C 428 715
not C 429 715
be C 430 715
cor C 431 715
- C 432 715
related C 433 715
with C 434 715
the C 435 715
basic C 436 715
etiology C 437 715
of C 438 715
the C 439 715
hydrocephalus C 440 715
, C 441 715
but C 442 715
did C 443 715
correlate C 444 715
in C 445 715
- C 446 715
versely C 447 715
with C 448 715
duration C 449 715
of C 450 715
increased C 451 715
in C 452 715
- C 453 715
tracranial C 454 715
pressure C 455 715
. C 456 715
the C 458 715
many C 459 715
etiologies C 460 715
of C 461 715
hydrocephalus C 462 715
require C 463 715
large C 464 715
numbers C 465 715
of C 466 715
patients C 467 715
in C 468 715
each C 469 715
group C 470 715
for C 471 715
thorough C 472 715
evaluation C 473 715
. C 474 715
factors C 476 715
favoring C 477 715
such C 478 715
studies C 479 715
should C 480 715
be C 481 715
carried C 482 715
out C 483 715
in C 484 715
medical C 485 715
centers C 486 715
where C 487 715
appropriate C 488 715
disciplines C 489 715
can C 490 715
study C 491 715
in C 492 715
depth C 493 715
. C 494 715
prevention C 496 715
should C 497 715
be C 498 715
the C 499 715
ultimate C 500 715
goal C 501 715
. C 502 715
in C 504 715
the C 505 715
operative C 506 715
group C 507 715
, C 508 715
only C 509 715
1 C 510 715
patient C 511 715
compensated C 512 715
his C 513 715
hydrocephalic C 514 715
process C 515 715
and C 516 715
no C 517 715
single C 518 715
patient C 519 715
demonstrated C 520 715
" C 521 715
arrest C 522 715
" C 523 715
of C 524 715
or C 525 715
recovery C 526 715
from C 527 715
the C 528 715
basic C 529 715
hydrocephalus C 530 715
- C 531 715
pro C 532 715
- C 533 715
ducing C 534 715
process C 535 715
in C 536 715
spite C 537 715
of C 538 715
numerous C 539 715
attempts C 540 715
to C 541 715
demonstrate C 542 715
this C 543 715
. C 544 715
this C 546 715
might C 547 715
imply C 548 715
a C 549 715
necessity C 550 715
for C 551 715
life C 552 715
- C 553 715
long C 554 715
shunting C 555 715
of C 556 715
cerebro C 557 715
- C 558 715
spinal C 559 715
fluid C 560 715
in C 561 715
these C 562 715
cases C 563 715
. C 564 715
hydrocephalus C 1 716
any C 2 716
present C 3 716
day C 4 716
definition C 5 716
of C 6 716
hydrocephalus C 7 716
is C 8 716
very C 9 716
loose C 10 716
. C 11 716
the C 13 716
authors C 14 716
would C 15 716
rather C 16 716
adopt C 17 716
the C 18 716
concept C 19 716
that C 20 716
hydrocephalus C 21 716
is C 22 716
an C 23 716
abnormal C 24 716
condition C 25 716
characterized C 26 716
by C 27 716
excessive C 28 716
amount C 29 716
of C 30 716
cerebrospi C 31 716
- C 32 716
nal C 33 716
fluid C 34 716
with C 35 716
or C 36 716
without C 37 716
enlarge C 38 716
- C 39 716
ment C 40 716
of C 41 716
the C 42 716
head C 43 716
. C 44 716
the C 46 716
most C 47 716
common C 48 716
cause C 49 716
of C 50 716
hydrocephalus C 51 716
is C 52 716
arachnoiditis C 53 716
fol C 54 716
- C 55 716
lowed C 56 716
by C 57 716
congenital C 58 716
anomalies C 59 716
. C 60 716
a C 62 716
neoplasm C 63 716
is C 64 716
a C 65 716
rare C 66 716
cause C 67 716
. C 68 716
the C 70 716
ideal C 71 716
surgical C 72 716
procedure C 73 716
is C 74 716
the C 75 716
placement C 76 716
of C 77 716
a C 78 716
ventriculo C 79 716
- C 80 716
atrial C 81 716
shunt C 82 716
, C 83 716
using C 84 716
either C 85 716
pudenz C 86 716
or C 87 716
halter C 88 716
valves C 89 716
. C 90 716
where C 92 716
these C 93 716
valves C 94 716
cannot C 95 716
be C 96 716
availed C 97 716
of C 98 716
the C 99 716
choice C 100 716
is C 101 716
between C 102 716
a C 103 716
conservative C 104 716
waiting C 105 716
with C 106 716
medical C 107 716
support C 108 716
and C 109 716
ventricular C 110 716
tapping C 111 716
from C 112 716
the C 113 716
older C 114 716
surgical C 115 716
shunting C 116 716
procedures C 117 716
, C 118 716
like C 119 716
, C 120 716
ventriculo C 121 716
- C 122 716
peritoneal C 123 716
, C 124 716
choroidoplex C 125 716
- C 126 716
ectomy C 127 716
, C 128 716
thecal C 129 716
- C 130 716
fimbia C 131 716
, C 132 716
subarach C 133 716
- C 134 716
noid C 135 716
- C 136 716
ureteral C 137 716
, C 138 716
and C 139 716
others C 140 716
. C 141 716
recognition C 1 717
and C 2 717
treatment C 3 717
of C 4 717
hydrocephalus C 5 717
following C 6 717
spontaneous C 7 717
subarachnoid C 8 717
hemorrhage C 9 717
eight C 10 717
adult C 11 717
patients C 12 717
with C 13 717
hydrocephalus C 14 717
secondary C 15 717
to C 16 717
spontaneous C 17 717
subarachnoid C 18 717
hem C 19 717
- C 20 717
orrhage C 21 717
have C 22 717
been C 23 717
presented C 24 717
with C 25 717
a C 26 717
discus C 27 717
- C 28 717
sion C 29 717
of C 30 717
diagnosis C 31 717
and C 32 717
treatment C 33 717
. C 34 717
a C 36 717
number C 37 717
of C 38 717
possible C 39 717
mechanisms C 40 717
for C 41 717
the C 42 717
development C 43 717
of C 44 717
ventricular C 45 717
dilatation C 46 717
in C 47 717
this C 48 717
condition C 49 717
have C 50 717
been C 51 717
advanced C 52 717
and C 53 717
pathological C 54 717
data C 55 717
have C 56 717
been C 57 717
presented C 58 717
in C 59 717
2 C 60 717
cases C 61 717
. C 62 717
congenital C 1 718
malformations C 2 718
. C 3 718
clinical C 5 718
and C 6 718
community C 7 718
considerations C 8 718
two C 9 718
of C 10 718
the C 11 718
most C 12 718
significant C 13 718
medical C 14 718
events C 15 718
of C 16 718
the C 17 718
century C 18 718
, C 19 718
the C 20 718
epidemic C 21 718
of C 22 718
post C 23 718
- C 24 718
rubella C 25 718
anomalies C 26 718
in C 27 718
australia C 28 718
during C 29 718
1940 C 30 718
and C 31 718
1941 C 32 718
and C 33 718
the C 34 718
pan C 35 718
- C 36 718
demic C 37 718
of C 38 718
thalidomide C 39 718
embryopathies C 40 718
in C 41 718
europe C 42 718
and C 43 718
elsewhere C 44 718
during C 45 718
1960 C 46 718
and C 47 718
1961 C 48 718
, C 49 718
have C 50 718
demonstrated C 51 718
clearly C 52 718
the C 53 718
importance C 54 718
of C 55 718
monitoring C 56 718
programs C 57 718
to C 58 718
record C 59 718
the C 60 718
occurrence C 61 718
of C 62 718
congenital C 63 718
malformations C 64 718
at C 65 718
group C 66 718
( C 67 718
for C 68 718
example C 69 718
, C 70 718
hospital C 71 718
) C 72 718
and C 73 718
community C 74 718
( C 75 718
especially C 76 718
city C 77 718
) C 78 718
levels C 79 718
. C 80 718
the C 82 718
principle C 83 718
of C 84 718
report C 85 718
- C 86 718
ing C 87 718
malformations C 88 718
and C 89 718
utilizing C 90 718
the C 91 718
data C 92 718
for C 93 718
service C 94 718
programs C 95 718
or C 96 718
, C 97 718
better C 98 718
still C 99 718
, C 100 718
for C 101 718
prevention C 102 718
, C 103 718
is C 104 718
not C 105 718
new C 106 718
, C 107 718
but C 108 718
the C 109 718
methodical C 110 718
use C 111 718
of C 112 718
vital C 113 718
statistics C 114 718
in C 115 718
a C 116 718
scientifically C 117 718
constructed C 118 718
surveil C 119 718
- C 120 718
lance C 121 718
system C 122 718
is C 123 718
new C 124 718
. C 125 718
so C 127 718
also C 128 718
is C 129 718
the C 130 718
joint C 131 718
endeavor C 132 718
on C 133 718
the C 134 718
part C 135 718
of C 136 718
clinicians C 137 718
, C 138 718
public C 139 718
health C 140 718
workers C 141 718
and C 142 718
basic C 143 718
scien C 144 718
- C 145 718
tists C 146 718
to C 147 718
reconstruct C 148 718
an C 149 718
epidemiology C 150 718
of C 151 718
deformity C 152 718
on C 153 718
the C 154 718
basis C 155 718
of C 156 718
time C 157 718
, C 158 718
place C 159 718
, C 160 718
person C 161 718
distributions C 162 718
of C 163 718
malformations C 164 718
. C 165 718
a C 167 718
primary C 168 718
need C 169 718
has C 170 718
been C 171 718
for C 172 718
stand C 173 718
- C 174 718
ardized C 175 718
methods C 176 718
of C 177 718
classifying C 178 718
and C 179 718
reporting C 180 718
congenital C 181 718
malformations C 182 718
. C 183 718
the C 1 719
family C 2 719
history C 3 719
of C 4 719
spina C 5 719
bifida C 6 719
cystica C 7 719
the C 8 719
family C 9 719
histories C 10 719
of C 11 719
722 C 12 719
infants C 13 719
who C 14 719
were C 15 719
born C 16 719
with C 17 719
spina C 18 719
bifida C 19 719
cystica C 20 719
were C 21 719
studied C 22 719
. C 23 719
the C 25 719
index C 26 719
cases C 27 719
were C 28 719
referred C 29 719
for C 30 719
sur C 31 719
- C 32 719
gical C 33 719
treatment C 34 719
and C 35 719
were C 36 719
not C 37 719
selected C 38 719
in C 39 719
any C 40 719
way C 41 719
from C 42 719
the C 43 719
genetic C 44 719
point C 45 719
of C 46 719
view C 47 719
. C 48 719
intensive C 50 719
inquiries C 51 719
were C 52 719
made C 53 719
to C 54 719
ob C 55 719
- C 56 719
tain C 57 719
a C 58 719
complete C 59 719
family C 60 719
pedigree C 61 719
, C 62 719
including C 63 719
a C 64 719
prospective C 65 719
follow C 66 719
- C 67 719
up C 68 719
of C 69 719
siblings C 70 719
born C 71 719
after C 72 719
the C 73 719
index C 74 719
case C 75 719
. C 76 719
of C 78 719
1 C 79 719
, C 80 719
256 C 81 719
siblings C 82 719
85 C 83 719
or C 84 719
6 C 85 719
. C 86 719
. C 87 719
% C 88 719
had C 89 719
gross C 90 719
malformation C 91 719
of C 92 719
the C 93 719
central C 94 719
nervous C 95 719
system C 96 719
: C 97 719
spina C 98 719
bifida C 99 719
cystica C 100 719
in C 101 719
54 C 102 719
, C 103 719
anencephaly C 104 719
in C 105 719
22 C 106 719
, C 107 719
and C 108 719
uncomplicated C 109 719
hydrocephalus C 110 719
in C 111 719
9 C 112 719
. C 113 719
of C 115 719
306 C 116 719
children C 117 719
born C 118 719
after C 119 719
the C 120 719
index C 121 719
case C 122 719
25 C 123 719
( C 124 719
8 C 125 719
% C 126 719
) C 127 719
or C 128 719
1 C 129 719
in C 130 719
12 C 131 719
were C 132 719
affected C 133 719
. C 134 719
there C 136 719
was C 137 719
a C 138 719
progressive C 139 719
increase C 140 719
in C 141 719
multiple C 142 719
cases C 143 719
in C 144 719
the C 145 719
family C 146 719
with C 147 719
increasing C 148 719
family C 149 719
size C 150 719
. C 151 719
in C 153 719
sibships C 154 719
of C 155 719
five C 156 719
or C 157 719
more C 158 719
, C 159 719
mul C 160 719
- C 161 719
tiple C 162 719
cases C 163 719
occurred C 164 719
in C 165 719
24 C 166 719
. C 167 719
. C 168 719
% C 169 719
. C 170 719
in C 172 719
118 C 173 719
families C 174 719
cases C 175 719
of C 176 719
gross C 177 719
malfor C 178 719
- C 179 719
mation C 180 719
of C 181 719
the C 182 719
central C 183 719
nervous C 184 719
system C 185 719
were C 186 719
known C 187 719
to C 188 719
have C 189 719
occurred C 190 719
among C 191 719
members C 192 719
of C 193 719
the C 194 719
family C 195 719
other C 196 719
than C 197 719
siblings C 198 719
. C 199 719
cases C 201 719
oc C 202 719
- C 203 719
curred C 204 719
in C 205 719
three C 206 719
generations C 207 719
. C 208 719
it C 210 719
is C 211 719
possible C 212 719
that C 213 719
spina C 214 719
bifida C 215 719
cystica C 216 719
might C 217 719
be C 218 719
a C 219 719
recessively C 220 719
inherited C 221 719
condition C 222 719
. C 223 719
pulmonary C 1 720
vascular C 2 720
changes C 3 720
complicating C 4 720
ventriculovascular C 5 720
shunting C 6 720
for C 7 720
hydrocephalus C 8 720
a C 9 720
patient C 10 720
is C 11 720
described C 12 720
in C 13 720
whom C 14 720
pulmonary C 15 720
hypertension C 16 720
and C 17 720
cor C 18 720
pulmonale C 19 720
were C 20 720
noted C 21 720
3 C 22 720
years C 23 720
after C 24 720
placement C 25 720
of C 26 720
a C 27 720
ventriculovascular C 28 720
shunting C 29 720
apparatus C 30 720
for C 31 720
treatment C 32 720
of C 33 720
hypdrocephalus C 34 720
. C 35 720
in C 37 720
addition C 38 720
, C 39 720
the C 40 720
histologic C 41 720
sections C 42 720
of C 43 720
lung C 44 720
tissue C 45 720
obtained C 46 720
from C 47 720
65 C 48 720
patients C 49 720
with C 50 720
hy C 51 720
- C 52 720
drocephalus C 53 720
who C 54 720
died C 55 720
at C 56 720
various C 57 720
intervals C 58 720
following C 59 720
placement C 60 720
of C 61 720
a C 62 720
ventriculovascular C 63 720
shunting C 64 720
apparatus C 65 720
were C 66 720
reviewed C 67 720
with C 68 720
regard C 69 720
to C 70 720
vas C 71 720
- C 72 720
cular C 73 720
alterations C 74 720
. C 75 720
a C 77 720
high C 78 720
incidence C 79 720
of C 80 720
" C 81 720
old C 82 720
" C 83 720
and C 84 720
" C 85 720
multiple C 86 720
" C 87 720
pulmonary C 88 720
vascular C 89 720
lesions C 90 720
was C 91 720
found C 92 720
in C 93 720
this C 94 720
group C 95 720
compared C 96 720
to C 97 720
the C 98 720
incidence C 99 720
in C 100 720
control C 101 720
subjects C 102 720
. C 103 720
this C 105 720
difference C 106 720
can C 107 720
be C 108 720
attributed C 109 720
to C 110 720
the C 111 720
operative C 112 720
procedure C 113 720
. C 114 720
the C 116 720
lesions C 117 720
in C 118 720
postmortem C 119 720
material C 120 720
were C 121 720
not C 122 720
widespread C 123 720
and C 124 720
did C 125 720
not C 126 720
suggest C 127 720
the C 128 720
diagnosis C 129 720
of C 130 720
pulmonary C 131 720
hypertension C 132 720
on C 133 720
purely C 134 720
histologic C 135 720
grounds C 136 720
. C 137 720
etiology C 1 721
of C 2 721
trypan C 3 721
blue C 4 721
induced C 5 721
antenatal C 6 721
hydrocephalus C 7 721
in C 8 721
the C 9 721
albino C 10 721
rat C 11 721
wistar C 12 721
strain C 13 721
albino C 14 721
rats C 15 721
were C 16 721
injected C 17 721
with C 18 721
1 C 19 721
cm C 20 721
3 C 21 721
of C 22 721
a C 23 721
1 C 24 721
% C 25 721
solution C 26 721
of C 27 721
trypan C 28 721
blue C 29 721
. C 30 721
three C 32 721
types C 33 721
of C 34 721
dye C 35 721
were C 36 721
used C 37 721
: C 38 721
matheson C 39 721
, C 40 721
coleman C 41 721
and C 42 721
bell C 43 721
, C 44 721
chroma C 45 721
- C 46 721
gesellschaft C 47 721
and C 48 721
a C 49 721
highly C 50 721
purified C 51 721
sample C 52 721
. C 53 721
the C 55 721
dyes C 56 721
were C 57 721
injected C 58 721
on C 59 721
days C 60 721
6 C 61 721
, C 62 721
7 C 63 721
, C 64 721
and C 65 721
8 C 66 721
of C 67 721
gestation C 68 721
. C 69 721
fetuses C 71 721
were C 72 721
excised C 73 721
from C 74 721
days C 75 721
16 C 76 721
through C 77 721
20 C 78 721
, C 79 721
fixed C 80 721
, C 81 721
decalcified C 82 721
where C 83 721
necessary C 84 721
, C 85 721
embedded C 86 721
in C 87 721
paraffin C 88 721
, C 89 721
serially C 90 721
sectioned C 91 721
and C 92 721
stained C 93 721
. C 94 721
newborn C 96 721
young C 97 721
were C 98 721
treated C 99 721
similarly C 100 721
. C 101 721
chroma C 103 721
- C 104 721
gesellschaft C 105 721
trypan C 106 721
blue C 107 721
was C 108 721
without C 109 721
reproductive C 110 721
or C 111 721
teratogenic C 112 721
effect C 113 721
at C 114 721
the C 115 721
above C 116 721
doses C 117 721
. C 118 721
increasing C 120 721
the C 121 721
dose C 122 721
did C 123 721
not C 124 721
increase C 125 721
the C 126 721
teratogenicity C 127 721
but C 128 721
did C 129 721
yield C 130 721
a C 131 721
decrease C 132 721
in C 133 721
litter C 134 721
size C 135 721
. C 136 721
both C 138 721
matheson C 139 721
, C 140 721
coleman C 141 721
and C 142 721
bell C 143 721
trypan C 144 721
blue C 145 721
and C 146 721
the C 147 721
purified C 148 721
sample C 149 721
were C 150 721
teratogenic C 151 721
. C 152 721
the C 154 721
most C 155 721
frequent C 156 721
neural C 157 721
defect C 158 721
observed C 159 721
was C 160 721
hydrocephalus C 161 721
. C 162 721
serial C 164 721
sections C 165 721
of C 166 721
the C 167 721
newborn C 168 721
hydrocephalics C 169 721
showed C 170 721
an C 171 721
occluded C 172 721
or C 173 721
extremely C 174 721
tenotic C 175 721
aqueduct C 176 721
of C 177 721
sylvius C 178 721
in C 179 721
31 C 180 721
of C 181 721
33 C 182 721
sectioned C 183 721
animals C 184 721
. C 185 721
the C 187 721
fetuses C 188 721
collected C 189 721
from C 190 721
days C 191 721
18 C 192 721
through C 193 721
20 C 194 721
also C 195 721
had C 196 721
occluded C 197 721
or C 198 721
stenotic C 199 721
aqueducts C 200 721
if C 201 721
hydrocephalic C 202 721
. C 203 721
aqueductal C 205 721
stenosis C 206 721
or C 207 721
occlusion C 208 721
was C 209 721
present C 210 721
in C 211 721
17 C 212 721
- C 213 721
day C 214 721
- C 215 721
old C 216 721
fetuses C 217 721
, C 218 721
but C 219 721
hydrocephalus C 220 721
was C 221 721
not C 222 721
conclusively C 223 721
demonstrated C 224 721
at C 225 721
this C 226 721
age C 227 721
. C 228 721
sixteen C 230 721
- C 231 721
day C 232 721
- C 233 721
old C 234 721
fetuses C 235 721
did C 236 721
not C 237 721
have C 238 721
aqueductal C 239 721
occlusion C 240 721
in C 241 721
any C 242 721
of C 243 721
those C 244 721
examined C 245 721
, C 246 721
but C 247 721
stenosis C 248 721
was C 249 721
evident C 250 721
. C 251 721
it C 253 721
is C 254 721
concluded C 255 721
that C 256 721
the C 257 721
defect C 258 721
predisposing C 259 721
to C 260 721
hydrocephalus C 261 721
in C 262 721
the C 263 721
young C 264 721
of C 265 721
trypan C 266 721
blue C 267 721
treated C 268 721
rats C 269 721
of C 270 721
this C 271 721
strain C 272 721
is C 273 721
aqueductal C 274 721
stenosis C 275 721
or C 276 721
occlusion C 277 721
. C 278 721
bilateral C 1 722
papilloma C 2 722
of C 3 722
the C 4 722
choroid C 5 722
plexus C 6 722
a C 7 722
rare C 8 722
case C 9 722
of C 10 722
bilateral C 11 722
papilloma C 12 722
of C 13 722
the C 14 722
choroid C 15 722
plexus C 16 722
in C 17 722
a C 18 722
five C 19 722
- C 20 722
and C 21 722
- C 22 722
a C 23 722
- C 24 722
half C 25 722
- C 26 722
year C 27 722
old C 28 722
hydrocephalic C 29 722
girl C 30 722
is C 31 722
pre C 32 722
- C 33 722
sented C 34 722
. C 35 722
the C 37 722
tumor C 38 722
encountered C 39 722
at C 40 722
autopsy C 41 722
was C 42 722
not C 43 722
suspected C 44 722
during C 45 722
life C 46 722
, C 47 722
the C 48 722
existing C 49 722
hydrocephalus C 50 722
being C 51 722
attributed C 52 722
to C 53 722
either C 54 722
cytomegalic C 55 722
inclusion C 56 722
disease C 57 722
or C 58 722
toxoplasmosis C 59 722
. C 60 722
after C 62 722
post C 63 722
mortem C 64 722
examination C 65 722
, C 66 722
it C 67 722
was C 68 722
evident C 69 722
that C 70 722
the C 71 722
hydrocephalus C 72 722
was C 73 722
due C 74 722
to C 75 722
two C 76 722
factors C 77 722
; C 78 722
hypersecretion C 79 722
from C 80 722
the C 81 722
tumor C 82 722
itself C 83 722
, C 84 722
and C 85 722
obstruction C 86 722
at C 87 722
the C 88 722
level C 89 722
of C 90 722
the C 91 722
sylvian C 92 722
aqueduct C 93 722
by C 94 722
a C 95 722
delicate C 96 722
, C 97 722
tense C 98 722
, C 99 722
translucent C 100 722
mem C 101 722
- C 102 722
brane C 103 722
. C 104 722
an C 106 722
interesting C 107 722
and C 108 722
uncommon C 109 722
additional C 110 722
feature C 111 722
of C 112 722
this C 113 722
case C 114 722
was C 115 722
the C 116 722
presence C 117 722
, C 118 722
within C 119 722
the C 120 722
choroidal C 121 722
papillo C 122 722
- C 123 722
ma C 124 722
, C 125 722
of C 126 722
well C 127 722
- C 128 722
formed C 129 722
haversian C 130 722
bone C 131 722
. C 132 722
a C 134 722
plea C 135 722
is C 136 722
made C 137 722
for C 138 722
regularly C 139 722
considering C 140 722
papilloma C 141 722
of C 142 722
the C 143 722
choroid C 144 722
plexus C 145 722
in C 146 722
the C 147 722
differential C 148 722
diagnosis C 149 722
of C 150 722
hydro C 151 722
- C 152 722
cephalus C 153 722
in C 154 722
children C 155 722
, C 156 722
for C 157 722
here C 158 722
, C 159 722
early C 160 722
diagnosis C 161 722
and C 162 722
treat C 163 722
- C 164 722
ment C 165 722
might C 166 722
conceivably C 167 722
result C 168 722
in C 169 722
total C 170 722
cure C 171 722
. C 172 722
the C 1 723
diagnosis C 2 723
of C 3 723
hydrocephalus C 4 723
the C 5 723
early C 6 723
diagnosis C 7 723
of C 8 723
hydrocephalus C 9 723
is C 10 723
imperative C 11 723
if C 12 723
definitive C 13 723
steps C 14 723
for C 15 723
its C 16 723
correction C 17 723
are C 18 723
to C 19 723
be C 20 723
effective C 21 723
. C 22 723
transillumination C 24 723
is C 25 723
a C 26 723
fairly C 27 723
accurate C 28 723
procedure C 29 723
that C 30 723
may C 31 723
offer C 32 723
the C 33 723
earliest C 34 723
means C 35 723
of C 36 723
determining C 37 723
whether C 38 723
or C 39 723
not C 40 723
the C 41 723
infant C 42 723
' C 43 723
s C 44 723
head C 45 723
is C 46 723
enlarging C 47 723
. C 48 723
however C 50 723
, C 51 723
serial C 52 723
head C 53 723
measurements C 54 723
constitute C 55 723
the C 56 723
easiest C 57 723
and C 58 723
most C 59 723
accurate C 60 723
method C 61 723
for C 62 723
early C 63 723
detection C 64 723
of C 65 723
hydrocephalus C 66 723
. C 67 723
charts C 69 723
of C 70 723
normal C 71 723
head C 72 723
size C 73 723
of C 74 723
full C 75 723
- C 76 723
term C 77 723
and C 78 723
premature C 79 723
infants C 80 723
are C 81 723
available C 82 723
to C 83 723
aid C 84 723
the C 85 723
physician C 86 723
in C 87 723
evaluating C 88 723
any C 89 723
deviation C 90 723
from C 91 723
normal C 92 723
. C 93 723
once C 95 723
the C 96 723
condition C 97 723
has C 98 723
been C 99 723
detected C 100 723
, C 101 723
it C 102 723
is C 103 723
up C 104 723
to C 105 723
the C 106 723
neurosurgeon C 107 723
to C 108 723
determine C 109 723
the C 110 723
treatment C 111 723
plan C 112 723
. C 113 723
the C 115 723
operative C 116 723
procedure C 117 723
most C 118 723
widely C 119 723
used C 120 723
for C 121 723
shunting C 122 723
the C 123 723
excessive C 124 723
cerebrospinal C 125 723
fluid C 126 723
is C 127 723
insertion C 128 723
of C 129 723
a C 130 723
spitz C 131 723
- C 132 723
holter C 133 723
valve C 134 723
. C 135 723
early C 137 723
detection C 138 723
and C 139 723
improved C 140 723
treatment C 141 723
methods C 142 723
will C 143 723
help C 144 723
prevent C 145 723
irreversible C 146 723
intellectual C 147 723
damage C 148 723
likely C 149 723
to C 150 723
develop C 151 723
if C 152 723
hydrocephalus C 153 723
continues C 154 723
unchecked C 155 723
. C 156 723
infantile C 1 724
hydrocephalus C 2 724
and C 3 724
hematoma C 4 724
in C 5 724
the C 6 724
posterior C 7 724
fossa C 8 724
we C 9 724
have C 10 724
presented C 11 724
a C 12 724
case C 13 724
of C 14 724
hydrocephalus C 15 724
in C 16 724
an C 17 724
infant C 18 724
, C 19 724
the C 20 724
basic C 21 724
cause C 22 724
being C 23 724
intracranial C 24 724
hemorrhage C 25 724
in C 26 724
the C 27 724
perinatal C 28 724
period C 29 724
. C 30 724
surgical C 32 724
re C 33 724
- C 34 724
moval C 35 724
of C 36 724
a C 37 724
hematoma C 38 724
in C 39 724
the C 40 724
posterior C 41 724
fossa C 42 724
did C 43 724
not C 44 724
give C 45 724
permanent C 46 724
relief C 47 724
of C 48 724
the C 49 724
raised C 50 724
intracranial C 51 724
pressure C 52 724
. C 53 724
a C 55 724
lumbar C 56 724
air C 57 724
study C 58 724
at C 59 724
this C 60 724
stage C 61 724
dis C 62 724
- C 63 724
closed C 64 724
information C 65 724
that C 66 724
the C 67 724
passage C 68 724
through C 69 724
the C 70 724
intracerebral C 71 724
cerebrospinal C 72 724
- C 73 724
fluid C 74 724
pathways C 75 724
was C 76 724
normalized C 77 724
whereas C 78 724
the C 79 724
extracerebral C 80 724
ones C 81 724
still C 82 724
were C 83 724
occluded C 84 724
by C 85 724
arachnoiditis C 86 724
. C 87 724
the C 89 724
condition C 90 724
necessitated C 91 724
a C 92 724
ventriculo C 93 724
- C 94 724
atrial C 95 724
shunt C 96 724
. C 97 724
urinary C 1 725
excretion C 2 725
of C 3 725
i C 4 725
131 C 5 725
- C 6 725
diodrast C 7 725
injected C 8 725
intraventricularly C 9 725
in C 10 725
communicating C 11 725
hydrocephalus C 12 725
and C 13 725
aqueduct C 14 725
stenosis C 15 725
nine C 16 725
cases C 17 725
of C 18 725
expansive C 19 725
infantile C 20 725
hydro C 21 725
- C 22 725
cephalus C 23 725
were C 24 725
investigated C 25 725
by C 26 725
injecting C 27 725
small C 28 725
amounts C 29 725
of C 30 725
i C 31 725
131 C 32 725
- C 33 725
diodrast C 34 725
intra C 35 725
- C 36 725
ventricularly C 37 725
. C 38 725
urinary C 40 725
excretion C 41 725
of C 42 725
the C 43 725
tracer C 44 725
was C 45 725
determined C 46 725
during C 47 725
the C 48 725
first C 49 725
4 C 50 725
- C 51 725
5 C 52 725
hours C 53 725
after C 54 725
injection C 55 725
. C 56 725
the C 58 725
cumulative C 59 725
excretion C 60 725
of C 61 725
diodrast C 62 725
from C 63 725
the C 64 725
c C 65 725
. C 66 725
. C 67 725
. C 68 725
. C 69 725
. C 70 725
dif C 72 725
- C 73 725
fers C 74 725
in C 75 725
cases C 76 725
with C 77 725
communicating C 78 725
hydro C 79 725
- C 80 725
cephalus C 81 725
from C 82 725
those C 83 725
with C 84 725
stenosis C 85 725
of C 86 725
the C 87 725
aqueduct C 88 725
. C 89 725
the C 91 725
investigation C 92 725
is C 93 725
rapid C 94 725
and C 95 725
easily C 96 725
performed C 97 725
and C 98 725
has C 99 725
not C 100 725
produced C 101 725
any C 102 725
side C 103 725
effects C 104 725
. C 105 725
gastrointestinal C 1 726
ulceration C 2 726
and C 3 726
central C 4 726
nervous C 5 726
system C 6 726
lesions C 7 726
there C 8 726
is C 9 726
both C 10 726
a C 11 726
real C 12 726
and C 13 726
an C 14 726
apparent C 15 726
in C 16 726
- C 17 726
crease C 18 726
in C 19 726
the C 20 726
incidence C 21 726
of C 22 726
severe C 23 726
gastroin C 24 726
- C 25 726
testinal C 26 726
ulceration C 27 726
due C 28 726
to C 29 726
central C 30 726
nervous C 31 726
lesions C 32 726
. C 33 726
some C 35 726
of C 36 726
this C 37 726
increased C 38 726
incidence C 39 726
reflects C 40 726
recently C 41 726
devised C 42 726
iatrogenic C 43 726
measures C 44 726
including C 45 726
new C 46 726
drugs C 47 726
and C 48 726
surgical C 49 726
therapy C 50 726
. C 51 726
in C 53 726
adults C 54 726
, C 55 726
cerebrovascular C 56 726
lesions C 57 726
are C 58 726
the C 59 726
commonest C 60 726
single C 61 726
cause C 62 726
of C 63 726
acute C 64 726
peptic C 65 726
ul C 66 726
- C 67 726
ceration C 68 726
found C 69 726
at C 70 726
autopsy C 71 726
. C 72 726
in C 74 726
children C 75 726
, C 76 726
we C 77 726
found C 78 726
25 C 79 726
instances C 80 726
of C 81 726
upper C 82 726
gastrointestinal C 83 726
ulceration C 84 726
due C 85 726
to C 86 726
central C 87 726
nervous C 88 726
system C 89 726
le C 90 726
- C 91 726
sions C 92 726
in C 93 726
1 C 94 726
, C 95 726
750 C 96 726
autopsies C 97 726
. C 98 726
two C 100 726
general C 101 726
ana C 102 726
- C 103 726
tomical C 104 726
categories C 105 726
could C 106 726
be C 107 726
recognized C 108 726
: C 109 726
acute C 110 726
ulceration C 111 726
and C 112 726
malacias C 113 726
. C 114 726
a C 116 726
variety C 117 726
of C 118 726
causative C 119 726
central C 120 726
nervous C 121 726
sys C 122 726
- C 123 726
tem C 124 726
lesions C 125 726
was C 126 726
responsible C 127 726
in C 128 726
these C 129 726
25 C 130 726
cases C 131 726
, C 132 726
the C 133 726
commonest C 134 726
being C 135 726
bacterial C 136 726
meningitis C 137 726
. C 138 726
other C 140 726
causes C 141 726
were C 142 726
poliomyelitis C 143 726
, C 144 726
brain C 145 726
tu C 146 726
- C 147 726
mor C 148 726
, C 149 726
hydrocephalus C 150 726
, C 151 726
etc C 152 726
. C 153 726
theories C 155 726
of C 156 726
pathogenesis C 157 726
are C 158 726
presented C 159 726
. C 160 726
more C 162 726
experience C 163 726
with C 164 726
both C 165 726
drug C 166 726
and C 167 726
surgical C 168 726
therapy C 169 726
is C 170 726
needed C 171 726
. C 172 726
the C 174 726
recent C 175 726
development C 176 726
of C 177 726
local C 178 726
freezing C 179 726
techniques C 180 726
offers C 181 726
promise C 182 726
for C 183 726
reduction C 184 726
of C 185 726
mortality C 186 726
. C 187 726
mansonia C 1 727
crassipes C 2 727
as C 3 727
the C 4 727
natural C 5 727
vector C 6 727
of C 7 727
filarioids C 8 727
, C 9 727
plasmodium C 10 727
gallinaceum C 11 727
and C 12 727
other C 13 727
plasmodia C 14 727
of C 15 727
fowls C 16 727
in C 17 727
ceylon C 18 727
it C 19 727
would C 20 727
appear C 21 727
from C 22 727
these C 23 727
observations C 24 727
that C 25 727
m C 26 727
. C 27 727
crassipes C 29 727
is C 30 727
the C 31 727
natural C 32 727
vector C 33 727
of C 34 727
p C 35 727
. C 36 727
gallinaceum C 38 727
of C 39 727
fowls C 40 727
in C 41 727
ceylon C 42 727
and C 43 727
possibly C 44 727
of C 45 727
other C 46 727
species C 47 727
of C 48 727
plasmodium C 49 727
of C 50 727
fowls C 51 727
or C 52 727
of C 53 727
related C 54 727
avian C 55 727
hosts C 56 727
. C 57 727
if C 59 727
one C 60 727
of C 61 727
the C 62 727
other C 63 727
plasmodia C 64 727
from C 65 727
m C 66 727
. C 67 727
crassipes C 69 727
is C 70 727
in C 71 727
fact C 72 727
p C 73 727
. C 74 727
lophurae C 76 727
then C 77 727
this C 78 727
will C 79 727
be C 80 727
the C 81 727
first C 82 727
record C 83 727
of C 84 727
p C 85 727
. C 86 727
lophurae C 88 727
from C 89 727
this C 90 727
part C 91 727
of C 92 727
the C 93 727
world C 94 727
. C 95 727
we C 97 727
are C 98 727
, C 99 727
however C 100 727
, C 101 727
not C 102 727
certain C 103 727
whether C 104 727
the C 105 727
fowl C 106 727
is C 107 727
the C 108 727
natural C 109 727
vertebrate C 110 727
host C 111 727
of C 112 727
p C 113 727
. C 114 727
lophurae C 116 727
in C 117 727
ceylon C 118 727
. C 119 727
we C 121 727
have C 122 727
seen C 123 727
crithidial C 124 727
forms C 125 727
in C 126 727
the C 127 727
midgut C 128 727
of C 129 727
engorged C 130 727
wild C 131 727
- C 132 727
caught C 133 727
m C 134 727
. C 135 727
crassipes C 137 727
. C 138 727
this C 140 727
mosquito C 141 727
may C 142 727
, C 143 727
therefore C 144 727
, C 145 727
prove C 146 727
to C 147 727
be C 148 727
the C 149 727
vector C 150 727
of C 151 727
the C 152 727
trypanosome C 153 727
as C 154 727
well C 155 727
. C 156 727
the C 158 727
trypanosome C 159 727
differs C 160 727
from C 161 727
trypanosoma C 162 727
gallinarum C 163 727
and C 164 727
t C 165 727
. C 166 727
calmettei C 168 727
which C 169 727
have C 170 727
previously C 171 727
been C 172 727
reported C 173 727
from C 174 727
fowls C 175 727
. C 176 727
filariasis C 1 728
in C 2 728
portuguese C 3 728
timor C 4 728
, C 5 728
with C 6 728
observations C 7 728
on C 8 728
a C 9 728
new C 10 728
microfilaria C 11 728
found C 12 728
in C 13 728
man C 14 728
the C 15 728
results C 16 728
are C 17 728
described C 18 728
of C 19 728
an C 20 728
investigation C 21 728
into C 22 728
filariasis C 23 728
in C 24 728
portuguese C 25 728
timor C 26 728
. C 27 728
two C 29 728
types C 30 728
of C 31 728
microfilariae C 32 728
were C 33 728
found C 34 728
in C 35 728
blood C 36 728
films C 37 728
: C 38 728
one C 39 728
was C 40 728
wuchereria C 41 728
bancrofti C 42 728
and C 43 728
the C 44 728
other C 45 728
, C 46 728
referred C 47 728
to C 48 728
as C 49 728
the C 50 728
timor C 51 728
microfilaria C 52 728
, C 53 728
is C 54 728
probably C 55 728
a C 56 728
new C 57 728
species C 58 728
. C 59 728
blood C 61 728
surveys C 62 728
showed C 63 728
that C 64 728
w C 65 728
. C 66 728
bancrofti C 68 728
and C 69 728
the C 70 728
timor C 71 728
microfilaria C 72 728
were C 73 728
widely C 74 728
distributed C 75 728
in C 76 728
the C 77 728
territory C 78 728
but C 79 728
that C 80 728
infection C 81 728
rates C 82 728
were C 83 728
usually C 84 728
low C 85 728
. C 86 728
clinical C 88 728
lesions C 89 728
were C 90 728
few C 91 728
and C 92 728
mild C 93 728
; C 94 728
elephantiasis C 95 728
was C 96 728
confined C 97 728
to C 98 728
oedema C 99 728
of C 100 728
the C 101 728
lower C 102 728
limbs C 103 728
below C 104 728
the C 105 728
knee C 106 728
. C 107 728
the C 109 728
timor C 110 728
microfilaria C 111 728
resembles C 112 728
that C 113 728
of C 114 728
brugia C 115 728
malayi C 116 728
in C 117 728
general C 118 728
staining C 119 728
reaction C 120 728
and C 121 728
appearance C 122 728
and C 123 728
in C 124 728
the C 125 728
possession C 126 728
of C 127 728
two C 128 728
nuclei C 129 728
in C 130 728
the C 131 728
terminal C 132 728
thread C 133 728
, C 134 728
but C 135 728
differs C 136 728
in C 137 728
over C 138 728
- C 139 728
all C 140 728
length C 141 728
, C 142 728
in C 143 728
cephalic C 144 728
- C 145 728
space C 146 728
ratio C 147 728
, C 148 728
and C 149 728
in C 150 728
failure C 151 728
of C 152 728
the C 153 728
sheath C 154 728
to C 155 728
stain C 156 728
with C 157 728
giemsa C 158 728
. C 159 728
it C 161 728
is C 162 728
nocturnally C 163 728
periodic C 164 728
. C 165 728
it C 167 728
was C 168 728
rapidly C 169 728
removed C 170 728
from C 171 728
the C 172 728
peripheral C 173 728
blood C 174 728
by C 175 728
treatment C 176 728
with C 177 728
diethylcarbamazine C 178 728
citrate C 179 728
in C 180 728
daily C 181 728
doses C 182 728
of C 183 728
9 C 184 728
. C 185 728
. C 186 728
- C 187 728
13 C 188 728
. C 189 728
. C 190 728
mgm C 191 728
. C 192 728
per C 194 728
kgm C 195 728
. C 196 728
body C 198 728
weight C 199 728
or C 200 728
3 C 201 728
. C 202 728
. C 203 728
- C 204 728
5 C 205 728
. C 206 728
. C 207 728
mgm C 208 728
. C 209 728
per C 211 728
kgm C 212 728
. C 213 728
body C 215 728
weight C 216 728
for C 217 728
seven C 218 728
days C 219 728
. C 220 728
only C 222 728
damaged C 223 728
fragments C 224 728
of C 225 728
adult C 226 728
female C 227 728
worms C 228 728
were C 229 728
recovered C 230 728
. C 231 728
the C 233 728
timor C 234 728
microfilaria C 235 728
was C 236 728
not C 237 728
found C 238 728
in C 239 728
cats C 240 728
, C 241 728
dogs C 242 728
or C 243 728
monkeys C 244 728
. C 245 728
the C 247 728
vectors C 248 728
of C 249 728
filariasis C 250 728
in C 251 728
timor C 252 728
are C 253 728
still C 254 728
unknown C 255 728
. C 256 728
dipetalonema C 1 729
obtusa C 2 729
( C 3 729
mccoy C 4 729
, C 5 729
1936 C 6 729
) C 7 729
comb C 8 729
. C 9 729
n C 11 729
. C 12 729
( C 14 729
filarioidea C 15 729
: C 16 729
onchocercidae C 17 729
) C 18 729
in C 19 729
colombian C 20 729
primates C 21 729
, C 22 729
with C 23 729
a C 24 729
description C 25 729
of C 26 729
the C 27 729
adult C 28 729
microfilaria C 29 729
obtusa C 30 729
mccoy C 31 729
, C 32 729
1936 C 33 729
, C 34 729
was C 35 729
identified C 36 729
in C 37 729
the C 38 729
blood C 39 729
of C 40 729
29 C 41 729
( C 42 729
31 C 43 729
% C 44 729
) C 45 729
of C 46 729
93 C 47 729
cebus C 48 729
capucinus C 49 729
and C 50 729
c C 51 729
. C 52 729
albifrons C 54 729
from C 55 729
northern C 56 729
colombia C 57 729
, C 58 729
but C 59 729
was C 60 729
not C 61 729
found C 62 729
in C 63 729
an C 64 729
additional C 65 729
42 C 66 729
c C 67 729
. C 68 729
apella C 70 729
and C 71 729
99 C 72 729
saimiri C 73 729
sciurea C 74 729
from C 75 729
other C 76 729
areas C 77 729
in C 78 729
colombia C 79 729
. C 80 729
the C 82 729
adult C 83 729
male C 84 729
and C 85 729
female C 86 729
, C 87 729
recovered C 88 729
from C 89 729
the C 90 729
peri C 91 729
- C 92 729
esophageal C 93 729
connective C 94 729
tissue C 95 729
of C 96 729
the C 97 729
infected C 98 729
animals C 99 729
, C 100 729
are C 101 729
described C 102 729
in C 103 729
detail C 104 729
. C 105 729
dipetalonema C 107 729
obtusa C 108 729
( C 109 729
mc C 110 729
- C 111 729
coy C 112 729
, C 113 729
1936 C 114 729
) C 115 729
comb C 116 729
. C 117 729
n C 119 729
. C 120 729
resembles C 122 729
tetrapetalonema C 123 729
marmosetae C 124 729
faust C 125 729
, C 126 729
1935 C 127 729
, C 128 729
but C 129 729
is C 130 729
smaller C 131 729
and C 132 729
the C 133 729
right C 134 729
spicule C 135 729
is C 136 729
complex C 137 729
, C 138 729
not C 139 729
simple C 140 729
. C 141 729
experimental C 1 730
onchocercal C 2 730
ocular C 3 730
lesions C 4 730
in C 5 730
the C 6 730
chimpanzee C 7 730
this C 8 730
is C 9 730
the C 10 730
first C 11 730
attempt C 12 730
to C 13 730
produce C 14 730
onchocercal C 15 730
eye C 16 730
lesions C 17 730
with C 18 730
microfilariae C 19 730
of C 20 730
o C 21 730
. C 22 730
volvulus C 24 730
in C 25 730
the C 26 730
chimpanzee C 27 730
. C 28 730
live C 30 730
microfilariae C 31 730
, C 32 730
once C 33 730
in C 34 730
the C 35 730
anterior C 36 730
chamber C 37 730
of C 38 730
the C 39 730
eye C 40 730
, C 41 730
could C 42 730
penetrate C 43 730
the C 44 730
an C 45 730
- C 46 730
gle C 47 730
of C 48 730
the C 49 730
anterior C 50 730
chamber C 51 730
, C 52 730
the C 53 730
iris C 54 730
, C 55 730
the C 56 730
ciliary C 57 730
body C 58 730
, C 59 730
the C 60 730
choroid C 61 730
and C 62 730
the C 63 730
vitreous C 64 730
. C 65 730
most C 67 730
of C 68 730
the C 69 730
microfilariae C 70 730
injected C 71 730
alive C 72 730
into C 73 730
the C 74 730
anterior C 75 730
chamber C 76 730
of C 77 730
the C 78 730
eyes C 79 730
of C 80 730
the C 81 730
chimpanzee C 82 730
died C 83 730
within C 84 730
a C 85 730
short C 86 730
time C 87 730
. C 88 730
com C 90 730
- C 91 730
parison C 92 730
, C 93 730
therefore C 94 730
, C 95 730
could C 96 730
not C 97 730
be C 98 730
made C 99 730
be C 100 730
- C 101 730
tween C 102 730
the C 103 730
effects C 104 730
of C 105 730
live C 106 730
and C 107 730
dead C 108 730
micro C 109 730
- C 110 730
filariae C 111 730
. C 112 730
microfilariae C 114 730
debris C 115 730
was C 116 730
demonstrated C 117 730
within C 118 730
giant C 119 730
cells C 120 730
for C 121 730
the C 122 730
first C 123 730
time C 124 730
. C 125 730
subconjunctival C 127 730
and C 128 730
limbal C 129 730
infiltration C 130 730
with C 131 730
incipient C 132 730
pannus C 133 730
, C 134 730
inflammation C 135 730
within C 136 730
the C 137 730
trabecular C 138 730
meshwork C 139 730
of C 140 730
the C 141 730
angle C 142 730
of C 143 730
the C 144 730
anterior C 145 730
chamber C 146 730
and C 147 730
extensive C 148 730
active C 149 730
iri C 150 730
- C 151 730
docyclitis C 152 730
were C 153 730
demonstrated C 154 730
in C 155 730
histologic C 156 730
sections C 157 730
, C 158 730
although C 159 730
the C 160 730
conditions C 161 730
were C 162 730
clini C 163 730
- C 164 730
cally C 165 730
quiescent C 166 730
. C 167 730
the C 169 730
posterior C 170 730
segment C 171 730
lesion C 172 730
of C 173 730
oncho C 174 730
- C 175 730
cercal C 176 730
chorioretinal C 177 730
degeneration C 178 730
could C 179 730
not C 180 730
be C 181 730
reproduced C 182 730
. C 183 730
subcutaneous C 185 730
and C 186 730
intravenous C 187 730
injec C 188 730
- C 189 730
tions C 190 730
of C 191 730
worm C 192 730
extracts C 193 730
, C 194 730
derived C 195 730
from C 196 730
human C 197 730
onchocercomas C 198 730
, C 199 730
may C 200 730
have C 201 730
contributed C 202 730
to C 203 730
the C 204 730
onset C 205 730
of C 206 730
active C 207 730
choroiditis C 208 730
. C 209 730
this C 211 730
sensitization C 212 730
alone C 213 730
, C 214 730
without C 215 730
the C 216 730
intraocular C 217 730
injection C 218 730
of C 219 730
microfilariae C 220 730
, C 221 730
had C 222 730
no C 223 730
effects C 224 730
on C 225 730
the C 226 730
eye C 227 730
. C 228 730
various C 230 730
aspects C 231 730
of C 232 730
the C 233 730
pathogenesis C 234 730
of C 235 730
human C 236 730
onchocerciasis C 237 730
are C 238 730
discussed C 239 730
on C 240 730
the C 241 730
basis C 242 730
of C 243 730
present C 244 730
experimentation C 245 730
. C 246 730
the C 1 731
occurence C 2 731
of C 3 731
dirofilaria C 4 731
magnilarvatum C 5 731
price C 6 731
and C 7 731
brugia C 8 731
sp C 9 731
. C 10 731
in C 12 731
philippine C 13 731
monkeys C 14 731
of C 15 731
356 C 16 731
macaca C 17 731
philippinensis C 18 731
examined C 19 731
, C 20 731
three C 21 731
were C 22 731
found C 23 731
infected C 24 731
with C 25 731
dirofilaria C 26 731
magnilarvatum C 27 731
price C 28 731
, C 29 731
1959 C 30 731
. C 31 731
one C 33 731
of C 34 731
these C 35 731
was C 36 731
infected C 37 731
also C 38 731
with C 39 731
a C 40 731
species C 41 731
of C 42 731
brugla C 43 731
. C 44 731
both C 46 731
species C 47 731
showed C 48 731
a C 49 731
sub C 50 731
- C 51 731
periodic C 52 731
type C 53 731
of C 54 731
microfilarial C 55 731
periodicity C 56 731
. C 57 731
these C 59 731
observations C 60 731
suggest C 61 731
that C 62 731
philippine C 63 731
macaques C 64 731
may C 65 731
serve C 66 731
as C 67 731
reservoirs C 68 731
for C 69 731
sub C 70 731
- C 71 731
periodic C 72 731
b C 73 731
. C 74 731
malayi C 76 731
on C 77 731
palawan C 78 731
, C 79 731
where C 80 731
high C 81 731
rates C 82 731
of C 83 731
infection C 84 731
have C 85 731
been C 86 731
found C 87 731
in C 88 731
people C 89 731
living C 90 731
in C 91 731
small C 92 731
villages C 93 731
in C 94 731
the C 95 731
forests C 96 731
. C 97 731
mansonia C 99 731
bonneae C 100 731
was C 101 731
found C 102 731
naturally C 103 731
infected C 104 731
with C 105 731
third C 106 731
stage C 107 731
larvae C 108 731
of C 109 731
d C 110 731
. C 111 731
magnilarvatum C 113 731
. C 114 731
it C 116 731
is C 117 731
sug C 118 731
- C 119 731
gested C 120 731
that C 121 731
monkeys C 122 731
may C 123 731
serve C 124 731
as C 125 731
reservoirs C 126 731
for C 127 731
sub C 128 731
- C 129 731
periodic C 130 731
b C 131 731
. C 132 731
malayi C 134 731
on C 135 731
the C 136 731
island C 137 731
of C 138 731
palawan C 139 731
, C 140 731
where C 141 731
high C 142 731
rates C 143 731
of C 144 731
infection C 145 731
with C 146 731
this C 147 731
species C 148 731
have C 149 731
been C 150 731
observed C 151 731
in C 152 731
people C 153 731
living C 154 731
in C 155 731
small C 156 731
villages C 157 731
in C 158 731
the C 159 731
forest C 160 731
. C 161 731
the C 1 732
filarial C 2 732
parasites C 3 732
of C 4 732
the C 5 732
eastern C 6 732
gorilla C 7 732
in C 8 732
the C 9 732
congo C 10 732
a C 11 732
survey C 12 732
for C 13 732
parasites C 14 732
has C 15 732
been C 16 732
undertaken C 17 732
in C 18 732
20 C 19 732
mountain C 20 732
gorillas C 21 732
( C 22 732
gorilla C 23 732
gorilla C 24 732
beringei C 25 732
) C 26 732
from C 27 732
the C 28 732
eastern C 29 732
congo C 30 732
kivu C 31 732
province C 32 732
. C 33 732
six C 35 732
full C 36 732
- C 37 732
grown C 38 732
( C 39 732
two C 40 732
males C 41 732
and C 42 732
four C 43 732
females C 44 732
) C 45 732
, C 46 732
three C 47 732
adolescents C 48 732
( C 49 732
one C 50 732
male C 51 732
and C 52 732
two C 53 732
females C 54 732
) C 55 732
, C 56 732
and C 57 732
eleven C 58 732
young C 59 732
gorillas C 60 732
were C 61 732
examined C 62 732
, C 63 732
some C 64 732
of C 65 732
them C 66 732
during C 67 732
several C 68 732
consecutive C 69 732
months C 70 732
. C 71 732
nine C 73 732
autopsies C 74 732
were C 75 732
performed C 76 732
. C 77 732
no C 79 732
protozoa C 80 732
were C 81 732
discovered C 82 732
in C 83 732
the C 84 732
blood C 85 732
. C 86 732
plasmodium C 88 732
parasites C 89 732
which C 90 732
are C 91 732
common C 92 732
in C 93 732
gorillas C 94 732
and C 95 732
chimpanzees C 96 732
from C 97 732
west C 98 732
africa C 99 732
were C 100 732
never C 101 732
found C 102 732
in C 103 732
the C 104 732
eastern C 105 732
congo C 106 732
primates C 107 732
, C 108 732
including C 109 732
ten C 110 732
other C 111 732
gorillas C 112 732
examined C 113 732
previously C 114 732
and C 115 732
some C 116 732
fifty C 117 732
chimpanzees C 118 732
. C 119 732
severe C 121 732
diarrhoea C 122 732
with C 123 732
a C 124 732
balantidiasis C 125 732
picture C 126 732
developed C 127 732
in C 128 732
two C 129 732
young C 130 732
gorillas C 131 732
. C 132 732
autopsy C 134 732
revealed C 135 732
however C 136 732
an C 137 732
intensive C 138 732
infection C 139 732
with C 140 732
oesophagostomum C 141 732
stephanostomum C 142 732
and C 143 732
resulting C 144 732
fatty C 145 732
degenera C 146 732
- C 147 732
tion C 148 732
of C 149 732
the C 150 732
liver C 151 732
. C 152 732
oligotrichida C 154 732
belonging C 155 732
to C 156 732
the C 157 732
genus C 158 732
troglodytella C 159 732
were C 160 732
commonly C 161 732
found C 162 732
in C 163 732
the C 164 732
intestinal C 165 732
tract C 166 732
. C 167 732
oesophagostomum C 169 732
stephanostomum C 170 732
eggs C 171 732
were C 172 732
consistently C 173 732
present C 174 732
in C 175 732
the C 176 732
stools C 177 732
of C 178 732
the C 179 732
gorillas C 180 732
and C 181 732
autoinfection C 182 732
caused C 183 732
the C 184 732
death C 185 732
of C 186 732
several C 187 732
young C 188 732
gorillas C 189 732
4 C 190 732
to C 191 732
6 C 192 732
weeks C 193 732
after C 194 732
their C 195 732
capture C 196 732
. C 197 732
many C 199 732
microfilariae C 200 732
were C 201 732
found C 202 732
in C 203 732
the C 204 732
blood C 205 732
and C 206 732
the C 207 732
skin C 208 732
. C 209 732
pre C 211 732
- C 212 732
liminary C 213 732
communications C 214 732
were C 215 732
published C 216 732
mentioning C 217 732
the C 218 732
existence C 219 732
of C 220 732
four C 221 732
different C 222 732
microfilariae C 223 732
in C 224 732
the C 225 732
blood C 226 732
of C 227 732
gorillas C 228 732
and C 229 732
of C 230 732
three C 231 732
others C 232 732
in C 233 732
the C 234 732
dermal C 235 732
layers C 236 732
of C 237 732
the C 238 732
skin C 239 732
. C 240 732
after C 242 732
a C 243 732
detailed C 244 732
study C 245 732
seven C 246 732
species C 247 732
have C 248 732
been C 249 732
identified C 250 732
and C 251 732
described C 252 732
: C 253 732
dipetalonema C 254 732
leopoldi C 255 732
, C 256 732
d C 257 732
. C 258 732
gorillae C 260 732
, C 261 732
d C 262 732
. C 263 732
vanhoofi C 265 732
, C 266 732
d C 267 732
. C 268 732
streptocercum C 270 732
, C 271 732
microfilaria C 272 732
binucleata C 273 732
, C 274 732
loa C 275 732
loa C 276 732
gorillae C 277 732
n C 278 732
. C 279 732
. C 280 732
. C 280 732
. C 280 732
. C 280 732
. C 280 732
. C 281 732
and C 283 732
onchocerca C 284 732
volvulus C 285 732
. C 286 732
three C 288 732
of C 289 732
the C 290 732
worms C 291 732
described C 292 732
have C 293 732
so C 294 732
far C 295 732
been C 296 732
discovered C 297 732
only C 298 732
in C 299 732
gorilla C 300 732
gorilla C 301 732
, C 302 732
namely C 303 732
dipetalonema C 304 732
leopoldi C 305 732
, C 306 732
d C 307 732
. C 308 732
gorillae C 310 732
and C 311 732
loa C 312 732
loa C 313 732
gorillae C 314 732
. C 315 732
two C 317 732
of C 318 732
them C 319 732
were C 320 732
previously C 321 732
known C 322 732
from C 323 732
the C 324 732
chimpanzee C 325 732
, C 326 732
namely C 327 732
d C 328 732
. C 329 732
vanhoofi C 331 732
and C 332 732
microfilaria C 333 732
binucleata C 334 732
. C 335 732
one C 337 732
species C 338 732
, C 339 732
d C 340 732
. C 341 732
strepto C 343 732
- C 344 732
cercum C 345 732
, C 346 732
first C 347 732
discovered C 348 732
in C 349 732
man C 350 732
and C 351 732
later C 352 732
described C 353 732
from C 354 732
the C 355 732
chimpan C 356 732
- C 357 732
zee C 358 732
, C 359 732
is C 360 732
now C 361 732
also C 362 732
known C 363 732
from C 364 732
gorilla C 365 732
gorilla C 366 732
. C 367 732
onchocerca C 369 732
volvulus C 370 732
has C 371 732
been C 372 732
found C 373 732
in C 374 732
only C 375 732
one C 376 732
of C 377 732
the C 378 732
20 C 379 732
gorillas C 380 732
examined C 381 732
. C 382 732
gorilla C 384 732
gorilla C 385 732
beringei C 386 732
in C 387 732
eastern C 388 732
congo C 389 732
might C 390 732
become C 391 732
through C 392 732
close C 393 732
contact C 394 732
with C 395 732
man C 396 732
and C 397 732
his C 398 732
filarial C 399 732
vectors C 400 732
an C 401 732
abnormal C 402 732
or C 403 732
accidental C 404 732
host C 405 732
of C 406 732
d C 407 732
. C 408 732
streptocercum C 410 732
and C 411 732
onchocerca C 412 732
volvulus C 413 732
or C 414 732
else C 415 732
might C 416 732
be C 417 732
considered C 418 732
as C 419 732
an C 420 732
original C 421 732
reservoir C 422 732
of C 423 732
these C 424 732
filarial C 425 732
parasites C 426 732
of C 427 732
man C 428 732
. C 429 732
a C 1 733
pilot C 2 733
project C 3 733
for C 4 733
the C 5 733
control C 6 733
of C 7 733
filariasis C 8 733
in C 9 733
thailand C 10 733
in C 11 733
a C 12 733
village C 13 733
in C 14 733
kanjanadit C 15 733
district C 16 733
of C 17 733
surat C 18 733
- C 19 733
thani C 20 733
province C 21 733
, C 22 733
south C 23 733
thailand C 24 733
, C 25 733
where C 26 733
a C 27 733
field C 28 733
station C 29 733
for C 30 733
filariasis C 31 733
studies C 32 733
had C 33 733
been C 34 733
established C 35 733
by C 36 733
the C 37 733
bangkok C 38 733
school C 39 733
of C 40 733
tropical C 41 733
medicine C 42 733
, C 43 733
blood C 44 733
films C 45 733
were C 46 733
examined C 47 733
from C 48 733
977 C 49 733
persons C 50 733
( C 51 733
95 C 52 733
. C 53 733
. C 54 733
per C 55 733
cent C 56 733
. C 57 733
of C 59 733
the C 60 733
total C 61 733
population C 62 733
of C 63 733
1 C 64 733
, C 65 733
023 C 66 733
) C 67 733
. C 68 733
two C 70 733
thick C 71 733
films C 72 733
( C 73 733
each C 74 733
of C 75 733
20 C 76 733
c C 77 733
. C 78 733
. C 79 733
. C 79 733
. C 80 733
) C 82 733
were C 83 733
prepared C 84 733
from C 85 733
each C 86 733
person C 87 733
and C 88 733
stained C 89 733
with C 90 733
giemsa C 91 733
. C 92 733
it C 94 733
was C 95 733
found C 96 733
that C 97 733
21 C 98 733
. C 99 733
. C 100 733
per C 101 733
cent C 102 733
. C 103 733
of C 105 733
the C 106 733
people C 107 733
harboured C 108 733
microfilariae C 109 733
( C 110 733
all C 111 733
brugia C 112 733
malayi C 113 733
) C 114 733
. C 115 733
elephantiasis C 117 733
was C 118 733
found C 119 733
in C 120 733
5 C 121 733
. C 122 733
. C 123 733
per C 124 733
cent C 125 733
. C 126 733
of C 128 733
the C 129 733
population C 130 733
. C 131 733
microfilarial C 133 733
periodicity C 134 733
was C 135 733
studied C 136 733
in C 137 733
25 C 138 733
persons C 139 733
; C 140 733
in C 141 733
every C 142 733
case C 143 733
it C 144 733
was C 145 733
found C 146 733
to C 147 733
be C 148 733
markedly C 149 733
nocturnal C 150 733
. C 151 733
the C 153 733
blood C 154 733
of C 155 733
98 C 156 733
cats C 157 733
, C 158 733
52 C 159 733
dogs C 160 733
and C 161 733
two C 162 733
monkeys C 163 733
was C 164 733
also C 165 733
examined C 166 733
. C 167 733
no C 169 733
b C 170 733
. C 171 733
malayi C 173 733
larvae C 174 733
were C 175 733
recovered C 176 733
. C 177 733
mosquitoes C 179 733
were C 180 733
caught C 181 733
and C 182 733
identified C 183 733
. C 184 733
in C 186 733
an C 187 733
initial C 188 733
survey C 189 733
, C 190 733
4 C 191 733
, C 192 733
557 C 193 733
mosquitoes C 194 733
were C 195 733
examined C 196 733
, C 197 733
of C 198 733
which C 199 733
568 C 200 733
were C 201 733
mansonia C 202 733
spp C 203 733
. C 204 733
in C 206 733
4 C 207 733
, C 208 733
136 C 209 733
dissections C 210 733
, C 211 733
b C 212 733
. C 213 733
malayi C 215 733
larvae C 216 733
in C 217 733
stage C 218 733
ii C 219 733
were C 220 733
found C 221 733
in C 222 733
one C 223 733
m C 224 733
. C 225 733
uniformis C 227 733
and C 228 733
in C 229 733
stage C 230 733
iii C 231 733
in C 232 733
another C 233 733
; C 234 733
the C 235 733
infection C 236 733
rate C 237 733
for C 238 733
m C 239 733
. C 240 733
uniformis C 242 733
was C 243 733
0 C 244 733
. C 245 733
. C 246 733
per C 247 733
cent C 248 733
. C 249 733
spraying C 251 733
with C 252 733
ddt C 253 733
was C 254 733
carried C 255 733
out C 256 733
in C 257 733
all C 258 733
the C 259 733
houses C 260 733
during C 261 733
the C 262 733
last C 263 733
phase C 264 733
of C 265 733
the C 266 733
investigation C 267 733
. C 268 733
it C 270 733
resulted C 271 733
in C 272 733
a C 273 733
slight C 274 733
decline C 275 733
in C 276 733
the C 277 733
numbers C 278 733
and C 279 733
percentage C 280 733
of C 281 733
mansonia C 282 733
mosquitoes C 283 733
caught C 284 733
. C 285 733
diethylcarbamazine C 287 733
was C 288 733
administered C 289 733
to C 290 733
as C 291 733
many C 292 733
of C 293 733
the C 294 733
villagers C 295 733
as C 296 733
possible C 297 733
, C 298 733
in C 299 733
a C 300 733
dose C 301 733
of C 302 733
5 C 303 733
mgm C 304 733
. C 305 733
of C 307 733
the C 308 733
citrate C 309 733
salt C 310 733
per C 311 733
kgm C 312 733
. C 313 733
body C 315 733
weight C 316 733
once C 317 733
weekly C 318 733
for C 319 733
six C 320 733
weeks C 321 733
. C 322 733
eight C 324 733
hundred C 325 733
and C 326 733
eighty C 327 733
- C 328 733
eight C 329 733
persons C 330 733
received C 331 733
the C 332 733
drug C 333 733
( C 334 733
86 C 335 733
. C 336 733
. C 337 733
per C 338 733
cent C 339 733
. C 340 733
of C 342 733
the C 343 733
population C 344 733
) C 345 733
. C 346 733
considerable C 348 733
side C 349 733
- C 350 733
effects C 351 733
were C 352 733
observed C 353 733
in C 354 733
nearly C 355 733
all C 356 733
microfilaria C 357 733
- C 358 733
carriers C 359 733
. C 360 733
blood C 362 733
examinations C 363 733
were C 364 733
repeated C 365 733
one C 366 733
month C 367 733
and C 368 733
again C 369 733
one C 370 733
year C 371 733
after C 372 733
cessation C 373 733
of C 374 733
the C 375 733
drug C 376 733
. C 377 733
it C 379 733
was C 380 733
found C 381 733
that C 382 733
the C 383 733
proportion C 384 733
of C 385 733
microfilaria C 386 733
- C 387 733
carriers C 388 733
had C 389 733
decreased C 390 733
from C 391 733
21 C 392 733
. C 393 733
. C 394 733
per C 395 733
cent C 396 733
. C 397 733
to C 399 733
2 C 400 733
. C 401 733
. C 402 733
and C 403 733
2 C 404 733
. C 405 733
. C 406 733
per C 407 733
cent C 408 733
. C 409 733
respectively C 411 733
, C 412 733
the C 413 733
filariasis C 414 733
infection C 415 733
rate C 416 733
from C 417 733
26 C 418 733
. C 419 733
. C 420 733
per C 421 733
cent C 422 733
. C 423 733
to C 425 733
8 C 426 733
. C 427 733
. C 428 733
and C 429 733
8 C 430 733
. C 431 733
. C 432 733
per C 433 733
cent C 434 733
. C 435 733
, C 437 733
and C 438 733
the C 439 733
mean C 440 733
microfilarial C 441 733
density C 442 733
of C 443 733
all C 444 733
films C 445 733
from C 446 733
4 C 447 733
. C 448 733
. C 449 733
per C 450 733
20 C 451 733
c C 452 733
. C 453 733
. C 454 733
. C 454 733
. C 455 733
blood C 457 733
to C 458 733
0 C 459 733
. C 460 733
. C 461 733
. C 461 733
and C 462 733
0 C 463 733
. C 464 733
. C 465 733
. C 465 733
. C 466 733
larvae C 468 733
of C 469 733
b C 470 733
. C 471 733
malayi C 473 733
were C 474 733
not C 475 733
found C 476 733
in C 477 733
mosquitoes C 478 733
dissected C 479 733
one C 480 733
month C 481 733
and C 482 733
one C 483 733
year C 484 733
after C 485 733
the C 486 733
mass C 487 733
therapy C 488 733
. C 489 733
studies C 1 734
on C 2 734
loiasis C 3 734
in C 4 734
monkeys C 5 734
. C 6 734
iv C 8 734
. C 9 734
- C 11 734
- C 12 734
experimental C 13 734
hybridization C 14 734
of C 15 734
the C 16 734
human C 17 734
and C 18 734
simian C 19 734
strains C 20 734
of C 21 734
loa C 22 734
in C 23 734
the C 24 734
cameroons C 25 734
rain C 26 734
- C 27 734
forest C 28 734
there C 29 734
exist C 30 734
two C 31 734
strains C 32 734
of C 33 734
loa C 34 734
, C 35 734
each C 36 734
apparently C 37 734
evolving C 38 734
in C 39 734
its C 40 734
own C 41 734
host C 42 734
- C 43 734
vector C 44 734
complex C 45 734
( C 46 734
duke C 47 734
and C 48 734
wijers C 49 734
, C 50 734
1958 C 51 734
) C 52 734
. C 53 734
the C 55 734
natural C 56 734
simian C 57 734
parasite C 58 734
which C 59 734
is C 60 734
found C 61 734
most C 62 734
abundantly C 63 734
in C 64 734
the C 65 734
drill C 66 734
( C 67 734
mandrillus C 68 734
leucophaeus C 69 734
) C 70 734
, C 71 734
is C 72 734
characterized C 73 734
by C 74 734
the C 75 734
large C 76 734
somatic C 77 734
size C 78 734
of C 79 734
the C 80 734
adult C 81 734
worms C 82 734
and C 83 734
microfilariae C 84 734
and C 85 734
by C 86 734
its C 87 734
nocturnal C 88 734
microfilariae C 89 734
periodicity C 90 734
. C 91 734
it C 93 734
is C 94 734
transmitted C 95 734
among C 96 734
the C 97 734
monkey C 98 734
population C 99 734
by C 100 734
the C 101 734
crepuscular C 102 734
canopy C 103 734
- C 104 734
dwelling C 105 734
chrysops C 106 734
langi C 107 734
and C 108 734
c C 109 734
. C 110 734
centurionis C 112 734
. C 113 734
the C 115 734
natural C 116 734
human C 117 734
parasite C 118 734
has C 119 734
diurnally C 120 734
periodic C 121 734
microfilariae C 122 734
and C 123 734
is C 124 734
transmitted C 125 734
by C 126 734
the C 127 734
day C 128 734
- C 129 734
biting C 130 734
anthropophilic C 131 734
c C 132 734
. C 133 734
silacea C 135 734
and C 136 734
c C 137 734
. C 138 734
dimidiata C 140 734
( C 141 734
bombe C 142 734
form C 143 734
) C 144 734
. C 145 734
it C 147 734
can C 148 734
also C 149 734
be C 150 734
transmitted C 151 734
experimentally C 152 734
to C 153 734
the C 154 734
drill C 155 734
, C 156 734
in C 157 734
which C 158 734
host C 159 734
the C 160 734
parasites C 161 734
are C 162 734
of C 163 734
small C 164 734
somatic C 165 734
size C 166 734
and C 167 734
maintain C 168 734
their C 169 734
diurnal C 170 734
periodicity C 171 734
. C 172 734
as C 174 734
the C 175 734
two C 176 734
strains C 177 734
of C 178 734
contrasting C 179 734
periodicity C 180 734
can C 181 734
be C 182 734
maintained C 183 734
in C 184 734
drills C 185 734
, C 186 734
it C 187 734
was C 188 734
decided C 189 734
to C 190 734
try C 191 734
cross C 192 734
- C 193 734
mating C 194 734
them C 195 734
to C 196 734
produce C 197 734
hybrids C 198 734
. C 199 734
the C 201 734
present C 202 734
paper C 203 734
describes C 204 734
the C 205 734
methods C 206 734
by C 207 734
which C 208 734
this C 209 734
was C 210 734
done C 211 734
, C 212 734
records C 213 734
the C 214 734
characteristics C 215 734
of C 216 734
the C 217 734
hybrid C 218 734
parasites C 219 734
, C 220 734
and C 221 734
suggests C 222 734
that C 223 734
, C 224 734
when C 225 734
interbreeding C 226 734
, C 227 734
the C 228 734
two C 229 734
strains C 230 734
segregate C 231 734
according C 232 734
to C 233 734
a C 234 734
simple C 235 734
mendelian C 236 734
pattern C 237 734
as C 238 734
regards C 239 734
periodicity C 240 734
and C 241 734
somatic C 242 734
size C 243 734
. C 244 734
development C 1 735
of C 2 735
dirofilaria C 3 735
immitis C 4 735
in C 5 735
anopheles C 6 735
quadri C 7 735
- C 8 735
maculatus C 9 735
after C 10 735
exposure C 11 735
of C 12 735
the C 13 735
microfilariae C 14 735
to C 15 735
a C 16 735
freezing C 17 735
temperature C 18 735
blood C 19 735
samples C 20 735
containing C 21 735
dirofilaria C 22 735
immitis C 23 735
microfilariae C 24 735
were C 25 735
stored C 26 735
frozen C 27 735
for C 28 735
periods C 29 735
ranging C 30 735
from C 31 735
24 C 32 735
hr C 33 735
to C 34 735
4 C 35 735
months C 36 735
, C 37 735
thawed C 38 735
at C 39 735
38 C 40 735
1 C 41 735
c C 42 735
and C 43 735
fed C 44 735
through C 45 735
an C 46 735
animal C 47 735
- C 48 735
derived C 49 735
bandrode C 50 735
membrane C 51 735
to C 52 735
laboratory C 53 735
- C 54 735
reared C 55 735
anopheles C 56 735
quadrimaculatus C 57 735
. C 58 735
the C 60 735
microfilariae C 61 735
were C 62 735
capable C 63 735
of C 64 735
developing C 65 735
to C 66 735
the C 67 735
third C 68 735
or C 69 735
infective C 70 735
larval C 71 735
stage C 72 735
and C 73 735
migrating C 74 735
to C 75 735
the C 76 735
head C 77 735
and C 78 735
labium C 79 735
of C 80 735
the C 81 735
mosquito C 82 735
. C 83 735
advances C 1 736
in C 2 736
filariasis C 3 736
especially C 4 736
concerning C 5 736
periodicity C 6 736
of C 7 736
microfilariae C 8 736
a C 9 736
review C 10 736
is C 11 736
given C 12 736
of C 13 736
some C 14 736
advances C 15 736
in C 16 736
our C 17 736
knowledge C 18 736
about C 19 736
filariasis C 20 736
during C 21 736
the C 22 736
past C 23 736
ten C 24 736
years C 25 736
. C 26 736
it C 28 736
is C 29 736
urged C 30 736
that C 31 736
investigations C 32 736
should C 33 736
be C 34 736
continued C 35 736
on C 36 736
methods C 37 736
to C 38 736
facilitate C 39 736
the C 40 736
control C 41 736
of C 42 736
filariasis C 43 736
in C 44 736
large C 45 736
populations C 46 736
, C 47 736
by C 48 736
means C 49 736
of C 50 736
diethylcarbamazine C 51 736
- C 52 736
- C 53 736
e C 54 736
. C 55 736
. C 56 736
. C 57 736
incorporation C 59 736
of C 60 736
the C 61 736
compound C 62 736
in C 63 736
cooking C 64 736
salt C 65 736
, C 66 736
as C 67 736
was C 68 736
done C 69 736
with C 70 736
chloroquine C 71 736
against C 72 736
malaria C 73 736
. C 74 736
furthermore C 76 736
, C 77 736
steps C 78 736
should C 79 736
be C 80 736
taken C 81 736
to C 82 736
protect C 83 736
young C 84 736
people C 85 736
against C 86 736
filariasis C 87 736
by C 88 736
systematic C 89 736
treatment C 90 736
in C 91 736
the C 92 736
schools C 93 736
. C 94 736
in C 96 736
order C 97 736
to C 98 736
understand C 99 736
the C 100 736
cyclical C 101 736
disappearance C 102 736
of C 103 736
microfilariae C 104 736
from C 105 736
the C 106 736
peripheral C 107 736
blood C 108 736
and C 109 736
their C 110 736
accumulation C 111 736
in C 112 736
the C 113 736
lungs C 114 736
, C 115 736
the C 116 736
movements C 117 736
of C 118 736
microfilariae C 119 736
in C 120 736
the C 121 736
pulmonary C 122 736
capillaries C 123 736
has C 124 736
been C 125 736
studied C 126 736
by C 127 736
cinematography C 128 736
. C 129 736
apparently C 131 736
their C 132 736
accumulation C 133 736
in C 134 736
the C 135 736
lungs C 136 736
is C 137 736
not C 138 736
due C 139 736
to C 140 736
mechanical C 141 736
retention C 142 736
, C 143 736
but C 144 736
perhaps C 145 736
they C 146 736
migrate C 147 736
round C 148 736
and C 149 736
round C 150 736
in C 151 736
the C 152 736
pre C 153 736
- C 154 736
capillary C 155 736
network C 156 736
of C 157 736
arterioles C 158 736
. C 159 736
the C 161 736
periodicity C 162 736
of C 163 736
microfilariae C 164 736
is C 165 736
best C 166 736
considered C 167 736
as C 168 736
a C 169 736
biological C 170 736
rhythm C 171 736
. C 172 736
apparently C 174 736
the C 175 736
microfilariae C 176 736
have C 177 736
a C 178 736
circadian C 179 736
rhythm C 180 736
of C 181 736
their C 182 736
own C 183 736
which C 184 736
is C 185 736
entrained C 186 736
and C 187 736
synchronized C 188 736
by C 189 736
stimuli C 190 736
from C 191 736
the C 192 736
circadian C 193 736
rhythm C 194 736
of C 195 736
the C 196 736
host C 197 736
. C 198 736
judging C 200 736
by C 201 736
experiments C 202 736
with C 203 736
monkeys C 204 736
containing C 205 736
microfilariae C 206 736
of C 207 736
edesonfilaria C 208 736
malayensis C 209 736
, C 210 736
the C 211 736
most C 212 736
effective C 213 736
of C 214 736
these C 215 736
stimuli C 216 736
from C 217 736
the C 218 736
host C 219 736
seems C 220 736
to C 221 736
be C 222 736
the C 223 736
rhythmic C 224 736
variation C 225 736
of C 226 736
body C 227 736
temperature C 228 736
which C 229 736
occurs C 230 736
every C 231 736
24 C 232 736
hours C 233 736
. C 234 736
attempts C 1 737
to C 2 737
transmit C 3 737
wuchereria C 4 737
bancrofti C 5 737
to C 6 737
cats C 7 737
and C 8 737
to C 9 737
a C 10 737
toque C 11 737
monkey C 12 737
there C 13 737
are C 14 737
no C 15 737
records C 16 737
of C 17 737
the C 18 737
larval C 19 737
development C 20 737
of C 21 737
wuchereria C 22 737
bancrofti C 23 737
in C 24 737
experimental C 25 737
animals C 26 737
. C 27 737
in C 29 737
attempts C 30 737
to C 31 737
transmit C 32 737
periodic C 33 737
w C 34 737
. C 35 737
bancrofti C 37 737
to C 38 737
domestic C 39 737
cats C 40 737
and C 41 737
to C 42 737
a C 43 737
toque C 44 737
monkey C 45 737
we C 46 737
recovered C 47 737
from C 48 737
one C 49 737
of C 50 737
the C 51 737
cats C 52 737
an C 53 737
infective C 54 737
larva C 55 737
that C 56 737
had C 57 737
undergone C 58 737
some C 59 737
development C 60 737
. C 61 737
this C 63 737
finding C 64 737
was C 65 737
reported C 66 737
in C 67 737
a C 68 737
preliminary C 69 737
note C 70 737
( C 71 737
dissanaike C 72 737
and C 73 737
niles C 74 737
, C 75 737
1963 C 76 737
) C 77 737
; C 78 737
the C 79 737
present C 80 737
paper C 81 737
gives C 82 737
the C 83 737
experimental C 84 737
details C 85 737
and C 86 737
describes C 87 737
the C 88 737
larva C 89 737
. C 90 737
the C 1 738
periodicity C 2 738
of C 3 738
microfilariae C 4 738
. C 5 738
x C 7 738
. C 8 738
the C 10 738
relation C 11 738
between C 12 738
the C 13 738
circadian C 14 738
temperature C 15 738
cycle C 16 738
of C 17 738
monkeys C 18 738
and C 19 738
the C 20 738
microfilarial C 21 738
cycle C 22 738
. C 23 738
monkeys C 25 738
were C 26 738
used C 27 738
whose C 28 738
blood C 29 738
contained C 30 738
the C 31 738
microfilariae C 32 738
of C 33 738
edesonfilaria C 34 738
malayensis C 35 738
, C 36 738
which C 37 738
has C 38 738
a C 39 738
nocturnal C 40 738
periodicity C 41 738
. C 42 738
artificial C 44 738
lowering C 45 738
of C 46 738
the C 47 738
body C 48 738
temperature C 49 738
during C 50 738
the C 51 738
daytime C 52 738
caused C 53 738
the C 54 738
microfilaria C 55 738
count C 56 738
in C 57 738
the C 58 738
blood C 59 738
to C 60 738
rise C 61 738
; C 62 738
and C 63 738
artificial C 64 738
raising C 65 738
of C 66 738
the C 67 738
body C 68 738
temperature C 69 738
during C 70 738
the C 71 738
night C 72 738
caused C 73 738
it C 74 738
to C 75 738
fall C 76 738
almost C 77 738
to C 78 738
zero C 79 738
, C 80 738
i C 81 738
. C 82 738
. C 83 738
. C 84 738
inversion C 86 738
of C 87 738
the C 88 738
normal C 89 738
circadian C 90 738
temperature C 91 738
rhythm C 92 738
of C 93 738
the C 94 738
body C 95 738
was C 96 738
followed C 97 738
by C 98 738
inversion C 99 738
of C 100 738
the C 101 738
microfilarial C 102 738
rhythm C 103 738
. C 104 738
the C 106 738
hypothesis C 107 738
is C 108 738
put C 109 738
forward C 110 738
that C 111 738
the C 112 738
circadian C 113 738
rhythm C 114 738
of C 115 738
the C 116 738
microfilariae C 117 738
of C 118 738
e C 119 738
. C 120 738
malayensis C 122 738
( C 123 738
but C 124 738
probably C 125 738
not C 126 738
of C 127 738
the C 128 738
microfilariae C 129 738
of C 130 738
some C 131 738
other C 132 738
species C 133 738
) C 134 738
is C 135 738
entrained C 136 738
by C 137 738
the C 138 738
circadian C 139 738
rhythm C 140 738
of C 141 738
body C 142 738
temperature C 143 738
, C 144 738
which C 145 738
thus C 146 738
provides C 147 738
the C 148 738
" C 149 738
effective C 150 738
stimuli C 151 738
" C 152 738
to C 153 738
which C 154 738
these C 155 738
microfilariae C 156 738
respond C 157 738
. C 158 738
the C 1 739
periodicity C 2 739
of C 3 739
microfilariae C 4 739
ix C 5 739
. C 6 739
transfusion C 8 739
of C 9 739
microfilariae C 10 739
( C 11 739
edesonfilaria C 12 739
) C 13 739
into C 14 739
monkeys C 15 739
at C 16 739
a C 17 739
different C 18 739
phase C 19 739
of C 20 739
the C 21 739
circadian C 22 739
rhythm C 23 739
this C 24 739
paper C 25 739
reports C 26 739
experiments C 27 739
in C 28 739
which C 29 739
microfilariae C 30 739
at C 31 739
one C 32 739
phase C 33 739
of C 34 739
their C 35 739
circadian C 36 739
rhythm C 37 739
were C 38 739
transfused C 39 739
into C 40 739
a C 41 739
host C 42 739
at C 43 739
another C 44 739
phase C 45 739
of C 46 739
the C 47 739
circadian C 48 739
rhythm C 49 739
, C 50 739
in C 51 739
an C 52 739
attempt C 53 739
to C 54 739
analyse C 55 739
the C 56 739
relative C 57 739
importance C 58 739
of C 59 739
the C 60 739
rhythms C 61 739
inherent C 62 739
in C 63 739
the C 64 739
microfilariae C 65 739
and C 66 739
of C 67 739
those C 68 739
in C 69 739
the C 70 739
host C 71 739
for C 72 739
the C 73 739
production C 74 739
of C 75 739
the C 76 739
well C 77 739
known C 78 739
periodic C 79 739
migrations C 80 739
. C 81 739
the C 83 739
experiments C 84 739
were C 85 739
performed C 86 739
with C 87 739
edesonfilaria C 88 739
malayensis C 89 739
( C 90 739
yeh C 91 739
, C 92 739
1960 C 93 739
) C 94 739
present C 95 739
in C 96 739
a C 97 739
macaca C 98 739
monkey C 99 739
from C 100 739
thailand C 101 739
. C 102 739
biliary C 1 740
tract C 2 740
morphology C 3 740
and C 4 740
prognosis C 5 740
of C 6 740
biliary C 7 740
atresia C 8 740
in C 9 740
86 C 10 740
infants C 11 740
who C 12 740
did C 13 740
not C 14 740
have C 15 740
extrahepatic C 16 740
" C 17 740
hepatic C 18 740
" C 19 740
ducts C 20 740
, C 21 740
present C 22 740
observation C 23 740
after C 24 740
use C 25 740
of C 26 740
artificial C 27 740
bile C 28 740
ducts C 29 740
suggests C 30 740
that C 31 740
the C 32 740
presence C 33 740
of C 34 740
the C 35 740
gallbladder C 36 740
may C 37 740
be C 38 740
of C 39 740
good C 40 740
prognostic C 41 740
significance C 42 740
in C 43 740
biliary C 44 740
atresia C 45 740
. C 46 740
there C 48 740
are C 49 740
11 C 50 740
long C 51 740
- C 52 740
term C 53 740
survivors C 54 740
( C 55 740
as C 56 740
of C 57 740
october C 58 740
1965 C 59 740
) C 60 740
up C 61 740
to C 62 740
8 C 63 740
1 C 64 740
/ C 65 740
4 C 66 740
years C 67 740
of C 68 740
age C 69 740
( C 70 740
100 C 71 740
months C 72 740
) C 73 740
after C 74 740
use C 75 740
of C 76 740
artificial C 77 740
bile C 78 740
ducts C 79 740
in C 80 740
86 C 81 740
babies C 82 740
. C 83 740
a C 85 740
gallbladder C 86 740
was C 87 740
identified C 88 740
in C 89 740
10 C 90 740
of C 91 740
the C 92 740
11 C 93 740
infants C 94 740
. C 95 740
other C 97 740
specific C 98 740
factors C 99 740
for C 100 740
this C 101 740
prolonged C 102 740
survival C 103 740
pattern C 104 740
in C 105 740
these C 106 740
infants C 107 740
with C 108 740
biliary C 109 740
atresia C 110 740
have C 111 740
not C 112 740
yet C 113 740
been C 114 740
identified C 115 740
, C 116 740
although C 117 740
suggestive C 118 740
correlations C 119 740
among C 120 740
minimal C 121 740
hepatic C 122 740
fibrosis C 123 740
, C 124 740
maximal C 125 740
bile C 126 740
ductule C 127 740
proliferations C 128 740
and C 129 740
the C 130 740
presence C 131 740
of C 132 740
the C 133 740
gallbladder C 134 740
were C 135 740
noted C 136 740
. C 137 740
it C 139 740
is C 140 740
suspected C 141 740
that C 142 740
if C 143 740
any C 144 740
opportunity C 145 740
for C 146 740
long C 147 740
- C 148 740
term C 149 740
survivals C 150 740
exists C 151 740
for C 152 740
infants C 153 740
to C 154 740
overcome C 155 740
the C 156 740
tragic C 157 740
occurrence C 158 740
of C 159 740
biliary C 160 740
atresia C 161 740
that C 162 740
the C 163 740
surgeon C 164 740
should C 165 740
avoid C 166 740
trauma C 167 740
to C 168 740
the C 169 740
hepatic C 170 740
pedicle C 171 740
. C 172 740
we C 174 740
may C 175 740
be C 176 740
able C 177 740
to C 178 740
provide C 179 740
a C 180 740
" C 181 740
guarded C 182 740
" C 183 740
rather C 184 740
than C 185 740
a C 186 740
" C 187 740
pessimistic C 188 740
" C 189 740
prog C 190 740
- C 191 740
nosis C 192 740
when C 193 740
the C 194 740
gallbladder C 195 740
is C 196 740
found C 197 740
in C 198 740
the C 199 740
babies C 200 740
with C 201 740
biliary C 202 740
atresia C 203 740
. C 204 740
current C 1 741
concepts C 2 741
in C 3 741
the C 4 741
management C 5 741
of C 6 741
congenital C 7 741
biliary C 8 741
atresia C 9 741
the C 10 741
current C 11 741
management C 12 741
of C 13 741
congenital C 14 741
biliary C 15 741
atresia C 16 741
at C 17 741
the C 18 741
university C 19 741
of C 20 741
cali C 21 741
- C 22 741
fornia C 23 741
, C 24 741
los C 25 741
angeles C 26 741
is C 27 741
reviewed C 28 741
. C 29 741
biliary C 31 741
enteric C 32 741
decompression C 33 741
was C 34 741
performed C 35 741
on C 36 741
18 C 37 741
of C 38 741
the C 39 741
27 C 40 741
patients C 41 741
, C 42 741
eight C 43 741
of C 44 741
whom C 45 741
are C 46 741
presently C 47 741
alive C 48 741
( C 49 741
29 C 50 741
. C 51 741
. C 52 741
% C 53 741
) C 54 741
. C 55 741
these C 57 741
figures C 58 741
are C 59 741
higher C 60 741
than C 61 741
the C 62 741
cure C 63 741
rate C 64 741
of C 65 741
8 C 66 741
% C 67 741
previously C 68 741
reported C 69 741
. C 70 741
described C 72 741
recently C 73 741
. C 74 741
five C 76 741
additional C 77 741
patients C 78 741
with C 79 741
extrahepatic C 80 741
atresia C 81 741
underwent C 82 741
biliary C 83 741
decompression C 84 741
by C 85 741
means C 86 741
of C 87 741
a C 88 741
hepatic C 89 741
lymphaticojejunostomy C 90 741
. C 91 741
early C 93 741
diagnosis C 94 741
of C 95 741
biliary C 96 741
atresia C 97 741
is C 98 741
im C 99 741
- C 100 741
perative C 101 741
in C 102 741
order C 103 741
that C 104 741
any C 105 741
corrective C 106 741
sur C 107 741
- C 108 741
gery C 109 741
may C 110 741
be C 111 741
performed C 112 741
before C 113 741
advanced C 114 741
biliary C 115 741
cirrhosis C 116 741
develops C 117 741
. C 118 741
congenital C 1 742
atresia C 2 742
of C 3 742
the C 4 742
extrahepatic C 5 742
bile C 6 742
ducts C 7 742
because C 8 742
congenital C 9 742
atresia C 10 742
of C 11 742
the C 12 742
extra C 13 742
- C 14 742
hepatic C 15 742
biliary C 16 742
tract C 17 742
is C 18 742
almost C 19 742
always C 20 742
fatal C 21 742
, C 22 742
exception C 23 742
to C 24 742
this C 25 742
course C 26 742
becomes C 27 742
of C 28 742
interest C 29 742
. C 30 742
the C 32 742
remarkable C 33 742
history C 34 742
of C 35 742
one C 36 742
such C 37 742
infant C 38 742
was C 39 742
reported C 40 742
in C 41 742
1960 C 42 742
when C 43 742
he C 44 742
had C 45 742
attained C 46 742
the C 47 742
age C 48 742
of C 49 742
2 C 50 742
1 C 51 742
/ C 52 742
2 C 53 742
years C 54 742
and C 55 742
, C 56 742
after C 57 742
three C 58 742
opera C 59 742
- C 60 742
tions C 61 742
, C 62 742
he C 63 742
was C 64 742
in C 65 742
good C 66 742
health C 67 742
developing C 68 742
nor C 69 742
- C 70 742
mally C 71 742
and C 72 742
free C 73 742
of C 74 742
jaundice C 75 742
. C 76 742
since C 78 742
he C 79 742
is C 80 742
now C 81 742
8 C 82 742
1 C 83 742
/ C 84 742
2 C 85 742
years C 86 742
of C 87 742
age C 88 742
, C 89 742
has C 90 742
had C 91 742
two C 92 742
more C 93 742
opera C 94 742
- C 95 742
tions C 96 742
, C 97 742
is C 98 742
still C 99 742
free C 100 742
of C 101 742
jaundice C 102 742
, C 103 742
and C 104 742
is C 105 742
again C 106 742
in C 107 742
good C 108 742
health C 109 742
, C 110 742
his C 111 742
further C 112 742
course C 113 742
since C 114 742
1960 C 115 742
should C 116 742
be C 117 742
of C 118 742
interest C 119 742
. C 120 742
neuroaxonal C 1 743
dystrophy C 2 743
in C 3 743
congenital C 4 743
biliary C 5 743
atresia C 6 743
neuroaxonal C 7 743
dystrophy C 8 743
has C 9 743
been C 10 743
described C 11 743
in C 12 743
8 C 13 743
patients C 14 743
with C 15 743
congenital C 16 743
biliary C 17 743
atresia C 18 743
. C 19 743
the C 21 743
characteristic C 22 743
changes C 23 743
include C 24 743
axonal C 25 743
dystrophy C 26 743
, C 27 743
a C 28 743
mild C 29 743
loss C 30 743
of C 31 743
nerve C 32 743
cells C 33 743
and C 34 743
a C 35 743
variable C 36 743
degree C 37 743
of C 38 743
astrocytic C 39 743
reaction C 40 743
, C 41 743
mainly C 42 743
in C 43 743
the C 44 743
gracile C 45 743
, C 46 743
cuneate C 47 743
and C 48 743
trigeminal C 49 743
nerve C 50 743
nuclei C 51 743
in C 52 743
the C 53 743
medulla C 54 743
, C 55 743
and C 56 743
rarely C 57 743
in C 58 743
other C 59 743
parts C 60 743
of C 61 743
the C 62 743
central C 63 743
nervous C 64 743
system C 65 743
. C 66 743
the C 68 743
neuroaxonal C 69 743
dystrophy C 70 743
in C 71 743
these C 72 743
patients C 73 743
is C 74 743
remarkably C 75 743
similar C 76 743
to C 77 743
that C 78 743
in C 79 743
patients C 80 743
with C 81 743
prolonged C 82 743
mucoviscidosis C 83 743
and C 84 743
in C 85 743
experimental C 86 743
vitamin C 87 743
e C 88 743
- C 89 743
deficient C 90 743
rats C 91 743
. C 92 743
it C 94 743
is C 95 743
strongly C 96 743
suggested C 97 743
that C 98 743
the C 99 743
neuroaxonal C 100 743
dystrophy C 101 743
in C 102 743
these C 103 743
patients C 104 743
with C 105 743
congenital C 106 743
biliary C 107 743
atresia C 108 743
is C 109 743
a C 110 743
manifestation C 111 743
of C 112 743
prolonged C 113 743
vitamin C 114 743
e C 115 743
deficiency C 116 743
. C 117 743
the C 119 743
neuroaxonal C 120 743
dystrophy C 121 743
in C 122 743
these C 123 743
patients C 124 743
is C 125 743
also C 126 743
similar C 127 743
to C 128 743
that C 129 743
seen C 130 743
in C 131 743
aging C 132 743
and C 133 743
bears C 134 743
resemblance C 135 743
to C 136 743
the C 137 743
axonal C 138 743
change C 139 743
encountered C 140 743
in C 141 743
a C 142 743
group C 143 743
of C 144 743
heredo C 145 743
- C 146 743
degenerative C 147 743
diseases C 148 743
, C 149 743
the C 150 743
various C 151 743
forms C 152 743
of C 153 743
" C 154 743
hallervorden C 155 743
- C 156 743
spatz C 157 743
disease C 158 743
" C 159 743
. C 160 743
the C 162 743
pathological C 163 743
similarity C 164 743
between C 165 743
these C 166 743
diverse C 167 743
conditions C 168 743
warrants C 169 743
further C 170 743
investigation C 171 743
as C 172 743
to C 173 743
the C 174 743
possible C 175 743
metabolic C 176 743
relationship C 177 743
between C 178 743
them C 179 743
. C 180 743
extrahepatic C 1 744
biliary C 2 744
atresia C 3 744
: C 4 744
comments C 5 744
on C 6 744
the C 7 744
frequency C 8 744
of C 9 744
potentially C 10 744
operable C 11 744
cases C 12 744
in C 13 744
a C 14 744
10 C 15 744
year C 16 744
period C 17 744
, C 18 744
35 C 19 744
infants C 20 744
with C 21 744
extrahepatic C 22 744
biliary C 23 744
atresia C 24 744
were C 25 744
encountered C 26 744
. C 27 744
twenty C 29 744
- C 30 744
eight C 31 744
babies C 32 744
, C 33 744
who C 34 744
were C 35 744
subjected C 36 744
to C 37 744
surgery C 38 744
and C 39 744
operative C 40 744
liver C 41 744
biopsy C 42 744
, C 43 744
are C 44 744
discussed C 45 744
. C 46 744
although C 48 744
an C 49 744
operable C 50 744
lesion C 51 744
was C 52 744
detected C 53 744
at C 54 744
laparotomy C 55 744
in C 56 744
only C 57 744
one C 58 744
baby C 59 744
, C 60 744
5 C 61 744
further C 62 744
potentially C 63 744
correctable C 64 744
lesions C 65 744
were C 66 744
discovered C 67 744
in C 68 744
the C 69 744
14 C 70 744
necropsies C 71 744
performed C 72 744
. C 73 744
review C 75 744
of C 76 744
the C 77 744
literature C 78 744
revealed C 79 744
that C 80 744
few C 81 744
authors C 82 744
have C 83 744
discussed C 84 744
necropsy C 85 744
findings C 86 744
and C 87 744
that C 88 744
confirmation C 89 744
of C 90 744
the C 91 744
diagnosis C 92 744
by C 93 744
liver C 94 744
biopsy C 95 744
has C 96 744
been C 97 744
neglected C 98 744
in C 99 744
many C 100 744
cases C 101 744
, C 102 744
including C 103 744
some C 104 744
of C 105 744
those C 106 744
claimed C 107 744
as C 108 744
surgical C 109 744
cures C 110 744
. C 111 744
it C 113 744
is C 114 744
concluded C 115 744
that C 116 744
the C 117 744
frequency C 118 744
of C 119 744
potentially C 120 744
operable C 121 744
forms C 122 744
of C 123 744
biliary C 124 744
atresia C 125 744
is C 126 744
not C 127 744
really C 128 744
known C 129 744
. C 130 744
metabolism C 1 745
and C 2 745
excretion C 3 745
of C 4 745
c C 5 745
14 C 6 745
- C 7 745
labeled C 8 745
bilirubin C 9 745
in C 10 745
children C 11 745
with C 12 745
biliary C 13 745
atresia C 14 745
and C 15 745
judson C 16 745
g C 17 745
. C 18 745
randolph C 20 745
radioactive C 21 745
bilirubin C 22 745
was C 23 745
injected C 24 745
intravenously C 25 745
into C 26 745
3 C 27 745
children C 28 745
with C 29 745
biliary C 30 745
atresia C 31 745
. C 32 745
the C 34 745
isotope C 35 745
over C 36 745
a C 37 745
period C 38 745
of C 39 745
ten C 40 745
to C 41 745
fourteen C 42 745
days C 43 745
was C 44 745
recovered C 45 745
principally C 46 745
in C 47 745
the C 48 745
urine C 49 745
. C 50 745
sixty C 52 745
per C 53 745
cent C 54 745
of C 55 745
the C 56 745
label C 57 745
in C 58 745
the C 59 745
urine C 60 745
was C 61 745
found C 62 745
to C 63 745
be C 64 745
in C 65 745
the C 66 745
form C 67 745
of C 68 745
bili C 69 745
- C 70 745
rubin C 71 745
. C 72 745
distribution C 74 745
of C 75 745
the C 76 745
radioisotope C 77 745
was C 78 745
observed C 79 745
to C 80 745
be C 81 745
principally C 82 745
extravascular C 83 745
but C 84 745
not C 85 745
, C 86 745
as C 87 745
in C 88 745
other C 89 745
forms C 90 745
of C 91 745
jaundice C 92 745
, C 93 745
in C 94 745
the C 95 745
same C 96 745
distribution C 97 745
as C 98 745
albumin C 99 745
. C 100 745
daily C 102 745
turnover C 103 745
of C 104 745
bilirubin C 105 745
was C 106 745
several C 107 745
times C 108 745
greater C 109 745
than C 110 745
the C 111 745
calculated C 112 745
normal C 113 745
daily C 114 745
production C 115 745
of C 116 745
bili C 117 745
- C 118 745
rubin C 119 745
. C 120 745
this C 122 745
was C 123 745
assumed C 124 745
to C 125 745
be C 126 745
due C 127 745
to C 128 745
increased C 129 745
hemoglobin C 130 745
breakdown C 131 745
, C 132 745
confirmed C 133 745
by C 134 745
survival C 135 745
studies C 136 745
of C 137 745
cr C 138 745
51 C 139 745
- C 140 745
tagged C 141 745
red C 142 745
cells C 143 745
. C 144 745
the C 146 745
serum C 147 745
half C 148 745
- C 149 745
life C 150 745
of C 151 745
intra C 152 745
- C 153 745
venously C 154 745
administered C 155 745
radioactive C 156 745
bilirubin C 157 745
may C 158 745
have C 159 745
useful C 160 745
prognostic C 161 745
value C 162 745
in C 163 745
children C 164 745
with C 165 745
biliary C 166 745
atresia C 167 745
. C 168 745
central C 1 746
regulation C 2 746
of C 3 746
enzyme C 4 746
activity C 5 746
and C 6 746
synthesis C 7 746
in C 8 746
embryonal C 9 746
and C 10 746
adult C 11 746
mammalian C 12 746
tissues C 13 746
activity C 14 746
of C 15 746
non C 16 746
- C 17 746
specific C 18 746
hexokinase C 19 746
( C 20 746
hk C 21 746
) C 22 746
in C 23 746
soluble C 24 746
fraction C 25 746
and C 26 746
, C 27 746
particularly C 28 746
, C 29 746
in C 30 746
mitochondria C 31 746
of C 32 746
embryonal C 33 746
liver C 34 746
is C 35 746
much C 36 746
higher C 37 746
than C 38 746
in C 39 746
the C 40 746
adult C 41 746
rabbit C 42 746
; C 43 746
it C 44 746
decreases C 45 746
in C 46 746
the C 47 746
prenatal C 48 746
period C 49 746
, C 50 746
gradually C 51 746
approaching C 52 746
adulthood C 53 746
values C 54 746
postnatally C 55 746
( C 56 746
fig C 57 746
. C 58 746
. C 59 746
) C 60 746
. C 61 746
embryonal C 63 746
liver C 64 746
lacks C 65 746
specific C 66 746
glucokinase C 67 746
( C 68 746
gk C 69 746
) C 70 746
( C 71 746
1 C 72 746
, C 73 746
2 C 74 746
) C 75 746
, C 76 746
although C 77 746
during C 78 746
the C 79 746
second C 80 746
half C 81 746
of C 82 746
embryonic C 83 746
development C 84 746
there C 85 746
occurs C 86 746
incretion C 87 746
of C 88 746
insulin C 89 746
, C 90 746
known C 91 746
to C 92 746
induce C 93 746
gk C 94 746
synthesis C 95 746
in C 96 746
the C 97 746
liver C 98 746
of C 99 746
alloxan C 100 746
diabetic C 101 746
animals C 102 746
( C 103 746
3 C 104 746
, C 105 746
4 C 106 746
) C 107 746
. C 108 746
activity C 110 746
of C 111 746
glucose C 112 746
- C 113 746
6 C 114 746
- C 115 746
phosphate C 116 746
dehydrogenase C 117 746
( C 118 746
g C 119 746
6 C 120 746
p C 121 746
dh C 122 746
) C 123 746
in C 124 746
soluble C 125 746
liver C 126 746
fraction C 127 746
is C 128 746
subject C 129 746
to C 130 746
quite C 131 746
similar C 132 746
changes C 133 746
during C 134 746
embryonic C 135 746
development C 136 746
. C 137 746
ribonuclease C 1 747
activity C 2 747
in C 3 747
hepatic C 4 747
nuclei C 5 747
during C 6 747
development C 7 747
mammalian C 8 747
liver C 9 747
undergoes C 10 747
marked C 11 747
qualitative C 12 747
and C 13 747
quantitative C 14 747
changes C 15 747
during C 16 747
the C 17 747
development C 18 747
from C 19 747
the C 20 747
embryonic C 21 747
to C 22 747
the C 23 747
adult C 24 747
stage C 25 747
. C 26 747
many C 28 747
of C 29 747
these C 30 747
events C 31 747
are C 32 747
associated C 33 747
with C 34 747
the C 35 747
derepression C 36 747
or C 37 747
repression C 38 747
of C 39 747
certain C 40 747
enzymes C 41 747
which C 42 747
may C 43 747
be C 44 747
related C 45 747
to C 46 747
specialized C 47 747
subcellular C 48 747
activity C 49 747
. C 50 747
the C 52 747
involvement C 53 747
of C 54 747
ribonucleic C 55 747
acid C 56 747
in C 57 747
the C 58 747
transcription C 59 747
of C 60 747
the C 61 747
information C 62 747
from C 63 747
the C 64 747
genome C 65 747
into C 66 747
the C 67 747
construction C 68 747
of C 69 747
a C 70 747
finished C 71 747
protein C 72 747
molecule C 73 747
has C 74 747
prompted C 75 747
a C 76 747
study C 77 747
of C 78 747
biosynthesis C 79 747
of C 80 747
the C 81 747
rna C 82 747
during C 83 747
differentiation C 84 747
. C 85 747
although C 87 747
considerable C 88 747
effort C 89 747
in C 90 747
this C 91 747
regard C 92 747
has C 93 747
been C 94 747
expended C 95 747
in C 96 747
amphibian C 97 747
1 C 98 747
- C 99 747
5 C 100 747
and C 101 747
avian C 102 747
6 C 103 747
, C 104 747
7 C 105 747
systems C 106 747
, C 107 747
as C 108 747
well C 109 747
as C 110 747
in C 111 747
the C 112 747
sea C 113 747
urchin C 114 747
8 C 115 747
- C 116 747
11 C 117 747
, C 118 747
a C 119 747
paucity C 120 747
of C 121 747
literature C 122 747
exists C 123 747
with C 124 747
mammalian C 125 747
liver C 126 747
. C 127 747
accordingly C 129 747
, C 130 747
an C 131 747
investigation C 132 747
of C 133 747
the C 134 747
alterations C 135 747
in C 136 747
rna C 137 747
metabolism C 138 747
which C 139 747
occur C 140 747
during C 141 747
the C 142 747
development C 143 747
of C 144 747
the C 145 747
rat C 146 747
embryonic C 147 747
liver C 148 747
has C 149 747
been C 150 747
undertaken C 151 747
. C 152 747
this C 154 747
report C 155 747
concerns C 156 747
the C 157 747
fluctuations C 158 747
in C 159 747
nuclear C 160 747
ribonuclease C 161 747
during C 162 747
hepatic C 163 747
development C 164 747
and C 165 747
some C 166 747
of C 167 747
the C 168 747
properties C 169 747
of C 170 747
the C 171 747
enzyme C 172 747
. C 173 747
an C 1 748
electron C 2 748
microscopic C 3 748
study C 4 748
of C 5 748
developing C 6 748
gall C 7 748
bladder C 8 748
epithelium C 9 748
in C 10 748
the C 11 748
rabbit C 12 748
the C 13 748
gall C 14 748
bladder C 15 748
epithelium C 16 748
of C 17 748
the C 18 748
adult C 19 748
rabbit C 20 748
consists C 21 748
of C 22 748
two C 23 748
types C 24 748
of C 25 748
cells C 26 748
. C 27 748
the C 29 748
first C 30 748
and C 31 748
more C 32 748
common C 33 748
type C 34 748
shows C 35 748
features C 36 748
associated C 37 748
with C 38 748
absorption C 39 748
, C 40 748
notably C 41 748
microvilli C 42 748
, C 43 748
limited C 44 748
pinocytosis C 45 748
, C 46 748
some C 47 748
lysosomes C 48 748
and C 49 748
an C 50 748
elaboration C 51 748
of C 52 748
the C 53 748
lateral C 54 748
cell C 55 748
membrane C 56 748
and C 57 748
intercellular C 58 748
spaces C 59 748
. C 60 748
the C 62 748
mitochondria C 63 748
are C 64 748
concentrated C 65 748
in C 66 748
a C 67 748
subapical C 68 748
band C 69 748
. C 70 748
the C 72 748
second C 73 748
and C 74 748
more C 75 748
infrequent C 76 748
type C 77 748
is C 78 748
a C 79 748
dark C 80 748
rod C 81 748
- C 82 748
shaped C 83 748
cell C 84 748
of C 85 748
unknown C 86 748
function C 87 748
but C 88 748
which C 89 748
may C 90 748
be C 91 748
a C 92 748
dehydrated C 93 748
epithelial C 94 748
cell C 95 748
. C 96 748
foetal C 98 748
epithelial C 99 748
cells C 100 748
lack C 101 748
the C 102 748
functional C 103 748
adult C 104 748
characteristics C 105 748
; C 106 748
the C 107 748
mito C 108 748
- C 109 748
chondria C 110 748
are C 111 748
uniformly C 112 748
distributed C 113 748
. C 114 748
in C 116 748
addition C 117 748
they C 118 748
display C 119 748
basal C 120 748
granules C 121 748
and C 122 748
apical C 123 748
apocrine C 124 748
bullae C 125 748
. C 126 748
epithelial C 128 748
cell C 129 748
damage C 130 748
and C 131 748
white C 132 748
cell C 133 748
infiltration C 134 748
occurs C 135 748
between C 136 748
24 C 137 748
days C 138 748
after C 139 748
birth C 140 748
or C 141 748
just C 142 748
after C 143 748
. C 144 748
just C 146 748
before C 147 748
birth C 148 748
some C 149 748
epithelial C 150 748
cells C 151 748
are C 152 748
very C 153 748
large C 154 748
and C 155 748
pale C 156 748
with C 157 748
smooth C 158 748
outlines C 159 748
, C 160 748
others C 161 748
are C 162 748
more C 163 748
dense C 164 748
and C 165 748
display C 166 748
vigorous C 167 748
pinocytosis C 168 748
. C 169 748
adult C 171 748
characteristics C 172 748
are C 173 748
acquired C 174 748
at C 175 748
or C 176 748
immediately C 177 748
after C 178 748
birth C 179 748
and C 180 748
pino C 181 748
- C 182 748
cytosis C 183 748
subsides C 184 748
. C 185 748
it C 187 748
is C 188 748
believed C 189 748
that C 190 748
water C 191 748
resorption C 192 748
occurs C 193 748
before C 194 748
the C 195 748
functional C 196 748
changes C 197 748
which C 198 748
allow C 199 748
continuous C 200 748
passage C 201 748
of C 202 748
water C 203 748
into C 204 748
the C 205 748
circulation C 206 748
. C 207 748
congenital C 1 749
anomalies C 2 749
of C 3 749
the C 4 749
cystic C 5 749
duct C 6 749
and C 7 749
phineas C 8 749
rabinovitch C 9 749
anomalies C 10 749
of C 11 749
the C 12 749
cystic C 13 749
duct C 14 749
, C 15 749
of C 16 749
four C 17 749
differ C 18 749
- C 19 749
ent C 20 749
types C 21 749
, C 22 749
are C 23 749
reported C 24 749
. C 25 749
the C 27 749
characteris C 28 749
- C 29 749
tic C 30 749
anatomic C 31 749
appearance C 32 749
and C 33 749
embryonic C 34 749
development C 35 749
of C 36 749
each C 37 749
of C 38 749
these C 39 749
anomalies C 40 749
are C 41 749
described C 42 749
and C 43 749
the C 44 749
clinical C 45 749
and C 46 749
surgical C 47 749
significance C 48 749
discussed C 49 749
. C 50 749
lesions C 1 750
of C 2 750
the C 3 750
liver C 4 750
in C 5 750
hereditary C 6 750
metabolic C 7 750
diseases C 8 750
whether C 9 750
the C 10 750
various C 11 750
cells C 12 750
of C 13 750
the C 14 750
liver C 15 750
, C 16 750
both C 17 750
parenchymal C 18 750
and C 19 750
stromal C 20 750
, C 21 750
receive C 22 750
genetic C 23 750
misinformation C 24 750
in C 25 750
all C 26 750
hereditary C 27 750
diseases C 28 750
caused C 29 750
by C 30 750
gene C 31 750
mutation C 32 750
is C 33 750
unknown C 34 750
, C 35 750
but C 36 750
the C 37 750
metabolic C 38 750
capabilities C 39 750
of C 40 750
these C 41 750
several C 42 750
cell C 43 750
types C 44 750
are C 45 750
so C 46 750
diverse C 47 750
that C 48 750
it C 49 750
is C 50 750
not C 51 750
surprising C 52 750
that C 53 750
their C 54 750
involvement C 55 750
in C 56 750
many C 57 750
such C 58 750
diseases C 59 750
can C 60 750
be C 61 750
demonstrated C 62 750
by C 63 750
clinical C 64 750
, C 65 750
pathological C 66 750
, C 67 750
or C 68 750
bio C 69 750
- C 70 750
chemical C 71 750
methods C 72 750
. C 73 750
repetitive C 75 750
abnormality C 76 750
of C 77 750
the C 78 750
liver C 79 750
has C 80 750
apparently C 81 750
not C 82 750
been C 83 750
defined C 84 750
for C 85 750
any C 86 750
disease C 87 750
caused C 88 750
by C 89 750
quantitative C 90 750
( C 91 750
i C 92 750
. C 93 750
. C 94 750
. C 95 750
, C 97 750
chromosomal C 98 750
) C 99 750
gene C 100 750
anomaly C 101 750
, C 102 750
whether C 103 750
produced C 104 750
by C 105 750
nondisjunction C 106 750
, C 107 750
translocation C 108 750
, C 109 750
or C 110 750
major C 111 750
deletion C 112 750
, C 113 750
perhaps C 114 750
because C 115 750
relatively C 116 750
few C 117 750
such C 118 750
diseases C 119 750
have C 120 750
been C 121 750
described C 122 750
. C 123 750
as C 125 750
a C 126 750
result C 127 750
, C 128 750
the C 129 750
genetically C 130 750
determined C 131 750
disorders C 132 750
of C 133 750
the C 134 750
liver C 135 750
surveyed C 136 750
in C 137 750
this C 138 750
paper C 139 750
appear C 140 750
to C 141 750
be C 142 750
the C 143 750
result C 144 750
of C 145 750
conventional C 146 750
" C 147 750
single C 148 750
gene C 149 750
" C 150 750
abnormalities C 151 750
, C 152 750
and C 153 750
to C 154 750
be C 155 750
transmitted C 156 750
in C 157 750
affected C 158 750
families C 159 750
by C 160 750
men C 161 750
- C 162 750
delian C 163 750
mechanisms C 164 750
. C 165 750
acid C 1 751
catabolic C 2 751
enzyme C 3 751
activity C 4 751
in C 5 751
relation C 6 751
to C 7 751
accessory C 8 751
limb C 9 751
and C 10 751
cancer C 11 751
initiation C 12 751
in C 13 751
amphibia C 14 751
cathepsin C 15 751
and C 16 751
acid C 17 751
phosphatase C 18 751
were C 19 751
determined C 20 751
in C 21 751
livers C 22 751
and C 23 751
kidneys C 24 751
of C 25 751
adult C 26 751
rana C 27 751
pipiens C 28 751
and C 29 751
triturus C 30 751
viridescens C 31 751
. C 32 751
organ C 34 751
- C 35 751
specific C 36 751
and C 37 751
species C 38 751
- C 39 751
specific C 40 751
differences C 41 751
in C 42 751
distribution C 43 751
of C 44 751
these C 45 751
enzymes C 46 751
were C 47 751
found C 48 751
, C 49 751
as C 50 751
well C 51 751
as C 52 751
considerable C 53 751
differences C 54 751
in C 55 751
the C 56 751
effect C 57 751
triton C 58 751
x C 59 751
- C 60 751
100 C 61 751
on C 62 751
the C 63 751
two C 64 751
enzymes C 65 751
. C 66 751
a C 68 751
heterogeneous C 69 751
population C 70 751
of C 71 751
lysosomes C 72 751
in C 73 751
respect C 74 751
to C 75 751
enzyme C 76 751
content C 77 751
and C 78 751
stability C 79 751
is C 80 751
deduced C 81 751
. C 82 751
we C 84 751
have C 85 751
found C 86 751
positive C 87 751
correlations C 88 751
between C 89 751
catheptic C 90 751
activity C 91 751
of C 92 751
the C 93 751
implant C 94 751
and C 95 751
host C 96 751
tissue C 97 751
dissociation C 98 751
, C 99 751
and C 100 751
between C 101 751
acid C 102 751
phosphatase C 103 751
and C 104 751
inducibility C 105 751
, C 106 751
as C 107 751
features C 108 751
of C 109 751
the C 110 751
phenomenon C 111 751
of C 112 751
implant C 113 751
- C 114 751
induced C 115 751
accessory C 116 751
limb C 117 751
formation C 118 751
in C 119 751
urodeles C 120 751
. C 121 751
further C 123 751
, C 124 751
we C 125 751
have C 126 751
found C 127 751
a C 128 751
positive C 129 751
correlation C 130 751
between C 131 751
catheptic C 132 751
activity C 133 751
and C 134 751
resistance C 135 751
to C 136 751
virus C 137 751
- C 138 751
induced C 139 751
renal C 140 751
adenocar C 141 751
- C 142 751
cinoma C 143 751
development C 144 751
in C 145 751
rana C 146 751
pipiens C 147 751
. C 148 751
neonatology C 1 752
considerable C 2 752
progress C 3 752
has C 4 752
been C 5 752
made C 6 752
in C 7 752
the C 8 752
knowledge C 9 752
of C 10 752
bilirubin C 11 752
metabolism C 12 752
since C 13 752
the C 14 752
char C 15 752
- C 16 752
acterization C 17 752
of C 18 752
" C 19 752
direct C 20 752
" C 21 752
( C 22 752
conjugated C 23 752
) C 24 752
bilirubin C 25 752
as C 26 752
an C 27 752
ester C 28 752
glucuronide C 29 752
. C 30 752
the C 32 752
metabolic C 33 752
pathway C 34 752
involved C 35 752
in C 36 752
this C 37 752
hepatic C 38 752
conjugation C 39 752
is C 40 752
now C 41 752
well C 42 752
established C 43 752
and C 44 752
has C 45 752
been C 46 752
the C 47 752
subject C 48 752
of C 49 752
excellent C 50 752
reviews C 51 752
by C 52 752
sherlock C 53 752
and C 54 752
billing C 55 752
. C 56 752
sherlock C 58 752
' C 59 752
s C 60 752
diagrammatic C 61 752
representations C 62 752
of C 63 752
biliru C 64 752
- C 65 752
bin C 66 752
metabolism C 67 752
( C 68 752
fig C 69 752
. C 70 752
1 C 72 752
) C 73 752
and C 74 752
of C 75 752
the C 76 752
possible C 77 752
mecha C 78 752
- C 79 752
nisms C 80 752
of C 81 752
jaundice C 82 752
( C 83 752
fig C 84 752
. C 85 752
2 C 87 752
) C 88 752
are C 89 752
reproduced C 90 752
here C 91 752
because C 92 752
they C 93 752
furnish C 94 752
a C 95 752
clear C 96 752
picture C 97 752
to C 98 752
serve C 99 752
as C 100 752
a C 101 752
reference C 102 752
point C 103 752
for C 104 752
the C 105 752
discussion C 106 752
to C 107 752
follow C 108 752
. C 109 752
it C 111 752
is C 112 752
interesting C 113 752
to C 114 752
re C 115 752
- C 116 752
examine C 117 752
current C 118 752
concepts C 119 752
of C 120 752
the C 121 752
etiology C 122 752
of C 123 752
physiologic C 124 752
jaundice C 125 752
with C 126 752
this C 127 752
dia C 128 752
- C 129 752
gram C 130 752
in C 131 752
mind C 132 752
. C 133 752
jaundice C 135 752
may C 136 752
occur C 137 752
for C 138 752
a C 139 752
number C 140 752
of C 141 752
reasons C 142 752
, C 143 752
described C 144 752
below C 145 752
. C 146 752
red C 1 753
cell C 2 753
glucose C 3 753
- C 4 753
6 C 5 753
- C 6 753
phosphate C 7 753
dehydrogenase C 8 753
deficiency C 9 753
- C 10 753
- C 11 753
a C 12 753
newly C 13 753
recognized C 14 753
cause C 15 753
of C 16 753
neonatal C 17 753
jaundice C 18 753
and C 19 753
kernicterus C 20 753
in C 21 753
canada C 22 753
seven C 23 753
male C 24 753
newborns C 25 753
of C 26 753
chinese C 27 753
, C 28 753
greek C 29 753
and C 30 753
italian C 31 753
origin C 32 753
presented C 33 753
with C 34 753
severe C 35 753
hemo C 36 753
- C 37 753
lytic C 38 753
jaundice C 39 753
due C 40 753
to C 41 753
red C 42 753
cell C 43 753
glucose C 44 753
- C 45 753
6 C 46 753
- C 47 753
phosphate C 48 753
dehydrogenase C 49 753
( C 50 753
g C 51 753
- C 52 753
6 C 53 753
- C 54 753
pd C 55 753
) C 56 753
defi C 57 753
- C 58 753
ciency C 59 753
. C 60 753
in C 62 753
five C 63 753
, C 64 753
the C 65 753
hemolysis C 66 753
was C 67 753
precipi C 68 753
- C 69 753
tated C 70 753
by C 71 753
inhalation C 72 753
of C 73 753
mothball C 74 753
vapours C 75 753
in C 76 753
the C 77 753
home C 78 753
. C 79 753
kernicterus C 81 753
was C 82 753
evident C 83 753
upon C 84 753
admission C 85 753
in C 86 753
six C 87 753
infants C 88 753
and C 89 753
was C 90 753
fatal C 91 753
in C 92 753
four C 93 753
of C 94 753
these C 95 753
. C 96 753
g C 98 753
- C 99 753
6 C 100 753
- C 101 753
pd C 102 753
deficiency C 103 753
should C 104 753
be C 105 753
suspected C 106 753
as C 107 753
a C 108 753
cause C 109 753
of C 110 753
jaundice C 111 753
in C 112 753
all C 113 753
full C 114 753
- C 115 753
term C 116 753
male C 117 753
infants C 118 753
of C 119 753
these C 120 753
ethnic C 121 753
groups C 122 753
. C 123 753
the C 125 753
diag C 126 753
- C 127 753
nosis C 128 753
can C 129 753
be C 130 753
confirmed C 131 753
in C 132 753
any C 133 753
hospital C 134 753
by C 135 753
the C 136 753
methemoglobin C 137 753
reduction C 138 753
test C 139 753
. C 140 753
in C 142 753
areas C 143 753
similar C 144 753
to C 145 753
toronto C 146 753
, C 147 753
canada C 148 753
, C 149 753
where C 150 753
these C 151 753
high C 152 753
- C 153 753
risk C 154 753
ethnic C 155 753
groups C 156 753
prevail C 157 753
, C 158 753
the C 159 753
follow C 160 753
- C 161 753
ing C 162 753
measures C 163 753
are C 164 753
recommended C 165 753
: C 166 753
( C 167 753
1 C 168 753
) C 169 753
detec C 170 753
- C 171 753
tion C 172 753
of C 173 753
g C 174 753
- C 175 753
6 C 176 753
- C 177 753
pd C 178 753
deficient C 179 753
newborns C 180 753
by C 181 753
screening C 182 753
cord C 183 753
bloods C 184 753
of C 185 753
all C 186 753
infants C 187 753
of C 188 753
these C 189 753
ethnic C 190 753
groups C 191 753
: C 192 753
( C 193 753
2 C 194 753
) C 195 753
protection C 196 753
of C 197 753
affected C 198 753
infants C 199 753
from C 200 753
potentially C 201 753
hemolytic C 202 753
agents C 203 753
such C 204 753
as C 205 753
naphthalene C 206 753
, C 207 753
certain C 208 753
vitamin C 209 753
k C 210 753
preparations C 211 753
, C 212 753
and C 213 753
sulfonamides C 214 753
; C 215 753
and C 216 753
( C 217 753
3 C 218 753
) C 219 753
ob C 220 753
- C 221 753
servation C 222 753
of C 223 753
serum C 224 753
bilirubin C 225 753
levels C 226 753
to C 227 753
assess C 228 753
the C 229 753
need C 230 753
for C 231 753
exchange C 232 753
transfusion C 233 753
for C 234 753
hyper C 235 753
- C 236 753
bilirubinemia C 237 753
. C 238 753
trisomy C 1 754
17 C 2 754
- C 3 754
18 C 4 754
syndrome C 5 754
with C 6 754
congenital C 7 754
extrahepatic C 8 754
biliary C 9 754
atresia C 10 754
and C 11 754
congenital C 12 754
amputation C 13 754
of C 14 754
the C 15 754
left C 16 754
foot C 17 754
the C 18 754
phenotypic C 19 754
characteristics C 20 754
of C 21 754
the C 22 754
17 C 23 754
- C 24 754
18 C 25 754
trisomy C 26 754
syndrome C 27 754
have C 28 754
been C 29 754
well C 30 754
described C 31 754
. C 32 754
among C 34 754
the C 35 754
most C 36 754
recently C 37 754
docu C 38 754
- C 39 754
mented C 40 754
cases C 41 754
of C 42 754
this C 43 754
syndrome C 44 754
are C 45 754
those C 46 754
with C 47 754
findings C 48 754
of C 49 754
agenesis C 50 754
or C 51 754
aplasia C 52 754
of C 53 754
various C 54 754
bones C 55 754
of C 56 754
the C 57 754
forearm C 58 754
and C 59 754
hand C 60 754
, C 61 754
in C 62 754
addition C 63 754
to C 64 754
the C 65 754
more C 66 754
classical C 67 754
symptoms C 68 754
. C 69 754
we C 71 754
have C 72 754
recently C 73 754
studied C 74 754
a C 75 754
case C 76 754
of C 77 754
trisomy C 78 754
17 C 79 754
- C 80 754
18 C 81 754
syndrome C 82 754
with C 83 754
congenital C 84 754
absence C 85 754
of C 86 754
the C 87 754
left C 88 754
foot C 89 754
, C 90 754
and C 91 754
congenital C 92 754
extrahepatic C 93 754
biliary C 94 754
atresia C 95 754
. C 96 754
differentiation C 1 755
of C 2 755
explanted C 3 755
fragments C 4 755
of C 5 755
early C 6 755
chick C 7 755
blastoderm C 8 755
ii C 9 755
. C 10 755
culture C 12 755
on C 13 755
protein C 14 755
- C 15 755
deficient C 16 755
medium C 17 755
enriched C 18 755
with C 19 755
rna C 20 755
posterior C 21 755
fragments C 22 755
of C 23 755
head C 24 755
process C 25 755
blastoderms C 26 755
were C 27 755
cultured C 28 755
in C 29 755
vitro C 30 755
for C 31 755
two C 32 755
days C 33 755
on C 34 755
a C 35 755
protein C 36 755
- C 37 755
deficient C 38 755
medium C 39 755
sup C 40 755
- C 41 755
plemented C 42 755
with C 43 755
various C 44 755
rna C 45 755
' C 46 755
s C 47 755
, C 48 755
after C 49 755
which C 50 755
they C 51 755
were C 52 755
grafted C 53 755
over C 54 755
the C 55 755
chorio C 56 755
- C 57 755
allantoic C 58 755
membrane C 59 755
for C 60 755
eight C 61 755
to C 62 755
nine C 63 755
days C 64 755
. C 65 755
pancreatic C 67 755
( C 68 755
adult C 69 755
) C 70 755
rna C 71 755
enhanced C 72 755
the C 73 755
development C 74 755
of C 75 755
the C 76 755
entodermal C 77 755
epi C 78 755
- C 79 755
thelium C 80 755
. C 81 755
heart C 83 755
( C 84 755
adult C 85 755
) C 86 755
rna C 87 755
caused C 88 755
hyper C 89 755
- C 90 755
plasia C 91 755
of C 92 755
the C 93 755
epidermis C 94 755
with C 95 755
, C 96 755
in C 97 755
some C 98 755
cases C 99 755
, C 100 755
keratinized C 101 755
papillary C 102 755
projections C 103 755
. C 104 755
brain C 106 755
( C 107 755
embryonic C 108 755
) C 109 755
rna C 110 755
produced C 111 755
a C 112 755
papillomatous C 113 755
epidermis C 114 755
with C 115 755
giant C 116 755
epi C 117 755
- C 118 755
dermal C 119 755
cysts C 120 755
that C 121 755
were C 122 755
keratinized C 123 755
and C 124 755
fibrillar C 125 755
as C 126 755
in C 127 755
feather C 128 755
formation C 129 755
. C 130 755
liver C 132 755
( C 133 755
embryonic C 134 755
) C 135 755
rna C 136 755
had C 137 755
no C 138 755
vis C 139 755
- C 140 755
ible C 141 755
tissue C 142 755
modifications C 143 755
. C 144 755
in C 146 755
the C 147 755
controls C 148 755
there C 149 755
was C 150 755
no C 151 755
keratini C 152 755
- C 153 755
zation C 154 755
, C 155 755
nor C 156 755
papillary C 157 755
formation C 158 755
of C 159 755
the C 160 755
epi C 161 755
- C 162 755
dermis C 163 755
. C 164 755
the C 166 755
epidermal C 167 755
cysts C 168 755
were C 169 755
very C 170 755
small C 171 755
, C 172 755
unkeratinized C 173 755
and C 174 755
devoid C 175 755
of C 176 755
fibrillar C 177 755
organization C 178 755
. C 179 755
the C 181 755
results C 182 755
are C 183 755
discussed C 184 755
in C 185 755
terms C 186 755
of C 187 755
relationships C 188 755
of C 189 755
proteins C 190 755
from C 191 755
brain C 192 755
, C 193 755
mus C 194 755
- C 195 755
cle C 196 755
and C 197 755
skin C 198 755
. C 199 755
the C 1 756
inhibition C 2 756
of C 3 756
cell C 4 756
aggregation C 5 756
by C 6 756
a C 7 756
pure C 8 756
serum C 9 756
protein C 10 756
the C 11 756
aggregation C 12 756
of C 13 756
embryonic C 14 756
chick C 15 756
and C 16 756
quail C 17 756
limb C 18 756
bud C 19 756
, C 20 756
heart C 21 756
and C 22 756
liver C 23 756
cells C 24 756
in C 25 756
a C 26 756
shaker C 27 756
system C 28 756
has C 29 756
been C 30 756
investigated C 31 756
in C 32 756
order C 33 756
to C 34 756
elucidate C 35 756
the C 36 756
mechanism C 37 756
of C 38 756
cell C 39 756
adhesion C 40 756
. C 41 756
a C 43 756
new C 44 756
method C 45 756
of C 46 756
assessing C 47 756
aggregation C 48 756
is C 49 756
described C 50 756
and C 51 756
evaluated C 52 756
; C 53 756
this C 54 756
method C 55 756
involved C 56 756
measurements C 57 756
of C 58 756
aggregation C 59 756
kinetics C 60 756
. C 61 756
it C 63 756
was C 64 756
found C 65 756
that C 66 756
the C 67 756
measured C 68 756
kinetics C 69 756
agree C 70 756
closely C 71 756
with C 72 756
flocculation C 73 756
kinetics C 74 756
, C 75 756
which C 76 756
provides C 77 756
a C 78 756
direct C 79 756
quantitative C 80 756
measurement C 81 756
of C 82 756
adhesiveness C 83 756
in C 84 756
terms C 85 756
of C 86 756
the C 87 756
probability C 88 756
of C 89 756
an C 90 756
adhesion C 91 756
forming C 92 756
on C 93 756
contact C 94 756
between C 95 756
two C 96 756
cells C 97 756
. C 98 756
using C 100 756
this C 101 756
technique C 102 756
it C 103 756
was C 104 756
confirmed C 105 756
that C 106 756
aggregation C 107 756
is C 108 756
inhibited C 109 756
at C 110 756
1 C 111 756
- C 112 756
2 C 113 756
c C 114 756
. C 115 756
in C 117 756
the C 118 756
presence C 119 756
of C 120 756
serum C 121 756
but C 122 756
not C 123 756
in C 124 756
its C 125 756
absence C 126 756
. C 127 756
the C 129 756
kinetics C 130 756
of C 131 756
aggregation C 132 756
in C 133 756
the C 134 756
presence C 135 756
of C 136 756
serum C 137 756
at C 138 756
37 C 139 756
c C 140 756
. C 141 756
, C 143 756
the C 144 756
lack C 145 756
of C 146 756
inhibition C 147 756
of C 148 756
aggregation C 149 756
at C 150 756
1 C 151 756
- C 152 756
2 C 153 756
c C 154 756
. C 155 756
by C 157 756
serum C 158 756
which C 159 756
has C 160 756
been C 161 756
' C 162 756
conditioned C 163 756
' C 164 756
by C 165 756
the C 166 756
presence C 167 756
of C 168 756
cells C 169 756
, C 170 756
and C 171 756
the C 172 756
similar C 173 756
lack C 174 756
of C 175 756
inhibitory C 176 756
power C 177 756
of C 178 756
serum C 179 756
which C 180 756
has C 181 756
been C 182 756
pre C 183 756
- C 184 756
treated C 185 756
with C 186 756
antiserum C 187 756
antibodies C 188 756
, C 189 756
all C 190 756
suggest C 191 756
that C 192 756
serum C 193 756
contains C 194 756
a C 195 756
factor C 196 756
which C 197 756
inhibits C 198 756
aggregation C 199 756
until C 200 756
destroyed C 201 756
by C 202 756
cellular C 203 756
metabolism C 204 756
. C 205 756
les C 1 757
icteres C 2 757
du C 3 757
nouveau C 4 757
- C 5 757
ne C 6 757
en C 7 757
dehors C 8 757
de C 9 757
l C 10 757
' C 11 757
incompatibilite C 12 757
foeto C 13 757
- C 14 757
maternelle C 15 757
statistical C 16 757
data C 17 757
pulled C 18 757
off C 19 757
a C 20 757
study C 21 757
of C 22 757
30 C 23 757
haemolytic C 24 757
neonatal C 25 757
icteri C 26 757
not C 27 757
linked C 28 757
to C 29 757
a C 30 757
foeto C 31 757
- C 32 757
maternal C 33 757
incompatibility C 34 757
, C 35 757
and C 36 757
of C 37 757
200 C 38 757
non C 39 757
haemo C 40 757
- C 41 757
lytic C 42 757
neonatal C 43 757
icteri C 44 757
. C 45 757
among C 47 757
this C 48 757
latter C 49 757
, C 50 757
the C 51 757
two C 52 757
most C 53 757
important C 54 757
groups C 55 757
are C 56 757
the C 57 757
malformative C 58 757
icteri C 59 757
( C 60 757
69 C 61 757
cases C 62 757
) C 63 757
and C 64 757
the C 65 757
neonatal C 66 757
hepatitis C 67 757
( C 68 757
109 C 69 757
cases C 70 757
) C 71 757
. C 72 757
the C 74 757
difficulties C 75 757
of C 76 757
the C 77 757
diagnosis C 78 757
frequently C 79 757
rencountered C 80 757
between C 81 757
these C 82 757
two C 83 757
groups C 84 757
clearly C 85 757
appear C 86 757
in C 87 757
the C 88 757
comparative C 89 757
statistical C 90 757
analysis C 91 757
of C 92 757
the C 93 757
clinical C 94 757
, C 95 757
histological C 96 757
and C 97 757
evolutive C 98 757
data C 99 757
. C 100 757
the C 1 758
immunological C 2 758
development C 3 758
of C 4 758
the C 5 758
human C 6 758
fetus C 7 758
the C 8 758
normal C 9 758
human C 10 758
fetus C 11 758
is C 12 758
said C 13 758
not C 14 758
to C 15 758
be C 16 758
engaged C 17 758
in C 18 758
the C 19 758
formation C 20 758
of C 21 758
immuno C 22 758
- C 23 758
globulins C 24 758
; C 25 758
the C 26 758
immunoglobulins C 27 758
present C 28 758
in C 29 758
the C 30 758
serum C 31 758
of C 32 758
the C 33 758
fetus C 34 758
and C 35 758
the C 36 758
newborn C 37 758
are C 38 758
considered C 39 758
to C 40 758
be C 41 758
of C 42 758
maternal C 43 758
origin C 44 758
. C 45 758
in C 47 758
favor C 48 758
of C 49 758
this C 50 758
opinion C 51 758
is C 52 758
the C 53 758
observation C 54 758
that C 55 758
directly C 56 758
after C 57 758
birth C 58 758
the C 59 758
serum C 60 758
of C 61 758
the C 62 758
newborn C 63 758
contains C 64 758
an C 65 758
appreciable C 66 758
amount C 67 758
of C 68 758
igg C 69 758
, C 70 758
with C 71 758
gm C 72 758
groups C 73 758
identical C 74 758
with C 75 758
those C 76 758
of C 77 758
the C 78 758
mother C 79 758
( C 80 758
68 C 81 758
- C 82 758
70 C 83 758
) C 84 758
. C 85 758
the C 87 758
level C 88 758
of C 89 758
the C 90 758
igg C 91 758
of C 92 758
the C 93 758
neonate C 94 758
decreases C 95 758
gradually C 96 758
during C 97 758
the C 98 758
first C 99 758
3 C 100 758
months C 101 758
( C 102 758
3 C 103 758
, C 104 758
27 C 105 758
, C 106 758
71 C 107 758
) C 108 758
, C 109 758
which C 110 758
is C 111 758
generally C 112 758
explained C 113 758
by C 114 758
the C 115 758
catabolism C 116 758
of C 117 758
the C 118 758
maternal C 119 758
igg C 120 758
, C 121 758
whereas C 122 758
the C 123 758
formation C 124 758
by C 125 758
the C 126 758
newborn C 127 758
infant C 128 758
is C 129 758
still C 130 758
inadequate C 131 758
to C 132 758
maintain C 133 758
the C 134 758
original C 135 758
level C 136 758
( C 137 758
16 C 138 758
, C 139 758
27 C 140 758
) C 141 758
. C 142 758
the C 144 758
best C 145 758
evidence C 146 758
for C 147 758
the C 148 758
transplacental C 149 758
passage C 150 758
is C 151 758
the C 152 758
almost C 153 758
complete C 154 758
absence C 155 758
of C 156 758
igg C 157 758
in C 158 758
the C 159 758
serum C 160 758
of C 161 758
newborn C 162 758
infants C 163 758
from C 164 758
mothers C 165 758
with C 166 758
agammaglobulinemia C 167 758
( C 168 758
3 C 169 758
, C 170 758
27 C 171 758
) C 172 758
. C 173 758
the C 175 758
transfer C 176 758
of C 177 758
the C 178 758
immunoglobulins C 179 758
appears C 180 758
to C 181 758
be C 182 758
a C 183 758
selective C 184 758
process C 185 758
( C 186 758
13 C 187 758
, C 188 758
15 C 189 758
) C 190 758
. C 191 758
while C 193 758
igg C 194 758
is C 195 758
readily C 196 758
transferred C 197 758
, C 198 758
there C 199 758
is C 200 758
little C 201 758
, C 202 758
if C 203 758
any C 204 758
, C 205 758
transfer C 206 758
of C 207 758
iga C 208 758
and C 209 758
igm C 210 758
, C 211 758
as C 212 758
has C 213 758
been C 214 758
shown C 215 758
by C 216 758
ultracentrifugation C 217 758
and C 218 758
immunoelectrophoretic C 219 758
studies C 220 758
of C 221 758
the C 222 758
serum C 223 758
( C 224 758
12 C 225 758
, C 226 758
16 C 227 758
, C 228 758
19 C 229 758
, C 230 758
20 C 231 758
) C 232 758
and C 233 758
the C 234 758
analysis C 235 758
of C 236 758
maternally C 237 758
- C 238 758
transferred C 239 758
antibodies C 240 758
( C 241 758
31 C 242 758
- C 243 758
33 C 244 758
) C 245 758
. C 246 758
with C 248 758
more C 249 758
sensitive C 250 758
techniques C 251 758
such C 252 758
as C 253 758
the C 254 758
double C 255 758
diffusion C 256 758
test C 257 758
in C 258 758
agar C 259 758
or C 260 758
quantitative C 261 758
immunochemical C 262 758
techniques C 263 758
, C 264 758
however C 265 758
, C 266 758
minute C 267 758
amounts C 268 758
of C 269 758
both C 270 758
igm C 271 758
and C 272 758
iga C 273 758
have C 274 758
been C 275 758
detected C 276 758
in C 277 758
fetal C 278 758
blood C 279 758
as C 280 758
well C 281 758
as C 282 758
in C 283 758
cord C 284 758
blood C 285 758
from C 286 758
mature C 287 758
and C 288 758
immature C 289 758
neonates C 290 758
( C 291 758
12 C 292 758
, C 293 758
19 C 294 758
, C 295 758
20 C 296 758
, C 297 758
23 C 298 758
, C 299 758
26 C 300 758
) C 301 758
. C 302 758
since C 304 758
large C 305 758
molecules C 306 758
do C 307 758
not C 308 758
pass C 309 758
the C 310 758
placenta C 311 758
, C 312 758
this C 313 758
may C 314 758
indicate C 315 758
that C 316 758
the C 317 758
trace C 318 758
amounts C 319 758
of C 320 758
igm C 321 758
originate C 322 758
in C 323 758
the C 324 758
fetus C 325 758
itself C 326 758
, C 327 758
but C 328 758
transplacental C 329 758
passage C 330 758
has C 331 758
not C 332 758
been C 333 758
completely C 334 758
excluded C 335 758
. C 336 758
the C 338 758
absence C 339 758
of C 340 758
immunoglobulin C 341 758
formation C 342 758
has C 343 758
been C 344 758
associated C 345 758
with C 346 758
the C 347 758
absence C 348 758
of C 349 758
plasma C 350 758
cells C 351 758
in C 352 758
the C 353 758
lymphoid C 354 758
tissues C 355 758
and C 356 758
bone C 357 758
marrow C 358 758
of C 359 758
the C 360 758
normal C 361 758
human C 362 758
fetus C 363 758
and C 364 758
the C 365 758
newborn C 366 758
. C 367 758
it C 369 758
has C 370 758
been C 371 758
reported C 372 758
that C 373 758
these C 374 758
cells C 375 758
do C 376 758
not C 377 758
appear C 378 758
until C 379 758
a C 380 758
few C 381 758
weeks C 382 758
after C 383 758
birth C 384 758
( C 385 758
2 C 386 758
, C 387 758
3 C 388 758
, C 389 758
14 C 390 758
, C 391 758
25 C 392 758
, C 393 758
34 C 394 758
) C 395 758
. C 396 758
however C 398 758
, C 399 758
in C 400 758
pathological C 401 758
conditions C 402 758
such C 403 758
as C 404 758
congenital C 405 758
syphilis C 406 758
and C 407 758
toxoplasmosis C 408 758
the C 409 758
human C 410 758
fetus C 411 758
has C 412 758
been C 413 758
found C 414 758
to C 415 758
respond C 416 758
to C 417 758
the C 418 758
antigenic C 419 758
stimulus C 420 758
with C 421 758
intrauterine C 422 758
formation C 423 758
of C 424 758
plasma C 425 758
cells C 426 758
after C 427 758
about C 428 758
the C 429 758
sixth C 430 758
month C 431 758
of C 432 758
gestation C 433 758
( C 434 758
24 C 435 758
, C 436 758
25 C 437 758
) C 438 758
. C 439 758
galactosemie C 1 759
congenitale C 2 759
this C 3 759
observation C 4 759
of C 5 759
a C 6 759
case C 7 759
of C 8 759
congenital C 9 759
galactosemia C 10 759
with C 11 759
a C 12 759
particular C 13 759
familial C 14 759
incidence C 15 759
gives C 16 759
the C 17 759
opportunity C 18 759
of C 19 759
a C 20 759
brief C 21 759
review C 22 759
on C 23 759
the C 24 759
subject C 25 759
. C 26 759
of C 28 759
a C 29 759
certain C 30 759
point C 31 759
of C 32 759
view C 33 759
we C 34 759
must C 35 759
consider C 36 759
that C 37 759
galac C 38 759
- C 39 759
tosemia C 40 759
is C 41 759
much C 42 759
more C 43 759
frequent C 44 759
than C 45 759
we C 46 759
suppose C 47 759
, C 48 759
that C 49 759
there C 50 759
are C 51 759
many C 52 759
severe C 53 759
cases C 54 759
with C 55 759
a C 56 759
reserved C 57 759
prognosis C 58 759
, C 59 759
that C 60 759
even C 61 759
with C 62 759
very C 63 759
slight C 64 759
degree C 65 759
of C 66 759
galactosemia C 67 759
, C 68 759
the C 69 759
disease C 70 759
must C 71 759
receive C 72 759
the C 73 759
most C 74 759
careful C 75 759
attention C 76 759
from C 77 759
the C 78 759
pediatrician C 79 759
. C 80 759
postnatal C 1 760
changes C 2 760
in C 3 760
the C 4 760
portal C 5 760
circulation C 6 760
during C 7 760
foetal C 8 760
development C 9 760
a C 10 760
large C 11 760
portion C 12 760
of C 13 760
the C 14 760
oxygenated C 15 760
umbilical C 16 760
blood C 17 760
flows C 18 760
through C 19 760
the C 20 760
umbilical C 21 760
recess C 22 760
directly C 23 760
into C 24 760
both C 25 760
main C 26 760
portal C 27 760
branches C 28 760
. C 29 760
accordingly C 31 760
, C 32 760
these C 33 760
are C 34 760
exposed C 35 760
to C 36 760
the C 37 760
umbilical C 38 760
blood C 39 760
pressure C 40 760
and C 41 760
have C 42 760
a C 43 760
wide C 44 760
by C 45 760
contrast C 46 760
, C 47 760
the C 48 760
trunk C 49 760
of C 50 760
the C 51 760
portal C 52 760
vein C 53 760
is C 54 760
narrow C 55 760
and C 56 760
there C 57 760
is C 58 760
probably C 59 760
only C 60 760
a C 61 760
small C 62 760
blood C 63 760
flow C 64 760
through C 65 760
it C 66 760
from C 67 760
the C 68 760
inactive C 69 760
digestive C 70 760
tract C 71 760
, C 72 760
though C 73 760
the C 74 760
pressure C 75 760
in C 76 760
it C 77 760
is C 78 760
approximately C 79 760
the C 80 760
same C 81 760
as C 82 760
in C 83 760
the C 84 760
umbilical C 85 760
vein C 86 760
or C 87 760
perhaps C 88 760
somewhat C 89 760
higher C 90 760
. C 91 760
immediately C 93 760
after C 94 760
birth C 95 760
the C 96 760
liver C 97 760
is C 98 760
deprived C 99 760
of C 100 760
the C 101 760
substantial C 102 760
umbilical C 103 760
blood C 104 760
flow C 105 760
. C 106 760
the C 108 760
portal C 109 760
venous C 110 760
pressure C 111 760
falls C 112 760
to C 113 760
about C 114 760
one C 115 760
- C 116 760
quarter C 117 760
of C 118 760
the C 119 760
umbilical C 120 760
venous C 121 760
pressure C 122 760
at C 123 760
birth C 124 760
. C 125 760
however C 127 760
the C 128 760
pressure C 129 760
gradient C 130 760
between C 131 760
the C 132 760
portal C 133 760
veins C 134 760
and C 135 760
inferior C 136 760
vena C 137 760
cava C 138 760
remains C 139 760
constant C 140 760
. C 141 760
pattern C 1 761
of C 2 761
serum C 3 761
transaminase C 4 761
activity C 5 761
in C 6 761
neonatal C 7 761
jaundice C 8 761
due C 9 761
to C 10 761
cytomegalic C 11 761
inclusion C 12 761
disease C 13 761
and C 14 761
toxoplasmosis C 15 761
with C 16 761
hepatic C 17 761
involvement C 18 761
the C 19 761
pattern C 20 761
of C 21 761
serum C 22 761
transaminase C 23 761
ac C 24 761
- C 25 761
tivity C 26 761
that C 27 761
evolved C 28 761
in C 29 761
a C 30 761
newborn C 31 761
infant C 32 761
with C 33 761
congenital C 34 761
toxoplasmosis C 35 761
and C 36 761
in C 37 761
another C 38 761
new C 39 761
- C 40 761
born C 41 761
infant C 42 761
with C 43 761
congenital C 44 761
cytomegalic C 45 761
in C 46 761
- C 47 761
clusion C 48 761
disease C 49 761
is C 50 761
described C 51 761
. C 52 761
this C 54 761
enzymatic C 55 761
pattern C 56 761
was C 57 761
unlike C 58 761
that C 59 761
found C 60 761
in C 61 761
infants C 62 761
with C 63 761
any C 64 761
other C 65 761
cause C 66 761
of C 67 761
neonatal C 68 761
jaundice C 69 761
studied C 70 761
to C 71 761
date C 72 761
. C 73 761
impaired C 1 762
development C 2 762
of C 3 762
rat C 4 762
liver C 5 762
enzyme C 6 762
activities C 7 762
at C 8 762
birth C 9 762
after C 10 762
irradiation C 11 762
in C 12 762
utero C 13 762
development C 14 762
of C 15 762
activity C 16 762
of C 17 762
three C 18 762
liver C 19 762
enzymes C 20 762
at C 21 762
birth C 22 762
was C 23 762
studied C 24 762
in C 25 762
rats C 26 762
re C 27 762
- C 28 762
ceiving C 29 762
180 C 30 762
rads C 31 762
of C 32 762
x C 33 762
- C 34 762
rays C 35 762
on C 36 762
day C 37 762
15 C 38 762
of C 39 762
gestation C 40 762
. C 41 762
at C 43 762
20 C 44 762
days C 45 762
of C 46 762
gestation C 47 762
, C 48 762
activities C 49 762
of C 50 762
lactic C 51 762
and C 52 762
glycerophosphate C 53 762
dehydrogenases C 54 762
and C 55 762
glucose C 56 762
- C 57 762
6 C 58 762
- C 59 762
phosphatase C 60 762
were C 61 762
not C 62 762
altered C 63 762
. C 64 762
the C 66 762
subsequent C 67 762
increases C 68 762
in C 69 762
enzyme C 70 762
activities C 71 762
in C 72 762
the C 73 762
3 C 74 762
days C 75 762
between C 76 762
20 C 77 762
days C 78 762
of C 79 762
gestation C 80 762
and C 81 762
1 C 82 762
day C 83 762
of C 84 762
age C 85 762
were C 86 762
only C 87 762
30 C 88 762
to C 89 762
60 C 90 762
% C 91 762
of C 92 762
those C 93 762
observed C 94 762
in C 95 762
controls C 96 762
. C 97 762
this C 99 762
finding C 100 762
suggests C 101 762
that C 102 762
irradiation C 103 762
in C 104 762
utero C 105 762
may C 106 762
alter C 107 762
later C 108 762
development C 109 762
of C 110 762
enzyme C 111 762
activity C 112 762
in C 113 762
the C 114 762
perinatal C 115 762
period C 116 762
. C 117 762
( C 1 763
cytological C 2 763
and C 3 763
cytochemical C 4 763
study C 5 763
of C 6 763
hepatic C 7 763
cells C 8 763
in C 9 763
the C 10 763
human C 11 763
embryo C 12 763
) C 13 763
changes C 14 763
in C 15 763
golgi C 16 763
apparatus C 17 763
and C 18 763
mitochondria C 19 763
as C 20 763
well C 21 763
as C 22 763
in C 23 763
the C 24 763
contents C 25 763
of C 26 763
nucleic C 27 763
acids C 28 763
, C 29 763
proteins C 30 763
, C 31 763
polysaccharides C 32 763
, C 33 763
lipids C 34 763
and C 35 763
iron C 36 763
in C 37 763
the C 38 763
hepatic C 39 763
cells C 40 763
of C 41 763
developing C 42 763
human C 43 763
embryo C 44 763
were C 45 763
studied C 46 763
; C 47 763
the C 48 763
data C 49 763
obtained C 50 763
in C 51 763
human C 52 763
embryos C 53 763
and C 54 763
adults C 55 763
were C 56 763
compared C 57 763
. C 58 763
it C 60 763
was C 61 763
found C 62 763
that C 63 763
during C 64 763
the C 65 763
developmental C 66 763
process C 67 763
some C 68 763
changes C 69 763
in C 70 763
localisations C 71 763
of C 72 763
golgi C 73 763
apparatus C 74 763
and C 75 763
iron C 76 763
salts C 77 763
were C 78 763
taking C 79 763
place C 80 763
. C 81 763
the C 83 763
contents C 84 763
of C 85 763
rna C 86 763
and C 87 763
polysaccharides C 88 763
in C 89 763
the C 90 763
cytoplasm C 91 763
increased C 92 763
: C 93 763
mitochondria C 94 763
in C 95 763
the C 96 763
form C 97 763
of C 98 763
granules C 99 763
were C 100 763
revealed C 101 763
throughout C 102 763
the C 103 763
embryonic C 104 763
period C 105 763
and C 106 763
in C 107 763
adults C 108 763
. C 109 763
no C 111 763
essential C 112 763
alterations C 113 763
in C 114 763
the C 115 763
contents C 116 763
of C 117 763
dna C 118 763
, C 119 763
proteins C 120 763
, C 121 763
and C 122 763
lipids C 123 763
were C 124 763
noted C 125 763
. C 126 763
risk C 1 764
of C 2 764
severe C 3 764
jaundice C 4 764
in C 5 764
glucose C 6 764
- C 7 764
6 C 8 764
- C 9 764
phosphate C 10 764
- C 11 764
dehydrogenase C 12 764
deficiency C 13 764
of C 14 764
the C 15 764
newborn C 16 764
the C 17 764
incidence C 18 764
of C 19 764
g C 20 764
. C 21 764
- C 23 764
6 C 24 764
- C 25 764
p C 26 764
. C 27 764
. C 28 764
. C 29 764
deficiency C 31 764
and C 32 764
neonatal C 33 764
jaundice C 34 764
in C 35 764
all C 36 764
male C 37 764
infants C 38 764
born C 39 764
in C 40 764
one C 41 764
year C 42 764
in C 43 764
an C 44 764
area C 45 764
of C 46 764
the C 47 764
island C 48 764
of C 49 764
lesbos C 50 764
was C 51 764
studied C 52 764
. C 53 764
of C 55 764
634 C 56 764
infants C 57 764
tested C 58 764
, C 59 764
29 C 60 764
( C 61 764
4 C 62 764
. C 63 764
. C 64 764
% C 65 764
) C 66 764
were C 67 764
found C 68 764
to C 69 764
be C 70 764
g C 71 764
. C 72 764
- C 74 764
6 C 75 764
- C 76 764
p C 77 764
. C 78 764
. C 79 764
. C 80 764
deficient C 82 764
. C 83 764
hyperbilirubinaemia C 85 764
of C 86 764
16 C 87 764
mg C 88 764
. C 89 764
per C 91 764
100 C 92 764
ml C 93 764
. C 94 764
or C 96 764
over C 97 764
was C 98 764
observed C 99 764
in C 100 764
34 C 101 764
% C 102 764
of C 103 764
g C 104 764
. C 105 764
- C 107 764
6 C 108 764
- C 109 764
p C 110 764
. C 111 764
. C 112 764
. C 113 764
- C 115 764
deficient C 116 764
newborn C 117 764
males C 118 764
and C 119 764
in C 120 764
9 C 121 764
. C 122 764
. C 123 764
% C 124 764
of C 125 764
those C 126 764
with C 127 764
normal C 128 764
enzyme C 129 764
activity C 130 764
- C 131 764
- C 132 764
in C 133 764
more C 134 764
than C 135 764
half C 136 764
of C 137 764
them C 138 764
in C 139 764
the C 140 764
absence C 141 764
of C 142 764
incompatibility C 143 764
or C 144 764
prematurity C 145 764
. C 146 764
this C 148 764
is C 149 764
the C 150 764
first C 151 764
time C 152 764
that C 153 764
such C 154 764
a C 155 764
high C 156 764
incidence C 157 764
of C 158 764
severe C 159 764
neonatal C 160 764
jaundice C 161 764
has C 162 764
been C 163 764
reported C 164 764
in C 165 764
both C 166 764
a C 167 764
g C 168 764
. C 169 764
- C 171 764
6 C 172 764
- C 173 764
p C 174 764
. C 175 764
. C 176 764
. C 177 764
- C 179 764
deficient C 180 764
and C 181 764
a C 182 764
g C 183 764
. C 184 764
- C 186 764
6 C 187 764
- C 188 764
p C 189 764
. C 190 764
. C 191 764
. C 192 764
- C 194 764
normal C 195 764
group C 196 764
. C 197 764
it C 199 764
is C 200 764
postulated C 201 764
that C 202 764
in C 203 764
the C 204 764
population C 205 764
of C 206 764
lesbos C 207 764
a C 208 764
second C 209 764
factor C 210 764
increases C 211 764
the C 212 764
incidence C 213 764
of C 214 764
neonatal C 215 764
jaundice C 216 764
, C 217 764
especially C 218 764
when C 219 764
this C 220 764
factor C 221 764
is C 222 764
combined C 223 764
with C 224 764
g C 225 764
. C 226 764
- C 228 764
6 C 229 764
- C 230 764
p C 231 764
. C 232 764
. C 233 764
. C 234 764
deficiency C 236 764
. C 237 764
studies C 1 765
of C 2 765
b C 3 765
- C 4 765
glucuronidase C 5 765
acti C 6 765
- C 7 765
vity C 8 765
in C 9 765
bile C 10 765
and C 11 765
liver C 12 765
of C 13 765
devel C 14 765
- C 15 765
oping C 16 765
chick C 17 765
embryos C 18 765
and C 19 765
chicks C 20 765
in C 21 765
search C 22 765
for C 23 765
the C 24 765
reason C 25 765
of C 26 765
the C 27 765
occur C 28 765
- C 29 765
rence C 30 765
of C 31 765
unconjugated C 32 765
bilirubin C 33 765
and C 34 765
biliverdin C 35 765
in C 36 765
chick C 37 765
- C 38 765
embryo C 39 765
and C 40 765
in C 41 765
chick C 42 765
bile C 43 765
the C 44 765
possibility C 45 765
of C 46 765
a C 47 765
b C 48 765
- C 49 765
glucuronidase C 50 765
function C 51 765
must C 52 765
be C 53 765
taken C 54 765
into C 55 765
serious C 56 765
con C 57 765
- C 58 765
sideration C 59 765
. C 60 765
jaundice C 1 766
in C 2 766
infancy C 3 766
most C 4 766
causes C 5 766
of C 6 766
jaundice C 7 766
in C 8 766
infancy C 9 766
are C 10 766
discussed C 11 766
. C 12 766
the C 14 766
empha C 15 766
- C 16 766
sis C 17 766
has C 18 766
been C 19 766
on C 20 766
those C 21 766
syndromes C 22 766
solely C 23 766
or C 24 766
usually C 25 766
encountered C 26 766
in C 27 766
the C 28 766
neonate C 29 766
and C 30 766
infant C 31 766
. C 32 766
absence C 1 767
of C 2 767
the C 3 767
cystic C 4 767
duct C 5 767
a C 6 767
case C 7 767
of C 8 767
congenital C 9 767
absence C 10 767
of C 11 767
the C 12 767
cystic C 13 767
duct C 14 767
is C 15 767
described C 16 767
, C 17 767
the C 18 767
18 C 19 767
th C 20 767
reported C 21 767
case C 22 767
in C 23 767
the C 24 767
literature C 25 767
. C 26 767
the C 28 767
embryogenetic C 29 767
basis C 30 767
of C 31 767
anomalies C 32 767
of C 33 767
the C 34 767
extrahepatic C 35 767
biliary C 36 767
tree C 37 767
is C 38 767
discussed C 39 767
. C 40 767
methods C 42 767
of C 43 767
early C 44 767
operative C 45 767
recognition C 46 767
and C 47 767
surgical C 48 767
management C 49 767
of C 50 767
the C 51 767
anomaly C 52 767
are C 53 767
suggested C 54 767
. C 55 767
familial C 1 768
extrahepatic C 2 768
biliary C 3 768
atresia C 4 768
a C 5 768
fifth C 6 768
family C 7 768
with C 8 768
familial C 9 768
congenital C 10 768
extrahepatic C 11 768
biliary C 12 768
is C 13 768
described C 14 768
. C 15 768
clinically C 17 768
and C 18 768
pathologically C 19 768
familial C 20 768
and C 21 768
nonfamilial C 22 768
biliary C 23 768
atresia C 24 768
are C 25 768
similar C 26 768
except C 27 768
for C 28 768
a C 29 768
predominance C 30 768
of C 31 768
males C 32 768
in C 33 768
the C 34 768
familial C 35 768
condition C 36 768
. C 37 768
the C 39 768
sex C 40 768
incidence C 41 768
and C 42 768
association C 43 768
of C 44 768
other C 45 768
congenital C 46 768
anomalies C 47 768
is C 48 768
discussed C 49 768
in C 50 768
relation C 51 768
to C 52 768
a C 53 768
possible C 54 768
etiology C 55 768
. C 56 768
further C 58 768
in C 59 768
- C 60 768
formation C 61 768
must C 62 768
be C 63 768
correlated C 64 768
and C 65 768
new C 66 768
facts C 67 768
uncovered C 68 768
before C 69 768
the C 70 768
nature C 71 768
of C 72 768
this C 73 768
syn C 74 768
- C 75 768
drome C 76 768
will C 77 768
be C 78 768
known C 79 768
. C 80 768
linfangiografia C 1 769
no C 2 769
estudo C 3 769
da C 4 769
filariase C 5 769
linfatica C 6 769
in C 7 769
the C 8 769
first C 9 769
part C 10 769
of C 11 769
the C 12 769
present C 13 769
paper C 14 769
a C 15 769
study C 16 769
is C 17 769
presented C 18 769
of C 19 769
the C 20 769
lymphangiogram C 21 769
of C 22 769
the C 23 769
normal C 24 769
african C 25 769
; C 26 769
the C 27 769
author C 28 769
has C 29 769
noticed C 30 769
that C 31 769
it C 32 769
is C 33 769
coincident C 34 769
with C 35 769
the C 36 769
one C 37 769
of C 38 769
the C 39 769
white C 40 769
indi C 41 769
- C 42 769
vidual C 43 769
. C 44 769
the C 46 769
second C 47 769
part C 48 769
includes C 49 769
the C 50 769
lymphangiographic C 51 769
examina C 52 769
- C 53 769
tion C 54 769
and C 55 769
the C 56 769
observation C 57 769
of C 58 769
lymph C 59 769
circulation C 60 769
( C 61 769
via C 62 769
risa C 63 769
) C 64 769
during C 65 769
the C 66 769
several C 67 769
stages C 68 769
of C 69 769
lymphatic C 70 769
filariasis C 71 769
. C 72 769
even C 74 769
during C 75 769
the C 76 769
asymptomatic C 77 769
stage C 78 769
, C 79 769
lymphangiography C 80 769
shows C 81 769
ganglial C 82 769
hypertrophy C 83 769
with C 84 769
a C 85 769
slight C 86 769
fibrosis C 87 769
and C 88 769
occa C 89 769
- C 90 769
sional C 91 769
discreet C 92 769
alterations C 93 769
of C 94 769
the C 95 769
lymphatic C 96 769
trunks C 97 769
. C 98 769
in C 100 769
the C 101 769
symptomatic C 102 769
stage C 103 769
, C 104 769
the C 105 769
lymphangiographic C 106 769
aspects C 107 769
vary C 108 769
according C 109 769
to C 110 769
the C 111 769
disease C 112 769
' C 113 769
s C 114 769
different C 115 769
stages C 116 769
and C 117 769
there C 118 769
is C 119 769
not C 120 769
always C 121 769
a C 122 769
relationship C 123 769
between C 124 769
the C 125 769
duration C 126 769
period C 127 769
of C 128 769
the C 129 769
symptoms C 130 769
and C 131 769
the C 132 769
changes C 133 769
observed C 134 769
. C 135 769
in C 137 769
lymphangites C 138 769
, C 139 769
there C 140 769
are C 141 769
frequent C 142 769
alterations C 143 769
of C 144 769
the C 145 769
lymphatic C 146 769
trunks C 147 769
, C 148 769
i C 149 769
. C 150 769
. C 151 769
. C 152 769
, C 154 769
increase C 155 769
in C 156 769
caliber C 157 769
, C 158 769
extensive C 159 769
and C 160 769
seg C 161 769
- C 162 769
mentary C 163 769
dilatations C 164 769
, C 165 769
numerical C 166 769
decrease C 167 769
with C 168 769
visualization C 169 769
of C 170 769
anastomoses C 171 769
and C 172 769
higher C 173 769
permeability C 174 769
. C 175 769
circulatory C 177 769
trouble C 178 769
evi C 179 769
- C 180 769
dences C 181 769
itself C 182 769
not C 183 769
only C 184 769
by C 185 769
a C 186 769
decrease C 187 769
in C 188 769
the C 189 769
rate C 190 769
of C 191 769
the C 192 769
lymph C 193 769
flow C 194 769
, C 195 769
but C 196 769
also C 197 769
by C 198 769
a C 199 769
very C 200 769
marked C 201 769
ganglial C 202 769
retention C 203 769
. C 204 769
in C 206 769
adenites C 207 769
, C 208 769
in C 209 769
spite C 210 769
of C 211 769
the C 212 769
marked C 213 769
ganglial C 214 769
hypertrophy C 215 769
due C 216 769
to C 217 769
intense C 218 769
sclerosis C 219 769
, C 220 769
there C 221 769
may C 222 769
be C 223 769
no C 224 769
considerable C 225 769
altera C 226 769
- C 227 769
tions C 228 769
in C 229 769
the C 230 769
lymphatics C 231 769
, C 232 769
but C 233 769
risa C 234 769
already C 235 769
shows C 236 769
clear C 237 769
circula C 238 769
- C 239 769
tion C 240 769
troubles C 241 769
leading C 242 769
to C 243 769
lymphatic C 244 769
stasis C 245 769
. C 246 769
in C 248 769
adenolymphoceles C 249 769
, C 250 769
the C 251 769
obstruction C 252 769
at C 253 769
the C 254 769
primitive C 255 769
- C 256 769
iliac C 257 769
level C 258 769
causes C 259 769
the C 260 769
lymph C 261 769
flow C 262 769
to C 263 769
deviate C 264 769
through C 265 769
the C 266 769
pre C 267 769
- C 268 769
sacral C 269 769
anastomoses C 270 769
and C 271 769
reflux C 272 769
to C 273 769
the C 274 769
inguinal C 275 769
glands C 276 769
, C 277 769
thus C 278 769
causing C 279 769
their C 280 769
dilatation C 281 769
and C 282 769
the C 283 769
formation C 284 769
of C 285 769
varicosities C 286 769
in C 287 769
the C 288 769
affe C 289 769
- C 290 769
rent C 291 769
lymphatics C 292 769
. C 293 769
in C 295 769
lymphedemas C 296 769
, C 297 769
our C 298 769
lymphangiographic C 299 769
results C 300 769
together C 301 769
with C 302 769
risa C 303 769
' C 304 769
s C 305 769
allow C 306 769
us C 307 769
to C 308 769
assume C 309 769
that C 310 769
the C 311 769
pathogeny C 312 769
is C 313 769
chiefly C 314 769
influenced C 315 769
by C 316 769
three C 317 769
factors C 318 769
: C 319 769
lymphatic C 320 769
obstruction C 321 769
due C 322 769
to C 323 769
lym C 324 769
- C 325 769
phangitis C 326 769
, C 327 769
insufficiency C 328 769
of C 329 769
the C 330 769
collateral C 331 769
ducts C 332 769
, C 333 769
and C 334 769
ganglial C 335 769
sclerosis C 336 769
. C 337 769
adjuvant C 1 770
chemotherapy C 2 770
in C 3 770
cancer C 4 770
of C 5 770
the C 6 770
large C 7 770
bowel C 8 770
the C 9 770
completeness C 10 770
of C 11 770
reporting C 12 770
, C 13 770
the C 14 770
avail C 15 770
- C 16 770
ability C 17 770
of C 18 770
continuous C 19 770
statistical C 20 770
analysis C 21 770
to C 22 770
warn C 23 770
of C 24 770
adverse C 25 770
effects C 26 770
, C 27 770
and C 28 770
the C 29 770
accumulation C 30 770
of C 31 770
300 C 32 770
cases C 33 770
a C 34 770
year C 35 770
have C 36 770
demonstrated C 37 770
that C 38 770
this C 39 770
cooperative C 40 770
study C 41 770
group C 42 770
can C 43 770
provide C 44 770
a C 45 770
rela C 46 770
- C 47 770
tively C 48 770
quick C 49 770
assessment C 50 770
of C 51 770
a C 52 770
new C 53 770
approach C 54 770
to C 55 770
treatment C 56 770
of C 57 770
cancer C 58 770
of C 59 770
the C 60 770
large C 61 770
bowel C 62 770
. C 63 770
it C 65 770
is C 66 770
hoped C 67 770
that C 68 770
a C 69 770
study C 70 770
begun C 71 770
in C 72 770
january C 73 770
, C 74 770
1962 C 75 770
, C 76 770
on C 77 770
the C 78 770
use C 79 770
of C 80 770
5 C 81 770
- C 82 770
fluorodeoxyuridine C 83 770
as C 84 770
an C 85 770
adjuvant C 86 770
to C 87 770
adequate C 88 770
excisional C 89 770
surgery C 90 770
may C 91 770
demon C 92 770
- C 93 770
strate C 94 770
that C 95 770
, C 96 770
with C 97 770
a C 98 770
drug C 99 770
known C 100 770
to C 101 770
produce C 102 770
objective C 103 770
remissions C 104 770
in C 105 770
20 C 106 770
per C 107 770
cent C 108 770
of C 109 770
a C 110 770
group C 111 770
of C 112 770
unresectable C 113 770
cases C 114 770
of C 115 770
colon C 116 770
carcinoma C 117 770
the C 118 770
five C 119 770
year C 120 770
survival C 121 770
rate C 122 770
in C 123 770
curative C 124 770
resections C 125 770
may C 126 770
be C 127 770
improved C 128 770
. C 129 770
cancer C 1 771
chemotherapy C 2 771
by C 3 771
prolonged C 4 771
arterial C 5 771
infusion C 6 771
our C 7 771
current C 8 771
experience C 9 771
is C 10 771
reported C 11 771
with C 12 771
136 C 13 771
patients C 14 771
treated C 15 771
by C 16 771
prolonged C 17 771
arterial C 18 771
infusion C 19 771
chemotherapy C 20 771
. C 21 771
the C 23 771
patients C 24 771
pre C 25 771
- C 26 771
sented C 27 771
a C 28 771
variety C 29 771
of C 30 771
far C 31 771
advanced C 32 771
cancers C 33 771
un C 34 771
- C 35 771
suitable C 36 771
for C 37 771
conventional C 38 771
surgical C 39 771
or C 40 771
roent C 41 771
- C 42 771
gen C 43 771
therapy C 44 771
. C 45 771
antimetabolite C 47 771
solution C 48 771
, C 49 771
either C 50 771
methotrexate C 51 771
or C 52 771
a C 53 771
fluorinated C 54 771
pyrimidine C 55 771
, C 56 771
was C 57 771
injected C 58 771
continuously C 59 771
through C 60 771
a C 61 771
small C 62 771
plastic C 63 771
catheter C 64 771
into C 65 771
the C 66 771
unobstructed C 67 771
artery C 68 771
to C 69 771
provide C 70 771
a C 71 771
high C 72 771
regional C 73 771
drug C 74 771
concentration C 75 771
for C 76 771
days C 77 771
to C 78 771
weeks C 79 771
. C 80 771
the C 82 771
patients C 83 771
have C 84 771
received C 85 771
drug C 86 771
infusion C 87 771
for C 88 771
up C 89 771
to C 90 771
45 C 91 771
days C 92 771
. C 93 771
their C 95 771
course C 96 771
has C 97 771
been C 98 771
followed C 99 771
for C 100 771
up C 101 771
to C 102 771
37 C 103 771
months C 104 771
after C 105 771
treatment C 106 771
. C 107 771
methotrexate C 109 771
with C 110 771
antidote C 111 771
therapy C 112 771
by C 113 771
systemic C 114 771
administration C 115 771
of C 116 771
citrovorum C 117 771
fac C 118 771
- C 119 771
tor C 120 771
was C 121 771
used C 122 771
preferentially C 123 771
in C 124 771
most C 125 771
patients C 126 771
. C 127 771
a C 129 771
fluorinated C 130 771
pyrimidine C 131 771
, C 132 771
most C 133 771
commonly C 134 771
, C 135 771
5 C 136 771
- C 137 771
fluoro C 138 771
- C 139 771
2 C 140 771
' C 141 771
- C 142 771
deoxyuridine C 143 771
, C 144 771
was C 145 771
preferred C 146 771
for C 147 771
hepatic C 148 771
artery C 149 771
infusion C 150 771
of C 151 771
liver C 152 771
metastases C 153 771
. C 154 771
the C 1 772
montgomery C 2 772
tube C 3 772
to C 4 772
palliate C 5 772
hypopharyngeal C 6 772
cancer C 7 772
three C 8 772
cases C 9 772
of C 10 772
advanced C 11 772
, C 12 772
incurable C 13 772
cancer C 14 772
of C 15 772
the C 16 772
hypopharynx C 17 772
have C 18 772
been C 19 772
presented C 20 772
. C 21 772
in C 23 772
each C 24 772
instance C 25 772
, C 26 772
the C 27 772
simple C 28 772
procedure C 29 772
of C 30 772
insert C 31 772
- C 32 772
ing C 33 772
an C 34 772
available C 35 772
prothesis C 36 772
served C 37 772
as C 38 772
an C 39 772
effective C 40 772
palliation C 41 772
for C 42 772
an C 43 772
otherwise C 44 772
difficult C 45 772
or C 46 772
hopeless C 47 772
situation C 48 772
. C 49 772
adjuvant C 1 773
cancer C 2 773
chemotherapy C 3 773
development C 4 773
of C 5 773
a C 6 773
dosage C 7 773
schedule C 8 773
for C 9 773
adjuvant C 10 773
cancer C 11 773
chemotherapy C 12 773
in C 13 773
surgical C 14 773
cases C 15 773
an C 16 773
account C 17 773
is C 18 773
given C 19 773
of C 20 773
the C 21 773
development C 22 773
of C 23 773
a C 24 773
dosage C 25 773
schedule C 26 773
for C 27 773
adjuvant C 28 773
can C 29 773
- C 30 773
cer C 31 773
chemotherapy C 32 773
for C 33 773
surgical C 34 773
patients C 35 773
. C 36 773
this C 38 773
treatment C 39 773
was C 40 773
administered C 41 773
for C 42 773
two C 43 773
purposes C 44 773
: C 45 773
as C 46 773
an C 47 773
adjuvant C 48 773
to C 49 773
radical C 50 773
surgery C 51 773
to C 52 773
reduce C 53 773
the C 54 773
risk C 55 773
of C 56 773
blood C 57 773
- C 58 773
borne C 59 773
metastases C 60 773
. C 61 773
as C 63 773
a C 64 773
palliative C 65 773
measure C 66 773
for C 67 773
non C 68 773
- C 69 773
ra C 70 773
- C 71 773
dically C 72 773
operated C 73 773
and C 74 773
inoperable C 75 773
pa C 76 773
- C 77 773
tients C 78 773
. C 79 773
for C 81 773
these C 82 773
purposes C 83 773
3 C 84 773
dosage C 85 773
levels C 86 773
were C 87 773
fixed C 88 773
: C 89 773
a C 90 773
maximum C 91 773
tolerated C 92 773
dose C 93 773
for C 94 773
ad C 95 773
- C 96 773
juvant C 97 773
therapy C 98 773
. C 99 773
a C 101 773
maximum C 102 773
tolerated C 103 773
dose C 104 773
for C 105 773
pa C 106 773
- C 107 773
renteral C 108 773
palliative C 109 773
therapy C 110 773
. C 111 773
a C 113 773
maximum C 114 773
tolerated C 115 773
dose C 116 773
for C 117 773
oral C 118 773
palliative C 119 773
therapy C 120 773
. C 121 773
for C 123 773
this C 124 773
treatment C 125 773
the C 126 773
authors C 127 773
used C 128 773
2 C 129 773
antimitotics C 130 773
, C 131 773
sp C 132 773
- C 133 773
i C 134 773
and C 135 773
sp C 136 773
- C 137 773
g C 138 773
, C 139 773
both C 140 773
of C 141 773
which C 142 773
are C 143 773
podophyllin C 144 773
derivatives C 145 773
. C 146 773
surgical C 1 774
palliation C 2 774
for C 3 774
lung C 4 774
cancer C 5 774
the C 6 774
results C 7 774
of C 8 774
resecting C 9 774
incurable C 10 774
lung C 11 774
cancer C 12 774
in C 13 774
an C 14 774
effort C 15 774
to C 16 774
improve C 17 774
the C 18 774
terminal C 19 774
course C 20 774
of C 21 774
a C 22 774
small C 23 774
number C 24 774
of C 25 774
patients C 26 774
are C 27 774
briefly C 28 774
presented C 29 774
. C 30 774
this C 32 774
is C 33 774
not C 34 774
a C 35 774
comparative C 36 774
study C 37 774
and C 38 774
no C 39 774
in C 40 774
- C 41 774
ferences C 42 774
or C 43 774
conclusions C 44 774
are C 45 774
justified C 46 774
regarding C 47 774
the C 48 774
choice C 49 774
of C 50 774
this C 51 774
form C 52 774
of C 53 774
therapy C 54 774
as C 55 774
palliation C 56 774
in C 57 774
preference C 58 774
to C 59 774
other C 60 774
forms C 61 774
of C 62 774
palliative C 63 774
ther C 64 774
- C 65 774
apy C 66 774
; C 67 774
however C 68 774
we C 69 774
do C 70 774
believe C 71 774
that C 72 774
the C 73 774
terminal C 74 774
course C 75 774
of C 76 774
the C 77 774
patient C 78 774
with C 79 774
lung C 80 774
cancer C 81 774
is C 82 774
bene C 83 774
- C 84 774
ficially C 85 774
effected C 86 774
by C 87 774
removal C 88 774
of C 89 774
the C 90 774
primary C 91 774
tumor C 92 774
whenever C 93 774
this C 94 774
is C 95 774
technically C 96 774
feasible C 97 774
. C 98 774
management C 1 775
of C 2 775
advanced C 3 775
endometrial C 4 775
adenocarcinoma C 5 775
with C 6 775
medroxyprogesterone C 7 775
acetate C 8 775
a C 9 775
basis C 10 775
for C 11 775
progestin C 12 775
therapy C 13 775
for C 14 775
patients C 15 775
with C 16 775
advanced C 17 775
endometrial C 18 775
adenocarcinoma C 19 775
is C 20 775
presented C 21 775
. C 22 775
the C 24 775
criteria C 25 775
for C 26 775
selection C 27 775
of C 28 775
patients C 29 775
for C 30 775
hormone C 31 775
therapy C 32 775
and C 33 775
the C 34 775
sched C 35 775
- C 36 775
ule C 37 775
of C 38 775
administration C 39 775
of C 40 775
medroxyprogester C 41 775
- C 42 775
one C 43 775
( C 44 775
provera C 45 775
) C 46 775
is C 47 775
discussed C 48 775
. C 49 775
evaluation C 51 775
of C 52 775
patients C 53 775
for C 54 775
objective C 55 775
changes C 56 775
only C 57 775
, C 58 775
i C 59 775
. C 60 775
. C 61 775
. C 62 775
, C 64 775
by C 65 775
visual C 66 775
, C 67 775
palpable C 68 775
, C 69 775
histologic C 70 775
, C 71 775
or C 72 775
roentgeno C 73 775
- C 74 775
logic C 75 775
means C 76 775
, C 77 775
revealed C 78 775
complete C 79 775
or C 80 775
partial C 81 775
remission C 82 775
with C 83 775
significant C 84 775
palliation C 85 775
in C 86 775
8 C 87 775
of C 88 775
20 C 89 775
patients C 90 775
( C 91 775
40 C 92 775
per C 93 775
cent C 94 775
) C 95 775
. C 96 775
response C 98 775
to C 99 775
me C 100 775
- C 101 775
droxyprogesterone C 102 775
therapy C 103 775
is C 104 775
apparently C 105 775
re C 106 775
- C 107 775
lated C 108 775
to C 109 775
degree C 110 775
of C 111 775
differentiation C 112 775
of C 113 775
the C 114 775
pri C 115 775
- C 116 775
mary C 117 775
neoplasm C 118 775
, C 119 775
the C 120 775
well C 121 775
- C 122 775
differentiated C 123 775
le C 124 775
- C 125 775
sions C 126 775
being C 127 775
more C 128 775
responsive C 129 775
. C 130 775
documentation C 132 775
of C 133 775
tumor C 134 775
effect C 135 775
by C 136 775
serial C 137 775
biopsies C 138 775
during C 139 775
treatment C 140 775
provides C 141 775
an C 142 775
index C 143 775
to C 144 775
the C 145 775
histologic C 146 775
changes C 147 775
this C 148 775
progestin C 149 775
produces C 150 775
in C 151 775
suscep C 152 775
- C 153 775
tible C 154 775
cases C 155 775
. C 156 775
the C 158 775
effects C 159 775
of C 160 775
therapy C 161 775
upon C 162 775
serial C 163 775
urinary C 164 775
hormone C 165 775
excretion C 166 775
rates C 167 775
is C 168 775
documented C 169 775
in C 170 775
several C 171 775
patients C 172 775
. C 173 775
on C 175 775
the C 176 775
basis C 177 775
of C 178 775
our C 179 775
experience C 180 775
, C 181 775
the C 182 775
treat C 183 775
- C 184 775
ment C 185 775
of C 186 775
patients C 187 775
with C 188 775
advanced C 189 775
endometrial C 190 775
adenocarcinoma C 191 775
with C 192 775
the C 193 775
potent C 194 775
progestin C 195 775
medroxyprogesterone C 196 775
seems C 197 775
justified C 198 775
. C 199 775
chemotherapy C 1 776
of C 2 776
breast C 3 776
cancer C 4 776
the C 5 776
majority C 6 776
of C 7 776
cancer C 8 776
patients C 9 776
who C 10 776
are C 11 776
referred C 12 776
for C 13 776
chemotherapy C 14 776
are C 15 776
in C 16 776
far C 17 776
advanced C 18 776
stages C 19 776
of C 20 776
the C 21 776
disease C 22 776
. C 23 776
the C 25 776
difficulty C 26 776
in C 27 776
deliver C 28 776
- C 29 776
ing C 30 776
an C 31 776
effective C 32 776
dose C 33 776
of C 34 776
an C 35 776
oncolytic C 36 776
agent C 37 776
to C 38 776
the C 39 776
involved C 40 776
areas C 41 776
may C 42 776
limit C 43 776
the C 44 776
results C 45 776
of C 46 776
treatment C 47 776
unless C 48 776
the C 49 776
patient C 50 776
' C 51 776
s C 52 776
tumor C 53 776
is C 54 776
an C 55 776
un C 56 776
- C 57 776
usually C 58 776
responsive C 59 776
one C 60 776
. C 61 776
the C 63 776
variability C 64 776
in C 65 776
re C 66 776
- C 67 776
sponse C 68 776
between C 69 776
apparently C 70 776
similar C 71 776
cases C 72 776
of C 73 776
cancer C 74 776
of C 75 776
the C 76 776
same C 77 776
cell C 78 776
type C 79 776
has C 80 776
become C 81 776
in C 82 776
- C 83 776
creasingly C 84 776
evident C 85 776
, C 86 776
and C 87 776
is C 88 776
as C 89 776
puzzling C 90 776
as C 91 776
the C 92 776
fact C 93 776
that C 94 776
20 C 95 776
per C 96 776
cent C 97 776
of C 98 776
patients C 99 776
with C 100 776
breast C 101 776
cancer C 102 776
will C 103 776
live C 104 776
5 C 105 776
years C 106 776
with C 107 776
no C 108 776
treatment C 109 776
. C 110 776
the C 112 776
decisions C 113 776
as C 114 776
to C 115 776
the C 116 776
choice C 117 776
between C 118 776
chemother C 119 776
- C 120 776
apy C 121 776
and C 122 776
hormone C 123 776
therapy C 124 776
, C 125 776
as C 126 776
well C 127 776
as C 128 776
to C 129 776
the C 130 776
choice C 131 776
of C 132 776
the C 133 776
chemotherapeutic C 134 776
agent C 135 776
to C 136 776
be C 137 776
employed C 138 776
, C 139 776
may C 140 776
be C 141 776
difficult C 142 776
. C 143 776
as C 145 776
experience C 146 776
increases C 147 776
, C 148 776
the C 149 776
usefulness C 150 776
of C 151 776
chemotherapy C 152 776
in C 153 776
the C 154 776
treatment C 155 776
of C 156 776
cancer C 157 776
is C 158 776
becoming C 159 776
increasingly C 160 776
apparent C 161 776
. C 162 776
it C 164 776
also C 165 776
has C 166 776
be C 167 776
- C 168 776
come C 169 776
apparent C 170 776
that C 171 776
chemotherapy C 172 776
cannot C 173 776
be C 174 776
regarded C 175 776
as C 176 776
a C 177 776
curative C 178 776
procedure C 179 776
in C 180 776
advanced C 181 776
cancer C 182 776
even C 183 776
though C 184 776
an C 185 776
occasional C 186 776
patient C 187 776
ap C 188 776
- C 189 776
pears C 190 776
to C 191 776
have C 192 776
been C 193 776
cured C 194 776
. C 195 776
however C 197 776
, C 198 776
the C 199 776
value C 200 776
of C 201 776
the C 202 776
oncolytic C 203 776
agents C 204 776
in C 205 776
prolonging C 206 776
useful C 207 776
survival C 208 776
time C 209 776
, C 210 776
ameliorating C 211 776
many C 212 776
of C 213 776
the C 214 776
dis C 215 776
- C 216 776
tressing C 217 776
symptoms C 218 776
associated C 219 776
with C 220 776
cancer C 221 776
, C 222 776
and C 223 776
providing C 224 776
the C 225 776
physician C 226 776
with C 227 776
an C 228 776
extra C 229 776
tool C 230 776
for C 231 776
a C 232 776
positive C 233 776
program C 234 776
in C 235 776
the C 236 776
care C 237 776
of C 238 776
the C 239 776
cancer C 240 776
patient C 241 776
is C 242 776
now C 243 776
established C 244 776
. C 245 776
clinical C 1 777
experience C 2 777
with C 3 777
palliation C 4 777
of C 5 777
metastatic C 6 777
adenocarcinoma C 7 777
with C 8 777
5 C 9 777
- C 10 777
fluorouracil C 11 777
chemotherapy C 12 777
chemotherapy C 13 777
of C 14 777
solid C 15 777
tumors C 16 777
is C 17 777
becoming C 18 777
a C 19 777
more C 20 777
and C 21 777
more C 22 777
helpful C 23 777
therapeutic C 24 777
tool C 25 777
. C 26 777
it C 28 777
is C 29 777
probable C 30 777
that C 31 777
within C 32 777
a C 33 777
few C 34 777
years C 35 777
chemother C 36 777
- C 37 777
apy C 38 777
will C 39 777
become C 40 777
firmly C 41 777
established C 42 777
as C 43 777
an C 44 777
ad C 45 777
- C 46 777
junct C 47 777
to C 48 777
the C 49 777
primary C 50 777
treatment C 51 777
of C 52 777
solid C 53 777
tumors C 54 777
. C 55 777
perhaps C 57 777
someday C 58 777
a C 59 777
cancerocidal C 60 777
chemical C 61 777
will C 62 777
be C 63 777
devised C 64 777
that C 65 777
can C 66 777
actually C 67 777
act C 68 777
as C 69 777
antibiotics C 70 777
do C 71 777
on C 72 777
bacteria C 73 777
. C 74 777
for C 76 777
this C 77 777
reason C 78 777
it C 79 777
is C 80 777
important C 81 777
for C 82 777
all C 83 777
surgeons C 84 777
interested C 85 777
in C 86 777
the C 87 777
treatment C 88 777
of C 89 777
cancer C 90 777
to C 91 777
try C 92 777
to C 93 777
keep C 94 777
abreast C 95 777
of C 96 777
the C 97 777
recent C 98 777
ad C 99 777
- C 100 777
vances C 101 777
in C 102 777
the C 103 777
field C 104 777
of C 105 777
chemotherapy C 106 777
. C 107 777
surgeons C 109 777
should C 110 777
also C 111 777
begin C 112 777
to C 113 777
use C 114 777
some C 115 777
of C 116 777
the C 117 777
technics C 118 777
for C 119 777
palliation C 120 777
of C 121 777
incurable C 122 777
patients C 123 777
so C 124 777
that C 125 777
when C 126 777
these C 127 777
drugs C 128 777
are C 129 777
added C 130 777
to C 131 777
the C 132 777
armamentarium C 133 777
of C 134 777
primary C 135 777
treatment C 136 777
of C 137 777
cancer C 138 777
, C 139 777
they C 140 777
will C 141 777
be C 142 777
familiar C 143 777
with C 144 777
the C 145 777
various C 146 777
technics C 147 777
and C 148 777
the C 149 777
mode C 150 777
of C 151 777
actions C 152 777
of C 153 777
the C 154 777
drugs C 155 777
. C 156 777
5 C 158 777
- C 159 777
fluorouracil C 160 777
( C 161 777
5 C 162 777
- C 163 777
fu C 164 777
) C 165 777
has C 166 777
had C 167 777
extensive C 168 777
clin C 169 777
- C 170 777
ical C 171 777
use C 172 777
and C 173 777
has C 174 777
produced C 175 777
significant C 176 777
palliation C 177 777
in C 178 777
breast C 179 777
and C 180 777
colon C 181 777
cancers C 182 777
with C 183 777
about C 184 777
a C 185 777
third C 186 777
of C 187 777
these C 188 777
patients C 189 777
receiving C 190 777
palliation C 191 777
for C 192 777
five C 193 777
to C 194 777
six C 195 777
months C 196 777
. C 197 777
pelvic C 1 778
perfusion C 2 778
and C 3 778
carcinoma C 4 778
of C 5 778
the C 6 778
rectum C 7 778
a C 8 778
method C 9 778
of C 10 778
regional C 11 778
chemotherapy C 12 778
through C 13 778
isolation C 14 778
of C 15 778
the C 16 778
pelvis C 17 778
has C 18 778
been C 19 778
presented C 20 778
. C 21 778
all C 23 778
of C 24 778
the C 25 778
subjects C 26 778
were C 27 778
near C 28 778
the C 29 778
terminal C 30 778
stage C 31 778
at C 32 778
the C 33 778
time C 34 778
of C 35 778
perfusion C 36 778
. C 37 778
the C 39 778
survival C 40 778
time C 41 778
and C 42 778
degree C 43 778
of C 44 778
palliation C 45 778
have C 46 778
been C 47 778
en C 48 778
- C 49 778
couraging C 50 778
. C 51 778
carcinoma C 1 779
of C 2 779
the C 3 779
esophagus C 4 779
a C 5 779
survey C 6 779
of C 7 779
fifty C 8 779
- C 9 779
seven C 10 779
patients C 11 779
with C 12 779
cancer C 13 779
of C 14 779
the C 15 779
esophagus C 16 779
occurring C 17 779
over C 18 779
a C 19 779
twenty C 20 779
year C 21 779
period C 22 779
is C 23 779
presented C 24 779
. C 25 779
the C 27 779
presenting C 28 779
complaints C 29 779
of C 30 779
the C 31 779
disease C 32 779
, C 33 779
methods C 34 779
of C 35 779
diagnosis C 36 779
, C 37 779
and C 38 779
char C 39 779
- C 40 779
acteristics C 41 779
of C 42 779
the C 43 779
disease C 44 779
are C 45 779
discussed C 46 779
. C 47 779
three C 49 779
equal C 50 779
treatment C 51 779
groups C 52 779
consisting C 53 779
of C 54 779
no C 55 779
treat C 56 779
- C 57 779
ment C 58 779
, C 59 779
x C 60 779
- C 61 779
ray C 62 779
treatment C 63 779
, C 64 779
and C 65 779
surgical C 66 779
resection C 67 779
were C 68 779
compared C 69 779
and C 70 779
the C 71 779
results C 72 779
were C 73 779
extremely C 74 779
poor C 75 779
. C 76 779
only C 78 779
one C 79 779
patient C 80 779
in C 81 779
all C 82 779
three C 83 779
groups C 84 779
sur C 85 779
- C 86 779
vived C 87 779
longer C 88 779
than C 89 779
two C 90 779
years C 91 779
. C 92 779
it C 94 779
was C 95 779
our C 96 779
con C 97 779
- C 98 779
clusion C 99 779
, C 100 779
supported C 101 779
by C 102 779
the C 103 779
opinion C 104 779
of C 105 779
others C 106 779
, C 107 779
that C 108 779
x C 109 779
- C 110 779
ray C 111 779
therapy C 112 779
gave C 113 779
the C 114 779
best C 115 779
palliation C 116 779
in C 117 779
most C 118 779
cases C 119 779
and C 120 779
that C 121 779
surgical C 122 779
resection C 123 779
for C 124 779
cure C 125 779
should C 126 779
be C 127 779
used C 128 779
in C 129 779
only C 130 779
the C 131 779
most C 132 779
suitable C 133 779
pa C 134 779
- C 135 779
tients C 136 779
. C 137 779
carcinoma C 1 780
of C 2 780
bladder C 3 780
: C 4 780
cobalt C 5 780
therapy C 6 780
from C 7 780
1959 C 8 780
to C 9 780
1962 C 10 780
, C 11 780
202 C 12 780
patients C 13 780
have C 14 780
received C 15 780
radiotherapy C 16 780
for C 17 780
carcinoma C 18 780
of C 19 780
the C 20 780
bladder C 21 780
. C 22 780
radi C 24 780
- C 25 780
cal C 26 780
therapy C 27 780
with C 28 780
cobalt C 29 780
- C 30 780
60 C 31 780
has C 32 780
been C 33 780
done C 34 780
in C 35 780
121 C 36 780
of C 37 780
these C 38 780
cases C 39 780
. C 40 780
these C 42 780
patients C 43 780
received C 44 780
tumor C 45 780
doses C 46 780
in C 47 780
excess C 48 780
of C 49 780
5000 C 50 780
rad C 51 780
in C 52 780
3 C 53 780
weeks C 54 780
. C 55 780
of C 57 780
49 C 58 780
pa C 59 780
- C 60 780
tients C 61 780
followed C 62 780
for C 63 780
2 C 64 780
years C 65 780
after C 66 780
radical C 67 780
treatment C 68 780
, C 69 780
28 C 70 780
are C 71 780
alive C 72 780
. C 73 780
sixteen C 75 780
out C 76 780
of C 77 780
32 C 78 780
patients C 79 780
with C 80 780
stage C 81 780
b C 82 780
2 C 83 780
, C 84 780
c C 85 780
or C 86 780
d C 87 780
tumors C 88 780
are C 89 780
alive C 90 780
; C 91 780
while C 92 780
15 C 93 780
pa C 94 780
- C 95 780
tients C 96 780
survived C 97 780
out C 98 780
of C 99 780
30 C 100 780
with C 101 780
tumors C 102 780
of C 103 780
grades C 104 780
3 C 105 780
and C 106 780
4 C 107 780
( C 108 780
broders C 109 780
' C 110 780
) C 111 780
. C 112 780
four C 114 780
of C 115 780
the C 116 780
28 C 117 780
survivors C 118 780
had C 119 780
cystectomy C 120 780
performed C 121 780
and C 122 780
none C 123 780
showed C 124 780
residual C 125 780
disease C 126 780
in C 127 780
the C 128 780
bladder C 129 780
or C 130 780
lymph C 131 780
nodes C 132 780
. C 133 780
the C 135 780
com C 136 780
- C 137 780
plications C 138 780
of C 139 780
radiotherapy C 140 780
presented C 141 780
were C 142 780
not C 143 780
considered C 144 780
to C 145 780
be C 146 780
excessive C 147 780
. C 148 780
we C 150 780
believe C 151 780
that C 152 780
radiotherapy C 153 780
should C 154 780
be C 155 780
the C 156 780
initial C 157 780
treatment C 158 780
for C 159 780
patients C 160 780
with C 161 780
infiltrative C 162 780
carcinoma C 163 780
of C 164 780
the C 165 780
bladder C 166 780
. C 167 780
the C 169 780
survivals C 170 780
pre C 171 780
- C 172 780
sented C 173 780
at C 174 780
2 C 175 780
years C 176 780
are C 177 780
better C 178 780
than C 179 780
those C 180 780
quoted C 181 780
for C 182 780
radical C 183 780
cystectomy C 184 780
( C 185 780
whitmore C 186 780
and C 187 780
marshall C 188 780
) C 189 780
and C 190 780
useful C 191 780
bladder C 192 780
function C 193 780
is C 194 780
preserved C 195 780
for C 196 780
the C 197 780
majority C 198 780
of C 199 780
survivors C 200 780
. C 201 780
we C 203 780
reserve C 204 780
cystectomy C 205 780
for C 206 780
specific C 207 780
indications C 208 780
. C 209 780
polyposis C 1 781
of C 2 781
colon C 3 781
as C 4 781
seen C 5 781
in C 6 781
private C 7 781
practice C 8 781
familial C 9 781
polyposis C 10 781
of C 11 781
the C 12 781
colon C 13 781
may C 14 781
present C 15 781
itself C 16 781
in C 17 781
a C 18 781
variety C 19 781
of C 20 781
clinical C 21 781
en C 22 781
- C 23 781
tities C 24 781
. C 25 781
from C 27 781
the C 28 781
cases C 29 781
discussed C 30 781
in C 31 781
this C 32 781
paper C 33 781
the C 34 781
following C 35 781
forms C 36 781
may C 37 781
be C 38 781
enu C 39 781
- C 40 781
merated C 41 781
: C 42 781
( C 43 781
1 C 44 781
) C 45 781
an C 46 781
asymptomatic C 47 781
phase C 48 781
with C 49 781
dis C 50 781
- C 51 781
crete C 52 781
polyposis C 53 781
. C 54 781
( C 56 781
2 C 57 781
) C 58 781
a C 59 781
mildly C 60 781
asymptomatic C 61 781
stage C 62 781
with C 63 781
diffuse C 64 781
polyposis C 65 781
. C 66 781
( C 68 781
3 C 69 781
) C 70 781
a C 71 781
premalignant C 72 781
phase C 73 781
with C 74 781
car C 75 781
- C 76 781
cinomas C 77 781
in C 78 781
situ C 79 781
. C 80 781
( C 82 781
4 C 83 781
) C 84 781
grossly C 85 781
malignant C 86 781
phase C 87 781
char C 88 781
- C 89 781
acterized C 90 781
by C 91 781
anemia C 92 781
and C 93 781
carcinomatosis C 94 781
, C 95 781
possibly C 96 781
of C 97 781
multicentric C 98 781
origin C 99 781
. C 100 781
to C 102 781
secure C 103 781
a C 104 781
complete C 105 781
cure C 106 781
it C 107 781
is C 108 781
im C 109 781
- C 110 781
perative C 111 781
that C 112 781
the C 113 781
clinician C 114 781
discover C 115 781
and C 116 781
the C 117 781
surgeon C 118 781
treat C 119 781
the C 120 781
disease C 121 781
in C 122 781
its C 123 781
pre C 124 781
- C 125 781
malignant C 126 781
state C 127 781
. C 128 781
worthwhile C 130 781
palliative C 131 781
results C 132 781
may C 133 781
be C 134 781
obtained C 135 781
by C 136 781
surgery C 137 781
in C 138 781
incurable C 139 781
cases C 140 781
by C 141 781
extensive C 142 781
resection C 143 781
of C 144 781
the C 145 781
primary C 146 781
lesions C 147 781
and C 148 781
subsequent C 149 781
resection C 150 781
of C 151 781
any C 152 781
recurrences C 153 781
or C 154 781
metastasis C 155 781
, C 156 781
whether C 157 781
local C 158 781
or C 159 781
distant C 160 781
by C 161 781
second C 162 781
and C 163 781
third C 164 781
looks C 165 781
is C 166 781
necessary C 167 781
. C 168 781
special C 170 781
emphasis C 171 781
should C 172 781
be C 173 781
paid C 174 781
to C 175 781
the C 176 781
emotional C 177 781
problems C 178 781
of C 179 781
the C 180 781
patients C 181 781
. C 182 781
an C 184 781
encouraging C 185 781
, C 186 781
sympathetic C 187 781
attitude C 188 781
on C 189 781
the C 190 781
part C 191 781
of C 192 781
the C 193 781
surgeon C 194 781
is C 195 781
essential C 196 781
and C 197 781
rewarding C 198 781
. C 199 781
systemic C 1 782
chemotherapy C 2 782
for C 3 782
cns C 4 782
metastases C 5 782
of C 6 782
solid C 7 782
tumors C 8 782
of C 9 782
the C 10 782
13 C 11 782
cases C 12 782
studied C 13 782
, C 14 782
remissions C 15 782
were C 16 782
ob C 17 782
- C 18 782
tained C 19 782
in C 20 782
eight C 21 782
. C 22 782
this C 24 782
62 C 25 782
% C 26 782
remission C 27 782
rate C 28 782
is C 29 782
not C 30 782
significant C 31 782
because C 32 782
of C 33 782
the C 34 782
number C 35 782
of C 36 782
variables C 37 782
present C 38 782
. C 39 782
however C 41 782
, C 42 782
we C 43 782
believe C 44 782
that C 45 782
chemother C 46 782
- C 47 782
apy C 48 782
for C 49 782
this C 50 782
type C 51 782
of C 52 782
patient C 53 782
is C 54 782
indicated C 55 782
, C 56 782
as C 57 782
sup C 58 782
- C 59 782
ported C 60 782
by C 61 782
the C 62 782
reported C 63 782
data C 64 782
. C 65 782
the C 67 782
results C 68 782
suggest C 69 782
that C 70 782
the C 71 782
blood C 72 782
supply C 73 782
to C 74 782
solid C 75 782
tumors C 76 782
is C 77 782
different C 78 782
from C 79 782
that C 80 782
of C 81 782
tumors C 82 782
associated C 83 782
with C 84 782
hematopoi C 85 782
- C 86 782
etic C 87 782
disorders C 88 782
. C 89 782
the C 91 782
latter C 92 782
respond C 93 782
very C 94 782
poorly C 95 782
, C 96 782
if C 97 782
at C 98 782
all C 99 782
, C 100 782
to C 101 782
systemic C 102 782
therapy C 103 782
. C 104 782
although C 106 782
we C 107 782
were C 108 782
not C 109 782
able C 110 782
to C 111 782
measure C 112 782
the C 113 782
central C 114 782
nervous C 115 782
system C 116 782
( C 117 782
cns C 118 782
) C 119 782
lesions C 120 782
exactly C 121 782
, C 122 782
the C 123 782
regression C 124 782
of C 125 782
the C 126 782
cns C 127 782
symptomatology C 128 782
was C 129 782
significant C 130 782
. C 131 782
in C 133 782
pa C 134 782
- C 135 782
tients C 136 782
who C 137 782
had C 138 782
other C 139 782
demonstrable C 140 782
metastatic C 141 782
disease C 142 782
, C 143 782
those C 144 782
lesions C 145 782
also C 146 782
regressed C 147 782
. C 148 782
with C 150 782
this C 151 782
evidence C 152 782
we C 153 782
feel C 154 782
that C 155 782
patients C 156 782
with C 157 782
metastatic C 158 782
cns C 159 782
lesions C 160 782
, C 161 782
even C 162 782
when C 163 782
these C 164 782
have C 165 782
recently C 166 782
resulted C 167 782
in C 168 782
paralysis C 169 782
or C 170 782
seizures C 171 782
, C 172 782
should C 173 782
be C 174 782
con C 175 782
- C 176 782
sidered C 177 782
for C 178 782
systemic C 179 782
chemotherapy C 180 782
. C 181 782
combined C 1 783
5 C 2 783
- C 3 783
fluorouracil C 4 783
and C 5 783
supervoltage C 6 783
radiation C 7 783
therapy C 8 783
in C 9 783
the C 10 783
palliative C 11 783
manage C 12 783
- C 13 783
ment C 14 783
of C 15 783
advanced C 16 783
gastrointestinal C 17 783
cancer C 18 783
: C 19 783
a C 20 783
pilot C 21 783
study C 22 783
malcolm C 23 783
y C 24 783
. C 25 783
colby C 27 783
, C 28 783
margaret C 29 783
a C 30 783
. C 31 783
holbrook C 33 783
5 C 34 783
- C 35 783
fluorouracil C 36 783
in C 37 783
combination C 38 783
with C 39 783
supervoltage C 40 783
radiation C 41 783
therapy C 42 783
was C 43 783
employed C 44 783
in C 45 783
the C 46 783
palliative C 47 783
treatment C 48 783
of C 49 783
44 C 50 783
pa C 51 783
- C 52 783
tients C 53 783
with C 54 783
advanced C 55 783
gastrointestinal C 56 783
carcinoma C 57 783
. C 58 783
a C 60 783
total C 61 783
dose C 62 783
of C 63 783
from C 64 783
40 C 65 783
to C 66 783
50 C 67 783
mg C 68 783
. C 69 783
per C 71 783
kilogram C 72 783
of C 73 783
body C 74 783
weight C 75 783
of C 76 783
5 C 77 783
- C 78 783
fluorouracil C 79 783
given C 80 783
by C 81 783
rapid C 82 783
intravenous C 83 783
injection C 84 783
at C 85 783
the C 86 783
onset C 87 783
of C 88 783
radiation C 89 783
therapy C 90 783
was C 91 783
found C 92 783
to C 93 783
be C 94 783
relatively C 95 783
safe C 96 783
and C 97 783
tolerable C 98 783
. C 99 783
larger C 101 783
doses C 102 783
were C 103 783
associated C 104 783
with C 105 783
excessive C 106 783
toxicity C 107 783
and C 108 783
mortality C 109 783
. C 110 783
a C 112 783
sufficient C 113 783
number C 114 783
of C 115 783
patients C 116 783
achieved C 117 783
objective C 118 783
and C 119 783
subjective C 120 783
palliation C 121 783
to C 122 783
justify C 123 783
controlled C 124 783
study C 125 783
of C 126 783
the C 127 783
possible C 128 783
additive C 129 783
or C 130 783
synergistic C 131 783
role C 132 783
that C 133 783
5 C 134 783
- C 135 783
fluorouracil C 136 783
may C 137 783
have C 138 783
when C 139 783
combined C 140 783
with C 141 783
radiation C 142 783
therapy C 143 783
. C 144 783
palliation C 1 784
by C 2 784
radiotherapy C 3 784
the C 4 784
purpose C 5 784
of C 6 784
radiotherapy C 7 784
in C 8 784
the C 9 784
management C 10 784
of C 11 784
cancer C 12 784
of C 13 784
the C 14 784
lung C 15 784
is C 16 784
first C 17 784
to C 18 784
cure C 19 784
the C 20 784
disease C 21 784
; C 22 784
second C 23 784
, C 24 784
to C 25 784
prolong C 26 784
useful C 27 784
and C 28 784
comfortable C 29 784
exist C 30 784
- C 31 784
ence C 32 784
; C 33 784
and C 34 784
third C 35 784
, C 36 784
to C 37 784
provide C 38 784
comfort C 39 784
and C 40 784
relief C 41 784
of C 42 784
suffering C 43 784
to C 44 784
those C 45 784
who C 46 784
are C 47 784
symptomatic C 48 784
and C 49 784
in C 50 784
- C 51 784
curable C 52 784
. C 53 784
cancers C 55 784
of C 56 784
the C 57 784
lung C 58 784
vary C 59 784
quite C 60 784
widely C 61 784
in C 62 784
their C 63 784
response C 64 784
to C 65 784
radiation C 66 784
. C 67 784
those C 69 784
of C 70 784
glandular C 71 784
origin C 72 784
, C 73 784
the C 74 784
adenocarcinoma C 75 784
, C 76 784
are C 77 784
more C 78 784
often C 79 784
than C 80 784
not C 81 784
of C 82 784
modest C 83 784
susceptibility C 84 784
and C 85 784
sometimes C 86 784
quite C 87 784
resis C 88 784
- C 89 784
tant C 90 784
. C 91 784
the C 93 784
very C 94 784
undifferentiated C 95 784
, C 96 784
the C 97 784
so C 98 784
- C 99 784
called C 100 784
oat C 101 784
- C 102 784
cell C 103 784
cancers C 104 784
, C 105 784
are C 106 784
often C 107 784
of C 108 784
exquisite C 109 784
sensitivity C 110 784
, C 111 784
re C 112 784
- C 113 784
sponding C 114 784
to C 115 784
irradiation C 116 784
almost C 117 784
like C 118 784
lymphomas C 119 784
. C 120 784
most C 122 784
cancer C 123 784
of C 124 784
the C 125 784
lung C 126 784
, C 127 784
however C 128 784
, C 129 784
is C 130 784
squamous C 131 784
- C 132 784
cell C 133 784
carcinoma C 134 784
and C 135 784
as C 136 784
such C 137 784
may C 138 784
be C 139 784
considered C 140 784
to C 141 784
be C 142 784
moderately C 143 784
radiosensitive C 144 784
in C 145 784
much C 146 784
the C 147 784
same C 148 784
order C 149 784
of C 150 784
magnitude C 151 784
as C 152 784
squamous C 153 784
- C 154 784
cell C 155 784
carcinoma C 156 784
of C 157 784
the C 158 784
skin C 159 784
, C 160 784
cervix C 161 784
or C 162 784
larynx C 163 784
, C 164 784
and C 165 784
should C 166 784
, C 167 784
in C 168 784
theory C 169 784
, C 170 784
be C 171 784
curable C 172 784
by C 173 784
this C 174 784
means C 175 784
in C 176 784
the C 177 784
same C 178 784
degree C 179 784
. C 180 784
unfor C 182 784
- C 183 784
tunately C 184 784
, C 185 784
this C 186 784
has C 187 784
to C 188 784
date C 189 784
not C 190 784
been C 191 784
found C 192 784
to C 193 784
be C 194 784
true C 195 784
. C 196 784
the C 198 784
reasons C 199 784
are C 200 784
principally C 201 784
two C 202 784
: C 203 784
first C 204 784
and C 205 784
foremost C 206 784
, C 207 784
by C 208 784
the C 209 784
time C 210 784
a C 211 784
diagnosis C 212 784
is C 213 784
made C 214 784
, C 215 784
cancer C 216 784
of C 217 784
the C 218 784
lung C 219 784
has C 220 784
more C 221 784
often C 222 784
than C 223 784
not C 224 784
, C 225 784
estimated C 226 784
at C 227 784
80 C 228 784
% C 229 784
and C 230 784
more C 231 784
, C 232 784
spread C 233 784
beyond C 234 784
the C 235 784
site C 236 784
of C 237 784
origin C 238 784
, C 239 784
thus C 240 784
making C 241 784
cure C 242 784
by C 243 784
any C 244 784
effective C 245 784
means C 246 784
presently C 247 784
available C 248 784
unlikely C 249 784
. C 250 784
second C 252 784
, C 253 784
the C 254 784
substrate C 255 784
in C 256 784
which C 257 784
the C 258 784
cancer C 259 784
grows C 260 784
, C 261 784
the C 262 784
lung C 263 784
, C 264 784
tolerates C 265 784
radiation C 266 784
less C 267 784
well C 268 784
than C 269 784
do C 270 784
the C 271 784
tissues C 272 784
which C 273 784
surround C 274 784
the C 275 784
highly C 276 784
radiocurable C 277 784
epithelial C 278 784
cancers C 279 784
such C 280 784
as C 281 784
carcinoma C 282 784
of C 283 784
the C 284 784
skin C 285 784
, C 286 784
cervix C 287 784
, C 288 784
and C 289 784
larynx C 290 784
, C 291 784
thus C 292 784
making C 293 784
an C 294 784
un C 295 784
- C 296 784
favorable C 297 784
therapeutic C 298 784
ratio C 299 784
. C 300 784
chlorambucil C 1 785
- C 2 785
prednisolone C 3 785
therapy C 4 785
for C 5 785
disseminated C 6 785
breast C 7 785
carcinoma C 8 785
over C 9 785
a C 10 785
7 C 11 785
1 C 12 785
/ C 13 785
2 C 14 785
- C 15 785
year C 16 785
period C 17 785
, C 18 785
71 C 19 785
patients C 20 785
with C 21 785
disseminated C 22 785
breast C 23 785
cancer C 24 785
were C 25 785
treated C 26 785
with C 27 785
combined C 28 785
alkylating C 29 785
- C 30 785
agent C 31 785
- C 32 785
cortico C 33 785
- C 34 785
steroid C 35 785
therapy C 36 785
. C 37 785
chlorambucil C 39 785
and C 40 785
pred C 41 785
- C 42 785
nisolone C 43 785
were C 44 785
the C 45 785
drugs C 46 785
of C 47 785
choice C 48 785
. C 49 785
these C 51 785
agents C 52 785
, C 53 785
administered C 54 785
orally C 55 785
, C 56 785
produced C 57 785
no C 58 785
serious C 59 785
or C 60 785
disagreeable C 61 785
toxic C 62 785
effects C 63 785
. C 64 785
twen C 66 785
- C 67 785
ty C 68 785
- C 69 785
four C 70 785
patients C 71 785
( C 72 785
33 C 73 785
. C 74 785
. C 75 785
% C 76 785
) C 77 785
had C 78 785
objective C 79 785
regression C 80 785
of C 81 785
six C 82 785
months C 83 785
' C 84 785
duration C 85 785
or C 86 785
long C 87 785
- C 88 785
er C 89 785
; C 90 785
average C 91 785
survival C 92 785
time C 93 785
after C 94 785
therapy C 95 785
was C 96 785
23 C 97 785
. C 98 785
. C 99 785
months C 100 785
. C 101 785
results C 103 785
are C 104 785
statistically C 105 785
similar C 106 785
to C 107 785
those C 108 785
obtained C 109 785
with C 110 785
sex C 111 785
- C 112 785
steroid C 113 785
and C 114 785
endocrine C 115 785
- C 116 785
ablation C 117 785
therapy C 118 785
, C 119 785
presum C 120 785
- C 121 785
ably C 122 785
because C 123 785
the C 124 785
three C 125 785
modalities C 126 785
have C 127 785
a C 128 785
similar C 129 785
mechanism C 130 785
of C 131 785
action C 132 785
, C 133 785
ie C 134 785
. C 135 785
suppres C 137 785
- C 138 785
sion C 139 785
and C 140 785
/ C 141 785
or C 142 785
eradication C 143 785
of C 144 785
endogenous C 145 785
estrogen C 146 785
. C 147 785
recent C 1 786
advances C 2 786
in C 3 786
the C 4 786
treatment C 5 786
of C 6 786
cancer C 7 786
of C 8 786
the C 9 786
esophagus C 10 786
whether C 11 786
combining C 12 786
surgery C 13 786
and C 14 786
supervoltage C 15 786
radiation C 16 786
therapy C 17 786
will C 18 786
noticeably C 19 786
improve C 20 786
the C 21 786
5 C 22 786
- C 23 786
year C 24 786
survival C 25 786
rate C 26 786
for C 27 786
carcinoma C 28 786
of C 29 786
the C 30 786
esopha C 31 786
- C 32 786
gus C 33 786
remains C 34 786
to C 35 786
be C 36 786
seen C 37 786
. C 38 786
it C 40 786
is C 41 786
encouraging C 42 786
, C 43 786
however C 44 786
, C 45 786
to C 46 786
observe C 47 786
at C 48 786
the C 49 786
time C 50 786
of C 51 786
operation C 52 786
that C 53 786
the C 54 786
previously C 55 786
irradiated C 56 786
esophagus C 57 786
is C 58 786
firmly C 59 786
encased C 60 786
in C 61 786
fibrous C 62 786
tissue C 63 786
, C 64 786
which C 65 786
gives C 66 786
the C 67 786
impression C 68 786
that C 69 786
the C 70 786
danger C 71 786
of C 72 786
disseminating C 73 786
tumor C 74 786
at C 75 786
the C 76 786
time C 77 786
of C 78 786
resection C 79 786
is C 80 786
diminished C 81 786
. C 82 786
in C 84 786
addition C 85 786
, C 86 786
the C 87 786
fibrosis C 88 786
sug C 89 786
- C 90 786
gests C 91 786
that C 92 786
the C 93 786
tumor C 94 786
that C 95 786
had C 96 786
spread C 97 786
locally C 98 786
, C 99 786
beyond C 100 786
the C 101 786
limits C 102 786
of C 103 786
surgical C 104 786
excision C 105 786
, C 106 786
may C 107 786
have C 108 786
been C 109 786
destroyed C 110 786
. C 111 786
cyclophosphamide C 1 787
in C 2 787
the C 3 787
management C 4 787
of C 5 787
advanced C 6 787
bronchial C 7 787
carcinoma C 8 787
forty C 9 787
patients C 10 787
suffering C 11 787
from C 12 787
advanced C 13 787
bronchial C 14 787
carcinoma C 15 787
who C 16 787
were C 17 787
treated C 18 787
with C 19 787
cyclophospha C 20 787
- C 21 787
mide C 22 787
are C 23 787
reviewed C 24 787
. C 25 787
the C 27 787
selective C 28 787
effect C 29 787
of C 30 787
the C 31 787
drug C 32 787
in C 33 787
tumours C 34 787
of C 35 787
the C 36 787
oat C 37 787
- C 38 787
cell C 39 787
type C 40 787
is C 41 787
noted C 42 787
. C 43 787
it C 45 787
is C 46 787
suggested C 47 787
that C 48 787
relapses C 49 787
which C 50 787
occur C 51 787
while C 52 787
the C 53 787
patient C 54 787
is C 55 787
on C 56 787
oral C 57 787
maintenance C 58 787
therapy C 59 787
may C 60 787
be C 61 787
controlled C 62 787
by C 63 787
a C 64 787
further C 65 787
intravenous C 66 787
course C 67 787
of C 68 787
cyclophosphamide C 69 787
. C 70 787
full C 72 787
clinical C 73 787
and C 74 787
statistical C 75 787
details C 76 787
of C 77 787
all C 78 787
the C 79 787
patients C 80 787
referred C 81 787
to C 82 787
in C 83 787
this C 84 787
paper C 85 787
are C 86 787
available C 87 787
on C 88 787
application C 89 787
to C 90 787
the C 91 787
author C 92 787
. C 93 787
esophageal C 1 788
obstruction C 2 788
the C 3 788
use C 4 788
of C 5 788
an C 6 788
endoscopically C 7 788
inserted C 8 788
tube C 9 788
in C 10 788
the C 11 788
care C 12 788
of C 13 788
esophageal C 14 788
carcinoma C 15 788
our C 16 788
experience C 17 788
suggests C 18 788
that C 19 788
the C 20 788
en C 21 788
- C 22 788
doscopic C 23 788
insertion C 24 788
of C 25 788
intraluminal C 26 788
tubes C 27 788
provides C 28 788
a C 29 788
relatively C 30 788
simple C 31 788
and C 32 788
reason C 33 788
- C 34 788
ably C 35 788
safe C 36 788
method C 37 788
of C 38 788
dealing C 39 788
with C 40 788
some C 41 788
of C 42 788
the C 43 788
problems C 44 788
which C 45 788
arise C 46 788
in C 47 788
the C 48 788
man C 49 788
- C 50 788
agement C 51 788
of C 52 788
patients C 53 788
with C 54 788
esophageal C 55 788
car C 56 788
- C 57 788
cinoma C 58 788
. C 59 788
such C 61 788
tubes C 62 788
would C 63 788
appear C 64 788
to C 65 788
be C 66 788
of C 67 788
particular C 68 788
use C 69 788
in C 70 788
handling C 71 788
the C 72 788
prob C 73 788
- C 74 788
lems C 75 788
of C 76 788
obstruction C 77 788
and C 78 788
regurgitation C 79 788
in C 80 788
patients C 81 788
with C 82 788
incurable C 83 788
tumors C 84 788
, C 85 788
but C 86 788
may C 87 788
also C 88 788
be C 89 788
helpful C 90 788
in C 91 788
preparing C 92 788
severely C 93 788
debilitated C 94 788
patients C 95 788
with C 96 788
esophageal C 97 788
car C 98 788
- C 99 788
cinoma C 100 788
to C 101 788
withstand C 102 788
the C 103 788
rigors C 104 788
of C 105 788
opera C 106 788
- C 107 788
tion C 108 788
and C 109 788
radiation C 110 788
therapy C 111 788
. C 112 788
palliative C 1 789
radiation C 2 789
therapy C 3 789
the C 4 789
care C 5 789
of C 6 789
the C 7 789
patient C 8 789
with C 9 789
" C 10 789
incurable C 11 789
" C 12 789
cancer C 13 789
may C 14 789
be C 15 789
directed C 16 789
by C 17 789
physicians C 18 789
of C 19 789
various C 20 789
backgrounds C 21 789
and C 22 789
per C 23 789
- C 24 789
suasions C 25 789
. C 26 789
if C 28 789
this C 29 789
physician C 30 789
has C 31 789
little C 32 789
experience C 33 789
in C 34 789
such C 35 789
care C 36 789
, C 37 789
he C 38 789
is C 39 789
prone C 40 789
to C 41 789
be C 42 789
influenced C 43 789
by C 44 789
still C 45 789
prevalent C 46 789
atti C 47 789
- C 48 789
tudes C 49 789
of C 50 789
therapeutic C 51 789
futility C 52 789
or C 53 789
by C 54 789
equally C 55 789
unjustified C 56 789
premature C 57 789
claims C 58 789
for C 59 789
widely C 60 789
publicized C 61 789
methods C 62 789
recent C 63 789
on C 64 789
the C 65 789
scene C 66 789
. C 67 789
surgery C 69 789
and C 70 789
radiation C 71 789
therapy C 72 789
remain C 73 789
the C 74 789
dominant C 75 789
treatment C 76 789
forces C 77 789
for C 78 789
the C 79 789
patient C 80 789
with C 81 789
cancer C 82 789
. C 83 789
it C 85 789
is C 86 789
unfortunate C 87 789
that C 88 789
lack C 89 789
of C 90 789
demonstration C 91 789
of C 92 789
good C 93 789
radiation C 94 789
therapy C 95 789
has C 96 789
led C 97 789
to C 98 789
unjustified C 99 789
condemnation C 100 789
of C 101 789
the C 102 789
method C 103 789
rather C 104 789
than C 105 789
the C 106 789
user C 107 789
, C 108 789
with C 109 789
resultant C 110 789
loss C 111 789
to C 112 789
the C 113 789
patient C 114 789
' C 115 789
s C 116 789
welfare C 117 789
. C 118 789
to C 120 789
obtain C 121 789
maximal C 122 789
benefit C 123 789
, C 124 789
radiation C 125 789
therapy C 126 789
must C 127 789
be C 128 789
allowed C 129 789
indications C 130 789
and C 131 789
contraindications C 132 789
like C 133 789
any C 134 789
therapeutic C 135 789
modality C 136 789
. C 137 789
these C 139 789
must C 140 789
be C 141 789
the C 142 789
responsibility C 143 789
of C 144 789
the C 145 789
therapeutic C 146 789
radiologist C 147 789
. C 148 789
application C 150 789
of C 151 789
realistically C 152 789
stringent C 153 789
indications C 154 789
and C 155 789
contraindications C 156 789
does C 157 789
not C 158 789
lessen C 159 789
useful C 160 789
accomplishment C 161 789
, C 162 789
but C 163 789
avoids C 164 789
unnecessary C 165 789
morbidity C 166 789
, C 167 789
waste C 168 789
of C 169 789
time C 170 789
, C 171 789
money C 172 789
and C 173 789
effort C 174 789
, C 175 789
and C 176 789
delay C 177 789
in C 178 789
seeking C 179 789
suitable C 180 789
treatment C 181 789
. C 182 789
carcinoma C 1 790
of C 2 790
the C 3 790
middle C 4 790
ear C 5 790
the C 6 790
results C 7 790
of C 8 790
radiotherapy C 9 790
in C 10 790
a C 11 790
relatively C 12 790
large C 13 790
number C 14 790
of C 15 790
cases C 16 790
of C 17 790
carcinoma C 18 790
of C 19 790
the C 20 790
middle C 21 790
ear C 22 790
are C 23 790
reported C 24 790
. C 25 790
the C 27 790
crude C 28 790
5 C 29 790
year C 30 790
survival C 31 790
rate C 32 790
of C 33 790
100 C 34 790
cases C 35 790
is C 36 790
29 C 37 790
% C 38 790
. C 39 790
there C 41 790
is C 42 790
no C 43 790
difference C 44 790
in C 45 790
survival C 46 790
between C 47 790
those C 48 790
cases C 49 790
who C 50 790
had C 51 790
a C 52 790
preliminary C 53 790
mastoidectomy C 54 790
and C 55 790
those C 56 790
who C 57 790
did C 58 790
not C 59 790
. C 60 790
the C 62 790
use C 63 790
of C 64 790
megavoltage C 65 790
x C 66 790
- C 67 790
rays C 68 790
probably C 69 790
increases C 70 790
the C 71 790
survival C 72 790
rate C 73 790
. C 74 790
sustained C 1 791
palliation C 2 791
in C 3 791
ovarian C 4 791
carcinoma C 5 791
management C 6 791
of C 7 791
64 C 8 791
cases C 9 791
of C 10 791
advanced C 11 791
ovarian C 12 791
carcinoma C 13 791
has C 14 791
been C 15 791
analyzed C 16 791
. C 17 791
an C 19 791
attempt C 20 791
is C 21 791
made C 22 791
to C 23 791
compare C 24 791
the C 25 791
value C 26 791
of C 27 791
radiation C 28 791
and C 29 791
the C 30 791
value C 31 791
of C 32 791
chloram C 33 791
- C 34 791
bucil C 35 791
, C 36 791
using C 37 791
salvage C 38 791
time C 39 791
and C 40 791
sustained C 41 791
pal C 42 791
- C 43 791
liation C 44 791
as C 45 791
end C 46 791
points C 47 791
. C 48 791
chlorambucil C 50 791
, C 51 791
an C 52 791
outpatient C 53 791
oral C 54 791
medi C 55 791
- C 56 791
cation C 57 791
, C 58 791
appears C 59 791
to C 60 791
be C 61 791
as C 62 791
efficacious C 63 791
as C 64 791
ra C 65 791
- C 66 791
diation C 67 791
in C 68 791
advanced C 69 791
ovarian C 70 791
carcinoma C 71 791
. C 72 791
chlorambucil C 74 791
may C 75 791
be C 76 791
used C 77 791
before C 78 791
or C 79 791
after C 80 791
irradiation C 81 791
therapy C 82 791
. C 83 791
pleural C 85 791
and C 86 791
peritoneal C 87 791
effusion C 88 791
respond C 89 791
favorably C 90 791
to C 91 791
chlorambucil C 92 791
80 C 93 791
% C 94 791
of C 95 791
the C 96 791
time C 97 791
. C 98 791
the C 100 791
possibility C 101 791
of C 102 791
using C 103 791
a C 104 791
different C 105 791
dosage C 106 791
schedule C 107 791
is C 108 791
discussed C 109 791
. C 110 791
clues C 1 792
in C 2 792
dealing C 3 792
with C 4 792
cancer C 5 792
patients C 6 792
it C 7 792
is C 8 792
clear C 9 792
that C 10 792
the C 11 792
patient C 12 792
with C 13 792
cancer C 14 792
changed C 15 792
his C 16 792
pattern C 17 792
of C 18 792
communication C 19 792
at C 20 792
different C 21 792
stages C 22 792
of C 23 792
the C 24 792
disease C 25 792
. C 26 792
these C 28 792
patterns C 29 792
in C 30 792
communication C 31 792
were C 32 792
the C 33 792
basis C 34 792
or C 35 792
clues C 36 792
for C 37 792
the C 38 792
doctor C 39 792
and C 40 792
paramedical C 41 792
personnel C 42 792
to C 43 792
consider C 44 792
in C 45 792
making C 46 792
total C 47 792
care C 48 792
more C 49 792
effective C 50 792
. C 51 792
the C 53 792
bedside C 54 792
clinician C 55 792
of C 56 792
past C 57 792
days C 58 792
knew C 59 792
these C 60 792
clues C 61 792
instinctively C 62 792
in C 63 792
his C 64 792
wise C 65 792
ministrations C 66 792
. C 67 792
thanks C 69 792
to C 70 792
a C 71 792
gifted C 72 792
social C 73 792
worker C 74 792
these C 75 792
have C 76 792
been C 77 792
now C 78 792
made C 79 792
manifest C 80 792
to C 81 792
help C 82 792
all C 83 792
of C 84 792
us C 85 792
in C 86 792
dealing C 87 792
with C 88 792
cancer C 89 792
and C 90 792
perhaps C 91 792
other C 92 792
chronic C 93 792
relentless C 94 792
diseases C 95 792
. C 96 792
radon C 1 793
and C 2 793
radioactive C 3 793
seed C 4 793
volume C 5 793
implants C 6 793
for C 7 793
extensive C 8 793
recurrent C 9 793
vaginal C 10 793
- C 11 793
pelvic C 12 793
cancer C 13 793
radioactive C 14 793
seed C 15 793
volume C 16 793
implants C 17 793
for C 18 793
extensive C 19 793
recurrent C 20 793
vaginal C 21 793
- C 22 793
pelvic C 23 793
cancer C 24 793
result C 25 793
in C 26 793
extended C 27 793
control C 28 793
of C 29 793
otherwise C 30 793
untreatable C 31 793
disease C 32 793
. C 33 793
immediate C 35 793
and C 36 793
early C 37 793
reactions C 38 793
are C 39 793
practically C 40 793
nonexistent C 41 793
. C 42 793
late C 44 793
complications C 45 793
are C 46 793
also C 47 793
rare C 48 793
, C 49 793
the C 50 793
most C 51 793
serious C 52 793
being C 53 793
severe C 54 793
hemorrhagic C 55 793
cystitis C 56 793
in C 57 793
2 C 58 793
of C 59 793
the C 60 793
author C 61 793
' C 62 793
s C 63 793
13 C 64 793
patients C 65 793
. C 66 793
terminal C 1 794
cancer C 2 794
nursed C 3 794
at C 4 794
home C 5 794
perhaps C 6 794
the C 7 794
most C 8 794
difficult C 9 794
part C 10 794
of C 11 794
mrs C 12 794
. C 13 794
brown C 15 794
' C 16 794
s C 17 794
illness C 18 794
, C 19 794
was C 20 794
that C 21 794
she C 22 794
herself C 23 794
knew C 24 794
all C 25 794
about C 26 794
it C 27 794
. C 28 794
she C 30 794
had C 31 794
been C 32 794
a C 33 794
nurse C 34 794
for C 35 794
most C 36 794
of C 37 794
her C 38 794
working C 39 794
life C 40 794
, C 41 794
and C 42 794
was C 43 794
only C 44 794
too C 45 794
aware C 46 794
of C 47 794
the C 48 794
deteriorating C 49 794
process C 50 794
of C 51 794
carcinoma C 52 794
. C 53 794
there C 55 794
were C 56 794
times C 57 794
, C 58 794
of C 59 794
course C 60 794
, C 61 794
when C 62 794
she C 63 794
would C 64 794
try C 65 794
to C 66 794
deceive C 67 794
herself C 68 794
, C 69 794
say C 70 794
- C 71 794
ing C 72 794
that C 73 794
there C 74 794
was C 75 794
always C 76 794
hope C 77 794
that C 78 794
something C 79 794
new C 80 794
in C 81 794
the C 82 794
way C 83 794
of C 84 794
treatment C 85 794
would C 86 794
turn C 87 794
up C 88 794
, C 89 794
and C 90 794
life C 91 794
would C 92 794
then C 93 794
be C 94 794
worth C 95 794
living C 96 794
again C 97 794
. C 98 794
advanced C 1 795
cancer C 2 795
of C 3 795
the C 4 795
breast C 5 795
treated C 6 795
primarily C 7 795
with C 8 795
irradiation C 9 795
the C 10 795
five C 11 795
- C 12 795
year C 13 795
results C 14 795
in C 15 795
109 C 16 795
patients C 17 795
treated C 18 795
primarily C 19 795
with C 20 795
irradiation C 21 795
for C 22 795
cancer C 23 795
of C 24 795
the C 25 795
breast C 26 795
, C 27 795
mostly C 28 795
in C 29 795
the C 30 795
late C 31 795
stages C 32 795
, C 33 795
have C 34 795
been C 35 795
analyzed C 36 795
. C 37 795
in C 39 795
all C 40 795
cases C 41 795
, C 42 795
the C 43 795
initial C 44 795
intent C 45 795
was C 46 795
to C 47 795
control C 48 795
with C 49 795
x C 50 795
radiation C 51 795
alone C 52 795
the C 53 795
primary C 54 795
tumor C 55 795
involving C 56 795
the C 57 795
breast C 58 795
and C 59 795
its C 60 795
entire C 61 795
lymphatic C 62 795
drainage C 63 795
. C 64 795
irradiation C 66 795
remained C 67 795
essentially C 68 795
the C 69 795
sole C 70 795
method C 71 795
of C 72 795
treatment C 73 795
in C 74 795
84 C 75 795
cases C 76 795
. C 77 795
postirradiation C 79 795
mastectomy C 80 795
was C 81 795
performed C 82 795
in C 83 795
the C 84 795
25 C 85 795
other C 86 795
patients C 87 795
, C 88 795
who C 89 795
initially C 90 795
had C 91 795
been C 92 795
considered C 93 795
inoperable C 94 795
. C 95 795
the C 97 795
plan C 98 795
of C 99 795
treatment C 100 795
has C 101 795
consisted C 102 795
of C 103 795
a C 104 795
single C 105 795
continuous C 106 795
course C 107 795
of C 108 795
radiation C 109 795
ther C 110 795
- C 111 795
apy C 112 795
, C 113 795
protracted C 114 795
over C 115 795
a C 116 795
period C 117 795
of C 118 795
seventy C 119 795
- C 120 795
five C 121 795
to C 122 795
one C 123 795
hundred C 124 795
days C 125 795
and C 126 795
administered C 127 795
in C 128 795
3 C 129 795
closely C 130 795
integrated C 131 795
phases C 132 795
. C 133 795
tissue C 135 795
doses C 136 795
, C 137 795
superficial C 138 795
and C 139 795
deep C 140 795
, C 141 795
must C 142 795
be C 143 795
brought C 144 795
to C 145 795
the C 146 795
highest C 147 795
levels C 148 795
required C 149 795
for C 150 795
maximum C 151 795
biological C 152 795
effects C 153 795
within C 154 795
the C 155 795
tolerance C 156 795
of C 157 795
the C 158 795
structures C 159 795
involved C 160 795
. C 161 795
the C 163 795
immediate C 164 795
effects C 165 795
of C 166 795
irradiation C 167 795
alone C 168 795
have C 169 795
been C 170 795
remarkable C 171 795
. C 172 795
the C 174 795
re C 175 795
- C 176 795
gression C 177 795
of C 178 795
neoplastic C 179 795
manifestations C 180 795
in C 181 795
the C 182 795
breast C 183 795
and C 184 795
palpable C 185 795
nodes C 186 795
, C 187 795
the C 188 795
degree C 189 795
of C 190 795
healing C 191 795
of C 192 795
ulcerated C 193 795
carcinoma C 194 795
, C 195 795
and C 196 795
the C 197 795
incidence C 198 795
of C 199 795
recurrence C 200 795
have C 201 795
been C 202 795
re C 203 795
- C 204 795
corded C 205 795
and C 206 795
assessed C 207 795
to C 208 795
determine C 209 795
the C 210 795
efficacy C 211 795
of C 212 795
treatment C 213 795
. C 214 795
the C 1 796
management C 2 796
of C 3 796
disseminated C 4 796
cancer C 5 796
of C 6 796
the C 7 796
breast C 8 796
when C 9 796
mammary C 10 796
cancer C 11 796
has C 12 796
spread C 13 796
to C 14 796
tissues C 15 796
beyond C 16 796
the C 17 796
breast C 18 796
and C 19 796
axilla C 20 796
, C 21 796
the C 22 796
disease C 23 796
is C 24 796
incurable C 25 796
by C 26 796
present C 27 796
day C 28 796
methods C 29 796
. C 30 796
however C 32 796
the C 33 796
patient C 34 796
may C 35 796
be C 36 796
greatly C 37 796
helped C 38 796
and C 39 796
tumor C 40 796
growth C 41 796
retarded C 42 796
by C 43 796
skillful C 44 796
and C 45 796
sympathetic C 46 796
application C 47 796
of C 48 796
irradiation C 49 796
, C 50 796
surgical C 51 796
ablation C 52 796
, C 53 796
hormone C 54 796
ad C 55 796
- C 56 796
ministration C 57 796
, C 58 796
and C 59 796
chemotherapy C 60 796
. C 61 796
given C 63 796
in C 64 796
conjunction C 65 796
with C 66 796
analgesics C 67 796
, C 68 796
sedatives C 69 796
, C 70 796
and C 71 796
ataractic C 72 796
drugs C 73 796
, C 74 796
these C 75 796
measures C 76 796
can C 77 796
frequently C 78 796
reduce C 79 796
disability C 80 796
and C 81 796
pain C 82 796
and C 83 796
prolong C 84 796
the C 85 796
period C 86 796
of C 87 796
useful C 88 796
comfortable C 89 796
life C 90 796
. C 91 796
toilet C 1 797
training C 2 797
of C 3 797
an C 4 797
autistic C 5 797
eight C 6 797
- C 7 797
year C 8 797
- C 9 797
old C 10 797
through C 11 797
conditioning C 12 797
therapy C 13 797
: C 14 797
a C 15 797
case C 16 797
report C 17 797
operant C 18 797
conditioning C 19 797
techniques C 20 797
have C 21 797
been C 22 797
successfully C 23 797
used C 24 797
in C 25 797
the C 26 797
treatment C 27 797
of C 28 797
a C 29 797
wide C 30 797
variety C 31 797
of C 32 797
be C 33 797
- C 34 797
havioral C 35 797
problems C 36 797
including C 37 797
hysterical C 38 797
blindness C 39 797
( C 40 797
brady C 41 797
and C 42 797
lind C 43 797
, C 44 797
1961 C 45 797
) C 46 797
, C 47 797
tics C 48 797
( C 49 797
barrett C 50 797
, C 51 797
1962 C 52 797
) C 53 797
, C 54 797
psychotic C 55 797
symptoms C 56 797
( C 57 797
lindsley C 58 797
, C 59 797
1956 C 60 797
; C 61 797
1960 C 62 797
, C 63 797
1961 C 64 797
) C 65 797
, C 66 797
reading C 67 797
disabilities C 68 797
( C 69 797
rachman C 70 797
, C 71 797
1962 C 72 797
) C 73 797
stuttering C 74 797
( C 75 797
flanagan C 76 797
et C 77 797
. C 78 797
al C 80 797
. C 81 797
, C 83 797
1958 C 84 797
) C 85 797
enuresis C 86 797
( C 87 797
mowrer C 88 797
and C 89 797
mowrer C 90 797
, C 91 797
1938 C 92 797
; C 93 797
lovibond C 94 797
, C 95 797
1961 C 96 797
, C 97 797
1963 C 98 797
a C 99 797
, C 100 797
b C 101 797
) C 102 797
and C 103 797
encopresis C 104 797
( C 105 797
neale C 106 797
, C 107 797
1963 C 108 797
; C 109 797
madsen C 110 797
, C 111 797
1965 C 112 797
) C 113 797
. C 114 797
neale C 116 797
( C 117 797
1963 C 118 797
) C 119 797
successfully C 120 797
treated C 121 797
three C 122 797
out C 123 797
of C 124 797
four C 125 797
encopretic C 126 797
children C 127 797
using C 128 797
operant C 129 797
training C 130 797
techniques C 131 797
. C 132 797
in C 134 797
the C 135 797
case C 136 797
of C 137 797
one C 138 797
9 C 139 797
- C 140 797
yr C 141 797
- C 142 797
old C 143 797
boy C 144 797
, C 145 797
with C 146 797
an C 147 797
18 C 148 797
month C 149 797
history C 150 797
of C 151 797
encopresis C 152 797
, C 153 797
going C 154 797
to C 155 797
the C 156 797
toilet C 157 797
was C 158 797
rewarded C 159 797
by C 160 797
a C 161 797
candy C 162 797
, C 163 797
praise C 164 797
and C 165 797
recording C 166 797
the C 167 797
event C 168 797
in C 169 797
a C 170 797
special C 171 797
book C 172 797
in C 173 797
the C 174 797
boy C 175 797
' C 176 797
s C 177 797
presence C 178 797
. C 179 797
soiling C 181 797
was C 182 797
not C 183 797
inadvertently C 184 797
rewarded C 185 797
( C 186 797
e C 187 797
. C 188 797
. C 189 797
. C 190 797
attention C 192 797
) C 193 797
or C 194 797
punished C 195 797
; C 196 797
the C 197 797
boy C 198 797
would C 199 797
be C 200 797
given C 201 797
a C 202 797
clean C 203 797
pair C 204 797
of C 205 797
pants C 206 797
without C 207 797
comment C 208 797
. C 209 797
neale C 211 797
reports C 212 797
that C 213 797
response C 214 797
to C 215 797
treatment C 216 797
was C 217 797
rapid C 218 797
and C 219 797
complete C 220 797
and C 221 797
6 C 222 797
months C 223 797
after C 224 797
toilet C 225 797
training C 226 797
there C 227 797
had C 228 797
been C 229 797
no C 230 797
relapse C 231 797
in C 232 797
bowel C 233 797
habits C 234 797
. C 235 797
procedures C 237 797
similar C 238 797
to C 239 797
those C 240 797
used C 241 797
by C 242 797
neale C 243 797
were C 244 797
used C 245 797
in C 246 797
the C 247 797
case C 248 797
reported C 249 797
here C 250 797
. C 251 797
positive C 253 797
and C 254 797
, C 255 797
in C 256 797
a C 257 797
small C 258 797
number C 259 797
of C 260 797
instances C 261 797
, C 262 797
negative C 263 797
reinforcement C 264 797
were C 265 797
used C 266 797
to C 267 797
toilet C 268 797
train C 269 797
an C 270 797
8 C 271 797
- C 272 797
yr C 273 797
- C 274 797
old C 275 797
boy C 276 797
diagnosed C 277 797
by C 278 797
a C 279 797
child C 280 797
psychiatrist C 281 797
/ C 282 797
neurologist C 283 797
as C 284 797
having C 285 797
infantile C 286 797
autism C 287 797
. C 288 797
incidence C 1 798
of C 2 798
symptoms C 3 798
of C 4 798
early C 5 798
infantile C 6 798
autism C 7 798
in C 8 798
subsequently C 9 798
hospitalized C 10 798
psychiatric C 11 798
patients C 12 798
this C 13 798
study C 14 798
was C 15 798
concerned C 16 798
with C 17 798
the C 18 798
relationship C 19 798
between C 20 798
the C 21 798
occurrence C 22 798
dur C 23 798
- C 24 798
ing C 25 798
the C 26 798
first C 27 798
two C 28 798
years C 29 798
of C 30 798
life C 31 798
of C 32 798
symptoms C 33 798
of C 34 798
early C 35 798
infantile C 36 798
autism C 37 798
, C 38 798
as C 39 798
retrospective C 40 798
- C 41 798
ly C 42 798
reported C 43 798
by C 44 798
the C 45 798
mothers C 46 798
of C 47 798
s C 48 798
' C 49 798
s C 50 798
and C 51 798
subsequent C 52 798
adjustment C 53 798
. C 54 798
the C 56 798
mothers C 57 798
of C 58 798
69 C 59 798
unmarried C 60 798
young C 61 798
hospitalized C 62 798
psychia C 63 798
- C 64 798
tric C 65 798
patients C 66 798
were C 67 798
interviewed C 68 798
to C 69 798
deter C 70 798
- C 71 798
mine C 72 798
the C 73 798
presence C 74 798
or C 75 798
absence C 76 798
of C 77 798
each C 78 798
of C 79 798
28 C 80 798
different C 81 798
signs C 82 798
contained C 83 798
in C 84 798
a C 85 798
check C 86 798
list C 87 798
. C 88 798
the C 90 798
signs C 91 798
represent C 92 798
characteristic C 93 798
features C 94 798
that C 95 798
are C 96 798
reportedly C 97 798
often C 98 798
found C 99 798
in C 100 798
conjunction C 101 798
with C 102 798
early C 103 798
infantile C 104 798
autism C 105 798
. C 106 798
as C 108 798
a C 109 798
control C 110 798
, C 111 798
50 C 112 798
mothers C 113 798
of C 114 798
high C 115 798
school C 116 798
students C 117 798
residing C 118 798
in C 119 798
the C 120 798
community C 121 798
and C 122 798
presenting C 123 798
no C 124 798
significant C 125 798
adjustment C 126 798
prob C 127 798
- C 128 798
lems C 129 798
were C 130 798
questioned C 131 798
in C 132 798
regard C 133 798
to C 134 798
the C 135 798
very C 136 798
same C 137 798
items C 138 798
. C 139 798
the C 141 798
results C 142 798
indicated C 143 798
that C 144 798
there C 145 798
were C 146 798
significantly C 147 798
more C 148 798
symptoms C 149 798
reported C 150 798
for C 151 798
patients C 152 798
than C 153 798
for C 154 798
normals C 155 798
, C 156 798
and C 157 798
that C 158 798
this C 159 798
finding C 160 798
applied C 161 798
to C 162 798
the C 163 798
overall C 164 798
number C 165 798
of C 166 798
symptoms C 167 798
as C 168 798
well C 169 798
as C 170 798
to C 171 798
several C 172 798
subcate C 173 798
- C 174 798
gories C 175 798
of C 176 798
symptoms C 177 798
. C 178 798
the C 180 798
items C 181 798
classified C 182 798
under C 183 798
the C 184 798
heading C 185 798
of C 186 798
" C 187 798
social C 188 798
withdrawal C 189 798
" C 190 798
appeared C 191 798
to C 192 798
be C 193 798
the C 194 798
most C 195 798
sensitive C 196 798
in C 197 798
dif C 198 798
- C 199 798
ferentiating C 200 798
the C 201 798
groups C 202 798
. C 203 798
it C 205 798
was C 206 798
also C 207 798
found C 208 798
that C 209 798
11 C 210 798
of C 211 798
the C 212 798
28 C 213 798
signs C 214 798
distinguished C 215 798
be C 216 798
- C 217 798
tween C 218 798
the C 219 798
patients C 220 798
and C 221 798
normals C 222 798
, C 223 798
with C 224 798
all C 225 798
except C 226 798
one C 227 798
occurring C 228 798
more C 229 798
frequently C 230 798
in C 231 798
the C 232 798
former C 233 798
group C 234 798
. C 235 798
it C 237 798
was C 238 798
concluded C 239 798
that C 240 798
a C 241 798
significant C 242 798
relationship C 243 798
existed C 244 798
between C 245 798
the C 246 798
reported C 247 798
presence C 248 798
of C 249 798
symptoms C 250 798
that C 251 798
are C 252 798
often C 253 798
associated C 254 798
with C 255 798
severe C 256 798
and C 257 798
early C 258 798
ego C 259 798
impairment C 260 798
and C 261 798
subsequent C 262 798
status C 263 798
as C 264 798
a C 265 798
mental C 266 798
hospital C 267 798
patient C 268 798
. C 269 798
this C 271 798
study C 272 798
does C 273 798
not C 274 798
provide C 275 798
any C 276 798
direct C 277 798
answer C 278 798
to C 279 798
the C 280 798
ques C 281 798
- C 282 798
tion C 283 798
of C 284 798
what C 285 798
proportion C 286 798
of C 287 798
children C 288 798
with C 289 798
infantile C 290 798
autism C 291 798
are C 292 798
later C 293 798
able C 294 798
to C 295 798
make C 296 798
an C 297 798
adequate C 298 798
adjustment C 299 798
outside C 300 798
of C 301 798
a C 302 798
mental C 303 798
hospital C 304 798
. C 305 798
eeg C 1 799
abnormalities C 2 799
in C 3 799
early C 4 799
childhood C 5 799
schizophrenia C 6 799
: C 7 799
a C 8 799
double C 9 799
- C 10 799
blind C 11 799
study C 12 799
of C 13 799
psychiatrically C 14 799
distrubed C 15 799
and C 16 799
normal C 17 799
children C 18 799
during C 19 799
promazine C 20 799
sedation C 21 799
eeg C 22 799
tracings C 23 799
during C 24 799
promazine C 25 799
sedation C 26 799
were C 27 799
obtained C 28 799
on C 29 799
58 C 30 799
children C 31 799
who C 32 799
had C 33 799
autistic C 34 799
or C 35 799
symbiotic C 36 799
childhood C 37 799
psychosis C 38 799
. C 39 799
for C 41 799
comparison C 42 799
eeg C 43 799
' C 44 799
s C 45 799
were C 46 799
done C 47 799
under C 48 799
identical C 49 799
conditions C 50 799
on C 51 799
4 C 52 799
other C 53 799
groups C 54 799
of C 55 799
children C 56 799
: C 57 799
44 C 58 799
with C 59 799
chronic C 60 799
undifferentiated C 61 799
schizophrenia C 62 799
; C 63 799
37 C 64 799
non C 65 799
- C 66 799
psychotic C 67 799
children C 68 799
with C 69 799
severe C 70 799
, C 71 799
acting C 72 799
- C 73 799
out C 74 799
behavior C 75 799
disorders C 76 799
; C 77 799
10 C 78 799
with C 79 799
neuroses C 80 799
; C 81 799
and C 82 799
13 C 83 799
psychiatrically C 84 799
normal C 85 799
children C 86 799
. C 87 799
final C 89 799
clinical C 90 799
diagnoses C 91 799
were C 92 799
made C 93 799
without C 94 799
knowledge C 95 799
of C 96 799
the C 97 799
eeg C 98 799
readings C 99 799
as C 100 799
determined C 101 799
for C 102 799
this C 103 799
study C 104 799
, C 105 799
and C 106 799
the C 107 799
eeg C 108 799
' C 109 799
s C 110 799
were C 111 799
all C 112 799
placed C 113 799
in C 114 799
random C 115 799
order C 116 799
and C 117 799
read C 118 799
without C 119 799
any C 120 799
knowledge C 121 799
of C 122 799
the C 123 799
clinical C 124 799
diagnosis C 125 799
. C 126 799
eeg C 128 799
abnormalities C 129 799
ac C 130 799
- C 131 799
cepted C 132 799
were C 133 799
focal C 134 799
slowing C 135 799
, C 136 799
focal C 137 799
spikes C 138 799
, C 139 799
paroxysmal C 140 799
spikes C 141 799
and C 142 799
waves C 143 799
, C 144 799
and C 145 799
par C 146 799
- C 147 799
oxysmal C 148 799
spikes C 149 799
and C 150 799
waves C 151 799
with C 152 799
independent C 153 799
spikes C 154 799
. C 155 799
among C 157 799
the C 158 799
149 C 159 799
patients C 160 799
51 C 161 799
% C 162 799
had C 163 799
abnormal C 164 799
records C 165 799
. C 166 799
none C 168 799
of C 169 799
the C 170 799
psychiatrically C 171 799
normal C 172 799
children C 173 799
had C 174 799
eeg C 175 799
abnormalities C 176 799
. C 177 799
except C 179 799
for C 180 799
the C 181 799
neurotics C 182 799
, C 183 799
the C 184 799
eeg C 185 799
abnormalities C 186 799
were C 187 799
qualitatively C 188 799
and C 189 799
quantitatively C 190 799
sim C 191 799
- C 192 799
ilar C 193 799
in C 194 799
the C 195 799
psychiatric C 196 799
patients C 197 799
. C 198 799
the C 200 799
most C 201 799
frequent C 202 799
abnormalities C 203 799
were C 204 799
ir C 205 799
- C 206 799
regular C 207 799
paroxysmal C 208 799
spike C 209 799
and C 210 799
wave C 211 799
com C 212 799
- C 213 799
plexes C 214 799
, C 215 799
often C 216 799
best C 217 799
seen C 218 799
during C 219 799
the C 220 799
transition C 221 799
from C 222 799
wake C 223 799
to C 224 799
sleep C 225 799
. C 226 799
of C 228 799
the C 229 799
149 C 230 799
patients C 231 799
, C 232 799
33 C 233 799
% C 234 799
had C 235 799
this C 236 799
complex C 237 799
, C 238 799
either C 239 799
alone C 240 799
or C 241 799
with C 242 799
independent C 243 799
spikes C 244 799
. C 245 799
although C 247 799
these C 248 799
complexes C 249 799
were C 250 799
most C 251 799
frequent C 252 799
in C 253 799
the C 254 799
au C 255 799
- C 256 799
tistic C 257 799
- C 258 799
symbiotic C 259 799
group C 260 799
, C 261 799
the C 262 799
incidence C 263 799
was C 264 799
not C 265 799
statistically C 266 799
significantly C 267 799
different C 268 799
from C 269 799
the C 270 799
higher C 271 799
performing C 272 799
, C 273 799
chronic C 274 799
undiffer C 275 799
- C 276 799
entiated C 277 799
schizophrenics C 278 799
who C 279 799
had C 280 799
communi C 281 799
- C 282 799
cative C 283 799
speech C 284 799
or C 285 799
the C 286 799
non C 287 799
- C 288 799
psychotic C 289 799
children C 290 799
with C 291 799
acting C 292 799
- C 293 799
out C 294 799
behavior C 295 799
disorders C 296 799
. C 297 799
of C 299 799
the C 300 799
58 C 301 799
autistic C 302 799
- C 303 799
symbiotic C 304 799
children C 305 799
, C 306 799
19 C 307 799
% C 308 799
had C 309 799
seizures C 310 799
, C 311 799
which C 312 799
is C 313 799
similar C 314 799
to C 315 799
the C 316 799
13 C 317 799
% C 318 799
seizure C 319 799
incidence C 320 799
in C 321 799
the C 322 799
remaining C 323 799
91 C 324 799
psy C 325 799
- C 326 799
chiatric C 327 799
patients C 328 799
. C 329 799
whether C 331 799
the C 332 799
cerebral C 333 799
dysfunction C 334 799
im C 335 799
- C 336 799
plied C 337 799
by C 338 799
this C 339 799
study C 340 799
is C 341 799
a C 342 799
primary C 343 799
disorder C 344 799
or C 345 799
is C 346 799
secondary C 347 799
to C 348 799
some C 349 799
factor C 350 799
such C 351 799
as C 352 799
the C 353 799
effect C 354 799
of C 355 799
prolonged C 356 799
anxiety C 357 799
on C 358 799
body C 359 799
chem C 360 799
- C 361 799
istry C 362 799
cannot C 363 799
be C 364 799
decided C 365 799
at C 366 799
this C 367 799
time C 368 799
. C 369 799
never C 371 799
- C 372 799
theless C 373 799
, C 374 799
an C 375 799
organic C 376 799
concomitant C 377 799
has C 378 799
been C 379 799
demonstrated C 380 799
in C 381 799
51 C 382 799
% C 383 799
of C 384 799
the C 385 799
psychiatrically C 386 799
disturbed C 387 799
children C 388 799
. C 389 799
by C 391 799
increasing C 392 799
the C 393 799
amount C 394 799
of C 395 799
time C 396 799
included C 397 799
in C 398 799
the C 399 799
eeg C 400 799
sam C 401 799
- C 402 799
ple C 403 799
, C 404 799
the C 405 799
incidence C 406 799
of C 407 799
electrical C 408 799
abnormalities C 409 799
might C 410 799
be C 411 799
even C 412 799
higher C 413 799
. C 414 799
on C 1 800
early C 2 800
infantile C 3 800
psychosis C 4 800
. C 5 800
the C 7 800
symbiotic C 8 800
and C 9 800
autistic C 10 800
syndromes C 11 800
in C 12 800
conclusion C 13 800
, C 14 800
i C 15 800
wish C 16 800
to C 17 800
state C 18 800
that C 19 800
the C 20 800
core C 21 800
of C 22 800
child C 23 800
psychosis C 24 800
must C 25 800
be C 26 800
sought C 27 800
in C 28 800
one C 29 800
or C 30 800
the C 31 800
other C 32 800
of C 33 800
the C 34 800
described C 35 800
distortions C 36 800
of C 37 800
the C 38 800
sym C 39 800
- C 40 800
biotic C 41 800
phase C 42 800
. C 43 800
in C 45 800
the C 46 800
first C 47 800
case C 48 800
, C 49 800
what C 50 800
lay C 51 800
at C 52 800
the C 53 800
heart C 54 800
of C 55 800
the C 56 800
psychotic C 57 800
dis C 58 800
- C 59 800
turbance C 60 800
was C 61 800
the C 62 800
marked C 63 800
emotional C 64 800
unavailability C 65 800
of C 66 800
the C 67 800
mother C 68 800
, C 69 800
which C 70 800
alternated C 71 800
with C 72 800
a C 73 800
purely C 74 800
physical C 75 800
extreme C 76 800
closeness C 77 800
during C 78 800
the C 79 800
breast C 80 800
- C 81 800
feeding C 82 800
situations C 83 800
, C 84 800
and C 85 800
particularly C 86 800
with C 87 800
the C 88 800
destructiveness C 89 800
of C 90 800
the C 91 800
mother C 92 800
' C 93 800
s C 94 800
unpredictable C 95 800
rage C 96 800
attacks C 97 800
. C 98 800
the C 100 800
contrasting C 101 800
experiences C 102 800
drove C 103 800
the C 104 800
child C 105 800
to C 106 800
the C 107 800
autistic C 108 800
warding C 109 800
off C 110 800
of C 111 800
any C 112 800
human C 113 800
contact C 114 800
and C 115 800
the C 116 800
de C 117 800
- C 118 800
animation C 119 800
of C 120 800
the C 121 800
world C 122 800
of C 123 800
reality C 124 800
. C 125 800
constitutional C 127 800
factors C 128 800
could C 129 800
not C 130 800
, C 131 800
in C 132 800
this C 133 800
case C 134 800
, C 135 800
be C 136 800
evaluated C 137 800
with C 138 800
any C 139 800
degree C 140 800
of C 141 800
accuracy C 142 800
. C 143 800
in C 145 800
the C 146 800
second C 147 800
case C 148 800
, C 149 800
it C 150 800
was C 151 800
, C 152 800
by C 153 800
contrast C 154 800
, C 155 800
the C 156 800
mother C 157 800
' C 158 800
s C 159 800
ever C 160 800
- C 161 800
presence C 162 800
that C 163 800
created C 164 800
an C 165 800
unendurable C 166 800
instrusion C 167 800
upon C 168 800
and C 169 800
interference C 170 800
with C 171 800
the C 172 800
structuralization C 173 800
of C 174 800
the C 175 800
budding C 176 800
ego C 177 800
, C 178 800
which C 179 800
constitutionally C 180 800
and C 181 800
perhaps C 182 800
predispositionally C 183 800
may C 184 800
have C 185 800
been C 186 800
very C 187 800
vulnerable C 188 800
. C 189 800
this C 191 800
made C 192 800
it C 193 800
impossible C 194 800
for C 195 800
the C 196 800
infant C 197 800
to C 198 800
experience C 199 800
the C 200 800
normal C 201 800
alternation C 202 800
of C 203 800
the C 204 800
gratification C 205 800
- C 206 800
frustration C 207 800
sequences C 208 800
at C 209 800
his C 210 800
own C 211 800
pace C 212 800
; C 213 800
it C 214 800
also C 215 800
made C 216 800
the C 217 800
process C 218 800
of C 219 800
individuation C 220 800
in C 221 800
the C 222 800
separation C 223 800
- C 224 800
individuation C 225 800
period C 226 800
one C 227 800
which C 228 800
was C 229 800
beset C 230 800
with C 231 800
abysmal C 232 800
panic C 233 800
. C 234 800
in C 236 800
both C 237 800
instances C 238 800
, C 239 800
we C 240 800
can C 241 800
see C 242 800
that C 243 800
it C 244 800
was C 245 800
primarily C 246 800
in C 247 800
the C 248 800
severe C 249 800
dis C 250 800
- C 251 800
tortions C 252 800
of C 253 800
the C 254 800
normal C 255 800
symbiosis C 256 800
that C 257 800
the C 258 800
child C 259 800
psychosis C 260 800
had C 261 800
its C 262 800
roots C 263 800
. C 264 800
autopathy C 1 801
: C 2 801
follow C 3 801
- C 4 801
up C 5 801
of C 6 801
cases C 7 801
the C 8 801
publication C 9 801
of C 10 801
two C 11 801
papers C 12 801
recently C 13 801
in C 14 801
the C 15 801
acta C 16 801
paedopsychiatrica C 17 801
by C 18 801
d C 19 801
. C 20 801
arn C 22 801
. C 23 801
van C 25 801
krevelen C 26 801
on C 27 801
the C 28 801
subject C 29 801
of C 30 801
" C 31 801
autistic C 32 801
psychopathy C 33 801
" C 34 801
, C 35 801
has C 36 801
stimulated C 37 801
the C 38 801
author C 39 801
to C 40 801
present C 41 801
5 C 42 801
cases C 43 801
which C 44 801
appear C 45 801
to C 46 801
conform C 47 801
to C 48 801
his C 49 801
description C 50 801
. C 51 801
the C 53 801
only C 54 801
value C 55 801
of C 56 801
this C 57 801
brief C 58 801
contribution C 59 801
lies C 60 801
in C 61 801
the C 62 801
fact C 63 801
that C 64 801
they C 65 801
have C 66 801
all C 67 801
been C 68 801
followed C 69 801
up C 70 801
for C 71 801
at C 72 801
least C 73 801
10 C 74 801
years C 75 801
, C 76 801
and C 77 801
this C 78 801
may C 79 801
give C 80 801
some C 81 801
idea C 82 801
of C 83 801
the C 84 801
eventual C 85 801
results C 86 801
in C 87 801
this C 88 801
type C 89 801
of C 90 801
cases C 91 801
. C 92 801
sensory C 1 802
dominance C 2 802
in C 3 802
autistic C 4 802
imbecile C 5 802
children C 6 802
and C 7 802
controls C 8 802
in C 9 802
a C 10 802
previous C 11 802
experiment C 12 802
( C 13 802
hermelin C 14 802
and C 15 802
o C 16 802
' C 17 802
connor C 18 802
, C 19 802
1964 C 20 802
) C 21 802
it C 22 802
was C 23 802
found C 24 802
that C 25 802
autistic C 26 802
and C 27 802
control C 28 802
imbecile C 29 802
children C 30 802
responded C 31 802
most C 32 802
frequently C 33 802
to C 34 802
a C 35 802
light C 36 802
stimulus C 37 802
in C 38 802
conditions C 39 802
of C 40 802
bimodal C 41 802
, C 42 802
simultaneous C 43 802
stimulation C 44 802
. C 45 802
however C 47 802
, C 48 802
the C 49 802
role C 50 802
of C 51 802
the C 52 802
relative C 53 802
intensity C 54 802
level C 55 802
of C 56 802
the C 57 802
stimuli C 58 802
remained C 59 802
to C 60 802
be C 61 802
determined C 62 802
. C 63 802
in C 65 802
the C 66 802
present C 67 802
experiment C 68 802
a C 69 802
light C 70 802
and C 71 802
a C 72 802
sound C 73 802
, C 74 802
or C 75 802
a C 76 802
light C 77 802
and C 78 802
a C 79 802
verbal C 80 802
command C 81 802
were C 82 802
presented C 83 802
simultaneously C 84 802
in C 85 802
various C 86 802
intensity C 87 802
combina C 88 802
- C 89 802
tions C 90 802
. C 91 802
all C 93 802
responses C 94 802
, C 95 802
irrespective C 96 802
of C 97 802
the C 98 802
stim C 99 802
- C 100 802
ulus C 101 802
to C 102 802
which C 103 802
they C 104 802
were C 105 802
made C 106 802
, C 107 802
were C 108 802
rewarded C 109 802
. C 110 802
autistic C 112 802
, C 113 802
mongol C 114 802
, C 115 802
and C 116 802
nonmongol C 117 802
imbecile C 118 802
children C 119 802
were C 120 802
tested C 121 802
. C 122 802
in C 124 802
addition C 125 802
to C 126 802
a C 127 802
tendency C 128 802
for C 129 802
visual C 130 802
dominance C 131 802
results C 132 802
showed C 133 802
that C 134 802
independent C 135 802
of C 136 802
modality C 137 802
, C 138 802
high C 139 802
intensities C 140 802
affected C 141 802
all C 142 802
groups C 143 802
. C 144 802
nonmongol C 146 802
imbecile C 147 802
children C 148 802
also C 149 802
responded C 150 802
significantly C 151 802
more C 152 802
frequently C 153 802
to C 154 802
the C 155 802
verbal C 156 802
than C 157 802
to C 158 802
the C 159 802
sound C 160 802
stimulus C 161 802
, C 162 802
while C 163 802
the C 164 802
other C 165 802
two C 166 802
groups C 167 802
did C 168 802
not C 169 802
. C 170 802
dreaming C 1 803
sleep C 2 803
in C 3 803
autistic C 4 803
twins C 5 803
each C 6 803
of C 7 803
5 C 8 803
- C 9 803
year C 10 803
- C 11 803
old C 12 803
identical C 13 803
autistic C 14 803
twins C 15 803
was C 16 803
observed C 17 803
during C 18 803
one C 19 803
spontaneous C 20 803
all C 21 803
night C 22 803
sleep C 23 803
session C 24 803
during C 25 803
which C 26 803
their C 27 803
electroencephalogram C 28 803
, C 29 803
eye C 30 803
movement C 31 803
, C 32 803
heart C 33 803
rate C 34 803
, C 35 803
and C 36 803
chin C 37 803
muscle C 38 803
potential C 39 803
were C 40 803
recorded C 41 803
. C 42 803
these C 44 803
autistic C 45 803
twins C 46 803
showed C 47 803
a C 48 803
similar C 49 803
patterning C 50 803
and C 51 803
amount C 52 803
of C 53 803
dreaming C 54 803
sleep C 55 803
to C 56 803
each C 57 803
other C 58 803
and C 59 803
to C 60 803
that C 61 803
reported C 62 803
for C 63 803
normal C 64 803
children C 65 803
of C 66 803
the C 67 803
same C 68 803
age C 69 803
. C 70 803
twins C 1 804
discordant C 2 804
for C 3 804
early C 4 804
infantile C 5 804
autism C 6 804
a C 7 804
pair C 8 804
of C 9 804
heterozygous C 10 804
twins C 11 804
discordant C 12 804
for C 13 804
early C 14 804
infantile C 15 804
autism C 16 804
is C 17 804
reported C 18 804
and C 19 804
the C 20 804
relevant C 21 804
literature C 22 804
reviewed C 23 804
. C 24 804
although C 26 804
mani C 27 804
- C 28 804
fest C 29 804
organic C 30 804
factors C 31 804
were C 32 804
ruled C 33 804
out C 34 804
, C 35 804
the C 36 804
twins C 37 804
' C 38 804
physical C 39 804
development C 40 804
was C 41 804
different C 42 804
. C 43 804
a C 45 804
spe C 46 804
- C 47 804
cific C 48 804
emotional C 49 804
etiology C 50 804
was C 51 804
not C 52 804
demon C 53 804
- C 54 804
strated C 55 804
. C 56 804
the C 58 804
few C 59 804
available C 60 804
twin C 61 804
studies C 62 804
offer C 63 804
findings C 64 804
consistent C 65 804
with C 66 804
the C 67 804
hypothesis C 68 804
that C 69 804
genetic C 70 804
factors C 71 804
are C 72 804
relevant C 73 804
to C 74 804
the C 75 804
develop C 76 804
- C 77 804
ment C 78 804
of C 79 804
childhood C 80 804
autism C 81 804
. C 82 804
evidence C 84 804
is C 85 804
also C 86 804
presented C 87 804
that C 88 804
impaired C 89 804
acquisition C 90 804
of C 91 804
lan C 92 804
- C 93 804
guage C 94 804
may C 95 804
have C 96 804
hereditary C 97 804
determinants C 98 804
. C 99 804
a C 101 804
second C 102 804
set C 103 804
of C 104 804
probably C 105 804
homozygous C 106 804
twins C 107 804
are C 108 804
reported C 109 804
who C 110 804
were C 111 804
also C 112 804
discordant C 113 804
for C 114 804
autism C 115 804
. C 116 804
this C 118 804
second C 119 804
case C 120 804
suggests C 121 804
that C 122 804
, C 123 804
although C 124 804
genetic C 125 804
factors C 126 804
may C 127 804
play C 128 804
a C 129 804
part C 130 804
, C 131 804
in C 132 804
some C 133 804
cases C 134 804
the C 135 804
syndrome C 136 804
of C 137 804
infantile C 138 804
autism C 139 804
appears C 140 804
to C 141 804
be C 142 804
a C 143 804
reversible C 144 804
one C 145 804
. C 146 804
in C 148 804
view C 149 804
of C 150 804
this C 151 804
set C 152 804
of C 153 804
twins C 154 804
and C 155 804
of C 156 804
kanner C 157 804
' C 158 804
s C 159 804
sibling C 160 804
data C 161 804
, C 162 804
the C 163 804
role C 164 804
of C 165 804
genetic C 166 804
factors C 167 804
remains C 168 804
obscure C 169 804
, C 170 804
and C 171 804
more C 172 804
twin C 173 804
studies C 174 804
properly C 175 804
documented C 176 804
with C 177 804
blood C 178 804
typing C 179 804
are C 180 804
needed C 181 804
. C 182 804
evaluation C 1 805
and C 2 805
treatment C 3 805
planning C 4 805
for C 5 805
autistic C 6 805
children C 7 805
infantile C 8 805
autism C 9 805
is C 10 805
considered C 11 805
to C 12 805
be C 13 805
a C 14 805
re C 15 805
- C 16 805
action C 17 805
on C 18 805
the C 19 805
part C 20 805
of C 21 805
an C 22 805
immature C 23 805
organism C 24 805
at C 25 805
a C 26 805
primitive C 27 805
and C 28 805
undifferentiated C 29 805
stage C 30 805
of C 31 805
ego C 32 805
development C 33 805
. C 34 805
little C 36 805
choice C 37 805
of C 38 805
defensive C 39 805
reactions C 40 805
is C 41 805
available C 42 805
; C 43 805
the C 44 805
possibility C 45 805
of C 46 805
sub C 47 805
- C 48 805
limation C 49 805
does C 50 805
not C 51 805
exist C 52 805
and C 53 805
, C 54 805
even C 55 805
though C 56 805
other C 57 805
object C 58 805
relationships C 59 805
are C 60 805
gradually C 61 805
developing C 62 805
, C 63 805
the C 64 805
mother C 65 805
is C 66 805
still C 67 805
the C 68 805
child C 69 805
' C 70 805
s C 71 805
primary C 72 805
object C 73 805
. C 74 805
at C 76 805
this C 77 805
vulnerable C 78 805
develop C 79 805
- C 80 805
mental C 81 805
stage C 82 805
, C 83 805
a C 84 805
wide C 85 805
range C 86 805
of C 87 805
pathological C 88 805
circumstances C 89 805
, C 90 805
ranging C 91 805
from C 92 805
the C 93 805
most C 94 805
severe C 95 805
family C 96 805
psychopathology C 97 805
to C 98 805
the C 99 805
most C 100 805
adventi C 101 805
- C 102 805
tious C 103 805
physiological C 104 805
traumata C 105 805
or C 106 805
the C 107 805
most C 108 805
un C 109 805
- C 110 805
fortunately C 111 805
malignant C 112 805
circumstances C 113 805
, C 114 805
may C 115 805
constitute C 116 805
an C 117 805
acute C 118 805
or C 119 805
cumulative C 120 805
cata C 121 805
- C 122 805
strophic C 123 805
stress C 124 805
. C 125 805
the C 127 805
primitive C 128 805
organism C 129 805
tends C 130 805
to C 131 805
respond C 132 805
to C 133 805
this C 134 805
overwhelming C 135 805
stress C 136 805
with C 137 805
a C 138 805
paranoid C 139 805
reaction C 140 805
which C 141 805
is C 142 805
directed C 143 805
at C 144 805
the C 145 805
mother C 146 805
( C 147 805
regardless C 148 805
of C 149 805
the C 150 805
actual C 151 805
etiologi C 152 805
- C 153 805
cal C 154 805
variables C 155 805
) C 156 805
because C 157 805
the C 158 805
mother C 159 805
is C 160 805
still C 161 805
the C 162 805
child C 163 805
' C 164 805
s C 165 805
primary C 166 805
object C 167 805
. C 168 805
we C 170 805
believe C 171 805
that C 172 805
the C 173 805
child C 174 805
then C 175 805
responds C 176 805
with C 177 805
an C 178 805
autistic C 179 805
reaction C 180 805
and C 181 805
shows C 182 805
varying C 183 805
degrees C 184 805
of C 185 805
simple C 186 805
with C 187 805
- C 188 805
drawal C 189 805
, C 190 805
obsessional C 191 805
behavior C 192 805
, C 193 805
magical C 194 805
or C 195 805
de C 196 805
- C 197 805
lusional C 198 805
thought C 199 805
processes C 200 805
, C 201 805
and C 202 805
consequent C 203 805
disruption C 204 805
of C 205 805
developmental C 206 805
skills C 207 805
, C 208 805
speech C 209 805
, C 210 805
and C 211 805
relationships C 212 805
with C 213 805
others C 214 805
. C 215 805
many C 217 805
families C 218 805
can C 219 805
and C 220 805
do C 221 805
make C 222 805
every C 223 805
effort C 224 805
to C 225 805
counter C 226 805
the C 227 805
paranoid C 228 805
reaction C 229 805
of C 230 805
the C 231 805
child C 232 805
and C 233 805
do C 234 805
not C 235 805
respond C 236 805
to C 237 805
his C 238 805
rejection C 239 805
with C 240 805
counterrejection C 241 805
and C 242 805
counterwithdrawal C 243 805
. C 244 805
some C 246 805
of C 247 805
the C 248 805
child C 249 805
' C 250 805
s C 251 805
autistic C 252 805
symptoms C 253 805
may C 254 805
abate C 255 805
without C 256 805
formal C 257 805
treatment C 258 805
. C 259 805
yet C 261 805
, C 262 805
since C 263 805
the C 264 805
mother C 265 805
( C 266 805
and C 267 805
family C 268 805
) C 269 805
are C 270 805
the C 271 805
primary C 272 805
objects C 273 805
of C 274 805
the C 275 805
child C 276 805
' C 277 805
s C 278 805
paranoid C 279 805
attitude C 280 805
, C 281 805
it C 282 805
is C 283 805
felt C 284 805
that C 285 805
formal C 286 805
therapeutic C 287 805
intervention C 288 805
is C 289 805
necessary C 290 805
to C 291 805
modify C 292 805
the C 293 805
paranoid C 294 805
core C 295 805
of C 296 805
the C 297 805
autistic C 298 805
reaction C 299 805
. C 300 805
a C 1 806
twenty C 2 806
- C 3 806
five C 4 806
year C 5 806
view C 6 806
of C 7 806
therapeutic C 8 806
results C 9 806
thus C 10 806
this C 11 806
group C 12 806
of C 13 806
ten C 14 806
patients C 15 806
shows C 16 806
a C 17 806
complete C 18 806
range C 19 806
of C 20 806
chronic C 21 806
schizophrenia C 22 806
from C 23 806
a C 24 806
bright C 25 806
pseudoneurotic C 26 806
never C 27 806
hospitalized C 28 806
, C 29 806
to C 30 806
an C 31 806
inaccessible C 32 806
patient C 33 806
chronically C 34 806
hospitalized C 35 806
for C 36 806
20 C 37 806
years C 38 806
. C 39 806
physiological C 41 806
therapy C 42 806
in C 43 806
the C 44 806
form C 45 806
of C 46 806
metrazol C 47 806
- C 48 806
induced C 49 806
convulsions C 50 806
given C 51 806
in C 52 806
the C 53 806
course C 54 806
of C 55 806
a C 56 806
puberty C 57 806
schizophrenic C 58 806
psychosis C 59 806
, C 60 806
has C 61 806
been C 62 806
helpful C 63 806
to C 64 806
some C 65 806
by C 66 806
making C 67 806
them C 68 806
more C 69 806
accessible C 70 806
for C 71 806
the C 72 806
total C 73 806
treat C 74 806
- C 75 806
ment C 76 806
program C 77 806
in C 78 806
the C 79 806
hospital C 80 806
or C 81 806
by C 82 806
raising C 83 806
their C 84 806
margin C 85 806
of C 86 806
tolerance C 87 806
sufficiently C 88 806
so C 89 806
that C 90 806
they C 91 806
could C 92 806
live C 93 806
at C 94 806
home C 95 806
and C 96 806
attend C 97 806
public C 98 806
schools C 99 806
at C 100 806
least C 101 806
for C 102 806
a C 103 806
time C 104 806
and C 105 806
at C 106 806
best C 107 806
, C 108 806
indefinitely C 109 806
. C 110 806
several C 112 806
of C 113 806
the C 114 806
most C 115 806
regressed C 116 806
, C 117 806
deteriorated C 118 806
patients C 119 806
in C 120 806
state C 121 806
hospitals C 122 806
for C 123 806
many C 124 806
years C 125 806
, C 126 806
have C 127 806
been C 128 806
brought C 129 806
back C 130 806
to C 131 806
some C 132 806
level C 133 806
of C 134 806
meaningful C 135 806
living C 136 806
again C 137 806
by C 138 806
the C 139 806
current C 140 806
drug C 141 806
therapy C 142 806
program C 143 806
, C 144 806
and C 145 806
are C 146 806
still C 147 806
im C 148 806
- C 149 806
proving C 150 806
. C 151 806
now C 153 806
we C 154 806
have C 155 806
not C 156 806
determined C 157 806
who C 158 806
the C 159 806
sinner C 160 806
may C 161 806
be C 162 806
. C 163 806
there C 165 806
are C 166 806
many C 167 806
who C 168 806
will C 169 806
believe C 170 806
that C 171 806
the C 172 806
mother C 173 806
is C 174 806
always C 175 806
the C 176 806
sinner C 177 806
; C 178 806
is C 179 806
she C 180 806
not C 181 806
schizophrenogenic C 182 806
? C 183 806
there C 184 806
are C 185 806
others C 186 806
who C 187 806
will C 188 806
believe C 189 806
that C 190 806
the C 191 806
individual C 192 806
himself C 193 806
is C 194 806
the C 195 806
sinner C 196 806
since C 197 806
, C 198 806
after C 199 806
all C 200 806
, C 201 806
is C 202 806
he C 203 806
not C 204 806
the C 205 806
one C 206 806
whose C 207 806
behavior C 208 806
and C 209 806
fantasies C 210 806
are C 211 806
schizophrenic C 212 806
? C 213 806
however C 214 806
, C 215 806
there C 216 806
will C 217 806
be C 218 806
many C 219 806
of C 220 806
you C 221 806
attending C 222 806
this C 223 806
fifty C 224 806
- C 225 806
second C 226 806
annual C 227 806
meeting C 228 806
of C 229 806
the C 230 806
american C 231 806
psychopathological C 232 806
association C 233 806
, C 234 806
who C 235 806
will C 236 806
judge C 237 806
the C 238 806
speaker C 239 806
to C 240 806
be C 241 806
the C 242 806
sinner C 243 806
, C 244 806
for C 245 806
have C 246 806
i C 247 806
not C 248 806
given C 249 806
you C 250 806
this C 251 806
wealth C 252 806
of C 253 806
clinical C 254 806
ma C 255 806
- C 256 806
terial C 257 806
without C 258 806
charts C 259 806
, C 260 806
graphs C 261 806
, C 262 806
or C 263 806
statistical C 264 806
evaluation C 265 806
? C 266 806
group C 1 807
psychotherapy C 2 807
with C 3 807
preschool C 4 807
psychotic C 5 807
children C 6 807
and C 7 807
collateral C 8 807
group C 9 807
therapy C 10 807
of C 11 807
their C 12 807
parents C 13 807
: C 14 807
a C 15 807
preliminary C 16 807
report C 17 807
of C 18 807
the C 19 807
first C 20 807
two C 21 807
years C 22 807
a C 23 807
group C 24 807
approach C 25 807
in C 26 807
the C 27 807
treatment C 28 807
of C 29 807
preschool C 30 807
- C 31 807
aged C 32 807
psychotic C 33 807
children C 34 807
is C 35 807
reported C 36 807
. C 37 807
autism C 39 807
is C 40 807
a C 41 807
defense C 42 807
against C 43 807
loss C 44 807
of C 45 807
the C 46 807
symbiotic C 47 807
partner C 48 807
. C 49 807
the C 51 807
group C 52 807
of C 53 807
children C 54 807
penetrates C 55 807
this C 56 807
defense C 57 807
and C 58 807
forms C 59 807
a C 60 807
" C 61 807
group C 62 807
ego C 63 807
, C 64 807
" C 65 807
which C 66 807
constitutes C 67 807
one C 68 807
pole C 69 807
of C 70 807
a C 71 807
new C 72 807
therapeutic C 73 807
symbiosis C 74 807
from C 75 807
which C 76 807
separation C 77 807
- C 78 807
individuation C 79 807
can C 80 807
occur C 81 807
. C 82 807
autistic C 1 808
reactions C 2 808
in C 3 808
early C 4 808
childhood C 5 808
: C 6 808
differential C 7 808
diagnostic C 8 808
considerations C 9 808
the C 10 808
term C 11 808
" C 12 808
autism C 13 808
" C 14 808
is C 15 808
frequently C 16 808
used C 17 808
today C 18 808
in C 19 808
the C 20 808
differential C 21 808
diagnosis C 22 808
of C 23 808
the C 24 808
severe C 25 808
emotional C 26 808
disturbances C 27 808
of C 28 808
early C 29 808
childhood C 30 808
. C 31 808
however C 33 808
, C 34 808
to C 35 808
label C 36 808
a C 37 808
child C 38 808
as C 39 808
" C 40 808
autistic C 41 808
" C 42 808
presents C 43 808
some C 44 808
formidable C 45 808
problems C 46 808
with C 47 808
regard C 48 808
to C 49 808
definition C 50 808
of C 51 808
the C 52 808
term C 53 808
, C 54 808
the C 55 808
specific C 56 808
etiological C 57 808
- C 58 808
diagnostic C 59 808
implications C 60 808
, C 61 808
and C 62 808
treatment C 63 808
considerations C 64 808
for C 65 808
any C 66 808
given C 67 808
child C 68 808
so C 69 808
designated C 70 808
. C 71 808
the C 73 808
purpose C 74 808
of C 75 808
this C 76 808
paper C 77 808
is C 78 808
to C 79 808
briefly C 80 808
review C 81 808
some C 82 808
of C 83 808
the C 84 808
historical C 85 808
psychiatric C 86 808
background C 87 808
of C 88 808
the C 89 808
term C 90 808
" C 91 808
autism C 92 808
" C 93 808
, C 94 808
its C 95 808
more C 96 808
recent C 97 808
ramifications C 98 808
, C 99 808
and C 100 808
our C 101 808
clinical C 102 808
experiences C 103 808
in C 104 808
this C 105 808
field C 106 808
. C 107 808
infantile C 1 809
autism C 2 809
: C 3 809
a C 4 809
family C 5 809
approach C 6 809
the C 7 809
autistic C 8 809
child C 9 809
appears C 10 809
to C 11 809
be C 12 809
unable C 13 809
to C 14 809
integrate C 15 809
or C 16 809
to C 17 809
respond C 18 809
to C 19 809
stimuli C 20 809
, C 21 809
both C 22 809
from C 23 809
an C 24 809
internal C 25 809
source C 26 809
, C 27 809
the C 28 809
body C 29 809
, C 30 809
as C 31 809
well C 32 809
as C 33 809
from C 34 809
external C 35 809
sources C 36 809
, C 37 809
such C 38 809
as C 39 809
human C 40 809
contact C 41 809
. C 42 809
we C 44 809
have C 45 809
noted C 46 809
in C 47 809
the C 48 809
children C 49 809
at C 50 809
our C 51 809
residential C 52 809
treatment C 53 809
center C 54 809
how C 55 809
in C 56 809
their C 57 809
preliminary C 58 809
period C 59 809
with C 60 809
us C 61 809
they C 62 809
appear C 63 809
to C 64 809
be C 65 809
unaware C 66 809
of C 67 809
their C 68 809
body C 69 809
; C 70 809
they C 71 809
give C 72 809
the C 73 809
impression C 74 809
of C 75 809
being C 76 809
insensitive C 77 809
to C 78 809
pain C 79 809
, C 80 809
display C 81 809
little C 82 809
autoerotic C 83 809
behavior C 84 809
, C 85 809
inflict C 86 809
injury C 87 809
on C 88 809
themselves C 89 809
, C 90 809
such C 91 809
as C 92 809
hitting C 93 809
their C 94 809
heads C 95 809
against C 96 809
objects C 97 809
and C 98 809
biting C 99 809
their C 100 809
own C 101 809
bodies C 102 809
, C 103 809
with C 104 809
little C 105 809
outward C 106 809
display C 107 809
of C 108 809
distress C 109 809
. C 110 809
in C 112 809
working C 113 809
with C 114 809
these C 115 809
children C 116 809
in C 117 809
therapy C 118 809
, C 119 809
one C 120 809
of C 121 809
the C 122 809
guideposts C 123 809
for C 124 809
change C 125 809
and C 126 809
for C 127 809
growth C 128 809
is C 129 809
a C 130 809
display C 131 809
on C 132 809
the C 133 809
child C 134 809
' C 135 809
s C 136 809
part C 137 809
of C 138 809
an C 139 809
increased C 140 809
body C 141 809
awareness C 142 809
and C 143 809
autoerotic C 144 809
behavior C 145 809
. C 146 809
for C 148 809
example C 149 809
, C 150 809
one C 151 809
child C 152 809
who C 153 809
developed C 154 809
polio C 155 809
during C 156 809
his C 157 809
early C 158 809
stay C 159 809
at C 160 809
the C 161 809
clinic C 162 809
residence C 163 809
did C 164 809
not C 165 809
communicate C 166 809
this C 167 809
to C 168 809
anyone C 169 809
and C 170 809
it C 171 809
was C 172 809
only C 173 809
made C 174 809
known C 175 809
by C 176 809
observing C 177 809
the C 178 809
child C 179 809
' C 180 809
s C 181 809
dragging C 182 809
one C 183 809
leg C 184 809
( C 185 809
memorial C 186 809
guid C 187 809
- C 188 809
ance C 189 809
clinic C 190 809
, C 191 809
1959 C 192 809
) C 193 809
. C 194 809
later C 196 809
, C 197 809
he C 198 809
was C 199 809
able C 200 809
to C 201 809
point C 202 809
to C 203 809
his C 204 809
body C 205 809
and C 206 809
to C 207 809
indicate C 208 809
pain C 209 809
. C 210 809
another C 212 809
child C 213 809
, C 214 809
who C 215 809
at C 216 809
first C 217 809
seemed C 218 809
to C 219 809
be C 220 809
quite C 221 809
unaware C 222 809
of C 223 809
both C 224 809
himself C 225 809
and C 226 809
others C 227 809
, C 228 809
concurrent C 229 809
with C 230 809
his C 231 809
growing C 232 809
display C 233 809
of C 234 809
affective C 235 809
expression C 236 809
toward C 237 809
the C 238 809
therapist C 239 809
also C 240 809
manifested C 241 809
pleasure C 242 809
through C 243 809
genital C 244 809
stimulation C 245 809
, C 246 809
was C 247 809
quite C 248 809
ticklish C 249 809
, C 250 809
and C 251 809
when C 252 809
injured C 253 809
would C 254 809
display C 255 809
the C 256 809
area C 257 809
of C 258 809
pain C 259 809
quite C 260 809
readily C 261 809
. C 262 809
an C 1 810
analysis C 2 810
of C 3 810
the C 4 810
language C 5 810
of C 6 810
fourteen C 7 810
schizophrenic C 8 810
children C 9 810
fourteen C 10 810
schizophrenic C 11 810
( C 12 810
autistic C 13 810
) C 14 810
children C 15 810
were C 16 810
studied C 17 810
by C 18 810
means C 19 810
of C 20 810
detailed C 21 810
behavioural C 22 810
histories C 23 810
and C 24 810
observations C 25 810
. C 26 810
the C 28 810
language C 29 810
recorded C 30 810
in C 31 810
history C 32 810
and C 33 810
observation C 34 810
protocols C 35 810
was C 36 810
analysed C 37 810
and C 38 810
compared C 39 810
with C 40 810
available C 41 810
data C 42 810
on C 43 810
normal C 44 810
children C 45 810
. C 46 810
all C 48 810
schizophrenic C 49 810
children C 50 810
were C 51 810
grossly C 52 810
retarded C 53 810
in C 54 810
their C 55 810
language C 56 810
development C 57 810
and C 58 810
all C 59 810
measures C 60 810
of C 61 810
this C 62 810
correlated C 63 810
highly C 64 810
with C 65 810
a C 66 810
previous C 67 810
overall C 68 810
clinical C 69 810
assessment C 70 810
of C 71 810
the C 72 810
severity C 73 810
of C 74 810
illness C 75 810
. C 76 810
the C 78 810
most C 79 810
striking C 80 810
abnormalities C 81 810
in C 82 810
the C 83 810
language C 84 810
of C 85 810
the C 86 810
children C 87 810
studied C 88 810
were C 89 810
stereotyped C 90 810
repetition C 91 810
of C 92 810
utterances C 93 810
appropriate C 94 810
to C 95 810
an C 96 810
earlier C 97 810
developmental C 98 810
level C 99 810
or C 100 810
to C 101 810
a C 102 810
previous C 103 810
environmental C 104 810
context C 105 810
, C 106 810
accompanied C 107 810
by C 108 810
a C 109 810
lack C 110 810
of C 111 810
normal C 112 810
expressions C 113 810
of C 114 810
curiosity C 115 810
and C 116 810
of C 117 810
responsiveness C 118 810
to C 119 810
changing C 120 810
environmental C 121 810
cues C 122 810
. C 123 810
a C 1 811
behavioural C 2 811
and C 3 811
electroencephalographic C 4 811
study C 5 811
of C 6 811
autistic C 7 811
children C 8 811
short C 9 811
biographies C 10 811
are C 11 811
given C 12 811
of C 13 811
10 C 14 811
children C 15 811
, C 16 811
age C 17 811
3 C 18 811
to C 19 811
6 C 20 811
years C 21 811
, C 22 811
diagnosed C 23 811
as C 24 811
suffering C 25 811
from C 26 811
kanner C 27 811
' C 28 811
s C 29 811
syndrome C 30 811
( C 31 811
early C 32 811
infantile C 33 811
autism C 34 811
) C 35 811
. C 36 811
an C 38 811
analysis C 39 811
was C 40 811
made C 41 811
of C 42 811
the C 43 811
free C 44 811
- C 45 811
field C 46 811
acti C 47 811
- C 48 811
vities C 49 811
of C 50 811
these C 51 811
children C 52 811
compared C 53 811
with C 54 811
a C 55 811
group C 56 811
of C 57 811
normal C 58 811
children C 59 811
of C 60 811
similar C 61 811
age C 62 811
. C 63 811
electro C 65 811
- C 66 811
encephalographic C 67 811
studies C 68 811
were C 69 811
also C 70 811
carried C 71 811
out C 72 811
on C 73 811
all C 74 811
10 C 75 811
children C 76 811
, C 77 811
and C 78 811
in C 79 811
two C 80 811
it C 81 811
was C 82 811
possible C 83 811
to C 84 811
carry C 85 811
out C 86 811
simultaneous C 87 811
behavioural C 88 811
and C 89 811
eeg C 90 811
observations C 91 811
by C 92 811
means C 93 811
of C 94 811
telemetry C 95 811
. C 96 811
the C 98 811
children C 99 811
were C 100 811
observed C 101 811
for C 102 811
three C 103 811
minute C 104 811
periods C 105 811
in C 106 811
four C 107 811
environments C 108 811
of C 109 811
varying C 110 811
complexity C 111 811
: C 112 811
a C 113 811
. C 114 811
an C 116 811
empty C 117 811
room C 118 811
; C 119 811
b C 120 811
. C 121 811
the C 123 811
same C 124 811
room C 125 811
with C 126 811
toy C 127 811
wooden C 128 811
blocks C 129 811
present C 130 811
; C 131 811
c C 132 811
. C 133 811
blocks C 135 811
plus C 136 811
passive C 137 811
adult C 138 811
; C 139 811
d C 140 811
. C 141 811
blocks C 143 811
plus C 144 811
active C 145 811
adult C 146 811
. C 147 811
except C 149 811
in C 150 811
a C 151 811
the C 152 811
visual C 153 811
fixations C 154 811
and C 155 811
manipulatory C 156 811
activities C 157 811
were C 158 811
of C 159 811
significantly C 160 811
shorter C 161 811
duration C 162 811
in C 163 811
the C 164 811
autistic C 165 811
children C 166 811
than C 167 811
in C 168 811
the C 169 811
normals C 170 811
, C 171 811
lacked C 172 811
clear C 173 811
' C 174 811
cut C 175 811
- C 176 811
off C 177 811
' C 178 811
points C 179 811
and C 180 811
showed C 181 811
relatively C 182 811
little C 183 811
variability C 184 811
between C 185 811
environments C 186 811
. C 187 811
the C 189 811
autistic C 190 811
children C 191 811
as C 192 811
a C 193 811
whole C 194 811
showed C 195 811
virtually C 196 811
no C 197 811
constructive C 198 811
play C 199 811
in C 200 811
contrast C 201 811
with C 202 811
the C 203 811
normals C 204 811
, C 205 811
though C 206 811
more C 207 811
time C 208 811
was C 209 811
spent C 210 811
in C 211 811
contact C 212 811
with C 213 811
play C 214 811
materials C 215 811
in C 216 811
the C 217 811
social C 218 811
environments C 219 811
. C 220 811
changes C 222 811
in C 223 811
the C 224 811
time C 225 811
spent C 226 811
in C 227 811
locomotion C 228 811
, C 229 811
gesturing C 230 811
, C 231 811
block C 232 811
- C 233 811
play C 234 811
and C 235 811
manipulation C 236 811
of C 237 811
other C 238 811
objects C 239 811
in C 240 811
the C 241 811
environment C 242 811
showed C 243 811
that C 244 811
the C 245 811
autistic C 246 811
children C 247 811
were C 248 811
acutely C 249 811
responsive C 250 811
to C 251 811
changes C 252 811
in C 253 811
their C 254 811
environment C 255 811
, C 256 811
including C 257 811
the C 258 811
presence C 259 811
of C 260 811
the C 261 811
social C 262 811
stimulus C 263 811
. C 264 811
if C 266 811
the C 267 811
autistic C 268 811
children C 269 811
were C 270 811
subdivided C 271 811
into C 272 811
those C 273 811
who C 274 811
characteristically C 275 811
showed C 276 811
stereotypies C 277 811
and C 278 811
those C 279 811
who C 280 811
did C 281 811
not C 282 811
, C 283 811
the C 284 811
latter C 285 811
sub C 286 811
- C 287 811
group C 288 811
showed C 289 811
a C 290 811
behaviour C 291 811
structure C 292 811
which C 293 811
was C 294 811
very C 295 811
similar C 296 811
to C 297 811
that C 298 811
of C 299 811
the C 300 811
normals C 301 811
, C 302 811
whereas C 303 811
the C 304 811
stereotypy C 305 811
sub C 306 811
- C 307 811
group C 308 811
was C 309 811
clearly C 310 811
differentiated C 311 811
from C 312 811
both C 313 811
the C 314 811
normal C 315 811
children C 316 811
and C 317 811
the C 318 811
non C 319 811
- C 320 811
stereotypy C 321 811
sub C 322 811
- C 323 811
group C 324 811
. C 325 811
eight C 327 811
autistic C 328 811
children C 329 811
had C 330 811
waking C 331 811
eeg C 332 811
records C 333 811
characterized C 334 811
by C 335 811
low C 336 811
voltage C 337 811
irregular C 338 811
activity C 339 811
without C 340 811
any C 341 811
established C 342 811
rhythms C 343 811
; C 344 811
one C 345 811
child C 346 811
, C 347 811
a C 348 811
record C 349 811
containing C 350 811
irregular C 351 811
alpha C 352 811
and C 353 811
another C 354 811
unstable C 355 811
theta C 356 811
activity C 357 811
. C 358 811
two C 360 811
of C 361 811
the C 362 811
children C 363 811
with C 364 811
' C 365 811
flat C 366 811
' C 367 811
laboratory C 368 811
eegs C 369 811
showed C 370 811
more C 371 811
rhythmic C 372 811
, C 373 811
higher C 374 811
voltage C 375 811
records C 376 811
when C 377 811
their C 378 811
eegs C 379 811
were C 380 811
telemetred C 381 811
in C 382 811
environment C 383 811
a C 384 811
. C 385 811
they C 387 811
also C 388 811
showed C 389 811
less C 390 811
stereotyped C 391 811
behaviour C 392 811
. C 393 811
in C 395 811
environments C 396 811
b C 397 811
and C 398 811
d C 399 811
they C 400 811
showed C 401 811
pro C 402 811
- C 403 811
gressively C 404 811
more C 405 811
irregular C 406 811
eeg C 407 811
activity C 408 811
and C 409 811
more C 410 811
stereotypy C 411 811
. C 412 811
the C 414 811
hypothesis C 415 811
is C 416 811
advanced C 417 811
that C 418 811
autistic C 419 811
children C 420 811
are C 421 811
in C 422 811
a C 423 811
chronically C 424 811
high C 425 811
state C 426 811
of C 427 811
physio C 428 811
- C 429 811
logical C 430 811
arousal C 431 811
. C 432 811
the C 434 811
findings C 435 811
of C 436 811
the C 437 811
present C 438 811
study C 439 811
and C 440 811
those C 441 811
of C 442 811
other C 443 811
workers C 444 811
are C 445 811
discussed C 446 811
with C 447 811
respect C 448 811
to C 449 811
this C 450 811
hypothesis C 451 811
. C 452 811
the C 1 812
autistic C 2 812
child C 3 812
in C 4 812
the C 5 812
school C 6 812
and C 7 812
the C 8 812
school C 9 812
- C 10 812
nurse C 11 812
teacher C 12 812
responsibility C 13 812
autistic C 14 812
children C 15 812
demonstrate C 16 812
a C 17 812
more C 18 812
persistent C 19 812
pattern C 20 812
of C 21 812
retreating C 22 812
from C 23 812
reality C 24 812
than C 25 812
is C 26 812
apparent C 27 812
in C 28 812
those C 29 812
children C 30 812
categorized C 31 812
as C 32 812
normal C 33 812
. C 34 812
some C 36 812
psychologists C 37 812
have C 38 812
established C 39 812
the C 40 812
cause C 41 812
of C 42 812
symptoms C 43 812
in C 44 812
the C 45 812
autistic C 46 812
child C 47 812
as C 48 812
extreme C 49 812
anxiety C 50 812
which C 51 812
forces C 52 812
withdrawal C 53 812
from C 54 812
social C 55 812
contact C 56 812
. C 57 812
such C 59 812
anxiety C 60 812
is C 61 812
reported C 62 812
to C 63 812
have C 64 812
its C 65 812
initial C 66 812
occurrance C 67 812
during C 68 812
the C 69 812
age C 70 812
range C 71 812
of C 72 812
one C 73 812
to C 74 812
five C 75 812
years C 76 812
. C 77 812
a C 79 812
sense C 80 812
of C 81 812
security C 82 812
which C 83 812
is C 84 812
considered C 85 812
es C 86 812
- C 87 812
sential C 88 812
for C 89 812
a C 90 812
child C 91 812
is C 92 812
gained C 93 812
through C 94 812
overt C 95 812
manifestations C 96 812
of C 97 812
love C 98 812
, C 99 812
care C 100 812
and C 101 812
approval C 102 812
of C 103 812
those C 104 812
adults C 105 812
most C 106 812
closely C 107 812
associated C 108 812
with C 109 812
him C 110 812
. C 111 812
when C 113 812
this C 114 812
need C 115 812
is C 116 812
not C 117 812
satisfied C 118 812
, C 119 812
the C 120 812
child C 121 812
' C 122 812
s C 123 812
attempts C 124 812
at C 125 812
self C 126 812
- C 127 812
realization C 128 812
and C 129 812
esteem C 130 812
are C 131 812
deterred C 132 812
or C 133 812
thwarted C 134 812
, C 135 812
and C 136 812
a C 137 812
state C 138 812
of C 139 812
anxiety C 140 812
may C 141 812
result C 142 812
. C 143 812
the C 145 812
severity C 146 812
of C 147 812
the C 148 812
anxiety C 149 812
may C 150 812
be C 151 812
the C 152 812
forerunner C 153 812
of C 154 812
a C 155 812
schizophrenic C 156 812
disorder C 157 812
. C 158 812
such C 160 812
a C 161 812
condition C 162 812
can C 163 812
develop C 164 812
in C 165 812
a C 166 812
child C 167 812
, C 168 812
an C 169 812
adolescent C 170 812
or C 171 812
an C 172 812
adult C 173 812
. C 174 812
schizo C 176 812
- C 177 812
phrenia C 178 812
, C 179 812
a C 180 812
serious C 181 812
mental C 182 812
illness C 183 812
, C 184 812
is C 185 812
considered C 186 812
to C 187 812
be C 188 812
a C 189 812
major C 190 812
cause C 191 812
for C 192 812
admitting C 193 812
patients C 194 812
to C 195 812
mental C 196 812
institutions C 197 812
. C 198 812
another C 200 812
school C 201 812
of C 202 812
thought C 203 812
has C 204 812
placed C 205 812
infantile C 206 812
autism C 207 812
in C 208 812
the C 209 812
category C 210 812
of C 211 812
a C 212 812
disturbance C 213 812
resulting C 214 812
from C 215 812
abnormalities C 216 812
of C 217 812
development C 218 812
during C 219 812
the C 220 812
intrauterine C 221 812
period C 222 812
. C 223 812
such C 225 812
a C 226 812
congenital C 227 812
condition C 228 812
is C 229 812
not C 230 812
categorized C 231 812
as C 232 812
mental C 233 812
retardation C 234 812
. C 235 812
yet C 237 812
another C 238 812
concept C 239 812
of C 240 812
autism C 241 812
conceives C 242 812
of C 243 812
the C 244 812
problem C 245 812
as C 246 812
the C 247 812
absence C 248 812
of C 249 812
an C 250 812
innate C 251 812
ability C 252 812
or C 253 812
capacity C 254 812
for C 255 812
developing C 256 812
meaningful C 257 812
contacts C 258 812
with C 259 812
other C 260 812
people C 261 812
. C 262 812
a C 264 812
detachment C 265 812
of C 266 812
varying C 267 812
degrees C 268 812
persists C 269 812
where C 270 812
human C 271 812
contacts C 272 812
are C 273 812
concerned C 274 812
. C 275 812
the C 1 813
autistic C 2 813
child C 3 813
the C 4 813
conditions C 5 813
most C 6 813
frequently C 7 813
mistaken C 8 813
for C 9 813
autism C 10 813
are C 11 813
speech C 12 813
disorder C 13 813
, C 14 813
brain C 15 813
damage C 16 813
and C 17 813
mental C 18 813
deficiency C 19 813
, C 20 813
each C 21 813
a C 22 813
prominent C 23 813
symptom C 24 813
of C 25 813
the C 26 813
psychotic C 27 813
child C 28 813
. C 29 813
careful C 31 813
his C 32 813
- C 33 813
tory C 34 813
and C 35 813
close C 36 813
observation C 37 813
to C 38 813
disclose C 39 813
symp C 40 813
- C 41 813
toms C 42 813
of C 43 813
withdrawal C 44 813
, C 45 813
lack C 46 813
of C 47 813
ego C 48 813
, C 49 813
compulsion C 50 813
for C 51 813
sameness C 52 813
, C 53 813
and C 54 813
displays C 55 813
of C 56 813
intelligence C 57 813
give C 58 813
incomplete C 59 813
clues C 60 813
to C 61 813
the C 62 813
diagnosis C 63 813
. C 64 813
the C 66 813
etiology C 67 813
of C 68 813
autism C 69 813
is C 70 813
uncertain C 71 813
. C 72 813
sev C 74 813
- C 75 813
eral C 76 813
factors C 77 813
seem C 78 813
significant C 79 813
. C 80 813
the C 82 813
important C 83 813
role C 84 813
of C 85 813
organic C 86 813
damage C 87 813
of C 88 813
the C 89 813
brain C 90 813
is C 91 813
under C 92 813
- C 93 813
scored C 94 813
by C 95 813
the C 96 813
coincidence C 97 813
of C 98 813
epilepsy C 99 813
, C 100 813
eeg C 101 813
and C 102 813
neurological C 103 813
abnormalities C 104 813
in C 105 813
these C 106 813
chil C 107 813
- C 108 813
dren C 109 813
. C 110 813
in C 112 813
our C 113 813
series C 114 813
seizures C 115 813
of C 116 813
various C 117 813
types C 118 813
occurred C 119 813
in C 120 813
25 C 121 813
% C 122 813
, C 123 813
eeg C 124 813
abnormalities C 125 813
in C 126 813
58 C 127 813
% C 128 813
, C 129 813
and C 130 813
minor C 131 813
neurological C 132 813
deficits C 133 813
in C 134 813
70 C 135 813
% C 136 813
of C 137 813
the C 138 813
cases C 139 813
. C 140 813
environmental C 142 813
factors C 143 813
are C 144 813
quite C 145 813
obviously C 146 813
important C 147 813
in C 148 813
many C 149 813
instances C 150 813
. C 151 813
the C 153 813
emotional C 154 813
and C 155 813
behavioral C 156 813
pattern C 157 813
of C 158 813
the C 159 813
par C 160 813
- C 161 813
ents C 162 813
toward C 163 813
the C 164 813
infant C 165 813
is C 166 813
often C 167 813
incriminated C 168 813
. C 169 813
separation C 171 813
, C 172 813
inattention C 173 813
, C 174 813
coldness C 175 813
, C 176 813
rejection C 177 813
, C 178 813
etc C 179 813
. C 180 813
have C 182 813
been C 183 813
found C 184 813
in C 185 813
many C 186 813
situations C 187 813
. C 188 813
fa C 190 813
- C 191 813
milial C 192 813
incidence C 193 813
of C 194 813
psychoses C 195 813
is C 196 813
low C 197 813
; C 198 813
so C 199 813
is C 200 813
that C 201 813
of C 202 813
autism C 203 813
in C 204 813
siblings C 205 813
. C 206 813
shadow C 1 814
therapy C 2 814
shadow C 3 814
therapy C 4 814
was C 5 814
developed C 6 814
at C 7 814
sunland C 8 814
training C 9 814
center C 10 814
in C 11 814
gainesville C 12 814
, C 13 814
florida C 14 814
, C 15 814
because C 16 814
of C 17 814
communica C 18 814
- C 19 814
tion C 20 814
difficulties C 21 814
with C 22 814
disturbed C 23 814
, C 24 814
psychotic C 25 814
children C 26 814
. C 27 814
it C 29 814
was C 30 814
con C 31 814
- C 32 814
jectured C 33 814
that C 34 814
subjects C 35 814
would C 36 814
reveal C 37 814
their C 38 814
anxieties C 39 814
and C 40 814
conflicts C 41 814
more C 42 814
readily C 43 814
in C 44 814
a C 45 814
simulated C 46 814
night C 47 814
situation C 48 814
. C 49 814
the C 51 814
therapy C 52 814
was C 53 814
conducted C 54 814
in C 55 814
a C 56 814
darkroom C 57 814
with C 58 814
projector C 59 814
light C 60 814
used C 61 814
to C 62 814
produce C 63 814
silhouettes C 64 814
and C 65 814
their C 66 814
accompanying C 67 814
shadows C 68 814
as C 69 814
additional C 70 814
stimuli C 71 814
. C 72 814
twelve C 74 814
subjects C 75 814
attended C 76 814
. C 77 814
in C 79 814
this C 80 814
article C 81 814
, C 82 814
the C 83 814
reaction C 84 814
of C 85 814
a C 86 814
child C 87 814
who C 88 814
was C 89 814
autistic C 90 814
and C 91 814
severely C 92 814
disturbed C 93 814
is C 94 814
used C 95 814
as C 96 814
an C 97 814
illustration C 98 814
of C 99 814
subject C 100 814
reactions C 101 814
. C 102 814
in C 104 814
the C 105 814
playroom C 106 814
, C 107 814
he C 108 814
exhibited C 109 814
static C 110 814
behavior C 111 814
; C 112 814
in C 113 814
the C 114 814
darkroom C 115 814
, C 116 814
re C 117 814
- C 118 814
gressive C 119 814
- C 120 814
transcendential C 121 814
behavior C 122 814
. C 123 814
he C 125 814
also C 126 814
transcended C 127 814
his C 128 814
usual C 129 814
level C 130 814
of C 131 814
vocalizing C 132 814
and C 133 814
socializing C 134 814
. C 135 814
language C 1 815
training C 2 815
in C 3 815
the C 4 815
treatment C 5 815
of C 6 815
the C 7 815
autistic C 8 815
child C 9 815
functioning C 10 815
on C 11 815
a C 12 815
retarded C 13 815
level C 14 815
a C 15 815
preliminary C 16 815
study C 17 815
to C 18 815
determine C 19 815
the C 20 815
effect C 21 815
of C 22 815
language C 23 815
and C 24 815
speech C 25 815
therapy C 26 815
on C 27 815
the C 28 815
development C 29 815
of C 30 815
communication C 31 815
and C 32 815
the C 33 815
lessening C 34 815
of C 35 815
un C 36 815
- C 37 815
relatedness C 38 815
in C 39 815
a C 40 815
group C 41 815
of C 42 815
non C 43 815
- C 44 815
verbal C 45 815
, C 46 815
autistic C 47 815
children C 48 815
functioning C 49 815
on C 50 815
a C 51 815
retarded C 52 815
level C 53 815
is C 54 815
reported C 55 815
. C 56 815
on C 58 815
the C 59 815
basis C 60 815
of C 61 815
the C 62 815
re C 63 815
- C 64 815
sults C 65 815
of C 66 815
the C 67 815
study C 68 815
, C 69 815
it C 70 815
is C 71 815
suggested C 72 815
that C 73 815
the C 74 815
inclusion C 75 815
of C 76 815
language C 77 815
and C 78 815
speech C 79 815
therapy C 80 815
techniques C 81 815
be C 82 815
considered C 83 815
in C 84 815
developing C 85 815
a C 86 815
treatment C 87 815
program C 88 815
for C 89 815
such C 90 815
children C 91 815
. C 92 815
the C 1 816
convergence C 2 816
and C 3 816
interaction C 4 816
of C 5 816
visual C 6 816
, C 7 816
auditory C 8 816
, C 9 816
and C 10 816
tactile C 11 816
responses C 12 816
in C 13 816
human C 14 816
nonspecific C 15 816
cortex C 16 816
the C 17 816
relation C 18 816
between C 19 816
the C 20 816
electrical C 21 816
responses C 22 816
in C 23 816
the C 24 816
human C 25 816
brain C 26 816
and C 27 816
mental C 28 816
processes C 29 816
of C 30 816
integration C 31 816
and C 32 816
association C 33 816
is C 34 816
perhaps C 35 816
the C 36 816
most C 37 816
chal C 38 816
- C 39 816
lenging C 40 816
of C 41 816
all C 42 816
the C 43 816
problems C 44 816
facing C 45 816
neurophysiologists C 46 816
today C 47 816
. C 48 816
until C 50 816
quite C 51 816
recently C 52 816
the C 53 816
prospect C 54 816
of C 55 816
unifying C 56 816
physiological C 57 816
and C 58 816
psychological C 59 816
concepts C 60 816
by C 61 816
electro C 62 816
- C 63 816
encephalographic C 64 816
( C 65 816
eeg C 66 816
) C 67 816
techniques C 68 816
seemed C 69 816
to C 70 816
be C 71 816
receding C 72 816
because C 73 816
of C 74 816
the C 75 816
baffling C 76 816
complexity C 77 816
of C 78 816
the C 79 816
intrinsic C 80 816
electrical C 81 816
rhythms C 82 816
, C 83 816
and C 84 816
this C 85 816
difficulty C 86 816
has C 87 816
still C 88 816
not C 89 816
been C 90 816
overcome C 91 816
. C 92 816
the C 94 816
most C 95 816
intriguing C 96 816
, C 97 816
and C 98 816
at C 99 816
the C 100 816
same C 101 816
time C 102 816
most C 103 816
elusive C 104 816
, C 105 816
of C 106 816
the C 107 816
properties C 108 816
of C 109 816
these C 110 816
rhythms C 111 816
is C 112 816
that C 113 816
, C 114 816
although C 115 816
often C 116 816
remarkably C 117 816
constant C 118 816
in C 119 816
their C 120 816
variations C 121 816
with C 122 816
respect C 123 816
to C 124 816
time C 125 816
, C 126 816
they C 127 816
fluctuate C 128 816
also C 129 816
, C 130 816
in C 131 816
a C 132 816
much C 133 816
less C 134 816
regular C 135 816
manner C 136 816
, C 137 816
within C 138 816
the C 139 816
three C 140 816
dimensional C 141 816
space C 142 816
of C 143 816
the C 144 816
brain C 145 816
. C 146 816
the C 148 816
continuous C 149 816
analysis C 150 816
and C 151 816
display C 152 816
of C 153 816
such C 154 816
a C 155 816
phenomenon C 156 816
presents C 157 816
serious C 158 816
difficulties C 159 816
, C 160 816
and C 161 816
no C 162 816
method C 163 816
has C 164 816
yet C 165 816
given C 166 816
entirely C 167 816
satisfactory C 168 816
results C 169 816
. C 170 816
the C 172 816
incentive C 173 816
to C 174 816
construct C 175 816
adequate C 176 816
equipment C 177 816
and C 178 816
to C 179 816
design C 180 816
and C 181 816
per C 182 816
- C 183 816
form C 184 816
crucial C 185 816
experiments C 186 816
is C 187 816
undoubtedly C 188 816
limited C 189 816
by C 190 816
the C 191 816
uncertainty C 192 816
as C 193 816
to C 194 816
whether C 195 816
the C 196 816
information C 197 816
likely C 198 816
to C 199 816
be C 200 816
obtained C 201 816
in C 202 816
this C 203 816
way C 204 816
is C 205 816
essential C 206 816
to C 207 816
understanding C 208 816
brain C 209 816
mechanisms C 210 816
; C 211 816
few C 212 816
experimenters C 213 816
imagine C 214 816
that C 215 816
it C 216 816
would C 217 816
be C 218 816
sufficient C 219 816
. C 220 816
infantile C 1 817
autism C 2 817
and C 3 817
the C 4 817
schizophrenias C 5 817
in C 6 817
a C 7 817
paper C 8 817
published C 9 817
in C 10 817
1943 C 11 817
, C 12 817
entitled C 13 817
" C 14 817
au C 15 817
- C 16 817
tistic C 17 817
disturbances C 18 817
of C 19 817
affective C 20 817
con C 21 817
- C 22 817
tact C 23 817
, C 24 817
" C 25 817
i C 26 817
reported C 27 817
from C 28 817
the C 29 817
children C 30 817
' C 31 817
s C 32 817
psychi C 33 817
- C 34 817
atric C 35 817
service C 36 817
of C 37 817
the C 38 817
johns C 39 817
hopkins C 40 817
hospital C 41 817
observations C 42 817
of C 43 817
11 C 44 817
children C 45 817
( C 46 817
8 C 47 817
boys C 48 817
and C 49 817
3 C 50 817
girls C 51 817
) C 52 817
who C 53 817
had C 54 817
in C 55 817
common C 56 817
a C 57 817
pattern C 58 817
of C 59 817
be C 60 817
- C 61 817
havior C 62 817
not C 63 817
previously C 64 817
considered C 65 817
in C 66 817
its C 67 817
striking C 68 817
uniqueness C 69 817
. C 70 817
the C 72 817
symptoms C 73 817
were C 74 817
viewed C 75 817
as C 76 817
a C 77 817
combination C 78 817
of C 79 817
extreme C 80 817
alone C 81 817
- C 82 817
ness C 83 817
from C 84 817
the C 85 817
beginning C 86 817
of C 87 817
life C 88 817
and C 89 817
an C 90 817
anx C 91 817
- C 92 817
iously C 93 817
obsessive C 94 817
desire C 95 817
for C 96 817
the C 97 817
preservation C 98 817
of C 99 817
sameness C 100 817
. C 101 817
i C 103 817
concluded C 104 817
the C 105 817
discussion C 106 817
by C 107 817
saying C 108 817
: C 109 817
" C 110 817
we C 111 817
must C 112 817
assume C 113 817
that C 114 817
these C 115 817
chil C 116 817
- C 117 817
dren C 118 817
have C 119 817
come C 120 817
into C 121 817
the C 122 817
world C 123 817
with C 124 817
an C 125 817
innate C 126 817
inability C 127 817
to C 128 817
form C 129 817
the C 130 817
usual C 131 817
, C 132 817
biologi C 133 817
- C 134 817
cally C 135 817
provided C 136 817
affective C 137 817
contact C 138 817
with C 139 817
people C 140 817
, C 141 817
just C 142 817
as C 143 817
other C 144 817
children C 145 817
come C 146 817
into C 147 817
the C 148 817
world C 149 817
with C 150 817
innate C 151 817
physical C 152 817
and C 153 817
intellectual C 154 817
handi C 155 817
- C 156 817
caps C 157 817
. C 158 817
if C 160 817
this C 161 817
assumption C 162 817
is C 163 817
correct C 164 817
, C 165 817
a C 166 817
further C 167 817
study C 168 817
of C 169 817
our C 170 817
children C 171 817
may C 172 817
help C 173 817
to C 174 817
furnish C 175 817
concrete C 176 817
criteria C 177 817
regarding C 178 817
the C 179 817
still C 180 817
diffuse C 181 817
notions C 182 817
about C 183 817
the C 184 817
constitutional C 185 817
components C 186 817
of C 187 817
emotional C 188 817
reactivity C 189 817
. C 190 817
for C 192 817
here C 193 817
we C 194 817
seem C 195 817
to C 196 817
have C 197 817
pure C 198 817
- C 199 817
culture C 200 817
examples C 201 817
of C 202 817
inborn C 203 817
au C 204 817
- C 205 817
tistic C 206 817
disturbances C 207 817
of C 208 817
affective C 209 817
contact C 210 817
. C 211 817
" C 213 817
in C 214 817
my C 215 817
search C 216 817
for C 217 817
an C 218 817
appropriate C 219 817
designa C 220 817
- C 221 817
tion C 222 817
, C 223 817
i C 224 817
decided C 225 817
in C 226 817
1944 C 227 817
, C 228 817
after C 229 817
much C 230 817
groping C 231 817
, C 232 817
on C 233 817
the C 234 817
term C 235 817
early C 236 817
infantile C 237 817
autism C 238 817
, C 239 817
thus C 240 817
accentuating C 241 817
the C 242 817
time C 243 817
of C 244 817
the C 245 817
first C 246 817
manifesta C 247 817
- C 248 817
tions C 249 817
and C 250 817
the C 251 817
children C 252 817
' C 253 817
s C 254 817
limited C 255 817
accessibility C 256 817
. C 257 817
autistic C 1 818
children C 2 818
autism C 3 818
is C 4 818
a C 5 818
form C 6 818
of C 7 818
childhood C 8 818
schizophrenia C 9 818
. C 10 818
a C 12 818
sudden C 13 818
separation C 14 818
from C 15 818
his C 16 818
mother C 17 818
or C 18 818
traumatic C 19 818
shock C 20 818
in C 21 818
early C 22 818
life C 23 818
causes C 24 818
the C 25 818
child C 26 818
to C 27 818
reject C 28 818
the C 29 818
world C 30 818
of C 31 818
nor C 32 818
- C 33 818
mal C 34 818
relationships C 35 818
. C 36 818
leading C 38 818
him C 39 818
back C 40 818
to C 41 818
the C 42 818
original C 43 818
traumatic C 44 818
situation C 45 818
is C 46 818
part C 47 818
of C 48 818
the C 49 818
treatment C 50 818
described C 51 818
in C 52 818
this C 53 818
article C 54 818
. C 55 818
gilles C 1 819
de C 2 819
la C 3 819
tourette C 4 819
syndrome C 5 819
in C 6 819
an C 7 819
autistic C 8 819
child C 9 819
a C 10 819
case C 11 819
of C 12 819
gilles C 13 819
de C 14 819
la C 15 819
tourette C 16 819
syndrome C 17 819
presenting C 18 819
an C 19 819
early C 20 819
infantile C 21 819
autism C 22 819
is C 23 819
described C 24 819
. C 25 819
the C 27 819
treatment C 28 819
applied C 29 819
is C 30 819
outlined C 31 819
. C 32 819
psychodrama C 1 820
for C 2 820
disturbed C 3 820
children C 4 820
psychodrama C 5 820
is C 6 820
especially C 7 820
adaptable C 8 820
to C 9 820
the C 10 820
treat C 11 820
- C 12 820
ment C 13 820
of C 14 820
mentally C 15 820
ill C 16 820
children C 17 820
. C 18 820
it C 20 820
evokes C 21 820
a C 22 820
degree C 23 820
of C 24 820
spontaneity C 25 820
and C 26 820
involvement C 27 820
that C 28 820
is C 29 820
difficult C 30 820
to C 31 820
attain C 32 820
with C 33 820
many C 34 820
group C 35 820
therapies C 36 820
, C 37 820
and C 38 820
it C 39 820
offers C 40 820
situa C 41 820
- C 42 820
tions C 43 820
in C 44 820
which C 45 820
the C 46 820
children C 47 820
can C 48 820
participate C 49 820
as C 50 820
actors C 51 820
or C 52 820
as C 53 820
observers C 54 820
. C 55 820
competition C 57 820
and C 58 820
restriction C 59 820
are C 60 820
minimal C 61 820
: C 62 820
the C 63 820
child C 64 820
can C 65 820
do C 66 820
what C 67 820
comes C 68 820
naturally C 69 820
. C 70 820
in C 72 820
- C 73 820
deed C 74 820
, C 75 820
much C 76 820
of C 77 820
children C 78 820
' C 79 820
s C 80 820
natural C 81 820
play C 82 820
is C 83 820
in C 84 820
the C 85 820
form C 86 820
of C 87 820
dramatic C 88 820
activity C 89 820
. C 90 820
their C 92 820
make C 93 820
- C 94 820
believe C 95 820
is C 96 820
, C 97 820
how C 98 820
- C 99 820
ever C 100 820
, C 101 820
more C 102 820
intense C 103 820
than C 104 820
acting C 105 820
, C 106 820
for C 107 820
a C 108 820
child C 109 820
becomes C 110 820
the C 111 820
person C 112 820
or C 113 820
thing C 114 820
he C 115 820
pretends C 116 820
to C 117 820
be C 118 820
: C 119 820
a C 120 820
fireman C 121 820
, C 122 820
an C 123 820
indian C 124 820
, C 125 820
a C 126 820
horse C 127 820
, C 128 820
a C 129 820
tiger C 130 820
. C 131 820
the C 1 821
speech C 2 821
and C 3 821
language C 4 821
abilities C 5 821
of C 6 821
emotionally C 7 821
disturbed C 8 821
children C 9 821
the C 10 821
speech C 11 821
and C 12 821
language C 13 821
disorders C 14 821
of C 15 821
these C 16 821
severely C 17 821
disturbed C 18 821
children C 19 821
can C 20 821
be C 21 821
divided C 22 821
into C 23 821
two C 24 821
categories C 25 821
which C 26 821
relate C 27 821
to C 28 821
the C 29 821
type C 30 821
of C 31 821
psychiatric C 32 821
disturbance C 33 821
. C 34 821
the C 36 821
autistic C 37 821
- C 38 821
schizophrenic C 39 821
children C 40 821
used C 41 821
bizarre C 42 821
forms C 43 821
of C 44 821
language C 45 821
or C 46 821
did C 47 821
not C 48 821
use C 49 821
communicative C 50 821
language C 51 821
at C 52 821
all C 53 821
. C 54 821
the C 56 821
non C 57 821
- C 58 821
autistic C 59 821
- C 60 821
schizophrenic C 61 821
, C 62 821
the C 63 821
neurotic C 64 821
, C 65 821
the C 66 821
primary C 67 821
behaviour C 68 821
disorder C 69 821
, C 70 821
and C 71 821
the C 72 821
minimally C 73 821
brain C 74 821
- C 75 821
damaged C 76 821
children C 77 821
as C 78 821
a C 79 821
group C 80 821
, C 81 821
had C 82 821
similar C 83 821
speech C 84 821
and C 85 821
language C 86 821
problems C 87 821
to C 88 821
normal C 89 821
children C 90 821
but C 91 821
of C 92 821
a C 93 821
more C 94 821
severe C 95 821
and C 96 821
frequent C 97 821
nature C 98 821
. C 99 821
their C 101 821
problems C 102 821
were C 103 821
predominantly C 104 821
in C 105 821
the C 106 821
areas C 107 821
of C 108 821
speech C 109 821
and C 110 821
language C 111 821
develop C 112 821
- C 113 821
ment C 114 821
, C 115 821
articulation C 116 821
, C 117 821
rate C 118 821
of C 119 821
speech C 120 821
and C 121 821
fluency C 122 821
. C 123 821
the C 125 821
children C 126 821
with C 127 821
primary C 128 821
be C 129 821
- C 130 821
haviour C 131 821
disorders C 132 821
had C 133 821
the C 134 821
more C 135 821
severe C 136 821
speech C 137 821
and C 138 821
language C 139 821
problems C 140 821
. C 141 821
a C 1 822
study C 2 822
of C 3 822
childhood C 4 822
schizophrenia C 5 822
and C 6 822
early C 7 822
infantile C 8 822
autism C 9 822
( C 10 822
part C 11 822
i C 12 822
- C 13 822
- C 14 822
description C 15 822
of C 16 822
the C 17 822
sample C 18 822
) C 19 822
following C 20 822
a C 21 822
period C 22 822
of C 23 822
observation C 24 822
of C 25 822
three C 26 822
months C 27 822
' C 28 822
duration C 29 822
, C 30 822
a C 31 822
group C 32 822
of C 33 822
twelve C 34 822
autistic C 35 822
schizophrenic C 36 822
children C 37 822
were C 38 822
se C 39 822
- C 40 822
lected C 41 822
for C 42 822
a C 43 822
treatment C 44 822
program C 45 822
. C 46 822
the C 48 822
group C 49 822
was C 50 822
selected C 51 822
on C 52 822
criteria C 53 822
which C 54 822
would C 55 822
allow C 56 822
a C 57 822
reasonable C 58 822
chance C 59 822
of C 60 822
suc C 61 822
- C 62 822
cessful C 63 822
treatment C 64 822
in C 65 822
a C 66 822
group C 67 822
homo C 68 822
- C 69 822
geneous C 70 822
enough C 71 822
to C 72 822
allow C 73 822
statistical C 74 822
con C 75 822
- C 76 822
siderations C 77 822
to C 78 822
be C 79 822
valid C 80 822
. C 81 822
younger C 83 822
age C 84 822
, C 85 822
average C 86 822
intellectual C 87 822
func C 88 822
- C 89 822
tioning C 90 822
, C 91 822
presence C 92 822
of C 93 822
an C 94 822
intact C 95 822
family C 96 822
in C 97 822
or C 98 822
near C 99 822
to C 100 822
metropolitan C 101 822
toronto C 102 822
and C 103 822
a C 104 822
firm C 105 822
diagnosis C 106 822
of C 107 822
autistic C 108 822
schizophrenia C 109 822
were C 110 822
the C 111 822
limiting C 112 822
factors C 113 822
. C 114 822
rather C 116 822
distinct C 117 822
differences C 118 822
were C 119 822
noted C 120 822
in C 121 822
this C 122 822
treatment C 123 822
group C 124 822
as C 125 822
opposed C 126 822
to C 127 822
the C 128 822
larger C 129 822
observation C 130 822
group C 131 822
. C 132 822
the C 134 822
dis C 135 822
- C 136 822
tinguishing C 137 822
characteristic C 138 822
was C 139 822
undoubted C 140 822
- C 141 822
ly C 142 822
the C 143 822
speech C 144 822
abnormalities C 145 822
present C 146 822
. C 147 822
discussion C 1 823
sur C 2 823
les C 3 823
pseudo C 4 823
- C 5 823
tumeurs C 6 823
osseuses C 7 823
des C 8 823
hemophiles C 9 823
doctors C 10 823
queneau C 11 823
and C 12 823
josso C 13 823
each C 14 823
described C 15 823
one C 16 823
case C 17 823
of C 18 823
pseudo C 19 823
- C 20 823
tumour C 21 823
of C 22 823
the C 23 823
calcaneum C 24 823
analagous C 25 823
to C 26 823
that C 27 823
described C 28 823
by C 29 823
trillat C 30 823
and C 31 823
favre C 32 823
- C 33 823
gilly C 34 823
; C 35 823
they C 36 823
demonstrated C 37 823
x C 38 823
- C 39 823
rays C 40 823
; C 41 823
dr C 42 823
. C 43 823
alagille C 45 823
referred C 46 823
to C 47 823
a C 48 823
haemophilic C 49 823
cyst C 50 823
of C 51 823
the C 52 823
maxilla C 53 823
and C 54 823
dr C 55 823
. C 56 823
favre C 58 823
- C 59 823
gilly C 60 823
to C 61 823
a C 62 823
cyst C 63 823
of C 64 823
the C 65 823
perineum C 66 823
; C 67 823
dr C 68 823
. C 69 823
kugler C 71 823
had C 72 823
seen C 73 823
a C 74 823
case C 75 823
where C 76 823
an C 77 823
erroneous C 78 823
diagnosis C 79 823
of C 80 823
osteosarcoma C 81 823
had C 82 823
been C 83 823
made C 84 823
. C 85 823
the C 1 824
effect C 2 824
of C 3 824
joint C 4 824
position C 5 824
on C 6 824
the C 7 824
pressure C 8 824
of C 9 824
intra C 10 824
- C 11 824
articular C 12 824
effusion C 13 824
it C 14 824
is C 15 824
known C 16 824
that C 17 824
joints C 18 824
with C 19 824
symptomatic C 20 824
effusions C 21 824
are C 22 824
held C 23 824
spontaneously C 24 824
in C 25 824
characteristic C 26 824
positions C 27 824
and C 28 824
that C 29 824
movement C 30 824
of C 31 824
these C 32 824
joints C 33 824
increases C 34 824
pain C 35 824
. C 36 824
in C 38 824
the C 39 824
study C 40 824
reported C 41 824
here C 42 824
, C 43 824
a C 44 824
correlation C 45 824
was C 46 824
made C 47 824
between C 48 824
the C 49 824
hydrostatic C 50 824
pressure C 51 824
of C 52 824
a C 53 824
joint C 54 824
effusion C 55 824
and C 56 824
the C 57 824
joint C 58 824
' C 59 824
s C 60 824
position C 61 824
. C 62 824
the C 64 824
results C 65 824
indicate C 66 824
a C 67 824
possible C 68 824
relationship C 69 824
between C 70 824
intra C 71 824
- C 72 824
articular C 73 824
pressure C 74 824
and C 75 824
pain C 76 824
. C 77 824
haemophilic C 1 825
blood C 2 825
cyst C 3 825
a C 4 825
mongol C 5 825
boy C 6 825
of C 7 825
ten C 8 825
, C 9 825
a C 10 825
known C 11 825
haemophiliac C 12 825
, C 13 825
was C 14 825
seen C 15 825
in C 16 825
the C 17 825
orthopaedic C 18 825
department C 19 825
of C 20 825
southmead C 21 825
hospital C 22 825
in C 23 825
may C 24 825
1962 C 25 825
with C 26 825
a C 27 825
swelling C 28 825
of C 29 825
the C 30 825
left C 31 825
foot C 32 825
. C 33 825
the C 35 825
parents C 36 825
were C 37 825
aware C 38 825
of C 39 825
a C 40 825
steady C 41 825
increase C 42 825
in C 43 825
size C 44 825
since C 45 825
the C 46 825
swelling C 47 825
was C 48 825
first C 49 825
noticed C 50 825
two C 51 825
months C 52 825
before C 53 825
. C 54 825
on C 56 825
examination C 57 825
, C 58 825
a C 59 825
cystic C 60 825
swelling C 61 825
was C 62 825
seen C 63 825
to C 64 825
occupy C 65 825
the C 66 825
forefoot C 67 825
, C 68 825
the C 69 825
skin C 70 825
on C 71 825
the C 72 825
dorsum C 73 825
being C 74 825
stretched C 75 825
over C 76 825
it C 77 825
and C 78 825
a C 79 825
dusky C 80 825
red C 81 825
in C 82 825
colour C 83 825
( C 84 825
fig C 85 825
. C 86 825
1 C 88 825
) C 89 825
. C 90 825
radiographs C 92 825
showed C 93 825
destruction C 94 825
of C 95 825
the C 96 825
proximal C 97 825
two C 98 825
- C 99 825
thirds C 100 825
of C 101 825
the C 102 825
third C 103 825
metatarsal C 104 825
bone C 105 825
, C 106 825
an C 107 825
appearance C 108 825
consistent C 109 825
, C 110 825
it C 111 825
was C 112 825
thought C 113 825
with C 114 825
destruction C 115 825
from C 116 825
within C 117 825
by C 118 825
an C 119 825
expanding C 120 825
lesion C 121 825
( C 122 825
fig C 123 825
. C 124 825
2 C 126 825
) C 127 825
. C 128 825
the C 130 825
diagnosis C 131 825
of C 132 825
a C 133 825
haemophilic C 134 825
blood C 135 825
cyst C 136 825
was C 137 825
made C 138 825
. C 139 825
treatment C 1 826
and C 2 826
prevention C 3 826
of C 4 826
chronic C 5 826
haemorrhagic C 6 826
arthropathy C 7 826
and C 8 826
contractures C 9 826
in C 10 826
haemophilia C 11 826
orthopaedic C 12 826
treatment C 13 826
of C 14 826
joint C 15 826
deformities C 16 826
in C 17 826
thirteen C 18 826
patients C 19 826
with C 20 826
haemophilia C 21 826
is C 22 826
reviewed C 23 826
over C 24 826
a C 25 826
period C 26 826
of C 27 826
seven C 28 826
years C 29 826
. C 30 826
forms C 32 826
of C 33 826
treatment C 34 826
discussed C 35 826
include C 36 826
open C 37 826
operation C 38 826
, C 39 826
manipulation C 40 826
under C 41 826
general C 42 826
anaesthesia C 43 826
, C 44 826
continuous C 45 826
traction C 46 826
, C 47 826
splintage C 48 826
and C 49 826
physiotherapy C 50 826
. C 51 826
the C 53 826
amount C 54 826
of C 55 826
intravenous C 56 826
therapy C 57 826
required C 58 826
for C 59 826
each C 60 826
form C 61 826
of C 62 826
treatment C 63 826
is C 64 826
indicated C 65 826
. C 66 826
in C 68 826
discussing C 69 826
prevention C 70 826
of C 71 826
joint C 72 826
deformity C 73 826
the C 74 826
histories C 75 826
of C 76 826
a C 77 826
further C 78 826
eighteen C 79 826
patients C 80 826
have C 81 826
been C 82 826
taken C 83 826
into C 84 826
account C 85 826
. C 86 826
it C 88 826
is C 89 826
concluded C 90 826
that C 91 826
initially C 92 826
painless C 93 826
haemarthroses C 94 826
provide C 95 826
the C 96 826
main C 97 826
threat C 98 826
to C 99 826
joint C 100 826
deformity C 101 826
in C 102 826
haemophilia C 103 826
. C 104 826
the C 106 826
best C 107 826
preventive C 108 826
treatment C 109 826
is C 110 826
early C 111 826
immobilisation C 112 826
followed C 113 826
by C 114 826
prolonged C 115 826
splintage C 116 826
and C 117 826
physiotherapy C 118 826
; C 119 826
intravenous C 120 826
therapy C 121 826
with C 122 826
antihaemophilic C 123 826
factor C 124 826
plays C 125 826
a C 126 826
less C 127 826
important C 128 826
role C 129 826
here C 130 826
than C 131 826
in C 132 826
other C 133 826
forms C 134 826
of C 135 826
haemorrhage C 136 826
. C 137 826
evidence C 139 826
is C 140 826
presented C 141 826
that C 142 826
joint C 143 826
deformity C 144 826
in C 145 826
severe C 146 826
haemophilia C 147 826
can C 148 826
often C 149 826
be C 150 826
entirely C 151 826
avoided C 152 826
. C 153 826
osteopatia C 1 827
in C 2 827
emofilia C 3 827
the C 4 827
aa C 5 827
. C 6 827
present C 8 827
the C 9 827
case C 10 827
material C 11 827
of C 12 827
the C 13 827
literature C 14 827
and C 15 827
one C 16 827
personal C 17 827
remark C 18 827
of C 19 827
extrarticular C 20 827
osteopathy C 21 827
in C 22 827
hemophilia C 23 827
. C 24 827
they C 26 827
examine C 27 827
the C 28 827
anatomic C 29 827
and C 30 827
clinical C 31 827
picture C 32 827
of C 33 827
the C 34 827
illness C 35 827
in C 36 827
its C 37 827
most C 38 827
important C 39 827
and C 40 827
less C 41 827
known C 42 827
peculiarities C 43 827
and C 44 827
they C 45 827
dwell C 46 827
upon C 47 827
the C 48 827
curative C 49 827
medico C 50 827
- C 51 827
surgical C 52 827
problems C 53 827
of C 54 827
the C 55 827
affection C 56 827
. C 57 827
la C 1 828
plasmatherapie C 2 828
a C 3 828
minima C 4 828
dans C 5 828
le C 6 828
traitement C 7 828
de C 8 828
la C 9 828
douleur C 10 828
des C 11 828
hemarthroses C 12 828
hemophiliques C 13 828
some C 14 828
fifty C 15 828
clinically C 16 828
similar C 17 828
cases C 18 828
of C 19 828
hemophilic C 20 828
hemarthrosis C 21 828
were C 22 828
, C 23 828
after C 24 828
immobilization C 25 828
, C 26 828
either C 27 828
treated C 28 828
with C 29 828
placebo C 30 828
and C 31 828
plasma C 32 828
perfusion C 33 828
or C 34 828
else C 35 828
with C 36 828
corticoids C 37 828
and C 38 828
analgesics C 39 828
. C 40 828
a C 42 828
very C 43 828
small C 44 828
quantity C 45 828
of C 46 828
plasma C 47 828
is C 48 828
sufficient C 49 828
to C 50 828
stop C 51 828
the C 52 828
pain C 53 828
for C 54 828
the C 55 828
following C 56 828
few C 57 828
hours C 58 828
. C 59 828
it C 61 828
is C 62 828
attempted C 63 828
to C 64 828
give C 65 828
a C 66 828
physio C 67 828
- C 68 828
pathologic C 69 828
explanation C 70 828
which C 71 828
would C 72 828
seem C 73 828
in C 74 828
accord C 75 828
with C 76 828
the C 77 828
pathogenic C 78 828
studies C 79 828
on C 80 828
hemophiliac C 81 828
by C 82 828
r C 83 828
. C 84 828
marx C 86 828
et C 87 828
al C 88 828
. C 89 828
effet C 1 829
analgesique C 2 829
immediat C 3 829
des C 4 829
injections C 5 829
de C 6 829
plasma C 7 829
pour C 8 829
hemarthroses C 9 829
recentes C 10 829
du C 11 829
genou C 12 829
des C 13 829
hemophiles C 14 829
a C 15 829
single C 16 829
injection C 17 829
of C 18 829
20 C 19 829
ml C 20 829
of C 21 829
lyophilized C 22 829
fresh C 23 829
plasma C 24 829
per C 25 829
kg C 26 829
body C 27 829
weight C 28 829
is C 29 829
proposed C 30 829
as C 31 829
a C 32 829
treatment C 33 829
in C 34 829
recent C 35 829
cases C 36 829
of C 37 829
knee C 38 829
hemarthrosis C 39 829
with C 40 829
an C 41 829
important C 42 829
distension C 43 829
of C 44 829
the C 45 829
capsule C 46 829
, C 47 829
so C 48 829
as C 49 829
to C 50 829
achieve C 51 829
hemostasis C 52 829
, C 53 829
and C 54 829
reduce C 55 829
the C 56 829
evolutive C 57 829
period C 58 829
. C 59 829
pain C 61 829
is C 62 829
always C 63 829
acute C 64 829
and C 65 829
permanent C 66 829
in C 67 829
such C 68 829
cases C 69 829
of C 70 829
hemarthrosis C 71 829
; C 72 829
it C 73 829
subsides C 74 829
during C 75 829
the C 76 829
plasma C 77 829
injection C 78 829
, C 79 829
or C 80 829
immediately C 81 829
afterwards C 82 829
. C 83 829
hip C 1 830
disarticulation C 2 830
in C 3 830
a C 4 830
patient C 5 830
with C 6 830
hemophilia C 7 830
disarticulation C 8 830
of C 9 830
the C 10 830
hip C 11 830
in C 12 830
a C 13 830
hemophiliac C 14 830
patient C 15 830
was C 16 830
performed C 17 830
because C 18 830
of C 19 830
a C 20 830
severe C 21 830
osteomyelitis C 22 830
involving C 23 830
the C 24 830
entire C 25 830
right C 26 830
femur C 27 830
and C 28 830
was C 29 830
lifesaving C 30 830
. C 31 830
the C 33 830
following C 34 830
are C 35 830
suggestions C 36 830
for C 37 830
hemotologic C 38 830
man C 39 830
- C 40 830
agement C 41 830
: C 42 830
( C 43 830
1 C 44 830
) C 45 830
infected C 46 830
wounds C 47 830
in C 48 830
hemophiliac C 49 830
pa C 50 830
- C 51 830
tients C 52 830
should C 53 830
be C 54 830
left C 55 830
open C 56 830
initially C 57 830
. C 58 830
( C 60 830
2 C 61 830
) C 62 830
electro C 63 830
- C 64 830
cautery C 65 830
should C 66 830
not C 67 830
be C 68 830
used C 69 830
in C 70 830
an C 71 830
infected C 72 830
wound C 73 830
of C 74 830
a C 75 830
hemophiliac C 76 830
patient C 77 830
. C 78 830
( C 80 830
3 C 81 830
) C 82 830
a C 83 830
safe C 84 830
fibrinogen C 85 830
prepa C 86 830
- C 87 830
ration C 88 830
potent C 89 830
in C 90 830
the C 91 830
antihemophilic C 92 830
factor C 93 830
is C 94 830
now C 95 830
available C 96 830
in C 97 830
this C 98 830
country C 99 830
and C 100 830
is C 101 830
a C 102 830
highly C 103 830
significant C 104 830
advance C 105 830
in C 106 830
the C 107 830
surgical C 108 830
treatment C 109 830
of C 110 830
hemophilia C 111 830
. C 112 830
haemophilia C 1 831
in C 2 831
sweden C 3 831
vii C 4 831
. C 5 831
incidence C 7 831
, C 8 831
treatment C 9 831
and C 10 831
prophylaxis C 11 831
of C 12 831
arthropathy C 13 831
and C 14 831
other C 15 831
musculo C 16 831
- C 17 831
skeletal C 18 831
manifestations C 19 831
of C 20 831
haemophilia C 21 831
a C 22 831
and C 23 831
b C 24 831
the C 25 831
clinical C 26 831
material C 27 831
consisted C 28 831
of C 29 831
242 C 30 831
of C 31 831
the C 32 831
308 C 33 831
known C 34 831
haemophiliacs C 35 831
( C 36 831
a C 37 831
and C 38 831
b C 39 831
) C 40 831
in C 41 831
sweden C 42 831
. C 43 831
the C 45 831
investigation C 46 831
included C 47 831
clinical C 48 831
examination C 49 831
of C 50 831
all C 51 831
major C 52 831
joints C 53 831
in C 54 831
95 C 55 831
of C 56 831
116 C 57 831
patients C 58 831
with C 59 831
severe C 60 831
haemophilia C 61 831
, C 62 831
in C 63 831
38 C 64 831
of C 65 831
65 C 66 831
patients C 67 831
with C 68 831
moderate C 69 831
haemophilia C 70 831
, C 71 831
and C 72 831
in C 73 831
24 C 74 831
of C 75 831
127 C 76 831
patients C 77 831
with C 78 831
mild C 79 831
haemophilia C 80 831
, C 81 831
and C 82 831
roentgen C 83 831
examination C 84 831
of C 85 831
practically C 86 831
all C 87 831
joints C 88 831
found C 89 831
to C 90 831
be C 91 831
abnormal C 92 831
at C 93 831
the C 94 831
clinical C 95 831
examination C 96 831
. C 97 831
in C 99 831
addition C 100 831
information C 101 831
about C 102 831
7 C 103 831
patients C 104 831
with C 105 831
severe C 106 831
haemophilia C 107 831
, C 108 831
21 C 109 831
with C 110 831
moderate C 111 831
haemophilia C 112 831
, C 113 831
and C 114 831
57 C 115 831
with C 116 831
mild C 117 831
haemophilia C 118 831
was C 119 831
obtained C 120 831
by C 121 831
questionnaire C 122 831
only C 123 831
. C 124 831
the C 126 831
degree C 127 831
of C 128 831
arthropathy C 129 831
( C 130 831
grades C 131 831
2 C 132 831
, C 133 831
3 C 134 831
and C 135 831
4 C 136 831
) C 137 831
was C 138 831
classified C 139 831
largely C 140 831
according C 141 831
to C 142 831
depalma C 143 831
and C 144 831
cotler C 145 831
( C 146 831
1956 C 147 831
) C 148 831
. C 149 831
evaluation C 151 831
of C 152 831
general C 153 831
disability C 154 831
was C 155 831
made C 156 831
with C 157 831
regard C 158 831
to C 159 831
ability C 160 831
to C 161 831
manage C 162 831
( C 163 831
walk C 164 831
, C 165 831
dress C 166 831
, C 167 831
eat C 168 831
, C 169 831
toilet C 170 831
) C 171 831
with C 172 831
- C 173 831
out C 174 831
help C 175 831
. C 176 831
this C 178 831
latter C 179 831
evaluation C 180 831
comprised C 181 831
also C 182 831
extra C 183 831
- C 184 831
articular C 185 831
manifesta C 186 831
- C 187 831
tions C 188 831
of C 189 831
haemophilia C 190 831
. C 191 831
interet C 1 832
de C 2 832
la C 3 832
radiotherapie C 4 832
dans C 5 832
les C 6 832
hemarthroses C 7 832
recidivantes C 8 832
du C 9 832
genou C 10 832
chez C 11 832
l C 12 832
' C 13 832
hemophile C 14 832
radiotherapy C 15 832
was C 16 832
delivered C 17 832
at C 18 832
a C 19 832
dose C 20 832
of C 21 832
100 C 22 832
r C 23 832
repeated C 24 832
from C 25 832
7 C 26 832
to C 27 832
10 C 28 832
times C 29 832
, C 30 832
to C 31 832
22 C 32 832
knees C 33 832
of C 34 832
haemo C 35 832
- C 36 832
philiac C 37 832
children C 38 832
presenting C 39 832
recurring C 40 832
arthropathies C 41 832
. C 42 832
irradiation C 44 832
had C 45 832
no C 46 832
harmful C 47 832
effect C 48 832
on C 49 832
growth C 50 832
of C 51 832
patients C 52 832
; C 53 832
it C 54 832
was C 55 832
beneficial C 56 832
in C 57 832
two C 58 832
thirds C 59 832
of C 60 832
the C 61 832
cases C 62 832
, C 63 832
reducing C 64 832
considerably C 65 832
the C 66 832
number C 67 832
per C 68 832
annum C 69 832
of C 70 832
haemarthrosis C 71 832
onsets C 72 832
; C 73 832
one C 74 832
third C 75 832
of C 76 832
the C 77 832
patients C 78 832
showed C 79 832
no C 80 832
significant C 81 832
result C 82 832
: C 83 832
the C 84 832
number C 85 832
of C 86 832
onsets C 87 832
was C 88 832
the C 89 832
same C 90 832
in C 91 832
the C 92 832
following C 93 832
year C 94 832
. C 95 832
totally C 97 832
the C 98 832
average C 99 832
of C 100 832
infirmary C 101 832
stays C 102 832
due C 103 832
to C 104 832
knee C 105 832
haemarthrosis C 106 832
was C 107 832
175 C 108 832
days C 109 832
in C 110 832
the C 111 832
year C 112 832
before C 113 832
radio C 114 832
- C 115 832
therapy C 116 832
and C 117 832
25 C 118 832
days C 119 832
in C 120 832
the C 121 832
following C 122 832
year C 123 832
. C 124 832
the C 126 832
authors C 127 832
think C 128 832
that C 129 832
these C 130 832
results C 131 832
justify C 132 832
this C 133 832
therapeutic C 134 832
method C 135 832
. C 136 832
discussion C 1 833
sur C 2 833
les C 3 833
donnees C 4 833
radiologiques C 5 833
dans C 6 833
les C 7 833
arthropathies C 8 833
des C 9 833
genoux C 10 833
professor C 11 833
marchal C 12 833
acts C 13 833
as C 14 833
moderator C 15 833
. C 16 833
dr C 18 833
. C 19 833
le C 21 833
coeur C 22 833
wonders C 23 833
if C 24 833
the C 25 833
fringed C 26 833
appearance C 27 833
of C 28 833
condyles C 29 833
has C 30 833
really C 31 833
a C 32 833
pathological C 33 833
significance C 34 833
; C 35 833
that C 36 833
appearance C 37 833
could C 38 833
be C 39 833
normal C 40 833
in C 41 833
young C 42 833
children C 43 833
, C 44 833
but C 45 833
, C 46 833
in C 47 833
the C 48 833
opinion C 49 833
of C 50 833
dr C 51 833
. C 52 833
queneau C 54 833
, C 55 833
it C 56 833
seems C 57 833
to C 58 833
be C 59 833
patho C 60 833
- C 61 833
logical C 62 833
in C 63 833
older C 64 833
children C 65 833
. C 66 833
it C 68 833
seems C 69 833
to C 70 833
dr C 71 833
. C 72 833
favre C 74 833
- C 75 833
gilly C 76 833
and C 77 833
dr C 78 833
. C 79 833
queneau C 81 833
that C 82 833
scalariform C 83 833
traits C 84 833
occur C 85 833
more C 86 833
frequently C 87 833
in C 88 833
haemo C 89 833
- C 90 833
philiac C 91 833
children C 92 833
than C 93 833
in C 94 833
normal C 95 833
ones C 96 833
. C 97 833
dr C 99 833
. C 100 833
le C 102 833
coeur C 103 833
thought C 104 833
that C 105 833
fibrillary C 106 833
decalcification C 107 833
was C 108 833
the C 109 833
ultimate C 110 833
stage C 111 833
of C 112 833
decalcification C 113 833
, C 114 833
whereas C 115 833
dr C 116 833
. C 117 833
favre C 119 833
- C 120 833
gilly C 121 833
has C 122 833
the C 123 833
impression C 124 833
that C 125 833
it C 126 833
represents C 127 833
in C 128 833
haemophiliac C 129 833
subjects C 130 833
an C 131 833
early C 132 833
stage C 133 833
anterior C 134 833
to C 135 833
homogeneous C 136 833
decalcification C 137 833
. C 138 833
according C 140 833
to C 141 833
brinkhous C 142 833
, C 143 833
densification C 144 833
of C 145 833
synovial C 146 833
membranes C 147 833
are C 148 833
a C 149 833
result C 150 833
of C 151 833
an C 152 833
infiltration C 153 833
of C 154 833
the C 155 833
joint C 156 833
cartilage C 157 833
due C 158 833
to C 159 833
haemosideraemia C 160 833
; C 161 833
this C 162 833
is C 163 833
also C 164 833
the C 165 833
opinion C 166 833
of C 167 833
dr C 168 833
. C 169 833
favre C 171 833
- C 172 833
gilly C 173 833
and C 174 833
dr C 175 833
. C 176 833
izarn C 178 833
. C 179 833
dr C 181 833
. C 182 833
izarn C 184 833
asks C 185 833
if C 186 833
geodes C 187 833
are C 188 833
caused C 189 833
by C 190 833
intra C 191 833
- C 192 833
osseous C 193 833
haemorrhages C 194 833
or C 195 833
necroses C 196 833
; C 197 833
dr C 198 833
. C 199 833
queneau C 201 833
and C 202 833
dr C 203 833
. C 204 833
de C 206 833
mourgues C 207 833
think C 208 833
that C 209 833
anatomical C 210 833
data C 211 833
con C 212 833
- C 213 833
cerning C 214 833
haemophiliac C 215 833
subjects C 216 833
are C 217 833
insufficient C 218 833
for C 219 833
that C 220 833
question C 221 833
to C 222 833
be C 223 833
answered C 224 833
. C 225 833
etude C 1 834
radiographique C 2 834
des C 3 834
genoux C 4 834
de C 5 834
100 C 6 834
hemophiles C 7 834
de C 8 834
7 C 9 834
a C 10 834
15 C 11 834
ans C 12 834
radiographic C 13 834
examination C 14 834
of C 15 834
the C 16 834
knee C 17 834
were C 18 834
syste C 19 834
- C 20 834
matically C 21 834
performed C 22 834
in C 23 834
100 C 24 834
haemophiliac C 25 834
subjects C 26 834
aged C 27 834
from C 28 834
7 C 29 834
to C 30 834
15 C 31 834
years C 32 834
, C 33 834
64 C 34 834
of C 35 834
whom C 36 834
had C 37 834
a C 38 834
bilateral C 39 834
haemarthrosis C 40 834
, C 41 834
30 C 42 834
had C 43 834
only C 44 834
one C 45 834
knee C 46 834
affected C 47 834
and C 48 834
6 C 49 834
were C 50 834
uninjured C 51 834
. C 52 834
an C 54 834
intra C 55 834
- C 56 834
articular C 57 834
opacification C 58 834
, C 59 834
observed C 60 834
in C 61 834
29 C 62 834
knees C 63 834
, C 64 834
corresponded C 65 834
to C 66 834
a C 67 834
recent C 68 834
haemarthrosis C 69 834
. C 70 834
densification C 72 834
of C 73 834
the C 74 834
synovial C 75 834
membrane C 76 834
was C 77 834
ob C 78 834
- C 79 834
served C 80 834
in C 81 834
25 C 82 834
knees C 83 834
and C 84 834
corresponded C 85 834
to C 86 834
iron C 87 834
deposits C 88 834
. C 89 834
an C 91 834
interlinear C 92 834
pinch C 93 834
was C 94 834
present C 95 834
in C 96 834
52 C 97 834
knees C 98 834
. C 99 834
erosions C 101 834
of C 102 834
articular C 103 834
surfaces C 104 834
are C 105 834
especially C 106 834
fre C 107 834
- C 108 834
quent C 109 834
( C 110 834
78 C 111 834
knees C 112 834
) C 113 834
or C 114 834
homogeneous C 115 834
( C 116 834
28 C 117 834
knees C 118 834
) C 119 834
. C 120 834
hypertrophy C 122 834
of C 123 834
condyles C 124 834
or C 125 834
knee C 126 834
- C 127 834
caps C 128 834
, C 129 834
broadening C 130 834
of C 131 834
intercondylian C 132 834
space C 133 834
, C 134 834
crushing C 135 834
of C 136 834
internal C 137 834
tibial C 138 834
disk C 139 834
, C 140 834
genu C 141 834
valgum C 142 834
and C 143 834
posterior C 144 834
subluxation C 145 834
of C 146 834
tibia C 147 834
are C 148 834
osseous C 149 834
deformations C 150 834
that C 151 834
are C 152 834
encountered C 153 834
. C 154 834
atrophy C 156 834
of C 157 834
femur C 158 834
diaphysis C 159 834
explains C 160 834
the C 161 834
frequency C 162 834
of C 163 834
fracture C 164 834
of C 165 834
femur C 166 834
. C 167 834
some C 169 834
of C 170 834
these C 171 834
aspects C 172 834
seem C 173 834
to C 174 834
occur C 175 834
early C 176 834
( C 177 834
inter C 178 834
- C 179 834
linear C 180 834
pinch C 181 834
, C 182 834
erosion C 183 834
of C 184 834
the C 185 834
surfaces C 186 834
) C 187 834
, C 188 834
others C 189 834
are C 190 834
tardier C 191 834
( C 192 834
geodes C 193 834
, C 194 834
decalcification C 195 834
) C 196 834
. C 197 834
a C 199 834
relation C 200 834
between C 201 834
the C 202 834
intensity C 203 834
of C 204 834
abnormal C 205 834
radio C 206 834
- C 207 834
logical C 208 834
findings C 209 834
and C 210 834
the C 211 834
severity C 212 834
of C 213 834
sequelae C 214 834
does C 215 834
not C 216 834
always C 217 834
exist C 218 834
, C 219 834
but C 220 834
one C 221 834
can C 222 834
observe C 223 834
major C 224 834
radio C 225 834
- C 226 834
logical C 227 834
alterations C 228 834
only C 229 834
when C 230 834
there C 231 834
is C 232 834
a C 233 834
major C 234 834
bio C 235 834
- C 236 834
logical C 237 834
disturbance C 238 834
. C 239 834
blood C 1 835
vascular C 2 835
disorders C 3 835
in C 4 835
connection C 5 835
with C 6 835
the C 7 835
nose C 8 835
, C 9 835
throat C 10 835
and C 11 835
ear C 12 835
these C 13 835
disorders C 14 835
include C 15 835
( C 16 835
1 C 17 835
) C 18 835
those C 19 835
having C 20 835
lesions C 21 835
primarily C 22 835
in C 23 835
the C 24 835
nose C 25 835
, C 26 835
throat C 27 835
or C 28 835
ear C 29 835
, C 30 835
and C 31 835
( C 32 835
2 C 33 835
) C 34 835
those C 35 835
producing C 36 835
symptoms C 37 835
and C 38 835
signs C 39 835
in C 40 835
nose C 41 835
, C 42 835
throat C 43 835
and C 44 835
/ C 45 835
or C 46 835
ear C 47 835
only C 48 835
as C 49 835
a C 50 835
part C 51 835
of C 52 835
their C 53 835
symptomatology C 54 835
and C 55 835
involve C 56 835
other C 57 835
organs C 58 835
as C 59 835
well C 60 835
. C 61 835
we C 63 835
will C 64 835
con C 65 835
- C 66 835
sider C 67 835
the C 68 835
lesions C 69 835
in C 70 835
connection C 71 835
with C 72 835
the C 73 835
nose C 74 835
, C 75 835
throat C 76 835
and C 77 835
ear C 78 835
separately C 79 835
. C 80 835
volkmann C 1 836
' C 2 836
s C 3 836
ischaemia C 4 836
volkmann C 5 836
' C 6 836
s C 7 836
ischaemia C 8 836
is C 9 836
the C 10 836
name C 11 836
given C 12 836
to C 13 836
a C 14 836
sequence C 15 836
of C 16 836
events C 17 836
originally C 18 836
described C 19 836
by C 20 836
volkmann C 21 836
in C 22 836
1881 C 23 836
. C 24 836
basically C 26 836
the C 27 836
condition C 28 836
consists C 29 836
of C 30 836
the C 31 836
replacement C 32 836
of C 33 836
the C 34 836
limb C 35 836
flexor C 36 836
muscles C 37 836
by C 38 836
fibrous C 39 836
tissue C 40 836
following C 41 836
injury C 42 836
or C 43 836
occlusion C 44 836
of C 45 836
the C 46 836
main C 47 836
arterial C 48 836
supply C 49 836
of C 50 836
blood C 51 836
to C 52 836
these C 53 836
muscles C 54 836
. C 55 836
the C 57 836
condition C 58 836
is C 59 836
rare C 60 836
fortunately C 61 836
- C 62 836
- C 63 836
mainly C 64 836
because C 65 836
of C 66 836
improved C 67 836
methods C 68 836
of C 69 836
prevention C 70 836
. C 71 836
the C 73 836
flexor C 74 836
muscles C 75 836
of C 76 836
the C 77 836
toes C 78 836
are C 79 836
sometimes C 80 836
affected C 81 836
, C 82 836
but C 83 836
the C 84 836
commonest C 85 836
group C 86 836
of C 87 836
muscles C 88 836
so C 89 836
damaged C 90 836
are C 91 836
the C 92 836
flexor C 93 836
muscles C 94 836
of C 95 836
the C 96 836
forearm C 97 836
. C 98 836
total C 100 836
arterial C 101 836
occlusion C 102 836
to C 103 836
a C 104 836
limb C 105 836
for C 106 836
several C 107 836
hours C 108 836
usually C 109 836
causes C 110 836
frank C 111 836
gangrene C 112 836
; C 113 836
partial C 114 836
or C 115 836
total C 116 836
occlusion C 117 836
for C 118 836
shorter C 119 836
periods C 120 836
may C 121 836
give C 122 836
rise C 123 836
to C 124 836
ischaemic C 125 836
contracture C 126 836
. C 127 836
the C 129 836
muscles C 130 836
, C 131 836
being C 132 836
deprived C 133 836
of C 134 836
their C 135 836
blood C 136 836
supply C 137 836
, C 138 836
die C 139 836
and C 140 836
are C 141 836
sub C 142 836
- C 143 836
sequently C 144 836
replaced C 145 836
by C 146 836
fibrous C 147 836
tissue C 148 836
. C 149 836
like C 151 836
all C 152 836
scars C 153 836
, C 154 836
the C 155 836
fibrous C 156 836
tissue C 157 836
contracts C 158 836
, C 159 836
producing C 160 836
the C 161 836
complete C 162 836
picture C 163 836
of C 164 836
volkmann C 165 836
' C 166 836
s C 167 836
ischaemic C 168 836
contracture C 169 836
. C 170 836
the C 172 836
forearm C 173 836
is C 174 836
thin C 175 836
and C 176 836
wasted C 177 836
, C 178 836
and C 179 836
the C 180 836
fingers C 181 836
are C 182 836
held C 183 836
in C 184 836
flexion C 185 836
owing C 186 836
to C 187 836
the C 188 836
overall C 189 836
shortening C 190 836
of C 191 836
the C 192 836
flexor C 193 836
muscles C 194 836
. C 195 836
in C 197 836
severe C 198 836
cases C 199 836
, C 200 836
if C 201 836
the C 202 836
nerves C 203 836
are C 204 836
also C 205 836
affected C 206 836
or C 207 836
if C 208 836
the C 209 836
entire C 210 836
muscle C 211 836
mass C 212 836
is C 213 836
replaced C 214 836
by C 215 836
fibrosis C 216 836
, C 217 836
the C 218 836
fingers C 219 836
may C 220 836
be C 221 836
totally C 222 836
paralysed C 223 836
as C 224 836
well C 225 836
. C 226 836
klinik C 1 837
der C 2 837
polyarthrosen C 3 837
among C 4 837
the C 5 837
degenerative C 6 837
affections C 7 837
of C 8 837
joints C 9 837
the C 10 837
symptoms C 11 837
of C 12 837
the C 13 837
arthrosis C 14 837
of C 15 837
the C 16 837
joints C 17 837
of C 18 837
the C 19 837
fingers C 20 837
with C 21 837
heberden C 22 837
- C 23 837
nodes C 24 837
, C 25 837
the C 26 837
bouchard C 27 837
- C 28 837
nodes C 29 837
of C 30 837
the C 31 837
inter C 32 837
- C 33 837
digital C 34 837
joints C 35 837
, C 36 837
the C 37 837
polyarthrosis C 38 837
- C 39 837
on C 40 837
those C 41 837
subjects C 42 837
coste C 43 837
and C 44 837
forestier C 45 837
wrote C 46 837
about C 47 837
and C 48 837
how C 49 837
they C 50 837
were C 51 837
described C 52 837
by C 53 837
lffb C 54 837
too C 55 837
- C 56 837
and C 57 837
the C 58 837
arthropathies C 59 837
of C 60 837
chronic C 61 837
gout C 62 837
are C 63 837
more C 64 837
thoroughly C 65 837
discussed C 66 837
. C 67 837
the C 69 837
rare C 70 837
conditions C 71 837
, C 72 837
as C 73 837
the C 74 837
arthrotic C 75 837
changes C 76 837
in C 77 837
hemo C 78 837
- C 79 837
philia C 80 837
, C 81 837
psoriasis C 82 837
and C 83 837
metabolic C 84 837
disorders C 85 837
are C 86 837
mentioned C 87 837
. C 88 837
a C 90 837
wider C 91 837
area C 92 837
is C 93 837
dedicated C 94 837
to C 95 837
the C 96 837
differentiation C 97 837
between C 98 837
degenerative C 99 837
and C 100 837
inflammatory C 101 837
diseases C 102 837
. C 103 837
it C 105 837
is C 106 837
refer C 107 837
- C 108 837
red C 109 837
to C 110 837
, C 111 837
that C 112 837
gout C 113 837
more C 114 837
often C 115 837
occurs C 116 837
in C 117 837
our C 118 837
days C 119 837
and C 120 837
one C 121 837
is C 122 837
forced C 123 837
to C 124 837
calculate C 125 837
with C 126 837
it C 127 837
more C 128 837
than C 129 837
some C 130 837
years C 131 837
ago C 132 837
. C 133 837
it C 135 837
is C 136 837
also C 137 837
referred C 138 837
to C 139 837
the C 140 837
significance C 141 837
of C 142 837
the C 143 837
serolo C 144 837
- C 145 837
gical C 146 837
reactions C 147 837
for C 148 837
the C 149 837
differential C 150 837
diagnosis C 151 837
. C 152 837
the C 154 837
most C 155 837
important C 156 837
diseases C 157 837
are C 158 837
enumerated C 159 837
, C 160 837
which C 161 837
do C 162 837
not C 163 837
belong C 164 837
to C 165 837
degenerative C 166 837
polyarticular C 167 837
affections C 168 837
of C 169 837
joints C 170 837
, C 171 837
but C 172 837
which C 173 837
very C 174 837
often C 175 837
get C 176 837
mixed C 177 837
up C 178 837
with C 179 837
them C 180 837
. C 181 837
major C 1 838
surgical C 2 838
procedures C 3 838
, C 4 838
including C 5 838
amputation C 6 838
, C 7 838
on C 8 838
a C 9 838
hemophiliac C 10 838
various C 11 838
surgical C 12 838
procedures C 13 838
in C 14 838
a C 15 838
hemo C 16 838
- C 17 838
philia C 18 838
a C 19 838
patient C 20 838
, C 21 838
including C 22 838
amputation C 23 838
above C 24 838
the C 25 838
knee C 26 838
, C 27 838
are C 28 838
reported C 29 838
. C 30 838
human C 32 838
cohn C 33 838
fraction C 34 838
i C 35 838
( C 36 838
fibrinogen C 37 838
/ C 38 838
ahg C 39 838
) C 40 838
was C 41 838
used C 42 838
to C 43 838
ensure C 44 838
normal C 45 838
hemostasis C 46 838
. C 47 838
the C 49 838
patient C 50 838
' C 51 838
s C 52 838
ability C 53 838
to C 54 838
form C 55 838
a C 56 838
firm C 57 838
clot C 58 838
within C 59 838
a C 60 838
normal C 61 838
time C 62 838
was C 63 838
measured C 64 838
and C 65 838
treatment C 66 838
was C 67 838
prescribed C 68 838
in C 69 838
accordance C 70 838
with C 71 838
serial C 72 838
studies C 73 838
with C 74 838
the C 75 838
thrombelastograph C 76 838
. C 77 838
the C 1 839
prevention C 2 839
of C 3 839
crippling C 4 839
in C 5 839
haemophilic C 6 839
children C 7 839
children C 8 839
who C 9 839
are C 10 839
severely C 11 839
affected C 12 839
with C 13 839
haemo C 14 839
- C 15 839
philia C 16 839
or C 17 839
christmas C 18 839
disease C 19 839
suffer C 20 839
repeated C 21 839
haemorrhages C 22 839
into C 23 839
joints C 24 839
and C 25 839
muscles C 26 839
after C 27 839
trivial C 28 839
injuries C 29 839
. C 30 839
these C 32 839
episodes C 33 839
of C 34 839
bleeding C 35 839
produce C 36 839
cumulative C 37 839
crippling C 38 839
. C 39 839
the C 41 839
haemarthroses C 42 839
tend C 43 839
to C 44 839
be C 45 839
recurrent C 46 839
; C 47 839
each C 48 839
episode C 49 839
produces C 50 839
some C 51 839
damage C 52 839
to C 53 839
the C 54 839
joint C 55 839
surface C 56 839
and C 57 839
the C 58 839
immobility C 59 839
during C 60 839
con C 61 839
- C 62 839
valescence C 63 839
leads C 64 839
to C 65 839
muscle C 66 839
weakness C 67 839
. C 68 839
thus C 70 839
after C 71 839
recovery C 72 839
the C 73 839
joint C 74 839
becomes C 75 839
increasingly C 76 839
liable C 77 839
to C 78 839
renewed C 79 839
bleeding C 80 839
. C 81 839
the C 83 839
deep C 84 839
muscle C 85 839
haematomata C 86 839
can C 87 839
produce C 88 839
crippling C 89 839
by C 90 839
actual C 91 839
destruction C 92 839
of C 93 839
muscle C 94 839
tissue C 95 839
, C 96 839
by C 97 839
pressure C 98 839
on C 99 839
important C 100 839
nerves C 101 839
or C 102 839
arteries C 103 839
, C 104 839
by C 105 839
contractures C 106 839
which C 107 839
develop C 108 839
during C 109 839
healing C 110 839
and C 111 839
by C 112 839
failure C 113 839
of C 114 839
resolution C 115 839
of C 116 839
the C 117 839
original C 118 839
haematoma C 119 839
leading C 120 839
to C 121 839
chronic C 122 839
cyst C 123 839
formation C 124 839
. C 125 839
throat C 1 840
and C 2 840
nose C 3 840
surgery C 4 840
in C 5 840
patients C 6 840
with C 7 840
constitutional C 8 840
haemostatic C 9 840
defects C 10 840
successful C 11 840
surgery C 12 840
in C 13 840
patients C 14 840
with C 15 840
defective C 16 840
haemostasis C 17 840
is C 18 840
becoming C 19 840
possible C 20 840
and C 21 840
it C 22 840
is C 23 840
of C 24 840
inter C 25 840
- C 26 840
est C 27 840
to C 28 840
detail C 29 840
the C 30 840
problems C 31 840
encountered C 32 840
in C 33 840
nose C 34 840
and C 35 840
throat C 36 840
surgery C 37 840
. C 38 840
hemophilic C 1 841
arthropathy C 2 841
jaromir C 3 841
priborsky C 4 841
, C 5 841
zora C 6 841
antalovska C 7 841
the C 8 841
authors C 9 841
report C 10 841
their C 11 841
experience C 12 841
with C 13 841
joint C 14 841
diseases C 15 841
in C 16 841
54 C 17 841
patients C 18 841
suffering C 19 841
from C 20 841
hemo C 21 841
- C 22 841
philia C 23 841
, C 24 841
49 C 25 841
of C 26 841
them C 27 841
being C 28 841
cases C 29 841
of C 30 841
hemophilia C 31 841
a C 32 841
, C 33 841
5 C 34 841
of C 35 841
hemophilia C 36 841
b C 37 841
. C 38 841
21 C 40 841
patients C 41 841
were C 42 841
children C 43 841
up C 44 841
to C 45 841
the C 46 841
age C 47 841
of C 48 841
14 C 49 841
years C 50 841
. C 51 841
bleeding C 53 841
into C 54 841
the C 55 841
joints C 56 841
occurred C 57 841
in C 58 841
66 C 59 841
. C 60 841
. C 61 841
% C 62 841
of C 63 841
patients C 64 841
. C 65 841
in C 67 841
the C 68 841
age C 69 841
group C 70 841
over C 71 841
14 C 72 841
years C 73 841
the C 74 841
cases C 75 841
of C 76 841
bleeding C 77 841
into C 78 841
the C 79 841
joints C 80 841
were C 81 841
more C 82 841
frequent C 83 841
( C 84 841
78 C 85 841
. C 86 841
. C 87 841
% C 88 841
) C 89 841
than C 90 841
in C 91 841
the C 92 841
age C 93 841
group C 94 841
up C 95 841
to C 96 841
14 C 97 841
years C 98 841
( C 99 841
47 C 100 841
. C 101 841
. C 102 841
% C 103 841
) C 104 841
. C 105 841
there C 107 841
were C 108 841
no C 109 841
differences C 110 841
as C 111 841
to C 112 841
bleeding C 113 841
into C 114 841
the C 115 841
joints C 116 841
and C 117 841
the C 118 841
seriousness C 119 841
of C 120 841
articular C 121 841
changes C 122 841
between C 123 841
the C 124 841
cases C 125 841
of C 126 841
hemophilia C 127 841
a C 128 841
and C 129 841
hemo C 130 841
- C 131 841
philia C 132 841
b C 133 841
. C 134 841
in C 136 841
most C 137 841
cases C 138 841
the C 139 841
bleeding C 140 841
into C 141 841
the C 142 841
joints C 143 841
began C 144 841
between C 145 841
the C 146 841
6 C 147 841
th C 148 841
and C 149 841
the C 150 841
14 C 151 841
th C 152 841
year C 153 841
of C 154 841
age C 155 841
. C 156 841
bleeding C 158 841
into C 159 841
the C 160 841
joints C 161 841
as C 162 841
the C 163 841
first C 164 841
manifestation C 165 841
of C 166 841
a C 167 841
hemophilic C 168 841
condition C 169 841
occurred C 170 841
only C 171 841
in C 172 841
9 C 173 841
. C 174 841
. C 175 841
% C 176 841
of C 177 841
patients C 178 841
; C 179 841
in C 180 841
most C 181 841
cases C 182 841
other C 183 841
hemophilic C 184 841
manifestations C 185 841
preceded C 186 841
. C 187 841
in C 189 841
spite C 190 841
of C 191 841
this C 192 841
fact C 193 841
the C 194 841
joint C 195 841
manifestations C 196 841
were C 197 841
often C 198 841
wrongly C 199 841
diagnosed C 200 841
as C 201 841
tuberculous C 202 841
arthritis C 203 841
, C 204 841
rheumatic C 205 841
fever C 206 841
, C 207 841
progressive C 208 841
arthritis C 209 841
, C 210 841
and C 211 841
were C 212 841
treated C 213 841
accordingly C 214 841
. C 215 841
most C 217 841
usually C 218 841
the C 219 841
large C 220 841
joints C 221 841
( C 222 841
knee C 223 841
, C 224 841
elbow C 225 841
, C 226 841
ankle C 227 841
) C 228 841
were C 229 841
affected C 230 841
with C 231 841
bleeding C 232 841
and C 233 841
in C 234 841
them C 235 841
the C 236 841
changes C 237 841
were C 238 841
also C 239 841
the C 240 841
most C 241 841
serious C 242 841
. C 243 841
the C 245 841
joints C 246 841
of C 247 841
both C 248 841
halves C 249 841
of C 250 841
the C 251 841
body C 252 841
were C 253 841
affected C 254 841
uniformly C 255 841
. C 256 841
in C 258 841
most C 259 841
cases C 260 841
several C 261 841
joints C 262 841
were C 263 841
affected C 264 841
while C 265 841
monoarticular C 266 841
localization C 267 841
was C 268 841
observed C 269 841
in C 270 841
16 C 271 841
. C 272 841
. C 273 841
% C 274 841
. C 275 841
the C 277 841
seriousness C 278 841
of C 279 841
articular C 280 841
changes C 281 841
was C 282 841
dependent C 283 841
mainly C 284 841
on C 285 841
the C 286 841
number C 287 841
of C 288 841
repeated C 289 841
bleedings C 290 841
into C 291 841
one C 292 841
and C 293 841
the C 294 841
same C 295 841
joint C 296 841
, C 297 841
although C 298 841
other C 299 841
factors C 300 841
( C 301 841
weight C 302 841
bearing C 303 841
of C 304 841
the C 305 841
joint C 306 841
, C 307 841
complexity C 308 841
of C 309 841
the C 310 841
joint C 311 841
, C 312 841
treatment C 313 841
) C 314 841
may C 315 841
be C 316 841
of C 317 841
decisive C 318 841
importance C 319 841
in C 320 841
the C 321 841
individual C 322 841
cases C 323 841
as C 324 841
well C 325 841
. C 326 841
according C 328 841
to C 329 841
clinical C 330 841
( C 331 841
especially C 332 841
from C 333 841
the C 334 841
functional C 335 841
point C 336 841
of C 337 841
view C 338 841
) C 339 841
and C 340 841
x C 341 841
- C 342 841
ray C 343 841
criteria C 344 841
the C 345 841
articular C 346 841
findings C 347 841
were C 348 841
classified C 349 841
into C 350 841
three C 351 841
groups C 352 841
: C 353 841
in C 354 841
the C 355 841
first C 356 841
group C 357 841
the C 358 841
function C 359 841
of C 360 841
the C 361 841
joint C 362 841
is C 363 841
preserved C 364 841
, C 365 841
in C 366 841
the C 367 841
second C 368 841
limited C 369 841
and C 370 841
in C 371 841
the C 372 841
third C 373 841
practically C 374 841
extinguished C 375 841
. C 376 841
the C 378 841
following C 379 841
laboratory C 380 841
tests C 381 841
were C 382 841
carried C 383 841
out C 384 841
: C 385 841
erythrocyte C 386 841
sedimentation C 387 841
reaction C 388 841
, C 389 841
latex C 390 841
test C 391 841
for C 392 841
the C 393 841
rheu C 394 841
- C 395 841
matoid C 396 841
factor C 397 841
, C 398 841
c C 399 841
- C 400 841
reactive C 401 841
protein C 402 841
, C 403 841
mecoprotein C 404 841
tyrosine C 405 841
and C 406 841
weltmann C 407 841
' C 408 841
s C 409 841
coagulation C 410 841
test C 411 841
. C 412 841
the C 414 841
findings C 415 841
were C 416 841
normal C 417 841
even C 418 841
in C 419 841
cases C 420 841
of C 421 841
irreparable C 422 841
articular C 423 841
changes C 424 841
unless C 425 841
acute C 426 841
bleeding C 427 841
into C 428 841
the C 429 841
joint C 430 841
or C 431 841
in C 432 841
some C 433 841
other C 434 841
localization C 435 841
, C 436 841
or C 437 841
some C 438 841
other C 439 841
complicating C 440 841
disorder C 441 841
was C 442 841
present C 443 841
simultaneously C 444 841
. C 445 841
the C 447 841
therapy C 448 841
of C 449 841
hemophilic C 450 841
arthropathy C 451 841
remains C 452 841
troublesome C 453 841
owing C 454 841
especially C 455 841
to C 456 841
a C 457 841
frequent C 458 841
occurrence C 459 841
of C 460 841
articular C 461 841
bleeding C 462 841
. C 463 841
a C 465 841
close C 466 841
cooperation C 467 841
of C 468 841
the C 469 841
hematologist C 470 841
and C 471 841
the C 472 841
rheumatologist C 473 841
or C 474 841
the C 475 841
orthopedist C 476 841
may C 477 841
con C 478 841
- C 479 841
tribute C 480 841
to C 481 841
the C 482 841
improvement C 483 841
of C 484 841
the C 485 841
fate C 486 841
of C 487 841
these C 488 841
patients C 489 841
. C 490 841
prevention C 1 842
and C 2 842
treatment C 3 842
of C 4 842
joint C 5 842
deformity C 6 842
in C 7 842
haemophilia C 8 842
experience C 9 842
in C 10 842
treating C 11 842
established C 12 842
joint C 13 842
deformities C 14 842
in C 15 842
27 C 16 842
patients C 17 842
, C 18 842
and C 19 842
preventing C 20 842
the C 21 842
development C 22 842
of C 23 842
deformtiy C 24 842
in C 25 842
10 C 26 842
younger C 27 842
patients C 28 842
, C 29 842
during C 30 842
the C 31 842
last C 32 842
8 C 33 842
years C 34 842
, C 35 842
has C 36 842
shown C 37 842
that C 38 842
there C 39 842
are C 40 842
two C 41 842
types C 42 842
of C 43 842
haemorrhage C 44 842
, C 45 842
which C 46 842
require C 47 842
different C 48 842
treatment C 49 842
to C 50 842
prevent C 51 842
chronic C 52 842
deformity C 53 842
. C 54 842
the C 1 843
haemophilic C 2 843
pseudotumour C 3 843
or C 4 843
haemophilic C 5 843
subperiosteal C 6 843
haematoma C 7 843
the C 8 843
case C 9 843
history C 10 843
of C 11 843
a C 12 843
haemophiliac C 13 843
in C 14 843
whom C 15 843
a C 16 843
large C 17 843
haematoma C 18 843
of C 19 843
the C 20 843
thigh C 21 843
was C 22 843
treated C 23 843
by C 24 843
amputation C 25 843
of C 26 843
the C 27 843
limb C 28 843
is C 29 843
described C 30 843
. C 31 843
examination C 33 843
of C 34 843
the C 35 843
available C 36 843
radiographs C 37 843
and C 38 843
of C 39 843
the C 40 843
histology C 41 843
led C 42 843
to C 43 843
the C 44 843
conclusion C 45 843
that C 46 843
the C 47 843
cyst C 48 843
was C 49 843
subperiosteal C 50 843
in C 51 843
origin C 52 843
. C 53 843
evidence C 55 843
is C 56 843
presented C 57 843
to C 58 843
support C 59 843
the C 60 843
hypothesis C 61 843
that C 62 843
haemophilic C 63 843
pseudotumours C 64 843
are C 65 843
always C 66 843
associated C 67 843
with C 68 843
subperiosteal C 69 843
haemorrhage C 70 843
, C 71 843
and C 72 843
that C 73 843
those C 74 843
haemophilic C 75 843
cysts C 76 843
which C 77 843
are C 78 843
confined C 79 843
to C 80 843
muscle C 81 843
have C 82 843
little C 83 843
or C 84 843
no C 85 843
effect C 86 843
on C 87 843
the C 88 843
adjacent C 89 843
bone C 90 843
. C 91 843
actinomycin C 1 844
d C 2 844
and C 3 844
the C 4 844
response C 5 844
to C 6 844
parathyroid C 7 844
hormone C 8 844
actinomycin C 9 844
d C 10 844
inhibits C 11 844
the C 12 844
effect C 13 844
of C 14 844
parathyroid C 15 844
hormone C 16 844
upon C 17 844
bone C 18 844
, C 19 844
as C 20 844
measured C 21 844
by C 22 844
ca C 23 844
mobilization C 24 844
, C 25 844
without C 26 844
altering C 27 844
its C 28 844
effects C 29 844
upon C 30 844
the C 31 844
renal C 32 844
excretion C 33 844
of C 34 844
phosphate C 35 844
and C 36 844
ca C 37 844
in C 38 844
rats C 39 844
. C 40 844
aspects C 1 845
of C 2 845
circadian C 3 845
periodic C 4 845
changes C 5 845
in C 6 845
phosphorus C 7 845
metabolism C 8 845
in C 9 845
mice C 10 845
kinetic C 11 845
studies C 12 845
on C 13 845
the C 14 845
p C 15 845
32 C 16 845
content C 17 845
of C 18 845
mouse C 19 845
brain C 20 845
phosphorus C 21 845
fractions C 22 845
following C 23 845
the C 24 845
intraperitoneal C 25 845
injection C 26 845
of C 27 845
p C 28 845
32 C 29 845
- C 30 845
labeled C 31 845
orthophosphate C 32 845
were C 33 845
performed C 34 845
during C 35 845
two C 36 845
selected C 37 845
segments C 38 845
of C 39 845
the C 40 845
24 C 41 845
- C 42 845
hour C 43 845
time C 44 845
scale C 45 845
. C 46 845
the C 48 845
results C 49 845
of C 50 845
these C 51 845
studies C 52 845
suggest C 53 845
that C 54 845
the C 55 845
circadian C 56 845
periodicity C 57 845
in C 58 845
relative C 59 845
specific C 60 845
activity C 61 845
of C 62 845
brain C 63 845
phospholipids C 64 845
is C 65 845
probably C 66 845
a C 67 845
consequence C 68 845
of C 69 845
a C 70 845
variation C 71 845
in C 72 845
the C 73 845
extent C 74 845
of C 75 845
p C 76 845
32 C 77 845
incorporation C 78 845
into C 79 845
brain C 80 845
inorganic C 81 845
phosphate C 82 845
and C 83 845
is C 84 845
not C 85 845
indicative C 86 845
of C 87 845
a C 88 845
periodicity C 89 845
in C 90 845
the C 91 845
rate C 92 845
of C 93 845
intermediary C 94 845
phospholipid C 95 845
metabolism C 96 845
. C 97 845
data C 99 845
on C 100 845
the C 101 845
postinjection C 102 845
time C 103 845
course C 104 845
of C 105 845
the C 106 845
specific C 107 845
activities C 108 845
of C 109 845
plasma C 110 845
inorganic C 111 845
phosphate C 112 845
, C 113 845
liver C 114 845
inorganic C 115 845
phosphate C 116 845
, C 117 845
and C 118 845
liver C 119 845
phospholipid C 120 845
suggest C 121 845
a C 122 845
similar C 123 845
explanation C 124 845
for C 125 845
the C 126 845
circadian C 127 845
periodic C 128 845
changes C 129 845
in C 130 845
relative C 131 845
specific C 132 845
activity C 133 845
of C 134 845
liver C 135 845
phospholipids C 136 845
. C 137 845
a C 139 845
circadian C 140 845
rhythm C 141 845
of C 142 845
inorganic C 143 845
phosphate C 144 845
concentration C 145 845
in C 146 845
mouse C 147 845
plasma C 148 845
is C 149 845
demonstrated C 150 845
. C 151 845
consideration C 153 845
of C 154 845
a C 155 845
mathematical C 156 845
model C 157 845
suggests C 158 845
that C 159 845
the C 160 845
observed C 161 845
within C 162 845
- C 163 845
day C 164 845
variation C 165 845
in C 166 845
p C 167 845
32 C 168 845
distribution C 169 845
and C 170 845
the C 171 845
circadian C 172 845
periodicity C 173 845
of C 174 845
phospholipid C 175 845
relative C 176 845
specific C 177 845
activity C 178 845
in C 179 845
liver C 180 845
and C 181 845
brain C 182 845
are C 183 845
a C 184 845
consequence C 185 845
of C 186 845
this C 187 845
periodicity C 188 845
in C 189 845
plasma C 190 845
phosphate C 191 845
content C 192 845
. C 193 845
a C 195 845
significant C 196 845
within C 197 845
- C 198 845
day C 199 845
variation C 200 845
in C 201 845
total C 202 845
phosphorus C 203 845
content C 204 845
of C 205 845
liver C 206 845
was C 207 845
observed C 208 845
. C 209 845
the C 211 845
disturbance C 212 845
of C 213 845
mice C 214 845
incident C 215 845
to C 216 845
p C 217 845
32 C 218 845
injection C 219 845
has C 220 845
a C 221 845
marked C 222 845
effect C 223 845
on C 224 845
the C 225 845
plasma C 226 845
content C 227 845
of C 228 845
inorganic C 229 845
phosphate C 230 845
and C 231 845
corticosterone C 232 845
. C 233 845
specificity C 1 846
of C 2 846
the C 3 846
inhibition C 4 846
of C 5 846
tubular C 6 846
phosphate C 7 846
reabsorption C 8 846
by C 9 846
certain C 10 846
amino C 11 846
- C 12 846
acids C 13 846
the C 14 846
inhibition C 15 846
of C 16 846
tubular C 17 846
phosphate C 18 846
reabsorption C 19 846
by C 20 846
certain C 21 846
amino C 22 846
- C 23 846
acids C 24 846
is C 25 846
a C 26 846
highly C 27 846
specific C 28 846
one C 29 846
in C 30 846
which C 31 846
differentiation C 32 846
between C 33 846
such C 34 846
closely C 35 846
related C 36 846
compunds C 37 846
as C 38 846
the C 39 846
d C 40 846
and C 41 846
l C 42 846
isomer C 43 846
is C 44 846
clearly C 45 846
possible C 46 846
. C 47 846
localization C 1 847
of C 2 847
phosphaturic C 3 847
effect C 4 847
of C 5 847
parathyroid C 6 847
hormone C 7 847
in C 8 847
nephron C 9 847
of C 10 847
the C 11 847
dog C 12 847
the C 13 847
renal C 14 847
mechanism C 15 847
and C 16 847
tubular C 17 847
site C 18 847
of C 19 847
the C 20 847
phosphaturic C 21 847
action C 22 847
of C 23 847
parathyroid C 24 847
hormone C 25 847
were C 26 847
investigated C 27 847
by C 28 847
clearance C 29 847
and C 30 847
stop C 31 847
- C 32 847
flow C 33 847
techniques C 34 847
in C 35 847
one C 36 847
intact C 37 847
and C 38 847
seven C 39 847
thyroparathyroidectomized C 40 847
dogs C 41 847
. C 42 847
administration C 44 847
of C 45 847
hormone C 46 847
caused C 47 847
a C 48 847
significant C 49 847
increase C 50 847
in C 51 847
the C 52 847
excretion C 53 847
of C 54 847
phosphate C 55 847
without C 56 847
increasing C 57 847
the C 58 847
filtered C 59 847
load C 60 847
. C 61 847
stop C 63 847
- C 64 847
flow C 65 847
analysis C 66 847
indicated C 67 847
that C 68 847
in C 69 847
the C 70 847
absence C 71 847
of C 72 847
parathyroid C 73 847
hormone C 74 847
most C 75 847
of C 76 847
the C 77 847
filtered C 78 847
phosphate C 79 847
was C 80 847
reabsorbed C 81 847
in C 82 847
the C 83 847
proximal C 84 847
tubule C 85 847
, C 86 847
and C 87 847
that C 88 847
the C 89 847
hormone C 90 847
increased C 91 847
the C 92 847
rate C 93 847
of C 94 847
phosphate C 95 847
excretion C 96 847
by C 97 847
inhibiting C 98 847
this C 99 847
reabsorptive C 100 847
mechanism C 101 847
. C 102 847
p C 104 847
32 C 105 847
injected C 106 847
during C 107 847
stopped C 108 847
flow C 109 847
showed C 110 847
no C 111 847
significant C 112 847
transport C 113 847
across C 114 847
the C 115 847
renal C 116 847
tubule C 117 847
despite C 118 847
the C 119 847
presence C 120 847
of C 121 847
excess C 122 847
parathyroid C 123 847
hormone C 124 847
. C 125 847
significant C 127 847
p C 128 847
32 C 129 847
activity C 130 847
appeared C 131 847
in C 132 847
the C 133 847
stop C 134 847
- C 135 847
flow C 136 847
collections C 137 847
simultaneously C 138 847
with C 139 847
the C 140 847
appearance C 141 847
of C 142 847
new C 143 847
filtrate C 144 847
. C 145 847
there C 147 847
was C 148 847
no C 149 847
evidence C 150 847
that C 151 847
parathyroid C 152 847
hormone C 153 847
mediated C 154 847
a C 155 847
secretory C 156 847
process C 157 847
for C 158 847
phosphate C 159 847
excretion C 160 847
. C 161 847
the C 1 848
regulation C 2 848
of C 3 848
growth C 4 848
hormone C 5 848
secretion C 6 848
in C 7 848
the C 8 848
present C 9 848
communication C 10 848
we C 11 848
summarize C 12 848
our C 13 848
investigations C 14 848
on C 15 848
the C 16 848
control C 17 848
of C 18 848
secretion C 19 848
of C 20 848
hgh C 21 848
using C 22 848
radioimmunoassay C 23 848
for C 24 848
the C 25 848
measurement C 26 848
of C 27 848
plasma C 28 848
gh C 29 848
. C 30 848
the C 32 848
assumption C 33 848
, C 34 848
implied C 35 848
throughout C 36 848
this C 37 848
presentation C 38 848
, C 39 848
that C 40 848
changes C 41 848
in C 42 848
secretory C 43 848
rate C 44 848
are C 45 848
responsible C 46 848
for C 47 848
acute C 48 848
changes C 49 848
in C 50 848
plasma C 51 848
concentration C 52 848
of C 53 848
hgh C 54 848
appears C 55 848
reasonable C 56 848
since C 57 848
the C 58 848
fluctuations C 59 848
in C 60 848
plasma C 61 848
hgh C 62 848
concentration C 63 848
are C 64 848
often C 65 848
too C 66 848
rapid C 67 848
to C 68 848
be C 69 848
caused C 70 848
solely C 71 848
by C 72 848
alterations C 73 848
in C 74 848
hormonal C 75 848
degradation C 76 848
or C 77 848
excretion C 78 848
. C 79 848
for C 81 848
slower C 82 848
changes C 83 848
in C 84 848
plasma C 85 848
hgh C 86 848
concentration C 87 848
, C 88 848
however C 89 848
, C 90 848
alterations C 91 848
in C 92 848
the C 93 848
rate C 94 848
of C 95 848
removal C 96 848
of C 97 848
hormone C 98 848
from C 99 848
the C 100 848
body C 101 848
fluids C 102 848
might C 103 848
play C 104 848
a C 105 848
contributory C 106 848
role C 107 848
. C 108 848
however C 110 848
, C 111 848
there C 112 848
is C 113 848
no C 114 848
evidence C 115 848
that C 116 848
important C 117 848
changes C 118 848
occur C 119 848
in C 120 848
the C 121 848
rate C 122 848
of C 123 848
removal C 124 848
of C 125 848
hgh C 126 848
from C 127 848
the C 128 848
circulation C 129 848
except C 130 848
in C 131 848
patients C 132 848
who C 133 848
have C 134 848
developed C 135 848
antibodies C 136 848
to C 137 848
hgh C 138 848
following C 139 848
treatment C 140 848
with C 141 848
hgh C 142 848
. C 143 848
early C 1 849
infantile C 2 849
autism C 3 849
and C 4 849
receptor C 5 849
processes C 6 849
the C 7 849
syndrome C 8 849
of C 9 849
early C 10 849
infantile C 11 849
autism C 12 849
is C 13 849
examined C 14 849
as C 15 849
a C 16 849
function C 17 849
of C 18 849
deviation C 19 849
in C 20 849
near C 21 849
- C 22 849
distance C 23 849
receptor C 24 849
usage C 25 849
. C 26 849
these C 28 849
receptor C 29 849
deviations C 30 849
are C 31 849
compared C 32 849
with C 33 849
normal C 34 849
receptor C 35 849
hierarchies C 36 849
developing C 37 849
from C 38 849
near C 39 849
to C 40 849
distance C 41 849
receptor C 42 849
dominance C 43 849
. C 44 849
the C 46 849
available C 47 849
information C 48 849
is C 49 849
consistent C 50 849
with C 51 849
the C 52 849
view C 53 849
that C 54 849
early C 55 849
infantile C 56 849
autism C 57 849
involves C 58 849
early C 59 849
sensory C 60 849
deprivation C 61 849
. C 62 849
this C 64 849
sensory C 65 849
deprivation C 66 849
results C 67 849
from C 68 849
an C 69 849
interaction C 70 849
between C 71 849
a C 72 849
constitutional C 73 849
deficiency C 74 849
inhibiting C 75 849
certain C 76 849
reticular C 77 849
arousal C 78 849
functions C 79 849
and C 80 849
mothering C 81 849
tending C 82 849
to C 83 849
understimulation C 84 849
. C 85 849
treatment C 87 849
of C 88 849
the C 89 849
young C 90 849
autistic C 91 849
child C 92 849
is C 93 849
suggested C 94 849
including C 95 849
stimulation C 96 849
and C 97 849
communication C 98 849
via C 99 849
the C 100 849
available C 101 849
near C 102 849
receptor C 103 849
systems C 104 849
. C 105 849
in C 107 849
the C 108 849
framework C 109 849
of C 110 849
sensory C 111 849
development C 112 849
, C 113 849
directions C 114 849
for C 115 849
the C 116 849
study C 117 849
of C 118 849
early C 119 849
diagnosis C 120 849
and C 121 849
treatment C 122 849
are C 123 849
indicated C 124 849
. C 125 849
studies C 1 850
on C 2 850
compensatory C 3 850
renal C 4 850
hypertrophy C 5 850
. C 6 850
i C 8 850
. C 9 850
effect C 11 850
of C 12 850
unilateral C 13 850
ureteral C 14 850
ligation C 15 850
and C 16 850
transection C 17 850
data C 18 850
are C 19 850
presented C 20 850
comparing C 21 850
the C 22 850
relative C 23 850
rate C 24 850
of C 25 850
compensatory C 26 850
renal C 27 850
hypertrophy C 28 850
and C 29 850
hyperplasia C 30 850
of C 31 850
the C 32 850
control C 33 850
kidney C 34 850
of C 35 850
rats C 36 850
following C 37 850
either C 38 850
unilateral C 39 850
ureteral C 40 850
transection C 41 850
, C 42 850
ligation C 43 850
, C 44 850
or C 45 850
nephrectomy C 46 850
. C 47 850
the C 49 850
growth C 50 850
of C 51 850
the C 52 850
control C 53 850
kidney C 54 850
on C 55 850
the C 56 850
unoperated C 57 850
side C 58 850
was C 59 850
strikingly C 60 850
slower C 61 850
after C 62 850
ureteral C 63 850
transection C 64 850
and C 65 850
ligation C 66 850
when C 67 850
compared C 68 850
with C 69 850
that C 70 850
resulting C 71 850
from C 72 850
the C 73 850
removal C 74 850
of C 75 850
one C 76 850
kidney C 77 850
. C 78 850
progressive C 80 850
hydronephrosis C 81 850
was C 82 850
observed C 83 850
on C 84 850
the C 85 850
operated C 86 850
side C 87 850
following C 88 850
ureteral C 89 850
transection C 90 850
and C 91 850
ligation C 92 850
and C 93 850
was C 94 850
more C 95 850
pronounced C 96 850
in C 97 850
the C 98 850
latter C 99 850
. C 100 850
degree C 102 850
of C 103 850
hypertrophy C 104 850
of C 105 850
the C 106 850
control C 107 850
kidney C 108 850
showed C 109 850
a C 110 850
close C 111 850
correlation C 112 850
with C 113 850
degree C 114 850
and C 115 850
duration C 116 850
of C 117 850
the C 118 850
hydronephrosis C 119 850
of C 120 850
the C 121 850
kidney C 122 850
on C 123 850
the C 124 850
operated C 125 850
side C 126 850
. C 127 850
these C 129 850
observations C 130 850
have C 131 850
been C 132 850
interpreted C 133 850
as C 134 850
indicating C 135 850
the C 136 850
operation C 137 850
of C 138 850
a C 139 850
control C 140 850
system C 141 850
regulating C 142 850
kidney C 143 850
growth C 144 850
in C 145 850
response C 146 850
to C 147 850
changes C 148 850
in C 149 850
some C 150 850
way C 151 850
related C 152 850
to C 153 850
kidney C 154 850
size C 155 850
. C 156 850
studies C 1 851
of C 2 851
the C 3 851
changes C 4 851
in C 5 851
growth C 6 851
and C 7 851
dna C 8 851
synthesis C 9 851
in C 10 851
the C 11 851
rat C 12 851
kidney C 13 851
during C 14 851
experimentally C 15 851
induced C 16 851
renal C 17 851
hypertrophy C 18 851
there C 19 851
is C 20 851
a C 21 851
high C 22 851
rate C 23 851
of C 24 851
accumulation C 25 851
of C 26 851
newly C 27 851
synthesized C 28 851
dna C 29 851
in C 30 851
the C 31 851
kidney C 32 851
after C 33 851
folic C 34 851
acid C 35 851
injection C 36 851
, C 37 851
compared C 38 851
with C 39 851
the C 40 851
small C 41 851
increase C 42 851
during C 43 851
the C 44 851
first C 45 851
few C 46 851
days C 47 851
after C 48 851
unilateral C 49 851
nephrectomy C 50 851
. C 51 851
there C 53 851
is C 54 851
a C 55 851
large C 56 851
increase C 57 851
in C 58 851
the C 59 851
water C 60 851
content C 61 851
of C 62 851
the C 63 851
kidney C 64 851
after C 65 851
folic C 66 851
acid C 67 851
which C 68 851
does C 69 851
not C 70 851
occur C 71 851
after C 72 851
unilateral C 73 851
nephrectomy C 74 851
. C 75 851
the C 77 851
changes C 78 851
in C 79 851
the C 80 851
wet C 81 851
and C 82 851
dry C 83 851
weight C 84 851
and C 85 851
the C 86 851
rna C 87 851
and C 88 851
dna C 89 851
content C 90 851
of C 91 851
the C 92 851
kidney C 93 851
have C 94 851
been C 95 851
compared C 96 851
after C 97 851
administration C 98 851
of C 99 851
folic C 100 851
acid C 101 851
, C 102 851
unilateral C 103 851
nephrectomy C 104 851
and C 105 851
unilateral C 106 851
nephrectomy C 107 851
followed C 108 851
by C 109 851
folic C 110 851
acid C 111 851
24 C 112 851
hr C 113 851
later C 114 851
in C 115 851
an C 116 851
attempt C 117 851
to C 118 851
study C 119 851
the C 120 851
nature C 121 851
of C 122 851
these C 123 851
differences C 124 851
. C 125 851
after C 127 851
unilateral C 128 851
nephrectomy C 129 851
there C 130 851
was C 131 851
a C 132 851
steady C 133 851
increase C 134 851
in C 135 851
wet C 136 851
weight C 137 851
, C 138 851
dry C 139 851
weight C 140 851
and C 141 851
rna C 142 851
content C 143 851
of C 144 851
the C 145 851
kidney C 146 851
, C 147 851
each C 148 851
parameter C 149 851
reaching C 150 851
about C 151 851
35 C 152 851
to C 153 851
40 C 154 851
% C 155 851
above C 156 851
normal C 157 851
by C 158 851
14 C 159 851
days C 160 851
, C 161 851
by C 162 851
which C 163 851
time C 164 851
the C 165 851
dna C 166 851
content C 167 851
had C 168 851
increased C 169 851
by C 170 851
only C 171 851
about C 172 851
25 C 173 851
% C 174 851
. C 175 851
an C 177 851
increased C 178 851
rate C 179 851
of C 180 851
dna C 181 851
synthesis C 182 851
was C 183 851
found C 184 851
between C 185 851
2 C 186 851
and C 187 851
4 C 188 851
days C 189 851
, C 190 851
returning C 191 851
almost C 192 851
to C 193 851
normal C 194 851
by C 195 851
7 C 196 851
days C 197 851
. C 198 851
after C 200 851
folic C 201 851
acid C 202 851
injection C 203 851
there C 204 851
were C 205 851
very C 206 851
large C 207 851
increases C 208 851
in C 209 851
wet C 210 851
weight C 211 851
( C 212 851
60 C 213 851
% C 214 851
) C 215 851
, C 216 851
rna C 217 851
content C 218 851
( C 219 851
100 C 220 851
% C 221 851
) C 222 851
and C 223 851
dna C 224 851
content C 225 851
( C 226 851
70 C 227 851
% C 228 851
) C 229 851
during C 230 851
the C 231 851
first C 232 851
4 C 233 851
days C 234 851
accompanied C 235 851
by C 236 851
a C 237 851
smaller C 238 851
increase C 239 851
in C 240 851
dry C 241 851
weight C 242 851
( C 243 851
30 C 244 851
% C 245 851
) C 246 851
. C 247 851
thereafter C 249 851
these C 250 851
parameters C 251 851
declined C 252 851
, C 253 851
relative C 254 851
to C 255 851
body C 256 851
weight C 257 851
, C 258 851
returning C 259 851
almost C 260 851
to C 261 851
normal C 262 851
by C 263 851
14 C 264 851
days C 265 851
. C 266 851
the C 268 851
rate C 269 851
of C 270 851
dna C 271 851
synthesis C 272 851
was C 273 851
greatly C 274 851
increased C 275 851
as C 276 851
early C 277 851
as C 278 851
24 C 279 851
hr C 280 851
after C 281 851
injection C 282 851
and C 283 851
reached C 284 851
a C 285 851
much C 286 851
higher C 287 851
level C 288 851
than C 289 851
that C 290 851
found C 291 851
after C 292 851
unilateral C 293 851
nephrectomy C 294 851
, C 295 851
before C 296 851
returning C 297 851
to C 298 851
the C 299 851
normal C 300 851
level C 301 851
by C 302 851
7 C 303 851
days C 304 851
. C 305 851
when C 307 851
unilateral C 308 851
nephrectomy C 309 851
was C 310 851
followed C 311 851
24 C 312 851
hr C 313 851
later C 314 851
by C 315 851
folic C 316 851
acid C 317 851
injection C 318 851
, C 319 851
the C 320 851
increases C 321 851
in C 322 851
weight C 323 851
, C 324 851
nucleic C 325 851
acid C 326 851
content C 327 851
and C 328 851
rate C 329 851
of C 330 851
dna C 331 851
synthesis C 332 851
were C 333 851
greater C 334 851
than C 335 851
at C 336 851
the C 337 851
corresponding C 338 851
times C 339 851
after C 340 851
either C 341 851
treatment C 342 851
alone C 343 851
. C 344 851
marked C 346 851
differences C 347 851
were C 348 851
found C 349 851
in C 350 851
the C 351 851
labeling C 352 851
indices C 353 851
of C 354 851
kidney C 355 851
cells C 356 851
after C 357 851
either C 358 851
unilateral C 359 851
nephrectomy C 360 851
or C 361 851
folic C 362 851
acid C 363 851
injection C 364 851
. C 365 851
the C 367 851
latter C 368 851
treatment C 369 851
resulted C 370 851
in C 371 851
very C 372 851
large C 373 851
increases C 374 851
in C 375 851
all C 376 851
three C 377 851
zones C 378 851
of C 379 851
the C 380 851
kidney C 381 851
, C 382 851
whereas C 383 851
after C 384 851
unilateral C 385 851
nephrectomy C 386 851
the C 387 851
responses C 388 851
of C 389 851
the C 390 851
cortex C 391 851
and C 392 851
outer C 393 851
medulla C 394 851
were C 395 851
much C 396 851
lower C 397 851
, C 398 851
with C 399 851
no C 400 851
significant C 401 851
increase C 402 851
in C 403 851
the C 404 851
inner C 405 851
medulla C 406 851
. C 407 851
when C 409 851
both C 410 851
treatments C 411 851
were C 412 851
combined C 413 851
, C 414 851
the C 415 851
response C 416 851
of C 417 851
the C 418 851
remaining C 419 851
kidney C 420 851
was C 421 851
similar C 422 851
to C 423 851
, C 424 851
though C 425 851
more C 426 851
exaggerated C 427 851
than C 428 851
, C 429 851
that C 430 851
of C 431 851
the C 432 851
normal C 433 851
kidney C 434 851
after C 435 851
folic C 436 851
acid C 437 851
injection C 438 851
. C 439 851
renal C 1 852
and C 2 852
adrenal C 3 852
relationships C 4 852
in C 5 852
compensatory C 6 852
hyperplasia C 7 852
the C 8 852
compensatory C 9 852
renal C 10 852
hyperplasia C 11 852
that C 12 852
normally C 13 852
follows C 14 852
unilateral C 15 852
nephrectomy C 16 852
is C 17 852
abolished C 18 852
by C 19 852
bilateral C 20 852
adrenalectomy C 21 852
if C 22 852
rats C 23 852
are C 24 852
maintained C 25 852
on C 26 852
fresh C 27 852
drinking C 28 852
water C 29 852
, C 30 852
but C 31 852
is C 32 852
restored C 33 852
when C 34 852
saline C 35 852
drinking C 36 852
water C 37 852
is C 38 852
provided C 39 852
or C 40 852
if C 41 852
such C 42 852
animals C 43 852
are C 44 852
injected C 45 852
with C 46 852
doca C 47 852
. C 48 852
the C 50 852
adrenals C 51 852
are C 52 852
also C 53 852
important C 54 852
for C 55 852
the C 56 852
increased C 57 852
proliferation C 58 852
caused C 59 852
by C 60 852
unilateral C 61 852
hydronephrosis C 62 852
. C 63 852
these C 65 852
experiments C 66 852
suggest C 67 852
that C 68 852
the C 69 852
role C 70 852
of C 71 852
the C 72 852
adrenal C 73 852
cortex C 74 852
in C 75 852
renal C 76 852
hyperplasia C 77 852
may C 78 852
be C 79 852
to C 80 852
secrete C 81 852
mineralocorticoids C 82 852
, C 83 852
which C 84 852
promote C 85 852
the C 86 852
retention C 87 852
of C 88 852
sodium C 89 852
and C 90 852
thereby C 91 852
stimulate C 92 852
cell C 93 852
division C 94 852
in C 95 852
the C 96 852
kidneys C 97 852
. C 98 852
a C 1 853
genetic C 2 853
study C 3 853
of C 4 853
neonatal C 5 853
obstructive C 6 853
jaundice C 7 853
58 C 8 853
children C 9 853
with C 10 853
extrahepatic C 11 853
biliary C 12 853
atresia C 13 853
, C 14 853
7 C 15 853
with C 16 853
intrahepatic C 17 853
biliary C 18 853
atresia C 19 853
and C 20 853
50 C 21 853
with C 22 853
' C 23 853
neonatal C 24 853
hepatitis C 25 853
' C 26 853
were C 27 853
analysed C 28 853
concerning C 29 853
diagnostic C 30 853
criteria C 31 853
, C 32 853
natural C 33 853
history C 34 853
, C 35 853
familial C 36 853
, C 37 853
clinical C 38 853
and C 39 853
pathological C 40 853
data C 41 853
. C 42 853
in C 44 853
extrahepatic C 45 853
biliary C 46 853
atresia C 47 853
, C 48 853
there C 49 853
is C 50 853
no C 51 853
evidence C 52 853
of C 53 853
a C 54 853
familial C 55 853
tendency C 56 853
, C 57 853
influence C 58 853
of C 59 853
maternal C 60 853
age C 61 853
, C 62 853
birth C 63 853
order C 64 853
or C 65 853
disturbance C 66 853
of C 67 853
foetal C 68 853
development C 69 853
. C 70 853
in C 72 853
' C 73 853
neonatal C 74 853
hepatitis C 75 853
' C 76 853
, C 77 853
there C 78 853
were C 79 853
4 C 80 853
consanguineous C 81 853
parents C 82 853
, C 83 853
suggesting C 84 853
a C 85 853
mutant C 86 853
autosomal C 87 853
gene C 88 853
in C 89 853
homozygous C 90 853
form C 91 853
. C 92 853
some C 94 853
infants C 95 853
with C 96 853
the C 97 853
genotype C 98 853
for C 99 853
' C 100 853
neonatal C 101 853
hepatitis C 102 853
' C 103 853
may C 104 853
manifest C 105 853
a C 106 853
very C 107 853
mild C 108 853
or C 109 853
a C 110 853
very C 111 853
severe C 112 853
form C 113 853
, C 114 853
so C 115 853
, C 116 853
a C 117 853
diagnosis C 118 853
was C 119 853
not C 120 853
made C 121 853
. C 122 853
an C 124 853
apparent C 125 853
excess C 126 853
of C 127 853
males C 128 853
over C 129 853
females C 130 853
may C 131 853
be C 132 853
another C 133 853
evidence C 134 853
of C 135 853
failure C 136 853
of C 137 853
manifestation C 138 853
of C 139 853
the C 140 853
genotype C 141 853
. C 142 853
but C 144 853
' C 145 853
neonatal C 146 853
hepatitis C 147 853
' C 148 853
may C 149 853
be C 150 853
a C 151 853
manifestation C 152 853
of C 153 853
more C 154 853
than C 155 853
one C 156 853
disease C 157 853
. C 158 853
in C 160 853
' C 161 853
neonatal C 162 853
hepatitis C 163 853
' C 164 853
the C 165 853
birth C 166 853
weight C 167 853
shows C 168 853
a C 169 853
marked C 170 853
decrease C 171 853
, C 172 853
perhaps C 173 853
as C 174 853
a C 175 853
sequence C 176 853
of C 177 853
disturbed C 178 853
liver C 179 853
function C 180 853
in C 181 853
the C 182 853
foetus C 183 853
. C 184 853
parathyroid C 1 854
extract C 2 854
- C 3 854
induced C 4 854
changes C 5 854
in C 6 854
the C 7 854
oxidation C 8 854
of C 9 854
citrate C 10 854
, C 11 854
succinate C 12 854
and C 13 854
other C 14 854
organic C 15 854
acids C 16 854
by C 17 854
liver C 18 854
. C 19 854
parathyroid C 21 854
extract C 22 854
( C 23 854
pte C 24 854
) C 25 854
or C 26 854
partially C 27 854
purified C 28 854
parathyroid C 29 854
hormone C 30 854
administered C 31 854
in C 32 854
vivo C 33 854
markedly C 34 854
altered C 35 854
the C 36 854
oxidation C 37 854
in C 38 854
vitro C 39 854
by C 40 854
rabbit C 41 854
liver C 42 854
minces C 43 854
of C 44 854
citrate C 45 854
, C 46 854
- C 47 854
keto C 48 854
glutarate C 49 854
- C 50 854
c C 51 854
, C 52 854
succinate C 53 854
- C 54 854
c C 55 854
, C 56 854
fumarate C 57 854
- C 58 854
c C 59 854
and C 60 854
lactate C 61 854
. C 62 854
with C 64 854
ca C 65 854
+ C 66 854
+ C 67 854
present C 68 854
in C 69 854
the C 70 854
incubation C 71 854
medium C 72 854
, C 73 854
minces C 74 854
from C 75 854
pte C 76 854
treated C 77 854
animals C 78 854
produced C 79 854
more C 80 854
co C 81 854
and C 82 854
had C 83 854
a C 84 854
greater C 85 854
o C 86 854
consumption C 87 854
than C 88 854
did C 89 854
control C 90 854
minces C 91 854
. C 92 854
this C 94 854
stimulation C 95 854
was C 96 854
due C 97 854
, C 98 854
in C 99 854
part C 100 854
at C 101 854
least C 102 854
, C 103 854
to C 104 854
a C 105 854
more C 106 854
rapid C 107 854
decline C 108 854
in C 109 854
metabolic C 110 854
activity C 111 854
of C 112 854
the C 113 854
control C 114 854
tissues C 115 854
. C 116 854
when C 118 854
ca C 119 854
+ C 120 854
+ C 121 854
was C 122 854
absent C 123 854
, C 124 854
total C 125 854
metabolism C 126 854
was C 127 854
increased C 128 854
and C 129 854
the C 130 854
tissue C 131 854
derived C 132 854
from C 133 854
pte C 134 854
treated C 135 854
animals C 136 854
was C 137 854
less C 138 854
active C 139 854
than C 140 854
the C 141 854
control C 142 854
tissue C 143 854
. C 144 854
the C 146 854
effect C 147 854
was C 148 854
detected C 149 854
as C 150 854
early C 151 854
as C 152 854
4 C 153 854
hr C 154 854
after C 155 854
injection C 156 854
( C 157 854
750 C 158 854
u C 159 854
/ C 160 854
kg C 161 854
) C 162 854
and C 163 854
could C 164 854
be C 165 854
elicited C 166 854
with C 167 854
as C 168 854
little C 169 854
as C 170 854
200 C 171 854
u C 172 854
( C 173 854
at C 174 854
14 C 175 854
hr C 176 854
) C 177 854
. C 178 854
the C 180 854
action C 181 854
of C 182 854
pte C 183 854
could C 184 854
not C 185 854
be C 186 854
duplicated C 187 854
by C 188 854
the C 189 854
injection C 190 854
of C 191 854
cacl C 192 854
into C 193 854
the C 194 854
animal C 195 854
. C 196 854
the C 198 854
data C 199 854
suggest C 200 854
that C 201 854
one C 202 854
effect C 203 854
of C 204 854
treatment C 205 854
was C 206 854
a C 207 854
general C 208 854
inhibition C 209 854
of C 210 854
oxidation C 211 854
. C 212 854
the C 214 854
stimulation C 215 854
of C 216 854
metabolism C 217 854
could C 218 854
be C 219 854
a C 220 854
consequence C 221 854
of C 222 854
this C 223 854
inhibition C 224 854
or C 225 854
a C 226 854
separate C 227 854
unrelated C 228 854
alteration C 229 854
. C 230 854
actinomycin C 1 855
and C 2 855
erythropoiesis C 3 855
and C 4 855
the C 5 855
production C 6 855
of C 7 855
erythropoietin C 8 855
in C 9 855
mice C 10 855
. C 11 855
in C 13 855
b C 14 855
6 C 15 855
d C 16 855
2 C 17 855
f C 18 855
female C 19 855
mice C 20 855
a C 21 855
single C 22 855
dose C 23 855
of C 24 855
10 C 25 855
of C 26 855
actinomycin C 27 855
will C 28 855
suppress C 29 855
normal C 30 855
erythropoiesis C 31 855
( C 32 855
fe C 33 855
erythrocyte C 34 855
uptake C 35 855
) C 36 855
. C 37 855
in C 39 855
polycythemic C 40 855
mice C 41 855
2 C 42 855
is C 43 855
enough C 44 855
to C 45 855
prevent C 46 855
the C 47 855
stimulatory C 48 855
effect C 49 855
of C 50 855
0 C 51 855
. C 52 855
. C 53 855
. C 53 855
a C 54 855
units C 55 855
of C 56 855
erythropoietin C 57 855
. C 58 855
the C 60 855
curves C 61 855
of C 62 855
suppression C 63 855
and C 64 855
recovery C 65 855
versus C 66 855
time C 67 855
support C 68 855
the C 69 855
hypothesis C 70 855
that C 71 855
erythropoietin C 72 855
acts C 73 855
for C 74 855
a C 75 855
short C 76 855
time C 77 855
in C 78 855
an C 79 855
early C 80 855
stage C 81 855
of C 82 855
erythropoiesis C 83 855
; C 84 855
after C 85 855
this C 86 855
early C 87 855
stage C 88 855
developing C 89 855
cells C 90 855
are C 91 855
no C 92 855
longer C 93 855
so C 94 855
sensitive C 95 855
to C 96 855
actinomycin C 97 855
. C 98 855
recovery C 100 855
, C 101 855
even C 102 855
from C 103 855
repeated C 104 855
doses C 105 855
, C 106 855
is C 107 855
rapid C 108 855
and C 109 855
adequate C 110 855
. C 111 855
amounts C 113 855
of C 114 855
actinomycin C 115 855
which C 116 855
are C 117 855
adequate C 118 855
to C 119 855
abolish C 120 855
erythropoiesis C 121 855
do C 122 855
not C 123 855
prevent C 124 855
the C 125 855
new C 126 855
appearance C 127 855
of C 128 855
erythropoietin C 129 855
in C 130 855
the C 131 855
plasma C 132 855
of C 133 855
hypoxic C 134 855
mice C 135 855
. C 136 855
the C 1 856
ultrastructure C 2 856
, C 3 856
histopathology C 4 856
, C 5 856
and C 6 856
histochemistry C 7 856
of C 8 856
the C 9 856
parathyroid C 10 856
glands C 11 856
of C 12 856
pregnant C 13 856
and C 14 856
nonpregnant C 15 856
cows C 16 856
fed C 17 856
a C 18 856
high C 19 856
level C 20 856
of C 21 856
vitamin C 22 856
d C 23 856
. C 24 856
the C 26 856
parathyroid C 27 856
glands C 28 856
of C 29 856
pregnant C 30 856
and C 31 856
nonpregnant C 32 856
cows C 33 856
were C 34 856
studied C 35 856
by C 36 856
light C 37 856
and C 38 856
electron C 39 856
microscopy C 40 856
following C 41 856
the C 42 856
daily C 43 856
feeding C 44 856
of C 45 856
30 C 46 856
million C 47 856
units C 48 856
of C 49 856
vit C 50 856
d C 51 856
for C 52 856
30 C 53 856
days C 54 856
and C 55 856
compared C 56 856
to C 57 856
untreated C 58 856
controls C 59 856
. C 60 856
in C 62 856
both C 63 856
the C 64 856
pregnant C 65 856
and C 66 856
nonpregnant C 67 856
cows C 68 856
the C 69 856
parathyroid C 70 856
glands C 71 856
became C 72 856
markedly C 73 856
atrophic C 74 856
with C 75 856
a C 76 856
diminution C 77 856
in C 78 856
the C 79 856
amount C 80 856
of C 81 856
parenchyma C 82 856
compared C 83 856
to C 84 856
the C 85 856
untreated C 86 856
controls C 87 856
. C 88 856
after C 90 856
vit C 91 856
d C 92 856
feeding C 93 856
the C 94 856
number C 95 856
of C 96 856
actively C 97 856
secreting C 98 856
dark C 99 856
and C 100 856
intermediate C 101 856
chief C 102 856
cells C 103 856
was C 104 856
reduced C 105 856
and C 106 856
the C 107 856
percentage C 108 856
of C 109 856
inactive C 110 856
( C 111 856
light C 112 856
) C 113 856
and C 114 856
atrophic C 115 856
chief C 116 856
cells C 117 856
was C 118 856
increased C 119 856
. C 120 856
the C 122 856
parathyroid C 123 856
glands C 124 856
of C 125 856
the C 126 856
vit C 127 856
d C 128 856
- C 129 856
fed C 130 856
, C 131 856
nonpregnant C 132 856
cows C 133 856
were C 134 856
dominated C 135 856
by C 136 856
severely C 137 856
atrophic C 138 856
chief C 139 856
cells C 140 856
. C 141 856
these C 143 856
cells C 144 856
were C 145 856
characterized C 146 856
by C 147 856
their C 148 856
highly C 149 856
irregular C 150 856
shape C 151 856
, C 152 856
shrunken C 153 856
nucleus C 154 856
and C 155 856
cytoplasm C 156 856
, C 157 856
widened C 158 856
intercellular C 159 856
spaces C 160 856
traversed C 161 856
by C 162 856
numerous C 163 856
cytoplasmic C 164 856
processes C 165 856
, C 166 856
increased C 167 856
electron C 168 856
density C 169 856
, C 170 856
few C 171 856
secretory C 172 856
granules C 173 856
, C 174 856
inactive C 175 856
ergastoplasm C 176 856
and C 177 856
golgi C 178 856
complexes C 179 856
. C 180 856
atrophic C 182 856
chief C 183 856
cells C 184 856
were C 185 856
not C 186 856
present C 187 856
in C 188 856
the C 189 856
untreated C 190 856
controls C 191 856
. C 192 856
the C 194 856
predominating C 195 856
cell C 196 856
type C 197 856
in C 198 856
the C 199 856
parathyroids C 200 856
of C 201 856
the C 202 856
vit C 203 856
d C 204 856
- C 205 856
fed C 206 856
pregnant C 207 856
cows C 208 856
were C 209 856
the C 210 856
inactive C 211 856
chief C 212 856
cells C 213 856
. C 214 856
in C 216 856
contrast C 217 856
to C 218 856
the C 219 856
atrophic C 220 856
chief C 221 856
cells C 222 856
, C 223 856
they C 224 856
were C 225 856
larger C 226 856
and C 227 856
more C 228 856
regular C 229 856
in C 230 856
shape C 231 856
with C 232 856
relatively C 233 856
straight C 234 856
cell C 235 856
membranes C 236 856
. C 237 856
they C 239 856
were C 240 856
comparatively C 241 856
electron C 242 856
- C 243 856
transparent C 244 856
, C 245 856
containing C 246 856
more C 247 856
glycogen C 248 856
and C 249 856
fewer C 250 856
secretory C 251 856
granules C 252 856
. C 253 856
organelles C 255 856
concerned C 256 856
with C 257 856
protein C 258 856
synthesis C 259 856
and C 260 856
packaging C 261 856
into C 262 856
secretory C 263 856
units C 264 856
were C 265 856
poorly C 266 856
developed C 267 856
. C 268 856
inactive C 270 856
chief C 271 856
cells C 272 856
were C 273 856
observed C 274 856
only C 275 856
occasionally C 276 856
in C 277 856
the C 278 856
parathyroid C 279 856
glands C 280 856
of C 281 856
untreated C 282 856
pregnant C 283 856
cows C 284 856
where C 285 856
the C 286 856
actively C 287 856
secreting C 288 856
dark C 289 856
and C 290 856
intermediate C 291 856
chief C 292 856
cells C 293 856
predominated C 294 856
. C 295 856
effect C 1 857
of C 2 857
heparin C 3 857
and C 4 857
parathyroid C 5 857
extract C 6 857
an C 7 857
acid C 8 857
phosphatase C 9 857
in C 10 857
bone C 11 857
. C 12 857
to C 14 857
test C 15 857
the C 16 857
theory C 17 857
that C 18 857
heparin C 19 857
might C 20 857
stimulate C 21 857
acid C 22 857
phosphatase C 23 857
in C 24 857
the C 25 857
bone C 26 857
of C 27 857
young C 28 857
rats C 29 857
, C 30 857
heparin C 31 857
, C 32 857
pte C 33 857
, C 34 857
or C 35 857
a C 36 857
combination C 37 857
of C 38 857
both C 39 857
were C 40 857
injected C 41 857
. C 42 857
after C 44 857
an C 45 857
appropriate C 46 857
time C 47 857
interval C 48 857
acid C 49 857
phosphatase C 50 857
activity C 51 857
of C 52 857
bone C 53 857
of C 54 857
treated C 55 857
animals C 56 857
was C 57 857
compared C 58 857
with C 59 857
controls C 60 857
. C 61 857
it C 63 857
was C 64 857
found C 65 857
that C 66 857
heparin C 67 857
enhanced C 68 857
the C 69 857
pte C 70 857
- C 71 857
stimulated C 72 857
acid C 73 857
phosphatase C 74 857
activity C 75 857
of C 76 857
both C 77 857
calvaria C 78 857
and C 79 857
metaphysis C 80 857
but C 81 857
not C 82 857
diaphysis C 83 857
. C 84 857
the C 86 857
possible C 87 857
relation C 88 857
of C 89 857
these C 90 857
facts C 91 857
to C 92 857
the C 93 857
presence C 94 857
of C 95 857
lysosomes C 96 857
in C 97 857
osteoclasts C 98 857
was C 99 857
discussed C 100 857
. C 101 857
the C 1 858
isolation C 2 858
of C 3 858
thyrocalcitonin C 4 858
and C 5 858
study C 6 858
of C 7 858
its C 8 858
effects C 9 858
in C 10 858
the C 11 858
rat C 12 858
. C 13 858
the C 15 858
thyroid C 16 858
secretes C 17 858
a C 18 858
polypeptide C 19 858
hormone C 20 858
( C 21 858
thyrocalcitionin C 22 858
) C 23 858
which C 24 858
is C 25 858
effective C 26 858
in C 27 858
lowering C 28 858
plasma C 29 858
calcium C 30 858
and C 31 858
phosphate C 32 858
. C 33 858
the C 35 858
hormone C 36 858
can C 37 858
be C 38 858
extracted C 39 858
from C 40 858
the C 41 858
thyroid C 42 858
of C 43 858
the C 44 858
rat C 45 858
, C 46 858
dog C 47 858
, C 48 858
pig C 49 858
, C 50 858
goat C 51 858
, C 52 858
ox C 53 858
, C 54 858
and C 55 858
monkey C 56 858
. C 57 858
the C 59 858
isolation C 60 858
of C 61 858
the C 62 858
hormone C 63 858
from C 64 858
pig C 65 858
thyroid C 66 858
by C 67 858
a C 68 858
combination C 69 858
of C 70 858
salt C 71 858
fractionation C 72 858
and C 73 858
gel C 74 858
filtration C 75 858
is C 76 858
described C 77 858
. C 78 858
one C 80 858
microgram C 81 858
of C 82 858
the C 83 858
pure C 84 858
material C 85 858
is C 86 858
very C 87 858
active C 88 858
in C 89 858
the C 90 858
rat C 91 858
. C 92 858
thyrocalcitonin C 94 858
remains C 95 858
effective C 96 858
after C 97 858
parathyroidectomy C 98 858
, C 99 858
after C 100 858
nephrectomy C 101 858
, C 102 858
after C 103 858
overdosage C 104 858
with C 105 858
vitamin C 106 858
d C 107 858
, C 108 858
during C 109 858
vitamin C 110 858
d C 111 858
deficiency C 112 858
, C 113 858
and C 114 858
during C 115 858
calcium C 116 858
or C 117 858
magnesium C 118 858
deficiency C 119 858
. C 120 858
its C 122 858
action C 123 858
is C 124 858
not C 125 858
prevented C 126 858
by C 127 858
prior C 128 858
administration C 129 858
of C 130 858
actinomycin C 131 858
d C 132 858
. C 133 858
a C 135 858
single C 136 858
injection C 137 858
does C 138 858
not C 139 858
change C 140 858
soft C 141 858
tissue C 142 858
calcium C 143 858
but C 144 858
infusion C 145 858
for C 146 858
12 C 147 858
hr C 148 858
lowers C 149 858
cardiac C 150 858
muscle C 151 858
calcium C 152 858
. C 153 858
it C 155 858
is C 156 858
concluded C 157 858
that C 158 858
this C 159 858
new C 160 858
thyroid C 161 858
hormone C 162 858
acts C 163 858
on C 164 858
bone C 165 858
and C 166 858
that C 167 858
it C 168 858
probably C 169 858
plays C 170 858
an C 171 858
important C 172 858
role C 173 858
in C 174 858
normal C 175 858
physiology C 176 858
. C 177 858
the C 1 859
effect C 2 859
of C 3 859
actinomycin C 4 859
d C 5 859
on C 6 859
parathyroid C 7 859
- C 8 859
induced C 9 859
change C 10 859
in C 11 859
bone C 12 859
and C 13 859
kidney C 14 859
. C 15 859
actinomycin C 17 859
d C 18 859
( C 19 859
amd C 20 859
) C 21 859
, C 22 859
an C 23 859
antibiotic C 24 859
known C 25 859
to C 26 859
inhibit C 27 859
dna C 28 859
- C 29 859
directed C 30 859
rna C 31 859
synthesis C 32 859
, C 33 859
was C 34 859
used C 35 859
to C 36 859
study C 37 859
parathyroid C 38 859
- C 39 859
induced C 40 859
changes C 41 859
in C 42 859
ca C 43 859
mobilization C 44 859
in C 45 859
vivo C 46 859
and C 47 859
in C 48 859
vitro C 49 859
as C 50 859
well C 51 859
as C 52 859
renal C 53 859
excretion C 54 859
of C 55 859
ca C 56 859
and C 57 859
phosphate C 58 859
in C 59 859
rats C 60 859
. C 61 859
intact C 63 859
and C 64 859
parathyroidectomized C 65 859
rats C 66 859
subjected C 67 859
to C 68 859
peritoneal C 69 859
lavage C 70 859
were C 71 859
administered C 72 859
amd C 73 859
, C 74 859
and C 75 859
changes C 76 859
in C 77 859
ca C 78 859
, C 79 859
p C 80 859
, C 81 859
and C 82 859
mg C 83 859
in C 84 859
lavage C 85 859
and C 86 859
serum C 87 859
were C 88 859
examined C 89 859
. C 90 859
amd C 92 859
consistently C 93 859
lowered C 94 859
the C 95 859
ca C 96 859
transfer C 97 859
into C 98 859
the C 99 859
peritoneal C 100 859
rinse C 101 859
in C 102 859
both C 103 859
the C 104 859
intact C 105 859
and C 106 859
parathyroidectomized C 107 859
animals C 108 859
, C 109 859
although C 110 859
the C 111 859
drop C 112 859
in C 113 859
ca C 114 859
was C 115 859
more C 116 859
acute C 117 859
if C 118 859
the C 119 859
animals C 120 859
were C 121 859
pretreated C 122 859
by C 123 859
subcutaneous C 124 859
injections C 125 859
of C 126 859
amd C 127 859
than C 128 859
if C 129 859
amd C 130 859
was C 131 859
administered C 132 859
as C 133 859
a C 134 859
component C 135 859
of C 136 859
the C 137 859
rinse C 138 859
. C 139 859
pretreatment C 141 859
of C 142 859
lavaged C 143 859
animals C 144 859
with C 145 859
amd C 146 859
prevented C 147 859
the C 148 859
expected C 149 859
increase C 150 859
in C 151 859
osteoclast C 152 859
numbers C 153 859
in C 154 859
the C 155 859
distal C 156 859
metaphysis C 157 859
of C 158 859
the C 159 859
femur C 160 859
but C 161 859
had C 162 859
no C 163 859
effect C 164 859
if C 165 859
administered C 166 859
as C 167 859
a C 168 859
component C 169 859
of C 170 859
the C 171 859
peritoneal C 172 859
rinse C 173 859
. C 174 859
the C 176 859
incubation C 177 859
of C 178 859
femora C 179 859
removed C 180 859
from C 181 859
both C 182 859
intact C 183 859
and C 184 859
parathyroidectomized C 185 859
animals C 186 859
resulted C 187 859
in C 188 859
media C 189 859
ca C 190 859
levels C 191 859
that C 192 859
were C 193 859
significantly C 194 859
lower C 195 859
after C 196 859
4 C 197 859
hr C 198 859
. C 199 859
incubation C 201 859
when C 202 859
amd C 203 859
was C 204 859
added C 205 859
in C 206 859
vitro C 207 859
. C 208 859
however C 210 859
, C 211 859
transfer C 212 859
of C 213 859
recently C 214 859
injected C 215 859
ca C 216 859
into C 217 859
the C 218 859
incubation C 219 859
medium C 220 859
from C 221 859
animals C 222 859
treated C 223 859
with C 224 859
amd C 225 859
was C 226 859
increased C 227 859
. C 228 859
in C 230 859
addition C 231 859
, C 232 859
parathyroidectomy C 233 859
of C 234 859
animals C 235 859
subsequent C 236 859
to C 237 859
administration C 238 859
of C 239 859
amd C 240 859
still C 241 859
resulted C 242 859
in C 243 859
expected C 244 859
changes C 245 859
in C 246 859
ca C 247 859
and C 248 859
p C 249 859
in C 250 859
the C 251 859
urine C 252 859
although C 253 859
amd C 254 859
significantly C 255 859
increased C 256 859
p C 257 859
excretion C 258 859
in C 259 859
both C 260 859
intact C 261 859
and C 262 859
parathyroidectomized C 263 859
animals C 264 859
. C 265 859
it C 267 859
was C 268 859
concluded C 269 859
that C 270 859
endogenous C 271 859
parathyroid C 272 859
hormone C 273 859
requires C 274 859
the C 275 859
continuous C 276 859
production C 277 859
of C 278 859
enzymes C 279 859
ultimately C 280 859
responsible C 281 859
for C 282 859
its C 283 859
action C 284 859
on C 285 859
bone C 286 859
and C 287 859
kidney C 288 859
, C 289 859
but C 290 859
that C 291 859
this C 292 859
action C 293 859
is C 294 859
not C 295 859
necessarily C 296 859
related C 297 859
directly C 298 859
to C 299 859
the C 300 859
production C 301 859
of C 302 859
m C 303 859
- C 304 859
rna C 305 859
. C 306 859
inhibition C 1 860
by C 2 860
actinomycin C 3 860
d C 4 860
of C 5 860
bone C 6 860
resorption C 7 860
induced C 8 860
by C 9 860
parathyroid C 10 860
hormone C 11 860
or C 12 860
vitamin C 13 860
a C 14 860
. C 15 860
actinomycin C 17 860
d C 18 860
inhibits C 19 860
cell C 20 860
proliferation C 21 860
in C 22 860
control C 23 860
cultures C 24 860
of C 25 860
embryonic C 26 860
rat C 27 860
bone C 28 860
and C 29 860
prevents C 30 860
the C 31 860
stimulation C 32 860
of C 33 860
bone C 34 860
resorption C 35 860
by C 36 860
parathyroid C 37 860
horome C 38 860
( C 39 860
pth C 40 860
) C 41 860
or C 42 860
vit C 43 860
. C 44 860
a C 46 860
. C 47 860
with C 49 860
a C 50 860
dose C 51 860
of C 52 860
0 C 53 860
. C 54 860
. C 55 860
. C 55 860
. C 55 860
/ C 56 860
ml C 57 860
. C 58 860
of C 60 860
actinomycin C 61 860
d C 62 860
, C 63 860
pth C 64 860
effects C 65 860
are C 66 860
only C 67 860
partially C 68 860
inhibited C 69 860
and C 70 860
this C 71 860
inhibition C 72 860
can C 73 860
be C 74 860
overcome C 75 860
by C 76 860
increasing C 77 860
the C 78 860
dose C 79 860
of C 80 860
pth C 81 860
. C 82 860
these C 84 860
findings C 85 860
suggest C 86 860
that C 87 860
these C 88 860
agents C 89 860
act C 90 860
competitively C 91 860
. C 92 860
j C 1 861
. C 2 861
clin C 4 861
. C 5 861
endocr C 7 861
. C 8 861
1965 C 10 861
, C 11 861
25 C 12 861
/ C 13 861
4 C 14 861
( C 15 861
457 C 16 861
- C 17 861
464 C 18 861
) C 19 861
. C 20 861
antagonism C 22 861
between C 23 861
parathyroid C 24 861
extract C 25 861
and C 26 861
adrenal C 27 861
cortical C 28 861
steroids C 29 861
in C 30 861
man C 31 861
. C 32 861
metabolic C 34 861
balance C 35 861
studies C 36 861
were C 37 861
done C 38 861
in C 39 861
2 C 40 861
patients C 41 861
with C 42 861
hypoparathyroidism C 43 861
who C 44 861
received C 45 861
hydrocortisone C 46 861
of C 47 861
prednisone C 48 861
during C 49 861
the C 50 861
administration C 51 861
of C 52 861
parathyroid C 53 861
extract C 54 861
. C 55 861
administration C 57 861
of C 58 861
prednisone C 59 861
was C 60 861
associated C 61 861
with C 62 861
phosphate C 63 861
retention C 64 861
, C 65 861
decreased C 66 861
urinary C 67 861
ca C 68 861
, C 69 861
decreased C 70 861
serum C 71 861
ca C 72 861
, C 73 861
citrate C 74 861
and C 75 861
glycoprotein C 76 861
concentrations C 77 861
, C 78 861
and C 79 861
increased C 80 861
serum C 81 861
phosphate C 82 861
. C 83 861
excretion C 85 861
of C 86 861
parathyroid C 87 861
activity C 88 861
in C 89 861
the C 90 861
urine C 91 861
of C 92 861
1 C 93 861
patient C 94 861
was C 95 861
uninfluenced C 96 861
by C 97 861
the C 98 861
administration C 99 861
of C 100 861
prednisone C 101 861
. C 102 861
it C 104 861
is C 105 861
concluded C 106 861
that C 107 861
the C 108 861
antagonistic C 109 861
effect C 110 861
of C 111 861
the C 112 861
adrenal C 113 861
cortical C 114 861
steroids C 115 861
was C 116 861
expressed C 117 861
at C 118 861
the C 119 861
biochemical C 120 861
sites C 121 861
of C 122 861
action C 123 861
of C 124 861
the C 125 861
parathyroid C 126 861
extract C 127 861
in C 128 861
bone C 129 861
and C 130 861
kidney C 131 861
, C 132 861
that C 133 861
the C 134 861
steroids C 135 861
reduce C 136 861
parathyroid C 137 861
secretion C 138 861
but C 139 861
that C 140 861
their C 141 861
administration C 142 861
probably C 143 861
does C 144 861
not C 145 861
result C 146 861
in C 147 861
degradation C 148 861
or C 149 861
inactivation C 150 861
of C 151 861
the C 152 861
hormone C 153 861
. C 154 861
tissue C 1 862
distribution C 2 862
of C 3 862
electrolytes C 4 862
, C 5 862
ca C 6 862
and C 7 862
mg C 8 862
in C 9 862
experimental C 10 862
hyper C 11 862
- C 12 862
and C 13 862
hypoparathyroidism C 14 862
. C 15 862
the C 17 862
effects C 18 862
of C 19 862
experimental C 20 862
hyper C 21 862
- C 22 862
and C 23 862
hypoparathyroidism C 24 862
on C 25 862
plasma C 26 862
and C 27 862
tissue C 28 862
distribution C 29 862
of C 30 862
electrolytes C 31 862
and C 32 862
tissue C 33 862
exchangeability C 34 862
with C 35 862
ca C 36 862
and C 37 862
mg C 38 862
were C 39 862
studied C 40 862
in C 41 862
dogs C 42 862
following C 43 862
acute C 44 862
renal C 45 862
pedicle C 46 862
ligation C 47 862
. C 48 862
in C 50 862
hyperparathyroidism C 51 862
, C 52 862
plasma C 53 862
concentrations C 54 862
of C 55 862
mg C 56 862
and C 57 862
inorganic C 58 862
p C 59 862
as C 60 862
well C 61 862
as C 62 862
ca C 63 862
were C 64 862
increased C 65 862
. C 66 862
a C 68 862
greater C 69 862
accumulation C 70 862
of C 71 862
ca C 72 862
occurred C 73 862
in C 74 862
some C 75 862
tissues C 76 862
and C 77 862
a C 78 862
lesser C 79 862
accumulation C 80 862
in C 81 862
others C 82 862
than C 83 862
in C 84 862
acute C 85 862
hypercalcemia C 86 862
of C 87 862
comparable C 88 862
severity C 89 862
and C 90 862
the C 91 862
fractional C 92 862
rate C 93 862
of C 94 862
exchange C 95 862
of C 96 862
tissue C 97 862
ca C 98 862
was C 99 862
30 C 100 862
% C 101 862
more C 102 862
rapid C 103 862
than C 104 862
in C 105 862
control C 106 862
and C 107 862
acute C 108 862
hypercalcemic C 109 862
dogs C 110 862
. C 111 862
bone C 113 862
exchange C 114 862
of C 115 862
ca C 116 862
was C 117 862
not C 118 862
significantly C 119 862
increased C 120 862
. C 121 862
cell C 123 862
mg C 124 862
concentrations C 125 862
were C 126 862
not C 127 862
appreciably C 128 862
altered C 129 862
by C 130 862
hyperparathyroidism C 131 862
except C 132 862
for C 133 862
a C 134 862
significant C 135 862
9 C 136 862
% C 137 862
decrease C 138 862
in C 139 862
myocardium C 140 862
, C 141 862
but C 142 862
the C 143 862
fractional C 144 862
rate C 145 862
of C 146 862
exchange C 147 862
of C 148 862
tissue C 149 862
mg C 150 862
was C 151 862
increased C 152 862
. C 153 862
acidsoluble C 155 862
p C 156 862
concentrations C 157 862
were C 158 862
decreased C 159 862
in C 160 862
3 C 161 862
tissues C 162 862
and C 163 862
na C 164 862
and C 165 862
c C 166 862
1 C 167 862
concentrations C 168 862
were C 169 862
decreased C 170 862
by C 171 862
10 C 172 862
to C 173 862
25 C 174 862
% C 175 862
in C 176 862
4 C 177 862
tissues C 178 862
. C 179 862
in C 181 862
hypoparathyroidism C 182 862
, C 183 862
in C 184 862
addition C 185 862
to C 186 862
a C 187 862
decreased C 188 862
plasma C 189 862
ca C 190 862
, C 191 862
the C 192 862
increment C 193 862
in C 194 862
plasma C 195 862
inorganic C 196 862
p C 197 862
that C 198 862
usually C 199 862
occurs C 200 862
after C 201 862
renal C 202 862
pedicle C 203 862
ligation C 204 862
was C 205 862
75 C 206 862
% C 207 862
less C 208 862
than C 209 862
in C 210 862
control C 211 862
dogs C 212 862
. C 213 862
cell C 215 862
ca C 216 862
concentrations C 217 862
were C 218 862
decreased C 219 862
by C 220 862
10 C 221 862
- C 222 862
40 C 223 862
% C 224 862
but C 225 862
the C 226 862
fractional C 227 862
rate C 228 862
of C 229 862
exchange C 230 862
of C 231 862
tissue C 232 862
ca C 233 862
was C 234 862
unaltered C 235 862
. C 236 862
although C 238 862
cell C 239 862
mg C 240 862
concentrations C 241 862
were C 242 862
unaltered C 243 862
a C 244 862
40 C 245 862
% C 246 862
increase C 247 862
occurred C 248 862
in C 249 862
the C 250 862
exchangeability C 251 862
of C 252 862
skeletal C 253 862
muscle C 254 862
mg C 255 862
. C 256 862
tissue C 258 862
na C 259 862
and C 260 862
c C 261 862
1 C 262 862
concentrations C 263 862
were C 264 862
decreased C 265 862
by C 266 862
20 C 267 862
% C 268 862
in C 269 862
2 C 270 862
tissues C 271 862
. C 272 862
it C 274 862
has C 275 862
been C 276 862
previously C 277 862
reported C 278 862
that C 279 862
hypercalcemia C 280 862
increases C 281 862
cell C 282 862
ca C 283 862
concentrations C 284 862
by C 285 862
raising C 286 862
the C 287 862
extracellular C 288 862
ca C 289 862
concentration C 290 862
gradient C 291 862
. C 292 862
evidence C 294 862
has C 295 862
also C 296 862
been C 297 862
presented C 298 862
that C 299 862
hypercalcemia C 300 862
directly C 301 862
inhibits C 302 862
cell C 303 862
influx C 304 862
of C 305 862
mg C 306 862
and C 307 862
na C 308 862
and C 309 862
cell C 310 862
efflux C 311 862
of C 312 862
k C 313 862
. C 314 862
with C 316 862
altered C 317 862
parathyroid C 318 862
activity C 319 862
, C 320 862
2 C 321 862
types C 322 862
of C 323 862
effects C 324 862
are C 325 862
observed C 326 862
: C 327 862
those C 328 862
which C 329 862
are C 330 862
dependent C 331 862
upon C 332 862
an C 333 862
abnormal C 334 862
extracellular C 335 862
ca C 336 862
concentration C 337 862
and C 338 862
those C 339 862
which C 340 862
appear C 341 862
to C 342 862
be C 343 862
due C 344 862
to C 345 862
intrinsic C 346 862
effects C 347 862
of C 348 862
parathormone C 349 862
on C 350 862
cell C 351 862
cation C 352 862
transport C 353 862
. C 354 862
the C 356 862
present C 357 862
data C 358 862
are C 359 862
compatible C 360 862
with C 361 862
the C 362 862
hypotheses C 363 862
that C 364 862
parathormone C 365 862
stimulates C 366 862
bidirectional C 367 862
transport C 368 862
of C 369 862
cell C 370 862
ca C 371 862
and C 372 862
p C 373 862
, C 374 862
stimulates C 375 862
cell C 376 862
influx C 377 862
of C 378 862
mg C 379 862
and C 380 862
opposes C 381 862
the C 382 862
effects C 383 862
of C 384 862
hypercalcemia C 385 862
on C 386 862
cell C 387 862
transport C 388 862
of C 389 862
univalent C 390 862
ions C 391 862
. C 392 862
the C 1 863
inhibition C 2 863
of C 3 863
respiration C 4 863
and C 5 863
phosphorylation C 6 863
in C 7 863
kidney C 8 863
mitochondria C 9 863
by C 10 863
parathyroid C 11 863
hormone C 12 863
administered C 13 863
in C 14 863
vivo C 15 863
. C 16 863
parathyroid C 18 863
hormone C 19 863
administered C 20 863
in C 21 863
vivo C 22 863
to C 23 863
rabbits C 24 863
produced C 25 863
a C 26 863
metabolic C 27 863
alteration C 28 863
in C 29 863
kidney C 30 863
cortex C 31 863
mitochondria C 32 863
, C 33 863
evidenced C 34 863
by C 35 863
diminished C 36 863
respiratory C 37 863
rate C 38 863
, C 39 863
respiratory C 40 863
control C 41 863
, C 42 863
and C 43 863
p C 44 863
: C 45 863
o C 46 863
ratio C 47 863
with C 48 863
a C 49 863
series C 50 863
of C 51 863
substrates C 52 863
including C 53 863
pyruvate C 54 863
plus C 55 863
fumarate C 56 863
, C 57 863
succinate C 58 863
, C 59 863
ketoglutarate C 60 863
, C 61 863
malate C 62 863
, C 63 863
citrate C 64 863
, C 65 863
and C 66 863
isocitrate C 67 863
. C 68 863
the C 70 863
adenosine C 71 863
triphosphate C 72 863
- C 73 863
inorganic C 74 863
phosphate C 75 863
exchange C 76 863
reaction C 77 863
rate C 78 863
was C 79 863
decreased C 80 863
and C 81 863
adenosine C 82 863
triphosphatase C 83 863
activity C 84 863
was C 85 863
increased C 86 863
compared C 87 863
to C 88 863
control C 89 863
mitochondria C 90 863
. C 91 863
these C 93 863
changes C 94 863
did C 95 863
not C 96 863
become C 97 863
apparent C 98 863
until C 99 863
about C 100 863
12 C 101 863
hr C 102 863
. C 103 863
after C 105 863
injection C 106 863
, C 107 863
were C 108 863
undiminished C 109 863
by C 110 863
24 C 111 863
hr C 112 863
. C 113 863
, C 115 863
and C 116 863
could C 117 863
be C 118 863
elicited C 119 863
with C 120 863
as C 121 863
little C 122 863
as C 123 863
200 C 124 863
usp C 125 863
units C 126 863
of C 127 863
hormone C 128 863
. C 129 863
under C 131 863
identical C 132 863
conditions C 133 863
liver C 134 863
mitochondria C 135 863
were C 136 863
unaffected C 137 863
. C 138 863
diphospho C 140 863
- C 141 863
and C 142 863
triphosphopyridine C 143 863
nucleotides C 144 863
in C 145 863
combination C 146 863
frequently C 147 863
elevated C 148 863
the C 149 863
respiration C 150 863
in C 151 863
parathyroid C 152 863
- C 153 863
treated C 154 863
mitochondria C 155 863
close C 156 863
to C 157 863
or C 158 863
above C 159 863
control C 160 863
levels C 161 863
with C 162 863
citrate C 163 863
and C 164 863
isocitrate C 165 863
but C 166 863
not C 167 863
with C 168 863
the C 169 863
remaining C 170 863
substrates C 171 863
and C 172 863
had C 173 863
no C 174 863
effect C 175 863
on C 176 863
respiratory C 177 863
control C 178 863
with C 179 863
any C 180 863
of C 181 863
the C 182 863
substrates C 183 863
. C 184 863
the C 186 863
effects C 187 863
of C 188 863
the C 189 863
hormone C 190 863
could C 191 863
not C 192 863
be C 193 863
duplicated C 194 863
by C 195 863
elevating C 196 863
and C 197 863
maintaining C 198 863
in C 199 863
otherwise C 200 863
normal C 201 863
rabbits C 202 863
serum C 203 863
ca C 204 863
concentrations C 205 863
at C 206 863
twice C 207 863
normal C 208 863
level C 209 863
for C 210 863
6 C 211 863
hr C 212 863
. C 213 863
it C 215 863
is C 216 863
concluded C 217 863
that C 218 863
the C 219 863
effects C 220 863
produced C 221 863
by C 222 863
parathyroid C 223 863
hormone C 224 863
on C 225 863
kidney C 226 863
are C 227 863
multiple C 228 863
in C 229 863
nature C 230 863
and C 231 863
related C 232 863
to C 233 863
the C 234 863
ca C 235 863
+ C 236 863
+ C 237 863
raising C 238 863
potency C 239 863
of C 240 863
the C 241 863
preparations C 242 863
. C 243 863
sudden C 1 864
hypocalcemia C 2 864
in C 3 864
normal C 4 864
and C 5 864
hypoparathyroid C 6 864
subjects C 7 864
. C 8 864
serum C 10 864
calcium C 11 864
concentration C 12 864
was C 13 864
suddenly C 14 864
decreased C 15 864
in C 16 864
10 C 17 864
normal C 18 864
and C 19 864
4 C 20 864
hypoparathyroid C 21 864
subjects C 22 864
by C 23 864
the C 24 864
infusion C 25 864
of C 26 864
50 C 27 864
mg C 28 864
/ C 29 864
kg C 30 864
of C 31 864
disodium C 32 864
edta C 33 864
over C 34 864
a C 35 864
30 C 36 864
- C 37 864
to C 38 864
45 C 39 864
- C 40 864
minute C 41 864
interval C 42 864
. C 43 864
the C 45 864
return C 46 864
rate C 47 864
to C 48 864
pre C 49 864
- C 50 864
infusion C 51 864
values C 52 864
of C 53 864
the C 54 864
serum C 55 864
calcium C 56 864
concentration C 57 864
was C 58 864
the C 59 864
same C 60 864
in C 61 864
both C 62 864
groups C 63 864
. C 64 864
serum C 66 864
phosphate C 67 864
showed C 68 864
a C 69 864
marked C 70 864
, C 71 864
transient C 72 864
decrease C 73 864
30 C 74 864
min C 75 864
after C 76 864
the C 77 864
infusion C 78 864
in C 79 864
normal C 80 864
individuals C 81 864
, C 82 864
but C 83 864
not C 84 864
in C 85 864
those C 86 864
with C 87 864
hypoparathyroidism C 88 864
. C 89 864
the C 91 864
hypophosphatemia C 92 864
was C 93 864
followed C 94 864
by C 95 864
a C 96 864
marked C 97 864
increase C 98 864
in C 99 864
phosphate C 100 864
clearance C 101 864
in C 102 864
the C 103 864
normal C 104 864
group C 105 864
and C 106 864
a C 107 864
decrease C 108 864
in C 109 864
the C 110 864
hypoparathyroid C 111 864
group C 112 864
. C 113 864
urine C 115 864
phosphate C 116 864
: C 117 864
urine C 118 864
creatinine C 119 864
x C 120 864
10 C 121 864
( C 122 864
up C 123 864
: C 124 864
uc C 125 864
x C 126 864
10 C 127 864
) C 128 864
and C 129 864
urine C 130 864
phosphate C 131 864
: C 132 864
urine C 133 864
osmolality C 134 864
x C 135 864
10 C 136 864
( C 137 864
up C 138 864
: C 139 864
uo C 140 864
x C 141 864
10 C 142 864
) C 143 864
ratios C 144 864
also C 145 864
reflected C 146 864
an C 147 864
increased C 148 864
phosphate C 149 864
excretion C 150 864
in C 151 864
the C 152 864
2 C 153 864
groups C 154 864
. C 155 864
a C 157 864
simple C 158 864
clinical C 159 864
measure C 160 864
of C 161 864
parathyroid C 162 864
function C 163 864
is C 164 864
suggested C 165 864
by C 166 864
determining C 167 864
the C 168 864
up C 169 864
: C 170 864
uo C 171 864
x C 172 864
10 C 173 864
or C 174 864
the C 175 864
up C 176 864
: C 177 864
uc C 178 864
x C 179 864
10 C 180 864
, C 181 864
or C 182 864
both C 183 864
, C 184 864
ratios C 185 864
before C 186 864
and C 187 864
3 C 188 864
to C 189 864
6 C 190 864
hr C 191 864
after C 192 864
intravenous C 193 864
infusion C 194 864
of C 195 864
disodium C 196 864
edta C 197 864
. C 198 864
parathyroid C 1 865
function C 2 865
in C 3 865
chronic C 4 865
renal C 5 865
failure C 6 865
. C 7 865
a C 9 865
statistical C 10 865
survey C 11 865
of C 12 865
the C 13 865
plasma C 14 865
biochemistry C 15 865
in C 16 865
azotaemic C 17 865
renal C 18 865
osteodystrophy C 19 865
. C 20 865
a C 22 865
collection C 23 865
has C 24 865
been C 25 865
made C 26 865
of C 27 865
134 C 28 865
personal C 29 865
and C 30 865
published C 31 865
cases C 32 865
of C 33 865
azotemic C 34 865
osteodystrophy C 35 865
in C 36 865
which C 37 865
adequate C 38 865
information C 39 865
was C 40 865
available C 41 865
concerning C 42 865
the C 43 865
pathological C 44 865
state C 45 865
of C 46 865
the C 47 865
bones C 48 865
. C 49 865
measurements C 51 865
were C 52 865
available C 53 865
of C 54 865
the C 55 865
plasma C 56 865
calcium C 57 865
, C 58 865
plasma C 59 865
phosphate C 60 865
, C 61 865
and C 62 865
blood C 63 865
- C 64 865
urea C 65 865
- C 66 865
nitrogen C 67 865
in C 68 865
all C 69 865
cases C 70 865
, C 71 865
and C 72 865
of C 73 865
plasma C 74 865
bicarbonate C 75 865
and C 76 865
plasma C 77 865
proteins C 78 865
in C 79 865
a C 80 865
representative C 81 865
sample C 82 865
. C 83 865
the C 85 865
plasma C 86 865
levels C 87 865
of C 88 865
calcium C 89 865
and C 90 865
phosphate C 91 865
in C 92 865
the C 93 865
whole C 94 865
series C 95 865
of C 96 865
134 C 97 865
cases C 98 865
were C 99 865
not C 100 865
related C 101 865
reciprocally C 102 865
but C 103 865
were C 104 865
correlated C 105 865
directly C 106 865
. C 107 865
these C 109 865
data C 110 865
were C 111 865
further C 112 865
analyzed C 113 865
by C 114 865
allocating C 115 865
each C 116 865
case C 117 865
to C 118 865
either C 119 865
of C 120 865
2 C 121 865
sub C 122 865
- C 123 865
groups C 124 865
, C 125 865
according C 126 865
to C 127 865
the C 128 865
type C 129 865
of C 130 865
pathological C 131 865
lesions C 132 865
present C 133 865
in C 134 865
the C 135 865
bones C 136 865
. C 137 865
in C 139 865
one C 140 865
group C 141 865
there C 142 865
was C 143 865
evidence C 144 865
of C 145 865
defective C 146 865
mineralization C 147 865
of C 148 865
skeletal C 149 865
tissues C 150 865
, C 151 865
in C 152 865
the C 153 865
form C 154 865
of C 155 865
either C 156 865
rickets C 157 865
or C 158 865
osteomalacia C 159 865
, C 160 865
and C 161 865
the C 162 865
plasma C 163 865
- C 164 865
calcium C 165 865
was C 166 865
found C 167 865
to C 168 865
be C 169 865
statistically C 170 865
sub C 171 865
- C 172 865
normal C 173 865
. C 174 865
in C 176 865
the C 177 865
other C 178 865
group C 179 865
there C 180 865
was C 181 865
no C 182 865
primary C 183 865
defect C 184 865
of C 185 865
mineralization C 186 865
but C 187 865
the C 188 865
lesions C 189 865
of C 190 865
generalized C 191 865
osteitis C 192 865
fibrosa C 193 865
were C 194 865
present C 195 865
and C 196 865
the C 197 865
plasma C 198 865
calcium C 199 865
was C 200 865
statistically C 201 865
normal C 202 865
. C 203 865
there C 205 865
was C 206 865
no C 207 865
significant C 208 865
correlation C 209 865
between C 210 865
the C 211 865
plasma C 212 865
levels C 213 865
of C 214 865
calcium C 215 865
and C 216 865
phosphate C 217 865
in C 218 865
either C 219 865
sub C 220 865
- C 221 865
group C 222 865
; C 223 865
and C 224 865
the C 225 865
plasma C 226 865
phosphate C 227 865
was C 228 865
significantly C 229 865
higher C 230 865
in C 231 865
the C 232 865
group C 233 865
with C 234 865
the C 235 865
higher C 236 865
plasma C 237 865
calcium C 238 865
levels C 239 865
. C 240 865
the C 242 865
data C 243 865
indicate C 244 865
that C 245 865
in C 246 865
patients C 247 865
with C 248 865
renal C 249 865
osteodystrophy C 250 865
, C 251 865
contrary C 252 865
to C 253 865
general C 254 865
belief C 255 865
, C 256 865
the C 257 865
plasma C 258 865
calcium C 259 865
varies C 260 865
independently C 261 865
of C 262 865
the C 263 865
plasma C 264 865
phosphate C 265 865
. C 266 865
since C 268 865
these C 269 865
results C 270 865
imply C 271 865
differences C 272 865
in C 273 865
parathyroid C 274 865
function C 275 865
among C 276 865
patients C 277 865
with C 278 865
azotemic C 279 865
osteodystrophy C 280 865
, C 281 865
a C 282 865
survey C 283 865
has C 284 865
also C 285 865
been C 286 865
made C 287 865
of C 288 865
the C 289 865
recorded C 290 865
parathyroid C 291 865
weights C 292 865
in C 293 865
chronic C 294 865
renal C 295 865
failure C 296 865
. C 297 865
generalized C 299 865
osteitis C 300 865
fibrosa C 301 865
and C 302 865
the C 303 865
accompanying C 304 865
normal C 305 865
levels C 306 865
of C 307 865
plasma C 308 865
calcium C 309 865
are C 310 865
associated C 311 865
with C 312 865
greater C 313 865
parathyroid C 314 865
hypertrophy C 315 865
than C 316 865
is C 317 865
found C 318 865
in C 319 865
most C 320 865
cases C 321 865
of C 322 865
chronic C 323 865
renal C 324 865
failure C 325 865
or C 326 865
cases C 327 865
with C 328 865
defective C 329 865
mineralization C 330 865
. C 331 865
the C 333 865
various C 334 865
data C 335 865
are C 336 865
interpreted C 337 865
in C 338 865
relation C 339 865
to C 340 865
the C 341 865
known C 342 865
metabolic C 343 865
disturbances C 344 865
and C 345 865
natural C 346 865
history C 347 865
of C 348 865
azotemic C 349 865
osteodystrophy C 350 865
. C 351 865
by C 353 865
analogy C 354 865
with C 355 865
states C 356 865
of C 357 865
simple C 358 865
vitamin C 359 865
d C 360 865
deficiency C 361 865
, C 362 865
it C 363 865
is C 364 865
suggested C 365 865
that C 366 865
hypocalcemia C 367 865
and C 368 865
relative C 369 865
unresponsiveness C 370 865
to C 371 865
the C 372 865
calcemic C 373 865
action C 374 865
of C 375 865
parathyroid C 376 865
hormone C 377 865
are C 378 865
related C 379 865
to C 380 865
an C 381 865
acquired C 382 865
resistance C 383 865
to C 384 865
vitamin C 385 865
d C 386 865
. C 387 865
the C 389 865
group C 390 865
of C 391 865
cases C 392 865
with C 393 865
statistically C 394 865
normal C 395 865
plasma C 396 865
- C 397 865
calcium C 398 865
prove C 399 865
that C 400 865
the C 401 865
parathyroid C 402 865
glands C 403 865
can C 404 865
function C 405 865
effectively C 406 865
in C 407 865
some C 408 865
patients C 409 865
with C 410 865
chronic C 411 865
renal C 412 865
failure C 413 865
, C 414 865
irrespective C 415 865
of C 416 865
the C 417 865
level C 418 865
of C 419 865
the C 420 865
plasma C 421 865
phosphate C 422 865
. C 423 865
the C 425 865
size C 426 865
of C 427 865
the C 428 865
glands C 429 865
and C 430 865
the C 431 865
effects C 432 865
of C 433 865
sub C 434 865
- C 435 865
total C 436 865
parathyroidectomy C 437 865
in C 438 865
patients C 439 865
of C 440 865
this C 441 865
group C 442 865
suggest C 443 865
that C 444 865
the C 445 865
normal C 446 865
plasma C 447 865
calcium C 448 865
results C 449 865
from C 450 865
an C 451 865
increased C 452 865
production C 453 865
of C 454 865
parathyroid C 455 865
hormone C 456 865
. C 457 865
the C 459 865
more C 460 865
advanced C 461 865
renal C 462 865
failure C 463 865
in C 464 865
the C 465 865
normocalcemic C 466 865
, C 467 865
as C 468 865
compared C 469 865
with C 470 865
the C 471 865
hypocalcemic C 472 865
, C 473 865
cases C 474 865
could C 475 865
mean C 476 865
that C 477 865
the C 478 865
development C 479 865
of C 480 865
an C 481 865
effective C 482 865
degree C 483 865
of C 484 865
secondary C 485 865
hyperparathyroidism C 486 865
is C 487 865
a C 488 865
function C 489 865
of C 490 865
the C 491 865
duration C 492 865
of C 493 865
the C 494 865
renal C 495 865
disease C 496 865
. C 497 865
it C 499 865
seems C 500 865
likely C 501 865
that C 502 865
when C 503 865
the C 504 865
parathyroid C 505 865
response C 506 865
is C 507 865
sufficient C 508 865
to C 509 865
overcome C 510 865
the C 511 865
effects C 512 865
of C 513 865
the C 514 865
vitamin C 515 865
d C 516 865
resistance C 517 865
it C 518 865
also C 519 865
entails C 520 865
the C 521 865
development C 522 865
of C 523 865
generalized C 524 865
osteitis C 525 865
fibrosa C 526 865
, C 527 865
healing C 528 865
of C 529 865
the C 530 865
defect C 531 865
of C 532 865
mineralization C 533 865
and C 534 865
increased C 535 865
liability C 536 865
to C 537 865
metastatic C 538 865
calcification C 539 865
. C 540 865
albright C 1 866
' C 2 866
s C 3 866
hereditary C 4 866
osteodystrophy C 5 866
. C 6 866
report C 8 866
of C 9 866
a C 10 866
family C 11 866
with C 12 866
studies C 13 866
of C 14 866
bone C 15 866
remodeling C 16 866
. C 17 866
two C 19 866
members C 20 866
of C 21 866
a C 22 866
single C 23 866
family C 24 866
, C 25 866
each C 26 866
representing C 27 866
different C 28 866
forms C 29 866
of C 30 866
albright C 31 866
' C 32 866
s C 33 866
hereditary C 34 866
osteodystrophy C 35 866
, C 36 866
have C 37 866
been C 38 866
presented C 39 866
. C 40 866
the C 42 866
kindred C 43 866
pattern C 44 866
is C 45 866
similar C 46 866
to C 47 866
those C 48 866
of C 49 866
other C 50 866
reported C 51 866
families C 52 866
and C 53 866
is C 54 866
consistent C 55 866
with C 56 866
a C 57 866
sex C 58 866
- C 59 866
linked C 60 866
or C 61 866
autosomal C 62 866
dominant C 63 866
mode C 64 866
of C 65 866
inheritance C 66 866
. C 67 866
the C 69 866
importance C 70 866
of C 71 866
a C 72 866
course C 73 866
of C 74 866
intramuscular C 75 866
parathyroid C 76 866
extract C 77 866
for C 78 866
proof C 79 866
of C 80 866
parathyroid C 81 866
hormone C 82 866
resistance C 83 866
is C 84 866
emphasized C 85 866
. C 86 866
biopsy C 88 866
specimens C 89 866
of C 90 866
rib C 91 866
, C 92 866
labeled C 93 866
in C 94 866
vivo C 95 866
with C 96 866
tetracycline C 97 866
, C 98 866
were C 99 866
studied C 100 866
microscopically C 101 866
. C 102 866
these C 104 866
new C 105 866
observations C 106 866
indicated C 107 866
cellular C 108 866
defects C 109 866
in C 110 866
bone C 111 866
remodeling C 112 866
shared C 113 866
by C 114 866
the C 115 866
propositus C 116 866
and C 117 866
case C 118 866
2 C 119 866
, C 120 866
which C 121 866
may C 122 866
explain C 123 866
the C 124 866
low C 125 866
rates C 126 866
of C 127 866
bone C 128 866
turnover C 129 866
found C 130 866
in C 131 866
each C 132 866
. C 133 866
immunologic C 135 866
studies C 136 866
established C 137 866
the C 138 866
presence C 139 866
of C 140 866
a C 141 866
substance C 142 866
antigenically C 143 866
similar C 144 866
to C 145 866
parathyroid C 146 866
hormone C 147 866
in C 148 866
the C 149 866
parathyroid C 150 866
tissue C 151 866
of C 152 866
the C 153 866
propositus C 154 866
. C 155 866
the C 157 866
pathogenesis C 158 866
of C 159 866
albright C 160 866
' C 161 866
s C 162 866
hereditary C 163 866
osteodystrophy C 164 866
and C 165 866
atypical C 166 866
forms C 167 866
of C 168 866
parathyroid C 169 866
hormone C 170 866
resistant C 171 866
hypocalcemia C 172 866
is C 173 866
discussed C 174 866
. C 175 866
acute C 1 867
hyperparathyroidism C 2 867
: C 3 867
a C 4 867
surgical C 5 867
emergency C 6 867
. C 7 867
acute C 9 867
hypercalcemic C 10 867
crisis C 11 867
of C 12 867
hyperparathyroidism C 13 867
is C 14 867
a C 15 867
surgical C 16 867
emergency C 17 867
. C 18 867
diagnosis C 20 867
is C 21 867
often C 22 867
difficult C 23 867
because C 24 867
of C 25 867
the C 26 867
polymorphous C 27 867
character C 28 867
of C 29 867
the C 30 867
symptoms C 31 867
. C 32 867
the C 34 867
variable C 35 867
clinical C 36 867
features C 37 867
of C 38 867
the C 39 867
syndrome C 40 867
are C 41 867
described C 42 867
emphasizing C 43 867
the C 44 867
frequent C 45 867
occurrence C 46 867
of C 47 867
gastrointestinal C 48 867
symptoms C 49 867
, C 50 867
especially C 51 867
duodenal C 52 867
ulcer C 53 867
of C 54 867
recurring C 55 867
pancreatitis C 56 867
in C 57 867
the C 58 867
antecedent C 59 867
history C 60 867
as C 61 867
well C 62 867
as C 63 867
the C 64 867
better C 65 867
known C 66 867
occurrence C 67 867
of C 68 867
renal C 69 867
and C 70 867
skeletal C 71 867
manifestations C 72 867
, C 73 867
which C 74 867
precede C 75 867
the C 76 867
crisis C 77 867
in C 78 867
all C 79 867
but C 80 867
a C 81 867
few C 82 867
cases C 83 867
. C 84 867
despite C 86 867
the C 87 867
variability C 88 867
of C 89 867
the C 90 867
clinical C 91 867
manifestations C 92 867
, C 93 867
the C 94 867
total C 95 867
syndrome C 96 867
forms C 97 867
a C 98 867
distinctive C 99 867
pattern C 100 867
which C 101 867
should C 102 867
be C 103 867
recognizable C 104 867
once C 105 867
it C 106 867
is C 107 867
known C 108 867
. C 109 867
previously C 111 867
reported C 112 867
cases C 113 867
have C 114 867
been C 115 867
reviewed C 116 867
and C 117 867
an C 118 867
additional C 119 867
case C 120 867
reported C 121 867
. C 122 867
the C 124 867
differential C 125 867
diagnosis C 126 867
, C 127 867
aids C 128 867
in C 129 867
identification C 130 867
of C 131 867
the C 132 867
tumor C 133 867
and C 134 867
prospects C 135 867
for C 136 867
more C 137 867
effective C 138 867
control C 139 867
of C 140 867
the C 141 867
hypercalcemia C 142 867
are C 143 867
discussed C 144 867
. C 145 867
at C 147 867
the C 148 867
present C 149 867
time C 150 867
, C 151 867
early C 152 867
surgical C 153 867
removal C 154 867
of C 155 867
the C 156 867
tumor C 157 867
is C 158 867
the C 159 867
only C 160 867
effective C 161 867
treatment C 162 867
. C 163 867
actinomycin C 1 868
d C 2 868
inhibition C 3 868
of C 4 868
intestinal C 5 868
transport C 6 868
of C 7 868
calcium C 8 868
and C 9 868
of C 10 868
vitamin C 11 868
d C 12 868
action C 13 868
. C 14 868
actinomycin C 16 868
d C 17 868
injection C 18 868
inhibits C 19 868
the C 20 868
actions C 21 868
of C 22 868
vit C 23 868
d C 24 868
in C 25 868
increasing C 26 868
concentrative C 27 868
transport C 28 868
of C 29 868
ca C 30 868
across C 31 868
the C 32 868
intestinal C 33 868
wall C 34 868
in C 35 868
vitro C 36 868
and C 37 868
in C 38 868
raising C 39 868
serum C 40 868
ca C 41 868
concentrations C 42 868
of C 43 868
fasted C 44 868
vit C 45 868
d C 46 868
- C 47 868
deficient C 48 868
rats C 49 868
. C 50 868
actinomycin C 52 868
d C 53 868
blocks C 54 868
the C 55 868
transport C 56 868
of C 57 868
ca C 58 868
across C 59 868
the C 60 868
mucosal C 61 868
surface C 62 868
of C 63 868
vit C 64 868
d C 65 868
deficient C 66 868
as C 67 868
well C 68 868
as C 69 868
vit C 70 868
d C 71 868
- C 72 868
treated C 73 868
rats C 74 868
so C 75 868
that C 76 868
its C 77 868
action C 78 868
is C 79 868
on C 80 868
the C 81 868
ca C 82 868
transport C 83 868
system C 84 868
, C 85 868
rather C 86 868
than C 87 868
on C 88 868
the C 89 868
stimulatory C 90 868
effect C 91 868
of C 92 868
vit C 93 868
d C 94 868
. C 95 868
this C 97 868
inhibitory C 98 868
effect C 99 868
of C 100 868
actinomycin C 101 868
d C 102 868
on C 103 868
ca C 104 868
transport C 105 868
is C 106 868
present C 107 868
within C 108 868
3 C 109 868
hr C 110 868
of C 111 868
its C 112 868
s C 113 868
. C 114 868
c C 116 868
. C 117 868
injection C 119 868
and C 120 868
is C 121 868
less C 122 868
marked C 123 868
at C 124 868
18 C 125 868
hr C 126 868
which C 127 868
suggests C 128 868
a C 129 868
direct C 130 868
interaction C 131 868
with C 132 868
the C 133 868
ca C 134 868
transport C 135 868
system C 136 868
. C 137 868
under C 139 868
the C 140 868
same C 141 868
conditions C 142 868
actinomycin C 143 868
d C 144 868
does C 145 868
not C 146 868
influence C 147 868
the C 148 868
transport C 149 868
of C 150 868
1 C 151 868
- C 152 868
tyrosine C 153 868
across C 154 868
the C 155 868
intestinal C 156 868
wall C 157 868
in C 158 868
vitro C 159 868
. C 160 868
studies C 1 869
on C 2 869
hydroxyproline C 3 869
excretion C 4 869
and C 5 869
corticosteroid C 6 869
- C 7 869
induced C 8 869
dwarfism C 9 869
: C 10 869
treatment C 11 869
with C 12 869
human C 13 869
growth C 14 869
hormone C 15 869
. C 16 869
two C 18 869
children C 19 869
who C 20 869
had C 21 869
been C 22 869
receiving C 23 869
large C 24 869
doses C 25 869
of C 26 869
corticosteroids C 27 869
for C 28 869
years C 29 869
and C 30 869
were C 31 869
growing C 32 869
at C 33 869
a C 34 869
retarded C 35 869
rate C 36 869
were C 37 869
treated C 38 869
with C 39 869
human C 40 869
growth C 41 869
hormone C 42 869
. C 43 869
growth C 45 869
rate C 46 869
increased C 47 869
2 C 48 869
. C 49 869
. C 50 869
to C 51 869
3 C 52 869
- C 53 869
fold C 54 869
and C 55 869
urinary C 56 869
hydroxyproline C 57 869
excretion C 58 869
which C 59 869
was C 60 869
initially C 61 869
low C 62 869
increased C 63 869
to C 64 869
the C 65 869
normal C 66 869
level C 67 869
. C 68 869
when C 70 869
treatment C 71 869
was C 72 869
stopped C 73 869
, C 74 869
growth C 75 869
rate C 76 869
and C 77 869
hydroxyproline C 78 869
excretion C 79 869
decreased C 80 869
promptly C 81 869
. C 82 869
a C 1 870
comparison C 2 870
of C 3 870
human C 4 870
placental C 5 870
lactogen C 6 870
( C 7 870
hpl C 8 870
) C 9 870
and C 10 870
human C 11 870
growth C 12 870
hormone C 13 870
( C 14 870
hgh C 15 870
) C 16 870
in C 17 870
hypopituitary C 18 870
patients C 19 870
. C 20 870
the C 22 870
conclusions C 23 870
based C 24 870
on C 25 870
the C 26 870
studies C 27 870
reported C 28 870
are C 29 870
that C 30 870
placental C 31 870
lactogen C 32 870
( C 33 870
hpl C 34 870
) C 35 870
at C 36 870
a C 37 870
dose C 38 870
level C 39 870
of C 40 870
200 C 41 870
mg C 42 870
. C 43 870
/ C 45 870
day C 46 870
did C 47 870
not C 48 870
induce C 49 870
a C 50 870
positive C 51 870
nitrogen C 52 870
balance C 53 870
in C 54 870
two C 55 870
hypopituitary C 56 870
subjects C 57 870
. C 58 870
in C 60 870
addition C 61 870
, C 62 870
lactogen C 63 870
does C 64 870
not C 65 870
augment C 66 870
the C 67 870
nitrogen C 68 870
retaining C 69 870
effect C 70 870
of C 71 870
growth C 72 870
hormone C 73 870
when C 74 870
given C 75 870
in C 76 870
a C 77 870
dose C 78 870
of C 79 870
200 C 80 870
mg C 81 870
. C 82 870
/ C 84 870
day C 85 870
. C 86 870
radiation C 1 871
necrosis C 2 871
of C 3 871
the C 4 871
brain C 5 871
in C 6 871
acromegaly C 7 871
. C 8 871
radiation C 10 871
therapy C 11 871
of C 12 871
pituitary C 13 871
tumors C 14 871
can C 15 871
cause C 16 871
necrosis C 17 871
of C 18 871
the C 19 871
brain C 20 871
( C 21 871
4 C 22 871
cases C 23 871
are C 24 871
reported C 25 871
) C 26 871
, C 27 871
particulary C 28 871
if C 29 871
a C 30 871
carefully C 31 871
considered C 32 871
schedule C 33 871
of C 34 871
dosimetry C 35 871
is C 36 871
exceeded C 37 871
. C 38 871
the C 40 871
error C 41 871
can C 42 871
be C 43 871
due C 44 871
to C 45 871
repeated C 46 871
courses C 47 871
of C 48 871
treatment C 49 871
or C 50 871
too C 51 871
rapid C 52 871
administration C 53 871
. C 54 871
the C 56 871
cerebral C 57 871
lesions C 58 871
develop C 59 871
after C 60 871
a C 61 871
latent C 62 871
period C 63 871
of C 64 871
months C 65 871
and C 66 871
are C 67 871
progressive C 68 871
and C 69 871
often C 70 871
fatal C 71 871
. C 72 871
appropriate C 74 871
pituitary C 75 871
surgery C 76 871
is C 77 871
preferable C 78 871
to C 79 871
multiple C 80 871
treatment C 81 871
with C 82 871
radiation C 83 871
. C 84 871
experiences C 1 872
with C 2 872
hgh C 3 872
treatment C 4 872
of C 5 872
twelve C 6 872
hypopituitary C 7 872
dwarfs C 8 872
for C 9 872
periods C 10 872
varying C 11 872
from C 12 872
6 C 13 872
to C 14 872
41 C 15 872
months C 16 872
are C 17 872
reported C 18 872
. C 19 872
all C 21 872
the C 22 872
patients C 23 872
were C 24 872
considered C 25 872
to C 26 872
have C 27 872
hypopituitarism C 28 872
from C 29 872
birth C 30 872
, C 31 872
four C 32 872
of C 33 872
them C 34 872
of C 35 872
the C 36 872
hereditary C 37 872
type C 38 872
, C 39 872
four C 40 872
possibly C 41 872
due C 42 872
to C 43 872
traumatic C 44 872
birth C 45 872
or C 46 872
neonatal C 47 872
asphyxia C 48 872
, C 49 872
and C 50 872
four C 51 872
from C 52 872
an C 53 872
unknown C 54 872
cause C 55 872
. C 56 872
in C 58 872
six C 59 872
patients C 60 872
detailed C 61 872
information C 62 872
concerning C 63 872
growth C 64 872
during C 65 872
the C 66 872
first C 67 872
year C 68 872
of C 69 872
life C 70 872
could C 71 872
be C 72 872
obtained C 73 872
. C 74 872
all C 76 872
of C 77 872
these C 78 872
patients C 79 872
had C 80 872
a C 81 872
degree C 82 872
of C 83 872
growth C 84 872
retardation C 85 872
before C 86 872
one C 87 872
year C 88 872
of C 89 872
age C 90 872
. C 91 872
we C 93 872
consider C 94 872
this C 95 872
to C 96 872
be C 97 872
the C 98 872
rule C 99 872
rather C 100 872
than C 101 872
the C 102 872
exception C 103 872
in C 104 872
pituitary C 105 872
dwarfism C 106 872
. C 107 872
the C 109 872
most C 110 872
important C 111 872
diagnostic C 112 872
evidence C 113 872
was C 114 872
a C 115 872
marked C 116 872
degree C 117 872
of C 118 872
growth C 119 872
retardation C 120 872
accompanied C 121 872
by C 122 872
a C 123 872
pronounced C 124 872
delay C 125 872
in C 126 872
skeletal C 127 872
maturation C 128 872
, C 129 872
and C 130 872
, C 131 872
in C 132 872
most C 133 872
cases C 134 872
, C 135 872
signs C 136 872
of C 137 872
secondary C 138 872
hypothyroidism C 139 872
, C 140 872
increased C 141 872
insulin C 142 872
sensitivity C 143 872
, C 144 872
and C 145 872
a C 146 872
poor C 147 872
response C 148 872
to C 149 872
metopyrone C 150 872
administration C 151 872
. C 152 872
none C 154 872
of C 155 872
the C 156 872
patients C 157 872
who C 158 872
had C 159 872
passed C 160 872
the C 161 872
normal C 162 872
age C 163 872
of C 164 872
puberty C 165 872
had C 166 872
maturated C 167 872
sexually C 168 872
. C 169 872
all C 171 872
twelve C 172 872
patients C 173 872
responded C 174 872
well C 175 872
to C 176 872
hgh C 177 872
therapy C 178 872
. C 179 872
during C 181 872
the C 182 872
first C 183 872
year C 184 872
of C 185 872
treatment C 186 872
the C 187 872
average C 188 872
height C 189 872
increment C 190 872
was C 191 872
10 C 192 872
cm C 193 872
. C 194 872
( C 196 872
' C 197 872
catch C 198 872
- C 199 872
up C 200 872
' C 201 872
growth C 202 872
) C 203 872
. C 204 872
with C 206 872
continued C 207 872
treatment C 208 872
a C 209 872
normal C 210 872
rate C 211 872
of C 212 872
growth C 213 872
, C 214 872
about C 215 872
6 C 216 872
cm C 217 872
. C 218 872
/ C 220 872
year C 221 872
, C 222 872
was C 223 872
obtained C 224 872
. C 225 872
there C 227 872
was C 228 872
no C 229 872
disproportionate C 230 872
acceleration C 231 872
of C 232 872
skeletal C 233 872
maturation C 234 872
in C 235 872
any C 236 872
of C 237 872
the C 238 872
patients C 239 872
. C 240 872
none C 242 872
of C 243 872
them C 244 872
has C 245 872
so C 246 872
far C 247 872
become C 248 872
resistant C 249 872
to C 250 872
hgh C 251 872
administration C 252 872
. C 253 872
the C 255 872
oldest C 256 872
patient C 257 872
has C 258 872
reached C 259 872
normal C 260 872
height C 261 872
. C 262 872
whether C 264 872
this C 265 872
will C 266 872
be C 267 872
possible C 268 872
not C 269 872
only C 270 872
in C 271 872
the C 272 872
moderately C 273 872
severe C 274 872
, C 275 872
but C 276 872
also C 277 872
in C 278 872
the C 279 872
most C 280 872
severe C 281 872
cases C 282 872
of C 283 872
pituitary C 284 872
dwarfism C 285 872
, C 286 872
can C 287 872
not C 288 872
yet C 289 872
be C 290 872
stated C 291 872
. C 292 872
the C 294 872
possibility C 295 872
of C 296 872
using C 297 872
human C 298 872
gonadotrophic C 299 872
hormones C 300 872
in C 301 872
an C 302 872
attempt C 303 872
to C 304 872
produce C 305 872
sexual C 306 872
maturation C 307 872
in C 308 872
these C 309 872
patients C 310 872
is C 311 872
discussed C 312 872
briefly C 313 872
. C 314 872
treatment C 1 873
of C 2 873
retarded C 3 873
growth C 4 873
with C 5 873
human C 6 873
growth C 7 873
hormone C 8 873
. C 9 873
results C 11 873
of C 12 873
treatment C 13 873
with C 14 873
human C 15 873
growth C 16 873
hormone C 17 873
in C 18 873
the C 19 873
following C 20 873
3 C 21 873
cases C 22 873
are C 23 873
discussed C 24 873
: C 25 873
female C 26 873
hypopituitary C 27 873
dwarf C 28 873
of C 29 873
17 C 30 873
yr C 31 873
. C 32 873
, C 34 873
who C 35 873
grew C 36 873
10 C 37 873
cm C 38 873
. C 39 873
in C 41 873
20 C 42 873
mth C 43 873
. C 44 873
; C 46 873
a C 47 873
boy C 48 873
of C 49 873
14 C 50 873
yr C 51 873
. C 52 873
with C 54 873
constitutional C 55 873
retarded C 56 873
growth C 57 873
, C 58 873
in C 59 873
whom C 60 873
the C 61 873
growth C 62 873
rate C 63 873
increased C 64 873
; C 65 873
and C 66 873
in C 67 873
a C 68 873
case C 69 873
of C 70 873
primordial C 71 873
dwarfism C 72 873
in C 73 873
a C 74 873
girl C 75 873
of C 76 873
10 C 77 873
yr C 78 873
. C 79 873
in C 81 873
whom C 82 873
the C 83 873
growth C 84 873
curve C 85 873
was C 86 873
unaffected C 87 873
by C 88 873
the C 89 873
treatment C 90 873
. C 91 873
genetic C 1 874
pituitary C 2 874
dwarfism C 3 874
with C 4 874
high C 5 874
serum C 6 874
concentration C 7 874
of C 8 874
growth C 9 874
hormone C 10 874
new C 11 874
inborn C 12 874
error C 13 874
of C 14 874
metabolism C 15 874
? C 16 874
. C 17 874
a C 19 874
description C 20 874
is C 21 874
given C 22 874
of C 23 874
three C 24 874
siblings C 25 874
with C 26 874
hypoglycemia C 27 874
and C 28 874
other C 29 874
clinical C 30 874
and C 31 874
laboratory C 32 874
signs C 33 874
of C 34 874
growth C 35 874
hormone C 36 874
deficiency C 37 874
but C 38 874
with C 39 874
abnormally C 40 874
high C 41 874
concentrations C 42 874
of C 43 874
immunoreactive C 44 874
serum C 45 874
growth C 46 874
hormone C 47 874
. C 48 874
since C 50 874
exogenous C 51 874
growth C 52 874
hormone C 53 874
was C 54 874
active C 55 874
in C 56 874
these C 57 874
patients C 58 874
, C 59 874
the C 60 874
endogenous C 61 874
secretion C 62 874
of C 63 874
an C 64 874
abnormal C 65 874
growth C 66 874
hormone C 67 874
molecule C 68 874
is C 69 874
postulated C 70 874
. C 71 874
growth C 1 875
- C 2 875
hormone C 3 875
deficiency C 4 875
in C 5 875
man C 6 875
: C 7 875
an C 8 875
isolated C 9 875
, C 10 875
recessively C 11 875
inherited C 12 875
defect C 13 875
. C 14 875
a C 16 875
deficiency C 17 875
of C 18 875
human C 19 875
growth C 20 875
hormone C 21 875
not C 22 875
associated C 23 875
with C 24 875
other C 25 875
pituitary C 26 875
deficiencies C 27 875
was C 28 875
observed C 29 875
in C 30 875
midgets C 31 875
with C 32 875
sexual C 33 875
ateliosis C 34 875
, C 35 875
a C 36 875
form C 37 875
of C 38 875
dwarfism C 39 875
inherited C 40 875
as C 41 875
an C 42 875
autosomal C 43 875
recessive C 44 875
trait C 45 875
. C 46 875
body C 48 875
proportions C 49 875
, C 50 875
sexual C 51 875
development C 52 875
, C 53 875
birth C 54 875
weight C 55 875
, C 56 875
and C 57 875
postpartum C 58 875
lactation C 59 875
are C 60 875
normal C 61 875
in C 62 875
this C 63 875
syndrome C 64 875
. C 65 875
treatment C 1 876
of C 2 876
short C 3 876
stature C 4 876
in C 5 876
children C 6 876
and C 7 876
adolescents C 8 876
with C 9 876
human C 10 876
pituitary C 11 876
growth C 12 876
hormone C 13 876
( C 14 876
raben C 15 876
) C 16 876
. C 17 876
experience C 19 876
with C 20 876
thirty C 21 876
- C 22 876
five C 23 876
cases C 24 876
. C 25 876
human C 27 876
pituitary C 28 876
growth C 29 876
hormone C 30 876
( C 31 876
raben C 32 876
) C 33 876
was C 34 876
evaluated C 35 876
by C 36 876
longitudinal C 37 876
study C 38 876
of C 39 876
growth C 40 876
as C 41 876
a C 42 876
therapeutic C 43 876
agent C 44 876
in C 45 876
the C 46 876
treatment C 47 876
of C 48 876
short C 49 876
stature C 50 876
. C 51 876
clinically C 53 876
significant C 54 876
increases C 55 876
in C 56 876
growth C 57 876
rate C 58 876
were C 59 876
achieved C 60 876
in C 61 876
11 C 62 876
of C 63 876
13 C 64 876
hypopituitary C 65 876
patients C 66 876
. C 67 876
no C 69 876
significant C 70 876
improvement C 71 876
in C 72 876
linear C 73 876
growth C 74 876
rate C 75 876
was C 76 876
noted C 77 876
with C 78 876
a C 79 876
dose C 80 876
of C 81 876
2 C 82 876
mg C 83 876
3 C 84 876
times C 85 876
weekly C 86 876
in C 87 876
children C 88 876
whose C 89 876
short C 90 876
stature C 91 876
was C 92 876
due C 93 876
to C 94 876
other C 95 876
conditions C 96 876
. C 97 876
no C 99 876
adverse C 100 876
reactions C 101 876
were C 102 876
noted C 103 876
; C 104 876
thyroidal C 105 876
, C 106 876
adrenal C 107 876
or C 108 876
gonadal C 109 876
activation C 110 876
was C 111 876
not C 112 876
observed C 113 876
. C 114 876
growth C 116 876
was C 117 876
stimulated C 118 876
, C 119 876
probably C 120 876
without C 121 876
an C 122 876
undue C 123 876
increase C 124 876
in C 125 876
bone C 126 876
age C 127 876
, C 128 876
though C 129 876
this C 130 876
point C 131 876
demands C 132 876
continued C 133 876
scrutiny C 134 876
. C 135 876
owing C 137 876
to C 138 876
the C 139 876
limited C 140 876
supply C 141 876
of C 142 876
this C 143 876
material C 144 876
it C 145 876
is C 146 876
recommended C 147 876
that C 148 876
it C 149 876
be C 150 876
used C 151 876
only C 152 876
in C 153 876
cases C 154 876
of C 155 876
documented C 156 876
growth C 157 876
failure C 158 876
, C 159 876
and C 160 876
a C 161 876
protocol C 162 876
for C 163 876
evaluation C 164 876
of C 165 876
therapeutic C 166 876
response C 167 876
is C 168 876
discussed C 169 876
. C 170 876
though C 172 876
not C 173 876
a C 174 876
panacea C 175 876
for C 176 876
treatment C 177 876
of C 178 876
short C 179 876
stature C 180 876
, C 181 876
human C 182 876
growth C 183 876
hormone C 184 876
fulfils C 185 876
a C 186 876
unique C 187 876
and C 188 876
invaluable C 189 876
role C 190 876
in C 191 876
replacement C 192 876
therapy C 193 876
for C 194 876
the C 195 876
hypopituitary C 196 876
dwarf C 197 876
. C 198 876
the C 1 877
development C 2 877
of C 3 877
bilateral C 4 877
adenomatous C 5 877
adrenal C 6 877
hyperplasia C 7 877
in C 8 877
a C 9 877
case C 10 877
of C 11 877
cushing C 12 877
' C 13 877
s C 14 877
syndrome C 15 877
of C 16 877
eighteen C 17 877
years C 18 877
' C 19 877
duration C 20 877
. C 21 877
a C 23 877
case C 24 877
of C 25 877
cushing C 26 877
' C 27 877
s C 28 877
syndrome C 29 877
of C 30 877
18 C 31 877
years C 32 877
' C 33 877
duration C 34 877
is C 35 877
presented C 36 877
. C 37 877
the C 39 877
disease C 40 877
began C 41 877
when C 42 877
the C 43 877
patient C 44 877
was C 45 877
8 C 46 877
years C 47 877
old C 48 877
and C 49 877
was C 50 877
partially C 51 877
controlled C 52 877
by C 53 877
pituitary C 54 877
radiation C 55 877
when C 56 877
she C 57 877
was C 58 877
13 C 59 877
. C 60 877
however C 62 877
, C 63 877
clinical C 64 877
evidence C 65 877
indicate C 66 877
low C 67 877
grade C 68 877
but C 69 877
continuous C 70 877
adrenocortical C 71 877
activity C 72 877
for C 73 877
the C 74 877
next C 75 877
13 C 76 877
years C 77 877
. C 78 877
the C 80 877
probable C 81 877
suppression C 82 877
of C 83 877
gh C 84 877
secretion C 85 877
by C 86 877
the C 87 877
increased C 88 877
steroid C 89 877
levels C 90 877
during C 91 877
her C 92 877
growth C 93 877
period C 94 877
provides C 95 877
a C 96 877
reasonable C 97 877
explanation C 98 877
for C 99 877
the C 100 877
dwarfism C 101 877
of C 102 877
the C 103 877
patient C 104 877
. C 105 877
the C 107 877
administration C 108 877
of C 109 877
8 C 110 877
mg C 111 877
of C 112 877
dexamethasone C 113 877
per C 114 877
day C 115 877
failed C 116 877
to C 117 877
decrease C 118 877
urinary C 119 877
steroid C 120 877
excretion C 121 877
. C 122 877
bilateral C 124 877
nodular C 125 877
hyperplasia C 126 877
was C 127 877
found C 128 877
at C 129 877
surgery C 130 877
. C 131 877
it C 133 877
is C 134 877
suggested C 135 877
from C 136 877
the C 137 877
evidence C 138 877
presented C 139 877
that C 140 877
this C 141 877
patient C 142 877
' C 143 877
s C 144 877
disease C 145 877
began C 146 877
first C 147 877
as C 148 877
a C 149 877
primary C 150 877
pituitary C 151 877
process C 152 877
but C 153 877
during C 154 877
the C 155 877
long C 156 877
duration C 157 877
of C 158 877
the C 159 877
acth C 160 877
secretion C 161 877
it C 162 877
evolved C 163 877
into C 164 877
one C 165 877
of C 166 877
autonomously C 167 877
functioning C 168 877
bilateral C 169 877
nodular C 170 877
hyperplasia C 171 877
. C 172 877
hypopituitarism C 1 878
: C 2 878
a C 3 878
study C 4 878
of C 5 878
growth C 6 878
hormone C 7 878
and C 8 878
other C 9 878
endocrine C 10 878
functions C 11 878
. C 12 878
pituitary C 14 878
function C 15 878
was C 16 878
evaluated C 17 878
in C 18 878
25 C 19 878
adults C 20 878
with C 21 878
evidence C 22 878
of C 23 878
hypopituitarism C 24 878
or C 25 878
enlargement C 26 878
of C 27 878
the C 28 878
sella C 29 878
turcica C 30 878
. C 31 878
growth C 33 878
hormone C 34 878
secretory C 35 878
function C 36 878
was C 37 878
measured C 38 878
by C 39 878
radioimmunoassay C 40 878
of C 41 878
plasma C 42 878
samples C 43 878
taken C 44 878
before C 45 878
and C 46 878
after C 47 878
insulin C 48 878
- C 49 878
induced C 50 878
hypoglycemia C 51 878
in C 52 878
a C 53 878
standardized C 54 878
test C 55 878
of C 56 878
growth C 57 878
hormone C 58 878
reserve C 59 878
. C 60 878
all C 62 878
patients C 63 878
exhibited C 64 878
significant C 65 878
defects C 66 878
in C 67 878
growth C 68 878
hormone C 69 878
secretion C 70 878
, C 71 878
as C 72 878
indicated C 73 878
by C 74 878
the C 75 878
failure C 76 878
of C 77 878
this C 78 878
hormone C 79 878
to C 80 878
rise C 81 878
to C 82 878
normal C 83 878
levels C 84 878
in C 85 878
response C 86 878
to C 87 878
hypoglycemia C 88 878
. C 89 878
the C 91 878
order C 92 878
of C 93 878
frequency C 94 878
of C 95 878
hormonal C 96 878
loss C 97 878
was C 98 878
: C 99 878
growth C 100 878
hormone C 101 878
, C 102 878
gonadotropin C 103 878
, C 104 878
adrenocorticotropic C 105 878
hormone C 106 878
, C 107 878
thyroid C 108 878
stimulating C 109 878
hormone C 110 878
. C 111 878
no C 113 878
pattern C 114 878
of C 115 878
deficiency C 116 878
was C 117 878
characteristic C 118 878
for C 119 878
any C 120 878
particular C 121 878
etiology C 122 878
of C 123 878
hypopituitarism C 124 878
. C 125 878
one C 127 878
patient C 128 878
with C 129 878
asymptomatic C 130 878
enlargement C 131 878
of C 132 878
the C 133 878
sella C 134 878
turcica C 135 878
( C 136 878
accidentally C 137 878
discovered C 138 878
) C 139 878
had C 140 878
an C 141 878
isolated C 142 878
loss C 143 878
of C 144 878
growth C 145 878
hormone C 146 878
secretory C 147 878
capacity C 148 878
. C 149 878
two C 151 878
patients C 152 878
in C 153 878
the C 154 878
series C 155 878
demonstrated C 156 878
intrinsic C 157 878
deficiency C 158 878
of C 159 878
thyroid C 160 878
as C 161 878
well C 162 878
as C 163 878
pituitary C 164 878
secretion C 165 878
, C 166 878
and C 167 878
both C 168 878
had C 169 878
elevated C 170 878
liters C 171 878
of C 172 878
antithyroid C 173 878
antibodies C 174 878
. C 175 878
this C 177 878
study C 178 878
represents C 179 878
the C 180 878
first C 181 878
direct C 182 878
evaluation C 183 878
, C 184 878
by C 185 878
radioimmunoassay C 186 878
of C 187 878
growth C 188 878
hormone C 189 878
function C 190 878
in C 191 878
a C 192 878
series C 193 878
of C 194 878
hypopituitary C 195 878
adults C 196 878
. C 197 878
it C 199 878
demonstrates C 200 878
a C 201 878
remarkably C 202 878
high C 203 878
prevalence C 204 878
of C 205 878
growth C 206 878
hormone C 207 878
loss C 208 878
, C 209 878
and C 210 878
suggests C 211 878
that C 212 878
the C 213 878
growth C 214 878
hormone C 215 878
response C 216 878
to C 217 878
hypoglycemia C 218 878
may C 219 878
be C 220 878
one C 221 878
of C 222 878
the C 223 878
most C 224 878
sensitive C 225 878
tests C 226 878
for C 227 878
the C 228 878
diagnosis C 229 878
of C 230 878
hypopituitarism C 231 878
. C 232 878
hypoglycemia C 1 879
and C 2 879
dwarfism C 3 879
associated C 4 879
with C 5 879
the C 6 879
isolated C 7 879
deficiency C 8 879
of C 9 879
growth C 10 879
hormone C 11 879
. C 12 879
the C 14 879
authors C 15 879
have C 16 879
studied C 17 879
a C 18 879
7 C 19 879
- C 20 879
year C 21 879
- C 22 879
old C 23 879
dwarfed C 24 879
boy C 25 879
with C 26 879
a C 27 879
history C 28 879
of C 29 879
severe C 30 879
, C 31 879
recurrent C 32 879
hypoglycemic C 33 879
episodes C 34 879
since C 35 879
age C 36 879
1 C 37 879
and C 38 879
retarded C 39 879
bone C 40 879
age C 41 879
. C 42 879
hepatic C 44 879
, C 45 879
adrenal C 46 879
, C 47 879
and C 48 879
thyroid C 49 879
function C 50 879
were C 51 879
normal C 52 879
. C 53 879
he C 55 879
demonstrated C 56 879
fasting C 57 879
hypoglycemia C 58 879
with C 59 879
blood C 60 879
sugars C 61 879
of C 62 879
30 C 63 879
- C 64 879
40 C 65 879
mg C 66 879
. C 67 879
/ C 69 879
100 C 70 879
ml C 71 879
. C 72 879
he C 74 879
was C 75 879
not C 76 879
sensitive C 77 879
to C 78 879
l C 79 879
- C 80 879
leucine C 81 879
but C 82 879
showed C 83 879
insulin C 84 879
sensitivity C 85 879
and C 86 879
hypoglycemic C 87 879
unresponsiveness C 88 879
. C 89 879
glycogenolysis C 91 879
in C 92 879
response C 93 879
to C 94 879
both C 95 879
adrenaline C 96 879
and C 97 879
glucagon C 98 879
was C 99 879
appropriate C 100 879
. C 101 879
fasting C 103 879
plasma C 104 879
gh C 105 879
levels C 106 879
were C 107 879
less C 108 879
than C 109 879
1 C 110 879
m C 111 879
g C 112 879
. C 113 879
/ C 115 879
ml C 116 879
. C 117 879
( C 119 879
normal C 120 879
1 C 121 879
- C 122 879
3 C 123 879
) C 124 879
, C 125 879
and C 126 879
no C 127 879
rise C 128 879
was C 129 879
seen C 130 879
after C 131 879
insulin C 132 879
- C 133 879
induced C 134 879
hypoglycemia C 135 879
. C 136 879
similarly C 138 879
, C 139 879
these C 140 879
low C 141 879
gh C 142 879
levels C 143 879
did C 144 879
not C 145 879
rise C 146 879
3 C 147 879
- C 148 879
6 C 149 879
hr C 150 879
. C 151 879
after C 153 879
a C 154 879
glucose C 155 879
tolerance C 156 879
test C 157 879
. C 158 879
treatment C 160 879
with C 161 879
hgh C 162 879
reversed C 163 879
the C 164 879
alterations C 165 879
in C 166 879
carbohydrate C 167 879
metabolism C 168 879
. C 169 879
it C 171 879
is C 172 879
concluded C 173 879
that C 174 879
the C 175 879
patient C 176 879
suffered C 177 879
from C 178 879
an C 179 879
isolated C 180 879
gh C 181 879
deficiency C 182 879
which C 183 879
resulted C 184 879
in C 185 879
dwarfism C 186 879
and C 187 879
alterations C 188 879
in C 189 879
carbohydrate C 190 879
metabolism C 191 879
. C 192 879
the C 1 880
effect C 2 880
of C 3 880
growth C 4 880
hormone C 5 880
in C 6 880
hypothalamo C 7 880
- C 8 880
pituitary C 9 880
dwarfism C 10 880
. C 11 880
i C 13 880
. C 14 880
the C 16 880
metabolic C 17 880
effects C 18 880
of C 19 880
human C 20 880
growth C 21 880
hormone C 22 880
. C 23 880
human C 25 880
growth C 26 880
hormone C 27 880
, C 28 880
isolated C 29 880
by C 30 880
raben C 31 880
' C 32 880
s C 33 880
method C 34 880
, C 35 880
was C 36 880
given C 37 880
in C 38 880
2 C 39 880
to C 40 880
5 C 41 880
mg C 42 880
. C 43 880
daily C 45 880
doses C 46 880
over C 47 880
periods C 48 880
from C 49 880
1 C 50 880
to C 51 880
12 C 52 880
days C 53 880
to C 54 880
7 C 55 880
patients C 56 880
with C 57 880
pituitary C 58 880
- C 59 880
hypothalamic C 60 880
dwarfism C 61 880
. C 62 880
the C 64 880
metabolic C 65 880
effects C 66 880
were C 67 880
as C 68 880
follows C 69 880
: C 70 880
nitrogen C 71 880
retention C 72 880
with C 73 880
a C 74 880
variable C 75 880
reduction C 76 880
in C 77 880
blood C 78 880
urea C 79 880
. C 80 880
the C 82 880
plasma C 83 880
amino C 84 880
- C 85 880
acid C 86 880
concentration C 87 880
did C 88 880
not C 89 880
alter C 90 880
after C 91 880
i C 92 880
. C 93 880
. C 94 880
. C 95 880
injection C 97 880
of C 98 880
the C 99 880
hormone C 100 880
during C 101 880
fasting C 102 880
. C 103 880
an C 105 880
accompanying C 106 880
retention C 107 880
of C 108 880
intracellular C 109 880
components C 110 880
, C 111 880
in C 112 880
such C 113 880
proportions C 114 880
required C 115 880
for C 116 880
protoplasm C 117 880
formation C 118 880
. C 119 880
isotonic C 121 880
expansion C 122 880
of C 123 880
the C 124 880
extracellular C 125 880
compartment C 126 880
, C 127 880
without C 128 880
change C 129 880
in C 130 880
the C 131 880
plasma C 132 880
electrolyte C 133 880
concentrations C 134 880
. C 135 880
retention C 137 880
of C 138 880
phosphorus C 139 880
, C 140 880
sometimes C 141 880
a C 142 880
rise C 143 880
in C 144 880
plasma C 145 880
phosphate C 146 880
; C 147 880
increased C 148 880
intestinal C 149 880
calcium C 150 880
absorption C 151 880
, C 152 880
hypercalciuria C 153 880
, C 154 880
no C 155 880
alteration C 156 880
in C 157 880
plasma C 158 880
calcium C 159 880
; C 160 880
an C 161 880
increase C 162 880
in C 163 880
plasma C 164 880
citrate C 165 880
and C 166 880
citrate C 167 880
urinary C 168 880
excretion C 169 880
; C 170 880
the C 171 880
calcium C 172 880
and C 173 880
phosphate C 174 880
retention C 175 880
was C 176 880
reversed C 177 880
on C 178 880
stopping C 179 880
treatment C 180 880
. C 181 880
mobilisation C 183 880
of C 184 880
fat C 185 880
stores C 186 880
with C 187 880
lipid C 188 880
catabolism C 189 880
: C 190 880
this C 191 880
was C 192 880
accompanied C 193 880
by C 194 880
a C 195 880
well C 196 880
marked C 197 880
increase C 198 880
in C 199 880
nefa C 200 880
concentration C 201 880
for C 202 880
some C 203 880
hours C 204 880
after C 205 880
hormone C 206 880
injection C 207 880
in C 208 880
the C 209 880
fasting C 210 880
state C 211 880
, C 212 880
after C 213 880
a C 214 880
period C 215 880
of C 216 880
hypoglycaemia C 217 880
and C 218 880
low C 219 880
nefa C 220 880
levels C 221 880
. C 222 880
a C 224 880
complex C 225 880
, C 226 880
biphasic C 227 880
action C 228 880
on C 229 880
glucose C 230 880
metabolism C 231 880
. C 232 880
fasting C 234 880
blood C 235 880
sugar C 236 880
levels C 237 880
are C 238 880
altered C 239 880
, C 240 880
as C 241 880
are C 242 880
the C 243 880
glycaemia C 244 880
in C 245 880
various C 246 880
tests C 247 880
such C 248 880
as C 249 880
fasting C 250 880
, C 251 880
insulin C 252 880
injections C 253 880
, C 254 880
tolbutamide C 255 880
administration C 256 880
, C 257 880
intestinal C 258 880
hyperglycaemia C 259 880
. C 260 880
acceleration C 262 880
of C 263 880
intermediate C 264 880
metabolism C 265 880
with C 266 880
increased C 267 880
blood C 268 880
citrate C 269 880
concentrations C 270 880
and C 271 880
24 C 272 880
hours C 273 880
urinary C 274 880
excretion C 275 880
of C 276 880
- C 277 880
ketoglutaric C 278 880
acid C 279 880
. C 280 880
in C 282 880
one C 283 880
test C 284 880
during C 285 880
fasting C 286 880
the C 287 880
blood C 288 880
citrate C 289 880
increased C 290 880
4 C 291 880
hours C 292 880
after C 293 880
hormone C 294 880
injection C 295 880
. C 296 880
after C 298 880
an C 299 880
oral C 300 880
load C 301 880
of C 302 880
sugar C 303 880
the C 304 880
blood C 305 880
citrate C 306 880
and C 307 880
- C 308 880
ketoglutaric C 309 880
acid C 310 880
concentrations C 311 880
did C 312 880
not C 313 880
alter C 314 880
. C 315 880
a C 317 880
progressive C 318 880
gain C 319 880
in C 320 880
weight C 321 880
has C 322 880
been C 323 880
found C 324 880
during C 325 880
treatment C 326 880
, C 327 880
partly C 328 880
reversible C 329 880
on C 330 880
stopping C 331 880
treatment C 332 880
, C 333 880
correlating C 334 880
with C 335 880
the C 336 880
intracellular C 337 880
nitrogen C 338 880
retention C 339 880
and C 340 880
expansion C 341 880
of C 342 880
the C 343 880
extracellular C 344 880
space C 345 880
, C 346 880
despite C 347 880
mobilisation C 348 880
of C 349 880
fat C 350 880
reserves C 351 880
. C 352 880
serum C 1 881
chorionic C 2 881
' C 3 881
growth C 4 881
hormone C 5 881
- C 6 881
prolactin C 7 881
' C 8 881
and C 9 881
serum C 10 881
pituitary C 11 881
growth C 12 881
hormone C 13 881
in C 14 881
mother C 15 881
and C 16 881
fetus C 17 881
at C 18 881
term C 19 881
. C 20 881
chorionic C 22 881
' C 23 881
growth C 24 881
hormone C 25 881
- C 26 881
prolactin C 27 881
' C 28 881
( C 29 881
cgp C 30 881
) C 31 881
and C 32 881
pituitary C 33 881
hgh C 34 881
were C 35 881
measured C 36 881
in C 37 881
maternal C 38 881
and C 39 881
fetal C 40 881
blood C 41 881
obtained C 42 881
simultaneously C 43 881
at C 44 881
term C 45 881
from C 46 881
29 C 47 881
pregnant C 48 881
women C 49 881
and C 50 881
their C 51 881
fetuses C 52 881
utilizing C 53 881
sensitive C 54 881
radioimmunoassay C 55 881
procedures C 56 881
. C 57 881
the C 59 881
mean C 60 881
concentration C 61 881
of C 62 881
serum C 63 881
cgp C 64 881
in C 65 881
maternal C 66 881
venous C 67 881
blood C 68 881
was C 69 881
5 C 70 881
. C 71 881
. C 72 881
g C 73 881
/ C 74 881
ml C 75 881
( C 76 881
sem C 77 881
0 C 78 881
. C 79 881
. C 80 881
. C 80 881
) C 81 881
whereas C 82 881
in C 83 881
umbilical C 84 881
venous C 85 881
serum C 86 881
the C 87 881
mean C 88 881
concentration C 89 881
was C 90 881
0 C 91 881
. C 92 881
. C 93 881
. C 93 881
. C 93 881
g C 94 881
/ C 95 881
ml C 96 881
( C 97 881
sem C 98 881
0 C 99 881
. C 100 881
. C 101 881
. C 101 881
. C 101 881
) C 102 881
, C 103 881
a C 104 881
300 C 105 881
- C 106 881
fold C 107 881
difference C 108 881
. C 109 881
contrariwise C 111 881
, C 112 881
the C 113 881
mean C 114 881
concentration C 115 881
of C 116 881
serum C 117 881
hgh C 118 881
in C 119 881
maternal C 120 881
serum C 121 881
was C 122 881
5 C 123 881
. C 124 881
. C 125 881
m C 126 881
g C 127 881
/ C 128 881
ml C 129 881
( C 130 881
sem C 131 881
0 C 132 881
. C 133 881
. C 134 881
. C 134 881
) C 135 881
and C 136 881
in C 137 881
umbilical C 138 881
venous C 139 881
serum C 140 881
the C 141 881
level C 142 881
was C 143 881
33 C 144 881
. C 145 881
. C 146 881
m C 147 881
g C 148 881
/ C 149 881
ml C 150 881
( C 151 881
sem C 152 881
4 C 153 881
. C 154 881
. C 155 881
) C 156 881
. C 157 881
the C 159 881
ratio C 160 881
of C 161 881
serum C 162 881
cgp C 163 881
/ C 164 881
hgh C 165 881
in C 166 881
maternal C 167 881
venous C 168 881
serum C 169 881
was C 170 881
1076 C 171 881
in C 172 881
contrast C 173 881
to C 174 881
0 C 175 881
. C 176 881
. C 177 881
. C 177 881
in C 178 881
umbilical C 179 881
venous C 180 881
serum C 181 881
. C 182 881
the C 184 881
findings C 185 881
strongly C 186 881
suggest C 187 881
that C 188 881
cgp C 189 881
is C 190 881
secreted C 191 881
by C 192 881
the C 193 881
syncytiotrophoblast C 194 881
almost C 195 881
exclusively C 196 881
in C 197 881
a C 198 881
unidirectional C 199 881
manner C 200 881
into C 201 881
the C 202 881
maternal C 203 881
circulation C 204 881
. C 205 881
further C 207 881
, C 208 881
it C 209 881
is C 210 881
unlikely C 211 881
that C 212 881
an C 213 881
appreciable C 214 881
exchange C 215 881
of C 216 881
hgh C 217 881
occurs C 218 881
between C 219 881
the C 220 881
maternal C 221 881
and C 222 881
fetal C 223 881
circulations C 224 881
. C 225 881
the C 227 881
data C 228 881
support C 229 881
the C 230 881
view C 231 881
that C 232 881
the C 233 881
growth C 234 881
hormone C 235 881
- C 236 881
like C 237 881
metabolic C 238 881
changes C 239 881
observed C 240 881
in C 241 881
pregnancy C 242 881
are C 243 881
attributable C 244 881
to C 245 881
the C 246 881
effects C 247 881
of C 248 881
cgp C 249 881
and C 250 881
are C 251 881
consistent C 252 881
with C 253 881
the C 254 881
hypothesis C 255 881
that C 256 881
cgp C 257 881
is C 258 881
an C 259 881
important C 260 881
metabolic C 261 881
hormone C 262 881
of C 263 881
pregnancy C 264 881
exerting C 265 881
its C 266 881
actions C 267 881
on C 268 881
the C 269 881
mother C 270 881
and C 271 881
possibly C 272 881
the C 273 881
placenta C 274 881
, C 275 881
but C 276 881
only C 277 881
indirectly C 278 881
on C 279 881
the C 280 881
fetus C 281 881
. C 282 881
effect C 1 882
of C 2 882
abdominal C 3 882
operation C 4 882
on C 5 882
glucose C 6 882
tolerance C 7 882
and C 8 882
serum C 9 882
levels C 10 882
of C 11 882
insulin C 12 882
, C 13 882
growth C 14 882
hormone C 15 882
, C 16 882
and C 17 882
hydrocortisone C 18 882
. C 19 882
abdominal C 21 882
operations C 22 882
of C 23 882
moderate C 24 882
severity C 25 882
are C 26 882
followed C 27 882
by C 28 882
high C 29 882
fasting C 30 882
blood C 31 882
- C 32 882
glucose C 33 882
levels C 34 882
and C 35 882
a C 36 882
reduced C 37 882
tolerance C 38 882
to C 39 882
intravenous C 40 882
glucose C 41 882
which C 42 882
persists C 43 882
for C 44 882
at C 45 882
least C 46 882
72 C 47 882
hours C 48 882
after C 49 882
operation C 50 882
. C 51 882
fasting C 53 882
plasma C 54 882
- C 55 882
insulin C 56 882
levels C 57 882
are C 58 882
raised C 59 882
after C 60 882
surgery C 61 882
. C 62 882
intravenous C 64 882
glucose C 65 882
produces C 66 882
much C 67 882
higher C 68 882
levels C 69 882
of C 70 882
serum C 71 882
- C 72 882
insulin C 73 882
and C 74 882
growth C 75 882
hormone C 76 882
in C 77 882
the C 78 882
immediate C 79 882
postoperative C 80 882
period C 81 882
. C 82 882
corticotrophin C 84 882
infusion C 85 882
increases C 86 882
the C 87 882
plasma C 88 882
- C 89 882
hydrocortisone C 90 882
levels C 91 882
and C 92 882
reduces C 93 882
glucose C 94 882
assimilation C 95 882
to C 96 882
a C 97 882
greater C 98 882
extent C 99 882
than C 100 882
operation C 101 882
, C 102 882
but C 103 882
has C 104 882
no C 105 882
effect C 106 882
on C 107 882
serum C 108 882
- C 109 882
insulin C 110 882
or C 111 882
growth C 112 882
- C 113 882
hormone C 114 882
levels C 115 882
. C 116 882
plasma C 1 883
growth C 2 883
hormone C 3 883
concentration C 4 883
in C 5 883
the C 6 883
rat C 7 883
determined C 8 883
by C 9 883
radioimmunoassay C 10 883
: C 11 883
influence C 12 883
of C 13 883
sex C 14 883
, C 15 883
pregnancy C 16 883
, C 17 883
lactation C 18 883
, C 19 883
anesthesia C 20 883
, C 21 883
hypophysectomy C 22 883
and C 23 883
extrasellar C 24 883
pituitary C 25 883
transplants C 26 883
. C 27 883
the C 29 883
assay C 30 883
used C 31 883
is C 32 883
described C 33 883
in C 34 883
detail C 35 883
. C 36 883
several C 38 883
experimental C 39 883
conditions C 40 883
were C 41 883
studied C 42 883
, C 43 883
both C 44 883
to C 45 883
validate C 46 883
the C 47 883
method C 48 883
and C 49 883
to C 50 883
determine C 51 883
factors C 52 883
which C 53 883
regulate C 54 883
gh C 55 883
secretion C 56 883
in C 57 883
this C 58 883
species C 59 883
. C 60 883
in C 62 883
fasting C 63 883
sprague C 64 883
- C 65 883
dawley C 66 883
rats C 67 883
weighing C 68 883
150 C 69 883
- C 70 883
200 C 71 883
g C 72 883
, C 73 883
mean C 74 883
plasma C 75 883
gh C 76 883
concentration C 77 883
in C 78 883
females C 79 883
was C 80 883
94 C 81 883
. C 82 883
. C 83 883
17 C 84 883
. C 85 883
. C 86 883
, C 87 883
and C 88 883
in C 89 883
males C 90 883
, C 91 883
54 C 92 883
. C 93 883
. C 94 883
12 C 95 883
. C 96 883
. C 97 883
m C 98 883
g C 99 883
/ C 100 883
ml C 101 883
. C 102 883
gh C 104 883
levels C 105 883
in C 106 883
lactating C 107 883
rats C 108 883
were C 109 883
determined C 110 883
to C 111 883
be C 112 883
in C 113 883
the C 114 883
normal C 115 883
range C 116 883
for C 117 883
females C 118 883
, C 119 883
thereby C 120 883
providing C 121 883
evidence C 122 883
that C 123 883
this C 124 883
assay C 125 883
does C 126 883
not C 127 883
detect C 128 883
prolactin C 129 883
. C 130 883
gh C 132 883
levels C 133 883
were C 134 883
not C 135 883
elevated C 136 883
in C 137 883
pregnant C 138 883
rats C 139 883
. C 140 883
hypophysectomy C 142 883
led C 143 883
to C 144 883
a C 145 883
fall C 146 883
below C 147 883
detectable C 148 883
levels C 149 883
of C 150 883
gh C 151 883
. C 152 883
intraocular C 154 883
pituitary C 155 883
transplants C 156 883
failed C 157 883
to C 158 883
raise C 159 883
gh C 160 883
levels C 161 883
in C 162 883
hypophysectomized C 163 883
hosts C 164 883
. C 165 883
gh C 167 883
levels C 168 883
in C 169 883
male C 170 883
, C 171 883
but C 172 883
not C 173 883
in C 174 883
female C 175 883
, C 176 883
rats C 177 883
are C 178 883
depressed C 179 883
by C 180 883
brief C 181 883
periods C 182 883
of C 183 883
ether C 184 883
anesthesia C 185 883
. C 186 883
these C 188 883
findings C 189 883
and C 190 883
the C 191 883
results C 192 883
of C 193 883
pituitary C 194 883
transplantation C 195 883
experiments C 196 883
are C 197 883
further C 198 883
evidence C 199 883
that C 200 883
the C 201 883
nervous C 202 883
system C 203 883
is C 204 883
involved C 205 883
in C 206 883
the C 207 883
regulation C 208 883
of C 209 883
gh C 210 883
secretion C 211 883
. C 212 883
clinical C 1 884
features C 2 884
of C 3 884
the C 4 884
alalies C 5 884
( C 6 884
russian C 7 884
) C 8 884
. C 9 884
the C 11 884
term C 12 884
' C 13 884
alalies C 14 884
' C 15 884
is C 16 884
applied C 17 884
to C 18 884
the C 19 884
various C 20 884
states C 21 884
of C 22 884
absence C 23 884
or C 24 884
insufficient C 25 884
development C 26 884
of C 27 884
speech C 28 884
in C 29 884
children C 30 884
, C 31 884
resulting C 32 884
from C 33 884
defective C 34 884
development C 35 884
or C 36 884
affections C 37 884
of C 38 884
the C 39 884
speech C 40 884
centers C 41 884
before C 42 884
the C 43 884
development C 44 884
of C 45 884
speech C 46 884
. C 47 884
from C 49 884
the C 50 884
clinical C 51 884
study C 52 884
it C 53 884
is C 54 884
possible C 55 884
to C 56 884
distinguish C 57 884
between C 58 884
several C 59 884
forms C 60 884
: C 61 884
motor C 62 884
, C 63 884
sensory C 64 884
, C 65 884
and C 66 884
semantic C 67 884
alaly C 68 884
with C 69 884
signs C 70 884
of C 71 884
amnesia C 72 884
. C 73 884
the C 75 884
causes C 76 884
are C 77 884
multiple C 78 884
: C 79 884
trauma C 80 884
, C 81 884
perinatal C 82 884
cerebral C 83 884
hemorrhage C 84 884
, C 85 884
inflammatory C 86 884
processes C 87 884
, C 88 884
metabolic C 89 884
disorders C 90 884
before C 91 884
the C 92 884
development C 93 884
of C 94 884
speech C 95 884
, C 96 884
and C 97 884
alimentary C 98 884
and C 99 884
trophic C 100 884
disorders C 101 884
. C 102 884
the C 104 884
alalies C 105 884
show C 106 884
varying C 107 884
degrees C 108 884
of C 109 884
severity C 110 884
. C 111 884
in C 113 884
most C 114 884
children C 115 884
suffering C 116 884
from C 117 884
alaly C 118 884
, C 119 884
neurological C 120 884
signs C 121 884
can C 122 884
be C 123 884
demonstrated C 124 884
on C 125 884
the C 126 884
right C 127 884
side C 128 884
, C 129 884
an C 130 884
indication C 131 884
of C 132 884
the C 133 884
organic C 134 884
nature C 135 884
of C 136 884
the C 137 884
condition C 138 884
. C 139 884
the C 141 884
presence C 142 884
of C 143 884
local C 144 884
symptoms C 145 884
in C 146 884
the C 147 884
various C 148 884
forms C 149 884
of C 150 884
alaly C 151 884
is C 152 884
often C 153 884
associated C 154 884
with C 155 884
signs C 156 884
indicating C 157 884
involvement C 158 884
of C 159 884
adjacent C 160 884
regions C 161 884
of C 162 884
the C 163 884
cerebral C 164 884
hemispheres C 165 884
in C 166 884
the C 167 884
pathological C 168 884
process C 169 884
which C 170 884
would C 171 884
explain C 172 884
why C 173 884
the C 174 884
alalies C 175 884
are C 176 884
often C 177 884
complex C 178 884
. C 179 884
the C 181 884
character C 182 884
of C 183 884
the C 184 884
alalies C 185 884
depends C 186 884
on C 187 884
functional C 188 884
disorders C 189 884
resulting C 190 884
from C 191 884
the C 192 884
lesion C 193 884
in C 194 884
the C 195 884
frontal C 196 884
, C 197 884
anterior C 198 884
, C 199 884
motor C 200 884
, C 201 884
temporal C 202 884
or C 203 884
parietal C 204 884
region C 205 884
of C 206 884
the C 207 884
dominant C 208 884
cerebral C 209 884
hemisphere C 210 884
. C 211 884
patients C 213 884
with C 214 884
alaly C 215 884
often C 216 884
show C 217 884
neurotic C 218 884
reactions C 219 884
, C 220 884
resulting C 221 884
from C 222 884
the C 223 884
disorders C 224 884
of C 225 884
the C 226 884
processes C 227 884
of C 228 884
inhibition C 229 884
and C 230 884
excitation C 231 884
of C 232 884
the C 233 884
cerebral C 234 884
cortex C 235 884
and C 236 884
the C 237 884
subcortical C 238 884
formations C 239 884
. C 240 884
early C 242 884
treatment C 243 884
of C 244 884
the C 245 884
alalies C 246 884
with C 247 884
drugs C 248 884
combined C 249 884
with C 250 884
logopedic C 251 884
and C 252 884
pedagogic C 253 884
measures C 254 884
gives C 255 884
good C 256 884
results C 257 884
. C 258 884
an C 1 885
unusual C 2 885
form C 3 885
of C 4 885
acquired C 5 885
aphasia C 6 885
in C 7 885
children C 8 885
. C 9 885
an C 11 885
unusual C 12 885
form C 13 885
of C 14 885
acquired C 15 885
aphasia C 16 885
- C 17 885
both C 18 885
receptive C 19 885
and C 20 885
executive C 21 885
is C 22 885
described C 23 885
as C 24 885
occurring C 25 885
in C 26 885
10 C 27 885
children C 28 885
, C 29 885
6 C 30 885
girls C 31 885
and C 32 885
4 C 33 885
boys C 34 885
. C 35 885
the C 37 885
onset C 38 885
occurred C 39 885
between C 40 885
5 C 41 885
and C 42 885
6 C 43 885
yr C 44 885
. C 45 885
of C 47 885
age C 48 885
with C 49 885
one C 50 885
or C 51 885
more C 52 885
epileptiform C 53 885
attacks C 54 885
- C 55 885
which C 56 885
were C 57 885
not C 58 885
repeated C 59 885
- C 60 885
but C 61 885
were C 62 885
followed C 63 885
by C 64 885
some C 65 885
degree C 66 885
of C 67 885
hearing C 68 885
loss C 69 885
( C 70 885
later C 71 885
improving C 72 885
) C 73 885
, C 74 885
failure C 75 885
to C 76 885
comprehend C 77 885
spoken C 78 885
language C 79 885
and C 80 885
finally C 81 885
loss C 82 885
or C 83 885
impairment C 84 885
of C 85 885
executive C 86 885
speech C 87 885
. C 88 885
examination C 90 885
of C 91 885
csf C 92 885
and C 93 885
peg C 94 885
yielded C 95 885
normal C 96 885
results C 97 885
. C 98 885
eeg C 100 885
' C 101 885
s C 102 885
were C 103 885
abnormal C 104 885
mainly C 105 885
in C 106 885
the C 107 885
temporal C 108 885
leads C 109 885
. C 110 885
the C 112 885
disorder C 113 885
appeared C 114 885
self C 115 885
- C 116 885
limiting C 117 885
and C 118 885
throughout C 119 885
non C 120 885
- C 121 885
verbal C 122 885
intelligence C 123 885
was C 124 885
not C 125 885
imparied C 126 885
. C 127 885
childhood C 1 886
echolalia C 2 886
in C 3 886
delayed C 4 886
, C 5 886
psychotic C 6 886
and C 7 886
neuropathologic C 8 886
speech C 9 886
patterns C 10 886
. C 11 886
some C 13 886
linguistic C 14 886
analytical C 15 886
procedures C 16 886
and C 17 886
preliminary C 18 886
findings C 19 886
from C 20 886
controlled C 21 886
tape C 22 886
- C 23 886
recorded C 24 886
samples C 25 886
of C 26 886
a C 27 886
group C 28 886
of C 29 886
echolalic C 30 886
children C 31 886
are C 32 886
reported C 33 886
together C 34 886
with C 35 886
the C 36 886
clinical C 37 886
and C 38 886
experimental C 39 886
rationale C 40 886
for C 41 886
the C 42 886
investigation C 43 886
. C 44 886
the C 46 886
subjects C 47 886
are C 48 886
echolalic C 49 886
3 C 50 886
- C 51 886
yr C 52 886
. C 53 886
olds C 55 886
and C 56 886
a C 57 886
group C 58 886
of C 59 886
young C 60 886
clinical C 61 886
referrals C 62 886
representing C 63 886
a C 64 886
variety C 65 886
of C 66 886
pathological C 67 886
conditions C 68 886
. C 69 886
variables C 71 886
selected C 72 886
for C 73 886
study C 74 886
include C 75 886
the C 76 886
proportion C 77 886
of C 78 886
echo C 79 886
to C 80 886
non C 81 886
- C 82 886
echo C 83 886
and C 84 886
silence C 85 886
, C 86 886
the C 87 886
quality C 88 886
and C 89 886
appropriateness C 90 886
of C 91 886
the C 92 886
non C 93 886
- C 94 886
echoed C 95 886
speech C 96 886
, C 97 886
the C 98 886
amount C 99 886
of C 100 886
the C 101 886
stimulus C 102 886
echoed C 103 886
, C 104 886
the C 105 886
nature C 106 886
of C 107 886
the C 108 886
triggering C 109 886
stimulus C 110 886
, C 111 886
the C 112 886
deviation C 113 886
of C 114 886
echo C 115 886
pattern C 116 886
from C 117 886
stimulus C 118 886
pattern C 119 886
, C 120 886
pitch C 121 886
- C 122 886
loudness C 123 886
- C 124 886
time C 125 886
variations C 126 886
, C 127 886
and C 128 886
the C 129 886
child C 130 886
' C 131 886
s C 132 886
chronological C 133 886
and C 134 886
mental C 135 886
ages C 136 886
. C 137 886
early C 139 886
quantitative C 140 886
results C 141 886
yielded C 142 886
very C 143 886
similar C 144 886
echo C 145 886
: C 146 886
non C 147 886
- C 148 886
echo C 149 886
: C 150 886
silence C 151 886
percentages C 152 886
with C 153 886
echolalia C 154 886
representing C 155 886
a C 156 886
mean C 157 886
of C 158 886
about C 159 886
40 C 160 886
% C 161 886
of C 162 886
the C 163 886
conversation C 164 886
of C 165 886
each C 166 886
experimental C 167 886
group C 168 886
. C 169 886
speech C 1 887
as C 2 887
a C 3 887
landmark C 4 887
in C 5 887
development C 6 887
. C 7 887
it C 9 887
is C 10 887
attempted C 11 887
to C 12 887
demonstrate C 13 887
how C 14 887
observations C 15 887
of C 16 887
children C 17 887
' C 18 887
s C 19 887
speech C 20 887
and C 21 887
language C 22 887
development C 23 887
may C 24 887
serve C 25 887
as C 26 887
valuable C 27 887
indicators C 28 887
of C 29 887
their C 30 887
general C 31 887
physical C 32 887
, C 33 887
intellectual C 34 887
, C 35 887
and C 36 887
emotional C 37 887
progress C 38 887
. C 39 887
speech C 41 887
lag C 42 887
or C 43 887
breakdown C 44 887
may C 45 887
corroborate C 46 887
other C 47 887
suspect C 48 887
areas C 49 887
of C 50 887
development C 51 887
or C 52 887
may C 53 887
point C 54 887
the C 55 887
way C 56 887
to C 57 887
them C 58 887
. C 59 887
speech C 61 887
and C 62 887
language C 63 887
disorders C 64 887
seldom C 65 887
originate C 66 887
in C 67 887
the C 68 887
mouth C 69 887
. C 70 887
ideas C 72 887
must C 73 887
precede C 74 887
speech C 75 887
, C 76 887
and C 77 887
speech C 78 887
is C 79 887
a C 80 887
direct C 81 887
correlate C 82 887
of C 83 887
intelligence C 84 887
. C 85 887
the C 1 888
applicability C 2 888
of C 3 888
individualized C 4 888
programed C 5 888
instruction C 6 888
in C 7 888
the C 8 888
education C 9 888
of C 10 888
deaf C 11 888
children C 12 888
. C 13 888
verbal C 15 888
behavior C 16 888
is C 17 888
learned C 18 888
behavior C 19 888
and C 20 888
as C 21 888
such C 22 888
is C 23 888
guided C 24 888
by C 25 888
the C 26 888
same C 27 888
principles C 28 888
as C 29 888
any C 30 888
other C 31 888
learned C 32 888
behavior C 33 888
. C 34 888
the C 36 888
parents C 37 888
' C 38 888
role C 39 888
is C 40 888
mainly C 41 888
to C 42 888
help C 43 888
the C 44 888
young C 45 888
deaf C 46 888
child C 47 888
conceive C 48 888
of C 49 888
language C 50 888
as C 51 888
a C 52 888
socializing C 53 888
process C 54 888
and C 55 888
to C 56 888
help C 57 888
shape C 58 888
language C 59 888
behavior C 60 888
toward C 61 888
the C 62 888
use C 63 888
of C 64 888
verbal C 65 888
symbols C 66 888
. C 67 888
the C 69 888
teacher C 70 888
' C 71 888
s C 72 888
role C 73 888
in C 74 888
the C 75 888
deaf C 76 888
child C 77 888
' C 78 888
s C 79 888
progress C 80 888
as C 81 888
a C 82 888
language C 83 888
user C 84 888
includes C 85 888
( C 86 888
1 C 87 888
) C 88 888
helping C 89 888
the C 90 888
child C 91 888
discover C 92 888
how C 93 888
the C 94 888
structure C 95 888
of C 96 888
his C 97 888
language C 98 888
operates C 99 888
and C 100 888
( C 101 888
2 C 102 888
) C 103 888
guiding C 104 888
him C 105 888
in C 106 888
the C 107 888
process C 108 888
of C 109 888
acquiring C 110 888
clear C 111 888
concepts C 112 888
. C 113 888
the C 115 888
learning C 116 888
of C 117 888
a C 118 888
language C 119 888
is C 120 888
a C 121 888
highly C 122 888
individualized C 123 888
process C 124 888
and C 125 888
requires C 126 888
thousands C 127 888
of C 128 888
hours C 129 888
of C 130 888
practice C 131 888
. C 132 888
efficiency C 134 888
in C 135 888
language C 136 888
teaching C 137 888
to C 138 888
the C 139 888
deaf C 140 888
has C 141 888
not C 142 888
been C 143 888
generally C 144 888
achieved C 145 888
by C 146 888
traditional C 147 888
methods C 148 888
. C 149 888
the C 151 888
teacher C 152 888
of C 153 888
the C 154 888
deaf C 155 888
needs C 156 888
extra C 157 888
help C 158 888
in C 159 888
order C 160 888
to C 161 888
provide C 162 888
the C 163 888
individualistic C 164 888
kind C 165 888
of C 166 888
teaching C 167 888
to C 168 888
insure C 169 888
verbal C 170 888
over C 171 888
- C 172 888
learning C 173 888
by C 174 888
the C 175 888
child C 176 888
. C 177 888
self C 179 888
- C 180 888
tutoring C 181 888
programed C 182 888
materials C 183 888
offer C 184 888
this C 185 888
help C 186 888
. C 187 888
programs C 189 888
are C 190 888
so C 191 888
constructed C 192 888
that C 193 888
a C 194 888
child C 195 888
proceeds C 196 888
through C 197 888
the C 198 888
program C 199 888
step C 200 888
by C 201 888
step C 202 888
with C 203 888
a C 204 888
probability C 205 888
of C 206 888
maximum C 207 888
success C 208 888
because C 209 888
of C 210 888
constant C 211 888
feedback C 212 888
as C 213 888
to C 214 888
correctness C 215 888
of C 216 888
his C 217 888
responses C 218 888
. C 219 888
for C 221 888
younger C 222 888
children C 223 888
the C 224 888
use C 225 888
of C 226 888
a C 227 888
machine C 228 888
seems C 229 888
desirable C 230 888
while C 231 888
for C 232 888
older C 233 888
children C 234 888
the C 235 888
program C 236 888
may C 237 888
appear C 238 888
in C 239 888
book C 240 888
form C 241 888
, C 242 888
on C 243 888
film C 244 888
strip C 245 888
, C 246 888
and C 247 888
any C 248 888
other C 249 888
visual C 250 888
medium C 251 888
. C 252 888
well C 254 888
constructed C 255 888
programs C 256 888
should C 257 888
be C 258 888
correlated C 259 888
with C 260 888
classroom C 261 888
instruction C 262 888
. C 263 888
the C 1 889
impact C 2 889
of C 3 889
individual C 4 889
differences C 5 889
on C 6 889
language C 7 889
learning C 8 889
. C 9 889
a C 11 889
matrix C 12 889
of C 13 889
extrinsic C 14 889
and C 15 889
intrinsic C 16 889
factors C 17 889
affecting C 18 889
language C 19 889
learning C 20 889
in C 21 889
the C 22 889
prelingually C 23 889
deaf C 24 889
child C 25 889
is C 26 889
considered C 27 889
. C 28 889
particular C 30 889
emphasis C 31 889
is C 32 889
placed C 33 889
on C 34 889
the C 35 889
effects C 36 889
of C 37 889
parental C 38 889
attitudes C 39 889
on C 40 889
both C 41 889
the C 42 889
emotional C 43 889
stability C 44 889
of C 45 889
the C 46 889
home C 47 889
and C 48 889
on C 49 889
the C 50 889
provision C 51 889
or C 52 889
restriction C 53 889
of C 54 889
experience C 55 889
. C 56 889
the C 1 890
oral C 2 890
language C 3 890
performance C 4 890
of C 5 890
premature C 6 890
children C 7 890
and C 8 890
controls C 9 890
. C 10 890
fifty C 12 890
- C 13 890
one C 14 890
premature C 15 890
children C 16 890
born C 17 890
in C 18 890
1955 C 19 890
and C 20 890
1956 C 21 890
were C 22 890
compared C 23 890
with C 24 890
55 C 25 890
normally C 26 890
born C 27 890
subjects C 28 890
with C 29 890
birth C 30 890
weights C 31 890
over C 32 890
2 C 33 890
, C 34 890
500 C 35 890
grams C 36 890
. C 37 890
they C 39 890
were C 40 890
tested C 41 890
on C 42 890
tapped C 43 890
patterns C 44 890
, C 45 890
auditory C 46 890
memory C 47 890
span C 48 890
, C 49 890
auditory C 50 890
discrimination C 51 890
, C 52 890
word C 53 890
recognition C 54 890
, C 55 890
language C 56 890
comprehension C 57 890
, C 58 890
articulation C 59 890
, C 60 890
resistance C 61 890
to C 62 890
articulation C 63 890
disintegration C 64 890
, C 65 890
word C 66 890
finding C 67 890
, C 68 890
story C 69 890
telling C 70 890
, C 71 890
number C 72 890
of C 73 890
words C 74 890
used C 75 890
, C 76 890
mean C 77 890
length C 78 890
of C 79 890
5 C 80 890
longest C 81 890
sentences C 82 890
, C 83 890
sentence C 84 890
elaboration C 85 890
, C 86 890
grammatical C 87 890
errors C 88 890
, C 89 890
definitions C 90 890
and C 91 890
categories C 92 890
. C 93 890
the C 95 890
mean C 96 890
age C 97 890
of C 98 890
both C 99 890
groups C 100 890
was C 101 890
5 C 102 890
. C 103 890
. C 104 890
and C 105 890
the C 106 890
premature C 107 890
children C 108 890
' C 109 890
s C 110 890
performance C 111 890
was C 112 890
inferior C 113 890
to C 114 890
that C 115 890
of C 116 890
children C 117 890
born C 118 890
at C 119 890
term C 120 890
. C 121 890
speech C 1 891
and C 2 891
reading C 3 891
problems C 4 891
in C 5 891
childhood C 6 891
. C 7 891
the C 9 891
following C 10 891
communicative C 11 891
disorders C 12 891
have C 13 891
been C 14 891
discussed C 15 891
: C 16 891
functional C 17 891
articulation C 18 891
defects C 19 891
, C 20 891
delayed C 21 891
speech C 22 891
development C 23 891
, C 24 891
stuttering C 25 891
, C 26 891
hearing C 27 891
loss C 28 891
, C 29 891
cleft C 30 891
palate C 31 891
, C 32 891
neurological C 33 891
disorders C 34 891
, C 35 891
and C 36 891
reading C 37 891
disorders C 38 891
. C 39 891
these C 41 891
disorders C 42 891
rarely C 43 891
have C 44 891
a C 45 891
single C 46 891
cause C 47 891
. C 48 891
they C 50 891
are C 51 891
the C 52 891
result C 53 891
of C 54 891
an C 55 891
intermingling C 56 891
of C 57 891
many C 58 891
factors C 59 891
, C 60 891
some C 61 891
physiological C 62 891
and C 63 891
some C 64 891
psychological C 65 891
, C 66 891
some C 67 891
residing C 68 891
within C 69 891
the C 70 891
child C 71 891
and C 72 891
some C 73 891
in C 74 891
the C 75 891
parents C 76 891
and C 77 891
environment C 78 891
in C 79 891
general C 80 891
. C 81 891
delayed C 83 891
or C 84 891
defective C 85 891
speech C 86 891
is C 87 891
a C 88 891
cause C 89 891
for C 90 891
great C 91 891
concern C 92 891
to C 93 891
most C 94 891
parents C 95 891
and C 96 891
teachers C 97 891
. C 98 891
the C 100 891
public C 101 891
health C 102 891
worker C 103 891
who C 104 891
listens C 105 891
with C 106 891
an C 107 891
attentive C 108 891
and C 109 891
sympathetic C 110 891
ear C 111 891
may C 112 891
allay C 113 891
some C 114 891
of C 115 891
this C 116 891
anxiety C 117 891
and C 118 891
thus C 119 891
help C 120 891
foster C 121 891
healthy C 122 891
emotional C 123 891
development C 124 891
in C 125 891
the C 126 891
child C 127 891
. C 128 891
the C 130 891
existence C 131 891
of C 132 891
a C 133 891
more C 134 891
serious C 135 891
condition C 136 891
underlying C 137 891
the C 138 891
presenting C 139 891
communication C 140 891
problem C 141 891
, C 142 891
even C 143 891
if C 144 891
sensed C 145 891
by C 146 891
the C 147 891
parents C 148 891
, C 149 891
is C 150 891
frequently C 151 891
denied C 152 891
. C 153 891
the C 155 891
public C 156 891
health C 157 891
worker C 158 891
can C 159 891
assist C 160 891
the C 161 891
parents C 162 891
in C 163 891
the C 164 891
painful C 165 891
process C 166 891
of C 167 891
facing C 168 891
up C 169 891
to C 170 891
their C 171 891
fears C 172 891
. C 173 891
a C 175 891
child C 176 891
with C 177 891
a C 178 891
communication C 179 891
problem C 180 891
is C 181 891
still C 182 891
a C 183 891
child C 184 891
and C 185 891
the C 186 891
public C 187 891
health C 188 891
worker C 189 891
by C 190 891
simply C 191 891
reflecting C 192 891
this C 193 891
to C 194 891
the C 195 891
parents C 196 891
and C 197 891
advising C 198 891
them C 199 891
on C 200 891
normal C 201 891
child C 202 891
- C 203 891
raising C 204 891
practices C 205 891
can C 206 891
, C 207 891
again C 208 891
, C 209 891
be C 210 891
of C 211 891
help C 212 891
to C 213 891
the C 214 891
child C 215 891
. C 216 891
children C 218 891
with C 219 891
speech C 220 891
deviations C 221 891
are C 222 891
exposed C 223 891
to C 224 891
an C 225 891
overabundance C 226 891
of C 227 891
well C 228 891
- C 229 891
intentioned C 230 891
speech C 231 891
correction C 232 891
at C 233 891
home C 234 891
. C 235 891
most C 237 891
of C 238 891
it C 239 891
is C 240 891
ineffective C 241 891
; C 242 891
some C 243 891
of C 244 891
it C 245 891
, C 246 891
unfortunately C 247 891
is C 248 891
harmful C 249 891
. C 250 891
while C 252 891
the C 253 891
worker C 254 891
may C 255 891
not C 256 891
be C 257 891
in C 258 891
a C 259 891
position C 260 891
to C 261 891
offer C 262 891
specific C 263 891
advice C 264 891
on C 265 891
a C 266 891
particular C 267 891
child C 268 891
, C 269 891
the C 270 891
manner C 271 891
in C 272 891
which C 273 891
the C 274 891
parents C 275 891
and C 276 891
teacher C 277 891
are C 278 891
handling C 279 891
the C 280 891
child C 281 891
' C 282 891
s C 283 891
communication C 284 891
problem C 285 891
can C 286 891
be C 287 891
explored C 288 891
and C 289 891
damaging C 290 891
practices C 291 891
possibly C 292 891
eliminated C 293 891
. C 294 891
the C 296 891
fact C 297 891
that C 298 891
there C 299 891
may C 300 891
be C 301 891
a C 302 891
diagnostic C 303 891
and C 304 891
treatment C 305 891
center C 306 891
to C 307 891
which C 308 891
the C 309 891
child C 310 891
can C 311 891
be C 312 891
referred C 313 891
does C 314 891
not C 315 891
vitiate C 316 891
the C 317 891
public C 318 891
health C 319 891
worker C 320 891
' C 321 891
s C 322 891
role C 323 891
. C 324 891
the C 326 891
public C 327 891
health C 328 891
physician C 329 891
and C 330 891
public C 331 891
health C 332 891
nurse C 333 891
have C 334 891
a C 335 891
valuable C 336 891
contribution C 337 891
to C 338 891
make C 339 891
in C 340 891
helping C 341 891
the C 342 891
parents C 343 891
, C 344 891
school C 345 891
, C 346 891
and C 347 891
child C 348 891
accept C 349 891
the C 350 891
chronic C 351 891
nature C 352 891
of C 353 891
the C 354 891
disorder C 355 891
. C 356 891
disorders C 1 892
of C 2 892
communication C 3 892
in C 4 892
young C 5 892
children C 6 892
. C 7 892
the C 9 892
normal C 10 892
development C 11 892
of C 12 892
spoken C 13 892
language C 14 892
is C 15 892
outlined C 16 892
. C 17 892
the C 19 892
causation C 20 892
, C 21 892
differential C 22 892
diagnosis C 23 892
, C 24 892
individual C 25 892
assessment C 26 892
and C 27 892
management C 28 892
of C 29 892
developmental C 30 892
disorders C 31 892
of C 32 892
communication C 33 892
in C 34 892
young C 35 892
children C 36 892
are C 37 892
briefly C 38 892
discussed C 39 892
. C 40 892
acquired C 1 893
aphasia C 2 893
in C 3 893
children C 4 893
. C 5 893
this C 7 893
report C 8 893
concerns C 9 893
the C 10 893
cases C 11 893
of C 12 893
21 C 13 893
boys C 14 893
and C 15 893
11 C 16 893
girls C 17 893
studied C 18 893
over C 19 893
a C 20 893
period C 21 893
of C 22 893
several C 23 893
years C 24 893
while C 25 893
rehabilitation C 26 893
was C 27 893
carried C 28 893
out C 29 893
. C 30 893
the C 32 893
general C 33 893
conclusions C 34 893
fall C 35 893
under C 36 893
3 C 37 893
headings C 38 893
: C 39 893
( C 40 893
1 C 41 893
) C 42 893
symptomatology C 43 893
as C 44 893
compared C 45 893
with C 46 893
that C 47 893
of C 48 893
aphasia C 49 893
in C 50 893
the C 51 893
adult C 52 893
; C 53 893
( C 54 893
2 C 55 893
) C 56 893
the C 57 893
course C 58 893
of C 59 893
the C 60 893
disorder C 61 893
; C 62 893
( C 63 893
3 C 64 893
) C 65 893
prospects C 66 893
of C 67 893
the C 68 893
level C 69 893
of C 70 893
intellectual C 71 893
performance C 72 893
in C 73 893
the C 74 893
future C 75 893
of C 76 893
the C 77 893
children C 78 893
. C 79 893
in C 81 893
13 C 82 893
cases C 83 893
, C 84 893
cerebral C 85 893
damage C 86 893
had C 87 893
resulted C 88 893
from C 89 893
traumatic C 90 893
contusion C 91 893
; C 92 893
in C 93 893
10 C 94 893
cases C 95 893
from C 96 893
an C 97 893
intracranial C 98 893
nontraumatic C 99 893
hematoma C 100 893
( C 101 893
vascular C 102 893
malformation C 103 893
, C 104 893
aneurysm C 105 893
or C 106 893
angioma C 107 893
) C 108 893
; C 109 893
in C 110 893
2 C 111 893
cases C 112 893
the C 113 893
aphasia C 114 893
followed C 115 893
operation C 116 893
for C 117 893
a C 118 893
cerebral C 119 893
astrocytoma C 120 893
; C 121 893
in C 122 893
2 C 123 893
further C 124 893
cases C 125 893
occlusion C 126 893
of C 127 893
the C 128 893
left C 129 893
middle C 130 893
cerebral C 131 893
artery C 132 893
had C 133 893
occurred C 134 893
; C 135 893
and C 136 893
in C 137 893
the C 138 893
remaining C 139 893
5 C 140 893
cases C 141 893
no C 142 893
precise C 143 893
diagnosis C 144 893
was C 145 893
made C 146 893
. C 147 893
the C 1 894
causes C 2 894
of C 3 894
delayed C 4 894
development C 5 894
of C 6 894
speech C 7 894
. C 8 894
speech C 10 894
develops C 11 894
parallelly C 12 894
and C 13 894
simultaneously C 14 894
with C 15 894
psychophysical C 16 894
development C 17 894
of C 18 894
the C 19 894
child C 20 894
, C 21 894
arising C 22 894
from C 23 894
internal C 24 894
need C 25 894
and C 26 894
under C 27 894
the C 28 894
influence C 29 894
of C 30 894
external C 31 894
factors C 32 894
. C 33 894
not C 35 894
all C 36 894
children C 37 894
are C 38 894
given C 39 894
the C 40 894
chance C 41 894
to C 42 894
develop C 43 894
in C 44 894
favorable C 45 894
conditions C 46 894
and C 47 894
to C 48 894
pass C 49 894
through C 50 894
all C 51 894
the C 52 894
phases C 53 894
of C 54 894
development C 55 894
without C 56 894
some C 57 894
injury C 58 894
. C 59 894
the C 61 894
various C 62 894
possibilities C 63 894
when C 64 894
a C 65 894
child C 66 894
may C 67 894
be C 68 894
injured C 69 894
and C 70 894
hampered C 71 894
in C 72 894
the C 73 894
development C 74 894
of C 75 894
speech C 76 894
are C 77 894
discussed C 78 894
. C 79 894
the C 81 894
testing C 82 894
of C 83 894
the C 84 894
sense C 85 894
of C 86 894
hearing C 87 894
in C 88 894
children C 89 894
with C 90 894
a C 91 894
cleft C 92 894
palate C 93 894
is C 94 894
also C 95 894
included C 96 894
- C 97 894
out C 98 894
of C 99 894
181 C 100 894
cases C 101 894
of C 102 894
cleft C 103 894
palate C 104 894
, C 105 894
in C 106 894
72 C 107 894
cases C 108 894
there C 109 894
was C 110 894
decrease C 111 894
of C 112 894
the C 113 894
sense C 114 894
of C 115 894
hearing C 116 894
exceeding C 117 894
30 C 118 894
db C 119 894
. C 120 894
this C 122 894
additional C 123 894
injury C 124 894
of C 125 894
the C 126 894
child C 127 894
with C 128 894
a C 129 894
cleft C 130 894
palate C 131 894
, C 132 894
if C 133 894
remaining C 134 894
unnoticed C 135 894
, C 136 894
may C 137 894
make C 138 894
the C 139 894
treatment C 140 894
of C 141 894
speech C 142 894
abnormality C 143 894
difficult C 144 894
. C 145 894
the C 147 894
necessity C 148 894
of C 149 894
diagnostic C 150 894
team C 151 894
investigation C 152 894
and C 153 894
the C 154 894
treatment C 155 894
of C 156 894
children C 157 894
with C 158 894
speech C 159 894
disturbances C 160 894
are C 161 894
emphasized C 162 894
. C 163 894
concept C 1 895
learning C 2 895
in C 3 895
culturally C 4 895
disadvantaged C 5 895
children C 6 895
as C 7 895
a C 8 895
function C 9 895
of C 10 895
verbal C 11 895
pretraining C 12 895
. C 13 895
while C 15 895
research C 16 895
indicates C 17 895
that C 18 895
verbal C 19 895
pretraining C 20 895
has C 21 895
a C 22 895
positive C 23 895
influence C 24 895
on C 25 895
the C 26 895
discrimination C 27 895
learning C 28 895
performance C 29 895
of C 30 895
subjects C 31 895
of C 32 895
normal C 33 895
intelligence C 34 895
, C 35 895
a C 36 895
comparable C 37 895
influence C 38 895
has C 39 895
not C 40 895
been C 41 895
shown C 42 895
for C 43 895
other C 44 895
types C 45 895
of C 46 895
conceptual C 47 895
tasks C 48 895
for C 49 895
retarded C 50 895
subjects C 51 895
. C 52 895
the C 54 895
purpose C 55 895
of C 56 895
this C 57 895
experiment C 58 895
was C 59 895
to C 60 895
investigate C 61 895
the C 62 895
effects C 63 895
of C 64 895
stimulus C 65 895
pretraining C 66 895
on C 67 895
concept C 68 895
learning C 69 895
by C 70 895
subjects C 71 895
who C 72 895
had C 73 895
a C 74 895
' C 75 895
high C 76 895
risk C 77 895
' C 78 895
of C 79 895
being C 80 895
classified C 81 895
as C 82 895
mentally C 83 895
retarded C 84 895
at C 85 895
some C 86 895
future C 87 895
time C 88 895
. C 89 895
a C 91 895
group C 92 895
of C 93 895
27 C 94 895
' C 95 895
higher C 96 895
risk C 97 895
' C 98 895
and C 99 895
27 C 100 895
' C 101 895
lower C 102 895
risk C 103 895
' C 104 895
subjects C 105 895
was C 106 895
randomly C 107 895
divided C 108 895
into C 109 895
3 C 110 895
pretraining C 111 895
groups C 112 895
: C 113 895
verbal C 114 895
label C 115 895
, C 116 895
attention C 117 895
, C 118 895
and C 119 895
control C 120 895
. C 121 895
subsequent C 123 895
to C 124 895
pretraining C 125 895
on C 126 895
the C 127 895
stimuli C 128 895
used C 129 895
for C 130 895
transfer C 131 895
task C 132 895
1 C 133 895
, C 134 895
subjects C 135 895
in C 136 895
each C 137 895
group C 138 895
were C 139 895
presented C 140 895
with C 141 895
a C 142 895
concept C 143 895
learning C 144 895
task C 145 895
( C 146 895
transfer C 147 895
task C 148 895
1 C 149 895
) C 150 895
. C 151 895
after C 153 895
reaching C 154 895
the C 155 895
criterion C 156 895
of C 157 895
learning C 158 895
on C 159 895
transfer C 160 895
task C 161 895
1 C 162 895
, C 163 895
subjects C 164 895
were C 165 895
presented C 166 895
with C 167 895
a C 168 895
second C 169 895
, C 170 895
new C 171 895
, C 172 895
concept C 173 895
learning C 174 895
task C 175 895
. C 176 895
analysis C 178 895
of C 179 895
the C 180 895
data C 181 895
revealed C 182 895
that C 183 895
there C 184 895
were C 185 895
no C 186 895
significant C 187 895
performance C 188 895
differences C 189 895
between C 190 895
risk C 191 895
groups C 192 895
and C 193 895
that C 194 895
pretraining C 195 895
had C 196 895
a C 197 895
significantly C 198 895
positive C 199 895
effect C 200 895
on C 201 895
performance C 202 895
. C 203 895
concept C 1 896
development C 2 896
and C 3 896
language C 4 896
instruction C 5 896
. C 6 896
the C 8 896
author C 9 896
describes C 10 896
factors C 11 896
related C 12 896
to C 13 896
, C 14 896
and C 15 896
the C 16 896
errors C 17 896
that C 18 896
may C 19 896
occur C 20 896
in C 21 896
concept C 22 896
development C 23 896
in C 24 896
children C 25 896
. C 26 896
the C 28 896
contributions C 29 896
of C 30 896
language C 31 896
for C 32 896
the C 33 896
deaf C 34 896
child C 35 896
' C 36 896
s C 37 896
conceptual C 38 896
development C 39 896
are C 40 896
stressed C 41 896
. C 42 896
included C 44 896
are C 45 896
a C 46 896
review C 47 896
of C 48 896
what C 49 896
concepts C 50 896
are C 51 896
, C 52 896
psychologically C 53 896
, C 54 896
and C 55 896
an C 56 896
example C 57 896
of C 58 896
how C 59 896
concepts C 60 896
may C 61 896
be C 62 896
presented C 63 896
, C 64 896
educationally C 65 896
, C 66 896
in C 67 896
the C 68 896
classroom C 69 896
. C 70 896
formal C 1 897
speech C 2 897
characteristics C 3 897
as C 4 897
a C 5 897
diagnostic C 6 897
aid C 7 897
in C 8 897
childhood C 9 897
psychosis C 10 897
. C 11 897
the C 13 897
frequency C 14 897
of C 15 897
use C 16 897
of C 17 897
various C 18 897
grammatical C 19 897
units C 20 897
in C 21 897
the C 22 897
spontaneous C 23 897
conversational C 24 897
speech C 25 897
of C 26 897
adults C 27 897
and C 28 897
children C 29 897
has C 30 897
been C 31 897
noted C 32 897
by C 33 897
many C 34 897
authors C 35 897
to C 36 897
be C 37 897
fairly C 38 897
stable C 39 897
. C 40 897
the C 42 897
hypothesis C 43 897
that C 44 897
idiosyncratic C 45 897
distributions C 46 897
might C 47 897
be C 48 897
found C 49 897
in C 50 897
certain C 51 897
specific C 52 897
disorders C 53 897
of C 54 897
ego C 55 897
functioning C 56 897
was C 57 897
tested C 58 897
in C 59 897
relationship C 60 897
to C 61 897
childhood C 62 897
psychosis C 63 897
. C 64 897
some C 66 897
support C 67 897
was C 68 897
found C 69 897
for C 70 897
this C 71 897
, C 72 897
as C 73 897
well C 74 897
as C 75 897
for C 76 897
some C 77 897
contemporary C 78 897
psychological C 79 897
and C 80 897
psychoanalytical C 81 897
interpretations C 82 897
of C 83 897
phenomena C 84 897
seen C 85 897
in C 86 897
childhood C 87 897
psychosis C 88 897
. C 89 897
cerebral C 1 898
dominance C 2 898
and C 3 898
speech C 4 898
acquistion C 5 898
in C 6 898
deaf C 7 898
children C 8 898
. C 9 898
in C 11 898
examining C 12 898
the C 13 898
prediction C 14 898
that C 15 898
left C 16 898
cerebral C 17 898
dominance C 18 898
, C 19 898
as C 20 898
indexed C 21 898
by C 22 898
hand C 23 898
and C 24 898
sighting C 25 898
preference C 26 898
, C 27 898
should C 28 898
be C 29 898
a C 30 898
positive C 31 898
accompaniment C 32 898
of C 33 898
speech C 34 898
learning C 35 898
in C 36 898
individuals C 37 898
whose C 38 898
cerebral C 39 898
speech C 40 898
areas C 41 898
are C 42 898
likely C 43 898
to C 44 898
be C 45 898
in C 46 898
the C 47 898
left C 48 898
hemisphere C 49 898
, C 50 898
it C 51 898
was C 52 898
found C 53 898
that C 54 898
over C 55 898
a C 56 898
10 C 57 898
- C 58 898
12 C 59 898
year C 60 898
period C 61 898
of C 62 898
formal C 63 898
education C 64 898
right C 65 898
- C 66 898
handed C 67 898
- C 68 898
right C 69 898
- C 70 898
sighting C 71 898
deaf C 72 898
students C 73 898
consistently C 74 898
earned C 75 898
higher C 76 898
speech C 77 898
grades C 78 898
than C 79 898
their C 80 898
right C 81 898
- C 82 898
handed C 83 898
- C 84 898
left C 85 898
- C 86 898
sighting C 87 898
and C 88 898
right C 89 898
- C 90 898
handed C 91 898
- C 92 898
mixed C 93 898
- C 94 898
sighting C 95 898
counterparts C 96 898
matched C 97 898
on C 98 898
the C 99 898
basis C 100 898
of C 101 898
hearing C 102 898
loss C 103 898
. C 104 898
this C 106 898
finding C 107 898
supports C 108 898
the C 109 898
hypothesis C 110 898
that C 111 898
the C 112 898
cerebral C 113 898
mechanisms C 114 898
relevant C 115 898
to C 116 898
speech C 117 898
acquisition C 118 898
are C 119 898
simplified C 120 898
, C 121 898
facilitated C 122 898
, C 123 898
and C 124 898
/ C 125 898
or C 126 898
less C 127 898
prone C 128 898
to C 129 898
interference C 130 898
when C 131 898
control C 132 898
of C 133 898
speech C 134 898
, C 135 898
hand C 136 898
, C 137 898
and C 138 898
eye C 139 898
is C 140 898
localized C 141 898
primarily C 142 898
in C 143 898
1 C 144 898
hemisphere C 145 898
of C 146 898
the C 147 898
brain C 148 898
. C 149 898
a C 1 899
color C 2 899
test C 3 899
for C 4 899
the C 5 899
measurement C 6 899
of C 7 899
antibody C 8 899
to C 9 899
the C 10 899
non C 11 899
- C 12 899
acid C 13 899
- C 14 899
forming C 15 899
human C 16 899
mycoplasma C 17 899
species C 18 899
. C 19 899
a C 21 899
metabolic C 22 899
inhibition C 23 899
test C 24 899
for C 25 899
the C 26 899
measurement C 27 899
of C 28 899
growth C 29 899
inhibiting C 30 899
antibodies C 31 899
to C 32 899
the C 33 899
non C 34 899
- C 35 899
acid C 36 899
producing C 37 899
human C 38 899
mycoplasma C 39 899
species C 40 899
is C 41 899
described C 42 899
. C 43 899
the C 45 899
test C 46 899
is C 47 899
based C 48 899
upon C 49 899
the C 50 899
ability C 51 899
of C 52 899
these C 53 899
organisms C 54 899
to C 55 899
metabolize C 56 899
arginine C 57 899
with C 58 899
a C 59 899
resultant C 60 899
alkaline C 61 899
shift C 62 899
in C 63 899
the C 64 899
ph C 65 899
of C 66 899
the C 67 899
medium C 68 899
. C 69 899
the C 71 899
alkaline C 72 899
shift C 73 899
is C 74 899
inhibited C 75 899
by C 76 899
specific C 77 899
antiserum C 78 899
. C 79 899
labile C 81 899
accessory C 82 899
factor C 83 899
( C 84 899
s C 85 899
) C 86 899
present C 87 899
in C 88 899
unheated C 89 899
guinea C 90 899
pig C 91 899
serum C 92 899
potentiates C 93 899
the C 94 899
inhibitory C 95 899
effect C 96 899
of C 97 899
antiserum C 98 899
. C 99 899
the C 101 899
test C 102 899
is C 103 899
sensitive C 104 899
and C 105 899
specific C 106 899
for C 107 899
the C 108 899
measurement C 109 899
of C 110 899
antibody C 111 899
to C 112 899
mycoplasmas C 113 899
in C 114 899
rabbit C 115 899
immune C 116 899
and C 117 899
human C 118 899
convalescent C 119 899
serum C 120 899
. C 121 899
serologic C 1 900
epidemiologic C 2 900
studies C 3 900
with C 4 900
m C 5 900
. C 6 900
pneumoniae C 8 900
. C 9 900
i C 11 900
. C 12 900
demonstration C 14 900
of C 15 900
an C 16 900
hemagglutinin C 17 900
and C 18 900
its C 19 900
inhibition C 20 900
by C 21 900
antibody C 22 900
. C 23 900
a C 25 900
new C 26 900
direct C 27 900
, C 28 900
specific C 29 900
hemagglutination C 30 900
reaction C 31 900
with C 32 900
live C 33 900
m C 34 900
. C 35 900
pneumoniae C 37 900
is C 38 900
described C 39 900
. C 40 900
this C 42 900
requires C 43 900
the C 44 900
presence C 45 900
of C 46 900
a C 47 900
natural C 48 900
antibody C 49 900
for C 50 900
the C 51 900
red C 52 900
cell C 53 900
in C 54 900
the C 55 900
horse C 56 900
serum C 57 900
employed C 58 900
in C 59 900
the C 60 900
diluent C 61 900
. C 62 900
although C 64 900
vervet C 65 900
monkey C 66 900
erythrocytes C 67 900
generally C 68 900
have C 69 900
been C 70 900
employed C 71 900
, C 72 900
human C 73 900
and C 74 900
rabbit C 75 900
cells C 76 900
may C 77 900
be C 78 900
used C 79 900
. C 80 900
hemagglutination C 82 900
can C 83 900
be C 84 900
inhibited C 85 900
by C 86 900
specific C 87 900
antibody C 88 900
but C 89 900
heat C 90 900
inactivation C 91 900
of C 92 900
the C 93 900
sera C 94 900
is C 95 900
required C 96 900
, C 97 900
whether C 98 900
they C 99 900
be C 100 900
human C 101 900
or C 102 900
animal C 103 900
in C 104 900
origin C 105 900
. C 106 900
antibodies C 108 900
persist C 109 900
for C 110 900
many C 111 900
years C 112 900
and C 113 900
are C 114 900
passively C 115 900
transferred C 116 900
to C 117 900
the C 118 900
fetus C 119 900
. C 120 900
a C 122 900
micro C 123 900
variation C 124 900
has C 125 900
been C 126 900
devised C 127 900
. C 128 900
the C 130 900
test C 131 900
is C 132 900
useful C 133 900
for C 134 900
diagnostic C 135 900
and C 136 900
epidemiologic C 137 900
studies C 138 900
and C 139 900
, C 140 900
in C 141 900
reverse C 142 900
, C 143 900
can C 144 900
be C 145 900
utilized C 146 900
for C 147 900
the C 148 900
rapid C 149 900
serologic C 150 900
identification C 151 900
of C 152 900
new C 153 900
isolates C 154 900
. C 155 900
the C 157 900
method C 158 900
is C 159 900
limited C 160 900
, C 161 900
at C 162 900
present C 163 900
, C 164 900
to C 165 900
m C 166 900
. C 167 900
pneumoniae C 169 900
. C 170 900
serologic C 1 901
epidemiologic C 2 901
studies C 3 901
with C 4 901
m C 5 901
. C 6 901
pneumoniae C 8 901
. C 9 901
ii C 11 901
. C 12 901
prevalence C 14 901
of C 15 901
antibodies C 16 901
in C 17 901
several C 18 901
populations C 19 901
. C 20 901
the C 22 901
prevalence C 23 901
of C 24 901
antibodies C 25 901
for C 26 901
m C 27 901
. C 28 901
pneumoniae C 30 901
was C 31 901
determined C 32 901
in C 33 901
6 C 34 901
populations C 35 901
by C 36 901
means C 37 901
of C 38 901
a C 39 901
new C 40 901
serologic C 41 901
test C 42 901
. C 43 901
among C 45 901
members C 46 901
of C 47 901
a C 48 901
population C 49 901
of C 50 901
' C 51 901
normal C 52 901
' C 53 901
families C 54 901
, C 55 901
no C 56 901
one C 57 901
under C 58 901
age C 59 901
15 C 60 901
had C 61 901
antibodies C 62 901
. C 63 901
none C 65 901
of C 66 901
the C 67 901
latter C 68 901
acquired C 69 901
an C 70 901
infection C 71 901
during C 72 901
the C 73 901
following C 74 901
year C 75 901
. C 76 901
of C 78 901
67 C 79 901
children C 80 901
in C 81 901
a C 82 901
home C 83 901
, C 84 901
only C 85 901
3 C 86 901
had C 87 901
antibodies C 88 901
. C 89 901
the C 91 901
7 C 92 901
cottage C 93 901
mates C 94 901
of C 95 901
one C 96 901
of C 97 901
these C 98 901
children C 99 901
who C 100 901
had C 101 901
acquired C 102 901
an C 103 901
infection C 104 901
, C 105 901
remained C 106 901
uninfected C 107 901
. C 108 901
in C 110 901
a C 111 901
group C 112 901
of C 113 901
124 C 114 901
elderly C 115 901
persons C 116 901
, C 117 901
65 C 118 901
( C 119 901
53 C 120 901
% C 121 901
) C 122 901
had C 123 901
antibodies C 124 901
. C 125 901
a C 127 901
similar C 128 901
proportion C 129 901
of C 130 901
76 C 131 901
persons C 132 901
attending C 133 901
a C 134 901
rheumatic C 135 901
fever C 136 901
prophylaxis C 137 901
clinic C 138 901
was C 139 901
positive C 140 901
. C 141 901
in C 143 901
this C 144 901
population C 145 901
it C 146 901
was C 147 901
demonstrated C 148 901
that C 149 901
antibodies C 150 901
could C 151 901
persist C 152 901
in C 153 901
undiminished C 154 901
titer C 155 901
for C 156 901
at C 157 901
least C 158 901
10 C 159 901
yr C 160 901
. C 161 901
of C 163 901
169 C 164 901
point C 165 901
barrow C 166 901
residents C 167 901
, C 168 901
68 C 169 901
% C 170 901
had C 171 901
antibodies C 172 901
. C 173 901
above C 175 901
age C 176 901
15 C 177 901
the C 178 901
rate C 179 901
was C 180 901
approximately C 181 901
90 C 182 901
% C 183 901
. C 184 901
two C 186 901
companies C 187 901
of C 188 901
naval C 189 901
recruits C 190 901
who C 191 901
had C 192 901
similar C 193 901
positive C 194 901
antibody C 195 901
rates C 196 901
at C 197 901
the C 198 901
beginning C 199 901
of C 200 901
training C 201 901
, C 202 901
acquired C 203 901
antibodies C 204 901
in C 205 901
rather C 206 901
divergent C 207 901
patterns C 208 901
, C 209 901
63 C 210 901
% C 211 901
in C 212 901
one C 213 901
and C 214 901
26 C 215 901
% C 216 901
in C 217 901
the C 218 901
other C 219 901
. C 220 901
m C 222 901
. C 223 901
pneumoniae C 225 901
infections C 226 901
seem C 227 901
to C 228 901
be C 229 901
sporadic C 230 901
and C 231 901
to C 232 901
produce C 233 901
epidemics C 234 901
only C 235 901
infrequently C 236 901
in C 237 901
civilian C 238 901
populations C 239 901
. C 240 901
growth C 1 902
and C 2 902
survival C 3 902
of C 4 902
mycoplasma C 5 902
neurolyticum C 6 902
in C 7 902
liquid C 8 902
media C 9 902
. C 10 902
maximal C 12 902
growth C 13 902
of C 14 902
m C 15 902
. C 16 902
neurolyticum C 18 902
( C 19 902
between C 20 902
10 C 21 902
and C 22 902
10 C 23 902
colony C 24 902
- C 25 902
forming C 26 902
units C 27 902
/ C 28 902
ml C 29 902
) C 30 902
was C 31 902
obtained C 32 902
after C 33 902
3 C 34 902
days C 35 902
of C 36 902
incubation C 37 902
at C 38 902
36 C 39 902
c C 40 902
in C 41 902
broth C 42 902
media C 43 902
containing C 44 902
10 C 45 902
% C 46 902
agama C 47 902
horse C 48 902
serum C 49 902
. C 50 902
when C 52 902
whole C 53 902
horse C 54 902
serum C 55 902
was C 56 902
used C 57 902
in C 58 902
the C 59 902
medium C 60 902
, C 61 902
a C 62 902
complement C 63 902
- C 64 902
mediated C 65 902
inhibition C 66 902
was C 67 902
observed C 68 902
. C 69 902
this C 71 902
inhibition C 72 902
could C 73 902
only C 74 902
be C 75 902
detected C 76 902
when C 77 902
growth C 78 902
was C 79 902
followed C 80 902
by C 81 902
daily C 82 902
plate C 83 902
counts C 84 902
. C 85 902
maximal C 87 902
growth C 88 902
was C 89 902
delayed C 90 902
for C 91 902
about C 92 902
24 C 93 902
hr C 94 902
by C 95 902
the C 96 902
horse C 97 902
serum C 98 902
, C 99 902
and C 100 902
the C 101 902
inhibition C 102 902
was C 103 902
spontaneously C 104 902
reversed C 105 902
at C 106 902
the C 107 902
temperature C 108 902
of C 109 902
incubation C 110 902
. C 111 902
penicillin C 113 902
g C 114 902
was C 115 902
also C 116 902
found C 117 902
to C 118 902
have C 119 902
a C 120 902
temporary C 121 902
inhibitory C 122 902
effect C 123 902
. C 124 902
this C 126 902
was C 127 902
detected C 128 902
with C 129 902
as C 130 902
little C 131 902
as C 132 902
40 C 133 902
units C 134 902
/ C 135 902
ml C 136 902
. C 137 902
maximal C 139 902
growth C 140 902
was C 141 902
delayed C 142 902
until C 143 902
the C 144 902
6 C 145 902
th C 146 902
day C 147 902
of C 148 902
incubation C 149 902
, C 150 902
when C 151 902
200 C 152 902
units C 153 902
/ C 154 902
ml C 155 902
was C 156 902
present C 157 902
, C 158 902
and C 159 902
until C 160 902
the C 161 902
16 C 162 902
th C 163 902
day C 164 902
, C 165 902
when C 166 902
1 C 167 902
, C 168 902
000 C 169 902
units C 170 902
/ C 171 902
ml C 172 902
was C 173 902
present C 174 902
. C 175 902
the C 177 902
survival C 178 902
of C 179 902
m C 180 902
. C 181 902
neurolyticum C 183 902
at C 184 902
undetectable C 185 902
levels C 186 902
in C 187 902
cultures C 188 902
during C 189 902
the C 190 902
incubation C 191 902
period C 192 902
presented C 193 902
an C 194 902
' C 195 902
eclipse C 196 902
' C 197 902
phenomenon C 198 902
which C 199 902
has C 200 902
not C 201 902
been C 202 902
explained C 203 902
. C 204 902
the C 206 902
recrudescence C 207 902
of C 208 902
growth C 209 902
in C 210 902
such C 211 902
cultures C 212 902
late C 213 902
in C 214 902
the C 215 902
incubation C 216 902
period C 217 902
illustrates C 218 902
the C 219 902
events C 220 902
which C 221 902
may C 222 902
occur C 223 902
when C 224 902
mycoplasmas C 225 902
are C 226 902
isolated C 227 902
from C 228 902
clinical C 229 902
material C 230 902
by C 231 902
prolonged C 232 902
incubation C 233 902
in C 234 902
the C 235 902
presence C 236 902
of C 237 902
inhibitors C 238 902
survival C 239 902
data C 240 902
showed C 241 902
that C 242 902
m C 243 902
. C 244 902
neurolyticum C 246 902
had C 247 902
greatest C 248 902
stability C 249 902
at C 250 902
ph C 251 902
8 C 252 902
. C 253 902
. C 254 902
, C 255 902
with C 256 902
reduced C 257 902
viability C 258 902
at C 259 902
ph C 260 902
9 C 261 902
. C 262 902
. C 263 902
, C 264 902
7 C 265 902
. C 266 902
. C 267 902
, C 268 902
10 C 269 902
. C 270 902
. C 271 902
, C 272 902
and C 273 902
6 C 274 902
. C 275 902
. C 276 902
, C 277 902
in C 278 902
that C 279 902
order C 280 902
. C 281 902
the C 283 902
data C 284 902
on C 285 902
growth C 286 902
and C 287 902
stability C 288 902
suggest C 289 902
a C 290 902
close C 291 902
relationship C 292 902
between C 293 902
the C 294 902
species C 295 902
of C 296 902
mycoplasma C 297 902
studies C 298 902
and C 299 902
bacteria C 300 902
. C 301 902
hela C 1 903
cells C 2 903
resistant C 3 903
to C 4 903
bromodeoxyuridine C 5 903
and C 6 903
deficient C 7 903
in C 8 903
thymidine C 9 903
kinase C 10 903
activity C 11 903
. C 12 903
mutant C 14 903
sublines C 15 903
of C 16 903
hela C 17 903
s C 18 903
3 C 19 903
cells C 20 903
resistant C 21 903
to C 22 903
growth C 23 903
inhibition C 24 903
by C 25 903
bromodeoxyuridine C 26 903
( C 27 903
budr C 28 903
) C 29 903
have C 30 903
been C 31 903
isolated C 32 903
. C 33 903
the C 35 903
resistant C 36 903
cell C 37 903
lines C 38 903
( C 39 903
hela C 40 903
bu C 41 903
- C 42 903
10 C 43 903
, C 44 903
hela C 45 903
bu C 46 903
- C 47 903
15 C 48 903
, C 49 903
hela C 50 903
bu C 51 903
- C 52 903
25 C 53 903
, C 54 903
hela C 55 903
bu C 56 903
- C 57 903
50 C 58 903
, C 59 903
and C 60 903
hela C 61 903
bu C 62 903
- C 63 903
100 C 64 903
) C 65 903
proliferated C 66 903
in C 67 903
the C 68 903
presence C 69 903
of C 70 903
10 C 71 903
, C 72 903
15 C 73 903
, C 74 903
25 C 75 903
, C 76 903
50 C 77 903
, C 78 903
and C 79 903
100 C 80 903
mg C 81 903
/ C 82 903
ml C 83 903
budr C 84 903
, C 85 903
respectively C 86 903
. C 87 903
extracts C 89 903
from C 90 903
hela C 91 903
bu C 92 903
- C 93 903
25 C 94 903
, C 95 903
hela C 96 903
bu C 97 903
- C 98 903
50 C 99 903
, C 100 903
and C 101 903
hela C 102 903
bu C 103 903
- C 104 903
100 C 105 903
cells C 106 903
exhibited C 107 903
2 C 108 903
- C 109 903
5 C 110 903
% C 111 903
of C 112 903
the C 113 903
thymidine C 114 903
- C 115 903
h C 116 903
, C 117 903
deoxyuridine C 118 903
- C 119 903
h C 120 903
, C 121 903
and C 122 903
bromodeoxyuridine C 123 903
- C 124 903
h C 125 903
phosphorylating C 126 903
activities C 127 903
of C 128 903
parental C 129 903
hela C 130 903
s C 131 903
3 C 132 903
cells C 133 903
. C 134 903
hela C 136 903
bu C 137 903
- C 138 903
10 C 139 903
and C 140 903
hela C 141 903
bu C 142 903
- C 143 903
15 C 144 903
cell C 145 903
extracts C 146 903
were C 147 903
also C 148 903
deficient C 149 903
in C 150 903
thymidine C 151 903
kinase C 152 903
activity C 153 903
, C 154 903
yielding C 155 903
approx C 156 903
. C 157 903
43 C 159 903
% C 160 903
and C 161 903
8 C 162 903
% C 163 903
, C 164 903
respectively C 165 903
, C 166 903
the C 167 903
thymidine C 168 903
kinase C 169 903
activity C 170 903
of C 171 903
parental C 172 903
hela C 173 903
s C 174 903
3 C 175 903
cells C 176 903
. C 177 903
the C 179 903
deficiency C 180 903
in C 181 903
thymidine C 182 903
kinase C 183 903
activity C 184 903
of C 185 903
hela C 186 903
bu C 187 903
- C 188 903
100 C 189 903
cells C 190 903
was C 191 903
not C 192 903
due C 193 903
to C 194 903
negative C 195 903
feedback C 196 903
inhibition C 197 903
by C 198 903
high C 199 903
levels C 200 903
of C 201 903
budr C 202 903
or C 203 903
to C 204 903
interference C 205 903
with C 206 903
the C 207 903
thymidine C 208 903
kinase C 209 903
assay C 210 903
by C 211 903
inhibitors C 212 903
or C 213 903
competing C 214 903
enzymes C 215 903
in C 216 903
the C 217 903
hela C 218 903
bu C 219 903
- C 220 903
100 C 221 903
cell C 222 903
extracts C 223 903
. C 224 903
following C 226 903
5 C 227 903
weekly C 228 903
passages C 229 903
in C 230 903
media C 231 903
lacking C 232 903
budr C 233 903
, C 234 903
the C 235 903
hela C 236 903
bu C 237 903
- C 238 903
100 C 239 903
cells C 240 903
did C 241 903
not C 242 903
exhibit C 243 903
increased C 244 903
thymidine C 245 903
kinase C 246 903
activity C 247 903
. C 248 903
moreover C 250 903
, C 251 903
mixtures C 252 903
of C 253 903
extracts C 254 903
from C 255 903
hela C 256 903
s C 257 903
3 C 258 903
and C 259 903
hela C 260 903
bu C 261 903
- C 262 903
100 C 263 903
cells C 264 903
displayed C 265 903
a C 266 903
thymidine C 267 903
kinase C 268 903
activity C 269 903
equivalent C 270 903
to C 271 903
the C 272 903
sum C 273 903
of C 274 903
the C 275 903
activities C 276 903
or C 277 903
extracts C 278 903
prepared C 279 903
, C 280 903
respectively C 281 903
, C 282 903
from C 283 903
the C 284 903
hela C 285 903
s C 286 903
3 C 287 903
and C 288 903
hela C 289 903
bu C 290 903
- C 291 903
100 C 292 903
cells C 293 903
. C 294 903
radioautographic C 296 903
studies C 297 903
have C 298 903
shown C 299 903
that C 300 903
after C 301 903
hela C 302 903
s C 303 903
3 C 304 903
cells C 305 903
were C 306 903
incubated C 307 903
for C 308 903
6 C 309 903
hr C 310 903
with C 311 903
thymidine C 312 903
- C 313 903
h C 314 903
, C 315 903
35 C 316 903
- C 317 903
45 C 318 903
% C 319 903
of C 320 903
the C 321 903
nuclei C 322 903
were C 323 903
heavily C 324 903
labeled C 325 903
with C 326 903
radioactivity C 327 903
. C 328 903
however C 330 903
, C 331 903
fewer C 332 903
hela C 333 903
bu C 334 903
- C 335 903
100 C 336 903
cells C 337 903
displayed C 338 903
labeled C 339 903
nuclei C 340 903
and C 341 903
the C 342 903
nuclei C 343 903
were C 344 903
only C 345 903
lightly C 346 903
labeled C 347 903
. C 348 903
hela C 350 903
bu C 351 903
- C 352 903
100 C 353 903
cell C 354 903
extracts C 355 903
contained C 356 903
normal C 357 903
amounts C 358 903
of C 359 903
thymidylate C 360 903
synthetase C 361 903
, C 362 903
thymidilate C 363 903
kinase C 364 903
, C 365 903
and C 366 903
uridine C 367 903
kinase C 368 903
activities C 369 903
. C 370 903
following C 372 903
infection C 373 903
by C 374 903
vaccinia C 375 903
virus C 376 903
, C 377 903
high C 378 903
levels C 379 903
of C 380 903
thymidine C 381 903
kinase C 382 903
activity C 383 903
were C 384 903
induced C 385 903
in C 386 903
hela C 387 903
bu C 388 903
- C 389 903
100 C 390 903
cells C 391 903
. C 392 903
a C 1 904
note C 2 904
on C 3 904
the C 4 904
taxonomic C 5 904
status C 6 904
of C 7 904
strains C 8 904
like C 9 904
' C 10 904
campo C 11 904
' C 12 904
, C 13 904
hitherto C 14 904
classified C 15 904
as C 16 904
mycoplasma C 17 904
hominis C 18 904
, C 19 904
type C 20 904
2 C 21 904
. C 22 904
the C 24 904
classification C 25 904
of C 26 904
strains C 27 904
similar C 28 904
to C 29 904
mycoplasma C 30 904
strain C 31 904
pg C 32 904
27 C 33 904
of C 34 904
' C 35 904
campo C 36 904
' C 37 904
as C 38 904
myc C 39 904
. C 40 904
hominis C 42 904
type C 43 904
2 C 44 904
should C 45 904
be C 46 904
withdrawn C 47 904
. C 48 904
these C 50 904
strains C 51 904
have C 52 904
now C 53 904
been C 54 904
identified C 55 904
as C 56 904
myc C 57 904
. C 58 904
arthritidis C 60 904
. C 61 904
chromosome C 1 905
studies C 2 905
of C 3 905
human C 4 905
cells C 5 905
infected C 6 905
in C 7 905
utero C 8 905
and C 9 905
in C 10 905
vitro C 11 905
with C 12 905
rubella C 13 905
virus C 14 905
. C 15 905
a C 17 905
cytologic C 18 905
study C 19 905
of C 20 905
metaphase C 21 905
chromosomes C 22 905
was C 23 905
undertaken C 24 905
to C 25 905
determine C 26 905
if C 27 905
damage C 28 905
to C 29 905
the C 30 905
genetic C 31 905
apparatus C 32 905
of C 33 905
human C 34 905
cells C 35 905
may C 36 905
be C 37 905
induced C 38 905
by C 39 905
rubella C 40 905
virus C 41 905
and C 42 905
whether C 43 905
such C 44 905
damage C 45 905
produces C 46 905
the C 47 905
pathology C 48 905
seen C 49 905
in C 50 905
newborns C 51 905
from C 52 905
mothers C 53 905
infected C 54 905
early C 55 905
in C 56 905
pregnancy C 57 905
. C 58 905
fibroblast C 60 905
cell C 61 905
strains C 62 905
were C 63 905
initiated C 64 905
in C 65 905
vitro C 66 905
from C 67 905
embryonic C 68 905
material C 69 905
obtained C 70 905
by C 71 905
therapeutic C 72 905
abortion C 73 905
of C 74 905
fetuses C 75 905
from C 76 905
rubella C 77 905
- C 78 905
infected C 79 905
mothers C 80 905
. C 81 905
embryonic C 83 905
material C 84 905
from C 85 905
spontaneous C 86 905
and C 87 905
non C 88 905
- C 89 905
rubella C 90 905
therapeutic C 91 905
abortions C 92 905
yielded C 93 905
similar C 94 905
cell C 95 905
strains C 96 905
for C 97 905
infection C 98 905
in C 99 905
vitro C 100 905
. C 101 905
the C 103 905
results C 104 905
from C 105 905
both C 106 905
types C 107 905
of C 108 905
studies C 109 905
were C 110 905
as C 111 905
follows C 112 905
: C 113 905
( C 114 905
a C 115 905
) C 116 905
virus C 117 905
shedding C 118 905
cell C 119 905
strains C 120 905
were C 121 905
obtained C 122 905
from C 123 905
all C 124 905
types C 125 905
of C 126 905
organs C 127 905
cultivated C 128 905
, C 129 905
which C 130 905
indicated C 131 905
wide C 132 905
dissemination C 133 905
of C 134 905
virus C 135 905
in C 136 905
the C 137 905
fetuses C 138 905
from C 139 905
rubella C 140 905
- C 141 905
infected C 142 905
mothers C 143 905
. C 144 905
( C 146 905
b C 147 905
) C 148 905
chronic C 149 905
infection C 150 905
could C 151 905
readily C 152 905
be C 153 905
established C 154 905
by C 155 905
in C 156 905
vitro C 157 905
infection C 158 905
and C 159 905
no C 160 905
cytopathic C 161 905
effect C 162 905
was C 163 905
noted C 164 905
. C 165 905
( C 167 905
c C 168 905
) C 169 905
although C 170 905
many C 171 905
strains C 172 905
continued C 173 905
to C 174 905
shed C 175 905
virus C 176 905
throughout C 177 905
months C 178 905
of C 179 905
in C 180 905
vitro C 181 905
cultivation C 182 905
, C 183 905
no C 184 905
changes C 185 905
in C 186 905
growth C 187 905
properties C 188 905
occurred C 189 905
with C 190 905
the C 191 905
exception C 192 905
that C 193 905
infected C 194 905
strains C 195 905
from C 196 905
lung C 197 905
tissue C 198 905
showed C 199 905
limited C 200 905
growth C 201 905
capacities C 202 905
. C 203 905
( C 205 905
d C 206 905
) C 207 905
from C 208 905
observations C 209 905
of C 210 905
over C 211 905
2 C 212 905
, C 213 905
000 C 214 905
metaphases C 215 905
, C 216 905
neither C 217 905
obvious C 218 905
chromosomal C 219 905
rearrangements C 220 905
nor C 221 905
non C 222 905
- C 223 905
disjunctional C 224 905
changes C 225 905
were C 226 905
observed C 227 905
in C 228 905
strains C 229 905
infected C 230 905
naturally C 231 905
or C 232 905
experimentally C 233 905
. C 234 905
( C 236 905
e C 237 905
) C 238 905
among C 239 905
17 C 240 905
rubella C 241 905
abortion C 242 905
- C 243 905
derived C 244 905
cell C 245 905
strains C 246 905
there C 247 905
was C 248 905
a C 249 905
marked C 250 905
elevation C 251 905
in C 252 905
frequency C 253 905
of C 254 905
chromosome C 255 905
breakage C 256 905
in C 257 905
3 C 258 905
instances C 259 905
( C 260 905
18 C 261 905
% C 262 905
, C 263 905
29 C 264 905
% C 265 905
, C 266 905
68 C 267 905
% C 268 905
, C 269 905
) C 270 905
. C 271 905
( C 273 905
f C 274 905
) C 275 905
a C 276 905
correlation C 277 905
between C 278 905
virus C 279 905
shedding C 280 905
in C 281 905
vitro C 282 905
and C 283 905
increased C 284 905
chromosome C 285 905
breakage C 286 905
was C 287 905
noted C 288 905
although C 289 905
this C 290 905
was C 291 905
not C 292 905
complete C 293 905
. C 294 905
( C 296 905
g C 297 905
) C 298 905
the C 299 905
combined C 300 905
average C 301 905
frequency C 302 905
of C 303 905
chromosome C 304 905
breakage C 305 905
in C 306 905
one C 307 905
set C 308 905
of C 309 905
7 C 310 905
rubella C 311 905
- C 312 905
abortion C 313 905
strains C 314 905
was C 315 905
18 C 316 905
% C 317 905
; C 318 905
in C 319 905
the C 320 905
other C 321 905
set C 322 905
of C 323 905
9 C 324 905
abortus C 325 905
strains C 326 905
, C 327 905
9 C 328 905
. C 329 905
. C 330 905
% C 331 905
. C 332 905
( C 334 905
h C 335 905
) C 336 905
similarly C 337 905
, C 338 905
a C 339 905
slight C 340 905
, C 341 905
but C 342 905
significant C 343 905
elevation C 344 905
in C 345 905
average C 346 905
chromosome C 347 905
break C 348 905
frequency C 349 905
( C 350 905
9 C 351 905
. C 352 905
. C 353 905
% C 354 905
) C 355 905
was C 356 905
obtained C 357 905
in C 358 905
four C 359 905
cell C 360 905
strains C 361 905
which C 362 905
had C 363 905
been C 364 905
experimentally C 365 905
infected C 366 905
in C 367 905
vitro C 368 905
with C 369 905
rubella C 370 905
virus C 371 905
( C 372 905
uninfected C 373 905
cells C 374 905
: C 375 905
5 C 376 905
. C 377 905
. C 378 905
% C 379 905
) C 380 905
. C 381 905
although C 383 905
effects C 384 905
upon C 385 905
the C 386 905
chromosomes C 387 905
were C 388 905
demonstrated C 389 905
, C 390 905
these C 391 905
were C 392 905
restricted C 393 905
to C 394 905
slight C 395 905
general C 396 905
elevations C 397 905
in C 398 905
frequency C 399 905
of C 400 905
breakage C 401 905
above C 402 905
normal C 403 905
values C 404 905
. C 405 905
very C 407 905
high C 408 905
increases C 409 905
in C 410 905
breaks C 411 905
were C 412 905
sporadic C 413 905
. C 414 905
it C 416 905
appears C 417 905
more C 418 905
likely C 419 905
that C 420 905
the C 421 905
general C 422 905
fetal C 423 905
abnormalities C 424 905
associated C 425 905
with C 426 905
rubella C 427 905
infection C 428 905
in C 429 905
vivo C 430 905
result C 431 905
from C 432 905
possible C 433 905
effects C 434 905
of C 435 905
the C 436 905
virus C 437 905
upon C 438 905
growth C 439 905
rather C 440 905
than C 441 905
from C 442 905
effects C 443 905
upon C 444 905
the C 445 905
chromosomes C 446 905
. C 447 905
however C 449 905
, C 450 905
the C 451 905
studies C 452 905
were C 453 905
restricted C 454 905
to C 455 905
fibroblasts C 456 905
cultured C 457 905
in C 458 905
vitro C 459 905
; C 460 905
and C 461 905
effects C 462 905
on C 463 905
other C 464 905
types C 465 905
of C 466 905
cells C 467 905
may C 468 905
have C 469 905
greater C 470 905
implications C 471 905
for C 472 905
this C 473 905
question C 474 905
. C 475 905
fine C 1 906
structure C 2 906
of C 3 906
staphylococccal C 4 906
l C 5 906
- C 6 906
forms C 7 906
. C 8 906
l C 10 906
forms C 11 906
of C 12 906
staph C 13 906
. C 14 906
aureus C 16 906
and C 17 906
bacterial C 18 906
cells C 19 906
were C 20 906
processed C 21 906
by C 22 906
the C 23 906
same C 24 906
technique C 25 906
for C 26 906
electron C 27 906
microscopy C 28 906
. C 29 906
ultrathin C 31 906
sections C 32 906
allowed C 33 906
comparison C 34 906
of C 35 906
structural C 36 906
units C 37 906
and C 38 906
indicated C 39 906
that C 40 906
staphylococcal C 41 906
l C 42 906
form C 43 906
units C 44 906
of C 45 906
all C 46 906
sizes C 47 906
lack C 48 906
the C 49 906
rigid C 50 906
cell C 51 906
wall C 52 906
and C 53 906
the C 54 906
compact C 55 906
, C 56 906
fibrillar C 57 906
nuclear C 58 906
area C 59 906
of C 60 906
bacterial C 61 906
cells C 62 906
. C 63 906
the C 65 906
l C 66 906
form C 67 906
units C 68 906
are C 69 906
bound C 70 906
by C 71 906
a C 72 906
typical C 73 906
' C 74 906
trilamellar C 75 906
' C 76 906
membrane C 77 906
comparable C 78 906
to C 79 906
that C 80 906
described C 81 906
for C 82 906
mycoplasma C 83 906
species C 84 906
. C 85 906
nuclear C 87 906
areas C 88 906
in C 89 906
staphylococcal C 90 906
l C 91 906
forms C 92 906
present C 93 906
a C 94 906
diffuse C 95 906
appearance C 96 906
and C 97 906
could C 98 906
not C 99 906
be C 100 906
correlated C 101 906
with C 102 906
size C 103 906
of C 104 906
any C 105 906
particular C 106 906
structural C 107 906
unit C 108 906
. C 109 906
many C 111 906
small C 112 906
units C 113 906
were C 114 906
seen C 115 906
within C 116 906
large C 117 906
bodies C 118 906
and C 119 906
possibly C 120 906
are C 121 906
involved C 122 906
in C 123 906
the C 124 906
reproductive C 125 906
process C 126 906
. C 127 906
no C 129 906
evidence C 130 906
of C 131 906
division C 132 906
by C 133 906
formation C 134 906
of C 135 906
septa C 136 906
or C 137 906
by C 138 906
pinching C 139 906
off C 140 906
of C 141 906
cytoplasmic C 142 906
fragments C 143 906
was C 144 906
obtained C 145 906
from C 146 906
the C 147 906
electron C 148 906
micrographs C 149 906
. C 150 906
respiratory C 1 907
virus C 2 907
vaccines C 3 907
. C 4 907
ii C 6 907
. C 7 907
mycoplasma C 9 907
pneumoniae C 10 907
( C 11 907
eaton C 12 907
agent C 13 907
) C 14 907
vaccines C 15 907
. C 16 907
purified C 18 907
and C 19 907
concentrated C 20 907
formalin C 21 907
- C 22 907
killed C 23 907
vaccines C 24 907
were C 25 907
prepared C 26 907
from C 27 907
m C 28 907
. C 29 907
pneumoniae C 31 907
propagated C 32 907
in C 33 907
serum C 34 907
- C 35 907
free C 36 907
artificial C 37 907
medium C 38 907
. C 39 907
the C 41 907
vaccines C 42 907
were C 43 907
aqueous C 44 907
or C 45 907
were C 46 907
incorporated C 47 907
in C 48 907
alum C 49 907
or C 50 907
emulsified C 51 907
peanut C 52 907
oil C 53 907
( C 54 907
adjuvant C 55 907
65 C 56 907
) C 57 907
adjuvant C 58 907
. C 59 907
two C 61 907
or C 62 907
3 C 63 907
different C 64 907
concentrations C 65 907
of C 66 907
mycoplasma C 67 907
were C 68 907
included C 69 907
in C 70 907
each C 71 907
preparation C 72 907
. C 73 907
serum C 75 907
neutralizing C 76 907
and C 77 907
cf C 78 907
antibody C 79 907
responses C 80 907
were C 81 907
measured C 82 907
in C 83 907
hamsters C 84 907
, C 85 907
monkeys C 86 907
, C 87 907
and C 88 907
in C 89 907
institutionalized C 90 907
persons C 91 907
following C 92 907
1 C 93 907
, C 94 907
2 C 95 907
, C 96 907
3 C 97 907
and C 98 907
sometimes C 99 907
4 C 100 907
vaccinations C 101 907
. C 102 907
all C 104 907
of C 105 907
the C 106 907
preparations C 107 907
were C 108 907
highly C 109 907
antigenic C 110 907
in C 111 907
animals C 112 907
and C 113 907
in C 114 907
man C 115 907
. C 116 907
alum C 118 907
vaccines C 119 907
were C 120 907
better C 121 907
than C 122 907
aqueous C 123 907
vaccines C 124 907
and C 125 907
those C 126 907
in C 127 907
adjuvant C 128 907
65 C 129 907
appeared C 130 907
to C 131 907
give C 132 907
best C 133 907
results C 134 907
although C 135 907
the C 136 907
bleeding C 137 907
times C 138 907
were C 139 907
not C 140 907
always C 141 907
optimal C 142 907
for C 143 907
demonstrating C 144 907
maximal C 145 907
effect C 146 907
. C 147 907
persons C 149 907
who C 150 907
were C 151 907
without C 152 907
detectable C 153 907
antibody C 154 907
initially C 155 907
and C 156 907
thus C 157 907
would C 158 907
be C 159 907
most C 160 907
vulnerable C 161 907
to C 162 907
infection C 163 907
gave C 164 907
better C 165 907
responses C 166 907
to C 167 907
the C 168 907
vaccine C 169 907
than C 170 907
did C 171 907
those C 172 907
with C 173 907
pre C 174 907
- C 175 907
existing C 176 907
antibody C 177 907
. C 178 907
alum C 180 907
vaccine C 181 907
is C 182 907
an C 183 907
acceptable C 184 907
formulation C 185 907
for C 186 907
use C 187 907
in C 188 907
man C 189 907
, C 190 907
and C 191 907
only C 192 907
2 C 193 907
doses C 194 907
of C 195 907
such C 196 907
vaccine C 197 907
were C 198 907
necessary C 199 907
to C 200 907
induce C 201 907
neutralizing C 202 907
antibody C 203 907
in C 204 907
90 C 205 907
% C 206 907
of C 207 907
the C 208 907
persons C 209 907
who C 210 907
were C 211 907
initially C 212 907
without C 213 907
detectable C 214 907
antibody C 215 907
. C 216 907
no C 218 907
local C 219 907
or C 220 907
systemic C 221 907
reaction C 222 907
of C 223 907
clinical C 224 907
consequence C 225 907
was C 226 907
noted C 227 907
in C 228 907
any C 229 907
of C 230 907
the C 231 907
persons C 232 907
vaccinated C 233 907
. C 234 907
recent C 236 907
unpublished C 237 907
findings C 238 907
, C 239 907
which C 240 907
indicate C 241 907
a C 242 907
high C 243 907
degree C 244 907
of C 245 907
effectiveness C 246 907
of C 247 907
the C 248 907
alum C 249 907
vaccine C 250 907
in C 251 907
stimulating C 252 907
antibody C 253 907
in C 254 907
preschool C 255 907
children C 256 907
and C 257 907
in C 258 907
protecting C 259 907
children C 260 907
and C 261 907
adults C 262 907
against C 263 907
the C 264 907
natural C 265 907
disease C 266 907
, C 267 907
are C 268 907
mentioned C 269 907
. C 270 907
isolation C 1 908
of C 2 908
mycoplasma C 3 908
pneumoniae C 4 908
from C 5 908
adults C 6 908
with C 7 908
respiratory C 8 908
infections C 9 908
. C 10 908
isolation C 12 908
of C 13 908
mycoplasma C 14 908
organisms C 15 908
from C 16 908
the C 17 908
sputum C 18 908
was C 19 908
attempted C 20 908
in C 21 908
254 C 22 908
patients C 23 908
with C 24 908
various C 25 908
syndrome C 26 908
of C 27 908
respiratory C 28 908
disease C 29 908
. C 30 908
isolates C 32 908
were C 33 908
obtained C 34 908
in C 35 908
56 C 36 908
% C 37 908
of C 38 908
the C 39 908
197 C 40 908
patients C 41 908
with C 42 908
pneumonia C 43 908
, C 44 908
50 C 45 908
% C 46 908
of C 47 908
patients C 48 908
with C 49 908
chronic C 50 908
bronchial C 51 908
diseases C 52 908
who C 53 908
were C 54 908
not C 55 908
treated C 56 908
with C 57 908
tetracycline C 58 908
, C 59 908
and C 60 908
33 C 61 908
% C 62 908
of C 63 908
persons C 64 908
with C 65 908
acute C 66 908
upper C 67 908
respiratory C 68 908
infection C 69 908
. C 70 908
these C 72 908
differences C 73 908
are C 74 908
not C 75 908
statistically C 76 908
significant C 77 908
and C 78 908
indicate C 79 908
a C 80 908
nonpathogenic C 81 908
role C 82 908
for C 83 908
m C 84 908
. C 85 908
pharyngis C 87 908
and C 88 908
m C 89 908
. C 90 908
salivarium C 92 908
which C 93 908
were C 94 908
the C 95 908
strains C 96 908
most C 97 908
frequently C 98 908
isolated C 99 908
. C 100 908
the C 102 908
highest C 103 908
frequency C 104 908
of C 105 908
isolation C 106 908
was C 107 908
from C 108 908
males C 109 908
15 C 110 908
to C 111 908
30 C 112 908
yr C 113 908
. C 114 908
of C 116 908
age C 117 908
. C 118 908
isolation C 120 908
of C 121 908
m C 122 908
. C 123 908
pneumoniae C 125 908
requires C 126 908
one C 127 908
to C 128 908
2 C 129 908
weeks C 130 908
: C 131 908
therefore C 132 908
, C 133 908
it C 134 908
is C 135 908
not C 136 908
useful C 137 908
for C 138 908
rapid C 139 908
diagnosis C 140 908
. C 141 908
also C 143 908
, C 144 908
it C 145 908
underestimates C 146 908
the C 147 908
prevalence C 148 908
of C 149 908
infection C 150 908
, C 151 908
especially C 152 908
if C 153 908
patients C 154 908
have C 155 908
received C 156 908
tetracycline C 157 908
. C 158 908
of C 160 908
the C 161 908
serologic C 162 908
tests C 163 908
, C 164 908
complement C 165 908
- C 166 908
fixation C 167 908
( C 168 908
cf C 169 908
) C 170 908
was C 171 908
the C 172 908
most C 173 908
specific C 174 908
. C 175 908
the C 177 908
growth C 178 908
inhibition C 179 908
test C 180 908
( C 181 908
tri C 182 908
) C 183 908
was C 184 908
the C 185 908
most C 186 908
sensitive C 187 908
and C 188 908
was C 189 908
significantly C 190 908
related C 191 908
to C 192 908
atypical C 193 908
pneumonia C 194 908
. C 195 908
the C 197 908
2 C 198 908
tests C 199 908
may C 200 908
measure C 201 908
different C 202 908
antibodies C 203 908
against C 204 908
m C 205 908
. C 206 908
pneumoniae C 208 908
. C 209 908
serum C 211 908
cold C 212 908
agglutinins C 213 908
developed C 214 908
in C 215 908
many C 216 908
cases C 217 908
of C 218 908
pneumonia C 219 908
and C 220 908
were C 221 908
poorly C 222 908
discriminatory C 223 908
in C 224 908
etiologic C 225 908
diagnosis C 226 908
. C 227 908
m C 229 908
. C 230 908
pneumoniae C 232 908
infection C 233 908
occurred C 234 908
in C 235 908
a C 236 908
minimum C 237 908
of C 238 908
8 C 239 908
% C 240 908
and C 241 908
a C 242 908
maximum C 243 908
of C 244 908
20 C 245 908
% C 246 908
of C 247 908
civilian C 248 908
patients C 249 908
hospitalized C 250 908
for C 251 908
pneumonia C 252 908
during C 253 908
the C 254 908
season C 255 908
studied C 256 908
. C 257 908
serologic C 259 908
evidence C 260 908
for C 261 908
m C 262 908
. C 263 908
pneumoniae C 265 908
was C 266 908
rare C 267 908
in C 268 908
lobar C 269 908
pneumonia C 270 908
. C 271 908
in C 273 908
nonlobar C 274 908
pneumonia C 275 908
, C 276 908
m C 277 908
. C 278 908
pneumoniae C 280 908
accounted C 281 908
etiologically C 282 908
for C 283 908
13 C 284 908
% C 285 908
to C 286 908
50 C 287 908
% C 288 908
of C 289 908
cases C 290 908
. C 291 908
the C 293 908
incidence C 294 908
of C 295 908
m C 296 908
. C 297 908
pneumoniae C 299 908
infection C 300 908
was C 301 908
constant C 302 908
in C 303 908
different C 304 908
seasons C 305 908
but C 306 908
greatest C 307 908
relative C 308 908
to C 309 908
the C 310 908
occurrence C 311 908
of C 312 908
pneumonia C 313 908
in C 314 908
the C 315 908
fall C 316 908
and C 317 908
spring C 318 908
. C 319 908
color C 1 909
test C 2 909
for C 3 909
the C 4 909
measurement C 5 909
of C 6 909
antibody C 7 909
to C 8 909
t C 9 909
- C 10 909
strain C 11 909
mycoplasmas C 12 909
. C 13 909
a C 15 909
metabolic C 16 909
inhibition C 17 909
technique C 18 909
for C 19 909
the C 20 909
measurement C 21 909
of C 22 909
antibody C 23 909
to C 24 909
t C 25 909
- C 26 909
strain C 27 909
mycoplasmas C 28 909
was C 29 909
developed C 30 909
, C 31 909
based C 32 909
upon C 33 909
the C 34 909
ability C 35 909
of C 36 909
t C 37 909
- C 38 909
strain C 39 909
mycoplasmas C 40 909
to C 41 909
metabolize C 42 909
urea C 43 909
with C 44 909
the C 45 909
concomitant C 46 909
production C 47 909
of C 48 909
ammonia C 49 909
, C 50 909
and C 51 909
the C 52 909
ability C 53 909
of C 54 909
specific C 55 909
, C 56 909
antiserum C 57 909
to C 58 909
inhibit C 59 909
this C 60 909
ammonia C 61 909
production C 62 909
. C 63 909
phenol C 65 909
red C 66 909
added C 67 909
to C 68 909
the C 69 909
medium C 70 909
served C 71 909
as C 72 909
an C 73 909
indicator C 74 909
of C 75 909
ph C 76 909
change C 77 909
resulting C 78 909
from C 79 909
ammonia C 80 909
production C 81 909
. C 82 909
specific C 84 909
antiserum C 85 909
to C 86 909
t C 87 909
- C 88 909
strain C 89 909
mycoplasma C 90 909
t C 91 909
- C 92 909
960 C 93 909
was C 94 909
prepared C 95 909
. C 96 909
the C 98 909
t C 99 909
- C 100 909
strain C 101 909
organism C 102 909
was C 103 909
shown C 104 909
to C 105 909
be C 106 909
serologically C 107 909
distinct C 108 909
from C 109 909
the C 110 909
recognized C 111 909
large C 112 909
- C 113 909
colony C 114 909
mycoplasmas C 115 909
. C 116 909
antibody C 118 909
to C 119 909
mycoplasma C 120 909
strain C 121 909
t C 122 909
- C 123 909
960 C 124 909
in C 125 909
human C 126 909
sera C 127 909
was C 128 909
demonstrated C 129 909
with C 130 909
the C 131 909
metabolic C 132 909
inhibition C 133 909
technique C 134 909
. C 135 909
effect C 1 910
of C 2 910
mycoplasma C 3 910
on C 4 910
interferon C 5 910
production C 6 910
and C 7 910
interferon C 8 910
assay C 9 910
in C 10 910
cell C 11 910
cultures C 12 910
. C 13 910
the C 15 910
influence C 16 910
of C 17 910
mycoplasma C 18 910
on C 19 910
the C 20 910
production C 21 910
and C 22 910
action C 23 910
of C 24 910
interferon C 25 910
was C 26 910
studied C 27 910
in C 28 910
cultures C 29 910
of C 30 910
both C 31 910
l C 32 910
and C 33 910
human C 34 910
embryonic C 35 910
kidney C 36 910
( C 37 910
hek C 38 910
) C 39 910
cells C 40 910
. C 41 910
m C 43 910
. C 44 910
hominis C 46 910
1 C 47 910
, C 48 910
the C 49 910
negroni C 50 910
agent C 51 910
, C 52 910
and C 53 910
the C 54 910
f C 55 910
12 C 56 910
mycoplasma C 57 910
were C 58 910
used C 59 910
for C 60 910
infection C 61 910
of C 62 910
l C 63 910
cells C 64 910
, C 65 910
and C 66 910
m C 67 910
. C 68 910
hominis C 70 910
1 C 71 910
and C 72 910
m C 73 910
. C 74 910
pneumoniae C 76 910
for C 77 910
inoculation C 78 910
of C 79 910
hek C 80 910
cells C 81 910
. C 82 910
all C 84 910
strains C 85 910
were C 86 910
capable C 87 910
of C 88 910
multiplication C 89 910
in C 90 910
the C 91 910
culture C 92 910
systems C 93 910
employed C 94 910
. C 95 910
none C 97 910
produced C 98 910
detectable C 99 910
levels C 100 910
of C 101 910
interferon C 102 910
, C 103 910
and C 104 910
responsiveness C 105 910
of C 106 910
the C 107 910
cells C 108 910
to C 109 910
induction C 110 910
of C 111 910
interferon C 112 910
by C 113 910
virus C 114 910
remained C 115 910
unaltered C 116 910
. C 117 910
infection C 119 910
with C 120 910
mycoplasma C 121 910
did C 122 910
not C 123 910
impair C 124 910
the C 125 910
sensitivity C 126 910
of C 127 910
the C 128 910
cells C 129 910
to C 130 910
the C 131 910
action C 132 910
of C 133 910
interferon C 134 910
, C 135 910
nor C 136 910
was C 137 910
the C 138 910
replication C 139 910
of C 140 910
vesicular C 141 910
stomatitis C 142 910
virus C 143 910
noticeably C 144 910
diminished C 145 910
. C 146 910
recovery C 1 911
and C 2 911
characterization C 3 911
of C 4 911
a C 5 911
herpes C 6 911
- C 7 911
like C 8 911
virus C 9 911
from C 10 911
dog C 11 911
kidney C 12 911
cell C 13 911
cultures C 14 911
. C 15 911
a C 17 911
transmissible C 18 911
agent C 19 911
was C 20 911
recovered C 21 911
from C 22 911
primary C 23 911
dktc C 24 911
which C 25 911
developed C 26 911
a C 27 911
spontaneous C 28 911
cpe C 29 911
. C 30 911
characterization C 32 911
and C 33 911
serological C 34 911
studies C 35 911
of C 36 911
the C 37 911
virus C 38 911
indicated C 39 911
that C 40 911
the C 41 911
virus C 42 911
was C 43 911
a C 44 911
new C 45 911
member C 46 911
of C 47 911
the C 48 911
herpes C 49 911
virus C 50 911
group C 51 911
. C 52 911
immunopathologic C 1 912
changes C 2 912
in C 3 912
rheumatoid C 4 912
arthritis C 5 912
synovium C 6 912
. C 7 912
synovial C 9 912
tissue C 10 912
from C 11 912
8 C 12 912
children C 13 912
and C 14 912
7 C 15 912
adults C 16 912
with C 17 912
rheumatoid C 18 912
arthritis C 19 912
was C 20 912
examined C 21 912
for C 22 912
localization C 23 912
of C 24 912
immunoglobulins C 25 912
and C 26 912
complement C 27 912
. C 28 912
three C 30 912
cases C 31 912
were C 32 912
found C 33 912
to C 34 912
have C 35 912
c C 36 912
' C 37 912
and C 38 912
immunoglobulins C 39 912
within C 40 912
the C 41 912
cytoplasm C 42 912
of C 43 912
synovial C 44 912
cells C 45 912
, C 46 912
four C 47 912
cases C 48 912
had C 49 912
discrete C 50 912
localization C 51 912
within C 52 912
the C 53 912
connective C 54 912
tissue C 55 912
stroma C 56 912
; C 57 912
the C 58 912
remaining C 59 912
7 C 60 912
cases C 61 912
demonstrated C 62 912
larger C 63 912
, C 64 912
more C 65 912
weakly C 66 912
staining C 67 912
collections C 68 912
which C 69 912
were C 70 912
found C 71 912
more C 72 912
diffusely C 73 912
throughout C 74 912
the C 75 912
synovium C 76 912
. C 77 912
no C 79 912
immunoglobulin C 80 912
or C 81 912
complement C 82 912
localization C 83 912
was C 84 912
present C 85 912
in C 86 912
10 C 87 912
out C 88 912
of C 89 912
11 C 90 912
additional C 91 912
patients C 92 912
with C 93 912
forms C 94 912
of C 95 912
joint C 96 912
disease C 97 912
other C 98 912
than C 99 912
rheumatoid C 100 912
arthritis C 101 912
. C 102 912
correlation C 104 912
of C 105 912
these C 106 912
results C 107 912
with C 108 912
the C 109 912
clinical C 110 912
findings C 111 912
and C 112 912
joint C 113 912
fluid C 114 912
c C 115 912
' C 116 912
assays C 117 912
was C 118 912
made C 119 912
. C 120 912
electron C 1 913
microscopic C 2 913
studies C 3 913
of C 4 913
mycoplasma C 5 913
( C 6 913
pplo C 7 913
strain C 8 913
880 C 9 913
) C 10 913
in C 11 913
artificial C 12 913
medium C 13 913
and C 14 913
in C 15 913
tissue C 16 913
culture C 17 913
. C 18 913
mycoplasma C 20 913
strain C 21 913
880 C 22 913
, C 23 913
isolated C 24 913
from C 25 913
a C 26 913
leukemic C 27 913
patient C 28 913
, C 29 913
was C 30 913
studied C 31 913
in C 32 913
broth C 33 913
cultures C 34 913
and C 35 913
in C 36 913
several C 37 913
cell C 38 913
culture C 39 913
lines C 40 913
. C 41 913
this C 43 913
strain C 44 913
exhibited C 45 913
considerable C 46 913
pleomorphism C 47 913
in C 48 913
size C 49 913
, C 50 913
internal C 51 913
structure C 52 913
, C 53 913
and C 54 913
shape C 55 913
, C 56 913
including C 57 913
forms C 58 913
with C 59 913
filamentous C 60 913
projections C 61 913
. C 62 913
the C 64 913
most C 65 913
common C 66 913
form C 67 913
observed C 68 913
was C 69 913
0 C 70 913
. C 71 913
. C 72 913
to C 73 913
1 C 74 913
in C 75 913
diameter C 76 913
and C 77 913
had C 78 913
a C 79 913
nuclear C 80 913
area C 81 913
of C 82 913
fibrillar C 83 913
strands C 84 913
, C 85 913
probably C 86 913
dna C 87 913
. C 88 913
the C 90 913
cytoplasm C 91 913
of C 92 913
the C 93 913
organisms C 94 913
contained C 95 913
ribosome C 96 913
- C 97 913
like C 98 913
granules C 99 913
and C 100 913
a C 101 913
flattened C 102 913
vacuole C 103 913
which C 104 913
indented C 105 913
the C 106 913
nuclear C 107 913
area C 108 913
. C 109 913
there C 111 913
were C 112 913
various C 113 913
other C 114 913
forms C 115 913
, C 116 913
including C 117 913
' C 118 913
elementary C 119 913
bodies C 120 913
' C 121 913
100 C 122 913
m C 123 913
in C 124 913
diameter C 125 913
that C 126 913
were C 127 913
very C 128 913
electron C 129 913
- C 130 913
dense C 131 913
. C 132 913
in C 134 913
the C 135 913
tissue C 136 913
culture C 137 913
lines C 138 913
in C 139 913
which C 140 913
the C 141 913
cells C 142 913
grew C 143 913
as C 144 913
a C 145 913
monolayer C 146 913
, C 147 913
the C 148 913
mycoplasma C 149 913
were C 150 913
closely C 151 913
associated C 152 913
with C 153 913
the C 154 913
cell C 155 913
surface C 156 913
and C 157 913
were C 158 913
occasionally C 159 913
seen C 160 913
in C 161 913
membrane C 162 913
- C 163 913
lined C 164 913
cytoplasmic C 165 913
vacuoles C 166 913
. C 167 913
in C 169 913
cell C 170 913
lines C 171 913
that C 172 913
did C 173 913
not C 174 913
attach C 175 913
to C 176 913
the C 177 913
glass C 178 913
, C 179 913
the C 180 913
mycoplasma C 181 913
were C 182 913
fewer C 183 913
and C 184 913
not C 185 913
attached C 186 913
to C 187 913
the C 188 913
cell C 189 913
surface C 190 913
. C 191 913
although C 193 913
the C 194 913
ultrastructure C 195 913
of C 196 913
this C 197 913
strain C 198 913
is C 199 913
similar C 200 913
to C 201 913
that C 202 913
of C 203 913
previously C 204 913
described C 205 913
strains C 206 913
, C 207 913
there C 208 913
are C 209 913
differences C 210 913
in C 211 913
details C 212 913
of C 213 913
structure C 214 913
which C 215 913
may C 216 913
be C 217 913
related C 218 913
either C 219 913
to C 220 913
the C 221 913
growth C 222 913
conditions C 223 913
used C 224 913
or C 225 913
to C 226 913
characteristics C 227 913
of C 228 913
the C 229 913
strain C 230 913
. C 231 913
the C 233 913
various C 234 913
forms C 235 913
of C 236 913
the C 237 913
organism C 238 913
are C 239 913
consistent C 240 913
with C 241 913
the C 242 913
suggestion C 243 913
that C 244 913
mycoplasma C 245 913
may C 246 913
have C 247 913
several C 248 913
mechanisms C 249 913
of C 250 913
reproduction C 251 913
( C 252 913
growth C 253 913
) C 254 913
. C 255 913
the C 257 913
intracellular C 258 913
mycoplasma C 259 913
may C 260 913
be C 261 913
protected C 262 913
from C 263 913
antibiotics C 264 913
. C 265 913
this C 267 913
would C 268 913
partly C 269 913
explain C 270 913
the C 271 913
difficulty C 272 913
of C 273 913
eradicating C 274 913
mycoplasma C 275 913
from C 276 913
infected C 277 913
cell C 278 913
cultures C 279 913
. C 280 913
long C 1 914
- C 2 914
term C 3 914
prognosis C 4 914
and C 5 914
the C 6 914
response C 7 914
of C 8 914
schizophrenic C 9 914
children C 10 914
to C 11 914
drug C 12 914
therapy C 13 914
: C 14 914
a C 15 914
controlled C 16 914
study C 17 914
of C 18 914
trifluoperazine C 19 914
. C 20 914
it C 22 914
is C 23 914
evident C 24 914
from C 25 914
this C 26 914
study C 27 914
that C 28 914
treatment C 29 914
and C 30 914
control C 31 914
groups C 32 914
must C 33 914
be C 34 914
matched C 35 914
for C 36 914
severity C 37 914
of C 38 914
illness C 39 914
, C 40 914
since C 41 914
this C 42 914
affects C 43 914
the C 44 914
responsiveness C 45 914
to C 46 914
pharmacological C 47 914
as C 48 914
well C 49 914
as C 50 914
to C 51 914
other C 52 914
types C 53 914
of C 54 914
treatments C 55 914
. C 56 914
the C 58 914
use C 59 914
of C 60 914
the C 61 914
double C 62 914
- C 63 914
blind C 64 914
technique C 65 914
does C 66 914
not C 67 914
of C 68 914
itself C 69 914
guarantee C 70 914
a C 71 914
well C 72 914
- C 73 914
controlled C 74 914
study C 75 914
; C 76 914
the C 77 914
comparison C 78 914
of C 79 914
2 C 80 914
or C 81 914
more C 82 914
treatment C 83 914
regimes C 84 914
may C 85 914
be C 86 914
misleading C 87 914
if C 88 914
the C 89 914
groups C 90 914
are C 91 914
not C 92 914
matched C 93 914
, C 94 914
or C 95 914
if C 96 914
the C 97 914
matching C 98 914
is C 99 914
not C 100 914
based C 101 914
on C 102 914
critical C 103 914
factors C 104 914
. C 105 914
in C 107 914
this C 108 914
study C 109 914
, C 110 914
both C 111 914
the C 112 914
response C 113 914
to C 114 914
the C 115 914
nonpharmacologic C 116 914
aspects C 117 914
of C 118 914
treatment C 119 914
and C 120 914
the C 121 914
type C 122 914
of C 123 914
response C 124 914
to C 125 914
the C 126 914
drug C 127 914
itself C 128 914
were C 129 914
related C 130 914
to C 131 914
the C 132 914
initial C 133 914
severity C 134 914
of C 135 914
language C 136 914
impairment C 137 914
. C 138 914
thus C 140 914
the C 141 914
major C 142 914
developmental C 143 914
defect C 144 914
which C 145 914
determines C 146 914
long C 147 914
- C 148 914
term C 149 914
outcome C 150 914
for C 151 914
schizophrenic C 152 914
children C 153 914
in C 154 914
this C 155 914
group C 156 914
also C 157 914
predicted C 158 914
the C 159 914
immediate C 160 914
responsiveness C 161 914
to C 162 914
treatment C 163 914
. C 164 914
within C 166 914
the C 167 914
2 C 168 914
major C 169 914
prognostic C 170 914
subgroups C 171 914
of C 172 914
young C 173 914
schizophrenic C 174 914
children C 175 914
, C 176 914
those C 177 914
with C 178 914
speech C 179 914
and C 180 914
those C 181 914
without C 182 914
, C 183 914
are C 184 914
children C 185 914
with C 186 914
different C 187 914
profiles C 188 914
of C 189 914
disordered C 190 914
development C 191 914
and C 192 914
different C 193 914
patterns C 194 914
of C 195 914
assets C 196 914
and C 197 914
handicaps C 198 914
. C 199 914
the C 1 915
long C 2 915
- C 3 915
term C 4 915
treatment C 5 915
of C 6 915
a C 7 915
psychotic C 8 915
child C 9 915
in C 10 915
a C 11 915
psychiatric C 12 915
hospital C 13 915
. C 14 915
description C 16 915
of C 17 915
one C 18 915
phase C 19 915
of C 20 915
the C 21 915
long C 22 915
term C 23 915
psychotherapy C 24 915
of C 25 915
a C 26 915
6 C 27 915
yr C 28 915
. C 29 915
old C 31 915
psychotic C 32 915
boy C 33 915
, C 34 915
within C 35 915
the C 36 915
framework C 37 915
of C 38 915
a C 39 915
mental C 40 915
hospital C 41 915
. C 42 915
the C 44 915
first C 45 915
part C 46 915
deals C 47 915
briefly C 48 915
with C 49 915
the C 50 915
lay C 51 915
- C 52 915
out C 53 915
and C 54 915
the C 55 915
structure C 56 915
of C 57 915
a C 58 915
new C 59 915
unit C 60 915
for C 61 915
emotionally C 62 915
disturbed C 63 915
children C 64 915
. C 65 915
underlining C 67 915
the C 68 915
well C 69 915
- C 70 915
known C 71 915
importance C 72 915
of C 73 915
the C 74 915
therapeutic C 75 915
milieu C 76 915
in C 77 915
the C 78 915
treatment C 79 915
and C 80 915
care C 81 915
of C 82 915
the C 83 915
mentally C 84 915
ill C 85 915
particularly C 86 915
important C 87 915
when C 88 915
the C 89 915
patients C 90 915
are C 91 915
children C 92 915
. C 93 915
the C 95 915
child C 96 915
presented C 97 915
was C 98 915
diagnosed C 99 915
, C 100 915
when C 101 915
admitted C 102 915
, C 103 915
as C 104 915
a C 105 915
case C 106 915
of C 107 915
severe C 108 915
childhood C 109 915
psychosis C 110 915
, C 111 915
of C 112 915
the C 113 915
autistic C 114 915
type C 115 915
. C 116 915
the C 118 915
unusually C 119 915
rich C 120 915
data C 121 915
at C 122 915
disposal C 123 915
were C 124 915
obtained C 125 915
through C 126 915
non C 127 915
- C 128 915
verbal C 129 915
communication C 130 915
, C 131 915
because C 132 915
the C 133 915
child C 134 915
has C 135 915
no C 136 915
language C 137 915
. C 138 915
nevertheless C 140 915
, C 141 915
he C 142 915
can C 143 915
express C 144 915
himself C 145 915
clearly C 146 915
through C 147 915
play C 148 915
and C 149 915
gestures C 150 915
. C 151 915
the C 153 915
analysis C 154 915
of C 155 915
this C 156 915
precious C 157 915
clinical C 158 915
material C 159 915
focuses C 160 915
the C 161 915
discussion C 162 915
on C 163 915
the C 164 915
existence C 165 915
and C 166 915
the C 167 915
quality C 168 915
of C 169 915
an C 170 915
object C 171 915
- C 172 915
relationship C 173 915
preceding C 174 915
the C 175 915
psychosis C 176 915
, C 177 915
the C 178 915
importance C 179 915
of C 180 915
the C 181 915
' C 182 915
early C 183 915
unusual C 184 915
sensitivities C 185 915
' C 186 915
in C 187 915
the C 188 915
formation C 189 915
of C 190 915
a C 191 915
premature C 192 915
and C 193 915
fragile C 194 915
ego C 195 915
and C 196 915
the C 197 915
method C 198 915
of C 199 915
choice C 200 915
in C 201 915
the C 202 915
treatment C 203 915
of C 204 915
childhood C 205 915
psychoses C 206 915
. C 207 915
comments C 1 916
on C 2 916
a C 3 916
case C 4 916
of C 5 916
infantile C 6 916
psychosis C 7 916
. C 8 916
an C 10 916
account C 11 916
is C 12 916
given C 13 916
of C 14 916
a C 15 916
case C 16 916
of C 17 916
infantile C 18 916
mutism C 19 916
which C 20 916
depended C 21 916
not C 22 916
so C 23 916
much C 24 916
upon C 25 916
a C 26 916
true C 27 916
autism C 28 916
as C 29 916
on C 30 916
a C 31 916
withdrawing C 32 916
into C 33 916
himself C 34 916
as C 35 916
a C 36 916
defence C 37 916
against C 38 916
a C 39 916
dangerous C 40 916
and C 41 916
threatening C 42 916
environment C 43 916
. C 44 916
there C 46 916
was C 47 916
a C 48 916
spectacular C 49 916
and C 50 916
unusual C 51 916
improvement C 52 916
of C 53 916
the C 54 916
symptomatology C 55 916
with C 56 916
psychotherapy C 57 916
. C 58 916
the C 1 917
problems C 2 917
of C 3 917
infantile C 4 917
autism C 5 917
and C 6 917
psychiatric C 7 917
nosology C 8 917
. C 9 917
in C 11 917
psychiatric C 12 917
literature C 13 917
the C 14 917
syndrome C 15 917
of C 16 917
early C 17 917
infantile C 18 917
autism C 19 917
has C 20 917
been C 21 917
divided C 22 917
into C 23 917
several C 24 917
subgroups C 25 917
( C 26 917
as C 27 917
, C 28 917
for C 29 917
instance C 30 917
, C 31 917
the C 32 917
subgroup C 33 917
of C 34 917
kanner C 35 917
and C 36 917
the C 37 917
subgroup C 38 917
of C 39 917
asperger C 40 917
) C 41 917
and C 42 917
has C 43 917
been C 44 917
assigned C 45 917
to C 46 917
different C 47 917
mental C 48 917
conditions C 49 917
( C 50 917
schizophrenia C 51 917
, C 52 917
psychopathy C 53 917
, C 54 917
neurosis C 55 917
) C 56 917
. C 57 917
these C 59 917
distinctions C 60 917
and C 61 917
classifications C 62 917
are C 63 917
thought C 64 917
to C 65 917
be C 66 917
controversial C 67 917
, C 68 917
so C 69 917
long C 70 917
as C 71 917
the C 72 917
etiology C 73 917
of C 74 917
early C 75 917
infantile C 76 917
autism C 77 917
is C 78 917
unknown C 79 917
. C 80 917
nor C 82 917
should C 83 917
any C 84 917
' C 85 917
psychiatric C 86 917
school C 87 917
' C 88 917
claim C 89 917
to C 90 917
have C 91 917
the C 92 917
' C 93 917
right C 94 917
' C 95 917
concept C 96 917
of C 97 917
schizophrenia C 98 917
, C 99 917
since C 100 917
the C 101 917
etiology C 102 917
of C 103 917
schizophrenia C 104 917
, C 105 917
too C 106 917
, C 107 917
has C 108 917
not C 109 917
yet C 110 917
been C 111 917
discovered C 112 917
. C 113 917
in C 115 917
this C 116 917
particular C 117 917
' C 118 917
pre C 119 917
- C 120 917
scientific C 121 917
' C 122 917
situation C 123 917
of C 124 917
psychiatry C 125 917
it C 126 917
seems C 127 917
more C 128 917
promising C 129 917
to C 130 917
analyze C 131 917
the C 132 917
individual C 133 917
mental C 134 917
case C 135 917
and C 136 917
to C 137 917
concentrate C 138 917
on C 139 917
clinical C 140 917
symptomatology C 141 917
instead C 142 917
of C 143 917
discussing C 144 917
arbitrary C 145 917
' C 146 917
nosological C 147 917
entities C 148 917
' C 149 917
. C 150 917
families C 1 918
of C 2 918
children C 3 918
with C 4 918
early C 5 918
childhood C 6 918
schizophrenia C 7 918
. C 8 918
emotionally C 10 918
disturbed C 11 918
children C 12 918
were C 13 918
divided C 14 918
into C 15 918
3 C 16 918
groups C 17 918
on C 18 918
the C 19 918
basis C 20 918
of C 21 918
their C 22 918
diagnoses C 23 918
of C 24 918
: C 25 918
( C 26 918
1 C 27 918
) C 28 918
autism C 29 918
or C 30 918
symbiosis C 31 918
, C 32 918
( C 33 918
2 C 34 918
) C 35 918
chronic C 36 918
undifferentiated C 37 918
schizophrenia C 38 918
, C 39 918
and C 40 918
( C 41 918
3 C 42 918
) C 43 918
other C 44 918
forms C 45 918
of C 46 918
emotional C 47 918
disturbance C 48 918
. C 49 918
the C 51 918
3 C 52 918
groups C 53 918
were C 54 918
compared C 55 918
statistically C 56 918
on C 57 918
the C 58 918
following C 59 918
demographic C 60 918
measures C 61 918
: C 62 918
( C 63 918
1 C 64 918
) C 65 918
educational C 66 918
level C 67 918
of C 68 918
parents C 69 918
; C 70 918
( C 71 918
2 C 72 918
) C 73 918
occupational C 74 918
level C 75 918
of C 76 918
father C 77 918
; C 78 918
( C 79 918
3 C 80 918
) C 81 918
prevalence C 82 918
of C 83 918
broken C 84 918
homes C 85 918
; C 86 918
( C 87 918
4 C 88 918
) C 89 918
male C 90 918
- C 91 918
female C 92 918
ratio C 93 918
in C 94 918
each C 95 918
patient C 96 918
group C 97 918
; C 98 918
( C 99 918
5 C 100 918
) C 101 918
ordinal C 102 918
position C 103 918
among C 104 918
siblings C 105 918
; C 106 918
( C 107 918
6 C 108 918
) C 109 918
ordinal C 110 918
position C 111 918
among C 112 918
siblings C 113 918
of C 114 918
same C 115 918
sex C 116 918
; C 117 918
and C 118 918
( C 119 918
7 C 120 918
) C 121 918
age C 122 918
of C 123 918
parents C 124 918
at C 125 918
birth C 126 918
of C 127 918
child C 128 918
. C 129 918
results C 131 918
indicated C 132 918
that C 133 918
families C 134 918
of C 135 918
children C 136 918
diagnosed C 137 918
as C 138 918
autistic C 139 918
or C 140 918
symbiotic C 141 918
show C 142 918
many C 143 918
similarities C 144 918
to C 145 918
those C 146 918
with C 147 918
the C 148 918
diagnosis C 149 918
of C 150 918
chronic C 151 918
undifferentiated C 152 918
schizophrenia C 153 918
. C 154 918
in C 156 918
general C 157 918
, C 158 918
the C 159 918
parents C 160 918
in C 161 918
these C 162 918
2 C 163 918
groups C 164 918
were C 165 918
better C 166 918
educated C 167 918
and C 168 918
were C 169 918
employed C 170 918
in C 171 918
more C 172 918
highly C 173 918
rated C 174 918
occupations C 175 918
than C 176 918
parents C 177 918
of C 178 918
otherwise C 179 918
disturbed C 180 918
subjects C 181 918
. C 182 918
broken C 184 918
homes C 185 918
were C 186 918
prevalent C 187 918
in C 188 918
the C 189 918
group C 190 918
of C 191 918
disturbed C 192 918
nonschizophrenic C 193 918
children C 194 918
, C 195 918
but C 196 918
not C 197 918
in C 198 918
the C 199 918
autistic C 200 918
or C 201 918
chronic C 202 918
undifferentiated C 203 918
schizophrenic C 204 918
groups C 205 918
. C 206 918
the C 208 918
male C 209 918
- C 210 918
female C 211 918
ratio C 212 918
was C 213 918
not C 214 918
significantly C 215 918
different C 216 918
among C 217 918
the C 218 918
3 C 219 918
groups C 220 918
; C 221 918
in C 222 918
the C 223 918
autistic C 224 918
group C 225 918
, C 226 918
specifically C 227 918
, C 228 918
it C 229 918
was C 230 918
2 C 231 918
. C 232 918
. C 233 918
: C 234 918
1 C 235 918
. C 236 918
the C 238 918
data C 239 918
revealed C 240 918
no C 241 918
trend C 242 918
in C 243 918
ordinal C 244 918
position C 245 918
. C 246 918
childhood C 1 919
psychosis C 2 919
. C 3 919
a C 5 919
description C 6 919
is C 7 919
given C 8 919
of C 9 919
the C 10 919
diagnostic C 11 919
criteria C 12 919
put C 13 919
forward C 14 919
by C 15 919
creak C 16 919
and C 17 919
her C 18 919
associates C 19 919
in C 20 919
1961 C 21 919
for C 22 919
what C 23 919
they C 24 919
have C 25 919
called C 26 919
' C 27 919
schizophrenic C 28 919
syndrome C 29 919
of C 30 919
childhood C 31 919
' C 32 919
. C 33 919
psychotic C 35 919
reactions C 36 919
in C 37 919
childhood C 38 919
are C 39 919
grouped C 40 919
into C 41 919
: C 42 919
( C 43 919
1 C 44 919
) C 45 919
childhood C 46 919
schizophrenia C 47 919
, C 48 919
( C 49 919
2 C 50 919
) C 51 919
organic C 52 919
states C 53 919
with C 54 919
psychosis C 55 919
, C 56 919
( C 57 919
3 C 58 919
) C 59 919
mental C 60 919
subnormality C 61 919
with C 62 919
psychosis C 63 919
, C 64 919
( C 65 919
4 C 66 919
) C 67 919
sensory C 68 919
deprivation C 69 919
, C 70 919
( C 71 919
5 C 72 919
) C 73 919
neurosis C 74 919
, C 75 919
and C 76 919
( C 77 919
6 C 78 919
) C 79 919
manic C 80 919
- C 81 919
depressive C 82 919
psychosis C 83 919
. C 84 919
it C 86 919
is C 87 919
suggested C 88 919
that C 89 919
the C 90 919
generic C 91 919
term C 92 919
' C 93 919
psychosis C 94 919
' C 95 919
is C 96 919
the C 97 919
best C 98 919
available C 99 919
, C 100 919
and C 101 919
a C 102 919
classification C 103 919
is C 104 919
presented C 105 919
and C 106 919
discussed C 107 919
. C 108 919
psychotic C 1 920
reactions C 2 920
of C 3 920
childhood C 4 920
: C 5 920
experiences C 6 920
of C 7 920
a C 8 920
mental C 9 920
retardation C 10 920
pilot C 11 920
project C 12 920
. C 13 920
clinical C 15 920
team C 16 920
evaluations C 17 920
are C 18 920
presented C 19 920
of C 20 920
a C 21 920
group C 22 920
of C 23 920
32 C 24 920
psychotic C 25 920
children C 26 920
who C 27 920
were C 28 920
initially C 29 920
thought C 30 920
to C 31 920
be C 32 920
mentally C 33 920
retarded C 34 920
. C 35 920
emphasis C 37 920
is C 38 920
placed C 39 920
on C 40 920
consideration C 41 920
of C 42 920
as C 43 920
many C 44 920
aspects C 45 920
of C 46 920
the C 47 920
total C 48 920
picture C 49 920
as C 50 920
possible C 51 920
with C 52 920
diagnosis C 53 920
resulting C 54 920
from C 55 920
a C 56 920
synthesis C 57 920
of C 58 920
the C 59 920
individual C 60 920
pieces C 61 920
of C 62 920
information C 63 920
. C 64 920
caution C 66 920
is C 67 920
suggested C 68 920
regarding C 69 920
interpretation C 70 920
of C 71 920
incomplete C 72 920
psychological C 73 920
test C 74 920
findings C 75 920
, C 76 920
especially C 77 920
in C 78 920
regard C 79 920
to C 80 920
prognosis C 81 920
. C 82 920
the C 84 920
results C 85 920
of C 86 920
this C 87 920
study C 88 920
offer C 89 920
guidelines C 90 920
for C 91 920
differential C 92 920
diagnosis C 93 920
between C 94 920
psychosis C 95 920
resulting C 96 920
from C 97 920
primary C 98 920
emotional C 99 920
disorders C 100 920
and C 101 920
psychosis C 102 920
superimposed C 103 920
on C 104 920
a C 105 920
chronic C 106 920
brain C 107 920
syndrome C 108 920
in C 109 920
children C 110 920
. C 111 920
questions C 113 920
are C 114 920
raised C 115 920
about C 116 920
early C 117 920
infantile C 118 920
autism C 119 920
as C 120 920
a C 121 920
unitary C 122 920
syndrome C 123 920
on C 124 920
the C 125 920
basis C 126 920
of C 127 920
etiology C 128 920
. C 129 920
the C 131 920
need C 132 920
for C 133 920
a C 134 920
better C 135 920
and C 136 920
more C 137 920
comprehensive C 138 920
diagnostic C 139 920
classification C 140 920
of C 141 920
the C 142 920
psychotic C 143 920
reactions C 144 920
of C 145 920
infancy C 146 920
and C 147 920
early C 148 920
childhood C 149 920
is C 150 920
stressed C 151 920
. C 152 920
this C 154 920
must C 155 920
be C 156 920
developed C 157 920
before C 158 920
valid C 159 920
comparisons C 160 920
of C 161 920
treatment C 162 920
and C 163 920
prognostic C 164 920
considerations C 165 920
can C 166 920
be C 167 920
made C 168 920
among C 169 920
groups C 170 920
of C 171 920
clinicians C 172 920
working C 173 920
in C 174 920
the C 175 920
field C 176 920
. C 177 920
modification C 1 921
of C 2 921
autistic C 3 921
behavior C 4 921
with C 5 921
lsd C 6 921
- C 7 921
25 C 8 921
. C 9 921
lsd C 11 921
- C 12 921
25 C 13 921
appears C 14 921
to C 15 921
offer C 16 921
a C 17 921
useful C 18 921
adjunct C 19 921
to C 20 921
the C 21 921
psychotherapy C 22 921
of C 23 921
autistic C 24 921
children C 25 921
because C 26 921
of C 27 921
its C 28 921
positive C 29 921
effect C 30 921
in C 31 921
areas C 32 921
which C 33 921
are C 34 921
closely C 35 921
related C 36 921
to C 37 921
the C 38 921
process C 39 921
of C 40 921
psychotherapy C 41 921
. C 42 921
a C 44 921
pair C 45 921
of C 46 921
identical C 47 921
male C 48 921
autistic C 49 921
twins C 50 921
was C 51 921
periodically C 52 921
administered C 53 921
50 C 54 921
of C 55 921
lsd C 56 921
- C 57 921
25 C 58 921
and C 59 921
observed C 60 921
for C 61 921
behavior C 62 921
changes C 63 921
. C 64 921
control C 66 921
and C 67 921
drug C 68 921
observations C 69 921
were C 70 921
made C 71 921
while C 72 921
the C 73 921
subjects C 74 921
were C 75 921
placed C 76 921
in C 77 921
a C 78 921
series C 79 921
of C 80 921
standard C 81 921
test C 82 921
situations C 83 921
referred C 84 921
to C 85 921
as C 86 921
the C 87 921
socialization C 88 921
test C 89 921
, C 90 921
social C 91 921
isolation C 92 921
test C 93 921
, C 94 921
peek C 95 921
- C 96 921
a C 97 921
- C 98 921
boo C 99 921
, C 100 921
pat C 101 921
- C 102 921
a C 103 921
- C 104 921
cake C 105 921
, C 106 921
face C 107 921
- C 108 921
to C 109 921
- C 110 921
face C 111 921
, C 112 921
hand C 113 921
- C 114 921
holding C 115 921
and C 116 921
following C 117 921
tests C 118 921
. C 119 921
diverse C 121 921
behaviors C 122 921
were C 123 921
recorded C 124 921
in C 125 921
the C 126 921
areas C 127 921
of C 128 921
self C 129 921
- C 130 921
stimulatory C 131 921
behavior C 132 921
, C 133 921
social C 134 921
interaction C 135 921
and C 136 921
affect C 137 921
. C 138 921
recordings C 140 921
were C 141 921
made C 142 921
using C 143 921
an C 144 921
esterline C 145 921
angus C 146 921
multiple C 147 921
pen C 148 921
recorder C 149 921
. C 150 921
all C 152 921
behaviors C 153 921
were C 154 921
measured C 155 921
in C 156 921
total C 157 921
time C 158 921
appearance C 159 921
and C 160 921
plotted C 161 921
as C 162 921
percent C 163 921
time C 164 921
in C 165 921
appearance C 166 921
. C 167 921
consistent C 169 921
behavioral C 170 921
changes C 171 921
resulted C 172 921
after C 173 921
lsd C 174 921
in C 175 921
that C 176 921
the C 177 921
subjects C 178 921
demonstrated C 179 921
an C 180 921
increase C 181 921
in C 182 921
eye C 183 921
- C 184 921
to C 185 921
- C 186 921
face C 187 921
contact C 188 921
, C 189 921
an C 190 921
increase C 191 921
in C 192 921
laughter C 193 921
and C 194 921
smiling C 195 921
behavior C 196 921
and C 197 921
decrease C 198 921
in C 199 921
self C 200 921
- C 201 921
stimulatory C 202 921
behavior C 203 921
. C 204 921
the C 1 922
influence C 2 922
of C 3 922
organic C 4 922
and C 5 922
emotional C 6 922
factors C 7 922
on C 8 922
the C 9 922
origins C 10 922
, C 11 922
nature C 12 922
and C 13 922
outcome C 14 922
of C 15 922
childhood C 16 922
psychosis C 17 922
. C 18 922
a C 20 922
group C 21 922
of C 22 922
65 C 23 922
children C 24 922
diagnosed C 25 922
as C 26 922
' C 27 922
child C 28 922
psychosis C 29 922
' C 30 922
( C 31 922
or C 32 922
one C 33 922
of C 34 922
its C 35 922
synonyms C 36 922
) C 37 922
was C 38 922
followed C 39 922
up C 40 922
for C 41 922
an C 42 922
average C 43 922
of C 44 922
15 C 45 922
yr C 46 922
. C 47 922
none C 49 922
of C 50 922
the C 51 922
parents C 52 922
were C 53 922
schizophrenic C 54 922
; C 55 922
6 C 56 922
( C 57 922
10 C 58 922
% C 59 922
) C 60 922
had C 61 922
a C 62 922
parent C 63 922
who C 64 922
had C 65 922
psychiatric C 66 922
treatment C 67 922
for C 68 922
neurosis C 69 922
. C 70 922
only C 72 922
2 C 73 922
children C 74 922
had C 75 922
a C 76 922
sib C 77 922
with C 78 922
transient C 79 922
autistic C 80 922
episode C 81 922
. C 82 922
none C 84 922
had C 85 922
sibs C 86 922
with C 87 922
the C 88 922
adult C 89 922
type C 90 922
of C 91 922
schizophrenia C 92 922
. C 93 922
these C 95 922
findings C 96 922
are C 97 922
felt C 98 922
to C 99 922
militate C 100 922
against C 101 922
the C 102 922
view C 103 922
that C 104 922
child C 105 922
psychosis C 106 922
is C 107 922
part C 108 922
of C 109 922
the C 110 922
schizophrenic C 111 922
group C 112 922
. C 113 922
among C 115 922
the C 116 922
65 C 117 922
children C 118 922
: C 119 922
40 C 120 922
% C 121 922
had C 122 922
an C 123 922
i C 124 922
. C 125 922
. C 126 922
. C 127 922
below C 129 922
50 C 130 922
, C 131 922
40 C 132 922
% C 133 922
between C 134 922
50 C 135 922
and C 136 922
80 C 137 922
and C 138 922
only C 139 922
20 C 140 922
% C 141 922
above C 142 922
80 C 143 922
. C 144 922
the C 146 922
i C 147 922
. C 148 922
. C 149 922
. C 150 922
was C 152 922
found C 153 922
in C 154 922
general C 155 922
to C 156 922
be C 157 922
a C 158 922
good C 159 922
predictor C 160 922
of C 161 922
later C 162 922
performances C 163 922
. C 164 922
mental C 166 922
retardation C 167 922
is C 168 922
regarded C 169 922
as C 170 922
a C 171 922
primary C 172 922
component C 173 922
of C 174 922
the C 175 922
clinical C 176 922
picture C 177 922
. C 178 922
evidence C 180 922
of C 181 922
brain C 182 922
damage C 183 922
was C 184 922
conclusive C 185 922
in C 186 922
15 C 187 922
children C 188 922
( C 189 922
24 C 190 922
% C 191 922
) C 192 922
who C 193 922
showed C 194 922
epileptic C 195 922
attacks C 196 922
( C 197 922
developing C 198 922
in C 199 922
10 C 200 922
of C 201 922
them C 202 922
during C 203 922
the C 204 922
follow C 205 922
- C 206 922
up C 207 922
) C 208 922
. C 209 922
speech C 211 922
disorders C 212 922
were C 213 922
the C 214 922
most C 215 922
outstanding C 216 922
manifestation C 217 922
. C 218 922
five C 220 922
children C 221 922
had C 222 922
confirmed C 223 922
receptive C 224 922
aphasia C 225 922
and C 226 922
14 C 227 922
others C 228 922
show C 229 922
some C 230 922
evidence C 231 922
of C 232 922
it C 233 922
. C 234 922
in C 236 922
75 C 237 922
% C 238 922
of C 239 922
the C 240 922
speaking C 241 922
children C 242 922
echolalia C 243 922
was C 244 922
noted C 245 922
; C 246 922
11 C 247 922
% C 248 922
had C 249 922
abnormalities C 250 922
of C 251 922
delivering C 252 922
spoken C 253 922
words C 254 922
. C 255 922
the C 257 922
view C 258 922
that C 259 922
reduction C 260 922
of C 261 922
speech C 262 922
is C 263 922
due C 264 922
to C 265 922
social C 266 922
withdrawal C 267 922
is C 268 922
rejected C 269 922
. C 270 922
psychogenic C 272 922
factors C 273 922
and C 274 922
parental C 275 922
attitude C 276 922
were C 277 922
not C 278 922
found C 279 922
to C 280 922
be C 281 922
relevant C 282 922
to C 283 922
the C 284 922
etiology C 285 922
. C 286 922
the C 288 922
psychosis C 289 922
is C 290 922
not C 291 922
considered C 292 922
primarily C 293 922
emotional C 294 922
in C 295 922
origin C 296 922
, C 297 922
although C 298 922
emotional C 299 922
relationships C 300 922
as C 301 922
well C 302 922
as C 303 922
educational C 304 922
management C 305 922
have C 306 922
considerable C 307 922
influence C 308 922
on C 309 922
the C 310 922
outcome C 311 922
of C 312 922
the C 313 922
disease C 314 922
. C 315 922
compliance C 1 923
and C 2 923
resistance C 3 923
in C 4 923
the C 5 923
conditioning C 6 923
of C 7 923
autistic C 8 923
children C 9 923
: C 10 923
an C 11 923
exploratory C 12 923
study C 13 923
. C 14 923
twelve C 16 923
autistic C 17 923
children C 18 923
between C 19 923
4 C 20 923
and C 21 923
9 C 22 923
yr C 23 923
of C 24 923
age C 25 923
were C 26 923
asked C 27 923
to C 28 923
choose C 29 923
red C 30 923
objects C 31 923
and C 32 923
square C 33 923
objects C 34 923
from C 35 923
a C 36 923
stimulus C 37 923
array C 38 923
. C 39 923
ten C 41 923
subjects C 42 923
made C 43 923
correct C 44 923
choices C 45 923
significantly C 46 923
less C 47 923
often C 48 923
than C 49 923
chance C 50 923
, C 51 923
that C 52 923
is C 53 923
, C 54 923
they C 55 923
avoided C 56 923
emitting C 57 923
correct C 58 923
responses C 59 923
. C 60 923
the C 62 923
subjects C 63 923
were C 64 923
given C 65 923
60 C 66 923
conditioning C 67 923
trials C 68 923
in C 69 923
which C 70 923
choices C 71 923
of C 72 923
either C 73 923
red C 74 923
or C 75 923
square C 76 923
objects C 77 923
were C 78 923
reinforced C 79 923
. C 80 923
those C 82 923
who C 83 923
attained C 84 923
either C 85 923
concept C 86 923
subsequently C 87 923
performed C 88 923
perfectly C 89 923
when C 90 923
asked C 91 923
to C 92 923
produce C 93 923
both C 94 923
red C 95 923
and C 96 923
square C 97 923
concepts C 98 923
; C 99 923
the C 100 923
other C 101 923
subjects C 102 923
continued C 103 923
giving C 104 923
fewer C 105 923
- C 106 923
than C 107 923
- C 108 923
chance C 109 923
correct C 110 923
responses C 111 923
. C 112 923
thus C 114 923
, C 115 923
conditioning C 116 923
trials C 117 923
elicited C 118 923
in C 119 923
some C 120 923
subjects C 121 923
an C 122 923
increased C 123 923
tendency C 124 923
to C 125 923
comply C 126 923
with C 127 923
the C 128 923
experimenter C 129 923
' C 130 923
s C 131 923
instructions C 132 923
. C 133 923
the C 135 923
results C 136 923
suggest C 137 923
that C 138 923
more C 139 923
attention C 140 923
should C 141 923
be C 142 923
paid C 143 923
to C 144 923
the C 145 923
distinction C 146 923
between C 147 923
responses C 148 923
that C 149 923
autistic C 150 923
children C 151 923
are C 152 923
unable C 153 923
to C 154 923
make C 155 923
and C 156 923
responses C 157 923
that C 158 923
they C 159 923
are C 160 923
unwilling C 161 923
to C 162 923
make C 163 923
. C 164 923
the C 1 924
etiology C 2 924
of C 3 924
autistic C 4 924
syndromes C 5 924
of C 6 924
children C 7 924
. C 8 924
examination C 10 924
and C 11 924
treatment C 12 924
of C 13 924
92 C 14 924
children C 15 924
and C 16 924
youths C 17 924
with C 18 924
the C 19 924
autistic C 20 924
syndromes C 21 924
of C 22 924
early C 23 924
childhood C 24 924
over C 25 924
a C 26 924
period C 27 924
of C 28 924
ten C 29 924
years C 30 924
led C 31 924
to C 32 924
the C 33 924
impression C 34 924
that C 35 924
these C 36 924
disorders C 37 924
are C 38 924
a C 39 924
primary C 40 924
organic C 41 924
syndrome C 42 924
of C 43 924
manifold C 44 924
etiology C 45 924
. C 46 924
this C 48 924
view C 49 924
is C 50 924
supported C 51 924
by C 52 924
many C 53 924
relevant C 54 924
clinical C 55 924
experiences C 56 924
and C 57 924
data C 58 924
, C 59 924
which C 60 924
are C 61 924
discussed C 62 924
in C 63 924
detail C 64 924
. C 65 924
acquisition C 1 925
of C 2 925
imitative C 3 925
speech C 4 925
by C 5 925
schizophrenic C 6 925
children C 7 925
. C 8 925
two C 10 925
mute C 11 925
schizophrenic C 12 925
children C 13 925
were C 14 925
taught C 15 925
imitative C 16 925
speech C 17 925
within C 18 925
an C 19 925
operant C 20 925
conditioning C 21 925
framework C 22 925
. C 23 925
the C 25 925
training C 26 925
procedure C 27 925
consisted C 28 925
of C 29 925
a C 30 925
series C 31 925
of C 32 925
increasingly C 33 925
fine C 34 925
verbal C 35 925
discriminations C 36 925
; C 37 925
the C 38 925
children C 39 925
were C 40 925
rewarded C 41 925
for C 42 925
closer C 43 925
and C 44 925
closer C 45 925
reproductions C 46 925
of C 47 925
the C 48 925
attending C 49 925
adults C 50 925
' C 51 925
speech C 52 925
. C 53 925
it C 55 925
is C 56 925
found C 57 925
that C 58 925
reward C 59 925
delivered C 60 925
contingent C 61 925
upon C 62 925
imitation C 63 925
was C 64 925
necessary C 65 925
for C 66 925
development C 67 925
of C 68 925
imitation C 69 925
. C 70 925
furthermore C 72 925
, C 73 925
the C 74 925
newly C 75 925
established C 76 925
imitation C 77 925
was C 78 925
shown C 79 925
to C 80 925
have C 81 925
acquired C 82 925
rewarding C 83 925
properties C 84 925
for C 85 925
the C 86 925
children C 87 925
. C 88 925
hallucinations C 1 926
in C 2 926
children C 3 926
at C 4 926
a C 5 926
state C 6 926
hospital C 7 926
. C 8 926
hallucinations C 10 926
in C 11 926
children C 12 926
at C 13 926
referral C 14 926
and C 15 926
upon C 16 926
admission C 17 926
to C 18 926
a C 19 926
state C 20 926
hospital C 21 926
were C 22 926
studied C 23 926
by C 24 926
reviewing C 25 926
randomly C 26 926
selected C 27 926
charts C 28 926
of C 29 926
current C 30 926
patients C 31 926
. C 32 926
there C 34 926
were C 35 926
no C 36 926
significant C 37 926
differences C 38 926
in C 39 926
the C 40 926
incidence C 41 926
of C 42 926
hallucinations C 43 926
in C 44 926
boys C 45 926
and C 46 926
girls C 47 926
, C 48 926
between C 49 926
racial C 50 926
groups C 51 926
, C 52 926
and C 53 926
between C 54 926
schizophrenic C 55 926
children C 56 926
under C 57 926
12 C 58 926
and C 59 926
over C 60 926
12 C 61 926
. C 62 926
the C 64 926
children C 65 926
diagnosed C 66 926
psychosis C 67 926
with C 68 926
convulsive C 69 926
disorder C 70 926
had C 71 926
the C 72 926
highest C 73 926
incidence C 74 926
of C 75 926
hallucinations C 76 926
( C 77 926
81 C 78 926
% C 79 926
) C 80 926
; C 81 926
those C 82 926
diagnosed C 83 926
childhood C 84 926
schizophrenia C 85 926
had C 86 926
an C 87 926
incidence C 88 926
of C 89 926
70 C 90 926
% C 91 926
; C 92 926
and C 93 926
children C 94 926
diagnosed C 95 926
primary C 96 926
behavior C 97 926
disorder C 98 926
had C 99 926
the C 100 926
lowest C 101 926
incidence C 102 926
( C 103 926
35 C 104 926
% C 105 926
) C 106 926
. C 107 926
specific C 109 926
auditory C 110 926
, C 111 926
visual C 112 926
, C 113 926
and C 114 926
olfactory C 115 926
hallucinations C 116 926
were C 117 926
described C 118 926
. C 119 926
the C 121 926
nature C 122 926
of C 123 926
hallucinations C 124 926
in C 125 926
boys C 126 926
and C 127 926
girls C 128 926
was C 129 926
similar C 130 926
. C 131 926
psychotic C 133 926
children C 134 926
tended C 135 926
to C 136 926
have C 137 926
more C 138 926
bizarre C 139 926
hallucinations C 140 926
than C 141 926
nonpsychotic C 142 926
children C 143 926
. C 144 926
there C 146 926
was C 147 926
no C 148 926
difference C 149 926
in C 150 926
the C 151 926
nature C 152 926
of C 153 926
hallucinations C 154 926
among C 155 926
the C 156 926
different C 157 926
groups C 158 926
of C 159 926
psychotic C 160 926
children C 161 926
. C 162 926
although C 164 926
this C 165 926
population C 166 926
consisted C 167 926
of C 168 926
severely C 169 926
disturbed C 170 926
and C 171 926
deprived C 172 926
children C 173 926
who C 174 926
had C 175 926
a C 176 926
high C 177 926
incidence C 178 926
of C 179 926
hallucinations C 180 926
, C 181 926
these C 182 926
hallucinations C 183 926
were C 184 926
of C 185 926
simple C 186 926
content C 187 926
and C 188 926
not C 189 926
organized C 190 926
into C 191 926
delusional C 192 926
systems C 193 926
. C 194 926
treatment C 1 927
of C 2 927
childhood C 3 927
schizophrenia C 4 927
. C 5 927
a C 7 927
three C 8 927
- C 9 927
year C 10 927
comparison C 11 927
of C 12 927
day C 13 927
and C 14 927
residential C 15 927
treatment C 16 927
. C 17 927
a C 19 927
carefully C 20 927
designed C 21 927
study C 22 927
of C 23 927
13 C 24 927
day C 25 927
- C 26 927
treatment C 27 927
children C 28 927
matched C 29 927
individually C 30 927
with C 31 927
13 C 32 927
residential C 33 927
children C 34 927
is C 35 927
presented C 36 927
. C 37 927
in C 39 927
each C 40 927
case C 41 927
the C 42 927
diagnosis C 43 927
of C 44 927
schizophrenia C 45 927
was C 46 927
carefully C 47 927
confirmed C 48 927
on C 49 927
the C 50 927
basis C 51 927
of C 52 927
impairment C 53 927
in C 54 927
human C 55 927
relationship C 56 927
, C 57 927
disturbance C 58 927
in C 59 927
personal C 60 927
identity C 61 927
, C 62 927
resistance C 63 927
to C 64 927
change C 65 927
, C 66 927
unusual C 67 927
preoccupations C 68 927
, C 69 927
perceptual C 70 927
and C 71 927
cognitive C 72 927
disorders C 73 927
, C 74 927
and C 75 927
panic C 76 927
reactions C 77 927
. C 78 927
the C 80 927
ages C 81 927
ranged C 82 927
between C 83 927
6 C 84 927
and C 85 927
11 C 86 927
. C 87 927
the C 89 927
children C 90 927
were C 91 927
selected C 92 927
, C 93 927
as C 94 927
the C 95 927
result C 96 927
of C 97 927
matching C 98 927
, C 99 927
with C 100 927
regard C 101 927
to C 102 927
age C 103 927
of C 104 927
onset C 105 927
, C 106 927
culture C 107 927
, C 108 927
and C 109 927
family C 110 927
organization C 111 927
. C 112 927
intactness C 114 927
of C 115 927
the C 116 927
family C 117 927
structure C 118 927
was C 119 927
required C 120 927
. C 121 927
residential C 123 927
treatment C 124 927
implied C 125 927
round C 126 927
- C 127 927
the C 128 927
- C 129 927
clock C 130 927
therapeutic C 131 927
interaction C 132 927
with C 133 927
the C 134 927
child C 135 927
for C 136 927
7 C 137 927
days C 138 927
each C 139 927
week C 140 927
, C 141 927
12 C 142 927
mth C 143 927
of C 144 927
the C 145 927
year C 146 927
. C 147 927
day C 149 927
treatment C 150 927
consisted C 151 927
of C 152 927
9 C 153 927
a C 154 927
. C 155 927
. C 156 927
. C 157 927
to C 159 927
4 C 160 927
: C 161 927
30 C 162 927
p C 163 927
. C 164 927
. C 165 927
. C 166 927
care C 168 927
5 C 169 927
days C 170 927
a C 171 927
week C 172 927
for C 173 927
9 C 174 927
mth C 175 927
of C 176 927
the C 177 927
year C 178 927
. C 179 927
staff C 181 927
distribution C 182 927
was C 183 927
identical C 184 927
in C 185 927
the C 186 927
2 C 187 927
groups C 188 927
, C 189 927
but C 190 927
in C 191 927
the C 192 927
day C 193 927
- C 194 927
care C 195 927
group C 196 927
the C 197 927
teacher C 198 927
assumed C 199 927
a C 200 927
larger C 201 927
relative C 202 927
position C 203 927
in C 204 927
the C 205 927
world C 206 927
established C 207 927
for C 208 927
the C 209 927
child C 210 927
. C 211 927
all C 213 927
children C 214 927
were C 215 927
matched C 216 927
in C 217 927
ego C 218 927
status C 219 927
at C 220 927
the C 221 927
beginning C 222 927
of C 223 927
the C 224 927
experiment C 225 927
by C 226 927
means C 227 927
of C 228 927
the C 229 927
wisc C 230 927
and C 231 927
psychiatric C 232 927
evaluation C 233 927
, C 234 927
changes C 235 927
in C 236 927
this C 237 927
status C 238 927
being C 239 927
measured C 240 927
by C 241 927
the C 242 927
wisc C 243 927
and C 244 927
the C 245 927
metropolitan C 246 927
achievement C 247 927
test C 248 927
series C 249 927
. C 250 927
the C 252 927
results C 253 927
indicated C 254 927
no C 255 927
significant C 256 927
improvement C 257 927
in C 258 927
either C 259 927
day C 260 927
or C 261 927
residence C 262 927
in C 263 927
those C 264 927
schizophrenic C 265 927
children C 266 927
who C 267 927
, C 268 927
on C 269 927
admission C 270 927
had C 271 927
unscorable C 272 927
wisc C 273 927
tests C 274 927
and C 275 927
who C 276 927
were C 277 927
the C 278 927
most C 279 927
severely C 280 927
impaired C 281 927
in C 282 927
ego C 283 927
structure C 284 927
. C 285 927
among C 287 927
the C 288 927
children C 289 927
scorable C 290 927
on C 291 927
the C 292 927
wisc C 293 927
, C 294 927
the C 295 927
organic C 296 927
groups C 297 927
in C 298 927
day C 299 927
and C 300 927
in C 301 927
residential C 302 927
treatment C 303 927
showed C 304 927
equivalent C 305 927
degrees C 306 927
of C 307 927
progress C 308 927
, C 309 927
the C 310 927
non C 311 927
- C 312 927
organic C 313 927
children C 314 927
in C 315 927
residence C 316 927
gave C 317 927
evidence C 318 927
of C 319 927
more C 320 927
improvement C 321 927
than C 322 927
did C 323 927
the C 324 927
matched C 325 927
children C 326 927
in C 327 927
day C 328 927
treatment C 329 927
. C 330 927
visual C 1 928
versus C 2 928
tactual C 3 928
receptor C 4 928
preference C 5 928
in C 6 928
normal C 7 928
and C 8 928
schizophrenic C 9 928
children C 10 928
. C 11 928
receptor C 13 928
preferences C 14 928
between C 15 928
visual C 16 928
or C 17 928
tactual C 18 928
stimuli C 19 928
were C 20 928
measured C 21 928
in C 22 928
schizophrenic C 23 928
and C 24 928
normal C 25 928
children C 26 928
; C 27 928
4 C 28 928
pairs C 29 928
of C 30 928
standardized C 31 928
choice C 32 928
situations C 33 928
between C 34 928
visual C 35 928
or C 36 928
tactual C 37 928
stimuli C 38 928
were C 39 928
used C 40 928
, C 41 928
with C 42 928
the C 43 928
time C 44 928
of C 45 928
engagement C 46 928
with C 47 928
either C 48 928
stimulus C 49 928
constituting C 50 928
the C 51 928
preference C 52 928
measure C 53 928
. C 54 928
schizophrenic C 56 928
children C 57 928
between C 58 928
the C 59 928
ages C 60 928
of C 61 928
7 C 62 928
and C 63 928
9 C 64 928
were C 65 928
compared C 66 928
with C 67 928
same C 68 928
aged C 69 928
normal C 70 928
children C 71 928
. C 72 928
a C 74 928
group C 75 928
of C 76 928
retardates C 77 928
were C 78 928
used C 79 928
for C 80 928
ma C 81 928
control C 82 928
. C 83 928
schizophrenics C 85 928
were C 86 928
significantly C 87 928
lower C 88 928
in C 89 928
visual C 90 928
preference C 91 928
than C 92 928
the C 93 928
same C 94 928
aged C 95 928
normals C 96 928
, C 97 928
and C 98 928
an C 99 928
age C 100 928
trend C 101 928
for C 102 928
increased C 103 928
visual C 104 928
preference C 105 928
was C 106 928
found C 107 928
in C 108 928
the C 109 928
normal C 110 928
sample C 111 928
. C 112 928
retardates C 114 928
showed C 115 928
greater C 116 928
visual C 117 928
preference C 118 928
than C 119 928
schizophrenics C 120 928
of C 121 928
comparable C 122 928
ma C 123 928
. C 124 928
some C 126 928
implications C 127 928
for C 128 928
theory C 129 928
of C 130 928
schizophrenia C 131 928
were C 132 928
discussed C 133 928
. C 134 928
the C 1 929
effect C 2 929
of C 3 929
folic C 4 929
acid C 5 929
on C 6 929
growth C 7 929
and C 8 929
deoxyribonucleic C 9 929
acid C 10 929
synthesis C 11 929
in C 12 929
the C 13 929
rat C 14 929
kidney C 15 929
. C 16 929
the C 18 929
effect C 19 929
of C 20 929
a C 21 929
single C 22 929
injection C 23 929
of C 24 929
folic C 25 929
acid C 26 929
( C 27 929
250 C 28 929
mg C 29 929
/ C 30 929
kg C 31 929
of C 32 929
body C 33 929
wt C 34 929
) C 35 929
on C 36 929
growth C 37 929
of C 38 929
the C 39 929
rat C 40 929
kidney C 41 929
was C 42 929
studied C 43 929
. C 44 929
the C 46 929
patterns C 47 929
of C 48 929
the C 49 929
response C 50 929
were C 51 929
found C 52 929
to C 53 929
be C 54 929
essentially C 55 929
similar C 56 929
in C 57 929
animals C 58 929
aged C 59 929
between C 60 929
3 C 61 929
wk C 62 929
and C 63 929
12 C 64 929
mth C 65 929
. C 66 929
maximum C 68 929
values C 69 929
of C 70 929
kidney C 71 929
weight C 72 929
and C 73 929
nucleic C 74 929
acid C 75 929
content C 76 929
, C 77 929
relative C 78 929
to C 79 929
body C 80 929
weight C 81 929
, C 82 929
were C 83 929
found C 84 929
at C 85 929
4 C 86 929
days C 87 929
at C 88 929
folate C 89 929
administration C 90 929
. C 91 929
the C 93 929
increases C 94 929
in C 95 929
wet C 96 929
and C 97 929
dry C 98 929
weights C 99 929
at C 100 929
this C 101 929
time C 102 929
were C 103 929
approx C 104 929
. C 105 929
80 C 107 929
% C 108 929
and C 109 929
30 C 110 929
% C 111 929
resp C 112 929
. C 113 929
above C 115 929
the C 116 929
control C 117 929
weights C 118 929
, C 119 929
and C 120 929
the C 121 929
percentage C 122 929
dry C 123 929
matter C 124 929
of C 125 929
the C 126 929
kidney C 127 929
was C 128 929
significantly C 129 929
lower C 130 929
than C 131 929
normal C 132 929
during C 133 929
this C 134 929
period C 135 929
. C 136 929
at C 138 929
4 C 139 929
days C 140 929
the C 141 929
rna C 142 929
content C 143 929
of C 144 929
the C 145 929
kidney C 146 929
was C 147 929
also C 148 929
maximal C 149 929
, C 150 929
being C 151 929
about C 152 929
90 C 153 929
% C 154 929
greater C 155 929
than C 156 929
the C 157 929
control C 158 929
value C 159 929
, C 160 929
and C 161 929
the C 162 929
dna C 163 929
content C 164 929
after C 165 929
4 C 166 929
days C 167 929
was C 168 929
increased C 169 929
by C 170 929
about C 171 929
60 C 172 929
% C 173 929
. C 174 929
whereas C 176 929
the C 177 929
dna C 178 929
values C 179 929
in C 180 929
6 C 181 929
- C 182 929
wk C 183 929
- C 184 929
old C 185 929
rats C 186 929
were C 187 929
slightly C 188 929
lower C 189 929
at C 190 929
7 C 191 929
and C 192 929
10 C 193 929
days C 194 929
than C 195 929
at C 196 929
4 C 197 929
days C 198 929
, C 199 929
in C 200 929
12 C 201 929
- C 202 929
mth C 203 929
- C 204 929
old C 205 929
animals C 206 929
a C 207 929
further C 208 929
small C 209 929
increase C 210 929
was C 211 929
observed C 212 929
at C 213 929
7 C 214 929
days C 215 929
, C 216 929
suggesting C 217 929
a C 218 929
prolongation C 219 929
of C 220 929
dna C 221 929
synthesis C 222 929
in C 223 929
the C 224 929
older C 225 929
animals C 226 929
. C 227 929
autoradiographic C 229 929
studies C 230 929
of C 231 929
dna C 232 929
synthesis C 233 929
with C 234 929
thymidine C 235 929
- C 236 929
h C 237 929
have C 238 929
shown C 239 929
a C 240 929
greatly C 241 929
increased C 242 929
labeling C 243 929
index C 244 929
in C 245 929
all C 246 929
zones C 247 929
of C 248 929
the C 249 929
kidney C 250 929
following C 251 929
folate C 252 929
injection C 253 929
. C 254 929
maximum C 256 929
values C 257 929
were C 258 929
observed C 259 929
at C 260 929
48 C 261 929
hr C 262 929
in C 263 929
the C 264 929
cortical C 265 929
zone C 266 929
, C 267 929
but C 268 929
the C 269 929
patterns C 270 929
of C 271 929
the C 272 929
changes C 273 929
in C 274 929
the C 275 929
medulla C 276 929
were C 277 929
less C 278 929
well C 279 929
defined C 280 929
. C 281 929
the C 283 929
labelling C 284 929
indices C 285 929
in C 286 929
the C 287 929
kidneys C 288 929
of C 289 929
12 C 290 929
- C 291 929
mth C 292 929
- C 293 929
old C 294 929
rats C 295 929
remained C 296 929
above C 297 929
normal C 298 929
for C 299 929
a C 300 929
longer C 301 929
period C 302 929
than C 303 929
in C 304 929
6 C 305 929
- C 306 929
wk C 307 929
- C 308 929
old C 309 929
rats C 310 929
. C 311 929
these C 313 929
results C 314 929
concur C 315 929
with C 316 929
the C 317 929
evidence C 318 929
of C 319 929
an C 320 929
increased C 321 929
dna C 322 929
contents C 323 929
of C 324 929
the C 325 929
kidneys C 326 929
of C 327 929
older C 328 929
rats C 329 929
between C 330 929
4 C 331 929
and C 332 929
7 C 333 929
days C 334 929
after C 335 929
folate C 336 929
. C 337 929
renal C 1 930
renin C 2 930
in C 3 930
unilaterally C 4 930
nephrectomized C 5 930
hypertensive C 6 930
rats C 7 930
. C 8 930
juxtaglomerular C 10 930
index C 11 930
, C 12 930
renal C 13 930
pressor C 14 930
activity C 15 930
and C 16 930
width C 17 930
of C 18 930
the C 19 930
zona C 20 930
glomerulosa C 21 930
were C 22 930
normal C 23 930
in C 24 930
unilaterally C 25 930
nephrectomized C 26 930
hypertensive C 27 930
rats C 28 930
maintained C 29 930
on C 30 930
a C 31 930
normal C 32 930
sodium C 33 930
intake C 34 930
, C 35 930
increased C 36 930
in C 37 930
those C 38 930
subjected C 39 930
to C 40 930
sodium C 41 930
depletion C 42 930
and C 43 930
decreased C 44 930
in C 45 930
those C 46 930
receiving C 47 930
1 C 48 930
% C 49 930
saline C 50 930
. C 51 930
this C 53 930
indicates C 54 930
that C 55 930
renin C 56 930
formation C 57 930
and C 58 930
secretion C 59 930
are C 60 930
most C 61 930
likely C 62 930
the C 63 930
result C 64 930
of C 65 930
the C 66 930
sodium C 67 930
state C 68 930
of C 69 930
the C 70 930
animal C 71 930
rather C 72 930
than C 73 930
loss C 74 930
of C 75 930
a C 76 930
renin C 77 930
- C 78 930
stimulating C 79 930
agent C 80 930
in C 81 930
the C 82 930
contralateral C 83 930
or C 84 930
unclipped C 85 930
kidney C 86 930
. C 87 930
failure C 89 930
of C 90 930
sodium C 91 930
to C 92 930
influence C 93 930
the C 94 930
degree C 95 930
of C 96 930
hypertension C 97 930
in C 98 930
unilaterally C 99 930
nephrectomized C 100 930
hypertensive C 101 930
rats C 102 930
militates C 103 930
against C 104 930
a C 105 930
direct C 106 930
quantitative C 107 930
relationship C 108 930
between C 109 930
blood C 110 930
pressure C 111 930
and C 112 930
the C 113 930
renin C 114 930
- C 115 930
angiotensin C 116 930
- C 117 930
aldosterone C 118 930
system C 119 930
. C 120 930
hypertensive C 1 931
vascular C 2 931
disease C 3 931
produced C 4 931
by C 5 931
homologous C 6 931
renin C 7 931
. C 8 931
administration C 10 931
of C 11 931
rat C 12 931
renin C 13 931
to C 14 931
uninephrectomized C 15 931
rats C 16 931
reproduced C 17 931
most C 18 931
, C 19 931
if C 20 931
not C 21 931
all C 22 931
, C 23 931
the C 24 931
changes C 25 931
( C 26 931
hypertension C 27 931
, C 28 931
vascular C 29 931
disease C 30 931
, C 31 931
hypertrophy C 32 931
of C 33 931
the C 34 931
zona C 35 931
glomerulosa C 36 931
of C 37 931
the C 38 931
adrenals C 39 931
) C 40 931
found C 41 931
after C 42 931
partial C 43 931
constriction C 44 931
of C 45 931
the C 46 931
renal C 47 931
artery C 48 931
. C 49 931
this C 51 931
is C 52 931
taken C 53 931
as C 54 931
evidence C 55 931
that C 56 931
the C 57 931
renal C 58 931
pressor C 59 931
system C 60 931
plays C 61 931
a C 62 931
major C 63 931
role C 64 931
in C 65 931
the C 66 931
pathogenesis C 67 931
of C 68 931
renal C 69 931
hypertension C 70 931
. C 71 931
effects C 1 932
of C 2 932
hypophysectomy C 3 932
and C 4 932
growth C 5 932
hormone C 6 932
on C 7 932
renal C 8 932
compensatory C 9 932
hypertrophy C 10 932
in C 11 932
rats C 12 932
. C 13 932
the C 15 932
effect C 16 932
of C 17 932
hypophysectomy C 18 932
on C 19 932
renal C 20 932
compensatory C 21 932
hypertrophy C 22 932
( C 23 932
rch C 24 932
) C 25 932
was C 26 932
observed C 27 932
in C 28 932
unilaterally C 29 932
nephrectomized C 30 932
rats C 31 932
receiving C 32 932
no C 33 932
therapy C 34 932
and C 35 932
those C 36 932
receiving C 37 932
replacement C 38 932
therapy C 39 932
and C 40 932
was C 41 932
compared C 42 932
to C 43 932
the C 44 932
rch C 45 932
attained C 46 932
by C 47 932
non C 48 932
- C 49 932
hypophysectomized C 50 932
unilaterally C 51 932
nephrectomized C 52 932
rats C 53 932
at C 54 932
2 C 55 932
, C 56 932
5 C 57 932
, C 58 932
and C 59 932
10 C 60 932
days C 61 932
. C 62 932
in C 64 932
the C 65 932
latter C 66 932
group C 67 932
there C 68 932
was C 69 932
an C 70 932
initial C 71 932
rapid C 72 932
rch C 73 932
seen C 74 932
at C 75 932
day C 76 932
2 C 77 932
which C 78 932
continued C 79 932
, C 80 932
but C 81 932
at C 82 932
a C 83 932
slower C 84 932
rate C 85 932
, C 86 932
through C 87 932
day C 88 932
10 C 89 932
. C 90 932
in C 92 932
the C 93 932
hypophysectomized C 94 932
group C 95 932
without C 96 932
replacement C 97 932
therapy C 98 932
there C 99 932
was C 100 932
also C 101 932
an C 102 932
initial C 103 932
rch C 104 932
in C 105 932
the C 106 932
first C 107 932
48 C 108 932
hrs C 109 932
. C 110 932
however C 112 932
, C 113 932
instead C 114 932
of C 115 932
the C 116 932
rch C 117 932
continuing C 118 932
there C 119 932
was C 120 932
a C 121 932
regression C 122 932
in C 123 932
kidney C 124 932
size C 125 932
at C 126 932
5 C 127 932
days C 128 932
and C 129 932
with C 130 932
no C 131 932
subsequent C 132 932
change C 133 932
at C 134 932
10 C 135 932
days C 136 932
. C 137 932
in C 139 932
the C 140 932
hypophysectomized C 141 932
group C 142 932
receiving C 143 932
hormone C 144 932
replacement C 145 932
there C 146 932
was C 147 932
an C 148 932
initial C 149 932
rch C 150 932
comparable C 151 932
to C 152 932
the C 153 932
other C 154 932
2 C 155 932
groups C 156 932
, C 157 932
but C 158 932
the C 159 932
further C 160 932
renal C 161 932
enlargement C 162 932
at C 163 932
10 C 164 932
days C 165 932
was C 166 932
much C 167 932
less C 168 932
than C 169 932
that C 170 932
of C 171 932
the C 172 932
non C 173 932
- C 174 932
hypophysectomized C 175 932
animals C 176 932
. C 177 932
the C 179 932
results C 180 932
of C 181 932
this C 182 932
experiment C 183 932
and C 184 932
of C 185 932
other C 186 932
reported C 187 932
studies C 188 932
imply C 189 932
existence C 190 932
of C 191 932
a C 192 932
renotropic C 193 932
factor C 194 932
which C 195 932
is C 196 932
not C 197 932
produced C 198 932
in C 199 932
the C 200 932
pituitary C 201 932
, C 202 932
but C 203 932
which C 204 932
requires C 205 932
an C 206 932
intact C 207 932
pituitary C 208 932
for C 209 932
full C 210 932
effectiveness C 211 932
. C 212 932
extrarenal C 1 933
fibromuscular C 2 933
hyperplasia C 3 933
. C 4 933
clinical C 6 933
, C 7 933
radiologic C 8 933
, C 9 933
and C 10 933
pathologic C 11 933
studies C 12 933
on C 13 933
19 C 14 933
patients C 15 933
with C 16 933
lesions C 17 933
in C 18 933
the C 19 933
extrarenal C 20 933
arteries C 21 933
that C 22 933
resembled C 23 933
fibromuscular C 24 933
hyperplasia C 25 933
are C 26 933
described C 27 933
. C 28 933
in C 30 933
11 C 31 933
patients C 32 933
fibromuscular C 33 933
hyperplasia C 34 933
was C 35 933
present C 36 933
in C 37 933
the C 38 933
renal C 39 933
arteries C 40 933
. C 41 933
patients C 43 933
with C 44 933
involvement C 45 933
of C 46 933
the C 47 933
celiac C 48 933
artery C 49 933
were C 50 933
the C 51 933
only C 52 933
ones C 53 933
who C 54 933
had C 55 933
symptoms C 56 933
of C 57 933
visceral C 58 933
ischemia C 59 933
. C 60 933
fibromuscular C 62 933
hyperplasia C 63 933
of C 64 933
the C 65 933
internal C 66 933
carotid C 67 933
arteries C 68 933
was C 69 933
observed C 70 933
in C 71 933
6 C 72 933
patients C 73 933
, C 74 933
2 C 75 933
of C 76 933
whom C 77 933
had C 78 933
symptoms C 79 933
of C 80 933
cerebral C 81 933
ischemia C 82 933
. C 83 933
nine C 85 933
patients C 86 933
with C 87 933
fibromuscular C 88 933
hyperplasia C 89 933
of C 90 933
the C 91 933
carotid C 92 933
or C 93 933
renal C 94 933
arteries C 95 933
had C 96 933
intracranial C 97 933
aneurysms C 98 933
, C 99 933
and C 100 933
in C 101 933
2 C 102 933
others C 103 933
intracranial C 104 933
hemorrhage C 105 933
developed C 106 933
in C 107 933
the C 108 933
absence C 109 933
of C 110 933
demonstrable C 111 933
aneurysms C 112 933
. C 113 933
the C 115 933
histologic C 116 933
similarities C 117 933
between C 118 933
intracranial C 119 933
aneurysms C 120 933
and C 121 933
other C 122 933
types C 123 933
of C 124 933
aneurysms C 125 933
that C 126 933
appear C 127 933
in C 128 933
patients C 129 933
with C 130 933
fibromuscular C 131 933
hyperplasia C 132 933
, C 133 933
the C 134 933
frequency C 135 933
of C 136 933
intracranial C 137 933
aneurysms C 138 933
in C 139 933
patients C 140 933
with C 141 933
extracranial C 142 933
fibromuscular C 143 933
hyperplasia C 144 933
, C 145 933
and C 146 933
the C 147 933
similar C 148 933
sex C 149 933
and C 150 933
age C 151 933
incidence C 152 933
suggest C 153 933
a C 154 933
common C 155 933
etiologic C 156 933
origin C 157 933
. C 158 933
some C 1 934
speculations C 2 934
on C 3 934
the C 4 934
nature C 5 934
and C 6 934
significance C 7 934
of C 8 934
developmentally C 9 934
small C 10 934
kidneys C 11 934
( C 12 934
renal C 13 934
hypoplasia C 14 934
) C 15 934
. C 16 934
renal C 18 934
hypoplasia C 19 934
may C 20 934
take C 21 934
several C 22 934
forms C 23 934
. C 24 934
among C 26 934
these C 27 934
the C 28 934
best C 29 934
known C 30 934
is C 31 934
perhaps C 32 934
renal C 33 934
dysplasia C 34 934
in C 35 934
which C 36 934
the C 37 934
parenchyma C 38 934
is C 39 934
maldeveloped C 40 934
. C 41 934
other C 43 934
forms C 44 934
of C 45 934
hypoplasia C 46 934
in C 47 934
which C 48 934
the C 49 934
renal C 50 934
parenchyma C 51 934
is C 52 934
normally C 53 934
formed C 54 934
but C 55 934
merely C 56 934
diminished C 57 934
in C 58 934
amount C 59 934
, C 60 934
do C 61 934
exist C 62 934
and C 63 934
may C 64 934
have C 65 934
severe C 66 934
clinical C 67 934
consequences C 68 934
. C 69 934
the C 71 934
finding C 72 934
at C 73 934
postmortem C 74 934
examination C 75 934
of C 76 934
anatomically C 77 934
small C 78 934
kidneys C 79 934
in C 80 934
children C 81 934
who C 82 934
suffered C 83 934
excessive C 84 934
or C 85 934
unexplained C 86 934
dehydration C 87 934
has C 88 934
prompted C 89 934
the C 90 934
thought C 91 934
that C 92 934
renal C 93 934
tubular C 94 934
insufficiency C 95 934
may C 96 934
result C 97 934
from C 98 934
renal C 99 934
hypoplasia C 100 934
. C 101 934
a C 1 935
study C 2 935
of C 3 935
induced C 4 935
renal C 5 935
hyperplasia C 6 935
using C 7 935
autoradiography C 8 935
. C 9 935
to C 11 935
establish C 12 935
a C 13 935
base C 14 935
line C 15 935
for C 16 935
future C 17 935
autoradiographic C 18 935
investigations C 19 935
, C 20 935
compensatory C 21 935
renal C 22 935
hyperplasia C 23 935
was C 24 935
studied C 25 935
using C 26 935
tritiated C 27 935
thymidine C 28 935
. C 29 935
labelled C 31 935
cells C 32 935
were C 33 935
infrequent C 34 935
in C 35 935
the C 36 935
tubular C 37 935
tissues C 38 935
of C 39 935
control C 40 935
kidneys C 41 935
. C 42 935
in C 44 935
the C 45 935
kidneys C 46 935
remaining C 47 935
after C 48 935
unilateral C 49 935
nephrectomy C 50 935
there C 51 935
was C 52 935
a C 53 935
5 C 54 935
- C 55 935
to C 56 935
6 C 57 935
- C 58 935
fold C 59 935
increase C 60 935
in C 61 935
the C 62 935
cortex C 63 935
and C 64 935
a C 65 935
12 C 66 935
- C 67 935
to C 68 935
13 C 69 935
- C 70 935
fold C 71 935
increase C 72 935
in C 73 935
the C 74 935
medulla C 75 935
of C 76 935
labelled C 77 935
tubular C 78 935
cells C 79 935
over C 80 935
the C 81 935
numbers C 82 935
seen C 83 935
in C 84 935
control C 85 935
tissues C 86 935
. C 87 935
the C 89 935
findings C 90 935
obtained C 91 935
here C 92 935
are C 93 935
in C 94 935
agreement C 95 935
with C 96 935
the C 97 935
observations C 98 935
made C 99 935
in C 100 935
earlier C 101 935
investigations C 102 935
with C 103 935
routine C 104 935
methods C 105 935
of C 106 935
staining C 107 935
and C 108 935
mitotic C 109 935
observation C 110 935
. C 111 935
compensatory C 1 936
structural C 2 936
and C 3 936
functional C 4 936
changes C 5 936
in C 6 936
the C 7 936
kidney C 8 936
. C 9 936
the C 11 936
radiographic C 12 936
assessment C 13 936
of C 14 936
the C 15 936
renal C 16 936
size C 17 936
and C 18 936
the C 19 936
factors C 20 936
influencing C 21 936
renal C 22 936
hypertrophy C 23 936
are C 24 936
discussed C 25 936
. C 26 936
the C 28 936
importance C 29 936
of C 30 936
compensatory C 31 936
hypertrophy C 32 936
and C 33 936
its C 34 936
prognostic C 35 936
significance C 36 936
is C 37 936
emphasised C 38 936
. C 39 936
the C 41 936
changes C 42 936
are C 43 936
correlated C 44 936
with C 45 936
renal C 46 936
function C 47 936
as C 48 936
measured C 49 936
by C 50 936
the C 51 936
glomerular C 52 936
filtration C 53 936
rate C 54 936
and C 55 936
renal C 56 936
plasma C 57 936
flow C 58 936
. C 59 936
bilateral C 1 937
renal C 2 937
hypoplasia C 3 937
of C 4 937
the C 5 937
pig C 6 937
. C 7 937
bilateral C 9 937
renal C 10 937
hypoplasia C 11 937
of C 12 937
the C 13 937
pig C 14 937
is C 15 937
described C 16 937
and C 17 937
is C 18 937
compared C 19 937
with C 20 937
a C 21 937
previous C 22 937
description C 23 937
. C 24 937
the C 26 937
defect C 27 937
was C 28 937
observed C 29 937
in C 30 937
19 C 31 937
piglets C 32 937
out C 33 937
of C 34 937
a C 35 937
total C 36 937
of C 37 937
73 C 38 937
born C 39 937
in C 40 937
8 C 41 937
litters C 42 937
, C 43 937
sired C 44 937
by C 45 937
one C 46 937
large C 47 937
white C 48 937
boar C 49 937
. C 50 937
twelve C 52 937
affected C 53 937
piglets C 54 937
died C 55 937
at C 56 937
or C 57 937
soon C 58 937
after C 59 937
birth C 60 937
and C 61 937
7 C 62 937
died C 63 937
between C 64 937
the C 65 937
ages C 66 937
of C 67 937
11 C 68 937
and C 69 937
69 C 70 937
days C 71 937
. C 72 937
inheritance C 74 937
by C 75 937
a C 76 937
simple C 77 937
autosomal C 78 937
recessive C 79 937
factor C 80 937
is C 81 937
suggested C 82 937
by C 83 937
the C 84 937
evidence C 85 937
. C 86 937
grossly C 88 937
the C 89 937
condition C 90 937
was C 91 937
characterized C 92 937
by C 93 937
varying C 94 937
degrees C 95 937
of C 96 937
hypoplasia C 97 937
and C 98 937
persistence C 99 937
of C 100 937
fetal C 101 937
lobulation C 102 937
. C 103 937
microscopically C 105 937
, C 106 937
the C 107 937
dominant C 108 937
feature C 109 937
was C 110 937
the C 111 937
poor C 112 937
development C 113 937
of C 114 937
the C 115 937
collecting C 116 937
tubule C 117 937
system C 118 937
. C 119 937
it C 121 937
is C 122 937
concluded C 123 937
that C 124 937
the C 125 937
basic C 126 937
defect C 127 937
is C 128 937
a C 129 937
failure C 130 937
of C 131 937
development C 132 937
of C 133 937
mesonephric C 134 937
mesenchyme C 135 937
. C 136 937
the C 1 938
effect C 2 938
of C 3 938
nortestosterone C 4 938
phenylpropionate C 5 938
on C 6 938
compensatory C 7 938
hypertrophy C 8 938
of C 9 938
the C 10 938
remaining C 11 938
kidney C 12 938
after C 13 938
unilateral C 14 938
nephrectomy C 15 938
. C 16 938
forty C 18 938
- C 19 938
eight C 20 938
hr C 21 938
. C 22 938
after C 24 938
unilateral C 25 938
nephrectomy C 26 938
, C 27 938
both C 28 938
in C 29 938
non C 30 938
- C 31 938
castrated C 32 938
and C 33 938
in C 34 938
castrated C 35 938
male C 36 938
mice C 37 938
the C 38 938
relative C 39 938
dry C 40 938
weight C 41 938
of C 42 938
the C 43 938
remaining C 44 938
kidney C 45 938
increased C 46 938
significantly C 47 938
. C 48 938
this C 50 938
compensatory C 51 938
hypertrophy C 52 938
was C 53 938
significantly C 54 938
stimulated C 55 938
as C 56 938
early C 57 938
as C 58 938
96 C 59 938
hr C 60 938
. C 61 938
after C 63 938
operation C 64 938
by C 65 938
treatment C 66 938
with C 67 938
19 C 68 938
- C 69 938
nortestosterone C 70 938
phenylpropionate C 71 938
( C 72 938
= C 73 938
npp C 74 938
) C 75 938
at C 76 938
the C 77 938
time C 78 938
of C 79 938
operation C 80 938
. C 81 938
the C 83 938
percentual C 84 938
increase C 85 938
of C 86 938
the C 87 938
kidney C 88 938
weight C 89 938
was C 90 938
approximately C 91 938
the C 92 938
same C 93 938
in C 94 938
non C 95 938
- C 96 938
castrated C 97 938
as C 98 938
in C 99 938
castrated C 100 938
mice C 101 938
. C 102 938
the C 104 938
absolute C 105 938
initial C 106 938
values C 107 938
as C 108 938
well C 109 938
as C 110 938
the C 111 938
resulting C 112 938
values C 113 938
96 C 114 938
hr C 115 938
. C 116 938
after C 118 938
operation C 119 938
were C 120 938
higher C 121 938
in C 122 938
non C 123 938
- C 124 938
castrated C 125 938
male C 126 938
mice C 127 938
than C 128 938
in C 129 938
castrated C 130 938
animals C 131 938
. C 132 938
the C 134 938
number C 135 938
of C 136 938
cells C 137 938
and C 138 938
the C 139 938
dna C 140 938
concentration C 141 938
per C 142 938
g C 143 938
. C 144 938
tissue C 146 938
decreased C 147 938
during C 148 938
the C 149 938
period C 150 938
of C 151 938
non C 152 938
- C 153 938
stimulated C 154 938
compensatory C 155 938
hypertrophy C 156 938
in C 157 938
both C 158 938
groups C 159 938
of C 160 938
animals C 161 938
. C 162 938
npp C 164 938
caused C 165 938
a C 166 938
still C 167 938
further C 168 938
decrease C 169 938
. C 170 938
the C 172 938
concentration C 173 938
of C 174 938
dna C 175 938
per C 176 938
cell C 177 938
did C 178 938
not C 179 938
change C 180 938
. C 181 938
following C 183 938
non C 184 938
- C 185 938
stimulated C 186 938
compensatory C 187 938
hypertrophy C 188 938
, C 189 938
there C 190 938
was C 191 938
no C 192 938
change C 193 938
in C 194 938
the C 195 938
rna C 196 938
concentration C 197 938
per C 198 938
g C 199 938
. C 200 938
tissue C 202 938
or C 203 938
per C 204 938
cell C 205 938
in C 206 938
castrated C 207 938
mice C 208 938
. C 209 938
in C 211 938
non C 212 938
- C 213 938
castrated C 214 938
mice C 215 938
the C 216 938
concentration C 217 938
increased C 218 938
. C 219 938
npp C 221 938
caused C 222 938
approximately C 223 938
the C 224 938
same C 225 938
percentual C 226 938
increase C 227 938
of C 228 938
rna C 229 938
concentration C 230 938
in C 231 938
non C 232 938
- C 233 938
castrated C 234 938
as C 235 938
in C 236 938
castrated C 237 938
animals C 238 938
during C 239 938
the C 240 938
period C 241 938
of C 242 938
compensatory C 243 938
hypertrophy C 244 938
. C 245 938
the C 247 938
difference C 248 938
between C 249 938
both C 250 938
groups C 251 938
of C 252 938
mice C 253 938
in C 254 938
the C 255 938
rna C 256 938
concentration C 257 938
in C 258 938
the C 259 938
remaining C 260 938
kidney C 261 938
following C 262 938
stimulation C 263 938
of C 264 938
the C 265 938
compensatory C 266 938
hypertrophy C 267 938
by C 268 938
npp C 269 938
was C 270 938
statistically C 271 938
significant C 272 938
. C 273 938
thyroid C 1 939
and C 2 939
pituitary C 3 939
gland C 4 939
activity C 5 939
during C 6 939
compensatory C 7 939
renal C 8 939
hypertrophy C 9 939
. C 10 939
autoradiographic C 12 939
studies C 13 939
with C 14 939
tritiated C 15 939
thymidine C 16 939
showed C 17 939
an C 18 939
increased C 19 939
synthesis C 20 939
of C 21 939
dna C 22 939
and C 23 939
cellular C 24 939
proliferation C 25 939
of C 26 939
the C 27 939
thyroid C 28 939
and C 29 939
pituitary C 30 939
during C 31 939
compensatory C 32 939
renal C 33 939
hypertrophy C 34 939
. C 35 939
the C 1 940
influence C 2 940
of C 3 940
thyroid C 4 940
hormone C 5 940
on C 6 940
renal C 7 940
function C 8 940
during C 9 940
the C 10 940
course C 11 940
of C 12 940
compensatory C 13 940
hypertrophy C 14 940
. C 15 940
during C 17 940
the C 18 940
course C 19 940
of C 20 940
compensatory C 21 940
hypertrophy C 22 940
of C 23 940
the C 24 940
kidney C 25 940
, C 26 940
glomerular C 27 940
filtration C 28 940
and C 29 940
renal C 30 940
plasma C 31 940
flow C 32 940
increased C 33 940
to C 34 940
a C 35 940
less C 36 940
extent C 37 940
in C 38 940
thyroidectomized C 39 940
animals C 40 940
than C 41 940
in C 42 940
control C 43 940
animals C 44 940
. C 45 940
the C 47 940
secretory C 48 940
capacity C 49 940
of C 50 940
the C 51 940
renal C 52 940
tubules C 53 940
of C 54 940
thyroidectomized C 55 940
animals C 56 940
increased C 57 940
insignificantly C 58 940
during C 59 940
compensatory C 60 940
hypertrophy C 61 940
, C 62 940
but C 63 940
increased C 64 940
markedly C 65 940
after C 66 940
administration C 67 940
of C 68 940
thyroid C 69 940
hormone C 70 940
. C 71 940
kidney C 1 941
cell C 2 941
proliferation C 3 941
after C 4 941
unilateral C 5 941
nephrectomy C 6 941
as C 7 941
related C 8 941
to C 9 941
age C 10 941
. C 11 941
the C 13 941
effect C 14 941
of C 15 941
unilateral C 16 941
nephrectomy C 17 941
on C 18 941
the C 19 941
number C 20 941
of C 21 941
cortical C 22 941
kidney C 23 941
cells C 24 941
undergoing C 25 941
dna C 26 941
synthesis C 27 941
and C 28 941
mitosis C 29 941
was C 30 941
measured C 31 941
by C 32 941
tritiated C 33 941
thymidine C 34 941
autoradiography C 35 941
in C 36 941
both C 37 941
weanling C 38 941
and C 39 941
adult C 40 941
rats C 41 941
. C 42 941
among C 44 941
the C 45 941
unoperated C 46 941
control C 47 941
animals C 48 941
, C 49 941
the C 50 941
weanling C 51 941
rat C 52 941
group C 53 941
showed C 54 941
a C 55 941
base C 56 941
line C 57 941
labeling C 58 941
index C 59 941
of C 60 941
0 C 61 941
. C 62 941
. C 63 941
. C 63 941
% C 64 941
, C 65 941
and C 66 941
the C 67 941
adult C 68 941
animals C 69 941
, C 70 941
one C 71 941
of C 72 941
0 C 73 941
. C 74 941
. C 75 941
. C 75 941
% C 76 941
. C 77 941
the C 79 941
response C 80 941
to C 81 941
unilateral C 82 941
nephrectomy C 83 941
resulted C 84 941
in C 85 941
a C 86 941
peak C 87 941
value C 88 941
of C 89 941
3 C 90 941
. C 91 941
. C 92 941
% C 93 941
in C 94 941
the C 95 941
weanling C 96 941
animals C 97 941
and C 98 941
1 C 99 941
. C 100 941
. C 101 941
% C 102 941
in C 103 941
the C 104 941
adult C 105 941
animals C 106 941
, C 107 941
both C 108 941
occurring C 109 941
at C 110 941
36 C 111 941
hr C 112 941
. C 113 941
mitotic C 115 941
indices C 116 941
were C 117 941
0 C 118 941
. C 119 941
. C 120 941
. C 120 941
. C 120 941
% C 121 941
in C 122 941
the C 123 941
weanling C 124 941
control C 125 941
animals C 126 941
and C 127 941
0 C 128 941
. C 129 941
. C 130 941
. C 130 941
. C 130 941
. C 130 941
% C 131 941
in C 132 941
the C 133 941
adults C 134 941
, C 135 941
with C 136 941
a C 137 941
peak C 138 941
of C 139 941
0 C 140 941
. C 141 941
. C 142 941
. C 142 941
% C 143 941
and C 144 941
0 C 145 941
. C 146 941
. C 147 941
. C 147 941
. C 147 941
% C 148 941
, C 149 941
resp C 150 941
. C 151 941
, C 153 941
at C 154 941
36 C 155 941
hr C 156 941
. C 157 941
separate C 159 941
counts C 160 941
of C 161 941
tubule C 162 941
and C 163 941
stromal C 164 941
cells C 165 941
in C 166 941
the C 167 941
cortex C 168 941
revealed C 169 941
that C 170 941
the C 171 941
maximum C 172 941
increase C 173 941
in C 174 941
% C 175 941
labeled C 176 941
cells C 177 941
occurred C 178 941
later C 179 941
in C 180 941
the C 181 941
stromal C 182 941
cells C 183 941
than C 184 941
in C 185 941
the C 186 941
tubule C 187 941
cells C 188 941
; C 189 941
the C 190 941
stromal C 191 941
cells C 192 941
not C 193 941
reaching C 194 941
a C 195 941
maximum C 196 941
until C 197 941
57 C 198 941
hr C 199 941
after C 200 941
nephrectomy C 201 941
. C 202 941
the C 204 941
findings C 205 941
indicate C 206 941
that C 207 941
, C 208 941
although C 209 941
the C 210 941
relative C 211 941
proliferative C 212 941
activity C 213 941
is C 214 941
much C 215 941
lower C 216 941
in C 217 941
adult C 218 941
animals C 219 941
, C 220 941
a C 221 941
similar C 222 941
response C 223 941
, C 224 941
qualitatively C 225 941
, C 226 941
is C 227 941
obtained C 228 941
in C 229 941
both C 230 941
groups C 231 941
after C 232 941
unilateral C 233 941
nephrectomy C 234 941
. C 235 941
influence C 1 942
of C 2 942
the C 3 942
adrenal C 4 942
glands C 5 942
on C 6 942
dna C 7 942
synthesis C 8 942
in C 9 942
normal C 10 942
and C 11 942
compensating C 12 942
kidneys C 13 942
. C 14 942
the C 16 942
role C 17 942
of C 18 942
the C 19 942
adrenal C 20 942
glands C 21 942
in C 22 942
controlling C 23 942
the C 24 942
synthesis C 25 942
of C 26 942
dna C 27 942
in C 28 942
normal C 29 942
and C 30 942
compensating C 31 942
kidneys C 32 942
of C 33 942
rats C 34 942
given C 35 942
saline C 36 942
drinking C 37 942
fluid C 38 942
was C 39 942
studied C 40 942
using C 41 942
tritiated C 42 942
- C 43 942
thymidine C 44 942
and C 45 942
radioautography C 46 942
. C 47 942
adrenalectomy C 49 942
alone C 50 942
increased C 51 942
significantly C 52 942
the C 53 942
labeling C 54 942
of C 55 942
the C 56 942
renal C 57 942
cortex C 58 942
and C 59 942
medulla C 60 942
of C 61 942
otherwise C 62 942
intact C 63 942
rats C 64 942
. C 65 942
two C 67 942
days C 68 942
following C 69 942
unilateral C 70 942
nephrectomy C 71 942
of C 72 942
rats C 73 942
with C 74 942
intact C 75 942
adrenal C 76 942
glands C 77 942
, C 78 942
the C 79 942
number C 80 942
of C 81 942
labeled C 82 942
nuclei C 83 942
in C 84 942
the C 85 942
remaining C 86 942
kidney C 87 942
increased C 88 942
by C 89 942
factors C 90 942
of C 91 942
about C 92 942
4 C 93 942
and C 94 942
2 C 95 942
. C 96 942
. C 97 942
in C 98 942
the C 99 942
cortex C 100 942
and C 101 942
the C 102 942
medulla C 103 942
, C 104 942
respectively C 105 942
. C 106 942
adrenalectomy C 108 942
moderately C 109 942
decreased C 110 942
the C 111 942
hyper C 112 942
- C 113 942
plastic C 114 942
response C 115 942
of C 116 942
the C 117 942
cortex C 118 942
of C 119 942
the C 120 942
remaining C 121 942
kidney C 122 942
, C 123 942
but C 124 942
increased C 125 942
still C 126 942
further C 127 942
the C 128 942
labeling C 129 942
index C 130 942
of C 131 942
the C 132 942
medulla C 133 942
. C 134 942
by C 136 942
5 C 137 942
days C 138 942
after C 139 942
unilateral C 140 942
nephrectomy C 141 942
of C 142 942
rats C 143 942
with C 144 942
intact C 145 942
adrenal C 146 942
glands C 147 942
, C 148 942
neither C 149 942
the C 150 942
cortex C 151 942
nor C 152 942
the C 153 942
medulla C 154 942
of C 155 942
the C 156 942
remaining C 157 942
kidney C 158 942
exhibited C 159 942
a C 160 942
marked C 161 942
hyperplastic C 162 942
response C 163 942
. C 164 942
in C 166 942
adrenalectomized C 167 942
animals C 168 942
, C 169 942
also C 170 942
, C 171 942
unilateral C 172 942
nephrectomy C 173 942
caused C 174 942
only C 175 942
slight C 176 942
increases C 177 942
in C 178 942
the C 179 942
labeling C 180 942
indices C 181 942
of C 182 942
the C 183 942
cortex C 184 942
and C 185 942
the C 186 942
medulla C 187 942
of C 188 942
the C 189 942
remaining C 190 942
kidney C 191 942
. C 192 942
auto C 1 943
- C 2 943
radiographic C 3 943
studies C 4 943
of C 5 943
the C 6 943
protein C 7 943
metabolism C 8 943
of C 9 943
the C 10 943
single C 11 943
kidney C 12 943
in C 13 943
the C 14 943
nephrectomized C 15 943
rat C 16 943
. C 17 943
rats C 19 943
were C 20 943
subjected C 21 943
to C 22 943
unilateral C 23 943
nephrectomy C 24 943
, C 25 943
following C 26 943
which C 27 943
the C 28 943
protein C 29 943
metabolism C 30 943
of C 31 943
the C 32 943
other C 33 943
kidney C 34 943
, C 35 943
which C 36 943
exerted C 37 943
a C 38 943
compensatory C 39 943
activity C 40 943
, C 41 943
was C 42 943
studied C 43 943
with C 44 943
h C 45 943
- C 46 943
labelled C 47 943
l C 48 943
- C 49 943
phenylalanine C 50 943
, C 51 943
at C 52 943
different C 53 943
intervals C 54 943
( C 55 943
3 C 56 943
hr C 57 943
. C 58 943
to C 60 943
7 C 61 943
wk C 62 943
. C 63 943
) C 65 943
. C 66 943
two C 68 943
phases C 69 943
of C 70 943
enhanced C 71 943
incorporation C 72 943
of C 73 943
amino C 74 943
- C 75 943
acids C 76 943
into C 77 943
the C 78 943
cells C 79 943
of C 80 943
the C 81 943
convoluted C 82 943
tubules C 83 943
were C 84 943
found C 85 943
, C 86 943
with C 87 943
one C 88 943
maximum C 89 943
after C 90 943
6 C 91 943
hr C 92 943
. C 93 943
, C 95 943
at C 96 943
which C 97 943
time C 98 943
the C 99 943
uptake C 100 943
is C 101 943
limited C 102 943
to C 103 943
the C 104 943
cytoplasm C 105 943
, C 106 943
and C 107 943
a C 108 943
2 C 109 943
nd C 110 943
maximum C 111 943
on C 112 943
the C 113 943
4 C 114 943
th C 115 943
day C 116 943
, C 117 943
when C 118 943
the C 119 943
nucleus C 120 943
is C 121 943
equally C 122 943
involved C 123 943
. C 124 943
in C 126 943
the C 127 943
course C 128 943
of C 129 943
the C 130 943
2 C 131 943
nd C 132 943
phase C 133 943
of C 134 943
enhanced C 135 943
amino C 136 943
- C 137 943
acid C 138 943
uptake C 139 943
, C 140 943
there C 141 943
is C 142 943
also C 143 943
an C 144 943
increased C 145 943
mitotic C 146 943
index C 147 943
of C 148 943
the C 149 943
epithelia C 150 943
of C 151 943
the C 152 943
tubules C 153 943
. C 154 943
in C 156 943
the C 157 943
collecting C 158 943
tubules C 159 943
, C 160 943
there C 161 943
was C 162 943
only C 163 943
one C 164 943
phase C 165 943
of C 166 943
enhanced C 167 943
amino C 168 943
- C 169 943
acid C 170 943
uptake C 171 943
, C 172 943
with C 173 943
a C 174 943
maximum C 175 943
on C 176 943
the C 177 943
4 C 178 943
th C 179 943
day C 180 943
, C 181 943
also C 182 943
coinciding C 183 943
with C 184 943
an C 185 943
increased C 186 943
mitotic C 187 943
index C 188 943
. C 189 943
the C 191 943
increase C 192 943
of C 193 943
the C 194 943
number C 195 943
of C 196 943
cells C 197 943
of C 198 943
the C 199 943
kidney C 200 943
was C 201 943
determined C 202 943
by C 203 943
a C 204 943
study C 205 943
of C 206 943
the C 207 943
variations C 208 943
of C 209 943
the C 210 943
mitotic C 211 943
index C 212 943
. C 213 943
the C 215 943
mean C 216 943
multiplication C 217 943
factor C 218 943
in C 219 943
the C 220 943
beginning C 221 943
amounts C 222 943
to C 223 943
1 C 224 943
. C 225 943
. C 226 943
. C 227 943
the C 229 943
protein C 230 943
metabolism C 231 943
is C 232 943
increased C 233 943
1 C 234 943
. C 235 943
. C 236 943
times C 237 943
. C 238 943
the C 240 943
increase C 241 943
of C 242 943
the C 243 943
volume C 244 943
( C 245 943
factor C 246 943
1 C 247 943
. C 248 943
. C 249 943
) C 250 943
and C 251 943
the C 252 943
increase C 253 943
of C 254 943
the C 255 943
protein C 256 943
metabolism C 257 943
per C 258 943
unit C 259 943
of C 260 943
volume C 261 943
( C 262 943
factor C 263 943
1 C 264 943
. C 265 943
. C 266 943
) C 267 943
of C 268 943
the C 269 943
hypertrophic C 270 943
kidney C 271 943
result C 272 943
in C 273 943
a C 274 943
total C 275 943
increase C 276 943
of C 277 943
the C 278 943
protein C 279 943
metabolism C 280 943
of C 281 943
2 C 282 943
. C 283 943
. C 284 943
times C 285 943
, C 286 943
once C 287 943
the C 288 943
adaptation C 289 943
process C 290 943
is C 291 943
complete C 292 943
, C 293 943
so C 294 943
that C 295 943
the C 296 943
residual C 297 943
kidney C 298 943
has C 299 943
approximately C 300 943
the C 301 943
same C 302 943
protein C 303 943
metabolism C 304 943
as C 305 943
2 C 306 943
normal C 307 943
kidneys C 308 943
. C 309 943
two C 1 944
brothers C 2 944
with C 3 944
nephrogenic C 4 944
diabetes C 5 944
insipidus C 6 944
. C 7 944
the C 9 944
patients C 10 944
, C 11 944
a C 12 944
5 C 13 944
- C 14 944
year C 15 944
- C 16 944
old C 17 944
and C 18 944
a C 19 944
13 C 20 944
- C 21 944
year C 22 944
- C 23 944
old C 24 944
boy C 25 944
, C 26 944
had C 27 944
suffered C 28 944
from C 29 944
polydypsia C 30 944
and C 31 944
polyuria C 32 944
since C 33 944
the C 34 944
age C 35 944
of C 36 944
1 C 37 944
yr C 38 944
. C 39 944
physical C 41 944
and C 42 944
mental C 43 944
retardation C 44 944
, C 45 944
hyperchloremia C 46 944
, C 47 944
and C 48 944
lowering C 49 944
of C 50 944
kidney C 51 944
concentrating C 52 944
power C 53 944
were C 54 944
observed C 55 944
. C 56 944
the C 58 944
patients C 59 944
were C 60 944
resistant C 61 944
to C 62 944
pitressin C 63 944
. C 64 944
they C 66 944
were C 67 944
considered C 68 944
to C 69 944
be C 70 944
suffering C 71 944
from C 72 944
nephrogenic C 73 944
diabetes C 74 944
insipidus C 75 944
caused C 76 944
by C 77 944
a C 78 944
recessive C 79 944
heredity C 80 944
factor C 81 944
. C 82 944
studies C 1 945
on C 2 945
the C 3 945
sweat C 4 945
in C 5 945
renal C 6 945
diabetes C 7 945
insipidus C 8 945
during C 9 945
treatment C 10 945
with C 11 945
saluretics C 12 945
. C 13 945
description C 15 945
of C 16 945
a C 17 945
5 C 18 945
- C 19 945
month C 20 945
- C 21 945
old C 22 945
boy C 23 945
suffering C 24 945
from C 25 945
familial C 26 945
diabetes C 27 945
insipidus C 28 945
. C 29 945
his C 31 945
sweat C 32 945
as C 33 945
well C 34 945
as C 35 945
that C 36 945
of C 37 945
his C 38 945
mother C 39 945
had C 40 945
an C 41 945
increased C 42 945
nacl C 43 945
content C 44 945
. C 45 945
chlorthalidone C 47 945
and C 48 945
fursemide C 49 945
had C 50 945
a C 51 945
different C 52 945
effect C 53 945
both C 54 945
on C 55 945
the C 56 945
quantity C 57 945
and C 58 945
on C 59 945
the C 60 945
nacl C 61 945
content C 62 945
of C 63 945
the C 64 945
sweat C 65 945
. C 66 945
a C 68 945
single C 69 945
dose C 70 945
of C 71 945
chlorthalidone C 72 945
decreased C 73 945
the C 74 945
nacl C 75 945
content C 76 945
for C 77 945
a C 78 945
short C 79 945
time C 80 945
, C 81 945
but C 82 945
increased C 83 945
the C 84 945
quantity C 85 945
of C 86 945
sweat C 87 945
during C 88 945
3 C 89 945
days C 90 945
. C 91 945
fursemide C 93 945
given C 94 945
intermittently C 95 945
produced C 96 945
a C 97 945
decrease C 98 945
of C 99 945
the C 100 945
sweat C 101 945
nacl C 102 945
also C 103 945
during C 104 945
the C 105 945
intervals C 106 945
and C 107 945
an C 108 945
increase C 109 945
of C 110 945
the C 111 945
quantity C 112 945
of C 113 945
sweat C 114 945
; C 115 945
however C 116 945
, C 117 945
as C 118 945
a C 119 945
contraregulation C 120 945
during C 121 945
the C 122 945
intervals C 123 945
, C 124 945
the C 125 945
quantity C 126 945
of C 127 945
sweat C 128 945
decreased C 129 945
and C 130 945
at C 131 945
the C 132 945
same C 133 945
time C 134 945
the C 135 945
urea C 136 945
content C 137 945
increased C 138 945
. C 139 945
from C 141 945
the C 142 945
isotonic C 143 945
serum C 144 945
filtrate C 145 945
in C 146 945
the C 147 945
sweat C 148 945
glands C 149 945
ho C 150 945
and C 151 945
nacl C 152 945
were C 153 945
reabsorbed C 154 945
in C 155 945
the C 156 945
ducts C 157 945
and C 158 945
the C 159 945
urea C 160 945
concentration C 161 945
increased C 162 945
but C 163 945
the C 164 945
reabsorption C 165 945
of C 166 945
ho C 167 945
and C 168 945
nacl C 169 945
did C 170 945
not C 171 945
go C 172 945
parallel C 173 945
, C 174 945
therefore C 175 945
the C 176 945
sweat C 177 945
is C 178 945
hypotonic C 179 945
. C 180 945
this C 182 945
regulation C 183 945
is C 184 945
altered C 185 945
in C 186 945
diabetes C 187 945
insipidus C 188 945
, C 189 945
therefore C 190 945
the C 191 945
high C 192 945
values C 193 945
of C 194 945
nacl C 195 945
. C 196 945
without C 198 945
changing C 199 945
the C 200 945
osmolarity C 201 945
, C 202 945
na C 203 945
is C 204 945
exchanged C 205 945
with C 206 945
k C 207 945
. C 208 945
this C 210 945
mechanism C 211 945
is C 212 945
accentuated C 213 945
if C 214 945
the C 215 945
na C 216 945
- C 217 945
concentration C 218 945
is C 219 945
high C 220 945
. C 221 945
diabetes C 1 946
insipidus C 2 946
treated C 3 946
with C 4 946
synthetic C 5 946
lysine C 6 946
vasopressin C 7 946
. C 8 946
a C 10 946
case C 11 946
of C 12 946
diabetes C 13 946
insipidus C 14 946
was C 15 946
associated C 16 946
with C 17 946
an C 18 946
eosinophilic C 19 946
granuloma C 20 946
in C 21 946
a C 22 946
2 C 23 946
. C 24 946
. C 25 946
- C 26 946
year C 27 946
- C 28 946
old C 29 946
child C 30 946
. C 31 946
partial C 33 946
control C 34 946
of C 35 946
symptoms C 36 946
was C 37 946
achieved C 38 946
with C 39 946
pitressin C 40 946
tannate C 41 946
in C 42 946
oil C 43 946
, C 44 946
7 C 45 946
. C 46 946
. C 47 946
u C 48 946
. C 49 946
i C 51 946
. C 52 946
. C 53 946
. C 54 946
on C 56 946
alternate C 57 946
days C 58 946
. C 59 946
synthetic C 61 946
lysine C 62 946
vasopressin C 63 946
i C 64 946
. C 65 946
. C 66 946
. C 67 946
controlled C 69 946
the C 70 946
urine C 71 946
output C 72 946
at C 73 946
a C 74 946
dose C 75 946
of C 76 946
5 C 77 946
u C 78 946
. C 79 946
8 C 81 946
- C 82 946
hourly C 83 946
, C 84 946
but C 85 946
the C 86 946
preparation C 87 946
was C 88 946
not C 89 946
well C 90 946
tolerated C 91 946
. C 92 946
it C 94 946
was C 95 946
therefore C 96 946
given C 97 946
by C 98 946
the C 99 946
nasal C 100 946
route C 101 946
, C 102 946
and C 103 946
over C 104 946
a C 105 946
6 C 106 946
- C 107 946
month C 108 946
period C 109 946
the C 110 946
diabetes C 111 946
was C 112 946
controlled C 113 946
with C 114 946
a C 115 946
dose C 116 946
of C 117 946
14 C 118 946
u C 119 946
. C 120 946
t C 122 946
. C 123 946
. C 124 946
. C 125 946
. C 126 946
. C 127 946
the C 1 947
action C 2 947
of C 3 947
vasopressin C 4 947
in C 5 947
renal C 6 947
diabetes C 7 947
insipidus C 8 947
. C 9 947
as C 11 947
the C 12 947
water C 13 947
- C 14 947
retaining C 15 947
action C 16 947
of C 17 947
antidiuretic C 18 947
hormone C 19 947
is C 20 947
eliminated C 21 947
in C 22 947
renal C 23 947
diabetes C 24 947
insipidus C 25 947
, C 26 947
the C 27 947
steps C 28 947
in C 29 947
na C 30 947
transport C 31 947
can C 32 947
be C 33 947
separately C 34 947
determined C 35 947
. C 36 947
vasopressin C 38 947
induced C 39 947
a C 40 947
prompt C 41 947
increase C 42 947
in C 43 947
freewater C 44 947
clearance C 45 947
and C 46 947
urinary C 47 947
volume C 48 947
, C 49 947
as C 50 947
well C 51 947
as C 52 947
a C 53 947
delayed C 54 947
increase C 55 947
in C 56 947
sodium C 57 947
clearance C 58 947
. C 59 947
it C 61 947
is C 62 947
suggested C 63 947
that C 64 947
vasopressin C 65 947
brings C 66 947
about C 67 947
stimulation C 68 947
of C 69 947
sodium C 70 947
reabsorption C 71 947
in C 72 947
the C 73 947
ascending C 74 947
limb C 75 947
of C 76 947
henle C 77 947
' C 78 947
s C 79 947
loop C 80 947
. C 81 947
it C 83 947
is C 84 947
supposed C 85 947
that C 86 947
both C 87 947
physiological C 88 947
actions C 89 947
of C 90 947
antidiuretic C 91 947
hormone C 92 947
- C 93 947
the C 94 947
antidiuretic C 95 947
and C 96 947
the C 97 947
sodium C 98 947
- C 99 947
active C 100 947
effect C 101 947
- C 102 947
become C 103 947
operative C 104 947
in C 105 947
two C 106 947
different C 107 947
places C 108 947
in C 109 947
the C 110 947
nephron C 111 947
and C 112 947
synergistically C 113 947
produce C 114 947
a C 115 947
maximum C 116 947
concentration C 117 947
of C 118 947
urine C 119 947
. C 120 947
pituitary C 1 948
diabetes C 2 948
insipidus C 3 948
associated C 4 948
with C 5 948
progressive C 6 948
urinary C 7 948
tract C 8 948
dilatation C 9 948
. C 10 948
a C 12 948
case C 13 948
of C 14 948
pituitary C 15 948
diabetes C 16 948
insipidus C 17 948
with C 18 948
associated C 19 948
obstructive C 20 948
urinary C 21 948
tract C 22 948
changes C 23 948
is C 24 948
described C 25 948
. C 26 948
the C 28 948
patient C 29 948
was C 30 948
treated C 31 948
both C 32 948
by C 33 948
surgical C 34 948
correction C 35 948
of C 36 948
lower C 37 948
tract C 38 948
obstruction C 39 948
as C 40 948
well C 41 948
as C 42 948
by C 43 948
control C 44 948
of C 45 948
the C 46 948
diabetes C 47 948
. C 48 948
reversal C 50 948
of C 51 948
anatomic C 52 948
changes C 53 948
over C 54 948
a C 55 948
1 C 56 948
- C 57 948
year C 58 948
followup C 59 948
period C 60 948
is C 61 948
demonstrated C 62 948
. C 63 948
the C 1 949
antidiuretic C 2 949
effect C 3 949
of C 4 949
angiotensin C 5 949
in C 6 949
diabetes C 7 949
insipidus C 8 949
. C 9 949
the C 11 949
effect C 12 949
of C 13 949
angiotensin C 14 949
( C 15 949
val C 16 949
- C 17 949
5 C 18 949
- C 19 949
hypertensinii C 20 949
- C 21 949
asp C 22 949
- C 23 949
- C 24 949
amide C 25 949
) C 26 949
was C 27 949
studied C 28 949
in C 29 949
2 C 30 949
children C 31 949
with C 32 949
diabetes C 33 949
insipidus C 34 949
( C 35 949
a C 36 949
9 C 37 949
yr C 38 949
old C 39 949
boy C 40 949
with C 41 949
diabetes C 42 949
insipidus C 43 949
neuro C 44 949
- C 45 949
hormonalis C 46 949
and C 47 949
a C 48 949
4 C 49 949
yr C 50 949
old C 51 949
girl C 52 949
with C 53 949
diabetes C 54 949
insipidus C 55 949
renalis C 56 949
) C 57 949
in C 58 949
whom C 59 949
the C 60 949
clearances C 61 949
of C 62 949
inulin C 63 949
, C 64 949
pah C 65 949
, C 66 949
na C 67 949
and C 68 949
urea C 69 949
and C 70 949
the C 71 949
osmolar C 72 949
and C 73 949
free C 74 949
- C 75 949
water C 76 949
clearances C 77 949
were C 78 949
examined C 79 949
. C 80 949
angiotensin C 82 949
produces C 83 949
a C 84 949
prompt C 85 949
antidiuresis C 86 949
which C 87 949
is C 88 949
combined C 89 949
with C 90 949
a C 91 949
gross C 92 949
decrease C 93 949
of C 94 949
the C 95 949
na C 96 949
- C 97 949
clearance C 98 949
. C 99 949
the C 101 949
osmolality C 102 949
of C 103 949
the C 104 949
urine C 105 949
is C 106 949
increased C 107 949
only C 108 949
slightly C 109 949
and C 110 949
the C 111 949
free C 112 949
- C 113 949
water C 114 949
clearance C 115 949
does C 116 949
not C 117 949
become C 118 949
negative C 119 949
, C 120 949
both C 121 949
effects C 122 949
being C 123 949
contrary C 124 949
to C 125 949
those C 126 949
seen C 127 949
with C 128 949
vasopressin C 129 949
. C 130 949
the C 132 949
antidiuresis C 133 949
and C 134 949
antinatriuresis C 135 949
can C 136 949
be C 137 949
produced C 138 949
in C 139 949
salt C 140 949
- C 141 949
loaded C 142 949
and C 143 949
salt C 144 949
- C 145 949
deprived C 146 949
states C 147 949
. C 148 949
furosemide C 150 949
reverses C 151 949
the C 152 949
effects C 153 949
of C 154 949
angiotensin C 155 949
. C 156 949
the C 158 949
clearance C 159 949
of C 160 949
urea C 161 949
is C 162 949
not C 163 949
changed C 164 949
by C 165 949
angiotensin C 166 949
as C 167 949
long C 168 949
as C 169 949
the C 170 949
glomerular C 171 949
filtration C 172 949
rate C 173 949
remains C 174 949
normal C 175 949
. C 176 949
polyuria C 1 950
in C 2 950
children C 3 950
. C 4 950
twelve C 6 950
polyuric C 7 950
children C 8 950
have C 9 950
been C 10 950
investigated C 11 950
in C 12 950
the C 13 950
present C 14 950
report C 15 950
from C 16 950
their C 17 950
etiologico C 18 950
- C 19 950
clinical C 20 950
aspect C 21 950
and C 22 950
they C 23 950
have C 24 950
been C 25 950
classified C 26 950
into C 27 950
four C 28 950
broad C 29 950
groups C 30 950
. C 31 950
the C 33 950
first C 34 950
group C 35 950
of C 36 950
diabetes C 37 950
insipidus C 38 950
syndrome C 39 950
included C 40 950
4 C 41 950
cases C 42 950
- C 43 950
3 C 44 950
of C 45 950
idiopathic C 46 950
type C 47 950
and C 48 950
one C 49 950
of C 50 950
the C 51 950
acquired C 52 950
variety C 53 950
due C 54 950
to C 55 950
hand C 56 950
- C 57 950
schuller C 58 950
- C 59 950
christian C 60 950
- C 61 950
disease C 62 950
. C 63 950
the C 65 950
4 C 66 950
cases C 67 950
in C 68 950
the C 69 950
second C 70 950
group C 71 950
of C 72 950
nephrogenic C 73 950
diabetes C 74 950
insipidus C 75 950
after C 76 950
further C 77 950
investigations C 78 950
were C 79 950
diagnosed C 80 950
as C 81 950
renal C 82 950
acidosis C 83 950
( C 84 950
1 C 85 950
case C 86 950
) C 87 950
, C 88 950
other C 89 950
renal C 90 950
tubular C 91 950
syndromes C 92 950
with C 93 950
multiple C 94 950
defects C 95 950
( C 96 950
2 C 97 950
cases C 98 950
) C 99 950
, C 100 950
and C 101 950
hypokalaemic C 102 950
nephropathy C 103 950
( C 104 950
1 C 105 950
case C 106 950
) C 107 950
. C 108 950
the C 110 950
third C 111 950
group C 112 950
of C 113 950
polyuria C 114 950
due C 115 950
to C 116 950
chronic C 117 950
renal C 118 950
failure C 119 950
has C 120 950
been C 121 950
exemplified C 122 950
by C 123 950
one C 124 950
case C 125 950
. C 126 950
the C 128 950
fourth C 129 950
group C 130 950
of C 131 950
3 C 132 950
cases C 133 950
had C 134 950
compulsive C 135 950
water C 136 950
drinking C 137 950
as C 138 950
the C 139 950
probable C 140 950
etiology C 141 950
. C 142 950
in C 144 950
addition C 145 950
to C 146 950
the C 147 950
illustrative C 148 950
case C 149 950
histories C 150 950
, C 151 950
a C 152 950
practical C 153 950
diagnostic C 154 950
approach C 155 950
in C 156 950
the C 157 950
context C 158 950
of C 159 950
physiopathology C 160 950
of C 161 950
normal C 162 950
urine C 163 950
excretion C 164 950
has C 165 950
been C 166 950
recommended C 167 950
. C 168 950
treatment C 1 951
of C 2 951
diabetes C 3 951
insipidus C 4 951
: C 5 951
synthetic C 6 951
lysine C 7 951
vasopressin C 8 951
nasal C 9 951
solution C 10 951
. C 11 951
twenty C 13 951
patients C 14 951
with C 15 951
vasopressin C 16 951
- C 17 951
deficient C 18 951
diabetes C 19 951
insipidus C 20 951
were C 21 951
treated C 22 951
with C 23 951
a C 24 951
nasal C 25 951
solution C 26 951
of C 27 951
synthetic C 28 951
lysine C 29 951
vasopressin C 30 951
. C 31 951
use C 33 951
of C 34 951
the C 35 951
nasal C 36 951
spray C 37 951
2 C 38 951
to C 39 951
8 C 40 951
times C 41 951
daily C 42 951
controlled C 43 951
polyuria C 44 951
in C 45 951
all C 46 951
patients C 47 951
without C 48 951
recurrence C 49 951
of C 50 951
the C 51 951
side C 52 951
effects C 53 951
occasionally C 54 951
observed C 55 951
with C 56 951
posterior C 57 951
pituitary C 58 951
preparations C 59 951
of C 60 951
animal C 61 951
origin C 62 951
. C 63 951
one C 65 951
pregnant C 66 951
patient C 67 951
was C 68 951
well C 69 951
controlled C 70 951
to C 71 951
term C 72 951
without C 73 951
undesirable C 74 951
uterine C 75 951
stimulation C 76 951
. C 77 951
because C 79 951
of C 80 951
its C 81 951
ease C 82 951
of C 83 951
administration C 84 951
, C 85 951
the C 86 951
absence C 87 951
of C 88 951
significant C 89 951
water C 90 951
retention C 91 951
( C 92 951
if C 93 951
used C 94 951
judiciously C 95 951
) C 96 951
and C 97 951
the C 98 951
freedom C 99 951
from C 100 951
potentially C 101 951
serious C 102 951
allergic C 103 951
reactions C 104 951
to C 105 951
foreign C 106 951
protein C 107 951
, C 108 951
this C 109 951
synthetic C 110 951
preparation C 111 951
is C 112 951
recommended C 113 951
for C 114 951
clinical C 115 951
use C 116 951
. C 117 951
synthetic C 1 952
lysine C 2 952
vasopressin C 3 952
nasal C 4 952
spray C 5 952
in C 6 952
the C 7 952
treatment C 8 952
of C 9 952
diabetes C 10 952
insipidus C 11 952
. C 12 952
thirteen C 14 952
patients C 15 952
with C 16 952
diabetes C 17 952
insipidus C 18 952
were C 19 952
satisfactorily C 20 952
and C 21 952
conveniently C 22 952
treated C 23 952
with C 24 952
synthetic C 25 952
lysine C 26 952
vasopressin C 27 952
nasal C 28 952
spray C 29 952
, C 30 952
the C 31 952
material C 32 952
being C 33 952
administered C 34 952
3 C 35 952
to C 36 952
5 C 37 952
times C 38 952
per C 39 952
day C 40 952
in C 41 952
a C 42 952
total C 43 952
daily C 44 952
dosage C 45 952
ranging C 46 952
from C 47 952
35 C 48 952
to C 49 952
125 C 50 952
u C 51 952
. C 52 952
a C 54 952
transient C 55 952
decrease C 56 952
in C 57 952
effectiveness C 58 952
was C 59 952
noted C 60 952
during C 61 952
periods C 62 952
of C 63 952
upper C 64 952
respiratory C 65 952
infection C 66 952
or C 67 952
allergic C 68 952
rhinitis C 69 952
. C 70 952
the C 72 952
only C 73 952
adverse C 74 952
effects C 75 952
of C 76 952
the C 77 952
nasal C 78 952
spray C 79 952
consisted C 80 952
of C 81 952
minor C 82 952
nasal C 83 952
irritation C 84 952
in C 85 952
3 C 86 952
patients C 87 952
and C 88 952
increased C 89 952
frequency C 90 952
of C 91 952
bowel C 92 952
movements C 93 952
in C 94 952
one C 95 952
child C 96 952
after C 97 952
he C 98 952
increased C 99 952
the C 100 952
dose C 101 952
in C 102 952
an C 103 952
effort C 104 952
to C 105 952
concentrate C 106 952
and C 107 952
restrict C 108 952
urine C 109 952
volume C 110 952
. C 111 952
in C 113 952
hydrated C 114 952
normal C 115 952
subjects C 116 952
, C 117 952
lysine C 118 952
vasopressin C 119 952
administered C 120 952
s C 121 952
. C 122 952
. C 123 952
. C 124 952
is C 126 952
7 C 127 952
. C 128 952
. C 129 952
times C 130 952
as C 131 952
effective C 132 952
as C 133 952
the C 134 952
nasal C 135 952
spray C 136 952
preparation C 137 952
. C 138 952
diabetes C 1 953
insipidus C 2 953
treatment C 3 953
with C 4 953
8 C 5 953
- C 6 953
lysine C 7 953
vasopressin C 8 953
in C 9 953
a C 10 953
nasal C 11 953
spray C 12 953
. C 13 953
synthetic C 15 953
8 C 16 953
- C 17 953
lysine C 18 953
vasopressin C 19 953
administered C 20 953
as C 21 953
a C 22 953
nasal C 23 953
spray C 24 953
to C 25 953
3 C 26 953
patients C 27 953
with C 28 953
diabetes C 29 953
insipidus C 30 953
resulted C 31 953
in C 32 953
excellent C 33 953
control C 34 953
in C 35 953
one C 36 953
. C 37 953
in C 39 953
the C 40 953
other C 41 953
2 C 42 953
it C 43 953
was C 44 953
of C 45 953
some C 46 953
value C 47 953
as C 48 953
therapy C 49 953
supplemental C 50 953
to C 51 953
pitressin C 52 953
tannate C 53 953
in C 54 953
oil C 55 953
. C 56 953
the C 58 953
patient C 59 953
who C 60 953
was C 61 953
adequately C 62 953
controlled C 63 953
with C 64 953
' C 65 953
spray C 66 953
therapy C 67 953
' C 68 953
alone C 69 953
required C 70 953
the C 71 953
sprays C 72 953
every C 73 953
3 C 74 953
hr C 75 953
. C 76 953
during C 78 953
the C 79 953
day C 80 953
, C 81 953
but C 82 953
none C 83 953
during C 84 953
the C 85 953
night C 86 953
. C 87 953
salt C 1 954
and C 2 954
water C 3 954
distribution C 4 954
in C 5 954
hereditary C 6 954
and C 7 954
in C 8 954
induced C 9 954
hypothalamic C 10 954
diabetes C 11 954
insipidus C 12 954
in C 13 954
the C 14 954
rat C 15 954
. C 16 954
salt C 18 954
and C 19 954
water C 20 954
metabolism C 21 954
and C 22 954
the C 23 954
distribution C 24 954
of C 25 954
na C 26 954
, C 27 954
k C 28 954
, C 29 954
and C 30 954
water C 31 954
in C 32 954
gastrocnemius C 33 954
and C 34 954
in C 35 954
aorta C 36 954
were C 37 954
measured C 38 954
in C 39 954
spontaneous C 40 954
hereditary C 41 954
hypothalamic C 42 954
and C 43 954
in C 44 954
surgically C 45 954
induced C 46 954
diabetes C 47 954
insipidus C 48 954
in C 49 954
the C 50 954
rat C 51 954
. C 52 954
the C 54 954
degree C 55 954
of C 56 954
severity C 57 954
in C 58 954
the C 59 954
2 C 60 954
types C 61 954
of C 62 954
the C 63 954
disease C 64 954
was C 65 954
estimated C 66 954
in C 67 954
terms C 68 954
of C 69 954
salt C 70 954
and C 71 954
water C 72 954
handling C 73 954
. C 74 954
water C 76 954
turnover C 77 954
in C 78 954
24 C 79 954
hr C 80 954
. C 81 954
was C 83 954
about C 84 954
equal C 85 954
to C 86 954
body C 87 954
weight C 88 954
in C 89 954
the C 90 954
hereditary C 91 954
disease C 92 954
and C 93 954
about C 94 954
60 C 95 954
% C 96 954
of C 97 954
body C 98 954
weight C 99 954
in C 100 954
the C 101 954
induced C 102 954
disease C 103 954
. C 104 954
skeletal C 106 954
muscle C 107 954
na C 108 954
increased C 109 954
more C 110 954
than C 111 954
20 C 112 954
% C 113 954
in C 114 954
the C 115 954
familial C 116 954
disease C 117 954
, C 118 954
and C 119 954
the C 120 954
gain C 121 954
involved C 122 954
both C 123 954
cells C 124 954
and C 125 954
environment C 126 954
. C 127 954
there C 129 954
was C 130 954
no C 131 954
corresponding C 132 954
loss C 133 954
of C 134 954
k C 135 954
. C 136 954
similar C 138 954
changes C 139 954
of C 140 954
lesser C 141 954
degree C 142 954
were C 143 954
noted C 144 954
in C 145 954
the C 146 954
induced C 147 954
disease C 148 954
. C 149 954
the C 151 954
degree C 152 954
of C 153 954
na C 154 954
accumulation C 155 954
appears C 156 954
to C 157 954
be C 158 954
partially C 159 954
dependent C 160 954
on C 161 954
the C 162 954
duration C 163 954
of C 164 954
the C 165 954
disease C 166 954
. C 167 954
antidiuresis C 1 955
induced C 2 955
by C 3 955
saluretics C 4 955
in C 5 955
diabetes C 6 955
insipidus C 7 955
. C 8 955
in C 10 955
hypothalamus C 11 955
- C 12 955
pituitary C 13 955
and C 14 955
less C 15 955
regularly C 16 955
in C 17 955
nephrogenic C 18 955
diabetes C 19 955
insipidus C 20 955
some C 21 955
diuretics C 22 955
cause C 23 955
a C 24 955
fall C 25 955
in C 26 955
diuresis C 27 955
mainly C 28 955
due C 29 955
to C 30 955
reduced C 31 955
excretion C 32 955
of C 33 955
free C 34 955
water C 35 955
. C 36 955
this C 38 955
adh C 39 955
- C 40 955
like C 41 955
action C 42 955
, C 43 955
not C 44 955
correlated C 45 955
with C 46 955
the C 47 955
extent C 48 955
of C 49 955
the C 50 955
natriuretic C 51 955
action C 52 955
or C 53 955
with C 54 955
salt C 55 955
depletion C 56 955
, C 57 955
depends C 58 955
on C 59 955
a C 60 955
direct C 61 955
effect C 62 955
of C 63 955
the C 64 955
drug C 65 955
on C 66 955
water C 67 955
permeability C 68 955
in C 69 955
the C 70 955
distal C 71 955
tubule C 72 955
and C 73 955
is C 74 955
suppressed C 75 955
by C 76 955
cortisone C 77 955
. C 78 955
it C 80 955
is C 81 955
maximal C 82 955
for C 83 955
the C 84 955
thiazide C 85 955
derivatives C 86 955
and C 87 955
diminishes C 88 955
progressively C 89 955
with C 90 955
mercurial C 91 955
compounds C 92 955
, C 93 955
spirolactones C 94 955
and C 95 955
triamterene C 96 955
in C 97 955
that C 98 955
order C 99 955
and C 100 955
is C 101 955
absent C 102 955
for C 103 955
acetazolamide C 104 955
. C 105 955
the C 107 955
reduction C 108 955
in C 109 955
glomerular C 110 955
filtration C 111 955
and C 112 955
increased C 113 955
proximal C 114 955
reabsorption C 115 955
of C 116 955
na C 117 955
following C 118 955
salt C 119 955
depletion C 120 955
induced C 121 955
by C 122 955
the C 123 955
diuretics C 124 955
is C 125 955
of C 126 955
less C 127 955
importance C 128 955
and C 129 955
irregular C 130 955
in C 131 955
appearance C 132 955
. C 133 955
congenital C 1 956
hydronephrosis C 2 956
. C 3 956
histological C 5 956
study C 6 956
of C 7 956
the C 8 956
renal C 9 956
parenchyma C 10 956
in C 11 956
cases C 12 956
of C 13 956
hydronephrosis C 14 956
is C 15 956
a C 16 956
guide C 17 956
for C 18 956
surgical C 19 956
treatment C 20 956
. C 21 956
if C 23 956
the C 24 956
renal C 25 956
parenchyma C 26 956
is C 27 956
reduced C 28 956
in C 29 956
thickness C 30 956
to C 31 956
3 C 32 956
mm C 33 956
. C 34 956
or C 36 956
less C 37 956
it C 38 956
leads C 39 956
to C 40 956
complete C 41 956
atrophy C 42 956
. C 43 956
but C 45 956
if C 46 956
the C 47 956
thickness C 48 956
is C 49 956
more C 50 956
than C 51 956
3 C 52 956
mm C 53 956
. C 54 956
conservative C 56 956
procedures C 57 956
are C 58 956
justified C 59 956
. C 60 956
neurohypophysial C 1 957
principles C 2 957
in C 3 957
rats C 4 957
with C 5 957
familial C 6 957
hypothalamic C 7 957
diabetes C 8 957
insipidus C 9 957
( C 10 957
brattleboro C 11 957
strain C 12 957
) C 13 957
. C 14 957
antidiuretic C 16 957
and C 17 957
oxytocic C 18 957
assays C 19 957
were C 20 957
performed C 21 957
on C 22 957
tissues C 23 957
from C 24 957
3 C 25 957
female C 26 957
rats C 27 957
with C 28 957
familial C 29 957
hypothalamic C 30 957
diabetes C 31 957
insipidus C 32 957
( C 33 957
di C 34 957
) C 35 957
and C 36 957
on C 37 957
3 C 38 957
normal C 39 957
females C 40 957
. C 41 957
oxytocic C 43 957
activity C 44 957
was C 45 957
only C 46 957
slightly C 47 957
lower C 48 957
in C 49 957
the C 50 957
pituitaries C 51 957
from C 52 957
the C 53 957
di C 54 957
rats C 55 957
. C 56 957
antidiuretic C 58 957
activity C 59 957
in C 60 957
the C 61 957
pituitaries C 62 957
from C 63 957
2 C 64 957
di C 65 957
rats C 66 957
was C 67 957
no C 68 957
more C 69 957
than C 70 957
that C 71 957
expected C 72 957
from C 73 957
their C 74 957
content C 75 957
of C 76 957
oxytocin C 77 957
. C 78 957
thus C 80 957
, C 81 957
these C 82 957
pituitaries C 83 957
appeared C 84 957
to C 85 957
contain C 86 957
oxytocin C 87 957
but C 88 957
not C 89 957
arginine C 90 957
vasopressin C 91 957
. C 92 957
the C 94 957
hypothalami C 95 957
from C 96 957
these C 97 957
2 C 98 957
rats C 99 957
showed C 100 957
minimal C 101 957
antidiuretic C 102 957
activity C 103 957
, C 104 957
which C 105 957
might C 106 957
have C 107 957
been C 108 957
due C 109 957
to C 110 957
oxytocin C 111 957
or C 112 957
vasopressin C 113 957
. C 114 957
the C 116 957
pituitary C 117 957
from C 118 957
the C 119 957
third C 120 957
di C 121 957
rat C 122 957
contained C 123 957
more C 124 957
antidiuretic C 125 957
activity C 126 957
than C 127 957
could C 128 957
be C 129 957
due C 130 957
to C 131 957
oxytocin C 132 957
. C 133 957
antidiuretic C 135 957
responses C 136 957
to C 137 957
extracts C 138 957
of C 139 957
pituitary C 140 957
and C 141 957
hypothalamus C 142 957
from C 143 957
this C 144 957
rat C 145 957
resembled C 146 957
those C 147 957
produced C 148 957
by C 149 957
arginine C 150 957
vasopressin C 151 957
. C 152 957
this C 154 957
pituitary C 155 957
appeared C 156 957
to C 157 957
contain C 158 957
about C 159 957
1 C 160 957
/ C 161 957
100 C 162 957
the C 163 957
normal C 164 957
amount C 165 957
of C 166 957
vasopressin C 167 957
. C 168 957
since C 170 957
vasopressin C 171 957
can C 172 957
inhibit C 173 957
diuresis C 174 957
in C 175 957
these C 176 957
di C 177 957
rats C 178 957
, C 179 957
it C 180 957
would C 181 957
appear C 182 957
that C 183 957
they C 184 957
have C 185 957
a C 186 957
specific C 187 957
deficiency C 188 957
of C 189 957
endogenous C 190 957
arginine C 191 957
vasopressin C 192 957
. C 193 957
familial C 1 958
renal C 2 958
diabetes C 3 958
insipidus C 4 958
. C 5 958
renal C 7 958
diabetes C 8 958
insipidus C 9 958
has C 10 958
been C 11 958
known C 12 958
for C 13 958
20 C 14 958
yr C 15 958
. C 16 958
only C 18 958
. C 19 958
the C 21 958
first C 22 958
german C 23 958
report C 24 958
on C 25 958
such C 26 958
a C 27 958
case C 28 958
appeared C 29 958
in C 30 958
1957 C 31 958
. C 32 958
nevertheless C 34 958
this C 35 958
disease C 36 958
appears C 37 958
to C 38 958
be C 39 958
more C 40 958
frequent C 41 958
, C 42 958
also C 43 958
in C 44 958
germany C 45 958
. C 46 958
a C 48 958
report C 49 958
is C 50 958
given C 51 958
on C 52 958
4 C 53 958
infants C 54 958
from C 55 958
2 C 56 958
families C 57 958
with C 58 958
a C 59 958
verified C 60 958
diagnosis C 61 958
. C 62 958
in C 64 958
the C 65 958
one C 66 958
family C 67 958
there C 68 958
were C 69 958
3 C 70 958
other C 71 958
cases C 72 958
with C 73 958
the C 74 958
features C 75 958
of C 76 958
the C 77 958
disease C 78 958
( C 79 958
polydipsia C 80 958
, C 81 958
polyuria C 82 958
, C 83 958
low C 84 958
sg C 85 958
of C 86 958
the C 87 958
urine C 88 958
) C 89 958
. C 90 958
in C 92 958
the C 93 958
other C 94 958
family C 95 958
anamnestic C 96 958
studies C 97 958
revealed C 98 958
5 C 99 958
such C 100 958
cases C 101 958
. C 102 958
evaluation C 1 959
of C 2 959
20 C 3 959
years C 4 959
' C 5 959
experience C 6 959
with C 7 959
the C 8 959
treatment C 9 959
of C 10 959
hydrocephalus C 11 959
in C 12 959
infants C 13 959
. C 14 959
a C 16 959
total C 17 959
of C 18 959
394 C 19 959
infants C 20 959
were C 21 959
examined C 22 959
between C 23 959
1943 C 24 959
and C 25 959
1962 C 26 959
. C 27 959
till C 29 959
1961 C 30 959
, C 31 959
369 C 32 959
infants C 33 959
were C 34 959
examined C 35 959
and C 36 959
246 C 37 959
were C 38 959
operated C 39 959
on C 40 959
( C 41 959
66 C 42 959
. C 43 959
. C 44 959
% C 45 959
) C 46 959
; C 47 959
this C 48 959
group C 49 959
is C 50 959
analyzed C 51 959
. C 52 959
laurence C 54 959
' C 55 959
s C 56 959
opinion C 57 959
on C 58 959
the C 59 959
favorable C 60 959
spontaneous C 61 959
evolution C 62 959
is C 63 959
not C 64 959
agreed C 65 959
to C 66 959
and C 67 959
the C 68 959
merits C 69 959
of C 70 959
surgical C 71 959
treatment C 72 959
are C 73 959
proved C 74 959
. C 75 959
a C 77 959
dynamic C 78 959
form C 79 959
of C 80 959
hydrocephalus C 81 959
in C 82 959
operated C 83 959
infants C 84 959
is C 85 959
shown C 86 959
; C 87 959
the C 88 959
patients C 89 959
who C 90 959
were C 91 959
not C 92 959
operated C 93 959
on C 94 959
suffered C 95 959
from C 96 959
other C 97 959
diseases C 98 959
combined C 99 959
with C 100 959
macrocephaly C 101 959
which C 102 959
must C 103 959
be C 104 959
distinguished C 105 959
from C 106 959
hydrocephalus C 107 959
. C 108 959
a C 110 959
spontaneous C 111 959
arrest C 112 959
of C 113 959
the C 114 959
process C 115 959
was C 116 959
observed C 117 959
in C 118 959
only C 119 959
14 C 120 959
children C 121 959
, C 122 959
e C 123 959
. C 124 959
. C 125 959
. C 126 959
3 C 128 959
. C 129 959
. C 130 959
% C 131 959
, C 132 959
as C 133 959
compared C 134 959
with C 135 959
laurence C 136 959
' C 137 959
s C 138 959
42 C 139 959
. C 140 959
. C 141 959
% C 142 959
. C 143 959
the C 145 959
cause C 146 959
and C 147 959
pathological C 148 959
findings C 149 959
are C 150 959
analyzed C 151 959
in C 152 959
102 C 153 959
infants C 154 959
operated C 155 959
on C 156 959
between C 157 959
1957 C 158 959
and C 159 959
1962 C 160 959
. C 161 959
a C 163 959
great C 164 959
discrepancy C 165 959
between C 166 959
the C 167 959
time C 168 959
of C 169 959
the C 170 959
onset C 171 959
of C 172 959
first C 173 959
symptoms C 174 959
and C 175 959
the C 176 959
time C 177 959
of C 178 959
operation C 179 959
was C 180 959
found C 181 959
. C 182 959
this C 184 959
disease C 185 959
manifests C 186 959
itself C 187 959
in C 188 959
50 C 189 959
% C 190 959
of C 191 959
infants C 192 959
in C 193 959
the C 194 959
first C 195 959
month C 196 959
of C 197 959
life C 198 959
, C 199 959
but C 200 959
the C 201 959
average C 202 959
age C 203 959
of C 204 959
infants C 205 959
at C 206 959
the C 207 959
time C 208 959
of C 209 959
operation C 210 959
is C 211 959
6 C 212 959
. C 213 959
. C 214 959
mth C 215 959
. C 216 959
only C 218 959
3 C 219 959
% C 220 959
of C 221 959
infants C 222 959
are C 223 959
operated C 224 959
on C 225 959
in C 226 959
the C 227 959
first C 228 959
month C 229 959
. C 230 959
thirteen C 232 959
operating C 233 959
procedures C 234 959
were C 235 959
used C 236 959
in C 237 959
the C 238 959
20 C 239 959
yr C 240 959
. C 241 959
under C 243 959
review C 244 959
. C 245 959
until C 247 959
the C 248 959
introduction C 249 959
of C 250 959
deviation C 251 959
of C 252 959
the C 253 959
csf C 254 959
into C 255 959
the C 256 959
jugular C 257 959
vein C 258 959
or C 259 959
into C 260 959
the C 261 959
cardiac C 262 959
atrium C 263 959
, C 264 959
15 C 265 959
. C 266 959
. C 267 959
. C 267 959
% C 268 959
of C 269 959
the C 270 959
infants C 271 959
survived C 272 959
1 C 273 959
yr C 274 959
. C 275 959
after C 277 959
operation C 278 959
. C 279 959
since C 281 959
the C 282 959
introduction C 283 959
of C 284 959
this C 285 959
procedure C 286 959
the C 287 959
survival C 288 959
rate C 289 959
of C 290 959
infants C 291 959
was C 292 959
67 C 293 959
. C 294 959
. C 295 959
% C 296 959
. C 297 959
in C 299 959
spite C 300 959
of C 301 959
the C 302 959
late C 303 959
operation C 304 959
about C 305 959
27 C 306 959
% C 307 959
of C 308 959
surviving C 309 959
children C 310 959
showed C 311 959
an C 312 959
average C 313 959
mental C 314 959
development C 315 959
. C 316 959
surgical C 318 959
treatment C 319 959
of C 320 959
dynamic C 321 959
hydrocephalus C 322 959
is C 323 959
advocated C 324 959
. C 325 959
they C 327 959
consider C 328 959
this C 329 959
method C 330 959
as C 331 959
the C 332 959
only C 333 959
means C 334 959
of C 335 959
helping C 336 959
the C 337 959
infant C 338 959
at C 339 959
present C 340 959
. C 341 959
cerebrospinal C 1 960
fluid C 2 960
dynamics C 3 960
in C 4 960
the C 5 960
arnold C 6 960
- C 7 960
chiari C 8 960
malformation C 9 960
. C 10 960
a C 12 960
method C 13 960
using C 14 960
radio C 15 960
- C 16 960
iodinated C 17 960
serum C 18 960
albumin C 19 960
to C 20 960
measure C 21 960
the C 22 960
volume C 23 960
of C 24 960
the C 25 960
ventricular C 26 960
system C 27 960
, C 28 960
and C 29 960
the C 30 960
rate C 31 960
of C 32 960
disappearance C 33 960
of C 34 960
csf C 35 960
from C 36 960
the C 37 960
lateral C 38 960
ventricles C 39 960
, C 40 960
has C 41 960
been C 42 960
described C 43 960
. C 44 960
newborn C 46 960
infants C 47 960
with C 48 960
a C 49 960
rate C 50 960
of C 51 960
flow C 52 960
less C 53 960
than C 54 960
70 C 55 960
ml C 56 960
. C 57 960
/ C 59 960
24 C 60 960
hr C 61 960
. C 62 960
after C 64 960
surgical C 65 960
repair C 66 960
of C 67 960
the C 68 960
myclomeningocele C 69 960
will C 70 960
develop C 71 960
progressive C 72 960
hydrocephalus C 73 960
requiring C 74 960
a C 75 960
ventriculo C 76 960
- C 77 960
atrial C 78 960
shunt C 79 960
. C 80 960
the C 82 960
test C 83 960
can C 84 960
be C 85 960
used C 86 960
to C 87 960
detect C 88 960
the C 89 960
patency C 90 960
of C 91 960
a C 92 960
ventriculo C 93 960
- C 94 960
atrial C 95 960
shunt C 96 960
, C 97 960
and C 98 960
may C 99 960
allow C 100 960
safe C 101 960
removal C 102 960
of C 103 960
the C 104 960
shunt C 105 960
in C 106 960
selected C 107 960
patients C 108 960
. C 109 960
coexistent C 1 961
cranial C 2 961
and C 3 961
spinal C 4 961
defects C 5 961
with C 6 961
hydrocephalus C 7 961
in C 8 961
five C 9 961
infants C 10 961
. C 11 961
the C 13 961
etiology C 14 961
and C 15 961
significance C 16 961
of C 17 961
craniolacunia C 18 961
in C 19 961
these C 20 961
defects C 21 961
. C 22 961
the C 24 961
clinical C 25 961
, C 26 961
roentgenographic C 27 961
and C 28 961
etiologic C 29 961
factors C 30 961
in C 31 961
5 C 32 961
infants C 33 961
with C 34 961
varying C 35 961
cranial C 36 961
defects C 37 961
( C 38 961
craniolacunia C 39 961
and C 40 961
craniofenestra C 41 961
or C 42 961
cranial C 43 961
meningocele C 44 961
) C 45 961
, C 46 961
hydrocephalus C 47 961
, C 48 961
and C 49 961
spinal C 50 961
defects C 51 961
( C 52 961
meningocele C 53 961
or C 54 961
myelomeningocele C 55 961
) C 56 961
are C 57 961
described C 58 961
. C 59 961
all C 61 961
of C 62 961
the C 63 961
infants C 64 961
expired C 65 961
of C 66 961
bacterial C 67 961
complications C 68 961
. C 69 961
the C 71 961
etiologic C 72 961
factors C 73 961
and C 74 961
significance C 75 961
of C 76 961
cranial C 77 961
defects C 78 961
in C 79 961
these C 80 961
coexistent C 81 961
malformations C 82 961
of C 83 961
the C 84 961
central C 85 961
nervous C 86 961
system C 87 961
are C 88 961
reviewed C 89 961
. C 90 961
hydrocephalus C 1 962
and C 2 962
myelomeningocele C 3 962
. C 4 962
central C 6 962
nervous C 7 962
system C 8 962
infection C 9 962
. C 10 962
a C 12 962
series C 13 962
of C 14 962
38 C 15 962
incidents C 16 962
of C 17 962
cns C 18 962
infection C 19 962
in C 20 962
34 C 21 962
patients C 22 962
with C 23 962
hydrocephalus C 24 962
, C 25 962
myelomeningocele C 26 962
, C 27 962
or C 28 962
both C 29 962
have C 30 962
been C 31 962
summarized C 32 962
. C 33 962
gram C 35 962
- C 36 962
positive C 37 962
organisms C 38 962
occurred C 39 962
more C 40 962
frequently C 41 962
and C 42 962
caused C 43 962
infections C 44 962
resulting C 45 962
in C 46 962
a C 47 962
mortality C 48 962
of C 49 962
33 C 50 962
% C 51 962
. C 52 962
the C 54 962
gram C 55 962
- C 56 962
negative C 57 962
organism C 58 962
induced C 59 962
infections C 60 962
resulted C 61 962
in C 62 962
a C 63 962
mortality C 64 962
of C 65 962
60 C 66 962
% C 67 962
. C 68 962
nearly C 70 962
50 C 71 962
% C 72 962
of C 73 962
the C 74 962
infections C 75 962
occurred C 76 962
in C 77 962
patients C 78 962
before C 79 962
any C 80 962
shunting C 81 962
procedure C 82 962
was C 83 962
done C 84 962
. C 85 962
the C 87 962
staphylococcus C 88 962
caused C 89 962
two C 90 962
- C 91 962
thirds C 92 962
of C 93 962
the C 94 962
infections C 95 962
in C 96 962
patients C 97 962
with C 98 962
a C 99 962
shunt C 100 962
in C 101 962
situ C 102 962
. C 103 962
no C 105 962
obvious C 106 962
portal C 107 962
of C 108 962
entry C 109 962
could C 110 962
be C 111 962
demonstrated C 112 962
in C 113 962
a C 114 962
majority C 115 962
of C 116 962
patients C 117 962
. C 118 962
of C 120 962
5 C 121 962
patients C 122 962
who C 123 962
received C 124 962
nonspecific C 125 962
prophylactic C 126 962
therapy C 127 962
because C 128 962
of C 129 962
an C 130 962
oozing C 131 962
myelomeningocele C 132 962
4 C 133 962
survived C 134 962
. C 135 962
of C 137 962
the C 138 962
5 C 139 962
given C 140 962
no C 141 962
prophylactic C 142 962
therapy C 143 962
, C 144 962
one C 145 962
survived C 146 962
. C 147 962
a C 149 962
combination C 150 962
of C 151 962
kanamycin C 152 962
, C 153 962
sodium C 154 962
methicillin C 155 962
, C 156 962
and C 157 962
chloramphenicol C 158 962
appeared C 159 962
in C 160 962
vitro C 161 962
to C 162 962
be C 163 962
effective C 164 962
against C 165 962
most C 166 962
of C 167 962
the C 168 962
gram C 169 962
- C 170 962
positive C 171 962
cocci C 172 962
. C 173 962
the C 175 962
combination C 176 962
of C 177 962
chloramphenicol C 178 962
, C 179 962
kanamycin C 180 962
, C 181 962
and C 182 962
polymixin C 183 962
b C 184 962
appeared C 185 962
in C 186 962
vitro C 187 962
to C 188 962
be C 189 962
an C 190 962
effective C 191 962
combination C 192 962
against C 193 962
most C 194 962
of C 195 962
the C 196 962
gram C 197 962
- C 198 962
negative C 199 962
bacilli C 200 962
. C 201 962
myelomeningocele C 1 963
and C 2 963
hydrocephalus C 3 963
. C 4 963
the C 6 963
first C 7 963
year C 8 963
of C 9 963
50 C 10 963
patients C 11 963
. C 12 963
fifty C 14 963
infants C 15 963
with C 16 963
hydrocephalus C 17 963
and C 18 963
myelomeningocele C 19 963
were C 20 963
treated C 21 963
comprehensively C 22 963
by C 23 963
a C 24 963
team C 25 963
of C 26 963
specialists C 27 963
. C 28 963
patients C 30 963
were C 31 963
evaluated C 32 963
at C 33 963
death C 34 963
or C 35 963
the C 36 963
first C 37 963
birthday C 38 963
, C 39 963
whichever C 40 963
occurred C 41 963
first C 42 963
. C 43 963
twenty C 45 963
patients C 46 963
died C 47 963
, C 48 963
13 C 49 963
from C 50 963
bacterial C 51 963
infection C 52 963
. C 53 963
thirteen C 55 963
of C 56 963
the C 57 963
survivors C 58 963
were C 59 963
classified C 60 963
as C 61 963
noncompetitive C 62 963
, C 63 963
that C 64 963
is C 65 963
, C 66 963
were C 67 963
thought C 68 963
to C 69 963
have C 70 963
a C 71 963
poor C 72 963
prognosis C 73 963
based C 74 963
on C 75 963
a C 76 963
developmental C 77 963
quotient C 78 963
of C 79 963
less C 80 963
than C 81 963
80 C 82 963
. C 83 963
seventeen C 85 963
patients C 86 963
were C 87 963
judged C 88 963
competitive C 89 963
; C 90 963
in C 91 963
each C 92 963
case C 93 963
the C 94 963
latest C 95 963
developmental C 96 963
quotient C 97 963
was C 98 963
more C 99 963
than C 100 963
79 C 101 963
and C 102 963
the C 103 963
urinary C 104 963
tract C 105 963
was C 106 963
not C 107 963
irreversibly C 108 963
decompensated C 109 963
. C 110 963
developmental C 112 963
quotient C 113 963
was C 114 963
based C 115 963
on C 116 963
motor C 117 963
development C 118 963
, C 119 963
adaptive C 120 963
behavior C 121 963
, C 122 963
language C 123 963
development C 124 963
, C 125 963
and C 126 963
personal C 127 963
- C 128 963
social C 129 963
development C 130 963
. C 131 963
this C 133 963
report C 134 963
is C 135 963
a C 136 963
progress C 137 963
report C 138 963
in C 139 963
a C 140 963
longitudinal C 141 963
study C 142 963
. C 143 963
in C 145 963
comparison C 146 963
with C 147 963
a C 148 963
previously C 149 963
surveyed C 150 963
group C 151 963
the C 152 963
results C 153 963
seem C 154 963
encouraging C 155 963
: C 156 963
current C 157 963
data C 158 963
from C 159 963
39 C 160 963
older C 161 963
patients C 162 963
followed C 163 963
6 C 164 963
to C 165 963
13 C 166 963
yr C 167 963
. C 168 963
show C 170 963
2 C 171 963
competitive C 172 963
survivors C 173 963
, C 174 963
11 C 175 963
noncompetitive C 176 963
survivors C 177 963
, C 178 963
and C 179 963
26 C 180 963
deaths C 181 963
. C 182 963
pneumoencephalographic C 1 964
changes C 2 964
in C 3 964
the C 4 964
cavum C 5 964
septi C 6 964
pellucidi C 7 964
and C 8 964
their C 9 964
clinical C 10 964
significance C 11 964
. C 12 964
the C 14 964
pneumoencephalographic C 15 964
appearances C 16 964
and C 17 964
clinical C 18 964
problems C 19 964
associated C 20 964
with C 21 964
communicating C 22 964
and C 23 964
non C 24 964
- C 25 964
communicating C 26 964
cavum C 27 964
septi C 28 964
pellucidi C 29 964
are C 30 964
discussed C 31 964
on C 32 964
the C 33 964
basis C 34 964
of C 35 964
11 C 36 964
cases C 37 964
. C 38 964
non C 40 964
- C 41 964
communicating C 42 964
csp C 43 964
may C 44 964
lead C 45 964
to C 46 964
intermittent C 47 964
headaches C 48 964
due C 49 964
to C 50 964
variations C 51 964
of C 52 964
intracranial C 53 964
pressure C 54 964
and C 55 964
obstruction C 56 964
to C 57 964
the C 58 964
flow C 59 964
of C 60 964
csf C 61 964
. C 62 964
in C 64 964
rare C 65 964
cases C 66 964
, C 67 964
representing C 68 964
a C 69 964
special C 70 964
etiological C 71 964
group C 72 964
, C 73 964
the C 74 964
foramina C 75 964
of C 76 964
monro C 77 964
and C 78 964
the C 79 964
aqueduct C 80 964
may C 81 964
be C 82 964
narrowed C 83 964
. C 84 964
a C 86 964
communicating C 87 964
csp C 88 964
is C 89 964
generally C 90 964
associated C 91 964
with C 92 964
mild C 93 964
to C 94 964
moderate C 95 964
symmetrical C 96 964
internal C 97 964
hydrocephalus C 98 964
. C 99 964
in C 101 964
the C 102 964
author C 103 964
' C 104 964
s C 105 964
opinion C 106 964
this C 107 964
is C 108 964
in C 109 964
most C 110 964
cases C 111 964
a C 112 964
direct C 113 964
result C 114 964
of C 115 964
the C 116 964
cavum C 117 964
, C 118 964
since C 119 964
fluid C 120 964
continues C 121 964
to C 122 964
be C 123 964
formed C 124 964
in C 125 964
the C 126 964
cavum C 127 964
after C 128 964
communication C 129 964
with C 130 964
the C 131 964
rest C 132 964
of C 133 964
the C 134 964
ventricular C 135 964
system C 136 964
has C 137 964
been C 138 964
established C 139 964
. C 140 964
the C 142 964
conditions C 143 964
resemble C 144 964
those C 145 964
in C 146 964
hypersecretory C 147 964
hydrocephalus C 148 964
. C 149 964
for C 151 964
these C 152 964
reasons C 153 964
the C 154 964
author C 155 964
rejects C 156 964
the C 157 964
view C 158 964
that C 159 964
a C 160 964
communicating C 161 964
csp C 162 964
is C 163 964
of C 164 964
no C 165 964
clinical C 166 964
significance C 167 964
. C 168 964
in C 170 964
some C 171 964
cases C 172 964
the C 173 964
possibility C 174 964
of C 175 964
a C 176 964
combination C 177 964
of C 178 964
a C 179 964
cavum C 180 964
with C 181 964
a C 182 964
cerebral C 183 964
malformation C 184 964
must C 185 964
be C 186 964
considered C 187 964
. C 188 964
posterior C 1 965
scalloping C 2 965
of C 3 965
vertebral C 4 965
bodies C 5 965
in C 6 965
uncontrolled C 7 965
hydrocephalus C 8 965
. C 9 965
two C 11 965
cases C 12 965
of C 13 965
extensive C 14 965
posterior C 15 965
scalloping C 16 965
of C 17 965
the C 18 965
vertebral C 19 965
bodies C 20 965
are C 21 965
presented C 22 965
in C 23 965
men C 24 965
aged C 25 965
17 C 26 965
and C 27 965
23 C 28 965
years C 29 965
, C 30 965
having C 31 965
long C 32 965
- C 33 965
standing C 34 965
hydrocephalus C 35 965
. C 36 965
two C 38 965
additional C 39 965
cases C 40 965
with C 41 965
scalloping C 42 965
of C 43 965
only C 44 965
one C 45 965
lumbar C 46 965
vertebra C 47 965
when C 48 965
partially C 49 965
controlled C 50 965
hydrocephalus C 51 965
has C 52 965
been C 53 965
present C 54 965
for C 55 965
a C 56 965
shorter C 57 965
time C 58 965
are C 59 965
also C 60 965
noted C 61 965
. C 62 965
no C 64 965
previous C 65 965
association C 66 965
between C 67 965
these C 68 965
entities C 69 965
has C 70 965
been C 71 965
recorded C 72 965
. C 73 965
it C 75 965
is C 76 965
supposed C 77 965
that C 78 965
the C 79 965
increased C 80 965
intraspinal C 81 965
pressure C 82 965
which C 83 965
must C 84 965
have C 85 965
been C 86 965
present C 87 965
in C 88 965
the C 89 965
first C 90 965
2 C 91 965
patients C 92 965
for C 93 965
many C 94 965
years C 95 965
, C 96 965
was C 97 965
present C 98 965
near C 99 965
the C 100 965
time C 101 965
of C 102 965
closure C 103 965
of C 104 965
the C 105 965
epiphysis C 106 965
at C 107 965
the C 108 965
junction C 109 965
of C 110 965
the C 111 965
arch C 112 965
and C 113 965
the C 114 965
bodies C 115 965
and C 116 965
caused C 117 965
not C 118 965
only C 119 965
widening C 120 965
of C 121 965
the C 122 965
spinal C 123 965
canal C 124 965
but C 125 965
also C 126 965
excavation C 127 965
of C 128 965
the C 129 965
vertebral C 130 965
bodies C 131 965
. C 132 965
scalloping C 134 965
of C 135 965
vertebral C 136 965
bodies C 137 965
has C 138 965
been C 139 965
described C 140 965
in C 141 965
: C 142 965
( C 143 965
1 C 144 965
) C 145 965
neoplasms C 146 965
( C 147 965
neurofibromas C 148 965
, C 149 965
meningiomas C 150 965
, C 151 965
gliomas C 152 965
, C 153 965
hemangio C 154 965
- C 155 965
endotheliomas C 156 965
, C 157 965
hemangiomas C 158 965
, C 159 965
lipomas C 160 965
) C 161 965
: C 162 965
( C 163 965
2 C 164 965
) C 165 965
intraspinal C 166 965
cysts C 167 965
( C 168 965
intradural C 169 965
arachnoid C 170 965
cysts C 171 965
, C 172 965
tarlov C 173 965
' C 174 965
s C 175 965
perineural C 176 965
cysts C 177 965
, C 178 965
thoracic C 179 965
extradural C 180 965
cysts C 181 965
in C 182 965
kyphosis C 183 965
dorsalis C 184 965
juvenilis C 185 965
) C 186 965
: C 187 965
( C 188 965
3 C 189 965
) C 190 965
congenital C 191 965
anomalies C 192 965
of C 193 965
the C 194 965
spine C 195 965
and C 196 965
cord C 197 965
( C 198 965
fusion C 199 965
defects C 200 965
, C 201 965
myelodysplasia C 202 965
, C 203 965
hydromyelia C 204 965
, C 205 965
absence C 206 965
of C 207 965
a C 208 965
single C 209 965
vertebral C 210 965
pedicle C 211 965
, C 212 965
meningoceles C 213 965
) C 214 965
: C 215 965
and C 216 965
( C 217 965
4 C 218 965
) C 219 965
neurofibromatosis C 220 965
( C 221 965
with C 222 965
or C 223 965
without C 224 965
a C 225 965
thoracic C 226 965
meningocele C 227 965
) C 228 965
. C 229 965
electroencephalographic C 1 966
picture C 2 966
of C 3 966
the C 4 966
infantile C 5 966
hydrocephalus C 6 966
. C 7 966
in C 9 966
50 C 10 966
% C 11 966
of C 12 966
33 C 13 966
cases C 14 966
of C 15 966
congenital C 16 966
hydrocephalus C 17 966
the C 18 966
eeg C 19 966
examinations C 20 966
were C 21 966
normal C 22 966
. C 23 966
asymmetry C 25 966
of C 26 966
the C 27 966
eeg C 28 966
recording C 29 966
was C 30 966
the C 31 966
most C 32 966
common C 33 966
abnormality C 34 966
encountered C 35 966
both C 36 966
in C 37 966
congenital C 38 966
and C 39 966
in C 40 966
acquired C 41 966
hydrocephalus C 42 966
. C 43 966
none C 45 966
of C 46 966
the C 47 966
children C 48 966
examined C 49 966
revealed C 50 966
any C 51 966
focal C 52 966
neurological C 53 966
symptoms C 54 966
. C 55 966
it C 57 966
is C 58 966
concluded C 59 966
that C 60 966
eeg C 61 966
examinations C 62 966
could C 63 966
be C 64 966
useful C 65 966
in C 66 966
differentiating C 67 966
congenital C 68 966
from C 69 966
acquired C 70 966
hydrocephalus C 71 966
, C 72 966
because C 73 966
a C 74 966
normal C 75 966
eeg C 76 966
recording C 77 966
suggested C 78 966
the C 79 966
congenital C 80 966
nature C 81 966
of C 82 966
the C 83 966
condition C 84 966
. C 85 966
consecutive C 1 967
hydrocephalus C 2 967
. C 3 967
report C 5 967
of C 6 967
2 C 7 967
cases C 8 967
. C 9 967
two C 11 967
patients C 12 967
, C 13 967
each C 14 967
with C 15 967
3 C 16 967
consecutive C 17 967
hydrocephalic C 18 967
newborns C 19 967
, C 20 967
are C 21 967
reported C 22 967
. C 23 967
consanguinity C 25 967
was C 26 967
present C 27 967
in C 28 967
both C 29 967
families C 30 967
. C 31 967
a C 33 967
genetic C 34 967
basis C 35 967
for C 36 967
the C 37 967
hydrocephalus C 38 967
is C 39 967
suggested C 40 967
. C 41 967
fanconi C 1 968
' C 2 968
s C 3 968
anaemia C 4 968
with C 5 968
hydrocephalus C 6 968
and C 7 968
thyroid C 8 968
abnormality C 9 968
. C 10 968
a C 12 968
case C 13 968
is C 14 968
described C 15 968
in C 16 968
a C 17 968
girl C 18 968
who C 19 968
suffered C 20 968
from C 21 968
dwarfism C 22 968
due C 23 968
to C 24 968
congenital C 25 968
hypoplasia C 26 968
of C 27 968
the C 28 968
pituitary C 29 968
and C 30 968
from C 31 968
other C 32 968
congenital C 33 968
malformations C 34 968
. C 35 968
the C 37 968
pancytopenia C 38 968
manifested C 39 968
itself C 40 968
at C 41 968
the C 42 968
age C 43 968
of C 44 968
2 C 45 968
yr C 46 968
. C 47 968
and C 49 968
was C 50 968
resistant C 51 968
to C 52 968
a C 53 968
combined C 54 968
corticosteroid C 55 968
- C 56 968
testosterone C 57 968
treatment C 58 968
. C 59 968
unusual C 61 968
findings C 62 968
in C 63 968
this C 64 968
case C 65 968
were C 66 968
congenital C 67 968
hydrocephalus C 68 968
, C 69 968
hypoplastic C 70 968
spleen C 71 968
, C 72 968
and C 73 968
hypoplasia C 74 968
of C 75 968
thyroid C 76 968
together C 77 968
with C 78 968
persistently C 79 968
high C 80 968
pbi C 81 968
serum C 82 968
levels C 83 968
but C 84 968
without C 85 968
apparent C 86 968
changes C 87 968
in C 88 968
thyroid C 89 968
function C 90 968
. C 91 968
dandy C 1 969
- C 2 969
walker C 3 969
- C 4 969
taggart C 5 969
' C 6 969
syndrome C 7 969
' C 8 969
( C 9 969
a C 10 969
case C 11 969
report C 12 969
) C 13 969
. C 14 969
dandy C 16 969
- C 17 969
walker C 18 969
- C 19 969
taggart C 20 969
' C 21 969
syndrome C 22 969
' C 23 969
in C 24 969
a C 25 969
6 C 26 969
- C 27 969
month C 28 969
- C 29 969
old C 30 969
girl C 31 969
has C 32 969
been C 33 969
substantiated C 34 969
by C 35 969
a C 36 969
correlation C 37 969
of C 38 969
clinical C 39 969
and C 40 969
pathological C 41 969
features C 42 969
. C 43 969
all C 45 969
3 C 46 969
exit C 47 969
foramina C 48 969
of C 49 969
the C 50 969
4 C 51 969
th C 52 969
ventricle C 53 969
have C 54 969
failed C 55 969
to C 56 969
open C 57 969
, C 58 969
resulting C 59 969
in C 60 969
severe C 61 969
cystic C 62 969
dilatation C 63 969
of C 64 969
the C 65 969
ventricle C 66 969
and C 67 969
hypoplastic C 68 969
distortion C 69 969
of C 70 969
posterior C 71 969
midline C 72 969
cerebellar C 73 969
structures C 74 969
. C 75 969
hydrocephalus C 1 970
due C 2 970
to C 3 970
smallpox C 4 970
occurring C 5 970
in C 6 970
the C 7 970
fetal C 8 970
period C 9 970
. C 10 970
out C 12 970
of C 13 970
450 C 14 970
cases C 15 970
of C 16 970
hydrocephalus C 17 970
in C 18 970
the C 19 970
years C 20 970
1959 C 21 970
- C 22 970
1962 C 23 970
, C 24 970
15 C 25 970
were C 26 970
found C 27 970
whose C 28 970
mothers C 29 970
had C 30 970
contracted C 31 970
variola C 32 970
after C 33 970
the C 34 970
3 C 35 970
rd C 36 970
month C 37 970
of C 38 970
pregnancy C 39 970
. C 40 970
based C 42 970
on C 43 970
these C 44 970
personal C 45 970
cases C 46 970
and C 47 970
the C 48 970
sparse C 49 970
data C 50 970
in C 51 970
the C 52 970
literature C 53 970
, C 54 970
the C 55 970
clinical C 56 970
, C 57 970
epidemiological C 58 970
, C 59 970
radiographical C 60 970
( C 61 970
skull C 62 970
) C 63 970
, C 64 970
biological C 65 970
and C 66 970
histopathological C 67 970
aspects C 68 970
are C 69 970
presented C 70 970
( C 71 970
2 C 72 970
fatal C 73 970
cases C 74 970
were C 75 970
histopathologically C 76 970
examined C 77 970
) C 78 970
. C 79 970
it C 81 970
could C 82 970
be C 83 970
demonstrated C 84 970
that C 85 970
the C 86 970
hydrocephalus C 87 970
occurred C 88 970
as C 89 970
a C 90 970
manifestation C 91 970
of C 92 970
a C 93 970
disease C 94 970
involving C 95 970
the C 96 970
fetus C 97 970
and C 98 970
was C 99 970
caused C 100 970
by C 101 970
a C 102 970
variola C 103 970
infection C 104 970
during C 105 970
gestation C 106 970
; C 107 970
inferences C 108 970
are C 109 970
given C 110 970
from C 111 970
the C 112 970
eeg C 113 970
and C 114 970
examination C 115 970
of C 116 970
the C 117 970
liquor C 118 970
. C 119 970
air C 1 971
- C 2 971
pantopaque C 3 971
ventriculography C 4 971
in C 5 971
congenital C 6 971
hydrocephalus C 7 971
and C 8 971
myelomeningocele C 9 971
. C 10 971
a C 12 971
study C 13 971
of C 14 971
the C 15 971
csf C 16 971
pathways C 17 971
by C 18 971
combined C 19 971
pantopaque C 20 971
- C 21 971
air C 22 971
ventriculography C 23 971
in C 24 971
infants C 25 971
with C 26 971
congenital C 27 971
hydrocephalus C 28 971
and C 29 971
myelomeningocele C 30 971
is C 31 971
presented C 32 971
. C 33 971
the C 35 971
advantages C 36 971
of C 37 971
this C 38 971
method C 39 971
are C 40 971
discussed C 41 971
. C 42 971
combined C 44 971
pantopaque C 45 971
and C 46 971
air C 47 971
ventriculography C 48 971
provides C 49 971
not C 50 971
only C 51 971
a C 52 971
demonstration C 53 971
of C 54 971
the C 55 971
extent C 56 971
of C 57 971
the C 58 971
hydrocephalus C 59 971
but C 60 971
also C 61 971
the C 62 971
exact C 63 971
location C 64 971
and C 65 971
cause C 66 971
of C 67 971
the C 68 971
obstruction C 69 971
. C 70 971
in C 72 971
infants C 73 971
with C 74 971
myelomeningocele C 75 971
it C 76 971
permits C 77 971
the C 78 971
disclosure C 79 971
of C 80 971
unmanifested C 81 971
hydrocephalus C 82 971
and C 83 971
coexistent C 84 971
intracranial C 85 971
malformations C 86 971
. C 87 971
the C 89 971
early C 90 971
detection C 91 971
of C 92 971
the C 93 971
latter C 94 971
is C 95 971
very C 96 971
important C 97 971
for C 98 971
the C 99 971
complete C 100 971
evaluation C 101 971
, C 102 971
management C 103 971
and C 104 971
prognosis C 105 971
. C 106 971
the C 108 971
introduction C 109 971
of C 110 971
pantopaque C 111 971
into C 112 971
the C 113 971
ventricular C 114 971
system C 115 971
of C 116 971
infants C 117 971
did C 118 971
not C 119 971
produce C 120 971
an C 121 971
immediate C 122 971
reaction C 123 971
and C 124 971
did C 125 971
not C 126 971
precipitate C 127 971
deterioration C 128 971
of C 129 971
the C 130 971
clinical C 131 971
status C 132 971
. C 133 971
retention C 135 971
of C 136 971
small C 137 971
amounts C 138 971
of C 139 971
pantopaque C 140 971
in C 141 971
the C 142 971
lateral C 143 971
ventricles C 144 971
did C 145 971
not C 146 971
interfere C 147 971
with C 148 971
the C 149 971
function C 150 971
of C 151 971
bypassing C 152 971
procedures C 153 971
. C 154 971
two C 1 972
cases C 2 972
of C 3 972
dandy C 4 972
walker C 5 972
' C 6 972
s C 7 972
syndrome C 8 972
. C 9 972
dandy C 11 972
walker C 12 972
' C 13 972
s C 14 972
syndrome C 15 972
refers C 16 972
to C 17 972
a C 18 972
particular C 19 972
kind C 20 972
of C 21 972
malformative C 22 972
hydrocephaly C 23 972
characterized C 24 972
anatomically C 25 972
by C 26 972
association C 27 972
with C 28 972
a C 29 972
more C 30 972
or C 31 972
less C 32 972
considerable C 33 972
agenesis C 34 972
of C 35 972
the C 36 972
cerebellar C 37 972
vermis C 38 972
and C 39 972
with C 40 972
an C 41 972
imperfection C 42 972
of C 43 972
the C 44 972
foramina C 45 972
of C 46 972
luschka C 47 972
and C 48 972
magendie C 49 972
. C 50 972
the C 52 972
dysgenetic C 53 972
nature C 54 972
of C 55 972
this C 56 972
picture C 57 972
is C 58 972
obvious C 59 972
, C 60 972
but C 61 972
the C 62 972
pathogenesis C 63 972
of C 64 972
the C 65 972
hydrocephaly C 66 972
is C 67 972
not C 68 972
simple C 69 972
and C 70 972
the C 71 972
etiology C 72 972
remains C 73 972
obscure C 74 972
. C 75 972
the C 77 972
malformation C 78 972
is C 79 972
compensated C 80 972
more C 81 972
or C 82 972
less C 83 972
quickly C 84 972
in C 85 972
the C 86 972
life C 87 972
of C 88 972
the C 89 972
subject C 90 972
. C 91 972
the C 93 972
clinical C 94 972
picture C 95 972
is C 96 972
that C 97 972
of C 98 972
a C 99 972
hydrocephaly C 100 972
by C 101 972
a C 102 972
tumor C 103 972
of C 104 972
the C 105 972
posterior C 106 972
fossa C 107 972
. C 108 972
the C 110 972
diagnosis C 111 972
can C 112 972
and C 113 972
must C 114 972
be C 115 972
carried C 116 972
out C 117 972
by C 118 972
x C 119 972
- C 120 972
ray C 121 972
examination C 122 972
, C 123 972
the C 124 972
ventriculographic C 125 972
images C 126 972
being C 127 972
pathognomonic C 128 972
. C 129 972
the C 131 972
extreme C 132 972
ease C 133 972
of C 134 972
surgical C 135 972
restoration C 136 972
of C 137 972
the C 138 972
passage C 139 972
of C 140 972
flow C 141 972
and C 142 972
the C 143 972
effectiveness C 144 972
of C 145 972
timely C 146 972
operation C 147 972
emphasize C 148 972
the C 149 972
interest C 150 972
of C 151 972
this C 152 972
syndrome C 153 972
, C 154 972
which C 155 972
turns C 156 972
out C 157 972
to C 158 972
be C 159 972
a C 160 972
rare C 161 972
kind C 162 972
of C 163 972
curable C 164 972
malformative C 165 972
hydrocephaly C 166 972
. C 167 972
the C 169 972
authors C 170 972
report C 171 972
2 C 172 972
unpublished C 173 972
cases C 174 972
in C 175 972
respect C 176 972
of C 177 972
3 C 178 972
- C 179 972
yr C 180 972
. C 181 972
- C 183 972
old C 184 972
children C 185 972
. C 186 972
the C 188 972
first C 189 972
, C 190 972
already C 191 972
going C 192 972
back C 193 972
several C 194 972
years C 195 972
( C 196 972
1945 C 197 972
) C 198 972
had C 199 972
unfavorable C 200 972
postoperational C 201 972
results C 202 972
. C 203 972
the C 205 972
second C 206 972
( C 207 972
1962 C 208 972
) C 209 972
recovered C 210 972
completely C 211 972
, C 212 972
without C 213 972
sequelae C 214 972
, C 215 972
after C 216 972
resection C 217 972
of C 218 972
the C 219 972
posterior C 220 972
wall C 221 972
of C 222 972
the C 223 972
cyst C 224 972
. C 225 972
incidence C 1 973
and C 2 973
treatment C 3 973
of C 4 973
post C 5 973
- C 6 973
meningitic C 7 973
hydrocephalus C 8 973
in C 9 973
the C 10 973
newborn C 11 973
. C 12 973
the C 14 973
incidence C 15 973
of C 16 973
meningitis C 17 973
in C 18 973
the C 19 973
first C 20 973
few C 21 973
weeks C 22 973
of C 23 973
life C 24 973
is C 25 973
higher C 26 973
than C 27 973
in C 28 973
any C 29 973
comparable C 30 973
period C 31 973
of C 32 973
life C 33 973
, C 34 973
even C 35 973
if C 36 973
cases C 37 973
associated C 38 973
with C 39 973
spina C 40 973
bifida C 41 973
cystica C 42 973
are C 43 973
excluded C 44 973
. C 45 973
the C 47 973
gravity C 48 973
of C 49 973
the C 50 973
prognosis C 51 973
even C 52 973
since C 53 973
the C 54 973
introduction C 55 973
of C 56 973
many C 57 973
powerful C 58 973
antibiotic C 59 973
drugs C 60 973
has C 61 973
been C 62 973
frequently C 63 973
emphasized C 64 973
. C 65 973
among C 67 973
the C 68 973
7 C 69 973
cases C 70 973
which C 71 973
occurred C 72 973
in C 73 973
a C 74 973
maternity C 75 973
unit C 76 973
, C 77 973
5 C 78 973
eventually C 79 973
made C 80 973
a C 81 973
complete C 82 973
recovery C 83 973
. C 84 973
in C 86 973
a C 87 973
group C 88 973
of C 89 973
19 C 90 973
infants C 91 973
who C 92 973
developed C 93 973
postmeningitic C 94 973
hydrocephalus C 95 973
and C 96 973
were C 97 973
referred C 98 973
either C 99 973
with C 100 973
still C 101 973
active C 102 973
meningitis C 103 973
or C 104 973
the C 105 973
postmeningitic C 106 973
state C 107 973
, C 108 973
only C 109 973
1 C 110 973
infant C 111 973
could C 112 973
not C 113 973
be C 114 973
treated C 115 973
by C 116 973
a C 117 973
ventriculocaval C 118 973
shunt C 119 973
. C 120 973
this C 122 973
infant C 123 973
and C 124 973
4 C 125 973
others C 126 973
died C 127 973
later C 128 973
. C 129 973
of C 131 973
the C 132 973
14 C 133 973
survivors C 134 973
, C 135 973
7 C 136 973
recovered C 137 973
without C 138 973
sequelae C 139 973
, C 140 973
in C 141 973
spite C 142 973
of C 143 973
extreme C 144 973
hydrocephalus C 145 973
which C 146 973
was C 147 973
demonstrated C 148 973
by C 149 973
air C 150 973
studies C 151 973
before C 152 973
operation C 153 973
. C 154 973
the C 156 973
degree C 157 973
of C 158 973
hydrocephalus C 159 973
, C 160 973
no C 161 973
matter C 162 973
how C 163 973
severe C 164 973
, C 165 973
is C 166 973
no C 167 973
contraindication C 168 973
to C 169 973
operation C 170 973
. C 171 973
comparative C 1 974
values C 2 974
of C 3 974
thick C 4 974
drop C 5 974
and C 6 974
concentration C 7 974
methods C 8 974
detection C 9 974
of C 10 974
filaria C 11 974
infection C 12 974
. C 13 974
blood C 15 974
was C 16 974
drawn C 17 974
from C 18 974
the C 19 974
finger C 20 974
and C 21 974
vein C 22 974
in C 23 974
246 C 24 974
students C 25 974
from C 26 974
11 C 27 974
p C 28 974
. C 29 974
. C 30 974
. C 31 974
to C 33 974
2 C 34 974
a C 35 974
. C 36 974
. C 37 974
. C 38 974
to C 40 974
compare C 41 974
the C 42 974
diagnostic C 43 974
efficacy C 44 974
of C 45 974
thick C 46 974
drop C 47 974
method C 48 974
vis C 49 974
- C 50 974
a C 51 974
- C 52 974
vis C 53 974
concentration C 54 974
method C 55 974
. C 56 974
infection C 58 974
rate C 59 974
was C 60 974
found C 61 974
to C 62 974
be C 63 974
the C 64 974
same C 65 974
( C 66 974
2 C 67 974
. C 68 974
. C 69 974
% C 70 974
) C 71 974
by C 72 974
both C 73 974
methods C 74 974
, C 75 974
and C 76 974
5 C 77 974
students C 78 974
harbouring C 79 974
infection C 80 974
were C 81 974
found C 82 974
to C 83 974
be C 84 974
positive C 85 974
by C 86 974
both C 87 974
methods C 88 974
. C 89 974
infestation C 91 974
rate C 92 974
in C 93 974
the C 94 974
concentration C 95 974
method C 96 974
was C 97 974
higher C 98 974
being C 99 974
14 C 100 974
per C 101 974
slide C 102 974
against C 103 974
4 C 104 974
per C 105 974
slide C 106 974
in C 107 974
the C 108 974
thick C 109 974
drop C 110 974
method C 111 974
. C 112 974
filariasis C 1 975
in C 2 975
its C 3 975
relation C 4 975
to C 5 975
a C 6 975
a C 7 975
bo C 8 975
, C 9 975
mn C 10 975
, C 11 975
kell C 12 975
, C 13 975
duffy C 14 975
and C 15 975
rhesus C 16 975
blood C 17 975
groups C 18 975
and C 19 975
secretor C 20 975
factor C 21 975
. C 22 975
603 C 24 975
filariasis C 25 975
patients C 26 975
have C 27 975
been C 28 975
studied C 29 975
for C 30 975
a C 31 975
a C 32 975
bo C 33 975
blood C 34 975
groups C 35 975
; C 36 975
281 C 37 975
for C 38 975
duffy C 39 975
, C 40 975
kell C 41 975
and C 42 975
rhesus C 43 975
blood C 44 975
groups C 45 975
; C 46 975
178 C 47 975
for C 48 975
secretor C 49 975
factor C 50 975
; C 51 975
and C 52 975
503 C 53 975
for C 54 975
mn C 55 975
blood C 56 975
groups C 57 975
, C 58 975
to C 59 975
find C 60 975
out C 61 975
if C 62 975
there C 63 975
is C 64 975
any C 65 975
association C 66 975
between C 67 975
filariasis C 68 975
and C 69 975
these C 70 975
blood C 71 975
groups C 72 975
. C 73 975
no C 75 975
association C 76 975
, C 77 975
whatsoever C 78 975
, C 79 975
has C 80 975
been C 81 975
found C 82 975
between C 83 975
the C 84 975
blood C 85 975
groups C 86 975
studied C 87 975
and C 88 975
filariasis C 89 975
. C 90 975
a C 1 976
polyethylene C 2 976
tube C 3 976
culture C 4 976
method C 5 976
for C 6 976
the C 7 976
diagnosis C 8 976
of C 9 976
parasitic C 10 976
infections C 11 976
by C 12 976
hookworms C 13 976
and C 14 976
related C 15 976
nematodes C 16 976
. C 17 976
studies C 19 976
were C 20 976
made C 21 976
in C 22 976
amami C 23 976
island C 24 976
and C 25 976
in C 26 976
bangkok C 27 976
to C 28 976
compare C 29 976
the C 30 976
diagnostic C 31 976
efficiency C 32 976
of C 33 976
direct C 34 976
microscopical C 35 976
examination C 36 976
, C 37 976
test C 38 976
tube C 39 976
culture C 40 976
and C 41 976
the C 42 976
newly C 43 976
devised C 44 976
polyethylene C 45 976
tube C 46 976
culture C 47 976
method C 48 976
for C 49 976
the C 50 976
detection C 51 976
of C 52 976
filariform C 53 976
larvae C 54 976
. C 55 976
the C 57 976
results C 58 976
show C 59 976
that C 60 976
the C 61 976
new C 62 976
technique C 63 976
has C 64 976
a C 65 976
number C 66 976
of C 67 976
advantages C 68 976
over C 69 976
the C 70 976
other C 71 976
methods C 72 976
. C 73 976
it C 75 976
is C 76 976
more C 77 976
sensitive C 78 976
than C 79 976
the C 80 976
others C 81 976
for C 82 976
the C 83 976
detection C 84 976
of C 85 976
cases C 86 976
of C 87 976
slight C 88 976
infection C 89 976
and C 90 976
greatly C 91 976
reduces C 92 976
the C 93 976
risk C 94 976
of C 95 976
overlooking C 96 976
small C 97 976
numbers C 98 976
of C 99 976
larvae C 100 976
. C 101 976
polyethylene C 103 976
tubes C 104 976
are C 105 976
extremely C 106 976
cheap C 107 976
, C 108 976
compact C 109 976
and C 110 976
light C 111 976
, C 112 976
and C 113 976
can C 114 976
be C 115 976
very C 116 976
easily C 117 976
disposed C 118 976
of C 119 976
after C 120 976
use C 121 976
. C 122 976
some C 1 977
observations C 2 977
on C 3 977
the C 4 977
effects C 5 977
in C 6 977
vivo C 7 977
of C 8 977
varying C 9 977
ambient C 10 977
temperatures C 11 977
on C 12 977
filarial C 13 977
worms C 14 977
of C 15 977
snakes C 16 977
. C 17 977
new C 19 977
information C 20 977
was C 21 977
obtained C 22 977
on C 23 977
the C 24 977
biology C 25 977
of C 26 977
filarial C 27 977
worms C 28 977
from C 29 977
experiments C 30 977
using C 31 977
constrictor C 32 977
constrictor C 33 977
mexicanus C 34 977
boas C 35 977
, C 36 977
infected C 37 977
with C 38 977
macdonaldius C 39 977
oschei C 40 977
worms C 41 977
. C 42 977
the C 44 977
microfilariae C 45 977
of C 46 977
m C 47 977
. C 48 977
oschei C 50 977
are C 51 977
aperiodic C 52 977
with C 53 977
respect C 54 977
to C 55 977
the C 56 977
light C 57 977
cycle C 58 977
, C 59 977
but C 60 977
fluctuate C 61 977
sharply C 62 977
in C 63 977
density C 64 977
from C 65 977
day C 66 977
to C 67 977
day C 68 977
. C 69 977
maximum C 71 977
minimum C 72 977
levels C 73 977
occur C 74 977
approx C 75 977
. C 76 977
2 C 78 977
days C 79 977
apart C 80 977
. C 81 977
the C 83 977
microfilariae C 84 977
are C 85 977
larger C 86 977
and C 87 977
more C 88 977
variable C 89 977
in C 90 977
size C 91 977
on C 92 977
the C 93 977
days C 94 977
of C 95 977
maximum C 96 977
density C 97 977
than C 98 977
on C 99 977
the C 100 977
days C 101 977
of C 102 977
minimum C 103 977
density C 104 977
. C 105 977
it C 107 977
is C 108 977
suggested C 109 977
that C 110 977
the C 111 977
smaller C 112 977
microfilariae C 113 977
on C 114 977
the C 115 977
days C 116 977
of C 117 977
low C 118 977
parasitemia C 119 977
are C 120 977
those C 121 977
that C 122 977
have C 123 977
been C 124 977
born C 125 977
recently C 126 977
and C 127 977
that C 128 977
they C 129 977
enlarge C 130 977
during C 131 977
the C 132 977
following C 133 977
48 C 134 977
hr C 135 977
. C 136 977
before C 138 977
they C 139 977
enter C 140 977
the C 141 977
peripheral C 142 977
capillaries C 143 977
. C 144 977
low C 146 977
ambient C 147 977
temperatures C 148 977
have C 149 977
little C 150 977
effect C 151 977
upon C 152 977
m C 153 977
. C 154 977
oschei C 156 977
. C 157 977
exposure C 159 977
of C 160 977
the C 161 977
host C 162 977
to C 163 977
ambient C 164 977
temperatures C 165 977
above C 166 977
36 C 167 977
c C 168 977
for C 169 977
a C 170 977
period C 171 977
of C 172 977
24 C 173 977
- C 174 977
48 C 175 977
hr C 176 977
. C 177 977
appears C 179 977
sufficient C 180 977
to C 181 977
kill C 182 977
adult C 183 977
m C 184 977
. C 185 977
oschei C 187 977
. C 188 977
all C 190 977
microfilariae C 191 977
apparently C 192 977
die C 193 977
within C 194 977
144 C 195 977
hr C 196 977
. C 197 977
at C 199 977
this C 200 977
temperature C 201 977
, C 202 977
and C 203 977
in C 204 977
slight C 205 977
infections C 206 977
. C 207 977
they C 209 977
disappeared C 210 977
from C 211 977
the C 212 977
blood C 213 977
altogether C 214 977
within C 215 977
that C 216 977
period C 217 977
. C 218 977
microfilariae C 220 977
from C 221 977
an C 222 977
infection C 223 977
20 C 224 977
times C 225 977
more C 226 977
severe C 227 977
, C 228 977
however C 229 977
, C 230 977
were C 231 977
not C 232 977
eliminated C 233 977
from C 234 977
the C 235 977
circulation C 236 977
prior C 237 977
to C 238 977
the C 239 977
death C 240 977
of C 241 977
the C 242 977
host C 243 977
after C 244 977
288 C 245 977
hr C 246 977
. C 247 977
, C 249 977
although C 250 977
all C 251 977
those C 252 977
observed C 253 977
were C 254 977
either C 255 977
decomposed C 256 977
or C 257 977
distorted C 258 977
and C 259 977
apparently C 260 977
dead C 261 977
. C 262 977
the C 264 977
indication C 265 977
that C 266 977
the C 267 977
temperature C 268 977
serves C 269 977
as C 270 977
a C 271 977
limiting C 272 977
factor C 273 977
for C 274 977
the C 275 977
parasite C 276 977
at C 277 977
a C 278 977
point C 279 977
several C 280 977
degrees C 281 977
lower C 282 977
than C 283 977
that C 284 977
postulated C 285 977
for C 286 977
the C 287 977
host C 288 977
species C 289 977
, C 290 977
is C 291 977
probably C 292 977
correlated C 293 977
with C 294 977
the C 295 977
nocturnal C 296 977
habits C 297 977
of C 298 977
the C 299 977
host C 300 977
. C 301 977
preliminary C 1 978
report C 2 978
on C 3 978
the C 4 978
leucoconcentration C 5 978
technique C 6 978
applied C 7 978
to C 8 978
the C 9 978
study C 10 978
of C 11 978
microfilaraemia C 12 978
. C 13 978
in C 15 978
a C 16 978
case C 17 978
of C 18 978
filariasis C 19 978
due C 20 978
to C 21 978
wuchereria C 22 978
bancrofti C 23 978
the C 24 978
routine C 25 978
leucoconcentration C 26 978
technique C 27 978
used C 28 978
in C 29 978
the C 30 978
demonstration C 31 978
of C 32 978
steinberg C 33 978
' C 34 978
s C 35 978
neoplasic C 36 978
cells C 37 978
in C 38 978
circulating C 39 978
blood C 40 978
was C 41 978
applied C 42 978
. C 43 978
this C 45 978
method C 46 978
makes C 47 978
it C 48 978
possible C 49 978
to C 50 978
obtain C 51 978
considerable C 52 978
enrichment C 53 978
. C 54 978
demonstration C 56 978
of C 57 978
filaria C 58 978
can C 59 978
be C 60 978
performed C 61 978
during C 62 978
daylight C 63 978
. C 64 978
from C 66 978
the C 67 978
material C 68 978
obtained C 69 978
, C 70 978
preparation C 71 978
of C 72 978
specific C 73 978
antigens C 74 978
, C 75 978
that C 76 978
make C 77 978
possible C 78 978
an C 79 978
immunological C 80 978
diagnosis C 81 978
, C 82 978
may C 83 978
be C 84 978
carried C 85 978
out C 86 978
. C 87 978
concentration C 1 979
techniques C 2 979
of C 3 979
sanguicolous C 4 979
microfilariae C 5 979
. C 6 979
a C 8 979
technique C 9 979
is C 10 979
described C 11 979
for C 12 979
concentration C 13 979
of C 14 979
sanguicolous C 15 979
microfilariae C 16 979
, C 17 979
a C 18 979
modified C 19 979
harris C 20 979
and C 21 979
summers C 22 979
method C 23 979
. C 24 979
pathology C 1 980
of C 2 980
schistosoma C 3 980
japonicum C 4 980
in C 5 980
the C 6 980
taiwanese C 7 980
monkey C 8 980
( C 9 980
macaca C 10 980
cyclopis C 11 980
) C 12 980
. C 13 980
i C 15 980
. C 16 980
comparison C 18 980
of C 19 980
formosan C 20 980
and C 21 980
japanese C 22 980
strains C 23 980
. C 24 980
ii C 26 980
. C 27 980
effect C 29 980
of C 30 980
passing C 31 980
the C 32 980
formosan C 33 980
strain C 34 980
through C 35 980
japanese C 36 980
snails C 37 980
. C 38 980
i C 40 980
. C 41 980
nearly C 43 980
equal C 44 980
recovery C 45 980
rates C 46 980
of C 47 980
adult C 48 980
worms C 49 980
from C 50 980
taiwanese C 51 980
monkeys C 52 980
( C 53 980
macaca C 54 980
cyclopis C 55 980
) C 56 980
infected C 57 980
with C 58 980
formosan C 59 980
or C 60 980
japanese C 61 980
strains C 62 980
of C 63 980
sch C 64 980
. C 65 980
japonicum C 67 980
were C 68 980
recorded C 69 980
. C 70 980
worm C 72 980
recovery C 73 980
rates C 74 980
from C 75 980
the C 76 980
monkeys C 77 980
were C 78 980
low C 79 980
when C 80 980
comparison C 81 980
was C 82 980
made C 83 980
with C 84 980
the C 85 980
highly C 86 980
susceptible C 87 980
laboratory C 88 980
rabbit C 89 980
, C 90 980
signifying C 91 980
only C 92 980
partial C 93 980
susceptibility C 94 980
. C 95 980
formosan C 97 980
strain C 98 980
granulomas C 99 980
in C 100 980
the C 101 980
liver C 102 980
contained C 103 980
fewer C 104 980
eggs C 105 980
but C 106 980
were C 107 980
considerably C 108 980
more C 109 980
severe C 110 980
and C 111 980
extensive C 112 980
than C 113 980
japanese C 114 980
strain C 115 980
granulomas C 116 980
. C 117 980
the C 119 980
possibility C 120 980
that C 121 980
the C 122 980
large C 123 980
, C 124 980
atypical C 125 980
granulomas C 126 980
could C 127 980
be C 128 980
reactions C 129 980
to C 130 980
young C 131 980
, C 132 980
degenerating C 133 980
formosan C 134 980
worms C 135 980
is C 136 980
discussed C 137 980
. C 138 980
an C 140 980
alternative C 141 980
hypothesis C 142 980
to C 143 980
explain C 144 980
the C 145 980
dissimilar C 146 980
reactions C 147 980
, C 148 980
that C 149 980
formosan C 150 980
strain C 151 980
eggs C 152 980
are C 153 980
stronger C 154 980
tissue C 155 980
irritants C 156 980
than C 157 980
those C 158 980
of C 159 980
the C 160 980
japanese C 161 980
strain C 162 980
, C 163 980
is C 164 980
proposed C 165 980
. C 166 980
ii C 168 980
. C 169 980
the C 171 980
formosan C 172 980
strain C 173 980
of C 174 980
sch C 175 980
. C 176 980
japonicum C 178 980
was C 179 980
passed C 180 980
through C 181 980
the C 182 980
japanese C 183 980
snail C 184 980
intermediate C 185 980
host C 186 980
( C 187 980
oncomelania C 188 980
nosophora C 189 980
) C 190 980
for C 191 980
4 C 192 980
consecutive C 193 980
generations C 194 980
. C 195 980
progressively C 197 980
rising C 198 980
rates C 199 980
of C 200 980
snail C 201 980
infection C 202 980
and C 203 980
mortality C 204 980
were C 205 980
recorded C 206 980
. C 207 980
the C 209 980
resultant C 210 980
laboratory C 211 980
strain C 212 980
of C 213 980
formosan C 214 980
schistosome C 215 980
was C 216 980
used C 217 980
to C 218 980
infect C 219 980
taiwanese C 220 980
monkeys C 221 980
. C 222 980
monkeys C 224 980
infected C 225 980
with C 226 980
the C 227 980
natural C 228 980
formosan C 229 980
strain C 230 980
and C 231 980
natural C 232 980
japanese C 233 980
strain C 234 980
served C 235 980
as C 236 980
controls C 237 980
. C 238 980
worm C 240 980
recovery C 241 980
rates C 242 980
were C 243 980
similar C 244 980
in C 245 980
the C 246 980
3 C 247 980
groups C 248 980
. C 249 980
granulomatous C 251 980
responses C 252 980
in C 253 980
the C 254 980
liver C 255 980
produced C 256 980
by C 257 980
the C 258 980
laboratory C 259 980
strain C 260 980
were C 261 980
compared C 262 980
with C 263 980
the C 264 980
large C 265 980
atypical C 266 980
granulomas C 267 980
of C 268 980
the C 269 980
natural C 270 980
formosan C 271 980
strain C 272 980
and C 273 980
the C 274 980
conventional C 275 980
granulomas C 276 980
of C 277 980
the C 278 980
natural C 279 980
japanese C 280 980
strain C 281 980
. C 282 980
the C 284 980
new C 285 980
formosan C 286 980
strain C 287 980
appeared C 288 980
altered C 289 980
toward C 290 980
characteristics C 291 980
possessed C 292 980
by C 293 980
the C 294 980
japanese C 295 980
strain C 296 980
. C 297 980
a C 1 981
review C 2 981
of C 3 981
immunologic C 4 981
methods C 5 981
for C 6 981
the C 7 981
diagnosis C 8 981
of C 9 981
filariasis C 10 981
. C 11 981
the C 13 981
author C 14 981
reviews C 15 981
the C 16 981
historical C 17 981
application C 18 981
of C 19 981
the C 20 981
skin C 21 981
test C 22 981
, C 23 981
cft C 24 981
, C 25 981
precipitin C 26 981
test C 27 981
, C 28 981
haemagglutination C 29 981
and C 30 981
bentonite C 31 981
flocculation C 32 981
, C 33 981
and C 34 981
prausnitz C 35 981
- C 36 981
kuestner C 37 981
test C 38 981
to C 39 981
the C 40 981
diagnosis C 41 981
of C 42 981
various C 43 981
filarial C 44 981
infections C 45 981
in C 46 981
man C 47 981
and C 48 981
animals C 49 981
, C 50 981
with C 51 981
a C 52 981
discussion C 53 981
of C 54 981
areas C 55 981
requiring C 56 981
further C 57 981
study C 58 981
. C 59 981
he C 61 981
is C 62 981
of C 63 981
the C 64 981
opinion C 65 981
that C 66 981
with C 67 981
standardization C 68 981
of C 69 981
techniques C 70 981
, C 71 981
immunologic C 72 981
methods C 73 981
can C 74 981
be C 75 981
made C 76 981
to C 77 981
furnish C 78 981
a C 79 981
reliable C 80 981
means C 81 981
of C 82 981
diagnosis C 83 981
, C 84 981
notwithstanding C 85 981
the C 86 981
past C 87 981
unreliability C 88 981
of C 89 981
such C 90 981
methods C 91 981
. C 92 981
a C 94 981
bibliography C 95 981
arranged C 96 981
in C 97 981
chronological C 98 981
order C 99 981
lists C 100 981
125 C 101 981
papers C 102 981
covering C 103 981
the C 104 981
period C 105 981
from C 106 981
1916 C 107 981
to C 108 981
1962 C 109 981
, C 110 981
and C 111 981
a C 112 981
supplementary C 113 981
list C 114 981
of C 115 981
references C 116 981
includes C 117 981
22 C 118 981
recent C 119 981
papers C 120 981
on C 121 981
general C 122 981
aspects C 123 981
of C 124 981
the C 125 981
subject C 126 981
. C 127 981
schultz C 1 982
- C 2 982
dale C 3 982
reaction C 4 982
with C 5 982
sera C 6 982
of C 7 982
eosinophilic C 8 982
lung C 9 982
patients C 10 982
- C 11 982
a C 12 982
preliminary C 13 982
report C 14 982
. C 15 982
schultz C 17 982
- C 18 982
dale C 19 982
tests C 20 982
have C 21 982
indicated C 22 982
that C 23 982
specific C 24 982
antibodies C 25 982
to C 26 982
metabolite C 27 982
products C 28 982
of C 29 982
microfilariae C 30 982
are C 31 982
present C 32 982
in C 33 982
the C 34 982
serum C 35 982
of C 36 982
an C 37 982
e C 38 982
. C 39 982
l C 41 982
. C 42 982
patient C 44 982
and C 45 982
that C 46 982
diethylcarbamazine C 47 982
in C 48 982
concentrations C 49 982
of C 50 982
1 C 51 982
: C 52 982
2000 C 53 982
- C 54 982
1 C 55 982
: C 56 982
1000 C 57 982
were C 58 982
required C 59 982
to C 60 982
cause C 61 982
perceptible C 62 982
cessation C 63 982
of C 64 982
contraction C 65 982
in C 66 982
intestinal C 67 982
strips C 68 982
used C 69 982
. C 70 982
sufficient C 72 982
tests C 73 982
have C 74 982
not C 75 982
yet C 76 982
been C 77 982
completed C 78 982
to C 79 982
indicate C 80 982
a C 81 982
consistent C 82 982
relationship C 83 982
between C 84 982
any C 85 982
particular C 86 982
filarial C 87 982
species C 88 982
and C 89 982
eosinophilic C 90 982
lung C 91 982
disease C 92 982
. C 93 982
an C 1 983
evaluation C 2 983
of C 3 983
the C 4 983
bentonite C 5 983
flocculation C 6 983
and C 7 983
indirect C 8 983
hemagglutination C 9 983
tests C 10 983
for C 11 983
the C 12 983
diagnosis C 13 983
of C 14 983
filariasis C 15 983
. C 16 983
the C 18 983
indirect C 19 983
haemagglutination C 20 983
test C 21 983
and C 22 983
the C 23 983
bentonite C 24 983
flocculation C 25 983
test C 26 983
utilizing C 27 983
a C 28 983
saline C 29 983
extract C 30 983
of C 31 983
dirofilaria C 32 983
immitis C 33 983
have C 34 983
been C 35 983
evaluated C 36 983
. C 37 983
the C 39 983
test C 40 983
was C 41 983
reactive C 42 983
with C 43 983
sera C 44 983
from C 45 983
individuals C 46 983
with C 47 983
infections C 48 983
of C 49 983
acanthocheilonema C 50 983
perstans C 51 983
and C 52 983
showed C 53 983
higher C 54 983
titres C 55 983
for C 56 983
symptomatic C 57 983
patients C 58 983
with C 59 983
microfilariae C 60 983
in C 61 983
the C 62 983
blood C 63 983
. C 64 983
in C 66 983
a C 67 983
group C 68 983
of C 69 983
42 C 70 983
symptomatic C 71 983
patients C 72 983
, C 73 983
92 C 74 983
% C 75 983
of C 76 983
13 C 77 983
microfilariae C 78 983
- C 79 983
positive C 80 983
patients C 81 983
and C 82 983
62 C 83 983
% C 84 983
of C 85 983
29 C 86 983
microfilariae C 87 983
- C 88 983
negative C 89 983
patients C 90 983
showed C 91 983
positive C 92 983
serologic C 93 983
tests C 94 983
. C 95 983
in C 97 983
a C 98 983
group C 99 983
of C 100 983
15 C 101 983
asymptomatic C 102 983
individuals C 103 983
with C 104 983
microfilariae C 105 983
in C 106 983
the C 107 983
blood C 108 983
, C 109 983
67 C 110 983
% C 111 983
were C 112 983
positive C 113 983
. C 114 983
from C 116 983
a C 117 983
group C 118 983
of C 119 983
295 C 120 983
asymptomatic C 121 983
microfilariae C 122 983
- C 123 983
negative C 124 983
individuals C 125 983
, C 126 983
21 C 127 983
sera C 128 983
( C 129 983
7 C 130 983
% C 131 983
) C 132 983
were C 133 983
positive C 134 983
. C 135 983
testing C 137 983
632 C 138 983
sera C 139 983
from C 140 983
295 C 141 983
normal C 142 983
missionaries C 143 983
, C 144 983
84 C 145 983
normal C 146 983
americans C 147 983
, C 148 983
and C 149 983
253 C 150 983
individuals C 151 983
with C 152 983
various C 153 983
other C 154 983
parasitic C 155 983
and C 156 983
bacterial C 157 983
infections C 158 983
, C 159 983
an C 160 983
overall C 161 983
non C 162 983
- C 163 983
specific C 164 983
response C 165 983
of C 166 983
10 C 167 983
% C 168 983
was C 169 983
obtained C 170 983
, C 171 983
utilizing C 172 983
the C 173 983
following C 174 983
criteria C 175 983
for C 176 983
a C 177 983
positive C 178 983
serologic C 179 983
test C 180 983
: C 181 983
( C 182 983
1 C 183 983
) C 184 983
haemagglutination C 185 983
titre C 186 983
of C 187 983
1 C 188 983
: C 189 983
200 C 190 983
or C 191 983
higher C 192 983
with C 193 983
a C 194 983
positive C 195 983
flocculation C 196 983
of C 197 983
1 C 198 983
: C 199 983
5 C 200 983
or C 201 983
higher C 202 983
, C 203 983
or C 204 983
( C 205 983
2 C 206 983
) C 207 983
a C 208 983
haemagglutination C 209 983
titre C 210 983
of C 211 983
1 C 212 983
: C 213 983
400 C 214 983
with C 215 983
a C 216 983
negative C 217 983
flocculation C 218 983
reaction C 219 983
. C 220 983
sera C 222 983
from C 223 983
141 C 224 983
patients C 225 983
with C 226 983
helminth C 227 983
diseases C 228 983
showed C 229 983
a C 230 983
non C 231 983
- C 232 983
specific C 233 983
rate C 234 983
of C 235 983
21 C 236 983
% C 237 983
. C 238 983
this C 240 983
high C 241 983
rate C 242 983
was C 243 983
due C 244 983
to C 245 983
cross C 246 983
- C 247 983
reactions C 248 983
with C 249 983
trichinosis C 250 983
sera C 251 983
( C 252 983
35 C 253 983
% C 254 983
) C 255 983
, C 256 983
schistosomiasis C 257 983
( C 258 983
20 C 259 983
% C 260 983
) C 261 983
and C 262 983
ascariasis C 263 983
( C 264 983
27 C 265 983
% C 266 983
) C 267 983
. C 268 983
since C 270 983
the C 271 983
schistosomiasis C 272 983
and C 273 983
ascariasis C 274 983
sera C 275 983
were C 276 983
from C 277 983
individuals C 278 983
born C 279 983
in C 280 983
an C 281 983
area C 282 983
endemic C 283 983
for C 284 983
filariasis C 285 983
, C 286 983
the C 287 983
reactions C 288 983
may C 289 983
represent C 290 983
a C 291 983
serologic C 292 983
response C 293 983
to C 294 983
past C 295 983
experience C 296 983
with C 297 983
filariasis C 298 983
. C 299 983
only C 301 983
5 C 302 983
% C 303 983
of C 304 983
112 C 305 983
sera C 306 983
from C 307 983
individuals C 308 983
with C 309 983
non C 310 983
- C 311 983
helminthic C 312 983
diseases C 313 983
and C 314 983
5 C 315 983
% C 316 983
of C 317 983
84 C 318 983
sera C 319 983
from C 320 983
normal C 321 983
individuals C 322 983
were C 323 983
positive C 324 983
. C 325 983
filariasis C 1 984
in C 2 984
mountain C 3 984
province C 4 984
, C 5 984
luzon C 6 984
, C 7 984
republic C 8 984
of C 9 984
the C 10 984
philippines C 11 984
. C 12 984
an C 14 984
endemic C 15 984
focus C 16 984
of C 17 984
w C 18 984
. C 19 984
bancrofti C 21 984
in C 22 984
mountain C 23 984
province C 24 984
, C 25 984
luzon C 26 984
( C 27 984
calaccad C 28 984
valley C 29 984
) C 30 984
, C 31 984
is C 32 984
discussed C 33 984
. C 34 984
an C 36 984
11 C 37 984
% C 38 984
microfilaremia C 39 984
rate C 40 984
was C 41 984
found C 42 984
. C 43 984
the C 45 984
parasites C 46 984
were C 47 984
probably C 48 984
brought C 49 984
into C 50 984
this C 51 984
area C 52 984
in C 53 984
the C 54 984
original C 55 984
human C 56 984
migration C 57 984
, C 58 984
as C 59 984
recent C 60 984
immigrants C 61 984
came C 62 984
from C 63 984
non C 64 984
- C 65 984
infected C 66 984
areas C 67 984
. C 68 984
no C 70 984
infection C 71 984
was C 72 984
found C 73 984
in C 74 984
children C 75 984
under C 76 984
12 C 77 984
yr C 78 984
. C 79 984
of C 81 984
age C 82 984
, C 83 984
which C 84 984
correlates C 85 984
with C 86 984
spraying C 87 984
of C 88 984
the C 89 984
area C 90 984
since C 91 984
1953 C 92 984
. C 93 984
however C 95 984
, C 96 984
some C 97 984
people C 98 984
live C 99 984
in C 100 984
unsprayed C 101 984
houses C 102 984
, C 103 984
and C 104 984
children C 105 984
may C 106 984
become C 107 984
infected C 108 984
. C 109 984
with C 111 984
coming C 112 984
road C 113 984
development C 114 984
and C 115 984
urbanization C 116 984
, C 117 984
culex C 118 984
p C 119 984
. C 120 984
fatigans C 122 984
will C 123 984
move C 124 984
in C 125 984
and C 126 984
undoubtedly C 127 984
increase C 128 984
transmission C 129 984
. C 130 984
currently C 132 984
anopheles C 133 984
minimus C 134 984
flavirostris C 135 984
is C 136 984
the C 137 984
most C 138 984
important C 139 984
local C 140 984
vector C 141 984
. C 142 984
aedes C 144 984
( C 145 984
finlaya C 146 984
) C 147 984
niveus C 148 984
was C 149 984
probably C 150 984
also C 151 984
a C 152 984
vector C 153 984
. C 154 984
immunological C 1 985
studies C 2 985
on C 3 985
filariasis C 4 985
. C 5 985
iii C 7 985
. C 8 985
isolation C 10 985
and C 11 985
purification C 12 985
of C 13 985
antigen C 14 985
for C 15 985
intradermal C 16 985
skin C 17 985
tests C 18 985
. C 19 985
an C 21 985
antigen C 22 985
for C 23 985
intradermal C 24 985
skin C 25 985
tests C 26 985
was C 27 985
extracted C 28 985
from C 29 985
the C 30 985
homogenate C 31 985
of C 32 985
dirofilaria C 33 985
immitis C 34 985
with C 35 985
a C 36 985
phosphate C 37 985
buffer C 38 985
at C 39 985
ph C 40 985
7 C 41 985
. C 42 985
. C 43 985
and C 44 985
purified C 45 985
by C 46 985
sephadex C 47 985
g C 48 985
- C 49 985
100 C 50 985
gel C 51 985
filtration C 52 985
, C 53 985
cm C 54 985
- C 55 985
cellulose C 56 985
chromatography C 57 985
and C 58 985
deae C 59 985
sephadex C 60 985
a C 61 985
- C 62 985
50 C 63 985
column C 64 985
chromatography C 65 985
. C 66 985
the C 68 985
finally C 69 985
purified C 70 985
antigen C 71 985
, C 72 985
fscd C 73 985
1 C 74 985
, C 75 985
was C 76 985
a C 77 985
protein C 78 985
with C 79 985
a C 80 985
small C 81 985
amount C 82 985
of C 83 985
carbohydrate C 84 985
( C 85 985
2 C 86 985
. C 87 985
. C 88 985
% C 89 985
) C 90 985
and C 91 985
gave C 92 985
a C 93 985
relatively C 94 985
broad C 95 985
band C 96 985
by C 97 985
electrophoresis C 98 985
on C 99 985
cellogel C 100 985
film C 101 985
. C 102 985
the C 104 985
aminoacids C 105 985
detected C 106 985
by C 107 985
high C 108 985
- C 109 985
voltage C 110 985
paper C 111 985
- C 112 985
electrophoresis C 113 985
of C 114 985
the C 115 985
acid C 116 985
hydrolyzate C 117 985
of C 118 985
the C 119 985
antigen C 120 985
were C 121 985
lysine C 122 985
, C 123 985
arginine C 124 985
, C 125 985
glycine C 126 985
, C 127 985
alanine C 128 985
, C 129 985
glutamic C 130 985
and C 131 985
aspartic C 132 985
acids C 133 985
, C 134 985
and C 135 985
valine C 136 985
. C 137 985
wheals C 139 985
and C 140 985
an C 141 985
erythema C 142 985
appeared C 143 985
within C 144 985
15 C 145 985
min C 146 985
. C 147 985
of C 149 985
the C 150 985
injection C 151 985
of C 152 985
the C 153 985
antigen C 154 985
0 C 155 985
. C 156 985
. C 157 985
. C 157 985
, C 158 985
on C 159 985
proved C 160 985
filariasis C 161 985
patients C 162 985
. C 163 985
cross C 165 985
reactions C 166 985
were C 167 985
examined C 168 985
in C 169 985
patients C 170 985
with C 171 985
p C 172 985
. C 173 985
westermani C 175 985
, C 176 985
s C 177 985
. C 178 985
japonicum C 180 985
, C 181 985
hookworm C 182 985
, C 183 985
a C 184 985
. C 185 985
lubricoides C 187 985
or C 188 985
e C 189 985
. C 190 985
vermicularis C 192 985
, C 193 985
but C 194 985
only C 195 985
weak C 196 985
skin C 197 985
reactions C 198 985
were C 199 985
noticed C 200 985
in C 201 985
all C 202 985
cases C 203 985
. C 204 985
the C 206 985
protein C 207 985
nature C 208 985
of C 209 985
the C 210 985
antigen C 211 985
was C 212 985
further C 213 985
proved C 214 985
by C 215 985
the C 216 985
fact C 217 985
that C 218 985
proteolytic C 219 985
enzymes C 220 985
destroyed C 221 985
the C 222 985
antigenic C 223 985
activity C 224 985
to C 225 985
a C 226 985
considerable C 227 985
extent C 228 985
. C 229 985
human C 1 986
filariasis C 2 986
. C 3 986
identification C 5 986
of C 6 986
species C 7 986
on C 8 986
the C 9 986
basis C 10 986
of C 11 986
staining C 12 986
and C 13 986
other C 14 986
morphologic C 15 986
characteristics C 16 986
of C 17 986
microfilariae C 18 986
. C 19 986
new C 21 986
staining C 22 986
procedures C 23 986
for C 24 986
human C 25 986
microfilariae C 26 986
are C 27 986
described C 28 986
. C 29 986
the C 31 986
morphologic C 32 986
details C 33 986
characteristic C 34 986
of C 35 986
each C 36 986
species C 37 986
are C 38 986
illustrated C 39 986
with C 40 986
apparent C 41 986
greater C 42 986
clarity C 43 986
than C 44 986
previously C 45 986
obtainable C 46 986
. C 47 986
a C 49 986
simple C 50 986
key C 51 986
to C 52 986
the C 53 986
human C 54 986
microfilariae C 55 986
is C 56 986
outlined C 57 986
, C 58 986
based C 59 986
on C 60 986
criteria C 61 986
clearly C 62 986
demonstrated C 63 986
with C 64 986
these C 65 986
stains C 66 986
. C 67 986
immunological C 1 987
studies C 2 987
on C 3 987
filariasis C 4 987
. C 5 987
iii C 7 987
. C 8 987
fractionation C 10 987
and C 11 987
purification C 12 987
of C 13 987
antigen C 14 987
for C 15 987
intradermal C 16 987
skin C 17 987
reaction C 18 987
in C 19 987
filariasis C 20 987
. C 21 987
it C 23 987
had C 24 987
been C 25 987
reported C 26 987
that C 27 987
the C 28 987
antigen C 29 987
tca C 30 987
obtained C 31 987
from C 32 987
adult C 33 987
worms C 34 987
of C 35 987
dirofilaria C 36 987
immitis C 37 987
produced C 38 987
noticeable C 39 987
reactions C 40 987
in C 41 987
filariasis C 42 987
patients C 43 987
in C 44 987
whose C 45 987
blood C 46 987
microfilariae C 47 987
could C 48 987
be C 49 987
demonstrated C 50 987
. C 51 987
further C 53 987
fractionation C 54 987
and C 55 987
purification C 56 987
of C 57 987
this C 58 987
antigen C 59 987
was C 60 987
attempted C 61 987
in C 62 987
order C 63 987
to C 64 987
study C 65 987
the C 66 987
substance C 67 987
responsible C 68 987
for C 69 987
the C 70 987
skin C 71 987
reaction C 72 987
and C 73 987
to C 74 987
obtain C 75 987
a C 76 987
more C 77 987
reliable C 78 987
antigen C 79 987
with C 80 987
high C 81 987
sensitivity C 82 987
and C 83 987
specificity C 84 987
. C 85 987
the C 87 987
fraction C 88 987
fs C 89 987
obtained C 90 987
by C 91 987
treatment C 92 987
similar C 93 987
to C 94 987
that C 95 987
described C 96 987
in C 97 987
the C 98 987
previous C 99 987
report C 100 987
was C 101 987
used C 102 987
as C 103 987
parent C 104 987
material C 105 987
. C 106 987
by C 108 987
gel C 109 987
- C 110 987
filtration C 111 987
and C 112 987
sephadex C 113 987
g C 114 987
- C 115 987
100 C 116 987
column C 117 987
chromatography C 118 987
of C 119 987
antigen C 120 987
fs C 121 987
, C 122 987
antigen C 123 987
fsi C 124 987
, C 125 987
which C 126 987
produced C 127 987
noticeable C 128 987
reactions C 129 987
in C 130 987
the C 131 987
filariasis C 132 987
patients C 133 987
, C 134 987
was C 135 987
obtained C 136 987
. C 137 987
this C 139 987
highly C 140 987
reactive C 141 987
antigen C 142 987
fsi C 143 987
was C 144 987
separated C 145 987
into C 146 987
6 C 147 987
fractions C 148 987
, C 149 987
viz C 150 987
. C 151 987
. C 152 987
. C 152 987
. C 152 987
- C 153 987
1 C 154 987
, C 155 987
fsc C 156 987
- C 157 987
2 C 158 987
, C 159 987
fsc C 160 987
- C 161 987
3 C 162 987
, C 163 987
fsc C 164 987
- C 165 987
4 C 166 987
, C 167 987
fsc C 168 987
- C 169 987
5 C 170 987
and C 171 987
fsc C 172 987
- C 173 987
6 C 174 987
, C 175 987
by C 176 987
cm C 177 987
cellulose C 178 987
chromatography C 179 987
. C 180 987
the C 182 987
6 C 183 987
antigens C 184 987
were C 185 987
tested C 186 987
at C 187 987
the C 188 987
1 C 189 987
( C 190 987
protein C 191 987
component C 192 987
) C 193 987
level C 194 987
on C 195 987
patients C 196 987
infected C 197 987
with C 198 987
wuchereria C 199 987
bancrofti C 200 987
. C 201 987
antigen C 203 987
fsc C 204 987
- C 205 987
4 C 206 987
, C 207 987
containing C 208 987
1 C 209 987
, C 210 987
500 C 211 987
of C 212 987
protein C 213 987
and C 214 987
40 C 215 987
of C 216 987
carbohydrate C 217 987
per C 218 987
ml C 219 987
. C 220 987
, C 222 987
was C 223 987
most C 224 987
active C 225 987
. C 226 987
next C 228 987
, C 229 987
the C 230 987
further C 231 987
fractionation C 232 987
of C 233 987
antigen C 234 987
fsc C 235 987
- C 236 987
4 C 237 987
by C 238 987
deae C 239 987
- C 240 987
sephadex C 241 987
a C 242 987
50 C 243 987
column C 244 987
chromatography C 245 987
was C 246 987
carried C 247 987
out C 248 987
to C 249 987
yield C 250 987
4 C 251 987
antigens C 252 987
, C 253 987
viz C 254 987
. C 255 987
. C 256 987
. C 256 987
. C 256 987
. C 256 987
- C 257 987
1 C 258 987
, C 259 987
fscd C 260 987
- C 261 987
2 C 262 987
, C 263 987
fscd C 264 987
- C 265 987
3 C 266 987
and C 267 987
fscd C 268 987
- C 269 987
4 C 270 987
. C 271 987
the C 273 987
4 C 274 987
antigens C 275 987
were C 276 987
tested C 277 987
at C 278 987
the C 279 987
0 C 280 987
. C 281 987
. C 282 987
. C 282 987
( C 283 987
protein C 284 987
component C 285 987
) C 286 987
level C 287 987
on C 288 987
filariasis C 289 987
patients C 290 987
. C 291 987
antigen C 293 987
fscd C 294 987
- C 295 987
1 C 296 987
produced C 297 987
the C 298 987
most C 299 987
noticeable C 300 987
skin C 301 987
reaction C 302 987
in C 303 987
the C 304 987
patients C 305 987
. C 306 987
the C 308 987
elimination C 309 987
of C 310 987
protein C 311 987
components C 312 987
from C 313 987
antigen C 314 987
fscd C 315 987
- C 316 987
1 C 317 987
was C 318 987
attempted C 319 987
with C 320 987
nagase C 321 987
( C 322 987
a C 323 987
proteolytic C 324 987
enzyme C 325 987
) C 326 987
and C 327 987
pronase C 328 987
to C 329 987
obtain C 330 987
antigens C 331 987
fscdn C 332 987
and C 333 987
fscdp C 334 987
. C 335 987
each C 337 987
of C 338 987
these C 339 987
2 C 340 987
antigens C 341 987
was C 342 987
tested C 343 987
on C 344 987
the C 345 987
patients C 346 987
proved C 347 987
to C 348 987
have C 349 987
filariasis C 350 987
, C 351 987
but C 352 987
the C 353 987
reaction C 354 987
produced C 355 987
by C 356 987
the C 357 987
injection C 358 987
of C 359 987
each C 360 987
antigen C 361 987
was C 362 987
weaker C 363 987
than C 364 987
that C 365 987
produced C 366 987
by C 367 987
antigen C 368 987
fscd C 369 987
- C 370 987
1 C 371 987
. C 372 987
it C 374 987
may C 375 987
be C 376 987
inferred C 377 987
from C 378 987
these C 379 987
studies C 380 987
that C 381 987
the C 382 987
substance C 383 987
responsible C 384 987
for C 385 987
the C 386 987
skin C 387 987
reaction C 388 987
is C 389 987
proteinic C 390 987
. C 391 987
identification C 1 988
of C 2 988
canine C 3 988
microfilariae C 4 988
. C 5 988
the C 7 988
importance C 8 988
of C 9 988
microfilarial C 10 988
identifications C 11 988
in C 12 988
diagnosing C 13 988
canine C 14 988
filariasis C 15 988
was C 16 988
emphasized C 17 988
by C 18 988
comparing C 19 988
the C 20 988
significance C 21 988
of C 22 988
infections C 23 988
due C 24 988
to C 25 988
different C 26 988
species C 27 988
. C 28 988
personal C 30 988
experiences C 31 988
and C 32 988
an C 33 988
analysis C 34 988
of C 35 988
published C 36 988
reports C 37 988
found C 38 988
the C 39 988
modified C 40 988
knott C 41 988
method C 42 988
to C 43 988
be C 44 988
the C 45 988
simplest C 46 988
and C 47 988
most C 48 988
practical C 49 988
of C 50 988
the C 51 988
reliable C 52 988
methods C 53 988
. C 54 988
its C 56 988
usefulness C 57 988
was C 58 988
improved C 59 988
by C 60 988
new C 61 988
morphologic C 62 988
criteria C 63 988
for C 64 988
differentiating C 65 988
microfilariae C 66 988
. C 67 988
microfilarial C 69 988
concentrations C 70 988
in C 71 988
peripheral C 72 988
blood C 73 988
from C 74 988
a C 75 988
number C 76 988
of C 77 988
naturally C 78 988
infected C 79 988
dogs C 80 988
were C 81 988
determined C 82 988
. C 83 988
the C 85 988
average C 86 988
count C 87 988
for C 88 988
44 C 89 988
dogs C 90 988
infected C 91 988
with C 92 988
dirofilaria C 93 988
immitis C 94 988
was C 95 988
only C 96 988
24 C 97 988
, C 98 988
430 C 99 988
( C 100 988
range C 101 988
: C 102 988
< C 103 988
50 C 104 988
to C 105 988
168 C 106 988
, C 107 988
350 C 108 988
) C 109 988
per C 110 988
ml C 111 988
. C 112 988
of C 114 988
blood C 115 988
compared C 116 988
with C 117 988
an C 118 988
average C 119 988
of C 120 988
235 C 121 988
( C 122 988
range C 123 988
: C 124 988
< C 125 988
50 C 126 988
to C 127 988
2 C 128 988
, C 129 988
450 C 130 988
) C 131 988
per C 132 988
ml C 133 988
. C 134 988
for C 136 988
100 C 137 988
dogs C 138 988
infected C 139 988
with C 140 988
dipetalonema C 141 988
reconditum C 142 988
only C 143 988
. C 144 988
of C 146 988
38 C 147 988
dogs C 148 988
with C 149 988
inapparent C 150 988
infections C 151 988
of C 152 988
d C 153 988
. C 154 988
immitis C 156 988
, C 157 988
17 C 158 988
had C 159 988
microfilarial C 160 988
concentrations C 161 988
within C 162 988
the C 163 988
range C 164 988
found C 165 988
for C 166 988
infections C 167 988
of C 168 988
d C 169 988
. C 170 988
reconditum C 172 988
only C 173 988
. C 174 988
male C 176 988
and C 177 988
female C 178 988
dogs C 179 988
with C 180 988
d C 181 988
. C 182 988
reconditum C 184 988
had C 185 988
similar C 186 988
concentrations C 187 988
of C 188 988
microfilariae C 189 988
. C 190 988
chemotherapy C 1 989
of C 2 989
metastatic C 3 989
gastro C 4 989
- C 5 989
intestinal C 6 989
cancer C 7 989
. C 8 989
cancer C 10 989
of C 11 989
the C 12 989
digestive C 13 989
tract C 14 989
is C 15 989
the C 16 989
commonest C 17 989
cause C 18 989
of C 19 989
death C 20 989
from C 21 989
neoplastic C 22 989
disease C 23 989
in C 24 989
the C 25 989
united C 26 989
states C 27 989
. C 28 989
a C 30 989
large C 31 989
number C 32 989
of C 33 989
patients C 34 989
with C 35 989
these C 36 989
forms C 37 989
of C 38 989
incurable C 39 989
cancer C 40 989
may C 41 989
be C 42 989
candidates C 43 989
for C 44 989
specific C 45 989
anti C 46 989
- C 47 989
tumor C 48 989
drug C 49 989
therapy C 50 989
. C 51 989
the C 53 989
criteria C 54 989
employed C 55 989
for C 56 989
the C 57 989
selection C 58 989
of C 59 989
patients C 60 989
for C 61 989
systemic C 62 989
or C 63 989
regional C 64 989
chemotherapy C 65 989
are C 66 989
reviewed C 67 989
and C 68 989
methods C 69 989
of C 70 989
treatment C 71 989
are C 72 989
outlined C 73 989
. C 74 989
systemic C 76 989
chemotherapy C 77 989
, C 78 989
using C 79 989
fluorinated C 80 989
pyrimidines C 81 989
, C 82 989
the C 83 989
antifol C 84 989
, C 85 989
methotrexate C 86 989
, C 87 989
and C 88 989
the C 89 989
alkylating C 90 989
agent C 91 989
, C 92 989
cytoxan C 93 989
, C 94 989
has C 95 989
been C 96 989
found C 97 989
to C 98 989
be C 99 989
of C 100 989
significant C 101 989
practical C 102 989
value C 103 989
in C 104 989
10 C 105 989
to C 106 989
30 C 107 989
% C 108 989
of C 109 989
the C 110 989
patients C 111 989
receiving C 112 989
these C 113 989
anticancer C 114 989
drugs C 115 989
. C 116 989
protracted C 118 989
hepatic C 119 989
artery C 120 989
infusion C 121 989
chemotherapy C 122 989
in C 123 989
patients C 124 989
with C 125 989
primary C 126 989
and C 127 989
secondary C 128 989
hepatic C 129 989
neoplasms C 130 989
and C 131 989
tumors C 132 989
of C 133 989
the C 134 989
biliary C 135 989
system C 136 989
has C 137 989
resulted C 138 989
in C 139 989
objective C 140 989
tumor C 141 989
response C 142 989
and C 143 989
associated C 144 989
clinical C 145 989
benefit C 146 989
in C 147 989
60 C 148 989
% C 149 989
of C 150 989
the C 151 989
patients C 152 989
treated C 153 989
. C 154 989
length C 156 989
of C 157 989
survival C 158 989
has C 159 989
been C 160 989
prolonged C 161 989
in C 162 989
patients C 163 989
with C 164 989
advanced C 165 989
metastatic C 166 989
liver C 167 989
cancer C 168 989
from C 169 989
primary C 170 989
tumors C 171 989
of C 172 989
the C 173 989
colorectum C 174 989
. C 175 989
it C 177 989
is C 178 989
concluded C 179 989
that C 180 989
systemic C 181 989
and C 182 989
regional C 183 989
cancer C 184 989
chemotherapy C 185 989
, C 186 989
in C 187 989
selected C 188 989
cases C 189 989
, C 190 989
has C 191 989
contributed C 192 989
to C 193 989
the C 194 989
practical C 195 989
management C 196 989
of C 197 989
patients C 198 989
with C 199 989
incurable C 200 989
cancer C 201 989
of C 202 989
the C 203 989
gastrointestinal C 204 989
tract C 205 989
. C 206 989
palliative C 1 990
treatment C 2 990
of C 3 990
osseous C 4 990
metastases C 5 990
from C 6 990
carcinoma C 7 990
of C 8 990
the C 9 990
breast C 10 990
and C 11 990
carcinoma C 12 990
of C 13 990
the C 14 990
prostate C 15 990
with C 16 990
radio C 17 990
- C 18 990
active C 19 990
phosphorus C 20 990
and C 21 990
testosterone C 22 990
. C 23 990
fifty C 25 990
- C 26 990
three C 27 990
patients C 28 990
suffering C 29 990
from C 30 990
pain C 31 990
arising C 32 990
in C 33 990
bony C 34 990
metastases C 35 990
from C 36 990
carcinoma C 37 990
of C 38 990
the C 39 990
breast C 40 990
and C 41 990
prostate C 42 990
are C 43 990
discussed C 44 990
. C 45 990
a C 47 990
method C 48 990
of C 49 990
palliative C 50 990
treatment C 51 990
is C 52 990
outlined C 53 990
and C 54 990
the C 55 990
results C 56 990
reported C 57 990
. C 58 990
regional C 1 991
chemotherapy C 2 991
by C 3 991
prolonged C 4 991
arterial C 5 991
infusions C 6 991
in C 7 991
head C 8 991
and C 9 991
neck C 10 991
tumors C 11 991
. C 12 991
methotrexate C 14 991
was C 15 991
injected C 16 991
into C 17 991
the C 18 991
superficial C 19 991
temporal C 20 991
or C 21 991
superior C 22 991
thyroid C 23 991
artery C 24 991
by C 25 991
perfusion C 26 991
: C 27 991
100 C 28 991
mg C 29 991
. C 30 991
/ C 32 991
1 C 33 991
. C 34 991
( C 36 991
20 C 37 991
drops C 38 991
/ C 39 991
min C 40 991
. C 41 991
) C 43 991
every C 44 991
day C 45 991
for C 46 991
8 C 47 991
days C 48 991
. C 49 991
the C 51 991
area C 52 991
to C 53 991
be C 54 991
irrigated C 55 991
was C 56 991
decided C 57 991
on C 58 991
by C 59 991
preliminary C 60 991
perfusion C 61 991
of C 62 991
patent C 63 991
blue C 64 991
violet C 65 991
11 C 66 991
% C 67 991
. C 68 991
results C 70 991
in C 71 991
54 C 72 991
inoperable C 73 991
patients C 74 991
were C 75 991
: C 76 991
deaths C 77 991
7 C 78 991
, C 79 991
failures C 80 991
19 C 81 991
, C 82 991
improvements C 83 991
28 C 84 991
, C 85 991
total C 86 991
regressions C 87 991
3 C 88 991
. C 89 991
pain C 91 991
was C 92 991
relieved C 93 991
in C 94 991
3 C 95 991
/ C 96 991
4 C 97 991
of C 98 991
the C 99 991
patients C 100 991
. C 101 991
intra C 1 992
- C 2 992
arterial C 3 992
infusion C 4 992
emphasizing C 5 992
treatment C 6 992
of C 7 992
malignant C 8 992
neoplasms C 9 992
. C 10 992
this C 12 992
review C 13 992
of C 14 992
the C 15 992
english C 16 992
medical C 17 992
literature C 18 992
summarizes C 19 992
most C 20 992
of C 21 992
the C 22 992
significant C 23 992
papers C 24 992
concerned C 25 992
with C 26 992
intra C 27 992
- C 28 992
arterial C 29 992
infusion C 30 992
. C 31 992
this C 33 992
technique C 34 992
of C 35 992
cancer C 36 992
therapy C 37 992
is C 38 992
effective C 39 992
for C 40 992
palliation C 41 992
of C 42 992
many C 43 992
advanced C 44 992
primary C 45 992
and C 46 992
recurrent C 47 992
cancer C 48 992
patients C 49 992
. C 50 992
head C 52 992
and C 53 992
neck C 54 992
cancer C 55 992
patients C 56 992
form C 57 992
the C 58 992
largest C 59 992
group C 60 992
of C 61 992
patients C 62 992
that C 63 992
have C 64 992
been C 65 992
treated C 66 992
because C 67 992
of C 68 992
the C 69 992
easily C 70 992
accessible C 71 992
arteries C 72 992
. C 73 992
however C 75 992
, C 76 992
almost C 77 992
any C 78 992
involved C 79 992
organ C 80 992
can C 81 992
be C 82 992
infused C 83 992
by C 84 992
external C 85 992
approaches C 86 992
to C 87 992
the C 88 992
femoral C 89 992
, C 90 992
brachial C 91 992
and C 92 992
common C 93 992
carotids C 94 992
. C 95 992
most C 97 992
oncolytic C 98 992
chemotherapeutic C 99 992
agents C 100 992
can C 101 992
be C 102 992
given C 103 992
via C 104 992
the C 105 992
intra C 106 992
- C 107 992
arterial C 108 992
route C 109 992
at C 110 992
notably C 111 992
increased C 112 992
dosages C 113 992
with C 114 992
the C 115 992
exception C 116 992
of C 117 992
5 C 118 992
fudr C 119 992
. C 120 992
partial C 122 992
and C 123 992
complete C 124 992
regression C 125 992
of C 126 992
many C 127 992
tumors C 128 992
can C 129 992
be C 130 992
obtained C 131 992
with C 132 992
present C 133 992
day C 134 992
chemotherapeutic C 135 992
agents C 136 992
for C 137 992
1 C 138 992
or C 139 992
2 C 140 992
mth C 141 992
. C 142 992
the C 144 992
best C 145 992
therapeutic C 146 992
results C 147 992
have C 148 992
been C 149 992
in C 150 992
patients C 151 992
with C 152 992
head C 153 992
and C 154 992
neck C 155 992
and C 156 992
pelvic C 157 992
tumors C 158 992
. C 159 992
currently C 161 992
infusion C 162 992
techniques C 163 992
using C 164 992
small C 165 992
mobile C 166 992
pumping C 167 992
units C 168 992
permit C 169 992
the C 170 992
patient C 171 992
to C 172 992
be C 173 992
ambulatory C 174 992
during C 175 992
course C 176 992
of C 177 992
anti C 178 992
- C 179 992
tumor C 180 992
therapy C 181 992
. C 182 992
complications C 184 992
from C 185 992
intra C 186 992
- C 187 992
arterial C 188 992
infusion C 189 992
are C 190 992
usually C 191 992
minor C 192 992
but C 193 992
serious C 194 992
complications C 195 992
do C 196 992
occur C 197 992
such C 198 992
as C 199 992
embolic C 200 992
phenomena C 201 992
to C 202 992
the C 203 992
cns C 204 992
with C 205 992
internal C 206 992
carotid C 207 992
infusion C 208 992
; C 209 992
aplastic C 210 992
bone C 211 992
marrow C 212 992
from C 213 992
drug C 214 992
toxicity C 215 992
, C 216 992
hemorrhage C 217 992
from C 218 992
tumor C 219 992
degeneration C 220 992
. C 221 992
technical C 223 992
complications C 224 992
of C 225 992
the C 226 992
infusion C 227 992
may C 228 992
not C 229 992
be C 230 992
life C 231 992
threatening C 232 992
but C 233 992
frequently C 234 992
prematurely C 235 992
terminate C 236 992
the C 237 992
therapy C 238 992
. C 239 992
continued C 241 992
interest C 242 992
in C 243 992
this C 244 992
form C 245 992
of C 246 992
therapy C 247 992
appears C 248 992
inevitable C 249 992
. C 250 992
prolonged C 1 993
intra C 2 993
- C 3 993
arterial C 4 993
chemotherapeutic C 5 993
infusion C 6 993
in C 7 993
cancer C 8 993
therapy C 9 993
; C 10 993
its C 11 993
indications C 12 993
and C 13 993
limits C 14 993
. C 15 993
in C 17 993
this C 18 993
review C 19 993
article C 20 993
( C 21 993
48 C 22 993
references C 23 993
) C 24 993
the C 25 993
principles C 26 993
of C 27 993
cancer C 28 993
treatment C 29 993
using C 30 993
continuous C 31 993
intra C 32 993
- C 33 993
arterial C 34 993
chemotherapy C 35 993
are C 36 993
described C 37 993
. C 38 993
selection C 40 993
of C 41 993
patients C 42 993
, C 43 993
operative C 44 993
technique C 45 993
and C 46 993
complications C 47 993
are C 48 993
dealt C 49 993
with C 50 993
. C 51 993
two C 53 993
cases C 54 993
are C 55 993
presented C 56 993
which C 57 993
have C 58 993
been C 59 993
infused C 60 993
with C 61 993
methotrexate C 62 993
( C 63 993
1050 C 64 993
and C 65 993
1600 C 66 993
mg C 67 993
. C 68 993
) C 70 993
with C 71 993
partial C 72 993
or C 73 993
complete C 74 993
objective C 75 993
remission C 76 993
: C 77 993
a C 78 993
woman C 79 993
of C 80 993
72 C 81 993
with C 82 993
a C 83 993
carcinoma C 84 993
of C 85 993
the C 86 993
amygdaloid C 87 993
fossa C 88 993
, C 89 993
and C 90 993
a C 91 993
man C 92 993
aged C 93 993
27 C 94 993
with C 95 993
a C 96 993
reticulosarcoma C 97 993
of C 98 993
the C 99 993
rhinopharynx C 100 993
. C 101 993
intra C 1 994
- C 2 994
arterial C 3 994
chemotherapy C 4 994
for C 5 994
cancer C 6 994
metastatic C 7 994
to C 8 994
liver C 9 994
. C 10 994
twenty C 12 994
- C 13 994
two C 14 994
patients C 15 994
with C 16 994
cancer C 17 994
metastatic C 18 994
to C 19 994
the C 20 994
liver C 21 994
were C 22 994
treated C 23 994
by C 24 994
the C 25 994
intra C 26 994
- C 27 994
arterial C 28 994
infusion C 29 994
of C 30 994
cancer C 31 994
chemotherapeutic C 32 994
agents C 33 994
. C 34 994
the C 36 994
drugs C 37 994
were C 38 994
introduced C 39 994
directly C 40 994
into C 41 994
the C 42 994
hepatic C 43 994
artery C 44 994
in C 45 994
10 C 46 994
patients C 47 994
and C 48 994
into C 49 994
the C 50 994
aorta C 51 994
to C 52 994
the C 53 994
level C 54 994
of C 55 994
the C 56 994
celiac C 57 994
axis C 58 994
in C 59 994
12 C 60 994
patients C 61 994
. C 62 994
no C 64 994
significant C 65 994
differences C 66 994
in C 67 994
results C 68 994
were C 69 994
observed C 70 994
in C 71 994
the C 72 994
2 C 73 994
groups C 74 994
. C 75 994
of C 77 994
the C 78 994
10 C 79 994
patients C 80 994
who C 81 994
received C 82 994
cancer C 83 994
chemotherapy C 84 994
via C 85 994
the C 86 994
hepatic C 87 994
artery C 88 994
, C 89 994
one C 90 994
remains C 91 994
alive C 92 994
2 C 93 994
mth C 94 994
. C 95 994
after C 97 994
treatment C 98 994
; C 99 994
3 C 100 994
died C 101 994
in C 102 994
the C 103 994
immediate C 104 994
posttreatment C 105 994
period C 106 994
; C 107 994
7 C 108 994
survived C 109 994
from C 110 994
1 C 111 994
- C 112 994
17 C 113 994
mths C 114 994
after C 115 994
treatment C 116 994
, C 117 994
an C 118 994
average C 119 994
survival C 120 994
of C 121 994
6 C 122 994
. C 123 994
. C 124 994
mth C 125 994
. C 126 994
all C 128 994
12 C 129 994
patients C 130 994
who C 131 994
were C 132 994
treated C 133 994
by C 134 994
the C 135 994
intra C 136 994
- C 137 994
aortic C 138 994
administration C 139 994
of C 140 994
cancer C 141 994
chemotherapy C 142 994
have C 143 994
died C 144 994
; C 145 994
3 C 146 994
patients C 147 994
died C 148 994
in C 149 994
the C 150 994
immediate C 151 994
posttreatment C 152 994
period C 153 994
; C 154 994
the C 155 994
survival C 156 994
time C 157 994
of C 158 994
the C 159 994
remaining C 160 994
9 C 161 994
averaged C 162 994
3 C 163 994
. C 164 994
. C 165 994
mth C 166 994
. C 167 994
an C 169 994
objective C 170 994
significant C 171 994
shrinkage C 172 994
of C 173 994
the C 174 994
metastases C 175 994
in C 176 994
the C 177 994
liver C 178 994
was C 179 994
observed C 180 994
in C 181 994
6 C 182 994
patients C 183 994
( C 184 994
3 C 185 994
treated C 186 994
by C 187 994
the C 188 994
intra C 189 994
- C 190 994
hepatic C 191 994
artery C 192 994
route C 193 994
and C 194 994
3 C 195 994
via C 196 994
the C 197 994
aorta C 198 994
) C 199 994
; C 200 994
this C 201 994
lasted C 202 994
from C 203 994
1 C 204 994
- C 205 994
10 C 206 994
mth C 207 994
. C 208 994
subjective C 210 994
palliation C 211 994
was C 212 994
observed C 213 994
in C 214 994
12 C 215 994
patients C 216 994
( C 217 994
5 C 218 994
treated C 219 994
by C 220 994
the C 221 994
intrahepatic C 222 994
artery C 223 994
route C 224 994
and C 225 994
7 C 226 994
by C 227 994
the C 228 994
intra C 229 994
- C 230 994
aortic C 231 994
route C 232 994
) C 233 994
. C 234 994
the C 236 994
major C 237 994
complication C 238 994
noted C 239 994
was C 240 994
leukopenia C 241 994
; C 242 994
to C 243 994
a C 244 994
lesser C 245 994
degree C 246 994
, C 247 994
hepatic C 248 994
failure C 249 994
. C 250 994
in C 252 994
those C 253 994
patients C 254 994
with C 255 994
poor C 256 994
metabolic C 257 994
reserve C 258 994
and C 259 994
in C 260 994
those C 261 994
who C 262 994
had C 263 994
received C 264 994
chemotherapy C 265 994
, C 266 994
irradiation C 267 994
or C 268 994
both C 269 994
in C 270 994
the C 271 994
immediate C 272 994
past C 273 994
, C 274 994
the C 275 994
complications C 276 994
were C 277 994
severe C 278 994
. C 279 994
the C 281 994
need C 282 994
for C 283 994
critical C 284 994
screening C 285 994
for C 286 994
the C 287 994
proper C 288 994
selection C 289 994
of C 290 994
patients C 291 994
as C 292 994
candidates C 293 994
for C 294 994
cancer C 295 994
chemotherapy C 296 994
is C 297 994
discussed C 298 994
. C 299 994
cancer C 1 995
chemotherapy C 2 995
by C 3 995
continuous C 4 995
intra C 5 995
- C 6 995
arterial C 7 995
infusion C 8 995
. C 9 995
experience C 11 995
of C 12 995
the C 13 995
veterans C 14 995
administration C 15 995
surgical C 16 995
adjuvant C 17 995
cancer C 18 995
chemotherapy C 19 995
infusion C 20 995
study C 21 995
group C 22 995
. C 23 995
two C 25 995
hundred C 26 995
fifty C 27 995
- C 28 995
one C 29 995
patients C 30 995
with C 31 995
advanced C 32 995
cancer C 33 995
have C 34 995
been C 35 995
treated C 36 995
with C 37 995
365 C 38 995
courses C 39 995
of C 40 995
intra C 41 995
- C 42 995
arterial C 43 995
cancer C 44 995
chemotherapy C 45 995
. C 46 995
this C 48 995
technique C 49 995
and C 50 995
its C 51 995
complications C 52 995
and C 53 995
results C 54 995
are C 55 995
analyzed C 56 995
and C 57 995
discussed C 58 995
. C 59 995
objective C 61 995
response C 62 995
was C 63 995
obtained C 64 995
in C 65 995
57 C 66 995
% C 67 995
of C 68 995
the C 69 995
patients C 70 995
treated C 71 995
. C 72 995
the C 74 995
best C 75 995
results C 76 995
were C 77 995
obtained C 78 995
in C 79 995
epidermoid C 80 995
carcinoma C 81 995
of C 82 995
the C 83 995
head C 84 995
and C 85 995
neck C 86 995
and C 87 995
the C 88 995
poorest C 89 995
in C 90 995
primary C 91 995
brain C 92 995
tumors C 93 995
and C 94 995
intra C 95 995
- C 96 995
abdominal C 97 995
adenocarcinomas C 98 995
. C 99 995
ten C 101 995
per C 102 995
cent C 103 995
of C 104 995
all C 105 995
patients C 106 995
receiving C 107 995
at C 108 995
least C 109 995
1 C 110 995
course C 111 995
of C 112 995
therapy C 113 995
and C 114 995
available C 115 995
for C 116 995
evaluation C 117 995
obtained C 118 995
worthwhile C 119 995
palliation C 120 995
for C 121 995
6 C 122 995
or C 123 995
more C 124 995
months C 125 995
. C 126 995
ten C 128 995
patients C 129 995
have C 130 995
had C 131 995
satisfactory C 132 995
results C 133 995
for C 134 995
periods C 135 995
of C 136 995
12 C 137 995
to C 138 995
28 C 139 995
months C 140 995
. C 141 995
it C 143 995
is C 144 995
concluded C 145 995
that C 146 995
arterial C 147 995
infusion C 148 995
chemotherapy C 149 995
may C 150 995
be C 151 995
of C 152 995
benefit C 153 995
in C 154 995
the C 155 995
palliation C 156 995
of C 157 995
patients C 158 995
in C 159 995
whom C 160 995
other C 161 995
more C 162 995
conventional C 163 995
methods C 164 995
have C 165 995
failed C 166 995
or C 167 995
are C 168 995
contraindicated C 169 995
. C 170 995
the C 172 995
frequency C 173 995
of C 174 995
serious C 175 995
complications C 176 995
suggests C 177 995
that C 178 995
at C 179 995
present C 180 995
this C 181 995
form C 182 995
of C 183 995
therapy C 184 995
should C 185 995
be C 186 995
used C 187 995
only C 188 995
by C 189 995
individuals C 190 995
and C 191 995
groups C 192 995
with C 193 995
special C 194 995
interest C 195 995
and C 196 995
experience C 197 995
in C 198 995
chemotherapy C 199 995
. C 200 995
much C 202 995
further C 203 995
study C 204 995
of C 205 995
this C 206 995
type C 207 995
of C 208 995
cancer C 209 995
treatment C 210 995
is C 211 995
needed C 212 995
and C 213 995
various C 214 995
areas C 215 995
of C 216 995
investigation C 217 995
are C 218 995
suggested C 219 995
. C 220 995
treatment C 1 996
of C 2 996
cancer C 3 996
by C 4 996
bacterial C 5 996
toxins C 6 996
. C 7 996
the C 9 996
initial C 10 996
experience C 11 996
with C 12 996
toxin C 13 996
therapy C 14 996
for C 15 996
sarcoma C 16 996
and C 17 996
melanoma C 18 996
is C 19 996
reported C 20 996
in C 21 996
3 C 22 996
groups C 23 996
of C 24 996
patients C 25 996
: C 26 996
toxins C 27 996
used C 28 996
as C 29 996
an C 30 996
adjunct C 31 996
to C 32 996
operation C 33 996
in C 34 996
potentially C 35 996
curable C 36 996
patients C 37 996
, C 38 996
palliative C 39 996
treatment C 40 996
for C 41 996
metastatic C 42 996
tumor C 43 996
and C 44 996
toxin C 45 996
therapy C 46 996
supplemented C 47 996
by C 48 996
radiotherapy C 49 996
for C 50 996
localized C 51 996
symptomatic C 52 996
tumor C 53 996
masses C 54 996
. C 55 996
the C 57 996
experience C 58 996
has C 59 996
not C 60 996
been C 61 996
encouraging C 62 996
in C 63 996
the C 64 996
first C 65 996
2 C 66 996
groups C 67 996
. C 68 996
in C 70 996
6 C 71 996
of C 72 996
8 C 73 996
patients C 74 996
in C 75 996
the C 76 996
3 C 77 996
rd C 78 996
group C 79 996
there C 80 996
was C 81 996
marked C 82 996
objective C 83 996
remission C 84 996
of C 85 996
tumor C 86 996
subsequent C 87 996
to C 88 996
irradiation C 89 996
. C 90 996
further C 92 996
study C 93 996
is C 94 996
indicated C 95 996
in C 96 996
the C 97 996
use C 98 996
of C 99 996
radiotherapy C 100 996
following C 101 996
' C 102 996
priming C 103 996
' C 104 996
with C 105 996
bacterial C 106 996
toxin C 107 996
injections C 108 996
. C 109 996
radiotherapy C 1 997
of C 2 997
malignant C 3 997
rectal C 4 997
and C 5 997
anal C 6 997
tumors C 7 997
. C 8 997
methods C 10 997
and C 11 997
results C 12 997
in C 13 997
271 C 14 997
cases C 15 997
. C 16 997
the C 18 997
results C 19 997
are C 20 997
given C 21 997
of C 22 997
the C 23 997
treatment C 24 997
of C 25 997
271 C 26 997
patients C 27 997
( C 28 997
9 C 29 997
cases C 30 997
of C 31 997
anal C 32 997
and C 33 997
262 C 34 997
of C 35 997
rectal C 36 997
carcinoma C 37 997
) C 38 997
with C 39 997
conventional C 40 997
deep C 41 997
therapy C 42 997
and C 43 997
ultrahigh C 44 997
kilovoltage C 45 997
irradiation C 46 997
. C 47 997
the C 49 997
total C 50 997
5 C 51 997
- C 52 997
year C 53 997
survival C 54 997
rate C 55 997
was C 56 997
14 C 57 997
% C 58 997
. C 59 997
with C 61 997
surgical C 62 997
treatment C 63 997
it C 64 997
is C 65 997
, C 66 997
according C 67 997
to C 68 997
a C 69 997
survey C 70 997
of C 71 997
the C 72 997
literature C 73 997
made C 74 997
by C 75 997
reifferscheid C 76 997
, C 77 997
19 C 78 997
. C 79 997
. C 80 997
% C 81 997
, C 82 997
according C 83 997
to C 84 997
guleke C 85 997
20 C 86 997
- C 87 997
25 C 88 997
% C 89 997
, C 90 997
and C 91 997
according C 92 997
to C 93 997
ottenheimer C 94 997
21 C 95 997
. C 96 997
. C 97 997
% C 98 997
. C 99 997
a C 101 997
total C 102 997
of C 103 997
39 C 104 997
patients C 105 997
received C 106 997
irradiation C 107 997
after C 108 997
questionable C 109 997
radical C 110 997
surgery C 111 997
, C 112 997
and C 113 997
11 C 114 997
patients C 115 997
received C 116 997
palliative C 117 997
irradiation C 118 997
after C 119 997
palliative C 120 997
surgery C 121 997
( C 122 997
in C 123 997
most C 124 997
of C 125 997
these C 126 997
cases C 127 997
an C 128 997
anus C 129 997
praeter C 130 997
was C 131 997
performed C 132 997
) C 133 997
. C 134 997
altogether C 136 997
48 C 137 997
patients C 138 997
received C 139 997
palliative C 140 997
irradiation C 141 997
without C 142 997
surgery C 143 997
, C 144 997
and C 145 997
45 C 146 997
patients C 147 997
received C 148 997
irradiation C 149 997
because C 150 997
of C 151 997
recurrence C 152 997
after C 153 997
apparent C 154 997
radical C 155 997
surgery C 156 997
; C 157 997
11 C 158 997
patients C 159 997
received C 160 997
irradiation C 161 997
because C 162 997
of C 163 997
metastases C 164 997
after C 165 997
apparent C 166 997
radical C 167 997
surgery C 168 997
and C 169 997
6 C 170 997
patients C 171 997
because C 172 997
of C 173 997
metastases C 174 997
after C 175 997
palliative C 176 997
surgery C 177 997
. C 178 997
ultrahigh C 180 997
kilovoltage C 181 997
radiation C 182 997
treatment C 183 997
showed C 184 997
better C 185 997
results C 186 997
than C 187 997
conventional C 188 997
deep C 189 997
therapy C 190 997
. C 191 997
irradiation C 193 997
with C 194 997
1 C 195 997
, C 196 997
200 C 197 997
- C 198 997
1 C 199 997
, C 200 997
600 C 201 997
r C 202 997
. C 203 997
on C 205 997
the C 206 997
site C 207 997
before C 208 997
surgery C 209 997
in C 210 997
stage C 211 997
c C 212 997
cases C 213 997
gives C 214 997
higher C 215 997
5 C 216 997
- C 217 997
year C 218 997
survival C 219 997
rates C 220 997
, C 221 997
according C 222 997
to C 223 997
dukes C 224 997
( C 225 997
henschke C 226 997
; C 227 997
stearns C 228 997
et C 229 997
al C 230 997
. C 231 997
) C 233 997
. C 234 997
the C 1 998
management C 2 998
of C 3 998
advanced C 4 998
cancer C 5 998
. C 6 998
patients C 8 998
with C 9 998
incurable C 10 998
cancer C 11 998
may C 12 998
receive C 13 998
substantial C 14 998
relief C 15 998
of C 16 998
disabling C 17 998
mental C 18 998
and C 19 998
physical C 20 998
symptoms C 21 998
by C 22 998
constant C 23 998
and C 24 998
continuous C 25 998
medical C 26 998
management C 27 998
. C 28 998
while C 30 998
usually C 31 998
of C 32 998
limited C 33 998
value C 34 998
, C 35 998
certain C 36 998
measures C 37 998
of C 38 998
both C 39 998
specific C 40 998
anticancer C 41 998
therapy C 42 998
and C 43 998
nonspecific C 44 998
supportive C 45 998
therapy C 46 998
may C 47 998
relieve C 48 998
the C 49 998
symptoms C 50 998
and C 51 998
sustain C 52 998
the C 53 998
patient C 54 998
' C 55 998
s C 56 998
morale C 57 998
. C 58 998
general C 60 998
supportive C 61 998
measures C 62 998
of C 63 998
value C 64 998
and C 65 998
the C 66 998
various C 67 998
cancer C 68 998
chemotherapeutic C 69 998
compounds C 70 998
and C 71 998
techniques C 72 998
of C 73 998
administration C 74 998
of C 75 998
these C 76 998
drugs C 77 998
are C 78 998
reviewed C 79 998
from C 80 998
the C 81 998
standpoint C 82 998
of C 83 998
patient C 84 998
selection C 85 998
, C 86 998
practical C 87 998
application C 88 998
to C 89 998
various C 90 998
forms C 91 998
of C 92 998
cancer C 93 998
, C 94 998
and C 95 998
limitations C 96 998
of C 97 998
these C 98 998
agents C 99 998
in C 100 998
patients C 101 998
with C 102 998
advanced C 103 998
cancer C 104 998
. C 105 998
evaluation C 1 999
of C 2 999
ileal C 3 999
conduit C 4 999
as C 5 999
a C 6 999
palliative C 7 999
procedure C 8 999
. C 9 999
during C 11 999
the C 12 999
6 C 13 999
. C 14 999
. C 15 999
yr C 16 999
. C 17 999
period C 19 999
ending C 20 999
july C 21 999
1963 C 22 999
, C 23 999
107 C 24 999
ileal C 25 999
conduit C 26 999
operations C 27 999
were C 28 999
performed C 29 999
at C 30 999
the C 31 999
city C 32 999
of C 33 999
hope C 34 999
medical C 35 999
center C 36 999
in C 37 999
the C 38 999
treatment C 39 999
of C 40 999
carcinoma C 41 999
of C 42 999
the C 43 999
bladder C 44 999
and C 45 999
other C 46 999
pelvic C 47 999
organs C 48 999
. C 49 999
the C 51 999
character C 52 999
and C 53 999
extent C 54 999
of C 55 999
the C 56 999
lesions C 57 999
are C 58 999
described C 59 999
in C 60 999
detail C 61 999
. C 62 999
the C 64 999
details C 65 999
of C 66 999
the C 67 999
surgical C 68 999
procedure C 69 999
are C 70 999
discussed C 71 999
. C 72 999
complications C 74 999
including C 75 999
pyelonephritis C 76 999
, C 77 999
uremia C 78 999
, C 79 999
enteric C 80 999
and C 81 999
urinary C 82 999
fistulas C 83 999
, C 84 999
wound C 85 999
infections C 86 999
, C 87 999
and C 88 999
thrombophlebitis C 89 999
were C 90 999
common C 91 999
. C 92 999
twenty C 94 999
- C 95 999
eight C 96 999
of C 97 999
the C 98 999
107 C 99 999
patients C 100 999
died C 101 999
during C 102 999
the C 103 999
postoperative C 104 999
period C 105 999
. C 106 999
fifty C 108 999
- C 109 999
nine C 110 999
of C 111 999
the C 112 999
79 C 113 999
surviving C 114 999
patients C 115 999
are C 116 999
known C 117 999
to C 118 999
have C 119 999
died C 120 999
, C 121 999
mostly C 122 999
as C 123 999
a C 124 999
result C 125 999
of C 126 999
recurrent C 127 999
, C 128 999
uncontrollable C 129 999
carcinoma C 130 999
. C 131 999
the C 133 999
procedure C 134 999
was C 135 999
considered C 136 999
palliative C 137 999
in C 138 999
39 C 139 999
patients C 140 999
. C 141 999
in C 143 999
12 C 144 999
of C 145 999
these C 146 999
patients C 147 999
the C 148 999
lesion C 149 999
was C 150 999
removed C 151 999
and C 152 999
the C 153 999
conduit C 154 999
established C 155 999
in C 156 999
one C 157 999
stage C 158 999
; C 159 999
2 C 160 999
patients C 161 999
died C 162 999
. C 163 999
in C 165 999
only C 166 999
1 C 167 999
of C 168 999
the C 169 999
surviving C 170 999
10 C 171 999
patients C 172 999
was C 173 999
the C 174 999
tumor C 175 999
under C 176 999
control C 177 999
. C 178 999
the C 180 999
average C 181 999
term C 182 999
of C 183 999
survival C 184 999
was C 185 999
8 C 186 999
. C 187 999
. C 188 999
mth C 189 999
. C 190 999
the C 192 999
procedure C 193 999
was C 194 999
carried C 195 999
out C 196 999
in C 197 999
2 C 198 999
stages C 199 999
in C 200 999
4 C 201 999
cases C 202 999
; C 203 999
2 C 204 999
patients C 205 999
died C 206 999
after C 207 999
the C 208 999
2 C 209 999
nd C 210 999
stage C 211 999
. C 212 999
the C 214 999
2 C 215 999
surviving C 216 999
patients C 217 999
lived C 218 999
1 C 219 999
. C 220 999
. C 221 999
and C 222 999
4 C 223 999
3 C 224 999
/ C 225 999
4 C 226 999
mth C 227 999
. C 228 999
, C 230 999
respectively C 231 999
. C 232 999
an C 234 999
ileal C 235 999
conduit C 236 999
alone C 237 999
was C 238 999
established C 239 999
in C 240 999
23 C 241 999
patients C 242 999
, C 243 999
8 C 244 999
of C 245 999
whom C 246 999
died C 247 999
after C 248 999
the C 249 999
operation C 250 999
. C 251 999
the C 253 999
average C 254 999
time C 255 999
of C 256 999
survival C 257 999
was C 258 999
4 C 259 999
. C 260 999
. C 261 999
mth C 262 999
. C 263 999
; C 265 999
1 C 266 999
patient C 267 999
was C 268 999
alive C 269 999
after C 270 999
11 C 271 999
mth C 272 999
. C 273 999
it C 275 999
is C 276 999
concluded C 277 999
that C 278 999
an C 279 999
ileal C 280 999
conduit C 281 999
in C 282 999
conjunction C 283 999
with C 284 999
total C 285 999
cystectomy C 286 999
in C 287 999
1 C 288 999
stage C 289 999
is C 290 999
indicated C 291 999
as C 292 999
a C 293 999
palliative C 294 999
procedure C 295 999
but C 296 999
only C 297 999
when C 298 999
severe C 299 999
intractable C 300 999
symptoms C 301 999
exist C 302 999
and C 303 999
only C 304 999
when C 305 999
patients C 306 999
are C 307 999
carefully C 308 999
selected C 309 999
. C 310 999
the C 312 999
procedure C 313 999
is C 314 999
poorly C 315 999
tolerated C 316 999
in C 317 999
older C 318 999
persons C 319 999
. C 320 999
cancer C 1 1000
chemotherapy C 2 1000
by C 3 1000
continuous C 4 1000
intra C 5 1000
- C 6 1000
arterial C 7 1000
infusion C 8 1000
of C 9 1000
methotrexate C 10 1000
. C 11 1000
continuous C 13 1000
intra C 14 1000
- C 15 1000
arterial C 16 1000
infusions C 17 1000
of C 18 1000
methotrexate C 19 1000
were C 20 1000
used C 21 1000
in C 22 1000
the C 23 1000
treatment C 24 1000
of C 25 1000
45 C 26 1000
patients C 27 1000
with C 28 1000
malignant C 29 1000
disease C 30 1000
of C 31 1000
the C 32 1000
head C 33 1000
and C 34 1000
neck C 35 1000
, C 36 1000
16 C 37 1000
patients C 38 1000
with C 39 1000
advanced C 40 1000
cancer C 41 1000
of C 42 1000
pelvic C 43 1000
organs C 44 1000
, C 45 1000
and C 46 1000
7 C 47 1000
with C 48 1000
malignant C 49 1000
lesions C 50 1000
of C 51 1000
the C 52 1000
lower C 53 1000
limb C 54 1000
. C 55 1000
in C 57 1000
4 C 58 1000
patients C 59 1000
with C 60 1000
epidermoid C 61 1000
lesions C 62 1000
of C 63 1000
the C 64 1000
head C 65 1000
and C 66 1000
neck C 67 1000
there C 68 1000
was C 69 1000
complete C 70 1000
regression C 71 1000
of C 72 1000
the C 73 1000
local C 74 1000
tumor C 75 1000
. C 76 1000
thirty C 78 1000
- C 79 1000
three C 80 1000
other C 81 1000
patients C 82 1000
benefited C 83 1000
from C 84 1000
treatment C 85 1000
for C 86 1000
varying C 87 1000
periods C 88 1000
of C 89 1000
time C 90 1000
, C 91 1000
but C 92 1000
the C 93 1000
remaining C 94 1000
30 C 95 1000
showed C 96 1000
no C 97 1000
response C 98 1000
. C 99 1000
eight C 101 1000
patients C 102 1000
died C 103 1000
during C 104 1000
or C 105 1000
immediately C 106 1000
after C 107 1000
treatment C 108 1000
; C 109 1000
all C 110 1000
had C 111 1000
advanced C 112 1000
cancers C 113 1000
of C 114 1000
the C 115 1000
head C 116 1000
- C 117 1000
and C 118 1000
- C 119 1000
neck C 120 1000
region C 121 1000
. C 122 1000
the C 124 1000
mean C 125 1000
total C 126 1000
dose C 127 1000
of C 128 1000
methotrexate C 129 1000
given C 130 1000
in C 131 1000
the C 132 1000
patients C 133 1000
with C 134 1000
no C 135 1000
response C 136 1000
was C 137 1000
significantly C 138 1000
less C 139 1000
than C 140 1000
in C 141 1000
those C 142 1000
with C 143 1000
partial C 144 1000
regression C 145 1000
of C 146 1000
the C 147 1000
tumor C 148 1000
. C 149 1000
this C 151 1000
suggests C 152 1000
that C 153 1000
the C 154 1000
greater C 155 1000
the C 156 1000
total C 157 1000
dose C 158 1000
of C 159 1000
methotrexate C 160 1000
tolerated C 161 1000
, C 162 1000
the C 163 1000
greater C 164 1000
the C 165 1000
chance C 166 1000
of C 167 1000
beneficial C 168 1000
response C 169 1000
. C 170 1000
the C 172 1000
role C 173 1000
of C 174 1000
continuous C 175 1000
intra C 176 1000
- C 177 1000
arterial C 178 1000
chemotherapy C 179 1000
in C 180 1000
the C 181 1000
management C 182 1000
of C 183 1000
malignant C 184 1000
disease C 185 1000
is C 186 1000
discussed C 187 1000
. C 188 1000
management C 1 1001
of C 2 1001
advanced C 3 1001
ovarian C 4 1001
carcinoma C 5 1001
. C 6 1001
the C 8 1001
life C 9 1001
graph C 10 1001
is C 11 1001
presented C 12 1001
for C 13 1001
the C 14 1001
purpose C 15 1001
of C 16 1001
illustrating C 17 1001
the C 18 1001
results C 19 1001
of C 20 1001
treatment C 21 1001
for C 22 1001
patients C 23 1001
with C 24 1001
ovarian C 25 1001
carcinoma C 26 1001
who C 27 1001
eventually C 28 1001
died C 29 1001
from C 30 1001
their C 31 1001
disease C 32 1001
. C 33 1001
it C 35 1001
includes C 36 1001
all C 37 1001
patients C 38 1001
regardless C 39 1001
of C 40 1001
initial C 41 1001
stage C 42 1001
of C 43 1001
disease C 44 1001
, C 45 1001
histology C 46 1001
of C 47 1001
the C 48 1001
tumor C 49 1001
, C 50 1001
or C 51 1001
therapy C 52 1001
employed C 53 1001
. C 54 1001
the C 56 1001
series C 57 1001
is C 58 1001
a C 59 1001
selected C 60 1001
one C 61 1001
because C 62 1001
of C 63 1001
the C 64 1001
type C 65 1001
of C 66 1001
patient C 67 1001
referred C 68 1001
to C 69 1001
the C 70 1001
medical C 71 1001
oncology C 72 1001
service C 73 1001
, C 74 1001
and C 75 1001
it C 76 1001
demonstrates C 77 1001
that C 78 1001
almost C 79 1001
2 C 80 1001
/ C 81 1001
3 C 82 1001
of C 83 1001
the C 84 1001
patients C 85 1001
died C 86 1001
within C 87 1001
2 C 88 1001
yr C 89 1001
. C 90 1001
of C 92 1001
diagnosis C 93 1001
. C 94 1001
all C 96 1001
patients C 97 1001
received C 98 1001
active C 99 1001
, C 100 1001
aggressive C 101 1001
anti C 102 1001
- C 103 1001
tumor C 104 1001
as C 105 1001
well C 106 1001
as C 107 1001
supportive C 108 1001
therapy C 109 1001
, C 110 1001
although C 111 1001
there C 112 1001
was C 113 1001
no C 114 1001
formal C 115 1001
protocol C 116 1001
for C 117 1001
patient C 118 1001
management C 119 1001
. C 120 1001
it C 122 1001
might C 123 1001
be C 124 1001
possible C 125 1001
, C 126 1001
employing C 127 1001
a C 128 1001
standardized C 129 1001
therapeutic C 130 1001
approach C 131 1001
- C 132 1001
irradiation C 133 1001
when C 134 1001
indicated C 135 1001
to C 136 1001
the C 137 1001
entire C 138 1001
abdomen C 139 1001
in C 140 1001
the C 141 1001
dose C 142 1001
range C 143 1001
of C 144 1001
3 C 145 1001
, C 146 1001
500 C 147 1001
rads C 148 1001
, C 149 1001
followed C 150 1001
by C 151 1001
judicious C 152 1001
use C 153 1001
of C 154 1001
currently C 155 1001
available C 156 1001
anticancer C 157 1001
drugs C 158 1001
when C 159 1001
the C 160 1001
disease C 161 1001
recurs C 162 1001
- C 163 1001
to C 164 1001
produce C 165 1001
a C 166 1001
modest C 167 1001
increase C 168 1001
in C 169 1001
the C 170 1001
2 C 171 1001
- C 172 1001
year C 173 1001
survival C 174 1001
figures C 175 1001
. C 176 1001
since C 178 1001
most C 179 1001
series C 180 1001
show C 181 1001
that C 182 1001
approximately C 183 1001
75 C 184 1001
% C 185 1001
of C 186 1001
patients C 187 1001
with C 188 1001
ovarian C 189 1001
carcinoma C 190 1001
are C 191 1001
in C 192 1001
stage C 193 1001
iii C 194 1001
of C 195 1001
iv C 196 1001
when C 197 1001
first C 198 1001
diagnosed C 199 1001
, C 200 1001
more C 201 1001
attention C 202 1001
might C 203 1001
be C 204 1001
directed C 205 1001
to C 206 1001
earlier C 207 1001
diagnosis C 208 1001
. C 209 1001
while C 211 1001
it C 212 1001
is C 213 1001
an C 214 1001
important C 215 1001
field C 216 1001
for C 217 1001
investigation C 218 1001
, C 219 1001
methods C 220 1001
of C 221 1001
facilitating C 222 1001
early C 223 1001
diagnosis C 224 1001
are C 225 1001
not C 226 1001
apparent C 227 1001
at C 228 1001
the C 229 1001
moment C 230 1001
. C 231 1001
controlled C 233 1001
trials C 234 1001
of C 235 1001
adjuvant C 236 1001
therapy C 237 1001
for C 238 1001
stage C 239 1001
i C 240 1001
and C 241 1001
ii C 242 1001
disease C 243 1001
in C 244 1001
which C 245 1001
approximately C 246 1001
40 C 247 1001
% C 248 1001
of C 249 1001
recurrences C 250 1001
are C 251 1001
seen C 252 1001
should C 253 1001
be C 254 1001
expanded C 255 1001
. C 256 1001
this C 258 1001
might C 259 1001
consist C 260 1001
of C 261 1001
instillation C 262 1001
of C 263 1001
radioactive C 264 1001
or C 265 1001
chemical C 266 1001
agents C 267 1001
into C 268 1001
the C 269 1001
abdominal C 270 1001
cavity C 271 1001
, C 272 1001
the C 273 1001
use C 274 1001
of C 275 1001
systemic C 276 1001
chemotherapy C 277 1001
during C 278 1001
or C 279 1001
immediately C 280 1001
after C 281 1001
operation C 282 1001
, C 283 1001
or C 284 1001
infusion C 285 1001
of C 286 1001
drugs C 287 1001
into C 288 1001
the C 289 1001
abdominal C 290 1001
aorta C 291 1001
. C 292 1001
for C 294 1001
stages C 295 1001
iii C 296 1001
and C 297 1001
iv C 298 1001
controlled C 299 1001
trials C 300 1001
of C 301 1001
drugs C 302 1001
alone C 303 1001
, C 304 1001
sequentially C 305 1001
, C 306 1001
or C 307 1001
in C 308 1001
combination C 309 1001
with C 310 1001
or C 311 1001
subsequent C 312 1001
to C 313 1001
irradiation C 314 1001
seem C 315 1001
indicated C 316 1001
. C 317 1001
finally C 319 1001
, C 320 1001
efforts C 321 1001
to C 322 1001
find C 323 1001
more C 324 1001
effective C 325 1001
anticancer C 326 1001
drugs C 327 1001
must C 328 1001
continue C 329 1001
. C 330 1001
liver C 1 1002
resections C 2 1002
for C 3 1002
embolic C 4 1002
metastases C 5 1002
from C 6 1002
cancer C 7 1002
of C 8 1002
the C 9 1002
colon C 10 1002
and C 11 1002
rectum C 12 1002
. C 13 1002
two C 15 1002
patients C 16 1002
, C 17 1002
who C 18 1002
underwent C 19 1002
resections C 20 1002
of C 21 1002
the C 22 1002
left C 23 1002
lobe C 24 1002
of C 25 1002
the C 26 1002
liver C 27 1002
for C 28 1002
embolic C 29 1002
metastases C 30 1002
from C 31 1002
primary C 32 1002
cancers C 33 1002
of C 34 1002
the C 35 1002
colon C 36 1002
and C 37 1002
rectum C 38 1002
, C 39 1002
are C 40 1002
reported C 41 1002
. C 42 1002
the C 44 1002
internal C 45 1002
anatomy C 46 1002
of C 47 1002
the C 48 1002
liver C 49 1002
, C 50 1002
as C 51 1002
it C 52 1002
relates C 53 1002
to C 54 1002
the C 55 1002
technic C 56 1002
and C 57 1002
terminology C 58 1002
of C 59 1002
resections C 60 1002
, C 61 1002
is C 62 1002
reviewed C 63 1002
. C 64 1002
cases C 66 1002
of C 67 1002
liver C 68 1002
resection C 69 1002
performed C 70 1002
for C 71 1002
embolic C 72 1002
metastases C 73 1002
from C 74 1002
cancer C 75 1002
of C 76 1002
the C 77 1002
colon C 78 1002
and C 79 1002
rectum C 80 1002
, C 81 1002
found C 82 1002
in C 83 1002
an C 84 1002
extensive C 85 1002
review C 86 1002
of C 87 1002
medical C 88 1002
literature C 89 1002
, C 90 1002
are C 91 1002
classified C 92 1002
and C 93 1002
the C 94 1002
results C 95 1002
are C 96 1002
analyzed C 97 1002
. C 98 1002
resection C 100 1002
of C 101 1002
either C 102 1002
half C 103 1002
of C 104 1002
the C 105 1002
liver C 106 1002
( C 107 1002
hemihepatectomy C 108 1002
) C 109 1002
for C 110 1002
embolic C 111 1002
metastasis C 112 1002
from C 113 1002
cancer C 114 1002
of C 115 1002
the C 116 1002
colon C 117 1002
or C 118 1002
rectum C 119 1002
, C 120 1002
so C 121 1002
rarely C 122 1002
cures C 123 1002
the C 124 1002
patient C 125 1002
and C 126 1002
carried C 127 1002
such C 128 1002
a C 129 1002
high C 130 1002
operative C 131 1002
mortality C 132 1002
rate C 133 1002
, C 134 1002
that C 135 1002
it C 136 1002
is C 137 1002
seldom C 138 1002
, C 139 1002
if C 140 1002
ever C 141 1002
, C 142 1002
justifiable C 143 1002
. C 144 1002
the C 146 1002
lesser C 147 1002
operations C 148 1002
( C 149 1002
left C 150 1002
lobectomy C 151 1002
or C 152 1002
right C 153 1002
- C 154 1002
lobe C 155 1002
metastasectomy C 156 1002
) C 157 1002
often C 158 1002
can C 159 1002
be C 160 1002
performed C 161 1002
simultaneously C 162 1002
with C 163 1002
the C 164 1002
primary C 165 1002
operation C 166 1002
and C 167 1002
are C 168 1002
occasionally C 169 1002
followed C 170 1002
by C 171 1002
freedom C 172 1002
from C 173 1002
recurrence C 174 1002
for C 175 1002
periods C 176 1002
of C 177 1002
5 C 178 1002
yr C 179 1002
or C 180 1002
more C 181 1002
. C 182 1002
they C 184 1002
are C 185 1002
justifiable C 186 1002
if C 187 1002
the C 188 1002
metastasis C 189 1002
is C 190 1002
situated C 191 1002
favorably C 192 1002
in C 193 1002
the C 194 1002
liver C 195 1002
for C 196 1002
complete C 197 1002
removal C 198 1002
, C 199 1002
and C 200 1002
if C 201 1002
the C 202 1002
primary C 203 1002
lesion C 204 1002
appears C 205 1002
to C 206 1002
be C 207 1002
curable C 208 1002
. C 209 1002
palliative C 1 1003
treatment C 2 1003
of C 3 1003
nonresectable C 4 1003
lung C 5 1003
cancer C 6 1003
by C 7 1003
upper C 8 1003
hemibody C 9 1003
perfusion C 10 1003
of C 11 1003
chlorimine C 12 1003
( C 13 1003
short C 14 1003
- C 15 1003
acting C 16 1003
alkylating C 17 1003
agent C 18 1003
) C 19 1003
. C 20 1003
experience C 22 1003
with C 23 1003
five C 24 1003
cases C 25 1003
. C 26 1003
a C 28 1003
method C 29 1003
is C 30 1003
discussed C 31 1003
for C 32 1003
providing C 33 1003
palliative C 34 1003
treatment C 35 1003
for C 36 1003
patients C 37 1003
with C 38 1003
nonresectable C 39 1003
lung C 40 1003
cancer C 41 1003
by C 42 1003
means C 43 1003
of C 44 1003
administering C 45 1003
a C 46 1003
short C 47 1003
- C 48 1003
acting C 49 1003
alkylating C 50 1003
agent C 51 1003
to C 52 1003
the C 53 1003
upper C 54 1003
half C 55 1003
of C 56 1003
the C 57 1003
body C 58 1003
while C 59 1003
temporarily C 60 1003
occluding C 61 1003
the C 62 1003
circulation C 63 1003
to C 64 1003
the C 65 1003
lower C 66 1003
half C 67 1003
of C 68 1003
the C 69 1003
body C 70 1003
. C 71 1003
with C 73 1003
proper C 74 1003
selection C 75 1003
of C 76 1003
patients C 77 1003
and C 78 1003
an C 79 1003
awareness C 80 1003
of C 81 1003
the C 82 1003
potential C 83 1003
complications C 84 1003
, C 85 1003
the C 86 1003
procedure C 87 1003
appears C 88 1003
to C 89 1003
be C 90 1003
safe C 91 1003
and C 92 1003
effective C 93 1003
. C 94 1003
congenital C 1 1004
extrahepatic C 2 1004
biliary C 3 1004
atresia C 4 1004
. C 5 1004
a C 7 1004
successful C 8 1004
operated C 9 1004
case C 10 1004
on C 11 1004
ductus C 12 1004
hepaticus C 13 1004
obstruction C 14 1004
. C 15 1004
the C 17 1004
author C 18 1004
briefly C 19 1004
reviews C 20 1004
the C 21 1004
history C 22 1004
and C 23 1004
the C 24 1004
anatomical C 25 1004
manifestations C 26 1004
and C 27 1004
the C 28 1004
genesis C 29 1004
of C 30 1004
congenital C 31 1004
extrahepatic C 32 1004
biliary C 33 1004
atresia C 34 1004
, C 35 1004
and C 36 1004
its C 37 1004
associations C 38 1004
with C 39 1004
other C 40 1004
abnormalities C 41 1004
. C 42 1004
he C 44 1004
collected C 45 1004
957 C 46 1004
cases C 47 1004
in C 48 1004
the C 49 1004
literature C 50 1004
from C 51 1004
ladd C 52 1004
' C 53 1004
s C 54 1004
first C 55 1004
successful C 56 1004
operated C 57 1004
case C 58 1004
up C 59 1004
to C 60 1004
the C 61 1004
end C 62 1004
of C 63 1004
the C 64 1004
year C 65 1004
1961 C 66 1004
. C 67 1004
in C 69 1004
publications C 70 1004
he C 71 1004
found C 72 1004
177 C 73 1004
theoretically C 74 1004
correctable C 75 1004
cases C 76 1004
and C 77 1004
124 C 78 1004
which C 79 1004
were C 80 1004
recovered C 81 1004
. C 82 1004
in C 84 1004
1 C 85 1004
of C 86 1004
2 C 87 1004
personal C 88 1004
cases C 89 1004
he C 90 1004
performed C 91 1004
successfully C 92 1004
a C 93 1004
hepatico C 94 1004
- C 95 1004
duodenostomy C 96 1004
in C 97 1004
a C 98 1004
7 C 99 1004
- C 100 1004
week C 101 1004
- C 102 1004
old C 103 1004
girl C 104 1004
. C 105 1004
four C 107 1004
years C 108 1004
later C 109 1004
the C 110 1004
girl C 111 1004
had C 112 1004
developed C 113 1004
normally C 114 1004
and C 115 1004
she C 116 1004
was C 117 1004
absolutely C 118 1004
without C 119 1004
symptoms C 120 1004
and C 121 1004
signs C 122 1004
. C 123 1004
the C 125 1004
author C 126 1004
, C 127 1004
discussing C 128 1004
the C 129 1004
differential C 130 1004
diagnostic C 131 1004
problems C 132 1004
, C 133 1004
stresses C 134 1004
the C 135 1004
diagnostic C 136 1004
value C 137 1004
of C 138 1004
the C 139 1004
gradually C 140 1004
increasing C 141 1004
direct C 142 1004
serum C 143 1004
bilirubin C 144 1004
, C 145 1004
proposing C 146 1004
the C 147 1004
term C 148 1004
' C 149 1004
ex C 150 1004
juvantibus C 151 1004
differentiation C 152 1004
' C 153 1004
alluding C 154 1004
to C 155 1004
the C 156 1004
differential C 157 1004
diagnostic C 158 1004
evaluation C 159 1004
of C 160 1004
the C 161 1004
time C 162 1004
which C 163 1004
passes C 164 1004
until C 165 1004
the C 166 1004
surgical C 167 1004
exploration C 168 1004
; C 169 1004
he C 170 1004
also C 171 1004
emphasizes C 172 1004
the C 173 1004
need C 174 1004
of C 175 1004
early C 176 1004
- C 177 1004
latest C 178 1004
up C 179 1004
to C 180 1004
the C 181 1004
age C 182 1004
of C 183 1004
8 C 184 1004
weeks C 185 1004
performed C 186 1004
- C 187 1004
surgical C 188 1004
exploration C 189 1004
. C 190 1004
according C 192 1004
to C 193 1004
him C 194 1004
the C 195 1004
administration C 196 1004
of C 197 1004
vit C 198 1004
. C 199 1004
k C 201 1004
is C 202 1004
advantageous C 203 1004
. C 204 1004
he C 206 1004
supposes C 207 1004
the C 208 1004
cause C 209 1004
of C 210 1004
the C 211 1004
postoperative C 212 1004
dehiscence C 213 1004
of C 214 1004
the C 215 1004
operative C 216 1004
wound C 217 1004
lies C 218 1004
in C 219 1004
the C 220 1004
metabolic C 221 1004
changes C 222 1004
as C 223 1004
a C 224 1004
result C 225 1004
of C 226 1004
icterus C 227 1004
. C 228 1004
the C 230 1004
author C 231 1004
in C 232 1004
his C 233 1004
own C 234 1004
case C 235 1004
, C 236 1004
the C 237 1004
relieved C 238 1004
drainage C 239 1004
of C 240 1004
the C 241 1004
bilio C 242 1004
- C 243 1004
digestive C 244 1004
anastomosis C 245 1004
solved C 246 1004
by C 247 1004
the C 248 1004
help C 249 1004
of C 250 1004
a C 251 1004
polyethylene C 252 1004
nasal C 253 1004
tube C 254 1004
and C 255 1004
which C 256 1004
could C 257 1004
be C 258 1004
most C 259 1004
safely C 260 1004
removed C 261 1004
by C 262 1004
the C 263 1004
surgeon C 264 1004
. C 265 1004
with C 267 1004
statistical C 268 1004
data C 269 1004
of C 270 1004
other C 271 1004
authors C 272 1004
and C 273 1004
personal C 274 1004
cases C 275 1004
, C 276 1004
the C 277 1004
author C 278 1004
points C 279 1004
out C 280 1004
that C 281 1004
the C 282 1004
correctable C 283 1004
cases C 284 1004
occur C 285 1004
in C 286 1004
19 C 287 1004
. C 288 1004
. C 289 1004
% C 290 1004
of C 291 1004
all C 292 1004
the C 293 1004
cases C 294 1004
. C 295 1004
one C 297 1004
may C 298 1004
hope C 299 1004
for C 300 1004
successful C 301 1004
operations C 302 1004
on C 303 1004
an C 304 1004
average C 305 1004
in C 306 1004
10 C 307 1004
. C 308 1004
. C 309 1004
% C 310 1004
of C 311 1004
all C 312 1004
the C 313 1004
cases C 314 1004
and C 315 1004
50 C 316 1004
. C 317 1004
. C 318 1004
% C 319 1004
of C 320 1004
the C 321 1004
correctable C 322 1004
ones C 323 1004
. C 324 1004
fatal C 326 1004
complications C 327 1004
, C 328 1004
the C 329 1004
author C 330 1004
believes C 331 1004
, C 332 1004
can C 333 1004
be C 334 1004
reduced C 335 1004
by C 336 1004
early C 337 1004
surgery C 338 1004
. C 339 1004
icterus C 1 1005
neonatorum C 2 1005
simplex C 3 1005
. C 4 1005
studies C 6 1005
in C 7 1005
50 C 8 1005
guinea C 9 1005
- C 10 1005
pigs C 11 1005
demonstrate C 12 1005
that C 13 1005
at C 14 1005
birth C 15 1005
there C 16 1005
is C 17 1005
no C 18 1005
activity C 19 1005
of C 20 1005
glucuronyltransferase C 21 1005
. C 22 1005
after C 24 1005
birth C 25 1005
activity C 26 1005
gradually C 27 1005
increases C 28 1005
and C 29 1005
reaches C 30 1005
its C 31 1005
highest C 32 1005
level C 33 1005
on C 34 1005
the C 35 1005
3 C 36 1005
rd C 37 1005
day C 38 1005
of C 39 1005
life C 40 1005
. C 41 1005
hereafter C 43 1005
a C 44 1005
gradual C 45 1005
decrease C 46 1005
can C 47 1005
be C 48 1005
shown C 49 1005
. C 50 1005
the C 52 1005
suggestion C 53 1005
is C 54 1005
made C 55 1005
that C 56 1005
glucuronyltransferase C 57 1005
is C 58 1005
an C 59 1005
adaptive C 60 1005
enzyme C 61 1005
. C 62 1005
the C 64 1005
results C 65 1005
support C 66 1005
the C 67 1005
hypothesis C 68 1005
that C 69 1005
neonatal C 70 1005
jaundice C 71 1005
is C 72 1005
caused C 73 1005
by C 74 1005
an C 75 1005
inability C 76 1005
of C 77 1005
the C 78 1005
liver C 79 1005
of C 80 1005
the C 81 1005
newborn C 82 1005
to C 83 1005
excrete C 84 1005
bilirubin C 85 1005
. C 86 1005
the C 1 1006
importance C 2 1006
of C 3 1006
steroid C 4 1006
hormones C 5 1006
in C 6 1006
hyperbilirubinemia C 7 1006
, C 8 1006
and C 9 1006
icterus C 10 1006
of C 11 1006
the C 12 1006
newborn C 13 1006
. C 14 1006
administration C 16 1006
of C 17 1006
naturally C 18 1006
occurring C 19 1006
steroids C 20 1006
( C 21 1006
estriol C 22 1006
, C 23 1006
pregnanediol C 24 1006
, C 25 1006
cortisone C 26 1006
) C 27 1006
between C 28 1006
the C 29 1006
7 C 30 1006
th C 31 1006
and C 32 1006
the C 33 1006
11 C 34 1006
th C 35 1006
day C 36 1006
of C 37 1006
life C 38 1006
increases C 39 1006
the C 40 1006
bilirubin C 41 1006
level C 42 1006
of C 43 1006
these C 44 1006
newborns C 45 1006
. C 46 1006
administration C 48 1006
of C 49 1006
the C 50 1006
same C 51 1006
steroids C 52 1006
or C 53 1006
of C 54 1006
progesterone C 55 1006
to C 56 1006
nursing C 57 1006
mothers C 58 1006
results C 59 1006
in C 60 1006
hyperbilirubinemia C 61 1006
of C 62 1006
their C 63 1006
infants C 64 1006
. C 65 1006
these C 67 1006
facts C 68 1006
explain C 69 1006
the C 70 1006
pathogenesis C 71 1006
of C 72 1006
neonatal C 73 1006
jaundice C 74 1006
. C 75 1006
interpretation C 77 1006
of C 78 1006
the C 79 1006
experimental C 80 1006
and C 81 1006
clinical C 82 1006
findings C 83 1006
leads C 84 1006
to C 85 1006
the C 86 1006
conclusion C 87 1006
that C 88 1006
the C 89 1006
high C 90 1006
amount C 91 1006
of C 92 1006
steroid C 93 1006
hormones C 94 1006
which C 95 1006
must C 96 1006
be C 97 1006
excreted C 98 1006
during C 99 1006
the C 100 1006
neonatal C 101 1006
period C 102 1006
in C 103 1006
conjunction C 104 1006
with C 105 1006
the C 106 1006
relative C 107 1006
insufficiency C 108 1006
of C 109 1006
the C 110 1006
neonatal C 111 1006
liver C 112 1006
is C 113 1006
responsible C 114 1006
for C 115 1006
the C 116 1006
inability C 117 1006
to C 118 1006
conjugate C 119 1006
bilirubin C 120 1006
with C 121 1006
glucuronic C 122 1006
acid C 123 1006
. C 124 1006
the C 126 1006
steroid C 127 1006
hormones C 128 1006
probably C 129 1006
compete C 130 1006
with C 131 1006
bilirubin C 132 1006
for C 133 1006
the C 134 1006
enzyme C 135 1006
and C 136 1006
substrate C 137 1006
necessary C 138 1006
for C 139 1006
conjugation C 140 1006
. C 141 1006
the C 143 1006
functional C 144 1006
capacity C 145 1006
of C 146 1006
the C 147 1006
neonatal C 148 1006
liver C 149 1006
is C 150 1006
not C 151 1006
high C 152 1006
enough C 153 1006
to C 154 1006
conjugate C 155 1006
both C 156 1006
bilirubin C 157 1006
and C 158 1006
steroids C 159 1006
. C 160 1006
only C 162 1006
after C 163 1006
excretion C 164 1006
of C 165 1006
the C 166 1006
placental C 167 1006
steroids C 168 1006
does C 169 1006
sufficient C 170 1006
conjugation C 171 1006
of C 172 1006
bilirubin C 173 1006
become C 174 1006
possible C 175 1006
. C 176 1006
furthermore C 178 1006
, C 179 1006
pregnanediol C 180 1006
appears C 181 1006
to C 182 1006
inhibit C 183 1006
the C 184 1006
enzyme C 185 1006
glucuronyl C 186 1006
transferase C 187 1006
. C 188 1006
these C 190 1006
mechanisms C 191 1006
show C 192 1006
the C 193 1006
importance C 194 1006
of C 195 1006
steroid C 196 1006
hormones C 197 1006
in C 198 1006
the C 199 1006
pathogenesis C 200 1006
of C 201 1006
neonatal C 202 1006
jaundice C 203 1006
and C 204 1006
their C 205 1006
importance C 206 1006
as C 207 1006
an C 208 1006
aggravating C 209 1006
factor C 210 1006
in C 211 1006
the C 212 1006
development C 213 1006
of C 214 1006
jaundice C 215 1006
due C 216 1006
to C 217 1006
erythroblastosis C 218 1006
. C 219 1006
these C 221 1006
newly C 222 1006
developed C 223 1006
concepts C 224 1006
may C 225 1006
have C 226 1006
therapeutic C 227 1006
implications C 228 1006
on C 229 1006
which C 230 1006
the C 231 1006
author C 232 1006
will C 233 1006
report C 234 1006
at C 235 1006
a C 236 1006
later C 237 1006
date C 238 1006
. C 239 1006
problems C 1 1007
in C 2 1007
neonatal C 3 1007
obstructive C 4 1007
jaundice C 5 1007
. C 6 1007
a C 8 1007
critical C 9 1007
analysis C 10 1007
of C 11 1007
57 C 12 1007
cases C 13 1007
of C 14 1007
neonatal C 15 1007
obstructive C 16 1007
jaundice C 17 1007
led C 18 1007
to C 19 1007
the C 20 1007
conclusion C 21 1007
that C 22 1007
proper C 23 1007
diagnosis C 24 1007
can C 25 1007
be C 26 1007
determined C 27 1007
by C 28 1007
study C 29 1007
of C 30 1007
liver C 31 1007
biopsy C 32 1007
. C 33 1007
the C 35 1007
very C 36 1007
low C 37 1007
percentage C 38 1007
of C 39 1007
surgically C 40 1007
correctable C 41 1007
lesions C 42 1007
among C 43 1007
patients C 44 1007
with C 45 1007
neonatal C 46 1007
obstructive C 47 1007
jaundice C 48 1007
and C 49 1007
the C 50 1007
seriousness C 51 1007
and C 52 1007
high C 53 1007
mortality C 54 1007
of C 55 1007
the C 56 1007
cases C 57 1007
of C 58 1007
hepatitis C 59 1007
treated C 60 1007
with C 61 1007
a C 62 1007
hazardous C 63 1007
operation C 64 1007
are C 65 1007
stressed C 66 1007
. C 67 1007
conservative C 69 1007
management C 70 1007
is C 71 1007
recommended C 72 1007
until C 73 1007
3 C 74 1007
mth C 75 1007
. C 76 1007
of C 78 1007
age C 79 1007
and C 80 1007
even C 81 1007
later C 82 1007
if C 83 1007
a C 84 1007
serial C 85 1007
fall C 86 1007
in C 87 1007
bilirubin C 88 1007
is C 89 1007
noted C 90 1007
. C 91 1007
clinical C 1 1008
study C 2 1008
and C 3 1008
histological C 4 1008
study C 5 1008
of C 6 1008
the C 7 1008
liver C 8 1008
in C 9 1008
hepatitis C 10 1008
in C 11 1008
infants C 12 1008
. C 13 1008
i C 15 1008
. C 16 1008
classification C 18 1008
and C 19 1008
findings C 20 1008
of C 21 1008
clinical C 22 1008
study C 23 1008
and C 24 1008
histological C 25 1008
study C 26 1008
of C 27 1008
the C 28 1008
liver C 29 1008
in C 30 1008
hepatitis C 31 1008
in C 32 1008
infants C 33 1008
( C 34 1008
japanese C 35 1008
) C 36 1008
. C 37 1008
clinical C 39 1008
observations C 40 1008
and C 41 1008
histological C 42 1008
studies C 43 1008
by C 44 1008
liver C 45 1008
biopsy C 46 1008
on C 47 1008
hepatitis C 48 1008
in C 49 1008
infancy C 50 1008
, C 51 1008
i C 52 1008
. C 53 1008
e C 55 1008
. C 56 1008
obstructive C 58 1008
jaundice C 59 1008
of C 60 1008
unknown C 61 1008
cause C 62 1008
in C 63 1008
infants C 64 1008
, C 65 1008
were C 66 1008
made C 67 1008
. C 68 1008
histologically C 70 1008
, C 71 1008
hepatitis C 72 1008
in C 73 1008
infancy C 74 1008
was C 75 1008
divisible C 76 1008
into C 77 1008
3 C 78 1008
types C 79 1008
: C 80 1008
( C 81 1008
1 C 82 1008
) C 83 1008
no C 84 1008
giant C 85 1008
cell C 86 1008
formation C 87 1008
was C 88 1008
observed C 89 1008
. C 90 1008
in C 92 1008
general C 93 1008
, C 94 1008
slight C 95 1008
degeneration C 96 1008
of C 97 1008
liver C 98 1008
cells C 99 1008
, C 100 1008
necrosis C 101 1008
and C 102 1008
inflammatory C 103 1008
changes C 104 1008
with C 105 1008
stasis C 106 1008
of C 107 1008
bile C 108 1008
were C 109 1008
characteristic C 110 1008
. C 111 1008
( C 113 1008
2 C 114 1008
) C 115 1008
the C 116 1008
so C 117 1008
- C 118 1008
called C 119 1008
giant C 120 1008
cell C 121 1008
hepatitis C 122 1008
was C 123 1008
characteristic C 124 1008
. C 125 1008
( C 127 1008
3 C 128 1008
) C 129 1008
specific C 130 1008
type C 131 1008
, C 132 1008
presenting C 133 1008
the C 134 1008
picture C 135 1008
of C 136 1008
cholangiolitis C 137 1008
. C 138 1008
histological C 140 1008
changes C 141 1008
in C 142 1008
the C 143 1008
liver C 144 1008
other C 145 1008
than C 146 1008
biliary C 147 1008
stasis C 148 1008
were C 149 1008
scanty C 150 1008
. C 151 1008
no C 153 1008
specific C 154 1008
changes C 155 1008
which C 156 1008
could C 157 1008
clinically C 158 1008
differentiate C 159 1008
the C 160 1008
3 C 161 1008
types C 162 1008
were C 163 1008
found C 164 1008
. C 165 1008
in C 167 1008
each C 168 1008
type C 169 1008
, C 170 1008
serum C 171 1008
bilirubin C 172 1008
, C 173 1008
sgot C 174 1008
and C 175 1008
sgpt C 176 1008
activities C 177 1008
had C 178 1008
slight C 179 1008
characteristic C 180 1008
points C 181 1008
in C 182 1008
clinical C 183 1008
and C 184 1008
laboratory C 185 1008
studies C 186 1008
. C 187 1008
in C 189 1008
type C 190 1008
1 C 191 1008
, C 192 1008
the C 193 1008
values C 194 1008
were C 195 1008
relatively C 196 1008
low C 197 1008
, C 198 1008
while C 199 1008
in C 200 1008
type C 201 1008
2 C 202 1008
they C 203 1008
were C 204 1008
markedly C 205 1008
high C 206 1008
. C 207 1008
in C 209 1008
type C 210 1008
3 C 211 1008
, C 212 1008
sgot C 213 1008
activity C 214 1008
was C 215 1008
within C 216 1008
normal C 217 1008
range C 218 1008
. C 219 1008
histological C 221 1008
characteristics C 222 1008
of C 223 1008
the C 224 1008
liver C 225 1008
of C 226 1008
type C 227 1008
1 C 228 1008
were C 229 1008
necrosis C 230 1008
of C 231 1008
liver C 232 1008
cells C 233 1008
, C 234 1008
formation C 235 1008
of C 236 1008
acidophilic C 237 1008
granules C 238 1008
and C 239 1008
balloon C 240 1008
cells C 241 1008
, C 242 1008
cellular C 243 1008
infiltration C 244 1008
in C 245 1008
glisson C 246 1008
' C 247 1008
s C 248 1008
capsule C 249 1008
, C 250 1008
and C 251 1008
biliary C 252 1008
stasis C 253 1008
in C 254 1008
the C 255 1008
liver C 256 1008
cells C 257 1008
and C 258 1008
fine C 259 1008
bile C 260 1008
ducts C 261 1008
. C 262 1008
morphologically C 264 1008
, C 265 1008
findings C 266 1008
of C 267 1008
viral C 268 1008
hepatitis C 269 1008
were C 270 1008
observed C 271 1008
. C 272 1008
in C 274 1008
type C 275 1008
2 C 276 1008
liver C 277 1008
tissue C 278 1008
was C 279 1008
replaced C 280 1008
by C 281 1008
many C 282 1008
multinuclear C 283 1008
giant C 284 1008
cells C 285 1008
. C 286 1008
extreme C 288 1008
distortion C 289 1008
of C 290 1008
cords C 291 1008
of C 292 1008
liver C 293 1008
cells C 294 1008
and C 295 1008
cellular C 296 1008
infiltration C 297 1008
in C 298 1008
glisson C 299 1008
' C 300 1008
s C 301 1008
capsule C 302 1008
and C 303 1008
lobules C 304 1008
were C 305 1008
noted C 306 1008
. C 307 1008
there C 309 1008
was C 310 1008
marked C 311 1008
biliary C 312 1008
stasis C 313 1008
in C 314 1008
the C 315 1008
capillary C 316 1008
bile C 317 1008
ducts C 318 1008
and C 319 1008
liver C 320 1008
cells C 321 1008
. C 322 1008
it C 324 1008
was C 325 1008
characteristic C 326 1008
that C 327 1008
proliferation C 328 1008
of C 329 1008
bile C 330 1008
ducts C 331 1008
and C 332 1008
bile C 333 1008
plugs C 334 1008
were C 335 1008
not C 336 1008
found C 337 1008
, C 338 1008
which C 339 1008
was C 340 1008
consistent C 341 1008
with C 342 1008
giant C 343 1008
cell C 344 1008
hepatitis C 345 1008
of C 346 1008
craing C 347 1008
- C 348 1008
landing C 349 1008
. C 350 1008
in C 352 1008
type C 353 1008
3 C 354 1008
, C 355 1008
degeneration C 356 1008
of C 357 1008
liver C 358 1008
cells C 359 1008
, C 360 1008
necrosis C 361 1008
and C 362 1008
inflammatory C 363 1008
changes C 364 1008
were C 365 1008
slight C 366 1008
. C 367 1008
biliary C 369 1008
stasis C 370 1008
in C 371 1008
the C 372 1008
hepatic C 373 1008
lobules C 374 1008
was C 375 1008
conspicuous C 376 1008
. C 377 1008
histological C 379 1008
findings C 380 1008
similar C 381 1008
to C 382 1008
cholangiolitic C 383 1008
hepatitis C 384 1008
due C 385 1008
to C 386 1008
drug C 387 1008
poisoning C 388 1008
were C 389 1008
observed C 390 1008
. C 391 1008
the C 1 1009
pathology C 2 1009
of C 3 1009
' C 4 1009
giant C 5 1009
cell C 6 1009
hepatitis C 7 1009
' C 8 1009
in C 9 1009
early C 10 1009
infancy C 11 1009
. C 12 1009
a C 14 1009
1 C 15 1009
- C 16 1009
month C 17 1009
- C 18 1009
old C 19 1009
male C 20 1009
infant C 21 1009
was C 22 1009
admitted C 23 1009
to C 24 1009
hospital C 25 1009
because C 26 1009
of C 27 1009
acute C 28 1009
cardiac C 29 1009
and C 30 1009
circulatory C 31 1009
failure C 32 1009
. C 33 1009
autopsy C 35 1009
revealed C 36 1009
macronodular C 37 1009
liver C 38 1009
cirrhosis C 39 1009
with C 40 1009
splenomegaly C 41 1009
, C 42 1009
left C 43 1009
ventricular C 44 1009
dilatation C 45 1009
of C 46 1009
the C 47 1009
heart C 48 1009
, C 49 1009
hydrothorax C 50 1009
, C 51 1009
and C 52 1009
ascites C 53 1009
. C 54 1009
histology C 56 1009
of C 57 1009
the C 58 1009
liver C 59 1009
showed C 60 1009
a C 61 1009
giant C 62 1009
cell C 63 1009
hepatitis C 64 1009
. C 65 1009
the C 67 1009
portal C 68 1009
areas C 69 1009
were C 70 1009
widened C 71 1009
, C 72 1009
with C 73 1009
foci C 74 1009
of C 75 1009
erythropoiesis C 76 1009
and C 77 1009
histiocytic C 78 1009
infiltrations C 79 1009
. C 80 1009
the C 82 1009
liver C 83 1009
cells C 84 1009
showed C 85 1009
vacuolar C 86 1009
and C 87 1009
degenerative C 88 1009
changes C 89 1009
. C 90 1009
the C 92 1009
giant C 93 1009
cells C 94 1009
, C 95 1009
present C 96 1009
in C 97 1009
the C 98 1009
margin C 99 1009
of C 100 1009
the C 101 1009
regeneration C 102 1009
areas C 103 1009
, C 104 1009
as C 105 1009
well C 106 1009
as C 107 1009
in C 108 1009
the C 109 1009
degenerated C 110 1009
lobules C 111 1009
has C 112 1009
irregular C 113 1009
borders C 114 1009
and C 115 1009
varied C 116 1009
in C 117 1009
size C 118 1009
from C 119 1009
45 C 120 1009
- C 121 1009
60 C 122 1009
ft C 123 1009
. C 124 1009
their C 126 1009
nuclei C 127 1009
were C 128 1009
large C 129 1009
, C 130 1009
sometimes C 131 1009
bizarre C 132 1009
. C 133 1009
their C 135 1009
basophile C 136 1009
cytoplasm C 137 1009
showed C 138 1009
granules C 139 1009
of C 140 1009
iron C 141 1009
pigment C 142 1009
which C 143 1009
was C 144 1009
also C 145 1009
found C 146 1009
in C 147 1009
some C 148 1009
normal C 149 1009
hepatic C 150 1009
cells C 151 1009
, C 152 1009
in C 153 1009
the C 154 1009
prominent C 155 1009
kupffer C 156 1009
cells C 157 1009
and C 158 1009
in C 159 1009
the C 160 1009
connective C 161 1009
tissue C 162 1009
. C 163 1009
in C 165 1009
the C 166 1009
spleen C 167 1009
there C 168 1009
were C 169 1009
proliferation C 170 1009
of C 171 1009
connective C 172 1009
tissue C 173 1009
and C 174 1009
scattered C 175 1009
areas C 176 1009
of C 177 1009
erythropoiesis C 178 1009
, C 179 1009
as C 180 1009
well C 181 1009
as C 182 1009
pigment C 183 1009
deposits C 184 1009
in C 185 1009
the C 186 1009
pulpa C 187 1009
. C 188 1009
iron C 190 1009
pigment C 191 1009
was C 192 1009
also C 193 1009
found C 194 1009
in C 195 1009
the C 196 1009
pancreas C 197 1009
and C 198 1009
salivary C 199 1009
glands C 200 1009
. C 201 1009
the C 203 1009
islets C 204 1009
of C 205 1009
langerhans C 206 1009
were C 207 1009
hyperplastic C 208 1009
. C 209 1009
the C 211 1009
etiology C 212 1009
of C 213 1009
giant C 214 1009
cell C 215 1009
hepatitis C 216 1009
is C 217 1009
still C 218 1009
unknown C 219 1009
. C 220 1009
its C 222 1009
pathogenesis C 223 1009
may C 224 1009
be C 225 1009
due C 226 1009
to C 227 1009
a C 228 1009
malformation C 229 1009
, C 230 1009
immunologic C 231 1009
response C 232 1009
to C 233 1009
some C 234 1009
type C 235 1009
of C 236 1009
antibody C 237 1009
, C 238 1009
inborn C 239 1009
errors C 240 1009
of C 241 1009
iron C 242 1009
metabolism C 243 1009
and C 244 1009
viral C 245 1009
infection C 246 1009
. C 247 1009
it C 249 1009
is C 250 1009
suggested C 251 1009
that C 252 1009
the C 253 1009
giant C 254 1009
cell C 255 1009
transformation C 256 1009
is C 257 1009
a C 258 1009
response C 259 1009
of C 260 1009
the C 261 1009
immature C 262 1009
liver C 263 1009
cell C 264 1009
to C 265 1009
a C 266 1009
variety C 267 1009
of C 268 1009
stimuli C 269 1009
. C 270 1009
this C 272 1009
case C 273 1009
is C 274 1009
of C 275 1009
interest C 276 1009
for C 277 1009
the C 278 1009
predominance C 279 1009
of C 280 1009
giant C 281 1009
cells C 282 1009
with C 283 1009
1 C 284 1009
or C 285 1009
2 C 286 1009
nuclei C 287 1009
, C 288 1009
presumably C 289 1009
it C 290 1009
is C 291 1009
an C 292 1009
intermediate C 293 1009
stage C 294 1009
or C 295 1009
a C 296 1009
variant C 297 1009
of C 298 1009
hepatitis C 299 1009
. C 300 1009
the C 1 1010
surgery C 2 1010
of C 3 1010
infantile C 4 1010
obstructive C 5 1010
jaundice C 6 1010
. C 7 1010
the C 9 1010
results C 10 1010
of C 11 1010
suruga C 12 1010
- C 13 1010
yamazaki C 14 1010
' C 15 1010
s C 16 1010
procedure C 17 1010
in C 18 1010
14 C 19 1010
cases C 20 1010
of C 21 1010
congenital C 22 1010
biliary C 23 1010
duct C 24 1010
atresia C 25 1010
are C 26 1010
reported C 27 1010
. C 28 1010
postoperative C 30 1010
anorexia C 31 1010
, C 32 1010
diarrhea C 33 1010
, C 34 1010
or C 35 1010
edema C 36 1010
due C 37 1010
to C 38 1010
circulatory C 39 1010
disturbance C 40 1010
in C 41 1010
the C 42 1010
upper C 43 1010
extremity C 44 1010
have C 45 1010
not C 46 1010
been C 47 1010
found C 48 1010
after C 49 1010
this C 50 1010
operation C 51 1010
. C 52 1010
the C 54 1010
operation C 55 1010
is C 56 1010
technically C 57 1010
difficult C 58 1010
. C 59 1010
postoperative C 61 1010
fat C 62 1010
, C 63 1010
protein C 64 1010
, C 65 1010
and C 66 1010
electrolyte C 67 1010
metabolism C 68 1010
is C 69 1010
a C 70 1010
problem C 71 1010
. C 72 1010
in C 74 1010
order C 75 1010
to C 76 1010
obtain C 77 1010
better C 78 1010
results C 79 1010
this C 80 1010
disease C 81 1010
should C 82 1010
be C 83 1010
differentiated C 84 1010
at C 85 1010
an C 86 1010
early C 87 1010
period C 88 1010
. C 89 1010
a C 91 1010
long C 92 1010
- C 93 1010
term C 94 1010
follow C 95 1010
- C 96 1010
up C 97 1010
and C 98 1010
continued C 99 1010
study C 100 1010
of C 101 1010
this C 102 1010
problem C 103 1010
is C 104 1010
required C 105 1010
. C 106 1010
transient C 1 1011
familial C 2 1011
neonatal C 3 1011
hyperbilirubinemia C 4 1011
. C 5 1011
a C 7 1011
syndrome C 8 1011
of C 9 1011
transient C 10 1011
familial C 11 1011
neonatal C 12 1011
unconjugated C 13 1011
hyperbilirubinemia C 14 1011
not C 15 1011
due C 16 1011
to C 17 1011
known C 18 1011
causes C 19 1011
has C 20 1011
been C 21 1011
described C 22 1011
in C 23 1011
24 C 24 1011
infants C 25 1011
of C 26 1011
8 C 27 1011
unrelated C 28 1011
, C 29 1011
healthy C 30 1011
caucasian C 31 1011
mothers C 32 1011
. C 33 1011
four C 35 1011
of C 36 1011
the C 37 1011
infants C 38 1011
developed C 39 1011
kernicterus C 40 1011
. C 41 1011
beginning C 43 1011
in C 44 1011
the C 45 1011
2 C 46 1011
nd C 47 1011
trimester C 48 1011
of C 49 1011
pregnancy C 50 1011
, C 51 1011
sera C 52 1011
from C 53 1011
the C 54 1011
8 C 55 1011
mothers C 56 1011
and C 57 1011
their C 58 1011
newborn C 59 1011
infants C 60 1011
inhibited C 61 1011
direct C 62 1011
- C 63 1011
reacting C 64 1011
bilirubin C 65 1011
and C 66 1011
o C 67 1011
- C 68 1011
aminophenol C 69 1011
glucuronide C 70 1011
formation C 71 1011
by C 72 1011
rat C 73 1011
liver C 74 1011
slices C 75 1011
and C 76 1011
homogenates C 77 1011
, C 78 1011
respectively C 79 1011
, C 80 1011
4 C 81 1011
to C 82 1011
10 C 83 1011
times C 84 1011
more C 85 1011
than C 86 1011
was C 87 1011
observed C 88 1011
with C 89 1011
sera C 90 1011
from C 91 1011
a C 92 1011
control C 93 1011
group C 94 1011
of C 95 1011
pregnant C 96 1011
women C 97 1011
and C 98 1011
their C 99 1011
infants C 100 1011
. C 101 1011
the C 103 1011
serum C 104 1011
inhibitory C 105 1011
factor C 106 1011
in C 107 1011
these C 108 1011
women C 109 1011
is C 110 1011
unidentified C 111 1011
. C 112 1011
the C 114 1011
fact C 115 1011
that C 116 1011
the C 117 1011
inhibitor C 118 1011
occurs C 119 1011
in C 120 1011
pregnancy C 121 1011
serum C 122 1011
suggests C 123 1011
that C 124 1011
it C 125 1011
is C 126 1011
probably C 127 1011
a C 128 1011
progestational C 129 1011
steroid C 130 1011
that C 131 1011
inhibits C 132 1011
glucuronyl C 133 1011
transferase C 134 1011
activity C 135 1011
in C 136 1011
the C 137 1011
liver C 138 1011
of C 139 1011
neonates C 140 1011
. C 141 1011
the C 143 1011
mechanism C 144 1011
responsible C 145 1011
for C 146 1011
increased C 147 1011
serum C 148 1011
inhibitor C 149 1011
factor C 150 1011
activity C 151 1011
in C 152 1011
these C 153 1011
women C 154 1011
is C 155 1011
unknown C 156 1011
and C 157 1011
requires C 158 1011
further C 159 1011
study C 160 1011
. C 161 1011
hepatitis C 1 1012
virus C 2 1012
in C 3 1012
neonatal C 4 1012
liver C 5 1012
disease C 6 1012
. C 7 1012
liver C 9 1012
- C 10 1012
biopsy C 11 1012
specimens C 12 1012
from C 13 1012
3 C 14 1012
babies C 15 1012
with C 16 1012
neonatal C 17 1012
hepatitis C 18 1012
, C 19 1012
and C 20 1012
3 C 21 1012
with C 22 1012
extrahepatic C 23 1012
biliary C 24 1012
atresia C 25 1012
, C 26 1012
were C 27 1012
studied C 28 1012
for C 29 1012
the C 30 1012
presence C 31 1012
of C 32 1012
hepatitis C 33 1012
virus C 34 1012
. C 35 1012
culture C 37 1012
yielded C 38 1012
positive C 39 1012
results C 40 1012
in C 41 1012
all C 42 1012
3 C 43 1012
babies C 44 1012
with C 45 1012
neonatal C 46 1012
hepatitis C 47 1012
and C 48 1012
in C 49 1012
1 C 50 1012
of C 51 1012
the C 52 1012
infants C 53 1012
with C 54 1012
biliary C 55 1012
atresia C 56 1012
. C 57 1012
neonatal C 1 1013
hepatitis C 2 1013
: C 3 1013
liver C 4 1013
biopsy C 5 1013
findings C 6 1013
and C 7 1013
clinical C 8 1013
features C 9 1013
. C 10 1013
on C 12 1013
22 C 13 1013
infants C 14 1013
with C 15 1013
a C 16 1013
clinical C 17 1013
diagnosis C 18 1013
of C 19 1013
neonatal C 20 1013
hepatitis C 21 1013
, C 22 1013
histologic C 23 1013
examination C 24 1013
of C 25 1013
the C 26 1013
liver C 27 1013
was C 28 1013
made C 29 1013
by C 30 1013
needle C 31 1013
biopsy C 32 1013
and C 33 1013
its C 34 1013
relation C 35 1013
to C 36 1013
the C 37 1013
clinical C 38 1013
course C 39 1013
was C 40 1013
investigated C 41 1013
. C 42 1013
histologic C 44 1013
findings C 45 1013
were C 46 1013
classified C 47 1013
provisionally C 48 1013
into C 49 1013
3 C 50 1013
types C 51 1013
: C 52 1013
type C 53 1013
i C 54 1013
showed C 55 1013
no C 56 1013
giant C 57 1013
cells C 58 1013
but C 59 1013
only C 60 1013
slight C 61 1013
damage C 62 1013
to C 63 1013
hepatic C 64 1013
cells C 65 1013
with C 66 1013
prominent C 67 1013
intracellular C 68 1013
cholestasis C 69 1013
; C 70 1013
type C 71 1013
ii C 72 1013
was C 73 1013
characterized C 74 1013
by C 75 1013
occurrence C 76 1013
of C 77 1013
numerous C 78 1013
giant C 79 1013
cells C 80 1013
; C 81 1013
the C 82 1013
specific C 83 1013
type C 84 1013
was C 85 1013
characterized C 86 1013
by C 87 1013
centrolobular C 88 1013
cholestasis C 89 1013
without C 90 1013
inflammatory C 91 1013
reaction C 92 1013
. C 93 1013
laboratory C 95 1013
examinations C 96 1013
revealed C 97 1013
that C 98 1013
increases C 99 1013
in C 100 1013
serum C 101 1013
transaminases C 102 1013
and C 103 1013
bilirubin C 104 1013
were C 105 1013
greater C 106 1013
in C 107 1013
type C 108 1013
ii C 109 1013
than C 110 1013
in C 111 1013
type C 112 1013
i C 113 1013
, C 114 1013
and C 115 1013
in C 116 1013
the C 117 1013
specific C 118 1013
type C 119 1013
there C 120 1013
was C 121 1013
no C 122 1013
increase C 123 1013
in C 124 1013
serum C 125 1013
transaminase C 126 1013
but C 127 1013
there C 128 1013
was C 129 1013
a C 130 1013
direct C 131 1013
hyperbilirubinemia C 132 1013
. C 133 1013
as C 135 1013
to C 136 1013
histologic C 137 1013
sequelae C 138 1013
, C 139 1013
the C 140 1013
results C 141 1013
of C 142 1013
serial C 143 1013
biopsy C 144 1013
revealed C 145 1013
that C 146 1013
in C 147 1013
type C 148 1013
i C 149 1013
hepatic C 150 1013
damage C 151 1013
healed C 152 1013
almost C 153 1013
completely C 154 1013
, C 155 1013
and C 156 1013
that C 157 1013
in C 158 1013
type C 159 1013
ii C 160 1013
giant C 161 1013
cells C 162 1013
disappeared C 163 1013
within C 164 1013
1 C 165 1013
yr C 166 1013
and C 167 1013
, C 168 1013
in C 169 1013
some C 170 1013
cases C 171 1013
, C 172 1013
hepatic C 173 1013
cirrhosis C 174 1013
resulted C 175 1013
. C 176 1013
the C 178 1013
prognosis C 179 1013
of C 180 1013
neonatal C 181 1013
hepatitis C 182 1013
may C 183 1013
be C 184 1013
said C 185 1013
to C 186 1013
be C 187 1013
good C 188 1013
in C 189 1013
type C 190 1013
i C 191 1013
, C 192 1013
poor C 193 1013
in C 194 1013
type C 195 1013
ii C 196 1013
, C 197 1013
and C 198 1013
undetermined C 199 1013
in C 200 1013
the C 201 1013
specific C 202 1013
type C 203 1013
. C 204 1013
spherocytic C 1 1014
anemia C 2 1014
with C 3 1014
early C 4 1014
deglobulisation C 5 1014
crisis C 6 1014
and C 7 1014
avitaminosis C 8 1014
a C 9 1014
. C 10 1014
from C 12 1014
birth C 13 1014
, C 14 1014
2 C 15 1014
homozygous C 16 1014
male C 17 1014
twins C 18 1014
had C 19 1014
had C 20 1014
a C 21 1014
series C 22 1014
of C 23 1014
hemolytic C 24 1014
crises C 25 1014
. C 26 1014
these C 28 1014
caused C 29 1014
a C 30 1014
low C 31 1014
crythrocyte C 32 1014
count C 33 1014
and C 34 1014
jaundice C 35 1014
on C 36 1014
the C 37 1014
one C 38 1014
hand C 39 1014
, C 40 1014
and C 41 1014
xerophthalmia C 42 1014
, C 43 1014
probably C 44 1014
owing C 45 1014
to C 46 1014
the C 47 1014
existence C 48 1014
, C 49 1014
proven C 50 1014
by C 51 1014
liver C 52 1014
biopsy C 53 1014
, C 54 1014
of C 55 1014
a C 56 1014
complicating C 57 1014
obstructive C 58 1014
biliary C 59 1014
syndrome C 60 1014
, C 61 1014
on C 62 1014
the C 63 1014
other C 64 1014
. C 65 1014
neonatal C 1 1015
hepatitis C 2 1015
or C 3 1015
familial C 4 1015
neonatal C 5 1015
obstructive C 6 1015
jaundice C 7 1015
? C 8 1015
. C 9 1015
four C 11 1015
siblings C 12 1015
all C 13 1015
of C 14 1015
whom C 15 1015
were C 16 1015
boys C 17 1015
with C 18 1015
chronic C 19 1015
obstructive C 20 1015
jaundice C 21 1015
are C 22 1015
described C 23 1015
. C 24 1015
the C 26 1015
onset C 27 1015
of C 28 1015
the C 29 1015
jaundice C 30 1015
varied C 31 1015
from C 32 1015
1 C 33 1015
day C 34 1015
to C 35 1015
4 C 36 1015
weeks C 37 1015
after C 38 1015
birth C 39 1015
. C 40 1015
two C 42 1015
other C 43 1015
boys C 44 1015
and C 45 1015
2 C 46 1015
girls C 47 1015
in C 48 1015
the C 49 1015
same C 50 1015
family C 51 1015
are C 52 1015
healthy C 53 1015
. C 54 1015
although C 56 1015
in C 57 1015
one C 58 1015
of C 59 1015
the C 60 1015
4 C 61 1015
cases C 62 1015
pathological C 63 1015
findings C 64 1015
were C 65 1015
the C 66 1015
same C 67 1015
as C 68 1015
in C 69 1015
neonatal C 70 1015
hepatitis C 71 1015
( C 72 1015
' C 73 1015
giant C 74 1015
cell C 75 1015
hepatitis C 76 1015
' C 77 1015
) C 78 1015
, C 79 1015
other C 80 1015
possibilities C 81 1015
could C 82 1015
not C 83 1015
be C 84 1015
excluded C 85 1015
. C 86 1015
what C 88 1015
has C 89 1015
been C 90 1015
described C 91 1015
hitherto C 92 1015
as C 93 1015
giant C 94 1015
cell C 95 1015
hepatitis C 96 1015
appears C 97 1015
to C 98 1015
be C 99 1015
only C 100 1015
a C 101 1015
morphological C 102 1015
picture C 103 1015
, C 104 1015
for C 105 1015
which C 106 1015
there C 107 1015
must C 108 1015
be C 109 1015
several C 110 1015
causes C 111 1015
. C 112 1015
it C 114 1015
is C 115 1015
concluded C 116 1015
from C 117 1015
the C 118 1015
findings C 119 1015
in C 120 1015
the C 121 1015
4 C 122 1015
patients C 123 1015
that C 124 1015
one C 125 1015
of C 126 1015
the C 127 1015
possible C 128 1015
causes C 129 1015
of C 130 1015
so C 131 1015
- C 132 1015
called C 133 1015
giant C 134 1015
cell C 135 1015
hepatitis C 136 1015
is C 137 1015
an C 138 1015
inborn C 139 1015
error C 140 1015
of C 141 1015
metabolism C 142 1015
. C 143 1015
hypoplasia C 1 1016
of C 2 1016
the C 3 1016
intrahepatic C 4 1016
bile C 5 1016
ducts C 6 1016
. C 7 1016
a C 9 1016
description C 10 1016
of C 11 1016
2 C 12 1016
cases C 13 1016
: C 14 1016
( C 15 1016
1 C 16 1016
) C 17 1016
a C 18 1016
boy C 19 1016
of C 20 1016
13 C 21 1016
days C 22 1016
old C 23 1016
had C 24 1016
atresia C 25 1016
of C 26 1016
the C 27 1016
small C 28 1016
intestine C 29 1016
and C 30 1016
pneumonia C 31 1016
, C 32 1016
and C 33 1016
a C 34 1016
slightly C 35 1016
enlarged C 36 1016
liver C 37 1016
with C 38 1016
faint C 39 1016
green C 40 1016
coloration C 41 1016
. C 42 1016
histological C 44 1016
examination C 45 1016
revealed C 46 1016
numerous C 47 1016
collapsed C 48 1016
bile C 49 1016
ducts C 50 1016
which C 51 1016
had C 52 1016
solid C 53 1016
ductular C 54 1016
cell C 55 1016
sprouts C 56 1016
reaching C 57 1016
the C 58 1016
liver C 59 1016
cells C 60 1016
; C 61 1016
the C 62 1016
minor C 63 1016
and C 64 1016
smallest C 65 1016
bile C 66 1016
ducts C 67 1016
were C 68 1016
empty C 69 1016
. C 70 1016
( C 72 1016
2 C 73 1016
) C 74 1016
a C 75 1016
girl C 76 1016
of C 77 1016
1 C 78 1016
yr C 79 1016
and C 80 1016
4 C 81 1016
mth C 82 1016
had C 83 1016
increasing C 84 1016
jaundice C 85 1016
since C 86 1016
birth C 87 1016
. C 88 1016
autopsy C 90 1016
revealed C 91 1016
a C 92 1016
hypoplastic C 93 1016
common C 94 1016
bile C 95 1016
duct C 96 1016
, C 97 1016
which C 98 1016
was C 99 1016
, C 100 1016
however C 101 1016
, C 102 1016
open C 103 1016
to C 104 1016
probing C 105 1016
, C 106 1016
and C 107 1016
marked C 108 1016
green C 109 1016
coloration C 110 1016
of C 111 1016
the C 112 1016
liver C 113 1016
. C 114 1016
also C 116 1016
in C 117 1016
this C 118 1016
case C 119 1016
, C 120 1016
the C 121 1016
bile C 122 1016
ducts C 123 1016
were C 124 1016
very C 125 1016
narrow C 126 1016
and C 127 1016
had C 128 1016
solid C 129 1016
ductular C 130 1016
cell C 131 1016
sprouts C 132 1016
reaching C 133 1016
the C 134 1016
liver C 135 1016
cells C 136 1016
. C 137 1016
this C 139 1016
type C 140 1016
of C 141 1016
bile C 142 1016
duct C 143 1016
corresponds C 144 1016
to C 145 1016
a C 146 1016
stage C 147 1016
in C 148 1016
ontogenesis C 149 1016
and C 150 1016
does C 151 1016
not C 152 1016
show C 153 1016
signs C 154 1016
of C 155 1016
proliferation C 156 1016
. C 157 1016
it C 159 1016
may C 160 1016
be C 161 1016
considered C 162 1016
a C 163 1016
form C 164 1016
of C 165 1016
hypoplasia C 166 1016
, C 167 1016
as C 168 1016
the C 169 1016
size C 170 1016
and C 171 1016
number C 172 1016
of C 173 1016
the C 174 1016
primordial C 175 1016
bile C 176 1016
ducts C 177 1016
is C 178 1016
reduced C 179 1016
. C 180 1016
when C 182 1016
present C 183 1016
the C 184 1016
anlage C 185 1016
shows C 186 1016
a C 187 1016
regular C 188 1016
connection C 189 1016
with C 190 1016
the C 191 1016
liver C 192 1016
cells C 193 1016
. C 194 1016
this C 196 1016
hypoplasia C 197 1016
is C 198 1016
to C 199 1016
be C 200 1016
distinguished C 201 1016
from C 202 1016
an C 203 1016
atresia C 204 1016
. C 205 1016
the C 207 1016
long C 208 1016
survival C 209 1016
of C 210 1016
the C 211 1016
second C 212 1016
case C 213 1016
can C 214 1016
be C 215 1016
explained C 216 1016
by C 217 1016
the C 218 1016
great C 219 1016
compensatory C 220 1016
capacity C 221 1016
of C 222 1016
the C 223 1016
liver C 224 1016
. C 225 1016
fetal C 1 1017
and C 2 1017
neonatal C 3 1017
hepatitis C 4 1017
and C 5 1017
its C 6 1017
consequences C 7 1017
. C 8 1017
the C 10 1017
author C 11 1017
reports C 12 1017
on C 13 1017
18 C 14 1017
fatal C 15 1017
cases C 16 1017
observed C 17 1017
in C 18 1017
infants C 19 1017
from C 20 1017
3 C 21 1017
weeks C 22 1017
to C 23 1017
1 C 24 1017
year C 25 1017
old C 26 1017
. C 27 1017
in C 29 1017
all C 30 1017
cases C 31 1017
, C 32 1017
jaundice C 33 1017
appeared C 34 1017
just C 35 1017
after C 36 1017
birth C 37 1017
or C 38 1017
during C 39 1017
the C 40 1017
first C 41 1017
days C 42 1017
of C 43 1017
life C 44 1017
, C 45 1017
and C 46 1017
was C 47 1017
persistent C 48 1017
. C 49 1017
the C 51 1017
stools C 52 1017
were C 53 1017
sometimes C 54 1017
discolored C 55 1017
. C 56 1017
there C 58 1017
was C 59 1017
no C 60 1017
blood C 61 1017
incompatibility C 62 1017
. C 63 1017
the C 65 1017
picture C 66 1017
was C 67 1017
similar C 68 1017
to C 69 1017
that C 70 1017
of C 71 1017
congenital C 72 1017
biliary C 73 1017
atresia C 74 1017
. C 75 1017
pathological C 77 1017
study C 78 1017
revealed C 79 1017
2 C 80 1017
groups C 81 1017
: C 82 1017
( C 83 1017
1 C 84 1017
) C 85 1017
with C 86 1017
pathological C 87 1017
changes C 88 1017
of C 89 1017
hepatitis C 90 1017
( C 91 1017
11 C 92 1017
cases C 93 1017
) C 94 1017
. C 95 1017
the C 97 1017
liver C 98 1017
is C 99 1017
enlarged C 100 1017
, C 101 1017
flabby C 102 1017
and C 103 1017
icteric C 104 1017
. C 105 1017
microscopy C 107 1017
shows C 108 1017
dissociation C 109 1017
of C 110 1017
the C 111 1017
cell C 112 1017
cords C 113 1017
and C 114 1017
polymorphism C 115 1017
of C 116 1017
the C 117 1017
hepatic C 118 1017
cells C 119 1017
( C 120 1017
necrotic C 121 1017
cells C 122 1017
, C 123 1017
balloon C 124 1017
cells C 125 1017
, C 126 1017
giant C 127 1017
cell C 128 1017
transformation C 129 1017
) C 130 1017
. C 131 1017
some C 133 1017
of C 134 1017
the C 135 1017
giant C 136 1017
cells C 137 1017
show C 138 1017
vacuoles C 139 1017
, C 140 1017
erythrocytes C 141 1017
, C 142 1017
lipids C 143 1017
and C 144 1017
acidophilic C 145 1017
material C 146 1017
in C 147 1017
their C 148 1017
cytoplasm C 149 1017
. C 150 1017
there C 152 1017
are C 153 1017
signs C 154 1017
of C 155 1017
regeneration C 156 1017
, C 157 1017
collapse C 158 1017
of C 159 1017
the C 160 1017
stromal C 161 1017
framework C 162 1017
, C 163 1017
proliferation C 164 1017
of C 165 1017
the C 166 1017
mesenchymal C 167 1017
cells C 168 1017
and C 169 1017
bile C 170 1017
retention C 171 1017
. C 172 1017
cells C 174 1017
of C 175 1017
the C 176 1017
erythrocytic C 177 1017
series C 178 1017
are C 179 1017
scattered C 180 1017
in C 181 1017
the C 182 1017
periportal C 183 1017
spaces C 184 1017
with C 185 1017
eosinophilic C 186 1017
leucocytes C 187 1017
, C 188 1017
lymphocytes C 189 1017
and C 190 1017
histiocytes C 191 1017
. C 192 1017
( C 194 1017
2 C 195 1017
) C 196 1017
with C 197 1017
fibrosis C 198 1017
and C 199 1017
cirrhosis C 200 1017
( C 201 1017
7 C 202 1017
cases C 203 1017
) C 204 1017
. C 205 1017
the C 207 1017
liver C 208 1017
is C 209 1017
green C 210 1017
, C 211 1017
firm C 212 1017
, C 213 1017
with C 214 1017
a C 215 1017
nodular C 216 1017
or C 217 1017
granular C 218 1017
surface C 219 1017
. C 220 1017
the C 222 1017
extra C 223 1017
- C 224 1017
hepatic C 225 1017
biliary C 226 1017
tree C 227 1017
is C 228 1017
normal C 229 1017
. C 230 1017
the C 232 1017
spleen C 233 1017
is C 234 1017
enlarged C 235 1017
. C 236 1017
microscopy C 238 1017
shows C 239 1017
bile C 240 1017
stasis C 241 1017
, C 242 1017
pericholangiolitic C 243 1017
fibrosis C 244 1017
, C 245 1017
and C 246 1017
proliferation C 247 1017
of C 248 1017
bile C 249 1017
ductules C 250 1017
. C 251 1017
the C 253 1017
periportal C 254 1017
, C 255 1017
interlobular C 256 1017
and C 257 1017
intralobular C 258 1017
fibrous C 259 1017
tissue C 260 1017
is C 261 1017
increased C 262 1017
, C 263 1017
and C 264 1017
shows C 265 1017
cellular C 266 1017
infiltrations C 267 1017
. C 268 1017
the C 270 1017
architecture C 271 1017
of C 272 1017
the C 273 1017
liver C 274 1017
is C 275 1017
disturbed C 276 1017
by C 277 1017
the C 278 1017
presence C 279 1017
of C 280 1017
pseudolobuli C 281 1017
in C 282 1017
the C 283 1017
regeneration C 284 1017
areas C 285 1017
. C 286 1017
it C 288 1017
is C 289 1017
suggested C 290 1017
that C 291 1017
these C 292 1017
cases C 293 1017
are C 294 1017
due C 295 1017
to C 296 1017
a C 297 1017
congenital C 298 1017
viral C 299 1017
hepatitis C 300 1017
, C 301 1017
which C 302 1017
is C 303 1017
not C 304 1017
only C 305 1017
the C 306 1017
result C 307 1017
of C 308 1017
an C 309 1017
intrauterine C 310 1017
infection C 311 1017
, C 312 1017
but C 313 1017
also C 314 1017
a C 315 1017
feature C 316 1017
of C 317 1017
fetal C 318 1017
hepatitis C 319 1017
, C 320 1017
with C 321 1017
secondary C 322 1017
pericholangiolitic C 323 1017
or C 324 1017
post C 325 1017
- C 326 1017
necrotic C 327 1017
liver C 328 1017
cirrhosis C 329 1017
. C 330 1017
the C 332 1017
neonatal C 333 1017
giant C 334 1017
cell C 335 1017
hepatitis C 336 1017
is C 337 1017
to C 338 1017
be C 339 1017
considered C 340 1017
as C 341 1017
the C 342 1017
result C 343 1017
of C 344 1017
a C 345 1017
cytotoxic C 346 1017
action C 347 1017
of C 348 1017
the C 349 1017
virus C 350 1017
. C 351 1017
the C 353 1017
author C 354 1017
considers C 355 1017
also C 356 1017
the C 357 1017
possibility C 358 1017
of C 359 1017
a C 360 1017
viral C 361 1017
etiology C 362 1017
in C 363 1017
cases C 364 1017
of C 365 1017
biliary C 366 1017
atresia C 367 1017
on C 368 1017
the C 369 1017
basis C 370 1017
of C 371 1017
their C 372 1017
morphological C 373 1017
similarity C 374 1017
with C 375 1017
congenital C 376 1017
viral C 377 1017
hepatitis C 378 1017
. C 379 1017
metabolism C 1 1018
and C 2 1018
excretion C 3 1018
of C 4 1018
bilirubin C 5 1018
c C 6 1018
in C 7 1018
experimental C 8 1018
obstructive C 9 1018
jaundice C 10 1018
. C 11 1018
bile C 13 1018
duct C 14 1018
ligation C 15 1018
was C 16 1018
carried C 17 1018
out C 18 1018
in C 19 1018
a C 20 1018
series C 21 1018
of C 22 1018
rhesus C 23 1018
monkeys C 24 1018
. C 25 1018
the C 27 1018
time C 28 1018
required C 29 1018
for C 30 1018
the C 31 1018
serum C 32 1018
bilirubin C 33 1018
to C 34 1018
stop C 35 1018
rising C 36 1018
and C 37 1018
achieve C 38 1018
a C 39 1018
relatively C 40 1018
stable C 41 1018
level C 42 1018
, C 43 1018
and C 44 1018
the C 45 1018
average C 46 1018
serum C 47 1018
bilirubin C 48 1018
reached C 49 1018
, C 50 1018
paralleled C 51 1018
closely C 52 1018
that C 53 1018
seen C 54 1018
clinically C 55 1018
. C 56 1018
after C 58 1018
the C 59 1018
serum C 60 1018
bilirubin C 61 1018
levels C 62 1018
had C 63 1018
stopped C 64 1018
rising C 65 1018
and C 66 1018
a C 67 1018
' C 68 1018
steady C 69 1018
state C 70 1018
' C 71 1018
had C 72 1018
been C 73 1018
reached C 74 1018
, C 75 1018
radioactive C 76 1018
bilirubin C 77 1018
was C 78 1018
injected C 79 1018
i C 80 1018
. C 81 1018
. C 82 1018
. C 83 1018
the C 85 1018
radioisotope C 86 1018
was C 87 1018
distributed C 88 1018
principally C 89 1018
extravascularly C 90 1018
and C 91 1018
not C 92 1018
in C 93 1018
the C 94 1018
same C 95 1018
ratio C 96 1018
as C 97 1018
albumin C 98 1018
, C 99 1018
as C 100 1018
in C 101 1018
other C 102 1018
forms C 103 1018
of C 104 1018
jaundice C 105 1018
. C 106 1018
daily C 108 1018
turnover C 109 1018
of C 110 1018
bilirubin C 111 1018
was C 112 1018
found C 113 1018
to C 114 1018
be C 115 1018
double C 116 1018
that C 117 1018
anticipated C 118 1018
from C 119 1018
normal C 120 1018
hb C 121 1018
breakdown C 122 1018
, C 123 1018
suggesting C 124 1018
increased C 125 1018
bilirubin C 126 1018
production C 127 1018
in C 128 1018
obstructive C 129 1018
jaundice C 130 1018
. C 131 1018
in C 133 1018
animals C 134 1018
followed C 135 1018
for C 136 1018
2 C 137 1018
wk C 138 1018
nearly C 139 1018
80 C 140 1018
% C 141 1018
of C 142 1018
injected C 143 1018
radioactivity C 144 1018
was C 145 1018
excreted C 146 1018
in C 147 1018
the C 148 1018
urine C 149 1018
, C 150 1018
indicating C 151 1018
that C 152 1018
in C 153 1018
obstructive C 154 1018
jaundice C 155 1018
the C 156 1018
kidney C 157 1018
takes C 158 1018
over C 159 1018
entirely C 160 1018
from C 161 1018
the C 162 1018
liver C 163 1018
the C 164 1018
function C 165 1018
of C 166 1018
bilirubin C 167 1018
excretion C 168 1018
. C 169 1018
major C 1 1019
surgery C 2 1019
on C 3 1019
the C 4 1019
severe C 5 1019
hemophiliac C 6 1019
, C 7 1019
lessons C 8 1019
in C 9 1019
management C 10 1019
. C 11 1019
three C 13 1019
cases C 14 1019
of C 15 1019
pseudotumor C 16 1019
of C 17 1019
the C 18 1019
thigh C 19 1019
which C 20 1019
required C 21 1019
surgical C 22 1019
amputation C 23 1019
and C 24 1019
one C 25 1019
case C 26 1019
of C 27 1019
open C 28 1019
pericardial C 29 1019
drainage C 30 1019
for C 31 1019
cardiac C 32 1019
tamponade C 33 1019
are C 34 1019
briefly C 35 1019
reported C 36 1019
in C 37 1019
severe C 38 1019
hemophiliacs C 39 1019
. C 40 1019
in C 42 1019
the C 43 1019
first C 44 1019
case C 45 1019
hemostasis C 46 1019
, C 47 1019
following C 48 1019
amputation C 49 1019
, C 50 1019
was C 51 1019
produced C 52 1019
, C 53 1019
but C 54 1019
the C 55 1019
patient C 56 1019
died C 57 1019
of C 58 1019
septicemia C 59 1019
secondary C 60 1019
to C 61 1019
proximally C 62 1019
infected C 63 1019
tissues C 64 1019
; C 65 1019
the C 66 1019
level C 67 1019
of C 68 1019
amputation C 69 1019
should C 70 1019
, C 71 1019
therefore C 72 1019
, C 73 1019
be C 74 1019
proximal C 75 1019
to C 76 1019
all C 77 1019
grossly C 78 1019
infected C 79 1019
tissues C 80 1019
. C 81 1019
in C 83 1019
the C 84 1019
second C 85 1019
case C 86 1019
, C 87 1019
with C 88 1019
infected C 89 1019
massive C 90 1019
pseudotumor C 91 1019
of C 92 1019
the C 93 1019
left C 94 1019
thigh C 95 1019
, C 96 1019
5 C 97 1019
separate C 98 1019
operative C 99 1019
procedures C 100 1019
were C 101 1019
performed C 102 1019
. C 103 1019
the C 105 1019
last C 106 1019
procedure C 107 1019
was C 108 1019
elective C 109 1019
revision C 110 1019
of C 111 1019
skin C 112 1019
flaps C 113 1019
at C 114 1019
the C 115 1019
hip C 116 1019
disarticulation C 117 1019
site C 118 1019
. C 119 1019
here C 121 1019
application C 122 1019
of C 123 1019
the C 124 1019
knowledge C 125 1019
gained C 126 1019
from C 127 1019
previous C 128 1019
experience C 129 1019
resulted C 130 1019
in C 131 1019
a C 132 1019
completely C 133 1019
uncomplicated C 134 1019
postoperative C 135 1019
course C 136 1019
by C 137 1019
dint C 138 1019
of C 139 1019
timing C 140 1019
of C 141 1019
the C 142 1019
surgical C 143 1019
procedure C 144 1019
in C 145 1019
relation C 146 1019
to C 147 1019
control C 148 1019
of C 149 1019
infection C 150 1019
, C 151 1019
loss C 152 1019
of C 153 1019
plasma C 154 1019
fastness C 155 1019
, C 156 1019
and C 157 1019
the C 158 1019
judicious C 159 1019
use C 160 1019
of C 161 1019
antibiotic C 162 1019
and C 163 1019
direct C 164 1019
- C 165 1019
current C 166 1019
electrocoagulation C 167 1019
therapy C 168 1019
. C 169 1019
a C 171 1019
plea C 172 1019
is C 173 1019
made C 174 1019
to C 175 1019
avoid C 176 1019
the C 177 1019
use C 178 1019
of C 179 1019
plasma C 180 1019
and C 181 1019
ahg C 182 1019
therapy C 183 1019
in C 184 1019
hemophilias C 185 1019
for C 186 1019
trivial C 187 1019
reasons C 188 1019
and C 189 1019
to C 190 1019
consider C 191 1019
patients C 192 1019
for C 193 1019
surgical C 194 1019
procedures C 195 1019
early C 196 1019
in C 197 1019
the C 198 1019
course C 199 1019
of C 200 1019
their C 201 1019
complications C 202 1019
, C 203 1019
which C 204 1019
demand C 205 1019
surgery C 206 1019
, C 207 1019
at C 208 1019
a C 209 1019
time C 210 1019
when C 211 1019
the C 212 1019
patient C 213 1019
is C 214 1019
still C 215 1019
responsive C 216 1019
to C 217 1019
hematologic C 218 1019
therapy C 219 1019
and C 220 1019
prior C 221 1019
to C 222 1019
the C 223 1019
onset C 224 1019
of C 225 1019
infection C 226 1019
in C 227 1019
areas C 228 1019
of C 229 1019
hematoma C 230 1019
. C 231 1019
it C 233 1019
is C 234 1019
felt C 235 1019
that C 236 1019
a C 237 1019
second C 238 1019
significant C 239 1019
hemorrhage C 240 1019
in C 241 1019
any C 242 1019
particular C 243 1019
site C 244 1019
constitutes C 245 1019
a C 246 1019
bona C 247 1019
fide C 248 1019
indication C 249 1019
for C 250 1019
surgical C 251 1019
intervention C 252 1019
, C 253 1019
long C 254 1019
before C 255 1019
the C 256 1019
time C 257 1019
when C 258 1019
surgery C 259 1019
is C 260 1019
considered C 261 1019
as C 262 1019
the C 263 1019
last C 264 1019
resort C 265 1019
by C 266 1019
the C 267 1019
physician C 268 1019
, C 269 1019
patient C 270 1019
and C 271 1019
family C 272 1019
. C 273 1019
although C 275 1019
the C 276 1019
authors C 277 1019
believe C 278 1019
that C 279 1019
surgery C 280 1019
in C 281 1019
the C 282 1019
hemophiliac C 283 1019
is C 284 1019
not C 285 1019
to C 286 1019
be C 287 1019
taken C 288 1019
lightly C 289 1019
, C 290 1019
they C 291 1019
do C 292 1019
not C 293 1019
endorse C 294 1019
the C 295 1019
prevailing C 296 1019
nihilistic C 297 1019
attitude C 298 1019
that C 299 1019
has C 300 1019
resulted C 301 1019
in C 302 1019
temporizing C 303 1019
delays C 304 1019
which C 305 1019
can C 306 1019
only C 307 1019
guarantee C 308 1019
a C 309 1019
fatal C 310 1019
outcome C 311 1019
. C 312 1019
immunological C 1 1020
demonstration C 2 1020
of C 3 1020
factor C 4 1020
viii C 5 1020
protein C 6 1020
in C 7 1020
the C 8 1020
plasma C 9 1020
of C 10 1020
hemophiliacs C 11 1020
and C 12 1020
its C 13 1020
value C 14 1020
for C 15 1020
an C 16 1020
insight C 17 1020
into C 18 1020
hemophilia C 19 1020
a C 20 1020
. C 21 1020
by C 23 1020
immunization C 24 1020
of C 25 1020
rabbits C 26 1020
one C 27 1020
obtains C 28 1020
antisera C 29 1020
against C 30 1020
human C 31 1020
factor C 32 1020
viii C 33 1020
, C 34 1020
the C 35 1020
action C 36 1020
of C 37 1020
the C 38 1020
immunsera C 39 1020
has C 40 1020
been C 41 1020
determined C 42 1020
using C 43 1020
a C 44 1020
modification C 45 1020
of C 46 1020
the C 47 1020
thromboplastingenerations C 48 1020
test C 49 1020
( C 50 1020
the C 51 1020
factor C 52 1020
viii C 53 1020
neutralization C 54 1020
test C 55 1020
) C 56 1020
. C 57 1020
the C 59 1020
antibodies C 60 1020
against C 61 1020
factor C 62 1020
viii C 63 1020
are C 64 1020
equally C 65 1020
absorbed C 66 1020
by C 67 1020
either C 68 1020
normal C 69 1020
or C 70 1020
hemophilia C 71 1020
a C 72 1020
plasma C 73 1020
. C 74 1020
this C 76 1020
observation C 77 1020
shows C 78 1020
that C 79 1020
hemophilia C 80 1020
a C 81 1020
plasma C 82 1020
contains C 83 1020
as C 84 1020
much C 85 1020
factor C 86 1020
viii C 87 1020
protein C 88 1020
as C 89 1020
normal C 90 1020
plasma C 91 1020
does C 92 1020
. C 93 1020
in C 95 1020
normal C 96 1020
and C 97 1020
hemophilia C 98 1020
a C 99 1020
serum C 100 1020
one C 101 1020
finds C 102 1020
at C 103 1020
a C 104 1020
lower C 105 1020
level C 106 1020
similar C 107 1020
concentrations C 108 1020
of C 109 1020
factor C 110 1020
viii C 111 1020
. C 112 1020
in C 114 1020
analogy C 115 1020
with C 116 1020
cross C 117 1020
- C 118 1020
reacting C 119 1020
substances C 120 1020
( C 121 1020
crm C 122 1020
) C 123 1020
in C 124 1020
bacteria C 125 1020
mutants C 126 1020
an C 127 1020
hypothesis C 128 1020
has C 129 1020
been C 130 1020
made C 131 1020
according C 132 1020
to C 133 1020
which C 134 1020
the C 135 1020
authors C 136 1020
are C 137 1020
dealing C 138 1020
with C 139 1020
the C 140 1020
product C 141 1020
of C 142 1020
a C 143 1020
genetically C 144 1020
altered C 145 1020
synthesis C 146 1020
of C 147 1020
factor C 148 1020
viii C 149 1020
. C 150 1020
this C 152 1020
product C 153 1020
is C 154 1020
functionally C 155 1020
less C 156 1020
active C 157 1020
but C 158 1020
possesses C 159 1020
the C 160 1020
same C 161 1020
antigenic C 162 1020
determinants C 163 1020
as C 164 1020
the C 165 1020
normal C 166 1020
factor C 167 1020
viii C 168 1020
. C 169 1020
some C 171 1020
inhibitor C 172 1020
properties C 173 1020
of C 174 1020
the C 175 1020
hemophilia C 176 1020
plasma C 177 1020
can C 178 1020
be C 179 1020
explained C 180 1020
by C 181 1020
competitive C 182 1020
inhibition C 183 1020
made C 184 1020
possible C 185 1020
by C 186 1020
the C 187 1020
similarity C 188 1020
of C 189 1020
structure C 190 1020
. C 191 1020
the C 193 1020
fact C 194 1020
that C 195 1020
the C 196 1020
inhibitor C 197 1020
discovered C 198 1020
by C 199 1020
mammen C 200 1020
and C 201 1020
factor C 202 1020
viii C 203 1020
have C 204 1020
similar C 205 1020
properties C 206 1020
support C 207 1020
the C 208 1020
hypothesis C 209 1020
. C 210 1020
the C 212 1020
theory C 213 1020
of C 214 1020
some C 215 1020
authors C 216 1020
according C 217 1020
to C 218 1020
which C 219 1020
the C 220 1020
plasma C 221 1020
of C 222 1020
an C 223 1020
hemophiliac C 224 1020
a C 225 1020
contains C 226 1020
normal C 227 1020
amounts C 228 1020
of C 229 1020
a C 230 1020
normal C 231 1020
factor C 232 1020
viii C 233 1020
blocked C 234 1020
by C 235 1020
a C 236 1020
specific C 237 1020
inhibitor C 238 1020
, C 239 1020
the C 240 1020
pathogenetic C 241 1020
agent C 242 1020
of C 243 1020
hemophilia C 244 1020
a C 245 1020
is C 246 1020
rejected C 247 1020
because C 248 1020
of C 249 1020
genetic C 250 1020
considerations C 251 1020
and C 252 1020
because C 253 1020
the C 254 1020
accelerator C 255 1020
appearing C 256 1020
after C 257 1020
ether C 258 1020
treatment C 259 1020
of C 260 1020
hemophilia C 261 1020
a C 262 1020
plasma C 263 1020
is C 264 1020
not C 265 1020
identical C 266 1020
with C 267 1020
factor C 268 1020
viii C 269 1020
. C 270 1020
haemophilic C 1 1021
pseudotumours C 2 1021
( C 3 1021
3 C 4 1021
cases C 5 1021
) C 6 1021
. C 7 1021
the C 9 1021
2 C 10 1021
first C 11 1021
cases C 12 1021
of C 13 1021
haemophilic C 14 1021
pseudo C 15 1021
- C 16 1021
tumours C 17 1021
in C 18 1021
2 C 19 1021
adults C 20 1021
affected C 21 1021
with C 22 1021
haemophilia C 23 1021
a C 24 1021
reported C 25 1021
are C 26 1021
remarkable C 27 1021
on C 28 1021
account C 29 1021
of C 30 1021
their C 31 1021
clinical C 32 1021
latency C 33 1021
and C 34 1021
their C 35 1021
intertrochanteric C 36 1021
localization C 37 1021
. C 38 1021
the C 40 1021
third C 41 1021
, C 42 1021
in C 43 1021
a C 44 1021
haemophiliac C 45 1021
b C 46 1021
, C 47 1021
is C 48 1021
very C 49 1021
extensive C 50 1021
and C 51 1021
is C 52 1021
accompanied C 53 1021
by C 54 1021
very C 55 1021
marked C 56 1021
clinical C 57 1021
symptoms C 58 1021
of C 59 1021
tumour C 60 1021
. C 61 1021
there C 63 1021
is C 64 1021
an C 65 1021
extensive C 66 1021
femoral C 67 1021
gap C 68 1021
with C 69 1021
a C 70 1021
subjacent C 71 1021
image C 72 1021
of C 73 1021
osseous C 74 1021
infarction C 75 1021
and C 76 1021
a C 77 1021
progressive C 78 1021
turgid C 79 1021
tumour C 80 1021
of C 81 1021
the C 82 1021
iliac C 83 1021
wing C 84 1021
of C 85 1021
the C 86 1021
same C 87 1021
side C 88 1021
. C 89 1021
the C 91 1021
literature C 92 1021
data C 93 1021
stress C 94 1021
the C 95 1021
discrepancy C 96 1021
between C 97 1021
the C 98 1021
progressive C 99 1021
character C 100 1021
of C 101 1021
this C 102 1021
veritable C 103 1021
tumour C 104 1021
and C 105 1021
the C 106 1021
absence C 107 1021
of C 108 1021
any C 109 1021
sign C 110 1021
of C 111 1021
histological C 112 1021
malignancy C 113 1021
. C 114 1021
protein C 1 1022
- C 2 1022
losing C 3 1022
enteropathy C 4 1022
complicating C 5 1022
prolonged C 6 1022
bleeding C 7 1022
in C 8 1022
hemophilia C 9 1022
. C 10 1022
gastrointestinal C 12 1022
bleeding C 13 1022
in C 14 1022
a C 15 1022
severe C 16 1022
hemophiliac C 17 1022
continued C 18 1022
for C 19 1022
110 C 20 1022
days C 21 1022
, C 22 1022
and C 23 1022
263 C 24 1022
pints C 25 1022
of C 26 1022
fresh C 27 1022
blood C 28 1022
were C 29 1022
replaced C 30 1022
. C 31 1022
treatment C 33 1022
with C 34 1022
eaca C 35 1022
, C 36 1022
steroids C 37 1022
, C 38 1022
and C 39 1022
factor C 40 1022
viii C 41 1022
, C 42 1022
rich C 43 1022
fibrinogen C 44 1022
did C 45 1022
not C 46 1022
control C 47 1022
bleeding C 48 1022
. C 49 1022
marked C 51 1022
hypoproteinemia C 52 1022
developed C 53 1022
by C 54 1022
the C 55 1022
94 C 56 1022
th C 57 1022
day C 58 1022
of C 59 1022
bleeding C 60 1022
. C 61 1022
a C 63 1022
protein C 64 1022
- C 65 1022
losing C 66 1022
enteropathy C 67 1022
was C 68 1022
suspected C 69 1022
on C 70 1022
the C 71 1022
basis C 72 1022
of C 73 1022
x C 74 1022
- C 75 1022
ray C 76 1022
findings C 77 1022
of C 78 1022
mucosal C 79 1022
thickening C 80 1022
and C 81 1022
altered C 82 1022
motility C 83 1022
. C 84 1022
discontinuance C 86 1022
of C 87 1022
steroids C 88 1022
and C 89 1022
protein C 90 1022
replacement C 91 1022
resulted C 92 1022
in C 93 1022
the C 94 1022
appearance C 95 1022
of C 96 1022
a C 97 1022
more C 98 1022
normal C 99 1022
small C 100 1022
bowel C 101 1022
mucosal C 102 1022
pattern C 103 1022
and C 104 1022
coincided C 105 1022
with C 106 1022
the C 107 1022
cessation C 108 1022
of C 109 1022
bleeding C 110 1022
. C 111 1022
bilateral C 1 1023
hemophilic C 2 1023
pseudotumors C 3 1023
of C 4 1023
the C 5 1023
calcaneus C 6 1023
and C 7 1023
cuboid C 8 1023
treated C 9 1023
by C 10 1023
irradiation C 11 1023
. C 12 1023
case C 14 1023
report C 15 1023
. C 16 1023
a C 18 1023
case C 19 1023
is C 20 1023
presented C 21 1023
in C 22 1023
which C 23 1023
bilateral C 24 1023
pseudotumors C 25 1023
of C 26 1023
the C 27 1023
calcaneus C 28 1023
and C 29 1023
cuboid C 30 1023
in C 31 1023
an C 32 1023
11 C 33 1023
- C 34 1023
year C 35 1023
- C 36 1023
old C 37 1023
boy C 38 1023
with C 39 1023
apparent C 40 1023
classic C 41 1023
hemophilia C 42 1023
responded C 43 1023
promptly C 44 1023
to C 45 1023
deep C 46 1023
x C 47 1023
- C 48 1023
ray C 49 1023
therapy C 50 1023
with C 51 1023
relief C 52 1023
of C 53 1023
pain C 54 1023
and C 55 1023
subsequent C 56 1023
disappearance C 57 1023
of C 58 1023
the C 59 1023
tumors C 60 1023
without C 61 1023
recurrence C 62 1023
for C 63 1023
2 C 64 1023
yr C 65 1023
. C 66 1023
and C 68 1023
8 C 69 1023
mth C 70 1023
. C 71 1023
after C 73 1023
treatment C 74 1023
. C 75 1023
although C 77 1023
previous C 78 1023
reports C 79 1023
on C 80 1023
the C 81 1023
effects C 82 1023
of C 83 1023
radiotherapy C 84 1023
for C 85 1023
pseudotumors C 86 1023
have C 87 1023
been C 88 1023
conflicting C 89 1023
, C 90 1023
the C 91 1023
results C 92 1023
in C 93 1023
this C 94 1023
case C 95 1023
were C 96 1023
dramatic C 97 1023
. C 98 1023
some C 1 1024
bone C 2 1024
lesions C 3 1024
in C 4 1024
the C 5 1024
course C 6 1024
of C 7 1024
blood C 8 1024
diseases C 9 1024
with C 10 1024
special C 11 1024
reference C 12 1024
to C 13 1024
the C 14 1024
formation C 15 1024
of C 16 1024
bony C 17 1024
callus C 18 1024
and C 19 1024
to C 20 1024
the C 21 1024
treatment C 22 1024
of C 23 1024
fractures C 24 1024
in C 25 1024
patients C 26 1024
suffering C 27 1024
from C 28 1024
blood C 29 1024
diseases C 30 1024
. C 31 1024
after C 33 1024
some C 34 1024
preliminary C 35 1024
remarks C 36 1024
on C 37 1024
the C 38 1024
embryology C 39 1024
and C 40 1024
physiology C 41 1024
of C 42 1024
the C 43 1024
bone C 44 1024
marrow C 45 1024
and C 46 1024
on C 47 1024
the C 48 1024
mechanism C 49 1024
of C 50 1024
coagulation C 51 1024
of C 52 1024
the C 53 1024
blood C 54 1024
, C 55 1024
the C 56 1024
authors C 57 1024
pass C 58 1024
on C 59 1024
to C 60 1024
a C 61 1024
consideration C 62 1024
of C 63 1024
the C 64 1024
genesis C 65 1024
of C 66 1024
bony C 67 1024
callus C 68 1024
, C 69 1024
and C 70 1024
the C 71 1024
treatment C 72 1024
of C 73 1024
fractures C 74 1024
in C 75 1024
patients C 76 1024
suffering C 77 1024
from C 78 1024
blood C 79 1024
diseases C 80 1024
. C 81 1024
an C 83 1024
account C 84 1024
is C 85 1024
given C 86 1024
on C 87 1024
the C 88 1024
basis C 89 1024
of C 90 1024
some C 91 1024
examples C 92 1024
of C 93 1024
pathological C 94 1024
fractures C 95 1024
, C 96 1024
and C 97 1024
also C 98 1024
of C 99 1024
some C 100 1024
traumatic C 101 1024
fractures C 102 1024
in C 103 1024
subjects C 104 1024
affected C 105 1024
by C 106 1024
various C 107 1024
kinds C 108 1024
of C 109 1024
blood C 110 1024
diseases C 111 1024
such C 112 1024
as C 113 1024
solitary C 114 1024
myeloma C 115 1024
, C 116 1024
polyosteotic C 117 1024
plasmocytoma C 118 1024
, C 119 1024
waldenstroem C 120 1024
' C 121 1024
s C 122 1024
syndrome C 123 1024
, C 124 1024
the C 125 1024
coagulopathic C 126 1024
syndrome C 127 1024
from C 128 1024
a C 129 1024
structural C 130 1024
defect C 131 1024
of C 132 1024
the C 133 1024
fibrin C 134 1024
coagulum C 135 1024
, C 136 1024
and C 137 1024
hemophilia C 138 1024
. C 139 1024
fractures C 141 1024
in C 142 1024
patients C 143 1024
with C 144 1024
blood C 145 1024
diseases C 146 1024
are C 147 1024
characterized C 148 1024
by C 149 1024
an C 150 1024
abnormal C 151 1024
course C 152 1024
, C 153 1024
and C 154 1024
, C 155 1024
for C 156 1024
an C 157 1024
effecient C 158 1024
cure C 159 1024
, C 160 1024
it C 161 1024
is C 162 1024
necessary C 163 1024
to C 164 1024
make C 165 1024
an C 166 1024
accurate C 167 1024
diagnosis C 168 1024
with C 169 1024
regard C 170 1024
to C 171 1024
the C 172 1024
pre C 173 1024
- C 174 1024
existing C 175 1024
blood C 176 1024
diseases C 177 1024
and C 178 1024
to C 179 1024
re C 180 1024
- C 181 1024
establish C 182 1024
hemostasis C 183 1024
when C 184 1024
this C 185 1024
has C 186 1024
been C 187 1024
changed C 188 1024
, C 189 1024
to C 190 1024
prevent C 191 1024
hemorrhages C 192 1024
, C 193 1024
and C 194 1024
to C 195 1024
correct C 196 1024
any C 197 1024
plasma C 198 1024
defect C 199 1024
that C 200 1024
may C 201 1024
be C 202 1024
present C 203 1024
and C 204 1024
which C 205 1024
are C 206 1024
reflected C 207 1024
in C 208 1024
the C 209 1024
formation C 210 1024
of C 211 1024
the C 212 1024
bony C 213 1024
callus C 214 1024
. C 215 1024
studies C 1 1025
of C 2 1025
the C 3 1025
antihemophilic C 4 1025
factor C 5 1025
( C 6 1025
ahf C 7 1025
, C 8 1025
factor C 9 1025
viii C 10 1025
) C 11 1025
produced C 12 1025
in C 13 1025
von C 14 1025
willebrand C 15 1025
' C 16 1025
s C 17 1025
disease C 18 1025
. C 19 1025
it C 21 1025
has C 22 1025
been C 23 1025
confirmed C 24 1025
that C 25 1025
persons C 26 1025
with C 27 1025
autosomal C 28 1025
ahf C 29 1025
deficiency C 30 1025
( C 31 1025
von C 32 1025
willebrand C 33 1025
' C 34 1025
s C 35 1025
disease C 36 1025
) C 37 1025
produce C 38 1025
large C 39 1025
quantities C 40 1025
of C 41 1025
ahf C 42 1025
when C 43 1025
transfused C 44 1025
with C 45 1025
ahf C 46 1025
- C 47 1025
deficient C 48 1025
plasma C 49 1025
from C 50 1025
persons C 51 1025
with C 52 1025
hemophilia C 53 1025
a C 54 1025
. C 55 1025
this C 57 1025
occurs C 58 1025
despite C 59 1025
the C 60 1025
fact C 61 1025
that C 62 1025
' C 63 1025
complementation C 64 1025
' C 65 1025
does C 66 1025
not C 67 1025
occur C 68 1025
in C 69 1025
vitro C 70 1025
. C 71 1025
one C 73 1025
prediction C 74 1025
from C 75 1025
a C 76 1025
model C 77 1025
suggesting C 78 1025
that C 79 1025
the C 80 1025
x C 81 1025
- C 82 1025
locus C 83 1025
for C 84 1025
ahf C 85 1025
is C 86 1025
structural C 87 1025
while C 88 1025
the C 89 1025
autosomal C 90 1025
locus C 91 1025
is C 92 1025
regulatory C 93 1025
is C 94 1025
that C 95 1025
the C 96 1025
ahf C 97 1025
which C 98 1025
appears C 99 1025
in C 100 1025
von C 101 1025
willebrand C 102 1025
' C 103 1025
s C 104 1025
disease C 105 1025
after C 106 1025
transfusion C 107 1025
will C 108 1025
be C 109 1025
structurally C 110 1025
normal C 111 1025
. C 112 1025
the C 114 1025
ahf C 115 1025
obtained C 116 1025
under C 117 1025
these C 118 1025
conditions C 119 1025
has C 120 1025
been C 121 1025
tested C 122 1025
by C 123 1025
methods C 124 1025
and C 125 1025
the C 126 1025
results C 127 1025
fulfil C 128 1025
the C 129 1025
prediction C 130 1025
. C 131 1025
this C 133 1025
may C 134 1025
imply C 135 1025
that C 136 1025
the C 137 1025
model C 138 1025
is C 139 1025
correct C 140 1025
. C 141 1025
on C 143 1025
the C 144 1025
other C 145 1025
hand C 146 1025
, C 147 1025
the C 148 1025
prediction C 149 1025
may C 150 1025
have C 151 1025
been C 152 1025
fulfilled C 153 1025
for C 154 1025
other C 155 1025
reasons C 156 1025
. C 157 1025
perhaps C 159 1025
the C 160 1025
wrong C 161 1025
parameters C 162 1025
were C 163 1025
examined C 164 1025
, C 165 1025
or C 166 1025
the C 167 1025
large C 168 1025
standard C 169 1025
errors C 170 1025
of C 171 1025
the C 172 1025
tests C 173 1025
masked C 174 1025
a C 175 1025
real C 176 1025
difference C 177 1025
. C 178 1025
further C 180 1025
tests C 181 1025
are C 182 1025
obviously C 183 1025
needed C 184 1025
before C 185 1025
one C 186 1025
can C 187 1025
feel C 188 1025
reasonably C 189 1025
certain C 190 1025
that C 191 1025
mutation C 192 1025
of C 193 1025
a C 194 1025
regulatory C 195 1025
gene C 196 1025
is C 197 1025
the C 198 1025
basis C 199 1025
of C 200 1025
von C 201 1025
willebrand C 202 1025
' C 203 1025
s C 204 1025
disease C 205 1025
. C 206 1025
an C 208 1025
examination C 209 1025
of C 210 1025
persons C 211 1025
with C 212 1025
sex C 213 1025
- C 214 1025
linked C 215 1025
and C 216 1025
autosomal C 217 1025
ahf C 218 1025
deficiency C 219 1025
using C 220 1025
an C 221 1025
antibody C 222 1025
prepared C 223 1025
against C 224 1025
wild C 225 1025
type C 226 1025
ahf C 227 1025
might C 228 1025
be C 229 1025
very C 230 1025
illuminating C 231 1025
. C 232 1025
also C 234 1025
, C 235 1025
transfusion C 236 1025
studies C 237 1025
should C 238 1025
be C 239 1025
carried C 240 1025
out C 241 1025
on C 242 1025
persons C 243 1025
homozygous C 244 1025
for C 245 1025
von C 246 1025
willebrand C 247 1025
' C 248 1025
s C 249 1025
disease C 250 1025
if C 251 1025
such C 252 1025
persons C 253 1025
can C 254 1025
be C 255 1025
found C 256 1025
. C 257 1025
failure C 259 1025
to C 260 1025
obtain C 261 1025
' C 262 1025
new C 263 1025
synthesis C 264 1025
' C 265 1025
in C 266 1025
a C 267 1025
homozygote C 268 1025
would C 269 1025
throw C 270 1025
great C 271 1025
doubt C 272 1025
on C 273 1025
a C 274 1025
model C 275 1025
which C 276 1025
implies C 277 1025
that C 278 1025
the C 279 1025
reduced C 280 1025
ahf C 281 1025
levels C 282 1025
in C 283 1025
von C 284 1025
willebrand C 285 1025
' C 286 1025
s C 287 1025
disease C 288 1025
heterozygotes C 289 1025
is C 290 1025
due C 291 1025
entirely C 292 1025
to C 293 1025
reduction C 294 1025
in C 295 1025
an C 296 1025
effector C 297 1025
substance C 298 1025
which C 299 1025
neutralizes C 300 1025
the C 301 1025
repressor C 302 1025
of C 303 1025
an C 304 1025
x C 305 1025
- C 306 1025
chromosome C 307 1025
operon C 308 1025
directly C 309 1025
coding C 310 1025
the C 311 1025
ahf C 312 1025
molecule C 313 1025
. C 314 1025
tumor C 1 1026
- C 2 1026
like C 3 1026
bone C 4 1026
lesions C 5 1026
in C 6 1026
hemophilia C 7 1026
. C 8 1026
this C 10 1026
report C 11 1026
deals C 12 1026
with C 13 1026
the C 14 1026
clinical C 15 1026
and C 16 1026
radiologic C 17 1026
findings C 18 1026
in C 19 1026
a C 20 1026
hemophilic C 21 1026
pseudotumor C 22 1026
of C 23 1026
the C 24 1026
femur C 25 1026
observed C 26 1026
over C 27 1026
a C 28 1026
period C 29 1026
of C 30 1026
10 C 31 1026
yr C 32 1026
. C 33 1026
the C 35 1026
pathogenesis C 36 1026
, C 37 1026
treatment C 38 1026
and C 39 1026
radiologic C 40 1026
differential C 41 1026
diagnosis C 42 1026
are C 43 1026
discussed C 44 1026
. C 45 1026
concurrent C 1 1027
hemophilia C 2 1027
and C 3 1027
christmas C 4 1027
' C 5 1027
disease C 6 1027
in C 7 1027
one C 8 1027
family C 9 1027
. C 10 1027
a C 12 1027
study C 13 1027
is C 14 1027
presented C 15 1027
of C 16 1027
a C 17 1027
number C 18 1027
of C 19 1027
generations C 20 1027
of C 21 1027
a C 22 1027
family C 23 1027
in C 24 1027
whom C 25 1027
two C 26 1027
members C 27 1027
had C 28 1027
christmas C 29 1027
' C 30 1027
disease C 31 1027
and C 32 1027
three C 33 1027
hemophilia C 34 1027
a C 35 1027
. C 36 1027
it C 38 1027
is C 39 1027
suspected C 40 1027
that C 41 1027
the C 42 1027
preceding C 43 1027
generations C 44 1027
must C 45 1027
have C 46 1027
been C 47 1027
afflicted C 48 1027
with C 49 1027
hemophilia C 50 1027
ab C 51 1027
, C 52 1027
or C 53 1027
a C 54 1027
mutation C 55 1027
in C 56 1027
x C 57 1027
- C 58 1027
chromosome C 59 1027
genes C 60 1027
which C 61 1027
are C 62 1027
responsible C 63 1027
for C 64 1027
both C 65 1027
types C 66 1027
of C 67 1027
hemophilia C 68 1027
must C 69 1027
have C 70 1027
occurred C 71 1027
in C 72 1027
the C 73 1027
grandmother C 74 1027
' C 75 1027
s C 76 1027
family C 77 1027
. C 78 1027
in C 80 1027
her C 81 1027
daughters C 82 1027
the C 83 1027
genes C 84 1027
responsible C 85 1027
for C 86 1027
hemophilia C 87 1027
ab C 88 1027
segregated C 89 1027
so C 90 1027
that C 91 1027
their C 92 1027
children C 93 1027
and C 94 1027
grandchildren C 95 1027
inherited C 96 1027
only C 97 1027
one C 98 1027
type C 99 1027
of C 100 1027
hemophilia C 101 1027
i C 102 1027
. C 103 1027
. C 104 1027
. C 105 1027
hemophilia C 107 1027
a C 108 1027
or C 109 1027
christmas C 110 1027
' C 111 1027
disease C 112 1027
. C 113 1027
relevant C 115 1027
genetic C 116 1027
considerations C 117 1027
are C 118 1027
briefly C 119 1027
reviewed C 120 1027
. C 121 1027
albinism C 1 1028
associated C 2 1028
with C 3 1028
angiohemophilia C 4 1028
. C 5 1028
report C 7 1028
of C 8 1028
a C 9 1028
case C 10 1028
. C 11 1028
a C 13 1028
case C 14 1028
is C 15 1028
presented C 16 1028
of C 17 1028
a C 18 1028
rare C 19 1028
association C 20 1028
of C 21 1028
albinism C 22 1028
and C 23 1028
angiohemophilia C 24 1028
, C 25 1028
occurring C 26 1028
in C 27 1028
a C 28 1028
man C 29 1028
of C 30 1028
25 C 31 1028
. C 32 1028
the C 34 1028
bone C 35 1028
marrow C 36 1028
contained C 37 1028
cells C 38 1028
resembling C 39 1028
proper C 40 1028
reticulum C 41 1028
cells C 42 1028
and C 43 1028
containing C 44 1028
large C 45 1028
basophilic C 46 1028
granules C 47 1028
. C 48 1028
major C 1 1029
surgery C 2 1029
in C 3 1029
classic C 4 1029
hemophilia C 5 1029
using C 6 1029
fraction C 7 1029
i C 8 1029
. C 9 1029
experience C 11 1029
in C 12 1029
twelve C 13 1029
operations C 14 1029
and C 15 1029
review C 16 1029
of C 17 1029
the C 18 1029
literature C 19 1029
. C 20 1029
a C 22 1029
therapeutic C 23 1029
regimen C 24 1029
that C 25 1029
provides C 26 1029
hemostasis C 27 1029
in C 28 1029
hemophiliacs C 29 1029
during C 30 1029
and C 31 1029
after C 32 1029
major C 33 1029
surgery C 34 1029
without C 35 1029
requiring C 36 1029
laboratory C 37 1029
control C 38 1029
has C 39 1029
been C 40 1029
established C 41 1029
with C 42 1029
a C 43 1029
factor C 44 1029
viii C 45 1029
concentrate C 46 1029
. C 47 1029
the C 49 1029
effectiveness C 50 1029
of C 51 1029
this C 52 1029
regimen C 53 1029
of C 54 1029
fraction C 55 1029
i C 56 1029
therapy C 57 1029
was C 58 1029
evaluated C 59 1029
in C 60 1029
major C 61 1029
surgery C 62 1029
of C 63 1029
6 C 64 1029
severely C 65 1029
deficient C 66 1029
and C 67 1029
4 C 68 1029
moderately C 69 1029
deficient C 70 1029
hemophiliacs C 71 1029
. C 72 1029
an C 74 1029
analysis C 75 1029
of C 76 1029
clinical C 77 1029
results C 78 1029
was C 79 1029
made C 80 1029
, C 81 1029
combining C 82 1029
the C 83 1029
12 C 84 1029
operations C 85 1029
of C 86 1029
the C 87 1029
series C 88 1029
with C 89 1029
the C 90 1029
116 C 91 1029
major C 92 1029
operative C 93 1029
procedures C 94 1029
on C 95 1029
hemophiliacs C 96 1029
recorded C 97 1029
in C 98 1029
the C 99 1029
english C 100 1029
literature C 101 1029
, C 102 1029
in C 103 1029
which C 104 1029
fraction C 105 1029
i C 106 1029
was C 107 1029
the C 108 1029
sole C 109 1029
or C 110 1029
major C 111 1029
source C 112 1029
of C 113 1029
factor C 114 1029
viii C 115 1029
therapy C 116 1029
. C 117 1029
dental C 119 1029
and C 120 1029
nondental C 121 1029
surgery C 122 1029
were C 123 1029
analyzed C 124 1029
separately C 125 1029
, C 126 1029
as C 127 1029
was C 128 1029
the C 129 1029
special C 130 1029
problem C 131 1029
of C 132 1029
blood C 133 1029
cysts C 134 1029
. C 135 1029
although C 137 1029
the C 138 1029
over C 139 1029
- C 140 1029
all C 141 1029
mortality C 142 1029
rate C 143 1029
following C 144 1029
major C 145 1029
surgery C 146 1029
in C 147 1029
hemophiliacs C 148 1029
is C 149 1029
presently C 150 1029
only C 151 1029
5 C 152 1029
to C 153 1029
10 C 154 1029
% C 155 1029
using C 156 1029
factor C 157 1029
viii C 158 1029
concentrates C 159 1029
, C 160 1029
problems C 161 1029
still C 162 1029
remain C 163 1029
. C 164 1029
these C 166 1029
include C 167 1029
the C 168 1029
continued C 169 1029
high C 170 1029
incidence C 171 1029
of C 172 1029
abnormal C 173 1029
postoperative C 174 1029
hemorrhage C 175 1029
, C 176 1029
the C 177 1029
variation C 178 1029
in C 179 1029
factor C 180 1029
viii C 181 1029
potency C 182 1029
of C 183 1029
different C 184 1029
lots C 185 1029
of C 186 1029
fraction C 187 1029
i C 188 1029
, C 189 1029
the C 190 1029
late C 191 1029
development C 192 1029
of C 193 1029
serum C 194 1029
hepatitis C 195 1029
, C 196 1029
hemolytic C 197 1029
anemia C 198 1029
due C 199 1029
to C 200 1029
contaminating C 201 1029
isoantibodies C 202 1029
and C 203 1029
the C 204 1029
high C 205 1029
cost C 206 1029
of C 207 1029
adequate C 208 1029
amounts C 209 1029
of C 210 1029
the C 211 1029
product C 212 1029
. C 213 1029
more C 215 1029
efficient C 216 1029
methods C 217 1029
of C 218 1029
preparing C 219 1029
purer C 220 1029
and C 221 1029
more C 222 1029
potent C 223 1029
factor C 224 1029
viii C 225 1029
concentrates C 226 1029
could C 227 1029
eliminate C 228 1029
most C 229 1029
of C 230 1029
these C 231 1029
difficulties C 232 1029
. C 233 1029
lengthening C 1 1030
of C 2 1030
the C 3 1030
thrombin C 4 1030
time C 5 1030
by C 6 1030
an C 7 1030
anti C 8 1030
- C 9 1030
equine C 10 1030
antithrombin C 11 1030
in C 12 1030
a C 13 1030
hyperthrombocyte C 14 1030
myelosis C 15 1030
. C 16 1030
a C 18 1030
report C 19 1030
is C 20 1030
given C 21 1030
on C 22 1030
a C 23 1030
patient C 24 1030
treated C 25 1030
with C 26 1030
numerous C 27 1030
i C 28 1030
. C 29 1030
. C 30 1030
. C 31 1030
injections C 33 1030
of C 34 1030
thrombase C 35 1030
( C 36 1030
equine C 37 1030
thrombin C 38 1030
) C 39 1030
for C 40 1030
chronic C 41 1030
gingivorrhagia C 42 1030
caused C 43 1030
by C 44 1030
a C 45 1030
hyperthrombocytic C 46 1030
myelosis C 47 1030
. C 48 1030
these C 50 1030
were C 51 1030
ineffective C 52 1030
and C 53 1030
an C 54 1030
antithrombin C 55 1030
specific C 56 1030
against C 57 1030
equine C 58 1030
thrombin C 59 1030
had C 60 1030
developed C 61 1030
. C 62 1030
this C 64 1030
did C 65 1030
not C 66 1030
cause C 67 1030
any C 68 1030
specific C 69 1030
disturbance C 70 1030
of C 71 1030
the C 72 1030
intrinsic C 73 1030
coagulation C 74 1030
. C 75 1030
the C 77 1030
observation C 78 1030
can C 79 1030
be C 80 1030
compared C 81 1030
with C 82 1030
two C 83 1030
cases C 84 1030
of C 85 1030
haemophilia C 86 1030
where C 87 1030
such C 88 1030
an C 89 1030
antithrombin C 90 1030
had C 91 1030
also C 92 1030
developed C 93 1030
after C 94 1030
repeated C 95 1030
injections C 96 1030
of C 97 1030
equine C 98 1030
thrombin C 99 1030
. C 100 1030
epsilon C 1 1031
- C 2 1031
aminocaproic C 3 1031
acid C 4 1031
( C 5 1031
e C 6 1031
- C 7 1031
aca C 8 1031
) C 9 1031
as C 10 1031
a C 11 1031
therapeutic C 12 1031
agent C 13 1031
based C 14 1031
on C 15 1031
5 C 16 1031
years C 17 1031
clinical C 18 1031
experience C 19 1031
. C 20 1031
experience C 22 1031
in C 23 1031
the C 24 1031
treatment C 25 1031
of C 26 1031
744 C 27 1031
patients C 28 1031
with C 29 1031
e C 30 1031
- C 31 1031
aca C 32 1031
suggested C 33 1031
that C 34 1031
the C 35 1031
use C 36 1031
of C 37 1031
the C 38 1031
preparation C 39 1031
is C 40 1031
indicated C 41 1031
in C 42 1031
the C 43 1031
following C 44 1031
situations C 45 1031
: C 46 1031
( C 47 1031
1 C 48 1031
) C 49 1031
fibrinolytic C 50 1031
haemorrhage C 51 1031
in C 52 1031
association C 53 1031
with C 54 1031
delivery C 55 1031
. C 56 1031
( C 58 1031
2 C 59 1031
) C 60 1031
acute C 61 1031
systemic C 62 1031
fibrinolysis C 63 1031
in C 64 1031
association C 65 1031
with C 66 1031
surgery C 67 1031
. C 68 1031
it C 70 1031
is C 71 1031
mainly C 72 1031
major C 73 1031
operations C 74 1031
on C 75 1031
the C 76 1031
thorax C 77 1031
, C 78 1031
pancreas C 79 1031
, C 80 1031
prostate C 81 1031
, C 82 1031
liver C 83 1031
and C 84 1031
genital C 85 1031
organs C 86 1031
that C 87 1031
are C 88 1031
complicated C 89 1031
by C 90 1031
fibrinolysis C 91 1031
, C 92 1031
but C 93 1031
fibrinolytic C 94 1031
bleedings C 95 1031
can C 96 1031
occur C 97 1031
after C 98 1031
any C 99 1031
operation C 100 1031
. C 101 1031
( C 103 1031
3 C 104 1031
) C 105 1031
acute C 106 1031
systemic C 107 1031
fibrinolysis C 108 1031
in C 109 1031
patients C 110 1031
with C 111 1031
cancer C 112 1031
, C 113 1031
particularly C 114 1031
cancer C 115 1031
of C 116 1031
the C 117 1031
prostate C 118 1031
and C 119 1031
pancreas C 120 1031
. C 121 1031
( C 123 1031
4 C 124 1031
) C 125 1031
systemic C 126 1031
fibrinolytic C 127 1031
states C 128 1031
complicating C 129 1031
various C 130 1031
disorders C 131 1031
, C 132 1031
especially C 133 1031
leukaemia C 134 1031
, C 135 1031
liver C 136 1031
cirrhosis C 137 1031
and C 138 1031
boeck C 139 1031
' C 140 1031
s C 141 1031
sarcoid C 142 1031
. C 143 1031
( C 145 1031
5 C 146 1031
) C 147 1031
as C 148 1031
an C 149 1031
antidote C 150 1031
in C 151 1031
thrombolytic C 152 1031
therapy C 153 1031
. C 154 1031
( C 156 1031
6 C 157 1031
) C 158 1031
local C 159 1031
fibrinolytic C 160 1031
activity C 161 1031
in C 162 1031
the C 163 1031
urinary C 164 1031
tract C 165 1031
in C 166 1031
the C 167 1031
following C 168 1031
situations C 169 1031
: C 170 1031
( C 171 1031
a C 172 1031
) C 173 1031
after C 174 1031
prostatectomy C 175 1031
. C 176 1031
e C 178 1031
- C 179 1031
aca C 180 1031
will C 181 1031
substantially C 182 1031
reduce C 183 1031
blood C 184 1031
losses C 185 1031
following C 186 1031
prostatectomy C 187 1031
, C 188 1031
especially C 189 1031
if C 190 1031
the C 191 1031
treatment C 192 1031
is C 193 1031
continued C 194 1031
until C 195 1031
the C 196 1031
urine C 197 1031
has C 198 1031
become C 199 1031
macroscopically C 200 1031
clear C 201 1031
. C 202 1031
( C 204 1031
b C 205 1031
) C 206 1031
haematuria C 207 1031
in C 208 1031
prostatic C 209 1031
cancer C 210 1031
, C 211 1031
prostatic C 212 1031
hyperplasia C 213 1031
, C 214 1031
prolonged C 215 1031
haematuria C 216 1031
after C 217 1031
traumatic C 218 1031
injury C 219 1031
of C 220 1031
the C 221 1031
kidney C 222 1031
, C 223 1031
haematuria C 224 1031
in C 225 1031
haemophilia C 226 1031
and C 227 1031
other C 228 1031
coagulation C 229 1031
defects C 230 1031
, C 231 1031
and C 232 1031
so C 233 1031
- C 234 1031
called C 235 1031
essential C 236 1031
haematuria C 237 1031
. C 238 1031
( C 240 1031
7 C 241 1031
) C 242 1031
ulcerative C 243 1031
colitis C 244 1031
. C 245 1031
the C 247 1031
drug C 248 1031
is C 249 1031
equally C 250 1031
effective C 251 1031
whether C 252 1031
given C 253 1031
orally C 254 1031
or C 255 1031
intravenously C 256 1031
. C 257 1031
in C 259 1031
states C 260 1031
with C 261 1031
increased C 262 1031
systemic C 263 1031
fibrinolytic C 264 1031
activity C 265 1031
a C 266 1031
dose C 267 1031
of C 268 1031
0 C 269 1031
. C 270 1031
. C 271 1031
g C 272 1031
per C 273 1031
kg C 274 1031
body C 275 1031
weight C 276 1031
every C 277 1031
4 C 278 1031
- C 279 1031
5 C 280 1031
hours C 281 1031
is C 282 1031
recommended C 283 1031
. C 284 1031
for C 286 1031
inhibition C 287 1031
of C 288 1031
local C 289 1031
fibrinolytic C 290 1031
activity C 291 1031
in C 292 1031
the C 293 1031
urinary C 294 1031
tract C 295 1031
, C 296 1031
a C 297 1031
dose C 298 1031
of C 299 1031
3 C 300 1031
g C 301 1031
three C 302 1031
times C 303 1031
a C 304 1031
day C 305 1031
has C 306 1031
proved C 307 1031
sufficient C 308 1031
. C 309 1031
the C 311 1031
side C 312 1031
- C 313 1031
effects C 314 1031
consisted C 315 1031
of C 316 1031
dizziness C 317 1031
, C 318 1031
nausea C 319 1031
and C 320 1031
diarrhoea C 321 1031
. C 322 1031
no C 324 1031
toxic C 325 1031
effects C 326 1031
of C 327 1031
the C 328 1031
drug C 329 1031
on C 330 1031
e C 331 1031
. C 332 1031
. C 333 1031
. C 334 1031
. C 335 1031
. C 336 1031
, C 338 1031
blood C 339 1031
picture C 340 1031
, C 341 1031
n C 342 1031
. C 343 1031
. C 344 1031
. C 345 1031
. C 346 1031
. C 347 1031
and C 349 1031
liver C 350 1031
function C 351 1031
tests C 352 1031
were C 353 1031
observed C 354 1031
, C 355 1031
not C 356 1031
even C 357 1031
in C 358 1031
cases C 359 1031
receiving C 360 1031
more C 361 1031
than C 362 1031
1000 C 363 1031
g C 364 1031
of C 365 1031
e C 366 1031
- C 367 1031
aca C 368 1031
. C 369 1031
nor C 371 1031
did C 372 1031
postmortem C 373 1031
examination C 374 1031
in C 375 1031
46 C 376 1031
cases C 377 1031
reveal C 378 1031
any C 379 1031
signs C 380 1031
of C 381 1031
a C 382 1031
toxic C 383 1031
effect C 384 1031
. C 385 1031
no C 387 1031
signs C 388 1031
of C 389 1031
intravascular C 390 1031
coagulation C 391 1031
in C 392 1031
connection C 393 1031
with C 394 1031
e C 395 1031
- C 396 1031
aca C 397 1031
therapy C 398 1031
were C 399 1031
observed C 400 1031
. C 401 1031
the C 403 1031
incidence C 404 1031
of C 405 1031
thromboembolic C 406 1031
complications C 407 1031
after C 408 1031
prostatectomy C 409 1031
in C 410 1031
patients C 411 1031
treated C 412 1031
with C 413 1031
e C 414 1031
- C 415 1031
aca C 416 1031
and C 417 1031
a C 418 1031
series C 419 1031
of C 420 1031
controls C 421 1031
was C 422 1031
identical C 423 1031
. C 424 1031
judging C 426 1031
from C 427 1031
the C 428 1031
authors C 429 1031
' C 430 1031
experience C 431 1031
in C 432 1031
this C 433 1031
material C 434 1031
e C 435 1031
- C 436 1031
aca C 437 1031
did C 438 1031
not C 439 1031
act C 440 1031
as C 441 1031
an C 442 1031
agent C 443 1031
inducing C 444 1031
thrombosis C 445 1031
. C 446 1031
femoral C 1 1032
neuropathy C 2 1032
in C 3 1032
hemophilia C 4 1032
. C 5 1032
six C 7 1032
new C 8 1032
cases C 9 1032
of C 10 1032
femoral C 11 1032
neuropathy C 12 1032
in C 13 1032
hemophilic C 14 1032
patients C 15 1032
are C 16 1032
described C 17 1032
. C 18 1032
the C 20 1032
syndrome C 21 1032
begins C 22 1032
with C 23 1032
severe C 24 1032
pain C 25 1032
in C 26 1032
the C 27 1032
groin C 28 1032
, C 29 1032
in C 30 1032
the C 31 1032
inferior C 32 1032
aspect C 33 1032
of C 34 1032
the C 35 1032
thigh C 36 1032
, C 37 1032
and C 38 1032
deep C 39 1032
in C 40 1032
the C 41 1032
hip C 42 1032
region C 43 1032
. C 44 1032
this C 46 1032
is C 47 1032
followed C 48 1032
by C 49 1032
a C 50 1032
pronounced C 51 1032
contracture C 52 1032
of C 53 1032
the C 54 1032
hip C 55 1032
in C 56 1032
flexion C 57 1032
and C 58 1032
external C 59 1032
rotation C 60 1032
. C 61 1032
a C 63 1032
tender C 64 1032
swelling C 65 1032
appears C 66 1032
in C 67 1032
the C 68 1032
iliac C 69 1032
fossa C 70 1032
and C 71 1032
groin C 72 1032
with C 73 1032
a C 74 1032
depression C 75 1032
in C 76 1032
the C 77 1032
center C 78 1032
corresponding C 79 1032
to C 80 1032
the C 81 1032
inguinal C 82 1032
ligament C 83 1032
. C 84 1032
finally C 86 1032
, C 87 1032
a C 88 1032
flaccid C 89 1032
paralysis C 90 1032
of C 91 1032
the C 92 1032
quadriceps C 93 1032
femoris C 94 1032
and C 95 1032
diminution C 96 1032
or C 97 1032
absence C 98 1032
of C 99 1032
sensation C 100 1032
in C 101 1032
the C 102 1032
anteromedial C 103 1032
aspect C 104 1032
of C 105 1032
the C 106 1032
thigh C 107 1032
and C 108 1032
proximal C 109 1032
portion C 110 1032
of C 111 1032
the C 112 1032
leg C 113 1032
, C 114 1032
with C 115 1032
a C 116 1032
depressed C 117 1032
or C 118 1032
absent C 119 1032
patellar C 120 1032
reflex C 121 1032
, C 122 1032
is C 123 1032
discovered C 124 1032
. C 125 1032
the C 127 1032
authors C 128 1032
propose C 129 1032
that C 130 1032
this C 131 1032
syndrome C 132 1032
is C 133 1032
the C 134 1032
result C 135 1032
of C 136 1032
hemorrhage C 137 1032
in C 138 1032
the C 139 1032
iliopsoas C 140 1032
muscle C 141 1032
at C 142 1032
the C 143 1032
musculotendinous C 144 1032
junction C 145 1032
beneath C 146 1032
the C 147 1032
iliacus C 148 1032
fascia C 149 1032
and C 150 1032
that C 151 1032
the C 152 1032
femoral C 153 1032
nerve C 154 1032
becomes C 155 1032
compressed C 156 1032
beneath C 157 1032
the C 158 1032
unyielding C 159 1032
inguinal C 160 1032
ligament C 161 1032
superiorly C 162 1032
and C 163 1032
the C 164 1032
iliopectineal C 165 1032
ligament C 166 1032
medially C 167 1032
. C 168 1032
treatment C 170 1032
consists C 171 1032
in C 172 1032
bed C 173 1032
rest C 174 1032
, C 175 1032
analgesics C 176 1032
, C 177 1032
and C 178 1032
freshfrozen C 179 1032
plasma C 180 1032
during C 181 1032
the C 182 1032
acute C 183 1032
phase C 184 1032
. C 185 1032
during C 187 1032
the C 188 1032
convalescent C 189 1032
phase C 190 1032
, C 191 1032
a C 192 1032
hessing C 193 1032
long C 194 1032
brace C 195 1032
is C 196 1032
used C 197 1032
to C 198 1032
protect C 199 1032
the C 200 1032
knee C 201 1032
from C 202 1032
hemarthrosis C 203 1032
until C 204 1032
functional C 205 1032
return C 206 1032
of C 207 1032
the C 208 1032
quadriceps C 209 1032
femoris C 210 1032
has C 211 1032
occurred C 212 1032
. C 213 1032
to C 215 1032
date C 216 1032
, C 217 1032
the C 218 1032
validity C 219 1032
of C 220 1032
the C 221 1032
theory C 222 1032
that C 223 1032
the C 224 1032
femoral C 225 1032
- C 226 1032
nerve C 227 1032
palsy C 228 1032
is C 229 1032
the C 230 1032
result C 231 1032
of C 232 1032
iliopsoas C 233 1032
hemorrhage C 234 1032
at C 235 1032
the C 236 1032
musculotendinous C 237 1032
junction C 238 1032
and C 239 1032
compression C 240 1032
of C 241 1032
the C 242 1032
femoral C 243 1032
nerve C 244 1032
beneath C 245 1032
the C 246 1032
inguinal C 247 1032
ligament C 248 1032
has C 249 1032
not C 250 1032
been C 251 1032
verified C 252 1032
. C 253 1032
the C 255 1032
authors C 256 1032
anticipate C 257 1032
some C 258 1032
day C 259 1032
seeing C 260 1032
a C 261 1032
non C 262 1032
- C 263 1032
hemophilic C 264 1032
patient C 265 1032
with C 266 1032
a C 267 1032
traumatic C 268 1032
iliacus C 269 1032
hemorrhage C 270 1032
and C 271 1032
femoral C 272 1032
neuropathy C 273 1032
. C 274 1032
should C 276 1032
such C 277 1032
an C 278 1032
opportunity C 279 1032
present C 280 1032
itself C 281 1032
, C 282 1032
exploration C 283 1032
beneath C 284 1032
poupart C 285 1032
' C 286 1032
s C 287 1032
ligament C 288 1032
may C 289 1032
show C 290 1032
the C 291 1032
femoral C 292 1032
nerve C 293 1032
to C 294 1032
be C 295 1032
compressed C 296 1032
and C 297 1032
thus C 298 1032
confirm C 299 1032
the C 300 1032
proposed C 301 1032
cause C 302 1032
of C 303 1032
the C 304 1032
clinical C 305 1032
picture C 306 1032
. C 307 1032
hemorrhagic C 1 1033
episodes C 2 1033
in C 3 1033
hemophilia C 4 1033
: C 5 1033
a C 6 1033
5 C 7 1033
- C 8 1033
year C 9 1033
prospective C 10 1033
study C 11 1033
. C 12 1033
medicosocial C 14 1033
studies C 15 1033
of C 16 1033
hemophilia C 17 1033
are C 18 1033
of C 19 1033
particular C 20 1033
clinical C 21 1033
importance C 22 1033
in C 23 1033
allowing C 24 1033
an C 25 1033
assessment C 26 1033
of C 27 1033
the C 28 1033
likely C 29 1033
course C 30 1033
of C 31 1033
the C 32 1033
disease C 33 1033
at C 34 1033
different C 35 1033
ages C 36 1033
and C 37 1033
for C 38 1033
differing C 39 1033
grades C 40 1033
of C 41 1033
severity C 42 1033
, C 43 1033
and C 44 1033
in C 45 1033
providing C 46 1033
knowledge C 47 1033
of C 48 1033
which C 49 1033
complications C 50 1033
cause C 51 1033
the C 52 1033
most C 53 1033
disability C 54 1033
, C 55 1033
loss C 56 1033
of C 57 1033
education C 58 1033
, C 59 1033
and C 60 1033
earning C 61 1033
capacity C 62 1033
. C 63 1033
they C 65 1033
also C 66 1033
overcome C 67 1033
the C 68 1033
distorted C 69 1033
clinical C 70 1033
impression C 71 1033
of C 72 1033
the C 73 1033
disease C 74 1033
which C 75 1033
arises C 76 1033
from C 77 1033
the C 78 1033
recurrent C 79 1033
admission C 80 1033
of C 81 1033
the C 82 1033
same C 83 1033
few C 84 1033
severely C 85 1033
affected C 86 1033
hemophiliacs C 87 1033
. C 88 1033
owing C 90 1033
to C 91 1033
the C 92 1033
considerable C 93 1033
individual C 94 1033
variation C 95 1033
in C 96 1033
the C 97 1033
number C 98 1033
and C 99 1033
severity C 100 1033
of C 101 1033
complications C 102 1033
in C 103 1033
different C 104 1033
hemophiliacs C 105 1033
an C 106 1033
accurate C 107 1033
individual C 108 1033
prognosis C 109 1033
can C 110 1033
never C 111 1033
be C 112 1033
given C 113 1033
. C 114 1033
in C 116 1033
general C 117 1033
, C 118 1033
however C 119 1033
, C 120 1033
the C 121 1033
number C 122 1033
of C 123 1033
spontaneous C 124 1033
episodes C 125 1033
per C 126 1033
year C 127 1033
decreases C 128 1033
with C 129 1033
age C 130 1033
, C 131 1033
while C 132 1033
the C 133 1033
severity C 134 1033
of C 135 1033
individual C 136 1033
episodes C 137 1033
tends C 138 1033
to C 139 1033
increase C 140 1033
, C 141 1033
at C 142 1033
least C 143 1033
until C 144 1033
the C 145 1033
age C 146 1033
of C 147 1033
21 C 148 1033
yr C 149 1033
. C 150 1033
there C 152 1033
is C 153 1033
general C 154 1033
agreement C 155 1033
that C 156 1033
the C 157 1033
bulk C 158 1033
of C 159 1033
hospital C 160 1033
hemophilic C 161 1033
admissions C 162 1033
are C 163 1033
due C 164 1033
to C 165 1033
hemarthroses C 166 1033
and C 167 1033
that C 168 1033
hemophilic C 169 1033
arthropathy C 170 1033
involves C 171 1033
the C 172 1033
knee C 173 1033
more C 174 1033
than C 175 1033
it C 176 1033
does C 177 1033
any C 178 1033
other C 179 1033
joint C 180 1033
. C 181 1033
the C 183 1033
increased C 184 1033
time C 185 1033
spent C 186 1033
in C 187 1033
hospital C 188 1033
per C 189 1033
episode C 190 1033
in C 191 1033
later C 192 1033
life C 193 1033
is C 194 1033
in C 195 1033
part C 196 1033
at C 197 1033
least C 198 1033
due C 199 1033
to C 200 1033
the C 201 1033
development C 202 1033
of C 203 1033
relatively C 204 1033
unstable C 205 1033
weight C 206 1033
- C 207 1033
bearing C 208 1033
joints C 209 1033
due C 210 1033
to C 211 1033
hemophilic C 212 1033
arthropathy C 213 1033
and C 214 1033
associated C 215 1033
muscle C 216 1033
atrophy C 217 1033
. C 218 1033
thus C 220 1033
the C 221 1033
correct C 222 1033
management C 223 1033
of C 224 1033
individual C 225 1033
hemarthroses C 226 1033
in C 227 1033
childhood C 228 1033
is C 229 1033
of C 230 1033
considerable C 231 1033
importance C 232 1033
, C 233 1033
and C 234 1033
at C 235 1033
the C 236 1033
present C 237 1033
time C 238 1033
too C 239 1033
little C 240 1033
is C 241 1033
known C 242 1033
of C 243 1033
the C 244 1033
best C 245 1033
possible C 246 1033
treatment C 247 1033
for C 248 1033
these C 249 1033
episodes C 250 1033
. C 251 1033
little C 253 1033
is C 254 1033
known C 255 1033
of C 256 1033
the C 257 1033
pathological C 258 1033
mechanisms C 259 1033
of C 260 1033
hemophilic C 261 1033
arthropathy C 262 1033
and C 263 1033
whether C 264 1033
it C 265 1033
is C 266 1033
the C 267 1033
presence C 268 1033
of C 269 1033
blood C 270 1033
or C 271 1033
its C 272 1033
presence C 273 1033
under C 274 1033
tension C 275 1033
which C 276 1033
leads C 277 1033
to C 278 1033
joint C 279 1033
destruction C 280 1033
. C 281 1033
thus C 283 1033
opinions C 284 1033
differ C 285 1033
concerning C 286 1033
the C 287 1033
routine C 288 1033
admission C 289 1033
of C 290 1033
all C 291 1033
hemarthroses C 292 1033
to C 293 1033
hospital C 294 1033
regardless C 295 1033
of C 296 1033
severity C 297 1033
and C 298 1033
also C 299 1033
about C 300 1033
the C 301 1033
advisability C 302 1033
of C 303 1033
joint C 304 1033
aspiration C 305 1033
in C 306 1033
an C 307 1033
attempt C 308 1033
to C 309 1033
avoid C 310 1033
the C 311 1033
development C 312 1033
of C 313 1033
destructive C 314 1033
arthropathy C 315 1033
. C 316 1033
because C 318 1033
of C 319 1033
the C 320 1033
individual C 321 1033
variation C 322 1033
between C 323 1033
patients C 324 1033
, C 325 1033
the C 326 1033
changes C 327 1033
in C 328 1033
the C 329 1033
pattern C 330 1033
of C 331 1033
the C 332 1033
disease C 333 1033
with C 334 1033
age C 335 1033
, C 336 1033
and C 337 1033
the C 338 1033
difficulty C 339 1033
of C 340 1033
obtaining C 341 1033
suitable C 342 1033
control C 343 1033
patients C 344 1033
these C 345 1033
questions C 346 1033
can C 347 1033
be C 348 1033
answered C 349 1033
only C 350 1033
by C 351 1033
further C 352 1033
longterm C 353 1033
prospective C 354 1033
medicosocial C 355 1033
studies C 356 1033
. C 357 1033
